PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fong, S; Yates, B; Sihn, CR; Mattis, AN; Mitchell, N; Liu, S; Russell, CB; Kim, B; Lawal, A; Rangarajan, S; Lester, W; Bunting, S; Pierce, GF; Pasi, KJ; Wong, WY				Fong, Sylvia; Yates, Bridget; Sihn, Choong-Ryoul; Mattis, Aras N.; Mitchell, Nina; Liu, Su; Russell, Chris B.; Kim, Benjamin; Lawal, Adebayo; Rangarajan, Savita; Lester, Will; Bunting, Stuart; Pierce, Glenn F.; Pasi, K. John; Wong, Wing Yen			Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A	NATURE MEDICINE			English	Article							FATTY LIVER-DISEASE; ER STRESS; VECTOR GENOMES; UNITED-STATES; TRANSCRIPTION; PERSISTENCE; PREVALENCE; PRIMATES; FVIII	Factor VIII gene transfer with a single intravenous infusion of valoctocogene roxaparvovec (AAV5-hFVIII-SQ) has demonstrated clinical benefits lasting 5 years to date in people with severe hemophilia A. Molecular mechanisms underlying sustained AAV5-hFVIII-SQ-derived FVIII expression have not been studied in humans. In a substudy of the phase 1/2 clinical trial (NCT02576795), liver biopsy samples were collected 2.6-4.1 years after gene transfer from five participants. Primary objectives were to examine effects on liver histopathology, determine the transduction pattern and percentage of hepatocytes transduced with AAV5-hFVIII-SQ genomes, characterize and quantify episomal forms of vector DNA and quantify transgene expression (hFVIII-SQ RNA and hFVIII-SQ protein). Histopathology revealed no dysplasia, architectural distortion, fibrosis or chronic inflammation, and no endoplasmic reticulum stress was detected in hepatocytes expressing hFVIII-SQ protein. Hepatocytes stained positive for vector genomes, showing a trend for more cells transduced with higher doses. Molecular analysis demonstrated the presence of full-length, inverted terminal repeat-fused, circular episomal genomes, which are associated with long-term expression. Interindividual differences in transgene expression were noted despite similar successful transduction, possibly influenced by host-mediated post-transduction mechanisms of vector transcription, hFVIII-SQ protein translation and secretion. Overall, these results demonstrate persistent episomal vector structures following AAV5-hFVIII-SQ administration and begin to elucidate potential mechanisms mediating interindividual variability.	[Fong, Sylvia; Yates, Bridget; Sihn, Choong-Ryoul; Mitchell, Nina; Liu, Su; Russell, Chris B.; Kim, Benjamin; Lawal, Adebayo; Bunting, Stuart; Wong, Wing Yen] BioMarin Pharmaceut, Novato, CA 94949 USA; [Mattis, Aras N.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Mattis, Aras N.] Univ Calif San Francisco, Liver Ctr, San Francisco, CA 94143 USA; [Rangarajan, Savita] Univ Hosp Southampton, Southampton, Hants, England; [Lester, Will] Univ Hosp Birmingham, Birmingham, W Midlands, England; [Pasi, K. John] Barts & London Queen Marys Sch Med & Dent, London, England	BioMarin Pharmaceutical Inc.; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Birmingham; University of London; Queen Mary University London	Fong, S (corresponding author), BioMarin Pharmaceut, Novato, CA 94949 USA.	sfong@bmrn.com	Mattis, Aras/AID-1427-2022	Mattis, Aras/0000-0002-5813-164X; Fong, Sylvia/0000-0002-3818-4146; Russell, Chris/0000-0002-0240-1815; Rangarajan, Savita/0000-0001-7367-133X	BioMarin Pharmaceutical	BioMarin Pharmaceutical(Johnson & Johnson)	Funding for this study was provided by BioMarin Pharmaceutical. The funder contributed to the study design, data collection and analysis, decision to publish and preparation of the manuscript, and is represented in the authorship, as described in the 'Author contributions' and 'Competing interests'. Medical writing support was provided by S. Hawley and M. Robinson of BioMarin Pharmaceutical, and K. Pieper of AlphaBioCom, funded by BioMarin Pharmaceutical. Additional medical writing support and preparation of artwork files was provided by J. Fitz-Gerald and J. A. C. Lee of FourWave Medical Communications, funded by BioMarin Pharmaceutical. N. Epie of BioMarin Pharmaceutical coordinated operations between sites and sponsors and provided logistical support. C. Vitelli of BioMarin Pharmaceutical prepared the tissue sections from the adult liver biopsy samples. R. Torres performed ITR-fusion analysis.	Abraham SC, 2008, AM J SURG PATHOL, V32, P965, DOI 10.1097/PAS.0b013e3181622490; Afione SA, 1996, J VIROL, V70, P3235, DOI 10.1128/JVI.70.5.3235-3241.1996; Armstrong MJ, 2012, J HEPATOL, V56, P234, DOI 10.1016/j.jhep.2011.03.020; Batty P., 2020, RES PRACT THROMB HAE, V4; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bhattarai KR, 2021, EXP MOL MED, V53, P151, DOI 10.1038/s12276-021-00560-8; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Bunting S, 2018, MOL THER, V26, P496, DOI 10.1016/j.ymthe.2017.12.009; Darby SC, 2007, BLOOD, V110, P815, DOI 10.1182/blood-2006-10-050435; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Fong S, 2020, MOL THER-METH CLIN D, V18, P620, DOI 10.1016/j.omtm.2020.07.005; Ghaderi S, 2018, J CELL BIOCHEM, V119, P1355, DOI 10.1002/jcb.26296; Gil-Farina I, 2016, MOL THER, V24, P1100, DOI 10.1038/mt.2016.52; Goodman ZD, 2007, J HEPATOL, V47, P598, DOI 10.1016/j.jhep.2007.07.006; Hirsch ML, 2013, MOL THER, V21, P2205, DOI 10.1038/mt.2013.184; Hu SQ, 2020, DIABETES METAB J, V44, P234, DOI 10.4093/dmj.2019.0243; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; John Wiley & Sons, GEN THER CLIN TRIALS; Kattenhorn LM, 2016, HUM GENE THER, V27, P947, DOI 10.1089/hum.2016.160; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Lange AM, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.64; Lazo M, 2013, AM J EPIDEMIOL, V178, P38, DOI 10.1093/aje/kws448; Malhotra JD, 2008, P NATL ACAD SCI USA, V105, P18525, DOI 10.1073/pnas.0809677105; Miao HZ, 2004, BLOOD, V103, P3412, DOI 10.1182/blood-2003-10-3591; Nakai H, 2003, HUM GENE THER, V14, P871, DOI 10.1089/104303403765701169; Nakai H, 2002, J VIROL, V76, P11343, DOI 10.1128/JVI.76.22.11343-11349.2002; Nguyen GN, 2021, NAT BIOTECHNOL, V39, P47, DOI 10.1038/s41587-020-0741-7; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]; Pasi KJ, 2021, HAEMOPHILIA, V27, P947, DOI 10.1111/hae.14391; Pasi KJ, 2020, NEW ENGL J MED, V382, P29, DOI 10.1056/NEJMoa1908490; Penaud-Budloo M, 2008, J VIROL, V82, P7875, DOI 10.1128/JVI.00649-08; Poothong J, 2020, BLOOD, V135, P1899, DOI 10.1182/blood.2019002867; Rambhai HK, 2020, MOL THER-METH CLIN D, V18, P159, DOI 10.1016/j.omtm.2020.05.019; Rosen S, 2020, BLOOD, V136, P2524, DOI 10.1182/blood.2020005683; Schnepp BC, 2016, HUM GENE THER, V27, P32, DOI 10.1089/hum.2015.136; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shu WQ, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00475-19; Sihn CR, 2022, MOL THER-METH CLIN D, V24, P142, DOI 10.1016/j.omtm.2021.12.004; Song SH, 2004, P NATL ACAD SCI USA, V101, P2112, DOI 10.1073/pnas.0307833100; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Srivastava A, 2020, HAEMOPHILIA, V26, P1, DOI 10.1111/hae.14046; Swystun LL, 2019, J THROMB HAEMOST, V17, P681, DOI 10.1111/jth.14404; U.S. Food and Drug Administration, APPR CELL GEN THER P; U.S. Food and Drug Administration, 2018, APPR CELL GEN THER P; van der Flier A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124930; Vincent-Lacaze N, 1999, J VIROL, V73, P1949, DOI 10.1128/JVI.73.3.1949-1955.1999; Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9; Wang JH, 2007, P NATL ACAD SCI USA, V104, P13104, DOI 10.1073/pnas.0702778104; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Zolotukhin I, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.63	55	4	4	2	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					789	+		10.1038/s41591-022-01751-0	http://dx.doi.org/10.1038/s41591-022-01751-0		APR 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35411075	Green Published, hybrid			2022-12-27	WOS:000780688100003
J	Marron, TU; Galsky, MD; Taouli, B; Fiel, MI; Ward, S; Kim, E; Yankelevitz, D; Doroshow, D; Guttman, E; Ungar, B; Mehandru, S; Golas, BJ; Labow, D; Sfakianos, J; Nair, SS; Chakravarty, D; Buckstein, M; Song, XY; Kenigsberg, E; Gnjatic, S; Brown, BD; Sparano, J; Tewari, A; Schwartz, M; Bhardwaj, N; Merad, M				Marron, Thomas U.; Galsky, Matthew D.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Yankelevitz, David; Doroshow, Deborah; Guttman, Emma; Ungar, Benjamin; Mehandru, Saurabh; Golas, Benjamin J.; Labow, Daniel; Sfakianos, John; Nair, Sujit S.; Chakravarty, Dimple; Buckstein, Michael; Song, Xiaoyu; Kenigsberg, Effi; Gnjatic, Sacha; Brown, Brian D.; Sparano, Joseph; Tewari, Ashutosh; Schwartz, Myron; Bhardwaj, Nina; Merad, Miriam			Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery	NATURE MEDICINE			English	Editorial Material								Window-of-opportunity trials, during which patients receive short-duration pre-surgical therapies, provide a platform for understanding the therapies' mechanisms of action, but will require a paradigm shift in trial design, specimen collection and analysis.	[Marron, Thomas U.; Galsky, Matthew D.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Yankelevitz, David; Doroshow, Deborah; Golas, Benjamin J.; Labow, Daniel; Sfakianos, John; Nair, Sujit S.; Chakravarty, Dimple; Buckstein, Michael; Song, Xiaoyu; Kenigsberg, Effi; Gnjatic, Sacha; Brown, Brian D.; Sparano, Joseph; Tewari, Ashutosh; Schwartz, Myron; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, NeoAdjuvant Res Grp Evaluate Therapeut TARGET, New York, NY 10029 USA; [Marron, Thomas U.; Guttman, Emma; Mehandru, Saurabh; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Immunotherapy & Novel TargEt Res Clin Teams Inter, New York, NY 10029 USA; [Marron, Thomas U.; Galsky, Matthew D.; Doroshow, Deborah; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Early Phase Trials Unit, Tisch Canc Inst, New York, NY 10029 USA; [Marron, Thomas U.; Galsky, Matthew D.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Yankelevitz, David; Doroshow, Deborah; Golas, Benjamin J.; Labow, Daniel; Sfakianos, John; Nair, Sujit S.; Chakravarty, Dimple; Buckstein, Michael; Song, Xiaoyu; Gnjatic, Sacha; Brown, Brian D.; Sparano, Joseph; Tewari, Ashutosh; Schwartz, Myron; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Marron, Thomas U.; Guttman, Emma; Mehandru, Saurabh; Kenigsberg, Effi; Gnjatic, Sacha; Brown, Brian D.; Schwartz, Myron; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Marron, Thomas U.; Galsky, Matthew D.; Doroshow, Deborah; Gnjatic, Sacha; Sparano, Joseph; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA; [Marron, Thomas U.; Yankelevitz, David; Doroshow, Deborah; Gnjatic, Sacha; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Ctr Thorac Oncol, Tisch Canc Inst, New York, NY 10029 USA; [Marron, Thomas U.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Buckstein, Michael; Schwartz, Myron; Merad, Miriam] Icahn Sch Med Mt Sinai, Ctr Excellence Liver & Bile Duct Canc, New York, NY 10029 USA; [Marron, Thomas U.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Buckstein, Michael; Schwartz, Myron; Merad, Miriam] Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, New York, NY 10029 USA; [Marron, Thomas U.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Buckstein, Michael; Schwartz, Myron; Merad, Miriam] Icahn Sch Med Mt Sinai, RM Transplant Inst, New York, NY 10029 USA; [Galsky, Matthew D.; Sfakianos, John; Nair, Sujit S.; Chakravarty, Dimple; Tewari, Ashutosh; Bhardwaj, Nina] Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA; [Taouli, Bachir] Icahn Sch Med Mt Sinai, Dept Diagnost Mol & Intervent Radiol, New York, NY 10029 USA; [Taouli, Bachir; Kim, Edward; Yankelevitz, David] Icahn Sch Med Mt Sinai, BioMed Engn & Imaging Inst, New York, NY 10029 USA; [Fiel, Maria Isabel; Ward, Stephen] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Kim, Edward; Yankelevitz, David; Ungar, Benjamin] Icahn Sch Med Mt Sinai, Div Intervent Radiol, New York, NY 10029 USA; [Guttman, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Mehandru, Saurabh] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY 10029 USA; [Ungar, Benjamin; Golas, Benjamin J.; Labow, Daniel; Schwartz, Myron] Icahn Sch Med Mt Sinai, Div Surg Oncol, New York, NY 10029 USA; [Buckstein, Michael] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA; [Song, Xiaoyu] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Kenigsberg, Effi; Gnjatic, Sacha; Brown, Brian D.; Sparano, Joseph; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Dept Ontol Sci, New York, NY 10029 USA; [Kenigsberg, Effi; Brown, Brian D.] Icahn Sch Med Mt Sinai, Dept Genom & Genet, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, NeoAdjuvant Res Grp Evaluate Therapeut TARGET, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Immunotherapy & Novel TargEt Res Clin Teams Inter, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Early Phase Trials Unit, Tisch Canc Inst, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Ctr Thorac Oncol, Tisch Canc Inst, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Ctr Excellence Liver & Bile Duct Canc, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, New York, NY 10029 USA.; Marron, TU; Merad, M (corresponding author), Icahn Sch Med Mt Sinai, RM Transplant Inst, New York, NY 10029 USA.	Thomas.marron@mssm.edu; Miriam.merad@mssm.edu	Doroshow, Deborah/GXF-4079-2022	Ungar, Benjamin/0000-0003-0882-8163				Buckley CD, 2021, NAT IMMUNOL, V22, P1344, DOI 10.1038/s41590-021-01044-7; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Giladi A, 2020, NAT BIOTECHNOL, V38, P629, DOI 10.1038/s41587-020-0442-2; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Leader AM, 2021, CANCER CELL, V39, P1594, DOI 10.1016/j.ccell.2021.10.009; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Maier B, 2020, NATURE, V580, P257, DOI 10.1038/s41586-020-2134-y; Merritt CR, 2020, NAT BIOTECHNOL, V38, P586, DOI 10.1038/s41587-020-0472-9; Pinato DJ, 2021, HEPATOLOGY, V74, P483, DOI 10.1002/hep.31697; Remark R, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf6925; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Rose SA, 2021, NAT IMMUNOL, V22, P914, DOI 10.1038/s41590-021-00944-y; Ruperto N, 2012, NEW ENGL J MED, V367, P2396, DOI 10.1056/NEJMoa1205099; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/nmeth.4380, 10.1038/NMETH.4380]; Upadhaya S, 2020, NAT REV DRUG DISCOV, V19, P751, DOI 10.1038/d41573-020-00166-1; Uppaluri R, 2020, CLIN CANCER RES, V26, P5140, DOI 10.1158/1078-0432.CCR-20-1695; Wu JN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.597741; Zhuang XW, 2021, NAT METHODS, V18, P18, DOI 10.1038/s41592-020-01037-8	25	2	2	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					626	629		10.1038/s41591-022-01681-x	http://dx.doi.org/10.1038/s41591-022-01681-x		MAR 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35347282				2022-12-27	WOS:000773833700004
J	Sattar, N; McGuire, DK; Pavo, I; Weerakkody, GJ; Nishiyama, H; Wiese, RJ; Zoungas, S				Sattar, Naveed; McGuire, Darren K.; Pavo, Imre; Weerakkody, Govinda J.; Nishiyama, Hiroshi; Wiese, Russell J.; Zoungas, Sophia			Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis	NATURE MEDICINE			English	Article							GLP-1 RECEPTOR AGONIST; DUAL GIP; OUTCOMES; SAFETY; MORTALITY; INSULIN; LIRAGLUTIDE; PROBABILITY	Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomized controlled trials with a duration of at least 26 weeks from the tirzepatide T2D clinical development program, SURPASS. The pre-specified primary objective of this meta-analysis was the comparison of the time to first occurrence of confirmed four-component major adverse cardiovascular events (MACE-4; cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina) between pooled tirzepatide groups and control groups. A stratified Cox proportional hazards model, with treatment as a fixed effect and trial-level cardiovascular risk as the stratification factor, was used for the estimation of hazard ratios (HRs) and confidence intervals (CIs) comparing tirzepatide to control. Data from 4,887 participants treated with tirzepatide and 2,328 control participants were analyzed. Overall, 142 participants, 109 from the trial with high cardiovascular risk and 33 from the six trials with lower cardiovascular risk, had at least one MACE-4 event. The HRs comparing tirzepatide versus controls were 0.80 (95% CI, 0.57-1.11) for MACE-4; 0.90 (95% CI, 0.50-1.61) for cardiovascular death; and 0.80 (95% CI, 0.51-1.25) for all-cause death. No evidence of effect modifications was observed for any subgroups, although the evidence was stronger for participants with high cardiovascular risk. Tirzepatide did not increase the risk of major cardiovascular events in participants with T2D versus controls. Meta-analysis of cardiovascular secondary outcomes from the SURPASS program, testing efficacy of a new novel dual GIP/GLP-1 receptor agonist tirzepatide, demonstrates cardiovascular safety in patients with type 2 diabetes.	[Sattar, Naveed] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [McGuire, Darren K.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [McGuire, Darren K.] Parkland Hlth & Hosp Syst, Dallas, TX USA; [Pavo, Imre] Eli Lilly Reg Operat GmbH, Vienna, Austria; [Weerakkody, Govinda J.; Nishiyama, Hiroshi; Wiese, Russell J.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Zoungas, Sophia] Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic, Australia	University of Glasgow; University of Texas System; University of Texas Southwestern Medical Center Dallas; Eli Lilly; Eli Lilly; Monash University	Sattar, N (corresponding author), Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.; Zoungas, S (corresponding author), Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic, Australia.	naveed.sattar@glasgow.ac.uk; sophia.zoungas@monash.edu		Sattar, Naveed/0000-0002-1604-2593	Eli Lilly and Company; British Heart Foundation Research Excellence Award [RE/18/6/34217]	Eli Lilly and Company(Eli Lilly); British Heart Foundation Research Excellence Award	The authors thank C. A. Karanikas (Eli Lilly and Company) for writing and editorial assistance. This study was supported by Eli Lilly and Company. N.S. is supported by the British Heart Foundation Research Excellence Award (RE/18/6/34217).	Benjamin, 2018, CIRCULATION, V137, pE493, DOI 10.1161/CIR.0000000000000573; Chandler J., 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD201601, DOI 10.1002/14651858.CD201601]; Coskun T, 2018, MOL METAB, V18, P3, DOI 10.1016/j.molmet.2018.09.009; Dahl D, 2022, JAMA-J AM MED ASSOC, V327, P534, DOI 10.1001/jama.2022.0078; Del Prato S, 2021, LANCET, V398, P1811, DOI 10.1016/S0140-6736(21)02188-7; Engel SS, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-3; European Medicines Agency Committee for Medicinal Products for Human Use, 2010, GUID CLIN INV MED PR; Ferdinand KC, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0355-z; Fisher M, 2015, LANCET DIABETES ENDO, V3, P697, DOI 10.1016/S2213-8587(15)00233-8; Frias JP, 2021, NEW ENGL J MED, V385, P503, DOI 10.1056/NEJMoa2107519; Frias JP, 2018, LANCET, V392, P2180, DOI 10.1016/S0140-6736(18)32260-8; Gerstein HC, 2019, LANCET, V394, P121, DOI 10.1016/S0140-6736(19)31149-3; Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858; Gore M Odette, 2009, Curr Cardiol Rep, V11, P258; Holst JJ, 2020, J CLIN ENDOCR METAB, V105, pE2710, DOI 10.1210/clinem/dgaa327; HORVITZ DG, 1952, J AM STAT ASSOC, V47, P663, DOI 10.2307/2280784; Husain M, 2019, NEW ENGL J MED, V381, P841, DOI 10.1056/NEJMoa1901118; HWANG IK, 1990, STAT MED, V9, P1439, DOI 10.1002/sim.4780091207; Iqbal N, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-33; Johansen OE, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-3; Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9; Ludvik B, 2021, LANCET, V398, P583, DOI 10.1016/S0140-6736(21)01443-4; Marso Steven P, 2017, N Engl J Med, V377, P723, DOI 10.1056/NEJMoa1615692; Marso SP, 2016, NEW ENGL J MED, V375, P1834, DOI 10.1056/NEJMoa1607141; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; Marso SP, 2011, DIABETES VASC DIS RE, V8, P237, DOI 10.1177/1479164111408937; McInnes G, 2015, DIABETES OBES METAB, V17, P1085, DOI 10.1111/dom.12548; Ratner R, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-22; Rawshani A, 2018, NEW ENGL J MED, V379, P633, DOI 10.1056/NEJMoa1800256; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Rosenstock J, 2021, LANCET, V398, P143, DOI 10.1016/S0140-6736(21)01324-6; Sattar N, 2021, LANCET DIABETES ENDO, V9, P653, DOI 10.1016/S2213-8587(21)00203-5; Scheen AJ, 2018, CIRC RES, V122, P1439, DOI 10.1161/CIRCRESAHA.117.311588; Sonesson C, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0356-y; Thomas MK, 2021, J CLIN ENDOCR METAB, V106, P388, DOI 10.1210/clinem/dgaa863; US Food and Drug Administration, 2020, GUID IND TYP 2 DIAB; US Food anrd Dug Administration, 2008, GUID IND DIAB MELL E; White WB, 2013, DIABETES OBES METAB, V15, P668, DOI 10.1111/dom.12093; Wilson JM, 2020, DIABETES OBES METAB, V22, P2451, DOI 10.1111/dom.14174; Xie J, 2005, STAT MED, V24, P3089, DOI 10.1002/sim.2174; Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827	41	22	22	12	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					591	+		10.1038/s41591-022-01707-4	http://dx.doi.org/10.1038/s41591-022-01707-4		FEB 2022	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35210595	hybrid, Green Published, Green Accepted			2022-12-27	WOS:000761879000001
J	Magnani, A; Semeraro, M; Adam, F; Booth, C; Dupre, L; Morris, EC; Gabrion, A; Roudaut, C; Borgel, D; Toubert, A; Clave, E; Abdo, C; Gorochov, G; Petermann, R; Guiot, M; Miyara, M; Moshous, D; Magrin, E; Denis, A; Suarez, F; Lagresle, C; Roche, AM; Everett, J; Trinquand, A; Guisset, M; Bayford, JX; Hacein-Bey-Abina, S; Kauskot, A; Elfeky, R; Rivat, C; Abbas, S; Gaspar, HB; Macintyre, E; Picard, C; Bushman, FD; Galy, A; Fischer, A; Six, E; Thrasher, AJ; Cavazzana, M				Magnani, A.; Semeraro, M.; Adam, F.; Booth, C.; Dupre, L.; Morris, E. C.; Gabrion, A.; Roudaut, C.; Borgel, D.; Toubert, A.; Clave, E.; Abdo, C.; Gorochov, G.; Petermann, R.; Guiot, M.; Miyara, M.; Moshous, D.; Magrin, E.; Denis, A.; Suarez, F.; Lagresle, C.; Roche, A. M.; Everett, J.; Trinquand, A.; Guisset, M.; Bayford, J. Xu; Hacein-Bey-Abina, S.; Kauskot, A.; Elfeky, R.; Rivat, C.; Abbas, S.; Gaspar, H. B.; Macintyre, E.; Picard, C.; Bushman, F. D.; Galy, A.; Fischer, A.; Six, E.; Thrasher, A. J.; Cavazzana, M.			Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome	NATURE MEDICINE			English	Article							WASP; TRANSPLANTATION; INTEGRATION; EXPRESSION; DIVERSITY; PATIENT	Patients with Wiskott-Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760) for eight patients with WAS having undergone phase I/II lentiviral vector-based gene therapy trials (nos NCT01347346 and NCT01347242), with a focus on thrombocytopenia and autoimmunity. Primary outcomes of the long-term study were to establish clinical and biological safety, efficacy and tolerability by evaluating the incidence and type of serious adverse events and clinical status and biological parameters including lentiviral genomic integration sites in different cell subpopulations from 3 years to 15 years after gene therapy. Secondary outcomes included monitoring the need for additional treatment and T cell repertoire diversity. An interim analysis shows that the study meets the primary outcome criteria tested given that the gene-corrected cells engrafted stably, and no serious treatment-associated adverse events occurred. Overall, severe infections and eczema resolved. Autoimmune disorders and bleeding episodes were significantly less frequent, despite only partial correction of the platelet compartment. The results suggest that lentiviral gene therapy provides sustained clinical benefits for patients with WAS.	[Magnani, A.; Gabrion, A.; Roudaut, C.; Guiot, M.; Magrin, E.; Cavazzana, M.] Hop Univ Necker Enfants Malad, Grp Hosp Paris Ctr, AP HP, Dept Biotherapy, Paris, France; [Magnani, A.; Gabrion, A.; Roudaut, C.; Magrin, E.; Cavazzana, M.] Grp Hosp Univ Paris Ctr, AP HP, Biotherapy Clin Invest Ctr, INSERM CIC 1416, Paris, France; [Semeraro, M.] Univ Paris, Hop Univ Necker Enfants Malad, Grp Hosp Paris Ctr, AP HP,Clin Invest Ctr CIC 1419, Paris, France; [Adam, F.; Borgel, D.; Kauskot, A.] Univ Paris Saclay, UMR S1176, INSERM, Le Kremlin Bicetre, France; [Booth, C.; Bayford, J. Xu; Elfeky, R.; Rivat, C.; Gaspar, H. B.; Thrasher, A. J.] Great Ormond St Hosp Sick Children, Dept Paediat Immunol, London, England; [Booth, C.; Thrasher, A. J.] UCL Great Ormond St Inst Child Hlth, Mol & Cellular Immunol Sect, London, England; [Dupre, L.; Guisset, M.] Toulouse III Paul Sabatier Univ, Toulouse Inst Infect & Inflammatory Dis INFINITy, CNRS, INSERM, Toulouse, France; [Dupre, L.] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Dupre, L.] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Morris, E. C.] UCL, Inst Immun & Transplantat, London, England; [Morris, E. C.] Royal Free London Hosp NHS Fdn Trust, Dept Immunol, London, England; [Borgel, D.] Hop Necker Enfants Malad, AP HP, Lab Hematol, Paris, France; [Toubert, A.; Clave, E.] Univ Paris, INSERM U1160, EMiLy, Inst Rech St Louis, Paris, France; [Toubert, A.] Hop St Louis, AP HP, Lab Immunol & Histocompatibilite, Paris, France; [Abdo, C.; Trinquand, A.; Macintyre, E.] Univ Paris 05, Inst Necker Enfants Malad INEM, INSERM U1151, Sorbonne Cite, Paris, France; [Abdo, C.; Trinquand, A.; Macintyre, E.] Necker Enfants Malad Univ Hosp, AP PH, Lab Oncohematol, Paris, France; [Gorochov, G.; Miyara, M.] Grp Hosp Pitie Salpetriere, AP HP, Dept Immunol, Paris, France; [Gorochov, G.; Miyara, M.] Sorbonne Univ, Ctr Immunol & Malad Infect Paris CIMI Paris, INSERM, Paris, France; [Petermann, R.] INTS, Platelet Immunol Dept, Paris, France; [Moshous, D.; Fischer, A.] Necker Enfants Malad Univ Hosp, AP HP, Dept Pediat Immunol Hematol & Rheumatol, Paris, France; [Moshous, D.; Suarez, F.; Picard, C.; Fischer, A.; Cavazzana, M.] Univ Paris Ctr, Imagine Inst, Paris, France; [Denis, A.; Lagresle, C.; Six, E.] Univ Paris, Imagine Inst, Human Lymphohematopoiesis Lab, INSERM,UMR 1163, Paris, France; [Suarez, F.] Ctr Univ Paris, Hop Necker Enfants Malad, AP HP, Serv Hematol Adultes, Paris, France; [Roche, A. M.; Everett, J.; Bushman, F. D.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; [Hacein-Bey-Abina, S.] Univ Paris, Unite Technol Chim & Biol Sante, INSERM, CNRS, Paris, France; [Hacein-Bey-Abina, S.] Hop Kremlin Bicetre, Grp Hosp Univ Paris Sud, AP HP, Clin Immunol Lab, Le Kremlin Bicetre, France; [Abbas, S.; Galy, A.] Genethon, Evry, France; [Picard, C.] Necker Enfants Malad Univ Hosp, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Galy, A.] Univ Paris Saclay, Univ Evry, Integrare Res Unit UMRS951, INSERM,Genethon, Evry, France; [Fischer, A.] Coll France, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Medical University of Vienna; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; College de France	Cavazzana, M (corresponding author), Hop Univ Necker Enfants Malad, Grp Hosp Paris Ctr, AP HP, Dept Biotherapy, Paris, France.; Cavazzana, M (corresponding author), Grp Hosp Univ Paris Ctr, AP HP, Biotherapy Clin Invest Ctr, INSERM CIC 1416, Paris, France.; Thrasher, AJ (corresponding author), Great Ormond St Hosp Sick Children, Dept Paediat Immunol, London, England.; Thrasher, AJ (corresponding author), UCL Great Ormond St Inst Child Hlth, Mol & Cellular Immunol Sect, London, England.; Cavazzana, M (corresponding author), Univ Paris Ctr, Imagine Inst, Paris, France.	a.thrasher@ucl.ac.uk; m.cavazzana@aphp.fr	dupre, loic/L-8174-2014; Kauskot, Alexandre/J-6794-2015; Trinquand, Amélie/AAV-7203-2021; Galy, Anne/GQI-4255-2022; Lagresle Peyrou, Chantal/H-2911-2017; Toubert, Antoine/Q-3404-2017; GABRION, AURELIE/K-1812-2017	dupre, loic/0000-0002-7278-6503; Kauskot, Alexandre/0000-0002-4064-8114; Galy, Anne/0000-0002-0153-4392; ADAM, Frederic/0000-0001-6603-2687; Morris, Emma/0000-0003-4834-1130; Lagresle Peyrou, Chantal/0000-0002-2216-6453; Toubert, Antoine/0000-0002-7308-7317; GABRION, AURELIE/0000-0002-1885-2071; Gorochov, Guy/0000-0003-2097-9677	Genethon (Evry France); AFM/Telethon; European Research Council [693762]; Agence Nationale de la Recherche under the Investissements d'avenir program [ANR-10-IAHU-01]; Paris Ile-de-France Region under the DIM Therapie genique initiative; European Union [693762-Gene]; National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust (London, UK); Wellcome Trust [104807/Z/14/Z, 217112/Z/19/Z]	Genethon (Evry France); AFM/Telethon(Association Francaise contre les Myopathies); European Research Council(European Research Council (ERC)European Commission); Agence Nationale de la Recherche under the Investissements d'avenir program(French National Research Agency (ANR)); Paris Ile-de-France Region under the DIM Therapie genique initiative; European Union(European Commission); National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust (London, UK); Wellcome Trust(Wellcome TrustEuropean Commission)	The study was sponsored by Genethon (Evry France) and supported by funding from AFM/Telethon. The present work was also supported by grants from the European Research Council (ERC-2015-AdG, GENEFORCURE, project 693762), by state funding from the Agence Nationale de la Recherche under the Investissements d'avenir program (ANR-10-IAHU-01), and by the Paris Ile-de-France Region under the DIM Therapie genique initiative. The project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement 693762-Gene For Cure. A.J.T., C.B., J.X.B., R.E., C.R. and H.B.G. received support from the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust (London, UK). A.J.T. was supported by the Wellcome Trust (104807/Z/14/Z and 217112/Z/19/Z). We thank the patients and their families for their cooperation in the study. We also thank J. Marouene (study coordinator at Assistance Publique-Hopitaux de Paris at the URC-CIC Paris Centre) for the study's implementation, monitoring and data management; A. Guilloux (LAMME, Evry University) for critical advice on statistical analysis; B. Beaurain, C. Colpin and C. Tran at Genethon for management of the sponsor activities, study pharmacovigilance and regulatory affairs, respectively; D. Lasne and T. Pascreau at Necker Children's Hospital (Hematology Department, Paris) and C. Reperant (U1176 INSERM, Le Kremlin-Bicetre) for their assistance with platelet studies; and the members of the Cytometry Facility at Necker Hospital and the Cell Imaging Facility at the Toulouse Institute for Infectious and Inflammatory Diseases.	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Adam F, 2003, J THROMB HAEMOST, V1, P798, DOI 10.1046/j.1538-7836.2003.00138.x; Adam F, 2010, BLOOD, V115, P4083, DOI 10.1182/blood-2009-07-233932; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Albert MH, 2011, CURR OPIN HEMATOL, V18, P42, DOI 10.1097/MOH.0b013e32834114bc; Arruda LCM, 2018, BLOOD ADV, V2, P126, DOI 10.1182/bloodadvances.2017011072; Astrakhan A, 2012, BLOOD, V119, P4395, DOI 10.1182/blood-2011-03-340711; Balashov D, 2018, BIOL BLOOD MARROW TR, V24, P1432, DOI 10.1016/j.bbmt.2018.03.006; Berry CC, 2017, MOL THER-METH CLIN D, V4, P17, DOI 10.1016/j.omtm.2016.11.003; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Bruggemann M, 2019, LEUKEMIA, V33, P2241, DOI 10.1038/s41375-019-0496-7; Burroughs LM, 2020, BLOOD, V135, P2094, DOI 10.1182/blood.2019002939; Candotti F, 2018, J CLIN IMMUNOL, V38, P13, DOI 10.1007/s10875-017-0453-z; Castiello MC, 2015, J ALLERGY CLIN IMMUN, V136, P692, DOI 10.1016/j.jaci.2015.01.035; Cavazzana M, 2019, NAT REV DRUG DISCOV, V18, P447, DOI 10.1038/s41573-019-0020-9; Charrier S, 2013, HAEMATOLOGICA, V98, P1300, DOI 10.3324/haematol.2012.077040; Davis BR, 2010, CLIN IMMUNOL, V135, P72, DOI 10.1016/j.clim.2009.12.011; Dupre L, 2004, MOL THER, V10, P903, DOI 10.1016/j.ymthe.2004.08.008; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Elfeky RA, 2018, J ALLERGY CLIN IMMUN, V142, P1654, DOI 10.1016/j.jaci.2018.06.042; Ferrua F, 2019, LANCET HAEMATOL, V6, pE239, DOI 10.1016/S2352-3026(19)30021-3; Houmadi R, 2018, CELL REP, V22, P979, DOI 10.1016/j.celrep.2017.12.088; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; KIEFEL V, 1987, BLOOD, V70, P1722; Mahlaoui N, 2013, BLOOD, V121, P1510, DOI 10.1182/blood-2012-08-448118; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Morris EC, 2017, BLOOD, V130, P1327, DOI 10.1182/blood-2017-04-777136; Munoz P, 2020, MOL THER-METH CLIN D, V19, P220, DOI 10.1016/j.omtm.2020.09.006; Nurden P, 2000, BRIT J HAEMATOL, V110, P704, DOI 10.1046/j.1365-2141.2000.02246.x; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Pala F, 2015, J CLIN INVEST, V125, P3941, DOI 10.1172/JCI82249; Picard Capucine, 2007, Rev Prat, V57, P1671; PIELOU EC, 1966, J THEOR BIOL, V13, P131, DOI 10.1016/0022-5193(66)90013-0; Ramezani H., 2012, Environment and Natural Resources Research, V2, P54; Rengan R, 2000, BLOOD, V95, P1283, DOI 10.1182/blood.V95.4.1283.004k44_1283_1292; Rivers E, 2019, J ALLER CL IMM-PRACT, V7, P1042, DOI 10.1016/j.jaip.2018.07.009; Sabri S, 2006, BLOOD, V108, P134, DOI 10.1182/blood-2005-03-1219; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Segel GB, 2008, PEDIATR REV, V29, P12, DOI 10.1542/pir.29-1-12; Sereni L, 2019, J ALLERGY CLIN IMMUN, V144, P825, DOI 10.1016/j.jaci.2019.03.012; Sereni L, 2018, J ALLERGY CLIN IMMUN, V142, P1272, DOI 10.1016/j.jaci.2017.12.1000; Sherman E, 2017, MOL THER-METH CLIN D, V4, P39, DOI 10.1016/j.omtm.2016.11.002; Shin CR, 2012, BONE MARROW TRANSPL, V47, P1428, DOI 10.1038/bmt.2012.31; Singh Sajal Sagar, 2016, Micro and Nano Systems Letters, V4, DOI 10.1186/s40486-016-0027-5; Six E, 2020, BLOOD, V135, P1219, DOI 10.1182/blood.2019002350; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Trifari S, 2010, J ALLERGY CLIN IMMUN, V125, P439, DOI 10.1016/j.jaci.2009.11.034; Wada T, 2003, J CLIN INVEST, V111, P1389, DOI 10.1172/JCI200315485; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	52	15	15	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					71	+		10.1038/s41591-021-01641-x	http://dx.doi.org/10.1038/s41591-021-01641-x		JAN 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35075289	hybrid, Green Published			2022-12-27	WOS:000746475000001
J	Houssami, N; Kerlikowske, K				Houssami, Nehmat; Kerlikowske, Karla			AI as a new paradigm for risk-based screening for breast cancer	NATURE MEDICINE			English	Editorial Material							MAMMOGRAPHY	AI may represent a new tool in the risk assessment and screening pathway of breast cancer. To realise its potential, the effect of AI-supported decisions on relevant clinical outcomes must be prospectively evaluated.	[Houssami, Nehmat] Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia; [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA	University of Sydney; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Houssami, N (corresponding author), Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia.	nehmat.houssami@sydney.edu.au			National Breast Cancer Foundation (NBCF) Chair in Breast Cancer Prevention grant [EC-21-001]	National Breast Cancer Foundation (NBCF) Chair in Breast Cancer Prevention grant	N.H. receives funding via the National Breast Cancer Foundation (NBCF) Chair in Breast Cancer Prevention grant (EC-21-001).	Aarts AMWM, 2019, J MED SCREEN, V26, P147, DOI 10.1177/0969141318814869; Choudhury PP, 2020, JNCI-J NATL CANCER I, V112, P278, DOI 10.1093/jnci/djz113; Eriksson M, 2020, RADIOLOGY, V297, P327, DOI 10.1148/radiol.2020201620; Esserman LJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0035-5; Houssami N, 2018, BREAST, V38, P150, DOI 10.1016/j.breast.2018.01.002; Kerlikowske K, 2021, JNCI-J NATL CANCER I, V113, P909, DOI 10.1093/jnci/djaa176; Lauby-Secretan B, 2015, NEW ENGL J MED, V372, P2353, DOI 10.1056/NEJMsr1504363; Pashayan N, 2020, NAT REV CLIN ONCOL, V17, P687, DOI 10.1038/s41571-020-0388-9; Terry MB, 2019, LANCET ONCOL, V20, P504, DOI 10.1016/S1470-2045(18)30902-1; Tice JA, 2015, J CLIN ONCOL, V33, P3137, DOI 10.1200/JCO.2015.60.8869; Trentham-Dietz A, 2016, ANN INTERN MED, V165, P700, DOI 10.7326/M16-0476; Yala A, 2022, NAT MED, V28, P136, DOI 10.1038/s41591-021-01599-w	12	2	2	6	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					29	30		10.1038/s41591-021-01649-3	http://dx.doi.org/10.1038/s41591-021-01649-3		JAN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35027759				2022-12-27	WOS:000742323900005
J	Stuart, EA; Dowdy, DW				Stuart, Elizabeth A.; Dowdy, David W.			Evidence-based COVID-19 policy-making in schools	NATURE MEDICINE			English	Editorial Material								New research can help policymakers make evidence-based decisions about the risks and benefits of in-person schooling; strategic use of the available data will be key to getting this right.	[Stuart, Elizabeth A.; Dowdy, David W.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Stuart, EA (corresponding author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA.	estuart@jhu.edu	kang, jiyeon/ABG-6484-2021		Hopkins Business of Health Initiative pilot grant; Johns Hopkins University Catalyst Award; Johns Hopkins University Discovery Award; National Institutes of Health [P50MH115842]	Hopkins Business of Health Initiative pilot grant; Johns Hopkins University Catalyst Award; Johns Hopkins University Discovery Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	D.W.D. was supported by a Hopkins Business of Health Initiative pilot grant and a Johns Hopkins University Catalyst Award. E.A.S. was supported by a Johns Hopkins University Discovery Award and by National Institutes of Health award P50MH115842 (PI: Daumit).	Cook TD, 2014, J POLICY ANAL MANAG, V33, P527, DOI 10.1002/pam.21750; Ertem, 2021, NAT MED, DOI [10.1038/s41591-021-01543-y, DOI 10.1038/S41591-021-01543-Y]; Fukumoto K, 2021, NAT MED, V27, P2111, DOI 10.1038/s41591-021-01571-8; Goodman-Bacon A, 2020, SURV RES METHODS-GER, V14, P153, DOI 10.18148/srm/2020.v14i2.7723; HOLLAND PW, 1986, J AM STAT ASSOC, V81, P945, DOI 10.2307/2289064; Lessler J, 2021, SCIENCE, V372, P1092, DOI 10.1126/science.abh2939; Orr LL, 2019, J POLICY ANAL MANAG, V38, P978, DOI 10.1002/pam.22154; Stuart E. A., AM J EPIDEMIOL; Wasserman L., PREPRINT; Young BC, 2021, LANCET, V398, P1217, DOI 10.1016/S0140-6736(21)01908-5	10	4	4	2	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2078	2079		10.1038/s41591-021-01585-2	http://dx.doi.org/10.1038/s41591-021-01585-2		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34824459	Bronze			2022-12-27	WOS:000722514700002
J	Keuroghlian, AS				Keuroghlian, Alex S.			Electronic health records as an equity tool for LGBTQIA plus people COMMENT	NATURE MEDICINE			English	Editorial Material							GENDER MINORITY HEALTH; TRANSGENDER; STRATEGIES	Collection of data on sexual orientation, gender identity and intersex status will help to reduce health disparities that affect people from sexual and gender minority communities.	[Keuroghlian, Alex S.] Fenway Inst, Fenway Hlth, Boston, MA 61724 USA; [Keuroghlian, Alex S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Keuroghlian, Alex S.] Harvard Med Sch, Boston, MA 02115 USA	Fenway Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Keuroghlian, AS (corresponding author), Fenway Inst, Fenway Hlth, Boston, MA 61724 USA.; Keuroghlian, AS (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Keuroghlian, AS (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	akeuroghlian@partners.org		Keuroghlian, Alex/0000-0002-6624-8354				Almazan AN, 2021, AM J PUBLIC HEALTH, V111, P2059, DOI 10.2105/AJPH.2021.306414; Almazan AN, 2021, JAMA SURG, V156, P611, DOI 10.1001/jamasurg.2021.0952; Ard KL, 2018, NEW ENGL J MED, V379, P2388, DOI 10.1056/NEJMp1810522; Cahill S, 2020, AM J PUBLIC HEALTH, V110, P1360, DOI 10.2105/AJPH.2020.305829; Cahill S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107104; Goldhammer H, 2021, J HEALTH CARE POOR U, V32, P18, DOI 10.1353/hpu.2021.0004; Goldhammer H, 2018, LGBT HEALTH, V5, P461, DOI 10.1089/lgbt.2018.0118; Grasso C, 2022, TRANSGENDER HEALTH, V7, P135, DOI 10.1089/trgh.2020.0155; Grasso C, 2021, J AM MED INFORM ASSN, V28, P2531, DOI 10.1093/jamia/ocab080; Grasso C, 2020, INT J MED INFORM, V142, DOI 10.1016/j.ijmedinf.2020.104245; Grasso C, 2019, AM J PUBLIC HEALTH, V109, P1111, DOI 10.2105/AJPH.2019.305130; Grasso C, 2019, J AM MED INFORM ASSN, V26, P66, DOI 10.1093/jamia/ocy137; Keuroghlian AS, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25728; Kronk CA, 2021, J AM MED INFORM ASSN, V29, P271, DOI 10.1093/jamia/ocab136; Loo S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255568; Marcus JL, 2019, LANCET HIV, V6, pE688, DOI 10.1016/S2352-3018(19)30137-7; McClure RC, 2021, J AM MED INFORM ASSN, V29, P354, DOI 10.1093/jamia/ocab196; McDowell MJ, 2020, PSYCHOSOMATICS, V61, P655, DOI 10.1016/j.psym.2020.04.021; Morenz AM, 2020, ANN FAM MED, V18, P73, DOI 10.1370/afm.2473; Singer S, 2020, LGBT HEALTH, V7, P216, DOI 10.1089/lgbt.2019.0313; Turban JL, 2021, J ADOLESCENT HEALTH, V69, P991, DOI 10.1016/j.jadohealth.2021.06.001; Turban JL, 2020, ANN INTERN MED, V173, P387, DOI 10.7326/M20-2004; Turban JL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1725	23	2	2	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2071	2073		10.1038/s41591-021-01592-3	http://dx.doi.org/10.1038/s41591-021-01592-3		NOV 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34811548	Bronze			2022-12-27	WOS:000721464800002
J	Bargmann, C; Claiborne, A; Valantine, H				Bargmann, Cori; Claiborne, Anne; Valantine, Hannah			A commitment to scientific equity from a philanthropic funder	NATURE MEDICINE			English	Editorial Material									[Bargmann, Cori] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Bargmann, Cori; Claiborne, Anne; Valantine, Hannah] Chan Zuckerberg Initiat, Redwood City, CA 94063 USA; [Valantine, Hannah] Stanford Univ, Stanford, CA 94305 USA	Rockefeller University; Stanford University	Valantine, H (corresponding author), Chan Zuckerberg Initiat, Redwood City, CA 94063 USA.; Valantine, H (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	hvvk@stanford.edu		Bargmann, Cornelia/0000-0002-8484-0618				[Anonymous], 2021, CHAN ZUCKERBERG INIT; [Anonymous], 2021, CHAN ZUCKERBERG INIT; Fraser N, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3000959; Hoppe TA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7238; Kalantar KL., 2020, GIGASCIENCE, V9, pGIAA111, DOI [10.1093/gigascience/giaa111, DOI 10.1093/gigascience/giaa111]; Mervis J, 2019, SCIENCE, DOI [10.1126/science.aay8489, DOI 10.1126/SCIENCE.AAY8489]; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Regev A, 2017, ELIFE, V6, DOI 10.7554/eLife.27041; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048	9	0	0	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1866	1867		10.1038/s41591-021-01531-2	http://dx.doi.org/10.1038/s41591-021-01531-2		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764482	Bronze			2022-12-27	WOS:000717406200005
J	Xu, BH; Zhang, QY; Zhang, P; Hu, XC; Li, W; Tong, ZS; Sun, T; Teng, YE; Wu, XH; Ouyang, QC; Yan, X; Cheng, J; Liu, Q; Feng, JF; Wang, XJ; Yin, YM; Shi, YX; Pan, YY; Wang, YS; Xie, WM; Yan, M; Liu, YJ; Yan, P; Wu, F; Zhu, XY; Zou, JJ				Xu, Binghe; Zhang, Qingyuan; Zhang, Pin; Hu, Xichun; Li, Wei; Tong, Zhongsheng; Sun, Tao; Teng, Yuee; Wu, Xinhong; Ouyang, Quchang; Yan, Xi; Cheng, Jing; Liu, Qiang; Feng, Jifeng; Wang, Xiaojia; Yin, Yongmei; Shi, Yanxia; Pan, Yueyin; Wang, Yongsheng; Xie, Weimin; Yan, Min; Liu, Yunjiang; Yan, Ping; Wu, Fei; Zhu, Xiaoyu; Zou, Jianjun		DAWNA-1 Study Consortium	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial	NATURE MEDICINE			English	Article								Blockade of the cyclin-dependent kinase 4 and 6 pathway has been shown to be effective in the treatment of hormone receptor-positive advanced breast cancer (ABC). We report the interim results of DAWNA-1 (NCT03927456), a double-blind, randomized, phase 3 trial of dalpiciclib (a new cyclin-dependent kinase 4 and 6 inhibitor) plus fulvestrant in hormone receptor-positive, HER2-negative ABC with disease progression after endocrine therapy. A total of 361 patients were randomized 2:1 to receive dalpiciclib plus fulvestrant or placebo plus fulvestrant. The study met the primary end point, showing significantly prolonged investigator-assessed progression-free survival with dalpiciclib plus fulvestrant versus placebo plus fulvestrant (median = 15.7, 95% confidence interval (CI) = 11.1-not reached versus 7.2, 95% CI = 5.6-9.2 months; hazard ratio = 0.42, 95% CI = 0.31-0.58; one-sided P < 0.0001 (boundary was P <= 0.008)). The most common grade 3 or 4 adverse events with dalpiciclib plus fulvestrant were neutropenia (84.2%) and leukopenia (62.1%). The incidence of serious adverse events was 5.8% with dalpiciclib plus fulvestrant versus 6.7% with placebo plus fulvestrant. Our findings support dalpiciclib plus fulvestrant as a new treatment option for pretreated hormone receptor-positive, HER2-negative ABC.	[Xu, Binghe; Zhang, Pin] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Cancer, Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China; [Xu, Binghe; Zhang, Pin] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Cancer, Natl Canc Ctr,Clin Trial Ctr, Beijing, Peoples R China; [Xu, Binghe; Zhang, Qingyuan; Zhang, Pin] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China; [Xu, Binghe; Zhang, Qingyuan; Zhang, Pin; Hu, Xichun] Fudan Univ, Dept Med Oncol, Canc Hosp, Shanghai, Peoples R China; [Li, Wei] First Hosp Jilin Univ, Dept Med Oncol, Changchun, Peoples R China; [Tong, Zhongsheng] Tianjin Med Univ Canc Inst & Hosp, Dept Med Oncol, Tianjin, Peoples R China; [Sun, Tao] China Med Univ, Dept Med Oncol, Canc Hosp, Liaoning Canc Hosp, Shenyang, Peoples R China; [Teng, Yuee] China Med Univ, Dept Med Oncol, Affiliated Hosp 1, Shenyang, Peoples R China; [Wu, Xinhong] Hubei Canc Hosp, Dept Breast Oncol, Wuhan, Peoples R China; [Ouyang, Quchang] Hunan Canc Hosp, Dept Med Oncol, Changsha, Peoples R China; [Yan, Xi] Sichuan Univ, West China Hosp, Dept Head & Neck Canc, Chengdu, Peoples R China; [Cheng, Jing] Huazhong Univ Sci Technol, Union Hosp, Tongji Med Coll, Dept Breast Oncol, Wuhan, Peoples R China; [Liu, Qiang] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Guangzhou, Peoples R China; [Feng, Jifeng] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China; [Wang, Xiaojia] Univ Chinese Acad Sci, Chinese Acad Sci, Inst Canc & Basic Med, Canc Hosp,Zhejiang Canc Hosp,Dept Med Oncol, Hangzhou, Peoples R China; [Yin, Yongmei] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China; [Shi, Yanxia] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China; [Pan, Yueyin] Anhui Prov Hosp, Dept Med Oncol Chemotherapy, Hefei, Peoples R China; [Wang, Yongsheng] Shandong Canc Hosp, Breast Canc Ctr, Jinan, Peoples R China; [Xie, Weimin] Guangxi Med Univ, Dept Breast, Bone Soft Tissue Oncol, Canc Hosp, Nanning, Peoples R China; [Yan, Min] Zhengzhou Univ, Dept Breast Dis, Affiliated Canc Hosp, Henan Breast Canc Ctr, Zhengzhou, Peoples R China; [Yan, Min] Henan Canc Hosp, Zhengzhou, Peoples R China; [Liu, Yunjiang] Hebei Med Univ, Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Yan, Ping] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Harbin Medical University; Fudan University; Jilin University; Tianjin Medical University; China Medical University; China Medical University; Sichuan University; Huazhong University of Science & Technology; Sun Yat Sen University; Nanjing Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Nanjing Medical University; Sun Yat Sen University; Shandong First Medical University & Shandong Academy of Medical Sciences; Guangxi Medical University; Zhengzhou University; Zhengzhou University; Hebei Medical University	Xu, BH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Cancer, Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China.; Xu, BH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Cancer, Natl Canc Ctr,Clin Trial Ctr, Beijing, Peoples R China.; Xu, BH (corresponding author), Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China.; Xu, BH (corresponding author), Fudan Univ, Dept Med Oncol, Canc Hosp, Shanghai, Peoples R China.	bhxu@hotmail.com	Liu, Qiang/HHZ-3181-2022	Xu, Binghe/0000-0003-4195-337X; Liu, Qiang/0000-0002-5451-4862	Jiangsu Hengrui Pharmaceuticals	Jiangsu Hengrui Pharmaceuticals	This study was funded by Jiangsu Hengrui Pharmaceuticals (formerly Jiangsu Hengrui Medicine). This trial was designed by the principal investigator in collaboration with the sponsor. The sponsor was involved in data collection, analysis and interpretation and preparation of the manuscript. We thank all patients and their families and all members of the collaborative group in this trial. Medical writing support was provided by X. Wu (medical writer at Hengrui) according to good publication practice guidelines.	Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Iwata H, 2017, J GLOB ONCOL, V3, P289, DOI 10.1200/JGO.2016.008318; Long F, 2019, CANCER SCI, V110, P1420, DOI 10.1111/cas.13957; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Rugo HS, 2016, J CLIN ONCOL, V34, P3069, DOI 10.1200/JCO.2016.67.1487; Slamon DJ, 2020, NEW ENGL J MED, V382, P514, DOI 10.1056/NEJMoa1911149; Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909; Sledge GW, 2020, JAMA ONCOL, V6, P116, DOI 10.1001/jamaoncol.2019.4782; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Wang JY, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1231-7; Yap YS, 2016, ANN ONCOL, V27; Zhang P, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-021-00271-2	17	12	13	9	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1904	+		10.1038/s41591-021-01562-9	http://dx.doi.org/10.1038/s41591-021-01562-9		NOV 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34737452	Bronze			2022-12-27	WOS:000714498500001
J	Nauck, MA; Quast, DR; Meier, JJ				Nauck, Michael A.; Quast, Daniel R.; Meier, Juris J.			Another milestone in the evolution of GLP-1-based diabetes therapies	NATURE MEDICINE			English	Editorial Material							GLYCEMIC CONTROL	The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.	[Nauck, Michael A.; Quast, Daniel R.; Meier, Juris J.] Ruhr Univ Bochum, St Josef Hosp, Katholische Klinikum Bochum, Diabet Div, Bochum, Germany; [Meier, Juris J.] Augusta Kliniken, Dept Internal Med, Bochum, Germany	Ruhr University Bochum	Nauck, MA (corresponding author), Ruhr Univ Bochum, St Josef Hosp, Katholische Klinikum Bochum, Diabet Div, Bochum, Germany.	michael.nauck@rub.de	Nauck, Michael Albrecht/ABA-9752-2021; Quast, Daniel/ACT-9481-2022	Nauck, Michael Albrecht/0000-0002-5749-6954; Quast, Daniel/0000-0003-4357-6846				Davies M, 2017, JAMA-J AM MED ASSOC, V318, P1460, DOI 10.1001/jama.2017.14752; Gabery S, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133429; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; Kawai T, 2020, P NATL ACAD SCI USA, V117, P29959, DOI 10.1073/pnas.2014879117; Meier JJ, 2015, DIABETES CARE, V38, P1263, DOI 10.2337/dc14-1984; Nauck MA, 2020, MOL METAB, V46, DOI 10.1016/j.molmet.2020.101102; Nauck MA, 2019, EUR J ENDOCRINOL, V181, pR211, DOI 10.1530/EJE-19-0566; Nauck MA, 2020, METABOLISM, V103, DOI 10.1016/j.metabol.2019.154031; Nauck MA, 2011, DIABETES, V60, P1561, DOI 10.2337/db10-0474; Parker JC, 1998, J PEPT RES, V52, P398; Saxena AR, 2021, NAT MED, V27, P1079, DOI 10.1038/s41591-021-01391-w; Sloop KW, 2010, DIABETES, V59, P3099, DOI 10.2337/db10-0689	12	1	1	1	22	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					952	953		10.1038/s41591-021-01394-7	http://dx.doi.org/10.1038/s41591-021-01394-7		JUN 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34127851				2022-12-27	WOS:000661414900001
J	Bassez, A; Vos, H; Van Dyck, L; Floris, G; Arijs, I; Desmedt, C; Boeckx, B; Vanden Bempt, M; Nevelsteen, I; Lambein, K; Punie, K; Neven, P; Garg, AD; Wildiers, H; Qian, JB; Smeets, A; Lambrechts, D				Bassez, Ayse; Vos, Hanne; Van Dyck, Laurien; Floris, Giuseppe; Arijs, Ingrid; Desmedt, Christine; Boeckx, Bram; Vanden Bempt, Marlies; Nevelsteen, Ines; Lambein, Kathleen; Punie, Kevin; Neven, Patrick; Garg, Abhishek D.; Wildiers, Hans; Qian, Junbin; Smeets, Ann; Lambrechts, Diether			A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	NATURE MEDICINE			English	Article							DENDRITIC CELLS; B-CELLS; IMMUNOTHERAPY; IMMUNITY; CHEMOTHERAPY; LYMPHOCYTES; SURVIVAL; ASSAY	Transcriptomic and proteomic profiling of breast cancer biopsies identifies baseline features of the tumor immune microenvironment associated with T cell clonal expansion following neoadjuvant anti-PD-1 treatment. Immune-checkpoint blockade (ICB) combined with neoadjuvant chemotherapy improves pathological complete response in breast cancer. To understand why only a subset of tumors respond to ICB, patients with hormone receptor-positive or triple-negative breast cancer were treated with anti-PD1 before surgery. Paired pre- versus on-treatment biopsies from treatment-naive patients receiving anti-PD1 (n = 29) or patients receiving neoadjuvant chemotherapy before anti-PD1 (n = 11) were subjected to single-cell transcriptome, T cell receptor and proteome profiling. One-third of tumors contained PD1-expressing T cells, which clonally expanded upon anti-PD1 treatment, irrespective of tumor subtype. Expansion mainly involved CD8(+) T cells with pronounced expression of cytotoxic-activity (PRF1, GZMB), immune-cell homing (CXCL13) and exhaustion markers (HAVCR2, LAG3), and CD4(+) T cells characterized by expression of T-helper-1 (IFNG) and follicular-helper (BCL6, CXCR5) markers. In pre-treatment biopsies, the relative frequency of immunoregulatory dendritic cells (PD-L1(+)), specific macrophage phenotypes (CCR2(+) or MMP9(+)) and cancer cells exhibiting major histocompatibility complex class I/II expression correlated positively with T cell expansion. Conversely, undifferentiated pre-effector/memory T cells (TCF7(+), GZMK(+)) or inhibitory macrophages (CX3CR1(+), C3(+)) were inversely correlated with T cell expansion. Collectively, our data identify various immunophenotypes and associated gene sets that are positively or negatively correlated with T cell expansion following anti-PD1 treatment. We shed light on the heterogeneity in treatment response to anti-PD1 in breast cancer.	[Bassez, Ayse; Van Dyck, Laurien; Arijs, Ingrid; Boeckx, Bram; Lambrechts, Diether] Katholieke Univ Leuven, Dept Human Genet, Lab Translat Genet, Leuven, Belgium; [Bassez, Ayse; Van Dyck, Laurien; Arijs, Ingrid; Boeckx, Bram; Vanden Bempt, Marlies; Lambrechts, Diether] VIB Ctr Canc Biol, Leuven, Belgium; [Vos, Hanne; Nevelsteen, Ines; Lambein, Kathleen; Smeets, Ann] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Surg Oncol, Leuven, Belgium; [Floris, Giuseppe] Katholieke Univ Leuven, Dept Imaging & Pathol, Lab Translat Cell & Tissue Res, Leuven, Belgium; [Floris, Giuseppe] Katholieke Univ Leuven, Dept Pathol, Univ Hosp Leuven, Leuven, Belgium; [Desmedt, Christine] Katholieke Univ Leuven, Lab Translat Breast Canc Res, Dept Oncol, Leuven, Belgium; [Punie, Kevin; Wildiers, Hans] Katholieke Univ Leuven, Dept Gen Med Oncol, Univ Hosp Leuven, Leuven, Belgium; [Neven, Patrick] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gynaecol & Obstet, Leuven, Belgium; [Garg, Abhishek D.] Katholieke Univ Leuven, Dept Cellular & Mol Med, Lab Cell Stress & Immun, Leuven, Belgium; [Qian, Junbin] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Zhejiang University	Lambrechts, D (corresponding author), Katholieke Univ Leuven, Dept Human Genet, Lab Translat Genet, Leuven, Belgium.; Lambrechts, D (corresponding author), VIB Ctr Canc Biol, Leuven, Belgium.; Smeets, A (corresponding author), Katholieke Univ Leuven, Univ Hosp Leuven, Dept Surg Oncol, Leuven, Belgium.; Qian, JB (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China.	dr_qian@zju.edu.cn; Ann.Smeets@uzleuven.be; Diether.Lambrechts@vib-kuleuven.be	Bempt, Marlies Vanden/AAG-8277-2020; Punie, Kevin/AAP-9729-2021; Punie, Kevin/AAL-9232-2020; Lambrechts, Diether/AAJ-3167-2020; Floris, Giuseppe/AAG-6754-2022; Lambein, Kathleen/GXG-4830-2022; Garg, Abhishek/D-5230-2012; wildiers, hans/AAV-8158-2021; Floris, Giuseppe/AFL-6620-2022; Desmedt, Christine/P-7438-2017	Bempt, Marlies Vanden/0000-0003-0111-0263; Punie, Kevin/0000-0002-1162-7963; Lambrechts, Diether/0000-0002-3429-302X; Floris, Giuseppe/0000-0003-2391-5425; Garg, Abhishek/0000-0002-9976-9922; Floris, Giuseppe/0000-0003-2391-5425; Desmedt, Christine/0000-0002-5223-5579; Qian, Junbin/0000-0003-1483-1836; Vos, Hanne/0000-0002-4629-4812; Arijs, Ingrid/0000-0002-9415-083X; Bassez, Ayse/0000-0002-0432-1536	MSD grant; Kom op Tegen Kanker; Stichting Tegen Kanker; Flemish Fund for Scientific Research (FWO) [G0B6120N]; Agilent Technologies (Thought Leader award); Flemish Government under Management Agreement 2017-2021 [VR 2016 2312 doc.1521/4]; European Union's Horizon 2020 Research and Innovation Programme [847912]; KU Leuven grant [C14/18/092]; Research Foundation Flanders (FWO) [G0B4620N, 30837538]; KU Leuven (C1 grant) [C14/19/098]; KU Leuven (POR award funds) [POR/16/040]; Kom op Tegen Kanker/KOTK [KOTK/2018/11509/1]; aspirant FWO grant; Research Foundation-Flanders (FWO); Flemish Government (department EWI); Klinsche Onderzoek en OpleidingsRaad (KOOR) of the University Hospitals Leuven; Fonds Nadine De Beauffort	MSD grant; Kom op Tegen Kanker; Stichting Tegen Kanker; Flemish Fund for Scientific Research (FWO)(FWO); Agilent Technologies (Thought Leader award); Flemish Government under Management Agreement 2017-2021; European Union's Horizon 2020 Research and Innovation Programme; KU Leuven grant; Research Foundation Flanders (FWO)(FWO); KU Leuven (C1 grant); KU Leuven (POR award funds); Kom op Tegen Kanker/KOTK; aspirant FWO grant; Research Foundation-Flanders (FWO)(FWO); Flemish Government (department EWI); Klinsche Onderzoek en OpleidingsRaad (KOOR) of the University Hospitals Leuven; Fonds Nadine De Beauffort	The BioKey study was supported by an MSD grant to A.S., by Fonds Nadine De Beauffort to A. S., by a `Kom op Tegen Kanker' to A.S. and H.W., by the Stichting Tegen Kanker and the Flemish Fund for Scientific Research (FWO; project G0B6120N) Belgium, by Agilent Technologies (Thought Leader award) to D.L. This VIB Grand Challenges project also received support from the Flemish Government under Management Agreement 2017-2021 (VR 2016 2312 doc.1521/4), from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no. 847912 (RESCUER) and from KU Leuven grant (C14/18/092) Symbiosys3. A.D.G. acknowledges financial support from the Research Foundation Flanders (FWO; Fundamental Research grant, G0B4620N; Excellence of Science/EOS grant, 30837538, for `DECODE' consortium), KU Leuven (C1 grant, C14/19/098; POR award funds, POR/16/040) and Kom op Tegen Kanker/KOTK (KOTK/2018/11509/1). L.V.D. was supported by an aspirant FWO grant. G.F. is recipient of a post-doctoral mandate from the Klinsche Onderzoek en OpleidingsRaad (KOOR) of the University Hospitals Leuven. The computational resources and services used in this work were provided by the VSC (Flemish Supercomputer Center), funded by the Research Foundation-Flanders (FWO) and the Flemish Government (department EWI). None of these funders had a role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank T. Van Brussel and R. Schepers for technical assistance.	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Bachelot T, 2021, NAT MED, V27, P250, DOI 10.1038/s41591-020-01189-2; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Bergen V, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0591-3; Boeckx B, 2020, INT J CANCER, V146, P3207, DOI 10.1002/ijc.32797; Bolotin DA, 2017, NAT BIOTECHNOL, V35, P908, DOI 10.1038/nbt.3979; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chow MT, 2019, IMMUNITY, V50, P1498, DOI 10.1016/j.immuni.2019.04.010; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586-018-0615-z; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1259, DOI 10.5858/arpa.2015-0544-OA; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Emancipator K, 2021, AAPS J, V23, DOI 10.1208/s12248-020-00525-1; Fairfax BP, 2020, NAT MED, V26, P193, DOI 10.1038/s41591-019-0734-6; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Fu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03059; Gubin MM, 2018, CELL, V175, P1014, DOI 10.1016/j.cell.2018.09.030; Gulley JL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw261; Hart KM, 2009, NEOPLASIA, V11, P564, DOI 10.1593/neo.09228; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Jackson SH, 2004, J IMMUNOL, V172, P2307, DOI 10.4049/jimmunol.172.4.2307; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korbecki J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103723; Kwak JW, 2018, CANCER RES, V78, P143, DOI 10.1158/0008-5472.CAN-17-0240; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lau CM, 2018, J EXP MED, V215, P2265, DOI 10.1084/jem.20172323; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Loibl S, 2019, ANN ONCOL, V30, P1279, DOI 10.1093/annonc/mdz158; Lopez-Abaitero A, 2009, J IMMUNOTHER, V32, P465, DOI 10.1097/CJI.0b013e3181a1c24e; Lorenzo-Herrero S, 2019, METHODS MOL BIOL, V1884, P119, DOI 10.1007/978-1-4939-8885-3_7; Maier B, 2020, NATURE, V580, P257, DOI 10.1038/s41586-020-2134-y; Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Qian JB, 2020, CELL RES, V30, P745, DOI 10.1038/s41422-020-0355-0; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Schmid P, 2020, ANN ONCOL, V31, P569, DOI 10.1016/j.annonc.2020.01.072; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Schmid P, 2020, LANCET ONCOL, V21, P44, DOI 10.1016/S1470-2045(19)30689-8; Shan Q, 2017, NAT IMMUNOL, V18, P931, DOI 10.1038/ni.3773; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/nmeth.4380, 10.1038/NMETH.4380]; Street K, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4772-0; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thomas PG, 2013, P NATL ACAD SCI USA, V110, P1839, DOI 10.1073/pnas.1222149110; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valpione S, 2020, NAT CANCER, V1, P210, DOI 10.1038/s43018-019-0022-x; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Vignesh KS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102197; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wagner J, 2019, CELL, V177, P1330, DOI 10.1016/j.cell.2019.03.005; Wauters E, 2021, CELL RES, V31, P272, DOI 10.1038/s41422-020-00455-9; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zha HR, 2019, CANCER IMMUNOL RES, V7, P193, DOI 10.1158/2326-6066.CIR-18-0272; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x; Zheng J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-141; Zhu W, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1051922	70	103	103	27	87	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					820	+		10.1038/s41591-021-01323-8	http://dx.doi.org/10.1038/s41591-021-01323-8		MAY 2021	40	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33958794				2022-12-27	WOS:000647954500001
J	Puttaraju, M; Jackson, M; Klein, S; Shilo, A; Bennett, CF; Gordon, L; Rigo, F; Misteli, T				Puttaraju, Madaiah; Jackson, Michaela; Klein, Stephanie; Shilo, Asaf; Bennett, C. Frank; Gordon, Leslie; Rigo, Frank; Misteli, Tom			Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome	NATURE MEDICINE			English	Article								Hutchinson-Gilford progeria syndrome (HGPS) is a rare, invariably fatal childhood premature aging disorder caused by a pre-messenger RNA (mRNA) splicing defect in the LMNA gene. We used combined in vitro screening and in vivo validation to systematically explore the effects of target sequence, backbone chemistry and mechanism of action to identify optimized antisense oligonucleotides (ASOs) for therapeutic use in HGPS. In a library of 198 ASOs, the most potent ASOs targeted the LMNA exon 12 junction and acted via non-RNase H-mediated mechanisms. Treatment with an optimized lead candidate resulted in extension of lifespan in a mouse model of HGPS. Progerin mRNA levels were robustly reduced in vivo, but the extent of progerin protein reduction differed between tissues, suggesting a long half-life and tissue-specific turnover of progerin in vivo. These results identify a novel therapeutic agent for HGPS and provide insight into the HGPS disease mechanism. Optimized antisense oligonucleotides that can reduce progerin tissue expression in vivo pave the way for development of a novel therapeutic approach for Hutchinson-Gilford progeria syndrome.	[Puttaraju, Madaiah; Shilo, Asaf; Misteli, Tom] NCI, NIH, Bethesda, MD 20892 USA; [Jackson, Michaela; Klein, Stephanie; Bennett, C. Frank; Rigo, Frank] Ionis Pharmaceut, Carlsbad, CA USA; [Gordon, Leslie] Brown Univ, Dept Pediat, Hasbro Childrens Hosp, Div Genet, Providence, RI 02912 USA; [Gordon, Leslie] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Gordon, Leslie] Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA; [Gordon, Leslie] Harvard Med Sch, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ionis Pharmaceuticals, Inc.; Brown University; Hasbro Children's Hospital; Brown University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Misteli, T (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov	Gordon, Leslie B./AAJ-5793-2021; shilo, asaf/GUR-9562-2022	Misteli, Tom/0000-0003-3530-3020				Bennett CF, 2019, ANNU REV MED, V70, P307, DOI 10.1146/annurev-med-041217-010829; Blondel S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.374; Buchwalter A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00322-z; Chappell AE, 2020, NUCLEIC ACIDS RES, V48, P4382, DOI 10.1093/nar/gkaa164; Clements CS, 2019, BIOGERONTOLOGY, V20, P337, DOI 10.1007/s10522-019-09807-4; Cubria MB, 2020, P NATL ACAD SCI USA, V117, P12029, DOI 10.1073/pnas.1906713117; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; DuBose AJ, 2018, P NATL ACAD SCI USA, V115, P4206, DOI 10.1073/pnas.1802811115; Erdos MR, 2021, NAT MED, V27, P536, DOI 10.1038/s41591-021-01274-0; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Fong LG, 2009, HUM MOL GENET, V18, P2462, DOI 10.1093/hmg/ddp184; Gabriel D, 2017, ONCOTARGET, V8, P64809, DOI 10.18632/oncotarget.19363; Gabriel D, 2015, AGING CELL, V14, P78, DOI 10.1111/acel.12300; Goodchild A, 2007, NUCLEIC ACIDS RES, V35, P4562, DOI 10.1093/nar/gkm465; Gordon LB, 2018, JAMA-J AM MED ASSOC, V319, P1687, DOI 10.1001/jama.2018.3264; Gordon LB, 2016, EMBO MOL MED, V8, P685, DOI 10.15252/emmm.201606280; Gordon LB, 2014, CELL, V156, P400, DOI 10.1016/j.cell.2013.12.028; Gordon LB, 2012, P NATL ACAD SCI USA, V109, P16666, DOI 10.1073/pnas.1202529109; Guilbert SM, 2021, METHODS, V190, P3, DOI 10.1016/j.ymeth.2020.04.005; Hua YM, 2007, PLOS BIOL, V5, P729, DOI 10.1371/journal.pbio.0050073; Kreienkamp R, 2016, ONCOTARGET, V7, P30018, DOI 10.18632/oncotarget.9065; Kubben N, 2016, METHODS, V96, P46, DOI 10.1016/j.ymeth.2015.08.024; Larrieu D, 2014, SCIENCE, V344, P527, DOI 10.1126/science.1252651; Lee JM, 2016, J CLIN INVEST, V126, P1592, DOI 10.1172/JCI85908; Lee SJ, 2016, J CLIN INVEST, V126, P3879, DOI 10.1172/JCI84164; Lo Cicero A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34798; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Ostergaard ME, 2019, NUCLEIC ACIDS RES, V47, P6045, DOI 10.1093/nar/gkz360; Passini MA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001777; Pellegrini C, 2015, ONCOTARGET, V6, P29914, DOI 10.18632/oncotarget.4939; Rigo F, 2012, NAT CHEM BIOL, V8, P555, DOI [10.1038/nchembio.939, 10.1038/NCHEMBIO.939]; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Shilo A, 2019, NUCLEIC ACIDS RES, V47, P5922, DOI 10.1093/nar/gkz259; Skotte NH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107434; Toyama BH, 2013, CELL, V154, P971, DOI 10.1016/j.cell.2013.07.037; Toyama BH, 2013, NAT REV MOL CELL BIO, V14, P55, DOI 10.1038/nrm3496; Ullrich Nicole J, 2015, Handb Clin Neurol, V132, P249, DOI 10.1016/B978-0-444-62702-5.00018-4; Varga R, 2006, P NATL ACAD SCI USA, V103, P3250, DOI 10.1073/pnas.0600012103; Xiong ZM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02419-3	42	16	16	1	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					526	+		10.1038/s41591-021-01262-4	http://dx.doi.org/10.1038/s41591-021-01262-4		MAR 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33707772				2022-12-27	WOS:000627662000001
J	McNutt, M; Castillo-Page, L				McNutt, Marcia; Castillo-Page, Laura			Promoting diversity and inclusion in STEMM starts at the top	NATURE MEDICINE			English	Editorial Material									[McNutt, Marcia; Castillo-Page, Laura] Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA; [Castillo-Page, Laura] Natl Acad Engn, Washington, DC 20418 USA; [Castillo-Page, Laura] Natl Acad Med, Washington, DC USA	National Academies of Sciences, Engineering & Medicine; National Academies of Sciences, Engineering & Medicine; National Academies of Sciences, Engineering & Medicine	McNutt, M (corresponding author), Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA.	naspresident@nas.edu						[Anonymous], 2021, NATL AC SCI ENG MED; [Anonymous], 2018, NATL AC SCI ENG MED, DOI [10.17226/24994, DOI 10.17226/24994]; [Anonymous], 2020, NATL AC SCI ENG MED, DOI [10.17226/25585, DOI 10.17226/25585]; [Anonymous], 2021, NATL ACAD SCI ENG ME, DOI [10.17226/26061(2021, DOI 10.17226/26061(2021]; Capers Q, J AM HEART ASSOC, DOI [10.1161/JAHA.120.018893(2021, DOI 10.1161/JAHA.120.018893(2021]; Clark US, 2020, NAT HUM BEHAV, V4, P774, DOI 10.1038/s41562-020-0917-7; Fair MA, 2021, SCIENCE, V372, P348, DOI 10.1126/science.abf6738; Swartz TH, 2019, J INFECT DIS, V220, pS33, DOI 10.1093/infdis/jiz174; Thompson H. S., JAMA NETW OPEN, DOI [10.1001/jamanetworkopen.2021.11629(2021), DOI 10.1001/JAMANETWORKOPEN.2021.11629(2021)]	9	3	3	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1864	1865		10.1038/s41591-021-01496-2	http://dx.doi.org/10.1038/s41591-021-01496-2		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764487	Bronze			2022-12-27	WOS:000717406200006
J	Forde, PM; Anagnostou, V; Sun, ZX; Dahlberg, SE; Kindler, HL; Niknafs, N; Purcell, T; Santana-Davila, R; Dudek, AZ; Borghaei, H; Lanis, M; Belcaid, Z; Smith, KN; Balan, A; White, JR; Cherry, C; Sivakumar, IKA; Shao, XM; Chan, HY; Singh, D; Thapa, S; Illei, PB; Pardoll, DM; Karchin, R; Velculescu, VE; Brahmer, JR; Ramalingam, SS				Forde, Patrick M.; Anagnostou, Valsamo; Sun, Zhuoxin; Dahlberg, Suzanne E.; Kindler, Hedy L.; Niknafs, Noushin; Purcell, Thomas; Santana-Davila, Rafael; Dudek, Arkadiusz Z.; Borghaei, Hossein; Lanis, Mara; Belcaid, Zineb; Smith, Kellie N.; Balan, Archana; White, James R.; Cherry, Christopher; Sivakumar, I. K. Ashok; Shao, Xiaoshan M.; Chan, Hok Yee; Singh, Dipika; Thapa, Sampriti; Illei, Peter B.; Pardoll, Drew M.; Karchin, Rachel; Velculescu, Victor E.; Brahmer, Julie R.; Ramalingam, Suresh S.			Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial	NATURE MEDICINE			English	Article							IMMUNE CHECKPOINT BLOCKADE; GERMLINE BAP1 MUTATIONS; OPEN-LABEL; SOMATIC MUTATIONS; CLASS-I; ASBESTOS; TUMOR; MULTICENTER; CISPLATIN; SAFETY	Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial (NCT02899195) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma.	[Forde, Patrick M.; Anagnostou, Valsamo; Niknafs, Noushin; Lanis, Mara; Belcaid, Zineb; Smith, Kellie N.; Balan, Archana; White, James R.; Cherry, Christopher; Chan, Hok Yee; Singh, Dipika; Thapa, Sampriti; Illei, Peter B.; Pardoll, Drew M.; Karchin, Rachel; Velculescu, Victor E.; Brahmer, Julie R.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD 21205 USA; [Forde, Patrick M.; Anagnostou, Valsamo; Smith, Kellie N.; Chan, Hok Yee; Singh, Dipika; Thapa, Sampriti; Pardoll, Drew M.; Velculescu, Victor E.; Brahmer, Julie R.] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sch Med, Baltimore, MD 21205 USA; [Sun, Zhuoxin] ECOG ACRIN Biostat Ctr, Boston, MA USA; [Sun, Zhuoxin] Frontier Sci Fdn, Boston, MA USA; [Dahlberg, Suzanne E.] Boston Childrens Hosp, Boston, MA USA; [Kindler, Hedy L.] Univ Chicago Med, Chicago, IL USA; [Purcell, Thomas; Santana-Davila, Rafael] Univ Washington, Sch Med, Seattle, WA USA; [Purcell, Thomas; Santana-Davila, Rafael] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Dudek, Arkadiusz Z.] Metrominnesota Community Oncol Res Consortium, St Louis Pk, MN USA; [Borghaei, Hossein] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Sivakumar, I. K. Ashok; Shao, Xiaoshan M.; Karchin, Rachel] Johns Hopkins Univ, Inst Computat Med, Baltimore, MD USA; [Shao, Xiaoshan M.; Karchin, Rachel; Velculescu, Victor E.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Illei, Peter B.; Velculescu, Victor E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Ramalingam, Suresh S.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Frontier Science Foundation; Harvard University; Boston Children's Hospital; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fox Chase Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University	Forde, PM; Anagnostou, V (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD 21205 USA.; Forde, PM; Anagnostou, V (corresponding author), Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sch Med, Baltimore, MD 21205 USA.	pforde1@jhmi.edu; vanagno1@jhmi.edu	Dudek, Arkadiusz Zbigniew/HGD-1339-2022; Karchin, Rachel/AFO-2592-2022	Dudek, Arkadiusz Zbigniew/0000-0002-9114-8945; Forde, Patrick/0000-0001-6925-6344; Anagnostou, Valsamo/0000-0001-9480-3047; Karchin, Rachel/0000-0002-5069-1239	AstraZeneca; PrECOG; Johns Hopkins SKCCC core grant [NCI CCSG P30 CA006973]; Department of Defense Congressionally Directed Medical Research Programs [CA190755]; National Institutes of Health [CA121113, CA006973, R37CA251447]; ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center [UG1CA233259]; Bloomberg-Kimmel Institute for Cancer Immunotherapy; V Foundation; IASLC Foundation; Lung Cancer Foundation of America; Swim Across America; Florence Lomax Eley Fund; LUNGevity Foundation	AstraZeneca(AstraZeneca); PrECOG; Johns Hopkins SKCCC core grant; Department of Defense Congressionally Directed Medical Research Programs(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center; Bloomberg-Kimmel Institute for Cancer Immunotherapy; V Foundation; IASLC Foundation; Lung Cancer Foundation of America; Swim Across America; Florence Lomax Eley Fund; LUNGevity Foundation	We would like to thank G. Pereira and A. Curry in the Upper Aerodigestive Biorepository for sample procurement and members of the SKCCC FEST and TCR Immunogenomics Core Facility for assistance with the MANAFEST assays. The PrE0505 clinical trial was sponsored by AstraZeneca and PrECOG. This work was supported, in part, by Johns Hopkins SKCCC core grant NCI CCSG P30 CA006973, Department of Defense Congressionally Directed Medical Research Programs grant CA190755 (V.A. and P.M.F.), National Institutes of Health grants CA121113 (V.A. and V.V.), CA006973 (V.V.) and R37CA251447 (K.N.S.), ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center grant UG1CA233259 (V.A., V.V., Z.S. and S.R.), the Bloomberg-Kimmel Institute for Cancer Immunotherapy (V.A, P.M.F. and K.N.S.), the V Foundation (V.A. and V.V.), the IASLC Foundation (K.N.S), the Lung Cancer Foundation of America (K.N.S.), Swim Across America (V.A. and K.N.S.), the Florence Lomax Eley Fund (V.A., P.M.F. and J.B.) and the LUNGevity Foundation (V.A., V.V. and K.N.S.).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alley EW, 2017, LANCET ONCOL, V18, P623, DOI 10.1016/S1470-2045(17)30169-9; Anagnostou V, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100139; Anagnostou V, 2020, NAT CANCER, V1, P99, DOI 10.1038/s43018-019-0008-8; Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Baas P, 2021, LANCET, V397, P375, DOI 10.1016/S0140-6736(20)32714-8; Baumann F, 2015, CARCINOGENESIS, V36, P76, DOI 10.1093/carcin/bgu227; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bononi A, 2020, P NATL ACAD SCI USA, V117, P33466, DOI 10.1073/pnas.2019652117; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Cao HP, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0076946, 10.1371/journal.pone.0052853]; Carbone M, 2020, CANCER DISCOV, V10, P1103, DOI 10.1158/2159-8290.CD-19-1220; Carbone M, 2020, NAT REV CANCER, V20, P533, DOI 10.1038/s41568-020-0265-y; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Chowell D, 2019, NAT MED, V25, P1715, DOI 10.1038/s41591-019-0639-4; Danilova L, 2018, CANCER IMMUNOL RES, V6, P888, DOI 10.1158/2326-6066.CIR-18-0129; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Ellrott K, 2018, CELL SYST, V6, P271, DOI 10.1016/j.cels.2018.03.002; Fennell DA, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2602-y; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Hassan R, 2019, P NATL ACAD SCI USA, V116, P9008, DOI 10.1073/pnas.1821510116; Hmeljaki J, 2018, CANCER DISCOV, V8, P1548, DOI 10.1158/2159-8290.CD-18-0804; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Jones S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7161; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Krug LM, 2014, LUNG CANCER, V85, P429, DOI 10.1016/j.lungcan.2014.06.008; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mansfield AS, 2019, J THORAC ONCOL, V14, P276, DOI 10.1016/j.jtho.2018.10.001; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; Napolitano A, 2016, ONCOGENE, V35, P1996, DOI 10.1038/onc.2015.243; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Niknafs N, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004416; Nowak AK, 2020, LANCET ONCOL, V21, P1213, DOI 10.1016/S1470-2045(20)30462-9; Odgerel CO, 2017, OCCUP ENVIRON MED, V74, P851, DOI 10.1136/oemed-2017-104298; Okada M, 2019, CLIN CANCER RES, V25, P5485, DOI 10.1158/1078-0432.CCR-19-0103; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pagel KA, 2020, JCO CLIN CANCER INFO, V4, P310, DOI 10.1200/CCI.19.00132; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Panou V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124327; Panou V, 2018, J CLIN ONCOL, V36, P2863, DOI 10.1200/JCO.2018.78.5204; Quispel-Janssen J, 2018, J THORAC ONCOL, V13, P1569, DOI 10.1016/j.jtho.2018.05.038; Robert C, 2020, NAT REV CLIN ONCOL, V17, P707, DOI 10.1038/s41571-020-0399-6; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Samstein RM, 2020, NAT CANCER, V1, P1188, DOI 10.1038/s43018-020-00139-8; Scagliotti GV, 2019, LANCET RESP MED, V7, P569, DOI 10.1016/S2213-2600(19)30139-0; Shao XM, 2020, CANCER IMMUNOL RES, V8, P396, DOI 10.1158/2326-6066.CIR-19-0464; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Sztupinszki Z, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0066-6; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tsao AS, 2019, J CLIN ONCOL, V37, P2537, DOI 10.1200/JCO.19.00269; Tsao AS, 2011, J THORAC ONCOL, V6, P598, DOI 10.1097/JTO.0b013e318208c83d; Tweedale G, 2002, NAT REV CANCER, V2, P311, DOI 10.1038/nrc774; Venkatesan S, 2018, ANN ONCOL, V29, P563, DOI 10.1093/annonc/mdy003; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wang T, 2018, CANCER DISCOV, V8, P1142, DOI 10.1158/2159-8290.CD-17-1246; Xie C, 2017, P NATL ACAD SCI USA, V114, P8059, DOI 10.1073/pnas.1707945114; Zalcman G, 2016, LANCET, V387, P1405, DOI 10.1016/S0140-6736(15)01238-6; Zhang JJ, 2019, METHOD ENZYMOL, V629, P443, DOI 10.1016/bs.mie.2019.08.006; Zhang M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21798-w	69	23	24	1	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1910	+		10.1038/s41591-021-01541-0	http://dx.doi.org/10.1038/s41591-021-01541-0		NOV 2021	33	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34750557	Green Published, hybrid			2022-12-27	WOS:000715714300006
J	Kataria, I				Kataria, Ishu			Youth priorities for global health	NATURE MEDICINE			English	Editorial Material								Young people must be involved in setting the global health agenda.	[Kataria, Ishu] RTI Int, Ctr Global Noncommunicable Dis, New Delhi, India	Research Triangle Institute	Kataria, I (corresponding author), RTI Int, Ctr Global Noncommunicable Dis, New Delhi, India.	ikataria@rti.org		Kataria, Ishu/0000-0002-8483-8243					0	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1497	1497		10.1038/s41591-021-01474-8	http://dx.doi.org/10.1038/s41591-021-01474-8		SEP 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34518680	Bronze			2022-12-27	WOS:000695470700001
J	Bentzen, HB; Castro, R; Fears, R; Griffin, G; ter Meulen, V; Ursin, G				Bentzen, Heidi Beate; Castro, Rosa; Fears, Robin; Griffin, George; ter Meulen, Volker; Ursin, Giske			Remove obstacles to sharing health data with researchers outside of the European Union	NATURE MEDICINE			English	Editorial Material								COVID-19 has shown that international collaborations and global data sharing are essential for health research, but legal obstacles are preventing data sharing for non-pandemic-related research among public researchers across the world, with potentially damaging effects for citizens and patients.	[Bentzen, Heidi Beate] Univ Oslo, Fac Law, Norwegian Res Ctr Comp & Law, Oslo, Norway; [Bentzen, Heidi Beate; Ursin, Giske] Canc Registry Norway, Oslo, Norway; [Castro, Rosa] Federat European Acad Med, Brussels, Belgium; [Fears, Robin; ter Meulen, Volker] German Natl Acad Sci Leopoldina, European Acad Sci Advisory Council, Halle, Germany; [Griffin, George] St Georges Univ London, Dept Infect Dis & Med, London, England; [Ursin, Giske] Univ Oslo, Inst Basic Med Sci, Oslo, Norway; [Ursin, Giske] Univ Southern Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA USA	University of Oslo; University of Oslo; St Georges University London; University of Oslo; University of Southern California	Castro, R (corresponding author), Federat European Acad Med, Brussels, Belgium.	rosa.castro@feam.eu		Bentzen, Heidi Beate/0000-0001-8285-818X	European Academies Science Advisory Council; Federation of European Academies of Medicine	European Academies Science Advisory Council; Federation of European Academies of Medicine	We acknowledge the support of the European Academies Science Advisory Council, the Federation of European Academies of Medicine, and All European Academies, as well as all members of the working group that contributed to writing the joint report3.	Bovenberg J, 2020, SCIENCE, V370, P40, DOI 10.1126/science.abd2499; Court of Justice of the European Union, 2020, INFOCURIA CASE LAW; Eiss R, 2020, NATURE, V584, P498, DOI [10.1038/d41586-020-02454-7, 10.1038/d41586-020-02324-2]; European Union, 2016, EUR LEX; European Union, 2012, EUR LEX; Peloquin D, 2020, EUR J HUM GENET, V28, P697, DOI 10.1038/s41431-020-0596-x; Rabesandratana T, 2019, SCI AAAS, DOI [10.1126/science.aba2926, DOI 10.1126/SCIENCE.ABA2926]; Richter G, 2019, EUR J HUM GENET, V27, P841, DOI 10.1038/s41431-019-0340-6; Scheibner J, 2021, J MED INTERNET RES, V23, DOI 10.2196/25120; Shilo S, 2020, NAT MED, V26, P29, DOI 10.1038/s41591-019-0727-5; Ursin G, 2019, LANCET, V394, P1902, DOI 10.1016/S0140-6736(19)32633-9; Wilkinson Mark D, 2016, Sci Data, V3, P160018, DOI 10.1038/sdata.2016.18	12	8	8	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1329	1333		10.1038/s41591-021-01460-0	http://dx.doi.org/10.1038/s41591-021-01460-0		AUG 2021	5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34345050	Green Published, Bronze, Green Accepted			2022-12-27	WOS:000680784600001
J	Vogl, T; Klompus, S; Leviatan, S; Kalka, IN; Weinberger, A; Wijmenga, C; Fu, JY; Zhernakova, A; Weersma, RK; Segal, E				Vogl, Thomas; Klompus, Shelley; Leviatan, Sigal; Kalka, Iris N.; Weinberger, Adina; Wijmenga, Cisca; Fu, Jingyuan; Zhernakova, Alexandra; Weersma, Rinse K.; Segal, Eran			Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota	NATURE MEDICINE			English	Article							MEMORY B-CELLS; RESPONSES; BACTERIA; DYSBIOSIS; INFECTION; INNATE; DRIVES	Serum antibodies can recognize both pathogens and commensal gut microbiota. However, our current understanding of antibody repertoires is largely based on DNA sequencing of the corresponding B-cell receptor genes, and actual bacterial antigen targets remain incompletely characterized. Here we have profiled the serum antibody responses of 997 healthy individuals against 244,000 rationally selected peptide antigens derived from gut microbiota and pathogenic and probiotic bacteria. Leveraging phage immunoprecipitation sequencing (PhIP-Seq) based on phage-displayed synthetic oligo libraries, we detect a wide breadth of individual-specific as well as shared antibody responses against microbiota that associate with age and gender. We also demonstrate that these antibody epitope repertoires are more longitudinally stable than gut microbiome species abundances. Serum samples of more than 200 individuals collected five years apart could be accurately matched and could serve as an immunologic fingerprint. Overall, our results suggest that systemic antibody responses provide a non-redundant layer of information about microbiota beyond gut microbial species composition. Phage immunoprecipitation sequencing illustrates the wide breadth of systemic microbiota-specific antibody responses, which are more longitudinally stable than gut microbiome species abundances in a cohort of healthy individuals.	[Vogl, Thomas; Klompus, Shelley; Leviatan, Sigal; Kalka, Iris N.; Weinberger, Adina; Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel; [Vogl, Thomas; Klompus, Shelley; Leviatan, Sigal; Kalka, Iris N.; Weinberger, Adina; Segal, Eran] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Wijmenga, Cisca; Fu, Jingyuan; Zhernakova, Alexandra] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Fu, Jingyuan] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands; [Weersma, Rinse K.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands	Weizmann Institute of Science; Weizmann Institute of Science; University of Groningen; University of Groningen; University of Groningen	Weinberger, A; Segal, E (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel.; Weinberger, A; Segal, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.	adina.weinberger@weizmann.ac.il; eran.segal@weizmann.ac.il	Weersma, Rinse/ABE-3807-2021; Vogl, Thomas/AAY-1434-2021; Fu, Jingyuan/ABE-6868-2020; Zhernakova, Alexandra/ABA-9372-2020	Fu, Jingyuan/0000-0001-5578-1236; Segal, Eran/0000-0002-6859-1164; Wijmenga, Cisca/0000-0002-5635-1614; Weinberger, Adina/0000-0003-2231-4687; Kalka, Iris/0000-0001-9375-2946; Peled-Leviatan, Sigal/0000-0003-2675-3257; Vogl, Thomas/0000-0002-3892-1740	European Research Council; Israel Science Foundation; Seerave Foundation; Austrian Science Fund (FWF, Erwin Schrodinger fellowship) [J4256]; Netherlands Organization for Scientific Research; ERC [715772]; Netherlands Organization for Scientific Research NWO-VIDI grant [016.178.056]; Netherlands Heart Foundation CVON grant [2018-27]; NWO Gravitation grant Exposome [NL 024.004.017]; NWO Gravitation Netherlands Organ-on-Chip Initiative [024.003.001]; ERC Consolidator grant [101001678]; NWO Gravitation grant [024.003.001]; NWO Spinoza Prize [SPI 92-266]	European Research Council(European Research Council (ERC)European Commission); Israel Science Foundation(Israel Science Foundation); Seerave Foundation; Austrian Science Fund (FWF, Erwin Schrodinger fellowship)(Austrian Science Fund (FWF)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); ERC(European Research Council (ERC)European Commission); Netherlands Organization for Scientific Research NWO-VIDI grant(Netherlands Organization for Scientific Research (NWO)); Netherlands Heart Foundation CVON grant; NWO Gravitation grant Exposome; NWO Gravitation Netherlands Organ-on-Chip Initiative; ERC Consolidator grant(European Research Council (ERC)); NWO Gravitation grant; NWO Spinoza Prize	A.W. is the Louis H. Sackin Research Fellow Chair in Computer Science. E.S. is supported by grants from the European Research Council, the Israel Science Foundation and by the Seerave Foundation. T.V. gratefully acknowledges support from the Austrian Science Fund (FWF, Erwin Schrodinger fellowship J4256). R.K.W. is supported by the Seerave Foundation and the Netherlands Organization for Scientific Research. A.Z. is supported by ERC Starting Grant 715772, the Netherlands Organization for Scientific Research NWO-VIDI grant 016.178.056, the Netherlands Heart Foundation CVON grant 2018-27 and the NWO Gravitation grant ExposomeNL 024.004.017. J.F. is supported by NWO Gravitation Netherlands Organ-on-Chip Initiative (024.003.001), ERC Consolidator grant 101001678 and the Netherlands Heart Foundation CVON grant 2018-27. C.W. is supported by NWO Gravitation grant 024.003.001 and NWO Spinoza Prize SPI 92-266. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Babu M, 2018, NAT BIOTECHNOL, V36, P103, DOI 10.1038/nbt.4024; Bashford-Rogers RJM, 2019, NATURE, V574, P122, DOI 10.1038/s41586-019-1595-3; Berglund L, 2008, PROTEIN SCI, V17, P606, DOI 10.1110/ps.073347208; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Bunker JJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9356; Bunker JJ, 2018, IMMUNITY, V49, P211, DOI 10.1016/j.immuni.2018.08.011; Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007; Chen K, 2020, NAT REV IMMUNOL, V20, P427, DOI 10.1038/s41577-019-0261-1; Chen LH, 2016, NUCLEIC ACIDS RES, V44, pD694, DOI 10.1093/nar/gkv1239; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Cohen D, 2014, EPIDEMIOL INFECT, V142, P2583, DOI 10.1017/S0950268814000260; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Fadlallah J, 2019, J ALLERGY CLIN IMMUN, V143, P1575, DOI 10.1016/j.jaci.2018.09.036; Forsstrom B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121673; Forsstrom B, 2014, MOL CELL PROTEOMICS, V13, P1585, DOI 10.1074/mcp.M113.033308; Gilbert JA, 2018, NAT MED, V24, P392, DOI 10.1038/nm.4517; Gotz S, 2008, NUCLEIC ACIDS RES, V36, P3420, DOI 10.1093/nar/gkn176; Klotz C, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01908-2; Koch MA, 2016, CELL, V165, P827, DOI 10.1016/j.cell.2016.04.055; Korem T, 2017, CELL METAB, V25, P1243, DOI 10.1016/j.cmet.2017.05.002; Landsverk OJB, 2017, J EXP MED, V214, P309, DOI 10.1084/jem.20161590; Larman HB, 2013, J AUTOIMMUN, V43, P1, DOI 10.1016/j.jaut.2013.01.013; Larman HB, 2011, NAT BIOTECHNOL, V29, P535, DOI 10.1038/nbt.1856; Lebeer S, 2018, CURR OPIN BIOTECH, V49, P217, DOI 10.1016/j.copbio.2017.10.007; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Li H, 2020, NATURE, V584, P274, DOI 10.1038/s41586-020-2564-6; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Lindner C, 2015, NAT IMMUNOL, V16, P880, DOI 10.1038/ni.3213; Magri G, 2017, IMMUNITY, V47, P118, DOI 10.1016/j.immuni.2017.06.013; Mattock E, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00064; McCoy KD, 2019, IMMUNOL CELL BIOL, V97, P625, DOI 10.1111/imcb.12273; Meng WZ, 2017, NAT BIOTECHNOL, V35, P879, DOI 10.1038/nbt.3942; Mina MJ, 2019, SCIENCE, V366, P599, DOI 10.1126/science.aay6485; Mohan D, 2018, NAT PROTOC, V13, P1958, DOI 10.1038/s41596-018-0025-6; Moor K, 2016, NAT PROTOC, V11, P1531, DOI 10.1038/nprot.2016.091; Palm NW, 2014, CELL, V158, P1000, DOI 10.1016/j.cell.2014.08.006; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Paull ML, 2018, CURR OPIN CHEM ENG, V19, P21, DOI 10.1016/j.coche.2017.12.001; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Rothschild D., 2020, ATLAS ROBUST MICROBI, DOI 10.1101/2020.05.28.122325; Rothschild D, 2018, NATURE, V555, P210, DOI 10.1038/nature25973; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8; Spitzer M, 2014, NAT METHODS, V11, P121, DOI 10.1038/nmeth.2811; Sterlin D, 2020, MUCOSAL IMMUNOL, V13, P3, DOI 10.1038/s41385-019-0192-y; Thevaranjan N, 2017, CELL HOST MICROBE, V21, P455, DOI 10.1016/j.chom.2017.03.002; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Ultsch M, 2017, PROTEIN ENG DES SEL, V30, P619, DOI 10.1093/protein/gzx029; Vazquez SE, 2020, ELIFE, V9, DOI 10.7554/eLife.55053; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; Wilmore JR, 2018, CELL HOST MICROBE, V23, P302, DOI 10.1016/j.chom.2018.01.005; Wilms E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57106-2; Wozniak JM, 2020, CELL, V182, P1311, DOI 10.1016/j.cell.2020.07.040; Xu GJ, 2016, P NATL ACAD SCI USA, V113, pE7526, DOI 10.1073/pnas.1615990113; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698; Zeevi D, 2019, NATURE, V568, P43, DOI 10.1038/s41586-019-1065-y; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zeng MY, 2016, IMMUNITY, V44, P647, DOI 10.1016/j.immuni.2016.02.006	61	13	14	2	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1442	+		10.1038/s41591-021-01409-3	http://dx.doi.org/10.1038/s41591-021-01409-3		JUL 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34282338	Green Published			2022-12-27	WOS:000674558700001
J	Liu, D; Lin, JR; Robitschek, EJ; Kasumova, GG; Heyde, A; Shi, A; Kraya, A; Zhang, G; Moll, T; Frederick, DT; Chen, YA; Wang, S; Schapiro, D; Ho, LL; Bi, K; Sahu, A; Mei, SL; Miao, BC; Sharova, T; Alvarez-Breckenridge, C; Stocking, JH; Kim, T; Fadden, R; Lawrence, D; Hoang, MP; Cahill, DP; Malehmir, M; Nowak, MA; Brastianos, PK; Lian, CG; Ruppin, E; Izar, B; Herlyn, M; Van Allen, EM; Nathanson, K; Flaherty, KT; Sullivan, RJ; Kellis, M; Sorger, PK; Boland, GM				Liu, David; Lin, Jia-Ren; Robitschek, Emily J.; Kasumova, Gyulnara G.; Heyde, Alex; Shi, Alvin; Kraya, Adam; Zhang, Gao; Moll, Tabea; Frederick, Dennie T.; Chen, Yu-An; Wang, Shu; Schapiro, Denis; Ho, Li-Lun; Bi, Kevin; Sahu, Avinash; Mei, Shaolin; Miao, Benchun; Sharova, Tatyana; Alvarez-Breckenridge, Christopher; Stocking, Jackson H.; Kim, Tommy; Fadden, Riley; Lawrence, Donald; Hoang, Mai P.; Cahill, Daniel P.; Malehmir, Mohsen; Nowak, Martin A.; Brastianos, Priscilla K.; Lian, Christine G.; Ruppin, Eytan; Izar, Benjamin; Herlyn, Meenhard; Van Allen, Eliezer M.; Nathanson, Katherine; Flaherty, Keith T.; Sullivan, Ryan J.; Kellis, Manolis; Sorger, Peter K.; Boland, Genevieve M.			Evolution of delayed resistance to immunotherapy in a melanoma responder	NATURE MEDICINE			English	Article							CHECKPOINT BLOCKADE THERAPY; ACQUIRED-RESISTANCE; BRANCHED EVOLUTION; TUMOR SAMPLES; CANCER; MUTATIONS; HETEROGENEITY; REVEALS; CELLS; PTEN	Despite initial responses(1-3), most melanoma patients develop resistance(4) to immune checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor samples over 9 years from a patient with metastatic melanoma with complete clinical response to ICB followed by delayed recurrence and death. Phylogenetic analysis revealed co-evolution of seven lineages with multiple convergent, but independent resistance-associated alterations. All recurrent tumors emerged from a lineage characterized by loss of chromosome 15q, with post-treatment clones acquiring additional genomic driver events. Deconvolution of bulk RNA sequencing and highly multiplexed immunofluorescence (t-CyCIF) revealed differences in immune composition among different lineages. Imaging revealed a vasculogenic mimicry phenotype in NGFR(hi) tumor cells with high PD-L1 expression in close proximity to immune cells. Rapid autopsy demonstrated two distinct NGFR spatial patterns with high polarity and proximity to immune cells in subcutaneous tumors versus a diffuse spatial pattern in lung tumors, suggesting different roles of this neural-crest-like program in different tumor microenvironments. Broadly, this study establishes a high-resolution map of the evolutionary dynamics of resistance to ICB, characterizes a de-differentiated neural-crest tumor population in melanoma immunotherapy resistance and describes site-specific differences in tumor-immune interactions via longitudinal analysis of a patient with melanoma with an unusual clinical course.	[Liu, David; Robitschek, Emily J.; Bi, Kevin; Sahu, Avinash; Mei, Shaolin; Van Allen, Eliezer M.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Liu, David; Robitschek, Emily J.; Shi, Alvin; Ho, Li-Lun; Bi, Kevin; Malehmir, Mohsen; Van Allen, Eliezer M.; Kellis, Manolis; Boland, Genevieve M.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Lin, Jia-Ren; Chen, Yu-An; Wang, Shu; Schapiro, Denis; Mei, Shaolin; Sorger, Peter K.] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02115 USA; [Kasumova, Gyulnara G.; Sharova, Tatyana; Kim, Tommy; Malehmir, Mohsen; Boland, Genevieve M.] Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02114 USA; [Heyde, Alex; Nowak, Martin A.] Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA; [Heyde, Alex; Nowak, Martin A.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; [Shi, Alvin; Kellis, Manolis] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kraya, Adam; Nathanson, Katherine] Univ Penn, Dept Med, Perelman Sch Med, Div Translat Med & Human Genet, Philadelphia, PA 19104 USA; [Zhang, Gao; Herlyn, Meenhard] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Zhang, Gao] Duke Univ, Sch Med, Dept Pathol, Preston Robert Tisch Brain Tumor Ctr,Dept Neurosu, Durham, NC 27706 USA; [Moll, Tabea; Frederick, Dennie T.; Miao, Benchun; Stocking, Jackson H.; Fadden, Riley; Lawrence, Donald; Brastianos, Priscilla K.; Flaherty, Keith T.; Sullivan, Ryan J.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Div Med Oncol,Dept Med, Boston, MA 02115 USA; [Schapiro, Denis] Broad Inst MIT & Harvard, Klarman Cell Observ, Cambridge, MA USA; [Alvarez-Breckenridge, Christopher; Cahill, Daniel P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Hoang, Mai P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; [Nowak, Martin A.] Harvard Univ, Dept Math, Cambridge, MA 02138 USA; [Lian, Christine G.] Harvard Med Sch, Brigham & Womans Hosp, Dept Pathol, Boston, MA 02115 USA; [Ruppin, Eytan] NCI, Canc Data Sci Lab, NIH, Bethesda, MD 20892 USA; [Izar, Benjamin] Columbia Univ, Irving Med Ctr, Div Hematol & Oncol, New York, NY USA; [Izar, Benjamin] Columbia Ctr Translat Immunol, New York, NY USA; [Nathanson, Katherine] Univ Penn, Perelman Sch Med, Basser Ctr BRCA, Philadelphia, PA 19104 USA; [Nathanson, Katherine] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Sorger, Peter K.] Harvard Med Sch, Dept Syst Biol, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Pennsylvania Medicine; The Wistar Institute; Duke University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University; NewYork-Presbyterian Hospital; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Boland, GM (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.; Boland, GM (corresponding author), Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02114 USA.	gmboland@mgh.harvard.edu		Liu, David/0000-0003-0346-5033; Wang, Shu/0000-0002-1178-1143; Schapiro, Denis/0000-0002-9391-5722; Lin, Jia-Ren/0000-0003-4702-7705; Stocking, Jackson/0000-0003-2759-2125; Mei, Shaolin/0000-0002-2193-764X; Hoang, Mai/0000-0002-1406-7981	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Harvard Ludwig Center for Cancer Research; National Science Foundation [DGE-1144152, 2016226995]; Conquer Cancer Foundation Young Investigator Award; Damon Runyon Cancer Research Foundation [DRQ-03-20]; National Institutes of Health [R01CA227388, K08CA222663, K08CA234458, U54-CA225088, P01 CA114046, P50 CA174523, U54 CA224070]; DoD - PRCRP [W81XWH-16-1-0119, CA150619]; DoD-CDMRP [W81XWH-19-1-0143]; Society for Immunotherapy of Cancer Translational Postdoctoral Fellowship; Burroughs Wellcome Fund Career Award for Medical Scientists; Louis V. Gerstner, Jr Scholars Program; Velocity Fellow Program; Abeloff V foundation scholar grant; Barr Award for Innovative Translational Research, Early Postdoc Mobility fellowship [P2ZHP3_181475]; Swiss National Science Foundation [P2ZHP3_178022]; BroadNext10	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Harvard Ludwig Center for Cancer Research; National Science Foundation(National Science Foundation (NSF)); Conquer Cancer Foundation Young Investigator Award; Damon Runyon Cancer Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD - PRCRP; DoD-CDMRP(United States Department of Defense); Society for Immunotherapy of Cancer Translational Postdoctoral Fellowship; Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund); Louis V. Gerstner, Jr Scholars Program; Velocity Fellow Program; Abeloff V foundation scholar grant; Barr Award for Innovative Translational Research, Early Postdoc Mobility fellowship; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); BroadNext10	This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (M.H.), the Harvard Ludwig Center for Cancer Research, the National Science Foundation (grant no. DGE-1144152, Graduate Research Fellowship no. 2016226995), the Conquer Cancer Foundation Young Investigator Award (D.L.), the Damon Runyon Cancer Research Foundation (Physician Scientist Training Grant (D.L.), Postdoctoral Fellowship (DRQ-03-20, D.S.)), the National Institutes of Health (grants R01CA227388, K08CA222663 (B.I.), K08CA234458 (D.L.) and U54-CA225088 (B.I., J.L., S.W., S.M., D.S. and P.K.S.), P01 CA114046 (M.H.), P50 CA174523 (M.H.), U54 CA224070 (M.H.)), DoD - PRCRP W81XWH-16-1-0119 (CA150619) (M.H.), DoD-CDMRP W81XWH-19-1-0143 (G.M.B.), BroadNext10 (E.M.V.A.), Society for Immunotherapy of Cancer Translational Postdoctoral Fellowship (D.L.), the Burroughs Wellcome Fund Career Award for Medical Scientists (B.I.), the Louis V. Gerstner, Jr Scholars Program (B.I.), the Velocity Fellow Program (B.I.), Abeloff V foundation scholar grant (B.I.), the Barr Award for Innovative Translational Research, Early Postdoc Mobility fellowship (no. P2ZHP3_181475) (D.S.) and the Swiss National Science Foundation (no. P2ZHP3_178022) (M.M).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Boshuizen J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17739-8; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; De Tomaso D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12235-0; Dewhurst SM, 2014, CANCER DISCOV, V4, P175, DOI 10.1158/2159-8290.CD-13-0285; Ding L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111153; Edwards J, 2019, CLIN CANCER RES, V25, P3247, DOI 10.1158/1078-0432.CCR-18-4011; Faltas BM, 2016, NAT GENET, V48, P1490, DOI 10.1038/ng.3692; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hundal J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0264-5; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lehraiki A, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.30; Leshchiner I., 2018, BMC BIOINFORMATICS, DOI [10.1101/508127, DOI 10.1101/508127]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Lin JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9390; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Liu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02320-7; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marsavela G, 2020, CLIN CANCER RES, V26, P5926, DOI 10.1158/1078-0432.CCR-20-2251; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Restivo G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01573-6; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shen RL, 2009, BIOINFORMATICS, V25, P2906, DOI 10.1093/bioinformatics/btp543; Shi A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb3461; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan LY, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.7; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Valyi-Nagy K, 2012, MOL VIS, V18, P588; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Xiao Q, 2018, NAT MED, V24, P262, DOI 10.1038/nm.4496; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	75	18	18	3	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					985	+		10.1038/s41591-021-01331-8	http://dx.doi.org/10.1038/s41591-021-01331-8		MAY 2021	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	33941922	Green Accepted, Green Submitted			2022-12-27	WOS:000646516200001
J	Nkengasong, JN				Nkengasong, John N.			COVID-19: unprecedented but expected	NATURE MEDICINE			English	Editorial Material									[Nkengasong, John N.] Africa Ctr Dis Control & Prevent, Addis Ababa, Ethiopia		Nkengasong, JN (corresponding author), Africa Ctr Dis Control & Prevent, Addis Ababa, Ethiopia.	nkengasongj@africa-union.org							0	8	8	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					364	364		10.1038/s41591-021-01269-x	http://dx.doi.org/10.1038/s41591-021-01269-x			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723449	Bronze			2022-12-27	WOS:000629708300006
J	Zhou, SR; Butler-Laporte, G; Nakanishi, T; Morrison, DR; Afilalo, J; Afilalo, M; Laurent, L; Pietzner, M; Kerrison, N; Zhao, KQ; Brunet-Ratnasingham, E; Henry, D; Kimchi, N; Afrasiabi, Z; Rezk, N; Bouab, M; Petitjean, L; Guzman, C; Xue, XQ; Tselios, C; Vulesevic, B; Adeleye, O; Abdullah, T; Almamlouk, N; Chen, YH; Chasse, M; Durand, M; Paterson, C; Normark, J; Frithiof, R; Lipcsey, M; Hultstrom, M; Greenwood, CMT; Zeberg, H; Langenberg, C; Thysell, E; Pollak, M; Mooser, V; Forgetta, V; Kaufmann, DE; Richards, JB				Zhou, Sirui; Butler-Laporte, Guillaume; Nakanishi, Tomoko; Morrison, David R.; Afilalo, Jonathan; Afilalo, Marc; Laurent, Laetitia; Pietzner, Maik; Kerrison, Nicola; Zhao, Kaiqiong; Brunet-Ratnasingham, Elsa; Henry, Danielle; Kimchi, Nofar; Afrasiabi, Zaman; Rezk, Nardin; Bouab, Meriem; Petitjean, Louis; Guzman, Charlotte; Xue, Xiaoqing; Tselios, Chris; Vulesevic, Branka; Adeleye, Olumide; Abdullah, Tala; Almamlouk, Noor; Chen, Yiheng; Chasse, Michael; Durand, Madeleine; Paterson, Clare; Normark, Johan; Frithiof, Robert; Lipcsey, Miklos; Hultstrom, Michael; Greenwood, Celia M. T.; Zeberg, Hugo; Langenberg, Claudia; Thysell, Elin; Pollak, Michael; Mooser, Vincent; Forgetta, Vincenzo; Kaufmann, Daniel E.; Richards, J. Brent			A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	NATURE MEDICINE			English	Article							RNASE L; PROTEINS; GENOME; GENES	To identify circulating proteins influencing Coronavirus Disease 2019 (COVID-19) susceptibility and severity, we undertook a two-sample Mendelian randomization (MR) study, rapidly scanning hundreds of circulating proteins while reducing bias due to reverse causation and confounding. In up to 14,134 cases and 1.2 million controls, we found that an s.d. increase in OAS1 levels was associated with reduced COVID-19 death or ventilation (odds ratio (OR) = 0.54, P = 7 x 10(-8)), hospitalization (OR = 0.61, P = 8 x 10(-8)) and susceptibility (OR = 0.78, P = 8 x 10(-6)). Measuring OAS1 levels in 504 individuals, we found that higher plasma OAS1 levels in a non-infectious state were associated with reduced COVID-19 susceptibility and severity. Further analyses suggested that a Neanderthal isoform of OAS1 in individuals of European ancestry affords this protection. Thus, evidence from MR and a case-control study support a protective role for OAS1 in COVID-19 adverse outcomes. Available pharmacological agents that increase OAS1 levels could be prioritized for drug development. A variant of the OAS1 gene, which encodes an enzyme that is critical for the innate immune response to viral infections, is associated with decreased risk of death in patients with COVID-19.	[Zhou, Sirui; Butler-Laporte, Guillaume; Nakanishi, Tomoko; Morrison, David R.; Afilalo, Jonathan; Afilalo, Marc; Laurent, Laetitia; Zhao, Kaiqiong; Henry, Danielle; Kimchi, Nofar; Afrasiabi, Zaman; Rezk, Nardin; Bouab, Meriem; Petitjean, Louis; Guzman, Charlotte; Xue, Xiaoqing; Tselios, Chris; Vulesevic, Branka; Adeleye, Olumide; Abdullah, Tala; Almamlouk, Noor; Chen, Yiheng; Greenwood, Celia M. T.; Pollak, Michael; Forgetta, Vincenzo; Richards, J. Brent] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Zhou, Sirui; Butler-Laporte, Guillaume; Afilalo, Jonathan; Zhao, Kaiqiong; Greenwood, Celia M. T.; Richards, J. Brent] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Nakanishi, Tomoko; Chen, Yiheng; Mooser, Vincent; Richards, J. Brent] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Nakanishi, Tomoko] Kyoto Univ, Grad Sch Med, Kyoto McGill Int Collaborat Sch Genom Med, Kyoto, Japan; [Nakanishi, Tomoko] Japan Soc Promot Sci, Tokyo, Japan; [Afilalo, Jonathan] McGill Univ, Div Cardiol, Dept Med, Montreal, PQ, Canada; [Afilalo, Marc] McGill Univ, Jewish Gen Hosp, Dept Emergency Med, Montreal, PQ, Canada; [Pietzner, Maik; Kerrison, Nicola; Langenberg, Claudia] Univ Cambridge, MRC Epidemiol Unit, Sch Clin Med, Cambridge, England; [Brunet-Ratnasingham, Elsa; Chasse, Michael; Durand, Madeleine; Kaufmann, Daniel E.] Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada; [Brunet-Ratnasingham, Elsa] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Paterson, Clare] SomaLog Inc, Boulder, CO USA; [Normark, Johan] Umea Univ, Mol Infect Med Sweden MIMS, Umea, Sweden; [Normark, Johan] Umea Univ, Sect Infect & Immunol, Dept Clin Microbiol, Wallenberg Ctr Mol Med, Umea, Sweden; [Frithiof, Robert; Lipcsey, Miklos; Hultstrom, Michael] Uppsala Univ, Dept Surg Sci, Anaesthesiol & Intens Care Med, Uppsala, Sweden; [Lipcsey, Miklos] Uppsala Univ, Dept Surg Sci, Hedenstierna Lab, CIRRUS,Anaesthesiol & Intens Care Med, Uppsala, Sweden; [Hultstrom, Michael] Uppsala Univ, Dept Med Cell Biol, Integrat Physiol, Uppsala, Sweden; [Greenwood, Celia M. T.] McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ, Canada; [Zeberg, Hugo] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Langenberg, Claudia] Charite Univ Med Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany; [Thysell, Elin] Umea Univ, Dept Med Biosci, Pathol, Umea, Sweden; [Pollak, Michael] McGill Univ, Dept Med, Montreal, PQ, Canada; [Pollak, Michael] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Kaufmann, Daniel E.] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Richards, J. Brent] Kings Coll London, Dept Twin Res, London, England	Lady Davis Institute; McGill University; McGill University; McGill University; Kyoto University; Japan Society for the Promotion of Science; McGill University; McGill University; University of Cambridge; Universite de Montreal; Universite de Montreal; Umea University; Umea University; Uppsala University; Uppsala University; Uppsala University; McGill University; Karolinska Institutet; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Umea University; McGill University; McGill University; Universite de Montreal; University of London; King's College London	Richards, JB (corresponding author), McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.; Richards, JB (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.; Richards, JB (corresponding author), McGill Univ, Dept Human Genet, Montreal, PQ, Canada.; Richards, JB (corresponding author), Kings Coll London, Dept Twin Res, London, England.	brent.richards@mcgill.ca	Langenberg, Claudia/ABG-9067-2021; Zeberg, Hugo/A-7567-2012; Hultström, Michael/H-3642-2019; Zeberg, Hugo/AAN-9147-2020	Langenberg, Claudia/0000-0002-5017-7344; Hultström, Michael/0000-0003-4675-1099; Zeberg, Hugo/0000-0001-7118-1249; Nakanishi, Tomoko/0000-0001-9510-5646; Chasse, Michael/0000-0001-7075-1924; Guzman, Charlotte L./0000-0002-2979-4436; Pollak, Michael/0000-0003-3047-0604; Pietzner, Maik/0000-0003-3437-9963; Morrison, David/0000-0001-8380-3615; Vulesevic, Branka/0000-0003-2297-2209; Afrasiabi, Zaman/0000-0003-4395-5168; Rezk, Nardin/0000-0001-5358-7704; Kerrison, Nicola/0000-0002-1471-953X	Canadian Institutes of Health Research (CIHR) [365825, 409511]; Lady Davis Institute of the Jewish General Hospital; Canadian Foundation for Innovation (CFI); NIH Foundation; Cancer Research UK; Genome Quebec; Public Health Agency of Canada; McGill Interdisciplinary Initiative in Infection and Immunity; Fonds de Recherche Quebec Sante (FRQS); CIHR fellowship; FRQS postdoctoral scholarship; CIHR scholarship; FRQS; Quebec Ministry of Health and Social Services scholarship; research fellowships of the Japan Society for the Promotion of Science for Young Scientists; FRQS Clinical Research Scholarship; Calcul Quebec; Compute Canada; Welcome Trust; Medical Research Council; European Union; National Institute for Health Research-funded BioResource and the Clinical Research Facility; Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust; King's College London; Canada Excellence Research Chair; Swedish Research Council [2014-02569, 2014-07606]; CIHR/CITF [VR2-173203]; AmFAR [110068-68-RGCV]; CFI; SciLifeLab/KAW national COVID-19 research program project grant [KAW 2020.0182]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Lady Davis Institute of the Jewish General Hospital; Canadian Foundation for Innovation (CFI)(Canada Foundation for Innovation); NIH Foundation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research UK(Cancer Research UK); Genome Quebec; Public Health Agency of Canada; McGill Interdisciplinary Initiative in Infection and Immunity; Fonds de Recherche Quebec Sante (FRQS); CIHR fellowship(Canadian Institutes of Health Research (CIHR)); FRQS postdoctoral scholarship; CIHR scholarship(Canadian Institutes of Health Research (CIHR)); FRQS; Quebec Ministry of Health and Social Services scholarship; research fellowships of the Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); FRQS Clinical Research Scholarship; Calcul Quebec; Compute Canada; Welcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); National Institute for Health Research-funded BioResource and the Clinical Research Facility; Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust; King's College London(General Electric); Canada Excellence Research Chair; Swedish Research Council(Swedish Research CouncilEuropean Commission); CIHR/CITF; AmFAR; CFI(Canada Foundation for Innovation); SciLifeLab/KAW national COVID-19 research program project grant	We thank N. Chomont for the discussion on the clinical phenotype of BQC19. We would like to also thank the MI4 and the MUHC Foundation that contributed for the SomaLogic panel. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante (FRQS). S.Z. is supported by a CIHR fellowship and a FRQS postdoctoral scholarship. G.B.L. is supported by a CIHR scholarship and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. T.N. is supported by research fellowships of the Japan Society for the Promotion of Science for Young Scientists. J.B.R. is supported by an FRQS Clinical Research Scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, the Medical Research Council, the European Union, the National Institute for Health Research-funded BioResource and the Clinical Research Facility and Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London. BQC19 is funded by FRQS, Genome Quebec and the Public Health Agency of Canada. These funding agencies had no role in the design, implementation or interpretation of this study. V.M. is supported by a Canada Excellence Research Chair. M.D. is supported by an FRQS Clinical Research Scholarship. R.F. is funded by the Swedish Research Council (2014-02569 and 2014-07606). The Kaufmann lab's COVID-19 work is supported by the CIHR/CITF (VR2-173203), AmFAR (110068-68-RGCV), the CFI and FRQS. M.H. is supported by a SciLifeLab/KAW national COVID-19 research program project grant (KAW 2020.0182).	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Arabi YM, 2020, NEW ENGL J MED, V383, P1645, DOI 10.1056/NEJMoa2015294; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bonnevie-Nielsen V, 2005, AM J HUM GENET, V76, P623, DOI 10.1086/429391; Burgess S, 2016, GENET EPIDEMIOL, V40, P597, DOI 10.1002/gepi.21998; Candia J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14755-5; Carey CM, 2019, CELL HOST MICROBE, V25, P336, DOI 10.1016/j.chom.2019.01.001; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Centers for Disease Control and Prevention, 2021, DUR IS PREC AD COVID; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Cheng GJ, 2011, AM J RESP CELL MOL, V45, P480, DOI 10.1165/rcmb.2010-0288OC; Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309; Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6; Emilsson V, 2018, SCIENCE, V361, P769, DOI 10.1126/science.aaq1327; Filbin Michael R, 2020, bioRxiv, DOI 10.1101/2020.11.02.365536; Folkersen L, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006706; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Hamano E, 2005, BIOCHEM BIOPH RES CO, V329, P1234, DOI 10.1016/j.bbrc.2005.02.101; Harari D, 2015, HUM MOL GENET, V24, P3192, DOI 10.1093/hmg/ddv071; Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hornung V, 2014, NAT REV IMMUNOL, V14, P521, DOI 10.1038/nri3719; Hu BX, 2016, SCI REP-UK, V6, DOI 10.1038/srep28075; Kristiansen H, 2010, J VIROL, V84, P11898, DOI 10.1128/JVI.01003-10; Lawlor DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/ije/dyw314; Li H, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006820; Li YI, 2018, NAT GENET, V50, P151, DOI 10.1038/s41588-017-0004-9; Li Yize, 2020, bioRxiv, DOI 10.1101/2020.09.24.312553; Lim JK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000321; Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015; Liu XJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17931-9; Mendez FL, 2013, MOL BIOL EVOL, V30, P798, DOI 10.1093/molbev/mst004; Meyer M, 2012, SCIENCE, V338, P222, DOI 10.1126/science.1224344; Min JY, 2006, P NATL ACAD SCI USA, V103, P7100, DOI 10.1073/pnas.0602184103; Monk PD, 2021, LANCET RESP MED, V9, P196, DOI 10.1016/S2213-2600(20)30511-7; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Pietzner M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19996-z; Prufer K, 2017, SCIENCE, V358, P655, DOI 10.1126/science.aao1887; Sams AJ, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1098-6; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Silverman RH, 2014, J INTERF CYTOK RES, V34, P455, DOI 10.1089/jir.2014.0007; Simon-Loriere E, 2015, J INFECT DIS, V212, P2011, DOI 10.1093/infdis/jiv321; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; SomaLogic, 2019, SHORT TECHNICAL NOTE; Staley JR, 2016, BIOINFORMATICS, V32, P3207, DOI 10.1093/bioinformatics/btw373; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Suhre K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14357; Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wood ER, 2015, J BIOL CHEM, V290, P19681, DOI 10.1074/jbc.M115.653113; Yao C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05512-x; Zeberg H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026309118; Zeberg H, 2020, NATURE, V587, P610, DOI 10.1038/s41586-020-2818-3; Zhang R, 2013, P NATL ACAD SCI USA, V110, P13114, DOI 10.1073/pnas.1306917110; Zhao L, 2012, CELL HOST MICROBE, V11, P607, DOI 10.1016/j.chom.2012.04.011; Zheng J, 2020, NAT GENET, V52, P1122, DOI 10.1038/s41588-020-0682-6	61	63	63	7	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01281-1	http://dx.doi.org/10.1038/s41591-021-01281-1		FEB 2021	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33633408	Green Submitted, Bronze			2022-12-27	WOS:000621738800001
J	Asnicar, F; Berry, SE; Valdes, AM; Nguyen, LH; Piccinno, G; Drew, DA; Leeming, E; Gibson, R; Le Roy, C; Al Khatib, H; Francis, L; Mazidi, M; Mompeo, O; Valles-Colomer, M; Tett, A; Beghini, F; Dubois, L; Bazzani, D; Thomas, AM; Mirzayi, C; Khleborodova, A; Oh, S; Hine, R; Bonnett, C; Capdevila, J; Danzanvilliers, S; Giordano, F; Geistlinger, L; Waldron, L; Davies, R; Hadjigeorgiou, G; Wolf, J; Ordovas, JM; Gardner, C; Franks, PW; Chan, ANT; Huttenhower, C; Spector, TD; Segata, N				Asnicar, Francesco; Berry, Sarah E.; Valdes, Ana M.; Nguyen, Long H.; Piccinno, Gianmarco; Drew, David A.; Leeming, Emily; Gibson, Rachel; Le Roy, Caroline; Al Khatib, Haya; Francis, Lucy; Mazidi, Mohsen; Mompeo, Olatz; Valles-Colomer, Mireia; Tett, Adrian; Beghini, Francesco; Dubois, Leonard; Bazzani, Davide; Thomas, Andrew Maltez; Mirzayi, Chloe; Khleborodova, Asya; Oh, Sehyun; Hine, Rachel; Bonnett, Christopher; Capdevila, Joan; Danzanvilliers, Serge; Giordano, Francesca; Geistlinger, Ludwig; Waldron, Levi; Davies, Richard; Hadjigeorgiou, George; Wolf, Jonathan; Ordovas, Jose M.; Gardner, Christopher; Franks, Paul W.; Chan, Andrew T.; Huttenhower, Curtis; Spector, Tim D.; Segata, Nicola			Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	NATURE MEDICINE			English	Article							ALL-CAUSE MORTALITY; HEALTHY EATING INDEX; PLANT-BASED DIETS; GUT MICROBIOME; CARDIOVASCULAR-DISEASE; SHOTGUN METAGENOMICS; RISK; POPULATION; DIVERSITY; CHOLESTEROL	The gut microbiome is shaped by diet and influences host metabolism; however, these links are complex and can be unique to each individual. We performed deep metagenomic sequencing of 1,203 gut microbiomes from 1,098 individuals enrolled in the Personalised Responses to Dietary Composition Trial (PREDICT 1) study, whose detailed long-term diet information, as well as hundreds of fasting and same-meal postprandial cardiometabolic blood marker measurements were available. We found many significant associations between microbes and specific nutrients, foods, food groups and general dietary indices, which were driven especially by the presence and diversity of healthy and plant-based foods. Microbial biomarkers of obesity were reproducible across external publicly available cohorts and in agreement with circulating blood metabolites that are indicators of cardiovascular disease risk. While some microbes, such as Prevotella copri and Blastocystis spp., were indicators of favorable postprandial glucose metabolism, overall microbiome composition was predictive for a large panel of cardiometabolic blood markers including fasting and postprandial glycemic, lipemic and inflammatory indices. The panel of intestinal species associated with healthy dietary habits overlapped with those associated with favorable cardiometabolic and postprandial markers, indicating that our large-scale resource can potentially stratify the gut microbiome into generalizable health levels in individuals without clinically manifest disease.	[Asnicar, Francesco; Piccinno, Gianmarco; Valles-Colomer, Mireia; Tett, Adrian; Beghini, Francesco; Dubois, Leonard; Bazzani, Davide; Thomas, Andrew Maltez; Segata, Nicola] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy; [Berry, Sarah E.; Gibson, Rachel] Kings Coll London, Dept Nutr Sci, London, England; [Valdes, Ana M.] Univ Nottingham, Sch Med, Nottingham, England; [Valdes, Ana M.] Nottingham Natl Inst Hlth Res, Biomed Res Ctr, Nottingham, England; [Nguyen, Long H.; Drew, David A.; Chan, Andrew T.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Leeming, Emily; Le Roy, Caroline; Mazidi, Mohsen; Mompeo, Olatz; Spector, Tim D.] Kings Coll London, Dept Twin Res, London, England; [Al Khatib, Haya; Francis, Lucy; Hine, Rachel; Bonnett, Christopher; Capdevila, Joan; Danzanvilliers, Serge; Giordano, Francesca; Davies, Richard; Hadjigeorgiou, George; Wolf, Jonathan] Zoe Global Ltd, London, England; [Mirzayi, Chloe; Khleborodova, Asya; Oh, Sehyun; Geistlinger, Ludwig; Waldron, Levi] CUNY, New York, NY 10021 USA; [Ordovas, Jose M.] Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Ordovas, Jose M.] Univ Autonoma Madrid, Inst Madrileno Estudios Avanzados Food Inst, Campus Int Excellence, Madrid, Spain; [Ordovas, Jose M.] CSIC, Madrid, Spain; [Gardner, Christopher] Stanford Univ, Stanford, CA 94305 USA; [Franks, Paul W.] Lund Univ, Dept Clin Sci, Malmo, Sweden; [Franks, Paul W.; Chan, Andrew T.; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Chan, Andrew T.; Huttenhower, Curtis] Broad Inst MIT & Harvard, Cambridge, MA USA; [Segata, Nicola] European Inst Oncol, Sci Inst Res Hospitalizat & Healthcare, Milan, Italy	University of Trento; University of London; King's College London; University of Nottingham; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of London; King's College London; City University of New York (CUNY) System; Tufts University; United States Department of Agriculture (USDA); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Stanford University; Lund University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; IRCCS European Institute of Oncology (IEO)	Segata, N (corresponding author), Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy.; Berry, SE (corresponding author), Kings Coll London, Dept Nutr Sci, London, England.; Segata, N (corresponding author), European Inst Oncol, Sci Inst Res Hospitalizat & Healthcare, Milan, Italy.	sarah.e.berry@kcl.ac.uk; nicola.segata@unitn.it	Beghini, Francesco/ABE-9981-2021; Piccinno, Gianmarco/N-4062-2016; Asnicar, Francesco/AAB-9255-2020; Waldron, Levi/H-2967-2019	Beghini, Francesco/0000-0002-8105-9607; Piccinno, Gianmarco/0000-0003-1947-1817; Asnicar, Francesco/0000-0003-3732-1468; Valles-Colomer, Mireia/0000-0002-1988-6054; Thomas, Andrew Maltez/0000-0001-5789-3354; Waldron, Levi/0000-0003-2725-0694; Gibson, Rachel/0000-0002-5823-6468; Valdes, Ana M./0000-0003-1141-4471; Nguyen, Long/0000-0002-5436-4219; Tett, Adrian/0000-0003-3141-3943; Le Roy, Caroline/0000-0002-0341-751X; Bazzani, Davide/0000-0002-2254-651X; Berry, Sarah/0000-0002-5819-5109	Nightingale Health and Affinity Biomarker Laboratories; Wellcome Trust [212904/Z/18/Z]; Medical Research Council/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension [MR/M016560/1]; European Research Council (ERC-STG) [MetaPG-716575]; MIUR 'Futuro in Ricerca' [RBFR13EWWI_001]; European H2020 program [ONCOBIOME-825410, MASTER-818368]; National Cancer Institute of the National Institutes of Health [1U01CA230551]; Premio Internazionale Lombardia e Ricerca 2019; Biotechnology and Biological Sciences Research Council [BB/NO12739/1]; European Research Council [CoG-2015_681742_NASCENT]; Swedish Research Council [IRC15-0067]; Novo Nordisk Foundation; Wellcome Trust; Medical Research Council; European Union; Chronic Disease Research Foundation; Zoe Global; National Institute for Health Research; MRC [MR/N01183X/1] Funding Source: UKRI	Nightingale Health and Affinity Biomarker Laboratories; Wellcome Trust(Wellcome Trust); Medical Research Council/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council (ERC-STG)(European Research Council (ERC)); MIUR 'Futuro in Ricerca'(Ministry of Education, Universities and Research (MIUR)); European H2020 program; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Premio Internazionale Lombardia e Ricerca 2019; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Research Council(European Research Council (ERC)European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Chronic Disease Research Foundation; Zoe Global; National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the participants of the PREDICT 1 study. We thank N. Atabaki-Pasdar for generating the liver fat score. We thank the staff of Zoe Global, the Department of Twin Research and the Massachusetts General Hospital and all the members of the Segata, Berry and Spector laboratories for their tireless work in contributing to the running of the study, data collection and data processing. We thank Nightingale Health and Affinity Biomarker Laboratories for their support and analytical work. This work was supported by Zoe Global and received support from grants from the Wellcome Trust (no. 212904/Z/18/Z) and Medical Research Council/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension (no. MR/M016560/1). The work was also supported by the European Research Council (ERC-STG project MetaPG-716575 to N.S.), MIUR 'Futuro in Ricerca' (grant no. RBFR13EWWI_001 to N.S.), the European H2020 program (ONCOBIOME-825410 and MASTER-818368 projects to N.S.), the National Cancer Institute of the National Institutes of Health (grant no. 1U01CA230551 to N.S.) and the Premio Internazionale Lombardia e Ricerca 2019 to N.S. S.E.B. was supported in part by a grant funded by the Biotechnology and Biological Sciences Research Council (grant no. BB/NO12739/1). P.W.F. was supported in part by grants from the European Research Council (grant no. CoG-2015_681742_NASCENT), Swedish Research Council (grant no. IRC15-0067) and Novo Nordisk Foundation. A.T.C. was supported in part as a Stuart and Suzanne Steele MGH Research Scholar. TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation, Zoe Global and the National Institute for Health Research-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.	[Anonymous], 2018, DAIR ALT YOUR DIET; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Atabaki-Pasdar N, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003149; Beaumont M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1052-7; Beghini F, 2017, ISME J, V11, P2848, DOI 10.1038/ismej.2017.139; Berry S., 2020, PROTOCOL EXCHANGE, DOI [10.21203/rs.2.20798/v1, DOI 10.21203/RS.2.20798/V1]; Berry SE, 2020, NAT MED, V26, P964, DOI 10.1038/s41591-020-0934-0; Bingham SA, 2001, PUBLIC HEALTH NUTR, V4, P847, DOI 10.1079/PHN2000102; Brouwer I., 2016, EFFECT TRANSFATTY AC; Brown JM, 2018, NAT REV MICROBIOL, V16, P171, DOI 10.1038/nrmicro.2017.149; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Clark CG, 2013, ADV PARASIT, V82, P1, DOI 10.1016/B978-0-12-407706-5.00001-0; Cohn JS, 1998, CAN J CARDIOL, V14, p18B; Costea PI, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20177589; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; De Filippis F, 2019, CELL HOST MICROBE, V25, P444, DOI 10.1016/j.chom.2019.01.004; de Souza RJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3978; Dhakan DB, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz004; Truong DT, 2017, GENOME RES, V27, P626, DOI 10.1101/gr.216242.116; Falony G, 2016, SCIENCE, V352, P560, DOI 10.1126/science.aad3503; Food Standards Agency, 2002, FOOD PORTION SIZES, V3rd; Frankenfield DC, 1998, J AM DIET ASSOC, V98, P439, DOI 10.1016/S0002-8223(98)00100-X; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Fu JY, 2015, CIRC RES, V117, P817, DOI 10.1161/CIRCRESAHA.115.306807; Fung TT, 2005, AM J CLIN NUTR, V82, P163; Gilbert JA, 2018, NAT MED, V24, P392, DOI 10.1038/nm.4517; Guenther PM, 2013, J ACAD NUTR DIET, V113, P569, DOI 10.1016/j.jand.2012.12.016; Hall AB, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0490-5; Hansen LBS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07019-x; Hodson L, 2008, PROG LIPID RES, V47, P348, DOI 10.1016/j.plipres.2008.03.003; Hrebicek J, 2002, J CLIN ENDOCR METAB, V87, P144, DOI 10.1210/jc.87.1.144; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Jie ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00900-1; Kang DWD, 2019, PEERJ, V7, DOI 10.7717/peerj.7359; Kettunen J, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.118.002234; Kim H, 2018, J NUTR, V148, P624, DOI 10.1093/jn/nxy019; Kim K, 2017, J AM HEART ASSOC, V6, DOI [10.1161/JAHA.117.005983, 10.1161/jaha.117.005983]; Ko CW, 2020, NAT REV GASTRO HEPAT, V17, P169, DOI 10.1038/s41575-019-0250-7; Kovatcheva-Datchary P, 2015, CELL METAB, V22, P971, DOI 10.1016/j.cmet.2015.10.001; Kurilshikov A, 2019, CIRC RES, V124, P1808, DOI 10.1161/CIRCRESAHA.118.314642; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Lukes J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005039; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mazidi M, 2019, CLIN NUTR, V38, P2833, DOI 10.1016/j.clnu.2018.12.015; McGuire S, 2011, ADV NUTR, V2, P293, DOI 10.3945/an.111.000430; McIver LJ, 2018, BIOINFORMATICS, V34, P1235, DOI 10.1093/bioinformatics/btx754; Mendes-Soares H, 2019, AM J CLIN NUTR, V110, P63, DOI 10.1093/ajcn/nqz028; Meslier V, 2020, GUT, V69, P1258, DOI 10.1136/gutjnl-2019-320438; Michaelsson K., 2014, The BMJ, V349; Mitrou PN, 2007, ARCH INTERN MED, V167, P2461, DOI 10.1001/archinte.167.22.2461; Monteiro CA, 2018, PUBLIC HEALTH NUTR, V21, P5, DOI 10.1017/S1368980017000234; Mulligan AA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004503; Ng M, 2014, LANCET, V384, P746; Nielsen HB, 2014, NAT BIOTECHNOL, V32, P822, DOI 10.1038/nbt.2939; Oksanen J., 2017, COMMUNITY ECOLOGY PA; Onvani S, 2017, J HUM NUTR DIET, V30, P216, DOI 10.1111/jhn.12415; Parks DH, 2015, GENOME RES, V25, P1043, DOI 10.1101/gr.186072.114; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Pasolli E, 2017, NAT METHODS, V14, P1023, DOI 10.1038/nmeth.4468; Pasolli E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004977; Pedersen HK, 2016, NATURE, V535, P376, DOI 10.1038/nature18646; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Petsini F, 2019, CRIT REV FOOD SCI, V59, P2061, DOI 10.1080/10408398.2018.1437388; Public Health England, 2014, MCCANCE WIDD COMP FO; Quince C, 2017, NAT BIOTECHNOL, V35, P833, DOI 10.1038/nbt.3935; Redondo-Useros N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030651; Reedy J, 2014, J NUTR, V144, P881, DOI 10.3945/jn.113.189407; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 2018, CIRCULATION, V138, pE35, DOI [10.1161/CIR.0000000000000574, 10.1161/cir.0000000000000574]; Sakamoto M, 2018, INT J SYST EVOL MICR, V68, P2074, DOI 10.1099/ijsem.0.002800; Satija A, 2017, J AM COLL CARDIOL, V70, P411, DOI 10.1016/j.jacc.2017.05.047; Satija A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002039; Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020; Skeggs JW, 2002, J LIPID RES, V43, P1264, DOI 10.1194/jlr.M100431-JLR200; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Sze MA, 2016, MBIO, V7, DOI 10.1128/mBio.01018-16; Tett A, 2019, CELL HOST MICROBE, V26, P666, DOI 10.1016/j.chom.2019.08.018; Thingholm LB, 2019, CELL HOST MICROBE, V26, P252, DOI 10.1016/j.chom.2019.07.004; Thomas AM, 2019, NAT MED, V25, P667, DOI 10.1038/s41591-019-0405-7; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Vadiveloo M, 2015, J NUTR, V145, P564, DOI 10.3945/jn.114.199125; Vadiveloo M, 2014, BRIT J NUTR, V112, P1562, DOI 10.1017/S0007114514002049; Valles-Colomer M, 2019, NAT MICROBIOL, V4, P623, DOI 10.1038/s41564-018-0337-x; Vojinovic D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13721-1; Wojczynski MK, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-181; Xie HL, 2016, CELL SYST, V3, P572, DOI 10.1016/j.cels.2016.10.004; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zeller G, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145645; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369; Zhong VW, 2019, JAMA-J AM MED ASSOC, V321, P1081, DOI 10.1001/jama.2019.1572	93	198	201	38	141	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					321	+		10.1038/s41591-020-01183-8	http://dx.doi.org/10.1038/s41591-020-01183-8		JAN 2021	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33432175	Green Submitted, Green Accepted			2022-12-27	WOS:000607036600006
J	Fisher, MJ; Shih, CS; Rhodes, SD; Armstrong, AE; Wolters, PL; Dombi, E; Zhang, C; Angus, SP; Johnson, GL; Packer, RJ; Allen, JC; Ullrich, NJ; Goldman, S; Gutmann, DH; Plotkin, SR; Rosser, T; Robertson, KA; Widemann, BC; Smith, AE; Bessler, WK; He, YZ; Park, SJ; Mund, JA; Jiang, L; Bijangi-Vishehsaraei, K; Robinson, CT; Cutter, GR; Korf, BR; Blakeley, JO; Clapp, DW				Fisher, Michael J.; Shih, Chie-Schin; Rhodes, Steven D.; Armstrong, Amy E.; Wolters, Pamela L.; Dombi, Eva; Zhang, Chi; Angus, Steven P.; Johnson, Gary L.; Packer, Roger J.; Allen, Jeffrey C.; Ullrich, Nicole J.; Goldman, Stewart; Gutmann, David H.; Plotkin, Scott R.; Rosser, Tena; Robertson, Kent A.; Widemann, Brigitte C.; Smith, Abbi E.; Bessler, Waylan K.; He, Yongzheng; Park, Su-Jung; Mund, Julie A.; Jiang, Li; Bijangi-Vishehsaraei, Khadijeh; Robinson, Coretta Thomas; Cutter, Gary R.; Korf, Bruce R.; Blakeley, Jaishri O.; Clapp, D. Wade		Neurofibromatosis Clinical Trials	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial	NATURE MEDICINE			English	Article							CLINICAL-TRIALS; RADIATION-THERAPY; MEK INHIBITION; CANCER; GENE; SUNITINIB; TUMORS; XL184; MODEL; MRI	Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1(fl/fl);Postn-Cre mice with cabozantinib, an inhibitor of multiple tyrosine kinases, caused a reduction in PN size and number and differential modulation of kinases in cell lineages that drive PN growth. Based on these findings, the Neurofibromatosis Clinical Trials Consortium conducted a phase II, open-label, nonrandomized Simon two-stage study to assess the safety, efficacy and biologic activity of cabozantinib in patients >= 16 years of age with NF1 and progressive or symptomatic, inoperable PN (). The trial met its primary outcome, defined as >= 25% of patients achieving a partial response (PR, defined as >= 20% reduction in target lesion volume as assessed by magnetic resonance imaging (MRI)) after 12 cycles of therapy. Secondary outcomes included adverse events (AEs), patient-reported outcomes (PROs) assessing pain and quality of life (QOL), pharmacokinetics (PK) and the levels of circulating endothelial cells and cytokines. Eight of 19 evaluable (42%) trial participants achieved a PR. The median change in tumor volume was 15.2% (range, +2.2% to -36.9%), and no patients had disease progression while on treatment. Nine patients required dose reduction or discontinuation of therapy due to AEs; common AEs included gastrointestinal toxicity, hypothyroidism, fatigue and palmar plantar erythrodysesthesia. A total of 11 grade 3 AEs occurred in eight patients. Patients with PR had a significant reduction in tumor pain intensity and pain interference in daily life but no change in global QOL scores. These data indicate that cabozantinib is active in NF1-associated PN, resulting in tumor volume reduction and pain improvement. Cabozantinib, an inhibitor of multiple receptor tyrosine kinases, has efficacy in a mouse model of neurofibromatosis type I and has clinical activity in reducing plexiform neurofibroma volume in a phase II trial of patients with NF1.	[Fisher, Michael J.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Shih, Chie-Schin; Rhodes, Steven D.; Armstrong, Amy E.; Angus, Steven P.; Robertson, Kent A.; Bijangi-Vishehsaraei, Khadijeh; Clapp, D. Wade] Indiana Univ Sch Med, Dept Pediat, Div Hematol Oncol, Riley Hosp Children,Indiana Univ Hlth, Indianapolis, IN 46202 USA; [Rhodes, Steven D.; Smith, Abbi E.; Bessler, Waylan K.; He, Yongzheng; Park, Su-Jung; Mund, Julie A.; Jiang, Li; Clapp, D. Wade] Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Wolters, Pamela L.; Dombi, Eva; Widemann, Brigitte C.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhang, Chi] Indiana Univ, Dept Med & Mol Genom, Indianapolis, IN 46204 USA; [Angus, Steven P.; Johnson, Gary L.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA; [Packer, Roger J.] Childrens Natl Med Ctr, Ctr Neurosci & Behav Med, Washington, DC 20010 USA; [Allen, Jeffrey C.] NYU, Sch Med, Dept Pediat, New York, NY USA; [Ullrich, Nicole J.] Dana Farber Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Goldman, Stewart] Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol, Chicago, IL 60611 USA; [Gutmann, David H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol & Neurooncol, Boston, MA 02114 USA; [Rosser, Tena] Childrens Hosp Los Angeles, Div Neurol, Los Angeles, CA 90027 USA; [Robinson, Coretta Thomas; Cutter, Gary R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA; [Korf, Bruce R.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Shih, Chie-Schin] Merck & Co Inc, Kenilworth, NJ USA; [Armstrong, Amy E.] Washington Univ, Sch Med, Div Pediat Hematol Oncol, St Louis, MO USA; [Angus, Steven P.] Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University Bloomington; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Indiana University System; Indiana University-Purdue University Indianapolis; University of North Carolina; University of North Carolina Chapel Hill; Children's National Health System; New York University; Harvard University; Boston Children's Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Children's Hospital Los Angeles; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Merck & Company; Washington University (WUSTL); Indiana University System; Indiana University Bloomington	Clapp, DW (corresponding author), Indiana Univ Sch Med, Dept Pediat, Div Hematol Oncol, Riley Hosp Children,Indiana Univ Hlth, Indianapolis, IN 46202 USA.; Clapp, DW (corresponding author), Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.; Blakeley, JO (corresponding author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.	jblakel3@jhmi.edu; dclapp@iu.edu	Cutter, Gary/AAY-5392-2021	Cutter, Gary/0000-0002-8455-980X; Allen, Jeffrey/0000-0001-9957-6664; Plotkin, Scott/0000-0002-6109-6419; Smith, Abbi/0000-0002-4402-8959	NCI NIH HHS [U54 CA196519] Funding Source: Medline; NICHD NIH HHS [K12 HD000850] Funding Source: Medline; US Army Medical Research and Development Command [W81XWH-12-01-0155] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [K12-HD000850] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [U54-CA196519-04] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); US Army Medical Research and Development Command(United States Department of DefenseUnited States ArmyUnited States Army Medical Research & Development Command (USAMRDC)); U.S. Department of Health &amp; Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)		Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; [Anonymous], 2016, Cancer Discov, V6, pOF3, DOI 10.1158/2159-8290.CD-NB2016-057; Armstrong AE, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28372; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Cabanillas ME, 2017, J CLIN ONCOL, V35, P3315, DOI 10.1200/JCO.2017.73.0226; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Dombi E, 2007, NEUROLOGY, V68, P643, DOI 10.1212/01.wnl.0000250332.89420.e6; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Dombi E, 2013, NEUROLOGY, V81, pS33, DOI 10.1212/01.wnl.0000435744.57038.af; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Estes Myka L, 2010, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0933s52; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Ferguson MJ, 2016, PEDIATR BLOOD CANCER, V63, P206, DOI 10.1002/pbc.25763; Ferner RE, 2013, HAND CLINIC, V115, P939, DOI 10.1016/B978-0-444-52902-2.00053-9; Friedman JM, 1999, AM J MED GENET, V89, P1; Gay CM, 2017, BRIT J CANCER, V116, P415, DOI 10.1038/bjc.2016.428; GREENBERG HM, 1981, INT J RADIAT ONCOL, V7, P305, DOI 10.1016/0360-3016(81)90102-4; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Gross AM, 2018, NEURO-ONCOLOGY, V20, P1643, DOI 10.1093/neuonc/noy067; Grullich Carsten, 2018, Recent Results Cancer Res, V211, P67, DOI 10.1007/978-3-319-91442-8_5; Gutmann DH, 2013, EXPERT OPIN INV DRUG, V22, P443, DOI 10.1517/13543784.2013.772979; Jakacki RI, 2017, NEURO-ONCOLOGY, V19, P289, DOI 10.1093/neuonc/now158; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Jousma E, 2015, PEDIATR BLOOD CANCER, V62, P1709, DOI 10.1002/pbc.25546; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Leibowitz-Amit R, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0747-y; Nguyen L, 2016, ANTI-CANCER DRUG, V27, P669, DOI 10.1097/CAD.0000000000000366; Lock R, 2016, J CLIN INVEST, V126, P2181, DOI 10.1172/JCI85183; Maertens O, 2017, CANCER RES, V77, P5706, DOI 10.1158/0008-5472.CAN-17-1789; Mautner VF, 2008, NEURO-ONCOLOGY, V10, P593, DOI 10.1215/15228517-2008-011; Munchhof AM, 2006, HUM MOL GENET, V15, P1858, DOI 10.1093/hmg/ddl108; Nutakki K, 2018, J NEURO-ONCOL, V137, P337, DOI 10.1007/s11060-017-2723-2; Packer RJ, 2018, J CHILD NEUROL, V33, P82, DOI 10.1177/0883073817739196; Pharmaceutical Research andManufacturers of America, 2016, DEC INN CHRON DIS; Plotkin SR, 2013, NEUROLOGY, V81, pS1, DOI 10.1212/01.wnl.0000435743.49414.b6; Pradhan KR, 2011, CYTOM PART B-CLIN CY, V80B, P335, DOI 10.1002/cyto.b.20602; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Rhodes SD, 2019, HUM MOL GENET, V28, P2752, DOI 10.1093/hmg/ddz095; Robertson KA, 2012, LANCET ONCOL, V13, P1218, DOI 10.1016/S1470-2045(12)70414-X; Schoumacher M, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0579-4; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Solomon J, 2004, COMPUT MED IMAG GRAP, V28, P257, DOI 10.1016/j.compmedimag.2004.03.002; Staser K, 2012, ANNU REV PATHOL-MECH, V7, P469, DOI 10.1146/annurev-pathol-011811-132441; Tolaney SM, 2017, ONCOLOGIST, V22, P25, DOI 10.1634/theoncologist.2016-0229; Viola D, 2013, FUTURE ONCOL, V9, P1083, DOI [10.2217/fon.13.128, 10.2217/FON.13.128]; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Weiss B, 2015, NEURO-ONCOLOGY, V17, P596, DOI 10.1093/neuonc/nou235; Wentworth S, 2009, INT J RADIAT ONCOL, V73, P208, DOI 10.1016/j.ijrobp.2008.03.073; Wu JQ, 2012, PEDIATR BLOOD CANCER, V58, P173, DOI 10.1002/pbc.23015; Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yavuz S, 2014, THYROID, V24, P1223, DOI 10.1089/thy.2013.0621	57	19	19	3	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					165	+		10.1038/s41591-020-01193-6	http://dx.doi.org/10.1038/s41591-020-01193-6			39	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442015	Green Accepted			2022-12-27	WOS:000607931400035
J	Norheim, OF; Abi-Rached, JM; Bright, LK; Baeroe, K; Ferraz, OLM; Gloppen, S; Voorhoeve, A				Norheim, Ole F.; Abi-Rached, Joelle M.; Bright, Liam Kofi; Baeroe, Kristine; Ferraz, Octavio L. M.; Gloppen, Siri; Voorhoeve, Alex			Difficult trade-offs in response to COVID-19: the case for open and inclusive decision making	NATURE MEDICINE			English	Editorial Material								We argue that deliberative decision making that is inclusive, transparent and accountable can contribute to more trustworthy and legitimate decisions on difficult ethical questions and political trade-offs during the pandemic and beyond.	[Norheim, Ole F.; Baeroe, Kristine] Univ Bergen, Bergen Ctr Eth & Prior Setting, Dept Global Publ Hlth & Primary Care, Bergen, Norway; [Norheim, Ole F.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Abi-Rached, Joelle M.] Ecole Normale Super, Dept Geog & Terr, Paris, France; [Abi-Rached, Joelle M.] Sci Po, Medialab, Paris, France; [Bright, Liam Kofi; Voorhoeve, Alex] London Sch Econ, Dept Philosophy Log & Sci Method, London, England; [Ferraz, Octavio L. M.] Kings Coll London, Dickson Poon Sch Law, Transnatl Law Inst, London, England; [Gloppen, Siri] Univ Bergen, Ctr Law & Social Transformat, Dept Comparat Polit, Bergen, Norway; [Voorhoeve, Alex] Erasmus Univ, Dept Appl Econ, Rotterdam, Netherlands; [Voorhoeve, Alex] Erasmus Univ, Dept Philosophy, Rotterdam, Netherlands	University of Bergen; Harvard University; Harvard T.H. Chan School of Public Health; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut d'Etudes Politiques Paris (Sciences Po); University of London; London School Economics & Political Science; University of London; King's College London; University of Bergen; Erasmus University Rotterdam; Erasmus University Rotterdam	Norheim, OF (corresponding author), Univ Bergen, Bergen Ctr Eth & Prior Setting, Dept Global Publ Hlth & Primary Care, Bergen, Norway.; Norheim, OF (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	ole.norheim@uib.no	Norheim, Ole Frithjof/AAC-8771-2020	Norheim, Ole Frithjof/0000-0002-5748-5956; Gloppen, Siri/0000-0001-5745-8109	Trond Mohn Foundation [BFS2019TMT02]; Norad through Bergen Centre for Ethics and Priority Setting (BCEPS) [RAF-18/0009, 813 596]	Trond Mohn Foundation; Norad through Bergen Centre for Ethics and Priority Setting (BCEPS)	This work was supported by Trond Mohn Foundation (BFS2019TMT02) and Norad (RAF-18/0009) through Bergen Centre for Ethics and Priority Setting (BCEPS; project number 813 596).	Alwan NA, 2020, LANCET, V396, pE71, DOI 10.1016/S0140-6736(20)32153-X; Charlier P, 2020, LANCET, V396, P1069, DOI 10.1016/S0140-6736(20)32068-7; Daniels N., 2008, SETTING LIMITS FAIRL, V2nd Ed.; Dryzek JS, 2019, SCIENCE, V363, P1144, DOI 10.1126/science.aaw2694; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Gutmann A., 2004, WHY DELIBERATIVE DEM; Heesen R, 2015, PHILOS STUD, V172, P2299, DOI 10.1007/s11098-014-0411-z; Human Technology, 2020, RAPPORT; Jansen MPM, 2018, INT J HEALTH POLICY, V7, P973, DOI 10.15171/ijhpm.2018.57; Kitcher P., 2003, SCI TRUTH DEMOCRACY; Lewandowsky S., 2020, TECHNOLOGY DEMOCRACY; Miller DT, 2001, ANNU REV PSYCHOL, V52, P527, DOI 10.1146/annurev.psych.52.1.527; OECD, 2020, INN CIT PART NEW DEM, DOI [10.1787/339306da-en, DOI 10.1787/339306DA-EN]; Participedia, GLOB NET CROWDS PLAT; Schroeder SA, 2017, PUBLIC HEALTH ETH-UK, V10, P176, DOI 10.1093/phe/phw032; SMITH GRAHAM, 2009, DEMOCRATIC INNOVATIO, DOI DOI 10.1017/CBO9780511609848; Steele K, 2012, PHILOS SCI, V79, P893, DOI 10.1086/667842; Tyler TR, 2006, ANNU REV PSYCHOL, V57, P375, DOI 10.1146/annurev.psych.57.102904.190038; Ward Z. B, HIST PHILOS SCI A	19	26	26	3	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					10	13		10.1038/s41591-020-01204-6	http://dx.doi.org/10.1038/s41591-020-01204-6		DEC 2020	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33340033	Bronze, Green Submitted			2022-12-27	WOS:000600087700001
J	Stower, H				Stower, Hannah			WHO declares Africa polio-free	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1805	1805		10.1038/s41591-020-01156-x	http://dx.doi.org/10.1038/s41591-020-01156-x			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288928				2022-12-27	WOS:000596579200009
J	[Anonymous]				[Anonymous]			Interferon linked to COVID-19 severity	NATURE MEDICINE			English	Editorial Material																			0	2	2	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1806	1806		10.1038/s41591-020-01164-x	http://dx.doi.org/10.1038/s41591-020-01164-x			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288943	Bronze			2022-12-27	WOS:000596579200013
J	Pertwee, E; Simas, C; Larson, HJ				Pertwee, Ed; Simas, Clarissa; Larson, Heidi J.			An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy	NATURE MEDICINE			English	Article								The COVID-19 'infodemic' continues to undermine trust in vaccination efforts aiming to bring an end to the pandemic. However, the challenge of vaccine hesitancy is not only a problem of the information ecosystem and it often has little to do with the vaccines themselves. In this Perspective, we argue that the epidemiological and social crises brought about by COVID-19 have magnified widely held social anxieties and trust issues that, in the unique circumstances of this global pandemic, have exacerbated skepticism toward vaccines. We argue that trust is key to overcoming vaccine hesitancy, especially in a context of widespread social uncertainty brought about by the pandemic, where public sentiment can be volatile. Finally, we draw out some implications of our argument for strategies to build vaccine confidence. In this Perspective, the authors discuss the new digital communications landscape in relation to vaccines and argue that trust is key to overcoming vaccine hesitancy.	[Pertwee, Ed; Simas, Clarissa; Larson, Heidi J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Larson, Heidi J.] Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USA	University of London; London School of Hygiene & Tropical Medicine; University of Washington; University of Washington Seattle	Pertwee, E (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.	ed.pertwee@lshtm.ac.uk	; Larson, Heidi J./N-1018-2017	Simas, Clarissa/0000-0003-0035-8419; Larson, Heidi J./0000-0002-8477-7583				Abalakina-Paap M, 1999, POLIT PSYCHOL, V20, P637, DOI 10.1111/0162-895X.00160; Ahmed W, 2020, J MED INTERNET RES, V22, DOI 10.2196/19458; [Anonymous], 2019, FACEBOOK NEWSROOM; Basol Melisa, 2020, J Cogn, V3, P2, DOI 10.5334/joc.91; Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728; Bellato Alessio, 2020, Soc Sci Humanit Open, V2, P100062, DOI 10.1016/j.ssaho.2020.100062; Bickert M., 2021, FACEBOOK NEWSROOM; Bruns A, 2020, MEDIA INT AUST, V177, P12, DOI 10.1177/1329878X20946113; Byford J, 2011, CONSPIRACY THEORIES: A CRITICAL INTRODUCTION, P1, DOI 10.1057/9780230349216; Center for Countering Digital Hate, 2020, ANT IND; Corlett E., 2021, GUARDIAN; de Figueiredo A, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101109; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Frankovic Kathy, 2021, WHY WONT AM GET VACC; GOERTZEL T, 1994, POLIT PSYCHOL, V15, P731, DOI 10.2307/3791630; Goldenberg A, 2020, CURR DIR PSYCHOL SCI, V29, P154, DOI 10.1177/0963721420901574; Gronke P, 2015, PS-POLIT SCI POLIT, V48, P3, DOI 10.1017/S1049096514001851; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Josephson A., 2020, TWITTER BLOG; Kahneman D, 2015, FORTUNE, V172, P20; Kennedy J, 2019, EUR J PUBLIC HEALTH, V29, P512, DOI 10.1093/eurpub/ckz004; Larson H.J., 2020, STUCK VACCINE RUMORS; Larson H, 2020, LANCET, V395, P768, DOI 10.1016/S0140-6736(20)30050-7; Larson HJ, 2021, SCIENCE, V371, P1289, DOI 10.1126/science.abi6488; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; ODonovan C., 2019, BUZZFEED NEWS; Ofri D, 2009, NEW ENGL J MED, V361, P2594, DOI 10.1056/NEJMp0911047; Paterson P., 2021, BMJ OPINION; Peretti-Watel Patrick, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Roozenbeek J, 2020, HARVARD KENNEDY SCH, V1, DOI [10.37016//mr-2020-008, DOI 10.37016//MR-2020-008]; Scrima F, 2022, PERS INDIV DIFFER, V184, DOI 10.1016/j.paid.2021.111188; Tariq K., 2019, FINLAND MOST RESILIE; Tengbeh AF, 2018, SOC SCI MED, V203, P35, DOI 10.1016/j.socscimed.2018.03.008; van Prooijen JW, 2017, MEM STUD, V10, P323, DOI 10.1177/1750698017701615; Ward JK, 2017, HEALTH RISK SOC, V19, P38, DOI 10.1080/13698575.2017.1299856; Waterson Jim, 2020, GUARDIAN; WHO Director General, 2020, MUN SEC C SPEECH; Wise J, 2001, BRIT MED J, V322, P194, DOI 10.1136/bmj.322.7280.194; YouGov, 2021, COVID 19 VACC WILL T; YouGov/Cambridge, 2020, GLOB 2020 GUARD CONS	43	21	21	28	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					456	459		10.1038/s41591-022-01728-z	http://dx.doi.org/10.1038/s41591-022-01728-z		MAR 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35273403	Bronze			2022-12-27	WOS:000767065500002
J	Castro, MC				Castro, Marcia C.			Improving health in the Amazon demands local involvement	NATURE MEDICINE			English	Editorial Material								The poor health outcomes of people in the Brazilian Amazon have been exacerbated by COVID-19, and can only be improved with a health equity approach that involves local people.	[Castro, Marcia C.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Castro, MC (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	mcastro@hsph.harvard.edu	Castro, Marcia/A-8834-2015	Castro, Marcia/0000-0003-4606-2795					0	0	0	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					435	435		10.1038/s41591-022-01710-9	http://dx.doi.org/10.1038/s41591-022-01710-9		MAR 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35260842	Bronze			2022-12-27	WOS:000766084100001
J	Uzzan, M; Martin, JC; Mesin, L; Livanos, AE; Castro-Dopico, T; Huang, RQ; Petralia, F; Magri, G; Kumar, S; Zhao, Q; Rosenstein, AK; Tokuyama, M; Sharma, K; Ungaro, R; Kosoy, R; Jha, D; Fischer, J; Singh, H; Keir, ME; Ramamoorthi, N; O' Gorman, WE; Cohen, BL; Rahman, A; Cossarini, F; Seki, A; Leyre, L; Vaquero, ST; Gurunathan, S; Grasset, EK; Losic, B; Dubinsky, M; Greenstein, AJ; Gottlieb, Z; Legnani, P; George, J; Irizar, H; Stojmirovic, A; Brodmerkel, C; Kasarkis, A; Sands, BE; Furtado, G; Lira, SA; Tuong, ZWK; Ko, HBM; Cerutti, A; Elson, CO; Clatworthy, MR; Merad, M; Suarez-Farinas, M; Argmann, C; Hackney, JA; Victora, GD; Randolph, GJ; Kenigsberg, E; Colombel, JF; Mehandru, S				Uzzan, Mathieu; Martin, Jerome C.; Mesin, Luka; Livanos, Alexandra E.; Castro-Dopico, Tomas; Huang, Ruiqi; Petralia, Francesca; Magri, Giuliana; Kumar, Shashi; Zhao, Qing; Rosenstein, Adam K.; Tokuyama, Minami; Sharma, Keshav; Ungaro, Ryan; Kosoy, Roman; Jha, Divya; Fischer, Jeremy; Singh, Harpriya; Keir, Mary E.; Ramamoorthi, Nandhini; O' Gorman, William E.; Cohen, Benjamin L.; Rahman, Adeeb; Cossarini, Francesca; Seki, Akihiro; Leyre, Louise; Vaquero, Sonia Tejedor; Gurunathan, Sakteesh; Grasset, Emilie K.; Losic, Bojan; Dubinsky, Marla; Greenstein, Alexander J.; Gottlieb, Zoe; Legnani, Peter; George, James; Irizar, Haritz; Stojmirovic, Aleksandar; Brodmerkel, Carrie; Kasarkis, Andrew; Sands, Bruce E.; Furtado, Glaucia; Lira, Sergio A.; Tuong, Zewen K.; Ko, Huaibin M.; Cerutti, Andrea; Elson, Charles O.; Clatworthy, Menna R.; Merad, Miriam; Suarez-Farinas, Mayte; Argmann, Carmen; Hackney, Jason A.; Victora, Gabriel D.; Randolph, Gwendalyn J.; Kenigsberg, Ephraim; Colombel, Jean Frederic; Mehandru, Saurabh			Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity	NATURE MEDICINE			English	Article							INFLAMMATORY-BOWEL-DISEASE; HELPER T-CELLS; CROHNS-DISEASE; INTERFERON-GAMMA; RNA-SEQ; B-CELLS; IGA; RECEPTOR; EXPRESSION; GUT	B cells, which are critical for intestinal homeostasis, remain understudied in ulcerative colitis (UC). In this study, we recruited three cohorts of patients with UC (primary cohort, n = 145; validation cohort 1, n = 664; and validation cohort 2, n = 143) to comprehensively define the landscape of B cells during UC-associated intestinal inflammation. Using single-cell RNA sequencing, single-cell IgH gene sequencing and protein-level validation, we mapped the compositional, transcriptional and clonotypic landscape of mucosal and circulating B cells. We found major perturbations within the mucosal B cell compartment, including an expansion of naive B cells and IgG(+) plasma cells with curtailed diversity and maturation. Furthermore, we isolated an auto-reactive plasma cell clone targeting integrin alpha v beta 6 from inflamed UC intestines. We also identified a subset of intestinal CXCL13-expressing TFH-like T peripheral helper cells that were associated with the pathogenic B cell response. Finally, across all three cohorts, we confirmed that changes in intestinal humoral immunity are reflected in circulation by the expansion of gut-homing plasmablasts that correlates with disease activity and predicts disease complications. Our data demonstrate a highly dysregulated B cell response in UC and highlight a potential role of B cells in disease pathogenesis. Multi-modal profiling reveals major alterations in colonic B cells in patients with ulcerative colitis, including reduced clonal diversity of plasma cells, and suggests that circulating gut-homing plasmablasts could serve as a biomarker for disease activity.	[Uzzan, Mathieu; Livanos, Alexandra E.; Castro-Dopico, Tomas; Rosenstein, Adam K.; Tokuyama, Minami; Sharma, Keshav; Ungaro, Ryan; Jha, Divya; Singh, Harpriya; Cohen, Benjamin L.; Seki, Akihiro; Leyre, Louise; Gurunathan, Sakteesh; Dubinsky, Marla; Gottlieb, Zoe; Legnani, Peter; George, James; Sands, Bruce E.; Colombel, Jean Frederic; Mehandru, Saurabh] Icahn Sch Med Mt Sinai, Dept Med, Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA; [Uzzan, Mathieu; Martin, Jerome C.; Livanos, Alexandra E.; Castro-Dopico, Tomas; Rosenstein, Adam K.; Sharma, Keshav; Jha, Divya; Fischer, Jeremy; Singh, Harpriya; Cossarini, Francesca; Seki, Akihiro; Leyre, Louise; Grasset, Emilie K.; Furtado, Glaucia; Lira, Sergio A.; Cerutti, Andrea; Merad, Miriam; Kenigsberg, Ephraim; Mehandru, Saurabh] Icahn Sch Med Mt Sinai, Precis Inst Immunol, New York, NY 10029 USA; [Uzzan, Mathieu] Paris Est Creteil Univ UPEC, Henri Mondor Hosp, AP HP, Federat Hosp Univ,Gastroenterol Dept,InnovaT TheR, Creteil, France; [Martin, Jerome C.] Univ Nantes, Ctr Rech Transplantat & Immunol, CHU Nantes, INSERM, Nantes, France; [Martin, Jerome C.] CHU Nantes, Lab Immunol, Ctr Immuno Monitoring Nantes Atlantique CIMNA, Nantes, France; [Mesin, Luka; Victora, Gabriel D.] Rockefeller Univ, Lab Lymphocyte Dynam, 1230 York Ave, New York, NY 10021 USA; [Castro-Dopico, Tomas; Tuong, Zewen K.; Clatworthy, Menna R.] Univ Cambridge, Dept Med, Mol Immun Unit, Cambridge, England; [Huang, Ruiqi; Losic, Bojan; Kasarkis, Andrew; Suarez-Farinas, Mayte; Argmann, Carmen] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Huang, Ruiqi; Petralia, Francesca; Kosoy, Roman; Rahman, Adeeb; Irizar, Haritz; Kenigsberg, Ephraim] Icahn Sch Med Mt Sinai, Icahn Inst Data Sci & Genom Technol, Dept Genet & Genom Sci, New York, NY 10029 USA; [Magri, Giuliana; Vaquero, Sonia Tejedor; Cerutti, Andrea] Hosp Mar, Translat Clin Res Program, Med Res Inst IMIM, Barcelona, Spain; [Kumar, Shashi; Randolph, Gwendalyn J.] Washington Univ, Sch Med, St Louis, MO USA; [Zhao, Qing; Elson, Charles O.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Kosoy, Roman; Losic, Bojan; Kasarkis, Andrew; Suarez-Farinas, Mayte; Argmann, Carmen] Icahn Inst Data Sci & Genom Technol, New York, NY USA; [Keir, Mary E.; Ramamoorthi, Nandhini] Genentech Inc, OMNI, Biomarker Discovery, San Francisco, CA 94080 USA; [O' Gorman, William E.] Genentech Inc, OMNI Biomarker Dev, San Francisco, CA 94080 USA; [Rahman, Adeeb] Icahn Sch Med Mt Sinai, Precis Inst Immunol, Human Immune Monitoring Core, New York, NY 10029 USA; [Rahman, Adeeb] Immunai, New York, NY USA; [Grasset, Emilie K.] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol, New York, NY 10029 USA; [Greenstein, Alexander J.] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA; [Stojmirovic, Aleksandar; Brodmerkel, Carrie] Spring House, Janssen R&D, Philadelphia, PA USA; [Kasarkis, Andrew] Sema4, Stamford, CT USA; [Tuong, Zewen K.; Clatworthy, Menna R.] Wellcome Sanger Inst, Cellular Genet, Hinxton, England; [Ko, Huaibin M.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Cerutti, Andrea] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain; [Hackney, Jason A.] Genentech Inc, Bioinformat & Computat Biol, San Francisco, CA 94080 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Rockefeller University; University of Cambridge; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; Roche Holding; Genentech; Roche Holding; Genentech; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Wellcome Trust Sanger Institute; Icahn School of Medicine at Mount Sinai; ICREA; Roche Holding; Genentech	Mehandru, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA.; Mehandru, S (corresponding author), Icahn Sch Med Mt Sinai, Precis Inst Immunol, New York, NY 10029 USA.		Martin, Jerome/GZG-4189-2022; gurunathan, sakteesh/GPK-5913-2022; Magri, Giuliana/K-6552-2014; Tuong, Zewen Kelvin/E-4419-2017	jha, divya/0000-0002-5038-241X; Magri, Giuliana/0000-0002-0163-3542; Tuong, Zewen Kelvin/0000-0002-6735-6808; Castro-Dopico, Tomas/0000-0002-6964-5478; Martin, Jerome/0000-0003-0068-8776; Hackney, Jason/0000-0002-5922-563X	NIH/NIDDK [R01 112296]; Rainin Foundation Synergy Grant; Ministerio de Ciencia, Innovacion y Universidades [RTI2018-093894-B-I00]; Crohn's and Colitis Foundation [R01 AI119006, R01 AI157137, DK121009, DK110352]; French National Society of Gastroenterology; Fondation pour la Recherche Medicale [FDM 41552]; Prix pour les jeunes chercheurs' de la Fondation Bettencourt-Schueller; Philippe Foundation; ANR JCJC [ANR-20-CE17-0009]; Swedish Research Council [201506486]; Takeda Pharmaceuticals; Medical Research Council New Investigator Research Grant [MR/N024907/1]; Wellcome Trust Investigator Award [220268/Z/20/Z]; ECCO-IOBD fellowship; NExT 'Junior Talent';  [P01 AI061093];  [K23KD111995]	NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Rainin Foundation Synergy Grant; Ministerio de Ciencia, Innovacion y Universidades(Spanish Government); Crohn's and Colitis Foundation; French National Society of Gastroenterology; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Prix pour les jeunes chercheurs' de la Fondation Bettencourt-Schueller; Philippe Foundation; ANR JCJC(French National Research Agency (ANR)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Takeda Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Medical Research Council New Investigator Research Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Investigator Award(Wellcome Trust); ECCO-IOBD fellowship; NExT 'Junior Talent'; ; 	We thank the patients who participated in the study. The authors would like to thank the Biorepository and Pathology Core at the Icahn School of Medicine at Mount Sinai for carrying out some of the immunostaining experiments. This work was supported by NIH/NIDDK grant R01 112296 (S.M.). Additional support was provided by a Rainin Foundation Synergy Grant to S.M., G.J.R. and J.F.C. A.C. was supported by P01 AI061093 and Ministerio de Ciencia, Innovacion y Universidades grants RTI2018-093894-B-I00 and RTI2018-093894-B-I00. Other sources of support included K23KD111995 (R.C. U.), a Career Development Award from the Crohn's and Colitis Foundation (R.C.U.), R01 AI119006 (G.D.V.), R01 AI157137 (G.D.V.), DK121009 (S.A.L.) and DK110352 (S.A.L.). M.U. was supported by an ECCO-IOBD fellowship, by a grant from the French National Society of Gastroenterology (Bourse Robert Tournut) and by the Fondation pour la Recherche Medicale (FDM 41552). J.C.M. was supported by `Prix pour les jeunes chercheurs' de la Fondation Bettencourt-Schueller, the Philippe Foundation, NExT `Junior Talent' and ANR JCJC (ANR-20-CE17-0009). E.K.G. was supported by a postdoctoral fellowship from the Swedish Research Council (201506486). Q.Z. is the recipient of a research fellowship from Takeda Pharmaceuticals. M.R.C. and T.D.C. were supported by a Medical Research Council New Investigator Research Grant (MR/N024907/1) and by a Wellcome Trust Investigator Award (220268/Z/20/Z). The sampling of the IBD cohort (Crohn's disease and UC) was jointly designed as part of the research alliance between Janssen Biotech and the Icahn School of Medicine at Mount Sinai. Beyond this exception, no other funders had a role in analyses, design or interpretation.	Alexander KL, 2021, GASTROENTEROLOGY, V161, P522, DOI 10.1053/j.gastro.2021.03.064; Amir EAD, 2018, J IMMUNOL METHODS, V453, P20, DOI 10.1016/j.jim.2017.08.011; BAKLIEN K, 1975, CLIN EXP IMMUNOL, V22, P197; Baran Y, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1812-2; Benckert J, 2011, J CLIN INVEST, V121, P1946, DOI 10.1172/JCI44447; Boland BS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb4432; Bollinger RR, 2006, MOL IMMUNOL, V43, P378, DOI 10.1016/j.molimm.2005.02.013; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Castro-Dopico T, 2020, CURR OPIN PHARMACOL, V55, P90, DOI 10.1016/j.coph.2020.10.002; Castro-Dopico T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00805; Castro-Dopico T, 2019, IMMUNITY, V50, P1099, DOI 10.1016/j.immuni.2019.02.006; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Dann E, 2022, NAT BIOTECHNOL, V40, P245, DOI 10.1038/s41587-021-01033-z; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Donaldson GP, 2018, SCIENCE, V360, P795, DOI 10.1126/science.aaq0926; DunnWalters DK, 1997, EUR J IMMUNOL, V27, P463, DOI 10.1002/eji.1830270217; Ekland EH, 2004, J IMMUNOL, V172, P4700, DOI 10.4049/jimmunol.172.8.4700; Faubion WA, 2013, AM J GASTROENTEROL, V108, P1891, DOI 10.1038/ajg.2013.354; Finak G, 2016, SCI REP-UK, V6, DOI 10.1038/srep20686; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Geissmann F, 2001, J IMMUNOL, V166, P346, DOI 10.4049/jimmunol.166.1.346; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Habtezion A, 2016, GASTROENTEROLOGY, V150, P340, DOI 10.1053/j.gastro.2015.10.046; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hayatsu N, 2017, IMMUNITY, V47, P268, DOI 10.1016/j.immuni.2017.07.008; Hombrink P, 2016, NAT IMMUNOL, V17, P1467, DOI 10.1038/ni.3589; Hosomi S, 2011, CLIN EXP IMMUNOL, V163, P215, DOI 10.1111/j.1365-2249.2010.04290.x; Hovhannisyan Z, 2011, GASTROENTEROLOGY, V140, P957, DOI 10.1053/j.gastro.2010.12.002; Jaitin DA, 2014, SCIENCE, V343, P776, DOI 10.1126/science.1247651; James KR, 2020, NAT IMMUNOL, V21, P343, DOI 10.1038/s41590-020-0602-z; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Kabbert J, 2020, J EXP MED, V217, DOI 10.1084/jem.20200275; Katewa A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90111; KETT K, 1987, GUT, V28, P1013, DOI 10.1136/gut.28.8.1013; KETT K, 1987, GASTROENTEROLOGY, V93, P919, DOI 10.1016/0016-5085(87)90552-X; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Kuwada T, 2021, GASTROENTEROLOGY, V160, P2383, DOI 10.1053/j.gastro.2021.02.019; Landsverk OJB, 2017, J EXP MED, V214, P309, DOI 10.1084/jem.20161590; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Long Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00104; MACDERMOTT RP, 1989, GASTROENTEROLOGY, V96, P764; Mackay LK, 2016, SCIENCE, V352, P459, DOI 10.1126/science.aad2035; Macpherson A, 1996, GUT, V38, P365, DOI 10.1136/gut.38.3.365; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008; McLoughlin K, 2016, CELL HOST MICROBE, V19, P550, DOI 10.1016/j.chom.2016.02.021; Obeng-Adjei N, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006576; Owczarczyk K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002432; Paul F, 2015, CELL, V163, P1663, DOI 10.1016/j.cell.2015.11.013; Peterson DA, 2007, CELL HOST MICROBE, V2, P328, DOI 10.1016/j.chom.2007.09.013; Phalipon A, 2003, TRENDS IMMUNOL, V24, P55, DOI 10.1016/S1471-4906(02)00031-5; Pilette C, 2010, IMMUNOL CELL BIOL, V88, P486, DOI 10.1038/icb.2009.120; Portugal S, 2015, ELIFE, V4, DOI 10.7554/eLife.07218; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Toellner KM, 1998, J EXP MED, V187, P1193, DOI 10.1084/jem.187.8.1193; Ueno H, 2015, NAT IMMUNOL, V16, P142, DOI 10.1038/ni.3054; Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2; Uo M, 2013, GUT, V62, P1734, DOI 10.1136/gutjnl-2012-303063; Van Den Bogaerde J, 2002, ALIMENT PHARM THER, V16, P1903, DOI 10.1046/j.1365-2036.2002.01360.x; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Wang XR, 2017, CLIN SCI, V131, P2933, DOI 10.1042/CS20171258; Wang ZL, 2014, TUMOR BIOL, V35, P9355, DOI 10.1007/s13277-014-2208-2; Wardemann Hedda, 2013, Methods Mol Biol, V971, P93, DOI 10.1007/978-1-62703-269-8_5; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Willinger T, 2006, J IMMUNOL, V176, P1439, DOI 10.4049/jimmunol.176.3.1439; Wong MT, 2016, IMMUNITY, V45, P442, DOI 10.1016/j.immuni.2016.07.007; Xue GH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014757; Yurasov S, 2007, CURR OPIN RHEUMATOL, V19, P421, DOI 10.1097/BOR.0b013e328277ef3b; Zemmour D, 2018, NAT IMMUNOL, V19, P291, DOI 10.1038/s41590-018-0051-0; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; ZHENG GX, 2017, NATURE, V0008	80	6	6	1	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					766	+		10.1038/s41591-022-01680-y	http://dx.doi.org/10.1038/s41591-022-01680-y		FEB 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35190725	Green Accepted, Green Submitted			2022-12-27	WOS:000758992300002
J	Rehm, HL				Rehm, Heidi L.			Time to make rare disease diagnosis accessible to all	NATURE MEDICINE			English	Editorial Material								Studies have demonstrated the value of genomic analysis for the diagnosis of rare diseases, but accessibility is still in its infancy; global data sharing is needed to further advance our knowledge of all causes of rare disease.	[Rehm, Heidi L.] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Rehm, Heidi L.] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Rehm, HL (corresponding author), Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA.; Rehm, HL (corresponding author), Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.	hrehm@mgh.harvard.edu						Austin-Tse, IN PRESS; AVE Alliance Founding Members, 2021, ZENODO, DOI [10.5281/zenodo.4989960, DOI 10.5281/ZENODO.4989960]; Bertoli-Avella AM, 2021, EUR J HUM GENET, V29, P141, DOI 10.1038/s41431-020-00713-9; Bragin E, 2014, NUCLEIC ACIDS RES, V42, pD993, DOI 10.1093/nar/gkt937; Costain G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18109; Landrum MJ, 2018, HUM MUTAT, V39, P1623, DOI 10.1002/humu.23641; Philippakis AA, 2015, HUM MUTAT, V36, P915, DOI 10.1002/humu.22858; Rehder C, 2021, GENET MED, V23, P1399, DOI 10.1038/s41436-021-01139-4; Rehm HL., 2021, CELL GENOM, V1, P100029, DOI [10.1016/j.xgen.2021.100029, DOI 10.1016/J.XGEN.2021.100029]; Smedley D, 2021, NEW ENGL J MED, V385, P1868, DOI 10.1056/NEJMoa2035790; Stranneheim H, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00855-5	11	2	2	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					241	242		10.1038/s41591-021-01657-3	http://dx.doi.org/10.1038/s41591-021-01657-3		FEB 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35132266	Green Accepted			2022-12-27	WOS:000752184200004
J	Wratil, PR; Stern, M; Priller, A; Willmann, A; Almanzar, G; Vogel, E; Feuerherd, M; Cheng, CC; Yazici, S; Christa, C; Jeske, S; Lupoli, G; Vogt, T; Albanese, M; Mejias-Perez, E; Bauernfried, S; Graf, N; Mijocevic, H; Vu, M; Tinnefeld, K; Wettengel, J; Hoffmann, D; Muenchhoff, M; Daechert, C; Mairhofer, H; Krebs, S; Fingerle, V; Graf, A; Steininger, P; Blum, H; Hornung, V; Liebl, B; Uberla, K; Prelog, M; Knolle, P; Keppler, OT; Protzer, U				Wratil, Paul R.; Stern, Marcel; Priller, Alina; Willmann, Annika; Almanzar, Giovanni; Vogel, Emanuel; Feuerherd, Martin; Cheng, Cho-Chin; Yazici, Sarah; Christa, Catharina; Jeske, Samuel; Lupoli, Gaia; Vogt, Tim; Albanese, Manuel; Mejias-Perez, Ernesto; Bauernfried, Stefan; Graf, Natalia; Mijocevic, Hrvoje; Vu, Martin; Tinnefeld, Kathrin; Wettengel, Jochen; Hoffmann, Dieter; Muenchhoff, Maximilian; Daechert, Christopher; Mairhofer, Helga; Krebs, Stefan; Fingerle, Volker; Graf, Alexander; Steininger, Philipp; Blum, Helmut; Hornung, Veit; Liebl, Bernhard; Ueberla, Klaus; Prelog, Martina; Knolle, Percy; Keppler, Oliver T.; Protzer, Ulrike			Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	NATURE MEDICINE			English	Article							MATURATION; ANTIBODIES; BREADTH; POTENCY	Infection-neutralizing antibody responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 vaccination are an essential component of antiviral immunity. Antibody-mediated protection is challenged by the emergence of SARS-CoV-2 variants of concern (VoCs) with immune escape properties, such as omicron (B.1.1.529), which is rapidly spreading worldwide. Here we report neutralizing antibody dynamics in a longitudinal cohort of coronavirus disease 2019 convalescent and infection-naive individuals vaccinated with mRNA BNT162b2 by quantifying SARS-CoV-2 spike protein antibodies and determining their avidity and neutralization capacity in serum. Using live-virus neutralization assays, we show that a superior infection-neutralizing capacity against all VoCs, including omicron, developed after either two vaccinations in convalescents or a third vaccination or breakthrough infection of twice-vaccinated, naive individuals. These three consecutive spike antigen exposures resulted in an increasing neutralization capacity per anti-spike antibody unit and were paralleled by stepwise increases in antibody avidity. We conclude that an infection-plus-vaccination-induced hybrid immunity or a triple immunization can induce high-quality antibodies with superior neutralization capacity against VoCs, including omicron.	[Wratil, Paul R.; Stern, Marcel; Lupoli, Gaia; Albanese, Manuel; Mejias-Perez, Ernesto; Muenchhoff, Maximilian; Daechert, Christopher; Mairhofer, Helga; Keppler, Oliver T.] LMU Munchen, Natl Reference Ctr Retroviruses, Max Von Pettenkofer Inst, Fac Med,Virol, Munich, Germany; [Wratil, Paul R.; Stern, Marcel; Lupoli, Gaia; Albanese, Manuel; Mejias-Perez, Ernesto; Muenchhoff, Maximilian; Daechert, Christopher; Mairhofer, Helga; Keppler, Oliver T.] LMU Munchen, Natl Reference Ctr Retroviruses, Gene Ctr, Fac Med,Virol, Munich, Germany; [Wratil, Paul R.; Wettengel, Jochen; Hoffmann, Dieter; Muenchhoff, Maximilian; Knolle, Percy; Keppler, Oliver T.; Protzer, Ulrike] German Ctr Infect Res DZIF, Partner Site, Munich, Germany; [Priller, Alina; Yazici, Sarah; Knolle, Percy] Tech Univ Munich TUM, Univ Hosp Rechts der Isar, Sch Med, Inst Mol Immunol & Expt Oncol, Munich, Germany; [Willmann, Annika; Vogel, Emanuel; Feuerherd, Martin; Cheng, Cho-Chin; Christa, Catharina; Jeske, Samuel; Graf, Natalia; Mijocevic, Hrvoje; Vu, Martin; Tinnefeld, Kathrin; Wettengel, Jochen; Hoffmann, Dieter; Protzer, Ulrike] TUM, Sch Med, Inst Virol, Helmholtz Ctr Munich, Munich, Germany; [Almanzar, Giovanni; Vogt, Tim; Prelog, Martina] Univ Hosp Wurzburg, Pediat Dept, Pediat Rheumatol Special Immunol, Wurzburg, Germany; [Bauernfried, Stefan; Hornung, Veit; Keppler, Oliver T.] LMU Munchen, Gene Ctr, Munich, Germany; [Bauernfried, Stefan; Hornung, Veit; Keppler, Oliver T.] LMU Munchen, Dept Biochem, Munich, Germany; [Krebs, Stefan; Graf, Alexander; Blum, Helmut] LMU Munchen, Lab Funct Genome Anal, Gene Ctr, Munich, Germany; [Fingerle, Volker; Liebl, Bernhard] Bavarian Hlth & Food Safety Author LGL, Oberschleissheim, Germany; [Steininger, Philipp; Ueberla, Klaus] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Clin & Mol Virol, Erlangen, Germany	University of Munich; University of Munich; German Center for Infection Research; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Wurzburg; University of Munich; University of Munich; University of Munich; Bavarian Health & Food Safety Authority; University of Erlangen Nuremberg	Keppler, OT (corresponding author), LMU Munchen, Natl Reference Ctr Retroviruses, Max Von Pettenkofer Inst, Fac Med,Virol, Munich, Germany.; Keppler, OT (corresponding author), LMU Munchen, Natl Reference Ctr Retroviruses, Gene Ctr, Fac Med,Virol, Munich, Germany.; Knolle, P; Keppler, OT; Protzer, U (corresponding author), German Ctr Infect Res DZIF, Partner Site, Munich, Germany.; Knolle, P (corresponding author), Tech Univ Munich TUM, Univ Hosp Rechts der Isar, Sch Med, Inst Mol Immunol & Expt Oncol, Munich, Germany.; Protzer, U (corresponding author), TUM, Sch Med, Inst Virol, Helmholtz Ctr Munich, Munich, Germany.; Keppler, OT (corresponding author), LMU Munchen, Gene Ctr, Munich, Germany.; Keppler, OT (corresponding author), LMU Munchen, Dept Biochem, Munich, Germany.	percy.knolle@tum.de; Keppler@mvp.uni-muenchen.de; protzer@tum.de	Albanese, Manuel/AHE-2316-2022; Jeske, Samuel/GQZ-6301-2022	Albanese, Manuel/0000-0002-4614-7599; Jeske, Samuel/0000-0003-1948-2057; Stern, Marcel/0000-0002-7692-6905; Fingerle, Volker/0000-0002-3835-5646; Yazici, Sarah/0000-0003-1524-9071; Mejias Perez, Ernesto/0000-0002-5208-8177; Priller, Alina/0000-0002-4982-0347; Feuerherd, Martin/0000-0002-5272-6503; Vogel, Emanuel/0000-0001-6560-0136; Christa, Catharina Johanna Leonie/0000-0003-3950-2481	BioSysM liquid handling unit (LMU Munich); BMBF initiative NaFoUniMedCovid19 [01KX2021]; Bavarian research alliance FOR-COVID; Bavarian research networks Bay-VOC; CoVaKo; project 'virological and immunological determinants of COVID-19 pathogenesis - lessons to get prepared for future pandemics' [KA1-Co-02]; Helmholtz Association's Initiative and Networking Fund; CoVRapid consortium - Bavarian Research Foundation	BioSysM liquid handling unit (LMU Munich); BMBF initiative NaFoUniMedCovid19; Bavarian research alliance FOR-COVID; Bavarian research networks Bay-VOC; CoVaKo; project 'virological and immunological determinants of COVID-19 pathogenesis - lessons to get prepared for future pandemics'; Helmholtz Association's Initiative and Networking Fund; CoVRapid consortium - Bavarian Research Foundation	We thank the BioSysM liquid handling unit (LMU Munich) for support. We thank the entire team of the COVID-19 vaccination center of the University Hospital Munchen Rechts der Isar (MRI) and the study team as well as T. Vogt for their help and appreciate the efforts of A. Herrmann and R. Bester to maintain the BSL3 laboratory. This study was supported by: BMBF initiative NaFoUniMedCovid19 (01KX2021), subproject B-FAST (P.A.K., O.T.K. and U.P.), the Bavarian research alliance FOR-COVID (M.M., O.T.K., P.K. and U.P.), the Bavarian research networks Bay-VOC (M.M., O.T.K., K.u. and U.P.) and CoVaKo (K.u. and U.P.), the the project 'virological and immunological determinants of COVID-19 pathogenesis - lessons to get prepared for future pandemics (KA1-Co-02 "COVIPA")', a grant from the Helmholtz Association's Initiative and Networking Fund. (U.P. and P.A.K) and the CoVRapid consortium funded by the Bavarian Research Foundation (U.P. and P.A.K.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Almanzar G, 2013, J IMMUNOL METHODS, V387, P36, DOI 10.1016/j.jim.2012.09.008; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; Dejnirattisai W, 2022, CELL, V185, P467, DOI 10.1016/j.cell.2021.12.046; Erber J, 2022, EMERG INFECT DIS, V28, P572, DOI 10.3201/eid2803.204436; Fujino T, 2021, EMERG INFECT DIS, V27, P1243, DOI 10.3201/eid2704.210138; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; Gruell H, 2022, NAT MED, V28, P477, DOI 10.1038/s41591-021-01676-0; Karim SSA, 2021, LANCET, V398, P2126, DOI 10.1016/S0140-6736(21)02758-6; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kneitz RH, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-33; Koerber Nina, 2022, Nat Commun, V13, P153, DOI 10.1038/s41467-021-27649-y; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Mohapatra RK, 2022, J MED VIROL, V94, P1780, DOI 10.1002/jmv.27561; Moriyama S, 2021, IMMUNITY, V54, P1841, DOI 10.1016/j.immuni.2021.06.015; Muecksch F, 2021, IMMUNITY, V54, P1853, DOI 10.1016/j.immuni.2021.07.008; Muenchhoff M, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.43.2002066; Munchhoff M, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.24.2001057; Nemet I, 2022, NEW ENGL J MED, V386, P492, DOI 10.1056/NEJMc2119358; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Schmidt F, 2021, NATURE, V600, P512, DOI 10.1038/s41586-021-04005-0; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Sokal A, 2021, CELL, V184, P1201, DOI 10.1016/j.cell.2021.01.050; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x; Walter EB, 2022, NEW ENGL J MED, V386, P35, DOI 10.1056/NEJMoa2116298; Wang Zijun, 2021, bioRxiv, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Weinberger T, 2021, CLIN INFECT DIS, V73, pE3055, DOI 10.1093/cid/ciaa1935	32	64	64	5	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					496	+		10.1038/s41591-022-01715-4	http://dx.doi.org/10.1038/s41591-022-01715-4		JAN 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35090165	Bronze, Green Submitted			2022-12-27	WOS:000770060800001
J	Lopez, ER; Borschel, WF; Traynor, BJ				Lopez, Elia R.; Borschel, William F.; Traynor, Bryan J.			New antisense oligonucleotide therapies reach first base in ALS	NATURE MEDICINE			English	Editorial Material							HEXANUCLEOTIDE REPEAT; SHAM CONTROL; NUSINERSEN; C9ORF72	Two studies highlight the evolution of antisense oligonucleotide therapy for amyotrophic lateral sclerosis, offering hope for an effective treatment.	[Lopez, Elia R.; Borschel, William F.; Traynor, Bryan J.] NIH, Therapeut Dev Branch, Natl Ctr Adv Translat Sci, Rockville, MD 20852 USA; [Traynor, Bryan J.] NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Traynor, BJ (corresponding author), NIH, Therapeut Dev Branch, Natl Ctr Adv Translat Sci, Rockville, MD 20852 USA.; Traynor, BJ (corresponding author), NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA.	traynorb@mail.nih.gov		Lopez, Elia/0000-0003-3867-1785	Intramural Research Programs of the National Center for Advancing Translational Sciences; National Institute on Aging, National Institutes of Health [Z01-AG000949-02]	Intramural Research Programs of the National Center for Advancing Translational Sciences; National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by the Intramural Research Programs of the National Center for Advancing Translational Sciences and the National Institute on Aging, National Institutes of Health (Z01-AG000949-02).	[Anonymous], 2021, BIOGEN 1017; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Gennemark P, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe9117; Kingwell K, 2021, NAT REV DRUG DISCOV, V20, P412, DOI 10.1038/d41573-021-00088-6; Korobeynikov VA, 2022, NAT MED, V28, P104, DOI 10.1038/s41591-021-01615-z; Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Nagata T, 2021, NAT BIOTECHNOL, V39, P1529, DOI 10.1038/s41587-021-00972-x; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Tran H, 2022, NAT MED, V28, P117, DOI 10.1038/s41591-021-01557-6	13	0	0	2	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					25	27		10.1038/s41591-021-01629-7	http://dx.doi.org/10.1038/s41591-021-01629-7		JAN 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35075291				2022-12-27	WOS:000746475000003
J	Apostolidis, SA; Kakara, M; Painter, MM; Goel, RR; Mathew, D; Lenzi, K; Rezk, A; Patterson, KR; Espinoza, DA; Kadri, JC; Markowitz, DM; Markowitz, CE; Mexhitaj, I; Jacobs, D; Babb, A; Betts, MR; Prak, ETL; Weiskopf, D; Grifoni, A; Lundgreen, KA; Gouma, S; Sette, A; Bates, P; Hensley, SE; Greenplate, AR; Wherry, EJ; Li, R; Bar-Or, A				Apostolidis, Sokratis A.; Kakara, Mihir; Painter, Mark M.; Goel, Rishi R.; Mathew, Divij; Lenzi, Kerry; Rezk, Ayman; Patterson, Kristina R.; Espinoza, Diego A.; Kadri, Jessy C.; Markowitz, Daniel M.; Markowitz, Clyde E.; Mexhitaj, Ina; Jacobs, Dina; Babb, Allison; Betts, Michael R.; Prak, Eline T. Luning; Weiskopf, Daniela; Grifoni, Alba; Lundgreen, Kendall A.; Gouma, Sigrid; Sette, Alessandro; Bates, Paul; Hensley, Scott E.; Greenplate, Allison R.; Wherry, E. John; Li, Rui; Bar-Or, Amit			Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	NATURE MEDICINE			English	Article							FC-GAMMA-RIIB; T-CELL; ANTIGEN PRESENTATION; IN-VIVO; B-CELLS; INFLUENZA VACCINATION; INFECTION; RECEPTOR; REVEALS; MEMORY	SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine-induced responses in immunosuppressed patients. We investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared with healthy controls (n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination. Treatment with anti-CD20 monoclonal antibody (aCD20) significantly reduced spike-specific and receptor-binding domain (RBD)-specific antibody and memory B cell responses in most patients, an effect ameliorated with longer duration from last aCD20 treatment and extent of B cell reconstitution. By contrast, all patients with MS treated with aCD20 generated antigen-specific CD4 and CD8 T cell responses after vaccination. Treatment with aCD20 skewed responses, compromising circulating follicular helper T (T-FH) cell responses and augmenting CD8 T cell induction, while preserving type 1 helper T (T(H)1) cell priming. Patients with MS treated with aCD20 lacking anti-RBD IgG had the most severe defect in circulating T-FH responses and more robust CD8 T cell responses. These data define the nature of the SARS-CoV-2 vaccine-induced immune landscape in aCD20-treated patients and provide insights into coordinated mRNA vaccine-induced immune responses in humans. Our findings have implications for clinical decision-making and public health policy for immunosuppressed patients including those treated with aCD20. SARS-CoV-2-specific antibodies and memory B cells are significantly reduced, but CD4(+) and CD8(+) T cells are robustly activated, in patients with multiple sclerosis on anti-CD20 monotherapy versus healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination.	[Apostolidis, Sokratis A.; Painter, Mark M.; Goel, Rishi R.; Mathew, Divij; Betts, Michael R.; Prak, Eline T. Luning; Gouma, Sigrid; Hensley, Scott E.; Greenplate, Allison R.; Wherry, E. John] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Apostolidis, Sokratis A.] Univ Penn, Dept Med, Perelman Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA; [Apostolidis, Sokratis A.; Painter, Mark M.; Goel, Rishi R.; Mathew, Divij; Greenplate, Allison R.; Wherry, E. John] Univ Penn, Immune Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kakara, Mihir; Rezk, Ayman; Patterson, Kristina R.; Espinoza, Diego A.; Kadri, Jessy C.; Markowitz, Daniel M.; Markowitz, Clyde E.; Mexhitaj, Ina; Jacobs, Dina; Babb, Allison; Li, Rui; Bar-Or, Amit] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kakara, Mihir; Lenzi, Kerry; Rezk, Ayman; Patterson, Kristina R.; Espinoza, Diego A.; Kadri, Jessy C.; Markowitz, Daniel M.; Markowitz, Clyde E.; Mexhitaj, Ina; Jacobs, Dina; Babb, Allison; Li, Rui; Bar-Or, Amit] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Painter, Mark M.; Goel, Rishi R.; Mathew, Divij; Wherry, E. John] Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA; [Espinoza, Diego A.] Univ Penn, Immunol Grad Grp, Perelman Sch Med, Philadelphia, PA 19104 USA; [Betts, Michael R.; Lundgreen, Kendall A.; Gouma, Sigrid; Bates, Paul; Hensley, Scott E.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Prak, Eline T. Luning] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA USA; [Lundgreen, Kendall A.; Bates, Paul] Univ Penn, Penn Ctr Res Coronavirus & Other Emerging Pathoge, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sette, Alessandro] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92093 USA; [Wherry, E. John] Univ Penn, Parker Inst Canc Immunotherapy, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; La Jolla Institute for Immunology; University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine	Wherry, EJ (corresponding author), Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Wherry, EJ (corresponding author), Univ Penn, Immune Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA.; Li, R; Bar-Or, A (corresponding author), Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.; Li, R; Bar-Or, A (corresponding author), Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Wherry, EJ (corresponding author), Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.; Wherry, EJ (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Perelman Sch Med, Philadelphia, PA 19104 USA.	wherry@pennmedicine.upenn.edu; lirui158@pennmedicine.upenn.edu; amitbar@pennmedicine.upenn.edu	Bar-Or, Amit/AIC-1416-2022; Li, Rui/O-7397-2016; Sette, Alessandro/AFO-8916-2022	Li, Rui/0000-0002-7210-8358; Espinoza, Diego/0000-0002-9627-6508; Kakara, Mihir/0000-0001-8951-8604; Painter, Mark M./0000-0002-0180-2748	National Institutes of Health (NIH) [AI105343, AI082630, AI108545, AI155577, AI149680, AI152236, P30-AI0450080, R01 AI118694, UC4 DK112217, T32 AR076951-01, T32 CA009140, U19AI082630, UM1 AI144288, NMSS SI-2011-37160]; Allen Institute for Immunology; Chen Family Research Fund; National Multiple Sclerosis Society-American Brain Foundation Clinician Scientist Award; Parker Institute for Cancer Immunotherapy; Penn Center for Research on Coronavirus and Other Emerging Pathogens; University of Pennsylvania Perelman School of Medicine COVID Fund; University of Pennsylvania Institute for Immunology Glick COVID-19 research award; University of Pennsylvania Perelman School of Medicine 21st Century Scholar Fund; NIH [75N9301900065]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Allen Institute for Immunology; Chen Family Research Fund; National Multiple Sclerosis Society-American Brain Foundation Clinician Scientist Award; Parker Institute for Cancer Immunotherapy; Penn Center for Research on Coronavirus and Other Emerging Pathogens; University of Pennsylvania Perelman School of Medicine COVID Fund; University of Pennsylvania Institute for Immunology Glick COVID-19 research award; University of Pennsylvania Perelman School of Medicine 21st Century Scholar Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the study participants for their generosity in making the study possible. We also thank the members of the Wherry and Bar-Or labs for helpful discussions and feedback. This work was supported by grants from the National Institutes of Health (NIH) nos. AI105343, AI082630, AI108545, AI155577, AI149680 (to E.J.W.), AI152236 (to P.B.), P30-AI0450080 (to E.T.L.P.), R01 AI118694 and UC4 DK112217 (to M.R.B.), T32 AR076951-01 (to S.A.A.), T32 CA009140 (to D.M.), U19AI082630 (to S.E.H. and E.J.W.), UM1 AI144288 (A.B.O.), NMSS SI-2011-37160 (A.B.O.), funding from the Allen Institute for Immunology (to S.A.A., E.J.W.), Chen Family Research Fund (to S.A.A.), the National Multiple Sclerosis Society-American Brain Foundation Clinician Scientist Award (to M.K.), Parker Institute for Cancer Immunotherapy (to E.J.W.), Penn Center for Research on Coronavirus and Other Emerging Pathogens (to P.B.), University of Pennsylvania Perelman School of Medicine COVID Fund (to R.R.G., E.J.W.), University of Pennsylvania Institute for Immunology Glick COVID-19 research award (to M.R.B.), University of Pennsylvania Perelman School of Medicine 21st Century Scholar Fund (to R.R.G.) and a philanthropic gift from J. Lurie, J. Embiid, J. Harris and D. Blitzer (to S.E.H.). Work in the Wherry lab is supported by the Parker Institute for Cancer Immunotherapy. This work was also supported by NIH contract no. dy75N9301900065 (to D.W. and A.S.).	Achiron A, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211012835; [Anonymous], 2021, MED, DOI DOI 10.1164/RCCM.202009-3442OC; Asano MS, 1996, J EXP MED, V183, P2165, DOI 10.1084/jem.183.5.2165; Avouac J, 2021, LANCET RHEUMATOL, V3, pE419, DOI 10.1016/S2665-9913(21)00059-X; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bange EM, 2021, NAT MED, V27, P1280, DOI 10.1038/s41591-021-01386-7; Bar-Or A, 2020, NEUROLOGY, V95, pE1999, DOI 10.1212/WNL.0000000000010380; Barnett LG, 2014, J IMMUNOL, V192, P3607, DOI 10.4049/jimmunol.1301284; Belkina AC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13055-y; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; Blass E, 2021, NAT REV CLIN ONCOL, V18, P215, DOI 10.1038/s41571-020-00460-2; Boldison J, 2020, CELL MOL IMMUNOL, V17, P843, DOI 10.1038/s41423-019-0324-z; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; Comi G, 2021, ANN NEUROL, V89, P13, DOI 10.1002/ana.25927; Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Deepak Parakkal, 2021, medRxiv, DOI 10.1101/2021.04.05.21254656; Dulery R, 2021, AM J HEMATOL, V96, P934, DOI 10.1002/ajh.26209; Eisenberg RA, 2013, J CLIN IMMUNOL, V33, P388, DOI 10.1007/s10875-012-9813-x; Flannery DD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd5709; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Giles JR, 2015, J IMMUNOL, V195, P2571, DOI 10.4049/jimmunol.1500792; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Greenplate AR, 2019, CANCER IMMUNOL RES, V7, P86, DOI 10.1158/2326-6066.CIR-17-0692; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152; Herati RS, 2014, J IMMUNOL, V193, P3528, DOI 10.4049/jimmunol.1302503; KURTJONES EA, 1988, J IMMUNOL, V140, P3773; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Lee DSW, 2021, NAT REV DRUG DISCOV, V20, P179, DOI 10.1038/s41573-020-00092-2; Li FB, 2014, J IMMUNOL, V192, P3021, DOI 10.4049/jimmunol.1302934; LIU Y, 1995, INT IMMUNOL, V7, P1353, DOI 10.1093/intimm/7.8.1353; Loebermann M, 2012, NAT REV NEUROL, V8, P143, DOI 10.1038/nrneurol.2012.8; Loonstra FC, 2020, MULT SCLER J, V26, P1256, DOI 10.1177/1352458520942198; Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McGinley MP, 2021, JAMA-J AM MED ASSOC, V325, P765, DOI 10.1001/jama.2020.26858; Merkenschlager J, 2021, NATURE, V591, P458, DOI 10.1038/s41586-021-03187-x; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Mohib K, 2020, AM J TRANSPLANT, V20, P52, DOI 10.1111/ajt.15546; Morris AB, 2020, IMMUNITY, V52, P136, DOI 10.1016/j.immuni.2019.12.006; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Olberg HK, 2014, MULT SCLER J, V20, P1074, DOI 10.1177/1352458513513970; Orlova DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151859; Painter MM., 2021, RAPID INDUCTION ANTI, P1, DOI [10.1101/2021.04.21.440862, DOI 10.1101/2021.04.21.440862]; Palanichamy A, 2014, J IMMUNOL, V193, P580, DOI 10.4049/jimmunol.1400118; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; RON Y, 1981, EUR J IMMUNOL, V11, P964, DOI 10.1002/eji.1830111203; RONCHESE F, 1993, J EXP MED, V177, P679, DOI 10.1084/jem.177.3.679; Samanovic Marie I, 2021, medRxiv, DOI 10.1101/2021.02.07.21251311; Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shanehbandi D, 2017, CURR CANCER DRUG TAR, V17, P423, DOI 10.2174/1568009617666170109151128; Smith KGC, 2010, NAT REV IMMUNOL, V10, P674, DOI 10.1038/nri2762; Sormani MP, 2021, ANN NEUROL, V89, P780, DOI 10.1002/ana.26028; Strangfeld A, 2021, ANN RHEUM DIS, V80, P930, DOI 10.1136/annrheumdis-2020-219498; SUNSHINE GH, 1991, J EXP MED, V174, P1653, DOI 10.1084/jem.174.6.1653; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; van Assen S, 2010, ARTHRITIS RHEUM-US, V62, P75, DOI 10.1002/art.25033; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Yang J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19238-2; Zabalza A, 2021, EUR J NEUROL, V28, P3384, DOI 10.1111/ene.14690	65	198	198	13	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1990	+		10.1038/s41591-021-01507-2	http://dx.doi.org/10.1038/s41591-021-01507-2		SEP 2021	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34522051	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000695785700001
J	Ma, BBY; Hui, EP; Chan, ATC				Ma, Brigette B. Y.; Hui, Edwin P.; Chan, Anthony T. C.			The expanding universe of checkpoint inhibitors for nasopharyngeal cancer	NATURE MEDICINE			English	Editorial Material								Three phase 3 studies show that an immune-checkpoint inhibitor combined with chemotherapy improves progression-free survival in recurrent or metastatic nasopharyngeal cancer.	[Chan, Anthony T. C.] Hong Kong Canc Inst, Dept Clin Oncol, Sir YK Pao Ctr Canc, State Key Lab Translat Oncol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Chan, ATC (corresponding author), Hong Kong Canc Inst, Dept Clin Oncol, Sir YK Pao Ctr Canc, State Key Lab Translat Oncol, Hong Kong, Peoples R China.	anthonytcchan@cuhk.edu.hk	B.Y., Brigette/H-4681-2017; Chan, Anthony Tak Cheung/R-3940-2018; Hui, Edwin/ABC-1818-2021	B.Y., Brigette/0000-0003-4802-1102; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Hui, Edwin Pun/0000-0002-8134-7019				Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Le QT, 2019, JNCI-J NATL CANCER I, V111, P655, DOI 10.1093/jnci/djz044; Mai HQ, 2021, NAT MED, V27, P1536, DOI 10.1038/s41591-021-01444-0; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Sun LT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58674-4; Wang FH, 2021, J CLIN ONCOL, V39, P704, DOI 10.1200/JCO.20.02712; Wong KCW, 2021, NAT REV CLIN ONCOL, V18, P679, DOI 10.1038/s41571-021-00524-x; Yang YP, 2021, LANCET ONCOL, V22, P1162, DOI 10.1016/S1470-2045(21)00302-8; Yu JX, 2020, NAT REV DRUG DISCOV, V19, P163, DOI 10.1038/d41573-019-00182-w; Zhang L, 2016, LANCET, V388, P1883, DOI 10.1016/S0140-6736(16)31388-5	10	2	2	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1512	1513		10.1038/s41591-021-01482-8	http://dx.doi.org/10.1038/s41591-021-01482-8		SEP 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34518676				2022-12-27	WOS:000695470700004
J	Landi, I; Kaji, DA; Cotter, L; Van Vleck, T; Belbin, G; Preuss, M; Loos, RJF; Kenny, E; Glicksberg, BS; Beckmann, ND; O'Reilly, P; Schadt, EE; Achtyes, ED; Buckley, PF; Lehrer, D; Malaspina, DP; McCarroll, SA; Rapaport, MH; Fanous, AH; Pato, MT; Pato, CN; Bigdeli, TB; Nadkarni, GN; Charney, AW				Landi, Isotta; Kaji, Deepak A.; Cotter, Liam; Van Vleck, Tielman; Belbin, Gillian; Preuss, Michael; Loos, Ruth J. F.; Kenny, Eimear; Glicksberg, Benjamin S.; Beckmann, Noam D.; O'Reilly, Paul; Schadt, Eric E.; Achtyes, Eric D.; Buckley, Peter F.; Lehrer, Douglas; Malaspina, Dolores P.; McCarroll, Steven A.; Rapaport, Mark H.; Fanous, Ayman H.; Pato, Michele T.; Pato, Carlos N.; Bigdeli, Tim B.; Nadkarni, Girish N.; Charney, Alexander W.			Prognostic value of polygenic risk scores for adults with psychosis	NATURE MEDICINE			English	Article							GENOME; PREDICTION; INSIGHTS; HEALTH	Polygenic risk scores (PRS) summarize genetic liability to a disease at the individual level, and the aim is to use them as biomarkers of disease and poor outcomes in real-world clinical practice. To date, few studies have assessed the prognostic value of PRS relative to standards of care. Schizophrenia (SCZ), the archetypal psychotic illness, is an ideal test case for this because the predictive power of the SCZ PRS exceeds that of most other common diseases. Here, we analyzed clinical and genetic data from two multi-ethnic cohorts totaling 8,541 adults with SCZ and related psychotic disorders, to assess whether the SCZ PRS improves the prediction of poor outcomes relative to clinical features captured in a standard psychiatric interview. For all outcomes investigated, the SCZ PRS did not improve the performance of predictive models, an observation that was generally robust to divergent case ascertainment strategies and the ancestral background of the study participants. The inclusion of polygenic risk scores does not improve the performance of standard-of-care predictive models of disease outcomes in patients with psychosis.	[Landi, Isotta; Kaji, Deepak A.; Cotter, Liam; Malaspina, Dolores P.; Charney, Alexander W.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Landi, Isotta; Kaji, Deepak A.; Cotter, Liam; Kenny, Eimear; Glicksberg, Benjamin S.; Beckmann, Noam D.; O'Reilly, Paul; Schadt, Eric E.; Malaspina, Dolores P.; Charney, Alexander W.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Landi, Isotta; Kaji, Deepak A.; Cotter, Liam; Van Vleck, Tielman; Glicksberg, Benjamin S.; Beckmann, Noam D.; Nadkarni, Girish N.; Charney, Alexander W.] Icahn Sch Med Mt Sinai, Mt Sinai Clin Intelligence Ctr, New York, NY 10029 USA; [Landi, Isotta; Cotter, Liam; Van Vleck, Tielman; Glicksberg, Benjamin S.; Nadkarni, Girish N.] Icahn Sch Med Mt Sinai, Hasso Plattner Inst Digital Hlth Mt Sinai, New York, NY 10029 USA; [Van Vleck, Tielman; Belbin, Gillian; Kenny, Eimear; Nadkarni, Girish N.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Van Vleck, Tielman; Preuss, Michael; Loos, Ruth J. F.; Nadkarni, Girish N.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA; [Belbin, Gillian; Kenny, Eimear] Icahn Sch Med Mt Sinai, Inst Genom Hlth, New York, NY 10029 USA; [Schadt, Eric E.] Sema4, Stamford, CT USA; [Achtyes, Eric D.] Cherry Hlth, Grand Rapids, MI USA; [Achtyes, Eric D.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA; [Buckley, Peter F.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA; [Lehrer, Douglas] Wright State Univ, Dept Psychiat, Dayton, OH 45435 USA; [McCarroll, Steven A.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA; [McCarroll, Steven A.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA; [Rapaport, Mark H.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Rapaport, Mark H.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; [Fanous, Ayman H.; Pato, Michele T.; Pato, Carlos N.; Bigdeli, Tim B.] Suny Downstate Med Ctr, Dept Psychiat & Behav Sci, Brooklyn, NY 11203 USA; [Fanous, Ayman H.; Bigdeli, Tim B.] VA New York Harbor Healthcare Syst, Brooklyn, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Michigan State University; Michigan State University College of Human Medicine; Virginia Commonwealth University; University System of Ohio; Wright State University Dayton; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Emory University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Landi, I; Charney, AW (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Landi, I; Charney, AW (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.; Landi, I; Charney, AW (corresponding author), Icahn Sch Med Mt Sinai, Mt Sinai Clin Intelligence Ctr, New York, NY 10029 USA.; Landi, I (corresponding author), Icahn Sch Med Mt Sinai, Hasso Plattner Inst Digital Hlth Mt Sinai, New York, NY 10029 USA.	isotta.landi2@mssm.edu; alexander.charney@mssm.edu	Loos, Ruth/GON-5877-2022; Achtyes, Eric/AAA-6372-2020; Achtyes, Eric/M-6024-2016; Loos, Ruth/Q-2862-2016	Preuss, Michael/0000-0001-5266-8465; Glicksberg, Benjamin/0000-0003-4515-8090; Achtyes, Eric/0000-0001-8939-1535; Loos, Ruth/0000-0002-8532-5087; Van Vleck, Tielman/0000-0002-4488-8174	National Institute of Mental Health (NIMH) [R01 MH121923]; NIMH [R01 MH085548, R01 MH104964, R01 MH123451-01]; NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation	National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation(NARSAD)	This study was supported by grant R01 MH121923 from the National Institute of Mental Health (NIMH). The authors thank A. Jain, A. Moscati, L. Zhou, Q. Song, S. Wenric and S. Ellis, all of whom are paid employees of the Icahn School of Medicine at Mount Sinai, for assisting with quality control and/or file handling for the BioMe exome sequencing and genome-wide genotyping data. The BioMe healthcare delivery cohort at Mount Sinai was established and maintained with a generous gift from the Andrea and Charles Bronfman Philanthropies. The authors also thank the Genomic Psychiatry Cohort (GPC) Investigators. The GPC was supported by grants R01 MH085548, R01 MH104964 and R01 MH123451-01 from the NIMH, and genotyping of samples was provided by the Stanley Center for Psychiatric Research at Broad Institute. T.B.B. is supported by a NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation.	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Belbin GM, 2021, CELL, V184, P2068, DOI 10.1016/j.cell.2021.03.034; Bigdeli TB, 2020, MOL PSYCHIATR, V25, P2455, DOI 10.1038/s41380-019-0517-y; Canty A., BOOT BOOTSTRAP R S P; Champely S., 2020, PWR BASIC FUNCTIONS; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Choi SW, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz082; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Davies RW, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1103-1; Davison AC, 1997, BOOTSTRAP METHODS TH, DOI [DOI 10.2307/1271471, 10.1017/CBO9780511802843]; Demontis D, 2019, NAT GENET, V51, P63, DOI 10.1038/s41588-018-0269-7; Goddard M, 2009, GENETICA, V136, P245, DOI 10.1007/s10709-008-9308-0; Green ED, 2020, NATURE, V586, P683, DOI 10.1038/s41586-020-2817-4; Haas ME, 2018, AM J HUM GENET, V103, P461, DOI 10.1016/j.ajhg.2018.08.004; Harrell F, RMS REGRESSION MODEL; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Jansen IE, 2019, NAT GENET, V51, P404, DOI 10.1038/s41588-018-0311-9; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Levey DF, 2020, AM J PSYCHIAT, V177, P223, DOI 10.1176/appi.ajp.2019.19030256; Lewis CM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00742-5; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; Meuwissen THE, 2001, GENETICS, V157, P1819; Misganaw B, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0497-3; Mosley JD, 2020, JAMA-J AM MED ASSOC, V323, P627, DOI 10.1001/jama.2019.21782; Mullins N, 2021, NAT GENET, V53, P817, DOI 10.1038/s41588-021-00857-4; Nalls MA, 2019, LANCET NEUROL, V18, P1091, DOI 10.1016/S1474-4422(19)30320-5; O'Connell J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004234; O'Donovan, 2020, MAPPING GENOMIC LOCI, DOI [10.1101/2020.09.12.20192922, DOI 10.1101/2020.09.12.20192922]; Oetjens MT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12869-0; Pato MT, 2013, AM J MED GENET B, V162B, P306, DOI 10.1002/ajmg.b.32160; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Perkins DO, 2020, AM J PSYCHIAT, V177, P155, DOI 10.1176/appi.ajp.2019.18060721; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Rosvall M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018209; Ruderfer DM, 2016, LANCET PSYCHIAT, V3, P350, DOI 10.1016/S2215-0366(15)00553-2; Soysal E, 2018, J AM MED INFORM ASSN, V25, P331, DOI 10.1093/jamia/ocx132; Suvisaari J, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00580; Tayo BO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019166; Vassos E, 2017, BIOL PSYCHIAT, V81, P470, DOI 10.1016/j.biopsych.2016.06.028; Warren M, 2018, NATURE, V562, P181, DOI 10.1038/d41586-018-06956-3; World Health Organization, 1993, ICD 10 CLASS MENT BE, V10th ed.; Wray NR, 2008, CURR OPIN GENET DEV, V18, P257, DOI 10.1016/j.gde.2008.07.006; Wray Naomi R, 2018, Nat Genet, V50, P668, DOI 10.1038/s41588-018-0090-3; Zhang JP, 2019, AM J PSYCHIAT, V176, P21, DOI 10.1176/appi.ajp.2018.17121363; Zheutlin AB, 2019, AM J PSYCHIAT, V176, P846, DOI 10.1176/appi.ajp.2019.18091085	50	15	15	3	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1576	+		10.1038/s41591-021-01475-7	http://dx.doi.org/10.1038/s41591-021-01475-7		SEP 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34489608	Green Accepted			2022-12-27	WOS:000692960600001
J	Perlmutter, JS				Perlmutter, Joel S.			Aducanumab: look before leaping	NATURE MEDICINE			English	Editorial Material									[Perlmutter, Joel S.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Perlmutter, Joel S.] Washington Univ, Dept Radiol, St Louis, MO 63110 USA; [Perlmutter, Joel S.] Washington Univ, Dept Neurosci, St Louis, MO 63110 USA; [Perlmutter, Joel S.] Washington Univ, Program Phys Therapy, St Louis, MO 63110 USA; [Perlmutter, Joel S.] Washington Univ, Program Occupat Therapy, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Perlmutter, JS (corresponding author), Washington Univ, Dept Neurol, St Louis, MO 63110 USA.; Perlmutter, JS (corresponding author), Washington Univ, Dept Radiol, St Louis, MO 63110 USA.; Perlmutter, JS (corresponding author), Washington Univ, Dept Neurosci, St Louis, MO 63110 USA.; Perlmutter, JS (corresponding author), Washington Univ, Program Phys Therapy, St Louis, MO 63110 USA.; Perlmutter, JS (corresponding author), Washington Univ, Program Occupat Therapy, St Louis, MO 63110 USA.	perlmutterjoel@wustl.edu							0	4	4	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1499	1499		10.1038/s41591-021-01477-5	http://dx.doi.org/10.1038/s41591-021-01477-5		AUG 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34413517				2022-12-27	WOS:000686447900001
J	Wang, MN; Herbst, RS; Boshoff, C				Wang, Meina; Herbst, Roy S.; Boshoff, Chris			Toward personalized treatment approaches for non-small-cell lung cancer	NATURE MEDICINE			English	Article							IMMUNE CHECKPOINT BLOCKADE; OPEN-LABEL; PD-1 BLOCKADE; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; 1ST-LINE NIVOLUMAB; ANTITUMOR-ACTIVITY; LIVER METASTASIS; SINGLE-ARM; PHASE-III	Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress. In this Perspective, we discuss some of the recent breakthrough therapies developed for NSCLC, focusing on immunotherapies and targeted therapies. We highlight our current understanding of mechanisms of resistance and the importance of incorporating genomic analyses into clinical studies to decipher these further. We underscore the future role of neoadjuvant and maintenance combination therapy approaches to potentially cure early disease. A major challenge to successful development of rational combination therapies will be the application of robust predictive biomarkers for clear-cut patient stratification, and we provide our views on clinical research areas that could influence how NSCLC will be managed over the coming decade. This Perspective discusses recent developments in NSCLC immunotherapy and targeted therapy, and highlights the key challenges and future directions for NSCLC management.	[Wang, Meina; Herbst, Roy S.; Boshoff, Chris] Yale Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06510 USA; [Boshoff, Chris] Pfizer Inc, New York, NY 10017 USA	Yale University; Pfizer	Herbst, RS; Boshoff, C (corresponding author), Yale Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06510 USA.; Boshoff, C (corresponding author), Pfizer Inc, New York, NY 10017 USA.	roy.herbst@yale.edu; christoffer.boshoff@pfizer.com						Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Ahn M., 2020, ANN ONCOL, V31, pS754; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; [Anonymous], 2020, STEP 1 CTDNA MON TRE; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Awad MM, 2021, J THORAC ONCOL, V16, P162, DOI 10.1016/j.jtho.2020.09.015; Bar-Sagi D, 2020, NAT CANCER, V1, P25, DOI 10.1038/s43018-019-0016-8; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Blackburn EH, 2011, CANCER PREV RES, V4, P787, DOI 10.1158/1940-6207.CAPR-11-0195; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Boyer M, 2021, J CLIN ONCOL, V39, P2327, DOI 10.1200/JCO.20.03579; Bristol Myers Squibb, 2021, NEOADJ OP NIV PLUS C; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Camidge DR, 2020, J CLIN ONCOL, V38, P3592, DOI 10.1200/JCO.20.00505; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Chaudhuri AA, 2017, CANCER DISCOV, V7, P1394, DOI 10.1158/2159-8290.CD-17-0716; Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445; Chen X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1047-2; Chin EN, 2020, SCIENCE, V369, P993, DOI 10.1126/science.abb4255; Corcoran RB, 2018, NEW ENGL J MED, V379, P1754, DOI 10.1056/NEJMra1706174; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Crispe IN, 2014, HEPATOLOGY, V60, P2109, DOI 10.1002/hep.27254; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010; Dhatchinamoorthy K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636568; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Drilon A, 2020, NEW ENGL J MED, V383, P813, DOI 10.1056/NEJMoa2005653; Drilon A, 2020, LANCET ONCOL, V21, P261, DOI 10.1016/S1470-2045(19)30690-4; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Garon EB, 2019, J CLIN ONCOL, V37, P2518, DOI 10.1200/JCO.19.00934; George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001; Gettinger S, 2018, J CLIN ONCOL, V36, P1675, DOI 10.1200/JCO.2017.77.0412; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Goldberg SB, 2020, LANCET ONCOL, V21, P655, DOI 10.1016/S1470-2045(20)30111-X; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gridelli C, 2011, LUNG CANCER, V71, P249, DOI 10.1016/j.lungcan.2010.12.008; Hegde PS, 2018, SEMIN CANCER BIOL, V52, P117, DOI 10.1016/j.semcancer.2017.12.002; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; HUTCHISON DJ, 1963, ADV CANCER RES, V7, P235, DOI 10.1016/S0065-230X(08)60984-7; Janssen Pharmaceutical Companies, 2021, NEW AM DAT CHRY SALI; Jiao XD, 2019, J THORAC DIS, V11, P4507, DOI 10.21037/jtd.2019.11.04; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Jones GD, 2021, CLIN CANCER RES, V27, P2604, DOI 10.1158/1078-0432.CCR-20-4772; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Langer CJ, 2019, J THORAC ONCOL, V14, P1839, DOI 10.1016/j.jtho.2019.05.029; Le Pechoux C, 2020, ANN ONCOL, V31, pS1178, DOI 10.1016/j.annonc.2020.08.2280; Lee JC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba0759; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Lipson EJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9503; Manieri NA, 2017, TRENDS IMMUNOL, V38, P20, DOI 10.1016/j.it.2016.10.002; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Middleton G, 2020, NATURE, V583, P807, DOI 10.1038/s41586-020-2481-8; Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2020, NAT MED, V26, P1733, DOI 10.1038/s41591-020-1044-8; Neal JW, 2020, J CLIN ONCOL, V38; Oyama T, 1998, J IMMUNOL, V160, P1224; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Pao W, 2018, CANCER DISCOV, V8, P395, DOI 10.1158/2159-8290.CD-17-1320; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Paz-Ares L, 2020, J THORAC ONCOL, V15, P1657, DOI 10.1016/j.jtho.2020.06.015; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Redman MW, 2020, LANCET ONCOL, V21, P1589, DOI 10.1016/S1470-2045(20)30475-7; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roche, 2021, PIVOT PHAS 3 STUD SH; Rodriguez-Abreu D, 2020, J CLIN ONCOL, V38; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84; Rousseau B, 2021, NEW ENGL J MED, V384, P1168, DOI 10.1056/NEJMc2031965; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sabari JK, 2021, J THORAC ONCOL, V16, pS108, DOI 10.1016/j.jtho.2021.01.284; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schoenfeld AJ, 2020, J THORAC ONCOL, V15, P18, DOI 10.1016/j.jtho.2019.11.005; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Settleman J, 2021, CANCER DISCOV, V11, P1016, DOI 10.1158/2159-8290.CD-20-1187; Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Shaw AT, 2019, ANN ONCOL, V30, P1121, DOI 10.1093/annonc/mdz131; Shaw AT, 2020, NEW ENGL J MED, V383, P2018, DOI 10.1056/NEJMoa2027187; Shaw AT, 2019, LANCET ONCOL, V20, P1691, DOI 10.1016/S1470-2045(19)30655-2; Shen SY, 2018, NATURE, V563, P579, DOI 10.1038/s41586-018-0703-0; Shen Y, 2020, CANCER CELL, V37, P800, DOI 10.1016/j.ccell.2020.05.005; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sistigu A, 2017, CYTOKINE GROWTH F R, V36, P67, DOI 10.1016/j.cytogfr.2017.05.008; Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Spigel DR, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8511; Spigel DR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9017; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Spreafico A, 2021, CANCER DISCOV, V11, P822, DOI 10.1158/2159-8290.CD-20-1301; Tanaka N, 2021, CANCER DISCOV, V11, P1913, DOI 10.1158/2159-8290.CD-21-0365; Taylor MH, 2020, J CLIN ONCOL, V38, P1154, DOI 10.1200/JCO.19.01598; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Tumeh PC, 2017, CANCER IMMUNOL RES, V5, P417, DOI 10.1158/2326-6066.CIR-16-0325; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1; Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; World Health Organization, 2018, CANCER; Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhong WZ, 2018, LANCET ONCOL, V19, P139, DOI 10.1016/S1470-2045(17)30729-5	157	84	85	16	43	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1345	1356		10.1038/s41591-021-01450-2	http://dx.doi.org/10.1038/s41591-021-01450-2		AUG 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385702				2022-12-27	WOS:000684533600005
J	Chemaitelly, H; Yassine, HM; Benslimane, FM; Al Khatib, HA; Tang, P; Hasan, MR; Malek, JA; Coyle, P; Ayoub, HH; Al Kanaani, Z; Al Kuwari, E; Jeremijenko, A; Kaleeckal, AH; Latif, AN; Shaik, RM; Rahim, HAF; Nasrallah, GK; Al Kuwari, MG; Al Romaihi, HE; Al-Thani, MH; Al Khal, A; Butt, AA; Bertollini, R; Abu-Raddad, LJ				Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Tang, Patrick; Hasan, Mohammad R.; Malek, Joel A.; Coyle, Peter; Ayoub, Houssein H.; Al Kanaani, Zaina; Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F.; Nasrallah, Gheyath K.; Al Kuwari, Mohamed Ghaith; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H.; Al Khal, Abdullatif; Butt, Adeel A.; Bertollini, Roberto; Abu-Raddad, Laith J.			mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	NATURE MEDICINE			English	Article							TEST-NEGATIVE DESIGN; INFECTION	A matched test-negative, case-control study using real-world data from a predominantly working-age population demonstrates efficacy of the mRNA-1273 vaccine to be 100% and 96.4% against the B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants of concern, respectively. The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) >= 14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) >= 14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.	[Chemaitelly, Hiam; Abu-Raddad, Laith J.] Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha, Qatar; [Chemaitelly, Hiam; Abu-Raddad, Laith J.] Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, World Hlth Org Collaborating Ctr Dis Epidemiol An, Doha, Qatar; [Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Coyle, Peter; Nasrallah, Gheyath K.] Qatar Univ, QU Hlth, Biomed Res Ctr, Doha, Qatar; [Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Nasrallah, Gheyath K.] Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, Doha, Qatar; [Tang, Patrick; Hasan, Mohammad R.] Sidra Med, Dept Pathol, Doha, Qatar; [Malek, Joel A.] Cornell Univ, Weill Cornell Med Qatar, Genom Lab, Doha, Qatar; [Malek, Joel A.] Cornell Univ, Weill Cornell Med Qatar, Dept Med Genet, Doha, Qatar; [Coyle, Peter; Al Kanaani, Zaina; Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Al Khal, Abdullatif; Butt, Adeel A.] Hamad Med Corp, Doha, Qatar; [Coyle, Peter] Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland; [Ayoub, Houssein H.] Qatar Univ, Dept Math Stat & Phys, Doha, Qatar; [Abdul Rahim, Hanan F.] Qatar Univ, QU Hlth, Coll Hlth Sci, Doha, Qatar; [Al Kuwari, Mohamed Ghaith] Primary Hlth Care Corp, Doha, Qatar; [Al Romaihi, Hamad Eid; Al-Thani, Mohamed H.; Bertollini, Roberto] Minist Publ Hlth, Doha, Qatar; [Butt, Adeel A.; Abu-Raddad, Laith J.] Cornell Univ, Weill Cornell Med, Dept Populat Hlth Sci, New York, NY USA	Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar University; Qatar University; Sidra Medical & Research Center; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Hamad Medical Corporation; Queens University Belfast; Qatar University; Qatar University; Hamad Medical Corporation; Primary Health Care Corporation (PHCC); Cornell University	Abu-Raddad, LJ (corresponding author), Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha, Qatar.; Abu-Raddad, LJ (corresponding author), Cornell Univ, Qatar Fdn Educ City, Weill Cornell Med Qatar, World Hlth Org Collaborating Ctr Dis Epidemiol An, Doha, Qatar.; Abu-Raddad, LJ (corresponding author), Cornell Univ, Weill Cornell Med, Dept Populat Hlth Sci, New York, NY USA.	lja2002@qatar-med.cornell.edu	YASSINE, HADI M./AAW-6475-2020; Nasrallah, Gheyath K/H-7949-2019	YASSINE, HADI M./0000-0001-7592-2788; Hasan, Mohammad/0000-0002-4658-7949; Tang, Patrick/0000-0003-1583-5484; Chemaitelly, Hiam/0000-0002-8756-6968; Al Khatib, Hebah/0000-0003-3321-7364; Jeremijenko, Andrew Martin/0000-0002-0375-2713; Al-Kuwari, Mohamed Ghaith/0000-0002-9158-5395; AYOUB, Houssein/0000-0003-2512-6657; Malek, Joel/0000-0002-1516-8477				Abu-Raddad L., 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1846, DOI 10.1093/CID/CIAA1846, 33315061]; Abu-Raddad L. J., J TRAVEL MED; Abu-Raddad L. J., NEW ENGL J MED; Abu-Raddad LJ, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100861; Abu-Raddad LJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85428-7; Al-Thani MH, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab221; [Anonymous], TRACK SARS COV 2 VAR; [Anonymous], COB SARS COV 2 QUAL; [Anonymous], RAP INCR SARS COV 2; [Anonymous], COVID 19 CLIN MAN LI; [Anonymous], INT GUID CERT CLASS; [Anonymous], QAT MONTHL STAT; [Anonymous], 2019, STAT SOFTW REL 16 1; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bertollini, JAMA-J AM MED ASSOC; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Coyle P., 2020, 20240416 MEDRXIV, DOI [10.1101/2020.11.29.20240416, DOI 10.1101/2020.11.29.20240416]; Coyle PV, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102646; DAUM RS, 1991, J INFECT DIS, V164, P1154, DOI 10.1093/infdis/164.6.1154; Galloway SE, 2021, MMWR-MORBID MORTAL W, V70, P95, DOI [10.15585/mmwr.mm7003e2, 10.15585/mmwr.mm7003e2externalicon]; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Hitchings M. D. T., EFFECTIVENESS CORONA, DOI 10.1101/2021.04.07.21255081v1(2021); Hunter P. R., ESTIMATING EFFECTIVE, DOI 10.1101/2021.02.01.21250957v1(2021); Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; Jacoby P, 2014, VACCINE, V32, P2942, DOI 10.1016/j.vaccine.2013.08.048; Jeremijenko A, 2021, EMERG INFECT DIS, V27, P1343, DOI [10.3201/eid2705.20.4365, 10.3201/eid2705.204365]; Kalikiri M. K. R., HIGH THROUGHPUT EXTR, DOI 10.1101/2020.04.08.20055731v1(2020); Kubina R, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10060434; National Project of Surveillance for Variants of Concern and Viral Genome Sequencing, 2021, QAT VIR GEN SEQ DAT; Pearce N, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i969; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; Thermo Fisher Scientific, TAQPATH COVID 19 CE; Verani JR, 2017, VACCINE, V35, P3295, DOI 10.1016/j.vaccine.2017.04.037; Vogels C., MULTIPLEXED RT QPCR, DOI 10.17504/protocols.io.br9vm966; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3	36	127	132	2	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1614	+		10.1038/s41591-021-01446-y	http://dx.doi.org/10.1038/s41591-021-01446-y		JUL 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34244681	Green Accepted, Bronze			2022-12-27	WOS:000671528900001
J	Aldridge, BB; Barros-Aguirre, D; Barry, CE; Bates, RH; Berthel, SJ; Boshoff, HI; Chibale, K; Chu, XJ; Cooper, CB; Dartois, V; Duncan, K; Fotouhi, N; Gusovsky, F; Hipskind, PA; Kempf, DJ; Lelievre, J; Lenaerts, AJ; McNamara, CW; Mizrahi, V; Nathan, C; Olsen, DB; Parish, T; Petrassi, HM; Pym, A; Rhee, KY; Robertson, GT; Rock, JM; Rubin, EJ; Russell, B; Russell, DG; Sacchettini, JC; Schnappinger, D; Schrimpf, M; Upton, AM; Warner, P; Wyatt, PG; Yuan, Y				Aldridge, Bree B.; Barros-Aguirre, David; Barry, Clifton E., III; Bates, Robert H.; Berthel, Steven J.; Boshoff, Helena I.; Chibale, Kelly; Chu, Xin-Jie; Cooper, Christopher B.; Dartois, Veronique; Duncan, Ken; Fotouhi, Nader; Gusovsky, Fabian; Hipskind, Philip A.; Kempf, Dale J.; Lelievre, Joel; Lenaerts, Anne J.; McNamara, Case W.; Mizrahi, Valerie; Nathan, Carl; Olsen, David B.; Parish, Tanya; Petrassi, H. Michael; Pym, Alexander; Rhee, Kyu Y.; Robertson, Gregory T.; Rock, Jeremy Michael; Rubin, Eric J.; Russell, Betsy; Russell, David G.; Sacchettini, James C.; Schnappinger, Dirk; Schrimpf, Michael; Upton, Anna M.; Warner, Peter; Wyatt, Paul Graham; Yuan, Ying			The Tuberculosis Drug Accelerator at year 10: what have we learned?	NATURE MEDICINE			English	Editorial Material							MEMBRANE; EFFICACY; TARGETS	The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium's achievements, advantages and limitations and advocate for the application of similar models to other diseases.	[Aldridge, Bree B.] Tufts Univ, Boston, MA 02111 USA; [Barros-Aguirre, David; Bates, Robert H.; Lelievre, Joel] GlaxoSmithKline, Tres Cantos, Spain; [Barry, Clifton E., III; Boshoff, Helena I.] NIH, Bldg 10, Bethesda, MD 20892 USA; [Berthel, Steven J.] Panorama Global, Seattle, WA USA; [Chibale, Kelly; Mizrahi, Valerie] Univ Cape Town, Cape Town, South Africa; [Chu, Xin-Jie; Yuan, Ying] Global Hlth Drug Discovery Inst, Beijing, Peoples R China; [Cooper, Christopher B.; Fotouhi, Nader] Global Alliance TB Drug Dev, New York, NY USA; [Dartois, Veronique] Hackensack Meridian Hlth Ctr Discovery & Innovat, Nutley, NJ USA; [Duncan, Ken; Warner, Peter] Bill & Melinda Gates Fdn, Seattle, WA USA; [Gusovsky, Fabian] Eisai, Andover, MA USA; [Hipskind, Philip A.] Lgenia, Fortville, IN USA; [Kempf, Dale J.; Schrimpf, Michael] AbbVie, N Chicago, IL USA; [Lenaerts, Anne J.; Robertson, Gregory T.] Colorado State Univ, Ft Collins, CO 80523 USA; [McNamara, Case W.; Petrassi, H. Michael] Calibr, La Jolla, CA USA; [Nathan, Carl; Rhee, Kyu Y.; Schnappinger, Dirk] Weill Cornell Med, New York, NY 10065 USA; [Olsen, David B.] Merck & Co Inc, West Point, PA USA; [Parish, Tanya] Seattle Childrens Res Inst, Seattle, WA USA; [Pym, Alexander] Janssen Cilag, High Wycombe, Bucks, England; [Rock, Jeremy Michael] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Rubin, Eric J.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Russell, Betsy] Bill & Melinda Gates Med Res Inst, Boston, MA USA; [Russell, David G.] Cornell Univ, Ithaca, NY USA; [Sacchettini, James C.] Texas A&M Univ, College Stn, TX USA; [Upton, Anna M.] Evotec, Lyon, France; [Wyatt, Paul Graham] Univ Dundee, Drug Discovery Unit, Dundee, Scotland	Tufts University; GlaxoSmithKline; National Institutes of Health (NIH) - USA; University of Cape Town; Bill & Melinda Gates Foundation; Eisai Co Ltd; AbbVie; Colorado State University; Cornell University; Merck & Company; Seattle Children's Hospital; Johnson & Johnson; Rockefeller University; Harvard University; Harvard T.H. Chan School of Public Health; Cornell University; Texas A&M University System; Texas A&M University College Station; Evotec; University of Dundee	Nathan, C (corresponding author), Weill Cornell Med, New York, NY 10065 USA.	cnathan@med.cornell.edu	Barry, Clifton E/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Aldridge, Bree/0000-0003-2236-1424; Boshoff, Helena/0000-0002-4333-206X				Aggarwal A, 2017, CELL, V170, P249, DOI 10.1016/j.cell.2017.06.025; Ballell L, 2013, CHEMMEDCHEM, V8, P313, DOI 10.1002/cmdc.201200428; Ballinger E, 2019, SCIENCE, V363, P498, DOI 10.1126/science.aau8959; Beites T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12956-2; Berube BJ, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.02661-18, 10.1128/aac.02661-18]; Blanc L, 2018, ELIFE, V7, DOI 10.7554/eLife.41115; Chakraborty S, 2013, SCIENCE, V339, P88, DOI 10.1126/science.1228980; Chengalroyen MD, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.582416; Cokol M, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701881; Conradie F, 2020, NEW ENGL J MED, V382, P893, DOI 10.1056/NEJMoa1901814; Cox JAG, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.6, 10.1038/nmicrobiol.2015.6]; Diacon AH, 2016, NEW ENGL J MED, V375, P393, DOI 10.1056/NEJMc1513236; Early J, 2019, ACS INFECT DIS, V5, P272, DOI 10.1021/acsinfecdis.8b00256; Evans JC, 2016, ACS INFECT DIS, V2, P70, DOI 10.1021/acsinfecdis.6b00150; Kim JH, 2013, P NATL ACAD SCI USA, V110, P19095, DOI 10.1073/pnas.1315860110; Marakalala MJ, 2016, NAT MED, V22, P531, DOI 10.1038/nm.4073; Park Y, 2017, ACS INFECT DIS, V3, P18, DOI 10.1021/acsinfecdis.6b00103; Prideaux B, 2015, NAT MED, V21, P1223, DOI 10.1038/nm.3937; Ray PC, 2021, ACS OMEGA, V6, P2284, DOI 10.1021/acsomega.0c05589; Sarathy JP, 2016, ACS INFECT DIS, V2, P552, DOI 10.1021/acsinfecdis.6b00051; Smith J, 2019, MEDCHEMCOMM, V10, P934, DOI 10.1039/c9md00088g; Strydom N, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002773; Tasneen R, 2016, ANTIMICROB AGENTS CH, V60, P270, DOI 10.1128/AAC.01691-15; Tiwari D, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aal1803; VanderVen BC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004679; Via LE, 2015, ACS INFECT DIS, V1, P203, DOI 10.1021/id500028m; Wang Q, 2020, SCIENCE, V367, P1147, DOI DOI 10.1126/science.aav5912; Wang Z, 2019, P NATL ACAD SCI USA, V116, P19646, DOI 10.1073/pnas.1907946116; Warrier T, 2015, ACS INFECT DIS, V1, P580, DOI 10.1021/acsinfecdis.5b00025; Xu J, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02418-20	30	17	17	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1333	1337		10.1038/s41591-021-01442-2	http://dx.doi.org/10.1038/s41591-021-01442-2		JUL 2021	5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34226736				2022-12-27	WOS:000669779100002
J	Dharan, NJ; Yeh, P; Bloch, M; Yeung, MM; Baker, D; Guinto, J; Roth, N; Ftouni, S; Ognenovska, K; Smith, D; Hoy, JF; Woolley, I; Pell, C; Templeton, DJ; Fraser, N; Rose, N; Hutchinson, J; Petoumenos, K; Dawson, SJ; Polizzotto, MN; Dawson, MA				Dharan, Nila J.; Yeh, Paul; Bloch, Mark; Yeung, Miriam M.; Baker, David; Guinto, Jerick; Roth, Norman; Ftouni, Sarah; Ognenovska, Katherine; Smith, Don; Hoy, Jennifer F.; Woolley, Ian; Pell, Catherine; Templeton, David J.; Fraser, Neil; Rose, Nectarios; Hutchinson, Jolie; Petoumenos, Kathy; Dawson, Sarah-Jane; Polizzotto, Mark N.; Dawson, Mark A.		ARCHIVE Study Grp	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults	NATURE MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; STEM-CELLS; COMBINATION; EXPOSURE; MDS; DNA	People with human immunodeficiency virus (HIV) have higher rates of certain comorbidities, particularly cardiovascular disease and cancer, than people without HIV1-5. In view of observations that somatic mutations associated with age-related clonal hematopoiesis (CH) are linked to similar comorbidities in the general population(6-10), we hypothesized that CH may be more prevalent in people with HIV. To address this issue, we established a prospective cohort study, the ARCHIVE study (NCT04641013), in which 220 HIV-positive and 226 HIV-negative participants aged 55 years or older were recruited in Australia. Demographic characteristics, clinical data and peripheral blood were collected to assess the presence of CH mutations and to identify potential risk factors for and clinical sequelae of CH. In total, 135 CH mutations were identified in 100 (22.4%) of 446 participants. CH was more prevalent in HIV-positive participants than in HIV-negative participants (28.2% versus 16.8%, P = 0.004), overall and across all age groups; the adjusted odds ratio for having CH in those with HIV was 2.16 (95% confidence interval 1.34-3.48, P = 0.002). The most common genes mutated overall were DNMT3A (47.4%), TET2 (20.0%) and ASXL1 (13.3%). CH and HIV infection were independently associated with increases in blood parameters and biomarkers associated with inflammation. These data suggest a selective advantage for the emergence of CH in the context of chronic infection and inflammation related to HIV infection.	[Dharan, Nila J.; Ognenovska, Katherine; Templeton, David J.; Rose, Nectarios; Hutchinson, Jolie; Petoumenos, Kathy; Polizzotto, Mark N.] Univ New South Wales Sydney, Kirby Inst, Sydney, NSW, Australia; [Yeh, Paul; Yeung, Miriam M.; Guinto, Jerick; Ftouni, Sarah; Dawson, Sarah-Jane; Dawson, Mark A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Yeh, Paul; Yeung, Miriam M.; Dawson, Sarah-Jane; Dawson, Mark A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Bloch, Mark] Holdsworth House Med Practice, Sydney, NSW, Australia; [Baker, David] East Sydney Doctors, Darlinghurst, NSW, Australia; [Roth, Norman] Prahran Market Clin, Melbourne, Vic, Australia; [Smith, Don] South Eastern Sydney Local Hosp Network, Albion Ctr, Sydney, NSW, Australia; [Smith, Don] Univ New South Wales Sydney, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Hoy, Jennifer F.] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia; [Hoy, Jennifer F.] Monash Univ, Melbourne, Vic, Australia; [Woolley, Ian] Monash Hlth, Monash Infect Dis, Clayton, Vic, Australia; [Woolley, Ian] Monash Univ, Ctr Inflammatory Dis, Clayton, Vic, Australia; [Pell, Catherine] Taylor Sq Private Clin, Darlinghurst, NSW, Australia; [Templeton, David J.] Sydney Local Hlth Dist, Dept Sexual Hlth Med, Sydney, NSW, Australia; [Templeton, David J.] Sydney Local Hlth Dist, Sexual Assault Med Serv, Sydney, NSW, Australia; [Templeton, David J.] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Discipline Med, Sydney, NSW, Australia; [Fraser, Neil] Posit Life, Sydney, NSW, Australia; [Dawson, Sarah-Jane; Dawson, Mark A.] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia; [Polizzotto, Mark N.] St Vincents Hosp, Darlinghurst, NSW, Australia	University of New South Wales Sydney; Kirby Institute; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of New South Wales Sydney; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; University of Sydney; University of Melbourne; St Vincents Hospital Sydney	Petoumenos, K; Polizzotto, MN (corresponding author), Univ New South Wales Sydney, Kirby Inst, Sydney, NSW, Australia.; Dawson, SJ; Dawson, MA (corresponding author), Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.; Dawson, SJ; Dawson, MA (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.; Dawson, SJ; Dawson, MA (corresponding author), Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia.; Polizzotto, MN (corresponding author), St Vincents Hosp, Darlinghurst, NSW, Australia.	kpetoumenos@kirby.unsw.edu.au; sarah-jane.dawson@petermac.org; mpolizzotto@kirby.unsw.edu.au; mark.dawson@petermac.org	Dawson, Mark A/B-9317-2017; Dharan, Nila/AEX-8364-2022	Dawson, Mark A/0000-0002-5464-5029; Dawson, Sarah-Jane/0000-0002-8276-0374; Yeung, Miriam/0000-0002-9455-1887; Woolley, Ian John/0000-0003-2928-1291; Rose, Nectarios/0000-0002-7384-9967; YEH, PAUL/0000-0002-4172-3614	Australian Government Department of Health and Ageing; NHMRC [1196749, 1196755, 1128984, 1213110, 1110067]; Cancer Council Victoria Dunlop Fellowship; Howard Hughes Medical Institute international research scholarship; CSL Centenary fellowship; NHMRC postgraduate scholarship; Cancer Institute of NSW Future Research Leader Fellowship [15-1-01]; NHMRC/MRFF investigator grant [1195030]; Snowdome Foundation/Maddie Riewoldt's vision; George and Yolanda Klempfner AO fellowship; Gilead	Australian Government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria Dunlop Fellowship; Howard Hughes Medical Institute international research scholarship; CSL Centenary fellowship; NHMRC postgraduate scholarship(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute of NSW Future Research Leader Fellowship; NHMRC/MRFF investigator grant(Medical Research Future Fund (MRFF)); Snowdome Foundation/Maddie Riewoldt's vision; George and Yolanda Klempfner AO fellowship; Gilead(Gilead Sciences)	The authors thank all of the individuals who participated in this study. We also acknowledge the following clinical site study coordinators: T. Vincent, Holdsworth House Medical Practice; R. Rosario, East Sydney Doctors; H. Lau, Prahran Market Clinic; F. Bascombe, St Vincent's Hospital Sydney; D. Smith, Albion Centre; S. Price, Alfred Hospital; J. O'Brien, Monash Health; H. T. L. Tan, Taylor Square Private Clinic; B. Sinclair, Department of Sexual Health Medicine, Sydney Local Health District. We also acknowledge K. Merlin, M. Starr, B. Catlett and the Clinical Trials & Biorepository/DBS Team at St Vincent's Centre for Applied Medical Research. Finally, we acknowledge P. Blombery, M. McBean and H. N. Goh for their assistance with ASXL1 fragment-length analysis. The Kirby Institute receives funding from the Australian Government Department of Health and Ageing. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Australian Government. We thank the following funders for fellowship and grant support: NHMRC investigator grant (1196749 to. M.A.D.), Cancer Council Victoria Dunlop Fellowship (to M.A. D.), Howard Hughes Medical Institute international research scholarship (to M. A.D.), NHMRC investigator grant (1196755 to S.-J.D.), CSL Centenary fellowship (to S.-J.D.), NHMRC postgraduate scholarship (to N.J.D.), NHMRC fellowship (1110067 to M.N.P.), Cancer Institute of NSW Future Research Leader Fellowship (15-1-01 to M.N.P.), NHMRC/MRFF investigator grant (1195030 to P.Y.), Snowdome Foundation/Maddie Riewoldt's vision (to P.Y.), George and Yolanda Klempfner AO fellowship (to P.Y.), Gilead (to P.Y.) and NHMRC project grants (1128984 (to S.-J.D. and M.A.D.) and 1213110).	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; [Anonymous], DEFINING ADULT OVERW; Autenrieth CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207005; Bick AG, 2020, CIRCULATION, V141, P124, DOI 10.1161/CIRCULATIONAHA.119.044362; Bogeska R, 2020, HEMATOPOIETIC STEM C, DOI [org/10.1101/2020.08.01.230433., 10.1101/2020.08.01.230433, DOI 10.1101/2020.08.01.230433]; Borate U, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128178; Busque L, 2020, BLOOD ADV, V4, P2430, DOI 10.1182/bloodadvances.2019000770; Cai ZG, 2018, CELL STEM CELL, V23, P833, DOI 10.1016/j.stem.2018.10.013; Cassol E, 2010, J INFECT DIS, V202, P723, DOI 10.1086/655229; Chow FC, 2014, AIDS, V28, P2573, DOI 10.1097/QAD.0000000000000452; Deeks Steven G, 2009, Top HIV Med, V17, P118; Desai P, 2018, NAT MED, V24, P1015, DOI 10.1038/s41591-018-0081-z; Doig KD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0427-z; Feinstein MJ, 2019, CIRCULATION, V140, pE98, DOI 10.1161/CIR.0000000000000695; Fenaux P, 2020, NEW ENGL J MED, V382, P140, DOI 10.1056/NEJMoa1908892; Frick M, 2019, J CLIN ONCOL, V37, P375, DOI 10.1200/JCO.2018.79.2184; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Grund B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155100; Gueler A, 2017, AIDS, V31, P427, DOI 10.1097/QAD.0000000000001335; Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626; Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jalbert E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075500; Kaner JD, 2019, LEUKEMIA LYMPHOMA, V60, P3529, DOI 10.1080/10428194.2019.1633631; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Marcus JL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7954; Meisel M, 2018, NATURE, V557, P580, DOI 10.1038/s41586-018-0125-z; Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749; Pietras EM, 2016, NAT CELL BIOL, V18, P607, DOI 10.1038/ncb3346; Pietras EM, 2014, J EXP MED, V211, P245, DOI 10.1084/jem.20131043; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rosenson RS, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013744; Sallman DA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126271; Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701; Shiels MS, 2017, CURR OPIN HIV AIDS, V12, P6, DOI 10.1097/COH.0000000000000327; Steensma DP, 2018, BLOOD ADV, V2, P3404, DOI 10.1182/bloodadvances.2018020222; Subbaraman R, 2007, CLIN INFECT DIS, V45, P1093, DOI 10.1086/521150; Triant VA, 2010, JAIDS-J ACQ IMM DEF, V55, P615, DOI 10.1097/QAI.0b013e3181f4b752; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733; Yannakou CK, 2017, BLOOD CANCER J, V7, DOI 10.1038/s41408-017-0025-8; Yeh P, 2017, BLOOD, V129, P1685, DOI 10.1182/blood-2016-09-740308	43	29	29	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1006	+		10.1038/s41591-021-01357-y	http://dx.doi.org/10.1038/s41591-021-01357-y		JUN 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34099923	Green Published, Green Submitted			2022-12-27	WOS:000658604700003
J	Ebinger, JE; Fert-Bober, J; Printsev, I; Wu, M; Sun, N; Prostko, JC; Frias, EC; Stewart, JL; Van Eyk, JE; Braun, JG; Cheng, SS; Sobhani, K				Ebinger, Joseph E.; Fert-Bober, Justyna; Printsev, Ignat; Wu, Min; Sun, Nancy; Prostko, John C.; Frias, Edwin C.; Stewart, James L.; Van Eyk, Jennifer E.; Braun, Jonathan G.; Cheng, Susan; Sobhani, Kimia			Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	NATURE MEDICINE			English	Article								Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.	[Ebinger, Joseph E.; Fert-Bober, Justyna; Wu, Min; Sun, Nancy; Van Eyk, Jennifer E.; Cheng, Susan] Cedars Sinai Med Ctr, Dept Cardiol, Smidt Heart Inst, Los Angeles, CA 90048 USA; [Fert-Bober, Justyna; Van Eyk, Jennifer E.] Cedars Sinai Med Ctr, Dept Biomed Sci, Adv Clin Biosyst Inst, Los Angeles, CA 90048 USA; [Printsev, Ignat; Braun, Jonathan G.] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel, Los Angeles, CA 90048 USA; [Printsev, Ignat; Braun, Jonathan G.] Cedars Sinai Med Ctr, Immunobiol Res Inst, Los Angeles, CA 90048 USA; [Prostko, John C.; Frias, Edwin C.; Stewart, James L.] Abbott Diagnost, Appl Res & Technol, Abbott Pk, IL USA; [Braun, Jonathan G.; Sobhani, Kimia] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cheng, SS (corresponding author), Cedars Sinai Med Ctr, Dept Cardiol, Smidt Heart Inst, Los Angeles, CA 90048 USA.; Braun, JG (corresponding author), Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel, Los Angeles, CA 90048 USA.; Braun, JG (corresponding author), Cedars Sinai Med Ctr, Immunobiol Res Inst, Los Angeles, CA 90048 USA.; Braun, JG; Sobhani, K (corresponding author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.	jonathan.braun2@cshs.org; susan.cheng@cshs.org; kimia.sobhani@cshs.org		Sobhani, Kimia/0000-0002-9297-3445; Cheng, Susan/0000-0002-4977-036X	Cedars-Sinai Medical Center; Erika J. Glazer Family Foundation; F. Widjaja Family Foundation; Helmsley Charitable Trust; National Institutes of Health [U54-CA260591, K23-HL153888]	Cedars-Sinai Medical Center; Erika J. Glazer Family Foundation; F. Widjaja Family Foundation; Helmsley Charitable Trust; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to all the frontline healthcare workers in our healthcare system who continue to be dedicated to delivering the highest quality care for all patients. We thank the following people for their collective effort: F. P. Aguirre; K. Ahmad; C. M. Albert; M. Alotaibi; A. Andres; M. Arditi; A. Balmanoukian; C. Becker; J. Beekley; D. Benliyan; A. H. Berg; E. Biener-Ramanujan; A. Binek; P. Botting; G. J. Botwin; D. Casero; C. Chavira; B. Chazarin Orgel; M. Che; P. Chen; V. Chiu; D. Choi; M. Chow; C. Chung; C. Climer; B. Coleman; S. Contreras; R. Coren; D. Costales; W. Cozen; T. Dar; J. Davis; T. Davis; P. Debbas; J. Diaz; J. Dos Santos; M. Driver; K. R. Dunn; R. Ely; M. Faries; B. Fields; J. C. Figueiredo; L. Florindez; J. Foley; N. Fontelera; S. Francis; J. A. Golden; A. Gonzalez; H. S. Goodridge; J. Gonzalez; J. D. Grein; G. Guidry; O. Hamid; M. Hanna; S. Hashemzadeh; M. Heath; E. Herrera; A. Hoang; L. Huang; K. Huballa; Q. Hurlburt; S. K. Hussain; C. A. Huynh; J. Ibrahim; U. Ihenacho; M. Jain; H. Jawanda; M. Jordan; A. Jose-Isip; S. Joung; M. Karin; E. H. Kim; L. Kim; M. M. Kittleson; E. Kowalewski; C. N. Le; N. A. Leonard; Y. Li; Y. Liu; J. Lloyd; E. Luong; A. Makaryan; B. Malladi; D.-M. Manalo; D. Marshall; A. McArdle; D. P. B. McGovern; I. Mehmi; D. Mejia; G. Y. Melmed; L. Mendez; E. Mengesha; A. Merchant; N. Merin; K. S. Michelsen; G. Milan; P. B. Miles; J. Miller; M. Minissian; R. Miranda-Peats; S. E. Mirzadeh; A. Moore; P. Moore; J. Moreno; A. Mujukian; N. Nguyen; T. T. Nguyen; M. Noval Rivas; F. N. Bitghe; M. Offner; J. Oft; E. Park; E. Park; V. Patel; C. Phebus; L. Piro; L. R. Polak; A. Porter; M. Puccio; K. Raedschelders; V. K. Ramanujan; R. Ramirez; G. Ramirez; M. Rashid; K. Reckamp; K. Rhoades; C. E. Riera; R. V. Riggs; A. Rivas; J. Robertson; M. Salas; M. Schafieh; R. Shane; S. Sharma; C. Simons; M. Soomar; S. Sternbach; N. Sun; C. Svendsen; B. Tep; R. O. Tompkins; W. G. Toutellotte; R. Vallejo; C. Velasco; M. Velasquez; K. Washington; K. Wentzel; S. White; B. Wong; M. Wong; M. Yatawara; R. Zabner; C. Zamudio; Y. Zhang; L. Zhou; P. Zvara. Funding: This work was supported, in part, by Cedars-Sinai Medical Center (J.E.E., M.W., N.S. and S.C.); the Erika J. Glazer Family Foundation (J.E.E., M.W., N.S., J.E.V.E. and S.C.); the F. Widjaja Family Foundation (I.P. and J.G.B.); the Helmsley Charitable Trust (I.P. and J.G.B.); and National Institutes of Health grants U54-CA260591 (J.E.E., J.F.B., M.W., J.E.V.E., J.G.B., S.C. and K.S.) and K23-HL153888 (J.E.E.).	Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; [Anonymous], 2020, SARS COV 2 IGG 2 QUA; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chew KL, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.05.036; Ebinger JE, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043584; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Harvey Raymond A, 2020, medRxiv, DOI 10.1101/2020.12.18.20248336; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Melgaco JG, 2020, CELL IMMUNOL, V353, DOI 10.1016/j.cellimm.2020.104114; Omer SB, 2020, JAMA-J AM MED ASSOC, V324, P2095, DOI 10.1001/jama.2020.20892; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Thomson E.C., 2020, AGE AGEING, V50, P279; Wang Zijun, 2021, bioRxiv, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]	21	315	317	3	26	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					981	+		10.1038/s41591-021-01325-6	http://dx.doi.org/10.1038/s41591-021-01325-6		APR 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	33795870	hybrid, Green Published			2022-12-27	WOS:000635886700002
J	Huang, SX; Lei, D; Yang, Q; Yang, Y; Jiang, CY; Shi, HP; Qian, B; Long, Q; Chen, WY; Chen, YM; Zhu, L; Yang, WJ; Wang, L; Hai, WX; Zhao, Q; You, ZW; Ye, XF				Huang, Shixing; Lei, Dong; Yang, Qi; Yang, Yang; Jiang, Chenyu; Shi, Hongpeng; Qian, Bei; Long, Qiang; Chen, Wenyi; Chen, Youming; Zhu, Lan; Yang, Wenjie; Wang, Lan; Hai, Wangxi; Zhao, Qiang; You, Zhengwei; Ye, Xiaofeng			A perfusable, multifunctional epicardial device improves cardiac function and tissue repair	NATURE MEDICINE			English	Article								Despite advances in technologies for cardiac repair after myocardial infarction (MI), new integrated therapeutic approaches still need to be developed. In this study, we designed a perfusable, multifunctional epicardial device (PerMed) consisting of a biodegradable elastic patch (BEP), permeable hierarchical microchannel networks (PHMs) and a system to enable delivery of therapeutic agents from a subcutaneously implanted pump. After its implantation into the epicardium, the BEP is designed to provide mechanical cues for ventricular remodeling, and the PHMs are designed to facilitate angiogenesis and allow for infiltration of reparative cells. In a rat model of MI, implantation of the PerMed improved ventricular function. When connected to a pump, the PerMed enabled targeted, sustained and stable release of platelet-derived growth factor-BB, amplifying the efficacy of cardiac repair as compared to the device without a pump. We also demonstrated the feasibility of minimally invasive surgical PerMed implantation in pigs, demonstrating its promise for clinical translation to treat heart disease. Implantation of a perfusable device into the epicardium enables delivery of therapeutic agents and infiltration of reparative cells into the heart, amplifying the therapeutic effects of FGF-23 in a rat model of myocardial infarction.	[Huang, Shixing; Yang, Qi; Jiang, Chenyu; Shi, Hongpeng; Qian, Bei; Long, Qiang; Zhao, Qiang; Ye, Xiaofeng] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Cardiovasc Surg, Sch Med, Shanghai, Peoples R China; [Lei, Dong; Chen, Wenyi; You, Zhengwei] Donghua Univ, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai Belt & Rd Joint Lab Adv Fiber & Low Dime, Coll Mat Sci & Engn,Shanghai Engn Res Ctr Nanobio, Shanghai, Peoples R China; [Yang, Yang] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Cardiothorac Surg, Sch Med, Shanghai, Peoples R China; [Chen, Youming] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Cardiol, Sch Med, Shanghai, Peoples R China; [Zhu, Lan; Yang, Wenjie; Wang, Lan] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Radiol, Sch Med, Shanghai, Peoples R China; [Hai, Wangxi] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Nucl Med, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Donghua University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhao, Q; Ye, XF (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Cardiovasc Surg, Sch Med, Shanghai, Peoples R China.; You, ZW (corresponding author), Donghua Univ, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai Belt & Rd Joint Lab Adv Fiber & Low Dime, Coll Mat Sci & Engn,Shanghai Engn Res Ctr Nanobio, Shanghai, Peoples R China.	zq11607@rjh.com.cn; zyou@dhu.edu.cn; xiaofengye@hotmail.com	You, Zhengwei/AAU-4307-2021	Jiang, Chenyu/0000-0003-2964-2309; Huang, Shixing/0000-0002-6348-7253				Annabi N, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7466; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Awada HK, 2015, J CONTROL RELEASE, V207, P7, DOI 10.1016/j.jconrel.2015.03.034; Beck RW, 2019, LANCET, V394, P1265, DOI 10.1016/S0140-6736(19)31142-0; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Braunwald E, 2015, LANCET, V385, P812, DOI 10.1016/S0140-6736(14)61889-4; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Carmichael BB, 2006, RADIOLOGY, V241, P710, DOI 10.1148/radiol.2413051440; Chachques JC, 2020, EUR J CARDIO-THORAC, V57, P545, DOI 10.1093/ejcts/ezz252; Chen QZ, 2008, BIOMATERIALS, V29, P47, DOI 10.1016/j.biomaterials.2007.09.010; Cohn WE, 2015, NAT REV CARDIOL, V12, P609, DOI 10.1038/nrcardio.2015.79; Dorn GW, 2016, CURR OPIN GENET DEV, V38, P38, DOI 10.1016/j.gde.2016.03.001; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Du JH, 2018, ACS APPL MATER INTER, V10, P28340, DOI 10.1021/acsami.8b08563; Dvir T, 2011, NAT NANOTECHNOL, V6, P13, DOI 10.1038/NNANO.2010.246; Engelmayr GC, 2008, NAT MATER, V7, P1003, DOI 10.1038/nmat2316; Feiner R, 2016, NAT MATER, V15, P679, DOI [10.1038/NMAT4590, 10.1038/nmat4590]; Frangogiannis NG, 2015, COMPR PHYSIOL, V5, P1841, DOI 10.1002/cphy.c150006; Fujimoto KL, 2007, J AM COLL CARDIOL, V49, P2292, DOI 10.1016/j.jacc.2007.02.050; Galan DT, 2016, AM J PHYSIOL-HEART C, V311, pH1075, DOI 10.1152/ajpheart.00945.2015; Gao L, 2018, CIRCULATION, V137, P1712, DOI 10.1161/CIRCULATIONAHA.117.030785; Gu XZ, 2017, BIOMATERIALS, V133, P132, DOI 10.1016/j.biomaterials.2017.04.015; Gullbrand SE, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau0670; Hastings CL, 2015, ADV DRUG DELIVER REV, V84, P85, DOI 10.1016/j.addr.2014.08.006; Holmes DF, 2018, P NATL ACAD SCI USA, V115, pE9288, DOI 10.1073/pnas.1801759115; Hsieh PCH, 2006, CIRCULATION, V114, P637, DOI 10.1161/CIRCULATIONAHA.106.639831; Hsieh PCH, 2006, J CLIN INVEST, V116, P237, DOI 10.1172/JCI25878; Huang SX, 2018, J THORAC DIS, V10, pS2312, DOI 10.21037/jtd.2017.12.92; Huynh K, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2017.137; Kilarski WW, 2009, NAT MED, V15, P657, DOI 10.1038/nm.1985; LaValley D.J., 2014, ADV REGENER BIOL, V1, P25247, DOI 10.3402/arb.v1.25247; Lee AS, 2018, NAT BIOMED ENG, V2, P104, DOI 10.1038/s41551-018-0191-4; Lei D, 2019, MATER HORIZ, V6, P1197, DOI 10.1039/c9mh00174c; Lei D, 2019, MATER HORIZ, V6, P394, DOI 10.1039/c8mh00937f; Lesman A, 2016, ADV DRUG DELIVER REV, V96, P176, DOI 10.1016/j.addr.2015.07.005; Lesman A, 2011, BIOMATERIALS, V32, P7856, DOI 10.1016/j.biomaterials.2011.07.003; Lin X, 2019, NAT BIOMED ENG, V3, P632, DOI 10.1038/s41551-019-0380-9; Liu BH, 2018, NAT BIOMED ENG, V2, P293, DOI 10.1038/s41551-018-0229-7; Liu NB, 2021, BIOACT MATER, V6, P1388, DOI 10.1016/j.bioactmat.2020.10.021; Madden LR, 2010, P NATL ACAD SCI USA, V107, P15211, DOI 10.1073/pnas.1006442107; McWhorter FY, 2015, CELL MOL LIFE SCI, V72, P1303, DOI 10.1007/s00018-014-1796-8; Montgomery M, 2017, NAT MATER, V16, P1038, DOI [10.1038/NMAT4956, 10.1038/nmat4956]; Nguyen MM, 2015, ADV MATER, V27, P5547, DOI 10.1002/adma.201502003; Owens AT, 2016, CIRC RES, V118, P480, DOI 10.1161/CIRCRESAHA.115.306567; Park SJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11091-2; Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577; Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017; Serpooshan V, 2013, BIOMATERIALS, V34, P9048, DOI 10.1016/j.biomaterials.2013.08.017; Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023; Sun XT, 2016, ADV DRUG DELIVER REV, V96, P183, DOI 10.1016/j.addr.2015.06.001; Tang JN, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat9365; Tang XQ, 2017, CIRCULATION, V136, P2051, DOI 10.1161/CIRCULATIONAHA.117.028728; Taylor DA, 2017, CIRC RES, V120, P30, DOI 10.1161/CIRCRESAHA.116.309959; Ternacle J, 2016, JACC-CARDIOVASC IMAG, V9, P126, DOI 10.1016/j.jcmg.2015.05.014; Urech L, 2005, BIOMATERIALS, V26, P1369, DOI 10.1016/j.biomaterials.2004.04.045; Vagnozzi RJ, 2020, NATURE, V577, P405, DOI 10.1038/s41586-019-1802-2; van den Borne SWM, 2010, NAT REV CARDIOL, V7, P30, DOI 10.1038/nrcardio.2009.199; Whyte W, 2018, NAT BIOMED ENG, V2, P416, DOI 10.1038/s41551-018-0247-5; Yacoub M, 2015, LANCET, V385, P2554, DOI 10.1016/S0140-6736(15)60683-3; Yan XX, 2017, CIRC RES, V120, P1116, DOI 10.1161/CIRCRESAHA.116.310260; Yang Y, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900065; Yeh YC, 2016, BIOFABRICATION, V8, DOI 10.1088/1758-5090/8/4/045004; Yuan ZZ, 2019, ACS APPL MATER INTER, V11, P38429, DOI 10.1021/acsami.9b12043; Zieber L, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/2/024102; Zimmermann WH, 2006, NAT MED, V12, P452, DOI 10.1038/nm1394	65	29	30	34	124	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					480	+		10.1038/s41591-021-01279-9	http://dx.doi.org/10.1038/s41591-021-01279-9			29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723455				2022-12-27	WOS:000629708300028
J	Tegally, H; Wilkinson, E; Lessells, RJ; Giandhari, J; Pillay, S; Msomi, N; Mlisana, K; Bhiman, JN; von Gottberg, A; Walaza, S; Fonseca, V; Allam, M; Ismail, A; Glass, AJ; Engelbrecht, S; Van Zyl, G; Preiser, W; Williamson, C; Petruccione, F; Sigal, A; Gazy, I; Hardie, D; Hsiao, NY; Martin, D; York, D; Goedhals, D; San, EJ; Giovanetti, M; Lourenco, J; Alcantara, LCJ; de Oliveira, T				Tegally, Houriiyah; Wilkinson, Eduan; Lessells, Richard J.; Giandhari, Jennifer; Pillay, Sureshnee; Msomi, Nokukhanya; Mlisana, Koleka; Bhiman, Jinal N.; von Gottberg, Anne; Walaza, Sibongile; Fonseca, Vagner; Allam, Mushal; Ismail, Arshad; Glass, Allison J.; Engelbrecht, Susan; Van Zyl, Gert; Preiser, Wolfgang; Williamson, Carolyn; Petruccione, Francesco; Sigal, Alex; Gazy, Inbal; Hardie, Diana; Hsiao, Nei-yuan; Martin, Darren; York, Denis; Goedhals, Dominique; San, Emmanuel James; Giovanetti, Marta; Lourenco, Jose; Alcantara, Luiz Carlos Junior; de Oliveira, Tulio			Sixteen novel lineages of SARS-CoV-2 in South Africa	NATURE MEDICINE			English	Article							SOFTWARE	The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in South Africa was identified on 5 March 2020, and by 26 March the country was in full lockdown (Oxford stringency index of 90)(1). Despite the early response, by November 2020, over 785,000 people in South Africa were infected, which accounted for approximately 50% of all known African infections(2). In this study, we analyzed 1,365 near whole genomes and report the identification of 16 new lineages of SARS-CoV-2 isolated between 6 March and 26 August 2020. Most of these lineages have unique mutations that have not been identified elsewhere. We also show that three lineages (B.1.1.54, B.1.1.56 and C.1) spread widely in South Africa during the first wave, comprising similar to 42% of all infections in the country at the time. The newly identified C lineage of SARS-CoV-2, C.1, which has 16 nucleotide mutations as compared with the original Wuhan sequence, including one amino acid change on the spike protein, D614G (ref. (3)), was the most geographically widespread lineage in South Africa by the end of August 2020. An early South African-specific lineage, B.1.106, which was identified in April 2020 (ref. (4)), became extinct after nosocomial outbreaks were controlled in KwaZulu-Natal Province. Our findings show that genomic surveillance can be implemented on a large scale in Africa to identify new lineages and inform measures to control the spread of SARS-CoV-2. Such genomic surveillance presented in this study has been shown to be crucial in the identification of the 501Y.V2 variant in South Africa in December 2020 (ref. (5)).	[Tegally, Houriiyah; Wilkinson, Eduan; Lessells, Richard J.; Giandhari, Jennifer; Pillay, Sureshnee; Fonseca, Vagner; Gazy, Inbal; San, Emmanuel James; de Oliveira, Tulio] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Innovat & Sequencing Platform K, Durban, South Africa; [Tegally, Houriiyah; Wilkinson, Eduan; Msomi, Nokukhanya] Univ KwaZulu Natal, Discipline Virol, Durban, South Africa; [Tegally, Houriiyah; Wilkinson, Eduan; Mlisana, Koleka] Natl Hlth Lab Serv, Springbok, South Africa; [Bhiman, Jinal N.; von Gottberg, Anne; Walaza, Sibongile; Allam, Mushal; Ismail, Arshad] Natl Hlth Lab Serv NHLS, Natl Inst Communicable Dis NICD, Johannesburg, South Africa; [von Gottberg, Anne; Glass, Allison J.] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa; [Walaza, Sibongile] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa; [Glass, Allison J.] Lancet Labs, Dept Mol Pathol, Johannesburg, South Africa; [Engelbrecht, Susan; Van Zyl, Gert; Preiser, Wolfgang] Univ Stellenbosch, NHLS Tygerberg Hosp, Div Med Virol, Stellenbosch, South Africa; [Williamson, Carolyn; Hardie, Diana; Hsiao, Nei-yuan] Univ Cape Town, NHLS Groote Schuur Hosp, Div Med Virol, Cape Town, South Africa; [Petruccione, Francesco] Univ KwaZulu Natal, Ctr Quantum Technol, Durban, South Africa; [Petruccione, Francesco] Natl Inst Theoret Phys NITheP, Kwa Zulu, South Africa; [Sigal, Alex] Africa Hlth Res Inst, Durban, South Africa; [Sigal, Alex] Univ KwaZulu Natal, Sch Lab Med & Med Sci, Durban, South Africa; [Sigal, Alex] Max Planck Inst Infect Biol, Berlin, Germany; [Martin, Darren] Univ Cape Town, Inst Infect Dis & Mol Med, Dept Integrat Biomed Sci, Div Computat Biol, Cape Town, South Africa; [York, Denis] Mol Diagnost Serv, Durban, South Africa; [Goedhals, Dominique] Univ Free State, NHLS Univ Acad Labs, Div Virol, Bloemfontein, South Africa; [Giovanetti, Marta; Alcantara, Luiz Carlos Junior] Fundacao Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil; [Lourenco, Jose] Univ Oxford, Dept Zool, Oxford, England; [Alcantara, Luiz Carlos Junior] Univ Fed Minas Gerais, ICB, Lab Genet Celular & Mol, Belo Horizonte, MG, Brazil; [de Oliveira, Tulio] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [de Oliveira, Tulio] Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa	University of Kwazulu Natal; University of Kwazulu Natal; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; Stellenbosch University; Tygerberg Hospital; University of Cape Town; University of Kwazulu Natal; Africa Health Research Institute; University of Kwazulu Natal; Max Planck Society; University of Cape Town; University of the Free State; Fundacao Oswaldo Cruz; University of Oxford; Universidade Federal de Minas Gerais; University of Washington; University of Washington Seattle	de Oliveira, T (corresponding author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Innovat & Sequencing Platform K, Durban, South Africa.; de Oliveira, T (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.; de Oliveira, T (corresponding author), Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa.	deoliveira@ukzn.ac.za	Alcantara, Luiz Carlos Júnior/AAK-9468-2021; Engelbrecht, Susan/G-7286-2011; Martin, Darren P/C-4599-2008; Sigal, Alex/GWC-7488-2022; Ismail, Arshad/B-8552-2019; Fonseca, Vagner/R-5813-2019; Preiser, Wolfgang/J-4875-2016; Martin, Darren/ABE-3614-2021; Allam, Mushal/E-2885-2016; Bhiman, Jinal/ABA-6029-2021; Mlisana, Koleka/N-6204-2013	Engelbrecht, Susan/0000-0002-1318-5994; Sigal, Alex/0000-0001-8571-2004; Ismail, Arshad/0000-0003-4672-5915; Fonseca, Vagner/0000-0001-5521-6448; Preiser, Wolfgang/0000-0002-0254-7910; Allam, Mushal/0000-0002-9875-6716; Bhiman, Jinal/0000-0001-6354-4003; de Oliveira, Tulio/0000-0002-3027-5254; von Gottberg, Anne/0000-0002-0243-7455; Lourenco, Jose/0000-0002-9318-2581; Mlisana, Koleka/0000-0002-8436-3268	South African Medical Research Council; MRC SHIP; Department of Science and Innovation of South Africa; South African Technology Innovation Agency	South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC SHIP; Department of Science and Innovation of South Africa; South African Technology Innovation Agency	This research was funded by the South African Medical Research Council, MRC SHIP and the Department of Science and Innovation of South Africa. The KwaZulu-Natal Research Innovation and Sequencing Platform is funded by a core award of the South African Technology Innovation Agency. We thank A. Rambaut and A. O'Toole for scientific discussion on how to include the South African lineages on PANGOLIN dynamic classification. We also thank all NGS-SA laboratories in South Africa that were responsible for producing the SARS-CoV-2 genomes that were the focus of the analysis in this paper. A full list of originating laboratories and authors is provided in Supplementary Table 2. Finally, we thank all other global laboratories for generating and making public the SARS-CoV-2 sequences (through GISAID) that were used as the reference dataset in this study. A complete list of individual contributors of sequences is provided in the Supplementary Information.	Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; [Anonymous], 2020, DISAS MANAGE; Cleemput S, 2020, BIOINFORMATICS, V36, P3552, DOI 10.1093/bioinformatics/btaa145; Cori A, 2013, AM J EPIDEMIOL, V178, P1505, DOI 10.1093/aje/kwt133; Dellicour S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03763-2; Dellicour S, 2016, BIOINFORMATICS, V32, P3204, DOI 10.1093/bioinformatics/btw384; Deng XD, 2020, SCIENCE, V369, P582, DOI 10.1126/science.abb9263; du Plessis L, 2021, SCIENCE, V371, P708, DOI 10.1126/science.abf2946; Eden JS, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa027; Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302; Giandhari J, 2021, INT J INFECT DIS, V103, P234, DOI 10.1016/j.ijid.2020.11.128; Goldstein E, 2009, P NATL ACAD SCI USA, V106, P21825, DOI 10.1073/pnas.0902958106; Gonzalez-Reiche AS, 2020, SCIENCE, V369, P297, DOI 10.1126/science.abc1917; Gostic KM, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008409; GRIFFITHS RC, 1994, PHILOS T ROY SOC B, V344, P403, DOI 10.1098/rstb.1994.0079; Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Hale T., 2020, OXFORD COVID 19 GOVT; Hodcroft E. B., 2020, YEAR LETT GENETIC CL, DOI [10.5281/ZENODO.3819126, DOI 10.5281/ZENODO.3819126]; Huisman J.S., 2020, ELIFE, DOI [10.1101/2020.11.26.20239368, DOI 10.1101/2020.11.26.20239368]; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300; Lemey P, 2010, MOL BIOL EVOL, V27, P1877, DOI 10.1093/molbev/msq067; Lessells R, 2020, REPORT NOSOCOMIAL OU; Leung KSS, 2021, EMERG INFECT DIS, V27, P196, DOI 10.3201/eid2701.201543; Marivate V., 2020, DATA SCI J, V19, P19, DOI DOI 10.5334/DSJ-2020-019; Marivate V, 2020, **DATA OBJECT**, DOI [10.5281/ZENODO.3819126, DOI 10.5281/ZENODO.3819126]; Meredith LW, 2020, LANCET INFECT DIS, V20, P1263, DOI 10.1016/S1473-3099(20)30562-4; Msomi N, 2020, LANCET MICROBE, V1, pE229, DOI 10.1016/S2666-5247(20)30116-6; Nordling Linda., 2020, PANDEMIC APPEARS HAV; Munnink BOB, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0997-y; Quick J., 2020, NCOV 2019 SEQUENCING; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007; Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Vilsker M, 2019, BIOINFORMATICS, V35, P871, DOI 10.1093/bioinformatics/bty695; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3	42	193	196	2	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					440	+		10.1038/s41591-021-01255-3	http://dx.doi.org/10.1038/s41591-021-01255-3		FEB 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33531709	Green Published, Bronze			2022-12-27	WOS:000614000700001
J	Yu, TW; Bodamer, O				Yu, Timothy W.; Bodamer, Olaf			A solid start for gene therapy in Tay-Sachs disease	NATURE MEDICINE			English	Editorial Material									[Yu, Timothy W.; Bodamer, Olaf] Boston Childrens Hosp, Div Genet & Gen, Boston, MA USA; [Yu, Timothy W.; Bodamer, Olaf] Broad Inst MIT & Harvard, Cambridge, MA USA; [Yu, Timothy W.; Bodamer, Olaf] Harvard Med Sch, Boston, MA 02115 USA; [Yu, Timothy W.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Yu, TW (corresponding author), Boston Childrens Hosp, Div Genet & Gen, Boston, MA USA.; Yu, TW (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA USA.; Yu, TW (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Yu, TW (corresponding author), Boston Childrens Hosp, Dept Neurol, Boston, MA USA.	timothy.yu@childrens.harvard.edu						Bailey RM, 2018, MOL THER-METH CLIN D, V9, P160, DOI 10.1016/j.omtm.2018.02.005; Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221; Bembi B, 2006, NEUROLOGY, V66, P278, DOI 10.1212/01.wnl.0000194225.78917.de; Eichler F, 2017, NEW ENGL J MED, V377, P1630, DOI 10.1056/NEJMoa1700554; Flotte TR, 2022, NAT MED, V28, P251, DOI 10.1038/s41591-021-01664-4; Hwu WL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003640; Maegawa GHB, 2009, MOL GENET METAB, V98, P215, DOI 10.1016/j.ymgme.2009.06.005; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Platt FM., 2018, NAT REV DIS PRIMERS, V4, P274	9	0	0	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					236	237		10.1038/s41591-022-01687-5	http://dx.doi.org/10.1038/s41591-022-01687-5		FEB 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35145310				2022-12-27	WOS:000753763500006
J	Andrews, SF; Raab, JE; Gorman, J; Gillespie, RA; Cheung, CSF; Rawi, R; Cominsky, LY; Boyington, JC; Creanga, A; Shen, CH; Harris, DR; Olia, AS; Nazzari, AF; Zhou, TQ; Houser, KV; Chen, GL; Mascola, JR; Graham, BS; Kanekiyo, M; Ledgerwood, JE; Kwong, PD; McDermott, AB				Andrews, Sarah F.; Raab, Julie E.; Gorman, Jason; Gillespie, Rebecca A.; Cheung, Crystal S. F.; Rawi, Reda; Cominsky, Lauren Y.; Boyington, Jeffrey C.; Creanga, Adrian; Shen, Chen-Hsiang; Harris, Darcy R.; Olia, Adam S.; Nazzari, Alexandra F.; Zhou, Tongqing; Houser, Katherine, V; Chen, Grace L.; Mascola, John R.; Graham, Barney S.; Kanekiyo, Masaru; Ledgerwood, Julie E.; Kwong, Peter D.; McDermott, Adrian B.			A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination	NATURE MEDICINE			English	Article							H5N1 VACCINATION; ANTIBODIES; RECOGNITION; VALIDATION; INDUCTION; MODEL; IG	Conserved epitopes on the influenza hemagglutinin (HA) stem are an attractive target for universal vaccine strategies as they elicit broadly neutralizing antibodies. Such antibody responses to stem-specific epitopes have been extensively characterized for HA subtypes H1 and H5 in humans. H2N2 influenza virus circulated 50 years ago and represents a pandemic threat due to the lack of widespread immunity, but, unlike H1 and H5, the H2 HA stem contains Phe45(HA2) predicted to sterically clash with HA stem-binding antibodies characterized to date. To understand the effect of Phe45(HA2), we compared the HA stem-specific B cell response in post hoc analyses of two phase 1 clinical trials, one testing vaccination with an H2 ferritin nanoparticle immunogen (NCT03186781) and one with an inactivated H5N1 vaccine (NCT01086657). In H2-naive individuals, the magnitude of the B cell response was equivalent, but H2-elicited HA stem-binding B cells displayed greater cross-reactivity than those elicited by H5. However, in individuals with childhood H2 exposure, H5-elicited HA stem-binding B cells also displayed high cross-reactivity, suggesting recall of memory B cells formed 50 years ago. Overall, we propose that a one-residue difference on an HA immunogen can alter establishment and expansion of broadly neutralizing memory B cells. These data have implications for stem-based universal influenza vaccination strategies.	[Andrews, Sarah F.; Raab, Julie E.; Gorman, Jason; Gillespie, Rebecca A.; Cheung, Crystal S. F.; Rawi, Reda; Cominsky, Lauren Y.; Boyington, Jeffrey C.; Creanga, Adrian; Shen, Chen-Hsiang; Harris, Darcy R.; Olia, Adam S.; Nazzari, Alexandra F.; Zhou, Tongqing; Houser, Katherine, V; Chen, Grace L.; Mascola, John R.; Graham, Barney S.; Kanekiyo, Masaru; Ledgerwood, Julie E.; Kwong, Peter D.; McDermott, Adrian B.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Andrews, SF; McDermott, AB (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	sarah.andrews2@nih.gov; adrian.mcdermott@nih.gov		Harris, Darcy/0000-0002-3671-6452; Nazzari, Alexandra/0000-0003-1891-8541	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Simons Foundation [SF349247]; National Institute of General Medical Sciences [GM103310]; NYSTAR; New York State Assembly Majority	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Simons Foundation; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NYSTAR; New York State Assembly Majority	We thank D. Ambrozak for help with flow cytometry sorting. Support for this work was provided by the Intramural Research Programs of the Vaccine Research Center and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Some of this work was performed at the Simons Electron Microscopy Center and the National Resource for Automated Molecular Microscopy, located at the New York Structural Biology Center, supported by grants from the Simons Foundation (SF349247) and the National Institute of General Medical Sciences (GM103310), with additional support from NYSTAR and the New York State Assembly Majority. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; Andrews SF, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2676; Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522; Avnir Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20842; Avnir Y, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004103; Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/NMETH.3541, 10.1038/nmeth.3541]; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Budeus B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146409; Carter DM, 2013, J VIROL, V87, P1400, DOI 10.1128/JVI.02257-12; Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Cortina-Ceballos B, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0239-y; Creanga A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21954-2; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Doria-Rose NA, 2016, J VIROL, V90, P76, DOI 10.1128/JVI.01791-15; Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Ellebedy AH, 2014, P NATL ACAD SCI USA, V111, P13133, DOI 10.1073/pnas.1414070111; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gostic KM, 2016, SCIENCE, V354, P722, DOI 10.1126/science.aag1322; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Lander GC, 2009, J STRUCT BIOL, V166, P95, DOI 10.1016/j.jsb.2009.01.002; Lang SS, 2017, CELL REP, V20, P2935, DOI 10.1016/j.celrep.2017.08.084; Ledgerwood JE, 2013, J INFECT DIS, V208, P418, DOI 10.1093/infdis/jit180; Ledgerwood JE, 2011, LANCET INFECT DIS, V11, P916, DOI 10.1016/S1473-3099(11)70240-7; Lee PS, 2015, J VIROL, V89, P7417, DOI 10.1128/JVI.00808-15; Lessler J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002802; Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109; Li Y, 2013, J EXP MED, V210, P1493, DOI 10.1084/jem.20130212; Linderman SL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005806; Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371; Miller MS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006637; Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764; Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943; Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/nmeth.4169, 10.1038/NMETH.4169]; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010; Terwilliger TC, 2020, NAT METHODS, V17, P923, DOI 10.1038/s41592-020-0914-9; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Voss NR, 2009, J STRUCT BIOL, V166, P205, DOI 10.1016/j.jsb.2009.01.004; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; Wheatley AK, 2015, J IMMUNOL, V195, P602, DOI 10.4049/jimmunol.1402835; Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; Wu NC, 2020, SCIENCE, V368, P1335, DOI 10.1126/science.aaz5143; Xu R, 2010, J VIROL, V84, P1715, DOI 10.1128/JVI.02162-09; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193	55	3	3	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					373	+		10.1038/s41591-021-01636-8	http://dx.doi.org/10.1038/s41591-021-01636-8		FEB 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35115707	Bronze			2022-12-27	WOS:000750724400001
J	Powles, T; Yuen, KC; Gillessen, S; Kadel, EE; Rathkopf, D; Matsubara, N; Drake, CG; Fizazi, K; Piulats, JM; Wysocki, PJ; Jr, GLB; Alekseev, B; Mellado, B; Karaszewska, B; Doss, JF; Rasuo, G; Datye, A; Mariathasan, S; Williams, P; Sweeney, CJ				Powles, Thomas; Yuen, Kobe C.; Gillessen, Silke; Kadel, Edward E.; Rathkopf, Dana; Matsubara, Nobuaki; Drake, Charles G.; Fizazi, Karim; Piulats, Josep M.; Wysocki, Piotr J.; Jr, Gary L. Buchschacher; Alekseev, Boris; Mellado, Begona; Karaszewska, Boguslawa; Doss, Jennifer F.; Rasuo, Grozdana; Datye, Asim; Mariathasan, Sanjeev; Williams, Patrick; Sweeney, Christopher J.			Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial	NATURE MEDICINE			English	Article							CLINICAL-IMPLICATIONS; DOUBLE-BLIND; OPEN-LABEL; III TRIAL; CHEMOTHERAPY; IPILIMUMAB; PLACEBO; MULTICENTER; ABIRATERONE; RADIOTHERAPY	Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The IMbassador250 trial (no. NCT03016312) enrolled 759 men with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone. The addition of atezolizumab to enzalutamide in an open-label randomized trial did not meet the primary endpoint of improved overall survival in unselected patients (stratified hazard ratio 1.12, 95% confidence interval (0.91, 1.37), P = 0.28), despite an acceptable safety profile. In archival tumor samples, prostate tumors showed comparatively low expression of key immune biomarkers. DNA damage-response alterations, phosphatase and tensin homolog status and PD-L1 expression levels were similar between hormone-sensitive and castration-resistant prostate cancers. In planned biomarker analysis, longer progression-free survival was seen with atezolizumab in patients with high PD-L1 IC2/3, CD8 expression and established immune gene signatures. Exploratory analysis linked progression-free survival in the atezolizumab arm with immune genes such as CXCL9 and TAP1, together with other potentially relevant biomarkers including phosphatase and tensin homolog alterations. Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer, albeit in fewer patients. Careful patient selection may be required for immune checkpoint inhibitors to identify subgroups of patients who may benefit from this treatment approach. In the phase 3 IMbassador250 clinical trial, a checkpoint immunotherapy combination with enzalutamide did not improve survival over enzalutamide alone in patients with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone. The study uncovered genomic and immune biomarkers that may identify patients deriving benefit.	[Powles, Thomas] Queen Mary Univ London, Barts Canc Inst, London, England; [Yuen, Kobe C.; Kadel, Edward E.; Doss, Jennifer F.; Mariathasan, Sanjeev; Williams, Patrick] Genentech Inc, San Francisco, CA 94080 USA; [Gillessen, Silke] EOC, Oncol Inst Southern Switzerland, Bellinzona, Switzerland; [Gillessen, Silke] Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland; [Rathkopf, Dana] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Matsubara, Nobuaki] Natl Canc Ctr Hosp East, Chiba, Japan; [Drake, Charles G.] Columbia Univ, Irving Med Ctr, New York, NY USA; [Fizazi, Karim] Univ Paris Saclay, Gustave Roussy, Villejuif, France; [Piulats, Josep M.] Inst Catala Oncol IDIBELL CIBERONC, Barcelona, Spain; [Wysocki, Piotr J.] Jagiellonian Univ Med Coll, Krakow, Poland; [Jr, Gary L. Buchschacher] Los Angeles Med Ctr, Kaiser Permanente Southern Calif, Los Angeles, CA USA; [Alekseev, Boris] Res Oncol Inst, Tomsk, Russia; [Mellado, Begona] Univ Barcelona, Hosp Clin & Prov, Inst Invest Biomed August Pi & Sunyer, Med Oncol Dept, Barcelona, Spain; [Karaszewska, Boguslawa] Przychodnia Lekarska KOMED, Konin, Poland; [Rasuo, Grozdana; Datye, Asim] F Hoffmann La Roche Ltd, Basel, Switzerland; [Sweeney, Christopher J.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; [Doss, Jennifer F.] Global Blood Therapeut Inc, San Francisco, CA USA	University of London; Queen Mary University London; Roche Holding; Genentech; Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Memorial Sloan Kettering Cancer Center; National Cancer Center - Japan; Columbia University; NewYork-Presbyterian Hospital; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Jagiellonian University; Collegium Medicum Jagiellonian University; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Roche Holding; Harvard University; Dana-Farber Cancer Institute	Powles, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, London, England.; Sweeney, CJ (corresponding author), Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.	thomas.powles1@nhs.net; Christopher_Sweeney@dfci.harvard.edu	Alekseev, Boris/O-1008-2017	Alekseev, Boris/0000-0002-3398-4128; Wysocki, Piotr/0000-0003-4003-5278	F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group; Kaiser Permanente NCI National Community Oncology Research Program [SUG1CA189821-08]; F. Hoffmann-La Roche Ltd.	F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group; Kaiser Permanente NCI National Community Oncology Research Program; F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche)	The study was supported by F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group. Disclosure forms, Methods and a data-sharing statement provided by the authors are available within the full text of this article at nature.com/nm. G.L.B. is partially funded by the Kaiser Permanente NCI National Community Oncology Research Program (grant no. SUG1CA189821-08). We thank the patients who participated in the trial and the clinical site investigators. Medical writing assistance for this manuscript was provided by P. Hong of Health Interactions, Inc. and was funded by F. Hoffmann-La Roche Ltd.	Abida W, 2019, JAMA ONCOL, V5, P471, DOI 10.1001/jamaoncol.2018.5801; Antonarakis ES, 2016, PROSTATE CANCER P D, V19, P231, DOI 10.1038/pcan.2016.17; Antonarakis ES, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01638; Basch E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju244; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Bou-Dargham MJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07058-y; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Danaher P, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0367-1; Donahue RN, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-4901; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Feng Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00858; Fernandez-Poma SM, 2017, CANCER RES, V77, P3672, DOI 10.1158/0008-5472.CAN-17-0236; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fizazi K, 2020, EUR UROL, V78, P822, DOI 10.1016/j.eururo.2020.07.032; Fizazi K, 2014, LANCET ONCOL, V15, P1147, DOI 10.1016/S1470-2045(14)70303-1; Graff JN, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000642; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Haffner MC, 2018, AM J PATHOL, V188, P1478, DOI 10.1016/j.ajpath.2018.02.014; Hansen AR, 2018, ANN ONCOL, V29, P1807, DOI 10.1093/annonc/mdy232; Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Konstantinopoulos PA, 2019, J CLIN ONCOL, V37, P2786, DOI 10.1200/JCO.19.01021; Kowanetz M, 2018, P NATL ACAD SCI USA, V115, pE10119, DOI 10.1073/pnas.1802166115; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470-2045(12)70473-4; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateo J, 2020, J CLIN INVEST, V130, P1743, DOI [10.1172/JCI132031, 10.1172/JCl132031]; Mateo J, 2020, LANCET ONCOL, V21, P162, DOI 10.1016/S1470-2045(19)30684-9; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Petrylak DP, 2021, CLIN CANCER RES, V27, P3360, DOI 10.1158/1078-0432.CCR-20-1981; Powles T, 2021, NAT MED, V27, P793, DOI 10.1038/s41591-021-01317-6; Powles T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.409; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Qi ZH, 2019, J MOL DIAGN, V21, P796, DOI 10.1016/j.jmoldx.2019.04.011; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Sharma M, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017257; Sharma P, 2020, CANCER CELL, V38, P489, DOI 10.1016/j.ccell.2020.08.007; Sokol ES, 2019, ONCOLOGIST, V24, P1526, DOI 10.1634/theoncologist.2019-0214; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; TECENTRIQ (atezolizumab), 2020, PRESCRIBING INFORM; Trabucco SE, 2019, J MOL DIAGN, V21, P1053, DOI 10.1016/j.jmoldx.2019.06.011; Vericiguat, 2021, SUMMARY PRODUCT CHAR; Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034	61	20	20	9	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					144	+		10.1038/s41591-021-01600-6	http://dx.doi.org/10.1038/s41591-021-01600-6		JAN 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35013615				2022-12-27	WOS:000741630800003
J	Marks, P				Marks, Peter			What regulators must learn from COVID-19	NATURE MEDICINE			English	Editorial Material									[Marks, Peter] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA)	Marks, P (corresponding author), US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	peter.marks@fda.hhs.gov		Marks, Peter/0000-0001-5619-4404					0	0	0	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1858	1858		10.1038/s41591-021-01559-4	http://dx.doi.org/10.1038/s41591-021-01559-4		OCT 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34711974	Bronze			2022-12-27	WOS:000712353600003
J	McIntosh, C; Conroy, L; Tjong, MC; Craig, T; Bayley, A; Catton, C; Gospodarowicz, M; Helou, J; Isfahanian, N; Kong, V; Lam, T; Raman, S; Warde, P; Chung, PT; Berlin, A; Purdie, TG				McIntosh, Chris; Conroy, Leigh; Tjong, Michael C.; Craig, Tim; Bayley, Andrew; Catton, Charles; Gospodarowicz, Mary; Helou, Joelle; Isfahanian, Naghmeh; Kong, Vickie; Lam, Tony; Raman, Srinivas; Warde, Padraig; Chung, Peter; Berlin, Alejandro; Purdie, Thomas G.			Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer	NATURE MEDICINE			English	Article							ARTIFICIAL-INTELLIGENCE; DOSE PREDICTION; CLASSIFICATION; OPTIMIZATION; SYSTEM; HEAD	Machine learning (ML) holds great promise for impacting healthcare delivery; however, to date most methods are tested in 'simulated' environments that cannot recapitulate factors influencing real-world clinical practice. We prospectively deployed and evaluated a random forest algorithm for therapeutic curative-intent radiation therapy (RT) treatment planning for prostate cancer in a blinded, head-to-head study with full integration into the clinical workflow. ML- and human-generated RT treatment plans were directly compared in a retrospective simulation with retesting (n = 50) and a prospective clinical deployment (n = 50) phase. Consistently throughout the study phases, treating physicians assessed ML- and human-generated RT treatment plans in a blinded manner following a priori defined standardized criteria and peer review processes, with the selected RT plan in the prospective phase delivered for patient treatment. Overall, 89% of ML-generated RT plans were considered clinically acceptable and 72% were selected over human-generated RT plans in head-to-head comparisons. RT planning using ML reduced the median time required for the entire RT planning process by 60.1% (118 to 47 h). While ML RT plan acceptability remained stable between the simulation and deployment phases (92 versus 86%), the number of ML RT plans selected for treatment was significantly reduced (83 versus 61%, respectively). These findings highlight that retrospective or simulated evaluation of ML methods, even under expert blinded review, may not be representative of algorithm acceptance in a real-world clinical setting when patient care is at stake. An artificial intelligence system prospectively deployed to design radiation therapy plans for patients with prostate cancer illustrates the real-world impact of machine learning in clinical practice and identifies factors influencing human-algorithm interaction	[McIntosh, Chris; Conroy, Leigh; Tjong, Michael C.; Craig, Tim; Bayley, Andrew; Catton, Charles; Gospodarowicz, Mary; Helou, Joelle; Isfahanian, Naghmeh; Kong, Vickie; Lam, Tony; Raman, Srinivas; Warde, Padraig; Chung, Peter; Berlin, Alejandro; Purdie, Thomas G.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [McIntosh, Chris; Conroy, Leigh; Craig, Tim; Berlin, Alejandro; Purdie, Thomas G.] Univ Hlth Network, Techna Inst, Toronto, ON, Canada; [McIntosh, Chris] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada; [McIntosh, Chris] Univ Hlth Network, Joint Dept Med Imaging, Toronto, ON, Canada; [McIntosh, Chris] Vector Inst, Toronto, ON, Canada; [McIntosh, Chris; Purdie, Thomas G.] Univ Toronto, Dept Med BioPhys, Toronto, ON, Canada; [Conroy, Leigh; Tjong, Michael C.; Craig, Tim; Bayley, Andrew; Catton, Charles; Gospodarowicz, Mary; Helou, Joelle; Isfahanian, Naghmeh; Kong, Vickie; Lam, Tony; Raman, Srinivas; Warde, Padraig; Chung, Peter; Berlin, Alejandro; Purdie, Thomas G.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Berlin, A; Purdie, TG (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Berlin, A; Purdie, TG (corresponding author), Univ Hlth Network, Techna Inst, Toronto, ON, Canada.; Purdie, TG (corresponding author), Univ Toronto, Dept Med BioPhys, Toronto, ON, Canada.; Berlin, A; Purdie, TG (corresponding author), Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.	alejandro.berlin@rmp.uhn.ca; tom.purdie@rmp.uhn.ca	McIntosh, Chris/ABE-7424-2021	McIntosh, Chris/0000-0003-1371-1250; Conroy, Leigh/0000-0003-0055-3660	Canadian Institutes of Health Research [381340]; Collaborative Health Research Projects (National Sciences and Engineering Research Council of Canada); Princess Margaret Cancer Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Collaborative Health Research Projects (National Sciences and Engineering Research Council of Canada); Princess Margaret Cancer Foundation(University of Toronto)	This work was supported by the Canadian Institutes of Health Research (funding grant no. 381340, to T.G.P. and C.M.) through the Collaborative Health Research Projects (National Sciences and Engineering Research Council of Canada partnered) and the Princess Margaret Cancer Foundation (to T.G.P., C.M. and A.B.). We thank M. Lupien and M. Mamdani for their critical reading of the manuscript and insightful comments in improving this work.	Abrams RA, 2012, INT J RADIAT ONCOL, V82, P809, DOI 10.1016/j.ijrobp.2010.11.039; Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1043, DOI 10.1001/jama.2020.1039; Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x; Babier A, 2020, MED PHYS, V47, P297, DOI 10.1002/mp.13896; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Challen R, 2019, BMJ QUAL SAF, V28, P231, DOI 10.1136/bmjqs-2018-008370; Challener DW, 2019, JAMA-J AM MED ASSOC, V321, P2405, DOI 10.1001/jama.2019.5284; Cornell M, 2020, INT J RADIAT ONCOL, V106, P430, DOI 10.1016/j.ijrobp.2019.10.036; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Gaube S, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00385-9; Hannun AY, 2019, NAT MED, V25, P65, DOI 10.1038/s41591-018-0268-3; He JX, 2019, NAT MED, V25, P30, DOI 10.1038/s41591-018-0307-0; Hollon TC, 2020, NAT MED, V26, P52, DOI 10.1038/s41591-019-0715-9; Holzinger A, 2019, WIRES DATA MIN KNOWL, V9, DOI 10.1002/widm.1312; Hong JC, 2020, J CLIN ONCOL, V38, P3652, DOI 10.1200/JCO.20.01688; Hyland SL, 2020, NAT MED, V26, P364, DOI 10.1038/s41591-020-0789-4; Jaffray DA, 2015, LANCET ONCOL, V16, P1144, DOI 10.1016/S1470-2045(15)00285-5; Kiser KJ, 2019, J MED ARTI INTELL, V2, P9, DOI 10.21037/jmai.2019.04.02; Komorowski M, 2018, NAT MED, V24, P1716, DOI 10.1038/s41591-018-0213-5; Liu XX, 2020, NAT MED, V26, P1364, DOI 10.1038/s41591-020-1034-x; Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2; McCarroll RE, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.18.00055; McIntosh C, 2017, PHYS MED BIOL, V62, P5926, DOI 10.1088/1361-6560/aa71f8; McIntosh C, 2016, IEEE T MED IMAGING, V35, P1000, DOI 10.1109/TMI.2015.2505188; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; Mclntosh C, 2017, PHYS MED BIOL, V62, P415, DOI 10.1088/1361-6560/62/2/415; Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689; Nimri R, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1045-7; Parikh RB, 2019, JAMA-J AM MED ASSOC, V322, P2377, DOI 10.1001/jama.2019.18058; Peters LJ, 2010, J CLIN ONCOL, V28, P2996, DOI 10.1200/JCO.2009.27.4498; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; Shilo S, 2020, NAT MED, V26, P29, DOI 10.1038/s41591-019-0727-5; Siddique S, 2020, REP PRACT ONCOL RADI, V25, P656, DOI 10.1016/j.rpor.2020.03.015; Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7; Wiens J, 2019, NAT MED, V25, P1337, DOI 10.1038/s41591-019-0548-6; Wijnberge M, 2020, JAMA-J AM MED ASSOC, V323, P1052, DOI 10.1001/jama.2020.0592	36	31	31	3	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					999	+		10.1038/s41591-021-01359-w	http://dx.doi.org/10.1038/s41591-021-01359-w		JUN 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34083812				2022-12-27	WOS:000657623700002
J	Ward, BJ; Gobeil, P; Seguin, A; Atkins, J; Boulay, I; Charbonneau, PY; Couture, M; D'aoust, MA; Dhaliwall, J; Finkle, C; Hager, K; Mahmood, A; Makarkov, A; Cheng, MP; Pillet, S; Schimke, P; St-Martin, S; Trepanier, S; Landry, N				Ward, Brian J.; Gobeil, Philipe; Seguin, Annie; Atkins, Judith; Boulay, Iohann; Charbonneau, Pierre-Yves; Couture, Manon; D'aoust, Marc-Andre; Dhaliwall, Jiwanjeet; Finkle, Carolyn; Hager, Karen; Mahmood, Asif; Makarkov, Alexander; Cheng, Matthew P.; Pillet, Stephane; Schimke, Patricia; St-Martin, Sylvie; Trepanier, Sonia; Landry, Nathalie			Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	NATURE MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; T-CELL RESPONSES; INFLUENZA VACCINE; SARS-COV-2; ANTIBODY; SAFETY; IMMUNOGENICITY; QUADRIVALENT; IMMUNITY	Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: ). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. Secondary outcomes in this ongoing study include safety and immunogenicity assessments up to 12 months after vaccination. Adults (18-55 years, n = 180) were randomized at two sites in Quebec, Canada, to receive two intramuscular doses of CoVLP (3.75 mu g, 7.5 mu g, and 15 mu g) 21 d apart, alone or adjuvanted with AS03 or CpG1018. All formulations were well tolerated, and adverse events after vaccination were generally mild to moderate, transient and highest in the adjuvanted groups. There was no CoVLP dose effect on serum NAbs, but titers increased significantly with both adjuvants. After the second dose, NAbs in the CoVLP + AS03 groups were more than tenfold higher than titers in Coronavirus 2019 convalescent sera. Both spike protein-specific interferon-gamma and interleukin-4 cellular responses were also induced. This pre-specified interim analysis supports further evaluation of the CoVLP vaccine candidate. Safety and immunogenicity results in humans of a two-dose SARS-CoV-2 vaccine made from plants support further assessment of potential efficacy.	[Ward, Brian J.; Gobeil, Philipe; Seguin, Annie; Atkins, Judith; Boulay, Iohann; Charbonneau, Pierre-Yves; Couture, Manon; D'aoust, Marc-Andre; Dhaliwall, Jiwanjeet; Finkle, Carolyn; Hager, Karen; Mahmood, Asif; Makarkov, Alexander; Pillet, Stephane; Schimke, Patricia; St-Martin, Sylvie; Trepanier, Sonia; Landry, Nathalie] Medicago Inc, Quebec City, PQ, Canada; [Ward, Brian J.; Cheng, Matthew P.] McGill Univ Hlth Ctr, Res Inst, Montreal, PQ, Canada	McGill University	Ward, BJ; Landry, N (corresponding author), Medicago Inc, Quebec City, PQ, Canada.; Ward, BJ (corresponding author), McGill Univ Hlth Ctr, Res Inst, Montreal, PQ, Canada.	wardb@medicago.com; landryn@medicago.com		Makarkov, Alexander/0000-0003-4255-7627; Ward, Brian/0000-0003-3251-958X	Medicago; Medicago Inc.	Medicago; Medicago Inc.	The authors acknowledge F. Roman, P. Boutet, R. Van Der Most, M. Ceregido Perez, M. Koutsoukos and G. Preyon from GlaxoSmithKline, as well as R. Spencer, R. Janssen, D. Campbell and D. Novack from Dynavax, for critical review of the manuscript. The authors acknowledge D. C. Vinh (Research institute of the McGill University Health Centre) for supplying convalescent plasma samples from hospitalized patients with COVID-19. The authors also acknowledge all the Medicago employees, their contractors and all of the volunteers who participated in the study, as well as the site investigators and their staff who conducted the studies with a high degree of professionalism. Funding: This study was sponsored by Medicago. Medicago Inc. received support for the CoVLP development program from the Federal Government on behalf of Her Majesty the Queen in right of Canada.	Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; [Anonymous], 2021, VACCINE, DOI DOI 10.1016/J.VACCINE.2021.01.055; [Anonymous], 2018, HEPLISAV B PACK INS; Arunachalam PS, 2021, NATURE, V594, P253, DOI 10.1038/s41586-021-03530-2; Attaway AH, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n436; Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745; Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077; Burki T, 2017, LANCET INFECT DIS, V17, P265, DOI 10.1016/S1473-3099(17)30062-2; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048; COVAX, 2021, WORKSH REP COVAX CLI; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; D'Aoust M. A., 2012, VIRUS PARTICLE PRODU, DOI [10.1038/s41467-020-20247-4, DOI 10.1038/s41467-020-20247-4]; D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; Dagotto G, 2020, CELL HOST MICROBE, V28, P364, DOI 10.1016/j.chom.2020.08.002; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Funk CD, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030418; Gomez-Rial J, 2020, INFECT DRUG RESIST, V13, P2485, DOI 10.2147/IDR.S258639; Grabowski GA, 2014, MOL GENET METAB, V112, P1, DOI 10.1016/j.ymgme.2014.02.011; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Herbert AS, 2020, P NATL ACAD SCI USA, V117, P3768, DOI 10.1073/pnas.1914985117; Hicks J, 2021, J CLIN IMMUNOL, V41, P906, DOI 10.1007/s10875-021-00997-6; Hodgins B, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00273-17; Huang Angkana T, 2020, Nat Commun, V11, P4704, DOI [10.1101/2020.04.14.20065771, 10.1038/s41467-020-18450-4]; Huang XP, 2010, EXPERT OPIN THER TAR, V14, P787, DOI 10.1517/14728222.2010.501333; Hyer R, 2018, VACCINE, V36, P2604, DOI 10.1016/j.vaccine.2018.03.067; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Koch T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030238; Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064; Landry N, 2014, CLIN IMMUNOL, V154, P164, DOI 10.1016/j.clim.2014.08.003; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Law B, 2020, SAFETY PLATFORM EMER; Lee K, 2009, GLOB INST, P1; Legros V, 2021, CELL MOL IMMUNOL, V18, P318, DOI 10.1038/s41423-020-00588-2; Makarkov AI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0111-y; Manenti A, 2020, J MED VIROL, V92, P2096, DOI 10.1002/jmv.25986; Marot S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21111-9; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Penn-Nicholson A, 2015, VACCINE, V33, P4025, DOI 10.1016/j.vaccine.2015.05.088; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Pillet S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216533; Pillet S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-017-0043-3; Poland GA, 2020, MAYO CLIN PROC, V95, P2172, DOI 10.1016/j.mayocp.2020.07.021; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Sturkenboom M., 2020, D2 3 PRIORITY LIST A; Sui YJ, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020138; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; van der Most RG, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00553-16, 10.1128/cvi.00553-16]; Wang M, 2021, BMJ SUPPORT PALLIAT, V11, P45, DOI 10.1136/bmjspcare-2020-002554; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Ward BJ, 2014, VACCINE, V32, P6098, DOI [10.1016/j.vaccine.2014.08.079, 10.10]; Williams TC, 2021, LANCET RESP MED, V9, P333, DOI 10.1016/S2213-2600(21)00075-8; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	64	102	104	5	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1071	+		10.1038/s41591-021-01370-1	http://dx.doi.org/10.1038/s41591-021-01370-1		MAY 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34007070	hybrid, Green Published			2022-12-27	WOS:000651666900001
J	Arnaout, R; Curran, L; Zhao, YL; Levine, JC; Chinn, E; Moon-Grady, AJ				Arnaout, Rima; Curran, Lara; Zhao, Yili; Levine, Jami C.; Chinn, Erin; Moon-Grady, Anita J.			An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease	NATURE MEDICINE			English	Article							FETAL ECHOCARDIOGRAPHY; SURVIVAL RATE; DIAGNOSIS; ANOMALIES; GUIDELINES; MANAGEMENT; OUTCOMES; INFANTS; AXIS	Deep learning can facilitate identification of congenital heart disease from fetal ultrasound screening, a diagnosis that in clinical practice is often missed. Congenital heart disease (CHD) is the most common birth defect. Fetal screening ultrasound provides five views of the heart that together can detect 90% of complex CHD, but in practice, sensitivity is as low as 30%. Here, using 107,823 images from 1,326 retrospective echocardiograms and screening ultrasounds from 18- to 24-week fetuses, we trained an ensemble of neural networks to identify recommended cardiac views and distinguish between normal hearts and complex CHD. We also used segmentation models to calculate standard fetal cardiothoracic measurements. In an internal test set of 4,108 fetal surveys (0.9% CHD, >4.4 million images), the model achieved an area under the curve (AUC) of 0.99, 95% sensitivity (95% confidence interval (CI), 84-99%), 96% specificity (95% CI, 95-97%) and 100% negative predictive value in distinguishing normal from abnormal hearts. Model sensitivity was comparable to that of clinicians and remained robust on outside-hospital and lower-quality images. The model's decisions were based on clinically relevant features. Cardiac measurements correlated with reported measures for normal and abnormal hearts. Applied to guideline-recommended imaging, ensemble learning models could significantly improve detection of fetal CHD, a critical and global diagnostic challenge.	[Arnaout, Rima; Curran, Lara; Chinn, Erin] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA; [Arnaout, Rima; Curran, Lara; Chinn, Erin] Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA; [Arnaout, Rima] Univ Calif San Francisco, Ctr Intelligent Imaging, San Francisco, CA 94143 USA; [Arnaout, Rima] Univ Calif San Francisco, Biol & Med Informat, San Francisco, CA 94143 USA; [Arnaout, Rima] Univ Calif San Francisco, Chan Zuckerberg Biohub, San Francisco, CA 94143 USA; [Zhao, Yili; Moon-Grady, Anita J.] Univ Calif San Francisco, Dept Pediat, Div Cardiol, San Francisco, CA USA; [Levine, Jami C.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA; [Levine, Jami C.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Arnaout, R (corresponding author), Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.; Arnaout, R (corresponding author), Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA.; Arnaout, R (corresponding author), Univ Calif San Francisco, Ctr Intelligent Imaging, San Francisco, CA 94143 USA.; Arnaout, R (corresponding author), Univ Calif San Francisco, Biol & Med Informat, San Francisco, CA 94143 USA.; Arnaout, R (corresponding author), Univ Calif San Francisco, Chan Zuckerberg Biohub, San Francisco, CA 94143 USA.	rima.arnaout@ucsf.edu		Zhao, Yili/0000-0003-1464-2787; Curran, Lara/0000-0003-1260-3741; Moon-Grady, Anita/0000-0003-3822-693X				American Institute of Ultrasound in Medicine, 2013, J Ultrasound Med, V32, P1067, DOI 10.7863/ultra.32.6.1067; [Anonymous], 2020, J ULTRAS MED, V39, pE5, DOI 10.1002/jum.15188; Arnaout R, 2019, NAT MED, V25, P12, DOI 10.1038/s41591-018-0318-x; Attia ZI, 2019, LANCET, V394, P861, DOI 10.1016/S0140-6736(19)31721-0; Bak GS, 2020, ULTRASOUND OBST GYN, V55, P758, DOI 10.1002/uog.21977; Baumgartner CF, 2017, IEEE T MED IMAGING, V36, P2204, DOI 10.1109/TMI.2017.2712367; Bensemlali M, 2017, CARDIOL YOUNG, V27, P344, DOI 10.1017/S1047951116000639; Best KE, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.002120; Carvalho JS, 2013, ULTRASOUND OBST GYN, V41, P348, DOI 10.1002/uog.12403; Chilamkurthy S, 2018, LANCET, V392, P2388, DOI 10.1016/S0140-6736(18)31645-3; Chu C, 2017, ACTA OBSTET GYN SCAN, V96, P454, DOI 10.1111/aogs.13085; Cohen L, 2010, J ULTRAS MED, V29, P751, DOI 10.7863/jum.2010.29.5.751; Corcoran S, 2016, EUR J OBSTET GYN R B, V203, P260, DOI 10.1016/j.ejogrb.2016.06.008; Donofrio MT, 2014, CIRCULATION, V129, P2183, DOI 10.1161/01.cir.0000437597.44550.5d; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Freud LR, 2014, CIRCULATION, V130, P638, DOI 10.1161/CIRCULATIONAHA.114.009032; Friedberg MK, 2009, J PEDIATR-US, V155, P26, DOI 10.1016/j.jpeds.2009.01.050; Goldinfeld M, 2004, PRENATAL DIAG, V24, P799, DOI 10.1002/pd.880; Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216; He KM, 2016, LECT NOTES COMPUT SC, V9908, P630, DOI 10.1007/978-3-319-46493-0_38; Holland BJ, 2015, ULTRASOUND OBST GYN, V45, P631, DOI 10.1002/uog.14882; LeCun Y., 2015, DEEP LEARNING NATURE, V521, P436, DOI [DOI 10.1038/NATURE14539, 10.1038/nature14539]; Letourneau KM, 2018, J ULTRAS MED, V37, P1073, DOI 10.1002/jum.14453; Li YF, 2016, WORLD J PEDIATR, V12, P298, DOI 10.1007/s12519-016-0016-z; Liu H, 2015, EUR J PREV CARDIOL, V22, P1531, DOI 10.1177/2047487314551547; Madani A, 2018, NPJ DIGIT MED, V1, DOI [10.1038/s41746-018-0065-x, 10.1038/s41746-017-0013-1]; Miceli Frances, 2015, Australas J Ultrasound Med, V18, P3, DOI 10.1002/j.2205-0140.2015.tb00024.x; Norgeot B, 2020, NAT MED, V26, P1320, DOI 10.1038/s41591-020-1041-y; Oster ME, 2014, AM J CARDIOL, V113, P1036, DOI 10.1016/j.amjcard.2013.11.066; Ouyang DV, 2020, NATURE, V580, P252, DOI 10.1038/s41586-020-2145-8; Peahl AF, 2020, AM J OBSTET GYNECOL, V223, P389, DOI 10.1016/j.ajog.2020.05.029; Pinheiro DO, 2019, REV BRAS GINECOL OBS, V41, P11, DOI 10.1055/s-0038-1676058; Ronneberger O., 2015, P MICCAI MUN GERM 5, P234, DOI DOI 10.1007/978-3-319-24574-4_28; Sekar P, 2015, CARDIOL YOUNG, V25, P35, DOI 10.1017/S1047951113001467; Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74; Sizarov A, 2017, CAN J CARDIOL, V33, P1150, DOI 10.1016/j.cjca.2017.06.009; Sklansky M, 2016, J ULTRAS MED, V35, P679, DOI 10.7863/ultra.15.07021; Springenberg JT, 2014, ARXIV; Sun HY, 2018, CONGENIT HEART DIS, V13, P748, DOI 10.1111/chd.12648; Tuncalp O, 2017, BJOG-INT J OBSTET GY, V124, P860, DOI 10.1111/1471-0528.14599; Wax JR, 2016, OBSTET GYNECOL, V128, pE231; World Health Organization, 2019, REC DIG INT HLTH SYT; Wright LK, 2014, AM J CARDIOL, V113, P1041, DOI 10.1016/j.amjcard.2013.11.065; Yagel S, 2001, ULTRASOUND OBST GYN, V17, P367, DOI 10.1046/j.1469-0705.2001.00414.x; Yeo L, 2019, J MATERN-FETAL NEO M, V32, P3699, DOI 10.1080/14767058.2018.1484088; Zhao Y, 2017, ULTRASOUND OBST GYN, V50, P58, DOI 10.1002/uog.15998	47	32	33	5	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					882	+		10.1038/s41591-021-01342-5	http://dx.doi.org/10.1038/s41591-021-01342-5			20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33990806	Green Accepted			2022-12-27	WOS:000650698900030
J	Kreple, CJ; Schoch, KM; Miller, TM				Kreple, Collin J.; Schoch, Kathleen M.; Miller, Timothy M.			Is presymptomatic ALS perivascular?	NATURE MEDICINE			English	Editorial Material									[Kreple, Collin J.; Schoch, Kathleen M.; Miller, Timothy M.] Washington Univ, Hope Ctr Neurol Disorders, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Miller, TM (corresponding author), Washington Univ, Hope Ctr Neurol Disorders, Dept Neurol, St Louis, MO 63110 USA.	miller.t@wustl.edu						Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Icer MA, 2018, CLIN BIOCHEM, V59, P17, DOI 10.1016/j.clinbiochem.2018.07.003; Li YK, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0253-16.2016; Manberg A, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01295-9; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Steinacker P, 2016, J NEUROL NEUROSUR PS, V87, P12, DOI 10.1136/jnnp-2015-311387; Taylor JP, 2016, NATURE, V539, P197, DOI 10.1038/nature20413; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; Winkler EA, 2014, P NATL ACAD SCI USA, V111, pE1035, DOI 10.1073/pnas.1401595111	9	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					585	586		10.1038/s41591-021-01311-y	http://dx.doi.org/10.1038/s41591-021-01311-y			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33859434				2022-12-27	WOS:000640612600012
J	Chen, RTE; Zhang, XW; Case, JB; Winkler, ES; Liu, Y; VanBlargan, LA; Liu, JY; Errico, JM; Xie, XP; Suryadevara, N; Gilchuk, P; Zost, SJ; Tahan, S; Droit, L; Turner, JS; Kim, W; Schmitz, AJ; Thapa, M; Wang, DV; Boon, ACM; Presti, RM; O'Halloran, JA; Kim, AHJ; Deepak, P; Pinto, D; Fremont, DH; Crowe, JE; Corti, D; Virgin, HW; Ellebedy, AH; Shi, PY; Diamond, MS				Chen, Rita E.; Zhang, Xianwen; Case, James Brett; Winkler, Emma S.; Liu, Yang; VanBlargan, Laura A.; Liu, Jianying; Errico, John M.; Xie, Xuping; Suryadevara, Naveenchandra; Gilchuk, Pavlo; Zost, Seth J.; Tahan, Stephen; Droit, Lindsay; Turner, Jackson S.; Kim, Wooseob; Schmitz, Aaron J.; Thapa, Mahima; Wang, David; Boon, Adrianus C. M.; Presti, Rachel M.; O'Halloran, Jane A.; Kim, Alfred H. J.; Deepak, Parakkal; Pinto, Dora; Fremont, Daved H.; Crowe, James E., Jr.; Corti, Davide; Virgin, Herbert W.; Ellebedy, Ali H.; Shi, Pei-Yong; Diamond, Michael S.			Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	NATURE MEDICINE			English	Article							RECEPTOR-BINDING DOMAIN	A comprehensive analysis of antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants shows markedly diminished neutralizing activity against the variant B.1.351, first identified in South Africa. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants. Many highly neutralizing mAbs engaging the receptor-binding domain or N-terminal domain and most convalescent sera and mRNA vaccine-induced immune sera showed reduced inhibitory activity against viruses containing an E484K spike mutation. As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.	[Chen, Rita E.; Case, James Brett; Winkler, Emma S.; VanBlargan, Laura A.; Boon, Adrianus C. M.; Presti, Rachel M.; O'Halloran, Jane A.; Kim, Alfred H. J.; Deepak, Parakkal; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Chen, Rita E.; Winkler, Emma S.; Errico, John M.; Turner, Jackson S.; Kim, Wooseob; Schmitz, Aaron J.; Thapa, Mahima; Boon, Adrianus C. M.; Virgin, Herbert W.; Ellebedy, Ali H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA; [Zhang, Xianwen; Liu, Yang; Xie, Xuping; Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Liu, Jianying] Univ Texas Med Branch, Dept Microbiol, Galveston, TX 77555 USA; [Liu, Jianying] Univ Texas Med Branch, Dept Immunol, Galveston, TX 77555 USA; [Liu, Jianying; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA; [Suryadevara, Naveenchandra; Gilchuk, Pavlo; Zost, Seth J.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA; [Tahan, Stephen; Droit, Lindsay; Wang, David; Boon, Adrianus C. M.; Ellebedy, Ali H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Pinto, Dora; Corti, Davide] Humabs BioMed SA, Bellinzona, Switzerland; [Fremont, Daved H.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Virgin, Herbert W.] Vir Biotechnol, San Francisco, CA USA; [Virgin, Herbert W.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Ellebedy, Ali H.; Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63130 USA; [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Washington University (WUSTL); Washington University (WUSTL); Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); University of Texas System; University of Texas Medical Branch Galveston	Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Ellebedy, AH; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.; Ellebedy, AH; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Ellebedy, AH; Diamond, MS (corresponding author), Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63130 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.	ellebedy@wustl.edu; peshi@utmb.edu; diamond@wusm.wustl.edu	Crowe, James/B-5549-2009; zhang, xian/GYA-0290-2022; Xie, Xuping/AAD-7406-2019; Kim, Alfred H.J./F-5699-2013; Suryadevara, Naveenchandra/AAQ-7626-2021	Crowe, James/0000-0002-0049-1079; Kim, Alfred H.J./0000-0003-4074-0516; Tahan, Stephen/0000-0002-5895-8698; Kim, Wooseob/0000-0002-9199-1000; Schmitz, Aaron/0000-0002-8077-6751; Fremont, Daved/0000-0002-8544-2689; Errico, John/0000-0002-4452-8152; Case, James/0000-0001-7331-5511	NIH [75N93019C00062, 75N93019C00051, 75N93019C00074, HHSN272201400006C, HHSN272201400008C, R01 AI157155, U01 AI151810, R01 AI142759, R01 AI134907, UL1 TR001439, P30 AR073752, U01 AI151801, U01AI141990]; Defense Advanced Research Project Agency [HR001117S0019]; Dolly Parton COVID-19 Research Fund at Vanderbilt University, Fast Grants (Mercatus Center); Future Insight Prize (Merck KGaA); Helen Hay Whitney Foundation postdoctoral fellowship [F30 AI152327, 5T32CA009547]; Sealy AMP; Smith Foundation; Kleberg Foundation; John S. Dunn Foundation; Amon G. Carter Foundation; Gilson Longenbaugh Foundation; Summerfield Robert Foundation; Junior Faculty Development Award from the American College of Gastroenterology; EPA Cephalosporin Early Career and Teaching Fellowship; Townsend Jeantet Charitable Trust [1011770]; Leona M. and Harry B. Helmsley Charitable Trust; Barnes-Jewish Hospital Foundation; Siteman Cancer Center grant from the National Cancer Institute of the National Institutes of Health [P30 CA091842]; Washington University in Saint Louis' Digestive Disease Research Core from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [P30 DK052574]; Washington University Institute of Clinical and Translational Sciences grant from the National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR002345]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Advanced Research Project Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Dolly Parton COVID-19 Research Fund at Vanderbilt University, Fast Grants (Mercatus Center); Future Insight Prize (Merck KGaA); Helen Hay Whitney Foundation postdoctoral fellowship; Sealy AMP; Smith Foundation; Kleberg Foundation; John S. Dunn Foundation; Amon G. Carter Foundation; Gilson Longenbaugh Foundation; Summerfield Robert Foundation; Junior Faculty Development Award from the American College of Gastroenterology; EPA Cephalosporin Early Career and Teaching Fellowship; Townsend Jeantet Charitable Trust; Leona M. and Harry B. Helmsley Charitable Trust; Barnes-Jewish Hospital Foundation; Siteman Cancer Center grant from the National Cancer Institute of the National Institutes of Health; Washington University in Saint Louis' Digestive Disease Research Core from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Washington University Institute of Clinical and Translational Sciences grant from the National Center for Advancing Translational Sciences of the National Institutes of Health	This study was supported by contracts and grants from NIH (75N93019C00062, 75N93019C00051, 75N93019C00074, HHSN272201400006C, HHSN272201400008C, R01 AI157155, U01 AI151810, R01 AI142759, R01 AI134907, UL1 TR001439, P30 AR073752, U01 AI151801 and U01AI141990) and the Defense Advanced Research Project Agency (HR001117S0019), the Dolly Parton COVID-19 Research Fund at Vanderbilt University, Fast Grants (Mercatus Center, George Mason University) and the Future Insight Prize (Merck KGaA to J.E.C.). J.B.C. is supported by a Helen Hay Whitney Foundation postdoctoral fellowship, E.S.W. is supported by F30 AI152327 and J.S.T. is supported by 5T32CA009547. P.-Y.S. is supported by awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation and the Summerfield Robert Foundation. P.D. is supported by a Junior Faculty Development Award from the American College of Gastroenterology. T.K.T. is funded by the EPA Cephalosporin Early Career and Teaching Fellowship and Townsend Jeantet Charitable Trust (charity no. 1011770). P.D., A.H.J.K. and A.H.E. also were supported by funding from the Leona M. and Harry B. Helmsley Charitable Trust. We thank R. Nargi and R. Carnahan for assistance with mAb generation and purification, G. Screaton for providing COVOX-40 and COVOX-384, L. Purcell for critical comments on experiments and the manuscript and A. Bailey, A. Creanga and B. Graham for the Vero-hACE2-TMPRSS2 cells and the Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH for the NHP immune sera. This study utilized samples obtained from the Washington University School of Medicine's COVID-19 biorepository, which is supported by the Barnes-Jewish Hospital Foundation; Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National Institutes of Health; Washington University in Saint Louis' Digestive Disease Research Core (P30 DK052574) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH. The authors also acknowledge C. Goss and P. Mudd for contributions.	Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583; Andreano Emanuele, 2020, bioRxiv, DOI 10.1101/2020.12.28.424451; Bailey AL, 2021, CELL, V184, P15, DOI 10.1016/j.cell.2020.12.003; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Bricker Traci L, 2020, bioRxiv, DOI [10.1016/j.celrep.2021.109400, 10.1101/2020.12.02.408823]; Cao LX, 2020, SCIENCE, V370, P426, DOI 10.1126/science.abd9909; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Case James Brett, 2020, bioRxiv, DOI 10.1101/2020.05.18.102038; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dejnirattisai W, 2021, CELL, V184, P2183, DOI 10.1016/j.cell.2021.02.032; Dong Jinhui, 2021, bioRxiv, DOI 10.1101/2021.01.27.428529; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Greaney Allison J, 2021, Cell Host Microbe, V29, P44, DOI [10.1101/2020.09.10.292078, 10.1016/j.chom.2020.11.007]; Hassan Ahmed O, 2021, bioRxiv, DOI [10.1016/j.xcrm.2021.100230, 10.1101/2021.01.26.428251]; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Jangra Sonia, 2021, medRxiv, DOI 10.1101/2021.01.26.21250543; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Klimstra William B, 2020, bioRxiv, DOI 10.1101/2020.06.19.154930; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI [10.1038/s41564-020-0688-y, 10.1101/2020.01.22.915660]; Leung K, 2021, EUROSURVEILLANCE, V26, P15, DOI 10.2807/1560-7917.ES.2020.26.1.2002106; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Liu Yang, 2021, N Engl J Med, DOI 10.1056/NEJMc2102017; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; McCallum M, 2021, CELL, V184, P2332, DOI [10.1101/2021.01.14.426475, 10.1016/j.cell.2021.03.028]; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poplin R, 2018, NAT BIOTECHNOL, V36, P983, DOI 10.1038/nbt.4235; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Rathe JA, 2021, J INFECT DIS, V223, P1120, DOI 10.1093/infdis/jiaa797; Rathnasinghe Raveen, 2021, medRxiv, DOI 10.1101/2021.01.19.21249592; Schafer A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201993; Sempowski GD, 2020, CELL, V181, P1458, DOI 10.1016/j.cell.2020.05.041; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Suryadevara Naveenchandra, 2021, Cell, V184, P2316, DOI [10.1101/2021.01.19.427324, 10.1016/j.cell.2021.03.029]; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.02.05.430003; Tortorici MA, 2020, SCIENCE, V370, P950, DOI 10.1126/science.abe3354; Turner Jackson S, 2020, Res Sq, DOI 10.21203/rs.3.rs-132821/v1; Wang Zijun, 2021, bioRxiv, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Wu K., 2021, BIORXIV, DOI [10.1101/2021.01.25.427948, DOI 10.1101/2021.01.25.427948]; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Xie XP, 2021, NAT PROTOC, V16, P1761, DOI 10.1038/s41596-021-00491-8; Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zohar T, 2020, CELL, V183, P1508, DOI 10.1016/j.cell.2020.10.052; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	57	466	470	11	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01294-w	http://dx.doi.org/10.1038/s41591-021-01294-w		MAR 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33664494	Bronze, Green Published, Green Accepted			2022-12-27	WOS:000626919600005
J	Muus, C; Luecken, MD; Eraslan, G; Sikkema, L; Waghray, A; Heimberg, G; Kobayashi, Y; Vaishnav, ED; Subramanian, A; Smillie, C; Jagadeesh, KA; Duong, ET; Fiskin, E; Triglia, ET; Ansari, M; Cai, PW; Lin, B; Buchanan, J; Chen, SJ; Shu, J; Haber, AL; Chung, H; Montoro, DT; Adams, T; Aliee, H; Allon, SJ; Andrusivova, Z; Angelidis, I; Ashenberg, O; Bassler, K; Becavin, C; Benhar, I; Bergenstrahle, J; Bergenstrahle, L; Bolt, L; Braun, E; Bui, LT; Callori, S; Chaffin, M; Chichelnitskiy, E; Chiou, J; Conlon, TM; Cuoco, MS; Cuomo, ASE; Deprez, M; Duclos, G; Fine, D; Fischer, DS; Ghazanfar, S; Gillich, A; Giotti, B; Gould, J; Guo, MZ; Gutierrez, AJ; Habermann, AC; Harvey, T; He, P; Hou, XM; Hu, LJ; Hu, Y; Jaiswal, A; Ji, L; Jiang, PY; Kapellos, TS; Kuo, CS; Larsson, L; Leney-Greene, MA; Lim, K; Litvinukova, M; Ludwig, LS; Lukassen, S; Luo, W; Maatz, H; Madissoon, E; Mamanova, L; Manakongtreecheep, K; Leroy, S; Mayr, CH; Mbano, IM; McAdams, AM; Nabhan, AN; Nyquist, SK; Penland, L; Poirion, OB; Poli, S; Qi, CC; Queen, R; Reichart, D; Rosas, I; Schupp, JC; Shea, CV; Shi, XY; Sinha, R; Sit, RV; Slowikowski, K; Slyper, M; Smith, NP; Sountoulidis, A; Strunz, M; Sullivan, TB; Sun, DW; Talavera-Lopez, C; Tan, P; Tantivit, J; Travaglini, KJ; Tucker, NR; Vernon, KA; Wadsworth, MH; Waldman, J; Wang, XT; Xu, K; Yan, WJ; Zhao, W; Ziegler, CGK				Muus, Christoph; Luecken, Malte D.; Eraslan, Gokcen; Sikkema, Lisa; Waghray, Avinash; Heimberg, Graham; Kobayashi, Yoshihiko; Vaishnav, Eeshit Dhaval; Subramanian, Ayshwarya; Smillie, Christopher; Jagadeesh, Karthik A.; Duong, Elizabeth Thu; Fiskin, Evgenij; Triglia, Elena Torlai; Ansari, Meshal; Cai, Peiwen; Lin, Brian; Buchanan, Justin; Chen, Sijia; Shu, Jian; Haber, Adam L.; Chung, Hattie; Montoro, Daniel T.; Adams, Taylor; Aliee, Hananeh; Allon, Samuel J.; Andrusivova, Zaneta; Angelidis, Ilias; Ashenberg, Orr; Bassler, Kevin; Becavin, Christophe; Benhar, Inbal; Bergenstrahle, Joseph; Bergenstrahle, Ludvig; Bolt, Liam; Braun, Emelie; Bui, Linh T.; Callori, Steven; Chaffin, Mark; Chichelnitskiy, Evgeny; Chiou, Joshua; Conlon, Thomas M.; Cuoco, Michael S.; Cuomo, Anna S. E.; Deprez, Marie; Duclos, Grant; Fine, Denise; Fischer, David S.; Ghazanfar, Shila; Gillich, Astrid; Giotti, Bruno; Gould, Joshua; Guo, Minzhe; Gutierrez, Austin J.; Habermann, Arun C.; Harvey, Tyler; He, Peng; Hou, Xiaomeng; Hu, Lijuan; Hu, Yan; Jaiswal, Alok; Ji, Lu; Jiang, Peiyong; Kapellos, Theodoros S.; Kuo, Christin S.; Larsson, Ludvig; Leney-Greene, Michael A.; Lim, Kyungtae; Litvinukova, Monika; Ludwig, Leif S.; Lukassen, Soeren; Luo, Wendy; Maatz, Henrike; Madissoon, Elo; Mamanova, Lira; Manakongtreecheep, Kasidet; Leroy, Sylvie; Mayr, Christoph H.; Mbano, Ian M.; McAdams, Alexi M.; Nabhan, Ahmad N.; Nyquist, Sarah K.; Penland, Lolita; Poirion, Olivier B.; Poli, Sergio; Qi, CanCan; Queen, Rachel; Reichart, Daniel; Rosas, Ivan; Schupp, Jonas C.; Shea, Conor, V; Shi, Xingyi; Sinha, Rahul; Sit, Rene, V; Slowikowski, Kamil; Slyper, Michal; Smith, Neal P.; Sountoulidis, Alex; Strunz, Maximilian; Sullivan, Travis B.; Sun, Dawei; Talavera-Lopez, Carlos; Tan, Peng; Tantivit, Jessica; Travaglini, Kyle J.; Tucker, Nathan R.; Vernon, Katherine A.; Wadsworth, Marc H.; Waldman, Julia; Wang, Xiuting; Xu, Ke; Yan, Wenjun; Zhao, William; Ziegler, Carly G. K.		NHLBI LungMap Consortium; Human Cell Atlas Lung Biol Network	Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	NATURE MEDICINE			English	Article								Angiotensin-converting enzyme 2 (ACE2) and accessory proteases (TMPRSS2 and CTSL) are needed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry, and their expression may shed light on viral tropism and impact across the body. We assessed the cell-type-specific expression of ACE2, TMPRSS2 and CTSL across 107 single-cell RNA-sequencing studies from different tissues. ACE2, TMPRSS2 and CTSL are coexpressed in specific subsets of respiratory epithelial cells in the nasal passages, airways and alveoli, and in cells from other organs associated with coronavirus disease 2019 (COVID-19) transmission or pathology. We performed a meta-analysis of 31 lung single-cell RNA-sequencing studies with 1,320,896 cells from 377 nasal, airway and lung parenchyma samples from 228 individuals. This revealed cell-type-specific associations of age, sex and smoking with expression levels of ACE2, TMPRSS2 and CTSL. Expression of entry factors increased with age and in males, including in airway secretory cells and alveolar type 2 cells. Expression programs shared by ACE2(+)TMPRSS2(+) cells in nasal, lung and gut tissues included genes that may mediate viral entry, key immune functions and epithelial-macrophage cross-talk, such as genes involved in the interleukin-6, interleukin-1, tumor necrosis factor and complement pathways. Cell-type-specific expression patterns may contribute to the pathogenesis of COVID-19, and our work highlights putative molecular pathways for therapeutic intervention. An integrated analysis of over 100 single-cell and single-nucleus transcriptomics studies illustrates severe acute respiratory syndrome coronavirus 2 viral entry gene coexpression patterns across different human tissues, and shows association of age, smoking status and sex with viral entry gene expression in respiratory cell populations.	[Muus, Christoph; Eraslan, Gokcen; Heimberg, Graham; Vaishnav, Eeshit Dhaval; Subramanian, Ayshwarya; Smillie, Christopher; Jagadeesh, Karthik A.; Fiskin, Evgenij; Triglia, Elena Torlai; Haber, Adam L.; Chung, Hattie; Montoro, Daniel T.; Ashenberg, Orr; Benhar, Inbal; Cuoco, Michael S.; Gould, Joshua; Harvey, Tyler; Jaiswal, Alok; Leney-Greene, Michael A.; Ludwig, Leif S.; Luo, Wendy; Slyper, Michal; Tan, Peng; Waldman, Julia] Broad Inst MIT & Harvard, Klarman Cell Observ, Cambridge, MA 02142 USA; [Muus, Christoph] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Luecken, Malte D.; Sikkema, Lisa] Helmholtz Zentrum Munchen, Inst Computat Biol, Neuherberg, Germany; [Waghray, Avinash] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA; [Waghray, Avinash; Lin, Brian] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Dept Internal Med, Boston, MA 02114 USA; [Waghray, Avinash; Lin, Brian] Massachusetts Gen Hosp, Dept Pediat, Pulm & Crit Care Unit, Boston, MA 02114 USA; [Waghray, Avinash; Lin, Brian] Harvard Stem Cell Inst, Cambridge, MA USA; [Kobayashi, Yoshihiko] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Vaishnav, Eeshit Dhaval] MIT, Dept Biol, Cambridge, MA USA; [Duong, Elizabeth Thu] Univ Calif San Diego, Dept Pediat, Div Resp Med, La Jolla, CA 92093 USA; [Ansari, Meshal; Angelidis, Ilias; Conlon, Thomas M.] Comprehens Pneumol Ctr CPC, German Ctr Lung Res DZL, Inst Lung Biol & Dis ILBD, Helmholtz Zentrum Munchen, Munich, Germany; [Ansari, Meshal; Aliee, Hananeh] Helmholtz Zentrum Munchen, Inst Computat Biol, Munich, Germany; [Cai, Peiwen; Fischer, David S.; Wang, Xiuting; Zhao, William] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Buchanan, Justin; Hou, Xiaomeng; Poirion, Olivier B.] Univ Calif San Diego, Sch Med, Ctr Epigen, La Jolla, CA 92093 USA; [Buchanan, Justin; Hou, Xiaomeng; Poirion, Olivier B.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Chen, Sijia] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA 02115 USA; [Shu, Jian; Allon, Samuel J.; Manakongtreecheep, Kasidet; Nyquist, Sarah K.; Slowikowski, Kamil; Tantivit, Jessica; Vernon, Katherine A.; Wadsworth, Marc H.; Ziegler, Carly G. K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Shu, Jian] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA; [Haber, Adam L.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Adams, Taylor; Poli, Sergio; Rosas, Ivan] Yale Univ, Sch Med, Pulm Crit Care & Sleep Med, New Haven, CT USA; [Allon, Samuel J.; Nyquist, Sarah K.; Wadsworth, Marc H.; Ziegler, Carly G. K.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Allon, Samuel J.; Nyquist, Sarah K.; Wadsworth, Marc H.; Ziegler, Carly G. K.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Allon, Samuel J.; Nyquist, Sarah K.; Wadsworth, Marc H.; Ziegler, Carly G. K.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA; [Andrusivova, Zaneta; Bergenstrahle, Joseph; Bergenstrahle, Ludvig] KTH Royal Inst Technol, Dept Gene Technol, SciLifeLab, Stockholm, Sweden; [Bassler, Kevin] Univ Bonn, LIMES Inst, Dept Genom & Immunoregulat, Bonn, Germany; [Becavin, Christophe; Deprez, Marie] Univ Cote Azur, IPMC, CNRS, Sophia Antipolis, France; [Bolt, Liam; He, Peng; Mamanova, Lira] Wellcome Sanger Inst, Hinxton, England; [Braun, Emelie; Hu, Lijuan] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Stockholm, Sweden; [Bui, Linh T.; Gutierrez, Austin J.] Translat Genom Res Inst, Phoenix, AZ USA; [Callori, Steven] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Callori, Steven] Boston Univ, Sch Med, Bioinformat Program, Boston, MA 02118 USA; [Chaffin, Mark; Tucker, Nathan R.] Broad Inst, Precis Cardiol Lab, Cambridge, MA USA; [Chichelnitskiy, Evgeny] Hannover Med Sch, Inst Transplant Immunol, MHH, Hannover, Germany; [Chichelnitskiy, Evgeny] German Ctr Infect Dis DZIF, Braunschweig, Germany; [Chiou, Joshua] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Cuomo, Anna S. E.; Madissoon, Elo] European Mol Biol Lab, European Bioinformat Inst, Wellcome Genome Campus, Hinxton, England; [Duclos, Grant] Boston Univ, Sch Med, Boston, MA 02118 USA; [Fine, Denise] Boston Univ, Med Ctr, Boston, MA USA; [Fischer, David S.] Tech Univ Munich, TUM Sch Life Sci Weihenstephan, Freising Weihenstephan, Germany; [Ghazanfar, Shila] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Gillich, Astrid; Nabhan, Ahmad N.; Penland, Lolita; Sit, Rene, V; Travaglini, Kyle J.] Dept Biochem, Stanford, CA USA; [Gillich, Astrid; Nabhan, Ahmad N.; Penland, Lolita; Sit, Rene, V; Travaglini, Kyle J.] Wall Ctr Pulm Vasc Dis, Stanford, CA USA; [Giotti, Bruno] Icahn Sch Med Mt Sinai, Genet & Genom Sci, New York, NY 10029 USA; [Guo, Minzhe] Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Habermann, Arun C.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; [Hu, Yan] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Ji, Lu; Jiang, Peiyong] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Kapellos, Theodoros S.] Univ Bonn, Life & Med Sci Limes Inst, Genom & Immunoregulat, Bonn, Germany; [Kuo, Christin S.] Stanford Univ, Dept Pediat, Div Pulm Med, Stanford, CA 94305 USA; [Larsson, Ludvig] KTH Royal Inst Technol, Dept Gene Technol, SciLifeLab, Stockholm, Sweden; [Lim, Kyungtae; Sun, Dawei] Univ Cambridge, Gurdon Inst, Cambridge, England; [Litvinukova, Monika; Madissoon, Elo] Wellcome Sanger Inst, Cellular Genet Programme, Wellcome Genome Campus, Hinxton, England; [Litvinukova, Monika; Maatz, Henrike] Helmholtz Assoc MDC, Cardiovasc & Metab Sci, Max Delbruck Ctr Mol Med, Berlin, Germany; [Ludwig, Leif S.] Harvard Med Sch, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Ludwig, Leif S.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Lukassen, Soeren] Charite Univ Med Berlin, Berlin, Germany; [Lukassen, Soeren] Free Univ Berlin, Berlin, Germany; [Lukassen, Soeren] Humboldt Univ, Berlin, Germany; [Lukassen, Soeren] Berlin Inst Hlth, Berlin, Germany; [Lukassen, Soeren] Ctr Digital Hlth, Berlin Inst Hlth BIH, Berlin, Germany; [Manakongtreecheep, Kasidet; Slowikowski, Kamil; Tantivit, Jessica] Massachusetts Gen Hosp, Dept Med, Ctr Canc Res, Boston, MA 02114 USA; [Manakongtreecheep, Kasidet; Slowikowski, Kamil; Tantivit, Jessica] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA USA; [Leroy, Sylvie] Univ Cote Azur, CHU Nice, Pulmonol Dept, Nice, France; [Leroy, Sylvie] CNRS, Inst Pharmacol Mol & Cellulaire, Sophia Antipolis, France; [Mayr, Christoph H.] Helmholtz Zentrum Munchen, Inst Lung Biol & Dis, Grp Syst Med Chron Lung Dis, German Ctr Lung Res DZL, Munich, Germany; [Mbano, Ian M.] Africa Hlth Res Inst, Durban, South Africa; [Mbano, Ian M.] Univ Kwazulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, Durban, South Africa; [McAdams, Alexi M.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA; [McAdams, Alexi M.] Massachusetts Eye & Ear, Boston, MA USA; [Nyquist, Sarah K.] MIT, Computat & Syst Biol, CSAIL, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Qi, CanCan] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [Qi, CanCan] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands; [Queen, Rachel] Newcastle Univ, Fac Med Sci, Int Ctr Life, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Reichart, Daniel] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA; [Reichart, Daniel] Univ Hamburg, Univ Heart & Vasc Ctr, Dept Cardiol, Hamburg, Germany; [Schupp, Jonas C.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT USA; [Shea, Conor, V; Shi, Xingyi; Xu, Ke] Boston Univ, Sch Med, Dept Med, Div Computat Biomed, Boston, MA 02118 USA; [Shi, Xingyi] Boston Univ, Bioinformat Program, Boston, MA 02215 USA; [Sinha, Rahul] Stanford Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA USA; [Smith, Neal P.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Sountoulidis, Alex] Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, Stockholm, Sweden; [Strunz, Maximilian] Helmholtz Zentrum Munchen, German Ctr Lung Res DZL, Comprehens Pneumol Ctr CPC, Munich, Germany; [Strunz, Maximilian] Helmholtz Zentrum Munchen, Inst Lung Biol & Dis ILBD, German Ctr Lung Res DZL, Munich, Germany; [Sullivan, Travis B.] Lahey Hosp & Med Ctr, Burlington, MA USA; [Talavera-Lopez, Carlos] Wellcome Sanger Inst, Cellular Genet Programme, Wellcome Genome Campus, Cambridge, England; [Tucker, Nathan R.] Masonic Med Res Inst, Utica, NY USA; [Vernon, Katherine A.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Vernon, Katherine A.] Harvard Med Sch, Boston, MA 02115 USA; [Wadsworth, Marc H.] MIT, Dept Chem, Inst Med Engn & Sci, Cambridge, MA 02139 USA; [Wadsworth, Marc H.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Yan, Wenjun] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA; [Yan, Wenjun] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Ziegler, Carly G. K.] MIT, Harvard Mit Hlth Sci & Technol, Inst Med Engn & Sci, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Duke University; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard T.H. Chan School of Public Health; Yale University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Royal Institute of Technology; SciLifeLab; University of Bonn; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Wellcome Trust Sanger Institute; Karolinska Institutet; Translational Genomics Research Institute; Boston University; Boston University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Hannover Medical School; German Center for Infection Research; University of California System; University of California San Diego; European Molecular Biology Laboratory (EMBL); Boston University; Boston University; Technical University of Munich; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Icahn School of Medicine at Mount Sinai; Cincinnati Children's Hospital Medical Center; Vanderbilt University; University of Colorado System; University of Colorado Anschutz Medical Campus; Chinese University of Hong Kong; University of Bonn; Stanford University; Royal Institute of Technology; SciLifeLab; University of Cambridge; Wellcome Trust Sanger Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Berlin Institute of Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Africa Health Research Institute; University of Kwazulu Natal; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Massachusetts Institute of Technology (MIT); University of Groningen; University of Groningen; Newcastle University - UK; Harvard University; Harvard Medical School; University of Hamburg; Yale University; Boston University; Boston University; Harvard University; Massachusetts General Hospital; Stockholm University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Lahey Hospital & Medical Center; Wellcome Trust Sanger Institute; Masonic Medical Research Laboratory; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT)	Muus, C (corresponding author), Broad Inst MIT & Harvard, Klarman Cell Observ, Cambridge, MA 02142 USA.; Muus, C (corresponding author), Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.; Luecken, MD (corresponding author), Helmholtz Zentrum Munchen, Inst Computat Biol, Neuherberg, Germany.	muus@broadinstitute.org; malte.luecken@helmholtz-muenchen.de	Shi, Xingyi/GQH-8966-2022; Zaragosi, Laure-Emmanuelle/P-9887-2016; Ji, Lu/GLV-2373-2022; Triglia, Elena Torlai/AAS-5807-2020; Lukassen, Soeren/A-3737-2019; Eraslan, Gokcen/ABH-1475-2021; Kobayashi, Yoshihiko/AAH-7324-2019; Talavera-Lopez, Carlos/AFH-6676-2022; Bécavin, Christophe/AAA-2046-2020; Lin, Brian/M-9339-2019; Ludwig, Leif S./A-1913-2015; Guo, Minzhe/Y-3982-2018; Cho, Josalyn/ABF-8931-2021; Lim, Kyungtae/GYU-3532-2022; Barbry, Pascal/O-5021-2016; Eils, Roland/B-6121-2009	Zaragosi, Laure-Emmanuelle/0000-0001-6747-7928; Triglia, Elena Torlai/0000-0002-6059-0116; Lukassen, Soeren/0000-0001-7045-6327; Eraslan, Gokcen/0000-0001-9579-2909; Kobayashi, Yoshihiko/0000-0001-7031-1478; Bécavin, Christophe/0000-0003-1555-3153; Lin, Brian/0000-0002-8851-3534; Ludwig, Leif S./0000-0002-2916-2164; Cho, Josalyn/0000-0002-0367-4495; Lim, Kyungtae/0000-0001-6044-2191; Xu, Ke/0000-0003-2628-2061; Muus, Christoph/0000-0003-2779-0893; Barbry, Pascal/0000-0001-9632-6483; Mayr, Christoph/0000-0001-5353-4768; Saeb-Parsy, Kourosh/0000-0002-0633-3696; Noseda, Michela/0000-0002-9553-5029; Talavera-Lopez, Carlos/0000-0001-8590-2393; Nikolic, Marko/0000-0001-6304-6848; ZERTI, DARIN/0000-0003-0865-8088; Cuomo, Anna/0000-0001-5168-6979; Tucker, Nathan/0000-0002-5071-4218; Poli, Sergio/0000-0001-5442-3189; Tan, Peng/0000-0001-6992-9000; Fiskin, Evgenij/0000-0002-9510-0826; Bui, Linh/0000-0003-3152-8978; Sikkema, Lisa/0000-0001-9686-6295; Hu, Yan/0000-0003-0586-6527; Schwarz, Roland/0000-0001-9155-4268; Nawijn, Martijn/0000-0003-3372-6521; Vaishnav, Eeshit Dhaval/0000-0003-3720-8051; Brazma, Alvis/0000-0001-5988-7409; Mbano, Ian/0000-0002-2583-4760; Deutsch, Gail/0000-0002-0571-0285; Tata, Purushothama Rao/0000-0003-4837-0337; Chichelnitskiy, Evgeny/0000-0002-6341-4177; Marioni, John/0000-0001-9092-0852; Schupp, Jonas/0000-0002-7714-8076; He, Peng/0000-0002-2457-3554; Eils, Roland/0000-0002-0034-4036; Luecken, Malte D/0000-0001-7464-7921; Gutierrez, Austin/0000-0003-2977-2189; Chiou, Joshua/0000-0002-4618-0647; GUO, MINZHE/0000-0002-5502-9172; Smillie, Chris/0000-0002-7606-3433; Qi, Cancan/0000-0003-3825-5802; Leney-Greene, Michael/0000-0002-3259-1728; Kaminski, Naftali/0000-0001-5917-4601; Litvinukova, Monika/0000-0002-6713-3647	National Institutes of Health (NIH)/NHLBI [R01HL145372]; Department of Defense [W81XWH1410234, 874656]; Medical Research Council (MRC) [MR/S035826/1]; European Research Council (ERC) [614620]; European Commission (ESPACE/HEuropean Union) [874710]; Stanford Child Health Research Institute (Woods Family Faculty Scholarship); Chan Zuckerberg Initiative (CZI) Seed Network; NIH [R01HL145372, 1U01 HL148867-01, R35HL140039, R01HL130938, R01HL127349, U01HL145567, R01HL141380, K08HL130595, R01 HL133153, HL135124, AG049665, AI135964, K08HL146943, U01 HL148856]; DFG [SFB 738, B3 (DFG FA-483/1-1)]; NIH award from Eunice Kennedy Shriver National Institute of Child Health and Human Development [5R24HD000836]; British Heart Foundation (BHF)/German Centre for Cardiovascular Research (DZHK) grant, ERC Advanced Grant under the Horizon 2020 Program; Federal Ministry of Education and Research of Germany in the framework of CaRNAtion; Three Lakes Foundation; Howard Hughes Medical Institute; Wall Center for Pulmonary Vascular Disease; Doris Duke Charitable Foundation; ERC [614620]; National Research Foundation of Korea; Stand Up to Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Reserach Grant [SU2C-AACR-DT23-17]; Stand Up to Cancer is a division of the Entertainment Industry Foundation; Janssen Pharmaceuticals; Knut and Alice Wallenberg Foundation [2018.0172]; Erling-Persson Family Foundation (Human Developmental Cell Atlas); Swedish Foundation for Strategic Research [SB16-0065, RIF14-0057]; Horizon2020 [874656]; Erling-Persson Family Foundation (HDCA); Wellcome Trust; MRC [MR/S035826/1]; CZI Foundation; Netherlands Lung Foundation [5.1.14.020, 4.1.18.226]; Rutherford Fund Fellowship; UK Regenerative Medicine Platform [MR/5005579/1]; Rosetrees Trust; BHF/DZHK grant; BHF [PG/16/47/32156]; CZI RFA CZF2019-002431e for Research Excellence; Centre for Regenerative Medicine, Imperial College London; Richard and Susan Smith Family Foundation; Canada Research Chair; Canadian Institute of Health Research; Heart and Stroke Foundation; Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center [R01HL146557]; NHLBI/NIH; Cancer Research UK [C6946/A24843]; Klarman Cell Observatory; Manton Foundation; Parker B. Francis Fellowship; ATS Foundation/Boehringer Ingelheim Pharmaceuticals Research Fellowship in idiopathic pulmonary fibrosis [1 U01 HL14555-01]; NIHR Cambridge Biomedical Research Centre; Swedish research Council; Swedish Cancer Society; German Center for Lung Research and Helmholtz Association; Boehringer Ingelheim; German Research Foundation (DFG) [EXC2151/1, 390873048, 329123747, 347286815]; HGF [sparse2big]; NIH (NHLBI) [2R01HL080494]; Beckman Young Investigator Program; Sloan Fellowship in Chemistry; Bill and Melinda Gates Foundation; NHLBI [R01HL119215]; NIAID Novel Alternative Model Systems [U19AI116482, CZF2019-002440]; Silicon Valley Community Foundation [CZF2019-002438]; Helmholtz Association's Initiative and Networking Fund through Helmholtz AI [ZT-I-PF-5-01]; German Center for Lung Research; National Science Foundation [IOS-2028295]; Cambridge University Hospitals NIHR Biomedical Research Centre; MRC of the Wellcome-MRC Cambridge Stem Cell Institute; Ministry of Economic Affairs and Climate Policy by means of the PPP [DK 043351, DK114784, AI142784, DK117263]; Agence Nationale de la Recherche [ANR-15-IDEX-01, ANR-19-CE14-0027, ANR-10-INBS-09-03]; Fondation pour la Recherche Medicale [DEQ20180339158]; CZI (Silicon Valley Foundation) [2017-175159-5022]; Conseil Departemental des Alpes Maritimes [2016-294DGADSH-CV, 2019-390DGADSH-CV]; National Key RD Program [2019YFA0801703]; National Natural Science Foundation of China [31871370]; NHLBI Molecular Atlas of Lung Development Program Human Tissue Core grants [U01HL122700, HL148861]; European Commission (ESPACE/HEuropean Union Horizon 2020 Research and Innovation Program) [874710]; HubMap consortium; Stanford Child Health Research Institute; CZI Seed Network grant; LENDULET-BIOMAG grant [2018-342]; CZI [CZF2019-002448]; British Heart Foundation (BHF)/German Centre for Cardiovascular Research (DZHK) grant; ERC Advanced Grant under the Horizon 2020 Program; Horizon2020 HCA 'discovAIR' project [874656]; CZI; Horizon 2020 [874656]; Wellcome Trust [206194/Z/17/Z, 211276/Z/18/Z]; CZI Foundation [CZF2019-002438]; GSK; Rosetrees Trust [M899]; Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center; CZI Biohub; LungMAP and CZI Seed Network; NHLBI/NIH [R01HL146557]; CZI-HCA Seed projects; ATS Foundation/Boehringer Ingelheim Pharmaceuticals Research Fellowship; CPI; Helmholtz Association; German Research Foundation (ImmunoSensation2-the immune sensory system) [390873048, 329123747, 347286815]; HGF grant sparse2big; NIAID Novel Alternative Model Systems for Enteric Diseases consortium [U19AI116482]; CZI DAF, an advised fund of Silicon Valley Community Foundation [CZF2019-002440]; ERC advanced grant New-Chol; Ministry of Economic Affairs and Climate Policy; Agence Nationale de la Recherche (UCAJEDI) [ANR-15-IDEX-01]; Agence Nationale de la Recherche (SAHARRA) [ANR-19-CE14-0027]; Agence Nationale de la Recherche (France Genomique) [ANR-10-INBS-09-03]	National Institutes of Health (NIH)/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Department of Defense(United States Department of Defense); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council (ERC)(European Research Council (ERC)European Commission); European Commission (ESPACE/HEuropean Union); Stanford Child Health Research Institute (Woods Family Faculty Scholarship); Chan Zuckerberg Initiative (CZI) Seed Network; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DFG(German Research Foundation (DFG)); NIH award from Eunice Kennedy Shriver National Institute of Child Health and Human Development; British Heart Foundation (BHF)/German Centre for Cardiovascular Research (DZHK) grant, ERC Advanced Grant under the Horizon 2020 Program; Federal Ministry of Education and Research of Germany in the framework of CaRNAtion; Three Lakes Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Wall Center for Pulmonary Vascular Disease; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); ERC(European Research Council (ERC)European Commission); National Research Foundation of Korea(National Research Foundation of Korea); Stand Up to Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Reserach Grant; Stand Up to Cancer is a division of the Entertainment Industry Foundation; Janssen Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Erling-Persson Family Foundation (Human Developmental Cell Atlas); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Horizon2020; Erling-Persson Family Foundation (HDCA); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CZI Foundation; Netherlands Lung Foundation; Rutherford Fund Fellowship; UK Regenerative Medicine Platform; Rosetrees Trust(Rosetrees Trust); BHF/DZHK grant; BHF(British Heart Foundation); CZI RFA CZF2019-002431e for Research Excellence; Centre for Regenerative Medicine, Imperial College London; Richard and Susan Smith Family Foundation; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation(Heart & Stroke Foundation of Canada); Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center; NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Cancer Research UK(Cancer Research UK); Klarman Cell Observatory; Manton Foundation; Parker B. Francis Fellowship; ATS Foundation/Boehringer Ingelheim Pharmaceuticals Research Fellowship in idiopathic pulmonary fibrosis; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Swedish research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); German Center for Lung Research and Helmholtz Association; Boehringer Ingelheim(Boehringer Ingelheim); German Research Foundation (DFG)(German Research Foundation (DFG)); HGF; NIH (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Beckman Young Investigator Program; Sloan Fellowship in Chemistry; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID Novel Alternative Model Systems; Silicon Valley Community Foundation; Helmholtz Association's Initiative and Networking Fund through Helmholtz AI; German Center for Lung Research; National Science Foundation(National Science Foundation (NSF)); Cambridge University Hospitals NIHR Biomedical Research Centre; MRC of the Wellcome-MRC Cambridge Stem Cell Institute; Ministry of Economic Affairs and Climate Policy by means of the PPP; Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); CZI (Silicon Valley Foundation); Conseil Departemental des Alpes Maritimes; National Key RD Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NHLBI Molecular Atlas of Lung Development Program Human Tissue Core grants; European Commission (ESPACE/HEuropean Union Horizon 2020 Research and Innovation Program)(European CommissionEuropean Commission Joint Research Centre); HubMap consortium; Stanford Child Health Research Institute; CZI Seed Network grant; LENDULET-BIOMAG grant; CZI; British Heart Foundation (BHF)/German Centre for Cardiovascular Research (DZHK) grant; ERC Advanced Grant under the Horizon 2020 Program; Horizon2020 HCA 'discovAIR' project; CZI; Horizon 2020; Wellcome Trust(Wellcome Trust); CZI Foundation; GSK(GlaxoSmithKline); Rosetrees Trust(Rosetrees Trust); Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center; CZI Biohub; LungMAP and CZI Seed Network; NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CZI-HCA Seed projects; ATS Foundation/Boehringer Ingelheim Pharmaceuticals Research Fellowship; CPI; Helmholtz Association(Helmholtz Association); German Research Foundation (ImmunoSensation2-the immune sensory system)(German Research Foundation (DFG)); HGF grant sparse2big; NIAID Novel Alternative Model Systems for Enteric Diseases consortium; CZI DAF, an advised fund of Silicon Valley Community Foundation; ERC advanced grant New-Chol; Ministry of Economic Affairs and Climate Policy; Agence Nationale de la Recherche (UCAJEDI)(French National Research Agency (ANR)); Agence Nationale de la Recherche (SAHARRA)(French National Research Agency (ANR)); Agence Nationale de la Recherche (France Genomique)(French National Research Agency (ANR))	We thank all donors, patients and their families for their contributions to the studies that are part of our integrated analysis. We thank L. Gaffney and A. Hupalowska for help with figure preparation, C. de Boer for critical reading of the manuscript and E. Spiegel from the statistical consulting core facility at the Institute of Computational Biology, Helmholtz Center Munich, for advice on statistical modeling. N.E.B. is supported by the National Institutes of Health (NIH)/NHLBI (R01HL145372) and the Department of Defense (W81XWH1910416). J.C. is supported by grants from the Medical Research Council (MRC; MR/S035826/1) and the European Research Council (ERC; 614620). R.E. and C.C. are supported by the European Commission (ESPACE/HEuropean Union Horizon 2020 Research and Innovation Program, 874710). T.D. is supported by HubMap consortium and Stanford Child Health Research Institute (Woods Family Faculty Scholarship). O.E. is supported by the Chan Zuckerberg Initiative (CZI) Seed Network and the NIH (1R01HL146519). C.S.F. is supported by DFG, SFB 738 project B3 (DFG FA-483/1-1). I.A.G. and the University of Washington Laboratory of Developmental Biology were supported by NIH award no. 5R24HD000836 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. A.G. is supported by a CZI Seed Network grant. P.H. acknowledges support from the LENDULET-BIOMAG grant (2018-342) and the CZI (CZF2019-002448). N.H. acknowledges support from a British Heart Foundation (BHF)/German Centre for Cardiovascular Research (DZHK) grant, ERC Advanced Grant under the Horizon 2020 Program and the Federal Ministry of Education and Research of Germany in the framework of CaRNAtion. W.J.J. received funding from the NIH (R35HL140039 and R01HL130938). N.K. received funding from NIH grants R01HL127349 and U01HL145567 and an unrestricted grant from Three Lakes Foundation. M.K. received funding from NIH grant R01HL141380. G.H.K. and M.K. received funding from Horizon2020 HCA 'discovAIR' project (no. 874656). M.A.K. received funding from Howard Hughes Medical Institute, CZI and Wall Center for Pulmonary Vascular Disease. J.A.K. received funding from NIH grants R01HL145372 (J.A.K./N.E.B.) and K08HL130595 (J.A.K.) and the Doris Duke Charitable Foundation (J.A.K.). M.L. received funding from the ERC (614620). H.L. acknowledges funding from the National Research Foundation of Korea. S.A.M., J.C., A.S., M.E.L. and J.B. acknowledge support from a Stand Up to Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Reserach Grant (SU2C-AACR-DT23-17 to S. M. Dubinett and A.S.). Stand Up to Cancer is a division of the Entertainment Industry Foundation. S.A.M., J.C., M.E.L. and J.B. acknowledge funding from Sponsored Research Agreements with Janssen Pharmaceuticals. J.B. and J.C. acknowledge funding from the Department of Defense (W81XWH1410234). S. Leroy acknowledges funding from Horizon 2020 under grant no. 874656 (discovAIR). S. Linnarsson acknowledges funding from the Knut and Alice Wallenberg Foundation (2015.0041 and 2018.0172), the Erling-Persson Family Foundation (Human Developmental Cell Atlas) and the Swedish Foundation for Strategic Research (SB16-0065 and RIF14-0057). J.L. acknowledges funding from Horizon2020 under grant no. 874656 (discovAIR), the Knut and Alice Wallenberg Foundation (2018.0172) and the Erling-Persson Family Foundation (HDCA). B.D.M. is supported by NIH grant R01 HL133153. K.B.M.; acknowledges funding from CZI grant 2017-174169 (5022), Wellcome Trust grants 206194/Z/17/Z and 211276/Z/18/Z, MRC grant MR/S035907/1 and Horizon2020 grant no. 874656 (discovAIR). A.V.M. acknowledges funding from NIH grants HL135124, AG049665 and AI135964 and grant number CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network. M.C.N. acknowledges funding from from grant number CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network, GSK, Netherlands Lung Foundation project nos. 5.1.14.020 and 4.1.18.226 and Horizon2020 under grant no. 874656 (discovAIR). M.Z.N. acknowledges funding from Rutherford Fund Fellowship allocated by the MRC and the UK Regenerative Medicine Platform (MR/5005579/1); Rosetrees Trust (grant no. M899). M.N. acknowledges funding from a BHF/DZHK grant and the BHF (PG/16/47/32156), CZI RFA CZF2019-002431e for Research Excellence and the Centre for Regenerative Medicine, Imperial College London. J.O.-M. acknowledges funding from the Richard and Susan Smith Family Foundation. G.Y.O. acknowledges support from the Canada Research Chair, the Canadian Institute of Health Research and the Heart and Stroke Foundation. D.P. acknowledges funding from the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center. S.R.Q. acknowledges funding from the CZI Biohub. J.R. acknowledges funding from LungMAP and CZI Seed Network. P.R.T. acknowledges funding from R01HL146557 from NHLBI/NIH and CZI-HCA Seed projects. E.L.R. acknowledges funding from the MRC (MR/S035907/1 and MR/P009581/1), Wellcome Trust (109146/Z/15/Z), Core support from the Wellcome Trust (203144/Z/16/Z) and Cancer Research UK (C6946/A24843). A.R. and O.R.-R. were supported by the Howard Hughes Medical Institute, the Klarman Cell Observatory, the Manton Foundation and the CZI. P.A.R. acknowledges funding from the NIH (K08HL146943), a Parker B. Francis Fellowship and an ATS Foundation/Boehringer Ingelheim Pharmaceuticals Research Fellowship in idiopathic pulmonary fibrosis. M.R. acknowledges funding from 1 U01 HL14555-01. K.S.-P. acknowledges funding from NIHR Cambridge Biomedical Research Centre. C.S. acknowledges funding from the Swedish research Council, Swedish Cancer Society, CPI and Horizon2020 under grant no. 874656 (discovAIR). H.S. was supported by grant number CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network, the German Center for Lung Research and Helmholtz Association, and Horizon2020 under grant no. 874656 (discovAIR). Work by J.S. was supported by J.L.S. funded in part by Boehringer Ingelheim, by the German Research Foundation (DFG; EXC2151/1, ImmunoSensation2-the immune sensory system; project nos. 390873048, 329123747 and 347286815) and by the HGF grant sparse2big. C.E.S. was supported by the Howard Hughes Medical Institute and the NIH (NHLBI; 2R01HL080494). J.G.S. was supported by the NIH (NHLBI; 2R01HL080494). A.K.S. was supported by the Beckman Young Investigator Program, a Sloan Fellowship in Chemistry, the NIH (5U24AI118672) and the Bill and Melinda Gates Foundation. D.P.S. was supported by the CZI Seed Network grant. J.R.S. is supported by the NHLBI (R01HL119215), by the NIAID Novel Alternative Model Systems for Enteric Diseases consortium (U19AI116482) and by grant no. CZF2019-002440 from the CZI DAF, an advised fund of Silicon Valley Community Foundation. F.J.T. was supported by grant no. CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network, the Helmholtz Association's Initiative and Networking Fund through Helmholtz AI (grant no.; ZT-I-PF-5-01), Horizon2020 under grant no. 874656 (discovAIR) and the German Center for Lung Research. A.M.T. was supported by CZI Lung Atlas and National Science Foundation award no. IOS-2028295. L.V. was supported by the ERC advanced grant New-Chol, the Cambridge University Hospitals NIHR Biomedical Research Centre and the core support grant from the Wellcome Trust and MRC of the Wellcome-MRC Cambridge Stem Cell Institute. M.V.D.B. was supported by the Ministry of Economic Affairs and Climate Policy by means of the PPP. R.J.X. was supported by DK 043351, DK114784, AI142784 and DK117263. L.E.Z. was supported by the Agence Nationale de la Recherche (UCAJEDI, ANR-15-IDEX-01; SAHARRA, ANR-19-CE14-0027; France Genomique, ANR-10-INBS-09-03), Fondation pour la Recherche Medicale (DEQ20180339158), CZI (Silicon Valley Foundation, 2017-175159-5022) and Conseil Departemental des Alpes Maritimes (2016-294DGADSH-CV and 2019-390DGADSH-CV). D.Z. was supported by the MRC (MR/S035826/1) and ERC (614620). H.Z. is supported by the National Key R&D Program (2019YFA0801703) and the National Natural Science Foundation of China (31871370). This study was supported by NHLBI Molecular Atlas of Lung Development Program Human Tissue Core grants U01HL122700 and HL148861. J.W., G.H.D. and Y.X. acknowledge support from the NIH, U01 HL148856 LungMap Phase II-building a multidimensional map of developing human lung. X.S. and, A.W. acknowledge support from the NIH, 1U01 HL148867-01.		0	130	130	12	50	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					546	+		10.1038/s41591-020-01227-z	http://dx.doi.org/10.1038/s41591-020-01227-z		MAR 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33654293	Green Submitted, Green Accepted, Bronze			2022-12-27	WOS:000624452300001
J	Becher, T; Palanisamy, S; Kramer, DJ; Eljalby, M; Marx, SJ; Wibmer, AG; Butler, SD; Jiang, CES; Vaughan, R; Schoder, H; Mark, A; Cohen, P				Becher, Tobias; Palanisamy, Srikanth; Kramer, Daniel J.; Eljalby, Mahmoud; Marx, Sarah J.; Wibmer, Andreas G.; Butler, Scott D.; Jiang, Caroline S.; Vaughan, Roger; Schoeder, Heiko; Mark, Allyn; Cohen, Paul			Brown adipose tissue is associated with cardiometabolic health	NATURE MEDICINE			English	Article							METABOLIC-RESPONSES; COLD; FAT; THERMOGENESIS; ACTIVATION; GLUCOSE; OBESITY; WHITE	Retrospective analysis of F-18-FDG PET/CT scans from over 50,000 patients reveals correlations between presence of brown adipose tissue and lower odds of having cardiometabolic conditions, such as type 2 diabetes, cardiovascular disease and hypertension. White fat stores excess energy, whereas brown and beige fat are thermogenic and dissipate energy as heat. Thermogenic adipose tissues markedly improve glucose and lipid homeostasis in mouse models, although the extent to which brown adipose tissue (BAT) influences metabolic and cardiovascular disease in humans is unclear(1,2). Here we retrospectively categorized 134,529 F-18-fluorodeoxyglucose positron emission tomography-computed tomography scans from 52,487 patients, by presence or absence of BAT, and used propensity score matching to assemble a study cohort. Scans in the study population were initially conducted for indications related to cancer diagnosis, treatment or surveillance, without previous stimulation. We report that individuals with BAT had lower prevalences of cardiometabolic diseases, and the presence of BAT was independently correlated with lower odds of type 2 diabetes, dyslipidemia, coronary artery disease, cerebrovascular disease, congestive heart failure and hypertension. These findings were supported by improved blood glucose, triglyceride and high-density lipoprotein values. The beneficial effects of BAT were more pronounced in individuals with overweight or obesity, indicating that BAT might play a role in mitigating the deleterious effects of obesity. Taken together, our findings highlight a potential role for BAT in promoting cardiometabolic health.	[Becher, Tobias; Palanisamy, Srikanth; Kramer, Daniel J.; Eljalby, Mahmoud; Marx, Sarah J.; Cohen, Paul] Rockefeller Univ, Lab Mol Metab, 1230 York Ave, New York, NY 10021 USA; [Becher, Tobias] DZHK German Ctr Cardiovasc Res, Partner Site Heidelberg Mannheim, Mannheim, Germany; [Becher, Tobias] Univ Med Ctr Mannheim, Div Cardiol, Dept Med 1, Mannheim, Germany; [Palanisamy, Srikanth; Kramer, Daniel J.; Eljalby, Mahmoud; Vaughan, Roger] Weill Cornell Med, New York, NY USA; [Kramer, Daniel J.] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY USA; [Wibmer, Andreas G.; Schoeder, Heiko] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA; [Butler, Scott D.] Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; [Jiang, Caroline S.; Vaughan, Roger] Rockefeller Univ, Ctr Clin & Translat Sci, 1230 York Ave, New York, NY 10021 USA; [Mark, Allyn] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA	Rockefeller University; German Centre for Cardiovascular Research; Ruprecht Karls University Heidelberg; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Rockefeller University; University of Iowa	Cohen, P (corresponding author), Rockefeller Univ, Lab Mol Metab, 1230 York Ave, New York, NY 10021 USA.	pcohen@rockefeller.edu		Becher, Tobias/0000-0001-7670-757X	National Center for Advancing Translational Sciences, NIH, through The Rockefeller University [UL1TR001866]; Sinsheimer Foundation; American Diabetes Association Pathway Program Accelerator Award [1-17-ACE-17]	National Center for Advancing Translational Sciences, NIH, through The Rockefeller University; Sinsheimer Foundation; American Diabetes Association Pathway Program Accelerator Award	We thank M.N. Singer and C. Poon for expert IT support and data extraction; R. Teng for assistance in accessing data; and B.S. Coller, A.J. Dannenberg, J.J. Moslehi and M.D. Curtis for valuable discussions during the preparation of this manuscript. T.B. was supported in part by the National Center for Advancing Translational Sciences, NIH, through The Rockefeller University (grant UL1TR001866). P.C. was supported by the Sinsheimer Foundation and by the American Diabetes Association Pathway Program Accelerator Award (grant 1-17-ACE-17).	Balaz M, 2019, CELL METAB, V29, P901, DOI 10.1016/j.cmet.2018.11.017; Bartelt A, 2011, NAT MED, V17, P200, DOI 10.1038/nm.2297; Becker AS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149458; Berbee JFP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7356; Blondin DP, 2017, CELL METAB, V25, P438, DOI 10.1016/j.cmet.2016.12.005; Blondin DP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14146; Blondin DP, 2015, DIABETES, V64, P2388, DOI 10.2337/db14-1651; Blondin DP, 2015, J PHYSIOL-LONDON, V593, P701, DOI 10.1113/jphysiol.2014.283598; Brendle C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37924-6; Cao Q, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-126; Chen KY, 2016, CELL METAB, V24, P210, DOI 10.1016/j.cmet.2016.07.014; Chondronikola M, 2016, CELL METAB, V23, P1200, DOI 10.1016/j.cmet.2016.04.029; Cohade C, 2003, J NUCL MED, V44, P170; Cronin CG, 2012, RADIOLOGY, V263, P836, DOI 10.1148/radiol.12100683; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Dieli-Conwright CM, 2016, CANCER-AM CANCER SOC, V122, P2646, DOI 10.1002/cncr.30104; Din MU, 2016, EUR J NUCL MED MOL I, V43, P1878, DOI 10.1007/s00259-016-3364-y; Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014; Finlin BS, 2020, J CLIN INVEST, V130, P2319, DOI 10.1172/JCI134892; Gadea E, 2014, NUTR CANCER, V66, P1092, DOI 10.1080/01635581.2014.948212; Ginzac A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6591-3; Hanssen MJW, 2015, NAT MED, V21, P863, DOI 10.1038/nm.3891; Hoeke G, 2017, J CLIN LIPIDOL, V11, P920, DOI 10.1016/j.jacl.2017.04.117; Hoeke G, 2016, CIRC RES, V118, P173, DOI 10.1161/CIRCRESAHA.115.306647; Langenberg C, 2018, LANCET, V391, P2463, DOI 10.1016/S0140-6736(18)31132-2; Leitner BP, 2017, P NATL ACAD SCI USA, V114, P8649, DOI 10.1073/pnas.1705287114; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Liu XM, 2013, CELL RES, V23, P851, DOI 10.1038/cr.2013.64; Muzik Otto, 2012, Front Endocrinol (Lausanne), V3, P15, DOI 10.3389/fendo.2012.00015; O'Mara AE, 2020, J CLIN INVEST, V130, P2209, DOI 10.1172/JCI131126; Orava J, 2011, CELL METAB, V14, P272, DOI 10.1016/j.cmet.2011.06.012; Raiko J, 2020, ARTERIOSCL THROM VAS, V40, P1289, DOI 10.1161/ATVBAHA.119.313806; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Steinberg JD, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20170093; Villarroya F, 2017, NAT REV ENDOCRINOL, V13, P26, DOI 10.1038/nrendo.2016.136; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Ward ZJ, 2019, NEW ENGL J MED, V381, P2440, DOI 10.1056/NEJMsa1909301; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; Yoneshiro T, 2013, J CLIN INVEST, V123, P3404, DOI 10.1172/JCI67803; Yoneshiro T, 2011, OBESITY, V19, P13, DOI 10.1038/oby.2010.105	40	153	156	21	66	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					58	+		10.1038/s41591-020-1126-7	http://dx.doi.org/10.1038/s41591-020-1126-7		JAN 2021	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33398160	Green Accepted			2022-12-27	WOS:000604849400003
J	Carvalho, T				Carvalho, Thiago			ACE2, the viral gateway	NATURE MEDICINE			English	Editorial Material																			0	0	0	1	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1807	1807		10.1038/s41591-020-01166-9	http://dx.doi.org/10.1038/s41591-020-01166-9			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288942	Bronze			2022-12-27	WOS:000596579200021
J	McCulloch, JA; Davar, D; Rodrigues, RR; Badger, JH; Fang, JR; Cole, AM; Balaji, AK; Vetizou, M; Prescott, SM; Fernandes, MR; Costa, RGF; Yuan, WX; Salcedo, R; Bahadiroglu, E; Roy, S; DeBlasio, RN; Morrison, RM; Chauvin, JM; Ding, QQ; Zidi, B; Lowin, A; Chakka, S; Gao, WT; Pagliano, O; Ernst, SJ; Rose, A; Newman, NK; Morgun, A; Zarour, HM; Trinchieri, G; Dzutsev, AK				McCulloch, John A.; Davar, Diwakar; Rodrigues, Richard R.; Badger, Jonathan H.; Fang, Jennifer R.; Cole, Alicia M.; Balaji, Ascharya K.; Vetizou, Marie; Prescott, Stephanie M.; Fernandes, Miriam R.; Costa, Raquel G. F.; Yuan, Wuxing; Salcedo, Rosalba; Bahadiroglu, Erol; Roy, Soumen; DeBlasio, Richelle N.; Morrison, Robert M.; Chauvin, Joe-Marc; Ding, Quanquan; Zidi, Bochra; Lowin, Ava; Chakka, Saranya; Gao, Wentao; Pagliano, Ornella; Ernst, Scarlett J.; Rose, Amy; Newman, Nolan K.; Morgun, Andrey; Zarour, Hassane M.; Trinchieri, Giorgio; Dzutsev, Amiran K.			Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1	NATURE MEDICINE			English	Article							GUT MICROBIOTA; NIVOLUMAB; EFFICACY; IMMUNOTHERAPY; ASSOCIATION; METABOLITES; MONOTHERAPY; RESISTANCE; THERAPY; MEGAHIT	Integrated analysis of microbiome and host cell transcriptional data on clinically annotated cohorts of patients with melanoma who were treated with anti-programmed cell death protein-1, uncovers new associations of streptococcus species with immune-related adverse effects and finds consistent microbiome associations with clinical outcomes. Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but inconsistencies exist between published microbial signatures associated with clinical outcomes. To resolve this, we evaluated a new melanoma cohort, along with four published datasets. Time-to-event analysis showed that baseline microbiota composition was optimally associated with clinical outcome at approximately 1 year after initiation of treatment. Meta-analysis and other bioinformatic analyses of the combined data show that bacteria associated with favorable response are confined within the Actinobacteria phylum and the Lachnospiraceae/Ruminococcaceae families of Firmicutes. Conversely, Gram-negative bacteria were associated with an inflammatory host intestinal gene signature, increased blood neutrophil-to-lymphocyte ratio, and unfavorable outcome. Two microbial signatures, enriched for Lachnospiraceae spp. and Streptococcaceae spp., were associated with favorable and unfavorable clinical response, respectively, and with distinct immune-related adverse effects. Despite between-cohort heterogeneity, optimized all-minus-one supervised learning algorithms trained on batch-corrected microbiome data consistently predicted outcomes to programmed cell death protein-1 therapy in all cohorts. Gut microbial communities (microbiotypes) with nonuniform geographical distribution were associated with favorable and unfavorable outcomes, contributing to discrepancies between cohorts. Our findings shed new light on the complex interaction between the gut microbiome and response to cancer immunotherapy, providing a roadmap for future studies.	[McCulloch, John A.; Rodrigues, Richard R.; Badger, Jonathan H.; Yuan, Wuxing] NCI, Genet & Microbiome Core, Lab Integrat Canc Immunol, Ctr Canc Res, Bethesda, MD 20892 USA; [Davar, Diwakar; DeBlasio, Richelle N.; Morrison, Robert M.; Chauvin, Joe-Marc; Ding, Quanquan; Zidi, Bochra; Lowin, Ava; Chakka, Saranya; Gao, Wentao; Pagliano, Ornella; Ernst, Scarlett J.; Rose, Amy; Zarour, Hassane M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Davar, Diwakar; DeBlasio, Richelle N.; Morrison, Robert M.; Chauvin, Joe-Marc; Ding, Quanquan; Zidi, Bochra; Lowin, Ava; Chakka, Saranya; Gao, Wentao; Pagliano, Ornella; Ernst, Scarlett J.; Rose, Amy; Zarour, Hassane M.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA 15260 USA; [Rodrigues, Richard R.; Yuan, Wuxing] Frederick Natl Lab Canc Res, Basic Sci Program, Frederick, MD USA; [Fang, Jennifer R.; Cole, Alicia M.; Balaji, Ascharya K.; Vetizou, Marie; Prescott, Stephanie M.; Fernandes, Miriam R.; Costa, Raquel G. F.; Salcedo, Rosalba; Bahadiroglu, Erol; Roy, Soumen; Trinchieri, Giorgio; Dzutsev, Amiran K.] NCI, Canc Immunobiol Sect, Lab Integrat Canc Immunol, Ctr Canc Res, Bethesda, MD 20892 USA; [Newman, Nolan K.; Morgun, Andrey] Oregon State Univ, Coll Pharm, Corvallis, OR 97331 USA; [Zarour, Hassane M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarour, HM (corresponding author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.; Zarour, HM (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA 15260 USA.; Trinchieri, G; Dzutsev, AK (corresponding author), NCI, Canc Immunobiol Sect, Lab Integrat Canc Immunol, Ctr Canc Res, Bethesda, MD 20892 USA.; Zarour, HM (corresponding author), Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA.	zarourhm@upmc.edu; trinchig@mail.nih.gov; amiran.dzutsev@nih.gov	zidi, Bochra/GQZ-1473-2022	Cole, Alicia/0000-0002-7792-2543; Fang, Jennifer/0000-0003-4930-4729; Balaji, Ascharya/0000-0003-1382-5864; Morrison, Robert/0000-0002-8421-8183	Intramural Research Program of the NIH, NCI, Center for Cancer Research; Melanoma Breakthrough Foundation Breakthrough Consortium; NIH/NCI [R01 CA228181, R01 CA222203]; James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research; Cancer Research Institute; NIH NCI Comprehensive Cancer Center Support Core grant [P30 CA047904]; University of Pittsburgh Center for Research Computing and Unified Flow Cytometry Core of the University of Pittsburgh's Department of Immunology	Intramural Research Program of the NIH, NCI, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Breakthrough Foundation Breakthrough Consortium; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research; Cancer Research Institute; NIH NCI Comprehensive Cancer Center Support Core grant; University of Pittsburgh Center for Research Computing and Unified Flow Cytometry Core of the University of Pittsburgh's Department of Immunology	We acknowledge all patients and families affected by metastatic melanoma. We acknowledge J. Wargo for providing unpublished metadata of the Houston melanoma patient cohort. This work was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research. D.D. is supported by the Melanoma Breakthrough Foundation Breakthrough Consortium. H.M.Z. is supported by the NIH/NCI (R01 CA228181 AND R01 CA222203) and the James W. and Frances G. McGlothlin Chair in Melanoma Immunotherapy Research. M.V. was supported by an Irvington postdoctoral fellowship from the Cancer Research Institute. Work of the University of Pittsburgh Medical Center HCC Microbiome Shared Facility and Cytometry Facility is supported by the NIH NCI Comprehensive Cancer Center Support Core grant (P30 CA047904). This research was supported in part by the University of Pittsburgh Center for Research Computing and Unified Flow Cytometry Core of the University of Pittsburgh's Department of Immunology through the resources provided.	Amir A, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00199-16; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Ascierto PA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0569-1; Asnicar F, 2021, NAT MED, V27, P321, DOI 10.1038/s41591-020-01183-8; Balomenou S, 2013, MOL MICROBIOL, V87, P867, DOI 10.1111/mmi.12137; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Benito M, 2004, BIOINFORMATICS, V20, P105, DOI 10.1093/bioinformatics/btg385; Bessman NJ, 2020, SCIENCE, V368, P186, DOI 10.1126/science.aau6481; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Brooks AW, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006842; Byrd AL, 2021, J EXP MED, V218, DOI 10.1084/jem.20200606; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Capone M, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0383-1; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Cortellini A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001361; Costea PI, 2018, NAT MICROBIOL, V3, P388, DOI 10.1038/s41564-018-0114-x; Das S, 2020, ONCOLOGIST, V25, P669, DOI 10.1634/theoncologist.2019-0637; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Davar D, 2018, J CLIN ONCOL, V36, P3450, DOI 10.1200/JCO.18.00632; Derosa L, 2020, EUR UROL, V78, P195, DOI 10.1016/j.eururo.2020.04.044; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Dwiyanto J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82311-3; Dzutsev A, 2015, EUR J IMMUNOL, V45, P17, DOI 10.1002/eji.201444972; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fan SQ, 2016, J BASIC MICROB, V56, P347, DOI 10.1002/jobm.201500582; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Freeman-Keller M, 2016, CLIN CANCER RES, V22, P886, DOI 10.1158/1078-0432.CCR-15-1136; Gevers D, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001377; Gharaibeh RZ, 2019, GUT, V68, P385, DOI 10.1136/gutjnl-2018-317220; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gorvitovskaia A, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0160-7; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haratani K, 2018, JAMA ONCOL, V4, P374, DOI 10.1001/jamaoncol.2017.2925; He Y, 2018, NAT MED, V24, P1532, DOI 10.1038/s41591-018-0164-x; Horvath A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48352-5; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kang DWD, 2019, PEERJ, V7, DOI 10.7717/peerj.7359; Kang DWD, 2015, PEERJ, V3, DOI 10.7717/peerj.1165; Kelsey CM, 2021, BRAIN BEHAV IMMUN, V91, P472, DOI 10.1016/j.bbi.2020.11.003; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Knight JM, 2014, SCI REP-UK, V4, DOI 10.1038/srep05453; Knights D, 2014, CELL HOST MICROBE, V16, P433, DOI 10.1016/j.chom.2014.09.013; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lazar C, 2013, BRIEF BIOINFORM, V14, P469, DOI 10.1093/bib/bbs037; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Li DH, 2016, METHODS, V102, P3, DOI 10.1016/j.ymeth.2016.02.020; Limeta A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140940; Luke NR, 2010, INFECT IMMUN, V78, P2017, DOI 10.1128/IAI.00016-10; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Matsuoka, 2020, BMC CANCER, V20; McDonald D, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00031-18; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; Ogluszka M, 2019, COMPUT METH PROG BIO, V177, P133, DOI 10.1016/j.cmpb.2019.05.023; Peters BA, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0672-4; Robert C, 2021, EUR J CANCER, V144, P182, DOI 10.1016/j.ejca.2020.11.010; Rodrigues RR, 2018, METHODS MOL BIOL, V1849, P227, DOI 10.1007/978-1-4939-8728-3_15; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shaikh FY, 2021, CLIN CANCER RES, V27, P2571, DOI 10.1158/1078-0432.CCR-20-4834; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Stacy A, 2021, CELL, V184, P615, DOI 10.1016/j.cell.2020.12.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suo A, 2020, ONCOLOGIST, V25, P438, DOI 10.1634/theoncologist.2019-0674; Tin Kam Ho, 1995, Proceedings of the Third International Conference on Document Analysis and Recognition, P278, DOI 10.1109/ICDAR.1995.598994; Valero C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20935-9; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Whitfield-Cargile CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13999-5; Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0; Wright DP, 2000, FEMS MICROBIOL LETT, V190, P73, DOI 10.1016/S0378-1097(00)00324-4; Yambartsev A, 2016, BIOL DIRECT, V11, DOI 10.1186/s13062-016-0155-0; Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504; Zhang RZ, 2021, BIOL DIRECT, V16, DOI 10.1186/s13062-020-00284-1	81	33	33	24	44	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					545	+		10.1038/s41591-022-01698-2	http://dx.doi.org/10.1038/s41591-022-01698-2		FEB 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35228752				2022-12-27	WOS:000762162700001
J	Van Kerkhove, MD				Van Kerkhove, Maria D.			COVID-19 in 2022: controlling the pandemic is within our grasp	NATURE MEDICINE			English	Editorial Material									[Van Kerkhove, Maria D.] WHO, Hlth Emergencies Programme, Geneva, Switzerland	World Health Organization	Van Kerkhove, MD (corresponding author), WHO, Hlth Emergencies Programme, Geneva, Switzerland.	vankerkhovem@who.int		Van Kerkhove, Maria/0000-0002-6135-0018					0	4	4	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2070	2070		10.1038/s41591-021-01616-y	http://dx.doi.org/10.1038/s41591-021-01616-y		DEC 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34907391	Bronze			2022-12-27	WOS:000730059200008
J	Vitanza, NA; Johnson, AJ; Wilson, AL; Brown, C; Yokoyama, JK; Kunkele, A; Chang, CA; Rawlings-Rhea, S; Huang, WJ; Seidel, K; Albert, CM; Pinto, N; Gust, J; Finn, LS; Ojemann, JG; Wright, J; Orentas, RJ; Baldwin, M; Gardner, RA; Jensen, MC; Park, JR				Vitanza, Nicholas A.; Johnson, Adam J.; Wilson, Ashley L.; Brown, Christopher; Yokoyama, Jason K.; Kunkele, Annette; Chang, Cindy A.; Rawlings-Rhea, Stephanie; Huang, Wenjun; Seidel, Kristy; Albert, Catherine M.; Pinto, Navin; Gust, Juliane; Finn, Laura S.; Ojemann, Jeffrey G.; Wright, Jason; Orentas, Rimas J.; Baldwin, Michael; Gardner, Rebecca A.; Jensen, Michael C.; Park, Julie R.			Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis	NATURE MEDICINE			English	Article							CHIMERIC ANTIGEN RECEPTOR; METASTATIC BREAST-CANCER; B-CELL; TRASTUZUMAB; EXPRESSION; HERCEPTIN; TRANSFORMATION; GLIOBLASTOMA; CHEMOTHERAPY; LYMPHOCYTES	Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective responses in adults with glioblastoma, but the feasibility and tolerability of this approach is yet to be evaluated for pediatric central nervous system (CNS) tumors. Here we show that engineering of a medium-length CAR spacer enhances the therapeutic efficacy of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR T cells in an orthotopic xenograft medulloblastoma model. We translated these findings into BrainChild-01 (NCT03500991), an ongoing phase 1 clinical trial at Seattle Children's evaluating repetitive locoregional dosing of these HER2-specific CAR T cells to children and young adults with recurrent/refractory CNS tumors, including diffuse midline glioma. Primary objectives are assessing feasibility, safety and tolerability; secondary objectives include assessing CAR T cell distribution and disease response. In the outpatient setting, patients receive infusions via CNS catheter into either the tumor cavity or the ventricular system. The initial three patients experienced no dose-limiting toxicity and exhibited clinical, as well as correlative laboratory, evidence of local CNS immune activation, including high concentrations of CXCL10 and CCL2 in the cerebrospinal fluid. This interim report supports the feasibility of generating HER2-specific CAR T cells for repeated dosing regimens and suggests that their repeated intra-CNS delivery might be well tolerated and activate a localized immune response in pediatric and young adult patients.	[Vitanza, Nicholas A.; Johnson, Adam J.; Wilson, Ashley L.; Yokoyama, Jason K.; Rawlings-Rhea, Stephanie; Huang, Wenjun; Orentas, Rimas J.; Baldwin, Michael; Gardner, Rebecca A.] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA 98101 USA; [Vitanza, Nicholas A.; Albert, Catherine M.; Pinto, Navin; Orentas, Rimas J.; Gardner, Rebecca A.; Jensen, Michael C.; Park, Julie R.] Univ Washington, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA 98195 USA; [Johnson, Adam J.; Wilson, Ashley L.; Brown, Christopher; Yokoyama, Jason K.; Rawlings-Rhea, Stephanie; Huang, Wenjun; Seidel, Kristy; Gardner, Rebecca A.; Jensen, Michael C.; Park, Julie R.] Seattle Childrens Therapeut, Seattle, WA USA; [Brown, Christopher] Seattle Childrens Res Inst, Therapeut Cell Prod Core, Seattle, WA USA; [Kunkele, Annette] Charite Univ Med Berlin, Dept Pediat Oncol & Hematol, Berlin, Germany; [Kunkele, Annette] Free Univ Berlin, Berlin, Germany; [Kunkele, Annette] Humboldt Univ, Berlin, Germany; [Kunkele, Annette] Berlin Inst Hlth, Berlin, Germany; [Kunkele, Annette] German Canc Consortium DKTK, Heidelberg, Germany; [Kunkele, Annette; Albert, Catherine M.; Pinto, Navin; Park, Julie R.] Seattle Childrens Res Inst, Ctr Clin & Translat Res, Seattle, WA USA; [Chang, Cindy A.] Seattle Childrens Res Inst, Off Anim Care, Seattle, WA USA; [Gust, Juliane] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Gust, Juliane] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USA; [Finn, Laura S.] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA; [Finn, Laura S.] Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA USA; [Ojemann, Jeffrey G.] Seattle Childrens Hosp, Dept Neurol Surg, Div Neurosurg, Seattle, WA USA; [Wright, Jason] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA; [Jensen, Michael C.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Helmholtz Association; German Cancer Research Center (DKFZ); Seattle Children's Hospital; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Vitanza, NA (corresponding author), Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA 98101 USA.; Vitanza, NA (corresponding author), Univ Washington, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA 98195 USA.	nicholas.vitanza@seattlechildrens.org	Park, Julie/HGC-0199-2022; HUANG, WENJUN/GXM-9167-2022	Johnson, Adam/0000-0002-9967-8959; Yokoyama, Jason/0000-0003-2520-8134; Kunkele, Annette/0000-0002-8406-5412; Wilson, Ashley/0000-0002-4440-001X	Seattle Run of Hope; Pediatric Brain Tumor Research Fund Guild of Seattle Children's Hospital; McKenna Claire Foundation; Unravel Pediatric Cancer; Team Cozzi Foundation; Love for Lucy; Julianna Sayler Foundation; Avery Huffman DIPG Foundation; Liv Like a Unicorn; ImmunoMomentum!; Amazon; DIPG All-In Initiative; St. Baldrick's Stand Up to Cancer (SU2C) Dream Team Translational Cancer Research Grants [SU2C-AACR-DT-27-17]; Alex's Lemonade Stand Foundation for Childhood Cancer; German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) [KU-2906/1-1]; National Center for Advancing Translational Sciences of the National Institutes of Health [U01TR002487]	Seattle Run of Hope; Pediatric Brain Tumor Research Fund Guild of Seattle Children's Hospital; McKenna Claire Foundation; Unravel Pediatric Cancer; Team Cozzi Foundation; Love for Lucy; Julianna Sayler Foundation; Avery Huffman DIPG Foundation; Liv Like a Unicorn; ImmunoMomentum!; Amazon; DIPG All-In Initiative; St. Baldrick's Stand Up to Cancer (SU2C) Dream Team Translational Cancer Research Grants; Alex's Lemonade Stand Foundation for Childhood Cancer; German Research Foundation (DFG, Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the children and families who bravely shoulder the burden of their disease and place their trust in Seattle Children's. We are indebted to our clinical research team, including H. Ullom, A. Thomsen, V. Weiss, K. Cilluffo, E. Stowe and G. Mun. We are grateful for the clinical expertise of our neuro-oncology team, including R. Geyer, J. Olson, S. Leary, N. Millard, A. Sato, E. Crotty, C. Hoeppner, S. Holtzclaw, S. Chaffee, A. Laurine, S. Stasi, B. Cole, F. Perez, M. Susun and W. Iwata. We thank J. Stevens, as well as the Seattle Children's Hospital's Department of Anatomic Pathology and Seattle Children's Tumor Bank, for assistance in tissue collection and research coordination, and C. Schubert for editorial assistance. We thank the Therapeutic Cell Production Core for their tireless efforts to manufacture infusion products and the Correlative Studies Lab for their assistance in research coordination and correlative sample processing. Funding: We are grateful for generous funding from the Seattle Run of Hope (N.A.V.), the Pediatric Brain Tumor Research Fund Guild of Seattle Children's Hospital (N.A.V.), the McKenna Claire Foundation (N.A.V.), Unravel Pediatric Cancer (N.A.V.), Team Cozzi Foundation (N.A.V.), Love for Lucy (N.A.V.), the Julianna Sayler Foundation (N.A.V.), the Avery Huffman DIPG Foundation (N.A.V.), Liv Like a Unicorn (N.A.V.), ImmunoMomentum! (N.A.V., N.P., M.C.J.), Amazon (N.A.V., M.C.J.), the DIPG All-In Initiative (N.A.V.) and St. Baldrick's Stand Up to Cancer (SU2C) Dream Team Translational Cancer Research Grants (SU2C-AACR-DT-27-17 to N.A.V., R.J.O., R.G., M.C.J. and J.R.P.). Stand Up to Cancer is a division of the Entertainment Industry Foundation, and research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. Funding was also provided by Alex's Lemonade Stand Foundation for Childhood Cancer (R.A.G.); by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft; KU-2906/1-1 to A.K.); and by the National Center for Advancing Translational Sciences of the National Institutes of Health (U01TR002487 to A.L.W., W.H., R.A.G. and J.R.P.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ahmed N, 2007, CANCER RES, V67, P5957, DOI 10.1158/0008-5472.CAN-06-4309; Ahmed N, 2017, JAMA ONCOL, V3, P1094, DOI 10.1001/jamaoncol.2017.0184; Akhavan D, 2019, IMMUNOL REV, V290, P60, DOI 10.1111/imr.12773; Andersch L, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6131-1; [Anonymous], 2014, R LANG ENV STAT COMP; Blaeschke F, 2018, CANCER IMMUNOL IMMUN, V67, P1053, DOI 10.1007/s00262-018-2155-7; Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332; Brown CE, 2018, MOL THER, V26, P31, DOI 10.1016/j.ymthe.2017.10.002; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brown CE, 2015, CLIN CANCER RES, V21, P4062, DOI 10.1158/1078-0432.CCR-15-0428; Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Choi BD, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.2.FOCUS17788; Devaud C, 2014, CANCER IMMUNOL IMMUN, V63, P869, DOI 10.1007/s00262-014-1581-4; Donovan LK, 2020, NAT MED, V26, P720, DOI 10.1038/s41591-020-0827-2; Erskine CL, 2012, JOVE-J VIS EXP, DOI 10.3791/3683; Fujita M, 2009, CANCER RES, V69, P1587, DOI 10.1158/0008-5472.CAN-08-2915; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; GILBERTSON RJ, 1995, BRIT J CANCER, V71, P473, DOI 10.1038/bjc.1995.96; Gong Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237646; Guedan S, 2019, MOL THER-METH CLIN D, V12, P145, DOI 10.1016/j.omtm.2018.12.009; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; Huang WS, 2015, J LEUKOCYTE BIOL, V97, P477, DOI 10.1189/jlb.1RI0614-293R; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Karin N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00976; Kunkele A, 2015, CANCER IMMUNOL RES, V3, P368, DOI 10.1158/2326-6066.CIR-14-0200; Kuhn NF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19833-3; Li XH, 2021, LEUKEMIA, V35, P506, DOI 10.1038/s41375-020-0874-1; Mineo JF, 2007, J NEURO-ONCOL, V85, P281, DOI 10.1007/s11060-007-9424-1; Nishimura F, 2006, CANCER RES, V66, P4478, DOI 10.1158/0008-5472.CAN-05-3825; Okada H, 2009, ANN NY ACAD SCI, V1174, P18, DOI 10.1111/j.1749-6632.2009.04932.x; Paiardini M, 2005, J IMMUNOL, V174, P2900, DOI 10.4049/jimmunol.174.5.2900; Pegram MD, 1999, SEMIN ONCOL, V26, P89; PELLOQUIN F, 1986, IN VITRO CELL DEV B, V22, P689; Pienkowski T, 2010, ANN ONCOL, V21, P917, DOI 10.1093/annonc/mdp353; Ravanpay Ali C, 2019, Oncotarget, V10, P7080, DOI 10.18632/oncotarget.27389; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Shen LX, 2019, ONCOL REP, V42, P1549, DOI 10.3892/or.2019.7263; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Theruvath J, 2020, NAT MED, V26, P712, DOI 10.1038/s41591-020-0821-8; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Wang XL, 2011, BLOOD, V118, P1255, DOI 10.1182/blood-2011-02-337360; Watanabe N, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1253656; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wilkins O, 2017, HUM GENE THER METHOD, V28, P61, DOI 10.1089/hgtb.2016.153; Zhang CC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv375; Zhang ZW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1711-1; Zhao YB, 2009, J IMMUNOL, V183, P5563, DOI 10.4049/jimmunol.0900447; Zhu XM, 2010, CANCER IMMUNOL IMMUN, V59, P1401, DOI 10.1007/s00262-010-0876-3	52	47	48	5	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1544	+		10.1038/s41591-021-01404-8	http://dx.doi.org/10.1038/s41591-021-01404-8		JUL 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34253928				2022-12-27	WOS:000672295500001
J	Wang, L; Sievert, D; Clark, AE; Lee, S; Federman, H; Gastfriend, BD; Shusta, EV; Palecek, SP; Carlin, AF; Gleeson, JG				Wang, Lu; Sievert, David; Clark, Alex E.; Lee, Sangmoon; Federman, Hannah; Gastfriend, Benjamin D.; Shusta, Eric V.; Palecek, Sean P.; Carlin, Aaron F.; Gleeson, Joseph G.			A human three-dimensional neural-perivascular 'assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology	NATURE MEDICINE			English	Article							CHOROID-PLEXUS; BRAIN; PERICYTES; CELLS	Findings from a pericyte-containing cortical organoid model suggests that pericytes provide an infection portal for SARS-CoV-2 and can serve as a viral amplification hub within neural tissue. Clinical evidence suggests the central nervous system is frequently impacted by SARS-CoV-2 infection, either directly or indirectly, although the mechanisms are unclear. Pericytes are perivascular cells within the brain that are proposed as SARS-CoV-2 infection points. Here we show that pericyte-like cells (PLCs), when integrated into a cortical organoid, are capable of infection with authentic SARS-CoV-2. Before infection, PLCs elicited astrocytic maturation and production of basement membrane components, features attributed to pericyte functions in vivo. While traditional cortical organoids showed little evidence of infection, PLCs within cortical organoids served as viral 'replication hubs', with virus spreading to astrocytes and mediating inflammatory type I interferon transcriptional responses. Therefore, PLC-containing cortical organoids (PCCOs) represent a new 'assembloid' model that supports astrocytic maturation as well as SARS-CoV-2 entry and replication in neural tissue; thus, PCCOs serve as an experimental model for neural infection.	[Wang, Lu; Sievert, David; Lee, Sangmoon; Federman, Hannah; Gleeson, Joseph G.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Wang, Lu; Sievert, David; Lee, Sangmoon; Federman, Hannah; Gleeson, Joseph G.] Rady Childrens Hosp, Rady Childrens Inst Genom Med, San Diego, CA 92123 USA; [Clark, Alex E.; Carlin, Aaron F.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Federman, Hannah] Rutgers State Univ, New Jersey Med Sch, Ctr Immun & Inflammat, Newark, NJ USA; [Gastfriend, Benjamin D.; Shusta, Eric V.; Palecek, Sean P.] Univ Wisconsin, Dept Chem & Biol Engn, Madison, WI USA; [Shusta, Eric V.] Univ Wisconsin, Dept Neurol Surg, Madison, WI USA; [Gleeson, Joseph G.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Diego	Gleeson, JG (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.; Gleeson, JG (corresponding author), Rady Childrens Hosp, Rady Childrens Inst Genom Med, San Diego, CA 92123 USA.; Carlin, AF (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA.; Gleeson, JG (corresponding author), Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA.	acarlin@health.ucsd.edu; jogleeson@health.ucsd.edu			BEI Resources Repository, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH): SARS-Related Coronavirus 2, Isolate USA [52281]; Rady Children's Hospital Neuroscience Endowment [R01NS106387]; Career Award for Medical Scientists from the Burroughs Wellcome Fund [K08Al130381]; Brain & Behavior Research Foundation NARSAD Young Investigator Grant; NIH [NS103844]; NIH Biotechnology Training Program [T32GM008349]; National Science Foundation Graduate Research Fellowship Program [1747503]; UCSD IGM Core Facility grant [P30NS047101, 1S10OD026929]	BEI Resources Repository, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH): SARS-Related Coronavirus 2, Isolate USA; Rady Children's Hospital Neuroscience Endowment; Career Award for Medical Scientists from the Burroughs Wellcome Fund(Burroughs Wellcome Fund); Brain & Behavior Research Foundation NARSAD Young Investigator Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Biotechnology Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation Graduate Research Fellowship Program(National Science Foundation (NSF)); UCSD IGM Core Facility grant	We thank R. Ellis, J. Esko, D. Chen and S. Shah for feedback and F. Gage and T. Rogers for the pLV-EGFP-puro and pcDNA3.1-hACE2 plasmids. We thank the UCSD Institute for Genomic Medicine (IGM) for sequencing support and the UCSD Proteomic Core for mass spectrometry support. The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through the BEI Resources Repository, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH): SARS-Related Coronavirus 2, Isolate USA-WA1/2020, no. 52281. The work was supported by the Rady Children's Hospital Neuroscience Endowment and grant no. R01NS106387 to J.G.G., a Career Award for Medical Scientists from the Burroughs Wellcome Fund and grant no. K08Al130381 to A.F.C., a Brain & Behavior Research Foundation NARSAD Young Investigator Grant to L.W., NIH NS103844 to E.V.S. and S.P.P., NIH Biotechnology Training Program grant T32GM008349 and National Science Foundation Graduate Research Fellowship Program grant no. 1747503 to B.D.G. and UCSD Neuroscience Microscopy Core Facility grant P30NS047101 and UCSD IGM Core Facility grant 1S10OD026929.	Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Barbar L, 2020, NEURON, V107, P436, DOI 10.1016/j.neuron.2020.05.014; Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chavkin NW, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00042; Crouch EE, 2015, J NEUROSCI, V35, P4528, DOI 10.1523/JNEUROSCI.1188-14.2015; Farahani RM, 2019, J COMP NEUROL, V527, P780, DOI 10.1002/cne.24565; Ghobrial M., HUMAN BRAIN VASCULAT, DOI 10.10.334664; Guilbert A, 2020, J CLIN EXP NEUROPSYC, V42, P975, DOI 10.1080/13803395.2020.1830033; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; He L., 2020, PERICYTE SPECIFIC VA, DOI [10.1101/2020.05.11.088500, DOI 10.1101/2020.05.11.088500, 10.1101/2020.05.11.088500., 10.1101/2020.05.11.088500v2]; Helms J, 2020, NEW ENGL J MED, V382, pe110; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Jacob F, 2020, CELL STEM CELL, V27, P937, DOI 10.1016/j.stem.2020.09.016; Jia CH, 2019, EXP NEUROL, V312, P20, DOI 10.1016/j.expneurol.2018.11.002; Kadoshima T, 2013, P NATL ACAD SCI USA, V110, P20284, DOI 10.1073/pnas.1315710110; Kantonen J, 2020, BRAIN PATHOL, V30, P1012, DOI 10.1111/bpa.12889; Khaddaj-Mallat R., SARS COV 2 SPIKE PRO, DOI [10.1101/2021.04.30.442194(2021, DOI 10.1101/2021.04.30.442194(2021]; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pellegrini L, 2020, CELL STEM CELL, V27, P951, DOI 10.1016/j.stem.2020.10.001; Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5; Perrin P, 2021, EUR J NEUROL, V28, P248, DOI 10.1111/ene.14491; Ramani A, 2020, EMBO J, V39, DOI 10.15252/embj.2020106230; Sloan SA, 2017, NEURON, V95, P779, DOI 10.1016/j.neuron.2017.07.035; Solomon T, 2021, NAT REV NEUROL, V17, P65, DOI 10.1038/s41582-020-00453-w; Song ER, 2021, J EXP MED, V218, DOI 10.1084/jem.20202135; Stebbins MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau7375; Susaki EA, 2015, NAT PROTOC, V10, P1709, DOI 10.1038/nprot.2015.085; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; Vogt N, 2021, NAT METHODS, V18, P27, DOI 10.1038/s41592-020-01025-y; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17454-4; Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031; Yang AC, 2021, NATURE, V595, P565, DOI 10.1038/s41586-021-03710-0; Ye MX, 2020, BRAIN BEHAV IMMUN, V88, P945, DOI [10.1016/j.bbi.2020.04.017, 10.1016/J.bbi.2020.04.017]; Zhang BZ, 2020, CELL RES, V30, P928, DOI 10.1038/s41422-020-0390-x; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	44	39	39	3	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1600	+		10.1038/s41591-021-01443-1	http://dx.doi.org/10.1038/s41591-021-01443-1		JUL 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34244682	Green Accepted, Bronze, Green Published			2022-12-27	WOS:000671528900002
J	Sims, EK; Carr, ALJ; Oram, RA; DiMeglio, LA; Evans-Molina, C				Sims, Emily K.; Carr, Alice L. J.; Oram, Richard A.; DiMeglio, Linda A.; Evans-Molina, Carmella			100 years of insulin: celebrating the past, present and future of diabetes therapy	NATURE MEDICINE			English	Review							BETA-CELL FUNCTION; HL-A ANTIGENS; ENDOPLASMIC-RETICULUM STRESS; EMBRYONIC STEM-CELLS; C-PEPTIDE RATIO; ISLET AUTOANTIBODIES; GLUCOSE-TOLERANCE; GLYCEMIC CONTROL; HUMAN THYMUS; IN-VITRO	Decades of scientific accomplishment have transformed diabetes treatment; this Review describes key milestones in our understanding of the insulin molecule and looks to the future of insulin therapy. The year 2021 marks the centennial of Banting and Best's landmark description of the discovery of insulin. This discovery and insulin's rapid clinical deployment effectively transformed type 1 diabetes from a fatal diagnosis into a medically manageable chronic condition. In this Review, we describe key accomplishments leading to and building on this momentous occasion in medical history, including advancements in our understanding of the role of insulin in diabetes pathophysiology, the molecular characterization of insulin and the clinical use of insulin. Achievements are also viewed through the lens of patients impacted by insulin therapy and the evolution of insulin pharmacokinetics and delivery over the past 100 years. Finally, we reflect on the future of insulin therapy and diabetes treatment, as well as challenges to be addressed moving forward, so that the full potential of this transformative discovery may be realized.	[Sims, Emily K.; DiMeglio, Linda A.; Evans-Molina, Carmella] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Sims, Emily K.; DiMeglio, Linda A.; Evans-Molina, Carmella] Indiana Univ Sch Med, Ctr Diabet & Metab, Indianapolis, IN 46202 USA; [Sims, Emily K.; DiMeglio, Linda A.; Evans-Molina, Carmella] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Carr, Alice L. J.; Oram, Richard A.] Univ Exeter, Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England; [Oram, Richard A.] Royal Devon & Exeter NHS Fdn Trust, Acad Kidney Unit, Exeter, Devon, England; [Evans-Molina, Carmella] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Evans-Molina, Carmella] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Evans-Molina, Carmella] Roudebush VA Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Exeter; University of Exeter; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Evans-Molina, C (corresponding author), Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.; Evans-Molina, C (corresponding author), Indiana Univ Sch Med, Ctr Diabet & Metab, Indianapolis, IN 46202 USA.; Evans-Molina, C (corresponding author), Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.; Evans-Molina, C (corresponding author), Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.; Evans-Molina, C (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Evans-Molina, C (corresponding author), Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.	cevansmo@iu.edu		Carr, Alice/0000-0003-0704-8843; Evans-Molina, Carmella/0000-0001-7764-8663				ADAMS MJ, 1969, NATURE, V224, P491, DOI 10.1038/224491a0; Agulnick AD, 2015, STEM CELL TRANSL MED, V4, P1214, DOI 10.5966/sctm.2015-0079; Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2; Al-Tabakha MM, 2015, J CONTROL RELEASE, V215, P25, DOI 10.1016/j.jconrel.2015.07.025; ALBISSER AM, 1974, DIABETES, V23, P389, DOI 10.2337/diab.23.5.389; ALLAN FN, 1953, DIABETES, V2, P74, DOI 10.2337/diab.2.1.74; ANDERSON JR, 1957, LANCET, V1, P1123; Banting FG, 1922, CAN MED ASSOC J, V7, P141; Battaglia M, 2020, DIABETES CARE, V43, P5, DOI 10.2337/dc19-0880; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Beran D, 2021, DIABETOLOGIA, V64, P954, DOI 10.1007/s00125-020-05375-2; Berg P, 2014, P NATL ACAD SCI USA, V111, P883, DOI 10.1073/pnas.1323264111; BERGMAN RN, 1981, J CLIN INVEST, V68, P1456, DOI 10.1172/JCI110398; Biester T, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0931-y; BLISS M, 1993, DIABETES CARE, V16, P4, DOI 10.2337/diacare.16.3.4; Bliss M., 1982, DISCOVERY INSULIN, DOI [10.1007/978-1-349-09612-1, DOI 10.1007/978-1-349-09612-1]; BORNSTEIN J, 1951, BRIT MED J, V1, P732, DOI 10.1136/bmj.1.4709.732; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; BOTTAZZO GF, 1986, DIABETIC MED, V3, P119, DOI 10.1111/j.1464-5491.1986.tb00722.x; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Butler AE, 2016, J CLIN ENDOCR METAB, V101, P523, DOI 10.1210/jc.2015-3566; Campbell-Thompson M, 2012, DIABETES-METAB RES, V28, P608, DOI 10.1002/dmrr.2316; Cefalu WT, 2018, DIABETES CARE, V41, P1299, DOI 10.2337/dci18-0019; CHANCE RE, 1968, SCIENCE, V161, P165, DOI 10.1126/science.161.3837.165; Clothier C, 2019, J DIABETES NURS, V23, P1; Crowfoot D, 1935, NATURE, V135, P591, DOI 10.1038/135591a0; CUDWORTH AG, 1974, LANCET, V2, P1153; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; de Brachene AC, 2018, DIABETOLOGIA, V61, P636, DOI 10.1007/s00125-017-4536-4; De Meyer J., 1909, ARCH PHYSIOL-PARIS, V7, P96; De Meyts P, 2004, BIOESSAYS, V26, P1351, DOI 10.1002/bies.20151; Deacon CF, 2020, NAT REV ENDOCRINOL, V16, P642, DOI 10.1038/s41574-020-0399-8; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dennis JM, 2019, LANCET DIABETES ENDO, V7, P442, DOI 10.1016/S2213-8587(19)30087-7; Dobson M, 1776, MED OBS INQU, V5, P298; Duggirala R, 1999, AM J HUM GENET, V64, P1127, DOI 10.1086/302316; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Eizirik DL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002552; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Evans-Molina C, 2013, DIABETES OBES METAB, V15, P159, DOI 10.1111/dom.12163; Evans-Molina C, 2009, CURR OPIN ORGAN TRAN, V14, P56, DOI 10.1097/MOT.0b013e3283186fc1; Falta W., 1931, KLIN WOCHENSCHR, V10, P438, DOI [DOI 10.1007/BF01736348, 10.1007/BF01736348]; Ferrat LA, 2020, NAT MED, V26, P1247, DOI 10.1038/s41591-020-0930-4; FEUTREN G, 1986, LANCET, V2, P119; Floyel T, 2014, P NATL ACAD SCI USA, V111, P10305, DOI 10.1073/pnas.1402571111; Fraser L., 2016, CLONING INSULIN; Gale EAM, 2001, DIABETES, V50, P217, DOI 10.2337/diabetes.50.2.217; Garin I, 2010, P NATL ACAD SCI USA, V107, P3105, DOI 10.1073/pnas.0910533107; GEMMILL CL, 1972, B NEW YORK ACAD MED, V48, P1033; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; Gill G., PRACT DIABETES INT, V20, P103; GOEDDEL DV, 1979, P NATL ACAD SCI USA, V76, P106, DOI 10.1073/pnas.76.1.106; GOET J P, 1953, Diabetes, V2, P322; Goldfine AB, 2003, P NATL ACAD SCI USA, V100, P2724, DOI 10.1073/pnas.0438009100; GOTTLIEB MS, 1968, DIABETES, V17, P693, DOI 10.2337/diab.17.11.693; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Guo SL, 2013, J CLIN INVEST, V123, P3305, DOI 10.1172/JCI65390; Haidar A, 2015, LANCET DIABETES ENDO, V3, P17, DOI 10.1016/S2213-8587(14)70226-8; HARRIS M, 1979, DIABETES, V28, P1039; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; HEYDINGER DK, 1974, DIABETES, V23, P579, DOI 10.2337/diab.23.7.579; Himsworth HP, 2013, INT J EPIDEMIOL, V42, P1594, DOI 10.1093/ije/dyt203; Himsworth HP, 1936, LANCET, V1, P127; Hirsch IB, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa015; Hogrebe NJ, 2020, NAT BIOTECHNOL, V38, P460, DOI 10.1038/s41587-020-0430-6; Howard JAK, 2003, NAT REV MOL CELL BIO, V4, P891, DOI 10.1038/nrm1243; Insel RA, 2015, DIABETES CARE, V38, P1964, DOI 10.2337/dc15-1419; Institute of Medicine, 1995, SOURCES MED TECHNOLO; IRVINE WJ, 1970, LANCET, V2, P163; KADISH AH, 1964, AM J MED ELECTRON, V3, P82; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; Katzung B.G., 2012, PHARMACOL TOXICOL; Kesavadev J, 2020, DIABETES THER, V11, P1251, DOI 10.1007/s13300-020-00831-z; Kesavadev J, 2020, DIABETES THER, V11, P1217, DOI 10.1007/s13300-020-00823-z; Kovatchev B, 2019, TRENDS ENDOCRIN MET, V30, P432, DOI 10.1016/j.tem.2019.04.008; Krischer JP, 2015, DIABETOLOGIA, V58, P980, DOI 10.1007/s00125-015-3514-y; Kurtzhals P, 2011, DIABETOLOGIA, V54, pS426; LACY PE, 1965, DIABETES, V14, P634, DOI 10.2337/diab.14.10.634; Laguesse E., 1893, CR SOC BIOL, V45, P819; Lancereaux E., 1880, UNION MED, V29, P161; Lavaux JP., 1973, INT C SER, V316, P40; LECOMPTE PM, 1958, ARCH PATHOL, V66, P450; Lee H, 2020, CELL METAB, V31, P822, DOI 10.1016/j.cmet.2020.03.002; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; Lindsten J., 2001, NOBEL PRIZE; Liu M, 2012, DIABETES, V61, P828, DOI 10.2337/db11-0878; Loopstra-Masters RC, 2011, DIABETOLOGIA, V54, P3047, DOI 10.1007/s00125-011-2322-2; Maclean H, 1926, Postgrad Med J, V1, P73; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; MAKINO S, 1985, EXP ANIM TOKYO, V34, P425, DOI 10.1538/expanim1978.34.4_425; Marroqui L, 2017, DIABETOLOGIA, V60, P656, DOI 10.1007/s00125-016-4201-3; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McCarthy MI, 2010, NEW ENGL J MED, V363, P2339, DOI 10.1056/NEJMra0906948; Morgan NG, 2018, DIABETOLOGIA, V61, P2499, DOI 10.1007/s00125-018-4731-y; MURRAY I, 1953, BRIT MED J, V2, P1023, DOI 10.1136/bmj.2.4844.1023; Nair GG, 2019, NAT CELL BIOL, V21, P263, DOI 10.1038/s41556-018-0271-4; NAKHOODA AF, 1978, DIABETOLOGIA, V14, P199, DOI 10.1007/BF00429781; NERUP J, 1974, P ROY SOC MED, V67, P506, DOI 10.1177/00359157740676P135; NERUP J, 1974, LANCET, V2, P864; Oleck Jacob, 2016, Diabetes Spectr, V29, P180, DOI 10.2337/diaspect.29.3.180; Ovalle F, 2018, CURR MED RES OPIN, V34, P1029, DOI 10.1080/03007995.2017.1409426; Padmore E, 2009, J DIABETES NURS, V10, P366; Pieber TR, 2000, DIABETES CARE, V23, P157, DOI 10.2337/diacare.23.2.157; Pincus G, 1934, AM J MED SCI, V188, P116, DOI 10.1097/00000441-193407000-00015; Polonsky KS, 2012, NEW ENGL J MED, V367, P1332, DOI 10.1056/NEJMra1110560; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; REAVEN GM, 1983, AM J MED, V75, P8, DOI 10.1016/0002-9343(83)90248-6; Rege NK, 2020, P NATL ACAD SCI USA, V117, P29618, DOI 10.1073/pnas.2010908117; Renold A. E., 1964, CIBA FDN S AETIOLOGY, V15, P122; Rezania A, 2014, NAT BIOTECHNOL, V32, P1121, DOI 10.1038/nbt.3033; Rieg T, 2018, DIABETOLOGIA, V61, P2079, DOI 10.1007/s00125-018-4654-7; ROITT IM, 1956, LANCET, V271, P820; Russell SJ, 2014, NEW ENGL J MED, V371, P313, DOI 10.1056/NEJMoa1314474; RYLE AP, 1955, BIOCHEM J, V60, P541, DOI 10.1042/bj0600541; SAAD MF, 1989, LANCET, V1, P1356; SAKULA A, 1988, J ROY SOC MED, V81, P414, DOI 10.1177/014107688808100718; SANGER F, 1953, BIOCHEM J, V53, P366, DOI 10.1042/bj0530366; SANGER F, 1951, BIOCHEM J, V49, P481, DOI 10.1042/bj0490481; SANGER F, 1951, BIOCHEM J, V49, P463, DOI 10.1042/bj0490463; SANGER F, 1953, BIOCHEM J, V53, P353, DOI 10.1042/bj0530353; SANGER F, 1959, SCIENCE, V129, P1340, DOI 10.1126/science.129.3359.1340; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sharpey-Schafer E. A., 1914, INTRO STUDY ENDOCRIN; SHEN SW, 1970, J CLIN INVEST, V49, P2151, DOI 10.1172/JCI106433; SHOELSON S, 1983, NATURE, V302, P540, DOI 10.1038/302540a0; Simeone JC, 2020, J MANAG CARE SPEC PH, V26, P1399, DOI 10.18553/jmcp.2020.26.11.1399; Sims EK, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc8980; Sims EK, 2016, DIABETES CARE, V39, P1519, DOI 10.2337/dc15-2849; SINGAL DP, 1973, DIABETES, V22, P429, DOI 10.2337/diab.22.6.429; Skyler JS, 2002, NEW ENGL J MED, V346, P1685; STEINER DF, 1967, P NATL ACAD SCI USA, V57, P473, DOI 10.1073/pnas.57.2.473; Steiner DF, 2011, J BIOL CHEM, V286, P17399, DOI 10.1074/jbc.X111.244764; STILLER CR, 1984, SCIENCE, V223, P1362, DOI 10.1126/science.6367043; Stoy J, 2007, P NATL ACAD SCI USA, V104, P15040, DOI 10.1073/pnas.0707291104; Tabak AG, 2009, LANCET, V373, P2215, DOI 10.1016/S0140-6736(09)60619-X; TATTERSALL RB, 1972, LANCET, V2, P1120; Thorsby E, 2009, TISSUE ANTIGENS, V74, P101, DOI 10.1111/j.1399-0039.2009.01291.x; Tibaldi JM, 2014, AM J MED, V127, pS25, DOI 10.1016/j.amjmed.2014.07.005; Trico D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124912; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Udler MS, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002654; UNGAR B, 1967, LANCET, V2, P77; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; US Food and Drug Administration, 2005, LEV INS DET RDNA OR; Utzschneider KM, 2009, DIABETES CARE, V32, P335, DOI 10.2337/dc08-1478; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; von Mering J., 1890, ARCH EXP PATHOL PH, V26, P371, DOI DOI 10.1007/BF01831214; Wild SH, 2013, INT J EPIDEMIOL, V42, P1600, DOI 10.1093/ije/dyt201; Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183; WITEBSKY E, 1957, JAMA-J AM MED ASSOC, V164, P1439, DOI 10.1001/jama.1957.02980130015004; WRENSHALL GA, 1952, DIABETES, V1, P87, DOI 10.2337/diab.1.2.87; YALOW RS, 1960, J CLIN INVEST, V39, P1157, DOI 10.1172/JCI104130; Ziegler AG, 2013, JAMA-J AM MED ASSOC, V309, P2473, DOI 10.1001/jama.2013.6285; Ziegler AG, 2020, JAMA-J AM MED ASSOC, V323, P339, DOI 10.1001/jama.2019.21565	156	26	29	14	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1154	1164		10.1038/s41591-021-01418-2	http://dx.doi.org/10.1038/s41591-021-01418-2			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34267380	Green Accepted			2022-12-27	WOS:000674414000017
J	Cesana, D; Calabria, A; Rudilosso, L; Gallina, P; Benedicenti, F; Spinozzi, G; Schiroli, G; Magnani, A; Acquati, S; Fumagalli, F; Calbi, V; Witzel, M; Bushman, FD; Cantore, A; Genovese, P; Klein, C; Fischer, A; Cavazzana, M; Six, E; Aiuti, A; Naldini, L; Montini, E				Cesana, Daniela; Calabria, Andrea; Rudilosso, Laura; Gallina, Pierangela; Benedicenti, Fabrizio; Spinozzi, Giulio; Schiroli, Giulia; Magnani, Alessandra; Acquati, Serena; Fumagalli, Francesca; Calbi, Valeria; Witzel, Maximilian; Bushman, Frederic D.; Cantore, Alessio; Genovese, Pietro; Klein, Christoph; Fischer, Alain; Cavazzana, Marina; Six, Emmanuelle; Aiuti, Alessandro; Naldini, Luigi; Montini, Eugenio			Retrieval of vector integration sites from cell-free DNA	NATURE MEDICINE			English	Article							GENE-THERAPY; HUMAN HEMATOPOIESIS; NUCLEIC-ACIDS; STEM-CELLS; LIVER; ACTIVATION; DYNAMICS; TRACKING; MODELS	A new approach called liquid biopsy integration site sequencing enables monitoring of genetically modified cells in solid tissues of patients receiving gene therapy. Gene therapy (GT) has rapidly attracted renewed interest as a treatment for otherwise incurable diseases, with several GT products already on the market and many more entering clinical testing for selected indications. Clonal tracking techniques based on vector integration enable monitoring of the fate of engineered cells in the blood of patients receiving GT and allow assessment of the safety and efficacy of these procedures. However, owing to the limited number of cells that can be tested and the impracticality of studying cells residing in peripheral organs without performing invasive biopsies, this approach provides only a partial snapshot of the clonal repertoire and dynamics of genetically modified cells and reduces the predictive power as a safety readout. In this study, we developed liquid biopsy integration site sequencing, or LiBIS-seq, a polymerase chain reaction technique optimized to quantitatively retrieve vector integration sites from cell-free DNA released into the bloodstream by dying cells residing in several tissues. This approach enabled longitudinal monitoring of in vivo liver-directed GT and clonal tracking in patients receiving hematopoietic stem cell GT, improving our understanding of the clonal composition and turnover of genetically modified cells in solid tissues and, in contrast to conventional analyses based only on circulating blood cells, enabling earlier detection of vector-marked clones that are aberrantly expanding in peripheral tissues.	[Cesana, Daniela; Calabria, Andrea; Rudilosso, Laura; Gallina, Pierangela; Benedicenti, Fabrizio; Spinozzi, Giulio; Schiroli, Giulia; Acquati, Serena; Fumagalli, Francesca; Calbi, Valeria; Cantore, Alessio; Genovese, Pietro; Aiuti, Alessandro; Naldini, Luigi; Montini, Eugenio] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy; [Cesana, Daniela; Calabria, Andrea; Rudilosso, Laura; Gallina, Pierangela; Benedicenti, Fabrizio; Spinozzi, Giulio; Schiroli, Giulia; Acquati, Serena; Fumagalli, Francesca; Calbi, Valeria; Cantore, Alessio; Genovese, Pietro; Aiuti, Alessandro; Naldini, Luigi; Montini, Eugenio] Ist Sci San Raffaele, IRCCS, Milan, Italy; [Magnani, Alessandra; Fischer, Alain; Cavazzana, Marina; Six, Emmanuelle] INSERM, Lab Human Lymphohematopoiesis, Paris, France; [Witzel, Maximilian; Klein, Christoph] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Munich, Germany; [Bushman, Frederic D.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Klein, Christoph] Ludwig Maximilians Univ Munchen, Gene Ctr, Munich, Germany; [Genovese, Pietro] Harvard Med Sch, Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA 02115 USA	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Munich; University of Pennsylvania; Pennsylvania Medicine; University of Munich; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Montini, E (corresponding author), Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy.; Montini, E (corresponding author), Ist Sci San Raffaele, IRCCS, Milan, Italy.	montini.eugenio@hsr.it	Spinozzi, Giulio/T-8085-2019; Montini, Eugenio/L-1152-2016; Fumagalli, Francesca/J-8697-2018; Genovese, Pietro/H-3710-2018; Cantore, Alessio/O-7193-2014; Six, Emmanuelle/H-7891-2017	Spinozzi, Giulio/0000-0002-4220-2474; Montini, Eugenio/0000-0003-1771-6067; Fumagalli, Francesca/0000-0001-7476-4087; Calabria, Andrea/0000-0003-3515-3384; Genovese, Pietro/0000-0001-9507-9003; Cantore, Alessio/0000-0002-9741-997X; Six, Emmanuelle/0000-0001-7806-0968; Cesana, Daniela/0000-0001-6366-4224	Telethon Foundation [TGT16B01, TGT16B03]; Italian Ministry of Health [GR-2016-02363681]	Telethon Foundation(Fondazione Telethon); Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by Telethon Foundation TGT16B01 and TGT16B03 to E.M. and Giovani Ricercatori Grant 2013 from the Italian Ministry of Health to A. Calabria and D.C. (GR-2016-02363681). We are grateful to all members of the Montini lab, especially A. Albertini and S. Esposito, for technical help and to L. Albano for support on the X-SCID mouse model of HSC GT. We are also grateful for the work of J. Everett and A. Roche Doto from the Bushman lab. Elements of Fig. 4 were obtained from Servier Medical Art (https://smart.servier.com), which is licensed under a Creative Commons Attribution 3.0 Unported License, and from Vecteezy (https://www.vecteezy.com).	Abstract_753, 2017, MOL THER, V25, P1; Adair JE, 2020, MOL THER-METH CLIN D, V17, P796, DOI 10.1016/j.omtm.2020.03.021; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Ballabio A, 2009, BBA-MOL CELL RES, V1793, P684, DOI 10.1016/j.bbamcr.2008.12.001; Benten D, 2005, HEPATOLOGY, V42, P140, DOI 10.1002/hep.20746; Berry CC, 2012, BIOINFORMATICS, V28, P755, DOI 10.1093/bioinformatics/bts004; Bianconi E, 2013, ANN HUM BIOL, V40, P463, DOI 10.3109/03014460.2013.807878; Biasco L, 2016, CELL STEM CELL, V19, P107, DOI 10.1016/j.stem.2016.04.016; Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158; Biffi A, 2011, BLOOD, V117, P5332, DOI 10.1182/blood-2010-09-306761; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Butt AN, 2008, ANN NY ACAD SCI, V1137, P236, DOI 10.1196/annals.1448.002; Cantore A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1405; Cavazzana M, 2019, NAT REV DRUG DISCOV, V18, P447, DOI 10.1038/s41573-019-0020-9; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; Cesana D, 2012, J CLIN INVEST, V122, P1667, DOI 10.1172/JCI62189; Chao A, 2001, STAT MED, V20, P3123, DOI 10.1002/sim.996.abs; CHAO A, 1987, BIOMETRICS, V43, P783, DOI 10.2307/2531532; Cicalese MP, 2015, HUM GENE THER, V26, P210, DOI 10.1089/hum.2015.047; Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Duncan AW, 2009, GASTROENTEROLOGY, V137, P466, DOI 10.1053/j.gastro.2009.05.044; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Firouzi S, 2014, GENOME MED, V6, DOI 10.1186/gm568; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Gillet NA, 2011, BLOOD, V117, P3113, DOI 10.1182/blood-2010-10-312926; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164; Haegeman B, 2013, ISME J, V7, P1092, DOI 10.1038/ismej.2013.10; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Kopp JL, 2016, NAT CELL BIOL, V18, P238, DOI 10.1038/ncb3309; Lusic M, 2017, NAT REV MICROBIOL, V15, P69, DOI 10.1038/nrmicro.2016.162; Marktel S, 2019, NAT MED, V25, P234, DOI 10.1038/s41591-018-0301-6; Meddeb R, 2019, CLIN CHEM, V65, P623, DOI 10.1373/clinchem.2018.298323; Milani M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7325; Montini E, 2009, J CLIN INVEST, V119, P964, DOI 10.1172/JCI37630; Moss J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07466-6; Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818; Nienhuis AW, 2017, MOL THER, V25, P1163, DOI 10.1016/j.ymthe.2017.03.033; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Peled M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71357-4; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Scala S, 2018, NAT MED, V24, P1683, DOI 10.1038/s41591-018-0195-3; Schiroli G, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0820; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Sessa M, 2016, LANCET, V388, P476, DOI 10.1016/S0140-6736(16)30374-9; Simonsen AT, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5063-5; Spinozzi G, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1937-9; Stanger BZ, 2015, ANNU REV PHYSIOL, V77, P179, DOI 10.1146/annurev-physiol-021113-170255; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Su Y, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6562-8; Tissot C, 2015, EUR RESPIR J, V46, P1773, DOI 10.1183/13993003.00676-2015; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Wang GP, 2010, BLOOD, V115, P4356, DOI 10.1182/blood-2009-12-257352; Wells DW, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-06924-0; Wells DW, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6647-4	62	10	10	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1458	+		10.1038/s41591-021-01389-4	http://dx.doi.org/10.1038/s41591-021-01389-4		JUN 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34140705				2022-12-27	WOS:000662941700004
J	Tatonetti, NP; Elhadad, N				Tatonetti, Nicholas P.; Elhadad, Noemie			Fine-scale genetic ancestry as a potential new tool for precision medicine	NATURE MEDICINE			English	Editorial Material									[Tatonetti, Nicholas P.; Elhadad, Noemie] Columbia Univ, Dept Biomed Informat, New York, NY 10027 USA	Columbia University	Tatonetti, NP; Elhadad, N (corresponding author), Columbia Univ, Dept Biomed Informat, New York, NY 10027 USA.	nick.tatonetti@columbia.edu; noemie.elhadad@columbia.edu		Tatonetti, Nicholas/0000-0002-2700-2597				Belbin GM, 2021, CELL, V184, P2068, DOI 10.1016/j.cell.2021.03.034; Denny JC, 2021, CELL, V184, P1415, DOI 10.1016/j.cell.2021.01.015; Hripcsak G, 2013, J AM MED INFORM ASSN, V20, P117, DOI 10.1136/amiajnl-2012-001145; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x	4	2	2	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1152	1153		10.1038/s41591-021-01405-7	http://dx.doi.org/10.1038/s41591-021-01405-7		JUN 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34140703				2022-12-27	WOS:000662941700002
J	Nutt, DJ; de Wit, H				Nutt, David J.; de Wit, Harriet			Putting the MD back into MDMA	NATURE MEDICINE			English	Editorial Material							3,4-METHYLENEDIOXYMETHAMPHETAMINE-ASSISTED PSYCHOTHERAPY; SAFETY; 1ST	A phase 3 study shows that MDMA may be a promising treatment for PTSD, which will require a shift in how this drug is perceived.	[Nutt, David J.] Imperial Coll London, Div Psychiat, London, England; [de Wit, Harriet] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA	Imperial College London; University of Chicago	Nutt, DJ (corresponding author), Imperial Coll London, Div Psychiat, London, England.	d.nutt@imperial.ac.uk		nutt, david/0000-0002-1286-1401				Bedi G, 2009, PSYCHOPHARMACOLOGY, V207, P73, DOI 10.1007/s00213-009-1635-z; Carhart-Harris RL, 2014, INT J NEUROPSYCHOPH, V17, P527, DOI 10.1017/S1461145713001405; Carhart-Harris RL, 2015, BIOL PSYCHIAT, V78, P554, DOI 10.1016/j.biopsych.2013.12.015; Feduccia AA, 2018, PROG NEURO-PSYCHOPH, V84, P221, DOI 10.1016/j.pnpbp.2018.03.003; Freudenmann RW, 2006, ADDICTION, V101, P1241, DOI 10.1111/j.1360-0443.2006.01511.x; Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161; Kuypers KPC, 2018, PSYCHOPHARMACOLOGY, V235, P481, DOI 10.1007/s00213-017-4699-1; Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3; Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371; Nardou R, 2019, NATURE, V569, P116, DOI 10.1038/s41586-019-1075-9; Sessa B, 2021, J PSYCHOPHARMACOL, V35, P375, DOI 10.1177/0269881121991792; Wardle MC, 2014, PSYCHOPHARMACOLOGY, V231, P4219, DOI 10.1007/s00213-014-3570-x	12	0	0	0	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					950	951		10.1038/s41591-021-01385-8	http://dx.doi.org/10.1038/s41591-021-01385-8		MAY 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34031606				2022-12-27	WOS:000653615900002
J	Dizman, N; Meza, L; Pal, SK				Dizman, Nazli; Meza, Luis; Pal, Sumanta K.			Biomarker approach harnessed in trials of personalized medicine for bladder cancer	NATURE MEDICINE			English	Editorial Material							EVEROLIMUS	A multi-arm clinical trial reports results of testing a strategy for the treatment of bladder cancer that uses standard immunotherapy plus biomarker assessment and targeted therapies.	[Dizman, Nazli] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Meza, Luis; Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA	Yale University; City of Hope	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.	spal@coh.org		Meza, Luis/0000-0002-0235-297X				de Bono J, 2020, NEW ENGL J MED, V382, P2091, DOI 10.1056/NEJMoa1911440; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jette NR, 2020, CANCERS, V12, DOI 10.3390/cancers12030687; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Milowsky MI, 2013, BJU INT, V112, P462, DOI 10.1111/j.1464-410X.2012.11720.x; Powles T, 2021, NAT MED, V27, P793, DOI 10.1038/s41591-021-01317-6; Powles T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.6_suppl.286; Powles T, 2016, EUR UROL, V69, P450, DOI 10.1016/j.eururo.2015.08.035; Robinson BD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10873-y; Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112; Siefker-Radtke AO, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4511; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990	12	4	4	4	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					761	763		10.1038/s41591-021-01300-1	http://dx.doi.org/10.1038/s41591-021-01300-1		MAY 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33941920				2022-12-27	WOS:000646516200003
J	Grover, S; Nguyen, JA; Viswanathan, V; Reinhart, RMG				Grover, Shrey; Nguyen, John A.; Viswanathan, Vighnesh; Reinhart, Robert M. G.			High-frequency neuromodulation improves obsessive-compulsive behavior	NATURE MEDICINE			English	Article							DIRECT-CURRENT STIMULATION; ALTERNATING-CURRENT STIMULATION; OSCILLATORY ACTIVITY; BRAIN-STIMULATION; NETWORK DYNAMICS; OCI-R; DISORDER; EEG; VALIDATION; CORTEX	Nearly one billion people worldwide suffer from obsessive-compulsive behaviors(1,2), yet our mechanistic understanding of these behaviors is incomplete, and effective therapeutics are unavailable. An emerging perspective characterizes obsessive-compulsive behaviors as maladaptive habit learning(3,4), which may be associated with abnormal beta-gamma neurophysiology of the orbitofrontal-striatal circuitry during reward processing(5,6). We target the orbitofrontal cortex with alternating current, personalized to the intrinsic beta-gamma frequency of the reward network, and show rapid, reversible, frequency-specific modulation of reward- but not punishment-guided choice behavior and learning, driven by increased exploration in the setting of an actor-critic architecture. Next, we demonstrate that chronic application of the procedure over 5 days robustly attenuates obsessive-compulsive behavior in a non-clinical population for 3 months, with the largest benefits for individuals with more severe symptoms. Finally, we show that convergent mechanisms underlie modulation of reward learning and reduction of obsessive-compulsive symptoms. The results contribute to neurophysiological theories of reward, learning and obsessive-compulsive behavior, suggest a unifying functional role of rhythms in the beta-gamma range, and set the groundwork for the development of personalized circuit-based therapeutics for related disorders.	[Grover, Shrey; Nguyen, John A.; Viswanathan, Vighnesh; Reinhart, Robert M. G.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Ctr Syst Neurosci, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Cognit Neuroimaging Ctr, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Ctr Res Sensory Commun & Emerging Neural Technol, Boston, MA 02215 USA	Boston University; Boston University; Boston University; Boston University	Reinhart, RMG (corresponding author), Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Ctr Syst Neurosci, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Cognit Neuroimaging Ctr, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Ctr Res Sensory Commun & Emerging Neural Technol, Boston, MA 02215 USA.	rmgr@bu.edu		Grover, Shrey/0000-0003-3168-5543; Viswanathan, Vighnesh/0000-0002-6717-8829	National Institutes of Health [R01-MH114877]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the National Institutes of Health (R01-MH114877) and a generous gift from an individual philanthropist awarded to R.M.G.R.	Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; Andersson E, 2012, PSYCHOL MED, V42, P2193, DOI 10.1017/S0033291712000244; Axmacher N, 2010, NEURON, V65, P541, DOI 10.1016/j.neuron.2010.02.006; Bloch MH, 2010, MOL PSYCHIATR, V15, P850, DOI 10.1038/mp.2009.50; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Burguiere E, 2015, CURR OPIN NEUROBIOL, V30, P59, DOI 10.1016/j.conb.2014.08.008; Camara E, 2009, FRONT NEUROSCI-SWITZ, V3, P350, DOI 10.3389/neuro.01.034.2009; Chasson GS, 2013, BEHAV COGN PSYCHOTH, V41, P249, DOI 10.1017/S1352465812000379; Clarke HF, 2014, J NEUROSCI, V34, P7663, DOI 10.1523/JNEUROSCI.0718-14.2014; Cocchi L, 2018, NEUROIMAGE-CLIN, V19, P661, DOI 10.1016/j.nicl.2018.05.029; Cohen JD, 2007, PHILOS T R SOC B, V362, P933, DOI 10.1098/rstb.2007.2098; Cohen MX, 2007, NEUROIMAGE, V35, P968, DOI 10.1016/j.neuroimage.2006.11.056; Cohen MX, 2011, TRENDS COGN SCI, V15, P558, DOI 10.1016/j.tics.2011.10.004; Dayan E, 2013, NAT NEUROSCI, V16, P838, DOI 10.1038/nn.3422; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dmochowski JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046011; Edwards D, 2013, NEUROIMAGE, V74, P266, DOI 10.1016/j.neuroimage.2013.01.042; Foa EB, 2002, PSYCHOL ASSESSMENT, V14, P485, DOI 10.1037//1040-3590.14.4.485; Frane JW, 1998, DRUG INF J, V32, P423, DOI 10.1177/009286159803200213; Fullana MA, 2009, AM J PSYCHIAT, V166, P329, DOI 10.1176/appi.ajp.2008.08071006; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gillan CM, 2017, PSYCHOL MED, V47, P1528, DOI 10.1017/S0033291716002786; Gold JM, 2012, ARCH GEN PSYCHIAT, V69, P129, DOI 10.1001/archgenpsychiatry.2011.1269; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Grossman N, 2017, CELL, V169, P1029, DOI 10.1016/j.cell.2017.05.024; Hajcak G, 2004, BEHAV RES THER, V42, P115, DOI 10.1016/j.brat.2003.08.002; Hernaus D, 2018, BIOL PSYCHIAT-COGN N, V3, P916, DOI 10.1016/j.bpsc.2018.03.014; Hollander E, 2000, PSYCHIAT CLIN N AM, V23, P643, DOI 10.1016/S0193-953X(05)70186-6; Howe MW, 2011, P NATL ACAD SCI USA, V108, P16801, DOI 10.1073/pnas.1113158108; Huppert JD, 2007, J ANXIETY DISORD, V21, P394, DOI 10.1016/j.janxdis.2006.05.006; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Karabanov AN, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00213; Kayser J, 2006, CLIN NEUROPHYSIOL, V117, P348, DOI 10.1016/j.clinph.2005.08.034; Kubota Y, 2019, PSYCHIAT RES-NEUROIM, V285, P40, DOI 10.1016/j.pscychresns.2019.01.012; Marco-Pallares J, 2008, NEUROPSYCHOLOGIA, V46, P241, DOI 10.1016/j.neuropsychologia.2007.07.016; Marco-Pallares J, 2015, NEUROSCI BIOBEHAV R, V49, P1, DOI 10.1016/j.neubiorev.2014.11.014; Marco-Pallares J, 2009, BIOL PSYCHIAT, V66, P154, DOI 10.1016/j.biopsych.2009.01.006; Mas-Herrero E, 2015, NEUROIMAGE, V119, P13, DOI 10.1016/j.neuroimage.2015.05.095; McClure S. M., 2006, ADV NEURAL INFORM PR, V18, P867, DOI DOI 10.1080/026999399379069; McDannald MA, 2011, J NEUROSCI, V31, P2700, DOI 10.1523/JNEUROSCI.5499-10.2011; Morris LS, 2016, NEUROPSYCHOPHARMACOL, V41, P940, DOI 10.1038/npp.2015.208; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Reinhart RMG, 2019, NAT NEUROSCI, V22, P820, DOI 10.1038/s41593-019-0371-x; Reinhart RMG, 2017, P NATL ACAD SCI USA, V114, P11542, DOI 10.1073/pnas.1710257114; Reinhart RMG, 2017, ATTEN PERCEPT PSYCHO, V79, P3, DOI 10.3758/s13414-016-1224-2; Reinhart RMG, 2016, CURR BIOL, V26, P1867, DOI 10.1016/j.cub.2016.05.019; Remijnse PL, 2006, ARCH GEN PSYCHIAT, V63, P1225, DOI 10.1001/archpsyc.63.11.1225; Robbins TW, 2019, NEURON, V102, P27, DOI 10.1016/j.neuron.2019.01.046; Ruscio AM, 2010, MOL PSYCHIATR, V15, P53, DOI 10.1038/mp.2008.94; Schreiner DC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29285-x; Simpson HB, 2008, AM J PSYCHIAT, V165, P621, DOI 10.1176/appi.ajp.2007.07091440; Srinivasan R, 2007, J NEUROSCI METH, V166, P41, DOI 10.1016/j.jneumeth.2007.06.026; Sutton R.S., 2015, REINFORCEMENT LEARNI, V2nd ed.; Thompson SL, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0558-7; Toffolo MBJ, 2014, J OBSESS-COMPULS REL, V3, P338, DOI 10.1016/j.jocrd.2014.08.004; Villamar MF, 2013, J PAIN, V14, P371, DOI 10.1016/j.jpain.2012.12.007; VOON V, 2015, TRANSL PSYCHIAT, V5; Vossen A, 2015, BRAIN STIMUL, V8, P499, DOI 10.1016/j.brs.2014.12.004	60	39	40	10	30	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					232	+		10.1038/s41591-020-01173-w	http://dx.doi.org/10.1038/s41591-020-01173-w		JAN 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33462447	Green Accepted			2022-12-27	WOS:000608674100002
J	Kampmann, B				Kampmann, Beate			Women and children last? Shaking up exclusion criteria for vaccine trials	NATURE MEDICINE			English	Editorial Material									[Kampmann, Beate] London Sch Hyg & Trop Med, Vaccine Ctr, London, England	University of London; London School of Hygiene & Tropical Medicine	Kampmann, B (corresponding author), London Sch Hyg & Trop Med, Vaccine Ctr, London, England.	beate.kampmann@lshtm.ac.uk		Kampmann, Beate/0000-0002-6546-4709	MRC [MC_PC_17221, MR/R005990/2] Funding Source: UKRI; Medical Research Council [MC_PC_17221, MR/R005990/2] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))			0	5	5	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					8	8		10.1038/s41591-020-01199-0	http://dx.doi.org/10.1038/s41591-020-01199-0			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442007	Bronze			2022-12-27	WOS:000607931400006
J	Lipkova, J; Chen, TY; Lu, MY; Chen, RJ; Shady, M; Williams, M; Wang, JW; Noor, Z; Mitchell, RN; Turan, M; Coskun, G; Yilmaz, F; Demir, D; Nart, D; Basak, K; Turhan, N; Ozkara, S; Banz, Y; Odening, KE; Mahmood, F				Lipkova, Jana; Chen, Tiffany Y.; Lu, Ming Y.; Chen, Richard J.; Shady, Maha; Williams, Mane; Wang, Jingwen; Noor, Zahra; Mitchell, Richard N.; Turan, Mehmet; Coskun, Gulfize; Yilmaz, Funda; Demir, Derya; Nart, Deniz; Basak, Kayhan; Turhan, Nesrin; Ozkara, Selvinaz; Banz, Yara; Odening, Katja E.; Mahmood, Faisal			Deep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsies	NATURE MEDICINE			English	Article							INTERNATIONAL SOCIETY; HEART; CANCER; SYSTEM	Endomyocardial biopsy (EMB) screening represents the standard of care for detecting allograft rejections after heart transplant. Manual interpretation of EMBs is affected by substantial interobserver and intraobserver variability, which often leads to inappropriate treatment with immunosuppressive drugs, unnecessary follow-up biopsies and poor transplant outcomes. Here we present a deep learning-based artificial intelligence (AI) system for automated assessment of gigapixel whole-slide images obtained from EMBs, which simultaneously addresses detection, subtyping and grading of allograft rejection. To assess model performance, we curated a large dataset from the United States, as well as independent test cohorts from Turkey and Switzerland, which includes large-scale variability across populations, sample preparations and slide scanning instrumentation. The model detects allograft rejection with an area under the receiver operating characteristic curve (AUC) of 0.962; assesses the cellular and antibody-mediated rejection type with AUCs of 0.958 and 0.874, respectively; detects Quilty B lesions, benign mimics of rejection, with an AUC of 0.939; and differentiates between low-grade and high-grade rejections with an AUC of 0.833. In a human reader study, the AI system showed non-inferior performance to conventional assessment and reduced interobserver variability and assessment time. This robust evaluation of cardiac allograft rejection paves the way for clinical trials to establish the efficacy of AI-assisted EMB assessment and its potential for improving heart transplant outcomes.	[Lipkova, Jana; Chen, Tiffany Y.; Lu, Ming Y.; Chen, Richard J.; Shady, Maha; Williams, Mane; Wang, Jingwen; Noor, Zahra; Mitchell, Richard N.; Mahmood, Faisal] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Lipkova, Jana; Chen, Tiffany Y.; Lu, Ming Y.; Chen, Richard J.; Shady, Maha; Williams, Mane; Wang, Jingwen; Mahmood, Faisal] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Lipkova, Jana; Chen, Tiffany Y.; Lu, Ming Y.; Chen, Richard J.; Shady, Maha; Williams, Mane; Wang, Jingwen; Mahmood, Faisal] Dana Farber Canc Inst, Boston, MA 02115 USA; [Lu, Ming Y.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Chen, Richard J.; Shady, Maha; Williams, Mane] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Wang, Jingwen] Univ Calif San Diego UCSD, Dept Comp Sci, La Jolla, CA USA; [Mitchell, Richard N.] Harvard MIT Hlth Sci & Technol HST, Cambridge, MA USA; [Turan, Mehmet; Coskun, Gulfize] Bogazici Univ, Inst Biomed Engn, Istanbul, Turkey; [Yilmaz, Funda; Demir, Derya; Nart, Deniz] Ege Univ, Dept Pathol, Fac Med, Izmir, Turkey; [Basak, Kayhan; Turhan, Nesrin; Ozkara, Selvinaz] Univ Hlth Sci, Dept Pathol, Ankara, Turkey; [Banz, Yara] Univ Bern, Inst Pathol, Bern, Switzerland; [Odening, Katja E.] Bern Univ Hosp, Inselspital, Dept Cardiol, Bern, Switzerland; [Odening, Katja E.] Univ Bern, Inst Physiol, Bern, Switzerland; [Mahmood, Faisal] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; [Mahmood, Faisal] Harvard Univ, Harvard Data Sci Initiat, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of California System; University of California San Diego; Bogazici University; Ege University; University of Health Sciences Turkey; University of Bern; University of Bern; University Hospital of Bern; University of Bern; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University	Mahmood, F (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.; Mahmood, F (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Mahmood, F (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.; Mahmood, F (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.; Mahmood, F (corresponding author), Harvard Univ, Harvard Data Sci Initiat, Cambridge, MA 02138 USA.	faisalmahmood@bwh.harvard.edu	Wang, Jin/GYA-2019-2022; wang, jing/GVT-8700-2022; wang, jing/GRS-7509-2022; Turan, Mehmet/AGZ-7356-2022; Basak, Kayhan/E-1823-2012; Mahmood, Faisal/C-1021-2015; Yilmaz, Funda/V-9938-2017	Basak, Kayhan/0000-0003-1960-8924; Lipkova, Jana/0000-0001-8101-4794; Mitchell, Richard/0000-0002-0329-7618; Mahmood, Faisal/0000-0001-7587-1562; Odening, Katja E/0000-0001-6999-841X; Chen, Tiffany/0000-0003-2546-2941; Yilmaz, Funda/0000-0003-1837-6498	BWH President's Fund; National Institute of General Medical Sciences (NIGMS) [R35GM138216]; Google Cloud Research Grant; Nvidia GPU Grant Program; BWH; Massachusetts General Hospital (MGH) Pathology; National Institutes of Health (NIH) National Library of Medicine (NLM) Biomedical Informatics and Data Science Research Training Program [T15LM007092]; NIH National Human Genome Research Institute (NHGRI) Ruth L. Kirschstein National Research Service Award Bioinformatics Training Grant [T32HG002295]; NIH National Cancer Institute (NCI) Ruth L. Kirschstein National Service Award [T32CA251062]; National Science Foundation (NSF) Graduate Fellowship	BWH President's Fund; National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Google Cloud Research Grant(Google Incorporated); Nvidia GPU Grant Program; BWH; Massachusetts General Hospital (MGH) Pathology; National Institutes of Health (NIH) National Library of Medicine (NLM) Biomedical Informatics and Data Science Research Training Program; NIH National Human Genome Research Institute (NHGRI) Ruth L. Kirschstein National Research Service Award Bioinformatics Training Grant; NIH National Cancer Institute (NCI) Ruth L. Kirschstein National Service Award; National Science Foundation (NSF) Graduate Fellowship(National Science Foundation (NSF))	We thank A.Bruce for scanning internal cohorts of patient histology slides at Brigham and Women's Hospital (BWH); K.Bronstein, L.Cirelli and E.Askeland for querying the BWH slide database and retrieving archival slides; C.Li for assistance with EMRs and the Research Patient Data Registry (RPDR); M.Bragg, T.Mellen, S.Zimmet and T. A.Mages for logistical support; and K.Tung for anatomical illustrations. Y.B. and K.E.O. thank the Translational Research Unit team at the Institute of Pathology of the University of Bern for technical assistance and IT assistance; in particular, M.Skowronska, L.Daminescu and S.Reinhard. This work was supported in part by the BWH President's Fund, National Institute of General Medical Sciences (NIGMS) R35GM138216 (to F.M.), Google Cloud Research Grant, Nvidia GPU Grant Program and internal funds from BWH and Massachusetts General Hospital (MGH) Pathology. M.S. was supported by the National Institutes of Health (NIH) National Library of Medicine (NLM) Biomedical Informatics and Data Science Research Training Program, T15LM007092. M.W. was funded by the NIH National Human Genome Research Institute (NHGRI) Ruth L. Kirschstein National Research Service Award Bioinformatics Training Grant, T32HG002295. T.Y.C. was funded by the NIH National Cancer Institute (NCI) Ruth L. Kirschstein National Service Award, T32CA251062. R.J.C. was funded by the National Science Foundation (NSF) Graduate Fellowship. The content is solely the responsibility of the authors and does not reflect the official views of the NIGMS, NIH, NLM, NHGRI, NCI or NSF.	Angelini A, 2011, J HEART LUNG TRANSPL, V30, P1214, DOI 10.1016/j.healun.2011.05.011; Anglicheau D, 2008, TRANSPLANTATION, V86, P192, DOI 10.1097/TP.0b013e31817eef7b; Badoe N., 2020, CONT HEART TRANSPLAN, P3; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Benjamin, 2018, CIRCULATION, V137, pE493, DOI 10.1161/CIR.0000000000000573; Biscotti CV, 2005, AM J CLIN PATHOL, V123, P281, DOI 10.1309/AGB1MJ9H5N43MEGX; Bulten W, 2020, LANCET ONCOL, V21, P233, DOI 10.1016/S1470-2045(19)30739-9; Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1; Chen PHC, 2019, NAT MED, V25, P1453, DOI 10.1038/s41591-019-0539-7; Chen RJ, 2022, IEEE T MED IMAGING, V41, P757, DOI 10.1109/TMI.2020.3021387; Colvin-Adams M, 2011, CLIN TRANSPLANT, V25, P175, DOI 10.1111/j.1399-0012.2010.01307.x; Costanzo MR, 2010, J HEART LUNG TRANSPL, V29, P914, DOI 10.1016/j.healun.2010.05.034; Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5; Crespo-Leiro MG, 2012, TRANSPLANTATION, V94, P1172, DOI 10.1097/TP.0b013e31826e19e2; De Vlaminck I, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007803; Dong Q, 2019, IEEE T PATTERN ANAL, V41, P1367, DOI 10.1109/TPAMI.2018.2832629; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Giarraputo A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020201; Halloran PF, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123674; Halloran PF, 2017, J HEART LUNG TRANSPL, V36, P1192, DOI 10.1016/j.healun.2017.05.029; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Ilse M, 2018, PR MACH LEARN RES, V80; Karimi D, 2020, MED IMAGE ANAL, V65, DOI 10.1016/j.media.2020.101759; Kather JN, 2020, NAT CANCER, V1, P789, DOI 10.1038/s43018-020-0087-6; Kennel PJ, 2018, J HEART LUNG TRANSPL, V37, P409, DOI 10.1016/j.healun.2017.07.012; Kfoury AG, 2009, J HEART LUNG TRANSPL, V28, P781, DOI 10.1016/j.healun.2009.04.035; Kobashigawa JA, 2017, CIRCULATION, V135, P936, DOI 10.1161/CIRCULATIONAHA.117.026752; Lu MY, 2021, NATURE, V594, P106, DOI 10.1038/s41586-021-03512-4; Lu MY, 2021, NAT BIOMED ENG, V5, P555, DOI 10.1038/s41551-020-00682-w; Lund LH, 2017, J HEART LUNG TRANSPL, V36, P1037, DOI 10.1016/j.healun.2017.07.019; Mahmood F, 2020, IEEE T MED IMAGING, V39, P3257, DOI 10.1109/TMI.2019.2927182; Matesanz R, 2009, TRANSPL P, V41, P2297, DOI 10.1016/j.transproceed.2009.05.004; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; Mitani A, 2021, NAT BIOMED ENG, V5, P487, DOI 10.1038/s41551-021-00747-4; Nirschl JJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192726; Orrego CM, 2012, J HEART LUNG TRANSPL, V31, P845, DOI 10.1016/j.healun.2012.03.015; Ouyang DV, 2020, NATURE, V580, P252, DOI 10.1038/s41586-020-2145-8; Peyster EG, 2021, EUR HEART J, V42, P2356, DOI 10.1093/eurheartj/ehab241; Peyster EG, 2018, TRANSPLANTATION, V102, P1230, DOI 10.1097/TP.0000000000002189; Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y; Schmauch B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17678-4; Sellaro Tiffany L, 2013, J Pathol Inform, V4, P21, DOI 10.4103/2153-3539.116866; Tan MX, 2019, PR MACH LEARN RES, V97; Tong L, 2017, 2017 IEEE EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL & HEALTH INFORMATICS (BHI), P1, DOI 10.1109/BHI.2017.7897190; Van Huyen JPD, 2014, EUR HEART J, V35, P3194, DOI 10.1093/eurheartj/ehu346; Ziaeian B, 2016, NAT REV CARDIOL, V13, P368, DOI 10.1038/nrcardio.2016.25	47	4	4	5	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					575	+		10.1038/s41591-022-01709-2	http://dx.doi.org/10.1038/s41591-022-01709-2			22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35314822	Green Accepted			2022-12-27	WOS:000771673100034
J	Simon, DA; Cohen, IG; Balatbat, C; Offodile, AC				Simon, David A.; Cohen, I. Glenn; Balatbat, Celynne; Offodile, Anaeze C., II			The hospital-at-home presents novel liabilities for physicians, hospitals, caregivers, and patients comment	NATURE MEDICINE			English	Editorial Material								Healthcare is increasingly provided in a patient's home, with potential cost savings and clinical improvements. But the hospital-at-home also raises unique liability issues not only for physicians and hospitals but also for caregivers and patients.	[Simon, David A.; Cohen, I. Glenn] Harvard Law Sch, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Cambridge, MA 02138 USA; [Cohen, I. Glenn] Harvard Law Sch, Cambridge, MA 02138 USA; [Balatbat, Celynne] Natl Acad Med, Washington, DC USA; [Offodile, Anaeze C., II] Univ Texas MD Anderson Canc Ctr, Dept Plast Surg, Div Surg, Houston, TX USA	Harvard University; Harvard University; National Academies of Sciences, Engineering & Medicine; University of Texas System; UTMD Anderson Cancer Center	Cohen, IG (corresponding author), Harvard Law Sch, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Cambridge, MA 02138 USA.; Cohen, IG (corresponding author), Harvard Law Sch, Cambridge, MA 02138 USA.	igcohen@law.harvard.edu		Cohen, Ivan/0000-0002-0223-3305	Moore Foundation [9974]; Rising Tide Foundation for Clinical Cancer Research [CCR-21-500]	Moore Foundation(Gordon and Betty Moore Foundation); Rising Tide Foundation for Clinical Cancer Research	D.A.S. and I.G.C. receive funding support from the Moore Foundation (grant 9974). A.C.O. receives funding support from the Rising Tide Foundation for Clinical Cancer Research (grant CCR-21-500).	Gerke S, 2020, JAMA-J AM MED ASSOC, V323, P601, DOI 10.1001/jama.2019.21699; Hui E, 2004, J AM GERIATR SOC, V52, pS141; Peters Jr. Philip G., 2000, WASHINGTON LEE LAW R, V57, P163	3	0	0	3	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					438	441		10.1038/s41591-022-01697-3	http://dx.doi.org/10.1038/s41591-022-01697-3		FEB 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35177864	Bronze			2022-12-27	WOS:000757243200004
J	Etienne, CF				Etienne, Carissa F.			COVID-19 has revealed a pandemic of inequality	NATURE MEDICINE			English	Editorial Material									[Etienne, Carissa F.] Pan Amer Hlth Org, Washington, DC 20037 USA	Pan American Health Organization	Etienne, CF (corresponding author), Pan Amer Hlth Org, Washington, DC 20037 USA.	director@paho.org							0	2	2	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					17	17		10.1038/s41591-021-01596-z	http://dx.doi.org/10.1038/s41591-021-01596-z		JAN 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35039656	Bronze			2022-12-27	WOS:000743459500004
J	Retzer, A; Aiyegbusi, OL; Rowe, A; Newsome, PN; Douglas-Pugh, J; Khan, S; Mittal, S; Wilson, R; O'Connor, D; Campbell, L; Mitchell, SA; Calvert, M				Retzer, Ameeta; Aiyegbusi, Olalekan Lee; Rowe, Anna; Newsome, Philip N.; Douglas-Pugh, Jessica; Khan, Sheeba; Mittal, Saloni; Wilson, Roger; O'Connor, Daniel; Campbell, Lisa; Mitchell, Sandra A.; Calvert, Melanie			The value of patient-reported outcomes in early-phase clinical trials	NATURE MEDICINE			English	Editorial Material							VALIDITY	If used correctly, patient-reported outcomes can provide preliminary evidence of efficacy and tolerability from a patient perspective, as well as supporting regulatory review.	[Retzer, Ameeta; Aiyegbusi, Olalekan Lee; Calvert, Melanie] Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcomes Res, Birmingham, W Midlands, England; [Retzer, Ameeta; Aiyegbusi, Olalekan Lee; Calvert, Melanie] Univ Birmingham, Appl Res Ctr West Midlands, Natl Inst Hlth Res, Birmingham, W Midlands, England; [Aiyegbusi, Olalekan Lee; Rowe, Anna; Newsome, Philip N.; Khan, Sheeba; Calvert, Melanie] Univ Hosp Birmingham NHS Fdn Trust, Birmingham Biomed Res Ctr, Natl Inst Hlth Res, Birmingham, W Midlands, England; [Aiyegbusi, Olalekan Lee; Calvert, Melanie] Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham, W Midlands, England; [Rowe, Anna; Douglas-Pugh, Jessica] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England; [Newsome, Philip N.; Khan, Sheeba] Univ Birmingham, Inst Immunol & Immunotherapy, Ctr Liver & Gastrointestinal Res, Birmingham, W Midlands, England; [Khan, Sheeba] Univ Hosp Birmingham NHS Fdn Trust, Liver Unit, Birmingham, W Midlands, England; [Mittal, Saloni] Univ Birmingham, Birmingham, W Midlands, England; [Wilson, Roger] NCRI Consumer Forum Natl Canc Res Inst, London, England; [O'Connor, Daniel; Campbell, Lisa] Med & Healthcare Prod Regulatory Agcy MHRA, London, England; [Mitchell, Sandra A.] NIH, Outcomes Res Branch, Div Canc Control & Populat Sci, Rockville, MD USA; [Calvert, Melanie] Univ Birmingham, Surg Reconstruct & Microbiol Res Ctr, Natl Inst Hlth Res, Birmingham, W Midlands, England; [Calvert, Melanie] Univ Birmingham, UK SPINE, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; Cancer Research UK; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; The Medicines & Healthcare Products Regulatory Agency; National Institutes of Health (NIH) - USA; University of Birmingham; University of Birmingham	Calvert, M (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcomes Res, Birmingham, W Midlands, England.; Calvert, M (corresponding author), Univ Birmingham, Appl Res Ctr West Midlands, Natl Inst Hlth Res, Birmingham, W Midlands, England.; Calvert, M (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham Biomed Res Ctr, Natl Inst Hlth Res, Birmingham, W Midlands, England.; Calvert, M (corresponding author), Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham, W Midlands, England.; Calvert, M (corresponding author), Univ Birmingham, Surg Reconstruct & Microbiol Res Ctr, Natl Inst Hlth Res, Birmingham, W Midlands, England.; Calvert, M (corresponding author), Univ Birmingham, UK SPINE, Birmingham, W Midlands, England.	m.calvert@bham.ac.uk	; Newsome, Philip/D-4495-2018	Retzer, Ameeta/0000-0002-4156-8386; Aiyegbusi, Olalekan Lee/0000-0001-9122-8251; Newsome, Philip/0000-0001-6085-3652	National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre; Midlands-Wales Advanced Therapies Treatment Centre (MW-ATTC) program grant from Innovate UK; Health Technology Wales; Welsh Blood Service; University of Birmingham [IUK: 104232]; Innovate UK (UK Research and Innovation) [104777]; NIHR Applied Research Collaboration, West Midlands (ARC); Brain Tumour Charity; NIHR Birmingham Biomedical Research Centre (BRC, West Midlands at the University of Birmingham); University Hospitals Birmingham NHS Foundation; Innovate UK (UK Research and Innovation); Gilead Sciences Ltd.; Janssen Pharmaceuticals Inc.; NIHR; UK Research and Innovation (UKRI); NIHR Birmingham Biomedical Research Centre; NIHR Surgical Reconstruction and Microbiology Research Centre; UK SPINE at the University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; Health Data Research UK; Innovate UK (part of UKRI); Macmillan Cancer Support; UCB; Gilead; Janssen; GSK Pharma	National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre; Midlands-Wales Advanced Therapies Treatment Centre (MW-ATTC) program grant from Innovate UK; Health Technology Wales; Welsh Blood Service; University of Birmingham; Innovate UK (UK Research and Innovation)(UK Research & Innovation (UKRI)Innovate UK); NIHR Applied Research Collaboration, West Midlands (ARC); Brain Tumour Charity; NIHR Birmingham Biomedical Research Centre (BRC, West Midlands at the University of Birmingham); University Hospitals Birmingham NHS Foundation; Innovate UK (UK Research and Innovation)(UK Research & Innovation (UKRI)Innovate UK); Gilead Sciences Ltd.(Gilead Sciences); Janssen Pharmaceuticals Inc.(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); NIHR(National Institute for Health Research (NIHR)); UK Research and Innovation (UKRI); NIHR Birmingham Biomedical Research Centre; NIHR Surgical Reconstruction and Microbiology Research Centre; UK SPINE at the University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; Health Data Research UK; Innovate UK (part of UKRI); Macmillan Cancer Support; UCB(UCB Pharma SA); Gilead(Gilead Sciences); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); GSK Pharma	We thank A. Filer, P. Trivedi, D. Chanouzas, S. Ghosh and A. Dueck for their advice and suggestions during this project. The author(s) disclose receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Midlands-Wales Advanced Therapies Treatment Centre (MW-ATTC) program grant from Innovate UK to a consortium of partners including Health Technology Wales, the Welsh Blood Service and the University of Birmingham (grant number: IUK: 104232) and Innovate UK (part of UK Research and Innovation) grant Patient-reported outcomes assessment to support accelerated access to advanced cell and gene therapies: PROmics (grant number: 104777). The funder was not involved in any aspect of the research work. O.L.A., A.R. and M.C. receive funding from the NIHR Applied Research Collaboration, West Midlands (ARC), and the Brain Tumour Charity. O.L.A, receives funding from the NIHR Birmingham Biomedical Research Centre (BRC, West Midlands at the University of Birmingham) and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals Inc. MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. She receives funding from the NIHR, UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and UK SPINE at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB, Gilead, Janssen and GSK Pharma. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the MHRA.	[Anonymous], 2018, J PATIENT REP OUTCOM, V2, P58; Basch E, 2016, EXPERT OPIN DRUG DIS, V11, P753, DOI 10.1080/17460441.2016.1193148; Basch E, 2009, JNCI-J NATL CANCER I, V101, P1624, DOI 10.1093/jnci/djp386; Calvert M, 2018, JAMA-J AM MED ASSOC, V319, P483, DOI 10.1001/jama.2017.21903; Chalasani Meghana, 2018, Res Involv Engagem, V4, P10, DOI 10.1186/s40900-018-0093-3; Chen AP, 2018, NOVEL DESIGNS OF EARLY PHASE TRIALS FOR CANCER THERAPEUTICS, P193, DOI 10.1016/B978-0-12-812512-0.00013-0; Coleman RL, 2021, ONCOLOGY-BASEL, DOI 10.1159/000514874; Dueck AC, 2015, JAMA ONCOL, V1, P1051, DOI 10.1001/jamaoncol.2015.2639; FDA, 2021, COR PAT REP OUTC CAN; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; Fiteni F, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5579-3; Kirkham JJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002447; Kluetz PG, 2018, VALUE HEALTH, V21, P742, DOI 10.1016/j.jval.2017.09.009; Kluetz PG, 2018, LANCET ONCOL, V19, pE267, DOI 10.1016/S1470-2045(18)30097-4; Kluetz PG, 2016, AM SOC CLIN ONCOL ED, V35, P67, DOI [10.1200/EDBK_159514, DOI 10.1200/EDBK_159514]; Pearman TP, 2018, CANCER-AM CANCER SOC, V124, P991, DOI 10.1002/cncr.31133; Shepshelovich D, 2019, ONCOLOGIST, V24, pE146, DOI 10.1634/theoncologist.2018-0332; Tavridou A, 2021, BRIT J CLIN PHARMACO, V87, P2459, DOI 10.1111/bcp.14672; Trask PC, 2018, CLIN TRIALS, V15, P616, DOI 10.1177/1740774518799985; Trotti A., 2003, SEMIN RAD ONCOL, V13, P176, DOI [10.1016/S1053-4296(03)00031-6, DOI 10.1016/S1053-4296(03)00031-6]; UK Medicines and Healthcare Products Regulatory Agency, INN LIC ACC PATHW; US Food and Drug Administration (FDA), 2018, DRUG DEV PROC STEP 3; West H, 2017, JAMA ONCOL, V3, P423, DOI 10.1001/jamaoncol.2016.5299	23	6	6	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					18	20		10.1038/s41591-021-01648-4	http://dx.doi.org/10.1038/s41591-021-01648-4		JAN 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35039659				2022-12-27	WOS:000743459500002
J	Patone, M; Mei, XW; Handunnetthi, L; Dixon, S; Zaccardi, F; Shankar-Hari, M; Watkinson, P; Khunti, K; Harnden, A; Coupland, CAC; Channon, KM; Mills, NL; Sheikh, A; Hippisley-Cox, J				Patone, Martina; Mei, Xue W.; Handunnetthi, Lahiru; Dixon, Sharon; Zaccardi, Francesco; Shankar-Hari, Manu; Watkinson, Peter; Khunti, Kamlesh; Harnden, Anthony; Coupland, Carol A. C.; Channon, Keith M.; Mills, Nicholas L.; Sheikh, Aziz; Hippisley-Cox, Julia			Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	NATURE MEDICINE			English	Article							CARDIOVASCULAR MAGNETIC-RESONANCE; TROPONIN; INJURY	A self-controlled case series using individual-patient-level data from over 38 million people aged 16 years and over, reveals an increased risk of myocarditis within a week of receiving a first dose of ChAdOx1, BNT162b2 and mRNA-1273 vaccines, which was further increased after a second dose of either mRNA vaccine. SARS-CoV-2 infection was associated with even greater risk of myocarditis, as well as pericarditis and cardiac arrhythmia. Although myocarditis and pericarditis were not observed as adverse events in coronavirus disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population. We undertook a self-controlled case series study of people aged 16 or older vaccinated for COVID-19 in England between 1 December 2020 and 24 August 2021 to investigate hospital admission or death from myocarditis, pericarditis and cardiac arrhythmias in the 1-28 days following adenovirus (ChAdOx1, n = 20,615,911) or messenger RNA-based (BNT162b2, n = 16,993,389; mRNA-1273, n = 1,006,191) vaccines or a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (n = 3,028,867). We found increased risks of myocarditis associated with the first dose of ChAdOx1 and BNT162b2 vaccines and the first and second doses of the mRNA-1273 vaccine over the 1-28 days postvaccination period, and after a SARS-CoV-2 positive test. We estimated an extra two (95% confidence interval (CI) 0, 3), one (95% CI 0, 2) and six (95% CI 2, 8) myocarditis events per 1 million people vaccinated with ChAdOx1, BNT162b2 and mRNA-1273, respectively, in the 28 days following a first dose and an extra ten (95% CI 7, 11) myocarditis events per 1 million vaccinated in the 28 days after a second dose of mRNA-1273. This compares with an extra 40 (95% CI 38, 41) myocarditis events per 1 million patients in the 28 days following a SARS-CoV-2 positive test. We also observed increased risks of pericarditis and cardiac arrhythmias following a positive SARS-CoV-2 test. Similar associations were not observed with any of the COVID-19 vaccines, apart from an increased risk of arrhythmia following a second dose of mRNA-1273. Subgroup analyses by age showed the increased risk of myocarditis associated with the two mRNA vaccines was present only in those younger than 40.	[Patone, Martina; Mei, Xue W.; Dixon, Sharon; Harnden, Anthony; Coupland, Carol A. C.; Hippisley-Cox, Julia] Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England; [Handunnetthi, Lahiru] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England; [Zaccardi, Francesco; Khunti, Kamlesh] Univ Leicester, Leicester Real World Evidence Unit, Diabet Res Ctr, Leicester, Leics, England; [Shankar-Hari, Manu; Mills, Nicholas L.; Sheikh, Aziz] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Shankar-Hari, Manu] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Shankar-Hari, Manu] Kings Coll London, Sch Immunol & Microbial Sci, London, England; [Watkinson, Peter] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Watkinson, Peter] Oxford Univ Hosp NHS Trust, NIHR Biomed Res Ctr, Oxford, England; [Coupland, Carol A. C.] Univ Nottingham, Sch Med, Div Primary Care, Nottingham, England; [Channon, Keith M.] Univ Oxford, John Radcliffe Hosp, NIHR Oxford Biomed Res Ctr, British Heart Fdn Ctr Res Excellence, Oxford, England; [Mills, Nicholas L.] Univ Edinburgh, BHF Univ Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Leicester; University of Edinburgh; University of Edinburgh; University of London; King's College London; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Nottingham; University of Oxford; University of Edinburgh	Hippisley-Cox, J (corresponding author), Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England.	julia.hippisley-cox@phc.ox.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020; Shankar-Hari, Manu/I-6948-2012	Hippisley-Cox, Julia/0000-0002-2479-7283; Shankar-Hari, Manu/0000-0002-5338-2538; Handunnetthi, Lahiru/0000-0002-8242-3722; Mills, Nicholas/0000-0003-0533-7991; Watkinson, Peter/0000-0003-1023-3927; Khunti, Kamlesh/0000-0003-2343-7099; channon, keith/0000-0002-1043-4342; Coupland, Carol/0000-0002-2327-3306; Mei, Xue/0000-0002-6279-4884	National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC-EM); NIHR Lifestyle BRC; National Institute for Health Research Clinician Scientist Award [NIHR-CS-2016-16-011]; NIHR Oxford Biomedical Research Centre; British Heart Foundation [CH/F/21/90010, CH/16/1/32013, RG/20/10/34966, RE/18/5/34216, RE18/3/34214]; Health Data Research United Kingdom BREATHE Hub; United Kingdom Research and Innovation [MC_PC_20029]	National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC-EM)(National Institute for Health Research (NIHR)); NIHR Lifestyle BRC; National Institute for Health Research Clinician Scientist Award; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); British Heart Foundation(British Heart Foundation); Health Data Research United Kingdom BREATHE Hub; United Kingdom Research and Innovation	This project involves data derived from patient-level information collected by the National Health Service (NHS), as part of the care and support of cancer patients. The SARS-Cov-2 test data are collated, maintained and quality assured by Public Health England (PHE). Access to the data was facilitated by the PHE Office for Data Release. The Hospital Episode Statistics, Secondary Users Service (SUS-PLUS) datasets and civil registration data are used by permission from NHS Digital who retain the copyright for that data. NHS Digital and PHE bear no responsibility for the analysis or interpretation of the data. K.K. is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC-EM) and NIHR Lifestyle BRC. M.S.-H. is supported by the National Institute for Health Research Clinician Scientist Award (NIHR-CS-2016-16-011). J.H.-C. and K.M.C. are supported by the NIHR Oxford Biomedical Research Centre. N.L.M. and K.M.C. are supported by the British Heart Foundation (Chair Awards CH/F/21/90010, CH/16/1/32013), Programme Grant (RG/20/10/34966) and Research Excellence Awards (RE/18/5/34216, RE18/3/34214). A.S. is supported by the Health Data Research United Kingdom BREATHE Hub. This research is part of the Data and Connectivity National Core Study, led by Health Data Research United Kingdom in partnership with the office of National Statistics and funded by United Kingdom Research and Innovation (grant MC_PC_20029). The investigators acknowledge the philanthropic support of the donors to the University of Oxford's COVID-19 Research Response Fund. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the United Kingdom NIHR or the Department of Health. The funders of this study had no role in the design and conduct of the study and did not review or approve the manuscript. The views expressed are those of the authors and not necessarily the funders. M.P., J.H.-C. and C.A.C.C. had full access to all the study data and J.H.-C. had final responsibility for submission. This project is supported by a patient and public involvement advisory panel, which we thank for its continued support and guidance. The input of the panel has helped us identify priority questions for consideration and also supported analysis. Patient and Public Involvement and Engagement advisers were supportive of the vital importance of reporting on cardiac risks associated with both vaccination against COVID-19 and COVID-19 itself.	[Anonymous], SEL ADV EV REP COVID; [Anonymous], 2021, COM SPIK POSS LINK V; [Anonymous], NUMB PEOPL VACC COVI; [Anonymous], 2021, SURV MYOC INFL HEART; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Bozkurt B, 2021, CIRCULATION, V144, P471, DOI 10.1161/CIRCULATIONAHA.121.056135; Chapman AR, 2020, CIRCULATION, V141, P1733, DOI 10.1161/CIRCULATIONAHA.120.047008; Dastidar AG, 2019, JACC-CARDIOVASC IMAG, V12, P1973, DOI 10.1016/j.jcmg.2018.12.023; De Michieli L, 2021, CLIN CHEM, V67, P1080, DOI 10.1093/clinchem/hvab062; Dorward DA, 2021, AM J RESP CRIT CARE, V203, P192, DOI 10.1164/rccm.202008-3265OC; Engler RJM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118283; Fairweather D, 2013, CURR PROB CARDIOLOGY, V38, P7, DOI 10.1016/j.cpcardiol.2012.07.003; Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165; Ferreira VM, 2018, J AM COLL CARDIOL, V72, P3158, DOI 10.1016/j.jacc.2018.09.072; Fonseca-Rodriguez O, 2021, STAT MED, V40, P6197, DOI 10.1002/sim.9179; Friedrich MG, 2009, J AM COLL CARDIOL, V53, P1475, DOI 10.1016/j.jacc.2009.02.007; Kim JY, 2021, J CARDIOVASC MAGN R, V23, DOI 10.1186/s12968-021-00792-7; Klein NP, 2021, JAMA-J AM MED ASSOC, V326, P1390, DOI 10.1001/jama.2021.15072; Kociol RD, 2020, CIRCULATION, V141, pE69, DOI 10.1161/CIR.0000000000000745; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Lala A, 2020, J AM COLL CARDIOL, V76, P533, DOI [10.1016/j.jacc.2020.06.007, 10.1101/2020.04.20.20072702]; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Makunts T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96467-5; Mei R, 2018, INT J CARDIOL, V273, P183, DOI 10.1016/j.ijcard.2018.09.054; Mevorach D, 2021, NEW ENGL J MED, V385, P2140, DOI 10.1056/NEJMoa2109730; Pasupathy S, 2015, CIRCULATION, V131, P861, DOI 10.1161/CIRCULATIONAHA.114.011201; Petersen I, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4515; Pollack A, 2015, NAT REV CARDIOL, V12, P670, DOI 10.1038/nrcardio.2015.108; Sandoval Y, 2020, J AM COLL CARDIOL, V76, P1244, DOI 10.1016/j.jacc.2020.06.068; Simone A., JAMA INTERN MED, DOI [10.1001/jamainternmed.2021.5511(2021, DOI 10.1001/JAMAINTERNMED.2021.5511(2021]; Wilson K, 2013, PHARMACOEPIDEM DR S, V22, P108, DOI 10.1002/pds.3337; Witberg G, 2021, NEW ENGL J MED, V385, P2132, DOI 10.1056/NEJMoa2110737	32	128	132	9	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					410	+		10.1038/s41591-021-01630-0	http://dx.doi.org/10.1038/s41591-021-01630-0		DEC 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	34907393	Green Published, hybrid			2022-12-27	WOS:000730059200003
J	Webster, P				Webster, Paul			COVID-19 timeline of events	NATURE MEDICINE			English	Editorial Material								The COVID-19 pandemic continued to rage in 2021, but this was increasingly an unequal pandemic, with rich countries receiving millions of doses of vaccine and ending lockdowns and travel bans. It was also a year when policymakers started to prepare for the next inevitable pandemic.				pchwebster@hotmail.com							0	3	3	1	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2054	2055		10.1038/s41591-021-01618-w	http://dx.doi.org/10.1038/s41591-021-01618-w		DEC 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34907389	Bronze			2022-12-27	WOS:000730059200005
J	August, A; Attarwala, HZ; Himansu, S; Kalidindi, S; Lu, S; Pajon, R; Han, S; Lecerf, JM; Tomassini, JE; Hard, M; Ptaszek, LM; Crowe, JE; Zaks, T				August, Allison; Attarwala, Husain Z.; Himansu, Sunny; Kalidindi, Shiva; Lu, Sophia; Pajon, Rolando; Han, Shu; Lecerf, Jean-Michel; Tomassini, Joanne E.; Hard, Marjie; Ptaszek, Leon M.; Crowe, James E.; Zaks, Tal			A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus	NATURE MEDICINE			English	Article							VACCINE; SAFETY; IMMUNOGENICITY; INFECTION; AGENTS	Chikungunya virus (CHIKV) infection causes acute disease characterized by fever, rash and arthralgia, which progresses to severe and chronic arthritis in up to 50% of patients. Moreover, CHIKV infection can be fatal in infants or immunocompromised individuals and has no approved therapy or prevention. This phase 1, first-in-human, randomized, placebo-controlled, proof-of-concept trial conducted from January 2019 to June 2020 evaluated the safety and pharmacology of mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody, CHKV-24 (). The primary outcome was to evaluate the safety and tolerability of escalating doses of mRNA-1944 administered via intravenous infusion in healthy participants aged 18-50 years. The secondary objectives included determination of the pharmacokinetics of mRNA encoding for CHKV-24 immunoglobulin heavy and light chains and ionizable amino lipid component and the pharmacodynamics of mRNA-1944 as assessed by serum concentrations of mRNA encoding for CHKV-24 immunoglobulin G (IgG), plasma concentrations of ionizable amino lipid and serum concentrations of CHKV-24 IgG. Here we report the results of a prespecified interim analysis of 38 healthy participants who received intravenous single doses of mRNA-1944 or placebo at 0.1, 0.3 and 0.6 mg kg(-1), or two weekly doses at 0.3 mg kg(-1). At 12, 24 and 48 h after single infusions, dose-dependent levels of CHKV-24 IgG with neutralizing activity were observed at titers predicted to be therapeutically relevant concentrations (>= 1 mu g ml(-1)) across doses that persisted for >= 16 weeks at 0.3 and 0.6 mg kg(-1) (mean t(1/2) approximately 69 d). A second 0.3 mg kg(-1) dose 1 week after the first increased CHKV-24 IgG levels 1.8-fold. Adverse effects were mild to moderate in severity, did not worsen with a second mRNA-1944 dose and none were serious. To our knowledge, mRNA-1944 is the first mRNA-encoded monoclonal antibody showing in vivo expression and detectable ex vivo neutralizing activity in a clinical trial and may offer a treatment option for CHIKV infection. Further evaluation of the potential therapeutic use of mRNA-1944 in clinical trials for the treatment of CHIKV infection is warranted.	[August, Allison; Attarwala, Husain Z.; Himansu, Sunny; Kalidindi, Shiva; Lu, Sophia; Pajon, Rolando; Han, Shu; Lecerf, Jean-Michel; Tomassini, Joanne E.; Hard, Marjie; Zaks, Tal] Moderna Inc, Cambridge, MA 02139 USA; [Ptaszek, Leon M.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Crowe, James E.] Vanderbilt Univ, Med Ctr, Nashville, TN USA	Harvard University; Massachusetts General Hospital; Vanderbilt University	August, A (corresponding author), Moderna Inc, Cambridge, MA 02139 USA.	Allison.august@modernatx.com	Crowe, James/B-5549-2009	Crowe, James/0000-0002-0049-1079; Himansu, Sunny/0000-0002-7954-9674	Moderna	Moderna	We thank the participants and study personnel for their contributions to the study and T. Brasel for performing the neutralizing antibody assay. We also gratefully acknowledge M. S. Diamond for his input to the study and critical review of the manuscript. The trial was funded by Moderna. Moderna was responsible for conceptualization and trial design, site selection and monitoring, data analysis, decision to publish and manuscript preparation. The authors received no specific funding for this work and vouch for the accuracy and completeness of the data and the fidelity of the trial to the protocol.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Abeyratne E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00304; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Aliprantis AO, 2021, HUM VACC IMMUNOTHER, V17, P1248, DOI 10.1080/21645515.2020.1829899; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Broeckel R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005637; Center for Biologics Evaluation and Research, 2007, TOX GRAD SCAL HEALTH; Chen GL, 2020, JAMA-J AM MED ASSOC, V323, P1369, DOI 10.1001/jama.2020.2477; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Claydon J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176152; Clayton AM, 2016, J INFECT DIS, V214, pS506, DOI 10.1093/infdis/jiw324; Cohen YZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219142; Couderc T, 2009, J INFECT DIS, V200, P516, DOI 10.1086/600381; Edington F, 2018, JOINT BONE SPINE, V85, P669, DOI 10.1016/j.jbspin.2018.03.019; Eli Lilly and Company, 2020, LILL ANN PROOF CONC; Emu B, 2018, NEW ENGL J MED, V379, P645, DOI 10.1056/NEJMoa1711460; Galatas B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004281; Gao S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02881; Garg H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61103-1; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Goyal M, 2018, DRUG DES DEV THER, V12, P4195, DOI 10.2147/DDDT.S181574; Hanfling D., 2017, PLOS CURR-TREE LIFE, V9; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Kam YW, 2012, EMBO MOL MED, V4, P330, DOI 10.1002/emmm.201200213; Kam YW, 2012, J INFECT DIS, V205, P1147, DOI 10.1093/infdis/jis033; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Marston HD, 2018, NEW ENGL J MED, V378, P1469, DOI 10.1056/NEJMp1802256; Masrinoul P, 2014, VIROLOGY, V464, P111, DOI 10.1016/j.virol.2014.05.038; Milligan GN, 2019, VACCINE, V37, P7427, DOI 10.1016/j.vaccine.2018.10.033; Moderna, 2020, MOD ANN ADD POS PHAS; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Nitatpattana N, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-183; Pal P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003312; Pan American Health Organization Regional Office for the Americas of the World Health Organization, 2017, CHIK DAT MAPS STAT; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Pierro A., 2015, New Microbes and New Infections, V7, P23, DOI 10.1016/j.nmni.2015.04.002; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Powers AM, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00104-16; Regeneron, 2020, REG REGN COV2 ANT CO; Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwameis M, 2016, HUM VACC IMMUNOTHER, V12, P716, DOI 10.1080/21645515.2015.1101197; Sievers SA, 2015, CURR OPIN HIV AIDS, V10, P151, DOI 10.1097/COH.0000000000000148; Smith SA, 2015, CELL HOST MICROBE, V18, P86, DOI 10.1016/j.chom.2015.06.009; Sparrow E, 2017, B WORLD HEALTH ORGAN, V95, P235, DOI [10.2471/BLT.16.178061, 10.2471/blt.16.178061]; Stadler CR, 2017, NAT MED, V23, P815, DOI 10.1038/nm.4356; Thran M, 2017, EMBO MOL MED, V9, P1434, DOI 10.15252/emmm.201707678; U.S. Department of Health and Human Services, 2017, COMMON TERMINOL CRIT; Van Hoecke L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1804-8; WHO, 2020, CHIK; Yoon IK, 2020, INT J INFECT DIS, V95, P167, DOI 10.1016/j.ijid.2020.03.073; Yoon IK, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003764; Zaid A, 2018, ARTHRITIS RHEUMATOL, V70, P484, DOI 10.1002/art.40403	60	21	21	4	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2224	+		10.1038/s41591-021-01573-6	http://dx.doi.org/10.1038/s41591-021-01573-6		DEC 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887572	Green Published, hybrid			2022-12-27	WOS:000728466100003
J	Keiser, MS; Ranum, PT; Yrigollen, CM; Carrell, EM; Smith, GR; Muehlmatt, AL; Chen, YH; Stein, JM; Wolf, RL; Radaelli, E; Lucas, TJ; Gonzalez-Alegre, P; Davidson, BL				Keiser, Megan S.; Ranum, Paul T.; Yrigollen, Carolyn M.; Carrell, Ellie M.; Smith, Geary R.; Muehlmatt, Amy L.; Chen, Yong Hong; Stein, Joel M.; Wolf, Ronald L.; Radaelli, Enrico; Lucas, Timothy J., II; Gonzalez-Alegre, Pedro; Davidson, Beverly L.			Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain	NATURE MEDICINE			English	Article							POLYGLUTAMINE-INDUCED NEURODEGENERATION; VECTOR; RECOVERY; SEQUENCE; SAFETY; MODEL; MICE	RNA interference (RNAi) for spinocerebellar ataxia type 1 can prevent and reverse behavioral deficits and neuropathological readouts in mouse models, with safety and benefit lasting over many months. The RNAi trigger, expressed from adeno-associated virus vectors (AAV.miS1), also corrected misregulated microRNAs (miRNA) such as miR150. Subsequently, we showed that the delivery method was scalable, and that AAV.miS1 was safe in short-term pilot nonhuman primate (NHP) studies. To advance the technology to patients, investigational new drug (IND)-enabling studies in NHPs were initiated. After AAV.miS1 delivery to deep cerebellar nuclei, we unexpectedly observed cerebellar toxicity. Both small-RNA-seq and studies using AAVs devoid of miRNAs showed that this was not a result of saturation of the endogenous miRNA processing machinery. RNA-seq together with sequencing of the AAV product showed that, despite limited amounts of cross-packaged material, there was substantial inverted terminal repeat (ITR) promoter activity that correlated with neuropathologies. ITR promoter activity was reduced by altering the miS1 expression context. The surprising contrast between our rodent and NHP findings highlight the need for extended safety studies in multiple species when assessing new therapeutics for human application. A preclinical safety study of adeno-associated viruses (AAVs) for RNA interference (RNAi) for spinocerebellar ataxia type 1 therapy showed toxicity in nonhuman primates but not rodents, due to unexpected AAV inverted terminal repeat transcriptional activity that was mitigated on altering the RNAi expression environment.	[Keiser, Megan S.; Ranum, Paul T.; Yrigollen, Carolyn M.; Carrell, Ellie M.; Smith, Geary R.; Muehlmatt, Amy L.; Chen, Yong Hong; Gonzalez-Alegre, Pedro; Davidson, Beverly L.] Childrens Hosp Philadelphia, Raymond G Perelman Ctr Cellular & Mol Therapeut, Res Inst, Philadelphia, PA 19104 USA; [Stein, Joel M.; Wolf, Ronald L.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Radaelli, Enrico] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Lucas, Timothy J., II] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Gonzalez-Alegre, Pedro] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Davidson, Beverly L.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Davidson, BL (corresponding author), Childrens Hosp Philadelphia, Raymond G Perelman Ctr Cellular & Mol Therapeut, Res Inst, Philadelphia, PA 19104 USA.	davidsonbl@chop.edu		Radaelli, Enrico/0000-0002-2885-0221; Yrigollen, Carolyn/0000-0002-2399-6176	NIH [NS094355, T32 HG009495]; Children's Hospital of Philadelphia Research Institute	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital of Philadelphia Research Institute	This work was funded by the NIH NS094355 (M.K., P.G.-A., T.J.L., B.L.D.), NIH T32 HG009495 (P.T.R.) and the Children's Hospital of Philadelphia Research Institute.	Ayuso E, 2010, GENE THER, V17, P503, DOI 10.1038/gt.2009.157; Boudreau RL, 2009, MOL THER, V17, P169, DOI 10.1038/mt.2008.231; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Chadeuf G, 2005, MOL THER, V12, P744, DOI 10.1016/j.ymthe.2005.06.003; Chen Yong Hong, 2018, Curr Protoc Mouse Biol, V8, pe58, DOI 10.1002/cpmo.58; Crespo-Barreto J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001021; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Earley LF, 2020, HUM GENE THER, V31, P151, DOI 10.1089/hum.2019.274; FLOTTE TR, 1992, AM J RESP CELL MOL, V7, P349, DOI 10.1165/ajrcmb/7.3.349; Friedrich J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123193; Gonzalez-Alegre P, 2019, HUM MOL GENET, V28, pR80, DOI 10.1093/hmg/ddz138; Keiser Megan S, 2018, Curr Protoc Mouse Biol, V8, pe57, DOI 10.1002/cpmo.57; Keiser MS, 2016, ANN NEUROL, V80, P754, DOI 10.1002/ana.24789; Keiser MS, 2015, BRAIN, V138, P3555, DOI 10.1093/brain/awv292; Keiser MS, 2014, MOL THER, V22, P588, DOI 10.1038/mt.2013.279; Keiser MS, 2013, NEUROBIOL DIS, V56, P6, DOI 10.1016/j.nbd.2013.04.003; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; Monteys AM, 2014, NUCLEIC ACIDS RES, V42, P13315, DOI 10.1093/nar/gku979; Nitschke L, 2020, GENE DEV, V34, P1147, DOI 10.1101/gad.339317.120; O'Callaghan B, 2020, MOL THER-NUCL ACIDS, V21, P1006, DOI 10.1016/j.omtn.2020.07.030; Oez G, 2011, EXP NEUROL, V232, P290, DOI 10.1016/j.expneurol.2011.09.021; Radukic MT, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqaa074; Rodriguez-Lebron E, 2013, NEUROBIOL DIS, V54, P456, DOI 10.1016/j.nbd.2013.01.019; Tai PWL, 2018, MOL THER-METH CLIN D, V9, P130, DOI 10.1016/j.omtm.2018.02.002; van Gestel MA, 2014, GENE THER, V21, P205, DOI 10.1038/gt.2013.76; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Zu T, 2004, J NEUROSCI, V24, P8853, DOI 10.1523/JNEUROSCI.2978-04.2004	30	10	10	3	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1982	+		10.1038/s41591-021-01522-3	http://dx.doi.org/10.1038/s41591-021-01522-3		OCT 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34663988	Green Accepted			2022-12-27	WOS:000708373000003
J	Shroff, RT; Chalasani, P; Wei, R; Pennington, D; Quirk, G; Schoenle, MV; Peyton, KL; Uhrlaub, JL; Ripperger, TJ; Jergovic, M; Dalgai, S; Wolf, A; Whitmer, R; Hammad, H; Carrier, A; Scott, AJ; Nikolich-Zugich, J; Worobey, M; Sprissler, R; Dake, M; LaFleur, BJ; Bhattacharya, D				Shroff, Rachna T.; Chalasani, Pavani; Wei, Ran; Pennington, Daniel; Quirk, Grace; Schoenle, Marta, V; Peyton, Kameron L.; Uhrlaub, Jennifer L.; Ripperger, Tyler J.; Jergovic, Mladen; Dalgai, Shelby; Wolf, Alexander; Whitmer, Rebecca; Hammad, Hytham; Carrier, Amy; Scott, Aaron J.; Nikolich-Zugich, Janko; Worobey, Michael; Sprissler, Ryan; Dake, Michael; LaFleur, Bonnie J.; Bhattacharya, Deepta			Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors	NATURE MEDICINE			English	Article							MEMORY B-CELLS; HUMORAL IMMUNITY; SARS-COV-2; ANTIBODIES	Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. In this study, we compared immune responses to the BNT162b2 mRNA Coronavirus Disease 2019 vaccine in patients with solid tumors (n = 53) who were on active cytotoxic anti-cancer therapy to a control cohort of participants without cancer (n = 50). Neutralizing antibodies were detected in 67% of patients with cancer after the first immunization, followed by a threefold increase in median titers after the second dose. Similar patterns were observed for spike protein-specific serum antibodies and T cells, but the magnitude of each of these responses was diminished relative to the control cohort. In most patients with cancer, we detected spike receptor-binding domain and other S1-specific memory B cell subsets as potential predictors of anamnestic responses to additional immunizations. We therefore initiated a phase 1 trial for 20 cancer cohort participants of a third vaccine dose of BNT162b2 (NCT04936997); primary outcomes were immune responses, with a secondary outcome of safety. At 1 week after a third immunization, 16 participants demonstrated a median threefold increase in neutralizing antibody responses, but no improvement was observed in T cell responses. Adverse events were mild. These results suggest that a third dose of BNT162b2 is safe, improves humoral immunity against SARS-CoV-2 and could be immunologically beneficial for patients with cancer on active chemotherapy.	[Shroff, Rachna T.; Chalasani, Pavani; Pennington, Daniel; Dalgai, Shelby; Wolf, Alexander; Hammad, Hytham; Carrier, Amy; Scott, Aaron J.] Univ Arizona, Dept Med, Div Hematol & Oncol, Canc Ctr, Tucson, AZ 85721 USA; [Wei, Ran; Schoenle, Marta, V; Peyton, Kameron L.; Uhrlaub, Jennifer L.; Ripperger, Tyler J.; Jergovic, Mladen; Nikolich-Zugich, Janko; Bhattacharya, Deepta] Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ 85721 USA; [Quirk, Grace; Schoenle, Marta, V; Nikolich-Zugich, Janko; Worobey, Michael; Sprissler, Ryan; LaFleur, Bonnie J.; Bhattacharya, Deepta] Univ Arizona, BIO5 Inst, Tucson, AZ 85721 USA; [Whitmer, Rebecca] Univ Arizona, Coll Med, Tucson, AZ USA; [Nikolich-Zugich, Janko] Univ Arizona, Coll Med, Ctr Aging, Tucson, AZ USA; [Worobey, Michael] Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ USA; [Sprissler, Ryan] Univ Arizona, Univ Arizona Genom Core, Tucson, AZ USA; [Sprissler, Ryan] Univ Arizona, Arizona Res Labs, Univ Arizona Genet Core, Tucson, AZ USA; [Dake, Michael] Univ Arizona, Off Senior Vice President Hlth Sci, Tucson, AZ USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Shroff, RT (corresponding author), Univ Arizona, Dept Med, Div Hematol & Oncol, Canc Ctr, Tucson, AZ 85721 USA.; Bhattacharya, D (corresponding author), Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ 85721 USA.; LaFleur, BJ; Bhattacharya, D (corresponding author), Univ Arizona, BIO5 Inst, Tucson, AZ 85721 USA.	rshroff@arizona.edu; blafleur@arizona.edu; deeptab@arizona.edu	LaFleur, Bonnie J/GPJ-9592-2022	LaFleur, Bonnie J/0000-0002-4939-9337	National Institutes of Health [R01AI099108, R01AI129945, R37AG020719, T32AG058503]; University of Arizona funds	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Arizona funds	This work was supported by National Institutes of Health grants R01AI099108 and R01AI129945 (D.B.), R37AG020719 (J.N.Z.) and T32AG058503 (T.J.R.) and by University of Arizona funds (D.B. and R.S.). We thank M. Pepper (University of Washington) and J. Netland (University of Washington) for technical assistance with tetramer stains. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Schema in Fig. 1a and Extended Data Fig. 9a were created using BioRender.	Abayasingam A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100228; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Angyal A, T CELL ANTIBODY RESP; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Cerutti G, 2021, CELL HOST MICROBE, V29, P819, DOI 10.1016/j.chom.2021.03.005; Deepak P, 2021, ANN INTERN MED, V174, P1572, DOI 10.7326/M21-1757; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; Edara VV, 2021, NEW ENGL J MED, V385, P664, DOI 10.1056/NEJMc2107799; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Greaney AJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abi9915; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568; Hurlburt N. K, 2021, STRUCTURAL DEFINITIO, DOI [10.1101/2021.08.02.454829v1, DOI 10.1101/2021.08.02.454829V1]; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Knox JJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92943; Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9; Kyu SY, 2009, J IMMUNOL METHODS, V340, P42, DOI 10.1016/j.jim.2008.09.025; Ladner JT, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2020.100189; Lau D, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai8153; Lavinder JJ, 2014, P NATL ACAD SCI USA, V111, P2259, DOI 10.1073/pnas.1317793111; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McCallum M, 2021, CELL, V184, P2332, DOI [10.1101/2021.01.14.426475, 10.1016/j.cell.2021.03.028]; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Ogbe A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21856-3; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; Nguyen-Contant P, 2020, MBIO, V11, DOI 10.1128/mBio.01991-20; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Purtha WE, 2011, J EXP MED, V208, P2599, DOI 10.1084/jem.20110740; Puthillath A, 2011, CANCER CHEMOTH PHARM, V67, P111, DOI 10.1007/s00280-010-1292-2; Reynolds CJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abf3698; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Schulien I, 2021, NAT MED, V27, P78, DOI 10.1038/s41591-020-01143-2; Seifert M, 2015, P NATL ACAD SCI USA, V112, pE546, DOI 10.1073/pnas.1416276112; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Smith KGC, 1997, EMBO J, V16, P2996, DOI 10.1093/emboj/16.11.2996; Song G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23074-3; Swadling L, 2021, PREEXISTING POLYMERA, DOI [10.1101/2021.06.26.21259239v1, DOI 10.1101/2021.06.26.21259239V1]; Turner JS, 2020, NATURE, V586, P127, DOI 10.1038/s41586-020-2711-0; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282; Wong R, 2020, IMMUNITY, V53, P1078, DOI 10.1016/j.immuni.2020.09.001; Woodruff MC, 2020, NAT IMMUNOL, V21, P1506, DOI 10.1038/s41590-020-00814-z; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wumkes ML, 2013, VACCINE, V31, P6177, DOI 10.1016/j.vaccine.2013.10.053; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zuccarino-Catania GV, 2014, NAT IMMUNOL, V15, P631, DOI 10.1038/ni.2914	60	79	79	6	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					2002	+		10.1038/s41591-021-01542-z	http://dx.doi.org/10.1038/s41591-021-01542-z		SEP 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34594036	Bronze, Green Published, Green Accepted			2022-12-27	WOS:000702264100001
J	Feng, S; Phillips, DJ; White, T; Sayal, H; Aley, PK; Bibi, S; Dold, C; Fuskova, M; Gilbert, SC; Hirsch, I; Humphries, HE; Jepson, B; Kelly, EJ; Plested, E; Shoemaker, K; Thomas, KM; Vekemans, J; Villafana, TL; Lambe, T; Pollard, AJ; Voysey, M				Feng, Shuo; Phillips, Daniel J.; White, Thomas; Sayal, Homesh; Aley, Parvinder K.; Bibi, Sagida; Dold, Christina; Fuskova, Michelle; Gilbert, Sarah C.; Hirsch, Ian; Humphries, Holly E.; Jepson, Brett; Kelly, Elizabeth J.; Plested, Emma; Shoemaker, Kathryn; Thomas, Kelly M.; Vekemans, Johan; Villafana, Tonya L.; Lambe, Teresa; Pollard, Andrew J.; Voysey, Merryn		Oxford COVID Vaccine Trial Grp	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	NATURE MEDICINE			English	Article							NCOV-19 AZD1222 VACCINE; COVID-19; CORONAVIRUS; EFFICACY; IMMUNITY	Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection. The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.	[Feng, Shuo; Phillips, Daniel J.; Aley, Parvinder K.; Bibi, Sagida; Dold, Christina; Plested, Emma; Pollard, Andrew J.; Voysey, Merryn] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England; [White, Thomas; Sayal, Homesh; Hirsch, Ian] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol R&I, Cambridge, England; [Fuskova, Michelle; Gilbert, Sarah C.; Lambe, Teresa] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England; [Humphries, Holly E.; Thomas, Kelly M.] Publ Hlth England, Natl Infect Serv, Salisbury, Wilts, England; [Jepson, Brett; Shoemaker, Kathryn; Villafana, Tonya L.] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol R&I, Gaithersburg, MD USA; [Jepson, Brett] Cytel Inc, Cambridge, MA USA; [Kelly, Elizabeth J.] AstraZeneca, BioPharmaceut R&D, Microbial Sci, Gaithersburg, MD USA; [Vekemans, Johan] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol R&I, Gothenburg, Sweden; [Lambe, Teresa] Univ Oxford, Chinese Acad Med Sci CAMS, Oxford Inst COI, Oxford, England; [Pollard, Andrew J.; Voysey, Merryn] NIHR Oxford Biomed Ctr, Oxford, England	University of Oxford; AstraZeneca; University of Oxford; Jenner Institute; Public Health England; AstraZeneca; AstraZeneca; AstraZeneca; University of Oxford	Voysey, M (corresponding author), Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.; Voysey, M (corresponding author), NIHR Oxford Biomed Ctr, Oxford, England.	merryn.voysey@paediatrics.ox.ac.uk	Thomson, Emma C/M-8690-2017; Folegatti, Pedro/AAD-5238-2019; Lambe, Teresa/E-5733-2016; Baker, Philip/ABI-2575-2020; Ewer, Katie/B-4328-2011	Thomson, Emma C/0000-0003-1482-0889; Folegatti, Pedro/0000-0001-5330-0240; Lambe, Teresa/0000-0001-7711-897X; Baker, Philip/0000-0002-4519-1563; Ewer, Katie/0000-0001-9827-9836; Gilbert, Sarah/0000-0002-6823-9750; Costa Clemens, Sue Ann/0000-0001-9576-0878; Feng, Elaine Shuo/0000-0001-7855-0991; Sanders, Katherine/0000-0002-4090-3277; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Green, Christopher/0000-0002-1984-4014; Anslow, Rachel/0000-0002-9111-2897; Lillie, Patrick/0000-0002-4811-4774; Felle, Sally/0000-0001-7855-4482; Allen, Lauren/0000-0003-1846-8181; Leung, Stephanie/0000-0002-8880-2977; Aley, Parvinder/0000-0002-0749-8329; Garlant, Harriet/0000-0001-7612-6441; Farooq Mujadidi, Yama/0000-0002-2342-8531	UK Research and Innovation [MC_PC_19055]; Engineering and Physical Sciences Research Council [EP/R013756/1]; National Institute for Health Research [COV19 OxfordVacc-01]; Coalition for Epidemic Preparedness Innovations; National Institute for Health Research Oxford Biomedical Research Centre (BRC4 Vaccines Theme); Thames Valley and South Midland's NIHR Clinical Research Network; AstraZeneca	UK Research and Innovation(UK Research & Innovation (UKRI)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Coalition for Epidemic Preparedness Innovations; National Institute for Health Research Oxford Biomedical Research Centre (BRC4 Vaccines Theme); Thames Valley and South Midland's NIHR Clinical Research Network; AstraZeneca(AstraZeneca)	This article reports independent research funded by UK Research and Innovation (MC_PC_19055: SG, AJP, TL), Engineering and Physical Sciences Research Council (EP/R013756/1: S.C.G., A.J.P., T.L.), National Institute for Health Research (COV19 OxfordVacc-01: S.C.G., A.J.P., T.L.), Coalition for Epidemic Preparedness Innovations (Outbreak Response To Novel Coronavirus (COVID-19: S.C.G., A.J.P., T.L.)), National Institute for Health Research Oxford Biomedical Research Centre (BRC4 Vaccines Theme), Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. We acknowledge support from Thames Valley and South Midland's NIHR Clinical Research Network and the staff and resources of NIHR Southampton Clinical Research Facility and the NIHR Oxford Biomedical Research Centre. A.J.P. is a NIHR Senior Investigator. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. AstraZeneca reviewed the final manuscript but the academic authors retained editorial control. Other funders had no role in study design, data collection and analysis, or decision to publish. We thank the volunteers who participated in this study. We thank P. B. Gilbert and P. Dull for their advice and contributions to the methodology. The authors appreciate the efforts of the Labcorp-Monogram Biosciences Clinical Reference Laboratory.	Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Box GE, 1992, BAYESIAN INFERENCE S; Brand J, 2019, STAT MED, V38, P210, DOI 10.1002/sim.7956; CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410; Centers for Disease Control and Prevention, JOHNS JOHNS JANSS CO; Chen HY, 2013, ENVIRONMETRICS, V24, P132, DOI 10.1002/env.2193; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Fischer Robert J, 2021, bioRxiv, DOI 10.1101/2021.03.11.435000; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gilbert P. B., IMMUNE CORRELATES AN, DOI 10.1101/2021.08.09.21261290(2021; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Phillips N, 2021, NATURE, V590, P382, DOI 10.1038/d41586-021-00396-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Public Health England, 2021, COVID 19 VACC SURV R; Qin L, 2007, J INFECT DIS, V196, P1304, DOI 10.1086/522428; R Core Team, 2021, R LANGUAGE ENV STAT; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; Urra JM, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108486; USG COVID-19 Response Team / Coronavirus Prevention Network (CoVPN) Biostatistics Team, VACC EFF TRIAL IMM C; van Doremalen N, 2020, NATURE, V586, P578, DOI [10.1101/2020.05.13.093195, 10.1038/s41586-020-2608-y]; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2004, J INFECT DIS, V190, P373, DOI 10.1086/421524; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x; World Health Organisation, 2021, COVID 19 CAND VACC L; Yang PH, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00780-6; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284	44	314	314	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					2032	+		10.1038/s41591-021-01540-1	http://dx.doi.org/10.1038/s41591-021-01540-1		SEP 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34588689	Green Submitted, Green Accepted, Green Published, hybrid			2022-12-27	WOS:000701366000001
J	Machingaidze, S; Wiysonge, CS				Machingaidze, Shingai; Wiysonge, Charles Shey			Understanding COVID-19 vaccine hesitancy	NATURE MEDICINE			English	Editorial Material								A new study unpacks the complexities of COVID-19 vaccine hesitancy and acceptance across low-, middle- and high-income countries.	[Machingaidze, Shingai] European & Developing Countries Clin Trials Partn, Africa Off, Cape Town, South Africa; [Machingaidze, Shingai; Wiysonge, Charles Shey] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Cape Town, South Africa; [Machingaidze, Shingai; Wiysonge, Charles Shey] South African Med Res Council, Cochrane South Africa, Cape Town, South Africa	University of Cape Town; South African Medical Research Council	Machingaidze, S (corresponding author), European & Developing Countries Clin Trials Partn, Africa Off, Cape Town, South Africa.; Machingaidze, S (corresponding author), Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Cape Town, South Africa.; Machingaidze, S (corresponding author), South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.	machingaidze@edctp.org						Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; [Anonymous], 2020, AFRICA CDCP; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McEachan RRC, 2011, HEALTH PSYCHOL REV, V5, P97, DOI 10.1080/17437199.2010.521684; Solis Arce J. S, NAT MED, DOI [10.1038/s41591-021-01454-y(2021), DOI 10.1038/S41591-021-01454-Y(2021)]; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	8	179	179	4	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1338	1339		10.1038/s41591-021-01459-7	http://dx.doi.org/10.1038/s41591-021-01459-7		JUL 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34272500	Bronze			2022-12-27	WOS:000673323800001
J	Rabinovici, GD				Rabinovici, Gil D.			Dominantly inherited Alzheimer's disease: a compass for drug development	NATURE MEDICINE			English	Editorial Material								The first phase 3 trial of amyloid-beta-targeting monoclonal antibodies in dominantly inherited Alzheimer's disease failed to slow cognitive decline in patients. Could it still help to inform future study design and drug development in this setting?	[Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Rabinovici, Gil D.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Rabinovici, Gil D.] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rabinovici, GD (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Rabinovici, GD (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.; Rabinovici, GD (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA.	gil.rabinovici@ucsf.edu						Apostolova LG, 2021, ALZHEIMERS DEMENT, V17, P2043, DOI 10.1002/alz.12350; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Cummings J, 2020, ALZH DEMENT-TRCI, V6, DOI 10.1002/trc2.12050; Fleisher AS, 2012, LANCET NEUROL, V11, P1057, DOI 10.1016/S1474-4422(12)70227-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Knopman DS, 2021, ALZHEIMERS DEMENT, V17, P696, DOI 10.1002/alz.12213; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; Ringman JM, 2016, J NEUROPATH EXP NEUR, V75, P284, DOI 10.1093/jnen/nlv028; Salloway S, 2021, NAT MED, V27, P1187, DOI 10.1038/s41591-021-01369-8; Strobel G, 2021, ALZFORUM; VandeVrede L, 2020, ALZHEIMERS DEMENT AM, V12, pe12101, DOI 10.1002/dad2.12101	12	0	0	2	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1148	1150		10.1038/s41591-021-01434-2	http://dx.doi.org/10.1038/s41591-021-01434-2		JUL 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34226734				2022-12-27	WOS:000669779100006
J	Aartsma-Rus, A				Aartsma-Rus, Annemieke			'N of 1' therapies need a better model	NATURE MEDICINE			English	Editorial Material								Oligonucleotides offer therapeutic potential for patients with genetic disorders carrying unique mutations, but developing individualized therapies is not supported by the current process for drug development.	[Aartsma-Rus, Annemieke] Leiden Univ, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Aartsma-Rus, A (corresponding author), Leiden Univ, Med Ctr, Leiden, Netherlands.	a.m.rus@lumc.nl		Aartsma-Rus, Annemieke/0000-0003-1565-654X					0	4	4	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					939	939		10.1038/s41591-021-01380-z	http://dx.doi.org/10.1038/s41591-021-01380-z		MAY 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34031602				2022-12-27	WOS:000653615900004
J	Schmidt, H; Weintraub, R; Williams, MA; Miller, K; Buttenheim, A; Sadecki, E; Wu, H; Doiphode, A; Nagpal, N; Gostin, LO; Shen, AA				Schmidt, Harald; Weintraub, Rebecca; Williams, Michelle A.; Miller, Kate; Buttenheim, Alison; Sadecki, Emily; Wu, Helen; Doiphode, Aditi; Nagpal, Neha; Gostin, Lawrence O.; Shen, Angela A.			Equitable allocation of COVID-19 vaccines in the United States	NATURE MEDICINE			English	Article							VULNERABILITY; RISK	An analysis of COVID-19 vaccine allocation frameworks in the United States across 64 Centers for Disease Control and Prevention jurisdictions reveals that, as of 31 March 2021, 37 jurisdictions had adopted disadvantage indices to reduce health disparities. The analysis also highlights the importance of vaccine prioritization based on health and place. Many vaccine rationing guidelines urge planners to recognize, and ideally reduce, inequities. In the United States, allocation frameworks are determined by each of the Centers for Disease Control and Prevention's 64 jurisdictions (50 states, the District of Columbia, five cities and eight territories). In this study, we analyzed vaccine allocation plans published by 8 November 2020, tracking updates through to 30 March 2021. We evaluated whether jurisdictions adopted proposals to reduce inequity using disadvantage indices and related place-based measures. By 30 March 2021, 14 jurisdictions had prioritized specific zip codes in combination with metrics such as COVID-19 incidence, and 37 jurisdictions (including 34 states) had adopted disadvantage indices, compared to 19 jurisdictions in November 2020. Uptake of indices doubled from 7 to 14 among the jurisdictions with the largest shares of disadvantaged communities. Five applications were distinguished: (1) prioritizing disadvantaged groups through increased shares of vaccines or vaccination appointments; (2) defining priority groups or areas; (3) tailoring outreach and communication; (4) planning the location of dispensing sites; and (5) monitoring receipt. To ensure that equity features centrally in allocation plans, policymakers at the federal, state and local levels should universalize the uptake of disadvantage indices and related place-based measures.	[Schmidt, Harald] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA; [Weintraub, Rebecca; Miller, Kate] Brigham & Womens Hosp, Ariadne Labs, 75 Francis St, Boston, MA 02115 USA; [Weintraub, Rebecca; Miller, Kate] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Williams, Michelle A.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Buttenheim, Alison] Univ Penn, Dept Family & Community Hlth, Philadelphia, PA 19104 USA; [Buttenheim, Alison] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [Buttenheim, Alison] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA; [Buttenheim, Alison] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Sadecki, Emily] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA; [Wu, Helen; Doiphode, Aditi; Nagpal, Neha] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA; [Gostin, Lawrence O.] Georgetown Univ, ONeill Inst Natl & Global Hlth Law, Washington, DC USA; [Shen, Angela A.] Childrens Hosp Philadelphia, Vaccine Educ Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Georgetown University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Schmidt, H (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.	schmidth@mail.med.upenn.edu		Schmidt, Harald/0000-0003-4806-8816; Sadecki, Emily/0000-0003-1631-5472				Acharya R, 2020, LANCET GLOB HEALTH, V8, pE1142, DOI 10.1016/S2214-109X(20)30300-4; Adair-Rohani H, 2013, GLOB HEALTH-SCI PRAC, V1, P249, DOI 10.9745/GHSP-D-13-00037; [Anonymous], 2021, NATL STRATEGY COVID; Bajak A., 2021, US TODAY; Bell BP, 2020, JAMA-J AM MED ASSOC, V324, P2025, DOI 10.1001/jama.2020.20847; Berwick DM, 2020, JAMA-J AM MED ASSOC, V324, P225, DOI 10.1001/jama.2020.11129; Braveman P, 2003, J EPIDEMIOL COMMUN H, V57, P254, DOI 10.1136/jech.57.4.254; Buttenheim AM, 2020, ANN INTERN MED, V173, P1018, DOI 10.7326/M20-6206; Centers for Disease Control and Prevention, COVID 19 VACC PROGR; Centers for Disease Control and Prevention, COVID DAT TRACK; Chetty R, 2020, Q J ECON, V135, P711, DOI 10.1093/qje/qjz042; CULYER AJ, 1995, SOC SCI MED, V40, P727, DOI 10.1016/0277-9536(94)00307-F; Dasgupta S, 2020, MMWR-MORBID MORTAL W, V69, P1535, DOI 10.15585/mmwr.mm6942a3; Dwyer-Lindgren L, 2017, JAMA INTERN MED, V177, P1003, DOI 10.1001/jamainternmed.2017.0918; Fleur N., 2020, STAT; Forde AT, 2020, HYPERTENSION, V76, P715, DOI 10.1161/HYPERTENSIONAHA.119.14492; Foster S., 2020, HLTH AFFAIRS BLOG; Funk C., 2021, BLACK AMERICANS STAN; Groppe M., 2021, NO CONSISTENT RATION; HSE, 2020, COVID 19 VACC PROGR; Joint Committee on Vaccination and Immunisation, 2021, JCVI STAT VACC CHILD; Kakani P, 2020, JAMA-J AM MED ASSOC, V324, P1000, DOI 10.1001/jama.2020.14978; Karmakar M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.36462; Khazanchi R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19933; McClung N, 2020, MMWR-MORBID MORTAL W, V69, P1782, DOI 10.15585/mmwr.mm6947e3; Navathe A., 2020, NY TIMES; Ndugga N, 2021, ARE STATES ADDRESSIN; Ndugga Nambi, 2022, LATEST DATA COVID 19; O'Brien R, 2020, SSM-POPUL HLTH, V11, DOI 10.1016/j.ssmph.2020.100564; Orenstein W, 2019, HUM VACC IMMUNOTHER, V15, P2786, DOI 10.1080/21645515.2019.1682360; Painter EM, 2021, MMWR-MORBID MORTAL W, V70, P174, DOI 10.15585/mmwr.mm7005e1; Paltiel AD, 2021, HEALTH AFFAIR, V40, P42, DOI 10.1377/hlthaff.2020.02054; Pathak P. A., 2021, PREPRINT; Phillips RL, 2016, HEALTH AFFAIR, V35, P1991, DOI 10.1377/hlthaff.2016.0709; Schmidt H., 2020, PREPRINT; Schmidt H., 2020, EQUITABLE ALLOCATION; Schmidt H, 2020, JAMA-J AM MED ASSOC, V324, P2023, DOI 10.1001/jama.2020.20571; Schmidt H, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3795; Schmidt H, 2020, HASTINGS CENT REP, V50, P46, DOI 10.1002/hast.1113; The National Academies of Science. Engineering and Medicine, 2020, FRAM EQ ALL VACC NOV; Weintraub RL, 2021, HEALTH AFFAIR, V40, P33, DOI 10.1377/hlthaff.2020.01523; WHO, 2020, WHO SAGE VAL FRAM AL; Yearby R, 2020, J LAW BIOSCI, V7, DOI 10.1093/jlb/lsaa036	43	32	32	1	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1298	+		10.1038/s41591-021-01379-6	http://dx.doi.org/10.1038/s41591-021-01379-6		MAY 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34007071	Bronze			2022-12-27	WOS:000651666900002
J	van der Laak, J; Litjens, G; Ciompi, F				van der Laak, Jeroen; Litjens, Geert; Ciompi, Francesco			Deep learning in histopathology: the path to the clinic	NATURE MEDICINE			English	Review							TUMOR-INFILTRATING LYMPHOCYTES; ARTIFICIAL-INTELLIGENCE; COMPUTATIONAL PATHOLOGY; MITOSIS DETECTION; PROSTATE-CANCER; BREAST-CANCER; SEGMENTATION; PREDICTION; VALIDATION; CHALLENGES	Recent advances in machine learning techniques have created opportunities to improve medical diagnostics, but implementing these advances in the clinic will not be without challenge. Machine learning techniques have great potential to improve medical diagnostics, offering ways to improve accuracy, reproducibility and speed, and to ease workloads for clinicians. In the field of histopathology, deep learning algorithms have been developed that perform similarly to trained pathologists for tasks such as tumor detection and grading. However, despite these promising results, very few algorithms have reached clinical implementation, challenging the balance between hope and hype for these new techniques. This Review provides an overview of the current state of the field, as well as describing the challenges that still need to be addressed before artificial intelligence in histopathology can achieve clinical value.	[van der Laak, Jeroen; Litjens, Geert; Ciompi, Francesco] Radboud Univ Nijmegen Med Ctr, Dept Pathol, Nijmegen, Netherlands; [van der Laak, Jeroen] Linkoping Univ, Ctr Med Image Sci & Visualizat, Linkoping, Sweden	Radboud University Nijmegen; Linkoping University	van der Laak, J (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Pathol, Nijmegen, Netherlands.; van der Laak, J (corresponding author), Linkoping Univ, Ctr Med Image Sci & Visualizat, Linkoping, Sweden.	jeroen.vanderlaak@radboudumc.nl	Ciompi, Francesco/P-5598-2015; van der Laak, Jeroen AWM/D-3057-2015; Litjens, Geert JS/A-2319-2016	Ciompi, Francesco/0000-0001-8327-9606; van der Laak, Jeroen AWM/0000-0001-7982-0754; Litjens, Geert JS/0000-0003-1554-1291				AbdulJabbar K, 2020, NAT MED, V26, P1054, DOI 10.1038/s41591-020-0900-x; Abels E, 2019, J PATHOL, V249, P286, DOI 10.1002/path.5331; Agarwalla A., 2017, REPRESENTATION AGGRE; Akbar S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50568-4; Alawad M, 2020, J AM MED INFORM ASSN, V27, P89, DOI 10.1093/jamia/ocz153; Albarqouni S, 2016, IEEE T MED IMAGING, V35, P1313, DOI 10.1109/TMI.2016.2528120; Allen TC, 2019, ARCH PATHOL LAB MED, V143, P1175, DOI 10.5858/arpa.2019-0229-ED; Amgad M, 2019, BIOINFORMATICS, V35, P3461, DOI 10.1093/bioinformatics/btz083; Awan R, 2018, LECT NOTES COMPUT SC, V10882, P788, DOI 10.1007/978-3-319-93000-8_89; Balkenhol MCA, 2019, LAB INVEST, V99, P1596, DOI 10.1038/s41374-019-0275-0; Beck AH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002564; Beede E, 2020, PROCEEDINGS OF THE 2020 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'20), DOI 10.1145/3313831.3376718; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Ben, 2019, P 2 INT C MED IM DEE, V102, P84; Bera K, 2019, NAT REV CLIN ONCOL, V16, P703, DOI 10.1038/s41571-019-0252-y; Brieu N., 2019, DOMAIN ADAPTATION BA; Bueno G, 2020, COMPUT METH PROG BIO, V184, DOI 10.1016/j.cmpb.2019.105273; Bulten W, 2020, LANCET ONCOL, V21, P233, DOI 10.1016/S1470-2045(19)30739-9; Bulten W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37257-4; Bychkov D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21758-3; Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1; Chen H, 2017, MED IMAGE ANAL, V36, P135, DOI 10.1016/j.media.2016.11.004; Chen H, 2016, I S BIOMED IMAGING, P1204, DOI 10.1109/ISBI.2016.7493482; Chen PHC, 2019, NAT MED, V25, P1453, DOI 10.1038/s41591-019-0539-7; Cho H., 2017, NEURAL STAIN STYLE T; Cires D. C., 2011, PROC 22 INT JOINT C, V22, P1237; Ciresan DC, 2013, LECT NOTES COMPUT SC, V8150, P411, DOI 10.1007/978-3-642-40763-5_51; Collins GS, 2019, LANCET, V393, P1577, DOI 10.1016/S0140-6736(19)30037-6; Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5; Courtiol P, 2019, NAT MED, V25, P1519, DOI 10.1038/s41591-019-0583-3; Couture HD, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0079-1; Cruz-Roa A, 2014, PROC SPIE, V9041, DOI 10.1117/12.2043872; Cui DN, 2020, J COMPUT BIOL, V27, P1264, DOI 10.1089/cmb.2019.0410; de Bel T, 2019, P 2 INT C MED IM DEE, P151; de Bel T, 2018, PROC SPIE, V10581, DOI 10.1117/12.2293717; Dong JS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01629; Dudgeon S. N., 2020, PATHOLOGIST ANNOTATE; Duran JM, 2021, J MED ETHICS, V47, P329, DOI 10.1136/medethics-2020-106820; Ertosun M. G, 2015, P AM MED INF ASS ANN; Feng YQ, 2020, IEEE ACM T COMPUT BI, V17, P91, DOI 10.1109/TCBB.2018.2858763; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Fuchs TJ, 2011, COMPUT MED IMAG GRAP, V35, P515, DOI 10.1016/j.compmedimag.2011.02.006; Gadermayr M, 2019, P MACH LEARN RES, V102, P175; Gao S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232840; Geessink OGF, 2019, CELL ONCOL, V42, P331, DOI 10.1007/s13402-019-00429-z; Gertych A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37638-9; Graham S, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101563; Graham S, 2019, MED IMAGE ANAL, V52, P199, DOI 10.1016/j.media.2018.12.001; Guidotti R, 2019, ACM COMPUT SURV, V51, DOI 10.1145/3236009; Hamet P, 2017, METABOLISM, V69, pS36, DOI 10.1016/j.metabol.2017.01.011; Hermsen M, 2019, J AM SOC NEPHROL, V30, P1968, DOI 10.1681/ASN.2019020144; Hou L, 2019, PATTERN RECOGN, V86, P188, DOI 10.1016/j.patcog.2018.09.007; Hou L, 2016, PROC CVPR IEEE, P2424, DOI 10.1109/CVPR.2016.266; Iizuka O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58467-9; Ilse M, 2018, PR MACH LEARN RES, V80; Janowczyk A, 2017, COMPUT MED IMAG GRAP, V57, P50, DOI 10.1016/j.compmedimag.2016.05.003; Jansen I, 2020, AM J PATHOL, V190, P1483, DOI 10.1016/j.ajpath.2020.03.013; Jia ZP, 2017, IEEE T MED IMAGING, V36, P2376, DOI 10.1109/TMI.2017.2724070; Kapil A., 2019, DASGAN JOINT DOMAIN, DOI 10.4103/ijmr.IJMR_1782_18; Karimi D, 2020, IEEE J BIOMED HEALTH, V24, P1413, DOI 10.1109/JBHI.2019.2944643; Kather JN, 2020, NAT CANCER, V1, P789, DOI 10.1038/s43018-020-0087-6; Kather JN, 2019, NAT MED, V25, P1054, DOI 10.1038/s41591-019-0462-y; Kather JN, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002730; Kather JN, 2016, SCI REP-UK, V6, DOI 10.1038/srep27988; Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2; Kiani A, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0232-8; Kleppe A, 2021, NAT REV CANCER, V21, P199, DOI 10.1038/s41568-020-00327-9; Kohl S, 2018, ADV NEURAL INF PROCE; Koohbanani NA, 2020, MED IMAGE ANAL, V65, DOI 10.1016/j.media.2020.101771; Korde LA, 2021, J CLIN ONCOL, V39, P1485, DOI 10.1200/JCO.20.03399; Kroll JA, 2018, PHILOS T R SOC A, V376, DOI 10.1098/rsta.2018.0084; Kulkarni PM, 2020, CLIN CANCER RES, V26, P1126, DOI 10.1158/1078-0432.CCR-19-1495; Kwok S, 2018, LECT NOTES COMPUT SC, V10882, P931, DOI 10.1007/978-3-319-93000-8_106; Lai MC, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-019-02204-y; Le H, 2020, AM J PATHOL, V190, P1491, DOI 10.1016/j.ajpath.2020.03.012; Lee B, 2018, LECT NOTES COMPUT SC, V11071, P841, DOI 10.1007/978-3-030-00934-2_93; Li C, 2019, MED IMAGE ANAL, V53, P165, DOI 10.1016/j.media.2019.01.013; Liang QK, 2019, IEEE J BIOMED HEALTH, V23, P1205, DOI 10.1109/JBHI.2018.2850040; Linmans J., 2020, P C MED IM DEEP LEAR, P465; Litjens G, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy065; Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005; Litjens G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26286; Liu S, 2020, SCI REP-UK, V10; Liu Y., 2017, DETECTING CANCER MET; Liu Y, 2019, ARCH PATHOL LAB MED, V143, P859, DOI 10.5858/arpa.2018-0147-OA; Long FX, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-019-3332-1; Louis DN, 2014, ARCH PATHOL LAB MED, V138, P1133, DOI 10.5858/arpa.2014-0034-ED; Lu MY, 2021, NAT BIOMED ENG, V5, P555, DOI 10.1038/s41551-020-00682-w; Madabhushi A, 2016, MED IMAGE ANAL, V33, P170, DOI 10.1016/j.media.2016.06.037; Mahmood T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030749; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; MENDELSOHN ML, 1965, POSTGRAD MED, V38, P567, DOI 10.1080/00325481.1965.11695692; Mobadersany P, 2018, P NATL ACAD SCI USA, V115, pE2970, DOI 10.1073/pnas.1717139115; Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689; Nagpal K, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0112-2; Naylor P, 2019, IEEE T MED IMAGING, V38, P448, DOI 10.1109/TMI.2018.2865709; Pawlowski N., 2019, NEEDLES HAYSTACKS CL; Pinckaers H., 2019, NEURAL ORDINARY DIFF; Pinckaers H, 2022, IEEE T PATTERN ANAL, V44, P1581, DOI 10.1109/TPAMI.2020.3019563; Price WN, 2019, NAT MED, V25, P37, DOI 10.1038/s41591-018-0272-7; Qaiser Talha, 2019, Digital Pathology. 15th European Congress, ECDP 2019. Proceedings: Lecture Notes in Computer Science (LNCS 11435), P163, DOI 10.1007/978-3-030-23937-4_19; Rawat RR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64156-4; Rieke N, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00323-1; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Saillard C, 2020, HEPATOLOGY, V72, P2000, DOI 10.1002/hep.31207; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Salle FG, 2020, J THORAC ONCOL, V15, P1037, DOI 10.1016/j.jtho.2020.01.025; Saltz J, 2018, CELL REP, V23, P181, DOI 10.1016/j.celrep.2018.03.086; Sari CT, 2019, IEEE T MED IMAGING, V38, P1139, DOI 10.1109/TMI.2018.2879369; Schmauch B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17678-4; Sha Lingdao, 2019, J Pathol Inform, V10, P24, DOI 10.4103/jpi.jpi_24_19; Shaban MT, 2019, I S BIOMED IMAGING, P953, DOI 10.1109/ISBI.2019.8759152; Sheller MJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69250-1; Sirinukunwattana K, 2021, GUT, V70, P544, DOI 10.1136/gutjnl-2019-319866; Sirinukunwattana K, 2017, MED IMAGE ANAL, V35, P489, DOI 10.1016/j.media.2016.08.008; Sirinukunwattana K, 2016, IEEE T MED IMAGING, V35, P1196, DOI 10.1109/TMI.2016.2525803; Skrede OJ, 2020, LANCET, V395, P350, DOI 10.1016/S0140-6736(19)32998-8; Song Z, 2020, NAT COMMUN, V11; Srinidhi CL, 2021, MED IMAGE ANAL, V67, DOI 10.1016/j.media.2020.101813; Staartjes VE, 2020, SPINE J, V20, P1159, DOI 10.1016/j.spinee.2020.02.016; Strom P, 2020, LANCET ONCOL, V21, P222, DOI 10.1016/S1470-2045(19)30738-7; Swiderska-Chadaj Z, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101547; Syrykh C, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0272-0; Tabibu S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46718-3; Tellez D, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101544; Tellez D, 2021, IEEE T PATTERN ANAL, V43, P567, DOI 10.1109/TPAMI.2019.2936841; Tellez D, 2018, IEEE T MED IMAGING, V37, P2126, DOI 10.1109/TMI.2018.2820199; US Food & Drug Administration (FDA), PROP REG FRAM MOD AR; Valkonen M, 2020, IEEE T MED IMAGING, V39, P534, DOI 10.1109/TMI.2019.2933656; Veta M, 2019, MED IMAGE ANAL, V54, P111, DOI 10.1016/j.media.2019.02.012; Wang D., 2016, DEEP LEARNING IDENTI; Wang X, 2020, IEEE T CYBERNETICS, V50, P3950, DOI 10.1109/TCYB.2019.2935141; Wei JW, 2019, SCI REP-UK, V9; Wong GLH, 2021, J GASTROEN HEPATOL, V36, P543, DOI 10.1111/jgh.15385; Wulczyn E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233678; Xu G, 2019, IEEE I CONF COMP VIS, P10681, DOI 10.1109/ICCV.2019.01078; Yang H, 2020, IEEE T MED IMAGING, V39, P1306, DOI 10.1109/TMI.2019.2948026; Yu KH, 2018, NAT BIOMED ENG, V2, P719, DOI 10.1038/s41551-018-0305-z; Zhang ZZ, 2019, NAT MACH INTELL, V1, P236, DOI 10.1038/s42256-019-0052-1; Zheng YS, 2021, IEEE J BIOMED HEALTH, V25, P337, DOI 10.1109/JBHI.2020.2983206; Zhou C, 2021, COMPUT MED IMAG GRAP, V88; Zwanenburg A, 2020, RADIOLOGY, V295, P328, DOI 10.1148/radiol.2020191145	144	97	97	24	73	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					775	784		10.1038/s41591-021-01343-4	http://dx.doi.org/10.1038/s41591-021-01343-4			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33990804				2022-12-27	WOS:000650698900017
J	Sudre, CH; Murray, B; Varsavsky, T; Graham, MS; Penfold, RS; Bowyer, RC; Pujol, JC; Klaser, K; Antonelli, M; Canas, LS; Molteni, E; Modat, M; Cardoso, MJ; May, A; Ganesh, S; Davies, R; Nguyen, LH; Drew, DA; Astley, CM; Joshi, AD; Merino, J; Tsereteli, N; Fall, T; Gomez, MF; Duncan, EL; Menni, C; Williams, FMK; Franks, PW; Chan, AT; Wolf, J; Ourselin, S; Spector, T; Steves, CJ				Sudre, Carole H.; Murray, Benjamin; Varsavsky, Thomas; Graham, Mark S.; Penfold, Rose S.; Bowyer, Ruth C.; Pujol, Joan Capdevila; Klaser, Kerstin; Antonelli, Michela; Canas, Liane S.; Molteni, Erika; Modat, Marc; Cardoso, M. Jorge; May, Anna; Ganesh, Sajaysurya; Davies, Richard; Nguyen, Long H.; Drew, David A.; Astley, Christina M.; Joshi, Amit D.; Merino, Jordi; Tsereteli, Neli; Fall, Tove; Gomez, Maria F.; Duncan, Emma L.; Menni, Cristina; Williams, Frances M. K.; Franks, Paul W.; Chan, Andrew T.; Wolf, Jonathan; Ourselin, Sebastien; Spector, Tim; Steves, Claire J.			Attributes and predictors of long COVID	NATURE MEDICINE			English	Article								Reports of long-lasting coronavirus disease 2019 (COVID-19) symptoms, the so-called 'long COVID', are rising but little is known about prevalence, risk factors or whether it is possible to predict a protracted course early in the disease. We analyzed data from 4,182 incident cases of COVID-19 in which individuals self-reported their symptoms prospectively in the COVID Symptom Study app(1). A total of 558 (13.3%) participants reported symptoms lasting >= 28 days, 189 (4.5%) for >= 8 weeks and 95 (2.3%) for >= 12 weeks. Long COVID was characterized by symptoms of fatigue, headache, dyspnea and anosmia and was more likely with increasing age and body mass index and female sex. Experiencing more than five symptoms during the first week of illness was associated with long COVID (odds ratio = 3.53 (2.76-4.50)). A simple model to distinguish between short COVID and long COVID at 7 days (total sample size, n = 2,149) showed an area under the curve of the receiver operating characteristic curve of 76%, with replication in an independent sample of 2,472 individuals who were positive for severe acute respiratory syndrome coronavirus 2. This model could be used to identify individuals at risk of long COVID for trials of prevention or treatment and to plan education and rehabilitation services.	[Sudre, Carole H.] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England; [Sudre, Carole H.] UCL, Dept Populat Hlth Sci, MRC Unit Lifelong Hlth & Ageing, London, England; [Sudre, Carole H.; Murray, Benjamin; Varsavsky, Thomas; Graham, Mark S.; Klaser, Kerstin; Antonelli, Michela; Canas, Liane S.; Molteni, Erika; Modat, Marc; Cardoso, M. Jorge; Ourselin, Sebastien] UCL, Dept Comp Sci, Ctr Med Image Comp, London, England; [Penfold, Rose S.; Duncan, Emma L.; Menni, Cristina; Williams, Frances M. K.; Franks, Paul W.; Spector, Tim; Steves, Claire J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England; [Bowyer, Ruth C.; Pujol, Joan Capdevila; May, Anna; Ganesh, Sajaysurya; Davies, Richard; Wolf, Jonathan] Zoe Global, London, England; [Nguyen, Long H.; Drew, David A.; Joshi, Amit D.; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA; [Astley, Christina M.] Boston Childrens Hosp, Div Endocrinol & Computat Epidemiol, Boston, MA USA; [Merino, Jordi] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; [Merino, Jordi] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Merino, Jordi] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA; [Merino, Jordi] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Tsereteli, Neli; Gomez, Maria F.; Franks, Paul W.] Lund Univ, Dept Clin Sci, Diabet Ctr, Malmo, Sweden; [Fall, Tove] Uppsala Univ, Dept Med Sci, Mol Epidemiol, Uppsala, Sweden; [Ourselin, Sebastien] Univ Cote dAzur, AI Inst 3IA Cote dAzur, Nice, France	University of London; King's College London; University of London; University College London; University of London; University College London; University of London; King's College London; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Lund University; Uppsala University; UDICE-French Research Universities; Universite Cote d'Azur	Steves, CJ (corresponding author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.	claire.j.steves@kcl.ac.uk	Fall, Tove/AID-4935-2022; Gomez, Maria F/D-3696-2014; Varsavsky, Thomas/AAU-7605-2021; Molteni, Erika/P-4564-2016; Merino, Jordi/AAH-6853-2019; Duncan, Emma/L-1224-2013; Ourselin, Sebastien/K-6960-2015	Fall, Tove/0000-0003-2071-5866; Gomez, Maria F/0000-0001-6210-3142; Varsavsky, Thomas/0000-0002-8624-8116; Molteni, Erika/0000-0001-7773-8140; Merino, Jordi/0000-0001-8312-1438; Duncan, Emma/0000-0002-8143-4403; Penfold, Rose/0000-0001-7023-7108; Ourselin, Sebastien/0000-0002-5694-5340; Murray, Benjamin/0000-0002-2413-923X; Graham, Mark/0000-0002-4170-1095; Bowyer, Ruth/0000-0002-6941-8160; Sudre, Carole/0000-0001-5753-428X; Modat, Marc/0000-0002-5277-8530; Steves, Claire/0000-0002-4910-0489	National Institute for Health Research (NIHR); UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare; Wellcome Trust; Medical Research Council (MRC); British Heart Foundation (BHF); Alzheimer's Society; European Union; NIHR; COVID-19 Driver Relief Fund (CDRF); KCL; French government, through the 3IA Cote d'Azur Investments in the Future project; National Research Agency (ANR) [ANR-19-P3IA-0002]; Stuart and Suzanne Steele MGH Research Scholar Award; Chronic Disease Research Foundation; MRC AimHy project grant; Massachusetts Consortium on Pathogen Readiness (MassCPR); European Commission [H2020-MSCA-IF-2015-703787]; Swedish Research Council; Swedish Heart-Lung Foundation; Swedish Foundation for Strategic Research [LUDC-IRC 15-0067]	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare; Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation (BHF)(British Heart Foundation); Alzheimer's Society; European Union(European Commission); NIHR(National Institute for Health Research (NIHR)); COVID-19 Driver Relief Fund (CDRF); KCL; French government, through the 3IA Cote d'Azur Investments in the Future project; National Research Agency (ANR)(French National Research Agency (ANR)); Stuart and Suzanne Steele MGH Research Scholar Award; Chronic Disease Research Foundation; MRC AimHy project grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Massachusetts Consortium on Pathogen Readiness (MassCPR); European Commission(European CommissionEuropean Commission Joint Research Centre); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research)	Zoe Global provided in-kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the National Institute for Health Research (NIHR)-funded Biomedical Research Centre based at Guy's and St Thomas' (GSTT) NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. Investigators also received support from the Wellcome Trust, Medical Research Council (MRC), British Heart Foundation (BHF), Alzheimer's Society, European Union, NIHR, COVID-19 Driver Relief Fund (CDRF) and the NIHR-funded BioResource, Clinical Research Facility and Biomedical Research Centre (BRC) based at GSTT NHS Foundation Trust in partnership with KCL. S.O. was supported by the French government, through the 3IA Cote d'Azur Investments in the Future project managed by the National Research Agency (ANR) with the reference number ANR-19-P3IA-0002. A.T.C. was supported by a Stuart and Suzanne Steele MGH Research Scholar Award. C.M. was funded by the Chronic Disease Research Foundation and by the MRC AimHy project grant. L.H.N., D.A.D., A.D.J. and A.T.C. were supported by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and M. Schwartz and L. Schwartz. J.M. was partially supported by the European Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787). The work performed on the Swedish study was supported by grants from the Swedish Research Council, Swedish Heart-Lung Foundation and the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067).	Alwan NA, 2020, NATURE, V584, P170, DOI 10.1038/d41586-020-02335-z; Drew DA, 2020, SCIENCE, V368, P1362, DOI 10.1126/science.abc0473; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2; Mitrani RD, 2020, HEART RHYTHM, V17, P1984, DOI 10.1016/j.hrthm.2020.06.026; National Institute for Health Research, LIV COVID19, DOI [10.3310/themedreview_41169, DOI 10.3310/THEMEDREVIEW_41169]; Padda Inderbir, 2020, SN Compr Clin Med, V2, P2025, DOI 10.1007/s42399-020-00527-2; Robinson LB, 2021, J ALLER CL IMM-PRACT, V9, P497, DOI 10.1016/j.jaip.2020.10.021; Sheehy Lisa Mary, 2020, JMIR Public Health Surveill, V6, pe19462, DOI 10.2196/19462; Spiel C, 2008, EUR PSYCHOL, V13, P180, DOI 10.1027/1016-9040.13.3.180; Sudre C.H., 2020, MEDRXIV, DOI 10.1101/2020.06.12.20129056; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839	12	627	635	57	90	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01292-y	http://dx.doi.org/10.1038/s41591-021-01292-y		MAR 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33692530	Bronze, Green Submitted, Green Accepted			2022-12-27	WOS:000627193300001
J	He, MX; Cuoco, MS; Crowdis, J; Bosma-Moody, A; Zhang, ZW; Bi, K; Kanodia, A; Su, MJ; Ku, SY; Garcia, MM; Sweet, AR; Rodman, C; DelloStritto, L; Silver, R; Steinharter, J; Shah, P; Izar, B; Walk, NC; Burke, KP; Bakouny, Z; Tewari, AK; Liu, D; Camp, SY; Vokes, NI; Salari, K; Park, J; Vigneau, S; Fong, L; Russo, JW; Yuan, X; Balk, SP; Beltran, H; Rozenblatt-Rosen, O; Regev, A; Rotem, A; Taplin, ME; Van Allen, EM				He, Meng Xiao; Cuoco, Michael S.; Crowdis, Jett; Bosma-Moody, Alice; Zhang, Zhenwei; Bi, Kevin; Kanodia, Abhay; Su, Mei-Ju; Ku, Sheng-Yu; Garcia, Maria Mica; Sweet, Amalia R.; Rodman, Christopher; DelloStritto, Laura; Silver, Rebecca; Steinharter, John; Shah, Parin; Izar, Benjamin; Walk, Nathan C.; Burke, Kelly P.; Bakouny, Ziad; Tewari, Alok K.; Liu, David; Camp, Sabrina Y.; Vokes, Natalie I.; Salari, Keyan; Park, Jihye; Vigneau, Sebastien; Fong, Lawrence; Russo, Joshua W.; Yuan, Xin; Balk, Steven P.; Beltran, Himisha; Rozenblatt-Rosen, Orit; Regev, Aviv; Rotem, Asaf; Taplin, Mary-Ellen; Van Allen, Eliezer M.			Transcriptional mediators of treatment resistance in lethal prostate cancer	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; ANDROGEN-RECEPTOR; EXPRESSION SIGNATURE; LINEAGE PLASTICITY; SPLICE VARIANTS; PROGNOSIS; CARCINOMA; INFERENCE	Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors(1). Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites. Irrespective of treatment exposure, adenocarcinoma cells pervasively coexpressed multiple androgen receptor isoforms, including truncated isoforms hypothesized to mediate resistance to androgen-targeting therapies(2,3). Resistance to enzalutamide was associated with cancer cell-intrinsic epithelial-mesenchymal transition and transforming growth factor-beta signaling. Small cell carcinoma cells exhibited divergent expression programs driven by transcriptional regulators promoting lineage plasticity and HOXB5, HOXB6 and NR1D2 (refs. (4-6)). Additionally, a subset of patients had high expression of dysfunction markers on cytotoxic CD8(+) T cells undergoing clonal expansion following enzalutamide treatment. Collectively, the transcriptional characterization of cancer and immune cells from human metastatic castration-resistant prostate cancer provides a basis for the development of therapeutic approaches complementing androgen signaling inhibition. Single-cell transcriptomic analysis of metastatic castration-resistant prostate cancer uncovers pervasive coexpression of androgen receptor isoforms and cancer cell-intrinsic and microenvironmental programs of treatment resistance	[He, Meng Xiao] Harvard Grad Program Biophys, Boston, MA USA; [He, Meng Xiao; Crowdis, Jett; Bosma-Moody, Alice; Zhang, Zhenwei; Bi, Kevin; Kanodia, Abhay; Su, Mei-Ju; Ku, Sheng-Yu; Garcia, Maria Mica; DelloStritto, Laura; Silver, Rebecca; Steinharter, John; Shah, Parin; Walk, Nathan C.; Burke, Kelly P.; Bakouny, Ziad; Tewari, Alok K.; Liu, David; Camp, Sabrina Y.; Vokes, Natalie I.; Park, Jihye; Vigneau, Sebastien; Beltran, Himisha; Rotem, Asaf; Taplin, Mary-Ellen; Van Allen, Eliezer M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [He, Meng Xiao; Cuoco, Michael S.; Crowdis, Jett; Bosma-Moody, Alice; Bi, Kevin; Rodman, Christopher; Liu, David; Camp, Sabrina Y.; Vokes, Natalie I.; Salari, Keyan; Park, Jihye; Vigneau, Sebastien; Rozenblatt-Rosen, Orit; Regev, Aviv; Rotem, Asaf; Van Allen, Eliezer M.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Bosma-Moody, Alice] Harvard Med Sch, Boston, MA 02115 USA; [Sweet, Amalia R.; Russo, Joshua W.; Yuan, Xin; Balk, Steven P.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; [DelloStritto, Laura; Vigneau, Sebastien; Rotem, Asaf; Van Allen, Eliezer M.] Dana Farber Canc Inst, Ctr Canc Genom, Boston, MA 02115 USA; [Izar, Benjamin] Columbia Ctr Translat Immunol, New York, NY USA; [Izar, Benjamin] Columbia Univ, Dept Med, Med Ctr, Div Hematol Oncol, New York, NY USA; [Burke, Kelly P.] Harvard Med Sch, Blavatnik Inst, Dept Immunol, Boston, MA 02115 USA; [Burke, Kelly P.] Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA; [Burke, Kelly P.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Salari, Keyan] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; [Fong, Lawrence] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA; [Regev, Aviv] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA USA; [Regev, Aviv] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Zhang, Zhenwei] Univ Massachusetts, Mem Med Ctr, Dept Pathol, Worcester, MA 01605 USA; [Vokes, Natalie I.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Oncol, Houston, TX 77030 USA; [Vokes, Natalie I.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Regev, Aviv] Genentech Inc, San Francisco, CA 94080 USA; [Rotem, Asaf] AstraZeneca, Waltham, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Columbia University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Genentech; AstraZeneca	Van Allen, EM (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Van Allen, EM (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.; Van Allen, EM (corresponding author), Dana Farber Canc Inst, Ctr Canc Genom, Boston, MA 02115 USA.	eliezerm_vanallen@dfci.harvard.edu	Rozenblatt-Rosen, Orit/HDN-4182-2022; Bakouny, Ziad/A-1149-2018	Kanodia, Abhay Rajkumar/0000-0002-7645-002X; Liu, David/0000-0003-0346-5033; Shah, Parin/0000-0003-4648-7830; Bakouny, Ziad/0000-0003-1906-5704				Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Ahrens-Fath I, 2005, FEBS J, V272, P74, DOI 10.1111/j.1432-1033.2004.04395.x; Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Annala M, 2018, CANCER DISCOV, V8, P444, DOI 10.1158/2159-8290.CD-17-0937; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Benjamini Y., 1995, J R STAT SOC B, V57, P289, DOI DOI 10.1111/J.2517-6161.1995.TB02031.X; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Borges GT, 2016, J CELL PHYSIOL, V231, P2040, DOI 10.1002/jcp.25313; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chen WS, 2019, EUR UROL, V76, P562, DOI 10.1016/j.eururo.2019.03.020; Crowdis J, 2020, BIOINFORMATICS, V36, P4348, DOI 10.1093/bioinformatics/btaa554; De Tomaso D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12235-0; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Finucane HK, 2018, NAT GENET, V50, P621, DOI 10.1038/s41588-018-0081-4; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Graff JN, 2016, ONCOTARGET, V7, P52810, DOI 10.18632/oncotarget.10547; Haas BJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1842-9; Hoki T., 2018, J IMMUNOL, V200, P58; Hu DG, 2014, HORM CANCER-US, V5, P61, DOI 10.1007/s12672-014-0171-4; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hudson WH, 2019, IMMUNITY, V51, P1043, DOI 10.1016/j.immuni.2019.11.002; Hwang JH, 2019, CELL REP, V29, P2355, DOI 10.1016/j.celrep.2019.10.068; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li YJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0428; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Lu J, 2015, NAT REV UROL, V12, P137, DOI 10.1038/nrurol.2015.13; Mancuso N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06302-1; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z; Puca L, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a030593; Ragnum HB, 2015, BRIT J CANCER, V112, P382, DOI 10.1038/bjc.2014.604; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rodrigues DN, 2018, J CLIN INVEST, V128, P4441, DOI [10.1172/JCI121924, 10.1172/JCI125184]; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Schumacher FR, 2018, NAT GENET, V50, P928, DOI 10.1038/s41588-018-0142-8; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Sweeney CJ, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-CT014; Teo MY, 2019, ANNU REV MED, V70, P479, DOI 10.1146/annurev-med-051517-011947; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wyatt AW, 2016, JAMA ONCOL, V2, P1598, DOI 10.1001/jamaoncol.2016.0494; Yuan FW, 2019, NUCLEIC ACIDS RES, V47, P10104, DOI 10.1093/nar/gkz790; Zander R, 2019, IMMUNITY, V51, P1028, DOI 10.1016/j.immuni.2019.10.009	60	36	36	6	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					426	+		10.1038/s41591-021-01244-6	http://dx.doi.org/10.1038/s41591-021-01244-6		MAR 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33664492	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000626919600006
J	Caswell-Jin, JL; Curtis, C				Caswell-Jin, Jennifer L.; Curtis, Christina			Androgen receptor agonists as breast cancer therapeutics	NATURE MEDICINE			English	Editorial Material									[Caswell-Jin, Jennifer L.; Curtis, Christina] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA 94305 USA; [Curtis, Christina] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Curtis, Christina] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford Cancer Institute; Stanford University	Caswell-Jin, JL; Curtis, C (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA 94305 USA.; Curtis, C (corresponding author), Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.; Curtis, C (corresponding author), Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.	caswell@stanford.edu; cncurtis@stanford.edu		Caswell-Jin, Jennifer/0000-0002-5711-8355; Curtis, Christina/0000-0003-0166-3802				ADAIR FE, 1946, ANN SURG, V123, P1023, DOI 10.1097/00000658-194606000-00006; Arruabarrena-Aristorena, 2020, CANCER CELL; D'Amato NC, 2016, MOL CANCER RES, V14, P1054, DOI 10.1158/1541-7786.MCR-16-0167; Garay JP, 2012, AM J CANCER RES, V2, P434; Hickey TE, 2021, NAT MED, V27, P310, DOI 10.1038/s41591-020-01168-7; Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021; KELLEY RM, 1971, CANCER, V28, P1686, DOI 10.1002/1097-0142(197112)28:6<1686::AID-CNCR2820280657>3.0.CO;2-6; Krop I, 2020, CLIN CANCER RES, V26, P6149, DOI 10.1158/1078-0432.CCR-20-1693; Michmerhuizen AR, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-00190-9; Palmieri, SAN ANT BREAST CANC; Schiff R, 2003, CLIN CANCER RES, V9, p447S; Vera-Badillo FE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt319	12	3	3	1	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					198	199		10.1038/s41591-021-01242-8	http://dx.doi.org/10.1038/s41591-021-01242-8		FEB 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33558723				2022-12-27	WOS:000616056700005
J	Kim, JH; Marks, F; Clemens, JD				Kim, Jerome H.; Marks, Florian; Clemens, John D.			Looking beyond COVID-19 vaccine phase 3 trials	NATURE MEDICINE			English	Article							ORAL CHOLERA VACCINES; ROTAVIRUS VACCINATION; DEVELOPING-COUNTRIES; PROTECTION; INTUSSUSCEPTION; EFFICACY; QUALITY; SAFETY; VIRUS; RISK	After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required. These considerations should include how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, the equitable distribution of vaccines and the logistics of global vaccine delivery, all of which are a prelude to a massive vaccination campaign targeting people of all ages. Furthermore, additional scientific questions about the vaccines remain that should be answered to improve vaccine efficacy, including questions regarding the optimization of vaccination regimens, booster doses, the correlates of protection, vaccine effectiveness, safety and enhanced surveillance. The timely and coordinated execution of these post-efficacy tasks will bring the pandemic to an effective, and efficient, close.	[Kim, Jerome H.; Marks, Florian; Clemens, John D.] Int Vaccine Inst, Seoul, South Korea; [Marks, Florian] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Sch Clin Med, Cambridge, England; [Marks, Florian] Univ Antananarivo, Antananarivo, Madagascar; [Clemens, John D.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh; [Clemens, John D.] UCLA, Fielding Sch Publ Hlth, Los Angeles, CA USA	International Vaccine Institute; University of Cambridge; University Antananarivo; International Centre for Diarrhoeal Disease Research (ICDDR); University of California System; University of California Los Angeles	Kim, JH (corresponding author), Int Vaccine Inst, Seoul, South Korea.	jerome.kim@ivi.int		Marks, Florian/0000-0002-6043-7170; Kim, Jerome/0000-0003-0461-6438				Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; Ainslie KEC, 2019, EXPERT REV VACCINES, V18, P615, DOI 10.1080/14760584.2019.1622419; Ali M, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00211; [Anonymous], 2002, Bull World Health Organ, V80, P983; [Anonymous], 2013, VACCINES; [Anonymous], 2020, BEHAV CONSIDERATIONS; [Anonymous], 2020, REUTERS; [Anonymous], 2013, EXP CONS US PLAC VAC; Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/S1473-3099(17)30359-6, 10.1016/s1473-3099(17)30359-6]; Bisgard KM, 2000, J INFECT DIS, V181, pS184, DOI 10.1086/315562; Chinazzi M., 2020, ESTIMATING EFFECT CO; Clark A, 2019, LANCET GLOB HEALTH, V7, pE1541, DOI 10.1016/S2214-109X(19)30412-7; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; Coalition for Epidemic Preparedness Innovations, 2020, CEPI FUND 3 PROGR DE; Coalition for Epidemic Preparedness Innovations, 2020, CEPI SURV ASS POT CO; Coons C, 2020, BLOOMBERG BUSINESS W; Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908; Cuddy A, 2020, CORONAVIRUS VACCINES; de Vrieze J, 2020, MORE PEOPLE ARE GETT; Dearlove B, 2020, P NATL ACAD SCI USA, V117, P23652, DOI 10.1073/pnas.2008281117; Definition and Application of Terms for Vaccine Pharmacovigilance, 2012, DEFINITION APPL TERM; Denoel PA, 2007, CLIN VACCINE IMMUNOL, V14, P1362, DOI 10.1128/CVI.00154-07; Duke Global Health Innovation Center, 2020, MAPP COVID 19 VACC P; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Freyman E., 2020, FOREIGN AFFAIRS; Gavi, 2020, GAV COVAX AMC EXPL; Gomes M Gabriela M, 2022, medRxiv, DOI 10.1101/2020.04.27.20081893; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Guarascio F, 2020, EXCLUSIVE WHO VACCIN; Haber M, 1995, INT J EPIDEMIOL, V24, P1249, DOI 10.1093/ije/24.6.1249; Higgins-Dunn N, 2020, COVAX GLOBAL COVID V; Hitchings MDT, 2018, AM J EPIDEMIOL, V187, P1763, DOI 10.1093/aje/kwy047; Holl K, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3738-x; Iwasaki A, 2021, LANCET INFECT DIS, V21, P3, DOI 10.1016/S1473-3099(20)30783-0; [Anonymous], 2020, Nat Rev Dis Primers, V6, P14, DOI [10.1038/s41572-020-0147-3, 10.1038/s41572-020-0154-4]; Jadhav S, 2014, CLIN MICROBIOL INFEC, V20, P37, DOI 10.1111/1469-0691.12568; Kahn R, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002632; Kamidani S., 2020, AAP NEWS, V41, P12; Kieny MP, 2016, LANCET, V387, P1509, DOI [10.1016/S0140-6736(16)00686-3, 10.1016/S0140-6736(16)32621-6]; Koch J, 2017, DTSCH ARZTEBL INT, V114, P255, DOI 10.3238/arztebl.2017.0255; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Krause PR, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2031373; Kupferschmidt K, 2020, SCIENCE, V369, P1553, DOI 10.1126/science.369.6511.1553; Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lofano G, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00238-8; Longini IM, 2007, PLOS MED, V4, P1776, DOI 10.1371/journal.pmed.0040336; Lu HL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12458; Lucas MES, 2005, NEW ENGL J MED, V352, P757, DOI 10.1056/NEJMoa043323; Mantel C, 2020, BUNDESGESUNDHEITSBLA, V63, P25, DOI 10.1007/s00103-019-03066-x; Mukandavire Z, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.VE-0011-2014; Parker EPK, 2020, NAT REV IMMUNOL, V20, P650, DOI 10.1038/s41577-020-00455-1; Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9; Peto TJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-7; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Plotkin SA, 2020, VACCINE, V38, P2250, DOI 10.1016/j.vaccine.2019.10.046; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roukens AH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001993; Sguazzin A, 2020, SA STUDY PUTS COVID; Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Sullivan SG, 2015, EPIDEMIOLOGY, V26, pE60, DOI 10.1097/EDE.0000000000000343; Sur D, 2009, NEW ENGL J MED, V361, P335, DOI 10.1056/NEJMoa0807521; Trombetta CM, 2018, HUM VACC IMMUNOTHER, V14, P657, DOI 10.1080/21645515.2017.1423153; Usher AD, 2020, LANCET, V395, P1822, DOI 10.1016/S0140-6736(20)31354-4; Uyoga S, 2021, SCIENCE, V371, P79, DOI 10.1126/science.abe1916; Verani JR, 2017, VACCINE, V35, P3295, DOI 10.1016/j.vaccine.2017.04.037; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; WHO, 2020, LIST STRING REG AUTH; Wilder-Smith A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0911-8; World Health Organization, 2021, NOV COR 2019 NCOV SI; World Health Organization, 2019, EB VACC CAND; Wu JT, 2016, LANCET, V388, P2904, DOI 10.1016/S0140-6736(16)31838-4; Yam E, 2020, WHY WE DONT KNOW REA; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zellweger RM, 2020, EXPERT REV VACCINES, V19, P691, DOI 10.1080/14760584.2020.1800463; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	79	282	287	13	59	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					205	211		10.1038/s41591-021-01230-y	http://dx.doi.org/10.1038/s41591-021-01230-y		JAN 2021	7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33469205	Bronze			2022-12-27	WOS:000608951900001
J	Bigenwald, C; Le Berichel, J; Chakraborty, R; Chen, ST; Akturk, G; Tabachnikova, A; Rafiei, A; Laface, I; Lim, H; Baccarini, A; Poulikakos, PI; Brown, BD; Gnjatic, S; Lujambio, A; Man, MG; McClain, KL; Picarsic, J; Allen, CE; Merad, M				Bigenwald, Camille; Le Berichel, Jessica; Chakraborty, Rikhia; Chen, Steven T.; Akturk, Guray; Tabachnikova, Alexandra; Rafiei, Anahita; Laface, Ilaria; Lim, Howard; Baccarini, Alessia; Poulikakos, Poulikos I.; Brown, Brian D.; Gnjatic, Sacha; Lujambio, Amaia; Man, Markus G.; McClain, Kenneth L.; Picarsic, Jennifer; Allen, Carl E.; Merad, Miriam			BRAFV600E-INDUCED SENESCENCE DRIVES LANGERHANS CELL HISTIOCYTOSIS PATHOPHYSIOLOGY	PEDIATRIC BLOOD & CANCER			English	Meeting Abstract									[Bigenwald, Camille; Le Berichel, Jessica; Chen, Steven T.; Akturk, Guray; Tabachnikova, Alexandra; Laface, Ilaria; Baccarini, Alessia; Brown, Brian D.; Gnjatic, Sacha; Lujambio, Amaia; Merad, Miriam] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Bigenwald, Camille; Le Berichel, Jessica; Chen, Steven T.; Akturk, Guray; Tabachnikova, Alexandra; Laface, Ilaria; Baccarini, Alessia; Brown, Brian D.; Gnjatic, Sacha; Lujambio, Amaia; Merad, Miriam] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Bigenwald, Camille; Le Berichel, Jessica; Chen, Steven T.; Akturk, Guray; Tabachnikova, Alexandra; Laface, Ilaria; Baccarini, Alessia; Poulikakos, Poulikos I.; Brown, Brian D.; Gnjatic, Sacha; Lujambio, Amaia; Merad, Miriam] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Chakraborty, Rikhia; Lim, Howard; McClain, Kenneth L.; Allen, Carl E.] Texas Childrens Hosp, Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Rafiei, Anahita; Man, Markus G.] Univ Hosp, Dept Med Oncol & Hematol, Zurich, Switzerland; [Rafiei, Anahita; Man, Markus G.] Univ Zurich, Zurich, Switzerland; [Picarsic, Jennifer] Cincinnati Childrens Hosp Med Ctr, Dept Pathol, Cincinnati, OH 45229 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Baylor College of Medicine; Texas Children's Cancer Center; University of Zurich; University Zurich Hospital; University of Zurich; Cincinnati Children's Hospital Medical Center				Tabachnikova, Alexandra/0000-0003-4695-2480; Wilk, Christian Matthias/0000-0001-5429-7143; Gnjatic, Sacha/0000-0001-5643-9520; Mancusi, Rebecca/0000-0002-4809-5569	NCI NIH HHS [R01 CA190400, R01 CA154947, R01 CA240362] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))			0	3	4	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1545-5009	1545-5017		PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	JAN	2021	68			1	SI									2	Oncology; Hematology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Hematology; Pediatrics	OY0ZH	33958797	Green Submitted, Green Accepted			2022-12-27	WOS:000593982700010
J	Barrett, JR; Belij-Rammerstorfer, S; Dold, C; Ewer, KJ; Folegatti, PM; Gilbride, C; Halkerston, R; Hill, J; Jenkin, D; Stockdale, L; Verheul, MK; Aley, PK; Angus, B; Bellamy, D; Berrie, E; Bibi, S; Bittaye, M; Carroll, MW; Cavell, B; Clutterbuck, EA; Edwards, N; Flaxman, A; Fuskova, M; Gorringe, A; Hallis, B; Kerridge, S; Lawrie, AM; Linder, A; Liu, XX; Madhavan, M; Makinson, R; Mellors, J; Minassian, A; Moore, M; Mujadidi, Y; Plested, E; Poulton, I; Ramasamy, MN; Robinson, H; Rollier, CS; Song, R; Snape, MD; Tarrant, R; Taylor, S; Thomas, KM; Voysey, M; Watson, MEE; Wright, D; Douglas, AD; Green, CM; Hill, AVS; Lambe, T; Gilbert, S; Pollard, AJ				Barrett, Jordan R.; Belij-Rammerstorfer, Sandra; Dold, Christina; Ewer, Katie J.; Folegatti, Pedro M.; Gilbride, Ciaran; Halkerston, Rachel; Hill, Jennifer; Jenkin, Daniel; Stockdale, Lisa; Verheul, Marije K.; Aley, Parvinder K.; Angus, Brian; Bellamy, Duncan; Berrie, Eleanor; Bibi, Sagida; Bittaye, Mustapha; Carroll, Miles W.; Cavell, Breeze; Clutterbuck, Elizabeth A.; Edwards, Nick; Flaxman, Amy; Fuskova, Michelle; Gorringe, Andrew; Hallis, Bassam; Kerridge, Simon; Lawrie, Alison M.; Linder, Aline; Liu, Xinxue; Madhavan, Meera; Makinson, Rebecca; Mellors, Jack; Minassian, Angela; Moore, Maria; Mujadidi, Yama; Plested, Emma; Poulton, Ian; Ramasamy, Maheshi N.; Robinson, Hannah; Rollier, Christine S.; Song, Rinn; Snape, Matthew D.; Tarrant, Richard; Taylor, Stephen; Thomas, Kelly M.; Voysey, Merryn; Watson, Marion E. E.; Wright, Daniel; Douglas, Alexander D.; Green, Catherine M.; Hill, Adrian V. S.; Lambe, Teresa; Gilbert, Sarah; Pollard, Andrew J.		Oxford COVID Vaccine Trial Grp	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	NATURE MEDICINE			English	Article							DOUBLE-BLIND; HIGH-THROUGHPUT; HIV-1 VACCINE; PROTECTION; IMMUNITY; ASSAY; DISEASE; ADULTS	More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 randomized controlled trial of healthy adults aged 18-55 years (NCT04324606). Now we describe safety and exploratory humoral and cellular immunogenicity of the vaccine, from subgroups of volunteers in that trial, who were subsequently allocated to receive a homologous full-dose (SD/SD D56; n = 20) or half-dose (SD/LD D56; n = 32) ChAdOx1 booster vaccine 56 d following prime vaccination. Previously reported immunogenicity data from the open-label 28-d interval prime-boost group (SD/SD D28; n = 10) are also presented to facilitate comparison. Additionally, we describe volunteers boosted with the comparator vaccine (MenACWY; n = 10). In this interim report, we demonstrate that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses. Using a systems serology approach we also demonstrate that anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster dose of vaccine. A booster dose of vaccine induced stronger antibody responses than a dose-sparing half-dose boost, although the magnitude of T cell responses did not increase with either boost dose. These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials.	[Barrett, Jordan R.; Belij-Rammerstorfer, Sandra; Ewer, Katie J.; Folegatti, Pedro M.; Gilbride, Ciaran; Jenkin, Daniel; Bellamy, Duncan; Bittaye, Mustapha; Edwards, Nick; Flaxman, Amy; Fuskova, Michelle; Kerridge, Simon; Lawrie, Alison M.; Madhavan, Meera; Makinson, Rebecca; Minassian, Angela; Poulton, Ian; Watson, Marion E. E.; Wright, Daniel; Douglas, Alexander D.; Hill, Adrian V. S.; Lambe, Teresa; Gilbert, Sarah] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England; [Dold, Christina; Hill, Jennifer; Stockdale, Lisa; Verheul, Marije K.; Aley, Parvinder K.; Bibi, Sagida; Clutterbuck, Elizabeth A.; Linder, Aline; Liu, Xinxue; Moore, Maria; Mujadidi, Yama; Plested, Emma; Ramasamy, Maheshi N.; Robinson, Hannah; Rollier, Christine S.; Song, Rinn; Snape, Matthew D.; Voysey, Merryn; Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England; [Halkerston, Rachel; Cavell, Breeze; Gorringe, Andrew; Hallis, Bassam; Mellors, Jack; Taylor, Stephen; Thomas, Kelly M.] Publ Hlth England, Salisbury, Wilts, England; [Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England; [Berrie, Eleanor; Carroll, Miles W.; Tarrant, Richard; Green, Catherine M.] Univ Oxford, Jenner Inst, Nuffield Dept Med, Clin BioMfg Facil, Oxford, England	University of Oxford; Jenner Institute; University of Oxford; Public Health England; University of Oxford; University of Oxford; Jenner Institute	Jenkin, D (corresponding author), Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England.; Pollard, AJ (corresponding author), Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.	Daniel.Jenkin@ndm.ox.ac.uk; Andrew.Pollard@paediatrics.ox.ac.uk	Baker, Philip/ABI-2575-2020; O'Connor, Daniel/AAF-4903-2019; Gorringe, Andrew R/L-6022-2017; Jenkin, Daniel/AAB-7042-2022; Noé, Andrés/AAU-9612-2020; Chelysheva, Irina/AAQ-5231-2021; Dold, Christina/ABA-4237-2021; Ewer, Katie J/B-4328-2011; Lambe, Teresa/E-5733-2016; Folegatti, Pedro/AAD-5238-2019; Tomic, Adriana/AAX-7203-2021; Schmid, Annina/F-3070-2010; Knight, Julian/W-2399-2019; Douglas, Alexander/E-7040-2012	Baker, Philip/0000-0002-4519-1563; O'Connor, Daniel/0000-0002-6902-9886; Gorringe, Andrew R/0000-0003-2193-7954; Noé, Andrés/0000-0002-6408-7032; Chelysheva, Irina/0000-0001-7802-7025; Ewer, Katie J/0000-0001-9827-9836; Lambe, Teresa/0000-0001-7711-897X; Folegatti, Pedro/0000-0001-5330-0240; Tomic, Adriana/0000-0001-9885-3535; Schmid, Annina/0000-0001-7759-0211; Hodgson, Susanne/0000-0002-0895-3442; Feng, Elaine Shuo/0000-0001-7855-0991; Knight, Julian/0000-0002-0377-5536; Snape, Matthew/0000-0003-0531-5426; Taylor, Stephen/0000-0002-9936-8539; Garlant, Harriet/0000-0001-7612-6441; Chadwick, Jim/0000-0001-9935-4762; Bibi, Sagida/0000-0002-0855-2737; Skelly, Donal/0000-0002-2426-3097; Jackson, Frederic/0000-0001-8230-083X; Matthews, Philippa/0000-0002-4036-4269; Themistocleous, Andreas/0000-0002-1089-1543; Marshall, Julia/0000-0002-9692-6769; Mellors, Jack/0000-0001-7761-8341; Allen, Lauren/0000-0003-1846-8181; Lias, Amelia/0000-0003-2939-7761; Minassian, Angela/0000-0001-7832-9824; Spencer, Alexandra/0000-0001-7958-6961; Sanders, Katherine/0000-0002-4090-3277; Moore, Maria/0000-0001-6456-927X; Frater, John/0000-0001-7163-7277; Marinou, Spyridoula/0000-0002-0764-5966; Jenkin, Daniel/0000-0003-3088-310X; Green, Catherine/0000-0002-7068-7106; Leung, Stephanie/0000-0002-8880-2977; dold, christina/0000-0003-2314-507X; Donnellan, Francesca/0000-0002-4723-3560; Thomas, Tonia/0000-0003-3091-5917; klenerman, paul/0000-0003-4307-9161; Makinson, Rebecca/0000-0001-7582-9073; Phillips, Dan/0000-0003-0686-5091; Anslow, Rachel/0000-0002-9111-2897; Felle, Sally/0000-0001-7855-4482; Bellamy, Duncan/0000-0003-3614-0032; Mentzer, Alexander/0000-0002-4502-2209; Coombes, Naomi/0000-0001-9631-6875; Douglas, Alexander/0000-0002-5410-7562; Sanders, Helen/0000-0002-9657-5524; Henry, Aaron/0000-0002-7650-0963; Fowler, Jamie/0000-0003-0258-9114; Aley, Parvinder/0000-0002-0749-8329; Hou, Mimi/0000-0002-8517-9147; Bewley, Kevin/0000-0002-9078-6734; Patrick-Smith, Maia/0000-0001-7679-3754; Ramos Lopez, Fernando/0000-0002-9997-7879; Dunachie, Susanna/0000-0001-5665-6293; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Dong, Tao/0000-0003-3545-3758; Farooq Mujadidi, Yama/0000-0002-2342-8531; Marchevsky, Natalie/0000-0003-1055-0033; Mallett, Garry/0000-0001-5475-9061; Screaton, Gavin/0000-0002-3549-4309; Morter, Richard/0000-0002-7005-1546; Wright, Daniel/0000-0002-8114-1838; Allen, Elizabeth/0000-0002-6406-4834; Mukhopadhyay, Ekta/0000-0002-6045-2522; Barrett, Jordan/0000-0003-0746-1945; Sharpe, Hannah/0000-0002-1194-2429; Khozoee, Baktash/0000-0002-2470-3283; Barnes, Eleanor/0000-0002-0860-0831	National Institute for Health Research (NIHR); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil [001]; EPSRC [EP/R013756/1] Funding Source: UKRI; MRC [MC_UU_00008/11, G0600520, G1001046, MC_PC_19058, MC_PC_19055, MR/L018942/1, MR/T001151/1] Funding Source: UKRI	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The funder had no role in the design, execution or analysis of this study. This report is independent research funded by the National Institute for Health Research (NIHR). The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care (DHSC). Additional resources for study delivery were provided by NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre; University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research Facility; and NIHR North West London, South London, Wessex and West of England Local Clinical Research Networks; and NIHR Oxford Health Biomedical Research Centre. P.M.F. received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). The control vaccine was provided free of charge by the UK DHSC. The authors are grateful to the volunteers who participated in this study. The investigators express their gratitude for the contribution of all the trial participants, the invaluable advice of the international DSMB (Supplementary Information) and the independent members of the trial steering committee. We are grateful for the advice and intellectual support from K.S. Campbell (Institute for Cancer Research, Philadelphia) with the NK cell line culture and use. The authors are grateful to the senior management at AstraZeneca for facilitating and funding the manufacture of the AZD1222 vaccine candidate, the pseudovirus neutralization assays and Meso Scale antibody assay used in this study. AstraZeneca reviewed the data from the study and the final manuscript before submission, but the authors retained editorial control. Finally, we acknowledge UKRI, NIHR, CEPI, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network and AstraZeneca.	Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1101/2020.03.17.20037713, 10.1038/s41591-020-0913-5]; Anywaine Z, 2019, J INFECT DIS, V220, P46, DOI 10.1093/infdis/jiz070; Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]; Binyamin L, 2008, J IMMUNOL, V180, P6392, DOI 10.4049/jimmunol.180.9.6392; Biswas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107903; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Douoguih M., 2020, SAFETY IMMUNOGENICIT, DOI [10.1101/ 2020.09.23.20199604, DOI 10.1101/2020.09.23.20199604]; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Excler JL, 2014, CLIN VACCINE IMMUNOL, V21, P1023, DOI 10.1128/CVI.00230-14; Fenrich M, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00229; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6; Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI [10.1056/NEJMoa1410863, 10.1056/nejmoa1410863]; Lesne E, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02108; Levin A. T., 2020, MEDRXIV PREPRINT, DOI [10.1101/2020.07.23.20160895, DOI 10.1101/2020.07.23.20160895, DOI 10.1172/jci.insight.93683]; Li JX, 2017, LANCET GLOB HEALTH, V5, pE324, DOI [10.1016/S2214-109X(16)30367-9, 10.1016/s2214-109x(16)30367-9]; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Payne RO, 2017, JCI INSIGHT, V2, DOI [10.1172/jci.insight.93683, 10.1172/jci.insight.96381]; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Seo SH, 2000, VIROLOGY, V269, P183, DOI 10.1006/viro.2000.0211; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06; WHO, 2020, COVID 19 DRAFT LANDS; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; Williams K, 2020, J INFECT DIS, V222, P979, DOI 10.1093/infdis/jiaa193; Wu F., 2020, MEDRXIV, DOI [10.1101/2020.03.30.20047365, 10.1101/2020.03.30.20047365v2, 10.1101/2020.03.30.20047365., DOI 10.1101/2020.03.30.20, 10.2139/ssrn.3566211]; Wyllie D., 2020, SARS COV 2 RESPONSIV, DOI [10.1101/2020.11.02.20222778, DOI 10.1101/2020.11.02.20222778]; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	54	153	157	3	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					279	+		10.1038/s41591-020-01179-4	http://dx.doi.org/10.1038/s41591-020-01179-4		DEC 2020	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33335322	Bronze, Green Submitted			2022-12-27	WOS:000599796800002
J	Stower, H				Stower, Hannah			New CARs in the therapeutic fleet	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	1	1	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1804	1805		10.1038/s41591-020-01151-2	http://dx.doi.org/10.1038/s41591-020-01151-2			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288934				2022-12-27	WOS:000596579200006
J	Stower, H				Stower, Hannah			RNA therapies prepare for the spotlight	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	1	1	1	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1805	1805		10.1038/s41591-020-01154-z	http://dx.doi.org/10.1038/s41591-020-01154-z			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288926				2022-12-27	WOS:000596579200011
J	Bruel, T; Hadjadj, J; Maes, P; Planas, D; Seve, A; Staropoli, I; Guivel-Benhassine, F; Porrot, F; Bolland, WH; Nguyen, Y; Casadevall, M; Charre, C; Pere, H; Veyer, D; Prot, M; Baidaliuk, A; Cuypers, L; Planchais, C; Mouquet, H; Baele, G; Mouthon, L; Hocqueloux, L; Simon-Loriere, E; Andre, E; Terrier, B; Prazuck, T; Schwartz, O				Bruel, Timothee; Hadjadj, Jerome; Maes, Piet; Planas, Delphine; Seve, Aymeric; Staropoli, Isabelle; Guivel-Benhassine, Florence; Porrot, Francoise; Bolland, William-Henry; Nguyen, Yann; Casadevall, Marion; Charre, Caroline; Pere, Helene; Veyer, David; Prot, Matthieu; Baidaliuk, Artem; Cuypers, Lize; Planchais, Cyril; Mouquet, Hugo; Baele, Guy; Mouthon, Luc; Hocqueloux, Laurent; Simon-Loriere, Etienne; Andre, Emmanuel; Terrier, Benjamin; Prazuck, Thierry; Schwartz, Olivier			Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	NATURE MEDICINE			English	Article								Therapeutic antibodies, and sera from immunocompromised individuals prophylactically treated with therapeutic antibodies, differ in neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, which could have implications for pre-exposure and post-exposure treatment. The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 mutations in its spike. In this study, we first compared the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs). In contrast to BA.1, BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. We then analyzed sera from 29 immunocompromised individuals up to 1 month after administration of Ronapreve (casirivimab and imdevimab) and/or Evusheld (cilgavimab and tixagevimab) antibody cocktails. All treated individuals displayed elevated antibody levels in their sera, which efficiently neutralized the Delta variant. Sera from Ronapreve recipients did not neutralize BA.1 and weakly inhibited BA.2. Neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 Evusheld recipients, respectively. As compared to the Delta variant, neutralizing titers were more markedly decreased against BA.1 (344-fold) than BA.2 (nine-fold). We further report four breakthrough Omicron infections among the 29 individuals, indicating that antibody treatment did not fully prevent infection. Collectively, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron neutralizing activity of Ronapreve and, to a lesser extent, that of Evusheld is reduced in patients' sera.	[Bruel, Timothee; Planas, Delphine; Staropoli, Isabelle; Guivel-Benhassine, Florence; Porrot, Francoise; Bolland, William-Henry; Schwartz, Olivier] Univ Paris Cite, Inst Pasteur, Virus & Immun Unit, CNRS,UMR3569, Paris, France; [Bruel, Timothee; Planas, Delphine; Schwartz, Olivier] Vaccine Res Inst, Creteil, France; [Hadjadj, Jerome; Nguyen, Yann; Casadevall, Marion; Mouthon, Luc; Terrier, Benjamin] Hop Cochin, AP HP, Natl Reference Ctr Rare Syst Autoimmune Dis, Dept Internal Med,AP HP CUP, Paris, France; [Maes, Piet; Baele, Guy] Katholieke Univ Leuven, Lab Clin & Epidemiol Virol, Dept Microbiol Immunol & Transplantat, Leuven, Belgium; [Seve, Aymeric; Hocqueloux, Laurent; Prazuck, Thierry] CHR Orleans, Serv Malad Infect, Orleans, France; [Bolland, William-Henry] Univ Paris Cite, Bcole Doctorale BioSPC 562, Paris, France; [Charre, Caroline] Univ Paris Cite, Fac Med, Paris, France; [Charre, Caroline] Inst Cochin, CNRS UMR8104, INSERM U1016, Paris, France; [Charre, Caroline] CHU Cochin, AP HP, Lab Virol, Paris, France; [Pere, Helene; Veyer, David] Univ Paris, Ctr Rech Cordeliers, INSERM, Funct Genom Solid Tumors FunGeST, Paris, France; [Pere, Helene; Veyer, David] Sorbonne Univ, Paris, France; [Pere, Helene; Veyer, David] Hop Europeen Georges Pompidou, AP HP, Serv Microbiol, Lab Virol, Paris, France; [Prot, Matthieu; Baidaliuk, Artem; Simon-Loriere, Etienne] Univ Paris Cite, Inst Pasteur, Evolutionary Genom RNA Viruses G5, Paris, France; [Cuypers, Lize; Andre, Emmanuel] Univ Hosp Leuven, Natl Reference Ctr Resp Pathogens, Dept Lab Med, Leuven, Belgium; [Planchais, Cyril; Mouquet, Hugo] Univ Paris Cite, Inst Pasteur, Humoral Immunol Lab, INSERM U1222, Paris, France; [Andre, Emmanuel] Katholieke Univ Leuven, Lab Clin Microbiol, Dept Microbiol Immunol & Transplantat, Leuven, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; Centre Hospitalier Regional d'Orleans; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven; University Hospital Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven	Bruel, T; Schwartz, O (corresponding author), Univ Paris Cite, Inst Pasteur, Virus & Immun Unit, CNRS,UMR3569, Paris, France.; Bruel, T; Schwartz, O (corresponding author), Vaccine Res Inst, Creteil, France.	timothee.bruel@pasteur.fr; olivier.schwartz@pasteur.fr	Hadjadj, Jerome/AGY-3817-2022; Charre, Caroline/AAY-9326-2020; Bruel, Timothée/AAI-4632-2020; Mouquet, Hugo/M-2750-2014; Maes, Piet/P-7782-2017	Charre, Caroline/0000-0002-4356-5146; Mouquet, Hugo/0000-0002-4230-610X; Nguyen, Yann/0000-0002-0866-3824; Maes, Piet/0000-0002-4571-5232; Andre, Emmanuel/0000-0001-8321-3770	European Health Emergency Preparedness and Response Authority (HERA); Institut Pasteur; Region.le-de-France (DIM1Health); KU Leuven University; Sciensano; Urgence COVID-19 Fundraising Campaign of Institut Pasteur; Fondation pour la Recherche Medicale (FRM); ANRS; Vaccine Research Institute [ANR-10-LABX-77]; Labex IBEID [ANR-10-LABX-62-IBEID]; ANR/FRM Flash Covid PROTEO-SARS-CoV-2; ANR Coronamito; ANR IDISCOVR; Region.le-de-France program DIM1Health; Vaccine Research Institute; Internal Funds KU Leuven [C14/18/094, 3M170314]; Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen) [G0E1420N, G098321N]; COVID-19 research grant of 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders [G0H4420N]; 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders [G0H4420N]; INCEPTION program (Investissements d'Avenir grant) [ANR-16-CONV-0005];  [ANR10-INSB-04-01]	European Health Emergency Preparedness and Response Authority (HERA); Institut Pasteur(European Commission); Region.le-de-France (DIM1Health); KU Leuven University(KU Leuven); Sciensano; Urgence COVID-19 Fundraising Campaign of Institut Pasteur; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); ANRS(ANRSFrench National Research Agency (ANR)); Vaccine Research Institute; Labex IBEID; ANR/FRM Flash Covid PROTEO-SARS-CoV-2; ANR Coronamito(French National Research Agency (ANR)); ANR IDISCOVR(French National Research Agency (ANR)); Region.le-de-France program DIM1Health; Vaccine Research Institute; Internal Funds KU Leuven; Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen)(FWO); COVID-19 research grant of 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders; 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders; INCEPTION program (Investissements d'Avenir grant)(French National Research Agency (ANR)); 	We thank the European Health Emergency Preparedness and Response Authority (HERA) for supporting the work being done at Institut Pasteur and UK Leuven. We thank J. Buchrieser, J. Puech and F. Gambaro for their help with the sequencing data analysis. We thank the patients who participated to this study. We thank Y. Yazdanpanah, members of the Virus and Immunity Unit and other teams for discussions and help, N. Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis. The Opera system was co-funded by Institut Pasteur and the Region.le-de-France (DIM1Health). We thank the KU Leuven University authorities and J. Arnout, B. Lambrecht, C. Van Geet and L. Sels for their support. We thank F. Peira, V. Legros and L. Courtellemont for their help with the cohorts. UZ Leuven, as national reference center for respiratory pathogens, is supported by Sciensano, which is gratefully acknowledged. Work in the O.S. lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale (FRM), ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, ANR Coronamito and IDISCOVR. Work in the UPBI facility is funded by grant ANR10-INSB-04-01 and the Region.le-de-France program DIM1Health. D.P. is supported by the Vaccine Research Institute. G.B. acknowledges support from the Internal Funds KU Leuven under grant agreement C14/18/094 and the Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, G0E1420N and G098321N). P.M. acknowledges support from a COVID-19 research grant of `Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders (grant G0H4420N). P.M. acknowledges support of a COVID-19 research grant from `Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders (grant G0H4420N) and `Internal Funds KU Leuven' (grant 3M170314). E.S.L. acknowledges funding from the INCEPTION program (Investissements d'Avenir grant ANR-16-CONV-0005). The funders of this study had no role in study design, data collection, analysis and interpretation or writing of the article.	Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Buchrieser J, 2020, EMBO J, V39, DOI 10.15252/embj.2020106267; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cao Y, 2021, NUMER LINEAR ALGEBR, V28, DOI [10.1038/s41586-021-04385-3, 10.1002/nla.2362]; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Cathcart A. L., 2021, DUAL FUNCTION MONOCL, DOI [10.1101/2021.03.09.434607v10, DOI 10.1101/2021.03.09.434607V10]; Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1; Crowe JE, 2022, ANNU REV IMMUNOL, V40, P349, DOI 10.1146/annurev-immunol-042718-041309; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; Grzelak L, 2021, J INFECT DIS, V224, P983, DOI 10.1093/infdis/jiab127; Hadjadj J, 2022, ANN RHEUM DIS, V81, P720, DOI 10.1136/annrheumdis-2021-221508; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Haute Autorite de Sante, 2021, EVUSHELD TIXAGEVIMAB; Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Kim C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20602-5; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Liu LJ, 2022, NUTR NEUROSCI, V25, P2302, DOI 10.1080/1028415X.2021.1959099; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1109/TKDE.2020.3004939, 10.1101/2020.06.17.153486]; Loo YM, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl8124; Mykytyn AZ., BIORXIV2022022348164, V2022; National Institutes of Health, 2022, ALL VAR REP IN VITR; O'Brien Meagan P, 2021, medRxiv, DOI 10.1101/2021.06.14.21258567; Pelleau S, 2021, J INFECT DIS, V224, P1489, DOI 10.1093/infdis/jiab375; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Planas D, 2022, NATURE, V602, P671, DOI 10.1038/s41586-021-04389-z; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Simon-Loriere E, 2022, NAT REV MICROBIOL, V20, P187, DOI 10.1038/s41579-022-00708-x; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; Viana R, 2022, NATURE, V603, P679, DOI 10.1038/s41586-022-04411-y; Westendorf K., 2022, LY COV1404 BEBTELOVI, DOI [10.1101/2021.04.30.442182v5, DOI 10.1101/2021.04.30.442182V5]; Yamasoba D., CELL, V185; Yu JY, 2022, NEW ENGL J MED, V386, DOI 10.1056/NEJMc2201849; Zhou H., 2022, NEUTRALIZATION SARS, DOI [10.1101/2022.02.15.480166v2, DOI 10.1101/2022.02.15.480166V2]; Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005	40	81	82	11	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1297	+		10.1038/s41591-022-01792-5	http://dx.doi.org/10.1038/s41591-022-01792-5		MAR 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35322239	Green Submitted, Bronze			2022-12-27	WOS:000782318100001
J	Carapito, R; Aouadi, I; Verniquet, M; Untrau, M; Pichot, A; Beaudrey, T; Bassand, X; Meyer, S; Faucher, L; Posson, J; Morlon, A; Kotova, I; Delbos, F; Walencik, A; Aarnink, A; Kennel, A; Suberbielle, C; Taupin, JL; Matern, BM; Spierings, E; Congy-Jolivet, N; Essaydi, A; Perrin, P; Blancher, A; Charron, D; Cereb, N; Maumy-Bertrand, M; Bertrand, F; Garrigue, V; Pernin, V; Weekers, L; Naesens, M; Kamar, N; Legendre, C; Glotz, D; Caillard, S; Ladriere, M; Giral, M; Anglicheau, D; Susal, C; Bahram, S				Carapito, Raphael; Aouadi, Ismail; Verniquet, Martin; Untrau, Meiggie; Pichot, Angelique; Beaudrey, Thomas; Bassand, Xavier; Meyer, Sebastien; Faucher, Loic; Posson, Juliane; Morlon, Aurore; Kotova, Irina; Delbos, Florent; Walencik, Alexandre; Aarnink, Alice; Kennel, Anne; Suberbielle, Caroline; Taupin, Jean-Luc; Matern, Benedict M.; Spierings, Eric; Congy-Jolivet, Nicolas; Essaydi, Arnaud; Perrin, Peggy; Blancher, Antoine; Charron, Dominique; Cereb, Nezih; Maumy-Bertrand, Myriam; Bertrand, Frederic; Garrigue, Valerie; Pernin, Vincent; Weekers, Laurent; Naesens, Maarten; Kamar, Nassim; Legendre, Christophe; Glotz, Denis; Caillard, Sophie; Ladriere, Marc; Giral, Magali; Anglicheau, Dany; Suesal, Caner; Bahram, Seiamak			The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation	NATURE MEDICINE			English	Article							HLA ANTIBODIES; REJECTION	The identity of histocompatibility loci, besides human leukocyte antigen (HLA), remains elusive. The major histocompatibility complex (MHC) class I MICA gene is a candidate histocompatibility locus. Here, we investigate its role in a French multicenter cohort of 1,356 kidney transplants. MICA mismatches were associated with decreased graft survival (hazard ratio (HR), 2.12; 95% confidence interval (CI): 1.45-3.11; P < 0.001). Both before and after transplantation anti-MICA donor-specific antibodies (DSA) were strongly associated with increased antibody-mediated rejection (ABMR) (HR, 3.79; 95% CI: 1.94-7.39; P < 0.001; HR, 9.92; 95% CI: 7.43-13.20; P < 0.001, respectively). This effect was synergetic with that of anti-HLA DSA before and after transplantation (HR, 25.68; 95% CI: 3.31-199.41; P = 0.002; HR, 82.67; 95% CI: 33.67-202.97; P < 0.001, respectively). De novo-developed anti-MICA DSA were the most harmful because they were also associated with reduced graft survival (HR, 1.29; 95% CI: 1.05-1.58; P = 0.014). Finally, the damaging effect of anti-MICA DSA on graft survival was confirmed in an independent cohort of 168 patients with ABMR (HR, 1.71; 95% CI: 1.02-2.86; P = 0.041). In conclusion, assessment of MICA matching and immunization for the identification of patients at high risk for transplant rejection and loss is warranted.	[Carapito, Raphael; Aouadi, Ismail; Verniquet, Martin; Untrau, Meiggie; Pichot, Angelique; Beaudrey, Thomas; Bassand, Xavier; Meyer, Sebastien; Perrin, Peggy; Caillard, Sophie; Bahram, Seiamak] Univ Strasbourg, Lab ImmunoRhumatol Mol,Fac Med,Federat Hosp Univ, Inst Natl Sante & Rech Med INSERM UMR S1109, Ctr Rech Immunol & Hematol,UMR S1109,Plateforme G, Strasbourg, France; [Carapito, Raphael; Aouadi, Ismail; Verniquet, Martin; Untrau, Meiggie; Pichot, Angelique; Beaudrey, Thomas; Bassand, Xavier; Meyer, Sebastien; Faucher, Loic; Morlon, Aurore; Kotova, Irina; Delbos, Florent; Walencik, Alexandre; Suberbielle, Caroline; Taupin, Jean-Luc; Congy-Jolivet, Nicolas; Perrin, Peggy; Blancher, Antoine; Charron, Dominique; Maumy-Bertrand, Myriam; Bertrand, Frederic; Garrigue, Valerie; Pernin, Vincent; Kamar, Nassim; Legendre, Christophe; Glotz, Denis; Caillard, Sophie; Giral, Magali; Anglicheau, Dany; Bahram, Seiamak] Univ Strasbourg, Fac Med, Lab Excellence LabEx TRANSPLANTEX, Strasbourg, France; [Carapito, Raphael; Aouadi, Ismail; Verniquet, Martin; Untrau, Meiggie; Pichot, Angelique; Meyer, Sebastien; Bahram, Seiamak] Inst Natl Sante & Rech Med INSERM, Franco Strasbourg Japanese Nagano Nextgen HLA Lab, Strasbourg, France; [Carapito, Raphael; Pichot, Angelique; Bahram, Seiamak] Nouvel Hop Civil, Plateau Tech Biol, Lab Immunol, Pole Biol, Strasbourg, France; [Carapito, Raphael; Aouadi, Ismail; Verniquet, Martin; Untrau, Meiggie; Beaudrey, Thomas; Bassand, Xavier; Meyer, Sebastien; Perrin, Peggy; Charron, Dominique; Maumy-Bertrand, Myriam; Bertrand, Frederic; Caillard, Sophie; Bahram, Seiamak] Inst Themat Interdisciplinaire ITI Med Precis Str, Strasbourg, France; [Beaudrey, Thomas; Bassand, Xavier; Perrin, Peggy; Caillard, Sophie] Univ Hosp, Nephrol Transplantat Dept, Strasbourg, France; [Faucher, Loic; Giral, Magali] Univ Nantes, CHU Nantes, INSERM, Ctr Rech Transplantat & Immunol,UMR 1064,ITUN, Nantes, France; [Posson, Juliane; Glotz, Denis] Inst Natl Sante & Rech Med INSERM, Paris Translat Res Ctr Organ Transplantat, UMR S 970, Paris, France; [Posson, Juliane; Glotz, Denis] St Louis Hosp, Assistance Publ Hop Paris, Kidney Transplant Dept, Paris, France; [Morlon, Aurore; Kotova, Irina] BIOMICA SAS, Strasbourg, France; [Delbos, Florent; Walencik, Alexandre] Etab Francais Sang EFS, Ctr Pays Loire, Lab HLA, Nantes, France; [Aarnink, Alice; Kennel, Anne] Ctr Hosp Reg Univ, Lab Histocompatibil, Nancy, France; [Suberbielle, Caroline; Taupin, Jean-Luc; Charron, Dominique] Univ Paris, Lab Jean Dausset, Lab Immunol & Histocompatibilite,Human Immunol Pa, Inst Natl Sante & Rech Med INSERM,UMR S 976, Paris, France; [Matern, Benedict M.; Spierings, Eric] Univ Med Ctr Utrecht, Ctr Translat Immunol HLA & Tissue Typing, Utrecht, Netherlands; [Congy-Jolivet, Nicolas; Blancher, Antoine] Univ Toulouse III, Univ Paul Sabatier, Lab Immunogenet Mol LIMT, EA 3034,Fac Med Purpan,UPS, Toulouse, France; [Congy-Jolivet, Nicolas; Blancher, Antoine] Ctr Hosp Univ Toulouse, Lab Immunol, Toulouse, France; [Essaydi, Arnaud] Etab Francais Sang EFS Grand Est, Lab HLA, Strasbourg, France; [Cereb, Nezih] Histogenetics, Ossining, NY USA; [Maumy-Bertrand, Myriam; Bertrand, Frederic] Univ Strasbourg, Inst Rech Math Avancee IRMA, Ctr Natl Rech Sci CNRS UMR 7501, Lab Excellence LabEx,Inst Rech Math Interact & Ap, Strasbourg, France; [Garrigue, Valerie; Pernin, Vincent] Ctr Hosp Univ Lapeyronie, Serv Nephrol Transplantat Dialyse Peritoneale, Montpellier, France; [Weekers, Laurent] Univ Liege Hosp ULiege CHU, Div Nephrol, Liege, Belgium; [Naesens, Maarten] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Leuven, Belgium; [Kamar, Nassim] Univ Toulouse III, Dept Nephrol, Ctr Hosp Univ Rangueil, INSERM UMR1291 CNRS UMR5051,Toulouse Inst Infect, Toulouse, France; [Kamar, Nassim] Univ Toulouse III, Dept Organ Transplantat, Ctr Hosp Univ Rangueil, INSERM UMR1291 CNRS UMR5051,Toulouse Inst Infect, Toulouse, France; [Kamar, Nassim] Univ Toulouse III Paul Sabatier, Toulouse, France; [Legendre, Christophe; Anglicheau, Dany] Univ Paris, Serv Transplantat Renale Adulte, Hop Necker, Assistance Publ Hop Paris, Paris, France; [Ladriere, Marc] Ctr Hosp Reg Univ, Dept Renal Transplantat, Nancy, France; [Anglicheau, Dany] Inst Natl Sante & Rech Med INSERM, UMR S 1151, Paris, France; [Suesal, Caner] Heidelberg Univ Hosp, Inst Immunol, Heidelberg, Germany; [Suesal, Caner] Koc Univ, Transplant Immunol Res Ctr Excellence, Istanbul, Turkey	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Montpellier; CHU de Montpellier; KU Leuven; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg; Koc University	Carapito, R; Bahram, S (corresponding author), Univ Strasbourg, Lab ImmunoRhumatol Mol,Fac Med,Federat Hosp Univ, Inst Natl Sante & Rech Med INSERM UMR S1109, Ctr Rech Immunol & Hematol,UMR S1109,Plateforme G, Strasbourg, France.; Carapito, R; Bahram, S (corresponding author), Univ Strasbourg, Fac Med, Lab Excellence LabEx TRANSPLANTEX, Strasbourg, France.; Carapito, R; Bahram, S (corresponding author), Inst Natl Sante & Rech Med INSERM, Franco Strasbourg Japanese Nagano Nextgen HLA Lab, Strasbourg, France.; Carapito, R; Bahram, S (corresponding author), Nouvel Hop Civil, Plateau Tech Biol, Lab Immunol, Pole Biol, Strasbourg, France.; Carapito, R; Bahram, S (corresponding author), Inst Themat Interdisciplinaire ITI Med Precis Str, Strasbourg, France.	carapito@unistra.fr; siamak@unistra.fr	Bahram, Seiamak/GZA-7150-2022; Carapito, Raphael/O-5317-2016	Spierings, Eric/0000-0001-9441-1019; Carapito, Raphael/0000-0002-7036-442X; MEYER, Sebastien/0000-0002-3066-3134; Bahram, Seiamak/0000-0002-6928-9952	France's National Research Agency (Agence Nationale de Recherche; ANR); Investment for the Future Program (Programme des Investissements d'Avenir; PIA) through a 'Laboratoire d'Excellence' (LabEx) TRANSPLANTEX [ANR-11-LABX-0070_TRANSPLANTEX]; Strasbourg's Interdisciplinary Thematic Institute (ITI) for Precision Medicine; TRANSPLANTEX NG, as part of the ITI 2021-2028 program of the University of Strasbourg; CNRS; INSERM - IdEx Unistra [ANR-10-IDEX-0002]; SFRI-STRAT'US [ANR-20-SFRI-0012]; INSERM [UMR_S 1109]; Institut Universitaire de France (IUF); Federation Hospitalo-Universitaire (FHU) OMICARE, MSD Avenir 'Autogen'; European regional development fund (European Union) INTERREG V program [3.2 TRIDIAG, PERSONALIS]	France's National Research Agency (Agence Nationale de Recherche; ANR)(French National Research Agency (ANR)); Investment for the Future Program (Programme des Investissements d'Avenir; PIA) through a 'Laboratoire d'Excellence' (LabEx) TRANSPLANTEX(French National Research Agency (ANR)); Strasbourg's Interdisciplinary Thematic Institute (ITI) for Precision Medicine; TRANSPLANTEX NG, as part of the ITI 2021-2028 program of the University of Strasbourg; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM - IdEx Unistra; SFRI-STRAT'US; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Institut Universitaire de France (IUF); Federation Hospitalo-Universitaire (FHU) OMICARE, MSD Avenir 'Autogen'; European regional development fund (European Union) INTERREG V program	The authors thank Y. Foucher (Nantes University, Nantes, France) and P. Ravaud (Paris Descartes University, Paris, France) for discussing the statistical approaches, and E. Nourisson for technical assistance. This work was supported by France's National Research Agency (Agence Nationale de Recherche; ANR), the Investment for the Future Program (Programme des Investissements d'Avenir; PIA) through a 'Laboratoire d'Excellence' (LabEx) TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX) as well as by Strasbourg's Interdisciplinary Thematic Institute (ITI) for Precision Medicine, TRANSPLANTEX NG, as part of the ITI 2021-2028 program of the University of Strasbourg, CNRS and INSERM, funded by IdEx Unistra (ANR-10-IDEX-0002) and SFRI-STRAT'US (ANR-20-SFRI-0012), all to S.B. Additional funding was provided by INSERM (UMR_S 1109), the Institut Universitaire de France (IUF), the Federation Hospitalo-Universitaire (FHU) OMICARE, MSD Avenir 'Autogen', all to S.B., and the European regional development fund (European Union) INTERREG V program (project no. 3.2 TRIDIAG and PERSONALIS) to R.C. and S.B.	BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Baranwal AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00182; Bohmig GA, 2019, TRANSPL INT, V32, P775, DOI 10.1111/tri.13436; Carapito R, 2016, BLOOD, V128, P1979, DOI 10.1182/blood-2016-05-719070; Carapito R, 2015, IMMUNOL REV, V267, P88, DOI 10.1111/imr.12328; Doxiadis ILN, 2004, TRANSPLANTATION, V77, P615, DOI 10.1097/01.TP.0000103725.72023.D7; Duquesnoy RJ, 2006, HUM IMMUNOL, V67, P847, DOI 10.1016/j.humimm.2006.08.001; Duquesnoy RJ, 2008, HUM IMMUNOL, V69, P826, DOI 10.1016/j.humimm.2008.10.003; Duquesnoy RJ, 2001, TRANSPL P, V33, P493, DOI 10.1016/S0041-1345(00)02108-4; Fodil N, 1996, IMMUNOGENETICS, V44, P351, DOI 10.1007/s002510050136; Fuerst D, 2016, BLOOD, V128, P3169, DOI [10.1182/blood-2016-05716357, 10.1182/blood-2016-05-716357]; Jackson AM, 2020, CURR OPIN ORGAN TRAN, V25, P536, DOI 10.1097/MOT.0000000000000811; Johnson RJ, 2010, TRANSPLANTATION, V89, P387, DOI 10.1097/TP.0b013e3181c9029d; Khongjaroensakun N, 2018, TRANSPL P, V50, P2371, DOI 10.1016/j.transproceed.2018.02.187; Knechtle S., 2019, KIDNEY TRANSPLANTATI; Leeaphorn N, 2018, CLIN J AM SOC NEPHRO, V13, P763, DOI 10.2215/CJN.10860917; Lim WH, 2016, CLIN J AM SOC NEPHRO, V11, P875, DOI 10.2215/CJN.11641115; Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291, DOI 10.1111/j.1399-0039.2010.01466.x; MERRILL JP, 1956, JAMA-J AM MED ASSOC, V160, P277, DOI 10.1001/jama.1956.02960390027008; Risti M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00179; Sasaki Nori, 2010, Clin Transpl, P261; Schinstock CA, 2021, TRANSPL INT, V34, P488, DOI 10.1111/tri.13813; Senev A, 2020, J AM SOC NEPHROL, V31, P2193, DOI 10.1681/ASN.2020010019; SNELL GD, 1981, SCIENCE, V213, P172, DOI 10.1126/science.7017931; SNELL GD, 1948, J GENET, V49, P87, DOI 10.1007/BF02986826; Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x; Susal Caner, 2012, Methods Mol Biol, V882, P267, DOI 10.1007/978-1-61779-842-9_15; Tambur AR, 2018, AM J TRANSPLANT, V18, P1604, DOI 10.1111/ajt.14752; Therneau T.M., 2000, MODELING SURVIVAL DA; Zou YZ, 2007, NEW ENGL J MED, V357, P1293, DOI 10.1056/NEJMoa067160	30	5	5	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					989	+		10.1038/s41591-022-01725-2	http://dx.doi.org/10.1038/s41591-022-01725-2		MAR 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35288692	Green Published, hybrid			2022-12-27	WOS:000770060900006
J	Gao, Y; Cai, C; Grifoni, A; Muller, TR; Niessl, J; Olofsson, A; Humbert, M; Hansson, L; Osterborg, A; Bergman, P; Chen, PR; Olsson, A; Sandberg, JK; Weiskopf, D; Price, DA; Ljunggren, HG; Karlsson, AC; Sette, A; Aleman, S; Buggert, M				Gao, Yu; Cai, Curtis; Grifoni, Alba; Muller, Thomas R.; Niessl, Julia; Olofsson, Anna; Humbert, Marion; Hansson, Lotta; Osterborg, Anders; Bergman, Peter; Chen, Puran; Olsson, Annika; Sandberg, Johan K.; Weiskopf, Daniela; Price, David A.; Ljunggren, Hans-Gustaf; Karlsson, Annika C.; Sette, Alessandro; Aleman, Soo; Buggert, Marcus			Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	NATURE MEDICINE			English	Article								The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact of coronavirus disease 2019 (COVID-19). Recent data have suggested that B.1.1.529 can readily infect people with naturally acquired or vaccine-induced immunity, facilitated in some cases by viral escape from antibodies that neutralize ancestral SARS-CoV-2. However, severe disease appears to be relatively uncommon in such individuals, highlighting a potential role for other components of the adaptive immune system. We report here that SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.1.529. The median relative frequencies of SARS-CoV-2 spike-specific CD4(+) T cells that cross-recognized B.1.1.529 in previously infected or BNT162b2-vaccinated individuals were 84% and 91%, respectively, and the corresponding median relative frequencies for SARS-CoV-2 spike-specific CD8(+) T cells were 70% and 92%, respectively. Pairwise comparisons across groups further revealed that SARS-CoV-2 spike-reactive CD4(+) and CD8(+) T cells were functionally and phenotypically similar in response to the ancestral strain or B.1.1.529. Collectively, our data indicate that established SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cell responses, especially after BNT162b2 vaccination, remain largely intact against B.1.1.529. Peripheral ancestral SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by BNT162b2 vaccination cross-react to the Omicron variant at higher levels than those induced by prior SARS-CoV-2 infection.	[Gao, Yu; Cai, Curtis; Muller, Thomas R.; Niessl, Julia; Sandberg, Johan K.; Ljunggren, Hans-Gustaf; Buggert, Marcus] Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden; [Grifoni, Alba; Weiskopf, Daniela; Sette, Alessandro] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA USA; [Olofsson, Anna; Humbert, Marion; Bergman, Peter; Karlsson, Annika C.] Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden; [Hansson, Lotta; Osterborg, Anders] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden; [Osterborg, Anders] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Bergman, Peter; Olsson, Annika; Aleman, Soo] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden; [Price, David A.] Cardiff Univ, Univ Wales Hosp, Div Infect & Immun, Sch Med, Cardiff, Wales; [Price, David A.] Cardiff Univ, Univ Wales Hosp, Syst Immun Res Inst, Sch Med, Cardiff, Wales; [Sette, Alessandro] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, Dept Med, San Diego, CA USA; [Aleman, Soo] Karolinska Inst, Dept Med Huddinge, Infect Dis & Dermatol Unit, Stockholm, Sweden	Karolinska Institutet; La Jolla Institute for Immunology; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Cardiff University; Cardiff University; University of California System; University of California San Diego; Karolinska Institutet	Buggert, M (corresponding author), Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.	marcus.buggert@ki.se	Sette, Alessandro/AFO-8916-2022; Price, David A/C-7876-2013	Price, David A/0000-0001-9416-2737; Bergman, Peter/0000-0003-3306-3713; Cai, Curtis/0000-0002-3490-4361; Muller, Thomas R/0000-0001-5331-5522; Niessl, Julia/0000-0001-8852-1924; GAO, Yu/0000-0002-4615-3614; Humbert, Marion/0000-0002-1710-1479	Karolinska Institute	Karolinska Institute(Karolinska Institutet)	Open access funding provided by Karolinska Institute.	Bergman P, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103705; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; Dyer O, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n3104; Ferguson N, 2021, 50 IMP COLL; Goga A, BREAKTHROUGH COVID 1, DOI [10.1101/2021.12.21.21268171(2021, DOI 10.1101/2021.12.21.21268171(2021]; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Israelow B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4509; Kalimuddin S, 2021, MED-CAMBRIDGE, V2, P682, DOI 10.1016/j.medj.2021.04.003; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Liu L, NATURE, DOI [10.1038/s41586-021-04388-0(2021, DOI 10.1038/S41586-021-04388-0(2021]; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Meng B, SARS COV 2 OMICRON S, DOI [10.1101/2021.12.17.473248(2021, DOI 10.1101/2021.12.17.473248(2021]; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Niessl J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abk0894; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Peng Y, 2020, NAT IMMUNOL, P1, DOI DOI 10.1038/s41590-020-0782-6; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Tan AT, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108728; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Wolter N, 2022, LANCET, V399, P437, DOI 10.1016/S0140-6736(22)00017-4	22	129	129	8	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					472	+		10.1038/s41591-022-01700-x	http://dx.doi.org/10.1038/s41591-022-01700-x		JAN 2022	7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35042228	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000760098700001
J	Koren, MJ; Moriarty, PM; Baum, SJ; Neutel, J; Hernandez-Illas, M; Weintraub, HS; Florio, M; Kassahun, H; Melquist, S; Varrieur, T; Haldar, SM; Sohn, W; Wang, H; Elliott-Davey, M; Rock, BM; Pei, T; Homann, O; Hellawell, J; Watts, GF				Koren, Michael J.; Moriarty, Patrick Maurice; Baum, Seth J.; Neutel, Joel; Hernandez-Illas, Martha; Weintraub, Howard S.; Florio, Monica; Kassahun, Helina; Melquist, Stacey; Varrieur, Tracy; Haldar, Saptarsi M.; Sohn, Winnie; Wang, Huei; Elliott-Davey, Mary; Rock, Brooke M.; Pei, Tao; Homann, Oliver; Hellawell, Jennifer; Watts, Gerald F.			Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)	NATURE MEDICINE			English	Article							ELEVATED LIPOPROTEIN(A); SERIES LIPOPROTEIN; DISEASE; RISK; ATHEROSCLEROSIS; OLIGONUCLEOTIDE; EXPRESSION; LEVEL; AGE	Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. Here we report the discovery and development of olpa siran, a first-in-class, synthetic, double-stranded, N-acetylgalactosamine-conjugated small interfering RNA (siRNA) designed to directly inhibit LPA messenger RNA translation in hepatocytes and potently reduce plasma Lp(a) concentration. Olpasiran reduced Lp(a) concentrations in transgenic mice and cynomolgus monkeys in a dose-responsive manner, achieving up to over 80% reduction from baseline for 5-8 weeks after administration of a single dose. In a phase 1 dose-escalation trial of olpasiran (ClinicalTrials.gov: NCT03626662), the primary outcome was safety and tolerability, and the secondary outcomes were the change in Lp(a) concentrations and olpasiran pharmacokinetic parameters. Participants tolerated single doses of olpasiran well and experienced a 71-97% reduction in Lp(a) concentration with effects persisting for several months after administration of doses of 9 mg or higher. Serum concentrations of olpasiran increased approximately dose proportionally. Collectively, these results validate the approach of using hepatocyte-targeted siRNA to potently lower Lp(a) in individuals with elevated plasma Lp(a) concentration.	[Koren, Michael J.] Jacksonville Ctr Clin Res, Jacksonville, FL 32216 USA; [Moriarty, Patrick Maurice] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; [Baum, Seth J.] Excel Med Clin Trials, Boca Raton, FL USA; [Neutel, Joel] Orange Cty Res Ctr, Tustin, CA USA; [Hernandez-Illas, Martha] QPS MRA, Miami, FL USA; [Weintraub, Howard S.] NYU, Langone Med Ctr, New York, NY USA; [Florio, Monica; Kassahun, Helina; Sohn, Winnie; Wang, Huei] Amgen Inc, Thousand Oaks, CA 91320 USA; [Melquist, Stacey] Arrowhead Pharmaceut Inc, Pasadena, CA USA; [Varrieur, Tracy] Amgen Inc, Cambridge, MA USA; [Haldar, Saptarsi M.; Rock, Brooke M.; Homann, Oliver; Hellawell, Jennifer] Amgen Inc, San Francisco, CA USA; [Elliott-Davey, Mary] Amgen Ltd, Cambridge, England; [Pei, Tao] Arrowhead Pharmaceut Inc, Madison, WI USA; [Watts, Gerald F.] Univ Western Australia, Perth, WA, Australia; [Watts, Gerald F.] Royal Perth Hosp, Perth, WA, Australia	University of Kansas; University of Kansas Medical Center; New York University; NYU Langone Medical Center; Amgen; Amgen; Amgen; Amgen; Amgen Limited; University of Western Australia; Royal Perth Hospital; University of Western Australia	Koren, MJ (corresponding author), Jacksonville Ctr Clin Res, Jacksonville, FL 32216 USA.	mkoren@encoredocs.com		Melquist, Stacey/0000-0002-2974-9635; Baum, Seth/0000-0003-1202-8126	Amgen, Inc.; Arrowhead Pharmaceuticals, Inc.; Amgen; E. Stoltzfus of Amgen	Amgen, Inc.(Amgen); Arrowhead Pharmaceuticals, Inc.; Amgen(Amgen); E. Stoltzfus of Amgen	Amgen, Inc. and Arrowhead Pharmaceuticals, Inc. funded this work. J. Murray, H. Hamilton, M. Stolina, D. Dwyer and P. Denis supported the in vitro screening and preclinical data. J. Hegge performed some of the preclinical work (mouse and monkey) and supported data preparation for the manuscript. P. Yamaguchi assisted in drafting the preclinical section of the manuscript. J. Wang and the Amgen Clinical Biomarker and Diagnostics group supported Lp(a) assay evaluation and selection. N. Shah and Z. Atter provided statistical support for the clinical study. W. Krall of Wanda Krall Medical Communications, funded by Amgen, and E. Stoltzfus of Amgen provided editorial support.	Artemeva NV, 2015, ATHEROSCLEROSIS SUPP, V18, P53, DOI 10.1016/j.atherosclerosissup.2015.02.008; Baum SJ, 2019, J CLIN LIPIDOL, V13, P901, DOI 10.1016/j.jacl.2019.10.003; Burgess S, 2018, JAMA CARDIOL, V3, P619, DOI 10.1001/jamacardio.2018.1470; Chi X, 2017, DRUG DISCOV TODAY, V22, P823, DOI 10.1016/j.drudis.2017.01.013; Clarke R, 2009, NEW ENGL J MED, V361, P2518, DOI 10.1056/NEJMoa0902604; Dati F, 2004, CLIN CHEM LAB MED, V42, P670, DOI 10.1515/CCLM.2004.114; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Gudbjartsson DF, 2019, J AM COLL CARDIOL, V74, P2982, DOI 10.1016/j.jacc.2019.10.019; Helgadottir A, 2012, J AM COLL CARDIOL, V60, P722, DOI 10.1016/j.jacc.2012.01.078; Judge DP, 2020, CARDIOVASC DRUG THER, V34, P357, DOI 10.1007/s10557-019-06919-4; Kamstrup PR, 2014, J AM COLL CARDIOL, V63, P470, DOI 10.1016/j.jacc.2013.09.038; Kamstrup PR, 2009, JAMA-J AM MED ASSOC, V301, P2331, DOI 10.1001/jama.2009.801; Kenski DM, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.4; Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027; Kral BG, 2016, AM J CARDIOL, V118, P656, DOI 10.1016/j.amjcard.2016.06.020; Kronenberg F, 2013, J INTERN MED, V273, P6, DOI 10.1111/j.1365-2796.2012.02592.x; Lamina C, 2019, JAMA CARDIOL, V4, P575, DOI 10.1001/jamacardio.2019.1041; Langlois MR, 2020, CLIN CHEM LAB MED, V58, P496, DOI 10.1515/cclm-2019-1253; Langsted A, 2019, EUR HEART J, V40, P2760, DOI 10.1093/eurheartj/ehy902; Madsen CM, 2020, ARTERIOSCL THROM VAS, V40, P255, DOI 10.1161/ATVBAHA.119.312951; Marcovina SM, 1996, J LIPID RES, V37, P2569; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; Marcovina SM, 2000, CLIN CHEM, V46, P1956; Nordestgaard BG, 2010, EUR HEART J, V31, P2844, DOI 10.1093/eurheartj/ehq386; Nugent A., 2019, J CLIN CARDIOL, V1, P16; Patel AP, 2021, ARTERIOSCL THROM VAS, V41, P465, DOI 10.1161/ATVBAHA.120.315291; Roberts TC, 2020, NAT REV DRUG DISCOV, V19, P673, DOI 10.1038/s41573-020-0075-7; Schmidt K, 2016, J LIPID RES, V57, P1339, DOI 10.1194/jlr.R067314; Shen XL, 2018, NUCLEIC ACIDS RES, V46, P1584, DOI 10.1093/nar/gkx1239; Springer AD, 2018, NUCLEIC ACID THER, V28, P109, DOI 10.1089/nat.2018.0736; Thanassoulis G, 2016, J LIPID RES, V57, P917, DOI 10.1194/jlr.R051870; Thanassoulis G, 2010, J AM COLL CARDIOL, V55, P2491, DOI 10.1016/j.jacc.2010.03.019; Tsimikas S, 2020, NEW ENGL J MED, V382, P244, DOI 10.1056/NEJMoa1905239; Tsimikas S, 2017, J AM COLL CARDIOL, V69, P692, DOI 10.1016/j.jacc.2016.11.042; Varvel S, 2016, ARTERIOSCL THROM VAS, V36, P2239, DOI 10.1161/ATVBAHA.116.308011; von Eckardstein A, 2017, EUR HEART J, V38, P1530, DOI 10.1093/eurheartj/ehx233; Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993; Willeit P, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.016318; Wooddell CI, 2008, J GENE MED, V10, P551, DOI 10.1002/jgm.1179; Yahya R, 2019, ATHEROSCLEROSIS, V289, P201, DOI 10.1016/j.atherosclerosis.2019.07.001; Yeang C, 2015, CURR OPIN LIPIDOL, V26, P169, DOI 10.1097/MOL.0000000000000171; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	46	41	41	25	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					96	+		10.1038/s41591-021-01634-w	http://dx.doi.org/10.1038/s41591-021-01634-w		JAN 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35027752				2022-12-27	WOS:000742323900007
J	Yala, A; Mikhael, PG; Lehman, C; Lin, GG; Strand, F; Wan, YL; Hughes, K; Satuluru, S; Kim, T; Banerjee, I; Gichoya, J; Trivedi, H; Barzilay, R				Yala, Adam; Mikhael, Peter G.; Lehman, Constance; Lin, Gigin G.; Strand, Fredrik; Wan, Yung-Liang; Hughes, Kevin; Satuluru, Siddharth; Kim, Thomas; Banerjee, Imon; Gichoya, Judy; Trivedi, Hari; Barzilay, Regina			Optimizing risk-based breast cancer screening policies with reinforcement learning	NATURE MEDICINE			English	Article							GUIDELINE UPDATE; MAMMOGRAPHY; WOMEN; DENSITY; BENEFITS	A reinforcement learning model can predict risk-based follow-up recommendations to improve early detection and reduce screening costs in breast cancer across diverse patient populations. Screening programs must balance the benefit of early detection with the cost of overscreening. Here, we introduce a novel reinforcement learning-based framework for personalized screening, Tempo, and demonstrate its efficacy in the context of breast cancer. We trained our risk-based screening policies on a large screening mammography dataset from Massachusetts General Hospital (MGH; USA) and validated this dataset in held-out patients from MGH and external datasets from Emory University (Emory; USA), Karolinska Institute (Karolinska; Sweden) and Chang Gung Memorial Hospital (CGMH; Taiwan). Across all test sets, we find that the Tempo policy combined with an image-based artificial intelligence (AI) risk model is significantly more efficient than current regimens used in clinical practice in terms of simulated early detection per screen frequency. Moreover, we show that the same Tempo policy can be easily adapted to a wide range of possible screening preferences, allowing clinicians to select their desired trade-off between early detection and screening costs without training new policies. Finally, we demonstrate that Tempo policies based on AI-based risk models outperform Tempo policies based on less accurate clinical risk models. Altogether, our results show that pairing AI-based risk models with agile AI-designed screening policies has the potential to improve screening programs by advancing early detection while reducing overscreening.	[Yala, Adam; Mikhael, Peter G.; Barzilay, Regina] MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Yala, Adam; Mikhael, Peter G.; Barzilay, Regina] MIT, Jameel Clin, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Lehman, Constance] Massachusetts Gen Hosp, Dept Radiol, Harvard Med Sch, Boston, MA 02114 USA; [Lin, Gigin G.; Wan, Yung-Liang] Chang Gung Mem Hosp Linkou, Dept Med Imaging & Intervent, Taoyuan, Taiwan; [Lin, Gigin G.; Wan, Yung-Liang] Chang Gung Univ, Coll Med, Dept Med Imaging & Radiol Sci, Taoyuan, Taiwan; [Strand, Fredrik] Karolinska Univ Hosp, Dept Imaging & Physiol, Breast Radiol Unit, Solna, Sweden; [Strand, Fredrik] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden; [Hughes, Kevin] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA; [Satuluru, Siddharth; Gichoya, Judy; Trivedi, Hari] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA; [Kim, Thomas] Georgia Inst Technol, Dept Comp Sci, Atlanta, GA 30332 USA; [Banerjee, Imon] Mayo Clin, Dept Radiol, Scottsdale, AZ USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital; Chang Gung Memorial Hospital; Chang Gung University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Medical University of South Carolina; Emory University; University System of Georgia; Georgia Institute of Technology; Mayo Clinic; Mayo Clinic Phoenix	Yala, A (corresponding author), MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Yala, A (corresponding author), MIT, Jameel Clin, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	adamyala@csail.mit.edu	Strand, Fredrik/AFH-8721-2022; Lin, Gigin/A-2676-2017	Strand, Fredrik/0000-0003-3910-7086; Banerjee, Imon/0000-0002-3327-8004; Lin, Gigin/0000-0001-7246-1058; Yala, Adam/0000-0001-9576-2590; Mikhael, Peter/0000-0002-6030-1636	Susan G. Komen; Breast Cancer Research Foundation; Quanta Computer; MIT Jameel Clinic; Chang Gung Medical Foundation [SMRPG3K0051]; Stockholm Lans Landsting HMT [201708002]; Cancer Center of Linkou CGMH [201901491B0C601]; Anonymous Foundation	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; Quanta Computer; MIT Jameel Clinic; Chang Gung Medical Foundation; Stockholm Lans Landsting HMT; Cancer Center of Linkou CGMH; Anonymous Foundation	This work was supported by grants from Susan G. Komen, the Breast Cancer Research Foundation, Quanta Computer, Anonymous Foundation and the MIT Jameel Clinic. This work was also supported by the Chang Gung Medical Foundation (grant SMRPG3K0051) and Stockholm Lans Landsting HMT (grant 201708002). We are grateful to the Cancer Center of Linkou CGMH for assistance with data collection under IRB no. 201901491B0C601 and R. Yang, J. Song and their team (Quanta Computer) for providing technical and computing support for analyzing the CGMH dataset.	Ahuja K, 2017, ADV NEUR IN, V30; Andrychowicz M., 2017, HINDSIGHT EXPERIENCE, V30, P5048; Ayer T, 2012, OPER RES, V60, P1019, DOI 10.1287/opre.1110.1019; Bakker MF, 2019, NEW ENGL J MED, V381, P2091, DOI 10.1056/NEJMoa1903986; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V315, P2564, DOI 10.1001/jama.2016.5989; Cho K., 2014, C EMPIRICAL METHODS, P1724; Coleman C, 2017, SEMIN ONCOL NURS, V33, P141, DOI 10.1016/j.soncn.2017.02.009; Curry SJ, 2018, OBSTET GYNECOL SURV, V73, P689, DOI [10.1001/jama.2018.10897, 10.1097/01.ogx.0000549540.69362.81]; Dembrower K, 2020, J DIGIT IMAGING, V33, P408, DOI 10.1007/s10278-019-00278-0; Dembrower K, 2020, RADIOLOGY, V294, P265, DOI 10.1148/radiol.2019190872; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Gier RA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17209-1; Le Boulc'h M, 2020, DIAGN INTERV IMAG, V101, P811, DOI 10.1016/j.diii.2020.07.004; Lotter W, 2021, NAT MED, V27, P244, DOI 10.1038/s41591-020-01174-9; Lu MT, 2020, ANN INTERN MED, V173, P704, DOI 10.7326/M20-1868; Maillart LM, 2008, OPER RES, V56, P1411, DOI 10.1287/opre.1080.0614; Mandelblatt JS, 2016, ANN INTERN MED, V164, P215, DOI 10.7326/M15-1536; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; Mnih V, 2015, NATURE, V518, P529, DOI 10.1038/nature14236; Monticciolo DL, 2018, J AM COLL RADIOL, V15, P408, DOI 10.1016/j.jacr.2017.11.034; Moyer VA, 2014, ANN INTERN MED, V160, P330, DOI 10.7326/M13-2771; Oeffinger KC, 2015, JAMA-J AM MED ASSOC, V314, P1599, DOI 10.1001/jama.2015.12783; Owens DK, 2019, JAMA-J AM MED ASSOC, V322, P857, DOI 10.1001/jama.2019.11885; Rodriguez-Ruiz A, 2019, EUR RADIOL, V29, P4825, DOI 10.1007/s00330-019-06186-9; Roijers DM, 2013, J ARTIF INTELL RES, V48, P67, DOI 10.1613/jair.3987; Schousboe JT, 2011, ANN INTERN MED, V155, P10, DOI 10.7326/0003-4819-155-1-201107050-00003; Shieh Y, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw290; Siu AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886; Smith RA, 2019, CA-CANCER J CLIN, V69, P184, DOI 10.3322/caac.21557; Sutton RS, 2018, ADAPT COMPUT MACH LE, P1; Trentham-Dietz A, 2016, ANN INTERN MED, V165, P700, DOI 10.7326/M16-0476; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; van Seijen M, 2019, BRIT J CANCER, V121, P285, DOI 10.1038/s41416-019-0478-6; Visvanathan K, 2009, J CLIN ONCOL, V27, P3235, DOI 10.1200/JCO.2008.20.5179; Wang F, 2018, OMEGA-INT J MANAGE S, V76, P70, DOI 10.1016/j.omega.2017.05.001; Wernli KJ, 2016, JAMA-J AM MED ASSOC, V316, P436, DOI 10.1001/jama.2016.5415; Yala A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aba4373; Yala A, 2019, RADIOLOGY, V292, P60, DOI 10.1148/radiol.2019182716; Yang R., 2019, ADV NEURAL INFORM PR, P14610	39	7	7	7	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					136	+		10.1038/s41591-021-01599-w	http://dx.doi.org/10.1038/s41591-021-01599-w		JAN 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35027757	Green Submitted			2022-12-27	WOS:000742323900002
J	DeAngelo, DJ; Radia, DH; George, TI; Robinson, WA; Quiery, AT; Drummond, MW; Bose, P; Hexner, EO; Winton, EF; Horny, HP; Tugnait, M; Schmidt-Kittler, O; Evans, EK; Lin, HM; Mar, BG; Verstovsek, S; Deininger, MW; Gotlib, J				DeAngelo, Daniel J.; Radia, Deepti H.; George, Tracy, I; Robinson, William A.; Quiery, Albert T.; Drummond, Mark W.; Bose, Prithviraj; Hexner, Elizabeth O.; Winton, Elliott F.; Horny, Hans-Peter; Tugnait, Meera; Schmidt-Kittler, Oleg; Evans, Erica K.; Lin, Hui-Min; Mar, Brenton G.; Verstovsek, Srdan; Deininger, Michael W.; Gotlib, Jason			Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial	NATURE MEDICINE			English	Article							MAST-CELL DISORDERS; MIDOSTAURIN; DIAGNOSIS; IMATINIB; NETWORK	Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM. The primary endpoints were the maximum tolerated dose, recommended phase 2 dose and safety of avapritinib. Secondary endpoints included overall response rate and changes in measures of mast cell burden. Avapritinib was evaluated at doses of 30-400 mg once daily in 86 patients, 69 with centrally confirmed AdvSM. Maximum tolerated dose was not reached, and 200 mg and 300 mg daily were studied in dose-expansion cohorts. The most frequent adverse events observed were periorbital edema (69%), anemia (55%), diarrhea (45%), thrombocytopenia (44%) and nausea (44%). Intracranial bleeding occurred in 13% overall, but in only 1% of patients without severe thrombocytopenia (platelets <50 x 10(9)/l). In 53 response-evaluable patients, the overall response rate was 75%. The complete remission rate was 36%. Avapritinib elicited >= 50% reductions in marrow mast cells and serum tryptase in 92% and 99% of patients, respectively. Avapritinib induced deep and durable responses, including molecular remission of KIT D816V in patients with AdvSM, and was well tolerated at the recommended phase 2 dose of 200 mg daily.	[DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Radia, Deepti H.] Guys & St Thomas NHS Fdn Trust, London, England; [George, Tracy, I] Univ Utah, ARUP Labs, Salt Lake City, UT USA; [Robinson, William A.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA; [Quiery, Albert T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Drummond, Mark W.] Beatson Canc Ctr, Glasgow, Lanark, Scotland; [Bose, Prithviraj; Verstovsek, Srdan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Hexner, Elizabeth O.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Winton, Elliott F.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Horny, Hans-Peter] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany; [Tugnait, Meera; Schmidt-Kittler, Oleg; Evans, Erica K.; Lin, Hui-Min; Mar, Brenton G.] Blueprint Med Corp, Cambridge, MA USA; [Deininger, Michael W.] Med Coll Wisconsin, Versiti Blood Res Inst, Milwaukee, WI 53226 USA; [Deininger, Michael W.] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [Gotlib, Jason] Stanford Univ, Sch Med, Stanford, CA USA; [Gotlib, Jason] Stanford Canc Inst, Stanford, CA USA	Harvard University; Dana-Farber Cancer Institute; Guy's & St Thomas' NHS Foundation Trust; Utah System of Higher Education; University of Utah; ARUP Laboratories; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Michigan System; University of Michigan; Beatson Oncology Centre; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Emory University; University of Munich; Medical College of Wisconsin; Medical College of Wisconsin; Stanford University; Stanford Cancer Institute	DeAngelo, DJ (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.	daniel_deangelo@dfci.harvard.edu	George, Tracy I./GRY-0951-2022	DeAngelo, Daniel/0000-0001-7865-2306; BOSE, PRITHVIRAJ/0000-0002-4343-5712; Hexner, Elizabeth/0000-0002-1125-4060; George, Tracy/0000-0001-5478-7847; Verstovsek, MD, PhD, Professor of Medicine, Srdan/0000-0002-6912-8569	Blueprint Medicines Corporation; National Cancer Institute (National Institutes of Health (NIH)) [P30 CA016672]; Stanford Cancer Institute Clinical Innovation Fund; National Cancer Institute (NIH) [1UE5CA24674401, P01-CA214278-03]; National Center for Advancing Translational Sciences (NIH) [NIH-NCATS UL1TR001878]; National Heart, Lung and Blood Institute (NIH) [R01-HL-148014-01A1]; Good Publication Practice (GPP3) guidelines	Blueprint Medicines Corporation; National Cancer Institute (National Institutes of Health (NIH))(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stanford Cancer Institute Clinical Innovation Fund; National Cancer Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Advancing Translational Sciences (NIH); National Heart, Lung and Blood Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Good Publication Practice (GPP3) guidelines	This study was funded by Blueprint Medicines Corporation. The authors thank the patients, their families and all investigators involved in this study. P.B. is supported by the National Cancer Institute (National Institutes of Health (NIH), no. P30 CA016672). J.G. is supported by an internal grant from the Stanford Cancer Institute Clinical Innovation Fund. E.O.H. is supported by the National Cancer Institute (NIH, nos. 1UE5CA24674401 and P01-CA214278-03), the National Center for Advancing Translational Sciences (NIH no. NIH-NCATS UL1TR001878) and the National Heart, Lung and Blood Institute (NIH no. R01-HL-148014-01A1). Pathology assessment was supported by K. Karner, K. Moser and A. Rets (all ARUP Laboratories, University of Utah). Data management support was provided by C. Langford (Stanford Cancer Institute). Medical writing support was provided by Danielle Russell, PhD and Jeremy Kennard, PhD (both of Paragon, Knutsford, UK), supported by Blueprint Medicines Corporation in accordance with Good Publication Practice (GPP3) guidelines (https://www.ismpp.org/gpp3).The sponsor was involved in the study design and collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions and data interpretation lies with the authors.	Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Alvarez-Twose I, 2017, ONCOTARGET, V8, P68950, DOI 10.18632/oncotarget.10711; Barete S, 2015, BLOOD, V126, P1009, DOI 10.1182/blood-2014-12-614743; Chatterjee A, 2015, ONCOTARGET, V6, P18250, DOI 10.18632/oncotarget.4213; DeAngelo DJ, 2018, LEUKEMIA, V32, P470, DOI 10.1038/leu.2017.234; DeAngelo DJ, 2017, BLOOD, V130; Droogendijk HJ, 2006, CANCER, V107, P345, DOI 10.1002/cncr.21996; Evans E, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.568.568; Evans EK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao1690; Evans EK, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.3217.3217; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; George S, 2021, ONCOLOGIST, V26, pE639, DOI 10.1002/onco.13674; Gilreath JA, 2019, CLIN PHARMACOL-ADV A, V11, P77, DOI 10.2147/CPAA.S206615; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Gotlib J, 2013, BLOOD, V121, P2393, DOI 10.1182/blood-2012-09-458521; Gotlib JR, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-112017; Gulen T, 2016, J INTERN MED, V279, P211, DOI 10.1111/joim.12410; Heinrich MC, 2020, LANCET ONCOL, V21, P935, DOI 10.1016/S1470-2045(20)30269-2; Hermine O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002266; Horny H-P., 2017, WHO CLASSIFICATION T, P61; Jawhar M, 2019, J CLIN ONCOL, V37, P2846, DOI 10.1200/JCO.19.00640; Jawhar M, 2017, BLOOD, V130, P137, DOI 10.1182/blood-2017-01-764423; Jawhar M, 2017, HAEMATOLOGICA, V102, P1035, DOI 10.3324/haematol.2017.163964; Jennings S, 2014, J ALLER CL IMM-PRACT, V2, P70, DOI 10.1016/j.jaip.2013.09.004; Klein J. P., 2003, SURVIVAL ANAL TECHNI; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Mazar I, 2016, VALUE HEALTH, V19, pA386; Novartis Europharm, 2017, RYD MID SUMM PROD CH; Novartis Pharmaceuticals, 2020, RYD MID FULL PRESCR; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Pardanani A, 2004, BLOOD, V104, P1931, DOI 10.1182/blood-2004-01-0246; Pardanani A, 2019, AM J HEMATOL, V94, P363, DOI 10.1002/ajh.25371; Pardanani A, 2009, BLOOD, V114, P3769, DOI 10.1182/blood-2009-05-220145; Reiter A, 2020, BLOOD, V135, P1365, DOI 10.1182/blood.2019000932; Schwaab J, 2020, J ALLER CL IMM-PRACT, V8, P3121, DOI 10.1016/j.jaip.2020.05.005; Taylor F, 2021, LEUKEMIA RES, V108, DOI 10.1016/j.leukres.2021.106606; Tzogani K, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000606; US Department of Health and Human Services, 2009, COMMON TERMINOLOGY C, V2020; US Food and Drug Administration, 2001, GLEEV IM MES HIGHL P; Vaes M, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00110; Vega-Ruiz A, 2009, LEUKEMIA RES, V33, P1481, DOI [10.1016/j.leukres.2008.12.020, 10.1016/j.leukres.2009.05.005]	41	21	21	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2183	+		10.1038/s41591-021-01538-9	http://dx.doi.org/10.1038/s41591-021-01538-9		DEC 2021	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34873347	Green Published, hybrid			2022-12-27	WOS:000727136800003
J	Zhang, FF; Karamagi, H; Nsenga, N; Nanyunja, M; Karinja, M; Amanfo, S; Chase-Topping, M; Calder-Gerver, G; McGibbon, M; Huber, A; Wagner-Gamble, T; Guo, CG; Haynes, S; Morrison, A; Ferguson, M; Awandare, GA; Mutapi, F; Yoti, Z; Cabore, J; Moeti, MR; Woolhouse, MEJ				Zhang, Feifei; Karamagi, Humphrey; Nsenga, Ngoy; Nanyunja, Miriam; Karinja, Miriam; Amanfo, Seth; Chase-Topping, Margo; Calder-Gerver, Giles; McGibbon, Miles; Huber, Alexandra; Wagner-Gamble, Tara; Guo, Chuan-Guo; Haynes, Samuel; Morrison, Alistair; Ferguson, Miranda; Awandare, Gordon A.; Mutapi, Francisca; Yoti, Zabulon; Cabore, Joseph; Moeti, Matshidiso R.; Woolhouse, Mark E. J.			Predictors of COVID-19 epidemics in countries of the World Health Organization African Region	NATURE MEDICINE			English	Article							MORTALITY	Countries of the World Health Organization (WHO) African Region have experienced a wide range of coronavirus disease 2019 (COVID-19) epidemics. This study aimed to identify predictors of the timing of the first COVID-19 case and the per capita mortality in WHO African Region countries during the first and second pandemic waves and to test for associations with the preparedness of health systems and government pandemic responses. Using a region-wide, country-based observational study, we found that the first case was detected earlier in countries with more urban populations, higher international connectivity and greater COVID-19 test capacity but later in island nations. Predictors of a high first wave per capita mortality rate included a more urban population, higher pre-pandemic international connectivity and a higher prevalence of HIV. Countries rated as better prepared and having more resilient health systems were worst affected by the disease, the imposition of restrictions or both, making any benefit of more stringent countermeasures difficult to detect. Predictors for the second wave were similar to the first. Second wave per capita mortality could be predicted from that of the first wave. The COVID-19 pandemic highlights unanticipated vulnerabilities to infectious disease in Africa that should be taken into account in future pandemic preparedness planning. A new study from the WHO African Region identifies features of countries that predict timing of the first case and the per capita mortality rate for the first and second waves of the COVID-19 epidemics.	[Zhang, Feifei; Calder-Gerver, Giles; McGibbon, Miles; Huber, Alexandra; Wagner-Gamble, Tara; Morrison, Alistair; Ferguson, Miranda; Woolhouse, Mark E. J.] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Karamagi, Humphrey; Nsenga, Ngoy; Nanyunja, Miriam; Yoti, Zabulon; Cabore, Joseph; Moeti, Matshidiso R.] WHO Reg Off Africa, Brazzaville, Rep Congo; [Karinja, Miriam] Univ Nairobi, Inst Trop & Infect Dis, Nairobi, Kenya; [Chase-Topping, Margo; Haynes, Samuel; Mutapi, Francisca] Univ Edinburgh, Sch Biol Sci, Edinburgh, Midlothian, Scotland; [Chase-Topping, Margo] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Chase-Topping, Margo] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Guo, Chuan-Guo] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China; [Awandare, Gordon A.] Univ Ghana, West African Ctr Cell Biol Infect Pathogens, Accra, Ghana	University of Edinburgh; University of Nairobi; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh; University of Hong Kong; University of Ghana	Zhang, FF (corresponding author), Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.	feifei.zhang@ed.ac.uk	; Karamagi, Humphrey/AAQ-5031-2020	Nsenga, Ngoy/0000-0003-1187-0362; Awandare, Gordon/0000-0002-8793-3641; Mutapi, Francisca/0000-0002-2537-3466; Karinja, Miriam/0000-0003-0474-9492; Zhang, Feifei/0000-0002-3718-243X; Karamagi, Humphrey/0000-0002-6277-2095; Huber, Alexandra/0000-0002-0980-2953; McGibbon, Miles/0000-0001-8277-3178	Darwin Trust of Edinburgh; National Institute for Health Research (NIHR) Global Health Research Programme [16/136/33]	Darwin Trust of Edinburgh; National Institute for Health Research (NIHR) Global Health Research Programme(National Institute for Health Research (NIHR))	Funding support is acknowledged from the Darwin Trust of Edinburgh, received by F.Z., and the National Institute for Health Research (NIHR) Global Health Research Programme (16/136/33) using UK aid from the UK Government, received by M.E.J.W., F.M. and G.A.A. The views expressed in this publication are those of the authors and are not necessarily those of the NIHR or the Department of Health and Social Care. The TIBA Pandemic Response Unit is part of the Tackling Infections to Benefit Africa partnership. We are grateful to H. Brown from the Roslin Institute, Edinburgh for statistical advice.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Arsalan M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155592; Asfahan S, 2020, MONALDI ARCH CHEST D, V90, P451, DOI 10.4081/monaldi.2020.1388; Azarpazhooh MR, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105089; Boulle A., 2020, CLIN INFECT DIS, pCIAA1198, DOI 10.1093/cid/ciaa1198; Brauer M, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP7200; Chaudhry R, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100464; Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757; Emiliano PC, 2014, COMPUT STAT DATA AN, V69, P141, DOI 10.1016/j.csda.2013.07.032; Fountoulakis KN, 2020, J PUBLIC HEALTH-UK, V42, P681, DOI 10.1093/pubmed/fdaa119; Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820002046; Hale T., 2020, OXFORD COVID 19 GOVT; Hashim MJ, 2020, J EPIDEMIOL GLOB HEA, V10, P204, DOI 10.2991/jegh.k.200721.001; Hazelton M. L., 2014, WILEY STATSREF STAT, DOI [10.1002/9781118445112.stat06538, DOI 10.1002/9781118445112.STAT06538]; Hradsky O, 2021, EUR J PUBLIC HEALTH, V31, P12, DOI 10.1093/eurpub/ckaa226; Hsiang S., 2020, NATURE, V584, P262, DOI [10.1038/s41586-020-2404-8, DOI 10.1038/s41586-020-2404-8]; Institute for Health Metrics and Evaluation, 2021, EST TOT MORT DUE COV; Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1; Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5; Khan JR, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00347; Kirigia JM, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-6; Lawal Y, 2021, INT J INFECT DIS, V102, P118, DOI 10.1016/j.ijid.2020.10.038; Leffler CT., 2020, AM J TROP MED HYG, V103, P2400, DOI [10.4269/ajtmh.20-1015, DOI 10.4269/ajtmh.20-1015]; Li MY, 2021, SCI TOTAL ENVIRON, V764, DOI 10.1016/j.scitotenv.2020.142810; Lu L, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004408; Mena G, 2021, SCIENCE, V372, P934, DOI 10.1126/science.abg5298; Moore M, 2016, IDENTIFYING FUTURE D; Ngoi JM, 2021, EXP BIOL MED, V246, P960, DOI 10.1177/1535370220975351; Norwegian Institute of Public Health, 2020, URB PREP OUTBR HIGH; Nouvellet P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21358-2; Okeahalam C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042750; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Rahman M, 2021, ENVIRON DEV SUSTAIN, V23, P9352, DOI 10.1007/s10668-020-01028-x; Rice BL, 2021, NAT MED, V27, P447, DOI 10.1038/s41591-021-01234-8; Salyer SJ, 2021, LANCET, V397, P1265, DOI 10.1016/S0140-6736(21)00632-2; Sanyaolu Adekunle, 2020, SN Compr Clin Med, V2, P1069, DOI 10.1007/s42399-020-00363-4; Ssentongo P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85359-3; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Tamuzi JL, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05450-4; Tian WJ, 2020, J MED VIROL, V92, P1875, DOI 10.1002/jmv.26050; TIBA Pandemic Response Unit, 2020, COVID 19 TEST REP WH; TIBA Pandemic Response Unit, 2020, COVID 19 MIT POL GOV; Tzampoglou P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217730; Vadlamannati KC, 2021, SCAND J PUBLIC HEALT, V49, P104, DOI 10.1177/1403494820982106; Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035; WHO, 2020, POL BRIEF ACC ASS TE; WHO, WHO COR DIS COVID 19; Woolhouse M, 2011, PHILOS T R SOC B, V366, P2045, DOI 10.1098/rstb.2010.0387; World Health Organization, 2020, WHO COVID 19 CASE DE; World Health Organization, 2020, INT GUID CERT CLASS; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	53	12	12	0	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					2041	+		10.1038/s41591-021-01491-7	http://dx.doi.org/10.1038/s41591-021-01491-7		SEP 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34480125	Green Published, hybrid			2022-12-27	WOS:000692308000002
J	Medeiros-Ribeiro, AC; Aikawa, NE; Saad, CGS; Yuki, EFN; Pedrosa, T; Fusco, SRG; Rojo, PT; Pereira, RMR; Shinjo, SK; Andrade, DCO; Sampaio-Barros, PD; Ribeiro, CT; Deveza, GBH; Martins, VAO; Silva, CA; Lopes, MH; Duarte, AJS; Antonangelo, L; Sabino, EC; Kallas, EG; Pasoto, SG; Bonfa, E				Medeiros-Ribeiro, Ana C.; Aikawa, Nadia E.; Saad, Carla G. S.; Yuki, Emily F. N.; Pedrosa, Tatiana; Fusco, Solange R. G.; Rojo, Priscila T.; Pereira, Rosa M. R.; Shinjo, Samuel K.; Andrade, Danieli C. O.; Sampaio-Barros, Percival D.; Ribeiro, Carolina T.; Deveza, Giordano B. H.; Martins, Victor A. O.; Silva, Clovis A.; Lopes, Marta H.; Duarte, Alberto J. S.; Antonangelo, Leila; Sabino, Ester C.; Kallas, Esper G.; Pasoto, Sandra G.; Bonfa, Eloisa			Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial	NATURE MEDICINE			English	Article							CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; SARS-COV-2; PREVALENCE; VALIDATION	CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- and sex-frequency-matched healthy adults (control group, CG), who received two doses of CoronaVac. The primary outcomes were reduction of >= 15% in both anti-SARS-CoV-2 IgG seroconversion (SC) and neutralizing antibody (NAb) positivity 6 weeks (day 69 (D69)) after the second dose in the ARD group compared with that in the CG. Secondary outcomes were IgG SC and NAb positivity at D28, IgG titers and neutralizing activity at D28 and D69 and vaccine safety. Prespecified endpoints were met, with lower anti-SARS-Cov-2 IgG SC (70.4 versus 95.5%, P < 0.001) and NAb positivity (56.3 versus 79.3%, P < 0.001) at D69 in the ARD group than in the CG. Moreover, IgG titers (12.1 versus 29.7, P < 0.001) and median neutralization activity (58.7 versus 64.5%, P = 0.013) were also lower at D69 in patients with ARD. At D28, patients with ARD presented with lower IgG frequency (18.7 versus 34.6%, P < 0.001) and NAb positivity (20.6 versus 36.3%, P < 0.001) than that of the CG. There were no moderate/severe adverse events. These data support the use of CoronaVac in patients with ARD, suggesting reduced but acceptable short-term immunogenicity. The trial is still ongoing to evaluate the long-term effectiveness/immunogenicity. In a large prospective phase 4 trial, vaccination with CoronaVac, an inactivated SARS-CoV-2 vaccine, elicited significantly lower virus-specific IgG antibodies and neutralizing antibodies in patients with autoimmune rheumatic diseases than in age- and sex-matched healthy control trial participants.	[Medeiros-Ribeiro, Ana C.; Aikawa, Nadia E.; Saad, Carla G. S.; Yuki, Emily F. N.; Pedrosa, Tatiana; Fusco, Solange R. G.; Rojo, Priscila T.; Pereira, Rosa M. R.; Shinjo, Samuel K.; Andrade, Danieli C. O.; Sampaio-Barros, Percival D.; Ribeiro, Carolina T.; Deveza, Giordano B. H.; Martins, Victor A. O.; Pasoto, Sandra G.; Bonfa, Eloisa] Univ Sao Paulo, Hosp Clin HCFMUSP, Rheumatol Div, Fac Med, Sao Paulo, Brazil; [Aikawa, Nadia E.; Silva, Clovis A.] Univ Sao Paulo, Inst Crianca, Hosp Clin HCFMUSP, Pediat Rheumatol Unit,Fac Med, Sao Paulo, Brazil; [Lopes, Marta H.; Sabino, Ester C.; Kallas, Esper G.] Univ Sao Paulo, Hosp Clin HCFMUSP, Infect Dis Dept, Fac Med, Sao Paulo, Brazil; [Duarte, Alberto J. S.; Antonangelo, Leila] Univ Sao Paulo, Hosp Clin HCFMUSP, Cent Lab Div, Fac Med, Sao Paulo, Brazil; [Sabino, Ester C.] Univ Sao Paulo, Inst Med Trop, Fac Med, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Bonfa, E (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Rheumatol Div, Fac Med, Sao Paulo, Brazil.	eloisa.bonfa@hc.fm.usp.br	PASOTO, SANDRA/E-1213-2012; Sabino, Ester C/F-7750-2010; Silva, Clovis Artur Almeida/J-3640-2017; Medeiros-Ribeiro, Ana Cristina/GRY-0453-2022; Aikawa, Nadia Emi/I-5962-2013; Pereira, Rosa M R/C-5192-2012; Shinjo, Samuel K/AAF-6221-2021; Bonfa, Eloisa/B-8438-2012; Antonangelo, Leila/H-9998-2012; Yuki, Emily Figueiredo Neves/L-4384-2017; do Nascimento Pedrosa, Tatiana/K-6813-2017	Sabino, Ester C/0000-0003-2623-5126; Medeiros-Ribeiro, Ana Cristina/0000-0001-7168-5906; Aikawa, Nadia Emi/0000-0002-7585-4348; Pereira, Rosa M R/0000-0002-3723-5028; Shinjo, Samuel K/0000-0002-3682-4517; Bonfa, Eloisa/0000-0002-0520-4681; Antonangelo, Leila/0000-0002-8634-5100; Yuki, Emily Figueiredo Neves/0000-0001-8801-405X; Pasoto, Sandra/0000-0002-7343-6804; Lopes, Marta Heloisa/0000-0001-5236-6248; do Nascimento Pedrosa, Tatiana/0000-0003-0009-1013	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2015/03756-4, 2017/14352-7, 2018/09937-9, 2020/11677-5, 2019/21173-7]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [305242/2019-9, 304984/2020-5, 305556/2017-7, 303379/2018-9]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	We thank the contribution of the Central Laboratory Division, Registry Division, Security Division, IT Division, Superintendence, Pharmacy Division and Vaccination Center for their technical support. We also thank the volunteers for participating in the three in-person visits of the protocol and for handling the biological material, and those responsible for the follow-up of all participants. This study was sponsored by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (no. 2015/03756-4 to N.E.A., S.G.P., C.A.S. and E.B.; no. 2017/14352-7 to T.P., no. 2018/09937-9 to V.A.O.M., no. 2020/11677-5 to G.B.H.D.; and no. 2019/21173-7 to C.T.R.) and from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (no. 305242/2019-9 to E.B.; no. 304984/2020-5 to C.A.S.; no. 305556/2017-7 to R.M.R.P.; and no. 303379/2018-9 to S.K.S.). Instituto Butantan supplied the study product and had no other role in the trial.	Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]; [Anonymous], PAIN COR; [Anonymous], [No title captured]; [Anonymous], 2007, GUID IND CLIN DAT NE; [Anonymous], 2021, WHO DRAFT GUID ADV; [Anonymous], 2018, GUID RISK MAN SYST M; [Anonymous], 2021, DIZ TEXT BUL PROFF S; [Anonymous], 2020, COR B COMPL; [Anonymous], REAL TIME PCR PROTOC; [Anonymous], MODEL BASED ESTIMATI, DOI [DOI 10.1101/2021.03.03.21252706V(2021), 10.1101/2021.03.03.21252706v(2021)]; [Anonymous], ANN RHEUM DIS; [Anonymous], [No title captured]; [Anonymous], EXPERT REV VACCINES, DOI [10.1080/14760584.2021(2021, DOI 10.1080/14760584.2021(2021]; AREND WP, 1990, ARTHRITIS RHEUM, V33, P1129; Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Bueno SM., 2021, INTERIM REPORT SAFET, DOI 10.1101/2021.03.31.21254494; Buss Lewis F, 2021, Science, V371, P288, DOI 10.1126/science.abe9728; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Davies Nicholas G, 2021, Science, V372, DOI 10.1126/science.abg3055; de Souza WM, 2020, NAT HUM BEHAV, V4, P856, DOI 10.1038/s41562-020-0928-4; Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Funk T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.16.2100348; Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647; Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272; Gianfrancesco M, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2020-218328; Grainger R, 2021, BEST PRACT RES CL RH, V35, DOI 10.1016/j.berh.2020.101657; Hallal PC, 2020, LANCET GLOB HEALTH, V8, pE1390, DOI 10.1016/S2214-109X(20)30387-9; Harpaz R, 2016, JAMA-J AM MED ASSOC, V316, P2547, DOI 10.1001/jama.2016.16477; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hunter PR, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n958; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Lee JJ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0435-y; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; Mikuls TR, 2021, ARTHRITIS RHEUMATOL, V73, pE1, DOI 10.1002/art.41596; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI 10.1136/annrheumdis-2020-218296; Palacios R, EFFICACY SAFETY COVI; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Rubbert-Roth A, 2021, LANCET RHEUMATOL, V3, pE470, DOI 10.1016/S2665-9913(21)00186-7; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Saad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250; Seyahi E, 2021, RHEUMATOL INT, V41, P1429, DOI 10.1007/s00296-021-04910-7; Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003; Simon D, 2021, ANN RHEUM DIS, V80, P1312, DOI 10.1136/annrheumdis-2021-220461; Spiera R, 2021, ANN RHEUM DIS, V80, P1357, DOI 10.1136/annrheumdis-2021-220604; Strangfeld A, 2021, ANN RHEUM DIS, V80, P930, DOI 10.1136/annrheumdis-2020-219498; Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20; Tillett W, 2012, J RHEUMATOL, V39, P154, DOI 10.3899/jrheum.110845; van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI [10.1136/annrheumdis-2013-204424, 10.1002/art.38098]; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Vogels CBF, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001236; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	60	86	87	3	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1744	+		10.1038/s41591-021-01469-5	http://dx.doi.org/10.1038/s41591-021-01469-5		JUL 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34331051	Green Submitted, Bronze			2022-12-27	WOS:000679626200001
J	Mimee, M; Nagler, CR				Mimee, Mark; Nagler, Cathryn R.			Engineered yeast tune down gut inflammation	NATURE MEDICINE			English	Editorial Material							THERAPEUTICS	A yeast strain engineered to regulate levels of pathogenic metabolites in the gut provides protection against colitis in mouse models.	[Mimee, Mark] Univ Chicago, Dept Microbiol, Biol Sci Div, Chicago, IL 60637 USA; [Mimee, Mark; Nagler, Cathryn R.] Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA; [Nagler, Cathryn R.] Univ Chicago, Dept Pathol, Biol Sci Div, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Nagler, CR (corresponding author), Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA.; Nagler, CR (corresponding author), Univ Chicago, Dept Pathol, Biol Sci Div, 5841 S Maryland Ave, Chicago, IL 60637 USA.	cnagler@bsd.uchicago.edu						D'Amico F, 2020, CURR OPIN PHARMACOL, V55, P141, DOI 10.1016/j.coph.2020.10.015; Fischbach MA, 2018, CELL, V174, P785, DOI 10.1016/j.cell.2018.07.038; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Isabella VM, 2018, NAT BIOTECHNOL, V36, P857, DOI 10.1038/nbt.4222; Jimenez M, 2019, J EXP MED, V216, P1005, DOI 10.1084/jem.20190609; Mimee M, 2016, ADV DRUG DELIVER REV, V105, P44, DOI 10.1016/j.addr.2016.04.032; Nagler CR, 2020, J EXP MED, V217, DOI 10.1084/jem.20191642; Neurath MF, 2019, NAT IMMUNOL, V20, P970, DOI 10.1038/s41590-019-0415-0; Scott BM, 2021, NAT MED, V27, P1212, DOI 10.1038/s41591-021-01390-x; Sonnenburg JL, 2019, SCIENCE, V366, P444, DOI 10.1126/science.aaw9255; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005	12	3	3	4	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1150	1151		10.1038/s41591-021-01420-8	http://dx.doi.org/10.1038/s41591-021-01420-8		JUN 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34183835				2022-12-27	WOS:000667622200001
J	Ogishi, M; Yang, R; Aytekin, C; Langlais, D; Bourgey, M; Khan, T; Al Ali, F; Rahman, M; Delmonte, OM; Chrabieh, M; Zhang, P; Gruber, C; Pelham, SJ; Spaan, AN; Rosain, J; Lei, WT; Drutman, S; Hellmann, MD; Callahan, MK; Adamow, M; Wong, P; Wolchok, JD; Rao, G; Ma, CS; Nakajima, Y; Yaguchi, T; Chamoto, K; Williams, SC; Emile, JF; Rozenberg, F; Glickman, MS; Rapaport, F; Kerner, G; Allington, G; Tezcan, I; Cagdas, D; Hosnut, FO; Dogu, F; Ikinciogullari, A; Rao, VK; Kainulainen, L; Beziat, V; Bustamante, J; Vilarinho, S; Lifton, RP; Boisson, B; Abel, L; Bogunovic, D; Marr, N; Notarangelo, LD; Tangye, SG; Honjo, T; Gros, P; Boisson-Dupuis, S; Casanova, JL				Ogishi, Masato; Yang, Rui; Aytekin, Caner; Langlais, David; Bourgey, Mathieu; Khan, Taushif; Al Ali, Fatima; Rahman, Mahbuba; Delmonte, Ottavia M.; Chrabieh, Maya; Zhang, Peng; Gruber, Conor; Pelham, Simon J.; Spaan, Andras N.; Rosain, Jeremie; Lei, Wei-Te; Drutman, Scott; Hellmann, Matthew D.; Callahan, Margaret K.; Adamow, Matthew; Wong, Phillip; Wolchok, Jedd D.; Rao, Geetha; Ma, Cindy S.; Nakajima, Yuka; Yaguchi, Tomonori; Chamoto, Kenji; Williams, Samuel C.; Emile, Jean-Francois; Rozenberg, Flore; Glickman, Michael S.; Rapaport, Franck; Kerner, Gaspard; Allington, Garrett; Tezcan, Ilhan; Cagdas, Deniz; Hosnut, Ferda O.; Dogu, Figen; Ikinciogullari, Aydan; Rao, V. Koneti; Kainulainen, Leena; Beziat, Vivien; Bustamante, Jacinta; Vilarinho, Silvia; Lifton, Richard P.; Boisson, Bertrand; Abel, Laurent; Bogunovic, Dusan; Marr, Nico; Notarangelo, Luigi D.; Tangye, Stuart G.; Honjo, Tasuku; Gros, Philippe; Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent			Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child	NATURE MEDICINE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; NATURAL-KILLER-CELLS; NEGATIVE T-CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSE; IFN-GAMMA; TNF-ALPHA; MUTATIONS; MYCOBACTERIUM; INFECTION	Dysregulated immune features in a patient with a homozygous loss-of-function mutation in PDCD1 suggest that IL-6, IL-23, STAT3 and ROR gamma T might be potential targets for treatment of PD-1 blockade-induced autoimmunity. The pathophysiology of adverse events following programmed cell death protein 1 (PD-1) blockade, including tuberculosis (TB) and autoimmunity, remains poorly characterized. We studied a patient with inherited PD-1 deficiency and TB who died of pulmonary autoimmunity. The patient's leukocytes did not express PD-1 or respond to PD-1-mediated suppression. The patient's lymphocytes produced only small amounts of interferon (IFN)-gamma upon mycobacterial stimuli, similarly to patients with inborn errors of IFN-gamma production who are vulnerable to TB. This phenotype resulted from a combined depletion of V delta 2(+) gamma delta T, mucosal-associated invariant T and CD56(bright) natural killer lymphocytes and dysfunction of other T lymphocyte subsets. Moreover, the patient displayed hepatosplenomegaly and an expansion of total, activated and ROR gamma T+ CD4(-)CD8(-) double-negative alpha beta T cells, similar to patients with STAT3 gain-of-function mutations who display lymphoproliferative autoimmunity. This phenotype resulted from excessive amounts of STAT3-activating cytokines interleukin (IL)-6 and IL-23 produced by activated T lymphocytes and monocytes, and the STAT3-dependent expression of ROR gamma T by activated T lymphocytes. Our work highlights the indispensable role of human PD-1 in governing both antimycobacterial immunity and self-tolerance, while identifying potentially actionable molecular targets for the diagnostic and therapeutic management of TB and autoimmunity in patients on PD-1 blockade.	[Ogishi, Masato; Yang, Rui; Zhang, Peng; Pelham, Simon J.; Spaan, Andras N.; Lei, Wei-Te; Drutman, Scott; Rapaport, Franck; Beziat, Vivien; Bustamante, Jacinta; Boisson, Bertrand; Abel, Laurent; Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Ma, Cindy S.] Rockefeller Univ, David Rockefeller Grad Program, 1230 York Ave, New York, NY 10021 USA; [Aytekin, Caner] Dr Sami Ulus Matern & Childrens Hlth & Dis Traini, Dept Pediat Immunol, Ankara, Turkey; [Langlais, David] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Bourgey, Mathieu] McGill Univ, Genome Ctr, Montreal, PQ, Canada; [Khan, Taushif; Al Ali, Fatima; Rahman, Mahbuba; Marr, Nico] Sidra Med, Res Branch, Dept Immunol, Doha, Qatar; [Delmonte, Ottavia M.; Notarangelo, Luigi D.] NIAID, Immune Deficiency Genet Sect, Lab Host Defenses, Div Intramural Res,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Chrabieh, Maya; Rosain, Jeremie; Kerner, Gaspard; Beziat, Vivien; Bustamante, Jacinta; Boisson, Bertrand; Abel, Laurent; Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent] INSERM U1163, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Chrabieh, Maya; Rosain, Jeremie; Kerner, Gaspard; Beziat, Vivien; Bustamante, Jacinta; Boisson, Bertrand; Abel, Laurent; Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent] Univ Paris, Imagine Inst, Paris, France; [Gruber, Conor; Bogunovic, Dusan] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Gruber, Conor; Bogunovic, Dusan] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Gruber, Conor; Bogunovic, Dusan] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA; [Gruber, Conor; Bogunovic, Dusan] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Hellmann, Matthew D.; Callahan, Margaret K.; Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Med, New York, NY 10029 USA; [Hellmann, Matthew D.; Callahan, Margaret K.; Wolchok, Jedd D.] Weill Cornell Med, New York, NY USA; [Adamow, Matthew; Wong, Phillip] Mem Sloan Kettering Canc Ctr, Immune Monitoring Core Facil, New York, NY 10029 USA; [Adamow, Matthew; Wolchok, Jedd D.] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Rao, Geetha; Ma, Cindy S.; Tangye, Stuart G.] Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Tangye, Stuart G.] UNSW Sydney, Fac Med, St Vincents Clin Sch, Darlinghurst, NSW, Australia; [Nakajima, Yuka; Yaguchi, Tomonori; Chamoto, Kenji; Honjo, Tasuku] Kyoto Univ, Ctr Canc Immunotherapy & Immunobiol, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; [Williams, Samuel C.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Williams, Samuel C.] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY USA; [Emile, Jean-Francois] Ambroise Hosp, AP HP, Dept Pathol, Boulogne, France; [Rozenberg, Flore] Univ Paris, Cochin Hosp, Dept Virol, Paris, France; [Glickman, Michael S.] Sloan Kettering Inst, Immunol Program, New York, NY USA; [Allington, Garrett; Vilarinho, Silvia; Lifton, Richard P.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Allington, Garrett; Vilarinho, Silvia] Yale Univ, Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06510 USA; [Allington, Garrett; Vilarinho, Silvia] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Tezcan, Ilhan; Cagdas, Deniz] Hacettepe Univ, Dept Pediat Immunol, Med Fac, Ankara, Turkey; [Hosnut, Ferda O.] Dr Sami Ulus Matern & Childrens Hlth & Dis Traini, Dept Pediat Gastroenterol, Ankara, Turkey; [Dogu, Figen; Ikinciogullari, Aydan] Ankara Univ, Dept Pediat Immunol & Allergy, Sch Med, Ankara, Turkey; [Rao, V. Koneti] NIAID, Lab Clin Immunol & Microbiol, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Kainulainen, Leena] Turku Univ Hosp, Dept Pediat, Turku, Finland; [Kainulainen, Leena] Turku Univ Hosp, Dept Med, Turku, Finland; [Bustamante, Jacinta] Necker Hosp Sick Children, Study Ctr Immunodeficiencies, Paris, France; [Lifton, Richard P.] Rockefeller Univ, Lab Human Genet & Genom, 1230 York Ave, New York, NY 10021 USA; [Marr, Nico] Hamad Bin Khalifa Univ, Coll Hlth & Life Sci, Doha, Qatar; [Gros, Philippe] McGill Res Ctr Complex Traits, Montreal, PQ, Canada; [Gros, Philippe] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY 10065 USA	Rockefeller University; Rockefeller University; Dr. Sami Ulus Education & Research Hospital; McGill University; McGill University; Sidra Medical & Research Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Garvan Institute of Medical Research; University of New South Wales Sydney; Kyoto University; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Memorial Sloan Kettering Cancer Center; Yale University; Yale University; Yale University; Hacettepe University; Dr. Sami Ulus Education & Research Hospital; Ankara University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Turku; University of Turku; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Qatar Foundation (QF); Hamad Bin Khalifa University-Qatar; McGill University; Howard Hughes Medical Institute	Ogishi, M; Boisson-Dupuis, S; Casanova, JL (corresponding author), Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA.; Boisson-Dupuis, S; Casanova, JL (corresponding author), INSERM U1163, Lab Human Genet Infect Dis, Necker Branch, Paris, France.; Boisson-Dupuis, S; Casanova, JL (corresponding author), Univ Paris, Imagine Inst, Paris, France.; Casanova, JL (corresponding author), Howard Hughes Med Inst, New York, NY 10065 USA.	mogishi@rockefeller.edu; stbo603@rockefeller.edu; casanova@rockefeller.edu	Hoşnut, Ferda/GXF-0457-2022; Cagdas, Deniz/I-9104-2013; Yang, Rui/AAX-2516-2021; Zhang, Peng/I-4665-2019; Boisson, Bertrand/I-2485-2017; Béziat, Vivien/AAT-4097-2021; Özbay Hoşnut, Ferda/GSJ-0760-2022; Marr, Nico/T-7741-2019; Rahman, Mahbuba/AAR-2085-2020; Boisson, Bertrand/AAC-6058-2019; Béziat, Vivien/G-2971-2011; S, Cindy/B-2340-2012	Cagdas, Deniz/0000-0003-2213-4627; Yang, Rui/0000-0003-4427-2158; Zhang, Peng/0000-0002-6129-567X; Boisson, Bertrand/0000-0001-5240-3555; Béziat, Vivien/0000-0002-4020-824X; Marr, Nico/0000-0002-1927-7072; Rahman, Mahbuba/0000-0003-4586-4067; Boisson, Bertrand/0000-0001-5240-3555; Béziat, Vivien/0000-0002-4020-824X; S, Cindy/0000-0001-5387-8413; Bourgey, Mathieu/0000-0002-8432-834X; Allington, Garrett/0000-0002-5458-6129; Langlais, David/0000-0003-4429-0110; Ogishi, Masato/0000-0003-2421-7389; Williams, Samuel/0000-0003-1916-1579; Aytekin, Caner/0000-0002-2921-5270; Kainulainen, Leena/0000-0002-7776-3626	Flow Cytometry Resource Center at the Rockefeller University; Empire State Stem Cell Fund for providing support through NYSDOH [C023046]; NIH/National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) [P30 CA008748]; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; Ludwig Center for Cancer Immunotherapy; Parker Institute for Cancer Immunotherapy; St. Giles Foundation; Rockefeller University; Institut National de la Sante et de la Recherche Medicale (INSERM); University of Paris; Sidra Medicine; National Institute of Allergy and Infectious Diseases [R37AI095983, U19AI142737, U19AI111143]; National Institute of Diabetes and Digestive and Kidney Diseases [K08 DK113109]; National Center for Research Resources; National Center for Advancing Sciences of the NIH [UL1TR001866]; NIH/NCI Cancer Center Support Grant (CCSG) [P30 CA008748]; NIH/NCI [R01 CA056821]; Swim Across America; Ludwig Institute for Cancer Research; Cancer Research Institute; French National Research Agency (ANR) [ANR-10-IAHU-01]; Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence [ANR-10-LABX-62-IBEID]; GENMSMD [ANR-16-CE17.0005-01]; French Foundation for Medical Research [EQU201903007798]; SCOR Corporate Foundation for Science; David Rockefeller Graduate Program; Funai Foundation for Information Technology; Honjo International Scholarship Foundation; New York Hideyo Noguchi Memorial Society; Cooperative Center on Human Immunology at The Rockefeller University; Immune Deficiency Foundation; Stony Wold-Herbert Fund; European Commission (EC Horizon 2020 Marie Sklodowska-Curie Individual Fellowship) [789645]; Dutch Research Council (NWO) [019.171LW.015]; European Molecular Biology Organization [ALTF 84-2017]; INSERM PhD program; Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH [T32GM007739]; Early-Mid Career Research Fellowship from the Department of Health of the New South Wales Government of Australia; NHMRC Leadership 3 Investigator grant [1176665]; NHMRC [1113904]	Flow Cytometry Resource Center at the Rockefeller University; Empire State Stem Cell Fund for providing support through NYSDOH; NIH/National Cancer Institute (NCI) Cancer Center Support Grant (CCSG); Marie-Josee and Henry R. Kravis Center for Molecular Oncology; Ludwig Center for Cancer Immunotherapy; Parker Institute for Cancer Immunotherapy; St. Giles Foundation; Rockefeller University; Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Paris; Sidra Medicine; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Sciences of the NIH; NIH/NCI Cancer Center Support Grant (CCSG); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swim Across America; Ludwig Institute for Cancer Research; Cancer Research Institute; French National Research Agency (ANR)(French National Research Agency (ANR)); Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence; GENMSMD; French Foundation for Medical Research(Fondation pour la Recherche Medicale); SCOR Corporate Foundation for Science; David Rockefeller Graduate Program; Funai Foundation for Information Technology; Honjo International Scholarship Foundation(Honjo International Scholarship Foundation); New York Hideyo Noguchi Memorial Society; Cooperative Center on Human Immunology at The Rockefeller University; Immune Deficiency Foundation; Stony Wold-Herbert Fund; European Commission (EC Horizon 2020 Marie Sklodowska-Curie Individual Fellowship)(European CommissionEuropean Commission Joint Research Centre); Dutch Research Council (NWO)(Netherlands Organization for Scientific Research (NWO)); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); INSERM PhD program; Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH; Early-Mid Career Research Fellowship from the Department of Health of the New South Wales Government of Australia; NHMRC Leadership 3 Investigator grant(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We thank the patients, their relatives and their physicians for participating in this study; D. Papandrea, Y. Nemirovskaya, M. Woollett, L. Lorenzo-Diaz and C. Patissier for administrative assistance; T. Kochetkov and J. Eun Han for technical assistance; and members of the laboratory for helpful discussions. We thank the Flow Cytometry Resource Center at the Rockefeller University and the Empire State Stem Cell Fund for providing support through NYSDOH contract no. C023046. We thank the Human Immune Monitoring Core at the Icahn School of Medicine at Mount Sinai for technical assistance with mass cytometry. We thank the NIH Tetramer Core Facility for providing the MR1 tetramer, which was developed jointly with J. McCluskey, J. Rossjohn and D. Fairlie. We thank Cycle for Survival, the Integrated Genomics Operation Core of the MSKCC, funded by the NIH/National Cancer Institute (NCI) Cancer Center Support Grant (CCSG, P30 CA008748), the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, the Ludwig Center for Cancer Immunotherapy and the Parker Institute for Cancer Immunotherapy, for technical assistance with RNA-seq. The study was supported in part by grants from the St. Giles Foundation, The Rockefeller University, Institut National de la Sante et de la Recherche Medicale (INSERM), University of Paris, Sidra Medicine, the National Institute of Allergy and Infectious Diseases (R37AI095983 to J.-L.C., U19AI142737 to S.B.-D. and U19AI111143 and to M.S.G.), the National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK113109 to S.V.), the National Center for Research Resources, the National Center for Advancing Sciences of the NIH (UL1TR001866), NIH/NCI Cancer Center Support Grant (CCSG, P30 CA008748), NIH/NCI R01 CA056821, the Swim Across America, the Ludwig Institute for Cancer Research, the Ludwig Center for Cancer Immunotherapy, the Cancer Research Institute, the Parker Institute for Cancer Immunotherapy, the French National Research Agency (ANR) under the 'Investments for the Future' program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), GENMSMD (ANR-16-CE17.0005-01 to J.B.), the French Foundation for Medical Research (EQU201903007798), and the SCOR Corporate Foundation for Science. M.O. was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology, the Honjo International Scholarship Foundation, the New York Hideyo Noguchi Memorial Society and the Cooperative Center on Human Immunology at The Rockefeller University. R.Y. was supported by the Immune Deficiency Foundation and The Stony Wold-Herbert Fund. A.N.S. was supported by the European Commission (EC Horizon 2020 Marie Skodowska-Curie Individual Fellowship no. 789645), the Dutch Research Council (NWO, Rubicon grant no. 019.171LW.015) and the European Molecular Biology Organization (Long-Term Fellowship no. ALTF 84-2017, non-stipendiary). J.R. was supported by the INSERM PhD program (poste d'accueil INSERM). S.C.W. was supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program (T32GM007739). C.S.M. is supported by an Early-Mid Career Research Fellowship from the Department of Health of the New South Wales Government of Australia. S.G.T. is supported by an NHMRC Leadership 3 Investigator grant (1176665) and NHMRC program grant (1113904).	Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999; Barber DL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat2702; Belkadi A, 2016, P NATL ACAD SCI USA, V113, P6713, DOI 10.1073/pnas.1606460113; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boisson-Dupuis S, 2020, HUM GENET, V139, P1001, DOI 10.1007/s00439-020-02126-6; Boisson-Dupuis S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau8714; Cantaert T, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3150; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Crispin JC, 2008, J IMMUNOL, V181, P8761, DOI 10.4049/jimmunol.181.12.8761; Crowell HL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19894-4; Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010; Fabre A, 2019, J ALLER CL IMM-PRACT, V7, P1958, DOI 10.1016/j.jaip.2019.02.018; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Forbes LR, 2018, J ALLERGY CLIN IMMUN, V142, P1665, DOI 10.1016/j.jaci.2018.07.020; Gentili M, 2015, SCIENCE, V349, P1232, DOI 10.1126/science.aab3628; Gold MC, 2015, IMMUNOL REV, V264, P154, DOI 10.1111/imr.12271; Gonzalez-Mancera MS, 2020, RESPIR MED CASE REP, V30, DOI 10.1016/j.rmcr.2020.101125; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Haghverdi L, 2018, NAT BIOTECHNOL, V36, P421, DOI 10.1038/nbt.4091; Harris J, 2010, CLIN EXP IMMUNOL, V161, P1, DOI 10.1111/j.1365-2249.2010.04146.x; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002119, 10.1371/journal.pmed.1002152]; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Itan Y, 2016, NAT METHODS, V13, P109, DOI 10.1038/nmeth.3739; Jacquelot N, 2019, CELL RES, V29, P846, DOI 10.1038/s41422-019-0224-x; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; KALLURI R, 1994, P NATL ACAD SCI USA, V91, P6201, DOI 10.1073/pnas.91.13.6201; Kauffman KD, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf3861; Kerner G, 2021, AM J HUM GENET, V108, P517, DOI 10.1016/j.ajhg.2021.02.009; Kerner G, 2020, J CLIN INVEST, V130, P3158, DOI 10.1172/JCI135460; Kerner G, 2019, P NATL ACAD SCI USA, V116, P10430, DOI 10.1073/pnas.1903561116; Kreins AY, 2015, J EXP MED, V212, P1641, DOI 10.1084/jem.20140280; Lazar-Molnar E, 2010, P NATL ACAD SCI USA, V107, P13402, DOI 10.1073/pnas.1007394107; Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890; Li H, 2021, CURR OPIN RHEUMATOL, V33, P163, DOI 10.1097/BOR.0000000000000778; Li M, 2014, J BIOL CHEM, V289, P17647, DOI 10.1074/jbc.M114.572420; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2016, J EXP MED, V213, P1589, DOI 10.1084/jem.20151467; Maffucci P, 2019, P NATL ACAD SCI USA, V116, P950, DOI 10.1073/pnas.1808403116; Magerus-Chatinet A, 2009, BLOOD, V113, P3027, DOI 10.1182/blood-2008-09-179630; Martins F, 2019, LANCET ONCOL, V20, pE54, DOI 10.1016/S1470-2045(18)30828-3; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Mina MJ, 2019, SCIENCE, V366, P599, DOI 10.1126/science.aay6485; Mohan D, 2018, NAT PROTOC, V13, P1958, DOI 10.1038/s41596-018-0025-6; Moreira-Teixeira L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19412-6; Nabhani S, 2017, CLIN IMMUNOL, V181, P32, DOI 10.1016/j.clim.2017.05.021; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012; Nguyen KB, 2000, NAT IMMUNOL, V1, P70, DOI 10.1038/76940; Nishino M, 2015, NEW ENGL J MED, V373, P288, DOI 10.1056/NEJMc1505197; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Picchi H, 2018, CLIN MICROBIOL INFEC, V24, P216, DOI 10.1016/j.cmi.2017.12.003; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; R Core Team, 2021, R LANGUAGE ENV STAT; Rapaport F, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2001248118; Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schwartz GW, 2020, NAT METHODS, V17, P405, DOI 10.1038/s41592-020-0748-5; Stroud CRG, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e21712; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Tousif S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019864; Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247; Wang JA, 2010, INT IMMUNOL, V22, P443, DOI 10.1093/intimm/dxq026; Wang LS, 2001, J IMMUNOL, V167, P6195, DOI 10.4049/jimmunol.167.11.6195; Wei SC, 2019, IMMUNITY, V50, P1084, DOI 10.1016/j.immuni.2019.03.004; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698; Yang R, 2020, CELL, V183, P1826, DOI 10.1016/j.cell.2020.10.046; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang BH, 2016, P NATL ACAD SCI USA, V113, P8490, DOI 10.1073/pnas.1608873113; ZHENG GX, 2017, NATURE, V0008	75	20	23	3	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1646	+		10.1038/s41591-021-01388-5	http://dx.doi.org/10.1038/s41591-021-01388-5		JUN 2021	35	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34183838	Green Accepted			2022-12-27	WOS:000667622200005
J	Villar, J; Gunier, RB; Tshivuila-Matala, COO; Rauch, SA; Nosten, F; Ochieng, R; Restrepo-Mendez, MC; McGready, R; Barros, FC; Fernandes, M; Carrara, VI; Victora, CG; Munim, S; Craik, R; Barsosio, HC; Carvalho, M; Berkley, JA; Ismail, LC; Norris, SA; Ohuma, EO; Stein, A; Lambert, A; Winsey, A; Uauy, R; Eskenazi, B; Bhutta, ZA; Papageorghiou, AT; Kennedy, SH				Villar, Jose; Gunier, Robert B.; Tshivuila-Matala, Chrystelle O. O.; Rauch, Stephen A.; Nosten, Francois; Ochieng, Roseline; Restrepo-Mendez, Maria C.; McGready, Rose; Barros, Fernando C.; Fernandes, Michelle; Carrara, Verena I.; Victora, Cesar G.; Munim, Shama; Craik, Rachel; Barsosio, Hellen C.; Carvalho, Maria; Berkley, James A.; Cheikh Ismail, Leila; Norris, Shane A.; Ohuma, Eric O.; Stein, Alan; Lambert, Ann; Winsey, Adele; Uauy, Ricardo; Eskenazi, Brenda; Bhutta, Zulfiqar A.; Papageorghiou, Aris T.; Kennedy, Stephen H.			Fetal cranial growth trajectories are associated with growth and neurodevelopment at 2 years of age: INTERBIO-21st Fetal Study	NATURE MEDICINE			English	Article							BODY-MASS INDEX; DEVELOPMENTAL TRAJECTORIES; CHILD GROWTH; STANDARDS; HEALTH	Many observational studies and some randomized trials demonstrate how fetal growth can be influenced by environmental insults (for example, maternal infections)(1) and preventive interventions (for example, multiple-micronutrient supplementation)(2) that can have a long-lasting effect on health, growth, neurodevelopment and even educational attainment and income in adulthood(3). In a cohort of pregnant women (n = 3,598), followed-up between 2012 and 2019 at six sites worldwide(4), we studied the associations between ultrasound-derived fetal cranial growth trajectories, measured longitudinally from <14 weeks' gestation, against international standards(5,6), and growth and neurodevelopment up to 2 years of age(7,8). We identified five trajectories associated with specific neurodevelopmental, behavioral, visual and growth outcomes, independent of fetal abdominal growth, postnatal morbidity and anthropometric measures at birth and age 2. The trajectories, which changed within a 20-25-week gestational age window, were associated with brain development at 2 years of age according to a mirror (positive/negative) pattern, mostly focused on maturation of cognitive, language and visual skills. Further research should explore the potential for preventive interventions in pregnancy to improve infant neurodevelopmental outcomes before the critical window of opportunity that precedes the divergence of growth at 20-25 weeks' gestation.	[Villar, Jose; Tshivuila-Matala, Chrystelle O. O.; Restrepo-Mendez, Maria C.; Fernandes, Michelle; Craik, Rachel; Ohuma, Eric O.; Lambert, Ann; Winsey, Adele; Papageorghiou, Aris T.; Kennedy, Stephen H.] Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, England; [Villar, Jose; Restrepo-Mendez, Maria C.; Lambert, Ann; Papageorghiou, Aris T.; Kennedy, Stephen H.] Univ Oxford, Oxford Maternal & Perinatal Hlth Inst, Green Templeton Coll, Oxford, England; [Gunier, Robert B.; Rauch, Stephen A.; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, Berkeley, CA 94720 USA; [Tshivuila-Matala, Chrystelle O. O.] Univ Witwatersrand, Dept Paediat & Child Hlth, SAMRC Dev Pathways Hlth Res Unit, Johannesburg, South Africa; [Tshivuila-Matala, Chrystelle O. O.] World Bank Grp, Hlth Nutr & Populat Global Practice, Washington, DC USA; [Nosten, Francois] Univ Oxford Old Rd Campus, Nuffield Dept Med Res Bldg, Ctr Trop Med & Global Hlth, Oxford, England; [Nosten, Francois; McGready, Rose; Carrara, Verena I.] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand; [Ochieng, Roseline] Aga Khan Univ, Fac Hlth Sci, Nairobi, Kenya; [McGready, Rose; Carrara, Verena I.; Berkley, James A.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Barros, Fernando C.] Univ Catolica Pelotas, Programa Posgrad Saude & Comportamento, Pelotas, RS, Brazil; [Fernandes, Michelle] Univ Southampton, Dept Paediat, Fac Med, Southampton, Hants, England; [Victora, Cesar G.] Univ Fed Pelotas, Programa Posgrad Epidemiol, Pelotas, RS, Brazil; [Munim, Shama] Aga Khan Univ, Div Women & Child Hlth, Dept Obstet & Gynaecol, Karachi, Pakistan; [Barsosio, Hellen C.] Univ Oxford, KEMRI Coast Ctr Geog Med & Res, Kilifi, Kenya; [Carvalho, Maria] Aga Khan Univ Hosp, Dept Obstet & Gynaecol, Fac Hlth Sci, Nairobi, Kenya; [Berkley, James A.] KEMRI Wellcome Trust Res Programme, Nairobi, Kenya; [Cheikh Ismail, Leila] Univ Sharjah, Clin Nutr & Dietet Dept, Sharjah, U Arab Emirates; [Norris, Shane A.] Univ Witwatersrand, Dept Paediat & Child Hlth, SAMRC Dev Pathways Hlth Res Unit, Johannesburg, South Africa; [Ohuma, Eric O.] London Sch Hyg & Trop Med, Maternal Adolescent Reprod & Child Hlth MARCH Ctr, London, England; [Stein, Alan] Univ Oxford, Dept Psychiat, Oxford, England; [Stein, Alan] Univ Witwatersrand, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Fac Hlth Sci, Johannesburg, South Africa; [Uauy, Ricardo] London Sch Hyg & Trop Med, Dept Nutr & Publ Hlth Intervent Res, London, England; [Bhutta, Zulfiqar A.] Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, Canada	University of Oxford; University of Oxford; University of California System; University of California Berkeley; University of Witwatersrand; The World Bank; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; Aga Khan University; University of Oxford; Universidade Catolica de Pelotas; Universidade Federal de Pelotas; University of Southampton; Universidade Federal de Pelotas; Aga Khan University; University of Sharjah; University of Witwatersrand; University of London; London School of Hygiene & Tropical Medicine; University of Oxford; University of Witwatersrand; University of London; London School of Hygiene & Tropical Medicine; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Villar, J (corresponding author), Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, England.; Villar, J (corresponding author), Univ Oxford, Oxford Maternal & Perinatal Hlth Inst, Green Templeton Coll, Oxford, England.	jose.villar@wrh.ox.ac.uk	Norris, Shane/C-4664-2014	Norris, Shane/0000-0001-7124-3788; Cheikh Ismail, Leila/0000-0003-3048-7481; Gunier, Robert/0000-0001-5485-9919; Nosten, Francois/0000-0002-7951-0745; Fernandes, Michelle Caroline/0000-0002-0051-3389; Papageorghiou, Aris T./0000-0001-8143-2232; carrara, verena/0000-0002-2758-0872; Berkley, James/0000-0002-1236-849X	Bill AMP; Melinda Gates Foundation [OPP49038]; Oxford Partnership Comprehensive Biomedical Research Centre; NIHR Biomedical Research Centre funding scheme	Bill AMP; Melinda Gates Foundation(CGIAR); Oxford Partnership Comprehensive Biomedical Research Centre; NIHR Biomedical Research Centre funding scheme(National Institute for Health Research (NIHR))	This project was supported by a generous grant (OPP49038) from the Bill & Melinda Gates Foundation to the University of Oxford, for which we are very grateful (J.V., R.B.G., S.A.R., M.C.R.M., M.F., R.C., L.C.I., E.O.O., A.L., A.W., B.E. and A.T.P.). A.T.P. is supported by the Oxford Partnership Comprehensive Biomedical Research Centre with funding from the NIHR Biomedical Research Centre funding scheme. The views expressed herein are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or any of the other funders. We would like to thank the health authorities in Pelotas, Brazil; Karachi, Pakistan; Kilifi, Kenya; Nairobi, Kenya; Johannesburg, South Africa; and Oxford, UK who facilitated the project by allowing participation of these study sites as collaborating centres. The participating hospitals included: Brazil, Pelotas (Hospital Miguel Piltcher, Hospital Sao Francisco de Paula, Santa Casa de Misericordia de Pelotas and Hospital Escola da Universidade Federal de Pelotas); Pakistan, Karachi (Aga Khan Hospital); Kenya, Kilifi, (The Kilifi District Hospital); Nairobi, Kenya (Aga Khan University Hospital); South Africa, Johannesburg (Chris Hani Baragwanath Academic Hospital); Thailand, Mae Sot (Maela Wang Pha and Mawker Thai Clinics); and UK, Oxford (John Radcliffe Hospital). We are extremely grateful to Philips Medical Systems which provided the ultrasound equipment and technical assistance throughout the project. We also thank MedSciNet for setting up the INTERBIO-21st website and for the development, maintenance and support of the online data management system. We thank the parents and infants who participated in the studies and the more than 200 members of the research teams who made the implementation of this project possible. Finally, we acknowledge the contributions of all the members of the INTERBIO-21st Committees and the local investigators listed below. Scientific Advisory Committee: M. Katz (Chair), M. K. Bhan, C. Garza, A. Langer, P. M. Rothwell, S. Zaidi. Steering Committee: R. Uauy (Chair), S. H. Kennedy (Co-Principal Investigator), J. Villar (Co-Principal Investigator), D. G. Altman, F. C. Barros, J. A. Berkley, F. Burton, M. Carvalho, L. Cheikh Ismail, W. C. Chumlea, A. Lambert, S. Munim, S. Norris, F. Nosten, A. T. Papageorghiou, C. Victora. Executive Committee: J. Villar (Chair), D. G. Altman (died in 2018), L. Cheikh Ismail, R. Craik, S. H. Kennedy, A. Lambert, A. T. Papageorghiou, R. Uauy. Study Coordinating Unit: J. Villar (Head), S. Ash, R. Craik, L. Cheikh Ismail, S. H. Kennedy, A. Lambert, A. T. Papageorghiou, M. Shorten. Data Analysis Group: D. G. Altman (Head), E. O. Ohuma, A. T. Papageorghiou, E. Staines Urias, J. Villar. Data Management Group: D. G. Altman (Head), I. Ahmed, S. Ash, C. Condon, M. Mainwaring, D. Muninzwa, M. F. da Silveira, E. Staines Urias, L. Walusuna, S. Wiladphaingern. Ultrasound Group: A. T. Papageorghiou (Head), L. Salomon (Senior External Advisor), M. Buckle, N. Jackson, A. Mitidieri, S. Munim, H. Mwangudzah, R. Napolitano, T. Norris, J. Sande, J. Shah, G. Zainab. Anthropometry Group: L. Cheikh Ismail (Head), W. C. Chumlea (Senior External Advisor), J. Kizidio, B. Monyepote, F. Puglia, M. Salim, R. Salam, V. I. Carrara. Laboratory Group: R. Craik (Head), D. Alam, Y. Guman, J. Kilonzo, A. Min, V. Ngami, I. Olivera, G. Deutsch. Neonatal Group: Z. A. Bhutta (Head), E. Bertino, F. Giuliani, R. Uauy. Environmental Health Group: B. Eskenazi (Head), J. Villar. Neurodevelopment Group: A. Stein (Head), M. Fernandes (Coordinator), A. Abubakar, J. Acedo, L.; r Aranzeta, L. Cheikh Ismail, F. Giuliani, D. Ibanez, S. H. Kennedy, M. Kihara, E. de Leon, C. R. Newton, S. Savini, A. Soria-Frisch, J. Villar, K. Wulff. INTERBIO-21st participating countries and local investigators: Brazil: F.C. Barros (Principal Investigator), M. Domingues, S. Fonseca, A. Leston, A. Mitidieri, D. Mota, I. K. Sclowitz, M. F. da Silveira. Kenya (Kilifi): J. A. Berkley (Principal Investigator), B. Kemp, H. Barsosio, S. Mwakio, H. Mwangudzah, V. Ngami, M. Salim, A. Seale, L. Walusuna. Kenya (Nairobi): M. Carvalho and W. Stones (Co-Principal Investigators), D. Muninzwa, J. Kilonzo, J. Kizidio, R. Ochieng, J. Sande, J. Shah. Pakistan: Z. Bhutta and S. Munim (Co-Principal Investigators), I. Ahmed, D. Alam, A. Raza, R. Salam, G. Zainab. South Africa: S. Norris (Principal Investigator), Y. Guman, T. Lephoto, S. Macauley, L. Malgas. Thailand: F. Nosten (Principal Investigator), N. Jackson, R. McGready, A. Min, V. I. Cararra, S. Wiladphaingern. UK: S. H. Kennedy (Principal Investigator), S. Ash, M. Baricco, A. Capp, L. Cheikh Ismail, R. Craik, S. Hussein, A. Laister, A. Lambert, T. Lewis, E. Maggiora, R. Napolitano, T. Norris, A. T. Papageorghiou, B. Patel, F. Puglia, F. Roseman, S. Roseman, M. Sharps, A. Varalda, R. Carew. Full acknowledgement of all those who contributed to the development of the project protocol appears at www.interbio21.org.uk.	Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; ADOH TO, 1992, OPTOMETRY VISION SCI, V69, P427, DOI 10.1097/00006324-199206000-00003; ANDERSON MA, 1995, B WORLD HEALTH ORGAN, V73, P165; Armstrong BG, 1998, OCCUP ENVIRON MED, V55, P651, DOI 10.1136/oem.55.10.651; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; Carter MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047065; Cheikh Ismail L, 2016, BMC NUTR, V2; de Boor C., 2001, PRACTICAL GUIDE SPLI, DOI 10.2307/2006241; de Onis M, 2006, ACTA PAEDIATR, V95, P5, DOI 10.1080/08035320500495373; de Onis Mercedes, 2004, Food Nutr Bull, V25, pS27; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Dewey KG, 2005, DEV VALIDATING SIMPL; Dupont C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28165-8; Fernandes M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035258; Fernando MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094188; Garza C, 2013, MATERN CHILD NUTR, V9, P58, DOI 10.1111/mcn.12085; Heggeseth B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131443; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Ismail LC, 2013, BJOG-INT J OBSTET GY, V120, P48, DOI 10.1111/1471-0528.12127; Keats EC, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004905.pub6; Kennedy Stephen H, 2018, Gates Open Res, V2, P49, DOI 10.12688/gatesopenres.12869.2; Kjaer M, 2017, CEREB CORTEX, V27, P5477, DOI 10.1093/cercor/bhw314; Lee ACC, 2013, LANCET GLOB HEALTH, V1, pE26, DOI 10.1016/S2214-109X(13)70006-8; Magee CA, 2013, J DEV BEHAV PEDIATR, V34, P165, DOI [10.1097/DBP.0b013e318289aa51., 10.1097/DBP.0b013e318289aa51]; McLachlan D, 2000, FINITE MIXTURE MODEL; Meyer U, 2007, NEUROSCIENTIST, V13, P241, DOI 10.1177/1073858406296401; Murray E, 2015, BJOG-INT J OBSTET GY, V122, P1062, DOI 10.1111/1471-0528.13435; Murray Elizabeth, 2018, PLoS One, V13, pe0193406, DOI 10.1371/journal.pone.0193406; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nolan TM, 1996, J PAEDIATR CHILD H, V32, P405, DOI 10.1111/j.1440-1754.1996.tb00939.x; Papageorghiou AT, 2014, ULTRASOUND OBST GYN, V44, P641, DOI 10.1002/uog.13448; Papageorghiou AT, 2014, LANCET, V384, P869, DOI 10.1016/S0140-6736(14)61490-2; Perumal N, 2015, J NUTR, V145, P2429, DOI 10.3945/jn.115.214064; Proust-Lima C, 2014, STAT METHODS MED RES, V23, P74, DOI 10.1177/0962280212445839; Pryor LE, 2011, ARCH PEDIAT ADOL MED, V165, P906, DOI 10.1001/archpediatrics.2011.153; Tanner J., 1990, FETUS MAN PHYS GROWT; Tanner J. C., 2015, 20153 IEG; Ventura AK, 2009, OBESITY, V17, P2067, DOI 10.1038/oby.2009.123; Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4; Villar J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07983-4; Villar J, 2018, AM J OBSTET GYNECOL, V218, pS841, DOI 10.1016/j.ajog.2017.11.564; Villar J, 2014, LANCET DIABETES ENDO, V2, P781, DOI 10.1016/S2213-8587(14)70121-4; Ziyab AH, 2014, J EPIDEMIOL COMMUN H, V68, P934, DOI 10.1136/jech-2014-203808; 2006, ACTA PAEDIATR, V450, P27, DOI DOI 10.1080/08035320500495456; 2006, ACTA PAEDIATR, V450, P86, DOI DOI 10.1080/08035320500495563	45	10	10	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					647	652		10.1038/s41591-021-01280-2	http://dx.doi.org/10.1038/s41591-021-01280-2		MAR 2021	6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33737749	Green Accepted, Green Submitted			2022-12-27	WOS:000630281500002
J	Meganck, RM; Baric, RS				Meganck, Rita M.; Baric, Ralph S.			Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases	NATURE MEDICINE			English	Review							RESPIRATORY SYNDROME CORONAVIRUS; FULLY HUMAN-ANTIBODIES; OPEN-LABEL; FUNCTIONAL RECEPTOR; DOUBLE-BLIND; HUMAN-CELLS; VIRUS; REPLICATION; EFFICACY; INHIBITION	The twenty-first century has already recorded more than ten major epidemic or pandemic virus emergence events, including the ongoing and devastating coronavirus disease 2019 (COVID-19) pandemic. As viral disease emergence is expected to accelerate, these data dictate a need for proactive approaches to develop broadly active family-specific and cross-family therapeutics for use in future disease outbreaks. Emphasis should focus not only on the development of broad-spectrum small-molecule and antibody direct-acting antivirals, but also on host-factor therapeutics, including repurposing previously approved or in-pipeline drugs. Another new class of therapeutics with great antiviral therapeutic potential is RNA-based therapeutics. Rather than only focusing on known risks, dedicated efforts must be made toward pre-emptive research focused on outbreak-prone virus families, ultimately offering a strategy to shorten the gap between outbreak and response. Emphasis should also focus on orally available drugs for outpatient use, if possible, and on identifying combination therapies that combat viral and immune-mediated pathologies, extend the effectiveness of therapeutic windows and reduce drug resistance. While such an undertaking will require new vision, dedicated funding and private, federal and academic partnerships, this approach offers hope that global populations need never experience future pandemics such as COVID-19. As the emergence of viral diseases is expected to accelerate, proactive programs to develop broadly active family-specific and cross-family antiviral therapeutics will be key to prepare for future disease outbreaks.	[Meganck, Rita M.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Baric, RS (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.	rbaric@email.unc.edu		Meganck, Rita/0000-0003-2799-3754; Baric, Ralph/0000-0001-6827-8701				Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020; Ahmed AE, 2019, J INFECT PUBLIC HEAL, V12, P767, DOI 10.1016/j.jiph.2019.04.002; Ahn DG, 2011, ANTIVIR RES, V91, P1, DOI 10.1016/j.antiviral.2011.04.009; Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anderson KP, 1996, ANTIMICROB AGENTS CH, V40, P2004, DOI 10.1128/AAC.40.9.2004; Andreakos E, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012465; Arankalle VA, 2007, J GEN VIROL, V88, P1967, DOI 10.1099/vir.0.82714-0; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Balwani M, 2020, NEW ENGL J MED, V382, P2289, DOI 10.1056/NEJMoa1913147; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793; Bente DA, 2013, ANTIVIR RES, V100, P159, DOI 10.1016/j.antiviral.2013.07.006; Braun E, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1073; Burt Felicity J, 2017, Lancet Infect Dis, V17, pe107, DOI 10.1016/S1473-3099(16)30385-1; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Carlsson L, 2018, MOL THER-METH CLIN D, V9, P330, DOI 10.1016/j.omtm.2018.04.003; Chen CC, 2021, FEBS J, V288, P5089, DOI 10.1111/febs.15696; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cherry James D, 2004, Paediatr Respir Rev, V5, P262, DOI 10.1016/j.prrv.2004.07.009; Chhabra P, 2019, J GEN VIROL, V100, P1393, DOI 10.1099/jgv.0.001318; Chong HT, 2001, ANN NEUROL, V49, P810, DOI 10.1002/ana.1062; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; de Graaf M, 2016, NAT REV MICROBIOL, V14, P421, DOI 10.1038/nrmicro.2016.48; de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; Dijkman R, 2013, J VIROL, V87, P6081, DOI 10.1128/JVI.03368-12; Eberhardt KA, 2019, INT J INFECT DIS, V87, P15, DOI 10.1016/j.ijid.2019.07.015; Edwards CE, 2020, P NATL ACAD SCI USA, V117, P26915, DOI [10.1073/pnas.2001046117, 10.1073/pnas.2001046117/-/DCSupplemental]; Epstein JH, 2017, REV SCI TECH OIE, V36, P499, DOI 10.20506/rst.36.2.2669; Field HE, 2016, CURR OPIN VIROL, V16, P120, DOI 10.1016/j.coviro.2016.02.004; Flies EJ, 2015, VECTOR-BORNE ZOONOT, V15, P397, DOI 10.1089/vbz.2014.1759; Forrester NL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005693; Garnett LE, 2019, CURR OPIN VIROL, V37, P123, DOI 10.1016/j.coviro.2019.07.009; Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2; Glasgow Anum, 2020, bioRxiv, DOI 10.1101/2020.07.31.231746; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Gorbea C, 2017, NATURE, V550, P275, DOI 10.1038/nature24034; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0; Hampson L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147917; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Hashem H, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.598038; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Himeidan YE, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00169; Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273]; Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685; Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310; Hung IFN, 2017, CHEST, V151, P1069, DOI 10.1016/j.chest.2016.11.012; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07; Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2; Jan E, 2016, ANNU REV VIROL, V3, P283, DOI 10.1146/annurev-virology-100114-055014; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09; Kalenga OI, 2019, NEW ENGL J MED, V381, P373, DOI 10.1056/NEJMsr1904253; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Kauffman EB, 2017, J INFECT DIS, V216, pS976, DOI 10.1093/infdis/jix405; Kim JI, 2012, J MICROBIOL, V50, P359, DOI 10.1007/s12275-012-2163-9; Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3; Klemm T, 2020, EMBO J, V39, DOI 10.15252/embj.2020106275; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113; Lindsey NP, 2018, AM J TROP MED HYG, V98, P1472, DOI 10.4269/ajtmh.17-0927; Linsky TW, 2020, SCIENCE, V370, P1208, DOI 10.1126/science.abe0075; Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Luo CM, 2018, J VIROL, V92, DOI 10.1128/JVI.00116-18; Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113; Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985; Meng B, 2006, MOL BIOTECHNOL, V33, P141, DOI 10.1385/MB:33:2:141; Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486; Middleton D, 2014, EMERG INFECT DIS, V20, P372, DOI 10.3201/eid2003.131159; Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17; Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021; Neumann G, 2010, CELL RES, V20, P51, DOI 10.1038/cr.2009.124; Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157; Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955; Osterholm MT, 2015, MBIO, V6, DOI 10.1128/mBio.00137-15; Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Phelps KL, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030240; Pillai VS, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040465; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prakash TP, 2014, NUCLEIC ACIDS RES, V42, P8796, DOI 10.1093/nar/gku531; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1; Rossignol JF, 2006, LANCET, V368, P124, DOI 10.1016/S0140-6736(06)68852-1; Sarker D, 2020, CLIN CANCER RES, V26, P3936, DOI 10.1158/1078-0432.CCR-20-0414; Sharif-Yakan A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004457; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653; Sissoko D, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001967; Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697; Sugo T, 2016, J CONTROL RELEASE, V237, P1, DOI 10.1016/j.jconrel.2016.06.036; Sun D, 2020, ACTA PHARMACOL SIN, V41, P119, DOI 10.1038/s41401-019-0288-7; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020; Szabat M, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110925; Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458; Tang HQ, 2021, BIOTECHNOL BIOENG, V118, P1405, DOI 10.1002/bit.27636; The Complex Trait Consortium, 2018, NAT GENET, V36, P1133; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; Wei J, 2021, CELL, V184, P76, DOI 10.1016/j.cell.2020.10.028; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163; Whitten-Bauer C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121555; Widagdo W, 2017, ONE HEALTH-AMSTERDAM, V3, P11, DOI 10.1016/j.onehlt.2016.12.001; Yang JW, 2020, CLIN MICROBIOL INFEC, V26, P1171, DOI 10.1016/j.cmi.2020.06.020; Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015; Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100; Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x; Zhang M, 2021, ADV SCI, V8, DOI 10.1002/advs.202002928; Zhang WF, 2020, J PHYS CHEM LETT, V11, P4430, DOI 10.1021/acs.jpclett.0c00571; Zhou JH, 2018, THERANOSTICS, V8, P1575, DOI 10.7150/thno.23085; Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou G, 2011, ANTIVIR RES, V91, P11, DOI 10.1016/j.antiviral.2011.05.001	128	49	49	8	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					401	410		10.1038/s41591-021-01282-0	http://dx.doi.org/10.1038/s41591-021-01282-0			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723456	Bronze, Green Submitted			2022-12-27	WOS:000629708300018
J	Menzies, AM; Amaria, RN; Rozeman, EA; Huang, AC; Tetzlaff, MT; van de Wiel, BA; Lo, SE; Tarhini, AA; Burton, EM; Pennington, TE; Saw, RPM; Xu, XW; Karakousis, GC; Ascierto, PA; Spillane, AJ; van Akkooi, ACJ; Davies, MA; Mitchell, TC; Tawbi, HA; Scolyer, RA; Wargo, JA; Blank, CU; Long, GV				Menzies, Alexander M.; Amaria, Rodabe N.; Rozeman, Elisa A.; Huang, Alexander C.; Tetzlaff, Michael T.; van de Wiel, Bart A.; Lo, Serigne; Tarhini, Ahmad A.; Burton, Elizabeth M.; Pennington, Thomas E.; Saw, Robyn P. M.; Xu, Xiaowei; Karakousis, Giorgos C.; Ascierto, Paolo A.; Spillane, Andrew J.; van Akkooi, Alexander C. J.; Davies, Michael A.; Mitchell, Tara C.; Tawbi, Hussein A.; Scolyer, Richard A.; Wargo, Jennifer A.; Blank, Christian U.; Long, Georgina V.			Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	NATURE MEDICINE			English	Article								A pooled analysis of neoadjuvant immunotherapy trials in melanoma shows that the degree of pathological response associates with patient survival and might represent a surrogate marker for long-term outcomes. The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK targeted therapy. In total, 192 patients were included; 141 received immunotherapy (104, combination of ipilimumab and nivolumab; 37, anti-PD-1 monotherapy), and 51 received targeted therapy. A pathological complete response (pCR) occurred in 40% of patients: 47% with targeted therapy and 33% with immunotherapy (43% combination and 20% monotherapy). pCR correlated with improved RFS (pCR 2-year 89% versus no pCR 50%, P < 0.001) and OS (pCR 2-year OS 95% versus no pCR 83%, P = 0.027). In patients with pCR, near pCR or partial pathological response with immunotherapy, very few relapses were seen (2-year RFS 96%), and, at this writing, no patient has died from melanoma, whereas, even with pCR from targeted therapy, the 2-year RFS was only 79%, and OS was only 91%. Pathological response should be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.	[Menzies, Alexander M.; Lo, Serigne; Pennington, Thomas E.; Saw, Robyn P. M.; Spillane, Andrew J.; Scolyer, Richard A.; Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Menzies, Alexander M.; Lo, Serigne; Pennington, Thomas E.; Saw, Robyn P. M.; Spillane, Andrew J.; Scolyer, Richard A.; Long, Georgina V.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Menzies, Alexander M.; Spillane, Andrew J.; Long, Georgina V.] Royal North Shore & Mater Hosp, Sydney, NSW, Australia; [Amaria, Rodabe N.; Tetzlaff, Michael T.; Burton, Elizabeth M.; Davies, Michael A.; Tawbi, Hussein A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Rozeman, Elisa A.; van de Wiel, Bart A.; van Akkooi, Alexander C. J.; Blank, Christian U.] Netherlands Canc Inst, Amsterdam, Netherlands; [Huang, Alexander C.; Xu, Xiaowei; Karakousis, Giorgos C.; Mitchell, Tara C.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Huang, Alexander C.] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Tarhini, Ahmad A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Pennington, Thomas E.] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Ascierto, Paolo A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy; [Scolyer, Richard A.] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Scolyer, Richard A.] New Hlth Pathol, Sydney, NSW, Australia	Melanoma Institute Australia; University of Sydney; University of Sydney; Royal North Shore Hospital; University of Texas System; UTMD Anderson Cancer Center; Netherlands Cancer Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; H Lee Moffitt Cancer Center & Research Institute; University of Sydney; IRCCS Fondazione Pascale; University of Sydney	Long, GV (corresponding author), Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia.; Long, GV (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.; Long, GV (corresponding author), Royal North Shore & Mater Hosp, Sydney, NSW, Australia.	georgina.long@sydney.edu.au	Burton, Elizabeth/AAB-9393-2021; Scolyer, Richard/AAE-8511-2019; Davies, Michael/GWV-2527-2022; Lo, Serigne N/L-6220-2018; Long, Georgina/C-1771-2013	Burton, Elizabeth/0000-0002-3424-4922; Scolyer, Richard/0000-0002-8991-0013; Lo, Serigne N/0000-0001-5092-5544; Long, Georgina/0000-0001-8894-3545	Cancer Institute NSW Fellowship; Melanoma Institute Australia; NIH/NCI [1 P50 CA221703-02]; NHMRC Practitioner Fellowships; University of Sydney Medical Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	Cancer Institute NSW Fellowship; Melanoma Institute Australia; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHMRC Practitioner Fellowships(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney Medical Foundation(University of Sydney); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	A.M.M. is supported by a Cancer Institute NSW Fellowship and Melanoma Institute Australia. R.P.M.S. is supported by Melanoma Institute Australia. M.A.D. is supported by NIH/NCI grant (1 P50 CA221703-02), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson Cancer Center. G.V.L. and R.A.S. are supported by NHMRC Practitioner Fellowships. G.V.L. is supported by the University of Sydney Medical Foundation and Melanoma Institute Australia. Support from the Melanoma Research Alliance/Rising Tide Foundation for a Clinical Cancer Research Grant for "Predictor of response to neoadjuvant therapy in melanoma" for salary support for A.M.M., N.R.A., M.T.T., M.A.D., R.A.S., G.V.L. is gratefully acknowledged. Support from colleagues at Melanoma Institute Australia, Mater Hospital, Royal North Shore Hospital, Royal Prince Alfred Hospital and NSW Health Pathology is gratefully acknowledged.	Amaria RN, 2019, LANCET ONCOL, V20, pE378, DOI 10.1016/S1470-2045(19)30332-8; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Amiri-Kordestani L, 2014, CLIN CANCER RES, V20, P5359, DOI 10.1158/1078-0432.CCR-14-1268; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Berger AC, 2005, J CLIN ONCOL, V23, P4330, DOI 10.1200/JCO.2005.05.017; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Bloemendal M, 2019, ANN SURG ONCOL, V26, P3945, DOI 10.1245/s10434-019-07274-2; Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6; Eggermont AMM, 2019, EUR J CANCER, V116, P148, DOI 10.1016/j.ejca.2019.05.020; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lee JH, 2019, ANN ONCOL, V30, P815, DOI 10.1093/annonc/mdz075; Lee JH, 2017, ANN ONCOL, V28, P1130, DOI 10.1093/annonc/mdx026; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2019, LANCET ONCOL, V20, P961, DOI 10.1016/S1470-2045(19)30331-6; Moschos SJ, 2006, J CLIN ONCOL, V24, P3164, DOI 10.1200/JCO.2005.05.2498; Park IJ, 2012, J CLIN ONCOL, V30, P1770, DOI 10.1200/JCO.2011.39.7901; Postow MA, 2020, J CLIN ONCOL, V38; Reijers I, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS9605; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Symmans WF, 2017, J CLIN ONCOL, V35, P1049, DOI 10.1200/JCO.2015.63.1010; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Vilain RE, 2017, CLIN CANCER RES, V23, P5024, DOI 10.1158/1078-0432.CCR-16-0698; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030	30	100	101	4	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					301	+		10.1038/s41591-020-01188-3	http://dx.doi.org/10.1038/s41591-020-01188-3		FEB 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33558722				2022-12-27	WOS:000616056700001
J	Stubbs, RJ				Stubbs, R. James			Impact of carbohydrates, fat and energy density on energy intake	NATURE MEDICINE			English	Editorial Material							WEIGHT-LOSS; FEEDBACK-CONTROL; FOODS	People on low-fat, low-energy-density diets have lower ad libitum energy intake than that of those on high-fat, high-energy-density diets.	[Stubbs, R. James] Univ Leeds, Sch Psychol, Fac Med & Hlth, Leeds, W Yorkshire, England	University of Leeds	Stubbs, RJ (corresponding author), Univ Leeds, Sch Psychol, Fac Med & Hlth, Leeds, W Yorkshire, England.	R.J.Stubbs@leeds.ac.uk	Stubbs, R James/AAH-4739-2021	Stubbs, R James/0000-0002-0843-9064				Buckland NJ, 2015, PHYSIOL BEHAV, V152, P340, DOI 10.1016/j.physbeh.2015.07.001; Hall KD, 2021, NAT MED, V27, P344, DOI 10.1038/s41591-020-01209-1; Hall KD, 2017, OBESITY, V25, P2088, DOI 10.1002/oby.21978; MacLean PS, 2015, OBESITY, V23, P7, DOI 10.1002/oby.20967; O'Driscoll R, 2020, J SPORT SCI, V38, P1496, DOI 10.1080/02640414.2020.1746088; Polidori D, 2016, OBESITY, V24, P2289, DOI 10.1002/oby.21653; Ritz C, 2020, P NUTR SOC, V79, pE151, DOI 10.1017/S0029665120000993; Stubbs J, 2000, CRIT REV FOOD SCI, V40, P481, DOI 10.1080/10408690091189248; Stubbs R.J., OBES FACTS; Stubbs RJ, 2019, P NUTR SOC, V78, P576, DOI 10.1017/S0029665119001083; Stubbs RJ, 2018, EUR J CLIN NUTR, V72, P698, DOI 10.1038/s41430-018-0146-6; Stubbs RJ, 2006, BRIT J NUTR, V95, P657, DOI 10.1079/BJN20041361	12	2	2	2	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					200	201		10.1038/s41591-021-01241-9	http://dx.doi.org/10.1038/s41591-021-01241-9		FEB 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33526931				2022-12-27	WOS:000613582400003
J	Brodin, P				Brodin, Petter			Immune determinants of COVID-19 disease presentation and severity	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTORS; RESPONSES; ACE2; CORONAVIRUS; POST; ACTIVATION; EXPRESSION; INFECTION; SYMPTOMS; PROTEIN	COVID-19, caused by SARS-CoV-2 infection, is mild to moderate in the majority of previously healthy individuals, but can cause life-threatening disease or persistent debilitating symptoms in some cases. The most important determinant of disease severity is age, with individuals over 65 years having the greatest risk of requiring intensive care, and men are more susceptible than women. In contrast to other respiratory viral infections, young children seem to be less severely affected. It is now clear that mild to severe acute infection is not the only outcome of COVID-19, and long-lasting symptoms are also possible. In contrast to severe acute COVID-19, such 'long COVID' is seemingly more likely in women than in men. Also, postinfectious hyperinflammatory disease has been described as an additional outcome after SARS-CoV-2 infection. Here I discuss our current understanding of the immunological determinants of COVID-19 disease presentation and severity and relate this to known immune-system differences between young and old people and between men and women, and other factors associated with different disease presentations and severity. The severity of COVID-19 varies by sex and age, and is linked to comorbidities. Differences in immune reactions may go some way to explain this.	[Brodin, Petter] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden; [Brodin, Petter] Karolinska Univ Hosp, Pediat Rheumatol, Solna, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Brodin, P (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden.; Brodin, P (corresponding author), Karolinska Univ Hosp, Pediat Rheumatol, Solna, Sweden.	petter.brodin@ki.se	Brodin, Petter/C-3317-2011	Brodin, Petter/0000-0002-8103-0046				Anderson Elizabeth M, 2020, medRxiv, DOI 10.1101/2020.11.06.20227215; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Belot A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.22.2001010; Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Brodin P, 2020, ACTA PAEDIATR, V109, P1082, DOI 10.1111/apa.15271; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Casanova JL, 2020, CELL, V181, P1194, DOI 10.1016/j.cell.2020.05.016; Clark DV, 2015, LANCET INFECT DIS, V15, P905, DOI 10.1016/S1473-3099(15)70152-0; Consiglio CR, 2020, CELL, V183, P968, DOI 10.1016/j.cell.2020.09.016; Consiglio CR, 2020, CELL, V180, P820, DOI 10.1016/j.cell.2020.02.021; Corwin DJ, 2020, PEDIATR EMERG CARE, V36, P554, DOI 10.1097/PEC.0000000000002248; Davido B, 2020, CLIN MICROBIOL INFEC, V26, P1448, DOI 10.1016/j.cmi.2020.07.028; Dennis A, 2020, BMJ, DOI [10.1101/2020.10.14.20212555, DOI 10.1101/2020.10.14.20212555, 10.1101/ 2020.10.14.20212555]; Diorio C, 2020, J CLIN INVEST, V130, P5967, DOI 10.1172/JCI140970; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Fung M., 2020, CLIN INFECT DIS, DOI [DOI 10.1093/CID/CIAA863, 10.1093/cid/ciaa863]; Gao Y, 2020, J INFECTION, V81, P93; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gruber Conor N, 2020, Cell, V183, P982, DOI [10.1101/2020.07.04.20142752, 10.1016/j.cell.2020.09.034]; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Guillot X, 2020, J INFECT DIS, V222, P1740, DOI 10.1093/infdis/jiaa261; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Han Y, 2020, AGING-US, V12, P11245, DOI 10.18632/aging.103372; Hickie I, 2006, BRIT MED J, V333, P575, DOI 10.1136/bmj.38933.585764.AE; Hikmet F, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209610; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Iwasaki A, 2021, LANCET INFECT DIS, V21, P3, DOI 10.1016/S1473-3099(20)30783-0; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Li J, 2015, J CLIN LAB ANAL, V29, P437, DOI 10.1002/jcla.21791; Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Marrani E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02974; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Miorin L, 2020, P NATL ACAD SCI USA, V117, P28344, DOI 10.1073/pnas.2016650117; Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P17513, DOI 10.1073/pnas.2008373117; Molony RD, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan2392; Morris SB, 2020, MMWR-MORBID MORTAL W, V69, P1450, DOI 10.15585/mmwr.mm6940e1; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010; Pido-Lopez J, 2001, CLIN EXP IMMUNOL, V125, P409, DOI 10.1046/j.1365-2249.2001.01640.x; Pierce CA, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd5487; Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0; Rodrigues TS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201707; Rodriguez L. S. T, 2020, ACHIEVING SYMPTOM RE, DOI [10.1101/2020.02.20.958249, DOI 10.1101/2020.02.20.958249]; Rodriguez L, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100078; Rostad CA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-018242; Saso A, 2017, SEMIN IMMUNOPATHOL, V39, P627, DOI 10.1007/s00281-017-0654-9; Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012; Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005; Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021; Takahashi Takehiro, 2020, medRxiv, DOI 10.1101/2020.06.06.20123414; Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Tso FY, 2021, INT J INFECT DIS, V102, P577, DOI 10.1016/j.ijid.2020.10.104; Uhlen M, 2019, SCIENCE, V366, P1471, DOI 10.1126/science.aax9198; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Wan Y, 2019, J VIROL, V94, pe02015; Webb K, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03167; Weisberg SP, 2021, NAT IMMUNOL, V22, P25, DOI 10.1038/s41590-020-00826-9; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; Wu CQ, 2019, IMMUNITY, V50, P1401, DOI 10.1016/j.immuni.2019.04.003; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-X, 10.1038/s41368-020-0074-x]; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4; Yilmaz H, 2015, DIABETES METAB SYND, V9, P299, DOI 10.1016/j.dsx.2014.04.009; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979	90	243	249	7	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					28	33		10.1038/s41591-020-01202-8	http://dx.doi.org/10.1038/s41591-020-01202-8			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442016	Bronze			2022-12-27	WOS:000607931400019
J	Derosa, L; Zitvogel, L				Derosa, Lisa; Zitvogel, Laurence			A probiotic supplement boosts response to cancer immunotherapy	NATURE MEDICINE			English	Editorial Material							MICROBIOME	Patients with kidney cancer who took probiotic supplements of Clostridium butyricum had improved response to immunotherapy, according to a randomized phase 1 study.	[Derosa, Lisa; Zitvogel, Laurence] Gustave Roussy, ClinicObiome, Villejuif, France; [Derosa, Lisa; Zitvogel, Laurence] INSERM U1015, Equipe Labellisee Ligue Natl Canc, Villejuif, France; [Derosa, Lisa; Zitvogel, Laurence] Gustave Roussy Canc Campus, Dept Med Oncol, Villejuif, France; [Derosa, Lisa; Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France; [Zitvogel, Laurence] Univ Paris Saclay, Le Kremlin Bicetre, France	UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Derosa, L (corresponding author), Gustave Roussy, ClinicObiome, Villejuif, France.; Derosa, L (corresponding author), INSERM U1015, Equipe Labellisee Ligue Natl Canc, Villejuif, France.; Derosa, L (corresponding author), Gustave Roussy Canc Campus, Dept Med Oncol, Villejuif, France.; Derosa, L (corresponding author), Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France.	deros.lisa@gmail.com	DEROSA, LISA/E-6814-2015	ZITVOGEL, laurence/0000-0003-1596-0998; Derosa, Lisa/0000-0003-0527-2964				Derosa L, 2021, CANCER DISCOV, V11, P2396, DOI 10.1158/2159-8290.CD-21-0236; Derosa L, 2020, EUR UROL, V78, P195, DOI 10.1016/j.eururo.2020.04.044; Dizman N, 2022, NAT MED, V28, P704, DOI 10.1038/s41591-022-01694-6; Isa K, 2016, HUM EXP TOXICOL, V35, P818, DOI 10.1177/0960327115607372; Mountzouris KC, 2002, BRIT J NUTR, V87, P405, DOI 10.1079/BJN2002563; Salgia NJ, 2020, EUR UROL, V78, P498, DOI 10.1016/j.eururo.2020.07.011; Seki H, 2003, PEDIATR INT, V45, P86, DOI 10.1046/j.1442-200X.2003.01671.x; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Spencer CN, 2021, SCIENCE, V374, P1632, DOI 10.1126/science.aaz7015; Stoeva MK, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1907272; Thana M, 2022, CLIN GENITOURIN CANC, V20, P210, DOI 10.1016/j.clgc.2021.12.003; Tomita Y, 2020, CANCER IMMUNOL RES, V8, P1236, DOI 10.1158/2326-6066.CIR-20-0051	12	1	1	13	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					633	634		10.1038/s41591-022-01723-4	http://dx.doi.org/10.1038/s41591-022-01723-4		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35288698				2022-12-27	WOS:000770060900003
J	Kumar, A; Im, K; Banjevic, M; Ng, PC; Tunstall, T; Garcia, G; Galhardo, L; Sun, JY; Schaedel, ON; Levy, B; Hongo, D; Kijacic, D; Kiehl, M; Tran, ND; Klatsky, PC; Rabinowitz, M				Kumar, Akash; Im, Kate; Banjevic, Milena; Ng, Pauline C.; Tunstall, Tate; Garcia, Geronimo; Galhardo, Luisa; Sun, Jiayi; Schaedel, Oren N.; Levy, Brynn; Hongo, Donna; Kijacic, Dusan; Kiehl, Michelle; Tran, Nam D.; Klatsky, Peter C.; Rabinowitz, Matthew			Whole-genome risk prediction of common diseases in human preimplantation embryos	NATURE MEDICINE			English	Article								Preimplantation genetic testing (PGT) of in-vitro-fertilized embryos has been proposed as a method to reduce transmission of common disease; however, more comprehensive embryo genetic assessment, combining the effects of common variants and rare variants, remains unavailable. Here, we used a combination of molecular and statistical techniques to reliably infer inherited genome sequence in 110 embryos and model susceptibility across 12 common conditions. We observed a genotype accuracy of 99.0-99.4% at sites relevant to polygenic risk scoring in cases from day-5 embryo biopsies and 97.2-99.1% in cases from day-3 embryo biopsies. Combining rare variants with polygenic risk score (PRS) magnifies predicted differences across sibling embryos. For example, in a couple with a pathogenic BRCA1 variant, we predicted a 15-fold difference in odds ratio (OR) across siblings when combining versus a 4.5-fold or 3-fold difference with BRCA1 or PRS alone. Our findings may inform the discussion of utility and implementation of genome-based PGT in clinical practice.	[Kumar, Akash; Im, Kate; Ng, Pauline C.; Tunstall, Tate; Garcia, Geronimo; Galhardo, Luisa; Sun, Jiayi; Schaedel, Oren N.; Hongo, Donna; Rabinowitz, Matthew] MyOme Inc, Menlo Pk, CA 94025 USA; [Banjevic, Milena; Kijacic, Dusan; Kiehl, Michelle; Rabinowitz, Matthew] Natera Inc, San Carlos, CA USA; [Levy, Brynn] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY USA; [Tran, Nam D.; Klatsky, Peter C.] Spring Fertil, San Francisco, CA USA	Columbia University; NewYork-Presbyterian Hospital	Kumar, A (corresponding author), MyOme Inc, Menlo Pk, CA 94025 USA.	akumar@myome.com		Kumar, Akash/0000-0001-9442-3597	UKB [48991]; Wellcome Trust [WT091310]; MyOme	UKB; Wellcome Trust(Wellcome TrustEuropean Commission); MyOme	We are grateful for the contributions of the families who participated in this research and physicians who referred patients to the study, as well as employees and advisors at MyOme. This research was conducted using the UKB resource (project 48991). This study makes use of data generated by the UK10K Consortium, derived from samples from EGAS00001000713. A full list of the investigators who contributed to the generation of the data is available from www.UK10K.org.Funding for UK10K was provided by the Wellcome Trust under award WT091310. The study was funded by MyOme. Editorial support was provided by Lauren Dembeck, PhD as well as Nature Research Editing Service, funded by MyOme.	Abdel-Razeq H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4079-1; Caballero M, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007979; Delaneau O, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13225-y; Fahed AC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17374-3; Gleicher N, 2021, TRENDS MOL MED, V27, P731, DOI 10.1016/j.molmed.2020.11.009; Handyside AH, 2010, FERTIL STERIL, V94, pS79, DOI 10.1016/j.fertnstert.2010.07.309; Johnson DS, 2010, MOL HUM REPROD, V16, P944, DOI 10.1093/molehr/gaq062; Karavani E, 2019, CELL, V179, P1424, DOI 10.1016/j.cell.2019.10.033; Khera AV, 2019, CIRCULATION, V139, P1593, DOI 10.1161/CIRCULATIONAHA.118.035658; Kumar A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0160-4; Lazaro-Munoz G, 2021, GENET MED, V23, P432, DOI 10.1038/s41436-020-01019-3; Lencz Todd, 2021, Elife, V10, DOI 10.7554/eLife.64716; Murphy NM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60704-0; Peters BA, 2015, GENOME RES, V25, P426, DOI 10.1101/gr.181255.114; Selzam S, 2019, AM J HUM GENET, V105, P351, DOI 10.1016/j.ajhg.2019.06.006; Tiegs AW, 2021, FERTIL STERIL, V115, P627, DOI 10.1016/j.fertnstert.2020.07.052; Torkamani A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/s41576-018-0018-x; Treff NR, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060648; Treff NR, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00845; Turley P, 2021, NEW ENGL J MED, V385, P78, DOI 10.1056/NEJMsr2105065; Zhang S, 2021, SOC SCI MED, V274, DOI 10.1016/j.socscimed.2021.113796; Zong CH, 2012, SCIENCE, V338, P1622, DOI 10.1126/science.1229164	22	8	8	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					513	+		10.1038/s41591-022-01735-0	http://dx.doi.org/10.1038/s41591-022-01735-0			17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35314819	Green Published, hybrid			2022-12-27	WOS:000771673100027
J	Magrin, E; Semeraro, M; Hebert, N; Joseph, L; Magnani, A; Chalumeau, A; Gabrion, A; Roudaut, C; Marouene, J; Lefrere, F; Diana, JS; Denis, A; Neven, B; Funck-Brentano, I; Negre, O; Renolleau, S; Brousse, V; Kiger, L; Touzot, F; Poirot, C; Bourget, P; El Nemer, W; Blanche, S; Treluyer, JM; Asmal, M; Walls, C; Beuzard, Y; Schmidt, M; Hacein-Bey-Abina, S; Asnafi, V; Guichard, I; Poiree, M; Monpoux, F; Touraine, P; Brouzes, C; de Montalembert, M; Payen, E; Six, E; Ribeil, JA; Miccio, A; Bartolucci, P; Leboulch, P; Cavazzana, M				Magrin, Elisa; Semeraro, Michaela; Hebert, Nicolas; Joseph, Laure; Magnani, Alessandra; Chalumeau, Anne; Gabrion, Aurelie; Roudaut, Cecile; Marouene, Jouda; Lefrere, Francois; Diana, Jean-Sebastien; Denis, Adeline; Neven, Benedicte; Funck-Brentano, Isabelle; Negre, Olivier; Renolleau, Sylvain; Brousse, Valentine; Kiger, Laurent; Touzot, Fabien; Poirot, Catherine; Bourget, Philippe; El Nemer, Wassim; Blanche, Stephane; Treluyer, Jean-Marc; Asmal, Mohammed; Walls, Courtney; Beuzard, Yves; Schmidt, Manfred; Hacein-Bey-Abina, Salima; Asnafi, Vahid; Guichard, Isabelle; Poiree, Maryline; Monpoux, Fabrice; Touraine, Philippe; Brouzes, Chantal; de Montalembert, Mariane; Payen, Emmanuel; Six, Emmanuelle; Ribeil, Jean-Antoine; Miccio, Annarita; Bartolucci, Pablo; Leboulch, Philippe; Cavazzana, Marina			Long-term outcomes of lentiviral gene therapy for the beta-hemoglobinopathies: the HGB-205 trial	NATURE MEDICINE			English	Article							SICKLE-CELL-DISEASE; PHASE-3 TRIAL; INTEGRATION; VECTOR; TRANSPLANTATION; THALASSEMIA; RISK	Sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 (NCT02151526) aimed at evaluating gene therapy by autologous CD34(+) cells transduced ex vivo with lentiviral vector BB305 that encodes the anti-sickling beta(A-T87Q)-globin expressed in the erythroid lineage. HGB-205 is a phase 1/2, open-label, single-arm, non-randomized interventional study of 2-year duration at a single center, followed by observation in long-term follow-up studies LTF-303 (NCT02633943) and LTF-307 (NCT04628585) for TDT and SCD, respectively. Inclusion and exclusion criteria were similar to those for allogeneic transplantation but restricted to patients lacking geno-identical, histocompatible donors. Four patients with TDT and three patients with SCD, ages 13-21 years, were treated after busulfan myeloablation 4.6-7.9 years ago, with a median follow-up of 4.5 years. Key primary endpoints included mortality, engraftment, replication-competent lentivirus and clonal dominance. No adverse events related to the drug product were observed. Clinical remission and remediation of biological hallmarks of the disease have been sustained in two of the three patients with SCD, and frequency of transfusions was reduced in the third. The patients with TDT are all transfusion free with improvement of dyserythropoiesis and iron overload.	[Magrin, Elisa; Joseph, Laure; Magnani, Alessandra; Gabrion, Aurelie; Roudaut, Cecile; Lefrere, Francois; Diana, Jean-Sebastien; Touzot, Fabien; Hacein-Bey-Abina, Salima; Ribeil, Jean-Antoine] Hop Univ Necker Enfants Malad, GH Paris Ctr, Biotherapy Dept, Paris, France; [Magrin, Elisa; Magnani, Alessandra; Gabrion, Aurelie; Roudaut, Cecile; Touzot, Fabien; Hacein-Bey-Abina, Salima; Ribeil, Jean-Antoine] Hop Univ Necker Enfants Malad, GH Paris Ctr, Ctr Invest Clin Biotherapie, Paris, France; [Semeraro, Michaela; Marouene, Jouda; Treluyer, Jean-Marc] Hop Univ Necker Enfants Malad, GH Paris Ctr, Ctr Invest Clin, Unite Rech Clin, Paris, France; [Semeraro, Michaela; Treluyer, Jean-Marc; Cavazzana, Marina] Univ Paris, Paris, France; [Hebert, Nicolas; Kiger, Laurent; Beuzard, Yves; Bartolucci, Pablo] Univ Paris Est Creteil, INSERM, EFS, IMRB, Creteil, France; [Hebert, Nicolas; Bartolucci, Pablo] Univ Paris Est Creteil, Hop Henri Mondor, AP HP, Creteil, France; [Chalumeau, Anne; Denis, Adeline; Six, Emmanuelle; Miccio, Annarita; Cavazzana, Marina] Univ Paris, Sorbonne Paris Cite, IMAGINE Inst, Paris, France; [Neven, Benedicte; Funck-Brentano, Isabelle; Blanche, Stephane] Hop Necker Enfants Malad, Pediat Immunol & Hematol Dept, Paris, France; [Negre, Olivier; Beuzard, Yves; Payen, Emmanuel; Leboulch, Philippe] Univ Paris Saclay, INSERM, CEA, Div Innovat Therapies,Inst Francois Jacob, Fontenay Aux Roses, France; [Negre, Olivier; Asmal, Mohammed; Walls, Courtney; Ribeil, Jean-Antoine] Bluebird Bio Inc, Cambridge, MA USA; [Renolleau, Sylvain] Hop Univ Necker Enfants Malad, GH Paris Ctr, Pediat Intens Care Unit, Paris, France; [Brousse, Valentine; de Montalembert, Mariane] Hop Univ Necker Enfants Malad, GH Paris Ctr, Dept Gen Pediat & Pediat Infect Dis, Paris, France; [Poirot, Catherine] Hop St Louis, Fertil Preservat, Dept Hematol, Paris, France; [Poirot, Catherine] Sorbonne Univ, Paris, France; [Bourget, Philippe] Hop Univ Necker Enfants Malad, GH Paris Ctr, Pharm Dept, Paris, France; [El Nemer, Wassim] Inst Natl Transfus Sanguine INTS, Paris, France; [Schmidt, Manfred] GeneWerk GmbH, Heidelberg, Germany; [Asnafi, Vahid] Univ Paris, Hop Necker Enfants Malad, AP HP, Inst Necker Enfants Malad,INSERM U1151, Paris, France; [Guichard, Isabelle] CHU St Etienne, Hop Nord, Serv Med Interne, Paris, France; [Poiree, Maryline] Ctr Hosp Univ Lenval, Dept Pediat Hematol Oncol, Nice, France; [Monpoux, Fabrice] Hop Archet 2, Unite Hematooncol Infantile, Nice, France; [Touraine, Philippe] La Pitie Salpetriere, AP HP, Dept Endocrinol & Reprod Med, Paris, France; [Touraine, Philippe] Sorbonne Univ, Pierre & Marie Curie Sch Med, Paris, France; [Brouzes, Chantal] Hop Necker Enfants Malad, Lab Oncohematol, Paris, France; [Leboulch, Philippe] Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA; [Leboulch, Philippe] Harvard Med Sch, Boston, MA 02115 USA; [Cavazzana, Marina] AP HP, INSERM, Biotherapy Dept, Paris, France; [Cavazzana, Marina] AP HP, INSERM, Clin Invest Ctr, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de St Etienne; CHU Nice; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cavazzana, M (corresponding author), Univ Paris, Paris, France.; Cavazzana, M (corresponding author), Univ Paris, Sorbonne Paris Cite, IMAGINE Inst, Paris, France.; Leboulch, P (corresponding author), Univ Paris Saclay, INSERM, CEA, Div Innovat Therapies,Inst Francois Jacob, Fontenay Aux Roses, France.; Leboulch, P (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.; Leboulch, P (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Cavazzana, M (corresponding author), AP HP, INSERM, Biotherapy Dept, Paris, France.; Cavazzana, M (corresponding author), AP HP, INSERM, Clin Invest Ctr, Paris, France.	pleboulch@rics.bwh.harvard.edu; m.cavazzana@aphp.fr	Miccio, Annarita/H-9585-2017; POIREE, Marilyne/O-5759-2016; GABRION, AURELIE/K-1812-2017	Miccio, Annarita/0000-0002-3409-9665; Hebert, Nicolas/0000-0003-0232-831X; GABRION, AURELIE/0000-0002-1885-2071	Bluebird Bio; France's Agence Nationale de la Recherche under 'Investissements d'avenir' program [ANR-10-IAHU-01]; Paris Ile de France Region under the 'DIM Therapie genique' initiative; Assistance Publique-Hopitaux de Paris; INSERM; Etablissement Francais du Sang; Imagine Institute; Commissariat a l'Energie Atomique et aux Energies Alternatives; Dior chair for tailored medicine; ANR's Chair of Excellence; Agence National de la Recherche	Bluebird Bio; France's Agence Nationale de la Recherche under 'Investissements d'avenir' program(French National Research Agency (ANR)); Paris Ile de France Region under the 'DIM Therapie genique' initiative; Assistance Publique-Hopitaux de Paris; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Etablissement Francais du Sang; Imagine Institute; Commissariat a l'Energie Atomique et aux Energies Alternatives; Dior chair for tailored medicine; ANR's Chair of Excellence(French National Research Agency (ANR)); Agence National de la Recherche(French National Research Agency (ANR))	We thank all the patients who participated in this study and staff members at the clinical and laboratory sites and at Bluebird Bio, including D. Davidson, P. Gregory, G. Veres and M. Finer. We also thank R. Pawliuk, K. A. Westerman, K. J. Takekoshi, C. J. Eaves, R. K. Humphries, S. P. Goff, R. Dorazio, E. Gluckman, F. Bernaudin, F. Galacteros, V. Jolaine and R. L. Maas for their contributions to this project through the years. This work was supported by Bluebird Bio; by grants from France's Agence Nationale de la Recherche under 'Investissements d'avenir' program (ANR-10-IAHU-01, M.C. and A. Miccio) and the Paris Ile de France Region under the 'DIM Therapie genique' initiative (M.C., P. Bartolucci and A. Miccio); by Assistance Publique-Hopitaux de Paris, INSERM, Etablissement Francais du Sang (P. Bartolucci and W.E.N.) and the Imagine Institute (M.C. and A. Miccio); by Commissariat a l'Energie Atomique et aux Energies Alternatives (P.L. and E.P.); by the Dior chair for tailored medicine to M.C.; and by ANR's Chair of Excellence and Industrial Chair of Excellence and Industrial Chair grants to P.L. from the Agence National de la Recherche. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript, except Bluebird Bio, the study sponsor. This article is dedicated to the memory of Irving London, Dorothy Tuan Lo, Ronald Nagel, Arthur Bank and Bill Solomon.	Ataga KI, 2017, NEW ENGL J MED, V376, P429, DOI 10.1056/NEJMoa1611770; Bolanos-Meade J, 2012, BLOOD, V120, P4285, DOI 10.1182/blood-2012-07-438408; Brunson A, 2017, BLOOD, V130, P1597, DOI 10.1182/blood-2017-05-783233; Brusson, 2021, NOVEL LENTIVIRAL VEC; Cao A, 2010, GENET MED, V12, P61, DOI [10.1097/GIM.0b013e3181cd68ed, 10.1038/gim.2016.173]; Cappellini MD, 2020, NEW ENGL J MED, V382, P1219, DOI 10.1056/NEJMoa1910182; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; CHAO A, 1984, SCAND J STAT, V11, P265; EATON WA, 1976, BLOOD, V47, P621; Hebert N, 2020, AM J HEMATOL, V95, P1235, DOI 10.1002/ajh.25937; Henry ER, 2020, P NATL ACAD SCI USA, V117, P15018, DOI 10.1073/pnas.1922004117; Ilboudo Y, 2018, AM J HEMATOL, V93, pE362, DOI 10.1002/ajh.25245; Imren S, 2004, J CLIN INVEST, V114, P953, DOI 10.1172/JCI200421838; Imren S, 2002, P NATL ACAD SCI USA, V99, P14380, DOI 10.1073/pnas.212507099; Jones RJ, 2021, BLOOD, V138, P942, DOI 10.1182/blood.2021011488; Magrin E, 2019, BLOOD, V134, P1203, DOI 10.1182/blood.2019000949; NAGEL RL, 1985, NEW ENGL J MED, V312, P880, DOI 10.1056/NEJM198504043121403; Negre O, 2015, CURR GENE THER, V15, P64; Niihara Y, 2018, NEW ENGL J MED, V379, P226, DOI 10.1056/NEJMoa1715971; Nualkaew T, 2021, MOL THER, V29, P2841, DOI 10.1016/j.ymthe.2021.04.037; Pasricha SR, 2018, NEW ENGL J MED, V379, P1675, DOI 10.1056/NEJMcibr1809628; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Philippidis A, 2021, HUM GENE THER, V32, P332, DOI 10.1089/hum.2021.29159.bfs; Ribeil JA, 2017, NEW ENGL J MED, V376, P848, DOI 10.1056/NEJMoa1609677; Ronen K, 2011, MOL THER, V19, P1273, DOI 10.1038/mt.2011.20; Seminog OO, 2016, J ROY SOC MED, V109, P303, DOI 10.1177/0141076816651037; Shah FT, 2019, BLOOD REV, V37, DOI 10.1016/j.blre.2019.100588; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI DOI 10.1002/J.1538-7305.1948.TB01338.X; Shimoni A, 2013, LEUKEMIA, V27, P829, DOI 10.1038/leu.2012.299; Srinivasulu S, 2006, PROTEIN J, V25, P503, DOI 10.1007/s10930-006-9034-3; TAKEKOSHI KJ, 1995, P NATL ACAD SCI USA, V92, P3014, DOI 10.1073/pnas.92.7.3014; Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342; Thompson AA, 2020, BLOOD, V136, DOI 10.1182/blood-2020-135857; Tisdale JF, 2021, MOL THER, V29, P101; Vichinsky E, 2019, NEW ENGL J MED, V381, P509, DOI 10.1056/NEJMoa1903212	35	13	13	6	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					81	+		10.1038/s41591-021-01650-w	http://dx.doi.org/10.1038/s41591-021-01650-w		JAN 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35075288				2022-12-27	WOS:000746475000002
J	Perez-Then, E; Lucas, C; Monteiro, VS; Miric, M; Brache, V; Cochon, L; Vogels, CBF; Malik, AA; De la Cruz, E; Jorge, A; De los Santos, M; Leon, P; Breban, MI; Billig, K; Yildirim, I; Pearson, C; Downing, R; Gagnon, E; Muyombwe, A; Razeq, J; Campbell, M; Ko, AI; Omer, SB; Grubaugh, ND; Vermund, SH; Iwasaki, A				Perez-Then, Eddy; Lucas, Carolina; Monteiro, Valter Silva; Miric, Marija; Brache, Vivian; Cochon, Leila; Vogels, Chantal B. F.; Malik, Amyn A.; De la Cruz, Elena; Jorge, Aidelis; De los Santos, Margarita; Leon, Patricia; Breban, Mallery, I; Billig, Kendall; Yildirim, Inci; Pearson, Claire; Downing, Randy; Gagnon, Emily; Muyombwe, Anthony; Razeq, Jafar; Campbell, Melissa; Ko, Albert, I; Omer, Saad B.; Grubaugh, Nathan D.; Vermund, Sten H.; Iwasaki, Akiko			Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	NATURE MEDICINE			English	Article								The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines. Here we evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants who had received a two-dose regimen of CoronaVac, an inactivated vaccine used globally. We found that a heterologous CoronaVac prime vaccination of two doses followed by a BNT162b2 booster induces elevated virus-specific antibody levels and potent neutralization activity against the ancestral virus and the Delta variant, resembling the titers obtained after two doses of mRNA vaccines. Although neutralization of Omicron was undetectable in participants who had received a two-dose regimen of CoronaVac, the BNT162b2 booster resulted in a 1.4-fold increase in neutralization activity against Omicron compared with the two-dose mRNA vaccine. Despite this increase, neutralizing antibody titers were reduced by 7.1-fold and 3.6-fold for Omicron compared with the ancestral strain and the Delta variant, respectively. These findings have immediate implications for multiple countries that previously used a CoronaVac regimen and reinforce the idea that the Omicron variant is associated with immune escape from vaccines or infection-induced immunity, highlighting the global need for vaccine boosters to combat the impact of emerging variants. BNT162b2 booster vaccination in individuals who had previously received two doses of CoronaVac elevates neutralizing antibodies against the Omicron variant, but titers remain reduced compared with those against the ancestral SARS-CoV-2 virus and the Delta variant.	[Perez-Then, Eddy; Iwasaki, Akiko] Minist Hlth, Santo Domingo, Dominican Rep; [Lucas, Carolina; Monteiro, Valter Silva] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; [Miric, Marija] Two Oceans Hlth, Santo Domingo, Dominican Rep; [Brache, Vivian; Cochon, Leila; De la Cruz, Elena; Jorge, Aidelis; De los Santos, Margarita] Biomed Res Dept, Profamilia, Santo Domingo, Dominican Rep; [Vogels, Chantal B. F.; Breban, Mallery, I; Billig, Kendall; Yildirim, Inci; Ko, Albert, I; Omer, Saad B.; Grubaugh, Nathan D.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA; [Malik, Amyn A.; Yildirim, Inci; Omer, Saad B.] Yale Univ, Yale Inst Global Hlth, New Haven, CT USA; [Malik, Amyn A.; Ko, Albert, I; Omer, Saad B.] Yale Univ, Sch Med, Dept Med, Sect Infect Dis, New Haven, CT 06510 USA; [Leon, Patricia] Lab Referencia, Santo Domingo, Dominican Rep; [Yildirim, Inci; Campbell, Melissa] Yale Univ, Sch Med, Dept Pediat, Sect Infect Dis & Global Hlth, New Haven, CT 06510 USA; [Pearson, Claire; Downing, Randy; Gagnon, Emily; Muyombwe, Anthony; Razeq, Jafar] Connecticut State Dept Publ Hlth, Rocky Hill, CT USA; [Ko, Albert, I] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil; [Grubaugh, Nathan D.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA; [Vermund, Sten H.] Yale Sch Publ Hlth, New Haven, CT USA; [Iwasaki, Akiko] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; PROFAMILIA; Yale University; Yale University; Yale University; Yale University; Fundacao Oswaldo Cruz; Yale University; Yale University; Howard Hughes Medical Institute	Iwasaki, A (corresponding author), Minist Hlth, Santo Domingo, Dominican Rep.; Lucas, C (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA.; Iwasaki, A (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	carolina.lucas@yale.edu; akiko.iwasaki@yale.edu	Ko, Albert/P-2343-2015; Silva Monteiro, Valter Vinicius/X-2891-2018	Ko, Albert/0000-0001-9023-2339; Lucas, Carolina/0000-0003-4590-2756; Vogels, Chantal/0000-0003-0027-6480; Silva Monteiro, Valter Vinicius/0000-0003-1785-6713	Government of the Dominican Republic; Dominican National Health Cabinet; Ministry of Health; Women's Health Research at Yale Pilot Project Program; Emergent Ventures at the Mercatus Center; Mathers Foundation; Ludwig Family Foundation; Department of Internal Medicine at the Yale School of Medicine; Beatrice Kleinberg Neuwirth Fund; CAPES-YALE fellowship; Yale School of Public Health	Government of the Dominican Republic; Dominican National Health Cabinet; Ministry of Health; Women's Health Research at Yale Pilot Project Program; Emergent Ventures at the Mercatus Center; Mathers Foundation; Ludwig Family Foundation; Department of Internal Medicine at the Yale School of Medicine; Beatrice Kleinberg Neuwirth Fund; CAPES-YALE fellowship; Yale School of Public Health	We thank the study participants who donated specimens for this study. We also thank M. Linehan for technical and logistical assistance and D. Mucida for discussions. This work was funded by the Government of the Dominican Republic and supported by the Dominican National Health Cabinet as well as the Ministry of Health. The Dominican Republic team thanks M. Caram (Profamilia) and M. Kelly (Laboratorio de Referencia) for their contributions to the set up of the study platform. The study was also supported by the Women's Health Research at Yale Pilot Project Program (A.I.), Fast Grant from Emergent Ventures at the Mercatus Center (A.I. and N.D.G.), Mathers Foundation, and the Ludwig Family Foundation, the Department of Internal Medicine at the Yale School of Medicine, Yale School of Public Health and the Beatrice Kleinberg Neuwirth Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. C.L. is a Pew Latin American Fellow. V.S.M. is supported by the CAPES-YALE fellowship.	Andrews, PREPRINT MEDRXIV, DOI [10.1101/2021.12.14.21267615 (2021, DOI 10.1101/2021.12.14.21267615(2021, 10.1101/2021.12.14.21267615(2021]; Basile, PREPRINT BIORXIV, DOI [10.1101/2021.12.12.472252 (2021, DOI 10.1101/2021.12.12.472252(2021]; Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Gruell H, 2022, NAT MED, V28, P477, DOI 10.1038/s41591-021-01676-0; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Kalinich CC, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000869; Lu L, 2022, CLIN INFECT DIS, V75, pE822, DOI 10.1093/cid/ciab1041; Lucas C, 2021, NATURE, V600, P523, DOI 10.1038/s41586-021-04085-y; Mao TY, 2022, J EXP MED, V219, DOI 10.1084/jem.20211818; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Nemet, NEW ENGL J MED, DOI [10.1056/NEJMc2119358 (2021, DOI 10.1056/NEJMC2119358(2021]; Pajon, NEW ENGL J MED, DOI [10.1056/NEJMc2119912 (2022, DOI 10.1056/NEJMC2119912(2022]; Pegu A, 2021, SCIENCE, V373, P1372, DOI 10.1126/science.abj4176; Pulliam JRC., 2021, INCREASED RISK SARS, DOI [10.1101/2021.11.11.21266068, 10.1101/2021.11.11.21266068:2021.11.11.21266068, DOI 10.1101/2021.11.11.21266068:2021.11.11.21266068]; Schmidt, NEW ENGL J MED, DOI [10.1056/NEJMc2119641 (2022, DOI 10.1056/NEJMC2119641(2022]	18	126	127	7	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					481	+		10.1038/s41591-022-01705-6	http://dx.doi.org/10.1038/s41591-022-01705-6		JAN 2022	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35051990	hybrid, Green Published			2022-12-27	WOS:000764509000001
J	Lozano, AX; Chaudhuri, AA; Nene, A; Bacchiocchi, A; Earland, N; Vesely, MD; Usmani, A; Turner, BE; Steen, CB; Luca, BA; Badri, T; Gulati, GS; Vahid, MR; Khameneh, F; Harris, PK; Chen, DY; Dhodapkar, K; Sznol, M; Halaban, R; Newman, AM				Lozano, Alexander X.; Chaudhuri, Aadel A.; Nene, Aishwarya; Bacchiocchi, Antonietta; Earland, Noah; Vesely, Matthew D.; Usmani, Abul; Turner, Brandon E.; Steen, Chloe B.; Luca, Bogdan A.; Badri, Ti; Gulati, Gunsagar S.; Vahid, Milad R.; Khameneh, Farnaz; Harris, Peter K.; Chen, David Y.; Dhodapkar, Kavita; Sznol, Mario; Halaban, Ruth; Newman, Aaron M.			T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma	NATURE MEDICINE			English	Article							IPILIMUMAB; PEMBROLIZUMAB; EXPRESSION; DIVERSITY; SURVIVAL; THERAPY; VISUALIZATION; ANTIBODIES; LANDSCAPE; PROFILES	Severe immune-related adverse events (irAEs) occur in up to 60% of patients with melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether a common baseline immunological state precedes irAE development. Here we applied mass cytometry by time of flight, single-cell RNA sequencing, single-cell V(D)J sequencing, bulk RNA sequencing and bulk T cell receptor (TCR) sequencing to study peripheral blood samples from patients with melanoma treated with anti-PD-1 monotherapy or anti-PD-1 and anti-CTLA-4 combination ICIs. By analyzing 93 pre- and early on-ICI blood samples and 3 patient cohorts (n = 27, 26 and 18), we found that 2 pretreatment factors in circulation-activated CD4 memory T cell abundance and TCR diversity-are associated with severe irAE development regardless of organ system involvement. We also explored on-treatment changes in TCR clonality among patients receiving combination therapy and linked our findings to the severity and timing of irAE onset. These results demonstrate circulating T cell characteristics associated with ICI-induced toxicity, with implications for improved diagnostics and clinical management. Clonally diverse and activated memory CD4(+) T cells at baseline are associated with the development of severe immune-related adverse events, irrespective of the affected organ system, in patients with melanoma treated with immune checkpoint inhibitors.	[Lozano, Alexander X.] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA; [Lozano, Alexander X.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Chaudhuri, Aadel A.; Earland, Noah; Usmani, Abul; Harris, Peter K.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA; [Chaudhuri, Aadel A.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Chaudhuri, Aadel A.] Washington Univ, Dept Comp Sci & Engn, St Louis, MO 63110 USA; [Chaudhuri, Aadel A.; Chen, David Y.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; [Nene, Aishwarya] Yale Univ, Yale Sch Med, New Haven, CT USA; [Bacchiocchi, Antonietta; Vesely, Matthew D.; Halaban, Ruth] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Turner, Brandon E.; Steen, Chloe B.; Gulati, Gunsagar S.; Vahid, Milad R.; Khameneh, Farnaz; Newman, Aaron M.] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Steen, Chloe B.; Newman, Aaron M.] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA; [Luca, Bogdan A.] Stanford Univ, Stanford Ctr Biomed Informat Res, Stanford, CA 94305 USA; [Badri, Ti] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Chen, David Y.] Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA; [Dhodapkar, Kavita] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA; [Sznol, Mario] Yale Univ, Sch Med, Dept Med, Div Med Oncol, New Haven, CT USA; [Sznol, Mario; Halaban, Ruth] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA	Stanford University; University of Toronto; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Yale University; Yale University; Stanford University; Stanford University; Stanford University; Yale University; Washington University (WUSTL); Children's Healthcare of Atlanta (CHOA); Emory University; Yale University; Yale University	Chaudhuri, AA (corresponding author), Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA.; Chaudhuri, AA (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.; Chaudhuri, AA (corresponding author), Washington Univ, Dept Comp Sci & Engn, St Louis, MO 63110 USA.; Chaudhuri, AA (corresponding author), Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA.; Newman, AM (corresponding author), Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.; Newman, AM (corresponding author), Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.	aadel@wustl.edu; amnewman@stanford.edu	Vesely, Matthew/AFM-2324-2022; Luca, Bogdan/ABD-2955-2022; Newman, Aaron M/ABE-1620-2021	Vesely, Matthew/0000-0001-9363-945X; Newman, Aaron M/0000-0002-1857-8172; Steen, Chloe/0000-0001-7290-7128; Turner, Brandon/0000-0002-8653-7524; Lozano, Alexander X/0000-0001-8424-291X; Usmani, Abul/0000-0001-5485-7323; Luca, Bogdan-Alexandru/0000-0003-1977-6311; Sznol, Mario/0000-0002-4359-8749; Nene, Aishwarya/0000-0002-5160-5080	National Cancer Institute [K08CA238711, K08CA237727, R01CA238471, R21CA218950, R00CA187192]; National Heart, Lung, and Blood Institute [T35HL007649]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR077926]; Natural Sciences and Engineering Research Council of Canada; Cancer Research Foundation Young Investigator Award; V Foundation for Cancer Research V Scholar Award; Melanoma Research Alliance [137453, 828544]; Virginia and D.K. Ludwig Fund for Cancer Research; Stinehart-Reed Foundation; Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program (IIP); Donald E. and Delia B. Baxter Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Cancer Research Foundation Young Investigator Award; V Foundation for Cancer Research V Scholar Award; Melanoma Research Alliance; Virginia and D.K. Ludwig Fund for Cancer Research; Stinehart-Reed Foundation; Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program (IIP); Donald E. and Delia B. Baxter Foundation	We thank the patients and families involved in this study. We thank A. Nassar and L. Chen for technical assistance with the CyTOF experiments, including provision of resources, staining and processing of samples. We thank G. Ansstas and C. Kaufman for clinical samples. We also thank T. Ley, S. Devarakonda and M. Tal for providing critical feedback on the manuscript. This work was supported by grants from the National Cancer Institute (no. K08CA238711 to A.A.C., no. K08CA237727 to D.Y.C., no. R01CA238471 to K.D., no. R21CA218950 to R.H. and no. R00CA187192 to A.M.N.), National Heart, Lung, and Blood Institute (no. T35HL007649 to A.N.), National Institute of Arthritis and Musculoskeletal and Skin Diseases (no. R01AR077926 to K.D.), a fellowship from the Natural Sciences and Engineering Research Council of Canada (A.X.L.), the Cancer Research Foundation Young Investigator Award (A.A.C.), V Foundation for Cancer Research V Scholar Award (A.A.C.), Washington University Alvin J. Siteman Cancer Research Fund (A.A.C.), Yale Cancer Center Meyers Award (M.S. and R.H.), a 10x Genomics Pilot Program Award (R.H.), the Melanoma Research Alliance (no. 137453 and no. 828544 to R.H.), the Virginia and D.K. Ludwig Fund for Cancer Research (A.M.N.), Stinehart-Reed Foundation (A.M.N.), Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program (IIP) (A.M.N.) and Donald E. and Delia B. Baxter Foundation (A.M.N.).	Amir ED, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01315; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Auslander N, 2018, NAT MED, V24, P1545, DOI 10.1038/s41591-018-0157-9; Bieber AK, 2020, JAMA-J AM MED ASSOC, V324, P1453, DOI 10.1001/jama.2020.10159; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Borcherding N, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01625-6; Boutros C, 2016, NAT REV CLIN ONCOL, V13, P473, DOI 10.1038/nrclinonc.2016.58; Brown LJ, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002121; Burczynski ME, 2006, J MOL DIAGN, V8, P51, DOI 10.2353/jmoldx.2006.050079; Campbell JJ, 2001, J IMMUNOL, V166, P877, DOI 10.4049/jimmunol.166.2.877; Carpintero MF, 2015, LUPUS, V24, P1057, DOI 10.1177/0961203315575586; Chaput N, 2019, ANN ONCOL, V30, P2012, DOI 10.1093/annonc/mdz224; Chen GM, 2021, CANCER DISCOV, V11, P2186, DOI 10.1158/2159-8290.CD-20-1677; Chiffelle J, 2020, CURR OPIN BIOTECH, V65, P284, DOI 10.1016/j.copbio.2020.07.010; Cohen J.E., 1988, STAT POWER ANAL BEHA; Croft M, 2009, IMMUNOL REV, V229, P173, DOI 10.1111/j.1600-065X.2009.00766.x; Das R, 2018, J CLIN INVEST, V128, P715, DOI 10.1172/JCI96798; Das S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0805-8; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1111/j.1654-1103.2003.tb02228.x; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Eggermont Alexander M M, 2018, Am Soc Clin Oncol Educ Book, V38, P197, DOI 10.1200/EDBK_201131; Fairfax BP, 2020, NAT MED, V26, P193, DOI 10.1038/s41591-019-0734-6; Fujimura Taku, 2018, Oncotarget, V9, P15542, DOI 10.18632/oncotarget.24509; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Haanen J B A G, 2018, Ann Oncol, V29, piv264, DOI 10.1093/annonc/mdy162; Hamid O, 2019, ANN ONCOL, V30, P582, DOI 10.1093/annonc/mdz011; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Hung T, 2015, SCIENCE, V350, P455, DOI 10.1126/science.aac7442; Hutchinson JA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21572-y; Jacquelot N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00608-2; Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-182; Jing Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18742-9; Johnson DB, 2019, NAT MED, V25, P1243, DOI 10.1038/s41591-019-0523-2; Johnson DB, 2016, JAMA ONCOL, V2, P234, DOI 10.1001/jamaoncol.2015.4368; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kennedy WP, 2015, LUPUS SCI MED, V2, DOI 10.1136/lupus-2014-000080; Krieg C, 2018, NAT MED, V24, P144, DOI 10.1038/nm.4466; Kumar V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00049; Lim SY, 2019, CLIN CANCER RES, V25, P1557, DOI 10.1158/1078-0432.CCR-18-2795; Liptak T., 1958, MAGYAR TUD AKAD MAT, V3, P171; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Lopez AT, 2018, ONCOLOGIST, V23, P1119, DOI 10.1634/theoncologist.2018-0128; Marschner D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132334; Menzies AM, 2017, ANN ONCOL, V28, P368, DOI 10.1093/annonc/mdw443; Morad G, 2021, CELL, V184, P5309, DOI 10.1016/j.cell.2021.09.020; Motulsky HJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-123; Nabet BY, 2020, CELL, V183, P363, DOI 10.1016/j.cell.2020.09.001; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Palmer NP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222952; Pavana A, 2019, ONCOLOGIST, V24, P1128, DOI 10.1634/theoncologist.2018-0563; Peters LA, 2017, NAT GENET, V49, P1437, DOI 10.1038/ng.3947; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; RENYI A, 1965, REV INST INT STAT, V33, P1, DOI 10.2307/1401301; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert L, 2014, CLIN CANCER RES, V20, P2424, DOI 10.1158/1078-0432.CCR-13-2648; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Shahabi V, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-75; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Sims JS, 2016, P NATL ACAD SCI USA, V113, pE3529, DOI 10.1073/pnas.1601012113; Singer Sean, 2019, JAAD Case Rep, V5, P898, DOI 10.1016/j.jdcr.2019.07.015; Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.1; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Steele NG, 2020, NAT CANCER, V1, P1097, DOI 10.1038/s43018-020-00121-4; Stouffer S. A., 1949, STUDIES SOCIAL PSYCH, P82; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subudhi SK, 2016, P NATL ACAD SCI USA, V113, P11919, DOI 10.1073/pnas.1611421113; Tahir SA, 2019, P NATL ACAD SCI USA, V116, P22246, DOI 10.1073/pnas.1908079116; Tang SD, 2021, CANCER RES TREAT, V53, P339, DOI 10.4143/crt.2020.790; Tarhini AA, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0081-1; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; van den Broek T, 2018, NAT REV IMMUNOL, V18, P363, DOI 10.1038/s41577-018-0001-y; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yasuda Y, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb7495	86	34	33	29	44	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					353	+		10.1038/s41591-021-01623-z	http://dx.doi.org/10.1038/s41591-021-01623-z		JAN 2022	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35027754	Green Accepted			2022-12-27	WOS:000742323900008
J	Niroula, A; Sekar, A; Murakami, MA; Trinder, M; Agrawal, M; Wong, WJ; Bick, AG; Uddin, MM; Gibson, CJ; Griffin, GK; Honigberg, MC; Zekavat, SM; Paruchuri, K; Natarajan, P; Ebert, BL				Niroula, Abhishek; Sekar, Aswin; Murakami, Mark A.; Trinder, Mark; Agrawal, Mridul; Wong, Waihay J.; Bick, Alexander G.; Uddin, Md Mesbah; Gibson, Christopher J.; Griffin, Gabriel K.; Honigberg, Michael C.; Zekavat, Seyedeh M.; Paruchuri, Kaavya; Natarajan, Pradeep; Ebert, Benjamin L.			Distinction of lymphoid and myeloid clonal hematopoiesis	NATURE MEDICINE			English	Article							B-CELL LYMPHOCYTOSIS; SOMATIC MUTATIONS; LANDSCAPE; EVOLUTION; GENETICS; LEUKEMIA; HODGKIN; RISK; PATHOGENESIS; PROGRESSION	Clonal hematopoiesis (CH) results from somatic genomic alterations that drive clonal expansion of blood cells. Somatic gene mutations associated with hematologic malignancies detected in hematopoietic cells of healthy individuals, referred to as CH of indeterminate potential (CHIP), have been associated with myeloid malignancies, while mosaic chromosomal alterations (mCAs) have been associated with lymphoid malignancies. Here, we analyzed CHIP in 55,383 individuals and autosomal mCAs in 420,969 individuals with no history of hematologic malignancies in the UK Biobank and Mass General Brigham Biobank. We distinguished myeloid and lymphoid somatic gene mutations, as well as myeloid and lymphoid mCAs, and found both to be associated with risk of lineage-specific hematologic malignancies. Further, we performed an integrated analysis of somatic alterations with peripheral blood count parameters to stratify the risk of incident myeloid and lymphoid malignancies. These genetic alterations can be readily detected in clinical sequencing panels and used with blood count parameters to identify individuals at high risk of developing hematologic malignancies. Genomic analyses in the UK Biobank show that clonal hematopoiesis of indeterminate potential in the lymphoid lineage is associated with a higher risk of developing lymphoid malignancies	[Niroula, Abhishek; Trinder, Mark; Wong, Waihay J.; Bick, Alexander G.; Uddin, Md Mesbah; Gibson, Christopher J.; Griffin, Gabriel K.; Honigberg, Michael C.; Zekavat, Seyedeh M.; Paruchuri, Kaavya; Natarajan, Pradeep; Ebert, Benjamin L.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Niroula, Abhishek; Sekar, Aswin; Murakami, Mark A.; Agrawal, Mridul; Gibson, Christopher J.; Ebert, Benjamin L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Niroula, Abhishek] Lund Univ, Dept Lab Med, Lund, Sweden; [Trinder, Mark] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Wong, Waihay J.; Griffin, Gabriel K.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Bick, Alexander G.] Vanderbilt Univ, Med Ctr, Dept Med, Div Genet Med, Nashville, TN USA; [Uddin, Md Mesbah; Paruchuri, Kaavya; Natarajan, Pradeep] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Honigberg, Michael C.; Paruchuri, Kaavya] Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02114 USA; [Zekavat, Seyedeh M.] Yale Univ, Sch Med, New Haven, CT USA; [Paruchuri, Kaavya; Natarajan, Pradeep] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Ebert, Benjamin L.] Howard Hughes Med Inst, Bethesda, MD 20817 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Lund University; University of British Columbia; Harvard University; Brigham & Women's Hospital; Vanderbilt University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Yale University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Ebert, BL (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ebert, BL (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Ebert, BL (corresponding author), Howard Hughes Med Inst, Bethesda, MD 20817 USA.	benjamin_ebert@dfci.harvard.edu	Niroula, Abhishek/AAB-3998-2022; Natarajan, Pradeep/H-9764-2019; Honigberg, Michael/AAF-1381-2019; Uddin, Md Mesbah/J-1276-2014	Niroula, Abhishek/0000-0002-5904-0635; Natarajan, Pradeep/0000-0001-8402-7435; Honigberg, Michael/0000-0001-8630-5021; Gibson, Christopher/0000-0002-3700-5310; Uddin, Md Mesbah/0000-0003-1846-0411	NIH [R01HL082945, P01CA108631, P50CA206963, R35CA253125]; Howard Hughes Medical Institute; Fondation Leducq [TNE-18CVD04]; Knut and Alice Wallenberg Foundation [KAW2017.0436]; National Heart, Lung, and Blood Institute [R01HL142711, R01HL148050, R01HL151283, R01HL148565, T32HL007208-43, T32HL094301-07]; Massachusetts General Hospital; Damon Runyon Cancer Research Foundation; Deutsche Forschungsgemeinschaft [AG252/1-1]; Fondation Leducq	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Fondation Leducq(Leducq Foundation); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Massachusetts General Hospital(General Electric); Damon Runyon Cancer Research Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fondation Leducq(Leducq Foundation)	This work was supported by the NIH (nos. R01HL082945, P01CA108631, P50CA206963 and R35CA253125), the Howard Hughes Medical Institute and the Fondation Leducq to B.L.E. A.N. was supported by funds from the Knut and Alice Wallenberg Foundation (no. KAW2017.0436). P.N. is supported by grants from the National Heart, Lung, and Blood Institute (nos. R01HL142711, R01HL148050, R01HL151283 and R01HL148565), Fondation Leducq (no. TNE-18CVD04) and Massachusetts General Hospital (Hassenfeld Research Scholar). M.C.H. is supported by the National Heart, Lung, and Blood Institute (no. T32HL094301-07). G.K.G. is supported by the Damon Runyon Cancer Research Foundation. M.A. received research support for this work from the Deutsche Forschungsgemeinschaft (no. AG252/1-1). K.P. is supported by the National Heart, Lung, and Blood Institute (no. T32HL007208-43).	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Agathangelidis A, 2018, HAEMATOLOGICA, V103, P865, DOI 10.3324/haematol.2017.177212; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Benjamin D S. T., 2019, BIORXIV, DOI [DOI 10.1101/861054, 10.1101/861054v1, 10.1101/861054]; Bick AG, 2021, NATURE, V591, pE27, DOI [10.1038/s41586-021-03280-1, 10.1038/s41586-020-2819-2, 10.1038/s41586-021-03280]; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapuy B, 2018, NAT MED, V24, P679, DOI 10.1038/s41591-018-0016-8; Condoluci A, 2018, HAEMATOLOGICA, V103, P751, DOI 10.3324/haematol.2018.191098; Almeida ACD, 2015, NAT GENET, V47, P1465, DOI 10.1038/ng.3442; Desai P, 2018, NAT MED, V24, P1015, DOI 10.1038/s41591-018-0081-z; Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381; Gao T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20565-7; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Gibson CJ, 2017, J CLIN ONCOL, V35, P1598, DOI 10.1200/JCO.2016.71.6712; Green MR, 2013, BLOOD, V121, P1604, DOI 10.1182/blood-2012-09-457283; Huret JL, 2013, NUCLEIC ACIDS RES, V41, pD920, DOI 10.1093/nar/gks1082; Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719; Jaiswal S, 2019, SCIENCE, V366, P586, DOI 10.1126/science.aan4673; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Loh PR, 2020, NATURE, V584, P136, DOI 10.1038/s41586-020-2430-6; Loh PR, 2018, NATURE, V559, P350, DOI 10.1038/s41586-018-0321-x; Malcovati L, 2017, BLOOD, V129, P3371, DOI 10.1182/blood-2017-01-763425; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; Mitchell SR, 2021, CURR OPIN GENET DEV, V66, P63, DOI 10.1016/j.gde.2020.12.004; Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509; Okosun J, 2014, NAT GENET, V46, P176, DOI 10.1038/ng.2856; Pastore A, 2015, LANCET ONCOL, V16, P1111, DOI 10.1016/S1470-2045(15)00169-2; Piris MA, 2017, BEST PRACT RES CL HA, V30, P56, DOI 10.1016/j.beha.2016.09.005; Pizzi M, 2018, ANNU REV PATHOL-MECH, V13, P293, DOI 10.1146/annurev-pathol-020117-043821; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; R Core Team, 2021, R LANGUAGE ENV STAT; Rawstron AC, 2008, NEW ENGL J MED, V359, P575, DOI 10.1056/NEJMoa075290; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Reichel J, 2015, BLOOD, V125, P1061, DOI 10.1182/blood-2014-11-610436; Royo C, 2011, SEMIN CANCER BIOL, V21, P322, DOI 10.1016/j.semcancer.2011.09.007; Sandell RF, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0582-9; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Singh M, 2020, CELL, V180, P878, DOI 10.1016/j.cell.2020.01.029; Smoller JW, 2016, J PERS MED, V6, DOI 10.3390/jpm6010005; Spina V, 2018, BLOOD, V131, P2413, DOI 10.1182/blood-2017-11-812073; Steensma DP, 2015, BLOOD, V126, P9, DOI 10.1182/blood-2015-03-631747; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Thol F, 2017, LEUKEMIA, V31, P1286, DOI 10.1038/leu.2016.345; Tiacci E, 2018, BLOOD, V131, P2454, DOI 10.1182/blood-2017-11-814913; Van Hout CV, 2020, NATURE, V586, P749, DOI 10.1038/s41586-020-2853-0; Wang LL, 2017, GENOME RES, V27, P1300, DOI 10.1101/gr.217331.116; Weigert O, 2012, CANCER DISCOV, V2, P47, DOI 10.1158/2159-8290.CD-11-0208; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wienand K, 2019, BLOOD ADV, V3, P4065, DOI 10.1182/bloodadvances.2019001012; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733; Zekavat SM, 2021, NAT MED, V27, P1012, DOI 10.1038/s41591-021-01371-0; Zhang J, 2014, BLOOD, V123, P2988, DOI 10.1182/blood-2013-07-517177	57	25	25	2	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1921	+		10.1038/s41591-021-01521-4	http://dx.doi.org/10.1038/s41591-021-01521-4		OCT 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34663986	Green Accepted			2022-12-27	WOS:000708373000001
J	Calle, RA; Amin, NB; Carvajal-Gonzalez, S; Ross, TT; Bergman, A; Aggarwal, S; Crowley, C; Rinaldi, A; Mancuso, J; Aggarwal, N; Somayaji, V; Inglot, M; Tuthill, TA; Kou, K; Boucher, M; Tesz, G; Dullea, R; Bence, KK; Kim, AM; Pfefferkorn, JA; Esler, WP				Calle, Roberto A.; Amin, Neeta B.; Carvajal-Gonzalez, Santos; Ross, Trenton T.; Bergman, Arthur; Aggarwal, Sudeepta; Crowley, Collin; Rinaldi, Anthony; Mancuso, Jessica; Aggarwal, Naresh; Somayaji, Veena; Inglot, Malgorzata; Tuthill, Theresa A.; Kou, Kou; Boucher, Magalie; Tesz, Greg; Dullea, Robert; Bence, Kendra K.; Kim, Albert M.; Pfefferkorn, Jeffrey A.; Esler, William P.			ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials	NATURE MEDICINE			English	Article							IMPROVES HEPATIC STEATOSIS; DE-NOVO LIPOGENESIS; LIPOPROTEIN-LIPASE; NATURAL-HISTORY; MALONYL-COA; APOLIPOPROTEINS; STEATOHEPATITIS; PATHOGENESIS; ASSOCIATION; MANAGEMENT	Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects of liver-directed ACC1/2 inhibition in adults with NAFLD. The first study (NCT03248882) examined the effects of monotherapy with a novel ACC1/2 inhibitor, PF-05221304 (2, 10, 25 and 50 mg once daily (QD)), versus placebo at 16 weeks of treatment; the second study (NCT03776175) investigated the effects of PF-05221304 (15 mg twice daily (BID)) co-administered with a DGAT2 inhibitor, PF-06865571 (300 mg BID), versus placebo after 6 weeks of treatment. The primary endpoint in both studies was percent change from baseline in liver fat assessed by magnetic resonance imaging-proton density fat fraction. Dose-dependent reductions in liver fat reached 50-65% with PF-05221304 monotherapy doses >= 10 mg QD; least squares mean (LSM) 80% confidence interval (CI) was -7.2 (-13.9, 0.0), -17.1 (-22.7, -11.1), -49.9 (-53.3, -46.2), -55.9 (-59.0, -52.4) and -64.8 (-67.5, -62.0) with 16 weeks placebo and PF-05221304 2, 10, 25 and 50 mg QD, respectively. The overall incidence of adverse events (AEs) did not increase with increasing PF-05221304 dose, except for a dose-dependent elevation in serum triglycerides (a known consequence of hepatic acetyl-coenzyme A carboxylase (ACC) inhibition) in 23/305 (8%) patients, leading to withdrawal in 13/305 (4%), and a dose-dependent elevation in other serum lipids. Co-administration of PF-05221304 and PF-06865571 lowered liver fat compared to placebo (placebo-adjusted LSM (90% CI) -44.6% (-54.8, -32.2)). Placebo-adjusted LSM (90% CI) reduction in liver fat was -44.5% (-55.0, -31.7) and -35.4% (-47.4, -20.7) after 6 weeks with PF-05221304 or PF-06865571 alone. AEs were reported for 10/28 (36%) patients after co-administered PF-05221304 and PF-06865571, with no discontinuations due to AEs, and the ACC inhibitor-mediated effect on serum triglycerides was mitigated, suggesting that PF-05221304 and PF-06865571 co-administration has the potential to address some of the limitations of ACC inhibition alone.	[Calle, Roberto A.; Amin, Neeta B.; Ross, Trenton T.; Crowley, Collin; Rinaldi, Anthony; Kou, Kou; Tesz, Greg; Dullea, Robert; Bence, Kendra K.; Kim, Albert M.; Pfefferkorn, Jeffrey A.; Esler, William P.] Pfizer Inc, Internal Med Res Unit, Cambridge, MA 02139 USA; [Carvajal-Gonzalez, Santos; Bergman, Arthur; Aggarwal, Sudeepta; Mancuso, Jessica; Somayaji, Veena; Tuthill, Theresa A.] Pfizer Inc, Early Clin Dev, Cambridge, MA USA; [Aggarwal, Naresh] Aggarwal & Associates Ltd, Brampton, ON, Canada; [Inglot, Malgorzata] Wroclaw Med Univ, Dept Infect Dis Liver Dis & Acquired Immune Defic, Wroclaw, Poland; [Inglot, Malgorzata] Dobrostan, Wroclaw, Poland; [Boucher, Magalie] Pfizer Worldwide Res & Dev, Drug Safety Res & Dev Global Pathol, Cambridge, MA USA	Pfizer; Pfizer; Wroclaw Medical University; Pfizer	Esler, WP (corresponding author), Pfizer Inc, Internal Med Res Unit, Cambridge, MA 02139 USA.	william.esler@Pfizer.com		Calle, Roberto/0000-0001-6577-5657; Inglot, Malgorzata/0000-0002-6173-7909	Pfizer Inc.; Pfizer	Pfizer Inc.(Pfizer); Pfizer(Pfizer)	These studies were sponsored by Pfizer Inc. The authors would like to thank the patients who offered their time, interest and participation as well as the staff across all sites who recruited at least one patient in the clinical studies. The authors would also like to thank colleagues at Nordic Bioscience, M. Karsdal and D. J. Leeming, for their help with analysis of the serum procollagens-Pro-C3, Pro-C4, Pro-C6 and Pro-C18-in NCT03248882; M. Birnbaum for helpful discussions; K. Kelly and D. Beebe for help with in vivo studies; J. Morin and D. Shanthappa for assistance with shear-wave elastography measurements; J. Travers and A. Robertson for histology; S. Vargas for microscopic imaging of histological sections; and P. Garnick for clinical study management. Medical writing support, under the direction of the authors, was provided by C. Cairney, CMC Connect, McCann Health Medical Communications, and was funded by Pfizer in accordance with Good Publication Practice guidelines (Ann. Intern. Med.<BOLD>163</BOLD>, 461-464 (2015)).	Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014; Amin NB, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav9701; Bates J, 2020, J HEPATOL, V73, P896, DOI 10.1016/j.jhep.2020.04.037; Bergman A, 2020, CLIN PHARM DRUG DEV, V9, P514, DOI 10.1002/cpdd.782; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Caussy C, 2018, HEPATOLOGY, V68, P763, DOI 10.1002/hep.29797; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Choi CS, 2007, J BIOL CHEM, V282, P22678, DOI 10.1074/jbc.M704213200; Dowman JK, 2010, QJM-INT J MED, V103, P71, DOI 10.1093/qjmed/hcp158; EASL, 2016, DIABETOLOGIA, V59, P1121, DOI 10.1007/s00125-016-3902-y; Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368; Esler WP, 2019, CELL MOL GASTROENTER, V8, P247, DOI 10.1016/j.jcmgh.2019.04.007; Fabbrini E, 2010, J CLIN ENDOCR METAB, V95, P2727, DOI 10.1210/jc.2009-2622; Fiorucci S, 2018, PHARMACOL RES, V134, P289, DOI 10.1016/j.phrs.2018.07.014; Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; Gluchowski NL, 2019, HEPATOLOGY, V70, P1972, DOI 10.1002/hep.30765; Goedeke L, 2018, HEPATOLOGY, V68, P2197, DOI 10.1002/hep.30097; Griffith DA, 2014, J MED CHEM, V57, P10512, DOI 10.1021/jm5016022; Harwood HJ, 2003, J BIOL CHEM, V278, P37099, DOI 10.1074/jbc.M304481200; Kanter JE, 2019, J CLIN INVEST, V129, P4165, DOI 10.1172/JCI127308; Kelly KL, 2020, NAT METAB, V2, P1163, DOI 10.1038/s42255-020-00272-9; Kim CW, 2017, CELL METAB, V26, P394, DOI 10.1016/j.cmet.2017.07.009; Lambert JE, 2014, GASTROENTEROLOGY, V146, P726, DOI 10.1053/j.gastro.2013.11.049; Lawitz EJ, 2019, HEPATOLOGY, V70, p1489A; Lawitz EJ, 2018, CLIN GASTROENTEROL H, V16, P1983, DOI 10.1016/j.cgh.2018.04.042; Lawler PR, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005549; Loomba R, 2019, J HEPATOL, V70, pE67, DOI 10.1016/S0618-8278(19)30118-5; Loomba R, 2018, GASTROENTEROLOGY, V155, P1463, DOI 10.1053/j.gastro.2018.07.027; Loomba R, 2015, HEPATOLOGY, V61, P1239, DOI 10.1002/hep.27647; Marengo A, 2016, CLIN LIVER DIS, V20, P313, DOI 10.1016/j.cld.2015.10.010; Mashhood A, 2013, J MAGN RESON IMAGING, V37, P1359, DOI 10.1002/jmri.23928; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Mora S, 2015, CIRCULATION, V132, P2220, DOI 10.1161/CIRCULATIONAHA.115.016857; Oscarsson J, 2018, J CLIN LIPIDOL, V12, P1390, DOI 10.1016/j.jacl.2018.08.003; Parker HM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020475; Patel J, 2016, THER ADV GASTROENTER, V9, P692, DOI 10.1177/1756283X16656735; Rafiq N, 2009, CLIN GASTROENTEROL H, V7, P234, DOI 10.1016/j.cgh.2008.11.005; Ross TT, 2020, CELL MOL GASTROENTER, V10, P829, DOI 10.1016/j.jcmgh.2020.06.001; Saggerson D, 2008, ANNU REV NUTR, V28, P253, DOI 10.1146/annurev.nutr.28.061807.155434; Savage DB, 2006, J CLIN INVEST, V116, P817, DOI 10.1172/JCI27300; Saxena A, 2019, HEPATOLOGY, V70, p1260A; Stiede K, 2017, HEPATOLOGY, V66, P324, DOI 10.1002/hep.29246; Stine JG, 2021, CLIN GASTROENTEROL H, V19, P2274, DOI 10.1016/j.cgh.2020.08.061; Le TA, 2012, HEPATOLOGY, V56, P922, DOI 10.1002/hep.25731; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; Yamaguchi K, 2007, HEPATOLOGY, V45, P1366, DOI 10.1002/hep.21655; Yen CLE, 2008, J LIPID RES, V49, P2283, DOI 10.1194/jlr.R800018-JLR200; Younossi ZM, 2021, HEPATOLOGY, V73, P1194, DOI 10.1002/hep.31420; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783	52	29	29	3	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1836	+		10.1038/s41591-021-01489-1	http://dx.doi.org/10.1038/s41591-021-01489-1		OCT 2021	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34635855				2022-12-27	WOS:000706015900007
J	Pishko, AM; Bussel, JB; Cines, DB				Pishko, Allyson M.; Bussel, James B.; Cines, Douglas B.			COVID-19 vaccination and immune thrombocytopenia	NATURE MEDICINE			English	Editorial Material							RISK	A prospective cohort analysis finds a link between the ChAdOx1 vaccine and an autoimmune disorder known as immune thrombocytopenia-but questions remain and causality is yet to be established.	[Pishko, Allyson M.; Cines, Douglas B.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Pishko, Allyson M.; Cines, Douglas B.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Bussel, James B.] Weill Cornell Med, Dept Pediat, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Cornell University	Cines, DB (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.; Cines, DB (corresponding author), Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	dcines@pennmedicine.upenn.edu		Pishko, Allyson/0000-0001-9997-454X	Sanofi Genzyme; Novo Nordisk; Amgen; Syntimmune/Attenuon	Sanofi Genzyme(Sanofi-AventisGenzyme Corporation); Novo Nordisk(Novo Nordisk); Amgen(Amgen); Syntimmune/Attenuon	A.M.P. has received research funding from an educational grant from Sanofi Genzyme and Novo Nordisk. J.B.B. has received research support from Amgen; has served as a consultant and/or on advisory boards for Amgen, Dova, Novartis, Rigel, UCB, Momenta-Johnson & Johnson, Argenix, Principia-Sanofi, RallyBIo and Regeneron; and was a member of the Data Safety Monitoring Board for UCB, CSL Behring. D.B.C. has received research support from Syntimmune/Attenuon and served as a consultant and/or on advisory boards for Novartis, Johnson & Johnson, Dova, Tavanta and Rigel.	Arnold DM, 2017, BLOOD ADV, V1, P2414, DOI 10.1182/bloodadvances.2017010942; Bussel, ENGL J MED, DOI [10.1056/NEJMe2106315(2021, DOI 10.1056/NEJME2106315(2021]; Condit RC, 2020, VACCINE, V38, P7708, DOI 10.1016/j.vaccine.2020.08.009; Grimaldi-Bensouda L, 2012, BLOOD, V120, P4938, DOI 10.1182/blood-2012-05-431098; Mantadakis E, 2010, J PEDIATR-US, V156, P623, DOI 10.1016/j.jpeds.2009.10.015; Moulis G, 2014, BLOOD, V124, P3308, DOI 10.1182/blood-2014-05-578336; OSKI FA, 1966, NEW ENGL J MED, V275, P352, DOI 10.1056/NEJM196608182750703; Schifferli A, 2021, BLOOD ADV, V5, P1617, DOI 10.1182/bloodadvances.2020003004; Simpson, NAT MED, DOI [10.1038/s41591-021-01408-4(2021), DOI 10.1038/S41591-021-01408-4(2021)]; Simpson Colin R, 2020, BMJ Open, V10, pe039097, DOI 10.1136/bmjopen-2020-039097; Tiede A, BLOOD, DOI [10.1182/blood.2021011958(2021), DOI 10.1182/BLOOD.2021011958(2021)]; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2	12	14	14	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1145	1146		10.1038/s41591-021-01419-1	http://dx.doi.org/10.1038/s41591-021-01419-1		JUN 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34108715	Bronze			2022-12-27	WOS:000659384400002
J	Pritchard, E; Matthews, PC; Stoesser, N; Eyre, DW; Gethings, O; Vihta, KD; Jones, J; House, T; VanSteenHouse, H; Bell, I; Bell, JI; Newton, JN; Farrar, J; Diamond, I; Rourke, E; Studley, R; Crook, D; Peto, TEA; Walker, AS; Pouwels, KB				Pritchard, Emma; Matthews, Philippa C.; Stoesser, Nicole; Eyre, David W.; Gethings, Owen; Vihta, Karina-Doris; Jones, Joel; House, Thomas; VanSteenHouse, Harper; Bell, Iain; Bell, John I.; Newton, John N.; Farrar, Jeremy; Diamond, Ian; Rourke, Emma; Studley, Ruth; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah; Pouwels, Koen B.			Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	NATURE MEDICINE			English	Article								The effectiveness of COVID-19 vaccination in preventing new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear. Here, we used the Office for National Statistics COVID-19 Infection Survey-a large community-based survey of individuals living in randomly selected private households across the United Kingdom-to assess the effectiveness of the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca; ChAdOx1) vaccines against any new SARS-CoV-2 PCR-positive tests, split according to self-reported symptoms, cycle threshold value (<30 versus >= 30; as a surrogate for viral load) and gene positivity pattern (compatible with B.1.1.7 or not). Using 1,945,071 real-time PCR results from nose and throat swabs taken from 383,812 participants between 1 December 2020 and 8 May 2021, we found that vaccination with the ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections >= 21 d after the first dose (61% (95% confidence interval (CI) = 54-68%) versus 66% (95% CI = 60-71%), respectively), with greater reductions observed after a second dose (79% (95% CI = 65-88%) versus 80% (95% CI = 73-85%), respectively). The largest reductions were observed for symptomatic infections and/or infections with a higher viral burden. Overall, COVID-19 vaccination reduced the number of new SARS-CoV-2 infections, with the largest benefit received after two vaccinations and against symptomatic and high viral burden infections, and with no evidence of a difference between the BNT162b2 and ChAdOx1 vaccines. Results from the Office of National Statistics COVID-19 Infection Survey in the United Kingdom demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.	[Pritchard, Emma; Matthews, Philippa C.; Stoesser, Nicole; Vihta, Karina-Doris; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England; [Pritchard, Emma; Stoesser, Nicole; Eyre, David W.; Vihta, Karina-Doris; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah; Pouwels, Koen B.] Univ Oxford, Hlth Protect Res Unit Healthcare Associated Infec, Natl Inst Hlth Res NIHR, Oxford, England; [Matthews, Philippa C.; Stoesser, Nicole; Eyre, David W.; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah] Univ Oxford, NIHR Oxford Biomed Res Ctr, Oxford, England; [Matthews, Philippa C.; Stoesser, Nicole; Eyre, David W.; Crook, Derrick; Peto, Tim E. A.] John Radcliffe Hosp, Univ Hosp NHS Fdn Trust, Dept Infect Dis & Microbiol, Oxford, England; [Eyre, David W.; Pouwels, Koen B.] Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Oxford, England; [Gethings, Owen; Jones, Joel; Bell, Iain; Diamond, Ian; Rourke, Emma; Studley, Ruth] Off Natl Stat, Newport, Shrops, England; [House, Thomas] Univ Manchester, Dept Math, Manchester, Lancs, England; [House, Thomas] Hartree Ctr, IBM Res, Daresbury, England; [VanSteenHouse, Harper] Glasgow Lighthouse Lab, Glasgow, Lanark, Scotland; [VanSteenHouse, Harper] BioClavis, Glasgow, Lanark, Scotland; [Bell, John I.] Univ Oxford, Off Regius Prof Med, Oxford, England; [Newton, John N.] Publ Hlth England, Hlth Improvement Directorate, London, England; [Farrar, Jeremy] Wellcome Trust Res Labs, London, England; [Pouwels, Koen B.] UCL, MRC Clin Trials Unit UCL, London, England; [Pouwels, Koen B.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England	University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Manchester; University of Oxford; Public Health England; Medical Research Council Clinical Trials Unit; University of London; University College London; University of Oxford	Pouwels, KB (corresponding author), Univ Oxford, Hlth Protect Res Unit Healthcare Associated Infec, Natl Inst Hlth Res NIHR, Oxford, England.; Pouwels, KB (corresponding author), Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Oxford, England.; Pouwels, KB (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.	koen.pouwels@ndph.ox.ac.uk	Newton, John/HCH-8693-2022; Farrar, Jeremy J./HGA-7610-2022; Stoesser, Nicole/H-3421-2019; Walker, Sarah/HDM-8717-2022; Eyre, David/P-6887-2016	Stoesser, Nicole/0000-0002-4508-7969; Eyre, David/0000-0001-5095-6367; Crook, Derrick/0000-0002-0590-2850; Newton, John/0000-0002-5641-6457; VanSteenhouse, Harper/0000-0002-9401-5929; Matthews, Philippa/0000-0002-4036-4269; Pritchard, Emma/0000-0002-0963-9260; Pouwels, Koen/0000-0001-7097-8950	Department of Health and Social Care; Department of Health (Northern Ireland Government); Scottish Government; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; Public Health England (PHE) [NIHR200915]; NIHR Oxford Biomedical Research Centre; Huo Family Foundation; Medical Research Council UK [MC_UU_12023/22]; Wellcome Trust [110110/Z/15/Z]; NIHR Oxford BRC Senior Fellowship award; Robertson Fellowship; NIHR Oxford BRC Senior Fellowship; COVID-19 Infection Survey team; Welsh Government	Department of Health and Social Care; Department of Health (Northern Ireland Government); Scottish Government; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; Public Health England (PHE); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Huo Family Foundation; Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); NIHR Oxford BRC Senior Fellowship award; Robertson Fellowship; NIHR Oxford BRC Senior Fellowship; COVID-19 Infection Survey team; Welsh Government	This study was funded by the Department of Health and Social Care, with in-kind support from the Welsh Government, Department of Health (on behalf of the Northern Ireland Government) and Scottish Government. E.P., K.B.P., A.S.W., T.E.A.P., N.S. and D.W.E. are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). A.S.W. and T.E.A.P. are also supported by the NIHR Oxford Biomedical Research Centre. E.P. and K.B.P. are also supported by the Huo Family Foundation. A.S.W. is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit (MC_UU_12023/22) and is an NIHR Senior Investigator. P.C.M. is funded by the Wellcome Trust (intermediate fellowship; grant reference 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. D.W.E. is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health or PHE. The funders/sponsors did not have any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication. All authors had full access to all data analysis outputs (reports and tables) and take responsibility for their integrity and accuracy. We are grateful for the support of all COVID-19 Infection Survey participants and the COVID-19 Infection Survey team.	[Anonymous], 2017, NO IR MULT DEP MEAS; [Anonymous], 2021, REG APPR COVID 19 VA; [Anonymous], 2020, SCOTT IND MULT DEP 2; [Anonymous], 2021, NHS TEST TRAC STAT E; [Anonymous], 2020, INV SARS COV 2 VAR C; [Anonymous], 2018, SCOTT GOVT URB RUR C; [Anonymous], 2016, RUR URB CLASS; [Anonymous], 2017, URB RUR CLASS; [Anonymous], 2019, ENGLISH INDICES DEPR; [Anonymous], 2020, REG APPR COVID 19 VA; [Anonymous], 2021, BOOK MAN YOUR COR CO; [Anonymous], VACC UK, P2021; [Anonymous], 2021, GOV ASKS VIEWS COVID; [Anonymous], 2020, ADV PRIOR GROUPS COV; [Anonymous], 2020, INT GUID DET CAS REI; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; CHIA WN, LANCET MICROBE, DOI DOI 10.1016/S2666-5247(21)00025-2(2021); Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; [dataset] Welsh Government, 2019, WELSH INDEX MULTIPLE; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Kojima N, 2021, CLIN INFECT DIS, V73, pE3106, DOI 10.1093/cid/ciaa1589; Lee, CLIN INFECT DIS, DOI [10.1093/cid/ciab421(2021, DOI 10.1093/CID/CIAB421(2021]; Lumley, OBSERVATIONAL COHORT, DOI [10.1101/2021.03.09.21253218(2021, DOI 10.1101/2021.03.09.21253218(2021]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pouwels KB, 2021, LANCET PUBLIC HEALTH, V6, pE30, DOI 10.1016/S2468-2667(20)30282-6; Saad-Roy CM, 2021, SCIENCE, V372, P363, DOI 10.1126/science.abg8663; Shrotri M., VACCINE EFFECTIVENES, DOI [10.1101/2021.03.26.21254391(2021, DOI 10.1101/2021.03.26.21254391(2021]; Singanayagam A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.32.2001483; Smith, CLIN INFECT DIS, DOI [10.1093/cid/ciab265(2021, DOI 10.1093/CID/CIAB265(2021]; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walker, INCREASED INFECT NOT, DOI [10.1101/2021.01.13.21249721(2021, DOI 10.1101/2021.01.13.21249721(2021]	39	140	142	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1370	+		10.1038/s41591-021-01410-w	http://dx.doi.org/10.1038/s41591-021-01410-w		JUN 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34108716	Green Published, hybrid			2022-12-27	WOS:000659384400003
J	Kinganda-Lusamaki, E; Black, A; Mukadi, DB; Hadfield, J; Mbala-Kingebeni, P; Pratt, CB; Aziza, A; Diagne, MM; White, B; Bisento, N; Nsunda, B; Akonga, M; Faye, M; Faye, O; Edidi-Atani, F; Matondo-Kuamfumu, M; Mambu-Mbika, F; Bulabula, J; Di Paola, N; Pauthner, MG; Andersen, KG; Palacios, G; Delaporte, E; Sall, AA; Peeters, M; Wiley, MR; Ahuka-Mundeke, S; Bedford, T; Tamfum, JJM				Kinganda-Lusamaki, Eddy; Black, Allison; Mukadi, Daniel B.; Hadfield, James; Mbala-Kingebeni, Placide; Pratt, Catherine B.; Aziza, Amuri; Diagne, Moussa M.; White, Bailey; Bisento, Nella; Nsunda, Bibiche; Akonga, Marceline; Faye, Martin; Faye, Ousmane; Edidi-Atani, Francois; Matondo-Kuamfumu, Meris; Mambu-Mbika, Fabrice; Bulabula, Junior; Di Paola, Nicholas; Pauthner, Matthias G.; Andersen, Kristian G.; Palacios, Gustavo; Delaporte, Eric; Sall, Amadou Alpha; Peeters, Martine; Wiley, Michael R.; Ahuka-Mundeke, Steve; Bedford, Trevor; Tamfum, Jean-Jacques Muyembe			Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo	NATURE MEDICINE			English	Article								On 1 August 2018, the Democratic Republic of the Congo (DRC) declared its tenth Ebola virus disease (EVD) outbreak. To aid the epidemiologic response, the Institut National de Recherche Biomedicale (INRB) implemented an end-to-end genomic surveillance system, including sequencing, bioinformatic analysis and dissemination of genomic epidemiologic results to frontline public health workers. We report 744 new genomes sampled between 27 July 2018 and 27 April 2020 generated by this surveillance effort. Together with previously available sequence data (n = 48 genomes), these data represent almost 24% of all laboratory-confirmed Ebola virus (EBOV) infections in DRC in the period analyzed. We inferred spatiotemporal transmission dynamics from the genomic data as new sequences were generated, and disseminated the results to support epidemiologic response efforts. Here we provide an overview of how this genomic surveillance system functioned, present a full phylodynamic analysis of 792 Ebola genomes from the Nord Kivu outbreak and discuss how the genomic surveillance data informed response efforts and public health decision making. Phylogeographic analysis of 792 Ebola virus genomes from the 2018 oubreak in the Democratic Republic of the Congo integrated into an end-to-end surveillance program demonstrates the feasibility of using genomic sequencing data to inform the public health epidemic response in near-real time.	[Kinganda-Lusamaki, Eddy; Mbala-Kingebeni, Placide; Aziza, Amuri; Bisento, Nella; Nsunda, Bibiche; Akonga, Marceline; Faye, Martin; Edidi-Atani, Francois; Matondo-Kuamfumu, Meris; Mambu-Mbika, Fabrice; Bulabula, Junior; Ahuka-Mundeke, Steve; Tamfum, Jean-Jacques Muyembe] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO; [Kinganda-Lusamaki, Eddy; Mukadi, Daniel B.; Mbala-Kingebeni, Placide; Edidi-Atani, Francois; Matondo-Kuamfumu, Meris; Mambu-Mbika, Fabrice; Bulabula, Junior; Ahuka-Mundeke, Steve; Tamfum, Jean-Jacques Muyembe] Clin Univ Kinshasa, Serv Microbiol, Kinshasa, DEM REP CONGO; [Black, Allison; Bedford, Trevor] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Black, Allison; Hadfield, James; Bedford, Trevor] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Pratt, Catherine B.; White, Bailey; Wiley, Michael R.] Univ Nebraska Med Ctr, Dept Environm Agr & Occupat Hlth, Omaha, NE USA; [Diagne, Moussa M.; Faye, Ousmane; Sall, Amadou Alpha] Inst Pasteur, Dakar, Senegal; [Di Paola, Nicholas; Palacios, Gustavo] US Army, Med Res Inst Infect Dis, Ctr Genome Sci, Frederick, MD USA; [Pauthner, Matthias G.; Andersen, Kristian G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA USA; [Delaporte, Eric; Peeters, Martine] Univ Montpellier, TransVIHMI, Inst Rech Dev, INSERM, Montpellier, France	Institute Nacional de Recherche Biomedical; Universite de Kinshasa; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Nebraska System; University of Nebraska Medical Center; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; Scripps Research Institute; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Kinganda-Lusamaki, E (corresponding author), Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO.; Kinganda-Lusamaki, E (corresponding author), Clin Univ Kinshasa, Serv Microbiol, Kinshasa, DEM REP CONGO.; Bedford, T (corresponding author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.; Bedford, T (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.	eddylusamaki@gmail.com; tbedford@fredhutch.org	faye, Ousmane/GMW-6500-2022; Palacios, Gustavo/I-7773-2015; Pratt, Catherine/AAD-6118-2022; FAYE, MARTIN/ABA-4738-2020	Palacios, Gustavo/0000-0001-5062-1938; Pratt, Catherine/0000-0001-6132-2570; FAYE, MARTIN/0000-0003-3207-6344; DIAGNE, Moussa Moise/0000-0001-5461-5623; Black, Allison/0000-0002-6618-4127; Kinganda Lusamaki, Eddy/0000-0001-9795-0165	Defense Biological Product Assurance Office [FA460012-D-9000]; Gates Foundation [INV-004176]; Institut National de la Sante et de la Recherche Medicale/the Ebola Task Force/REACTing; EBO-SURSY project - European Union; Institut de Recherche pour le Developpement (IRD); National Science Foundation Graduate Research Fellowship Program [DGE-1256082]; NIH [U01AI151812, U19AI135995, UL1TR002550, R35 GM119774-01]; Fogarty International Center (NIH/CRDF Global) [FOGX-19-90402-1]; Bill and Melinda Gates Foundation [INV-003565]	Defense Biological Product Assurance Office; Gates Foundation(Bill & Melinda Gates Foundation); Institut National de la Sante et de la Recherche Medicale/the Ebola Task Force/REACTing; EBO-SURSY project - European Union; Institut de Recherche pour le Developpement (IRD); National Science Foundation Graduate Research Fellowship Program(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fogarty International Center (NIH/CRDF Global); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Sequencing activities were supported by the Defense Biological Product Assurance Office through a task order award to the National Strategic Research Institute (no. FA460012-D-9000) and Gates Foundation (no. INV-004176) awarded to C.P.P. This work was supported in part by grants from Institut National de la Sante et de la Recherche Medicale/the Ebola Task Force/REACTing, EBO-SURSY project funded by the European Union and Institut de Recherche pour le Developpement (IRD). A.B. was supported by the National Science Foundation Graduate Research Fellowship Program under grant no. DGE-1256082. P.M.-K. was awarded a PhD grant from IRD. K.G.A. is a Pew Biomedical Scholar and is supported by NIH grant nos. U01AI151812, U19AI135995 and UL1TR002550. T.B. is a Pew Biomedical Scholar and is supported by NIH grant no. R35 GM119774-01. Computational infrastructure and in-country training were supported by the Fogarty International Center (NIH/CRDF Global, no. FOGX-19-90402-1) and the Bill and Melinda Gates Foundation (no. INV-003565). The content of this article does not necessarily represent the official policy or views of the US Department of the Army, the US Department of Defense, the US Department of Health and Human Services, the US Government or the institutions or companies affiliated with the authors.	[Anonymous], 2017, COND SAF DIGN BUR PA; Armstrong GL, 2019, NEW ENGL J MED, V381, P2569, DOI 10.1056/NEJMsr1813907; Black A, 2020, NAT MED, V26, P832, DOI 10.1038/s41591-020-0935-z; Diehl WE, 2016, CELL, V167, P1088, DOI 10.1016/j.cell.2016.10.014; Dudas G, 2017, NATURE, V544, P309, DOI 10.1038/nature22040; Grubaugh ND, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1618-7; Hadfield J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008042; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Hall MD, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew003; Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300; Mate SE, 2015, NEW ENGL J MED, V373, P2448, DOI 10.1056/NEJMoa1509773; Mbala-Kingebeni P., NEW ENGL J MED; Mbala-Kingebeni P, 2019, LANCET INFECT DIS, V19, P648, DOI 10.1016/S1473-3099(19)30118-5; Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218; Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066; Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042; Urbanowicz RA, 2016, CELL, V167, P1079, DOI 10.1016/j.cell.2016.10.013	19	8	7	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01302-z	http://dx.doi.org/10.1038/s41591-021-01302-z		APR 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33846610	Green Accepted, Bronze			2022-12-27	WOS:000639643400003
J	Stower, H				Stower, Hannah			A shift in cholesterol geography	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1804	1804		10.1038/s41591-020-01150-3	http://dx.doi.org/10.1038/s41591-020-01150-3			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288931				2022-12-27	WOS:000596579200005
J	Sailor, KA; Agoranos, G; Lopez-Manzaneda, S; Tada, S; Gillet-Legrand, B; Guerinot, C; Masson, JB; Vestergaard, CL; Bonner, M; Gagnidze, K; Veres, G; Lledo, PM; Cartier, N				Sailor, Kurt A.; Agoranos, George; Lopez-Manzaneda, Sergio; Tada, Satoru; Gillet-Legrand, Beatrix; Guerinot, Corentin; Masson, Jean-Baptiste; Vestergaard, Christian L.; Bonner, Melissa; Gagnidze, Khatuna; Veres, Gabor; Lledo, Pierre-Marie; Cartier, Nathalie			Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain	NATURE MEDICINE			English	Article							IONIZING-RADIATION; BUSULFAN; APOPTOSIS; PROTEIN; KI-67; PROLIFERATION; TURNOVER	Hematopoietic stem cell transplantation (HSCT) is a therapy used for multiple malignant and nonmalignant diseases, with chemotherapy used for pretransplantation myeloablation. The post-HSCT brain contains peripheral engrafted parenchymal macrophages, despite their absence in the normal brain, with the engraftment mechanism still undefined. Here we show that HSCT chemotherapy broadly disrupts mouse brain regenerative populations, including a permanent loss of adult neurogenesis. Microglial density was halved, causing microglial process expansion, coinciding with indicators of broad senescence. Although microglia expressed cell proliferation markers, they underwent cell cycle arrest in S phase with a majority expressing the senescence and antiapoptotic marker p21. In vivo single-cell tracking of microglia after recovery from chemical depletion showed loss of their regenerative capacity, subsequently replaced with donor macrophages. We propose that HSCT chemotherapy causes microglial senescence with a gradual decrease to a critical microglial density, providing a permissive niche for peripheral macrophage engraftment of the brain. Hematopoietic stem cell transplantation chemotherapy with busulfan causes senescence of brain microglia, rapid loss of adult neurogenesis and engraftment of peripheral donor macrophages into the brain of mice post transplantation.	[Sailor, Kurt A.; Agoranos, George; Guerinot, Corentin; Lledo, Pierre-Marie] Univ Paris, Inst Pasteur, Percept & Memory Unit, CNRS,UMR 3571, Paris, France; [Lopez-Manzaneda, Sergio; Tada, Satoru; Gillet-Legrand, Beatrix; Cartier, Nathalie] Univ Paris Saclay, Univ Paris Sud, INSERM, UMR1169, Orsay, France; [Lopez-Manzaneda, Sergio; Tada, Satoru; Gillet-Legrand, Beatrix; Cartier, Nathalie] Hop La Pitie Salpetriere, Inst Cerveau & Moelle Epiniere, Therapie Cellulaire & Gen Malad Neurol Enfant & A, Paris, France; [Guerinot, Corentin; Masson, Jean-Baptiste; Vestergaard, Christian L.] Univ Paris, Inst Pasteur, Decis & Bayesian Computat, USR 3756,CNRS, Paris, France; [Guerinot, Corentin; Masson, Jean-Baptiste; Vestergaard, Christian L.] Univ Paris, Inst Pasteur, Neurosci Dept, CNRS,UMR 3751, Paris, France; [Guerinot, Corentin] Sorbonne Univ, Coll Doctoral ED3C, Paris, France; [Bonner, Melissa; Gagnidze, Khatuna; Veres, Gabor] Bluebird Bio Inc, Cambridge, MA USA; [Cartier, Nathalie] Asklepios Biopharmaceut Inc, Inst Cerveau ICM, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite	Sailor, KA; Lledo, PM (corresponding author), Univ Paris, Inst Pasteur, Percept & Memory Unit, CNRS,UMR 3571, Paris, France.; Cartier, N (corresponding author), Univ Paris Saclay, Univ Paris Sud, INSERM, UMR1169, Orsay, France.; Cartier, N (corresponding author), Hop La Pitie Salpetriere, Inst Cerveau & Moelle Epiniere, Therapie Cellulaire & Gen Malad Neurol Enfant & A, Paris, France.; Cartier, N (corresponding author), Asklepios Biopharmaceut Inc, Inst Cerveau ICM, Paris, France.	ksailor@pasteur.fr; pierre-marie.lledo@pasteur.fr; ncartier@askbio.com	Sailor, Kurt Andrew/AFN-4046-2022; Sailor, Kurt/GSO-2237-2022	Sailor, Kurt Andrew/0000-0002-9574-6838; Sailor, Kurt/0000-0002-9574-6838; Gillet-Legrand, Beatrix/0000-0002-1159-5949; Agoranos, Georgios/0000-0002-6088-6283; Tada, Satoru/0000-0002-0323-5644; Vestergaard, Christian L./0000-0001-5329-475X	bluebird bio, Inc.; Agence Nationale de la Recherche [ANR-15-CE37-0004-01, ANR-15-NEUC-0004]; life insurance company 'AG2R-La-Mondiale'; Agence Nationale de la Recherche `Investissements d'avenir' program [ANR-19-P3IA-0001]; Laboratory for Excellence (LabEx) 'Revive' [ANR-10-LABX-73]; program "Investissements d'avenir" [ANR-10-IAIHU-06, ANR11-INBS-0011-NeurATRIS]	bluebird bio, Inc.; Agence Nationale de la Recherche(French National Research Agency (ANR)); life insurance company 'AG2R-La-Mondiale'; Agence Nationale de la Recherche `Investissements d'avenir' program(French National Research Agency (ANR)); Laboratory for Excellence (LabEx) 'Revive'; program "Investissements d'avenir"(French National Research Agency (ANR))	We thank P. Aubourg for his inspiration to initiate this study; J. Strauch, I. Bernstein and G. Dufayet-Chaffaud for experimental support; E. Gomez Perdiguero, G. Lepousez, I. Gabanyi, S. Voytek, F. Koukouli, H. Song, G. Eberl, L. Peduto, F. Jagot-Brunner, G. Parsons and A. Giniatullina for advice; and T. Sailor for two-photon stage fabrication. This work was partly funded by bluebird bio, Inc. as part of a collaboration (K.A.S., P.-M.L. and N.C.), Agence Nationale de la Recherche (no. ANR-15-CE37-0004-01, to K.A.S. and P.-M.L.), Agence Nationale de la Recherche (no. ANR-15-NEUC-0004, Circuit-OPL, to K.A.S. and P.-M.L.), the life insurance company 'AG2R-La-Mondiale' (to K.A.S. and P.-M.L.), the Agence Nationale de la Recherche `Investissements d'avenir' program (no. ANR-19-P3IA-0001, PRAIRIE 31A Institute, to C.G., J.-B.M. and C.L.V.) and a pre-and postdoctoral fellowship from the Laboratory for Excellence (LabEx) `Revive' (no. ANR-10-LABX-73, to C.G. and K.A.S.). S.L.-M, S.T., B.G.-L. and N.C. funding from the program "Investissements d'avenir" ANR-10-IAIHU-06 and ANR11-INBS-0011-NeurATRIS: Translational Research Infrastructure for Biotherapies in Neurosciences. Part of this work was carried out in the PHENOPARC core facility, CELIS core facility and ICAN core facility of ICM.	Askew K, 2017, CELL REP, V18, P391, DOI 10.1016/j.celrep.2016.12.041; AUBOURG P, 1990, NEW ENGL J MED, V322, P1860, DOI 10.1056/NEJM199006283222607; Barr AR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14728; Ben Abdallah NMB, 2010, NEUROBIOL AGING, V31, P151, DOI 10.1016/j.neurobiolaging.2008.03.002; Bottcher C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080260; Buchbinder D, 2018, BONE MARROW TRANSPL, V53, P535, DOI 10.1038/s41409-017-0055-7; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Capotondo A, 2012, P NATL ACAD SCI USA, V109, P15018, DOI 10.1073/pnas.1205858109; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Ciurea SO, 2009, BIOL BLOOD MARROW TR, V15, P523, DOI 10.1016/j.bbmt.2008.12.489; Cronk JC, 2018, J EXP MED, V215, P1627, DOI 10.1084/jem.20180247; Egeland M, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.68; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Ghanbari A, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.404; Holtmaat A, 2009, NAT PROTOC, V4, P1128, DOI 10.1038/nprot.2009.89; Huang YB, 2018, NAT NEUROSCI, V21, P530, DOI 10.1038/s41593-018-0090-8; Iwanoto T, 2004, CANCER SCI, V95, P454, DOI 10.1111/j.1349-7006.2004.tb03231.x; Janicke RU, 2007, CELL CYCLE, V6, P407; Jonas RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030763; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kierdorf K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058544; Lampron A, 2012, CELL TRANSPLANT, V21, P1149, DOI 10.3727/096368911X593154; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lombardi D, 2016, NEPHROL DIAL TRANSPL, V31, P1243, DOI 10.1093/ndt/gfv262; Lund H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07295-7; Meng A, 2003, EXP HEMATOL, V31, P1348, DOI 10.1016/j.exphem.2003.08.014; Meng AM, 2003, CANCER RES, V63, P5414; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Oosterhof N, 2018, CELL REP, V24, P1203, DOI 10.1016/j.celrep.2018.06.113; Orchard PJ, 2010, SEMIN HEMATOL, V47, P70, DOI 10.1053/j.seminhematol.2009.10.006; Peake K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00075; Peake K, 2015, JOVE-J VIS EXP, DOI 10.3791/52553; Probin V, 2006, J PHARMACOL EXP THER, V319, P551, DOI 10.1124/jpet.106.107771; Reu P, 2017, CELL REP, V20, P779, DOI 10.1016/j.celrep.2017.07.004; Sailor KA, 2016, NEURON, V91, P384, DOI 10.1016/j.neuron.2016.06.004; SASAKI K, 1988, CANCER, V62, P989, DOI 10.1002/1097-0142(19880901)62:5<989::AID-CNCR2820620525>3.0.CO;2-U; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shemer A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07548-5; Sun GJ, 2013, J NEUROSCI, V33, P11400, DOI 10.1523/JNEUROSCI.1374-13.2013; Tay TL, 2017, NAT NEUROSCI, V20, P793, DOI 10.1038/nn.4547; Valley MT, 2009, FRONT NEUROSCI-SWITZ, V3, DOI 10.3389/neuro.22.003.2009; van Oijen MGCT, 1998, AM J CLIN PATHOL, V110, P24; Wolf NI, 2020, ANN CLIN TRANSL NEUR, V7, P169, DOI 10.1002/acn3.50975; Xu Z, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108041; Zhan LH, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000134	48	9	9	3	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					517	+		10.1038/s41591-022-01691-9	http://dx.doi.org/10.1038/s41591-022-01691-9		FEB 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35190726	hybrid			2022-12-27	WOS:000758992300001
J	Kjeldsen, JW; Lorentzen, CL; Martinenaite, E; Ellebaek, E; Donia, M; Holmstroem, RB; Klausen, TW; Madsen, CO; Ahmed, SM; Weis-Banke, SE; Holmstrom, MO; Hendel, HW; Ehrnrooth, E; Zocca, MB; Pedersen, AW; Andersen, MH; Svane, IM				Kjeldsen, Julie Westerlin; Lorentzen, Cathrine Lund; Martinenaite, Evelina; Ellebaek, Eva; Donia, Marco; Holmstroem, Rikke Boedker; Klausen, Tobias Wirenfeldt; Madsen, Cecilie Oelvang; Ahmed, Shamaila Munir; Weis-Banke, Stine Emilie; Holmstrom, Morten Orebo; Hendel, Helle Westergren; Ehrnrooth, Eva; Zocca, Mai-Britt; Pedersen, Ayako Wakatsuki; Andersen, Mads Hald; Svane, Inge Marie			A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma	NATURE MEDICINE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; ADOPTIVE CELL THERAPY; PD-1 BLOCKADE; LUNG-CANCER; RESPONSES; IPILIMUMAB; ANTI-PD-1; SURVIVAL	Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study (, NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7-90.5%) was reached, with 43% (CI, 27.4-60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4-69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of >93% of patients during vaccination. Vaccine-reactive T cells comprised CD4(+) and CD8(+) T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach.	[Kjeldsen, Julie Westerlin; Lorentzen, Cathrine Lund; Martinenaite, Evelina; Ellebaek, Eva; Donia, Marco; Holmstroem, Rikke Boedker; Klausen, Tobias Wirenfeldt; Madsen, Cecilie Oelvang; Ahmed, Shamaila Munir; Weis-Banke, Stine Emilie; Holmstrom, Morten Orebo; Andersen, Mads Hald; Svane, Inge Marie] Copenhagen Univ Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark; [Martinenaite, Evelina; Ehrnrooth, Eva; Zocca, Mai-Britt; Pedersen, Ayako Wakatsuki] IO Biotech Aps, Copenhagen, Denmark; [Hendel, Helle Westergren] Copenhagen Univ Hosp, Dept Clin Physiol & Nucl Med, Herlev, Denmark; [Andersen, Mads Hald] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen	Svane, IM (corresponding author), Copenhagen Univ Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark.	inge.mane.svane@regionh.dk		Svane, Inge Marie/0000-0002-9451-6037; Ellebaek, Eva/0000-0001-6748-9232; Donia, Marco/0000-0003-4966-9752; Holmstrom, Rikke/0000-0002-5476-9937; Lorentzen, Cathrine Lund/0000-0003-2131-2188; Andersen, Mads Hald/0000-0002-2914-9605; Weis-Banke, Stine Emilie/0000-0002-6037-494X	Herlev Hospital; Oncology Department at Herlev Hospital; IO Biotech; CCIT-DK	Herlev Hospital; Oncology Department at Herlev Hospital; IO Biotech; CCIT-DK	We thank all patients and their relatives for being a part of the trial. We thank o. Met, M. Jonassen, S. Ullitz Faerch, B. Saxild, S. Wendt and C. GrOnhOj for technical support. We thank M. Cumberbatch for input with translational analysis. We thank the nurses at clinic 5 and the head of the Oncology Department at Herlev and Gentofte Hospital, L. SengelOv. The study was funded through a research funding agreement between IO Biotech and the CCIT-DK, Herlev Hospital and the Oncology Department at Herlev Hospital.	Ahmad SM, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.50; Ahmad SM, 2014, LEUKEMIA, V28, P236, DOI 10.1038/leu.2013.261; Ahmad SM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1202391; Ahmad SM, 2016, CANCER IMMUNOL IMMUN, V65, P797, DOI 10.1007/s00262-015-1783-4; Andersen MH, 2019, CELL STRESS, V3, P139, DOI 10.15698/cst2019.05.185; Andersen MH, 2019, SEMIN IMMUNOPATHOL, V41, P1, DOI 10.1007/s00281-018-0711-z; Andersen MH, 2018, CANCER RES, V78, P1379, DOI 10.1158/0008-5472.CAN-17-3607; Andersen MH, 2012, ONCOIMMUNOLOGY, V1, P1211, DOI 10.4161/onci.20780; Andersen MH, 2012, CANCER IMMUNOL IMMUN, V61, P1289, DOI 10.1007/s00262-012-1234-4; Andersen R, 2016, CLIN CANCER RES, V22, P3734, DOI 10.1158/1078-0432.CCR-15-1879; Ascierto PA, 2017, ANN ONCOL, V28; Bastholt L, 2019, EUR J CANCER, V119, P122, DOI 10.1016/j.ejca.2019.06.022; Benjamini Y, 2009, ANN APPL STAT, V3, P179, DOI 10.1214/08-AOAS194; Bookout Angie L, 2006, Curr Protoc Mol Biol, VChapter 15, DOI 10.1002/0471142727.mb1508s73; Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Dey S, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000605; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Donia M, 2012, SCAND J IMMUNOL, V75, P157, DOI 10.1111/j.1365-3083.2011.02640.x; Ellebaek E, 2021, CANCER EPIDEMIOL, V73, DOI 10.1016/j.canep.2021.101943; Godard B, 2004, HUM IMMUNOL, V65, P1307, DOI 10.1016/j.humimm.2004.06.006; Hobo W, 2010, BLOOD, V116, P4501, DOI 10.1182/blood-2010-04-278739; Huang XZ, 2020, IMMUNOTHERAPY-UK, V12, P587, DOI 10.2217/imt-2019-0124; Iversen TZ, 2014, CLIN CANCER RES, V20, P221, DOI 10.1158/1078-0432.CCR-13-1560; Jorgensen NG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.595035; Khozin S, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx187; Kjeldsen JW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02145; Kugel CH, 2018, CLIN CANCER RES, V24, P5347, DOI 10.1158/1078-0432.CCR-18-1116; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Long G, 2020, J IMMUNOTHER CANCER, V8, pA261, DOI 10.1136/jitc-2020-SITC2020.0429; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Meier A, 2005, CANCER IMMUNOL IMMUN, V54, P219, DOI 10.1007/s00262-004-0578-9; Met O, 2011, BREAST CANCER RES TR, V125, P395, DOI 10.1007/s10549-010-0844-9; Moodie Z, 2010, CANCER IMMUNOL IMMUN, V59, P1489, DOI 10.1007/s00262-010-0875-4; Mullinax JE, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00044; Munir S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23991; Munir S, 2013, CANCER RES, V73, P1764, DOI 10.1158/0008-5472.CAN-12-3507; Munir S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034568; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Poh A, 2018, CANCER DISCOV, V8, P670, DOI 10.1158/2159-8290.CD-ND2018-004; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robins H, 2012, J IMMUNOL METHODS, V375, P14, DOI 10.1016/j.jim.2011.09.001; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sorensen RB, 2011, CANCER RES, V71, P2038, DOI 10.1158/0008-5472.CAN-10-3403; Sorensen RB, 2011, BLOOD, V117, P2200, DOI 10.1182/blood-2010-06-288498; Sorensen RB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006910; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Vilain RE, 2017, CLIN CANCER RES, V23, P5024, DOI 10.1158/1078-0432.CCR-16-0698; Wang TT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03915-4; Weber JS, 2016, ONCOLOGIST, V21, P1230, DOI 10.1634/theoncologist.2016-0055; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yan X, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01671	59	31	33	9	30	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2212	+		10.1038/s41591-021-01544-x	http://dx.doi.org/10.1038/s41591-021-01544-x		DEC 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887574	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000728466100007
J	O'Leary, K				O'Leary, Karen			The Yearbook	NATURE MEDICINE			English	Editorial Material								We take stock of who made headlines this year for enlightening or disappointing us in 2021.				karen.oleary@nature.com							0	0	0	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2052	2053		10.1038/s41591-021-01603-3	http://dx.doi.org/10.1038/s41591-021-01603-3			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34907392	Bronze			2022-12-27	WOS:000730754000002
J	Cordoba, S; Onuoha, S; Thomas, S; Pignataro, DS; Hough, R; Ghorashian, S; Vora, A; Bonney, D; Veys, P; Rao, K; Lucchini, G; Chiesa, R; Chu, J; Clark, L; Fung, MM; Smith, K; Peticone, C; Al-Hajj, M; Baldan, V; Ferrari, M; Srivastava, S; Jha, R; Vargas, FA; Duffy, K; Day, W; Virgo, P; Wheeler, L; Hancock, J; Farzaneh, F; Domning, S; Zhang, YY; Khokhar, NZ; Peddareddigari, VGR; Wynn, R; Pule, M; Amrolia, PJ				Cordoba, Shaun; Onuoha, Shimobi; Thomas, Simon; Pignataro, Daniela Soriano; Hough, Rachael; Ghorashian, Sara; Vora, Ajay; Bonney, Denise; Veys, Paul; Rao, Kanchan; Lucchini, Giovanna; Chiesa, Robert; Chu, Jan; Clark, Liz; Fung, Mei Mei; Smith, Koval; Peticone, Carlotta; Al-Hajj, Muhammad; Baldan, Vania; Ferrari, Mathieu; Srivastava, Saket; Jha, Ram; Vargas, Frederick Arce; Duffy, Kevin; Day, William; Virgo, Paul; Wheeler, Lucy; Hancock, Jeremy; Farzaneh, Farzin; Domning, Sabine; Zhang, Yiyun; Khokhar, Nushmia Z.; Peddareddigari, Vijay G. R.; Wynn, Robert; Pule, Martin; Amrolia, Persis J.			CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial	NATURE MEDICINE			English	Article							CHIMERIC RECEPTORS; THERAPY	Bicistronic CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in pediatric and young adult patients with B cell acute lymphoblastic leukemia, with relapses associated with limited CAR T cell persistence. Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss. Dual antigen targeting could potentially prevent this, but the clinical safety and efficacy of CAR T cells targeting both CD19 and CD22 remain unclear. We conducted a phase 1 trial in pediatric and young adult patients with relapsed or refractory B-ALL (n = 15) to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 CARs (AMELIA trial, EUDRA CT 2016-004680-39). The primary endpoints were the incidence of grade 3-5 toxicity in the dose-limiting toxicity period and the frequency of dose-limiting toxicities. Secondary endpoints included the rate of morphological remission (complete response or complete response with incomplete bone marrow recovery) with minimal residual disease-negative response, as well as the frequency and severity of adverse events, expansion and persistence of AUTO3, duration of B cell aplasia, and overall and event-free survival. The study endpoints were met. AUTO3 showed a favorable safety profile, with no dose-limiting toxicities or cases of AUTO3-related severe cytokine release syndrome or neurotoxicity reported. At 1 month after treatment the remission rate (that is, complete response or complete response with incomplete bone marrow recovery) was 86% (13 of 15 patients). The 1 year overall and event-free survival rates were 60% and 32%, respectively. Relapses were probably due to limited long-term AUTO3 persistence. Strategies to improve CAR T cell persistence are needed to fully realize the potential of dual targeting CAR T cell therapy in B-ALL.	[Cordoba, Shaun; Onuoha, Shimobi; Thomas, Simon; Pignataro, Daniela Soriano; Clark, Liz; Fung, Mei Mei; Smith, Koval; Peticone, Carlotta; Al-Hajj, Muhammad; Baldan, Vania; Ferrari, Mathieu; Srivastava, Saket; Jha, Ram; Vargas, Frederick Arce; Duffy, Kevin; Day, William; Zhang, Yiyun; Khokhar, Nushmia Z.; Peddareddigari, Vijay G. R.; Pule, Martin] Autolus PLC, London, England; [Hough, Rachael] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England; [Ghorashian, Sara; Vora, Ajay; Veys, Paul; Rao, Kanchan; Lucchini, Giovanna; Chiesa, Robert; Chu, Jan; Amrolia, Persis J.] Great Ormond St Hosp Sick Children, Dept Bone Marrow Transplant, London, England; [Ghorashian, Sara; Vora, Ajay; Veys, Paul; Rao, Kanchan; Lucchini, Giovanna; Chiesa, Robert; Chu, Jan; Amrolia, Persis J.] Great Ormond St Hosp Sick Children, Dept Haematol, London, England; [Bonney, Denise; Wynn, Robert] Royal Manchester Childrens Hosp, Dept Blood & Marrow Transplant, Manchester, Lancs, England; [Virgo, Paul; Wheeler, Lucy] North Bristol NHS Trust, Dept Immunol & Immunogenet, Bristol, Avon, England; [Hancock, Jeremy] North Bristol NHS Trust, Bristol Genet Lab, Bristol, Avon, England; [Farzaneh, Farzin; Domning, Sabine] Kings Coll London, Rayne Inst, London, England; [Pule, Martin] UCL, Canc Inst, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Royal Manchester Children's Hospital; North Bristol NHS Trust; North Bristol NHS Trust; University of London; King's College London; University of London; University College London	Pule, M (corresponding author), Autolus PLC, London, England.; Pule, M (corresponding author), UCL, Canc Inst, London, England.	m.pule@autolus.com		Pule, Martin/0000-0002-8347-9867	Biotechnology and Biological Sciences Research Council [BB/E005896/1, BB/D014301/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Finney HM, 2004, J IMMUNOL, V172, P104, DOI 10.4049/jimmunol.172.1.104; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Gao SH, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-55; Gardner R, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113126; Gardner RA, 2019, BLOOD, V134, P2149, DOI 10.1182/blood.2019001463; Gattinoni L, 2012, NAT REV CANCER, V12, P671, DOI 10.1038/nrc3322; Ghassemi S, 2018, CANCER IMMUNOL RES, V6, P1100, DOI 10.1158/2326-6066.CIR-17-0405; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Imai C, 2004, LEUKEMIA, V18, P676, DOI 10.1038/sj.leu.2403302; Joss L, 1998, ANAL BIOCHEM, V261, P203, DOI 10.1006/abio.1998.2744; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Ma BY, 2005, BLOOD, V106, P2002, DOI 10.1182/blood-2004-04-1622; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Oliveira G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8265; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Pezzutto A., 1986, LEUKOCYTE TYPING 2, P391, DOI [10.1007/978-1-4612-4848-4_33, DOI 10.1007/978-1-4612-4848-4_33]; Philipson BI, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8248; Porter D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0571-y; Rivat C, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125916; Schultz LM, 2019, BLOOD, V134, DOI 10.1182/blood-2019-129411; Shah BD, 2021, BLOOD, V138, P11, DOI 10.1182/blood.2020009098; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Skolnik JM, 2008, J CLIN ONCOL, V26, P190, DOI 10.1200/JCO.2007.12.7712; Spiegel JY, 2021, NAT MED, V27, P1419, DOI 10.1038/s41591-021-01436-0; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Wang N, 2020, BLOOD, V135, P17, DOI 10.1182/blood.2019000017; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Zhu K, 2014, PROTEINS, V82, P1646, DOI 10.1002/prot.24551	30	27	30	6	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1797	+		10.1038/s41591-021-01497-1	http://dx.doi.org/10.1038/s41591-021-01497-1		OCT 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642489	Green Published, hybrid			2022-12-27	WOS:000706587600003
J	Sahoo, SS; Pastor, VB; Goodings, C; Voss, RK; Kozyra, EJ; Szvetnik, A; Noellke, P; Dworzak, M; Stary, J; Locatelli, F; Masetti, R; Schmugge, M; De Moerloose, B; Catala, A; Kallay, K; Turkiewicz, D; Hasle, H; Buechner, J; Jahnukainen, K; Ussowicz, M; Polychronopoulou, S; Smith, OP; Fabri, O; Barzilai, S; de Haas, V; Baumann, I; Schwarz-Furlan, S; Niewisch, MR; Sauer, MG; Burkhardt, B; Lang, P; Bader, P; Beier, R; Muller, I; Albert, MH; Meisel, R; Schulz, A; Cario, G; Panda, PK; Wehrle, J; Hirabayashi, S; Derecka, M; Durruthy-Durruthy, R; Gohring, G; Yoshimi-Noellke, A; Ku, M; Lebrecht, D; Erlacher, M; Flotho, C; Strahm, B; Niemeyer, CM; Wlodarski, MW				Sahoo, Sushree S.; Pastor, Victor B.; Goodings, Charnise; Voss, Rebecca K.; Kozyra, Emilia J.; Szvetnik, Amina; Noellke, Peter; Dworzak, Michael; Stary, Jan; Locatelli, Franco; Masetti, Riccardo; Schmugge, Markus; De Moerloose, Barbara; Catala, Albert; Kallay, Krisztian; Turkiewicz, Dominik; Hasle, Henrik; Buechner, Jochen; Jahnukainen, Kirsi; Ussowicz, Marek; Polychronopoulou, Sophia; Smith, Owen P.; Fabri, Oksana; Barzilai, Shlomit; de Haas, Valerie; Baumann, Irith; Schwarz-Furlan, Stephan; Niewisch, Marena R.; Sauer, Martin G.; Burkhardt, Birgit; Lang, Peter; Bader, Peter; Beier, Rita; Mueller, Ingo; Albert, Michael H.; Meisel, Roland; Schulz, Ansgar; Cario, Gunnar; Panda, Pritam K.; Wehrle, Julius; Hirabayashi, Shinsuke; Derecka, Marta; Durruthy-Durruthy, Robert; Goehring, Gudrun; Yoshimi-Noellke, Ayami; Ku, Manching; Lebrecht, Dirk; Erlacher, Miriam; Flotho, Christian; Strahm, Brigitte; Niemeyer, Charlotte M.; Wlodarski, Marcin W.		European Working Grp MDS Chil	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes	NATURE MEDICINE			English	Article							SAMD9L MUTATIONS CAUSE; BONE-MARROW FAILURE; MIRAGE SYNDROME; MYELODYSPLASTIC SYNDROME; PATHOGENICITY; IDENTIFICATION; DISEASES; VARIANTS; PATTERNS; DISTINCT	This analysis of a large, clinically annotated cohort of individuals with predisposition to myelodysplastic syndromes reveals insights into the genetic determinants of disease progression and their relationship with clinical manifestations and therapy outcome. Germline SAMD9 and SAMD9L mutations (SAMD9/9L(mut)) predispose to myelodysplastic syndromes (MDS) with propensity for somatic rescue. In this study, we investigated a clinically annotated pediatric MDS cohort (n = 669) to define the prevalence, genetic landscape, phenotype, therapy outcome and clonal architecture of SAMD9/9L syndromes. In consecutively diagnosed MDS, germline SAMD9/9L(mut) accounted for 8% and were mutually exclusive with GATA2 mutations present in 7% of the cohort. Among SAMD9/9L(mut) cases, refractory cytopenia was the most prevalent MDS subtype (90%); acquired monosomy 7 was present in 38%; constitutional abnormalities were noted in 57%; and immune dysfunction was present in 28%. The clinical outcome was independent of germline mutations. In total, 67 patients had 58 distinct germline SAMD9/9L(mut) clustering to protein middle regions. Despite inconclusive in silico prediction, 94% of SAMD9/9L(mut) suppressed HEK293 cell growth, and mutations expressed in CD34(+) cells induced overt cell death. Furthermore, we found that 61% of SAMD9/9L(mut) patients underwent somatic genetic rescue (SGR) resulting in clonal hematopoiesis, of which 95% was maladaptive (monosomy 7 +/- cancer mutations), and 51% had adaptive nature (revertant UPD7q, somatic SAMD9/9L(mut)). Finally, bone marrow single-cell DNA sequencing revealed multiple competing SGR events in individual patients. Our findings demonstrate that SGR is common in SAMD9/9L(mut) MDS and exemplify the exceptional plasticity of hematopoiesis in children.	[Sahoo, Sushree S.; Goodings, Charnise; Wlodarski, Marcin W.] St Jude Childrens Res Hosp, Dept Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Sahoo, Sushree S.; Pastor, Victor B.; Voss, Rebecca K.; Kozyra, Emilia J.; Szvetnik, Amina; Noellke, Peter; Niewisch, Marena R.; Panda, Pritam K.; Hirabayashi, Shinsuke; Yoshimi-Noellke, Ayami; Ku, Manching; Lebrecht, Dirk; Erlacher, Miriam; Flotho, Christian; Strahm, Brigitte; Niemeyer, Charlotte M.; Wlodarski, Marcin W.] Univ Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, Med Ctr,Fac Med, Freiburg, Germany; [Kozyra, Emilia J.] Univ Freiburg, Fac Biol, Freiburg, Germany; [Dworzak, Michael] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat, Vienna, Austria; [Dworzak, Michael] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Stary, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Locatelli, Franco] Sapienza Univ Rome, Dept Pediat Hematol & Oncol, IRCCS Osped Pediat Bambino Gesu, Rome, Italy; [Masetti, Riccardo] IRCCS Azienda Osped Univ Bologna, Paediat Oncol & Haematol, Bologna, Italy; [Schmugge, Markus] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [De Moerloose, Barbara] Univ Ghent, Dept Paediat Haematol Oncol, Hosp Ghent, Ghent, Belgium; [Catala, Albert] Hosp San Juan Dios, Dept Hematol & Oncol, Barcelona, Spain; [Kallay, Krisztian] Cent Hosp Southern Pest, Dept Pediat Hematol & Stem Cell Transplant, Natl Inst Hematol & Infect Dis, Budapest, Hungary; [Turkiewicz, Dominik] Skane Univ Hosp, Dept Pediat Oncol Hematol, Lund, Sweden; [Hasle, Henrik] Aarhus Univ Hosp, Dept Pediat, Aarhus, Denmark; [Buechner, Jochen] Oslo Univ Hosp, Dept Pediat Hematol & Oncol, Oslo, Norway; [Jahnukainen, Kirsi] Univ Helsinki, Div Hematol Oncol, Helsinki, Finland; [Jahnukainen, Kirsi] Univ Helsinki, SCT Childrens Hosp, Helsinki, Finland; [Jahnukainen, Kirsi] Helsinki Univ Hosp, Helsinki, Finland; [Ussowicz, Marek] Wroclaw Med Univ, Dept Paediat Bone Marrow Transplantat Oncol & Hem, Wroclaw, Poland; [Polychronopoulou, Sophia] Aghia Sophia Childrens Hosp, Dept Pediat Hematol Oncol, Athens, Greece; [Smith, Owen P.] Childrens Hlth Ireland Crumlin, Dept Pediat Haematol Oncol, Dublin, Ireland; [Fabri, Oksana] Comenius Univ, Natl Inst Childrens Dis, Dept Haematol & Transfusiol, Fac Med, Bratislava, Slovakia; [Barzilai, Shlomit] Tel Aviv Univ, Pediat Hematol Oncol, Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Barzilai, Shlomit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [de Haas, Valerie] Dutch Childhood Oncol Grp, Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Baumann, Irith; Schwarz-Furlan, Stephan] Klinikum Kaufbeuren Ravensburg, Inst Pathol, Kaufbeuren, Germany; [Schwarz-Furlan, Stephan] Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany; [Sauer, Martin G.] Hannover Med Sch, Dept Pediat Hematol & Oncol, Hannover, Germany; [Burkhardt, Birgit] Univ Hosp Muenster, Pediat Hematol & Oncol, Munster, Germany; [Lang, Peter] Univ Tubingen, Childrens Univ Hosp, Dept Hematol Oncol & Gen Pediat, Tubingen, Germany; [Bader, Peter] Univ Hosp Frankfurt, Dept Children & Adolescents, Div Stem Cell Transplantat & Immunol, Frankfurt, Germany; [Beier, Rita] Univ Hosp Essen, Pediat Haematol & Oncol, Essen, Germany; [Mueller, Ingo] Univ Med Ctr Hamburg Eppendorf, Clin Pedatr Hematol & Oncol, Div Pediat Hematol & Oncol, Hamburg, Germany; [Albert, Michael H.] Ludwig Maximilians Univ Munchen, Univ Hosp, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany; [Meisel, Roland] Heinrich Heine Univ, Med Fac, Div Pediat Stem Cell Therapy, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Schulz, Ansgar] Univ Med Ctr Ulm, Dept Pediat, Ulm, Germany; [Cario, Gunnar] Univ Hosp Schleswig Holstein, Dept Pediat, Campus Kiel, Kiel, Germany; [Wehrle, Julius] Univ Freiburg, Med Ctr, Dept Med 1, Fac Med, Freiburg, Germany; [Wehrle, Julius] Univ Freiburg, Inst Digitalizat Med, Fac Med, Freiburg, Germany; [Durruthy-Durruthy, Robert] Mission Bio Inc, San Francisco, CA USA; [Goehring, Gudrun] Hannover Med Sch, Dept Human Genet, Hannover, Germany; [Erlacher, Miriam; Flotho, Christian; Niemeyer, Charlotte M.] German Canc Consortium DKTK, Heidelberg, Germany	St Jude Children's Research Hospital; University of Freiburg; University of Freiburg; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna; Saint Anna Children's Hospital; Charles University Prague; Motol University Hospital; IRCCS Bambino Gesu; Sapienza University Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University Children's Hospital Zurich; Ghent University; University of Barcelona; Lund University; Skane University Hospital; Aarhus University; University of Oslo; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Wroclaw Medical University; The Aghia Sophia Children's Hospital; Comenius University Bratislava; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Dutch Childhood Oncology Group; University of Erlangen Nuremberg; Hannover Medical School; University of Munster; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Hamburg; University Medical Center Hamburg-Eppendorf; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Heinrich Heine University Dusseldorf; Ulm University; University of Kiel; Schleswig Holstein University Hospital; University of Freiburg; University of Freiburg; Hannover Medical School; Helmholtz Association; German Cancer Research Center (DKFZ)	Wlodarski, MW (corresponding author), St Jude Childrens Res Hosp, Dept Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.; Wlodarski, MW (corresponding author), Univ Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, Med Ctr,Fac Med, Freiburg, Germany.	marcin.wlodarski@stjude.org	Ussowicz, Marek/T-7487-2019; PANDA, PRITAM Kumar/E-8002-2015; Sahoo, Sushree/AAA-8361-2022; Erlacher, Miriam/GRR-7418-2022; Masetti, Riccardo/G-6837-2011	Ussowicz, Marek/0000-0001-5725-4835; PANDA, PRITAM Kumar/0000-0003-4879-2302; Erlacher, Miriam/0000-0002-7261-1447; Masetti, Riccardo/0000-0002-1264-057X; Schmugge, Markus/0000-0003-4745-8572; Muller, Ingo/0000-0002-7477-6632; Niewisch, Marena R./0000-0002-9565-5565; CATALA, ALBERT/0000-0003-0133-1752; Noellke, Peter/0000-0002-0281-4732; Kozyra, Emilia/0000-0003-1107-8818	Deutsche Krebshilfe Max-Eder-Nachwuchsgruppenprogramm [70109005]; ERA PerMED GATA2-HuMo German Federal Ministry of Education and Research (BMBF) [2018-123/01KU1904]; German Cancer Consortium DKTK; Fritz-Thyssen Foundation [10.17.1.026MN]; Deutsche Kinderkrebsstifung [2017.03]; BMBF MyPred [01GM1911A]; Jose Carreras Leukamie-Stiftung; DFG [SFB1160]; AIRC (Associazione Italiana Ricerca sul Cancro) [21147]; Cancer Center Core Grant [CA021765]; Spemann Graduate School of Biology and Medicine scholarship; Cooperative Centers of Excellence in Hematology NIDDK U54 grant [DK106829]	Deutsche Krebshilfe Max-Eder-Nachwuchsgruppenprogramm(Deutsche Krebshilfe); ERA PerMED GATA2-HuMo German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Cancer Consortium DKTK; Fritz-Thyssen Foundation; Deutsche Kinderkrebsstifung; BMBF MyPred(Federal Ministry of Education & Research (BMBF)); Jose Carreras Leukamie-Stiftung; DFG(German Research Foundation (DFG)); AIRC (Associazione Italiana Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Cancer Center Core Grant; Spemann Graduate School of Biology and Medicine scholarship; Cooperative Centers of Excellence in Hematology NIDDK U54 grant	This work was supported by grants from the Deutsche Krebshilfe Max-Eder-Nachwuchsgruppenprogramm 70109005 (to M.W.W.), ERA PerMED GATA2-HuMo German Federal Ministry of Education and Research (BMBF) 2018-123/01KU1904 (to M.W.W.), German Cancer Consortium DKTK (to M.W.W. and C.M.N.), Fritz-Thyssen Foundation 10.17.1.026MN (to M.W.W.), Deutsche Kinderkrebsstifung 2017.03 (to M.W.W.), BMBF MyPred 01GM1911A (to M.W.W., M.E., C.M.N., G.G., B.S. and C.F.), Jose Carreras Leukamie-Stiftung (to V.B.P.), DFG SFB1160 (to M.K.), AIRC (Associazione Italiana Ricerca sul Cancro) Special Program Metastatic disease: the key unmet need in oncology 5 per mille 2018, project code 21147 (to F.L.), Cancer Center Core Grant (CA021765, to St. Jude) and Cooperative Centers of Excellence in Hematology NIDDK U54 grant (DK106829 to Fred Hutchinson Cancer Research Center). S.S.S. is a previous recipient of a Spemann Graduate School of Biology and Medicine scholarship. We thank S. Krueger, C. Jaeger, S. Zolles, S. Hollander, M. Teller and A.-R. Kaya for excellent laboratory assistance; A. Breier, A. Fischer, W. Truckenmueller, M. Siskou-Zwecker, A. Gebert, M. Boerries and H. Busch for data management (all University of Freiburg); D. Cullins (St. Jude) for FACS services; and P. Mitra for technical support. We extend great appreciation to M. Weiss and J. Crispino (St. Jude) for valuable and constructive discussions. We also acknowledge the Hilda Biobank Freiburg and Genomics Core Facility at the German Cancer Research Center/DKFZ for specimen processing. Patient care within the EWOG-MDS consortium would not have been possible without the continuous effort of the National Reference Pathologists, National Reference Cytogeneticists, physicians, nurses and other staff of pediatric oncology units and transplant centers in all 17 participating countries (www.ewog-mds-saa.org).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ahmed IA, 2019, BIOL BLOOD MARROW TR, V25, P2186, DOI 10.1016/j.bbmt.2019.07.007; Allenspach EJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20201195; Amano N, 2017, EUR J ENDOCRINOL, V177, P187, DOI 10.1530/EJE-17-0027; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Baumann, 2017, WHO CLASSIFICATION T; Bluteau O, 2018, BLOOD, V131, P717, DOI 10.1182/blood-2017-09-806489; Buonocore F, 2017, J CLIN INVEST, V127, P1700, DOI 10.1172/JCI91913; Cheah JJC, 2019, HAEMATOLOGICA, V104, DOI 10.3324/haematol.2018.207316; Chen DH, 2016, AM J HUM GENET, V98, P1146, DOI 10.1016/j.ajhg.2016.04.009; Cordero MD, 2018, J AUTOIMMUN, V91, P13, DOI 10.1016/j.jaut.2018.03.002; Csillag B, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27589; de Jesus AA, 2020, J CLIN INVEST, V130, P1669, DOI 10.1172/JCI129301; de Matos AL, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-121; Duployez N, 2020, LEUKEMIA, V34, P1450, DOI 10.1038/s41375-019-0675-6; Erickson RP, 2010, MUTAT RES-REV MUTAT, V705, P96, DOI 10.1016/j.mrrev.2010.04.002; Gelb BD, 2018, GENET MED, V20, P1334, DOI 10.1038/gim.2018.3; Gohring G, 2010, BLOOD, V116, P3766, DOI 10.1182/blood-2010-04-280313; Grobner SN, 2018, NATURE, V555, P321, DOI 10.1038/nature25480; Huisman SA, 2013, J MED GENET, V50, P339, DOI 10.1136/jmedgenet-2012-101477; Ioannidis NM, 2016, AM J HUM GENET, V99, P877, DOI 10.1016/j.ajhg.2016.08.016; Ishiwa S, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02011-4; Jeffries L, 2018, AM J MED GENET A, V176, P415, DOI 10.1002/ajmg.a.38557; Jiang QJ, 2011, J INVEST DERMATOL, V131, P1428, DOI 10.1038/jid.2011.61; Jordan DM, 2015, NATURE, V524, P225, DOI 10.1038/nature14497; Kaasinen E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09198-7; Kim YM, 2018, BMC MED GENET, V19, DOI 10.1186/s12881-018-0546-4; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lelpe DD, 2004, J MOL BIOL, V343, P1, DOI 10.1016/j.jmb.2004.08.023; Li CF, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-92; Lindsley RC, 2017, NEW ENGL J MED, V376, P536, DOI 10.1056/NEJMoa1611604; Liu J, 2015, J VIROL, V89, P1925, DOI 10.1128/JVI.02262-14; Liu J, 2011, J VIROL, V85, P3270, DOI 10.1128/JVI.02243-10; Liu XM, 2016, HUM MUTAT, V37, P235, DOI 10.1002/humu.22932; Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795; Mather CA, 2016, GENET MED, V18, P1269, DOI 10.1038/gim.2016.44; Mekhedov SL, 2017, BIOL DIRECT, V12, DOI 10.1186/s13062-017-0185-2; Meng XZ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006884; Meng XZ, 2015, P NATL ACAD SCI USA, V112, P14858, DOI 10.1073/pnas.1515354112; Mengen E, 2020, J CLIN RES PEDIATR E, V12, P206, DOI 10.4274/jcrpe.galenos.2019.2019.0053; Nagamachi A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140147; Nagamachi A, 2013, CANCER CELL, V24, P305, DOI 10.1016/j.ccr.2013.08.011; Narumi S, 2016, NAT GENET, V48, P792, DOI 10.1038/ng.3569; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Nounamo B, 2017, VIROLOGY, V503, P94, DOI 10.1016/j.virol.2017.01.004; Nykamp K, 2017, GENET MED, V19, P1105, DOI 10.1038/gim.2017.37; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Pastor V, 2017, LEUKEMIA, V31, P759, DOI 10.1038/leu.2016.342; Pastor VB, 2018, HAEMATOLOGICA, V103, P427, DOI 10.3324/haematol.2017.180778; Perisa MP, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27726; Quang D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/bioinformatics/btu703; Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407; Revy P, 2019, NAT REV GENET, V20, P582, DOI 10.1038/s41576-019-0139-x; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Sarthy J, 2018, BLOOD ADV, V2, P120, DOI 10.1182/bloodadvances.2017012682; Schwartz JR, 2017, LEUKEMIA, V31, P1827, DOI 10.1038/leu.2017.142; Schwartz JR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01590-5; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Shihab HA, 2015, BIOINFORMATICS, V31, P1536, DOI 10.1093/bioinformatics/btv009; Shima H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206184; Shima H, 2018, J MED GENET, V55, P81, DOI 10.1136/jmedgenet-2017-105020; Takaoka K, 2019, LEUKEMIA, V33, P1773, DOI 10.1038/s41375-019-0385-0; Tesi B, 2017, BLOOD, V129, P2266, DOI 10.1182/blood-2016-10-743302; Thomas ME, 2021, LEUKEMIA, V35, P3232, DOI 10.1038/s41375-021-01212-6; Thunstrom S, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1319-1; Topaz O, 2006, AM J HUM GENET, V79, P759, DOI 10.1086/508069; van der Velde KJ, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1141-7; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wlodarski MW, 2017, SEMIN HEMATOL, V54, P81, DOI 10.1053/j.seminhematol.2017.05.002; Wong JC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121086; Wu L, 2016, ONCOL LETT, V11, P945, DOI 10.3892/ol.2015.4000; Yoshida M, 2020, BRIT J HAEMATOL, V191, P835, DOI 10.1111/bjh.17006; Zhang MY, 2015, NAT GENET, V47, P180, DOI 10.1038/ng.3177	75	28	28	3	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1806	+		10.1038/s41591-021-01511-6	http://dx.doi.org/10.1038/s41591-021-01511-6		OCT 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34621053	Green Accepted			2022-12-27	WOS:000704942800003
J	Alonso, PL				Alonso, Pedro L.			Malaria: a problem to be solved and a time to be bold	NATURE MEDICINE			English	Editorial Material									[Alonso, Pedro L.] WHO, Global Malaria Programme, Geneva, Switzerland	World Health Organization	Alonso, PL (corresponding author), WHO, Global Malaria Programme, Geneva, Switzerland.	alonsop@who.int			World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Alonso P, 2017, LANCET, V390, P2532, DOI 10.1016/S0140-6736(17)33080-5; [Anonymous], 2000, B WORLD HEALTH ORGAN, V78, P868; Datoo MS, 2021, LANCET, V397, P1809, DOI 10.1016/S0140-6736(21)00943-0; Kleinschmidt I., 2016, LANCET, V9, P1325; Lengeler C, 2004, COCHRANE DB SYST REV, V2; Mwakingwe-Omari A, 2021, NATURE, V595, P289, DOI 10.1038/s41586-021-03684-z	6	5	5	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1506	1509		10.1038/s41591-021-01492-6	http://dx.doi.org/10.1038/s41591-021-01492-6		SEP 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34518678	Bronze			2022-12-27	WOS:000695470700006
J	Kyriazopoulou, E; Poulakou, G; Milionis, H; Metallidis, S; Adamis, G; Tsiakos, K; Fragkou, A; Rapti, A; Damoulari, C; Fantoni, M; Kalomenidis, I; Chrysos, G; Angheben, A; Kainis, I; Alexiou, Z; Castelli, F; Serino, FS; Tsilika, M; Bakakos, P; Nicastri, E; Tzavara, V; Kostis, E; Dagna, L; Koufargyris, P; Dimakou, K; Savvanis, S; Tzatzagou, G; Chini, M; Cavalli, G; Bassetti, M; Katrini, K; Kotsis, V; Tsoukalas, G; Selmi, C; Bliziotis, I; Samarkos, M; Doumas, M; Ktena, S; Masgala, A; Papanikolaou, I; Kosmidou, M; Myrodia, DM; Argyraki, A; Cardellino, CS; Koliakou, K; Katsigianni, EI; Rapti, V; Giannitsioti, E; Cingolani, A; Micha, S; Akinosoglou, K; Liatsis-Douvitsas, O; Symbardi, S; Gatselis, N; Mouktaroudi, M; Ippolito, G; Florou, E; Kotsaki, A; Netea, MG; Eugen-Olsen, J; Kyprianou, M; Panagopoulos, P; Dalekos, GN; Giamarellos-Bourboulis, EJ				Kyriazopoulou, Evdoxia; Poulakou, Garyfallia; Milionis, Haralampos; Metallidis, Simeon; Adamis, Georgios; Tsiakos, Konstantinos; Fragkou, Archontoula; Rapti, Aggeliki; Damoulari, Christina; Fantoni, Massimo; Kalomenidis, Ioannis; Chrysos, Georgios; Angheben, Andrea; Kainis, Ilias; Alexiou, Zoi; Castelli, Francesco; Serino, Francesco Saverio; Tsilika, Maria; Bakakos, Petros; Nicastri, Emanuele; Tzavara, Vassiliki; Kostis, Evangelos; Dagna, Lorenzo; Koufargyris, Panagiotis; Dimakou, Katerina; Savvanis, Spyridon; Tzatzagou, Glykeria; Chini, Maria; Cavalli, Giulio; Bassetti, Matteo; Katrini, Konstantina; Kotsis, Vasileios; Tsoukalas, George; Selmi, Carlo; Bliziotis, Ioannis; Samarkos, Michael; Doumas, Michael; Ktena, Sofia; Masgala, Aikaterini; Papanikolaou, Ilias; Kosmidou, Maria; Myrodia, Dimitra-Melia; Argyraki, Aikaterini; Cardellino, Chiara Simona; Koliakou, Katerina; Katsigianni, Eleni-Ioanna; Rapti, Vassiliki; Giannitsioti, Efthymia; Cingolani, Antonella; Micha, Styliani; Akinosoglou, Karolina; Liatsis-Douvitsas, Orestis; Symbardi, Styliani; Gatselis, Nikolaos; Mouktaroudi, Maria; Ippolito, Giuseppe; Florou, Eleni; Kotsaki, Antigone; Netea, Mihai G.; Eugen-Olsen, Jesper; Kyprianou, Miltiades; Panagopoulos, Periklis; Dalekos, George N.; Giamarellos-Bourboulis, Evangelos J.			Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	NATURE MEDICINE			English	Article							PNEUMONIA; HYPERINFLAMMATION; BLOCKADE	Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1 alpha/beta inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR >= 6 ng ml(-1), 85.9% (n = 510) of whom were receiving dexamethasone. At day 28, the adjusted proportional odds of having a worse clinical status (assessed by the 11-point World Health Organization Clinical Progression Scale (WHO-CPS)) with anakinra, as compared to placebo, was 0.36 (95% confidence interval 0.26-0.50). The median WHO-CPS decrease on day 28 from baseline in the placebo and anakinra groups was 3 and 4 points, respectively (odds ratio (OR) = 0.40, P < 0.0001); the respective median decrease of Sequential Organ Failure Assessment (SOFA) score on day 7 from baseline was 0 and 1 points (OR = 0.63, P = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45, P = 0.045), and hospital stay was shorter. The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1 alpha/beta inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor.	[Kyriazopoulou, Evdoxia; Damoulari, Christina; Tsilika, Maria; Koufargyris, Panagiotis; Katrini, Konstantina; Ktena, Sofia; Mouktaroudi, Maria; Kotsaki, Antigone; Giamarellos-Bourboulis, Evangelos J.] Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Sch Med, Athens, Greece; [Poulakou, Garyfallia; Myrodia, Dimitra-Melia; Rapti, Vassiliki] Natl & Kapodistrian Univ Athens, Dept Internal Med 3, Sch Med, Athens, Greece; [Milionis, Haralampos; Kosmidou, Maria] Univ Ioannina, Dept Internal Med 1, Sch Med, Ioannina, Greece; [Metallidis, Simeon] Aristotle Univ Thessaloniki, Dept Internal Med 1, Sch Med, Thessaloniki, Greece; [Adamis, Georgios] G Gennimatas Gen Hosp Athens, Dept Internal Med 1, Athens, Greece; [Tsiakos, Konstantinos; Rapti, Aggeliki] Sotiria Gen Hosp Chest Dis, Dept Pulm Med 2, Athens, Greece; [Fragkou, Archontoula; Savvanis, Spyridon] Elpis Gen Hosp, Dept Internal Med, Athens, Greece; [Fantoni, Massimo; Cingolani, Antonella] Fdn Policlin Gemelli IRCCS, Dipartimento Sci Lab & Infettivol, Rome, Italy; [Kalomenidis, Ioannis] Natl & Kapodistrian Univ Athens, Evangelismos Gen Hosp, Dept Crit Care & Pulm Med 1, Sch Med, Athens, Greece; [Chrysos, Georgios; Giannitsioti, Efthymia] Tzaneio Gen Hosp Piraeus, Dept Internal Med 2, Athens, Greece; [Angheben, Andrea; Cardellino, Chiara Simona] IRCSS Sacro Cuore Hosp, Dept Infect Trop Dis & Microbiol, Verona, Italy; [Kainis, Ilias] Sotiria Gen Hosp Chest Dis Athens, Dept Pulm Med 10, Athens, Greece; [Alexiou, Zoi] Thriasio Gen Hosp Eleusis, Dept Internal Med 2, Athens, Greece; [Castelli, Francesco] Univ Brescia, Brescia ASST Spedali Civili Hosp, Spedali Civili, Brescia, Italy; [Serino, Francesco Saverio] Hosp Jesolo, Dept Internal Med, Jesolo, Italy; [Bakakos, Petros] Natl & Kapodistrian Univ Athens, Dept Chest Med 1, Sch Med, Athens, Greece; [Nicastri, Emanuele; Ippolito, Giuseppe] Spallanzani Inst Rome, Dept Internal Med, Rome, Italy; [Tzavara, Vassiliki] Korgialene Benake Gen Hosp, Dept Internal Med, Athens, Greece; [Kostis, Evangelos] Natl & Kapodistrian Univ Athens, Dept Therapeut, Sch Med, Athens, Greece; [Dagna, Lorenzo; Cavalli, Giulio] IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, Milan, Italy; [Dagna, Lorenzo; Cavalli, Giulio] Univ Vita Salute San Raffaele, Milan, Italy; [Dimakou, Katerina] Sotiria Gen Hosp Chest Dis, Dept Pulm Med 5, Athens, Greece; [Tzatzagou, Glykeria] Papageorgiou Gen Hosp Thessaloniki, Dept Internal Med 1, Thessaloniki, Greece; [Chini, Maria] Korgialene Benake Gen Hosp, Dept Internal Med 3, Athens, Greece; [Chini, Maria] Korgialene Benake Gen Hosp, Infect Dis Unit, Athens, Greece; [Bassetti, Matteo] Univ Genoa, Osped Policlin San Martino IRCCS, Infect Dis Clin, Genoa, Italy; [Bassetti, Matteo] Univ Genoa, Dept Hlth Sci, Genoa, Italy; [Kotsis, Vasileios] Aristotle Univ Thessaloniki, Dept Internal Med 3, Sch Med, Thessaloniki, Greece; [Tsoukalas, George] Sotiria Gen Hosp Chest Dis, Dept Pulm Med 4, Athens, Greece; [Selmi, Carlo] Humanitas Res Hosp, Milan, Italy; [Bliziotis, Ioannis] Asklepieio Gen Hosp Voula, Dept Internal Med 1, Athens, Greece; [Samarkos, Michael] Natl & Kapodistrian Univ Athens, Dept Internal Med 1, Sch Med, Athens, Greece; [Doumas, Michael] Aristotle Univ Thessaloniki, Dept Propedeut Med 2, Sch Med, Thessaloniki, Greece; [Masgala, Aikaterini] Konstantopouleio Gen Hosp, Dept Internal Med 2, Athens, Greece; [Papanikolaou, Ilias] Gen Hosp Kerkyra, Dept Pulm Med, Corfu, Greece; [Argyraki, Aikaterini] Sotiria Gen Hosp Chest Dis, Dept Internal Med, Athens, Greece; [Koliakou, Katerina; Katsigianni, Eleni-Ioanna; Micha, Styliani; Liatsis-Douvitsas, Orestis; Mouktaroudi, Maria; Florou, Eleni; Kyprianou, Miltiades; Giamarellos-Bourboulis, Evangelos J.] Hellen Inst Study Sepsis, Athens, Greece; [Akinosoglou, Karolina] Univ Patras, Dept Internal Med, Rion, Greece; [Symbardi, Styliani] Thriasio Gen Hosp Eleusis, Dept Internal Med 1, Athens, Greece; [Gatselis, Nikolaos; Dalekos, George N.] Gen Univ Hosp Larissa, Dept Med, Larisa, Greece; [Gatselis, Nikolaos; Dalekos, George N.] Gen Univ Hosp Larissa, Res Lab Internal Med, Natl Expertise Ctr Greece Autoimmune Liver Dis, Larisa, Greece; [Netea, Mihai G.] Radboud Univ Nijmegen, Dept Internal Med, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, Bonn, Germany; [Eugen-Olsen, Jesper] Copenhagen Univ Hosp, Dept Clin Res, Amager, Denmark; [Eugen-Olsen, Jesper] Copenhagen Univ Hosp, Dept Clin Res, Hvidovre, Denmark; [Panagopoulos, Periklis] Democritus Univ Thrace, Dept Internal Med 2, Sch Med, Alexandroupolis, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; University of Ioannina; Aristotle University of Thessaloniki; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Athens Medical School; Evangelismos Hospital; National & Kapodistrian University of Athens; University of Brescia; Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Papageorgiou Hospital; University of Genoa; University of Genoa; Aristotle University of Thessaloniki; Athens Medical School; National & Kapodistrian University of Athens; Aristotle University of Thessaloniki; University of Patras; General University Hospital of Larissa; General University Hospital of Larissa; Radboud University Nijmegen; Radboud University Nijmegen; University of Bonn; University of Copenhagen; University of Copenhagen; Democritus University of Thrace	Giamarellos-Bourboulis, EJ (corresponding author), Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Sch Med, Athens, Greece.	egiamarel@med.uoa.gr	Rapti, Vasiliki/AGY-3601-2022; Fantoni, Massimo/AAB-7371-2022; Selmi, Carlo/ABG-4899-2021; Angheben, Andrea/C-9167-2013; Samarkos, Michael/Q-5104-2019; Giannitsioti, Efthymia/AAQ-5897-2020	Rapti, Vasiliki/0000-0002-8322-635X; Selmi, Carlo/0000-0002-0323-0376; Angheben, Andrea/0000-0003-4545-8034; Samarkos, Michael/0000-0001-9630-9712; Kyriazopoulou, Evdoxia/0000-0002-9585-517X; Tsiakos, Konstantinos/0000-0002-9167-905X; KOTSIS, VASILIOS/0000-0002-3755-8097; GIANNITSIOTI, EFTHYMIA/0000-0003-2715-7457	Hellenic Institute for the Study of Sepsis (HISS); HISS; Swedish Orphan Biovitrum (Sobi)	Hellenic Institute for the Study of Sepsis (HISS); HISS; Swedish Orphan Biovitrum (Sobi)	The authors wish to express their gratitude to the members of the Data Monitoring and Safety Committee and to M. Niederman, J. W. M. van der Meer and K. Reinhart for their valuable contributions and for their critical review of the submitted manuscript. This trial was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) and funded, in part, by HISS and, in part, by Swedish Orphan Biovitrum (Sobi). HISS was responsible for the conceptualization and design of the study, data collection, analysis, decision to publish and preparation of the manuscript. Sobi had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Azam TU, 2020, J AM SOC NEPHROL, V31, P2725, DOI 10.1681/ASN.2020060829; Balkhair A, 2021, INT J INFECT DIS, V103, P288, DOI 10.1016/j.ijid.2020.11.149; Bozzi G, 2021, J ALLERGY CLIN IMMUN, V147, P561, DOI 10.1016/j.jaci.2020.11.006; Caricchio R, 2021, JAMA-J AM MED ASSOC, V326, P230, DOI 10.1001/jama.2021.9508; Caricchio R, 2021, ANN RHEUM DIS, V80, P88, DOI 10.1136/annrheumdis-2020-218323; Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI 10.1056/NEJMoa2100433; Guimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567; Kooistra EJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03364-w; Kyriazopoulou E, 2021, ELIFE, V10, DOI 10.7554/eLife.66125; Manson JJ, 2020, LANCET RHEUMATOL, V2, pE594, DOI 10.1016/S2665-9913(20)30275-7; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Pontali E, 2021, J ALLERGY CLIN IMMUN, V147, P1217, DOI 10.1016/j.jaci.2021.01.024; Potere N, 2021, ANN RHEUM DIS, V80, P271, DOI 10.1136/annrheumdis-2020-218243; Renieris G., IL 1 MEDIATES TISSUE, DOI 10.1101/2021.04.09.21255190(2021; Rodrigues TS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201707; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rovina N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02897-4; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI 10.1056/NEJMoa2030340; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Webb BJ, 2020, LANCET RHEUMATOL, V2, pE754, DOI 10.1016/S2665-9913(20)30343-X	26	147	148	2	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1752	+		10.1038/s41591-021-01499-z	http://dx.doi.org/10.1038/s41591-021-01499-z		SEP 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34480127	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000692308000001
J	Scott, BM; Gutierrez-Vazquez, C; Sanmarco, LM; Pereira, JAD; Li, ZR; Plasencia, A; Hewson, P; Cox, LM; O'Brien, M; Chen, SK; Moraes-Vieira, PM; Chang, BSW; Peisajovich, SG; Quintana, FJ				Scott, Benjamin M.; Gutierrez-Vazquez, Cristina; Sanmarco, Liliana M.; Pereira, Jessica A. da Silva; Li, Zhaorong; Plasencia, Agustin; Hewson, Patrick; Cox, Laura M.; O'Brien, Madelynn; Chen, Steven K.; Moraes-Vieira, Pedro M.; Chang, Belinda S. W.; Peisajovich, Sergio G.; Quintana, Francisco J.			Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease	NATURE MEDICINE			English	Article							T-CELL RESPONSE; EXTRACELLULAR ATP; HOST; ACTIVATION; MICROBIOTA; IMMUNITY; COLITIS; GUT; WEB; RECOGNITION	A synthetic yeast-based therapeutic that secretes an ATP-degrading enzyme in response to pro-inflammatory extracellular ATP in the gut reduces intestinal inflammation, fibrosis and dysbiosis in mouse models of colitis and enteritis. Inflammatory bowel disease (IBD) is a complex chronic inflammatory disorder of the gastrointestinal tract. Extracellular adenosine triphosphate (eATP) produced by the commensal microbiota and host cells activates purinergic signaling, promoting intestinal inflammation and pathology. Based on the role of eATP in intestinal inflammation, we developed yeast-based engineered probiotics that express a human P2Y2 purinergic receptor with up to a 1,000-fold increase in eATP sensitivity. We linked the activation of this engineered P2Y2 receptor to the secretion of the ATP-degrading enzyme apyrase, thus creating engineered yeast probiotics capable of sensing a pro-inflammatory molecule and generating a proportional self-regulated response aimed at its neutralization. These self-tunable yeast probiotics suppressed intestinal inflammation in mouse models of IBD, reducing intestinal fibrosis and dysbiosis with an efficacy similar to or higher than that of standard-of-care therapies usually associated with notable adverse events. By combining directed evolution and synthetic gene circuits, we developed a unique self-modulatory platform for the treatment of IBD and potentially other inflammation-driven pathologies.	[Scott, Benjamin M.; Chen, Steven K.; Chang, Belinda S. W.; Peisajovich, Sergio G.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada; [Scott, Benjamin M.] NIST, Biosyst & Biomat Div, Gaithersburg, MD 20899 USA; [Scott, Benjamin M.] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; [Gutierrez-Vazquez, Cristina; Sanmarco, Liliana M.; Pereira, Jessica A. da Silva; Li, Zhaorong; Plasencia, Agustin; Hewson, Patrick; Cox, Laura M.; O'Brien, Madelynn; Quintana, Francisco J.] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA; [Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil; [Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Expt Med Res Cluster EMRC, Campinas, SP, Brazil; [Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Obes & Comorbid Res Ctr OCRC, Campinas, SP, Brazil; [Chang, Belinda S. W.] Univ Toronto, Dept Ecol & Evolutionary Biol, Toronto, ON, Canada; [Chang, Belinda S. W.; Peisajovich, Sergio G.] Univ Toronto, Ctr Anal Genome Evolut & Funct, Toronto, ON, Canada; [Quintana, Francisco J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Scott, Benjamin M.] Concordia Univ, Montreal, PQ, Canada; [Peisajovich, Sergio G.] Illumina Inc, San Diego, CA USA	University of Toronto; National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland College Park; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual de Campinas; Universidade Estadual de Campinas; University of Toronto; University of Toronto; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Concordia University - Canada; Illumina	Quintana, FJ (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA.; Quintana, FJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.	fquintana@rics.bwh.harvard.edu	Moraes-Vieira, Pedro/C-8701-2014	Moraes-Vieira, Pedro/0000-0002-8263-786X; Scott, Benjamin/0000-0003-4782-7139; Li, Zhaorong/0000-0002-5268-6986; Chen, Steven K./0000-0001-5008-4351; Pereira, Jessica Aparecida da Silva/0000-0002-8503-1732; Plasencia, Agustin/0000-0002-7415-0947	NIH [NS102807, ES02530, ES029136, AI126880]; National MS Society [RG4111A1]; International Progressive MS Alliance [PA-1604-08459]; NSERC from the Natural Sciences Engineering Research Council of Canada [492911]; Ontario Graduate Scholarship; National Institute of Standards and Technology (NIST); University of Maryland; Alfonso Martin Escudero Foundation from the European Molecular Biology Organization [ALTF 610-2017]; Sao Paulo Research Foundation (FAPESP) [2019/04780-7]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National MS Society(National Multiple Sclerosis Society); International Progressive MS Alliance; NSERC from the Natural Sciences Engineering Research Council of Canada; Ontario Graduate Scholarship(Ontario Graduate Scholarship); National Institute of Standards and Technology (NIST)(National Institute of Standards & Technology (NIST) - USA); University of Maryland; Alfonso Martin Escudero Foundation from the European Molecular Biology Organization; Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by grants NS102807, ES02530, ES029136 and AI126880 from the NIH; RG4111A1 from the National MS Society; PA-1604-08459 from the International Progressive MS Alliance; and NSERC 492911 from the Natural Sciences Engineering Research Council of Canada. B.M.S. was supported by an Ontario Graduate Scholarship and by the Professional Research Experience Program agreement between the National Institute of Standards and Technology (NIST) and the University of Maryland. C.G.-V. was supported by an Alfonso Martin Escudero Foundation postdoctoral fellowship and by postdoctoral fellowship ALTF 610-2017 from the European Molecular Biology Organization. J.P. was supported by grant 2019/04780-7 from the SAo Paulo Research Foundation (FAPESP). This paper is dedicated to the memory of Dan S. Tawfik. We thank Z. Kelman and J. Marino of the University of Maryland Institute for Bioscience and Biotechnology Research for use of their incubators and W. Shaw of Imperial College London for providing yeast codon-optimized sfGFP. We thank the Harvard Medical School Rodent Histopathology Core, which provided histopathology service. We thank the NeuroTechnology Studio at Brigham and Women's Hospital for providing access to the Leica DMi8 fluorescent microscope and consultation on data acquisition and data analysis. B.M.S. is an International Associate of the NIST. The NIST notes that certain commercial equipment, instruments and materials are identified in this paper to describe an experimental procedure as completely as possible. In no case does this identification imply a recommendation or endorsement by the NIST, nor does it imply that the materials, instruments or equipment are necessarily the best available for the purpose. The opinions expressed in this article are the authors' own and do not necessarily represent the views of the NIST.	Aggarwal N, 2020, CURR OPIN BIOTECH, V65, P171, DOI 10.1016/j.copbio.2020.02.016; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bashor CJ, 2008, SCIENCE, V319, P1539, DOI 10.1126/science.1151153; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Blander JM, 2017, NAT IMMUNOL, V18, P851, DOI 10.1038/ni.3780; Braat H, 2006, CLIN GASTROENTEROL H, V4, P754, DOI 10.1016/j.cgh.2006.03.028; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Chen Y, 2020, NAT MICROBIOL, V5, P1349, DOI 10.1038/s41564-020-0757-2; Chiaro, 2017, SCI TRANSL MED, V9; Cox LM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54187-x; DERKX B, 1993, LANCET, V342, P173, DOI 10.1016/0140-6736(93)91375-V; Di Virgilio F, 2016, METHODS MOL BIOL, V1417, P115, DOI 10.1007/978-1-4939-3566-6_7; Dotan I, 2020, MED RES REV, V40, P245, DOI 10.1002/med.21601; Durmusoglu D, 2021, ACS SYNTH BIOL, V10, P1039, DOI 10.1021/acssynbio.0c00562; Enaud R, 2018, MICROORGANISMS, V6, DOI 10.3390/microorganisms6010022; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Goettel JA, 2016, CELL REP, V17, P1318, DOI 10.1016/j.celrep.2016.09.082; Goretsky T, 2012, AM J PATHOL, V181, P1306, DOI 10.1016/j.ajpath.2012.06.016; Gulbransen BD, 2012, NAT MED, V18, P600, DOI 10.1038/nm.2679; He Q, 2016, APPL MICROBIOL BIOT, V100, P4485, DOI 10.1007/s00253-015-7205-x; Hillmann P, 2009, J MED CHEM, V52, P2762, DOI 10.1021/jm801442p; Huang HL, 2017, NATURE, V547, P173, DOI 10.1038/nature22969; Hudson LE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112660; Hwang IY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15028; Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Knowles AF, 2011, PURINERG SIGNAL, V7, P21, DOI 10.1007/s11302-010-9214-7; Komoszynski MA, 1996, COMP BIOCHEM PHYS B, V113, P581, DOI 10.1016/0305-0491(95)02062-4; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; Lee GR, 2016, NUCLEIC ACIDS RES, V44, pW502, DOI 10.1093/nar/gkw360; Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Machiels K, 2014, GUT, V63, P1275, DOI 10.1136/gutjnl-2013-304833; Martins FS, 2011, INT J MED MICROBIOL, V301, P359, DOI 10.1016/j.ijmm.2010.11.002; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; McKay R, 2018, BIOENG TRANSL MED, V3, P209, DOI 10.1002/btm2.10113; Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; Nash AK, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0373-4; Neurath MF, 2019, NAT IMMUNOL, V20, P970, DOI 10.1038/s41590-019-0415-0; Nourizad N, 2003, PROTEIN EXPRES PURIF, V27, P229, DOI 10.1016/S1046-5928(02)00605-8; Nowarski R, 2017, CELL, V168, P362, DOI 10.1016/j.cell.2016.11.040; Pliatsika V, 2015, BIOL DIRECT, V10, DOI 10.1186/s13062-015-0035-z; Plichta DR, 2019, CELL, V178, P1041, DOI 10.1016/j.cell.2019.07.045; Prykhozhij SV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119372; Rafehi M, 2017, J MED CHEM, V60, P8425, DOI 10.1021/acs.jmedchem.7b00854; Rinaldi M, 2013, CLIN REV ALLERG IMMU, V45, P152, DOI 10.1007/s12016-012-8344-9; Rizzetto L, 2016, J BIOL CHEM, V291, P7961, DOI 10.1074/jbc.M115.699645; Rothhammer V, 2018, NATURE, V557, P724, DOI 10.1038/s41586-018-0119-x; Ryan OW, 2014, ELIFE, V3, DOI 10.7554/eLife.03703; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schutz, 2016, SCI REP-UK, V6; Scott BM, 2019, GENETICS, V211, P597, DOI 10.1534/genetics.118.301733; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sen S, 2020, FUNGAL GENET BIOL, V137, DOI 10.1016/j.fgb.2020.103333; Shaw WM, 2019, CELL, V177, P782, DOI 10.1016/j.cell.2019.02.023; Shen C, 2007, INFLAMM BOWEL DIS, V13, P308, DOI 10.1002/ibd.20005; Sokol H, 2017, GUT, V66, P1039, DOI [10.1136/gutjnl-2015-310746, 10.1136/gutjnl-20]; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Suez J, 2019, NAT MED, V25, P716, DOI 10.1038/s41591-019-0439-x; Takemura N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan0333; Takenaka MC, 2019, NAT NEUROSCI, V22, P729, DOI 10.1038/s41593-019-0370-y; Takenaka MC, 2016, TRENDS IMMUNOL, V37, P427, DOI 10.1016/j.it.2016.04.009; Tiago FCP, 2015, BENEF MICROBES, V6, P807, DOI 10.3920/BM2015.0018; Trivedi PP, 2012, MUTAT RES-GEN TOX EN, V744, P172, DOI 10.1016/j.mrgentox.2012.03.001; Ueno N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097456; Venkatakrishnan AJ, 2016, NATURE, V536, P484, DOI 10.1038/nature19107; Vuerich M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00507; Wan, 2016, SCI REP-UK, V6; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Yoon SH, 2017, INT J SYST EVOL MICR, V67, P1613, DOI 10.1099/ijsem.0.001755; Zanello G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018573	80	44	43	25	84	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1212	+		10.1038/s41591-021-01390-x	http://dx.doi.org/10.1038/s41591-021-01390-x		JUN 2021	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34183837				2022-12-27	WOS:000667622200003
J	Khoury, DS; Cromer, D; Reynaldi, A; Schlub, TE; Wheatley, AK; Juno, JA; Subbarao, K; Kent, SJ; Triccas, JA; Davenport, MP				Khoury, David S.; Cromer, Deborah; Reynaldi, Arnold; Schlub, Timothy E.; Wheatley, Adam K.; Juno, Jennifer A.; Subbarao, Kanta; Kent, Stephen J.; Triccas, James A.; Davenport, Miles P.			Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	NATURE MEDICINE			English	Article							VACCINE; TITERS; CORRELATE	Predictive models of immune protection from COVID-19 are urgently needed to identify correlates of protection to assist in the future deployment of vaccines. To address this, we analyzed the relationship between in vitro neutralization levels and the observed protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using data from seven current vaccines and from convalescent cohorts. We estimated the neutralization level for 50% protection against detectable SARS-CoV-2 infection to be 20.2% of the mean convalescent level (95% confidence interval (CI) = 14.4-28.4%). The estimated neutralization level required for 50% protection from severe infection was significantly lower (3% of the mean convalescent level; 95% CI = 0.7-13%, P = 0.0004). Modeling of the decay of the neutralization titer over the first 250 d after immunization predicts that a significant loss in protection from SARS-CoV-2 infection will occur, although protection from severe disease should be largely retained. Neutralization titers against some SARS-CoV-2 variants of concern are reduced compared with the vaccine strain, and our model predicts the relationship between neutralization and efficacy against viral variants. Here, we show that neutralization level is highly predictive of immune protection, and provide an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic. Estimates of the levels of neutralizing antibodies necessary for protection against symptomatic SARS-CoV-2 or severe COVID-19 are a fraction of the mean level in convalescent serum and will be useful in guiding vaccine rollouts.	[Khoury, David S.; Cromer, Deborah; Reynaldi, Arnold; Schlub, Timothy E.; Davenport, Miles P.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia; [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Fac Med & Hlth, Sydney, NSW, Australia; [Wheatley, Adam K.; Juno, Jennifer A.; Subbarao, Kanta; Kent, Stephen J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Subbarao, Kanta] Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia; [Kent, Stephen J.] Univ Melbourne, Ctr Excellence Convergent Bionano Sci & Technol, Australian Res Council, Melbourne, Vic, Australia; [Kent, Stephen J.] Monash Univ, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia; [Kent, Stephen J.] Monash Univ, Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia; [Kent, Stephen J.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Triccas, James A.] Univ Sydney, Sch Med Sci, Fac Med & Hlth, Sydney, NSW, Australia; [Triccas, James A.] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia; [Triccas, James A.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia	University of New South Wales Sydney; Kirby Institute; University of Sydney; University of Melbourne; World Health Organization; University of Melbourne; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; University of Sydney; University of Sydney; University of Sydney	Davenport, MP (corresponding author), Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.; Triccas, JA (corresponding author), Univ Sydney, Sch Med Sci, Fac Med & Hlth, Sydney, NSW, Australia.; Triccas, JA (corresponding author), Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia.; Triccas, JA (corresponding author), Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia.	jamie.triccas@sydney.edu.au; m.davenport@unsw.edu.au		Juno, Jennifer/0000-0002-9072-1017; Wheatley, Adam/0000-0002-5593-9387; Kent, Stephen/0000-0002-8539-4891; Davenport, Miles/0000-0002-4751-1831	Australian Government Medical Research Future Fund [GNT2002073, MRF2005544, MRF2005760, GNT1149990]; NHMRC [CRE 1153493]; Victorian Government; NHMRC fellowships; NHMRC Investigator grants; Jack Ma Foundation; A2 Milk Company; Australian Government Department of Health	Australian Government Medical Research Future Fund(Medical Research Future Fund (MRFF)); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government; NHMRC fellowships(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Investigator grants(National Health and Medical Research Council (NHMRC) of Australia); Jack Ma Foundation; A2 Milk Company; Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing)	This work is supported by Australian Government Medical Research Future Fund awards GNT2002073 (to S.J.K., M.P.D. and A.K.W.), MRF2005544 (to S.J.K., A.K.W., J.A.J. and M.P.D.) and MRF2005760 (to M.P.D.), an NHMRC program grant GNT1149990 (to S.J.K. and M.P.D.), NHMRC CRE 1153493 (to J.A.T.), and by the Victorian Government (S.J.K., A.K.W., J.A.J.). J.A.J., D.S.K. and S.J.K. are supported by NHMRC fellowships. A.K.W., D.C., K.S. and M.P.D. are supported by NHMRC Investigator grants. This study was supported by the Jack Ma Foundation (K.S.) and the A2 Milk Company (K.S.). The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.	Aho K, 2015, METHODS ECOL EVOL, V6, P121, DOI 10.1111/2041-210X.12304; AITCHISON J, 1980, BIOMETRIKA, V67, P261, DOI 10.2307/2335470; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Andreano E, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103154118; [Anonymous], 2021, CORONAVIRUS COVID 19; [Anonymous], 2021, S AFR UN RAT HITS NE; Antia A, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006601; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662; CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Cheng LW, 2012, J VIROL METHODS, V182, P43, DOI 10.1016/j.jviromet.2012.03.004; Chia WN, 2021, LANCET MICROBE, V2, pE240, DOI 10.1016/S2666-5247(21)00025-2; Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18; Crawford KHD, 2021, J INFECT DIS, V223, P197, DOI 10.1093/infdis/jiaa618; Cromer D, 2021, NAT REV IMMUNOL, V21, P395, DOI 10.1038/s41577-021-00550-x; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dunning AJ, 2006, STAT MED, V25, P1485, DOI 10.1002/sim.2282; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(21)00070-0, 10.1016/S1473-3099(20)30942-7]; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Hoef JMV, 2012, AM STAT, V66, P124, DOI 10.1080/00031305.2012.687494; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Janssen, 2021, JOHNSON JOHNSON ANNO; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Khoury DS, 2020, NAT REV IMMUNOL, V20, P727, DOI 10.1038/s41577-020-00471-1; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Laurie KL, 2015, CLIN VACCINE IMMUNOL, V22, P957, DOI 10.1128/CVI.00278-15; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Mattiuzzo G., 2020, ESTABLISHMENT WHO IN; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Memoli MJ, 2020, CLIN INFECT DIS, V70, P748, DOI 10.1093/cid/ciz281; Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pradenas E, 2021, MED-CAMBRIDGE, V2, P313, DOI 10.1016/j.medj.2021.01.005; Qin L, 2007, J INFECT DIS, V196, P1304, DOI 10.1086/522428; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.21203/rs.3.rs-57112/v1, 10.1101/2020.08.11.20171843]; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Vaida F, 2009, J COMPUT GRAPH STAT, V18, P797, DOI 10.1198/jcgs.2009.07130; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang P., 2021, RESEARCHSQUARE, V593, P130, DOI [11.17.516888, DOI 10.21203/RS.3.RS-1708394/V1]; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	58	1457	1467	19	71	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1205	+		10.1038/s41591-021-01377-8	http://dx.doi.org/10.1038/s41591-021-01377-8		MAY 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34002089	Bronze, Green Submitted			2022-12-27	WOS:000651469300002
J	Lucas, C; Klein, J; Sundaram, ME; Liu, FM; Wong, P; Silva, J; Mao, TY; Oh, JE; Mohanty, S; Huang, JF; Tokuyama, M; Lu, PW; Venkataraman, A; Park, A; Israelow, B; Vogels, CBF; Muenker, MC; Chang, CH; Casanovas-Massana, A; Moore, AJ; Zell, J; Fournier, JB; Obaid, A; Robertson, AJ; Lu-Culligan, A; Zhao, A; Nelson, A; Brito, A; Nunez, A; Martin, A; Watkins, AE; Geng, B; Chun, CJ; Kalinich, CC; Harden, CA; Todeasa, C; Jensen, C; Dorgay, CE; Kim, D; McDonald, D; Shepard, D; Courchaine, E; White, EB; Song, E; Silva, E; Kudo, E; DeIuliis, G; Rahming, H; Park, HJ; Matos, I; Ott, I; Nouws, J; Valdez, J; Fauver, J; Lim, J; Rose, KA; Anastasio, K; Brower, K; Glick, L; Sharma, L; Sewanan, L; Knaggs, L; Minasyan, M; Batsu, M; Petrone, M; Kuang, M; Nakahata, M; Linehan, M; Askenase, MH; Simonov, M; Smolgovsky, M; Balkcom, NC; Sonnert, N; Naushad, N; Vijayakumar, P; Martinello, R; Datta, R; Handoko, R; Bermejo, S; Prophet, S; Bickerton, S; Velazquez, S; Alpert, T; Rice, T; Khoury-Hanold, W; Peng, XH; Yang, YX; Cao, YY; Strong, Y; Lin, ZT; Wyllie, AL; Campbell, M; Lee, A; Chun, HJ; Grubaugh, ND; Schulz, WL; Farhadian, S; Dela Cruz, C; Ring, AM; Shaw, AC; Wisnewski, AV; Yildirim, I; Ko, ALI; Omer, S; Iwasaki, A				Lucas, Carolina; Klein, Jon; Sundaram, Maria E.; Liu, Feimei; Wong, Patrick; Silva, Julio; Mao, Tianyang; Oh, Ji Eun; Mohanty, Subhasis; Huang, Jiefang; Tokuyama, Maria; Lu, Peiwen; Venkataraman, Arvind; Park, Annsea; Israelow, Benjamin; Vogels, Chantal B. F.; Muenker, M. Catherine; Chang, C-Hong; Casanovas-Massana, Arnau; Moore, Adam J.; Zell, Joseph; Fournier, John B.; Obaid, Abeer; Robertson, Alexander James; Lu-Culligan, Alice; Zhao, Alice; Nelson, Allison; Brito, Anderson; Nunez, Angela; Martin, Anjelica; Watkins, Anne E.; Geng, Bertie; Chun, Caitlin J.; Kalinich, Chaney C.; Harden, Christina A.; Todeasa, Codruta; Jensen, Cole; Dorgay, Coriann E.; Kim, Daniel; McDonald, David; Shepard, Denise; Courchaine, Edward; White, Elizabeth B.; Song, Eric; Silva, Erin; Kudo, Eriko; DeIuliis, Giuseppe; Rahming, Harold; Park, Hong-Jai; Matos, Irene; Ott, Isabel; Nouws, Jessica; Valdez, Jordan; Fauver, Joseph; Lim, Joseph; Rose, Kadi-Ann; Anastasio, Kelly; Brower, Kristina; Glick, Laura; Sharma, Lokesh; Sewanan, Lorenzo; Knaggs, Lynda; Minasyan, Maksym; Batsu, Maria; Petrone, Mary; Kuang, Maxine; Nakahata, Maura; Linehan, Melissa; Askenase, Michael H.; Simonov, Michael; Smolgovsky, Mikhail; Balkcom, Natasha C.; Sonnert, Nicole; Naushad, Nida; Vijayakumar, Pavithra; Martinello, Rick; Datta, Rupak; Handoko, Ryan; Bermejo, Santos; Prophet, Sarah; Bickerton, Sean; Velazquez, Sofia; Alpert, Tara; Rice, Tyler; Khoury-Hanold, William; Peng, Xiaohua; Yang, Yexin; Cao, Yiyun; Strong, Yvette; Lin, Zitong; Wyllie, Anne L.; Campbell, Melissa; Lee, Alfred; Chun, Hyung J.; Grubaugh, Nathan D.; Schulz, Wade L.; Farhadian, Shelli; Dela Cruz, Charles; Ring, Aaron M.; Shaw, Albert C.; Wisnewski, Adam V.; Yildirim, Inci; Ko, Albert I.; Omer, Saad; Iwasaki, Akiko		Yale IMPACT Res Team	Delayed production of neutralizing antibodies correlates with fatal COVID-19	NATURE MEDICINE			English	Article								Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). However, the exact features of antibody responses that govern COVID-19 disease outcomes remain unclear. In this study, we analyzed humoral immune responses in 229 patients with asymptomatic, mild, moderate and severe COVID-19 over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-spike (S) immunoglobulin G (IgG) levels, length of hospitalization and clinical parameters associated with worse clinical progression. Although high anti-S IgG levels correlated with worse disease severity, such correlation was time dependent. Deceased patients did not have higher overall humoral response than discharged patients. However, they mounted a robust, yet delayed, response, measured by anti-S, anti-receptor-binding domain IgG and neutralizing antibody (NAb) levels compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, although sera from 85% of patients displayed some neutralization capacity during their disease course, NAb generation before 14 d of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se but, rather, with the delayed kinetics of NAb production. A longitudinal analysis of humoral immune responses in patients with COVID-19 with varying disease severities reveals that mortality does not correlate with antiviral antibody levels but, instead, with slower seroconversion.	[Lucas, Carolina; Klein, Jon; Liu, Feimei; Wong, Patrick; Silva, Julio; Mao, Tianyang; Oh, Ji Eun; Mohanty, Subhasis; Huang, Jiefang; Tokuyama, Maria; Lu, Peiwen; Venkataraman, Arvind; Park, Annsea; Israelow, Benjamin; Obaid, Abeer; Lu-Culligan, Alice; Martin, Anjelica; Kim, Daniel; Song, Eric; Kudo, Eriko; Linehan, Melissa; Sonnert, Nicole; Rice, Tyler; Khoury-Hanold, William; Yang, Yexin; Cao, Yiyun; Ring, Aaron M.; Shaw, Albert C.; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; [Sundaram, Maria E.] ICES, Toronto, ON, Canada; [Sundaram, Maria E.; Obaid, Abeer; Martinello, Rick] Univ Toronto, Dalla Lana Sch Publ Hlth, Ctr Vaccine Preventable Dis, Toronto, ON, Canada; [Mohanty, Subhasis; Huang, Jiefang; Israelow, Benjamin; Fournier, John B.; Obaid, Abeer; Datta, Rupak; Campbell, Melissa; Farhadian, Shelli; Shaw, Albert C.; Ko, Albert I.; Omer, Saad] Yale Univ, Sch Med, Dept Med, Sect Infect Dis, New Haven, CT 06510 USA; [Vogels, Chantal B. F.; Muenker, M. Catherine; Casanovas-Massana, Arnau; Moore, Adam J.; Obaid, Abeer; Robertson, Alexander James; Zhao, Alice; Brito, Anderson; Watkins, Anne E.; Chun, Caitlin J.; Kalinich, Chaney C.; Harden, Christina A.; Jensen, Cole; Dorgay, Coriann E.; White, Elizabeth B.; Ott, Isabel; Fauver, Joseph; Brower, Kristina; Petrone, Mary; Kuang, Maxine; Balkcom, Natasha C.; Lin, Zitong; Wyllie, Anne L.; Grubaugh, Nathan D.; Ko, Albert I.; Omer, Saad] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA; [Chang, C-Hong; Chun, Hyung J.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Zell, Joseph; Wisnewski, Adam V.] Yale Univ, Sch Med, Dept Internal Med, Sect Gen Med, New Haven, CT 06510 USA; [Lee, Alfred] Yale Univ, Sch Med, Dept Hematol, New Haven, CT USA; [Schulz, Wade L.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; [Obaid, Abeer; Shepard, Denise; Schulz, Wade L.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Dela Cruz, Charles] Yale Univ, Sch Med, Dept Med, Sect Pulm & Crit Care Med, New Haven, CT 06510 USA; [Yildirim, Inci] Yale Univ, Sch Med, Dept Pediat, Sect Infect Dis & Global Hlth, New Haven, CT 06510 USA; [Yildirim, Inci; Omer, Saad] Yale Univ, Yale Inst Global Hlth, New Haven, CT USA; [Iwasaki, Akiko] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Nelson, Allison; Nunez, Angela; Geng, Bertie; Todeasa, Codruta; McDonald, David; Silva, Erin; DeIuliis, Giuseppe; Rahming, Harold; Park, Hong-Jai; Matos, Irene; Nouws, Jessica; Valdez, Jordan; Rose, Kadi-Ann; Glick, Laura; Sharma, Lokesh; Sewanan, Lorenzo; Knaggs, Lynda; Minasyan, Maksym; Batsu, Maria; Nakahata, Maura; Simonov, Michael; Smolgovsky, Mikhail; Naushad, Nida; Vijayakumar, Pavithra; Handoko, Ryan; Bermejo, Santos; Peng, Xiaohua; Strong, Yvette] Yale Sch Med, New Haven, CT USA; [Courchaine, Edward; Bickerton, Sean] Yale Univ, Sch Med, Dept Biochem & Mol Biol, New Haven, CT USA; [Lim, Joseph] Yale Univ, Sch Med, Yale Viral Hepatitis Program, New Haven, CT USA; [Anastasio, Kelly; Alpert, Tara] Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT USA; [Askenase, Michael H.; Velazquez, Sofia] Yale Univ, Sch Med, Dept Neurol, New Haven, CT USA; [Prophet, Sarah] Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, New Haven, CT USA	Yale University; University of Toronto; University of Toronto; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Iwasaki, A (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA.; Iwasaki, A (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	akiko.iwasaki@yale.edu	Rice, Tyler/GZL-7820-2022; Ko, Albert/P-2343-2015; Casanovas-Massana, Arnau/H-5806-2019	Ko, Albert/0000-0001-9023-2339; Casanovas-Massana, Arnau/0000-0002-3301-6143; Lucas, Carolina/0000-0003-4590-2756; Oh, Ji Eun/0000-0003-2511-7064; Klein, Jonathan/0000-0002-3552-7684; Valdez, Jordan/0000-0003-1313-190X; Silva, Julio/0000-0001-8212-7440; Rose, Kadi-Ann/0000-0003-4664-2757; Velazquez, Sofia/0000-0001-5954-3518; Mao, Tianyang/0000-0001-9251-8592; Liu, Feimei/0000-0003-2663-6544; Venkataraman, Arvind/0000-0003-1148-4402; Obaid, Abeer/0000-0002-9846-1045	Women's Health Research at Yale Pilot Project Program; Emergent Ventures at the Mercatus Center; Mathers Foundation; Ludwig Family Foundation; Department of Internal Medicine at the Yale School of Medicine; Yale School of Public Health; Beatrice Kleinberg Neuwirth Fund; Yale COVID-19 Research Resource Fund; Gruber Foundation; National Science Foundation; National Institute of Allergy and Infectious Diseases [2T32AI007517-16]; NWO Rubicon [019.181EN.004]	Women's Health Research at Yale Pilot Project Program; Emergent Ventures at the Mercatus Center; Mathers Foundation; Ludwig Family Foundation; Department of Internal Medicine at the Yale School of Medicine; Yale School of Public Health; Beatrice Kleinberg Neuwirth Fund; Yale COVID-19 Research Resource Fund; Gruber Foundation; National Science Foundation(National Science Foundation (NSF)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NWO Rubicon(Netherlands Organization for Scientific Research (NWO))	We thank M. Linehan for technical and logistical assistance and C. Wilen, D. Mucida and T. Castro for discussions. We also thank C. Wilen for kindly providing the virus. This work was supported in part by the Women's Health Research at Yale Pilot Project Program, the Fast Grant from Emergent Ventures at the Mercatus Center, the Mathers Foundation, the Ludwig Family Foundation, the Department of Internal Medicine at the Yale School of Medicine, the Yale School of Public Health and the Beatrice Kleinberg Neuwirth Fund. IMPACT received support from the Yale COVID-19 Research Resource Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. C.L. is a Pew Latin American Fellow. P.Y. is supported by the Gruber Foundation and the National Science Foundation. B.I. is supported by National Institute of Allergy and Infectious Diseases 2T32AI007517-16. C.B.F.V. is supported by NWO Rubicon 019.181EN.004.	ABRY P, 2020, PLOS ONE, V15; Agarwal A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3939; Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1101/2020.03.17.20037713, 10.1038/s41591-020-0913-5]; [Anonymous], 2020, FDA AUTHORIZES MONOC; Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Brugger SD, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005633; Chai KL, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013600.pub2, 10.1002/14651858.CD013600.pub3]; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Chen YX, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008796; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1038/s41591-020-1051-9, 10.1101/2020.05.28.20115758]; Eli Lilly and Company, 2020, LILL STAT REG NIHS A; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Garcia-Beltran Wilfredo F, 2020, medRxiv, DOI [10.1101/2020.10.15.20213512, 10.1016/j.cell.2020.12.015]; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; GUTHMILLER JJ, 2021, MBIO; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; HOLLIMAN R, 1987, BRIT J UROL, V60, P419, DOI 10.1111/j.1464-410X.1987.tb05006.x; Hu WT, 2020, EMERG INFECT DIS, V26, P2974, DOI 10.3201/eid2612.203334; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kaneko Naoki, 2020, SSRN, P3652322, DOI [10.1016/j.cell.2020.08.025, 10.2139/ssrn.3652322]; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; May, REGENERON HALTS ENRO; Pathak EB, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4072; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Rodriguez L, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100078; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Schmidt Fabian, 2020, bioRxiv, DOI [10.1084/jem.20201181, 10.1101/2020.06.08.140871]; Vogels CBF, 2020, NAT MICROBIOL, V5, P1299, DOI 10.1038/s41564-020-0761-6; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Wyllie AL, 2020, NEW ENGL J MED, V383, P1283, DOI 10.1056/NEJMc2016359; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Yu KKQ, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146242; Zhou ZQ, 2021, ACTA PHARMACOL SIN B, V11, P304, DOI 10.1016/j.apsb.2020.10.025; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017; Zohar T, 2020, CELL, V183, P1508, DOI 10.1016/j.cell.2020.10.052	42	101	102	5	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1178	+		10.1038/s41591-021-01355-0	http://dx.doi.org/10.1038/s41591-021-01355-0		MAY 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	33953384	Bronze, Green Accepted			2022-12-27	WOS:000647522300001
J	Schor, NF				Schor, Nina F.			Career equity in medicine	NATURE MEDICINE			English	Editorial Material									[Schor, Nina F.] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Schor, NF (corresponding author), NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	nina.schor@nih.gov		Schor, Nina/0000-0002-3817-7376				Chervenak FA, 2019, AM J OBSTET GYNECOL, V220, P558, DOI 10.1016/j.ajog.2019.01.001; Regan L, 2016, ACAD MED, V91, P1642, DOI 10.1097/ACM.0000000000001110; Schor N.F., 2021, J WOMEN ED LEADERSHI, DOI [10.32873/unl.dc.jwel.198, DOI 10.32873/UNL.DC.JWEL.198]; Schor NF, 2018, ACAD MED, V93, P237, DOI 10.1097/ACM.0000000000001863	4	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					746	746		10.1038/s41591-021-01239-3	http://dx.doi.org/10.1038/s41591-021-01239-3		FEB 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33589824				2022-12-27	WOS:000618129800002
J	Chang, WH; Lai, AG				Chang, Wai Hoong; Lai, Alvina G.			Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers	NATURE MEDICINE			English	Article							TESTICULAR CANCER; PARANEOPLASTIC SYNDROMES; MENTAL-DISORDERS; OF-LIFE; DEPRESSION; CARE; INDIVIDUALS; DIAGNOSIS; SURVIVORS; SUICIDE	Cancer is a life-altering event causing considerable psychological distress. However, information on the total burden of psychiatric disorders across all common adult cancers and therapy exposures has remained scarce. Here, we estimated the risk of self-harm after incident psychiatric disorder diagnosis in patients with cancer and the risk of unnatural deaths after self-harm in 459,542 individuals. Depression was the most common psychiatric disorder in patients with cancer. Patients who received chemotherapy, radiotherapy and surgery had the highest cumulative burden of psychiatric disorders. Patients treated with alkylating agent chemotherapeutics had the highest burden of psychiatric disorders, whereas those treated with kinase inhibitors had the lowest burden. All mental illnesses were associated with an increased risk of subsequent self-harm, where the highest risk was observed within 12 months of the mental illness diagnosis. Patients who harmed themselves were 6.8 times more likely to die of unnatural causes of death compared with controls within 12 months of self-harm (hazard ratio (HR), 6.8; 95% confidence interval (CI), 4.3-10.7). The risk of unnatural death after 12 months was markedly lower (HR, 2.0; 95% CI, 1.5-2.7). We provide an extensive knowledge base to help inform collaborative cancer-psychiatric care initiatives by prioritizing patients who are most at risk. A large-scale population analysis quantifies the burden of mental illness and self-harm events in patients diagnosed with the most common adult cancers and highlights opportunities for advancing patient care.	[Chang, Wai Hoong; Lai, Alvina G.] UCL, Inst Hlth Informat, London, England	University of London; University College London	Lai, AG (corresponding author), UCL, Inst Hlth Informat, London, England.	Alvina.lai@ucl.ac.uk		Lai, Alvina/0000-0001-8960-8095; Chang, Wai/0000-0001-5832-2000	Wellcome Trust [204841/Z/16/Z]; National Institute for Health Research University College London Hospitals Biomedical Research Centre [BRC714/HI/RW/101440]; National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre [19RX02]; Academy of Medical Sciences [SBF006\1084]	Wellcome Trust(Wellcome Trust); National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric); National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre; Academy of Medical Sciences(Academy of Medical Sciences (AMS))	A.G.L. is supported by funding from the Wellcome Trust (204841/Z/16/Z), National Institute for Health Research University College London Hospitals Biomedical Research Centre (BRC714/HI/RW/101440), National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre (19RX02) and Academy of Medical Sciences (SBF006\1084).	Ahn MH, 2015, PSYCHO-ONCOLOGY, V24, P601, DOI 10.1002/pon.3705; Benros ME, 2009, INT J CANCER, V124, P2917, DOI 10.1002/ijc.24274; Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; Breitbart W, 2014, PSYCHO-ONCOLOGY, V23, P339, DOI 10.1002/pon.3422; Chai Y, 2020, LANCET PSYCHIAT, V7, P135, DOI 10.1016/S2215-0366(20)30004-3; Choi EK, 2014, PSYCHO-ONCOLOGY, V23, P1103, DOI 10.1002/pon.3531; Choi SM, 2001, J KOREAN MED SCI, V16, P328, DOI 10.3346/jkms.2001.16.3.328; Choi Y, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049358; COLLINS C, 1988, AUST NZ J PSYCHIAT, V22, P207, DOI 10.3109/00048678809158962; Dahl AA, 2005, J CLIN ONCOL, V23, P2389, DOI 10.1200/JCO.2005.05.061; Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Denaxas S, 2019, J AM MED INFORM ASSN, V26, P1545, DOI 10.1093/jamia/ocz105; Depp CA, 2004, BIPOLAR DISORD, V6, P343, DOI 10.1111/j.1399-5618.2004.00139.x; Dong HR, 2015, AM J EPIDEMIOL, V181, P532, DOI 10.1093/aje/kwu289; El Hayek S, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr-2019-233403; Ellis J, 2009, J CLIN ONCOL, V27, P699, DOI 10.1200/JCO.2007.15.4864; Erlangsen A, 2017, LANCET PSYCHIAT, V4, P937, DOI 10.1016/S2215-0366(17)30429-7; Fond G, 2019, LANCET PUBLIC HEALTH, V4, pE583, DOI 10.1016/S2468-2667(19)30187-2; Fung C, 2018, ADV UROL, V2018, DOI 10.1155/2018/8671832; GALASKO D, 1988, PSYCHIAT CLIN N AM, V11, P151; Grov EK, 2009, ACTA ONCOL, V48, P842, DOI 10.1080/02841860902795232; Ha JH, 2011, PSYCHIAT INVEST, V8, P71, DOI 10.4306/pi.2011.8.1.71; Hartl K, 2010, PSYCHO-ONCOLOGY, V19, P160, DOI 10.1002/pon.1536; Henson KE, 2019, JAMA PSYCHIAT, V76, P51, DOI 10.1001/jamapsychiatry.2018.3181; Irwin KE, 2014, CANCER-AM CANCER SOC, V120, P323, DOI 10.1002/cncr.28431; Kayser MS, 2010, AM J PSYCHIAT, V167, P1039, DOI 10.1176/appi.ajp.2010.09101547; Kenna HA, 2011, PSYCHIAT CLIN NEUROS, V65, P549, DOI 10.1111/j.1440-1819.2011.02260.x; Kisely S, 2013, JAMA PSYCHIAT, V70, P209, DOI 10.1001/jamapsychiatry.2013.278; Krebber AMH, 2014, PSYCHO-ONCOLOGY, V23, P121, DOI 10.1002/pon.3409; Kuan V, 2019, LANCET DIGIT HEALTH, V1, pE63, DOI 10.1016/S2589-7500(19)30012-3; Lai AG, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-043828; Laursen TM, 2019, SCHIZOPHR RES, V206, P284, DOI 10.1016/j.schres.2018.11.003; Li M, 2016, J ONCOL PRACT, V12, P747, DOI 10.1200/JOP.2016.011072; Lin J, 2016, CANCER EPIDEM BIOMAR, V25, P1564, DOI 10.1158/1055-9965.EPI-16-0316; Linsley KR, 2001, BRIT J PSYCHIAT, V178, P465, DOI 10.1192/bjp.178.5.465; Maheu C, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.644932; McFarland DC., 2019, ONCOLOGY-BASEL, V28; Morgan C, 2018, LANCET PSYCHIAT, V5, P905, DOI 10.1016/S2215-0366(18)30348-1; Musuuza JS, 2013, CANCER-AM CANCER SOC, V119, P2469, DOI 10.1002/cncr.28091; Naser AY, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.585534; Nohr L, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246501; Palmer BA, 2005, ARCH GEN PSYCHIAT, V62, P247, DOI 10.1001/archpsyc.62.3.247; Peteet JR, 2011, J ONCOL PRACT, V7, P242, DOI 10.1200/JOP.2010.000122; Phillips MR, 2009, LANCET, V373, P2041, DOI 10.1016/S0140-6736(09)60660-7; Pitman A, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1415; Plana-Ripoll O, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228073; Plana-Ripoll O, 2019, LANCET, V394, P1827, DOI 10.1016/S0140-6736(19)32316-5; Raphael MJ, 2021, J CLIN ONCOL, V39, P779, DOI 10.1200/JCO.20.02298; Rees JH, 2004, J NEUROL NEUROSUR PS, V75, P43, DOI 10.1136/jnnp.2004.040378; Sharpe M, 2014, LANCET, V384, P1099, DOI 10.1016/S0140-6736(14)61231-9; Shi W, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00442; Skaali T, 2009, PSYCHO-ONCOLOGY, V18, P580, DOI 10.1002/pon.1437; Smith A, 2018, PSYCHO-ONCOLOGY, V27, P1129, DOI 10.1002/pon.4596; Stonier T., 2013, BMJ OPEN QUAL, V2; Stouten-Kemperman MM, 2015, HUM BRAIN MAPP, V36, P4638, DOI 10.1002/hbm.22942; Warren KN, 2019, CUREUS, V11, DOI 10.7759/cureus.5436; Zaorsky NG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08170-1	57	6	6	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					860	+		10.1038/s41591-022-01740-3	http://dx.doi.org/10.1038/s41591-022-01740-3		MAR 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35347280	Green Published, hybrid			2022-12-27	WOS:000773833700002
J	Heinrich, M; Hofmann, L; Baurecht, H; Kreuzer, PM; Knuttel, H; Leitzmann, MF; Seliger, C				Heinrich, Michael; Hofmann, Luisa; Baurecht, Hansjoerg; Kreuzer, Peter M.; Knuettel, Helge; Leitzmann, Michael F.; Seliger, Corinna			Suicide risk and mortality among patients with cancer	NATURE MEDICINE			English	Article							AFRICAN-AMERICAN SUICIDE; 1ST YEAR; CARE; STRATEGIES; LITHUANIA; DIAGNOSIS; SUPPORT; COHORT; DEATH; LIFE	Despite substantial progress in cancer therapy in recent decades, patients with cancer remain at high suicide risk. Data from individual studies have not been comprehensively quantified and specific risk factors are ill-defined. We assessed suicide mortality risk according to cancer prognosis, stage, time since diagnosis, gender, ethnicity, marital status, year of recruitment and geographic region. We searched EMBASE, MEDLINE, PsycINFO, Web of Science, CINAHL and Google Scholar for relevant articles up to February 2021. We used a random effects model, performed meta-regression meta-analysis and assessed heterogeneity and publication bias using I-2, funnel plots and Egger's and Begg's tests. We performed a systematic review including 62 studies and 46,952,813 patients. To avoid patient sample overlap, the meta-analysis was performed on 28 studies, involving 22,407,690 patients with cancer. Suicide mortality was significantly increased compared with the general population (standardized mortality ratio = 1.85, 95% confidence interval = 1.55-2.20). Risk was strongly related to cancer prognosis, cancer stage, time since diagnosis and geographic region. Patients with cancer, particularly those with specific risk factors, should be closely monitored for suicidality and need specialized care to reduce short- and long-term risks of suicide. A global analysis across 62 studies, of which 28 were meta-analyzed, reveals an increased risk of death by suicide in patients with cancer and underscores the need for comprehensive psycho-oncological therapy during clinical routine to improve the quality of life of patients.	[Heinrich, Michael; Hofmann, Luisa; Kreuzer, Peter M.] Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany; [Baurecht, Hansjoerg; Leitzmann, Michael F.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany; [Knuettel, Helge] Univ Regensburg, Univ Lib, Regensburg, Germany; [Seliger, Corinna] Univ Hosp Heidelberg, Dept Neurol, Heidelberg, Germany	University of Regensburg; University of Regensburg; University of Regensburg; Ruprecht Karls University Heidelberg	Seliger, C (corresponding author), Univ Hosp Heidelberg, Dept Neurol, Heidelberg, Germany.	Corinna.Seliger-Behme@med.uni-heidelberg.de	Seliger, Corinna/GSE-3989-2022; Baurecht, Hansjorg/C-4035-2013	Baurecht, Hansjorg/0000-0002-9265-5594; Heinrich, Michael/0000-0002-6462-1151				Ahn MH, 2015, PSYCHO-ONCOLOGY, V24, P601, DOI 10.1002/pon.3705; ALLEBECK P, 1991, PSYCHOL MED, V21, P979, DOI 10.1017/S0033291700029962; ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; Amiri S, 2020, ARCH SUICIDE RES, V24, pS94, DOI 10.1080/13811118.2019.1596182; Angermeyer MC, 2017, WORLD PSYCHIATRY, V16, P50, DOI 10.1002/wps.20383; Beauplet B, 2021, SUPPORT CARE CANCER, V29, P563, DOI 10.1007/s00520-020-05682-9; Boudreaux ED, 2016, AM J PREV MED, V50, P445, DOI 10.1016/j.amepre.2015.09.029; Brunckhorst O, 2021, PROSTATE CANCER P D, V24, P281, DOI 10.1038/s41391-020-00286-0; Cancer Resaearch UK, 2021, HEAD NECK CANC SURV; Carlson LE, 2019, J PSYCHOSOC ONCOL, V37, P5, DOI 10.1080/07347332.2018.1521490; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; Christensen MLM, 2006, EUR J CANCER PREV, V15, P266, DOI 10.1097/01.cej.0000195712.64448.ba; Control CfD Prevention, 1998, MMWR-MORBID MORTAL W, V47, pi, DOI DOI 10.1001/jamahealthforum.2021.0325; Cordova MJ, 2017, LANCET PSYCHIAT, V4, P330, DOI 10.1016/S2215-0366(17)30014-7; Crocetti E, 1998, BRIT J CANCER, V77, P1194, DOI 10.1038/bjc.1998.199; de Kock S, 2020, INT J TECHNOL ASSESS, V37, DOI 10.1017/S0266462320002135; DeNavas-Walt C, 2011, INCOME POVERTY HLTH; Dormer NRC, 2008, MED J AUSTRALIA, V188, P140, DOI 10.5694/j.1326-5377.2008.tb01555.x; Du L, 2020, J AFFECT DISORDERS, V276, P711, DOI 10.1016/j.jad.2020.07.082; Filiberti A, 2001, J PAIN SYMPTOM MANAG, V22, P544, DOI 10.1016/S0885-3924(01)00295-0; Fitzmaurice C, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.1568; Fluchter P, 2012, MED KLIN-INTENSIVMED, V107, P469, DOI 10.1007/s00063-012-0123-0; Gibbs JT, 1997, SUICIDE LIFE-THREAT, V27, P68; Guo ZL, 2021, UROL ONCOL-SEMIN ORI, V39, P171, DOI 10.1016/j.urolonc.2020.11.022; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; Hannah R, 2017, OUR WORLD DATA; HARRIS EC, 1994, MEDICINE, V73, P281, DOI 10.1097/00005792-199411000-00001; HEIKKINEN M, 1994, ACTA PSYCHIAT SCAND, V89, P65, DOI 10.1111/j.1600-0447.1994.tb05805.x; Hem E, 2004, J CLIN ONCOL, V22, P4209, DOI 10.1200/jco.2004.02.052; Henson K., 2018, J GLOB ONCOL, V4, p228s; Innos K, 2003, EUR J CANCER, V39, P2223, DOI 10.1016/S0959-8049(03)00598-7; Jones G, 2019, LANCET ONCOL, V20, pE601, DOI 10.1016/S1470-2045(19)30517-0; Kaceniene A, 2017, EUR J CANCER PREV, V26, pS197, DOI 10.1097/CEJ.0000000000000375; Kim S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073339; Klaassen Z, 2019, CANCER-AM CANCER SOC, V125, P2886, DOI 10.1002/cncr.32146; Klaassen Z, 2015, CANCER-AM CANCER SOC, V121, P1864, DOI 10.1002/cncr.29274; LEVI F, 1991, ONCOLOGY, V48, P44; Lunny C, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-021-01269-y; Luoma JB, 2002, AM J PSYCHIAT, V159, P909, DOI 10.1176/appi.ajp.159.6.909; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Massetti GM, 2018, PSYCHO-ONCOLOGY, V27, P1750, DOI 10.1002/pon.4720; McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021; Misono S, 2008, J CLIN ONCOL, V26, P4731, DOI 10.1200/JCO.2007.13.8941; Moher David, 2009, Open Med, V3, pe123; Ostuzzi G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011006.pub3; Polanczyk GV, 2017, REV ASSOC MED BRAS, V63, P557, DOI 10.1590/1806-9282.63.07.557; Ravaioli A, 2020, EUR J CANCER, V125, P104, DOI 10.1016/j.ejca.2019.08.019; Rehkopf DH, 2006, PSYCHOL MED, V36, P145, DOI 10.1017/S003329170500588X; Rethlefsen ML, 2021, SYST REV-LONDON, V10, DOI 10.1186/s13643-020-01542-z; Robinson D, 2009, BRIT J CANCER, V101, P198, DOI 10.1038/sj.bjc.6605110; Rockett IRH, 2006, SOC SCI MED, V63, P2165, DOI 10.1016/j.socscimed.2006.05.017; Roser M., 2015, CANCER; Saad AM, 2019, CANCER-AM CANCER SOC, V125, P972, DOI 10.1002/cncr.31876; Schairer C, 2006, JNCI-J NATL CANCER I, V98, P1416, DOI 10.1093/jnci/djj377; SEER*Explorer, 2021, INT WEBS SEER CANC S; Shepard DS, 2016, SUICIDE LIFE-THREAT, V46, P352, DOI 10.1111/sltb.12225; Smailyte G, 2013, CANCER EPIDEMIOL, V37, P714, DOI 10.1016/j.canep.2013.05.009; Smith DP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198679; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tanaka H, 1999, JPN J CANCER RES, V90, P812, DOI 10.1111/j.1349-7006.1999.tb00820.x; Utsey SO, 2007, DEATH STUD, V31, P399, DOI 10.1080/07481180701244553; Visser MRM, 1998, SUPPORT CARE CANCER, V6, P101, DOI 10.1007/s005200050142; Volkers N, 1999, J NATL CANCER I, V91, P1712, DOI 10.1093/jnci/91.20.1712; Wells GA., 2011, NEWCASTLE OTTAWA SCA; WHO, 2018, INT STAT CLASS DIS R; Wolfe A., 2000, NEW YORK TIMES MAGAZ; Yousaf U, 2005, BRIT J CANCER, V92, P995, DOI 10.1038/sj.bjc.6602424; Zebrack BJ, 2014, PSYCHO-ONCOLOGY, V23, P1267, DOI 10.1002/pon.3533	68	9	9	15	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					852	+		10.1038/s41591-022-01745-y	http://dx.doi.org/10.1038/s41591-022-01745-y		MAR 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35347279	Green Published, Green Submitted			2022-12-27	WOS:000773833700001
J	Vandenbroucke-Grauls, CMJE; Kluytmans, JAJW				Vandenbroucke-Grauls, Christina M. J. E.; Kluytmans, Jan A. J. W.			Tracing the origins of antibiotic resistance	NATURE MEDICINE			English	Editorial Material							STAPHYLOCOCCUS-AUREUS; MECA; HOMOLOG; GENE	Antibiotic resistance genes evolve in the environment, in animals, and in humans; strategic action is needed on all three fronts to help understand resistance and to limit its spread.	[Vandenbroucke-Grauls, Christina M. J. E.] Aarhus Univ, Dept Clin Epidemiol, Dept Clin Med, Aarhus, Denmark; [Vandenbroucke-Grauls, Christina M. J. E.] Amsterdam Univ Med Ctr, Locat VUmc, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands; [Kluytmans, Jan A. J. W.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands	Aarhus University; Utrecht University; Utrecht University Medical Center	Vandenbroucke-Grauls, CMJE (corresponding author), Aarhus Univ, Dept Clin Epidemiol, Dept Clin Med, Aarhus, Denmark.; Vandenbroucke-Grauls, CMJE (corresponding author), Amsterdam Univ Med Ctr, Locat VUmc, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands.	vandenbrouckegrauls@amsterdamumc.nl		Vandenbroucke-Grauls, Christina/0000-0003-2074-1597				D'Andrea MM, 2013, INT J MED MICROBIOL, V303, P305, DOI 10.1016/j.ijmm.2013.02.008; D'Costa VM, 2011, NATURE, V477, P457, DOI 10.1038/nature10388; Garcia-Alvarez L, 2011, LANCET INFECT DIS, V11, P595, DOI 10.1016/S1473-3099(11)70126-8; Harkins CP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1252-9; Hendriksen RS, 2011, MBIO, V2, DOI [10.1128/mBio.00157-11, 10.1128/mBio.00305-11]; Kinross P, 2017, EUROSURVEILLANCE, V22, P32, DOI 10.2807/1560-7917.ES.2017.22.44.16-00696; Larsen J, 2022, NATURE, V602, P135, DOI 10.1038/s41586-021-04265-w; Lozano C, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101615; Spoor LE, 2013, MBIO, V4, DOI 10.1128/mBio.00356-13; UBUKATA K, 1989, J BACTERIOL, V171, P2882, DOI 10.1128/jb.171.5.2882-2885.1989; van Loo I, 2007, EMERG INFECT DIS, V13, P1834, DOI 10.3201/eid1312.070384; Wu SW, 1996, MICROB DRUG RESIST, V2, P435, DOI 10.1089/mdr.1996.2.435	12	0	0	9	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					638	640		10.1038/s41591-022-01752-z	http://dx.doi.org/10.1038/s41591-022-01752-z		MAR 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35318464				2022-12-27	WOS:000771833800002
J	Theruvath, J; Menard, M; Smith, BAH; Linde, MH; Coles, GL; Dalton, GN; Wu, W; Kiru, L; Delaidelli, A; Sotillo, E; Silberstein, JL; Geraghty, AC; Banuelos, A; Radosevich, MT; Dhingra, S; Heitzeneder, S; Tousley, A; Lattin, J; Xu, P; Huang, J; Nasholm, N; He, A; Kuo, TC; Sangalang, ERB; Pons, J; Barkal, A; Brewer, RE; Marjon, KD; Vilches-Moure, JG; Marshall, PL; Fernandes, R; Monje, M; Cochran, JR; Sorensen, PH; Daldrup-Link, HE; Weissman, IL; Sage, J; Majeti, R; Bertozzi, CR; Weiss, WA; Mackall, CL; Majzner, RG				Theruvath, Johanna; Menard, Marie; Smith, Benjamin A. H.; Linde, Miles H.; Coles, Garry L.; Dalton, Guillermo Nicolas; Wu, Wei; Kiru, Louise; Delaidelli, Alberto; Sotillo, Elena; Silberstein, John L.; Geraghty, Anna C.; Banuelos, Allison; Radosevich, Molly Thomas; Dhingra, Shaurya; Heitzeneder, Sabine; Tousley, Aidan; Lattin, John; Xu, Peng; Huang, Jing; Nasholm, Nicole; He, Andy; Kuo, Tracy C.; Sangalang, Emma R. B.; Pons, Jaume; Barkal, Amira; Brewer, Rachel E.; Marjon, Kristopher D.; Vilches-Moure, Jose G.; Marshall, Payton L.; Fernandes, Ricardo; Monje, Michelle; Cochran, Jennifer R.; Sorensen, Poul H.; Daldrup-Link, Heike E.; Weissman, Irving L.; Sage, Julien; Majeti, Ravindra; Bertozzi, Carolyn R.; Weiss, William A.; Mackall, Crystal L.; Majzner, Robbie G.			Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY 3F8; GANGLIOSIDE GD2; DISIALOGANGLIOSIDE GD2; THERAPEUTIC TARGET; STEM-CELLS; EXPRESSION; NEUROBLASTOMA; CHILDREN; GLYCOSPHINGOLIPIDS; RITUXIMAB	The combination of anti-GD2 and CD47 blockade mediates robust anti-tumor activity in mouse models of neuroblastoma, osteosarcoma and small-cell lung cancer by reorienting macrophage activity toward tumor cell phagocytosis. The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children with high-risk neuroblastoma. However, approximately 40% of patients with neuroblastoma still relapse, and anti-GD2 has not mediated significant clinical activity in any other GD2(+) malignancy. Macrophages are important mediators of anti-tumor immunity, but tumors resist macrophage phagocytosis through expression of the checkpoint molecule CD47, a so-called 'Don't eat me' signal. In this study, we establish potent synergy for the combination of anti-GD2 and anti-CD47 in syngeneic and xenograft mouse models of neuroblastoma, where the combination eradicates tumors, as well as osteosarcoma and small-cell lung cancer, where the combination significantly reduces tumor burden and extends survival. This synergy is driven by two GD2-specific factors that reorient the balance of macrophage activity. Ligation of GD2 on tumor cells (a) causes upregulation of surface calreticulin, a pro-phagocytic 'Eat me' signal that primes cells for removal and (b) interrupts the interaction of GD2 with its newly identified ligand, the inhibitory immunoreceptor Siglec-7. This work credentials the combination of anti-GD2 and anti-CD47 for clinical translation and suggests that CD47 blockade will be most efficacious in combination with monoclonal antibodies that alter additional pro- and anti-phagocytic signals within the tumor microenvironment.	[Theruvath, Johanna; Coles, Garry L.; Dalton, Guillermo Nicolas; Radosevich, Molly Thomas; Dhingra, Shaurya; Tousley, Aidan; Lattin, John; Xu, Peng; Huang, Jing; He, Andy; Monje, Michelle; Daldrup-Link, Heike E.; Sage, Julien; Mackall, Crystal L.; Majzner, Robbie G.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Menard, Marie; Nasholm, Nicole; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; [Menard, Marie; Nasholm, Nicole; Weiss, William A.] Univ Calif San Francisco, Dept Pediat, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; [Menard, Marie; Nasholm, Nicole; Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; [Smith, Benjamin A. H.; Bertozzi, Carolyn R.] Stanford Univ, ChEM H Inst, Stanford, CA 94305 USA; [Smith, Benjamin A. H.; Bertozzi, Carolyn R.] Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Linde, Miles H.; Silberstein, John L.] Stanford Univ, Sch Med, Immunol Grad Program, Stanford, CA 94305 USA; [Linde, Miles H.; Banuelos, Allison; Barkal, Amira; Brewer, Rachel E.; Marjon, Kristopher D.; Monje, Michelle; Daldrup-Link, Heike E.; Weissman, Irving L.; Majeti, Ravindra] Inst Stem Cell Biol & Regenerat Med, Stanford, CA USA; [Linde, Miles H.; Coles, Garry L.; Sotillo, Elena; Banuelos, Allison; Heitzeneder, Sabine; Barkal, Amira; Brewer, Rachel E.; Marjon, Kristopher D.; Monje, Michelle; Weissman, Irving L.; Sage, Julien; Majeti, Ravindra; Mackall, Crystal L.; Majzner, Robbie G.] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA; [Linde, Miles H.; Majeti, Ravindra; Mackall, Crystal L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Wu, Wei; Kiru, Louise; Daldrup-Link, Heike E.] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA; [Delaidelli, Alberto; Sorensen, Poul H.] British Columbia Canc Agcy, Vancouver, BC, Canada; [Silberstein, John L.; Cochran, Jennifer R.] Stanford Univ, Sch Engn, Dept Bioengn, Stanford, CA 94305 USA; [Silberstein, John L.; Cochran, Jennifer R.] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA; [Geraghty, Anna C.; Monje, Michelle] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Kuo, Tracy C.; Sangalang, Emma R. B.; Pons, Jaume] ALX Oncol, Burlingame, CA USA; [Barkal, Amira; Brewer, Rachel E.; Marjon, Kristopher D.; Monje, Michelle; Weissman, Irving L.; Majeti, Ravindra] Stanford Univ, Sch Med, Ludwig Ctr Canc Stem Cell Res & Med, Stanford, CA 94305 USA; [Barkal, Amira; Marshall, Payton L.] Stanford Univ, Stanford Med Scientist Training Program, Stanford, CA 94305 USA; [Vilches-Moure, Jose G.] Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; [Fernandes, Ricardo] Univ Oxford, Chinese Acad Med Sci CAMS, Oxford Inst COI, Oxford, England; [Fernandes, Ricardo] Univ Oxford, Nuffield Dept Med, Oxford, England; [Monje, Michelle; Weissman, Irving L.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University; Stanford University; Stanford Cancer Institute; Stanford University; Stanford University; Stanford University; British Columbia Cancer Agency; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; University of Oxford; University of Oxford; Stanford University	Majzner, RG (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.; Majzner, RG (corresponding author), Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.	rmajzner@stanford.edu		Linde, Miles/0000-0003-2553-2890; Smith, Benjamin/0000-0001-8802-416X; Heitzeneder, Sabine/0000-0001-8770-2192; Majeti, Ravindra/0000-0002-5814-0984	Alex's Lemonade Stand 'A' Award; National Institutes of Health [P01 CA217959]; German Cancer Aid (Deutsche Krebshilfe) [P-91650709]; National Cancer Institute [R01-CA227942, F30-CA232541, U01-CA217864, U01-CA213273, R35-CA231997]; American Cancer Society; Virginia and D. K. Ludwig Fund for Cancer Research; Stanford School of Medicine Medical Scientist Training Program [T32-GM007365]; Blavatnik Family Fellowship; Stanford Bio-X Bowes Fellowship; Stanford Medical Scientist Training Program; Waxman Family Research Fund	Alex's Lemonade Stand 'A' Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Virginia and D. K. Ludwig Fund for Cancer Research; Stanford School of Medicine Medical Scientist Training Program; Blavatnik Family Fellowship; Stanford Bio-X Bowes Fellowship; Stanford Medical Scientist Training Program; Waxman Family Research Fund	This work was supported by an Alex's Lemonade Stand `A' Award (R.G.M.) and National Institutes of Health P01 CA217959 (C.L.M., W.A.W. and R.G.M.). R.G.M. is the Taube Distinguished Scholar for Pediatric Immunotherapy at Stanford University School of Medicine. J.T. is supported by German Cancer Aid (Deutsche Krebshilfe) grant number P-91650709. This work was supported by the National Cancer Institute (R01-CA227942 to C.R.B., F30-CA232541 to B.A.H.S., U01-CA217864 to W.A.W. and U01-CA213273 and R35-CA231997 to J.S.), the American Cancer Society (postdoctoral fellowship to G.L.C.) and the Virginia and D. K. Ludwig Fund for Cancer Research (I.W., and M. Monje). B.A.H.S. is supported by the Stanford School of Medicine Medical Scientist Training Program (T32-GM007365). M.H.L. is supported by a Blavatnik Family Fellowship. P.L.L. is supported by the Stanford Bio-X Bowes Fellowship and the Stanford Medical Scientist Training Program. A.C.G. is supported by the Waxman Family Research Fund. We thank the Stanford Neuropathology Department for their help with immunohistochemistry. We thank K. Stegmaier and N. Mabe for providing the SY5Y-GD2-high cell line as well as expertise and advice. All cartoons were created with BioRender.com.	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Aghighi M, 2018, CLIN CANCER RES, V24, P4110, DOI 10.1158/1078-0432.CCR-18-0673; Asgharzadeh S, 2012, J CLIN ONCOL, V30, P3525, DOI 10.1200/JCO.2011.40.9169; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0; Battula VL, 2012, J CLIN INVEST, V122, P2066, DOI 10.1172/JCI59735; Best SA, 2020, J THORAC ONCOL, V15, P1507, DOI 10.1016/j.jtho.2020.05.008; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Chen Y, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07536-3; CHERESH DA, 1986, CANCER RES, V46, P5112; Cheung NKV, 2012, J CLIN ONCOL, V30, P3264, DOI 10.1200/JCO.2011.41.3807; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Desai AV, 2014, CANCER CHEMOTH PHARM, V74, P1047, DOI 10.1007/s00280-014-2575-9; Dobrenkov K, 2016, PEDIATR BLOOD CANCER, V63, P1780, DOI 10.1002/pbc.26097; Doronin II, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-295; Edelman M, 2020, J CLIN ONCOL, V38; Fisher GA, 2020, J CLIN ONCOL, V38; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Gibson TM, 2018, LANCET ONCOL, V19, P1590, DOI 10.1016/S1470-2045(18)30537-0; Grant SC, 1996, EUR J NUCL MED, V23, P145, DOI 10.1007/BF01731837; Gray MA, 2020, NAT CHEM BIOL, V16, P1376, DOI 10.1038/s41589-020-0622-x; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hingorani P, 2020, J CLIN ONCOL, V38; Hobbie WL, 2008, PEDIATR BLOOD CANCER, V51, P679, DOI 10.1002/pbc.21683; Jaffe Norman, 2013, Sarcoma, V2013, P203531, DOI 10.1155/2013/203531; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Ladenstein R, 2018, LANCET ONCOL, V19, P1617, DOI 10.1016/S1470-2045(18)30578-3; LAMMIE GA, 1993, INT J ONCOL, V3, P909; Lo M, 2017, J BIOL CHEM, V292, P3900, DOI 10.1074/jbc.M116.767749; Long AH, 2016, CANCER IMMUNOL RES, V4, P869, DOI 10.1158/2326-6066.CIR-15-0230; Loo D, 2012, CLIN CANCER RES, V18, P3834, DOI 10.1158/1078-0432.CCR-12-0715; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Majzner RG, 2020, CANCER DISCOV, V10, P702, DOI 10.1158/2159-8290.CD-19-0945; Majzner RG, 2017, CANCER-AM CANCER SOC, V123, P3807, DOI 10.1002/cncr.30724; Mohanty S, 2019, MOL ONCOL, V13, P2049, DOI 10.1002/1878-0261.12556; Moreno L, 2017, PEDIATR BLOOD CANCER, V64, P25, DOI 10.1002/pbc.26192; Mount CW, 2018, NAT MED, V24, P572, DOI 10.1038/s41591-018-0006-x; Ngamukote S, 2007, J NEUROCHEM, V103, P2327, DOI 10.1111/j.1471-4159.2007.04910.x; Poh A, 2020, CANCER DISCOV, V10, P7, DOI 10.1158/2159-8290.CD-NB2019-136; Roth M, 2014, CANCER-AM CANCER SOC, V120, P548, DOI 10.1002/cncr.28461; Rudin CM, 2020, J CLIN ONCOL, V38, P2369, DOI 10.1200/JCO.20.00793; SCHULZ G, 1984, CANCER RES, V44, P5914; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sikic BI, 2019, J CLIN ONCOL, V37, P946, DOI 10.1200/JCO.18.02018; Slart R, 1997, PAIN, V69, P119, DOI 10.1016/S0304-3959(96)03247-2; Sockolosky JT, 2016, P NATL ACAD SCI USA, V113, pE2646, DOI 10.1073/pnas.1604268113; Song LP, 2009, J CLIN INVEST, V119, P1524, DOI 10.1172/JCI37869; Sorkin LS, 2010, PAIN, V149, P135, DOI 10.1016/j.pain.2010.01.024; Suh E, 2020, LANCET ONCOL, V21, P421, DOI 10.1016/S1470-2045(19)30800-9; SVENNERHOLM L, 1994, BBA-LIPID LIPID MET, V1214, P115, DOI 10.1016/0005-2760(94)90034-5; Tsao CY, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1023975; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wei JS, 2018, CLIN CANCER RES, V24, P5673, DOI 10.1158/1078-0432.CCR-18-0599; Weiskopf K, 2013, SCIENCE, V341, P88, DOI 10.1126/science.1238856; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; White P, 2002, J IMMUNOL, V168, P869, DOI 10.4049/jimmunol.168.2.869; Wiebel M., CANC REP HOBOKEN, V4, P1394; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Wu HW, 2019, CLIN CANCER RES, V25, P4761, DOI 10.1158/1078-0432.CCR-18-3358; Xiao WH, 1997, PAIN, V69, P145, DOI 10.1016/S0304-3959(96)03280-0; Yamaji T, 2005, GLYCOBIOLOGY, V15, P667, DOI 10.1093/glycob/cwi048; Yoshida S, 2001, CANCER RES, V61, P4244; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Zhang SL, 1997, INT J CANCER, V73, P42, DOI 10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1	67	16	16	19	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					333	+		10.1038/s41591-021-01625-x	http://dx.doi.org/10.1038/s41591-021-01625-x		JAN 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35027753	Green Accepted			2022-12-27	WOS:000742323900006
J	Ruff, CT; Baron, M; Im, K; O'Donoghue, ML; Fiedorek, FT; Sabatine, MS				Ruff, Christian T.; Baron, Michelle; Im, KyungAh; O'Donoghue, Michelle L.; Fiedorek, Fred T.; Sabatine, Marc S.			Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial	NATURE MEDICINE			English	Article							GLP-1 RECEPTOR AGONIST; ITCA 650; INJECTIONS; DELIVERY	Glucagon-like peptide 1 receptor agonists (GLP-1RAs) injected periodically have been shown to not increase and, for some members of this class, decrease the risk of cardiovascular events. The cardiovascular safety of delivering a continuous subcutaneous infusion of the GLP-1RA exenatide (ITCA 650) is unknown. Here, we randomly assigned patients with type 2 diabetes with, or at risk for, atherosclerotic cardiovascular disease (ASCVD) to receive ITCA 650 or placebo to assess cardiovascular safety in a pre-approval trial (NCT01455896). The primary outcome was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina. On the basis of 2008 guidance from the US Food and Drug Administration, a non-inferiority margin of 1.8 for the upper bound of the 95% confidence interval (CI) of the hazard ratio (HR) was used. We randomized 4,156 patients (2,075 assigned to receive ITCA 650 and 2,081 assigned to receive placebo) who were followed for a median of 16 months. The primary outcome occurred in 4.6% (95/2,075) of patients in the ITCA 650 group and 3.8% (79/2,081) of patients in the placebo group, meeting the pre-specified non-inferiority criterion (HR = 1.21, 95% CI, 0.90-1.63, Pnon-inferiority = 0.004). Serious adverse events were similar between the two groups. Adverse events were more frequent in the ITCA 650 group (72%, 1,491/2,074) than in the placebo group (63.9%, 1,325/2,070), mainly due to an increase in gastrointestinal events and disorders while on ITCA 650. In patients with type 2 diabetes with, or at risk for, ASCVD, ITCA 650 was non-inferior to placebo. A larger and longer-duration cardiovascular outcomes trial is needed to define more precisely the cardiovascular effects of ITCA 650 in this population.	[Ruff, Christian T.; Im, KyungAh; O'Donoghue, Michelle L.; Sabatine, Marc S.] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA 02115 USA; [Baron, Michelle; Fiedorek, Fred T.] Intarcia Therapeut, Hayward, CA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ruff, CT (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA 02115 USA.	cruff@bwh.harvard.edu						Di Angelantonio E, 2015, JAMA-J AM MED ASSOC, V314, P52, DOI 10.1001/jama.2015.7008; Gerstein HC, 2021, NEW ENGL J MED, V385, P896, DOI 10.1056/NEJMoa2108269; Henry R, 2018, DIABETES OBES METAB, V20, P638, DOI 10.1111/dom.13133; Henry RR, 2018, DIABETES CARE, V41, P613, DOI 10.2337/dc17-1519; Henry RR, 2014, J DIABETES COMPLICAT, V28, P393, DOI 10.1016/j.jdiacomp.2013.12.009; Henry RR, 2013, DIABETES CARE, V36, P2559, DOI 10.2337/dc12-2410; Henry RR, 2013, CLIN THER, V35, P634, DOI 10.1016/j.clinthera.2013.03.011; Holman RR, 2017, NEW ENGL J MED, V377, P1228, DOI 10.1056/NEJMoa1612917; Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Rosenstock, 2016, DIABETES, V65, P183; Rosenstock J, 2018, DIABETES CARE, V41, P333, DOI 10.2337/dc17-1306; Rothmann M, 2003, STAT MED, V22, P239, DOI 10.1002/sim.1400; US Food and Drug Administration, 2008, GUID IND DIAB MELL E; Zelniker TA, 2019, CIRCULATION, V139, P2022, DOI 10.1161/CIRCULATIONAHA.118.038868; Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X	19	7	7	4	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					89	+		10.1038/s41591-021-01584-3	http://dx.doi.org/10.1038/s41591-021-01584-3		DEC 2021	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34873344				2022-12-27	WOS:000727136800001
J	Odedina, FT; Stern, MC				Odedina, Folakemi T.; Stern, Mariana C.			Role of funders in addressing the continued lack of diversity in science and medicine	NATURE MEDICINE			English	Editorial Material									[Odedina, Folakemi T.] Mayo Clin Florida, Div Hematol Oncol, Jacksonville, FL 32224 USA; [Odedina, Folakemi T.] Mayo Clin Florida, Ctr Hlth Equ & Community Engagement Res CHCR, Jacksonville, FL 32224 USA; [Stern, Mariana C.] Norris Comprehens Canc Ctr, Dept Populat & Publ Hlth Sci & Urol, Keck Sch Med USC, Los Angeles, CA USA	Mayo Clinic; Mayo Clinic	Odedina, FT (corresponding author), Mayo Clin Florida, Div Hematol Oncol, Jacksonville, FL 32224 USA.; Odedina, FT (corresponding author), Mayo Clin Florida, Ctr Hlth Equ & Community Engagement Res CHCR, Jacksonville, FL 32224 USA.	Odedina.Folakemi@mayo.edu		Odedina, Folakemi/0000-0003-3796-1385				Addo Isaac Yeboah, 2020, Soc Sci Humanit Open, V2, P100074, DOI 10.1016/j.ssaho.2020.100074; Bhattacharjee Y, 2012, SCIENCE, V336, P969, DOI 10.1126/science.336.6084.969; Collins FS, 2021, CELL, V184, P3075, DOI 10.1016/j.cell.2021.05.014; Erosheva EA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4868; Ginther DK, 2011, SCIENCE, V333, P1015, DOI 10.1126/science.1196783; Hofstra B, 2020, P NATL ACAD SCI USA, V117, P9284, DOI 10.1073/pnas.1915378117; Hoppe TA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7238; Jeste DV, 2009, AM J PUBLIC HEALTH, V99, pS31, DOI 10.2105/AJPH.2008.154633; Kaatz A, 2016, ACAD MED, V91, P1080, DOI 10.1097/ACM.0000000000001272; Kamerlin SCL, 2020, EMBO REP, V21, DOI 10.15252/embr.202051994; Nikaj S, 2018, FASEB J, V32, P6410, DOI 10.1096/fj.201800639; Shavers VL, 2005, J NATL MED ASSOC, V97, P1063; Trejo J, 2020, MOL BIOL CELL, V31, P2752, DOI 10.1091/mbc.E20-08-0567	13	4	4	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1859	1861		10.1038/s41591-021-01555-8	http://dx.doi.org/10.1038/s41591-021-01555-8		NOV 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764483	Bronze			2022-12-27	WOS:000717406200001
J	Choi, A; Koch, M; Wu, K; Chu, L; Ma, LZ; Hill, A; Nunna, N; Huang, WM; Oestreicher, J; Colpitts, T; Bennett, H; Legault, H; Paila, Y; Nestorova, B; Ding, BY; Montefiori, D; Pajon, R; Miller, JM; Leav, B; Carfi, A; McPhee, R; Edwards, DK				Choi, Angela; Koch, Matthew; Wu, Kai; Chu, Laurence; Ma, LingZhi; Hill, Anna; Nunna, Naveen; Huang, Wenmei; Oestreicher, Judy; Colpitts, Tonya; Bennett, Hamilton; Legault, Holly; Paila, Yamuna; Nestorova, Biliana; Ding, Baoyu; Montefiori, David; Pajon, Rolando; Miller, Jacqueline M.; Leav, Brett; Carfi, Andrea; McPhee, Roderick; Edwards, Darin K.			Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	NATURE MEDICINE			English	Article								The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) with decreased susceptibility to neutralization has generated interest in assessments of booster doses and variant-specific vaccines. Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study (NCT04405076) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n = 20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned (P < 0.0001) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated. All boosters, including mRNA-1273, numerically increased neutralization titers against the wild-type D614G virus compared to peak titers against wild-type D614G measured 1 month after the primary series; significant increases were observed for mRNA-1273 and mRNA-1273.211 (P < 0.0001). In addition, all boosters increased neutralization titers against key VOCs and VOIs, including B.1.351, P.1. and B.1.617.2, that were statistically equivalent to peak titers measured after the primary vaccine series against wild-type D614G virus, with superior titers against some VOIs.	[Choi, Angela; Koch, Matthew; Wu, Kai; Ma, LingZhi; Hill, Anna; Nunna, Naveen; Huang, Wenmei; Oestreicher, Judy; Colpitts, Tonya; Bennett, Hamilton; Legault, Holly; Paila, Yamuna; Nestorova, Biliana; Ding, Baoyu; Pajon, Rolando; Miller, Jacqueline M.; Leav, Brett; Carfi, Andrea; McPhee, Roderick; Edwards, Darin K.] Moderna Inc, Cambridge, MA 02139 USA; [Chu, Laurence] Benchmark Res, Austin, TX USA; [Montefiori, David] Duke Univ, Med Ctr, Immune Assay Team, Durham, NC USA	Duke University	Edwards, DK (corresponding author), Moderna Inc, Cambridge, MA 02139 USA.	darin.edwards@modernatx.com			Moderna; phase 2a mRNA-1273 P201 trial/open-label extension [NCT04405076]; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [75A50120C00034]	Moderna; phase 2a mRNA-1273 P201 trial/open-label extension; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority	We thank M. Brunner and M. Whitt at the University of Tennessee Health Science Center for their kind support on recombinant VSV-based SARS-CoV-2 pseudovirus production. We would like to thank C.-W. Hsiao at Moderna for statistical analysis of study results. Moreover, we would like to thank the Immune Assay Team at Duke University Medical Center (K. Engel, D. Beaumont, R. Beerman, K. Bradley, J. Chen, X. Daniell, T. Denny, E. Domin, A. Eaton, W. Feng, J. Gao, H. Gao, K. Greene, S. Hiles, M. Jessup-Cumming, L. Liu, K. Long, K. Lund, K. Lyons, C. McDanal, F. Suman, H. Tang, J. Tong and O. Widman) for their work on validated lentivirus PsVN assays supporting our clinical study evaluations. Medical writing and editorial assistance, under the direction of the authors, was provided by F. J. Dutko and J. E. Tomassini, consultants to Moderna, and K. Russin and S. Ramachandran of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines and funded by Moderna. Employees of the study sponsor, Moderna, contributed to the study design, data collection, analysis and interpretation and writing of the report. We thank the participants of the P201 study for their involvement in this clinical trial. Funding: The phase 2a mRNA-1273 P201 trial/open-label extension (NCT04405076) was supported, in part, with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number 75A50120C00034, and Moderna.	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Choi A., SERUM NEUTRALIZING A, DOI [10.1101/2021.06.28.449914v1(2021), DOI 10.1101/2021.06.28.449914V1(2021)]; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Shen Xiaoying, 2021, Cell Host Microbe, V29, P529, DOI [10.1101/2021.01.27.428516, 10.1016/j.chom.2021.03.002]; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179	14	150	152	6	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					2025	+		10.1038/s41591-021-01527-y	http://dx.doi.org/10.1038/s41591-021-01527-y		SEP 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34526698	Green Published, hybrid			2022-12-27	WOS:000696140200001
J	Boughton, CK; Tripyla, A; Hartnell, S; Daly, A; Herzig, D; Wilinska, ME; Czerlau, C; Fry, A; Bally, L; Hovorka, R				Boughton, Charlotte K.; Tripyla, Afroditi; Hartnell, Sara; Daly, Aideen; Herzig, David; Wilinska, Malgorzata E.; Czerlau, Cecilia; Fry, Andrew; Bally, Lia; Hovorka, Roman			Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial	NATURE MEDICINE			English	Article							GLYCEMIC CONTROL; HEMODIALYSIS; HYPOGLYCEMIA; DELIVERY	We evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 +/- 11 years (mean +/- s.d.), diabetes duration of 20 +/- 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart ('closed-loop') with standard insulin therapy and a masked continuous glucose monitor ('control') in random order. The primary endpoint was time in target glucose range (5.6-10.0 mmol l(-1)). Thirteen participants received closed-loop first and thirteen received control therapy first. The proportion of time in target glucose range (5.6-10.0 mmol l(-1); primary endpoint) was 52.8 +/- 12.5% with closed-loop versus 37.7 +/- 20.5% with control; mean difference, 15.1 percentage points (95% CI 8.0-22.2; P < 0.001). Mean glucose was lower with closed-loop than control (10.1 +/- 1.3 versus 11.6 +/- 2.8 mmol l(-1); P = 0.003). Time in hypoglycemia (<3.9 mmol l(-1)) was reduced with closed-loop versus control (median (IQR) 0.1 (0.0-0.4%) versus 0.2 (0.0-0.9%); P = 0.040). No severe hypoglycemia events occurred during the control period, whereas one severe hypoglycemic event occurred during the closed-loop period, but not during closed-loop operation. Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. The trial registration number is NCT04025775. A new randomized, crossover clinical trial testing rapid-acting insulin aspart delivered in a closed-loop system compared with standard care demonstrates increased time in range in patients with type 2 diabetes who require dialysis in the outpatient setting.	[Boughton, Charlotte K.; Daly, Aideen; Wilinska, Malgorzata E.; Hovorka, Roman] Addenbrookes Hosp, MRC Inst Metab Sci, Wellcome Trust, Cambridge, England; [Boughton, Charlotte K.; Hartnell, Sara] Cambridge Univ Hosp NHS Fdn Trust, Wolfson Diabet & Endocrine Clin, Cambridge, England; [Tripyla, Afroditi; Daly, Aideen; Bally, Lia] Bern Univ Hosp, Dept Diabet Endocrinol Nutr Med & Metab, Inselspital, Bern, Switzerland; [Tripyla, Afroditi; Herzig, David; Czerlau, Cecilia; Bally, Lia] Univ Bern, Bern, Switzerland; [Czerlau, Cecilia] Bern Univ Hosp, Dept Nephrol & Hypertens, Bern, Switzerland; [Fry, Andrew] Univ Cambridge, Cambridge Univ Hosp NHS Fdn Trust, Dept Renal Med, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Cambridge	Boughton, CK (corresponding author), Addenbrookes Hosp, MRC Inst Metab Sci, Wellcome Trust, Cambridge, England.; Boughton, CK (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Wolfson Diabet & Endocrine Clin, Cambridge, England.	cb2000@medschl.cam.ac.uk	Hovorka, Roman/J-4123-2016	Hovorka, Roman/0000-0003-2901-461X; Boughton, Charlotte/0000-0003-3272-9544; Daly, Aideen/0000-0001-5003-9630; Czerlau, Cecilia/0000-0002-9453-2766	National Institute for Health Research Cambridge Biomedical Research Centre; Novo Nordisk UK Research Foundation; Swiss Society for Endocrinology and Diabetes (SGED/SSED); Swiss Diabetes Foundation; Swiss Kidney Foundation	National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Novo Nordisk UK Research Foundation; Swiss Society for Endocrinology and Diabetes (SGED/SSED); Swiss Diabetes Foundation; Swiss Kidney Foundation	Dexcom supplied discounted continuous glucose monitoring devices and sensors for the study. Company representatives had no role in the study conduct. The study was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. C.B. was supported by a grant from The Novo Nordisk UK Research Foundation and L.B. was supported by a grant from the Swiss Society for Endocrinology and Diabetes (SGED/SSED) and a grant from the Swiss Diabetes Foundation and Swiss Kidney Foundation. We are grateful to all study participants for their contribution, time and support. We acknowledge administrative support from N. Ashcroft at the University of Cambridge. We thank D. Studer, C. Piazza and N. Truffer, who contributed to patient care and study logistics in Bern, and the Diabetes Center Bern for providing infrastructure for the study team in Bern. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or other funders.	Abe M, 2015, NAT REV NEPHROL, V11, P302, DOI 10.1038/nrneph.2015.38; Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS73, DOI 10.2337/dc21-S006; [Anonymous], 2016, MAN AD DIAB HAEM UN; [Anonymous], 2020, ERA EDTA REG ANN REP; [Anonymous], 2020, UK REN REG 22 ANN RE; Bally L, 2019, KIDNEY INT, V96, P593, DOI 10.1016/j.kint.2019.03.006; Bally L, 2018, NEW ENGL J MED, V379, P547, DOI 10.1056/NEJMoa1805233; Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028; Boughton CK, 2019, LANCET DIABETES ENDO, V7, P368, DOI 10.1016/S2213-8587(19)30061-0; Chu YW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174601; Copur S, 2021, ACTA DIABETOL, V58, P81, DOI 10.1007/s00592-020-01581-x; COX DJ, 1987, DIABETES CARE, V10, P617, DOI 10.2337/diacare.10.5.617; Frankel AH, 2018, DIABETIC MED, V35, P1018, DOI 10.1111/dme.13676; Galindo RJ, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa017; Herrero P, 2021, DIABETES TECHNOL THE, V23, P314, DOI 10.1089/dia.2020.0387; Hill CJ, 2014, AM J KIDNEY DIS, V63, P84, DOI 10.1053/j.ajkd.2013.06.020; Hovorka R, 2011, NAT REV ENDOCRINOL, V7, P385, DOI 10.1038/nrendo.2011.32; Jones B., 2014, DESIGN ANAL CROSS OV; Jung HS, 2010, DIABETES TECHNOL THE, V12, P801, DOI 10.1089/dia.2010.0067; Kazempour-Ardebili S, 2009, DIABETES CARE, V32, P1137, DOI 10.2337/dc08-1688; Leelarathna L, 2020, DIABETES CARE, V43, pE38, DOI 10.2337/dc19-2041; POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754; Polonsky WH, 2017, DIABETES TECHNOL THE, V19, P131, DOI 10.1089/dia.2016.0366; Thabit H, 2017, LANCET DIABETES ENDO, V5, P117, DOI 10.1016/S2213-8587(16)30280-7	24	14	15	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1471	+		10.1038/s41591-021-01453-z	http://dx.doi.org/10.1038/s41591-021-01453-z		AUG 2021	10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34349267	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000681270700001
J	Mocanu, V; Zhang, ZX; Deehan, EC; Kao, DH; Hotte, N; Karmali, S; Birch, DW; Samarasinghe, KK; Walter, J; Madsen, KL				Mocanu, Valentin; Zhang, Zhengxiao; Deehan, Edward C.; Kao, Dina H.; Hotte, Naomi; Karmali, Shahzeer; Birch, Daniel W.; Samarasinghe, Kalutota K.; Walter, Jens; Madsen, Karen L.			Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial	NATURE MEDICINE			English	Article							GUT MICROBIOTA; INSULIN SENSITIVITY; INTESTINAL MICROBIOTA; INDIVIDUALS; MODULATION; MANAGEMENT; COST	Fecal microbial transplantation (FMT) from lean donors to patients with obesity has been associated with metabolic benefits, yet results so far have been inconsistent. In this study, we tested the application of daily fiber supplementation as an adjunct to FMT therapy to modulate cardiometabolic outcomes. We performed a double-blind randomized trial in patients with severe obesity and metabolic syndrome receiving oral FMT, to test high-fermentable (HF) and low-fermentable (LF) fiber supplements (NCT03477916). Seventy participants were randomized to the FMT-HF (n = 17), FMT-LF (n = 17), HF (n = 17) and LF (n = 19) groups. The primary outcome was the assessment of change in insulin sensitivity from baseline to 6 weeks using the homeostatic model assessment (HOMA2-IR/IS). After 6 weeks, only patients in the FMT-LF group had significant improvements in HOMA2-IR (3.16 +/- 3.01 at 6 weeks versus 3.77 +/- 3.57 at baseline; P = 0.02). No difference in HOMA2-IR was observed over this period for those in the FMT-HF group (3.25 +/- 1.70 at 6 weeks versus 3.17 +/- 1.72 at baseline; P = 0.8), the HF group (3.49 +/- 1.43 at 6 weeks versus 3.26 +/- 1.33 at baseline; P = 0.8) or the LF group (3.76 +/- 2.01 at 6 weeks versus 3.56 +/- 1.81 at baseline; P = 0.8). Interventions were safe and well-tolerated with no treatment-attributed serious adverse events. We provide proof of concept for the use of a single-dose oral FMT combined with daily low-fermentable fiber supplementation to improve insulin sensitivity in patients with severe obesity and metabolic syndrome. Results from a phase 2 randomized controlled trial demonstrate improved insulin sensitivity in patients with severe obesity and metabolic syndrome following single-dose fecal microbial transplantation and daily supplementation with low-fermentable fiber for 6 weeks.	[Mocanu, Valentin; Karmali, Shahzeer; Birch, Daniel W.] Univ Alberta, Dept Surg, Edmonton, AB, Canada; [Zhang, Zhengxiao; Deehan, Edward C.; Hotte, Naomi] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Zhang, Zhengxiao] Jimei Univ, Coll Food & Biol Engn, Xiamen, Peoples R China; [Kao, Dina H.; Madsen, Karen L.] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada; [Samarasinghe, Kalutota K.] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada; [Walter, Jens] Univ Coll Cork, APC Microbiome Ireland, Sch Microbiol, Cork, Ireland; [Walter, Jens] Univ Coll Cork, Dept Med, Cork, Ireland	University of Alberta; University of Alberta; Jimei University; University of Alberta; University of Alberta; University College Cork; University College Cork	Madsen, KL (corresponding author), Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada.	kmadsen@ualberta.ca	Madsen, Karen L/H-5898-2011; Zhang, Zhengxiao/AAM-7779-2020; Deehan, Edward C./ABF-6669-2020; Walter, Jens/AAA-7636-2020	Zhang, Zhengxiao/0000-0002-6977-4309; Deehan, Edward C./0000-0001-7697-1418; Walter, Jens/0000-0003-1754-172X; Birch, Daniel/0000-0001-8737-4184; Samarasinghe, Kalutota Kuruwe Arachchige Sajana Indula/0000-0002-4173-4161; Madsen, Karen/0000-0002-8636-0714	Canadian Institutes of Health Research (CIHR); Alberta Innovates; Clinical Investigator Program; W. Garfield Weston Foundation [RES0048879]; Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates; Clinical Investigator Program; W. Garfield Weston Foundation; Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)	We thank the Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) for the infrastructure and support provided throughout the project. We also thank M. Emberg for his support with FMT preparation, R. Odsen for his help with trial coordination, and T. Dang for his help with fecal 16s rRNA extraction. We acknowledge S. Jamieson and D. Turner-Crerar as members of the University of Alberta Quality Management in Clinical Research Department (QMCR) for providing safety oversight. V.M. is the recipient of scholarships from the Canadian Institutes of Health Research (CIHR), Alberta Innovates, and the Clinical Investigator Program. Last, we thank the W. Garfield Weston Foundation (RES0048879) for the funding that made this project possible. The funders had no role in the study design, data collection and analysis, decision to publish or the preparation of the paper.	Abenavoli L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112690; Allegretti J, 2017, INFLAMM BOWEL DIS, V23, P1710, DOI 10.1097/MIB.0000000000001247; [Anonymous], 11 HLTH CAN; Aron-Wisnewsky J, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1180-z; Atzeni A, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9020346; Babiker R, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-111; Bakker G. J., 2017, MICROBIOL SPECTR, V5, DOI [DOI 10.1128/MICROBIOLSPEC.BAD-0008-2017, DOI 10.1128/microbiolspec.BAD-0008-2017]; Bindels LB, 2015, CURR OPIN CLIN NUTR, V18, P559, DOI 10.1097/MCO.0000000000000223; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Chassard C, 2010, FEMS MICROBIOL ECOL, V74, P205, DOI 10.1111/j.1574-6941.2010.00941.x; Chis R, 2018, PHYSIOL HEALTH DIS, P279, DOI 10.1007/978-1-4939-7534-1_11; Dahiya DK, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00563; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; de Groot PF, 2017, GUT MICROBES, V8, P253, DOI 10.1080/19490976.2017.1293224; de Groot P, 2020, GUT, V69, P502, DOI 10.1136/gutjnl-2019-318320; Dovrolis N, 2019, ANN GASTROENTEROL, V32, P233, DOI 10.20524/aog.2019.0373; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Finkelstein EA, 2012, AM J PREV MED, V42, P563, DOI 10.1016/j.amepre.2011.10.026; Gill SK, 2021, NAT REV GASTRO HEPAT, V18, P101, DOI 10.1038/s41575-020-00375-4; Gribble FM, 2019, NAT REV ENDOCRINOL, V15, P226, DOI 10.1038/s41574-019-0168-8; Hiippala K, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.575455; Holscher HD, 2015, AM J CLIN NUTR, V101, P55, DOI 10.3945/ajcn.114.092064; Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x; Ianiro G, 2014, CURR DRUG TARGETS, V15, P762, DOI 10.2174/1389450115666140606111402; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Kao D, 2017, JAMA-J AM MED ASSOC, V318, P1985, DOI 10.1001/jama.2017.17077; Klebanoff MJ, 2017, JAMA SURG, V152, P136, DOI 10.1001/jamasurg.2016.3640; Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008; Kuk J. L, 2020, CANADIAN ADULT OBESI; Laffin M, 2018, INFLAMM BOWEL DIS, V24, P101, DOI 10.1093/ibd/izx033; le Roux CW, 2017, LANCET, V389, P1399, DOI 10.1016/S0140-6736(17)30069-7; Lee P, 2019, DIABETES OBES METAB, V21, P479, DOI 10.1111/dom.13561; Leshem A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01341; Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Marotz Clarisse A., 2016, Yale Journal of Biology and Medicine, V89, P383; Mehta A, 2017, OBES SCI PRACT, V3, P3, DOI 10.1002/osp4.84; Meijnikman AS, 2018, ENDOCR REV, V39, P133, DOI 10.1210/er.2017-00192; Naderpoor N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040452; National Health and Nutriton Examination Survey. (NHANES), 2011, ANTHR PROC MAN; National institutes of Health National Heart Lung ABI, 2000, PRACT GUID ID EV TRE; Oksanen J., **DATA OBJECT**; Paradis, 2012, ANAL PHYOGENETICS EV; Parekh PJ, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.16; Porras D, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01813; Pradhan B, 2017, BIOMED REV, V27, P1, DOI DOI 10.14748/BMR.V27.2108; Sbahi H, 2016, BMJ OPEN GASTROENTER, V3, DOI 10.1136/bmjgast-2016-000087; Schaub M, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0013115, 10.1371/journal.pone.0015046]; Stripling J, 2018, AM J MED SCI, V356, P424, DOI 10.1016/j.amjms.2018.08.010; Tan WSK, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040961; Twells Laurie K, 2014, CMAJ Open, V2, pE18, DOI 10.9778/cmajo.20130016; Upadhyaya B, 2016, SCI REP-UK, V6, DOI 10.1038/srep28797; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Walter J, 2018, CURR OPIN BIOTECH, V49, P129, DOI 10.1016/j.copbio.2017.08.008; Wang TY, 2020, APPL MICROBIOL BIOT, V104, P7143, DOI 10.1007/s00253-020-10689-7; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x; Zhang ZX, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102291; Zou J, 2018, CELL HOST MICROBE, V23, P41, DOI 10.1016/j.chom.2017.11.003	59	47	47	9	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1272	+		10.1038/s41591-021-01399-2	http://dx.doi.org/10.1038/s41591-021-01399-2		JUL 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34226737				2022-12-27	WOS:000669779100001
J	Haldane, V; Foo, CD; Abdalla, SM; Jung, AS; Tan, M; Wu, SS; Chua, A; Verma, M; Shrestha, P; Singh, S; Perez, T; Tan, SM; Bartos, M; Mabuchi, S; Bonk, M; McNab, C; Werner, GK; Panjabi, R; Nordstrom, A; Legido-Quigley, H				Haldane, Victoria; De Foo, Chuan; Abdalla, Salma M.; Jung, Anne-Sophie; Tan, Melisa; Wu, Shishi; Chua, Alvin; Verma, Monica; Shrestha, Pami; Singh, Sudhvir; Perez, Tristana; Tan, See Mieng; Bartos, Michael; Mabuchi, Shunsuke; Bonk, Mathias; McNab, Christine; Werner, George K.; Panjabi, Raj; Nordstrom, Anders; Legido-Quigley, Helena			Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	NATURE MEDICINE			English	Review							IMPACTS; EBOLA	A review of COVID-19 responses in 28 selected countries identifies elements of highly effective public health responses and offers recommendations toward strengthening health systems resilience. Health systems resilience is key to learning lessons from country responses to crises such as coronavirus disease 2019 (COVID-19). In this perspective, we review COVID-19 responses in 28 countries using a new health systems resilience framework. Through a combination of literature review, national government submissions and interviews with experts, we conducted a comparative analysis of national responses. We report on domains addressing governance and financing, health workforce, medical products and technologies, public health functions, health service delivery and community engagement to prevent and mitigate the spread of COVID-19. We then synthesize four salient elements that underlie highly effective national responses and offer recommendations toward strengthening health systems resilience globally.	[Haldane, Victoria] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [De Foo, Chuan; Tan, Melisa; Wu, Shishi; Chua, Alvin; Verma, Monica; Shrestha, Pami; Tan, See Mieng; Legido-Quigley, Helena] Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Abdalla, Salma M.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Abdalla, Salma M.; Singh, Sudhvir; Bartos, Michael; Mabuchi, Shunsuke; Bonk, Mathias; McNab, Christine; Werner, George K.; Panjabi, Raj; Nordstrom, Anders; Legido-Quigley, Helena] Independent Panel Pandem Preparedness & Response, Geneva, Switzerland; [Jung, Anne-Sophie; Perez, Tristana; Legido-Quigley, Helena] London Sch Hyg & Trop Med, London, England; [Singh, Sudhvir] Univ Auckland, Fac Med & Hlth Sci, Auckland, New Zealand; [Bartos, Michael] Australian Natl Univ, Sch Sociol, Canberra, ACT, Australia; [Bonk, Mathias] Berlin Inst Global Hlth, Berlin, Germany	University of Toronto; Boston University; University of London; London School of Hygiene & Tropical Medicine; University of Auckland; Australian National University	Legido-Quigley, H (corresponding author), Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.; Legido-Quigley, H (corresponding author), Independent Panel Pandem Preparedness & Response, Geneva, Switzerland.; Legido-Quigley, H (corresponding author), London Sch Hyg & Trop Med, London, England.	ephhlq@nus.edu.sg	Chua, Alvin Qijia/GQH-3027-2022; Foo, Chuan De/AAJ-9844-2021	Chua, Alvin Qijia/0000-0001-6920-1204; Foo, Chuan De/0000-0001-7254-4881; Haldane, Victoria/0000-0002-8674-4099; Abdalla, Salma/0000-0001-5474-4521; Singh, Sudhvir/0000-0002-9915-6755; Verma, Monica/0000-0003-1054-0337; Jung, Anne-Sophie/0000-0001-7039-7830	Independent Panel for Pandemic Preparedness and Response	Independent Panel for Pandemic Preparedness and Response	Data for this review were collected under the auspices of the Independent Panel for Pandemic Preparedness and Response. The analysis of this paper is separate from the Independent Panel's Final Report and has been facilitated by the Independent Panel Secretariat. The Secretariat of the Independent Panel for Pandemic Preparedness and Response is independent and impartial. The views expressed in this work are solely that of the authors and do not represent the views of the Independent Panel for Pandemic Preparedness and Response.	ABOUT US, AFRICA MED SUPPLIES; Alwan NA, 2020, LANCET, V396, pE24, DOI 10.1016/S0140-6736(20)31823-7; [Anonymous], 2020, HEALTH HUM RIGHTS; [Anonymous], 2020, HLTH HUM RIGHTS; Baker MG, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4907; Ballard M, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002550; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Barker KM, 2020, HEALTH POLICY PLANN, V35, P416, DOI 10.1093/heapol/czz174; Baum F, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n91; Bhutta Z.A., 2010, GLOB HLTH WORKFORCE, V1, P61; Bonell C, 2020, J EPIDEMIOL COMMUN H, V74, P617, DOI 10.1136/jech-2020-214290; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8., 10.1016/S0140-6736(20)30460-8]; Cevik M, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n224; China CDC, 2020, LAUNCH INFECT DIS RE; Chiolero A, 2013, EUR J PUBLIC HEALTH, V23, P350, DOI 10.1093/eurpub/ckt044; Chua AQ, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003317; Davies SE, 2016, INT AFF, V92, P1041, DOI 10.1111/1468-2346.12704; Ebi KL, 2008, AM J PREV MED, V35, P501, DOI 10.1016/j.amepre.2008.08.018; El Bcheraoui C, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00645-5; Endo Akira, 2020, Wellcome Open Res, V5, P239, DOI 10.12688/wellcomeopenres.16344.1; Etienne CF, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003509; Gilmore B, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003188; Glover RE, 2020, J CLIN EPIDEMIOL, V128, P35, DOI 10.1016/j.jclinepi.2020.06.004; Haldane V, 2021, HEALTH POLICY PLANN, V36, P134, DOI 10.1093/heapol/czaa169; Haldane V, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-041622; Haldane V, 2017, LANCET, V389, P1513, DOI 10.1016/S0140-6736(17)30946-7; Hao XJ, 2020, NATURE, V584, P420, DOI 10.1038/s41586-020-2554-8; Harman S, 2016, THIRD WORLD Q, V37, P524, DOI 10.1080/01436597.2015.1108827; Her M, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100137; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; International Trade Center, 2020, COVID 19 TEMP TRAD M; Jajosky RA, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-29; Keshet Y, 2020, ISR J HEALTH POLICY, V9, DOI 10.1186/s13584-020-00429-7; Khan MS, 2017, HEALTH POLICY PLANN, V32, P12, DOI 10.1093/heapol/czx051; Klenk M, 2021, ETHICS INF TECHNOL, V23, P69, DOI 10.1007/s10676-020-09544-0; Koo Denise, 2012, Am J Public Health, V102 Suppl 3, pS307, DOI 10.2105/AJPH.2012.300824; Kruk ME, 2015, LANCET, V385, P1910, DOI 10.1016/S0140-6736(15)60755-3; Lal A, 2021, LANCET, V397, P61, DOI 10.1016/S0140-6736(20)32228-5; Lee K, 2009, GLOB INST, P1; Legido-Quigley H, 2018, RESILIENT PEOPLE CTR; Legido-Quigley H, 2020, LANCET, V395, P848, DOI 10.1016/S0140-6736(20)30551-1; Lewis D, 2020, NATURE, V588, P384, DOI 10.1038/d41586-020-03518-4; Luo HB, 2020, AUTOMAT CONSTR, V119, DOI 10.1016/j.autcon.2020.103345; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; Megnin-Viggars O, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241473; Ministry of Economy T. and I, 2020, CURR STAT PROD SUPPL; Ministry of Health New Zealand, 2020, COVID 19 ADV ALL HLT; Monaghesh E, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09301-4; Mukherjee S., 2020, MARUTI SUZUKI HELP P; Nigeria Centre for Disease Control, 2020, NCDC UNICEF LAUNCH C; Nishtar S, 2010, B WORLD HEALTH ORGAN, V88, P74, DOI 10.2471/BLT.09.067868; Nuzzo JB, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7707-z; Organization WH, 2020, COR DIS COVID 19 TEC; Pung R, 2020, LANCET, V395, P1039, DOI 10.1016/S0140-6736(20)30528-6; Shadmi E, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01218-z; Social Science in Humanitarian Action, 2020, KEY CONS QUAR CONT C; The World Bank, 2020, POP LEV NAT TEST STR; United Nations System Chief Executives Board for Coordination (CEB), 2016, UN PLAN ACT DIS RISK; Veillard J., 2020, TESTING TESTING ESSE; Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2; WHO, 2020, STRENGTH PARTN FAITH; WHO, 2010, MONITORING BUILDING; WHO (World Health Organization), 2019, UNIVERSAL HLTH COVER; World Bank, 2020, SAV LIV SCAL UP IMP; World Bank. World Bank Group, 2020, 100 COUNTR GET SUPP; World Health Organization, 2020, UK GIVES 13000000 FI; World Health Organization, 2020, RAT US PERS PROD EQ; World Health Organization, 2020, COVID 19 SUPPL CHAIN; World Health Organization, 2020, DIG TOOLS COVID 19 C; World Health Organization, 2020, FAST TRACK REV GUID; World Health Organization, 2020, HLTH WORKFORCE POLIC; World Health Organization Western Pacific, 2020, COVID 19 VULN HIGH R	72	137	141	45	74	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					964	980		10.1038/s41591-021-01381-y	http://dx.doi.org/10.1038/s41591-021-01381-y		MAY 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34002090	Bronze			2022-12-27	WOS:000651469300001
J	Gaziano, L; Giambartolomei, C; Pereira, AC; Gaulton, A; Posner, DC; Swanson, SA; Ho, YL; Iyengar, SK; Kosik, NM; Vujkovic, M; Gagnon, DR; Bento, AP; Barrio-Hernandez, I; Ronnblom, L; Hagberg, N; Lundtoft, C; Langenberg, C; Pietzner, M; Valentine, D; Gustincich, S; Tartaglia, GG; Allara, E; Surendran, P; Burgess, S; Zhao, JH; Peters, JE; Prins, BP; Di Angelantonio, E; Devineni, P; Shi, YL; Lynch, KE; DuVall, SL; Garcon, H; Thomann, LO; Zhou, JJ; Gorman, BR; Huffman, JE; O'Donnell, CJ; Tsao, PS; Beckham, JC; Pyarajan, S; Muralidhar, S; Huang, GD; Ramoni, R; Beltrao, P; Danesh, J; Hung, AAM; Chang, KM; Sun, YV; Joseph, J; Leach, AR; Edwards, TL; Cho, K; Gaziano, JM; Butterworth, AS; Casas, JP				Gaziano, Liam; Giambartolomei, Claudia; Pereira, Alexandre C.; Gaulton, Anna; Posner, Daniel C.; Swanson, Sonja A.; Ho, Yuk-Lam; Iyengar, Sudha K.; Kosik, Nicole M.; Vujkovic, Marijana; Gagnon, David R.; Bento, A. Patricia; Barrio-Hernandez, Inigo; Ronnblom, Lars; Hagberg, Niklas; Lundtoft, Christian; Langenberg, Claudia; Pietzner, Maik; Valentine, Dennis; Gustincich, Stefano; Tartaglia, Gian Gaetano; Allara, Elias; Surendran, Praveen; Burgess, Stephen; Zhao, Jing Hua; Peters, James E.; Prins, Bram P.; Angelantonio, Emanuele Di; Devineni, Poornima; Shi, Yunling; Lynch, Kristine E.; DuVall, Scott L.; Garcon, Helene; Thomann, Lauren O.; Zhou, Jin J.; Gorman, Bryan R.; Huffman, Jennifer E.; O'Donnell, Christopher J.; Tsao, Philip S.; Beckham, Jean C.; Pyarajan, Saiju; Muralidhar, Sumitra; Huang, Grant D.; Ramoni, Rachel; Beltrao, Pedro; Danesh, John; Hung, Adriana M.; Chang, Kyong-Mi; Sun, Yan V.; Joseph, Jacob; Leach, Andrew R.; Edwards, Todd L.; Cho, Kelly; Gaziano, J. Michael; Butterworth, Adam S.; Casas, Juan P.		VA Million Vet Program CO	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19	NATURE MEDICINE			English	Article							INTERFERON-ALPHA; IN-VITRO; RECEPTOR	Large-scale Mendelian randomization and colocalization analyses using gene expression and soluble protein data for 1,263 actionable druggable genes, which encode protein targets for approved drugs or drugs in clinical development, identify IFNAR2 and ACE2 as the most promising therapeutic targets for early management of COVID-19. Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2, P = 1.6 x 10(-6); IFNAR2, P = 9.8 x 10(-11) and IL-10RB, P = 2.3 x 10(-14)) using cis-expression quantitative trait loci genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared expression quantitative trait loci signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.	[Gaziano, Liam; Posner, Daniel C.; Ho, Yuk-Lam; Kosik, Nicole M.; Gagnon, David R.; Devineni, Poornima; Shi, Yunling; Garcon, Helene; Thomann, Lauren O.; Gorman, Bryan R.; Pyarajan, Saiju; Joseph, Jacob; Cho, Kelly; Gaziano, J. Michael; Casas, Juan P.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Boston, MA 02130 USA; [Gaziano, Liam; Allara, Elias; Surendran, Praveen; Zhao, Jing Hua; Prins, Bram P.; Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Univ Cambridge, Dept Publ Hlth & Primary Care, BHF Cardiovasc Epidemiol Unit, Cambridge, England; [Giambartolomei, Claudia; Gustincich, Stefano; Tartaglia, Gian Gaetano] Ist Italiano Tecnol, Cent RNA Lab, Genoa, Italy; [Giambartolomei, Claudia] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Pereira, Alexandre C.] Univ Sao Paulo, Heart Inst, Lab Genet & Mol Cardiol, Sao Paulo, Brazil; [Pereira, Alexandre C.] Harvard Univ, Harvard Med Sch, Genet Dept, Boston, MA 02115 USA; [Gaulton, Anna; Bento, A. Patricia; Leach, Andrew R.] European Bioinformat Inst, European Mol Biol Lab, Chem Biol, Hinxton, England; [Swanson, Sonja A.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Iyengar, Sudha K.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA; [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Iyengar, Sudha K.] Cleveland VA, Louis Stoke, Cleveland, OH USA; [Vujkovic, Marijana] Univ Penn, Perelman Sch Med, Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA; [Vujkovic, Marijana; Chang, Kyong-Mi] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gagnon, David R.] Boston Univ, Sch Publ Hlth, Biostat, Boston, MA USA; [Barrio-Hernandez, Inigo; Beltrao, Pedro] European Bioinformat Inst, European Mol Biol Lab, Hinxton, England; [Ronnblom, Lars; Hagberg, Niklas; Lundtoft, Christian] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Langenberg, Claudia] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany; [Langenberg, Claudia; Pietzner, Maik] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Valentine, Dennis] UCL, Inst Hlth Informat, London, England; [Valentine, Dennis] UCL, Hlth Data Res, London, England; [Surendran, Praveen; Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Univ Cambridge, British Heart Fdn Ctr Res Excellence, Cambridge, England; [Surendran, Praveen; Peters, James E.; Prins, Bram P.; Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England; [Surendran, Praveen; Peters, James E.; Prins, Bram P.; Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Univ Cambridge, Cambridge, England; [Surendran, Praveen; Burgess, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Burgess, Stephen] Univ Cambridge, MRC Biostat Unit, Cambridge, England; [Peters, James E.] Imperial Coll, Dept Immunol & Inflammat, Ctr Inflammatory Dis, London, England; [Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Univ Cambridge, Natl Inst Hlth Res, Blood & Transplant Res Unit Donor Hlth & Genom, Cambridge, England; [Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Univ Cambridge, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England; [Angelantonio, Emanuele Di; Danesh, John; Butterworth, Adam S.] Cambridge Univ Hosp, Cambridge, England; [Lynch, Kristine E.; DuVall, Scott L.] VA Salt Lake City Hlth Care Syst, VA Informat & Comp Infrastruct, Salt Lake City, UT USA; [Lynch, Kristine E.; DuVall, Scott L.] Univ Utah, Dept Internal Med, Epidemiol, Salt Lake City, UT 84112 USA; [Zhou, Jin J.] Univ Arizona, Dept Epidemiol & Biostat, Tucson, AZ USA; [Zhou, Jin J.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA; [Huffman, Jennifer E.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Ctr Populat Genom, Boston, MA USA; [O'Donnell, Christopher J.] VA Boston Healthcare Syst, Cardiol, Boston, MA USA; [O'Donnell, Christopher J.] Harvard Med Sch, Brigham & Womens Hosp, Med, Boston, MA 02115 USA; [Tsao, Philip S.] VA Palo Alto Hlth Care Syst, Epidemiol Res & Informat Ctr ERIC, Palo Alto, CA USA; [Tsao, Philip S.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA; [Beckham, Jean C.] Durham VA Med Ctr, MIRECC, Durham, NC USA; [Beckham, Jean C.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA; [Muralidhar, Sumitra; Huang, Grant D.; Ramoni, Rachel] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [Hung, Adriana M.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA; [Hung, Adriana M.] Vanderbilt Univ, Nephrol & Hypertens, 221 Kirkland Hall, Nashville, TN 37235 USA; [Chang, Kyong-Mi] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA; [Sun, Yan V.] Atlanta VA Hlth Care Syst, Decatur, GA USA; [Sun, Yan V.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Joseph, Jacob] VA Boston Healthcare Syst, Med, Cardiovasc, Boston, MA USA; [Joseph, Jacob] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Edwards, Todd L.] Vanderbilt Univ, US Dept Vet Affairs, Tennessee Valley Healthcare Syst, 221 Kirkland Hall, Nashville, TN 37235 USA; [Edwards, Todd L.] Vanderbilt Univ, Med Ctr, Vanderbilt Genet Inst, Med,Epidemiol, Nashville, TN USA; [Cho, Kelly; Gaziano, J. Michael; Casas, Juan P.] Harvard Med Sch, Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; University of Cambridge; Istituto Italiano di Tecnologia - IIT; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Universidade de Sao Paulo; Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL); Erasmus University Rotterdam; Erasmus MC; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Boston University; European Molecular Biology Laboratory (EMBL); Uppsala University; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; University of London; University College London; University of London; University College London; University of Cambridge; University of Cambridge; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Imperial College London; University of Cambridge; University of Cambridge; University of Cambridge; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; University of Arizona; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; US Department of Veterans Affairs; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Emory University; Rollins School Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Casas, JP (corresponding author), VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Boston, MA 02130 USA.; Butterworth, AS (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, BHF Cardiovasc Epidemiol Unit, Cambridge, England.; Butterworth, AS (corresponding author), Univ Cambridge, British Heart Fdn Ctr Res Excellence, Cambridge, England.; Butterworth, AS (corresponding author), Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England.; Butterworth, AS (corresponding author), Univ Cambridge, Cambridge, England.; Butterworth, AS (corresponding author), Univ Cambridge, Natl Inst Hlth Res, Blood & Transplant Res Unit Donor Hlth & Genom, Cambridge, England.; Butterworth, AS (corresponding author), Univ Cambridge, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England.; Butterworth, AS (corresponding author), Cambridge Univ Hosp, Cambridge, England.; Casas, JP (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.	asb38@medschl.cam.ac.uk; jpcasasromero@bwh.harvard.edu	Langenberg, Claudia/ABG-9067-2021; Vujković, Marijana/S-9414-2019; Allara, Elias/ABF-2273-2021; Pereira, Alexandre/HHN-1038-2022; Joseph, Jacob/GYR-1361-2022; Leach, Andrew/N-9949-2017	Langenberg, Claudia/0000-0002-5017-7344; Vujković, Marijana/0000-0003-4924-5714; Allara, Elias/0000-0002-1634-8330; Joseph, Jacob/0000-0002-7279-4896; Di Angelantonio, Emanuele/0000-0001-8776-6719; Lundtoft, Christian/0000-0001-5872-4253; Santos Franco Ferreira Bento, Ana Patricia/0000-0003-1424-480X; DuVall, Scott/0000-0002-4898-3865; Pietzner, Maik/0000-0003-3437-9963; Leach, Andrew/0000-0001-8178-0253; Posner, Daniel C/0000-0002-3056-6924; Kosik, Nicole/0000-0003-1384-7035; Gustincich, Stefano/0000-0002-2749-2514; Beltrao, Pedro/0000-0002-2724-7703; Burgess, Stephen/0000-0001-5365-8760; Barrio-Hernandez, Inigo/0000-0002-5686-0451	Department of Veterans Affairs [MVP001]; European Union's Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant [754490]; MINDED project; Member States of the European Molecular Biology Laboratory; Open Targets [OTAR-044]; Medical Research Council [MC_UU_12015/1, MC_PC_13046]; University of Cambridge; Somalogic; UK Research and Innovation Fellowship at Health Data Research UK [MR/S004068/2]; Swedish Research Council; EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart [116074]; British Heart Foundation Programme [RG/18/13/33946]; UK Medical Research Council [MR/L003120/1]; British Heart Foundation [RG/18/13/33946, RG/13/13/30194]; National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre [BRC-1215-20014]; NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR) [BTRU-201410024]; Health Data Research UK - UK Medical Research Council; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome; NIHR Senior Investigator Award;  [MVP035]	Department of Veterans Affairs(US Department of Veterans Affairs); European Union's Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant; MINDED project; Member States of the European Molecular Biology Laboratory; Open Targets; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Cambridge(University of Cambridge); Somalogic; UK Research and Innovation Fellowship at Health Data Research UK; Swedish Research Council(Swedish Research CouncilEuropean Commission); EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart; British Heart Foundation Programme(British Heart Foundation); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR); Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome; NIHR Senior Investigator Award; 	We are grateful to the Host Genetic Initiative for making their data publicly available (full acknowledgements can be found at https://www.covid19hg.org/acknowledgements/).This research is based on data from the MVP, Office of Research and Development, VA and was supported by award no. MVP035. This research was also supported by additional Department of Veterans Affairs awards grant no. MVP001. This publication does not represent the views of the Department of Veteran Affairs or the US Government. Full acknowledgements for the VA MVP COVID-19 Science Initiative can be found in Supplementary Methods. C.G. has received funding from the European Union's Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant agreement no. 754490, MINDED project. A.G., P.B. and A.R.L. are funded by the Member States of the European Molecular Biology Laboratory. I.B.-H. received funding from Open Targets (grant agreement OTAR-044). The Fenland study59 is funded by the Medical Research Council (MC_UU_12015/1); we are grateful to all the volunteers and to the General Practitioners and practice staff for assistance with recruitment; we thank the Fenland Study Investigators, Fenland Study Co-ordination team and the Epidemiology Field, Data and Laboratory teams; we further acknowledge support for genomics from the Medical Research Council (MC_PC_13046); proteomic measurements were supported and governed by a collaboration agreement between the University of Cambridge and Somalogic. J.E.P. is supported by UK Research and Innovation Fellowship at Health Data Research UK (MR/S004068/2). L.R., N.H. and C.L. are supported by the Swedish Research Council. E.A. was supported by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant no. 116074 and by the British Heart Foundation Programme grant RG/18/13/33946. We thank A. Wood for feedback on statistical analyses used in the paper. We thank the INTERVAL Study investigators, co-ordination team and the epidemiology field, data and laboratory teams, who were supported by core funding from the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (RG/13/13/30194; RG/18/13/33946), the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014) (the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care) and the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-201410024). This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Department of Health and Social Care (England), the Chief Scientist Office of the Scottish Government Health and Social Care Directorates, the Health and Social Care Research and Development Division (Welsh Government), the Public Health Agency (Northern Ireland), the British Heart Foundation and Wellcome. J.D. holds a British Heart Foundation Professorship and an NIHR Senior Investigator Award.	[Anonymous], 2020, FDA NEWS; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Casassus P, 2002, BRIT J HAEMATOL, V119, P1090, DOI 10.1046/j.1365-2141.2002.03944.x; Chapman A. B., 2020, NATURAL LANGUAGE PRO; Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410; Clementi N, 2020, J INFECT DIS, V222, P722, DOI 10.1093/infdis/jiaa350; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6; Dinnon KH, 2020, NATURE, V586, P560, DOI 10.1038/s41586-020-2708-8; Emilsson V, 2018, SCIENCE, V361, P769, DOI 10.1126/science.aaq1327; Finan C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1166; Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016; Giambartolomei C, 2018, BIOINFORMATICS, V34, P2538, DOI 10.1093/bioinformatics/bty147; Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Hemnes AR, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02638-2017; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Hunter-Zinck H, 2020, AM J HUM GENET, V106, P535, DOI 10.1016/j.ajhg.2020.03.004; Jia HY, 2018, THROMB RES, V163, P105, DOI 10.1016/j.thromres.2018.01.039; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9; Labrecque J, 2018, CURR EPIDEMIOL REP, V5, P214, DOI 10.1007/s40471-018-0152-1; Liu D, 2021, J INFECTION, V82, P126, DOI 10.1016/j.jinf.2020.11.031; Lokugamage KG, 2020, J VIROL, V94, DOI 10.1128/JVI.01410-20; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Lopalco L, 2010, VIRUSES-BASEL, V2, P574, DOI 10.3390/v2020574; Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424; Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075; Monteil V, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013426; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Nelson CP, 2020, CIRCULATION, V142, P1117, DOI 10.1161/CIRCULATIONAHA.120.049007; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Onabajo OO, 2020, NAT GENET, V52, P1283, DOI 10.1038/s41588-020-00731-9; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Pietzner M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19996-z; Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2013400, 10.1056/NEJMc2011400]; Rohloff JC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.49; Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163; Song ER, 2021, J EXP MED, V218, DOI 10.1084/jem.20202135; Staley JR, 2016, BIOINFORMATICS, V32, P3207, DOI 10.1093/bioinformatics/btw373; Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2; Swanson SA, 2017, EPIDEMIOLOGY, V28, P653, DOI 10.1097/EDE.0000000000000699; Swerdlow DI, 2012, LANCET, V379, P1214, DOI 10.1016/S0140-6736(12)60110-X; van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wallace C, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008720; Wareham N., 2016, FENLAND STUDY VERSIO, DOI [10.22025/2017.10.101.00001, DOI 10.22025/2017.10.101.00001]; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zoufaly A, 2020, LANCET RESP MED, V8, P1154, DOI 10.1016/S2213-2600(20)30418-5	58	36	37	4	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01310-z	http://dx.doi.org/10.1038/s41591-021-01310-z		APR 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33837377	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-27	WOS:000638540100001
J	Bartsch, YC; Wang, CQ; Zohar, T; Fischinger, S; Atyeo, C; Burke, JS; Kang, J; Edlow, AG; Fasano, A; Baden, LR; Nilles, EJ; Woolley, AE; Karlson, EW; Hopke, AR; Irimia, D; Fischer, ES; Ryan, ET; Charles, RC; Julg, BD; Lauffenburger, DA; Yonker, LM; Alter, G				Bartsch, Yannic C.; Wang, Chuangqi; Zohar, Tomer; Fischinger, Stephanie; Atyeo, Caroline; Burke, John S.; Kang, Jaewon; Edlow, Andrea G.; Fasano, Alessio; Baden, Lindsey R.; Nilles, Eric J.; Woolley, Ann E.; Karlson, Elizabeth W.; Hopke, Alex R.; Irimia, Daniel; Fischer, Eric S.; Ryan, Edward T.; Charles, Richelle C.; Julg, Boris D.; Lauffenburger, Douglas A.; Yonker, Lael M.; Alter, Galit			Humoral signatures of protective and pathological SARS-CoV-2 infection in children	NATURE MEDICINE			English	Article								A study of multisystem inflammatory syndrome in children (MIS-C) shows maintenance of elevated levels of monocyte-activating pathogen-specific IgG not seen in children infected with SARS-CoV-2 who do not develop MIS-C. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread relentlessly, associated with a high frequency of respiratory failure and mortality. Children experience largely asymptomatic disease, with rare reports of multisystem inflammatory syndrome in children (MIS-C). Identifying immune mechanisms that result in these disparate clinical phenotypes in children could provide critical insights into coronavirus disease 2019 (COVID-19) pathogenesis. Using systems serology, in this study we observed in 25 children with acute mild COVID-19 a functional phagocyte and complement-activating IgG response to SARS-CoV-2, similar to the acute responses generated in adults with mild disease. Conversely, IgA and neutrophil responses were significantly expanded in adults with severe disease. Moreover, weeks after the resolution of SARS-CoV-2 infection, children who develop MIS-C maintained highly inflammatory monocyte-activating SARS-CoV-2 IgG antibodies, distinguishable from acute disease in children but with antibody levels similar to those in convalescent adults. Collectively, these data provide unique insights into the potential mechanisms of IgG and IgA that might underlie differential disease severity as well as unexpected complications in children infected with SARS-CoV-2.	[Bartsch, Yannic C.; Zohar, Tomer; Fischinger, Stephanie; Atyeo, Caroline; Burke, John S.; Kang, Jaewon; Julg, Boris D.; Alter, Galit] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA; [Wang, Chuangqi; Zohar, Tomer; Lauffenburger, Douglas A.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Edlow, Andrea G.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA 02114 USA; [Fasano, Alessio; Yonker, Lael M.] Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Boston, MA 02114 USA; [Fasano, Alessio; Yonker, Lael M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Baden, Lindsey R.; Nilles, Eric J.; Woolley, Ann E.; Karlson, Elizabeth W.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Hopke, Alex R.; Irimia, Daniel; Ryan, Edward T.; Charles, Richelle C.] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Boston, MA 02114 USA; [Fischer, Eric S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Fischer, Eric S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Alter, G (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.; Yonker, LM (corresponding author), Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Boston, MA 02114 USA.; Yonker, LM (corresponding author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.	lyonker@mgh.harvard.edu; galter@mgh.harvard.edu	Nilles, Eric/ABA-4757-2021; Juelg, Boris/ABA-1955-2020	Nilles, Eric/0000-0001-7044-5257; Juelg, Boris/0000-0002-4687-9626; Burke, John/0000-0003-1282-8211; Edlow, Andrea/0000-0003-2915-5949; Wang, Chuangqi/0000-0002-4779-2231; Atyeo, Caroline/0000-0002-7489-0232; Kang, Jaewon/0000-0003-0846-4611; Fasano, Alessio/0000-0002-2134-0261; Fischinger, Stephanie/0000-0003-2307-3379; Zohar, Tomer/0000-0001-9965-2559	National Heart, Lung and Blood Institute [5K08HL143183]; Cystic Fibrosis Foundation [YONKER18Q0]; National Institute for Allergy and Infectious Diseases [U19 AI135995]; SAMANA Kay MGH Research Scholars Award; Ragon Institute of MGH, MIT; Massachusetts Consortium on Pathogen Readiness; NIH [3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, CIVIC75N93019C00052]; Centers for Disease Control and Prevention [U01CK000490]; Musk Foundation; Gates Foundation Global Health Vaccine Accelerator Platform [OPP1146996]; NIH SeroNet [U01CA260476]	National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); National Institute for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); SAMANA Kay MGH Research Scholars Award; Ragon Institute of MGH, MIT; Massachusetts Consortium on Pathogen Readiness; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Musk Foundation; Gates Foundation Global Health Vaccine Accelerator Platform; NIH SeroNet(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	L.M.Y. received funding from the National Heart, Lung and Blood Institute (5K08HL143183) and the Cystic Fibrosis Foundation (YONKER18Q0). D.A.L. was partially supported by the National Institute for Allergy and Infectious Diseases (U19 AI135995). We thank N. Zimmerman, M. and L. Schwartz, an anonymous donor (financial support), T. and S. Ragon and the SAMANA Kay MGH Research Scholars Award for their support. We would also like to thank Y. Cai and B. Chen for S protein production efforts and J. Feldman, B. M. Hauser, T. Caradonna and A. Schmidt for generating receptor-binding domain antigens. We acknowledge support from the Ragon Institute of MGH, MIT, the Massachusetts Consortium on Pathogen Readiness, the NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-01, CIVIC75N93019C00052), Centers for Disease Control and Prevention U01CK000490, NIH SeroNet U01CA260476, the Musk Foundation, and the Gates Foundation Global Health Vaccine Accelerator Platform funding (OPP1146996). We would also like to thank X. Yu, A. Piechocka-Trocha and K. Lefteri for their support on the collection and processing of adult MassCPR cohorts.	Abe J, 2005, J IMMUNOL, V174, P5837, DOI 10.4049/jimmunol.174.9.5837; Aleyd E, 2014, J IMMUNOL, V192, P2374, DOI 10.4049/jimmunol.1300261; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Godfred-Cato S, 2020, MMWR-MORBID MORTAL W, V69, P1074, DOI 10.15585/mmwr.mm6932e2; Hamre R, 2003, SCAND J IMMUNOL, V57, P506, DOI 10.1046/j.1365-3083.2003.01220.x; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981; Ladner JT, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2020.100189; Laforge M, 2020, NAT REV IMMUNOL, V20, P515, DOI 10.1038/s41577-020-0407-1; Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Mahan AE, 2015, J IMMUNOL METHODS, V417, P34, DOI 10.1016/j.jim.2014.12.004; MASON WH, 1985, PEDIATR INFECT DIS J, V4, P48, DOI 10.1097/00006454-198501000-00012; Menikou S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01156; Nagelkerke SQ, 2014, BLOOD, V124, P3709, DOI 10.1182/blood-2014-05-576835; Pattemore P.K., 2008, PEDIAT RESP MED, V2nd ed., P435, DOI DOI 10.1016/B978-032304048-8.50035-9; Richards JO, 2008, MOL CANCER THER, V7, P2517, DOI 10.1158/1535-7163.MCT-08-0201; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/50140-6736(20)31094-1, 10.1016/S0140-6736(20)31094-1]; Roy V, 2020, J IMMUNOL METHODS, V484, DOI 10.1016/j.jim.2020.112832; Takahashi Kei, 2010, Ann Vasc Dis, V3, P173, DOI 10.3400/avd.sasvp01003; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Weemaes C, 2003, SCAND J IMMUNOL, V58, P642, DOI 10.1111/j.1365-3083.2003.01344.x; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9; Woof JM, 2004, IMMUNOLOGY, V113, P175, DOI 10.1111/j.1365-2567.2004.01958.x; Zohar T, 2020, NAT REV IMMUNOL, V20, P392, DOI 10.1038/s41577-020-0359-5	31	61	61	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					454	+		10.1038/s41591-021-01263-3	http://dx.doi.org/10.1038/s41591-021-01263-3		FEB 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33589825	Bronze, Green Accepted, Green Published			2022-12-27	WOS:000618129400001
J	Park, J; Lucas, AM; Zhang, XY; Chaudhary, K; Cho, JH; Nadkarni, G; Dobbyn, A; Chittoor, G; Josyula, NS; Katz, N; Breeyear, JH; Ahmadmehrabi, S; Drivas, TG; Chavali, VRM; Fasolino, M; Sawada, H; Daugherty, A; Li, YM; Zhang, C; Bradford, Y; Weaver, J; Verma, A; Judy, RL; Kember, RL; Overton, JD; Reid, JG; Ferreira, MAR; Li, AH; Baras, A; LeMaire, SA; Shen, YH; Naji, A; Kaestner, KH; Vahedi, G; Edwards, TL; Chen, JB; Damrauer, SM; Justice, AE; Do, R; Ritchie, MD; Rader, DJ				Park, Joseph; Lucas, Anastasia M.; Zhang, Xinyuan; Chaudhary, Kumardeep; Cho, Judy H.; Nadkarni, Girish; Dobbyn, Amanda; Chittoor, Geetha; Josyula, Navya S.; Katz, Nathan; Breeyear, Joseph H.; Ahmadmehrabi, Shadi; Drivas, Theodore G.; Chavali, Venkata R. M.; Fasolino, Maria; Sawada, Hisashi; Daugherty, Alan; Li, Yanming; Zhang, Chen; Bradford, Yuki; Weaver, JoEllen; Verma, Anurag; Judy, Renae L.; Kember, Rachel L.; Overton, John D.; Reid, Jeffrey G.; Ferreira, Manuel A. R.; Li, Alexander H.; Baras, Aris; LeMaire, Scott A.; Shen, Ying H.; Naji, Ali; Kaestner, Klaus H.; Vahedi, Golnaz; Edwards, Todd L.; Chen, Jinbo; Damrauer, Scott M.; Justice, Anne E.; Do, Ron; Ritchie, Marylyn D.; Rader, Daniel J.			Exome-wide evaluation of rare coding variants using electronic health records identifies new gene-phenotype associations	NATURE MEDICINE			English	Article							EXPRESSION; BIOBANK; TISSUE; GLAUCOMA; PROTEIN; CELLS	The clinical impact of rare loss-of-function variants has yet to be determined for most genes. Integration of DNA sequencing data with electronic health records (EHRs) could enhance our understanding of the contribution of rare genetic variation to human disease(1). By leveraging 10,900 whole-exome sequences linked to EHR data in the Penn Medicine Biobank, we addressed the association of the cumulative effects of rare predicted loss-of-function variants for each individual gene on human disease on an exome-wide scale, as assessed using a set of diverse EHR phenotypes. After discovering 97 genes with exome-by-phenome-wide significant phenotype associations (P < 10(-6)), we replicated 26 of these in the Penn Medicine Biobank, as well as in three other medical biobanks and the population-based UK Biobank. Of these 26 genes, five had associations that have been previously reported and represented positive controls, whereas 21 had phenotype associations not previously reported, among which were genes implicated in glaucoma, aortic ectasia, diabetes mellitus, muscular dystrophy and hearing loss. These findings show the value of aggregating rare predicted loss-of-function variants into 'gene burdens' for identifying new gene-disease associations using EHR phenotypes in a medical biobank. We suggest that application of this approach to even larger numbers of individuals will provide the statistical power required to uncover unexplored relationships between rare genetic variation and disease phenotypes. Analysis of 10,900 whole-exome sequences linked to electronic health care records in the Penn Medicine Biobank enabled an exome-wide study of the phenotypic effects of rare loss-of-function gene variants, identifying new gene-disease associations that replicated across other biobanks.	[Park, Joseph; Lucas, Anastasia M.; Zhang, Xinyuan; Ahmadmehrabi, Shadi; Fasolino, Maria; Bradford, Yuki; Verma, Anurag; Kember, Rachel L.; Kaestner, Klaus H.; Vahedi, Golnaz; Ritchie, Marylyn D.; Rader, Daniel J.] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA; [Park, Joseph; Katz, Nathan; Drivas, Theodore G.; Rader, Daniel J.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Park, Joseph; Lucas, Anastasia M.; Zhang, Xinyuan; Bradford, Yuki; Verma, Anurag; Ritchie, Marylyn D.] Univ Penn, Inst Biomed Informat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Chaudhary, Kumardeep; Cho, Judy H.; Nadkarni, Girish; Dobbyn, Amanda; Do, Ron] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA; [Chaudhary, Kumardeep; Cho, Judy H.; Nadkarni, Girish; Dobbyn, Amanda; Do, Ron] Icahn Sch Med Mt Sinai, Bio Phen Ctr, New York, NY 10029 USA; [Chaudhary, Kumardeep; Cho, Judy H.; Nadkarni, Girish; Dobbyn, Amanda; Do, Ron] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Chittoor, Geetha; Josyula, Navya S.; Justice, Anne E.] Geisinger, Dept Populat Hlth Sci, Danville, PA USA; [Breeyear, Joseph H.; Edwards, Todd L.] Vanderbilt Univ, Med Ctr, Vanderbilt Genet Inst, Nashville, TN USA; [Chavali, Venkata R. M.] Univ Penn, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Fasolino, Maria; Kaestner, Klaus H.; Vahedi, Golnaz] Univ Penn, Penn Epigenet Inst, Philadelphia, PA 19104 USA; [Sawada, Hisashi; Daugherty, Alan] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY USA; [Daugherty, Alan] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Li, Yanming; Zhang, Chen; LeMaire, Scott A.; Shen, Ying H.] Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Li, Yanming; Zhang, Chen; LeMaire, Scott A.; Shen, Ying H.] Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX 77025 USA; [Weaver, JoEllen; Rader, Daniel J.] Univ Penn, Inst Translat Med & Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA; [Judy, Renae L.; Naji, Ali; Damrauer, Scott M.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Overton, John D.; Reid, Jeffrey G.; Ferreira, Manuel A. R.; Li, Alexander H.; Baras, Aris] Regeneron Pharmaceut, Regeneron Genet Ctr, Tarrytown, NY USA; [Chen, Jinbo] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Kentucky; University of Kentucky; Baylor College of Medicine; Texas Heart Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Regeneron; University of Pennsylvania; Pennsylvania Medicine	Rader, DJ (corresponding author), Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA.; Rader, DJ (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.; Rader, DJ (corresponding author), Univ Penn, Inst Translat Med & Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.	rader@pennmedicine.upenn.edu	shen, ying/HHS-5635-2022; Li, Yanming/HGB-2849-2022; Daugherty, Alan/C-8282-2009; Chaudhary, Kumardeep/Q-9740-2018	Li, Yanming/0000-0002-8213-9166; Daugherty, Alan/0000-0003-2093-3775; Justice, Anne/0000-0002-8903-8712; Josyula, Navya Shilpa/0000-0003-2782-8812; Park, Joseph/0000-0002-3313-641X; LeMaire, Scott/0000-0002-8736-4266; Chaudhary, Kumardeep/0000-0002-4117-6403; Drivas, Theodore/0000-0002-8717-0111; Verma, Anurag/0000-0002-5063-9107; Zhang, Xinyuan/0000-0002-8885-1146; Cho, Judy/0000-0002-7959-0466	American Heart Association (American Heart Association, Inc.) [18SFRN33960163, 18SFRN33960114] Funding Source: Medline; Medical Research Council [MC_QA137853, MC_PC_17228] Funding Source: Medline; NCATS NIH HHS [UL1 TR001878] Funding Source: Medline; NEI NIH HHS [R21 EY028273] Funding Source: Medline; NHGRI NIH HHS [F30 HG010442] Funding Source: Medline; NHLBI NIH HHS [R01 HL143359] Funding Source: Medline; U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH) [1R01HL143359] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) [UL1TR001878] Funding Source: Medline; CSRD VA [IK2 CX001780] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Human Genome Research Institute (NHGRI) [F30HG010442] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Eye Institute (NEI) [R21EY028273-01A1] Funding Source: Medline	American Heart Association (American Heart Association, Inc.)(American Heart Association); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Health &amp; Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); CSRD VA; U.S. Department of Health &amp; Human Services | NIH | National Human Genome Research Institute (NHGRI); U.S. Department of Health &amp; Human Services | NIH | National Eye Institute (NEI)		Baron M, 2016, CELL SYST, V3, P346, DOI 10.1016/j.cels.2016.08.011; Battaglia A, 2005, BRAIN DEV-JPN, V27, P358, DOI 10.1016/j.braindev.2004.03.011; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bonventre JA, 2019, MOL BIOL CELL, V30, P293, DOI 10.1091/mbc.E18-06-0401; Bowl MR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00595-4; Burgess RW, 2004, MOL CELL BIOL, V24, P1096, DOI 10.1128/MCB.24.3.1096-1105.2004; Bush WS, 2016, NAT REV GENET, V17, P129, DOI 10.1038/nrg.2015.36; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cacciottolo M, 2011, EUR J HUM GENET, V19, P974, DOI 10.1038/ejhg.2011.70; Campbell-Thompson M, 2012, DIABETES-METAB RES, V28, P608, DOI 10.1002/dmrr.2316; Carroll RJ, 2014, BIOINFORMATICS, V30, P2375, DOI 10.1093/bioinformatics/btu197; Casals T, 2004, CLIN GENET, V65, P490, DOI 10.1111/j.0009-9163.2004.00265.x; Chavali VRM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68811-8; Ciesielski TH, 2014, BIODATA MIN, V7, DOI 10.1186/1756-0381-7-10; Cirulli ET, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14288-y; Cui SY, 2019, AM J PHYSIOL-ENDOC M, V317, pE1205, DOI 10.1152/ajpendo.00117.2019; Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749; Dewey FE, 2016, SCIENCE, V354, DOI 10.1126/science.aaf6814; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; ELBEDOUR K, 1994, AM J MED GENET, V52, P164, DOI 10.1002/ajmg.1320520208; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; Gauderman W, QUANTO 1 1 COMPUTER; Gilling CE, 2009, IN VITRO CELL DEV-AN, V45, P243, DOI 10.1007/s11626-009-9175-8; Gronich N, 2010, CHANNELS, V4, P101, DOI 10.4161/chan.4.2.10975; Guo MH, 2018, AM J HUM GENET, V103, P522, DOI 10.1016/j.ajhg.2018.08.016; Haggerty CM, 2019, CIRCULATION, V140, P42, DOI 10.1161/CIRCULATIONAHA.119.039573; Harrison PF, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1674-7; Haufroid V, 2015, CLIN TOXICOL, V53, P501, DOI 10.3109/15563650.2015.1049355; Howell GR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-429; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Ingham NJ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000194; Ioannidis NM, 2016, AM J HUM GENET, V99, P877, DOI 10.1016/j.ajhg.2016.08.016; Ji HL, 2012, AM J PHYSIOL-LUNG C, V303, pL1013, DOI 10.1152/ajplung.00206.2012; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Laizure SC, 2013, PHARMACOTHERAPY, V33, P210, DOI 10.1002/phar.1194; Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009; Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130; Liu HZ, 2014, J NEUROSCI, V34, P11085, DOI 10.1523/JNEUROSCI.1690-14.2014; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Mori M, 2006, BIOCHEM BIOPH RES CO, V341, P121, DOI 10.1016/j.bbrc.2005.12.159; Nickells RW, 1999, SURV OPHTHALMOL, V43, pS151, DOI 10.1016/S0039-6257(99)00029-6; Park J, 2020, GENET MED, V22, P102, DOI 10.1038/s41436-019-0625-8; Pinard A, 2019, CIRC RES, V124, P588, DOI 10.1161/CIRCRESAHA.118.312436; Pliner HA, 2019, NAT METHODS, V16, P983, DOI 10.1038/s41592-019-0535-3; Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005; Schwartz GW, 2020, NAT METHODS, V17, P405, DOI 10.1038/s41592-020-0748-5; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Stessman HA, 2014, CELL, V156, P872, DOI 10.1016/j.cell.2014.02.002; Stoetzel C, 2006, NAT GENET, V38, P521, DOI 10.1038/ng1771; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Verkuil L, 2019, BRIT J OPHTHALMOL, V103, P188, DOI 10.1136/bjophthalmol-2018-313086; Verma A, 2019, AM J HUM GENET, V104, P55, DOI 10.1016/j.ajhg.2018.11.006; Wagner AH, 2013, EXP EYE RES, V111, P105, DOI 10.1016/j.exer.2013.03.004; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang TY, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2599-6; Wang YJ, 2016, DIABETES, V65, P3028, DOI 10.2337/db16-0405; Wilson AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094175; Yang WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134995; Zhang CL, 2018, J MOL CELL CARDIOL, V116, P135, DOI 10.1016/j.yjmcc.2018.02.006; Zhang XY, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-018-2591-6; Zhao ZC, 2020, AM J HUM GENET, V106, P3, DOI 10.1016/j.ajhg.2019.11.012; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8	65	19	19	2	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					66	+		10.1038/s41591-020-1133-8	http://dx.doi.org/10.1038/s41591-020-1133-8		JAN 2021	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33432171	Green Accepted			2022-12-27	WOS:000607036600001
J	Sender, R; Milo, R				Sender, Ron; Milo, Ron			The distribution of cellular turnover in the human body	NATURE MEDICINE			English	Article							SMALL-INTESTINAL MUCOSA; LIFE-SPAN; MORPHOMETRIC-ANALYSIS; CANCER-RISK; CELLS; BACTERIAL; NUMBER; HEALTH; MOUSE; MODEL	We integrated ubiquity, mass and lifespan of all major cell types to achieve a comprehensive quantitative description of cellular turnover. We found a total cellular mass turnover of 80 +/- 20 grams per day, dominated by blood cells and gut epithelial cells. In terms of cell numbers, close to 90% of the (0.33 +/- 0.02) x 10(12) cells per day turnover was blood cells. A comprehensive census of the dynamics of death and regeneration of cells and tissues provides an estimation of the distribution of cellular turnover in the human body.	[Sender, Ron; Milo, Ron] Weizmann Inst Sci, Dept Plant & Environm Sci, Rehovot, Israel	Weizmann Institute of Science	Milo, R (corresponding author), Weizmann Inst Sci, Dept Plant & Environm Sci, Rehovot, Israel.	ron.milo@weizmann.ac.il		Sender, Ron/0000-0002-1165-9818; Briceno Rondon, Wilmar de Jesus/0000-0002-4523-0104; Milo, Ron/0000-0003-1641-2299				AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350; An GH, 2016, AAPS J, V18, P1182, DOI 10.1208/s12248-016-9923-0; AOYAGI Y, 1988, COMP BIOCHEM PHYS A, V91, P765, DOI 10.1016/0300-9629(88)90962-0; Apostoaei A. J, 2010, REV SYNTHESIS APPL I, P12; Bianconi E, 2013, ANN HUM BIOL, V40, P463, DOI 10.3109/03014460.2013.807878; Boer P, 1984, AM J PHYSIOL, V007, P632; Borghans JAM, 2018, IMMUNOL REV, V285, P233, DOI 10.1111/imr.12693; Brown CT, 2016, NAT BIOTECHNOL, V34, P1256, DOI 10.1038/nbt.3704; COLOTTA F, 1992, BLOOD, V80, P2012; Crapo J D, 1982, Am Rev Respir Dis, V125, P740; CROSBY WH, 1961, AM J DIG DIS, V6, P492, DOI 10.1007/BF02231066; CROWE PT, 1993, VIRCHOWS ARCH A, V422, P459, DOI 10.1007/BF01606454; CUMMINGS JH, 1992, GASTROENTEROLOGY, V103, P1783, DOI 10.1016/0016-5085(92)91435-7; Darwich AS, 2014, DRUG METAB DISPOS, V42, P2016, DOI 10.1124/dmd.114.058404; Delgado FF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067590; Di Mascio M, 2009, BLOOD, V114, P328, DOI 10.1182/blood-2008-12-192203; DINANT HJ, 1978, BRIT J HAEMATOL, V39, P437, DOI 10.1111/j.1365-2141.1978.tb01114.x; Forte J. G., 1996, P1239; Franco RS, 2012, TRANSFUS MED HEMOTH, V39, P302, DOI 10.1159/000342232; FRY RJ, 1961, AM J PHYSIOL, V201, P213, DOI 10.1152/ajplegacy.1961.201.1.213; Gibson B, 2018, P ROY SOC B-BIOL SCI, V285, DOI 10.1098/rspb.2018.0789; Gilbert S. F, 2009, DEV BIOL; Han CZ, 2011, CELL, V147, P1442, DOI 10.1016/j.cell.2011.12.006; Hoath SB, 2003, J INVEST DERMATOL, V121, P1440, DOI 10.1046/j.1523-1747.2003.12606.x; HOGBEN C A M, 1974, Gastroenterology, V67, P1143; ICRP (International Commission on Radiological Protection), 2003, ICRP PUBL, V89, P161; Kim MH, 2011, BLOOD, V117, P3343, DOI 10.1182/blood-2010-07-296970; Korem T, 2015, SCIENCE, V349, P1101, DOI 10.1126/science.aac4812; KUSE R, 1985, BLUT, V50, P243, DOI 10.1007/BF00320301; Lahoz-Beneytez J, 2016, BLOOD, V127, P3431, DOI 10.1182/blood-2016-03-700336; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lockshin RA, 2007, J CELL MOL MED, V11, P1214, DOI 10.1111/j.1582-4934.2007.00150.x; LOEHRY CA, 1969, GUT, V10, P6, DOI 10.1136/gut.10.1.6; Lurie S, 2000, EUR J OBSTET GYN R B, V93, P185, DOI 10.1016/S0301-2115(00)00290-6; Lynch M, 2015, P NATL ACAD SCI USA, V112, P15690, DOI 10.1073/pnas.1514974112; Lynnerup N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001529; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Marsh MN, 2000, METH MOLEC MED, V41, P125, DOI 10.1385/1-59259-082-9:125; MEHL LE, 1991, J SURG ONCOL, V47, P243, DOI 10.1002/jso.2930470409; MERRICK DD, 1975, ABSTR PAP AM CHEM S, P23; NOZICK R, 1981, PHILOS EXPLANATIONS; Peth A, 2013, J BIOL CHEM, V288, P29215, DOI 10.1074/jbc.M113.482570; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; QUEVEDO WC, 1975, AM J PHYS ANTHROPOL, V43, P393, DOI 10.1002/ajpa.1330430321; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rew DA, 2000, EUR J SURG ONCOL, V26, P405, DOI 10.1053/ejso.1999.0907; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Shrestha RP, 2016, J PHARMACOKINET PHAR, V43, P259, DOI 10.1007/s10928-016-9470-4; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; STEPHEN AM, 1980, J MED MICROBIOL, V13, P45, DOI 10.1099/00222615-13-1-45; STONE KC, 1992, AM J RESP CELL MOL, V6, P235, DOI 10.1165/ajrcmb/6.2.235; Tak T, 2013, J LEUKOCYTE BIOL, V94, P595, DOI 10.1189/jlb.1112571; Thierry AR, 2016, CANCER METAST REV, V35, P347, DOI 10.1007/s10555-016-9629-x; TINGBEALL HP, 1993, BLOOD, V81, P2774; Tomasetti C, 2019, P NATL ACAD SCI USA, V116, P20482, DOI 10.1073/pnas.1905722116; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; TREPEL F, 1974, KLIN WOCHENSCHR, V52, P511, DOI 10.1007/BF01468720; Turner SM, 2011, BLOOD, V117, P6052, DOI 10.1182/blood-2010-12-322271; VANPUTTEN LM, 1958, BLOOD, V13, P789, DOI 10.1182/blood.V13.8.789.789; Wang ZM, 2004, AM J PHYSIOL-ENDOC M, V286, pE123, DOI 10.1152/ajpendo.00227.2003; Waterlow JC, 2006, PROTEIN TURNOVER, P1; WEINSTEIN GD, 1985, J INVEST DERMATOL, V85, P579, DOI 10.1111/1523-1747.ep12283594; WELLE S, 1990, AM J PHYSIOL, V258, pE990, DOI 10.1152/ajpendo.1990.258.6.E990; WESTERMANN J, 1992, CLIN INVESTIGATOR, V70, P539	65	60	62	2	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					45	+		10.1038/s41591-020-01182-9	http://dx.doi.org/10.1038/s41591-020-01182-9		JAN 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33432173				2022-12-27	WOS:000607036600005
J	Wagner, R; Heni, M; Tabak, AG; Machann, J; Schick, F; Randrianarisoa, E; de Angelis, MH; Birkenfeld, AL; Stefan, N; Peter, A; Haring, HU; Fritsche, A				Wagner, Robert; Heni, Martin; Tabak, Adam G.; Machann, Juergen; Schick, Fritz; Randrianarisoa, Elko; Hrabe de Angelis, Martin; Birkenfeld, Andreas L.; Stefan, Norbert; Peter, Andreas; Haering, Hans-Ulrich; Fritsche, Andreas			Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	NATURE MEDICINE			English	Article							INTIMA-MEDIA THICKNESS; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; ADIPOSE-TISSUE; SENSITIVITY; ASSOCIATION; SMOKING; OBESITY; MICROALBUMINURIA	The state of intermediate hyperglycemia is indicative of elevated risk of developing type 2 diabetes(1). However, the current definition of prediabetes neither reflects subphenotypes of pathophysiology of type 2 diabetes nor is predictive of future metabolic trajectories. We used partitioning on variables derived from oral glucose tolerance tests, MRI-measured body fat distribution, liver fat content and genetic risk in a cohort of extensively phenotyped individuals who are at increased risk for type 2 diabetes(2,3) to identify six distinct clusters of subphenotypes. Three of the identified subphenotypes have increased glycemia (clusters 3, 5 and 6), but only individuals in clusters 5 and 3 have imminent diabetes risks. By contrast, those in cluster 6 have moderate risk of type 2 diabetes, but an increased risk of kidney disease and all-cause mortality. Findings were replicated in an independent cohort using simple anthropomorphic and glycemic constructs(4). This proof-of-concept study demonstrates that pathophysiological heterogeneity exists before diagnosis of type 2 diabetes and highlights a group of individuals who have an increased risk of complications without rapid progression to overt type 2 diabetes. Clustering of patients with prediabetes using simple clinical features reveals six distinct groups with differing risk of developing type 2 diabetes and its associated complications.	[Wagner, Robert; Heni, Martin; Machann, Juergen; Randrianarisoa, Elko; Birkenfeld, Andreas L.; Stefan, Norbert; Peter, Andreas; Haering, Hans-Ulrich; Fritsche, Andreas] Univ Tubingen, Inst Diabet Res & Metab Dis, Helmholtz Ctr Munich, Tubingen, Germany; [Wagner, Robert; Heni, Martin; Machann, Juergen; Schick, Fritz; Randrianarisoa, Elko; Hrabe de Angelis, Martin; Birkenfeld, Andreas L.; Stefan, Norbert; Peter, Andreas; Haering, Hans-Ulrich; Fritsche, Andreas] German Ctr Diabet Res DZD eV, Neuherberg, Germany; [Wagner, Robert; Heni, Martin; Birkenfeld, Andreas L.; Stefan, Norbert; Fritsche, Andreas] Eberhard Karls Univ Tubingen, Div Diabetol Endocrinol & Nephrol, Dept Internal Med, Tubingen, Germany; [Heni, Martin; Peter, Andreas] Univ Hosp Tubingen, Inst Clin Chem & Pathobiochem, Dept Diagnost Lab Med, Tubingen, Germany; [Tabak, Adam G.] UCL, Dept Epidemiol & Publ Hlth, London, England; [Tabak, Adam G.] Semmelweis Univ, Dept Internal Med & Oncol, Fac Med, Budapest, Hungary; [Tabak, Adam G.] Semmelweis Univ, Fac Med, Dept Publ Hlth, Budapest, Hungary; [Machann, Juergen; Schick, Fritz] Eberhard Karls Univ Tubingen, Univ Dept Radiol, Sect Expt Radiol, Tubingen, Germany; [Hrabe de Angelis, Martin] Helmholtz Zentrum Munchen, Inst Expt Genet, Neuherberg, Germany; [Hrabe de Angelis, Martin] Helmholtz Zentrum Munchen, German Mouse Clin, Neuherberg, Germany; [Hrabe de Angelis, Martin] Tech Univ Munich, TUM Sch Life Sci SoLS, Chair Expt Genet, Freising Weihenstephan, Germany; [Stefan, Norbert] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA	Eberhard Karls University of Tubingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of London; University College London; Semmelweis University; Semmelweis University; Eberhard Karls University of Tubingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Harvard University; Harvard Medical School	Wagner, R (corresponding author), Univ Tubingen, Inst Diabet Res & Metab Dis, Helmholtz Ctr Munich, Tubingen, Germany.; Wagner, R (corresponding author), German Ctr Diabet Res DZD eV, Neuherberg, Germany.; Wagner, R (corresponding author), Eberhard Karls Univ Tubingen, Div Diabetol Endocrinol & Nephrol, Dept Internal Med, Tubingen, Germany.	robert.wagner@uni-tuebingen.de	Birkenfeld, Andreas L./U-3954-2019; Wagner, Robert/B-3689-2012; de Angelis, Martin Hrabe/F-5531-2012	Birkenfeld, Andreas L./0000-0003-1407-9023; Wagner, Robert/0000-0002-6120-0191; de Angelis, Martin Hrabe/0000-0002-7898-2353; Stefan, Norbert/0000-0002-2186-9595; Schick, Fritz/0000-0002-4231-3406; Tabak, Adam/0000-0002-6234-3936	Federal Ministry of Education and Research (BMBF) [01GI0925]; state of Baden-Wurttemberg [325400/58/2]; UK Medical Research Council [MR/K013351/1, G0902037]; British Heart Foundation [RG/13/2/30098]; US National Institutes of Health [R01HL36310, R01AG013196]; MRC [MR/R024227/1] Funding Source: UKRI	Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); state of Baden-Wurttemberg; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank all the research volunteers for their participation. We thank all participants in the Whitehall II Study, Whitehall II researchers and support staff who made the study possible. We gratefully acknowledge the excellent technical assistance of the Diabetes Research Unit Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tubingen, Germany. We thank J. Kriebel and H. Grallert (Molecular Epidemiology, Helmholtz Center Munich) for generating the Global Screening Array data. This study was supported in part by a grant (01GI0925) from the Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.) and from the state of Baden-Wurttemberg to R.W. and A.F. (325400/58/2, Forum Gesundheitsstandort Baden-Wurttemberg). The UK Medical Research Council (MR/K013351/1; G0902037), British Heart Foundation (RG/13/2/30098) and the US National Institutes of Health (R01HL36310, R01AG013196) have supported collection of data in the Whitehall II Study.	Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2; Artunc F, 2016, NAT REV NEPHROL, V12, P721, DOI 10.1038/nrneph.2016.145; Ausk KJ, 2010, DIABETES CARE, V33, P1179, DOI 10.2337/dc09-2110; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Bouillon K, 2011, HEART, V97, P923, DOI 10.1136/hrt.2010.216309; Cirillo M, 1998, ARCH INTERN MED, V158, P1933, DOI 10.1001/archinte.158.17.1933; Davidson MB, 2011, DIABETES CARE, V34, P524, DOI 10.2337/dc10-1689; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; Dennis JM, 2019, LANCET DIABETES ENDO, V7, P442, DOI 10.1016/S2213-8587(19)30087-7; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; El-Atat FA, 2004, J AM SOC NEPHROL, V15, P2816, DOI 10.1097/01.ASN.0000133698.80390.37; Ferrie JE, 2013, ATHEROSCLEROSIS, V227, P178, DOI 10.1016/j.atherosclerosis.2012.12.027; Gerst F, 2017, DIABETOLOGIA, V60, P2240, DOI 10.1007/s00125-017-4385-1; Heni M, 2010, DIABETES-METAB RES, V26, P200, DOI 10.1002/dmrr.1073; Hennig C, 2007, COMPUT STAT DATA AN, V52, P258, DOI 10.1016/j.csda.2006.11.025; Herzberg-Schafer SA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014194; Hogan SL, 2007, RENAL FAILURE, V29, P133, DOI 10.1080/08860220601098888; Hulman A, 2018, DIABETES CARE, V41, P1740, DOI 10.2337/dc18-0279; Jaghutriz BA, 2020, EXP CLIN ENDOCR DIAB, V128, P804, DOI 10.1055/a-0896-8671; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Machann J, 2005, J MAGN RESON IMAGING, V21, P455, DOI 10.1002/jmri.20292; Mahajan A, 2018, NAT GENET, V50, P559, DOI 10.1038/s41588-018-0084-1; Marmot M, 2005, INT J EPIDEMIOL, V34, P251, DOI 10.1093/ije/dyh372; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; O'Connor LJ, 2018, NAT GENET, V50, P1728, DOI 10.1038/s41588-018-0255-0; Parvanova AI, 2006, DIABETES, V55, P1456, DOI 10.2337/db05-1484; R Core Team, 2013, R LANG ENV STAT COMP; Reynolds A.P., 2006, J MATH MODEL ALGORIT, V5, P475, DOI [DOI 10.1007/S10852-005-9022-1, 10.1007/s10852-005-9022-1]; Schmid V, 2017, DIABETOLOGIA, V60, P2341, DOI 10.1007/s00125-017-4407-z; Siegel-Axel DI, 2016, REV ENDOCR METAB DIS, V17, P51, DOI 10.1007/s11154-016-9346-3; Stefan N, 2008, ARCH INTERN MED, V168, P1609, DOI 10.1001/archinte.168.15.1609; Stefan N, 2018, LANCET DIABETES ENDO, V6, P249, DOI 10.1016/S2213-8587(17)30292-9; Stefan N, 2017, CELL METAB, V26, P292, DOI 10.1016/j.cmet.2017.07.008; Stefan N, 2014, LANCET DIABETES ENDO, V2, P406, DOI 10.1016/S2213-8587(13)70170-0; Stefan N, 2008, ENDOCR REV, V29, P939, DOI 10.1210/er.2008-0009; Stidsen JV, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.3005; Stumvoll M, 2002, DIABETES, V51, P37, DOI 10.2337/diabetes.51.1.37; Stumvoll M, 2001, DIABETES CARE, V24, P796, DOI 10.2337/diacare.24.4.796; Tabak AG, 2012, LANCET, V379, P2279, DOI 10.1016/S0140-6736(12)60283-9; Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145; Udler MS, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002654; UNGER RH, 1985, DIABETOLOGIA, V28, P119; Vilhjalmsson BJ, 2015, AM J HUM GENET, V97, P576, DOI 10.1016/j.ajhg.2015.09.001; Wagner R, 2012, DIABETOLOGIA, V55, P2054, DOI 10.1007/s00125-012-2551-z; Wagner R, 2016, ACTA DIABETOL, V53, P1037, DOI 10.1007/s00592-016-0930-5; Wannamethee SG, 2001, DIABETES CARE, V24, P1590, DOI 10.2337/diacare.24.9.1590; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; YIP J, 1993, LANCET, V342, P883, DOI 10.1016/0140-6736(93)91943-G; Zaharia OP, 2019, LANCET DIABETES ENDO, V7, P684, DOI 10.1016/S2213-8587(19)30187-1	50	92	94	16	63	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					49	+		10.1038/s41591-020-1116-9	http://dx.doi.org/10.1038/s41591-020-1116-9		JAN 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33398163	Green Submitted			2022-12-27	WOS:000604849400004
J	Ibrahim, SA				Ibrahim, Said A.			Artificial intelligence for disparities in knee pain assessment	NATURE MEDICINE			English	Editorial Material							HIP; OSTEOARTHRITIS; PREVALENCE	An algorithm developed through machine learning on existing radiological data from diverse people has the potential to improve the diagnosis and management of knee pain from osteoarthritis and reduce racial disparities in the assessment of knee pain.	[Ibrahim, Said A.] Weill Cornell Med, Div Healthcare Delivery Sci & Innovat, Dept Populat Hlth Sci, New York, NY 10065 USA	Cornell University	Ibrahim, SA (corresponding author), Weill Cornell Med, Div Healthcare Delivery Sci & Innovat, Dept Populat Hlth Sci, New York, NY 10065 USA.	sai2009@med.cornell.edu			National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24AR05529]	National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	S.A.I. is supported in part by a K24 Mid-Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K24AR05529).	Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-116; Cai XY, 2012, CLIN ORTHOP RELAT R, V470, P1185, DOI 10.1007/s11999-011-2032-6; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HOAGLUND FT, 1995, ANN RHEUM DIS, V54, P107, DOI 10.1136/ard.54.2.107; Ibrahim SA, 2002, ARTHRITIS RHEUM-US, V46, P2429, DOI 10.1002/art.10494; Ibrahim SA, 2002, MED CARE, V40, P44; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Pierson E., 2020, Z NAT MED, DOI [10.1038/s41591-020-01192-7, DOI 10.1038/S41591-020-01192-7]; SHARKNESS CM, 1993, PUBLIC HEALTH REP, V108, P70; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57	12	1	1	2	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					22	23		10.1038/s41591-020-01196-3	http://dx.doi.org/10.1038/s41591-020-01196-3			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442017				2022-12-27	WOS:000607931400016
J	Stower, H				Stower, Hannah			Treatment of one eye affects both	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					21	21		10.1038/s41591-020-01218-0	http://dx.doi.org/10.1038/s41591-020-01218-0			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442013				2022-12-27	WOS:000607931400012
J	Stower, H				Stower, Hannah			Science strikes for Black lives	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1805	1805		10.1038/s41591-020-01155-y	http://dx.doi.org/10.1038/s41591-020-01155-y			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288927	Bronze			2022-12-27	WOS:000596579200010
J	Koup, RA; Donis, RO; Gilbert, PB; Li, AW; Shah, NA; Houchens, CR				Koup, Richard A.; Donis, Ruben O.; Gilbert, Peter B.; Li, Andrew W.; Shah, Najaf A.; Houchens, Christopher R.			Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis (vol 27, pg 1493, 2021)	NATURE MEDICINE			English	Correction												rkoup@mail.nih.gov; ruben.donis@hhs.gov						Koup RA, 2021, NAT MED, V27, P1493, DOI 10.1038/s41591-021-01484-6	1	0	0	1	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					214	214		10.1038/s41591-021-01671-5	http://dx.doi.org/10.1038/s41591-021-01671-5		JAN 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35022577	Bronze			2022-12-27	WOS:000741964100001
J	May, M				May, Mike			Eight unanswered questions about the COVID-19 pandemic	NATURE MEDICINE			English	Editorial Material								We asked experts around the world what surprised them about SARS-CoV-2 and COVID-19, and what questions remain unanswered.				mike@techtyper.com							0	0	0	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2058	2061		10.1038/s41591-021-01598-x	http://dx.doi.org/10.1038/s41591-021-01598-x		DEC 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34907383	Bronze			2022-12-27	WOS:000730059200002
J	McMurray, JJV				McMurray, John J. V.			Can an implanted minipump deliver for diabetes patients?	NATURE MEDICINE			English	Editorial Material							CONTINUOUS SUBCUTANEOUS DELIVERY; GLP-1 RECEPTOR AGONIST; ITCA 650; EXENATIDE; INJECTIONS; OUTCOMES		[McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland	University of Glasgow	McMurray, JJV (corresponding author), Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.	john.mcmurray@glasgow.ac.uk		mcmurray, john/0000-0002-6317-3975				Henry R, 2018, DIABETES OBES METAB, V20, P638, DOI 10.1111/dom.13133; Henry RR, 2018, DIABETES CARE, V41, P613, DOI 10.2337/dc17-1519; Henry RR, 2014, J DIABETES COMPLICAT, V28, P393, DOI 10.1016/j.jdiacomp.2013.12.009; Henry RR, 2013, DIABETES CARE, V36, P2559, DOI 10.2337/dc12-2410; Henry RR, 2013, CLIN THER, V35, P634, DOI 10.1016/j.clinthera.2013.03.011; Holman RR, 2017, NEW ENGL J MED, V377, P1228, DOI 10.1056/NEJMoa1612917; Rosenstock J, 2018, DIABETES CARE, V41, P333, DOI 10.2337/dc17-1306; Rubino D, 2021, JAMA-J AM MED ASSOC, V325, P1414, DOI 10.1001/jama.2021.3224; Ruff C. T, 2021, NAT MED, DOI [10.1028/s41591-021-01584-3, DOI 10.1028/S41591-021-01584-3]; Sattar N, 2021, LANCET DIABETES ENDO, V9, P653, DOI 10.1016/S2213-8587(21)00203-5; US Department of Health and Human Services Food and Drug Administration, 2021, FED REGISTER, V86, P49334	11	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					27	28		10.1038/s41591-021-01628-8	http://dx.doi.org/10.1038/s41591-021-01628-8		DEC 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34903896	Green Accepted			2022-12-27	WOS:000729637800001
J	Fu, S; Litwin, SE; Tedford, RJ				Fu, Sheng; Litwin, Sheldon E.; Tedford, Ryan J.			Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies	NATURE MEDICINE			English	Editorial Material									[Fu, Sheng; Litwin, Sheldon E.; Tedford, Ryan J.] Med Univ South Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA; [Litwin, Sheldon E.] Ralph H Johnson Vet Affairs Med Ctr, Div Cardiol, Charleston, SC USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Tedford, RJ (corresponding author), Med Univ South Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA.	TedfordR@musc.edu		Tedford, Ryan/0000-0001-9045-7722; Fu, Sheng/0000-0002-7970-3467				Abraham WT, 2021, EUR HEART J, V42, P700, DOI 10.1093/eurheartj/ehaa943; Anker S. D., NEW ENGL J MED, DOI [10.1056/NEJMoa2107038(2021, DOI 10.1056/NEJMOA2107038(2021]; Anker SD, 2019, EUR J HEART FAIL, V21, P1279, DOI 10.1002/ejhf.1596; [Anonymous], 2019, TREATM HEART FAIL EN; Butler J, 2020, EUR J HEART FAIL, V22, P999, DOI 10.1002/ejhf.1810; Greene SJ, 2018, CIRCULATION, V138, P1039, DOI 10.1161/CIRCULATIONAHA.118.034668; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Nassif M. E., NAT MED, DOI [10.1038/s41591-021-01536-x(2021), DOI 10.1038/S41591-021-01536-X(2021)]; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Pedro FJ., 2016, J AM COLL CARDIOL, V68, P2690, DOI [10.1016/j.jacc.2016.09.936, DOI 10.1016/J.JACC.2016.09.936]; Reddy YNV, 2020, EUR J HEART FAIL, V22, P1009, DOI 10.1002/ejhf.1788; Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010	12	0	0	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1872	1873		10.1038/s41591-021-01565-6	http://dx.doi.org/10.1038/s41591-021-01565-6		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764484				2022-12-27	WOS:000717406200003
J	Tang, AL; Oskotsky, T; Sirota, M				Tang, Alice; Oskotsky, Tomiko; Sirota, Marina			Personalizing routine lab tests with machine learning	NATURE MEDICINE			English	Editorial Material									[Tang, Alice; Oskotsky, Tomiko; Sirota, Marina] Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA 94143 USA; [Tang, Alice; Oskotsky, Tomiko; Sirota, Marina] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Tang, Alice] Univ Calif San Francisco, Bioengn Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sirota, M (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.	marina.sirota@ucsf.edu		Tang, Alice/0000-0003-4745-0714				Berger MF, 2018, NAT REV CLIN ONCOL, V15, P353, DOI 10.1038/s41571-018-0002-6; Cohen NM, 2021, NAT MED, V27, P1582, DOI 10.1038/s41591-021-01468-6; Denny JC, 2021, CELL, V184, P1415, DOI 10.1016/j.cell.2021.01.015; Glicksberg BS, 2016, BIOINFORMATICS, V32, P101, DOI 10.1093/bioinformatics/btw282; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Maric I, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.639804; Rappoport N, 2018, J APPL LAB MED, V3, P366, DOI 10.1373/jalm.2018.026492; Tarca AL, 2007, PLOS COMPUT BIOL, V3, P953, DOI 10.1371/journal.pcbi.0030116; Wainberg M, 2018, NAT BIOTECHNOL, V36, P829, DOI 10.1038/nbt.4233; Yee SW, 2021, CLIN PHARMACOL THER, V110, P108, DOI 10.1002/cpt.2236	10	0	0	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1514	1515		10.1038/s41591-021-01486-4	http://dx.doi.org/10.1038/s41591-021-01486-4		SEP 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34518677				2022-12-27	WOS:000695470700007
J	Saiki, R; Momozawa, Y; Nannya, Y; Nakagawa, MM; Ochi, Y; Yoshizato, T; Terao, C; Kuroda, Y; Shiraishi, Y; Chiba, K; Tanaka, H; Niida, A; Imoto, S; Matsuda, K; Morisaki, T; Murakami, Y; Kamatani, Y; Matsuda, S; Kubo, M; Miyano, S; Makishima, H; Ogawa, S				Saiki, Ryunosuke; Momozawa, Yukihide; Nannya, Yasuhito; Nakagawa, Masahiro M.; Ochi, Yotaro; Yoshizato, Tetsuichi; Terao, Chikashi; Kuroda, Yutaka; Shiraishi, Yuichi; Chiba, Kenichi; Tanaka, Hiroko; Niida, Atsushi; Imoto, Seiya; Matsuda, Koichi; Morisaki, Takayuki; Murakami, Yoshinori; Kamatani, Yoichiro; Matsuda, Shuichi; Kubo, Michiaki; Miyano, Satoru; Makishima, Hideki; Ogawa, Seishi			Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis	NATURE MEDICINE			English	Article							X-INACTIVATION PATTERNS; ACUTE MYELOID-LEUKEMIA; MUTATIONS; RISK; AGE; TET2; HAPLOINSUFFICIENCY; CLASSIFICATION; MOSAICISM; RATIOS	Analysis of single-nucleotide variants and copy number alterations gives a more complete picture of clonal hematopoiesis and its impact on hematological malignancy and cardiovascular disease. Clonal hematopoiesis (CH) in apparently healthy individuals is implicated in the development of hematological malignancies (HM) and cardiovascular diseases. Previous studies of CH analyzed either single-nucleotide variants and indels (SNVs/indels) or copy number alterations (CNAs), but not both. Here, using a combination of targeted sequencing of 23 CH-related genes and array-based CNA detection of blood-derived DNA, we have delineated the landscape of CH-related SNVs/indels and CNAs in 11,234 individuals without HM from the BioBank Japan cohort, including 672 individuals with subsequent HM development, and studied the effects of these somatic alterations on mortality from HM and cardiovascular disease, as well as on hematological and cardiovascular phenotypes. The total number of both types of CH-related lesions and their clone size positively correlated with blood count abnormalities and mortality from HM. CH-related SNVs/indels and CNAs exhibited statistically significant co-occurrence in the same individuals. In particular, co-occurrence of SNVs/indels and CNAs affecting DNMT3A, TET2, JAK2 and TP53 resulted in biallelic alterations of these genes and was associated with higher HM mortality. Co-occurrence of SNVs/indels and CNAs also modulated risks for cardiovascular mortality. These findings highlight the importance of detecting both SNVs/indels and CNAs in the evaluation of CH.	[Saiki, Ryunosuke; Nannya, Yasuhito; Nakagawa, Masahiro M.; Ochi, Yotaro; Yoshizato, Tetsuichi; Makishima, Hideki; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Momozawa, Yukihide] RIKEN, Lab Genotyping Dev, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Nakagawa, Masahiro M.; Ogawa, Seishi] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Kyoto, Japan; [Terao, Chikashi; Kamatani, Yoichiro] RIKEN, Lab Stat & Translat Genet, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Kuroda, Yutaka; Matsuda, Shuichi] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto, Japan; [Shiraishi, Yuichi; Chiba, Kenichi] Natl Canc Ctr, Div Cellular Signaling, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Dept Integrated Data Sci, Tokyo, Japan; [Niida, Atsushi] Univ Tokyo, Human Genome Ctr, Inst Med Sci, Lab Mol Med, Tokyo, Japan; [Imoto, Seiya] Univ Tokyo, Human Genome Ctr, Inst Med Sci, Div Hlth Med Intelligence, Tokyo, Japan; [Matsuda, Koichi; Kamatani, Yoichiro] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Tokyo, Japan; [Morisaki, Takayuki; Murakami, Yoshinori] Univ Tokyo, Inst Med Sci, Div Mol Pathol, Tokyo, Japan; [Kubo, Michiaki] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Ogawa, Seishi] Karolinska Inst, Ctr Haematol & Regenerat Med, Dept Med, Stockholm, Sweden	Kyoto University; RIKEN; Kyoto University; RIKEN; Kyoto University; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; RIKEN; Karolinska Institutet	Ogawa, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan.; Ogawa, S (corresponding author), Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Kyoto, Japan.; Ogawa, S (corresponding author), Karolinska Inst, Ctr Haematol & Regenerat Med, Dept Med, Stockholm, Sweden.	sogawa-tky@umin.ac.jp	Ochi, Yotaro/ABC-5162-2020; Yoshizato, Tetsuichi/AAD-7308-2019; Terao, Chikashi/AAY-1207-2021	Ochi, Yotaro/0000-0001-8472-6164; Yoshizato, Tetsuichi/0000-0003-4283-2983; Terao, Chikashi/0000-0002-6452-4095; Saiki, Ryunosuke/0000-0001-6984-7187; Nakagawa, Masahiro/0000-0002-6420-2555	Japan Agency for Medical Research and Development [JP15cm0106056h0005, JP19cm0106501h0004, JP16ck0106073h0003, JP19ck0106250h0003, JP17km0405110h0005, JP19ck0106470h0001, JP19ck0106353h0003]; Core Research for Evolutional Science and Technology [JP19gm1110011]; Ministry of Education, Culture, Sports, Science and Technology of Japan; High Performance Computing Infrastructure System Research Project [hp160219, hp170227, hp180198, hp190158]; Japan Society for the Promotion of Science [JP15H05909, JP15H05912]; KAKENHI [JP26221308, JP19H05656, JP16H05338, JP19H01053, JP15H05707]; Takeda Science Foundation; JSPS Core-to-Core Program A: Advanced Research Networks	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Core Research for Evolutional Science and Technology(Core Research for Evolutional Science and Technology (CREST)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); High Performance Computing Infrastructure System Research Project; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); JSPS Core-to-Core Program A: Advanced Research Networks	This work was supported by the Japan Agency for Medical Research and Development (nos. JP15cm0106056h0005, JP19cm0106501h0004, JP16ck0106073h0003 and JP19ck0106250h0003 to S.O.; nos. JP17km0405110h0005 and JP19ck0106470h0001 to H.M.; and no. JP19ck0106353h0003 to Y.N.); the Core Research for Evolutional Science and Technology (no. JP19gm1110011 to S.O.); the Ministry of Education, Culture, Sports, Science and Technology of Japan; the High Performance Computing Infrastructure System Research Project (nos. hp160219, hp170227, hp180198 and hp190158 to S.O. and S. Miyano) (this research used computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project); the Japan Society for the Promotion of Science; Scientific Research on Innovative Areas (nos. JP15H05909 to S.O. and S. Miyano and JP15H05912 to S. Miyano) and KAKENHI (nos. JP26221308 and JP19H05656 to S.O., JP16H05338 and JP19H01053 to H.M. and JP15H05707 to S. Miyano); and the Takeda Science Foundation (to S.O., H.M. and T.Y.). S.O. is a recipient of the JSPS Core-to-Core Program A: Advanced Research Networks. DNA samples and subjects' clinical data were provided by BBJ, the Institute of Medical Science, the University of Tokyo. The supercomputing resource was provided by the Human Genome Center, the Institute of Medical Science, the University of Tokyo. We thank K. Matsuo at the Aichi Cancer Center Research Institute (Nagoya, Japan), who suggested the design of the case-cohort study for estimation of cumulative mortality from, and incidence of, hematological malignancies. We thank the TCGA Consortium and all its members for making publicly available their invaluable data.	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bernard E, 2020, NAT MED, V26, P1549, DOI 10.1038/s41591-020-1008-z; Bolton KL, 2020, NAT GENET, V52, P1219, DOI 10.1038/s41588-020-00710-0; Busque L, 1996, BLOOD, V88, P59; Busque L, 2009, BLOOD, V113, P3472, DOI 10.1182/blood-2008-12-195677; Champion KM, 1997, BRIT J HAEMATOL, V97, P920, DOI 10.1046/j.1365-2141.1997.1933010.x; Coombs CC, 2017, CELL STEM CELL, V21, P374, DOI 10.1016/j.stem.2017.07.010; Desai P, 2018, NAT MED, V24, P1015, DOI 10.1038/s41591-018-0081-z; FEY MF, 1994, BLOOD, V83, P931; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381; GALE RE, 1991, BRIT J HAEMATOL, V79, P193, DOI 10.1111/j.1365-2141.1991.tb04521.x; Gao T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20565-7; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Harismendy O, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r124; Hirata M, 2017, J EPIDEMIOL, V27, pS22, DOI 10.1016/j.je.2016.12.006; Jacobs KB, 2012, NAT GENET, V44, P651, DOI 10.1038/ng.2270; Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jasek M, 2010, LEUKEMIA, V24, P216, DOI 10.1038/leu.2009.189; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Loh PR, 2020, NATURE, V584, P136, DOI 10.1038/s41586-020-2430-6; Loh PR, 2018, NATURE, V559, P350, DOI 10.1038/s41586-018-0321-x; Momozawa Y, 2016, HUM MOL GENET, V25, P5027, DOI 10.1093/hmg/ddw335; Muto H, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.83; Nagai A, 2017, J EPIDEMIOL, V27, pS2, DOI 10.1016/j.je.2016.12.005; Niida A, 2012, BIOINFORMATICS, V28, pI115, DOI 10.1093/bioinformatics/bts203; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Ochi Y, 2020, CANCER DISCOV, V10, P836, DOI 10.1158/2159-8290.CD-19-0982; Ogawa S, 2019, BLOOD, V133, P1049, DOI 10.1182/blood-2018-10-844621; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Schneider RK, 2016, NAT MED, V22, P288, DOI 10.1038/nm.4047; Shiraishi Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt126; Shlush LI, 2018, BLOOD, V131, P496, DOI 10.1182/blood-2017-07-746453; Steensma DP, 2015, BLOOD, V126, P9, DOI 10.1182/blood-2015-03-631747; Stoddart A, 2014, BLOOD, V123, P1069, DOI 10.1182/blood-2013-07-517953; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tefferi A, 2009, NEW ENGL J MED, V361, P1117, DOI 10.1056/NEJMc091348; Terao C, 2020, NATURE, V584, P130, DOI 10.1038/s41586-020-2426-2; Thoennissen NH, 2010, BLOOD, V115, P2882, DOI 10.1182/blood-2009-07-235119; Watatani Y, 2019, LEUKEMIA, V33, P2867, DOI 10.1038/s41375-019-0473-1; Wolkewitz M, 2016, J CLIN EPIDEMIOL, V74, P187, DOI 10.1016/j.jclinepi.2015.11.011; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Yoshizato T, 2017, BLOOD, V129, P2347, DOI 10.1182/blood-2016-12-754796; Young AL, 2019, HAEMATOLOGICA, V104, P2410, DOI 10.3324/haematol.2018.215269; Young AL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12484	50	23	23	4	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1239	+		10.1038/s41591-021-01411-9	http://dx.doi.org/10.1038/s41591-021-01411-9		JUL 2021	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34239136	Green Accepted, Green Submitted			2022-12-27	WOS:000672339400006
J	Naveca, FG; Nascimento, V; de Souza, VC; Corado, AD; Nascimento, F; Silva, G; Costa, A; Duarte, D; Pessoa, K; Mejia, M; Brandao, MJ; Jesus, M; Goncalves, L; da Costa, CF; Sampaio, V; Barros, D; Silva, M; Mattos, T; Pontes, G; Abdalla, L; Santos, JH; Arantes, I; Dezordi, FZ; Siqueira, MM; Wallau, GL; Resende, PC; Delatorre, E; Graf, T; Bello, G				Naveca, Felipe Gomes; Nascimento, Valdinete; de Souza, Victor Costa; Corado, Andre de Lima; Nascimento, Fernanda; Silva, George; Costa, Agatha; Duarte, Debora; Pessoa, Karina; Mejia, Matilde; Brandao, Maria Julia; Jesus, Michele; Goncalves, Luciana; da Costa, Cristiano Fernandes; Sampaio, Vanderson; Barros, Daniel; Silva, Marineide; Mattos, Tirza; Pontes, Gemilson; Abdalla, Ligia; Santos, Joao Hugo; Arantes, Ighor; Dezordi, Filipe Zimmer; Siqueira, Marilda Mendonca; Wallau, Gabriel Luz; Resende, Paola Cristina; Delatorre, Edson; Graf, Tiago; Bello, Gonzalo			COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	NATURE MEDICINE			English	Article							ALIGNMENT; SPREAD; FORMAT	The northern state of Amazonas is among the regions in Brazil most heavily affected by the COVID-19 epidemic and has experienced two exponentially growing waves, in early and late 2020. Through a genomic epidemiology study based on 250 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from different Amazonas municipalities sampled between March 2020 and January 2021, we reveal that the first exponential growth phase was driven mostly by the dissemination of lineage B.1.195, which was gradually replaced by lineage B.1.1.28 between May and June 2020. The second wave coincides with the emergence of the variant of concern (VOC) P.1, which evolved from a local B.1.1.28 clade in late November 2020 and replaced the parental lineage in <2 months. Our findings support the conclusion that successive lineage replacements in Amazonas were driven by a complex combination of variable levels of social distancing measures and the emergence of a more transmissible VOC P.1 virus. These data provide insights to understanding the mechanisms underlying the COVID-19 epidemic waves and the risk of dissemination of SARS-CoV-2 VOC P.1 in Brazil and, potentially, worldwide. Analysis of circulating SARS-CoV-2 viruses during the first and second waves of COVID-19 in Amazonas, Brazil, shows successive lineage replacements led to predominance of the variant of concern P.1 and are associated with variable levels of social distancing.	[Naveca, Felipe Gomes; Nascimento, Valdinete; de Souza, Victor Costa; Corado, Andre de Lima; Nascimento, Fernanda; Silva, George; Costa, Agatha; Duarte, Debora; Pessoa, Karina; Mejia, Matilde; Brandao, Maria Julia] Fiocruz MS, Lab Ecol Doencas Transmissiveis Amazonia, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil; [Jesus, Michele] Fiocruz MS, Lab Diversidade Microbiana Amazonia Importancia S, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil; [Goncalves, Luciana; da Costa, Cristiano Fernandes; Sampaio, Vanderson; Barros, Daniel] Fundacao Vigilancia Saude Amazonas, Manaus, Amazonas, Brazil; [Silva, Marineide; Mattos, Tirza] Lab Cent Saude Publ Amazonas, Manaus, Amazonas, Brazil; [Pontes, Gemilson] Inst Nacl de Pesquisas da Amazonia, Manaus, Amazonas, Brazil; [Abdalla, Ligia] Univ Estado Amazonas, Manaus, Amazonas, Brazil; [Santos, Joao Hugo] Hosp Adventista Manaus, Manaus, Amazonas, Brazil; [Arantes, Ighor; Bello, Gonzalo] Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Dezordi, Filipe Zimmer; Wallau, Gabriel Luz] Fiocruz MS, Inst Aggeu Magalhaes, Dept Entomol & Nucleo Bioinformat, Recife, PE, Brazil; [Siqueira, Marilda Mendonca; Resende, Paola Cristina] Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Sarampo, Rio De Janeiro, Brazil; [Delatorre, Edson] Univ Fed Espirito Santo, Dept Biol, Ctr Ciencias Exatas Nat & Saude, Alegre, Brazil; [Graf, Tiago] Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Institute Nacional de Pesquisas da Amazonia; Universidade do Estado do Amazonas; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal do Espirito Santo; Fundacao Oswaldo Cruz	Naveca, FG (corresponding author), Fiocruz MS, Lab Ecol Doencas Transmissiveis Amazonia, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.; Bello, G (corresponding author), Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.	felipe.naveca@fiocruz.br; gbellobr@gmail.com	Silva, George Allan Villarouco/GQP-7023-2022; Pessoa, Karina Pinheiro/GPX-8092-2022; Naveca, Felipe/H-1130-2012; Resende, Paola Cristina/P-5002-2015; Wallau, Gabriel Luz/B-5911-2008; Gräf, Tiago/S-8535-2019; Delatorre, Edson/J-8330-2015; Sampaio, Vanderson/M-4337-2015; Pontes, Gemilson Soares/B-6103-2016	Silva, George Allan Villarouco/0000-0001-9803-1996; Pessoa, Karina Pinheiro/0000-0002-1275-5940; Naveca, Felipe/0000-0002-2888-1060; Resende, Paola Cristina/0000-0002-2884-3662; Wallau, Gabriel Luz/0000-0002-1419-5713; Gräf, Tiago/0000-0003-4921-7975; Delatorre, Edson/0000-0002-5746-0820; Sampaio, Vanderson/0000-0001-7307-8851; Pontes, Gemilson Soares/0000-0001-9001-7954; Dezordi, Filipe/0000-0003-3259-3456	Fundacao de Amparo a Pesquisa do Estado do Amazonas - FAPEAM; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq [403276/2020-9]; Inova Fiocruz/Fundacao Oswaldo Cruz [VPPCB-007-FIO-18-2-30-Geracao de conhecimento]; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ [E-26/202.896/2018]; CNPq [306146/2017-7, 302317/2017-1]; Respiratory Viruses Genomic Surveillance Network of the General Laboratory Coordination of the Brazilian Ministry of Health, Brazilian Central Laboratory States	Fundacao de Amparo a Pesquisa do Estado do Amazonas - FAPEAM(Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Inova Fiocruz/Fundacao Oswaldo Cruz; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Respiratory Viruses Genomic Surveillance Network of the General Laboratory Coordination of the Brazilian Ministry of Health, Brazilian Central Laboratory States	We thank all the health care workers and scientists who have worked hard to deal with this pandemic threat, the GISAID team and all the EpiCoV database submitters-in particular, the Japanese National Institute of Infectious Diseases members T. Sekizuka, K. Itokawa, R. Tanaka and M. Hashino-for publication of genomes. A GISAID acknowledgment table containing sequences used in this study is shown in Supplementary Table 8. We also thank N. Faria for sharing unpublished findings regarding the SARS-CoV-2 B.1.1.28 lineage. We also appreciate the support of Genomic Coronavirus Fiocruz Network members and the Respiratory Viruses Genomic Surveillance Network of the General Laboratory Coordination of the Brazilian Ministry of Health, Brazilian Central Laboratory States and the Amazonas surveillance teams for their partnership in viral surveillance in Brazil. Funding support is acknowledged from Fundacao de Amparo a Pesquisa do Estado do Amazonas - FAPEAM (PCTI-EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (grant no. 403276/2020-9) and Inova Fiocruz/Fundacao Oswaldo Cruz (grant no. VPPCB-007-FIO-18-2-30-Geracao de conhecimento), received by F.G.N., and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ (grant no. E-26/202.896/2018), received by G.B. F.G.N. and G.B. are also supported by CNPq through their productivity research fellowships (306146/2017-7 and 302317/2017-1, respectively). In loving memory of F. R. Naveca, C. R. dos Santos, V. L. Costa de Souza and all the relatives and colleagues we have lost to COVID-19.	[Anonymous], CELL HOST MICROBE; Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; BOUCKAERT R, 2019, PLOS COMPUT BIOL, V15, DOI DOI 10.1371/JOURNAL; Buss Lewis F, 2021, Science, V371, P288, DOI 10.1126/science.abe9728; Candido DS, 2020, SCIENCE, V369, P1255, DOI 10.1126/science.abd2161; Costa C, 2021, RES SQUARE, DOI [10.21203/rs.3.rs-318392/v1, DOI 10.21203/RS.3.RS-318392/V1]; Coutinho Renato Mendes, 2021, Commun Med (Lond), V1, P48, DOI 10.1038/s43856-021-00048-6; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055; do Nascimento VA, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760200310; Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI [10.1093/molbev/msi103, 10.1093/molbev/mss075]; Drummond AJ, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-114; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302; Fujino T, 2021, EMERG INFECT DIS, V27, P1243, DOI 10.3201/eid2704.210138; FundacAo em Vigilancia e Saude do Amazonas, 2021, B DIAR CAS COVID 19; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006, 10.1101/2021.02.14.21251704]; He D., 2021, UNEXPECTED DYNAMICS, DOI 10.1101/2021.02.18.21251809; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Ishikawa SA, 2019, MOL BIOL EVOL, V36, P2069, DOI 10.1093/molbev/msz131; Kalyaanamoorthy S, 2017, NAT METHODS, V14, P587, DOI [10.1038/NMETH.4285, 10.1038/nmeth.4285]; Katoh Kazutaka, 2013, Mol Biol Evol, V30, P772, DOI 10.1093/molbev/mst010; Kissler S.M., 2021, DENSELY SAMPLED VIRA, DOI 10.1101/2021.02.16.21251535; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lemey P, 2010, MOL BIOL EVOL, V27, P1877, DOI 10.1093/molbev/msq067; Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Martin Darren P, 2021, medRxiv, DOI 10.1101/2021.02.23.21252268; McCormick KD, 2021, SCIENCE, V371, P1306, DOI 10.1126/science.abg4493; Mellan, 2020, SUBNATIONAL ANAL COV, DOI 10.1101/2020.05.09.20096701; Mercatelli D, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01800; Nguyen Lam-Tung, 2015, Mol Biol Evol, V32, P268, DOI 10.1093/molbev/msu300; Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Resende PC, 2021, VIRUS EVOL, V7, DOI 10.1093/ve/veab069; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042; Stadler T, 2013, P NATL ACAD SCI USA, V110, P228, DOI 10.1073/pnas.1207965110; Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016; Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244; Tavare S., 1986, LECT MATH LIFE SCI, V17, P57; TEGALLY H, NATURE; Yoder AD, 2000, MOL BIOL EVOL, V17, P1081, DOI 10.1093/oxfordjournals.molbev.a026389	45	138	141	1	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1230	+		10.1038/s41591-021-01378-7	http://dx.doi.org/10.1038/s41591-021-01378-7		MAY 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34035535	Green Submitted, Bronze			2022-12-27	WOS:000654097800001
J	Berry-Kravis, EM; Harnett, MD; Reines, SA; Reese, MA; Ethridge, LE; Outterson, AH; Michalak, C; Furman, J; Gurney, ME				Berry-Kravis, Elizabeth M.; Harnett, Mark D.; Reines, Scott A.; Reese, Melody A.; Ethridge, Lauren E.; Outterson, Abigail H.; Michalak, Claire; Furman, Jeremiah; Gurney, Mark E.			Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial	NATURE MEDICINE			English	Article							LONG-TERM-MEMORY; IDENTIFIES PDE4D MUTATIONS; GENE FMR-1; DROSOPHILA; COGNITION; SPINES; DESIGN; FUTURE; MICE	The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with fragile X syndrome (FXS). This phase 2 trial was a 24-week randomized, placebo-controlled, two-way crossover study in 30 adult male patients (age 18-41 years) with FXS. Participants received oral doses of BPN14770 25 mg twice daily or placebo. Primary outcomes were prespecified as safety and tolerability with secondary efficacy outcomes of cognitive performance, caregiver rating scales and physician rating scales (ClinicalTrials.gov identifier: ). The study met the primary outcome measure since BPN14770 was well tolerated with no meaningful differences between the active and placebo treatment arms. The study also met key secondary efficacy measures of cognition and daily function. Cognitive benefit was demonstrated using the National Institutes of Health Toolbox Cognition Battery assessments of Oral Reading Recognition (least squares mean difference +2.81, P = 0.0157), Picture Vocabulary (+5.81, P = 0.0342) and Cognition Crystallized Composite score (+5.31, P = 0.0018). Benefit as assessed by visual analog caregiver rating scales was judged to be clinically meaningful for language (+14.04, P = 0.0051) and daily functioning (+14.53, P = 0.0017). Results from this study using direct, computer-based assessment of cognitive performance by adult males with FXS indicate significant cognitive improvement in domains related to language with corresponding improvement in caregiver scales rating language and daily functioning.	[Berry-Kravis, Elizabeth M.; Outterson, Abigail H.; Michalak, Claire; Furman, Jeremiah] Rush Univ, Med Ctr, Dept Pediat Neurol Sci & Biochem, Chicago, IL 60612 USA; [Harnett, Mark D.; Reines, Scott A.; Gurney, Mark E.] Tetra Therapeut, Grand Rapids, MI 49506 USA; [Reese, Melody A.; Ethridge, Lauren E.] Univ Oklahoma, Dept Psychol, Norman, OK 73019 USA; [Ethridge, Lauren E.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA	Rush University; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma Health Sciences Center	Berry-Kravis, EM (corresponding author), Rush Univ, Med Ctr, Dept Pediat Neurol Sci & Biochem, Chicago, IL 60612 USA.; Gurney, ME (corresponding author), Tetra Therapeut, Grand Rapids, MI 49506 USA.	Elizabeth_Berry-Kravis@rush.edu; mark@tetratherapeutics.com		Reese, Melody/0000-0002-8288-7914	FRAXA Research Foundation [HD076189]	FRAXA Research Foundation	We thank the patients and their families for participating in the clinical trial. Direct clinical costs were funded by the FRAXA Research Foundation. Access to and training on the NIH-TCB was obtained in association with work on HD076189 (E.M.B.K.). Tetra Therapeutics provided drug product and funded trial administration and independent data analysis.	Al-Tawashi A, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-47; BAKKER CE, 1994, CELL, V78, P23; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Baumgartel K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22193-0; Berry-Kravis E, 1998, J NEUROSCI RES, V51, P41, DOI 10.1002/(SICI)1097-4547(19980101)51:1<41::AID-JNR4>3.0.CO;2-L; Berry-Kravis E, 2017, J NEURODEV DISORD, V9, DOI 10.1186/s11689-016-9181-6; Berry-Kravis E, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aab4109; Berry-Kravis EM, 2018, NAT REV DRUG DISCOV, V17, P280, DOI 10.1038/nrd.2017.221; Berry-Kravis EM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004214; BERRYKRAVIS E, 1992, ANN NEUROL, V31, P22, DOI 10.1002/ana.410310105; BERRYKRAVIS E, 1995, PEDIATR RES, V38, P638, DOI 10.1203/00006450-199511000-00002; Bourtchouladze R, 2003, P NATL ACAD SCI USA, V100, P10518, DOI 10.1073/pnas.1834280100; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Briet C, 2017, HUM MOL GENET, V26, P3883, DOI 10.1093/hmg/ddx271; Budimirovic DB, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10100694; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; Choi CH, 2015, J NEUROSCI, V35, P396, DOI 10.1523/JNEUROSCI.1356-12.2015; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; Ethridge LE, 2019, FRONT INTEGR NEUROSC, V13, DOI 10.3389/fnint.2019.00060; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Gurney ME, 2019, J MED CHEM, V62, P4884, DOI 10.1021/acs.jmedchem.9b00193; Gurney ME, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15028-x; Hagerman RJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.65; He CX, 2013, NEUROSCIENCE, V251, P120, DOI 10.1016/j.neuroscience.2012.03.049; Hessl D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209984; Hessl D, 2016, J NEURODEV DISORD, V8, DOI 10.1186/s11689-016-9167-4; Irwin SA, 2000, CEREB CORTEX, V10, P1038, DOI 10.1093/cercor/10.10.1038; Kandel ER, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-14; Kanellopoulos AK, 2012, J NEUROSCI, V32, P13111, DOI 10.1523/JNEUROSCI.1347-12.2012; Kelley DJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000931; Klaiman C, 2014, PEDIATRICS, V134, P315, DOI 10.1542/peds.2013-3990; Knox A, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-2; Lee H, 2012, AM J HUM GENET, V90, P746, DOI 10.1016/j.ajhg.2012.03.004; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; Linglart A, 2012, J CLIN ENDOCR METAB, V97, pE2328, DOI 10.1210/jc.2012-2326; Lynch DC, 2013, HUM MUTAT, V34, P97, DOI 10.1002/humu.22222; Menke LA, 2018, AM J MED GENET A, V176, P862, DOI 10.1002/ajmg.a.38626; Michot C, 2012, AM J HUM GENET, V90, P740, DOI 10.1016/j.ajhg.2012.03.003; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Riley C, 2017, PEDIATRICS, V139, pS147, DOI 10.1542/peds.2016-1159B; Sansone SM, 2014, J NEURODEV DISORD, V6, DOI 10.1186/1866-1955-6-16; Shields RH, 2020, NEUROLOGY, V94, pE1229, DOI 10.1212/WNL.0000000000009131; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wakabayashi Y, 2020, ACS CHEM NEUROSCI, V11, P1311, DOI 10.1021/acschemneuro.0c00077; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Yi F, 2016, SCIENCE, V352, DOI 10.1126/science.aaf2669; Zhang C, 2018, NEUROPSYCHOPHARMACOL, V43, P2299, DOI 10.1038/s41386-018-0178-6	49	19	19	2	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					862	+		10.1038/s41591-021-01321-w	http://dx.doi.org/10.1038/s41591-021-01321-w		APR 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33927413				2022-12-27	WOS:000645518600002
J	Bausch, DG				Bausch, Daniel G.			The need for a new strategy for Ebola vaccination	NATURE MEDICINE			English	Editorial Material							RING VACCINATION; OUTBREAK	News of two new outbreaks of Ebola virus disease in the Democratic Republic of the Congo and Republic of Guinea, on the backdrop of the COVID-19 pandemic, signals the need for a change of direction in vaccination strategies in the area.	[Bausch, Daniel G.] London Sch Hyg & Trop Med, Publ Hlth England, UK Publ Hlth Rapid Support Team, London, England	Public Health England; University of London; London School of Hygiene & Tropical Medicine	Bausch, DG (corresponding author), London Sch Hyg & Trop Med, Publ Hlth England, UK Publ Hlth Rapid Support Team, London, England.	daniel.bausch@lshtm.ac.uk			UK Department of Health and Social Care	UK Department of Health and Social Care	The UK Public Health Rapid Support Team is funded by the UK Department of Health and Social Care. The views expressed in this publication are those of the author and not necessarily those of the National Health System, the National Institute for Health Research or the Department of Health and Social Care. The author thanks R. Grais and S. Nichol for feedback on the manuscript.	Bausch D.G., 2015, J INFECT DIS; Bausch DG, 2020, J INFECT DIS, V222, P521, DOI 10.1093/infdis/jiz520; Bausch DG, 2017, CURR TOP MICROBIOL, V411, P63, DOI 10.1007/82_2017_69; Bausch DG, 2016, LANCET INFECT DIS, V16, pe82, DOI [10.1016/S1473-3099(16)00077-3, DOI 10.1016/S1473-3099(16)00077-3]; Feldmann H, 2020, NEW ENGL J MED, V382, P1832, DOI 10.1056/NEJMra1901594; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Huber C, 2018, J INFECT DIS, V218, pS698, DOI 10.1093/infdis/jiy213; Kraemer MUG, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01574-1; Kucharski AJ, 2016, EMERG INFECT DIS, V22, P105, DOI 10.3201/eid2201.151410; Robert A, 2019, EPIDEMICS-NETH, V27, P106, DOI 10.1016/j.epidem.2019.03.001; Vetter Pauline, 2020, Rev Med Suisse, V16, P739	11	10	10	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					580	581		10.1038/s41591-021-01313-w	http://dx.doi.org/10.1038/s41591-021-01313-w		APR 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33820993	Bronze			2022-12-27	WOS:000636931100006
J	Planas, D; Bruel, T; Grzelak, L; Guivel-Benhassine, F; Staropoli, I; Porrot, F; Planchais, C; Buchrieser, J; Rajah, MM; Bishop, E; Albert, M; Donati, F; Prot, M; Behillil, S; Enouf, V; Maquart, M; Smati-Lafarge, M; Varon, E; Schortgen, F; Yahyaoui, L; Gonzalez, M; De Seze, JM; Pere, H; Veyer, D; Seve, A; Simon-Loriere, E; Fafi-Kremer, S; Stefic, K; Mouquet, H; Hocqueloux, L; van der Werf, S; Prazuck, T; Schwartz, O				Planas, Delphine; Bruel, Timothee; Grzelak, Ludivine; Guivel-Benhassine, Florence; Staropoli, Isabelle; Porrot, Francoise; Planchais, Cyril; Buchrieser, Julian; Rajah, Maaran Michael; Bishop, Elodie; Albert, Melanie; Donati, Flora; Prot, Matthieu; Behillil, Sylvie; Enouf, Vincent; Maquart, Marianne; Smati-Lafarge, Mounira; Varon, Emmanuelle; Schortgen, Frederique; Yahyaoui, Layla; Gonzalez, Maria; De Seze, Jerome; Pere, Helene; Veyer, David; Seve, Aymeric; Simon-Loriere, Etienne; Fafi-Kremer, Samira; Stefic, Karl; Mouquet, Hugo; Hocqueloux, Laurent; van der Werf, Sylvie; Prazuck, Thierry; Schwartz, Olivier			Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	NATURE MEDICINE			English	Article							MUTATIONS	Sera from convalescent individuals with coronavirus disease 2019 and from individuals vaccinated with BNT162b2 have reduced ability to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351, but antibody potency against the variants increases after two vaccine doses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants were first identified in the United Kingdom and South Africa, respectively, and have since spread to many countries. These variants harboring diverse mutations in the gene encoding the spike protein raise important concerns about their immune evasion potential. Here, we isolated infectious B.1.1.7 and B.1.351 strains from acutely infected individuals. We examined sensitivity of the two variants to SARS-CoV-2 antibodies present in sera and nasal swabs from individuals infected with previously circulating strains or who were recently vaccinated, in comparison with a D614G reference virus. We utilized a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection. Sera from 58 convalescent individuals collected up to 9 months after symptoms, similarly neutralized B.1.1.7 and D614G. In contrast, after 9 months, convalescent sera had a mean sixfold reduction in neutralizing titers, and 40% of the samples lacked any activity against B.1.351. Sera from 19 individuals vaccinated twice with Pfizer Cominarty, longitudinally tested up to 6 weeks after vaccination, were similarly potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Neutralizing titers increased after the second vaccine dose, but remained 14-fold lower against B.1.351. In contrast, sera from convalescent or vaccinated individuals similarly bound the three spike proteins in a flow cytometry-based serological assay. Neutralizing antibodies were rarely detected in nasal swabs from vaccinees. Thus, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Our results indicate that B1.351, but not B.1.1.7, may increase the risk of infection in immunized individuals.	[Planas, Delphine; Bruel, Timothee; Grzelak, Ludivine; Guivel-Benhassine, Florence; Staropoli, Isabelle; Porrot, Francoise; Buchrieser, Julian; Rajah, Maaran Michael; Bishop, Elodie; Schwartz, Olivier] Inst Pasteur, Dept Virol, Virus & Immun Unit, Paris, France; [Planas, Delphine; Bruel, Timothee; Grzelak, Ludivine; Guivel-Benhassine, Florence; Staropoli, Isabelle; Porrot, Francoise; Buchrieser, Julian; Rajah, Maaran Michael; Bishop, Elodie; Schwartz, Olivier] CNRS UMR 3569, Paris, France; [Planas, Delphine; Bruel, Timothee; Grzelak, Ludivine; Guivel-Benhassine, Florence; Staropoli, Isabelle; Porrot, Francoise; Buchrieser, Julian; Rajah, Maaran Michael; Bishop, Elodie; Schwartz, Olivier] Vaccine Res Inst, Creteil, France; [Grzelak, Ludivine; Rajah, Maaran Michael; Bishop, Elodie] Univ Paris, Sorbonne Paris Cite, Paris, France; [Planchais, Cyril; Mouquet, Hugo] Inst Pasteur, Dept Immunol, Lab Humoral Immunol, INSERM U1222, Paris, France; [Albert, Melanie; Donati, Flora; Behillil, Sylvie; Enouf, Vincent; van der Werf, Sylvie] Univ Paris, Inst Pasteur CNRS UMR 3569, Dept Virol, Mol Genet RNA Viruses, Paris, France; [Albert, Melanie; Donati, Flora; Behillil, Sylvie; Enouf, Vincent; van der Werf, Sylvie] Inst Pasteur, Natl Reference Ctr Resp Viruses, Paris, France; [Prot, Matthieu; Simon-Loriere, Etienne] Inst Pasteur, G5 Evolutionary Genom RNA Viruses, Paris, France; [Maquart, Marianne; Stefic, Karl] Univ Tours, INSERM U1259, Tours, France; [Smati-Lafarge, Mounira; Varon, Emmanuelle] CHI Creteil, Serv Biol Med, Creteil, France; [Schortgen, Frederique] CHI Creteil, Serv Reanimat, Creteil, France; [Yahyaoui, Layla] CHI Creteil, Serv Urgences, Creteil, France; [Gonzalez, Maria] CHU Strasbourg, Serv Pathol Profess & Med Travail, Strasbourg, France; [De Seze, Jerome] CHU Strasbourg, Ctr Invest Clin INSERM 1434, Strasbourg, France; [De Seze, Jerome] CHU Strasbourg, Serv Neurol, Strasbourg, France; [Pere, Helene; Veyer, David] Univ Paris, Ctr Rech Cordeliers, INSERM, Funct Genom Solid Tumors FunGeST, Paris, France; [Pere, Helene; Veyer, David] Sorbonne Univ, Paris, France; [Veyer, David] Hop Europeen Georges Pompidou, Serv Virol, Paris, France; [Seve, Aymeric; Hocqueloux, Laurent; Prazuck, Thierry] CHR Orleans, Serv Malad Infect, Orleans, France; [Fafi-Kremer, Samira] CHU Strasbourg, Lab Virol, Strasbourg, France; [Fafi-Kremer, Samira] Univ Strasbourg, INSERM, IRM UMR S 1109, Strasbourg, France; [Stefic, Karl] CHRU Tours, Natl Reference Ctr HIV Associated Lab, Tours, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Regional d'Orleans; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Tours	Schwartz, O (corresponding author), Inst Pasteur, Dept Virol, Virus & Immun Unit, Paris, France.; Schwartz, O (corresponding author), CNRS UMR 3569, Paris, France.; Schwartz, O (corresponding author), Vaccine Res Inst, Creteil, France.	olivier.schwartz@pasteur.fr	Schwartz, Olivier/AAZ-3765-2021; Bruel, Timothée/AAI-4632-2020; Mouquet, Hugo/M-2750-2014; maquart, marianne/AAX-8356-2021; Stefic, Karl/C-5052-2019	Schwartz, Olivier/0000-0002-0729-1475; Mouquet, Hugo/0000-0002-4230-610X; Stefic, Karl/0000-0002-9686-9194; Planas, Delphine/0000-0002-2509-9954; Planchais, Cyril/0000-0002-5142-7253; Rajah, Maaran Michael/0000-0002-6674-8850; Fafi-Kremer, Samira/0000-0003-3886-7833; Bruel, Timothee/0000-0002-3952-4261; BISHOP, Elodie/0000-0002-1310-2239; Buchrieser, Julian/0000-0003-4790-7577	Institut Pasteur; ANRS; Vaccine Research Institute [ANR-10-LABX-77]; Labex IBEID [ANR-10-LABX-62-IBEID]; ANR/FRM Flash COVID PROTEO-SARS-CoV-2; IDISCOVR; Region Ile-de-France program DIM1-Health; French Ministry of Higher Education, Research and Innovation; Milieu Interieur Program [ANR-10-LABX-69-01]; INSERM; REACTing EU (RECOVER) grants; CNRS; Universite de Paris; Sante publique France; Strasbourg University Hospital (SeroCoV-HUS) [PRI 7782]; Programme Hospitalier de Recherche Clinique (PHRC N 2017-HUS) [6997]; Agence Nationale de la Recherche [ANR-18-CE17-0028]; Laboratoire d'Excellence TRANSPLANTEX [ANR11-LABX-0070_TRANSPLANTEX]; Institut National de la Sante et de la Recherche Medicale [UMR_S 1109]; COREVIH Centre Val de Loire; Urgence COVID19 Fundraising Campaign of Institut Pasteur;  [ANR-10-INSB-04-01]	Institut Pasteur(European Commission); ANRS(ANRSFrench National Research Agency (ANR)); Vaccine Research Institute; Labex IBEID; ANR/FRM Flash COVID PROTEO-SARS-CoV-2; IDISCOVR; Region Ile-de-France program DIM1-Health; French Ministry of Higher Education, Research and Innovation; Milieu Interieur Program; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); REACTing EU (RECOVER) grants; CNRS(Centre National de la Recherche Scientifique (CNRS)); Universite de Paris; Sante publique France; Strasbourg University Hospital (SeroCoV-HUS); Programme Hospitalier de Recherche Clinique (PHRC N 2017-HUS); Agence Nationale de la Recherche(French National Research Agency (ANR)); Laboratoire d'Excellence TRANSPLANTEX; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); COREVIH Centre Val de Loire; Urgence COVID19 Fundraising Campaign of Institut Pasteur; 	We thank F. Rey and L. Chakrabarti (Institut Pasteur) for critical reading of the manuscript. We thank the patients who participated in this study; members of the Virus and Immunity Unit for discussions and help; N. Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis; and M. Backovic (Institut Pasteur) for the ACE2 construct. We thank the DRCI, CIC, Medecine du travail and Pole de Biologie teams (CHU de Strasbourg) for the management of the Strasbourg cohort and serology testing. Work in the laboratory of O.S. is funded by Institut Pasteur, Urgence COVID19 Fundraising Campaign of Institut Pasteur, ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash COVID PROTEO-SARS-CoV-2 and IDISCOVR. Work in UPBI is funded by grant ANR-10-INSB-04-01 and Region Ile-de-France program DIM1-Health. D.P. is supported by the Vaccine Research Institute. L.G. is supported by the French Ministry of Higher Education, Research and Innovation. The laboratory of H.M. is funded by the Institut Pasteur, the Milieu Interieur Program (ANR-10-LABX-69-01), the INSERM, REACTing and EU (RECOVER) grants. The laboratory of S.v.d.W. is funded by Institut Pasteur, CNRS, Universite de Paris, Sante publique France, Labex IBEID (ANR-10-LABX62-IBEID), REACTing, EU grant RECOVER. The laboratory of S.F.-K. is funded by Strasbourg University Hospital (SeroCoV-HUS; PRI 7782), Programme Hospitalier de Recherche Clinique (PHRC N 2017-HUS no. 6997), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d'Excellence TRANSPLANTEX (ANR11-LABX-0070_TRANSPLANTEX) and Institut National de la Sante et de la Recherche Medicale (UMR_S 1109). Work in CHR Orleans is funded by COREVIH Centre Val de Loire. The funders of this study had no role in study design, data collection, analysis and interpretation or writing of the article.	Andreano Emanuele, 2020, bioRxiv, DOI 10.1101/2020.12.28.424451; Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Buchrieser J, 2020, EMBO J, V39, DOI 10.15252/embj.2020106267; Buss LF, 2021, SCIENCE, V371, P288, DOI 10.1126/science.abe9728; Cele S, 2021, MEDRXIV, DOI [10.1101/2021.01.26.21250224, DOI 10.1101/2021.01.26.21250224, 10.1101/2021.03.07.21252647]; Dagotto G, 2020, CELL HOST MICROBE, V28, P364, DOI 10.1016/j.chom.2020.08.002; Fafi-Kremer S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102915; Faria NR., 2021, VIROLOGICAL, V372, P815, DOI DOI 10.1126/SCIENCE.ABH2644; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Grzelak L, 2021, J INFECT DIS, V224, P983, DOI 10.1093/infdis/jiab127; Grzelak L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3103; Harvey, 2020, SSRN ELECT J, DOI [DOI 10.2139/SSRN.3780277, 10.1101/2020.12.14.422555 (2021, 10.1101/2020.12.14.422555]; Haynes W.A., 2021, MEDRXIV, DOI 10.1101/2021.01.06.20248960; Ioannidis JPA, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13423; Kemp SA, 2021, NATURE, V592, P277, DOI 10.1038/s41586-021-03291-y; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Lorin V, 2015, J IMMUNOL METHODS, V422, P102, DOI 10.1016/j.jim.2015.04.010; McCarthy KR, 2021, SCIENCE, V371, P1139, DOI 10.1126/science.abf6950; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Munnink BBO, 2021, SCIENCE, V371, P172, DOI 10.1126/science.abe5901; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rambaut A., 2020, COVID 19 GENOMICS CO; Starr TN, 2021, SCIENCE, V371, P850, DOI 10.1126/science.abf9302; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Thomson EC, 2021, CELL, V184, P1171, DOI 10.1016/j.cell.2021.01.037; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; Weissman D, 2021, CELL HOST MICROBE, V29, P23, DOI 10.1016/j.chom.2020.11.012; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wu K., 2021, BIORXIV, DOI [10.1101/2021.01.25.427948, DOI 10.1101/2021.01.25.427948]; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Yurkovetskiy L, 2020, CELL, V183, P739, DOI 10.1016/j.cell.2020.09.032; Zahradnik J., 2021, SARS COV 2 RBD IN VI, DOI [10.1101/2021.01.06.425392, DOI 10.1101/2021.01.06.425392]	39	344	349	4	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					917	+		10.1038/s41591-021-01318-5	http://dx.doi.org/10.1038/s41591-021-01318-5		MAR 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33772244	Green Submitted, Bronze			2022-12-27	WOS:000633281900001
J	Revechon, G; Whisenant, D; Eriksson, M				Revechon, Gwladys; Whisenant, Daniel; Eriksson, Maria			Splice-inhibition therapy targets progeria	NATURE MEDICINE			English	Editorial Material									[Revechon, Gwladys; Whisenant, Daniel; Eriksson, Maria] Karolinska Inst, Dept Biosci & Nutr, Ctr Innovat Med, Huddinge, Sweden	Karolinska Institutet	Eriksson, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Ctr Innovat Med, Huddinge, Sweden.	maria.eriksson.2@ki.se		Revechon, Gwladys/0000-0002-4824-6793; Whisenant, Daniel/0000-0001-8210-5639				Aguado J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13018-3; Bennett CF, 2019, ANNU REV MED, V70, P307, DOI 10.1146/annurev-med-041217-010829; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Erdos MR, 2021, NAT MED, V27, P536, DOI 10.1038/s41591-021-01274-0; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Gordon LB, 2014, CELL, V156, P400, DOI 10.1016/j.cell.2013.12.028; Koblan LW, 2021, NATURE, V589, P608, DOI 10.1038/s41586-020-03086-7; Lee JM, 2016, J CLIN INVEST, V126, P1592, DOI 10.1172/JCI85908; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Puttaraju M, 2021, NAT MED, V27, P526, DOI 10.1038/s41591-021-01262-4; Rosengardten Y, 2011, AGING CELL, V10, P1011, DOI 10.1111/j.1474-9726.2011.00743.x	11	1	1	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					377	379		10.1038/s41591-021-01267-z	http://dx.doi.org/10.1038/s41591-021-01267-z		MAR 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33707774				2022-12-27	WOS:000627703000004
J	Neelapu, SS; Dickinson, M; Munoz, J; Ulrickson, ML; Thieblemont, C; Oluwole, OO; Herrera, AF; Ujjani, CS; Lin, Y; Riedell, PA; Kekre, N; de Vos, S; Lui, C; Milletti, F; Dong, JH; Xu, HR; Chavez, JC				Neelapu, Sattva S.; Dickinson, Michael; Munoz, Javier; Ulrickson, Matthew L.; Thieblemont, Catherine; Oluwole, Olalekan O.; Herrera, Alex F.; Ujjani, Chaitra S.; Lin, Yi; Riedell, Peter A.; Kekre, Natasha; de Vos, Sven; Lui, Christine; Milletti, Francesca; Dong, Jinghui; Xu, Hairong; Chavez, Julio C.			Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial	NATURE MEDICINE			English	Article							PROGNOSTIC VALUE; RESPONSE ASSESSMENT; CLINICAL-OUTCOMES; SINGLE-ARM; FDG-PET; MULTICENTER; CHEMOTHERAPY; TOMOGRAPHY; PREDICTOR	In a phase 2 trial, first-line treatment with axicabtagene ciloleucel, an autologous CD19-targeting CAR T-cell therapy, exhibited a high complete response rate and a manageable safety profile in adults with high-risk large B-cell lymphoma. High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in 40 patients with high-risk LBCL. This trial has completed accrual. The primary outcome was complete response rate (CRR). Secondary outcomes were objective response rate (ORR), duration of response (DOR), event-free survival (EFS), progression-free survival (PFS), overall survival (OS), assessment of safety, central nervous system (CNS) relapse and blood levels of CAR T cells and cytokines. The primary endpoint in efficacy-evaluable patients (n = 37) was met, with 78% CRR (95% confidence interval (CI), 62-90) and 89% ORR (95% CI, 75-97). As of 17 May 2021 (median follow-up, 15.9 months), 73% of patients remained in objective response; median DOR, EFS and PFS were not reached. Grade >= 3 cytokine release syndrome (CRS) and neurologic events occurred in three patients (8%) and nine patients (23%), respectively. There were no treatment-related grade 5 events. Robust CAR T-cell expansion occurred in all patients with a median time to peak of 8 days. We conclude that axi-cel is highly effective as part of first-line therapy for high-risk LBCL, with a manageable safety profile.	[Neelapu, Sattva S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Dickinson, Michael] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Dickinson, Michael] Univ Melbourne, Melbourne, Vic, Australia; [Munoz, Javier; Ulrickson, Matthew L.] Banner MD Anderson Canc Ctr, Gilbert, AZ USA; [Thieblemont, Catherine] Univ Paris, Hop St Louis, AP HP, DMU HI,Hematooncol, Paris, France; [Thieblemont, Catherine] Res Unit NF KappaB Differenciat & Canc, Paris, France; [Oluwole, Olalekan O.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Herrera, Alex F.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Ujjani, Chaitra S.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA; [Lin, Yi] Mayo Clin, Rochester, MN USA; [Riedell, Peter A.] Univ Chicago Med, Chicago, IL USA; [Kekre, Natasha] Ottawa Hosp, Dept Med, Ottawa, ON, Canada; [de Vos, Sven] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA; [Lui, Christine; Milletti, Francesca; Dong, Jinghui; Xu, Hairong] Kite, Santa Monica, CA USA; [Chavez, Julio C.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	University of Texas System; UTMD Anderson Cancer Center; Peter Maccallum Cancer Center; Royal Melbourne Hospital; University of Melbourne; Banner Research; Banner Health; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Vanderbilt University; City of Hope; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance; Mayo Clinic; University of Ottawa; Ottawa Hospital Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; H Lee Moffitt Cancer Center & Research Institute	Neelapu, SS (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	sneelapu@mdanderson.org		Dickinson, Michael/0000-0002-1492-5966; Lin, Yi/0000-0002-1556-6416	Kite	Kite	This study was funded by Kite, which participated in the study design, data collection, analysis and interpretation and writing of the report. We thank the patients who participated in this trial and their families, caregivers and friends; the trial investigators, coordinators and healthcare staff at each site; I. Kloos, J. Kawashima, C. Bunton, C. Williams, P. Gontijo, L. Xie and J. Hewitt of Kite, for support with medical monitoring, clinical operations, pharmacology analyses, statistical analyses and medical/regulatory writing, respectively; and Nexus Global Group Science for medical writing assistance.	Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; [Anonymous], 2008, WHO CLASSIFICATION T, V4th ed; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Bartlett NL, 2019, J CLIN ONCOL, V37, P1790, DOI 10.1200/JCO.18.01994; Bishop MR, 2022, NEW ENGL J MED, V386, P629, DOI 10.1056/NEJMoa2116596; Casasnovas RO, 2017, BLOOD, V130, P1315, DOI 10.1182/blood-2017-02-766691; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Costa RD, 2016, NUCL MED COMMUN, V37, P1095, DOI 10.1097/MNM.0000000000000553; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Friedberg JW, 2017, BLOOD, V130, P590, DOI 10.1182/blood-2017-04-737320; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Itti E, 2013, EUR J NUCL MED MOL I, V40, P1312, DOI 10.1007/s00259-013-2435-6; Jacobson C., 2021, BLOOD, V138, P1764, DOI [10.1182/blood-2021-148078, DOI 10.1182/BLOOD-2021-148078]; Jacobson CA, 2022, LANCET ONCOL, V23, P91, DOI 10.1016/S1470-2045(21)00591-X; Kamdar M, 2021, BLOOD, V138, DOI 10.1182/blood-2021-147913; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Locke FL, 2022, NEW ENGL J MED, V386, P640, DOI 10.1056/NEJMoa2116133; Locke FL, 2020, BLOOD ADV, V4, P4898, DOI 10.1182/bloodadvances.2020002394; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Locke FL, 2017, MOL THER, V25, P285, DOI 10.1016/j.ymthe.2016.10.020; Mamot C, 2015, J CLIN ONCOL, V33, P2523, DOI 10.1200/JCO.2014.58.9846; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2021, BLOOD ADV, V5, P4149, DOI [10.1182/bloodadvances.2020003848., 10.1182/bloodadvances.2020003848]; Petrich AM, 2014, BLOOD, V124, P2354, DOI 10.1182/blood-2014-05-578963; Roschewski M, 2022, NEW ENGL J MED, V386, P692, DOI 10.1056/NEJMe2118899; Schoder H, 2020, BLOOD, V135, P2224, DOI 10.1182/blood.2019003277; Schuster SJ, 2021, LANCET ONCOL, V22, P1403, DOI 10.1016/S1470-2045(21)00375-2; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Sehn LH, 2021, NEW ENGL J MED, V384, P842, DOI 10.1056/NEJMra2027612; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Wang MH, 2020, NEW ENGL J MED, V382, P1331, DOI 10.1056/NEJMoa1914347; YESCARTA&REG;, AX CIL SUMM PROD CHA; Zhu DX, 2015, INT J CLIN EXP MED, V8, P15340; Ziepert M, 2010, J CLIN ONCOL, V28, P2373, DOI 10.1200/JCO.2009.26.2493	36	22	22	4	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					735	+		10.1038/s41591-022-01731-4	http://dx.doi.org/10.1038/s41591-022-01731-4		MAR 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35314842	hybrid, Green Published			2022-12-27	WOS:000771548300003
J	Spertus, JA; Birmingham, MC; Nassif, M; Damaraju, CV; Abbate, A; Butler, J; Lanfear, DE; Lingvay, I; Kosiborod, MN; Januzzi, JL				Spertus, John A.; Birmingham, Mary C.; Nassif, Michael; Damaraju, C., V; Abbate, Antonio; Butler, Javed; Lanfear, David E.; Lingvay, Ildiko; Kosiborod, Mikhail N.; Januzzi, James L.			The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial	NATURE MEDICINE			English	Article							CITY CARDIOMYOPATHY QUESTIONNAIRE; CLINICAL-TRIALS; HEALTH-STATUS; DESIGN	Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemic, we sought to confirm these benefits in a new type of trial that was patient centered and conducted in a completely remote fashion. In the CHIEF-HF trial (NCT04252287), 476 participants with HF, regardless of EF or diabetes status, were randomized to 100 mg of canagliflozin or placebo. Enrollment was stopped early due to shifting sponsor priorities, without unblinding. The primary outcome was change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at 12 weeks. The 12-week change in KCCQ TSS was 4.3 points (95% confidence interval, 0.8-7.8; P=0.016) higher with canagliflozin than with placebo, meeting the primary endpoint. Similar effects were observed in participants with HFpEF and in those with HFrEF and in participants with and without diabetes, demonstrating that canagliflozin significantly improves symptom burden in HF, regardless of EF or diabetes status. This randomized, double-blind trial, conducted without in-person interactions between doctor and patient, can serve as a model for future all-virtual clinical trials.	[Spertus, John A.; Nassif, Michael; Kosiborod, Mikhail N.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA; [Birmingham, Mary C.] Janssen Sci Affairs LLC, Titusville, NJ USA; [Damaraju, C., V] Janssen Res & Dev LLC, Raritan, NJ USA; [Abbate, Antonio] Virginia Commonwealth Univ, Wright Ctr Clin & Translat Res, Richmond, VA USA; [Abbate, Antonio] Virginia Commonwealth Univ, Pauley Heart Ctr, Richmond, VA USA; [Butler, Javed] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Lanfear, David E.] Henry Ford Hlth Syst, Detroit, MI USA; [Lingvay, Ildiko] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Januzzi, James L.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Januzzi, James L.] Baim Inst Clin Res, Boston, MA USA	Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Virginia Commonwealth University; Virginia Commonwealth University; University of Mississippi; University of Mississippi Medical Center; Henry Ford Health System; Henry Ford Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Massachusetts General Hospital	Spertus, JA (corresponding author), Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA.	spertusj@umkc.edu	Kosiborod, Mikhail/HDO-1541-2022	Kosiborod, Mikhail/0000-0002-3750-9789; Lanfear, David/0000-0001-6471-1483; Januzzi, James/0000-0002-8338-1798; Spertus, John/0000-0002-2839-2611; Birmingham, Mary/0000-0002-5803-8410				Abraham WT, 2020, JACC-HEART FAIL, V8, P423, DOI 10.1016/j.jchf.2020.03.005; Anker SD, 2021, NEW ENGL J MED, V385, P1451, DOI 10.1056/NEJMoa2107038; [Anonymous], 2020, 000084 DDT COA; Antman EM, 2012, JAMA-J AM MED ASSOC, V308, P1743, DOI 10.1001/jama.2012.14841; Berndt E., 2013, NBER WORKING PAPERS, V18918; Bhatt DL, 2021, NEW ENGL J MED, V384, P117, DOI 10.1056/NEJMoa2030183; Butler J, 2017, EUR J HEART FAIL, V19, P1390, DOI 10.1002/ejhf.933; Dreyer RP, 2016, QUAL LIFE RES, V25, P2213, DOI 10.1007/s11136-016-1267-9; Executive Office of the President,, 2020, DECL NAT EM NOV COR; Fordyce CB, 2015, J AM COLL CARDIOL, V65, P1567, DOI 10.1016/j.jacc.2015.03.016; Frobert O, 2010, AM HEART J, V160, P1042, DOI 10.1016/j.ahj.2010.08.040; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; Harrington D, 2019, NEW ENGL J MED, V381, P285, DOI 10.1056/NEJMe1906559; Jones WS, 2021, NEW ENGL J MED, V384, P1981, DOI [10.1056/NEJMoa2102137Copyright<(c)>2021Massachusetts, 10.1056/NEJMoa2102137]; Joseph SM, 2013, CIRC-HEART FAIL, V6, P1139, DOI 10.1161/CIRCHEARTFAILURE.113.000359; Kosiborod M, 2007, CIRCULATION, V115, P1975, DOI 10.1161/CIRCULATIONAHA.106.670901; Kosiborod MN, 2020, CIRCULATION, V141, P90, DOI 10.1161/CIRCULATIONAHA.119.044138; Lauer MS, 2017, NAT REV CARDIOL, V14, P493, DOI 10.1038/nrcardio.2017.60; Lindenfeld J, 2021, LANCET, V398, P991, DOI 10.1016/S0140-6736(21)01754-2; Marquis-Gravel G, 2020, JAMA CARDIOL, V5, P598, DOI 10.1001/jamacardio.2020.0116; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Nassif ME, 2021, NAT MED, V27, P1954, DOI 10.1038/s41591-021-01536-x; Nassif ME, 2019, CIRCULATION, V140, P1463, DOI 10.1161/CIRCULATIONAHA.119.042929; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Petrie MC, 2020, JAMA-J AM MED ASSOC, V323, P1353, DOI 10.1001/jama.2020.1906; Pokharel Y, 2017, JAMA CARDIOL, V2, P1315, DOI 10.1001/jamacardio.2017.3983; Soto GE, 2004, CIRCULATION, V110, P546, DOI 10.1161/01.CIR.0000136991.85540.A9; Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010; Spertus JA, 2021, CIRC-HEART FAIL, V14, P396, DOI 10.1161/CIRCHEARTFAILURE.120.007767; Spertus JA, 2020, J AM COLL CARDIOL, V76, P2379, DOI 10.1016/j.jacc.2020.09.542; Spertus JA, 2015, CIRC-CARDIOVASC QUAL, V8, P469, DOI 10.1161/CIRCOUTCOMES.115.001958; Tahhan AS, 2016, J CARD FAIL, V22, P171, DOI 10.1016/j.cardfail.2015.06.014; US Food and Drug Administration, 2019, TREATM HEART FAIL EN; US Food and Drug Administration, 2020, FDA GUID COND CLIN T; Zinman B, 2016, NEW ENGL J MED, V374, P1094, DOI 10.1056/NEJMc1600827	35	24	24	11	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					809	+		10.1038/s41591-022-01703-8	http://dx.doi.org/10.1038/s41591-022-01703-8		FEB 2022	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35228753	hybrid, Green Published			2022-12-27	WOS:000762162700005
J	Powles, T; Sridhar, SS; Loriot, Y; Bellmunt, J; Mu, XJ; Ching, KA; Pu, J; Sternberg, CN; Petrylak, DP; Tambaro, R; Dourthe, LM; Alvarez-Fernandez, C; Aarts, M; di Pietro, A; Grivas, P; Davis, CB				Powles, Thomas; Sridhar, Srikala S.; Loriot, Yohann; Bellmunt, Joaquim; Mu, Xinmeng Jasmine; Ching, Keith A.; Pu, Jie; Sternberg, Cora N.; Petrylak, Daniel P.; Tambaro, Rosa; Dourthe, Louis M.; Alvarez-Fernandez, Carlos; Aarts, Maureen; di Pietro, Alessandra; Grivas, Petros; Davis, Craig B.			Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial	NATURE MEDICINE			English	Article							DNA-DAMAGE RESPONSE; OPEN-LABEL; PD-1/PD-L1 BLOCKADE; CLINICAL BENEFIT; CANCER; TUMOR; MULTICENTER; REGULARIZATION; IMMUNOTHERAPY; PEMBROLIZUMAB	In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer (JAVELIN Bladder 100; NCT02603432), avelumab/best supportive care (BSC) significantly prolonged overall survival relative to BSC alone as maintenance therapy after first-line chemotherapy. Exploratory biomarker analyses were performed to identify biological pathways that might affect survival benefit. Tumor molecular profiling by immunohistochemistry, whole-exome sequencing and whole-transcriptome sequencing revealed that avelumab survival benefit was positively associated with PD-L1 expression by tumor cells, tumor mutational burden, APOBEC mutation signatures, expression of genes underlying innate and adaptive immune activity and the number of alleles encoding high-affinity variants of activating Fc gamma receptors. Pathways connected to tissue growth and angiogenesis might have been associated with reduced survival benefit. Individual biomarkers did not comprehensively identify patients who could benefit from therapy; however, multi-parameter models incorporating genomic alteration, immune responses and tumor growth showed promising predictive utility. These results characterize the complex biologic pathways underlying survival benefit from immune checkpoint inhibition in advanced urothelial cancer and suggest that multiple biomarkers might be needed to identify patients who would benefit from treatment.	[Powles, Thomas] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England; [Sridhar, Srikala S.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Loriot, Yohann] Univ Paris Saclay, Gustave Roussy, INSERMU981, Villejuif, France; [Bellmunt, Joaquim] Harvard Med Sch, Dept Med Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Bellmunt, Joaquim] Harvard Med Sch, IMIM PSMAR Lab, Boston, MA 02115 USA; [Mu, Xinmeng Jasmine; Ching, Keith A.] Pfizer, Computat Biol, Oncol Res & Dev, La Jolla, CA USA; [Pu, Jie] Pfizer, Global Biometr & Data Management, Stat, La Jolla, CA USA; [Sternberg, Cora N.] Meyer Canc Ctr, Englander Inst Precis Med, Weill Cornell Med Hematol Oncol, New York, NY USA; [Petrylak, Daniel P.] Yale Canc Ctr, New Haven, CT USA; [Tambaro, Rosa] IRCCS Fdn Giovanni Pascale, Ist Nazl Studio Cura Tumori, Naples, Italy; [Dourthe, Louis M.] Serv Oncol Med, Clinique St Anne, Strasbourg, France; [Alvarez-Fernandez, Carlos] Hosp Univ Cent Asturias Inst Invest Sanitaria, Dept Med Oncol, Oviedo, Spain; [Aarts, Maureen] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Med Oncol, Maastricht, Netherlands; [di Pietro, Alessandra] Pfizer Italia srl, Milan, Italy; [Grivas, Petros] Univ Washington, Div Med Oncol, Fred Hutchinson Canc Res Ctr, Dept Med,Clin Res Div,Seattle Canc Care Alliance, Seattle, WA USA; [Davis, Craig B.] Pfizer, Translat Oncol, La Jolla, CA 92121 USA	University of London; Queen Mary University London; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Pfizer; Pfizer; Yale University; IRCCS Fondazione Pascale; Maastricht University; Pfizer; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle; Pfizer	Powles, T (corresponding author), Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England.; Davis, CB (corresponding author), Pfizer, Translat Oncol, La Jolla, CA 92121 USA.	thomas.powles1@nhs.net; craig.davis@pfizer.com	Loriot, Yohann/W-5572-2019; Alvarez-Fernandez, Carlos/AAA-5842-2019	Alvarez-Fernandez, Carlos/0000-0002-2500-074X; Bellmunt, Joaquim/0000-0003-2328-3421	Pfizer; healthcare business of Merck KGaA	Pfizer(Pfizer); healthcare business of Merck KGaA	This trial was sponsored by Pfizer as part of an alliance between Pfizer and the healthcare business of Merck KGaA (CrossRef Funder ID: 10.13039/100009945), which provided the study drugs. The investigators worked with Pfizer on the trial design, collection and analysis of data and interpretation of results. Datasets were reviewed by the authors, and all authors participated fully in developing and reviewing the report for publication. Funding for a professional medical writer with access to the data was provided by the sponsors. All authors had full access to all data, and the first author had final responsibility for the decision to submit for publication. The authors vouch for the completeness and accuracy of the data and their analysis and the fidelity of the trial to the protocol and statistical analysis plan. The authors thank the patients and their families, investigators, co-investigators and the study teams at each of the participating centers. The authors also thank A. Donahue and P. Robbins for study setup and supervision of biospecimen acquisition; L. Swaim and S. Dahm for establishing and overseeing performance of the SP263 assay; J. Chelliserry for guiding data acquisition; and H. Campanozzi for overseeing quality control. We thank the scientific team at CytoReason for collaborative work on cell estimates. Medical writing support was provided by M. Holland of ClinicalThinking and was funded by Pfizer and the healthcare business of Merck KGaA.	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Apolo AB, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001246; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2; Ballman KV, 2015, J CLIN ONCOL, V33, P3968, DOI 10.1200/JCO.2015.63.3651; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2017, CANCER TREAT REV, V54, P58, DOI 10.1016/j.ctrv.2017.01.007; Boichard A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1550341; Boyerinas B, 2015, CANCER IMMUNOL RES, V3, P1148, DOI 10.1158/2326-6066.CIR-15-0059; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chiu DKC, 2020, GASTROENTEROLOGY, V159, P609, DOI 10.1053/j.gastro.2020.03.074; Ciardiello D, 2020, ANN ONCOL, V31, P1336, DOI 10.1016/j.annonc.2020.07.009; Eckstein M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000162; European Medicines Agency, GUID INV SUBGR CONF; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Galsky MD, 2020, J CLIN ONCOL, V38; Glaser AP, 2018, ONCOTARGET, V9, P4537, DOI 10.18632/oncotarget.23344; Halbert B, 2021, UROLOGY, V147, P119, DOI 10.1016/j.urology.2020.10.030; Harjunpaa H, 2020, CLIN EXP IMMUNOL, V200, P108, DOI 10.1111/cei.13407; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Higgs BW, 2018, CLIN CANCER RES, V24, P3857, DOI 10.1158/1078-0432.CCR-17-3451; Houssaini Mohammed Sqalli, 2020, Cancer Treat Res Commun, V25, P100239, DOI 10.1016/j.ctarc.2020.100239; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Law EK, 2020, J EXP MED, V217, DOI 10.1084/jem.20200261; Leiserson MDM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208422; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Marcovecchio PM, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002045; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Messina JL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00765; Motzer RJ, 2020, NAT MED, V26, P1733, DOI 10.1038/s41591-020-1044-8; Mullane SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep27702; Nassif EF, 2021, CANCERS, V13, DOI 10.3390/cancers13030494; Necchi A, 2018, J CLIN ONCOL, V36, P3353, DOI 10.1200/JCO.18.01148; Neo SY, 2020, ADV EXP MED BIOL, V1231, P45, DOI 10.1007/978-3-030-36667-4_5; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Petljak M, 2020, DNA REPAIR, V94, DOI 10.1016/j.dnarep.2020.102905; Powles T, 2020, LANCET ONCOL, V21, P1574, DOI 10.1016/S1470-2045(20)30541-6; Powles T, 2020, NEW ENGL J MED, V383, P1218, DOI 10.1056/NEJMoa2002788; Powles T, 2020, CANCER TREAT REV, V82, DOI 10.1016/j.ctrv.2019.101925; Powles T, 2019, NAT MED, V25, P1706, DOI 10.1038/s41591-019-0628-7; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Qi ZH, 2019, J MOL DIAGN, V21, P796, DOI 10.1016/j.jmoldx.2019.04.011; Qu Y, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108115; Robinson BD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10873-y; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Samstein RM, 2020, NAT CANCER, V1, P1188, DOI 10.1038/s43018-020-00139-8; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Teo MY, 2018, J CLIN ONCOL, V36, P1685, DOI 10.1200/JCO.2017.75.7740; Teo MY, 2017, CLIN CANCER RES, V23, P3610, DOI 10.1158/1078-0432.CCR-16-2520; Therneau T.M., 2000, MODELING SURVIVAL DA; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007; Tsao MS, 2018, J THORAC ONCOL, V13, P1302, DOI 10.1016/j.jtho.2018.05.013; Gandhy SU, 2020, IMMUNOTHERAPY-UK, V12, P819, DOI 10.2217/imt-2020-0054; Ventana & Roche, VENTANA PD L1 SP263; Wang L, 2021, CLIN CANCER RES, V27, P4287, DOI 10.1158/1078-0432.CCR-20-4574; Yuen KC, 2020, NAT MED, V26, P693, DOI 10.1038/s41591-020-0860-1; Zajac M, 2019, DIAGN PATHOL, V14, DOI 10.1186/s13000-019-0873-6; Zhang L, 2021, J IMMUNOL METHODS, V494, DOI 10.1016/j.jim.2021.113041; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	67	19	19	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2200	+		10.1038/s41591-021-01579-0	http://dx.doi.org/10.1038/s41591-021-01579-0		DEC 2021	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34893775	Green Accepted			2022-12-27	WOS:000729031100004
J	Egozi, A; Llivichuzhca-Loja, D; McCourt, BT; Halpern, KB; Farack, L; An, XJ; Wang, FJ; Chen, K; Konnikova, L; Itzkovitz, S				Egozi, Adi; Llivichuzhca-Loja, Dhana; McCourt, Blake T.; Halpern, Keren Bahar; Farack, Lydia; An, Xiaojing; Wang, Fujing; Chen, Kong; Konnikova, Liza; Itzkovitz, Shalev			Insulin is expressed by enteroendocrine cells during human fetal development	NATURE MEDICINE			English	Article							GLUCAGON	Single-cell transcriptomic analyses of human fetal and neonatal intestinal cells reveal a subpopulation of enteroendocrine cells that produce insulin during development. Generation of beta cells via transdifferentiation of other cell types is a promising avenue for the treatment of diabetes. Here we reconstruct a single-cell atlas of the human fetal and neonatal small intestine. We identify a subset of fetal enteroendocrine K/L cells that express high levels of insulin and other beta cell genes. Our findings highlight a potential extra-pancreatic source of beta cells and expose its molecular blueprint.	[Egozi, Adi; Halpern, Keren Bahar; Farack, Lydia; Itzkovitz, Shalev] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Llivichuzhca-Loja, Dhana; McCourt, Blake T.; Konnikova, Liza] Yale Med Sch, Dept Pediat, New Haven, CT 06510 USA; [Llivichuzhca-Loja, Dhana; McCourt, Blake T.; Konnikova, Liza] Yale Med Sch, Dept Obstet Gynecol & Reprod Sci Human & Translat, New Haven, CT 06510 USA; [An, Xiaojing; Wang, Fujing; Chen, Kong] Univ Pittsburgh, Med Ctr, Montefiore Hosp, Dept Med, Pittsburgh, PA USA	Weizmann Institute of Science; Yale University; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	Itzkovitz, S (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.; Konnikova, L (corresponding author), Yale Med Sch, Dept Pediat, New Haven, CT 06510 USA.; Konnikova, L (corresponding author), Yale Med Sch, Dept Obstet Gynecol & Reprod Sci Human & Translat, New Haven, CT 06510 USA.	liza.konnikova@yale.edu; shalev.itzkovitz@weizmann.ac.il	An, Xiaojing/HHM-9859-2022	McCourt, Blake/0000-0002-1488-2572; Konnikova, Yelizaveta/0000-0003-4804-5497	Wolfson Family Charitable Trust; Edmond de Rothschild Foundations; Fannie Sherr Fund; Dr. Beth Rom-Rymer Stem Cell Research Fund; Minerva Stiftung grant; Israel Science Foundation [1486/16]; Broad Institute-Israel Science Foundation [2615/18]; European Research Council under the European Union [768956]; Chan Zuckerberg Initiative [CZF2019-002434]; network of Pancreatic Organ Donors with Diabetes (nPOD); Bert L. and N. Kuggie Vallee Foundation; Howard Hughes Medical Institute; University of Pittsburgh; Yale University; Binational Science Foundation [2019075]; National Institute of Health (NIH) [R21TR002639, R21HD102565]	Wolfson Family Charitable Trust; Edmond de Rothschild Foundations; Fannie Sherr Fund; Dr. Beth Rom-Rymer Stem Cell Research Fund; Minerva Stiftung grant; Israel Science Foundation(Israel Science Foundation); Broad Institute-Israel Science Foundation; European Research Council under the European Union(European Research Council (ERC)); Chan Zuckerberg Initiative; network of Pancreatic Organ Donors with Diabetes (nPOD); Bert L. and N. Kuggie Vallee Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); University of Pittsburgh(University of Pittsburgh); Yale University; Binational Science Foundation(US-Israel Binational Science Foundation); National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Y. Dor and R. Scharfmann for insightful comments. S.I. is supported by the Wolfson Family Charitable Trust, the Edmond de Rothschild Foundations, the Fannie Sherr Fund, the Dr. Beth Rom-Rymer Stem Cell Research Fund, the Minerva Stiftung grant, Israel Science Foundation grant number 1486/16, Broad Institute-Israel Science Foundation grant number 2615/18, the European Research Council under the European Union's Horizon 2020 Research and Innovation Program (grant no. 768956), Chan Zuckerberg Initiative grant number CZF2019-002434, the network of Pancreatic Organ Donors with Diabetes (nPOD), the Bert L. and N. Kuggie Vallee Foundation and the Howard Hughes Medical Institute international research scholar award. L.K. is supported by previous start-up funds from the University of Pittsburgh and current start-up funds from Yale University, Binational Science Foundation award number 2019075 and National Institute of Health (NIH) grants R21TR002639 and R21HD102565. No NIH funds were used for the fetal work of these studies.	Baron M, 2016, CELL SYST, V3, P346, DOI 10.1016/j.cels.2016.08.011; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blum B, 2012, NAT BIOTECHNOL, V30, P261, DOI 10.1038/nbt.2141; Bouchi R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5242; BUSE MG, 1962, J CLIN INVEST, V41, P29, DOI 10.1172/JCI104464; Cao JY, 2020, SCIENCE, V370, P808, DOI 10.1126/science.aba7721; Chen YJ, 2014, CELL REP, V6, P1046, DOI 10.1016/j.celrep.2014.02.013; Elmentaite R, 2020, DEV CELL, V55, P771, DOI 10.1016/j.devcel.2020.11.010; Farack L, 2019, DEV CELL, V48, P115, DOI 10.1016/j.devcel.2018.11.001; Gross S, 2016, DEVELOPMENT, V143, P2616, DOI 10.1242/dev.130682; Habib AM, 2012, ENDOCRINOLOGY, V153, P3054, DOI 10.1210/en.2011-2170; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Jennings RE, 2015, DEVELOPMENT, V142, P3126, DOI 10.1242/dev.120063; Kaspi H, 2014, TRENDS ENDOCRIN MET, V25, P285, DOI 10.1016/j.tem.2014.01.003; Konnikova L, 2018, MUCOSAL IMMUNOL, V11, P1684, DOI 10.1038/s41385-018-0047-y; Luo JD, 2020, METHODS MOL BIOL, V2111, P35, DOI 10.1007/978-1-0716-0266-9_3; Manco R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23245-2; Massalha H, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209682; Matschinsky FM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00148; Menon RK, 1996, ENDOCRIN METAB CLIN, V25, P633, DOI 10.1016/S0889-8529(05)70344-3; Merrell AJ, 2016, NAT REV MOL CELL BIO, V17, P413, DOI 10.1038/nrm.2016.24; Nowak-Sliwinska P, 2019, BRIT J CANCER, V120, P218, DOI 10.1038/s41416-018-0347-8; Olaloye OO, 2021, J EXP MED, V218, DOI 10.1084/jem.20200344; Salomon LJ, 2007, ULTRASOUND OBST GYN, V29, P550, DOI 10.1002/uog.4019; Scharfmann R, 2019, J CLIN INVEST, V129, P3511, DOI 10.1172/JCI129484; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Sender R, 2021, NAT MED, V27, P45, DOI 10.1038/s41591-020-01182-9; Stras SF, 2019, DEV CELL, V51, P357, DOI 10.1016/j.devcel.2019.09.008; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Suissa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070397; Talchai C, 2012, NAT GENET, V44, P406, DOI 10.1038/ng.2215; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; van de Sande B, 2020, NAT PROTOC, V15, P2247, DOI 10.1038/s41596-020-0336-2; van den Brink SC, 2017, NAT METHODS, V14, P935, DOI 10.1038/nmeth.4437; Vivot K, 2016, MOL METAB, V5, P988, DOI 10.1016/j.molmet.2016.08.010; Xin HY, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02084-2	36	0	0	5	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2104	+		10.1038/s41591-021-01586-1	http://dx.doi.org/10.1038/s41591-021-01586-1		DEC 2021	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887578	Green Submitted			2022-12-27	WOS:000728466100001
J	Deeks, SG; Archin, N; Cannon, P; Collins, S; Jones, RB; de Jong, MAWP; Lambotte, O; Lamplough, R; Ndung'u, T; Sugarman, J; Tiemessen, CT; Vandekerckhove, L; Lewin, SR				Deeks, Steven G.; Archin, Nancie; Cannon, Paula; Collins, Simon; Jones, R. Brad; de Jong, Marein A. W. P.; Lambotte, Olivier; Lamplough, Rosanne; Ndung'u, Thumbi; Sugarman, Jeremy; Tiemessen, Caroline T.; Vandekerckhove, Linos; Lewin, Sharon R.		Int AIDS Soc IAS Global Sci Strate	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021	NATURE MEDICINE			English	Review							CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY; TREATMENT INTERRUPTION; PROVIRUSES PRODUCE; VIRUS REACTIVATION; INFECTED PATIENTS; LATENCY REVERSAL; EX-VIVO; RESERVOIR; REPLICATION	Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These latently infected cells are not recognized as foreign because they are largely transcriptionally silent, but contain replication-competent virus that drives resurgence of the infection once ART is stopped. With a combination of immune activators, neutralizing antibodies, and therapeutic vaccines, some nonhuman primate models have been cured, providing optimism for these approaches now being evaluated in human clinical trials. In vivo delivery of gene-editing tools to either target the virus, boost immunity or protect cells from infection, also holds promise for future HIV cure strategies. In this Review, we discuss advances related to HIV cure in the last 5 years, highlight remaining knowledge gaps and identify priority areas for research for the next 5 years. An effective and scalable cure strategy is a top priority for the HIV research field; this Review discusses recent advances, knowledge gaps, and priority research areas for the next 5 years.	[Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Archin, Nancie] Univ N Carolina, Dept Med, UNC HIV Cure Ctr, Chapel Hill Sch Med, Chapel Hill, NC USA; [Cannon, Paula] Univ Southern Calif, Los Angeles, CA 90007 USA; [Collins, Simon] HIV i Base, London, England; [Jones, R. Brad] Cornell Univ, Weill Cornell Med, New York, NY 10021 USA; [de Jong, Marein A. W. P.] Aidsfonds, Amsterdam, Netherlands; [Lambotte, Olivier] Univ Paris Saclay, Bicetre Hosp, AP HP, UMR1184 INSERM CEA, Paris, France; [Lamplough, Rosanne] Int AIDS Soc, Geneva, Switzerland; [Ndung'u, Thumbi] Africa Hlth Res Inst, Durban, South Africa; [Ndung'u, Thumbi] Univ KwaZulu Natal, Durban, South Africa; [Ndung'u, Thumbi] UCL, London, England; [Ndung'u, Thumbi] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA; [Ndung'u, Thumbi] Harvard Univ, Cambridge, MA 02138 USA; [Sugarman, Jeremy] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA; [Sugarman, Jeremy] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Tiemessen, Caroline T.] Univ Witwatersrand, Natl Inst Communicable Dis, Johannesburg, South Africa; [Tiemessen, Caroline T.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa; [Vandekerckhove, Linos] UZ Ghent, Ghent, Belgium; [Lewin, Sharon R.] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Serv, Melbourne, Vic, Australia; [Lewin, Sharon R.] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia; [Lewin, Sharon R.] Monash Univ, Melbourne, Vic, Australia; [Lewin, Sharon R.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; Cornell University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Africa Health Research Institute; University of Kwazulu Natal; University of London; University College London; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Johns Hopkins University; Johns Hopkins University; National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; Ghent University; Ghent University Hospital; Royal Melbourne Hospital; Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne	Deeks, SG (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Lewin, SR (corresponding author), Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Serv, Melbourne, Vic, Australia.; Lewin, SR (corresponding author), Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia.; Lewin, SR (corresponding author), Monash Univ, Melbourne, Vic, Australia.; Lewin, SR (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia.	Steve.deeks@ucsf.edu; Sharon.lewin@unimelb.edu.au	Søgaard, Ole Schmeltz/AEP-7968-2022; Lambotte, Olivier/GRT-0160-2022; Kankaka, Edward Nelson/ACZ-1367-2022	Søgaard, Ole Schmeltz/0000-0001-9107-2023; Kankaka, Edward Nelson/0000-0001-6977-3405; Cannon, Paula/0000-0003-0059-354X; Collins, Simon/0000-0002-3537-2432; Orta-Resendiz, Aurelio/0000-0002-6632-883X; Matoga, Mitch/0000-0002-6542-8193; Mothe, Beatriz/0000-0001-9975-407X	National Institutes of Health Delaney AIDS Research Enterprise (DARE) [UM1AI126611, UM1AI164560]; National Health and Medical Research Council (NHMRC) of Australia [GNT1149990]; Australian Centre for HIV and Hepatitis; NIH [UM1AI64565, HL156247, AI164561, 1UM1AI126619, R01AI134363]; South African Research Chairs Initiative of the Department of Science and Innovation; National Research Foundation of South Africa [84177, 64809]; ANRS; Sidaction; University Paris Saclay; Inserm; CEA (Commissariat a l'Energie Atomique); Bill and Melinda Gates Foundation [INV-033558]; International AIDS Vaccine Initiative [UKZNRSA1001]; DFG German-African Network grant [AL 1043/6-1]	National Institutes of Health Delaney AIDS Research Enterprise (DARE); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Centre for HIV and Hepatitis; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); South African Research Chairs Initiative of the Department of Science and Innovation; National Research Foundation of South Africa(National Research Foundation - South Africa); ANRS(ANRSFrench National Research Agency (ANR)); Sidaction; University Paris Saclay; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CEA (Commissariat a l'Energie Atomique)(French Atomic Energy Commission); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); International AIDS Vaccine Initiative; DFG German-African Network grant(German Research Foundation (DFG))	We acknowledge the generous contribution of all the participants in the working groups, the key opinion leaders who read and provided feedback on the strategy, participants in the online survey and secretarial support from the International AIDS Society. S.R.L. and S. G.D. are funded by National Institutes of Health Delaney AIDS Research Enterprise (DARE) Collaboratory (UM1AI126611 and UM1AI164560). S.R.L. is also funded by the National Health and Medical Research Council (NHMRC; grant number GNT1149990) of Australia and the Australian Centre for HIV and Hepatitis. R.B.J. is funded by the NIH UM1AI64565. C.T.T. is funded by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa (grant 84177). O.L. is funded by the ANRS, Sidaction, University Paris Saclay, Inserm, and CEA (Commissariat a l'Energie Atomique). P.C. is funded by the NIH (HL156247 and AI164561); N.A. is funded by the NIH Delaney CARE Collaboratory 1UM1AI126619 and from R01AI134363; T.N. is funded by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa (grant 64809), The Bill and Melinda Gates Foundation (INV-033558), the International AIDS Vaccine Initiative (UKZNRSA1001) and DFG German-African Network grant (grant number AL 1043/6-1).	Abdel-Mohsen M, 2020, NAT MED, V26, P1339, DOI 10.1038/s41591-020-1022-1; Abrahams MR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw5589; Adair J. E., ACCESS ALL 1 WORKING, DOI [10.1038/s41434-021-00284-4, DOI 10.1038/S41434-021-00284-4]; Ahlenstiel C, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.31; Anderson EM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020136; Anderson JL, 2020, J INFECT DIS, V221, P744, DOI 10.1093/infdis/jiz509; Bertagnolli LN, 2020, P NATL ACAD SCI USA, V117, P32066, DOI 10.1073/pnas.2020617117; Besnard E, 2016, CELL HOST MICROBE, V20, P785, DOI 10.1016/j.chom.2016.11.001; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Borducchi EN, 2016, NATURE, V540, P284, DOI 10.1038/nature20583; Bricker KM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008954; Brodin J, 2016, ELIFE, V5, DOI 10.7554/eLife.18889; Bruner KM, 2016, NAT MED, V22, P1043, DOI 10.1038/nm.4156; Bui JK, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006283; Canoui E, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx064; Casado C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58696-y; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2013, J INFECT DIS, V208, P1443, DOI 10.1093/infdis/jit306; Cillo AR, 2014, P NATL ACAD SCI USA, V111, P7078, DOI 10.1073/pnas.1402873111; Cohn LB, 2015, CELL, V160, P420, DOI 10.1016/j.cell.2015.01.020; Colby DJ, 2020, NAT MED, V26, P498, DOI 10.1038/s41591-020-0774-y; Conway JM, 2015, P NATL ACAD SCI USA, V112, P5467, DOI 10.1073/pnas.1419162112; Cummins NW, 2017, J VIROL, V91, DOI 10.1128/JVI.00012-17; Das B, 2018, P NATL ACAD SCI USA, V115, pE7795, DOI 10.1073/pnas.1803468115; De Scheerder MA, 2019, CELL HOST MICROBE, V26, P347, DOI 10.1016/j.chom.2019.08.003; Deeks SG, 2016, NAT MED, V22, P839, DOI 10.1038/nm.4108; Deeks SG, 2012, NAT REV IMMUNOL, V12, P607, DOI 10.1038/nri3262; Dhummakupt A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134105; Draz MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06727-8; Dube K., CONSIDERATIONS INCRE, DOI [10.1089/AID.2021.0023(2021, DOI 10.1089/AID.2021.0023(2021]; Dybul M, 2021, LANCET HIV, V8, pe51, DOI 10.1016/S2352-3018(20)30232-0; Elliott JH, 2015, LANCET HIV, V2, pE520, DOI 10.1016/S2352-3018(15)00226-X; Elsheikh MM, 2019, EBIOMEDICINE, V45, P624, DOI 10.1016/j.ebiom.2019.06.020; Eriksson S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003174; Falcinelli SD, 2020, J INFECT DIS, V222, P1843, DOI 10.1093/infdis/jiaa298; Fidler S, 2021, J VIRUS ERAD, V7, DOI 10.1016/j.jve.2020.100025; Fidler S, 2020, LANCET, V395, P888, DOI 10.1016/S0140-6736(19)32990-3; Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111; Frange P, 2016, LANCET HIV, V3, pE49, DOI 10.1016/S2352-3018(15)00232-5; Fromentin R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005761; Gaebler C, 2021, J VIROL, V95, DOI 10.1128/JVI.01986-20; Galvez C, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102830; Gandhi RT, 2021, J INFECT DIS, V223, P225, DOI 10.1093/infdis/jiaa532; Gardner MR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5409; Garner SA, 2017, J VIRUS ERAD, V3, P82; Gautam R, 2012, J VIROL, V86, P8516, DOI 10.1128/JVI.00644-12; Gavegnano C, 2014, ANTIMICROB AGENTS CH, V58, P1977, DOI 10.1128/AAC.02496-13; Gay CL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61878-3; Gillmore JD, 2021, NEW ENGL J MED, V385, P493, DOI 10.1056/NEJMoa2107454; Gondim MVP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd8179; Goonetilleke N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01966; Gosselin A, 2017, AIDS, V31, P35, DOI 10.1097/QAD.0000000000001309; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Gupta RK, 2020, LANCET HIV, V7, pE340, DOI 10.1016/S2352-3018(20)30069-2; Gutierrez C, 2016, AIDS, V30, P1385, DOI 10.1097/QAD.0000000000001064; Halvas EK, 2020, J CLIN INVEST, V130, P5847, DOI 10.1172/JCI138099; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Henrich TJ, 2021, AM J TRANSPLANT, V21, P1765, DOI 10.1111/ajt.16244; Herzig E, 2019, CELL, V179, P880, DOI 10.1016/j.cell.2019.10.002; Hessell AJ, 2016, NAT MED, V22, P362, DOI 10.1038/nm.4063; Hill AL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005535; Hosmane NN, 2017, J EXP MED, V214, P959, DOI 10.1084/jem.20170193; Huang DL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19650-8; Huang SH, 2018, J CLIN INVEST, V128, P876, DOI [10.1172/JCI97555, 10.1172/jci97555]; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Huot N, 2017, NAT MED, V23, P1277, DOI 10.1038/nm.4421; Imamichi H, 2020, P NATL ACAD SCI USA, V117, P3704, DOI 10.1073/pnas.1917876117; Imamichi H, 2016, P NATL ACAD SCI USA, V113, P8783, DOI 10.1073/pnas.1609057113; Jiang CY, 2020, NATURE, V585, P261, DOI 10.1038/s41586-020-2651-8; Johnston RE, 2015, AIDS RES HUM RETROV, V31, P85, DOI [10.1089/aid.2014.0205, 10.1089/AID.2014.0205]; Julg B, 2019, LANCET HIV, V6, pE259, DOI 10.1016/S2352-3018(19)30052-9; Karpinski J, 2016, NAT BIOTECHNOL, V34, P401, DOI 10.1038/nbt.3467; Kessing CF, 2017, CELL REP, V21, P600, DOI 10.1016/j.celrep.2017.09.080; Khanal S, 2020, J VIROL, V94, DOI 10.1128/JVI.01420-19; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; Koelsch KK, 2017, JAIDS-J ACQ IMM DEF, V75, P328, DOI 10.1097/QAI.0000000000001381; Kok YL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28161-y; Kuo HH, 2018, IMMUNITY, V48, P1183, DOI 10.1016/j.immuni.2018.04.004; Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142; Lee GQ, 2017, J CLIN INVEST, V127, P2689, DOI 10.1172/JCI93289; Leth S, 2016, LANCET HIV, V3, pE463, DOI 10.1016/S2352-3018(16)30055-8; Lewin SR, 2021, LANCET HIV, V8, P42, DOI 10.1016/S2352-3018(20)30234-4; Lorenzi JCC, 2016, P NATL ACAD SCI USA, V113, pE7908, DOI 10.1073/pnas.1617789113; Luzuriaga K, 2015, NEW ENGL J MED, V372, P786, DOI 10.1056/NEJMc1413931; Madec Y, 2013, AIDS, V27, P2451, DOI 10.1097/01.aids.0000431945.72365.01; Maldarelli F, 2014, SCIENCE, V345, P179, DOI 10.1126/science.1254194; Mancuso P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19821-7; Marconi V. C., CLIN INFECT DIS, Vciab212; Margolis DM, 2020, CELL, V181, P189, DOI 10.1016/j.cell.2020.03.005; Martinez-Navio JM, 2019, IMMUNITY, V50, P567, DOI 10.1016/j.immuni.2019.02.005; Mavigner M, 2018, J VIROL, V92, DOI 10.1128/JVI.00562-18; McBrien JB, 2020, NATURE, V578, P154, DOI 10.1038/s41586-020-1946-0; McMahon JH, 2022, AIDS, V36, P75, DOI 10.1097/QAD.0000000000003091; McMahon JH, 2021, EBIOMEDICINE, V65, DOI 10.1016/j.ebiom.2021.103252; McManus WR, 2019, J CLIN INVEST, V129, P4529, DOI 10.1172/JCI126714; Mendoza D, 2012, BLOOD, V119, P4645, DOI 10.1182/blood-2011-10-381996; Mendoza P, 2020, J EXP MED, V217, DOI 10.1084/jem.20200051; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mitchell JL, 2020, J CLIN INVEST, V130, P2845, DOI 10.1172/JCI130597; Mori L, 2021, J VIROL, V95, DOI 10.1128/JVI.01247-20; Mothe B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00823; Mousseau G, 2015, MBIO, V6, DOI 10.1128/mBio.00465-15; Nahmad AD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19649-1; Namazi G, 2018, J INFECT DIS, V218, P1954, DOI 10.1093/infdis/jiy479; Neidleman J, 2020, ELIFE, V9, DOI 10.7554/eLife.60933; Nixon CC, 2020, NATURE, V578, P160, DOI 10.1038/s41586-020-1951-3; Obregon-Perko V, 2021, J VIROL, V95, DOI 10.1128/JVI.01669-20; Okoye AA, 2018, NAT MED, V24, P1430, DOI 10.1038/s41591-018-0130-7; Papasavvas E, 2021, AIDS RES HUM RETROV, V37, P433, DOI [10.1089/aid.2020.0243, 10.1089/AID.2020.0243]; Pardons M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007619; Passaes C, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108174; Peluso MJ, 2020, J VIRUS ERAD, V6, P34; Peluso MJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132997; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Pollack RA, 2017, CELL HOST MICROBE, V21, P494, DOI 10.1016/j.chom.2017.03.008; Priddy FH, 2019, LANCET HIV, V6, pE230, DOI 10.1016/S2352-3018(19)30003-7; Prodger JL, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139287; Protiere C, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25443; Rasmussen TA, 2021, CLIN INFECT DIS, V73, pE1973, DOI 10.1093/cid/ciaa1530; Ren YQ, 2020, J CLIN INVEST, V130, P2542, DOI 10.1172/JCI132374; Richart V., AIDS, DOI [10.1097/QAD.0000000000003058(2021), DOI 10.1097/QAD.0000000000003058(2021)]; Riddler SA, 2021, CLIN INFECT DIS, V72, pE815, DOI 10.1093/cid/ciaa1534; Rust BJ, 2020, BLOOD, V136, P1722, DOI 10.1182/blood.2020006372; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Salgado M, 2018, ANN INTERN MED, V169, P674, DOI 10.7326/M18-0759; Santangelo PJ, 2015, NAT METHODS, V12, P427, DOI [10.1038/NMETH.3320, 10.1038/nmeth.3320]; Sarabia I, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121104; Schaller T, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002439; Schuster SJ, 2017, NEW ENGL J MED, V377, P2545, DOI 10.1056/NEJMoa1708566; Scully EP, 2019, J INFECT DIS, V219, P1084, DOI 10.1093/infdis/jiy617; Scully EP, 2018, CURR HIV-AIDS REP, V15, P136, DOI 10.1007/s11904-018-0383-2; SenGupta D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg3071; Shapiro MB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13972-y; Simonetti FR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145254; Simonetti FR, 2016, P NATL ACAD SCI USA, V113, P1883, DOI 10.1073/pnas.1522675113; Singh A, 2010, BIOPHYS J, V98, pL32, DOI 10.1016/j.bpj.2010.03.001; Spudich S, 2019, J CLIN INVEST, V129, P3339, DOI 10.1172/JCI127413; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Szotek EL, 2013, VIROLOGY, V443, P375, DOI 10.1016/j.virol.2013.05.027; Tebas P, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144486; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; Timmons A, 2020, P NATL ACAD SCI USA, V117, P15763, DOI 10.1073/pnas.1916290117; Tombacz I, 2021, MOL THER, V29, P3293, DOI 10.1016/j.ymthe.2021.06.004; Vibholm L, 2017, CLIN INFECT DIS, V64, P1686, DOI 10.1093/cid/cix201; Violari A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08311-0; Wagner TA, 2014, SCIENCE, V345, P570, DOI 10.1126/science.1256304; Wu GX, 2021, J INFECT DIS, V224, P1593, DOI 10.1093/infdis/jiab121; Yeh YHJ, 2020, J CLIN INVEST, V130, P4969, DOI 10.1172/JCI137371; Yukl SA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9927; Yukl SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003347; Zerbato JM, 2021, EBIOMEDICINE, V65, DOI 10.1016/j.ebiom.2021.103241	151	40	40	7	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2085	2098		10.1038/s41591-021-01590-5	http://dx.doi.org/10.1038/s41591-021-01590-5		DEC 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34848888	Bronze			2022-12-27	WOS:000724095500001
J	Sinha, S; Rosin, NL; Arora, R; Labit, E; Jaffer, A; Cao, LL; Farias, R; Nguyen, AP; de Almeida, LGN; Dufour, A; Bromley, A; McDonald, B; Gillrie, MR; Fritzler, MJ; Yipp, BG; Biernaskie, J				Sinha, Sarthak; Rosin, Nicole L.; Arora, Rohit; Labit, Elodie; Jaffer, Arzina; Cao, Leslie; Farias, Raquel; Nguyen, Angela P.; de Almeida, Luiz G. N.; Dufour, Antoine; Bromley, Amy; McDonald, Braedon; Gillrie, Mark R.; Fritzler, Marvin J.; Yipp, Bryan G.; Biernaskie, Jeff			Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19	NATURE MEDICINE			English	Article							ANNEXIN A1; RESOLUTION; SUBSETS	New results shed light on the molecular mechanisms of dexamethasone action, underlying its therapeutic benefit in patients with severe COVID-19. Although critical for host defense, innate immune cells are also pathologic drivers of acute respiratory distress syndrome (ARDS). Innate immune dynamics during Coronavirus Disease 2019 (COVID-19) ARDS, compared to ARDS from other respiratory pathogens, is unclear. Moreover, mechanisms underlying the beneficial effects of dexamethasone during severe COVID-19 remain elusive. Using single-cell RNA sequencing and plasma proteomics, we discovered that, compared to bacterial ARDS, COVID-19 was associated with expansion of distinct neutrophil states characterized by interferon (IFN) and prostaglandin signaling. Dexamethasone during severe COVID-19 affected circulating neutrophils, altered IFNactive neutrophils, downregulated interferon-stimulated genes and activated IL-1R2(+) neutrophils. Dexamethasone also expanded immunosuppressive immature neutrophils and remodeled cellular interactions by changing neutrophils from information receivers into information providers. Male patients had higher proportions of IFNactive neutrophils and preferential steroid-induced immature neutrophil expansion, potentially affecting outcomes. Our single-cell atlas (see 'Data availability' section) defines COVID-19-enriched neutrophil states and molecular mechanisms of dexamethasone action to develop targeted immunotherapies for severe COVID-19.	[Sinha, Sarthak; Rosin, Nicole L.; Arora, Rohit; Labit, Elodie; Jaffer, Arzina; Cao, Leslie; Biernaskie, Jeff] Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB, Canada; [Farias, Raquel; Nguyen, Angela P.; McDonald, Braedon; Gillrie, Mark R.; Fritzler, Marvin J.; Yipp, Bryan G.] Univ Calgary, Cumming Sch Med, Calvin Phoebe & Joan Snyder Inst Chron Dis, Calgary, AB, Canada; [Farias, Raquel; Nguyen, Angela P.; McDonald, Braedon; Yipp, Bryan G.] Univ Calgary, Cumming Sch Med, Dept Crit Care Med, Calgary, AB, Canada; [de Almeida, Luiz G. N.; Dufour, Antoine] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada; [de Almeida, Luiz G. N.; Dufour, Antoine] Univ Calgary, McCaig Inst Bone & Joint Hlth, Calgary, AB, Canada; [Bromley, Amy] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Gillrie, Mark R.] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Gillrie, Mark R.; Fritzler, Marvin J.] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada; [Biernaskie, Jeff] Univ Calgary, Cumming Sch Med, Dept Surg, Calgary, AB, Canada; [Biernaskie, Jeff] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Biernaskie, Jeff] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; Alberta Childrens Hospital; University of Calgary	Rosin, NL; Biernaskie, J (corresponding author), Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB, Canada.; Yipp, BG (corresponding author), Univ Calgary, Cumming Sch Med, Calvin Phoebe & Joan Snyder Inst Chron Dis, Calgary, AB, Canada.; Yipp, BG (corresponding author), Univ Calgary, Cumming Sch Med, Dept Crit Care Med, Calgary, AB, Canada.; Biernaskie, J (corresponding author), Univ Calgary, Cumming Sch Med, Dept Surg, Calgary, AB, Canada.; Biernaskie, J (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.; Biernaskie, J (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada.	nicole.rosin@ucalgary.ca; bgyipp@ucalgary.ca; jeff.biernaskie@ucalgary.ca		Jaffer, Arzina/0000-0002-9197-9060; Dufour, Antoine/0000-0002-3429-4188; Labit, Elodie/0000-0002-7659-6248; Cao, Leslie/0000-0002-7075-0443; Sinha, Sarthak/0000-0002-0770-3150	Thistledown Foundation; Calgary Firefighters Burn Treatment Society; CIHR Vanier doctoral scholarship; Alberta Innovates doctoral scholarship; Killam doctoral scholarship; Alberta Children's Hospital Research Institute postdoctoral fellowship	Thistledown Foundation; Calgary Firefighters Burn Treatment Society; CIHR Vanier doctoral scholarship(Canadian Institutes of Health Research (CIHR)); Alberta Innovates doctoral scholarship; Killam doctoral scholarship; Alberta Children's Hospital Research Institute postdoctoral fellowship	This work was funded by a FastGrant from the Thistledown Foundation (J.B. and B.Y.) and the Calgary Firefighters Burn Treatment Society (J.B.). S.S. received CIHR Vanier, Alberta Innovates and Killam doctoral scholarships. E.L received an Alberta Children's Hospital Research Institute postdoctoral fellowship. B.G.Y is a Tier II Canada Research Chair in Pulmonary, Immunology, Inflammation and Host Defence. We acknowledge the assistance of the nurse practitioners C. Elton-Lacasse, K. Deemer and R. Ralph as well as the healthcare teams from the Calgary adult ICUs at South Health Campus, Rockyview General Hospital, Foothills Medical Center and Peter Lougheed Center. We thank Haiyan Hou for cytokine analysis and Daniel Young and Laurent Brechenmacher for sample preparation and mass spectrometry. We thank K. Fiest and the ICU study coordinators C. Codan, Z. Slavikova and O. Dmitrieva. We acknowledge D. Jones, C. Curr and the eCritical team (Alberta Health Services) for their help in data acquisition and extraction via eCritical databases. Mortality predictions using dexamethasone-suppressed gene signatures were completed by repurposing computational workflows that were kindly shared by A. Wilk and C. Blish (Stanford University).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Alberta Health Services, INFL IMM DAT STAT; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; [Anonymous], 2015, J STAT SOFTW, DOI [DOI 10.18637/JSS.V067.I01, DOI 10.18637/jss.v067.i01]; [Anonymous], [No title captured]; Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Arlauckas SP, 2018, THERANOSTICS, V8, P5842, DOI 10.7150/thno.26888; Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bergen V, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0591-3; Brundin-Mather R, 2018, J CRIT CARE, V47, P295, DOI 10.1016/j.jcrc.2018.07.021; Busse DC, 2020, J VIROL, V94, DOI 10.1128/JVI.00297-20; Chen JNS, 2021, J VIROL, V95, DOI 10.1128/JVI.00014-21; Combes Alexis J, 2021, Nature, V591, P124, DOI [10.1038/s41586-021-03234-7, 10.1101/2020.10.28.359935]; Demichev V, 2021, CELL SYST, V12, P780, DOI 10.1016/j.cels.2021.05.005; Derakhshani A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051051; Feng ZC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18786-x; Gupta S, 2020, P NATL ACAD SCI USA, V117, P16481, DOI 10.1073/pnas.2003603117; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hsu J, 2016, CELL CYCLE, V15, P3183, DOI 10.1080/15384101.2016.1234551; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Jones N, 2020, NATURE, V588, P388, DOI 10.1038/d41586-020-03519-3; Kelly-Scumpia KM, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101050; Kiselev VY, 2019, NAT REV GENET, V20, P273, DOI 10.1038/s41576-018-0088-9; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Ledford JG, 2007, J IMMUNOL, V178, P5132, DOI 10.4049/jimmunol.178.8.5132; Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Loske J, 2022, NAT BIOTECHNOL, V40, P319, DOI 10.1038/s41587-021-01037-9; Mahler M, 2021, EXPERT REV CLIN IMMU, V17, P431, DOI 10.1080/1744666X.2021.1905526; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Monk PD, 2021, LANCET RESP MED, V9, P196, DOI 10.1016/S2213-2600(20)30511-7; Nestorowa S, 2016, BLOOD, V128, pE20, DOI 10.1182/blood-2016-05-716480; Okun JG, 2015, MOL METAB, V4, P732, DOI 10.1016/j.molmet.2015.07.006; Oliveira LG, 2017, J IMMUNOL, V198, P3227, DOI 10.4049/jimmunol.1602028; Overmyer KA, 2021, CELL SYST, V12, P23, DOI 10.1016/j.cels.2020.10.003; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Park J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-80120-8; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Qiu X., 2021, MAPPING TRANSCRIPTOM, DOI [10.1101/696724v2, DOI 10.1101/696724V2]; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Raredon M. S. B., 2021, BIORXIV, DOI [10.1101/2021.01.21.427529v1, DOI 10.1101/2021.01.21.427529]; Reusch N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652470; Rorvig S, 2009, J LEUKOCYTE BIOL, V86, P1439, DOI 10.1189/jlb.1008606; Rosin N. L., 2021, SARS COV 2 INFECT CI, DOI [10.1101/2021.01.19.427282v1.full, DOI 10.1101/2021.01.19.427282V1.FULL]; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Schlenner SM, 2010, IMMUNITY, V32, P426, DOI 10.1016/j.immuni.2010.03.005; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Shaath H, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112374; Shah S, 2016, NEURON, V92, P342, DOI 10.1016/j.neuron.2016.10.001; Shu T, 2020, IMMUNITY, V53, P1108, DOI 10.1016/j.immuni.2020.10.008; Stuart T., 2019, CELL, V177, P1888, DOI [DOI 10.1016/j.cell.2019.05.031, DOI 10.1016/J.CELL.2019.05.031]; Takashima A, 2015, J LEUKOCYTE BIOL, V98, P489, DOI 10.1189/jlb.1MR1014-502R; Uhel F, 2017, AM J RESP CRIT CARE, V196, P315, DOI 10.1164/rccm.201606-1143OC; Vago JP, 2012, J LEUKOCYTE BIOL, V92, P249, DOI 10.1189/jlb.0112008; Veras FP, 2020, J EXP MED, V217, DOI 10.1084/jem.20201129; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Wang N, 2020, CELL HOST MICROBE, V28, P455, DOI 10.1016/j.chom.2020.07.005; Wauters E, 2021, CELL RES, V31, P272, DOI 10.1038/s41422-020-00455-9; Wilk AJ, 2021, J EXP MED, V218, DOI [10.1084/jem.20210582, 10.1126/sciimmunol.aay6017]; Wilk AJ, 2020, NAT MED, V26, P1070, DOI [10.1101/2020.04.17.20069930, 10.1038/s41591-020-0944-y]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xie GG, 2021, ALLERGY, V76, P471, DOI 10.1111/all.14465; Xie XM, 2020, NAT IMMUNOL, V21, P1119, DOI 10.1038/s41590-020-0736-z; Zhang Q, 2020, MED-CAMBRIDGE, V1, P14, DOI 10.1016/j.medj.2020.12.001; Zhao Y, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf6692; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009	75	35	35	7	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					201	+		10.1038/s41591-021-01576-3	http://dx.doi.org/10.1038/s41591-021-01576-3		NOV 2021	35	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34782790	hybrid, Green Published			2022-12-27	WOS:000718766800002
J	Thomsen, G; Burghes, AHM; Hsieh, CE; Do, J; Chu, BTT; Perry, S; Barkho, B; Kaufmann, P; Sproule, DM; Feltner, DE; Chung, WK; McGovern, VL; Hevner, RF; Conces, M; Pierson, CR; Scoto, M; Muntoni, F; Mendell, JR; Foust, KD				Thomsen, Gretchen; Burghes, Arthur H. M.; Hsieh, Caroline; Do, Janet; Chu, Binh T. T.; Perry, Stephanie; Barkho, Basam; Kaufmann, Petra; Sproule, Douglas M.; Feltner, Douglas E.; Chung, Wendy K.; McGovern, Vicki L.; Hevner, Robert F.; Conces, Miriam; Pierson, Christopher R.; Scoto, Mariacristina; Muntoni, Francesco; Mendell, Jerry R.; Foust, Kevin D.			Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue	NATURE MEDICINE			English	Article							SPINAL MUSCULAR-ATROPHY; GENE-THERAPY; SINGLE NUCLEOTIDE; NATURAL-HISTORY; CARDIAC DEFECTS; 2 COPIES; EXPRESSION; MODEL; SEVERITY; DELIVERY	Spinal muscular atrophy type 1 (SMA1) is a debilitating neurodegenerative disease resulting from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec (formerly AVXS-101) is a gene therapy that restores SMN production via one-time systemic administration. The present study demonstrates widespread biodistribution of vector genomes and transgenes throughout the central nervous system (CNS) and peripheral organs, after intravenous administration of an AAV9-mediated gene therapy. Two symptomatic infants with SMA1 enrolled in phase III studies received onasemnogene abeparvovec. Both patients died of respiratory complications unrelated to onasemnogene abeparvovec. One patient had improved motor function and the other died shortly after administration before appreciable clinical benefit could be observed. In both patients, onasemnogene abeparvovec DNA and messenger RNA distribution were widespread among peripheral organs and in the CNS. The greatest concentration of vector genomes was detected in the liver, with an increase over that detected in CNS tissues of 300-1,000-fold. SMN protein, which was low in an untreated SMA1 control, was clearly detectable in motor neurons, brain, skeletal muscle and multiple peripheral organs in treated patients. These data support the fact that onasemnogene abeparvovec has effective distribution, transduction and expression throughout the CNS after intravenous administration and restores SMN expression in humans. Biodistribution analysis of two patients with spinal muscular atrophy shows widespread onasemnogene abeparvovec DNA, mRNA and SMN protein throughout the central nervous system and peripheral organs following intravenous gene therapy administration.	[Thomsen, Gretchen; Hsieh, Caroline; Do, Janet; Chu, Binh T. T.; Perry, Stephanie; Barkho, Basam; Kaufmann, Petra; Sproule, Douglas M.; Feltner, Douglas E.; Foust, Kevin D.] Novartis Gene Therapies, Bannockburn, IL USA; [Burghes, Arthur H. M.; Mendell, Jerry R.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Burghes, Arthur H. M.; McGovern, Vicki L.] Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA; [Chung, Wendy K.] Columbia Univ, Dept Pediat, New York, NY 10027 USA; [Chung, Wendy K.] Columbia Univ, Dept Med, New York, NY USA; [Hevner, Robert F.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Conces, Miriam; Pierson, Christopher R.] Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH USA; [Conces, Miriam; Pierson, Christopher R.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Scoto, Mariacristina; Muntoni, Francesco] UCL, Great Ormond St Inst Child Hlth, Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Scoto, Mariacristina; Muntoni, Francesco] Great Ormond St Hosp Trust, London, England; [Mendell, Jerry R.] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA; [Mendell, Jerry R.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Columbia University; Columbia University; University of California System; University of California San Diego; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Burghes, AHM (corresponding author), Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA.; Burghes, AHM (corresponding author), Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA.	burghes.1@osu.edu		Burghes, Arthur/0000-0001-9031-1555	Novartis Gene Therapies, Inc.	Novartis Gene Therapies, Inc.	The authors thank and are indebted to the families and patients for making this research possible. Writing and editorial support for the original manuscript was provided by Cadent Medical Communications (New York, NY, USA). Funding was provided by Novartis Gene Therapies, Inc.	Al-Zaidy SA, 2019, J NEUROMUSCULAR DIS, V6, P307, DOI 10.3233/JND-190403; Bartus RT, 2015, NEUROBIOL DIS, V78, P162, DOI 10.1016/j.nbd.2015.03.023; Bernal S, 2010, J MED GENET, V47, P640, DOI 10.1136/jmg.2010.079004; Bevan AK, 2011, MOL THER, V19, P1971, DOI 10.1038/mt.2011.157; Bevan AK, 2010, HUM MOL GENET, V19, P3895, DOI 10.1093/hmg/ddq300; Blatnik AJ, 2020, HUM MOL GENET, V29, P3477, DOI 10.1093/hmg/ddaa229; Buchlis G, 2012, BLOOD, V119, P3038, DOI 10.1182/blood-2011-09-382317; Burghes A.H.M., 2017, MOL CELLULAR THERAPI, P121; Burnett BG, 2009, MOL CELL BIOL, V29, P1107, DOI 10.1128/MCB.01262-08; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Castle MJ, 2020, HUM GENE THER, V31, P415, DOI 10.1089/hum.2019.367; Chand D, 2021, J HEPATOL, V74, P560, DOI 10.1016/j.jhep.2020.11.001; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; D'Amico A, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-71; Day JW, 2021, DRUG SAFETY, V44, P1109, DOI 10.1007/s40264-021-01107-6; Day JW, 2021, LANCET NEUROL, V20, P284, DOI 10.1016/S1474-4422(21)00001-6; Duque S, 2009, MOL THER, V17, P1187, DOI 10.1038/mt.2009.71; Duque SI, 2015, ANN NEUROL, V77, P399, DOI 10.1002/ana.24332; Farrar MA, 2017, ANN NEUROL, V81, P355, DOI 10.1002/ana.24864; Feldkotter M, 2002, AM J HUM GENET, V70, P358, DOI 10.1086/338627; Feldman AG, 2020, J PEDIATR-US, V225, P252, DOI 10.1016/j.jpeds.2020.05.044; Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741; Finkel RS, 2013, NEUROMUSCULAR DISORD, V23, P112, DOI 10.1016/j.nmd.2012.09.006; Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515; Heier CR, 2010, HUM MOL GENET, V19, P3906, DOI 10.1093/hmg/ddq330; Hinderer C, 2018, HUM GENE THER, V29, P285, DOI 10.1089/hum.2018.015; Hudry E, 2019, NEURON, V101, P839, DOI 10.1016/j.neuron.2019.02.017; Iascone Daniel M, 2015, F1000Prime Rep, V7, P04, DOI 10.12703/P7-04; Kolb SJ, 2017, ANN NEUROL, V82, P883, DOI 10.1002/ana.25101; Kolb SJ, 2015, NEUROL CLIN, V33, P831, DOI 10.1016/j.ncl.2015.07.004; Le TT, 2011, HUM MOL GENET, V20, P3578, DOI 10.1093/hmg/ddr275; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lutz CM, 2011, J CLIN INVEST, V121, P3029, DOI 10.1172/JCI57291; Lykken EA, 2018, J NEURODEV DISORD, V10, DOI 10.1186/s11689-018-9234-0; Mailman MD, 2002, GENET MED, V4, P20, DOI 10.1097/00125817-200201000-00004; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mendell JR, 2021, JAMA NEUROL, V78, P834, DOI 10.1001/jamaneurol.2021.1272; Mercuri E, 2021, LANCET NEUROL, V20, P832, DOI 10.1016/S1474-4422(21)00251-9; Meyer K, 2015, MOL THER, V23, P477, DOI 10.1038/mt.2014.210; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Oskoui M, 2017, SPINAL MUSCULAR ATROPHY: DISEASE MECHANISMS AND THERAPY, P3, DOI 10.1016/B978-0-12-803685-3.00001-X; Prior TW, 2009, AM J HUM GENET, V85, P408, DOI 10.1016/j.ajhg.2009.08.002; Rindt H, 2015, HUM MOL GENET, V24, P4094, DOI 10.1093/hmg/ddv148; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; Shababi M, 2010, HUM MOL GENET, V19, P4059, DOI 10.1093/hmg/ddq329; Sheng L, 2020, NUCLEIC ACIDS RES, V48, P2853, DOI 10.1093/nar/gkaa126; Strauss K, 2021, NEUROLOGY, V96; Swoboda KJ, 2005, ANN NEUROL, V57, P704, DOI 10.1002/ana.20473; Van Alstyne M, 2021, NAT NEUROSCI, V24, P930, DOI 10.1038/s41593-021-00827-3; Vukojicic A, 2019, CELL REP, V29, P3087, DOI 10.1016/j.celrep.2019.11.013; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Wijngaarde CA, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0613-5; Wood MJA, 2017, HUM MOL GENET, V26, pR151, DOI 10.1093/hmg/ddx215; Xu LF, 2001, HUM GENE THER, V12, P563, DOI 10.1089/104303401300042500; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	59	21	21	5	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1701	+		10.1038/s41591-021-01483-7	http://dx.doi.org/10.1038/s41591-021-01483-7		OCT 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34608334				2022-12-27	WOS:000703378900002
J	Ho, CY; Day, SM; Axelsson, A; Russell, MW; Zahka, K; Lever, HM; Pereira, AC; Colan, SD; Margossian, R; Murphy, AM; Canter, C; Bach, RG; Wheeler, MT; Rossano, JW; Owens, AT; Bundgaard, H; Benson, L; Mestroni, L; Taylor, MRG; Patel, AR; Wilmot, I; Thrush, P; Vargas, JD; Soslow, JH; Becker, JR; Seidman, CE; Lakdawala, NK; Cirino, AL; Burns, KM; McMurray, JJV; MacRae, CA; Solomon, SD; Orav, EJ; Braunwald, E				Ho, Carolyn Y.; Day, Sharlene M.; Axelsson, Anna; Russell, Mark W.; Zahka, Kenneth; Lever, Harry M.; Pereira, Alexandre C.; Colan, Steven D.; Margossian, Renee; Murphy, Anne M.; Canter, Charles; Bach, Richard G.; Wheeler, Matthew T.; Rossano, Joseph W.; Owens, Anjali T.; Bundgaard, Henning; Benson, Lee; Mestroni, Luisa; Taylor, Matthew R. G.; Patel, Amit R.; Wilmot, Ivan; Thrush, Philip; Vargas, Jose D.; Soslow, Jonathan H.; Becker, Jason R.; Seidman, Christine E.; Lakdawala, Neal K.; Cirino, Allison L.; Burns, Kristin M.; McMurray, John J. V.; MacRae, Calum A.; Solomon, Scott D.; Orav, E. John; Braunwald, Eugene		VANISH Investigators	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial	NATURE MEDICINE			English	Article							MUTATION CARRIERS; LOSARTAN; DISEASE; EVOLUTION; FIBROSIS; EFFICACY; BURDEN	In a randomized phase 2 clinical trial, the angiotensin receptor blocker valsartan improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, a condition for which there are no effective therapies for modifying disease progression. Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and increased risk of heart failure and arrhythmias. There are no existing therapies to modify disease progression. In this study, we conducted a multi-center, double-blind, placebo-controlled phase 2 clinical trial to assess the safety and efficacy of the angiotensin II receptor blocker valsartan in attenuating disease evolution in early HCM. In total, 178 participants with early-stage sarcomeric HCM were randomized (1:1) to receive valsartan (320 mg daily in adults; 80-160 mg daily in children) or placebo for 2 years (). Standardized changes from baseline to year 2 in LV wall thickness, mass and volumes; left atrial volume; tissue Doppler diastolic and systolic velocities; and serum levels of high-sensitivity troponin T and N-terminal pro-B-type natriuretic protein were integrated into a single composite z-score as the primary outcome. Valsartan (n = 88) improved cardiac structure and function compared to placebo (n = 90), as reflected by an increase in the composite z-score (between-group difference +0.231, 95% confidence interval (+0.098, +0.364); P = 0.001), which met the primary endpoint of the study. Treatment was well-tolerated. These results indicate a key opportunity to attenuate disease progression in early-stage sarcomeric HCM with an accessible and safe medication.	[Ho, Carolyn Y.; Seidman, Christine E.; Lakdawala, Neal K.; Cirino, Allison L.; MacRae, Calum A.; Solomon, Scott D.; Orav, E. John; Braunwald, Eugene] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Day, Sharlene M.; Russell, Mark W.] Univ Michigan, Ann Arbor, MI 48109 USA; [Axelsson, Anna; Bundgaard, Henning] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Copenhagen, Denmark; [Zahka, Kenneth; Lever, Harry M.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Pereira, Alexandre C.] Univ Sao Paulo, Med Sch, Lab Genet & Mol Cardiol, Heart Inst, Sao Paulo, Brazil; [Colan, Steven D.; Margossian, Renee] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA; [Murphy, Anne M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Cardiol, Baltimore, MD 21205 USA; [Canter, Charles; Bach, Richard G.] Washington Univ, Sch Med, St Louis, MO USA; [Wheeler, Matthew T.] Stanford Univ, Sch Med, Dept Med, Div Cardiovasc Med, Stanford, CA USA; [Rossano, Joseph W.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Bundgaard, Henning] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Benson, Lee] Toronto Hosp Sick Children, Toronto, ON, Canada; [Mestroni, Luisa; Taylor, Matthew R. G.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA; [Patel, Amit R.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Patel, Amit R.] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA; [Wilmot, Ivan] Cincinnati Childrens Hosp Med Ctr, Heart Inst, Cincinnati, OH 45229 USA; [Thrush, Philip] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Vargas, Jose D.] MedStar Heart & Vasc Inst, Washington, DC USA; [Soslow, Jonathan H.; Becker, Jason R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Seidman, Christine E.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Burns, Kristin M.] NIH, NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA; [McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Day, Sharlene M.; Owens, Anjali T.] Univ Penn, Perelman Sch Med, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA; [Becker, Jason R.] Univ Pittsburgh, Sch Med, Div Cardiol, Pittsburgh, PA USA; [Becker, Jason R.] UPMC, Pittsburgh, PA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Michigan System; University of Michigan; Rigshospitalet; University of Copenhagen; Cleveland Clinic Foundation; Universidade de Sao Paulo; Harvard University; Boston Children's Hospital; Johns Hopkins University; Washington University (WUSTL); Stanford University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Copenhagen; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Chicago; University of Chicago; Cincinnati Children's Hospital Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Vanderbilt University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Glasgow; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ho, CY (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.	cho@bwh.harvard.edu	Bundgaard, Henning/AAA-4381-2020; Pereira, Alexandre/HHN-1038-2022; Day, Sharlene/AEV-1016-2022; Patel, Amit/B-2464-2014	Bundgaard, Henning/0000-0002-0563-7049; Ho, Carolyn/0000-0002-7334-7924; Axelsson Raja, Anna/0000-0001-8665-3309; Patel, Amit/0000-0001-7621-6463; Colan, Steven/0000-0002-7941-0947	National Heart, Lung, and Blood Institute [P50HL112349]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are indebted to the families and individuals who partnered with us in conducing this trial. This study was funded by the National Heart, Lung, and Blood Institute (P50HL112349 to C.Y.H.). The views expressed in this manuscript are those of the authors and do not reflect official positions of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Study medication (blinded valsartan and matching placebo) was provided by Novartis. Novartis was not involved in the design or conduct of the study; data collection, data management, data analysis or data interpretation; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.	Araujo AQ, 2005, AM J CARDIOL, V96, P1563, DOI 10.1016/j.amjcard.2005.07.065; Axelsson A, 2015, LANCET DIABETES ENDO, V3, P123, DOI 10.1016/S2213-8587(14)70241-4; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Ho CY, 2018, CIRCULATION, V138, P1387, DOI 10.1161/CIRCULATIONAHA.117.033200; Ho CY, 2017, AM HEART J, V187, P145, DOI 10.1016/j.ahj.2017.02.008; Ho CY, 2017, JAMA CARDIOL, V2, P419, DOI 10.1001/jamacardio.2016.5670; Ho CY, 2016, HEART, V102, P1805, DOI 10.1136/heartjnl-2016-310015; Ho CY, 2015, JACC-HEART FAIL, V3, P180, DOI 10.1016/j.jchf.2014.08.003; Ho CY, 2009, CIRC-CARDIOVASC GENE, V2, P314, DOI 10.1161/CIRCGENETICS.109.862128; Kawano H, 2005, CIRC J, V69, P1244, DOI 10.1253/circj.69.1244; Kim JB, 2007, SCIENCE, V316, P1481, DOI 10.1126/science.1137325; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lopez B, 2010, CIRCULATION, V121, P1645, DOI 10.1161/CIRCULATIONAHA.109.912774; Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI 10.1016/j.jacc.2014.02.537; Penicka M, 2009, J MOL DIAGN, V11, P35, DOI 10.2353/jmoldx.2009.080082; Raja AA, 2019, CIRC-HEART FAIL, V12, DOI 10.1161/CIRCHEARTFAILURE.119.006231; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Seidman CE, 2011, CIRC RES, V108, P743, DOI 10.1161/CIRCRESAHA.110.223834; Semsarian C, 2002, J CLIN INVEST, V109, P1013, DOI 10.1172/JCI200214677; Shimada YJ, 2013, JACC-HEART FAIL, V1, P480, DOI 10.1016/j.jchf.2013.09.001; Sun HR, 2012, CIRC-HEART FAIL, V5, P742, DOI 10.1161/CIRCHEARTFAILURE.112.969154; Teekakirikul P, 2010, J CLIN INVEST, V120, P3520, DOI 10.1172/JCI42028; Yamazaki T, 2007, INT HEART J, V48, P715, DOI 10.1536/ihj.48.715	23	15	16	4	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1818	+		10.1038/s41591-021-01505-4	http://dx.doi.org/10.1038/s41591-021-01505-4		SEP 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34556856	Green Accepted			2022-12-27	WOS:000698552200001
J	Oneko, M; Steinhardt, LC; Yego, R; Wiegand, RE; Swanson, PA; Natasha, KC; Akach, D; Sang, T; Gutman, JR; Nzuu, EL; Dungani, A; Sim, BKL; Oloo, PN; Otieno, K; Bii, DK; Billingsley, PF; James, ER; Kariuki, S; Samuels, AM; Jongo, S; Chebore, W; Abdulla, S; Daubenberger, C; Mpina, M; Styers, D; Potter, GE; Abarbanell, G; Richie, TL; Hoffman, SL; Seder, RA				Oneko, Martina; Steinhardt, Laura C.; Yego, Reuben; Wiegand, Ryan E.; Swanson, Phillip A.; Natasha, K. C.; Akach, Dorcas; Sang, Tony; Gutman, Julie R.; Nzuu, Elizabeth L.; Dungani, Allan; Sim, B. Kim Lee; Oloo, Paul Ndaya; Otieno, Kephas; Bii, Dennis K.; Billingsley, Peter F.; James, Eric R.; Kariuki, Simon; Samuels, Aaron M.; Jongo, Said; Chebore, Winnie; Abdulla, Salim; Daubenberger, Claudia; Mpina, Maxmillian; Styers, David; Potter, Gail E.; Abarbanell, Ginnie; Richie, Thomas L.; Hoffman, Stephen L.; Seder, Robert A.			Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial	NATURE MEDICINE			English	Article							DELTA T-CELLS; FALCIPARUM SPOROZOITE VACCINE; DIRECT VENOUS INOCULATION; PLASMODIUM-FALCIPARUM; PROTECTION; IMMUNOSUPPRESSION; ANTIBODIES; CHILDREN; AFRICA; MICE	The radiation-attenuated Plasmodium falciparum sporozoite (PfSPZ) vaccine provides protection against P. falciparum infection in malaria-naive adults. Preclinical studies show that T cell-mediated immunity is required for protection and is readily induced in humans after vaccination. However, previous malaria exposure can limit immune responses and vaccine efficacy (VE) in adults. We hypothesized that infants with less previous exposure to malaria would have improved immunity and protection. We conducted a multi-arm, randomized, double-blind, placebo-controlled trial in 336 infants aged 5-12 months to determine the safety, tolerability, immunogenicity and efficacy of the PfSPZ Vaccine in infants in a high-transmission malaria setting in western Kenya (NCT02687373). Groups of 84 infants each received 4.5 x 10(5), 9.0 x 10(5) or 1.8 x 10(6) PfSPZ Vaccine or saline three times at 8-week intervals. The vaccine was well tolerated; 52 (20.6%) children in the vaccine groups and 20 (23.8%) in the placebo group experienced related solicited adverse events (AEs) within 28 d postvaccination and most were mild. There was 1 grade 3-related solicited AE in the vaccine group (0.4%) and 2 in the placebo group (2.4%). Seizures were more common in the highest-dose group (14.3%) compared to 6.0% of controls, with most being attributed to malaria. There was no significant protection against P. falciparum infection in any dose group at 6 months (VE in the 9.0 x 10(5) dose group = -6.5%, P = 0.598, the primary statistical end point of the study). VE against clinical malaria 3 months after the last dose in the highest-dose group was 45.8% (P = 0.027), an exploratory end point. There was a dose-dependent increase in antibody responses that correlated with VE at 6 months in the lowest- and highest-dose groups. T cell responses were undetectable across all dose groups. Detection of V delta 2(+)V gamma 9(+) T cells, which have been correlated with induction of PfSPZ Vaccine T cell immunity and protection in adults, were infrequent. These data suggest that PfSPZ Vaccine-induced T cell immunity is age-dependent and may be influenced by V delta 2(+)V gamma 9(+) T cell frequency. Since there was no significant VE at 6 months in these infants, these vaccine regimens will likely not be pursued further in this age group.	[Oneko, Martina; Yego, Reuben; Akach, Dorcas; Sang, Tony; Nzuu, Elizabeth L.; Dungani, Allan; Oloo, Paul Ndaya; Otieno, Kephas; Bii, Dennis K.; Kariuki, Simon; Chebore, Winnie] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya; [Steinhardt, Laura C.; Wiegand, Ryan E.; Gutman, Julie R.; Samuels, Aaron M.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA; [Swanson, Phillip A.; Seder, Robert A.] NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; [Natasha, K. C.; Billingsley, Peter F.; James, Eric R.; Richie, Thomas L.; Hoffman, Stephen L.] Sanaria, Rockville, MD USA; [Samuels, Aaron M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Kisumu, Kenya; [Jongo, Said; Abdulla, Salim; Mpina, Maxmillian] Ifakara Hlth Inst, Bagamoyo Res & Training Ctr, Bagamoyo, Tanzania; [Daubenberger, Claudia] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Daubenberger, Claudia] Univ Basel, Basel, Switzerland; [Styers, David; Potter, Gail E.] Emmes Corp, Rockville, MD USA; [Abarbanell, Ginnie] Washington Univ, Sch Med, St Louis, MO USA; [Abarbanell, Ginnie] St Louis Childrens Hosp, St Louis, MO 63178 USA	Kenya Medical Research Institute; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; Sanaria Inc.; Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Emmes Corporation; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Oneko, M (corresponding author), Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.; Seder, RA (corresponding author), NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA.	tinaoneko@gmail.com; rseder@mail.nih.gov	Kariuki, Simon/AFT-6596-2022	Wiegand, Ryan/0000-0002-9486-1850; Gutman, Julie/0000-0001-6769-7322; Daubenberger, Claudia/0000-0001-7136-0642; Oneko, Martina/0000-0003-0021-3324; Samuels, Aaron/0000-0002-8355-8186	Kenya Medical Research Institute; NIH Vaccine Research Center; National Institute of Allergy and Infectious Diseases, NIH [5R44AI055229-09A1, 2R44AI058375-06A1]	Kenya Medical Research Institute; NIH Vaccine Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the caregivers and infants and the study staff who made this study possible. We thank the data safety and monitoring board members for their careful review of safety data and recommendations: K. Kester (chair), A. Durbin, M. Molyneux, M. Spring, J. Ciolino and J. Otieno (local safety monitor). We thank the Sanaria Manufacturing and Quality Teams for providing the PfSPZ Vaccine for this study and W. Wijayalath for pharmaceutical operations support. We also thank the Sanaria Clinical and Regulatory team for supporting this trial. We thank the Kenya Medical Research Institute for support and for providing permission to publish the results. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention. This work was supported by the NIH Vaccine Research Center. Manufacturing and quality control release and stability assays for the PfSPZ Vaccine were supported in part by the National Institute of Allergy and Infectious Diseases, NIH (Small Business Innovation Research grant nos. 5R44AI055229-09A1 and 2R44AI058375-06A1 to S.L.H.).	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; [Anonymous], 2015, MICR DET ID QUANT MA; [Anonymous], 2006, INF CONS QUAL CONTR; Bedda M, 2016, J IMMUNOL METHODS, V439, P74, DOI 10.1016/j.jim.2016.08.009; Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; CHAROENVIT Y, 1991, SCIENCE, V251, P668, DOI 10.1126/science.1704150; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; De Rosa SC, 2004, J IMMUNOL, V172, P1637, DOI 10.4049/jimmunol.172.3.1637; Diallo H, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2702-5; Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health, 2014, DIV AIDS DAIDS TABL; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; Epstein JE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89154; GREENWOOD BM, 1972, LANCET, V1, P169; Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6; HO M, 1986, J INFECT DIS, V153, P763, DOI 10.1093/infdis/153.4.763; Illingworth J, 2013, J IMMUNOL, V190, P1038, DOI 10.4049/jimmunol.1202438; Ishizuka AS, 2016, NAT MED, V22, P614, DOI 10.1038/nm.4110; Jagannathan P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10624-3; Jongo SA, 2019, AM J TROP MED HYG, V100, P1433, DOI 10.4269/ajtmh.18-0835; Jongo SA, 2018, AM J TROP MED HYG, V99, P338, DOI 10.4269/ajtmh.17-1014; Kisalu NK, 2019, NAT MED, V25, P188, DOI 10.1038/s41591-018-0315-0; Lyke KE, 2017, P NATL ACAD SCI USA, V114, P2711, DOI 10.1073/pnas.1615324114; MCBRIDE JS, 1977, IMMUNOLOGY, V33, P253; Monaco G, 2016, BIOINFORMATICS, V32, P2473, DOI 10.1093/bioinformatics/btw191; Mordmuller B, 2017, NATURE, V542, P445, DOI 10.1038/nature21060; Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600-065X.2006.00479.x; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; RTS,S Clinical Trials Partnership, 2014, PLoS Med, V11, pe1001685, DOI 10.1371/journal.pmed.1001685; SCHOFIELD L, 1987, J IMMUNOL, V139, P2020; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/S1473-3099(17)30104-4, 10.1016/s1473-3099(17)30104-4]; Steinhardt LC, 2020, CLIN INFECT DIS, V71, P1063, DOI 10.1093/cid/ciz925; Swanson PA, 2020, CYTOM PART A, V97, P1032, DOI 10.1002/cyto.a.24189; Swysen C, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-223; Taylor SM, 2014, J CLIN MICROBIOL, V52, P2144, DOI 10.1128/JCM.00565-14; Teirlinck AC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002389; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; U.S. Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases, 2007, DIV MICR INF DIS DMI; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; White MT, 2015, LANCET INFECT DIS, V15, P1450, DOI 10.1016/S1473-3099(15)00239-X; WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0; Zaidi I, 2017, J IMMUNOL, V199, P3781, DOI 10.4049/jimmunol.1700314; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	46	16	16	1	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1636	+		10.1038/s41591-021-01470-y	http://dx.doi.org/10.1038/s41591-021-01470-y		SEP 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34518679				2022-12-27	WOS:000695470700005
J	Mai, HQ; Chen, QY; Chen, DP; Hu, CS; Yang, KY; Wen, JY; Li, JG; Shi, YR; Jin, F; Xu, RL; Pan, JJ; Qu, SH; Li, P; Hu, CH; Liu, YC; Jiang, Y; He, X; Wang, HM; Lim, WT; Liao, WJ; He, XH; Chen, XZ; Liu, ZG; Yuan, XL; Li, Q; Lin, XY; Jing, SH; Chen, YJ; Lu, Y; Hsieh, CY; Yang, MH; Yen, CJ; Samol, J; Feng, H; Yao, S; Keegan, P; Xu, RH				Mai, Hai-Qiang; Chen, Qiu-Yan; Chen, Dongping; Hu, Chaosu; Yang, Kunyu; Wen, Jiyu; Li, Jingao; Shi, Ying-Rui; Jin, Feng; Xu, Ruilian; Pan, Jianji; Qu, Shenhong; Li, Ping; Hu, Chunhong; Liu, Yi-Chun; Jiang, Yi; He, Xia; Wang, Hung-Ming; Lim, Wan-Teck; Liao, Wangjun; He, Xiaohui; Chen, Xiaozhong; Liu, Zhigang; Yuan, Xianglin; Li, Qi; Lin, Xiaoyan; Jing, Shanghua; Chen, Yanju; Lu, Yin; Hsieh, Ching-Yun; Yang, Muh-Hwa; Yen, Chia-Jui; Samol, Jens; Feng, Hui; Yao, Sheng; Keegan, Patricia; Xu, Rui-Hua			Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	NATURE MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; ANTITUMOR-ACTIVITY; NIVOLUMAB; SAFETY; RECURRENT; SURVIVAL; PEMBROLIZUMAB; RADIOTHERAPY; EFFICACY	Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind, phase 3 trial (ClinicalTrials.gov identifier: NCT03581786), 289 patients with RM-NPC and no previous chemotherapy for recurrent or metastatic disease were randomized (1/1) to receive either toripalimab, a monoclonal antibody against human programmed death-1 (PD-1), or placebo in combination with GP every 3 weeks for up to six cycles, followed by monotherapy with toripalimab or placebo. The primary endpoint was progression-free survival (PFS) as assessed by a blinded independent review committee according to RECIST v.1.1. At the prespecified interim PFS analysis, a significant improvement in PFS was detected in the toripalimab arm compared to the placebo arm: median PFS of 11.7 versus 8.0 months, hazard ratio (HR) = 0.52 (95% confidence interval (CI): 0.36-0.74), P = 0.0003. An improvement in PFS was observed across key subgroups, including PD-L1 expression. As of 18 February 2021, a 40% reduction in risk of death was observed in the toripalimab arm compared to the placebo arm (HR = 0.603 (95% CI: 0.364-0.997)). The incidence of grade >= 3 adverse events (AEs) (89.0 versus 89.5%), AEs leading to discontinuation of toripalimab/placebo (7.5 versus 4.9%) and fatal AEs (2.7 versus 2.8%) was similar between the two arms; however, immune-related AEs (39.7 versus 18.9%) and grade >= 3 infusion reactions (7.5 versus 0.7%) were more frequent in the toripalimab arm. In conclusion, the addition of toripalimab to GP chemotherapy as a first-line treatment for patients with RM-NPC provided superior PFS compared to GP alone, and with a manageable safety profile. Interim analysis from the randomized phase 3 JUPITER-02 trial shows that the addition of anti-PD-1 toripalimab to standard gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma has manageable toxicity and improves progression-free survival, suggesting a potential new treatment standard in this setting.	[Mai, Hai-Qiang; Chen, Qiu-Yan] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China; [Chen, Dongping] Inst Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou, Peoples R China; [Hu, Chaosu] Fudan Univ, Ctr Canc, Shanghai, Peoples R China; [Yang, Kunyu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Wen, Jiyu] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China; [Li, Jingao] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China; [Shi, Ying-Rui] Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China; [Jin, Feng] Guizhou Med Univ, Guizhou Canc Hosp, Guiyang, Peoples R China; [Xu, Ruilian] Shenzhen Peoples Hosp, Shenzhen, Peoples R China; [Pan, Jianji] Fujian Prov Canc Hosp, Fuzhou, Peoples R China; [Qu, Shenhong] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China; [Li, Ping] Sichuan Univ, West China Hosp, Chengdu, Peoples R China; [Hu, Chunhong] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China; [Liu, Yi-Chun] Taichung Vet Gen Hosp, Taichung, Taiwan; [Jiang, Yi] Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China; [He, Xia] Jiangsu Canc Hosp, Nanjing, Peoples R China; [Wang, Hung-Ming] Chang Gung Mem Hosp, Taoyuan, Taiwan; [Lim, Wan-Teck] Natl Canc Ctr, Singapore, Singapore; [Liao, Wangjun] Nanfang Hosp, Guangzhou, Peoples R China; [He, Xiaohui] Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Beijing, Peoples R China; [Chen, Xiaozhong] Zhejiang Canc Hosp, Hangzhou, Peoples R China; [Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 1, Zhuhai, Peoples R China; [Yuan, Xianglin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China; [Li, Qi] Shanghai Gen Hosp, Shanghai, Peoples R China; [Lin, Xiaoyan] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China; [Jing, Shanghua] Hebei Med Univ, Hebei Canc Hosp, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Chen, Yanju] Hainan Gen Hosp, Haikou, Hainan, Peoples R China; [Lu, Yin] Liuzhou Workers Hosp, Liuzhou, Peoples R China; [Hsieh, Ching-Yun] China Med Univ Hosp, Taichung, Taiwan; [Yang, Muh-Hwa] Taipei Vet Gen Hosp, Taipei, Taiwan; [Yen, Chia-Jui] Natl Cheng Kung Univ, Tainan, Taiwan; [Samol, Jens] Tan Tock Seng Hosp, Singapore, Singapore; [Samol, Jens] Johns Hopkins Univ, Baltimore, MD USA; [Feng, Hui; Yao, Sheng; Keegan, Patricia] Shanghai Junshi Biosci, Shanghai, Peoples R China; [Feng, Hui; Yao, Sheng; Keegan, Patricia] Top Alliance Biosci, Rockville, MD USA; [Xu, Rui-Hua] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Fudan University; Huazhong University of Science & Technology; Guangdong Medical University; Guizhou Medical University; Jinan University; Sichuan University; Central South University; Taichung Veterans General Hospital; Shantou University; Nanjing Medical University; Chang Gung Memorial Hospital; National Cancer Centre Singapore (NCCS); Southern Medical University - China; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Zhejiang Cancer Hospital; Sun Yat Sen University; Huazhong University of Science & Technology; Fujian Medical University; Hebei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Taipei Veterans General Hospital; National Cheng Kung University; Tan Tock Seng Hospital; Johns Hopkins University; State Key Lab Oncology South China; Sun Yat Sen University	Xu, RH (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China.	xurh@sysucc.org.cn	Xu, Rui-Hua/AAW-4766-2021; xu, rui/GRX-5734-2022; liu, yi/GXE-9662-2022; Lim, Darren Wan Teck/L-2007-2016	Xu, Rui-Hua/0000-0001-9771-8534; Lim, Darren Wan Teck/0000-0002-4655-0206	National Major Science & Technology Major Projects [2017ZX09302009]; Shanghai Science and Technology Committee Technology Grant [17431900700]; Shanghai Junshi Biosciences	National Major Science & Technology Major Projects; Shanghai Science and Technology Committee Technology Grant; Shanghai Junshi Biosciences	This study is sponsored by Shanghai Junshi Biosciences. The authors thank the patients who participated in this study and their families. This work was supported by National Major Science & Technology Major Projects (no. 2017ZX09302009) awarded to H.F., and a Shanghai Science and Technology Committee Technology Grant awarded to H.F. (no. 17431900700).	Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Chen YP, 2021, J CLIN ONCOL, V39, P840, DOI 10.1200/JCO.20.03237; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chen YP, 2015, RADIOTHER ONCOL, V116, P157, DOI 10.1016/j.radonc.2015.07.030; Chin YM, 2015, INT J CANCER, V136, P678, DOI 10.1002/ijc.29035; Corry J, 2006, INT J RADIAT ONCOL, V64, P63, DOI 10.1016/j.ijrobp.2005.06.041; Fang WF, 2018, LANCET ONCOL, V19, P1338, DOI 10.1016/S1470-2045(18)30495-9; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Hsu C, 2017, J CLIN ONCOL, V35, P4050, DOI 10.1200/JCO.2017.73.3675; Huang ZL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0863-5; Hui EP, 2018, CLIN CANCER RES, V24, P1030, DOI 10.1158/1078-0432.CCR-17-1667; Ma BBY, 2018, J CLIN ONCOL, V36, P1412, DOI 10.1200/JCO.2017.77.0388; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Ngan HL, 2018, CANCERS, V10, DOI 10.3390/cancers10070210; Ou SHI, 2007, ANN ONCOL, V18, P29, DOI 10.1093/annonc/mdl320; Ren C, 2020, J CLIN ONCOL, V38; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Sun LM, 2007, AM J EPIDEMIOL, V165, P271, DOI [10.1093/aje/kwm271, 10.1093/aje/kwk008]; Tang BX, 2020, CLIN CANCER RES, V26, P4250, DOI 10.1158/1078-0432.CCR-19-3922; Tang LQ, 2013, J CLIN ONCOL, V31, P2861, DOI 10.1200/JCO.2012.46.0816; Tian W, 2015, TISSUE ANTIGENS, V86, P15, DOI 10.1111/tan.12576; Wang FH, 2021, J CLIN ONCOL, V39, P704, DOI 10.1200/JCO.20.02712; Wang ZJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13770; Wei XL, 2020, CANCER COMMUN, V40, P345, DOI 10.1002/cac2.12068; Zhang L, 2016, LANCET, V388, P1883, DOI 10.1016/S0140-6736(16)31388-5; Zhao C, 2019, ANN ONCOL, V30, P637, DOI 10.1093/annonc/mdz020	26	58	58	7	63	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1536	+		10.1038/s41591-021-01444-0	http://dx.doi.org/10.1038/s41591-021-01444-0		AUG 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34341578				2022-12-27	WOS:000680370900001
J	Chen, RBY; Mostafa, I; Hibberd, MC; Das, S; Lynn, HM; Webber, DM; Mahfuz, M; Barratt, MJ; Ahmed, T; Gordon, JI				Chen, Robert Y.; Mostafa, Ishita; Hibberd, Matthew C.; Das, Subhasish; Lynn, Hannah M.; Webber, Daniel M.; Mahfuz, Mustafa; Barratt, Michael J.; Ahmed, Tahmeed; Gordon, Jeffrey I.			Melding microbiome and nutritional science with early child development	NATURE MEDICINE			English	Editorial Material									[Chen, Robert Y.; Hibberd, Matthew C.; Lynn, Hannah M.; Webber, Daniel M.; Barratt, Michael J.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Edison Family Ctr Genome Sci & Syst Biol, St Louis, MO 63130 USA; [Chen, Robert Y.; Hibberd, Matthew C.; Lynn, Hannah M.; Webber, Daniel M.; Barratt, Michael J.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Gut Microbiome & Nutr Res, St Louis, MO 63130 USA; [Mostafa, Ishita; Das, Subhasish; Mahfuz, Mustafa; Ahmed, Tahmeed] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh	Washington University (WUSTL); Washington University (WUSTL); International Centre for Diarrhoeal Disease Research (ICDDR)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Edison Family Ctr Genome Sci & Syst Biol, St Louis, MO 63130 USA.; Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Gut Microbiome & Nutr Res, St Louis, MO 63130 USA.	jgordon@wustl.edu	Mahfuz, Mustafa/H-5923-2017; Das, Subhasish/AAW-3940-2021	Mahfuz, Mustafa/0000-0002-4090-785X; Das, Subhasish/0000-0002-7852-6569; Lynn, Hannah Marie/0000-0002-6063-5820; /0000-0001-6520-677X	Bill & Melinda Gates Foundation; US National Institutes of Health; Gut Microbiome and Immunity Project	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gut Microbiome and Immunity Project	Work performed in the authors' labs described in this Comment was supported by the Bill & Melinda Gates Foundation and the US National Institutes of Health. We are indebted to our fellow investigators of the Breast Milk, Gut Microbiome and Immunity Project, including N.N. Naila, M.M. Islam, S. Huq, M.A. Alam, M.U. Zaman, H.-W. Chang, Y. Wang, A. Osterman, D. Rodionov, C. Newgard and C. Lebrilla.	Amicucci MJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17778-1; Chen RY, 2021, NEW ENGL J MED, V384, P1517, DOI 10.1056/NEJMoa2023294; Dmitrienko A, 2018, NEW ENGL J MED, V378, P2115, DOI 10.1056/NEJMra1709701; Gehrig JL, 2019, SCIENCE, V365, P139, DOI 10.1126/science.aau4732; Kolodziejczyk AA, 2019, NAT REV MICROBIOL, V17, P742, DOI 10.1038/s41579-019-0256-8; Onis M. de, 2006, Acta Paediatrica, V95, P76; Raman AS, 2019, SCIENCE, V365, P140, DOI 10.1126/science.aau4735; Sanderson J, 2013, INTELLECTUAL PROPERTY AND FOOD PROJECT: FROM REWARDING INNOVATION AND CREATION TO FEEDING THE WORLD, P145; Wesener DA, 2021, ELIFE, V10, DOI 10.7554/eLife.64478; Wilkinson JE, 2021, NAT MED, V27, P766, DOI 10.1038/s41591-021-01258-0	10	1	1	2	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1503	1506		10.1038/s41591-021-01451-1	http://dx.doi.org/10.1038/s41591-021-01451-1		JUL 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34326550	Green Accepted			2022-12-27	WOS:000679255200002
J	Excler, JL; Saville, M; Berkley, S; Kim, JH				Excler, Jean-Louis; Saville, Melanie; Berkley, Seth; Kim, Jerome H.			Vaccine development for emerging infectious diseases	NATURE MEDICINE			English	Review							ANTIMICROBIAL RESISTANCE; IMMUNOGENICITY; CORONAVIRUS; EFFICACY; LESSONS; VARIANT; SAFETY; FEVER	Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies. Vaccine manufacturing and distribution are complex and challenging. While speed is essential, clinical development to emergency use authorization and licensure, pharmacovigilance of vaccine safety and surveillance of virus variants are also critical. Access to vaccines and vaccination needs to be prioritized in low- and middle-income countries. The combination of these factors will weigh heavily on the ultimate success of efforts to bring the current and any future emerging infectious disease pandemics to a close. Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics can offer critical lessons to prepare for future public health emergencies.	[Excler, Jean-Louis; Kim, Jerome H.] Int Vaccine Inst, Seoul, South Korea; [Saville, Melanie] Coalit Epidem Preparedness Innovat CEPI, London, England; [Berkley, Seth] Gavi, Geneva, Switzerland	International Vaccine Institute	Excler, JL; Kim, JH (corresponding author), Int Vaccine Inst, Seoul, South Korea.	Jeanlouis.excler@ivi.int; Jerome.kim@ivi.int		Excler, Jean-Louis/0000-0002-6462-5101; Kim, Jerome/0000-0003-0461-6438				Adalja AA, 2020, HEALTH SECUR, V18, P59, DOI 10.1089/hs.2019.0148; Andrews JR, 2019, LANCET INFECT DIS, V19, pE26, DOI 10.1016/S1473-3099(18)30350-5; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Ball P, 2021, NATURE, V589, P16, DOI 10.1038/d41586-020-03626-1; BBC, COV S AFR HALTS ASTR; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; D'Souza MP, 2010, AIDS, V24, P803, DOI 10.1097/QAD.0b013e3283379712; European Medicines Agency, EMA REC COVID 19 VAC; European Medicines Agency, EMA REC 1 COVID 19 V; European Medicines Agency, PHARM PLAN EU REG NE; European Pharmaceutical Review, ASTRAZENECA TEST COM; Excler JL, 2019, EXPERT REV VACCINES, V18, P765, DOI 10.1080/14760584.2019.1640117; Faria NR, 2020, VIROLOGICAL; Feldmann H, 2018, ANNU REV MICROBIOL, V72, P423, DOI 10.1146/annurev-micro-090817-062414; Follmann D, ASSESSING DURABILITY, DOI 10.1101/2020.12.14.20248137v1; Friedler A, 2021, GLOB PUBLIC HEALTH, V16, P17, DOI 10.1080/17441692.2020.1828982; Fritzell B, 1998, Dev Biol Stand, V95, P181; Gouglas D, 2019, EPIDEMIOL REV, V41, P28, DOI 10.1093/epirev/mxz012; Gully Paul R, 2020, Healthc Manage Forum, V33, P164, DOI 10.1177/0840470420901532; Hou Yixuan J, 2020, bioRxiv, DOI 10.1101/2020.09.28.317685; Hu DL, 2016, P NATL ACAD SCI USA, V113, pE7730, DOI 10.1073/pnas.1608732113; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; [Anonymous], 2020, Nat Rev Dis Primers, V6, P14, DOI [10.1038/s41572-020-0147-3, 10.1038/s41572-020-0154-4]; Juan-Giner A, 2021, LANCET, V397, P119, DOI 10.1016/S0140-6736(20)32520-4; Kieny MP, 2016, EXPERT REV VACCINES, V15, P1075, DOI 10.1080/14760584.2016.1188695; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Klemm EJ, 2018, MBIO, V9, DOI 10.1128/mBio.00105-18; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Krause PR, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMp2033538; Krubiner CB, 2021, VACCINE, V39, P85, DOI 10.1016/j.vaccine.2019.01.011; Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064; Lee GM, 2020, JAMA-J AM MED ASSOC, V324, P1937, DOI 10.1001/jama.2020.19692; Lin JT, 2007, ANTIVIR THER, V12, P1107; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Marchello CS, 2020, AM J TROP MED HYG, V103, P2518, DOI 10.4269/ajtmh.20-0258; Marston HD, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009872; Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026; Menendez C, 2015, LANCET GLOB HEALTH, V3, pE130, DOI 10.1016/S2214-109X(15)70009-4; Morens DM, 2020, CELL, V182, P1077, DOI 10.1016/j.cell.2020.08.021; Morens DM, 2020, NEW ENGL J MED, V382, P1293, DOI 10.1056/NEJMp2002106; Morens DM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003467; Phillips N, 2021, NATURE, V590, P382, DOI 10.1038/d41586-021-00396-2; PLANTE JA, NATURE; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard A.J, LANCET INFECT DIS, DOI 10.1016/S1473-3099(20)30476-X; Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P178, DOI 10.12932/AP-100518-0309; Qamar FN, 2020, CLIN INFECT DIS, V71, pS276, DOI 10.1093/cid/ciaa1323; Rottingen JA, 2017, NEW ENGL J MED, V376, P610, DOI 10.1056/NEJMp1613577; Sacchetto L, 2020, EMERG TOP LIFE SCI, V4, P411, DOI 10.1042/ETLS20200187; Sandbrink JB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608460; Shaikh H, 2020, VACCINE, V38, pA118, DOI 10.1016/j.vaccine.2019.12.011; Smith MJ, 2020, LANCET, V396, P1707, DOI 10.1016/S0140-6736(20)32337-0; The PREVENT Working Group, PREGN WOM VACC EM EP; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; US Department of Health and Human Health Services, EXPL OP WARP SPEED; US Food and Drug Administration, FDA TAK ADD ACT FIGH; US Food and Drug Administration, FDA TAK KEY ACT FIGH; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Volz Erik, 2021, Cell, V184, P64, DOI 10.1016/j.cell.2020.11.020; Wang D, 2020, J AEROSPACE ENG, V33, DOI 10.1061/(ASCE)AS.1943-5525.0001149; WHO, DRAFT LANDSC TRACK C; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wolf J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0204-7; World Health Organization, YELLOW FEVER; World Health Organization, GLOB ADV COMM VACC S; World Health Organization, COVID 19 VACC SAF SU; Yousafzai MT, 2019, CLIN INFECT DIS, V68, pS16, DOI 10.1093/cid/ciy877; Zellweger RM, 2020, EXPERT REV VACCINES, V19, P691, DOI 10.1080/14760584.2020.1800463; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	72	58	60	12	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					591	600		10.1038/s41591-021-01301-0	http://dx.doi.org/10.1038/s41591-021-01301-0		APR 2021	10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33846611	Bronze			2022-12-27	WOS:000639643400001
J	Lanas, F; Seron, P				Lanas, Fernando; Seron, Pamela			Understanding life and death in Latin America	NATURE MEDICINE			English	Editorial Material								An analysis of life expectancy and cause of death in 363 Latin American cities unveils wide differences between cities in the same country, and sheds light on the socioeconomic factors that determine how long people live and how they die.	[Lanas, Fernando; Seron, Pamela] Univ La Frontera, Internal Med Dept, Temuco, Chile; [Lanas, Fernando; Seron, Pamela] Univ La Frontera, Cardiovasc Dis Res Ctr, Temuco, Chile	Universidad de La Frontera; Universidad de La Frontera	Lanas, F (corresponding author), Univ La Frontera, Internal Med Dept, Temuco, Chile.	lanastomas@gmail.com	Lanas, Fernando/AAE-8842-2022; Seron, Pamela/AAN-3304-2021	Seron, Pamela/0000-0003-0190-8988; Lanas, Fernando/0000-0003-3595-9759				Atun R, 2015, LANCET, V385, P1230, DOI 10.1016/S0140-6736(14)61646-9; Bilal U, 2021, NAT MED, V27, P463, DOI 10.1038/s41591-020-01214-4; Bilal U, 2019, LANCET PLANET HEALTH, V3, pE503, DOI 10.1016/S2542-5196(19)30235-9; Mackenbach JP, 2019, LANCET PUBLIC HEALTH, V4, pE529, DOI 10.1016/S2468-2667(19)30147-1; Marmot M, 2012, LANCET, V380, P1011, DOI 10.1016/S0140-6736(12)61228-8; de Andrade LOM, 2015, LANCET, V385, P1343, DOI 10.1016/S0140-6736(14)61494-X; Permanyer I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215742; Rosengren A, 2019, LANCET GLOB HEALTH, V7, pE748, DOI 10.1016/S2214-109X(19)30045-2; United Nations Department of Economic and Social Affairs, 2019, POPULATION DIVISION; Yusuf S, 2020, LANCET, V395, P795, DOI 10.1016/S0140-6736(19)32008-2	10	0	0	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					373	375		10.1038/s41591-021-01277-x	http://dx.doi.org/10.1038/s41591-021-01277-x		MAR 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33664489				2022-12-27	WOS:000626919600001
J	Ma, J; Lv, XL; Zhang, X; Han, SZ; Wang, ZD; Li, L; Sun, HT; Ma, LX; Cheng, ZL; Shao, JW; Chen, C; Zhao, YH; Sui, LY; Liu, LN; Qian, J; Wang, W; Liu, Q				Ma, Jun; Lv, Xiao-Long; Zhang, Xu; Han, Shu-Zheng; Wang, Ze-Dong; Li, Liang; Sun, He-Ting; Ma, Li-Xin; Cheng, Zheng-Lei; Shao, Jian-Wei; Chen, Chen; Zhao, Ying-Hua; Sui, Liyan; Liu, Lin-Na; Qian, Jun; Wang, Wei; Liu, Quan			Identification of a new orthonairovirus associated with human febrile illness in China	NATURE MEDICINE			English	Article								The genus Orthonairovirus, which is part of the family Nairoviridae, includes the important tick-transmitted pathogens Crimean-Congo hemorrhagic fever virus and Nairobi sheep disease virus, as well as many other poorly characterized viruses found in ticks, birds and mammals(1,2). In this study, we identified a new orthonairovirus, Songling virus (SGLV), from patients who reported being bitten by ticks in Heilongjiang Province in northeastern China. SGLV shared similar genomic and morphological features with orthonairoviruses and phylogenetically formed a unique clade in Tamdy orthonairovirus of the Nairoviridae family. The isolated SGLV induced cytopathic effects in human hepatoma cells in vitro. SGLV infection was confirmed in 42 hospitalized patients analyzed between 2017 and 2018, with the main clinical manifestations being headache, fever, depression, fatigue and dizziness. More than two-thirds (69%) of patients generated virus-specific antibody responses in the acute phase. Taken together, these results suggest that this newly discovered orthonairovirus is associated with human febrile illness in China.	[Ma, Jun; Zhang, Xu; Shao, Jian-Wei; Liu, Quan] Foshan Univ, Sch Life Sci & Engn, Foshan, Guangdong, Peoples R China; [Ma, Jun; Li, Liang; Liu, Quan] Acad Mil Med Sci, Military Vet Inst, Changchun, Jilin, Peoples R China; [Lv, Xiao-Long; Han, Shu-Zheng; Wang, Wei] Inner Mongolia Univ Nationalities, Inner Mongolia Gen Forestry Hosp, Affiliated Hosp 2, Yakeshi, Inner Mongolia, Peoples R China; [Wang, Ze-Dong; Chen, Chen; Zhao, Ying-Hua; Sui, Liyan; Liu, Quan] First Hosp Jilin Univ, Changchun, Jilin, Peoples R China; [Sun, He-Ting] State Forestry & Grassland Adm, Shenyang, Liaoning, Peoples R China; [Ma, Li-Xin] Alongshan Forestry Bur, Yakeshi, Inner Mongolia, Peoples R China; [Cheng, Zheng-Lei] Alongshan Forest Pest Control Stn, Yakeshi, Inner Mongolia, Peoples R China; [Liu, Lin-Na; Qian, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China	Foshan University; Academy of Military Medical Sciences - China; Inner Mongolia University for Nationalities; Jilin University; Sun Yat Sen University	Liu, Q (corresponding author), Foshan Univ, Sch Life Sci & Engn, Foshan, Guangdong, Peoples R China.; Liu, Q (corresponding author), Acad Mil Med Sci, Military Vet Inst, Changchun, Jilin, Peoples R China.; Wang, W (corresponding author), Inner Mongolia Univ Nationalities, Inner Mongolia Gen Forestry Hosp, Affiliated Hosp 2, Yakeshi, Inner Mongolia, Peoples R China.; Liu, Q (corresponding author), First Hosp Jilin Univ, Changchun, Jilin, Peoples R China.; Qian, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.	qianj9@mail.sysu.edu.cn; hlbewangwei@163.com; liuquan1973@hotmail.com	Liu, Quan/ABH-2947-2020; Ma, Jun/GPK-2342-2022; Wang, Zedong/AAY-1545-2020	Jun, Ma/0000-0001-9955-4625; Liu, Quan/0000-0003-3411-3196	National Key R&D Program of China [2017YFD0501700]; National Natural Science Foundation of China [31672542, 31372430]; Pearl River Talent Plan in Guangdong Province of China [2019CX01N111]; 'Three Major' scientific research projects of Sun Yat-sen University in 2020 [50000-31143406]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Pearl River Talent Plan in Guangdong Province of China; 'Three Major' scientific research projects of Sun Yat-sen University in 2020	We thank J.-F. Wang and S.-D. Wang at Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, for electron microscopic analysis of virus. This work was supported by the National Key R&D Program of China (project no. 2017YFD0501700, to Q.L.), the National Natural Science Foundation of China (project nos. 31672542 and 31372430, to Q.L.), the Pearl River Talent Plan in Guangdong Province of China (project no. 2019CX01N111, to Q.L.) and the 'Three Major' scientific research projects of Sun Yat-sen University in 2020 (project no. 50000-31143406, to J.Q.).	Bartikova P, 2017, ACTA VIROL, V61, P413, DOI 10.4149/av_2017_403; Biggerstaff B, 2005, VECTOR-BORNE ZOONOT, V5, P420, DOI 10.1089/vbz.2005.5.420; bin Tarif A, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-71; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Burt FJ, 1996, EPIDEMIOL INFECT, V116, P353, DOI 10.1017/S0950268800052687; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Chastel C, 1998, B ACAD NAT MED PARIS, V182, P801; CONVERSE JD, 1975, AM J TROP MED HYG, V24, P1010, DOI 10.4269/ajtmh.1975.24.1010; DANDAWAT.CN, 1969, INDIAN J MED RES, V57, P975; Darriba D, 2011, BIOINFORMATICS, V27, P1164, DOI 10.1093/bioinformatics/btr088; Dayer MR, 2015, PROTEIN J, V34, P91, DOI 10.1007/s10930-015-9601-6; Dilcher M, 2012, VIRUS GENES, V45, P426, DOI 10.1007/s11262-012-0796-8; Dogan HO, 2018, ARCH VIROL, V163, P609, DOI 10.1007/s00705-017-3653-1; DONETS MA, 1977, INTERVIROLOGY, V8, P294, DOI 10.1159/000148904; Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2; Garrison AR, 2020, J GEN VIROL, V101, P798, DOI 10.1099/jgv.0.001485; Gauci PJ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120373; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Honig JE, 2004, VIROLOGY, V321, P29, DOI 10.1016/j.virol.2003.09.042; Hosainzadegan H, 2020, EUR J CLIN MICROBIOL, V39, P215, DOI 10.1007/s10096-019-03681-1; Jia N, 2013, NEW ENGL J MED, V369, P1178, DOI 10.1056/NEJMc1303004; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kinsella E, 2004, VIROLOGY, V321, P23, DOI 10.1016/j.virol.2003.09.046; Kuhn JH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060164; L'VOV D K, 1984, Voprosy Virusologii, V29, P487; Lasecka L, 2014, ARCH VIROL, V159, P1249, DOI 10.1007/s00705-013-1940-z; Li CX, 2015, ELIFE, V4, DOI 10.7554/eLife.05378; Li H, 2015, LANCET INFECT DIS, V15, P663, DOI 10.1016/S1473-3099(15)70051-4; Liu XF, 2020, CLIN INFECT DIS, V70, P2155, DOI 10.1093/cid/ciz602; Mohan KVK, 2020, TRANSFUSION, V60, P1624, DOI 10.1111/trf.15752; Mokili JL, 2012, CURR OPIN VIROL, V2, P63, DOI 10.1016/j.coviro.2011.12.004; Ontiveros SJ, 2010, VIROLOGY, V401, P165, DOI 10.1016/j.virol.2010.02.018; Payne AF, 2006, J VIROL METHODS, V134, P183, DOI 10.1016/j.jviromet.2006.01.003; Roca B, 2016, HIV CLIN TRIALS, V17, P218, DOI 10.1080/15284336.2016.1220712; Sanchez AJ, 2002, J VIROL, V76, P7263, DOI 10.1128/JVI.76.14.7263-7275.2002; Spengler JR, 2019, CURR OPIN VIROL, V34, P70, DOI 10.1016/j.coviro.2018.12.002; Wang ZD, 2019, NEW ENGL J MED, V380, P2116, DOI 10.1056/NEJMoa1805068; Zhang L, 2018, TRANSBOUND EMERG DIS, V65, P1733, DOI 10.1111/tbed.12946; Zhang X, 2020, CURR OPIN VIROL, V40, P11, DOI 10.1016/j.coviro.2020.02.001; Zhou H, 2019, EMERG INFECT DIS, V25, P2136, DOI 10.3201/eid2511.190512	40	19	21	7	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					434	+		10.1038/s41591-020-01228-y	http://dx.doi.org/10.1038/s41591-020-01228-y		FEB 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33603240	Green Submitted			2022-12-27	WOS:000619508200001
J	Pierson, E; Cutler, DM; Leskovec, J; Mullainathan, S; Obermeyer, Z				Pierson, Emma; Cutler, David M.; Leskovec, Jure; Mullainathan, Sendhil; Obermeyer, Ziad			An algorithmic approach to reducing unexplained pain disparities in underserved populations	NATURE MEDICINE			English	Article							SYMPTOMATIC KNEE OSTEOARTHRITIS; IMPACT; RATES; RISK	Underserved populations experience higher levels of pain. These disparities persist even after controlling for the objective severity of diseases like osteoarthritis, as graded by human physicians using medical images, raising the possibility that underserved patients' pain stems from factors external to the knee, such as stress. Here we use a deep learning approach to measure the severity of osteoarthritis, by using knee X-rays to predict patients' experienced pain. We show that this approach dramatically reduces unexplained racial disparities in pain. Relative to standard measures of severity graded by radiologists, which accounted for only 9% (95% confidence interval (CI), 3-16%) of racial disparities in pain, algorithmic predictions accounted for 43% of disparities, or 4.7x more (95% CI, 3.2-11.8x), with similar results for lower-income and less-educated patients. This suggests that much of underserved patients' pain stems from factors within the knee not reflected in standard radiographic measures of severity. We show that the algorithm's ability to reduce unexplained disparities is rooted in the racial and socioeconomic diversity of the training set. Because algorithmic severity measures better capture underserved patients' pain, and severity measures influence treatment decisions, algorithmic predictions could potentially redress disparities in access to treatments like arthroplasty. An algorithmic, machine-learning approach to measuring severe pain from osteoarthritis applied to X-ray images of knees suggests that reported disparities in knee pain in underserved populations can be reduced by comparison with use of standard radiographic measures of disease severity.	[Pierson, Emma] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Pierson, Emma] Microsoft Res, Cambridge, MA USA; [Cutler, David M.] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA; [Leskovec, Jure] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Mullainathan, Sendhil] Univ Chicago, Booth Sch Business, Chicago, IL 60637 USA; [Obermeyer, Ziad] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Stanford University; Microsoft; Harvard University; Stanford University; University of Chicago; University of California System; University of California Berkeley	Mullainathan, S (corresponding author), Univ Chicago, Booth Sch Business, Chicago, IL 60637 USA.	sendhil.mullainathan@chicagobooth.edu		Leskovec, Jure/0000-0002-5411-923X; Cutler, David/0000-0002-4949-8917	US Social Security Administration [RDR18000003] Funding Source: Medline	US Social Security Administration		Allen KD, 2010, OSTEOARTHR CARTILAGE, V18, P160, DOI 10.1016/j.joca.2009.09.010; Allen KD, 2009, OSTEOARTHR CARTILAGE, V17, P1132, DOI 10.1016/j.joca.2009.03.003; Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, pA1, DOI 10.1016/j.joca.2006.11.009; Anderson KO, 2009, J PAIN, V10, P1187, DOI 10.1016/j.jpain.2009.10.002; Antony J, 2016, INT C PATT RECOG, P1195, DOI 10.1109/ICPR.2016.7899799; Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-116; Bien N, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002699; Bolen J, 2010, PREV CHRONIC DIS, V7; Cheek N. N., 2020, BEHAV PUBLIC POLICY, V4, P1; Collins JE, 2014, OSTEOARTHR CARTILAGE, V22, P622, DOI 10.1016/j.joca.2014.03.009; Cutler David M., 2020, 27974 NBER; Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848; Deveza L. A., 2019, MANAGEMENT KNEE OSTE; Eberly L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195075; Englund M, 2003, ARTHRITIS RHEUM-US, V48, P2178, DOI 10.1002/art.11088; Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216; Haug W., 2002, DEMOGRAPHIC CHARACTE, V38; Hochberg MC, 2019, JAMA-J AM MED ASSOC, V322, P1360, DOI 10.1001/jama.2019.14735; Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113; Hunter DJ, 2011, OSTEOARTHR CARTILAGE, V19, P990, DOI 10.1016/j.joca.2011.05.004; Kaiming He, 2016, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), P770, DOI 10.1109/CVPR.2016.90; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kingma D., 2014, P 3 INT C LEARNING R, DOI DOI 10.1038/S41598-021-83424-5; Kohn MD, 2016, CLIN ORTHOP RELAT R, V474, P1886, DOI 10.1007/s11999-016-4732-4; Krause N, 1997, SCAND J WORK ENV HEA, V23, P179, DOI 10.5271/sjweh.196; Lingard EA, 2007, J BONE JOINT SURG AM, V89A, P1161, DOI 10.2106/JBJS.F.00914; Losina E, 2015, ARTHRIT CARE RES, V67, P203, DOI 10.1002/acr.22412; Losina E, 2012, J BONE JOINT SURG AM, V94A, P201, DOI [10.2106/JBJS.J.01958, 10.2106/JBJS.K.00009, 10.2106/JBJS.J.101958]; Neogi T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2844; Perez L., 2017, PREPRINT; Poleshuck EL, 2008, PAIN, V136, P235, DOI 10.1016/j.pain.2008.04.003; Rajpurkar P., 2017, PREPRINT; Rankin EA, 2004, J BONE JOINT SURG AM, V86A, P1328; Riddle DL, 2015, ARTHRIT CARE RES, V67, P349, DOI 10.1002/acr.22428; Rogers MW, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-163; Roos EM, 1998, J ORTHOP SPORT PHYS, V28, P88, DOI 10.2519/jospt.1998.28.2.88; Sayre EC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176833; Sheehy L, 2015, OSTEOARTHR CARTILAGE, V23, P1491, DOI 10.1016/j.joca.2015.05.003; Skinner J, 2003, NEW ENGL J MED, V349, P1350, DOI 10.1056/NEJMsa021569; Steiner DF, 2018, AM J SURG PATHOL, V42, P1636, DOI 10.1097/PAS.0000000000001151; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tiulpin A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20132-7; Uyumazturk B., 2019, MACHINE LEARNING HLT; Vina ER, 2018, OSTEOARTHR CARTILAGE, V26, P471, DOI 10.1016/j.joca.2018.01.020; Xu YW, 2019, CLIN CANCER RES, V25, P3266, DOI 10.1158/1078-0432.CCR-18-2495; Zeiler MD, 2014, LECT NOTES COMPUT SC, V8689, P818, DOI 10.1007/978-3-319-10590-1_53; Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.cger.2010.03.001, 10.1016/j.rdc.2012.10.004]; Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319	49	58	59	4	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					136	+		10.1038/s41591-020-01192-7	http://dx.doi.org/10.1038/s41591-020-01192-7			15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442014				2022-12-27	WOS:000607931400032
J	[Anonymous]				[Anonymous]			New year, new outbreak	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1806	1806		10.1038/s41591-020-01160-1	http://dx.doi.org/10.1038/s41591-020-01160-1			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288937	Bronze			2022-12-27	WOS:000596579200012
J	[Anonymous]				[Anonymous]			COVID-19 clusters	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1806	1806		10.1038/s41591-020-01159-8	http://dx.doi.org/10.1038/s41591-020-01159-8			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288938	Bronze			2022-12-27	WOS:000596579200015
J	Valkenburg, SA; Poon, LLM				Valkenburg, Sophie A.; Poon, Leo L. M.			Exploring the landscape of immune responses to influenza infection and vaccination	NATURE MEDICINE			English	Editorial Material								The antibody landscape after H3N2 vaccination may be shaped largely by recent infections; further exploration of immune dynamics could inform influenza vaccination strategies.	[Valkenburg, Sophie A.; Poon, Leo L. M.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China; [Poon, Leo L. M.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Publ Hlth Lab Sci, Hong Kong, Peoples R China; [Poon, Leo L. M.] Ctr Immunol & Infect, Hong Kong Sci Pk, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Poon, LLM (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China.; Poon, LLM (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Publ Hlth Lab Sci, Hong Kong, Peoples R China.; Poon, LLM (corresponding author), Ctr Immunol & Infect, Hong Kong Sci Pk, Hong Kong, Peoples R China.	llmpoon@hku.hk	Poon, Leo/AAP-6887-2020; Poon, Leo/C-4382-2009	Poon, Leo/0000-0002-9101-7953				Andrews SF, 2022, NAT MED, V28, P373, DOI 10.1038/s41591-021-01636-8; Auladell M., 2022, NAT MED, DOI [10.1038/s41591-022-1690-w, DOI 10.1038/S41591-022-1690-W]; Auladell M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01400; Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554; Boyoglu-Barnum S, 2021, NATURE, V592, P623, DOI 10.1038/s41586-021-03365-x; Bull MB, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091779; Francis T, 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; Gostic KM, 2016, SCIENCE, V354, P722, DOI 10.1126/science.aag1322; Gouma S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18465-x; Houser KV, 2022, NAT MED, V28, P383, DOI 10.1038/s41591-021-01660-8; Monto AS, 2017, J INFECT DIS, V215, P1782, DOI 10.1093/infdis/jix173; Music N, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0123-7; Skowronski DM, 2017, J INFECT DIS, V215, P1059, DOI 10.1093/infdis/jix074; Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001	14	0	0	5	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					239	240		10.1038/s41591-021-01656-4	http://dx.doi.org/10.1038/s41591-021-01656-4		FEB 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35177856				2022-12-27	WOS:000757243200009
J	Cerqueira-Silva, T; Katikireddi, SV; Oliveira, VD; Flores-Ortiz, R; Bertoldo, J; Paixao, ES; Robertson, C; Penna, GO; Werneck, GL; Barreto, ML; Pearce, N; Sheikh, A; Barral-Netto, M; Boaventura, VS				Cerqueira-Silva, Thiago; Katikireddi, Srinivasa Vittal; Oliveira, Vinicius de Araujo; Flores-Ortiz, Renzo; Bertoldo Junior, Juracy; Paixao, Enny S.; Robertson, Chris; Penna, Gerson O.; Werneck, Guilherme L.; Barreto, Mauritio L.; Pearce, Neil; Sheikh, Aziz; Barral-Netto, Manoel; Boaventura, Viviane S.			Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil	NATURE MEDICINE			English	Article								There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (similar to 16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14-30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3-55.7) against confirmed infection and 82.1% (95% CI: 81.4-82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1-36.2) against infection and 72.5% (95% CI: 70.9-74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0-94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1-98.1) 14-30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.	[Cerqueira-Silva, Thiago; Barral-Netto, Manoel; Boaventura, Viviane S.] Inst Goncalo Moniz, LIB & LEITV Labs, Salvador, BA, Brazil; [Cerqueira-Silva, Thiago; Oliveira, Vinicius de Araujo; Bertoldo Junior, Juracy; Barreto, Mauritio L.; Barral-Netto, Manoel; Boaventura, Viviane S.] Univ Fed Bahia UFBA, Salvador, BA, Brazil; [Katikireddi, Srinivasa Vittal] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Katikireddi, Srinivasa Vittal; Robertson, Chris] Publ Hlth Scotland, Glasgow, Lanark, Scotland; [Oliveira, Vinicius de Araujo; Flores-Ortiz, Renzo; Bertoldo Junior, Juracy; Barreto, Mauritio L.; Barral-Netto, Manoel] Ctr Data & Knowledge Integrat Hlth CIDACS, Inst Goncalo Moniz, Salvador, BA, Brazil; [Paixao, Enny S.; Pearce, Neil] London Sch Hyg & Trop Med, London, England; [Robertson, Chris] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland; [Penna, Gerson O.] Univ Brasilia, FIOCRUZ, Escola Fiocruz Governo, Nucl Med Trop, Brasilia, DF, Brazil; [Werneck, Guilherme L.] Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil; [Sheikh, Aziz] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland	Universidade Federal da Bahia; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of London; London School of Hygiene & Tropical Medicine; University of Strathclyde; Fundacao Oswaldo Cruz; Universidade de Brasilia; Universidade do Estado do Rio de Janeiro; University of Edinburgh	Boaventura, VS (corresponding author), Inst Goncalo Moniz, LIB & LEITV Labs, Salvador, BA, Brazil.; Boaventura, VS (corresponding author), Univ Fed Bahia UFBA, Salvador, BA, Brazil.	viviane.boaventura@fiocruz.br	Barral-Netto, Manoel/B-3904-2009; Cerqueira-Silva, Thiago/AAV-8975-2021; Werneck, Guilherme/A-2841-2013	Barral-Netto, Manoel/0000-0002-5823-7903; Cerqueira-Silva, Thiago/0000-0003-4534-2509; Werneck, Guilherme/0000-0003-1169-1436; Katikireddi, Srinivasa/0000-0001-6593-9092; Flores-Ortiz, Renzo Joel/0000-0001-7639-2627; Bertoldo Santos Junior, Juracy/0000-0003-3589-2494; Boaventura, Viviane/0000-0002-7241-6844; Paixao, Enny/0000-0002-4797-908X	CNPq; Brazilian National Research Council; FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro [E-26/210.180/2020]; Post-Graduation Program in Health Sciences-UFBA - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil [001]; NRS Senior Clinical Fellowship [SCAF/15/02]; Medical Research Council [MC_UU_00022/2]; Scottish Government Chief Scientist Office [SPHSU17]; Health Data Research UK; Office for National Statistics; UK Research and Innovation [MC_ PC_20058]; UK Government [GHRG/16/137/99]	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian National Research Council(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Post-Graduation Program in Health Sciences-UFBA - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil; NRS Senior Clinical Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Scottish Government Chief Scientist Office; Health Data Research UK; Office for National Statistics; UK Research and Innovation(UK Research & Innovation (UKRI)); UK Government	The present study is part of the Fiocruz VigiVac project on continuous digital evaluation of the national anti-COVID-19 immunization campaign. This study was partially supported by a donation from the `Fazer o bem faz bem' program. We thank DATASUS for its excellent work in providing unidentified databases. G. L.W., M.L.B. and M.B.-N. are research fellows from CNPq, the Brazilian National Research Council. G.L.W. acknowledges funding from FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, E-26/210.180/2020). T.C.-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA, which is supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil, finance code 001. S.V.K. acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). A.S. and C.R. are supported by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref. MC_ PC_20058). This partnership between Brazil and Scotland was established through funding from the National Institute for Health Research (GHRG/16/137/99) using UK aid from the UK Government to support global health research.	Andrews N, 2022, NEW ENGL J MED, V386, P340, DOI 10.1056/NEJMoa2115481; [Anonymous], 2021, EV COVID 19 VACC EFF; [Anonymous], 2021, PLAN NAC OP VAC COVI; Bichara CDA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101169; Boum Y, 2021, LANCET INFECT DIS, V21, P1089, DOI 10.1016/S1473-3099(21)00132-8; Cerqueira-Silva Thiago, 2022, Lancet Reg Health Am, V6, P100154, DOI 10.1016/j.lana.2021.100154; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Hunsawong T, 2021, EMERG INFECT DIS, V27, P3178, DOI 10.3201/eid2712.211772; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Karamese M, 2022, J MED VIROL, V94, P173, DOI 10.1002/jmv.27289; Katikireddi SV, 2022, LANCET, V399, P25, DOI 10.1016/S0140-6736(21)02754-9; Keskin AU, 2022, J MED VIROL, V94, P39, DOI 10.1002/jmv.27350; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Mallapaty S, 2021, NATURE, V600, P580, DOI 10.1038/d41586-021-03686-x; Medeiros G. X., 2021, REDUCED T CELL ANTIB, DOI [10.1101/2021.08.16.21262069, DOI 10.1101/2021.08.16.21262069]; R Core Team, 2021, R LANGUAGE ENV STAT; Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015; Saure D, 2022, LANCET INFECT DIS, V22, P56, DOI 10.1016/S1473-3099(21)00479-5; Souza WM, 2021, LANCET MICROBE, V2, pE527, DOI 10.1016/S2666-5247(21)00129-4; Vandenbroucke JP, 2019, EPIDEMIOLOGY, V30, P838, DOI 10.1097/EDE.0000000000001088; Wickham H., 2019, J OPEN SOURCE SOFTW, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]; Wood SN, 2004, J AM STAT ASSOC, V99, P673, DOI 10.1198/016214504000000980; Zhang JL, 2021, EMERG MICROBES INFEC, V10, P1598, DOI 10.1080/22221751.2021.1957401	23	26	27	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					838	+		10.1038/s41591-022-01701-w	http://dx.doi.org/10.1038/s41591-022-01701-w		FEB 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35140406	Green Accepted, hybrid, Green Published, Green Submitted			2022-12-27	WOS:000753254400001
J	Xie, Y; Xu, E; Bowe, B; Al-Aly, Z				Xie, Yan; Xu, Evan; Bowe, Benjamin; Al-Aly, Ziyad			Long-term cardiovascular outcomes of COVID-19	NATURE MEDICINE			English	Article							DIFFERENCE; POLICY	Individuals with COVID-19 are at increased long-term risk for a wide range of cardiovascular disorders, even for individuals who were not hospitalized during the acute phase of the infection. The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of Veterans Affairs to build a cohort of 153,760 individuals with COVID-19, as well as two sets of control cohorts with 5,637,647 (contemporary controls) and 5,859,411 (historical controls) individuals, to estimate risks and 1-year burdens of a set of pre-specified incident cardiovascular outcomes. We show that, beyond the first 30 d after infection, individuals with COVID-19 are at increased risk of incident cardiovascular disease spanning several categories, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure and thromboembolic disease. These risks and burdens were evident even among individuals who were not hospitalized during the acute phase of the infection and increased in a graded fashion according to the care setting during the acute phase (non-hospitalized, hospitalized and admitted to intensive care). Our results provide evidence that the risk and 1-year burden of cardiovascular disease in survivors of acute COVID-19 are substantial. Care pathways of those surviving the acute episode of COVID-19 should include attention to cardiovascular health and disease.	[Xie, Yan; Xu, Evan; Bowe, Benjamin; Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, Res & Dev Serv, St Louis, MO 63106 USA; [Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad] Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA; [Xie, Yan] St Louis Univ, Dept Epidemiol & Biostat, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA; [Xu, Evan] St Louis Univ, Sch Med, St Louis, MO USA; [Al-Aly, Ziyad] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA; [Al-Aly, Ziyad] Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)	Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, Res & Dev Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA.; Al-Aly, Z (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA.	zalaly@gmail.com	; Al-Aly, Ziyad/S-4439-2016	Xu, Evan/0000-0001-6132-8374; Al-Aly, Ziyad/0000-0002-2600-0434; Xie, Yan/0000-0002-2457-9382	US Department of Veterans Affairs; two American Society of Nephrology and KidneyCure fellowship awards	US Department of Veterans Affairs(US Department of Veterans Affairs); two American Society of Nephrology and KidneyCure fellowship awards	This study used data from the VA COVID-19 Shared Data Resource. This research was funded by the US Department of Veterans Affairs (to Z.A.-A.) and two American Society of Nephrology and KidneyCure fellowship awards (to Y.X. and B.B.). The contents do not represent the views of the US Department of Veterans Affairs or the US government.	Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Alwan NA, 2021, SCIENCE, V373, P491, DOI 10.1126/science.abg7113; [Anonymous], 2020, LONG TERM IMMUNOLOGI; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Ayoubkhani D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n693; Bowe B, 2021, J AM SOC NEPHROL, V32, P2851, DOI 10.1681/ASN.2021060734; Bowe B, 2021, CLIN J AM SOC NEPHRO, V16, P14, DOI 10.2215/CJN.09610620; Briggs A, 2021, NATURE, V593, P502, DOI 10.1038/d41586-021-01392-2; Cai M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-047369; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Chung MK, 2021, CIRC RES, V128, P1214, DOI 10.1161/CIRCRESAHA.121.317997; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Delorey TM, 2021, NATURE, V595, P107, DOI 10.1038/s41586-021-03570-8; Di Toro A, 2021, EUR HEART J SUPPL, V23, pE1, DOI 10.1093/eurheartj/suab080; Dimick JB, 2014, JAMA-J AM MED ASSOC, V312, P2401, DOI 10.1001/jama.2014.16153; Farshidfar F, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.148980; Funk MJ, 2011, AM J EPIDEMIOL, V173, P761, DOI 10.1093/aje/kwq439; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; IMBENS GW, 1994, ECONOMETRICA, V62, P467, DOI 10.2307/2951620; Katsoularis I, 2021, LANCET, V398, P599, DOI 10.1016/S0140-6736(21)00896-5; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Lechner Michael, 2011, Foundations and Trends in Econometrics, V4, P165, DOI 10.1561/0800000014; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nishiga M, 2020, NAT REV CARDIOL, V17, P543, DOI 10.1038/s41569-020-0413-9; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Song WC, 2020, J CLIN INVEST, V130, P3950, DOI 10.1172/JCI140183; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Wing C, 2018, ANNU REV PUBL HEALTH, V39, P453, DOI 10.1146/annurev-publhealth-040617-013507; Xie Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26513-3; Xie Y, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4677; Zhang LG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2105968118	35	218	221	62	79	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					583	+		10.1038/s41591-022-01689-3	http://dx.doi.org/10.1038/s41591-022-01689-3		FEB 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35132265	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000752184200003
J	Yuen, MF; Heo, J; Jang, JW; Yoon, JH; Kweon, YO; Park, SJ; Tami, Y; You, SY; Yates, P; Tao, Y; Cremer, J; Campbell, F; Elston, R; Theodore, D; Paff, M; Bennett, CF; Kwoh, TJ				Yuen, Man-Fung; Heo, Jeong; Jang, Jeong-Won; Yoon, Jung-Hwan; Kweon, Young-Oh; Park, Sung-Jae; Tami, Yvonne; You, Shihyun; Yates, Phillip; Tao, Yu; Cremer, Jennifer; Campbell, Fiona; Elston, Robert; Theodore, Dickens; Paff, Melanie; Bennett, C. Frank; Kwoh, T. Jesse			Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial	NATURE MEDICINE			English	Article							HBSAG SEROCLEARANCE; NONHUMAN-PRIMATES; SURFACE-ANTIGEN; REDUCTION; INHIBIT; MONKEYS; DNA	Chronic infection with hepatitis B virus (HBV) leads to an increased risk of death from cirrhosis and hepatocellular carcinoma. Functional cure rates are low with current treatment options (nucleos(t)ide analogs (NAs) and pegylated interferons). Bepirovirsen is an antisense oligonucleotide targeting all HBV messenger RNAs; in cell culture and animal models, bepirovirsen leads to reductions in HBV-derived RNAs, HBV DNA and viral proteins. This phase 2 double-blinded, randomized, placebo-controlled trial is the first evaluation of the safety and activity of an antisense oligonucleotide targeting HBV RNA in both treatment-naive and virally suppressed individuals with chronic HBV infection. The primary objective was to assess the safety and tolerability of bepirovirsen in individuals with chronic hepatitis B (CHB) (NCT02981602). The secondary objective was to assess antiviral activity, including the change from baseline to day 29 in serum hepatitis B surface antigen (HBsAg) concentration. Participants with CHB infection >= 6 months and serum HBsAg >= 50 IU ml(-1) were enrolled from seven centers across Hong Kong and the Republic of Korea and randomized (3:1 within each dose cohort) to receive bepirovirsen or placebo via subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8 and 11) and once weekly during weeks 3 and 4 (days 15 and 22). Participants were then followed for 26 weeks. Twenty-four participants were treatment-naive and seven were receiving stable NA therapy. Treatment-emergent adverse events were mostly mild/moderate (most commonly injection site reactions). Eleven (61.1%) and three (50.0%) treatment-naive participants experienced one or more treatment-emergent adverse event in the bepirovirsen and placebo groups, respectively. In participants receiving NA therapy, the corresponding numbers were three (60.0%) and one (50.0%). Transient, self-resolving alanine aminotransferase flares (>= 2x upper limit of normal) were observed in eight treatment-naive participants and three participants on stable NA regimens in the bepirovirsen treatment arms. HBsAg reductions were observed and were significant versus placebo for treatment-naive participants receiving bepirovirsen 300 mg (P = 0.001), but not for the bepirovirsen 150 mg group (P = 0.245) or participants receiving stable NA therapy (P = 0.762). Two participants in each of the 300 mg dose groups achieved HBsAg levels below the lower limit of quantitation by day 29 (n = 3) or day 36 (n = 1). Bepirovirsen had a favorable safety profile. These preliminary observations warrant further investigation of the safety and activity of bepirovirsen in a larger CHB patient population. A first-in-human study of an antisense oligonucleotide targeting hepatitis B virus (HBV) RNA provides initial insights into this potential new therapeutic modality for individuals with chronic HBV infection.	[Yuen, Man-Fung] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China; [Yuen, Man-Fung] Univ Hong Kong, Queen Mary Hosp, State Key Lab Liver Res, Hong Kong, Peoples R China; [Heo, Jeong] Pusan Natl Univ, Coll Med, Busan, South Korea; [Heo, Jeong] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; [Jang, Jeong-Won] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea; [Yoon, Jung-Hwan] Seoul Natl Univ Hosp, Seoul, South Korea; [Kweon, Young-Oh] Kyungpook Natl Univ Hosp, Daegu, South Korea; [Park, Sung-Jae] Inje Univ, Busan Paik Hosp, Busan, South Korea; [Tami, Yvonne; Bennett, C. Frank; Kwoh, T. Jesse] Ionis Pharmaceut Inc, Carlsbad, CA USA; [You, Shihyun; Tao, Yu; Paff, Melanie] GlaxoSmithKline, Collegeville, PA USA; [Yates, Phillip; Campbell, Fiona; Elston, Robert] GlaxoSmithKline, Stevenage, Herts, England; [Cremer, Jennifer; Theodore, Dickens] GlaxoSmithKline, Res Triangle Pk, NC USA	University of Hong Kong; University of Hong Kong; Pusan National University; Pusan National University; Pusan National University Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Seoul National University (SNU); Seoul National University Hospital; Kyungpook National University; Kyungpook National University Hospital; Inje University; Ionis Pharmaceuticals, Inc.; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Yuen, MF (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.; Yuen, MF (corresponding author), Univ Hong Kong, Queen Mary Hosp, State Key Lab Liver Res, Hong Kong, Peoples R China.	mfyuen@hkucc.hku.hk	Yuen, Richard Man Fung/C-4466-2009	Yuen, Richard Man Fung/0000-0001-7985-7725; Heo, Jeong/0000-0003-0961-7851				Ackermann EJ, 2016, AMYLOID, V23, P148, DOI 10.1080/13506129.2016.1191458; [Anonymous], 2015, GUIDELINES PREVENTIO; Bertoletti A, 2012, GUT, V61, P1754, DOI 10.1136/gutjnl-2011-301073; Billioud G, 2016, J HEPATOL, V64, P781, DOI 10.1016/j.jhep.2015.11.032; Cornberg M, 2020, HEPATOLOGY, V71, P1070, DOI [10.1016/j.jhep.2019.11.003, 10.1002/hep.31030]; Crooke ST, 2016, MOL THER, V24, P1771, DOI 10.1038/mt.2016.136; Dickens, 2019, FRONTIERS DRUG DEV V, pUSA; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Flaim JD, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000560; Funk ML, 2002, J VIRAL HEPATITIS, V9, P52, DOI 10.1046/j.1365-2893.2002.00304.x; Graham MJ, 2013, CIRC RES, V112, P1479, DOI 10.1161/CIRCRESAHA.111.300367; Kim GA, 2014, GUT, V63, P1325, DOI 10.1136/gutjnl-2013-305517; Lam YF, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.51; Levin AA, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P201; Lok AS, 2017, HEPATOLOGY, V66, P1296, DOI 10.1002/hep.29323; Polaris Observatory Collaborators, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Seto WK, 2013, J HEPATOL, V59, P709, DOI 10.1016/j.jhep.2013.06.007; Sheehan JP, 2001, BIOCHEMISTRY-US, V40, P4980, DOI 10.1021/bi002396x; Sheehan JP, 1998, BLOOD, V92, P1617, DOI 10.1182/blood.V92.5.1617.417k13_1617_1625; Shen LJ, 2014, J PHARMACOL EXP THER, V351, P709, DOI 10.1124/jpet.114.219378; Swayze E. E., 2014, GOOGLE PATENTS; Tan A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021428; Wong DKH, 2013, CLIN GASTROENTEROL H, V11, P1004, DOI 10.1016/j.cgh.2013.01.026; Wong D, 2018, LIVER INT, V38, P1760, DOI 10.1111/liv.13716; Wooddell CI, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0241; You S., 2020, LP41 AASLD LP41; Yuen M -F, 2020, J HEPATOL, V73, pS19; Yuen M-F., 2020, HEPATOL INT, V14, pS20; Yuen MF, 2019, HEPATOLOGY, V70, p437A; Yuen MF, 2008, GASTROENTEROLOGY, V135, P1192, DOI 10.1053/j.gastro.2008.07.008	30	26	27	6	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1725	+		10.1038/s41591-021-01513-4	http://dx.doi.org/10.1038/s41591-021-01513-4		OCT 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642494	Green Published, hybrid			2022-12-27	WOS:000706587600007
J	Marks, M; Cohen, IG				Marks, Mason; Cohen, I. Glenn			Psychedelic therapy: a roadmap for wider acceptance and utilization	NATURE MEDICINE			English	Editorial Material								Psychedelics have shown great promise in treating mental-health conditions, but their use is severely limited by legal obstacles, which could be overcome.	[Marks, Mason; Cohen, I. Glenn] Harvard Law Sch, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Project Psychedel Law & Regulat POPLAR, Cambridge, MA 02138 USA; [Marks, Mason] Univ New Hampshire, Franklin Pierce Sch Law, Concord, NH 03301 USA; [Cohen, I. Glenn] Harvard Law Sch, Cambridge, MA USA	Harvard University; University System Of New Hampshire; University of New Hampshire; Harvard University	Marks, M (corresponding author), Harvard Law Sch, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Project Psychedel Law & Regulat POPLAR, Cambridge, MA 02138 USA.; Marks, M (corresponding author), Univ New Hampshire, Franklin Pierce Sch Law, Concord, NH 03301 USA.	mmarks@law.harvard.edu		Cohen, Ivan/0000-0002-0223-3305; Marks, Mason/0000-0002-4310-9183	Saisei Foundation	Saisei Foundation	We are grateful for the support of the Saisei Foundation and thank E. Wright Clayton and R. Sachs for helpful comments on an earlier draft of this article.	Acker L., 2021, OREGONIAN; Agin-Liebes GI, 2020, J PSYCHOPHARMACOL, V34, P155, DOI 10.1177/0269881119897615; Angermayer, LINKEDIN; [Anonymous], US Patent, Patent No. [10,947,257, 10947257]; [Anonymous], 2019, MEDSCAPE; Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285; de Veen BTH, 2017, EXPERT REV NEUROTHER, V17, P203, DOI 10.1080/14737175.2016.1220834; Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513; Hickey, 2020, C RES SERV; Johnson MW, 2018, NEUROPHARMACOLOGY, V142, P143, DOI 10.1016/j.neuropharm.2018.05.012; Lidsky, 2019, STAT 1 OPINION; Love S., 2021, MOTHERBOARD; Marks M., 2020, GIZMODO; Marks M, 2018, NYU J LEGIS PUBLIC P, V21, P69; Marks MM, 2020, ADMIN LAW REV, V72, P649; McCall, 2020, NAT MED; Michaels TI, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1824-6; Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5; Richert L., 2021, PSYCHOL TODAY; Schreck, 2011, MAPS B, V21, P26; van Amsterdam J, 2011, REGUL TOXICOL PHARM, V59, P423, DOI 10.1016/j.yrtph.2011.01.006	21	10	10	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1669	1671		10.1038/s41591-021-01530-3	http://dx.doi.org/10.1038/s41591-021-01530-3		OCT 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34608331	Bronze			2022-12-27	WOS:000703378900001
J	Lewis, GA; Dodd, S; Clayton, D; Bedson, E; Eccleson, H; Schelbert, EB; Naish, JH; Jimenez, BD; Williams, SG; Cunnington, C; Ahmed, FZ; Cooper, A; Viswesvaraiah, R; Russell, S; McDonagh, T; Williamson, PR; Miller, CA				Lewis, Gavin A.; Dodd, Susanna; Clayton, Dannii; Bedson, Emma; Eccleson, Helen; Schelbert, Erik B.; Naish, Josephine H.; Jimenez, Beatriz Duran; Williams, Simon G.; Cunnington, Colin; Ahmed, Fozia Zahir; Cooper, Anne; Viswesvaraiah, Rajavarma; Russell, Stuart; McDonagh, Theresa; Williamson, Paula R.; Miller, Christopher A.			Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial	NATURE MEDICINE			English	Article							MYOCARDIAL FIBROSIS; PRECISION MEDICINE; COLLAGEN; DISEASE; PERHEXILINE; DYSFUNCTION; REGRESSION; STIFFNESS; CAPACITY; EXERCISE	In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent without hemodynamic effect, is efficacious and safe for the treatment of HFpEF is unknown. In this double-blind, phase 2 trial (NCT02932566), we enrolled patients with heart failure, an ejection fraction of 45% or higher and elevated levels of natriuretic peptides. Eligible patients underwent cardiovascular magnetic resonance and those with evidence of myocardial fibrosis, defined as a myocardial extracellular volume of 27% or greater, were randomly assigned to receive pirfenidone or placebo for 52 weeks. Forty-seven patients were randomized to each of the pirfenidone and placebo groups. The primary outcome was change in myocardial extracellular volume, from baseline to 52 weeks. In comparison to placebo, pirfenidone reduced myocardial extracellular volume (between-group difference, -1.21%; 95% confidence interval, -2.12 to -0.31; P = 0.009), meeting the predefined primary outcome. Twelve patients (26%) in the pirfenidone group and 14 patients (30%) in the placebo group experienced one or more serious adverse events. The most common adverse events in the pirfenidone group were nausea, insomnia and rash. In conclusion, among patients with HFpEF and myocardial fibrosis, administration of pirfenidone for 52 weeks reduced myocardial fibrosis. The favorable effects of pirfenidone in patients with HFpEF will need to be confirmed in future trials.	[Lewis, Gavin A.; Naish, Josephine H.; Ahmed, Fozia Zahir; Miller, Christopher A.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Med Sci,Div Cardiovasc Sci, Manchester, Lancs, England; [Lewis, Gavin A.; Jimenez, Beatriz Duran; Williams, Simon G.; Cunnington, Colin; Ahmed, Fozia Zahir; Miller, Christopher A.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Dodd, Susanna; Williamson, Paula R.] Univ Liverpool, Dept Hlth Data Sci, Liverpool Hlth Partners, Liverpool, Merseyside, England; [Clayton, Dannii; Bedson, Emma; Eccleson, Helen] Univ Liverpool, Alder Hey Childrens NHS Fdn Trust, Liverpool Clin Trials Ctr, Inst Child Hlth, Liverpool, Merseyside, England; [Schelbert, Erik B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Schelbert, Erik B.] UPMC Cardiovasc Magnet Resonance Ctr, Heart & Vasc Inst, Pittsburgh, PA USA; [Schelbert, Erik B.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Cooper, Anne] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Viswesvaraiah, Rajavarma] Stockport NHS Fdn Trust, Stepping Hill Hosp, Stockport, Lancs, England; [Russell, Stuart] East Cheshire NHS Trust, Macclesfield, Cheshire, England; [McDonagh, Theresa] Kings Coll Hosp London, London, England; [Miller, Christopher A.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol,Div Cell Matrix Biol & Regenerat Med,Wel, Manchester, Lancs, England	University of Manchester; University of Liverpool; Alder Hey Children's NHS Foundation Trust; University of Liverpool; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Salford Royal NHS Foundation Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Manchester	Miller, CA (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Med Sci,Div Cardiovasc Sci, Manchester, Lancs, England.; Miller, CA (corresponding author), Manchester Univ NHS Fdn Trust, Manchester, Lancs, England.; Miller, CA (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol,Div Cell Matrix Biol & Regenerat Med,Wel, Manchester, Lancs, England.	Christopher.Miller@manchester.ac.uk		Lewis, Gavin/0000-0001-6754-836X; Cunnington, Colin/0000-0001-8829-5920; Clayton, Dannii/0000-0003-3535-3466; Miller, Christopher/0000-0002-5957-7088	United Kingdom National Institute for Health Research [CS-2015-15-003]; Manchester University NHS Foundation Trust	United Kingdom National Institute for Health Research(National Institute for Health Research (NIHR)); Manchester University NHS Foundation Trust	We thank the members of the Trial Steering Committee, A.L. Clark (Chair), R. Gardner, C. Graham and N. Hartshorne-Evans, and members of the Independent Data and Safety Monitoring Committee, R. Emsley, S. Garg and M. Mamas. This study was funded by the United Kingdom National Institute for Health Research (grant no. CS-2015-15-003, C.A.M.). The funder of the study had no role in the design and conduct of the study, the collection, management, analysis and interpretation of the data, the preparation, review or approval of the manuscript, and the decision to submit the manuscript for publication. Manchester University NHS Foundation Trust acted as the study sponsor, and participated in the design, conduct and management of the study. The sponsor conducted a factual accuracy check of this manuscript, but had no role in the collection, analysis or interpretation of the data, the preparation of the manuscript or the decision to submit the manuscript for publication.	Abozguia K, 2010, CIRCULATION, V122, P1562, DOI 10.1161/CIRCULATIONAHA.109.934059; Antman EM, 2016, NAT REV CARDIOL, V13, P591, DOI 10.1038/nrcardio.2016.101; Beadle RM, 2015, JACC-HEART FAIL, V3, P202, DOI 10.1016/j.jchf.2014.09.009; Beadle RM, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-140; Branch KR, 2019, CIRCULATION, V140, P529, DOI 10.1161/CIRCULATIONAHA.119.039609; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; Butler J, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.116.003800; Diez J, 2002, CIRCULATION, V105, P2512, DOI 10.1161/01.CIR.0000017264.66561.3D; Garg R, 2015, DIABETES, V64, P236, DOI 10.2337/db14-0670; Giri SN, 2004, CANCER CHEMOTH PHARM, V53, P141, DOI 10.1007/s00280-003-0703-z; Hudsmith LE, 2009, JACC-CARDIOVASC IMAG, V2, P87, DOI 10.1016/j.jcmg.2008.08.005; Izawa H, 2005, CIRCULATION, V112, P2940, DOI 10.1161/CIRCULATIONAHA.105.571653; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; Lee KW, 2006, CIRCULATION, V114, P1703, DOI 10.1161/CIRCULATIONAHA.106.624320; Lewis GA, 2019, CARDIOVASC DRUG THER, V33, P461, DOI 10.1007/s10557-019-06876-y; Lewis GA, 2017, J AM COLL CARDIOL, V70, P2186, DOI 10.1016/j.jacc.2017.09.006; Li CD, 2017, SCI REP-UK, V7, DOI 10.1038/srep41331; Lopez B, 2012, HYPERTENSION, V60, P677, DOI 10.1161/HYPERTENSIONAHA.112.196113; Macias-Barragan J, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-16; Maurer MS, 2018, NEW ENGL J MED, V379, P1007, DOI 10.1056/NEJMoa1805689; Miric G, 2001, BRIT J PHARMACOL, V133, P687, DOI 10.1038/sj.bjp.0704131; Mirkovic S, 2002, BRIT J PHARMACOL, V135, P961, DOI 10.1038/sj.bjp.0704539; Nguyen DT, 2010, HEART RHYTHM, V7, P1438, DOI 10.1016/j.hrthm.2010.04.030; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Obokata M, 2017, CIRCULATION, V135, P825, DOI 10.1161/CIRCULATIONAHA.116.024822; Phan TT, 2009, J AM COLL CARDIOL, V54, P402, DOI 10.1016/j.jacc.2009.05.012; Redfield MM, 2016, NEW ENGL J MED, V375, P1868, DOI 10.1056/NEJMcp1511175; Rommel KP, 2016, J AM COLL CARDIOL, V67, P1815, DOI 10.1016/j.jacc.2016.02.018; Roy C, 2018, J CARDIOVASC MAGN R, V20, DOI 10.1186/s12968-018-0477-4; Santos M, 2015, CIRC-HEART FAIL, V8, P749, DOI 10.1161/CIRCHEARTFAILURE.115.002161; Schelbert EB, 2017, JAMA CARDIOL, V2, P995, DOI 10.1001/jamacardio.2017.2511; Shah SJ, 2017, J CARDIOVASC TRANSL, V10, P322, DOI 10.1007/s12265-017-9759-8; Sharifov OF, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002530; Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Treibel TA, 2018, J AM COLL CARDIOL, V71, P860, DOI 10.1016/j.jacc.2017.12.035; Vaduganathan M, 2013, NAT REV CARDIOL, V10, P85, DOI 10.1038/nrcardio.2012.181; Van Erp C, 2006, MUSCLE NERVE, V34, P327, DOI 10.1002/mus.20590; Wang YL, 2013, CARDIOLOGY, V126, P1, DOI 10.1159/000351179; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4; Yamazaki T, 2012, HYPERTENS RES, V35, P34, DOI 10.1038/hr.2011.139; Zile MR, 2015, CIRCULATION, V131, P1247, DOI 10.1161/CIRCULATIONAHA.114.013215	42	35	37	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1477	+		10.1038/s41591-021-01452-0	http://dx.doi.org/10.1038/s41591-021-01452-0		AUG 2021	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385704	Green Submitted			2022-12-27	WOS:000684533600003
J	Vogel, JW; Young, AL; Oxtoby, NP; Smith, R; Ossenkoppele, R; Strandberg, OT; La Joie, R; Aksman, LM; Grothe, MJ; Iturria-Medina, Y; Pontecorvo, MJ; Devous, MD; Rabinovici, GD; Alexander, DC; Lyoo, CH; Evans, AC; Hansson, O				Vogel, Jacob W.; Young, Alexandra L.; Oxtoby, Neil P.; Smith, Ruben; Ossenkoppele, Rik; Strandberg, Olof T.; La Joie, Renaud; Aksman, Leon M.; Grothe, Michel J.; Iturria-Medina, Yasser; Pontecorvo, Michael J.; Devous, Michael D.; Rabinovici, Gil D.; Alexander, Daniel C.; Lyoo, Chul Hyoung; Evans, Alan C.; Hansson, Oskar			Four distinct trajectories of tau deposition identified in Alzheimer's disease	NATURE MEDICINE			English	Article							DEFINED SUBTYPES; NEUROFIBRILLARY PATHOLOGY; COGNITIVE IMPAIRMENT; PET PATTERNS; ASSOCIATION; VARIABILITY	Systematic characterization of longitudinal tau variability in human Alzheimer's disease using an unbiased subtyping algorithm reveals four trajectories of tau deposition with distinct clinical features. Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, although recent work has demonstrated substantial variability in the population with AD. Using tau-positron emission tomography scans from 1,612 individuals, we identified 4 distinct spatiotemporal trajectories of tau pathology, ranging in prevalence from 18 to 33%. We replicated previously described limbic-predominant and medial temporal lobe-sparing patterns, while also discovering posterior and lateral temporal patterns resembling atypical clinical variants of AD. These 'subtypes' were stable during longitudinal follow-up and were replicated in a separate sample using a different radiotracer. The subtypes presented with distinct demographic and cognitive profiles and differing longitudinal outcomes. Additionally, network diffusion models implied that pathology originates and spreads through distinct corticolimbic networks in the different subtypes. Together, our results suggest that variation in tau pathology is common and systematic, perhaps warranting a re-examination of the notion of 'typical AD' and a revisiting of tau pathological staging.	[Vogel, Jacob W.; Iturria-Medina, Yasser; Evans, Alan C.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Young, Alexandra L.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Neuroimaging, London, England; [Oxtoby, Neil P.; Aksman, Leon M.; Alexander, Daniel C.] UCL, Ctr Med Image Comp, London, England; [Oxtoby, Neil P.; Alexander, Daniel C.] UCL, Dept Comp Sci, London, England; [Smith, Ruben; Ossenkoppele, Rik; Strandberg, Olof T.; Hansson, Oskar] Lund Univ, Clin Memory Res Unit, Lund, Sweden; [Smith, Ruben] Sickle Univ Hosp, Dept Neurol, Lund, Sweden; [Ossenkoppele, Rik] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam Neurosci, Dept Neurol,Alzheimer Ctr Amsterdam, Amsterdam, Netherlands; [La Joie, Renaud; Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, Memory & Aging Ctr, San Francisco, CA USA; [Aksman, Leon M.] UCL, Dept Med Phys & Biomed Engn, London, England; [Grothe, Michel J.] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden; [Grothe, Michel J.] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Seville, Spain; [Pontecorvo, Michael J.; Devous, Michael D.] Avid Radiopharmaceut, Philadelphia, PA USA; [Rabinovici, Gil D.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Lyoo, Chul Hyoung] Yonsei Univ, Gangnam Severance Hosp, Dept Neurol, Coll Med, Seoul, South Korea; [Hansson, Oskar] Skane Univ Hosp, Memory Clin, Malmo, Sweden	McGill University; University of London; King's College London; University of London; University College London; University of London; University College London; Lund University; Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; University of London; University College London; University of Gothenburg; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; University of California System; University of California San Francisco; Yonsei University; Yonsei University Health System; Lund University; Skane University Hospital	Vogel, JW (corresponding author), McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.; Hansson, O (corresponding author), Lund Univ, Clin Memory Res Unit, Lund, Sweden.; Hansson, O (corresponding author), Skane Univ Hosp, Memory Clin, Malmo, Sweden.	jacob.vogel@mail.mcgill.ca; oskar.hansson@med.lu.se	Hsiung, Robin/AAT-1661-2021; Preda, Adrian/K-8889-2013; Ossenkoppele, Rik/J-5826-2013; Hansson, Oskar/A-7134-2013; Grothe, Michel/S-7374-2018	Hsiung, Robin/0000-0002-8017-0856; Preda, Adrian/0000-0003-3373-2438; Hansson, Oskar/0000-0001-8467-7286; Grothe, Michel/0000-0003-2600-9022; Alexander, Daniel/0000-0003-2439-350X; Lyoo, Chul Hyoung/0000-0003-2231-672X; La Joie, Renaud/0000-0003-2581-8100; Ossenkoppele, Rik/0000-0003-1584-7477; Miller, Bruce/0000-0002-2152-4220; Snyder, Peter/0000-0003-0555-4654; Vogel, Jacob/0000-0001-6394-9940; Iturria Medina, Yasser/0000-0002-9345-0347; Ponto, Laura/0000-0003-1197-6714; Senjem, Matthew/0000-0001-9308-9275; Smith, Ruben/0000-0001-7147-0112; Obisesan, Thomas Olabode/0000-0002-0291-512X	government of Canada through a tri-council Vanier Canada Graduate Doctoral fellowship from the McGill Centre for Integrative Neuroscience and the Healthy Brains, Healthy Lives initiative; National Institutes of Health (NIH) [T32MH019112]; Medical Research Council Skills Development Fellowship [MR/T027800/1]; UK Research and Innovation Future Leaders Fellow [MR/S03546X/1]; UK National Institute for Health Research University College London Hospitals Biomedical Research Centre; Engineering and Physical Sciences Research Council [EP/M020533/1]; Miguel Servet program [CP19/00031]; Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional [PI20/00613]; NIH [K99AG065501]; European Union's Horizon 2020 research and innovation programme [666992]; Swedish Research Council [2016-00906]; Knut and Alice Wallenberg Foundation [2017-0383]; Marianne and Marcus Wallenberg Foundation [2015.0125]; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University; Swedish Alzheimer's Foundation [AF-939932]; Swedish Brain Foundation [FO2019-0326]; Swedish Parkinson Foundation [1280/20]; Skane University Hospital Foundation [2020-O000028]; Regionalt Forskningsstod [2020-0314]; Swedish Federal Government under the ALF agreement [2018-Projekt0279]; Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [NRF2018R1D1A1B07049386, NRF2020R1F1A1076154]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HI18C1159]; National Institute on Aging (NIA) [R01 AG045611, P50 AG23501, P01 AG019724]; GE Healthcare; ADNI (NIH) [U01 AG024904]; Department of Defense ADNI [W81XWH-12-2-0012]; NIA; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; Bioclinica; Biogen; Bristol Myers Squibb; CereSpir; Cogstate; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; EUROIMMUN; F. Hoffmann-La Roche; Genentech; Fujirebio; IXICO; Janssen Alzheimer Immunotherapy Research Development; Johnson & Johnson Pharmaceutical Research Development; Lumosity; Lundbeck; Merck; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research	government of Canada through a tri-council Vanier Canada Graduate Doctoral fellowship from the McGill Centre for Integrative Neuroscience and the Healthy Brains, Healthy Lives initiative; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council Skills Development Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Research and Innovation Future Leaders Fellow; UK National Institute for Health Research University College London Hospitals Biomedical Research Centre; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Miguel Servet program; Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union's Horizon 2020 research and innovation programme; Swedish Research Council(Swedish Research CouncilEuropean Commission); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Marianne and Marcus Wallenberg Foundation; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University; Swedish Alzheimer's Foundation; Swedish Brain Foundation; Swedish Parkinson Foundation; Skane University Hospital Foundation; Regionalt Forskningsstod; Swedish Federal Government under the ALF agreement; Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education(Ministry of Education (MOE), Republic of KoreaNational Research Foundation of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea; National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); GE Healthcare(General ElectricGE Healthcare); ADNI (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense ADNI(United States Department of Defense); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); AbbVie(AbbVie); Alzheimer's Association(Alzheimer's Association); Alzheimer's Drug Discovery Foundation; Araclon Biotech; Bioclinica; Biogen(Biogen); Bristol Myers Squibb(Bristol-Myers Squibb); CereSpir; Cogstate(CogState Limited); Eisai(Eisai Co Ltd); Elan Pharmaceuticals; Eli Lilly and Company(Eli Lilly); EUROIMMUN; F. Hoffmann-La Roche(Hoffmann-La Roche); Genentech(Roche HoldingGenentech); Fujirebio; IXICO; Janssen Alzheimer Immunotherapy Research Development; Johnson & Johnson Pharmaceutical Research Development(Johnson & JohnsonJohnson & Johnson USA); Lumosity; Lundbeck(Lundbeck Corporation); Merck(Merck & Company); Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation(Novartis); Pfizer(Pfizer); Piramal Imaging; Servier(Servier); Takeda Pharmaceutical Company(Takeda Pharmaceutical Company Ltd); Transition Therapeutics; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank M. Chakravarty, B. Misic, P. Bellec, P. Rosa-Neto, A. Dagher, E. Hamel and W. Seeley for feedback during the composition of this manuscript. J.W.V. acknowledges support from the government of Canada through a tri-council Vanier Canada Graduate Doctoral fellowship from the McGill Centre for Integrative Neuroscience and the Healthy Brains, Healthy Lives initiative, and from the National Institutes of Health (NIH) (no. T32MH019112). A.L.Y. is supported by a Medical Research Council Skills Development Fellowship (MR/T027800/1). N.P.O. is a UK Research and Innovation Future Leaders Fellow (no. MR/S03546X/1). N.P.O. and D.C.A. acknowledge support from the UK National Institute for Health Research University College London Hospitals Biomedical Research Centre, and D.C.A. acknowledges support from the Engineering and Physical Sciences Research Council grant no. EP/M020533/1. M.J.G. is supported by the Miguel Servet program (no. CP19/00031) and a research grant (no. PI20/00613) of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional. R.L.J. acknowledges support from the NIH (no. K99AG065501). This project received funding from the European Union's Horizon 2020 research and innovation programme under grant no. 666992. The BioFINDER studies are supported by the Swedish Research Council (no. 2016-00906), the Knut and Alice Wallenberg Foundation (no. 2017-0383), the Marianne and Marcus Wallenberg Foundation (no. 2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer's Foundation (no. AF-939932), the Swedish Brain Foundation (no. FO2019-0326), the Swedish Parkinson Foundation (no. 1280/20), the Skane University Hospital Foundation (no. 2020-O000028), Regionalt Forskningsstod (no. 2020-0314) and the Swedish Federal Government under the ALF agreement (no. 2018-Projekt0279). The Tau PET study in Gangnam Severance Hospital was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (nos. NRF2018R1D1A1B07049386 and NRF2020R1F1A1076154) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health and Welfare, Republic of Korea (grant no. HI18C1159). We also thank B. L. Miller, H. J. Rosen, M. Gorno Tempini and W. Jagust for supporting the UCSF tau-PET studies, which were funded through the following sources: National Institute on Aging (NIA) no. R01 AG045611 (G.D.R.), no. P50 AG23501 (B.L.M., H.J.R., G.D.R.), no. P01 AG019724 (B.L.M., H.J.R., G.D.R.). The precursor of 18F-flortaucipir was provided by AVID Radiopharmaceuticals. The precursor of 18F-flutemetamol was sponsored by GE Healthcare. The precursor of 18F-RO948 was provided by Roche. Data collection and sharing for this project were funded by ADNI (NIH grant no. U01 AG024904) and Department of Defense ADNI (award no. W81XWH-12-2-0012). ADNI is funded by the NIA, the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; Bioclinica; Biogen; Bristol Myers Squibb; CereSpir; Cogstate; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; EUROIMMUN; F.; Hoffmann-La Roche and its affiliated company Genentech; Fujirebio; GE Healthcare; IXICO; Janssen Alzheimer Immunotherapy Research Development; Johnson & Johnson Pharmaceutical Research Development; Lumosity; Lundbeck; Merck; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Finally, we thank all participants of this study and the families and caregivers of the patients included for their support in volunteering data for this study. Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu/).As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.	Al-Shaikh FSH, 2020, JAMA NEUROL, V77, P225, DOI 10.1001/jamaneurol.2019.3606; Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Aoyagi A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat8462; Baker SL, 2019, J NUCL MED, V60, P1444, DOI 10.2967/jnumed.118.224113; Bejanin A, 2017, BRAIN, V140, P3286, DOI 10.1093/brain/awx243; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Cho H, 2018, NEUROBIOL AGING, V68, P76, DOI 10.1016/j.neurobiolaging.2018.04.007; Craddock C., 2013, FRONT NEUROINFORM, DOI DOI 10.3389/CONF.FNINF.2014.08.00117; Crist A. M, 2020, LEVERAGING SELECTIVE, DOI [10.1101/2020.12.18.423469, DOI 10.1101/2020.12.18.423469]; Crutch SJ, 2017, ALZHEIMERS DEMENT, V13, P870, DOI 10.1016/j.jalz.2017.01.014; Dong AY, 2017, BRAIN, V140, P735, DOI 10.1093/brain/aww319; Drummond E, 2017, ACTA NEUROPATHOL, V133, P933, DOI 10.1007/s00401-017-1691-0; Dujardin S, 2020, NAT MED, V26, P1256, DOI 10.1038/s41591-020-0938-9; Ferreira D, 2020, NEUROLOGY, V94, P436, DOI 10.1212/WNL.0000000000009058; Fleisher AS, 2020, JAMA NEUROL, V77, P829, DOI 10.1001/jamaneurol.2020.0528; Franzmeier N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd1327; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13787-x; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; Hyman BT, 2014, NEURON, V82, P1189, DOI 10.1016/j.neuron.2014.06.004; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Iturria-Medina Y, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003956; Jack CR, 2020, BRAIN, V143, P3136, DOI 10.1093/brain/awaa248; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Koedam ELGE, 2010, J ALZHEIMERS DIS, V19, P1401, DOI 10.3233/JAD-2010-1337; La Joie R, 2021, NEUROLOGY, V96, pE650, DOI 10.1212/WNL.0000000000011270; La Joie R, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aau5732; Lemoine Laetitia, 2018, Alzheimers Dement (Amst), V10, P232, DOI 10.1016/j.dadm.2018.01.007; Leng K, 2021, NAT NEUROSCI, V24, P276, DOI 10.1038/s41593-020-00764-7; Leuzy A, 2020, JAMA NEUROL, V77, P955, DOI 10.1001/jamaneurol.2020.0989; Lowe VJ, 2020, ALZHEIMERS DEMENT, V16, P561, DOI 10.1016/j.jalz.2019.09.079; Machado A, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00620-7; Marshall GA, 2007, J GERIATR PSYCH NEUR, V20, P29, DOI 10.1177/0891988706297086; McKee AC, 2006, J NEUROPATH EXP NEUR, V65, P621, DOI 10.1097/00005072-200606000-00010; Miller ZA, 2019, BRAIN COMMUN, V1, DOI 10.1093/braincomms/fcz027; MUKAETOVALADINSKA EB, 1992, DEMENTIA, V3, P61, DOI 10.1159/000106996; Murray ME, 2011, LANCET NEUROL, V10, P785, DOI 10.1016/S1474-4422(11)70156-9; Noh Y, 2014, NEUROLOGY, V83, P1936, DOI 10.1212/WNL.0000000000001003; Ossenkoppele R, 2020, ALZHEIMERS DEMENT, V16, P335, DOI 10.1016/j.jalz.2019.08.201; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Ossenkoppele R, 2016, BRAIN, V139, P1551, DOI 10.1093/brain/aww027; Ossenkoppele R, 2015, BRAIN, V138, P2732, DOI 10.1093/brain/awv191; Pikkarainen M, 2009, J NEUROPATH EXP NEUR, V68, P653, DOI 10.1097/NEN.0b013e3181a6ee45; Pontecorvo MJ, 2019, BRAIN, V142, P1723, DOI 10.1093/brain/awz090; Risacher SL, 2017, NEUROLOGY, V89, P2176, DOI 10.1212/WNL.0000000000004670; Rogalski E, 2008, ARCH NEUROL-CHICAGO, V65, P244, DOI 10.1001/archneurol.2007.34; Scholl M, 2016, NEURON, V89, P971, DOI 10.1016/j.neuron.2016.01.028; Schwarz AJ, 2016, BRAIN, V139, P1539, DOI 10.1093/brain/aww023; Smith R, 2020, EUR J NUCL MED MOL I, V47, P342, DOI 10.1007/s00259-019-04496-0; Smith R, 2019, JAMA NEUROL, V76, P310, DOI 10.1001/jamaneurol.2018.3692; Soleimani-Meigooni DN, 2020, BRAIN, V143, P3477, DOI 10.1093/brain/awaa276; Sun NB, 2019, NEUROIMAGE, V201, DOI 10.1016/j.neuroimage.2019.116043; Tam A, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz055; Vogel JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15701-2; Vogel JW, 2019, HUM BRAIN MAPP, V40, P638, DOI 10.1002/hbm.24401; Whitwell JL, 2019, ALZHEIMERS DEMENT, V15, P675, DOI 10.1016/j.jalz.2018.12.016; Whitwell JL, 2012, LANCET NEUROL, V11, P868, DOI 10.1016/S1474-4422(12)70200-4; Young AL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05892-0	60	128	128	17	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					871	+		10.1038/s41591-021-01309-6	http://dx.doi.org/10.1038/s41591-021-01309-6		APR 2021	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33927414	Green Accepted, Green Submitted			2022-12-27	WOS:000645518600001
J	Mac Aogain, M; Narayana, JK; Tiew, PY; Ali, NABM; Yong, VFL; Jaggi, TK; Lim, AYH; Keir, HR; Dicker, AJ; Thng, KX; Tsang, A; Ivan, FX; Poh, ME; Oriano, M; Aliberti, S; Blasi, F; Low, TB; Ong, TH; Oliver, B; Giam, YH; Tee, A; Koh, MS; Abisheganaden, JA; Tsaneva-Atanasova, K; Chalmers, JD; Chotirmall, SH				Mac Aogain, Micheal; Narayana, Jayanth Kumar; Tiew, Pei Yee; Ali, Nur A'tikah Binte Mohamed; Yong, Valerie Fei Lee; Jaggi, Tavleen Kaur; Lim, Albert Yick Hou; Keir, Holly R.; Dicker, Alison J.; Thng, Kai Xian; Tsang, Akina; Ivan, Fransiskus Xaverius; Poh, Mau Ern; Oriano, Martina; Aliberti, Stefano; Blasi, Francesco; Low, Teck Boon; Ong, Thun How; Oliver, Brian; Giam, Yan Hui; Tee, Augustine; Koh, Mariko Siyue; Abisheganaden, John Arputhan; Tsaneva-Atanasova, Krasimira; Chalmers, James D.; Chotirmall, Sanjay H.			Integrative microbiomics in bronchiectasis exacerbations	NATURE MEDICINE			English	Article							IMPACT; SPUTUM	Bronchiectasis, a progressive chronic airway disease, is characterized by microbial colonization and infection. We present an approach to the multi-biome that integrates bacterial, viral and fungal communities in bronchiectasis through weighted similarity network fusion (https://integrative-microbiomics.ntu.edu.sg). Patients at greatest risk of exacerbation have less complex microbial co-occurrence networks, reduced diversity and a higher degree of antagonistic interactions in their airway microbiome. Furthermore, longitudinal interactome dynamics reveals microbial antagonism during exacerbation, which resolves following treatment in an otherwise stable multi-biome. Assessment of the Pseudomonas interactome shows that interaction networks, rather than abundance alone, are associated with exacerbation risk, and that incorporation of microbial interaction data improves clinical prediction models. Shotgun metagenomic sequencing of an independent cohort validated the multi-biome interactions detected in targeted analysis and confirmed the association with exacerbation. Integrative microbiomics captures microbial interactions to determine exacerbation risk, which cannot be appreciated by the study of a single microbial group. Antibiotic strategies probably target the interaction networks rather than individual microbes, providing a fresh approach to the understanding of respiratory infection.	[Mac Aogain, Micheal; Narayana, Jayanth Kumar; Tiew, Pei Yee; Ali, Nur A'tikah Binte Mohamed; Yong, Valerie Fei Lee; Jaggi, Tavleen Kaur; Thng, Kai Xian; Tsang, Akina; Ivan, Fransiskus Xaverius; Chotirmall, Sanjay H.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Tiew, Pei Yee; Ong, Thun How; Koh, Mariko Siyue] Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore; [Lim, Albert Yick Hou; Abisheganaden, John Arputhan] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, Singapore, Singapore; [Keir, Holly R.; Dicker, Alison J.; Giam, Yan Hui; Chalmers, James D.] Univ Dundee, Sch Med, Ninewells Hosp & Med Sch, Dundee, Scotland; [Poh, Mau Ern] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia; [Oriano, Martina; Aliberti, Stefano; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit, Milan, Italy; [Oriano, Martina; Aliberti, Stefano; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cyst Fibrosis Adult Ctr, Milan, Italy; [Oriano, Martina; Aliberti, Stefano; Blasi, Francesco] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Low, Teck Boon; Tee, Augustine] Changi Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore; [Oliver, Brian] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Oliver, Brian] Univ Technol Sydney, Sch Life Sci, Sydney, NSW, Australia; [Tsaneva-Atanasova, Krasimira] Univ Exeter, Dept Math, Coll Engn Math & Phys Sci, Exeter, Devon, England; [Tsaneva-Atanasova, Krasimira] Univ Exeter, Living Syst Inst, Coll Engn Math & Phys Sci, Exeter, Devon, England	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Singapore General Hospital; Tan Tock Seng Hospital; University of Dundee; Universiti Malaya; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Changi General Hospital; University of Sydney; Woolcock Institute of Medical Research; University of Technology Sydney; University of Exeter; University of Exeter	Chotirmall, SH (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.	schotirmall@ntu.edu.sg	Narayana, Jayanth Kumar/AAQ-3712-2021; Oliver, Brian/E-7939-2010; tiew, Pei yee/AFQ-3311-2022; Aogáin, Micheál Mac/M-6782-2013; Chotirmall, Sanjay Haresh/K-4127-2015; POH, MAU-ERN/A-3442-2017; Blasi, Francesco/O-5885-2017	Narayana, Jayanth Kumar/0000-0001-8794-9048; Oliver, Brian/0000-0002-7122-9262; tiew, Pei yee/0000-0002-6346-2072; Aogáin, Micheál Mac/0000-0002-1726-7700; Chotirmall, Sanjay Haresh/0000-0003-0417-7607; POH, MAU-ERN/0000-0003-0971-2795; Keir, Holly Rachael/0000-0001-7197-701X; Tsaneva-Atanasova, Krasimira/0000-0002-6294-7051; Koh, Mariko Siyue/0000-0002-1230-0129; lim, yick hou/0000-0003-4917-8144; Dicker, Alison/0000-0002-4791-3259; Yong, Valerie/0000-0003-4243-3659; Chalmers, James/0000-0001-5514-7868; Jaggi, Tavleen Kaur/0000-0003-0097-8853; Blasi, Francesco/0000-0002-2285-9970	Singapore Ministry of Health's National Medical Research Council under its Transition Award [NMRC/TA/0048/2016]; Clinician-Scientist Individual Research Grant [MOH-000141]; NTU Integrated Medical, Biological and Environmental Life Sciences (NIMBELS) [NIM/03/2018]; British Lung Foundation through the GSK/British Lung Foundation Chair of Respiratory Research; Scottish Government Chief Scientist Office [SCAF/17/03]; EPSRC [EP/N014391/1]	Singapore Ministry of Health's National Medical Research Council under its Transition Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Clinician-Scientist Individual Research Grant; NTU Integrated Medical, Biological and Environmental Life Sciences (NIMBELS); British Lung Foundation through the GSK/British Lung Foundation Chair of Respiratory Research; Scottish Government Chief Scientist Office; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This research is supported by the Singapore Ministry of Health's National Medical Research Council under its Transition Award (NMRC/TA/0048/2016 to S.H.C.); the Clinician-Scientist Individual Research Grant (MOH-000141 to S.H.C.); NTU Integrated Medical, Biological and Environmental Life Sciences (NIMBELS) (NIM/03/2018 to S.H.C.); the British Lung Foundation through the GSK/British Lung Foundation Chair of Respiratory Research (to J.D.C.) and the Scottish Government Chief Scientist Office (SCAF/17/03). K.T.-A. gratefully acknowledges the financial support of the EPSRC via grant EP/N014391/1.	AITCHISON J, 1982, J ROY STAT SOC B MET, V44, P139; Ali NABM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204991; Aliberti S, 2016, EUR RESPIR J, V47, P1113, DOI 10.1183/13993003.01899-2015; Alneberg J, 2014, NAT METHODS, V11, P1144, DOI [10.1038/NMETH.3103, 10.1038/nmeth.3103]; Aragon T.J., PACKAGE EPITOOLS; Araujo D, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01953-2017; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Budden KF, 2019, LANCET RESP MED, V7, P907, DOI 10.1016/S2213-2600(18)30510-1; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chalmers JD, 2019, LANCET RESP MED, V7, P845, DOI 10.1016/S2213-2600(19)30191-2; Chalmers JD, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0042-3; Chalmers JD, 2018, LANCET RESP MED, V6, P715, DOI 10.1016/S2213-2600(18)30053-5; Chalmers JD, 2018, AM J RESP CRIT CARE, V197, P1410, DOI 10.1164/rccm.201711-2202OC; Chalmers JD, 2014, AM J RESP CRIT CARE, V189, P576, DOI 10.1164/rccm.201309-1575OC; Chotirmall SH, 2019, LANCET GLOB HEALTH, V7, pE1162, DOI 10.1016/S2214-109X(19)30311-0; Chotirmall SH, 2010, CHEST, V138, P1186, DOI 10.1378/chest.09-2996; Coughlan CA, 2012, AM J RESP CRIT CARE, V186, P999, DOI 10.1164/rccm.201203-0478OC; Cox MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170622; Crichton ML, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0108-2018; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Dickson RP, 2017, THORAX, V72, P10, DOI 10.1136/thoraxjnl-2016-209180; Durack J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03157-4; Faust K, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002606; Finch S, 2015, ANN AM THORAC SOC, V12, P1602, DOI 10.1513/AnnalsATS.201506-333OC; Flume PA, 2018, LANCET, V392, P880, DOI 10.1016/S0140-6736(18)31767-7; FRIEDMAN JH, 1991, ANN STAT, V19, P1, DOI 10.1214/aos/1176347963; Gusareva ES, 2019, P NATL ACAD SCI USA, V116, P23299, DOI 10.1073/pnas.1908493116; Hahn A, 2016, J MICROBIOL METH, V130, P95, DOI 10.1016/j.mimet.2016.09.002; Hill AT, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00051-2017; Jiang D, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00995; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Koljalg U, 2013, MOL ECOL, V22, P5271, DOI 10.1111/mec.12481; Kuijjer ML, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6235-7; Kumpitsch C, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0703-z; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Laska IF, 2019, LANCET RESP MED, V7, P855, DOI 10.1016/S2213-2600(19)30185-7; Layeghifard M, 2017, TRENDS MICROBIOL, V25, P217, DOI 10.1016/j.tim.2016.11.008; Li CX, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01930-2017; Li DH, 2015, BIOINFORMATICS, V31, P1674, DOI 10.1093/bioinformatics/btv033; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li Y, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368-019-0045-2; Mac Aogain M, 2019, AM J RESP CRIT CARE, V199, P842, DOI 10.1164/rccm.201807-1355OC; Mac Aogain M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00766-2018; MacDonald PL, 2000, EDUC PSYCHOL MEAS, V60, P735, DOI 10.1177/00131640021970871; Meyer F, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-386; Mitchell AB, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0636-2; Morgan M, 2009, BIOINFORMATICS, V25, P2607, DOI 10.1093/bioinformatics/btp450; Muhlebach MS, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00242-2018; Oksanen J., **DATA OBJECT**; Ong SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060811; Panigrahi P, 2017, NATURE, V548, P407, DOI 10.1038/nature23480; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ren J, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0283-5; Rogers GB, 2014, LANCET RESP MED, V2, P988, DOI 10.1016/S2213-2600(14)70213-9; Rogers Geraint B, 2014, Ann Am Thorac Soc, V11, P496, DOI 10.1513/AnnalsATS.201310-335OC; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shkoporov AN, 2019, CELL HOST MICROBE, V26, P527, DOI 10.1016/j.chom.2019.09.009; Sibila O, 2019, AM J RESP CRIT CARE, V200, P33, DOI 10.1164/rccm.201809-1651OC; Sulaiman I, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00810-2018; Tiew PY, 2020, EUR RESPIR J, V56, DOI [10.1183/13993003.00418-2020, 10.1183/13993003.02050-2020]; Tunney MM, 2008, AM J RESP CRIT CARE, V177, P995, DOI 10.1164/rccm.200708-1151OC; Van Landeghem S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-015-0863-y; Vandeplassche E, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0041-2019; Wagg C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12798-y; Wang B, 2014, NAT METHODS, V11, P333, DOI [10.1038/NMETH.2810, 10.1038/nmeth.2810]; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Ward TL, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00140-17; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Woo TE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42862-y	74	38	38	4	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01289-7	http://dx.doi.org/10.1038/s41591-021-01289-7		APR 2021	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33820995	Bronze, Green Accepted			2022-12-27	WOS:000636931100003
J	Happi, AN; Ugwu, CA; Happi, CT				Happi, Anise N.; Ugwu, Chinedu A.; Happi, Christian T.			Tracking the emergence of new SARS-CoV-2 variants in South Africa	NATURE MEDICINE			English	Editorial Material								A large genomic surveillance effort in South Africa produced 1,365 high-quality whole genomes of SARS-CoV-2; this has identified 16 new lineages of the virus that had not been identified in other countries.	[Happi, Anise N.; Ugwu, Chinedu A.; Happi, Christian T.] Redeemers Univ, African Ctr Excellence Genom Infect Dis, Ede, Nigeria; [Ugwu, Chinedu A.; Happi, Christian T.] Redeemers Univ, Dept Biol Sci, Fac Nat Sci, Ede, Nigeria	Redeemers University; Redeemers University	Happi, CT (corresponding author), Redeemers Univ, African Ctr Excellence Genom Infect Dis, Ede, Nigeria.; Happi, CT (corresponding author), Redeemers Univ, Dept Biol Sci, Fac Nat Sci, Ede, Nigeria.	happic@run.edu.ng		Happi, Anise/0000-0001-8959-5175				Constantinos K.W., 2021, PREPRINT BIORXIV, DOI [10.1101/2021.01.18.427166, DOI 10.1101/2021.01.18.427166]; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Tegally H, 2021, NAT MED, V27, P440, DOI 10.1038/s41591-021-01255-3; Tessema SK, 2020, LANCET MICROBE, V1, pE227, DOI 10.1016/S2666-5247(20)30117-8	4	14	14	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					372	373		10.1038/s41591-021-01265-1	http://dx.doi.org/10.1038/s41591-021-01265-1			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723453	Bronze			2022-12-27	WOS:000629708300011
J	Tao, YL; Vermilyea, SC; Zammit, M; Lu, JF; Olsen, M; Metzger, JM; Yao, L; Chen, YJ; Phillips, S; Holden, JE; Bondarenko, V; Block, WF; Barnhart, TE; Schultz-Darken, N; Brunner, K; Simmons, H; Christian, BT; Emborg, ME; Zhang, SC				Tao, Yunlong; Vermilyea, Scott C.; Zammit, Matthew; Lu, Jianfeng; Olsen, Miles; Metzger, Jeanette M.; Yao, Lin; Chen, Yuejun; Phillips, Sean; Holden, James E.; Bondarenko, Viktoriya; Block, Walter F.; Barnhart, Todd E.; Schultz-Darken, Nancy; Brunner, Kevin; Simmons, Heather; Christian, Bradley T.; Emborg, Marina E.; Zhang, Su-Chun			Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys	NATURE MEDICINE			English	Article								Degeneration of dopamine (DA) neurons in the midbrain underlies the pathogenesis of Parkinson's disease (PD). Supplement of DA via L-DOPA alleviates motor symptoms but does not prevent the progressive loss of DA neurons. A large body of experimental studies, including those in nonhuman primates, demonstrates that transplantation of fetal mesencephalic tissues improves motor symptoms in animals, which culminated in open-label and double-blinded clinical trials of fetal tissue transplantation for PD1. Unfortunately, the outcomes are mixed, primarily due to the undefined and unstandardized donor tissues(1,2). Generation of induced pluripotent stem cells enables standardized and autologous transplantation therapy for PD. However, its efficacy, especially in primates, remains unclear. Here we show that over a 2-year period without immunosuppression, PD monkeys receiving autologous, but not allogenic, transplantation exhibited recovery from motor and depressive signs. These behavioral improvements were accompanied by robust grafts with extensive DA neuron axon growth as well as strong DA activity in positron emission tomography (PET). Mathematical modeling reveals correlations between the number of surviving DA neurons with PET signal intensity and behavior recovery regardless autologous or allogeneic transplant, suggesting a predictive power of PET and motor behaviors for surviving DA neuron number.	[Tao, Yunlong; Zammit, Matthew; Lu, Jianfeng; Yao, Lin; Chen, Yuejun; Christian, Bradley T.; Zhang, Su-Chun] Univ Wisconsin, Waisman Ctr, Madison, WI 53706 USA; [Vermilyea, Scott C.; Metzger, Jeanette M.; Phillips, Sean; Bondarenko, Viktoriya; Schultz-Darken, Nancy; Brunner, Kevin; Simmons, Heather; Emborg, Marina E.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA; [Zammit, Matthew; Olsen, Miles; Holden, James E.; Block, Walter F.; Barnhart, Todd E.; Christian, Bradley T.; Emborg, Marina E.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA; [Zhang, Su-Chun] Univ Wisconsin, Dept Neurol, Dept Neurosci, Madison, WI 53706 USA; [Zhang, Su-Chun] Duke NUS Med Sch, Program Neurosci & Behav Disorders, Singapore, Singapore	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National University of Singapore	Zhang, SC (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53706 USA.; Emborg, ME (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.; Emborg, ME (corresponding author), Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA.; Zhang, SC (corresponding author), Univ Wisconsin, Dept Neurol, Dept Neurosci, Madison, WI 53706 USA.; Zhang, SC (corresponding author), Duke NUS Med Sch, Program Neurosci & Behav Disorders, Singapore, Singapore.	emborg@primate.wisc.edu; suchun.zhang@wisc.edu	Zammit, Matthew/AAE-9950-2022; Zammit, Matthew/ADH-8345-2022; Tao, Yunlong/I-8328-2019	Tao, Yunlong/0000-0003-0377-7133; Chen, Yuejun/0000-0002-4625-2604; Barnhart, Todd/0000-0002-9981-2150; Zammit, Matthew/0000-0001-8966-8397	National Institutes of Health-National Institute of Neurological Disorders and Stroke [NS076352, NS096282, NS086604]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [U54 HD090256, P51OD011106]; National Medical Research Council of Singapore [MOH-000212, MOH-000207]; Dr. Ralph & Marian Falk Medical Research Trust; University of Wisconsin-Madison Office of Vice Chancellor for Research and Graduate Education; Cellular and Molecular Pathology Graduate Program; Neuroscience Training Program; Departments of Radiology and Medical Physics at the University of Wisconsin-Madison	National Institutes of Health-National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Medical Research Council of Singapore(National Medical Research Council, Singapore); Dr. Ralph & Marian Falk Medical Research Trust; University of Wisconsin-Madison Office of Vice Chancellor for Research and Graduate Education; Cellular and Molecular Pathology Graduate Program; Neuroscience Training Program; Departments of Radiology and Medical Physics at the University of Wisconsin-Madison	This research was supported by grants from the National Institutes of Health-National Institute of Neurological Disorders and Stroke (NS076352, NS096282 and NS086604), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54 HD090256), P51OD011106, the National Medical Research Council of Singapore (MOH-000212 and MOH-000207), the Dr. Ralph & Marian Falk Medical Research Trust, the University of Wisconsin-Madison Office of Vice Chancellor for Research and Graduate Education, the Cellular and Molecular Pathology Graduate Program, the Neuroscience Training Program and the Departments of Radiology and Medical Physics at the University of Wisconsin-Madison. This project was possible due to the dedication and support of Wisconsin National Primate Research Center veterinarians and animal care technicians, especially C. Boettcher, K. Fuchs and D. Schalk. We are grateful to P. Perez Toro, S. Brady, K. MacManus, A. Payne and L. Fox for facilitating behavioral testing procedures during their undergraduate studies.	Ahlskog JE, 2002, JAMA-J AM MED ASSOC, V288, P311, DOI 10.1001/jama.288.3.311; Barker RA, 2017, CELL STEM CELL, V21, P569, DOI 10.1016/j.stem.2017.09.014; Barker RA, 2013, LANCET NEUROL, V12, P84, DOI 10.1016/S1474-4422(12)70295-8; Bjorklund A, 2017, J PARKINSON DIS, V7, pS23, DOI 10.3233/JPD-179002; Daadi MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041120; Emborg ME, 2013, CELL REP, V3, P646, DOI 10.1016/j.celrep.2013.02.016; Emborg-Knott ME, 1998, EXP NEUROL, V152, P214, DOI 10.1006/exnr.1998.6845; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348; Gash DM, 1999, J NEUROSCI METH, V89, P111, DOI 10.1016/S0165-0270(99)00051-5; Gonzalez C, 2016, CURR STEM CELL RES T, V11, P561, DOI 10.2174/1574888X10666150531172612; Hallett PJ, 2015, CELL STEM CELL, V16, P269, DOI 10.1016/j.stem.2015.01.018; Hallett PJ, 2014, CELL REP, V7, P1755, DOI 10.1016/j.celrep.2014.05.027; Hsiao IT, 2014, JAMA NEUROL, V71, P758, DOI 10.1001/jamaneurol.2014.290; Ichise M, 2003, J CEREBR BLOOD F MET, V23, P1096, DOI 10.1097/01.WCB.0000085441.37552.CA; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jewett DM, 1997, NUCL MED BIOL, V24, P197, DOI 10.1016/S0969-8051(96)00213-2; Kikuchi T, 2017, NATURE, V548, P592, DOI 10.1038/nature23664; Kikuchi T, 2011, J PARKINSON DIS, V1, P395, DOI 10.3233/JPD-2011-11070; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Li W, 2016, P NATL ACAD SCI USA, V113, P6544, DOI 10.1073/pnas.1605245113; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Morizane A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00926-5; Ohshima-Hosoyama S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039036; Reeve A, 2014, AGEING RES REV, V14, P19, DOI 10.1016/j.arr.2014.01.004; Schweitzer JS, 2020, NEW ENGL J MED, V382, P1926, DOI 10.1056/NEJMoa1915872; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; Tao YL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050000; Tiklova K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16225-5; Vermilyea SC, 2017, CELL TRANSPLANT, V26, P613, DOI 10.3727/096368916X692979; Wakeman DR, 2014, CELL TRANSPLANT, V23, P981, DOI 10.3727/096368913X664865; Wang SY, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.12; Wang YK, 2018, STEM CELL REP, V11, P171, DOI 10.1016/j.stemcr.2018.05.010; Wu J, 2015, NATURE, V521, P316, DOI 10.1038/nature14413; Xi JJ, 2012, STEM CELLS, V30, P1655, DOI 10.1002/stem.1152; Yin DL, 2009, J NEUROSCI METH, V176, P200, DOI 10.1016/j.jneumeth.2008.08.027; Zhu L, 2014, CHEM SOC REV, V43, P6683, DOI 10.1039/c3cs60430f	40	26	27	3	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01257-1	http://dx.doi.org/10.1038/s41591-021-01257-1		MAR 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33649496	Green Accepted			2022-12-27	WOS:000623751100002
J	Hu, ZT; Leet, DE; Allesoe, RL; Oliveira, G; Li, SQ; Luoma, AM; Liu, JY; Forman, J; Huang, T; Iorgulescu, JB; Holden, R; Sarkizova, S; Gohil, SH; Redd, RA; Sun, J; Elagina, L; Giobbie-Hurder, A; Zhang, WD; Peter, L; Ciantra, Z; Rodig, S; Olive, O; Shetty, K; Pyrdol, J; Uduman, M; Lee, PC; Bachireddy, P; Buchbinder, EI; Yoon, CH; Neuberg, D; Pentelute, BL; Hacohen, N; Livak, KJ; Shukla, SA; Olsen, LR; Barouch, DH; Wucherpfennig, KW; Fritsch, EF; Keskin, DB; Wu, CJ; Ott, PA				Hu, Zhuting; Leet, Donna E.; Allesoe, Rosa L.; Oliveira, Giacomo; Li, Shuqiang; Luoma, Adrienne M.; Liu, Jinyan; Forman, Juliet; Huang, Teddy; Iorgulescu, J. Bryan; Holden, Rebecca; Sarkizova, Siranush; Gohil, Satyen H.; Redd, Robert A.; Sun, Jing; Elagina, Liudmila; Giobbie-Hurder, Anita; Zhang, Wandi; Peter, Lauren; Ciantra, Zoe; Rodig, Scott; Olive, Oriol; Shetty, Keerthi; Pyrdol, Jason; Uduman, Mohamed; Lee, Patrick C.; Bachireddy, Pavan; Buchbinder, Elizabeth I.; Yoon, Charles H.; Neuberg, Donna; Pentelute, Bradley L.; Hacohen, Nir; Livak, Kenneth J.; Shukla, Sachet A.; Olsen, Lars Ronn; Barouch, Dan H.; Wucherpfennig, Kai W.; Fritsch, Edward F.; Keskin, Derin B.; Wu, Catherine J.; Ott, Patrick A.			Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	NATURE MEDICINE			English	Article							RNA-SEQ; EXPRESSION; QUANTIFICATION; PREDICTION; IMMUNITY; CANCER	Personal neoantigen vaccines have been envisioned as an effective approach to induce, amplify and diversify antitumor T cell responses. To define the long-term effects of such a vaccine, we evaluated the clinical outcome and circulating immune responses of eight patients with surgically resected stage IIIB/C or IVM1a/b melanoma, at a median of almost 4 years after treatment with NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient (). All patients were alive and six were without evidence of active disease. We observed long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype. We also found diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. Furthermore, we detected evidence of tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma. Personalized neoantigen vaccination in patients with melanoma elicits durable and specific memory T cell clones that have cytotoxic gene signatures and can diversify to include nonvaccine neoantigen specificities.	[Hu, Zhuting; Leet, Donna E.; Oliveira, Giacomo; Forman, Juliet; Iorgulescu, J. Bryan; Gohil, Satyen H.; Sun, Jing; Zhang, Wandi; Olive, Oriol; Shetty, Keerthi; Lee, Patrick C.; Bachireddy, Pavan; Buchbinder, Elizabeth I.; Livak, Kenneth J.; Shukla, Sachet A.; Fritsch, Edward F.; Keskin, Derin B.; Wu, Catherine J.; Ott, Patrick A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Leet, Donna E.; Iorgulescu, J. Bryan; Lee, Patrick C.; Bachireddy, Pavan; Buchbinder, Elizabeth I.; Yoon, Charles H.; Hacohen, Nir; Barouch, Dan H.; Wucherpfennig, Kai W.; Wu, Catherine J.; Ott, Patrick A.] Harvard Med Sch, Boston, MA 02115 USA; [Allesoe, Rosa L.] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn, Ctr Prot Res, Copenhagen, Denmark; [Li, Shuqiang; Forman, Juliet; Sarkizova, Siranush; Gohil, Satyen H.; Elagina, Liudmila; Bachireddy, Pavan; Pentelute, Bradley L.; Hacohen, Nir; Shukla, Sachet A.; Fritsch, Edward F.; Keskin, Derin B.; Wu, Catherine J.; Ott, Patrick A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Li, Shuqiang; Forman, Juliet; Huang, Teddy; Livak, Kenneth J.; Shukla, Sachet A.; Keskin, Derin B.] Dana Farber Canc Inst, Translat Immunogen Lab, Boston, MA 02115 USA; [Luoma, Adrienne M.; Pyrdol, Jason; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA; [Liu, Jinyan; Peter, Lauren; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA; [Iorgulescu, J. Bryan; Rodig, Scott] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Holden, Rebecca; Pentelute, Bradley L.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Gohil, Satyen H.] UCL, Dept Acad Haematol, London, England; [Redd, Robert A.; Giobbie-Hurder, Anita; Uduman, Mohamed; Neuberg, Donna] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA; [Ciantra, Zoe; Rodig, Scott; Uduman, Mohamed] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA; [Bachireddy, Pavan; Buchbinder, Elizabeth I.; Wu, Catherine J.; Ott, Patrick A.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Yoon, Charles H.] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA; [Pentelute, Bradley L.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Hacohen, Nir] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Olsen, Lars Ronn] Tech Univ Denmark, Dept Hlth Technol, Sect Bioinformat, Lyngby, Denmark; [Olsen, Lars Ronn] Copenhagen Univ Hosp, Ctr Genom Med, Copenhagan, Denmark; [Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Novo Nordisk Foundation; University of Copenhagen; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); University of London; University College London; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Technical University of Denmark; University of Copenhagen; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute	Ott, PA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Ott, PA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Ott, PA (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ott, PA (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	patrick_ott@dfci.harvard.edu	Giobbie-Hurder, Anita/AAU-6193-2021	Bachireddy, Pavan/0000-0002-8698-4957; Leet, Donna/0000-0002-4494-1705; Iorgulescu, J. Bryan/0000-0003-1405-3667; Olsen, Lars Ronn/0000-0002-6725-7850	National Institutes of Health [NCI-R50 CA251956, NCI-R01 CA229261, NCI P01 CA163222, NCI-R01 CA238039, 5P30 CA006516, NCI-K12CA090354]; Team Science Award from the Melanoma Research Alliance; Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund; Faircloth Family Research Fund; Bender Family Research Fund; DFCI Center for Cancer Immunotherapy Research fellowship; Damon Runyon Cancer Research Foundation; Be The Match Foundation; American Society of Hematology Fellow Scholar Award; NSF Graduate Research Fellowships Program fellowship; Kay Kendall Leukaemia Fund Fellowship; Free Research Fund Denmark [8048-00078A]; G. Harold and Leila Y. Mathers Foundation; Koch Institute for Integrative Cancer Research at MIT; Dana-Farber/Harvard Cancer Center; Howard Hughes Medical Institute Medical Research Fellows Program; Novo Nordisk Foundation [NNF14CC0001]; National Institutes of Health (NIH/NCI) [R21 CA216772-01A1, NCI-SPORE-2P50CA101942-11A1, U24CA224331, R01CA155010, NCI-R50 RCA211482A];  [5 T32 CA 207021-3]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Team Science Award from the Melanoma Research Alliance; Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund; Faircloth Family Research Fund; Bender Family Research Fund; DFCI Center for Cancer Immunotherapy Research fellowship; Damon Runyon Cancer Research Foundation; Be The Match Foundation; American Society of Hematology Fellow Scholar Award; NSF Graduate Research Fellowships Program fellowship; Kay Kendall Leukaemia Fund Fellowship; Free Research Fund Denmark; G. Harold and Leila Y. Mathers Foundation; Koch Institute for Integrative Cancer Research at MIT; Dana-Farber/Harvard Cancer Center; Howard Hughes Medical Institute Medical Research Fellows Program(Howard Hughes Medical Institute); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); National Institutes of Health (NIH/NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); 	The authors thank J. Russell, M. Manos, M. Severgnini and the Center for Immuno-Oncology staff, M. Copersino (Regulatory Affairs), B. Meyers, C. Harvey and S. Bartel (Clinical Pharmacy), M. Bowden (Center for Molecular Oncologic Pathology), O. Sturtevant, H. Negre, S.Y. Kim and M.A. Kelley (Cell Manipulation Core Facility), the Pasquarello Tissue Bank (all at DFCI), T. Bowman (DFHCC Specialized Histopathology Core Laboratory), M. Harden, N. Lennon, S. Gabriel, S. Pollack (the Broad Institute's Biological Samples, Genetic Analysis and Genome Sequencing Platform), J. Ritz (DFCI) and I. Leshchiner, G. Getz (Broad Institute), for discussions. This research was made possible by a generous gift from the Blavatnik Family Foundation, and was supported by grants from the National Institutes of Health (NIH/NCI (R21 CA216772-01A1 and NCI-SPORE-2P50CA101942-11A1 (to D.B.K.); U24CA224331 and R01CA155010 (to C.J.W.); NCI-R50 RCA211482A (to S.A.S.)); NCI-R50 CA251956 (to S.L.); NCI-R01 CA229261 (to P.A.O.); NCI P01 CA163222; NCI-R01 CA238039 (to K.W.W.); 5P30 CA006516 (to A.G.H., R.R. and D.N.) and NCI-K12CA090354 (to J.B.I.)); a Team Science Award from the Melanoma Research Alliance (to C.J.W. and P.A.O.); the Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund (to P.A.O.); the Faircloth Family Research Fund (to P.A.O.); the Bender Family Research Fund (to P.A.O.), and the DFCI Center for Cancer Immunotherapy Research fellowship and 5 T32 CA 207021-3 (to Z.H. and A.M.L.); a Physician-Scientist Training Award from the Damon Runyon Cancer Research Foundation (to P.B.); an Amy Strelzer Manasevit Scholar Award from the Be The Match Foundation (to P.B.); an American Society of Hematology Fellow Scholar Award (to P.B.); an NSF Graduate Research Fellowships Program fellowship (to R.H.); a Kay Kendall Leukaemia Fund Fellowship (to S.H.G.). L.R.O. is funded by The Free Research Fund Denmark (8048-00078A). C.J.W. is a scholar of the Leukemia and Lymphoma Society. We also acknowledge a gift from a donor to the Developing Innovative Immunological Therapies for Intractable Cancers Fund. This work was further supported in part by The G. Harold and Leila Y. Mathers Foundation and the Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center, the Howard Hughes Medical Institute Medical Research Fellows Program and the Novo Nordisk Foundation (grant agreement NNF14CC0001).	Abelin JG, 2019, IMMUNITY, V51, P766, DOI 10.1016/j.immuni.2019.08.012; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Cai A, 2012, CLIN CANCER RES, V18, P5761, DOI 10.1158/1078-0432.CCR-12-1182; Call MJ, 2009, J IMMUNOL, V182, P6342, DOI 10.4049/jimmunol.0803464; Carey CD, 2017, BLOOD, V130, P2420, DOI 10.1182/blood-2017-03-770719; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196; Deng Q, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1061-7; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dodt Matthias, 2012, Biology (Basel), V1, P895, DOI 10.3390/biology1030895; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Gattinoni L, 2017, NAT MED, V23, P18, DOI 10.1038/nm.4241; Haabeth OA, 2016, LEUKEMIA, V30, P1216, DOI 10.1038/leu.2015.278; Haga-Friedman A, 2012, J IMMUNOL, V188, P5538, DOI 10.4049/jimmunol.1103020; Hirschhorn-Cymerman D, 2012, J EXP MED, V209, P2113, DOI 10.1084/jem.20120532; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Hu ZT, 2018, BLOOD, V132, P1911, DOI 10.1182/blood-2018-04-843763; Jang MH, 2003, J IMMUNOL, V171, P4175, DOI 10.4049/jimmunol.171.8.4175; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li SQ, 2019, NAT PROTOC, V14, P2571, DOI 10.1038/s41596-019-0195-x; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Lundegaard C, 2011, J IMMUNOL METHODS, V374, P26, DOI 10.1016/j.jim.2010.10.011; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Nussing S, 2019, IMMUNOL CELL BIOL, V97, P498, DOI 10.1111/imcb.12233; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pauken KE, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107827; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Roemer MGM, 2016, CANCER IMMUNOL RES, V4, P910, DOI 10.1158/2326-6066.CIR-16-0201; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Truex NL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56943-5; Verma V, 2019, NAT IMMUNOL, V20, P1231, DOI 10.1038/s41590-019-0441-y; Willinger T, 2006, J IMMUNOL, V176, P1439, DOI 10.4049/jimmunol.176.3.1439	45	121	125	27	122	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					515	+		10.1038/s41591-020-01206-4	http://dx.doi.org/10.1038/s41591-020-01206-4		JAN 2021	33	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33479501	Green Submitted, Green Accepted			2022-12-27	WOS:000609385500001
J	Hickey, TE; Selth, LA; Chia, KM; Laven-Law, G; Milioli, HH; Roden, D; Jindal, S; Hui, M; Finlay-Schultz, J; Ebrahimie, E; Birrell, SN; Stelloo, S; Iggo, R; Alexandrou, S; Caldon, CE; Abdel-Fatah, TM; Ellis, IO; Zwart, W; Palmieri, C; Sartorius, CA; Swarbrick, A; Lim, E; Carroll, JS; Tilley, WD				Hickey, Theresa E.; Selth, Luke A.; Chia, Kee Ming; Laven-Law, Geraldine; Milioli, Heloisa H.; Roden, Daniel; Jindal, Shalini; Hui, Mun; Finlay-Schultz, Jessica; Ebrahimie, Esmaeil; Birrell, Stephen N.; Stelloo, Suzan; Iggo, Richard; Alexandrou, Sarah; Caldon, C. Elizabeth; Abdel-Fatah, Tarek M.; Ellis, Ian O.; Zwart, Wilbert; Palmieri, Carlo; Sartorius, Carol A.; Swarbrick, Alex; Lim, Elgene; Carroll, Jason S.; Tilley, Wayne D.			The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer	NATURE MEDICINE			English	Article							DIFFERENTIAL EXPRESSION; ENDOCRINE RESISTANCE; READ ALIGNMENT; SEQ DATA; ALPHA; INHIBITOR; MECHANISM; ACCURATE; THERAPY; GROWTH	The role of the androgen receptor (AR) in estrogen receptor (ER)-alpha-positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we demonstrate that AR activation, not suppression, exerts potent antitumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Notably, AR agonists combined with standard-of-care agents enhanced therapeutic responses. Mechanistically, agonist activation of AR altered the genomic distribution of ER and essential co-activators (p300, SRC-3), resulting in repression of ER-regulated cell cycle genes and upregulation of AR target genes, including known tumor suppressors. A gene signature of AR activity positively predicted disease survival in multiple clinical ER-positive breast cancer cohorts. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER-positive breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.	[Hickey, Theresa E.; Selth, Luke A.; Laven-Law, Geraldine; Jindal, Shalini; Ebrahimie, Esmaeil; Birrell, Stephen N.; Iggo, Richard; Tilley, Wayne D.] Univ Adelaide, Adelaide Med Sch, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Selth, Luke A.] Flinders Univ S Australia, Flinders Hlth & Med Res Inst, Adelaide, SA, Australia; [Selth, Luke A.; Tilley, Wayne D.] Univ Adelaide, Freemasons Fdn Ctr Mens Hlth, Adelaide, SA, Australia; [Chia, Kee Ming; Milioli, Heloisa H.; Roden, Daniel; Hui, Mun; Alexandrou, Sarah; Caldon, C. Elizabeth; Swarbrick, Alex; Lim, Elgene] Univ New South Wales, Garvan Inst Med Res, Sydney, NSW, Australia; [Chia, Kee Ming; Milioli, Heloisa H.; Roden, Daniel; Hui, Mun; Alexandrou, Sarah; Caldon, C. Elizabeth; Swarbrick, Alex; Lim, Elgene] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Finlay-Schultz, Jessica; Sartorius, Carol A.] Univ Colorado, Aurora, CO USA; [Stelloo, Suzan; Zwart, Wilbert] Netherlands Canc Inst, Oncode Inst, Amsterdam, Netherlands; [Iggo, Richard] Univ Bordeaux, Inst Bergonie, Bordeaux, France; [Abdel-Fatah, Tarek M.; Ellis, Ian O.] Univ Nottingham, Nottingham, England; [Palmieri, Carlo] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England; [Palmieri, Carlo] Clatterbridge Ctr NHS Fdn Trust, Liverpool, Merseyside, England; [Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Stelloo, Suzan] Radboud Univ Nijmegen, Oncode Inst, Nijmegen, Netherlands	University of Adelaide; Flinders University South Australia; University of Adelaide; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; University of Colorado System; University of Colorado Anschutz Medical Campus; Netherlands Cancer Institute; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; University of Nottingham; University of Liverpool; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Radboud University Nijmegen	Tilley, WD (corresponding author), Univ Adelaide, Adelaide Med Sch, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia.; Tilley, WD (corresponding author), Univ Adelaide, Freemasons Fdn Ctr Mens Hlth, Adelaide, SA, Australia.	wayne.tilley@adelaide.edu.au	Selth, Luke/AAH-4823-2021	Selth, Luke/0000-0002-4686-1418; Lim, Elgene/0000-0001-8065-8838; Laven-Law, Geraldine/0000-0001-5326-1931; Milioli, Heloisa Helena/0000-0001-5104-487X; Finlay-Schultz, Jessica/0000-0002-7855-9870; Ebrahimie, Esmaeil/0000-0002-4431-2861; Hickey, Theresa/0000-0002-2752-730X; Swarbrick, Alexander/0000-0002-3051-5676; Roden, Daniel/0000-0003-2393-5805; Carroll, Jason/0000-0003-3643-0080	National Health and Medical Research Council of Australia [1084416, 1130077, 1093801]; National Breast Cancer Foundation (NBCF) [PS-15-041, ECF-17-002]; Movember & National Breast Cancer Foundation Collaboration Initiative grant [MNBCF-17-012]; Cancer Australia [1107170]; Cancer Institute of New South Wales [ECF-17-1156]; Hospital Research Foundation; US Department of Defense Breast Cancer Research Program [BC103923]; Royal Adelaide Hospital Research Foundation (Adelaide, Australia); Movember Foundation [NKI01]; Dutch Cancer Society/Alpe D'HuZes [10084]; Netherlands Organisation for Scientific Research Vidi grant [91716401]; NIH [R01CA140985]; Breast Cancer Research Foundation; CRUK Fund [A17197]; NBCF Endowed Chair; NBCF [IIRS-19-009]; University of Adelaide	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation (NBCF); Movember & National Breast Cancer Foundation Collaboration Initiative grant; Cancer Australia; Cancer Institute of New South Wales; Hospital Research Foundation; US Department of Defense Breast Cancer Research Program(United States Department of Defense); Royal Adelaide Hospital Research Foundation (Adelaide, Australia); Movember Foundation; Dutch Cancer Society/Alpe D'HuZes; Netherlands Organisation for Scientific Research Vidi grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; CRUK Fund; NBCF Endowed Chair; NBCF; University of Adelaide	The authors thank C. Hoffmann, N. Dean and the teams supporting them for consenting and recruiting tissue donors, as well as tissue donors themselves. We thank A. Welm for PDX model provision; J. Robinson, M. Pickering, Z. Kikhtyak and N. Ryan for experimental assistance; and our institutional animal care facilities and genomics cores. This work was supported by grants from the National Health and Medical Research Council of Australia (W.D.T., J.S.C., T.E.H., E.L., L.A.S., E.E., S.N.B., C.P. and A.S.; ID 1084416, ID 1130077; K.M.C.; ID 1093801), the National Breast Cancer Foundation (NBCF; W.D.T.; ID PS-15-041; C.E.C.; ID ECF-17-002) and a Movember & National Breast Cancer Foundation Collaboration Initiative grant (MNBCF-17-012 to W.D.T., J.S.C., E.L., T.E.H. and L.A.S.), Cancer Australia (W.D.T., E.L., T.E.H., J.S.C.; ID 1107170), Cancer Institute of New South Wales (H.H.M.; ID ECF-17-1156) and The Hospital Research Foundation (T.E.H., L.A.S., W.D.T.). T.E.H. held fellowship awards from the US Department of Defense Breast Cancer Research Program (ID BC103923) and the Royal Adelaide Hospital Research Foundation (Adelaide, Australia). W.Z. and S.S. were supported by the Movember Foundation (ID NKI01), Dutch Cancer Society/Alpe D'HuZes (ID 10084) and the Netherlands Organisation for Scientific Research Vidi grant (ID 91716401). C.A.S. and J.F.S. were supported by NIH R01CA140985 and the Breast Cancer Research Foundation. J.S.C. and C.P. are supported by CRUK Funding (grant no. A17197 to J.S.C.). E.L. is supported by an NBCF Endowed Chair. K.M.C. is an NHMRC PhD Scholar. T.E.H. is currently supported by an NBCF Fellowship (IIRS-19-009) and the University of Adelaide.	Abdel-Fatah TMA, 2016, LANCET ONCOL, V17, P1004, DOI 10.1016/S1470-2045(16)00174-1; Baggerly KA, 2003, BIOINFORMATICS, V19, P1477, DOI 10.1093/bioinformatics/btg173; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Buluwela L, 2005, GENE THER, V12, P452, DOI 10.1038/sj.gt.3302421; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Cazet AS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05220-6; Centenera MM, 2018, MOL ONCOL, V12, P1608, DOI 10.1002/1878-0261.12354; Chia K, 2019, ENDOCR-RELAT CANCER, V26, P251, DOI 10.1530/ERC-18-0333; Clarke R, 2015, MOL CELL ENDOCRINOL, V418, P220, DOI 10.1016/j.mce.2015.09.035; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Amato NC, 2016, MOL CANCER RES, V14, P1054, DOI 10.1158/1541-7786.MCR-16-0167; De Amicis F, 2010, BREAST CANCER RES TR, V121, P1, DOI 10.1007/s10549-009-0436-8; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Elston C W, 2002, Histopathology, V41, P154; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Finlay-Schultz J, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01300-y; Finlay-Schultz J, 2017, CANCER RES, V77, P4934, DOI 10.1158/0008-5472.CAN-16-3541; GOLDENBERG IS, 1964, JAMA-J AM MED ASSOC, V188, P1069; Guertin MJ, 2014, MOL ENDOCRINOL, V28, P1522, DOI 10.1210/me.2014-1130; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hu DG, 2016, CANCER RES, V76, P5881, DOI 10.1158/0008-5472.CAN-15-3372; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Ji HK, 2008, NAT BIOTECHNOL, V26, P1293, DOI 10.1038/nbt.1505; Jordan VC, 2007, STEROIDS, V72, P7, DOI 10.1016/j.steroids.2006.10.009; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; KENNEDY B. J., 1958, NEW ENGLAND JOUR MED, V259, P673, DOI 10.1056/NEJM195810022591404; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Law AMK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15885-6; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li ZQ, 2018, CANCER CELL, V34, P893, DOI 10.1016/j.ccell.2018.11.006; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lim E, 2016, ENDOCR-RELAT CANCER, V23, pT227, DOI 10.1530/ERC-16-0427; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Lonning PE, 2009, ACTA ONCOL, V48, P1092, DOI 10.3109/02841860903117816; Lundberg A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1121-4; Lydon JP, 2011, ENDOCRINOLOGY, V152, P19, DOI 10.1210/en.2010-1012; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Moore NL, 2020, J STEROID BIOCHEM, V199, DOI 10.1016/j.jsbmb.2019.105548; Murakami S, 2017, GENE DEV, V31, P1535, DOI 10.1101/gad.302182.117; Narayanan R, 2018, MOL CELL ENDOCRINOL, V465, P134, DOI 10.1016/j.mce.2017.06.013; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Pike J, 2004, ONCOGENE, V23, P7561, DOI 10.1038/sj.onc.1208030; Portman N, 2019, ENDOCR-RELAT CANCER, V26, pR15, DOI 10.1530/ERC-18-0317; POULIN R, 1988, BREAST CANCER RES TR, V12, P213, DOI 10.1007/BF01805942; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Ricciardelli C, 2018, CLIN CANCER RES, V24, P2328, DOI 10.1158/1078-0432.CCR-17-1199; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Santagata S, 2014, J CLIN INVEST, V124, P859, DOI 10.1172/JCI70941; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Schmidt SF, 2016, BIOESSAYS, V38, P618, DOI 10.1002/bies.201600034; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Singh AA, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800115; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Somboonporn W, 2004, ENDOCR REV, V25, P374, DOI 10.1210/er.2003-0016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tishchenko I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158259; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527; Ur-Rehman S, 2013, BREAST CANCER RES TR, V139, P907, DOI 10.1007/s10549-013-2593-z; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Wang X, 2009, CANCER INVEST, V27, P971, DOI 10.3109/07357900802392659; Weinert BT, 2018, CELL, V174, P231, DOI 10.1016/j.cell.2018.04.033; Wingett Steven W, 2018, F1000Res, V7, P1338, DOI 10.12688/f1000research.15931.2; Xiao WH, 2003, CANCER RES, V63, P4698; Yi P, 2015, MOL CELL, V57, P1047, DOI 10.1016/j.molcel.2015.01.025; Yu XZ, 2020, MOL CELL, V79, P812, DOI 10.1016/j.molcel.2020.06.031; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	85	55	59	13	58	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					310	+		10.1038/s41591-020-01168-7	http://dx.doi.org/10.1038/s41591-020-01168-7		JAN 2021	35	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33462444	Green Submitted			2022-12-27	WOS:000608677800001
J	Ward, JK; Gauna, F; Gagneux-Brunon, A; Botelho-Nevers, E; Cracowski, JL; Khouri, C; Launay, O; Verger, P; Peretti-Watel, P				Ward, Jeremy K.; Gauna, Fatima; Gagneux-Brunon, Amandine; Botelho-Nevers, Elisabeth; Cracowski, Jean-Luc; Khouri, Charles; Launay, Odile; Verger, Pierre; Peretti-Watel, Patrick			The French health pass holds lessons for mandatory COVID-19 vaccination	NATURE MEDICINE			English	Editorial Material								The passe sanitaire increased levels of vaccination, but to a lower extent among the most vulnerable, and did not reduce vaccine hesitancy itself, showing the importance of outreach to underserved communities and the potential limits of mandatory vaccination policies.	[Ward, Jeremy K.] Univ Paris, CNRS, INSERM, CERMES3,EHESS, Villejuif, France; [Ward, Jeremy K.; Peretti-Watel, Patrick] Aix Marseille Univ, IRD, AP HM, VITROME,SSA, Marseille, France; [Gauna, Fatima; Verger, Pierre; Peretti-Watel, Patrick] Aix Marseille Univ, Observ Reg Sante PACA ORS Paca, Marseille, France; [Gagneux-Brunon, Amandine; Botelho-Nevers, Elisabeth] Univ Claude Bernard Lyon 1, Univ Jean Monnet, Univ Lyon,Team GIMAP, CNRS,UMR 530,INSERM,U111Ctr Int Rech Infectiol, Lyon, France; [Gagneux-Brunon, Amandine; Botelho-Nevers, Elisabeth] CHU St Etienne, INSERM, CIC Vaccinol 1408, St Etienne, France; [Gagneux-Brunon, Amandine; Botelho-Nevers, Elisabeth] Univ Jean Monnet, Chaire PREVACCI, St Etienne, France; [Gagneux-Brunon, Amandine; Botelho-Nevers, Elisabeth; Launay, Odile; Verger, Pierre] INSERM, F CRIN, I REIVAC, COVIREIVAC, Paris, France; [Cracowski, Jean-Luc; Khouri, Charles] Grenoble Alpes Univ Hosp, Pharmacovigilance Unit, Grenoble, France; [Khouri, Charles] Univ Grenoble Alpes, INSERM, U1300, HP2 Lab, Grenoble, France; [Launay, Odile] Univ Paris, Hop Cochin, AP HP, INSERM,Ctr Invest Clin CIC 1417,CIC Cochin Pasteu, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU de St Etienne; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ward, JK (corresponding author), Univ Paris, CNRS, INSERM, CERMES3,EHESS, Villejuif, France.; Ward, JK (corresponding author), Aix Marseille Univ, IRD, AP HM, VITROME,SSA, Marseille, France.	jeremy.ward@inserm.fr		ward, jeremy/0000-0003-3389-6870; Gauna, Fatima/0000-0001-7476-4474	Agence Nationale de la Recherche [ANR SLAVACO: 20-COV8-0009-01]; Institut national de la sante et de la recherche medicale (INSERM); Ministry of Health; Ministry of Higher Education and Research	Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut national de la sante et de la recherche medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ministry of Health; Ministry of Higher Education and Research(Ministry of Higher Education & Scientific Research (MHESR))	This research benefited from the financial support of the Agence Nationale de la Recherche (ANR SLAVACO: 20-COV8-0009-01) and the Institut national de la sante et de la recherche medicale (INSERM), the Ministry of Health, and The Ministry of Higher Education and Research via the CORIVEIVAC platform (intended for COVID-19 vaccine clinical research). The funding sources had no role in the design of the study, analysis of the data or writing of the paper. We thank C. Berenger, S. Cortaredona, L. Fressard and G. Maradan for data collection and analysis.	Attwell K, 2019, MILBANK Q, V97, P978, DOI 10.1111/1468-0009.12417; de Figueiredo A, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101109; Goldenberg M. J, VACCINE HESISTANCY, P2021; Gostin LO, 2021, JAMA-J AM MED ASSOC, V325, P6; Lindholt MF, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-048172; McCoy CA, 2019, J HEALTH POLIT POLIC, V44, P823, DOI 10.1215/03616878-7785775; Omer SB, 2019, NATURE, V571, P469, DOI 10.1038/d41586-019-02232-0; Petersen MB, 2021, NATURE, V598, P237, DOI 10.1038/d41586-021-02758-2; Reich J.A., 2016, CALLING SHOTS WHY PA; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Sprengholz P, 2021, APPL PSYCHOL-HLTH WE, V13, P986, DOI 10.1111/aphw.12285; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095	13	27	27	1	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					232	235		10.1038/s41591-021-01661-7	http://dx.doi.org/10.1038/s41591-021-01661-7		JAN 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35022575	Bronze			2022-12-27	WOS:000741964100006
J	Fowler, NH; Dickinson, M; Dreyling, M; Martinez-Lopez, J; Kolstad, A; Butler, J; Ghosh, M; Popplewell, L; Chavez, JC; Bachy, E; Kato, K; Harigae, H; Kersten, MJ; Andreadis, C; Riedell, PA; Ho, PJ; Perez-Simon, JA; Chen, AI; Nastoupil, LJ; von Tresckow, B; Ferreri, AJM; Teshima, T; Patten, PEM; McGuirk, JP; Petzer, AL; Offner, F; Viardot, A; Zinzani, PL; Malladi, R; Zia, A; Awasthi, R; Masood, A; Anak, O; Schuster, SJ; Thieblemont, C				Fowler, Nathan Hale; Dickinson, Michael; Dreyling, Martin; Martinez-Lopez, Joaquin; Kolstad, Arne; Butler, Jason; Ghosh, Monalisa; Popplewell, Leslie; Chavez, Julio C.; Bachy, Emmanuel; Kato, Koji; Harigae, Hideo; Kersten, Marie Jose; Andreadis, Charalambos; Riedell, Peter A.; Ho, P. Joy; Perez-Simon, Jose Antonio; Chen, Andy, I; Nastoupil, Loretta J.; von Tresckow, Bastian; Ferreri, Andres Jose Maria; Teshima, Takanori; Patten, Piers E. M.; McGuirk, Joseph P.; Petzer, Andreas L.; Offner, Fritz; Viardot, Andreas; Zinzani, Pier Luigi; Malladi, Ram; Zia, Aiesha; Awasthi, Rakesh; Masood, Aisha; Anak, Oezlem; Schuster, Stephen J.; Thieblemont, Catherine			Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	NATURE MEDICINE			English	Article							CELLULAR KINETICS; RITUXIMAB; IDELALISIB; INHIBITION; MANAGEMENT	Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a complete response (CR). Here we report the primary, prespecified interim analysis of the ELARA phase 2 multinational trial of tisagenlecleucel in adults with r/r FL after two or more treatment lines or who relapsed after autologous stem cell transplant (no. NCT03568461). The primary endpoint was CR rate (CRR). Secondary endpoints included overall response rate (ORR), duration of response, progression-free survival, overall survival, pharmacokinetics and safety. As of 29 March 2021, 97/98 enrolled patients received tisagenlecleucel (median follow-up, 16.59 months; interquartile range, 13.8-20.21). The primary endpoint was met. In the efficacy set (n = 94), CRR was 69.1% (95% confidence interval, 58.8-78.3) and ORR 86.2% (95% confidence interval, 77.5-92.4). Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5% (grade >= 3, 0%), neurological events 37.1% (grade >= 3, 3%) and immune effector cell-associated neurotoxicity syndrome (ICANS) 4.1% (grade >= 3, 1%) in the safety set (n = 97), with no treatment-related deaths. Tisagenlecleucel is safe and effective in extensively pretreated r/r FL, including in high-risk patients. In a prespecified interim analysis of a pivotal phase 2 trial, tisagenlecleucel, an autologous CD19-targeting CAR-T cell therapy, produced a high rate of complete responses with a manageable safety profile in adults with relapsed or refractory follicular lymphoma	[Fowler, Nathan Hale; Nastoupil, Loretta J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Fowler, Nathan Hale] BostonGene, Waltham, MA 02453 USA; [Dickinson, Michael] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Dickinson, Michael] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Dreyling, Martin] LMU Klinikum, Med Klin 3, Munich, Germany; [Martinez-Lopez, Joaquin] Univ Complutense Madrid, CNIO, Hosp 12 Octubre, Madrid, Spain; [Kolstad, Arne] Oslo Univ Hosp, Oslo, Norway; [Butler, Jason] Royal Brisbane Hosp, Herston, Qld, Australia; [Ghosh, Monalisa] Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA; [Popplewell, Leslie] City Hope Comprehens Canc Ctr, Duarte, CA USA; [Chavez, Julio C.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Bachy, Emmanuel] Hosp Civils Lyon, Lyon, France; [Bachy, Emmanuel] Univ Claude Bernard Lyon 1, Lyon, France; [Kato, Koji] Kyushu Univ Hosp, Fukuoka, Japan; [Harigae, Hideo] Tohoku Univ Hosp, Sendai, Miyagi, Japan; [Kersten, Marie Jose] Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; [Andreadis, Charalambos] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Riedell, Peter A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA; [Ho, P. Joy] Royal Prince Alfred Hosp, Camperdown, NSW, Australia; [Ho, P. Joy] Univ Sydney, Camperdown, NSW, Australia; [Perez-Simon, Jose Antonio] Univ Seville, Inst Biomed Sevilla, Dept Hematol, Univ Hosp Virgen del Rocio, Seville, Spain; [Chen, Andy, I] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [von Tresckow, Bastian] Univ Cologne, Med Fac, Dept Internal Med 1, Cologne, Germany; [von Tresckow, Bastian] Univ Cologne, Univ Hosp Cologne, Cologne, Germany; [von Tresckow, Bastian] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Hematol & Stem Cell Transplantat, Essen, Germany; [Ferreri, Andres Jose Maria] IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy; [Teshima, Takanori] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan; [Patten, Piers E. M.] Kings Coll London, Comprehens Canc Ctr, London, England; [Patten, Piers E. M.] Kings Coll Hosp London, Dept Haematol, London, England; [McGuirk, Joseph P.] Univ Kansas Hosp & Med Ctr, Westwood, KS USA; [Petzer, Andreas L.] Ordensklinikum Linz Barmherzige Schwestern Elisab, Internal Med 1, Linz, Austria; [Offner, Fritz] UZ Gent, Ghent, Belgium; [Viardot, Andreas] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany; [Zinzani, Pier Luigi] IRCCS Azienda Osped Univ Bologna Ist Ematol Serag, Bologna, Italy; [Zinzani, Pier Luigi] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Bologna, Italy; [Malladi, Ram] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England; [Zia, Aiesha; Anak, Oezlem] Novartis Pharma AG, Basel, Switzerland; [Awasthi, Rakesh] Novartis Inst BioMed Res, E Hanover, NJ USA; [Masood, Aisha] Novartis Pharmaceut, E Hanover, NJ USA; [Schuster, Stephen J.] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA; [Thieblemont, Catherine] Hop St Louis, Paris, France	University of Texas System; UTMD Anderson Cancer Center; Peter Maccallum Cancer Center; Royal Melbourne Hospital; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne; University of Munich; Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid; Hospital Universitario 12 de Octubre; University of Oslo; Royal Brisbane & Women's Hospital; University of Michigan System; University of Michigan; City of Hope; H Lee Moffitt Cancer Center & Research Institute; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Kyushu University; Tohoku University; University of Amsterdam; Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Chicago; University of Chicago Medical Center; University of Sydney; University of Sydney; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Oregon Health & Science University; University of Cologne; University of Cologne; University of Duisburg Essen; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Hokkaido University; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Ghent University; Ghent University Hospital; Ulm University; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Cambridge; Novartis; Novartis; Novartis; University of Pennsylvania; Pennsylvania Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Fowler, NH (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.; Fowler, NH (corresponding author), BostonGene, Waltham, MA 02453 USA.	nfowler@mdanderson.org	Patten, Piers/GPC-7894-2022; martinez, joaquin/AAN-6939-2020	martinez, joaquin/0000-0001-7908-0063; Patten, Piers/0000-0003-3320-3034; Butler, Jason/0000-0002-6422-4404; Dickinson, Michael/0000-0002-1492-5966	Novartis Pharmaceuticals Corporation - Novartis Pharmaceuticals Corporation	Novartis Pharmaceuticals Corporation - Novartis Pharmaceuticals Corporation(Novartis)	The study was sponsored and designed by Novartis Pharmaceuticals Corporation and was approved by the IRB at each participating institution. Data were analyzed and interpreted by the sponsor and the authors. All authors reviewed the manuscript and approved of the final version before submission. We vouch for the data and analysis and for the adherence of the study to the protocol. We thank A. A. Abozeid (former employee of Novartis) for his contributions to the analyses presented herein. Medical writing support was provided by R. Parthasarathy (Healthcare Consultancy Group) and was funded by Novartis Pharmaceuticals Corporation.	Assouline SE, 2020, BLOOD, V136, DOI 10.1182/blood-2020-135839; Awasthi R, 2020, BLOOD ADV, V4, P560, DOI 10.1182/bloodadvances.2019000525; Bodor C, 2013, BLOOD, V122, P3165, DOI 10.1182/blood-2013-04-496893; Bruna R, 2019, HAEMATOLOGICA, V104, P2241, DOI 10.3324/haematol.2018.209932; Casulo C, 2015, J CLIN ONCOL, V33, P2516, DOI 10.1200/JCO.2014.59.7534; Chavey WE, 2001, AM FAM PHYSICIAN, V64, P769; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Chong EA, 2019, 15 INT C MAL LYMPH A, V37, P137; Chong EA, 2021, NEW ENGL J MED, V384, P673, DOI 10.1056/NEJMc2030164; Dreyling M, 2017, J CLIN ONCOL, V35, P3898, DOI 10.1200/JCO.2017.75.4648; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Hutchings M, 2021, J CLIN ONCOL, V39, P1959, DOI 10.1200/JCO.20.03175; Jacobson, 2020, 62 ASH ANN M EXP ABS; Lansigan F, 2019, CANCER MED-US, V8, P165, DOI 10.1002/cam4.1918; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Leonard JP, 2019, J CLIN ONCOL, V37, P1188, DOI 10.1200/JCO.19.00010; Link BK, 2019, BRIT J HAEMATOL, V184, P660, DOI 10.1111/bjh.15149; Marcus R, 2017, NEW ENGL J MED, V377, P1331, DOI 10.1056/NEJMoa1614598; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Morschhauser F, 2020, LANCET ONCOL, V21, P1433, DOI 10.1016/S1470-2045(20)30441-1; Mueller KT, 2017, BLOOD, V130, P2317, DOI 10.1182/blood-2017-06-786129; Rivas-Delgado A, 2019, BRIT J HAEMATOL, V184, P753, DOI 10.1111/bjh.15708; Rummel M. J., 2020, 25 C EUR HEM ASS EHA; Salles G, 2017, HAEMATOLOGICA, V102, pE156, DOI 10.3324/haematol.2016.151738; Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7; Sarkozy C, 2019, J CLIN ONCOL, V37, P144, DOI 10.1200/JCO.18.00400; Schuster SJ, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123742; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; US FDA, 2019, FDA APPR LEN FOLL MA; US Food and Drug Administration, FDA GRANTS ACC APPR; Zinzani, 2017, DYNAMO PHASE 2 STUDY	32	22	22	4	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					325	+		10.1038/s41591-021-01622-0	http://dx.doi.org/10.1038/s41591-021-01622-0		DEC 2021	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	34921238	Green Submitted			2022-12-27	WOS:000731198400001
J	Juno, JA; Wheatley, AK				Juno, Jennifer A.; Wheatley, Adam K.			Boosting immunity to COVID-19 vaccines	NATURE MEDICINE			English	Editorial Material									[Juno, Jennifer A.; Wheatley, Adam K.] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia	University of Melbourne	Wheatley, AK (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.	a.wheatley@unimelb.edu.au		Wheatley, Adam/0000-0002-5593-9387; Juno, Jennifer/0000-0002-9072-1017	National Health and Medical Research Council fellowships	National Health and Medical Research Council fellowships(National Health and Medical Research Council (NHMRC) of Australia)	J.A.J. and A.K.W. are supported by National Health and Medical Research Council fellowships.	Adeniji OS, 2021, MBIO, V12, DOI 10.1128/mBio.00281-21; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Falsey AR, 2021, NEW ENGL J MED, V385, P1627, DOI 10.1056/NEJMc2113468; Keehner J, 2021, NEW ENGL J MED, V385, P1330, DOI 10.1056/NEJMc2112981; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z	10	25	25	1	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1874	1875		10.1038/s41591-021-01560-x	http://dx.doi.org/10.1038/s41591-021-01560-x		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764485				2022-12-27	WOS:000717406200007
J	Thornton, JM; Laskowski, RA; Borkakoti, N				Thornton, Janet M.; Laskowski, Roman A.; Borkakoti, Neera			AlphaFold heralds a data-driven revolution in biology and medicine	NATURE MEDICINE			English	Editorial Material								Protein structures predicted using artificial intelligence will aid medical research, but the greatest benefit will come if clinical data can be similarly used to better understand human disease.	[Thornton, Janet M.; Laskowski, Roman A.; Borkakoti, Neera] European Bioinformat Inst, European Mol Biol Lab EMBL, South Bldg,Wellcome Genome Campus, Hinxton, England	European Molecular Biology Laboratory (EMBL)	Thornton, JM (corresponding author), European Bioinformat Inst, European Mol Biol Lab EMBL, South Bldg,Wellcome Genome Campus, Hinxton, England.	thornton@ebi.ac.uk		Thornton, Janet/0000-0003-0824-4096; Laskowski, Roman/0000-0001-5528-0087				AlQuraishi M, 2021, CURR OPIN CHEM BIOL, V65, P1, DOI 10.1016/j.cbpa.2021.04.005; [Anonymous], COVID 19 PROTEIN STR; [Anonymous], DARWIN TREE LIFE; [Anonymous], CASP14 14 COMMUNITY; Baek M, 2021, SCIENCE, V373, P871, DOI 10.1126/science.abj8754; Bateman A, 2021, NUCLEIC ACIDS RES, V49, pD480, DOI 10.1093/nar/gkaa1100; Batool M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112783; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD520, DOI 10.1093/nar/gky949; Diwan G. D., 2021, J MOL BIOL; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Jones DT., 2021, CRYSTALLOGR NEWS, V156, P6; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Landrum MJ, 2020, NUCLEIC ACIDS RES, V48, pD835, DOI 10.1093/nar/gkz972; Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289; Lewin HA, 2018, P NATL ACAD SCI USA, V115, P4325, DOI 10.1073/pnas.1720115115; Mirdita M., PREPRINT, DOI [10.1101/2021.08.15.456425(2021, DOI 10.1101/2021.08.15.456425(2021]; Stefl S, 2013, J MOL BIOL, V425, P3919, DOI 10.1016/j.jmb.2013.07.014; Tunyasuvunakool K, 2021, NATURE, V596, P590, DOI 10.1038/s41586-021-03828-1; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Workman P., 2021, I CANC RES BLOGS	20	27	27	6	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1666	1669		10.1038/s41591-021-01533-0	http://dx.doi.org/10.1038/s41591-021-01533-0		OCT 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642488	Bronze			2022-12-27	WOS:000706587600001
J	Wade, KH; Lam, BYH; Melvin, A; Pan, W; Corbin, LJ; Hughes, DA; Rainbow, K; Chen, JH; Duckett, K; Liu, XM; Mokrosinski, J; Morseburg, A; Neaves, S; Williamson, A; Zhang, C; Farooqi, IS; Yeo, GSH; Timpson, NJ; O'Rahilly, S				Wade, Kaitlin H.; Lam, Brian Y. H.; Melvin, Audrey; Pan, Warren; Corbin, Laura J.; Hughes, David A.; Rainbow, Kara; Chen, Jian-Hua; Duckett, Katie; Liu, Xiaoming; Mokrosinski, Jacek; Morseburg, Alexander; Neaves, Sam; Williamson, Alice; Zhang, Chen; Farooqi, I. Sadaf; Yeo, Giles S. H.; Timpson, Nicholas J.; O'Rahilly, Stephen			Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort	NATURE MEDICINE			English	Article							BODY-MASS INDEX; GENE-MUTATIONS; FRAMESHIFT MUTATION; OBESITY; MC4R; DEFICIENCY; LEPTIN; CHILDHOOD; VARIANTS; RISK	Mutations in the melanocortin 4 receptor gene (MC4R) are associated with obesity but little is known about the prevalence and impact of such mutations throughout human growth and development. We examined the MC4R coding sequence in 5,724 participants from the Avon Longitudinal Study of Parents and Children, functionally characterized all nonsynonymous MC4R variants and examined their association with anthropometric phenotypes from childhood to early adulthood. The frequency of heterozygous loss-of-function (LoF) mutations in MC4R was similar to 1 in 337 (0.30%), considerably higher than previous estimates. At age 18 years, mean differences in body weight, body mass index and fat mass between carriers and noncarriers of LoF mutations were 17.76 kg (95% CI 9.41, 26.10), 4.84 kg m(-2) (95% CI 2.19, 7.49) and 14.78 kg (95% CI 8.56, 20.99), respectively. MC4R LoF mutations may be more common than previously reported and carriers of such variants may enter adult life with a substantial burden of excess adiposity.	[Wade, Kaitlin H.; Corbin, Laura J.; Hughes, David A.; Neaves, Sam; Timpson, Nicholas J.] Univ Bristol, Integrat Epidemiol Unit IEU, Med Res Council MRC, Bristol, Avon, England; [Wade, Kaitlin H.; Corbin, Laura J.; Hughes, David A.; Neaves, Sam; Timpson, Nicholas J.] Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Bristol, Avon, England; [Lam, Brian Y. H.; Melvin, Audrey; Pan, Warren; Rainbow, Kara; Chen, Jian-Hua; Duckett, Katie; Liu, Xiaoming; Mokrosinski, Jacek; Morseburg, Alexander; Williamson, Alice; Zhang, Chen; Farooqi, I. Sadaf; Yeo, Giles S. H.; O'Rahilly, Stephen] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Cambridge, England; [Lam, Brian Y. H.; Melvin, Audrey; Pan, Warren; Rainbow, Kara; Chen, Jian-Hua; Duckett, Katie; Liu, Xiaoming; Mokrosinski, Jacek; Morseburg, Alexander; Williamson, Alice; Zhang, Chen; Farooqi, I. Sadaf; Yeo, Giles S. H.; O'Rahilly, Stephen] Univ Cambridge, NIHR Cambridge Biomed Res Ctr, Cambridge, England	University of Bristol; University of Bristol; University of Cambridge; University of Cambridge	Timpson, NJ (corresponding author), Univ Bristol, Integrat Epidemiol Unit IEU, Med Res Council MRC, Bristol, Avon, England.; Timpson, NJ (corresponding author), Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Bristol, Avon, England.; O'Rahilly, S (corresponding author), Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Cambridge, England.; O'Rahilly, S (corresponding author), Univ Cambridge, NIHR Cambridge Biomed Res Ctr, Cambridge, England.	n.j.timpson@bristol.ac.uk; so104@medschl.cam.ac.uk	Corbin, Laura/AAN-1230-2020; Hughes, David/E-7190-2015; Timpson, Nicholas John/O-7548-2015; O'Rahilly, Stephen/ABF-6509-2020	Corbin, Laura/0000-0002-4032-9500; Hughes, David/0000-0002-9644-8998; Timpson, Nicholas John/0000-0002-7141-9189; O'Rahilly, Stephen/0000-0003-2199-4449; Williamson, Alice/0000-0002-7599-9301; Yeo, Giles See How/0000-0001-8823-3615; Mokrosinski, Jacek/0000-0001-5008-0457; Lam, Brian/0000-0002-3638-9025; Farooqi, Sadaf/0000-0001-7609-3504; Morseburg, Alexander/0000-0003-4832-4007; Pan, Warren/0000-0003-4931-8864	Wellcome Trust [102215/2/13/2, 204813/Z/16/Z, 202802/Z/16/Z, 098497/Z/12/Z, WT 095515/Z/11/Z, 208363/Z/17/Z]; MRC Metabolic Diseases Unit funding [MC_UU_00014/1]; Elizabeth Blackwell Institute for Health Research, University of Bristol; Cancer Research UK programme [C18281/A19169]; BBSRC [BB/S017593/1]; University of Cambridge Experimental Medicine Training Initiative programme; AstraZeneca; NIHR Cambridge Biomedical Research Centre; Bernard Wolfe Health Neuroscience Endowment; Wellcome Developing Concept Fund award; MRC Metabolic Disease Unit [MC_UU_00014/1]; National Institute for Health Research Cambridge Biomedical Research Centre; Medical Research Council [MC_UU_00014/5]; MRC Integrative Epidemiology Unit [MC_UU_00011]; Botnar Fondation	Wellcome Trust(Wellcome Trust); MRC Metabolic Diseases Unit funding; Elizabeth Blackwell Institute for Health Research, University of Bristol; Cancer Research UK programme(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); University of Cambridge Experimental Medicine Training Initiative programme; AstraZeneca(AstraZeneca); NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Bernard Wolfe Health Neuroscience Endowment; Wellcome Developing Concept Fund award; MRC Metabolic Disease Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Integrative Epidemiology Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Botnar Fondation	We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. We acknowledge the technical support of Tolulope Osunnuyi and the NIHR BRC-MRC BioRepository at Cambridge Biomedical Research Centre. We also thank staff members of the Wellcome Trust-MRC Institute of Metabolic Science Genomics and Transcriptomic core and the Genomics Core at the CRUK Cambridge Institute for their experimental support for next-generation sequencing. WES was obtained from ALSPAC (under proposal no. B2680) for comparison to the current study and we thank E. Robinson and B. Neale from the BROAD Institute for their contribution to exome sequencing. The UK MRC and Wellcome Trust (grant ref. I) and the University of Bristol provide core support for ALSPAC. Genome-wide association data were generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. Mutational screening, sequencing and functional analyses were supported by MRC Metabolic Diseases Unit funding (MC_UU_00014/1). This publication is the work of all authors and K.H.W., N.J.T. and S.O. serve as guarantors for the contents of this paper. K.H.W. was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). N.J.T. is a Wellcome Trust Investigator (202802/Z/16/Z), a workpackage lead in the Integrative Cancer Epidemiology Programme that is supported by a Cancer Research UK programme grant (C18281/A19169) and works within the University of Bristol National Institute for Health Research Biomedical Research Centre. D.A.H. and L.J.C. are supported by N.J.T.'s Wellcome Trust Investigator grant (202802/Z/16/Z) and work within the MRC Integrative Epidemiology Unit (MC_UU_00011). B.Y.H.L. is supported by a BBSRC Project Grant (BB/S017593/1). A. Melvin holds a PhD studentship supported jointly by the University of Cambridge Experimental Medicine Training Initiative programme in partnership with AstraZeneca. I.S.F. was supported by the Wellcome Trust (098497/Z/12/Z), the NIHR Cambridge Biomedical Research Centre, the Botnar Fondation and the Bernard Wolfe Health Neuroscience Endowment and a Wellcome Developing Concept Fund award (with J.M.). S.O.R. and G.S.H.Y. is supported by the MRC Metabolic Disease Unit (MC_UU_00014/1) and S.O.R. by a Wellcome Trust Investigator award (WT 095515/Z/11/Z) and National Institute for Health Research Cambridge Biomedical Research Centre. The Wellcome-MRC Institute of Metabolic Science Genomics and transcriptomics core facility is supported by the Medical Research Council (MC_UU_00014/5) and the Wellcome Trust (208363/Z/17/Z).	Apovian CM, 2016, NEW ENGL J MED, V374, P177, DOI 10.1056/NEJMe1514957; Baker JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMoa072515; Bjerregaard LG, 2018, NEW ENGL J MED, V378, P1302, DOI [10.1056/NEJMoa1713231, 10.1056/nejmoa1713231]; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Chami N, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003196; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Collet TH, 2017, MOL METAB, V6, P1321, DOI 10.1016/j.molmet.2017.06.015; Cornish RP, 2021, INT J EPIDEMIOL, V50, P293, DOI 10.1093/ije/dyaa192; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Dempfle A, 2004, J MED GENET, V41, P795, DOI 10.1136/jmg.2004.018614; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Fraser A, 2013, INT J EPIDEMIOL, V42, P97, DOI 10.1093/ije/dys066; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Goncalves JPL, 2018, TRENDS PHARMACOL SCI, V39, P402, DOI 10.1016/j.tips.2018.01.004; Greenfield JR, 2009, NEW ENGL J MED, V360, P44, DOI 10.1056/NEJMoa0803085; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Hinney A, 2006, J CLIN ENDOCR METAB, V91, P1761, DOI 10.1210/jc.2005-2056; Howe LD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015186; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Khera AV, 2019, CELL, V177, P587, DOI 10.1016/j.cell.2019.03.028; Krakoff J, 2008, DIABETES, V57, P3267, DOI 10.2337/db08-0577; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Leckie G, 2013, J STAT SOFTW, V52, P1; Lotta LA, 2019, CELL, V177, P597, DOI 10.1016/j.cell.2019.03.044; Majithia AR, 2016, NAT GENET, V48, P1570, DOI 10.1038/ng.3700; Martinelli CE, 2011, J CLIN ENDOCR METAB, V96, pE181, DOI 10.1210/jc.2010-1369; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Northstone Kate, 2019, Wellcome Open Res, V4, P51, DOI 10.12688/wellcomeopenres.15132.1; Richardson TG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1203; Stutzmann F, 2008, DIABETES, V57, P2511, DOI 10.2337/db08-0153; Thearle MS, 2012, DIABETES, V61, P250, DOI 10.2337/db11-0708; Tunc S, 2017, J CLIN RES PEDIATR E, V9, P216, DOI 10.4274/jcrpe.4225; Turcot V, 2018, NAT GENET, V50, P26, DOI 10.1038/s41588-017-0011-x; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Wade KH, 2018, CIRCULATION, V138, P2187, DOI 10.1161/CIRCULATIONAHA.117.033278; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	43	23	23	5	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1088	+		10.1038/s41591-021-01349-y	http://dx.doi.org/10.1038/s41591-021-01349-y		MAY 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34045736	Green Accepted, Green Submitted			2022-12-27	WOS:000655586900004
J	Adler, AI				Adler, Amanda I.			The STEP 1 trial for weight loss: a step change in treating obesity?	NATURE MEDICINE			English	Editorial Material									[Adler, Amanda I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England	University of Oxford	Adler, AI (corresponding author), Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.	amanda.adler@dtu.ox.ac.uk			National Institute of Health and Care Excellence; NIHR Oxford Biomedical Research Centre	National Institute of Health and Care Excellence; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR))	A.I.A. receives partial salary support from the National Institute of Health and Care Excellence and the NIHR Oxford Biomedical Research Centre.	Elgot Jessica, 2015, GUARDIAN; Goettler A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014632; Kolotkin RL, 2017, CLIN OBES, V7, P273, DOI 10.1111/cob.12203; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; Ryan DH, 2020, AM HEART J, V229, P61, DOI 10.1016/j.ahj.2020.07.008; Sandman L, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00539-6; Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183	7	1	1	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					589	590		10.1038/s41591-021-01319-4	http://dx.doi.org/10.1038/s41591-021-01319-4			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33859431				2022-12-27	WOS:000640612600014
J	Rodriguez-Bano, J				Rodriguez-Bano, Jesus			Making treatment decisions in a void of information	NATURE MEDICINE			English	Editorial Material								Revisiting the challenges of the beginning of the COVID-19 pandemic, when doctors and patients had to make treatment decisions without the support of scientific evidence, can provide valuable clues on how to prepare for future pandemics.	[Rodriguez-Bano, Jesus] Hosp Univ Virgen Macarena, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville, Spain; [Rodriguez-Bano, Jesus] Univ Seville, Dept Med, Seville, Spain; [Rodriguez-Bano, Jesus] Inst Biomed Sevilla, Seville, Spain	Hospital Universitario Virgen Macarena; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS)	Rodriguez-Bano, J (corresponding author), Hosp Univ Virgen Macarena, Unidad Clin Enfermedades Infecciosas & Microbiol, Seville, Spain.; Rodriguez-Bano, J (corresponding author), Univ Seville, Dept Med, Seville, Spain.; Rodriguez-Bano, J (corresponding author), Inst Biomed Sevilla, Seville, Spain.	jesusrb@us.es	Rodríguez-Baño, Jesús/F-2453-2011	Rodríguez-Baño, Jesús/0000-0001-6732-9001					0	0	0	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					575	575		10.1038/s41591-021-01293-x	http://dx.doi.org/10.1038/s41591-021-01293-x		MAR 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33753936	Bronze			2022-12-27	WOS:000631496800001
J	Sklavenitis-Pistofidis, R; Getz, G; Ghobrial, I				Sklavenitis-Pistofidis, Romanos; Getz, Gad; Ghobrial, Irene			Single-cell RNA sequencing: one step closer to the clinic	NATURE MEDICINE			English	Editorial Material							MULTIPLE-MYELOMA; SURVIVAL; RISK	Single-cell RNA-sequencing can help in the prediction of drug resistance in patients with multiple myeloma.	[Sklavenitis-Pistofidis, Romanos; Ghobrial, Irene] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Sklavenitis-Pistofidis, Romanos; Getz, Gad; Ghobrial, Irene] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Getz, Gad] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; [Ghobrial, Irene] Dana Farber Canc Inst, Ctr Prevent Progress Blood Canc, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Ghobrial, I (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Ghobrial, I (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ghobrial, I (corresponding author), Dana Farber Canc Inst, Ctr Prevent Progress Blood Canc, Boston, MA 02115 USA.	irene_ghobrial@dfci.harvard.edu		Getz, Gad/0000-0002-0936-0753; Ghobrial, Irene/0000-0001-7361-3092				Cohen YC, 2021, NAT MED, V27, P491, DOI 10.1038/s41591-021-01232-w; Gooding S, 2021, BLOOD, V137, P232, DOI 10.1182/blood.2020007081; Kuiper R, 2015, BLOOD, V126, P1996, DOI 10.1182/blood-2015-05-644039; Kumar SK, 2012, LEUKEMIA, V26, P149, DOI 10.1038/leu.2011.196; Kumar SK, 2018, NAT REV CLIN ONCOL, V15, P409, DOI 10.1038/s41571-018-0018-y; Liu YF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80607-4; Nunnelee J, 2019, BLOOD, V134, DOI 10.1182/blood-2019-121845; Oberle A, 2017, HAEMATOLOGICA, V102, P1105, DOI 10.3324/haematol.2016.161414; Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407; Scheijen B, 2019, LEUKEMIA, V33, P2227, DOI 10.1038/s41375-019-0508-7; Thorsteinsdottir S, 2018, HAEMATOLOGICA, V103, pE412, DOI 10.3324/haematol.2017.183475	11	5	5	1	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					375	376		10.1038/s41591-021-01276-y	http://dx.doi.org/10.1038/s41591-021-01276-y		MAR 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33664491				2022-12-27	WOS:000626919600002
J	Cascone, T; William, WN; Weissferdt, A; Leung, CH; Lin, HY; Pataer, A; Godoy, MCB; Carter, BW; Federico, L; Reuben, A; Khan, MAW; Dejima, H; Francisco-Cruz, A; Parra, ER; Solis, LM; Fujimoto, J; Tran, HT; Kalhor, N; Fossella, FV; Mott, FE; Tsao, AS; Blumenschein, G; Le, XN; Zhang, JJ; Skoulidis, F; Kurie, JM; Altan, M; Lu, C; Glisson, BS; Byers, LA; Elamin, YY; Mehran, RJ; Rice, DC; Walsh, GL; Hofstetter, WL; Roth, JA; Antonoff, MB; Kadara, H; Haymaker, C; Bernatchez, C; Ajami, NJ; Jenq, RR; Sharma, P; Allison, JP; Futreal, A; Wargo, JA; Wistuba, II; Swisher, SG; Lee, JJ; Gibbons, DL; Vaporciyan, AA; Heymach, JV; Sepesi, B				Cascone, Tina; William, William N., Jr.; Weissferdt, Annikka; Leung, Cheuk H.; Lin, Heather Y.; Pataer, Apar; Godoy, Myrna C. B.; Carter, Brett W.; Federico, Lorenzo; Reuben, Alexandre; Khan, Md Abdul Wadud; Dejima, Hitoshi; Francisco-Cruz, Alejandro; Parra, Edwin R.; Solis, Luisa M.; Fujimoto, Junya; Tran, Hai T.; Kalhor, Neda; Fossella, Frank V.; Mott, Frank E.; Tsao, Anne S.; Blumenschein, George, Jr.; Le, Xiuning; Zhang, Jianjun; Skoulidis, Ferdinandos; Kurie, Jonathan M.; Altan, Mehmet; Lu, Charles; Glisson, Bonnie S.; Byers, Lauren Averett; Elamin, Yasir Y.; Mehran, Reza J.; Rice, David C.; Walsh, Garrett L.; Hofstetter, Wayne L.; Roth, Jack A.; Antonoff, Mara B.; Kadara, Humam; Haymaker, Cara; Bernatchez, Chantale; Ajami, Nadim J.; Jenq, Robert R.; Sharma, Padmanee; Allison, James P.; Futreal, Andrew; Wargo, Jennifer A.; Wistuba, Ignacio I.; Swisher, Stephen G.; Lee, J. Jack; Gibbons, Don L.; Vaporciyan, Ara A.; Heymach, John V.; Sepesi, Boris			Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	NATURE MEDICINE			English	Article							OPEN-LABEL; SINGLE-ARM; CHEMOTHERAPY; MULTICENTER; ATEZOLIZUMAB; ANTI-CTLA-4; ANTI-PD-1; SURVIVAL; THERAPY	Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 randomized NEOSTAR trial (NCT03158129) of neoadjuvant nivolumab or nivolumab + ipilimumab followed by surgery in 44 patients with operable NSCLC, using major pathologic response (MPR) as the primary endpoint. The MPR rate for each treatment arm was tested against historical controls of neoadjuvant chemotherapy. The nivolumab + ipilimumab arm met the prespecified primary endpoint threshold of 6 MPRs in 21 patients, achieving a 38% MPR rate (8/21). We observed a 22% MPR rate (5/23) in the nivolumab arm. In 37 patients resected on trial, nivolumab and nivolumab + ipilimumab produced MPR rates of 24% (5/21) and 50% (8/16), respectively. Compared with nivolumab, nivolumab + ipilimumab resulted in higher pathologic complete response rates (10% versus 38%), less viable tumor (median 50% versus 9%), and greater frequencies of effector, tissue-resident memory and effector memory T cells. Increased abundance of gut Ruminococcus and Akkermansia spp. was associated with MPR to dual therapy. Our data indicate that neoadjuvant nivolumab + ipilimumab-based therapy enhances pathologic responses, tumor immune infiltrates and immunologic memory, and merits further investigation in operable NSCLC. Neoadjuvant treatment with nivolumab plus ipilimumab is well tolerated and demonstrates clinical efficacy in patients with early stage lung cancer.	[Cascone, Tina; William, William N., Jr.; Reuben, Alexandre; Tran, Hai T.; Fossella, Frank V.; Mott, Frank E.; Tsao, Anne S.; Blumenschein, George, Jr.; Le, Xiuning; Zhang, Jianjun; Skoulidis, Ferdinandos; Kurie, Jonathan M.; Altan, Mehmet; Lu, Charles; Glisson, Bonnie S.; Byers, Lauren Averett; Elamin, Yasir Y.; Wistuba, Ignacio I.; Gibbons, Don L.; Heymach, John V.] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Weissferdt, Annikka; Kalhor, Neda] Univ Texas MD Anderson Canc Ctr, Pathol, Houston, TX 77030 USA; [Weissferdt, Annikka; Pataer, Apar; Mehran, Reza J.; Rice, David C.; Walsh, Garrett L.; Hofstetter, Wayne L.; Roth, Jack A.; Antonoff, Mara B.; Swisher, Stephen G.; Vaporciyan, Ara A.; Sepesi, Boris] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA; [Leung, Cheuk H.; Lin, Heather Y.; Lee, J. Jack] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX 77030 USA; [Godoy, Myrna C. B.; Carter, Brett W.] Univ Texas MD Anderson Canc Ctr, Thorac Imaging, Houston, TX 77030 USA; [Federico, Lorenzo; Bernatchez, Chantale] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA; [Khan, Md Abdul Wadud; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Surg Oncol, Houston, TX 77030 USA; [Dejima, Hitoshi; Francisco-Cruz, Alejandro; Parra, Edwin R.; Solis, Luisa M.; Fujimoto, Junya; Kadara, Humam; Haymaker, Cara; Bernatchez, Chantale; Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Translat Mol Pathol, Houston, TX 77030 USA; [Ajami, Nadim J.; Jenq, Robert R.; Futreal, Andrew] Univ Texas MD Anderson Canc Ctr, Genom Med, Houston, TX 77030 USA; [Jenq, Robert R.] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Jenq, Robert R.] CPRIT Scholar Canc Res, Houston, TX USA; [Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA; [Sharma, Padmanee; Allison, James P.] Univ Texas MD Anderson Canc Ctr, Immunol, Houston, TX 77030 USA; [Heymach, John V.] Univ Texas MD Anderson Canc Ctr, Canc Biol, Houston, TX 77030 USA; [William, William N., Jr.] Hosp BP, Oncol Ctr, Sao Paulo, Brazil; [Dejima, Hitoshi] Teikyo Univ, Sch Med, Itabashi Ku, Tokyo, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Teikyo University	Cascone, T (corresponding author), Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.	tcascone@mdanderson.org	Francisco-Cruz, Alejandro/AIC-9273-2022; Altan, Orhan/AAD-4550-2022; William, William/GRX-5352-2022; Lee, Jack/P-7331-2019	Lee, Jack/0000-0002-4584-929X; Lee, J. Jack/0000-0001-5469-9214; Tran, Hai/0000-0003-4065-9355; Haymaker, Cara/0000-0002-1317-9287; Reuben, Alexandre/0000-0003-4510-0382	Bristol Myers Squibb; National Institutes of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence (SPORE) [5P50CA070907]; NIH/NCI [P30 CA016672]; Cancer Center Support Grant; Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018 [12895]; Connie Rasor Endowment for Cancer Research; Bruton Endowed Chair in Tumor Biology; TMP-IL at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center; T. J. Martell Foundation	Bristol Myers Squibb(Bristol-Myers Squibb); National Institutes of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence (SPORE); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018; Connie Rasor Endowment for Cancer Research; Bruton Endowed Chair in Tumor Biology; TMP-IL at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center; T. J. Martell Foundation	We thank the patients and their families for participating in this study. We thank all the members of our regulatory, clinical, data coordination and translational research teams in the Departments of Thoracic/Head and Neck Medical Oncology and Thoracic Surgery at the MD Anderson Cancer Center for their support on this trial. We thank the members of the strategic alliance teams at Bristol Myers Squibb and the MD Anderson Cancer Center (E. B. Roarty and A. Spelman) for their support. We thank the members of the Translational Molecular Pathology Immune-Profiling Laboratory (TMP-IL) B. Sanchez Espiridon, S. Wijeratne, for their assistance with sample procurement and inventory, C.-W. B. Chow, W. Lu, L. Kakarala, M. Jiang, A. Tamegnon, and J. Zhou for their technical assistance, and D. Lorenzini for pathology assistance in imaging analysis. We thank L. Little and C. Gumbs from the Department of Genomic Medicine for assistance with TCR sequencing. We thank the MD Anderson's Program for Innovative Microbiome and Translational Research (PRIME-TR) for supporting the analysis and interpretation of the microbiome results presented herein (Drs. J. A. Wargo and N. J. Ajami are the program director and executive scientific director for PRIME-TR, respectively). We thank Mr. D. Aten, Sr. Medical Illustrator in Creative Communications at MD Anderson Cancer Center, for his assistance with figure formatting. Funding support for the clinical trial was provided by Bristol Myers Squibb. Support for the study was also partially provided by the National Institutes of Health (NIH)/National Cancer Institute (NCI) through the University of Texas Lung Specialized Program of Research Excellence (SPORE; grant no. 5P50CA070907 to T.C., L.A.B., F.S., J.M.K., J.A.R., I.I.W., D.L.G. and J.V.H.), the NIH/NCI P30 CA016672 Cancer Center Support Grant, the Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award 2018 Project ID 12895 (to T.C.), the Connie Rasor Endowment for Cancer Research (to D.L.G.), the Bruton Endowed Chair in Tumor Biology (to J.V.H.), and the TMP-IL at the Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center. The study was also partially supported by the generous philanthropic contributions to the University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program, the University of Texas MD Anderson Cancer Center Physician Scientist Program (from the T. J. Martell Foundation, to T.C). the Khalifa Bin Zayed Al Nahyan Foundation (to T.C.), the Ford Petrin Donation (to J.V.H.), the Rexanna's Foundation for Fighting Lung Cancer (to T.C., D.L.G., J.V.H. and B.S.) and the Bob Mayberry Foundation (to T.C.).	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Bentebibel SE, 2019, CANCER DISCOV, V9, P711, DOI 10.1158/2159-8290.CD-18-1495; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Cascone T, 2020, CLIN CANCER RES, V26, P3525, DOI 10.1158/1078-0432.CCR-19-4180; Cascone T, 2018, ANN THORAC SURG, V105, P418, DOI 10.1016/j.athoracsur.2017.08.052; Chaft JE, 2013, J THORAC ONCOL, V8, P1084, DOI 10.1097/JTO.0b013e31829923ec; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Edgar R.C., 2016, UNOISE2 IMPROVED ERR, DOI 10.1101/081257; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gao SG, 2020, J THORAC ONCOL, V15, P816, DOI 10.1016/j.jtho.2020.01.017; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Hellmann MD, 2014, LANCET ONCOL, V15, pE42, DOI 10.1016/S1470-2045(13)70334-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kwiatkowski DJ, 2019, J CLIN ONCOL, V37; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martin J, 2002, J CLIN ONCOL, V20, P1989, DOI 10.1200/JCO.2002.08.092; Parra ER, 2018, APPL IMMUNOHISTO M M, V26, P83, DOI 10.1097/PAI.0000000000000531; Parra ER, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13942-8; Parra ER, 2020, CANCERS, V12, DOI 10.3390/cancers12020255; Parra ER, 2019, CANCERS, V11, DOI 10.3390/cancers11020247; Pataer A, 2012, J THORAC ONCOL, V7, P825, DOI 10.1097/JTO.0b013e318247504a; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ramalingam SS, 2020, J CLIN ONCOL, V38; Reck M, 2020, J CLIN ONCOL, V38; Reuben A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14273-0; Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sepesi B, 2019, J THORAC ONCOL, V14, pS745, DOI 10.1016/j.jtho.2019.08.1595; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Thall PF, 1996, J CLIN ONCOL, V14, P296, DOI 10.1200/JCO.1996.14.1.296; Tsao MS, 2018, J THORAC ONCOL, V13, P1302, DOI 10.1016/j.jtho.2018.05.013; Wei SC, 2019, P NATL ACAD SCI USA, V116, P22699, DOI 10.1073/pnas.1821218116; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Weissferdt A, 2020, CLIN LUNG CANCER, V21, P341, DOI 10.1016/j.cllc.2019.11.003; William WN, 2013, J THORAC ONCOL, V8, P222, DOI 10.1097/JTO.0b013e3182774108; Woolson RFC., 2002, STAT METHODS ANAL BI, Ved 2; Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8	45	144	150	16	52	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					504	+		10.1038/s41591-020-01224-2	http://dx.doi.org/10.1038/s41591-020-01224-2		FEB 2021	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33603241	Green Accepted			2022-12-27	WOS:000619508200002
J	Dunbar, CE				Dunbar, Cynthia E.			A plethora of gene therapies for hemoglobinopathies	NATURE MEDICINE			English	Editorial Material								CRISPR-Cas gene editing enters the field of promising clinical approaches for mitigating hemoglobin defects in patients with hemoglobinopathies.	[Dunbar, Cynthia E.] NHLBI, Translat Stem Cell Biol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Dunbar, CE (corresponding author), NHLBI, Translat Stem Cell Biol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	dunbarc@nhlbi.nih.gov		Dunbar, Cynthia/0000-0002-7645-838X	intramural program of the National Heart, Lung, and Blood Institute	intramural program of the National Heart, Lung, and Blood Institute	C.E.D. is funded by the intramural program of the National Heart, Lung, and Blood Institute.	Bauer DE, 2015, CURR OPIN GENET DEV, V33, P62, DOI 10.1016/j.gde.2015.08.001; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Esrick EB, 2021, NEW ENGL J MED, V384, P205, DOI 10.1056/NEJMoa2029392; Ferrari S, 2020, NAT BIOTECHNOL, V38, P1298, DOI 10.1038/s41587-020-0551-y; Fischer A, 2020, J EXP MED, V217, DOI 10.1084/jem.20190607; Fitzhugh CD, 2017, BLOOD, V130, P1946, DOI 10.1182/blood-2017-03-772392; Frangoul H, 2021, NEW ENGL J MED, V384, P252, DOI 10.1056/NEJMoa2031054; Marktel S, 2019, NAT MED, V25, P234, DOI 10.1038/s41591-018-0301-6; Naldini L, 2016, SCIENCE, V353, P1101, DOI 10.1126/science.aah6192; Ribeil JA, 2017, NEW ENGL J MED, V376, P848, DOI 10.1056/NEJMoa1609677; Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342; Zeng J, 2020, NAT MED, V26, P535, DOI 10.1038/s41591-020-0790-y	13	3	3	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					202	204		10.1038/s41591-021-01235-7	http://dx.doi.org/10.1038/s41591-021-01235-7		FEB 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33526930				2022-12-27	WOS:000613582400005
J	Bilal, U; Hessel, P; Perez-Ferrer, C; Michael, YL; Alfaro, T; Tenorio-Mucha, J; Friche, AAL; Pina, MF; Vives, A; Quick, H; Alazraqui, M; Rodriguez, DA; Miranda, JJ; Diez-Roux, AV; Alazraqui, M; Alazraqui, M; Spinelli, H; Guevel, C; Di Cecco, V; Tisnes, A; Leveau, C; Santoro, A; Herkovits, D; Trotta, A; Aguirre, P; Lopez, SR; Tumas, N; Gouveia, N; Mascolli, MA; Slovic, AD; Martins, LS; Kanai, CM; Barreto, M; Santos, G; de Freitas, AD; De Castro, CP; Sousa, JFD; Bell, MID; Andrade, RFS; Cardoso, L; Menezes, MCD; Pina, MDD; Skaba, DA; Guimaraes, JMN; Matos, VPD; Caiaffa, WT; Friche, AAD; Andrade, ACD; Vaz, CT; Coelho, DM; Sales, DM; Aguilar, GAS; Nascimento, JD; Morais, LMD; Santos, MD; Silva, UM; Frenz, P; Alfaro, T; Cordova, C; Ruiz, P; Fuentes, M; Castillo, M; Pedrero, S; Rodriguez, L; Doberti, T; Vergara, AV; Salazar, A; Cortinez-O'Ryan, A; Schmitt, C; Gonzalez, F; Baeza, F; Angelini, F; Orlando, L; Sarmiento, OL; Higuera, D; Gonzalez, C; Montes, F; Useche, AF; Guaje, O; Jaramillo, AM; Guzman, LA; Cuesta, DL; Guerra, JA; Bonilla, JA; Guzman, LA; Linares, M; Hessel, P; Morales, R; Triana, C; Wilches, MA; Palacio, A; Pena, FC; Sabogal, JHJ; Lopez, J; Fajardo, K; Botero, M; Cely, N; Martinez, P; Moncada, C; Meisel, JD; Martinez, E; Kroker-Lobos, MF; Ramirez-Zea, M; Mazariegos, M; Morales, A; Barrientos-Gutierrez, T; Perez-Ferrer, C; Prado-Galbarro, J; Lopez-Olmedo, NP; de Castro, F; Rojas-Martinez, R; Jauregui, A; Stern, D; Riojas, H; Texcalac, JL; Perez, DV; Miranda, JJ; Vasquez, AH; Diez-Canseco, F; Garcia, LS; Hammond, R; Rodriguez, D; Dronova, I; Wang, XZ; Moran, M; Zhao, YN; Ju, Y; Delclos-Alio, X; Hovmand, P; Ballard, E; Kuhlberg, J; Diez-Roux, AV; Auchincloss, A; Barber, S; Bilal, U; Garcia-Espana, F; Langellier, B; Lovasi, G; McClure, L; Michael, Y; Moore, K; Ortigoza, A; Quick, H; Quistberg, DA; Sanchez, BN; Stankov, I; Tapia-Granados, J; Yamada, G; Rodriguez-Hernandez, J; Melly, S; Avila-Palencia, I; Kephart, J; Mullachery, P; Trejo, B; Braverman, A; Fry, D; Henson, RM; Martinez-Folgar, K; Slesinski, SC; Indvik, K; Bolinaga, A				Bilal, Usama; Hessel, Philipp; Perez-Ferrer, Carolina; Michael, Yvonne L.; Alfaro, Tania; Tenorio-Mucha, Janeth; Friche, Amelia A. L.; Pina, Maria Fatima; Vives, Alejandra; Quick, Harrison; Alazraqui, Marcio; Rodriguez, Daniel A.; Miranda, J. Jaime; Diez-Roux, Ana V.; Alazraqui, Marcio; Alazraqui, Marcio; Spinelli, Hugo; Guevel, Carlos; Di Cecco, Vanessa; Tisnes, Adela; Leveau, Carlos; Santoro, Adrian; Herkovits, Damian; Trotta, Andres; Aguirre, Patricia; Lopez, Santiago Rodriguez; Tumas, Natalia; Gouveia, Nelson; Mascolli, Maria Antonietta; Slovic, Anne Dorothee; Martins, Lucas Soriano; Kanai, Claudio Makoto; Barreto, Mauricio; Santos, Gervasio; de Freitas, Anderson Dias; De Castro, Caio Porto; Filho, Jose Firmino de Sousa; Bell, Maria Izabel dos Santos; Andrade, Roberto Fernandes Silva; Cardoso, Leticia; Menezes, Mariana Carvalho de; Pina, Maria de Fatima de; Skaba, Daniel Albert; Guimaraes, Joanna Miguez Nery; Matos, Vanderlei Pascoal de; Caiaffa, Waleska Teixeira; Friche, Amelia Augusta de Lima; Andrade, Amanda Cristina de Souza; Vaz, Camila Teixeira; Coelho, Debora Moraes; Sales, Denise Marques; Aguilar, Guilherme Aparecido Santos; Nascimento, Julia de Carvalho; Morais, Lidia Maria de Oliveira; Santos, Mariana de Melo; Silva, Uriel Moreira; Frenz, Patricia; Alfaro, Tania; Cordova, Cynthia; Ruiz, Pablo; Fuentes, Mauricio; Castillo, Marianela; Pedrero, Sebastian; Rodriguez, Lorena; Doberti, Tamara; Vergara, Alejandra Vives; Salazar, Alejandro; Cortinez-O'Ryan, Andrea; Schmitt, Cristian; Gonzalez, Francisca; Baeza, Fernando; Angelini, Flavia; Orlando, Laura; Sarmiento, Olga Lucia; Higuera, Diana; Gonzalez, Catalina; Montes, Felipe; Useche, Andres F.; Guaje, Oscar; Jaramillo, Ana Maria; Guzman, Luis Angel; Cuesta, Diego Lucumi; Guerra, John Alexis; Bonilla, Jorge Alexander; Guzman, Luis Angel; Linares, Mario; Hessel, Philipp; Morales, Ricardo; Triana, Camilo; Wilches, Maria Alejandra; Palacio, Alejandro; Pena, Fabian Camilo; Sabogal, Joaquin Hernando Jaramillo; Lopez, Julieth; Fajardo, Karen; Botero, Marcelo; Cely, Natalia; Martinez, Paola; Moncada, Carlos; Meisel, Jose David; Martinez, Eliana; Kroker-Lobos, Maria Fernanda; Ramirez-Zea, Manuel; Mazariegos, Monica; Morales, Anali; Barrientos-Gutierrez, Tonatiuh; Perez-Ferrer, Carolina; Prado-Galbarro, Javier; Lopez-Olmedo, Nancy Paulina; de Castro, Filipa; Rojas-Martinez, Rosalba; Jauregui, Alejandra; Stern, Dalia; Riojas, Horacio; Texcalac, Jose Luis; Perez, Desiree Vidana; Miranda, J. Jaime; Vasquez, Akram Hernandez; Diez-Canseco, Francisco; Garcia, Lorena Saavedra; Hammond, Ross; Rodriguez, Daniel; Dronova, Iryna; Wang, Xize; Moran, Mika; Zhao, Yuanyuan; Ju, Yang; Delclos-Alio, Xavier; Hovmand, Peter; Ballard, Ellis; Kuhlberg, Jill; Diez-Roux, Ana V.; Auchincloss, Amy; Barber, Sharrelle; Bilal, Usama; Garcia-Espana, Felipe; Langellier, Brent; Lovasi, Gina; McClure, Leslie; Michael, Yvonne; Moore, Kari; Ortigoza, Ana; Quick, Harrison; Quistberg, D. Alex; Sanchez, Brisa N.; Stankov, Ivana; Tapia-Granados, Jose; Yamada, Goro; Rodriguez-Hernandez, Jordan; Melly, Steve; Avila-Palencia, Ione; Kephart, Josiah; Mullachery, Pricila; Trejo, Bricia; Braverman, Ariela; Fry, Dustin; Henson, Rosie Mae; Martinez-Folgar, Kevin; Slesinski, S. Claire; Indvik, Katherine; Bolinaga, Andrea		the SALURBAL group	Life expectancy and mortality in 363 cities of Latin America	NATURE MEDICINE			English	Article							EPIDEMIOLOGIC TRANSITION; ADULT MORTALITY; GLOBAL BURDEN; MEXICO; HEALTH; PATTERNS; DISEASE; STATES	The concept of a so-called urban advantage in health ignores the possibility of heterogeneity in health outcomes across cities. Using a harmonized dataset from the SALURBAL project, we describe variability and predictors of life expectancy and proportionate mortality in 363 cities across nine Latin American countries. Life expectancy differed substantially across cities within the same country. Cause-specific mortality also varied across cities, with some causes of death (unintentional and violent injuries and deaths) showing large variation within countries, whereas other causes of death (communicable, maternal, neonatal and nutritional, cancer, cardiovascular disease and other noncommunicable diseases) varied substantially between countries. In multivariable mixed models, higher levels of education, water access and sanitation and less overcrowding were associated with longer life expectancy, a relatively lower proportion of communicable, maternal, neonatal and nutritional deaths and a higher proportion of deaths from cancer, cardiovascular disease and other noncommunicable diseases. These results highlight considerable heterogeneity in life expectancy and causes of death across cities of Latin America, revealing modifiable factors that could be amenable to urban policies aimed toward improving urban health in Latin America and more generally in other urban environments. City-level analysis of data from the SALURBAL project shows vast heterogeneity in life expectancy across cities within the same country, in addition to substantive differences in causes of death among nine Latin American countries, revealing modifiable factors that could be leveraged by municipal-level policies aimed toward improving health in urban environments.	[Bilal, Usama; Michael, Yvonne L.; Quick, Harrison; Diez-Roux, Ana V.] Drexel Dornsife Sch Publ Hlth, Urban Hlth Collaborat, Philadelphia, PA 19104 USA; [Bilal, Usama; Michael, Yvonne L.; Quick, Harrison; Diez-Roux, Ana V.] Drexel Dornsife Sch Publ Hlth, Dept Epidmiol & BioStat, Philadelphia, PA 19104 USA; [Hessel, Philipp] Univ Los Andes, Alberto Lleras Camargo Sch Govt, Bogota, Colombia; [Perez-Ferrer, Carolina] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Perez-Ferrer, Carolina] Natl Council Sci & Technol, CONACYT, Mexico City, DF, Mexico; [Alfaro, Tania] Univers Chile, Escuela Salud Publ, Santiago, Chile; [Tenorio-Mucha, Janeth; Miranda, J. Jaime] Univ Peruana Cayetano Heredia, CRON Ctr Excellence Chron Dis, Lima, Peru; [Friche, Amelia A. L.] Univ Fed Minas Gerais, Sch Med, Observ Urban Hlth, Belo Horizonte, Brazil; [Pina, Maria Fatima] Fiocruz MS, Inst Informat & Commun Hlth, Rio De Janeiro, Brazil; [Pina, Maria Fatima] i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Vives, Alejandra] Pontificia Univ Catolica Chile, Dept Salud Publ, Santiago, Chile; [Vives, Alejandra] Ctr Desarrollo Urbano Sostenible, Santiago, Chile; [Alazraqui, Marcio; Alazraqui, Marcio; Alazraqui, Marcio; Spinelli, Hugo; Guevel, Carlos; Di Cecco, Vanessa; Tisnes, Adela; Leveau, Carlos; Santoro, Adrian; Herkovits, Damian; Trotta, Andres; Aguirre, Patricia] Univ Nacl Lanus, Inst Salud Colect, Buenos Aires, DF, Argentina; [Rodriguez, Daniel A.; Hammond, Ross] Univ Calif Berkeley, Dept City & Reg Planning, Berkeley, CA 94720 USA; [Alazraqui, Marcio; Lopez, Santiago Rodriguez; Tumas, Natalia] Univ Nacl Cordoba, Ctr Invest & Estudios Cultura & Sociedad, Cordoba, Argentina; [Alazraqui, Marcio; Gouveia, Nelson; Mascolli, Maria Antonietta; Slovic, Anne Dorothee; Martins, Lucas Soriano; Kanai, Claudio Makoto] Univ Sao Paulo, Sao Paulo, Brazil; [Alazraqui, Marcio; Barreto, Mauricio; Santos, Gervasio; de Freitas, Anderson Dias; De Castro, Caio Porto; Filho, Jose Firmino de Sousa; Bell, Maria Izabel dos Santos; Andrade, Roberto Fernandes Silva] Fundacao Oswaldo Cruz, Salvador, Ba, Brazil; [Alazraqui, Marcio; Cardoso, Leticia; Menezes, Mariana Carvalho de; Pina, Maria de Fatima de; Skaba, Daniel Albert; Guimaraes, Joanna Miguez Nery; Matos, Vanderlei Pascoal de] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil; [Alazraqui, Marcio; Caiaffa, Waleska Teixeira; Friche, Amelia Augusta de Lima; Andrade, Amanda Cristina de Souza; Vaz, Camila Teixeira; Coelho, Debora Moraes; Sales, Denise Marques; Aguilar, Guilherme Aparecido Santos; Nascimento, Julia de Carvalho; Morais, Lidia Maria de Oliveira; Santos, Mariana de Melo; Silva, Uriel Moreira] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Alazraqui, Marcio; Frenz, Patricia; Alfaro, Tania; Cordova, Cynthia; Ruiz, Pablo; Fuentes, Mauricio; Castillo, Marianela; Pedrero, Sebastian; Rodriguez, Lorena; Doberti, Tamara] Univ Chile, Sch Publ Hlth, Santiago, Chile; [Alazraqui, Marcio; Vergara, Alejandra Vives; Salazar, Alejandro; Cortinez-O'Ryan, Andrea; Schmitt, Cristian; Gonzalez, Francisca; Baeza, Fernando; Angelini, Flavia; Orlando, Laura] Pontificia Unic Catolica Chile, Dept Publ Hlth, Santiago, Chile; [Alazraqui, Marcio; Sarmiento, Olga Lucia; Higuera, Diana; Gonzalez, Catalina; Montes, Felipe; Useche, Andres F.; Guaje, Oscar; Jaramillo, Ana Maria; Guzman, Luis Angel; Cuesta, Diego Lucumi; Guerra, John Alexis; Bonilla, Jorge Alexander; Guzman, Luis Angel; Linares, Mario; Hessel, Philipp; Morales, Ricardo; Triana, Camilo; Wilches, Maria Alejandra; Palacio, Alejandro; Sabogal, Joaquin Hernando Jaramillo; Lopez, Julieth; Fajardo, Karen; Botero, Marcelo; Cely, Natalia; Martinez, Paola; Moncada, Carlos; Meisel, Jose David] Univ Los Andes, Bogota, Colombia; [Martinez, Eliana] Univ Ibague, Ibague, Colombia; [Kroker-Lobos, Maria Fernanda] Univ Antioquia, Medellin, Colombia; [Ramirez-Zea, Manuel; Mazariegos, Monica; Morales, Anali; Barrientos-Gutierrez, Tonatiuh] Inst Nutr Cent Amer & Panama, INCAP Res Ctr Prevent Chron Dis, Guatemala City, Guatemala; [Perez-Ferrer, Carolina; Prado-Galbarro, Javier; Lopez-Olmedo, Nancy Paulina; de Castro, Filipa; Rojas-Martinez, Rosalba; Jauregui, Alejandra; Stern, Dalia; Riojas, Horacio; Texcalac, Jose Luis; Perez, Desiree Vidana; Miranda, J. Jaime; Vasquez, Akram Hernandez] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico; [Diez-Canseco, Francisco; Garcia, Lorena Saavedra; Hammond, Ross] Univ Peruana Cayetano Heredia, Sch Med, Lima, Peru; [Rodriguez, Daniel] Brookings Inst, Washington, DC 20036 USA; [Ballard, Ellis; Kuhlberg, Jill; Diez-Roux, Ana V.] Washington Univ, St Louis, MO 63110 USA; [Auchincloss, Amy; Barber, Sharrelle; Bilal, Usama; Garcia-Espana, Felipe; Langellier, Brent; Lovasi, Gina; McClure, Leslie; Michael, Yvonne; Moore, Kari; Ortigoza, Ana; Quick, Harrison; Quistberg, D. Alex; Sanchez, Brisa N.; Stankov, Ivana; Tapia-Granados, Jose; Yamada, Goro; Rodriguez-Hernandez, Jordan; Melly, Steve; Avila-Palencia, Ione; Kephart, Josiah; Mullachery, Pricila; Trejo, Bricia; Braverman, Ariela; Fry, Dustin; Henson, Rosie Mae; Martinez-Folgar, Kevin; Slesinski, S. Claire; Indvik, Katherine; Bolinaga, Andrea; the SALURBAL group] Drexel Univ, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA	Drexel University; Drexel University; Universidad de los Andes (Colombia); Instituto Nacional de Salud Publica; Universidad Peruana Cayetano Heredia; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Pontificia Universidad Catolica de Chile; University of California System; University of California Berkeley; National University of Cordoba; Universidade de Sao Paulo; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais; Universidad de Chile; Universidad de los Andes (Colombia); Universidad de Antioquia; Institute of Nutrition of Central America & Panama (INCAP); Instituto Nacional de Salud Publica; Universidad Peruana Cayetano Heredia; Brookings Institution; Washington University (WUSTL); Drexel University	Bilal, U (corresponding author), Drexel Dornsife Sch Publ Hlth, Urban Hlth Collaborat, Philadelphia, PA 19104 USA.; Bilal, U (corresponding author), Drexel Dornsife Sch Publ Hlth, Dept Epidmiol & BioStat, Philadelphia, PA 19104 USA.	ubilal@drexel.edu	Lovasi, Gina/C-2781-2009; Meisel, Jose/AAV-8857-2021; Wang, Xize/AAL-4880-2021; Slovic, Anne Dorothee/N-8506-2013; RODRIGUEZ, Daniel/GWC-3563-2022; Morais, Lidia/AAO-6708-2021; Tisnes, Adela/GZL-2097-2022; Silva, Uriel Moreira/AAR-6130-2021; Gouveia, Nelson C/C-4580-2013; Filho, José Firmino Sousa/AAU-2252-2021; Pina, Maria de Fatima/N-7574-2014	Lovasi, Gina/0000-0003-2613-9599; Wang, Xize/0000-0002-4861-6002; Slovic, Anne Dorothee/0000-0002-4780-5813; Silva, Uriel Moreira/0000-0001-7640-2530; Gouveia, Nelson C/0000-0003-0625-0265; Filho, José Firmino Sousa/0000-0001-5057-385X; Andrade, Roberto/0000-0002-9323-1400; Bilal, Usama/0000-0002-9868-7773; Spinelli, Hugo/0000-0001-5021-6377; Tenorio-Mucha, Janeth/0000-0003-2837-5149; Ju, Yang/0000-0002-1947-7533; Hessel, Philipp/0000-0002-8754-5710; Tisnes, Adela/0000-0002-6642-6608; Pina, Maria de Fatima/0000-0002-1521-7865; Diez-Canseco, Francisco/0000-0002-7611-8190; Martinez-Folgar, Kevin/0000-0001-9262-298X; Alfaro, Tania/0000-0002-2528-1457; Santos, Gervasio/0000-0002-3545-3590; Mullachery, Pricila H./0000-0003-4758-3875	Wellcome Trust [205177/Z/16/Z]; Office of the Director of the National Institutes of Health [DP5OD26429]	Wellcome Trust(Wellcome Trust); Office of the Director of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We acknowledge the help of A. Peralta in discussing some of the methods. SALURBAL acknowledges the contributions of many different agencies in generating, processing, facilitating access to data or assisting with other aspects of the project. A comprehensive list of these agencies can be found here: https://drexel.edu/lac/data-evidence/data-acknowledgements.The SALURBAL/Urban Health in Latin America project is funded by the Wellcome Trust (205177/Z/16/Z). U.B. was also supported by the Office of the Director of the National Institutes of Health under award number DP5OD26429. The funding sources had no role in the analysis, writing or decision to submit the manuscript.	Adair T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197047; Andrade F, 2009, REV PANAM SALUD PUBL, V26, P9, DOI 10.1590/S1020-49892009000700002; [Anonymous], 2017, DDM DEATH REG COV ES; BENNETT NG, 1984, DEMOGRAPHY, V21, P217, DOI 10.2307/2061041; Bettencourt LMA, 2007, P NATL ACAD SCI USA, V104, P7301, DOI 10.1073/pnas.0610172104; Bilal U, 2019, LANCET PLANET HEALTH, V3, pE503, DOI 10.1016/S2542-5196(19)30235-9; Browning CR, 2010, J RES CRIME DELINQ, V47, P329, DOI 10.1177/0022427810365906; Dandona L, 2017, LANCET, V390, P2437, DOI 10.1016/S0140-6736(17)32804-0; Dye C, 2008, SCIENCE, V319, P766, DOI 10.1126/science.1150198; Fagliano JA, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002621; Franco M, 2015, J EPIDEMIOL COMMUN H, V69, P509, DOI 10.1136/jech-2014-203865; Gomez-Dantes H, 2016, LANCET, V388, P2386, DOI 10.1016/S0140-6736(16)31773-1; Gomez-Lievano A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040393; Gonzaga Marcos Roberto, 2016, Rev. bras. estud. popul., V33, P629, DOI 10.20947/s0102-30982016c0009; Hastings KG, 2018, ANN INTERN MED, V169, P836, DOI 10.7326/M17-0796; Hijar M, 2012, TRAFFIC INJ PREV, V13, P5, DOI 10.1080/15389588.2011.631065; Hill K, 1987, Asian Pac Popul Forum, V1, P8; Hill K, 2017, 201702 POP DIV; Hill K, 2009, DEMOGR RES, V21, P235, DOI 10.4054/DemRes.2009.21.9; Howe LD, 2012, INT J EPIDEMIOL, V41, P871, DOI 10.1093/ije/dys037; Kashnitsky I., 2019, DEMOTOOLS R PACKAGE, DOI DOI 10.1016/S0140-6736(14)60569-9; Konteh FH, 2009, HEALTH PLACE, V15, P69, DOI 10.1016/j.healthplace.2008.02.003; Lonnroth K, 2009, SOC SCI MED, V68, P2240, DOI 10.1016/j.socscimed.2009.03.041; Mathers CD, 2015, LANCET, V385, P540, DOI 10.1016/S0140-6736(14)60569-9; Matthews Z, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000327; McKeown RE, 2009, AM J LIFESTYLE MED, V3, p19S, DOI 10.1177/1559827609335350; Miranda JJ, 2019, NAT MED, V25, P1667, DOI 10.1038/s41591-019-0644-7; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; Murray CJL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000262; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Naghavi M, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-9; Office for National Statistics, 2016, METH CHANG LIF HLTH; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Palloni A, 2011, INT HANDB POPUL, V2, P101, DOI 10.1007/978-90-481-9996-9_5; Patz JA, 2004, ENVIRON HEALTH PERSP, V112, P1092, DOI 10.1289/ehp.6877; Peralta A, 2019, POPUL HEALTH METR, V17, DOI 10.1186/s12963-019-0183-y; Quistberg DA, 2019, J URBAN HEALTH, V96, P311, DOI 10.1007/s11524-018-00326-0; Rosero-Bixby L, 2018, DEMOGR RES, V38, P95, DOI 10.4054/DemRes.2018.38.3; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Roux AVD, 2019, GLOB CHALL, V3, DOI 10.1002/gch2.201800013; Rubin DB., 1987, MULTIPLE IMPUTATION, DOI 10.1002/9780470316696; Russell B, 2019, ANTIPODE, V51, P989, DOI 10.1111/anti.12520; Rydin Y, 2012, LANCET, V379, P2079, DOI 10.1016/S0140-6736(12)60435-8; Schmertmann CP, 2018, DEMOGRAPHY, V55, P1363, DOI 10.1007/s13524-018-0695-2; Seaman R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2358-1; Tracey JA, 2014, ECOSPHERE, V5, DOI 10.1890/ES13-00376.1; UN-HABITAT, 2016, URB DEV EM FUT WORLD; UNDP Population Division, 2018, WORLD URB PROSP 2018; United Nations Population Division, 2019, WORLD POP PROSP 2019; Whitmee S, 2015, LANCET, V386, P1973, DOI 10.1016/S0140-6736(15)60901-1; World Bank, 2017, WORLD BANK COUNTR LE; World Health Organization, 2014, GLOB HLTH EST DEATHS, P9; World Health Organization, 2018, GLOB HLTH EST DIS BU	53	24	25	3	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					463	+		10.1038/s41591-020-01214-4	http://dx.doi.org/10.1038/s41591-020-01214-4		JAN 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33495602	hybrid, Green Published, Green Accepted			2022-12-27	WOS:000611467500002
J	Jin, J; Agarwala, N; Kundu, P; Harvey, B; Zhang, YQ; Wallace, E; Chatterjee, N				Jin, Jin; Agarwala, Neha; Kundu, Prosenjit; Harvey, Benjamin; Zhang, Yuqi; Wallace, Eliza; Chatterjee, Nilanjan			Individual and community-level risk for COVID-19 mortality in the United States	NATURE MEDICINE			English	Article								A new risk calculator calibrated specifically for the US population provides estimates of risk for COVID-19 for individuals and at the community level, using socioeconomic factors, demography, pre-existing conditions and mortality rates by age and ethnicity. Reducing COVID-19 burden for populations will require equitable and effective risk-based allocations of scarce preventive resources, including vaccinations(1). To aid in this effort, we developed a general population risk calculator for COVID-19 mortality based on various sociodemographic factors and pre-existing conditions for the US population, combining information from the UK-based OpenSAFELY study with mortality rates by age and ethnicity across US states. We tailored the tool to produce absolute risk estimates in future time frames by incorporating information on pandemic dynamics at the community level. We applied the model to data on risk factor distribution from a variety of sources to project risk for the general adult population across 477 US cities and for the Medicare population aged 65 years and older across 3,113 US counties, respectively. Validation analyses using 54,444 deaths from 7 June to 1 October 2020 show that the model is well calibrated for the US population. Projections show that the model can identify relatively small fractions of the population (for example 4.3%) that might experience a disproportionately large number of deaths (for example 48.7%), but there is wide variation in risk across communities. We provide a web-based risk calculator and interactive maps for viewing community-level risks.	[Jin, Jin; Kundu, Prosenjit; Harvey, Benjamin; Chatterjee, Nilanjan] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Agarwala, Neha] Univ Maryland Baltimore Cty, Dept Math & Stat, Baltimore, MD 21228 USA; [Zhang, Yuqi] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Wallace, Eliza] PolicyMap Inc, Philadelphia, PA USA; [Chatterjee, Nilanjan] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore County; Johns Hopkins University; Johns Hopkins University	Chatterjee, N (corresponding author), Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.; Chatterjee, N (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.	nilanjan@jhu.edu	Kundu, Prosenjit/ABB-5220-2021	Zhang, Yuqi/0000-0002-4266-8688; Agarwala, Neha/0000-0002-9975-9492	Bloomberg Distinguished Professorship endowment	Bloomberg Distinguished Professorship endowment	We thank A. Meisner from the John Hopkins University, Biostatistics Department and M. Garcia-Closas from the Division of Cancer Epidemiology and Genetics at the NCI for their comments on a previous version of the manuscript. This research was funded by the Bloomberg Distinguished Professorship endowment.	Adams ML, 2020, EMERG INFECT DIS, V26, P1831, DOI 10.3201/eid2608.200679; Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0; Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757; Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3; Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Giordano G, 2020, NAT MED, V26, P855, DOI 10.1038/s41591-020-0883-7; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Khunti K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1548; Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218; Kundu P, 2019, BIOMETRIKA, V106, P567, DOI 10.1093/biomet/asz030; Link A, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2004794; National Academies of Sciences Engineering Medicine, 2020, FRAMEWORK EQUITABLE; Nguyen Long H, 2020, Lancet Public Health, V5, pe475, DOI [10.1101/2020.04.29.20084111, 10.1016/S2468-2667(20)30164-X]; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Parohan M, 2020, AGING MALE, V23, P1416, DOI 10.1080/13685538.2020.1774748; Rasmussen SA, 2020, JAMA-J AM MED ASSOC, V324, P933, DOI 10.1001/jama.2020.14992; Ray EL., 2020, ENSEMBLE FORECASTS C, DOI 10.1101/2020.08.19.20177493; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Smith GD, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2063; van Bunnik B, 2020, SEGMENTATION SHIELDI, DOI [10.1101/2020.05.04.20090597, DOI 10.1101/2020.05.04.20090597]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548	30	32	31	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					264	+		10.1038/s41591-020-01191-8	http://dx.doi.org/10.1038/s41591-020-01191-8		DEC 2020	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33311702	Bronze			2022-12-27	WOS:000597776900001
J	Casazza, JP; Cale, EM; Narpala, S; Yamshchikov, GV; Coates, EE; Hendel, CS; Novik, L; Holman, LA; Widge, AT; Apte, P; Gordon, I; Gaudinski, MR; Conan-Cibotti, M; Lin, BC; Nason, MC; Trofymenko, O; Telscher, S; Plummer, SH; Wycuff, D; Adams, WC; Pandey, JP; McDermott, A; Roederer, M; Sukienik, AN; O'Dell, S; Gall, JG; Flach, B; Terry, TL; Choe, M; Shi, W; Chen, XJ; Kaltovich, F; Saunders, KO; Stein, JA; Doria-Rose, NA; Schwartz, RM; Balazs, AB; Baltimore, D; Nabel, GJ; Koup, RA; Graham, BS; Ledgerwood, JE; Mascola, JR				Casazza, Joseph P.; Cale, Evan M.; Narpala, Sandeep; Yamshchikov, Galina, V; Coates, Emily E.; Hendel, Cynthia S.; Novik, Laura; Holman, LaSonji A.; Widge, Alicia T.; Apte, Preeti; Gordon, Ingelise; Gaudinski, Martin R.; Conan-Cibotti, Michelle; Lin, Bob C.; Nason, Martha C.; Trofymenko, Olga; Telscher, Shinyi; Plummer, Sarah H.; Wycuff, Diane; Adams, William C.; Pandey, Janardan P.; McDermott, Adrian; Roederer, Mario; Sukienik, Avery N.; O'Dell, Sijy; Gall, Jason G.; Flach, Britta; Terry, Travis L.; Choe, Misook; Shi, Wei; Chen, Xuejun; Kaltovich, Florence; Saunders, Kevin O.; Stein, Judy A.; Doria-Rose, Nicole A.; Schwartz, Richard M.; Balazs, Alejandro B.; Baltimore, David; Nabel, Gary J.; Koup, Richard A.; Graham, Barney S.; Ledgerwood, Julie E.; Mascola, John R.		VRC 603 Study Team	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial	NATURE MEDICINE			English	Article							N-GLYCAN RECOGNITION; ADENOASSOCIATED VIRUS; GENE-TRANSFER; THERAPEUTIC LEVELS; NONHUMAN-PRIMATES; FACTOR-IX; PROTECTION; INFECTION; HEMOPHILIA; VACCINATION	Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination or by repeated infusions of bnAbs. In this study, we administered a recombinant bicistronic adeno-associated virus (AAV8) vector coding for both the light and heavy chains of the potent broadly neutralizing HIV-1 antibody VRCO7 (AAV8-VRCO7) to eight adults living with HIV. All participants remained on effective anti-retroviral therapy (viral load (VL) <50 copies per milliliter) throughout this phase 1, dose-escalation clinical trial (NCT03374202). AAV8-VRCO7 was given at doses of 5 x 10(10), 5 x 10(11) and 2.5 x 10(12) vector genomes per kilogram by intramuscular (IM) injection. Primary endpoints of this study were to assess the safety and tolerability of AAV8-VRCO7; to determine the pharmacokinetics and immunogenicity of in vivo VRCO7 production; and to describe the immune response directed against AAV8-VRCO7 vector and its products. Secondary endpoints were to assess the clinical effects of AAV8-VRCO7 on CD4 T cell count and VL and to assess the persistence of VRCO7 produced in participants. In this cohort, IM injection of AAV8-VRCO7 was safe and well tolerated. No clinically significant change in CD4 T cell count or VL occurred during the 1-3 years of follow-up reported here. In participants who received AAV8-VRCO7, concentrations of VRCO7 were increased 6 weeks (P = 0.008) and 52 weeks (P = 0.016) after IM injection of the product. All eight individuals produced measurable amounts of serum VRCO7, with maximal VRCO7 concentrations >1 mu g ml(-1) in three individuals. In four individuals, VRCO7 serum concentrations remained stable near maximal concentration for up to 3 years of follow-up. In exploratory analyses, neutralizing activity of in vivo produced VRCO7 was similar to that of in vitro produced VRCO7. Three of eight participants showed a non-idiotypic anti-drug antibody (ADA) response directed against the Fab portion of VRCO7. This ADA response appeared to decrease the production of serum VRCO7 in two of these three participants. These data represent a proof of concept that adeno-associated viral vectors can durably produce biologically active, difficult-to-induce bnAbs in vivo, which could add valuable new tools to the fight against infectious diseases.	[Casazza, Joseph P.; Cale, Evan M.; Narpala, Sandeep; Yamshchikov, Galina, V; Coates, Emily E.; Hendel, Cynthia S.; Novik, Laura; Holman, LaSonji A.; Widge, Alicia T.; Apte, Preeti; Gordon, Ingelise; Gaudinski, Martin R.; Conan-Cibotti, Michelle; Lin, Bob C.; Trofymenko, Olga; Telscher, Shinyi; Plummer, Sarah H.; Wycuff, Diane; Adams, William C.; McDermott, Adrian; Roederer, Mario; Sukienik, Avery N.; O'Dell, Sijy; Gall, Jason G.; Flach, Britta; Terry, Travis L.; Choe, Misook; Shi, Wei; Chen, Xuejun; Kaltovich, Florence; Stein, Judy A.; Doria-Rose, Nicole A.; Schwartz, Richard M.; Koup, Richard A.; Graham, Barney S.; Ledgerwood, Julie E.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Nason, Martha C.] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Pandey, Janardan P.] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Balazs, Alejandro B.] MIT & Harvard, Ragon Inst MGH, Cambridge, MA USA; [Baltimore, David] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA; [Saunders, Kevin O.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA; [Schwartz, Richard M.] Vaxart Inc, San Francisco, CA USA; [Nabel, Gary J.] ModeX Therapeut, Natick, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Medical University of South Carolina; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; California Institute of Technology; Duke University	Casazza, JP (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jcasazza@mail.nih.gov		Widge, Alicia/0000-0001-7615-8320; Balazs, Alejandro/0000-0002-1767-3944; Gaudinski, Martin/0000-0002-3743-5281	National Institute of Allergy and Infectious Diseases through the National Institutes of Health Intramural Research Program; National Institutes for Drug Abuse Avenir New Innovator Award [DP2DA040254]; MGH Transformative Scholars Program; Charles H. Hood Foundation; Leidos Biomedical Research, Inc.	National Institute of Allergy and Infectious Diseases through the National Institutes of Health Intramural Research Program; National Institutes for Drug Abuse Avenir New Innovator Award; MGH Transformative Scholars Program; Charles H. Hood Foundation; Leidos Biomedical Research, Inc.	We would like to acknowledge J. Gilly and C. Case of Science Applications International Corporation for their contributions to study product manufacturing as well as P. Johnson and F. Wright of Children's Hospital of Philadelphia for providing critical AAV expertise. We thank R. Kothera for technical assistance in GM allotyping. We would like to thank our trial volunteers for their contribution and commitment to developing an effective clinical intervention for the prevention and control of HIV. This work was supported by intramural funding from the National Institute of Allergy and Infectious Diseases through the National Institutes of Health Intramural Research Program. A.B.B. is supported by National Institutes for Drug Abuse Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation. J.P.P. received funding from Leidos Biomedical Research, Inc. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Balazs AB, 2014, NAT MED, V20, P296, DOI 10.1038/nm.3471; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Bonsignori M, 2017, IMMUNOL REV, V275, P145, DOI [10.1111/imr.12509, 10.]; Brady JM, 2017, IMMUNOL REV, V275, P324, DOI 10.1111/imr.12478; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158; Calcedo R, 2009, J INFECT DIS, V199, P381, DOI 10.1086/595830; Cale EM, 2020, J CLIN INVEST, V130, P3299, DOI 10.1172/JCI134395; Casazza JP, 2013, J INFECT DIS, V207, P1829, DOI 10.1093/infdis/jit098; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Crowell TA, 2019, LANCET HIV, V6, pE297, DOI 10.1016/S2352-3018(19)30053-0; Cunningham CK, 2020, J INFECT DIS, V222, P628, DOI 10.1093/infdis/jiz532; Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08; de la Pena AT, 2017, CELL REP, V20, P1805, DOI 10.1016/j.celrep.2017.07.077; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Fang JM, 2007, MOL THER, V15, P1153, DOI 10.1038/sj.mt.6300142; Fang JM, 2005, NAT BIOTECHNOL, V23, P584, DOI 10.1038/nbt1087; Fuchs SP, 2020, MOL THER-METH CLIN D, V16, P94, DOI 10.1016/j.omtm.2019.11.010; Fuchs SP, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.68; Fuchs SP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005090; Gaudinski MR, 2019, LANCET HIV, V6, pE667, DOI 10.1016/S2352-3018(19)30181-X; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Gift SK, 2017, J VIROL, V91, DOI 10.1128/JVI.01216-17; Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171; Huang JH, 2016, IMMUNITY, V45, P1108, DOI 10.1016/j.immuni.2016.10.027; Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544; Jefferis R, 2009, MABS, V1, P332, DOI 10.4161/mabs.1.4.9122; Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967; Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Kwong PD, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007278; Ledgerwood JE, 2015, CLIN EXP IMMUNOL, V182, P289, DOI 10.1111/cei.12692; Lisowski L, 2015, CURR OPIN PHARMACOL, V24, P59, DOI 10.1016/j.coph.2015.07.006; Liu JY, 2016, SCIENCE, V353, P1045, DOI 10.1126/science.aag0491; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Martinez-Navio JM, 2019, IMMUNITY, V50, P567, DOI 10.1016/j.immuni.2019.02.005; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Nathwani AC, 2014, NEW ENGL J MED, V371, P1994, DOI 10.1056/NEJMoa1407309; Nowrouzi A, 2012, MOL THER, V20, P1177, DOI 10.1038/mt.2012.47; Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600; Pandey JP, 2019, J ALZHEIMERS DIS, V70, P917, DOI 10.3233/JAD-190265; Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]; Penaud-Budloo M, 2008, J VIROL, V82, P7875, DOI 10.1128/JVI.00649-08; Prabhakaran M, 2021, J IMMUNOL METHODS, V491, DOI 10.1016/j.jim.2021.112995; Priddy FH, 2019, LANCET HIV, V6, pE230, DOI 10.1016/S2352-3018(19)30003-7; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Riddler SA, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy242; Rudicell RS, 2014, J VIROL, V88, P12669, DOI 10.1128/JVI.02213-14; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Saunders KO, 2015, J VIROL, V89, P8334, DOI 10.1128/JVI.00908-15; Saunders KO, 2015, J VIROL, V89, P5895, DOI 10.1128/JVI.00210-15; Schambach A, 2006, GENE THER, V13, P641, DOI 10.1038/sj.gt.3302698; Schanfield M., 1986, HDB EXPT IMMUNOLOGY, V94, P1; Schiller J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004254; Schnepp BC, 2014, CURR OPIN HIV AIDS, V9, P250, DOI 10.1097/COH.0000000000000056; Seaman MS, 2020, J IMMUNOL METHODS, V479, DOI 10.1016/j.jim.2020.112736; Sharon D, 2018, BIOTECHNOL BIOENG, V115, P25, DOI 10.1002/bit.26461; Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111; Srivastava A, 2016, CURR OPIN VIROL, V21, P75, DOI 10.1016/j.coviro.2016.08.003; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Welles HC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007395; Wu XL, 2018, ADV EXP MED BIOL, V1075, P53, DOI 10.1007/978-981-13-0484-2_3; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012	69	4	4	4	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1022	+		10.1038/s41591-022-01762-x	http://dx.doi.org/10.1038/s41591-022-01762-x		APR 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35411076				2022-12-27	WOS:000780688100004
J	Arsenault, C; Gage, A; Kim, MK; Kapoor, NR; Akweongo, P; Amponsah, F; Aryal, A; Asai, D; Awoonor-Williams, JK; Ayele, W; Bedregal, P; Doubova, SV; Dulal, M; Gadeka, DD; Gordon-Strachan, G; Mariam, DH; Hensman, D; Joseph, JP; Kaewkamjornchai, P; Eshetu, MK; Gelaw, SK; Kubota, S; Leerapan, B; Margozzini, P; Mebratie, AD; Mehata, S; Moshabela, M; Mthethwa, L; Nega, A; Oh, J; Park, S; Passi-Solar, A; Perez-Cuevas, R; Phengsavanh, A; Reddy, T; Rittiphairoj, T; Sapag, JC; Thermidor, R; Tlou, B; Guinez, FV; Bauhoff, S; Kruk, ME				Arsenault, Catherine; Gage, Anna; Kim, Min Kyung; Kapoor, Neena R.; Akweongo, Patricia; Amponsah, Freddie; Aryal, Amit; Asai, Daisuke; Awoonor-Williams, John Koku; Ayele, Wondimu; Bedregal, Paula; Doubova, Svetlana, V; Dulal, Mahesh; Gadeka, Dominic Dormenyo; Gordon-Strachan, Georgiana; Mariam, Damen Haile; Hensman, Dilipkumar; Joseph, Jean Paul; Kaewkamjornchai, Phanuwich; Eshetu, Munir Kassa; Gelaw, Solomon Kassahun; Kubota, Shogo; Leerapan, Borwornsom; Margozzini, Paula; Mebratie, Anagaw Derseh; Mehata, Suresh; Moshabela, Mosa; Mthethwa, Londiwe; Nega, Adiam; Oh, Juhwan; Park, Sookyung; Passi-Solar, Alvaro; Perez-Cuevas, Ricardo; Phengsavanh, Alongkhone; Reddy, Tarylee; Rittiphairoj, Thanitsara; Sapag, Jaime C.; Thermidor, Roody; Tlou, Boikhutso; Guinez, Francisco Valenzuela; Bauhoff, Sebastian; Kruk, Margaret E.			COVID-19 and resilience of healthcare systems in ten countries	NATURE MEDICINE			English	Article							IMPACT; SERVICES; COVERAGE; LOCKDOWN; PROFILE; AFRICA; WOMEN; UK	Declines in health service use during the Coronavirus Disease 2019 (COVID-19) pandemic could have important effects on population health. In this study, we used an interrupted time series design to assess the immediate effect of the pandemic on 31 health services in two low-income (Ethiopia and Haiti), six middle-income (Ghana, Lao People's Democratic Republic, Mexico, Nepal, South Africa and Thailand) and high-income (Chile and South Korea) countries. Despite efforts to maintain health services, disruptions of varying magnitude and duration were found in every country, with no clear patterns by country income group or pandemic intensity. Disruptions in health services often preceded COVID-19 waves. Cancer screenings, TB screening and detection and HIV testing were most affected (26-96% declines). Total outpatient visits declined by 9-40% at national levels and remained lower than predicted by the end of 2020. Maternal health services were disrupted in approximately half of the countries, with declines ranging from 5% to 33%. Child vaccinations were disrupted for shorter periods, but we estimate that catch-up campaigns might not have reached all children missed. By contrast, provision of antiretrovirals for HIV was not affected. By the end of 2020, substantial disruptions remained in half of the countries. Preliminary data for 2021 indicate that disruptions likely persisted. Although a portion of the declines observed might result from decreased needs during lockdowns (from fewer infectious illnesses or injuries), a larger share likely reflects a shortfall of health system resilience. Countries must plan to compensate for missed healthcare during the current pandemic and invest in strategies for better health system resilience for future emergencies.	[Arsenault, Catherine; Gage, Anna; Kapoor, Neena R.; Bauhoff, Sebastian; Kruk, Margaret E.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Kim, Min Kyung; Oh, Juhwan] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Akweongo, Patricia; Awoonor-Williams, John Koku; Gadeka, Dominic Dormenyo] Univ Ghana, Sch Publ Hlth, Accra, Ghana; [Amponsah, Freddie] Ghana Hlth Serv, Policy Planning Monitoring & Evaluat, Accra, Ghana; [Aryal, Amit; Dulal, Mahesh] Off Member Fed Parliament Gagan Kumar Thapa, Kathmandu, Nepal; [Asai, Daisuke; Hensman, Dilipkumar; Kubota, Shogo] WHO, Viangchan, Laos; [Ayele, Wondimu; Mariam, Damen Haile; Mebratie, Anagaw Derseh; Nega, Adiam] Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, Ethiopia; [Bedregal, Paula; Margozzini, Paula; Passi-Solar, Alvaro; Sapag, Jaime C.; Guinez, Francisco Valenzuela] Pontificia Univ Catolica Chile, Fac Med, Publ Hlth Dept, Santiago, Chile; [Doubova, Svetlana, V] Mexican Inst Social Secur, Epidemiol & Hlth Serv Res Unit CMN Siglo XXI, Mexico City, DF, Mexico; [Gordon-Strachan, Georgiana] Univ West Indies, Caribbean Inst Hlth Res, Jamaica, NY USA; [Joseph, Jean Paul] Zanmi Lasante, Hop Univ Mirebalais, Arrondissement De Mireba, Mirebalais, Haiti; [Kaewkamjornchai, Phanuwich; Leerapan, Borwornsom; Rittiphairoj, Thanitsara] Madidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand; [Eshetu, Munir Kassa; Gelaw, Solomon Kassahun] Minist Hlth Ethiopia, Addis Ababa, Ethiopia; [Mehata, Suresh] Govt Nepal, Minist Hlth & Populat, Kathmandu, Nepal; [Moshabela, Mosa; Mthethwa, Londiwe; Tlou, Boikhutso] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Durban, South Africa; [Park, Sookyung] Hlth Insurance Res Inst, Korea Natl Hlth Insurance Serv, Gangwon Do, South Korea; [Perez-Cuevas, Ricardo] Interamer Dev Bank, Div Social Protect & Hlth, Jamaica, NY USA; [Phengsavanh, Alongkhone] Univ Hlth Sci, Fac Med, Viangchan, Laos; [Reddy, Tarylee] South African Med Res Council, Biostat Unit, Durban, South Africa; [Thermidor, Roody] Minist Publ Hlth & Populat, Studies & Planning Unit, Port Au Prince, Haiti	Harvard University; Harvard T.H. Chan School of Public Health; Seoul National University (SNU); University of Ghana; Ghana Health Service; World Health Organization; Addis Ababa University; Pontificia Universidad Catolica de Chile; Instituto Mexicano del Seguro Social; Mahidol University; University of Kwazulu Natal; South African Medical Research Council	Arsenault, C (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	carsenault@hsph.harvard.edu	Kaewkamjornchai, Phanuwich/GOJ-9959-2022; TLOU, BOIKHUTSO/AEA-3161-2022	Kaewkamjornchai, Phanuwich/0000-0003-3591-7401; Reddy, Tarylee/0000-0002-9521-2692; Bauhoff, Sebastian/0000-0001-6017-4991; Arsenault, Catherine/0000-0003-2410-3015; Passi-Solar, Alvaro/0000-0002-1744-1705	Bill & Melinda Gates Foundation; Minderoo Foundation; Bill & Melinda Gates Foundation [INV-005254, INV-017293, OPP1135922]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Minderoo Foundation; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	The authors would like to thank R. A. Rascon Pacheco and L. R. Perez Enriquez (Mexican Institute for Social Security), H. H. Leslie (University of California, San Francisco), T. Lewis, C. Hategeka and E. R. Katz (Harvard T. H. Chan School of Public Health) and J. L. Garcia Montero. This work is part of the Grand Challenges ICODA pilot initiative, delivered by Health Data Research UK and funded by the Bill & Melinda Gates Foundation and the Minderoo Foundation. We also acknowledge funding from the Bill & Melinda Gates Foundation (grants INV-005254, INV-017293 and OPP1135922).	Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/S2214-109X(20)30308-9, 10.1016/52214-109X(20)30308-9]; Amegah AK, 2020, LANCET GLOB HEALTH, V8, pE1110, DOI 10.1016/S2214-109X(20)30353-3; [Anonymous], 2017, 2016 ANN REP; [Anonymous], 2020, WHO DIRECTOR GEN OPE; APO Group, 2020, COR GHAN EAS COVID 1; Arsenault C, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006216; Ashish KC, 2020, LANCET GLOB HEALTH, V8, pE1273, DOI [10.10161/52214-109X(20)30345-4, 10.1016/S2214-109X(20)30345-4]; Ayele W, 2021, ETHIOP J HEALTH DEV, V35, P90; Barasa E, 2021, CENT GLOB DEV; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Bertrand M, 2004, Q J ECON, V119, P249, DOI 10.1162/003355304772839588; Burt JF, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006102; Cameron AC, 2008, REV ECON STAT, V90, P414, DOI 10.1162/rest.90.3.414; Carr MJ, 2021, LANCET PUBLIC HEALTH, V6, pe124, DOI 10.1016/S2468-2667(20)30288-7; Cash R, 2020, LANCET, V395, P1687, DOI 10.1016/S0140-6736(20)31089-8; Castanon A, 2021, LANCET PUBLIC HEALTH, V6, pE522, DOI 10.1016/S2468-2667(21)00078-5; Causey Kate, 2021, Lancet, V398, P522, DOI 10.1016/S0140-6736(21)01337-4; Chang AY, 2021, J INTERN MED, V289, P450, DOI 10.1111/joim.13184; Chmielewska B, 2021, LANCET GLOB HEALTH, V9, pE759, DOI 10.1016/S2214-109X(21)00079-6; Chu KM, 2022, DRUG ALCOHOL REV, V41, P13, DOI 10.1111/dar.13310; Cohen J, 2010, Q J ECON, V125, P1, DOI 10.1162/qjec.2010.125.1.1; Department of Health KwaZulu-Natal, 2020, REV STRAT PLAN 2020; Department of Health Services Ministry of Health and Population Government of Nepal, 2019, 207677 GOV NEP MIN H; dhis2, DHIS2; Dorward J, 2021, LANCET HIV, V8, pe158, DOI 10.1016/S2352-3018(20)30359-3; Doubova SV, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006204; Federal Democratic Republic of Ethiopia Ministry of Health Policy Planning Directorate, 2017, HLTH HLTH REL IND; Geldsetzer P, 2019, LANCET, V394, P652, DOI 10.1016/S0140-6736(19)30955-9; Geng EH, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002809; Global Fund The, 2021, RES REP 2021; Haldane V, 2021, NAT MED, V27, P964, DOI 10.1038/s41591-021-01381-y; Hategeka C, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005955; Health Information Unit Ministry of Health Lao People's Democratic Republic, 2020, HLTH MAN INF SYST; Hogan AB, 2020, LANCET GLOB HEALTH, V8, pE1132, DOI 10.1016/S2214-109X(20)30288-6; Hung YW, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05660-1; Instituto Mexicano del Seguro Social, CAT UN UN MED SERV C; Kola L, 2021, LANCET PSYCHIAT, V8, P535, DOI 10.1016/S2215-0366(21)00025-0; Kruk ME, 2018, LANCET GLOB HEALTH, V6, pE1196, DOI 10.1016/S2214-109X(18)30386-3; Kruk ME, 2015, LANCET, V385, P1910, DOI 10.1016/S0140-6736(15)60755-3; Kuehn BM, 2021, JAMA-J AM MED ASSOC, V325, P925, DOI 10.1001/jama.2021.1977; Lancet Infect Dis, 2021, LANCET INFECT DIS, V21, P1193, DOI 10.1016/S1473-3099(21)00486-2; Lattus Olmos J., 2007, REV OBSTET GINECOL H, V2, P271; Lawn Joy E, 2016, Lancet, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; Liu L, 2021, BMC ANESTHESIOL, V21, DOI 10.1186/s12871-021-01382-x; Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8; Maiga A, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001849; Manne-Goehler J, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002751; Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0; McQuaid CF, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01718-2020; Meara JG, 2015, SURGERY, V158, P3, DOI [10.1016/j.surg.2015.04.011, 10.1016/S0140-6736(15)60160-X]; Mesnier J, 2020, LANCET PUBLIC HEALTH, V5, pE536, DOI 10.1016/S2468-2667(20)30188-2; Miller MJ, 2021, MMWR-MORBID MORTAL W, V70, P109, DOI [10.15585/mmwr.mm7004a1externalicon, 10.15585/mmwr.mm7004a1]; Moynihan R, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045343; O'Reilly-Shah VN, 2020, B WORLD HEALTH ORGAN, V98, P671, DOI 10.2471/BLT.20.264044; Oh J, 2020, HEALTH SYST REFORM, V6, DOI 10.1080/23288604.2020.1753464; Our World in Data, 2021, STAT RES COR PAND CO; Pillay Y, 2021, SAMJ S AFR MED J, V111, P714, DOI 10.7196/SAMJ.2021.v111i8.15786; Poudel A., 2020, KATHMANDU POST; QuEST: Quality Evidence for Health System Transformation, 2021, HLTH SYSTEM RESILIEN; Republique d'Haiti Ministere de la Sante Publique et de la Population (MSPP) Institut Haitien de l'Enfance The DHS Program, 2018, EV PREST SERV SOINS; Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1; Roy CM, 2021, EUR J PUBLIC HEALTH, V31, P634, DOI 10.1093/eurpub/ckab047; Santomauro DF, 2021, LANCET, V398, P1700, DOI 10.1016/S0140-6736(21)02143-7; Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253; Shapira G, 2021, HEALTH POLICY PLANN, V36, P1140, DOI 10.1093/heapol/czab064; Sherrard-Smith E, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1025-y; Siedner MJ, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-043763; Singh DR., 2021, BMC HEALTH SERV RES, V21; Songsermpong S, 2021, GLOB HEART, V16, DOI 10.5334/gh.1003; South Korea Ministry of Health and Welfare, 2020, HLTH WELF STAT YB 20; Strategy and Planning Division Ministry of Public Health of Thailand, 2021, GUID DAT QUAL AUD BA; Thornicroft G, 2017, BRIT J PSYCHIAT, V210, P119, DOI 10.1192/bjp.bp.116.188078; Tisdale RL, 2021, GLOB HEART, V16, DOI 10.5334/gh.978; UNFPA, 2020, IMP COVID 19 ACC CON; United Nations Development Programme, 2021, UNDP ACC PROGR POV E; van Zyl AGP, 2022, TRAUMA, V24, P316, DOI 10.1177/14604086211019163; Verguet S, 2021, NAT MED, V27, P380, DOI 10.1038/s41591-021-01268-y; Weiss DJ, 2021, LANCET INFECT DIS, V21, P59, DOI 10.1016/S1473-3099(20)30700-3; WHO, 2016, WHO TECH REP SER, V997, P1; Wood SN, 2021, LANCET GLOB HEALTH, V9, pE793, DOI 10.1016/S2214-109X(21)00105-4; World Health Organisation (WHO), 2020, PULS SURV CONT ESS H; World Health Organization, 2017, DAT QUAL REV MOD; Yasin YJ, 2021, WORLD J EMERG SURG, V16, DOI 10.1186/s13017-021-00401-z; Zimmerman L. A., 2021, PLoS Global Public Health, V2, DOI 10.1371/journal.pgph.0000023	84	16	16	9	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1314	+		10.1038/s41591-022-01750-1	http://dx.doi.org/10.1038/s41591-022-01750-1		MAR 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35288697	Green Published, hybrid			2022-12-27	WOS:000770060900009
J	Moura, FA; Scirica, BM; Ruff, CT				Moura, Filipe A.; Scirica, Benjamin M.; Ruff, Christian T.			Tirzepatide for diabetes: on track to SURPASS current therapy	NATURE MEDICINE			English	Editorial Material								A prospective meta-analysis supports the cardiovascular safety of the dual incretin receptor agonist tirzepatide, after promising clinical outcomes in the SURPASS-4 study.	[Moura, Filipe A.; Scirica, Benjamin M.; Ruff, Christian T.] Harvard Med Sch, Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ruff, CT (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc Med, Boston, MA 02115 USA.	cruff@bwh.harvard.edu	Moura, Filipe A/H-1559-2012	Moura, Filipe A/0000-0001-8017-1675				Anker SD, 2021, NEW ENGL J MED, V385, P1451, DOI 10.1056/NEJMoa2107038; Christensen MB, 2014, J CLIN ENDOCR METAB, V99, pE418, DOI 10.1210/jc.2013-3644; Del Prato S, 2021, LANCET, V398, P1811, DOI 10.1016/S0140-6736(21)02188-7; Frias JP, 2021, NEW ENGL J MED, V385, P503, DOI 10.1056/NEJMoa2107519; Gerstein HC, 2019, LANCET, V394, P121, DOI 10.1016/S0140-6736(19)31149-3; Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Mentis N, 2011, DIABETES, V60, P1270, DOI 10.2337/db10-1332; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; Nauck MA, 2021, DIABETES OBES METAB, V23, P5, DOI 10.1111/dom.14496; Sattar N, 2022, NAT MED, V28, P591, DOI 10.1038/s41591-022-01707-4	11	2	2	4	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					450	451		10.1038/s41591-022-01733-2	http://dx.doi.org/10.1038/s41591-022-01733-2		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35260841				2022-12-27	WOS:000766084100003
J	Gleicher, N; Albertini, DF; Patrizio, P; Orvieto, R; Adashi, EY				Gleicher, Norbert; Albertini, David F.; Patrizio, Pasquale; Orvieto, Raoul; Adashi, Eli Y.			The uncertain science of preimplantation and prenatal genetic testing	NATURE MEDICINE			English	Editorial Material							HUMAN EMBRYOS		[Gleicher, Norbert; Albertini, David F.; Patrizio, Pasquale] Ctr Human Reprod CHR, New York, NY 10021 USA; [Gleicher, Norbert] Fdn Reprod Med, New York, NY 10022 USA; [Gleicher, Norbert] Rockefeller Univ, Stem Cell & Embryol Lab, 1230 York Ave, New York, NY 10021 USA; [Gleicher, Norbert] Med Univ Vienna, Vienna, Austria; [Albertini, David F.] Bedford Res Fdn, Bedford, MA USA; [Patrizio, Pasquale] Univ Miami, Miller Sch Med, Dept Obstet Gynecol & Reprod Sci, Miami, FL 33136 USA; [Orvieto, Raoul] Tel Aviv Univ, Sackler Fac Med, Dept Obstet & Gynecol, Infertil & IVF Unit,Dept Obstet & Gynecol, Tel Aviv, Israel; [Adashi, Eli Y.] Brown Univ, Warren Alpert Med Sch, Dept Med Sci, Providence, RI 02912 USA	Rockefeller University; Medical University of Vienna; University of Miami; Tel Aviv University; Sackler Faculty of Medicine; Brown University	Gleicher, N (corresponding author), Ctr Human Reprod CHR, New York, NY 10021 USA.; Gleicher, N (corresponding author), Fdn Reprod Med, New York, NY 10022 USA.; Gleicher, N (corresponding author), Rockefeller Univ, Stem Cell & Embryol Lab, 1230 York Ave, New York, NY 10021 USA.; Gleicher, N (corresponding author), Med Univ Vienna, Vienna, Austria.	ngleicher@thechr.com	Patrizio, Pasquale/AGO-0674-2022	Adashi, Eli/0000-0001-7730-1192; Gleicher, Norbert/0000-0002-0202-4167				Adeyemo A, 2021, NAT MED, V27, P1876, DOI 10.1038/s41591-021-01549-6; Chatzimeletiou K, 2007, ZYGOTE, V15, P81, DOI 10.1017/S0967199406004059; Chatzimeletiou K, 2005, HUM REPROD, V20, P672, DOI 10.1093/humrep/deh652; Coorens THH, 2021, NATURE, V592, P80, DOI 10.1038/s41586-021-03345-1; Costello JF, 2021, NEW ENGL J MED, V385, P87, DOI 10.1056/NEJMcibr2106321; Coticchio G, 2021, HUM REPROD UPDATE, V27, P848, DOI 10.1093/humupd/dmab016; Forzano F, 2022, EUR J HUM GENET, V30, P493, DOI 10.1038/s41431-021-01000-x; Gamage TKJB, 2018, BIOL OPEN, V7, DOI 10.1242/bio.034884; GLEICHER N, 1979, OBSTET GYNECOL, V54, P335; Gleicher N, 2021, TRENDS MOL MED, V27, P731, DOI 10.1016/j.molmed.2020.11.009; Gleicher N, 2011, AUTOIMMUN REV, V10, P361, DOI 10.1016/j.autrev.2010.12.004; Hanson BM, 2021, FERTIL STERIL, V115, P1461, DOI 10.1016/j.fertnstert.2021.01.028; Kiessling AA, 2010, J ASSIST REPROD GEN, V27, P265, DOI 10.1007/s10815-010-9407-6; Kliff S., 2022, NEW YORK TIMES; Lee A, 2017, J ASSIST REPROD GEN, V34, P15, DOI 10.1007/s10815-016-0845-7; Lee JM, 2021, MOL DIAGN THER, V25, P351, DOI 10.1007/s40291-021-00523-9; Lencz Todd, 2021, Elife, V10, DOI 10.7554/eLife.64716; Mastenbroek S, 2021, NEW ENGL J MED, V385, P2096, DOI 10.1056/NEJMsb2101718; Orvieto R, 2021, HUM REPROD, V36, P1186, DOI 10.1093/humrep/deab042; Ottolini CS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09693-1; Park S, 2021, NATURE, V597, P393, DOI 10.1038/s41586-021-03786-8; Popovic M, 2020, HUM REPROD UPDATE, V26, P313, DOI 10.1093/humupd/dmz050; Starostik MR, 2020, GENOME RES, V30, P814, DOI 10.1101/gr.262774.120; Turley P, 2021, NEW ENGL J MED, V385, P78, DOI 10.1056/NEJMsr2105065; Yan JH, 2021, NEW ENGL J MED, V385, P2047, DOI 10.1056/NEJMoa2103613; Yang M, 2021, NAT CELL BIOL, V23, P314, DOI 10.1038/s41556-021-00660-7	26	1	1	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					442	444		10.1038/s41591-022-01712-7	http://dx.doi.org/10.1038/s41591-022-01712-7			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35314820				2022-12-27	WOS:000771673100010
J	Tran, H; Moazami, MP; Yang, HY; McKenna-Yasek, D; Douthwright, CL; Pinto, C; Metterville, J; Shin, M; Sanil, N; Dooley, C; Puri, A; Weiss, A; Wightman, N; Gray-Edwards, H; Marosfoi, M; King, RM; Kenderdine, T; Fabris, D; Bowser, R; Watts, JK; Brown, RH				Tran, Helene; Moazami, Michael P.; Yang, Huiya; McKenna-Yasek, Diane; Douthwright, Catherine L.; Pinto, Courtney; Metterville, Jake; Shin, Minwook; Sanil, Nitasha; Dooley, Craig; Puri, Ajit; Weiss, Alexandra; Wightman, Nicholas; Gray-Edwards, Heather; Marosfoi, Miklos; King, Robert M.; Kenderdine, Thomas; Fabris, Daniele; Bowser, Robert; Watts, Jonathan K.; Brown, Robert H., Jr.			Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide	NATURE MEDICINE			English	Article							DIPEPTIDE-REPEAT PROTEINS; RNA FOCI; PATHOLOGICAL FEATURES; HEXANUCLEOTIDE REPEAT; GGGGCC REPEAT; EXPANSION; TOXICITY; ALS; NEURODEGENERATION; MICE	Expansions of a G(4)C(2) repeat in the C9ORF72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two devastating adult-onset neurodegenerative disorders. Using C9-ALS/FTD patient-derived cells and C9ORF72 BAC transgenic mice, we generated and optimized antisense oligonucleotides (ASOs) that selectively blunt expression of G(4)C(2) repeat-containing transcripts and effectively suppress tissue levels of poly(GP) dipeptides. ASOs with reduced phosphorothioate content showed improved tolerability without sacrificing efficacy. In a single patient harboring mutant C9ORF72 with the G(4)C(2) repeat expansion, repeated dosing by intrathecal delivery of the optimal ASO was well tolerated, leading to significant reductions in levels of cerebrospinal fluid poly(GP). This report provides insight into the effect of nucleic acid chemistry on toxicity and, to our knowledge, for the first time demonstrates the feasibility of clinical suppression of the C9ORF72 gene. Additional clinical trials will be required to demonstrate safety and efficacy of this therapy in patients with C9ORF72 gene mutations.	[Tran, Helene; Yang, Huiya; McKenna-Yasek, Diane; Douthwright, Catherine L.; Pinto, Courtney; Metterville, Jake; Weiss, Alexandra; Wightman, Nicholas; Brown, Robert H., Jr.] Univ Massachusetts, Med Sch, Dept Neurol, Worcester, MA 01605 USA; [Moazami, Michael P.; Shin, Minwook; Watts, Jonathan K.] Univ Massachusetts, Med Sch, RNA Therapeut Inst, Worcester, MA 01605 USA; [Sanil, Nitasha; Dooley, Craig] Univ Massachusetts, Med Sch, Res Pharm, Worcester, MA 01605 USA; [Puri, Ajit; Gray-Edwards, Heather; Marosfoi, Miklos; King, Robert M.] Univ Massachusetts, Med Sch, Dept Radiol, Worcester, MA 01605 USA; [King, Robert M.] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA; [Kenderdine, Thomas; Fabris, Daniele] Univ Connecticut, Dept Chem, U-60, Storrs, CT USA; [Bowser, Robert] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA; [Bowser, Robert] Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Worcester Polytechnic Institute; University of Connecticut; Barrow Neurological Institute; Barrow Neurological Institute	Brown, RH (corresponding author), Univ Massachusetts, Med Sch, Dept Neurol, Worcester, MA 01605 USA.; Watts, JK (corresponding author), Univ Massachusetts, Med Sch, RNA Therapeut Inst, Worcester, MA 01605 USA.	jonathan.watts@umassmed.edu; robert.brown@umassmed.edu	shin, minwook/HGA-4297-2022		National Institutes of Health [R01 NS111990]; Angel Fund for ALS Research; Ono Pharmaceutical Foundation; ALSOne; ALS Finding a Cure; Cellucci Fund for ALS Research; Max Rosenfeld Fund; University of Massachusetts Clinical and Translational Science Award from the National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR001453]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Angel Fund for ALS Research; Ono Pharmaceutical Foundation(Ono Pharmaceutical Co Ltd); ALSOne; ALS Finding a Cure; Cellucci Fund for ALS Research; Max Rosenfeld Fund; University of Massachusetts Clinical and Translational Science Award from the National Center for Advancing Translational Sciences of the National Institutes of Health	The authors thank the Brown and Watts laboratories, Wave Life Sciences, the Animal Medicine and DERC Morphology Cores and F. Ladam for advice, technical support and manuscript review. Funding: This work was funded by the National Institutes of Health (R01 NS111990 to R.H.B. and J.K.W.), the Angel Fund for ALS Research and the Ono Pharmaceutical Foundation (Breakthrough Science Award to J.K.W.). R.H.B. also acknowledges funding from ALSOne, ALS Finding a Cure, the Cellucci Fund for ALS Research and the Max Rosenfeld Fund. We also acknowledge the NEALS Biorepository for providing all or part of the biofluids from the ALS, healthy controls and non-ALS neurological controls used in this study. The project described in this publication was supported, in part, by the University of Massachusetts Clinical and Translational Science Award (no. UL1TR001453) from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aditi, 2015, MOL BIOL CELL, V26, P1476, DOI 10.1091/mbc.E14-11-1523; Almeida S, 2013, ACTA NEUROPATHOL, V126, P385, DOI 10.1007/s00401-013-1149-y; Amick J, 2017, TRAFFIC, V18, P267, DOI 10.1111/tra.12477; Ash PEA, 2013, NEURON, V77, P639, DOI 10.1016/j.neuron.2013.02.004; Becker LA, 2017, NATURE, V544, P367, DOI 10.1038/nature22038; Belzil VV, 2013, ACTA NEUROPATHOL, V126, P895, DOI 10.1007/s00401-013-1199-1; Burberry A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6038; Cook C, 2019, NEURON, V101, P1057, DOI 10.1016/j.neuron.2019.02.032; Cook CN, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb3774; Coyne AN, 2020, NEURON, V107, P1124, DOI 10.1016/j.neuron.2020.06.027; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; DeVos SL, 2013, JOVE-J VIS EXP, DOI 10.3791/50326; Donnelly CJ, 2013, NEURON, V80, P415, DOI 10.1016/j.neuron.2013.10.015; Eckstein F, 2014, NUCLEIC ACID THER, V24, P374, DOI 10.1089/nat.2014.0506; Freibaum BD, 2015, NATURE, V525, P129, DOI 10.1038/nature14974; Gendron TF, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7866; Jafar-Nejad, 2020, NUCLEIC ACIDS RES, V49, P657; Jiang J, 2016, NEURON, V90, P535, DOI 10.1016/j.neuron.2016.04.006; Jovicic A, 2015, NAT NEUROSCI, V18, P1226, DOI 10.1038/nn.4085; Khvorova A, 2017, NAT BIOTECHNOL, V35, P238, DOI 10.1038/nbt.3765; Kumar R, 1998, BIOORG MED CHEM LETT, V8, P2219, DOI 10.1016/S0960-894X(98)00366-7; Lagier-Tourenne C, 2013, P NATL ACAD SCI USA, V110, pE4530, DOI 10.1073/pnas.1318835110; Loveland, 2020, RIBOSOME INHIBITION, DOI [10.1101/2020.08.30.274597v1, DOI 10.1101/2020.08.30.274597V1]; McCampbell A, 2018, J CLIN INVEST, V128, P3558, DOI 10.1172/JCI99081; Meng LY, 2015, NATURE, V518, P409, DOI 10.1038/nature13975; Mizielinska S, 2014, SCIENCE, V345, P1192, DOI 10.1126/science.1256800; Moazami, 2021, QUANTIFYING MITIGATI, DOI [10.1101/2021.02.14.431096v1, DOI 10.1101/2021.02.14.431096V1]; Moens TG, 2019, ACTA NEUROPATHOL, V137, P487, DOI 10.1007/s00401-018-1946-4; Mohan A, 2018, PAIN, V159, P139, DOI 10.1097/j.pain.0000000000001074; Mori K, 2013, SCIENCE, V339, P1335, DOI 10.1126/science.1232927; O'Rourke JG, 2016, SCIENCE, V351, P1324, DOI 10.1126/science.aaf1064; O'Rourke JG, 2015, NEURON, V88, P892, DOI 10.1016/j.neuron.2015.10.027; Peters OM, 2015, NEURON, V88, P902, DOI 10.1016/j.neuron.2015.11.018; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Rigo F, 2014, J PHARMACOL EXP THER, V350, P46, DOI 10.1124/jpet.113.212407; Sareen D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007529; Shi YX, 2018, NAT MED, V24, P313, DOI 10.1038/nm.4490; Shin M, 2022, NUCLEIC ACID THER, V32, P66, DOI 10.1089/nat.2021.0040; Sztainberg Y, 2015, NATURE, V528, P123, DOI 10.1038/nature16159; Tabrizi SJ, 2019, NEW ENGL J MED, V381, P1181, DOI 10.1056/NEJMc1910544; Tabrizi SJ, 2019, NEW ENGL J MED, V380, P2307, DOI 10.1056/NEJMoa1900907; Tao ZT, 2015, HUM MOL GENET, V24, P2426, DOI 10.1093/hmg/ddv005; Tran H, 2015, NEURON, V87, P1207, DOI 10.1016/j.neuron.2015.09.015; Waite AJ, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2014.01.016; Yuva-Aydemir Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13477-8; Zhang K, 2015, NATURE, V525, P56, DOI 10.1038/nature14973; Zhang YJ, 2018, NAT MED, V24, P1136, DOI 10.1038/s41591-018-0071-1; Zhao HT, 2017, MOL THER-NUCL ACIDS, V8, P508, DOI 10.1016/j.omtn.2017.08.002; Zhu Q, 2020, NAT NEUROSCI, V23, P615, DOI 10.1038/s41593-020-0619-5; Zu T, 2013, P NATL ACAD SCI USA, V110, pE4968, DOI 10.1073/pnas.1315438110	50	18	18	6	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					117	+		10.1038/s41591-021-01557-6	http://dx.doi.org/10.1038/s41591-021-01557-6		DEC 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34949835	Green Accepted, Green Submitted			2022-12-27	WOS:000734145100001
J	Jabbari, E; Duff, KE				Jabbari, Edwin; Duff, Karen E.			Tau-targeting antibody therapies: too late, wrong epitope or wrong target?	NATURE MEDICINE			English	Editorial Material							PROGRESSIVE SUPRANUCLEAR PALSY	Two phase 2 studies of N-terminal tau-targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.	[Jabbari, Edwin] UCL Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, London, England; [Jabbari, Edwin] UCL Queen Sq Inst Neurol, Movement Disorders Ctr, London, England; [Duff, Karen E.] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10027 USA; [Duff, Karen E.] UCL, UK Dementia Res Inst, London, England	University of London; University College London; University of London; University College London; Columbia University; NewYork-Presbyterian Hospital; University of London; University College London	Jabbari, E (corresponding author), UCL Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, London, England.; Jabbari, E (corresponding author), UCL Queen Sq Inst Neurol, Movement Disorders Ctr, London, England.; Duff, KE (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10027 USA.; Duff, KE (corresponding author), UCL, UK Dementia Res Inst, London, England.	e.jabbari@ucl.ac.uk; k.duff@ucl.ac.uk	Jabbari, Edwin/G-4268-2018	Jabbari, Edwin/0000-0001-6844-882X; Duff, Karen/0000-0002-6177-868X				Dam T., NAT MED, DOI [10.1038/s41591-021-01455-x(2021, DOI 10.1038/S41591-021-01455-X(2021]; Evans L.D., PREPRINT BIORXIV, DOI [10.1101/2020.08.11.246363(2020, DOI 10.1101/2020.08.11.246363(2020]; Golbe LI, 2007, BRAIN, V130, P1552, DOI 10.1093/brain/awm032; Hoglinger GU, 2021, LANCET NEUROL, V20, P182, DOI 10.1016/S1474-4422(20)30489-0; Jabbari E, 2021, LANCET NEUROL, V20, P107, DOI 10.1016/S1474-4422(20)30394-X; Jabbari E, 2018, ANN NEUROL, V84, P485, DOI 10.1002/ana.25308; Jadhav S, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0664-z; Ji CY, 2021, DRUGS, V81, P1135, DOI 10.1007/s40265-021-01546-6; Kim, ACTA NEUROPATHOL, DOI [10.1007/s00401-021-02318-y(2021, DOI 10.1007/S00401-021-02318-Y(2021]; Myeku N, 2016, NAT MED, V22, P46, DOI 10.1038/nm.4011; Sopko R, 2020, NEUROBIOL DIS, V146, DOI 10.1016/j.nbd.2020.105120; Yanamandra K, 2015, ANN CLIN TRANSL NEUR, V2, P278, DOI 10.1002/acn3.176	12	3	3	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1341	1342		10.1038/s41591-021-01465-9	http://dx.doi.org/10.1038/s41591-021-01465-9		AUG 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385709	Green Submitted			2022-12-27	WOS:000684533600002
J	Schmidt, T; Klemis, V; Schub, D; Mihm, J; Hielscher, F; Marx, S; Abu-Omar, A; Ziegler, L; Guckelmus, C; Urschel, R; Schneitler, S; Becker, SL; Gartner, BC; Sester, U; Sester, M				Schmidt, Tina; Klemis, Verena; Schub, David; Mihm, Janine; Hielscher, Franziska; Marx, Stefanie; Abu-Omar, Amina; Ziegler, Laura; Guckelmus, Candida; Urschel, Rebecca; Schneitler, Sophie; Becker, Soeren L.; Gaertner, Barbara C.; Sester, Urban; Sester, Martina			Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	NATURE MEDICINE			English	Article								In healthy adults, booster vaccination with an mRNA vaccine, irrespective of the vaccine used for the first dose, was well tolerated and elicited higher levels of spike-specific antibodies and spike-specific T cells than booster vaccination with ChAdOx1 nCov-19. Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. In this observational study we show that, in healthy adult individuals (n = 96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n = 55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n = 62). Moreover, spike-specific CD8 T cell levels after heterologous vaccination were significantly higher than after both homologous regimens. Spike-specific T cells were predominantly polyfunctional with largely overlapping cytokine-producing phenotypes in all three regimens. Recipients of both the homologous vector regimen and the heterologous vector/mRNA combination reported greater reactogenicity following the priming vector vaccination, whereas heterologous boosting was well tolerated and comparable to homologous mRNA boosting. Taken together, heterologous vector/mRNA boosting induces strong humoral and cellular immune responses with acceptable reactogenicity profiles.	[Schmidt, Tina; Klemis, Verena; Schub, David; Hielscher, Franziska; Marx, Stefanie; Abu-Omar, Amina; Ziegler, Laura; Guckelmus, Candida; Urschel, Rebecca; Sester, Martina] Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany; [Mihm, Janine; Sester, Urban] Saarland Univ, Dept Internal Med 4, Homburg, Germany; [Schneitler, Sophie; Becker, Soeren L.; Gaertner, Barbara C.] Saarland Univ, Inst Med Microbiol & Hyg, Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Sester, M (corresponding author), Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany.	martina.sester@uks.eu	Sester, Martina/AAA-3383-2022	Mihm, Janine/0000-0002-0357-6828; Schmidt, Tina/0000-0001-7929-5283; Becker, Soeren/0000-0003-3634-8802; Schub, David/0000-0002-8995-3080	State Chancellery of the Saarland	State Chancellery of the Saarland	We thank C. Baum and the team at the occupational health care center at Saarland University medical center, and S. Brehmer and I. Vallar for their valuable support in enrolling participants. We also thank all participants in this study who contributed to the gain in knowledge from this project. Financial support was given by the State Chancellery of the Saarland.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Borobia AM, 2021, LANCET, V398, P121, DOI 10.1016/S0140-6736(21)01420-3; Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard AJ, 2021, LANCET INFECT DIS, V21, P493, DOI 10.1016/S1473-3099(20)30476-X; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6; Schmidt T., 2021, CELLULAR IMMUNITY PR, DOI [10.1101/2021.05.07.21256809v1, DOI 10.1101/2021.05.07.21256809V1]; Schub D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142167; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01158-2, 10.1016/S0140-6736(21)01115-6]; Skelly D. T., VACCINE INDUCED IMMU; Spencer AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23173-1; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Vygen-Bonnet S., 2021, EPIDEMIOL B, V19, P24	21	145	145	5	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1530	+		10.1038/s41591-021-01464-w	http://dx.doi.org/10.1038/s41591-021-01464-w		JUL 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34312554	Green Published, hybrid			2022-12-27	WOS:000679014800004
J	Morley, TJ; Han, L; Castro, VM; Morra, J; Perlis, RH; Cox, NJ; Bastarache, L; Ruderfer, DM				Morley, Theodore J.; Han, Lide; Castro, Victor M.; Morra, Jonathan; Perlis, Roy H.; Cox, Nancy J.; Bastarache, Lisa; Ruderfer, Douglas M.			Phenotypic signatures in clinical data enable systematic identification of patients for genetic testing	NATURE MEDICINE			English	Article							BARRIERS	Machine learning of electronic health records identifies individuals with a high suspicion of a wide range of genetic diseases and prioritizes those individuals for genetic testing. Around 5% of the population is affected by a rare genetic disease, yet most endure years of uncertainty before receiving a genetic test. A common feature of genetic diseases is the presence of multiple rare phenotypes that often span organ systems. Here, we use diagnostic billing information from longitudinal clinical data in the electronic health records (EHRs) of 2,286 patients who received a chromosomal microarray test, and 9,144 matched controls, to build a model to predict who should receive a genetic test. The model achieved high prediction accuracies in a held-out test sample (area under the receiver operating characteristic curve (AUROC), 0.97; area under the precision-recall curve (AUPRC), 0.92), in an independent hospital system (AUROC, 0.95; AUPRC, 0.62), and in an independent set of 172,265 patients in which cases were broadly defined as having an interaction with a genetics provider (AUROC, 0.9; AUPRC, 0.63). Patients carrying a putative pathogenic copy number variant were also accurately identified by the model. Compared with current approaches for genetic test determination, our model could identify more patients for testing while also increasing the proportion of those tested who have a genetic disease. We demonstrate that phenotypic patterns representative of a wide range of genetic diseases can be captured from EHRs to systematize decision-making for genetic testing, with the potential to speed up diagnosis, improve care and reduce costs.	[Morley, Theodore J.; Han, Lide; Cox, Nancy J.; Ruderfer, Douglas M.] Vanderbilt Univ, Med Ctr, Dept Med, Div Genet Med, Nashville, TN 37235 USA; [Morley, Theodore J.; Han, Lide; Cox, Nancy J.; Bastarache, Lisa; Ruderfer, Douglas M.] Vanderbilt Univ, Med Ctr, Vanderbilt Genet Inst, Nashville, TN 37235 USA; [Castro, Victor M.; Perlis, Roy H.] Massachusetts Gen Hosp, Div Clin Res, Ctr Quantitat Hlth, Boston, MA 02114 USA; [Morra, Jonathan] Zefr, Los Angeles, CA USA; [Bastarache, Lisa; Ruderfer, Douglas M.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Ctr Precis Med, Nashville, TN 37235 USA; [Ruderfer, Douglas M.] Vanderbilt Univ, Med Ctr, Dept Psychiat & Behav Sci, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Harvard University; Massachusetts General Hospital; Vanderbilt University; Vanderbilt University	Ruderfer, DM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Genet Med, Nashville, TN 37235 USA.; Ruderfer, DM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Genet Inst, Nashville, TN 37235 USA.; Ruderfer, DM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Ctr Precis Med, Nashville, TN 37235 USA.; Ruderfer, DM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Psychiat & Behav Sci, Nashville, TN 37235 USA.	douglas.ruderfer@vanderbilt.edu	Castro, Victor M/CAF-9395-2022; Castro, Victor M/CAH-3428-2022	Castro, Victor M/0000-0001-7390-6354; Castro, Victor M/0000-0001-7390-6354; han, lide/0000-0002-0132-2656	NIH [S10RR025141]; CTSA grants [UL1TR002243, UL1TR000445, UL1RR024975]; Wellcome;  [R01MH111776];  [R01MH113362];  [R01LM010685];  [U01HG009068];  [U01HG004798];  [R01NS032830];  [RC2GM092618];  [P50GM115305];  [U01HG006378];  [U19HL065962];  [R01HD074711]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSA grants; Wellcome; ; ; ; ; ; ; ; ; ; ; 	This work was supported by R01MH111776 (to D.M.R.), R01MH113362 (to N.J.C. and D.M.R.), R01LM010685 (to L.B.) and U01HG009068 (to N.J.C.). This study makes use of data generated by the DECIPHER community. A full list of centers that contributed to the generation of the data is available from https://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk.Funding for the project was provided by Wellcome. The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU, which is supported by institutional funding, private agencies and federal grants. These include the NIH-funded Shared Instrumentation Grant S10RR025141, and CTSA grants UL1TR002243, UL1TR000445 and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962 and R01HD074711; and additional funding sources listed at https://victr.vanderbilt.edu/pub/biovu/.	Amemiya HM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45839-z; Bastarache L, 2019, J AM MED INFORM ASSN, V26, P1437, DOI 10.1093/jamia/ocz179; Bastarache L, 2018, SCIENCE, V359, P1233, DOI 10.1126/science.aal4043; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brokamp C, 2019, ANN EPIDEMIOL, V30, P37, DOI 10.1016/j.annepidem.2018.11.008; Cooper DN, 2013, HUM GENET, V132, P1077, DOI 10.1007/s00439-013-1331-2; Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749; Diskin SJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn556; Ferreira CR, 2019, AM J MED GENET A, V179, P885, DOI 10.1002/ajmg.a.61124; Firth HV, 2009, AM J HUM GENET, V84, P524, DOI 10.1016/j.ajhg.2009.03.010; Girirajan S, 2012, NEW ENGL J MED, V367, P1321, DOI 10.1056/NEJMoa1200395; Goel S., 2018, ARXIV180800023; Goldstein BA, 2017, J AM MED INFORM ASSN, V24, P198, DOI 10.1093/jamia/ocw042; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9; McKusick VA, 2007, AM J HUM GENET, V80, P588, DOI 10.1086/514346; Moreno-De-Luca D, 2020, JAMA PSYCHIAT, V77, P979, DOI 10.1001/jamapsychiatry.2020.0950; Noll A, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0047-y; OMIM, ONLINE MENDELIAN INH; Posey JE, 2017, NEW ENGL J MED, V376, P21, DOI 10.1056/NEJMoa1516767; Rosenthal ET, 2001, AM J MED GENET, V103, P106, DOI 10.1002/ajmg.1527; Suther S, 2009, GENET MED, V11, P655, DOI 10.1097/GIM.0b013e3181ab22aa; Wakap SN, 2020, EUR J HUM GENET, V28, P165, DOI 10.1038/s41431-019-0508-0; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907	24	6	6	2	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1097	+		10.1038/s41591-021-01356-z	http://dx.doi.org/10.1038/s41591-021-01356-z		JUN 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34083811	Green Accepted, Green Submitted			2022-12-27	WOS:000657623700003
J	Zard, M; Lau, LS; Bowser, DM; Fouad, FM; Lucumi, DI; Samari, G; Harker, A; Shepard, DS; Zeng, W; Moresky, RT; Audi, MN; Greene, CM; Kachur, SP				Zard, Monette; Lau, Ling San; Bowser, Diana M.; Fouad, Fouad M.; Lucumi, Diego I.; Samari, Goleen; Harker, Arturo; Shepard, Donald S.; Zeng, Wu; Moresky, Rachel T.; Audi, Mhd Nour; Greene, Claire M.; Kachur, S. Patrick			Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations	NATURE MEDICINE			English	Editorial Material								Ensuring access to vaccines against COVID-19 for refugee and displaced populations and addressing health inequities are vital for an effective pandemic response.	[Zard, Monette; Lau, Ling San; Samari, Goleen; Moresky, Rachel T.; Audi, Mhd Nour; Greene, Claire M.; Kachur, S. Patrick] Columbia Univ, Program Forced Migrat & Hlth, Heilbrunn Dept Populat & Family Hlth, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Bowser, Diana M.; Shepard, Donald S.] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA; [Fouad, Fouad M.] Amer Univ Beirut, Fac Hlth Sci, Beirut, Lebanon; [Lucumi, Diego I.; Harker, Arturo] Univ Andes, Sch Govt, Bogota, Colombia; [Zeng, Wu] Georgetown Univ, Dept Int Hlth, Sch Nursing & Hlth Studies, Washington, DC USA; [Moresky, Rachel T.] Columbia Univ Irving Med Ctr, Dept Emergency Med, New York, NY USA	Columbia University; Brandeis University; American University of Beirut; Universidad de los Andes (Colombia); Georgetown University; NewYork-Presbyterian Hospital	Zard, M (corresponding author), Columbia Univ, Program Forced Migrat & Hlth, Heilbrunn Dept Populat & Family Hlth, Mailman Sch Publ Hlth, New York, NY 10032 USA.	mz2621@cumc.columbia.edu	Kachur, Patrick/ABE-7220-2021; Harker Roa, Arturo/L-5619-2013	Zeng, Wu/0000-0002-3473-3638; Harker Roa, Arturo/0000-0003-2343-1965; Samari, Goleen/0000-0002-9506-3586	UK aid through the Foreign, Commonwealth and Development Office (FCDO)	UK aid through the Foreign, Commonwealth and Development Office (FCDO)	We thank S. Guyer and K. McCann for research and editorial support. The authors of this Comment are members of a research consortium led by Columbia University's Program on Forced Migration and Health, with the American University of Beirut, Brandeis University, Georgetown University and Universidad de los Andes. The consortium is conducting a two-year research project that aims to provide evidence and guidance to strengthen health systems to address the needs of displaced and host populations in contexts of protracted displacement. The program is funded by UK aid through the Foreign, Commonwealth and Development Office (FCDO). It is managed by the World Bank Group (WBG) and was established in partnership with the United Nations High Commissioner for Refugees (UNHCR). This work does not necessarily reflect the views of UK Aid, the WBG or UNHCR.	[Anonymous], 2021, ANN BAS LIN MOD YEAR; Burchett HED, 2014, VACCINE, V32, P6505, DOI 10.1016/j.vaccine.2014.09.031; Camlin CS, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25136; Collins K., 2021, NY TIMES; de Quadros C., 2013, SCI AM; Figueroa JP, 2021, LANCET, V397, P562, DOI 10.1016/S0140-6736(21)00242-7; Lam E, 2015, HUM VACC IMMUNOTHER, V11, P2627, DOI 10.1080/21645515.2015.1096457; Nachega JB, 2020, LANCET GLOB HEALTH, V8, P991, DOI 10.1016/S2214-109X(20)30281-3; Nair S, 2020, REFUGEES INT; Nnadi C, 2017, J INFECT DIS, V216, pS368, DOI 10.1093/infdis/jix175; Parkin Daniels J, GUARDIAN; Phelan AL, 2020, LANCET, V396, P800, DOI 10.1016/S0140-6736(20)31873-0; Rohan H, 2020, NAT IMMUNOL, V21, P591, DOI 10.1038/s41590-020-0675-8; Romero S., 2021, NY TIMES; Toppenberg-Pejcic D, 2019, HEALTH COMMUN, V34, P437, DOI 10.1080/10410236.2017.1405488; Welsh T, 2021, DEVEX	16	11	11	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					747	749		10.1038/s41591-021-01328-3	http://dx.doi.org/10.1038/s41591-021-01328-3		APR 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33875889	Bronze			2022-12-27	WOS:000641244600002
J	Levine-Tiefenbrun, M; Yelin, I; Katz, R; Herzel, E; Golan, Z; Schreiber, L; Wolf, T; Nadler, V; Ben-Tov, A; Kuint, J; Gazit, S; Patalon, T; Chodick, G; Kishony, R				Levine-Tiefenbrun, Matan; Yelin, Idan; Katz, Rachel; Herzel, Esma; Golan, Ziv; Schreiber, Licita; Wolf, Tamar; Nadler, Varda; Ben-Tov, Amir; Kuint, Jacob; Gazit, Sivan; Patalon, Tal; Chodick, Gabriel; Kishony, Roy			Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	NATURE MEDICINE			English	Article								Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19) vaccines might reduce viral load in breakthrough infection and thereby further suppress onward transmission. In this analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine, we found that the viral load was substantially reduced for infections occurring 12-37 d after the first dose of vaccine. These reduced viral loads hint at a potentially lower infectiousness, further contributing to vaccine effect on virus spread. Breakthrough infections of SARS-CoV-2 occurring 12 or more days after the first dose of the BNT162b2 mRNA vaccine were associated with lower viral loads than those found in unvaccinated individuals, suggesting that the vaccine might reduce infectiousness.	[Levine-Tiefenbrun, Matan; Yelin, Idan; Kishony, Roy] Technion Israel Inst Technol, Fac Biol, Haifa, Israel; [Katz, Rachel; Herzel, Esma; Ben-Tov, Amir; Kuint, Jacob; Gazit, Sivan; Patalon, Tal; Chodick, Gabriel] Maccabitech, Maccabi Hlth Serv, Tel Aviv, Israel; [Golan, Ziv; Schreiber, Licita; Wolf, Tamar; Nadler, Varda] Maccabi Healthcare Serv, Maccabi Mega Lab, Rehovot, Israel; [Ben-Tov, Amir; Kuint, Jacob; Chodick, Gabriel] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Kishony, Roy] Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel	Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Technion Israel Institute of Technology	Yelin, I; Kishony, R (corresponding author), Technion Israel Inst Technol, Fac Biol, Haifa, Israel.; Kishony, R (corresponding author), Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel.	idany@technion.ac.il; rkishony@technion.ac.il		Levine-Tiefenbrun, Matan/0000-0003-0569-3566; Yelin, Idan/0000-0003-2515-4113; /0000-0002-5189-8995; Patalon, Tal/0000-0001-7415-1053	Israel Science Foundation as part of the KillCorona-Curbing Coronavirus Research Program [3633/19]	Israel Science Foundation as part of the KillCorona-Curbing Coronavirus Research Program	This work was supported by the Israel Science Foundation (grant no. 3633/19 to R. Kishony and G.C.) as part of the KillCorona-Curbing Coronavirus Research Program.	Cevik M, 2021, CLIN INFECT DIS, V73, pS170, DOI 10.1093/cid/ciaa1442; Chodick G., 2021, EFFECTIVENESS 1 DOSE, DOI [10.1101/2021.01.27.21250612, DOI 10.1101/2021.01.27.21250612, 10.1101/2021.01.27.21250612v1]; Connors M, 2021, ANN INTERN MED, V174, P687, DOI 10.7326/M21-0111; Gallagher ME, 2021, NAT MED, V27, P4, DOI 10.1038/s41591-020-01172-x; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; Levine-Tiefenbrun M., 2020, ASS COVID 19 RT QPCR, DOI [10.1101/2020.10.30.20222935, DOI 10.1101/2020.10.30.20222935, 10.1101/2020.10.30.20222935v2]; Lipsitch M, 2020, SCIENCE, V370, P763, DOI 10.1126/science.abe5938; Mina MJ, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2025631; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P129, DOI 10.1038/s41577-020-00497-5; Pujadas E, 2020, LANCET RESP MED, V8, pE70, DOI 10.1016/S2213-2600(20)30354-4; Rubin EJ, 2020, NEW ENGL J MED, V383, P2677, DOI 10.1056/NEJMe2034717; Strategic Advisory Group of Experts on Immunization (SAGE), INT REC US PFIZ BION	13	253	258	2	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					790	+		10.1038/s41591-021-01316-7	http://dx.doi.org/10.1038/s41591-021-01316-7		MAR 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33782619	Bronze, Green Submitted			2022-12-27	WOS:000634637300001
J	Wang, DD; Nguyen, LH; Li, YP; Yan, Y; Ma, WJ; Rinott, E; Ivey, KL; Shai, I; Willett, WC; Hu, FB; Rimm, EB; Stampfer, MJ; Chan, AT; Huttenhower, C				Wang, Dong D.; Nguyen, Long H.; Li, Yanping; Yan, Yan; Ma, Wenjie; Rinott, Ehud; Ivey, Kerry L.; Shai, Iris; Willett, Walter C.; Hu, Frank B.; Rimm, Eric B.; Stampfer, Meir J.; Chan, Andrew T.; Huttenhower, Curtis			The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	NATURE MEDICINE			English	Article							REPRODUCIBILITY; VALIDITY; METABOLOME; METATRANSCRIPTOME; QUESTIONNAIRE; ALIGNMENT; PATHWAYS; MARKERS; IMPACT; CANCER	The beneficial effects of a Mediterranean diet on cardiometabolic health are associated with specific changes in the gut microbiome, suggesting a personalized approach towards cardiometabolic disease prevention. To address how the microbiome might modify the interaction between diet and cardiometabolic health, we analyzed longitudinal microbiome data from 307 male participants in the Health Professionals Follow-Up Study, together with long-term dietary information and measurements of biomarkers of glucose homeostasis, lipid metabolism and inflammation from blood samples. Here, we demonstrate that a healthy Mediterranean-style dietary pattern is associated with specific functional and taxonomic components of the gut microbiome, and that its protective associations with cardiometabolic health vary depending on microbial composition. In particular, the protective association between adherence to the Mediterranean diet and cardiometabolic disease risk was significantly stronger among participants with decreased abundance of Prevotella copri. Our findings advance the concept of precision nutrition and have the potential to inform more effective and precise dietary approaches for the prevention of cardiometabolic disease mediated through alterations in the gut microbiome.	[Wang, Dong D.; Willett, Walter C.; Hu, Frank B.; Rimm, Eric B.; Stampfer, Meir J.; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Wang, Dong D.; Willett, Walter C.; Hu, Frank B.; Rimm, Eric B.; Stampfer, Meir J.; Chan, Andrew T.] Harvard Med Sch, Boston, MA 02115 USA; [Wang, Dong D.; Li, Yanping; Ivey, Kerry L.; Willett, Walter C.; Hu, Frank B.; Rimm, Eric B.; Stampfer, Meir J.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Nguyen, Long H.; Ma, Wenjie; Chan, Andrew T.] Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Boston, MA 02114 USA; [Nguyen, Long H.; Ma, Wenjie; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA; [Yan, Yan; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Rinott, Ehud; Shai, Iris] Ben Gurion Univ Negev, Negev, Israel; [Ivey, Kerry L.] South Australian Hlth & Med Res Inst, Infect & Immun Theme, Adelaide, SA, Australia; [Ivey, Kerry L.] Flinders Univ S Australia, Coll Nursing & Hlth Sci, Dept Nutr & Dietet, Adelaide, SA, Australia; [Willett, Walter C.; Hu, Frank B.; Rimm, Eric B.; Stampfer, Meir J.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Huttenhower, Curtis] Broad Inst MIT & Harvard, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Ben Gurion University; South Australian Health & Medical Research Institute (SAHMRI); Flinders University South Australia; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Huttenhower, C (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.; Huttenhower, C (corresponding author), Broad Inst MIT & Harvard, Boston, MA 02114 USA.	chuttenh@hsph.harvard.edu	Wang, Dong D./AAU-2951-2021; Li, Yanping/H-6437-2011	Wang, Dong D./0000-0002-0897-3048; Shai, Iris/0000-0001-9050-4605; Nguyen, Long/0000-0002-5436-4219; Li, Yanping/0000-0002-0412-2748; Ma, Wenjie/0000-0001-9894-7072; Ivey, Kerry/0000-0001-9855-2599; Rinott, Ehud/0000-0003-3028-5492	National Institutes of Health (NIH) [R00DK119412, R01HL060712, P30DK046200, R01CA202704, K24DK098311, U54DE023798]; STARR Cancer Consortium [I7-A714]; Boston Nutrition and Obesity Research Center - National Institute of Diabetes and Digestive and Kidney Diseases [P30DK046200]; National Cancer Institute [U01CA152904]; NIH [U01CA167552, R01HL035464]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); STARR Cancer Consortium; Boston Nutrition and Obesity Research Center - National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by R00DK119412 (D.D.W.), R01HL060712 (F.B.H.), P30DK046200 (F.B.H.), R01CA202704 (A.T.C. and C.H.), K24DK098311 (A.T.C.) and U54DE023798 (C.H.) from the National Institutes of Health (NIH), STARR Cancer Consortium award no. #I7-A714 to C.H., and a Pilot and Feasibility award to D.D.W. from the Boston Nutrition and Obesity Research Center funded by the National Institute of Diabetes and Digestive and Kidney Diseases (P30DK046200). The Men's Lifestyle Validation Study was supported by U01CA152904 from the National Cancer Institute. The Health Professionals Follow-Up Study is supported by research grants nos. U01CA167552 and R01HL035464 from the NIH. The funding source had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We are indebted to the participants in the Health Professionals Follow-up Study for their continuing outstanding level of cooperation and to the staff of the Health Professionals Follow-up Study for their valuable contributions. The authors assume full responsibility for analyses and interpretation of these data.	Abu-Ali GS, 2018, NAT MICROBIOL, V3, P356, DOI 10.1038/s41564-017-0084-4; Amato KR, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0120-7; Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS73, DOI 10.2337/dc18-S008; Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938; Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176; Caspi R, 2016, NUCLEIC ACIDS RES, V44, pD471, DOI 10.1093/nar/gkv1164; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Chung WSF, 2016, BMC BIOL, V14, DOI 10.1186/s12915-015-0224-3; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; De Angelis M, 2015, APPL ENVIRON MICROB, V81, P7945, DOI 10.1128/AEM.02507-15; De Filippis F, 2019, CELL HOST MICROBE, V25, P444, DOI 10.1016/j.chom.2019.01.004; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; De Vadder F, 2016, CELL METAB, V24, P151, DOI 10.1016/j.cmet.2016.06.013; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Faith JJ, 2011, SCIENCE, V333, P101, DOI 10.1126/science.1206025; Falony G, 2016, SCIENCE, V352, P560, DOI 10.1126/science.aad3503; Ferslew BC, 2015, DIGEST DIS SCI, V60, P3318, DOI 10.1007/s10620-015-3776-8; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Foerster J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109606; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Franzosa EA, 2014, P NATL ACAD SCI USA, V111, pE2329, DOI 10.1073/pnas.1319284111; Fung TT, 2005, AM J CLIN NUTR, V82, P163; Ghosh TS, 2020, GUT, V69, P1218, DOI 10.1136/gutjnl-2019-319654; Gomez-Arango LF, 2018, GUT MICROBES, V9, P189, DOI 10.1080/19490976.2017.1406584; Haro C, 2016, J CLIN ENDOCR METAB, V101, P232, DOI 10.1210/jc.2015-3351; Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578; Jia W, 2018, NAT REV GASTRO HEPAT, V15, P111, DOI 10.1038/nrgastro.2017.119; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Koren O, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002863; Koropatkin NM, 2012, NAT REV MICROBIOL, V10, P323, DOI 10.1038/nrmicro2746; Kovatcheva-Datchary P, 2015, CELL METAB, V22, P971, DOI 10.1016/j.cmet.2015.10.001; Kurilshikov A, 2019, CIRC RES, V124, P1808, DOI 10.1161/CIRCRESAHA.118.314642; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9; Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889; Luis AS, 2018, NAT MICROBIOL, V3, P210, DOI 10.1038/s41564-017-0079-1; Martinez-Medina M, 2014, GUT, V63, P116, DOI 10.1136/gutjnl-2012-304119; McIver LJ, 2018, BIOINFORMATICS, V34, P1235, DOI 10.1093/bioinformatics/btx754; Mehta RS, 2018, NAT MICROBIOL, V3, P347, DOI 10.1038/s41564-017-0096-0; Meslier V, 2020, GUT, V69, P1258, DOI 10.1136/gutjnl-2019-320438; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Pedersen HK, 2016, NATURE, V535, P376, DOI 10.1038/nature18646; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Shi YY, 2011, NAT GENET, V43, P1215, DOI 10.1038/ng.978; Smits SA, 2017, SCIENCE, V357, P802, DOI 10.1126/science.aan4834; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Suzek BE, 2007, BIOINFORMATICS, V23, P1282, DOI 10.1093/bioinformatics/btm098; Tett A, 2019, CELL HOST MICROBE, V26, P666, DOI 10.1016/j.chom.2019.08.018; Thingholm LB, 2019, CELL HOST MICROBE, V26, P252, DOI 10.1016/j.chom.2019.07.004; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Vallim TQD, 2013, CELL METAB, V17, P657, DOI 10.1016/j.cmet.2013.03.013; Vangay P, 2018, CELL, V175, P962, DOI 10.1016/j.cell.2018.10.029; Vatanen T, 2018, NATURE, V562, P589, DOI 10.1038/s41586-018-0620-2; Wegner K, 2017, ANAL BIOANAL CHEM, V409, P1231, DOI 10.1007/s00216-016-0048-1; Willett Walter C., 1995, American Journal of Clinical Nutrition, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Ye YZ, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000465; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369	69	89	92	27	97	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					333	+		10.1038/s41591-020-01223-3	http://dx.doi.org/10.1038/s41591-020-01223-3		FEB 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33574608	Green Accepted			2022-12-27	WOS:000617100300001
J	van der Linden, S				van der Linden, Sander			Misinformation: susceptibility, spread, and interventions to immunize the public	NATURE MEDICINE			English	Review							FAKE NEWS; SCIENCE LITERACY; IMPACT; MECHANISMS; PERSUASION; PSYCHOLOGY; RESISTANCE; MESSAGES; BELIEF; FIGHT	The spread of misinformation poses a considerable threat to public health and the successful management of a global pandemic. For example, studies find that exposure to misinformation can undermine vaccination uptake and compliance with public-health guidelines. As research on the science of misinformation is rapidly emerging, this conceptual Review summarizes what we know along three key dimensions of the infodemic: susceptibility, spread, and immunization. Extant research is evaluated on the questions of why (some) people are (more) susceptible to misinformation, how misinformation spreads in online social networks, and which interventions can help to boost psychological immunity to misinformation. Implications for managing the infodemic are discussed. This Review provides an overview of the psychology of misinformation, from susceptibility to spread and interventions to help boost psychological immunity.	[van der Linden, Sander] Univ Cambridge, Sch Biol, Dept Psychol, Cambridge, England	University of Cambridge	van der Linden, S (corresponding author), Univ Cambridge, Sch Biol, Dept Psychol, Cambridge, England.	sander.vanderlinden@psychol.cam.ac.uk			IRIS Infodemic Coalition (UK Government) [SCH-00001-3391]; JITSUVAX (EU 2020 Horizon) [964728]	IRIS Infodemic Coalition (UK Government); JITSUVAX (EU 2020 Horizon)	I am grateful for support from the IRIS Infodemic Coalition (UK Government, no. SCH-00001-3391) and JITSUVAX (EU 2020 Horizon no. 964728). I thank the Cambridge Social Decision-Making Lab and credit R. Maertens in particular for his help with designing Fig. 2.	Abbasi J, 2021, JAMA-J AM MED ASSOC, V325, P208, DOI 10.1001/jama.2020.22018; Aghababaeian H, 2020, ALCOHOL, V88, P29, DOI 10.1016/j.alcohol.2020.07.006; Aikin KJ, 2015, J COMMUN, V65, P596, DOI 10.1111/jcom.12167; Albarracin D, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9959; Allcott H, 2017, J ECON PERSPECT, V31, P211, DOI 10.1257/jep.31.2.211; Allen J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3539; Altay S, 2022, DIGIT JOURNAL, V10, P373, DOI 10.1080/21670811.2021.1941163; [Anonymous], 2018, EUR FAK NEWS ONL DIS; [Anonymous], 2021, WHAT IS GO VIR; Armstrong Gary M., 1983, J PUBLIC POLICY MARK, V2, P16; Bago B, 2020, J EXP PSYCHOL GEN, V149, P1608, DOI 10.1037/xge0000729; Banas JA, 2010, COMMUN MONOGR, V77, P281, DOI 10.1080/03637751003758193; Basol M, 2021, BIG DATA SOC, V8, DOI 10.1177/20539517211013868; Basol Melisa, 2020, J Cogn, V3, P2, DOI 10.5334/joc.91; Benton J., 2021, FACEBOOK SENT TON TR; Bolsen T, 2014, POLIT BEHAV, V36, P235, DOI 10.1007/s11109-013-9238-0; Brashier NM, 2020, CURR DIR PSYCHOL SCI, V29, P316, DOI 10.1177/0963721420915872; Bronstein MV, 2019, J APPL RES MEM COGN, V8, P108, DOI 10.1016/j.jarmac.2018.09.005; Chan MPS, 2017, PSYCHOL SCI, V28, P1531, DOI 10.1177/0956797617714579; Chido-Amajuoyi OG, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6935; Choi D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57272-3; Cinelli M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2023301118; Cinelli Matteo, 2020, Sci Rep, V10, P16598, DOI 10.1038/s41598-020-73510-5; Compton J, 2021, SOC PERSONAL PSYCHOL, V15, DOI 10.1111/spc3.12602; Compton J, 2020, COMMUN THEOR, V30, P330, DOI 10.1093/ct/qtz004; Compton J, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00122; Connor P., 2020, BEHAV PUBLIC POLICY, P1, DOI [DOI 10.1017/BPP.2020.32, 10.1017/bpp.2020.32]; Cook J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175799; De keersmaecker J, 2020, PERS SOC PSYCHOL B, V46, P204, DOI 10.1177/0146167219853844; De Keersmaecker J, 2017, INTELLIGENCE, V65, P107, DOI 10.1016/j.intell.2017.10.005; Dechene A, 2010, PERS SOC PSYCHOL REV, V14, P238, DOI 10.1177/1088868309352251; Del Vicario M, 2016, P NATL ACAD SCI USA, V113, P554, DOI 10.1073/pnas.1517441113; Druckman JN, 2019, NAT CLIM CHANGE, V9, P111, DOI 10.1038/s41558-018-0360-1; Drummond C, 2017, P NATL ACAD SCI USA, V114, P9587, DOI 10.1073/pnas.1704882114; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Evans JST, 2003, TRENDS COGN SCI, V7, P454, DOI 10.1016/j.tics.2003.08.012; Fazio LK, 2019, PSYCHON B REV, V26, P1705, DOI 10.3758/s13423-019-01651-4; Fazio LK, 2015, J EXP PSYCHOL GEN, V144, P993, DOI 10.1037/xge0000098; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Gawronski B, 2021, TRENDS COGN SCI, V25, P723, DOI 10.1016/j.tics.2021.05.001; Greene CM, 2021, MEMORY, V29, P587, DOI 10.1080/09658211.2021.1923754; Grinberg N, 2019, SCIENCE, V363, P374, DOI 10.1126/science.aau2706; Guess A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau4586; Guess AM, 2021, AM J POLIT SCI, V65, P1007, DOI 10.1111/ajps.12589; Guess AM, 2020, NAT HUM BEHAV, V4, P472, DOI 10.1038/s41562-020-0833-x; Haglin K, 2017, RES POLITICS, V4, DOI 10.1177/2053168017716547; Iles IA, 2021, SCI COMMUN, V43, P768, DOI 10.1177/10755470211048480; Imhoff R, 2022, NAT HUM BEHAV, V6, P392, DOI 10.1038/s41562-021-01258-7; Imhoff R, 2020, SOC PSYCHOL PERS SCI, V11, P1110, DOI 10.1177/1948550620934692; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Jolley D, 2020, BRIT J SOC PSYCHOL, V59, P628, DOI 10.1111/bjso.12394; Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453; Juul JL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100786118; Kahan D.M., 2016, EMERGING TRENDS SOCI; Kahan DM, 2012, NAT CLIM CHANGE, V2, P732, DOI 10.1038/NCLIMATE1547; Kalla JL, 2018, AM POLIT SCI REV, V112, P148, DOI 10.1017/S0003055417000363; Krishna A, 2021, AM BEHAV SCI, V65, P316, DOI 10.1177/0002764219878223; Kucharski A, 2016, NATURE, V540, P525, DOI 10.1038/540525a; KUNDA Z, 1990, PSYCHOL BULL, V108, P480, DOI 10.1037/0033-2909.108.3.480; Lazer DMJ, 2018, SCIENCE, V359, P1094, DOI 10.1126/science.aao2998; Lewandowsky S, 2020, DEBUNKING HDB; Lewandowsky S, 2021, EUR REV SOC PSYCHOL, V32, P348, DOI 10.1080/10463283.2021.1876983; Lewandowsky S, 2012, PSYCHOL SCI PUBL INT, V13, P106, DOI 10.1177/1529100612451018; Lewis T., 2020, SCI AM; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Maertens R., 2021, MISINFORMATION SUSCE, DOI [10.31234/osf.io/gk68h, DOI 10.31234/OSF.IO/GK68H]; Maertens R, 2021, J EXP PSYCHOL-APPL, V27, P1, DOI 10.1037/xap0000315; Marsh EJ, 2018, Informat Austin, P15; Matz SC, 2017, P NATL ACAD SCI USA, V114, P12714, DOI 10.1073/pnas.1710966114; MCGUIRE WJ, 1964, ADV EXP SOC PSYCHOL, V1, P191, DOI 10.1016/S0065-2601(08)60052-0; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Oliver A, 2013, BEHAVIOURAL PUBLIC POLICY, P1; Osmundsen M, 2021, AM POLIT SCI REV, V115, P999, DOI 10.1017/S0003055421000290; PAPAGEORGIS D, 1961, J ABNORM SOC PSYCH, V62, P475, DOI 10.1037/h0048430; Paynter J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210746; Pennycook G, 2021, TRENDS COGN SCI, V25, P388, DOI 10.1016/j.tics.2021.02.007; Pennycook G, 2021, NATURE, V592, P590, DOI 10.1038/s41586-021-03344-2; Pennycook G, 2020, PSYCHOL SCI, V31, P770, DOI 10.1177/0956797620939054; Pennycook G, 2020, J PERS, V88, P185, DOI 10.1111/jopy.12476; Pennycook G, 2018, J EXP PSYCHOL GEN, V147, P1865, DOI 10.1037/xge0000465; Pennycook G, 2019, COGNITION, V188, P39, DOI 10.1016/j.cognition.2018.06.011; Persson E, 2021, COGNITION, V214, DOI 10.1016/j.cognition.2021.104768; Poutoglidou F, 2021, EXPERT REV RESP MED, V15, P979, DOI 10.1080/17476348.2021.1951239; Rathje S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024292118; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Roozenbeek J, 2020, HKS MISINFO REV, DOI [10.37016/mr-2020-47, DOI 10.37016/MR-2020-47]; Roozenbeek J., PSYCHOL SCI, DOI [10.25384/SAGE.12594110.v2(2022), DOI 10.25384/SAGE.12594110.V2(2022), 10.25384/SAGE.12594110.v2, DOI 10.25384/SAGE.12594110.V2]; Roozenbeek J, 2021, PSYCHOL SCI, V32, P1169, DOI 10.1177/09567976211024535; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Roozenbeek J, 2019, PALGR COMMUN, V5, DOI 10.1057/s41599-019-0279-9; Sagarin BJ, 2002, J PERS SOC PSYCHOL, V83, P526, DOI 10.1037//0022-3514.83.3.526; Saunders J, 2010, MEMORY, V18, P1, DOI 10.1080/09658210903376268; Scales D, 2021, NEW ENGL J MED, V385, P678, DOI 10.1056/NEJMp2103798; Scherer LD, 2021, HEALTH PSYCHOL, V40, P274, DOI 10.1037/hea0000978; Smith P, 2011, AM J PREV MED, V40, P690, DOI 10.1016/j.amepre.2011.01.020; Southwell BG, 2019, AM J PREV MED, V57, P282, DOI 10.1016/j.amepre.2019.03.009; Swami V, 2014, COGNITION, V133, P572, DOI 10.1016/j.cognition.2014.08.006; Swire-Thompson B, 2020, J APPL RES MEM COGN, V9, P286, DOI 10.1016/j.jarmac.2020.06.006; Tandoc EC, 2018, DIGIT JOURNAL, V6, P137, DOI 10.1080/21670811.2017.1360143; Tappin B, 2021, J EXP PSYCHOL GEN, V150, P1095, DOI 10.1037/xge0000974; Tappin B, 2020, CURR OPIN BEHAV SCI, V34, P81, DOI 10.1016/j.cobeha.2020.01.003; Traberg CS, 2022, PERS INDIV DIFFER, V185, DOI 10.1016/j.paid.2021.111269; Van Bavel JJ, 2021, SOC ISS POLICY REV, V15, P84, DOI 10.1111/sipr.12077; van der Linden S, 2020, PSYCHOL FAKE NEWS AC, P147, DOI [10.4324/9780429295379-11, DOI 10.4324/9780429295379-11]; van der Linden S, 2021, SPAN J PSYCHOL, V24, DOI 10.1017/SJP.2021.23; van der Linden S, 2021, POLIT PSYCHOL, V42, P23, DOI 10.1111/pops.12681; van der Linden S, 2020, MEDIA CULT SOC, V42, P460, DOI 10.1177/0163443720906992; van der Linden S, 2018, NAT HUM BEHAV, V2, P2, DOI 10.1038/s41562-017-0259-2; van der Linden S, 2017, GLOB CHALL, V1, DOI 10.1002/gch2.201600008; Vosoughi S, 2018, SCIENCE, V359, P1146, DOI 10.1126/science.aap9559; Vraga EK, 2020, POLIT COMMUN, V37, P136, DOI 10.1080/10584609.2020.1716500; Walter N, 2021, HEALTH COMMUN, V36, P1776, DOI 10.1080/10410236.2020.1794553; Walter N, 2020, COMMUN RES, V47, P155, DOI 10.1177/0093650219854600; Walter N, 2018, COMMUN MONOGR, V85, P423, DOI 10.1080/03637751.2018.1467564; Wang WC, 2016, J COGNITIVE NEUROSCI, V28, P739, DOI 10.1162/jocn_a_00923; Wardle C., 2017, INFORM DISORDER INTE; Wood T, 2019, POLIT BEHAV, V41, P135, DOI 10.1007/s11109-018-9443-y; Yang KC, 2021, BIG DATA SOC, V8, DOI 10.1177/20539517211013861; Yousuf H, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100881; Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X; Zollo F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181821	123	16	16	37	65	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					460	467		10.1038/s41591-022-01713-6	http://dx.doi.org/10.1038/s41591-022-01713-6		MAR 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35273402	Bronze			2022-12-27	WOS:000767065500001
J	Li, JX; Hou, LH; Guo, XL; Jin, PF; Wu, SP; Zhu, JH; Pan, HX; Wang, X; Song, ZZ; Wan, JX; Cui, LB; Li, JQ; Chen, Y; Wang, XW; Jin, LR; Liu, JX; Shi, FJ; Xu, XY; Zhu, T; Chen, W; Zhu, FC				Li, Jingxin; Hou, Lihua; Guo, Xiling; Jin, Pengfei; Wu, Shipo; Zhu, Jiahong; Pan, Hongxing; Wang, Xue; Song, Zhizhou; Wan, Jingxuan; Cui, Lunbiao; Li, Junqiang; Chen, Yin; Wang, Xuewen; Jin, Lairun; Liu, Jingxian; Shi, Fengjuan; Xu, Xiaoyu; Zhu, Tao; Chen, Wei; Zhu, Fengcai			Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	NATURE MEDICINE			English	Article							COVID-19 VACCINE; EFFICACY; STRATEGY; SAFETY; VECTOR	The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial (NCT04892459). Adults who had received two doses of CoronaVac in the past 3-6 months were vaccinated with Convidecia (n = 96) or CoronaVac (n = 102). Adults who had received one dose of CoronaVac in the past 1-3 months were also vaccinated with Convidecia (n = 51) or CoronaVac (n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.	[Li, Jingxin; Guo, Xiling; Jin, Pengfei; Pan, Hongxing; Cui, Lunbiao; Chen, Yin; Liu, Jingxian; Shi, Fengjuan; Zhu, Fengcai] Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing, Peoples R China; [Li, Jingxin; Zhu, Fengcai] China Pharmaceut Univ, Inst Global Hlth & Emergency Pharm, Nanjing, Peoples R China; [Hou, Lihua; Wu, Shipo; Chen, Wei] Acad Mil Med Sci, Inst Biotechnol, Beijing, Peoples R China; [Zhu, Jiahong; Song, Zhizhou] Lianshui Cty Ctr Dis Control & Prevent, Lianshui Cty, Peoples R China; [Wang, Xue; Wan, Jingxuan; Li, Junqiang; Zhu, Tao] CanSino Biol Inc, Tianjin, Peoples R China; [Wang, Xuewen] Canming Med Technol Co Ltd, Shanghai, Peoples R China; [Jin, Lairun] Southeast Univ, Dept Publ Hlth, Nanjing, Peoples R China; [Xu, Xiaoyu] Vazyme Biotech Co Ltd, Nanjing, Peoples R China; [Zhu, Fengcai] Nanjing Med Univ, Ctr Global Hlth, Nanjing, Peoples R China	Jiangsu Provincial Center for Disease Control & Prevention; China Pharmaceutical University; Academy of Military Medical Sciences - China; Southeast University - China; Nanjing Medical University	Zhu, FC (corresponding author), Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing, Peoples R China.; Zhu, FC (corresponding author), China Pharmaceut Univ, Inst Global Hlth & Emergency Pharm, Nanjing, Peoples R China.; Chen, W (corresponding author), Acad Mil Med Sci, Inst Biotechnol, Beijing, Peoples R China.; Zhu, FC (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Nanjing, Peoples R China.	cw0226@foxmail.com; jszfc@vip.sina.com	Li, Jing/GYU-5036-2022		National Natural Science Foundation of China; Jiangsu Provincial Key Research and Development Program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Key Research and Development Program	This work is funded by the National Natural Science Foundation of China (Jingxin L.) and the Jiangsu Provincial Key Research and Development Program (F.Z.). We acknowledge CanSino and Sinovac for providing the vaccines for this trial.	Atmar Robert L, 2021, medRxiv, DOI 10.1101/2021.10.10.21264827; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Excler JL, 2019, EXPERT REV VACCINES, V18, P765, DOI 10.1080/14760584.2019.1640117; Halperin SA, 2022, LANCET, V399, P237, DOI 10.1016/S0140-6736(21)02753-7; He Q, 2021, EMERG MICROBES INFEC, V10, P629, DOI 10.1080/22221751.2021.1902245; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Juno JA, 2021, NAT MED, V27, P1874, DOI 10.1038/s41591-021-01560-x; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Lim WW, 2021, LANCET MICROBE, V2, pE423, DOI 10.1016/S2666-5247(21)00177-4; Liu XX, 2021, LANCET, V398, P856, DOI 10.1016/S0140-6736(21)01694-9; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Lustig Y, 2021, LANCET RESP MED, V9, P999, DOI 10.1016/S2213-2600(21)00220-4; Nauta J, 2010, STATISTICS IN CLINICAL VACCINE TRIALS, P1, DOI 10.1007/978-3-642-14691-6_1; Normark J, 2021, NEW ENGL J MED, V385, P1049, DOI 10.1056/NEJMc2110716; Palacios R., EFFICACY SAFETY COVI, DOI [10.2139/ssrn.3822780, DOI 10.2139/SSRN.3822780]; Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Schwarz T, SAFETY REACTOGENICIT, DOI [10.1101/2021.05.19.21257334, DOI 10.1101/2021.05.19.21257334]; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01158-2, 10.1016/S0140-6736(21)01115-6]; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Victora C, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101036; VIPER Group COVID19 Vaccine Tracker Team, 2021, COVID19 VACC TRACK T; Xinhua, 2021, 1 8 BLN DOS COVID 19; Zeng G, 2022, LANCET INFECT DIS, V22, P483, DOI 10.1016/S1473-3099(21)00681-2; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2022, CLIN INFECT DIS, V75, pE783, DOI 10.1093/cid/ciab845	29	31	35	11	41	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					401	+		10.1038/s41591-021-01677-z	http://dx.doi.org/10.1038/s41591-021-01677-z		JAN 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35087233	Green Published, hybrid			2022-12-27	WOS:000749043100001
J	Barak, T; Ristori, E; Ercan-Sencicek, AG; Miyagishima, DF; Nelson-Williams, C; Dong, WL; Jin, SC; Prendergast, A; Armero, W; Henegariu, O; Erson-Omay, EZ; Harmanal, AS; Guy, M; Gultekin, B; Kilic, D; Rai, DK; Goc, N; Aguilera, SM; Gulez, B; Altinok, S; Ozcan, K; Yarman, Y; Coskun, S; Sempou, E; Deniz, E; Hintzen, J; Cox, A; Fomchenko, E; Jung, SW; Ozturk, AK; Louvi, A; Bilguvar, K; Connolly, ES; Khokha, MK; Kahle, KT; Yasuno, K; Lifton, RP; Mishra-Gorur, K; Nicoli, S; Gunel, M				Barak, Tanyeri; Ristori, Emma; Ercan-Sencicek, A. Gulhan; Miyagishima, Danielle F.; Nelson-Williams, Carol; Dong, Weilai; Jin, Sheng Chih; Prendergast, Andrew; Armero, William; Henegariu, Octavian; Erson-Omay, E. Zeynep; Harmanal, Akdes Serin; Guy, Mikhael; Gultekin, Batur; Kilic, Deniz; Rai, Devendra K.; Goc, Nukte; Aguilera, Stephanie Marie; Gulez, Burcu; Altinok, Selin; Ozcan, Kent; Yarman, Yanki; Coskun, Suleyman; Sempou, Emily; Deniz, Engin; Hintzen, Jared; Cox, Andrew; Fomchenko, Elena; Jung, Su Woong; Ozturk, Ali Kemal; Louvi, Angeliki; Bilguvar, Kaya; Connolly, E. Sander, Jr.; Khokha, Mustafa K.; Kahle, Kristopher T.; Yasuno, Katsuhito; Lifton, Richard P.; Mishra-Gorur, Ketu; Nicoli, Stefania; Gunel, Murat			PPIL4 is essential for brain angiogenesis and implicated in intracranial aneurysms in humans	NATURE MEDICINE			English	Article							PROTEIN 6 JMJD6; SUBARACHNOID HEMORRHAGE; CELLS; FRAMEWORK; CNS; STRATIFICATION; ARCHITECTURE; ASSOCIATION; EXPRESSION; DISEASE	Genomic analyses in individuals with index and familial intracranial aneurysms and experiments in vertebrate models identify pathogenic variants in the PPIL4 gene implicated in cerebral angiogenesis and cerebrovascular integrity, through the Wnt signaling pathway. Intracranial aneurysm (IA) rupture leads to subarachnoid hemorrhage, a sudden-onset disease that often causes death or severe disability. Although genome-wide association studies have identified common genetic variants that increase IA risk moderately, the contribution of variants with large effect remains poorly defined. Using whole-exome sequencing, we identified significant enrichment of rare, deleterious mutations in PPIL4, encoding peptidyl-prolyl cis-trans isomerase-like 4, in both familial and index IA cases. Ppil4 depletion in vertebrate models causes intracerebral hemorrhage, defects in cerebrovascular morphology and impaired Wnt signaling. Wild-type, but not IA-mutant, PPIL4 potentiates Wnt signaling by binding JMJD6, a known angiogenesis regulator and Wnt activator. These findings identify a novel PPIL4-dependent Wnt signaling mechanism involved in brain-specific angiogenesis and maintenance of cerebrovascular integrity and implicate PPIL4 gene mutations in the pathogenesis of IA.	[Barak, Tanyeri; Ercan-Sencicek, A. Gulhan; Miyagishima, Danielle F.; Henegariu, Octavian; Erson-Omay, E. Zeynep; Harmanal, Akdes Serin; Gultekin, Batur; Kilic, Deniz; Rai, Devendra K.; Goc, Nukte; Aguilera, Stephanie Marie; Gulez, Burcu; Altinok, Selin; Ozcan, Kent; Yarman, Yanki; Coskun, Suleyman; Fomchenko, Elena; Kahle, Kristopher T.; Yasuno, Katsuhito; Mishra-Gorur, Ketu; Gunel, Murat] Yale Sch Med, Dept Neurosurg, New Haven, CT 06510 USA; [Barak, Tanyeri; Ristori, Emma; Ercan-Sencicek, A. Gulhan; Miyagishima, Danielle F.; Nelson-Williams, Carol; Dong, Weilai; Jin, Sheng Chih; Armero, William; Henegariu, Octavian; Erson-Omay, E. Zeynep; Harmanal, Akdes Serin; Rai, Devendra K.; Coskun, Suleyman; Cox, Andrew; Bilguvar, Kaya; Khokha, Mustafa K.; Yasuno, Katsuhito; Lifton, Richard P.; Mishra-Gorur, Ketu; Nicoli, Stefania; Gunel, Murat] Yale Sch Med, Dept Genet, New Haven, CT 06510 USA; [Barak, Tanyeri; Ercan-Sencicek, A. Gulhan; Miyagishima, Danielle F.; Henegariu, Octavian; Erson-Omay, E. Zeynep; Harmanal, Akdes Serin; Rai, Devendra K.; Coskun, Suleyman; Yasuno, Katsuhito; Mishra-Gorur, Ketu; Gunel, Murat] Yale Sch Med, Dept Neurosci, New Haven, CT 06510 USA; [Barak, Tanyeri; Ercan-Sencicek, A. Gulhan; Miyagishima, Danielle F.; Henegariu, Octavian; Erson-Omay, E. Zeynep; Harmanal, Akdes Serin; Rai, Devendra K.; Coskun, Suleyman; Bilguvar, Kaya; Yasuno, Katsuhito; Mishra-Gorur, Ketu; Gunel, Murat] Yale Sch Med, Yale Program Neurogenet, New Haven, CT 06510 USA; [Ristori, Emma; Prendergast, Andrew; Armero, William; Hintzen, Jared; Nicoli, Stefania] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Internal Med, Sect Cardiol, New Haven, CT 06510 USA; [Dong, Weilai; Jin, Sheng Chih; Lifton, Richard P.] Rockefeller Univ, Lab Human Genet & Genom, 1230 York Ave, New York, NY 10021 USA; [Jin, Sheng Chih] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Guy, Mikhael] Yale Univ, Yale Ctr Res Comp, New Haven, CT USA; [Sempou, Emily; Deniz, Engin; Khokha, Mustafa K.] Yale Sch Med, Dept Pediat, New Haven, CT USA; [Jung, Su Woong] Kyung Hee Univ Hosp Gangdong, Dept Internal Med, Div Nephrol, Seoul, South Korea; [Ozturk, Ali Kemal] Univ Penn Hlth Syst, Penn Hosp, Dept Neurosurg, Philadelphia, PA USA; [Bilguvar, Kaya] Yale Univ, Yale Ctr Genome Anal, New Haven, CT USA; [Connolly, E. Sander, Jr.] Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; [Louvi, Angeliki; Kahle, Kristopher T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Louvi, Angeliki; Kahle, Kristopher T.] Harvard Med Sch, Boston, MA 02115 USA; [Kahle, Kristopher T.] Boston Childrens Hosp, Div Genet & Genom, Boston, MA USA; [Kahle, Kristopher T.] MIT, Broad Inst MIT & Harvard, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Nicoli, Stefania] Yale Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Rockefeller University; Washington University (WUSTL); Yale University; Yale University; Kyung Hee University; Kyung Hee University Hospital; University of Pennsylvania; Pennsylvania Medicine; Yale University; Columbia University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Yale University	Mishra-Gorur, K; Gunel, M (corresponding author), Yale Sch Med, Dept Neurosurg, New Haven, CT 06510 USA.; Mishra-Gorur, K; Nicoli, S; Gunel, M (corresponding author), Yale Sch Med, Dept Genet, New Haven, CT 06510 USA.; Mishra-Gorur, K; Gunel, M (corresponding author), Yale Sch Med, Dept Neurosci, New Haven, CT 06510 USA.; Mishra-Gorur, K; Gunel, M (corresponding author), Yale Sch Med, Yale Program Neurogenet, New Haven, CT 06510 USA.; Nicoli, S (corresponding author), Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Internal Med, Sect Cardiol, New Haven, CT 06510 USA.; Nicoli, S (corresponding author), Yale Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.	ketu.mishra@yale.edu; stefania.nicoli@vale.edu; murat.gunel@yale.edu		Miyagishima, Danielle/0000-0003-3257-5469; Jung, Su Woong/0000-0002-9053-924X; Cox, Andrew/0000-0002-9394-5702; Jin, Sheng Chih/0000-0002-5777-7262; Yarman, Yanki/0000-0002-7584-6903; Coskun, Suleyman/0000-0002-4830-0606; Dong, Weilai/0000-0002-8376-1758; Ristori, Emma/0000-0001-9999-2780; Deniz, Engin/0000-0002-2999-0429	Yale University funds; National Institutes of Health [4R01NS057756-10, 1R01NS111935-01, R01 NS109160-04, R01 HL130246-05]	Yale University funds; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are indebted to the patients and families who have contributed to this study. We would like to thank M. Cavanaugh for the zebrafish husbandry. Funding: This work was supported by Yale University funds (to M. Gunel) and National Institutes of Health grants 4R01NS057756-10 (to M. Gunel.), 1R01NS111935-01 (to M. Gunel, A.L. and K.M.-G.) and R01 NS109160-04 and R01 HL130246-05 (to S.N.).	Akhtar S, 2013, ARTERIOSCL THROM VAS, V33, P679, DOI 10.1161/ATVBAHA.112.301162; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Ando K, 2016, DEVELOPMENT, V143, P1328, DOI 10.1242/dev.132654; Bilguvar K, 2008, NAT GENET, V40, P1472, DOI 10.1038/ng.240; Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108; Bor ASE, 2014, LANCET NEUROL, V13, P385, DOI 10.1016/S1474-4422(14)70021-3; Bose Jens, 2004, J Biol, V3, P15, DOI 10.1186/jbiol10; Bourcier R, 2018, AM J HUM GENET, V102, P133, DOI 10.1016/j.ajhg.2017.12.006; Brend Tim, 2009, J Vis Exp, DOI 10.3791/1229; Chen XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13666-5; Cho C, 2017, NEURON, V95, P1056, DOI 10.1016/j.neuron.2017.07.031; Cras TY, 2020, STROKE, V51, P2103, DOI 10.1161/STROKEAHA.120.029296; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; GRAF CJ, 1966, J NEUROSURG, V25, P304, DOI 10.3171/jns.1966.25.3.0304; Hanes SD, 2015, BBA-GEN SUBJECTS, V1850, P2017, DOI 10.1016/j.bbagen.2014.10.028; He LQ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.160; HILLEN B, 1988, J BIOMECH, V21, P807, DOI 10.1016/0021-9290(88)90013-9; Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366; Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043; Kamoun WS, 2010, NAT METHODS, V7, P655, DOI [10.1038/NMETH.1475, 10.1038/nmeth.1475]; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Kasper DM, 2017, DEV CELL, V40, P552, DOI 10.1016/j.devcel.2017.02.021; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kissela BM, 2002, STROKE, V33, P1321, DOI 10.1161/01.STR.0000014773.57733.3E; Korja M, 2016, NEUROLOGY, V87, P1118, DOI 10.1212/WNL.0000000000003091; Korja M, 2013, NEUROLOGY, V80, P481, DOI 10.1212/WNL.0b013e31827f0fb5; Krumm N, 2015, NAT GENET, V47, P582, DOI 10.1038/ng.3303; Landrum MJ, 2018, NUCLEIC ACIDS RES, V46, pD1062, DOI 10.1093/nar/gkx1153; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; Li JC, 2018, NUCLEIC ACIDS RES, V46, pD1039, DOI 10.1093/nar/gkx1039; Liberzon A, 2014, METHODS MOL BIOL, V1150, P153, DOI 10.1007/978-1-4939-0512-6_9; Lindbohm JV, 2017, STROKE, V48, P2399, DOI 10.1161/STROKEAHA.117.018118; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martin M, 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, 10.10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Moon KR, 2019, NAT BIOTECHNOL, V37, P1482, DOI 10.1038/s41587-019-0336-3; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; Moro E, 2012, DEV BIOL, V366, P327, DOI 10.1016/j.ydbio.2012.03.023; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Santiago-Sim T, 2016, STROKE, V47, P3005, DOI 10.1161/STROKEAHA.116.014161; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; Schneider Jurgen E, 2004, BMC Dev Biol, V4, P16, DOI 10.1186/1471-213X-4-16; Smedley D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-22; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; TAYLOR CL, 1995, J NEUROSURG, V83, P812, DOI 10.3171/jns.1995.83.5.0812; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Vanhollebeke B, 2015, ELIFE, V4, DOI 10.7554/eLife.06489; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Wang CL, 2014, NAT GENET, V46, P409, DOI 10.1038/ng.2924; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Yasuno K, 2011, P NATL ACAD SCI USA, V108, P19707, DOI 10.1073/pnas.1117137108; Yasuno K, 2010, NAT GENET, V42, P420, DOI 10.1038/ng.563; Zeng L, 2001, CYTOGENET CELL GENET, V95, P43, DOI 10.1159/000057015; Zhang XN, 2015, J BIOL CHEM, V290, P20273, DOI 10.1074/jbc.M115.646554; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]; Zhang ZW, 2017, LIFE SCI, V188, P163, DOI 10.1016/j.lfs.2017.09.002; Zhou DX, 2017, NEOPLASMA, V64, P700, DOI 10.4149/neo_2017_507; Zhou SR, 2016, AM J HUM GENET, V99, P1072, DOI 10.1016/j.ajhg.2016.09.001; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	67	2	2	3	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2165	+		10.1038/s41591-021-01572-7	http://dx.doi.org/10.1038/s41591-021-01572-7		DEC 2021	36	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887573	Green Accepted			2022-12-27	WOS:000728466100004
J	Ertem, Z; Schechter-Perkins, E; Oster, E; van den Berg, P; Epshtein, I; Chaiyakunapruk, N; Wilson, F; Perenchevich, E; Pettey, W; Branch-Elliman, W; Nelson, R				Ertem, Zeynep; Schechter-Perkins, Elissa; Oster, Emily; van den Berg, Polly; Epshtein, Isabella; Chaiyakunapruk, Nathorn; Wilson, Fernando; Perenchevich, Elli; Pettey, Warren; Branch-Elliman, Westyn; Nelson, Richard			The impact of school opening model on SARS-CoV-2 community incidence and mortality	NATURE MEDICINE			English	Article							TRANSMISSION; COVID-19; COUNTY; ALCOHOL	Results from a nationwide cohort study in the United States indicates that schools can reopen for in-person learning without substantially increasing community case rates of SARS-CoV-2. The role that traditional and hybrid in-person schooling modes contribute to the community incidence of SARS-CoV-2 infections relative to fully remote schooling is unknown. We conducted an event study using a retrospective nationwide cohort evaluating the effect of school mode on SARS-CoV-2 cases during the 12 weeks after school opening (July-September 2020, before the Delta variant was predominant), stratified by US Census region. After controlling for case rate trends before school start, state-level mitigation measures and community activity level, SARS-CoV-2 incidence rates were not statistically different in counties with in-person learning versus remote school modes in most regions of the United States. In the South, there was a significant and sustained increase in cases per week among counties that opened in a hybrid or traditional mode versus remote, with weekly effects ranging from 9.8 (95% confidence interval (CI) = 2.7-16.1) to 21.3 (95% CI = 9.9-32.7) additional cases per 100,000 persons, driven by increasing cases among 0-9 year olds and adults. Schools can reopen for in-person learning without substantially increasing community case rates of SARS-CoV-2; however, the impacts are variable. Additional studies are needed to elucidate the underlying reasons for the observed regional differences more fully.	[Ertem, Zeynep] SUNY Binghamton, Syst Sci & Ind Engn Dept, New York, NY USA; [Schechter-Perkins, Elissa] Boston Univ, Sch Med, Dept Emergency Med, Boston, MA 02118 USA; [Schechter-Perkins, Elissa] Boston Med Ctr, Boston, MA USA; [Oster, Emily] Brown Univ, Watson Inst Int & Publ Affairs, Providence, RI 02912 USA; [van den Berg, Polly] Beth Israel Deaconess Med Ctr, Dept Med, Sect Infect Dis, Boston, MA 02215 USA; [Epshtein, Isabella; Branch-Elliman, Westyn] VA Boston Ctr Healthcare Org & Implementat Res CH, Boston, MA 02130 USA; [Chaiyakunapruk, Nathorn; Pettey, Warren] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA; [Wilson, Fernando; Nelson, Richard] Univ Utah, Matheson Ctr Hlth Care Studies, Salt Lake City, UT USA; [Perenchevich, Elli] Iowa City VA Hlth Care Syst, Ctr Access & Delivery Res & Evaluat, Iowa City, IA USA; [Perenchevich, Elli] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA; [Pettey, Warren; Nelson, Richard] Vet Affairs Salt Lake City Hlth Care Syst, IDEAS Ctr, Salt Lake City, UT USA; [Pettey, Warren; Nelson, Richard] Univ Utah, Sch Med, Div Epidemiol, Salt Lake City, UT USA; [Branch-Elliman, Westyn] VA Boston Healthcare Syst, Sect Infect Dis, Dept Med, Boston, MA 02130 USA; [Branch-Elliman, Westyn] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Binghamton; Boston University; Boston Medical Center; Brown University; Harvard University; Beth Israel Deaconess Medical Center; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School	Branch-Elliman, W (corresponding author), VA Boston Ctr Healthcare Org & Implementat Res CH, Boston, MA 02130 USA.; Branch-Elliman, W (corresponding author), VA Boston Healthcare Syst, Sect Infect Dis, Dept Med, Boston, MA 02130 USA.; Branch-Elliman, W (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	westyn.branch-elliman@va.gov		Schechter-Perkins, Elissa/0000-0003-1798-9663; Pettey, Warren/0000-0002-4436-3319; Chaiyakunapruk, Nathorn/0000-0003-4572-8794; Perencevich, Eli/0000-0002-3721-3355	National Institutes of Health [1K12HL138049-01]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Support for this study was provided by a National Institutes of Health grant no. 1K12HL138049-01 (to W.B.-E.). The views expressed are those of the study authors and do not imply endorsement from the US Federal Government.	Alonso S, 2021, PEDIATR INFECT DIS J, V40, P955, DOI 10.1097/INF.0000000000003279; Anderson DM, 2014, AM J PUBLIC HEALTH, V104, P2369, DOI 10.2105/AJPH.2013.301612; [Anonymous], 2021, BURBIOS METHODOLOGY; [Anonymous], 2021, COVID 19 COMMUNITY M; [Anonymous], 2021, COVID 19 CASE SURVEI; [Anonymous], 2021, WHAT IS CASE SURVEIL; Auger KA, 2020, JAMA-J AM MED ASSOC, V324, P859, DOI 10.1001/jama.2020.14348; Bellou A, 2013, J HEALTH ECON, V32, P353, DOI 10.1016/j.jhealeco.2012.12.001; Bitler MP, 2016, AM ECON J-ECON POLIC, V8, P39, DOI 10.1257/pol.20120298; Bosslet G. T, CLIN INFECT DIS, DOI [10.1093/cid/ciab306(2021, DOI 10.1093/CID/CIAB306(2021]; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Courtemanche C.J., 2021, SCH REOPENINGS MOBIL; Dawson P, 2021, MMWR-MORBID MORTAL W, V70, P449, DOI 10.15585/mmwr.mm7012e4; Espana G, 2021, EPIDEMICS-NETH, V37, DOI 10.1016/j.epidem.2021.100487; Falk A, 2021, MMWR-MORBID MORTAL W, V70, P136, DOI [10.15585/mmwr.mm7004e3, 10.15585/mmwr.mm7004e3externalicon]; Gold JAW, 2021, MMWR-MORBID MORTAL W, V70, P289, DOI 10.15585/mmwr.mm7008e4; Goldhaber D., 2021, WHAT EXTENT DOES PER; Grijalva CG, 2020, MMWR-MORBID MORTAL W, V69, P1631, DOI [10.15585/mmwr.mm6944e1, 10.15585/mmwr. mm6944e1]; Hallas L., 2020, VARIATION US STATES; Harris DN, 2021, EFFECTS SCH REOPENIN; Haug N, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-01009-0; Hershow RB, 2021, MMWR-MORBID MORTAL W, V70, P442, DOI 10.15585/mmwr.mm7012e3; Jackson Charlotte, 2013, BMJ Open, V3, DOI 10.1136/bmjopen-2012-002149; Khullar D, 2021, JAMA-HEALTH FORUM, V2, DOI 10.1001/jamahealthforum.2021.0290; Kim J, 2021, ARCH DIS CHILD, V106, P709, DOI 10.1136/archdischild-2020-319910; Lee B, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09799-8; Lessler J, 2021, SCIENCE, V372, P1092, DOI 10.1126/science.abh2939; Li X, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.011101; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1525, DOI 10.1111/apa.15371; Marcus J, 2015, J PUBLIC ECON, V123, P55, DOI 10.1016/j.jpubeco.2014.12.010; Naimark D, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.3793; Paik M, 2013, J EMPIR LEGAL STUD, V10, P639, DOI 10.1111/jels.12022; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Simon D, 2016, AM ECON J-APPL ECON, V8, P128, DOI 10.1257/app.20150476; Stein-Zamir C, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.29.2001352; VANDENBERG P, 2021, CLIN INFECT DIS; Varma JK, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2021-050605; Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X; Vlachos J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020834118; Walsh S, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-053371; Whaley C. M., 2021, BACK SCH EFFECT SCH; Wing C, 2018, ANNU REV PUBL HEALTH, V39, P453, DOI 10.1146/annurev-publhealth-040617-013507	42	12	12	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2120	+		10.1038/s41591-021-01563-8	http://dx.doi.org/10.1038/s41591-021-01563-8		OCT 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34707317	Bronze, Green Published			2022-12-27	WOS:000712497200002
J	Tang, WM; Wu, D; Yang, F; Wang, C; Gong, WF; Gray, K; Tucker, JD				Tang, Weiming; Wu, Dan; Yang, Fan; Wang, Cheng; Gong, Wenfeng; Gray, Kurt; Tucker, Joseph D.			How kindness can be contagious in healthcare	NATURE MEDICINE			English	Editorial Material							MEN; SEX	Pay-it-forward programs, whereby someone receives a gift or free service and then gives a gift to another person in return, have expanded during the COVID-19 pandemic and provide an opportunity for healthcare providers to reduce costs, increase uptake of interventions such as testing and vaccines, and promote sustainability.	[Tang, Weiming; Tucker, Joseph D.] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA; [Tang, Weiming; Yang, Fan; Tucker, Joseph D.] Univ North Carolina Project China, Guangzhou, Guangdong, Peoples R China; [Tang, Weiming; Wu, Dan; Yang, Fan; Tucker, Joseph D.] SESH Global, Guangzhou, Peoples R China; [Wu, Dan; Wang, Cheng] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China; [Yang, Fan] Peking Univ, Inst Populat Res, Beijing, Peoples R China; [Gong, Wenfeng] Bill & Melinda Gates Fdn, Beijing, Peoples R China; [Gray, Kurt] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27515 USA; [Tucker, Joseph D.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Clin Res Dept, London, England	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Southern Medical University - China; Peking University; University of North Carolina; University of North Carolina Chapel Hill; University of London; London School of Hygiene & Tropical Medicine	Tucker, JD (corresponding author), Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA.; Tucker, JD (corresponding author), Univ North Carolina Project China, Guangzhou, Guangdong, Peoples R China.; Tucker, JD (corresponding author), SESH Global, Guangzhou, Peoples R China.; Tucker, JD (corresponding author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Clin Res Dept, London, England.	jdtucker@med.unc.edu		Wu, Dan/0000-0003-0415-5467; Gong, Wenfeng/0000-0002-8929-2008; Tucker, Joseph/0000-0003-2804-1181; Yang, Fan/0000-0003-2853-7769	US National Institutes of Health [NIAID K24AI143471, R01AI158826]; Bill and Melinda Gates Foundation; UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Charles Koch Foundation (Center for the Science of Moral Understanding); Guangdong Provincial Dermatology Hospital	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Charles Koch Foundation (Center for the Science of Moral Understanding); Guangdong Provincial Dermatology Hospital	Supported by the US National Institutes of Health (NIAID K24AI143471 and R01AI158826), the Bill and Melinda Gates Foundation Grand Challenges, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, the Charles Koch Foundation (Center for the Science of Moral Understanding) and the Guangdong Provincial Dermatology Hospital. The funding sources had no part in the study design, collection, analysis, or interpretation of the data, writing of the report, and decision to submit the paper for publication.	Beheshti N., 2019, FORBES; City of London, CROWDFUNDER; Curry OS, 2018, J EXP SOC PSYCHOL, V76, P320, DOI 10.1016/j.jesp.2018.02.014; Fowler JH, 2010, P NATL ACAD SCI USA, V107, P5334, DOI 10.1073/pnas.0913149107; Franklin, 1917, AUTOBIOGRAPHY B FRAN; Hoffman, GOFUNDME; Hoffman Paul, 1998, MAN WHO LOVED ONLY N; Hui BPH, 2020, PSYCHOL BULL, V146, P1084, DOI 10.1037/bul0000298; Juban N., 2018, SOC INNOVATION HLTH; Lee C, 2020, PUBLIC HEALTH, V180, P117, DOI 10.1016/j.puhe.2019.11.011; Li KT, 2020, SEX TRANSM DIS, V47, P395, DOI 10.1097/OLQ.0000000000001161; McBride AB, 2019, J PROF NURS, V35, P156, DOI 10.1016/j.profnurs.2018.11.003; Oxford University Press, 2000, OXFORD ENGLISH DICT; Solnit Rebecca, 2009, PARADISE BUILT HELL; Tucker JD, 2019, PEERJ, V7, DOI 10.7717/peerj.6762; van Ryneveld M, 2022, INT J HEALTH POLICY, V11, P5, DOI 10.34172/ijhpm.2020.167; Yan, BEIJING REV; Yang F, 2020, LANCET INFECT DIS, V20, P976, DOI [10.1016/51473-3099(20)30172-9, 10.1016/S1473-3099(20)30172-9]	18	1	1	5	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1142	1144		10.1038/s41591-021-01401-x	http://dx.doi.org/10.1038/s41591-021-01401-x		JUN 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34127853	Green Submitted, hybrid			2022-12-27	WOS:000661414900004
J	Furer, N; Kaushansky, N; Shlush, LI				Furer, Nili; Kaushansky, Nathali; Shlush, Liran I.			The vicious and virtuous circles of clonal hematopoiesis	NATURE MEDICINE			English	Editorial Material							AGE		[Furer, Nili; Kaushansky, Nathali; Shlush, Liran I.] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel	Weizmann Institute of Science	Shlush, LI (corresponding author), Weizmann Inst Sci, Dept Immunol, Rehovot, Israel.	liranshlush3@gmail.com		Shlush, Liran/0000-0002-3700-270X				Bick AG, 2021, NATURE, V591, pE27, DOI [10.1038/s41586-021-03280-1, 10.1038/s41586-020-2819-2, 10.1038/s41586-021-03280]; Bolton KL, 2020, NAT GENET, V52, P1219, DOI 10.1038/s41588-020-00710-0; Buscarlet M, 2017, BLOOD, V130, P753, DOI 10.1182/blood-2017-04-777029; Cai ZG, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140707; Dharan NJ, 2021, NAT MED, V27, P1006, DOI 10.1038/s41591-021-01357-y; Frick M, 2019, J CLIN ONCOL, V37, P375, DOI 10.1200/JCO.2018.79.2184; Heyde A, 2021, CELL, V184, P1348, DOI 10.1016/j.cell.2021.01.049; Hormaechea-Agulla D, CELL STEM CELL, DOI [10.1016/j.stem.2021.03.002(2021, DOI 10.1016/J.STEM.2021.03.002(2021]; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Meisel M, 2018, NATURE, V557, P580, DOI 10.1038/s41586-018-0125-z; Shlush LI, 2018, BLOOD, V131, P496, DOI 10.1182/blood-2017-07-746453; Yoshizato T, 2015, NEW ENGL J MED, V373, P35, DOI 10.1056/NEJMoa1414799; Zekavat SM, 2021, NAT MED, V27, P1012, DOI 10.1038/s41591-021-01371-0	13	2	2	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					949	950		10.1038/s41591-021-01396-5	http://dx.doi.org/10.1038/s41591-021-01396-5		JUN 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34099925	Bronze			2022-12-27	WOS:000658604700001
J	Deczkowska, A; David, E; Ramadori, P; Pfister, D; Safran, M; The, BA; Giladi, A; Jaitin, DA; Barboy, O; Cohen, M; Yofe, I; Gur, C; Shlomi-Loubaton, S; Henri, S; Suhail, Y; Qiu, MJ; Kam, S; Hermon, H; Lahat, E; Yakov, GB; Cohen-Ezra, O; Davidov, Y; Likhter, M; Goitein, D; Roth, S; Weber, A; Malissen, B; Weiner, A; Ben-Ari, Z; Heikenwalder, M; Elinav, E; Amit, I				Deczkowska, Aleksandra; David, Eyal; Ramadori, Pierluigi; Pfister, Dominik; Safran, Michael; The, Baoguo At; Giladi, Amir; Jaitin, Diego Adhemar; Barboy, Oren; Cohen, Merav; Yofe, Ido; Gur, Chamutal; Shlomi-Loubaton, Shir; Henri, Sandrine; Suhail, Yousuf; Qiu, Mengjie; Kam, Shing; Hermon, Hila; Lahat, Eylon; Yakov, Gil Ben; Cohen-Ezra, Oranit; Davidov, Yana; Likhter, Mariya; Goitein, David; Roth, Susanne; Weber, Achim; Malissen, Bernard; Weiner, Assaf; Ben-Ari, Ziv; Heikenwalder, Mathias; Elinav, Eran; Amit, Ido			XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis	NATURE MEDICINE			English	Article							T-CELLS; LANDSCAPE; NASH; DIFFERENTIATION; MACROPHAGES; PROGRESSION; RECRUITMENT; HOMEOSTASIS; ACTIVATION; DISTINCT	Single-cell analyses reveal cDC1 as conserved immunological drivers of non-alcoholic steatohepatitis in mice and humans Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions that underlie the development of life-threatening cirrhosis, liver failure and liver cancer. Chronic necro-inflammation is a critical factor in development of NASH, yet the cellular and molecular mechanisms of immune dysregulation in this disease are poorly understood. Here, using single-cell transcriptomic analysis, we comprehensively profiled the immune composition of the mouse liver during NASH. We identified a significant pathology-associated increase in hepatic conventional dendritic cells (cDCs) and further defined their source as NASH-induced boost in cycling of cDC progenitors in the bone marrow. Analysis of blood and liver from patients on the NAFLD/NASH spectrum showed that type 1 cDCs (cDC1) were more abundant and activated in disease. Sequencing of physically interacting cDC-T cell pairs from liver-draining lymph nodes revealed that cDCs in NASH promote inflammatory T cell reprogramming, previously associated with NASH worsening. Finally, depletion of cDC1 in XCR1(DTA) mice or using anti-XCL1-blocking antibody attenuated liver pathology in NASH mouse models. Overall, our study provides a comprehensive characterization of cDC biology in NASH and identifies XCR1(+) cDC1 as an important driver of liver pathology.	[Deczkowska, Aleksandra; David, Eyal; The, Baoguo At; Giladi, Amir; Jaitin, Diego Adhemar; Barboy, Oren; Cohen, Merav; Yofe, Ido; Gur, Chamutal; Shlomi-Loubaton, Shir; Weiner, Assaf; Elinav, Eran; Amit, Ido] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel; [Ramadori, Pierluigi; Pfister, Dominik; Kam, Shing; Heikenwalder, Mathias] German Canc Res Ctr Heidelberg DKFZ, Div Chron Inflammat & Canc, Heidelberg, Germany; [Safran, Michael; Yakov, Gil Ben; Cohen-Ezra, Oranit; Davidov, Yana; Likhter, Mariya; Ben-Ari, Ziv] Sheba Med Ctr, Liver Dis Ctr, Tel Hashomer, Israel; [Cohen, Merav] Tel Aviv Univ, Sackler Fac Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel; [Gur, Chamutal] Hadassah Hebrew Univ Hosp, Dept Med, Jerusalem, Israel; [Henri, Sandrine; Malissen, Bernard] Aix Marseille Univ, Ctr Immunol Marseille Luminy, CNRS, INSERM, Marseille, France; [Suhail, Yousuf; Qiu, Mengjie; Roth, Susanne] Univ Klinikum Heidelberg, Chirurg Klin, Allgemein Viszeral & Transplantat Chirurg, Heidelberg, Germany; [Hermon, Hila; Goitein, David] Sheba Med Ctr, Dept Surg C, Tel Hashomer, Israel; [Lahat, Eylon] Sheba Med Ctr, Dept Surg B, Tel Hashomer, Israel; [Goitein, David; Ben-Ari, Ziv] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Weber, Achim] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland; [Malissen, Bernard] Aix Marseille Univ, Ctr Immunophenom, CNRS, INSERM, Marseille, France; [Elinav, Eran] German Canc Res Ctr Heidelberg DKFZ, Div Microbiome & Canc, Heidelberg, Germany; [Deczkowska, Aleksandra] Inst Pasteur, Dept Immunol, Paris, France; [Deczkowska, Aleksandra] Inst Pasteur, Dept Neurosci, Paris, France	Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ); Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Ruprecht Karls University Heidelberg; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Zurich; University Zurich Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Helmholtz Association; German Cancer Research Center (DKFZ); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deczkowska, A; Elinav, E; Amit, I (corresponding author), Weizmann Inst Sci, Dept Immunol, Rehovot, Israel.; Heikenwalder, M (corresponding author), German Canc Res Ctr Heidelberg DKFZ, Div Chron Inflammat & Canc, Heidelberg, Germany.; Elinav, E (corresponding author), German Canc Res Ctr Heidelberg DKFZ, Div Microbiome & Canc, Heidelberg, Germany.; Deczkowska, A (corresponding author), Inst Pasteur, Dept Immunol, Paris, France.; Deczkowska, A (corresponding author), Inst Pasteur, Dept Neurosci, Paris, France.	aleksandra.deczkowska@pasteur.fr; m.heikenwaelder@dkfz-heidelberg.de; eran.elinav@weizmann.ac.il; ido.amit@weizmann.ac.il	Ramadori, Pierluigi/AAZ-7533-2021; Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342; Pfister, Dominik/0000-0002-0542-2638; Ramadori, Pierluigi/0000-0001-6581-9648	Short-Term EMBO Fellowship [7395]; Helmholtz Future Inflammation and Immunology; ERC; EOS [SFBTR179, SFBTR 209, SFBTR1335]; Horizon 2020; Research Foundation Flanders [30826052]; Deutsche Krebshilfe [70113166, 70113167]; German-Israeli Cooperation in Cancer Research (DKFZ-MOST); Helmholtz-Gemeinschaft, Zukunftsthema `Immunology and Inflammation' [ZT-0027]; Leona M. and Harry B. Helmsley Charitable Trust; Adelis Foundation; Pearl Welinsky Merlo Scientific Progress Research Fund; Park Avenue Charitable Fund; Hanna and Dr. Ludwik Wallach Cancer Research Fund; Daniel Morris Trust; Wolfson Family Charitable Trust; Wolfson Foundation; Ben B. and Joyce E. Eisenberg Foundation; White Rose International Foundation; Estate of Bernard Bishin for the WIS-Clalit Program; Else Kroener Fresenius Foundation; Jeanne and Joseph Nissim Center for Life Sciences Research; Vainboim Family; V. R. Schwartz Research Fellow Chair; Swiss Society Institute for Cancer Prevention Research at the Weizmann Institute of Science, Rehovot, Israel; European Research Council; Israel Science Foundation; Israel Ministry of Science and Technology; Israel Ministry of Health; Helmholtz Foundation; Garvan Institute; European Crohn's and Colitis Organization; Deutsch-Israelische Projektkooperation; IDSA Foundation; Welcome Trust; Merck KGaA, Darmstadt, Germany; Chan Zuckerberg Initiative; Howard Hughes Medical Institute International Scholar award; European Research Council [724471-HemTree2.0]; Single Cell Analysis (SCA) award of the Wolfson Foundation; Thompson Family Foundation, a Melanoma Research Alliance Established Investigator Award [509044]; Israel Science Foundation [703/15]; Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine; Helen and Martin Kimmel award for innovative investigation; NeuroMac DFG/Transregional Collaborative Research Center Grant; International Progressive MS Alliance/NMSS [PA-1604 08459]; ISF Israel Precision Medicine Program (IPMP) [607/20]; Adelis Foundation grant	Short-Term EMBO Fellowship; Helmholtz Future Inflammation and Immunology; ERC(European Research Council (ERC)European Commission); EOS; Horizon 2020; Research Foundation Flanders(FWO); Deutsche Krebshilfe(Deutsche Krebshilfe); German-Israeli Cooperation in Cancer Research (DKFZ-MOST); Helmholtz-Gemeinschaft, Zukunftsthema `Immunology and Inflammation'; Leona M. and Harry B. Helmsley Charitable Trust; Adelis Foundation; Pearl Welinsky Merlo Scientific Progress Research Fund; Park Avenue Charitable Fund; Hanna and Dr. Ludwik Wallach Cancer Research Fund; Daniel Morris Trust; Wolfson Family Charitable Trust; Wolfson Foundation; Ben B. and Joyce E. Eisenberg Foundation; White Rose International Foundation; Estate of Bernard Bishin for the WIS-Clalit Program; Else Kroener Fresenius Foundation; Jeanne and Joseph Nissim Center for Life Sciences Research; Vainboim Family; V. R. Schwartz Research Fellow Chair; Swiss Society Institute for Cancer Prevention Research at the Weizmann Institute of Science, Rehovot, Israel; European Research Council(European Research Council (ERC)European Commission); Israel Science Foundation(Israel Science Foundation); Israel Ministry of Science and Technology(Ministry of Science, Technology and Space (MOST), Israel); Israel Ministry of Health; Helmholtz Foundation(Helmholtz Association); Garvan Institute; European Crohn's and Colitis Organization; Deutsch-Israelische Projektkooperation; IDSA Foundation; Welcome Trust(Wellcome Trust); Merck KGaA, Darmstadt, Germany; Chan Zuckerberg Initiative; Howard Hughes Medical Institute International Scholar award(Howard Hughes Medical Institute); European Research Council(European Research Council (ERC)European Commission); Single Cell Analysis (SCA) award of the Wolfson Foundation; Thompson Family Foundation, a Melanoma Research Alliance Established Investigator Award; Israel Science Foundation(Israel Science Foundation); Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine; Helen and Martin Kimmel award for innovative investigation; NeuroMac DFG/Transregional Collaborative Research Center Grant; International Progressive MS Alliance/NMSS; ISF Israel Precision Medicine Program (IPMP); Adelis Foundation grant	We thank T. Wiesel and T. Bigdary from the Scientific Illustration unit of the Weizmann Institute for artwork, C. Raanan for histology, M. Guilliams, A. Schlitzer and members of the Amit laboratory for fruitful discussions. We thank A. Leshem, H. Keren-Shaul, F. Sheban, L. Geirsdottir, E. Tatirovsky, F. Muller, J. Hetzer and D. Heide for technical support. A.D. is a recipient of Short-Term EMBO Fellowship no. 7395 and is supported by Eden and Steven Romick. D.P. is supported by the Helmholtz Future; Inflammation and Immunology. M.H.W. is supported by an ERC Consolidator grant (HepatoMetaboPath), an EOS grant, SFBTR179, SFBTR 209, SFBTR1335, Horizon 2020, Research Foundation Flanders under grant 30826052 (EOS Convention MODEL-IDI), Deutsche Krebshilfe projects 70113166 and 70113167, German-Israeli Cooperation in Cancer Research (DKFZ-MOST) and the Helmholtz-Gemeinschaft, Zukunftsthema `Immunology and Inflammation' (ZT-0027). E.E. is supported by the Leona M. and Harry B. Helmsley Charitable Trust; Adelis Foundation; Pearl Welinsky Merlo Scientific Progress Research Fund; Park Avenue Charitable Fund; The Hanna and Dr. Ludwik Wallach Cancer Research Fund; Daniel Morris Trust; The Wolfson Family Charitable Trust and The Wolfson Foundation; Ben B. and Joyce E. Eisenberg Foundation; White Rose International Foundation; Estate of Malka Moskowitz; Estate of Myron H. Ackerman; Estate of Bernard Bishin for the WIS-Clalit Program; Else Kroener Fresenius Foundation; Jeanne and Joseph Nissim Center for Life Sciences Research; Aliza Moussaieff; Miel de Botton; Vainboim Family; Alex Davidoff; the V. R. Schwartz Research Fellow Chair; the Swiss Society Institute for Cancer Prevention Research at the Weizmann Institute of Science, Rehovot, Israel and by grants funded by the European Research Council; Israel Science Foundation; Israel Ministry of Science and Technology; Israel Ministry of Health; the Helmholtz Foundation; Garvan Institute; European Crohn's and Colitis Organization; Deutsch-Israelische Projektkooperation; IDSA Foundation; and Welcome Trust. E.E. is the incumbent of the Sir Marc and Lady Tania Feldmann Professorial Chair; a senior fellow, Canadian Institute of Advanced Research; and an international scholar, The Bill and Melinda Gates Foundation and Howard Hughes Medical Institute. I.A. is an Eden and Steven Romick Professorial Chair, supported by Merck KGaA, Darmstadt, Germany, the Chan Zuckerberg Initiative, the Howard Hughes Medical Institute International Scholar award, the European Research Council Consolidator Grant 724471-HemTree2.0, a Single Cell Analysis (SCA) award of the Wolfson Foundation and Family Charitable Trust, the Thompson Family Foundation, a Melanoma Research Alliance Established Investigator Award (509044), the Israel Science Foundation (703/15), the Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine, the Helen and Martin Kimmel award for innovative investigation, the NeuroMac DFG/Transregional Collaborative Research Center Grant, an International Progressive MS Alliance/NMSS PA-1604 08459, the ISF Israel Precision Medicine Program (IPMP) 607/20 grant and an Adelis Foundation grant.	Aarts S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50976-6; Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7; Baran Y, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1812-2; Bhattacharjee J, 2017, HEPATOL COMMUN, V1, P299, DOI 10.1002/hep4.1041; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Breuer DA, 2020, AM J PHYSIOL-GASTR L, V318, pG211, DOI 10.1152/ajpgi.00040.2019; Brunt EM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.80; Cabeza-Cabrerizo M, 2021, ANNU REV IMMUNOL, V39, P131, DOI 10.1146/annurev-immunol-061020-053707; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Daemen S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108626; Devisscher L, 2017, CELL IMMUNOL, V322, P74, DOI 10.1016/j.cellimm.2017.10.006; Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519; Dudek Michael, 2021, Nature (London), V592, DOI 10.1038/s41586-021-03233-8; Farrell G, 2019, HEPATOLOGY, V69, P2241, DOI 10.1002/hep.30333; Febbraio MA, 2019, CELL METAB, V29, P18, DOI 10.1016/j.cmet.2018.10.012; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9; Ghazarian M, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7616; Giladi A, 2020, NAT BIOTECHNOL, V38, P629, DOI 10.1038/s41587-020-0442-2; Giladi A, 2018, NAT CELL BIOL, V20, P836, DOI 10.1038/s41556-018-0121-4; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Haas JT, 2019, NAT METAB, V1, P604, DOI 10.1038/s42255-019-0076-1; Halpern KB, 2017, NATURE, V542, P352, DOI 10.1038/nature21065; Hart KM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3694; Heier EC, 2017, J HEPATOL, V66, P1241, DOI 10.1016/j.jhep.2017.01.008; Henning JR, 2013, HEPATOLOGY, V58, P589, DOI 10.1002/hep.26267; Jaitin DA, 2019, CELL, V178, P686, DOI 10.1016/j.cell.2019.05.054; Jiao JJ, 2012, HEPATOLOGY, V55, P243, DOI 10.1002/hep.24621; Keren-Shaul H, 2019, NAT PROTOC, V14, P1841, DOI 10.1038/s41596-019-0164-4; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Krenkel O, 2020, GUT, V69, P551, DOI 10.1136/gutjnl-2019-318382; Krenkel O, 2017, NAT REV IMMUNOL, V17, P306, DOI 10.1038/nri.2017.11; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Lee W, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.157; Li JH, 2017, CYTOKINE GROWTH F R, V37, P47, DOI 10.1016/j.cytogfr.2017.07.004; Liaskou E, 2013, HEPATOLOGY, V57, P385, DOI 10.1002/hep.26016; Macpherson AJ, 2016, CELL HOST MICROBE, V20, P561, DOI 10.1016/j.chom.2016.10.016; Malehmir M, 2019, NAT MED, V25, P641, DOI 10.1038/s41591-019-0379-5; Mederacke I, 2015, NAT PROTOC, V10, P305, DOI 10.1038/nprot.2015.017; Montandon SA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53346-4; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Nutt SL, 2020, IMMUNITY, V52, P942, DOI 10.1016/j.immuni.2020.05.005; Parhizkar S, 2019, NAT NEUROSCI, V22, P191, DOI 10.1038/s41593-018-0296-9; Perugorria MJ, 2019, GUT, V68, P533, DOI 10.1136/gutjnl-2017-314107; Pfister D., NATURE; Ramachandran P, 2019, NATURE, V575, P512, DOI 10.1038/s41586-019-1631-3; Reid DT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159524; Reid DT, 2015, NUTR RES REV, V28, P133, DOI 10.1017/S0954422415000128; Remmerie A, 2020, IMMUNITY, V53, P641, DOI 10.1016/j.immuni.2020.08.004; Schlitzer A, 2015, SEMIN CELL DEV BIOL, V41, P9, DOI 10.1016/j.semcdb.2015.03.011; Schlitzer A, 2015, NAT IMMUNOL, V16, P718, DOI 10.1038/ni.3200; Schultze JL, 2019, IMMUNITY, V50, P288, DOI 10.1016/j.immuni.2019.01.019; Seillet C, 2013, BLOOD, V121, P1574, DOI 10.1182/blood-2012-07-445650; Soucie EL, 2016, SCIENCE, V351, DOI 10.1126/science.aad5510; Sun YF, 2021, CELL, V184, P404, DOI 10.1016/j.cell.2020.11.041; Swiderska M, 2017, CLIN EXP HEPATOL, V3, P127, DOI 10.5114/ceh.2017.68466; Tosello-Trampont AC, 2016, HEPATOLOGY, V63, P799, DOI 10.1002/hep.28389; Trak-Smayra V, 2011, INT J EXP PATHOL, V92, P413, DOI 10.1111/j.1365-2613.2011.00793.x; Tran S, 2020, IMMUNITY, V53, P627, DOI 10.1016/j.immuni.2020.06.003; Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531; Wohn C, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba1896; Wolf MJ, 2014, CANCER CELL, V26, P549, DOI 10.1016/j.ccell.2014.09.003; Xiong XL, 2019, MOL CELL, V75, P644, DOI 10.1016/j.molcel.2019.07.028; Yu JL, 2017, J AUTOIMMUN, V84, P109, DOI 10.1016/j.jaut.2017.08.005; Zang SF, 2015, CELL BIOCHEM BIOPHYS, V73, P479, DOI 10.1007/s12013-015-0682-9; Zhang QM, 2019, CELL, V179, P829, DOI 10.1016/j.cell.2019.10.003	66	36	36	11	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1043	+		10.1038/s41591-021-01344-3	http://dx.doi.org/10.1038/s41591-021-01344-3		MAY 2021	36	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34017133	Green Published			2022-12-27	WOS:000652454300001
J	Mitchell, JM; Bogenschutz, M; Lilienstein, A; Harrison, C; Kleiman, S; Parker-Guilbert, K; Ot'alora, GM; Garas, W; Paleos, C; Gorman, I; Nicholas, C; Mithoefer, M; Carlin, S; Poulter, B; Mithoefer, A; Quevedo, S; Wells, G; Klaire, SS; van der Kolk, B; Tzarfaty, K; Amiaz, R; Worthy, R; Shannon, S; Woolley, JD; Marta, C; Gelfand, Y; Hapke, E; Amar, S; Wallach, Y; Brown, R; Hamilton, S; Wang, JB; Coker, A; Matthews, R; de Boer, A; Yazar-Klosinski, B; Emerson, A; Doblin, R				Mitchell, Jennifer M.; Bogenschutz, Michael; Lilienstein, Alia; Harrison, Charlotte; Kleiman, Sarah; Parker-Guilbert, Kelly; Ot'alora, Marcela G.; Garas, Wael; Paleos, Casey; Gorman, Ingmar; Nicholas, Christopher; Mithoefer, Michael; Carlin, Shannon; Poulter, Bruce; Mithoefer, Ann; Quevedo, Sylvestre; Wells, Gregory; Klaire, Sukhpreet S.; van der Kolk, Bessel; Tzarfaty, Keren; Amiaz, Revital; Worthy, Ray; Shannon, Scott; Woolley, Joshua D.; Marta, Cole; Gelfand, Yevgeniy; Hapke, Emma; Amar, Simon; Wallach, Yair; Brown, Randall; Hamilton, Scott; Wang, Julie B.; Coker, Allison; Matthews, Rebecca; de Boer, Alberdina; Yazar-Klosinski, Berra; Emerson, Amy; Doblin, Rick			MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	NATURE MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PSYCHOTHERAPY; POLYMORPHISM; EFFICACY; DROPOUT; ECSTASY; SAFETY	Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study. MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was -24.4 (s.d. 11.6) in the MDMA group and -13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation. Results from a phase 3, double-blind, randomized, placebo-controlled trial demonstrate that MDMA-assisted therapy is safe and effective in treating severe post-traumatic stress disorder.	[Mitchell, Jennifer M.; Coker, Allison] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mitchell, Jennifer M.; Quevedo, Sylvestre; Woolley, Joshua D.] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA 94143 USA; [Bogenschutz, Michael] NYU, Dept Psychiat, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA; [Lilienstein, Alia; Yazar-Klosinski, Berra; Doblin, Rick] Multidisciplinary Assoc Psychedel Studies MAPS, San Jose, CA USA; [Harrison, Charlotte; Mithoefer, Michael; Carlin, Shannon; Wang, Julie B.; Coker, Allison; Matthews, Rebecca; de Boer, Alberdina; Emerson, Amy] MAPS Publ Benefit Corp MAPS PBC, San Jose, CA USA; [Kleiman, Sarah] Kleiman Consulting & Psychol Serv, Sayreville, NJ USA; [Parker-Guilbert, Kelly] KPG Psychol Serv LLC, Brunswick, ME USA; [Ot'alora, Marcela G.; Garas, Wael; Poulter, Bruce] Aguazul Bluewater Inc, Boulder, CO USA; [Ot'alora, Marcela G.; Mithoefer, Michael; Carlin, Shannon; Poulter, Bruce; Mithoefer, Ann; Tzarfaty, Keren] MAPS Publ Benefit Corp, MDMA Therapy Training Program, San Jose, CA USA; [Paleos, Casey] Nautilus Sanctuary, New York, NY USA; [Gorman, Ingmar; Brown, Randall] Fluence, Woodstock, NY USA; [Nicholas, Christopher] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, Madison, WI USA; [Mithoefer, Michael] Med Univ South Carolina, Charleston, SC 29425 USA; [Quevedo, Sylvestre; Wells, Gregory] San Francisco Insight & Integrat Ctr, San Francisco, CA USA; [Klaire, Sukhpreet S.] British Columbia Ctr Subst Use, Vancouver, BC, Canada; [van der Kolk, Bessel] Boston Univ, Sch Med, Boston, MA 02118 USA; [Amiaz, Revital] Chaim Sheba Med Ctr, Tel Hashomer, Israel; [Worthy, Ray] Ray Worthy Psychiat LLC, New Orleans, LA USA; [Shannon, Scott] Wholeness Ctr, Ft Collins, CO USA; [Marta, Cole] New Sch Res LLC, North Hollywood, CA USA; [Gelfand, Yevgeniy] Zen Therapeut Solut, Mt Pleasant, SC USA; [Hapke, Emma] Univ Toronto, Toronto, ON, Canada; [Amar, Simon] Dr Simon Amar Inc, Montreal, PQ, Canada; [Wallach, Yair] Beer Yaakov Ness Ziona Mental Hlth Ctr, Beer Yaagov, Israel; [Hamilton, Scott] Stanford Sch Med, Stanford, CA 94305 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; New York University; University of Wisconsin System; University of Wisconsin Madison; Medical University of South Carolina; Boston University; Chaim Sheba Medical Center; University of Toronto; Stanford University	Mitchell, JM (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.; Mitchell, JM (corresponding author), Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA 94143 USA.	jennifer.mitchell@ucsf.edu		Brown, Randall/0000-0002-5445-8119; Wang, Julie/0000-0001-7039-6061; Paleos, MD, Casey A./0000-0002-9698-511X; Bogenschutz, Michael/0000-0003-4530-3470; Gorman, Ingmar/0000-0003-4674-2969	MAPS; MDMA	MAPS; MDMA	The authors thank all of the participants who screened for and participated in this challenging research study, and acknowledge the oversight of the principal investigators, T. Nachsoni (Be'er Ya'akov, Israel) and N. Puri (University of British Columbia, Canada). The authors thank the study coordinators S. Sadler, K. Brown, C. Marsicano, M. Wimsatt, B. Bendixsen, D. Bissell, S. Serice, M. Gaffigan, C. Miller, R. Bacigalupi, B. Deyo, A. Baltes, T. Baron, L. Owens, S. Robison, D. Gumpel, C. Battistelli, A. Samkavitz, K. Blommaert, A. Menier, D. Katz, E. Pushkarski, N. Somech and M. Bar Haim for their work at their respective study sites. The authors are especially grateful to Charleston study coordinator S. Sadler, who passed away prior to the end of this study after a decade of work on this and several prior Multidisciplinary Association for Psychedelic Studies (MAPS) clinical trials. The authors also acknowledge the following study therapists for their skillful treatment of study participants: S. Braswell, W. Reynolds, C. Reusche, E. Passow, S. Gael Giron, D. May, J. Beachy, K. Cooper, A. Schnaitter, C. Hancock, C. Heacock, B. Balliett, E. Siegal, N. Bruss, V. Kraft, A. Booth, J. McCowan, S. Taylor, M. Skellie, Z. Hippel, M. Alavi, C. Stauffer, D. McDivitt, A. Rosati, K. Peoples, E. Sola, A. Penn, S.E. Sienknecht, G. Herzberg, H. Schwartz, V. Gold, J. Andries, C. Thomas, S. Ross, J. Guss, J.H. Duane, E. Nielson, K. O'Donnell, W. Hall, E. Nielson, P. Lister, E. Horowitz, A. Belser, J. Guss, J. Silverman, S. Walker, J. Hopper, M. Alpert, F. Guerriero, A. St. Goar, E. Call, C. Jackson, J. Simundic, H. Rubensohn, K. Lutz, S. Adams, T. Nachsoni, N. Halberstadt, D. Dogon, K.T. and I. Siemion. The authors thank the site physicians, nurses, research assistants, volunteers, night attendants, physical examiners and all site staff who contributed their time and effort to the study. The authors acknowledge the following select members of the MAPS PBC internal team who organized the study: M. Brown and G. Fortier, for their work in clinical trial management; A. Nary, P. Perl, E. Shainer, A. Pace and S. Ndukwe for careful monitoring of study data; A. Schwind, P. Llorach, M. Leighton, D. Iszak, S. Ramey-Wright and E. Gworek for tireless support of the study administration; S. Garcia-Velazquez for her review of participant safety data; J. Lindgren for coordination of IRB submissions; E. Heimler for dedicated effort in coordinating the independent rater pool; A. Wang, J. Lin and A. Garcia for overseeing the adherence rating and supervision programs; S. Scheld for supporting therapist and supervisor training and the development of the Code of Ethics; J. Poncini, C. Shelley, M. Tromba and A. O'Keefe for developing the technology and procedures to collect and manage session recordings with security and care; H. Clouting, B. Melton and K. Cohn for coordinating drug supply; A. Feduccia for her work on the phase 2 program that paved the way for this phase 3 trial; and C. Hennigan for the creation of the clinical databases. The authors also thank G. More for statistical programming, the teams of independent raters for their attention to detail and care for participants during outcome assessments, and the adherence raters for their close evaluation of the therapeutic delivery. No compensation was provided beyond normal compensation of employment. This clinical trial was sponsored by MAPS, a 501(c)(3) non-profit organization. MAPS provided the MDMA and fully funded this study from private donations.; MAPS Public Benefit Corporation (MAPS PBC), wholly owned by MAPS, was the trial organizer. MAPS PBC provided the study design and the monitoring of study data; analysis, management and interpretation of data; reviewed and approved the paper; and submitted the paper for publication. The funder had no role in the collection of data or in conducting the study.	Bauer EP, 2015, BEHAV BRAIN RES, V277, P68, DOI 10.1016/j.bbr.2014.07.028; Bedi G, 2009, PSYCHOPHARMACOLOGY, V207, P73, DOI 10.1007/s00213-009-1635-z; Bershad AK, 2016, J PSYCHOPHARMACOL, V30, P1248, DOI 10.1177/0269881116663120; Bisson JI, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub4; Bureau of Labor and Statistics, 2021, EMPL SIT VET 2020 NE; Cloitre M, 2012, DEPRESS ANXIETY, V29, P709, DOI 10.1002/da.21920; Congressional Budget Office, 2018, 54881 CBO; Dewey D, 2014, PSYCHOL REP, V115, P1, DOI 10.2466/16.02.PR0.115c11z7; Feduccia AA, 2021, PSYCHOPHARMACOLOGY, V238, P581, DOI 10.1007/s00213-020-05710-w; Feduccia AA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00650; Fortenbaugh FC, 2020, J TRAUMA STRESS, V33, P750, DOI 10.1002/jts.22501; Frewen PA, 2006, ANN NY ACAD SCI, V1071, P110, DOI 10.1196/annals.1364.010; Funk KA, 2013, ANN PHARMACOTHER, V47, P1330, DOI 10.1177/1060028013501994; Gutner CA, 2016, PSYCHOL TRAUMA-US, V8, P115, DOI 10.1037/tra0000062; Hake HS, 2019, PHYSIOL BEHAV, V199, P343, DOI 10.1016/j.physbeh.2018.12.007; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Hegel MT, 2005, AM J GERIAT PSYCHIAT, V13, P48, DOI 10.1176/appi.ajgp.13.1.48; Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161; Imel ZE, 2013, J CONSULT CLIN PSYCH, V81, P394, DOI 10.1037/a0031474; Johnson PL, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0368-y; Kamboj SK, 2015, J PSYCHOPHARMACOL, V29, P961, DOI 10.1177/0269881115587143; KAWAHARA H, 1993, NEUROSCI LETT, V162, P81, DOI 10.1016/0304-3940(93)90565-3; Keller SM, 2010, J CONSULT CLIN PSYCH, V78, P974, DOI 10.1037/a0020758; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Lee DJ, 2016, DEPRESS ANXIETY, V33, P792, DOI 10.1002/da.22511; Lee HJ, 2005, DEPRESS ANXIETY, V21, P135, DOI 10.1002/da.20064; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Marseille E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239997; Mithoefer, 2015, AM PSYCH ASS ANN M T; Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5; Nardou R, 2019, NATURE, V569, P116, DOI 10.1038/s41586-019-1075-9; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Steenkamp MM, 2015, JAMA-J AM MED ASSOC, V314, P489, DOI 10.1001/jama.2015.8370; Tarrier N, 2008, BEHAV MODIF, V32, P77, DOI 10.1177/0145445507304728; Vizeli P, 2017, J PSYCHOPHARMACOL, V31, P576, DOI 10.1177/0269881117691569; Watkins LE, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00258; Weathers FW, 2018, PSYCHOL ASSESSMENT, V30, P383, DOI 10.1037/pas0000486; Widom CS, 1999, AM J PSYCHIAT, V156, P1223; Wolf EJ, 2016, J CONSULT CLIN PSYCH, V84, P95, DOI 10.1037/ccp0000036; Yehuda R, 2010, PSYCHOPHARMACOLOGY, V212, P405, DOI 10.1007/s00213-010-1969-6	40	156	156	29	66	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1025	+		10.1038/s41591-021-01336-3	http://dx.doi.org/10.1038/s41591-021-01336-3		MAY 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	33972795	Green Published, hybrid			2022-12-27	WOS:000648805100002
J	Morris, SA; Lopez, KN				Morris, Shaine A.; Lopez, Keila N.			Deep learning for detecting congenital heart disease in the fetus	NATURE MEDICINE			English	Editorial Material							POPULATION	New advances in machine learning could facilitate and reduce disparities in the prenatal diagnosis of congenital health disease, the most common and lethal birth defect.	[Morris, Shaine A.] Baylor Coll Med, Dept Pediat, Div Pediat Cardiol, Houston, TX 77030 USA; Texas Childrens Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Morris, SA (corresponding author), Baylor Coll Med, Dept Pediat, Div Pediat Cardiol, Houston, TX 77030 USA.	shainem@bcm.edu		Morris, Shaine/0000-0002-8056-0934				Arnaout R, 2021, NAT MED, V27, P882, DOI 10.1038/s41591-021-01342-5; Campbell MJ, 2021, PRENATAL DIAG, V41, P341, DOI 10.1002/pd.5864; Cuocolo R, 2019, J GERIATR CARDIOL, V16, P601, DOI 10.11909/j.issn.1671-5411.2019.08.002; Ghorbani A, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-019-0216-8; Hancock HS, 2018, CARDIOL YOUNG, V28, P561, DOI 10.1017/S1047951117002761; Krishnan A, 2021, CIRCULATION, V143, P2049, DOI 10.1161/CIRCULATIONAHA.120.053062; Marelli AJ, 2007, CIRCULATION, V115, P163, DOI 10.1161/CIRCULATIONAHA.106.627224; Peyvandi S, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2015.4450; Pinto NM, 2012, ULTRASOUND OBST GYN, V40, P418, DOI 10.1002/uog.10116; Quartermain MD, 2019, PEDIATR CARDIOL, V40, P489, DOI 10.1007/s00246-018-1995-4; Quartermain MD, 2015, PEDIATRICS, V136, pE378, DOI 10.1542/peds.2014-3783; van Nisselrooij AEL, 2020, ULTRASOUND OBST GYN, V55, P747, DOI 10.1002/uog.20358; Wu Y, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2019.5316	13	7	7	6	30	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					764	765		10.1038/s41591-021-01354-1	http://dx.doi.org/10.1038/s41591-021-01354-1			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33990805				2022-12-27	WOS:000650698900015
J	Zhao, MM; Hoti, K; Wang, H; Raghu, A; Katabi, D				Zhao, Mingmin; Hoti, Kreshnik; Wang, Hao; Raghu, Aniruddh; Katabi, Dina			Assessment of medication self-administration using artificial intelligence	NATURE MEDICINE			English	Article							INHALER TECHNIQUE; ADHERENCE; BARRIERS; ASTHMA; ERRORS	Artificial intelligence coupled with wireless home sensors can monitor the use of insulin pens and inhalers by patients and alert of errors in self-medication in an unobtrusive manner. Errors in medication self-administration (MSA) lead to poor treatment adherence, increased hospitalizations and higher healthcare costs. These errors are particularly common when medication delivery involves devices such as inhalers or insulin pens. We present a contactless and unobtrusive artificial intelligence (AI) framework that can detect and monitor MSA errors by analyzing the wireless signals in the patient's home, without the need for physical contact. The system was developed by observing self-administration conducted by volunteers and evaluated by comparing its prediction with human annotations. Findings from this study demonstrate that our approach can automatically detect when patients use their inhalers (area under the curve (AUC) = 0.992) or insulin pens (AUC = 0.967), and assess whether patients follow the appropriate steps for using these devices (AUC = 0.952). The work shows the potential of leveraging AI-based solutions to improve medication safety with minimal overhead for patients and health professionals.	[Zhao, Mingmin; Hoti, Kreshnik; Wang, Hao; Raghu, Aniruddh; Katabi, Dina] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Hoti, Kreshnik] Univ Prishtina, Fac Med, Div Pharm, Prishtina, Kosovo	Massachusetts Institute of Technology (MIT)	Zhao, MM; Hoti, K (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Hoti, K (corresponding author), Univ Prishtina, Fac Med, Div Pharm, Prishtina, Kosovo.	mingmin@mit.edu; kreshnik@mit.edu		Hoti, Kreshnik/0000-0001-7652-6074; Zhao, Mingmin/0000-0001-5226-9085	Fulbright scholarship; Delta Electronics [6934407]	Fulbright scholarship; Delta Electronics	We thank the editor and the reviewers for their insightful comments and feedback. We are grateful to S. Desselle, L. Celi, L. Xing, X. Li, H. Hsu, J. Stokes, Z. Hussain, U. Munir, D. Vasisht, C.-Y. Hsu, G. Zhang, S. Yue, H. He, L. Fan, Y. Yang, T. Li, Y. Liu, H. Rahul, Z. Kabelac and R. Hristov for their comments on our manuscript. We also thank all the individuals who participated in our study. D.K., M.Z., H.W. and A.R. are funded by Delta Electronics (6934407). K.H. is funded by a Fulbright scholarship.	Adib F, 2015, CHI 2015: PROCEEDINGS OF THE 33RD ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P837, DOI 10.1145/2702123.2702200; Adib Fadel, 2014, P 11 USENIX C NETW S, P317, DOI DOI 10.5555/2616448.2616478; Aldeer M, 2018, APPL SYST INNOV, V1, DOI 10.3390/asi1020014; [Anonymous], 2016, INT C LEARN REPR; Cohen JL, 2009, ANN ALLERG ASTHMA IM, V103, P325, DOI 10.1016/S1081-1206(10)60532-7; Cooke CE, 2010, CURR MED RES OPIN, V26, P231, DOI 10.1185/03007990903421994; Fan L, 2020, P IEEE CVF C COMP VI, P10699; Frid AH, 2016, MAYO CLIN PROC, V91, P1231, DOI 10.1016/j.mayocp.2016.06.010; Giraud V, 2011, RESP MED, V105, P1815, DOI 10.1016/j.rmed.2011.07.004; Goris S, 2013, J AEROSOL MED PULM D, V26, P336, DOI 10.1089/jamp.2012.1017; Graves A, 2012, STUD COMPUT INTELL, V385, P1, DOI [10.1007/978-3-642-24797-2, 10.1162/neco.1997.9.1.1]; Graves A., 2006, ACM INT C PROCEEDING, P369; Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319; Hsu C.-Y., 2019, P 2019 CHI C HUM FAC, P1, DOI DOI 10.13031/AIM.201901464; Hsu CY, 2017, PROCEEDINGS OF THE 2017 ACM SIGCHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'17), P2116, DOI 10.1145/3025453.3025937; Iuga AO, 2014, RISK MANAG HEALTHC P, V7, P35, DOI 10.2147/RMHP.S19801; Kabelac Zachary, 2019, Digit Biomark, V3, P22, DOI 10.1159/000498922; Kelly P, 2013, AM J PREV MED, V44, P314, DOI 10.1016/j.amepre.2012.11.006; Lam WY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/217047; Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410; Lavorini F, 2008, RESP MED, V102, P593, DOI 10.1016/j.rmed.2007.11.003; Lavorini F, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619884532; Lippi G, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105941; Melani AS, 2011, RESP MED, V105, P930, DOI 10.1016/j.rmed.2011.01.005; Molimard M, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01794-2016; Murphy A, 2020, EVALUATION-US, V14, P19; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Peyrot M, 2012, DIABETIC MED, V29, P682, DOI 10.1111/j.1464-5491.2012.03605.x; Price D, 2013, RESP MED, V107, P37, DOI 10.1016/j.rmed.2012.09.017; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Ruud KW, 2018, PATIENT EDUC COUNS, V101, P1828, DOI 10.1016/j.pec.2018.05.018; Samaranayake NR., 2013, ADV PHARMACOEPIDEMIO, V2, P1; Selvin E, 2016, DIABETES CARE, V39, pE33, DOI 10.2337/dc15-2229; Spain CV, 2016, CLIN THER, V38, P1653, DOI 10.1016/j.clinthera.2016.05.009; Spollett G, 2016, DIABETES EDUCATOR, V42, P379, DOI 10.1177/0145721716648017; Stegemann S, 2012, EUR GERIATR MED, V3, P254, DOI 10.1016/j.eurger.2012.05.004; Trief Paula M, 2016, Clin Diabetes, V34, P25, DOI 10.2337/diaclin.34.1.25; Truong TH, 2017, DIABETES THER, V8, P221, DOI 10.1007/s13300-017-0242-y; URQUHART J, 1994, CLIN PHARMACOKINET, V27, P202, DOI 10.2165/00003088-199427030-00004; Viswanathan M, 2012, ANN INTERN MED, V157, P785, DOI 10.7326/0003-4819-157-11-201212040-00538; Wang W, 2016, UBICOMP'16: PROCEEDINGS OF THE 2016 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING, P363, DOI 10.1145/2971648.2971670; Wu YX, 2018, LECT NOTES COMPUT SC, V11217, P3, DOI 10.1007/978-3-030-01261-8_1; Yonglong Tian, 2018, Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies, V2, DOI 10.1145/3264947; Zhao MM, 2018, PROC CVPR IEEE, P7356, DOI 10.1109/CVPR.2018.00768; Zhao MM, 2018, PROCEEDINGS OF THE 2018 CONFERENCE OF THE ACM SPECIAL INTEREST GROUP ON DATA COMMUNICATION (SIGCOMM '18), P267, DOI 10.1145/3230543.3230579; Zhao MM, 2017, PR MACH LEARN RES, V70; Zhao MM, 2016, MOBICOM'16: PROCEEDINGS OF THE 22ND ANNUAL INTERNATIONAL CONFERENCE ON MOBILE COMPUTING AND NETWORKING, P95, DOI 10.1145/2973750.2973762; Zullig Leah L, 2015, Patient Prefer Adherence, V9, P139, DOI 10.2147/PPA.S69651	48	3	3	3	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01273-1	http://dx.doi.org/10.1038/s41591-021-01273-1		MAR 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33737750	Bronze			2022-12-27	WOS:000630281500003
J	Vitale, I; Shema, E; Loi, S; Galluzzi, L				Vitale, Ilio; Shema, Efrat; Loi, Sherene; Galluzzi, Lorenzo			Intratumoral heterogeneity in cancer progression and response to immunotherapy	NATURE MEDICINE			English	Review								Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these factors on tumor evolution changes over space and time, ultimately favoring the establishment of a neoplastic microenvironment that exhibits considerable genetic, phenotypic, and behavioral heterogeneity in all its components. Here, we discuss the main sources of intratumoral heterogeneity and its impact on the natural history of the disease, including sensitivity to treatment, as we delineate potential strategies to target such a detrimental feature of aggressive malignancies. The many levels of heterogeneity within tumors dictate their response to therapy and should be considered in future therapeutic regimes.	[Vitale, Ilio] IIGM Italian Inst Genom Med, IRCSS Candiolo, Turin, Italy; [Vitale, Ilio] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy; [Shema, Efrat] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Loi, Sherene] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Loi, Sherene] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Galluzzi, Lorenzo] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA; [Galluzzi, Lorenzo] Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA; [Galluzzi, Lorenzo] Caryl & Israel Englander Inst Precis Med, New York, NY 10021 USA; [Galluzzi, Lorenzo] Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Galluzzi, Lorenzo] Univ Paris, Paris, France	Italian Institute for Genomic Medicine (IIGM); IRCCS Fondazione del Piemonte per l'Oncologia; Weizmann Institute of Science; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Cornell University; Yale University; UDICE-French Research Universities; Universite Paris Cite	Vitale, I (corresponding author), IIGM Italian Inst Genom Med, IRCSS Candiolo, Turin, Italy.; Vitale, I (corresponding author), IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy.; Galluzzi, L (corresponding author), Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA.; Galluzzi, L (corresponding author), Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA.; Galluzzi, L (corresponding author), Caryl & Israel Englander Inst Precis Med, New York, NY 10021 USA.; Galluzzi, L (corresponding author), Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA.; Galluzzi, L (corresponding author), Univ Paris, Paris, France.	iliovit@gmail.com; deadoc80@gmail.com	Shema, Efrat/AHC-5041-2022; Loi, Sherene/H-1979-2016	Shema, Efrat/0000-0002-3718-593X; Loi, Sherene/0000-0001-6137-9171	Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017) [20417]; Italian Institute for Genomic Medicine (Candiolo, Turin, Italy); Compagnia di San Paolo (Torino, Italy); European Research Council [ERC801655]; Israeli Science Foundation [1881/19]; Minerva; National Breast Cancer Foundation of Australia; Breast Cancer Research Foundation; Breakthrough Level 2 grant from the US Department of Defense (DoD); Breast Cancer Research Program (BRCP) [BC180476P1]; 2019 Laura Ziskin Prize in Translational Research from the Stand Up to Cancer (SU2C) program [ZP-6177]; Mantle Cell Lymphoma Research Initiative (MCL-RI) grant from the Leukemia and Lymphoma Society (LLS); department of radiation oncology at Weill Cornell Medicine (New York, US); Rapid Response Grant from the Functional Genomics Initiative (New York, US); Lytix (Oslo, Norway); Phosplatin (New York, US)	Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017)(Fondazione AIRC per la ricerca sul cancro); Italian Institute for Genomic Medicine (Candiolo, Turin, Italy); Compagnia di San Paolo (Torino, Italy)(Compagnia di San Paolo); European Research Council(European Research Council (ERC)European Commission); Israeli Science Foundation(Israel Science Foundation); Minerva; National Breast Cancer Foundation of Australia; Breast Cancer Research Foundation; Breakthrough Level 2 grant from the US Department of Defense (DoD); Breast Cancer Research Program (BRCP); 2019 Laura Ziskin Prize in Translational Research from the Stand Up to Cancer (SU2C) program; Mantle Cell Lymphoma Research Initiative (MCL-RI) grant from the Leukemia and Lymphoma Society (LLS); department of radiation oncology at Weill Cornell Medicine (New York, US); Rapid Response Grant from the Functional Genomics Initiative (New York, US); Lytix (Oslo, Norway); Phosplatin (New York, US)	We thank G. Inghirami (Weill Cornell Medical College, New York, NY, US) for kindly providing micrographs included in Fig. 2, as well as K. Gouin and S. Knott (Cedars Sinai, Los Angeles, CA, US) for kindly providing UMAPs included in Fig. 3. I.V. is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017 #20417) and a startup grant from the Italian Institute for Genomic Medicine (Candiolo, Turin, Italy) and Compagnia di San Paolo (Torino, Italy). E.S. is an incumbent of the Lisa and Jeffrey Aronin Family Career Development Chair, and she is supported by grants from the European Research Council (#ERC801655), The Israeli Science Foundation (#1881/19), and Minerva. S.L. is supported by the National Breast Cancer Foundation of Australia and the Breast Cancer Research Foundation. L.G. is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from the Stand Up to Cancer (SU2C) program, by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a startup grant from the department of radiation oncology at Weill Cornell Medicine (New York, US), by a Rapid Response Grant from the Functional Genomics Initiative (New York, US), by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US), and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), and Sotio (Prague, Czech Republic).	AbdulJabbar K, 2020, NAT MED, V26, P1054, DOI 10.1038/s41591-020-0900-x; Albrengues J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10204; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Andor N, 2017, CANCER RES, V77, P2179, DOI 10.1158/0008-5472.CAN-16-1553; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Andrejeva G, 2017, CELL METAB, V26, P49, DOI 10.1016/j.cmet.2017.06.004; Angelova M, 2018, CELL, V175, P751, DOI 10.1016/j.cell.2018.09.018; Aoki T, 2020, CANCER DISCOV, V10, P406, DOI 10.1158/2159-8290.CD-19-0680; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Barthel FP, 2019, NATURE, V576, P112, DOI 10.1038/s41586-019-1775-1; Bartoschek M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07582-3; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Bernard V, 2019, CLIN CANCER RES, V25, P2194, DOI 10.1158/1078-0432.CCR-18-1955; Bhaduri A, 2020, CELL STEM CELL, V26, P48, DOI 10.1016/j.stem.2019.11.015; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Buque A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17644-0; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Crowther MD, 2020, NAT IMMUNOL, V21, P178, DOI 10.1038/s41590-019-0578-8; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Demircioglu F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15104-3; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; DeSelm C, 2018, MOL THER, V26, P2542, DOI 10.1016/j.ymthe.2018.09.008; Rodriguez-Ruiz ME, 2020, NAT IMMUNOL, V21, P120, DOI 10.1038/s41590-019-0561-4; Fang J, 2018, P NATL ACAD SCI USA, V115, P9598, DOI 10.1073/pnas.1806355115; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Gaiti F, 2019, NATURE, V569, P576, DOI 10.1038/s41586-019-1198-z; GALLUZZI L, 2020, CANCER DISCOV, V8, DOI DOI 10.1136/JITC-2019-000337; Galluzzi L, 2018, NAT REV MOL CELL BIO, V19, P731, DOI 10.1038/s41580-018-0068-0; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673; Gerstung M, 2020, NATURE, V578, P122, DOI 10.1038/s41586-019-1907-7; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Goveia J, 2020, CANCER CELL, V37, P21, DOI 10.1016/j.ccell.2019.12.001; Grasso CS, 2018, CANCER DISCOV, V8, P730, DOI 10.1158/2159-8290.CD-17-1327; Grosselin K, 2019, NAT GENET, V51, P1060, DOI 10.1038/s41588-019-0424-9; Gubin MM, 2018, CELL, V175, P1014, DOI 10.1016/j.cell.2018.09.030; Gujar S, 2018, TRENDS IMMUNOL, V39, P209, DOI 10.1016/j.it.2017.11.006; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Harel M, 2019, CELL, V179, P236, DOI 10.1016/j.cell.2019.08.012; Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hoang-Minh LB, 2018, EMBO J, V37, DOI 10.15252/embj.201798772; Hollern DP, 2019, CELL, V179, P1191, DOI 10.1016/j.cell.2019.10.028; Hu Z, 2020, NAT GENET, V52, P701, DOI 10.1038/s41588-020-0628-z; Ishak CA, 2018, TRENDS CANCER, V4, P583, DOI 10.1016/j.trecan.2018.05.008; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jemaa M, 2013, CELL DEATH DIFFER, V20, P1532, DOI 10.1038/cdd.2013.105; Jenzer M, 2019, CANCER IMMUNOL IMMUN, V68, P1621, DOI 10.1007/s00262-019-02393-x; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Jones PA, 2019, NAT REV CANCER, V19, P151, DOI 10.1038/s41568-019-0109-9; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kalbasi Anusha, 2020, Nat Rev Immunol, V20, P25, DOI 10.1038/s41577-019-0218-4; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; Kedia-Mehta N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10015-4; Keenan TE, 2019, NAT MED, V25, P389, DOI 10.1038/s41591-019-0382-x; Kepp O, 2020, NAT REV CLIN ONCOL, V17, P49, DOI 10.1038/s41571-019-0272-7; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Li S, 2016, NAT MED, V22, P792, DOI 10.1038/nm.4125; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Lin DC, 2017, CANCER RES, V77, P2255, DOI 10.1158/0008-5472.CAN-16-2822; Losic B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14050-z; Ma KY, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121387; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Mascaux C, 2019, NATURE, V571, P570, DOI 10.1038/s41586-019-1330-0; Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017; Mayoux M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav7431; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Miao D, 2018, NAT GENET, V50, P1271, DOI 10.1038/s41588-018-0200-2; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Miao YX, 2019, CELL, V177, P1172, DOI 10.1016/j.cell.2019.03.025; Michealraj KA, 2020, CELL, V181, P1329, DOI 10.1016/j.cell.2020.04.047; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Montesion Meagan, 2021, Cancer Discov, V11, P282, DOI 10.1158/2159-8290.CD-20-0672; Morris LGT, 2016, ONCOTARGET, V7, P10051, DOI 10.18632/oncotarget.7067; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Ocasio J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13657-6; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Patten DK, 2018, NAT MED, V24, P1469, DOI 10.1038/s41591-018-0091-x; Quintanal-Villalonga A, 2020, NAT REV CLIN ONCOL, V17, P360, DOI 10.1038/s41571-020-0340-z; Raynaud F, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007669; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Renner K, 2019, CELL REP, V29, P135, DOI 10.1016/j.celrep.2019.08.068; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roper N, 2019, CELL REP, V26, P2651, DOI 10.1016/j.celrep.2019.02.028; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Russo M, 2019, SCIENCE, V366, P1473, DOI 10.1126/science.aav4474; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Salmon H, 2019, NAT REV CANCER, V19, P215, DOI 10.1038/s41568-019-0125-9; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Sansregret L, 2018, NAT REV CLIN ONCOL, V15, P139, DOI 10.1038/nrclinonc.2017.198; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Sharma A, 2019, CELL REP, V29, P2164, DOI 10.1016/j.celrep.2019.10.045; Sharma P, 2020, NAT REV IMMUNOL, V20, P75, DOI 10.1038/s41577-020-0275-8; Sheffield NC, 2017, NAT MED, V23, P386, DOI 10.1038/nm.4273; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Slaney CY, 2018, CANCER DISCOV, V8, P924, DOI 10.1158/2159-8290.CD-18-0297; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Suda K, 2018, J THORAC ONCOL, V13, P1496, DOI 10.1016/j.jtho.2018.05.039; Sulkowski PL, 2020, NATURE, V582, P586, DOI 10.1038/s41586-020-2363-0; Tasdogan A, 2020, NATURE, V577, P115, DOI 10.1038/s41586-019-1847-2; Teixeira VH, 2019, NAT MED, V25, P517, DOI 10.1038/s41591-018-0323-0; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Touat M, 2020, NATURE, V580, P517, DOI 10.1038/s41586-020-2209-9; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Van den Eynden J, 2019, NAT GENET, V51, P1741, DOI 10.1038/s41588-019-0532-6; van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568-019-0235-4; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Vitale I, 2019, TRENDS CELL BIOL, V29, P396, DOI 10.1016/j.tcb.2019.01.003; Vitale I, 2015, TRENDS CANCER, V1, P124, DOI 10.1016/j.trecan.2015.08.001; von Loga K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13915-7; Wang JG, 2016, NAT GENET, V48, P768, DOI 10.1038/ng.3590; Watkins TBK, 2020, NATURE, V587, P126, DOI 10.1038/s41586-020-2698-6; Weber EW, 2020, CELL, V181, P46, DOI 10.1016/j.cell.2020.03.001; Wolf Y, 2019, CELL, V179, P219, DOI 10.1016/j.cell.2019.08.032; Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8; Xiao ZT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11738-0; Yamaguchi H, 2002, BIOCHEM BIOPH RES CO, V290, P722, DOI 10.1006/bbrc.2001.6277; Yamamoto TN, 2019, NAT MED, V25, P1488, DOI 10.1038/s41591-019-0596-y; Yamazaki T, 2016, CELL DEATH DIFFER, V23, P1004, DOI 10.1038/cdd.2016.35; Yamazaki T, 2020, NAT IMMUNOL, V21, P1160, DOI 10.1038/s41590-020-0751-0; Yan T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09255-1; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang AW, 2018, CELL, V173, P1755, DOI 10.1016/j.cell.2018.03.073; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x; Zhou H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.47; Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580-019-0123-5; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	167	147	150	23	99	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					212	224		10.1038/s41591-021-01233-9	http://dx.doi.org/10.1038/s41591-021-01233-9		FEB 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33574607				2022-12-27	WOS:000617100300002
J	Scangos, KW; Makhoul, GS; Sugrue, LP; Chang, EF; Krystal, AD				Scangos, Katherine W.; Makhoul, Ghassan S.; Sugrue, Leo P.; Chang, Edward F.; Krystal, Andrew D.			State-dependent responses to intracranial brain stimulation in a patient with depression	NATURE MEDICINE			English	Article							VENTRAL CAPSULE/VENTRAL STRIATUM	Deep brain stimulation is a promising treatment for severe depression, but lack of efficacy in randomized trials raises questions regarding anatomical targeting. We implanted multi-site intracranial electrodes in a severely depressed patient and systematically assessed the acute response to focal electrical neuromodulation. We found an elaborate repertoire of distinctive emotional responses that were rapid in onset, reproducible, and context and state dependent. Results provide proof of concept for personalized, circuit-specific medicine in psychiatry.	[Scangos, Katherine W.; Makhoul, Ghassan S.; Krystal, Andrew D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Chang, Edward F.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Sugrue, Leo P.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scangos, KW (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.	katherine.scangos@ucsf.edu			National Institutes of Health [U24 DA041123, K23NS110962, U01NS098971, R01MH114860, R01MH111444, R01DC015504, R01DC01237, UH3 NS109556, UH3NS115631, R01 NS105675, P01AG019724, R01 HL142051-01, R01AG059794, R01DK117953, UH3 NS109556-01, R01AG060477-01A1]; NARSAD Young Investigator grant from the Brain and Behavioral Research Foundation; Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at the University of California, San Francisco; New York Stem Cell Foundation; Howard Hughes Medical Institute; McKnight Foundation; Shurl and Kay Curci Foundation; William K. Bowes Foundation; PCORI; Janssen; Jazz; Axsome [AXS-05-301]; Reveal Biosensors	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NARSAD Young Investigator grant from the Brain and Behavioral Research Foundation(NARSAD); Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at the University of California, San Francisco(University of California System); New York Stem Cell Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); McKnight Foundation; Shurl and Kay Curci Foundation; William K. Bowes Foundation; PCORI(Patient-Centered Outcomes Research Institute - PCORI); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Jazz(Jazz Pharmaceuticals); Axsome; Reveal Biosensors	This work was supported by National Institutes of Health award K23NS110962 (to K.W.S.), a NARSAD Young Investigator grant from the Brain and Behavioral Research Foundation (to K.W.S.) and the Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at the University of California, San Francisco (to K.W.S., A.D.K., E.F.C. and L.P.S.). E.F.C. was supported by the National Institutes of Health (U01NS098971, R01MH114860, R01MH111444, R01DC015504, R01DC01237, UH3 NS109556, UH3NS115631 and R01 NS105675), the New York Stem Cell Foundation, the Howard Hughes Medical Institute, the McKnight Foundation, the Shurl and Kay Curci Foundation and the William K. Bowes Foundation. A.D.K. acknowledges support from the National Institutes of Health (P01AG019724, R01 HL142051-01, R01AG059794, R01DK117953, UH3 NS109556-01 and R01AG060477-01A1), PCORI, Janssen, Jazz, Axsome (AXS-05-301) and Reveal Biosensors. L.P.S. receives support from the National Institutes of Health (U24 DA041123).	[Anonymous], 2005, SCIENCE, DOI DOI 10.1126/science.1109237; Bergfeld IO, 2016, JAMA PSYCHIAT, V73, P456, DOI 10.1001/jamapsychiatry.2016.0152; BISHOP MP, 1963, SCIENCE, V140, P394, DOI 10.1126/science.140.3565.394; Choi KS, 2015, JAMA NEUROL, V72, P1252, DOI 10.1001/jamaneurol.2015.2564; Dougherty DD, 2015, BIOL PSYCHIAT, V78, P240, DOI 10.1016/j.biopsych.2014.11.023; Fraguas D, 2017, PSYCHOL MED, V47, P193, DOI 10.1017/S0033291716001355; Holtzheimer PE, 2017, LANCET PSYCHIAT, V4, P839, DOI 10.1016/S2215-0366(17)30371-1; Howland RH, 2008, J PSYCHOSOC NURS MEN, V46, P21; Inman CS, 2020, NEUROPSYCHOLOGIA, V145, DOI 10.1016/j.neuropsychologia.2018.03.019; Kirkby LA, 2018, CELL, V175, P1688, DOI 10.1016/j.cell.2018.10.005; Machado A, 2009, CLIN NEUROPHYSIOL, V120, P1941, DOI 10.1016/j.clinph.2009.05.030; Malone DA, 2009, BIOL PSYCHIAT, V65, P267, DOI 10.1016/j.biopsych.2008.08.029; Mayberg HS, 2016, JAMA PSYCHIAT, V73, P439, DOI 10.1001/jamapsychiatry.2016.0173; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Rao VR, 2018, CURR BIOL, V28, P3893, DOI 10.1016/j.cub.2018.10.026; Riva-Posse P, 2018, MOL PSYCHIATR, V23, P843, DOI 10.1038/mp.2017.59; Scangos KW, 2020, J NEUROPSYCH CLIN N, V32, P185, DOI 10.1176/appi.neuropsych.19030081; Scangos KW, 2018, BIOL PSYCHIAT, V84, pE55, DOI 10.1016/j.biopsych.2018.08.005; Tharin S, 2007, NEUROSURGERY, V60, P185, DOI 10.1227/01.0000255386.95464.52; Timmerby N, 2017, PSYCHOTHER PSYCHOSOM, V86, P141, DOI 10.1159/000457131	20	44	47	6	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					229	+		10.1038/s41591-020-01175-8	http://dx.doi.org/10.1038/s41591-020-01175-8		JAN 2021	7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33462446	Green Accepted			2022-12-27	WOS:000608674100006
J	Stower, H				Stower, Hannah			KRAS inhibitors at last	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1804	1804		10.1038/s41591-020-01149-w	http://dx.doi.org/10.1038/s41591-020-01149-w			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288930				2022-12-27	WOS:000596579200004
J	Narayan, V; Barber-Rotenberg, JS; Jung, IY; Lacey, SF; Rech, AJ; Davis, MM; Hwang, WT; Lal, P; Carpenter, EL; Maude, SL; Plesa, G; Vapiwala, N; Chew, A; Moniak, M; Sebro, RA; Farwell, MD; Marshall, A; Gilmore, J; Lledo, L; Dengel, K; Church, SE; Hether, TD; Xu, J; Gohil, M; Buckingham, TH; Yee, SS; Gonzalez, VE; Kulikovskaya, I; Chen, F; Tian, LF; Tien, K; Gladney, W; Nobles, CL; Raymond, HE; Hexner, EO; Siegel, DL; Bushman, FD; June, CH; Fraietta, JA; Haas, NB				Narayan, Vivek; Barber-Rotenberg, Julie S.; Jung, In-Young; Lacey, Simon F.; Rech, Andrew J.; Davis, Megan M.; Hwang, Wei-Ting; Lal, Priti; Carpenter, Erica L.; Maude, Shannon L.; Plesa, Gabriela; Vapiwala, Neha; Chew, Anne; Moniak, Michael; Sebro, Ronnie A.; Farwell, Michael D.; Marshall, Amy; Gilmore, Joan; Lledo, Lester; Dengel, Karen; Church, Sarah E.; Hether, Tyler D.; Xu, Jun; Gohil, Mercy; Buckingham, Thomas H.; Yee, Stephanie S.; Gonzalez, Vanessa E.; Kulikovskaya, Irina; Chen, Fang; Tian, Lifeng; Tien, Kyle; Gladney, Whitney; Nobles, Christopher L.; Raymond, Hayley E.; Hexner, Elizabeth O.; Siegel, Donald L.; Bushman, Frederic D.; June, Carl H.; Fraietta, Joseph A.; Haas, Naomi B.		Prostate Canc Cellular Therapy Pro	PSMA-targeting TGF beta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	NATURE MEDICINE			English	Article							MEMBRANE ANTIGEN-EXPRESSION; REDUCED CLINICAL BENEFIT; CLONAL EXPANSION; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; DNA INTEGRATION; EFFICACY; THERAPY; DIFFERENTIATION; ADENOCARCINOMA	Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high levels of multiple inhibitory factors, including transforming growth factor (TGF)-beta. We report results from an in-human phase 1 trial of castration-resistant, prostate cancer-directed CAR T cells armored with a dominant-negative TGF-beta receptor (NCT03089203). Primary endpoints were safety and feasibility, while secondary objectives included assessment of CAR T cell distribution, bioactivity and disease response. All prespecified endpoints were met. Eighteen patients enrolled, and 13 subjects received therapy across four dose levels. Five of the 13 patients developed grade >= 2 cytokine release syndrome (CRS), including one patient who experienced a marked clonal CAR T cell expansion, >98% reduction in prostate-specific antigen (PSA) and death following grade 4 CRS with concurrent sepsis. Acute increases in inflammatory cytokines correlated with manageable high-grade CRS events. Three additional patients achieved a PSA reduction of >= 30%, with CAR T cell failure accompanied by upregulation of multiple TME-localized inhibitory molecules following adoptive cell transfer. CAR T cell kinetics revealed expansion in blood and tumor trafficking. Thus, clinical application of TGF-beta-resistant CAR T cells is feasible and generally safe. Future studies should use superior multipronged approaches against the TME to improve outcomes. CAR T cells targeting PSMA and engineered to be resistant to immunosuppressive TGF beta signaling exhibit dose-dependent toxicity and expansion following infusion, with some transient antitumor activity, in patients with metastatic castration-resistant prostate cancer	[Narayan, Vivek; Haas, Naomi B.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Narayan, Vivek; Jung, In-Young; Rech, Andrew J.; Lal, Priti; Carpenter, Erica L.; Vapiwala, Neha; Sebro, Ronnie A.; Farwell, Michael D.; Buckingham, Thomas H.; Yee, Stephanie S.; Hexner, Elizabeth O.; June, Carl H.; Fraietta, Joseph A.; Haas, Naomi B.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Barber-Rotenberg, Julie S.; Jung, In-Young; Lacey, Simon F.; Rech, Andrew J.; Davis, Megan M.; Plesa, Gabriela; Chew, Anne; Moniak, Michael; Marshall, Amy; Gilmore, Joan; Lledo, Lester; Dengel, Karen; Xu, Jun; Gohil, Mercy; Gonzalez, Vanessa E.; Kulikovskaya, Irina; Chen, Fang; Tian, Lifeng; Gladney, Whitney; Hexner, Elizabeth O.; Siegel, Donald L.; June, Carl H.; Fraietta, Joseph A.] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA; [Jung, In-Young; Nobles, Christopher L.; Raymond, Hayley E.; Bushman, Frederic D.; Fraietta, Joseph A.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lacey, Simon F.; Rech, Andrew J.; Lal, Priti; Siegel, Donald L.; June, Carl H.; Fraietta, Joseph A.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rech, Andrew J.; Carpenter, Erica L.; Buckingham, Thomas H.; Yee, Stephanie S.; Tien, Kyle; June, Carl H.; Fraietta, Joseph A.] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Hwang, Wei-Ting] Univ Penn, Dept Biostat Epidemiol & Informat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Maude, Shannon L.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Maude, Shannon L.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sebro, Ronnie A.; Farwell, Michael D.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Church, Sarah E.; Hether, Tyler D.] NanoString Technol Inc, Seattle, WA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Haas, NB (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.; Fraietta, JA; Haas, NB (corresponding author), Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.; Fraietta, JA (corresponding author), Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.; Fraietta, JA (corresponding author), Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Fraietta, JA (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.; Fraietta, JA (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.	cjune@upenn.edu; jfrai@upenn.edu; naomi.haas@pennmedicine.upenn.edu		Narayan, Vivek/0000-0002-8205-738X	University of Pennsylvania; Prostate Cancer Foundation Challenge Award; Tmunity Therapeutics, Inc.; George Weiss Funding Group; Alliance for Cancer Gene Therapy Investigator Award in Cell and Gene Therapy for Cancer; Prostate Cancer Foundation Young Investigator Award; ACC P30 Core Grant [P30 CA016520-42];  [U54 CA244711-01];  [R01 CA241762-03]	University of Pennsylvania; Prostate Cancer Foundation Challenge Award; Tmunity Therapeutics, Inc.; George Weiss Funding Group; Alliance for Cancer Gene Therapy Investigator Award in Cell and Gene Therapy for Cancer; Prostate Cancer Foundation Young Investigator Award; ACC P30 Core Grant; ; 	We thank the patients and their families for participation in this clinical trial, which was sponsored by the University of Pennsylvania. We acknowledge the Human Immunology Core at the University of Pennsylvania for providing leukocytes; the Hospital of the University of Pennsylvania Apheresis Unit for PBMC collections; and the Data Safety Monitoring Board for data analysis. We also thank the contributors who supported development and execution of the clinical trial: the Clinical Cell and Vaccine Production Facility, the Translational and Correlative Studies Laboratory and the Product Development Lab from the University of Pennsylvania Center for Cellular Immunotherapies. We thank D. Maseda for the kind gift of Y664F NPMALK-transformed Tcells and lentiviral constructs encoding NPM-ALK fusion kinases. This work was supported by a Prostate Cancer Foundation Challenge Award (N.B.H. and C.H.J.), Tmunity Therapeutics, Inc., the George Weiss Funding Group, an Alliance for Cancer Gene Therapy Investigator Award in Cell and Gene Therapy for Cancer (J.A.F. and N.B.H.), a Prostate Cancer Foundation Young Investigator Award (V.N.), U54 CA244711-01 (C.H.J. and J.A.F.), R01 CA241762-03 (F.D.B. and J.A.F.) and ACC P30 Core Grant no. P30 CA016520-42 (S.F.L., W.-T.H., J.A.F. and N.H.).	Adusumilli PS, 2021, CANCER DISCOV, V11, P2748, DOI 10.1158/2159-8290.CD-21-0407; Adusumilli PS, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010162; Barbosa FD, 2020, CANCER IMAGING, V20, DOI 10.1186/s40644-020-00300-7; Basch E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju244; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bendle GM, 2013, J IMMUNOL, V191, P3232, DOI 10.4049/jimmunol.1301270; Berry C, 2006, PLOS COMPUT BIOL, V2, P1450, DOI 10.1371/journal.pcbi.0020157; Berry CC, 2014, BIOINFORMATICS, V30, P1493, DOI 10.1093/bioinformatics/btu035; Berry CC, 2012, BIOINFORMATICS, V28, P755, DOI 10.1093/bioinformatics/bts004; Bettencourt MC, 1998, J UROLOGY, V160, P459, DOI 10.1016/S0022-5347(01)62925-2; Bollard CM, 2018, J CLIN ONCOL, V36, P1128, DOI 10.1200/JCO.2017.74.3179; Brady T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr140; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Brown CE, 2018, MOL THER, V26, P31, DOI 10.1016/j.ymthe.2017.10.002; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brusa D, 2013, INT J UROL, V20, P971, DOI 10.1111/iju.12086; Chang SS, 1999, CANCER RES, V59, P3192; Curtsinger JM, 2003, J IMMUNOL, V171, P5165, DOI 10.4049/jimmunol.171.10.5165; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Foroozan M, 2017, PATHOL RES PRACT, V213, P612, DOI 10.1016/j.prp.2017.04.027; Foster AE, 2008, J IMMUNOTHER, V31, P500, DOI 10.1097/CJI.0b013e318177092b; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Fraietta JA, 2016, BLOOD, V127, P1117, DOI 10.1182/blood-2015-11-679134; Gattinoni L, 2012, NAT REV CANCER, V12, P671, DOI 10.1038/nrc3322; Gevaert T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32711-9; Geyer MB, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122627; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; He ZL, 2008, APPL ENVIRON MICROB, V74, P2957, DOI 10.1128/AEM.02536-07; Hirayama AV, 2019, BLOOD, V133, P1876, DOI 10.1182/blood-2018-11-887067; Hossain DMS, 2015, CLIN CANCER RES, V21, P3771, DOI 10.1158/1078-0432.CCR-14-3145; Ishigame H, 2013, J IMMUNOL, V190, P6340, DOI 10.4049/jimmunol.1300397; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kiuchi Z, 2019, FASEB J, V33, P7387, DOI 10.1096/fj.201800344RR; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Matthews E, 2000, BRIT J CANCER, V83, P519, DOI 10.1054/bjoc.2000.1257; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Medvec AR, 2018, MOL THER-METH CLIN D, V8, P65, DOI 10.1016/j.omtm.2017.11.001; Merritt CR, 2020, NAT BIOTECHNOL, V38, P586, DOI 10.1038/s41587-020-0472-9; Mhawech-Fauceglia P, 2007, HISTOPATHOLOGY, V50, P472, DOI 10.1111/j.1365-2559.2007.02635.x; Mulazzani M, 2019, P NATL ACAD SCI USA, V116, P24275, DOI 10.1073/pnas.1903854116; Nakamura R, 2015, CANCER SCI, V106, P656, DOI 10.1111/cas.12649; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Nobles CL, 2020, J CLIN INVEST, V130, P673, DOI 10.1172/JCI130144; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Pape KA, 1997, J IMMUNOL, V159, P591; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Pawlicki JM, 2021, CANCER RES, V81, P3241, DOI 10.1158/0008-5472.CAN-20-2297; Perner S, 2007, HUM PATHOL, V38, P696, DOI 10.1016/j.humpath.2006.11.012; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Priceman SJ, 2018, CLIN CANCER RES, V24, P95, DOI 10.1158/1078-0432.CCR-17-2041; Rubtsov YP, 2007, NAT REV IMMUNOL, V7, P443, DOI 10.1038/nri2095; Schalper KA, 2020, NAT MED, V26, P688, DOI 10.1038/s41591-020-0856-x; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scholler J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003761; SCHUSTER SJ, 2017, NEW ENGL J MED, V377, P2545, DOI [10.1056/NEJMoa1708566, DOI 10.1056/NEJMOA1708566]; Shah NN, 2019, BLOOD ADV, V3, P2317, DOI 10.1182/bloodadvances.2019000219; Silver DA, 1997, CLIN CANCER RES, V3, P81; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; Stuber T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000676; Sweat SD, 1998, UROLOGY, V52, P637, DOI 10.1016/S0090-4295(98)00278-7; Tang N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133977; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Theruvath J, 2020, NAT MED, V26, P712, DOI 10.1038/s41591-020-0821-8; TIMME TL, 1994, ENDOCRINOLOGY, V134, P1039, DOI 10.1210/en.134.3.1039; Trojan L, 2004, ANTICANCER RES, V24, P1651; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Venkatachalam S, 2021, CANCERS, V13, DOI 10.3390/cancers13092187; Vitanza NA, 2021, NAT MED, V27, P1544, DOI 10.1038/s41591-021-01404-8; Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078; Westdorp H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00191; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Wikstrom P, 2001, MICROSC RES TECHNIQ, V52, P411, DOI 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8; Wolf P, 2010, J IMMUNOTHER, V33, P262, DOI 10.1097/CJI.0b013e3181c5495c; Wright GL, 1996, UROLOGY, V48, P326, DOI 10.1016/S0090-4295(96)00184-7; Yuen KC, 2020, NAT MED, V26, P693, DOI 10.1038/s41591-020-0860-1; Zhang L, 2013, GENE THER, V20, P575, DOI 10.1038/gt.2012.75	82	25	25	17	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4								10.1038/s41591-022-01726-1	http://dx.doi.org/10.1038/s41591-022-01726-1		MAR 2022	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0P3TN	35314843				2022-12-27	WOS:000771548300005
J	Tschernia, NP; Norberg, SM; Gulley, JL				Tschernia, Nicholas P.; Norberg, Scott M.; Gulley, James L.			CAR T cells reach clinical milestone in prostate cancer	NATURE MEDICINE			English	Editorial Material									[Tschernia, Nicholas P.; Norberg, Scott M.; Gulley, James L.] NCI, Genitourinary Malignancies Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gulley, JL (corresponding author), NCI, Genitourinary Malignancies Branch, Bethesda, MD 20892 USA.	gulleyj@mail.nih.gov	Gulley, James/K-4139-2016	Gulley, James/0000-0002-6569-2912				Biasco L, 2021, NAT CANCER, V2, DOI 10.1038/s43018-021-00207-7; Dorff TB, 2022, CLIN CANCER RES, V28, P576, DOI 10.1158/1078-0432.CCR-21-1483; Fabrizio VA, 2022, BLOOD ADV, V6, P1961, DOI 10.1182/bloodadvances.2021006418; Fan AC, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9233; Narayan V, 2022, NAT MED, V28, DOI 10.1038/s41591-022-01726-1; Neelapu SS, 2019, BLOOD, V133, P1799, DOI 10.1182/blood-2019-03-900928; Netto G. J., 2011, DIAGNOSTIC IMMUNOHIS, P593; Rafiq S, 2020, NAT REV CLIN ONCOL, V17, P147, DOI 10.1038/s41571-019-0297-y; Rosa, 2021, ONCLIVE; Stultz J, 2021, PROSTATE CANCER P D, V24, P697, DOI 10.1038/s41391-021-00340-5	10	0	0	4	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					635	636		10.1038/s41591-022-01742-1	http://dx.doi.org/10.1038/s41591-022-01742-1		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35314844				2022-12-27	WOS:000771548300002
J	Trudel, G; Shahin, N; Ramsay, T; Laneuville, O; Louati, H				Trudel, Guy; Shahin, Nibras; Ramsay, Timothy; Laneuville, Odette; Louati, Hakim			Hemolysis contributes to anemia during long-duration space flight	NATURE MEDICINE			English	Article							SPACEFLIGHT; IMMOBILIZATION; MICROGRAVITY; MYOGLOBIN; INCREASE; MASS	Anemia in astronauts has been noted since the first space missions, but the mechanisms contributing to anemia in space flight have remained unclear. Here, we show that space flight is associated with persistently increased levels of products of hemoglobin degradation, carbon monoxide in alveolar air and iron in serum, in 14 astronauts throughout their 6-month missions onboard the International Space Station. One year after landing, erythrocytic effects persisted, including increased levels of hemolysis, reticulocytosis and hemoglobin. These findings suggest that the destruction of red blood cells, termed hemolysis, is a primary effect of microgravity in space flight and support the hypothesis that the anemia associated with space flight is a hemolytic condition that should be considered in the screening and monitoring of both astronauts and space tourists. Biomarkers of red blood cell destruction were elevated in astronauts while on long-duration missions on the International Space Station, suggesting that hemolysis is a major contributor to space anemia.	[Trudel, Guy; Shahin, Nibras; Louati, Hakim] Ottawa Hosp Res Inst, Bone & Joint Res Lab, Ottawa, ON, Canada; [Trudel, Guy] Univ Ottawa, Div Phys Med & Rehabil, Dept Med, Ottawa, ON, Canada; [Trudel, Guy] Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON, Canada; [Ramsay, Timothy] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Laneuville, Odette] Univ Ottawa, Fac Sci, Dept Biol, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Trudel, G (corresponding author), Ottawa Hosp Res Inst, Bone & Joint Res Lab, Ottawa, ON, Canada.; Trudel, G (corresponding author), Univ Ottawa, Div Phys Med & Rehabil, Dept Med, Ottawa, ON, Canada.; Trudel, G (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON, Canada.	gtrudel@toh.ca		Shahin, Nibras/0000-0003-1099-147X; Ramsay, Tim/0000-0001-8478-8170; , Odette Laneuville/0000-0003-3124-3892	Canadian Space Agency [9F053-120589, 9F008-140254]	Canadian Space Agency(Canadian Space Agency)	We thank all 14 participants, who generously consented to the collection of these specimens in addition to their other mission duties, as well as the NASA Increment Science Coordinators at JSC and Reta Warren at the JSC Clinical Laboratory for the care of the blood samples. Special thanks to Steven Beck of the JSC Toxicology and Environmental Chemistry laboratory and his team for conditioning the canisters used for this study and to Doug Worthy and Michele Rauh of the Green House Gases Program at Environment Canada for their assistance with the gas chromatograph methods and dilution testing of the CO controls used in this study; Sandy Bookalam and her team at the Eastern Ontario Regional Laboratory Association and Cathy Andrusiak at In-Common Laboratories for blood analyses; Theresa Backlund, the study coordinator for MARROW; Nicole Buckley, Didier Yovo, Denis Charlebois, Stanislav Chrastina, Bruce Nicayenzi and Valerie Gill from Space Exploration at the Canadian Space Agency; Carolynn Cook for preparing the graphs; Martin Richard for video production; and Hans Uhthoff for his critical review of the manuscript. This work was funded by Canadian Space Agency Contracts 9F053-120589 to G.T. and 9F008-140254 to G.T., O.L. and H.L. The funder was not involved in the analysis, decision to publish or preparation of the manuscript.	Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Adler BJ, 2014, NAT REV ENDOCRINOL, V10, P737, DOI 10.1038/nrendo.2014.169; Afshinnekoo E, 2020, CELL, V183, P1162, DOI 10.1016/j.cell.2020.10.050; Alfrey CP, 1997, LANCET, V349, P1389, DOI 10.1016/S0140-6736(96)09208-2; Barcellini W, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/635670; Beheshti A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55869-2; Borg J, 2011, HAEMATOL-HEMATOL J, V96, P635, DOI 10.3324/haematol.2011.043265; Borg J, 2010, NAT GENET, V42, P801, DOI 10.1038/ng.630; Culliton K, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526-021-00132-0; da Silveira WA, 2020, CELL, V183, P1185, DOI 10.1016/j.cell.2020.11.002; FISCHER CL, 1967, J AMER MED ASSOC, V200, P579, DOI 10.1001/jama.200.7.579; Ganz T, 2019, NEW ENGL J MED, V381, P1148, DOI 10.1056/NEJMra1804281; Garrett-Bakelman FE, 2019, SCIENCE, V364, P144, DOI 10.1126/science.aau8650; Giardine B, 2014, NUCLEIC ACIDS RES, V42, pD1063, DOI 10.1093/nar/gkt911; Gore CJ, 2013, BRIT J SPORT MED, V47, P31, DOI 10.1136/bjsports-2013-092840; Gunga HC, 1996, J APPL PHYSIOL, V81, P761; Gunga HC, 1999, LANCET, V353, P470, DOI 10.1016/S0140-6736(98)05323-9; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; JANSSON E, 1988, ACTA PHYSIOL SCAND, V132, P515, DOI 10.1111/j.1748-1716.1988.tb08358.x; Klein M, 2021, ACTA PHYSIOL, V232, DOI 10.1111/apha.13647; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kunz H., 2017, BMC HEMATOL, V17, P12, DOI [10.1186/s12878-017-0083-y, DOI 10.1186/S12878-017-0083-Y]; LEACH CS, 1984, SCIENCE, V225, P216, DOI 10.1126/science.6729477; Lee JU, 2013, J PHYS THER SCI, V25, P1617, DOI 10.1589/jpts.25.1617; Mitlyng BL, 2006, AM J HEMATOL, V81, P432, DOI 10.1002/ajh.20644; Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228; OPPENHEIM A, 1985, BLOOD, V66, P1202; Panda S, 2016, SCIENCE, V354, P1008, DOI 10.1126/science.aah4967; Shahin N, 2020, ANN BIOMED ENG, V48, P1540, DOI 10.1007/s10439-020-02473-5; Shelhamer M, 2020, NPJ MICROGRAVITY, V6, DOI 10.1038/s41526-020-0095-y; Stepanek J, 2019, NEW ENGL J MED, V380, P1053, DOI 10.1056/NEJMra1609012; Trudel G, 2020, AM J HEMATOL, V95, P267, DOI 10.1002/ajh.25699; Velten L, 2017, NAT CELL BIOL, V19, P271, DOI 10.1038/ncb3493; WHO, 2011, WHO TECH REP SER, V959, P1	34	7	7	6	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					59	+		10.1038/s41591-021-01637-7	http://dx.doi.org/10.1038/s41591-021-01637-7		JAN 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35031790	Green Published, hybrid			2022-12-27	WOS:000742617400001
J	Ward, JL; Harwood, R; Smith, C; Kenny, S; Clark, M; Davis, P; Draper, E; Hargreaves, D; Ladhani, S; Linney, M; Luyt, K; Turner, S; Whittaker, E; Fraser, LK; Viner, RM				Ward, J. L.; Harwood, R.; Smith, C.; Kenny, S.; Clark, M.; Davis, Pj; Draper, Es; Hargreaves, D.; Ladhani, S.; Linney, M.; Luyt, K.; Turner, S.; Whittaker, E.; Fraser, L. K.; Viner, R. M.			Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year	NATURE MEDICINE			English	Article								The risk of intensive care unit admission among children with COVID-19 or its sequelae is affected by age, ethnicity and comorbidities. Understanding these modifiers might help identify at-risk children and guide interventions. Identifying which children and young people (CYP) are most vulnerable to serious infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important to guide protective interventions. To address this question, we used data for all hospitalizations in England among 0-17 year olds from 1 February 2019 to 31 January 2021. We examined how sociodemographic factors and comorbidities might be risk factors for pediatric intensive care unit (PICU) admission among hospitalizations due to the following causes: Coronavirus Disease 2019 (COVID-19) and pediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the first pandemic year (2020-2021); hospitalizations due to all other non-traumatic causes in 2020-2021; hospitalizations due to all non-traumatic causes in 2019-2020; and hospitalizations due to influenza in 2019-2020. Risk of PICU admission and death from COVID-19 or PIMS-TS in CYP was very low. We identified 6,338 hospitalizations with COVID-19, of which 259 were admitted to a PICU and eight CYP died. We identified 712 hospitalizations with PIMS-TS, of which 312 were admitted to a PICU and fewer than five CYP died. Hospitalizations with COVID-19 and PIMS-TS were more common among males, older CYP, those from socioeconomically deprived neighborhoods and those who were of non-White ethnicity (Black, Asian, Mixed or Other). The odds of PICU admission were increased in CYP younger than 1 month old and decreased among 15-17 year olds compared to 1-4 year olds with COVID-19; increased in older CYP and females with PIMS-TS; and increased for Black compared to White ethnicity in patients with COVID-19 and PIMS-TS. Odds of PICU admission in COVID-19 were increased for CYP with comorbidities and highest for CYP with multiple medical problems. Increases in odds of PICU admission associated with different comorbidities in COVID-19 showed a similar pattern to other causes of hospitalization examined and, thus, likely reflect background vulnerabilities. These findings identify distinct risk factors associated with PICU admission among CYP with COVID-19 or PIMS-TS that might aid treatment and prevention strategies.	[Ward, J. L.; Viner, R. M.] UCL Great Ormond St Inst Child Hlth, London, England; [Harwood, R.; Kenny, S.] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England; [Harwood, R.; Kenny, S.] Alder Hey Childrens NHS Fdn Trust, Dept Paediat Surg, Liverpool, Merseyside, England; [Smith, C.; Kenny, S.; Clark, M.; Davis, Pj] NHS England & Improvement, Leeds, W Yorkshire, England; [Davis, Pj] Bristol Royal Hosp Children, Paediat Intens Care Unit, Bristol, Avon, England; [Draper, Es] Univ Leicester, Dept Hlth Sci, PICANet, Leicester, Leics, England; [Hargreaves, D.] Imperial Coll London, Mohn Ctr Childrens Hlth & Wellbeing, London, England; [Ladhani, S.] Publ Hlth England, Immunisat & Countermeasures, London, England; [Linney, M.] Univ Hosp Sussex NHS Fdn Trust, Brighton, E Sussex, England; [Luyt, K.] Univ Bristol, Bristol Med Sch, Natl Child Mortal Database, Bristol, Avon, England; [Turner, S.] NHS Grampian, Aberdeen, Scotland; [Turner, S.] Univ Aberdeen, Aberdeen, Scotland; [Whittaker, E.] Imperial Coll Healthcare NHS Trust, Paediat Infect Dis, London, England; [Whittaker, E.] Imperial Coll London, Sect Paediat Infect Dis, London, England; [Fraser, L. K.] Univ York, Martin House Res Ctr, Dept Hlth Sci, York, N Yorkshire, England	University of London; University College London; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Bristol Royal Hospital For Children; University of Leicester; Imperial College London; Public Health England; University of Bristol; University of Aberdeen; Imperial College London; Imperial College London; University of York - UK	Ward, JL (corresponding author), UCL Great Ormond St Inst Child Hlth, London, England.	joseph.ward@ucl.ac.uk	Luyt, Karen/ABE-4921-2021; Viner, Russell/A-1441-2009	Luyt, Karen/0000-0002-9806-1092; Whittaker, Elizabeth/0000-0002-7944-8793; Clark, Matthew/0000-0002-3570-5241; Davis, Peter/0000-0003-0669-2485; Hargreaves, Dougal/0000-0003-0722-9847; Viner, Russell/0000-0003-3047-2247; Kenny, Simon/0000-0002-5917-8554; Harwood, Rachel/0000-0003-3440-3142	Medical Research Council fellowship [MR/R00160X/1]; Kidney Research UK [TF_010_20171124]; Martin House Children's Hospice; National Institute of Health Research [NIHR202322]; National Institute for Health Research through the National School for Public Health Research Programme; Applied Health Research Programme for North West London	Medical Research Council fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Kidney Research UK(Kidney Research UK (KRUK)); Martin House Children's Hospice; National Institute of Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research through the National School for Public Health Research Programme; Applied Health Research Programme for North West London	We would like to thank the National Child Mortality Database; the Paediatric Intensive Care Audit Network; Public Health England; NHS Digital; NHS England; and the NHS Improvement Children and Young People Team, particularly R. Owen, S. Solti, T. Watson-Koszel, M. Ambia, C. Styles and A. Wojciechowska, for their support in identifying, linking and making the data used in this study available for analysis. J.L.W. is in receipt of a Medical Research Council fellowship (grant no. MR/R00160X/1). R.H. is in receipt of a fellowship from Kidney Research UK (grant no. TF_010_20171124). L.K.F. is in receipt of funding from Martin House Children's Hospice (there is no specific grant number for this). R.M.V. is in receipt of a grant from the National Institute of Health Research to support this work (grant no. NIHR202322). D.H. is supported by the National Institute for Health Research through the National School for Public Health Research Programme and the Applied Health Research Programme for North West London. Funders had no role in study design, data collection, analysis, decision to publish or preparation of the manuscript.	Ahmed M, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100527; Lopes ADA, 2021, TROP MED INT HEALTH, V26, P115, DOI 10.1111/tmi.13529; Belay ED, 2021, JAMA PEDIATR, V175, P837, DOI 10.1001/jamapediatrics.2021.0630; Bhaskaran K, 2021, LANCET REG HEALTH-EU, V6, DOI 10.1016/j.lanepe.2021.100109; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Boyd A., 2017, UNDERSTANDING HOSP E; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Davies P, 2020, LANCET CHILD ADOLESC, V4, P669, DOI 10.1016/S2352-4642(20)30215-7; Docherty A.B., 2020, MEDRXIV, DOI [10.1136/bmj.m1985, 10.1101/2020.04.23.20076042v1, DOI 10.1101/2020.04.23.20076042]; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Flood J, 2021, LANCET REG HEALTH-EU, V3, DOI 10.1016/j.lanepe.2021.100075; Fraser LK, 2012, PEDIATRICS, V129, pE923, DOI 10.1542/peds.2011-2846; Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2; Hardelid P, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005331; Harwood R, 2021, PREPRINT, DOI [10.1101/2021.06.30.21259763v1, DOI 10.1101/2021.06.30.21259763V1]; Kanthimathinathan HK, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03779-z; Kompaniyets L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11182; Mathur R, 2021, LANCET, V397, P1711, DOI 10.1016/S0140-6736(21)00634-6; McCormick DW, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052273; NHS Digital, 2021, CONTR PAT INF COPI N; Royal College of Paediatrics and Child Health, 2021, COVID 19 GUID CLIN E; Smith C, 2022, NAT MED, V28, P185, DOI 10.1038/s41591-021-01578-1; Song XY, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.20495; Swann OV, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3249; The Nation, 2021, COVID 19 SCH EARLY C; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yates T, 2021, OBESITY, V29, P1223, DOI 10.1002/oby.23178	28	26	26	6	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					193	+		10.1038/s41591-021-01627-9	http://dx.doi.org/10.1038/s41591-021-01627-9		DEC 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34931076	Green Submitted, Green Published, Bronze			2022-12-27	WOS:000733433100001
J	Provenza, NR; Sheth, SA; Dastin-van Rijn, EM; Mathura, RK; Ding, YH; Vogt, GS; Avendano-Ortega, M; Ramakrishnan, N; Peled, N; Gelin, LFF; Xing, D; Jeni, LA; Ertugrul, IO; Barrios-Anderson, A; Matteson, E; Wiese, AD; Xu, JQ; Viswanathan, A; Harrison, MT; Bijanki, KR; Storch, EA; Cohn, JF; Goodman, WK; Borton, DA				Provenza, Nicole R.; Sheth, Sameer A.; Dastin-van Rijn, Evan M.; Mathura, Raissa K.; Ding, Yaohan; Vogt, Gregory S.; Avendano-Ortega, Michelle; Ramakrishnan, Nithya; Peled, Noam; Gelin, Luiz Fernando Fracassi; Xing, David; Jeni, Laszlo A.; Ertugrul, Itir Onal; Barrios-Anderson, Adriel; Matteson, Evan; Wiese, Andrew D.; Xu, Junqian; Viswanathan, Ashwin; Harrison, Matthew T.; Bijanki, Kelly R.; Storch, Eric A.; Cohn, Jeffrey F.; Goodman, Wayne K.; Borton, David A.			Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder	NATURE MEDICINE			English	Article							DEEP BRAIN-STIMULATION; MULTISOURCE INTERFERENCE TASK; LOCAL-FIELD POTENTIALS; DBS; NUCLEUS; INFANT; OPTIMIZATION; REGISTRATION; EXPRESSION; SEVERITY	Detection of neural signatures related to pathological behavioral states could enable adaptive deep brain stimulation (DBS), a potential strategy for improving efficacy of DBS for neurological and psychiatric disorders. This approach requires identifying neural biomarkers of relevant behavioral states, a task best performed in ecologically valid environments. Here, in human participants with obsessive-compulsive disorder (OCD) implanted with recording-capable DBS devices, we synchronized chronic ventral striatum local field potentials with relevant, disease-specific behaviors. We captured over 1,000 h of local field potentials in the clinic and at home during unstructured activity, as well as during DBS and exposure therapy. The wide range of symptom severity over which the data were captured allowed us to identify candidate neural biomarkers of OCD symptom intensity. This work demonstrates the feasibility and utility of capturing chronic intracranial electrophysiology during daily symptom fluctuations to enable neural biomarker identification, a prerequisite for future development of adaptive DBS for OCD and other psychiatric disorders. The identification of candidate neural biomarkers of obsessive-compulsive disorder symptom intensity in ecologically valid environments.	[Provenza, Nicole R.; Dastin-van Rijn, Evan M.; Xing, David; Matteson, Evan; Borton, David A.] Brown Univ, Sch Engn, Providence, RI 02912 USA; [Provenza, Nicole R.] Charles Stark Draper Lab, Cambridge, MA USA; [Sheth, Sameer A.; Mathura, Raissa K.; Viswanathan, Ashwin; Bijanki, Kelly R.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Ding, Yaohan] Univ Pittsburgh, Intelligent Syst Program, Pittsburgh, PA USA; [Vogt, Gregory S.; Avendano-Ortega, Michelle; Ramakrishnan, Nithya; Wiese, Andrew D.; Xu, Junqian; Bijanki, Kelly R.; Storch, Eric A.; Goodman, Wayne K.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Peled, Noam] MGH HST Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Peled, Noam] Harvard Med Sch, Cambridge, MA USA; [Gelin, Luiz Fernando Fracassi] Brown Univ, Ctr Computat & Visualizat, Providence, RI 02912 USA; [Jeni, Laszlo A.] Carnegie Mellon Univ, Robot Inst, Pittsburgh, PA 15213 USA; [Ertugrul, Itir Onal] Tilburg Univ, Dept Cognit Sci & Artificial Intelligence, Tilburg, Netherlands; [Barrios-Anderson, Adriel] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Wiese, Andrew D.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Xu, Junqian] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Harrison, Matthew T.] Brown Univ, Div Appl Math, Providence, RI 02912 USA; [Cohn, Jeffrey F.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Borton, David A.] Brown Univ, Carney Inst Brain Sci, Providence, RI 02912 USA; [Borton, David A.] Dept Vet Affairs, Rehabil R&D Serv, Ctr Neurorestorat & Neurotechnol, Providence, RI 02908 USA	Brown University; The Charles Stark Draper Laboratory, Inc.; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Brown University; Carnegie Mellon University; Tilburg University; Brown University; University of Missouri System; University of Missouri Kansas City; Baylor College of Medicine; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Brown University	Borton, DA (corresponding author), Brown Univ, Sch Engn, Providence, RI 02912 USA.; Borton, DA (corresponding author), Brown Univ, Carney Inst Brain Sci, Providence, RI 02912 USA.; Borton, DA (corresponding author), Dept Vet Affairs, Rehabil R&D Serv, Ctr Neurorestorat & Neurotechnol, Providence, RI 02908 USA.	david_borton@brown.edu	Xu, Junqian/D-2247-2009	Xu, Junqian/0000-0001-8438-2066; Dastin-van Rijn, Evan/0000-0002-1428-0723; Vogt, Gregory/0000-0001-8259-5885; Peled, Nir/0000-0003-3714-4377	National Institutes of Health (NIH) NINDS BRAIN Initiative [UH3NS100549, UH3NS103549]; Charles Stark Draper Laboratory Fellowship; McNair Foundation; Texas Higher Education Coordinating Board [NIH 1RF1MH121371, U54HD083092]; Karen T. Romer Undergraduate Teaching and Research Award at Brown University; NIH [MH096951, K01MH116364, R21NS104953, 3R25MH10107605S2, 1S10OD025181]	National Institutes of Health (NIH) NINDS BRAIN Initiative; Charles Stark Draper Laboratory Fellowship; McNair Foundation; Texas Higher Education Coordinating Board; Karen T. Romer Undergraduate Teaching and Research Award at Brown University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank the participants and their families for their involvement in the research program. The authors also thank K. Lane for artistic contribution in the creation of Fig. 1. This work relied heavily on the community expertise and resources made available by the Open Mind Consortium (https://openmind-consortium.github.io/).Summit RC + S devices were donated by Medtronic as part of the BRAIN Initiative Public-Private Partnership Program. We thank J. Murphy for expertise and contributions in designing and machining equipment used in this study. Part of this research was conducted with the help of research staff at the Center for Computation and Visualization, Brown University (senior research software engineers B. Roarr and M. McGrath). The research was supported by the National Institutes of Health (NIH) NINDS BRAIN Initiative via contracts UH3NS100549 (to S.A.S., J.F.C., D.A.B., E.A.S. and W.K.G.) and UH3NS103549 (to S.A.S.), the Charles Stark Draper Laboratory Fellowship (to N.R.P.), the McNair Foundation (to S.A.S.), the Texas Higher Education Coordinating Board NIH 1RF1MH121371 and U54HD083092 (to E.A.S.), NIH MH096951 (to J.F.C.), K01MH116364 and R21NS104953 (to K.B.), 3R25MH10107605S2 (to A.B.-A.), award 1S10OD025181 (to J. Sanes at Brown University for computational resources) and the Karen T. Romer Undergraduate Teaching and Research Award at Brown University (E.M.D.-v.R. under the guidance of D.A.B.).	Alonso P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133591; Angst J, 2004, EUR ARCH PSY CLIN N, V254, P156, DOI 10.1007/s00406-004-0459-4; Baker JK, 2010, INT J BEHAV DEV, V34, P88, DOI 10.1177/0165025409350365; Basu I, CLOSED LOOP ENHANCEM, DOI [10.1101/2020.04.24.059964(2020, DOI 10.1101/2020.04.24.059964(2020]; Bergey GK, 2015, NEUROLOGY, V84, P810, DOI 10.1212/WNL.0000000000001280; Bijanki KR, 2019, J CLIN INVEST, V129, P1152, DOI 10.1172/JCI120110; Bouthour W, 2019, NAT REV NEUROL, V15, P343, DOI 10.1038/s41582-019-0166-4; Bush G, 2003, MOL PSYCHIATR, V8, P60, DOI 10.1038/sj.mp.4001217; Bush G, 2006, NAT PROTOC, V1, P308, DOI 10.1038/nprot.2006.48; Cohn J. F, 2016, P IEEE C COMP VIS PA, P87; Cohn JF, 2018, ICMI'18: PROCEEDINGS OF THE 20TH ACM INTERNATIONAL CONFERENCE ON MULTIMODAL INTERACTION, P40, DOI 10.1145/3242969.3243023; Cowen AS, 2021, NATURE, V589, P251, DOI 10.1038/s41586-020-3037-7; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126; Denys D, 2020, AM J PSYCHIAT, V177, P265, DOI 10.1176/appi.ajp.2019.19060656; Dibeklioglu H, 2018, IEEE J BIOMED HEALTH, V22, P525, DOI 10.1109/JBHI.2017.2676878; Ding YH, 2020, COMPANION PUBLICATON OF THE 2020 INTERNATIONAL CONFERENCE ON MULTIMODAL INTERACTION (ICMI '20 COMPANION), P354, DOI 10.1145/3395035.3425354; Eijsker N, 2020, ENEURO, V7, DOI 10.1523/ENEUR0.0105-20.2020; Ekman P., 2002, MANUAL INVESTIGATORS; Ekman P., 2005, WHAT FACE REVEALS BA, DOI DOI 10.1093/ACPROF:OSO/9780195179644.001.0001; Ertugrul Itir Onal, 2019, Proc Int Conf Autom Face Gesture Recognit, V2019, DOI 10.1109/FG.2019.8756623; Felsenstein O., 2019, MULTIMODAL NEUROIMAG; Figee M, 2021, NAT MED, V27, P196, DOI 10.1038/s41591-021-01243-7; Figee M, 2013, NAT NEUROSCI, V16, P386, DOI 10.1038/nn.3344; Figee M, 2011, BIOL PSYCHIAT, V69, P867, DOI 10.1016/j.biopsych.2010.12.003; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Frank AC, 2021, BRAIN STIMUL, V14, P1002, DOI 10.1016/j.brs.2021.06.009; Fullana MA, 2020, NEUROSCI BIOBEHAV R, V118, P504, DOI 10.1016/j.neubiorev.2020.08.008; Gibson WS, 2017, CEREB CORTEX, V27, P2183, DOI 10.1093/cercor/bhw074; Gillan CM, 2016, ELIFE, V5, DOI 10.7554/eLife.11305; Gilron R, 2021, NAT BIOTECHNOL, V39, P1078, DOI 10.1038/s41587-021-00897-5; Goodman WK, 2021, AM J PSYCHIAT, V178, P17, DOI 10.1176/appi.ajp.2020.20111601; Goodman WK, 2010, BIOL PSYCHIAT, V67, P535, DOI 10.1016/j.biopsych.2009.11.028; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Graat I, 2017, INT REV PSYCHIATR, V29, P178, DOI 10.1080/09540261.2017.1282439; Grover S, 2021, NAT MED, V27, P232, DOI 10.1038/s41591-020-01173-w; Haber SN, 2021, BIOL PSYCHIAT, V90, P667, DOI 10.1016/j.biopsych.2020.06.031; Haeffel GJ, 2010, AM J PSYCHOL, V123, P181, DOI 10.5406/amerjpsyc.123.2.0181; Haines N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211735; Hammal Z., 2015, FRONT ICT, V2, P21, DOI [10.3389/fict.2015.00021, DOI 10.3389/FICT.2015.00021]; Hammal Z, 2019, PRS-GLOB OPEN, V7, DOI 10.1097/GOX.0000000000002081; Hammal Z, 2015, IEEE T AFFECT COMPUT, V6, P361, DOI 10.1109/TAFFC.2015.2422702; Hammal Z, 2014, IEEE T AFFECT COMPUT, V5, P155, DOI 10.1109/TAFFC.2014.2326408; Jeni LA, 2017, IMAGE VISION COMPUT, V58, P13, DOI 10.1016/j.imavis.2016.05.009; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Joshi A, 2011, NEUROINFORMATICS, V9, P69, DOI 10.1007/s12021-010-9092-8; Kacem A, 2018, IEEE INT CONF AUTOMA, P739, DOI 10.1109/FG.2018.00116; Kremen V, 2018, IEEE J TRANSL ENG HE, V6, DOI 10.1109/JTEHM.2018.2869398; Le Yang, 2019, 2019 8th International Conference on Affective Computing and Intelligent Interaction (ACII). Proceedings, P538, DOI 10.1109/ACII.2019.8925514; Lega BC, 2011, NEUROREPORT, V22, P795, DOI 10.1097/WNR.0b013e32834b2975; Li NF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16734-3; Liebrand LC, 2019, BRAIN STIMUL, V12, P353, DOI 10.1016/j.brs.2018.11.014; Little S, 2016, J NEUROL NEUROSUR PS, V87, P717, DOI 10.1136/jnnp-2015-310972; Mataix-Cols D, 2002, AM J PSYCHIAT, V159, P263, DOI 10.1176/appi.ajp.159.2.263; Mercier MR, 2017, NEUROIMAGE, V147, P219, DOI 10.1016/j.neuroimage.2016.08.037; Messinger DS, 2009, INFANCY, V14, P285, DOI 10.1080/15250000902839963; Miller KJ, 2019, J NEUROPHYSIOL, V121, P2336, DOI 10.1152/jn.00096.2019; Neumann WJ, 2014, MOL PSYCHIATR, V19, P1186, DOI 10.1038/mp.2014.2; Niinuma Koichiro, 2019, BMVC, V2019; Nota JA, 2014, J COGN PSYCHOTHER, V28, P134, DOI 10.1891/0889-8391.28.2.134; Okun MS, 2010, EXPERT REV NEUROTHER, V10, P1847, DOI 10.1586/ERN.10.156; Olsen ST, 2020, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.569973; Ertugrul IO, 2019, FRONT COMP SCI-SWITZ, V1, DOI 10.3389/fcomp.2019.00011; Ooms P, 2014, J NEUROL NEUROSUR PS, V85, P153, DOI 10.1136/jnnp-2012-302550; Opri E, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay7680; Pallanti S, 2004, J CLIN PSYCHIAT, V65, P6; Peled N., 2017, GITHUB REPOSITORY; Powers R, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd7865; Prkachin KM, 2008, PAIN, V139, P267, DOI 10.1016/j.pain.2008.04.010; Provenza NR, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/ab2c58; Provenza NR, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00152; Provenza Nicole R, BRAZ J PSYCHIAT, DOI [10.1590/1516-4446-2020-1675(2021, DOI 10.1590/1516-4446-2020-1675(2021]; Scangos KW, 2021, NAT MED, V27, P229, DOI 10.1038/s41591-020-01175-8; Schwabe K, 2021, J NEURAL TRANSM, V128, P215, DOI 10.1007/s00702-020-02297-6; Sellers KK, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.714256; Sildatke E, 2021, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.627564; Smith EH, 2019, NAT NEUROSCI, V22, P1883, DOI 10.1038/s41593-019-0494-0; Smith EE, 2020, NEUROIMAGE, V220, DOI 10.1016/j.neuroimage.2020.117138; Stanslaski S, 2018, IEEE T BIOMED CIRC S, V12, P1230, DOI 10.1109/TBCAS.2018.2880148; Stenner MP, 2015, J NEUROPHYSIOL, V114, P29, DOI 10.1152/jn.00988.2014; Storch EA, 2015, COMPR PSYCHIAT, V63, P30, DOI 10.1016/j.comppsych.2015.08.007; Storch EA, 2010, J ANXIETY DISORD, V24, P650, DOI 10.1016/j.janxdis.2010.04.010; Sun FT, 2014, EXPERT REV MED DEVIC, V11, P563, DOI 10.1586/17434440.2014.947274; Swann NC, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aabc9b; Topalovic U, 2020, NEURON, V108, P322, DOI 10.1016/j.neuron.2020.08.021; Tyagi H, 2019, BIOL PSYCHIAT, V85, P726, DOI 10.1016/j.biopsych.2019.01.017; Ung HM, 2017, J NEURAL ENG, V14, DOI 10.1088/1741-2552/aa7f40; Voon V, 2017, BRAIN, V140, P442, DOI 10.1093/brain/aww309; Widge AS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09557-4; Widge AS, 2017, EXP NEUROL, V287, P461, DOI 10.1016/j.expneurol.2016.07.021; Wingeier B, 2006, EXP NEUROL, V197, P244, DOI 10.1016/j.expneurol.2005.09.016; Wu H, 2018, P NATL ACAD SCI USA, V115, P192, DOI 10.1073/pnas.1712214114; Zhang Z, 2016, PROC CVPR IEEE, P3438, DOI 10.1109/CVPR.2016.374	93	7	7	4	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2154	+		10.1038/s41591-021-01550-z	http://dx.doi.org/10.1038/s41591-021-01550-z		DEC 2021	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887577	Green Accepted			2022-12-27	WOS:000728466100005
J	Smith, C; Odd, D; Harwood, R; Ward, J; Linney, M; Clark, M; Hargreaves, D; Ladhani, SN; Draper, E; Davis, PJ; Kenny, SE; Whittaker, E; Luyt, K; Viner, R; Fraser, LK				Smith, Clare; Odd, David; Harwood, Rachel; Ward, Joseph; Linney, Mike; Clark, Matthew; Hargreaves, Dougal; Ladhani, Shamez N.; Draper, Elizabeth; Davis, Peter J.; Kenny, Simon E.; Whittaker, Elizabeth; Luyt, Karen; Viner, Russell; Fraser, Lorna K.			Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year	NATURE MEDICINE			English	Article							EPIDEMIOLOGY	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is rarely fatal in children and young people (CYP, <18 years old), but quantifying the risk of death is challenging because CYP are often infected with SARS-CoV-2 exhibiting no or minimal symptoms. To distinguish between CYP who died as a result of SARS-CoV-2 infection and those who died of another cause but were coincidentally infected with the virus, we undertook a clinical review of all CYP deaths with a positive SARS-CoV-2 test from March 2020 to February 2021. The predominant SARS-CoV-2 variants were wild-type and Alpha. Here we show that, of 12,023,568 CYP living in England, 3,105 died, including 61 who were positive for SARS-CoV-2. Of these deaths, 25 were due to SARS-CoV-2 infection (mortality rate, two per million), including 22 due to coronavirus disease 2019-the clinical disease associated with SARS-CoV-2 infection-and 3 were due to pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. In total, 99.995% of CYP with a positive SARS-CoV-2 test survived. CYP older than 10 years, Asian and Black ethnic backgrounds and comorbidities were over-represented in SARS-CoV-2-related deaths compared with other CYP deaths. These results are important for guiding decisions on shielding and vaccinating children. New variants might have different mortality risks and should be evaluated in a similar way. A clinical review of all pediatric deaths in England from March 2020 to February 2021 attributes 25 deaths to SARS-CoV-2 infection and identifies risk factors to guide interventions.	[Smith, Clare; Clark, Matthew; Davis, Peter J.; Kenny, Simon E.] NHS England, London, England; [Smith, Clare; Clark, Matthew; Davis, Peter J.; Kenny, Simon E.] NHS Improvement, London, England; [Smith, Clare; Davis, Peter J.] Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol Royal Hosp Children, Paediat Intens Care Unit, Bristol, Avon, England; [Odd, David] Cardiff Univ, Div Populat Med, Cardiff, Wales; [Odd, David; Luyt, Karen] Univ Bristol, Natl Child Mortal Database, Bristol, Avon, England; [Harwood, Rachel; Kenny, Simon E.] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England; [Harwood, Rachel; Kenny, Simon E.] Dept Paediat Surg, Alder Hey Pk, Liverpool, Merseyside, England; [Ward, Joseph; Viner, Russell] UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice Dept, London, England; [Linney, Mike] Royal Coll Paediat & Child Hlth, London, England; [Linney, Mike] Univ Hosp Sussex NHS Fdn Trust, Dept Paediat, Brighton, E Sussex, England; [Hargreaves, Dougal] Imperial Coll London, Sch Publ Hlth, London, England; [Ladhani, Shamez N.] Publ Hlth England, Immunisat & Countermeasures, London, England; [Ladhani, Shamez N.] St Georges Univ London, Paediat Infect Dis Res Grp, London, England; [Draper, Elizabeth] Univ Leicester, Dept Hlth Sci, Paediat Intens Care Audit Network PICANet, Leicester, Leics, England; [Whittaker, Elizabeth] Imperial Coll Healthcare NHS Trust, Dept Paediat Infect Dis, London, England; [Whittaker, Elizabeth] Imperial Coll London, Fac Med, Sect Paediat Infect Dis, London, England; [Fraser, Lorna K.] Univ York, Martin House Res Ctr, York, N Yorkshire, England	Bristol Royal Hospital For Children; Cardiff University; University of Bristol; University of Liverpool; University of London; University College London; Imperial College London; Public Health England; St Georges University London; University of Leicester; Imperial College London; Imperial College London; University of York - UK	Smith, C (corresponding author), NHS England, London, England.; Smith, C (corresponding author), NHS Improvement, London, England.; Smith, C (corresponding author), Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol Royal Hosp Children, Paediat Intens Care Unit, Bristol, Avon, England.	clare.smith107@nhs.net	Luyt, Karen/ABE-4921-2021; Viner, Russell/A-1441-2009	Luyt, Karen/0000-0002-9806-1092; Hargreaves, Dougal/0000-0003-0722-9847; Whittaker, Elizabeth/0000-0002-7944-8793; Clark, Matthew/0000-0002-3570-5241; Viner, Russell/0000-0003-3047-2247; Kenny, Simon/0000-0002-5917-8554; Davis, Peter/0000-0003-0669-2485; Harwood, Rachel/0000-0003-3440-3142	NHS Digital; NHS England; NHS Improvement Children and Young People teams; National Institute of Health Research (NIHR)through the National School for Public Health Research Programme; Applied Research Collaboration North West London; Royal College of Paediatrics and Child Health; Kidney Research UK [TF_010_20171124]; Medical Research Council Fellowship [MR/R00160X/1]; Martin House Childrens Hospice; NIHR [NIHR202322]	NHS Digital; NHS England; NHS Improvement Children and Young People teams; National Institute of Health Research (NIHR)through the National School for Public Health Research Programme; Applied Research Collaboration North West London; Royal College of Paediatrics and Child Health; Kidney Research UK(Kidney Research UK (KRUK)); Medical Research Council Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Martin House Childrens Hospice; NIHR(National Institute for Health Research (NIHR))	We would like to thank the three senior clinical expert reviewers who independently reviewed clinical case notes of the CYP who died with a positive SARS-CoV-2 test: P. Fleming, Professor of Infant Health and Developmental Physiology, University of Bristol; G. Rossouw, General Paediatrics and Neonates, Research Fellow, National Child Mortality Database (NCMD); and D. Alison Perry, Paediatric Intensive Care, Bristol Royal Hospital for Children. We are grateful to members of the Child Death Overview Panels for their support and expertise and all child death review professionals for submitting data and providing additional information when requested. The entire NCMD team (particularly N. Cook, S. Stoianova, V. Sleap and T. Williams) have been very helpful in providing data for linkage and supporting analysis. We thank the NHS Digital and the NHS England and NHS Improvement Children and Young People teams (particularly R. Owen,S. Solti and T. Watson-Koszel) for their contributions and support. We thank Public Health England's Field Service and National Child and Maternal Health Intelligence Network teams for their collaboration in establishing the real-time surveillance system on child deaths potentially related to COVID-19 and their ongoing support in the daily linkage with SARS-CoV-2 test results. We would like to acknowledge support from the National Institute of Health Research (NIHR) through the National School for Public Health Research Programme and the Applied Research Collaboration North West London. We would like to thank the Royal College of Paediatrics and Child Health for their contributions and support. Parent and public involvement is at the heart of the NCMD program. We are indebted to C. Bevan (Stillbirth and Neonatal Death Charity), T. McAlorum (Child Bereavement UK) and J. Ward (Lullaby Trust), who represent bereaved families on the NCMD program steering group, for their advice and support with setting up the real-time child mortality surveillance system at the beginning of the COVID-19 pandemic. The authors received no specific funding for this work. Three of the authors are in receipt of research funding for their broader employment. R.H. is in receipt of a funded fellowship from Kidney Research UK (grant no. TF_010_20171124). J.W. is in receipt of a Medical Research Council Fellowship (grant reference MR/R00160X/1). L.K.F. is in receipt of funding from Martin House Childrens Hospice (there is no specific grant number for this funding). R.V. is in receipt of a grant from the NIHR (grant no. NIHR202322, 'Understanding the disruption of children and young people's health and healthcare use during and after COVID-19 to inform healthcare and policy responses'). These funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The NCMD program, including this work, is funded by NHS England and commissioned by the Healthcare Quality Improvement Partnership as part of the National Clinical Audit and Patient Outcomes Programme.	Anastassopoulou C, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00290-4; [Anonymous], CHILDREN YOUNG PEOPL; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; Davies P, 2020, LANCET CHILD ADOLESC, V4, P669, DOI 10.1016/S2352-4642(20)30215-7; de Souza TH, 2020, PEDIATR PULM, V55, P1892, DOI 10.1002/ppul.24885; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Flood J., 2020, LANCET REG HEALTH-EU, V3, P1; Fraser LK, 2012, PEDIATRICS, V129, pE923, DOI 10.1542/peds.2011-2846; Hardelid P, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005331; Herbert A, 2017, INT J EPIDEMIOL, V46, P1093, DOI 10.1093/ije/dyx015; Odd D, 2021, ARCH DIS CHILD, P1, DOI DOI 10.1038/s41586-020-2521-4; Office for National Statistics, 2019, CENS GEOGR OV VAR GE; Parslow RC, 2009, ARCH DIS CHILD, V94, P210, DOI 10.1136/adc.2007.134403; Petretto Donatella Rita, 2020, Clin Pract Epidemiol Ment Health, V16, P189, DOI 10.2174/1745017902016010189; Royal College of Paediatrics and Child Health, 2021, COVID 19 GUID CLIN E; Swann OV, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3249; Viner RM, 2021, ARCH DIS CHILD, V106, P802, DOI 10.1136/archdischild-2020-320972; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	21	40	39	4	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					185	+		10.1038/s41591-021-01578-1	http://dx.doi.org/10.1038/s41591-021-01578-1		NOV 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34764489	Green Accepted, Green Submitted, Bronze			2022-12-27	WOS:000717406200009
J	Cummings, J				Cummings, Jeffrey			Why aducanumab is important	NATURE MEDICINE			English	Editorial Material									[Cummings, Jeffrey] Univ Nevada, Sch Integrated Hlth Sci, Dept Brain Hlth, Chambers Grundy Ctr Transformat Neurosci, Las Vegas, NV 89154 USA	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Cummings, J (corresponding author), Univ Nevada, Sch Integrated Hlth Sci, Dept Brain Hlth, Chambers Grundy Ctr Transformat Neurosci, Las Vegas, NV 89154 USA.	jcummings@cnsinnovations.com							0	6	6	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1498	1498		10.1038/s41591-021-01478-4	http://dx.doi.org/10.1038/s41591-021-01478-4		AUG 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34413516				2022-12-27	WOS:000686447900003
J	Turbe, V; Herbst, C; Mngomezulu, T; Meshkinfamfard, S; Dlamini, N; Mhlongo, T; Smit, T; Cherepanova, V; Shimada, K; Budd, J; Arsenov, N; Gray, S; Pillay, D; Herbst, K; Shahmanesh, M; McKendry, RA				Turbe, Valerian; Herbst, Carina; Mngomezulu, Thobeka; Meshkinfamfard, Sepehr; Dlamini, Nondumiso; Mhlongo, Thembani; Smit, Theresa; Cherepanova, Valeriia; Shimada, Koki; Budd, Jobie; Arsenov, Nestor; Gray, Steven; Pillay, Deenan; Herbst, Kobus; Shahmanesh, Maryam; McKendry, Rachel A.			Deep learning of HIV field-based rapid tests	NATURE MEDICINE			English	Article							DIAGNOSTICS; SETTINGS; QUALITY; CANCER	Although deep learning algorithms show increasing promise for disease diagnosis, their use with rapid diagnostic tests performed in the field has not been extensively tested. Here we use deep learning to classify images of rapid human immunodeficiency virus (HIV) tests acquired in rural South Africa. Using newly developed image capture protocols with the Samsung SM-P585 tablet, 60 fieldworkers routinely collected images of HIV lateral flow tests. From a library of 11,374 images, deep learning algorithms were trained to classify tests as positive or negative. A pilot field study of the algorithms deployed as a mobile application demonstrated high levels of sensitivity (97.8%) and specificity (100%) compared with traditional visual interpretation by humans-experienced nurses and newly trained community health worker staff-and reduced the number of false positives and false negatives. Our findings lay the foundations for a new paradigm of deep learning-enabled diagnostics in low- and middle-income countries, termed REASSURED diagnostics(1), an acronym for real-time connectivity, ease of specimen collection, affordable, sensitive, specific, user-friendly, rapid, equipment-free and deliverable. Such diagnostics have the potential to provide a platform for workforce training, quality assurance, decision support and mobile connectivity to inform disease control strategies, strengthen healthcare system efficiency and improve patient outcomes and outbreak management in emerging infections.	[Turbe, Valerian; Meshkinfamfard, Sepehr; Budd, Jobie; Arsenov, Nestor; McKendry, Rachel A.] UCL, London Ctr Nanotechnol, London, England; [Herbst, Carina; Mngomezulu, Thobeka; Dlamini, Nondumiso; Mhlongo, Thembani; Smit, Theresa; Pillay, Deenan; Herbst, Kobus; Shahmanesh, Maryam] Nelson R Mandela Med Sch, Africa Hlth Res Inst, Durban, South Africa; [Cherepanova, Valeriia; Shimada, Koki] UCL, Dept Comp Sci, London, England; [Budd, Jobie; McKendry, Rachel A.] UCL, Div Med, London, England; [Gray, Steven] UCL Ctr Adv Spatial Anal, London, England; [Pillay, Deenan] UCL, Div Infect & Immun, London, England; [Herbst, Kobus] DSI MRC South African Populat Res Infrastruct Net, Durban, South Africa; [Shahmanesh, Maryam] UCL, Inst Global Hlth, London, England	University of London; University College London; Africa Health Research Institute; University of Kwazulu Natal; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London	Turbe, V; McKendry, RA (corresponding author), UCL, London Ctr Nanotechnol, London, England.; Herbst, K; Shahmanesh, M (corresponding author), Nelson R Mandela Med Sch, Africa Hlth Res Inst, Durban, South Africa.; McKendry, RA (corresponding author), UCL, Div Med, London, England.; Herbst, K (corresponding author), DSI MRC South African Populat Res Infrastruct Net, Durban, South Africa.; Shahmanesh, M (corresponding author), UCL, Inst Global Hlth, London, England.	v.turbe@ucl.ac.uk; Kobus.Herbst@ahri.org; m.shahmanesh@ucl.ac.uk; r.a.mckendry@ucl.ac.uk		Meshkinfamfard, Sepehr/0000-0002-8594-1314; Gray, Steven/0000-0001-7673-9993; Turbe, Valerian/0000-0002-4979-197X	m-Africa Medical Research Council GCRF Global Infections Foundation Award [MR/P024378/1]; European Union; i-sense Engineering and Physical Sciences Research Council Interdisciplinary Research Collaboration (EPSRC IRC) in Early Warning Sensing Systems for Infectious Disease [EP/K031953/1]; i-sense: EPSRC IRC in Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance [EP/R00529X/1]; National Institute for Health Research University College London Hospitals Biomedical Research Centre; Wellcome Trust [082384/Z/07/Z]	m-Africa Medical Research Council GCRF Global Infections Foundation Award; European Union(European Commission); i-sense Engineering and Physical Sciences Research Council Interdisciplinary Research Collaboration (EPSRC IRC) in Early Warning Sensing Systems for Infectious Disease; i-sense: EPSRC IRC in Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric); Wellcome Trust(Wellcome Trust)	We thank the community of the uMkhanyakude district and the study participants, as well as the AHRI team of fieldworkers and their supervisors. We thank A. Koza, Z. Thabethe, T. Madini, N. Okesola and S. Msane for their help with the pilot study; D. Gareta and J. Dreyer for IT support; V. Lampos and I. J. Cox for useful discussions; and E. Manning and J. McHugh for their help with editing and project management. This research was funded by the m-Africa Medical Research Council GCRF Global Infections Foundation Award (no. MR/P024378/1, to C.H., D.P., K. H., M.S., R.A.M. and V.T.) and is part of the EDCTP2 program supported by the European Union, i-sense Engineering and Physical Sciences Research Council Interdisciplinary Research Collaboration (EPSRC IRC) in Early Warning Sensing Systems for Infectious Disease (no. EP/K031953/1, to R.A.M., V.T., D.P., S.M., S.G., N.A. and M.S.), the i-sense: EPSRC IRC in Agile Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance (no. EP/R00529X/1, to R.A.M., V. T., D.P., S.G., N.A. and S.M.) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre (R.A.M. and S.M.). We thank the m-Africa and i-sense investigators and advisory boards. The AHRI is supported by core funding from the Wellcome Trust (core grant no. 082384/Z/07/Z, to T.S., D.P. and K. H.).	Aicken CRH, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3648-y; Allan-Blitz LT, 2018, SEX TRANSM INFECT, V94, P589, DOI 10.1136/sextrans-2017-053511; [Anonymous], 2019, NAT MATER, V18, P407, DOI 10.1038/s41563-019-0360-1; [Anonymous], 2019, 2 WHO MOD LIST ESS I; Baveewo Steven, 2012, BMC Res Notes, V5, P154, DOI 10.1186/1756-0500-5-154; Carrio A, 2015, SENSORS-BASEL, V15, P29569, DOI 10.3390/s151129569; Cham F, 2012, AFR J LAB MED, V1, DOI 10.4102/ajlm.v1i1.39; Chaturvedi Saket S., 2021, Advanced Machine Learning Technologies and Applications. Proceedings of AMLTA 2020. Advances in Intelligent Systems and Computing (1141), P165, DOI 10.1007/978-981-15-3383-9_15; Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387; Crucitti T, 2011, CLIN VACCINE IMMUNOL, V18, P1480, DOI 10.1128/CVI.05069-11; De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Feng S, 2014, ACS NANO, V8, P3069, DOI 10.1021/nn500614k; Figueroa C, 2018, LANCET HIV, V5, pE277, DOI 10.1016/S2352-3018(18)30044-4; Galiwango RM, 2013, J VIROL METHODS, V192, P25, DOI 10.1016/j.jviromet.2013.04.003; Garcia PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066905; Gareta D, 2021, INT J EPIDEMIOL, V50, P33, DOI 10.1093/ije/dyaa264; Ghani AC, 2015, NATURE, V528, pS50, DOI 10.1038/nature16038; Gray RH, 2007, BRIT MED J, V335, P188, DOI 10.1136/bmj.39210.582801.BE; Guan Q., 2018, DIAGNOSE RADIOLOGIST; Howard A, 2019, IEEE I CONF COMP VIS, P1314, DOI 10.1109/ICCV.2019.00140; Johnson CC, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.7.21755; Klarkowski DB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004351; Land KJ, 2019, NAT MICROBIOL, V4, P46, DOI 10.1038/s41564-018-0295-3; Learmonth KM, 2008, J CLIN MICROBIOL, V46, P1692, DOI 10.1128/JCM.01761-07; Louis FJ, 2013, AM J CLIN PATHOL, V140, P867, DOI 10.1309/AJCPYWX49IZSQKFS; Martin EG, 2011, J CLIN VIROL, V52, pS11, DOI 10.1016/j.jcv.2011.09.014; Doan M, 2019, NAT MATER, V18, P414, DOI 10.1038/s41563-019-0339-y; Mudanyali O, 2012, LAB CHIP, V12, P2678, DOI [10.1039/c2lc40235a, 10.1039/c21c40235a]; Neuman M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6120-3; Nsabimana AP, 2018, JMIR PUBLIC HLTH SUR, V4, P56, DOI 10.2196/11203; Peck RB, 2014, AIDS BEHAV, V18, pS422, DOI 10.1007/s10461-014-0818-8; Peeling RW, 2015, INT HEALTH, V7, P384, DOI 10.1093/inthealth/ihv062; Sacks R, 2012, INT J STD AIDS, V23, P644, DOI 10.1258/ijsa.2012.011422; Sandler M, 2018, PROC CVPR IEEE, P4510, DOI 10.1109/CVPR.2018.00474; Silver D, 2018, SCIENCE, V362, P1140, DOI 10.1126/science.aar6404; Tegbaru Belete, 2007, Ethiop Med J, V45, P293; Witzel TC, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4370-0; Xu YW, 2019, CLIN CANCER RES, V25, P3266, DOI 10.1158/1078-0432.CCR-18-2495; Zeng NY, 2016, COGN COMPUT, V8, P684, DOI 10.1007/s12559-016-9404-x	41	8	9	4	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1165	+		10.1038/s41591-021-01384-9	http://dx.doi.org/10.1038/s41591-021-01384-9		JUN 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34140702	Green Submitted, Bronze, Green Accepted			2022-12-27	WOS:000662941700001
J	Li, JX; Hui, AM; Zhang, X; Yang, YM; Tang, R; Ye, HY; Ji, RR; Lin, M; Zhu, ZK; Tureci, O; Lagkadinou, E; Jia, SY; Pan, HX; Peng, FZ; Ma, ZL; Wu, ZG; Guo, XL; Shi, YF; Muik, A; Sahin, U; Zhu, L; Zhu, FC				Li, Jingxin; Hui, Aimin; Zhang, Xiang; Yang, Yumei; Tang, Rong; Ye, Huayue; Ji, Ruiru; Lin, Mei; Zhu, Zhongkui; Tureci, Ozlem; Lagkadinou, Eleni; Jia, Siyue; Pan, Hongxing; Peng, Fuzhong; Ma, Zhilong; Wu, Zhenggang; Guo, Xiling; Shi, Yunfeng; Muik, Alexander; Sahin, Ugur; Zhu, Li; Zhu, Fengcai			Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study	NATURE MEDICINE			English	Article							CAPACITY	An effective vaccine is needed to end the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we assess the preliminary safety, tolerability and immunogenicity data from an ongoing single-center (in Jiangsu province, China), parallel-group, double-blind phase 1 trial of the vaccine candidate BNT162b1 in 144 healthy SARS-CoV-2-naive Chinese participants. These participants are randomized 1:1:1 to receive prime and boost vaccinations of 10 mu g or 30 mu g BNT162b1 or placebo, given 21 d apart, with equal allocation of younger (aged 18-55 years) and older adults (aged 65-85 years) to each treatment group (ChiCTR2000034825). BNT162b1 encodes the SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD) and is one of several messenger RNA-based vaccine candidates under clinical investigation. Local reactions and systemic events were generally dose dependent, transient and mild to moderate. Fever was the only grade 3 adverse event. BNT162b1 induced robust interferon-gamma T cell responses to a peptide pool including the RBD in both younger and older Chinese adults, and geometric mean neutralizing titers reached 2.1-fold (for younger participants) and 1.3-fold (for the older participants) that of a panel of COVID-19 convalescent human sera obtained at least 14 d after positive SARS-CoV-2 polymerase chain reaction test. In summary, BNT162b1 has an acceptable safety profile and produces high levels of humoral and T cell responses in an Asian population. Phase 1 trial results of the messenger RNA vaccine candidate BNT162b1, which encodes the receptor-binding domain of the SARS-CoV-2 spike protein, show safety and elicitation of antibody and T cell responses in both younger and older Chinese adults.	[Li, Jingxin; Tang, Rong; Jia, Siyue; Pan, Hongxing; Guo, Xiling; Shi, Yunfeng; Zhu, Fengcai] Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing, Peoples R China; [Hui, Aimin; Ji, Ruiru] Fosun Pharma, Boston, MA 01862 USA; [Zhang, Xiang; Zhu, Zhongkui; Ma, Zhilong] Taizhou City Ctr Dis Control & Prevent, Taizhou, Peoples R China; [Yang, Yumei] Fosun Pharma, Beijing, Peoples R China; [Ye, Huayue; Peng, Fuzhong] Taizhou Vaccine Clin Res Ctr, Taizhou, Peoples R China; [Ye, Huayue] Army Med Univ, Dept Pharm, Chongqing, Peoples R China; [Lin, Mei; Peng, Fuzhong; Wu, Zhenggang; Zhu, Li] Taizhou Peoples Hosp, Taizhou, Peoples R China; [Tureci, Ozlem; Lagkadinou, Eleni; Muik, Alexander; Sahin, Ugur] BioNTech SE, Mainz, Germany; [Zhu, Fengcai] Nanjing Med Univ, Ctr Global Hlth, Nanjing, Peoples R China	Jiangsu Provincial Center for Disease Control & Prevention; Army Medical University; BioNTech SE; Nanjing Medical University	Zhu, FC (corresponding author), Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing, Peoples R China.; Hui, AM (corresponding author), Fosun Pharma, Boston, MA 01862 USA.; Zhu, L (corresponding author), Taizhou Peoples Hosp, Taizhou, Peoples R China.; Zhu, FC (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Nanjing, Peoples R China.	aimin.hui@fosunpharma.com; tzheart@126.com; jszfc@vip.sina.com	Li, Jing/GYU-5036-2022; Wu, Zhenggang/AAE-7103-2019		Fosun; BioNTech	Fosun; BioNTech	We thank M. Bushway, E. Derhovanessian and D. Maurus for critically reviewing the manuscript, M. Bexon for critically reviewing the manuscript and for his contribution to the planning and design of the study, and A. Finlayson for editorial and medical writing support. We also thank L. Zhu for providing the convalescent serum for the microneutralization assay. This trial was funded by Fosun and BioNTech and was registered under ChiCTR2000034825 at ChiCTR.	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2020, BUSINESS WIRE; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Doener F, 2019, VACCINE, V37, P1819, DOI 10.1016/j.vaccine.2019.02.024; Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Medicines & Healthcare Products Regulatory Agency, SUMM PUBL ASS REP PF; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; National Medical Products Administration, 2019, GUIDELINES ADVERSE E; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Sahin U., 2020, MEDRXIBNT 162B2 INDU, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175V1]; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Tsai MY, 2005, J LAB CLIN MED, V145, P323, DOI 10.1016/j.lab.2005.03.009; U.S. Food and Drug Administration, 2007, TOX GRAD SCAL HLTH A; US Food and Drug Administration, PFIZER BIONTECH COVI; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WHO, 2021, VACC EFF COV 19 VACC; World Health Organization, 2021, COVID 19 VACC PROGR; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]	29	63	64	6	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1062	+		10.1038/s41591-021-01330-9	http://dx.doi.org/10.1038/s41591-021-01330-9		APR 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	33888900	Green Submitted, Bronze			2022-12-27	WOS:000642382600001
J	Wagar, LE; Salahudeen, A; Constantz, CM; Wendel, BS; Lyons, MM; Mallajosyula, V; Jatt, LP; Adamska, JZ; Blum, LK; Gupta, N; Jackson, KJL; Yang, F; Roltgen, K; Roskin, KM; Blaine, KM; Meister, KD; Ahmad, IN; Cortese, M; Dora, EG; Tucker, SN; Sperling, AI; Jain, A; Davies, DH; Felgner, PL; Hammer, GB; Kim, PS; Robinson, WH; Boyd, SD; Kuo, CJ; Davis, MM				Wagar, Lisa E.; Salahudeen, Ameeny; Constantz, Christian M.; Wendel, Ben S.; Lyons, Michael M.; Mallajosyula, Vamsee; Jatt, Lauren P.; Adamska, Julia Z.; Blum, Lisa K.; Gupta, Neha; Jackson, Katherine J. L.; Yang, Fan; Roltgen, Katharina; Roskin, Krishna M.; Blaine, Kelly M.; Meister, Kara D.; Ahmad, Iram N.; Cortese, Mario; Dora, Emery G.; Tucker, Sean N.; Sperling, Anne I.; Jain, Aarti; Davies, D. Huw; Felgner, Philip L.; Hammer, Gregory B.; Kim, Peter S.; Robinson, William H.; Boyd, Scott D.; Kuo, Calvin J.; Davis, Mark M.			Modeling human adaptive immune responses with tonsil organoids	NATURE MEDICINE			English	Article							PLASMACYTOID DENDRITIC CELLS; HUMAN LYMPHOID-TISSUE; CD4 T-CELLS; HIV-1 VACCINE; INFLUENZA-A; IN-VITRO; CULTURE; ANTIGEN; ANTIBODIES; EFFICACY	An in vitro human tonsil tissue-based system captures key features of a functional germinal center and can be used to study humoral immune responses to vaccines, new antigens and adjuvants. Most of what we know about adaptive immunity has come from inbred mouse studies, using methods that are often difficult or impossible to confirm in humans. In addition, vaccine responses in mice are often poorly predictive of responses to those same vaccines in humans. Here we use human tonsils, readily available lymphoid organs, to develop a functional organotypic system that recapitulates key germinal center features in vitro, including the production of antigen-specific antibodies, somatic hypermutation and affinity maturation, plasmablast differentiation and class-switch recombination. We use this system to define the essential cellular components necessary to produce an influenza vaccine response. We also show that it can be used to evaluate humoral immune responses to two priming antigens, rabies vaccine and an adenovirus-based severe acute respiratory syndrome coronavirus 2 vaccine, and to assess the effects of different adjuvants. This system should prove useful for studying critical mechanisms underlying adaptive immunity in much greater depth than previously possible and to rapidly test vaccine candidates and adjuvants in an entirely human system.	[Wagar, Lisa E.; Wendel, Ben S.; Lyons, Michael M.; Davis, Mark M.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Salahudeen, Ameeny; Kuo, Calvin J.] Stanford Univ, Dept Med, Sch Med, Div Hematol, Stanford, CA 94305 USA; [Constantz, Christian M.; Mallajosyula, Vamsee; Jatt, Lauren P.; Gupta, Neha; Davis, Mark M.] Stanford Univ, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA; [Adamska, Julia Z.; Blum, Lisa K.; Robinson, William H.] Stanford Univ, Dept Med, Div Rheumatol & Immunol, Sch Med, Stanford, CA 94305 USA; [Adamska, Julia Z.; Blum, Lisa K.; Robinson, William H.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA; [Jackson, Katherine J. L.; Yang, Fan; Roltgen, Katharina; Roskin, Krishna M.; Boyd, Scott D.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Blaine, Kelly M.; Sperling, Anne I.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Meister, Kara D.; Ahmad, Iram N.] Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA; [Meister, Kara D.] Lucile Packard Childrens Hosp, Aerodigest & Airway Reconstruct Ctr, Stanford, CA USA; [Cortese, Mario; Dora, Emery G.; Tucker, Sean N.] Vaxart, San Francisco, CA USA; [Jain, Aarti; Davies, D. Huw; Felgner, Philip L.] Univ Calif Irvine, Dept Physiol & Biophys, Vaccine Res & Dev Ctr, Irvine, CA 92717 USA; [Hammer, Gregory B.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Hammer, Gregory B.] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Sch Med, Stanford, CA 94305 USA; [Kim, Peter S.] Stanford Univ, Dept Biochem, Stanford ChEM H, Stanford, CA 94305 USA; [Kim, Peter S.] Stanford Univ, Chan Zuckerberg Biohub, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Wagar, Lisa E.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA; [Salahudeen, Ameeny] Univ Illinois, Dept Med, Chicago, IL USA	Stanford University; Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Chicago; Stanford University; Lucile Packard Children's Hospital (LPCH); University of California System; University of California Irvine; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Irvine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Davis, MM (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA.; Davis, MM (corresponding author), Stanford Univ, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA.; Davis, MM (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	mmdavis@stanford.edu	Yang, Fan/V-6555-2019; Sperling, Anne/ACZ-2351-2022; Blum, Lisa/ABG-5826-2020	Yang, Fan/0000-0003-4821-6583; Blum, Lisa/0000-0002-7921-8939; Mallajosyula, Vamsee/0000-0002-0658-3652; Roltgen, Katharina/0000-0002-1582-1720; Jatt, Lauren/0000-0001-7034-9046; Kuo, Calvin/0000-0002-7427-5985; Tucker, Sean/0000-0002-6233-225X; Wagar, Lisa/0000-0001-5980-3586; A Salahudeen, Ameen/0000-0001-9037-3481; Sperling, Anne I./0000-0002-4265-9212; Adamska, Julia/0000-0001-8657-4141; Meister, Kara/0000-0002-4983-3068; Davis, Mark/0000-0001-6868-657X; Gupta, Neha/0000-0002-6300-1671; Robinson, William/0000-0003-4385-704X	Howard Hughes Medical Institute (HHMI) [N/A] Funding Source: Medline; NCI NIH HHS [U01 CA217851, U54 CA224081] Funding Source: Medline; NCRR NIH HHS [S10 RR027431, S10 RR025518] Funding Source: Medline; NIAID NIH HHS [R01 AI130398, U19 AI057229, R01 AI127877, U19 AI116484] Funding Source: Medline; NIDCR NIH HHS [K08 DE027730] Funding Source: Medline; NIDDK NIH HHS [U01 DK085527] Funding Source: Medline; U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH) [U54CA224081, 1R01AI130398, 5U19AI05722915, U01CA217851, U19AI116484, U01DK085527] Funding Source: Medline	Howard Hughes Medical Institute (HHMI)(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Beguelin W, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01029-x; Behring E, 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [10.1055/s-0029-1207589, DOI 10.1055/S-0029-1207589]; Behring Emil, 1890, DEUT MED WOCHENSCHR, V50, P1145, DOI 10.1055/s-0029-1207609; Blum LK, 2018, EUR J IMMUNOL, V48, P874, DOI 10.1002/eji.201747460; Brinkman DMC, 2003, J CLIN IMMUNOL, V23, P528, DOI 10.1023/B:JOCI.0000010429.36461.6b; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Byers AM, 2009, BIOLOGICALS, V37, P148, DOI 10.1016/j.biologicals.2009.02.018; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; de Assis RR, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-020-20095-2, 10.1101/2020.04.15.043364]; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; EDWARDS KM, 1986, J INFECT DIS, V153, P41, DOI 10.1093/infdis/153.1.41; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; FERRO LM, 1993, IMMUNOBIOLOGY, V188, P51, DOI 10.1016/S0171-2985(11)80486-9; Gerner MY, 2017, J EXP MED, V214, P3105, DOI 10.1084/jem.20170335; Giese C, 2006, ARTIF ORGANS, V30, P803, DOI 10.1111/j.1525-1594.2006.00303.x; Giese C, 2014, ADV DRUG DELIVER REV, V69, P103, DOI 10.1016/j.addr.2013.12.011; Giese C, 2010, J BIOTECHNOL, V148, P38, DOI 10.1016/j.jbiotec.2010.03.001; Grivel JC, 2009, NAT PROTOC, V4, P256, DOI 10.1038/nprot.2008.245; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOFFMANN P, 1995, J IMMUNOL METHODS, V179, P37, DOI 10.1016/0022-1759(94)00268-2; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Jackson KJL, 2014, CELL HOST MICROBE, V16, P105, DOI 10.1016/j.chom.2014.05.013; James K., 1996, Human Antibodies and Hybridomas, V7, P138; Jameson SC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029132; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Jenkinson E J, 1990, Semin Immunol, V2, P51; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Kaufmann SHE, 2008, NAT IMMUNOL, V9, P705, DOI 10.1038/ni0708-705; Kaufmann SHE, 2017, NAT REV IMMUNOL, V17, P341, DOI 10.1038/nri.2017.37; Kim L, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121077; Kinslow JD, 2016, ARTHRITIS RHEUMATOL, V68, P2372, DOI 10.1002/art.39771; KLINMAN NR, 1972, J EXP MED, V136, P241, DOI 10.1084/jem.136.2.241; Kuzin I, 2011, BIOTECHNOL BIOENG, V108, P1430, DOI 10.1002/bit.23055; Liebowitz D, 2020, LANCET INFECT DIS, V20, P435, DOI 10.1016/S1473-3099(19)30584-5; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; McCloskey ML, 2011, J EXP MED, V208, P135, DOI 10.1084/jem.20100354; Mesin L, 2020, CELL, V180, P92, DOI 10.1016/j.cell.2019.11.032; MILLER JFA, 1967, NATURE, V216, P659, DOI 10.1038/216659a0; Miller JFAP, 2002, IMMUNOL REV, V185, P7, DOI 10.1034/j.1600-065X.2002.18502.x; Monto AS, 2009, NEW ENGL J MED, V361, P1260, DOI 10.1056/NEJMoa0808652; Nair N, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam5434; Nakajima R, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00592-18; Purwada A, 2019, BIOMATERIALS, V198, P27, DOI 10.1016/j.biomaterials.2018.06.034; Purwada A, 2017, NAT PROTOC, V12, DOI 10.1038/nprot.2016.157; Purwada A, 2015, BIOMATERIALS, V63, P24, DOI 10.1016/j.biomaterials.2015.06.002; Qi H, 2014, ANNU REV CELL DEV BI, V30, P141, DOI 10.1146/annurev-cellbio-100913-013254; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Radtke AJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004637; ROBINSON JH, 1977, CLIN EXP IMMUNOL, V27, P322; Roskin KM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1216; Shah HB, 2015, METHODS MOL BIOL, V1312, P419, DOI 10.1007/978-1-4939-2694-7_42; Skibinski G, 1998, Dev Immunol, V6, P273, DOI 10.1155/1998/81637; Skibinski G, 1997, J IMMUNOL METHODS, V205, P115, DOI 10.1016/S0022-1759(97)00058-6; Soto-Rivera J, 2013, AM J REPROD IMMUNOL, V69, P52, DOI 10.1111/aji.12018; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Tan YC, 2014, CLIN IMMUNOL, V151, P55, DOI 10.1016/j.clim.2013.12.008; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; van Laar JM, 2007, AM J PATHOL, V171, P917, DOI 10.2353/ajpath.2007.070005; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Vinuesa CG, 2010, IMMUNOL REV, V237, P72, DOI 10.1111/j.1600-065X.2010.00937.x; Wagar LE, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0584-8; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Wendel BS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00645-x; Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13; Wolf AI, 2009, J IMMUNOL, V182, P871, DOI 10.4049/jimmunol.182.2.871; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	72	52	52	11	27	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					125	+		10.1038/s41591-020-01145-0	http://dx.doi.org/10.1038/s41591-020-01145-0		JAN 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33432170	Bronze, Green Accepted			2022-12-27	WOS:000607036600002
J	Wang, RP; Dang, MH; Harada, K; Han, GC; Wang, F; Pizzi, MP; Zhao, MA; Tatlonghari, G; Zhang, SJ; Hao, DP; Lu, Y; Zhao, ST; Badgwell, BD; Murphy, MB; Shanbhag, N; Estrella, JS; Roy-Chowdhuri, S; Abdelhakeem, AAF; Wang, YX; Peng, G; Hanash, S; Calin, GA; Song, XZ; Chu, YS; Zhang, JH; Li, MY; Chen, K; Lazar, AJ; Futreal, A; Song, SM; Ajani, JA; Wang, LH				Wang, Ruiping; Dang, Minghao; Harada, Kazuto; Han, Guangchun; Wang, Fang; Pool Pizzi, Melissa; Zhao, Meina; Tatlonghari, Ghia; Zhang, Shaojun; Hao, Dapeng; Lu, Yang; Zhao, Shuangtao; Badgwell, Brian D.; Blum Murphy, Mariela; Shanbhag, Namita; Estrella, Jeannelyn S.; Roy-Chowdhuri, Sinchita; Abdelhakeem, Ahmed Adel Fouad; Wang, Yuanxin; Peng, Guang; Hanash, Samir; Calin, George A.; Song, Xingzhi; Chu, Yanshuo; Zhang, Jianhua; Li, Mingyao; Chen, Ken; Lazar, Alexander J.; Futreal, Andrew; Song, Shumei; Ajani, Jaffer A.; Wang, Linghua			Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma	NATURE MEDICINE			English	Article							B-CELLS; CANCER; IMMUNOTHERAPY; SURVIVAL; SUBTYPES; RESISTANCE; INHIBITORS; PROGNOSIS	Intratumoral heterogeneity (ITH) is a fundamental property of cancer; however, the origins of ITH remain poorly understood. We performed single-cell transcriptome profiling of peritoneal carcinomatosis (PC) from 15 patients with gastric adenocarcinoma (GAC), constructed a map of 45,048 PC cells, profiled the transcriptome states of tumor cell populations, incisively explored ITH of malignant PC cells and identified significant correlates with patient survival. The links between tumor cell lineage/state compositions and ITH were illustrated at transcriptomic, genotypic, molecular and phenotypic levels. We uncovered the diversity in tumor cell lineage/state compositions in PC specimens and defined it as a key contributor to ITH. Single-cell analysis of ITH classified PC specimens into two subtypes that were prognostically independent of clinical variables, and a 12-gene prognostic signature was derived and validated in multiple large-scale GAC cohorts. The prognostic signature appears fundamental to GAC carcinogenesis and progression and could be practical for patient stratification. Single-cell analysis of gastric cancer samples tracks the cell of origin of metastatic lesions and identifies an independent prognostic signature of the clinical outcome.	[Wang, Ruiping; Dang, Minghao; Han, Guangchun; Zhang, Shaojun; Hao, Dapeng; Zhao, Shuangtao; Wang, Yuanxin; Song, Xingzhi; Chu, Yanshuo; Zhang, Jianhua; Futreal, Andrew] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Harada, Kazuto; Pool Pizzi, Melissa; Zhao, Meina; Tatlonghari, Ghia; Blum Murphy, Mariela; Shanbhag, Namita; Abdelhakeem, Ahmed Adel Fouad; Song, Shumei; Ajani, Jaffer A.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Wang, Fang; Chen, Ken] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Lu, Yang] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA; [Badgwell, Brian D.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Estrella, Jeannelyn S.; Roy-Chowdhuri, Sinchita; Lazar, Alexander J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Peng, Guang; Hanash, Samir] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Li, Mingyao] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Lazar, Alexander J.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Wang, Linghua] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Harada, Kazuto] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Kumamoto University	Ajani, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.; Wang, LH (corresponding author), Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.	jajani@mdanderson.org; LWang22@mdanderson.org	Abdelhakeem, Ahmed Adel/GVR-8607-2022; Abdelhakeem, Ahmed/AAV-8251-2021; Chen, Ken/AAU-1432-2021; Han, Guangchun/AAU-8230-2021	Abdelhakeem, Ahmed/0000-0001-7186-1332; Chen, Ken/0000-0003-4013-5279; Wang, Linghua/0000-0001-9380-0266; Zhang, Shaojun/0000-0001-5760-5797; , guangchun/0000-0001-9277-2507	UT MD Anderson Cancer Center (MDACC); Andrew Sabin Family Fellowship Program; Andrew Sabin Family Foundation; DOD [CA150334, CA160445, CA160433, CA170906]; Schecter Private Foundation; Rivercreek Foundation; Kevin Fund; Myer Fund; V. Foundation; Dio Fund; Milrod Fund; NIH [1S10OD024977-01]; Advanced Technology Genomics Core (ATGC) [CA016672]; Stupid Strong Foundation	UT MD Anderson Cancer Center (MDACC); Andrew Sabin Family Fellowship Program; Andrew Sabin Family Foundation; DOD(United States Department of Defense); Schecter Private Foundation; Rivercreek Foundation; Kevin Fund; Myer Fund; V. Foundation; Dio Fund; Milrod Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Advanced Technology Genomics Core (ATGC); Stupid Strong Foundation	This study was supported by the start-up research fund provided to L.W. by the UT MD Anderson Cancer Center (MDACC); the Andrew Sabin Family Fellowship Program to L.W. by the Andrew Sabin Family Foundation; the DOD grants no. CA150334 and no. CA160445 to J.A.A.; the DOD grants no. CA160433 and no. CA170906 to S.S.; and the generous support from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Vanstekelenberg, Planjery, McNeil, Hyland and Cantu families; as well as from the Schecter Private Foundation, the Rivercreek Foundation, the Kevin Fund, the Myer Fund, the Stupid Strong Foundation, the V. Foundation, the Dio Fund, the Milrod Fund and the MDACC multidisciplinary grant programs. This study was also supported by the NIH grant no. 1S10OD024977-01 Award to the Advanced Technology Genomics Core (ATGC) and the Core grant no. CA016672 (ATGC). We thank E. J. Thompson and D. P. Pollock from the ATGC for their excellent technical assistance. We thank all of the patients who participated in this study.	Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Amin MB, 2017, AJCC CANC STAGING MA; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Barros R, 2012, TRENDS MOL MED, V18, P555, DOI 10.1016/j.molmed.2012.07.006; Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buttner M, 2019, NAT METHODS, V16, P43, DOI 10.1038/s41592-018-0254-1; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; Chen C, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1581547; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cillo AR, 2020, IMMUNITY, V52, P183, DOI 10.1016/j.immuni.2019.11.014; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Coker EA, 2019, NUCLEIC ACIDS RES, V47, pD917, DOI 10.1093/nar/gky1129; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2; Galili T, 2015, BIOINFORMATICS, V31, P3718, DOI 10.1093/bioinformatics/btv428; Gullo I, 2018, PATHOBIOLOGY, V85, P50, DOI 10.1159/000473881; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586-020-2157-4; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hicks SC, 2018, BIOSTATISTICS, V19, P562, DOI 10.1093/biostatistics/kxx053; Hudler P, 2015, WORLD J GASTROENTERO, V21, P10510, DOI 10.3748/wjg.v21.i37.10510; Ikoma N, 2018, GASTRIC CANCER, V21, P1004, DOI 10.1007/s10120-018-0832-z; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kang J, 2012, JNCI-J NATL CANCER I, V104, P670, DOI 10.1093/jnci/djs177; Karam SM, 2010, WORLD J GASTROENTERO, V16, P538, DOI 10.3748/wjg.v16.i5.538; Kaya DM, 2018, J SURG ONCOL, V117, P678, DOI 10.1002/jso.24912; Kaya DM, 2017, EXPERT REV CLIN PHAR, V10, P263, DOI 10.1080/17512433.2017.1279969; Kim HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016694; Kiselev VY, 2017, NAT METHODS, V14, P483, DOI [10.1038/NMETH.4236, 10.1038/nmeth.4236]; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lau SK, 2007, J CLIN ONCOL, V25, P5562, DOI 10.1200/JCO.2007.12.0352; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; McInnes L., 2018, UMAP UNIFORM MANIFOL; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; MERZEL J, 1969, AM J ANAT, V124, P281, DOI 10.1002/aja.1001240303; Michor F, 2010, CANCER PREV RES, V3, P1361, DOI 10.1158/1940-6207.CAPR-10-0234; Moghimi-Dehkordi Bijan, 2009, Saudi J Gastroenterol, V15, P18, DOI 10.4103/1319-3767.43284; Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Peng FD, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0666-z; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Petrelli F, 2017, J GASTROINTEST ONCOL, V8, P148, DOI 10.21037/jgo.2017.01.10; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Qiu MZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-58; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Shiozaki H, 2016, J SURG ONCOL, V113, P29, DOI 10.1002/jso.24087; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; STEVENS CE, 1953, ANAT REC, V115, P231, DOI 10.1002/ar.1091150206; Taieb J, 2018, CANCER TREAT REV, V66, P104, DOI 10.1016/j.ctrv.2018.04.004; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Wang RP, 2020, GUT, V69, P18, DOI 10.1136/gutjnl-2018-318070; Yoon SJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06814-4; Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586-018-0694-x	73	58	58	16	58	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					141	+		10.1038/s41591-020-1125-8	http://dx.doi.org/10.1038/s41591-020-1125-8		JAN 2021	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33398161	Green Accepted			2022-12-27	WOS:000604849400002
J	Carvalho, T				Carvalho, Thiago			Cross-reactive T cells	NATURE MEDICINE			English	Editorial Material																			0	1	1	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1807	1807		10.1038/s41591-020-01161-0	http://dx.doi.org/10.1038/s41591-020-01161-0			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288940	Bronze			2022-12-27	WOS:000596579200017
J	Daws, RE; Timmermann, C; Giribaldi, B; Sexton, JD; Wall, MB; Erritzoe, D; Roseman, L; Nutt, D; Carhart-Harris, R				Daws, Richard E.; Timmermann, Christopher; Giribaldi, Bruna; Sexton, James D.; Wall, Matthew B.; Erritzoe, David; Roseman, Leor; Nutt, David; Carhart-Harris, Robin			Increased global integration in the brain after psilocybin therapy for depression	NATURE MEDICINE			English	Article							MAJOR DEPRESSION; COMMUNITY STRUCTURE; DEFAULT-MODE; NETWORK; STATE; FMRI; ADOLESCENTS; SEROTONIN	Psilocybin therapy shows antidepressant potential, but its therapeutic actions are not well understood. We assessed the subacute impact of psilocybin on brain function in two clinical trials of depression. The first was an open-label trial of orally administered psilocybin (10 mg and 25 mg, 7 d apart) in patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI) was recorded at baseline and 1 d after the 25-mg dose. Beck's depression inventory was the primary outcome measure (MR/J00460X/1). The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients with major depressive disorder received either 2 x 25 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo ('psilocybin arm') or 2 x 1 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily escitalopram (10-20 mg) ('escitalopram arm'). fMRI was recorded at baseline and 3 weeks after the second psilocybin dose (NCT03429075). In both trials, the antidepressant response to psilocybin was rapid, sustained and correlated with decreases in fMRI brain network modularity, implying that psilocybin's antidepressant action may depend on a global increase in brain network integration. Network cartography analyses indicated that 5-HT2A receptor-rich higher-order functional networks became more functionally interconnected and flexible after psilocybin treatment. The antidepressant response to escitalopram was milder and no changes in brain network organization were observed. Consistent efficacy-related brain changes, correlating with robust antidepressant effects across two studies, suggest an antidepressant mechanism for psilocybin therapy: global increases in brain network integration.	[Daws, Richard E.; Timmermann, Christopher] Imperial Coll London, Computat Cognit & Clin Neuroimaging Lab C3NL, London, England; [Daws, Richard E.] Kings Coll London, Ctr Neuroimaging Sci, London, England; [Timmermann, Christopher; Giribaldi, Bruna; Sexton, James D.; Erritzoe, David; Roseman, Leor; Nutt, David; Carhart-Harris, Robin] Imperial Coll London, Div Acad Psychiat, Ctr Psychedel Res, London, England; [Wall, Matthew B.] Hammersmith Hosp, Invicro London, London, England; [Wall, Matthew B.] Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, London, England; [Wall, Matthew B.] UCL, Clin Psychopharmacol Unit, London, England; [Carhart-Harris, Robin] Univ Calif San Francisco, Dept Neurol, Psychedel Div, Neuroscape, San Francisco, CA USA	Imperial College London; University of London; King's College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London; University of California System; University of California San Francisco	Daws, RE (corresponding author), Imperial Coll London, Computat Cognit & Clin Neuroimaging Lab C3NL, London, England.; Daws, RE (corresponding author), Kings Coll London, Ctr Neuroimaging Sci, London, England.	richard.daws@kcl.ac.uk		Roseman, Leor/0000-0001-9990-6029; nutt, david/0000-0002-1286-1401; Daws, Richard/0000-0002-6639-5768; Sexton, James/0000-0002-3402-2748	Engineering and Physical Sciences Research Council PhD scholarship at the Imperial College London Centre for Neurotechnology [EP/L016737/1]; Medical Research Council clinical development scheme grant [MR/J00460X/1]; Alexander Mosley Charitable Trust	Engineering and Physical Sciences Research Council PhD scholarship at the Imperial College London Centre for Neurotechnology; Medical Research Council clinical development scheme grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alexander Mosley Charitable Trust	R.E.D. was supported by an Engineering and Physical Sciences Research Council PhD scholarship at the Imperial College London Centre for Neurotechnology (EP/L016737/1). The research was carried out at the National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility. The open-label trial was funded by a Medical Research Council clinical development scheme grant (MR/J00460X/1). The DB-RCT was funded by a private donation from the Alexander Mosley Charitable Trust, supplemented by Founders of Imperial College London's Centre for Psychedelic Research.	Andersen KAA, 2021, ACTA PSYCHIAT SCAND, V143, P101, DOI 10.1111/acps.13249; Andrews-Hanna JR, 2014, ANN NY ACAD SCI, V1316, P29, DOI 10.1111/nyas.12360; [Anonymous], 2017, DEPRESSION OTHER COM; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Barrett FS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59282-y; Bassett DS, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003171; Beck A.T., 1988, ANXIETY RES, V1, P23, DOI [DOI 10.1080/10615808808248218, 10.1080/10615808808248218]; Beliveau V, 2020, NEUROIMAGE, V205, DOI 10.1016/j.neuroimage.2019.116240; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Carhart-Harris RL, 2019, PHARMACOL REV, V71, P316, DOI 10.1124/pr.118.017160; Carhart-Harris RL, 2017, J PSYCHOPHARMACOL, V31, P1091, DOI 10.1177/0269881117725915; Carhart-Harris RL., 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-13282-71:CAS:528:DC%2BC1MXhtVCiu7w%3D, DOI 10.1038/S41598-017-13282-71:CAS:528:DC%2BC1MXHTVCIU7W%3D]; Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994; Carhart-Harris RL, 2022, J PSYCHOPHARMACOL, V36, P6, DOI 10.1177/02698811211008567; Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710; Carhart-Harris RL, 2012, P NATL ACAD SCI USA, V109, P2138, DOI 10.1073/pnas.1119598109; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Daws R. E., 2021, OPTIMISATION BRAIN S, DOI [10.1101/2020.06.17.156570, DOI 10.1101/2020.06.17.156570]; Feurer C, 2021, DEPRESS ANXIETY, V38, P488, DOI 10.1002/da.23142; Finc K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15631-z; Fried EI, 2017, J AFFECT DISORDERS, V208, P191, DOI 10.1016/j.jad.2016.10.019; Goodman ZT, 2021, CEREB CORTEX, V31, P4867, DOI 10.1093/cercor/bhab047; Gu BM, 2008, BRAIN, V131, P155, DOI 10.1093/brain/awm277; Haddad P, 1998, J PSYCHOPHARMACOL, V12, P305, DOI 10.1177/026988119801200311; Hamilton JP, 2011, BIOL PSYCHIAT, V70, P327, DOI 10.1016/j.biopsych.2011.02.003; Hampshire A, 2019, NEUROIMAGE, V192, P88, DOI 10.1016/j.neuroimage.2019.03.002; Hofmann SG, 2017, COGN BEHAV THERAPY, V46, P265, DOI 10.1080/16506073.2017.1304445; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Kendler KS, 2016, AM J PSYCHIAT, V173, P771, DOI 10.1176/appi.ajp.2016.15121509; Kim C, 2012, HUM BRAIN MAPP, V33, P130, DOI 10.1002/hbm.21199; Leonardi N, 2015, NEUROIMAGE, V104, P430, DOI 10.1016/j.neuroimage.2014.09.007; Locher C, 2017, JAMA PSYCHIAT, V74, P1011, DOI 10.1001/jamapsychiatry.2017.2432; Lord LD, 2019, NEUROIMAGE, V199, P127, DOI 10.1016/j.neuroimage.2019.05.060; Luppi AI, 2021, NEUROIMAGE, V227, DOI 10.1016/j.neuroimage.2020.117653; Lydon-Staley DM, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0560-0; Lyons T, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01721; Margulies DS, 2016, P NATL ACAD SCI USA, V113, P12574, DOI 10.1073/pnas.1608282113; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mattar MG, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004533; Mucha PJ, 2010, SCIENCE, V328, P876, DOI 10.1126/science.1184819; Murphy-Beiner A, 2020, PSYCHOPHARMACOLOGY, V237, P1161, DOI 10.1007/s00213-019-05445-3; Newman MEJ, 2004, PHYS REV E, V70, DOI [10.1103/PhysRevE.70.056131, 10.1103/PhysRevE.69.026113]; Nutt D, 2021, JAMA PSYCHIAT, V78, P121, DOI 10.1001/jamapsychiatry.2020.2171; Nutt D, 2020, CELL, V181, P24, DOI 10.1016/j.cell.2020.03.020; Parkes L, 2020, CURR OPIN NEUROBIOL, V65, P120, DOI 10.1016/j.conb.2020.10.016; Pasquini L, 2020, J PSYCHOPHARMACOL, V34, P623, DOI 10.1177/0269881120909409; Rabeea SA, 2021, DARU, V29, P217, DOI 10.1007/s40199-021-00390-z; Rolls ET, 2016, NEUROSCI BIOBEHAV R, V68, P47, DOI 10.1016/j.neubiorev.2016.05.007; Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974; Rubinov M, 2011, NEUROIMAGE, V56, P2068, DOI 10.1016/j.neuroimage.2011.03.069; Schaefer A, 2018, CEREB CORTEX, V28, P3095, DOI 10.1093/cercor/bhx179; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Soreq E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22199-9; Steinert C, 2014, J AFFECT DISORDERS, V168, P107, DOI 10.1016/j.jad.2014.06.043; Tagliazucchi E, 2014, NEURON, V82, P695, DOI 10.1016/j.neuron.2014.03.020; Tang F, 2021, PSYCHOL HEALTH, V36, P164, DOI 10.1080/08870446.2020.1782410; Turnbull A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66698-z; Vollenweider FX, 1998, NEUROREPORT, V9, P3897, DOI 10.1097/00001756-199812010-00024; Wang X, 2016, HARVARD REV PSYCHIAT, V24, P188, DOI 10.1097/HRP.0000000000000081; Watanabe T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16048; Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585; Wei MB, 2017, J MAGN RESON IMAGING, V45, P1135, DOI 10.1002/jmri.25429; Wilkinson PO, 2006, J CHILD PSYCHOL PSYC, V47, P1284, DOI 10.1111/j.1469-7610.2006.01660.x; Ye M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133775; Zeifman RJ, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00782	66	29	28	28	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4								10.1038/s41591-022-01744-z	http://dx.doi.org/10.1038/s41591-022-01744-z		APR 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0P3TN	35411074	Bronze, Green Submitted			2022-12-27	WOS:000780688100001
J	Russell, SR; Drack, AV; Cideciyan, AV; Jacobson, SG; Leroy, BP; Van Cauwenbergh, C; Ho, AC; Dumitrescu, AV; Han, IC; Martin, M; Pfeifer, WL; Sohn, EH; Walshire, J; Garafalo, AV; Krishnan, AK; Powers, CA; Sumaroka, A; Roman, AJ; Vanhonsebrouck, E; Jones, E; Nerinckx, F; De Zaeytijd, J; Collin, RWJ; Hoyng, C; Adamson, P; Cheetham, ME; Schwartz, MR; den Hollander, W; Asmus, F; Platenburg, G; Rodman, D; Girach, A				Russell, Stephen R.; Drack, Arlene, V; Cideciyan, Artur, V; Jacobson, Samuel G.; Leroy, Bart P.; Van Cauwenbergh, Caroline; Ho, Allen C.; Dumitrescu, Alina, V; Han, Ian C.; Martin, Mitchell; Pfeifer, Wanda L.; Sohn, Elliott H.; Walshire, Jean; Garafalo, Alexandra, V; Krishnan, Arun K.; Powers, Christian A.; Sumaroka, Alexander; Roman, Alejandro J.; Vanhonsebrouck, Eva; Jones, Eltanara; Nerinckx, Fanny; De Zaeytijd, Julie; Collin, Rob W. J.; Hoyng, Carel; Adamson, Peter; Cheetham, Michael E.; Schwartz, Michael R.; den Hollander, Wilhelmina; Asmus, Friedrich; Platenburg, Gerard; Rodman, David; Girach, Aniz			Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial	NATURE MEDICINE			English	Article							MOLECULAR-GENETICS; COUNTING FINGERS; SHAM CONTROL; HAND MOTION; MUTATIONS; CEP290; FEATURES; THERAPY; IDENTIFICATION; NUSINERSEN	CEP290-associated Leber congenital amaurosis type 10 (LCA10) is a retinal disease resulting in childhood blindness. Sepofarsen is an RNA antisense oligonucleotide targeting the c.2991+1655A>G variant in the CEP290 gene to treat LCA10. In this open-label, phase 1b/2 (NCT03140969), 12-month, multicenter, multiple-dose, dose-escalation trial, six adult patients and five pediatric patients received <= 4 doses of intravitreal sepofarsen into the worse-seeing eye. The primary objective was to evaluate sepofarsen safety and tolerability via the frequency and severity of ocular adverse events (AEs); secondary objectives were to evaluate pharmacokinetics and efficacy via changes in functional outcomes. Six patients received sepofarsen 160 mu g/80 mu g, and five patients received sepofarsen 320 mu g/160 mu g. Ten of 11 (90.9%) patients developed ocular AEs in the treated eye (5/6 with 160 mu g/80 mu g; 5/5 with 320 mu g/160 mu g) versus one of 11 (9.1%) in the untreated eye; most were mild in severity and dose dependent. Eight patients developed cataracts, of which six (75.0%) were categorized as serious (2/3 with 160 mu g/80 mu g; 4/5 with 320 mu g/160 mu g), as lens replacement was required. As the 160-mu g/80-mu g group showed a better benefit-risk profile, higher doses were discontinued or not initiated. Statistically significant improvements in visual acuity and retinal sensitivity were reported (post hoc analysis). The manageable safety profile and improvements reported in this trial support the continuation of sepofarsen development.	[Russell, Stephen R.; Drack, Arlene, V; Dumitrescu, Alina, V; Han, Ian C.; Martin, Mitchell; Pfeifer, Wanda L.; Sohn, Elliott H.; Walshire, Jean] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA; [Cideciyan, Artur, V; Jacobson, Samuel G.; Garafalo, Alexandra, V; Krishnan, Arun K.; Powers, Christian A.; Sumaroka, Alexander; Roman, Alejandro J.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA; [Leroy, Bart P.] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Leroy, Bart P.; Van Cauwenbergh, Caroline; Vanhonsebrouck, Eva; Jones, Eltanara; Nerinckx, Fanny; De Zaeytijd, Julie] Univ Ghent, Dept Ophthalmol, Ghent, Belgium; [Leroy, Bart P.; Van Cauwenbergh, Caroline; Vanhonsebrouck, Eva; Jones, Eltanara; Nerinckx, Fanny; De Zaeytijd, Julie] Ghent Univ Hosp, Ghent, Belgium; [Leroy, Bart P.] Childrens Hosp Philadelphia, Div Ophthalmol, Philadelphia, PA 19104 USA; [Leroy, Bart P.] Childrens Hosp Philadelphia, Ctr Cellular & Mol Therapeut, Philadelphia, PA 19104 USA; [Ho, Allen C.] Wills Eye Hosp Mid Atlantic Retina, Philadelphia, PA USA; [Collin, Rob W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; [Collin, Rob W. J.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands; [Hoyng, Carel] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands; [Adamson, Peter; Cheetham, Michael E.] UCL Inst Ophthalmol, London, England; [Schwartz, Michael R.; Platenburg, Gerard; Girach, Aniz] ProQR Therapeut, Leiden, Netherlands; [den Hollander, Wilhelmina] 3D PharmXchange, Tilburg, Netherlands; [Asmus, Friedrich] Oxular Ltd, Magdalen Ctr, Oxford, England; [Rodman, David] Mineralys Therapeut, Radnor, PA USA	University of Iowa; University of Pennsylvania; Pennsylvania Medicine; Ghent University; Ghent University Hospital; Ghent University; Ghent University; Ghent University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; University of London; University College London	Russell, SR (corresponding author), Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.	steve-russell@uiowa.edu	De Zaeytijd, Julie/GXA-3099-2022	Jacobson, Samuel/0000-0003-2122-169X; LEROY, Bart Peter/0000-0002-9899-2081; Ho, Allen/0000-0003-3921-608X	ProQR Therapeutics; Senior Clinical Investigator of the Scientific Research Fund Flanders [1803816N]	ProQR Therapeutics; Senior Clinical Investigator of the Scientific Research Fund Flanders	We thank the patients and their families for participating in this trial as well as I. MacDonald for referring a patient to this study. We also thank the members of the data safety monitoring committee for monitoring patient safety and treatment efficacy during the study. Editorial support for the preparation of this manuscript (under the guidance of the authors) was provided by R. Franklin of Fishawack Communications and S. Flowers of Apothecom and was funded by ProQR Therapeutics. Organization of this support was coordinated by A. Plichta of ProQR Therapeutics. This trial was sponsored and funded by ProQR Therapeutics. Statistical support (funded by ProQR Therapeutics) was provided by U. Garczarek from Cytel. B.P.L. is a Senior Clinical Investigator of the Scientific Research Fund Flanders (grant no. 1803816N).	[Anonymous], CEP290 MUT DAT; Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399; Bailey IL, 2012, OPTOMETRY VISION SCI, V89, P1257, DOI 10.1097/OPX.0b013e318264e85a; BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793; Betleja E, 2010, CURR BIOL, V20, pR928, DOI 10.1016/j.cub.2010.09.058; Cideciyan AV, 2007, HUM MUTAT, V28, P1074, DOI 10.1002/humu.20565; Cideciyan AV, 2021, NAT MED, V27, P785, DOI 10.1038/s41591-021-01297-7; Cideciyan AV, 2019, NAT MED, V25, P225, DOI 10.1038/s41591-018-0295-0; Coco-Martin RM, 2021, CLIN OPHTHALMOL, V15, P1075, DOI 10.2147/OPTH.S293381; Collin RWJ, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.3; Collison FT, 2014, RETINA-J RET VIT DIS, V34, P1888, DOI 10.1097/IAE.0000000000000144; Coppieters F, 2010, HUM MUTAT, V31, pE1709, DOI 10.1002/humu.21336; den Hollander AI, 2006, AM J HUM GENET, V79, P556, DOI 10.1086/507318; Dulla K, 2018, MOL THER-NUCL ACIDS, V12, P730, DOI 10.1016/j.omtn.2018.07.010; Erdogan G, 2016, INT OPHTHALMOL, V36, P527, DOI 10.1007/s10792-015-0156-5; Feldhaus B, 2020, AM J OPHTHALMOL, V211, P142, DOI 10.1016/j.ajo.2019.11.012; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Chacon-Camacho OF, 2015, WORLD J CLIN CASES, V3, P112, DOI 10.12998/wjcc.v3.i2.112; Gerard X, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.21; Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y; Holladay JT, 1997, J REFRACT SURG, V13, P388; Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014; Khadka J, 2010, BRIT J OPHTHALMOL, V94, P730, DOI 10.1136/bjo.2009.171181; Kim J, 2019, NEW ENGL J MED, V381, P1644, DOI 10.1056/NEJMoa1813279; Klein M, 2009, DOC OPHTHALMOL, V119, P217, DOI 10.1007/s10633-009-9204-7; Kuijper EC, 2021, J INHERIT METAB DIS, V44, P72, DOI 10.1002/jimd.12251; Kumaran N, 2017, BRIT J OPHTHALMOL, V101, P1147, DOI 10.1136/bjophthalmol-2016-309975; Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0; McAnany JJ, 2013, JAMA OPHTHALMOL, V131, P178, DOI 10.1001/2013.jamaophthalmol.354; Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504; Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021; Perrault Isabelle, 2007, Hum Mutat, V28, P416, DOI 10.1002/humu.9485; Pruett R C, 1983, Trans Am Ophthalmol Soc, V81, P693; Rachel RA, 2015, HUM MOL GENET, V24, P3775, DOI 10.1093/hmg/ddv123; Roman AJ, 2007, PHYSIOL MEAS, V28, pN51, DOI 10.1088/0967-3334/28/8/N02; Russell SR, 2020, INVEST OPHTH VIS SCI, V61; Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981; Sheck L, 2018, OPHTHALMOLOGY, V125, P894, DOI 10.1016/j.ophtha.2017.12.013; Simonelli F, 2007, INVEST OPHTH VIS SCI, V48, P4284, DOI 10.1167/iovs.07-0068; Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277; SLOAN LL, 1951, AMA ARCH OPHTHALMOL, V45, P704, DOI 10.1001/archopht.1951.01700010719013; Stone EM, 2007, AM J OPHTHALMOL, V144, P791, DOI 10.1016/j.ajo.2007.08.022; Valkenburg D, 2018, INVEST OPHTH VIS SCI, V59, P4384, DOI 10.1167/iovs.18-24817; Witztum JL, 2019, NEW ENGL J MED, V381, P531, DOI 10.1056/NEJMoa1715944; Yu-Wai-Man P, 2020, INVEST OPHTH VIS SCI, V61; Yzer S, 2012, MOL VIS, V18, P412	49	5	5	3	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1014	+		10.1038/s41591-022-01755-w	http://dx.doi.org/10.1038/s41591-022-01755-w		APR 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35379979	hybrid, Green Published			2022-12-27	WOS:000777871200001
J	Khabirova, E; Jardine, L; Coorens, THH; Webb, S; Treger, TD; Engelbert, J; Porter, T; Prigmore, E; Collord, G; Piapi, A; Teichmann, SA; Inglott, S; Williams, O; Heidenreich, O; Young, MD; Straathof, K; Bomken, S; Bartram, J; Haniffa, M; Behjati, S				Khabirova, Eleonora; Jardine, Laura; Coorens, Tim H. H.; Webb, Simone; Treger, Taryn D.; Engelbert, Justin; Porter, Tarryn; Prigmore, Elena; Collord, Grace; Piapi, Alice; Teichmann, Sarah A.; Inglott, Sarah; Williams, Owen; Heidenreich, Olaf; Young, Matthew D.; Straathof, Karin; Bomken, Simon; Bartram, Jack; Haniffa, Muzlifah; Behjati, Sam			Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia	NATURE MEDICINE			English	Article							REARRANGEMENTS; T(4/11)	KMT2A-rearranged infant ALL is an aggressive childhood leukemia with poor prognosis. Here, we investigated the developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia (B-ALL) using bulk messenger RNA (mRNA) meta-analysis and examination of single lymphoblast transcriptomes against a developing bone marrow reference. KMT2A-rearranged infant B-ALL was uniquely dominated by an early lymphocyte precursor (ELP) state, whereas less adverse NUTM1-rearranged infant ALL demonstrated signals of later developing B cells, in line with most other childhood B-ALLs. We compared infant lymphoblasts with ELP cells and revealed that the cancer harbored hybrid myeloid-lymphoid features, including nonphysiological antigen combinations potentially targetable to achieve cancer specificity. We validated surface coexpression of exemplar combinations by flow cytometry. Through analysis of shared mutations in separate leukemias from a child with infant KMT2A-rearranged B-ALL relapsing as AML, we established that KMT2A rearrangement occurred in very early development, before hematopoietic specification, emphasizing that cell of origin cannot be inferred from the transcriptional state.	[Khabirova, Eleonora; Coorens, Tim H. H.; Treger, Taryn D.; Porter, Tarryn; Prigmore, Elena; Collord, Grace; Teichmann, Sarah A.; Young, Matthew D.; Haniffa, Muzlifah; Behjati, Sam] Wellcome Sanger Inst, Hinxton, England; [Jardine, Laura; Webb, Simone; Engelbert, Justin; Haniffa, Muzlifah] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Jardine, Laura] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Haematol Dept, Newcastle Upon Tyne, Tyne & Wear, England; [Treger, Taryn D.; Behjati, Sam] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England; [Treger, Taryn D.; Behjati, Sam] Univ Cambridge, Dept Paediat, Cambridge, England; [Collord, Grace] Univ Coll London Hosp, Dept Haematol, London, England; [Collord, Grace] UCL, Dept Haematol, Canc Inst, London, England; [Piapi, Alice; Inglott, Sarah; Straathof, Karin; Bartram, Jack] Great Ormond St Hosp Children NHS Fdn Trust, London, England; [Piapi, Alice; Inglott, Sarah; Straathof, Karin; Bartram, Jack] NIHR Great Ormond St Hosp Biomed Res Ctr, London, England; [Williams, Owen; Straathof, Karin; Bartram, Jack] UCL Great Ormond St Inst Child Hlth, London, England; [Heidenreich, Olaf] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Heidenreich, Olaf; Bomken, Simon] Newcastle Univ, Wolfson Childhood Canc Res Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Bomken, Simon] Newcastle Upon Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Haniffa, Muzlifah] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England; [Haniffa, Muzlifah] Newcastle Upon Tyne Hosp NHS Fdn Trust, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England	Wellcome Trust Sanger Institute; Newcastle University - UK; Newcastle Freeman Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Haniffa, M; Behjati, S (corresponding author), Wellcome Sanger Inst, Hinxton, England.; Haniffa, M (corresponding author), Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.; Behjati, S (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.; Behjati, S (corresponding author), Univ Cambridge, Dept Paediat, Cambridge, England.; Bartram, J (corresponding author), Great Ormond St Hosp Children NHS Fdn Trust, London, England.; Bartram, J (corresponding author), NIHR Great Ormond St Hosp Biomed Res Ctr, London, England.; Bartram, J (corresponding author), UCL Great Ormond St Inst Child Hlth, London, England.; Bomken, S (corresponding author), Newcastle Univ, Wolfson Childhood Canc Res Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.; Bomken, S (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England.; Haniffa, M (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England.; Haniffa, M (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.	s.n.bomken@newcastle.ac.uk; Jack.Bartram@gosh.nhs.uk; m.a.haniffa@newcastle.ac.uk; sb31@sanger.ac.uk		Khabirova, Eleonora/0000-0002-5891-6789; williams, owen/0000-0002-1760-6880; Engelbert, Justin/0000-0002-4255-9668; Piapi, Alice/0000-0001-8251-3309; Webb, Simone/0000-0003-3058-8952; Coorens, Tim/0000-0002-5826-3554; Haniffa, Muzlifah/0000-0002-3927-2084	Wellcome Trust [WT206194, WT110104/Z/15/Z, WT107931/Z/15/Z]; Lister Institute of Preventative Medicine; Newcastle National Institute for Health Research-Biomedical Research Centre; National Institute for Health Research; CRUK [C27943/A12788]; Kay Kendall Leukaemia Fund [KKL1142]; Children with Cancer UK [14-169, 17-249]; National Institute for Health Research-Great Ormond Street Hospital Biomedical Research Centre; Medical Research Council [MR/S021590/1]; Kika program [329]	Wellcome Trust(Wellcome Trust); Lister Institute of Preventative Medicine; Newcastle National Institute for Health Research-Biomedical Research Centre; National Institute for Health Research(National Institute for Health Research (NIHR)); CRUK(Cancer Research UK); Kay Kendall Leukaemia Fund; Children with Cancer UK; National Institute for Health Research-Great Ormond Street Hospital Biomedical Research Centre; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Kika program	We thank I. Roberts and A. Roy, both from the University of Oxford, and A. Maartens (science writer at the Wellcome Sanger Institute) for critical review of the manuscript. We thank A. Filby and his team at the Flow Cytometry Core Facility, Newcastle University, for their advice and support. Samples were contributed by the SIHMDS at Great Ormond Street Hospital and by the Newcastle Biobank http://www.ncl.ac.uk/biobanks/.We are indebted to patients and their families for participating in our research. This study was funded by Wellcome Trust grants WT206194 (Wellcome Sanger Institute), WT110104/Z/15/Z (S. Behjati) and WT107931/Z/15/Z (M.H.); the Lister Institute of Preventative Medicine (M.H.); the Newcastle National Institute for Health Research-Biomedical Research Centre (M.H. and L.J.); the National Institute for Health Research Academic Clinical Lectureship (L.J.); Medical Research Council clinician scientist fellowship MR/S021590/1 (S. Bomken); CRUK program grant C27943/A12788 (O.H.); the Kay Kendall Leukaemia Fund (KKL1142) (O.H.); Kika program grant 329 (O.H.); Children with Cancer UK grant 14-169,17-249; and the National Institute for Health Research-Great Ormond Street Hospital Biomedical Research Centre (O.W.).	Agraz-Doblas A, 2019, HAEMATOLOGICA, V104, P1176, DOI 10.3324/haematol.2018.206375; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Bassan R, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-00383-2; Behjati S, 2014, NATURE, V513, P422, DOI 10.1038/nature13448; Boer JM, 2021, LEUKEMIA, V35, P2978, DOI 10.1038/s41375-021-01333-y; Bomken S, 2013, LEUKEMIA, V27, P718, DOI 10.1038/leu.2012.206; Buels R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0924-1; Bullerwell CE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81000-5; Coorens THH, 2021, BLOOD, V137, P2992, DOI 10.1182/blood.2020010150; Coorens THH, 2021, NATURE, V592, P80, DOI 10.1038/s41586-021-03345-1; Coorens THH, 2020, NEW ENGL J MED, V383, P1860, DOI 10.1056/NEJMoa2000962; Coorens THH, 2019, SCIENCE, V366, P1247, DOI 10.1126/science.aax1323; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gardner R, 2016, BLOOD, V127, P2406, DOI 10.1182/blood-2015-08-665547; Gori K., SIGFIT FLEXIBLE BAYE, DOI [10.1101/372896 (2020, DOI 10.1101/372896(2020]; Goulden N., 2013, UK NATL RANDOMISED T; Gu ZH, 2019, NAT GENET, V51, P296, DOI 10.1038/s41588-018-0315-5; Gu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13331; Heaton H, 2020, NAT METHODS, V17, P615, DOI 10.1038/s41592-020-0820-1; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Hussen KA, 2017, IMMUNITY, V47, P680, DOI 10.1016/j.immuni.2017.09.009; Jardine L, 2021, NATURE, V598, P327, DOI 10.1038/s41586-021-03929-x; Jones David, 2016, Curr Protoc Bioinformatics, V56, DOI 10.1002/cpbi.20; Kerry J, 2017, CELL REP, V18, P482, DOI 10.1016/j.celrep.2016.12.054; Kildisiute G, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd3311; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Menendez P, 2009, J EXP MED, V206, P3131, DOI 10.1084/jem.20091050; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Muthuirulan P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24345-9; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Nix MA, 2021, CANCER DISCOV, V11, P2032, DOI 10.1158/2159-8290.CD-20-0242; O'Byrne S, 2019, BLOOD, V134, P1059, DOI 10.1182/blood.2019001289; Park S, 2021, NATURE, V597, P393, DOI 10.1038/s41586-021-03786-8; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Peham M, 2002, BRIT J HAEMATOL, V117, P315, DOI 10.1046/j.1365-2141.2002.03428.x; Pellin D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10291-0; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pieters R, 2019, J CLIN ONCOL, V37, P2246, DOI 10.1200/JCO.19.00261; Pincez T, 2020, GENE CHROMOSOME CANC, V59, P125, DOI 10.1002/gcc.22808; Popescu DM, 2019, NATURE, V574, P365, DOI 10.1038/s41586-019-1652-y; Ramakers-van Woerden NL, 2004, LEUKEMIA, V18, P521, DOI 10.1038/sj.leu.2403253; Sison EAR, 2013, HEMATOL-AM SOC HEMAT, P601, DOI 10.1182/asheducation-2013.1.601; Chapman MS, 2021, NATURE, V595, P85, DOI 10.1038/s41586-021-03548-6; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Ye K, 2018, METHODS MOL BIOL, V1833, P95, DOI 10.1007/978-1-4939-8666-8_7; Young MD, 2018, SCIENCE, V361, P594, DOI 10.1126/science.aat1699; ZHENG GX, 2017, NATURE, V0008	52	3	3	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					743	+		10.1038/s41591-022-01720-7	http://dx.doi.org/10.1038/s41591-022-01720-7		MAR 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35288693	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000770060900007
J	Heijtz, RD; Gressens, P; Swann, JR				Heijtz, Rochellys Diaz; Gressens, Pierre; Swann, Jonathan R.			Targeting microbial metabolites to treat autism	NATURE MEDICINE			English	Editorial Material								A first-in-class therapeutic that targets neuroactive microbial metabolites in the gut shows promising target engagement, safety and behavioral improvements in adolescents with autism spectrum disorder.	[Heijtz, Rochellys Diaz; Gressens, Pierre; Swann, Jonathan R.] Karolinska Inst, Dept Neurosci, Biomed, Stockholm, Sweden; [Heijtz, Rochellys Diaz] Univ Rouen Normandy, INSERM U1239, Rouen, France; [Gressens, Pierre] Univ Paris, INSERM, NeuroDiderot, Paris, France; [Swann, Jonathan R.] Univ Southampton, Fac Med, Sch Human Dev & Hlth, Southampton, Hants, England	Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southampton	Heijtz, RD (corresponding author), Karolinska Inst, Dept Neurosci, Biomed, Stockholm, Sweden.; Heijtz, RD (corresponding author), Univ Rouen Normandy, INSERM U1239, Rouen, France.	rochellys.heijtz@ki.se		/0000-0002-0909-4221; Swann, Jonathan/0000-0002-6485-4529	Swedish Research Council; Swedish Brain Foundation; Frimurare Barnhus Foundation; European Union [859890]; Inserm; Universite de Paris; Horizon 2020 Framework Program of the European Union [874721/PREMSTEM]; ANR; Fondation Grace de Monaco; Fondation des Gueules Cassees; Investissement d'Avenir [ANR-11-INBS-0011]; National Institute for Health Research Southampton Biomedical Research Centre; Biotechnology and Biological Sciences Research Council [BB/W00139X/1]; Medical Research Council [MR/W003597/1]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Brain Foundation; Frimurare Barnhus Foundation; European Union(European Commission); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Paris; Horizon 2020 Framework Program of the European Union; ANR(French National Research Agency (ANR)); Fondation Grace de Monaco; Fondation des Gueules Cassees; Investissement d'Avenir(French National Research Agency (ANR)); National Institute for Health Research Southampton Biomedical Research Centre; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	R.D.H. is supported by the Swedish Research Council, the Swedish Brain Foundation, the Frimurare Barnhus Foundation and the European Union (ITN SmartAge, grant agreement number 859890). P.G. is supported by Inserm, the Universite de Paris, the Horizon 2020 Framework Program of the European Union (grant agreement no. 874721/PREMSTEM), the ANR, the Fondation Grace de Monaco, the Fondation des Gueules Cassees and an additional grant from "Investissement d'Avenir-ANR-11-INBS-0011"-NeurATRIS. J.R.S. is supported by the National Institute for Health Research Southampton Biomedical Research Centre, Biotechnology and Biological Sciences Research Council (BB/W00139X/1) and Medical Research Council (MR/W003597/1).	Campbell AS, 2022, NAT MED, V28, P528, DOI 10.1038/s41591-022-01683-9; Cryan JF, 2019, PHYSIOL REV, V99, P1877, DOI 10.1152/physrev.00018.2018; Hoban AE, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.42; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Kujawa Autumn, 2016, Biol Psychiatry Cogn Neurosci Neuroimaging, V1, P345; Muller RA, 2018, TRENDS COGN SCI, V22, P1103, DOI 10.1016/j.tics.2018.09.008; Needham BD, 2022, NATURE, V602, P647, DOI 10.1038/s41586-022-04396-8; Needham BD, 2021, BIOL PSYCHIAT, V89, P451, DOI 10.1016/j.biopsych.2020.09.025; Phan BN, 2020, NAT NEUROSCI, V23, P375, DOI 10.1038/s41593-019-0578-x; Swann JR, 2020, METABOLITES, V10, DOI 10.3390/metabo10050172; Tan QM, 2021, AUTISM RES, V14, P1820, DOI 10.1002/aur.2560; Yap CX, 2021, CELL, V184, P5916, DOI 10.1016/j.cell.2021.10.015; Zheng YP, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.738220	13	0	0	4	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					448	450		10.1038/s41591-022-01711-8	http://dx.doi.org/10.1038/s41591-022-01711-8		FEB 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35165452	Green Accepted			2022-12-27	WOS:000754955000001
J	Bulten, W; Kartasalo, K; Chen, PHC; Strom, P; Pinckaers, H; Nagpal, K; Cai, YN; Steiner, DF; van Boven, H; Vink, R; Hulsbergen-van de Kaa, C; van der Laak, J; Amin, MB; Evans, AJ; van der Kwast, T; Allan, R; Humphrey, PA; Gronberg, H; Samaratunga, H; Delahunt, B; Tsuzuki, T; Hakkinen, T; Egevad, L; Demkin, M; Dane, S; Tan, F; Valkonen, M; Corrado, GS; Peng, L; Mermel, CH; Ruusuvuori, P; Litjens, G; Eklund, M				Bulten, Wouter; Kartasalo, Kimmo; Chen, Po-Hsuan Cameron; Strom, Peter; Pinckaers, Hans; Nagpal, Kunal; Cai, Yuannan; Steiner, David F.; van Boven, Hester; Vink, Robert; Hulsbergen-van de Kaa, Christina; van der Laak, Jeroen; Amin, Mahul B.; Evans, Andrew J.; van der Kwast, Theodorus; Allan, Robert; Humphrey, Peter A.; Gronberg, Henrik; Samaratunga, Hemamali; Delahunt, Brett; Tsuzuki, Toyonori; Hakkinen, Tomi; Egevad, Lars; Demkin, Maggie; Dane, Sohier; Tan, Fraser; Valkonen, Masi; Corrado, Greg S.; Peng, Lily; Mermel, Craig H.; Ruusuvuori, Pekka; Litjens, Geert; Eklund, Martin		PANDA Challenge Consortium	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge	NATURE MEDICINE			English	Article							ISUP CONSENSUS CONFERENCE; INTERNATIONAL SOCIETY; INTEROBSERVER; REPRODUCIBILITY; CARCINOMA; BIOPSIES	Through a community-driven competition, the PANDA challenge provides a curated diverse dataset and a catalog of models for prostate cancer pathology, and represents a blueprint for evaluating AI algorithms in digital pathology. Artificial intelligence (AI) has shown promise for diagnosing prostate cancer in biopsies. However, results have been limited to individual studies, lacking validation in multinational settings. Competitions have been shown to be accelerators for medical imaging innovations, but their impact is hindered by lack of reproducibility and independent validation. With this in mind, we organized the PANDA challenge-the largest histopathology competition to date, joined by 1,290 developers-to catalyze development of reproducible AI algorithms for Gleason grading using 10,616 digitized prostate biopsies. We validated that a diverse set of submitted algorithms reached pathologist-level performance on independent cross-continental cohorts, fully blinded to the algorithm developers. On United States and European external validation sets, the algorithms achieved agreements of 0.862 (quadratically weighted kappa, 95% confidence interval (CI), 0.840-0.884) and 0.868 (95% CI, 0.835-0.900) with expert uropathologists. Successful generalization across different patient populations, laboratories and reference standards, achieved by a variety of algorithmic approaches, warrants evaluating AI-based Gleason grading in prospective clinical trials.	[Bulten, Wouter; Pinckaers, Hans; van der Laak, Jeroen; Litjens, Geert] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Dept Pathol, Nijmegen, Netherlands; [Kartasalo, Kimmo; Strom, Peter; Gronberg, Henrik; Eklund, Martin] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Kartasalo, Kimmo; Hakkinen, Tomi; Ruusuvuori, Pekka] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Chen, Po-Hsuan Cameron; Nagpal, Kunal; Cai, Yuannan; Steiner, David F.; Tan, Fraser; Corrado, Greg S.; Peng, Lily; Mermel, Craig H.] Google Hlth, Palo Alto, CA 94304 USA; [van Boven, Hester] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands; [Vink, Robert; Hulsbergen-van de Kaa, Christina; Eklund, Martin] Lab Pathol East Netherlands, Hengelo, Netherlands; [van der Laak, Jeroen] Linkoping Univ, Ctr Med Image Sci & Visualizat, Linkoping, Sweden; [Amin, Mahul B.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN USA; [Evans, Andrew J.] Mackenzie Hlth, Lab Med, Toronto, ON, Canada; [van der Kwast, Theodorus] Univ Hlth Network, Dept Pathol Lab Med & Pathol, Toronto, ON, Canada; [van der Kwast, Theodorus] Univ Toronto, Toronto, ON, Canada; [Allan, Robert] Univ Florida, Dept Pathol Immunol & Lab Med, North Florida South Georgia Vet Hlth Syst, Pathol & Lab Med Serv, Gainesville, FL USA; [Humphrey, Peter A.] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Gronberg, Henrik] Capio St Gorans Hosp, Dept Surg, Stockholm, Sweden; [Samaratunga, Hemamali] Aquesta Uropathol, Brisbane, Qld, Australia; [Samaratunga, Hemamali] Univ Queensland, Brisbane, Qld, Australia; [Delahunt, Brett] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Pathol & Mol Med, Wellington, New Zealand; [Tsuzuki, Toyonori] Aichi Med Univ, Sch Med, Dept Surg Pathol, Nagakute, Aichi, Japan; [Egevad, Lars] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Demkin, Maggie; Dane, Sohier] Kaggle Inc, Mountain View, CA USA; [Valkonen, Masi; Ruusuvuori, Pekka] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland; [Valkonen, Masi; Ruusuvuori, Pekka] Univ Turku, FICAN West Canc Ctr, Turku, Finland; [Valkonen, Masi; Ruusuvuori, Pekka] Turku Univ Hosp, Turku, Finland	Radboud University Nijmegen; Karolinska Institutet; Tampere University; Netherlands Cancer Institute; Linkoping University; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; State University System of Florida; University of Florida; Yale University; Saint Goran's Hospital; University of Queensland; University of Otago; Aichi Medical University; Karolinska Institutet; University of Turku; University of Turku; University of Turku	Bulten, W (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Dept Pathol, Nijmegen, Netherlands.; Kartasalo, K (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.; Kartasalo, K (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.; Chen, PHC (corresponding author), Google Hlth, Palo Alto, CA 94304 USA.	wouter@wouterbulten.com; kimmo.kartasalo@ki.se; cameronchen@google.com	Bulten, Wouter/E-8746-2017; Yoshioka, Kentaro/AAS-7495-2020; Tsuzuki, Toyonori/GRJ-7409-2022; Litjens, Geert JS/A-2319-2016; van der Laak, Jeroen/D-3057-2015	Bulten, Wouter/0000-0002-6129-5039; Yoshioka, Kentaro/0000-0001-5640-2250; Tsuzuki, Toyonori/0000-0002-4855-4366; Litjens, Geert JS/0000-0003-1554-1291; Grechka, Dmitry/0000-0003-4038-0434; Farre, Xavier/0000-0001-8702-4643; van der Laak, Jeroen/0000-0001-7982-0754; Yoshihara, Hiroshi/0000-0001-5297-3822; Ruusuvuori, Pekka/0000-0001-9086-9591; Chen, Po-Hsuan Cameron/0000-0002-0083-4991; Kartasalo, Kimmo/0000-0002-9470-4783	Dutch Cancer Society [KUN 2015-7970]; Netherlands Organization for Scientific Research [016.186.152]; Swedish Research Council [201901466, 2020-00692]; Swedish Cancer Society (CAN) [2018/741]; Swedish eScience Research Center; Ake Wiberg Foundation; Prostatacancerforbundet; Academy of Finland [341967, 335976]; Cancer Foundation Finland; Google LLC; MICCAI board challenge working group; Verily Life Sciences; EIT Health; Karolinska Institutet; MICCAI 2020 satellite event team; ERAPerMed [334782]	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society (CAN)(Swedish Cancer Society); Swedish eScience Research Center; Ake Wiberg Foundation; Prostatacancerforbundet; Academy of Finland(Academy of Finland); Cancer Foundation Finland; Google LLC(Google Incorporated); MICCAI board challenge working group; Verily Life Sciences; EIT Health; Karolinska Institutet(Karolinska Institutet); MICCAI 2020 satellite event team; ERAPerMed	We were supported by the Dutch Cancer Society (grant no. KUN 2015-7970, to W.B., H.P. and G.L.); Netherlands Organization for Scientific Research (grant no. 016.186.152, to G.L.); Google LLC, Verily Life Sciences, Swedish Research Council (grant nos. 201901466 and 2020-00692, to M.E.); Swedish Cancer Society (CAN, grant no. 2018/741, to M.E.); Swedish eScience Research Center, EIT Health, Karolinska Institutet, Ake Wiberg Foundation and Prostatacancerforbundet (all to M.E.); Academy of Finland (grant nos. 341967 and 335976, to P.Ruusuvuori), Cancer Foundation Finland (project `Computational pathology for enhanced cancer grading and patient stratification', to P.Ruusuvuori) and ERAPerMed (grant no. 334782, 2020-22, to P.Ruusuvuori). Google LLC approved the publication of the manuscript, and the remaining funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank the MICCAI board challenge working group, the MICCAI 2020 satellite event team and the MICCAI challenge reviewers for their support in the challenge workshop and review of the challenge design. We thank Kaggle for hosting the competition, providing compute resources and the competition prizes. We thank CSC-IT Center for Science, Finland, for providing computational resources. We thank E. Wulczyn, A. Um'rani, Y. Liu and D. Webster for their feedback on the manuscript and guidance of the project. We thank our collaborators at NMCSD, particularly N. Olson, for internal reuse of de-identified data, which contributed to the US external validation set.	Allsbrook WC, 2001, HUM PATHOL, V32, P74, DOI 10.1053/hupa.2001.21134; [Anonymous], 2018, NATURE, V555, P285, DOI 10.1038/d41586-018-03067-x; Bandi P, 2019, IEEE T MED IMAGING, V38, P550, DOI 10.1109/TMI.2018.2867350; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Bulten W., 2020, ZENODO, DOI [DOI 10.1136/bmjqs-2018-008370, 10.5281/zenodo.3715938, DOI 10.5281/ZENODO.3715938]; Bulten W., 2020, **DATA OBJECT**, DOI 10.5281/zenodo.5592578; Bulten W, 2021, MODERN PATHOL, V34, P660, DOI 10.1038/s41379-020-0640-y; Bulten W, 2020, LANCET ONCOL, V21, P233, DOI 10.1016/S1470-2045(19)30739-9; Caicedo JC, 2019, NAT METHODS, V16, P1247, DOI 10.1038/s41592-019-0612-7; Challen R, 2019, BMJ QUAL SAF, V28, P231, DOI 10.1136/bmjqs-2018-008370; Egevad L, 2013, HISTOPATHOLOGY, V62, P247, DOI 10.1111/his.12008; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Epstein JI, 2010, J UROLOGY, V183, P433, DOI 10.1016/j.juro.2009.10.046; Gianfrancesco MA, 2018, JAMA INTERN MED, V178, P1544, DOI 10.1001/jamainternmed.2018.3763; Goldenberg SL, 2019, NAT REV UROL, V16, P391, DOI 10.1038/s41585-019-0193-3; Han WC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66849-2; Hartman Douglas Joseph, 2020, J Pathol Inform, V11, P7, DOI 10.4103/jpi.jpi_64_19; Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2; Kott O, 2021, EUR UROL FOCUS, V7, P347, DOI 10.1016/j.euf.2019.11.003; Kurtzer GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177459; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005; Maier-Hein L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07619-7; Melia J, 2006, HISTOPATHOLOGY, V48, P644, DOI 10.1111/j.1365-2559.2006.02393.x; Merkel Dirk, 2014, LINUX J, V239, P2, DOI DOI 10.5555/2600239.2600241; Mohler JL, 2019, J NATL COMPR CANC NE, V17, P479, DOI 10.6004/jnccn.2019.0023; Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689; Nagpal K, 2020, JAMA ONCOL, V6, P1372, DOI 10.1001/jamaoncol.2020.2485; Nagpal K, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0112-2; Nir G, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0442; Ozkan TA, 2016, SCAND J UROL, V50, P420, DOI 10.1080/21681805.2016.1206619; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Rajkomar A, 2018, ANN INTERN MED, V169, P866, DOI 10.7326/M18-1990; Steiner DF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.23267; Strom P, 2020, LANCET ONCOL, V21, P222, DOI 10.1016/S1470-2045(19)30738-7; van der Laak J, 2019, NAT BIOMED ENG, V3, P855, DOI 10.1038/s41551-019-0472-6; van Leenders GJLH, 2020, AM J SURG PATHOL, V44, pE87, DOI 10.1097/PAS.0000000000001497; Yasaka K, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002707	39	24	24	11	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					154	+		10.1038/s41591-021-01620-2	http://dx.doi.org/10.1038/s41591-021-01620-2		JAN 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35027755	Green Published, hybrid			2022-12-27	WOS:000742323900003
J	Bernard, MA; Johnson, AC; Hopkins-Laboy, T; Tabak, LA				Bernard, Marie A.; Johnson, Alfred C.; Hopkins-Laboy, Treava; Tabak, Lawrence A.			The US National Institutes of Health approach to inclusive excellence	NATURE MEDICINE			English	Editorial Material							DIVERSITY; RACISM		[Bernard, Marie A.] NIH, Off Chief Officer Sci Workforce Divers, Off Director, Bldg 10, Bethesda, MD 20892 USA; [Johnson, Alfred C.] NIH, Ice Management, Off Director, Bldg 10, Bethesda, MD 20892 USA; [Hopkins-Laboy, Treava] NIH, Off Equ Divers & Inclus, Off Director, Bldg 10, Bethesda, MD 20892 USA; [Tabak, Lawrence A.] NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Bernard, MA (corresponding author), NIH, Off Chief Officer Sci Workforce Divers, Off Director, Bldg 10, Bethesda, MD 20892 USA.	marie.bernard@nih.gov		Tabak, Lawrence/0000-0002-4261-7856	Intramural NIH HHS [Z99 OD999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AlShebli BK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07634-8; Beech BM, 2013, ACAD MED, V88, P541, DOI 10.1097/ACM.0b013e31828589e3; Bennett CL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235190; Campbell AG, 2013, CBE-LIFE SCI EDUC, V12, P394, DOI 10.1187/cbe.13-02-0025; Campbell LG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079147; Collins FS, 2021, CELL, V184, P3075, DOI 10.1016/j.cell.2021.05.014; Freeman RB, 2015, J LABOR ECON, V33, pS289, DOI 10.1086/678973; Gomez LE, 2019, J NATL MED ASSOC, V111, P383, DOI 10.1016/j.jnma.2019.01.006; Herring C, 2009, AM SOCIOL REV, V74, P208, DOI 10.1177/000312240907400203; Hoppe TA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7238; Hrabowski FA, 2020, P NATL ACAD SCI USA, V117, P18137, DOI 10.1073/pnas.2013588117; Kalev A, 2006, AM SOCIOL REV, V71, P589, DOI 10.1177/000312240607100404; Lauer MS, 2021, ELIFE, V10, DOI 10.7554/eLife.67173; Smith-Doerr L, 2017, ENGAG SCI TECHNOL SO, V3, P139, DOI 10.17351/ests2017.142; Wingfield AH, 2020, SCIENCE, V369, P351, DOI 10.1126/science.abd8825	15	7	7	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1861	1864		10.1038/s41591-021-01532-1	http://dx.doi.org/10.1038/s41591-021-01532-1		NOV 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764481	Green Accepted			2022-12-27	WOS:000717406200002
J	Li, Q; Hagberg, CE; Cascales, HS; Lang, S; Hyvonen, MT; Salehzadeh, F; Chen, P; Alexandersson, I; Terezaki, E; Harms, MJ; Kutschke, M; Arifen, N; Kramer, N; Aouadi, M; Knibbe, C; Boucher, J; Thorell, A; Spalding, KL				Li, Qian; Hagberg, Carolina E.; Silva Cascales, Helena; Lang, Shuai; Hyvonen, Mervi T.; Salehzadeh, Firoozeh; Chen, Ping; Alexandersson, Ida; Terezaki, Eleni; Harms, Matthew J.; Kutschke, Maria; Arifen, Nahida; Kramer, Niels; Aouadi, Myriam; Knibbe, Carole; Boucher, Jeremie; Thorell, Anders; Spalding, Kirsty L.			Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce	NATURE MEDICINE			English	Article							ADIPOSE-TISSUE; DNA-DAMAGE; SECRETORY PHENOTYPE; OXIDATIVE STRESS; HISTONE H3; ENDOREPLICATION; PHOSPHORYLATION; PROGRESSION; INHIBITION; POLYPLOIDY	Obesity is considered an important factor for many chronic diseases, including diabetes, cardiovascular disease and cancer. The expansion of adipose tissue in obesity is due to an increase in both adipocyte progenitor differentiation and mature adipocyte cell size. Adipocytes, however, are thought to be unable to divide or enter the cell cycle. We demonstrate that mature human adipocytes unexpectedly display a gene and protein signature indicative of an active cell cycle program. Adipocyte cell cycle progression associates with obesity and hyperinsulinemia, with a concomitant increase in cell size, nuclear size and nuclear DNA content. Chronic hyperinsulinemia in vitro or in humans, however, is associated with subsequent cell cycle exit, leading to a premature senescent transcriptomic and secretory profile in adipocytes. Premature senescence is rapidly becoming recognized as an important mediator of stress-induced tissue dysfunction. By demonstrating that adipocytes can activate a cell cycle program, we define a mechanism whereby mature human adipocytes senesce. We further show that by targeting the adipocyte cell cycle program using metformin, it is possible to influence adipocyte senescence and obesity-associated adipose tissue inflammation. Studies in mature human adipocytes demonstrate that obesity and hyperinsulinemia can induce reentry into the cell cycle and induce senescence.	[Li, Qian; Lang, Shuai; Hyvonen, Mervi T.; Kramer, Niels; Spalding, Kirsty L.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Hagberg, Carolina E.; Silva Cascales, Helena; Salehzadeh, Firoozeh; Chen, Ping; Terezaki, Eleni; Kutschke, Maria; Arifen, Nahida; Aouadi, Myriam; Spalding, Kirsty L.] Karolinska Inst, Dept Med Huddinge, AstraZeneca Integrated Cardio Metab Ctr KI AZ ICM, Stockholm, Sweden; [Hagberg, Carolina E.] Dept Med, Cardiovasc Med Div, Solna, Sweden; [Hagberg, Carolina E.] Karolinska Inst, Stockholm, Sweden; [Hyvonen, Mervi T.] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Chen, Ping; Aouadi, Myriam] Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden; [Alexandersson, Ida; Harms, Matthew J.; Boucher, Jeremie] AstraZeneca, BioPharmaceut R&D, Biosci Metab Res & Early Dev, Cardiovasc Renal & Metab CVRM, Gothenburg, Sweden; [Kutschke, Maria] Stockholm Univ, Wenner Gren Inst, Dept Mol Biosci, Stockholm, Sweden; [Knibbe, Carole] Lyon Univ, INRIA, INSA Lyon, CarMeN Lab, Lyon, France; [Boucher, Jeremie] Univ Gothenburg, Lundberg Lab Diabet Res, Gothenburg, Sweden; [Boucher, Jeremie] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden; [Thorell, Anders] Karolinska Inst, Danderyds Hosp, Dept Clin Sci, Stockholm, Sweden; [Thorell, Anders] Karolinska Inst, Ersta Hosp, Dept Surg, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Eastern Finland; Karolinska Institutet; AstraZeneca; Stockholm University; Inria; Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Gothenburg; University of Gothenburg; Danderyds Hospital; Karolinska Institutet; Ersta Sjukhus; Karolinska Institutet	Spalding, KL (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.; Spalding, KL (corresponding author), Karolinska Inst, Dept Med Huddinge, AstraZeneca Integrated Cardio Metab Ctr KI AZ ICM, Stockholm, Sweden.	kirsty.spalding@ki.se	Chen, Ping/AAL-8264-2020; Spalding, Kirsty/CAF-4248-2022; Carmen, Team1/Y-7382-2019; Knibbe, Carole/AAE-3273-2022	Chen, Ping/0000-0002-8068-1891; Spalding, Kirsty/0000-0002-5189-7028; Carmen, Team1/0000-0003-4234-1746; Knibbe, Carole/0000-0002-2026-2580; Alexandersson, Ida/0000-0003-3038-3893; Li, Qian/0000-0002-9895-1415; Lab, Carmen/0000-0002-5935-3236; Hyvonen, Mervi/0000-0001-5517-7442; Terezaki, Eleni/0000-0001-5836-0672; Kramer, Niels/0000-0001-5937-9893; Hagberg, Carolina/0000-0002-5497-2855	Swedish Research Council [542-2013-8358, 350-2012-6538]; Strategic Research Program for Diabetes at Karolinska Institutet [C5471152]; Novo Nordisk Foundation [NNF12OC1016064]; Karolinska Institutet/AstraZeneca Integrated Cardiometabolic Centre [H725701603]; Erling-Persson Family Foundation [140604]; Swedish Foundation for Strategic Research; Vallee Foundation Vallee Scholar Award [C5471234]; Swedish Society for Medical Research [P13-0057]; Wilhelm och Else Stockmanns Stiftelse	Swedish Research Council(Swedish Research CouncilEuropean Commission); Strategic Research Program for Diabetes at Karolinska Institutet; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Karolinska Institutet/AstraZeneca Integrated Cardiometabolic Centre; Erling-Persson Family Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Vallee Foundation Vallee Scholar Award; Swedish Society for Medical Research; Wilhelm och Else Stockmanns Stiftelse	We acknowledge the assistance of research nurses A. Bratt and A. -S. Andersson (Ersta Hospital) and laboratory technicians L. Appelsved and A. Olsson. This study was supported by grants from the Swedish Research Council (no. 542-2013-8358 to K.S., no. 350-2012-6538 to C.E.H.), the Strategic Research Program for Diabetes at Karolinska Institutet (no. C5471152 to K.S.), the Novo Nordisk Foundation (Excellence Project Award no. NNF12OC1016064 to K.S.), the Karolinska Institutet/AstraZeneca Integrated Cardiometabolic Centre (no. H725701603 to K.S.), the Erling-Persson Family Foundation (no. 140604 to A.T.), the Swedish Foundation for Strategic Research (I.A.) and the Vallee Foundation Vallee Scholar Award (no. C5471234 to K.S.). C.E.H. was supported by the Swedish Society for Medical Research (no. P13-0057) and Wilhelm och Else Stockmanns Stiftelse.	Aguayo-Mazzucato C, 2019, CELL METAB, V30, P129, DOI 10.1016/j.cmet.2019.05.006; Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-12; Arner P, 2019, NAT MED, V25, P1385, DOI 10.1038/s41591-019-0565-5; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Bian XH, 2019, BMJ OPEN DIAB RES CA, V7, DOI 10.1136/bmjdrc-2019-000720; Biran A, 2017, AGING CELL, V16, P661, DOI 10.1111/acel.12592; Blagosklonny MV, 2018, CELL CYCLE, V17, P2655, DOI 10.1080/15384101.2018.1554781; Burton DGA, 2018, BIOGERONTOLOGY, V19, P447, DOI 10.1007/s10522-018-9763-7; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Celton-Morizur S, 2009, J CLIN INVEST, V119, P1880, DOI 10.1172/JCI38677; Chen YW, 2015, P NATL ACAD SCI USA, V112, pE4556, DOI 10.1073/pnas.1506954112; Chow HM, 2019, NAT NEUROSCI, V22, P1806, DOI 10.1038/s41593-019-0505-1; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Deng YF, 2010, ANN NY ACAD SCI, V1212, pE1, DOI 10.1111/j.1749-6632.2010.05875.x; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Edgar BA, 2014, NAT REV MOL CELL BIO, V15, P197, DOI 10.1038/nrm3756; Feringa FM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06308-9; Ferrari SLP, 2004, J APPL STAT, V31, P799, DOI 10.1080/0266476042000214501; Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531; Fung A, 2016, J INSULIN RESIST, V1, pA18, DOI [DOI 10.4102/JIR.V1I1.18, 10.4102/jir.v1i1.18]; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; Gandarillas A, 2018, CELL DEATH DIFFER, V25, P471, DOI 10.1038/s41418-017-0040-0; Gentric G, 2014, AM J PATHOL, V184, P322, DOI 10.1016/j.ajpath.2013.06.035; Gillooly JF, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019091; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Greten TF, 2017, HEPAT ONCOL, V4, P123, DOI 10.2217/hep-2017-0011; Grosse Laurent, 2020, Cell Metab, V32, P87, DOI 10.1016/j.cmet.2020.05.002; Gustafson B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10688-x; Hagberg CE, 2018, CELL REP, V24, P2746, DOI 10.1016/j.celrep.2018.08.006; Hammarstedt A, 2018, PHYSIOL REV, V98, P1911, DOI 10.1152/physrev.00034.2017; Harms MJ, 2019, CELL REP, V27, P213, DOI 10.1016/j.celrep.2019.03.026; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Hesse M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2089; Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069; Hoffstedt J, 2010, DIABETOLOGIA, V53, P2496, DOI 10.1007/s00125-010-1889-3; Hydbring P, 2016, NAT REV MOL CELL BIO, V17, P280, DOI 10.1038/nrm.2016.27; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Kim DE, 2019, METHODS MOL BIOL, V1896, P71, DOI 10.1007/978-1-4939-8931-7_8; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lagarrigue S, 2016, J CLIN INVEST, V126, P335, DOI 10.1172/JCI81480; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Levine EM, 2004, DEVELOPMENT, V131, P2241, DOI 10.1242/dev.01180; Li DW, 2005, CELL RES, V15, P120, DOI 10.1038/sj.cr.7290276; Liu ZH, 2018, DIABETES, V67, P2397, DOI 10.2337/db18-0684; Matsui-Hirai H, 2011, J PHARMACOL EXP THER, V337, P591, DOI 10.1124/jpet.110.177584; McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092; Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014; Monickaraj F, 2013, J BIOSCIENCES, V38, P113, DOI 10.1007/s12038-012-9289-0; Morgan D. O., 2007, CELL CYCLE PRINCIPLE; Murdolo G, 2013, BIOCHIMIE, V95, P585, DOI 10.1016/j.biochi.2012.12.014; Neurohr GE, 2019, CELL, V176, P1083, DOI 10.1016/j.cell.2019.01.018; Nevzorova YA, 2009, GASTROENTEROLOGY, V137, P691, DOI 10.1053/j.gastro.2009.05.003; Orr-Weaver TL, 2015, TRENDS GENET, V31, P307, DOI 10.1016/j.tig.2015.03.011; Ospina R, 2010, STAT PAP, V51, P111, DOI 10.1007/s00362-008-0125-4; Palmer AK, 2019, AGING CELL, V18, DOI 10.1111/acel.12950; Ramskold D, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000598; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Ruscetti M, 2018, SCIENCE, V362, P1416, DOI 10.1126/science.aas9090; Ryden M, 2017, J INTERN MED, V282, P220, DOI 10.1111/joim.12641; Ryden M, 2015, CELL METAB, V22, P408, DOI 10.1016/j.cmet.2015.06.011; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Sher N, 2013, P NATL ACAD SCI USA, V110, P9368, DOI 10.1073/pnas.1304889110; Shimizu I, 2014, CELL METAB, V20, P967, DOI 10.1016/j.cmet.2014.10.008; Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006-1055; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Tchkonia T, 2010, AGING CELL, V9, P667, DOI 10.1111/j.1474-9726.2010.00608.x; te Poele RH, 2002, CANCER RES, V62, P1876; Terzi MY, 2016, MOL BIOL REP, V43, P1213, DOI 10.1007/s11033-016-4065-0; Tu WZ, 2013, FEBS LETT, V587, P3437, DOI 10.1016/j.febslet.2013.08.028; van der Meijden CMJ, 2002, CANCER RES, V62, P3233; van Harmelen V, 2003, INT J OBESITY, V27, P889, DOI 10.1038/sj.ijo.0802314; Vergoni B, 2016, DIABETES, V65, P3062, DOI 10.2337/db16-0014; Wang MJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.167; Xu MQ, 2015, ECS ELECTROCHEM LETT, V4, DOI 10.1149/2.0021508eel; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112	82	22	22	8	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1941	+		10.1038/s41591-021-01501-8	http://dx.doi.org/10.1038/s41591-021-01501-8		OCT 2021	33	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34608330				2022-12-27	WOS:000703378900006
J	Cohen, NM; Schwartzman, O; Jaschek, R; Lifshitz, A; Hoichman, M; Balicer, R; Shlush, LI; Barbash, G; Tanay, A				Cohen, Netta Mendelson; Schwartzman, Omer; Jaschek, Ram; Lifshitz, Aviezer; Hoichman, Michael; Balicer, Ran; Shlush, Liran, I; Barbash, Gabi; Tanay, Amos			Personalized lab test models to quantify disease potentials in healthy individuals	NATURE MEDICINE			English	Article							GERIATRIC AGES ESTABLISHMENT; ADULT REFERENCE INTERVALS; CELL DISTRIBUTION WIDTH; AMINOTRANSFERASE ACTIVITY; BIG DATA; MORTALITY; TRAJECTORIES; POPULATION; HEMOGLOBIN; PREVALENCE	A new approach based on machine-learning integration of 2.1 billion lab measurements of 92 different lab tests from 2.8 million adults, over a span of 18 years, produces models that can stratify one's risk of having a future abnormal lab test level and subsequent emerging disease. Standardized lab tests are central for patient evaluation, differential diagnosis and treatment. Interpretation of these data is nevertheless lacking quantitative and personalized metrics. Here we report on the modeling of 2.1 billion lab measurements of 92 different lab tests from 2.8 million adults over a span of 18 years. Following unsupervised filtering of 131 chronic conditions and 5,223 drug-test pairs we performed a virtual survey of lab tests distributions in healthy individuals. Age and sex alone explain less than 10% of the within-normal test variance in 89 out of 92 tests. Personalized models based on patients' history explain 60% of the variance for 17 tests and over 36% for half of the tests. This allows for systematic stratification of the risk for future abnormal test levels and subsequent emerging disease. Multivariate modeling of within-normal lab tests can be readily implemented as a basis for quantitative patient evaluation.	[Cohen, Netta Mendelson; Schwartzman, Omer; Jaschek, Ram; Lifshitz, Aviezer; Hoichman, Michael; Tanay, Amos] Weizmann Inst Sci, Dept Math & Comp Sci, Rehovot, Israel; [Schwartzman, Omer] Tel Aviv Sourasky Med Ctr, Div Internal Med, Tel Aviv, Israel; [Balicer, Ran] Clalit Hlth Serv, Clalit Res Inst, Innovat Div, Tel Aviv, Israel; [Shlush, Liran, I] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel; [Barbash, Gabi] Weizmann Inst Sci, Bench Bedside Program, Rehovot, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Clalit Health Services; Weizmann Institute of Science; Weizmann Institute of Science	Tanay, A (corresponding author), Weizmann Inst Sci, Dept Math & Comp Sci, Rehovot, Israel.	amos.tanay@weizmann.ac.il		Schwartzman, Omer/0000-0002-4122-8111; Lifshitz, Aviezer/0000-0002-8458-9507; Mendelson Cohen, Netta/0000-0002-0512-6847	D. Dan and Betty Kahn Foundation, Israel precision medicine program; European Research Council	D. Dan and Betty Kahn Foundation, Israel precision medicine program; European Research Council(European Research Council (ERC)European Commission)	We thank the Division of Information Systems and Digital at Clalit and the Clalit Research Institute for help with data transition and de-identification within the Clalit-Weizmann Initiative. We thank members of the Tanay group for discussions. Research was supported in part by the D. Dan and Betty Kahn Foundation, Israel precision medicine program and the European Research Council.	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Adeli K, 2015, CLIN CHEM, V61, P1049, DOI 10.1373/clinchem.2015.240515; Adeli K, 2015, CLIN CHEM, V61, P1075, DOI 10.1373/clinchem.2015.240531; American Board of Internal Medicine, 2021, ABIM LAB TEST REF RA; Avati A, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0677-8; Balicer RD, 2017, LANCET, V389, P2451, DOI 10.1016/S0140-6736(17)30876-0; Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Cheng Calvino Ka-Wing, 2004, Lab Hematol, V10, P42, DOI 10.1532/LH96.04010; den Bossche, 2002, CLIN CHEM LAB MED, DOI 10.1515/CCLM.2002.014; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; EDDY DM, 1982, NEW ENGL J MED, V306, P1263, DOI 10.1056/NEJM198205273062104; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; Ge T, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006711; Gebregziabher M, 2010, AM J EPIDEMIOL, V171, P1090, DOI 10.1093/aje/kwq070; Goldshtein I, 2010, EUR J CANCER PREV, V19, P342, DOI 10.1097/CEJ.0b013e32833c1be0; HARRIS EK, 1974, CLIN CHEM, V20, P1535; Heianza Y, 2012, DIABETES CARE, V35, P1050, DOI 10.2337/dc11-1793; HOFFMANN RG, 1963, JAMA-J AM MED ASSOC, V185, P864, DOI 10.1001/jama.1963.03060110068020; Horne BD, 2005, J AM COLL CARDIOL, V45, P1638, DOI 10.1016/j.jacc.2005.02.054; Hsieh MM, 2007, ANN INTERN MED, V146, P486, DOI 10.7326/0003-4819-146-7-200704030-00004; Hu LH, 2017, ONCOTARGET, V8, P16027, DOI 10.18632/oncotarget.13784; Hulsen T, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00034; Ioannou GN, 2006, AM J GASTROENTEROL, V101, P76, DOI 10.1111/j.1572-0241.2005.00341.x; Katayev A, 2010, AM J CLIN PATHOL, V133, P180, DOI 10.1309/AJCPN5BMTSF1CDYP; KRITCHEVSKY D, 1980, P SOC EXP BIOL MED, V165, P193, DOI 10.3181/00379727-165-40957; Li L, 2012, AM J KIDNEY DIS, V59, P504, DOI 10.1053/j.ajkd.2011.12.009; Lundberg SM, 2017, ADV NEUR IN, V30; Murdoch TB, 2013, JAMA-J AM MED ASSOC, V309, P1351, DOI 10.1001/jama.2013.393; Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181; Patel KV, 2010, J GERONTOL A-BIOL, V65, P258, DOI 10.1093/gerona/glp163; Patel KV, 2009, ARCH INTERN MED, V169, P515, DOI 10.1001/archinternmed.2009.11; Polubriaginof FCG, 2018, CELL, V173, P1692, DOI 10.1016/j.cell.2018.04.032; Raghupathi W, 2014, HEALTH INF SCI SYST, V2, DOI 10.1186/2047-2501-2-3; Rappoport N, 2018, J APPL LAB MED, V3, P366, DOI 10.1373/jalm.2018.026492; Razavian N, 2015, BIG DATA, V3, P277, DOI 10.1089/big.2015.0020; ROSS DW, 1988, AM J CLIN PATHOL, V90, P262, DOI 10.1093/ajcp/90.3.262; Ruhl CE, 2013, AM J EPIDEMIOL, V178, P1702, DOI 10.1093/aje/kwt209; Singer SR, 2012, AM J MANAG CARE, V18; Smellie WSA, 2006, J CLIN PATHOL, V59, P1005, DOI 10.1136/jcp.2005.035048; Weng SF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174944; Whyte MB, 2018, POSTGRAD MED J, V94, P613, DOI 10.1136/postgradmedj-2018-135983	43	3	3	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1582	+		10.1038/s41591-021-01468-6	http://dx.doi.org/10.1038/s41591-021-01468-6		AUG 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34426707				2022-12-27	WOS:000687518700002
J	Breza, E; Stanford, FC; Alsan, M; Alsan, B; Banerjee, A; Chandrasekhar, AG; Eichmeyer, S; Glushko, T; Goldsmith-Pinkham, P; Holland, K; Hoppe, E; Karnani, M; Liegl, S; Loisel, T; Ogbu-Nwobodo, L; Olken, BA; Torres, C; Vautrey, PL; Warner, ET; Wootton, S; Duflo, E				Breza, Emily; Stanford, Fatima Cody; Alsan, Marcella; Alsan, Burak; Banerjee, Abhijit; Chandrasekhar, Arun G.; Eichmeyer, Sarah; Glushko, Traci; Goldsmith-Pinkham, Paul; Holland, Kelly; Hoppe, Emily; Karnani, Mohit; Liegl, Sarah; Loisel, Tristan; Ogbu-Nwobodo, Lucy; Olken, Benjamin A.; Torres, Carlos; Vautrey, Pierre-Luc; Warner, Erica T.; Wootton, Susan; Duflo, Esther			Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trial	NATURE MEDICINE			English	Article								During the Coronavirus Disease 2019 (COVID-19) epidemic, many health professionals used social media to promote preventative health behaviors. We conducted a randomized controlled trial of the effect of a Facebook advertising campaign consisting of short videos recorded by doctors and nurses to encourage users to stay at home for the Thanksgiving and Christmas holidays (NCT04644328 and AEARCTR-0006821). We randomly assigned counties to high intensity (n = 410 (386) at Thanksgiving (Christmas)) or low intensity (n = 410 (381)). The intervention was delivered to a large fraction of Facebook subscribers in 75% and 25% of randomly assigned zip codes in high- and low-intensity counties, respectively. In total, 6,998 (6,716) zip codes were included, and 11,954,109 (23,302,290) users were reached at Thanksgiving (Christmas). The first two primary outcomes were holiday travel and fraction leaving home, both measured using mobile phone location data of Facebook users. Average distance traveled in high-intensity counties decreased by -0.993 percentage points (95% confidence interval (CI): -1.616, -0.371; P = 0.002) for the 3 days before each holiday compared to low-intensity counties. The fraction of people who left home on the holiday was not significantly affected (adjusted difference: 0.030; 95% CI: -0.361, 0.420; P = 0.881). The third primary outcome was COVID-19 infections recorded at the zip code level in the 2-week period starting 5 days after the holiday. Infections declined by 3.5% (adjusted 95% CI: -6.2%, -0.7%; P = 0.013) in intervention compared to control zip codes. Social media messages recorded by health professionals before the winter holidays in the United States led to a significant reduction in holiday travel and subsequent COVID-19 infections.	[Breza, Emily] Harvard Univ, Dept Econ, Cambridge, MA 02138 USA; [Stanford, Fatima Cody] Massachusetts Gen Hosp, Dept Med, Dept Pediat, Neuroendocrine Unit,Endocrinol, Boston, MA 02114 USA; [Stanford, Fatima Cody; Ogbu-Nwobodo, Lucy; Torres, Carlos; Warner, Erica T.] Harvard Med Sch, Boston, MA 02115 USA; [Alsan, Marcella] Harvard Kennedy Sch Govt, Cambridge, MA USA; [Alsan, Burak] Online Care Grp, Boston, MA USA; [Banerjee, Abhijit; Karnani, Mohit; Olken, Benjamin A.; Vautrey, Pierre-Luc; Duflo, Esther] MIT, Dept Econ, Cambridge, MA 02139 USA; [Chandrasekhar, Arun G.] Stanford Univ, Dept Econ, Stanford, CA 94305 USA; [Eichmeyer, Sarah] Ludwig Maximilian Univ Munich, Dept Econ, Munich, Germany; [Glushko, Traci] Bozeman Hlth Deaconess Hosp, Bozeman, MT USA; [Goldsmith-Pinkham, Paul] Yale Univ, Sch Management, New Haven, CT USA; [Holland, Kelly] Lynn Community Hlth Ctr, Lynn, MA USA; [Hoppe, Emily] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; [Liegl, Sarah] St Anthony North Family Med, Westminster, CO USA; [Loisel, Tristan] Paris Sch Econ, Paris, France; [Ogbu-Nwobodo, Lucy] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Ogbu-Nwobodo, Lucy] McLean Hosp, Dept Psychiat, 115 Mill St, Belmont, MA 02178 USA; [Torres, Carlos] Massachusetts Gen Hosp Children, Dept Pediat, Gen Pediat, Boston, MA USA; [Warner, Erica T.] Massachusetts Gen Hosp, Dept Med, Clin & Translat Epidemiol Unit, Mongan Inst, Boston, MA 02114 USA; [Wootton, Susan] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA	Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Stanford University; University of Munich; Yale University; Johns Hopkins University; Paris School of Economics; Harvard University; Massachusetts General Hospital; Harvard University; McLean Hospital; Harvard University; Massachusetts General Hospital; University of Texas System; University of Texas Health Science Center Houston	Duflo, E (corresponding author), MIT, Dept Econ, Cambridge, MA 02139 USA.	eduflo@mit.edu		Breza, Emily/0000-0002-4745-4689; Goldsmith-Pinkham, Paul/0000-0002-4959-8192; Stanford, Fatima/0000-0003-4616-533X; Holland, Kelly/0000-0002-9610-1134; Hoppe, Emily/0000-0001-8034-0600	Facebook; National Science Foundation [2029880]; Executive Committee on Research at Massachusetts General Hospital; National Institutes of Health [P30 DK040561, L30 DK118710]	Facebook(Facebook Inc); National Science Foundation(National Science Foundation (NSF)); Executive Committee on Research at Massachusetts General Hospital; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the health team at Facebook for their in-kind financial support that allowed us to run the campaign and for their logistical help. In particular, we thank N. Deolalikar. We also thank advisors D. Bernard and S. Francis. We thank the team at AdGlow, in particular C. Orellano and L. Novak, for running the campaign. We thank A. Pompe from Facebook Data for Good for helping us to understand the Facebook mobility data. We thank the team at Damage Control, in particular P. Saha, for their tireless work in editing the videos. We thank N. Shankar and M. J. Kim for excellent research assistance. We are particularly grateful to all of the members of the 'COVID-19 Messaging Working Group' with whom we developed and tested the original messages that led to this at-scale study. The research benefitted from grant support from the National Science Foundation under award number 2029880 (M.A. and E.D.), the Physician/Scientist Development Award granted by the Executive Committee on Research at Massachusetts General Hospital (F.C.S.) and National Institutes of Health P30 DK040561 (F.C.S.) and L30 DK118710 (F.C.S.). Facebook provided the ad credits used to show the ads and connected the research team with AdGlow, the marketing partner. The ad content went through the usual internal policy review at Facebook for compliance with policies. AdGlow was responsible for running the ad campaigns. Facebook had no other role in the design or conduct of the trial and no role in the interpretation of the data or preparation of the manuscript. The findings and conclusions expressed are solely those of the authors and do not represent the views of their funders. T.L. (co-author) conducted the statistical analysis (and was not involved in the design of the trial). E.D. (principal investigator) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Alatas V., 2019, CELEBRITIES SPEAK NA; Alsan M, 2021, ANN INTERN MED, V174, P484, DOI 10.7326/M20-6141; Altman D., 2021, WHY DOCTORS NURSES C; [Anonymous], 2020, WHATS GOOD FACEBOOK; Bailey M, 2018, J ECON PERSPECT, V32, P259, DOI 10.1257/jep.32.3.259; Banerjee A., 2020, MESSAGES COVID 19 PR; BURBIDGE JB, 1988, J AM STAT ASSOC, V83, P123, DOI 10.2307/2288929; Centers for Disease Control and Prevention, 2021, HOL TIPS; Chernozhukov V, 2018, ECONOMET J, V21, pC1, DOI 10.1111/ectj.12097; Digital, 2020, APR GLOB STATSH REP; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Frey, 2021, BIDEN WON COUNTIES A; Gramlich J., 2021, 10 FACTS AM FACEBOOK; Hamel L., 2021, COVID 19 VACCINE MON; Imbens GW, 2015, CAUSAL INFERENCE FOR STATISTICS, SOCIAL, AND BIOMEDICAL SCIENCES: AN INTRODUCTION, P1, DOI 10.1017/CBO9781139025751; Maas P, 2019, KDD'19: PROCEEDINGS OF THE 25TH ACM SIGKDD INTERNATIONAL CONFERENCCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P3173, DOI 10.1145/3292500.3340412; McDonnell Nieto del Rio G., 2020, NEW YORK TIMES; Movement Range Maps, FAC DAT GOOD; Social Connectedness Index, 2020, FAC DAT GOOD; Torres C, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.17115; Whaley CM, 2021, JAMA INTERN MED, V181, P1090, DOI 10.1001/jamainternmed.2021.2915; Wooldridge JM, 2003, AM ECON REV, V93, P133, DOI 10.1257/000282803321946930; Zhang M., 2000, HLTH SERVICES OUTCOM, V1, P165, DOI [DOI 10.1023/A:1012593022758, 10.1023/a:1012593022758]	23	8	8	5	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1622	+		10.1038/s41591-021-01487-3	http://dx.doi.org/10.1038/s41591-021-01487-3		AUG 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34413518	Green Published, hybrid			2022-12-27	WOS:000686447900002
J	Cleland, JGF; Pellicori, P; Gonzalez, A				Cleland, John G. F.; Pellicori, Pierpaolo; Gonzalez, Arantxa			A novel treatment for heart failure targets myocardial fibrosis	NATURE MEDICINE			English	Editorial Material								A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.	[Cleland, John G. F.; Pellicori, Pierpaolo] Univ Glasgow, Glasgow Royal Infirm, Robertson Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Gonzalez, Arantxa] Univ Navarra, Program Cardiovasc Dis, CIMA, Pamplona, Spain; [Gonzalez, Arantxa] IdiSNA, Pamplona, Spain; [Gonzalez, Arantxa] Carlos III Inst Hlth, CIBERCV, Madrid, Spain	University of Glasgow; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Instituto de Salud Carlos III	Cleland, JGF (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Robertson Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland.	john.cleland@glasgow.ac.uk	Pellicori, Pierpaolo/N-1880-2013; González, Arantxa/D-6860-2017	Pellicori, Pierpaolo/0000-0001-7175-0464; González, Arantxa/0000-0001-5986-6528; Cleland, John/0000-0002-1471-7016				Aimo A, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104694; Cleland JGF, 2021, EUR HEART J, V42, P2331, DOI 10.1093/eurheartj/ehab082; Cleland JGF, 2021, EUR HEART J, V42, P684, DOI 10.1093/eurheartj/ehaa758; Cleland JGF, 2018, EUR HEART J, V39, P26, DOI 10.1093/eurheartj/ehx564; Gonzalez A, 2018, J AM COLL CARDIOL, V71, P1696, DOI 10.1016/j.jacc.2018.02.021; Lewis GA, 2021, NAT MED, V27, P1477, DOI 10.1038/s41591-021-01452-0; Lopez B, 2021, NAT REV CARDIOL, V18, P479, DOI 10.1038/s41569-020-00504-1; Lopez B, 2016, J AM COLL CARDIOL, V67, P251, DOI 10.1016/j.jacc.2015.10.063; Mason T, 2021, JACC-CARDIOVASC IMAG, V14, P1164, DOI 10.1016/j.jcmg.2020.10.017; PELLICORI P, 2021, EUR J HEART FAIL; Pellicori P, 2020, CARDIOVASC RES, V116, P91, DOI 10.1093/cvr/cvz198; Pellicori P, 2020, EUR J HEART FAIL, V22, P1711, DOI 10.1002/ejhf.1716	12	5	6	1	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1343	1344		10.1038/s41591-021-01457-9	http://dx.doi.org/10.1038/s41591-021-01457-9		AUG 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385705				2022-12-27	WOS:000684533600007
J	Veatch, JR; Simon, S; Riddell, SR				Veatch, Joshua R.; Simon, Sylvain; Riddell, Stanley R.			Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer	NATURE MEDICINE			English	Editorial Material							IMMUNOTHERAPY; THERAPY	A phase 1 trial shows promising anti-tumor activity of tumor-infiltrating-lymphocyte therapy in patients with advanced non-small-cell lung cancer.	[Veatch, Joshua R.; Simon, Sylvain; Riddell, Stanley R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Veatch, Joshua R.; Riddell, Stanley R.] Univ Washington, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Riddell, SR (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.; Riddell, SR (corresponding author), Univ Washington, Seattle, WA 98195 USA.	sriddell@fredhutch.org						Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Creelan BC, 2021, NAT MED, V27, P1410, DOI 10.1038/s41591-021-01462-y; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Ghorani E, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0066-y; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Muranski P, 2006, NAT CLIN PRACT ONCOL, V3, P668, DOI 10.1038/ncponc0666; Sharma P, 2020, NAT REV IMMUNOL, V20, P75, DOI 10.1038/s41577-020-0275-8; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Stevanovic S, 2019, CLIN CANCER RES, V25, P1486, DOI 10.1158/1078-0432.CCR-18-2722; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8	12	2	2	2	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1339	1341		10.1038/s41591-021-01445-z	http://dx.doi.org/10.1038/s41591-021-01445-z		AUG 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385706				2022-12-27	WOS:000684533600008
J	Blomberg, B; Mohn, KGI; Brokstad, KA; Zhou, F; Linchausen, DW; Hansen, BA; Lartey, S; Onyango, TB; Kuwelker, K; Saevik, M; Bartsch, H; Tondel, C; Kittang, BR; Cox, RJ; Langeland, N				Blomberg, Bjorn; Mohn, Kristin Greve-Isdahl; Brokstad, Karl Albert; Zhou, Fan; Linchausen, Dagrun Waag; Hansen, Bent-Are; Lartey, Sarah; Onyango, Therese Bredholt; Kuwelker, Kanika; Saevik, Marianne; Bartsch, Hauke; Tondel, Camilla; Kittang, Bard Reiakvam; Cox, Rebecca Jane; Langeland, Nina		Bergen COVID-19 Res Grp	Long COVID in a prospective cohort of home-isolated patients	NATURE MEDICINE			English	Article							FATIGUE SYNDROMES	Long-term complications after coronavirus disease 2019 (COVID-19) are common in hospitalized patients, but the spectrum of symptoms in milder cases needs further investigation. We conducted a long-term follow-up in a prospective cohort study of 312 patients-247 home-isolated and 65 hospitalized-comprising 82% of total cases in Bergen during the first pandemic wave in Norway. At 6 months, 61% (189/312) of all patients had persistent symptoms, which were independently associated with severity of initial illness, increased convalescent antibody titers and pre-existing chronic lung disease. We found that 52% (32/61) of home-isolated young adults, aged 16-30 years, had symptoms at 6 months, including loss of taste and/or smell (28%, 17/61), fatigue (21%, 13/61), dyspnea (13%, 8/61), impaired concentration (13%, 8/61) and memory problems (11%, 7/61). Our findings that young, home-isolated adults with mild COVID-19 are at risk of long-lasting dyspnea and cognitive symptoms highlight the importance of infection control measures, such as vaccination. Analysis of a prospectively enrolled cohort of patients with SARS-CoV-2 infections in Bergen, Norway, reveals a high proportion of patients who experienced long COVID symptoms at 6 months, despite being relatively young and having only mild to moderate acute COVID-19 symptoms.	[Blomberg, Bjorn; Kuwelker, Kanika; Kittang, Bard Reiakvam; Langeland, Nina] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Blomberg, Bjorn; Kuwelker, Kanika; Langeland, Nina] Haukeland Hosp, Natl Advisory Unit Trop Infect Dis, Bergen, Norway; [Blomberg, Bjorn; Mohn, Kristin Greve-Isdahl; Kuwelker, Kanika; Saevik, Marianne; Langeland, Nina] Haukeland Hosp, Dept Med, Bergen, Norway; [Mohn, Kristin Greve-Isdahl; Zhou, Fan; Lartey, Sarah; Onyango, Therese Bredholt; Kuwelker, Kanika; Cox, Rebecca Jane] Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway; [Brokstad, Karl Albert] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway; [Brokstad, Karl Albert] Western Norway Univ Appl Sci, Dept Safety, Chem & Biomed Lab Sci, Bergen, Norway; [Linchausen, Dagrun Waag] Bergen Municipal Emergency Clin, Bergen, Norway; [Hansen, Bent-Are; Kittang, Bard Reiakvam] Haraldsplass Deaconess Hosp, Dept Med, Bergen, Norway; [Bartsch, Hauke] Haukeland Hosp, Mohn Med Imaging & Visualizat Ctr, Dept Radiol, Bergen, Norway; [Bartsch, Hauke] Univ Bergen, Dept Informat, Bergen, Norway; [Tondel, Camilla] Haukeland Hosp, Dept Paediat, Bergen, Norway; [Tondel, Camilla] Haukeland Hosp, Dept Res & Innovat, Bergen, Norway; [Cox, Rebecca Jane] Haukeland Hosp, Dept Microbiol, Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Western Norway University of Applied Sciences; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Blomberg, B; Langeland, N (corresponding author), Univ Bergen, Dept Clin Sci, Bergen, Norway.; Blomberg, B; Langeland, N (corresponding author), Haukeland Hosp, Natl Advisory Unit Trop Infect Dis, Bergen, Norway.; Blomberg, B; Langeland, N (corresponding author), Haukeland Hosp, Dept Med, Bergen, Norway.; Cox, RJ (corresponding author), Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway.; Cox, RJ (corresponding author), Haukeland Hosp, Dept Microbiol, Bergen, Norway.	bjorn.blomberg@uib.no; rebecca.cox@uib.no; nina.langeland@uib.no	; Blomberg, Bjorn/B-9605-2015	Saevik, Marianne/0000-0002-4670-4957; Blomberg, Bjorn/0000-0001-5647-4297; Bartsch, Hauke/0000-0003-1486-4128; Bansal, Amit/0000-0002-0681-932X; Ertesvag, Nina Urke/0000-0001-5243-9101; Mohn, Kristin/0000-0002-3249-1719; Kuwelker, Kanika/0000-0003-1302-950X; Bredholt, Geir/0000-0002-8953-8821	Trond Mohn Stiftelse (RUHS) [TMS2020TMT05]; Ministry of Health and Care Services, Norway; Helse Vest [F-11628]; Faculty of Medicine, University of Bergen, Norway; Norwegian Research Council Globvac [284930]; European Union [EU IMI115672, H2020 874866, H2020 101037867]; Nanomedicines Flunanoair [ERA-NETet EuroNanoMed2 i JTC2016]	Trond Mohn Stiftelse (RUHS); Ministry of Health and Care Services, Norway; Helse Vest; Faculty of Medicine, University of Bergen, Norway; Norwegian Research Council Globvac(Research Council of Norway); European Union(European Commission); Nanomedicines Flunanoair	We thank F. Krammer, Department of Microbiology, Icahn School of Medicine, Mount Sinai, New York, for supplying the RBD and spike constructs. We thank the Research Unit for Health Surveys (RUHS), where data were collected for the home-isolated patients. This work was supported by the Trond Mohn Stiftelse (RUHS, R.J.C., grant no. TMS2020TMT05); the Ministry of Health and Care Services, Norway; Helse Vest (R.J.C., grant no. F-11628); and the Faculty of Medicine, University of Bergen, Norway. The Influenza Centre is funded by the Norwegian Research Council Globvac (R.J.C., grant no. 284930); the European Union (R.J.C., grant nos. EU IMI115672, FLUCOP, H2020 874866 INCENTIVE and H2020 101037867 Vaccelerate); the Faculty of Medicine, University of Bergen, Norway; and Nanomedicines Flunanoair (R.J.C., grant no. ERA-NETet EuroNanoMed2 i JTC2016).	Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1101/2020.03.17.20037713, 10.1038/s41591-020-0913-5]; [Anonymous], 2020, NAT MED, V26, P1803, DOI 10.1038/s41591-020-01177-6; Ayres JG, 1996, LANCET, V347, P978, DOI 10.1016/S0140-6736(96)91470-1; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bellan M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.36142; Buchwald DS, 2000, AM J MED, V109, P531, DOI 10.1016/S0002-9343(00)00560-X; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Geense W. W, AM J RESP CRIT CARE, DOI [10.1164/rccm.202009-3381OC(2021), DOI 10.1164/RCCM.202009-3381OC(2021)]; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Hanevik K, 2014, CLIN INFECT DIS, V59, P1394, DOI 10.1093/cid/ciu629; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; KERR WR, 1966, LANCET, V2, P1181; Kuwelker K, 2021, LANCET REG HEALTH-EU, V3, DOI 10.1016/j.lanepe.2020.100014; Lam MHB, 2009, ARCH INTERN MED, V169, P2142, DOI 10.1001/archinternmed.2009.384; Loge JH, 1998, J PSYCHOSOM RES, V45, P53, DOI 10.1016/S0022-3999(97)00291-2; Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Seet RCS, 2007, J CLIN VIROL, V38, P1, DOI 10.1016/j.jcv.2006.10.011; Sykes DL, 2021, EUR RESPIR J, V58, DOI [10.1007/s00408-021-00423-z, 10.1183/13993003.congress-2021.OA4189]; Trieu MC, 2021, J INFECT DIS, V223, P589, DOI 10.1093/infdis/jiaa737; Venkatesan P, 2021, LANCET RESP MED, V9, P129, DOI 10.1016/S2213-2600(21)00031-X; Venturelli S, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821000145; von Weyhern CH, 2020, LANCET, V395, pE109, DOI 10.1016/S0140-6736(20)31282-4; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; White PD, 2001, LANCET, V358, P1946, DOI 10.1016/S0140-6736(01)06961-6; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	27	184	183	7	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1607	+		10.1038/s41591-021-01433-3	http://dx.doi.org/10.1038/s41591-021-01433-3		JUN 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34163090	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000664834700001
J	Rodo, X; San-Jose, A; Kirchgatter, K; Lopez, L				Rodo, Xavier; San-Jose, Adria; Kirchgatter, Karin; Lopez, Leonardo			Changing climate and the COVID-19 pandemic: more than just heads or tails	NATURE MEDICINE			English	Editorial Material								Climate change can both facilitate zoonotic spillovers and have an effect on transmission chains. These effects, alongside human behavior and awareness, need to be integrated in pandemic forecasting models.	[Rodo, Xavier] IICREA Catalan Inst Res & Adv Studies, Barcelona, Spain; [Rodo, Xavier; San-Jose, Adria; Lopez, Leonardo] ISGlobal, Climate & Hlth Program, Barcelona, Spain; [Kirchgatter, Karin] Univ Sao Paulo, Inst Med Trop, Dept Lab Especializados Superintendencia Controle, Sao Paulo, Brazil; [Lopez, Leonardo] UNL CONICET, Res Inst Signals Syst & Computat Intelligence, Santa Fe, Argentina	ISGlobal; Universidade de Sao Paulo; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the Littoral	Rodo, X (corresponding author), IICREA Catalan Inst Res & Adv Studies, Barcelona, Spain.; Rodo, X (corresponding author), ISGlobal, Climate & Hlth Program, Barcelona, Spain.	xavier.rodo@isglobal.org	Kirchgatter, Karin/D-8376-2013; Rodo, Xavier/F-7663-2017	Kirchgatter, Karin/0000-0002-2449-2316; San Jose Plana, Adria/0000-0002-5988-4352; Rodo, Xavier/0000-0003-4843-6180; Lopez, Leonardo/0000-0002-5351-9899	Spanish Ministry of Science and Innovation through the 'Centro de Excelencia Severo Ochoa 2019-2023' Program [CEX2018000806S]; Generalitat de Catalunya through the CERCA Program; 'la Caixa' Foundation, Spain [100010434, LCF/BQ/DR19/11740017]	Spanish Ministry of Science and Innovation through the 'Centro de Excelencia Severo Ochoa 2019-2023' Program(Spanish Government); Generalitat de Catalunya through the CERCA Program; 'la Caixa' Foundation, Spain(La Caixa Foundation)	X.R. acknowledges support from the Spanish Ministry of Science and Innovation through the 'Centro de Excelencia Severo Ochoa 2019 2023' Program (CEX2018 000806S), and support from the Generalitat de Catalunya through the CERCA Program. A.S.J. was supported by a fellowship from 'la Caixa' Foundation, Spain (ID 100010434; fellowship code LCF/BQ/DR19/11740017).	[Anonymous], 2021, ENVIRON RES, DOI DOI 10.1016/J.ENVRES.2021.110874; Bartlow AW, 2019, VET SCI, V6, DOI 10.3390/vetsci6020040; dos Cunha MP., 2019, SCI REP-UK, V9, DOI DOI 10.1038/S41598-019-56650-1; Durham DP, 2012, J R SOC INTERFACE, V9, P562, DOI 10.1098/rsif.2011.0325; Giovanetti M, 2020, J VIROL, V94, DOI 10.1128/JVI.01623-19; Gortazar C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004129; Hu DL, 2016, P NATL ACAD SCI USA, V113, pE7730, DOI 10.1073/pnas.1608732113; Jenkins CN, 2013, P NATL ACAD SCI USA, V110, pE2602, DOI 10.1073/pnas.1302251110; Johnson CK, 2020, P ROY SOC B-BIOL SCI, V287, DOI 10.1098/rspb.2019.2736; Krishnamurthy V, 2000, J CLIMATE, V13, P579, DOI 10.1175/1520-0442(2000)013<0579:IMEROI>2.0.CO;2; Lipsitch M, 2009, P NATL ACAD SCI USA, V106, P3645, DOI 10.1073/pnas.0900933106; Lone SA, 2020, EMERG MICROBES INFEC, V9, P1300, DOI 10.1080/22221751.2020.1775132; Lopez L, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.101030; Lopez L, 2020, NAT HUM BEHAV, V4, P746, DOI 10.1038/s41562-020-0908-8; Lowen AC, 2008, J VIROL, V82, P5650, DOI 10.1128/JVI.00325-08; Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392; Njenga MK, 2020, AM J TROP MED HYG, V103, P564, DOI 10.4269/ajtmh.20-0474; Noor Rashed, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00628-5; Nunez S, 2019, CLIMATIC CHANGE, V154, P351, DOI 10.1007/s10584-019-02420-x; Plowright RK, 2017, NAT REV MICROBIOL, V15, P502, DOI 10.1038/nrmicro.2017.45; Rodo X, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21815-y; Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106; Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426; Wen F, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.1312; Zaitchik BF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19546-7	25	18	17	6	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					576	579		10.1038/s41591-021-01303-y	http://dx.doi.org/10.1038/s41591-021-01303-y		APR 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33820994	Bronze			2022-12-27	WOS:000636931100005
J	Bachelot, T; Filleron, T; Bieche, I; Arnedos, M; Campone, M; Dalenc, F; Coussy, F; Sablin, MP; Debled, M; Lefeuvre-Plesse, C; Goncalves, A; Reynier, MAM; Jacot, W; You, B; Barthelemy, P; Verret, B; Isambert, N; Tchiknavorian, X; Levy, C; Thery, JC; L'Haridon, T; Ferrero, JM; Mege, A; Del Piano, F; Rouleau, E; Tran-Dien, A; Adam, J; Lusque, A; Jimenez, M; Jacquet, A; Garberis, I; Andre, F				Bachelot, Thomas; Filleron, Thomas; Bieche, Ivan; Arnedos, Monica; Campone, Mario; Dalenc, Florence; Coussy, Florence; Sablin, Marie-Paule; Debled, Marc; Lefeuvre-Plesse, Claudia; Goncalves, Anthony; Reynier, Marie-Ange Mouret; Jacot, William; You, Benoit; Barthelemy, Philippe; Verret, Benjamin; Isambert, Nicolas; Tchiknavorian, Xavier; Levy, Christelle; Thery, Jean-Christophe; L'Haridon, Tifenn; Ferrero, Jean-Marc; Mege, Alice; Del Piano, Francesco; Rouleau, Etienne; Tran-Dien, Alicia; Adam, Julien; Lusque, Amelie; Jimenez, Marta; Jacquet, Alexandra; Garberis, Ingrid; Andre, Fabrice			Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial	NATURE MEDICINE			English	Article							HOMOLOGOUS RECOMBINATION DEFICIENCY	The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after six to eight cycles of chemotherapy. Patients (n = 199) were randomized to either durvalumab (10 mg kg(-1) every 2 weeks) or maintenance chemotherapy. In the overall population, durvalumab did not improve progression-free survival (adjusted hazard ratio (HR): 1.40, 95% confidence interval (CI): 1.00-1.96; P = 0.047) or overall survival (OS; adjusted HR: 0.84, 95% CI: 0.54-1.29; P = 0.423). In an exploratory subgroup analysis, durvalumab improved OS in patients with triple-negative breast cancer (TNBC; n = 82; HR: 0.54, 95% CI: 0.30-0.97, P = 0.0377). Exploratory analysis showed that the HR of death was 0.37 (95% CI: 0.12-1.13) for patients with PD-L1(+) TNBC (n = 32) and 0.49 (95% CI: 0.18-1.34) for those with PD-L1(-) TNBC (n = 29). In patients with TNBC, exploratory analyses showed that the HR for durvalumab efficacy (OS) was 0.18 (95% CI: 0.05-0.71; log-rank test, P = 0.0059) in patients with CD274 gain/amplification (n = 23) and 1.12 (95% CI: 0.42-2.99; log-rank test, P = 0.8139) in patients with CD274 normal/loss (n = 32). Tumor infiltration by lymphocytes (CD8, FoxP3 and CD103 expressions) and homologous recombination deficiency did not predict sensitivity to durvalumab in exploratory analyses. This latter finding should be interpreted with caution since only one patient presented a germline BRCA mutation. The present study provides a rationale to evaluate single-agent durvalumab in maintenance therapy in patients with TNBC. Exploratory analyses identified CD274 amplification as a potential biomarker of sensitivity. Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease.	[Bachelot, Thomas] Ctr Leon Berard, Dept Med Oncol, Lyon, France; [Filleron, Thomas; Lusque, Amelie] Inst Claudius Regaud, Dept Biostat, IUCT Oncopole, Toulouse, France; [Bieche, Ivan] Descartes Univ, Inst Curie, Dept Genet, Paris, France; [Arnedos, Monica; Verret, Benjamin; Andre, Fabrice] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France; [Campone, Mario] Inst Cancerol Ouest, Rene Gauducheau, Angers, France; [Dalenc, Florence] Inst Claudius Regaud, IUCT Oncopole, Dept Med Oncol, Toulouse, France; [Dalenc, Florence] Univ Paul Sabatier, Toulouse, France; [Coussy, Florence; Sablin, Marie-Paule] Institut Curie, Dept Med Oncol, Paris, France; [Debled, Marc] Inst Bergonie, Dept Med Oncol, Bordeaux, France; [Lefeuvre-Plesse, Claudia] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France; [Goncalves, Anthony] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France; [Reynier, Marie-Ange Mouret] Ctr Jean Perrin, Dept Med Oncol, Clermont Ferrand, France; [Jacot, William] INSERM U1194, Inst Cancerol Montpellier, Inst Rech Cancerol Montpellier, Dept Med Oncol,IRCM, Montpellier, France; [Jacot, William] Montpellier Univ, Montpellier, France; [You, Benoit] Univ Lyon, Univ Claude Bernard Lyon 1,GINECO, Inst Cancerol Hosp Civils Lyon,EMR UCBL HCL 3738, Ctr Invest Therapeut Oncol & Hematol Lyon CITOHL, Lyon, France; [You, Benoit] Ctr Hosp Lyon Sud, Pierre Benite, France; [Barthelemy, Philippe] Inst Cancerol Strasbourg, Strasbourg, France; [Barthelemy, Philippe] Hop Univ Strasbourg, Strasbourg, France; [Isambert, Nicolas] Ctr Georges Francois Leclerc, Dept Med Oncol, Dijon, France; [Tchiknavorian, Xavier] Hop St Musse, Ctr Hosp Intercommunal Toulon Seyne, Toulon, France; [Levy, Christelle] Ctr Francois Baclesse, Dept Med Oncol, Caen, France; [Thery, Jean-Christophe] Univ Med Rouen, Ctr Henri Becquerel, Dept Med Oncol, Rouen, France; [L'Haridon, Tifenn] Ctr Hosp Departemental Vendee, Roche, France; [Ferrero, Jean-Marc] Univ Cote d'Azur, Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France; [Mege, Alice] Inst St Catherine, Avignon, France; [Del Piano, Francesco] Hosp Leman, Bains, France; [Rouleau, Etienne] Gustave Roussy Canc Campus, Dept Pathol & Med Biol, Canc Genet Lab, Villejuif, France; [Tran-Dien, Alicia; Garberis, Ingrid; Andre, Fabrice] INSERM UMR981, Gustave Roussy Canc Campus, Dept Pathol & Med Biol, Villejuif, France; [Tran-Dien, Alicia; Garberis, Ingrid; Andre, Fabrice] Univ Paris Saclay, Le Kremlin Bicetre, France; [Adam, Julien] Gustave Roussy Canc Campus, Dept Pathol, Villejuif, France; [Adam, Julien] Gustave Roussy Canc Campus, INSERM U1186, Villejuif, France; [Jimenez, Marta; Jacquet, Alexandra] UniCanc, Paris, France	UNICANCER; Centre Leon Berard; UNICANCER; Institut Claudius Regaud; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Institut Bergonie; UNICANCER; Centre Eugene Marquis; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Georges-Francois Leclerc; UNICANCER; Centre Francois Baclesse; UNICANCER; Centre Henri Becquerel; CHD Vendee; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER	Andre, F (corresponding author), Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France.; Andre, F (corresponding author), INSERM UMR981, Gustave Roussy Canc Campus, Dept Pathol & Med Biol, Villejuif, France.; Andre, F (corresponding author), Univ Paris Saclay, Le Kremlin Bicetre, France.	fabrice.andre@gustaveroussy.fr	filleron, thomas/C-3554-2014; ANDRE, Fabrice/AAL-2683-2020; Jimenez, Marta/HCH-7687-2022	filleron, thomas/0000-0003-0724-0659; ANDRE, Fabrice/0000-0001-5795-8357; Jimenez, Marta/0000-0001-7940-4945; ARNEDOS, MONICA/0000-0001-5269-1251	Fondation ARC; AstraZeneca; Breast Cancer Research Foundation	Fondation ARC; AstraZeneca(AstraZeneca); Breast Cancer Research Foundation	We thank the patients and their families, as well as the investigators and staff involved in SAFIR02-BREAST and especially M.A., M.C., F.D., F.C., M.-P.S., M.D., C.L.-P., A.G., M.-A.M.R., W.J., B.Y., P.B., N.I., X.T., C.L., J.-C. T., T.L'H., J.-M.F., A.M. and F.D.P. We thank I.G. and J.A. for performing IHC analysis, as well as T.F. and A.L. for performing the statistical analyses and A.T.-D. for performing the bioinformatics analyses. We also thank I.B., E. R. and B.V. for valuable discussions on results. We are grateful to UNICANCER for promoting the clinical trial and especially to M.J. and A.J. in charge of the SAFIR02-BREAST clinical trial and all the members of their team that lead the monitoring of the clinical data, samples and genomic analyses. We are also grateful to the members of the Independent Data Monitoring Committee: N. Turner, S. Loibl, S. Novello, E. Felip, S. Litiere and D. Beltram. The study was funded by Fondation ARC, AstraZeneca and the Breast Cancer Research Foundation. AstraZeneca also supported the duvalumab supply to the study sites.	Adams S, 2019, ANN ONCOL, V30, P405, DOI 10.1093/annonc/mdy518; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Commo F, 2016, BIOINFORMATICS, V32, P1402, DOI 10.1093/bioinformatics/btv718; CORTES J, 2020, J CLIN ONCOL S, V38; Dieci MV, 2014, ANN ONCOL, V25, P611, DOI 10.1093/annonc/mdt556; EMENS LA, 2019, CANCER RES, V79; Emens LA, 2019, JAMA ONCOL, V5, P74, DOI 10.1001/jamaoncol.2018.4224; Force J, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0634-5; Goodman AM, 2018, JAMA ONCOL, V4, P1237, DOI 10.1001/jamaoncol.2018.1701; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Hui RN, 2019, LANCET ONCOL, V20, P1670, DOI 10.1016/S1470-2045(19)30519-4; Karn T, 2020, ANN ONCOL, V31, P1216, DOI 10.1016/j.annonc.2020.05.015; Lacour M, 2019, CLIN LUNG CANCER, V20, P391, DOI 10.1016/j.cllc.2019.05.013; Lamberti G, 2020, ANN ONCOL, V31, P807, DOI 10.1016/j.annonc.2020.02.017; Loi S, 2017, ANN ONCOL, V28; Nanda R, 2020, JAMA ONCOL, V6, P676, DOI 10.1001/jamaoncol.2019.6650; Pelekanou V, 2018, MOL CANCER THER, V17, P1324, DOI 10.1158/1535-7163.MCT-17-1005; Powles T., 2020, J CLIN ONCOL, V38, pLBA1, DOI 10.1200/JCO.2020.38.18_suppl.LBA1; Rugo HS, 2018, CLIN CANCER RES, V24, P2804, DOI 10.1158/1078-0432.CCR-17-3452; Sakai H, 2019, LUNG CANCER, V127, P59, DOI 10.1016/j.lungcan.2018.11.025; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schwartz LH, 2016, EUR J CANCER, V62, P132, DOI 10.1016/j.ejca.2016.03.081; Takaya H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59671-3; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4; Winer EP, 2020, J CLIN ONCOL, V38; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Zhao EY, 2017, CLIN CANCER RES, V23, P7521, DOI 10.1158/1078-0432.CCR-17-1941	31	44	44	2	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					250	+		10.1038/s41591-020-01189-2	http://dx.doi.org/10.1038/s41591-020-01189-2		JAN 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33462450				2022-12-27	WOS:000608674100005
J	Lindblad, KE; Lujambio, A				Lindblad, Katherine E.; Lujambio, Amaia			Liver metastases inhibit immunotherapy efficacy	NATURE MEDICINE			English	Editorial Material								Liver metastases lead to resistance to immunotherapy through the 'siphoning' of tumor antigen-specific CD8(+) T cells into the liver, which results in a systemic 'immune desert' incapable of controlling tumor burden.	[Lindblad, Katherine E.; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Lindblad, Katherine E.; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, Dept Med,Tisch Canc Inst, New York, NY 10029 USA; [Lindblad, Katherine E.; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Lindblad, Katherine E.; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Lujambio, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.; Lujambio, A (corresponding author), Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, Dept Med,Tisch Canc Inst, New York, NY 10029 USA.; Lujambio, A (corresponding author), Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA.; Lujambio, A (corresponding author), Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.	amaia.lujambio@mssm.edu		Lujambio, Amaia/0000-0002-2798-1481	U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) [2T32AI078892] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [R37CA230636, 1R01CA251155] Funding Source: Medline; Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) [DR52-18] Funding Source: Medline	U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI); Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation)		Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Forrester JV, 2008, MUCOSAL IMMUNOL, V1, P372, DOI 10.1038/mi.2008.27; Lee JC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba0759; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Medina-Echeverz J, 2015, CANCER IMMUNOL IMMUN, V64, P931, DOI 10.1007/s00262-015-1736-y; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ringelhan M, 2018, NAT IMMUNOL, V19, P222, DOI 10.1038/s41590-018-0044-z; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Yu JL, 2021, NAT MED, V27, P152, DOI 10.1038/s41591-020-1131-x	11	8	8	2	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					25	27		10.1038/s41591-020-01190-9	http://dx.doi.org/10.1038/s41591-020-01190-9			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442002				2022-12-27	WOS:000607931400018
J	Ewer, KJ; Barrett, JR; Belij-Rammerstorfer, S; Sharpe, H; Makinson, R; Morter, R; Flaxman, A; Wright, D; Bellamy, D; Bittaye, M; Dold, C; Provine, NM; Aboagye, J; Fowler, J; Silk, SE; Alderson, J; Aley, PK; Angus, B; Berrie, E; Bibi, S; Cicconi, P; Clutterbuck, EA; Chelysheva, I; Folegatti, PM; Fuskova, M; Green, CM; Jenkin, D; Kerridge, S; Lawrie, A; Minassian, AM; Moore, M; Mujadidi, Y; Plested, E; Poulton, I; Ramasamy, MN; Robinson, H; Song, R; Snape, MD; Tarrant, R; Voysey, M; Watson, MEE; Douglas, AD; Hill, AVS; Gilbert, SC; Pollard, AJ; Lambe, T				Ewer, Katie J.; Barrett, Jordan R.; Belij-Rammerstorfer, Sandra; Sharpe, Hannah; Makinson, Rebecca; Morter, Richard; Flaxman, Amy; Wright, Daniel; Bellamy, Duncan; Bittaye, Mustapha; Dold, Christina; Provine, Nicholas M.; Aboagye, Jeremy; Fowler, Jamie; Silk, Sarah E.; Alderson, Jennifer; Aley, Parvinder K.; Angus, Brian; Berrie, Eleanor; Bibi, Sagida; Cicconi, Paola; Clutterbuck, Elizabeth A.; Chelysheva, Irina; Folegatti, Pedro M.; Fuskova, Michelle; Green, Catherine M.; Jenkin, Daniel; Kerridge, Simon; Lawrie, Alison; Minassian, Angela M.; Moore, Maria; Mujadidi, Yama; Plested, Emma; Poulton, Ian; Ramasamy, Maheshi N.; Robinson, Hannah; Song, Rinn; Snape, Matthew D.; Tarrant, Richard; Voysey, Merryn; Watson, Marion E. E.; Douglas, Alexander D.; Hill, Adrian V. S.; Gilbert, Sarah C.; Pollard, Andrew J.; Lambe, Teresa		Oxford COVID Vaccine Trial Grp	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	NATURE MEDICINE			English	Article							ENHANCEMENT; HIV-1	A single dose of the ChAdOx1 nCoV-19 vaccine elicits antibodies and cytokine-producing T cells that might help control or prevent SARS-CoV-2 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed(1). Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses(2) and might reduce the potential for disease enhancement(3). Cytotoxic T cells clear virus-infected host cells and contribute to control of infection(4). Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. (5,6)). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)(7) given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-gamma and tumor necrosis factor-alpha cytokine secretion by CD4(+) T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8(+) T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy.	[Ewer, Katie J.; Barrett, Jordan R.; Belij-Rammerstorfer, Sandra; Sharpe, Hannah; Makinson, Rebecca; Morter, Richard; Flaxman, Amy; Wright, Daniel; Bellamy, Duncan; Bittaye, Mustapha; Aboagye, Jeremy; Fowler, Jamie; Silk, Sarah E.; Folegatti, Pedro M.; Fuskova, Michelle; Jenkin, Daniel; Lawrie, Alison; Minassian, Angela M.; Poulton, Ian; Watson, Marion E. E.; Douglas, Alexander D.; Hill, Adrian V. S.; Gilbert, Sarah C.; Lambe, Teresa] Univ Oxford, Jenner Inst, Oxford, England; [Dold, Christina; Aley, Parvinder K.; Bibi, Sagida; Cicconi, Paola; Clutterbuck, Elizabeth A.; Chelysheva, Irina; Kerridge, Simon; Moore, Maria; Mujadidi, Yama; Plested, Emma; Ramasamy, Maheshi N.; Robinson, Hannah; Song, Rinn; Snape, Matthew D.; Voysey, Merryn; Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England; [Provine, Nicholas M.; Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England; [Alderson, Jennifer] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Berrie, Eleanor; Green, Catherine M.; Tarrant, Richard] Univ Oxford, Nuffield Dept Med, Clin Biomfg Facil, Oxford, England	University of Oxford; Jenner Institute; University of Oxford; University of Oxford; University of Oxford; University of Oxford	Ewer, KJ; Lambe, T (corresponding author), Univ Oxford, Jenner Inst, Oxford, England.	katie.ewer@ndm.ox.ac.uk; Teresa.lambe@ndm.ox.ac.uk	Chelysheva, Irina/AAQ-5231-2021; Noé, Andrés/AAU-9612-2020; Folegatti, Pedro/AAD-5238-2019; Ewer, Katie J/B-4328-2011; Baker, Philip/ABI-2575-2020; Tomic, Adriana/AAX-7203-2021; Jenkin, Daniel/AAB-7042-2022; O'Connor, Daniel/AAF-4903-2019; Dold, Christina/ABA-4237-2021; Lambe, Teresa/E-5733-2016; Knight, Julian/W-2399-2019; Douglas, Alexander/E-7040-2012	Chelysheva, Irina/0000-0001-7802-7025; Noé, Andrés/0000-0002-6408-7032; Folegatti, Pedro/0000-0001-5330-0240; Ewer, Katie J/0000-0001-9827-9836; Baker, Philip/0000-0002-4519-1563; Tomic, Adriana/0000-0001-9885-3535; O'Connor, Daniel/0000-0002-6902-9886; Lambe, Teresa/0000-0001-7711-897X; Screaton, Gavin/0000-0002-3549-4309; Wright, Daniel/0000-0002-8114-1838; Moore, Maria/0000-0001-6456-927X; Felle, Sally/0000-0001-7855-4482; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Makinson, Rebecca/0000-0001-7582-9073; Minassian, Angela/0000-0001-7832-9824; Lias, Amelia/0000-0003-2939-7761; Jenkin, Daniel/0000-0003-3088-310X; Dunachie, Susanna/0000-0001-5665-6293; Coombes, Naomi/0000-0001-9631-6875; Frater, John/0000-0001-7163-7277; Marshall, Julia/0000-0002-9692-6769; Flaxman, Amy/0000-0001-6460-1372; Alderson, Jennifer/0000-0002-0526-7797; Knight, Julian/0000-0002-0377-5536; Morter, Richard/0000-0002-7005-1546; Barrett, Jordan/0000-0003-0746-1945; Green, Catherine/0000-0002-7068-7106; Mirtorabi, Neginsadat/0000-0003-0587-3196; Mentzer, Alexander/0000-0002-4502-2209; Themistocleous, Andreas/0000-0002-1089-1543; Douglas, Alexander/0000-0002-5410-7562; Spencer, Alexandra/0000-0001-7958-6961; Feng, Elaine Shuo/0000-0001-7855-0991; Anslow, Rachel/0000-0002-9111-2897; Phillips, Dan/0000-0003-0686-5091; Skelly, Donal/0000-0002-2426-3097; Sharpe, Hannah/0000-0002-1194-2429; Patrick-Smith, Maia/0000-0001-7679-3754; Snape, Matthew/0000-0003-0531-5426; Farooq Mujadidi, Yama/0000-0002-2342-8531; Mallett, Garry/0000-0001-5475-9061; Jackson, Frederic/0000-0001-8230-083X; klenerman, paul/0000-0003-4307-9161; Bewley, Kevin/0000-0002-9078-6734; Hou, Mimi/0000-0002-8517-9147; Fowler, Jamie/0000-0003-0258-9114; Marinou, Spyridoula/0000-0002-0764-5966; Barnes, Eleanor/0000-0002-0860-0831; Ramos Lopez, Fernando/0000-0002-9997-7879; Sanders, Katherine/0000-0002-4090-3277; Bibi, Sagida/0000-0002-0855-2737; Aley, Parvinder/0000-0002-0749-8329; dold, christina/0000-0003-2314-507X; Bellamy, Duncan/0000-0003-3614-0032; Henry, Aaron/0000-0002-7650-0963; Sanders, Helen/0000-0002-9657-5524; Thomas, Tonia/0000-0003-3091-5917; Dong, Tao/0000-0003-3545-3758; Allen, Elizabeth/0000-0002-6406-4834	UK Research and Innovation [MC_PC_19055]; Engineering and Physical Sciences Research Council [EP/R013756/1]; Coalition for Epidemic Preparedness Innovations (CEPI); National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil [001]; U.S. National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance [HHSN272201400008C]; Huo Family Foundation; Medical Sciences Division; Versus Arthritis [21509]; Wellcome MSD ISSF [BRD00010]; Kennedy Trust for Rheumatology Research; Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China [2018-I2M-2-002]; Nuffield Department of Medicine; Department of Paediatrics; Oxford Immunology Network COVID Consortium, Clinical Trials Research Governance; Public Affairs Directorate; Clinical Biomanufacturing Facility; Oxford University Hospitals NHS Foundation Trust; Oxford Health NHS Foundation Trust; AstraZeneca; EPSRC [EP/R013756/1] Funding Source: UKRI; MRC [G1001046, MC_UU_00008/11, MC_PC_19055, MC_PC_19058, G0600520, MR/L018942/1, MR/T001151/1] Funding Source: UKRI	UK Research and Innovation(UK Research & Innovation (UKRI)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Coalition for Epidemic Preparedness Innovations (CEPI); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); U.S. National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance; Huo Family Foundation; Medical Sciences Division; Versus Arthritis(Versus Arthritis); Wellcome MSD ISSF; Kennedy Trust for Rheumatology Research; Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China; Nuffield Department of Medicine; Department of Paediatrics; Oxford Immunology Network COVID Consortium, Clinical Trials Research Governance; Public Affairs Directorate; Clinical Biomanufacturing Facility; Oxford University Hospitals NHS Foundation Trust; Oxford Health NHS Foundation Trust; AstraZeneca(AstraZeneca); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by UK Research and Innovation (MC_PC_19055); the Engineering and Physical Sciences Research Council (EP/R013756/1); the Coalition for Epidemic Preparedness Innovations (CEPI); and the National Institute for Health Research (NIHR) and the NIHR Oxford Biomedical Research Centre. Additional resources for study delivery were provided by the NIHR Southampton Clinical Research Facility and the NIHR Southampton Biomedical Research Centre; University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research Facility; and the NIHR North West London, South London, Wessex and West of England Local Clinical Research Networks and the NIHR Oxford Health Biomedical Research Centre. P.M.F. received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). Development of SARS-CoV-2 reagents was partially supported by the U.S. National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance contract HHSN272201400008C. The research reagent for SARS-CoV-2 RNA (NIBSC 20/130) was obtained from the National Institute for Biological Standards and Control, UK. The control vaccine was provided free of charge by the UK Department of Health and Social Care. We received invaluable additional financial support through generous philanthropic donations to the University of Oxford, including from the Huo Family Foundation. The University of Oxford has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCov-19 (AZD1222). The authors are grateful to the senior management at AstraZeneca for facilitating and funding the manufacture of the AZD1222 vaccine candidate, the pseudovirus neutralization assays and the Meso Scale antibody assay used in this study. AstraZeneca reviewed the data from the study and the final manuscript before submission, but the authors retained editorial control. The investigators express their gratitude for the contribution of all the trial participants, the invaluable advice of the international Data Safety Monitoring Board (R. Heyderman, M. Sadarangani, S. Black, G. Bouliotis, G. Hussey, B. Ogutu, W. Orenstein, S. Ramos, C. Dekker and E. Bukusi) and the independent members of the Trial Steering Committee. We additionally acknowledge the broader support from the various teams within the University of Oxford, including the Medical Sciences Division, the Nuffield Department of Medicine (R. Cornall and O. Velicka) and the Department of Paediatrics (G. A. Hollander, J. Bagniewska, E. Derow and S. Vanderslott), the Oxford Immunology Network COVID Consortium, Clinical Trials Research Governance (H. House, C. Riddle, R. Bahadori and A. Brindle), Research Services (C. Banner and S. Pelling-Deeves), the Public Affairs Directorate (J. Colman, A. Buxton, C. McIntyre and S. Pritchard) and the Clinical Biomanufacturing Facility, as well as the Oxford University Hospitals NHS Foundation Trust (B. Holthof) and the Oxford Health NHS Foundation Trust and the trial sites. We are grateful for the input of the protein production team at the Jenner Institute. The MSD Quickplex was purchased using joint support from Versus Arthritis (grant reference 21509), Wellcome MSD ISSF (BRD00010) and the Kennedy Trust for Rheumatology Research.; The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care, UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, the National Institute for Health Research, the NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network or AstraZeneca. A.F.'s post was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China (grant number 2018-I2M-2-002).	Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032; [Anonymous], 2020, LANCET, V395, P1168, DOI 10.1016/S0140-6736(20)30823-0; [Anonymous], 2015, BLUEPR R PREP RESP P; Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bhopal SS, 2020, LANCET, V396, P532, DOI 10.1016/S0140-6736(20)31748-7; Bowyer G, 2020, J EXP MED, V217, DOI 10.1084/jem.20200004; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011; Darboe A, 2017, EUR J IMMUNOL, V47, P1040, DOI 10.1002/eji.201746974; de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1038/s41591-020-1051-9, 10.1101/2020.05.28.20115758]; Douoguih M., 2020, SAFETY IMMUNOGENICIT, DOI [10.1101/ 2020.09.23.20199604, DOI 10.1101/2020.09.23.20199604]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gilbert SC, 2017, VACCINE, V35, P4461, DOI 10.1016/j.vaccine.2017.04.085; Gouglas D, 2019, EPIDEMIOL REV, V41, P28, DOI 10.1093/epirev/mxz012; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6; Hodgson SH, 2014, MOL THER, V22, P2142, DOI 10.1038/mt.2014.157; Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Jorquera PA, 2016, EXPERT REV VACCINES, V15, P173, DOI 10.1586/14760584.2016.1115353; Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064; Marston HD, 2017, JAMA-J AM MED ASSOC, V318, P1757, DOI 10.1001/jama.2017.15033; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Ndiaye BP, 2015, LANCET RESP MED, V3, P190, DOI 10.1016/S2213-2600(15)00037-5; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Sahin U, 2020, CONCURRENT HUMAN ANT, DOI [10.1101/2020.07.17.20140533, DOI 10.1101/2020.07.17.20140533]; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002; van Doremalen N, 2020, NATURE, V586, P578, DOI [10.1101/2020.05.13.093195, 10.1038/s41586-020-2608-y]; Wajnberg A, 2020, SARS COV 2 INFECT IN, DOI 14.20151126.; Wolff D, 2021, INFECTION, V49, P15, DOI 10.1007/s15010-020-01509-1; World Health Organization, 2020, DRAFT LANDSC COVID 1; Wyllie D., 2020, SARS COV 2 RESPONSIV, DOI [10.1101/2020.11.02.20222778, DOI 10.1101/2020.11.02.20222778]; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	41	284	287	4	37	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					270	+		10.1038/s41591-020-01194-5	http://dx.doi.org/10.1038/s41591-020-01194-5		DEC 2020	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33335323	Green Submitted, Bronze			2022-12-27	WOS:000599796800001
J	Shaked, A; Loza, BL; Van Loon, E; Olthoff, KM; Guan, WH; Jacobson, PA; Zhu, A; Fishman, CE; Gao, H; Oetting, WS; Israni, AK; Testa, G; Trotter, J; Klintmalm, G; Naesens, M; Asrani, SK; Keating, BJ				Shaked, Abraham; Loza, Bao-Li; Van Loon, Elisabet; Olthoff, Kim M.; Guan, Weihua; Jacobson, Pamala A.; Zhu, Andrew; Fishman, Claire E.; Gao, Hui; Oetting, William S.; Israni, Ajay K.; Testa, Giuliano; Trotter, James; Klintmalm, Goran; Naesens, Maarten; Asrani, Sumeet K.; Keating, Brendan J.			Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes	NATURE MEDICINE			English	Article							MELLITUS; TRANSPLANTATION; ASSOCIATION; COMPLICATIONS; DEFINITIONS; METABOLISM; TACROLIMUS	Post-transplant diabetes mellitus (PTDM) reduces allograft and recipient life span. Polygenic risk scores (PRSs) show robust association with greater risk of developing type 2 diabetes (T2D). We examined the association of PTDM with T2D PRS in liver recipients (n = 1,581) and their donors (n = 1,555), and kidney recipients (n = 2,062) and their donors (n = 533). Recipient T2D PRS was associated with pre-transplant T2D and the development of PTDM. T2D PRS in liver donors, but not in kidney donors, was an independent risk factor for PTDM development. The inclusion of a combined liver donor and recipient T2D PRS significantly improved PTDM prediction compared with a model that included only clinical characteristics: the area under the curve (AUC) was 67.6% (95% confidence interval (CI) 64.1-71.1%) for the combined T2D PRS versus 62.3% (95% CI 58.8-65.8%) for the clinical characteristics model (P= 0.0001). Liver recipients in the highest quintile of combined donor and recipient T2D PRS had the greatest risk of PTDM, with an odds ratio of 3.22 (95% CI 2.07-5.00) (P =1.92x10(-7)) compared with those in the lowest quintile. In conclusion, T2D PRS identifies transplant candidates with high risk of PTDM for which pre-emptive diabetes management and donor selection may be warranted.	[Shaked, Abraham; Loza, Bao-Li; Olthoff, Kim M.; Gao, Hui; Keating, Brendan J.] Univ Penn, Penn Transplant Inst, Perelman Sch Med, Dept Surg, Philadelphia, PA USA; [Van Loon, Elisabet; Naesens, Maarten] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Nephrol, Leuven, Belgium; [Van Loon, Elisabet; Naesens, Maarten] Univ Hosp Leuven, Dept Nephrol & Renal Transplantat, Leuven, Belgium; [Guan, Weihua] Univ Minnesota, Div Biostat, Minneapolis, MN USA; [Jacobson, Pamala A.] Univ Minnesota, Dept Expt & Clin Pharmacol, Coll Pharm, Minneapolis, MN USA; [Zhu, Andrew] Weill Cornell Med, New York, NY USA; [Fishman, Claire E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Israni, Ajay K.] Hennepin Healthcare Res Inst, Minneapolis, MN USA; [Israni, Ajay K.] Hennepin Healthcare, Dept Nephrol, Minneapolis, MN USA; [Israni, Ajay K.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Testa, Giuliano; Trotter, James; Klintmalm, Goran; Asrani, Sumeet K.] Baylor Univ, Med Ctr, Dallas, TX USA	University of Pennsylvania; Pennsylvania Medicine; KU Leuven; KU Leuven; University Hospital Leuven; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cornell University; University of Pennsylvania; Pennsylvania Medicine; University of Minnesota System; University of Minnesota Twin Cities; Baylor University; Baylor University Medical Center	Shaked, A (corresponding author), Univ Penn, Penn Transplant Inst, Perelman Sch Med, Dept Surg, Philadelphia, PA USA.	Abraham.Shaked@pennmedicine.upenn.edu; baoli@pennmedicine.upenn.edu	Van Loon, Elisabet/AAN-3094-2020	Van Loon, Elisabet/0000-0001-9796-9157	Fred and Suzanne Biesecker Pediatric Liver Center at Children's Hospital of Philadelphia; National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) [U01AI152960-01]; Gift-of-Life Organ Procurement Organization	Fred and Suzanne Biesecker Pediatric Liver Center at Children's Hospital of Philadelphia; National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Gift-of-Life Organ Procurement Organization	Funding for this study was received from the Fred and Suzanne Biesecker Pediatric Liver Center at Children's Hospital of Philadelphia (A.S.), Gift-of-Life Organ Procurement Organization (A.S.), and National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) grant no. U01AI152960-01 (A.S. and B.J.K.).	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Ali IH, 2011, TRANSPL P, V43, P568, DOI 10.1016/j.transproceed.2011.01.032; Benson KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147323; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Castedal M, 2018, SCAND J GASTROENTERO, V53, P741, DOI 10.1080/00365521.2018.1463390; Chand S, 2014, CURR OPIN NEPHROL HY, V23, P605, DOI 10.1097/MNH.0000000000000068; Choi SW, 2020, NAT PROTOC, V15, P2759, DOI 10.1038/s41596-020-0353-1; Cosio FG, 2005, KIDNEY INT, V67, P2415, DOI 10.1111/j.1523-1755.2005.00349.x; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Depczynski B, 2000, DIABETIC MED, V17, P15, DOI 10.1046/j.1464-5491.2000.00206.x; EKSTRAND AV, 1992, TRANSPLANTATION, V53, P563, DOI 10.1097/00007890-199203000-00014; Feng S, 2021, HEPATOLOGY, V73, P1985, DOI 10.1002/hep.31520; First MR, 2013, TRANSPLANTATION, V96, P58, DOI 10.1097/TP.0b013e318293fcf8; Francioli LC, 2014, NAT GENET, V46, P818, DOI 10.1038/ng.3021; Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382; Halden TAS, 2016, DIABETES CARE, V39, P617, DOI 10.2337/dc15-2383; Han HS, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.122; Hecking M, 2021, TRANSPL INT, V34, P27, DOI 10.1111/tri.13783; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Jenssen T, 2019, NAT REV ENDOCRINOL, V15, P172, DOI 10.1038/s41574-018-0137-7; Jenssen T, 2015, NAT REV NEPHROL, V11, P465, DOI 10.1038/nrneph.2015.59; Jimenez-Perez M, 2016, WORLD J GASTROENTERO, V22, P6416, DOI 10.3748/wjg.v22.i28.6416; Johnston O, 2008, J AM SOC NEPHROL, V19, P1411, DOI 10.1681/ASN.2007111202; Jucaud V, 2019, HEPATOLOGY, V69, P1273, DOI 10.1002/hep.30281; Kang ES, 2009, TRANSPLANTATION, V88, P693, DOI 10.1097/TP.0b013e3181b29c41; Kautzky-Willer A, 2016, ENDOCR REV, V37, P278, DOI 10.1210/er.2015-1137; Keating BJ, 2015, TRANSPLANTATION, V99, P2401, DOI 10.1097/TP.0000000000000913; Lancia P, 2018, PEDIATR NEPHROL, V33, P1045, DOI 10.1007/s00467-017-3881-3; Langenberg C, 2018, LANCET, V391, P2463, DOI 10.1016/S0140-6736(18)31132-2; Li YR, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0211-x; Ling Q, 2020, AM J TRANSPLANT, V20, P701, DOI 10.1111/ajt.15665; Luan FL, 2011, TRANSPLANTATION, V91, P334, DOI 10.1097/TP.0b013e318203c25f; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; McCaughan JA, 2014, J AM SOC NEPHROL, V25, P1037, DOI 10.1681/ASN.2013040383; Montori VM, 2002, DIABETES CARE, V25, P583, DOI 10.2337/diacare.25.3.583; Necking M, 2012, J AM SOC NEPHROL, V23, P739, DOI 10.1681/ASN.2011080835; O'Leary JG, 2015, AM J TRANSPLANT, V15, P1003, DOI 10.1111/ajt.13153; Oetting WS, 2019, TRANSPLANTATION, V103, P1131, DOI 10.1097/TP.0000000000002625; Peer N, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005266.pub2; Pelaez-Jaramillo MJ, 2018, DIABETES THER, V9, P521, DOI 10.1007/s13300-018-0374-8; Pham P. T., 2000, ENDOTEXT; Porrini EL, 2016, NEPHROL DIAL TRANSPL, V31, P495, DOI 10.1093/ndt/gfv368; Povysil G, 2019, NAT REV GENET, V20, P747, DOI 10.1038/s41576-019-0177-4; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Quteineh L, 2017, PHARMACOGENOMICS J, V17, P69, DOI 10.1038/tpj.2015.82; Roccaro GA, 2018, AM J TRANSPLANT, V18, P207, DOI 10.1111/ajt.14401; Rodrigo E, 2006, J AM SOC NEPHROL, V17, pS291, DOI 10.1681/ASN.2006080929; Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI 10.1002/cphy.c130024; Saigi-Morgui N, 2019, PHARMACOGENOMICS J, V19, P53, DOI 10.1038/s41397-017-0001-5; Shaked A, 2019, AM J TRANSPLANT, V19, P1397, DOI 10.1111/ajt.15205; Sharif A, 2014, AM J TRANSPLANT, V14, P1992, DOI 10.1111/ajt.12850; Sharif A, 2010, NAT REV NEPHROL, V6, P415, DOI 10.1038/nrneph.2010.66; Sudmant PH, 2015, NATURE, V526, P75, DOI 10.1038/nature15394; Sullivan KM, 2020, NAT REV NEPHROL, V16, P628, DOI 10.1038/s41581-020-0298-1; Tam V, 2019, NAT REV GENET, V20, P467, DOI 10.1038/s41576-019-0127-1; Udler MS, 2019, ENDOCR REV, V40, P1500, DOI 10.1210/er.2019-00088; Valderhaug TG, 2011, DIABETOLOGIA, V54, P1341, DOI 10.1007/s00125-011-2105-9; Vanrenterghem Y, 2011, TRANSPLANTATION, V91, P976, DOI 10.1097/TP.0b013e31820c10eb; VanWagner LB, 2014, LIVER TRANSPLANT, V20, P1306, DOI 10.1002/lt.23950; Vujkovic M, 2020, NAT GENET, V52, P680, DOI 10.1038/s41588-020-0637-y; Wallia A, 2016, MED CLIN N AM, V100, P535, DOI 10.1016/j.mcna.2016.01.005; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Wissing KM, 2018, AM J TRANSPLANT, V18, P1726, DOI 10.1111/ajt.14665	65	2	2	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					999	+		10.1038/s41591-022-01758-7	http://dx.doi.org/10.1038/s41591-022-01758-7		APR 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35393535				2022-12-27	WOS:000779215700001
J	Campbell, AS; Needham, BD; Meyer, CR; Tan, J; Conrad, M; Preston, GM; Bolognani, F; Rao, SG; Heussler, H; Griffith, R; Guastella, AJ; Janes, AC; Frederick, B; Donabedian, DH; Mazmanian, SK				Campbell, A. Stewart; Needham, Brittany D.; Meyer, Christopher R.; Tan, Joanna; Conrad, Mary; Preston, Gregory M.; Bolognani, Federico; Rao, Srinivas G.; Heussler, Helen; Griffith, Rebecca; Guastella, Adam J.; Janes, Amy C.; Frederick, Blaise; Donabedian, David H.; Mazmanian, Sarkis K.			Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial	NATURE MEDICINE			English	Article							ABERRANT BEHAVIOR CHECKLIST; FUNCTIONAL CONNECTIVITY; REPETITIVE BEHAVIOR; SULFORAPHANE TREATMENT; MOTION ARTIFACT; RATING-SCALE; CHILDREN; IRRITABILITY; ROBUST; METABOLOMICS	Autism spectrum disorder (ASD) is defined by hallmark behaviors involving reduced communication and social interaction as well as repetitive activities and restricted interests. ASD represents a broad spectrum, from minimally affected individuals to those requiring intense support, with additional manifestations often including anxiety, irritability/aggression and altered sensory processing. Gastrointestinal (GI) issues are also common in ASD, and studies have identified changes in the gut microbiome of individuals with ASD compared to control populations, complementing recent findings of differences in gut-derived metabolites in feces and circulation. However, a role for the GI tract or microbiome in ASD remains controversial. Here we report that an oral GI-restricted adsorbent (AB-2004) that has affinity for small aromatic or phenolic molecules relieves anxiety-like behaviors that are driven by a gut microbial metabolite in mice. Accordingly, a pilot human study was designed and completed to evaluate the safety of AB-2004 in an open-label, single-cohort, multiple-ascending-dose clinical trial that enrolled 30 adolescents with ASD and GI symptoms in New Zealand and Australia. AB-2004 was shown to have good safety and tolerability across all dose levels, and no drug-related serious adverse events were identified. Significant reductions in specific urinary and plasma levels of gut bacterial metabolites were observed between baseline and end of AB-2004 treatment, demonstrating likely target engagement. Furthermore, we observed improvements in multiple exploratory behavioral endpoints, most significantly in post hoc analysis of anxiety and irritability, as well as GI health, after 8 weeks of treatment. These results from an open-label study (trial registration no. ACTRN12618001956291) suggest that targeting gut-derived metabolites with an oral adsorbent is a safe and well-tolerated approach to improving symptoms associated with ASD, thereby emboldening larger placebo-controlled trials. An open-label clinical trial of an oral absorbent that sequesters phenolic molecules in the gut shows safety and tolerability in adolescents with autism, reduces levels of gut-derived metabolites in circulation and reduces anxiety and irritability.	[Campbell, A. Stewart; Meyer, Christopher R.; Tan, Joanna; Conrad, Mary; Preston, Gregory M.; Bolognani, Federico; Rao, Srinivas G.; Donabedian, David H.] Axial Therapeut, Woburn, MA 01801 USA; [Needham, Brittany D.; Mazmanian, Sarkis K.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA; [Heussler, Helen] Queensland Childrens Hosp, Ctr Clin Trials Rare Neurodev Disorders, Brisbane, Qld, Australia; [Griffith, Rebecca] Optimal Clin Trials, Auckland, New Zealand; [Guastella, Adam J.] Univ Sydney, Childrens Hosp Westmead Clin Sch, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia; [Janes, Amy C.] Consulting Neuroscientist Axial Therapeut, Woburn, MA USA; [Frederick, Blaise] Consulting MR Physicist Axial Therapeut, Woburn, MA USA	California Institute of Technology; University of Sydney	Campbell, AS (corresponding author), Axial Therapeut, Woburn, MA 01801 USA.; Mazmanian, SK (corresponding author), CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.	stewart@axialtx.com; sarkis@caltech.edu	Frederick, Blaise/G-6098-2012	Frederick, Blaise/0000-0001-5832-5279; Needham, Brittany/0000-0002-0280-1886; Campbell, Anthony/0000-0001-5094-9714	Axial Therapeutics	Axial Therapeutics	We acknowledge the study participants and their families for their generous contributions of time and effort to this study. This work was supported by funds from Axial Therapeutics and was conducted by, and in collaboration with, the company.	Adams JB, 2019, PROCESSES, V7, DOI 10.3390/pr7110806; Adams JB, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-22; Altieri L, 2011, BIOMARKERS, V16, P252, DOI 10.3109/1354750X.2010.548010; AMAN MG, 1985, AM J MENT DEF, V89, P485; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Bermudez-Martin P, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01103-z; Bitar T, 2018, J PHARMACEUT BIOMED, V152, P57, DOI 10.1016/j.jpba.2018.01.007; Burger-Caplan R., 2018, ENCY CLIN NEUROPSYCH; Chatham CH, 2018, AUTISM RES, V11, P270, DOI 10.1002/aur.1874; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Constantino JN., 2012, SRS2 SOCIAL RESPONSI, V2nd ed; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; De Angelis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076993; Dieme B, 2015, J PROTEOME RES, V14, P5273, DOI 10.1021/acs.jproteome.5b00699; DIMENAS E, 1995, SCAND J GASTROENTERO, V30, P1046, DOI 10.3109/00365529509101605; Elbe D, 2012, J CAN ACAD CHILD ADO, V21, P130; Esteban O, 2020, NIPY NIPYPE 1 5 1; Esteban O, 2019, NAT METHODS, V16, P111, DOI 10.1038/s41592-018-0235-4; Evans AC, 2012, NEUROIMAGE, V62, P911, DOI 10.1016/j.neuroimage.2012.01.024; Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579-020-0433-9; Farmer C, 2020, J INTELL DISABIL RES, V64, P18, DOI 10.1111/jir.12691; Fishman I, 2018, J AM ACAD CHILD PSY, V57, P764, DOI 10.1016/j.jaac.2018.06.015; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Gabriele S, 2014, BIOMARKERS, V19, P463, DOI 10.3109/1354750X.2014.936911; Gamage N, 2006, TOXICOL SCI, V90, P5, DOI 10.1093/toxsci/kfj061; Garcia-Gutierrez E, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.578666; Garrett WS, 2020, NAT REV IMMUNOL, V20, P91, DOI 10.1038/s41577-019-0252-2; Gevi F, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0109-5; Goel R, 2018, INT REV PSYCHIATR, V30, P78, DOI 10.1080/09540261.2018.1458706; Gorgolewski Krzysztof, 2011, Front Neuroinform, V5, P13, DOI 10.3389/fninf.2011.00013; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Guo BL, 2019, NAT NEUROSCI, V22, P1223, DOI 10.1038/s41593-019-0445-9; Hardan AY, 2019, AUTISM, V23, P2096, DOI 10.1177/1362361318824103; Ho LKH, 2020, GUT PATHOG, V12, DOI 10.1186/s13099-020-0346-1; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Humer E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134784; Jaglin M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00216; Janes AC, 2018, NEUROPSYCHOPHARMACOL, V43, P2445, DOI 10.1038/s41386-018-0069-x; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jiang HY, 2016, BRAIN BEHAV IMMUN, V58, P165, DOI 10.1016/j.bbi.2016.06.005; Johnco CJ, 2015, J AUTISM DEV DISORD, V45, P3232, DOI 10.1007/s10803-015-2483-9; Jones RM, 2017, AUTISM RES, V10, P1567, DOI 10.1002/aur.1798; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kaluzna-Czaplinska J, 2011, CLIN BIOCHEM, V44, P686, DOI 10.1016/j.clinbiochem.2011.01.015; Kang DW, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00314-20; Kang DW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42183-0; Kang DW, 2018, ANAEROBE, V49, P121, DOI 10.1016/j.anaerobe.2017.12.007; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Karbowska M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66421-y; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Klein A, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005350; Komada Munekazu, 2008, J Vis Exp, DOI 10.3791/1088; Konjevod M, 2021, J PHARMACEUT BIOMED, V194, DOI 10.1016/j.jpba.2020.113681; Koomar T., 2020, SCI REP-UK, V10; Krajmalnik-Brown Rosa, 2015, Microbial Ecology in Health and Disease, V26, P26914, DOI 10.3402/mehd.v26.26914; Krishnaswami S, 2011, PEDIATRICS, V127, pE1322, DOI 10.1542/peds.2011-0428; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lanczos C, 1964, J SOC IND APPL MAT B, V1, P76, DOI [DOI 10.1137/0701007, 10.1137/0701007]; Li C, 2018, AM J MED GENET B, V177, P580, DOI 10.1002/ajmg.b.32662; Liang YJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6105608; Loebel A, 2016, J AUTISM DEV DISORD, V46, P1153, DOI 10.1007/s10803-015-2628-x; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Lussu M, 2017, AUTISM RES, V10, P1058, DOI 10.1002/aur.1748; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P3063, DOI 10.2147/NDT.S174622; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McCarthy JM, 2017, DRUG ALCOHOL DEPEN, V181, P1, DOI 10.1016/j.drugalcdep.2017.09.009; McGuinness G, 2020, EXCLI J, V19, P892, DOI 10.17179/excli2020-2487; Ming X, 2012, J PROTEOME RES, V11, P5856, DOI 10.1021/pr300910n; Mosinska P, 2015, THER ADV GASTROENTER, V8, P278, DOI 10.1177/1756283X15587866; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Needham BD, 2021, BIOL PSYCHIAT, V89, P451, DOI 10.1016/j.biopsych.2020.09.025; Needham BD, 2020, NAT REV NEUROSCI, V21, P717, DOI 10.1038/s41583-020-00381-0; Nikolenko VN, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10080502; NIWA T, 1991, NEPHROL DIAL TRANSPL, V6, P105, DOI 10.1093/ndt/6.2.105; ODONNELL LJD, 1990, BMJ-BRIT MED J, V300, P439, DOI 10.1136/bmj.300.6722.439; Odriozola P, 2019, DEV COGN NEUROS-NETH, V37, DOI 10.1016/j.dcn.2018.12.001; Potter LA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00810; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Pruim RHR, 2015, NEUROIMAGE, V112, P267, DOI 10.1016/j.neuroimage.2015.02.064; Pulikkan J, 2019, ADV EXP MED BIOL, V1118, P253, DOI 10.1007/978-3-030-05542-4_13; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Riddle MA, 2002, J AM ACAD CHILD PSY, V41, P1061, DOI 10.1097/01.CHI.0000020259.43550.F4; Rolls ET, 2019, BRAIN STRUCT FUNCT, V224, P3001, DOI 10.1007/s00429-019-01945-2; Rossignol DA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.4; Rylaarsdam L, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00385; Satterthwaite TD, 2013, NEUROIMAGE, V64, P240, DOI 10.1016/j.neuroimage.2012.08.052; Schulman G, 2014, INT J NEPHROL RENOV, V7, P49, DOI 10.2147/IJNRD.S41339; Sharon G, 2019, CELL, V177, P1600, DOI 10.1016/j.cell.2019.05.004; Simms ML, 2009, ACTA NEUROPATHOL, V118, P673, DOI 10.1007/s00401-009-0568-2; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Sun CY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186687; Szekely A, 2017, SOC COGN AFFECT NEUR, V12, P476, DOI 10.1093/scan/nsw137; Thakkar KN, 2008, BRAIN, V131, P2464, DOI 10.1093/brain/awn099; Treiber JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152472; Troost PW, 2005, J AM ACAD CHILD PSY, V44, P1137, DOI 10.1097/01.chi.0000177055.11229.76; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Veenstra-VanderWeele J, 2017, NEUROPSYCHOPHARMACOL, V42, P1390, DOI 10.1038/npp.2016.237; Velenosi TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22526; Wang L, 2012, DIGEST DIS SCI, V57, P2096, DOI 10.1007/s10620-012-2167-7; Warren Z, 2011, PEDIATRICS, V127, pE1303, DOI 10.1542/peds.2011-0426; Xiong W., 2017, AM J PSYCHIAT RESIDE, V12, P3; Yap CX, 2021, CELL, V184, P5916, DOI 10.1016/j.cell.2021.10.015; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zhong CC, 2020, AUTISM RES, V13, P1634, DOI 10.1002/aur.2402; Zhou YY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151879	108	14	14	8	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					528	+		10.1038/s41591-022-01683-9	http://dx.doi.org/10.1038/s41591-022-01683-9		FEB 2022	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35165451	Bronze			2022-12-27	WOS:000754955000003
J	Houser, KV; Chen, GL; Carter, C; Crank, MC; Nguyen, TA; Florez, MCB; Berkowitz, NM; Mendoza, F; Hendel, CS; Gordon, IJ; Coates, EE; Vazquez, S; Stein, J; Case, CL; Lawlor, H; Carlton, K; Gaudinski, MR; Strom, L; Hofstetter, AR; Liang, CJ; Narpala, S; Hatcher, C; Gillespie, RA; Creanga, A; Kanekiyo, M; Raab, JE; Andrews, SF; Zhang, Y; Yang, ES; Wang, LS; Leung, K; Kong, WP; Freyn, AW; Nachbagauer, R; Palese, P; Bailer, RT; McDermott, AB; Koup, RA; Gall, JG; Arnold, F; Mascola, JR; Graham, BS; Ledgerwood, JE				Houser, Katherine, V; Chen, Grace L.; Carter, Cristina; Crank, Michelle C.; Nguyen, Thuy A.; Florez, Maria Claudia Burgos; Berkowitz, Nina M.; Mendoza, Floreliz; Hendel, Cynthia Starr; Gordon, Ingelise J.; Coates, Emily E.; Vazquez, Sandra; Stein, Judy; Case, Christopher L.; Lawlor, Heather; Carlton, Kevin; Gaudinski, Martin R.; Strom, Larisa; Hofstetter, Amelia R.; Liang, C. Jason; Narpala, Sandeep; Hatcher, Christian; Gillespie, Rebecca A.; Creanga, Adrian; Kanekiyo, Masaru; Raab, Julie E.; Andrews, Sarah F.; Zhang, Yi; Yang, Eun Sung; Wang, Lingshu; Leung, Kwanyee; Kong, Wing-Pui; Freyn, Alec W.; Nachbagauer, Raffael; Palese, Peter; Bailer, Robert T.; McDermott, Adrian B.; Koup, Richard A.; Gall, Jason G.; Arnold, Frank; Mascola, John R.; Graham, Barney S.; Ledgerwood, Julie E.		VRC 316 Study Team	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial	NATURE MEDICINE			English	Article							HEMAGGLUTININ-STEM; ANTIBODIES; INDUCTION	Currently, licensed seasonal influenza vaccines display variable vaccine effectiveness, and there remains a need for novel vaccine platforms capable of inducing broader responses against viral protein domains conserved among influenza subtypes. We conducted a first-in-human, randomized, open-label, phase 1 clinical trial (NCT03186781) to evaluate a novel ferritin (H2HA-Ferritin) nanoparticle influenza vaccine platform. The H2 subtype has not circulated in humans since 1968. Adults born after 1968 have been exposed to only the H1 subtype of group 1 influenza viruses, which shares a conserved stem with H2. Including both H2-naive and H2-exposed adults in the trial allowed us to evaluate memory responses against the conserved stem domain in the presence or absence of pre-existing responses against the immunodominant HA head domain. Fifty healthy participants 18-70 years of age received H2HA-Ferritin intramuscularly as a single 20-mu g dose (n = 5) or a 60-mu g dose either twice in a homologous (n = 25) prime-boost regimen or once in a heterologous (n = 20) prime-boost regimen after a matched H2 DNA vaccine prime. The primary objective of this trial was to evaluate the safety and tolerability of H2HA-Ferritin either alone or in prime-boost regimens. The secondary objective was to evaluate antibody responses after vaccination. Both vaccines were safe and well tolerated, with the most common solicited symptom being mild headache after both H2HA-Ferritin (n = 15, 22%) and H2 DNA (n = 5, 25%). Exploratory analyses identified neutralizing antibody responses elicited by the H2HA-Ferritin vaccine in both H2-naive and H2-exposed populations. Furthermore, broadly neutralizing antibody responses against group 1 influenza viruses, including both seasonal H1 and avian H5 subtypes, were induced in the H2-naive population through targeting the HA stem. This ferritin nanoparticle vaccine technology represents a novel, safe and immunogenic platform with potential application for pandemic preparedness and universal influenza vaccine development.	[Houser, Katherine, V; Chen, Grace L.; Carter, Cristina; Crank, Michelle C.; Nguyen, Thuy A.; Florez, Maria Claudia Burgos; Berkowitz, Nina M.; Mendoza, Floreliz; Hendel, Cynthia Starr; Gordon, Ingelise J.; Coates, Emily E.; Vazquez, Sandra; Stein, Judy; Lawlor, Heather; Carlton, Kevin; Gaudinski, Martin R.; Strom, Larisa; Hofstetter, Amelia R.; Narpala, Sandeep; Hatcher, Christian; Gillespie, Rebecca A.; Creanga, Adrian; Kanekiyo, Masaru; Raab, Julie E.; Andrews, Sarah F.; Zhang, Yi; Yang, Eun Sung; Wang, Lingshu; Leung, Kwanyee; Kong, Wing-Pui; Bailer, Robert T.; McDermott, Adrian B.; Koup, Richard A.; Gall, Jason G.; Arnold, Frank; Mascola, John R.; Graham, Barney S.; Ledgerwood, Julie E.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Case, Christopher L.] Leidos Biomed Res Inc, Vaccine Clin Mat Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Gaudinski, Martin R.] US PHS, Commissioned Corps, Rockville, MD USA; [Liang, C. Jason] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Freyn, Alec W.; Palese, Peter] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Nachbagauer, Raffael; Palese, Peter] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Public Health Service; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Houser, KV (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	katherine.houser@nih.gov	Strom, Larisa/HCI-4729-2022	Gaudinski, Martin/0000-0002-3743-5281	National Institute of Allergy and Infectious Diseases (NIAID) through the National Institutes of Health (NIH) Intramural Research Program; NIAID [P01 AI097092-07, R01 AI145870-03, 75N93021C00014]; Collaborative Vaccine Innovation Centers [75N93019C00051]	National Institute of Allergy and Infectious Diseases (NIAID) through the National Institutes of Health (NIH) Intramural Research Program; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Collaborative Vaccine Innovation Centers	We thank the trial participants for their involvement as well as PharmaJet for the use of the needle-free Stratis device in this clinical trial. This work was supported by intramural funding from the National Institute of Allergy and Infectious Diseases (NIAID) through the National Institutes of Health (NIH) Intramural Research Program (K.V.H., G.L.C., C.C., M.C.C., T.A.N., M.C.B.F., N.M.B., F.M., C.S.H., I.J.G., E.E.C., S.V., J.S., C.L.C., H.L., K.C., M.R.G., L.S., A.R.H., C.J.L., S.N., C.H., R.A.G., A.C., M.K., J.E.R., S.F.A., Y.Z., E.S.Y., L.W., K.L., W-P.K., R.T.B., A.B.M., R.A.K., J.G.G., F.A., J.R.M., B.S.G. and J.E.L.). This work was partially funded by the NIAID-funded Centers of Excellence for Influenza Research and Response (75N93021C00014, to A.W.F., R.N. and P.P.), by NIAID grant P01 AI097092-07 (to A.W.F., R.N. and P.P.), by NIAID grant R01 AI145870-03 (to A.W.F., R.N. and P.P.) and by the Collaborative Vaccine Innovation Centers contract 75N93019C00051 (to A.W.F., R.N. and P.P.). The Vaccine Research Center (VRC) and its investigators had complete control over study conceptualization and design, data collection and analysis, decision to publish and preparation of this manuscript. Study team representative: Floreliz Mendoza, VRC, NIAID, NIH (email: floreliz.mendoza@nih.gov; phone: 301-451-8715).	Andrews SF, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029413; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Bernstein DI, 2020, LANCET INFECT DIS, V20, P80, DOI 10.1016/S1473-3099(19)30393-7; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Darricarrere N, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe5449; DeZure AD, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0016-6; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ellebedy AH, 2014, P NATL ACAD SCI USA, V111, P13133, DOI 10.1073/pnas.1414070111; Hehme N, 2002, MED MICROBIOL IMMUN, V191, P203, DOI 10.1007/s00430-002-0147-9; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Isakova-Sivak I, 2015, HUM VACC IMMUNOTHER, V11, P970, DOI 10.1080/21645515.2015.1010859; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jones JC, 2014, J VIROL, V88, P1175, DOI 10.1128/JVI.02526-13; Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043; Kanekiyo M, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038448; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Krammer F, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028845; Krammer F, 2014, J VIROL, V88, P2340, DOI 10.1128/JVI.03183-13; Ledgerwood JE, 2013, J INFECT DIS, V208, P418, DOI 10.1093/infdis/jit180; Ledgerwood JE, 2011, LANCET INFECT DIS, V11, P916, DOI 10.1016/S1473-3099(11)70240-7; Nabel GJ, 2011, NATURE, V471, P157, DOI 10.1038/471157a; Nabel GJ, 2010, NAT MED, V16, P1389, DOI 10.1038/nm1210-1389; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15; Nachbagauer R, 2016, J VIROL, V90, P3268, DOI 10.1128/JVI.02481-15; Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x; Sangesland M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020125; Stadlbauer D, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00502-17; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Talaat KR, 2013, INFLUENZA OTHER RESP, V7, P66, DOI 10.1111/j.1750-2659.2012.00350.x; Taubenberger JK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5485; US Food and Drug Administration, 2007, GUID IND CLIN DAT NE; Vanderven HA, 2017, CURR OPIN VIROL, V22, P89, DOI 10.1016/j.coviro.2016.12.002; Wei CJ, 2020, NAT REV DRUG DISCOV, V19, P239, DOI 10.1038/s41573-019-0056-x; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; World Health Organization, SEAS INFL; Wu NC, 2018, NAT STRUCT MOL BIOL, V25, P115, DOI 10.1038/s41594-018-0025-9; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zarnitsyna VI, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005692	41	10	10	6	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					383	+		10.1038/s41591-021-01660-8	http://dx.doi.org/10.1038/s41591-021-01660-8		FEB 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35115706	Bronze			2022-12-27	WOS:000750724400004
J	Ward, JH				Ward, Jillian Hastings			Health data: when children reach the age of consent	NATURE MEDICINE			English	Editorial Material									[Ward, Jillian Hastings] Genom England, Participant Panel, London, England		Ward, JH (corresponding author), Genom England, Participant Panel, London, England.	jillian@curegrin.org		Hastings Ward, Jillian/0000-0001-5146-5498					0	1	1	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					225	225		10.1038/s41591-021-01561-w	http://dx.doi.org/10.1038/s41591-021-01561-w		JAN 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	34992262	Bronze			2022-12-27	WOS:000739773300003
J	Nassif, ME; Windsor, SL; Borlaug, BA; Kitzman, DW; Shah, SJ; Tang, FM; Khariton, Y; Malik, AO; Khumri, T; Umpierrez, G; Lamba, S; Sharma, K; Khan, SS; Chandra, L; Gordon, RA; Ryan, JJ; Chaudhry, SP; Joseph, SM; Chow, CH; Kanwar, MK; Pursley, M; Siraj, ES; Lewis, GD; Clemson, BS; Fong, M; Kosiborod, MN				Nassif, Michael E.; Windsor, Sheryl L.; Borlaug, Barry A.; Kitzman, Dalane W.; Shah, Sanjiv J.; Tang, Fengming; Khariton, Yevgeniy; Malik, Ali O.; Khumri, Taiyeb; Umpierrez, Guillermo; Lamba, Sumant; Sharma, Kavita; Khan, Sadiya S.; Chandra, Lokesh; Gordon, Robert A.; Ryan, John J.; Chaudhry, Sunit-Preet; Joseph, Susan M.; Chow, Chen H.; Kanwar, Manreet K.; Pursley, Michael; Siraj, Elias S.; Lewis, Gregory D.; Clemson, Barry S.; Fong, Michael; Kosiborod, Mikhail N.			The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	NATURE MEDICINE			English	Article							QUALITY-OF-LIFE	In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking. Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7-10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6-34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1-7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05-2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01-1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF.	[Nassif, Michael E.; Windsor, Sheryl L.; Tang, Fengming; Khariton, Yevgeniy; Malik, Ali O.; Khumri, Taiyeb; Kosiborod, Mikhail N.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA; [Nassif, Michael E.; Khariton, Yevgeniy; Malik, Ali O.; Kosiborod, Mikhail N.] Univ Missouri, Kansas City, MO 64110 USA; [Borlaug, Barry A.] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA; [Kitzman, Dalane W.] Wake Forest Sch Med, Dept Internal Med, Sect Cardiovasc Med, Winston Salem, NC 27101 USA; [Kitzman, Dalane W.] Wake Forest Sch Med, Dept Internal Med, Sect Geriatr, Winston Salem, NC 27101 USA; [Shah, Sanjiv J.; Khan, Sadiya S.] Northwestern Univ, Dept Med, Div Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA; [Shah, Sanjiv J.; Khan, Sadiya S.] Northwestern Univ, Bluhm Cardiovasc Inst, Feinberg Sch Med, Chicago, IL 60611 USA; [Umpierrez, Guillermo] Emory Univ, Atlanta, GA 30322 USA; [Lamba, Sumant] First Coast Cardiovasc Inst, Jacksonville, FL USA; [Sharma, Kavita] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Chandra, Lokesh] Chicago Med Res, Hazel Crest, IL USA; [Gordon, Robert A.] NorthShore Univ Hlth Syst, Evanston, IL USA; [Ryan, John J.] Univ Utah, Salt Lake City, UT USA; [Chaudhry, Sunit-Preet] Ascens St Vincent, Indianapolis, IN USA; [Joseph, Susan M.] Univ Maryland, Sch Med, Div Cardiovasc Med, Baltimore, MD 21201 USA; [Chow, Chen H.] Stormont Vail Hlth, Topeka, KS USA; [Kanwar, Manreet K.] Allegheny Hlth Network, Cardiovasc Inst, Pittsburgh, PA USA; [Pursley, Michael] Heart Grp Eastern Shore, Fairhope, AL USA; [Siraj, Elias S.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA; [Lewis, Gregory D.] Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02114 USA; [Clemson, Barry S.] OSF HealthCare Cardiovasc Inst, Peoria, IL USA; [Fong, Michael] Univ Southern Calif, Los Angeles, CA 90007 USA; [Kosiborod, Mikhail N.] George Inst Global Hlth, Sydney, NSW, Australia; [Kosiborod, Mikhail N.] Univ New South Wales, Sydney, NSW, Australia	Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; Mayo Clinic; Wake Forest University; Wake Forest University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Emory University; Johns Hopkins University; NorthShore University Health System; Utah System of Higher Education; University of Utah; University System of Maryland; University of Maryland Baltimore; Eastern Virginia Medical School; Harvard University; Massachusetts General Hospital; University of Southern California; George Institute for Global Health; University of Sydney; University of New South Wales Sydney	Kosiborod, MN (corresponding author), St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA.; Kosiborod, MN (corresponding author), Univ Missouri, Kansas City, MO 64110 USA.; Kosiborod, MN (corresponding author), George Inst Global Hlth, Sydney, NSW, Australia.; Kosiborod, MN (corresponding author), Univ New South Wales, Sydney, NSW, Australia.	mkosiborod@saint-lukes.org	Shah, Sanjiv J./AFQ-9480-2022; Kosiborod, Mikhail/HDO-1541-2022	Kosiborod, Mikhail/0000-0002-3750-9789; Borlaug, Barry/0000-0001-9375-0596; Shah, Sanjiv/0000-0002-5655-8201	AstraZeneca [ESR-16-12141]; AstraZeneca	AstraZeneca(AstraZeneca); AstraZeneca(AstraZeneca)	We thank S. Roche, D. Peterman, K. Waybright, M. Jones, A. Blanton, K. Calvin, D. Cocca-Spofford, R. Farrell, J. Ferree, I. Griffin, D. Horner, A. Howarter, B. Garcia, J. Huckleberry, M. Hudson, M. Kauffman, N. S. Kuhn, K. Lepkowska, P. Mathiason, D'A. Mauer, R. Newland, H. K. Parson, B. Penn and the Gordon family, L. Pierchala, M. Ramos, E. Ricketts, D. Roshevsky, E. Temponi, V. Shaffer and B. Vargas for their contributions to the PRESERVED-HF Trial. This study was funded by AstraZeneca (grant no. ESR-16-12141, M.N.K.). The funder of the study had no role in the design and conduct of the study, the collection, management, analysis and interpretation of the data, the preparation, review or approval of the manuscript, and the decision to submit the manuscript for publication. This study was an investigator-initiated trial funded by AstraZeneca and conducted by Saint Luke's Mid America Heart Institute independent of the funding source.	Abraham WT, 2021, EUR HEART J, V42, P700, DOI 10.1093/eurheartj/ehaa943; Anker SD, 2021, NEW ENGL J MED, V385, P1451, DOI 10.1056/NEJMoa2107038; Anker SD, 2020, EUR J HEART FAIL, V22, P2383, DOI 10.1002/ejhf.2064; Bhatt DL, 2021, NEW ENGL J MED, V384, P129, DOI 10.1056/NEJMoa2030186; Chandra A, 2019, JACC-HEART FAIL, V7, P862, DOI 10.1016/j.jchf.2019.05.015; Cowie MR, 2020, NAT REV CARDIOL, V17, P761, DOI 10.1038/s41569-020-0406-8; Dunlay SM, 2019, CIRCULATION, V140, pE294, DOI 10.1161/CIR.0000000000000691; Dunlay SM, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2017.65; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Juni RP, 2019, JACC-BASIC TRANSL SC, V4, P575, DOI 10.1016/j.jacbts.2019.04.003; Lewis EF, 2001, J HEART LUNG TRANSPL, V20, P1016, DOI 10.1016/S1053-2498(01)00298-4; Lewis EF, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.114.001937; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Nambu H, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172810; Nassif ME, 2021, CIRCULATION, V143, P1673, DOI 10.1161/CIRCULATIONAHA.120.052503; Nassif ME, 2019, CIRCULATION, V140, P1463, DOI 10.1161/CIRCULATIONAHA.119.042929; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Obokata M, 2017, CIRCULATION, V136, P6, DOI 10.1161/CIRCULATIONAHA.116.026807; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Pandey A, 2020, J AM COLL CARDIOL, V78, P1166, DOI 10.1016/j.jacc.2021.07.014; Pandey A, 2015, CIRC-HEART FAIL, V8, P33, DOI 10.1161/CIRCHEARTFAILURE.114.001615; Pfeffer MA, 2019, CIRC RES, V124, P1598, DOI 10.1161/CIRCRESAHA.119.313572; Reddy P, 2000, PHARMACOTHERAPY, V20, P679, DOI 10.1592/phco.20.7.679.35178; Reddy Yogesh N V, 2020, J Am Coll Cardiol, V76, P1051, DOI 10.1016/j.jacc.2020.07.009; Reddy YNV, 2020, EUR J HEART FAIL, V22, P1009, DOI 10.1002/ejhf.1788; Reed SD, 2019, CIRC-CARDIOVASC INTE, V12, DOI 10.1161/CIRCINTERVENTIONS.119.008051; Shah SJ, 2018, EUR HEART J, V39, P3439, DOI 10.1093/eurheartj/ehy531; Solomon SD, 2019, NEW ENGL J MED, V381, P1609, DOI 10.1056/NEJMoa1908655; Solomon SD, 2021, EUR J HEART FAIL, V23, P1217, DOI 10.1002/ejhf.2249; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; US Food and Drug Administration, 2019, TREATM HEART FAIL EN; van Veldhuisen DJ, 2013, J AM COLL CARDIOL, V61, P1498, DOI 10.1016/j.jacc.2012.12.044; Verma Subodh, 2018, JACC Basic Transl Sci, V3, P575, DOI 10.1016/j.jacbts.2018.07.006; Wang L, 2017, CIRCULATION, V135; Warraich HJ, 2018, CIRC-HEART FAIL, V11, DOI 10.1161/CIRCHEARTFAILURE.117.004830; Wolsk E, 2018, EUR J HEART FAIL, V20, P715, DOI 10.1002/ejhf.976	37	115	113	13	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1954	+		10.1038/s41591-021-01536-x	http://dx.doi.org/10.1038/s41591-021-01536-x		OCT 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34711976	Green Published, hybrid			2022-12-27	WOS:000712353600002
J	Pouwels, KB; Pritchard, E; Matthews, PC; Stoesser, N; Eyre, DW; Vihta, KD; House, T; Hay, J; Bell, JI; Newton, JN; Farrar, J; Crook, D; Cook, D; Rourke, E; Studley, R; Peto, TEA; Diamond, I; Walker, AS				Pouwels, Koen B.; Pritchard, Emma; Matthews, Philippa C.; Stoesser, Nicole; Eyre, David W.; Vihta, Karina-Doris; House, Thomas; Hay, Jodie; Bell, John, I; Newton, John N.; Farrar, Jeremy; Crook, Derrick; Cook, Duncan; Rourke, Emma; Studley, Ruth; Peto, Tim E. A.; Diamond, Ian; Walker, A. Sarah			Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	NATURE MEDICINE			English	Article							MESSENGER-RNA-1273 COVID-19 VACCINES; BNT162B2	The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this study, we investigated the effectiveness of these vaccines in a large, community-based survey of randomly selected households across the United Kingdom. We found that the effectiveness of BNT162b2 and ChAdOx1 against infections (new polymerase chain reaction (PCR)-positive cases) with symptoms or high viral burden is reduced with the B.1.617.2 variant (absolute difference of 10-13% for BNT162b2 and 16% for ChAdOx1) compared to the B.1.1.7 (Alpha) variant. The effectiveness of two doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity after second doses differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positive cases but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence that effectiveness varied by dosing interval, but protection was higher in vaccinated individuals after a prior infection and in younger adults. With B.1.617.2, infections occurring after two vaccinations had similar peak viral burden as those in unvaccinated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden are reduced with B.1.617.2. A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant.	[Pouwels, Koen B.; Pritchard, Emma; Stoesser, Nicole; Eyre, David W.; Vihta, Karina-Doris; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah] Univ Oxford, Natl Inst Hlth Res, Hlth Protect Res Unit, Healthcare Associated Infect & Antimicrobial, Oxford, England; [Pouwels, Koen B.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England; [Pritchard, Emma; Matthews, Philippa C.; Stoesser, Nicole; Eyre, David W.; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England; [Matthews, Philippa C.; Stoesser, Nicole; Eyre, David W.; Crook, Derrick; Peto, Tim E. A.; Walker, A. Sarah] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Dept Infect Dis & Microbiol, Oxford, England; [Matthews, Philippa C.; Stoesser, Nicole; Crook, Derrick; Peto, Tim E. A.] Univ Oxford, Natl Inst Hlth Res, Oxford Biomed Res Ctr, Oxford, England; [Eyre, David W.] Univ Oxford, Nuffield Dept Populat Hlth, Big Data Inst, Oxford, England; [Vihta, Karina-Doris] Univ Oxford, Dept Engn, Oxford, England; [House, Thomas] Univ Manchester, Dept Math, Manchester, Lancs, England; [House, Thomas] IBM Res, Hartree Ctr, Sci Tech Daresbury, Warrington, Cheshire, England; [Hay, Jodie] Glasgow Lighthouse Lab, Glasgow, Lanark, Scotland; [Hay, Jodie] Univ Glasgow, Glasgow, Lanark, Scotland; [Bell, John, I] Univ Oxford, Off Regius Prof Med, Oxford, England; [Newton, John N.] Publ Hlth England, Hlth Improvement Directorate, London, England; [Farrar, Jeremy] Wellcome Trust Res Labs, London, England; [Cook, Duncan; Rourke, Emma; Studley, Ruth; Diamond, Ian] Off Natl Stat, Newport, Wales; [Walker, A. Sarah] UCL, MRC Clin Trials Unit UCL, London, England	University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Manchester; STFC Daresbury Laboratory; University of Glasgow; University of Oxford; Public Health England; Medical Research Council Clinical Trials Unit; University of London; University College London	Pouwels, KB (corresponding author), Univ Oxford, Natl Inst Hlth Res, Hlth Protect Res Unit, Healthcare Associated Infect & Antimicrobial, Oxford, England.; Pouwels, KB (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.	koen.pouwels@ndph.ox.ac.uk	Stoesser, Nicole/H-3421-2019; Walker, Sarah/HDM-8717-2022; Farrar, Jeremy J./HGA-7610-2022; Newton, John/HCH-8693-2022; Brown, Brent/HIR-3281-2022; Eyre, David/P-6887-2016	Stoesser, Nicole/0000-0002-4508-7969; Brown, Brent/0000-0001-5238-6943; Pouwels, Koen/0000-0001-7097-8950; Eyre, David/0000-0001-5095-6367; Pritchard, Emma/0000-0002-0963-9260; House, Thomas/0000-0001-5835-8062; Hay, Jodie/0000-0002-2000-2578; Vihta, Karina-Doris/0000-0002-4111-7577; Crook, Derrick/0000-0002-0590-2850; Matthews, Philippa/0000-0002-4036-4269; Newton, John/0000-0002-5641-6457	Department of Health and Social Care; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; Public Health England (PHE) [NIHR200915]; NIHR Oxford Biomedical Research Centre; Huo Family Foundation; Medical Research Council (MRC) UK [MC_UU_12023/22A]; Wellcome [110110/Z/15/Z]; Robertson Fellowship; NIHR Oxford BRC Senior Fellowship; COVID-19 Infection Survey participants; COVID-19 Infection Survey team: Office for National Statistics	Department of Health and Social Care; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; Public Health England (PHE); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Huo Family Foundation; Medical Research Council (MRC) UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome; Robertson Fellowship; NIHR Oxford BRC Senior Fellowship; COVID-19 Infection Survey participants; COVID-19 Infection Survey team: Office for National Statistics	This study is funded by the Department of Health and Social Care, with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. E.P., K.B.P., A.S.W., T.E.A.P., N.S. and D.E. are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, in partnership with Public Health England (PHE) (NIHR200915). A.S.W. and T.E.A.P. are also supported by the NIHR Oxford Biomedical Research Centre. E.P. and K.B.P. are also supported by the Huo Family Foundation. A.S.W. is also supported by core support from the Medical Research Council (MRC) UK to the MRC Clinical Trials Unit (MC_UU_12023/22A) and is an NIHR Senior Investigator. P.C.M. is funded by Wellcome (intermediate fellowship, grant no. 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. D.W.E. is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and are not necessarily those of the National Health Service, the NIHR, the Department of Health or PHE. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. All authors had full access to all data analysis outputs (reports and tables) and take responsibility for their integrity and accuracy. We are grateful for the support of all COVID-19 Infection Survey participants and the COVID-19 Infection Survey team: Office for National Statistics: I. Diamond, E. Rourke, R. Studley, T. Thomas, D. Cook, D. Ayoubkhani, R. Black, A. Felton, M. Crees, J. Jones, L. Lloyd and E. Sutherland; University of Oxford, Nuffield Department of Medicine: A. S. Walker, D. Crook, P. C. Matthews, T. Peto, E. Pritchard, N. Stoesser, K.-D. Vihta, J. Wei, A. Howarth, G. Doherty, J. Kavanagh, K. K. Chau, S. B. Hatch, D. Ebner, L. Martins Ferreira, T. Christott, B. D. Marsden, W. Dejnirattisai, J. Mongkolsapaya, S. Cameron, P. Tamblin-Hopper, M. Wolna, R. Brown, S. Hoosdally, R. Cornall, D. I. Stuart and G. Screaton; University of Oxford, Nuffield Department of Population Health: K. Pouwels; University of Oxford, Big Data Institute: D. W. Eyre, K. Lythgoe, D. Bonsall, T. Golubchik and H. Fryer; University of Oxford, Radcliffe Department of Medicine: J. Bell; Oxford University Hospitals NHS Foundation Trust: S. Cox, K. Paddon and T. James; University of Manchester: T. House; Wellcome Trust: J. Farrar; Public Health England: J. Newton, J. Robotham and P. Birrell; IQVIA: H. Jordan, T. Sheppard, G. Athey, D. Moody, L. Curry and P. Brereton; National Biocentre: I. Jarvis, A. Godsmark, G. Morris, B. Mallick and P. Eeles; Glasgow Lighthouse Laboratory: J. Hay and H. VanSteenhouse; Department of Health and Social Care: J. Lee; Welsh Government: S. White, T. Evans and L. Bloemberg; Scottish Government: K. Allison, A. Pandya and S. Davis; Public Health Scotland: D. I. Conway, M. MacLeod and C. Cunningham.	Arkin, 2019, SCIENCE, DOI [10.1126/science.364.6438.320, 10.1126/science.abe9728]; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; Chia PY, 2022, CLIN MICROBIOL INFEC, V28, DOI 10.1016/j.cmi.2021.11.010; Chung H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1943; DAVIS C, 2021, REDUCED NEUTRALISATI; Evans SJW, 2021, NEW ENGL J MED, V385, P650, DOI 10.1056/NEJMe2110605; Fell DB, 2021, MEDRXIV, DOI [10.1101/2021.06.28.21259420, 10.1101/2021.06.28.21259420v2, DOI 10.1101/2021.06.28.21259420V2]; Florek K. R., 2021, SHEDDING INFECT SARS, DOI 10.1101/2021.08.15.21262077v1.full; Goldberg Y., 2021, WANING IMMUNITY BNT1, DOI 10.1101/2021.08.24.21262423v1; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hay JA, 2021, SCIENCE, V373, DOI 10.1126/science.abh0635; Huang HL, 2022, CLIN INFECT DIS, V74, P1507, DOI 10.1093/cid/ciab756; Imai N., WELLCOME OPEN RES, V6, P185; Israel Ariel, 2021, medRxiv, DOI 10.1101/2021.08.03.21261496; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Lavelle EC, 2021, NAT REV IMMUNOL; Lewnard JA, 2021, EPIDEMIOLOGY, V32, P508, DOI 10.1097/EDE.0000000000001366; Mizrahi B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26672-3; Mlcochova P., 2021, SARS COV 2 B16172 DE, DOI 10.1101/2021.05.08.443253; Noori M, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2277; Pouwels KB, 2021, LANCET PUBLIC HEALTH, V6, pE30, DOI 10.1016/S2468-2667(20)30282-6; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shrotri M, 2021, LANCET INFECT DIS, V21, P1529, DOI 10.1016/S1473-3099(21)00289-9; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Tang P., BNT162B2 MRNA 1273 C, DOI 10.1101/2021.08.11.21261885v1(2021); Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; van Doremalen N, 2020, NATURE, V586, P578, DOI [10.1101/2020.05.13.093195, 10.1038/s41586-020-2608-y]; Walker AS, 2021, ELIFE, V10, DOI 10.7954/eLife.64683; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3	34	210	211	5	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2127	+		10.1038/s41591-021-01548-7	http://dx.doi.org/10.1038/s41591-021-01548-7		OCT 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34650248	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000707284000001
J	Kane, PB; Bittlinger, M; Kimmelman, J				Kane, Patrick Bodilly; Bittlinger, Merlin; Kimmelman, Jonathan			Individualized therapy trials: navigating patient care, research goals and ethics	NATURE MEDICINE			English	Article							ESTIMATE POPULATION TREATMENT; DEEP BRAIN-STIMULATION; N-OF-1 TRIALS; RANDOMIZED TRIALS; ONCOLOGY TRIALS; INTERVENTIONS; INFORMATION; EQUIPOISE; QUALITY; BENEFIT	'Individualized therapy' trials (sometimes called n-of-1 trials) use patients as their own controls to evaluate treatments. Here we divide such trials into three categories: multi-crossover trials aimed at individual patient management, multi-crossover trial series and pre-post trials. These trials all customize interventions for patients; however, the latter two categories also aim to inform medical practice and thus embody tensions between the goals of care and research that are typical of other types of clinical trials. In this Perspective, we discuss four domains where such tensions play out-clinical equipoise, informed consent, reporting and funding, and we provide recommendations for addressing each. In this Perspective, the authors discuss the ethical challenges of individualized therapy (also called n-of-1) trials and argue that, although customized for the patient, these constitute 'research' nonetheless.	[Kane, Patrick Bodilly; Bittlinger, Merlin; Kimmelman, Jonathan] McGill Univ, Biomed Eth Unit, Studies Translat Eth & Med, Montreal, PQ, Canada	McGill University	Kimmelman, J (corresponding author), McGill Univ, Biomed Eth Unit, Studies Translat Eth & Med, Montreal, PQ, Canada.	jonathan.kimmelman@mcgill.ca	Bittlinger, Merlin/M-9415-2017	Bittlinger, Merlin/0000-0002-4460-7037; Kimmelman, Jonathan/0000-0003-1614-6779	CIHR Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		Anderson JA, 2010, KENNEDY INST ETHIC J, V20, P75, DOI 10.1353/ken.0.0307; [Anonymous], 2019, NAT MED, V25, P1797, DOI 10.1038/s41591-019-0700-3; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Araujo A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167167; Arnold SE, 2018, ANN NEUROL, V84, P168, DOI 10.1002/ana.25280; Berlin JA, 2010, J CLIN EPIDEMIOL, V63, P1283, DOI 10.1016/j.jclinepi.2010.05.006; Berman JZ, 2018, PSYCHOL SCI, V29, P834, DOI 10.1177/0956797617747648; Blackston JW, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7040137; Brierley J, 2009, ARCH DIS CHILD, V94, P651, DOI 10.1136/adc.2008.155317; Carlisle B, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k959; Carlisle B, 2015, CLIN TRIALS, V12, P77, DOI 10.1177/1740774514558307; Center for Drug Evaluation and Research, 2021, IND SUBM IND ANT OL; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Chow S.-C, 2020, INNOVATIVE METHODS R, P67; Collette L, 2015, LANCET ONCOL, V16, P885, DOI 10.1016/S1470-2045(15)00062-5; Committee for Medicinal Products for Human Use, 2017, GUID STRAT ID MIT RI; Cornu C, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-48; Earl J, 2020, INTERN MED J, V50, P1583, DOI 10.1111/imj.15117; Emmerich CH, 2021, NAT REV DRUG DISCOV, V20, P64, DOI 10.1038/s41573-020-0087-3; Fajgenbaum DC, 2019, J CLIN INVEST, V129, P4451, DOI 10.1172/JCI126091; Fetherstonhaugh D, 1997, J RISK UNCERTAINTY, V14, P283, DOI 10.1023/A:1007744326393; Fins JJ, 2011, HEALTH AFFAIR, V30, P302, DOI 10.1377/hlthaff.2010.0157; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Gabler NB, 2011, MED CARE, V49, P761, DOI 10.1097/MLR.0b013e318215d90d; Gelinas L, 2019, CONTEMP CLIN TRIALS, V84, DOI 10.1016/j.cct.2019.105812; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358; Hartman AL, 2021, NEUROLOGY, V96, P513, DOI 10.1212/WNL.0000000000011603; Hayden E. C., 2019, MIT TECHNOL REV; hhs, 1979, BELM REP ETH PRINC G; Joseph A., 2021, HUNTINGTONS COMMUNIT; Kane P. B., ELIFE, P67; Kim J, 2019, NEW ENGL J MED, V381, P1644, DOI 10.1056/NEJMoa1813279; Kim SYH, 2015, J MED ETHICS, V41, P391, DOI 10.1136/medethics-2013-101987; Kimmelman J, 2007, HASTINGS CENT REP, V37, P36, DOI 10.1353/hcr.2007.0092; Kimmelman J, 2019, JAMA PEDIATR, V173, P8, DOI 10.1001/jamapediatrics.2018.3629; Kimmelman J, 2017, NATURE, V542, P25, DOI 10.1038/542025a; Kimmelman J, 2015, HASTINGS CENT REP, V45, P27, DOI 10.1002/hast.433; Kimmelman J, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001863; Kimmelman J, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-173; Kogut T, 2005, J BEHAV DECIS MAKING, V18, P157, DOI 10.1002/bdm.492; Kravitz RL, 2008, MILBANK Q, V86, P533, DOI 10.1111/j.1468-0009.2008.00533.x; Kravitz RL, 2004, MILBANK Q, V82, P661, DOI 10.1111/j.0887-378X.2004.00327.x; Kulkarni JA, 2021, NAT NANOTECHNOL, V16, P630, DOI 10.1038/s41565-021-00898-0; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Li J, 2016, J CLIN EPIDEMIOL, V76, P57, DOI 10.1016/j.jclinepi.2015.11.016; Lilford RJ, 2000, BRIT MED J, V320, P43, DOI 10.1136/bmj.320.7226.43; Lillie EO, 2011, PERS MED, V8, P161, DOI 10.2217/PME.11.7; London A. J., 2020, OXFORD HDB RES ETHIC; London AJ, 2010, SCIENCE, V328, P829, DOI 10.1126/science.1189369; Mahon J, 1996, BRIT MED J, V312, P1069; Mastroleo Ignacio, 2020, Law, Innovation and Technology, V12, P318, DOI 10.1080/17579961.2020.1815405; Muller AR, 2021, NEUROLOGY, V96, P529, DOI 10.1212/WNL.0000000000011597; Mullard A, 2020, NAT REV DRUG DISCOV, V19, P151, DOI 10.1038/d41573-020-00027-x; Nick JA, 2020, J CYST FIBROS, V19, P91, DOI 10.1016/j.jcf.2019.09.013; Pentz RD, 2012, CANCER-AM CANCER SOC, V118, P4571, DOI 10.1002/cncr.27397; Porcino AJ, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m122; Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Raman G, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017641; Schlaepfer TE, 2010, JAMA-J AM MED ASSOC, V303, P775, DOI 10.1001/jama.2010.140; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Schweitzer JS, 2020, NEW ENGL J MED, V382, P1926, DOI 10.1056/NEJMoa1915872; Senarathne SGJ, 2020, STAT MED, V39, P4499, DOI 10.1002/sim.8737; Senior M, 2017, NAT BIOTECHNOL, V35, P491, DOI 10.1038/nbt0617-491; Senn SS, 2008, STAT ISSUES DRUG DEV; Senn S, 2019, STAT METHODS MED RES, V28, P372, DOI 10.1177/0962280217726801; Sertkaya A., 2014, EXAMINATION CLIN TRI; Sertkaya A, 2016, CLIN TRIALS, V13, P117, DOI 10.1177/1740774515625964; Shamseer L, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1793; Shrestha S, 2021, STAT MED, V40, P1825, DOI 10.1002/sim.8873; Sulmasy DP, 2010, CANCER-AM CANCER SOC, V116, P3702, DOI 10.1002/cncr.25201; Tate RL, 2016, J SCHOOL PSYCHOL, V56, P133, DOI 10.1016/j.jsp.2016.04.001; Tate RL, 2013, NEUROPSYCHOL REHABIL, V23, P619, DOI 10.1080/09602011.2013.824383; Turner L, 2016, CELL STEM CELL, V19, P154, DOI 10.1016/j.stem.2016.06.007; US National Institute of Medicine, FDAAA 801 FIN RUL; US National Institutes of Health, 2017, NIH POL DISS NIH FUN; van Overbeeke E, 2021, DRUG DISCOV TODAY, V26, P399, DOI 10.1016/j.drudis.2020.11.024; Vohra S., 2014, DESIGN IMPLEMENTATIO, P13; Vohra S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1738; Weijer C, 2004, NAT MED, V10, P570, DOI 10.1038/nm0604-570; Weinfurt KP, 2012, J CLIN ONCOL, V30, P4396, DOI 10.1200/JCO.2011.40.6587; Wenner DM, 2018, HASTINGS CENT REP, V48, P25, DOI 10.1002/hast.934; Wenner DM, 2015, CELL STEM CELL, V17, P135, DOI 10.1016/j.stem.2015.07.016; Woodcock J, 2019, NEW ENGL J MED, V381, P1678, DOI 10.1056/NEJMe1911295; Zarin DA, 2019, JAMA-J AM MED ASSOC, V322, P813, DOI 10.1001/jama.2019.9892; Zarin DA, 2011, NEW ENGL J MED, V364, P852, DOI 10.1056/NEJMsa1012065; Zhai JB, 2016, J CLIN EPIDEMIOL, V76, P99, DOI 10.1016/j.jclinepi.2016.02.023; Zhang SX, 2020, JNCI-J NATL CANCER I, V112, P886, DOI 10.1093/jnci/djaa044; Zucker DR, 2010, J CLIN EPIDEMIOL, V63, P1312, DOI 10.1016/j.jclinepi.2010.04.020; Zucker DR, 1997, J CLIN EPIDEMIOL, V50, P401, DOI 10.1016/S0895-4356(96)00429-5	92	7	7	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1679	1686		10.1038/s41591-021-01519-y	http://dx.doi.org/10.1038/s41591-021-01519-y		OCT 2021	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642487				2022-12-27	WOS:000706587600004
J	Dummer, R; Gyorki, DE; Hyngstrom, J; Berger, AC; Conry, R; Demidov, L; Sharma, A; Treichel, SA; Radcliffe, H; Gorski, KS; Anderson, A; Chan, E; Faries, M; Ross, MI				Dummer, R.; Gyorki, D. E.; Hyngstrom, J.; Berger, A. C.; Conry, R.; Demidov, L.; Sharma, A.; Treichel, S. A.; Radcliffe, H.; Gorski, K. S.; Anderson, A.; Chan, E.; Faries, M.; Ross, M. I.			Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial	NATURE MEDICINE			English	Article							III MELANOMA; BIOCHEMOTHERAPY; INTERFERON-ALPHA-2B; MULTICENTER; THERAPY; RISK	Intralesional injection of an oncolytic virus prior to surgery shows favorable clinical activity over surgery alone in patients with locally advanced, resectable melanoma, supporting further evaluation in the neoadjuvant setting for this population. Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma. The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free survival (RFS) of patients with advanced resectable melanoma. An open-label, phase 2 trial (NCT02211131) was conducted in 150 patients with resectable stage IIIB-IVM1a melanoma who were randomized to receive T-VEC followed by surgery (arm 1, n = 76) or surgery alone (arm 2, n = 74). The primary endpoint was a 2-year RFS in the intention-to-treat population. Secondary and exploratory endpoints included overall survival (OS), pathological complete response (pCR), safety and biomarker analyses. The 2-year RFS was 29.5% in arm 1 and 16.5% in arm 2 (overall hazard ratio (HR) = 0.75, 80% confidence interval (CI) = 0.58-0.96). The 2-year OS was 88.9% for arm 1 and 77.4% for arm 2 (overall HR = 0.49, 80% CI = 0.30-0.79). The RFS and OS differences between arms persisted at 3 years. In arm 1, 17.1% achieved a pCR. Increased CD8(+) density correlated with clinical outcomes in an exploratory analysis. Arm 1 adverse events were consistent with previous reports for T-VEC. The present study met its primary endpoint and estimated a 25% reduction in the risk of disease recurrence for neoadjuvant T-VEC plus surgery versus upfront surgery for patients with resectable stage IIIB-IVM1a melanoma.	[Dummer, R.] Univ Hosp Zurich, Zurich, Switzerland; [Gyorki, D. E.] Austin Hlth, Olivia Newton John Canc Ctr, Heidelberg, Vic, Australia; [Hyngstrom, J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Berger, A. C.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; [Conry, R.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Demidov, L.] NN Blokhin Russian Canc Res Ctr, Moscow, Russia; [Sharma, A.; Anderson, A.; Chan, E.] Amgen Inc, Thousand Oaks, CA 91320 USA; [Treichel, S. A.; Gorski, K. S.] Amgen Inc, San Francisco, CA USA; [Radcliffe, H.] Amgen Inc, Uxbridge, Middx, England; [Faries, M.] John Wayne Canc Inst, Santa Monica, CA USA; [Ross, M. I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Berger, A. C.] Canc Inst New Jersey, New Brunswick, NJ USA; [Faries, M.] Angeles Clin & Res Inst, Los Angeles, CA USA	University of Zurich; University Zurich Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Jefferson University; University of Alabama System; University of Alabama Birmingham; N.N. Blokhin Russian Cancer Research Center; Amgen; Amgen; Amgen; Amgen Limited; John Wayne Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Angeles Clinic & Research Institute	Dummer, R (corresponding author), Univ Hosp Zurich, Zurich, Switzerland.	Reinhard.Dummer@usz.ch			Amgen Inc.	Amgen Inc.(Amgen)	Medical writing support was provided by C. Nosala of Amgen Inc. The authors thank J. Gansert of Amgen Inc. for designing the study and R. Andtbacka for contributions to study design. This study was sponsored by Amgen Inc.	Amaria RN, 2019, LANCET ONCOL, V20, pE378, DOI 10.1016/S1470-2045(19)30332-8; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Andtbacka RHI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0623-z; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buzaid AC, 1998, MELANOMA RES, V8, P549, DOI 10.1097/00008390-199812000-00010; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eggermont AMM, 2008, LANCET, V372, P117, DOI 10.1016/S0140-6736(08)61033-8; Garutti M, 2020, CANCERS, V12, DOI 10.3390/cancers12071941; Gogas H, 2018, ANN ONCOL, V29, P443; Helmink B, 2019, LANCET ONCOL, V20, P892, DOI 10.1016/S1470-2045(19)30377-8; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958; Larocca CA, 2020, AM J CLIN DERMATOL, V21, P821, DOI 10.1007/s40257-020-00554-8; Lewis KD, 2006, J CLIN ONCOL, V24, P3157, DOI 10.1200/JCO.2005.04.5344; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Long GV, 2019, LANCET ONCOL, V20, P961, DOI 10.1016/S1470-2045(19)30331-6; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Michielin O, 2019, ANN ONCOL, V30, P1884, DOI 10.1093/annonc/mdz411; Miller CJ, 2017, J AM ACAD DERMATOL, V77, P333, DOI 10.1016/j.jaad.2017.03.025; Moschos SJ, 2006, J CLIN ONCOL, V24, P3164, DOI 10.1200/JCO.2005.05.2498; O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Versluis JM, 2020, NAT MED, V26, P475, DOI 10.1038/s41591-020-0829-0	28	16	16	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1789	+		10.1038/s41591-021-01510-7	http://dx.doi.org/10.1038/s41591-021-01510-7		OCT 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34608333				2022-12-27	WOS:000703378900007
J	Spiegel, JY; Patel, S; Muffly, L; Hossain, NM; Oak, J; Baird, JH; Frank, MJ; Shiraz, P; Sahaf, B; Craig, J; Iglesias, M; Younes, S; Natkunam, Y; Ozawa, MG; Yang, E; Tamaresis, J; Chinnasamy, H; Ehlinger, Z; Reynolds, W; Lynn, R; Rotiroti, MC; Gkitsas, N; Arai, S; Johnston, L; Lowsky, R; Majzner, RG; Meyer, E; Negrin, RS; Rezvani, AR; Sidana, S; Shizuru, J; Weng, WK; Mullins, C; Jacob, A; Kirsch, I; Bazzano, M; Zhou, J; Mackay, S; Bornheimer, SJ; Schultz, L; Ramakrishna, S; Davis, KL; Kong, KA; Shah, NN; Qin, HY; Fry, T; Feldman, S; Mackall, CL; Miklos, DB				Spiegel, Jay Y.; Patel, Shabnum; Muffly, Lori; Hossain, Nasheed M.; Oak, Jean; Baird, John H.; Frank, Matthew J.; Shiraz, Parveen; Sahaf, Bita; Craig, Juliana; Iglesias, Maria; Younes, Sheren; Natkunam, Yasodha; Ozawa, Michael G.; Yang, Eric; Tamaresis, John; Chinnasamy, Harshini; Ehlinger, Zach; Reynolds, Warren; Lynn, Rachel; Rotiroti, Maria Caterina; Gkitsas, Nikolaos; Arai, Sally; Johnston, Laura; Lowsky, Robert; Majzner, Robbie G.; Meyer, Everett; Negrin, Robert S.; Rezvani, Andrew R.; Sidana, Surbhi; Shizuru, Judith; Weng, Wen-Kai; Mullins, Chelsea; Jacob, Allison; Kirsch, Ilan; Bazzano, Magali; Zhou, Jing; Mackay, Sean; Bornheimer, Scott J.; Schultz, Liora; Ramakrishna, Sneha; Davis, Kara L.; Kong, Katherine A.; Shah, Nirali N.; Qin, Haiying; Fry, Terry; Feldman, Steven; Mackall, Crystal L.; Miklos, David B.			CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	NATURE MEDICINE			English	Article							SURFACE-ANTIGEN; TUMOR-ANTIGEN; RECEPTOR; EFFICACY; LYMPHOMA; THERAPY; REMISSIONS; EXPRESSION; EXPANSION; ESCAPE	Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19- or CD19lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (NCT03233854) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19-/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22-/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency.	[Spiegel, Jay Y.; Muffly, Lori; Baird, John H.; Frank, Matthew J.; Shiraz, Parveen; Craig, Juliana; Iglesias, Maria; Arai, Sally; Johnston, Laura; Lowsky, Robert; Meyer, Everett; Negrin, Robert S.; Rezvani, Andrew R.; Sidana, Surbhi; Shizuru, Judith; Weng, Wen-Kai; Miklos, David B.] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Stanford, CA 94305 USA; [Patel, Shabnum; Muffly, Lori; Sahaf, Bita; Chinnasamy, Harshini; Ehlinger, Zach; Reynolds, Warren; Lynn, Rachel; Gkitsas, Nikolaos; Majzner, Robbie G.; Schultz, Liora; Ramakrishna, Sneha; Davis, Kara L.; Kong, Katherine A.; Feldman, Steven; Mackall, Crystal L.; Miklos, David B.] Stanford Univ, Stanford Canc Inst, Ctr Canc Cell Therapy, Sch Med, Stanford, CA 94305 USA; [Hossain, Nasheed M.] Loyola Univ Med Ctr, Div Hematol Oncol, Chicago, IL USA; [Oak, Jean; Younes, Sheren; Natkunam, Yasodha; Ozawa, Michael G.; Yang, Eric] Stanford Univ, Dept Clin Pathol, Sch Med, Stanford, CA 94305 USA; [Tamaresis, John] Stanford Univ, Dept Biomed Data Sci, Sch Med, Stanford, CA 94305 USA; [Rotiroti, Maria Caterina; Majzner, Robbie G.; Schultz, Liora; Ramakrishna, Sneha; Davis, Kara L.; Mackall, Crystal L.] Stanford Univ, Dept Pediat Hematol Oncol, Sch Med, Stanford, CA 94305 USA; [Mullins, Chelsea; Jacob, Allison; Kirsch, Ilan] Adapt Biotechnol, Seattle, WA USA; [Bazzano, Magali; Zhou, Jing; Mackay, Sean] IsoPlexis, Brantford, CT USA; [Bornheimer, Scott J.] BD Biosci, San Jose, CA USA; [Schultz, Liora; Shah, Nirali N.; Qin, Haiying; Fry, Terry] NIH, Pediat Oncol Branch Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA; [Fry, Terry] Univ Colorado Anschutz & Childrens Hosp Colorado, Dept Pediat Hematol Oncol, Denver, CO USA; [Lynn, Rachel] Lyell Immunopharma, San Francisco, CA USA	Stanford University; Stanford Cancer Institute; Stanford University; Stanford University; Stanford University; Stanford University; National Institutes of Health (NIH) - USA	Miklos, DB (corresponding author), Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Stanford, CA 94305 USA.; Mackall, CL; Miklos, DB (corresponding author), Stanford Univ, Stanford Canc Inst, Ctr Canc Cell Therapy, Sch Med, Stanford, CA 94305 USA.; Mackall, CL (corresponding author), Stanford Univ, Dept Pediat Hematol Oncol, Sch Med, Stanford, CA 94305 USA.	cmackall@stanford.edu; dmiklos@stanford.edu	Baird, John H./AFO-5626-2022	Baird, John H./0000-0001-8291-6546; Patel, Shabnum/0000-0002-4782-9540; ROTIROTI, MARIA CATERINA/0000-0002-3214-1540; Reynolds, Warren/0000-0002-1755-2835; Muffly, Lori/0000-0002-9887-6136; Ehlinger, Zachary/0000-0003-0849-1089; Ramakrishna, Sneha/0000-0001-7445-3190; Oak, Jean/0000-0001-5220-4628; Spiegel, Jay/0000-0001-6491-0044; Craig, Juliana/0000-0002-5644-2292; Iglesias, Maria/0000-0001-9775-7744; Hossain, Nasheed/0000-0002-3278-655X; Sidana, Surbhi/0000-0003-3288-7614	California Institute for Regenerative Medicine [CLIN2-10846]; National Cancer Institute [5P30CA124435, U54 CA232568-01, 2P01CA049605-29A1]; Stanford University Cancer Immunotherapy Program; Virginia and D.K. Ludwig Fund for Cancer Research; National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) [75N92019D00018]; American Society of Hematology Research Training Award; Maternal and Child Health Research Institute	California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stanford University Cancer Immunotherapy Program; Virginia and D.K. Ludwig Fund for Cancer Research; National Heart, Lung, and Blood Institute, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Society of Hematology Research Training Award; Maternal and Child Health Research Institute	This work was supported by the California Institute for Regenerative Medicine (award no. CLIN2-10846 to C.L.M., principal investigator) and from the National Cancer Institute (grant no. 5P30CA124435 to C.L.M., grant no. U54 CA232568-01 to C.L.M and grant no. 2P01CA049605-29A1 to C.L.M. and D.M.). C.L.M. is a member of the Parker Institute for Cancer Immunotherapy, which supports the Stanford University Cancer Immunotherapy Program. The work was also supported by the Virginia and D.K. Ludwig Fund for Cancer Research (C.L.M.). This work received testing support from the National Gene Vector Biorepository, which is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), contract no. 75N92019D00018. J.Y.S. received support from a 2019-2020 American Society of Hematology Research Training Award for Fellows. K.L.D. is supported by the Maternal and Child Health Research Institute as the Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases. R.G.M. is the Taube Distinguished Scholar for Pediatric Immunotherapy at Stanford University School of Medicine. We thank our contract manufacturing organizations: the Laboratory of Cell and Gene Medicine, Stanford University and Miltenyi Biotec. We thank Adaptive Biotechnologies for their collaboration in measuring cell-free MRD and Becton Dickinson for assistance in developing the antigen quantitation assays. We thank IsoPlexis for their collaboration in performing the single-cell cytokine analysis on manufactured CAR T products in Fig. 4j. Figs. 2 and 4 and Extended Data Fig. 1 were created using BioRender.com.	Abramson JS, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127508; Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903; Amrolia PJ, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123424; Asnani M, 2020, LEUKEMIA, V34, P1202, DOI 10.1038/s41375-019-0580-z; Bagashev A, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00383-18; Baird JH, 2021, BLOOD, V137, P2321, DOI 10.1182/blood.2020009432; Bielamowicz K, 2018, NEURO-ONCOLOGY, V20, P506, DOI 10.1093/neuonc/nox182; Blaeschke F, 2018, CANCER IMMUNOL IMMUN, V67, P1053, DOI 10.1007/s00262-018-2155-7; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Ching T, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07077-9; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Dai HR, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00856-8; Fousek K, 2021, LEUKEMIA, V35, P75, DOI 10.1038/s41375-020-0792-2; Frank MJ, 2021, J CLIN ONCOL, V39, P3034, DOI 10.1200/JCO.21.00377; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Gardner R, 2016, BLOOD, V127, P2406, DOI 10.1182/blood-2015-08-665547; Gardner RA, 2020, J CLIN ONCOL, V38; Grada Z, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.32; Guest RD, 2005, J IMMUNOTHER, V28, P203, DOI 10.1097/01.cji.0000161397.96582.59; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; Hay KA, 2019, BLOOD, V133, P1652, DOI 10.1182/blood-2018-11-883710; He X, 2020, BLOOD, V135, P713, DOI 10.1182/blood.2019002779; Hegde M, 2016, J CLIN INVEST, V126, P3036, DOI 10.1172/JCI83416; Hombach AA, 2016, MOL THER, V24, P1423, DOI 10.1038/mt.2016.82; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; Jacoby E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12320; Jena B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057838; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Li D, 2020, GASTROENTEROLOGY, V158, P2250, DOI 10.1053/j.gastro.2020.02.011; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Long AH, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23621; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Majzner RG, 2020, CANCER DISCOV, V10, P702, DOI 10.1158/2159-8290.CD-19-0945; Majzner RG, 2019, CLIN CANCER RES, V25, P2560, DOI 10.1158/1078-0432.CCR-18-0432; Majzner RG, 2018, CANCER DISCOV, V8, P1219, DOI 10.1158/2159-8290.CD-18-0442; Marinelli RJ, 2008, NUCLEIC ACIDS RES, V36, pD871, DOI 10.1093/nar/gkm861; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Nastoupil LJ, 2020, J CLIN ONCOL, V38, P3119, DOI 10.1200/JCO.19.02104; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126218; Oak J, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-120206; Olejniczak SH, 2006, IMMUNOL INVEST, V35, P93, DOI 10.1080/08820130500496878; Orlando EJ, 2018, NAT MED, V24, P1504, DOI 10.1038/s41591-018-0146-z; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Pasquini MC, 2020, BLOOD ADV, V4, P5414, DOI 10.1182/bloodadvances.2020003092; Qin HY, 2018, MOL THER-ONCOLYTICS, V11, P127, DOI 10.1016/j.omto.2018.10.006; Raponi S, 2011, LEUKEMIA LYMPHOMA, V52, P1098, DOI 10.3109/10428194.2011.559668; Schmidts A, 2019, BLOOD ADV, V3, P3248, DOI 10.1182/bloodadvances.2019000703; SCHUSTER SJ, 2017, NEW ENGL J MED, V377, P2545, DOI [10.1056/NEJMoa1708566, DOI 10.1056/NEJMOA1708566]; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Shah NN, 2015, PEDIATR BLOOD CANCER, V62, P964, DOI 10.1002/pbc.25410; Shah NN, 2020, NAT MED, V26, P1569, DOI 10.1038/s41591-020-1081-3; Shalabi H, 2018, HAEMATOLOGICA, V103, pE215, DOI 10.3324/haematol.2017.183459; Singh N, 2019, BLOOD, V134, DOI 10.1182/blood-2019-131024; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Spiegel JY, 2021, BLOOD, V137, P1832, DOI 10.1182/blood.2020006245; Tedder TF, 2005, ADV IMMUNOL, V88, P1, DOI 10.1016/S0065-2776(05)88001-0; Tong C, 2020, BLOOD, V136, P1632, DOI 10.1182/blood.2020005278; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Walker AJ, 2017, MOL THER, V25, P2189, DOI 10.1016/j.ymthe.2017.06.008; Watanabe K, 2015, J IMMUNOL, V194, P911, DOI 10.4049/jimmunol.1402346; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yu H, 2017, AM J HEMATOL, V92, pE11, DOI 10.1002/ajh.24594; Zah E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16160-5; Zah E, 2016, CANCER IMMUNOL RES, V4, P498, DOI 10.1158/2326-6066.CIR-15-0231	70	79	80	11	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1419	+		10.1038/s41591-021-01436-0	http://dx.doi.org/10.1038/s41591-021-01436-0		JUL 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34312556	Green Published, hybrid			2022-12-27	WOS:000679014800003
J	Barros-Martins, J; Hammerschmidt, SI; Cossmann, A; Odak, I; Stankov, MV; Ramos, GM; Dopfer-Jablonka, A; Heidemann, A; Ritter, C; Friedrichsen, M; Schultze-Florey, C; Ravens, I; Willenzon, S; Bubke, A; Ristenpart, J; Janssen, A; Ssebyatika, G; Bernhardt, G; Munch, J; Hoffmann, M; Pohlmann, S; Krey, T; Bosnjak, B; Forster, R; Behrens, GMN				Barros-Martins, Joana; Hammerschmidt, Swantje, I; Cossmann, Anne; Odak, Ivan; Stankov, Metodi, V; Ramos, Gema Morillas; Dopfer-Jablonka, Alexandra; Heidemann, Annika; Ritter, Christiane; Friedrichsen, Michaela; Schultze-Florey, Christian; Ravens, Inga; Willenzon, Stefanie; Bubke, Anja; Ristenpart, Jasmin; Janssen, Anika; Ssebyatika, George; Bernhardt, Gunter; Muench, Jan; Hoffmann, Markus; Poehlmann, Stefan; Krey, Thomas; Bosnjak, Berislav; Foerster, Reinhold; Behrens, Georg M. N.			Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	NATURE MEDICINE			English	Article								In a study of healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19, booster vaccination with BNT162b2 elicited more neutralizing antibodies with greater breadth, as well as higher frequencies of virus-specific T cells, than ChAdOx-1 nCoV-19. Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer's BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4(+) and CD8(+) T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.	[Barros-Martins, Joana; Hammerschmidt, Swantje, I; Odak, Ivan; Ritter, Christiane; Friedrichsen, Michaela; Schultze-Florey, Christian; Ravens, Inga; Willenzon, Stefanie; Bubke, Anja; Ristenpart, Jasmin; Janssen, Anika; Bernhardt, Gunter; Bosnjak, Berislav; Foerster, Reinhold] Hannover Med Sch, Inst Immunol, Hannover, Germany; [Cossmann, Anne; Stankov, Metodi, V; Ramos, Gema Morillas; Dopfer-Jablonka, Alexandra; Heidemann, Annika; Behrens, Georg M. N.] Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany; [Dopfer-Jablonka, Alexandra; Foerster, Reinhold; Behrens, Georg M. N.] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, Hannover, Germany; [Schultze-Florey, Christian] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany; [Ssebyatika, George; Krey, Thomas] Univ Lubeck, Inst Biochem, Lubeck, Germany; [Muench, Jan] Ulm Univ, Inst Mol Virol, Med Ctr, Ulm, Germany; [Hoffmann, Markus; Poehlmann, Stefan] German Primate Ctr, Infect Biol Unit, Gottingen, Germany; [Hoffmann, Markus; Poehlmann, Stefan] Georg August Univ Gottingen, Fac Biol & Psychol, Gottingen, Germany; [Krey, Thomas] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, Hamburg, Germany; [Krey, Thomas] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, Hamburg, Germany; [Foerster, Reinhold] Hannover Med Sch, Cluster Excellence RESIST EXC 2155, Hannover, Germany; [Behrens, Georg M. N.] Ctr Individualised Infect Med, CiiM, Hannover, Germany	Hannover Medical School; Hannover Medical School; German Center for Infection Research; Hannover Medical School; University of Lubeck; Ulm University; Deutsches Primatenzentrum (DPZ); University of Gottingen; German Center for Infection Research; German Center for Infection Research; Hannover Medical School	Bosnjak, B; Forster, R (corresponding author), Hannover Med Sch, Inst Immunol, Hannover, Germany.; Behrens, GMN (corresponding author), Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany.; Forster, R; Behrens, GMN (corresponding author), German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, Hannover, Germany.; Forster, R (corresponding author), Hannover Med Sch, Cluster Excellence RESIST EXC 2155, Hannover, Germany.; Behrens, GMN (corresponding author), Ctr Individualised Infect Med, CiiM, Hannover, Germany.	bosnjak.berislav@mh-hannover.de; foerster.reinhold@mh-hannover.de; behrens.georg@mh-hannover.de	Hoffmann, Markus/J-7836-2018; Pöhlmann, Stefan/H-2395-2011; Odak, Ivan/GLQ-7411-2022; Bernhardt, Günter/F-6946-2012; Behrens, Georg MN/Q-4486-2016	Hoffmann, Markus/0000-0003-4603-7696; Pöhlmann, Stefan/0000-0001-6086-9136; Odak, Ivan/0000-0003-0408-5091; Bernhardt, Günter/0000-0002-0510-2853; Cossmann, Anne/0000-0002-0029-8455; Jan, Munch/0000-0001-7316-7141; Morillas Ramos, Gema/0000-0002-4835-5172; Martins, Joana/0000-0002-3370-4990; Stankov, Metodi/0000-0003-3001-2478; Ssebyatika, George/0000-0001-5350-3371	German Center for Infection Research [TTU 01.938, 80018019238, TTU 04.820]; Deutsche Forschungsgemeinschaft (German Research Foundation) [EXC 2155, 39087428]; State of Lower Saxony [14-76103-184 CORONA-11/20]; BMBF [FKZ: 01KX2021]; Deutsche Forschungsgemeinschaft [SFB 900/3, 158989968]	German Center for Infection Research; Deutsche Forschungsgemeinschaft (German Research Foundation)(German Research Foundation (DFG)); State of Lower Saxony(European Commission); BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the German Center for Infection Research TTU 01.938 (grant no. 80018019238, to G.M.N.B and R.F.) and TTU 04.820, to G.M.N.B.; by the Deutsche Forschungsgemeinschaft (German Research Foundation) Excellence Strategy EXC 2155 'RESIST' (Project ID 39087428, to R.F.); by funds of the State of Lower Saxony (14-76103-184 CORONA-11/20, to R.F.); by funds of the BMBF (NaFoUniMedCovid19 FKZ: 01KX2021; Projects B-FAST, to R.F.); and by Deutsche Forschungsgemeinschaft, SFB 900/3 (Projects B1, 158989968, to R.F.). We thank the CoCo Study participants for their support and the entire CoCo Study team for help. We would like to thank F. Klawonn for statistical advice and L. Manthey, H. Bartmann, T. Redeker, J. Topal, K. Strache, B. Heinisch, M. Stephan, M. Nohre, S. Muller, O. Dragicevic, A. T. Tran, K. D. T. Hoang, A.-L. Boeck, A. Kempf, I. Nehlmeier and M. Wortmann for technical and logistical support.	Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Behrens GMN, 2020, INFECT DIS THER, V9, P837, DOI 10.1007/s40121-020-00334-1; Behrens GMN, 2020, INFECTION, V48, P631, DOI 10.1007/s15010-020-01461-0; Bosnjak B, 2021, CELL MOL IMMUNOL, V18, P936, DOI 10.1038/s41423-020-00573-9; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Jablonka A., 2020, PROTOCOL LONGITUDINA, DOI 10.1101/2020.12.02.20242479v1.full; Liu Yang, 2021, N Engl J Med, DOI 10.1056/NEJMc2102017; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01158-2, 10.1016/S0140-6736(21)01115-6]; Supasa P, 2021, CELL, V184, P2201, DOI 10.1016/j.cell.2021.02.033; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699	22	187	191	3	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1525	+		10.1038/s41591-021-01449-9	http://dx.doi.org/10.1038/s41591-021-01449-9		JUL 2021	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34262158	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000673488700001
J	Wu, JH				Wu, Jo-Hsuan			Asian healthcare workers in the COVID-19 pandemic: a long road to recovery	NATURE MEDICINE			English	Editorial Material								Asian healthcare workers have experienced racism during the COVID-19 pandemic, including from the medical community, with potentially long-term consequences for those affected.	[Wu, Jo-Hsuan] Univ Calif San Diego, Shiley Eye Inst, San Diego, CA 92103 USA; [Wu, Jo-Hsuan] Univ Calif San Diego, Viterbi Family Dept Ophthalmol, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wu, JH (corresponding author), Univ Calif San Diego, Shiley Eye Inst, San Diego, CA 92103 USA.; Wu, JH (corresponding author), Univ Calif San Diego, Viterbi Family Dept Ophthalmol, San Diego, CA 92103 USA.	Uuuuuu1swu@gmail.com	Wu, Jo-Hsuan/AAK-8899-2021	Wu, Jo-Hsuan/0000-0002-9435-746X					0	2	2	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1135	1135		10.1038/s41591-021-01424-4	http://dx.doi.org/10.1038/s41591-021-01424-4		JUN 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34183834	Bronze			2022-12-27	WOS:000667622200004
J	Palmqvist, S; Tideman, P; Cullen, N; Zetterberg, H; Blennow, K; Dage, JL; Stomrud, E; Janelidze, S; Mattsson-Carlgren, N; Hansson, O				Palmqvist, Sebastian; Tideman, Pontus; Cullen, Nicholas; Zetterberg, Henrik; Blennow, Kaj; Dage, Jeffery L.; Stomrud, Erik; Janelidze, Shorena; Mattsson-Carlgren, Niklas; Hansson, Oskar		Alzheimer's Dis Neuroimaging Ini	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures	NATURE MEDICINE			English	Article							MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; CROSS-VALIDATION; ACCURACY; ASSOCIATION; DIAGNOSIS; BIOMARKER; KINETICS; RISK; CARE	Plasma P-tau, in combination with clinical measures, predicts future Alzheimer's disease dementia in two independent cohorts with high accuracy and is superior to the clinical diagnostic predictions of specialists. A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer's disease (AD) dementia. We examined this in participants with subjective cognitive decline and mild cognitive impairment from the BioFINDER (n = 340) and Alzheimer's Disease Neuroimaging Initiative (ADNI) (n = 543) studies. Plasma P-tau, plasma A beta 42/A beta 40, plasma neurofilament light, APOE genotype, brief cognitive tests and an AD-specific magnetic resonance imaging measure were examined using progression to AD as outcome. Within 4 years, plasma P-tau217 predicted AD accurately (area under the curve (AUC) = 0.83) in BioFINDER. Combining plasma P-tau217, memory, executive function and APOE produced higher accuracy (AUC = 0.91, P < 0.001). In ADNI, this model had similar AUC (0.90) using plasma P-tau181 instead of P-tau217. The model was implemented online for prediction of the individual probability of progressing to AD. Within 2 and 6 years, similar models had AUCs of 0.90-0.91 in both cohorts. Using cerebrospinal fluid P-tau, A beta 42/A beta 40 and neurofilament light instead of plasma biomarkers did not improve the accuracy significantly. The clinical predictions by memory clinic physicians had significantly lower accuracy (4-year AUC = 0.71). In summary, plasma P-tau, in combination with brief cognitive tests and APOE genotyping, might greatly improve the diagnostic prediction of AD and facilitate recruitment for AD trials.	[Palmqvist, Sebastian; Tideman, Pontus; Cullen, Nicholas; Stomrud, Erik; Janelidze, Shorena; Mattsson-Carlgren, Niklas; Hansson, Oskar] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Lund, Sweden; [Palmqvist, Sebastian; Tideman, Pontus; Stomrud, Erik; Hansson, Oskar] Skane Univ Hosp, Memory Clin, Malmo, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Dage, Jeffery L.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Mattsson-Carlgren, Niklas] Skane Univ Hosp, Dept Neurol, Lund, Sweden; [Mattsson-Carlgren, Niklas] Lund Univ, Wallenberg Ctr Mol Med, Lund, Sweden	Lund University; Lund University; Skane University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of London; University College London; University of London; University College London; Eli Lilly; Lund University; Skane University Hospital; Lund University	Palmqvist, S; Hansson, O (corresponding author), Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Lund, Sweden.; Palmqvist, S; Hansson, O (corresponding author), Skane Univ Hosp, Memory Clin, Malmo, Sweden.	sebastian.palmqvist@med.lu.se; oskar.hansson@med.lu.se	Palmqvist, Sebastian/AAU-1148-2021; Palmqvist, Sebastian/AFQ-9019-2022; Hansson, Oskar/A-7134-2013	Palmqvist, Sebastian/0000-0002-9267-1930; Hansson, Oskar/0000-0001-8467-7286; Zetterberg, Henrik/0000-0003-3930-4354	Swedish Research Council [2016-00906, 2018-02052, 2017-00915, 2018-02532]; Knut and Alice Wallenberg Foundation [2017-0383]; Marianne and Marcus Wallenberg Foundation [2015.0125]; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University; Swedish Alzheimer Foundation [AF-745911, AF-940046, AF-742881]; Swedish Brain Foundation [FO2019-0326, FO2020-0271]; Parkinson Foundation of Sweden [1280/20]; Skane University Hospital Foundation [2020-O000028, 2020-0383]; Swedish federal government under the ALF agreement [2018-Projekt0279, 2018-Projekt0226]; European Research Council [681712]; Swedish State Support for Clinical Research [ALFGBG-720931]; Alzheimer Drug Discovery Foundation, USA [RDAPB-201809-2016615]; Alzheimer's Association [ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C]; European Union's Horizon 2020 Research and Innovation Programme under Marie Sklodowska-Curie grant [860197]; UK Dementia Research Institute at University College London; Hjarnfonden, Sweden [FO2017-0243]; Swedish government [ALFGBG-715986]; County Councils, the ALF agreement [ALFGBG-715986]; European Union Joint Program for Neurodegenerative Disorders [JPND2019-466-236]; GE Healthcare; Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health) [U01 AG024904]; Department of Defense [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica; Biogen; Bristol-Myers Squibb Company; CereSpir; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche and its affiliated company; Genentech; Fujirebio; Johnson & Johnson Pharmaceutical Research Development; Lumosity; Lundbeck; Merck Co.; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Cogstate; Canadian Institutes of Health Research; Regionalt Forskningsstod [2020-0383, 2020-0314]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Marianne and Marcus Wallenberg Foundation; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University; Swedish Alzheimer Foundation; Swedish Brain Foundation; Parkinson Foundation of Sweden; Skane University Hospital Foundation; Swedish federal government under the ALF agreement; European Research Council(European Research Council (ERC)European Commission); Swedish State Support for Clinical Research; Alzheimer Drug Discovery Foundation, USA; Alzheimer's Association(Alzheimer's Association); European Union's Horizon 2020 Research and Innovation Programme under Marie Sklodowska-Curie grant; UK Dementia Research Institute at University College London; Hjarnfonden, Sweden; Swedish government; County Councils, the ALF agreement; European Union Joint Program for Neurodegenerative Disorders; GE Healthcare(General ElectricGE Healthcare); Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); AbbVie(AbbVie); Alzheimer's Association(Alzheimer's Association); Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica; Biogen(Biogen); Bristol-Myers Squibb Company(Bristol-Myers Squibb); CereSpir; Eisai(Eisai Co Ltd); Elan Pharmaceuticals; Eli Lilly and Company(Eli Lilly); EuroImmun; F. Hoffmann-La Roche and its affiliated company(Hoffmann-La Roche); Genentech(Roche HoldingGenentech); Fujirebio; Johnson & Johnson Pharmaceutical Research Development(Johnson & JohnsonJohnson & Johnson USA); Lumosity; Lundbeck(Lundbeck Corporation); Merck Co.(Merck & Company); Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals(Novartis); Pfizer(Pfizer); Piramal Imaging; Servier(Servier); Takeda Pharmaceutical Company(Takeda Pharmaceutical Company Ltd); Transition Therapeutics; Cogstate(CogState Limited); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Regionalt Forskningsstod	Work at the authors' research center was supported by the Swedish Research Council (2016-00906 (O.H.) and 2018-02052 (S.P.)), the Knut and Alice Wallenberg Foundation (2017-0383 (O.H.)), the Marianne and Marcus Wallenberg Foundation (2015.0125 (O.H.)), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-745911 (O.H.) and AF-940046 (S.P.)), the Swedish Brain Foundation (FO2019-0326 (O.H.) and FO2020-0271 (S.P.)), the Parkinson Foundation of Sweden (1280/20 (O.H.)), the Skane University Hospital Foundation (2020-O000028 (S.P.)), Regionalt Forskningsstod (2020-0314 (O.H.) and 2020-0383 (S.P.)) and the Swedish federal government under the ALF agreement (2018-Projekt0279 (O.H.) and 2018-Projekt0226 (S.P.)). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation, USA (201809-2016862), AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C), the European Union's Horizon 2020 Research and Innovation Programme under Marie Sklodowska-Curie grant agreement no. 860197 (MIRIADE) and the UK Dementia Research Institute at University College London. K.B. is supported by the Swedish Research Council (2017-00915), the Alzheimer Drug Discovery Foundation, USA (RDAPB-201809-2016615), the Swedish Alzheimer Foundation (AF-742881), Hjarnfonden, Sweden (FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-715986) and the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). The precursor of <SUP>18</SUP>F-flutemetamol was sponsored by GE Healthcare. The precursor of <SUP>18</SUP>F-RO948 was provided by Roche. ADNI data collection and sharing was funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health grant U01 AG024904) and Department of Defense award no. W81XWH-12-2-0012. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica; Biogen; Bristol-Myers Squibb Company; CereSpir; Cogstate; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche and its affiliated company, Genentech; Fujirebio; GE Healthcare; IXICO; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Lumosity; Lundbeck; Merck & Co.; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. ADNI investigators contributed to the design and implementation of the ADNI database and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).; The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.	Aisen PS, 2015, ALZHEIMERS DEMENT, V11, P734, DOI 10.1016/j.jalz.2015.05.005; Barthelemy NR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200861; Barthelemy NR, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00596-4; Borland E, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00592-8; Borland E, 2017, J ALZHEIMERS DIS, V59, P893, DOI [10.3233/JAD-170203, 10.3233/jad-170203]; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Cullen NC., 2020, NAT AGING, V1, P114, DOI [10.1038/s43587-020-00003-5, DOI 10.1038/S43587-020-00003-5]; Ferdinando P, 2020, J ALZHEIMERS DIS, V75, P1191, DOI 10.3233/JAD-191191; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gothlin M, 2017, DEMENT GERIATR COGN, V43, P330, DOI 10.1159/000477341; Hansson O, 2018, ALZHEIMERS DEMENT, V14, P1470, DOI 10.1016/j.jalz.2018.01.010; Insel PS, 2019, NEUROLOGY, V93, pE322, DOI 10.1212/WNL.0000000000007831; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Jack CR, 2017, ALZHEIMERS DEMENT, V13, P205, DOI 10.1016/j.jalz.2016.08.005; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Janelidze S, 2016, ANN CLIN TRANSL NEUR, V3, P154, DOI 10.1002/acn3.274; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Karikari TK, 2021, MOL PSYCHIATR, V26, P429, DOI 10.1038/s41380-020-00923-z; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Landau SM, 2012, ANN NEUROL, V72, P578, DOI 10.1002/ana.23650; Leuzy A, 2020, JAMA NEUROL, V77, P955, DOI 10.1001/jamaneurol.2020.0989; Lopponen M, 2003, AGE AGEING, V32, P606, DOI 10.1093/ageing/afg097; Mattsson N, 2019, JAMA NEUROL, V76, P1319, DOI 10.1001/jamaneurol.2019.2214; Mattsson-Carlgren N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19957-6; Mattsson-Carlgren N, 2020, BRAIN, V143, P3234, DOI 10.1093/brain/awaa286; Mattsson-Carlgren N, 2020, NEUROLOGY, V94, pE2233, DOI 10.1212/WNL.0000000000009485; Mattsson-Carlgren N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz2387; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P989, DOI 10.1016/j.jalz.2018.02.013; Olofsen Erik, 2013, F1000Res, V2, P71, DOI 10.12688/f1000research.2-71.v1; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Ovod V, 2017, ALZHEIMERS DEMENT, V13, P841, DOI 10.1016/j.jalz.2017.06.2266; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Palmqvist S, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201911170; Palmqvist S, 2019, JAMA NEUROL, V76, P1060, DOI 10.1001/jamaneurol.2019.1632; Palmqvist S, 2019, ALZHEIMERS DEMENT, V15, P194, DOI 10.1016/j.jalz.2018.08.014; Palmqvist S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01150-x; Palmqvist S, 2014, JAMA NEUROL, V71, P1282, DOI 10.1001/jamaneurol.2014.1358; Palmqvist S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038639; Papp Kathryn V, 2017, Alzheimers Dement (N Y), V3, P668, DOI 10.1016/j.trci.2017.10.004; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Rabinovici GD, 2019, JAMA-J AM MED ASSOC, V321, P1286, DOI 10.1001/jama.2019.2000; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Scheyer O, 2018, JPAD-J PREV ALZHEIM, V5, P225, DOI 10.14283/jpad.2018.34; Schindler SE, 2019, NEUROLOGY, V93, pE1647, DOI 10.1212/WNL.0000000000008081; Shulman KI, 2000, INT J GERIATR PSYCH, V15, P548, DOI 10.1002/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U; strand R., 2009, ACTA NEUROL SCAND, V121, P384; Toledo JB, 2011, ACTA NEUROPATHOL, V122, P401, DOI 10.1007/s00401-011-0861-8; Valcour VG, 2000, ARCH INTERN MED, V160, P2964, DOI 10.1001/archinte.160.19.2964	54	95	95	22	62	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1034	+		10.1038/s41591-021-01348-z	http://dx.doi.org/10.1038/s41591-021-01348-z		MAY 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34031605	Green Submitted			2022-12-27	WOS:000653615900006
J	Bange, EM; Han, NA; Wileyto, P; Kim, JY; Gouma, S; Robinson, J; Greenplate, AR; Hwee, MA; Porterfield, F; Owoyemi, O; Naik, K; Zheng, C; Galantino, M; Weisman, AR; Ittner, CAG; Kugler, EM; Baxter, AE; Oniyide, O; Agyekum, RS; Dunn, TG; Jones, TK; Giannini, HM; Weirick, ME; McAllister, CM; Babady, NE; Kumar, A; Widman, AJ; DeWolf, S; Boutemine, SR; Roberts, C; Budzik, KR; Tollett, S; Wright, C; Perloff, T; Sun, L; Mathew, D; Giles, JR; Oldridge, DA; Wu, JE; Alanio, C; Adamski, S; Garfall, AL; Vella, LA; Kerr, SJ; Cohen, JV; Oyer, RA; Massa, R; Maillard, IP; Maxwell, KN; Reilly, JP; Maslak, PG; Vonderheide, RH; Wolchok, JD; Hensley, SE; Wherry, EJ; Meyer, NJ; DeMichele, AM; Vardhana, SA; Mamtani, R; Huang, AC				Bange, Erin M.; Han, Nicholas A.; Wileyto, Paul; Kim, Justin Y.; Gouma, Sigrid; Robinson, James; Greenplate, Allison R.; Hwee, Madeline A.; Porterfield, Florence; Owoyemi, Olutosin; Naik, Karan; Zheng, Cathy; Galantino, Michael; Weisman, Ariel R.; Ittner, Caroline A. G.; Kugler, Emily M.; Baxter, Amy E.; Oniyide, Olutwatosin; Agyekum, Roseline S.; Dunn, Thomas G.; Jones, Tiffanie K.; Giannini, Heather M.; Weirick, Madison E.; McAllister, Christopher M.; Babady, N. Esther; Kumar, Anita; Widman, Adam J.; DeWolf, Susan; Boutemine, Sawsan R.; Roberts, Charlotte; Budzik, Krista R.; Tollett, Susan; Wright, Carla; Perloff, Tara; Sun, Lova; Mathew, Divij; Giles, Josephine R.; Oldridge, Derek A.; Wu, Jennifer E.; Alanio, Cecile; Adamski, Sharon; Garfall, Alfred L.; Vella, Laura A.; Kerr, Samuel J.; Cohen, Justine, V; Oyer, Randall A.; Massa, Ryan; Maillard, Ivan P.; Maxwell, Kara N.; Reilly, John P.; Maslak, Peter G.; Vonderheide, Robert H.; Wolchok, Jedd D.; Hensley, Scott E.; Wherry, E. John; Meyer, Nuala J.; DeMichele, Angela M.; Vardhana, Santosha A.; Mamtani, Ronac; Huang, Alexander C.			CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer	NATURE MEDICINE			English	Article							SARS-COV-2; IMMUNITY; MORTALITY; MILD	Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses. A study of hospitalized patients infected with SARS-CoV-2 and who have liquid or solid cancer suggests that hematologic malignancy is an independent risk factor for mortality and that CD8(+) T cells might limit infection in this setting irrespective of humoral immunity.	[Bange, Erin M.; Han, Nicholas A.; Kim, Justin Y.; Porterfield, Florence; Owoyemi, Olutosin; Naik, Karan; Kugler, Emily M.; Sun, Lova; Garfall, Alfred L.; Massa, Ryan; Maillard, Ivan P.; Maxwell, Kara N.; DeMichele, Angela M.; Mamtani, Ronac; Huang, Alexander C.] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Bange, Erin M.; Wileyto, Paul; Robinson, James; Zheng, Cathy; Galantino, Michael; Roberts, Charlotte; Budzik, Krista R.; Tollett, Susan; Wright, Carla; Perloff, Tara; Sun, Lova; Garfall, Alfred L.; Kerr, Samuel J.; Cohen, Justine, V; Oyer, Randall A.; Massa, Ryan; Maillard, Ivan P.; Maxwell, Kara N.; Vonderheide, Robert H.; DeMichele, Angela M.; Mamtani, Ronac; Huang, Alexander C.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Han, Nicholas A.; Kim, Justin Y.; Greenplate, Allison R.; Baxter, Amy E.; Mathew, Divij; Giles, Josephine R.; Oldridge, Derek A.; Wu, Jennifer E.; Alanio, Cecile; Adamski, Sharon; Vonderheide, Robert H.; Hensley, Scott E.; Wherry, E. John; Meyer, Nuala J.; Huang, Alexander C.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA; [Wileyto, Paul] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA USA; [Gouma, Sigrid; Weirick, Madison E.; McAllister, Christopher M.; Hensley, Scott E.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Greenplate, Allison R.; Baxter, Amy E.; Mathew, Divij; Giles, Josephine R.; Wu, Jennifer E.; Alanio, Cecile; Adamski, Sharon; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA USA; [Hwee, Madeline A.; Wolchok, Jedd D.; Vardhana, Santosha A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Weisman, Ariel R.; Ittner, Caroline A. G.; Giannini, Heather M.; Reilly, John P.; Meyer, Nuala J.] Univ Penn, Perelman Sch Med, Dept Med, Div Pulm & Crit Care, Philadelphia, PA USA; [Oniyide, Olutwatosin; Agyekum, Roseline S.; Dunn, Thomas G.; Jones, Tiffanie K.; Massa, Ryan] Presbyterian Hosp, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA USA; [Babady, N. Esther; Kumar, Anita; Widman, Adam J.; DeWolf, Susan; Boutemine, Sawsan R.; Maslak, Peter G.; Wolchok, Jedd D.; Vardhana, Santosha A.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Babady, N. Esther; Maslak, Peter G.] Mem Sloan Kettering Canc Ctr, Dept Lab Med, New York, NY USA; [Perloff, Tara; Cohen, Justine, V] Penn Hosp, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA USA; [Giles, Josephine R.; Wu, Jennifer E.; Alanio, Cecile; Vonderheide, Robert H.; Wolchok, Jedd D.; Wherry, E. John; Vardhana, Santosha A.; Huang, Alexander C.] Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Oldridge, Derek A.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA; [Vella, Laura A.] Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kerr, Samuel J.; Oyer, Randall A.] Lancaster Gen Hosp, Dept Med, Div Hematol Oncol, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Mamtani, R; Huang, AC (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.; Mamtani, R; Huang, AC (corresponding author), Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.; Huang, AC (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.; Vardhana, SA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.; Vardhana, SA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.; Vardhana, SA; Huang, AC (corresponding author), Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.	vardhans@mskcc.org; mamtani@pennmedicine.upenn.edu; alexander.huang@pennmedicine.upenn.edu	Wu, Jennifer/GRX-1831-2022	Han, Nicholas/0000-0003-1410-9931; Bange, Erin/0000-0003-0000-6093; Kim, Justin/0000-0003-0774-8137; Garfall, Alfred/0000-0003-2791-5748; Agyekum, Roseline/0000-0001-7145-5609; Weisman, Ariel/0000-0002-7187-304X; Hamilton, Jacob/0000-0003-1277-6925; Owoyemi, Olutosin/0000-0002-7527-5768; McAllister, Christopher/0000-0002-0011-4089; Giannini, Heather/0000-0002-8979-3806; Reilly, John/0000-0003-3937-5320	NIH [CA230157, HL137006, HL137915, AI155577, AI112521, AI082630, AI201085, AI123539, AI117950]; Tara Miller Foundation; Mentored Clinical Scientist Career Development Award from NIAID/NIH [K08 AI136660]; Leukemia and Lymphoma Society Scholar in Clinical Research Award; Parker Institute for Cancer Immunotherapy; Cancer Immunology program at the University of Pennsylvania; Allen Institute for Immunology; Pershing Square Sohn Cancer Research Foundation; Conrad Hilton Foundation; ASCO Young Investigator Award;  [T32 T32CA009140];  [T32 T32-CA-09679];  [T32 CA009140];  [T32CA009512]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tara Miller Foundation; Mentored Clinical Scientist Career Development Award from NIAID/NIH; Leukemia and Lymphoma Society Scholar in Clinical Research Award; Parker Institute for Cancer Immunotherapy; Cancer Immunology program at the University of Pennsylvania; Allen Institute for Immunology; Pershing Square Sohn Cancer Research Foundation(Pershing Square Sohn Cancer Research Alliance); Conrad Hilton Foundation; ASCO Young Investigator Award; ; ; ; 	The authors thank patients and blood donors, their families and surrogates and medical personnel. In addition, we thank the University of Pennsylvania COVID Processing Unit: a unit of individuals from diverse laboratories at the University of Pennsylvania who volunteered time and effort to enable the study of patients with COVID-19 during the pandemic (Supplementary Table 9). Funding: A.C.H. was funded by grant CA230157 from the NIH and funding from the Tara Miller Foundation. D.O. was funded by T32 T32CA009140. L.A.V. is funded by a Mentored Clinical Scientist Career Development Award from NIAID/NIH (K08 AI136660). E.B. was funded by T32 T32-CA-09679. N.J.M. was supported by NIH HL137006 and HL137915. D.M. was funded by T32 CA009140. J.R.G. is a Cancer Research Institute-Mark Foundation Fellow. A.L.G. was supported by the Leukemia and Lymphoma Society Scholar in Clinical Research Award. J.R.G., J.E.W., C.A., A.C.H. and E.J.W. are supported by the Parker Institute for Cancer Immunotherapy, which supports the Cancer Immunology program at the University of Pennsylvania. E.J.W. was supported by NIH grants AI155577, AI112521, AI082630, AI201085, AI123539 and AI117950 and funding from the Allen Institute for Immunology. S.A.V. was supported by funding from the Pershing Square Sohn Cancer Research Foundation, the Conrad Hilton Foundation and the Parker Institute for Cancer Immunotherapy. S.D. was funded, in part, by T32CA009512 and an ASCO Young Investigator Award. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abdul-Jawad S, 2021, CANCER CELL, V39, P257, DOI 10.1016/j.ccell.2021.01.001; Albiges L, 2020, NAT CANCER, V1, P965, DOI 10.1038/s43018-020-00120-5; [Anonymous], 2020, CORONAVIRUS COVID 19; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Assaad S, 2020, EUR J CANCER, V135, P251, DOI 10.1016/j.ejca.2020.05.028; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Chari A, 2020, BLOOD, V136, P3033, DOI 10.1182/blood.2020008150; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Cook AM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1066062; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1101/2020.06.11.145920, 10.1038/s41586-020-2622-0]; Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422; De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4; Flannery DD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd5709; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Grivas P, 2021, ANN ONCOL, V32, P787, DOI 10.1016/j.annonc.2021.02.024; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X; Jee J, 2020, J CLIN ONCOL, V38, P3538, DOI 10.1200/JCO.20.01307; Kared H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145476; Karlsson AC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe8063; Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Lamure S, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100549; Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554; Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9; Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3; Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; Mann ER, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6197; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Mato AR, 2020, BLOOD, V136, P1134, DOI 10.1182/blood.2020006965; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516; Miyashita H, 2021, HIV MED, V22, pE1, DOI 10.1111/hiv.12920; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Orlova DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151859; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0; Rugge M, 2020, NAT CANCER, V1, P784, DOI 10.1038/s43018-020-0104-9; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Saini KS, 2020, EUR J CANCER, V139, P43, DOI 10.1016/j.ejca.2020.08.011; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Su YP, 2020, CELL, V183, P1479, DOI 10.1016/j.cell.2020.10.037; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; Vijenthira A, 2020, BLOOD, V136, P2881, DOI 10.1182/blood.2020008824; WEIDT G, 1994, J IMMUNOL, V153, P2554; West H, 2015, JAMA ONCOL, V1, P998, DOI 10.1001/jamaoncol.2015.3113; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu D, 2020, INT J ACCOUNT INF MA, V28, P184, DOI [10.1108/IJAIM-12-2018-0148, 10.1016/j.ijid.2020.03.004]; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Zhang BC, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00157; Zhao JW, 2020, ADV POLYM SCI, V285, P1, DOI 10.1007/12_2020_62; Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	67	175	177	11	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1280	+		10.1038/s41591-021-01386-7	http://dx.doi.org/10.1038/s41591-021-01386-7		MAY 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34017137	Green Accepted, Bronze, Green Published			2022-12-27	WOS:000652454300003
J	Cideciyan, AV; Jacobson, SG; Ho, AC; Garafalo, AV; Roman, AJ; Sumaroka, A; Krishnan, AK; Swider, M; Schwartz, MR; Girach, A				Cideciyan, Artur V.; Jacobson, Samuel G.; Ho, Allen C.; Garafalo, Alexandra V.; Roman, Alejandro J.; Sumaroka, Alexander; Krishnan, Arun K.; Swider, Malgorzata; Schwartz, Michael R.; Girach, Aniz			Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report	NATURE MEDICINE			English	Article								Leber congenital amaurosis due to CEP290 ciliopathy is being explored by treatment with the antisense oligonucleotide (AON) sepofarsen. One patient who was part of a larger cohort (ClinicalTrials.gov NCT03140969) was studied for 15 months after a single intravitreal sepofarsen injection. Concordant measures of visual function and retinal structure reached a substantial efficacy peak near 3 months after injection. At 15 months, there was sustained efficacy, even though there was evidence of reduction from peak response. Efficacy kinetics can be explained by the balance of AON-driven new CEP290 protein synthesis and a slow natural rate of CEP290 protein degradation in human fovea! cone photoreceptors.	[Cideciyan, Artur V.; Jacobson, Samuel G.; Garafalo, Alexandra V.; Roman, Alejandro J.; Sumaroka, Alexander; Krishnan, Arun K.; Swider, Malgorzata] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA; [Ho, Allen C.] Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA; [Schwartz, Michael R.; Girach, Aniz] ProQR Therapeut, Leiden, Netherlands	University of Pennsylvania; Pennsylvania Medicine; Jefferson University	Cideciyan, AV (corresponding author), Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.	artur.cideciyan@pennmedicine.upenn.edu	Krishnan, Arun Kumar/ABF-7662-2021	Krishnan, Arun Kumar/0000-0002-3888-2614; Ho, Allen/0000-0003-3921-608X	ProQR Therapeutics; National Institutes of Health [UL1 TR001878]	ProQR Therapeutics; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a clinical trial contract from ProQR Therapeutics to A.V.C., administered by the University of Pennsylvania. There was also partial support by the National Institutes of Health grant UL1 TR001878.	Baehr W, 2019, PROG RETIN EYE RES, V71, P26, DOI 10.1016/j.preteyeres.2018.12.004; Cideciyan AV, 2007, HUM MUTAT, V28, P1074, DOI 10.1002/humu.20565; Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457; Cideciyan AV, 2019, INVEST OPHTH VIS SCI, V60, P1680, DOI 10.1167/iovs.19-26672; Cideciyan AV, 2019, NAT MED, V25, P225, DOI 10.1038/s41591-018-0295-0; Cideciyan AV, 2015, INVEST OPHTH VIS SCI, V56, P526, DOI 10.1167/iovs.14-15895; Cideciyan AV, 2013, HUM GENE THER, V24, P993, DOI 10.1089/hum.2013.153; Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415; Cideciyan AV, 2011, HUM MOL GENET, V20, P1411, DOI 10.1093/hmg/ddr022; Collison FT, 2015, INVEST OPHTH VIS SCI, V56, P7130, DOI 10.1167/iovs.15-17467; Collison FT, 2014, RETINA-J RET VIT DIS, V34, P1888, DOI 10.1097/IAE.0000000000000144; den Hollander AI, 2006, AM J HUM GENET, V79, P556, DOI 10.1086/507318; Doudna JA, 2020, NATURE, V578, P229, DOI 10.1038/s41586-020-1978-5; Dulla K, 2018, MOL THER-NUCL ACIDS, V12, P730, DOI 10.1016/j.omtn.2018.07.010; Feldhaus B, 2020, AM J OPHTHALMOL, V211, P142, DOI 10.1016/j.ajo.2019.11.012; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471; Granholm E, 2003, INT J PSYCHOPHYSIOL, V47, P95, DOI 10.1016/S0167-8760(02)00122-8; Hanany M, 2020, P NATL ACAD SCI USA, V117, P2710, DOI 10.1073/pnas.1913179117; Henry SP, 2001, INVEST OPHTH VIS SCI, V42, P2646; Herrera W, 2008, INVEST OPHTH VIS SCI, V49, P2651, DOI 10.1167/iovs.07-1505; Jacobson SG, 2017, INVEST OPHTH VIS SCI, V58, P2609, DOI 10.1167/iovs.17-21560; Jacobson SG, 2013, HUM MOL GENET, V22, P168, DOI 10.1093/hmg/dds421; Klein M, 2009, DOC OPHTHALMOL, V119, P217, DOI 10.1007/s10633-009-9204-7; Kocaoglu OP, 2016, BIOMED OPT EXPRESS, V7, P4554, DOI 10.1364/BOE.7.004554; Krishnan AK, 2020, VISION RES, V168, P53, DOI 10.1016/j.visres.2020.01.006; Littink KW, 2010, INVEST OPHTH VIS SCI, V51, P3646, DOI 10.1167/iovs.09-5074; Maeder ML, 2019, NAT MED, V25, P229, DOI 10.1038/s41591-018-0327-9; Pasadhika S, 2010, INVEST OPHTH VIS SCI, V51, P2608, DOI 10.1167/iovs.09-3734; Roman AJ, 2005, EXP EYE RES, V80, P259, DOI 10.1016/j.exer.2004.09.008; Roman AJ, 2007, PHYSIOL MEAS, V28, pN51, DOI 10.1088/0967-3334/28/8/N02; SALETU B, 1988, J CLIN PSYCHIAT, V49, P59; Schoch KM, 2017, NEURON, V94, P1056, DOI 10.1016/j.neuron.2017.04.010; Sheck L, 2018, OPHTHALMOLOGY, V125, P894, DOI 10.1016/j.ophtha.2017.12.013; Sumaroka A, 2019, INVEST OPHTH VIS SCI, V60, P2551, DOI 10.1167/iovs.19-27156; Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009; Trapani I, 2018, TRENDS MOL MED, V24, P669, DOI 10.1016/j.molmed.2018.06.006; Walia S, 2010, OPHTHALMOLOGY, V117, P1190, DOI 10.1016/j.ophtha.2009.09.056; Wensel T.G., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.10.28.357806, DOI 10.1101/2020.10.28.357806]; Yzer S, 2012, MOL VIS, V18, P412	40	21	21	3	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					785	+		10.1038/s41591-021-01297-7	http://dx.doi.org/10.1038/s41591-021-01297-7		APR 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33795869	Green Accepted			2022-12-27	WOS:000635886700001
J	Nalbandian, A; Sehgal, K; Gupta, A; Madhavan, MV; McGroder, C; Stevens, JS; Cook, JR; Nordvig, AS; Shalev, D; Sehrawat, TS; Ahluwalia, N; Bikdeli, B; Dietz, D; Der-Nigoghossian, C; Liyanage-Don, N; Rosner, GF; Bernstein, EJ; Mohan, S; Beckley, AA; Seres, DS; Choueiri, TK; Uriel, N; Ausiello, JC; Accili, D; Freedberg, DE; Baldwin, M; Schwartz, A; Brodie, D; Garcia, CK; Elkind, MSV; Connors, JM; Bilezikian, JP; Landry, DW; Wan, EEY				Nalbandian, Ani; Sehgal, Kartik; Gupta, Aakriti; Madhavan, Mahesh V.; McGroder, Claire; Stevens, Jacob S.; Cook, Joshua R.; Nordvig, Anna S.; Shalev, Daniel; Sehrawat, Tejasav S.; Ahluwalia, Neha; Bikdeli, Behnood; Dietz, Donald; Der-Nigoghossian, Caroline; Liyanage-Don, Nadia; Rosner, Gregg F.; Bernstein, Elana J.; Mohan, Sumit; Beckley, Akinpelumi A.; Seres, David S.; Choueiri, Toni K.; Uriel, Nir; Ausiello, John C.; Accili, Domenico; Freedberg, Daniel E.; Baldwin, Matthew; Schwartz, Allan; Brodie, Daniel; Garcia, Christine Kim; Elkind, Mitchell S. V.; Connors, Jean M.; Bilezikian, John P.; Landry, Donald W.; Wan, Elaine Y.			Post-acute COVID-19 syndrome	NATURE MEDICINE			English	Review							LUNG TRANSPLANTATION; PATIENT	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics. A comprehensive review of the current literature on post-acute COVID-19, also referred to as long COVID, its pathophysiology and its organ-specific sequelae highlights the need for multidisciplinary follow-up and care of COVID-19 survivors.	[Nalbandian, Ani; Gupta, Aakriti; Madhavan, Mahesh V.; Rosner, Gregg F.; Uriel, Nir; Schwartz, Allan; Wan, Elaine Y.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Div Cardiol,Dept Med,Vagelos Coll Phys & Surg, New York, NY 10027 USA; [Sehgal, Kartik; Choueiri, Toni K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Sehgal, Kartik; Choueiri, Toni K.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Sehgal, Kartik; Bikdeli, Behnood; Choueiri, Toni K.; Connors, Jean M.] Harvard Med Sch, Boston, MA 02115 USA; [Gupta, Aakriti; Madhavan, Mahesh V.; Bikdeli, Behnood] Cardiovasc Res Fdn, Clin Trials Ctr, New York, NY USA; [Gupta, Aakriti; Bikdeli, Behnood] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [McGroder, Claire; Baldwin, Matthew; Brodie, Daniel; Garcia, Christine Kim] Columbia Univ, Div Pulm Allergy & Crit Care Med, Vagelos Coll Phys & Surg, Dept Med,New York Presbyterian,Irving Med Ctr, New York, NY USA; [Stevens, Jacob S.; Mohan, Sumit; Landry, Donald W.] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, Div Nephrol,Dept Med,New York Presbyterian, New York, NY USA; [Cook, Joshua R.; Ausiello, John C.; Accili, Domenico; Bilezikian, John P.] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, Div Endocrinol,Dept Med,New York Presbyterian, New York, NY USA; [Nordvig, Anna S.; Elkind, Mitchell S. V.] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York Presbyterian,Irving Med Ctr, New York, NY USA; [Shalev, Daniel] Columbia Univ, Vagelos Coll Phys & Surg, New York Presbyterian, Irving Med Ctr,Dept Psychiat, New York, NY USA; [Shalev, Daniel] New York State Psychiat Inst & Hosp, New York, NY 10032 USA; [Sehrawat, Tejasav S.] Mayo Clin, Div Gastroenterol & Hepatol, Dept Med, Rochester, MN USA; [Ahluwalia, Neha] Icahn Sch Med Mt Sinai, Div Cardiol, Dept Pediat, New York, NY 10029 USA; [Bikdeli, Behnood] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA; [Dietz, Donald] Columbia Univ, Vagelos Coll Phys & Surg, Div Infect Dis, Dept Med,New York Presbyterian,Irving Med Ctr, New York, NY USA; [Der-Nigoghossian, Caroline] Columbia Univ, Irving Med Ctr, Clin Pharm, New York Presbyterian Hosp, New York, NY USA; [Liyanage-Don, Nadia] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, New York Presbyterian,Irving Med Ctr, New York, NY USA; [Bernstein, Elana J.] Columbia Univ, Vagelos Coll Phys & Surg, New York Presbyterian, Div Rheumatol,Dept Med,Irving Med Ctr, New York, NY USA; [Beckley, Akinpelumi A.] Columbia Univ, Dept Rehabil & Regenerat Med, New York Presbyterian, Irving Med Ctr, New York, NY USA; [Seres, David S.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Vagelos Coll Phys & Surg,Inst Human Nutr, New York, NY USA; [Seres, David S.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Div Prevent Med & Nutr,Dept Med,Vagelos Coll Phys, New York, NY USA; [Freedberg, Daniel E.] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Div Digest & Liver Dis,Dept Med,New York Presbyte, New York, NY USA; [Elkind, Mitchell S. V.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, 75 Francis St, Boston, MA 02115 USA	Columbia University; NewYork-Presbyterian Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Cardiovascular Research Foundation (CRF); Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; New York State Psychiatry Institute; Mayo Clinic; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Harvard University; Brigham & Women's Hospital	Wan, EEY (corresponding author), Columbia Univ, Irving Med Ctr, New York Presbyterian, Div Cardiol,Dept Med,Vagelos Coll Phys & Surg, New York, NY 10027 USA.; Sehgal, K (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Sehgal, K (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Sehgal, K (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	Kartik_sehgal@dfci.harvard.edu; eyw2003@cumc.columbia.edu	Sehgal, Kartik/B-5837-2019; Choueiri, Toni/K-5238-2019; Baldwin, Matthew/GQY-7234-2022; Mohan, Sumit/I-5625-2019	Sehgal, Kartik/0000-0003-4391-6943; Choueiri, Toni/0000-0002-9201-3217; Mohan, Sumit/0000-0002-5305-9685; McGroder, Claire/0000-0003-1157-4627; Shalev, Daniel/0000-0002-8168-2255; Gupta, Aakriti/0000-0001-9103-9872; Sehrawat, Tejasav/0000-0001-7346-5683; Nordvig, Anna Starikovsky/0000-0003-3360-9157; Nalbandian, Ani/0000-0002-5615-7328; Der-Nigoghossian, Caroline/0000-0001-5445-9421; Cook, Joshua Robert/0000-0001-6004-0504	National Institutes of Health [K23 DK111847]; Department of Defense [PR181960]; National Institutes of Health/National Heart, Lung, and Blood Institute [T32 HL007854]; National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK114893, R01-MD014161, U01-DK116066]; National Science Foundation [2032726]; National Institute of Neurological Disorders and Stroke [T32 NS007153-36]; National Institute on Aging [P30 AG066462-01]; NIH [R01 HL152236, R03 HL146881]; Esther Aboodi Endowed Professorship at Columbia University; Foundation for Gender-Specific Medicine; Wu Family Research Fund; Louis V. Gerstner, Jr. Scholars Program	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Science Foundation(National Science Foundation (NSF)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Esther Aboodi Endowed Professorship at Columbia University; Foundation for Gender-Specific Medicine; Wu Family Research Fund; Louis V. Gerstner, Jr. Scholars Program	We acknowledge J. Der-Nigoghossian and BioRender for design support for the figures. D.E.F. was supported in part by National Institutes of Health grant K23 DK111847 and by Department of Defense funding PR181960. M.V.M. was supported by an institutional grant from the National Institutes of Health/National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854). S.M. was supported by National Institute of Diabetes and Digestive and Kidney Diseases grants R01-DK114893, R01-MD014161 and U01-DK116066, as well as National Science Foundation grant 2032726. A.S.N. was supported by National Institute of Neurological Disorders and Stroke grant T32 NS007153-36 and National Institute on Aging grant P30 AG066462-01. E.Y.W. was supported by NIH R01 HL152236 and R03 HL146881, the Esther Aboodi Endowed Professorship at Columbia University, the Foundation for Gender-Specific Medicine, the Louis V. Gerstner, Jr. Scholars Program and the Wu Family Research Fund. The funders had no role in the design or conduct of the study; collection, management, analysis or interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Agarwal AK, 2007, POSTGRAD MED J, V83, P478, DOI 10.1136/pgmj.2006.055046; Ahmed H, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2694; Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247; Ameres M, 2020, J NEUROL, V267, P3476, DOI 10.1007/s00415-020-10050-y; [Anonymous], CIRC RES, DOI [10.1161/CIRCRESAHA.120.317803, DOI 10.1161/CIRCRESAHA.120.317803]; [Anonymous], INT AIDS C; [Anonymous], JAMA PSYCHIAT, DOI [10.1001/jamapsychiatry.2020.2795, DOI 10.1001/JAMAPSYCHIATRY.2020.2795]; [Anonymous], SINGAPORE MED J, DOI [10.11622/smedj.2018150, DOI 10.11622/SMEDJ.2018150]; [Anonymous], HEADACHE, DOI [10.1111/head.13856, DOI 10.1111/HEAD.13856]; [Anonymous], CLIN MICROBIOL INFEC, DOI [10.1016/j.cmi.2020.08.028, DOI 10.1016/J.CMI.2020.08.028]; [Anonymous], PAEDIAT MULTISYSTEM; [Anonymous], INFORM HEALTHCARE PR; [Anonymous], NATURE; [Anonymous], J MED VIROL, DOI [10.1002/jmv.26339, DOI 10.1002/JMV.26339]; [Anonymous], HEAD NECK SURG, DOI [10.1001/jamaoto.2020.2366, DOI 10.1001/JAMAOTO.2020.2366]; [Anonymous], CLIN REV BONE MINER, DOI [10.1007/s12018-020-09274-3, DOI 10.1007/S12018-020-09274-3]; [Anonymous], 2017, CLIN PRACT, DOI [10.1212/CPJ.0000000000000897, DOI 10.1212/CPJ.0000000000000897, DOI 10.1212/CPJ.0000000000000381]; [Anonymous], P AHSAME 2020 VIRT A; [Anonymous], ANN NEUROL; [Anonymous], EUR J PHYS REHABIL M, DOI [10.23736/S1973-9087.21.06549-7, DOI 10.23736/S1973-9087.21.06549-7]; [Anonymous], 2009, NEUROLOGY, DOI [10.1212/WNL.0000000000010111, DOI 10.1212/WNL.0000000000010111, DOI 10.1212/WNL.0B013E3181B389F1]; [Anonymous], COVID 19 VTE ANTICOG; [Anonymous], INT J DERMATOL, DOI [10.1111/ijd.15168, DOI 10.1111/IJD.15168]; [Anonymous], ANN INT MED, DOI [10.7326/M20-6306, DOI 10.7326/M20-6306]; [Anonymous], MULTISYSTEM INFLAMMA; Arca Karissa N, 2020, SN Compr Clin Med, V2, P1200, DOI 10.1007/s42399-020-00369-y; Arnold David T, 2021, Thorax, V76, P399, DOI 10.1136/thoraxjnl-2020-216086; Bai CX, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0287-2020; Bajaj NS, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002797; Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z; Belvis R, 2020, HEADACHE, V60, P1422, DOI 10.1111/head.13841; Bharat A, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abe4282; Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Bortolato B, 2015, CURR NEUROPHARMACOL, V13, P558, DOI 10.2174/1570159X13666150630171433; Bozkurt B, 2020, J CARD FAIL, V26, P370, DOI 10.1016/j.cardfail.2020.04.013; Bradley KC, 2019, CELL REP, V28, P245, DOI 10.1016/j.celrep.2019.05.105; Brancatella A, 2020, J CLIN ENDOCR METAB, V105, P2367, DOI 10.1210/clinem/dgaa276; Brigham E, 2021, AM J MED, V134, P462, DOI 10.1016/j.amjmed.2020.12.009; Brugliera L, 2020, EUR J CLIN NUTR, V74, P860, DOI 10.1038/s41430-020-0664-x; Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V324, P1567, DOI 10.1001/jama.2020.17386; Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412; Burnham EL, 2013, CRIT CARE MED, V41, P445, DOI 10.1097/CCM.0b013e31826a5062; Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5; Carvalho-Schneider C, 2021, CLIN MICROBIOL INFEC, V27, P258, DOI 10.1016/j.cmi.2020.09.052; Chang Y, 2018, TRANSPLANTATION, V102, P829, DOI 10.1097/TP.0000000000002004; Chaudhary R, 2020, THROMB HAEMOSTASIS, V120, P1594, DOI 10.1055/s-0040-1714217; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen J, 2020, CHEST, V157, p453A, DOI 10.1016/j.chest.2020.05.513; Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065; Chiasakul T, 2019, THROMB RES, V184, P58, DOI 10.1016/j.thromres.2019.10.027; Chopra V, 2021, ANN INTERN MED, V174, P576, DOI 10.7326/M20-5661; Chowkwanyun M, 2020, NEW ENGL J MED, V383, P201, DOI 10.1056/NEJMp2012910; Coker RK, 2001, THORAX, V56, P549, DOI 10.1136/thorax.56.7.549; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Corrigan D, 2016, CLIN EXP EMERG MED, V3, P117, DOI 10.15441/ceem.16.146; Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006; Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Datta SD, 2020, JAMA-J AM MED ASSOC, V324, P2251, DOI 10.1001/jama.2020.22717; De Michele S, 2020, AM J CLIN PATHOL, V154, P748, DOI 10.1093/ajcp/aqaa156; Desai AD, 2021, CURR CARDIOL REP, V23, DOI 10.1007/s11886-020-01434-7; Desforges M, 2014, VIRUS RES, V194, P145, DOI 10.1016/j.virusres.2014.09.011; DiMeglio LA, 2018, LANCET, V391, P2449, DOI 10.1016/S0140-6736(18)31320-5; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Engelen M., 2021, RES PRACT THROMB HAE; Freeman EE, 2020, J AM ACAD DERMATOL, V83, P1118, DOI 10.1016/j.jaad.2020.06.1016; Garrigues E, 2020, J INFECTION, V81, pE4, DOI 10.1016/j.jinf.2020.08.029; Gemayel C, 2001, J AM COLL CARDIOL, V38, P1773, DOI 10.1016/S0735-1097(01)01654-0; Genovese G, 2021, DERMATOLOGY, V237, P1, DOI 10.1159/000512932; Gentile S, 2020, DIABETES OBES METAB, V22, P2507, DOI 10.1111/dom.14170; George PM, 2020, THORAX, V75, P1009, DOI 10.1136/thoraxjnl-2020-215314; George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3; Golmai P, 2020, J AM SOC NEPHROL, V31, P1944, DOI 10.1681/ASN.2020050683; Goshua George, 2020, Lancet Haematol, V7, pe575, DOI 10.1016/S2352-3026(20)30216-7; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Gu T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25197; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Harel Z, 2013, KIDNEY INT, V83, P901, DOI 10.1038/ki.2012.451; Hendaus MA, 2021, J BIOMOL STRUCT DYN, V39, P4185, DOI 10.1080/07391102.2020.1772110; Hendaus MA, 2015, THER CLIN RISK MANAG, V11, P1265, DOI 10.2147/TCRM.S87789; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1791, DOI 10.1002/art.41454; Hendren NS, 2020, CIRCULATION, V141, P1903, DOI 10.1161/CIRCULATIONAHA.120.047349; Heneka MT, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00640-3; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hosey MM, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0201-1; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang YY, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01429-6; Hui DS, 2005, THORAX, V60, P401, DOI 10.1136/thx.2004.030205; Huppert LA, 2019, SEMIN RESP CRIT CARE, V40, P31, DOI 10.1055/s-0039-1683996; Inoue S, 2019, ACUTE MED SURG, V6, P233, DOI 10.1002/ams2.415; Jabri A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14780; Jacobs LG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243882; Jhaveri KD, 2020, KIDNEY INT, V98, P509, DOI 10.1016/j.kint.2020.05.025; Jiang L, 2020, LANCET INFECT DIS, V20, pE276, DOI 10.1016/S1473-3099(20)30651-4; Kaseda ET, 2020, CLIN NEUROPSYCHOL, V34, P1498, DOI 10.1080/13854046.2020.1811894; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Kociol RD, 2020, CIRCULATION, V141, pE69, DOI 10.1161/CIR.0000000000000745; Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390; Kudose S, 2020, J AM SOC NEPHROL, V31, P1959, DOI 10.1681/ASN.2020060802; Lam MHB, 2009, ARCH INTERN MED, V169, P2142, DOI 10.1001/archinternmed.2009.384; Lang M, 2020, LANCET INFECT DIS, V20, P1365, DOI 10.1016/S1473-3099(20)30367-4; Lau ST, 2005, INT J CARDIOL, V100, P167, DOI 10.1016/j.ijcard.2004.06.022; Lazzerini PE, 2019, NAT REV IMMUNOL, V19, P63, DOI 10.1038/s41577-018-0098-z; Le TTT, 2014, J IMMUNOL, V193, P3755, DOI 10.4049/jimmunol.1302470; Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405; Lee SH, 2019, PSYCHIAT INVEST, V16, P59, DOI 10.30773/pi.2018.10.22.3; Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561; Lescure FX., 2020, LANCET INFECT DIS, V20, P697; Libby P, 2020, EUR HEART J, V41, P3038, DOI 10.1093/eurheartj/ehaa623; Lim W, 2015, CRIT CARE MED, V43, P401, DOI 10.1097/CCM.0000000000000713; Lin JE, 2021, NEUROSCI LETT, V743, DOI 10.1016/j.neulet.2020.135567; Lindner D, 2020, JAMA CARDIOL, V5, P1281, DOI 10.1001/jamacardio.2020.3551; Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549; Liu W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133698; Lopes RD, 2021, JAMA-J AM MED ASSOC, V325, P254, DOI 10.1001/jama.2020.25864; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Luks AM, 2020, ANN AM THORAC SOC, V17, P1040, DOI 10.1513/AnnalsATS.202005-418FR; Mangion K, 2020, CARDIOVASC RES, V116, P2185, DOI 10.1093/cvr/cvaa209; Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214; Maron BJ, 2015, J AM COLL CARDIOL, V66, P2362, DOI 10.1016/j.jacc.2015.09.035; Martin-Villares C, 2021, EUR ARCH OTO-RHINO-L, V278, P1605, DOI 10.1007/s00405-020-06220-3; Masiero S, 2020, AM J PHYS MED REHAB, V99, P677, DOI 10.1097/PHM.0000000000001478; Mateu-Salat M, 2020, J ENDOCRINOL INVEST, V43, P1527, DOI 10.1007/s40618-020-01366-7; Mazza MG, 2020, BRAIN BEHAV IMMUN, V89, P594, DOI 10.1016/j.bbi.2020.07.037; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC; Meier P, 2011, CLIN J AM SOC NEPHRO, V6, P2215, DOI 10.2215/CJN.01880211; Mendez R, 2021, ANN AM THORAC SOC, V18, P1253, DOI 10.1513/AnnalsATS.202011-1452RL; Merrill JT, 2020, NAT REV RHEUMATOL, V16, P581, DOI 10.1038/s41584-020-0474-5; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Miquel S, 2013, CURR OPIN MICROBIOL, V16, P255, DOI 10.1016/j.mib.2013.06.003; Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020; Moldofsky H, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-37; Moodley YP, 2003, AM J PATHOL, V163, P345, DOI 10.1016/S0002-9440(10)63658-9; Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559; Moreno-Perez O, 2021, J INFECTION, V82, P378, DOI 10.1016/j.jinf.2021.01.004; Muccioli L, 2020, ANN NEUROL, V88, P860, DOI 10.1002/ana.25855; Myall KJ, 2021, ANN AM THORAC SOC, V18, P799, DOI 10.1513/AnnalsATS.202008-1002OC; Nakra NA, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7070069; Needham DM, 2013, AM J RESP CRIT CARE, V188, P567, DOI 10.1164/rccm.201304-0651OC; Nougier C, 2020, J THROMB HAEMOST, V18, P2215, DOI 10.1111/jth.15016; Novak Peter, 2020, eNeurologicalSci, V21, P100276, DOI 10.1016/j.ensci.2020.100276; Ong KC, 2004, EUR RESPIR J, V24, P436, DOI 10.1183/09031936.04.00007104; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Parauda SC, 2020, J NEUROL SCI, V416, DOI 10.1016/j.jns.2020.117019; Patell R, 2020, BLOOD, V136, P1342, DOI 10.1182/blood.2020007938; Paterson RW, 2020, BRAIN, V143, P3104, DOI 10.1093/brain/awaa240; Pavoni V, 2020, J THROMB THROMBOLYS, V50, P281, DOI 10.1007/s11239-020-02130-7; Peleg Y, 2020, KIDNEY INT REP, V5, P940, DOI 10.1016/j.ekir.2020.04.017; Perrin R, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110055; Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Raghu G, 2020, LANCET RESP MED, V8, P839, DOI 10.1016/S2213-2600(20)30349-0; Raj SR, 2009, CIRCULATION, V120, P725, DOI 10.1161/CIRCULATIONAHA.108.846501; Rajpal S, 2021, JAMA CARDIOL, V6, P116, DOI 10.1001/jamacardio.2020.4916; Ramlall V, 2020, NAT MED, V26, P1609, DOI 10.1038/s41591-020-1021-2; Reichard RR, 2020, ACTA NEUROPATHOL, V140, P1, DOI 10.1007/s00401-020-02166-2; Rey JR, 2020, EUR J HEART FAIL, V22, P2205, DOI 10.1002/ejhf.1990; Ritchie K, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa069; Robbins-Juarez SY, 2020, KIDNEY INT REP, V5, P1149, DOI 10.1016/j.ekir.2020.06.013; Roberts LN, 2020, BLOOD, V136, P1347, DOI 10.1182/blood.2020008086; Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0; Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937; Rowley AH, 2020, NAT REV IMMUNOL, V20, P453, DOI 10.1038/s41577-020-0367-5; Rubin R, 2020, JAMA-J AM MED ASSOC, V324, P1381, DOI 10.1001/jama.2020.17709; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]; Ruggeri RM, 2021, HORM-INT J ENDOCRINO, V20, P219, DOI 10.1007/s42000-020-00230-w; Sakusic A, 2018, CURR OPIN CRIT CARE, V24, P410, DOI 10.1097/MCC.0000000000000527; Salisbury R, 2020, BLOOD ADV, V4, P6230, DOI 10.1182/bloodadvances.2020003349; Santoriello D, 2020, J AM SOC NEPHROL, V31, P2158, DOI 10.1681/ASN.2020050744; Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907; Schupper AJ, 2020, CHILD NERV SYST, V36, P1579, DOI 10.1007/s00381-020-04755-8; Shah AS, 2021, THORAX, V76, P402, DOI 10.1136/thoraxjnl-2020-216308; Shah W, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n136; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Sharma P, 2020, J AM SOC NEPHROL, V31, P1948, DOI 10.1681/ASN.2020050699; Simpson R, 2020, AM J PHYS MED REHAB, V99, P470, DOI 10.1097/PHM.0000000000001443; Siripanthong B, 2020, HEART RHYTHM, V17, P1463, DOI 10.1016/j.hrthm.2020.05.001; Skendros P, 2020, J CLIN INVEST, V130, P6151, DOI 10.1172/JCI141374; Sosnowski K, 2015, AUST CRIT CARE, V28, P216, DOI 10.1016/j.aucc.2015.05.002; South K, 2020, INT J STROKE, V15, P722, DOI 10.1177/1747493020943815; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Stevens JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244131; Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tankisi H, 2020, CLIN NEUROPHYSIOL, V131, P1931, DOI 10.1016/j.clinph.2020.06.003; Taquet M, 2021, LANCET PSYCHIAT, V8, P130, DOI 10.1016/S2215-0366(20)30462-4; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI [10.15585/mmwr.mm6930e1, 10.15585/mmwr.mm6930e1externalicon]; Thachil J, 2020, J THROMB HAEMOST, V18, P3109, DOI 10.1111/jth.15029; Do TP, 2019, NEUROLOGY, V92, P134, DOI 10.1212/WNL.0000000000006697; Trejo-Gabriel-Galan JM, 2020, NEUROLOGIA, V35, P318, DOI 10.1016/j.nrl.2020.04.015; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; van Kampen JJA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20568-4; VARGA Z, 2020, LANCET, V395, P1417, DOI [DOI 10.1016/S0140-6736(20)30937-5, 10.1016/S0140-6736(20)30937-5]; Velez JCQ, 2020, NAT REV NEPHROL, V16, P565, DOI 10.1038/s41581-020-0332-3; Wang Q, 2019, ANN THORAC SURG, V108, pE233, DOI 10.1016/j.athoracsur.2019.02.035; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598; Wilbers TJ, 2020, J CRIT CARE, V60, P103, DOI 10.1016/j.jcrc.2020.07.025; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09536-z; Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4; Zahariadis George, 2006, Can Respir J, V13, P17; Zeppa SD, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.576551; Zhao YM, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100463; Zheng Z., 2003, CHIN J RESPIR CRIT C, V2, P270; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zuo T, 2020, GASTROENTEROLOGY, V159, P944, DOI 10.1053/j.gastro.2020.05.048; Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999	226	1259	1289	210	475	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					601	615		10.1038/s41591-021-01283-z	http://dx.doi.org/10.1038/s41591-021-01283-z		MAR 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33753937	Bronze, Green Accepted			2022-12-27	WOS:000631496800002
J	Cromer, MK; Camarena, J; Martin, RM; Lesch, BJ; Vakulskas, CA; Bode, NM; Kurgan, G; Collingwood, MA; Rettig, GR; Behlke, MA; Lemgart, VT; Zhang, YK; Goyal, A; Zhao, FF; Ponce, E; Srifa, W; Bak, RO; Uchida, N; Majeti, R; Sheehan, VA; Tisdale, JF; Dever, DP; Porteus, MH				Cromer, M. Kyle; Camarena, Joab; Martin, Renata M.; Lesch, Benjamin J.; Vakulskas, Christopher A.; Bode, Nicole M.; Kurgan, Gavin; Collingwood, Michael A.; Rettig, Garrett R.; Behlke, Mark A.; Lemgart, Viktor T.; Zhang, Yankai; Goyal, Ankush; Zhao, Feifei; Ponce, Ezequiel; Srifa, Waracharee; Bak, Rasmus O.; Uchida, Naoya; Majeti, Ravindra; Sheehan, Vivien A.; Tisdale, John F.; Dever, Daniel P.; Porteus, Matthew H.			Gene replacement of alpha-globin with beta-globin restores hemoglobin balance in beta-thalassemia-derived hematopoietic stem and progenitor cells	NATURE MEDICINE			English	Article							MIXED CHIMERISM; ERYTHROPOIESIS; THERAPY	beta-Thalassemia pathology is due not only to loss of beta-globin (HBB), but also to erythrotoxic accumulation and aggregation of the beta-globin-binding partner, alpha-globin (HBA1/2). Here we describe a Cas9/AAV6-mediated genome editing strategy that can replace the entire HBA1 gene with a full-length HBB transgene in beta-thalassemia-derived hematopoietic stem and progenitor cells (HSPCs), which is sufficient to normalize beta-globin:alpha-globin messenger RNA and protein ratios and restore functional adult hemoglobin tetramers in patient-derived red blood cells. Edited HSPCs were capable of long-term and bilineage hematopoietic reconstitution in mice, establishing proof of concept for replacement of HBA1 with HBB as a novel therapeutic strategy for curing beta-thalassemia. A new genome editing strategy can normalize the beta-globin:alpha-globin balance in human hematopoietic stem cells from patients with beta-thalassemia and restore functional adult hemoglobin tetramers in patient-derived red blood cells.	[Cromer, M. Kyle; Camarena, Joab; Martin, Renata M.; Lesch, Benjamin J.; Lemgart, Viktor T.; Ponce, Ezequiel; Srifa, Waracharee; Dever, Daniel P.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Vakulskas, Christopher A.; Bode, Nicole M.; Kurgan, Gavin; Collingwood, Michael A.; Rettig, Garrett R.; Behlke, Mark A.] Integrated DNA Technol Inc, Coralville, IA USA; [Zhang, Yankai; Goyal, Ankush; Sheehan, Vivien A.] Baylor Coll Med, Dept Pediat, Div Hematol Oncol, Houston, TX 77030 USA; [Zhao, Feifei; Majeti, Ravindra] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA; [Zhao, Feifei; Majeti, Ravindra; Porteus, Matthew H.] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Bak, Rasmus O.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Bak, Rasmus O.] Aarhus Univ, Aarhus Inst Adv Studies, Aarhus, Denmark; [Uchida, Naoya; Tisdale, John F.] NHLBI, Cellular & Mol Therapeut Branch, NIH, Bldg 10, Bethesda, MD 20892 USA	Stanford University; Baylor College of Medicine; Stanford University; Stanford University; Aarhus University; Aarhus University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Dever, DP (corresponding author), Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.; Porteus, MH (corresponding author), Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.	ddever1@stanford.edu; mporteus@stanford.edu	Bak, Rasmus O./AAH-9748-2021	Bak, Rasmus O./0000-0002-7383-0297; Vakulskas, Christopher/0000-0001-8510-4332; Martin, Renata/0000-0003-2996-4260; Behlke, Mark/0000-0002-4218-857X; Bode, Nicole/0000-0001-7209-303X; Srifa, Waracharee/0000-0002-6821-2451; Cromer, Kyle/0000-0002-8198-5010; Majeti, Ravindra/0000-0002-5814-0984; Camarena, Joab/0000-0002-3102-5820; Kurgan, Gavin/0000-0002-4047-1427; Rettig, Garrett/0000-0003-4634-5787; Collingwood, Michael/0000-0002-8849-4038	Doris Duke Charitable Trust [22399]; NIH NHLBI [T32-HL120824, R01-HL135607]	Doris Duke Charitable Trust(Doris Duke Charitable Foundation (DDCF)); NIH NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank the following funding sources that made this work possible: Doris Duke Charitable Trust (no. 22399) to M.H.P., NIH NHLBI (no. R01-HL135607) to M.H.P. and D.P.D., and NIH NHLBI (no. T32-HL120824) to M.K.C.	ALTER BP, 1979, EXP HEMATOL, V7, P200; Andreani M, 2000, BONE MARROW TRANSPL, V25, P401, DOI 10.1038/sj.bmt.1702151; Andreani M, 1996, BLOOD, V87, P3494, DOI 10.1182/blood.V87.8.3494.bloodjournal8783494; Aurnhammer C, 2012, HUM GENE THER METHOD, V23, P18, DOI 10.1089/hgtb.2011.034; Bak RO, 2018, NAT PROTOC, V13, P358, DOI 10.1038/nprot.2017.143; Bak RO, 2017, ELIFE, V6, DOI 10.7554/eLife.27873.001; Bak RO, 2017, CELL REP, V20, P750, DOI 10.1016/j.celrep.2017.06.064; Breda L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032345; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Canver MC, 2015, NATURE, V527, P192, DOI 10.1038/nature15521; Cao A, 2010, GENET MED, V12, P61, DOI [10.1097/GIM.0b013e3181cd68ed, 10.1038/gim.2016.173]; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; Charlesworth CT, 2018, MOL THER-NUCL ACIDS, V12, P89, DOI 10.1016/j.omtn.2018.04.017; Cradick TJ, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.64; Cromer MK, 2018, MOL THER, V26, P2431, DOI 10.1016/j.ymthe.2018.06.002; De Ravin SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3480; Dever DP, 2016, NATURE, V539, P384, DOI 10.1038/nature20134; DeWitt MA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9336; Dulmovits BM, 2016, BLOOD, V127, P1481, DOI 10.1182/blood-2015-09-667923; Dye DE, 2011, J COMMUN GENET, V2, P81, DOI 10.1007/s12687-011-0043-3; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; Ferrari S, 2020, NAT BIOTECHNOL, V38, P1298, DOI 10.1038/s41587-020-0551-y; Fleischhauer K, 2006, BLOOD, V107, P2984, DOI 10.1182/blood-2005-08-3374; Gomez-Ospina N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11962-8; Hendel A, 2015, NAT BIOTECHNOL, V33, P985, DOI 10.1038/nbt.3290; Hu JP, 2013, BLOOD, V121, P3246, DOI 10.1182/blood-2013-01-476390; Khan IF, 2011, NAT PROTOC, V6, P482, DOI 10.1038/nprot.2011.301; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Marktel S, 2019, NAT MED, V25, P234, DOI 10.1038/s41591-018-0301-6; Martin RM, 2019, CELL STEM CELL, V24, P821, DOI 10.1016/j.stem.2019.04.001; McDermott SP, 2010, BLOOD, V116, P193, DOI 10.1182/blood-2010-02-271841; Mentzer WC, 2001, JAMA-J AM MED ASSOC, V285, P640, DOI 10.1001/jama.285.5.640; Mettananda S, 2015, BLOOD, V125, P3694, DOI 10.1182/blood-2015-03-633594; Negre O, 2016, HUM GENE THER, V27, P148, DOI 10.1089/hum.2016.007; Nemati H, 2011, MOL BIOL REP, V38, P3213, DOI 10.1007/s11033-010-9994-4; Park SH, 2019, NUCLEIC ACIDS RES, V47, P7955, DOI 10.1093/nar/gkz475; Pattabhi S, 2019, MOL THER-NUCL ACIDS, V17, P277, DOI 10.1016/j.omtn.2019.05.025; Pavel-Dinu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09614-y; Puthenveetil G, 2004, BLOOD, V104, P3445, DOI 10.1182/blood-2004-04-1427; Schiroli G, 2019, CELL STEM CELL, V24, P551, DOI 10.1016/j.stem.2019.02.019; Schiroli G, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0820; Sharma R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20792-y; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; STAMATOYANNOPOULOS G, 1985, ANN NY ACAD SCI, V445, P188, DOI 10.1111/j.1749-6632.1985.tb17188.x; Thein SL, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011700; Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342; Weatherall D, 2004, AM J HUM GENET, V74, P385, DOI 10.1086/381402; Wunderlich M, 2010, LEUKEMIA, V24, P1785, DOI 10.1038/leu.2010.158; Xu L, 2019, NEW ENGL J MED, V381, P1240, DOI 10.1056/NEJMoa1817426	49	14	14	4	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01284-y	http://dx.doi.org/10.1038/s41591-021-01284-y		MAR 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33737751	Green Accepted, Green Submitted			2022-12-27	WOS:000630281500001
J	Nakatsuji, T; Hata, TR; Tong, Y; Cheng, JYY; Shafiq, F; Butcher, AM; Salem, SS; Brinton, SL; Spergel, ARK; Johnson, K; Jepson, B; Calatroni, A; David, G; Ramirez-Gama, M; Taylor, P; Leung, DYM; Gallo, RL				Nakatsuji, Teruaki; Hata, Tissa R.; Tong, Yun; Cheng, Joyce Y.; Shafiq, Faiza; Butcher, Anna M.; Salem, Secilia S.; Brinton, Samantha L.; Rudman Spergel, Amanda K.; Johnson, Keli; Jepson, Brett; Calatroni, Agustin; David, Gloria; Ramirez-Gama, Marco; Taylor, Patricia; Leung, Donald Y. M.; Gallo, Richard L.			Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial	NATURE MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL PEPTIDES; EPIDERMIDIS; SEVERITY; CHILDREN; STRAINS; DISEASE; ECZEMA; IDENTIFICATION; CATHELICIDIN	Staphylococcus aureus colonizes patients with atopic dermatitis (AD) and exacerbates disease by promoting inflammation. The present study investigated the safety and mechanisms of action of Staphylococcus hominis A9 (ShA9), a bacterium isolated from healthy human skin, as a topical therapy for AD. ShA9 killed S. aureus on the skin of mice and inhibited expression of a toxin from S. aureus (psm alpha) that promotes inflammation. A first-in-human, phase 1, double-blinded, randomized 1-week trial of topical ShA9 or vehicle on the forearm skin of 54 adults with S. aureus-positive AD (NCT03151148) met its primary endpoint of safety, and participants receiving ShA9 had fewer adverse events associated with AD. Eczema severity was not significantly different when evaluated in all participants treated with ShA9 but a significant decrease in S. aureus and increased ShA9 DNA were seen and met secondary endpoints. Some S. aureus strains on participants were not directly killed by ShA9, but expression of mRNA for psm alpha was inhibited in all strains. Improvement in local eczema severity was suggested by post-hoc analysis of participants with S. aureus directly killed by ShA9. These observations demonstrate the safety and potential benefits of bacteriotherapy for AD. First-in-human test of topical application of a commensal bacterium on skin of individuals with atopic dermatitis reduces colonization by proinflammatory Staphylococcus aureus.	[Nakatsuji, Teruaki; Hata, Tissa R.; Tong, Yun; Cheng, Joyce Y.; Shafiq, Faiza; Butcher, Anna M.; Salem, Secilia S.; Brinton, Samantha L.; Gallo, Richard L.] Univ Calif San Diego, Dept Dermatol, La Jolla, CA 92093 USA; [Rudman Spergel, Amanda K.] NIAID, Div Allergy Immunol & Transplantat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Johnson, Keli; Jepson, Brett; Calatroni, Agustin; David, Gloria] Rho Fed Syst Div Inc, Durham, NC USA; [Ramirez-Gama, Marco; Taylor, Patricia; Leung, Donald Y. M.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health	Gallo, RL (corresponding author), Univ Calif San Diego, Dept Dermatol, La Jolla, CA 92093 USA.	rgallo@health.ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Brinton, Samantha/0000-0003-1014-2566; Tong, Yun/0000-0003-2003-1843	Atopic Dermatitis Research Network (ADRN) [U19AI117673, 1UM1AI151958, UM2AI117870]; National Institutes of Health [R01AR076082, R01AR064781, R01AI116576, R37AI052453, R01AI153185]; NIH/NCATS Colorado CTSA [UL1 TR002535]	Atopic Dermatitis Research Network (ADRN); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCATS Colorado CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The present study was funded by the Atopic Dermatitis Research Network (ADRN) (grant nos. U19AI117673 and 1UM1AI151958 to R.L.G. and D.Y.M.L., and UM2AI117870 to Rho Federal Systems Division), and National Institutes of Health grants (nos. R01AR076082, R01AR064781 and R01AI116576 to R.L.G. and T.N., R37AI052453 and R01AI153185 to R.L.G.) and NIH/NCATS Colorado CTSA grant no. UL1 TR002535 to D.Y.M.L.	Bae T, 2006, PLASMID, V55, P58, DOI 10.1016/j.plasmid.2005.05.005; Bath-Hextall FJ, 2010, BRIT J DERMATOL, V163, P12, DOI 10.1111/j.1365-2133.2010.09743.x; Bekeredjian-Ding I, 2007, J IMMUNOL, V178, P2803, DOI 10.4049/jimmunol.178.5.2803; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bin LH, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0158-5; Brown MM, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00172-20; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Callewaert C, 2020, J INVEST DERMATOL, V140, P191, DOI 10.1016/j.jid.2019.05.024; CARTER CH, 1960, J BACTERIOL, V79, P753, DOI 10.1128/JB.79.5.753-754.1960; Cau, 2020, J ALLERGY CLIN IMMUN; Chopra R, 2017, ANN ALLERG ASTHMA IM, V119, P435, DOI 10.1016/j.anai.2017.08.289; Cogen AL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008557; Cogen AL, 2010, J INVEST DERMATOL, V130, P192, DOI 10.1038/jid.2009.243; Coyte KZ, 2015, SCIENCE, V350, P663, DOI 10.1126/science.aad2602; Ernst CM, 2018, MBIO, V9, DOI 10.1128/mBio.01659-18; Fishbein AB, 2020, J ALLER CL IMM-PRACT, V8, P91, DOI 10.1016/j.jaip.2019.06.044; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hata TR, 2010, BRIT J DERMATOL, V163, P659, DOI 10.1111/j.1365-2133.2010.09892.x; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kim DW, 2009, J DERMATOL, V36, P75, DOI 10.1111/j.1346-8138.2009.00592.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Langan SM, 2020, LANCET, V396, P345, DOI 10.1016/S0140-6736(20)31286-1; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Li DQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058288; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; Lomholt H, 2005, J INVEST DERMATOL, V125, P977, DOI 10.1111/j.0022-202X.2005.23916.x; Mallbris L, 2010, EXP DERMATOL, V19, P442, DOI 10.1111/j.1600-0625.2009.00918.x; Martinez-Barricarte R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau6759; Miedzobrodzki J, 2002, EUR J CLIN MICROBIOL, V21, P269, DOI 10.1007/s10096-002-0706-4; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Nakagawa S, 2017, CELL HOST MICROBE, V22, P667, DOI 10.1016/j.chom.2017.10.008; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nakatsuji T, 2019, ANN ALLERG ASTHMA IM, V122, P263, DOI 10.1016/j.anai.2018.12.003; Nakatsuji T, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao4502; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Nutten S, 2015, ANN NUTR METAB, V66, P8, DOI 10.1159/000370220; O'Neill AM, 2020, J INVEST DERMATOL, V140, P1619, DOI 10.1016/j.jid.2019.12.026; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; PARISI JT, 1986, DIAGN MICR INFEC DIS, V4, P29, DOI 10.1016/0732-8893(86)90053-2; Reed B, 2018, ALLERGY ASTHMA PROC, V39, P406, DOI 10.2500/aap.2018.39.4175; Reich A, 2012, ACTA DERM-VENEREOL, V92, P497, DOI 10.2340/00015555-1265; Sawada Y, 2019, J ALLERGY CLIN IMMUN, V143, P1946, DOI 10.1016/j.jaci.2019.01.009; Scharschmidt TC, 2017, CELL HOST MICROBE, V21, P467, DOI 10.1016/j.chom.2017.03.001; Schreiber K, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2017.103, 10.1038/nrdp.2018.5]; Simpson E, 2020, J AM ACAD DERMATOL, V83, P839, DOI 10.1016/j.jaad.2020.04.104; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Williams MR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat8329	55	66	68	12	60	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01256-2	http://dx.doi.org/10.1038/s41591-021-01256-2		FEB 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33619370	Green Accepted			2022-12-27	WOS:000620458400004
J	Hall, KD; Guo, J; Courville, AB; Boring, J; Brychta, R; Chen, KY; Darcey, V; Forde, CG; Gharib, AM; Gallagher, I; Howard, R; Joseph, PV; Milley, L; Ouwerkerk, R; Raisinger, K; Rozga, I; Schick, A; Stagliano, M; Torres, S; Walter, M; Walter, P; Yang, SN; Chung, SIT				Hall, Kevin D.; Guo, Juen; Courville, Amber B.; Boring, James; Brychta, Robert; Chen, Kong Y.; Darcey, Valerie; Forde, Ciaran G.; Gharib, Ahmed M.; Gallagher, Isabelle; Howard, Rebecca; Joseph, Paule V.; Milley, Lauren; Ouwerkerk, Ronald; Raisinger, Klaudia; Rozga, Irene; Schick, Alex; Stagliano, Michael; Torres, Stephan; Walter, Mary; Walter, Peter; Yang, Shanna; Chung, Stephanie T.			Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake	NATURE MEDICINE			English	Article							BODY-COMPOSITION CHANGES; FOOD-INTAKE; WEIGHT-LOSS; COVERT MANIPULATION; HYDRATION STATUS; GLYCEMIC LOAD; CARBOHYDRATE; APPETITE; DENSITY; EXPENDITURE	The carbohydrate-insulin model of obesity posits that high-carbohydrate diets lead to excess insulin secretion, thereby promoting fat accumulation and increasing energy intake. Thus, low-carbohydrate diets are predicted to reduce ad libitum energy intake as compared to low-fat, high-carbohydrate diets. To test this hypothesis, 20 adults aged 29.9 +/- 1.4 (mean +/- s.e.m.) years with body mass index of 27.8 +/- 1.3 kg m(-2) were admitted as inpatients to the National Institutes of Health Clinical Center and randomized to consume ad libitum either a minimally processed, plant-based, low-fat diet (10.3% fat, 75.2% carbohydrate) with high glycemic load (85 g 1,000 kcal(-1)) or a minimally processed, animal-based, ketogenic, low-carbohydrate diet (75.8% fat, 10.0% carbohydrate) with low glycemic load (6 g 1,000 kcal(-1)) for 2 weeks followed immediately by the alternate diet for 2 weeks. One participant withdrew due to hypoglycemia during the low-carbohydrate diet. The primary outcomes compared mean daily ad libitum energy intake between each 2-week diet period as well as between the final week of each diet. We found that the low-fat diet led to 689 +/- 73 kcal d(-1) less energy intake than the low-carbohydrate diet over 2 weeks (P < 0.0001) and 544 +/- 68 kcal d(-1) less over the final week (P < 0.0001). Therefore, the predictions of the carbohydrate-insulin model were inconsistent with our observations. This study was registered on ClinicalTrials.gov as . In an inpatient, randomized controlled crossover trial, participants consumed 550-700 kcal day(-1) fewer calories when following a plant-based, low-fat diet with a high glycemic load compared with an animal-based, low-carbohydrate diet with a low glycemic load; weight loss was comparable between the two diets and there were no significant differences in hunger or enjoyment of the meals.	[Hall, Kevin D.; Guo, Juen; Courville, Amber B.; Brychta, Robert; Chen, Kong Y.; Darcey, Valerie; Gharib, Ahmed M.; Gallagher, Isabelle; Howard, Rebecca; Milley, Lauren; Ouwerkerk, Ronald; Rozga, Irene; Schick, Alex; Stagliano, Michael; Walter, Mary; Walter, Peter; Chung, Stephanie T.] NIDDK, Bethesda, MD 20892 USA; [Boring, James; Raisinger, Klaudia; Torres, Stephan; Yang, Shanna] NIH, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Forde, Ciaran G.] Singapore Inst Food & Biotechnol Innovat, Singapore, Singapore; [Joseph, Paule V.] NINR, Bethesda, MD 20892 USA; [Joseph, Paule V.] NIAAA, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Nursing Research (NINR); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Hall, KD (corresponding author), NIDDK, Bethesda, MD 20892 USA.	kevinh@niddk.nih.gov	Ouwerkerk, Ronald/AAM-3517-2021; Hall, Kevin/F-2383-2010; Joseph, Paule/N-2701-2013; Chen, Kong/L-6972-2017	Ouwerkerk, Ronald/0000-0003-3882-9757; Hall, Kevin/0000-0003-4062-3133; Joseph, Paule/0000-0002-1198-9622; Gallagher, Isabelle/0000-0003-1686-2134; Schick, Alex/0000-0003-3015-9138; Darcey, Valerie/0000-0002-5053-4567; Forde, Ciaran/0000-0002-4001-9182; Chen, Kong/0000-0002-0306-1904; , Amber/0000-0002-1419-3937; Brychta, Robert/0000-0001-9491-7968	Intramural Research Program of the NIH, National Institute of Diabetes & Digestive & Kidney Diseases [1ZIADK013037]; National Institute of Nursing Research [1ZIANR000035-01]; Office of Workforce Diversity; Rockefeller University Heilbrunn Nurse Scholar Award	Intramural Research Program of the NIH, National Institute of Diabetes & Digestive & Kidney Diseases; National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); Office of Workforce Diversity; Rockefeller University Heilbrunn Nurse Scholar Award	This work was supported by the Intramural Research Program of the NIH, National Institute of Diabetes & Digestive & Kidney Diseases under award number 1ZIADK013037. P.V.J. is supported by the National Institute of Nursing Research under award number 1ZIANR000035-01, The Office of Workforce Diversity and the Rockefeller University Heilbrunn Nurse Scholar Award. We thank the nursing and nutrition staff at the NIH Metabolic Clinical Research Unit for their invaluable assistance with this study. We thank K. Klatt, J. Speakman and E. Weiss for helpful comments. We thank the study participants who volunteered to participate in this demanding protocol.	Blundell JE, 1997, ANN NY ACAD SCI, V827, P392, DOI 10.1111/j.1749-6632.1997.tb51850.x; Blundell JE, 1997, J AM DIET ASSOC, V97, pS63, DOI 10.1016/S0002-8223(97)00733-5; Boden G, 2005, ANN INTERN MED, V142, P403, DOI 10.7326/0003-4819-142-6-200503150-00006; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Bray GA, 2008, AM J CLIN NUTR, V88, P1504, DOI 10.3945/ajcn.2008.26289; Clark MJ, 2013, J AM COLL NUTR, V32, P200, DOI 10.1080/07315724.2013.791194; Das SK, 2007, AM J CLIN NUTR, V85, P1023, DOI 10.1093/ajcn/85.4.1023; de Graaf C, 2010, NAT REV ENDOCRINOL, V6, P290, DOI 10.1038/nrendo.2010.41; EDHOLM OG, 1970, BRIT J NUTR, V24, P1091, DOI 10.1079/BJN19700112; Flood A, 2006, J AM DIET ASSOC, V106, P393, DOI 10.1016/j.jada.2005.12.008; Forde CG, 2020, CURR DEV NUTR, V4, DOI 10.1093/cdn/nzaa019; Freedhoff Y, 2016, LANCET, V388, P849, DOI 10.1016/S0140-6736(16)31338-1; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Georgiou E, 1997, METABOLISM, V46, P1059, DOI 10.1016/S0026-0495(97)90278-X; Gibson AA, 2015, OBES REV, V16, P64, DOI 10.1111/obr.12230; GOING SB, 1993, AM J CLIN NUTR, V57, P845, DOI 10.1093/ajcn/57.6.845; Hall KD, 2019, INT J OBESITY, V43, P2350, DOI 10.1038/s41366-019-0456-3; Hall KD, 2019, CELL METAB, V30, P67, DOI 10.1016/j.cmet.2019.05.008; Hall KD, 2019, AM J CLIN NUTR, V109, P1328, DOI 10.1093/ajcn/nqy390; Hall KD, 2018, OBESITY, V26, P11, DOI 10.1002/oby.22073; Hall KD, 2016, AM J CLIN NUTR, V104, P324, DOI 10.3945/ajcn.116.133561; Hall KD, 2015, CELL METAB, V22, P427, DOI 10.1016/j.cmet.2015.07.021; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hervik AK, 2019, J NUTR METAB, V2019, DOI 10.1155/2019/4983657; Hopkins M, 2016, BRIT J NUTR, V115, P1875, DOI 10.1017/S0007114516000775; HORBER FF, 1992, BRIT J RADIOL, V65, P895, DOI 10.1259/0007-1285-65-778-895; Johnstone AM, 2008, AM J CLIN NUTR, V87, P44, DOI 10.1093/ajcn/87.1.44; Ledikwe JH, 2005, J NUTR, V135, P273, DOI 10.1093/jn/135.2.273; Leidy HJ, 2015, AM J CLIN NUTR, V101, p1320S, DOI 10.3945/ajcn.114.084038; LISSNER L, 1987, AM J CLIN NUTR, V46, P886, DOI 10.1093/ajcn/46.6.886; Ludwig DS, 2018, JAMA INTERN MED, V178, P1098, DOI 10.1001/jamainternmed.2018.2933; Ludwig DS, 2014, JAMA-J AM MED ASSOC, V311, P2167, DOI 10.1001/jama.2014.4133; Mohorko N, 2019, NUTR RES, V62, P64, DOI 10.1016/j.nutres.2018.11.007; Monteiro CA, 2019, PUBLIC HEALTH NUTR, V22, P936, DOI 10.1017/S1368980018003762; Ouwerkerk R, 2012, RADIOLOGY, V265, P565, DOI 10.1148/radiol.12112344; Paoli A, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00027; PHINNEY SD, 1983, METABOLISM, V32, P769, DOI 10.1016/0026-0495(83)90106-3; PHINNEY SD, 1980, J CLIN INVEST, V66, P1152, DOI 10.1172/JCI109945; Raubenheimer D, 2019, OBESITY, V27, P1225, DOI 10.1002/oby.22531; Rolls BJ, 2009, PHYSIOL BEHAV, V97, P609, DOI 10.1016/j.physbeh.2009.03.011; Sandesara PB, 2019, ENDOCR REV, V40, P537, DOI 10.1210/er.2018-00184; Schoffelen PFM, 2008, PHYSIOL BEHAV, V94, P158, DOI 10.1016/j.physbeh.2007.12.013; Sherrier M, 2019, AM J CLIN NUTR, V110, P562, DOI 10.1093/ajcn/nqz145; Shimy KJ, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvaa062; SHINTANI TT, 1991, AM J CLIN NUTR, V53, pS1647; Smethers AD, 2018, MED CLIN N AM, V102, P107, DOI 10.1016/j.mcna.2017.08.009; Steele EM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009892; Stinson EJ, 2020, OBESITY, V28, P2020, DOI 10.1002/oby.23008; Stubbs RJ, 1998, P NUTR SOC, V57, P341, DOI 10.1079/PNS19980052; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P330, DOI 10.1093/ajcn/62.2.330; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316; Sun SR, 2017, PHYSIOLOGY, V32, P453, DOI 10.1152/physiol.00016.2017; TARASUK V, 1992, APPETITE, V18, P43, DOI 10.1016/0195-6663(92)90209-O; Taylor J. R., 1982, INTRO ERROR ANAL STU; Toomey CM, 2017, EUR J APPL PHYSIOL, V117, P567, DOI 10.1007/s00421-017-3552-x; Xia JG, 2019, HEART LUNG CIRC, V28, P553, DOI 10.1016/j.hlc.2018.10.019	57	48	48	13	74	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					344	+		10.1038/s41591-020-01209-1	http://dx.doi.org/10.1038/s41591-020-01209-1		JAN 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33479499				2022-12-27	WOS:000609385500002
J	Zhan, L; Rao, JS; Sethia, N; Slama, MQ; Han, ZH; Tobolt, D; Etheridge, M; Peterson, QP; Dutcher, CS; Bischof, JC; Finger, EB				Zhan, Li; Rao, Joseph Sushil; Sethia, Nikhil; Slama, Michael Q.; Han, Zonghu; Tobolt, Diane; Etheridge, Michael; Peterson, Quinn P.; Dutcher, Cari S.; Bischof, John C.; Finger, Erik B.			Pancreatic islet cryopreservation by vitrification achieves high viability, function, recovery and clinical scalability for transplantation	NATURE MEDICINE			English	Article							NYLON MESH DEVICE; BETA-CELLS; PHASE-3 TRIAL; RAT ISLETS; TYPE-1; LANGERHANS; SURVIVAL; MASS	Pancreatic islet transplantation can cure diabetes but requires accessible, high-quality islets in sufficient quantities. Cryopreservation could solve islet supply chain challenges by enabling quality-controlled banking and pooling of donor islets. Unfortunately, cryopreservation has not succeeded in this objective, as it must simultaneously provide high recovery, viability, function and scalability. Here, we achieve this goal in mouse, porcine, human and human stem cell (SC)-derived beta cell (SC-beta) islets by comprehensive optimization of cryoprotectant agent (CPA) composition, CPA loading and unloading conditions and methods for vitrification and rewarming (VR). Post-VR islet viability, relative to control, was 90.5% for mouse, 92.1% for SC-beta, 87.2% for porcine and 87.4% for human islets, and it remained unchanged for at least 9 months of cryogenic storage. VR islets had normal macroscopic, microscopic, and ultrastructural morphology. Mitochondrial membrane potential and adenosine triphosphate (ATP) levels were slightly reduced, but all other measures of cellular respiration, including oxygen consumption rate (OCR) to produce ATP, were unchanged. VR islets had normal glucose-stimulated insulin secretion (GSIS) function in vitro and in vivo. Porcine and SC-beta islets made insulin in xenotransplant models, and mouse islets tested in a marginal mass syngeneic transplant model cured diabetes in 92% of recipients within 24-48 h after transplant. Excellent glycemic control was seen for 150 days. Finally, our approach processed 2,500 islets with >95% islets recovery at >89% post-thaw viability and can readily be scaled up for higher throughput. These results suggest that cryopreservation can now be used to supply needed islets for improved transplantation outcomes that cure diabetes.	[Zhan, Li; Han, Zonghu; Etheridge, Michael; Dutcher, Cari S.; Bischof, John C.] Univ Minnesota, Dept Mech Engn, 111 Church St SE, Minneapolis, MN 55455 USA; [Rao, Joseph Sushil; Tobolt, Diane; Finger, Erik B.] Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA; [Rao, Joseph Sushil] Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN USA; [Sethia, Nikhil; Dutcher, Cari S.] Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA; [Slama, Michael Q.; Peterson, Quinn P.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA; [Peterson, Quinn P.] Mayo Clin, Ctr Regenerat Med, Rochester, MN USA; [Bischof, John C.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities	Finger, EB (corresponding author), Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.	efinger@umn.edu		Bischof, John/0000-0001-6726-7111; Rao, Dr. Joseph Sushil/0000-0002-0197-6107; Slama, Michael/0000-0002-0808-3547; Etheridge, Michael/0000-0002-3359-0188; Sethia, Nikhil/0000-0002-5499-9425; Dutcher, Cari/0000-0003-4325-9197	Schulze Diabetes Institute at the Department of Surgery, University of Minnesota; Division of Transplantation at the Department of Surgery, University of Minnesota; Regenerative Medicine Minnesota; National Science Foundation [EEC 1941543]; National Institutes of Health [R01DK131209, R01DK117425, R01HL135046]; University of Minnesota; Kuhrmeyer Chair in Mechanical Engineering from the University of Minnesota; Bakken Chair in the Institute for Engineering in Medicine from the University of Minnesota; J.W Kieckhefer Foundation; Stephen and Barbara Slaggie Family; Khalifa Bin Zayed Al Nahyan Foundation	Schulze Diabetes Institute at the Department of Surgery, University of Minnesota; Division of Transplantation at the Department of Surgery, University of Minnesota(University of Minnesota System); Regenerative Medicine Minnesota; National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Minnesota(University of Minnesota System); Kuhrmeyer Chair in Mechanical Engineering from the University of Minnesota; Bakken Chair in the Institute for Engineering in Medicine from the University of Minnesota; J.W Kieckhefer Foundation; Stephen and Barbara Slaggie Family; Khalifa Bin Zayed Al Nahyan Foundation	J.S.R. was supported by Schulze Diabetes Institute and Division of Transplantation at the Department of Surgery, University of Minnesota. The authors thank F. Zhou and W. Zhang from Characterization Facility of the University of Minnesota for help with TEM and C. Forster and A. Lewis of the University of Minnesota Clinical and Translational Science Institute for technical assistance with histology experiments. The authors acknowledge Schulze Diabetes Institute, Department of Surgery for use of their confocal microscope and for providing porcine islets. This work is supported by grants from Regenerative Medicine Minnesota (E.B.F. and J.C.B.), the National Science Foundation (EEC 1941543, J.C.B. and E.B.F.) and the National Institutes of Health (R01DK131209, J.C.B. and E.B.F.; R01DK117425, J.C.B. and E.B.F.; and R01HL135046, J.C.B. and E.B.F.). L.Z. acknowledges the Doctoral Dissertation Fellowship from the University of Minnesota, and J.C.B. acknowledges support from the Kuhrmeyer Chair in Mechanical Engineering and the Bakken Chair in the Institute for Engineering in Medicine from the University of Minnesota. P.P.Q. would like to thank the J.W Kieckhefer Foundation, the Stephen and Barbara Slaggie Family, and the Khalifa Bin Zayed Al Nahyan Foundation for supporting this work.	Anazawa T, 2010, TRANSPL P, V42, P2032, DOI 10.1016/j.transproceed.2010.05.110; BANK HL, 1981, CRYOBIOLOGY, V18, P489, DOI 10.1016/0011-2240(81)90208-X; Bischof John C, CRYOPRESERVATION PAN, DOI [10.13020/yrva-zr31 (2022, DOI 10.13020/YRVA-ZR31(2022]; Cattral MS, 1998, CELL TRANSPLANT, V7, P373, DOI 10.1016/S0963-6897(98)00013-X; deFreitas RC, 1997, CRYOBIOLOGY, V35, P230, DOI 10.1006/cryo.1997.2045; Emamaullee JA, 2008, DIABETES, V57, P1556, DOI 10.2337/db07-1452; Gaber AO, 2004, CELL BIOCHEM BIOPHYS, P49; Hering BJ, 2016, DIABETES CARE, V39, P1230, DOI 10.2337/dc15-1988; JUTTE NHPM, 1987, CRYOBIOLOGY, V24, P292, DOI 10.1016/0011-2240(87)90033-2; Kaddis JS, 2010, AM J TRANSPLANT, V10, P646, DOI 10.1111/j.1600-6143.2009.02962.x; Khosla K, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000138; Khosla K, 2019, LANGMUIR, V35, P7364, DOI 10.1021/acs.langmuir.8b03011; Kin T, 2008, TRANSPL INT, V21, P1029, DOI 10.1111/j.1432-2277.2008.00719.x; Kleinhans FW, 1998, CRYOBIOLOGY, V37, P271, DOI 10.1006/cryo.1998.2135; Kojayan G, 2019, CRYOBIOLOGY, V88, P23, DOI 10.1016/j.cryobiol.2019.04.004; Kojayan GG, 2018, ISLETS, V10, P40, DOI 10.1080/19382014.2017.1405202; Lakey JRT, 1996, CELL TRANSPLANT, V5, P395, DOI 10.1016/0963-6897(95)02025-X; Latres E, 2019, CELL METAB, V29, P545, DOI 10.1016/j.cmet.2019.02.007; Melli K, 2009, J IMMUNOL, V182, P2590, DOI 10.4049/jimmunol.0803543; Miranda PM, 2013, ISLETS, V5, P188, DOI 10.4161/isl.26304; Miyamoto M, 2001, CELL TRANSPLANT, V10, P363; Nagaya M, 2016, HORM METAB RES, V48, P540, DOI 10.1055/s-0042-102628; NAKAGAWARA G, 1981, TRANSPLANT P, V13, P1503; Nakayama-Iwatsuki K, 2020, ISLETS, V12, P145, DOI 10.1080/19382014.2020.1849928; Odorico J, 2018, TRANSPLANTATION, V102, P1223, DOI 10.1097/TP.0000000000002217; Pagliuca FW, 2014, CELL, V159, P428, DOI 10.1016/j.cell.2014.09.040; Papas KK, 2007, AM J TRANSPLANT, V7, P707, DOI 10.1111/j.1600-6143.2006.01655.x; Papas KK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134428; Pepper AR, 2019, DIABETES, V68, P953, DOI 10.2337/db18-0788; Peterson QP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16049-3; Plesner A, 2011, J TRANSPLANT, V2011, DOI 10.1155/2011/979527; RAJOTTE RV, 1984, WORLD J SURG, V8, P179, DOI 10.1007/BF01655133; RAJOTTE RV, 1977, CRYOBIOLOGY, V14, P116, DOI 10.1016/0011-2240(77)90130-4; Ricordi C, 2016, DIABETES, V65, P3418, DOI 10.2337/db16-0234; Sasamoto H, 2012, J ARTIF ORGANS, V15, P283, DOI 10.1007/s10047-012-0635-7; SCHARP DW, 1991, TRANSPLANTATION, V51, P76, DOI 10.1097/00007890-199101000-00012; Schmied BM, 2001, PANCREAS, V23, P157, DOI 10.1097/00006676-200108000-00006; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Singh A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11338-y; Song YC, 2000, NAT BIOTECHNOL, V18, P296, DOI 10.1038/73737; Taylor MJ, 2009, ORGANOGENESIS, V5, P155, DOI 10.4161/org.5.3.9812; Tremmel DM, 2019, CURR OPIN ORGAN TRAN, V24, P574, DOI 10.1097/MOT.0000000000000687; Vantyghem MC, 2019, DIABETES CARE, V42, P2042, DOI 10.2337/dc19-0401; Vegas AJ, 2016, NAT MED, V22, P306, DOI 10.1038/nm.4030; Velazco-Cruz L, 2019, STEM CELL REP, V12, P351, DOI 10.1016/j.stemcr.2018.12.012; Veres A, 2019, NATURE, V569, P368, DOI 10.1038/s41586-019-1168-5; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89, DOI 10.1007/BF00400857; WARNOCK GL, 1991, DIABETOLOGIA, V34, P55, DOI 10.1007/BF00404026; Yamanaka T, 2017, BIOPRESERV BIOBANK, V15, P457, DOI 10.1089/bio.2017.0044; Yamanaka T, 2016, CRYOBIOLOGY, V73, P376, DOI 10.1016/j.cryobiol.2016.09.003; Zhan L, 2021, ADV SCI, V8, DOI 10.1002/advs.202004605; Zhan L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22694-z	52	10	10	15	34	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					798	+		10.1038/s41591-022-01718-1	http://dx.doi.org/10.1038/s41591-022-01718-1		MAR 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35288694	Green Published, hybrid			2022-12-27	WOS:000770060900002
J	Johnston, J; Matthews, LJ				Johnston, Josephine; Matthews, Lucas J.			Polygenic embryo testing: understated ethics, unclear utility	NATURE MEDICINE			English	Editorial Material									[Johnston, Josephine; Matthews, Lucas J.] Hastings Ctr, Garrison, NY 10524 USA; [Johnston, Josephine] Univ Otago, Dunedin, New Zealand; [Matthews, Lucas J.] Columbia Univ, New York, NY USA	University of Otago; Columbia University	Johnston, J (corresponding author), Hastings Ctr, Garrison, NY 10524 USA.; Johnston, J (corresponding author), Univ Otago, Dunedin, New Zealand.	johnstonj@thehastingscenter.org		Matthews, Lucas/0000-0002-3476-7571	National Human Genome Research Institute of the National Institutes of Health [RM1HG007257-07, K01HG011683]	National Human Genome Research Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This research was supported in part by the National Human Genome Research Institute of the National Institutes of Health under awards RM1HG007257-07 and K01HG011683. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Bayefsky M., 2015, REGULATING PREIMPLAN; Kumar A, 2022, NAT MED, V28, P513, DOI 10.1038/s41591-022-01735-0; Lazaro-Munoz G, 2021, GENET MED, V23, P432, DOI 10.1038/s41436-020-01019-3; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Martin AR, 2017, AM J HUM GENET, V100, P635, DOI 10.1016/j.ajhg.2017.03.004; Matthews LJ, 2022, STUD HIST PHILOS SCI, V91, P1, DOI 10.1016/j.shpsa.2021.10.021; Mostafavi H, 2020, ELIFE, V9, DOI 10.7554/eLife.48376; Roche K, 2021, J ASSIST REPROD GEN, V38, P1045, DOI 10.1007/s10815-021-02078-4; Sandel MJL, 2009, PHIL CULTURE, V3, P153; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048; Suter SM, 2002, AM J LAW MED, V28, P233; Takahashi S, 2019, GENET MED, V21, P1038, DOI 10.1038/s41436-018-0314-z	12	2	2	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					446	448		10.1038/s41591-022-01743-0	http://dx.doi.org/10.1038/s41591-022-01743-0			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35314818	Green Accepted			2022-12-27	WOS:000771673100012
J	Adeyemo, A; Balaconis, MK; Darnes, DR; Fatumo, S; Moreno, PG; Hodonsky, CJ; Inouye, M; Kanai, M; Kato, K; Knoppers, BM; Lewis, ACF; Martin, AR; McCarthy, MI; Meyer, MN; Okada, Y; Richards, JB; Richter, L; Ripatti, S; Rotimi, CN; Sanderson, SC; Sturm, AC; Verdugo, RA; Widen, E; Willer, CJ; Wojcik, GL; Zhou, A				Adeyemo, Adebowale; Balaconis, Mary K.; Darnes, Deanna R.; Fatumo, Segun; Granados Moreno, Palmira; Hodonsky, Chani J.; Inouye, Michael; Kanai, Masahiro; Kato, Kazuto; Knoppers, Bartha M.; Lewis, Anna C. F.; Martin, Alicia R.; McCarthy, Mark I.; Meyer, Michelle N.; Okada, Yukinori; Richards, J. Brent; Richter, Lucas; Ripatti, Samuli; Rotimi, Charles N.; Sanderson, Saskia C.; Sturm, Amy C.; Verdugo, Ricardo A.; Widen, Elisabeth; Willer, Cristen J.; Wojcik, Genevieve L.; Zhou, Alicia		Int Common Dis Alliance	Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	NATURE MEDICINE			English	Article							CORONARY-HEART-DISEASE; GENETIC RISK; PREDICTION; ASSOCIATION; PREVENTION; ATTITUDES; MEDICINE; IMPACTS; TYPE-1; RACE	Polygenic risk scores (PRSs) aggregate the many small effects of alleles across the human genome to estimate the risk of a disease or disease-related trait for an individual. The potential benefits of PRSs include cost-effective enhancement of primary disease prevention, more refined diagnoses and improved precision when prescribing medicines. However, these must be weighed against the potential risks, such as uncertainties and biases in PRS performance, as well as potential misunderstanding and misuse of these within medical practice and in wider society. By addressing key issues including gaps in best practices, risk communication and regulatory frameworks, PRSs can be used responsibly to improve human health. Here, the International Common Disease Alliance's PRS Task Force, a multidisciplinary group comprising expertise in genetics, law, ethics, behavioral science and more, highlights recent research to provide a comprehensive summary of the state of polygenic score research, as well as the needs and challenges as PRSs move closer to widespread use in the clinic. As polygenic risk scores move closer to widespread clinical use, this Perspective summarizes the benefits, risks and challenges to be overcome.	[Adeyemo, Adebowale; Rotimi, Charles N.] NHGRI, Ctr Res Genom & Global Hlth, NIH, Bethesda, MD 20892 USA; [Balaconis, Mary K.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Darnes, Deanna R.] Fetal Care Ctr Dallas, Genet Counselling Serv, Dallas, TX USA; [Fatumo, Segun] London Sch Hyg & Trop Med, London, England; [Fatumo, Segun] Uganda Med Informat Ctr UMIC, MRC UVRI & LSHTM Uganda Res Unit, Entebbe, Uganda; [Fatumo, Segun] Natl Biotechnol Dev Agcy CGRI, Ctr Genom Res & Innovat CGRI, H3Africa Bioinformat Network H3ABioNet Node, NABDA, Abuja, Nigeria; [Granados Moreno, Palmira; Knoppers, Bartha M.] McGill Univ, Dept Human Genet, Ctr Genom & Policy, Fac Med, Montreal, PQ, Canada; [Hodonsky, Chani J.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA; [Inouye, Michael] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge Baker Syst Genom Initiat, Cambridge, England; [Inouye, Michael] Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Vic, Australia; [Inouye, Michael] Univ Cambridge, Dept Publ Hlth & Primary Care, British Heart Fdn, Cardiovasc Epidemiol Unit, Cambridge, England; [Inouye, Michael] Univ Cambridge, Sch Clin Med, British Heart Fdn, Cambridge Ctr Res Excellence, Cambridge, England; [Inouye, Michael] Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England; [Inouye, Michael] Univ Cambridge, Cambridge, England; [Inouye, Michael] Cambridge Univ Hosp NHS Fdn Trust, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England; [Inouye, Michael] Alan Turing Inst, London, England; [Kanai, Masahiro; Martin, Alicia R.; Ripatti, Samuli] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Kanai, Masahiro; Martin, Alicia R.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA USA; [Kanai, Masahiro; Martin, Alicia R.; Ripatti, Samuli] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA; [Kanai, Masahiro; Okada, Yukinori] Osaka Univ, Grad Sch Med, Dept Stat Genet, Suita, Osaka, Japan; [Kato, Kazuto] Osaka Univ, Grad Sch Med, Dept Biomed Eth & Publ Policy, Suita, Osaka, Japan; [Lewis, Anna C. F.] Harvard Univ, EJ Safra Ctr Eth, Cambridge, MA 02138 USA; [McCarthy, Mark I.] Genentech Inc, San Francisco, CA USA; [Meyer, Michelle N.] Geisinger, Ctr Translat Bioeth & Hlth Care Policy, Danville, PA USA; [Richards, J. Brent] Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Clin Epidemiol, Montreal, PQ, Canada; [Richards, J. Brent] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Richards, J. Brent] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Richter, Lucas] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Ripatti, Samuli] Univ Helsinki, Clinicum, Dept Publ Hlth, Helsinki, Finland; [Ripatti, Samuli; Widen, Elisabeth] Univ Helsinki, Inst Mol Med Finland, Biomedicum 2U, HiLIFE,FIMM, Helsinki, Finland; [Sanderson, Saskia C.] UCL, Dept Behav Sci & Hlth, London, England; [Sanderson, Saskia C.] Our Future Hlth, London, England; [Sanderson, Saskia C.] PHG Fdn, Cambridge, England; [Sturm, Amy C.] Geisinger, Genom Med Inst, Danville, PA USA; [Verdugo, Ricardo A.] Univ Chile, Human Genet Program, ICBM, Fac Med, Santiago, Chile; [Verdugo, Ricardo A.] Fac Med, Dept Basic Clin Oncol, Santiago, Chile; [Willer, Cristen J.] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; [Willer, Cristen J.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Willer, Cristen J.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Wojcik, Genevieve L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Zhou, Alicia] Color Genom, Burlingame, CA USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of London; London School of Hygiene & Tropical Medicine; McGill University; University of Virginia; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Osaka University; Osaka University; Harvard University; Roche Holding; Genentech; Lady Davis Institute; McGill University; McGill University; McGill University; Vanderbilt University; University of Helsinki; University of Helsinki; University of London; University College London; Universidad de Chile; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Inouye, M (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge Baker Syst Genom Initiat, Cambridge, England.; Inouye, M (corresponding author), Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Vic, Australia.; Inouye, M (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, British Heart Fdn, Cardiovasc Epidemiol Unit, Cambridge, England.; Inouye, M (corresponding author), Univ Cambridge, Sch Clin Med, British Heart Fdn, Cambridge Ctr Res Excellence, Cambridge, England.; Inouye, M (corresponding author), Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England.; Inouye, M (corresponding author), Univ Cambridge, Cambridge, England.; Inouye, M (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England.; Inouye, M (corresponding author), Alan Turing Inst, London, England.; Willer, CJ (corresponding author), Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.; Willer, CJ (corresponding author), Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; Willer, CJ (corresponding author), Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.	mi336@medschl.cam.ac.uk; mi336@medschl.cam.ac.uk; cristen@umich.edu	Kanai, Masahiro/AAD-6726-2021	Kanai, Masahiro/0000-0001-5165-4408; Kato, Kazuto/0000-0001-9006-9551; Inouye, Michael/0000-0001-9413-6520; Hodonsky, Chani/0000-0001-8566-5877; Darnes, Deanna/0000-0002-1323-3845	NIH [HL135824, HL109946, HL127564, R00 MH117229]; JSPS KAKENHI [19H01021, 20K21834]; AMED [JP21km0405211, JP21ek0109413, JP21gm4010006, JP21km0405217, JP21ek0410075]; JST Moonshot RD [JPMJMS2021]; Academy of Finland Center of Excellence in Complex Disease Genetics [312062, 336820]; Horizon 2020 Research and Innovation Programme [101016775]; PERSPECTIVE IAMP;I project - Government of Canada through Genome Canada; Canadian Institutes of Health Research; Ministere de l'Economie et de l'Innovation du Quebec through Genome Quebec; Quebec Breast Cancer Foundation; CHU de Quebec Foundation; Ontario Research Fund; Canada Research Chair in Law and Medicine; Open Philanthropy [010623-00001]; Russell Sage Foundation; JPB Foundation [1903-13498]; National Institute on Aging [R01AG042568-04, R24AG065184]; Canadian Institutes of Health Research [CIHR: 365825, 409511, 100558, 169303]; McGill Interdisciplinary Initiative in Infection and Immunity (MI4); Lady Davis Institute of the Jewish General Hospital; Jewish General Hospital Foundation; Canadian Foundation for Innovation; NIH Foundation; Cancer Research UK; Genome Quebec; Public Health Agency of Canada; McGill University; Cancer Research UK [C18281/A29019]; Fonds de Recherche Quebec Sante (FRQS); FRQS Merite Clinical Research Scholarship; Calcul Quebec; Compute Canada; Welcome Trust; Medical Research Council; European Union; National Institute for Health Research (NIHR); Munz Chair of Cardiovascular Prediction and Prevention; Victorian Government's Operational Infrastructure Support (OIS) program; UK Medical Research Council [MR/L003120/1]; British Heart Foundation [RG/13/13/30194, RG/18/13/33946]; National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust); Health Data Research UK - UK Medical Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome; UK Economic and Social Research Council (ESRC) [ES/T013192/1]; Wellcome International Intermediate fellowship at the MRC/UVRI [220740/Z/20/Z]; LSHTM; ANID Chile [FONDEF D10E1007, FONDECYT 1191948, COVID0961]; Engineering and Physical Sciences Research Council	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED; JST Moonshot RD; Academy of Finland Center of Excellence in Complex Disease Genetics(Academy of Finland); Horizon 2020 Research and Innovation Programme; PERSPECTIVE IAMP;I project - Government of Canada through Genome Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ministere de l'Economie et de l'Innovation du Quebec through Genome Quebec; Quebec Breast Cancer Foundation; CHU de Quebec Foundation; Ontario Research Fund; Canada Research Chair in Law and Medicine; Open Philanthropy; Russell Sage Foundation; JPB Foundation; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); McGill Interdisciplinary Initiative in Infection and Immunity (MI4); Lady Davis Institute of the Jewish General Hospital; Jewish General Hospital Foundation; Canadian Foundation for Innovation(Canada Foundation for Innovation); NIH Foundation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research UK(Cancer Research UK); Genome Quebec; Public Health Agency of Canada; McGill University; Cancer Research UK(Cancer Research UK); Fonds de Recherche Quebec Sante (FRQS); FRQS Merite Clinical Research Scholarship; Calcul Quebec; Compute Canada; Welcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Munz Chair of Cardiovascular Prediction and Prevention; Victorian Government's Operational Infrastructure Support (OIS) program; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust); Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome; UK Economic and Social Research Council (ESRC)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Wellcome International Intermediate fellowship at the MRC/UVRI; LSHTM; ANID Chile; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We are grateful to the International Common Disease Alliance (ICDA). In particular, we acknowledge the leadership of E. Lander, C. Lindgren, M. Daly, and R. Liao, the ICDA Ethics & Policy Working Group and its co-chairs C. Hutter and M. Zawati, and the administrative support of A. Trankiem. We are also grateful to T. Gjorgjieva for research assistance. Funding: C.J.W. is supported by NIH grants HL135824, HL109946, and HL127564. A.R.M. is supported by NIH grant R00 MH117229. Y.O. is supported by JSPS KAKENHI (19H01021 and 20K21834) and AMED (JP21km0405211, JP21ek0109413, JP21gm4010006, JP21km0405217, JP21ek0410075), JST Moonshot R&D (JPMJMS2021). S.R. is supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (grant numbers 312062 and 336820) and Horizon 2020 Research and Innovation Programme (grant number 101016775 'INTERVENE'). B.M.K. and P.G.M. are supported by the PERSPECTIVE I&I project, which is funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministere de l'Economie et de l'Innovation du Quebec through Genome Quebec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund. B.M.K. is supported by the Canada Research Chair in Law and Medicine. M.N.M. is supported by Open Philanthropy (010623-00001), the Russell Sage Foundation and the JPB Foundation (1903-13498), and National Institute on Aging (R01AG042568-04 and R24AG065184). The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, McGill University, Cancer Research UK (grant number C18281/A29019), and the Fonds de Recherche Quebec Sante (FRQS). J.B.R. is supported by a FRQS Merite Clinical Research Scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. These funding agencies had no role in the design, implementation, or interpretation of this study. M.I. is supported by the Munz Chair of Cardiovascular Prediction and Prevention. This study was supported by the Victorian Government's Operational Infrastructure Support (OIS) program and by core funding from: the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and the National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome.; r The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The support of the UK Economic and Social Research Council (ESRC) is gratefully acknowledged (ES/T013192/1). S.F. is funded by the Wellcome International Intermediate fellowship (220740/Z/20/Z) at the MRC/UVRI and LSHTM. S.F. is funded by the Wellcome International Intermediate fellowship (220740/Z/20/Z) at the MRC/UVRI and LSHTM. R.A.V. is supported by ANID Chile (FONDEF D10E1007, FONDECYT 1191948, COVID0961). R.A.V. is supported by ANID Chile (FONDEF D10E1007, FONDECYT 1191948, COVID0961).	Abacan M, 2019, EUR J HUM GENET, V27, P183, DOI 10.1038/s41431-018-0252-x; Abraham G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004374; Abraham G, 2016, EUR HEART J, V37, P3267, DOI 10.1093/eurheartj/ehw450; Abraham G, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0196-5; Aizawa Y, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.646177; Akiyama M, 2017, NAT GENET, V49, P1458, DOI 10.1038/ng.3951; [Anonymous], 2016, CARD DIS RISK ASS RE; Barnes DR, 2020, GENET MED, V22, P1653, DOI 10.1038/s41436-020-0862-x; Bitarello BD, 2020, G3-GENES GENOM GENET, V10, P4027, DOI 10.1534/g3.120.401658; Brockman DG, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-01056-0; Brown SAN, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.116.001613; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Canada, 2020, GUID DOC SOFTW MED D; Canovas R, 2020, ANN RHEUM DIS, V79, P1572, DOI 10.1136/annrheumdis-2020-217421; Carver T, 2021, CANCER EPIDEM BIOMAR, V30, P469, DOI 10.1158/1055-9965.EPI-20-1319; Cerdena JP, 2020, LANCET, V396, P1125, DOI 10.1016/S0140-6736(20)32076-6; Cragun D, 2017, CANCER-AM CANCER SOC, V123, P2497, DOI 10.1002/cncr.30621; Damask A, 2020, CIRCULATION, V141, P624, DOI 10.1161/CIRCULATIONAHA.119.044434; Dikilitas O, 2020, AM J HUM GENET, V106, P707, DOI 10.1016/j.ajhg.2020.04.002; Ding, PREPRINT, DOI [10.1101/2020.11.30.403188 (2021, DOI 10.1101/2020.11.30.403188(2021]; Ekoru K, 2021, INT J EPIDEMIOL, V50, P1283, DOI 10.1093/ije/dyab046; Elliott J, 2020, JAMA-J AM MED ASSOC, V323, P636, DOI 10.1001/jama.2019.22241; Esserman LJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0035-5; Fahed AC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17374-3; Ferrat LA, 2020, NAT MED, V26, P1247, DOI 10.1038/s41591-020-0930-4; Food and Drug Administration, CLASS YOUR MED DEV; Food & Drug Administration,, SOFTW MED DEV SAMD; Forgetta Vincenzo, 2020, PLoS Med, V17, pe1003152, DOI 10.1371/journal.pmed.1003152; Ganna A, 2013, ARTERIOSCL THROM VAS, V33, P2267, DOI 10.1161/ATVBAHA.113.301218; Green R. C., HUM GENET GENOM ADV, DOI [10.1016/j.xhgg.2021.100047(2021, DOI 10.1016/J.XHGG.2021.100047(2021]; Heck PR, 2019, MED CLIN N AM, V103, P1077, DOI 10.1016/j.mcna.2019.08.004; HOLTZMAN NA, 1992, AM J HUM GENET, V50, P457; IMDRF Good Regulatory Review Practices Group, 2018, ESSENTIAL PRINCIPLES; IMDRF SaMD Working Group, 2013, SOFTW MED DEV SAMD K; IMDRF SaMD Working Group, 2015, SOFTW MED DEV SAMD A; IMDRF SaMD Working Group, SOFTW MED DEV SAMD; IMDRF Software as Medical Device (SaMD) Working Group, 2014, SOFTW MED DEV POSS F; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Jiang GZ, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003209; Kerminen S, 2019, AM J HUM GENET, V104, P1169, DOI 10.1016/j.ajhg.2019.05.001; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Khera AV, 2016, NEW ENGL J MED, V375, P2349, DOI 10.1056/NEJMoa1605086; Knoppers BM, 2021, J PERS MED, V11, DOI 10.3390/jpm11080736; Kullo IJ, 2016, CIRCULATION, V133, P1181, DOI 10.1161/CIRCULATIONAHA.115.020109; Lambert SA, 2021, NAT GENET, V53, P420, DOI 10.1038/s41588-021-00783-5; Lambert SA, 2019, HUM MOL GENET, V28, pR133, DOI 10.1093/hmg/ddz187; Lee A, 2019, GENET MED, V21, P1708, DOI 10.1038/s41436-018-0406-9; Lewis ACF, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00829-7; Lewis CM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00742-5; Li ZX, 2021, ANN RHEUM DIS, V80, P1168, DOI 10.1136/annrheumdis-2020-219446; Lineweaver TT, 2014, AM J PSYCHIAT, V171, P201, DOI 10.1176/appi.ajp.2013.12121590; Malina D, 2021, NEW ENGL J MED, V384, P474, DOI 10.1056/NEJMms2029562; Marnetto D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15464-w; Mars N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19966-5; Marston NA, 2020, CIRCULATION, V141, P616, DOI 10.1161/CIRCULATIONAHA.119.043805; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Martin AR, 2017, AM J HUM GENET, V100, P635, DOI 10.1016/j.ajhg.2017.03.004; Matthew DB, 2019, ETHNIC DIS, V29, P629, DOI 10.18865/ed.29.S3.629; Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002; McBride CM, 2010, ANNU REV PUBL HEALTH, V31, P89, DOI 10.1146/annurev.publhealth.012809.103532; Mega JL, 2015, LANCET, V385, P2264, DOI 10.1016/S0140-6736(14)61730-X; Meisel SF, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0188-5; Mills MC, 2020, NAT GENET, V52, P242, DOI 10.1038/s41588-020-0580-y; Mittman I, 1998, J Genet Couns, V7, P49, DOI 10.1023/A:1022816128420; Morales J, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1396-2; Mostafavi H, 2020, ELIFE, V9, DOI 10.7554/eLife.48376; Multhaup, 2019, SCI 23ANDMES TYPE 2; Naik RP, 2015, HEMATOL-AM SOC HEMAT, P160, DOI 10.1182/asheducation-2015.1.160; Natarajan P, 2017, CIRCULATION, V135, P2091, DOI 10.1161/CIRCULATIONAHA.116.024436; Oram RA, 2016, DIABETES CARE, V39, P337, DOI 10.2337/dc15-1111; Parens E, 2019, HASTINGS CENT REP, V49, pS2, DOI 10.1002/hast.1011; Peters N, 2004, CANCER EPIDEM BIOMAR, V13, P361; Romanos J, 2014, GUT, V63, P415, DOI 10.1136/gutjnl-2012-304110; Ruan, IMPROVING POLYGENIC, DOI [10.1101/2020.12.27.20248738 (2021, DOI 10.1101/2020.12.27.20248738(2021]; Sakaue S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15194-z; Savulescu, J MED ETHICS, DOI [10.1136/medethics-2020-106588(2021, DOI 10.1136/MEDETHICS-2020-106588(2021]; Saya S, 2020, PUBLIC HEALTH GENOM, V23, P110, DOI 10.1159/000508963; Scally, LANGUAGE RACE ETHNIC; Schwartz MLB, 2018, AM J HUM GENET, V103, P328, DOI 10.1016/j.ajhg.2018.07.009; Sharp SA, 2020, ALIMENT PHARM THER, V52, P1165, DOI 10.1111/apt.15826; Sharp SA, 2019, DIABETES CARE, V42, P200, DOI 10.2337/dc18-1785; Smith CE, 2016, HEALTH AFFAIR, V35, P1367, DOI 10.1377/hlthaff.2015.1476; Sun LL, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003498; Surakka, SEX SPECIFIC SURVIVA, DOI [10.1101/2021.06.23.21259247(2021, DOI 10.1101/2021.06.23.21259247(2021]; Tada H, 2016, EUR HEART J, V37, P561, DOI 10.1093/eurheartj/ehv462; Thelwall M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229578; Thomas NJ, 2019, DIABETOLOGIA, V62, P1167, DOI 10.1007/s00125-019-4863-8; Thomas NJ, 2018, LANCET DIABETES ENDO, V6, P122, DOI 10.1016/S2213-8587(17)30362-5; Thorogood A, 2018, HUM MUTAT, V39, P1702, DOI 10.1002/humu.23621; Tikkanen E, 2013, ARTERIOSCL THROM VAS, V33, P2261, DOI 10.1161/ATVBAHA.112.301120; Torkamani A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/s41576-018-0018-x; Turley P, 2021, OBSTET GYNECOL SURV, V76, P609, DOI 10.1097/OGX.0000000000000972; Turnwald BP, 2019, NAT HUM BEHAV, V3, P48, DOI 10.1038/s41562-018-0483-4; Udler MS, 2019, ENDOCR REV, V40, P1500, DOI 10.1210/er.2019-00088; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Washington H. A., 2006, DOUBLEDAY; Weissbrod O., LEVERAGING FINE MAPP, DOI [10.1101/2021.01.19.21249483(2021, DOI 10.1101/2021.01.19.21249483(2021]; Widen E., 2020, COMMUNICATING POLYGE, DOI [10.1101/2020.09.18.20197137, DOI 10.1101/2020.09.18.20197137]	98	54	54	3	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1876	1884		10.1038/s41591-021-01549-6	http://dx.doi.org/10.1038/s41591-021-01549-6		NOV 2021	9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34782789	Bronze			2022-12-27	WOS:000718766800001
J	Cader, MZ; Kaser, A				Cader, M. Zaeem; Kaser, Arthur			Finding the right target for drug-resistant inflammatory bowel disease	NATURE MEDICINE			English	Editorial Material							MAINTENANCE THERAPY; INDUCTION; VEDOLIZUMAB	A translational study reveals a role for interleukin-1-fibroblast-neutrophil signaling in drug-resistant inflammatory bowel disease, opening a potential path to targeted treatment.	[Kaser, Arthur] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Jeffrey Cheah Biomed Ctr, Cambridge, England; Univ Cambridge, Dept Med, Cambridge, England	University of Cambridge; University of Cambridge	Kaser, A (corresponding author), Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Jeffrey Cheah Biomed Ctr, Cambridge, England.	ak729@cam.ac.uk						Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329; Buechler MB, 2021, NATURE, V593, P575, DOI 10.1038/s41586-021-03549-5; D'Haens GR, 2021, GUT, V70, P1396, DOI 10.1136/gutjnl-2019-320022; Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773; Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734; Friedrich M, NAT MED, DOI [10.1038/s41591-021-01520-5(2021), DOI 10.1038/S41591-021-01520-5(2021)]; Kinchen J, 2018, CELL, V175, P372, DOI 10.1016/j.cell.2018.08.067; Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Thomas MG, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023765; West NR, 2017, NAT MED, V23, P579, DOI 10.1038/nm.4307; Zhou L, 2019, NATURE, V568, P405, DOI 10.1038/s41586-019-1082-x	12	0	0	4	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1870	1871		10.1038/s41591-021-01551-y	http://dx.doi.org/10.1038/s41591-021-01551-y		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34750554				2022-12-27	WOS:000715714300001
J	Tang, P; Hasan, MR; Chemaitelly, H; Yassine, HM; Benslimane, FM; Al Khatib, HA; AlMukdad, S; Coyle, P; Ayoub, HH; Al Kanaani, Z; Al Kuwari, E; Jeremijenko, A; Kaleeckal, AH; Latif, AN; Shaik, RM; Rahim, HFA; Nasrallah, GK; Al Kuwari, MG; Al Romaihi, HE; Butt, AA; Al-Thani, MH; Al Khal, A; Bertollini, R; Abu-Raddad, LJ				Tang, Patrick; Hasan, Mohammad R.; Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; AlMukdad, Sawsan; Coyle, Peter; Ayoub, Houssein H.; Al Kanaani, Zaina; Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F.; Nasrallah, Gheyath K.; Al Kuwari, Mohamed Ghaith; Al Romaihi, Hamad Eid; Butt, Adeel A.; Al-Thani, Mohamed H.; Al Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.			BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	NATURE MEDICINE			English	Article							TEST-NEGATIVE DESIGN; PREDOMINANCE; INFECTION; STATES; TIME; RISK	mRNA COVID-19 vaccines are highly effective at preventing severe outcomes and death caused by the SARS-CoV-2 Delta variant (B.1.617.2) in Qatar despite substantially lower effectiveness at blocking infection. With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) >= 14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) >= 14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021. Corresponding mRNA-1273 effectiveness >= 14 d after the first or second dose was 73.7% (95% CI, 58.1-83.5%) and 73.1% (95% CI, 67.5-77.8%), respectively. Notably, effectiveness against Delta-induced severe, critical or fatal disease was 93.4% (95% CI, 85.4-97.0%) for BNT162b2 and 96.1% (95% CI, 71.6-99.5%) for mRNA-1273 >= 14 d after the second dose. Our findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT162b2 vaccine.	[Tang, Patrick; Hasan, Mohammad R.] Sidra Med, Dept Pathol, Doha, Qatar; [Chemaitelly, Hiam; AlMukdad, Sawsan; Abu-Raddad, Laith J.] Cornell Univ, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha, Qatar; [Chemaitelly, Hiam; AlMukdad, Sawsan; Abu-Raddad, Laith J.] Cornell Univ, Qatar Fdn Educ City, World Hlth Org Collaborating Ctr Dis Epidemiol An, Weill Cornell Med Qatar,Sexually Transmitted Infe, Doha, Qatar; [Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Coyle, Peter; Nasrallah, Gheyath K.] Qatar Univ, QU Hlth, Biomed Res Ctr, Doha, Qatar; [Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Nasrallah, Gheyath K.] Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, Doha, Qatar; [Coyle, Peter; Al Kanaani, Zaina; Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Butt, Adeel A.; Al Khal, Abdullatif] Hamad Med Corp, Doha, Qatar; [Coyle, Peter] Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland; [Ayoub, Houssein H.] Qatar Univ, Coll Arts & Sci, Dept Math Stat & Phys, Math Program, Doha, Qatar; [Abdul Rahim, Hanan F.; Abu-Raddad, Laith J.] Qatar Univ, QU Hlth, Dept Publ Hlth, Coll Hlth Sci, Doha, Qatar; [Al Kuwari, Mohamed Ghaith] Primary Hlth Care Corp, Doha, Qatar; [Al-Thani, Mohamed H.; Bertollini, Roberto] Minist Publ Hlth, Doha, Qatar; [Butt, Adeel A.; Abu-Raddad, Laith J.] Cornell Univ, Weill Cornell Med, Dept Populat Hlth Sci, New York, NY 10021 USA	Sidra Medical & Research Center; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar University; Qatar University; Hamad Medical Corporation; Queens University Belfast; Qatar University; Qatar University; Hamad Medical Corporation; Primary Health Care Corporation (PHCC); Cornell University	Abu-Raddad, LJ (corresponding author), Cornell Univ, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha, Qatar.; Abu-Raddad, LJ (corresponding author), Cornell Univ, Qatar Fdn Educ City, World Hlth Org Collaborating Ctr Dis Epidemiol An, Weill Cornell Med Qatar,Sexually Transmitted Infe, Doha, Qatar.; Abu-Raddad, LJ (corresponding author), Qatar Univ, QU Hlth, Dept Publ Hlth, Coll Hlth Sci, Doha, Qatar.; Abu-Raddad, LJ (corresponding author), Cornell Univ, Weill Cornell Med, Dept Populat Hlth Sci, New York, NY 10021 USA.	lja2002@qatar-med.cornell.edu	Nasrallah, Gheyath K/H-7949-2019; YASSINE, HADI M./AAW-6475-2020	YASSINE, HADI M./0000-0001-7592-2788; Al Khatib, Hebah/0000-0003-3321-7364; Hasan, Mohammad/0000-0002-4658-7949; Jeremijenko, Andrew Martin/0000-0002-0375-2713; AYOUB, Houssein/0000-0003-2512-6657; Chemaitelly, Hiam/0000-0002-8756-6968; Tang, Patrick/0000-0003-1583-5484				Abu-Raddad L. J., 2021, EFFECT VACCINATION P, DOI [10.1093/ofid/ofab221, DOI 10.1093/ofid/ofab221, 10.1101/2021.07.28.21261086, DOI 10.1101/2021.07.28.21261086V1]; Abu-Raddad LJ, 2021, JAMA-J AM MED ASSOC, V326, P1930, DOI 10.1001/jama.2021.19623; Abu-Raddad LJ, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab083; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Abu-Raddad LJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85428-7; Al-Thani MH, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab221; Andersson O., 2021, SSRN, DOI [10.1172/JCI153662, DOI 10.1172/JCI153662, DOI 10.2139/SSRN.3765329]; Andrews N, 2021, MEDRXIV, DOI [10.1101/2021.09.15.21263583, DOI 10.1101/2021.09.15.21263583]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bajema KL, 2021, MMWR-MORBID MORTAL W, V70, P1294, DOI 10.15585/mmwr.mm7037e3; Benslimane F. M, ONE YEAR SARS COV 2, DOI [10.1101/2021.05.19.21257433(2021, DOI 10.1101/2021.05.19.21257433(2021, 10.1101/2021.07.29.21261317, DOI 10.1101/2021.07.29.21261317V1]; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bertollini R, 2021, JAMA-J AM MED ASSOC, V326, P185, DOI 10.1001/jama.2021.9970; Butt AA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI153662; Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605; Chemaitelly H, 2021, NEW ENGL J MED, V385, pE83, DOI 10.1056/NEJMoa2114114; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; Coyle PV, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102646; Fowlkes A, 2021, MMWR-MORBID MORTAL W, V70, P1167, DOI 10.15585/mmwr.mm7034e4; Grannis SJ, 2021, MMWR-MORBID MORTAL W, V70, P1291, DOI 10.15585/mmwr.mm7037e2; Hasan MR, 2021, INT J INFECT DIS, V112, P52, DOI 10.1016/j.ijid.2021.09.006; Israel A., ELAPSED BNT162B2 VAC, DOI [10.1101/2021.08.03.21261496(2021, DOI 10.1101/2021.08.03.21261496(2021]; Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; Jacoby P, 2014, VACCINE, V32, P2942, DOI 10.1016/j.vaccine.2013.08.048; Jeremijenko A, 2021, EMERG INFECT DIS, V27, P1343, DOI [10.3201/eid2705.20.4365, 10.3201/eid2705.204365]; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Makhoul M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040668; Ministry of Public Health, NAT COV 19 TEST VACC; Mizrahi B., 2021, CORRELATION SARS COV, DOI [10.1101/2021.07.29.21261317, DOI 10.1101/2021.07.29.21261317V1, DOI 10.1101/2021.07.29.21261317]; Nanduri S, 2021, MMWR-MORBID MORTAL W, V70, P1163, DOI 10.15585/mmwr.mm7034e3; Nasreen S, 2021, EFFECTIVENESS COVID, DOI [10.1101/2021.06.28.21259420, DOI 10.1101/2021.06.28.21259420]; National Project of Surveillance for Variants of Concern and Viral Genome Sequencing, 2021, DAT RAN COLL SAMPL; Pearce N, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i969; Planning and Statistics Authority-State of Qatar, 2020, QAT MONTHL STAT; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Puranik Arjun, 2021, medRxiv, DOI 10.1101/2021.08.06.21261707; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; Saththasivam J, 2021, SCI TOTAL ENVIRON, V774, DOI 10.1016/j.scitotenv.2021.145608; Seedat S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97606-8; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; StataCorp, 2021, STATA STAT SOFTWARE; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P1156, DOI 10.15585/mmwr.mm7034e2; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Usherwood T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91514-7; Verani JR, 2017, VACCINE, V35, P3295, DOI 10.1016/j.vaccine.2017.04.037; Vogels C., 2021, PROTOCOLS, DOI [10.17504/protocols.io.br9vm966, DOI 10.17504/PROTOCOLS.IO.BR9VM966]; WHO, 2021, COVID 19 CLIN MAN LI; World Health Organization, 2020, INT GUID CERT CLASS	49	140	140	9	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2136	+		10.1038/s41591-021-01583-4	http://dx.doi.org/10.1038/s41591-021-01583-4		NOV 2021	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34728831	Green Submitted, Bronze, Green Published			2022-12-27	WOS:000713960400001
J	Kinyoki, D; Osgood-Zimmerman, AE; Bhattacharjee, NV; Kassebaum, NJ; Hay, SI				Kinyoki, Damaris; Osgood-Zimmerman, Aaron E.; Bhattacharjee, Natalia, V; Kassebaum, Nicholas J.; Hay, Simon, I		Local Burden Dis Anaemia Collabora	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018	NATURE MEDICINE			English	Article							CHILD GROWTH FAILURE; IRON-DEFICIENCY; GLOBAL BURDEN; PREGNANCY; MODELS		[Kinyoki, Damaris; Osgood-Zimmerman, Aaron E.; Bhattacharjee, Natalia, V; Kassebaum, Nicholas J.; Hay, Simon, I] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Kinyoki, Damaris; Kassebaum, Nicholas J.; Hay, Simon, I] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Kassebaum, Nicholas J.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Kassebaum, Nicholas J.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hay, SI (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Hay, SI (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	sihay@uw.edu	Zhang, Yunquan/M-9828-2017; Banik, Palash Chandra/P-7613-2016; Shannawaz, Mohd/AAF-9702-2020; Chattu, Vijay Kumar/C-2778-2014; Bijani, Ali/B-1718-2017; Foroutan, Masoud/AAD-6837-2020; Pirouzpanah, Saeed/J-6262-2015; Khalid, Nauman/G-8134-2015; Kisa, Adnan/Q-2081-2019; Abbasi-Kangevari, Mohsen/AAB-8908-2022; Fasanmi, Abidemi/AAO-2105-2020; Lopez, Jaifred Christian Felicilda/A-3262-2017; Monasta, Lorenzo/B-1388-2012; Nabhan, Ashraf/A-1718-2008; Leonardo, Roever MHS, PhD, Post-Doctorate, MBA (Data Science)/F-5315-2012; Hassan, Amr/AAP-3025-2021; Saeedi Moghaddam, Sahar/AEO-8071-2022; Shivarov, Velizar/B-4553-2008; Ayza, Muluken Altaye/AAE-2377-2022; Okello, Daniel Micheal/K-1329-2018; Al-Mekhlafi, Hesham Mahyoub Sarhan/R-3568-2016; Bell, Michelle/Y-4608-2018; Sintayehu, Yitagesu/AAI-8506-2021; Michalek, Irmina/J-8448-2019; Yeshaneh, Alex/AAD-1562-2021; Borzouei, Shiva/F-6269-2017; Mohammed, Shafiu/P-2016-2014; Awoke, Nefsu/AFV-2432-2022; Getacher, Lemma/AAE-8421-2021; Anteneh, Zelalem Alamrew/AAD-1052-2022; Anwer, Razique/AAN-7825-2020; Diaz, Daniel/P-1916-2018; Wickramasinghe, Nuwan Darshana/I-3578-2019; T., Olagunju Andrew/B-4746-2017; Regassa, Lemma Demissie/V-3091-2019; Hoogar, Praveen/AGP-1691-2022; Kapoor, Neeti/J-4177-2019; Titova, Mariya/P-6428-2019; Ferrara, Pietro/AAF-4113-2019; Umeokonkwo, Chukwuma David/U-7112-2019; Abolhassani, Hassan/B-3465-2014; Rahman, Muhammad Aziz/B-3380-2009; Shamali, Mahdi/A-2087-2017; Duko, Bereket/P-8904-2019; Rwegerera, Godfrey Mutashambara/J-1475-2019; atan, edinur hisham/F-3946-2014; Meitei, Wahengbam Bigyananda/T-5412-2019; El-Sherbiny, Yasser M/I-4055-2013; Fomenkov, Artem Alekseevich/F-5640-2017; Skryabin, Valentin/B-6244-2019; Wang, Yuan-Pang/A-4863-2008; Hasan, Syed Shahzad/V-9082-2018; Fauk, Nelsensius/L-8024-2015; Hasaballah, Ahmed I./G-6829-2019; Kamath, Ashwin/T-1880-2019; Badiye, Ashish/I-9468-2019; Krishan, Kewal/I-3285-2014; Mirrakhimov, Erkin/E-6900-2017; Syed, ZQ/K-2887-2018; Caetano dos Santos, Florentino Luciano/D-3502-2015; Jha, Ravi Prakash/ABC-6588-2020; karimi, salah/R-6999-2019; Mamun, Abdullah A/A-4673-2011; Uddin, Riaz/M-1477-2017; Nguefack-Tsague, Georges/N-3277-2019; Tilahune, Asres Bedaso/AAP-9464-2020; Tahbaz, Sahel Valadan/ABB-9520-2020; Abd-Elsalam, sherief M/L-3274-2018; Bairwa, Mohan/G-9463-2015; Aghaali, Mohammad/M-2225-2015; Chowdhury, Mohiuddin Ahsanul Kabir/AAY-9871-2020; Costa, Vera Marisa/D-6284-2013; Nwatah, Vincent/AAA-8353-2019; Sajadi, Prof. Dr. S. Mohammad/D-9086-2014; Hay, Simon Iain/F-8967-2015; Laurens, Matthew/E-7293-2013; Gilani, Syed Amir/A-9458-2019; Shamsizadeh, Morteza/C-6000-2014; Ranandeh Kalankesh, Leila/L-8756-2017; yadollahpour, ali/K-9098-2015; Guo, Yuming/I-8353-2018; Castaneda-Orjuela, Carlos/N-2601-2017; Russowsky Brunoni, Andre/H-8394-2012; Saraswathy, Sivan/E-3869-2013; Herteliu, Claudiu/K-4643-2014; Fernandes, Eduarda/D-4943-2013; Pandey, Anamika/B-3723-2012; Miazgowski, Tomasz/H-9448-2014; Waheed, Yasir/F-6390-2015; Koolivand, Ali/D-4524-2016; Ortiz Arduan, Alberto/Y-7582-2018; Martins-Melo, Francisco Rogerlandio/I-4868-2012; Santos, Itamar/K-7055-2012; Olusanya, Bolajoko/F-4504-2012; Pakshir, Keyvan/U-6856-2017; El Tantawi, Maha/K-4336-2014; Dianatinasab, Mostafa/T-6904-2017; Salam, Nasir/C-8049-2015; shams-beyranvand, mehran/S-2695-2017	Zhang, Yunquan/0000-0002-2618-5088; Banik, Palash Chandra/0000-0003-2395-9049; Shannawaz, Mohd/0000-0001-5114-5814; Chattu, Vijay Kumar/0000-0001-9840-8335; Bijani, Ali/0000-0003-2233-8726; Foroutan, Masoud/0000-0002-8661-7217; Pirouzpanah, Saeed/0000-0001-5461-2115; Khalid, Nauman/0000-0002-8045-199X; Kisa, Adnan/0000-0001-7825-3436; Abbasi-Kangevari, Mohsen/0000-0001-8405-7482; Fasanmi, Abidemi/0000-0002-5549-6870; Lopez, Jaifred Christian Felicilda/0000-0002-8273-992X; Monasta, Lorenzo/0000-0001-7774-548X; Nabhan, Ashraf/0000-0003-4572-2210; Leonardo, Roever MHS, PhD, Post-Doctorate, MBA (Data Science)/0000-0002-7517-5548; Hassan, Amr/0000-0001-7374-7074; Saeedi Moghaddam, Sahar/0000-0002-3112-9179; Shivarov, Velizar/0000-0001-5362-7999; Ayza, Muluken Altaye/0000-0001-6196-0361; Okello, Daniel Micheal/0000-0003-2967-2428; Al-Mekhlafi, Hesham Mahyoub Sarhan/0000-0003-2582-7410; Bell, Michelle/0000-0002-3965-1359; Sintayehu, Yitagesu/0000-0002-4325-4241; Michalek, Irmina/0000-0001-8367-5916; Yeshaneh, Alex/0000-0001-5876-7325; Borzouei, Shiva/0000-0001-6826-9872; Mohammed, Shafiu/0000-0001-5715-966X; Awoke, Nefsu/0000-0002-1037-5004; Getacher, Lemma/0000-0002-9237-117X; Anteneh, Zelalem Alamrew/0000-0003-4879-675X; Anwer, Razique/0000-0002-9223-1951; Diaz, Daniel/0000-0003-2302-1982; Wickramasinghe, Nuwan Darshana/0000-0001-6025-6022; T., Olagunju Andrew/0000-0003-1736-9886; Regassa, Lemma Demissie/0000-0002-5461-5348; Hoogar, Praveen/0000-0003-2170-5643; Kapoor, Neeti/0000-0002-3646-5139; Titova, Mariya/0000-0002-4571-3712; Ferrara, Pietro/0000-0002-0349-3221; Umeokonkwo, Chukwuma David/0000-0002-0050-2874; Abolhassani, Hassan/0000-0002-4838-0407; Rahman, Muhammad Aziz/0000-0003-1665-7966; Shamali, Mahdi/0000-0001-7628-0887; Duko, Bereket/0000-0002-4419-0016; Rwegerera, Godfrey Mutashambara/0000-0002-5896-6065; atan, edinur hisham/0000-0002-3379-6063; Meitei, Wahengbam Bigyananda/0000-0003-2671-707X; El-Sherbiny, Yasser M/0000-0003-4791-3475; Fomenkov, Artem Alekseevich/0000-0002-9213-7180; Skryabin, Valentin/0000-0002-4942-8556; Wang, Yuan-Pang/0000-0001-7076-8312; Hasan, Syed Shahzad/0000-0002-4058-2215; Fauk, Nelsensius/0000-0002-1325-2640; Hasaballah, Ahmed I./0000-0003-1596-1958; Kamath, Ashwin/0000-0002-9609-0199; Badiye, Ashish/0000-0001-8097-7249; Krishan, Kewal/0000-0001-5321-0958; Mirrakhimov, Erkin/0000-0003-2982-6108; Syed, ZQ/0000-0002-1435-899X; Caetano dos Santos, Florentino Luciano/0000-0001-8151-3585; Jha, Ravi Prakash/0000-0001-5230-1436; karimi, salah/0000-0002-1542-0214; Mamun, Abdullah A/0000-0002-1535-8086; Uddin, Riaz/0000-0001-8133-9732; Nguefack-Tsague, Georges/0000-0002-3847-3490; Tilahune, Asres Bedaso/0000-0001-7859-0264; Abd-Elsalam, sherief M/0000-0003-4366-2218; Bairwa, Mohan/0000-0001-7763-2530; Aghaali, Mohammad/0000-0003-3417-1580; Chowdhury, Mohiuddin Ahsanul Kabir/0000-0001-6551-5919; Costa, Vera Marisa/0000-0002-0471-2756; Nwatah, Vincent/0000-0002-6833-4002; Sajadi, Prof. Dr. S. Mohammad/0000-0001-8284-5178; Hay, Simon Iain/0000-0002-0611-7272; Laurens, Matthew/0000-0003-3874-581X; Maulik, Pallab Kumar/0000-0001-6835-6175; SAGAR, RAJESH/0000-0003-4563-7841; Gilani, Syed Amir/0000-0002-2996-0764; Shamsizadeh, Morteza/0000-0002-8153-5482; Bhattarai, Suraj/0000-0001-6843-6677; Faris, Pawan/0000-0001-6867-0359; Mahasha, Phetole/0000-0002-5750-3595; Adekanmbi, Victor/0000-0002-7394-1640; Bekele, Muluken/0000-0002-3464-2584; Omar Bali, ahmed/0000-0002-4458-5683; Ranandeh Kalankesh, Leila/0000-0002-4832-3170; Postma, Maarten/0000-0002-6306-3653; yadollahpour, ali/0000-0002-1216-2109; Ayanore, Martin/0000-0002-4095-3047; shetty, suresh/0000-0002-8499-1942; Guo, Yuming/0000-0002-1766-6592; Pescarini, Julia/0000-0001-8711-9589; Valadan Tahbaz, Sahel/0000-0001-8038-6350; Kamyari, Naser/0000-0001-6245-5447; Bohlouli, Mahdi/0000-0002-6659-5524; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Russowsky Brunoni, Andre/0000-0002-6310-3571; Saraswathy, Sivan/0000-0002-5633-9631; Asadi-Aliabadi, Mehran/0000-0003-1582-5489; Herteliu, Claudiu/0000-0001-8860-9547; Lad, Deepesh/0000-0003-3754-7774; Magdy Abd El Razek, Hassan/0000-0002-8857-0408; /0000-0001-5266-0201; Fernandes, Eduarda/0000-0001-6424-0976; Gubari, Mohammed Ibrahim Mohialdeen/0000-0002-2873-3981; Khan, Md Nuruzzaman/0000-0002-4550-4363; Ghith, Nermin/0000-0002-5863-5442; Pandey, Anamika/0000-0001-8644-8540; Kelkay, Bayew/0000-0003-3530-6264; Miazgowski, Tomasz/0000-0002-4819-9376; Usman, Muhammad/0000-0001-9747-8892; Aqeel, Muhammad/0000-0001-8007-6723; Waheed, Yasir/0000-0002-5789-4215; Ahmadi, Keivan/0000-0001-5674-2765; arabloo, Jalal/0000-0003-1223-4528; Wangdi, Dr Kinley/0000-0002-8857-2665; Koolivand, Ali/0000-0002-9375-4631; Gesesew, Hailay/0000-0002-3531-4400; Li, Shanshan/0000-0002-9021-8470; Tessema, Masresha/0000-0002-7155-4815; Olusanya, Jacob/0000-0002-1566-9554; Tekalegn, Yohannes/0000-0001-6628-8180; Landires, Ivan/0000-0001-6323-1170; Ortiz Arduan, Alberto/0000-0002-9805-9523; Martins-Melo, Francisco Rogerlandio/0000-0003-3690-5023; Meretoja, Tuomo/0000-0002-2691-0710; Kabir, Zubair/0000-0003-1529-004X; Derso, Henok Dagne/0000-0001-7161-0904; Santos, Itamar/0000-0003-3212-8466; Davletov, Kairat/0000-0001-8534-1899; Freitas, Marisa/0000-0001-9114-9967; Hegazy, Mohamed/0000-0001-5012-3998; Olusanya, Bolajoko/0000-0002-3826-0583; Rahim, Fakher/0000-0002-2857-4562; Ribeiro, Ana Isabel/0000-0001-8880-6962; Daneshpajouhnejad, Parnaz/0000-0002-8845-5813; Mini, GK/0000-0003-2775-629X; Shafaat, Omid/0000-0001-8793-7901; Wonde, Tewodros/0000-0003-3323-8202; Alanzi, Turki/0000-0001-6598-1274; Pakshir, Keyvan/0000-0001-7809-4690; Moradi, Masoud/0000-0003-2036-5333; Ayano, Getinet/0000-0002-9137-4141; Sha, Feng/0000-0002-0966-5733; Hargono, Arief/0000-0001-8978-9877; El Tantawi, Maha/0000-0003-4989-6584; Rai, Rajesh Kumar/0000-0002-5249-9937; Shalash, Ali/0000-0001-7012-5907; Majeed, Azeem/0000-0002-2357-9858; Yeshaw, Yigizie/0000-0003-4587-7925; Gizachew, Yordanos/0000-0002-6002-7358; Deribe, Kebede/0000-0002-8526-6996; ziapour, arash/0000-0001-8687-7484; Dianatinasab, Mostafa/0000-0002-0185-5807; Amugsi, DICKSON A/0000-0002-5261-8481; Kurmi, Om Prakash/0000-0002-9518-4716; Ribeiro, Daniela/0000-0001-9733-7934; Tabuchi, Takahiro/0000-0002-1050-3125; Hanif, Asif/0000-0002-2670-6402; Salam, Nasir/0000-0001-9133-1304; shams-beyranvand, mehran/0000-0001-9474-0955; Pourchamani, Hadis/0000-0003-0112-549X				Akseer N, 2020, AM J CLIN NUTR, V112, p792S, DOI 10.1093/ajcn/nqaa152; Alamo IG, 2016, J TRAUMA ACUTE CARE, V81, P705, DOI 10.1097/TA.0000000000001163; Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; [Anonymous], CHERG IRON REPORT MA; [Anonymous], 2018, WHOUNICEF DISCUSSION; [Anonymous], 2004, GLOB LAK WETL DAT LE; [Anonymous], 2015, GLOB ADM UN LAYERS G; Bene C, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0301-5; Bhattacharjee NV, 2019, NAT MED, V25, P1205, DOI 10.1038/s41591-019-0525-0; BLACK AK, 1994, J NUTR, V124, P1179, DOI 10.1093/jn/124.8.1179; Burstein R, 2019, NATURE, V574, P353, DOI 10.1038/s41586-019-1545-0; Calis JCJ, 2010, AIDS, V24, P2883, DOI 10.1097/QAD.0b013e32833fed27; Davis E, 2021, STATPEARLS; Dicker D, 2018, LANCET, V392, P1684, DOI [10.1016/S0140-6736(18)31891-9, 10.1016/s0140-6736(18)31891-9]; Diggle PJ, 2007, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-48536-2; Dwyer-Lindgren L, 2019, NATURE, V570, P189, DOI 10.1038/s41586-019-1200-9; Fienberg SE., 2007, ANAL CROSS CLASSIFIE; Friedl M., 2019, NASA EOSDIS L PROCES, DOI [10.5067/MODIS/MCD12Q1.006, DOI 10.5067/MODIS/MCD12Q1.006]; Girard AW, 2012, PAEDIATR PERINAT EP, V26, P205, DOI 10.1111/j.1365-3016.2012.01282.x; Global Administrative Areas (GADM), GADM MAPS DAT; Haas JD, 2001, J NUTR, V131, p676S, DOI 10.1093/jn/131.2.676S; Horton S, 2003, FOOD POLICY, V28, P51, DOI 10.1016/S0306-9192(02)00070-2; Institute for Health Metrics and Evaluation, GBD COMPARE; Jose A, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2200-3; Kassebaum NJ, 2016, HEMATOL ONCOL CLIN N, V30, P247, DOI 10.1016/j.hoc.2015.11.002; Kavle JA, 2008, J HEALTH POPUL NUTR, V26, P232; Keats EC, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004905.pub6; Kinyoki DK, 2020, NAT MED, V26, P750, DOI 10.1038/s41591-020-0807-6; Kinyoki DK, 2020, NATURE, V577, P231, DOI 10.1038/s41586-019-1878-8; Lehner B, 2004, J HYDROL, V296, P1, DOI 10.1016/j.jhydrol.2004.03.028; Leone F, 2019, NEW INDICATORS AMR D; Lindgren F, 2011, J R STAT SOC B, V73, P423, DOI 10.1111/j.1467-9868.2011.00777.x; Lumley T., 2004, J STAT SOFTW, V9, P1, DOI [10.18637/jss.v009.i08, DOI 10.18637/JSS.V009.I08]; Martinsson A, 2014, EUR J EPIDEMIOL, V29, P489, DOI 10.1007/s10654-014-9929-9; Murray CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Njua-Yafi C, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1111-2; Osgood-Zimmerman A, 2018, NATURE, V555, P41, DOI 10.1038/nature25760; Patil AP, 2011, TRENDS PARASITOL, V27, P245, DOI 10.1016/j.pt.2011.01.003; Pullan RL, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-81; Rasmussen KM, 2001, J NUTR, V131, p590S, DOI 10.1093/jn/131.2.590S; Reiner RC, 2020, LANCET, V395, P1779, DOI 10.1016/S0140-6736(20)30114-8; Roberts DR, 2017, ECOGRAPHY, V40, P913, DOI 10.1111/ecog.02881; Rue H, 2009, J R STAT SOC B, V71, P319, DOI 10.1111/j.1467-9868.2008.00700.x; Scharlemann JPW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001408; Semba RD, 2002, EUR J CLIN NUTR, V56, P271, DOI 10.1038/sj.ejcn.1601320; Smith ER, 2017, LANCET GLOB HEALTH, V5, pE1090, DOI 10.1016/S2214-109X(17)30371-6; Stein J, 2016, WORLD J GASTROENTERO, V22, P7908, DOI 10.3748/wjg.v22.i35.7908; Stein M.L., 1999, INTERPOLATION SPATIA; Sustainable Development Solutions Network, IND MON FRAM GOAL 02; Tatem AJ, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.4; The Malaria Atlas Project, INH BLOOD DIS; Weiss DJ, 2019, LANCET, V394, P322, DOI 10.1016/S0140-6736(19)31097-9; White NJ, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2509-9; WHO, 2011, WHO TECH REP SER, V959, P1; WHO, 2017, NUTR AN TOOLS EFF PR; WHO-WORLD HEALTH ORGANIZATION, 2014, GLOB NUTR TARG 2025; World Health Organization, 2019, GLOB TARG TRACK TOOL; World Health Organization (WHO), 2015, GLOB PREV AN 2011, DOI DOI 10.1017/S1368980008002401; WorldPop, OP SPAT DEM DAT RES	60	15	15	10	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1761	+		10.1038/s41591-021-01498-0	http://dx.doi.org/10.1038/s41591-021-01498-0		OCT 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642490	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000706587600002
J	Nalam, V; Huang, H				Nalam, Varun; Huang, He (Helen)			Empowering prosthesis users with a hip exoskeleton	NATURE MEDICINE			English	Editorial Material							AMPUTATION; WALKING; BALANCE	A phase 1 trial shows the feasibility of a novel approach combining a powered hip exoskeleton with a passive leg prosthesis to improve the energy efficiency of walking.	[Nalam, Varun; Huang, He (Helen)] North Carolina State Univ, Joint Dept Biomed Engn, Raleigh, NC 27695 USA; [Nalam, Varun; Huang, He (Helen)] Univ North Carolina Chapel Hill, Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA	University of North Carolina; North Carolina State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Huang, H (corresponding author), North Carolina State Univ, Joint Dept Biomed Engn, Raleigh, NC 27695 USA.; Huang, H (corresponding author), Univ North Carolina Chapel Hill, Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA.	hhuang11@ncsu.edu	Nalam, Varun/ABJ-9188-2022	Nalam, Varun/0000-0003-0837-1175; Huang, He/0000-0001-5581-1423				Brandt A, 2019, J NEUROENG REHABIL, V16, DOI 10.1186/s12984-019-0625-6; Farris DJ, 2012, J R SOC INTERFACE, V9, P110, DOI 10.1098/rsif.2011.0182; Gailey R, 2008, J REHABIL RES DEV, V45, P15, DOI 10.1682/JRRD.2006.11.0147; Hafner BJ, 2015, J REHABIL RES DEV, V52, P677, DOI 10.1682/JRRD.2014.09.0210; Huang H, 2021, CURR OPIN BIOMED ENG, V20, DOI 10.1016/j.cobme.2021.100314; Ishmael MK, 2021, NAT MED, V27, P1783, DOI 10.1038/s41591-021-01515-2; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1031, DOI 10.1053/apmr.2001.24295; Monaco V, 2017, SCI REP-UK, V7, DOI 10.1038/srep46721; Nielsen, 2013, ORTHOTICS PROSTHET, pXII; Schaarschmidt M, 2012, HUM MOVEMENT SCI, V31, P907, DOI 10.1016/j.humov.2011.09.004; Thatte N, 2016, IEEE T BIO-MED ENG, V63, P904, DOI 10.1109/TBME.2015.2472533; Windrich M, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0284-9	12	0	0	4	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1677	1678		10.1038/s41591-021-01529-w	http://dx.doi.org/10.1038/s41591-021-01529-w		OCT 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34635853				2022-12-27	WOS:000706015900001
J	Scangos, KW; Khambhati, AN; Daly, PM; Makhoul, GS; Sugrue, LP; Zamanian, H; Liu, TX; Rao, VKR; Sellers, KK; Dawes, HE; Starr, PA; Krystal, AD; Chang, EDF				Scangos, Katherine W.; Khambhati, Ankit N.; Daly, Patrick M.; Makhoul, Ghassan S.; Sugrue, Leo P.; Zamanian, Hashem; Liu, Tony X.; Rao, Vikram R.; Sellers, Kristin K.; Dawes, Heather E.; Starr, Philip A.; Krystal, Andrew D.; Chang, Edward F.			Closed-loop neuromodulation in an individual with treatment-resistant depression	NATURE MEDICINE			English	Article							DEEP BRAIN-STIMULATION; VENTRAL CAPSULE/VENTRAL STRIATUM; CONNECTIVITY; SYSTEM; SCALE	Deep brain stimulation is a promising treatment for neuropsychiatric conditions such as major depression. It could be optimized by identifying neural biomarkers that trigger therapy selectively when symptom severity is elevated. We developed an approach that first used multi-day intracranial electrophysiology and focal electrical stimulation to identify a personalized symptom-specific biomarker and a treatment location where stimulation improved symptoms. We then implanted a chronic deep brain sensing and stimulation device and implemented a biomarker-driven closed-loop therapy in an individual with depression. Closed-loop therapy resulted in a rapid and sustained improvement in depression. Future work is required to determine if the results and approach of this n-of-1 study generalize to a broader population.	[Scangos, Katherine W.; Khambhati, Ankit N.; Daly, Patrick M.; Makhoul, Ghassan S.; Sugrue, Leo P.; Zamanian, Hashem; Liu, Tony X.; Rao, Vikram R.; Sellers, Kristin K.; Dawes, Heather E.; Starr, Philip A.; Krystal, Andrew D.; Chang, Edward F.] Univ Calif San Francsico, Weill Inst Neurosci, San Francsico, CA 94143 USA; [Scangos, Katherine W.; Daly, Patrick M.; Makhoul, Ghassan S.; Zamanian, Hashem; Liu, Tony X.; Krystal, Andrew D.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Khambhati, Ankit N.; Sellers, Kristin K.; Dawes, Heather E.; Starr, Philip A.; Chang, Edward F.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA; [Sugrue, Leo P.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Rao, Vikram R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scangos, KW (corresponding author), Univ Calif San Francsico, Weill Inst Neurosci, San Francsico, CA 94143 USA.; Scangos, KW (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.	katherine.scangos@ucsf.edu	Khambhati, Ankit/AFL-4288-2022	Khambhati, Ankit/0000-0001-6182-4677; Rao, Vikram/0000-0002-6389-2638; Liu, Tony/0000-0001-9334-8492; Sellers, Kristin/0000-0002-0517-2296	National Institutes of Health [K23NS110962]; NARSAD Young Investigator grant from the Brain & Behavior Research Foundation; 1907 Trailblazer Award; Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at UCSF	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NARSAD Young Investigator grant from the Brain & Behavior Research Foundation(NARSAD); 1907 Trailblazer Award; Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at UCSF	This work was supported by a National Institutes of Health award no. K23NS110962 (K.W.S.), NARSAD Young Investigator grant from the Brain & Behavior Research Foundation (K.W.S.), 1907 Trailblazer Award (K.W.S.) and a Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at UCSF (K.W.S., A.D.K., E.F.C., L.P.S., A.N.K., P.M.S., G.S.M., H.Z., T.X.L., V.R.R., K.K.S. and H.E.D.).	Bassett DS, 2017, NAT NEUROSCI, V20, P353, DOI 10.1038/nn.4502; Bergfeld IO, 2016, JAMA PSYCHIAT, V73, P456, DOI 10.1001/jamapsychiatry.2016.0152; Bouthour W, 2019, NAT REV NEUROL, V15, P343, DOI 10.1038/s41582-019-0166-4; Campbell MC, 2012, J NEUROPSYCH CLIN N, V24, P28, DOI 10.1176/appi.neuropsych.11030060; Chang EF, 2015, NEURON, V86, P68, DOI 10.1016/j.neuron.2015.03.037; Choi KS, 2015, JAMA NEUROL, V72, P1252, DOI 10.1001/jamaneurol.2015.2564; Dougherty DD, 2015, BIOL PSYCHIAT, V78, P240, DOI 10.1016/j.biopsych.2014.11.023; Dunner DL, 2006, J CLIN PSYCHIAT, V67, P688, DOI 10.4088/JCP.v67n0501; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Giorgino T, 2009, J STAT SOFTW, V31, P1, DOI 10.18637/jss.v031.i07; Haq IU, 2011, NEUROIMAGE, V54, pS247, DOI 10.1016/j.neuroimage.2010.03.009; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Holtzheimer PE, 2017, LANCET PSYCHIAT, V4, P839, DOI 10.1016/S2215-0366(17)30371-1; Howland RH, 2008, J PSYCHOSOC NURS MEN, V46, P21; Keller CJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0528; Khambhati AN, 2019, NETW NEUROSCI, V3, P848, DOI 10.1162/netn_a_00089; Kirkby LA, 2018, CELL, V175, P1688, DOI 10.1016/j.cell.2018.10.005; Malone DA, 2009, BIOL PSYCHIAT, V65, P267, DOI 10.1016/j.biopsych.2008.08.029; Matsumoto R, 2004, BRAIN, V127, P2316, DOI 10.1093/brain/awh246; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Price JL, 2010, NEUROPSYCHOPHARMACOL, V35, P192, DOI 10.1038/npp.2009.104; Rabiner L., 1993, FUNDAMENTALS SPEECH; Rao VR, 2018, CURR BIOL, V28, P3893, DOI 10.1016/j.cub.2018.10.026; Riva-Posse P, 2018, MOL PSYCHIATR, V23, P843, DOI 10.1038/mp.2017.59; Riva-Posse P, 2014, BIOL PSYCHIAT, V76, P963, DOI 10.1016/j.biopsych.2014.03.029; SAKOE H, 1978, IEEE T ACOUST SPEECH, V26, P43, DOI 10.1109/TASSP.1978.1163055; Salloum NC, 2019, DEPRESS ANXIETY, V36, P235, DOI 10.1002/da.22875; Scangos KW, 2021, NAT MED, V27, P229, DOI 10.1038/s41591-020-01175-8; SCHIFF SJ, 1994, ELECTROEN CLIN NEURO, V91, P442, DOI 10.1016/0013-4694(94)90165-1; Sokolov AA, 2019, BRAIN STRUCT FUNCT, V224, P205, DOI 10.1007/s00429-018-1760-8; Sun FT, 2014, EXPERT REV MED DEVIC, V11, P563, DOI 10.1586/17434440.2014.947274; Timmerby N, 2017, PSYCHOTHER PSYCHOSOM, V86, P141, DOI 10.1159/000457131; Waltz E, 2020, NAT BIOTECHNOL, V38, P1014, DOI 10.1038/s41587-020-0664-3; Williams LM, 2016, LANCET PSYCHIAT, V3, P472, DOI 10.1016/S2215-0366(15)00579-9; Yeung AWK, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00086	36	40	44	14	78	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1696	+		10.1038/s41591-021-01480-w	http://dx.doi.org/10.1038/s41591-021-01480-w		OCT 2021	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34608328				2022-12-27	WOS:000703378900004
J	Salje, H; Alera, MT; Chua, MN; Hunsawong, T; Ellison, D; Srikiatkhachorn, A; Jarman, RG; Gromowski, GD; Rodriguez-Barraquer, I; Cauchemez, S; Cummings, DAT; Macareo, L; Yoon, IK; Fernandez, S; Rothman, AL				Salje, Henrik; Alera, Maria Theresa; Chua, Mary Noreen; Hunsawong, Taweewun; Ellison, Damon; Srikiatkhachorn, Anon; Jarman, Richard G.; Gromowski, Gregory D.; Rodriguez-Barraquer, Isabel; Cauchemez, Simon; Cummings, Derek A. T.; Macareo, Louis; Yoon, In-Kyu; Fernandez, Stefan; Rothman, Alan L.			Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection	NATURE MEDICINE			English	Article							VIRUS-INFECTIONS; CHILDREN; SAFETY	Multiyear analysis of antibody responses in recipients of the dengue vaccine Dengvaxia in the Philippines supports their utility as a predictor of protection against disease, and reveals that Dengvaxia efficacy declines 3 years after complete vaccination. More than half of the world's population lives in areas at risk for dengue virus infection. A vaccine will be pivotal to controlling spread, however, the only licensed vaccine, Dengvaxia, has been shown to increase the risk of severe disease in a subset of individuals. Vaccine efforts are hampered by a poor understanding of antibody responses, including those generated by vaccines, and whether antibody titers can be used as a marker of protection from infection or disease. Here we present the results of an ancillary study to a phase III vaccine study (n = 611). All participants received three doses of either Dengvaxia or placebo and were followed for 6 years. We performed neutralization tests on annual samples and during confirmed dengue episodes (n = 16,508 total measurements). We use mathematical models to reconstruct long-term antibody responses to vaccination and natural infection, and to identify subclinical infections. There were 87 symptomatic infections reported, and we estimated that there were a further 351 subclinical infections. Cumulative vaccine efficacy was positive for both subclinical and symptomatic infection, although the protective effect of the vaccine was concentrated in the first 3 years following vaccination. Among individuals with the same antibody titer, we found no difference between the risk of subsequent infection or disease between placebo and vaccine recipients, suggesting that antibody titers are a good predictor of both protection and disease risk.	[Salje, Henrik] Univ Cambridge, Dept Genet, Cambridge, England; [Salje, Henrik; Cummings, Derek A. T.] Univ Florida, Dept Biol, Gainesville, FL USA; [Alera, Maria Theresa; Hunsawong, Taweewun; Srikiatkhachorn, Anon; Macareo, Louis; Fernandez, Stefan] Armed Forces Res Inst Med Sci, Dept Virol, Bangkok, Thailand; [Chua, Mary Noreen] Chong Hua Hosp, Cebu, Philippines; [Ellison, Damon] Walter Reed Army Inst Res, Bacterial Dis Branch, Silver Spring, MD USA; [Srikiatkhachorn, Anon; Rothman, Alan L.] Univ Rhode Isl, Inst Immunol & Informat, Dept Cell & Mol Biol, Providence, RI USA; [Srikiatkhachorn, Anon] King Mongkuts Inst Technol Ladkrabang, Fac Med, Bangkok, Thailand; [Jarman, Richard G.; Gromowski, Gregory D.] Walter Reed Army Inst Res, Viral Dis Branch, Silver Spring, MD USA; [Rodriguez-Barraquer, Isabel] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Cauchemez, Simon] Inst Pasteur, Math Modelling Infect Dis Unit, Paris, France; [Cummings, Derek A. T.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA; [Yoon, In-Kyu] Coalit Epidem Preparedness Innovat, Washington, DC USA	University of Cambridge; State University System of Florida; University of Florida; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Rhode Island; King Mongkuts Institute of Technology Ladkrabang; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of California System; University of California San Francisco; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; State University System of Florida; University of Florida	Salje, H (corresponding author), Univ Cambridge, Dept Genet, Cambridge, England.; Salje, H (corresponding author), Univ Florida, Dept Biol, Gainesville, FL USA.	hs743@cam.ac.uk		Jarman, Richard/0000-0002-5765-0173; Salje, Henrik/0000-0003-3626-4254	National Institutes of Health; National Institute of Allergy and Infectious Diseases [P01AI034533, 5R01AI114703-05]; US Military Infectious Diseases Research Program; European Research Council [804744]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US Military Infectious Diseases Research Program; European Research Council(European Research Council (ERC)European Commission)	This work was supported by the National Institutes of Health and National Institute of Allergy and Infectious Diseases (grant numbers P01AI034533, 5R01AI114703-05), the US Military Infectious Diseases Research Program and the European Research Council (grant number. 804744). The funders had no role in the study design, data collection or analysis, decision to publish or preparation of the manuscript. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or as reflecting the true views of the National Institutes of Health, Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70-25.	Chotpitayasunondh T, 2017, VACCINE, V35, P299, DOI 10.1016/j.vaccine.2016.11.062; Ferguson NM, 2016, SCIENCE, V353, P1033, DOI 10.1126/science.aaf9590; Fried JR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000617; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Katzelnick LC, 2015, SCIENCE, V349, P1338, DOI 10.1126/science.aac5017; Moi Meng Ling, 2016, Trop Med Health, V44, P1, DOI 10.1186/s41182-016-0004-y; Olivera-Botello G, 2016, J INFECT DIS, V214, P994, DOI 10.1093/infdis/jiw297; Reich NG, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0414; RUSSELL PK, 1967, J IMMUNOL, V99, P285; SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30; Salje H, 2018, NATURE, V557, P719, DOI 10.1038/s41586-018-0157-4; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Stanaway JD, 2016, LANCET INFECT DIS, V16, P712, DOI 10.1016/S1473-3099(16)00026-8; Thomas SJ, 2009, AM J TROP MED HYG, V81, P825, DOI 10.4269/ajtmh.2009.08-0625; Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8	17	4	4	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1395	+		10.1038/s41591-021-01392-9	http://dx.doi.org/10.1038/s41591-021-01392-9		JUN 2021	9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34168334	Green Submitted, Green Accepted			2022-12-27	WOS:000665683600001
J	Sahel, JA; Boulanger-Scemama, E; Pagot, C; Arleo, A; Galluppi, F; Martel, JN; Esposti, SD; Delaux, A; Aubert, JBD; de Montleau, C; Gutman, E; Audo, I; Duebel, J; Picaud, S; Dalkara, D; Blouin, L; Taiel, M; Roska, B				Sahel, Jose-Alain; Boulanger-Scemama, Elise; Pagot, Chloe; Arleo, Angelo; Galluppi, Francesco; Martel, Joseph N.; Esposti, Simona Degli; Delaux, Alexandre; de Saint Aubert, Jean-Baptiste; de Montleau, Caroline; Gutman, Emmanuel; Audo, Isabelle; Duebel, Jens; Picaud, Serge; Dalkara, Deniz; Blouin, Laure; Taiel, Magali; Roska, Botond			Partial recovery of visual function in a blind patient after optogenetic therapy	NATURE MEDICINE			English	Article							RETINITIS-PIGMENTOSA; ALPHA-RHYTHM; UVEITIS NOMENCLATURE; RESPONSES; STANDARDIZATION; ATTENTION	Optogenetics may enable mutation-independent, circuit-specific restoration of neuronal function in neurological diseases. Retinitis pigmentosa is a neurodegenerative eye disease where loss of photoreceptors can lead to complete blindness. In a blind patient, we combined intraocular injection of an adeno-associated viral vector encoding ChrimsonR with light stimulation via engineered goggles. The goggles detect local changes in light intensity and project corresponding light pulses onto the retina in real time to activate optogenetically transduced retinal ganglion cells. The patient perceived, located, counted and touched different objects using the vector-treated eye alone while wearing the goggles. During visual perception, multichannel electroencephalographic recordings revealed object-related activity above the visual cortex. The patient could not visually detect any objects before injection with or without the goggles or after injection without the goggles. This is the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy. Combined intraocular injection of an adeno-associated viral vector, encoding an optogenetic sensor, with light stimulation via engineered goggles enables partial recovery of visual function in a blind patient.	[Sahel, Jose-Alain; Arleo, Angelo; Delaux, Alexandre; de Saint Aubert, Jean-Baptiste; Audo, Isabelle; Duebel, Jens; Picaud, Serge; Dalkara, Deniz] Sorbonne Univ, Inst Vis, Ctr Natl Rech Sci, Inst Natl Sante & Rech Med, Paris, France; [Sahel, Jose-Alain; Martel, Joseph N.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA; [Sahel, Jose-Alain; Boulanger-Scemama, Elise; Audo, Isabelle] Ctr Hosp Natl Ophtalmol Quinze Vingts, Ctr Invest Clin 1423, Inst Natl Sante & Rech Med, Paris, France; [Sahel, Jose-Alain; Boulanger-Scemama, Elise] Fdn Ophtalmol Rothschild, Dept Ophtalmol, Paris, France; [Pagot, Chloe; de Montleau, Caroline; Gutman, Emmanuel] Inst Vis, Streetlab, Paris, France; [Galluppi, Francesco; Blouin, Laure; Taiel, Magali] GenSight Biol, Paris, France; [Esposti, Simona Degli] Moorfields Eye Hosp, Moorfields Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Esposti, Simona Degli] UCL Inst Ophthalmol, London, England; [Roska, Botond] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland; [Roska, Botond] Univ Basel, Dept Ophthalmol, Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; CHNO des Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London; University of Basel	Sahel, JA (corresponding author), Sorbonne Univ, Inst Vis, Ctr Natl Rech Sci, Inst Natl Sante & Rech Med, Paris, France.; Sahel, JA (corresponding author), Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.; Sahel, JA (corresponding author), Ctr Hosp Natl Ophtalmol Quinze Vingts, Ctr Invest Clin 1423, Inst Natl Sante & Rech Med, Paris, France.; Sahel, JA (corresponding author), Fdn Ophtalmol Rothschild, Dept Ophtalmol, Paris, France.; Roska, B (corresponding author), Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.; Roska, B (corresponding author), Univ Basel, Dept Ophthalmol, Basel, Switzerland.	sahelja@upmc.edu; botond.roska@iob.ch	; Sahel, Jose-Alain/F-3172-2017	Arleo, Angelo/0000-0002-1990-1971; Pagot, Chloe/0000-0003-1827-1979; de Montleau, Caroline/0000-0003-0764-4514; de Saint Aubert, Jean-Baptiste/0000-0001-8304-4989; Delaux, Alexandre/0000-0002-4553-9371; Sahel, Jose-Alain/0000-0002-4831-1153	GenSight Biologics; French Programme Investissements d'Avenir IHU FOReSIGHT [ANR-18-IAHU-01]; BPI France [2014-PRSP-15]; Foundation Fighting Blindness; Federation des Aveugles de France; French National Research Agency [ANR-18-CHIN-0002]; French Programme Investissements d'Avenir RHU LIGHT4DEAF [ANR-15-RHU-0001]	GenSight Biologics; French Programme Investissements d'Avenir IHU FOReSIGHT(French National Research Agency (ANR)); BPI France; Foundation Fighting Blindness(European Commission); Federation des Aveugles de France; French National Research Agency(French National Research Agency (ANR)); French Programme Investissements d'Avenir RHU LIGHT4DEAF(French National Research Agency (ANR))	The PIONEER study group members were H. Akolkar, F. Arcizet, E. Bamberg, S. Bentobji, S. Bertin, E. Bochin, E. Boyden, A. Chaffiol, G. Chenegros, C. Ciavrs-Roux, C. Coen, D. Dagostinoz, M.-C. Despiau, M. Desrosiers, C. Devisme, G. Gauvain, J.-F. Girmens, A. Grimaud, R. Hosseini, C. Jaillard, L. Karbunarevic, J. Labbe, M. Laurent, J. P. Marques, O. Marre, G. Martin, R. Mecheri, N. Messeca, M. Michaelides, S. Mohand-Said, P. Pouget, P. Queromes, M. Roux, S. Sancho, I. Scarabin, P. Shabestary, W. Smith, A. Tufail, A. Webster. We thank M. Cattaneo for help with statistical analysis. We thank R. Benosman and his lab for their contribution to the development of the stimulation goggles and to the preclinical development. The study was supported by the following sources of funding: GenSight Biologics; French Programme Investissements d'Avenir IHU FOReSIGHT, no. ANR-18-IAHU-01 (J.-A.S., A.A. and I.A.) and RHU LIGHT4DEAF no. ANR-15-RHU-0001 (J.-A.S. and I.A.), BPI France (grant no. 2014-PRSP-15 to J.-A.S.), Foundation Fighting Blindness (J.-A.S. and I.A.) and Federation des Aveugles de France and French National Research Agency (no. ANR-18-CHIN-0002 to A.A.).	Alexander KR, 2005, INVEST OPHTH VIS SCI, V46, P2967, DOI 10.1167/iovs.05-0231; American National Standards Institute ANSI Z136.1-2014, 2014, Z13612014 ANSI LAS I; Audo I, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-8; Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026; Bottari D, 2016, SCI REP-UK, V6, DOI 10.1038/srep24683; Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897; Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708; EBE M, 1964, TOHOKU J EXP MED, V84, P92, DOI 10.1620/tjem.84.92; Ergenoglu T, 2004, COGNITIVE BRAIN RES, V20, P376, DOI 10.1016/j.cogbrainres.2004.03.009; Eudy JD, 1998, SCIENCE, V280, P1753, DOI 10.1126/science.280.5370.1753; Feng WF, 2017, NEUROIMAGE, V150, P318, DOI 10.1016/j.neuroimage.2017.02.033; FRANCOIS J, 1954, Ann Ocul (Paris), V187, P908; Freunberger R, 2008, NEUROIMAGE, V42, P928, DOI 10.1016/j.neuroimage.2008.05.020; Gauvain G, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01594-w; GILLESPIE FD, 1964, AM J OPHTHALMOL, V57, P1045, DOI 10.1016/0002-9394(64)91053-0; Hamilton R, 2021, DOC OPHTHALMOL, V142, P25, DOI 10.1007/s10633-020-09770-3; International Commission on Non-Ionizing Protection, 1997, HLTH PHYS; International Electrotechnical Commission, 2014, SAF LAS PROD 1, V3rd; International Standards Organization, 2007, 1500422007 ISO; Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Klapoetke NC, 2014, NAT METHODS, V11, P338, DOI [10.1038/NMETH.2836, 10.1038/nmeth.2836]; KRILL AE, 1960, AM J OPHTHALMOL, V49, P762, DOI 10.1016/0002-9394(60)92051-1; Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117; Myers MH, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0640-y; Nishiguchi KM, 2013, P NATL ACAD SCI USA, V110, P16139, DOI 10.1073/pnas.1308243110; NUSSENBLATT RB, 1985, OPHTHALMOLOGY, V92, P467; Paranhos FRL, 1999, DOC OPHTHALMOL, V96, P321; Parisi V, 2010, CLIN NEUROPHYSIOL, V121, P380, DOI 10.1016/j.clinph.2009.09.032; Picaud S, 2019, P NATL ACAD SCI USA, V116, P26280, DOI 10.1073/pnas.1902292116; Pion-Tonachini L, 2019, NEUROIMAGE, V198, P181, DOI 10.1016/j.neuroimage.2019.05.026; Posch C, 2011, IEEE J SOLID-ST CIRC, V46, P259, DOI 10.1109/JSSC.2010.2085952; Posch C, 2011, IEEE INT SYMP CIRC S, P1572, DOI 10.1109/ISCAS.2011.5937877; Romei V, 2008, CEREB CORTEX, V18, P2010, DOI 10.1093/cercor/bhm229; Romei V, 2010, J NEUROSCI, V30, P8692, DOI 10.1523/JNEUROSCI.0160-10.2010; Roska B, 2018, NATURE, V557, P359, DOI 10.1038/s41586-018-0076-4; Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8; Sahel JA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2324; Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304; Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838; Song J, 2011, INVEST OPHTH VIS SCI, V52, P9053, DOI 10.1167/iovs.11-7978; STREIFLER M, 1955, Ophthalmologica, V130, P116; Thut G, 2006, J NEUROSCI, V26, P9494, DOI 10.1523/JNEUROSCI.0875-06.2006; Trusko B, 2013, METHOD INFORM MED, V52, P259, DOI 10.3414/ME12-01-0063; Van Dijk H, 2008, J NEUROSCI, V28, P1816, DOI 10.1523/JNEUROSCI.1853-07.2008; Vandewalle G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35400-9; Vanni S, 1997, J NEUROSCI, V17, P7141; Wyart V, 2008, J NEUROSCI, V28, P2667, DOI 10.1523/JNEUROSCI.4748-07.2008; Zumer JM, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001965	49	126	126	19	57	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1223	+		10.1038/s41591-021-01351-4	http://dx.doi.org/10.1038/s41591-021-01351-4		MAY 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34031601	Bronze, Green Published			2022-12-27	WOS:000653615900003
J	Henley, P; Igihozo, G; Wotton, L				Henley, Phaedra; Igihozo, Gloria; Wotton, Laura			One Health approaches require community engagement, education, and international collaborations-a lesson from Rwanda	NATURE MEDICINE			English	Editorial Material									[Henley, Phaedra; Igihozo, Gloria; Wotton, Laura] Univ Global Hlth Equ, Ctr One Hlth, Kigali, Rwanda		Henley, P (corresponding author), Univ Global Hlth Equ, Ctr One Hlth, Kigali, Rwanda.	phenley@ughe.org		Igihozo, Gloria/0000-0001-9641-2509				Binagwaho A., 2020, MEDICALNEWSTODAY; Buregyeya E, 2020, J EPIDEMIOL GLOB HEA, V10, P250, DOI 10.2991/jegh.k.200825.001; Cleaveland S, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0168; Destoumieux-Garzon D, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00014; Grace D, 2012, TROP ANIM HEALTH PRO, V44, pS67, DOI 10.1007/s11250-012-0209-y; Nhamo G, 2019, JAMBA-J DISASTER RIS, V11, DOI 10.4102/jamba.v11i1.644; Nyatanyi T, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000121; Rwanda One Health Steering Committee, 2019, ON HLTH POL, P1; Rwanda One Health Steering Committee, 2014, ON HLTH STRAT PLAN 2, P1	9	3	3	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					947	948		10.1038/s41591-021-01350-5	http://dx.doi.org/10.1038/s41591-021-01350-5		MAY 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34017132	Bronze			2022-12-27	WOS:000652454300005
J	Otu, A; Effa, E; Meseko, C; Cadmus, S; Ochu, C; Athingo, R; Namisango, E; Ogoina, D; Okonofua, F; Ebenso, B				Otu, Akaninyene; Effa, Emmanuel; Meseko, Clement; Cadmus, Simeon; Ochu, Chinwe; Athingo, Rauna; Namisango, Eve; Ogoina, Dimie; Okonofua, Friday; Ebenso, Bassey			Africa needs to prioritize One Health approaches that focus on the environment, animal health and human health	NATURE MEDICINE			English	Editorial Material									[Otu, Akaninyene] Leeds Teaching Hosp NHS Trust, Dept Infect & Travel Med, Leeds, W Yorkshire, England; [Otu, Akaninyene; Effa, Emmanuel] Univ Calabar, Coll Med Sci, Dept Internal Med, Calabar, Nigeria; [Meseko, Clement] Natl Vet Res Inst, Vom, Nigeria; [Cadmus, Simeon] Univ Ibadan, Ctr Control & Prevent Zoonoses, Ibadan, Nigeria; [Ochu, Chinwe] Nigeria Ctr Dis Control, Abuja, Nigeria; [Athingo, Rauna] Subdiv North West, Anim Dis Control, Oshakati, Namibia; [Namisango, Eve] African Palliat Care Assoc, Kampala, Uganda; [Ogoina, Dimie] Nigerian Infect Dis Soc, Abuja, Nigeria; [Ogoina, Dimie] Niger Delta Univ, Niger Delta Univ Teaching Hosp, Yenagoa, Nigeria; [Okonofua, Friday] Nigerian Acad Sci, Abuja, Nigeria; [Okonofua, Friday] Univ Benin, Coll Med Sci, Benin, Nigeria; [Ebenso, Bassey] Univ Leeds, Leeds Inst Hlth Sci, Nuffield Ctr Int Hlth & Dev, Leeds, W Yorkshire, England	University of Leeds; University of Calabar; University of Ibadan; University of Benin; University of Leeds	Otu, A (corresponding author), Leeds Teaching Hosp NHS Trust, Dept Infect & Travel Med, Leeds, W Yorkshire, England.; Otu, A (corresponding author), Univ Calabar, Coll Med Sci, Dept Internal Med, Calabar, Nigeria.	akanotu@yahoo.com	Ebenso, Dr. Bassey E./H-5536-2017; Ogoina, Dimie/H-4091-2019; Effa, Emmanuel Edet/AAA-6009-2022	Ebenso, Dr. Bassey E./0000-0003-4147-0968; Ogoina, Dimie/0000-0002-2098-6300; Effa, Emmanuel Edet/0000-0002-5654-2963; meseko, clement/0000-0001-7003-7528				Abdullahi IN, 2020, PROC SINGAP HEALTHC, V29, P190, DOI 10.1177/2010105820932616; [Anonymous], 2020, UN C TRAD DEV; Athingo R, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010012; Caminade C, 2019, ANN NY ACAD SCI, V1436, P157, DOI 10.1111/nyas.13950; Ebenso B, 2020, LANCET GLOB HEALTH, V8, pE770, DOI 10.1016/S2214-109X(20)30101-7; Elimian KO, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7559-6; Fasanmi O.G, 2020, ONE HLTH LANDSCAPE S; Gebreyes WA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003257; Hasler B, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.578649; Kamani TM, 2015, VET REC, V176, P496, DOI 10.1136/vr.h2461; Killewo J., 2017, INT ENCY PUBLIC HLTH, V2nd, P342; MacDonald AJ, 2019, P NATL ACAD SCI USA, V116, P22212, DOI 10.1073/pnas.1905315116; Okello AL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002884; Otu A, 2021, NAT MED, V27, P744, DOI 10.1038/s41591-021-01327-4; Otu A, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010339; Penrose K, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000631; Ren MH, 2018, LANCET GLOB HEALTH, V6, pE828, DOI 10.1016/S2214-109X(18)30302-4; Talisuna AO, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-019-0540-4; Yaya S, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00581-4; Zimmer Katarina., 2019, NATL GEOGR; Zinsstag J, 2012, ONDERSTEPOORT J VET, V79, DOI 10.4102/ojvr.v79i2.492	21	8	8	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					943	946		10.1038/s41591-021-01375-w	http://dx.doi.org/10.1038/s41591-021-01375-w		MAY 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34017135	Bronze, Green Accepted			2022-12-27	WOS:000652454300004
J	Rossman, H; Shilo, S; Meir, T; Gorfine, M; Shalit, U; Segal, E				Rossman, Hagai; Shilo, Smadar; Meir, Tomer; Gorfine, Malka; Shalit, Uri; Segal, Eran			COVID-19 dynamics after a national immunization program in Israel	NATURE MEDICINE			English	Article								A retrospective analysis of data from the Israeli Ministry of Health collected between 28 August 2020 and 24 February 2021 documents the real-life effect of a national vaccination campaign on the pandemic dynamics. Studies on the real-life effect of the BNT162b2 vaccine for Coronavirus Disease 2019 (COVID-19) prevention are urgently needed. In this study, we conducted a retrospective analysis of data from the Israeli Ministry of Health collected between 28 August 2020 and 24 February 2021. We studied the temporal dynamics of the number of new COVID-19 cases and hospitalizations after the vaccination campaign, which was initiated on 20 December 2020. To distinguish the possible effects of the vaccination on cases and hospitalizations from other factors, including a third lockdown implemented on 8 January 2021, we performed several comparisons: (1) individuals aged 60 years and older prioritized to receive the vaccine first versus younger age groups; (2) the January lockdown versus the September lockdown; and (3) early-vaccinated versus late-vaccinated cities. A larger and earlier decrease in COVID-19 cases and hospitalization was observed in individuals older than 60 years, followed by younger age groups, by the order of vaccination prioritization. This pattern was not observed in the previous lockdown and was more pronounced in early-vaccinated cities. Our analysis demonstrates the real-life effect of a national vaccination campaign on the pandemic dynamics.	[Rossman, Hagai; Shilo, Smadar; Meir, Tomer; Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel; [Rossman, Hagai; Shilo, Smadar; Meir, Tomer; Segal, Eran] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Shilo, Smadar] Rambam Hlth Care Campus, Inst Diabet Endocrinol & Metab, Pediat Diabet Clin, Haifa, Israel; [Gorfine, Malka] Tel Aviv Univ, Dept Stat & Operat Res, Ramat Aviv, Israel; [Shalit, Uri] Technion Israel Inst Technol, Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Rambam Health Care Campus; Tel Aviv University; Technion Israel Institute of Technology	Segal, E (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel.; Segal, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.; Gorfine, M (corresponding author), Tel Aviv Univ, Dept Stat & Operat Res, Ramat Aviv, Israel.; Shalit, U (corresponding author), Technion Israel Inst Technol, Haifa, Israel.	gorfinem@tauex.tau.ac.il; urishalit@technion.ac.il; eran.segal@weizmann.ac.il	Gorfine, Malka/AAV-1242-2021; Gorfine, Malka/AAD-1468-2022	Segal, Eran/0000-0002-6859-1164; Rossman, Hagai/0000-0002-5613-8004; Shilo, Smadar/0000-0003-2399-1866	Israeli Council for Higher Education via the Weizmann Data Science Research Center; Madame Olga Klein-Astrachan	Israeli Council for Higher Education via the Weizmann Data Science Research Center; Madame Olga Klein-Astrachan	We thank M. Bruhim, M. Goldberg and E. Sitbon for their contributions to our efforts. H.R. is supported by the Israeli Council for Higher Education via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein-Astrachan.	[Anonymous], 2021, TIMES ISRAEL    0109; Aran D., 2021, ESTIMATING REAL WORL, DOI [10.1101/2021.02.05.21251139v2, DOI 10.1101/2021.02.05.21251139V2]; Caspi G., 2021, SOCIOECONOMIC DISPAR, DOI [10.1101/2021.01.28.21250716v1, DOI 10.1101/2021.01.28.21250716V1]; Chodick G, 2021, EFFECTIVENESS 1 DOES, DOI [10.1101/2021.01.27.21250612v1, DOI 10.1101/2021.01.27.21250612V1]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271; Gazit D., 2021, 1 INDICATION EFFECT, DOI [10.1101/2021.02.02.21250630v1, DOI 10.1101/2021.02.02.21250630V1]; Gerlic M., 2021, RISE SARS COV 2 VARI, DOI [10.1101/2021.02.16.21251819v1, DOI 10.1101/2021.02.16.21251819V1]; Hanquet G, 2013, VACCINE, V31, P5634, DOI 10.1016/j.vaccine.2013.07.006; Iacobucci G, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n230; Lang PO, 2011, AGEING RES REV, V10, P389, DOI 10.1016/j.arr.2010.09.005; Mac Aogain Micheal, 2021, NAT MED, V27, P688, DOI [10.1038/s41591-021-01289-7, DOI 10.1038/S41591-021-01289-7, 10.1038/s41591-021-01659-1, DOI 10.1038/S41591-021-01337-2]; Ministry of Health, START TUESD 12 1 21; Ministry of Health, OP HOZR LEHAYIM EXP; Ministry of Health, BACK LIF VACC COR; Ministry of Health, 2021, MIN HLTH DIR GEN ORD; Ministry of Health, 2020, UN DEF SEV DIS HOSP; Ministry of Health, 18 POS SAMPL ENGL VA; National Institutes of Health, COVID 19 RES; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; Shilo S, 2021, NAT REV IMMUNOL, V21, P198, DOI 10.1038/s41577-021-00531-0; Tanne JH, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4799; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wise J, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4857	26	101	102	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1055	+		10.1038/s41591-021-01337-2	http://dx.doi.org/10.1038/s41591-021-01337-2		APR 2021	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	33875890	Green Submitted, Bronze			2022-12-27	WOS:000641244600001
J	Giordano, G; Colaneri, M; Di Filippo, A; Blanchini, F; Bolzern, P; De Nicolao, G; Sacchi, P; Colaneri, P; Bruno, R				Giordano, Giulia; Colaneri, Marta; Di Filippo, Alessandro; Blanchini, Franco; Bolzern, Paolo; De Nicolao, Giuseppe; Sacchi, Paolo; Colaneri, Patrizio; Bruno, Raffaele			Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy	NATURE MEDICINE			English	Article							COVID-19 VACCINE; NEW-ZEALAND	Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19)(1), population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model(2), which predicts the spread of SARS-CoV-2 infections, with a new data-based model that projects new cases onto casualties and healthcare system costs. Based on the Italian case study, we outline several scenarios: mass vaccination campaigns with different paces, different transmission rates due to new variants and different enforced countermeasures, including the alternation of opening and closure phases. Our results demonstrate that non-pharmaceutical interventions (NPIs) have a higher effect on the epidemic evolution than vaccination alone, advocating for the need to keep NPIs in place during the first phase of the vaccination campaign. Our model predicts that, from April 2021 to January 2022, in a scenario with no vaccine rollout and weak NPIs (R-0 = 1.27), as many as 298,000 deaths associated with COVID-19 could occur. However, fast vaccination rollouts could reduce mortality to as few as 51,000 deaths. Implementation of restrictive NPIs (R-0 = 0.9) could reduce COVID-19 deaths to 30,000 without vaccinating the population and to 18,000 with a fast rollout of vaccines. We also show that, if intermittent open-close strategies are adopted, implementing a closing phase first could reduce deaths (from 47,000 to 27,000 with slow vaccine rollout) and healthcare system costs, without substantive aggravation of socioeconomic losses.	[Giordano, Giulia] Univ Trento, Dept Ind Engn, Trento, Italy; [Colaneri, Marta; Di Filippo, Alessandro; Sacchi, Paolo; Bruno, Raffaele] Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, Pavia, Italy; [Blanchini, Franco] Univ Udine, Dipartimento Sci Matemat Informat & Fis, Udine, Italy; [Bolzern, Paolo; Colaneri, Patrizio] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy; [De Nicolao, Giuseppe] Univ Pavia, Dept Elect Comp & Biomed Engn, Pavia, Italy; [Colaneri, Patrizio] CNR, IEIIT, Milan, Italy; [Bruno, Raffaele] Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, Pavia, Italy	University of Trento; IRCCS Fondazione San Matteo; University of Udine; Polytechnic University of Milan; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Elettronica e di Ingegneria dell'Informazione e delle Telecomunicazioni (IEIIT-CNR); University of Pavia	Giordano, G (corresponding author), Univ Trento, Dept Ind Engn, Trento, Italy.	giulia.giordano@unitn.it	Giordano, Giulia/L-5209-2015; Colaneri, Marta/AAC-3198-2022; Bruno, Raffaele/AAB-9491-2022; Blanchini, Franco/A-6513-2008	Giordano, Giulia/0000-0002-8600-1738; Colaneri, Marta/0000-0002-5939-9576; Bruno, Raffaele/0000-0002-0235-9207; Blanchini, Franco/0000-0002-4109-5531	Italian grant PRIN 2017 'Monitoring and Control Underpinning the Energy-Aware Factory of the Future: Novel Methodologies and Industrial Validation' [2017YKXYXJ]; European Union [101016233]	Italian grant PRIN 2017 'Monitoring and Control Underpinning the Energy-Aware Factory of the Future: Novel Methodologies and Industrial Validation'; European Union(European Commission)	We acknowledge financial support through the Italian grant PRIN 2017 'Monitoring and Control Underpinning the Energy-Aware Factory of the Future: Novel Methodologies and Industrial Validation' (ID 2017YKXYXJ). This research has also received funding from the European Union's Horizon 2020 Research and Innovation Program 'PERISCOPE: Pan European Response to the ImpactS of COvid-19 and future Pandemics and Epidemics' under grant agreement no. 101016233, H2020-SC1-PHE-CORONAVIRUS-2020-2-RTD.	Abbasi K, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3093; Abbott S., 2021, LOCAL AREA REPROD NU; [Anonymous], 2021, TASK FORCE COVID 19; [Anonymous], 2020, MATLAB SYSTEM IDENTI; ANSA, 2021, 1 MODERNA VACCINE DO; ANSA, 2020, PFIZ VACC ARR IT; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bin M, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008604; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Burki T, 2021, LANCET, V397, P462, DOI 10.1016/S0140-6736(21)00298-1; Callaway E, 2021, NATURE, V589, P177, DOI 10.1038/d41586-021-00031-0; Cousins S, 2020, LANCET, V395, P1474, DOI 10.1016/S0140-6736(20)31097-7; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; D'Arienzo Marco, 2020, Biosaf Health, V2, P57, DOI 10.1016/j.bsheal.2020.03.004; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies Nicholas G, 2021, Science, V372, DOI 10.1126/science.abg3055; European Medicines Agency, 2021, COVID 19 VACCINE AST; Fontanet A, 2021, LANCET, V397, P952, DOI 10.1016/S0140-6736(21)00370-6; Fouda A, 2020, HEALTH POLICY TECHN, V9, P510, DOI 10.1016/j.hlpt.2020.08.015; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Giordano G, 2020, NAT MED, V26, P855, DOI 10.1038/s41591-020-0883-7; GOV.UK, CORONAVIRUS COVID 19; Grundel S, 2020, PREPRINT MEDRXIV, DOI 10.1101/2020.12.22.20248707; Horby P, 2021, NERVTAG NOTE B117 SE; Italian Ministry of Health, VACC ANTI SARS COV 2; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Lauring AS, 2021, JAMA-J AM MED ASSOC, V325, P529, DOI 10.1001/jama.2020.27124; Lopez Bernal J, 2021, PREPRINT MEDRXIV, DOI 10.1101/2021.03.01.21252652; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Ministero della salute (Italian Ministry of Health), 2020, VACCINAZIONE ANTISAR; MOORE JP, 2021, JAMA-J AM MED ASSOC; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Presidenza del Consiglio dei Ministri. Ministero della Salute, 2021, REPORT VACCINI ANTIC; Priesemann V, 2021, LANCET, V397, P469, DOI 10.1016/S0140-6736(21)00150-1; Priesemann V, 2021, LANCET, V397, P92, DOI 10.1016/S0140-6736(20)32625-8; RAMOS AM, 2021, PREPRINT RESEARCHGAT; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Reuters, 2020, ITALY KICKS VACCINAT; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Rypdal K, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249592; Starr Tyler N, 2021, Science, V371, P850, DOI [10.1101/2020.11.30.405472, 10.1126/science.abf9302]; Stasi C, 2020, EUR J PHARMACOL, V889, DOI 10.1016/j.ejphar.2020.173644; Tetteh J.N.A., 2020, PREPRINT MEDRXIV, DOI 10.1101/2020.12.22.20248693; U.S. Food and Drug Administration (FDA), 2021, VACC REL BIOL PROD A; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3	49	82	82	3	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					993	+		10.1038/s41591-021-01334-5	http://dx.doi.org/10.1038/s41591-021-01334-5		APR 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	33864052	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000640748100001
J	Gehrung, M; Crispin-Ortuzar, M; Berman, AG; O'Donovan, M; Fitzgerald, RC; Markowetz, F				Gehrung, Marcel; Crispin-Ortuzar, Mireia; Berman, Adam G.; O'Donovan, Maria; Fitzgerald, Rebecca C.; Markowetz, Florian			Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning	NATURE MEDICINE			English	Article							CLASSIFICATION	Deep learning methods have been shown to achieve excellent performance on diagnostic tasks, but how to optimally combine them with expert knowledge and existing clinical decision pathways is still an open challenge. This question is particularly important for the early detection of cancer, where high-volume workflows may benefit from (semi-)automated analysis. Here we present a deep learning framework to analyze samples of the Cytosponge-TFF3 test, a minimally invasive alternative to endoscopy, for detecting Barrett's esophagus, which is the main precursor of esophageal adenocarcinoma. We trained and independently validated the framework on data from two clinical trials, analyzing a combined total of 4,662 pathology slides from 2,331 patients. Our approach exploits decision patterns of gastrointestinal pathologists to define eight triage classes of varying priority for manual expert review. By substituting manual review with automated review in low-priority classes, we can reduce pathologist workload by 57% while matching the diagnostic performance of experienced pathologists. A clinician-in-the-loop deep learning system streamlines the workflow of pathologists for detection of Barrett's esophagus and retains the diagnostic accuracy of full manual review.	[Gehrung, Marcel; Crispin-Ortuzar, Mireia; Berman, Adam G.; Markowetz, Florian] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Gehrung, Marcel] Alan Turing Inst, London, England; [O'Donovan, Maria; Fitzgerald, Rebecca C.] Univ Cambridge, MRC Canc Unit, Cambridge, England; [O'Donovan, Maria] Cambridge Univ Hosp NHS Trust, Dept Pathol, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge	Markowetz, F (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.; Fitzgerald, RC (corresponding author), Univ Cambridge, MRC Canc Unit, Cambridge, England.	RCF29@MRC-CU.cam.ac.uk; florian.markowetz@cruk.cam.ac.uk		Fitzgerald, Rebecca/0000-0002-3434-3568; Gehrung, Marcel/0000-0001-6915-9552; Markowetz, Florian/0000-0002-2784-5308; Crispin-Ortuzar, Mireia/0000-0002-4351-3709	Cancer Research UK [C14303/A17197, 12088, 16893]; Medical Research Council [RG84369]; Cambridge University Hospitals NHS Foundation Trust; Alan Turing Institute; University of Cambridge; Trinity College, Cambridge; NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]; NIHR Cambridge Experimental Cancer Medicine Centre; UK National Institute for Health Research Cambridge Biomedical Research Centre, from Addenbrookes Hospital; Histopathology core facility at the Cancer Research UK Cambridge Institute; Pathognomics Ltd.	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cambridge University Hospitals NHS Foundation Trust; Alan Turing Institute; University of Cambridge(University of Cambridge); Trinity College, Cambridge; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Cambridge Experimental Cancer Medicine Centre; UK National Institute for Health Research Cambridge Biomedical Research Centre, from Addenbrookes Hospital; Histopathology core facility at the Cancer Research UK Cambridge Institute; Pathognomics Ltd.	This research was supported by Cancer Research UK (FM: C14303/A17197), the Medical Research Council (RCF: RG84369) and Cambridge University Hospitals NHS Foundation Trust. BEST2 was funded by Cancer Research UK (12088 and 16893). M.G. acknowledges support from an Enrichment Fellowship from the Alan Turing Institute. M.C.O. acknowledges support from a Borysiewicz Fellowship from the University of Cambridge and a Junior Research Fellowship from Trinity College, Cambridge. F.M. is a Royal Society Wolfson Research Merit Award holder. We thank M. Schneider, R. Drews, P. Martinez-Gonzalez and T. Whitmarsh for valuable input on this work. The authors thank the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and the Experimental Cancer Medicine Centre for their support and for providing the infrastructure for the research procedures in Cambridge. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. In addition, we thank the Human Research Tissue Bank, which is supported by the UK National Institute for Health Research Cambridge Biomedical Research Centre, from Addenbrookes Hospital. Finally, we thank the BEST2 trial team, the Histopathology core facility at the Cancer Research UK Cambridge Institute and Pathognomics Ltd. for their support.	Andrew Zisserman, 2015, Arxiv, DOI arXiv:1409.1556; BEJNORDI BE, 2014, MEDICAL IMAGING 2014; Bien N, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002699; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1; Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5; Courtiol P, 2019, NAT MED, V25, P1519, DOI 10.1038/s41591-019-0583-3; Cyr PR, 2008, AM FAM PHYSICIAN, V78, P735; Echle A, 2020, GASTROENTEROLOGY, V159, P1406, DOI 10.1053/j.gastro.2020.06.021; El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269; Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z; Fan XQ, 2009, DIGEST DIS SCI, V54, P572, DOI 10.1007/s10620-008-0395-7; Fitzgerald RC, 2020, LANCET, V396, P333, DOI 10.1016/S0140-6736(20)31099-0; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Freeman M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013901; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Hawkes N, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l408; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Hekler A, 2019, EUR J CANCER, V120, P114, DOI 10.1016/j.ejca.2019.07.019; Elizondo JLH, 2017, REV GASTROENTEROL ME, V82, P296, DOI 10.1016/j.rgmx.2017.01.006; Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243; Iizuka O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58467-9; Imperiale TF, 2014, NEW ENGL J MED, V370, P1287, DOI 10.1056/NEJMoa1311194; Kadri SR, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4372; Kather JN, 2020, NAT CANCER, V1, P789, DOI 10.1038/s43018-020-0087-6; Kather JN, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002730; Keutzer K, 2016, ARXIV160207360; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; Kyono T, 2020, J AM COLL RADIOL, V17, P56, DOI 10.1016/j.jacr.2019.05.012; Lao-Sirieix P, 2009, GUT, V58, P1451, DOI 10.1136/gut.2009.180281; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Liu MC, 2020, ANN ONCOL, V31, P745, DOI 10.1016/j.annonc.2020.02.011; Maung R, 2016, DIAGN HISTOPATHOL, V22, DOI [10.1016/j.mpdhp.2016.07.004, DOI 10.1016/J.MPDHP.2016.07.004]; Miotto R, 2018, BRIEF BIOINFORM, V19, P1236, DOI 10.1093/bib/bbx044; Mobadersany P, 2018, P NATL ACAD SCI USA, V115, pE2970, DOI 10.1073/pnas.1717139115; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; Odze R, 2018, DIGEST DIS SCI, V63, P2042, DOI 10.1007/s10620-018-5151-z; Paszke A, 2019, ADV NEUR IN, V32; Paterson AL, 2020, DIAGN CYTOPATHOL, V48, P253, DOI 10.1002/dc.24354; Peters Y, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0086-z; Pohl H, 2010, CANCER EPIDEM BIOMAR, V19, P1468, DOI 10.1158/1055-9965.EPI-10-0012; Rex DK, 2003, GASTROENTEROLOGY, V125, P1670, DOI 10.1053/j.gastro.2003.09.030; Ross-Innes CS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001780; Saillard C, 2020, HEPATOLOGY, V72, P2000, DOI 10.1002/hep.31207; Schiffman Joshua D, 2015, Am Soc Clin Oncol Educ Book, P57, DOI 10.14694/EdBook_AM.2015.35.57; Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7; Sharma P, 2006, GASTROENTEROLOGY, V131, P1392, DOI 10.1053/j.gastro.2006.08.032; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Spechler SJ, 2014, NEW ENGL J MED, V371, P836, DOI 10.1056/NEJMra1314704; Steiner DF, 2018, AM J SURG PATHOL, V42, P1636, DOI 10.1097/PAS.0000000000001151; Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308; Talbot I., 2006, BIOPSY PATHOLOGY COL; Tizhoosh, 2017 7 INT C IM PROC; Tschandl P, 2020, NAT MED, V26, P1229, DOI 10.1038/s41591-020-0942-0; Yu KH, 2018, NAT BIOMED ENG, V2, P719, DOI 10.1038/s41551-018-0305-z	55	25	26	3	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					833	+		10.1038/s41591-021-01287-9	http://dx.doi.org/10.1038/s41591-021-01287-9		APR 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33859411	Green Submitted			2022-12-27	WOS:000640483600004
J	Erdos, MR; Cabral, WA; Tavarez, UL; Cao, K; Gvozdenovic-Jeremic, J; Narisu, N; Zerfas, PM; Crumley, S; Boku, Y; Hanson, G; Mourich, DV; Kole, R; Eckhaus, MA; Gordon, LB; Collins, FS				Erdos, Michael R.; Cabral, Wayne A.; Tavarez, Urraca L.; Cao, Kan; Gvozdenovic-Jeremic, Jelena; Narisu, Narisu; Zerfas, Patricia M.; Crumley, Stacy; Boku, Yoseph; Hanson, Gunnar; Mourich, Dan V.; Kole, Ryszard; Eckhaus, Michael A.; Gordon, Leslie B.; Collins, Francis S.			A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome	NATURE MEDICINE			English	Article								Hutchinson-Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder characterized by premature death from myocardial infarction or stroke. It is caused by de novo single-nucleotide mutations in the LMNA gene that activate a cryptic splice donor site, resulting in the production of a toxic form of lamin A, which is termed progerin. Here we present a potential genetic therapeutic strategy that utilizes antisense peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) to block pathogenic splicing of mutant transcripts. Of several candidates, PPMO SRP-2001 provided the most significant decrease in progerin transcripts in patient fibroblasts. Intravenous delivery of SRP-2001 to a transgenic mouse model of HGPS produced significant reduction of progerin transcripts in the aorta, a particularly critical target tissue in HGPS. Long-term continuous treatment with SRP-2001 yielded a 61.6% increase in lifespan and rescue of vascular smooth muscle cell loss in large arteries. These results provide a rationale for proceeding to human trials. A modified antisense oligonucleotide that blocks pathogenic splicing of progeria transcripts reduces the production of progerin in key target organs and extends animal lifespan in mouse model of progeria syndrome.	[Erdos, Michael R.; Cabral, Wayne A.; Tavarez, Urraca L.; Gvozdenovic-Jeremic, Jelena; Narisu, Narisu; Boku, Yoseph; Collins, Francis S.] NHGRI, Mol Genet Sect, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA; [Cao, Kan] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; [Zerfas, Patricia M.; Eckhaus, Michael A.] NIH, Diagnost & Res Serv Branch, Div Vet Resources, Off Res Serv, Bldg 10, Bethesda, MD 20892 USA; [Crumley, Stacy; Hanson, Gunnar; Kole, Ryszard] Sarepta Therapeut Inc, Cambridge, MA USA; [Mourich, Dan V.] Oregon State Univ, Dept Vet Hlth Sci, Corvallis, OR 97331 USA; [Kole, Ryszard] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA; [Gordon, Leslie B.] Brown Univ, Dept Pediat, Hasbro Childrens Hosp, Providence, RI 02912 USA; [Gordon, Leslie B.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Gordon, Leslie B.] Boston Childrens Hosp, Dept Anesthesiol Preoperat & Pain Med, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; Oregon State University; University of North Carolina; University of North Carolina Chapel Hill; Brown University; Hasbro Children's Hospital; Brown University; Harvard University; Boston Children's Hospital	Collins, FS (corresponding author), NHGRI, Mol Genet Sect, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA.	collinsf@mail.nih.gov	Gordon, Leslie B./AAJ-5793-2021	Boku, Yoseph/0000-0002-6560-6607; Narisu, Narisu/0000-0002-8483-1156; Tavarez, Urraca/0000-0002-2577-5377				Aljada A, 2016, CELL ONCOL, V39, P161, DOI 10.1007/s13402-015-0265-1; Burke B, 2013, NAT REV MOL CELL BIO, V14, P13, DOI 10.1038/nrm3488; Cao K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002346; Capell BC, 2006, NAT REV GENET, V7, P940, DOI 10.1038/nrg1906; Cubria MB, 2020, P NATL ACAD SCI USA, V117, P12029, DOI 10.1073/pnas.1906713117; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Dechat T, 2008, GENE DEV, V22, P832, DOI 10.1101/gad.1652708; Dreesen O, 2013, J CELL BIOL, V200, P605, DOI 10.1083/jcb.201206121; Echigoya Y, 2017, P NATL ACAD SCI USA, V114, P4213, DOI 10.1073/pnas.1613203114; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Evangelisti C, 2016, BRIT J CLIN PHARMACO, V82, P1229, DOI 10.1111/bcp.12928; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Gerhard-Herman M, 2012, HYPERTENSION, V59, P92, DOI 10.1161/HYPERTENSIONAHA.111.180919; Gordon LB, 2018, JAMA-J AM MED ASSOC, V319, P1687, DOI 10.1001/jama.2018.3264; Gordon LB, 2014, CIRCULATION, V130, P27, DOI 10.1161/CIRCULATIONAHA.113.008285; Gordon LB, 2012, P NATL ACAD SCI USA, V109, P16666, DOI 10.1073/pnas.1202529109; Guo YX, 2014, MOL BIOL CELL, V25, P1287, DOI 10.1091/mbc.E13-11-0644; Hanson G.J, US Patent, Patent No. [US9161948, 9161948]; Harhouri K, 2018, NUCLEUS-PHILA, V9, P246, DOI 10.1080/19491034.2018.1460045; Hennekam RCM, 2006, AM J MED GENET A, V140A, P2603, DOI 10.1002/ajmg.a.31346; Jearawiriyapaisarn N, 2008, MOL THER, V16, P1624, DOI 10.1038/mt.2008.120; Kole R, 2015, ADV DRUG DELIVER REV, V87, P104, DOI 10.1016/j.addr.2015.05.008; Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002; Maharshi V, 2017, CLIN DRUG INVEST, V37, P807, DOI 10.1007/s40261-017-0557-5; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Olive M, 2010, ARTERIOSCL THROM VAS, V30, P2301, DOI 10.1161/ATVBAHA.110.209460; Osorio FG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002847; Rusinol AE, 2006, J CELL SCI, V119, P3265, DOI 10.1242/jcs.03156; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Sazani P, 2001, NUCLEIC ACIDS RES, V29, P3965, DOI 10.1093/nar/29.19.3965; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111; Skvortsov S, 2011, J PROTEOME RES, V10, P259, DOI 10.1021/pr100921j; Stehbens WE, 2001, CARDIOVASC PATHOL, V10, P133, DOI 10.1016/S1054-8807(01)00069-2; Syed YY, 2016, DRUGS, V76, P1699, DOI 10.1007/s40265-016-0657-1; Tsai MY, 2006, SCIENCE, V311, P1887, DOI 10.1126/science.1122771; Van Berlo JH, 2005, HUM MOL GENET, V14, P2839, DOI 10.1093/hmg/ddi316; Varga R, 2006, P NATL ACAD SCI USA, V103, P3250, DOI 10.1073/pnas.0600012103; Wu D, 2016, NUCLEUS-PHILA, V7, P585, DOI 10.1080/19491034.2016.1260803; Young SG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005229	42	22	22	1	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					536	+		10.1038/s41591-021-01274-0	http://dx.doi.org/10.1038/s41591-021-01274-0		MAR 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33707773				2022-12-27	WOS:000627703000003
J	Hassan, I; Mukaigawara, M; King, L; Fernandes, G; Sridhar, D				Hassan, Ines; Mukaigawara, Mitsuru; King, Lois; Fernandes, Genevie; Sridhar, Devi			Hindsight is 2020? Lessons in global health governance one year into the pandemic	NATURE MEDICINE			English	Article								Fourteen months into the SARS-CoV-2 pandemic, we identify key lessons in the global and national responses to the pandemic. The World Health Organization has played a pivotal technical, normative and coordinating role, but has been constrained by its lack of authority over sovereign member states. Many governments also mistakenly attempted to manage COVID-19 like influenza, resulting in repeated lockdowns, high excess morbidity and mortality, and poor economic recovery. Despite the incredible speed of the development and approval of effective and safe vaccines, the emergence of new SARS-CoV-2 variants means that all countries will have to rely on a globally coordinated public health effort for several years to defeat this pandemic. Global coordination of public health efforts will be needed to defeat the COVID-19 pandemic and to prepare for future public health emergencies.	[Hassan, Ines; King, Lois; Fernandes, Genevie; Sridhar, Devi] Univ Edinburgh, Edinburgh Med Sch, Global Hlth Governance Programme, Edinburgh, Midlothian, Scotland; [Mukaigawara, Mitsuru] Harvard Kennedy Sch, Cambridge, MA USA; [Mukaigawara, Mitsuru] Okinawa Chubu Hosp, Div Infect Dis, Dept Med, Uruma, Okinawa, Japan	University of Edinburgh; Harvard University; Okinawa Chubu Central Hospital	Sridhar, D (corresponding author), Univ Edinburgh, Edinburgh Med Sch, Global Hlth Governance Programme, Edinburgh, Midlothian, Scotland.	devi.sridhar@ed.ac.uk	Mukaigawara, Mitsuru/L-2144-2016	Mukaigawara, Mitsuru/0000-0001-6530-2083; King, Lois/0000-0002-9319-7089				Albeck-Ripka L., 2020, NEW YORK TIMES; [Anonymous], 2020, NEW ENGL J MED, V383, P1479, DOI 10.1056/NEJMe2029812; [Anonymous], 2020, COMMUNICATION 0529; [Anonymous], 2021, INDEPENDENT PANEL PA; [Anonymous], 2021, ECONOMIST 0123; Baker MG, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4907; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Brooks JT, 2020, JAMA-J AM MED ASSOC, V324, P635, DOI 10.1001/jama.2020.13107; Callaway E, 2021, NATURE, V589, P177, DOI 10.1038/d41586-021-00031-0; Cameron-Blake E., 2020, VARIATION RESPONSE C; Centers for Disease Control and Prevention, 2020, PROT YOURS OTH; Centers for Disease Control and Prevention, 2020, SCI BRIEF SARS COV 2; Clinton C, 2017, LANCET, V390, P324, DOI 10.1016/S0140-6736(16)32402-3; Correia S, 2020, ELECT J, DOI DOI 10.2139/SSRN.3561560; Cutler DM, 2020, JAMA-J AM MED ASSOC, V324, P1495, DOI 10.1001/jama.2020.19759; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Emergency and Health Protection Directorate, 2020, COR ACT PLAN GUID WH; Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Gallagher J, BBC NEWS; Gilsinan Kathy, 2020, ATLANTIC; Gostin LO, 2015, PUBLIC HEALTH, V129, P854, DOI 10.1016/j.puhe.2015.05.002; Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2361, DOI [10.1001/jama.2020.8486, 10.1001/jamahealthforum.2020.0559]; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Horton R, 2020, LANCET, V395, P935, DOI 10.1016/S0140-6736(20)30669-3; International Health Conference, 2002, Bull World Health Organ, V80, P983; International Monetary Fund, 2020, WORLD EC OUTL LONG D; Jefferies S, 2020, LANCET PUBLIC HEALTH, V5, pE612, DOI 10.1016/S2468-2667(20)30225-5; Joseph A., SCI MONITOR CORONAVI; Kaminska I., 2020, FINANCIAL TIMES 0602; Kayo T, 2020, ASIA-PAC REV, V27, P46, DOI 10.1080/13439006.2020.1841949; Kupferschmidt K, 2020, SCIENCE, V370, P1395, DOI 10.1126/science.370.6523.1395; Kuznetsova L, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00470; Legge DG, 2020, GLOB SOC POLICY, V20, P383, DOI 10.1177/1468018120966659; Lehmann C., 2020, MANY METRICS MEASURE; Lu GY, 2021, GLOBAL HEALTH ACTION, V14, DOI 10.1080/16549716.2021.1875601; Ma JX, 2021, CLIN INFECT DIS, V72, pE652, DOI 10.1093/cid/ciaa1283; Oliver, 2020, LONG TERM EFF COVID, V13, P12; Paton C, 2022, HEALTH ECON POLICY L, V17, P238, DOI 10.1017/S174413312000033X; Pavlik Melissa, 2020, GREAT SUDDEN CHANGE; Phelan AL, 2020, GOVERNANCE PREPAREDN; Richardson J, 2003, HEALTH ECON, V12, P355, DOI 10.1002/hec.761; Safi M., GUARDIAN 0122; Scally G, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1932; Soy A, 2021, CNN 0122; Sridhar D, 2020, NAT MED, V26, P1812, DOI 10.1038/s41591-020-01170-z; Summers Lawrence, 2020, WASH POST; Trout LJ, 2020, FRONT SOCIOL, V5, DOI 10.3389/fsoc.2020.579991; Tworek H., 2020, DEMOCRATIC HLTH COMM; UK data on hospital capacity and occupancy, 2020, UK DAT HOSP CAP OCC; US Department of Health and Human Services, 2021, COVID 19 REP PAT IMP; Vaughan R., 2021, PRITI PATEL BLAMES M; Wenham C, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0307; WHO, 2020, LIST WHOS RESP COV 1; WHO-China Joint Mission Members, 2020, REP WHO CHIN JOINT M; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2020, TRANSM SARS COV2 IMP; World Health Organization (WHO), 2016, INT HLTH REG 2005; Yamaguchi M., 2020, AP NEWS 0408	61	12	12	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					396	400		10.1038/s41591-021-01272-2	http://dx.doi.org/10.1038/s41591-021-01272-2			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723454	Green Accepted, Bronze			2022-12-27	WOS:000629708300017
J	Hsu, NS; Hendriks, S; Ramos, KM; Grady, C				Hsu, Nina S.; Hendriks, Saskia; Ramos, Khara M.; Grady, Christine			Ethical considerations of COVID-19-related adjustments to clinical research	NATURE MEDICINE			English	Editorial Material								Unexpected direct and indirect risks of participating in clinical trials have emerged during COVID-19 that investigators and institutional review boards may not be sure how to investigate. How should existing guidance and ethical frameworks for clinical trials be applied in a pandemic setting?	[Hsu, Nina S.; Hendriks, Saskia; Ramos, Khara M.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Hendriks, Saskia; Grady, Christine] NIH, Dept Bioeth, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Hsu, NS (corresponding author), NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	nina.hsu@nih.gov			Intramural Research Program of the NIH	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank the members of the NIH BRAIN Initiative Neuroethics Working Group, meeting presenters (M. Franceschini, L. Hochberg and S. Sheth) and the participants and organizers of the neuroethics-focused session at the BRAIN Initiative Investigators Meeting. This research was supported in part by the Intramural Research Program of the NIH. The views expressed are the authors' own and do not necessarily reflect those of the National Institutes of Health, the Department of Health and Human Services, or the United States government.	Byrd JB, 2020, CIRCULATION, V141, P2045, DOI 10.1161/CIRCULATIONAHA.120.047347; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Gilbertson A, 2019, AIDS RES HUM RETROV, V35, P100, DOI [10.1089/AID.2017.0224, 10.1089/aid.2017.0224]; hhs, 1979, BELM REP ETH PRINC G; Kim SYH, 2020, NEUROLOGY, V94, P1007, DOI 10.1212/WNL.0000000000009520; King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x; Kostick K, 2020, BRAIN STIMUL, V13, P1642, DOI 10.1016/j.brs.2020.09.023; Nycum G, 2007, KENNEDY INST ETHIC J, V17, P321; Shuman AG, 2020, ONCOLOGIST, V25, P458, DOI 10.1634/theoncologist.2020-0221; Taubenberger JK, 2007, JAMA-J AM MED ASSOC, V297, P2025, DOI 10.1001/jama.297.18.2025; Wendler D, 2019, CRIT CARE MED, V47, P149, DOI 10.1097/CCM.0000000000003503; Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067	12	6	6	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					191	193		10.1038/s41591-020-01216-2	http://dx.doi.org/10.1038/s41591-020-01216-2		JAN 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33495603	Bronze			2022-12-27	WOS:000611467500001
J	Ding, XB; Wang, XX; Xia, DH; Liu, H; Tian, HY; Fu, Y; Chen, YK; Qin, C; Wang, JQ; Xiang, Z; Zhang, ZX; Cao, QC; Wang, W; Li, JY; Wu, EX; Tang, BS; Ma, MM; Teng, JF; Wang, XJ				Ding, Xue-Bing; Wang, Xin-Xin; Xia, Dan-Hao; Liu, Han; Tian, Hai-Yan; Fu, Yu; Chen, Yong-Kang; Qin, Chi; Wang, Jiu-Qi; Xiang, Zhi; Zhang, Zhong-Xian; Cao, Qin-Chen; Wang, Wei; Li, Jia-Yi; Wu, Erxi; Tang, Bei-Sha; Ma, Ming-Ming; Teng, Jun-Fang; Wang, Xue-Jing			Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease	NATURE MEDICINE			English	Article							CLEARANCE PATHWAYS; GLYMPHATIC SYSTEM; RATING-SCALE; BRAIN; DIAGNOSIS; VALIDATION; MOTION; MODEL	Animal studies implicate meningeal lymphatic dysfunction in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (PD). However, there is no direct evidence in humans to support this role(1-5). In this study, we used dynamic contrast-enhanced magnetic resonance imaging to assess meningeal lymphatic flow in cognitively normal controls and patients with idiopathic PD (iPD) or atypical Parkinsonian (AP) disorders. We found that patients with iPD exhibited significantly reduced flow through the meningeal lymphatic vessels (mLVs) along the superior sagittal sinus and sigmoid sinus, as well as a notable delay in deep cervical lymph node perfusion, compared to patients with AP. There was no significant difference in the size (cross-sectional area) of mLVs in patients with iPD or AP versus controls. In mice injected with alpha-synuclein (alpha-syn) preformed fibrils, we showed that the emergence of alpha-syn pathology was followed by delayed meningeal lymphatic drainage, loss of tight junctions among meningeal lymphatic endothelial cells and increased inflammation of the meninges. Finally, blocking flow through the mLVs in mice treated with alpha-syn preformed fibrils increased alpha-syn pathology and exacerbated motor and memory deficits. These results suggest that meningeal lymphatic drainage dysfunction aggravates alpha-syn pathology and contributes to the progression of PD.	[Ding, Xue-Bing; Wang, Xin-Xin; Xia, Dan-Hao; Liu, Han; Tian, Hai-Yan; Fu, Yu; Chen, Yong-Kang; Qin, Chi; Wang, Jiu-Qi; Xiang, Zhi; Teng, Jun-Fang; Wang, Xue-Jing] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Peoples R China; [Ding, Xue-Bing; Wang, Xin-Xin; Xia, Dan-Hao; Liu, Han; Tian, Hai-Yan; Fu, Yu; Chen, Yong-Kang; Qin, Chi; Wang, Jiu-Qi; Xiang, Zhi; Teng, Jun-Fang; Wang, Xue-Jing] Zhengzhou Univ, Inst Parkinson & Movement Disorder, Zhengzhou, Peoples R China; [Zhang, Zhong-Xian] Zhengzhou Univ, Acad Med Sci, Natl Ctr Int Res Cell & Gene Therapy, Zhengzhou, Peoples R China; [Cao, Qin-Chen] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiat Therapy, Zhengzhou, Peoples R China; [Wang, Wei] Henan Med Assoc, Zhengzhou, Peoples R China; [Li, Jia-Yi] Lund Univ, Dept Expt Med Sci, Wallenberg Neurosci Ctr, Neural Plast & Repair Unit, Lund, Sweden; [Li, Jia-Yi] China Med Univ, Inst Hlth Sci, Shenyang, Peoples R China; [Wu, Erxi] Baylor Scott & White Hlth, Neurosci Inst, Temple, TX USA; [Wu, Erxi] Baylor Scott & White Hlth, Dept Neurosurg, Temple, TX USA; [Wu, Erxi] Texas A&M Univ, Coll Med & Pharm, College Stn, TX USA; [Wu, Erxi] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78712 USA; [Wu, Erxi] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX 78712 USA; [Tang, Bei-Sha] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha, Peoples R China; [Tang, Bei-Sha] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China; [Ma, Ming-Ming] Zhengzhou Univ, Henan Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Neurol, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University; Lund University; China Medical University; Baylor Health Care System; Baylor Health Care System; Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Central South University; Central South University; Zhengzhou University	Teng, JF; Wang, XJ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Peoples R China.; Teng, JF; Wang, XJ (corresponding author), Zhengzhou Univ, Inst Parkinson & Movement Disorder, Zhengzhou, Peoples R China.; Ma, MM (corresponding author), Zhengzhou Univ, Henan Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Neurol, Zhengzhou, Peoples R China.	macklon12@zzu.edu.cn; 13838210077@163.com; fccwangxj2@zzu.edu.cn	Xia, Danhao/AAC-3578-2021; Wang, Xin/AAN-8435-2021	Xia, Danhao/0000-0001-9505-2521; Wang, Xin/0000-0002-4457-7376; Ding, Xuebing/0000-0003-4827-4548; Tian, Hai-yan/0000-0002-7452-1007; liu, liu han/0000-0002-2224-1652	National Natural Science Foundation of China [81671267]; Natural Science Foundation of Henan Province for Excellent Young Scholars [202300410357]; National Key Plan for Scientific Research and Development of China [2016YFC1306000]; Swedish Research Council [2019-01551]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Henan Province for Excellent Young Scholars; National Key Plan for Scientific Research and Development of China; Swedish Research Council(Swedish Research CouncilEuropean Commission)	X.-J.W. was supported by grants from the National Natural Science Foundation of China (no. 81873791, 81471307) and the Natural Science Foundation of Henan Province for Excellent Young Scholars (no. 202300410357). J.-F.T. was supported by grants from the National Natural Science Foundation of China (no. 81671267). B.-S.T. was supported by the National Key Plan for Scientific Research and Development of China (no. 2016YFC1306000). J.-Y.L. was supported by the Swedish Research Council (2019-01551). We thank all our collaborators at the First Affiliated Hospital of Zhengzhou University for their assistance with imaging examinations. Specially, we thank Y. Li for her excellent technical support and we also appreciate Z. Yang and L. Zhou's assistance with image processing and Euni Wu's efforts for language editing.	Ahn JH, 2019, NATURE, V572, P62, DOI 10.1038/s41586-019-1419-5; Antila S, 2017, J EXP MED, V214, P3645, DOI 10.1084/jem.20170391; Armstrong MJ, 2013, NEUROLOGY, V80, P496, DOI 10.1212/WNL.0b013e31827f0fd1; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Azuma M, 2015, MAGN RESON MED SCI, V14, P285, DOI 10.2463/mrms.2014-0120; Bazin PL, 2007, J NEUROSCI METH, V165, P111, DOI 10.1016/j.jneumeth.2007.05.024; Bolte AC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18113-4; Bou-Assaly W., 2016, J RADIOL IMAGING, V1, P9, DOI [10.14312/2399-8172.2016-3, DOI 10.14312/2399-8172.2016-3]; Bower NI, 2018, J MOL MED, V96, P383, DOI 10.1007/s00109-018-1634-9; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Coles JA, 2017, PROG NEUROBIOL, V156, P107, DOI 10.1016/j.pneurobio.2017.05.002; Cromer WE, 2014, ANGIOGENESIS, V17, P395, DOI 10.1007/s10456-013-9393-2; Da Mesquita S, 2018, NEURON, V100, P375, DOI 10.1016/j.neuron.2018.09.022; Da Mesquita S, 2018, NATURE, V560, P185, DOI 10.1038/s41586-018-0368-8; Ding XB, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101166; Dohgu S, 2019, MICROVASC RES, V124, P61, DOI 10.1016/j.mvr.2019.03.005; Eide PK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25666-4; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gilman S, 2008, NEUROLOGY, V70, pA229, DOI 10.1212/01.wnl.0000324625.00404.15; Goetz CG, 2003, MOVEMENT DISORD, V18, P738, DOI 10.1002/mds.10473; Golbe LI, 2007, BRAIN, V130, P1552, DOI 10.1093/brain/awm032; Greene DJ, 2018, NEUROIMAGE, V171, P234, DOI 10.1016/j.neuroimage.2018.01.023; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987; Hsu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08163-0; Hu XT, 2020, CELL RES, V30, P229, DOI 10.1038/s41422-020-0287-8; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Kuan WL, 2016, EXP NEUROL, V285, P72, DOI 10.1016/j.expneurol.2016.09.003; Lindholm B, 2016, J NEUROL, V263, P2462, DOI 10.1007/s00415-016-8287-9; Louveau A, 2018, NAT NEUROSCI, V21, P1380, DOI 10.1038/s41593-018-0227-9; Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; MA Q, 2017, NAT COMMUN, V8, DOI [DOI 10.1038/S41467-017-01484-6, 10.1038/s41467-017-01484-6]; Maloveska M, 2018, NEUROL RES, V40, P372, DOI 10.1080/01616412.2018.1446282; Nistal D, 2018, WORLD NEUROSURG, V109, P449, DOI 10.1016/j.wneu.2017.11.028; Ogul H, 2020, WORLD NEUROSURG, V135, DOI 10.1016/j.wneu.2019.12.016; Ondas O, 2020, OPHTHALMIC RES, V63, P341, DOI 10.1159/000502980; Patel TK, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0312-x; Peelaerts W, 2018, CELL TISSUE RES, V373, P195, DOI 10.1007/s00441-018-2839-5; Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424; Rasmussen MK, 2018, LANCET NEUROL, V17, P1016, DOI 10.1016/S1474-4422(18)30318-1; Reeves BC, 2020, TRENDS MOL MED, V26, P285, DOI 10.1016/j.molmed.2019.11.008; Rektor I, 2006, J NEUROL SCI, V248, P185, DOI 10.1016/j.jns.2006.05.026; Seitz J, 2000, INVEST RADIOL, V35, P380, DOI 10.1097/00004424-200006000-00007; Shahnawaz M, 2020, NATURE, V578, P273, DOI 10.1038/s41586-020-1984-7; Sun BL, 2018, PROG NEUROBIOL, V163, P118, DOI 10.1016/j.pneurobio.2017.08.007; Tan PWW, 2016, ANN PLAS SURG, V76, P117, DOI 10.1097/SAP.0000000000000582; Tang Hui, 2019, Zhongguo Yi Liao Qi Xie Za Zhi, V43, P326, DOI 10.3969/j.issn.1671-7104.2019.05.004; Tarasoff-Conway JM, 2015, NAT REV NEUROL, V11, P457, DOI 10.1038/nrneurol.2015.119; Valenza M, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01656; Van der Perren A, 2020, ACTA NEUROPATHOL, V139, P977, DOI 10.1007/s00401-020-02157-3; Wang LM, 2019, BRAIN PATHOL, V29, P176, DOI 10.1111/bpa.12656; Wang X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15476-6; Weller RO, 2009, ACTA NEUROPATHOL, V117, P1, DOI 10.1007/s00401-008-0457-0; Wen YR, 2018, NEURAL REGEN RES, V13, P709, DOI 10.4103/1673-5374.230299; Wenning GK, 2004, MOVEMENT DISORD, V19, P1391, DOI 10.1002/mds.20255; Yamada M, 2020, J MOV DISORD, V13, P1, DOI 10.14802/jmd.19052; Yoo JE, 2020, MOVEMENT DISORD, V35, P1263, DOI 10.1002/mds.28055; Zou WY, 2019, TRANSL NEURODEGENER, V8, DOI 10.1186/s40035-019-0147-y	58	58	60	18	87	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					411	+		10.1038/s41591-020-01198-1	http://dx.doi.org/10.1038/s41591-020-01198-1		JAN 2021	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33462448				2022-12-27	WOS:000608674100001
J	Lotter, W; Diab, AR; Haslam, B; Kim, JG; Grisot, G; Wu, E; Wu, K; Onieva, JO; Boyer, Y; Boxerman, JL; Wang, MY; Bandler, M; Vijayaraghavan, GR; Sorensen, AG				Lotter, William; Diab, Abdul Rahman; Haslam, Bryan; Kim, Jiye G.; Grisot, Giorgia; Wu, Eric; Wu, Kevin; Onieva, Jorge Onieva; Boyer, Yun; Boxerman, Jerrold L.; Wang, Meiyun; Bandler, Mack; Vijayaraghavan, Gopal R.; Gregory Sorensen, A.			Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	NATURE MEDICINE			English	Article							COMPUTER-AIDED DETECTION; PERFORMANCE BENCHMARKS; SYSTEM	Breast cancer remains a global challenge, causing over 600,000 deaths in 2018 (ref. (1)). To achieve earlier cancer detection, health organizations worldwide recommend screening mammography, which is estimated to decrease breast cancer mortality by 20-40% (refs. (2,3)). Despite the clear value of screening mammography, significant false positive and false negative rates along with non-uniformities in expert reader availability leave opportunities for improving quality and access(4,5). To address these limitations, there has been much recent interest in applying deep learning to mammography(6-18), and these efforts have highlighted two key difficulties: obtaining large amounts of annotated training data and ensuring generalization across populations, acquisition equipment and modalities. Here we present an annotation-efficient deep learning approach that (1) achieves state-of-the-art performance in mammogram classification, (2) successfully extends to digital breast tomosynthesis (DBT; '3D mammography'), (3) detects cancers in clinically negative prior mammograms of patients with cancer, (4) generalizes well to a population with low screening rates and (5) outperforms five out of five full-time breast-imaging specialists with an average increase in sensitivity of 14%. By creating new 'maximum suspicion projection' (MSP) images from DBT data, our progressively trained, multiple-instance learning approach effectively trains on DBT exams using only breast-level labels while maintaining localization-based interpretability. Altogether, our results demonstrate promise towards software that can improve the accuracy of and access to screening mammography worldwide.	[Lotter, William; Diab, Abdul Rahman; Haslam, Bryan; Kim, Jiye G.; Grisot, Giorgia; Wu, Eric; Wu, Kevin; Onieva, Jorge Onieva; Boyer, Yun; Gregory Sorensen, A.] DeepHealth Inc, RadNet AI Solut, Cambridge, MA 02139 USA; [Boxerman, Jerrold L.] Rhode Isl Hosp, Dept Diagnost Imaging, Providence, RI USA; [Boxerman, Jerrold L.] Brown Univ, Alpert Med Sch, Dept Diagnost Imaging, Providence, RI 02912 USA; [Wang, Meiyun] Henan Prov Peoples Hosp, Dept Med Imaging, Zhengzhou, Henan, Peoples R China; [Bandler, Mack] Medford Radiol Grp, Medford, OR USA; [Vijayaraghavan, Gopal R.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA USA; [Wu, Eric] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; [Wu, Kevin] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Zhengzhou University; University of Massachusetts System; University of Massachusetts Worcester; Stanford University; Stanford University	Lotter, W; Sorensen, AG (corresponding author), DeepHealth Inc, RadNet AI Solut, Cambridge, MA 02139 USA.	wlotter@deep.health; asorensen@deep.health		Boxerman, Jerrold/0000-0002-0594-1542	National Cancer Institute [1R37CA240403-01A1, 1R44CA240022-01A1]; National Science Foundation [SBIR 1938387]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation(National Science Foundation (NSF))	We are grateful to S. Venkataraman, E. Ghosh, A. Newburg, M. Tyminski and N. Amornsiripanitch for participation in the study. We also thank C. Lee, D. Kopans, E. Pisano, P. Golland and J. Holt for guidance and valuable discussions. We additionally thank T. Witzel, I. Swofford, M. Tomlinson, J. Roubil, J. Watkins, Y. Wu, H. Tan and S. Vedantham for assistance in data acquisition and processing. This work was supported in part by grants from the National Cancer Institute (1R37CA240403-01A1 and 1R44CA240022-01A1) and the National Science Foundation (SBIR 1938387) received by DeepHealth. All of the non-public datasets used in the study were collected retrospectively and de-identified under IRB-approved protocols in which informed consent was waived.	Bae Jong-Myon, 2016, J Prev Med Public Health, V49, P367; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Bowser D, 2017, PUBLIC HEALTH, V152, P58, DOI 10.1016/j.puhe.2017.07.020; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Conant EF, 2019, RADIOL-ARTIF INTELL, V1, DOI 10.1148/ryai.2019180096; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Deng J., 2009, PROC CVPR IEEE, P248, DOI DOI 10.1109/CVPR.2009.5206848; Evans KK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064366; Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9; Fenton JJ, 2007, NEW ENGL J MED, V356, P1399, DOI 10.1056/NEJMoa066099; Gallas BD, 2019, J MED IMAGING, V6, DOI 10.1117/1.JMI.6.1.015501; Geras K. J., 2017, HIGH RESOLUTION BREA; Halling-Brown M. D, 2020, OPTIMAM MAMMOGRAPHY; Hart D, 1998, BRIT J CANCER, V78, P382, DOI 10.1038/bjc.1998.503; Heath M, 2001, IWDM 2000: 5TH INTERNATIONAL WORKSHOP ON DIGITAL MAMMOGRAPHY, P212; Henriksen EL, 2019, ACTA RADIOL, V60, P13, DOI 10.1177/0284185118770917; Hoff SR, 2011, ACAD RADIOL, V18, P454, DOI 10.1016/j.acra.2010.11.014; Ikeda DM, 2003, RADIOLOGY, V226, P494, DOI 10.1148/radiol.2262011634; Kaiming He, 2016, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), P770, DOI 10.1109/CVPR.2016.90; Kim HE, 2020, LANCET DIGIT HEALTH, V2, pE138, DOI 10.1016/S2589-7500(20)30003-0; Kingma DP., 2014, ADAM METHOD STOCHAST; Kooi T, 2017, MED IMAGE ANAL, V35, P303, DOI 10.1016/j.media.2016.07.007; Kopans DB, 2014, AM J ROENTGENOL, V202, P299, DOI 10.2214/AJR.13.11520; Lehman CD, 2016, JAMA INTERN MED, V33, P839; Lehman CD, 2017, RADIOLOGY, V283, P49, DOI 10.1148/radiol.2016161174; Lin Tsung-Yi, 2020, IEEE Trans Pattern Anal Mach Intell, V42, P318, DOI 10.1109/TPAMI.2018.2858826; Lotter W., 2017, DEEP LEARNING MED IM; Majid AS, 2003, RADIOGRAPHICS, V23, P881, DOI 10.1148/rg.234025083; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Park SH, 2019, RADIOLOGY, V290, P272, DOI 10.1148/radiol.2018182294; Ribli D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22437-z; Rodriguez-Ruiz A, 2019, JNCI-J NATL CANCER I, V111, P916, DOI 10.1093/jnci/djy222; Rodriguez-Ruiz A, 2019, RADIOLOGY, V290, P305, DOI 10.1148/radiol.2018181371; Rosenberg RD, 2006, RADIOLOGY, V241, P55, DOI 10.1148/radiol.2411051504; Saarenmaa I, 1999, EUR J CANCER, V35, P1118, DOI 10.1016/S0959-8049(99)00103-3; Schaffter T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0265; Seely JM, 2018, CURR ONCOL, V25, pS115, DOI 10.3747/co.25.3770; Sickles EA, 2013, ACR BI RADS ATLAS BR; Tchou PM, 2010, RADIOLOGY, V257, P40, DOI 10.1148/radiol.10092170; Weedon-Fekjaer H, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2092; Wu K, 2019, FAIR ML HLTH WORKSH; Wu N, 2020, IEEE T MED IMAGING, V39, P1184, DOI 10.1109/TMI.2019.2945514; Yala A, 2019, RADIOLOGY, V293, P38, DOI 10.1148/radiol.2019182908; Yala A, 2019, RADIOLOGY, V292, P60, DOI 10.1148/radiol.2019182716	45	55	56	11	51	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					244	+		10.1038/s41591-020-01174-9	http://dx.doi.org/10.1038/s41591-020-01174-9		JAN 2021	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33432172	Green Accepted, Green Submitted, Green Published			2022-12-27	WOS:000607036600007
J	Lee, JJ; Kim, HJ; Ceko, M; Park, BY; Lee, SA; Park, H; Roy, M; Kim, SG; Wager, TD; Woo, CW				Lee, Jae-Joong; Kim, Hong Ji; Ceko, Marta; Park, Bo-yong; Lee, Soo Ahn; Park, Hyunjin; Roy, Mathieu; Kim, Seong-Gi; Wager, Tor D.; Woo, Choong-Wan			A neuroimaging biomarker for sustained experimental and clinical pain	NATURE MEDICINE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; FUNCTIONAL CONNECTIVITY; BRAIN ACTIVITY; MODULATION; ORGANIZATION; PERCEPTION; STIMULATION; MECHANISMS; INTENSITY; BEHAVIOR	Sustained pain is a major characteristic of clinical pain disorders, but it is difficult to assess in isolation from co-occurring cognitive and emotional features in patients. In this study, we developed a functional magnetic resonance imaging signature based on whole-brain functional connectivity that tracks experimentally induced tonic pain intensity and tested its sensitivity, specificity and generalizability to clinical pain across six studies (total n = 334). The signature displayed high sensitivity and specificity to tonic pain across three independent studies of orofacial tonic pain and aversive taste. It also predicted clinical pain severity and classified patients versus controls in two independent studies of clinical low back pain. Tonic and clinical pain showed similar network-level representations, particularly in somatomotor, frontoparietal and dorsal attention networks. These patterns were distinct from representations of experimental phasic pain. This study identified a brain biomarker for sustained pain with high potential for clinical translation. The functional magnetic resonance imaging connectivity pattern of tonic experimental orofacial pain can be used as a quantitative and unbiased biomarker of clinical pain.	[Lee, Jae-Joong; Kim, Hong Ji; Park, Bo-yong; Lee, Soo Ahn; Park, Hyunjin; Kim, Seong-Gi; Woo, Choong-Wan] Inst Basic Sci, Ctr Neurosci Imaging Res, Suwon, South Korea; [Lee, Jae-Joong; Kim, Hong Ji; Lee, Soo Ahn; Kim, Seong-Gi; Woo, Choong-Wan] Sungkyunkwan Univ, Dept Biomed Engn, Suwon, South Korea; [Ceko, Marta] Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA; [Ceko, Marta] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Park, Bo-yong] McGill Univ, Montreal Neurol Inst & Hosp, McConnell Brain Imaging Ctr, Montreal, PQ, Canada; [Park, Hyunjin] Sungkyunkwan Univ, Sch Elect & Elect Engn, Suwon, South Korea; [Roy, Mathieu] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Roy, Mathieu] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada; [Wager, Tor D.] Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA; [Woo, Choong-Wan] Sungkyunkwan Univ, Biomed Inst Convergence, SKKU, Suwon, South Korea; [Woo, Choong-Wan] Sungkyunkwan Univ, Dept Intelligent Precis Healthcare Convergence, Suwon, South Korea	Institute for Basic Science - Korea (IBS); Sungkyunkwan University (SKKU); University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; McGill University; Sungkyunkwan University (SKKU); McGill University; McGill University; Dartmouth College; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU)	Woo, CW (corresponding author), Inst Basic Sci, Ctr Neurosci Imaging Res, Suwon, South Korea.; Woo, CW (corresponding author), Sungkyunkwan Univ, Dept Biomed Engn, Suwon, South Korea.; Wager, TD (corresponding author), Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA.; Woo, CW (corresponding author), Sungkyunkwan Univ, Biomed Inst Convergence, SKKU, Suwon, South Korea.; Woo, CW (corresponding author), Sungkyunkwan Univ, Dept Intelligent Precis Healthcare Convergence, Suwon, South Korea.	tor.d.wager@dartmouth.edu; waniwoo@skku.edu	Ceko, Marta/AAD-2011-2022; Lee, Jae-Joong/AAK-7063-2020; Woo, Choong-Wan/J-2030-2019; Park, Hyunjin/A-1164-2007	Lee, Jae-Joong/0000-0002-7353-8683; Woo, Choong-Wan/0000-0002-7423-5422; Park, Hyunjin/0000-0001-5681-8918; WAGER, TOR/0000-0002-1936-5574; CEKO, MARTA/0000-0001-8679-8145	Institute for Basic Science [IBS-R015-D1]; National Research Foundation of Korea [2019R1C1C1004512, 2018H1A2A1059844]; Ministry of Science and ICT, Korea [18-BR-03, 2019-0-01367-BabyMind]; National Institutes of Health [R01DA035484, R01MH076136]	Institute for Basic Science; National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Science and ICT, Korea; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank M. C. Reddan for help with conducting experiments; the OpenPain Project (principal investigator: A. V. Apkarian) for data sharing; and M. A. Lindquist for helpful comments on using dynamic connectivity analysis tools. This work was supported by IBS-R015-D1 (Institute for Basic Science; to C.-W.W.), 2019R1C1C1004512 (National Research Foundation of Korea; to C.-W.W.), 18-BR-03 and 2019-0-01367-BabyMind (Ministry of Science and ICT, Korea; to C.-W.W.); by R01DA035484 and R01MH076136 (National Institutes of Health; to T.D.W.); and by 2018H1A2A1059844 (National Research Foundation of Korea; to J.-J.L.).	Allen EA, 2014, CEREB CORTEX, V24, P663, DOI 10.1093/cercor/bhs352; Apkarian AV, 2008, CURR OPIN NEUROBIOL, V18, P464, DOI 10.1016/j.conb.2008.09.012; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Atlas LY, 2010, J NEUROSCI, V30, P12964, DOI 10.1523/JNEUROSCI.0057-10.2010; Ayoub LJ, 2018, NEUROIMAGE-CLIN, V20, P901, DOI 10.1016/j.nicl.2018.09.018; Baars BJ, 2005, PROG BRAIN RES, V150, P45, DOI 10.1016/S0079-6123(05)50004-9; Baliki MN, 2006, J NEUROSCI, V26, P12165, DOI 10.1523/JNEUROSCI.3576-06.2006; Baliki MN, 2015, NEURON, V87, P474, DOI 10.1016/j.neuron.2015.06.005; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Basbaum AI, 1999, P NATL ACAD SCI USA, V96, P7739, DOI 10.1073/pnas.96.14.7739; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; Buckner RL, 2011, J NEUROPHYSIOL, V106, P2322, DOI 10.1152/jn.00339.2011; Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516; Bushnell MC, 1999, P NATL ACAD SCI USA, V96, P7705, DOI 10.1073/pnas.96.14.7705; Chapman CR, 1999, LANCET, V353, P2233, DOI 10.1016/S0140-6736(99)01308-2; Choi EY, 2012, J NEUROPHYSIOL, V108, P2242, DOI 10.1152/jn.00270.2012; Cochran WG., 1963, SAMPLING TECHNIQUES; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934, DOI 10.1152/jn.1999.82.4.1934; Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2; Davis KD, 2017, NAT REV NEUROL, V13, P624, DOI 10.1038/nrneurol.2017.122; Diedrichsen J, 2011, NEUROIMAGE, V54, P1786, DOI 10.1016/j.neuroimage.2010.10.035; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Fan LZ, 2016, CEREB CORTEX, V26, P3508, DOI 10.1093/cercor/bhw157; Gabrieli JDE, 2015, NEURON, V85, P11, DOI 10.1016/j.neuron.2014.10.047; GARCIA J, 1974, SCIENCE, V185, P824, DOI 10.1126/science.185.4154.824; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Glasser MF, 2016, NATURE, V536, P171, DOI 10.1038/nature18933; Hashmi JA, 2013, BRAIN, V136, P2751, DOI 10.1093/brain/awt211; Horing B, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000205; Huang TW, 2019, NATURE, V565, P86, DOI 10.1038/s41586-018-0793-8; Khoutorsky A, 2018, TRENDS NEUROSCI, V41, P100, DOI 10.1016/j.tins.2017.11.006; Kong J, 2013, PAIN, V154, P459, DOI 10.1016/j.pain.2012.12.004; Kucyi A, 2014, J NEUROSCI, V34, P3969, DOI 10.1523/JNEUROSCI.5055-13.2014; Lindquist MA, 2014, NEUROIMAGE, V101, P531, DOI 10.1016/j.neuroimage.2014.06.052; Loggia ML, 2013, PAIN, V154, P24, DOI 10.1016/j.pain.2012.07.029; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Mano Hiroaki, 2018, Wellcome Open Res, V3, P19, DOI 10.12688/wellcomeopenres.14069.1; Mazzola L, 2012, BRAIN, V135, P631, DOI 10.1093/brain/awr265; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Ploner M, 2011, CEREB CORTEX, V21, P719, DOI 10.1093/cercor/bhq146; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; RAINVILLE P, 1992, SOMATOSENS MOT RES, V9, P265, DOI 10.3109/08990229209144776; Reckziegel D, 2019, PAIN, V160, pS37, DOI 10.1097/j.pain.0000000000001529; Rodriguez E, 2017, NAT NEUROSCI, V20, P1734, DOI 10.1038/s41593-017-0012-1; Rosenberg MD, 2017, TRENDS COGN SCI, V21, P290, DOI 10.1016/j.tics.2017.01.011; Roy M, 2009, P NATL ACAD SCI USA, V106, P20900, DOI 10.1073/pnas.0904706106; Scheinost D, 2019, NEUROIMAGE, V193, P35, DOI 10.1016/j.neuroimage.2019.02.057; Segerdahl AR, 2015, NAT NEUROSCI, V18, P499, DOI 10.1038/nn.3969; Seminowicz DA, 2007, J NEUROPHYSIOL, V97, P3651, DOI 10.1152/jn.01210.2006; Seminowicz DA, 2017, J PAIN, V18, P1027, DOI 10.1016/j.jpain.2017.03.008; Senkowski D, 2014, TRENDS COGN SCI, V18, P319, DOI 10.1016/j.tics.2014.03.005; Seymour B, 2005, NAT NEUROSCI, V8, P1234, DOI 10.1038/nn1527; Shen XL, 2017, NAT PROTOC, V12, P506, DOI 10.1038/nprot.2016.178; Stohler CS, 1999, PAIN, V79, P165, DOI 10.1016/S0304-3959(98)00171-7; Tetreault P, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002570; Tibshirani R., 2009, SPRINGER SERIES STAT, DOI [10.1007/978-0-387-84858-7, DOI 10.1007/978-0-387-84858-7]; Vachon-Presseau E, 2016, BRAIN, V139, P1958, DOI 10.1093/brain/aww100; Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471; Wager TD, 2011, J NEUROSCI, V31, P439, DOI 10.1523/JNEUROSCI.3420-10.2011; Wiech K, 2005, NEUROIMAGE, V27, P59, DOI 10.1016/j.neuroimage.2005.03.044; Wiech K, 2008, TRENDS COGN SCI, V12, P306, DOI 10.1016/j.tics.2008.05.005; Woo CW, 2017, NAT NEUROSCI, V20, P365, DOI 10.1038/nn.4478; Woo CW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14211; Woo CW, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002036; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zhang SY, 2018, ELIFE, V7, DOI 10.7554/eLife.31949	68	53	57	16	52	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					174	+		10.1038/s41591-020-1142-7	http://dx.doi.org/10.1038/s41591-020-1142-7		JAN 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33398159	Green Accepted			2022-12-27	WOS:000604849400005
J	Carvalho, T				Carvalho, Thiago			Vaccines in the fast lane	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1807	1807		10.1038/s41591-020-01167-8	http://dx.doi.org/10.1038/s41591-020-01167-8			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288945	Bronze			2022-12-27	WOS:000596579200020
J	Mukaigawara, M; Hassan, I; Fernandes, G; King, L; Patel, J; Sridhar, D				Mukaigawara, Mitsuru; Hassan, Ines; Fernandes, Genevie; King, Lois; Patel, Jay; Sridhar, Devi			An equitable roadmap for ending the COVID-19 pandemic	NATURE MEDICINE			English	Editorial Material								Many governments are rolling back restrictions, but the pandemic will end only with a renewed focus on equitable distribution of vaccines and therapeutics, responsive public health plans, and policies to protect the vulnerable.	[Mukaigawara, Mitsuru] Harvard Univ, Dept Govt, Cambridge, MA 02138 USA; [Hassan, Ines; Fernandes, Genevie; King, Lois; Patel, Jay; Sridhar, Devi] Univ Edinburgh, Edinburgh Med Sch, Usher Inst, Global Hlth Governance Programme, Edinburgh, Midlothian, Scotland	Harvard University; University of Edinburgh	Sridhar, D (corresponding author), Univ Edinburgh, Edinburgh Med Sch, Usher Inst, Global Hlth Governance Programme, Edinburgh, Midlothian, Scotland.	devi.sridhar@ed.ac.uk	Mukaigawara, Mitsuru/L-2144-2016	Mukaigawara, Mitsuru/0000-0001-6530-2083; King, Lois/0000-0002-9319-7089	Wellcome Trust	Wellcome Trust(Wellcome Trust)	D.S. advises the UK and Scottish Governments and receives research funding for her team from the Wellcome Trust. The other authors declare no competing interests.	Bajaj, LANCET, DOI [10.1016/S0140-6736(22)00328-2 (2022, DOI 10.1016/S0140-6736(22)00328-2(2022]; Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Dighe A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01791-8; Fernandes G, 2022, B WORLD HEALTH ORGAN, V100, P174, DOI 10.2471/BLT.21.287177; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Leo CG, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.750529; Lim VW, 2021, B WORLD HEALTH ORGAN, V99, P92, DOI 10.2471/BLT.20.269142; Madhi, NEW ENGL J MED, DOI [10.1056/NEJMoa2119658 (2022, DOI 10.1056/NEJMOA2119658(2022]; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Patel J, 2020, LANCET REG HEALTH-W, V5, DOI 10.1016/j.lanwpc.2020.100062; Pollock A, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013779; Stegger, PREPRINT MEDRXIV, DOI [10.1101/2022.02.19.22271112 (2022, DOI 10.1101/2022.02.19.22271112(2022]; Ward, PREPRINT MEDRXIV, DOI [10.1101/2022.02.24.22271466 (2022, DOI 10.1101/2022.02.24.22271466(2022]; Yang KF, 2020, AM REV PUBLIC ADM, V50, P706, DOI 10.1177/0275074020942406	14	9	9	7	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					893	896		10.1038/s41591-022-01787-2	http://dx.doi.org/10.1038/s41591-022-01787-2		APR 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35383313	Bronze			2022-12-27	WOS:000779604100001
J	Bergerot, CD; Pal, SK				Bergerot, Cristiane Decat; Pal, Sumanta K.			Shining a light on the psychological burden of cancer	NATURE MEDICINE			English	Editorial Material							DISTRESS	Two studies incorporating data from millions of patients highlight the need for consistent screening and access to supportive care.	[Bergerot, Cristiane Decat] Ctr Canc Brasilia, Inst Unity Ensino & Pesquisa, Brasilia, DF, Brazil; [Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Dept Med Oncol 6 Expt Therapeut, Duarte, CA 91010 USA	City of Hope	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol 6 Expt Therapeut, Duarte, CA 91010 USA.	spal@coh.org	Bergerot, Cristiane Decat/C-4514-2015	Bergerot, Cristiane Decat/0000-0003-0037-0303				Bultz BD, 2005, J CLIN ONCOL, V23, P6440, DOI 10.1200/JCO.2005.02.3259; Chang WH, 2022, NAT MED, V28, P860, DOI 10.1038/s41591-022-01740-3; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Heinrich M, 2022, NAT MED, V28, P852, DOI 10.1038/s41591-022-01745-y; Loo V, 2019, TARGET ONCOL, V14, P639, DOI 10.1007/s11523-019-00676-y; Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X; Riba MB, 2019, J NATL COMPR CANC NE, V17, P1229, DOI 10.6004/jnccn.2019.0048	7	1	1	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					637	638		10.1038/s41591-022-01763-w	http://dx.doi.org/10.1038/s41591-022-01763-w		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35347283				2022-12-27	WOS:000773833700003
J	Gurevich, I; Agarwal, P; Zhang, PP; Dolorito, JA; Oliver, S; Liu, H; Reitze, N; Sarma, N; Bagci, IS; Sridhar, K; Kakarla, V; Yenamandra, VK; O'Malley, M; Prisco, M; Tufa, SF; Keene, DR; South, AP; Krishnan, SM; Marinkovich, MP				Gurevich, Irina; Agarwal, Pooja; Zhang, PeiPei; Dolorito, John A.; Oliver, Stacie; Liu, Henry; Reitze, Nicholas; Sarma, Nikhil; Bagci, Isin Sinem; Sridhar, Kunju; Kakarla, Visesha; Yenamandra, Vamsi K.; O'Malley, Mark; Prisco, Marco; Tufa, Sara F.; Keene, Douglas R.; South, Andrew P.; Krishnan, Suma M.; Marinkovich, M. Peter			In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial	NATURE MEDICINE			English	Article							VII COLLAGEN; IMMUNE EVASION; VECTORS; RECOMBINANT; DOMAIN; INJECTION; CORRECTS; DISEASE; MODEL; NC1	Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDEB mice and human RDEB xenografts. Subsequently, a randomized, placebo-controlled, phase 1 and 2 clinical trial (NCT03536143) evaluated matched wounds from nine RDEB patients receiving topical B-VEC or placebo repeatedly over 12 weeks. No grade 2 or above B-VEC-related adverse events or vector shedding or tissue-bound skin immunoreactants were noted. HSV-1 and C7 antibodies sometimes presented at baseline or increased after B-VEC treatment without an apparent impact on safety or efficacy. Primary and secondary objectives of C7 expression, anchoring fibril assembly, wound surface area reduction, duration of wound closure, and time to wound closure following B-VEC treatment were met. A patient-reported pain-severity secondary outcome was not assessed given the small proportion of wounds treated. A global assessment secondary endpoint was not pursued due to redundancy with regard to other endpoints. These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB. Preclinical data and results from a phase 1 and 2 trial demonstrate preliminary safety and efficacy of topical gene therapy for recessive dystrophic epidermolysis bullosa	[Gurevich, Irina; Dolorito, John A.; Bagci, Isin Sinem; Sridhar, Kunju; Yenamandra, Vamsi K.; Marinkovich, M. Peter] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; [Gurevich, Irina; Dolorito, John A.; Bagci, Isin Sinem; Sridhar, Kunju; Yenamandra, Vamsi K.; Marinkovich, M. Peter] Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA; [Agarwal, Pooja; Zhang, PeiPei; Oliver, Stacie; Liu, Henry; Reitze, Nicholas; Sarma, Nikhil; Kakarla, Visesha; O'Malley, Mark; Krishnan, Suma M.] Krystal Biotech, Pittsburgh, PA USA; [Prisco, Marco; South, Andrew P.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Tufa, Sara F.; Keene, Douglas R.] Shriners Hosp Children, Microscopy Unit, Portland, OR 97201 USA; [Marinkovich, M. Peter] Vet Affairs Med Ctr, Stanford, CA 94305 USA	Stanford University; Stanford University; Jefferson University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Marinkovich, MP (corresponding author), Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA.; Marinkovich, MP (corresponding author), Stanford Univ, Sch Med, Dept Dermatol, Stanford, CA 94305 USA.; Marinkovich, MP (corresponding author), Vet Affairs Med Ctr, Stanford, CA 94305 USA.	mpm@stanford.edu		Zhang, Peipei/0000-0003-0918-0610; Kakarla, Visesha/0000-0002-7681-7223; gurevich, irina/0000-0001-9576-0456	Office of Research and Development at the Palo Alto Veterans Affairs Medical Center	Office of Research and Development at the Palo Alto Veterans Affairs Medical Center	The authors thank A. Ponakala, S. Boddu, P. Khuu and T. Parry for their assistance with this study, and all of the patients who participated in this trial. This study was funded by Krystal Biotech through a sponsored research award administered through the Stanford University Office of Research Management. M.P.M. also received funding from the Office of Research and Development at the Palo Alto Veterans Affairs Medical Center.	[Anonymous], 2021, NAT MED, V27, P563, DOI 10.1038/s41591-021-01333-6; Ayoub HH, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1285-x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; Chandler RJ, 2015, J CLIN INVEST, V125, P870, DOI 10.1172/JCI79213; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Cho RJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aas9668; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Eichstadt S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130554; Eng VA, 2021, J AM ACAD DERMATOL, V85, P1161, DOI 10.1016/j.jaad.2020.03.028; Epstein AL, 2005, CURR GENE THER, V5, P445, DOI 10.2174/156652305774329285; Fan HR, 1999, NAT BIOTECHNOL, V17, P870, DOI 10.1038/12856; Fine JD, 2016, JAMA DERMATOL, V152, P1231, DOI 10.1001/jamadermatol.2016.2473; Fritsch A, 2008, J CLIN INVEST, V118, P1669, DOI 10.1172/JCI34292; Goins WF, 2020, METHODS MOL BIOL, V2060, P73, DOI 10.1007/978-1-4939-9814-2_4; Gorell ES, 2015, BRIT J DERMATOL, V173, P821, DOI 10.1111/bjd.13737; Has C, 2020, BRIT J DERMATOL, V183, P614, DOI 10.1111/bjd.18921; Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z; Hirsch T, 2017, NATURE, V551, P327, DOI 10.1038/nature24487; Ishii N, 2004, BRIT J DERMATOL, V150, P843, DOI 10.1111/j.1365-2133.2004.05933.x; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; Knight S, 2013, CURR GENE THER, V13, P211, DOI 10.2174/1566523211313030006; Koster MI, 2009, ANN NY ACAD SCI, V1170, P7, DOI 10.1111/j.1749-6632.2009.04363.x; Kotterman MA, 2015, ANNU REV BIOMED ENG, V17, P63, DOI 10.1146/annurev-bioeng-071813-104938; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lwin SM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126243; Marinkovich M. P., 2019, FITZPATRICKS DERMATO; Marinkovich MP, 2019, J INVEST DERMATOL, V139, P1221, DOI 10.1016/j.jid.2018.11.036; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; Oldham ML, 2016, NATURE, V529, P537, DOI 10.1038/nature16506; Ortiz-Urda S, 2003, J CLIN INVEST, V111, P251, DOI 10.1172/JCI200317193; Remington J, 2009, MOL THER, V17, P26, DOI 10.1038/mt.2008.234; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; Shirley JL, 2020, MOL THER, V28, P709, DOI 10.1016/j.ymthe.2020.01.001; Siprashvili Z, 2016, JAMA-J AM MED ASSOC, V316, P1808, DOI 10.1001/jama.2016.15588; Solis DC, 2021, J AM ACAD DERMATOL, V85, P1296, DOI 10.1016/j.jaad.2020.08.118; Supp DM, 2019, CELL TRANSPLANT, V28, P1242, DOI 10.1177/0963689719857657; Tang JY, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01811-7; Tognarelli EI, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00127; Wagner JE, 2010, NEW ENGL J MED, V363, P629, DOI 10.1056/NEJMoa0910501; Wilson JM, 2009, MOL GENET METAB, V96, P151, DOI 10.1016/j.ymgme.2008.12.016; Woodley DT, 2017, J CLIN INVEST, V127, P3028, DOI 10.1172/JCI92707; Yang LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02196	44	11	11	2	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					780	+		10.1038/s41591-022-01737-y	http://dx.doi.org/10.1038/s41591-022-01737-y		MAR 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35347281	hybrid, Green Published			2022-12-27	WOS:000773833700005
J	Kachroo, P; Stewart, ID; Kelly, RS; Stav, M; Mendez, K; Dahlin, A; Soeteman, DI; Chu, SH; Huang, MN; Cote, M; Knilhtila, HM; Lee-Sarwar, K; McGeachie, M; Wang, A; Wu, AC; Virkud, Y; Zhang, P; Wareham, NJ; Karlson, EW; Wheelock, CE; Clish, C; Weiss, ST; Langenberg, C; Lasky-Su, JA				Kachroo, Priyadarshini; Stewart, Isobel D.; Kelly, Rachel S.; Stav, Meryl; Mendez, Kevin; Dahlin, Amber; Soeteman, Djora I.; Chu, Su H.; Huang, Mengna; Cote, Margaret; Knilhtila, Hanna M.; Lee-Sarwar, Kathleen; McGeachie, Michael; Wang, Alberta; Wu, Ann Chen; Virkud, Yamini; Zhang, Pei; Wareham, Nicholas J.; Karlson, Elizabeth W.; Wheelock, Craig E.; Clish, Clary; Weiss, Scott T.; Langenberg, Claudia; Lasky-Su, Jessica A.			Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma	NATURE MEDICINE			English	Article							BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; SALIVARY CORTISOL; AXIS SUPPRESSION; CHILDREN; INSUFFICIENCY; BUDESONIDE; GENETICS; STEROIDS; RISK	The application of large-scale metabolomic profiling provides new opportunities for realizing the potential of omics-based precision medicine for asthma. By leveraging data from over 14,000 individuals in four distinct cohorts, this study identifies and independently replicates 17 steroid metabolites whose levels were significantly reduced in individuals with prevalent asthma. Although steroid levels were reduced among all asthma cases regardless of medication use, the largest reductions were associated with inhaled corticosteroid (ICS) treatment, as confirmed in a 4-year low-dose ICS clinical trial. Effects of ICS treatment on steroid levels were dose dependent; however, significant reductions also occurred with low-dose ICS treatment. Using information from electronic medical records, we found that cortisol levels were substantially reduced throughout the entire 24-hour daily period in patients with asthma who were treated with ICS compared to those who were untreated and to patients without asthma. Moreover, patients with asthma who were treated with ICS showed significant increases in fatigue and anemia as compared to those without ICS treatment. Adrenal suppression in patients with asthma treated with ICS might, therefore, represent a larger public health problem than previously recognized. Regular cortisol monitoring of patients with asthma treated with ICS is needed to provide the optimal balance between minimizing adverse effects of adrenal suppression while capitalizing on the established benefits of ICS treatment. Metabolomic profiling identified widespread adrenal insufficiency in patients with asthma receiving inhaled corticosteroids, which is a mainstay of asthma treatment, arguing for the need for regular monitoring of such patients to avoid adverse effects of adrenal suppression.	[Kachroo, Priyadarshini; Kelly, Rachel S.; Stav, Meryl; Mendez, Kevin; Dahlin, Amber; Soeteman, Djora I.; Chu, Su H.; Huang, Mengna; Cote, Margaret; Knilhtila, Hanna M.; Lee-Sarwar, Kathleen; McGeachie, Michael; Wang, Alberta; Weiss, Scott T.; Lasky-Su, Jessica A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Kachroo, Priyadarshini; Kelly, Rachel S.; Stav, Meryl; Mendez, Kevin; Dahlin, Amber; Soeteman, Djora I.; Chu, Su H.; Huang, Mengna; Cote, Margaret; Knilhtila, Hanna M.; Lee-Sarwar, Kathleen; McGeachie, Michael; Wang, Alberta; Virkud, Yamini; Karlson, Elizabeth W.; Lasky-Su, Jessica A.] Harvard Med Sch, Boston, MA 02115 USA; [Stewart, Isobel D.; Wareham, Nicholas J.; Langenberg, Claudia] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Soeteman, Djora I.] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA USA; [Knilhtila, Hanna M.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Wu, Ann Chen] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Boston, MA 02115 USA; [Wu, Ann Chen] Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA; [Virkud, Yamini] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Zhang, Pei; Wheelock, Craig E.] Gunma Univ, Gunma Univ Initiat Adv Res GIAR, Maebashi, Gumma, Japan; [Zhang, Pei; Wheelock, Craig E.] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden; [Karlson, Elizabeth W.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA; [Wheelock, Craig E.] Karolinska Univ Hosp, Dept Resp Med & Allergy, Stockholm, Sweden; [Clish, Clary] Broad Inst, Cambridge, MA USA; [Langenberg, Claudia] Charite Univ Med Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Cambridge; Harvard University; Harvard T.H. Chan School of Public Health; Stanford University; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Gunma University; Karolinska Institutet; Harvard University; Brigham & Women's Hospital; Karolinska Institutet; Karolinska University Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lasky-Su, JA (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.; Lasky-Su, JA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	rejas@channing.harvard.edu	Kachroo, Priyadarshini/M-1923-2019	Kachroo, Priyadarshini/0000-0002-5807-1333; Kelly, Rachel/0000-0003-3023-1822; Cote, Margaret/0000-0001-8079-7221; Wang, Alberta/0000-0002-2151-4823; Knihtila, Hanna/0000-0001-7339-1880; Langenberg, Claudia/0000-0002-5017-7344; Stav, Meryl/0000-0001-6565-3617	National Heart, Lung, and Blood Institute, National Institutes of Health (NIH/NHLBI) [P01HL132825]; Medical Research Council [MC_UU_00006/1, MR/N003284/1 MC-UU_12015/1]; NIH/NHLBI [R01HL123915, K01HL146980, K01HL153941, R01HL141826, 1R01HL152244, R01HL155742, K08HL148178, R01HL139634, K23HL151819]; US Department of Defense [W81XWH-17-1-0533]; Jane and Aatos Erkko Foundation; Paulo Foundation; Pediatric Research Foundation; Thrasher Research Fund Award [15115]; National Institute of Child Health and Human Development [1R01HD085993]; National Institute of Allergy and Infectious Diseases [K23AI130408]; NIH [U01HG008685]; Japan Society for the Promotion of Science KAKENHI Grant [JP19K21239]; Japanese Environment Research and Technology Development Fund [5-1752]; Gunma University Initiative for Advanced Research; Japan Society for the Promotion of Science [JPJSBP-1201854]; Swedish Foundation for International Cooperation in Research and Higher Education [JPJSBP-1201854]; Swedish Heart Lung Foundation [HLF 20180290, HLF 20200693]; Swedish Research Council [2016-02798]; Cancer Research UK [C864/A14136]; MRC Cambridge Initiative in Metabolic Science [MR/L00002/1]; Innovative Medicines Initiative Joint Undertaking under European Medical Information Framework grant [115372]	National Heart, Lung, and Blood Institute, National Institutes of Health (NIH/NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US Department of Defense(United States Department of Defense); Jane and Aatos Erkko Foundation; Paulo Foundation; Pediatric Research Foundation; Thrasher Research Fund Award; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japanese Environment Research and Technology Development Fund; Gunma University Initiative for Advanced Research; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Swedish Foundation for International Cooperation in Research and Higher Education; Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Research UK(Cancer Research UK); MRC Cambridge Initiative in Metabolic Science(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Innovative Medicines Initiative Joint Undertaking under European Medical Information Framework grant	The external funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Effort from P.K., J.A.L.S. and S.T.W. is supported by P01HL132825 from the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH/NHLBI). I.D.S. is funded by the Medical Research Council (MC_UU_00006/1-Etiology and Mechanisms). Effort from R.K., D.I.S., M.C., K.M., M.S. and J.A.L.S. is supported by R01HL123915 from the NIH/NHLBI and W81XWH-17-1-0533 from the US Department of Defense. Effort from R.S.K. is supported by K01HL146980 from the NIH/NHLBI. Effort from S.H.C. is supported by K01HL153941 from the NIH/NHLBI. Effort from M.H. and J.A.L.S. is supported by R01HL141826 from the NIH/NHLBI. Effort from A.D. is supported by K01HL130629 from the NIH/NHLBI. Effort from A.D. and J.A.L.S. is supported by 1R01HL152244 from the NIH/NHLBI. Effort from M.M. and J.A.L.S. is supported by R01HL155742 from the NIH/NHLBI. Effort from H.K. is supported by the Jane and Aatos Erkko Foundation, the Paulo Foundation and the Pediatric Research Foundation. Effort from K.L.S. is supported by K08HL148178 from the NIH/NHLBI. Effort from M.M. is supported by R01HL139634 from the NIH/NHLBI. Effort from A.W. is supported by K23HL151819 from the NIH/NHLBI and the Thrasher Research Fund Award (15115). Effort from A.C.W. is supported by 1R01HD085993 from the National Institute of Child Health and Human Development. Effort from Y.V. is supported by K23AI130408 from the National Institute of Allergy and Infectious Diseases. Effort from J.A.L.S., S.T.W. and E.W.K. is supported by NIH U01HG008685. Effort from P.Z. and C.E.W. was supported by the Japan Society for the Promotion of Science KAKENHI Grant (JP19K21239), the Japanese Environment Research and Technology Development Fund (5-1752), the Gunma University Initiative for Advanced Research, the Japan-Sweden Research Cooperative Program between the Japan Society for the Promotion of Science and the Swedish Foundation for International Cooperation in Research and Higher Education (JPJSBP-1201854), the Swedish Heart Lung Foundation (HLF 20180290 and HLF 20200693) and the Swedish Research Council (2016-02798). The EPIC-Norfolk study (https://doi.org/10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 MC-UU_12015/1 and MC_UU_00006/1) and Cancer Research UK (C864/A14136). Metabolite measurements in the EPIC-Norfolk study were supported by the MRC Cambridge Initiative in Metabolic Science (MR/L00002/1) and the Innovative Medicines Initiative Joint Undertaking under European Medical Information Framework grant agreement number 115372. We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We thank the staff and participants of the EPIC-Norfolk, Mass General Brigham Biobank and Childhood Asthma Management Program studies for their contributions. Figure 1 was created with BioRender (https://biorender.com/).	Aalbers R, 2016, RESP MED, V111, P1, DOI 10.1016/j.rmed.2015.11.002; Adamko DJ, 2012, CHEST, V141, P1295, DOI 10.1378/chest.11-2028; Afilalo M, 1999, ANN EMERG MED, V33, P304, DOI 10.1016/S0196-0644(99)70367-7; Ahmet A, 2011, ALLERGY ASTHMA CL IM, V7, DOI [10.1186/1710-1492-7-13, 10.1186/1710-1492-7-S1-S2]; Allen David B, 2007, Expert Rev Respir Med, V1, P65, DOI 10.1586/17476348.1.1.65; Bakkeheim E, 2010, ACTA PAEDIATR, V99, P1705, DOI 10.1111/j.1651-2227.2009.01598.x; Becker AB, 2017, CURR OPIN ALLERGY CL, V17, P99, DOI 10.1097/ACI.0000000000000346; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOE J, 1994, EUR RESPIR J, V7, P2179, DOI 10.1183/09031936.94.07122179; Bush A, 2018, INDIAN J PEDIATR, V85, P643, DOI 10.1007/s12098-017-2520-0; Cazzola M, 2020, PHARMACOGEN PERS MED, V13, P261, DOI 10.2147/PGPM.S231471; Centers for Disease Control and Prevention, DAT STAT SURV ASTHM; CHANG CCC, 1991, J PAEDIATR CHILD H, V27, P232, DOI 10.1111/j.1440-1754.1991.tb00398.x; Checkley W, 2016, RESP MED, V121, P59, DOI 10.1016/j.rmed.2016.10.011; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Cho MH, 2018, LANCET RESP MED, V6, P407, DOI 10.1016/S2213-2600(18)30101-2; Crompton Graham, 2006, Prim Care Respir J, V15, P326, DOI 10.1016/j.pcrj.2006.09.002; Day N, 1999, BRIT J CANCER, V80, P95; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Donovan BM, 2019, ANN ALLERG ASTHMA IM, V123, P550, DOI 10.1016/j.anai.2019.08.460; Dorsey MJ, 2006, ANN ALLERG ASTHMA IM, V97, P182, DOI 10.1016/S1081-1206(10)60010-5; Drake AJ, 2002, BMJ-BRIT MED J, V324, P1081, DOI 10.1136/bmj.324.7345.1081; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V102, P699, DOI 10.1016/S0091-6749(98)70292-1; Figueiredo RG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084251; Frey LJ, 2018, PERS MED, V15, P543, DOI 10.2217/pme-2018-0035; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; GREALLY M, 1982, IRISH MED J, V75, P403; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Gurnell M, 2021, J INTERN MED, V290, P240, DOI 10.1111/joim.13273; Hawcutt DB, 2018, LANCET RESP MED, V6, P442, DOI 10.1016/S2213-2600(18)30058-4; Hay CM, 2014, ENDOCRINOL DIAB META, DOI 10.1530/EDM-13-0080; Haynes W., 2013, ENCY SYSTEMBIOL, P2303, DOI DOI 10.1007/978-1-4419-9863-7_1212; Hernandez-Pacheco N, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00006; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Kannisto S, 2000, J CLIN ENDOCR METAB, V85, P652, DOI 10.1210/jc.85.2.652; Keeley D, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6934; Kelly RS, 2018, CLIN EXP ALLERGY, V48, P1297, DOI 10.1111/cea.13183; Kelly RS, 2018, CHEST, V154, P335, DOI 10.1016/j.chest.2018.05.038; Kelly RS, 2017, BBA-MOL BASIS DIS, V1863, P1590, DOI 10.1016/j.bbadis.2017.02.006; Kelly RS, 2017, CHEST, V151, P262, DOI 10.1016/j.chest.2016.10.008; Keskin O, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-018-0239-2; Lapi F, 2013, EUR RESPIR J, V42, P79, DOI 10.1183/09031936.00080912; Louisias M, 2019, IMMUNOL ALLERGY CLIN, V39, P163, DOI 10.1016/j.iac.2018.12.005; Macdessi JS, 2003, MED J AUSTRALIA, V178, P214, DOI 10.5694/j.1326-5377.2003.tb05165.x; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McGeachie MJ, 2015, IMMUN INFLAMM DIS, V3, P224, DOI 10.1002/iid3.61; Meyers DA, 2014, LANCET RESP MED, V2, P405, DOI 10.1016/S2213-2600(14)70012-8; Neary N, 2010, CURR OPIN ENDOCRINOL, V17, P217, DOI 10.1097/MED.0b013e328338f608; O'Byrne P, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00491-2019; Pazderska A, 2017, CLIN MED, V17, P258, DOI 10.7861/clinmedicine.17-3-258; Pite H, 2018, CURR OPIN PULM MED, V24, P94, DOI 10.1097/MCP.0000000000000437; R Core Team, 2021, R LANGUAGE ENV STAT; Reinke SN, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01740-2016; Sannarangappa Vishnu, 2014, Open Respir Med J, V8, P93, DOI 10.2174/1874306401408010093; Santiago AH, 2010, INT J PEDIATR ENDOCR, DOI 10.1155/2010/749239; Sharma S, 2014, THORAX, V69, P481, DOI 10.1136/thoraxjnl-2014-205166; Shin YS, 2014, ALLERGY ASTHMA IMMUN, V6, P463, DOI 10.4168/aair.2014.6.5.463; Smith RW, 2012, PAED CHILD HEALT-CAN, V17, pE34, DOI 10.1093/pch/17.5.e34; Snowden S, 2012, BIOANALYSIS, V4, P2265, DOI [10.4155/bio.12.218, 10.4155/BIO.12.218]; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; SVENDSEN UG, 1992, ALLERGY, V47, P174, DOI 10.1111/j.1398-9995.1992.tb00960.x; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Todd GRG, 2002, EUR RESPIR J, V19, P1207, DOI 10.1183/09031936.02.00274402; Todd GRG, 1999, J ALLERGY CLIN IMMUN, V103, P956, DOI 10.1016/S0091-6749(99)70447-1; Vijverberg SJH, 2018, EXPERT REV RESP MED, V12, P55, DOI 10.1080/17476348.2018.1403318; Wade M, 2010, EUR J ENDOCRINOL, V162, P109, DOI 10.1530/EJE-09-0746; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Yu S, 2015, J AM MED INFORM ASSN, V22, P993, DOI 10.1093/jamia/ocv034	71	11	11	5	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4								10.1038/s41591-022-01714-5	http://dx.doi.org/10.1038/s41591-022-01714-5		MAR 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0P3TN	35314841	Green Accepted, Green Submitted			2022-12-27	WOS:000771548300001
J	Jasra, S; Giricz, O; Zeig-Owens, R; Pradhan, K; Goldfarb, DG; Barreto-Galvez, A; Silver, AJ; Chen, JH; Sahu, S; Gordon-Mitchell, S; Choudhary, GS; Aluri, S; Bhagat, TD; Shastri, A; Bejan, CA; Stockton, SS; Spaulding, TP; Thiruthuvanathan, V; Goto, H; Gerhardt, J; Haider, SH; Veerappan, A; Bartenstein, M; Nwankwo, G; Landgren, O; Weiden, MD; Lekostaj, J; Bender, R; Fletcher, F; Greenberger, L; Ebert, BL; Steidl, U; Will, B; Nolan, A; Madireddy, A; Savona, MR; Prezant, DJ; Verma, A				Jasra, Sakshi; Giricz, Orsi; Zeig-Owens, Rachel; Pradhan, Kith; Goldfarb, David G.; Barreto-Galvez, Angelica; Silver, Alexander J.; Chen, Jiahao; Sahu, Srabani; Gordon-Mitchell, Shanisha; Choudhary, Gaurav S.; Aluri, Srinivas; Bhagat, Tushar D.; Shastri, Aditi; Bejan, Cosmin A.; Stockton, Shannon S.; Spaulding, Travis P.; Thiruthuvanathan, Victor; Goto, Hiroki; Gerhardt, Jeannine; Haider, Syed Hissam; Veerappan, Arul; Bartenstein, Matthias; Nwankwo, George; Landgren, Ola; Weiden, Michael D.; Lekostaj, Jacqueline; Bender, Ryan; Fletcher, Frederick; Greenberger, Lee; Ebert, Benjamin L.; Steidl, Ulrich; Will, Britta; Nolan, Anna; Madireddy, Advaitha; Savona, Michael R.; Prezant, David J.; Verma, Amit			High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster	NATURE MEDICINE			English	Article							COMMON	The terrorist attacks on the World Trade Center (WTC) created an unprecedented environmental exposure to aerosolized dust, gases and potential carcinogens. Clonal hematopoiesis (CH) is defined as the acquisition of somatic mutations in blood cells and is associated with smoking and exposure to genotoxic stimuli. Here we show that deep targeted sequencing of blood samples identified a significantly higher proportion of WTC-exposed first responders with CH (10%; 48 out of 481) when compared with non-WTC-exposed firefighters (6.7%; 17 out of 255; odds ratio, 3.14; 95% confidence interval, 1.64-6.03; P = 0.0006) after controlling for age, sex and race/ethnicity. The frequency of somatic mutations in WTC-exposed first responders showed an age-related increase and predominantly affected DNMT3A, TET2 and other CH-associated genes. Exposure of lymphoblastoid cells to WTC particulate matter led to dysregulation of DNA replication at common fragile sites in vitro. Moreover, mice treated with WTC particulate matter developed an increased burden of mutations in hematopoietic stem and progenitor cell compartments. In summary, the high burden of CH in WTC-exposed first responders provides a rationale for enhanced screening and preventative efforts in this population. First responders to the World Trade Center disaster, who were exposed to particulate matter containing potential carcinogens, have a high burden of somatic mutations in blood cells, raising their risk for cancer and other diseases and highlighting the need for enhanced health screening of these individuals.	[Jasra, Sakshi; Giricz, Orsi; Pradhan, Kith; Chen, Jiahao; Sahu, Srabani; Gordon-Mitchell, Shanisha; Choudhary, Gaurav S.; Aluri, Srinivas; Bhagat, Tushar D.; Shastri, Aditi; Thiruthuvanathan, Victor; Goto, Hiroki; Bartenstein, Matthias; Nwankwo, George; Steidl, Ulrich; Will, Britta; Verma, Amit] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Blood Canc Inst, Bronx, NY 10467 USA; [Zeig-Owens, Rachel; Goldfarb, David G.; Prezant, David J.] Montefiore Med Ctr, Dept Med, Pulm Med Div, Bronx, NY 10467 USA; [Zeig-Owens, Rachel; Goldfarb, David G.; Weiden, Michael D.; Nolan, Anna; Prezant, David J.] Bur Hlth Serv, Fire Dept City New York, Brooklyn, NY 11201 USA; [Zeig-Owens, Rachel] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Barreto-Galvez, Angelica; Madireddy, Advaitha] Univ Med & Dent New Jersey, Rutgers Canc Inst New Jersey, Dept Pediat Hematol Oncol, New Brunswick, NJ 08901 USA; [Silver, Alexander J.; Bejan, Cosmin A.; Stockton, Shannon S.; Spaulding, Travis P.; Savona, Michael R.] Vanderbilt Univ, Dept Med, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37235 USA; [Gerhardt, Jeannine] Weill Cornell Med, Ronald O Perelman & Claudia Cohen Ctr Reprod Med, New York, NY USA; [Haider, Syed Hissam; Veerappan, Arul; Weiden, Michael D.; Nolan, Anna] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA; [Landgren, Ola] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA; [Lekostaj, Jacqueline; Bender, Ryan; Fletcher, Frederick] Genoptix, Neogenom, Carlsbad, CA USA; [Greenberger, Lee] Leukemia Lymphoma Soc, New York, NY USA; [Ebert, Benjamin L.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Ebert, Benjamin L.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Jasra, Sakshi] Univ Vermont, Larner Coll Med, Div Hematol & Med Oncol, Burlington, VT USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Vanderbilt University; Cornell University; New York University; University of Miami; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; University of Vermont	Verma, A (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Blood Canc Inst, Bronx, NY 10467 USA.; Prezant, DJ (corresponding author), Montefiore Med Ctr, Dept Med, Pulm Med Div, Bronx, NY 10467 USA.; Nolan, A; Prezant, DJ (corresponding author), Bur Hlth Serv, Fire Dept City New York, Brooklyn, NY 11201 USA.; Madireddy, A (corresponding author), Univ Med & Dent New Jersey, Rutgers Canc Inst New Jersey, Dept Pediat Hematol Oncol, New Brunswick, NJ 08901 USA.; Savona, MR (corresponding author), Vanderbilt Univ, Dept Med, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37235 USA.; Nolan, A (corresponding author), NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.	Anna.Nolan@nyulangone.org; advaitha.madireddy@rutgers.edu; michael.savona@vanderbilt.edu; David.Prezant@fdny.nyc.gov; amit.verma@einsteinmed.org	Nolan, Anna/C-2796-2012; Zeig-Owens, Rachel/HIA-8364-2022	Nolan, Anna/0000-0002-0631-1171; Will, Britta/0000-0002-9534-6690; Chen, Jiahao/0000-0001-7719-3216; Giricz, Orsolya/0000-0002-1328-3682; Veerappan, Arul/0000-0002-6617-5335; Madireddy, Advaitha/0000-0002-4730-5325; Silver, Alexander/0000-0001-8255-3140	National Institutes of Health [U01OH011933, U01OH012271, U01OH11300, F30DK127699, R01HL119326, R00HL136870, T32GM007347]; NIOSH [200-2011-39383, 200-2011-39378, 200-2017-93326]; Jane and Myles Dempsey Fund; Leukemia Lymphoma Society; Evans MDS Foundation; Valvano Foundation; Adventure Alle Fund; Biff Ruttenberg Foundation; Ann Melly Scholarship; NIH [S10RR025141, S10OD025092, S10OD017985]; CTSA [UL1TR002243, UL1TR000445, UL1RR024975]; Beverly and George Rawlings Directorship;  [U01HG004798];  [R01NS032830];  [RC2GM092618];  [P50GM115305];  [U01HG006378];  [U19HL065962];  [R01HD074711]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIOSH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); Jane and Myles Dempsey Fund; Leukemia Lymphoma Society(Leukemia and Lymphoma Society); Evans MDS Foundation; Valvano Foundation; Adventure Alle Fund; Biff Ruttenberg Foundation; Ann Melly Scholarship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Beverly and George Rawlings Directorship; ; ; ; ; ; ; 	The work was supported by National Institutes of Health grants U01OH011933 (A.V.), U01OH012271 (A.V., R.Z.-O.), U01OH11300 (A.N.), F30DK127699 (A.J.S.), R01HL119326 (A.N.), R00HL136870 (A.M.) and T32GM007347 (A.J.S), NIOSH contracts 200-2011-39383, 200-2011-39378 and 200-2017-93326 (R.Z.-O.), the Jane and Myles Dempsey Fund (A.V.), Leukemia Lymphoma Society (A.V., M.R.S), the Evans MDS Foundation (A.V., M.R.S.), the Valvano Foundation (A.V.), the Adventure Alle Fund (M.R.S.), the Biff Ruttenberg Foundation (M.R.S.), the Beverly and George Rawlings Directorship (M.R.S.), the Ann Melly Scholarship (AJS) and a gift from the Leinbach family (A.V.). The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by numerous sources: institutional funding, private agencies and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141, S10OD025092 and S10OD017985; and CTSA grants UL1TR002243, UL1TR000445 and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bick AG, 2021, NATURE, V591, pE27, DOI [10.1038/s41586-021-03280-1, 10.1038/s41586-020-2819-2, 10.1038/s41586-021-03280]; Caraher EJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184331; Chen JH, 2019, NAT MED, V25, P103, DOI 10.1038/s41591-018-0267-4; Cohen HW, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9775; Coombs CC, 2017, CELL STEM CELL, V21, P374, DOI 10.1016/j.stem.2017.07.010; Fantini D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75062-0; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Landgren O, 2018, JAMA ONCOL, V4, P821, DOI 10.1001/jamaoncol.2018.0509; Li JH, 2022, JNCI-J NATL CANCER I, V114, P210, DOI 10.1093/jnci/djab165; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703, DOI 10.1289/ehp.02110703; Madireddy A, 2016, MOL CELL, V64, P388, DOI 10.1016/j.molcel.2016.09.017; Maya-Mendoza A, 2018, NATURE, V559, P279, DOI 10.1038/s41586-018-0261-5; McGee JK, 2003, ENVIRON HEALTH PERSP, V111, P972, DOI 10.1289/ehp.5930; Nik-Zainal S, 2015, MUTAGENESIS, V30, P763, DOI 10.1093/mutage/gev073; Trowbridge JJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20201544; Weiden MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040016; Zamborszky J, 2017, ONCOGENE, V36, P5085, DOI 10.1038/onc.2017.213; Zeig-Owens R, 2011, LANCET, V378, P898, DOI 10.1016/S0140-6736(11)60989-6	20	4	4	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					468	+		10.1038/s41591-022-01708-3	http://dx.doi.org/10.1038/s41591-022-01708-3		MAR 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35256801	Green Accepted			2022-12-27	WOS:000765689400001
J	Du, ZW; Wang, L; Pandey, A; Lim, WW; Chinazzi, M; Piontti, APY; Lau, EHY; Wu, P; Malani, A; Cobey, S; Cowling, BJ				Du, Zhanwei; Wang, Lin; Pandey, Abhishek; Lim, Wey Wen; Chinazzi, Matteo; Piontti, Ana Pastore Y.; Lau, Eric H. Y.; Wu, Peng; Malani, Anup; Cobey, Sarah; Cowling, Benjamin J.			Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India	NATURE MEDICINE			English	Article							IMPACT	A multi-scale model using population-level transmission and individual-level vaccination data suggests that vaccine dose fractionation could be a cost-effective strategy for mitigating the COVID-19 pandemic in India. Given global Coronavirus Disease 2019 (COVID-19) vaccine shortages and inequity of vaccine distributions, fractionation of vaccine doses might be an effective strategy for reducing public health and economic burden, notwithstanding the emergence of new variants of concern. In this study, we developed a multi-scale model incorporating population-level transmission and individual-level vaccination to estimate the costs of hospitalization and vaccination and the economic benefits of reducing COVID-19 deaths due to dose-fractionation strategies in India. We used large-scale survey data of the willingness to pay together with data of vaccine and hospital admission costs to build the model. We found that fractional doses of vaccines could be an economically viable vaccination strategy compared to alternatives of either full-dose vaccination or no vaccination. Dose-sparing strategies could save a large number of lives, even with the emergence of new variants with higher transmissibility.	[Du, Zhanwei; Lim, Wey Wen; Lau, Eric H. Y.; Wu, Peng; Cowling, Benjamin J.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Hong Kong, Peoples R China; [Du, Zhanwei; Lau, Eric H. Y.; Wu, Peng; Cowling, Benjamin J.] Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth Ltd D24H, Hong Kong, Peoples R China; [Wang, Lin] Univ Cambridge, Dept Genet, Cambridge, England; [Pandey, Abhishek] Yale Sch Publ Hlth, Ctr Infect Dis Modeling & Anal, New Haven, CT USA; [Chinazzi, Matteo; Piontti, Ana Pastore Y.] Northeastern Univ, Lab Modeling Biol & Sociotech Syst, Boston, MA 02115 USA; [Malani, Anup] Univ Chicago, Law Sch, Chicago, IL 60637 USA; [Cobey, Sarah] Univ Chicago, Dept Ecol & Evolutionary Biol, Chicago, IL 60637 USA	University of Hong Kong; World Health Organization; University of Cambridge; Yale University; Northeastern University; University of Chicago; University of Chicago	Cowling, BJ (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Hong Kong, Peoples R China.; Cowling, BJ (corresponding author), Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth Ltd D24H, Hong Kong, Peoples R China.	bcowling@hku.hk	Wang, Lin/B-4145-2013; Du, Zhanwei/HGF-3197-2022; Lau, Eric/C-4487-2009	Wang, Lin/0000-0002-5371-2138; Lau, Eric/0000-0002-6688-9637; Lim, Wey Wen/0000-0001-8514-2048; Wu, Peng/0000-0003-1157-9401	AIR@InnoHK; Research Grants Council of the Hong Kong Special Administrative Region Government [C712320G]; National Natural Science Foundation of China [72104208]; Engineering and Physical Sciences Research Council Impact Acceleration Grant [RG90413]; European Research Council [804744]; Grand Challenges ICODA pilot initiative; Bill & Melinda Gates Foundation; Minderoo Foundation	AIR@InnoHK; Research Grants Council of the Hong Kong Special Administrative Region Government(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Engineering and Physical Sciences Research Council Impact Acceleration Grant(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); European Research Council(European Research Council (ERC)European Commission); Grand Challenges ICODA pilot initiative; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Minderoo Foundation	We acknowledge financial support from AIR@InnoHK, administered by the Innovation and Technology Commission; the Collaborative Research Fund (project no. C712320G) of the Research Grants Council of the Hong Kong Special Administrative Region Government; the National Natural Science Foundation of China (grant no. 72104208); the Engineering and Physical Sciences Research Council Impact Acceleration Grant (grant no. RG90413); the European Research Council (grant no. 804744); and the Grand Challenges ICODA pilot initiative, delivered by Health Data Research UK and funded by the Bill & Melinda Gates Foundation and the Minderoo Foundation. We are thankful to S. Ramachandran at the University of California, San Diego, for help evaluating the WTP in India based on the Indian Economy's Consumer Pyramids Household Survey.	Aleta A, 2020, NAT HUM BEHAV, V4, P964, DOI 10.1038/s41562-020-0931-9; Ali A, 2014, PATHOG GLOB HEALTH, V108, P11, DOI 10.1179/2047773214Y.0000000126; Andersen C., 2021, S ASIA VACCINATES CO; Andrews N, 2022, NAT MED, V28, P831, DOI 10.1038/s41591-022-01699-1; [Anonymous], LOW MIDDL INC; [Anonymous], 2020, COVID 19 TREATMENT C; [Anonymous], 2021, SHARE SARS COV 2 SEQ; [Anonymous], 2020, COVID 19 TREATMENT A; Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062; Barnabas RV, 2021, ANN INTERN MED, V174, P552, DOI 10.7326/M20-8060; Biggerstaff M., 2020, MODELING STRATEGIES; Casey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430; Centre for Monitoring Indian Economy, CONS PYR HOUS SURV; Cobey S, 2021, NAT REV IMMUNOL, V21, P330, DOI 10.1038/s41577-021-00544-9; Cowling BJ, 2021, NAT MED, V27, P1321, DOI 10.1038/s41591-021-01440-4; Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6; de Jesus, 2020, IMMUNITY COVID 19 MA; Du ZW, 2021, LANCET PUBLIC HEALTH, V6, pE184, DOI 10.1016/S2468-2667(21)00002-5; Dyer O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1856; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006, 10.1101/2021.02.14.21251704]; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kozlov M, 2021, NATURE, V599, P18, DOI 10.1038/d41586-021-02947-z; Lachmann M., 2020, TEXAS TRAUMA SERVICE; McEvoy D, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-042354; Mistry D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20544-y; Nagarajan R., 2021, TIMES INDIA; NHS Confederation & NHS Providers, 2021, OUR COV 19 APP; Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020; Office of the Registrar General & Census Commissioner India, CENS IND HH SER HOUS; Office of the Registrar General & Census Commissioner India, 2019, SRS BAS ABR LIF TABL; Pandey A, 2021, J GLOB HEALTH, V11, DOI 10.7189/jogh.11.03083; Ritchie H., CORONAVIRUS COVID 19; Ritchie H, CORONAVIRUS PANDEMIC; Stockdale JE, 2020, TRANSMISSION INTERVA, DOI [10.1101/2020.03.03.20029983, DOI 10.1101/2020.03.03.20029983, 10.1101/2020.03.03.20029983v1]; Tuite AR, 2021, ANN INTERN MED, V174, P570, DOI 10.7326/M20-8137; Tyson A, 2020, PEW RES CTR; US Food and Drug Administration, 2020, VACC REL BIOL PROD A; US Food & Drug Administration, 2021, FDA AUTH PFIZ BIOTEC; Usher AD, 2021, LANCET, V397, P2322, DOI 10.1016/S0140-6736(21)01367-2; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang XT, 2021, EMERG INFECT DIS, V27, P1976, DOI 10.3201/eid2707.210118; Wang XT, 2020, EMERG INFECT DIS, V26, P2361, DOI [10.3201/eid2510.201702, 10.3201/eid2610.201702]; WHO, 2021, INT STAT DOS SPAR ST; Wilder-Smith A, 2021, NAT MED, V27, P1856, DOI 10.1038/s41591-021-01534-z; World Health Organization, 2016, POL VACCS WHO POS PA; World Health Organization, TRACK SARS COV 2 VAR; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wu JT, 2016, LANCET, V388, P2904, DOI 10.1016/S0140-6736(16)31838-4; Zimmer C, NEW YORK TIMES	51	9	9	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					934	+		10.1038/s41591-022-01736-z	http://dx.doi.org/10.1038/s41591-022-01736-z		FEB 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35210596	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000761879000003
J	Shen, XY				Shen, Xiaoying			Boosting immunity to Omicron	NATURE MEDICINE			English	Editorial Material									[Shen, Xiaoying] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Shen, Xiaoying] Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC 27708 USA	Duke University; Duke University	Shen, XY (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.; Shen, XY (corresponding author), Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC 27708 USA.	sxshen@duke.edu						Accorsi EK, 2022, JAMA-J AM MED ASSOC, V327, P639, DOI 10.1001/jama.2022.0470; Cheng SMS, 2022, NAT MED, V28, P486, DOI 10.1038/s41591-022-01704-7; Cohen AA, 2021, SCIENCE, V371, P735, DOI 10.1126/science.abf6840; Gilbert Peter B, 2021, medRxiv, DOI 10.1101/2021.08.09.21261290; Gruell H, 2022, NAT MED, V28, P477, DOI 10.1038/s41591-021-01676-0; Hastie KM, 2021, SCIENCE, V374, P472, DOI 10.1126/science.abh2315; Johnson Amelia G, 2022, MMWR Morb Mortal Wkly Rep, V71, P132, DOI 10.15585/mmwr.mm7104e2; Kuhlmann C., 2022, LANCET, DOI [10.1016/S0140- 6736(22)00090-3 (2022), DOI 10.1016/S0140-6736(22)00090-3(2022)]; Liu LJ, 2022, NUTR NEUROSCI, V25, P2302, DOI 10.1080/1028415X.2021.1959099; Muik A, 2022, SCIENCE, V375, P678, DOI 10.1126/science.abn7591; Pajon R, 2022, NEW ENGL J MED, V386, P1088, DOI 10.1056/NEJMc2119912; Perez-Then E, 2022, NAT MED, V28, P481, DOI 10.1038/s41591-022-01705-6; Saunders KO, 2021, NATURE, V594, P553, DOI 10.1038/s41586-021-03594-0; Thompson MG., 2022, MMWR-MORBID MORTAL W; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y	15	13	13	2	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					445	446		10.1038/s41591-022-01727-0	http://dx.doi.org/10.1038/s41591-022-01727-0		FEB 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35210597	Bronze			2022-12-27	WOS:000761879000004
J	Talmor-Barkan, Y; Bar, N; Shaul, AA; Shahaf, N; Godneva, A; Bussi, Y; Lotan-Pompan, M; Weinberger, A; Shechter, A; Chezar-Azerrad, C; Arow, Z; Hammer, Y; Chechi, K; Forslund, SK; Fromentin, S; Dumas, ME; Ehrlich, SD; Pedersen, O; Kornowski, R; Segal, E				Talmor-Barkan, Yeela; Bar, Noam; Shaul, Aviv A.; Shahaf, Nir; Godneva, Anastasia; Bussi, Yuval; Lotan-Pompan, Maya; Weinberger, Adina; Shechter, Alon; Chezar-Azerrad, Chava; Arow, Ziad; Hammer, Yoav; Chechi, Kanta; Forslund, Sofia K.; Fromentin, Sebastien; Dumas, Marc-Emmanuel; Ehrlich, S. Dusko; Pedersen, Oluf; Kornowski, Ran; Segal, Eran			Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE METABOLOMICS; CARDIOVASCULAR-DISEASE; GUT MICROBIOTA; HEART-DISEASE; P-CRESOL; MORTALITY; ERGOTHIONEINE; EPIDEMIOLOGY; NUTRITION; ALIGNMENT	Multi-omic profiling of patients with coronary artery disease reveals links between alterations in the serum metabolome with genetics, diet and the microbiome and also implicates these metabolomic alterations with metabolic impairment preceding clinically overt coronary artery disease. Complex diseases, such as coronary artery disease (CAD), are often multifactorial, caused by multiple underlying pathological mechanisms. Here, to study the multifactorial nature of CAD, we performed comprehensive clinical and multi-omic profiling, including serum metabolomics and gut microbiome data, for 199 patients with acute coronary syndrome (ACS) recruited from two major Israeli hospitals, and validated these results in a geographically distinct cohort. ACS patients had distinct serum metabolome and gut microbial signatures as compared with control individuals, and were depleted in a previously unknown bacterial species of the Clostridiaceae family. This bacterial species was associated with levels of multiple circulating metabolites in control individuals, several of which have previously been linked to an increased risk of CAD. Metabolic deviations in ACS patients were found to be person specific with respect to their potential genetic or environmental origin, and to correlate with clinical parameters and cardiovascular outcomes. Moreover, metabolic aberrations in ACS patients linked to microbiome and diet were also observed to a lesser extent in control individuals with metabolic impairment, suggesting the involvement of these aberrations in earlier dysmetabolic phases preceding clinically overt CAD. Finally, a metabolomics-based model of body mass index (BMI) trained on the non-ACS cohort predicted higher-than-actual BMI when applied to ACS patients, and the excess BMI predictions independently correlated with both diabetes mellitus (DM) and CAD severity, as defined by the number of vessels involved. These results highlight the utility of the serum metabolome in understanding the basis of risk-factor heterogeneity in CAD.	[Talmor-Barkan, Yeela; Shaul, Aviv A.; Shechter, Alon; Chezar-Azerrad, Chava; Arow, Ziad; Hammer, Yoav; Kornowski, Ran] Rabin Med Ctr, Dept Cardiol, Petah Tiqwa, Israel; [Talmor-Barkan, Yeela; Shaul, Aviv A.; Shechter, Alon; Chezar-Azerrad, Chava; Arow, Ziad; Hammer, Yoav; Kornowski, Ran] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Talmor-Barkan, Yeela; Bar, Noam; Shahaf, Nir; Godneva, Anastasia; Bussi, Yuval; Lotan-Pompan, Maya; Weinberger, Adina; Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel; [Talmor-Barkan, Yeela; Bar, Noam; Shahaf, Nir; Godneva, Anastasia; Bussi, Yuval; Lotan-Pompan, Maya; Weinberger, Adina; Segal, Eran] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Chechi, Kanta; Dumas, Marc-Emmanuel] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, Genom & Environm Med, London, England; [Chechi, Kanta; Dumas, Marc-Emmanuel] Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, Div Syst Med, London, England; [Chechi, Kanta] Imperial Coll London, Fac Med, Sch Publ Hlth, St Marys Hosp, Med Sch Bldg, London, England; [Forslund, Sofia K.] Expt & Clin Res Ctr, Berlin, Germany; [Forslund, Sofia K.] Max Delbruck Ctr Mol Med MDC, Berlin, Germany; [Forslund, Sofia K.] MCharite Univ Hosp, Berlin, Germany; [Forslund, Sofia K.] DZHK German Ctr Cardiovasc Res, Berlin, Germany; [Fromentin, Sebastien; Ehrlich, S. Dusko] UCL, Dept Clin & Movement Neurosci, London, England; [Dumas, Marc-Emmanuel] Univ Lille, Lille Univ Hosp, European Genom Inst Diabet, Inst Pasteur Lille,UMR1283 8199,INSERM,CNRS, Lille, France; [Pedersen, Oluf] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Weizmann Institute of Science; Imperial College London; Imperial College London; Imperial College London; Helmholtz Association; Max Delbruck Center for Molecular Medicine; German Centre for Cardiovascular Research; University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Novo Nordisk Foundation; University of Copenhagen	Segal, E (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel.; Segal, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.	eran.segal@weizmann.ac.il	; Dumas, Marc-Emmanuel/C-1736-2008	Shechter, Alon/0000-0001-9670-4026; Weinberger, Adina/0000-0003-2231-4687; Chechi, Kanta/0000-0003-1929-4128; Bussi, Yuval/0000-0003-0365-431X; Forslund, Sofia K/0000-0003-4285-6993; Dumas, Marc-Emmanuel/0000-0001-9523-7024	Tel Aviv University Faculty Funds; Gassner Fund for Medical Research; Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center; Estate of Tully and Michele Plesser; Crown Human Genome Center; European Research Council; Israel Science Foundation; NIHR Imperial Biomedical Research Centre; French National Research Agency [ANR-10-LABX-46]; National Center for Precision Diabetic Medici-e - PreciDIAB; French National Agency for Research [ANR-18-IBHU-0001]; European Union (FEDER); Hauts-de-France Regional Council [20001891/NP0025517, 20002845]; European Metropolis of Lille (MEL) [2019_ESR_11]; Isite ULNE [R-002-20-TALENT-DUMAS]; ANR [ANR-16-IDEX-0004-ULNE]; European Metropolis of Lille (MEL); Medical Research Council (MRC) Skills Development Fellowship [MR/S020039/1]; Wellcome Trust [204834/Z/16/Z]	Tel Aviv University Faculty Funds; Gassner Fund for Medical Research; Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center; Estate of Tully and Michele Plesser; Crown Human Genome Center; European Research Council(European Research Council (ERC)European Commission); Israel Science Foundation(Israel Science Foundation); NIHR Imperial Biomedical Research Centre; French National Research Agency(French National Research Agency (ANR)); National Center for Precision Diabetic Medici-e - PreciDIAB; French National Agency for Research(French National Research Agency (ANR)); European Union (FEDER)(European Commission); Hauts-de-France Regional Council; European Metropolis of Lille (MEL); Isite ULNE; ANR(French National Research Agency (ANR)); European Metropolis of Lille (MEL); Medical Research Council (MRC) Skills Development Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)	We thank past and present members of the Segal group and the Cardiology Department at Rabin Medical Center for useful discussions. Y.T.-B. received a research grant from the Tel Aviv University Faculty Funds, and from the Gassner Fund for Medical Research. N.B. received a PhD scholarship for Data Science from the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and is supported by a research grant from the Estate of Tully and Michele Plesser. E.S. is supported by the Crown Human Genome Center, by D. L. Schwarz, J. N. Halpern and L. Steinberg, and by grants funded by the European Research Council and the Israel Science Foundation. M.-E.D. is supported by the NIHR Imperial Biomedical Research Centre, and by grants from the French National Research Agency (ANR-10-LABX-46 [European Genomics Institute for Diabetes]), from the National Center for Precision Diabetic Medici-e - PreciDIAB, which is jointly supported by the French National Agency for Research (ANR-18-IBHU-0001), by the European Union (FEDER), by the Hauts-de-France Regional Council (Agreement 20001891/NP0025517), by the European Metropolis of Lille (MEL, Agreement 2019_ESR_11) and Isite ULNE (R-002-20-TALENT-DUMAS), also jointly funded by ANR (ANR-16-IDEX-0004-ULNE), the Hauts-de-France Regional Council (20002845) and by the European Metropolis of Lille (MEL). K.C. is supported by Medical Research Council (MRC) Skills Development Fellowship (grant number MR/S020039/1) and Wellcome Trust funded Institutional Strategic Support Fellowship (grant number 204834/Z/16/Z).	Bar N, 2020, NATURE, V588, P135, DOI 10.1038/s41586-020-2896-2; Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609; Brown JM, 2014, CURR OPIN LIPIDOL, V25, P48, DOI 10.1097/MOL.0000000000000036; Carnevale R, 2020, EUR HEART J, V41, P3156, DOI 10.1093/eurheartj/ehz893; Cheah IK, 2012, BBA-MOL BASIS DIS, V1822, P784, DOI 10.1016/j.bbadis.2011.09.017; Cirulli ET, 2019, CELL METAB, V29, P488, DOI 10.1016/j.cmet.2018.09.022; Dhingra R, 2012, MED CLIN N AM, V96, P87, DOI 10.1016/j.mcna.2011.11.003; Forslund SK, 2021, NATURE, V600, P500, DOI 10.1038/s41586-021-04177-9; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gaziano JM, 2018, LANCET, V392, P1036, DOI 10.1016/S0140-6736(18)31924-X; Goossens GH, 2017, OBESITY FACTS, V10, P207, DOI 10.1159/000471488; Jie ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00900-1; Ke GL, 2017, ADV NEUR IN, V30; Korem T, 2015, SCIENCE, V349, P1101, DOI 10.1126/science.aac4812; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Leopold JA, 2018, CIRC RES, V122, P1302, DOI 10.1161/CIRCRESAHA.117.310782; Liu J, 2020, NAT MED, V26, P110, DOI 10.1038/s41591-019-0722-x; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Lundberg S.M, 2018, CONSISTENT INDIVIDUA; Lundberg SM, 2017, ADV NEUR IN, V30; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Maier L, 2018, NATURE, V555, P623, DOI 10.1038/nature25979; Marco-Sola S, 2012, NAT METHODS, V9, P1185, DOI [10.1038/NMETH.2221, 10.1038/nmeth.2221]; Martinez I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069621; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Meijers BKI, 2010, CLIN J AM SOC NEPHRO, V5, P1182, DOI 10.2215/CJN.07971109; Nemet I, 2020, CELL, V180, P862, DOI 10.1016/j.cell.2020.02.016; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Pertiwi K, 2020, DIABETES CARE, V43, P358, DOI 10.2337/dc19-1483; Pickens CA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05785-0; Poesen R, 2016, J AM SOC NEPHROL, V27, P3479, DOI 10.1681/ASN.2015121302; Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/CIRCULATIONAHA.106.171016; Poulter N, 1999, AM J HYPERTENS, V12, p92S; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; RINGQVIST I, 1983, J CLIN INVEST, V71, P1854, DOI 10.1172/JCI110941; Roth GA, 2015, CIRCULATION, V132, P1667, DOI 10.1161/CIRCULATIONAHA.114.008720; Rothschild D, 2018, NATURE, V555, P210, DOI 10.1038/nature25973; Smith E, 2020, HEART, V106, P691, DOI 10.1136/heartjnl-2019-315485; Soininen P, 2015, CIRC-CARDIOVASC GENE, V8, P192, DOI 10.1161/CIRCGENETICS.114.000216; Soneson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100335; Tang WHW, 2017, CIRC RES, V120, P1183, DOI 10.1161/CIRCRESAHA.117.309715; Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400; Vangipurapu J, 2020, DIABETES CARE, V43, P1319, DOI 10.2337/dc19-2533; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; Wilkins JT, 2012, JAMA-J AM MED ASSOC, V308, P1795, DOI 10.1001/jama.2012.14312; Winter SE, 2014, GUT MICROBES, V5, P71, DOI 10.4161/gmic.27129; Yousri NA, 2014, METABOLOMICS, V10, P1005, DOI 10.1007/s11306-014-0629-y; Zeevi D, 2019, NATURE, V568, P43, DOI 10.1038/s41586-019-1065-y; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zhu WF, 2016, CELL, V165, P111, DOI 10.1016/j.cell.2016.02.011; Zong G, 2019, DIABETES CARE, V42, P1406, DOI 10.2337/dc19-0412	53	12	12	38	64	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					295	+		10.1038/s41591-022-01686-6	http://dx.doi.org/10.1038/s41591-022-01686-6		FEB 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35177859				2022-12-27	WOS:000757243200005
J	Welch, NL; Zhu, ML; Hua, C; Weller, J; Mirhashemi, ME; Nguyen, TG; Mantena, S; Bauer, MR; Shaw, BM; Ackerman, CM; Thakku, SG; Tse, MW; Kehe, J; Uwera, MM; Eversley, JS; Bielwaski, DA; McGrath, G; Braidt, J; Johnson, J; Cerrato, F; Moreno, GK; Krasilnikova, LA; Petros, BA; Gionet, GL; King, E; Huard, RC; Jalbert, SK; Cleary, ML; Fitzgerald, NA; Gabriel, SB; Gallagher, GR; Smole, SC; Madoff, LC; Brown, CM; Keller, MW; Wilson, MM; Kirby, MK; Barnes, JR; Park, DJ; Siddle, KJ; Happi, CT; Hung, DT; Springer, M; MacInnis, BL; Lemieux, JE; Rosenberg, E; Branda, JA; Blainey, PC; Sabeti, PC; Myhrvold, C				Welch, Nicole L.; Zhu, Meilin; Hua, Catherine; Weller, Juliane; Mirhashemi, Marzieh Ezzaty; Nguyen, Tien G.; Mantena, Sreekar; Bauer, Matthew R.; Shaw, Bennett M.; Ackerman, Cheri M.; Thakku, Sri Gowtham; Tse, Megan W.; Kehe, Jared; Uwera, Marie-Martine; Eversley, Jacqueline S.; Bielwaski, Derek A.; McGrath, Graham; Braidt, Joseph; Johnson, Jeremy; Cerrato, Felecia; Moreno, Gage K.; Krasilnikova, Lydia A.; Petros, Brittany A.; Gionet, Gabrielle L.; King, Ewa; Huard, Richard C.; Jalbert, Samantha K.; Cleary, Michael L.; Fitzgerald, Nicholas A.; Gabriel, Stacey B.; Gallagher, Glen R.; Smole, Sandra C.; Madoff, Lawrence C.; Brown, Catherine M.; Keller, Matthew W.; Wilson, Malania M.; Kirby, Marie K.; Barnes, John R.; Park, Daniel J.; Siddle, Katherine J.; Happi, Christian T.; Hung, Deborah T.; Springer, Michael; MacInnis, Bronwyn L.; Lemieux, Jacob E.; Rosenberg, Eric; Branda, John A.; Blainey, Paul C.; Sabeti, Pardis C.; Myhrvold, Cameron			Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants	NATURE MEDICINE			English	Article							NUCLEIC-ACID DETECTION; PCR	A microfluidic CRISPR-based platform enables multiplexed and high-throughput identification of a wide range of respiratory viruses, including the ability to identify specific SARS-CoV-2 variants such as Delta and Omicron. The coronavirus disease 2019 (COVID-19) pandemic has demonstrated a clear need for high-throughput, multiplexed and sensitive assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses and their emerging variants. Here, we present a cost-effective virus and variant detection platform, called microfluidic Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (mCARMEN), which combines CRISPR-based diagnostics and microfluidics with a streamlined workflow for clinical use. We developed the mCARMEN respiratory virus panel to test for up to 21 viruses, including SARS-CoV-2, other coronaviruses and both influenza strains, and demonstrated its diagnostic-grade performance on 525 patient specimens in an academic setting and 166 specimens in a clinical setting. We further developed an mCARMEN panel to enable the identification of 6 SARS-CoV-2 variant lineages, including Delta and Omicron, and evaluated it on 2,088 patient specimens with near-perfect concordance to sequencing-based variant classification. Lastly, we implemented a combined Cas13 and Cas12 approach that enables quantitative measurement of SARS-CoV-2 and influenza A viral copies in samples. The mCARMEN platform enables high-throughput surveillance of multiple viruses and variants simultaneously, enabling rapid detection of SARS-CoV-2 variants.	[Welch, Nicole L.; Zhu, Meilin; Hua, Catherine; Weller, Juliane; Mirhashemi, Marzieh Ezzaty; Nguyen, Tien G.; Mantena, Sreekar; Bauer, Matthew R.; Shaw, Bennett M.; Ackerman, Cheri M.; Thakku, Sri Gowtham; Tse, Megan W.; Kehe, Jared; Uwera, Marie-Martine; Johnson, Jeremy; Cerrato, Felecia; Moreno, Gage K.; Krasilnikova, Lydia A.; Petros, Brittany A.; Gionet, Gabrielle L.; Fitzgerald, Nicholas A.; Gabriel, Stacey B.; Park, Daniel J.; Siddle, Katherine J.; Happi, Christian T.; Hung, Deborah T.; Springer, Michael; MacInnis, Bronwyn L.; Lemieux, Jacob E.; Blainey, Paul C.; Sabeti, Pardis C.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Welch, Nicole L.] Harvard Med Sch, Div Med Sci, Harvard Program Virol, Boston, MA 02115 USA; [Zhu, Meilin; Ackerman, Cheri M.; Tse, Megan W.; Kehe, Jared; Blainey, Paul C.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Hua, Catherine; Shaw, Bennett M.; Eversley, Jacqueline S.; Bielwaski, Derek A.; McGrath, Graham; Braidt, Joseph; Lemieux, Jacob E.; Rosenberg, Eric] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA; [Weller, Juliane] Wellcome Sanger Inst, Wellcome Genome Campus, Hinxton, England; [Bauer, Matthew R.] Harvard Med Sch, Harvard Program Biol & Biomed Sci, Boston, MA 02115 USA; [Thakku, Sri Gowtham; Petros, Brittany A.] Harvard Med Sch, Div Hlth Sci & Technol, Cambridge, MA USA; [Thakku, Sri Gowtham; Petros, Brittany A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Krasilnikova, Lydia A.; Siddle, Katherine J.; Branda, John A.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; [Petros, Brittany A.] Harvard Med Sch, Harvard MIT MD PhD Program, Boston, MA 02115 USA; [Petros, Brittany A.; Jalbert, Samantha K.; Cleary, Michael L.; Springer, Michael] Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA; [King, Ewa; Huard, Richard C.] Rhode Isl Dept Hlth, State Hlth Labs, Providence, RI 02908 USA; [Gallagher, Glen R.; Smole, Sandra C.; Madoff, Lawrence C.; Brown, Catherine M.] Massachusetts Dept Publ Hlth, Boston, MA USA; [Keller, Matthew W.; Wilson, Malania M.; Kirby, Marie K.; Barnes, John R.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Happi, Christian T.] Redeemers Univ, African Ctr Excellence Genom Infect Dis, Ede, Nigeria; [Happi, Christian T.] Redeemers Univ, Coll Nat Sci, Dept Biol Sci, Ede, Nigeria; [Hung, Deborah T.] Massachusetts Gen Hosp, Mol Biol Dept, Boston, MA 02114 USA; [Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA; [MacInnis, Bronwyn L.; Sabeti, Pardis C.] Harvard Univ, Dept Immunol & Infect Dis, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Rosenberg, Eric] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Rosenberg, Eric] Harvard Med Sch, Boston, MA 02115 USA; [Blainey, Paul C.; Sabeti, Pardis C.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Sabeti, Pardis C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Myhrvold, Cameron] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Wellcome Trust Sanger Institute; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Department of Public Health; Centers for Disease Control & Prevention - USA; Redeemers University; Redeemers University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Princeton University	Welch, NL; Sabeti, PC (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Welch, NL (corresponding author), Harvard Med Sch, Div Med Sci, Harvard Program Virol, Boston, MA 02115 USA.; Sabeti, PC (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.; Sabeti, PC (corresponding author), Harvard Univ, Dept Immunol & Infect Dis, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.; Sabeti, PC (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Sabeti, PC (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.; Myhrvold, C (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	nicole_welch@g.harvard.edu; pardis@broadinstitute.org; cmyhrvol@princeton.edu	Sabeti, Pardis/GQH-8610-2022	Weller, Juliane/0000-0002-1310-6168; Hua, Catherine/0000-0003-0455-5364; Welch, Nicole/0000-0002-1163-7002; Myhrvold, Cameron/0000-0002-8971-184X	Defense Advanced Research Projects Agency [D18AC00006]; Flu laboratory; Centers for Disease Control and Prevention (CDC) COVID-19 baseline genomic surveillance contract sequencing [75D30121C10501]; CDC Broad Agency Announcement [75D30120C09605]; National Institute of Allergy and Infectious Diseases [U19AI110818, U01AI151812]; National Science Foundation Graduate Research Fellowship [1745302]; National Institute of General Medical Sciences [T32GM007753]; Howard Hughes Medical Institute; Princeton University	Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Flu laboratory; Centers for Disease Control and Prevention (CDC) COVID-19 baseline genomic surveillance contract sequencing(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); CDC Broad Agency Announcement; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Princeton University(Princeton University)	We thank the Blainey and Hung laboratories at the Broad Institute for providing additional laboratory space to perform the work; J. Arizti Sanz, Y. Zhang and A. Bradley for helping with guide design or sharing reagents; G. Adams, S. Dobbins, S. Slack, K. DeRuff and other members of the Sabeti laboratory COVID-19 sequencing team for providing patient samples; K. Carpenter-Azevedo from RIDOH for organizing and sending the Rhode Island patient samples; C. Tomkins-Tinch, C. Loreth and other Sabeti laboratory members for providing assistance with the NGS analysis on Terra; B. Zhou for helping provide the SARS-CoV-2 VOC seed stocks and patient samples; and H. Metsky, C. Freije, J. Arizti Sanz and S. Siddiqui for their thoughtful discussions and reading of the manuscript. We also acknowledge all members of the Massachusetts Department of Public Health, Broad Institute SARS-CoV-2 Genomics and Data Science Platforms and the Rhode Island Department of Public Health. Funding was provided by the Defense Advanced Research Projects Agency (no. D18AC00006). This work was made possible by support from the Flu laboratory and a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, Skoll Foundation and Open Philanthropy. Funding for NGS was provided by the Centers for Disease Control and Prevention (CDC) COVID-19 baseline genomic surveillance contract sequencing (no. 75D30121C10501 to the Clinical Research Sequencing Platform), a CDC Broad Agency Announcement (no. 75D30120C09605 to B.L.M.) and the National Institute of Allergy and Infectious Diseases (nos. U19AI110818 and U01AI151812 to P.C.S.). M.Z. and M.W.T. were supported by the National Science Foundation Graduate Research Fellowship under grant no. 1745302. B.A.P. was supported by the National Institute of General Medical Sciences grant no. T32GM007753. P.C.S. was supported by the Howard Hughes Medical Institute and Merck KGaA Future Insight Prize. C.M. was supported by start-up funds from Princeton University. The views, opinions, conclusions and/or findings expressed should not be interpreted as representing the official views or policies, either expressed or implied, of the Department of Defense, US Government, National Institute of General Medical Sciences, Department of Homeland Security (DHS) or the National Institutes of Health. The DHS does not endorse any products or commercial services mentioned in this presentation. In no event shall the DHS, Battelle National Biodefense Institute or National Biodefense Analysis and Countermeasures Center have any responsibility or liability for any use, misuse, inability to use or reliance on the information contained herein. In addition, no warranty of fitness for a particular purpose, merchantability, accuracy or adequacy is provided regarding the contents of this document. The US Government retains and the publisher, by accepting the article for publication, acknowledges that the US Government retains a nonexclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published form of this manuscript, or allow others to do so, for US Government purposes. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. The use of trade names and commercial sources is for identification purposes only and does not imply endorsement.	Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573; Ackerman CM, 2020, NATURE, V582, P277, DOI 10.1038/s41586-020-2279-8; Arizti-Sanz J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19097-x; Borges V, 2021, EUROSURVEILLANCE, V26, P2, DOI 10.2807/1560-7917.ES.2021.26.10.2100130; Brandal LT, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.50.2101147; Brito Anderson F, 2021, medRxiv, DOI 10.1101/2021.08.21.21262393; Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4; Bruch R, 2021, BIOSENS BIOELECTRON, V177, DOI 10.1016/j.bios.2020.112887; Bruch R, 2019, TRENDS BIOTECHNOL, V37, P791, DOI 10.1016/j.tibtech.2019.04.005; Burki T, 2021, LANCET, V397, P462, DOI 10.1016/S0140-6736(21)00298-1; Chen JS, 2018, SCIENCE, V360, P436, DOI 10.1126/science.aar6245; Crowe JE., 2014, REFERENCE MODULE BIO, DOI [10.1016/B978-0-12-801238-3.02600-3, DOI 10.1016/B978-0-12-801238-3.02600-3, 10.1016/b978-0-12-801238-3.02600-3]; Dyson L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25915-7; Eckbo EJ, 2021, DIAGN MICR INFEC DIS, V99, DOI 10.1016/j.diagmicrobio.2020.115260; Fozouni P, 2021, CELL, V184, P323, DOI 10.1016/j.cell.2020.12.001; Fernandez XG, 2020, ENFERM INFEC MICR CL, V38, P297, DOI 10.1016/j.eimc.2019.09.010; Gootenberg JS, 2018, SCIENCE, V360, P439, DOI 10.1126/science.aaq0179; Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Heggestad JT, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4901; Houldcroft CJ, 2017, NAT REV MICROBIOL, V15, P183, DOI 10.1038/nrmicro.2016.182; Huang HS, 2018, CLIN MICROBIOL INFEC, V24, P1055, DOI 10.1016/j.cmi.2017.11.018; Jacky L, 2021, ANAL CHEM, V93, P4208, DOI 10.1021/acs.analchem.0c04626; Jiao CL, 2021, SCIENCE, V372, P941, DOI 10.1126/science.abe7106; Joung J, 2020, NEW ENGL J MED, V383, P1492, DOI 10.1056/NEJMc2026172; Kaminski MM, 2021, NAT BIOMED ENG, V5, P643, DOI 10.1038/s41551-021-00760-7; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kirkland PD, 2020, PATHOLOGY, V52, P811, DOI 10.1016/j.pathol.2020.09.013; Konings F, 2021, NAT MICROBIOL, V6, P821, DOI 10.1038/s41564-021-00932-w; Lemieux JE, 2021, SCIENCE, V371, P588, DOI 10.1126/science.abe3261; Li A, 2022, J MED VIROL, V94, P1784, DOI 10.1002/jmv.27562; Li SY, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0028-z; Mackay IM, 2002, NUCLEIC ACIDS RES, V30, P1292, DOI 10.1093/nar/30.6.1292; Matranga CB, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0519-7; Metsky HC, 2022, NAT BIOTECHNOL, DOI 10.1038/s41587-022-01213-5; Mina MJ, 2021, SCIENCE, V371, P126, DOI 10.1126/science.abe9187; Myhrvold C, 2018, SCIENCE, V360, P444, DOI 10.1126/science.aas8836; Nalefski EA, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102996; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Patchsung M, 2020, NAT BIOMED ENG, V4, P1140, DOI 10.1038/s41551-020-00603-x; Peddu V, 2020, CLIN CHEM, V66, P966, DOI 10.1093/clinchem/hvaa106; Perrine CG, 2021, MMWR-MORBID MORTAL W, V70, P1731, DOI 10.15585/mmwr.mm7050e1; Pham J, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01669-20; Pulliam JRC., 2021, INCREASED RISK SARS, DOI [10.1101/2021.11.11.21266068, 10.1101/2021.11.11.21266068:2021.11.11.21266068, DOI 10.1101/2021.11.11.21266068:2021.11.11.21266068]; Rasmussen AL, 2021, SCIENCE, V371, P1206, DOI 10.1126/science.abf9569; Thakku S. G., 2021, MULTIPLEXED DETECTIO, DOI [10.1101/2021.11.12.468388, DOI 10.1101/2021.11.12.468388]; Tian T, 2022, BIOSENS BIOELECTRON, V196, DOI 10.1016/j.bios.2021.113701; Vogels CBF, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001236; Winichakoon P, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00297-20; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Woloshin S, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2015897; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Xuan JK, 2013, CANCER LETT, V340, P284, DOI 10.1016/j.canlet.2012.11.025; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	54	30	30	103	186	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1083	+		10.1038/s41591-022-01734-1	http://dx.doi.org/10.1038/s41591-022-01734-1		FEB 2022	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35130561	hybrid, Green Published			2022-12-27	WOS:000770526800001
J	Cheng, SMS; Mok, CKP; Leung, YWY; Ng, SS; Chan, KCK; Ko, FW; Chen, CK; Yiu, K; Lam, BHS; Lau, EHY; Chan, KKP; Luk, LLH; Li, JKC; Tsang, LCH; Poon, LLM; Hui, DSC; Peiris, M				Cheng, Samuel M. S.; Mok, Chris Ka Pun; Leung, Yonna W. Y.; Ng, Susanna S.; Chan, Karl C. K.; Ko, Fanny W.; Chen, Chunke; Yiu, Karen; Lam, Bosco H. S.; Lau, Eric H. Y.; Chan, Ken K. P.; Luk, Leo L. H.; Li, John K. C.; Tsang, Leo C. H.; Poon, Leo L. M.; Hui, David S. C.; Peiris, Malik			Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	NATURE MEDICINE			English	Article								Serum neutralizing antibody titers against the SARS-CoV-2 Omicron variant markedly increase after a third dose of BNT162b2 vaccine in individuals who previously received either two doses of the BNT162b2 vaccine or two doses of the CoronaVac vaccine. The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in the serum of convalescent or vaccinated individuals to understand potential loss of protection against infection by Omicron. We previously established that a 50% plaque reduction neutralization antibody titer (PRNT50) >= 25.6 in our live virus assay corresponded to the threshold for 50% protection from infection against wild-type (WT) SARS-CoV-2. Here we show markedly reduced serum antibody titers against the Omicron variant (geometric mean titer (GMT) < 10) compared to WT virus 3-5 weeks after two doses of BNT162b2 (GMT = 218.8) or CoronaVac vaccine (GMT = 32.5). A BNT162b2 booster dose elicited Omicron PRNT50 titers >= 25.6 in 88% of individuals (22 of 25) who previously received 2 doses of BNT162b2 and 80% of individuals (24 of 30) who previously received CoronaVac. However, few (3%) previously infected individuals (1 of 30) or those vaccinated with three doses of CoronaVac (1 of 30) met this threshold. Our findings suggest that countries primarily using CoronaVac vaccines should consider messenger RNA vaccine boosters in response to the spread of Omicron. Studies evaluating the effectiveness of different vaccines against the Omicron variant are urgently needed.	[Cheng, Samuel M. S.; Leung, Yonna W. Y.; Chan, Karl C. K.; Lau, Eric H. Y.; Luk, Leo L. H.; Li, John K. C.; Tsang, Leo C. H.; Poon, Leo L. M.; Peiris, Malik] Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Mok, Chris Ka Pun; Chen, Chunke] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Mok, Chris Ka Pun; Chen, Chunke] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Fac Med, Hong Kong, Peoples R China; [Ng, Susanna S.; Ko, Fanny W.; Yiu, Karen; Chan, Ken K. P.; Hui, David S. C.] Chinese Univ Hong, Dept Med & Therapeut, Fac Med, Hong Kong, Peoples R China; [Lam, Bosco H. S.] North Lantau Hosp, Dept Pathol, Hong Kong, Peoples R China; [Lau, Eric H. Y.] Lab Data Discovery Hlth Ltd, Hong Kong Sci Pk, Hong Kong, Peoples R China; [Poon, Leo L. M.; Peiris, Malik] Ctr Immunol & Infect, Sci Pk,Hong, Hong Kong, Peoples R China; [Hui, David S. C.] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Fac Med, Hong Kong, Peoples R China	University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Peiris, M (corresponding author), Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Hong Kong, Peoples R China.; Hui, DSC (corresponding author), Chinese Univ Hong, Dept Med & Therapeut, Fac Med, Hong Kong, Peoples R China.; Peiris, M (corresponding author), Ctr Immunol & Infect, Sci Pk,Hong, Hong Kong, Peoples R China.; Hui, DSC (corresponding author), Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Fac Med, Hong Kong, Peoples R China.	dschui@cuhk.edu.hk; malik@hku.hk	Hui, David Shu-Cheong/O-2754-2015; Cheng, samuel M.S./GNH-2164-2022; Poon, Leo/AAP-6887-2020; Lau, Eric/C-4487-2009	Hui, David Shu-Cheong/0000-0003-4382-2445; Cheng, samuel M.S./0000-0001-7293-2331; Lau, Eric/0000-0002-6688-9637	Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR [COVID1903003, COVID190126]; National Institutes of Health [AI151810]; National Natural Science Foundation of China/Research Grants Council (RGC) Joint Research Scheme [N_HKU737/18]; RGC theme-based research schemes [T11-712/19-N, T11-705/21-N]; Guangdong Province International Scientific and Technological Cooperation Projects [2020A0505100063]; National Research Foundation (NRF) of Korea grant through the Korea government [NRF-2018M3A9H4055203]; AIR@InnoHK; C2i	Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China/Research Grants Council (RGC) Joint Research Scheme; RGC theme-based research schemes; Guangdong Province International Scientific and Technological Cooperation Projects; National Research Foundation (NRF) of Korea grant through the Korea government; AIR@InnoHK; C2i	This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003 and COVID190126) (C.K.P.M., D.S.C.H. and M.P.), the National Institutes of Health (grant no. U01-Grant AI151810) (M.P.), National Natural Science Foundation of China/Research Grants Council (RGC) Joint Research Scheme (no. N_HKU737/18) (C.K.P.M. and M.P.), RGC theme-based research schemes (nos. T11-712/19-N and T11-705/21-N) (D.S.C.H., M.P.), Guangdong Province International Scientific and Technological Cooperation Projects (no. 2020A0505100063) (C.K.P.M.), the National Research Foundation (NRF) of Korea grant funded through the Korea government (no. NRF-2018M3A9H4055203) (C.K.P.M.), AIR@InnoHK(E.H.Y.L.) and C2i (L.L.M.P., M.P.) administered by the Innovation and Technology Commission of Hong Kong. Author	Addetia Amin, 2020, medRxiv, DOI 10.1101/2020.08.13.20173161; [Anonymous], 2021, BANGKOK POST 0617; Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1; Cromer D, 2022, LANCET MICROBE, V3, pE52, DOI 10.1016/S2666-5247(21)00267-6; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Khan K., 2021, PREPRINT, DOI [10.1101/2021.12.27.21268439, DOI 10.1101/2021.12.27.21268439]; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lau EHY, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101174; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Levine-Tiefenbrun M., 2021, WANING SARS COV 2 BO, DOI [10.1101/2021.12.27.21268424, DOI 10.1101/2021.12.27.21268424]; Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mok CKP, 2022, AM J RESP CRIT CARE, V205, P844, DOI 10.1164/rccm.202111-2655LE; Mok CKP, 2022, RESPIROLOGY, V27, P301, DOI 10.1111/resp.14191; Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421; Schmidt F, 2022, NEW ENGL J MED, V386, P599, DOI 10.1056/NEJMc2119641; Viana, NATURE; World Health Organization, CLASS OM B 1 1 529 S; Zeng G, 2022, LANCET INFECT DIS, V22, P483, DOI 10.1016/S1473-3099(21)00681-2; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	20	119	119	10	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					486	+		10.1038/s41591-022-01704-7	http://dx.doi.org/10.1038/s41591-022-01704-7		JAN 2022	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35051989	Green Published, Bronze, Green Accepted			2022-12-27	WOS:000760098500001
J	Rajpurkar, P; Chen, E; Banerjee, O; Topol, EJ				Rajpurkar, Pranav; Chen, Emma; Banerjee, Oishi; Topol, Eric J.			AI in health and medicine	NATURE MEDICINE			English	Review							ARTIFICIAL-INTELLIGENCE; DIABETIC-RETINOPATHY; IMAGING DATA; DEEP; PREDICTION; SYSTEM; CANCER; CLASSIFICATION; PERFORMANCE; VALIDATION	AI has the potential to reshape medicine and make healthcare more accurate, efficient and accessible; this Review discusses recent progress, opportunities and challenges toward achieving this goal. Artificial intelligence (AI) is poised to broadly reshape medicine, potentially improving the experiences of both clinicians and patients. We discuss key findings from a 2-year weekly effort to track and share key developments in medical AI. We cover prospective studies and advances in medical image analysis, which have reduced the gap between research and deployment. We also address several promising avenues for novel medical AI research, including non-image data sources, unconventional problem formulations and human-AI collaboration. Finally, we consider serious technical and ethical challenges in issues spanning from data scarcity to racial bias. As these challenges are addressed, AI's potential may be realized, making healthcare more accurate, efficient and accessible for patients worldwide.	[Rajpurkar, Pranav] Harvard Univ, Dept Biomed Informat, Cambridge, MA 02138 USA; [Chen, Emma; Banerjee, Oishi] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Topol, Eric J.] Scripps Translat Sci Inst, San Diego, CA 92037 USA	Harvard University; Stanford University	Topol, EJ (corresponding author), Scripps Translat Sci Inst, San Diego, CA 92037 USA.	etopol@scripps.edu		Topol, Eric/0000-0002-1478-4729; Rajpurkar, Pranav/0000-0002-8030-3727; Chen, Emma/0000-0002-7528-5229	US National Institutes of Health [UL1TR002550]	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank A. Tamkin and N. Phillips for their feedback. E.J.T. receives funding support from US National Institutes of Health grant UL1TR002550.	Amodio M, 2019, NAT METHODS, V16, P1139, DOI 10.1038/s41592-019-0576-7; Arcadu F, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0172-3; Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x; Attia ZI, 2019, LANCET, V394, P861, DOI 10.1016/S0140-6736(19)31721-0; Beam AL, 2020, JAMA-J AM MED ASSOC, V323, P305, DOI 10.1001/jama.2019.20866; Beede E, 2020, PROCEEDINGS OF THE 2020 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'20), DOI 10.1145/3313831.3376718; Benjamens S, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00324-0; Bera K, 2019, NAT REV CLIN ONCOL, V16, P703, DOI 10.1038/s41571-019-0252-y; Bhattacharyya RP, 2019, NAT MED, V25, P1858, DOI 10.1038/s41591-019-0650-9; Brbic M, 2020, NAT METHODS, V17, P1200, DOI 10.1038/s41592-020-00979-3; Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1; Centers for Medicare & Medicaid Services, 2020, MEDICAREPROGRAM HOSP, V85, P58432; Chabon JJ, 2020, NATURE, V580, P245, DOI 10.1038/s41586-020-2140-0; Chan J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav1102; Chen PHC, 2019, NAT MED, V25, P1453, DOI 10.1038/s41591-019-0539-7; Cirillo D, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0288-5; Claassen J, 2019, NEW ENGL J MED, V380, P2497, DOI 10.1056/NEJMoa1812757; Courtiol P, 2019, NAT MED, V25, P1519, DOI 10.1038/s41591-019-0583-3; Cristiano S, 2019, NATURE, V570, P385, DOI 10.1038/s41586-019-1272-6; Cutillo CM, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0254-2; DeGrave AJ, 2021, NAT MACH INTELL, V3, P610, DOI 10.1038/s42256-021-00338-7; Ehsan U., 2021, WHO EXPLAINABLE AI A, DOI DOI 10.1001/jamaoncol.2019.1800; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Freedman D, 2020, IEEE T MED IMAGING, V39, P3451, DOI 10.1109/TMI.2020.2994221; Fries JA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11012-3; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Gainza P, 2020, NAT METHODS, V17, P184, DOI 10.1038/s41592-019-0666-6; Gerke S, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0262-2; Ghorbani A, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-019-0216-8; Gong DX, 2020, LANCET GASTROENTEROL, V5, P352, DOI 10.1016/S2468-1253(19)30413-3; Green EM, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0130-0; Greener JG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11994-0; Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216; Hannun AY, 2019, NAT MED, V25, P65, DOI 10.1038/s41591-018-0268-3; Hollon TC, 2020, NAT MED, V26, P52, DOI 10.1038/s41591-019-0715-9; Huang P, 2019, LANCET DIGIT HEALTH, V1, pE353, DOI 10.1016/S2589-7500(19)30159-1; Huang SC, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00341-z; Huynh E, 2020, NAT REV CLIN ONCOL, V17, P771, DOI 10.1038/s41571-020-0417-8; Irvin J, 2019, AAAI CONF ARTIF INTE, P590; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Jain A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.7249; Jin LH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15784-x; Kaissis GA, 2020, NAT MACH INTELL, V2, P305, DOI 10.1038/s42256-020-0186-1; Kanagasingam Y, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2665; Kather JN, 2019, NAT MED, V25, P1054, DOI 10.1038/s41591-019-0462-y; Kehl KL, 2019, JAMA ONCOL, V5, P1421, DOI 10.1001/jamaoncol.2019.1800; Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2; Kiani A, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0232-8; Kim HE, 2020, LANCET DIGIT HEALTH, V2, pE138, DOI 10.1016/S2589-7500(20)30003-0; Larrazabal AJ, 2020, P NATL ACAD SCI USA, V117, P12592, DOI 10.1073/pnas.1919012117; Larson DB, 2020, RADIOLOGY, V295, P675, DOI 10.1148/radiol.2020192536; Lee CS, 2020, LANCET DIGIT HEALTH, V2, pE279, DOI 10.1016/S2589-7500(20)30102-3; Lee J, 2020, BIOINFORMATICS, V36, P1234, DOI 10.1093/bioinformatics/btz682; Li XJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15851-3; Li Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16378-3; Lin HT, 2019, ECLINICALMEDICINE, V9, P52, DOI 10.1016/j.eclinm.2019.03.001; Liu C., 2020, REPLICABILITY REPROD; Liu HR, 2019, JAMA OPHTHALMOL, V137, P1353, DOI 10.1001/jamaophthalmol.2019.3501; Liu XX, 2020, LANCET DIGIT HEALTH, V2, pE537, DOI [10.1016/S2589-7500(20)30218-1, 10.1016/S2589-7500(20)30219-3]; Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2; Luo HY, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax7533; Masutani EM, 2020, RADIOLOGY, V295, P552, DOI 10.1148/radiol.2020192173; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; Milea D, 2020, NEW ENGL J MED, V382, P1687, DOI 10.1056/NEJMoa1917130; Morley J., 2019, DEBATE ETHICS HLTH C, DOI [10.2139/ssrn.3486518, DOI 10.2139/SSRN.3486518]; Nimri R, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1045-7; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Ouyang DV, 2020, NATURE, V580, P252, DOI 10.1038/s41586-020-2145-8; Park A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.5600; Patel BN, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0189-7; Phillips M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.13436; Porter P, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1046-6; Porumb M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56927-5; Price WN, 2019, JAMA-J AM MED ASSOC, V322, P1765, DOI 10.1001/jama.2019.15064; Rajpurkar P, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00322-2; Rajpurkar P, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002686; Rana A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5111; Reyes M, 2020, RADIOL-ARTIF INTELL, V2, DOI 10.1148/ryai.2020190043; Rivera SC, 2020, NAT MED, V26, P1351, DOI 10.1038/s41591-020-1037-7; Saporta A., 2021, DEEP LEARNING SALIEN, DOI [10.1101/2021.02.28.21252634, DOI 10.1101/2021.02.28.21252634, 10. 1101/2021.02.28.21252634]; Sarker A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.14672; Seah JCY, 2021, LANCET DIGIT HEALTH, V3, pE496, DOI 10.1016/S2589-7500(21)00106-0; Sendak MP, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0253-3; Senior AW, 2020, NATURE, V577, P706, DOI 10.1038/s41586-019-1923-7; Seymour CW, 2019, JAMA-J AM MED ASSOC, V321, P2003, DOI 10.1001/jama.2019.5791; Sim Y, 2020, RADIOLOGY, V294, P199, DOI 10.1148/radiol.2019182465; Smit A., 2020, P 2020 C EMP METH NA, P1500; Steiner DF, 2018, AM J SURG PATHOL, V42, P1636, DOI 10.1097/PAS.0000000000001151; Stokes JM, 2020, CELL, V181, P475, DOI 10.1016/j.cell.2020.04.001; Thorsen-Meyer HC, 2020, LANCET DIGIT HEALTH, V2, pE179, DOI 10.1016/S2589-7500(20)30018-2; Tomasev N, 2019, NATURE, V572, P116, DOI 10.1038/s41586-019-1390-1; Tschandl P, 2020, NAT MED, V26, P1229, DOI 10.1038/s41591-020-0942-0; Tshitoyan V, 2019, NATURE, V571, P95, DOI 10.1038/s41586-019-1335-8; Urteaga I, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0292-9; US Food and Drug Administration, 2019, PROP REG FRAM MOD AR; van der Laak J, 2021, NAT MED, V27, P775, DOI 10.1038/s41591-021-01343-4; Vishnevskiy V, 2020, NAT MACH INTELL, V2, P228, DOI 10.1038/s42256-020-0165-6; Vyas DA, 2020, NEW ENGL J MED, V383, P874, DOI 10.1056/NEJMms2004740; Wang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12969-x; Wang DQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12281-8; Wang P, 2020, LANCET GASTROENTEROL, V5, P343, DOI [10.1016/S2468-1253(19)30411-X, 10.1016/S2468-1253(19)30411-x]; Wiens J, 2019, NAT MED, V25, P1337, DOI 10.1038/s41591-019-0548-6; Wijnberge M, 2020, JAMA-J AM MED ASSOC, V323, P1052, DOI 10.1001/jama.2020.0592; Willemink MJ, 2020, RADIOLOGY, V295, P4, DOI 10.1148/radiol.2020192224; Willett FR, 2021, NATURE, V593, P249, DOI 10.1038/s41586-021-03506-2; Wismuller A., 2020, MED IMAGING 2020 BIO, V11317; Wolf RM, 2020, JAMA OPHTHALMOL, V138, P1063, DOI 10.1001/jamaophthalmol.2020.3190; Wu N, 2020, IEEE T MED IMAGING, V39, P1184, DOI 10.1109/TMI.2019.2945514; Xie YC, 2020, LANCET DIGIT HEALTH, V2, pE240, DOI 10.1016/S2589-7500(20)30060-1; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Zhao SB, 2019, GASTROENTEROLOGY, V156, P1661, DOI 10.1053/j.gastro.2019.01.260; Zhavoronkov A, 2019, NAT BIOTECHNOL, V37, P1038, DOI 10.1038/s41587-019-0224-x; Zhou DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16777-6; Zhu Y, 2020, J BIOMED INFORM, V106, DOI [10.1016/j.jbl.2020.103451, 10.1016/j.jbi.2020.103451]	115	73	74	119	167	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					31	38		10.1038/s41591-021-01614-0	http://dx.doi.org/10.1038/s41591-021-01614-0		JAN 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35058619				2022-12-27	WOS:000745382100001
J	Zhang, P; Narayanan, E; Liu, QB; Tsybovsky, Y; Boswell, K; Ding, SL; Hu, ZH; Follmann, D; Lin, Y; Miao, HY; Schmeisser, H; Rogers, D; Falcone, S; Elbashir, SM; Presnyak, V; Bahl, K; Prabhakaran, M; Chen, XJ; Sarfo, EK; Ambrozak, DR; Gautam, R; Martin, MA; Swerczek, J; Herbert, R; Weiss, D; Misamore, J; Ciaramella, G; Himansu, S; Stewart-Jones, G; McDermott, A; Koup, RA; Mascola, JR; Finzi, A; Carfi, A; Fauci, AS; Lusso, P				Zhang, Peng; Narayanan, Elisabeth; Liu, Qingbo; Tsybovsky, Yaroslav; Boswell, Kristin; Ding, Shilei; Hu, Zonghui; Follmann, Dean; Lin, Yin; Miao, Huiyi; Schmeisser, Hana; Rogers, Denise; Falcone, Samantha; Elbashir, Sayda M.; Presnyak, Vladimir; Bahl, Kapil; Prabhakaran, Madhu; Chen, Xuejun; Sarfo, Edward K.; Ambrozak, David R.; Gautam, Rajeev; Martin, Malcom A.; Swerczek, Joanna; Herbert, Richard; Weiss, Deborah; Misamore, Johnathan; Ciaramella, Giuseppe; Himansu, Sunny; Stewart-Jones, Guillaume; McDermott, Adrian; Koup, Richard A.; Mascola, John R.; Finzi, Andres; Carfi, Andrea; Fauci, Anthony S.; Lusso, Paolo			A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques	NATURE MEDICINE			English	Article							HIV-1 ENVELOPE TRIMERS; SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS; NEUTRALIZING ANTIBODIES; NONHUMAN-PRIMATES; T-CELLS; IMMUNOGENICITY; RESPONSES; PARTICLES; PROTEIN; IDENTIFICATION	An mRNA vaccine platform to prevent HIV-1 infection generated broadly neutralizing antibodies in non-human primates and protected some animals from infection, raising hope that optimization of this approach might lead to an effective HIV vaccine. The development of a protective vaccine remains a top priority for the control of the HIV/AIDS pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing membrane-anchored HIV-1 envelope (Env) and simian immunodeficiency virus (SIV) Gag proteins to generate virus-like particles (VLPs) induces antibodies capable of broad neutralization and reduces the risk of infection in rhesus macaques. In mice, immunization with co-formulated env and gag mRNAs was superior to env mRNA alone in inducing neutralizing antibodies. Macaques were primed with a transmitted-founder clade-B env mRNA lacking the N276 glycan, followed by multiple booster immunizations with glycan-repaired autologous and subsequently bivalent heterologous envs (clades A and C). This regimen was highly immunogenic and elicited neutralizing antibodies against the most prevalent (tier-2) HIV-1 strains accompanied by robust anti-Env CD4(+) T cell responses. Vaccinated animals had a 79% per-exposure risk reduction upon repeated low-dose mucosal challenges with heterologous tier-2 simian-human immunodeficiency virus (SHIV AD8). Thus, the multiclade env-gag VLP mRNA platform represents a promising approach for the development of an HIV-1 vaccine.	[Zhang, Peng; Liu, Qingbo; Lin, Yin; Miao, Huiyi; Schmeisser, Hana; Rogers, Denise; Fauci, Anthony S.; Lusso, Paolo] NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Narayanan, Elisabeth; Falcone, Samantha; Elbashir, Sayda M.; Presnyak, Vladimir; Bahl, Kapil; Ciaramella, Giuseppe; Himansu, Sunny; Stewart-Jones, Guillaume; Carfi, Andrea] Moderna Inc, Cambridge, MA USA; [Tsybovsky, Yaroslav] Leidos Biomed Res Inc, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Boswell, Kristin; Prabhakaran, Madhu; Chen, Xuejun; Sarfo, Edward K.; Ambrozak, David R.; McDermott, Adrian; Koup, Richard A.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Ding, Shilei; Finzi, Andres] Univ Montreal, Montreal, PQ, Canada; [Hu, Zonghui; Follmann, Dean] NIAID, Biostat Res Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gautam, Rajeev; Martin, Malcom A.] NIAID, Lab Mol Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Swerczek, Joanna; Herbert, Richard] NIAID, Expt Primate Virol Sect, Poolesville, MD USA; [Weiss, Deborah; Misamore, Johnathan] Bioqual Inc, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); BIOQUAL Inc.	Lusso, P (corresponding author), NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	plusso@niaid.nih.gov	Prabhakaran, Madhu/AEY-7127-2022	Humphris-Narayanan, Elisabeth/0000-0001-8836-181X; Himansu, Sunny/0000-0002-7954-9674; Sarfo, Edward/0000-0001-9015-3446	Intramural Research Program of the Division of Intramural Research; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH; NIH Office of AIDS Research; Bill and Melinda Gates Foundation; Frederick National Laboratory for Cancer Research, NIH [HHSN261200800001]	Intramural Research Program of the Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH Office of AIDS Research; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Frederick National Laboratory for Cancer Research, NIH	The authors thank the animal care personnel at Bioqual Inc. and at the Poolesville NIH Animal Facility. The authors also thank J. Moore (Weill-Cornell Medicine, New York) for the BG505 SOSIP.664 plasmid, J. Van Schooten (University of Amsterdam, The Netherlands) for plasmids to produce monoclonal antibodies RM20A3, RM20C, RM20E1, RM20F, RM20G, RM20J, RM15E and RM54B1, and the National Institutes of Health (NIH) AIDS Reagent Program for the reagents listed in the Methods section. This study was supported by the Intramural Research Program of the Division of Intramural Research and the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, by a grant from the NIH Office of AIDS Research, by the Bill and Melinda Gates Foundation, and by federal funds from the Frederick National Laboratory for Cancer Research, NIH, under contract HHSN261200800001 (to Y.T.).	Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202; Andersson AMC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010010; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]; Bradley T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15711; Buonaguro L, 2001, ANTIVIR RES, V49, P35, DOI 10.1016/S0166-3542(00)00136-4; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158; Chen CW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.573157; Chen XJ, 2021, IMMUNITY, V54, P324, DOI 10.1016/j.immuni.2020.12.014; Cohen J, 2020, SCIENCE, V367, P611, DOI 10.1126/science.367.6478.611; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corey L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7732; Cottrell CA, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008753; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; de la Pena AT, 2017, CELL REP, V20, P1805, DOI 10.1016/j.celrep.2017.07.077; de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056; deCamp A, 2014, J VIROL, V88, P2489, DOI 10.1128/JVI.02853-13; Do Kwon Y, 2015, NAT STRUCT MOL BIOL, V22, P522, DOI 10.1038/nsmb.3051; Duan HY, 2018, IMMUNITY, V49, P301, DOI 10.1016/j.immuni.2018.07.005; Easterhoff D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131437; Effio CL, 2015, BIOTECHNOL J, V10, P715, DOI 10.1002/biot.201400392; Excler JL, 2016, CURR OPIN HIV AIDS, V11, P607, DOI 10.1097/COH.0000000000000312; Felber BK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107624; Garrido C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj3684; Gautam R, 2018, NAT MED, V24, P610, DOI 10.1038/s41591-018-0001-2; Gautam R, 2016, NATURE, V533, P105, DOI 10.1038/nature17677; Gautam R, 2012, J VIROL, V86, P8516, DOI 10.1128/JVI.00644-12; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; HAFFAR O, 1990, J VIROL, V64, P2653, DOI 10.1128/JVI.64.6.2653-2659.1990; Han Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13854-3; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Haynes BF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaz2686; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2018, EXPERT REV VACCINES, V17, P127, DOI 10.1080/14760584.2018.1425619; Hu JK, 2015, J VIROL, V89, P10383, DOI 10.1128/JVI.01653-15; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kelsoe G, 2017, IMMUNOL REV, V275, P79, DOI 10.1111/imr.12508; Klasse PJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005864; Kong R, 2019, CELL, V178, P567, DOI 10.1016/j.cell.2019.06.030; Kothe DL, 2007, VIROLOGY, V360, P218, DOI 10.1016/j.virol.2006.10.017; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; Li H, 2016, P NATL ACAD SCI USA, V113, pE3413, DOI 10.1073/pnas.1606636113; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; McCoy LE, 2016, CELL REP, V16, P2327, DOI 10.1016/j.celrep.2016.07.074; Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109; Montefiori DC, 2009, CURR OPIN HIV AIDS, V4, P347, DOI 10.1097/COH.0b013e32832f4a4d; Moyo N, 2019, MOL THER-METH CLIN D, V12, P32, DOI 10.1016/j.omtm.2018.10.010; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Nogal B, 2020, CELL REP, V30, P3755, DOI 10.1016/j.celrep.2020.02.061; Om K, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008764; Painter MM, 2021, IMMUNITY, V54, P2133, DOI 10.1016/j.immuni.2021.08.001; Pardi N, 2019, MOL THER-NUCL ACIDS, V15, P36, DOI 10.1016/j.omtn.2019.03.003; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prevost J, 2018, J VIROL, V92, DOI 10.1128/JVI.00484-18; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Richard J, 2018, MBIO, V9, DOI 10.1128/mBio.00358-18; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Saunders KO, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00307-6; Saunders KO, 2019, SCIENCE, V366, P1215, DOI 10.1126/science.aay7199; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Sullivan JT, 2017, J VIROL, V91, DOI 10.1128/JVI.00862-17; van Schooten J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009736; Vassena L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002636; Voss JE, 2017, CELL REP, V21, P222, DOI 10.1016/j.celrep.2017.09.024; Xu K, 2018, NAT MED, V24, P857, DOI 10.1038/s41591-018-0042-6; Zhang P, 2018, CELL HOST MICROBE, V23, P832, DOI 10.1016/j.chom.2018.05.002; Zhou TQ, 2017, CELL REP, V19, P719, DOI 10.1016/j.celrep.2017.04.013; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	84	19	20	8	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2234	+		10.1038/s41591-021-01574-5	http://dx.doi.org/10.1038/s41591-021-01574-5		DEC 2021	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887575	Bronze			2022-12-27	WOS:000728466100002
J	Fukumoto, K; McClean, CT; Nakagawa, K				Fukumoto, Kentaro; McClean, Charles T.; Nakagawa, Kuninori			No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020	NATURE MEDICINE			English	Article							MULTIVARIATE; BALANCE; DEMAND; IMPACT	Among tool kits to combat the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, school closures are one of the most frequent non-pharmaceutical interventions. However, school closures bring about substantial costs, such as learning loss. To date, studies have not reached a consensus about the effectiveness of these policies at mitigating community transmission, partly because they lack rigorous causal inference. Here we assess the causal effect of school closures in Japan on reducing the spread of COVID-19 in spring 2020. By matching each municipality with open schools to a municipality with closed schools that is the most similar in terms of potential confounders, we can estimate how many cases the municipality with open schools would have had if it had closed its schools. We do not find any evidence that school closures in Japan reduced the spread of COVID-19. Our null results suggest that policies on school closures should be reexamined given the potential negative consequences for children and parents. School closures in municipalities in Japan at the start of the COVID-19 pandemic showed no significant reduction in cases compared with case counts in municipalities with open schools, questioning the utility of school closures in mitigating community spread of severe acute respiratory syndrome coronavirus 2.	[Fukumoto, Kentaro] Gakushuin Univ, Dept Polit Sci, Tokyo, Japan; [McClean, Charles T.] Harvard Univ, Program US Japan Relat, Cambridge, MA USA; [McClean, Charles T.] Univ Michigan, Ctr Japanese Studies, Ann Arbor, MI USA; [Nakagawa, Kuninori] Shizuoka Univ, Dept Econ, Shizuoka, Japan	Gakushuin University; Harvard University; University of Michigan System; University of Michigan; Shizuoka University	Fukumoto, K (corresponding author), Gakushuin Univ, Dept Polit Sci, Tokyo, Japan.	kentaro.fukumoto@gakushuin.ac.jp	Fukumoto, Kentaro/I-7542-2019	Fukumoto, Kentaro/0000-0003-3704-9054; McClean, Charles/0000-0002-6780-6194; Nakagawa, Kuninori/0000-0003-2429-7630	Japan Society for the Promotion of Science KAKENHI [JP19K21683]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Japan Society for the Promotion of Science KAKENHI (grant no. JP19K21683). We obtained part of the survey data from the MEXT. The funder and the MEXT had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Amodio E, COVID EC, V65, P47; Andrew A, 2020, FISC STUD, V41, P653, DOI 10.1111/1475-5890.12240; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2020, SCH CLOS CAUS COR CO; Auger KA, 2020, JAMA-J AM MED ASSOC, V324, P859, DOI 10.1001/jama.2020.14348; Banholzer N, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252827; Baron EJ, 2020, J PUBLIC ECON, V190, DOI 10.1016/j.jpubeco.2020.104258; Bayham J, 2020, LANCET PUBLIC HEALTH, V5, pE271, DOI 10.1016/S2468-2667(20)30082-7; Brauner JM, 2021, SCIENCE, V371, P802, DOI 10.1126/science.abd9338; Castex Gonzalo, 2021, Econ Disaster Clim Chang, V5, P135, DOI 10.1007/s41885-020-00076-x; Chang SL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19393-6; Chen X., 2020, ARXIV PREPRINT ARXIV; Chernozhukov V., 2021, ASS OPENING K 12 SCH; Chernozhukov V, 2021, J ECONOMETRICS, V220, P23, DOI 10.1016/j.jeconom.2020.09.003; Chyl K, 2018, J CHILD PSYCHOL PSYC, V59, P76, DOI 10.1111/jcpp.12774; Collins C, 2021, GENDER SOC, V35, P180, DOI 10.1177/08912432211001300; Courtemanche C. J., 2021, SCH REOPENINGS MOBIL; Davies NG, 2020, LANCET PUBLIC HEALTH, V5, pE375, DOI 10.1016/S2468-2667(20)30133-X; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Diamond A, 2013, REV ECON STAT, V95, P932, DOI 10.1162/REST_a_00318; Engzell P, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022376118; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Forastiere L, 2021, J AM STAT ASSOC, V116, P901, DOI 10.1080/01621459.2020.1768100; Gandini S, 2021, LANCET REG HEALTH-EU, V5, DOI 10.1016/j.lanepe.2021.100092; Gaure S., 2019, **DATA OBJECT**; Goldhaber D., 2021, WHAT EXTENT DOES IN; Greifer N., **DATA OBJECT**; Hanushek E.A, 2020, EC IMPACTS LEARNING; Harris DN, 2021, EFFECTS SCH REOPENIN; Haug N, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-01009-0; Head JR, 2021, J R SOC INTERFACE, V18, DOI 10.1098/rsif.2020.0970; Ho DE, 2007, POLIT ANAL, V15, P199, DOI 10.1093/pan/mpl013; Ho DE, 2011, J STAT SOFTW, V42; Hsiang S, 2020, NATURE, V584, P262, DOI 10.1038/s41586-020-2404-8; Imai K, 2014, J R STAT SOC B, V76, P243, DOI 10.1111/rssb.12027; Imbens GW, 2015, CAUSAL INFERENCE FOR STATISTICS, SOCIAL, AND BIOMEDICAL SCIENCES: AN INTRODUCTION, P1, DOI 10.1017/CBO9781139025751; Isphording IE, 2021, J PUBLIC ECON, V198, DOI 10.1016/j.jpubeco.2021.104426; Iwata K, 2020, INT J INFECT DIS, V99, P57, DOI 10.1016/j.ijid.2020.07.052; Jang Y., 2020, COVID EC VETTED REAL, V57, P46; Kim S, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e143; King G, 2019, POLIT ANAL, V27, P435, DOI 10.1017/pan.2019.11; Kinsey EW, 2020, AM J PUBLIC HEALTH, V110, P1635, DOI 10.2105/AJPH.2020.305875; Kisho Gyomu Shien Senta, 2016, MESSH HEIN 2010; Lee B, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09799-8; Li Y, 2021, LANCET INFECT DIS, V21, P193, DOI 10.1016/S1473-3099(20)30785-4; Liu Y, 2021, BMC MED, V19, DOI 10.1186/s12916-020-01872-8; Lumley Thomas, 2020, CRAN; Matzinger P., 2020, STRONG IMPACT CLOSIN; Meissner C.M, 2020, COVID EC, V14, P85; Panovska-Griffiths J, 2020, LANCET CHILD ADOLESC, V4, P817, DOI 10.1016/S2352-4642(20)30250-9; Plumper T., 2020, SUMMER SCH HOLIDAYS, DOI 10.11.20210773v2; R Core Team, 2021, R LANGUAGE ENV STAT; Sekhon JS, 2011, J STAT SOFTW, V42, P1; Sun KY, 2021, SCIENCE, V371, P254, DOI 10.1126/science.abe2424; Takaku R, 2021, J PUBLIC ECON, V195, DOI 10.1016/j.jpubeco.2020.104364; Venables W.N., 2002, MODERN APPL STAT S, Vfourth, DOI [DOI 10.1007/978-0-387-21706-2, 10.1007/978-0-387-21706-2]; Vlachos J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020834118; von Bismarck-Osten C., 2020, ROLE SCH TRANSMISSIO; Walsh S, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-053371; Wang XT, 2020, EMERG INFECT DIS, V26, P2361, DOI [10.3201/eid2510.201702, 10.3201/eid2610.201702]; Xie XY, 2020, JAMA PEDIATR, V174, P898, DOI 10.1001/jamapediatrics.2020.1619; Yamamura E, 2021, J POPUL ECON, V34, P1261, DOI 10.1007/s00148-021-00844-3; Yehya N., 2020, CLIN INFECT DIS, V73, P1863; Yoon Y, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e414; Zeileis A., 2004, J STAT SOFTW, V11, P1, DOI [10.18637/jss.v011.i10, DOI 10.18637/JSS.V011.I10]; Zeileis A, 2020, J STAT SOFTW, V95, P1, DOI 10.18637/jss.v095.i01; Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001	68	19	19	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2111	+		10.1038/s41591-021-01571-8	http://dx.doi.org/10.1038/s41591-021-01571-8		OCT 2021	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34707318	hybrid, Green Published			2022-12-27	WOS:000712497200001
J	Philippi, A; Heller, S; Costa, IG; Senee, V; Breunig, M; Li, ZJ; Kwon, G; Russell, R; Illing, A; Lin, Q; Hohwieler, M; Degavre, A; Zalloua, P; Liebau, S; Schuster, M; Krumm, J; Zhang, X; Geusz, R; Benthuysen, JR; Wang, A; Chiou, J; Gaulton, K; Neubauer, H; Simon, E; Klein, T; Wagner, M; Nair, G; Besse, C; Dandine-Roulland, C; Olaso, R; Deleuze, JF; Kuster, B; Hebrok, M; Seufferlein, T; Sander, M; Boehm, BO; Oswald, F; Nicolino, M; Julier, C; Kleger, A				Philippi, Anne; Heller, Sandra; Costa, Ivan G.; Senee, Valerie; Breunig, Markus; Li, Zhijian; Kwon, Gino; Russell, Ronan; Illing, Anett; Lin, Qiong; Hohwieler, Meike; Degavre, Anne; Zalloua, Pierre; Liebau, Stefan; Schuster, Michael; Krumm, Johannes; Zhang, Xi; Geusz, Ryan; Benthuysen, Jacqueline R.; Wang, Allen; Chiou, Joshua; Gaulton, Kyle; Neubauer, Heike; Simon, Eric; Klein, Thomas; Wagner, Martin; Nair, Gopika; Besse, Celine; Dandine-Roulland, Claire; Olaso, Robert; Deleuze, Jean-Francois; Kuster, Bernhard; Hebrok, Matthias; Seufferlein, Thomas; Sander, Maike; Boehm, Bernhard O.; Oswald, Franz; Nicolino, Marc; Julier, Cecile; Kleger, Alexander			Mutations and variants of ONECUT1 in diabetes	NATURE MEDICINE			English	Article							HEPATOCYTE NUCLEAR FACTOR-6; TRANSCRIPTION FACTORS; ENRICHMENT ANALYSIS; PROGENITOR CELLS; HUMAN PANCREAS; GENE; DIFFERENTIATION; EXPRESSION; MELLITUS; ADULT	Genes involved in distinct diabetes types suggest shared disease mechanisms. Here we show that One Cut Homeobox 1 (ONECUT1) mutations cause monogenic recessive syndromic diabetes in two unrelated patients, characterized by intrauterine growth retardation, pancreas hypoplasia and gallbladder agenesis/hypoplasia, and early-onset diabetes in heterozygous relatives. Heterozygous carriers of rare coding variants of ONECUT1 define a distinctive subgroup of diabetic patients with early-onset, nonautoimmune diabetes, who respond well to diabetes treatment. In addition, common regulatory ONECUT1 variants are associated with multifactorial type 2 diabetes. Directed differentiation of human pluripotent stem cells revealed that loss of ONECUT1 impairs pancreatic progenitor formation and a subsequent endocrine program. Loss of ONECUT1 altered transcription factor binding and enhancer activity and NKX2.2/NKX6.1 expression in pancreatic progenitor cells. Collectively, we demonstrate that ONECUT1 controls a transcriptional and epigenetic machinery regulating endocrine development, involved in a spectrum of diabetes, encompassing monogenic (recessive and dominant) as well as multifactorial inheritance. Our findings highlight the broad contribution of ONECUT1 in diabetes pathogenesis, marking an important step toward precision diabetes medicine. Clinical and genetic phenotyping of consanguineous family cases of neonatal syndromic diabetes and type 2 diabetes, combined with in-depth functional studies in pluripotent stem cells, reveals a role for genetic variants of ONECUT1 in monogenic and multifactorial diabetes.	[Philippi, Anne; Senee, Valerie; Degavre, Anne; Julier, Cecile] Univ Paris, Inst Cochin, INSERM U1016, CNRS,UMR 8104, Paris, France; [Heller, Sandra; Breunig, Markus; Kwon, Gino; Illing, Anett; Hohwieler, Meike; Zhang, Xi; Wagner, Martin; Seufferlein, Thomas; Oswald, Franz; Kleger, Alexander] Ulm Univ, Dept Internal Med 1, Ulm, Germany; [Costa, Ivan G.; Li, Zhijian; Lin, Qiong] Rhein Westfal TH Aachen, Inst Computat Genom, Med Sch, Aachen, Germany; [Russell, Ronan; Nair, Gopika; Hebrok, Matthias] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; [Zalloua, Pierre] Univ Balamand, Sch Med, Amioun, Lebanon; [Zalloua, Pierre] Khalifa Univ Sci & Technol, Coll Med & Hlth Sci, Abu Dhabi, U Arab Emirates; [Liebau, Stefan] Eberhard Karls Univ Tuebingen, Inst Neuroanat & Dev Biol, Tubingen, Germany; [Schuster, Michael] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Krumm, Johannes; Kuster, Bernhard] Tech Univ Munich TUM, Chair Prote & Bioanalyt, Freising Weihenstephan, Germany; [Geusz, Ryan; Benthuysen, Jacqueline R.; Wang, Allen; Chiou, Joshua; Gaulton, Kyle; Sander, Maike] Univ Calif San Diego, Pediat Diabet Res Ctr, La Jolla, CA 92093 USA; [Neubauer, Heike; Klein, Thomas] Boehringer Ingelheim Pharma GmbH & Co KG, CardioMetab Dis Res, Biberach, Germany; [Simon, Eric] Boehringer Ingelheim Pharma GmbH & Co KG, Global Computat Biol & Digital Sci, Biberach, Germany; [Besse, Celine; Dandine-Roulland, Claire; Olaso, Robert; Deleuze, Jean-Francois] Univ Paris Saclay, Ctr Natl Rech Genom Humaine CNRGH, Inst Biol Francois Jacob, Commissariat Energie Atom, Evry, France; [Kuster, Bernhard] Tech Univ Munich TUM, Bavarian Biomol Mass Spectrometry Ctr BayBioMS, Freising Weihenstephan, Germany; [Boehm, Bernhard O.] Nanyang Technol Univ, LKC Sch Med, Singapore, Singapore; [Nicolino, Marc] Hosp Civils Lyon, Serv Endocrinol & Diabetol Pediat, Hop Femme Mere Enfant, Bron, France; [Nicolino, Marc] Hosp Civils Lyon, Ctr PRISIS, Hop Femme Mere Enfant, Pathol Rares Insulino Secret & Insulino Sensibili, Bron, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ulm University; RWTH Aachen University; University of California System; University of California San Francisco; University Balamand; Khalifa University of Science & Technology; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Technical University of Munich; University of California System; University of California San Diego; Boehringer Ingelheim; Boehringer Ingelheim; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Technical University of Munich; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; CHU Lyon; CHU Lyon	Julier, C (corresponding author), Univ Paris, Inst Cochin, INSERM U1016, CNRS,UMR 8104, Paris, France.; Kleger, A (corresponding author), Ulm Univ, Dept Internal Med 1, Ulm, Germany.	cecile.julier@inserm.fr; alexander.kleger@uni-ulm.de	Costa, Ivan G./D-5335-2014; JULIER, Cécile/M-9824-2017; Breunig, Markus/AAD-3987-2022; senee, valerie/M-9854-2017	Costa, Ivan G./0000-0003-2890-8697; JULIER, Cécile/0000-0002-1538-0240; Breunig, Markus/0000-0002-2817-1974; Heller, Sandra/0000-0002-8704-2646; Chiou, Joshua/0000-0002-4618-0647; senee, valerie/0000-0001-7012-3944; Schuster, Michael/0000-0003-2975-8969; Kwon, Gino/0000-0002-4269-6638; Zhang, Xi/0000-0001-6485-4564; Li, Zhijian/0000-0002-1523-1333	Boehringer Ingelheim Ulm University BioCenter (BIU); ANR-DFG collaborative research project [ANR-18-CE92-0031, DFG KL 2544/5-1]; Deutsche Forschungsgemeinschaft (DFG) grant [KL 2544/6-1, KL 2544/7-1, KL 2544/8-1, KL 2544/1-2, GE 2811/3-1, SFB1074/A3, OS287/4-1]; Agence Nationale pour la Recherche [ANR-09-GENO-021]; European Foundation for the Study of Diabetes/JDRF/Novo Nordisk; Assistance Publique-Hopitaux de Paris Programme Hospitalier de Recherche Clinique (project DIAGENE); France Genomique (project DIAPED); E: MED Consortia Fibromap - German Ministry of Education and Science (BMBF); NIH [DK068471, DK105541, GM008666, DK105831]; Centre of Excellence Metabolic Disorders Baden-Wuerttemberg, Germany [DFG-GrK1041]; Ministry of Education, Singapore [MOE2018-T2-1-085]; France Genomique National infrastructure, Investissements d'Avenir program [ANR-10-INBS-09]	Boehringer Ingelheim Ulm University BioCenter (BIU); ANR-DFG collaborative research project(French National Research Agency (ANR)); Deutsche Forschungsgemeinschaft (DFG) grant(German Research Foundation (DFG)); Agence Nationale pour la Recherche(French National Research Agency (ANR)); European Foundation for the Study of Diabetes/JDRF/Novo Nordisk; Assistance Publique-Hopitaux de Paris Programme Hospitalier de Recherche Clinique (project DIAGENE); France Genomique (project DIAPED); E: MED Consortia Fibromap - German Ministry of Education and Science (BMBF)(Federal Ministry of Education & Research (BMBF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centre of Excellence Metabolic Disorders Baden-Wuerttemberg, Germany; Ministry of Education, Singapore(Ministry of Education, Singapore); France Genomique National infrastructure, Investissements d'Avenir program(French National Research Agency (ANR))	We thank R. Gowdru Bijegatte, K. Kohn, R. Kohntop, S. Schirmer, R. Rittelmann and J. Kruger from the Department of Internal Medicine I, Ulm University, Germany for their technical support. We thank S. Warth at the Core Facility Cytometry, Ulm University Medical Faculty, Germany for FACS-mediated cell sorting and M. Groth at Leibnitz Institute of Aging in Jena, Germany for performing RNA sequencing of our samples. We are also grateful to Kuhn Elektro-Technik GmbH for supporting our work. We thank S. Hays from the Neonatal Unit, Lyon, France for clinical management of the newborn patient and I. Plotton from the Biochemistry Laboratory, Lyon, France for her contribution to the hormonal evaluations. We thank C. Bonaldi and the Institut de Veille Sanitaire for providing data on IFG and T2D prevalence in the French population and the Centre National de Recherche en Genomique Humaine for providing access to their genomic platform. We thank the patients and their families for participating in this study. This project was funded by the Boehringer Ingelheim Ulm University BioCenter (BIU) as well as by the ANR-DFG collaborative research project (grant no. ANR-18-CE92-0031, DFG KL 2544/5-1) to C.J. and A.K. and via additional funding by the Deutsche Forschungsgemeinschaft (DFG) grant nos. KL 2544/6-1, KL 2544/7-1, 'Fokus-Forderung COVID-19' KL 2544/8-1 and KL 2544/1-2 to A.K.; by the Agence Nationale pour la Recherche (grant no. ANR-09-GENO-021), the European Foundation for the Study of Diabetes/JDRF/Novo Nordisk, the Assistance Publique-Hopitaux de Paris Programme Hospitalier de Recherche Clinique (project DIAGENE) and France Genomique (project DIAPED) to C.J.; by a grant from the E: MED Consortia Fibromap funded by the German Ministry of Education and Science (BMBF) and by the DFG grant no. GE 2811/3-1 to I.G.C.; as well as grant no. SFB1074/A3, OS287/4-1 to F.O., NIH grants no. DK068471 and no. DK105541 as well as NIH T32 grant no. GM008666 to M. Sander and grant no. DFG-GrK1041, Centre of Excellence Metabolic Disorders Baden-Wuerttemberg, Germany as well as Ministry of Education, Singapore, MOE2018-T2-1-085 to B.O.B. Work in M. Hebrok's laboratory was supported by a grant from the NIH (grant no. DK105831). This work was also supported by the France Genomique National infrastructure, funded as part of the Investissements d'Avenir program managed by the Agence Nationale pour la Recherche (grant no. ANR-10-INBS-09).	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Allada R, 2021, NEW ENGL J MED, V384, P550, DOI 10.1056/NEJMra1802337; Allhoff M, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw680; Bansal V, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0977-3; Barker JM, 2008, DIABETES, V57, P3152, DOI 10.2337/db08-0605; Bonaldi C, 2011, DIABETIC MED, V28, P583, DOI 10.1111/j.1464-5491.2011.03250.x; Breunig M, 2021, CELL STEM CELL, V28, P1105, DOI 10.1016/j.stem.2021.03.005; Cebola I, 2015, NAT CELL BIOL, V17, P615, DOI 10.1038/ncb3160; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chung WK, 2020, DIABETES CARE, V43, P1617, DOI 10.2337/dci20-0022; Churchill AJ, 2017, ELIFE, V6, DOI 10.7554/eLife.20010; Clotman F, 2002, DEVELOPMENT, V129, P1819; Conforto TL, 2015, MOL ENDOCRINOL, V29, P1286, DOI 10.1210/me.2015-1028; Ding QR, 2013, CELL STEM CELL, V12, P393, DOI 10.1016/j.stem.2013.03.006; Flannick J, 2019, NATURE, V570, P71, DOI 10.1038/s41586-019-1231-2; Flannick J, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.179; Fu D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055727; Fuchsberger C, 2016, NATURE, V536, P41, DOI 10.1038/nature18642; Geusz RJ, 2021, ELIFE, V10, DOI 10.7554/eLife.59067; Hattersley AT, 2017, DIABETOLOGIA, V60, P769, DOI 10.1007/s00125-017-4226-2; Heller S, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.648284; Henley KD, 2016, CELL REP, V15, P2637, DOI 10.1016/j.celrep.2016.05.040; Hohwieler M, 2017, GUT, V66, P473, DOI 10.1136/gutjnl-2016-312423; Howson JMM, 2011, DIABETES, V60, P2645, DOI 10.2337/db11-0364; Hrvatin S, 2014, P NATL ACAD SCI USA, V111, P3038, DOI 10.1073/pnas.1400709111; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Jennings RE, 2013, DIABETES, V62, P3514, DOI 10.2337/db12-1479; Johnson MB, 2019, DIABETES, V68, P1528, DOI 10.2337/db19-0045; Kim YS, 2012, MOL CELLS, V34, P193, DOI 10.1007/s10059-012-0109-z; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lee K, 2019, CELL REP, V28, P382, DOI 10.1016/j.celrep.2019.06.034; Li ZJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1642-2; Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402; Mahaddalkar PU, 2020, NAT BIOTECHNOL, V38, P1061, DOI 10.1038/s41587-020-0492-5; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Miguel-Escalada I, 2019, NAT GENET, V51, P1137, DOI 10.1038/s41588-019-0457-0; Moller AM, 1999, DIABETOLOGIA, V42, P1011, DOI 10.1007/s001250051261; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Oliver-Krasinski JM, 2008, GENE DEV, V22, P1998, DOI 10.1101/gad.1670808; Oliver-Krasinski JM, 2009, J CLIN INVEST, V119, P1888, DOI 10.1172/JCI37028; Oram RA, 2016, DIABETES CARE, V39, P337, DOI 10.2337/dc15-1111; Pasquali L, 2014, NAT GENET, V46, P136, DOI 10.1038/ng.2870; Patel KA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00895-9; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Rezania A, 2014, NAT BIOTECHNOL, V32, P1121, DOI 10.1038/nbt.3033; Rong EG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1286480; Salat D, 2008, MOL CELL BIOL, V28, P3502, DOI 10.1128/MCB.01966-07; Schaffer AE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003274; Schaffer AE, 2010, DEV CELL, V18, P1022, DOI 10.1016/j.devcel.2010.05.015; Shields BM, 2017, DIABETES CARE, V40, P1017, DOI 10.2337/dc17-0224; Smith RJ, 2010, J CLIN ENDOCR METAB, V95, P1566, DOI 10.1210/jc.2009-1966; Smith SB, 2010, NATURE, V463, P775, DOI 10.1038/nature08748; Stanger BZ, 2007, NATURE, V445, P886, DOI 10.1038/nature05537; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thatava T, 2011, GENE THER, V18, P283, DOI 10.1038/gt.2010.145; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tweedie E, 2006, DIABETES, V55, P3264, DOI 10.2337/db06-0090; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/nmeth.3901, 10.1038/NMETH.3901]; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wacker SA, 2011, EMBO J, V30, P43, DOI 10.1038/emboj.2010.289; Wang A, 2015, CELL STEM CELL, V16, P386, DOI 10.1016/j.stem.2015.02.013; Wiedenmann S, 2021, NAT BIOMED ENG, V5, P897, DOI 10.1038/s41551-021-00757-2; Yang YS, 2016, ENDOCR REV, V37, P190, DOI 10.1210/er.2015-1116; Zalloua P, 2008, HUM MOL GENET, V17, P4012, DOI 10.1093/hmg/ddn304; Zecha J, 2019, MOL CELL PROTEOMICS, V18, P1468, DOI 10.1074/mcp.TIR119.001385; Zhang HJ, 2009, MECH DEVELOP, V126, P958, DOI 10.1016/j.mod.2009.09.006; Zhang YX, 2016, GENE DEV, V30, P1636, DOI 10.1101/gad.281972.116; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8; Zhu Q, 2001, DIABETES RES CLIN PR, V52, P171, DOI 10.1016/S0168-8227(01)00222-4; Zorn AM, 2009, ANNU REV CELL DEV BI, V25, P221, DOI 10.1146/annurev.cellbio.042308.113344	75	11	11	4	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1928	+		10.1038/s41591-021-01502-7	http://dx.doi.org/10.1038/s41591-021-01502-7		OCT 2021	42	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34663987	Bronze, Green Accepted			2022-12-27	WOS:000708373000002
J	Cai, N; Gomez-Duran, A; Yonova-Doing, E; Kundu, K; Burgess, AI; Golder, ZJ; Calabrese, C; Bonder, MJ; Camacho, M; Lawson, RA; Li, LX; Williams-Gray, CH; Di Angelantonio, E; Roberts, DJ; Watkins, NA; Ouwehand, WH; Butterworth, AS; Stewart, ID; Pietzner, M; Wareham, NJ; Langenberg, C; Danesh, J; Walter, K; Rothwell, PM; Howson, JMM; Stegle, O; Chinnery, PF; Soranzo, N				Cai, Na; Gomez-Duran, Aurora; Yonova-Doing, Ekaterina; Kundu, Kousik; Burgess, Annette, I; Golder, Zoe J.; Calabrese, Claudia; Bonder, Marc J.; Camacho, Marta; Lawson, Rachael A.; Li, Lixin; Williams-Gray, Caroline H.; Di Angelantonio, Emanuele; Roberts, David J.; Watkins, Nick A.; Ouwehand, Willem H.; Butterworth, Adam S.; Stewart, Isobel D.; Pietzner, Maik; Wareham, Nick J.; Langenberg, Claudia; Danesh, John; Walter, Klaudia; Rothwell, Peter M.; Howson, Joanna M. M.; Stegle, Oliver; Chinnery, Patrick F.; Soranzo, Nicole		ICICLE-PD Study Grp	Mitochondrial DNA variants modulate N-formylmethionine, proteostasis and risk of late-onset human diseases	NATURE MEDICINE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; HEREDITARY OPTIC NEUROPATHY; OXIDATIVE-PHOSPHORYLATION; PROTEIN-SYNTHESIS; POINT MUTATION; MTDNA; HETEROPLASMY; POPULATION; STRESS; SELECTION	The association between certain mitochondrial DNA variants and increased risk of late-onset diseases in humans could be explained by a direct role of mitochondrial DNA in the regulation of cellular proteostasis. Mitochondrial DNA (mtDNA) variants influence the risk of late-onset human diseases, but the reasons for this are poorly understood. Undertaking a hypothesis-free analysis of 5,689 blood-derived biomarkers with mtDNA variants in 16,220 healthy donors, here we show that variants defining mtDNA haplogroups Uk and H4 modulate the level of circulating N-formylmethionine (fMet), which initiates mitochondrial protein translation. In human cytoplasmic hybrid (cybrid) lines, fMet modulated both mitochondrial and cytosolic proteins on multiple levels, through transcription, post-translational modification and proteolysis by an N-degron pathway, abolishing known differences between mtDNA haplogroups. In a further 11,966 individuals, fMet levels contributed to all-cause mortality and the disease risk of several common cardiovascular disorders. Together, these findings indicate that fMet plays a key role in common age-related disease through pleiotropic effects on cell proteostasis.	[Cai, Na; Kundu, Kousik; Ouwehand, Willem H.; Danesh, John; Walter, Klaudia; Soranzo, Nicole] Wellcome Sanger Inst WT, Human Genet Dept, Hinxton, England; [Cai, Na; Bonder, Marc J.; Stegle, Oliver] European Bioinformat Inst EMBL EBI, Hinxton, England; [Cai, Na] Helmholtz Zentrum Munchen, Helmholtz Pioneer Campus, Neuherberg, Germany; [Gomez-Duran, Aurora; Golder, Zoe J.; Calabrese, Claudia; Camacho, Marta; Williams-Gray, Caroline H.; Chinnery, Patrick F.] Univ Cambridge, Sch Clin Med, Dept Clin Neurosci, Cambridge Biomed Campus, Cambridge, England; [Gomez-Duran, Aurora; Golder, Zoe J.; Calabrese, Claudia; Chinnery, Patrick F.] Univ Cambridge, Med Res Council Mitochondrial Biol Unit, Cambridge Biomed Campus, Cambridge, England; [Gomez-Duran, Aurora] Consejo Super Invest Cient CIB CSIC, Ctr Invest Biol Margarita Salas, Madrid, Spain; [Yonova-Doing, Ekaterina; Di Angelantonio, Emanuele; Butterworth, Adam S.; Danesh, John; Howson, Joanna M. M.] Univ Cambridge, British Heart Fdn Cardiovasc Epidemiol Unit, Dept Primary Publ Hlth & Primary Care, Cambridge, England; [Yonova-Doing, Ekaterina; Howson, Joanna M. M.] Novo Nordisk Res Ctr Oxford, Dept Genet, Oxford, England; [Burgess, Annette, I; Li, Lixin; Rothwell, Peter M.] Univ Oxford, John Radcliffe Hosp, Wolfson Ctr Prevent Stroke & Dementia, Nuffield Dept Clin Neurosci, Oxford, England; [Bonder, Marc J.; Stegle, Oliver] German Canc Res Ctr, Div Computat Genom & Syst Genet, Heidelberg, Germany; [Lawson, Rachael A.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Di Angelantonio, Emanuele; Ouwehand, Willem H.; Butterworth, Adam S.; Danesh, John; Soranzo, Nicole] Univ Cambridge, British Heart Fdn Ctr Res Excellence, Cambridge, England; [Di Angelantonio, Emanuele; Roberts, David J.; Butterworth, Adam S.; Danesh, John; Soranzo, Nicole] Univ Cambridge, Natl Inst Hlth Res Blood & Transplant Res Unit Do, Cambridge, England; [Di Angelantonio, Emanuele; Butterworth, Adam S.; Danesh, John] Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England; [Di Angelantonio, Emanuele; Butterworth, Adam S.; Danesh, John] Univ Cambridge, Cambridge, England; [Roberts, David J.] John Radcliffe Hosp, NHS Blood & Transplant Oxford Ctr, Oxford, England; [Roberts, David J.] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Watkins, Nick A.; Ouwehand, Willem H.] Cambridge Biomed Campus, NHS Blood & Transplant, Cambridge, England; [Ouwehand, Willem H.; Soranzo, Nicole] Univ Cambridge, Dept Haematol, Cambridge, England; [Stewart, Isobel D.; Pietzner, Maik; Wareham, Nick J.; Langenberg, Claudia] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Stegle, Oliver] European Mol Biol Lab, Heidelberg, Germany; [Soranzo, Nicole] Human Technopole, Genom Res Ctr, Milan, Italy	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Cambridge; University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ); Newcastle University - UK; University of Cambridge; University of Cambridge; University of Cambridge; University of Oxford; University of Oxford; University of Cambridge; University of Cambridge; European Molecular Biology Laboratory (EMBL); Human Technopole	Soranzo, N (corresponding author), Wellcome Sanger Inst WT, Human Genet Dept, Hinxton, England.; Stegle, O (corresponding author), European Bioinformat Inst EMBL EBI, Hinxton, England.; Chinnery, PF (corresponding author), Univ Cambridge, Sch Clin Med, Dept Clin Neurosci, Cambridge Biomed Campus, Cambridge, England.; Chinnery, PF (corresponding author), Univ Cambridge, Med Res Council Mitochondrial Biol Unit, Cambridge Biomed Campus, Cambridge, England.; Stegle, O (corresponding author), German Canc Res Ctr, Div Computat Genom & Syst Genet, Heidelberg, Germany.; Soranzo, N (corresponding author), Univ Cambridge, British Heart Fdn Ctr Res Excellence, Cambridge, England.; Soranzo, N (corresponding author), Univ Cambridge, Natl Inst Hlth Res Blood & Transplant Res Unit Do, Cambridge, England.; Soranzo, N (corresponding author), Univ Cambridge, Dept Haematol, Cambridge, England.; Stegle, O (corresponding author), European Mol Biol Lab, Heidelberg, Germany.; Soranzo, N (corresponding author), Human Technopole, Genom Res Ctr, Milan, Italy.	o.stegle@dkfz-heidelberg.de; pfc25@cam.ac.uk; ns6@sanger.ac.uk	Gomez-Duran, Aurora/ABE-1973-2021; Gomez-Duran, Aurora/T-6392-2017	Soranzo, Nicole/0000-0003-1095-3852; Chinnery, Patrick/0000-0002-7065-6617; Pietzner, Maik/0000-0003-3437-9963; Cai, Na/0000-0001-7496-2075; Kundu, Kousik/0000-0002-1019-8351; Di Angelantonio, Emanuele/0000-0001-8776-6719; Williams-Gray, Caroline/0000-0002-2648-9743; Lawson, Rachael/0000-0003-2608-8285; Burgess, Annette/0000-0003-3442-8083; Stegle, Oliver/0000-0002-8818-7193; Gomez-Duran, Aurora/0000-0002-5895-6860	NIHR, the NIHR BioResource; NIHR Cambridge Biomedical Research Centre [146281]; NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR) [BTRU-2014-10024]; UK Medical Research Council [MR/L003120/1]; British Heart Foundation [SP/09/002, RG/13/13/30194, RG/18/13/33946]; NIHR Cambridge BRC [BRC-1215-20014]; Health Data Research UK - UK Medical Research Council; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); Wellcome; EBI-Sanger Postdoctoral Fellowship; Medical Research Council Mitochondrial Biology Unit [MC_UU_00015/9]; Evelyn Trust; NIHR Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; RCUK/UKRI Research Innovation Fellowship by the Medical Research Council [MR/R007446/1]; Wellcome Trust [098051, 206194]; Cambridge BHF Centre of Research Excellence [RE/18/1/34212]; NIHR Cambridge Biomedical Research Centre Biomedical Resources Grant, University of Cambridge [RG64226]; NIHR Senior Investigator Award; Parkinson's UK [J-0802, G-1301, G-1507]; NIHR BioResource; European Commission Framework Programme 7 [HEALTH-F2-2012-279233]; Lockhart Parkinson's Disease Research Fund; NIHR Newcastle Biomedical Research Unit; Medical Research Council [MC_PC_13048]; Cancer Research UK [C864/A14136]; MRC Cambridge Initiative in Metabolic Science [MR/L00002/1]; Innovative Medicines Initiative Joint Undertaking under EMIF [115372]; NIHR Biomedical Research Centre, Oxford; Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge Joint Research Grants Scheme	NIHR, the NIHR BioResource; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); NIHR Cambridge BRC; Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); Wellcome; EBI-Sanger Postdoctoral Fellowship; Medical Research Council Mitochondrial Biology Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Evelyn Trust; NIHR Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust; University of Cambridge(University of Cambridge); RCUK/UKRI Research Innovation Fellowship by the Medical Research Council; Wellcome Trust(Wellcome Trust); Cambridge BHF Centre of Research Excellence; NIHR Cambridge Biomedical Research Centre Biomedical Resources Grant, University of Cambridge; NIHR Senior Investigator Award; Parkinson's UK(Parkinson's UK); NIHR BioResource; European Commission Framework Programme 7; Lockhart Parkinson's Disease Research Fund; NIHR Newcastle Biomedical Research Unit; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); MRC Cambridge Initiative in Metabolic Science(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Innovative Medicines Initiative Joint Undertaking under EMIF; NIHR Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR)); Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge Joint Research Grants Scheme	Participants in the INTERVAL randomized controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (https://www.nhsbt.nhs.uk/), which has supported field work and other elements of the trial. DNA extraction and genotyping was co-funded by the NIHR, the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)*. The academic coordinating center for INTERVAL was supported by core funding from the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR, BTRU-2014-10024), the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (SP/09/002, RG/13/13/30194, RG/18/13/33946) and the NIHR Cambridge BRC (BRC-1215-20014)*. A complete list of investigators for and contributors to the INTERVAL trial is provided in ref. 73. The academic coordinating center thanks blood donor center staff and blood donors for participating in the INTERVAL trial. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Department of Health and Social Care (England), the Chief Scientist Office of the Scottish Government Health and Social Care Directorates, the Health and Social Care Research and Development Division (Welsh Government), the Public Health Agency (Northern Ireland), the British Heart Foundation and Wellcome. N.C. is supported by an EBI-Sanger Postdoctoral Fellowship. A.G.-D. receives funding from the NIHR Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust. E.Y.-D. was funded by the Isaac Newton Trust/Wellcome Trust ISSF/University of Cambridge Joint Research Grants Scheme. J.M.M.H. was funded by the NIHR Cambridge BRC (BRC-1215-20014)*. P.F.C. is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Evelyn Trust and the NIHR Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. C.H.W.-G. is supported by a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1) and by the Cambridge Centre for Parkinson-Plus. N.S. is supported by the Wellcome Trust (grant number 098051 until 30 September 2016 and 206194 from 1 October 2016), the Cambridge BHF Centre of Research Excellence (RE/18/1/34212) and the NIHR Cambridge Biomedical Research Centre Biomedical Resources Grant, University of Cambridge, Cardiovascular Theme (RG64226). J.D. holds a British Heart Foundation Professorship and an NIHR Senior Investigator Award*. R.A.L. is supported by grants from Parkinson's UK. Sequencing of INTERVAL samples was supported by the Wellcome Trust (grant number 206194). Metabolon metabolomics assays were funded by the NIHR BioResource, the Wellcome Trust (grant number 206194) and the NIHR Cambridge BRC (BRC-1215-20014)*. Nightingale Health NMR assays were funded by the European Commission Framework Programme 7 (HEALTH-F2-2012-279233). SomaLogic assays were funded by Merck and the NIHR Cambridge BRC (BRC-1215-20014)*. ICICLE-PD was funded by Parkinson's UK (J-0802, G-1301, G-1507) and the Lockhart Parkinson's Disease Research Fund and supported by the NIHR Newcastle Biomedical Research Unit and the NIHR Cambridge Biomedical Research Centre (146281). The EPIC-Norfolk study (https://doi.org/10.22025/2019.10.105.; 00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). Genetic work in the EPIC-Norfolk study was funded by the Medical Research Council (MC_PC_13048). Metabolite measurements in the EPIC-Norfolk study were supported by the MRC Cambridge Initiative in Metabolic Science (MR/L00002/1) and the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372. We are grateful to all participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. The collection of samples and assay work performed on the Oxford Vascular Study cohort was funded by the NIHR Biomedical Research Centre, Oxford, and the Wellcome Trust. *The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We thank all members of the ICICLE-PD consortium for their support of this work.	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arguello T, 2018, J BIOL CHEM, V293, P15021, DOI 10.1074/jbc.RA118.003838; Aschard H, 2017, NAT GENET, V49, P1789, DOI 10.1038/ng.3975; Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042; Bi R, 2015, NEUROBIOL AGING, V36, DOI 10.1016/j.neurobiolaging.2014.10.009; BIANCHETTI R, 1977, J BIOL CHEM, V252, P2519; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MD, 2000, J BIOL CHEM, V275, P39831, DOI 10.1074/jbc.M006476200; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Calabrese C, 2014, BIOINFORMATICS, V30, P3115, DOI 10.1093/bioinformatics/btu483; Chinnery PF, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.048876; Chinnery PF, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00682; Chinnery PF, 2010, LANCET NEUROL, V9, P498, DOI 10.1016/S1474-4422(10)70083-1; Couvillion MT, 2016, NATURE, V533, P499, DOI 10.1038/nature18015; Day N, 1999, BRIT J CANCER, V80, P95; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Derenko M, 2014, BMC EVOL BIOL, V14, DOI 10.1186/s12862-014-0217-9; Di Angelantonio E, 2017, LANCET, V390, P2360, DOI 10.1016/S0140-6736(17)31928-1; Eldeeb MA, 2019, TRENDS BIOCHEM SCI, V44, P181, DOI 10.1016/j.tibs.2018.12.008; Eldeeb MA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113414; Floros VI, 2018, NAT CELL BIOL, V20, P144, DOI 10.1038/s41556-017-0017-8; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Gomez-Duran A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246; Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hinttala R, 2015, HUM MOL GENET, V24, P4103, DOI 10.1093/hmg/ddv149; Howell N, 1996, AM J HUM GENET, V59, P749; Hudson G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004369; Hudson G, 2013, NEUROLOGY, V80, P2042, DOI 10.1212/WNL.0b013e318294b434; Ji FY, 2012, P NATL ACAD SCI USA, V109, P7391, DOI 10.1073/pnas.1202484109; Kielbasa SM, 2011, GENOME RES, V21, P487, DOI 10.1101/gr.113985.110; Kim JM, 2018, SCIENCE, V362, P1019, DOI 10.1126/science.aat0174; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373; Kofler B, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-35; Lane N, 2010, NATURE, V467, P929, DOI 10.1038/nature09486; Larman TC, 2012, P NATL ACAD SCI USA, V109, P14087, DOI 10.1073/pnas.1211502109; Levin L, 2013, GENOME BIOL EVOL, V5, P876, DOI 10.1093/gbe/evt058; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Lippert C, 2014, LIMIX GENETIC ANAL M, DOI 10.1101/003905; Lippold S., 2014, INVESTIG GENET, V5; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; Marom S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43449; Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Moore C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-363; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Neeve VCM, 2013, MITOCHONDRION, V13, P743, DOI 10.1016/j.mito.2013.03.002; Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5; Nishigaki Y, 2007, HUM GENET, V120, P827, DOI 10.1007/s00439-006-0269-z; Pacheu-Grau D, 2010, DRUG DISCOV TODAY, V15, P33, DOI 10.1016/j.drudis.2009.10.008; Pello R, 2008, HUM MOL GENET, V17, P4001, DOI 10.1093/hmg/ddn303; Pereira L, 2011, AM J HUM GENET, V88, P433, DOI 10.1016/j.ajhg.2011.03.006; Picard M, 2014, P NATL ACAD SCI USA, V111, pE4033, DOI 10.1073/pnas.1414028111; Poplin R., 2017, SCALING ACCURATE GEN, DOI [DOI 10.1101/201178, 10.1101/201178, 10]; Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Rajbhandary U. L., 1994, TRNA STRUCTURE BIOSY, P511; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434; Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927; Shemorry A, 2013, MOL CELL, V50, P540, DOI 10.1016/j.molcel.2013.03.018; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Sorrentino V, 2017, NATURE, V552, P187, DOI 10.1038/nature25143; Speed D, 2017, NAT GENET, V49, P986, DOI 10.1038/ng.3865; Stegle O, 2012, NAT PROTOC, V7, P500, DOI 10.1038/nprot.2011.457; Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966; Stone AC, 1998, AM J HUM GENET, V62, P1153, DOI 10.1086/301838; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Su N, 2008, J BIOL CHEM, V283, P35106, DOI 10.1074/jbc.M806874200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suhre K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14357; Suissa S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000474; Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2; Torroni A, 1996, GENETICS, V144, P1835; Tranah GJ, 2011, MITOCHONDRION, V11, P855, DOI 10.1016/j.mito.2011.04.005; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; Tucker EJ, 2011, CELL METAB, V14, P428, DOI 10.1016/j.cmet.2011.07.010; van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921; VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026871; Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW58, DOI 10.1093/nar/gkw233; Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW64, DOI 10.1093/nar/gkw247; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Wrobel L, 2015, NATURE, V524, P485, DOI 10.1038/nature14951; Yao C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05512-x; Yarnall AJ, 2014, NEUROLOGY, V82, P308, DOI 10.1212/WNL.0000000000000066; Yuan Y, 2020, NAT GENET, V52, P342, DOI 10.1038/s41588-019-0557-x; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	106	12	12	3	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1564	+		10.1038/s41591-021-01441-3	http://dx.doi.org/10.1038/s41591-021-01441-3		AUG 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34426706	Green Submitted			2022-12-27	WOS:000687518700003
J	Arce, JSS; Warren, SS; Meriggi, NF; Scacco, A; McMurry, N; Voors, M; Syunyaev, G; Malik, AA; Aboutajdine, S; Adeojo, O; Anigo, D; Armand, A; Asad, S; Atyera, M; Augsburg, B; Awasthi, M; Ayesiga, GE; Bancalari, A; Nyqvist, MB; Borisova, E; Bosancianu, CM; Garcia, MRC; Cheema, A; Collins, E; Cuccaro, F; Farooqi, AZ; Fatima, T; Fracchia, M; Soria, MLG; Guariso, A; Hasanain, A; Jaramillo, S; Kallon, S; Kamwesigye, A; Kharel, A; Kreps, S; Levine, M; Littman, R; Malik, M; Manirabaruta, G; Mfura, JLH; Momoh, F; Mucauque, A; Mussa, I; Nsabimana, JA; Obara, I; Otalora, MJ; Ouedraogo, BW; Pare, TB; Platas, MR; Polanco, L; Qureshi, JA; Raheem, M; Ramakrishna, V; Rendra, I; Shah, T; Shaked, SE; Shapiro, JN; Svensson, J; Tariq, A; Tchibozo, AM; Tiwana, HA; Trivedi, B; Vernot, C; Vicente, PC; Weissinger, LB; Zafar, B; Zhang, BB; Karlan, D; Callen, M; Teachout, M; Humphreys, M; Mobarak, AM; Omer, SB				Arce, Julio S. Solis; Warren, Shana S.; Meriggi, Niccolo F.; Scacco, Alexandra; McMurry, Nina; Voors, Maarten; Syunyaev, Georgiy; Malik, Amyn Abdul; Aboutajdine, Samya; Adeojo, Opeyemi; Anigo, Deborah; Armand, Alex; Asad, Saher; Atyera, Martin; Augsburg, Britta; Awasthi, Manisha; Ayesiga, Gloria Eden; Bancalari, Antonella; Nyqvist, Martina Bjorkman; Borisova, Ekaterina; Bosancianu, Constantin Manuel; Cabra Garcia, Magarita Rosa; Cheema, Ali; Collins, Elliott; Cuccaro, Filippo; Farooqi, Ahsan Zia; Fatima, Tatheer; Fracchia, Mattia; Galindo Soria, Mery Len; Guariso, Andrea; Hasanain, Ali; Jaramillo, Sofia; Kallon, Sellu; Kamwesigye, Anthony; Kharel, Arjun; Kreps, Sarah; Levine, Madison; Littman, Rebecca; Malik, Mohammad; Manirabaruta, Gisele; Mfura, Jean Leodomir Habarimana; Momoh, Fatoma; Mucauque, Alberto; Mussa, Imamo; Nsabimana, Jean Aime; Obara, Isaac; Juliana Otalora, Maria; Ouedraogo, Bechir Wendemi; Pare, Touba Bakary; Platas, Melina R.; Polanco, Laura; Qureshi, Javaeria Ashraf; Raheem, Mariam; Ramakrishna, Vasudha; Rendra, Ismail; Shah, Taimur; Shaked, Sarene Eyla; Shapiro, Jacob N.; Svensson, Jakob; Tariq, Ahsan; Tchibozo, Achille Mignondo; Tiwana, Hamid Ali; Trivedi, Bhartendu; Vernot, Corey; Vicente, Pedro C.; Weissinger, Laurin B.; Zafar, Basit; Zhang, Baobao; Karlan, Dean; Callen, Michael; Teachout, Matthieu; Humphreys, Macartan; Mobarak, Ahmed Mushfiq; Omer, Saad B.			COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	NATURE MEDICINE			English	Article							HERD-IMMUNITY; HEALTH; CONFIDENCE; SCALE; BEHAVIOR	Survey data collected across ten low-income and middle-income countries (LMICs) in Asia, Africa and South America compared with surveys from Russia and the United States reveal heterogeneity in vaccine confidence in LMICs, with healthcare providers being trusted sources of information, as well as greater levels of vaccine acceptance in these countries than in Russia and the United States. Widespread acceptance of COVID-19 vaccines is crucial for achieving sufficient immunization coverage to end the global pandemic, yet few studies have investigated COVID-19 vaccination attitudes in lower-income countries, where large-scale vaccination is just beginning. We analyze COVID-19 vaccine acceptance across 15 survey samples covering 10 low- and middle-income countries (LMICs) in Asia, Africa and South America, Russia (an upper-middle-income country) and the United States, including a total of 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in our LMIC samples (mean 80.3%; median 78%; range 30.1 percentage points) compared with the United States (mean 64.6%) and Russia (mean 30.4%). Vaccine acceptance in LMICs is primarily explained by an interest in personal protection against COVID-19, while concern about side effects is the most common reason for hesitancy. Health workers are the most trusted sources of guidance about COVID-19 vaccines. Evidence from this sample of LMICs suggests that prioritizing vaccine distribution to the Global South should yield high returns in advancing global immunization coverage. Vaccination campaigns should focus on translating the high levels of stated acceptance into actual uptake. Messages highlighting vaccine efficacy and safety, delivered by healthcare workers, could be effective for addressing any remaining hesitancy in the analyzed LMICs.	[Arce, Julio S. Solis; Scacco, Alexandra; McMurry, Nina; Syunyaev, Georgiy; Bosancianu, Constantin Manuel; Humphreys, Macartan] WZB Berlin Social Sci Ctr, Berlin, Germany; [Warren, Shana S.; Collins, Elliott; Karlan, Dean] Innovat Poverty Act IPA, New York, NY USA; [Meriggi, Niccolo F.; Aboutajdine, Samya; Teachout, Matthieu] Int Growth Ctr IGC, Freetown, Sierra Leone; [Voors, Maarten; Kallon, Sellu; Levine, Madison] Wageningen Univ & Res, Wageningen, Netherlands; [Syunyaev, Georgiy; Borisova, Ekaterina] HSE Univ, Int Ctr Study Inst & Dev ICSID, Moscow, Russia; [Syunyaev, Georgiy; Humphreys, Macartan] Columbia Univ, New York, NY USA; [Malik, Amyn Abdul; Omer, Saad B.] Yale Inst Global Hlth, New Haven, CT 06520 USA; [Adeojo, Opeyemi; Obara, Isaac] Busara Ctr Behav Econ, Lagos, Nigeria; [Adeojo, Opeyemi] Univ Lagos, Dept Sociol, Lagos, Nigeria; [Anigo, Deborah] Busara Nigeria, Lagos, Nigeria; [Anigo, Deborah] Fed Capital Terr Adm, Agr & Rural Dev Secretariat, Abuja, Nigeria; [Armand, Alex; Fracchia, Mattia; Vicente, Pedro C.] Nova Sch Business & Econ, Lisbon, Portugal; [Armand, Alex; Augsburg, Britta; Bancalari, Antonella] Inst Fiscal Studies, London, England; [Asad, Saher; Cheema, Ali; Hasanain, Ali] Lahore Univ Management Sci, Lahore, Pakistan; [Atyera, Martin; Ayesiga, Gloria Eden; Kamwesigye, Anthony; Shaked, Sarene Eyla] Innovat Poverty Act IPA Uganda, Kampala, Uganda; [Awasthi, Manisha; Fatima, Tatheer; Trivedi, Bhartendu] Morsel Res & Dev, Lucknow, Uttar Pradesh, India; [Bancalari, Antonella] Univ St Andrews, St Andrews, Fife, Scotland; [Bancalari, Antonella] Redes Peru, Lima, Peru; [Nyqvist, Martina Bjorkman] Stockholm Sch Econ & Misum, Stockholm, Sweden; [Borisova, Ekaterina] Univ Ghent, Dept Econ, Ghent, Belgium; [Cabra Garcia, Magarita Rosa; Galindo Soria, Mery Len; Jaramillo, Sofia; Juliana Otalora, Maria; Polanco, Laura] Innovat Poverty Act IPA Colombia, Bogota, Colombia; [Cheema, Ali; Farooqi, Ahsan Zia; Malik, Mohammad; Tariq, Ahsan; Tiwana, Hamid Ali] Inst Dev & Econ Alternat, Lahore, Pakistan; [Cuccaro, Filippo; Momoh, Fatoma] Innovat Poverty Act IPA Sierra Leone, Freetown, Sierra Leone; [Fracchia, Mattia; Vicente, Pedro C.] NOVAFRICA, Lisbon, Portugal; [Guariso, Andrea] Trinity Coll Dublin, Dublin, Ireland; [Kallon, Sellu] Univ Sierra Leone, Inst Publ Adm & Management, Freetown, Sierra Leone; [Kharel, Arjun] Ctr Study Labour & Mobil CESLAM, Kathmandu, Nepal; [Kreps, Sarah; Zhang, Baobao] Cornell Univ, Ithaca, NY USA; [Littman, Rebecca; Qureshi, Javaeria Ashraf] Univ Illinois, Chicago, IL USA; [Manirabaruta, Gisele; Mfura, Jean Leodomir Habarimana; Nsabimana, Jean Aime] Innovat Poverty Act IPA Rwanda, Kigali, Rwanda; [Mucauque, Alberto; Mussa, Imamo; Rendra, Ismail] Assoc NOVAFRICA Desenvolvimento Empresarial & Eco, Maputo, Mozambique; [Ouedraogo, Bechir Wendemi; Pare, Touba Bakary; Tchibozo, Achille Mignondo] Innovat Poverty Act IPA Burkina Faso, Ouagadougou, Burkina Faso; [Platas, Melina R.] NYU Abu Dhabi, Abu Dhabi, U Arab Emirates; [Raheem, Mariam; Shah, Taimur; Zafar, Basit] Ctr Econ Res Pakistan CERP, Lahore, Pakistan; [Ramakrishna, Vasudha; Vernot, Corey] Yale Res Initiat Innovat & Scale Y RISE, New Haven, CT USA; [Shapiro, Jacob N.] Princeton Univ, Princeton, NJ 08544 USA; [Svensson, Jakob] Stockholm Univ, Inst Int Econ Studies IIES, Stockholm, Sweden; [Weissinger, Laurin B.] Tufts Univ, Medford, MA 02155 USA; [Zafar, Basit] Univ Michigan, Ann Arbor, MI 48109 USA; [Karlan, Dean] Northwestern Univ, Kellogg Sch Management, Evanston, IL USA; [Callen, Michael] London Sch Econ & Polit Sci, London, England; [Mobarak, Ahmed Mushfiq] Yale Univ, New Haven, CT 06520 USA	Wageningen University & Research; HSE University (National Research University Higher School of Economics); Columbia University; University of Lagos; Universidade Nova de Lisboa; University of London; London School Economics & Political Science; Lahore University of Management Sciences; University of St Andrews; Ghent University; Trinity College Dublin; Cornell University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Princeton University; Stockholm University; Tufts University; University of Michigan System; University of Michigan; Northwestern University; University of London; London School Economics & Political Science; Yale University	Omer, SB (corresponding author), Yale Inst Global Hlth, New Haven, CT 06520 USA.; Mobarak, AM (corresponding author), Yale Univ, New Haven, CT 06520 USA.	ahmed.mobarak@yale.edu; saad.omer@yale.edu	Malik, Amyn A./AAF-4883-2021; Syunyaev, Georgiy/GPK-5770-2022; Fracchia, Mattia/AAW-6239-2021; Borisova, Ekaterina/I-3499-2015	Malik, Amyn A./0000-0003-4875-9916; Syunyaev, Georgiy/0000-0002-4391-6313; Scacco, Alexandra/0000-0002-7282-2762; Meriggi, Niccolo Francesco/0000-0002-6757-1284; Voors, Maarten/0000-0001-5907-3253; Bosancianu, Constantin Manuel/0000-0001-7950-9798; Armand, Alex/0000-0003-1326-7348; Solis Arce, Julio/0000-0002-0759-4142; Augsburg, Britta/0000-0002-8864-7751; Vicente, Pedro/0000-0002-9864-5012; Fracchia, Mattia/0000-0002-5365-9613; Shah, Taimur/0000-0003-1642-1208; Kharel, Arjun/0000-0002-0053-5473; Shapiro, Jacob/0000-0002-7484-229X; Borisova, Ekaterina/0000-0002-0961-8021; Guariso, Andrea/0000-0003-2128-7322	IPA New York; IPA Washington, DC; Beyond Conflict; Bill and Melinda Gates Foundation; Columbia University; Givewell.org; Ghent University; HSE University Basic Research Program; International Growth Centre; Jameel Poverty Action Lab Crime and Violence Initiative; London School of Economics and Political Science; Mulago Foundation; NOVAFRICA at the Nova School of Business and Economics; NYU Abu Dhabi; Energy for Economic Growth (EEG) programme - UK Aid; Princeton University; Social Science Research Council; Trinity College Dublin COVID19 Response Funding; UK Aid; UKRI GCRF/Newton Fund; United Nations Office for Project Services; Weiss Family Fund; WZB Berlin Social Science Center; Yale Institute for Global Health; Yale Macmillan Center	IPA New York; IPA Washington, DC; Beyond Conflict; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Columbia University; Givewell.org; Ghent University(Ghent University); HSE University Basic Research Program; International Growth Centre; Jameel Poverty Action Lab Crime and Violence Initiative; London School of Economics and Political Science; Mulago Foundation; NOVAFRICA at the Nova School of Business and Economics; NYU Abu Dhabi; Energy for Economic Growth (EEG) programme - UK Aid; Princeton University(Princeton University); Social Science Research Council; Trinity College Dublin COVID19 Response Funding; UK Aid(CGIAR); UKRI GCRF/Newton Fund(UK Research & Innovation (UKRI)); United Nations Office for Project Services; Weiss Family Fund; WZB Berlin Social Science Center; Yale Institute for Global Health; Yale Macmillan Center	This work would not have been possible without the hard work and ingenuity of many. For valuable contributions to data collection during the challenging context of the global pandemic, we would like to thank the following people. Burkina Faso: IPA Burkina Faso staff in Ouagadougou for their support of the RECOVR (Research for Effective Covid Response) survey from which the questions used in this study were drawn. Colombia: IPA Colombia staff in Bogota for their support of the RECOVR survey from which the questions used in this study were drawn. India: P. Sen (Country Director), K. Das (Program Policy Manager) and B. Mohanty (Country Economist) at IGC India and Morsel Research and Development's field team. Mozambique: F. Mendonca and S. Paiva from NOVAFRICA Mozambique office. Nepal: field staff at the Centre for the Study of Labour and Mobility (CESLAM) in Kathmandu. Nigeria: S. Fayomi and A. Kumar at the Busara Center for Behavioral Economics and S. Ryan (University of Illinois at Chicago) for research assistance. Pakistan survey 1: staff at the Institute for Development and Economic Alternatives (IDEAS) in Lahore for their contributions to the Sheikhupura police study sample from which the questions used in the Pakistan survey 1 study were drawn. Pakistan survey 2: staff of the internal survey firm at the Centre for Economic Research Pakistan (CERP) for their contributions to the Economic Vulnerability Assessment (EVA) project from which the questions used in the Pakistan survey 2 study were drawn. Rwanda: IPA Rwanda staff in Kigali for their support of the RECOVR survey from which the questions used in this study were drawn. Russia: staff at Online Market Intelligence Survey Agency, Kirill Chmel (HSE University) and Vladimir Zabolotsky (HSE University and University of Bologna) for their intellectual contributions and research assistance. Sierra Leone survey 1: IPA Sierra Leone staff in Freetown for their support of the RECOVR survey from which the questions used in this study were drawn. Sierra Leone survey 2: J. Nabieu (Field Supervisor), M. Flee (Field Supervisor), H. Kai, M. Lamin (Field Supervisor) and all enumerators at IGC Sierra Leone Freetown office and Wageningen University's Project 'Tracking the Economic Consequences of COVID-19 in Sierra Leone'. Uganda survey 1: staff at IPA Uganda for their intellectual contributions, research assistance and support throughout the study. Uganda survey 2: Co-PIs Ana Garcia Hernandez, P. Kiwanuka-Mukiibi, L. Rosenzweig, L. Tsai and E. Atuhumuza and the team of survey enumerators and support staff at IPA Uganda. United States: staff at Lucid (survey firm) for distributing the survey and providing the online survey sample. IGC thanks the resident country teams in Sierra Leone, Uganda, Pakistan and Mozambique for their continued guidance, coordination of activities with researchers and direct engagement and dissemination activities with national policymakers: H. McLeod (Country Director) and A. Bakarr Kamara (Country Economist) at IGC Sierra Leone. R. Newfarmer (Country Director), P. Manwaring (Country Economist) and J. Rauschendorfer (Country Economist) at IGC-Uganda. I. Nabi (Country Director), H. Shaikh (Country Economist) and U. Naeem (Country Economist) at IGC-Pakistan. C. Frischtak (Country Director) and E. Daniel (Country Economist) at IGC Mozambique. IPA thanks staff from its global offices for their research assistance and support throughout the RECOVR survey. At IPA New York and Washington, DC, M. Rosenbaum and S. Henderson provided research support. NOVAFRICA thanks C.; Batista (NOVA SBE), S. Sequeira (LSE) and I. Vilela (Royal Holloway, University of London and NOVAFRICA) for their intellectual contributions. Funding was provided by Beyond Conflict, Bill and Melinda Gates Foundation, Columbia University, Givewell.org, Ghent University, HSE University Basic Research Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence Initiative, London School of Economics and Political Science, Mulago Foundation, NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Energy for Economic Growth (EEG) programme led by Oxford Policy Management, funded by UK Aid, Princeton University, Social Science Research Council, Trinity College Dublin COVID19 Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale Institute for Global Health, Yale Macmillan Center and anonymous donors to IPA and Y-RISE.	Alatas V., 2019, 25589 NBER; Ali M, 2019, LANCET, V394, P915, DOI 10.1016/S0140-6736(19)32101-4; [Anonymous], 2021, GLOBAL HLTH OBSERVAT; [Anonymous], 2020, BEHAV CONSIDERATIONS; [Anonymous], 2021, COVID 19 VACCINE TRA; [Anonymous], 2021, GLOBAL ATTITUDES COV; [Anonymous], 2021, COVID 19 WHAT WE KNO; [Anonymous], 2017, WORLD DEV REPORT 201; [Anonymous], 2018, WORLD DEV INDICATORS; [Anonymous], 2021, DRAFT LANDSCAPE TRAC; [Anonymous], 2020, IMPACT CONDITIONAL C; [Anonymous], 2021, SARS COV2 VARIANTS N; [Anonymous], 2019, WORLD BANK STAFF EST; Argote P., MESSAGING INTERVENTI; Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2; Ashraf N, 2014, J PUBLIC ECON, V120, P1, DOI 10.1016/j.jpubeco.2014.06.014; Aslund A, 2020, EURASIAN GEOGR ECON, V61, P532, DOI 10.1080/15387216.2020.1778499; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banerjee AV, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2220; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590; Biccard BM, 2021, LANCET, V397, P1885, DOI 10.1016/S0140-6736(21)00441-4; Blair RA, 2017, SOC SCI MED, V172, P89, DOI 10.1016/j.socscimed.2016.11.016; Bokemper SE, 2021, VACCINE, V39, P825, DOI 10.1016/j.vaccine.2020.12.048; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Burki TK, 2020, LANCET RESP MED, V8, pE85, DOI 10.1016/S2213-2600(20)30402-1; Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Christensen D, 2021, Q J ECON, V136, P1145, DOI 10.1093/qje/qjaa039; Coppock A, 2019, RES POLITICS, V6, DOI 10.1177/2053168018822174; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Deserranno E., 2021, CEPR DISCUSSION PAPE; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI [10.1016/S2214-109X(17)30072-4, 10.1016/s2214-109x(17)30072-4]; Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007; Goldstein S, 2015, VACCINE, V33, P4212, DOI 10.1016/j.vaccine.2015.04.042; Hornsey MJ, 2020, J EXP SOC PSYCHOL, V88, DOI 10.1016/j.jesp.2019.103947; Jalloh MF, 2020, HUM VACC IMMUNOTHER, V16, P1208, DOI 10.1080/21645515.2019.1661206; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Karing A., 2021, SOCIAL SIGNALING CHI; Katzman JG, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/21501327211007026; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee K, 2009, GLOB INST, P1; Levine G, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247485; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Lowes S, 2021, AM ECON REV, V111, P1284, DOI 10.1257/aer.20180284; Maeda JM, 2021, SCIENCE, V371, P27, DOI 10.1126/science.abf8832Article; Malik AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100495; Martinez-Bravo M, 2022, J EUR ECON ASSOC, V20, P150, DOI 10.1093/jeea/jvab018; McEachan RRC, 2011, HEALTH PSYCHOL REV, V5, P97, DOI 10.1080/17437199.2010.521684; McNeil D.G., 2020, NEW YORK TIMES 1224; Milkman K. L., MEGA STUDY TEXT MESS; Milkman KL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101165118; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Ong SWX, 2021, LANCET INFECT DIS, V21, P1195, DOI 10.1016/S1473-3099(21)00201-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rice BL, 2021, NAT MED, V27, P447, DOI 10.1038/s41591-021-01234-8; Robbins A, 2012, J PUBLIC HEALTH POL, V33, P387, DOI 10.1057/jphp.2012.37; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Stein Richard A, 2017, Germs, V7, P168, DOI 10.18683/germs.2017.1122; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wadman M, 2020, SCIENCE, V370, P1022, DOI 10.1126/science.370.6520.1022; Wellcome Global Monitor, 2018, TOUCH SURG; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	76	285	289	12	69	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1385	+		10.1038/s41591-021-01454-y	http://dx.doi.org/10.1038/s41591-021-01454-y		JUL 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34272499	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000673323800002
J	Moneer, O; Miller, JE; Shah, NID; Ross, JS				Moneer, Osman; Miller, Jennifer E.; Shah, Nilay D.; Ross, Joseph S.			Direct-to-consumer personal genomic tests need better regulation	NATURE MEDICINE			English	Editorial Material									[Moneer, Osman] Yale Sch Med, New Haven, CT USA; [Miller, Jennifer E.; Ross, Joseph S.] Yale Sch Med, Dept Med, Sect Gen Med, New Haven, CT 06510 USA; [Shah, Nilay D.] Mayo Clin, Div Hlth Care Delivery Res, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA; [Ross, Joseph S.] Yale Sch Med, Yale Natl Clinician Scholars Program, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Ross, Joseph S.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA	Yale University; Yale University; Mayo Clinic; Yale University; Yale University	Ross, JS (corresponding author), Yale Sch Med, Dept Med, Sect Gen Med, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale Sch Med, Yale Natl Clinician Scholars Program, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA.; Ross, JS (corresponding author), Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA.	joseph.ross@yale.edu		Moneer, Osman/0000-0003-3191-8028; Ross, Joseph/0000-0002-9218-3320				Brodwin E, 2020, STAT-US; Cameron T, 2021, NAT REV DRUG DISCOV, V20, P93, DOI 10.1038/d41573-021-00019-5; Downing NS, 2014, JAMA-J AM MED ASSOC, V311, P793, DOI 10.1001/jama.2014.148; Eissenberg Joel C, 2017, Mo Med, V114, P26; Hall M.A., 2009, IOWA LAW REV; Hazel J., 2018, CORNELL J LAW PUBLIC; Janssens A.C.J.W., 2019, CLIN GENOME SEQUENCI, P89; Loria K., 2019, CONSUM REP; Muoio D, 2020, MOBIHEALTHNEWS; Na LY, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.6040; Office for Civil Rights, 2008, HHS; Owermohle S., 2021, POLITICO; Regalado Antonio, 2019, MIT TECHNOL REV; Ross C., 2021, STAT-US; Rothstein M. A., 2009, GENE WATCH, V22, P9; Tanner A., 2016, UNDARK; The European Parliament and the Council of the European Union, 2016, EUR LEX; Yaraghi N., 2018, BROOKINGS	18	3	3	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					940	943		10.1038/s41591-021-01368-9	http://dx.doi.org/10.1038/s41591-021-01368-9		MAY 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34017136				2022-12-27	WOS:000652454300006
J	Wu, E; Wu, K; Daneshjou, R; Ouyang, D; Ho, DE; Zou, J				Wu, Eric; Wu, Kevin; Daneshjou, Roxana; Ouyang, David; Ho, Daniel E.; Zou, James			How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	NATURE MEDICINE			English	Editorial Material							ARTIFICIAL-INTELLIGENCE	A comprehensive overview of medical AI devices approved by the US Food and Drug Administration sheds new light on limitations of the evaluation process that can mask vulnerabilities of devices when they are deployed on patients.	[Wu, Eric; Zou, James] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; [Wu, Kevin; Daneshjou, Roxana; Zou, James] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA; [Daneshjou, Roxana] Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA; [Ouyang, David] Cedars Sinai Med Ctr, Dept Cardiol, Smidt Heart Inst, Los Angeles, CA 90048 USA; [Ho, Daniel E.] Stanford Univ, Stanford Law Sch, Stanford, CA 94305 USA; [Zou, James] Chan Zuckerberg Biohub, San Francisco, CA 94158 USA	Stanford University; Stanford University; Stanford University; Cedars Sinai Medical Center; Stanford University	Zou, J (corresponding author), Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA.; Zou, J (corresponding author), Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.; Zou, J (corresponding author), Chan Zuckerberg Biohub, San Francisco, CA 94158 USA.	jamesz@stanford.edu	Daneshjou, Roxana/ABE-7764-2021	Daneshjou, Roxana/0000-0001-7988-9356; Ho, Daniel/0000-0002-2195-5469	National Science Foundation [CCF 1763191, CAREER 1942926]; US National Institutes of Health [T32 5T32AR007422-38, P30AG059307, U01MH098953]; Silicon Valley Foundation; Chan-Zuckerberg Initiative	National Science Foundation(National Science Foundation (NSF)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Silicon Valley Foundation; Chan-Zuckerberg Initiative	J.Z. is supported by the National Science Foundation (CCF 1763191 and CAREER 1942926), the US National Institutes of Health (P30AG059307 and U01MH098953) and grants from the Silicon Valley Foundation and the Chan-Zuckerberg Initiative. R.D. is supported by the US National Institutes of Health (T32 5T32AR007422-38). Our compiled database of approved medical AI devices, analysis code, and models used for the case study are all available at https://ericwu09.github.io/medical-ai-evaluation.	Benjamens S, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00324-0; Ferryman K, 2020, J AM MED INFORM ASSN, V27, P2016, DOI 10.1093/jamia/ocaa133; Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243; Irvin J, 2019, AAAI CONF ARTIF INTE, P590; Johnson AEW, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0322-0; Kaushal A, 2020, JAMA-J AM MED ASSOC, V324, P1212, DOI 10.1001/jama.2020.12067; Liu XX, 2020, NAT MED, V26, P1364, DOI 10.1038/s41591-020-1034-x; Norgeot B, 2020, NAT MED, V26, P1320, DOI 10.1038/s41591-020-1041-y; Rivera SC, 2020, NAT MED, V26, P1351, DOI 10.1038/s41591-020-1037-7; Seyyed-Kalantari L, 2021, PACIFIC SYMPOSIUM ON BICOMPUTING 2021, P232; Wang XS, 2017, PROC CVPR IEEE, P3462, DOI 10.1109/CVPR.2017.369	11	89	90	4	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					582	584		10.1038/s41591-021-01312-x	http://dx.doi.org/10.1038/s41591-021-01312-x		APR 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33820998				2022-12-27	WOS:000636931100002
J	Verguet, S; Hailu, A; Eregata, GT; Memirie, ST; Johansson, KA; Norheim, OF				Verguet, Stephane; Hailu, Alemayehu; Eregata, Getachew Teshome; Memirie, Solomon Tessema; Johansson, Kjell Arne; Norheim, Ole Frithjof			Toward universal health coverage in the post-COVID-19 era	NATURE MEDICINE			English	Article								All countries worldwide have signed up to the United Nations Sustainable Development Goals and have committed to the objective of achieving 'universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all'. During the COVID-19 pandemic and beyond, advancement toward universal health coverage (UHC) will become more difficult for many countries, demonstrating that locally led priority setting is urgently needed to provide health services with appropriate financial protection to all. Because resources are limited and no national constituency can provide an unlimited number of services to their whole population in a sustainable manner, rationing and setting priorities for the selection of interventions to be included in a defined package of services is critical. In this Perspective, we discuss how packages of essential health services can be developed in resource-constrained settings, and detail how experts and the public can decide on principles and criteria, use a comprehensive array of analytical methods and choose which services to be provided free of charge. We illustrate these main steps while drawing on a recently conducted exercise of revising the national essential health services package in Ethiopia, which we compare with examples from other countries that have defined their essential benefits packages. This Perspective also provides recommendations for other low- and middle-income countries on their pathway to UHC. All countries worldwide have signed up to the United Nations Sustainable Development Goals and committed to the objective of achieving universal health coverage. Getting there will require understanding how packages of essential health services can be developed in resource-constrained settings and how experts and the public can make decisions about which health services should be provided free of charge.	[Verguet, Stephane; Norheim, Ole Frithjof] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Hailu, Alemayehu; Eregata, Getachew Teshome] Fed Minist Hlth Ethiopia, Addis Ababa, Ethiopia; [Hailu, Alemayehu; Eregata, Getachew Teshome; Johansson, Kjell Arne; Norheim, Ole Frithjof] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway; [Memirie, Solomon Tessema] Addis Ababa Univ, Dept Pediat & Child Hlth, Coll Hlth Sci, Addis Ababa, Ethiopia	Harvard University; Harvard T.H. Chan School of Public Health; Federal Ministry of Health - Ethiopia (FMOH); University of Bergen; Addis Ababa University	Norheim, OF (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.; Norheim, OF (corresponding author), Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway.	Ole.Norheim@uib.no	Hailu, Alemayehu/AAZ-5206-2020; Norheim, Ole Frithjof/AAC-8771-2020; Johansson, Kjell Arne/ABE-3628-2020	Hailu, Alemayehu/0000-0003-4872-8036; Norheim, Ole Frithjof/0000-0002-5748-5956; Johansson, Kjell Arne/0000-0001-8912-8710				[Anonymous], 2020, COST EFFECTIVENESS A; [Anonymous], 2010, WORLD MALARIA REPORT; [Anonymous], 2011, LIBERIA ESSENTIAL PA; [Anonymous], 2020, STILLBIRTH CHILD MOR; [Anonymous], 2019, ETH ESS HLTH SERV PA; [Anonymous], 2020, FIN GLOB HLTH; [Anonymous], 2016, BANGL ESS HLTH SERV; [Anonymous], 2020, WORLD BANK COUNTRY L; [Anonymous], 2014, MAKING FAIR CHOICES; [Anonymous], 2019, GLOBAL BURDEN DIS ST, DOI 10.1016/S0140-6736(18)32203-7; [Anonymous], 2019, WORLD POPULATION PRO; [Anonymous], 2009, BAS HLTH SERV PACK I; [Anonymous], 2015, HLTH SECT TRANSF PLA; [Anonymous], 2017, TRACK UN HLTH COV 20; [Anonymous], 2020, ETH PASS LANDM EXC T; [Anonymous], 2010, ESSENTIAL HLTH SERVI; [Anonymous], 2020, WORLD DEV IND; [Anonymous], 2005, ESSENTIAL HLTH SERVI; [Anonymous], 2018, DCP3 DIS CONTROL PRI; [Anonymous], 2015, **NON-TRADITIONAL**, DOI DOI 10.1016/J.VACCINE.2014.12.049; [Anonymous], 2020, COST EFF STRAT PLANN; [Anonymous], 2015, GOING UNIVERSAL 24 D; [Anonymous], 2019, EXTENDED HLTH SERVIC; [Anonymous], 2017, HLTH SERVICE PACKAGE; [Anonymous], 2020, IMPLEMENTATION GUIDE; Assefa Y, 2019, GLOBALIZATION HEALTH, V15, DOI 10.1186/s12992-019-0470-1; Atun R, 2015, LANCET, V385, P1230, DOI 10.1016/S0140-6736(14)61646-9; Baltussen R, 2019, VALUE HEALTH, V22, P1283, DOI 10.1016/j.jval.2019.06.014; Bitran R, 2013, AUGE BENEFITS PACKAG, V21; Blanchet K, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003675; Ruiz AC, 2018, HEALTH SYST REFORM, V4, P194, DOI 10.1080/23288604.2018.1488505; Cookson R, 2017, VALUE HEALTH, V20, P206, DOI 10.1016/j.jval.2016.11.027; Dabak SV, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0378-x; Daniels N., 2008, SETTING LIMITS FAIRL, V2nd Ed.; Drummond MF, 2015, METHODS EC EVALUATIO, V4th; Eregata GT, 2021, COST EFFECT RESOUR A, V19, DOI 10.1186/s12962-020-00255-3; Eregata GT, 2020, HEALTH SYST REFORM, V6, DOI 10.1080/23288604.2020.1829313; Erlangga D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219731; Giedion U, 2017, WHATS WHATS OUT DESI, P30; Glassman A., 2017, WHATS WHATS OUT DESI, P141; Gonzalez-Pier E, 2006, LANCET, V368, P1608, DOI 10.1016/S0140-6736(06)69567-6; Haakenstad A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1266-0; Hailu A., HEALTH SYST REFORM; Hollingworth Samantha A, 2020, F1000Res, V9, P364, DOI 10.12688/f1000research.23263.1; Jamison DT, 2018, LANCET, V391, P1108, DOI 10.1016/S0140-6736(17)32906-9; Johansson KA, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001320; Manthalu G., 2017, WHATS WHATS OUT DESI, P235; McCoy M., 2020, GLOBAL HLTH PRIORITY; McIntyre, 2014, FISCAL SPACE DOMESTI; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P717; Neumann PJ, 2016, COST EFFECTIVENESS H; Norheim OF, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0624-4; Ochalek J, 2016, SUPPORTING DEV ESSEN; Reich MR, 2016, LANCET, V387, P811, DOI 10.1016/S0140-6736(15)60002-2; Roberts M.J., 2019, GETTING HLTH REFORM; Rumbold B, 2017, LANCET, V390, P712, DOI 10.1016/S0140-6736(17)30931-5; Sepulveda J, 2006, LANCET, V368, P2017, DOI 10.1016/S0140-6736(06)69569-X; Stenberg K, 2017, LANCET GLOB HEALTH, V5, pE875, DOI [10.1016/S2214-109X(17)30263-2, 10.1016/s2214-109x(17)30263-2]; Sundewall J., 2019, PRIORITIZING ESSENTI; United Nations Report, 2015, TRANSFORMING OUR WOR; Verguet S, 2016, PHARMACOECONOMICS, V34, P913, DOI 10.1007/s40273-016-0414-z; Verguet S, 2015, LANCET GLOB HEALTH, V3, pE288, DOI 10.1016/S2214-109X(14)70346-8; Wagstaff A, 2018, LANCET GLOB HEALTH, V6, pE169, DOI [10.1016/S2214-109X(17)30486-2, 10.1016/S2214-109X(17)30429-1, 10.1016/s2214-109x(17)30486-2]; Watkins DA, 2017, DIS CONTROL PRIORITI, V3rd; Wilkinson T, 2016, VALUE HEALTH, V19, P921, DOI 10.1016/j.jval.2016.04.015; Woldemariam A.T.H, 2017, 18 U WASHSH; Wong JQ, 2018, HEALTH SYST REFORM, V4, P19, DOI 10.1080/23288604.2017.1368432; Wright J., 2015, ESSENTIAL PACKAGE HL; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1	69	17	17	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					380	387		10.1038/s41591-021-01268-y	http://dx.doi.org/10.1038/s41591-021-01268-y			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723458	Bronze			2022-12-27	WOS:000629708300015
J	Yu, JL; Green, MD; Li, SS; Sun, YL; Journey, SN; Choi, JE; Rizvi, SM; Qin, AN; Waninger, JJ; Lang, XT; Chopra, Z; El Naqa, I; Zhou, JJ; Bian, YJ; Jiang, L; Tezel, A; Skvarce, J; Achar, RK; Sitto, M; Rosen, BS; Su, FY; Narayanan, SP; Cao, XH; Wei, S; Szeliga, W; Vatan, L; Mayo, C; Morgan, MA; Schonewolf, CA; Cuneo, K; Kryczek, I; Ma, VCT; Lao, CSD; Lawrence, TS; Ramnath, N; Wen, F; Chinnaiyan, AM; Cieslik, M; Alva, A; Zou, WP				Yu, Jiali; Green, Michael D.; Li, Shasha; Sun, Yilun; Journey, Sara N.; Choi, Jae Eun; Rizvi, Syed Monem; Qin, Angel; Waninger, Jessica J.; Lang, Xueting; Chopra, Zoey; El Naqa, Issam; Zhou, Jiajia; Bian, Yingjie; Jiang, Long; Tezel, Alangoya; Skvarce, Jeremy; Achar, Rohan K.; Sitto, Merna; Rosen, Benjamin S.; Su, Fengyun; Narayanan, Sathiya P.; Cao, Xuhong; Wei, Shuang; Szeliga, Wojciech; Vatan, Linda; Mayo, Charles; Morgan, Meredith A.; Schonewolf, Caitlin A.; Cuneo, Kyle; Kryczek, Ilona; Ma, Vincent T.; Lao, Christopher D.; Lawrence, Theodore S.; Ramnath, Nithya; Wen, Fei; Chinnaiyan, Arul M.; Cieslik, Marcin; Alva, Ajjai; Zou, Weiping			Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	NATURE MEDICINE			English	Article							DRAINING LYMPH-NODES; CANCER-IMMUNITY; BLOCKADE; RADIATION; MECHANISMS; APOPTOSIS; CONTACT; PD-L1	Metastasis is the primary cause of cancer mortality, and cancer frequently metastasizes to the liver. It is not clear whether liver immune tolerance mechanisms contribute to cancer outcomes. We report that liver metastases diminish immunotherapy efficacy systemically in patients and preclinical models. Patients with liver metastases derive limited benefit from immunotherapy independent of other established biomarkers of response. In multiple mouse models, we show that liver metastases siphon activated CD8(+) T cells from systemic circulation. Within the liver, activated antigen-specific Fas(+)CD8(+) T cells undergo apoptosis following their interaction with FasL(+)CD11b(+)F4/80(+) monocyte-derived macrophages. Consequently, liver metastases create a systemic immune desert in preclinical models. Similarly, patients with liver metastases have reduced peripheral T cell numbers and diminished tumoral T cell diversity and function. In preclinical models, liver-directed radiotherapy eliminates immunosuppressive hepatic macrophages, increases hepatic T cell survival and reduces hepatic siphoning of T cells. Thus, liver metastases co-opt host peripheral tolerance mechanisms to cause acquired immunotherapy resistance through CD8(+) T cell deletion, and the combination of liver-directed radiotherapy and immunotherapy could promote systemic antitumor immunity. Liver metastases reduce clinical and preclinical immune-checkpoint inhibitor efficacy through hepatic siphoning of circulating activated CD8(+) T cells, but therapeutic benefit can be improved by combining immunotherapy with liver-directed radiotherapy.	[Yu, Jiali; Li, Shasha; Wei, Shuang; Szeliga, Wojciech; Vatan, Linda; Kryczek, Ilona; Zou, Weiping] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Yu, Jiali; Green, Michael D.; Li, Shasha; Lang, Xueting; Zhou, Jiajia; Bian, Yingjie; Jiang, Long; Wei, Shuang; Szeliga, Wojciech; Vatan, Linda; Kryczek, Ilona; Alva, Ajjai; Zou, Weiping] Univ Michigan, Michigan Rogel Canc Ctr, Ctr Excellence Canc Immunol & Immunotherapy, Ann Arbor, MI USA; [Green, Michael D.; Sun, Yilun; El Naqa, Issam; Jiang, Long; Sitto, Merna; Rosen, Benjamin S.; Mayo, Charles; Morgan, Meredith A.; Schonewolf, Caitlin A.; Cuneo, Kyle; Lawrence, Theodore S.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Green, Michael D.; Ramnath, Nithya] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA; [Li, Shasha; Cieslik, Marcin] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Sun, Yilun] Univ Michigan, Dept Biostat, Ann Arbor, MI USA; [Journey, Sara N.; Waninger, Jessica J.; Chopra, Zoey; Tezel, Alangoya; Skvarce, Jeremy; Achar, Rohan K.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Choi, Jae Eun; Su, Fengyun; Narayanan, Sathiya P.; Cao, Xuhong; Chinnaiyan, Arul M.; Cieslik, Marcin; Zou, Weiping] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Choi, Jae Eun; Waninger, Jessica J.; Su, Fengyun; Narayanan, Sathiya P.; Cao, Xuhong; Chinnaiyan, Arul M.; Cieslik, Marcin] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Rizvi, Syed Monem; Wen, Fei] Univ Michigan, Chem Engn, Ann Arbor, MI 48109 USA; [Qin, Angel; Ma, Vincent T.; Lao, Christopher D.; Ramnath, Nithya; Alva, Ajjai] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [El Naqa, Issam] H Lee Moffitt Canc Ctr & Res Inst, Machine Learning Dept, Tampa, FL USA; [Achar, Rohan K.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Cao, Xuhong; Chinnaiyan, Arul M.] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Zou, Weiping] Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI USA; [Zou, Weiping] Univ Michigan, Sch Med, Grad Program Canc Biol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; H Lee Moffitt Cancer Center & Research Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zou, WP (corresponding author), Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.; Green, MD; Zou, WP (corresponding author), Univ Michigan, Michigan Rogel Canc Ctr, Ctr Excellence Canc Immunol & Immunotherapy, Ann Arbor, MI USA.; Green, MD (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.; Green, MD (corresponding author), Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA.; Zou, WP (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI USA.; Zou, WP (corresponding author), Univ Michigan, Sch Med, Grad Program Canc Biol, Ann Arbor, MI USA.	migr@med.umich.edu; wzou@med.umich.edu	Sun, Yilun/X-8775-2019; Ma, Vincent/GLV-1899-2022; Bian, Yingjie/AAS-4576-2020; Narayanan, Sathiya Pandi/AFS-0744-2022; Cuneo, Kyle/DZG-3141-2022; Ma, Vincent/ABE-4599-2020	Sun, Yilun/0000-0002-1341-382X; Bian, Yingjie/0000-0002-9599-9907; Ma, Vincent/0000-0002-8417-2787; Journey, Sara/0000-0002-0987-9774; Chopra, Zoey/0000-0002-6349-2431; Green, Michael/0000-0003-4951-7118	NIH/NCI [CA248430, CA123088, CA099985, CA193136, CA152470, 1UM1HG006508, U01CA216449, CA233487, S10OD020053, CA240515]; NIH through the University of Michigan Rogel Cancer Center Support Grant [P30CA46592]; University of Michigan Experimental Irradiation Shared Resource; Immune Monitoring Core; Vector Core; University of Michigan Center for Molecular Imaging; Vivo Animal Core and the Advanced Genomics Core	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH through the University of Michigan Rogel Cancer Center Support Grant; University of Michigan Experimental Irradiation Shared Resource; Immune Monitoring Core; Vector Core; University of Michigan Center for Molecular Imaging; Vivo Animal Core and the Advanced Genomics Core	This work was supported in part by research grants from the NIH/NCI grants for WZ (CA248430, CA123088, CA099985, CA193136, and CA152470); AC (1UM1HG006508); TSL (U01CA216449); IEN (CA233487); FW (S10OD020053); MAM (CA240515) and the NIH through the University of Michigan Rogel Cancer Center Support Grant (P30CA46592). We would like to thank all members of the Zou and Green laboratories for their insightful feedback, as well as L. Fecher. We also acknowledge the support of the University of Michigan Experimental Irradiation Shared Resource, the Immune Monitoring Core, the Vector Core, the University of Michigan Center for Molecular Imaging, the In Vivo Animal Core and the Advanced Genomics Core.	Billi AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127291; Bleriot C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02694; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; Crispe IN, 2000, IMMUNOL REV, V174, P47, DOI 10.1034/j.1600-0528.2002.017412.x; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; David BA, 2016, GASTROENTEROLOGY, V151, P1176, DOI 10.1053/j.gastro.2016.08.024; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2; Doherty DG, 2016, J AUTOIMMUN, V66, P60, DOI 10.1016/j.jaut.2015.08.020; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Formenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2; Golden EB, 2013, CANCER IMMUNOL RES, V1, P365, DOI 10.1158/2326-6066.CIR-13-0115; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Horst AK, 2016, CELL MOL IMMUNOL, V13, P277, DOI 10.1038/cmi.2015.112; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Imai K, 2014, J R STAT SOC B, V76, P243, DOI 10.1111/rssb.12027; Jackson WC, 2018, INT J RADIAT ONCOL, V100, P950, DOI 10.1016/j.ijrobp.2017.12.014; Jiao S, 2019, CELL, V179; John B, 2004, J IMMUNOL, V172, P5222, DOI 10.4049/jimmunol.172.9.5222; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lee JC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba0759; Li FL, 2013, CELL MOL IMMUNOL, V10, P292, DOI 10.1038/cmi.2013.7; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Li W, 2018, CELL METAB, V28, P87, DOI 10.1016/j.cmet.2018.04.022; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113; Ma C, 2018, SCIENCE, V360, DOI 10.1126/science.aan5931; Mayo Charles S, 2016, Adv Radiat Oncol, V1, P260, DOI 10.1016/j.adro.2016.10.001; Medina-Echeverz J, 2015, CANCER IMMUNOL IMMUN, V64, P931, DOI 10.1007/s00262-015-1736-y; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mould KJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126556; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Petrelli F, 2019, MELANOMA RES, V29, P1, DOI 10.1097/CMR.0000000000000520; Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Saio M, 2001, J IMMUNOL, V167, P5583, DOI 10.4049/jimmunol.167.10.5583; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; SIJTS AJAM, 1994, J IMMUNOL, V152, P106; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061; Theelen WSME, 2019, JAMA ONCOL, V5, P1276, DOI 10.1001/jamaoncol.2019.1478; Topalian SL, 2019, JAMA ONCOL, V5, P1411, DOI 10.1001/jamaoncol.2019.2187; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Tumeh PC, 2017, CANCER IMMUNOL RES, V5, P417, DOI 10.1158/2326-6066.CIR-16-0325; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Warren A, 2006, HEPATOLOGY, V44, P1182, DOI 10.1002/hep.21378; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Welsh JW, 2019, CANCER IMMUNOL RES, V7, P1903, DOI 10.1158/2326-6066.CIR-18-0793; Yarchoan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126908; Yu JL, 2017, J AUTOIMMUN, V84, P109, DOI 10.1016/j.jaut.2017.08.005; Zeng ZT, 2016, J EXP MED, V213, P1079, DOI 10.1084/jem.20151218; Zhang L, 2020, CELL, V181, P442, DOI 10.1016/j.cell.2020.03.048; Zhang Q, 2019, CANCER RES, V79, P3940, DOI 10.1158/0008-5472.CAN-19-0761; Zheng MJ, 2013, CELL MOL IMMUNOL, V10, P143, DOI 10.1038/cmi.2012.59; Zhu JJ, 2019, CANCER IMMUNOL IMMUN, V68, P835, DOI 10.1007/s00262-018-2269-y; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	64	184	186	36	167	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					152	+		10.1038/s41591-020-1131-x	http://dx.doi.org/10.1038/s41591-020-1131-x		JAN 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33398162	Green Accepted			2022-12-27	WOS:000604849400001
J	Stower, H				Stower, Hannah			Therapy for NASH	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	2	2	2	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					21	21		10.1038/s41591-020-01219-z	http://dx.doi.org/10.1038/s41591-020-01219-z			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442011				2022-12-27	WOS:000607931400013
J	Udler, MS				Udler, Miriam S.			Identifying subgroups of people at risk for type 2 diabetes	NATURE MEDICINE			English	Editorial Material								Analysis of glycemic and non-glycemic characteristics in individuals at risk for type 2 diabetes identifies six putative subgroups that differ in terms of risk of diabetes progression and complications.	[Udler, Miriam S.] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; [Udler, Miriam S.] Massachusetts Gen Hosp, Dept Med, Ctr Genom Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Udler, MS (corresponding author), Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA.; Udler, MS (corresponding author), Massachusetts Gen Hosp, Dept Med, Ctr Genom Med, Boston, MA 02114 USA.	mudler@mgh.harvard.edu			NIDDK NIH HHS [L30 DK106874, K23 DK114551] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases) [1K23DK114551] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); U.S. Department of Health &amp; Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases)		Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2; Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS14, DOI 10.2337/dc20-S002; [Anonymous], 2003, DIABETES CARE, V26, P2518, DOI DOI 10.2337/diacare.26.9.2518; [Anonymous], 2020, NAT DIAB STAT REP 20, P2020; Colagiuri S, 2002, DIABETES CARE, V25, P1378, DOI 10.2337/diacare.25.8.1378; Crandall JP, 2008, NAT CLIN PRACT ENDOC, V4, P382, DOI 10.1038/ncpendmet0843; Dennis JM, 2019, LANCET DIABETES ENDO, V7, P442, DOI 10.1016/S2213-8587(19)30087-7; Federation ID, 2019, IDF DIAB ATL 2019, V9th; Richter B, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012661.pub2; Tabak AG, 2012, LANCET, V379, P2279, DOI 10.1016/S0140-6736(12)60283-9; Udler MS, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002654; Wagner R, 2021, NAT MED, V27, P49, DOI 10.1038/s41591-020-1116-9; WHO, 2016, GLOB REP PSOR	13	1	1	2	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					23	25		10.1038/s41591-020-01208-2	http://dx.doi.org/10.1038/s41591-020-01208-2			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442006				2022-12-27	WOS:000607931400017
J	Monteiro, C; Miarka, L; Perea-Garcia, M; Priego, N; Garcia-Gomez, P; Alvaro-Espinosa, L; de Pablos-Aragoneses, A; Yebra, N; Retana, D; Baena, P; Fustero-Torre, C; Grana-Castro, O; Troule, K; Caleiras, E; Tezanos, P; Muela, P; Cintado, E; Trejo, JL; Sepulveda, JM; Gonzalez-Leon, P; Jimenez-Roldan, L; Moreno, LM; Esteban, O; Perez-Nunez, A; Hernandez-Lain, A; Gallego, JM; Ferrer, I; Suarez, R; Garrido-Martin, EM; Paz-Ares, L; Dalmasso, C; Moyal, ECJ; Siegfried, A; Hegarty, A; Keelan, S; Vareslija, D; Young, LS; Mohme, M; Goy, Y; Wikman, H; Fernandez-Alen, J; Blasco, G; Alcazar, L; Cabanuz, C; Grivennikov, SI; Ianus, A; Shemesh, N; Faria, CC; Lee, R; Lorigan, P; Le Rhun, E; Weller, M; Soffietti, R; Bertero, L; Ricardi, U; Bosch-Barrera, J; Sais, E; Teixidor, E; Hernandez-Martinez, A; Calvo, A; Aristu, J; Martin, SM; Gonzalez, A; Adler, O; Erez, N; Valiente, M				Monteiro, Catia; Miarka, Lauritz; Perea-Garcia, Maria; Priego, Neibla; Garcia-Gomez, Pedro; Alvaro-Espinosa, Laura; de Pablos-Aragoneses, Ana; Yebra, Natalia; Retana, Diana; Baena, Patricia; Fustero-Torre, Coral; Grana-Castro, Osvaldo; Troule, Kevin; Caleiras, Eduardo; Tezanos, Patricia; Muela, Pablo; Cintado, Elisa; Luis Trejo, Jose; Manuel Sepulveda, Juan; Gonzalez-Leon, Pedro; Jimenez-Roldan, Luis; Miguel Moreno, Luis; Esteban, Olga; Perez-Nunez, Angel; Hernandez-Lain, Aurelio; Mazarico Gallego, Jose; Ferrer, Irene; Suarez, Rocio; Garrido-Martin, Eva M.; Paz-Ares, Luis; Dalmasso, Celine; Moyal, Elizabeth Cohen-Jonathan; Siegfried, Aurore; Hegarty, Aisling; Keelan, Stephen; Vareslija, Damir; Young, Leonie S.; Mohme, Malte; Goy, Yvonne; Wikman, Harriet; Fernandez-Alen, Jose; Blasco, Guillermo; Alcazar, Lucia; Cabanuz, Clara; Grivennikov, Sergei, I; Ianus, Andrada; Shemesh, Noam; Faria, Claudia C.; Lee, Rebecca; Lorigan, Paul; Le Rhun, Emilie; Weller, Michael; Soffietti, Riccardo; Bertero, Luca; Ricardi, Umberto; Bosch-Barrera, Joaquim; Sais, Elia; Teixidor, Eduard; Hernandez-Martinez, Alejandro; Calvo, Alfonso; Aristu, Javier; Martin, Santiago M.; Gonzalez, Alvaro; Adler, Omer; Erez, Neta; Valiente, Manuel		RENACER	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism	NATURE MEDICINE			English	Article							SET ENRICHMENT ANALYSIS; GLYCATION END-PRODUCTS; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY; MOUSE-BRAIN; CANCER; CELL; RAGE; RADIOTHERAPY; RECEPTOR	A comprehensive analysis of models of brain metastasis and multiple cohorts of patient samples identifies a targetable molecular mechanism underlying the resistance to whole-brain radiotherapy that can inform patient selection for personalized radiotherapy. Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9-RAGE-NF-kappa B-JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.	[Monteiro, Catia; Miarka, Lauritz; Perea-Garcia, Maria; Priego, Neibla; Garcia-Gomez, Pedro; Alvaro-Espinosa, Laura; de Pablos-Aragoneses, Ana; Yebra, Natalia; Retana, Diana; Baena, Patricia; Valiente, Manuel] CNIO, Brain Metastasis Grp, Madrid, Spain; [Fustero-Torre, Coral; Grana-Castro, Osvaldo; Troule, Kevin] CNIO, Bioinformat Unit, Madrid, Spain; [Caleiras, Eduardo] CNIO, Histopathol Core Unit, Madrid, Spain; [Tezanos, Patricia; Muela, Pablo; Cintado, Elisa; Luis Trejo, Jose] CSIC, Dept Translat Neurosci, Cajal Inst, Madrid, Spain; [Manuel Sepulveda, Juan] Hosp Univ 12 Octubre, Neurooncol Unit, Madrid, Spain; [Gonzalez-Leon, Pedro; Jimenez-Roldan, Luis; Miguel Moreno, Luis; Esteban, Olga; Perez-Nunez, Angel] Hosp Univ 12 Octubre, Neurosurg Unit, Madrid, Spain; [Jimenez-Roldan, Luis; Perez-Nunez, Angel] Univ Complutense Madrid, Dept Surg, Madrid, Spain; [Hernandez-Lain, Aurelio] Hosp Univ 12 Octubre, Neuropathol Unit, Madrid, Spain; [Mazarico Gallego, Jose; Paz-Ares, Luis] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain; [Ferrer, Irene; Suarez, Rocio; Garrido-Martin, Eva M.; Paz-Ares, Luis] Fdn Invest Biomed I 12, CNIO H12O Clin Canc Res Unit, Madrid, Spain; [Ferrer, Irene; Suarez, Rocio; Garrido-Martin, Eva M.; Paz-Ares, Luis] CNIO, Madrid, Spain; [Ferrer, Irene; Suarez, Rocio; Garrido-Martin, Eva M.; Paz-Ares, Luis; Calvo, Alfonso] CIBERONC, Madrid, Spain; [Paz-Ares, Luis] Univ Complutense Madrid, Dept Med, Madrid, Spain; [Dalmasso, Celine; Moyal, Elizabeth Cohen-Jonathan] IUCT Oncopole, Radiat Oncol Dept, Inst Claudius Regaud, Toulouse, France; [Siegfried, Aurore] CHU Toulouse, IUCT Oncopole, Anatomopathol Dept, Toulouse, France; [Hegarty, Aisling; Keelan, Stephen; Vareslija, Damir; Young, Leonie S.] RCSI Univ Med & Hlth Sci, Endocrine Oncol Res Grp, Dublin, Ireland; [Mohme, Malte] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany; [Goy, Yvonne] Univ Med Ctr Hamburg Eppendorf, Dept Radiat Oncol, Hamburg, Germany; [Wikman, Harriet] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany; [Fernandez-Alen, Jose; Blasco, Guillermo; Alcazar, Lucia] Hosp Univ La Princesa, Dept Neurosurg, Madrid, Spain; [Cabanuz, Clara] Hosp Univ La Paz, Dept Pathol, Madrid, Spain; [Grivennikov, Sergei, I] Fox Chase Canc Ctr, Canc Prevent & Control Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Ianus, Andrada; Shemesh, Noam] Champalimaud Ctr Unknown, Champalimaud Res, Lisbon, Portugal; [Faria, Claudia C.] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal; [Faria, Claudia C.] Ctr Hosp Univ Lisboa Norte CHULN, Hosp Santa Maria, Dept Neurosurg, Lisbon, Portugal; [Lee, Rebecca; Lorigan, Paul] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Lee, Rebecca; Lorigan, Paul] Christie NHS Fdn Trust, Manchester, Lancs, England; [Le Rhun, Emilie; Weller, Michael] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland; [Soffietti, Riccardo] Univ Turin, Dept Neurosci Rita Levi Montalcini, Div Neurooncol, Turin, Italy; [Bertero, Luca] Univ Turin, Dept Med Sci, Turin, Italy; [Ricardi, Umberto] Univ Turin, Dept Oncol, Turin, Italy; [Bosch-Barrera, Joaquim; Sais, Elia; Teixidor, Eduard; Hernandez-Martinez, Alejandro] Doctor Josep Trueta Univ Hosp, Catalan Inst Oncol, Dept Med Oncol, Girona, Spain; [Bosch-Barrera, Joaquim; Sais, Elia; Teixidor, Eduard; Hernandez-Martinez, Alejandro] Girona Biomed Res Inst IDIBGi, Salt, Spain; [Bosch-Barrera, Joaquim] Univ Girona, Dept Med Sci, Girona, Spain; [Calvo, Alfonso] Univ Navarra, Ctr Appl Med Res CIMA, Program Solid Tumors, IDISNA, Pamplona, Spain; [Aristu, Javier] Univ Clin Navarra, Dept Oncol, Madrid, Spain; [Martin, Santiago M.] Univ Clin Navarra, Dept Oncol, Pamplona, Spain; [Gonzalez, Alvaro] Univ Clin Navarra, Dept Biochem, Pamplona, Spain; [Adler, Omer; Erez, Neta] Tel Aviv Univ, Sackler Fac Med, Dept Pathol, Tel Aviv, Israel; [Grivennikov, Sergei, I] Cedars Sinai Med Ctr, Cedars Sinai Canc, Dept Med, Los Angeles, CA 90048 USA; [Grivennikov, Sergei, I] Cedars Sinai Med Ctr, Cedars Sinai Canc, Dept Biomed Sci, Los Angeles, CA 90048 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Complutense University of Madrid; UNICANCER; Institut Claudius Regaud; CHU de Toulouse; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hospital de La Princesa; Hospital Universitario La Paz; Fox Chase Cancer Center; Fundacao Champalimaud; Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria; University of Manchester; Christie NHS Foundation Trust; University of Zurich; University Zurich Hospital; University of Turin; University of Turin; University of Turin; Catalan Institute of Oncology; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Universitat de Girona; University of Navarra; University of Navarra; University of Navarra; University of Navarra; Tel Aviv University; Sackler Faculty of Medicine; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Valiente, M (corresponding author), CNIO, Brain Metastasis Grp, Madrid, Spain.	mvaliente@cnio.es	García-Gómez, Pedro/K-7715-2017; Shemesh, Noam/GPK-7972-2022; Perez-Nuñez, Angel/AAG-4422-2020; Grivennikov, Sergei/AAE-7365-2019; Calvo, Alfonso/V-7945-2017; Lorigan, Paul/J-6898-2015; Fernandez Alen, Jose/G-4990-2018	García-Gómez, Pedro/0000-0003-0694-3942; Perez-Nuñez, Angel/0000-0002-2391-6586; Grivennikov, Sergei/0000-0003-2987-0555; Calvo, Alfonso/0000-0003-4074-4242; Lorigan, Paul/0000-0002-8875-2164; Lee, Rebecca/0000-0003-2540-2009; Bosch-Barrera, Joaquim/0000-0002-0893-7821; Erez, Neta/0000-0001-6506-9074; Cabanuz, Clara/0000-0002-5345-9435; Keelan, Stephen/0000-0002-3632-5128; Muela Martinez, Pablo/0000-0001-5032-2129; Fernandez Alen, Jose/0000-0002-3321-983X; Weller, Michael/0000-0002-1748-174X	Pla Director d'Oncologia de Catalunya; MINECO [SAF2017-89643-R]; Fundacio La Marato de TV3 [201906-30-31-32]; Fundacion Ramon Areces [CIVP19S8163, CIVP20S10662]; Worldwide Cancer Research [19-0177]; Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018) [54545]; AECC (Coordinated Translational Groups 2017) [GCTRA16015SEOA]; LAB AECC 2019 [LABAE19002VALI]; ERC CoG [864759]; Portuguese Foundation for Science and Technology [SFRH/bd/100089/2014]; Boehringer-Ingelheim Fonds MD Fellowship; La Caixa International PhD Program Fellowship-Marie Skodowska-Curie [LCF/BQ/DI17/11620028]; La Caixa INPhINIT Fellowship [LCF/BQ/DI19/11730044]; MINECO-Severo Ochoa PhD Fellowship [BES-2017-081995]; AECC postdoctoral fellowship [POSTD19016PRIE]; Gertrud and Erich Roggenbuck Stiftung; Science Foundation Ireland [19/FFP/6443, 18/SPP/3522, 20/FFP-P/8597]; Breast Cancer Now [2019AugSF1310]; Paradifference Foundation; "la Caixa" Foundation [100010434]; European Union's Horizon 2020 research and innovation programme under Marie Skodowska-Curie grant [847648 (CF/BQ/PI20/11760029)]; Champalimaud Centre for the Unknown; Lisboa Regional Operational Programme (Lisboa 2020) [LISBOA01-0145-FEDER-022170]; NCI [R01 CA227629, R01 CA218133]; Fundacio Roses Contra el Cancer; Ministerio de Universidades FPU Fellowship [FPU 18/00069]; MICIN-Agencia Estatal de Investigacion Fellowships [PRE2020-093032, BES-2017-080415]; Ministerio de Ciencia, Innovacion y Universidades [E050251, PID2019-110292RB-I00]; FCT [PTDC/MED-ONC/32222/2017]; Fundacao Millennium bcp; Foundation for Applied Cancer Research in Zurich	Pla Director d'Oncologia de Catalunya; MINECO(Spanish Government); Fundacio La Marato de TV3; Fundacion Ramon Areces; Worldwide Cancer Research; Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018); AECC (Coordinated Translational Groups 2017); LAB AECC 2019; ERC CoG; Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Boehringer-Ingelheim Fonds MD Fellowship; La Caixa International PhD Program Fellowship-Marie Skodowska-Curie; La Caixa INPhINIT Fellowship; MINECO-Severo Ochoa PhD Fellowship; AECC postdoctoral fellowship; Gertrud and Erich Roggenbuck Stiftung; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Breast Cancer Now; Paradifference Foundation; "la Caixa" Foundation(La Caixa Foundation); European Union's Horizon 2020 research and innovation programme under Marie Skodowska-Curie grant; Champalimaud Centre for the Unknown; Lisboa Regional Operational Programme (Lisboa 2020); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fundacio Roses Contra el Cancer; Ministerio de Universidades FPU Fellowship; MICIN-Agencia Estatal de Investigacion Fellowships; Ministerio de Ciencia, Innovacion y Universidades(Spanish Government); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Fundacao Millennium bcp; Foundation for Applied Cancer Research in Zurich	We thank all members of the Brain Metastasis Group and A. Chalmers, E. Wagner, O. Fernandez-Capetillo, R. Ciervide and A. Hidalgo for critical discussion of the manuscript; the CNIO Core Facilities for their excellent assistance; and Fox Chase Cancer Center Transgenic Facility for generation of S100A9 mice. We thank EuCOMM repository for providing S100A9 targeted embryonic stem cells. We also thank J. Massague (MSKCC) for some of the BrM cell lines and M. Bosenberg (Yale) for the YUMM1.1 cell line. Samples from patients included in this study that provided by the Girona Biomedical Research Institute (IDIBGI) Biobank (Biobanc IDIBGI, B.0000872) are integrated into the Spanish National Biobanks Network and in the Xarxa de Bancs de Tumors de Catalunya (XBTC) financed by the Pla Director d'Oncologia de Catalunya. All patients consented to the storage of these samples in the biobank and for their use in research projects. This study was funded by MINECO (SAF2017-89643-R) (M.V.), Fundacio La Marato de TV3 (201906-30-31-32) (J.B.-B., M.V. and A.C.), Fundacion Ramon Areces (CIVP19S8163) (M.V.) and CIVP20S10662 (E.O.P.), Worldwide Cancer Research (19-0177) (M.V. and E.C.-J.M.), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018 (54545) (M.V.), AECC (Coordinated Translational Groups 2017 (GCTRA16015SEOA) (M.V.), LAB AECC 2019 (LABAE19002VALI) (M.V.), ERC CoG (864759) (M.V.), Portuguese Foundation for Science and Technology (SFRH/bd/100089/2014) (C.M.), Boehringer-Ingelheim Fonds MD Fellowship (L.M.), La Caixa International PhD Program Fellowship-Marie Skodowska-Curie (LCF/BQ/DI17/11620028) (P.G.-G.), La Caixa INPhINIT Fellowship (LCF/BQ/DI19/11730044) (A.P.-A.), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995) (L.A.-E.) and an AECC postdoctoral fellowship (POSTD19016PRIE) (N.P.). M.V. is an EMBO YIP member (4053). Additional support was provided by Gertrud and Erich Roggenbuck Stiftung (M.M.), Science Foundation Ireland Frontiers for the Future Award (19/FFP/6443) (L.Y.), Science Foundation Ireland Strategic Partnership Programme, Precision Oncology Ireland (18/SPP/3522) (L.Y.), Breast Cancer Now Fellowship Award with the generous support of Walk the Walk (2019AugSF1310) (D.V.), Science Foundation Ireland (20/FFP-P/8597) (D.V.), Paradifference Foundation (C.F.-T.), "la Caixa" Foundation (ID 100010434) (A.I.), European Union's Horizon 2020 research and innovation programme under Marie Skodowska-Curie grant agreement 847648 (CF/BQ/PI20/11760029) (A.I.), Champalimaud Centre for the Unknown (N.S.), Lisboa Regional Operational Programme (Lisboa 2020) (LISBOA01-0145-FEDER-022170) (N.S.), NCI (R01 CA227629; R01 CA218133) (S.I.G.), Fundacio Roses Contra el Cancer (J.B.-B.), Ministerio de Universidades FPU Fellowship (FPU 18/00069) (P.T.), MICIN-Agencia Estatal de Investigacion Fellowships (PRE2020-093032 and BES-2017-080415) (P.M. and E. Cintado, respectively), Ministerio de Ciencia, Innovacion y Universidades-E050251 (PID2019-110292RB-I00) (J.L.T.), FCT (PTDC/MED-ONC/32222/2017) (C.C.F.), FundacAo Millennium bcp (C.C.F.), private donations (C.C.F.) and the Foundation for Applied Cancer Research in Zurich (E.L.R. and M.W.).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483; Badr CE, 2009, MOL IMAGING, V8, P278, DOI 10.2310/7290.2009.00026; Baschnagel A, 2009, MOL CANCER THER, V8, P1589, DOI 10.1158/1535-7163.MCT-09-0038; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Berghoff AS, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000024; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bhat K, 2020, NEURO-ONCOLOGY, V22, P1484, DOI 10.1093/neuonc/noaa095; Biecek P, 2019, R PACKAGE SURVMINER; Biswas AK, 2022, CANCER DISCOV, V12, P1002, DOI 10.1158/2159-8290.CD-21-0910; Boretius S, 2009, NEUROIMAGE, V47, P1252, DOI 10.1016/j.neuroimage.2009.05.095; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brown PD, 2017, LANCET ONCOL, V18, P1049, DOI 10.1016/S1470-2045(17)30441-2; Brown PD, 2016, JAMA-J AM MED ASSOC, V316, P401, DOI 10.1001/jama.2016.9839; Burstein AH, 2018, JPAD-J PREV ALZHEIM, V5, P149, DOI 10.14283/jpad.2018.18; Burstein Aaron H, 2014, BMC Neurol, V14, P12, DOI 10.1186/1471-2377-14-12; Cagney DN, 2017, NEURO-ONCOLOGY, V19, P1511, DOI 10.1093/neuonc/nox077; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; Cheloni S, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-00872-8; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Choi SH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-211; Choy C, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0844-3; Cosgrove N, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-27987-5; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Does MD, 2019, MAGN RESON MED, V81, P3503, DOI 10.1002/mrm.27658; Donovan EK, 2019, CURR ONCOL, V26, pE328, DOI 10.3747/co.26.4749; Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58; Eichner C, 2015, NEUROIMAGE, V122, P373, DOI 10.1016/j.neuroimage.2015.07.074; Eisenblaetter M, 2017, THERANOSTICS, V7, P2392, DOI 10.7150/thno.17138; Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8; Frankish A, 2021, NUCLEIC ACIDS RES, V49, pD916, DOI 10.1093/nar/gkaa1087; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garaulet G, 2019, CANCER GENE THER, V26, P216, DOI 10.1038/s41417-018-0076-4; Garaulet G, 2013, MOL THER, V21, P119, DOI 10.1038/mt.2012.131; Garcia-Jimeno L, 2022, BIOINFORMATICS, V38, P1155, DOI 10.1093/bioinformatics/btab758; Grana O, 2018, CURR BIOINFORM, V13, P583, DOI 10.2174/1574893612666170810153850; Hammelrath L, 2016, NEUROIMAGE, V125, P144, DOI 10.1016/j.neuroimage.2015.10.009; Hermani A, 2005, EXP CELL RES, V312, P184, DOI 10.1016/j.yexcr.2005.10.013; Hibino T, 2013, CANCER RES, V73, P172, DOI 10.1158/0008-5472.CAN-11-3843; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hong AM, 2019, J CLIN ONCOL, V37, P3132, DOI 10.1200/JCO.19.01414; Hothorn T, 2003, COMPUT STAT DATA AN, V43, P121, DOI 10.1016/S0167-9473(02)00225-6; Johnstone CN, 2015, DIS MODEL MECH, V8, P237, DOI 10.1242/dmm.017830; Kamide T, 2012, NEUROCHEM INT, V60, P220, DOI 10.1016/j.neuint.2011.12.008; Kellner E, 2016, MAGN RESON MED, V76, P1574, DOI 10.1002/mrm.26054; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Le Rhun E, 2021, ANN ONCOL, V32, P1332, DOI 10.1016/j.annonc.2021.07.016; Leder K, 2014, CELL, V156, P603, DOI 10.1016/j.cell.2013.12.029; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lim SY, 2016, ONCOGENE, V35, P5735, DOI 10.1038/onc.2016.107; Lin QT, 2010, NEOPLASIA, V12, P748, DOI 10.1593/neo.10602; Ma L, 2003, BRAIN RES, V966, P167, DOI 10.1016/S0006-8993(02)04149-5; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Markarian M, 2021, CANCER RES, V81, P1732, DOI 10.1158/0008-5472.CAN-20-2565; Markowitz J, 2013, BBA-REV CANCER, V1835, P100, DOI 10.1016/j.bbcan.2012.10.003; Martin AM, 2018, JAMA ONCOL, V4, P1123, DOI 10.1001/jamaoncol.2017.3993; Martinez-Aranda A, 2013, INT J MOL SCI, V14, P8306, DOI 10.3390/ijms14048306; McGreevy KR, 2019, P NATL ACAD SCI USA, V116, P10103, DOI 10.1073/pnas.1816781116; Minniti G, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-48; Moding EJ, 2013, NAT REV DRUG DISCOV, V12, P526, DOI 10.1038/nrd4003; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Mulvenna P, 2016, LANCET, V388, P2004, DOI 10.1016/S0140-6736(16)30825-X; Nabors LB, 2017, J NATL COMPR CANC NE, V15, P1331, DOI 10.6004/jnccn.2017.0166; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Patchell RA, 1998, JAMA-J AM MED ASSOC, V280, P1485, DOI 10.1001/jama.280.17.1485; Priego N, 2018, NAT MED, V24, P1024, DOI 10.1038/s41591-018-0044-4; Sabbagh MN, 2011, ALZ DIS ASSOC DIS, V25, P206, DOI 10.1097/WAD.0b013e318204b550; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Schildge S, 2013, JOVE-J VIS EXP, DOI 10.3791/50079; Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485; Shabani F, 2018, INFLAMM RES, V67, P801, DOI 10.1007/s00011-018-1173-4; Slyper M, 2020, NAT MED, V26, P792, DOI 10.1038/s41591-020-0844-1; Smart D, 2015, CLIN EXP METASTAS, V32, P717, DOI 10.1007/s10585-015-9739-9; Smith DL, 2016, INT J RADIAT ONCOL, V96, P179, DOI 10.1016/j.ijrobp.2016.04.014; Soffietti R, 2017, NEURO-ONCOLOGY, V19, P162, DOI 10.1093/neuonc/now241; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suh JH, 2020, NAT REV CLIN ONCOL, V17, P279, DOI 10.1038/s41571-019-0320-3; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsao MN, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003869.pub4; Valiente M, 2018, TRENDS CANCER, V4, P176, DOI 10.1016/j.trecan.2018.01.003; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; van der Meer M, 2001, LAB ANIM-UK, V35, P379, DOI 10.1258/0023677011911859; Vareslija D, 2019, JNCI-J NATL CANCER I, V111, P388, DOI 10.1093/jnci/djy110; Veraart J, 2016, NEUROIMAGE, V142, P384, DOI 10.1016/j.neuroimage.2016.08.016; Wang R, 2019, INT J CANCER, V144, P200, DOI 10.1002/ijc.31907; Wasilewski D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00298; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yang CZ, 2018, CANCER RES, V78, P1069, DOI 10.1158/0008-5472.CAN-17-2143; Yang H, 2013, LAB INVEST, V93, P344, DOI 10.1038/labinvest.2012.180; Zhao Z, 2021, GENOM PROTEOM BIOINF, V19, P1, DOI 10.1016/j.gpb.2020.10.005; Zhu L, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202114552	105	6	6	2	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					752	+		10.1038/s41591-022-01749-8	http://dx.doi.org/10.1038/s41591-022-01749-8		APR 2022	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35411077	Green Published, hybrid			2022-12-27	WOS:000780688100006
J	Ganan-Gomez, I; Colla, S				Ganan-Gomez, Irene; Colla, Simona			Overcoming myelodysplastic syndrome progression after frontline therapy	NATURE MEDICINE			English	Article								Analyses of primary myelodysplastic syndrome (MDS) samples from the largest cohort ever evaluated demonstrate that the hematopoietic stem cell populations that originate MDS have distinct differentiation phenotypes and associated signaling pathways. These differences can be targeted with selective therapies that could benefit patients with progressed disease.	[Ganan-Gomez, Irene; Colla, Simona] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ganan-Gomez, I (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.		Ganan-Gomez, Irene/GRF-3018-2022	Ganan-Gomez, Irene/0000-0001-8354-3139				Chen JH, 2019, NAT MED, V25, P103, DOI 10.1038/s41591-018-0267-4; Garcia-Manero G, 2008, CURR OPIN ONCOL, V20, P705, DOI 10.1097/CCO.0b013e328313699c; Kadia TM, 2011, SEMIN ONCOL, V38, P682, DOI 10.1053/j.seminoncol.2011.04.011; Shastri A, 2017, BLOOD, V129, P1586, DOI 10.1182/blood-2016-10-696062; Sperling AS, 2017, NAT REV CANCER, V17, P5, DOI 10.1038/nrc.2016.112	5	0	0	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					454	455		10.1038/s41591-022-01716-3	http://dx.doi.org/10.1038/s41591-022-01716-3		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35241843	hybrid			2022-12-27	WOS:000763900400003
J	Fromentin, S; Forslund, SK; Chechi, K; Aron-Wisnewsky, J; Chakaroun, R; Nielsen, T; Tremaroli, V; Ji, BY; Prifti, E; Myridakis, A; Chilloux, J; Andrikopoulos, P; Fan, Y; Olanipekun, MT; Alves, R; Adiouch, S; Bar, N; Talmor-Barkan, Y; Belda, E; Caesar, R; Coelho, LP; Falony, G; Fellahi, S; Galan, P; Galleron, N; Helft, G; Hoyles, L; Isnard, R; Le Chatelier, E; Julienne, H; Olsson, L; Pedersen, HK; Pons, N; Quinquis, B; Rouault, C; Roume, H; Salem, JE; Schmidt, TSB; Vieira-Silva, S; Li, PS; Zimmermann-Kogadeeva, M; Lewinter, C; Sondertoft, NB; Hansen, TH; Gauguier, D; Gotze, JP; Kober, L; Kornowski, R; Vestergaard, H; Hansen, T; Zucker, JD; Hercberg, S; Letunic, I; Backhed, F; Oppert, JM; Nielsen, J; Raes, J; Bork, P; Stumvoll, M; Segal, E; Clement, K; Dumas, ME; Ehrlich, SD; Pedersen, O				Fromentin, Sebastien; Forslund, Sofia K.; Chechi, Kanta; Aron-Wisnewsky, Judith; Chakaroun, Rima; Nielsen, Trine; Tremaroli, Valentina; Ji, Boyang; Prifti, Edi; Myridakis, Antonis; Chilloux, Julien; Andrikopoulos, Petros; Fan, Yong; Olanipekun, Michael T.; Alves, Renato; Adiouch, Solia; Bar, Noam; Talmor-Barkan, Yeela; Belda, Eugeni; Caesar, Robert; Coelho, Luis Pedro; Falony, Gwen; Fellahi, Soraya; Galan, Pilar; Galleron, Nathalie; Helft, Gerard; Hoyles, Lesley; Isnard, Richard; Le Chatelier, Emmanuelle; Julienne, Hanna; Olsson, Lisa; Pedersen, Helle Krogh; Pons, Nicolas; Quinquis, Benoit; Rouault, Christine; Roume, Hugo; Salem, Joe-Elie; Schmidt, Thomas S. B.; Vieira-Silva, Sara; Li, Peishun; Zimmermann-Kogadeeva, Maria; Lewinter, Christian; Sondertoft, Nadja B.; Hansen, Tue H.; Gauguier, Dominique; Gotze, Jens Peter; Kober, Lars; Kornowski, Ran; Vestergaard, Henrik; Hansen, Torben; Zucker, Jean-Daniel; Hercberg, Serge; Letunic, Ivica; Backhed, Fredrik; Oppert, Jean-Michel; Nielsen, Jens; Raes, Jeroen; Bork, Peer; Stumvoll, Michael; Segal, Eran; Clement, Karine; Dumas, Marc-Emmanuel; Ehrlich, S. Dusko; Pedersen, Oluf			Microbiome and metabolome features of the cardiometabolic disease spectrum	NATURE MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; GUT MICROBIOTA; P-CRESOL; HEART; RISK; IMPACT; SERUM; SIGNATURES; PLASMA; HEALTH	By studying individuals along a spectrum of cardiometabolic disease and adjusting for effects of lifestyle and medication, this investigation identifies alterations of the metabolome and microbiome from dysmetabolic conditions, such as obesity and type 2 diabetes, to ischemic heart disease. Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages-acute coronary syndrome, chronic IHD and IHD with heart failure-and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.	[Fromentin, Sebastien; Galan, Pilar; Galleron, Nathalie; Le Chatelier, Emmanuelle; Julienne, Hanna; Pons, Nicolas; Quinquis, Benoit; Roume, Hugo; Ehrlich, S. Dusko] Univ Paris Saclay, INRAe, MetaGenoPolis, AgroParisTech, Paris, France; [Forslund, Sofia K.; Alves, Renato; Coelho, Luis Pedro; Schmidt, Thomas S. B.; Zimmermann-Kogadeeva, Maria; Bork, Peer] European Mol Biol Lab, Struct & Computat Biol, Heidelberg, Germany; [Forslund, Sofia K.] Expt & Clin Res Ctr, Berlin, Germany; [Forslund, Sofia K.] Max Delbruck Ctr Mol Med MDC, Berlin, Germany; [Forslund, Sofia K.] Charite, Berlin, Germany; [Forslund, Sofia K.] DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany; [Chechi, Kanta; Myridakis, Antonis; Chilloux, Julien; Andrikopoulos, Petros; Olanipekun, Michael T.; Hoyles, Lesley; Dumas, Marc-Emmanuel] Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, Div Syst Med,Sect Biomol Med, London, England; [Chechi, Kanta] Imperial Coll London, Sch Publ Hlth, Fac Med, St Marys Hosp, Med Sch Bldg, London, England; [Chechi, Kanta; Andrikopoulos, Petros; Olanipekun, Michael T.; Dumas, Marc-Emmanuel] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, Genom & Environm Med, London, England; [Aron-Wisnewsky, Judith; Prifti, Edi; Adiouch, Solia; Belda, Eugeni; Rouault, Christine; Zucker, Jean-Daniel; Clement, Karine] Sorbonne Univ, INSERM, Nutr & Obes Syst Approaches Nutri, Paris, France; [Aron-Wisnewsky, Judith; Oppert, Jean-Michel; Clement, Karine] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Nutr Dept, Paris, France; [Chakaroun, Rima; Stumvoll, Michael] Univ Leipzig Med Ctr, Med Dept Endocrinol Nephrol Rheumatol 3, Leipzig, Germany; [Nielsen, Trine; Fan, Yong; Pedersen, Helle Krogh; Sondertoft, Nadja B.; Hansen, Tue H.; Vestergaard, Henrik; Hansen, Torben; Backhed, Fredrik; Pedersen, Oluf] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark; [Tremaroli, Valentina; Caesar, Robert; Olsson, Lisa; Backhed, Fredrik] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med,Wallenberg Lab, Gothenburg, Sweden; [Ji, Boyang; Li, Peishun; Nielsen, Jens] Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, Sweden; [Prifti, Edi; Zucker, Jean-Daniel] uMMISCO, Unite Modelisat Math & Informat Syst Complexes, Bondy, France; [Bar, Noam; Talmor-Barkan, Yeela; Segal, Eran] Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel; [Bar, Noam; Talmor-Barkan, Yeela; Segal, Eran] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Talmor-Barkan, Yeela; Kornowski, Ran] Rabin Med Ctr, Dept Cardiol, Petah Tiqwa, Israel; [Talmor-Barkan, Yeela] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Belda, Eugeni] Inst Cardiometab & Nutr, Integr Unit, Paris, France; [Belda, Eugeni] Integrat Phen, Paris, France; [Falony, Gwen; Vieira-Silva, Sara; Raes, Jeroen] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Mol Bacteriol, Rega Inst, Leuven, Belgium; [Falony, Gwen; Vieira-Silva, Sara; Raes, Jeroen] VIB, Ctr Microbiol, Leuven, Belgium; [Fellahi, Soraya] Hop Univ Henri Mondor, Assistance Publ Hop Paris, Dept Biochim Pharmacol Biol Mol Genet Med, Creteil, France; [Helft, Gerard; Isnard, Richard] Hop La Pitie Salpetriere, Cardiol Dept, Assistance Publ Hop Paris, Paris, France; [Hoyles, Lesley] Nottingham Trent Univ, Sch Sci & Technol, Dept Biosci, Nottingham, England; [Salem, Joe-Elie] Hop La Pitie Salpetriere, AP HP, uNICO Cardiooncol Program, CIC 1421, Paris, France; [Salem, Joe-Elie] Sorbonne Univ, INSERM, Paris, France; [Lewinter, Christian; Kober, Lars] Univ Copenhagen, Rigshosp, Dept Cardiol, Copenhagen, Denmark; [Gauguier, Dominique] Univ Paris, INSERM UMR 1124, Paris, France; [Gotze, Jens Peter] Univ Copenhagen, Dept Clin Biochem, Rigshop, Copenhagen, Denmark; [Vestergaard, Henrik] Bornholms Hosp, Dept Med, Ronne, Denmark; [Hercberg, Serge] Univ Paris 13, Sorbonne Paris Cite, Epidemiol & Stat Res Ctr CRESS, U1153 Inserm,U1125,Inra,Cnam,Nutr Epidemiol Res T, Bobigny, France; [Letunic, Ivica] Biobyte Solut GmbH, Heidelberg, Germany; [Dumas, Marc-Emmanuel] Univ Lille, Lille Univ Hosp, European Genom Inst Diabet, Inst Pasteur Lille,UMR1283 8199 INSERM,CNRS, Lille, France; [Ehrlich, S. Dusko] UCL, Dept Clin & Movement Neurosci, London, England	AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Imperial College London; Imperial College London; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Leipzig University; Novo Nordisk Foundation; University of Copenhagen; University of Gothenburg; Chalmers University of Technology; UDICE-French Research Universities; Sorbonne Universite; Cadi Ayyad University of Marrakech; Hanoi University of Science & Technology; Institut de Recherche pour le Developpement (IRD); University Cheikh Anta Diop Dakar; University of Yaounde I; Weizmann Institute of Science; Weizmann Institute of Science; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; UDICE-French Research Universities; Sorbonne Universite; KU Leuven; Flanders Institute for Biotechnology (VIB); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Nottingham Trent University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Rigshospitalet; University of Copenhagen; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Copenhagen; heSam Universite; Conservatoire National Arts & Metiers (CNAM); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; University of London; University College London	Ehrlich, SD (corresponding author), Univ Paris Saclay, INRAe, MetaGenoPolis, AgroParisTech, Paris, France.; Dumas, ME (corresponding author), Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, Div Syst Med,Sect Biomol Med, London, England.; Clement, K (corresponding author), Sorbonne Univ, INSERM, Nutr & Obes Syst Approaches Nutri, Paris, France.; Clement, K (corresponding author), Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Nutr Dept, Paris, France.; Pedersen, O (corresponding author), Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark.; Dumas, ME (corresponding author), Univ Lille, Lille Univ Hosp, European Genom Inst Diabet, Inst Pasteur Lille,UMR1283 8199 INSERM,CNRS, Lille, France.; Ehrlich, SD (corresponding author), UCL, Dept Clin & Movement Neurosci, London, England.	karine.clement@inserm.fr; m.dumas@imperial.ac.uk; s.ehrlich@ucl.ac.uk; oluf@sund.ku.dk	Hansen, Tue Haldor/S-7724-2016; Li, Peishun/AGC-8756-2022; Letunic, Ivica/A-6032-2009; Letunic, Ivica/K-1102-2019; Tremaroli, Valentina/AAE-8001-2019; Coelho, Luis Pedro/D-1260-2009; Falony, Gwen/AAN-5011-2020; Prifti, Edi/F-3967-2019; Hoyles, Lesley/N-9847-2015; Dumas, Marc-Emmanuel/C-1736-2008; Bork, Peer/F-1813-2013; Raes, Jeroen/D-7835-2018; Schmidt, Thomas/F-3022-2014	Hansen, Tue Haldor/0000-0001-5948-8993; Li, Peishun/0000-0003-4200-0474; Letunic, Ivica/0000-0003-3560-4288; Tremaroli, Valentina/0000-0002-9150-4233; Coelho, Luis Pedro/0000-0002-9280-7885; Falony, Gwen/0000-0003-2450-0782; Prifti, Edi/0000-0001-8861-1305; Hoyles, Lesley/0000-0002-6418-342X; Dumas, Marc-Emmanuel/0000-0001-9523-7024; Bork, Peer/0000-0002-2627-833X; Forslund, Sofia K/0000-0003-4285-6993; Kober, Lars/0000-0002-6635-1466; Adriouch, Solia/0000-0002-7372-4398; Hansen, Torben/0000-0001-8748-3831; Andrikopoulos, Petros/0000-0002-1555-3498; Raes, Jeroen/0000-0002-1337-041X; Ji, Boyang/0000-0002-7269-4342; Vieira-Silva, Sara/0000-0002-4616-7602; Vestergaard, Henrik/0000-0003-3090-269X; Schmidt, Thomas/0000-0001-8587-4177; Nielsen, Trine/0000-0002-2066-7895; Olanipekun, Michael/0000-0001-7844-0370; Chechi, Kanta/0000-0003-1929-4128; Fan, Yong/0000-0003-4813-7017; Julienne, Hanna/0000-0001-8214-9412; Myridakis, Antonis/0000-0003-1690-6651; Salem, Joe-Elie/0000-0002-0331-3307	European Union [HEALTH-F4-2012-305312]; Metagenopolis grant [ANR-11-DPBS-0001]; Leducq Foundation,; Novo Nordisk Foundation; NIHR Imperial Biomedical Research Centre; French National Research Agency [ANR-10-LABX-46]; French National Agency for Research [ANR-18-IBHU-0001]; European Union (FEDER); Hauts-de-France Regional Council [20001891/NP0025517, 20002845]; European Metropolis of Lille [2019_ESR_11]; ANR [ANR-16-IDEX-0004-ULNE]; European Metropolis of Lille; Medical Research Council Skills Development Fellowship [MR/S020039/1]; Wellcome Trust [204834/Z/16/Z]; Medical Research Council Intermediate Research Fellowship in Data Science (UK Med-Bio) [MR/L01632X/1]; German Centre for Cardiovascular Research; German Research Council [SFB1365, SFB1470, KFO339]; German Ministry of Education and Research; National Center for Precision Diabetic Medicine	European Union(European Commission); Metagenopolis grant; Leducq Foundation,(Leducq Foundation); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); NIHR Imperial Biomedical Research Centre; French National Research Agency(French National Research Agency (ANR)); French National Agency for Research(French National Research Agency (ANR)); European Union (FEDER)(European Commission); Hauts-de-France Regional Council; European Metropolis of Lille; ANR(French National Research Agency (ANR)); European Metropolis of Lille; Medical Research Council Skills Development Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council Intermediate Research Fellowship in Data Science (UK Med-Bio); German Centre for Cardiovascular Research; German Research Council(German Research Foundation (DFG)); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); National Center for Precision Diabetic Medicine	We are indebted to the MetaCardis study participants and patient associations (Alliance du Coeur and CNAO) for their input and interface. Similarly, we are indebted to the MetaCardis consortium (http://www.metacardis.net/) collaborators for contributions at multiple levels since the consortium start in 2012. A full list of collaborators is given in the Supplementary Information. We further thank D. Bonnefont-Rousselot (Department of Metabolic Biochemistry, Pitie-Salpetriere Hospital) for the analysis of plasma lipid profiles. We greatly appreciate the assistance of nurses, dietitians, laboratory technicians, clinical research assistants and data managers at the Novo Nordisk Foundation Center for Basic Metabolic Research; the Clinical Research Unit at Fredriksberg and Bispebjerg Hospitals, Copenhagen; the Clinical Investigation Platform at the Institute of Cardiometabolism and Nutrition for Patient Investigations and the Clinical Investigation Center from Pitie-Salpetriere Hospital, Paris; and the University of Leipzig Medical Center, Leipzig. Quanta Medical provided regulatory oversight of the clinical study and contributed to the processing and management of electronic data. Our study, Metagenomics in Cardiometabolic Diseases, with the acronym METACARDIS, was sponsored by the European Union's Seventh Framework Program for research, technological development and demonstration under grant agreement HEALTH-F4-2012-305312. Assistance Publique-Hopitaux de Paris is the promoter of the clinical investigation. Parts of the studies were also supported by Metagenopolis grant ANR-11-DPBS-0001, the Leducq Foundation, the Novo Nordisk Foundation and the NIHR Imperial Biomedical Research Centre and by grants from the French National Research Agency (ANR-10-LABX-46 (European Genomics Institute for Diabetes)), the National Center for Precision Diabetic Medicine, which is jointly supported by the French National Agency for Research (ANR-18-IBHU-0001), the European Union (FEDER), the Hauts-de-France Regional Council (Agreement 20001891/NP0025517), the European Metropolis of Lille (agreement 2019_ESR_11) and site ULNE (R-002-20-TALENT-DUMAS), which is also jointly funded by ANR (ANR-16-IDEX-0004-ULNE), the Hauts-de-France Regional Council (20002845) and the European Metropolis of Lille. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research institution at the University of Copenhagen, partially funded by an unrestricted donation from the Novo Nordisk Foundation. K. Chechi is supported by the Medical Research Council Skills Development Fellowship (grant no. MR/S020039/1) and the Wellcome Trust-funded Institutional Strategic Support Fellowship (grant no. 204834/Z/16/Z). L.H. was in receipt of a Medical Research Council Intermediate Research Fellowship in Data Science (grant no. MR/L01632X/1, UK Med-Bio). S.K.F. was supported by the German Centre for Cardiovascular Research, the German Research Council (projects SFB1365, SFB1470 and KFO339) and the German Ministry of Education and Research.	Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002; Andriamihaja M, 2015, FREE RADICAL BIO MED, V85, P219, DOI 10.1016/j.freeradbiomed.2015.04.004; Aron-Wisnewsky J, 2019, GUT, V68, P70, DOI 10.1136/gutjnl-2018-316103; Cotillard A, 2013, NATURE, V500, P585, DOI 10.1038/nature12480; Criscuolo A, 2013, GENOMICS, V102, P500, DOI 10.1016/j.ygeno.2013.07.011; Cui X, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18756-2; Darzi Y, 2016, ISME J, V10, P1025, DOI 10.1038/ismej.2015.188; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Dona AC, 2016, COMPUT STRUCT BIOTEC, V14, P135, DOI 10.1016/j.csbj.2016.02.005; Dona AC, 2014, ANAL CHEM, V86, P9887, DOI 10.1021/ac5025039; Einarson TR, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0728-6; Emoto T, 2017, HEART VESSELS, V32, P39, DOI 10.1007/s00380-016-0841-y; Falony G, 2015, ANNU REV MICROBIOL, V69, P305, DOI 10.1146/annurev-micro-091014-104422; Feng Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep22525; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Forslund SK, 2021, NATURE, V600, P500, DOI 10.1038/s41586-021-04177-9; Gu SX, 2015, BLOOD, V125, P3851, DOI 10.1182/blood-2015-01-544676; Heymsfield SB, 2017, NEW ENGL J MED, V376, P254, DOI 10.1056/NEJMra1514009; Hunter I, 2011, J IMMUNOL METHODS, V370, P104, DOI 10.1016/j.jim.2011.06.005; Jang MK, 2004, BIOCHEM BIOPH RES CO, V323, P898, DOI 10.1016/j.bbrc.2004.08.178; Jeurnink SM, 2012, INT J CANCER, V131, pE963, DOI 10.1002/ijc.27517; Jie ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00900-1; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198; Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266; Kelly TN, 2016, CIRC RES, V119, P956, DOI 10.1161/CIRCRESAHA.116.309219; Koren O, 2011, P NATL ACAD SCI USA, V108, P4592, DOI 10.1073/pnas.1011383107; Kroger J, 2014, DIABETOLOGIA, V57, P321, DOI 10.1007/s00125-013-3092-9; Kurilshikov A, 2019, CIRC RES, V124, P1808, DOI 10.1161/CIRCRESAHA.118.314642; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lanter BB, 2014, MBIO, V5, DOI 10.1128/mBio.01206-14; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Lee YC, 2011, CIRCULATION, V124, P1160, DOI 10.1161/CIRCULATIONAHA.111.027375; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Li J, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0222-x; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Liu HH, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0683-9; Long T, 2017, NAT GENET, V49, P568, DOI 10.1038/ng.3809; Lopaschuk GD, 2010, PHYSIOL REV, V90, P207, DOI 10.1152/physrev.00015.2009; Maier L, 2018, NATURE, V555, P623, DOI 10.1038/nature25979; Matey-Hernandez ML, 2018, PHYSIOL GENOMICS, V50, P117, DOI 10.1152/physiolgenomics.00053.2017; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nemet I, 2020, CELL, V180, P862, DOI 10.1016/j.cell.2020.02.016; Ott SJ, 2006, CIRCULATION, V113, P929, DOI 10.1161/CIRCULATIONAHA.105.579979; Pallister T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13722-4; Pasini E, 2016, JACC-HEART FAIL, V4, P220, DOI 10.1016/j.jchf.2015.10.009; Patel KP, 2012, CLIN J AM SOC NEPHRO, V7, P982, DOI 10.2215/CJN.12491211; Pedersen HK, 2016, NATURE, V535, P376, DOI 10.1038/nature18646; Poesen R, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-87; Pons N., 2010, JOURNEES OUVERTES BI; Prest EI, 2013, WATER RES, V47, P7131, DOI 10.1016/j.watres.2013.07.051; Razavi AC, 2020, J MOL CELL CARDIOL, V140, P22, DOI 10.1016/j.yjmcc.2020.02.005; Rodriguez-Martinez A, 2017, ANAL CHEM, V89, P11405, DOI 10.1021/acs.analchem.7b02374; Rothschild D, 2018, NATURE, V555, P210, DOI 10.1038/nature25973; Sacks Frank M., 1995, Annals of Epidemiology, V5, P108, DOI 10.1016/1047-2797(94)00055-X; Sanchez-Alcoholado L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01936; Smith E, 2020, HEART, V106, P691, DOI 10.1136/heartjnl-2019-315485; Talmor-Barkan Y, 2022, NAT MED, V28, P295, DOI 10.1038/s41591-022-01686-6; Tang WHW, 2019, J AM COLL CARDIOL, V73, P2089, DOI 10.1016/j.jacc.2019.03.024; Valles-Colomer M, 2019, NAT MICROBIOL, V4, P623, DOI 10.1038/s41564-018-0337-x; Vandeputte D, 2017, NATURE, V551, P507, DOI 10.1038/nature24460; Velusamy R, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5030121; Vieira-Silva S, 2020, NATURE, V581, P310, DOI 10.1038/s41586-020-2269-x; Vieira-Silva S, 2019, NAT MICROBIOL, V4, P1826, DOI 10.1038/s41564-019-0483-9; Vieira-Silva S, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.88, 10.1038/NMICROBIOL.2016.88]; Vujkovic-Cvijin I, 2020, NATURE, V587, P448, DOI 10.1038/s41586-020-2881-9; Wan Y, 2019, GUT, V68, P1417, DOI 10.1136/gutjnl-2018-317609; Yin J, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002699; Zheng YY, 2020, J AGR FOOD CHEM, V68, P3548, DOI 10.1021/acs.jafc.0c00225; Zhu Q, 2018, PHYSIOL GENOMICS, V50, P893, DOI 10.1152/physiolgenomics.00070.2018; Ziegler M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100935	72	17	17	32	64	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					303	+		10.1038/s41591-022-01688-4	http://dx.doi.org/10.1038/s41591-022-01688-4		FEB 2022	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35177860	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000757243200006
J	Biffi, A				Biffi, Alessandra			Gene therapy goes the distance in Wiskott-Aldrich syndrome	NATURE MEDICINE			English	Editorial Material							EFFICACY	Long-term follow-up data reinforce the curative potential of hematopoietic stem-cell gene therapy for this rare primary immunodeficiency disorder.	[Biffi, Alessandra] Padua Univ Hosp, Pediat Hematol Oncol & Stem Cell Transplant Div, Padua, Italy; [Biffi, Alessandra] Dana Farber Boston Childrens Canc & Blood Disorde, Gene Therapy Program, Boston, MA 02115 USA	University of Padua; Azienda Ospedaliera - Universita di Padova; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute	Biffi, A (corresponding author), Padua Univ Hosp, Pediat Hematol Oncol & Stem Cell Transplant Div, Padua, Italy.; Biffi, A (corresponding author), Dana Farber Boston Childrens Canc & Blood Disorde, Gene Therapy Program, Boston, MA 02115 USA.	alessandra.biffi@unipd.it						Albert MH, 2011, CURR OPIN HEMATOL, V18, P42, DOI 10.1097/MOH.0b013e32834114bc; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Burroughs LM, 2020, BLOOD, V135, P2094, DOI 10.1182/blood.2019002939; Dupre L, 2006, HUM GENE THER, V17, P303, DOI 10.1089/hum.2006.17.303; Ferrua F, 2020, J ALLERGY CLIN IMMUN, V146, P262, DOI 10.1016/j.jaci.2020.06.018; Kohn LA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648951; Magnani A, 2022, NAT MED, V28, P71, DOI 10.1038/s41591-021-01641-x; Marangoni F, 2009, MOL THER, V17, P1073, DOI 10.1038/mt.2009.31; Notarangelo LD, 2008, CURR OPIN HEMATOL, V15, P30, DOI 10.1097/MOH.0b013e3282f30448; Pai SY, 2010, IMMUNOL ALLERGY CLIN, V30, P179, DOI 10.1016/j.iac.2010.02.001	11	0	0	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					24	25		10.1038/s41591-021-01653-7	http://dx.doi.org/10.1038/s41591-021-01653-7		JAN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35075290				2022-12-27	WOS:000746475000006
J	Mansilla-Soto, J; Eyquem, J; Haubner, S; Hamieh, M; Feucht, J; Paillon, N; Zucchetti, AE; Li, ZN; Sjostrand, M; Lindenbergh, PL; Saetersmoen, M; Dobrin, A; Maurin, M; Iyer, A; Angus, AG; Miele, MM; Zhao, ZG; Giavridis, T; van der Stegen, SJC; Tamzalit, F; Riviere, I; Huse, M; Hendrickson, RC; Hivroz, C; Sadelain, M				Mansilla-Soto, Jorge; Eyquem, Justin; Haubner, Sascha; Hamieh, Mohamad; Feucht, Judith; Paillon, Noemie; Zucchetti, Andres Ernesto; Li, Zhuoning; Sjostrand, Maria; Lindenbergh, Pieter L.; Saetersmoen, Michelle; Dobrin, Anton; Maurin, Mathieu; Iyer, Archana; Angus, Andreina Garcia; Miele, Matthew M.; Zhao, Zeguo; Giavridis, Theodoros; van der Stegen, Sjoukje J. C.; Tamzalit, Fella; Riviere, Isabelle; Huse, Morgan; Hendrickson, Ronald C.; Hivroz, Claire; Sadelain, Michel			HLA-independent T cell receptors for targeting tumors with low antigen density	NATURE MEDICINE			English	Article							B-CELL; CAR; EXPRESSION; THERAPY; COMPLEX; PROTEIN; DESIGN; NAIVE; CD80	HLA-independent T cell receptors, in which the heavy and light chains of a chimeric antigen receptor are incorporated into the endogenous T cell receptor locus, are more effective than CD28-based chimeric antigen receptors at targeting tumors with low antigen expression. Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor-CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR. We demonstrate that these HLA-independent T cell receptors (HIT receptors) consistently afford high antigen sensitivity and mediate tumor recognition beyond what CD28-based CARs, the most sensitive design to date, can provide. We demonstrate that the functional persistence of HIT T cells can be augmented by constitutive coexpression of CD80 and 4-1BBL. Finally, we validate the increased antigen sensitivity afforded by HIT receptors in xenograft mouse models of B cell leukemia and acute myeloid leukemia, targeting CD19 and CD70, respectively. Overall, HIT receptors are well suited for targeting cell surface antigens of low abundance.	[Mansilla-Soto, Jorge; Eyquem, Justin; Haubner, Sascha; Hamieh, Mohamad; Feucht, Judith; Sjostrand, Maria; Lindenbergh, Pieter L.; Saetersmoen, Michelle; Dobrin, Anton; Iyer, Archana; Angus, Andreina Garcia; Zhao, Zeguo; Giavridis, Theodoros; van der Stegen, Sjoukje J. C.; Riviere, Isabelle; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA; [Mansilla-Soto, Jorge; Eyquem, Justin; Haubner, Sascha; Hamieh, Mohamad; Feucht, Judith; Sjostrand, Maria; Lindenbergh, Pieter L.; Saetersmoen, Michelle; Dobrin, Anton; Iyer, Archana; Angus, Andreina Garcia; Zhao, Zeguo; Giavridis, Theodoros; van der Stegen, Sjoukje J. C.; Tamzalit, Fella; Huse, Morgan; Sadelain, Michel] Sloan Kettering Inst, Immunol Program, New York, NY 10065 USA; [Paillon, Noemie; Zucchetti, Andres Ernesto; Maurin, Mathieu; Hivroz, Claire] Univ PSL, Inst Curie, Integrat Anal T Cell Activat Team, INSERM,U932, Paris, France; [Li, Zhuoning; Miele, Matthew M.; Hendrickson, Ronald C.] Sloan Kettering Inst, Microchem & Prote Core Lab, New York, NY USA; [Riviere, Isabelle] Mem Sloan Kettering Canc Ctr, Cell Therapy & Cell Engn Facil, 1275 York Ave, New York, NY 10021 USA; [Riviere, Isabelle; Hendrickson, Ronald C.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, 1275 York Ave, New York, NY 10021 USA; [Eyquem, Justin] Univ Calif San Francisco, Dept Med, Div Hematooncol, San Francisco, CA 94143 USA; [Feucht, Judith] Univ Childrens Hosp Tubingen, Cluster Excellence iFIT, Tubingen, Germany; [Saetersmoen, Michelle] Oslo Univ Hosp, Inst Canc Res, Dept Canc Immunol, Oslo, Norway; [Giavridis, Theodoros] Mnemo Therapeut, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Oslo	Mansilla-Soto, J; Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA.; Mansilla-Soto, J; Sadelain, M (corresponding author), Sloan Kettering Inst, Immunol Program, New York, NY 10065 USA.	mansillj@mskcc.org; m-sadelain@ski.mskcc.org	Haubner, Sascha/GNP-5476-2022; Sjostrand, Maria/AGG-8610-2022	Miele, Matthew/0000-0001-7495-2133; Eyquem, Justin/0000-0001-8262-1190; Paillon, Noemie/0000-0002-6848-3016; Haubner, Sascha/0000-0002-5348-1456; Lindenbergh, Pieter Leonard/0000-0001-8345-2405	Lake Road Foundation; Lymphoma and Leukemia Society; Leopold Griffuel award; NCI Cancer Center Support Grant [P30 CA008748]; Cycle for Survival; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; NCI [P30 CA08748]; Canadian Institutes of Health Research; Fogarty Foundation; Alexander S. Onassis Public Benefit Foundation; Tow Foundation; Pasteur-Weizmann/Servier award	Lake Road Foundation; Lymphoma and Leukemia Society(Leukemia and Lymphoma Society); Leopold Griffuel award; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cycle for Survival; Marie-Josee and Henry R. Kravis Center for Molecular Oncology; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fogarty Foundation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Alexander S. Onassis Public Benefit Foundation; Tow Foundation; Pasteur-Weizmann/Servier award	We thank Gertrude Gunset for logistical and technical assistance. We also thank the SKI Cell Therapy and Cell Engineering (CTCEF), Molecular Cytology, Flow Cytometry, Integrated Genomics Operation, Microchemistry and Proteomics, Antitumor Assessment and Animal Core Facilities for their expert assistance. This work was supported by the Lake Road Foundation, the Lymphoma and Leukemia Society, the Pasteur-Weizmann/Servier award, the Leopold Griffuel award and the NCI Cancer Center Support Grant no. P30 CA008748. SKI cores were in part supported by the Tow Foundation, Cycle for Survival, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology and NCI grant P30 CA08748. A.D., M.S. and T.G. were supported by fellowships from the Canadian Institutes of Health Research, the Fogarty Foundation and the Alexander S. Onassis Public Benefit Foundation, respectively.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Baeuerle PA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10097-0; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Brudno JN, 2018, NAT REV CLIN ONCOL, V15, P31, DOI 10.1038/nrclinonc.2017.128; Brugnoni D, 1997, IMMUNOL LETT, V55, P99, DOI 10.1016/S0165-2478(96)02693-4; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Dong R, 2020, EMBO J, V39, DOI 10.15252/embj.2020104730; Eshhar Z, 1996, SPRINGER SEMIN IMMUN, V18, P199, DOI 10.1007/BF00820666; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Feucht J, 2019, NAT MED, V25, P82, DOI 10.1038/s41591-018-0290-5; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Hamieh M, 2019, NATURE, V568, P112, DOI 10.1038/s41586-019-1054-1; Helsen CW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05395-y; Hendel A, 2015, NAT BIOTECHNOL, V33, P985, DOI 10.1038/nbt.3290; Henrickson SE, 2008, NAT IMMUNOL, V9, P282, DOI 10.1038/ni1559; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kimachi K, 1997, EUR J IMMUNOL, V27, P3310, DOI 10.1002/eji.1830271230; KUWANA Y, 1987, BIOCHEM BIOPH RES CO, V149, P960, DOI 10.1016/0006-291X(87)90502-X; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Libert D, 2020, LEUKEMIA, V34, P3064, DOI 10.1038/s41375-020-0760-x; Liu XJ, 2016, CANCER RES, V76, P1578, DOI 10.1158/0008-5472.CAN-15-2524; MacKay M, 2020, NAT BIOTECHNOL, V38, P233, DOI 10.1038/s41587-019-0329-2; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Majzner RG, 2020, CANCER DISCOV, V10, P702, DOI 10.1158/2159-8290.CD-19-0945; Majzner RG, 2018, CANCER DISCOV, V8, P1219, DOI 10.1158/2159-8290.CD-18-0442; Matza D, 2008, IMMUNITY, V28, P64, DOI 10.1016/j.immuni.2007.11.020; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Navarrete-Perea J, 2018, J PROTEOME RES, V17, P2226, DOI 10.1021/acs.jproteome.8b00217; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Oda SK, 2017, BLOOD, V130, P2410, DOI 10.1182/blood-2017-04-777052; Papapetrou EP, 2011, NAT BIOTECHNOL, V29, P73, DOI 10.1038/nbt.1717; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Perna F, 2017, CANCER CELL, V32, P506, DOI 10.1016/j.ccell.2017.09.004; Nguyen P, 2020, MOL THER-ONCOLYTICS, V18, P202, DOI 10.1016/j.omto.2020.06.018; Priceman SJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1380764; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Randzavola LO, 2019, J CLIN INVEST, V129, P5600, DOI 10.1172/JCI129388; Riether C, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0910-8; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Schwartzberg PL, 2009, NAT REV IMMUNOL, V9, P39, DOI 10.1038/nri2456; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; SHER BT, 1985, P NATL ACAD SCI USA, V82, P1175, DOI 10.1073/pnas.82.4.1175; Stephan MT, 2007, NAT MED, V13, P1440, DOI 10.1038/nm1676; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; van der Stegen SJC, 2015, NAT REV DRUG DISCOV, V14, P499, DOI 10.1038/nrd4597; Xu XJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02664; Xu YY, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0066-6; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004; Zucchetti AE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10891-w	58	10	10	4	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					345	+		10.1038/s41591-021-01621-1	http://dx.doi.org/10.1038/s41591-021-01621-1		JAN 2022	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35027758				2022-12-27	WOS:000742323900001
J	Alavi, A; Bogu, GK; Wang, M; Rangan, ES; Brooks, AW; Wang, QW; Higgs, E; Celli, A; Mishra, T; Metwally, AA; Cha, KX; Knowles, P; Alavi, AA; Bhasin, R; Panchamukhi, S; Celis, D; Aditya, T; Honkala, A; Rolnik, B; Hunting, E; Dagan-Rosenfeld, O; Chauhanl, A; Li, JW; Bejikian, C; Krishnan, V; McGuire, L; Li, X; Bahmani, A; Snyder, MP				Alavi, Arash; Bogu, Gireesh K.; Wang, Meng; Rangan, Ekanath Srihari; Brooks, Andrew W.; Wang, Qiwen; Higgs, Emily; Celli, Alessandra; Mishra, Tejaswini; Metwally, Ahmed A.; Cha, Kexin; Knowles, Peter; Alavi, Amir A.; Bhasin, Rajat; Panchamukhi, Shrinivas; Celis, Diego; Aditya, Tagore; Honkala, Alexander; Rolnik, Benjamin; Hunting, Erika; Dagan-Rosenfeld, Orit; Chauhanl, Arshdeep; Li, Jessi W.; Bejikian, Caroline; Krishnan, Vandhana; McGuire, Lettie; Li, Xiao; Bahmani, Amir; Snyder, Michael P.			Real-time alerting system for COVID-19 and other stress events using wearable data	NATURE MEDICINE			English	Article								Early detection of infectious diseases is crucial for reducing transmission and facilitating early intervention. In this study, we built a real-time smartwatch-based alerting system that detects aberrant physiological and activity signals (heart rates and steps) associated with the onset of early infection and implemented this system in a prospective study. In a cohort of 3,318 participants, of whom 84 were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this system generated alerts for pre-symptomatic and asymptomatic SARS-CoV-2 infection in 67 (80%) of the infected individuals. Pre-symptomatic signals were observed at a median of 3 days before symptom onset. Examination of detailed survey responses provided by the participants revealed that other respiratory infections as well as events not associated with infection, such as stress, alcohol consumption and travel, could also trigger alerts, albeit at a much lower mean frequency (1.15 alert days per person compared to 3.42 alert days per person for coronavirus disease 2019 cases). Thus, analysis of smartwatch signals by an online detection algorithm provides advance warning of SARS-CoV-2 infection in a high percentage of cases. This study shows that a real-time alerting system can be used for early detection of infection and other stressors and employed on an open-source platform that is scalable to millions of users. In a prospective study, a smartwatch-based alerting system was able to detect pre-symptomatic and asymptomatic SARS-CoV-2 infection in a high percentage of cases.	[Alavi, Arash; Bogu, Gireesh K.; Wang, Meng; Rangan, Ekanath Srihari; Brooks, Andrew W.; Higgs, Emily; Celli, Alessandra; Mishra, Tejaswini; Metwally, Ahmed A.; Cha, Kexin; Knowles, Peter; Alavi, Amir A.; Bhasin, Rajat; Panchamukhi, Shrinivas; Celis, Diego; Aditya, Tagore; Honkala, Alexander; Rolnik, Benjamin; Hunting, Erika; Dagan-Rosenfeld, Orit; Chauhanl, Arshdeep; Li, Jessi W.; Bejikian, Caroline; Krishnan, Vandhana; McGuire, Lettie; Bahmani, Amir; Snyder, Michael P.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Wang, Qiwen; Celis, Diego] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Li, Xiao] Case Western Univ, Dept Biochem, Cleveland, OH USA; [Li, Xiao] Case Western Univ, Ctr RNA Sci & Therapeut, Cleveland, OH USA; [Li, Xiao] Case Western Univ, Dept Comp & Data Sci, Cleveland, OH USA	Stanford University; Stanford University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Bahmani, A; Snyder, MP (corresponding author), Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.	abahman@stanford.edu; mpsnyder@stanford.edu	Mishra, Tejaswini/D-3528-2018	Mishra, Tejaswini/0000-0001-9931-1260; Rangan, Ekanath/0000-0001-5168-3508; Chauhan, Arshdeep/0000-0001-6310-5123; Bahmani, Amir/0000-0003-4533-9334; Alavi, Arash/0000-0002-7245-6889; Tagore, Aditya/0000-0001-5631-842X; McGuire, Lettie Margaret/0000-0003-0899-3521; Snyder, Michael/0000-0003-0784-7987; Brooks, Andrew/0000-0002-9237-5349	NIH [1R01NR02010501, 1S10OD023452-01]; Stanford Genetics department; Amazon Web Services Diagnostic Development Initiative; Google; Stanford School of Medicine Research Office; National Center for Research Resources, National Institutes of Health [UL1 TR001085]; National Center for Advancing Translational Sciences, National Institutes of Health [UL1 TR001085]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford Genetics department; Amazon Web Services Diagnostic Development Initiative; Google(Google Incorporated); Stanford School of Medicine Research Office; National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by NIH grants (1R01NR02010501 and 1S10OD023452-01) and gifts from the Flu Laboratory as well as departmental funding from the Stanford Genetics department. This study was supported by the Amazon Web Services Diagnostic Development Initiative. The Google Cloud Platform costs were covered by Google for Education academic research and COVID-19 grant awards. This research also received support through the generosity of Eric and Wendy Schmidt by recommendation of the Schmidt Futures program. We acknowledge the Stanford Genetics Bioinformatics Service Center for providing the gateway to the SCG cluster, Google Cloud Platform and Amazon Web Services for this research. The Stanford REDCap platform (http://redcap.stanford.edu) was developed and operated by the Stanford Medicine Research IT team. The REDCap platform services at Stanford are subsidized by (1) the Stanford School of Medicine Research Office and (2) the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1 TR001085.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chang D, 2020, AM J RESP CRIT CARE, V201, P1150, DOI 10.1164/rccm.202003-0524LE; Dunn J, 2021, NAT MED, V27, P1105, DOI 10.1038/s41591-021-01339-0; Grant MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234765; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Huang CZ, 2020, LIMIT ANALYSIS THEORY OF THE SOIL MASS AND ITS APPLICATION, P1, DOI 10.1007/978-981-15-1572-9_1; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Li X, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2001402; Liu FT, 2008, IEEE DATA MINING, P413, DOI 10.1109/ICDM.2008.17; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Mishra T, 2020, NAT BIOMED ENG, V4, P1208, DOI 10.1038/s41551-020-00640-6; Moore Edward F., 1956, AUTOMATA STUDIES, V34, P129, DOI DOI 10.1515/9781400882618-006; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollock AM, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4851; Quer G, 2021, NAT MED, V27, P73, DOI 10.1038/s41591-020-1123-x; Quer G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227709; Seshadri Dhruv R, 2020, Front Digit Health, V2, P8, DOI 10.3389/fdgth.2020.00008; Snyder M. P., 2021, DEEP LEARNING BASED, DOI [10.1101/2021.01.08.21249474v1, DOI 10.1101/2021.01.08.21249474V1]; Watson J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1808; World Health Organization, 2020, TECHNICAL REPORT	21	10	10	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					175	+		10.1038/s41591-021-01593-2	http://dx.doi.org/10.1038/s41591-021-01593-2		NOV 2021	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34845389	hybrid, Green Published			2022-12-27	WOS:000723511300002
J	Perez-Garcia, JM; Cortes, J; Llombart-Cussac, A				Perez-Garcia, Jose Manuel; Cortes, Javier; Llombart-Cussac, Antonio			CDK4/6 inhibitors in breast cancer: spotting the difference	NATURE MEDICINE			English	Editorial Material								A phase 3 study with dalpiciclib reinforces the efficacy of CDK4/6 inhibitors in select patients with metastatic breast cancer; with several such inhibitors available, more evidence is needed to help guide treatment decisions.	[Perez-Garcia, Jose Manuel; Cortes, Javier] Quironsalud Grp, Int Breast Canc Ctr IBCC, Oncol Dept, Barcelona, Spain; [Perez-Garcia, Jose Manuel; Cortes, Javier; Llombart-Cussac, Antonio] Med Scientia Innovat Res MedSIR, Barcelona, Spain; [Perez-Garcia, Jose Manuel; Cortes, Javier; Llombart-Cussac, Antonio] Med Scientia Innovat Res MedSIR, Ridgewood, NJ USA; [Cortes, Javier] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain; [Cortes, Javier] Vall dHebron Inst Oncol VHIO, Breast Canc Res program, Barcelona, Spain; [Llombart-Cussac, Antonio] Arnau Vilanova Univ Hosp, Oncol Dept, Valencia, Spain	quironsalud Group; European University of Madrid; Vall d'Hebron Institut d'Oncologia (VHIO)	Cortes, J (corresponding author), Quironsalud Grp, Int Breast Canc Ctr IBCC, Oncol Dept, Barcelona, Spain.; Cortes, J (corresponding author), Med Scientia Innovat Res MedSIR, Barcelona, Spain.; Cortes, J (corresponding author), Med Scientia Innovat Res MedSIR, Ridgewood, NJ USA.; Cortes, J (corresponding author), Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain.; Cortes, J (corresponding author), Vall dHebron Inst Oncol VHIO, Breast Canc Res program, Barcelona, Spain.	jacortes@vhio.net		Cortes, Javier/0000-0001-7623-1583				Cortes J, 2020, CA-CANCER J CLIN, V70, P105, DOI 10.3322/caac.21597; Llombart-Cussac, 2019, ANN ONCOL, V30, pV141, DOI [10.1093/annonc/mdz242.082, DOI 10.1093/ANNONC/MDZ242.082]; Long F, 2019, CANCER SCI, V110, P1420, DOI 10.1111/cas.13957; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Ogata R, 2021, BREAST CANCER-TOKYO, V28, P206, DOI 10.1007/s12282-020-01150-8; Prat A, 2021, J CLIN ONCOL, V39, P1458, DOI 10.1200/JCO.20.02977; Slamon DJ, 2020, NEW ENGL J MED, V382, P514, DOI 10.1056/NEJMoa1911149; Sledge GW, 2020, JAMA ONCOL, V6, P116, DOI 10.1001/jamaoncol.2019.4782; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527; Xu BH, 2021, NAT MED, V27, P1904, DOI 10.1038/s41591-021-01562-9; Zheng JN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233571	12	0	0	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1868	1869		10.1038/s41591-021-01570-9	http://dx.doi.org/10.1038/s41591-021-01570-9		NOV 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34750558				2022-12-27	WOS:000715714300002
J	Blazkova, J; Gao, F; Marichannegowda, MH; Justement, JS; Shi, V; Whitehead, EJ; Schneck, RF; Huiting, ED; Gittens, K; Cottrell, M; Benko, E; Kovacs, C; Lack, J; Sneller, MC; Moir, S; Fauci, AS; Chun, TW				Blazkova, Jana; Gao, Feng; Marichannegowda, Manukumar Honnayakanahalli; Justement, J. Shawn; Shi, Victoria; Whitehead, Emily J.; Schneck, Rachel F.; Huiting, Erin D.; Gittens, Kathleen; Cottrell, Mackenzie; Benko, Erika; Kovacs, Colin; Lack, Justin; Sneller, Michael C.; Moir, Susan; Fauci, Anthony S.; Chun, Tae-Wook			Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy	NATURE MEDICINE			English	Article							RESPONSES	CD8 T cell activity or neutralizing antibodies might control HIV-1 viral rebound after cessation of anti-retroviral therapy. Certain infected individuals suppress human immunodeficiency virus (HIV) in the absence of anti-retroviral therapy (ART). Elucidating the underlying mechanism(s) is of high interest. Here we present two contrasting case reports of HIV-infected individuals who controlled plasma viremia for extended periods after undergoing analytical treatment interruption (ATI). In Participant 04, who experienced viral blips and initiated undisclosed self-administration of suboptimal ART detected shortly before day 1,250, phylogenetic analyses of plasma HIV env sequences suggested continuous viral evolution and/or reactivation of pre-existing viral reservoirs over time. Antiviral CD8(+) T cell activities were higher in Participant 04 than in Participant 30. In contrast, Participant 30 exhibited potent plasma-IgG-mediated neutralization activity against autologous virus that became ineffective when he experienced sudden plasma viral rebound 1,434 d after ATI due to HIV superinfection. Our data provide insight into distinct mechanisms of post-treatment interruption control and highlight the importance of frequent monitoring of undisclosed use of ART and superinfection during the ATI phase.	[Blazkova, Jana; Justement, J. Shawn; Shi, Victoria; Whitehead, Emily J.; Schneck, Rachel F.; Huiting, Erin D.; Sneller, Michael C.; Moir, Susan; Fauci, Anthony S.; Chun, Tae-Wook] NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gao, Feng; Marichannegowda, Manukumar Honnayakanahalli] Duke Univ, Dept Med, Durham, NC USA; [Gittens, Kathleen] NIH, Crit Care Med Dept, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Cottrell, Mackenzie] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA; [Benko, Erika; Kovacs, Colin] Toronto, Maple Leaf Med Clin, Toronto, ON, Canada; [Lack, Justin] NIAID, NIAID Collaborat Bioinformat Resource, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lack, Justin] Frederick Natl Lab Canc Res, Adv Biomed Computat Sci, Frederick, MD USA; [Gao, Feng] Jinan Univ, Sch Med, Guangzhou, Peoples R China; [Marichannegowda, Manukumar Honnayakanahalli] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Duke University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jinan University; University System of Maryland; University of Maryland Baltimore	Chun, TW (corresponding author), NIAID, Lab Immunoregulat, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	twchun@nih.gov	; H.M, Manukumar/H-4266-2018	Blazkova, Jana/0000-0002-6000-202X; Huiting, Erin/0000-0002-5454-2679; H.M, Manukumar/0000-0002-6488-7136	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to the study volunteers for their participation in this study. We thank the National Institute of Allergy and Infectious Diseases HIV Outpatient Clinic staff for their assistance in the execution of this study. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Barouch DH, 2014, SCIENCE, V345, P169, DOI 10.1126/science.1255512; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Chun TW, 2015, NAT IMMUNOL, V16, P584, DOI 10.1038/ni.3152; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Etemad B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01749; Fogel JM, 2013, J INFECT DIS, V208, P1624, DOI 10.1093/infdis/jit390; Gondim MVP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd8179; Imaz A, 2019, CLIN INFECT DIS, V69, P1403, DOI 10.1093/cid/ciy1074; Jiang CY, 2020, NATURE, V585, P261, DOI 10.1038/s41586-020-2651-8; Lee SA, 2020, JAIDS-J ACQ IMM DEF, V83, P530, DOI 10.1097/QAI.0000000000002287; Lewin SR, 2020, LANCET, V395, P844, DOI 10.1016/S0140-6736(20)30264-6; Margolis DM, 2020, CELL, V181, P189, DOI 10.1016/j.cell.2020.03.005; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; Namazi G, 2018, J INFECT DIS, V218, P1954, DOI 10.1093/infdis/jiy479; Qu K, 2015, CELL SYST, V1, P51, DOI 10.1016/j.cels.2015.06.003; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Redd AD, 2013, LANCET INFECT DIS, V13, P622, DOI 10.1016/S1473-3099(13)70066-5; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Smith DM, 2005, J INFECT DIS, V192, P438, DOI 10.1086/431682; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; Song HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04217-5; Sykes W, 2019, J INFECT DIS, V220, P643, DOI 10.1093/infdis/jiz145; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Weber MD, 2018, ANTIVIR THER, V23, P495, DOI 10.3851/IMP3236	29	5	5	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1893	+		10.1038/s41591-021-01503-6	http://dx.doi.org/10.1038/s41591-021-01503-6		OCT 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34711975				2022-12-27	WOS:000712353600001
J	Friedrich, M; Pohin, M; Jackson, MA; Korsunsky, I; Bullers, SJ; Rue-Albrecht, K; Christoforidou, Z; Sathananthan, D; Thomas, T; Ravindran, R; Tandon, R; Peres, RS; Sharpe, H; Wei, KV; Watts, GFM; Mann, EH; Geremia, A; Attar, M; Barone, F; Barone, F; Brenner, M; Buckley, CD; Coles, M; Frei, AP; Lassen, KG; Powrie, FM; McCuaig, S; Thomas, L; Collantes, E; Uhlig, HH; Sansom, SN; Easton, A; Raychaudhuri, S; Travis, SP; Powrie, FM				Friedrich, Matthias; Pohin, Mathilde; Jackson, Matthew A.; Korsunsky, Ilya; Bullers, Samuel J.; Rue-Albrecht, Kevin; Christoforidou, Zoe; Sathananthan, Dharshan; Thomas, Tom; Ravindran, Rahul; Tandon, Ruchi; Peres, Raphael Sanches; Sharpe, Hannah; Wei, Kevin; Watts, Gerald F. M.; Mann, Elizabeth H.; Geremia, Alessandra; Attar, Moustafa; Barone, Francesca; Barone, Francesca; Brenner, Michael; Buckley, Christopher D.; Coles, Mark; Frei, Andreas P.; Lassen, Kara G.; Powrie, Fiona M.; McCuaig, Sarah; Thomas, Lloyd; Collantes, Elena; Uhlig, Holm H.; Sansom, Stephen N.; Easton, Alistair; Raychaudhuri, Soumya; Travis, Simon P.; Powrie, Fiona M.			IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies	NATURE MEDICINE			English	Article							INTESTINAL INFLAMMATION; ONSET COLITIS; TRANSCRIPTOME; IL-1-ALPHA; IL-1-BETA; COLON; IBD	Transcriptomic and histological profiling of gut biopsies from multiple independent cohorts of patients with inflammatory bowel disease identifies distinct histopathological, molecular and cellular features associated with treatment response, providing insights for patient stratification and precision therapy. Current inflammatory bowel disease (IBD) therapies are ineffective in a high proportion of patients. Combining bulk and single-cell transcriptomics, quantitative histopathology and in situ localization across three cohorts of patients with IBD (total n = 376), we identify coexpressed gene modules within the heterogeneous tissular inflammatory response in IBD that map to distinct histopathological and cellular features (pathotypes). One of these pathotypes is defined by high neutrophil infiltration, activation of fibroblasts and vascular remodeling at sites of deep ulceration. Activated fibroblasts in the ulcer bed display neutrophil-chemoattractant properties that are IL-1R, but not TNF, dependent. Pathotype-associated neutrophil and fibroblast signatures are increased in nonresponders to several therapies across four independent cohorts (total n = 343). The identification of distinct, localized, tissular pathotypes will aid precision targeting of current therapeutics and provides a biological rationale for IL-1 signaling blockade in ulcerating disease.	[Friedrich, Matthias; Pohin, Mathilde; Jackson, Matthew A.; Bullers, Samuel J.; Rue-Albrecht, Kevin; Peres, Raphael Sanches; Mann, Elizabeth H.; Attar, Moustafa; McCuaig, Sarah; Sansom, Stephen N.; Powrie, Fiona M.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Kennedy Inst Rheumatol, Oxford, England; [Korsunsky, Ilya; Raychaudhuri, Soumya] Brigham & Womens Hosp, Ctr Data Sci, 75 Francis St, Boston, MA 02115 USA; [Korsunsky, Ilya; Raychaudhuri, Soumya] Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA; [Korsunsky, Ilya; Raychaudhuri, Soumya] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Korsunsky, Ilya; Raychaudhuri, Soumya] MIT & Harvard, Broad Inst, Program Med & Populat Genet, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Korsunsky, Ilya; Wei, Kevin; Watts, Gerald F. M.; Raychaudhuri, Soumya] Brigham & Womens Hosp, Dept Med, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA; [Korsunsky, Ilya; Wei, Kevin; Watts, Gerald F. M.; Raychaudhuri, Soumya] Harvard Med Sch, Boston, MA 02115 USA; [Christoforidou, Zoe] Univ Oxford, John Radcliffe Hosp, Radcliffe Dept Med, MRC Weatherall Inst Mol Med, Oxford, England; [Sathananthan, Dharshan; Thomas, Tom; Ravindran, Rahul; Tandon, Ruchi; Geremia, Alessandra; Thomas, Lloyd; Collantes, Elena; Uhlig, Holm H.; Travis, Simon P.] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, NIHR Oxford Biomed Res Ctr, Translat Gastroenterol Unit, Oxford, England; [Sharpe, Hannah] Univ Oxford, Nuffield Dept Med, Jenner Inst, Oxford, England; [Attar, Moustafa] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Uhlig, Holm H.] John Radcliffe Hosp, Dept Paediat, Oxford, England; [Easton, Alistair] Univ Oxford, Div Med Sci, Dept Oncol, Old Rd Campus Res Bldg, Oxford, England; [Raychaudhuri, Soumya] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Genet & Genom Versus Arthrit, Manchester, Lancs, England	University of Oxford; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Jenner Institute; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of Manchester	Powrie, FM (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Kennedy Inst Rheumatol, Oxford, England.	fiona.powrie@kennedy.ox.ac.uk	Christoforidou, Zoe/AAB-3157-2020; Rue-Albrecht, Kevin/G-6316-2011	Christoforidou, Zoe/0000-0002-2242-8660; Sharpe, Hannah/0000-0002-1194-2429; Rue-Albrecht, Kevin/0000-0003-3899-3872; POHIN, Mathilde/0000-0003-2809-9498	Roche postdoctoral fellowship (2016-2017); Oxford-UCB-prize fellowship scheme (2017-2021); Kennedy Trust for Rheumatology Research [MSP141501]; Linacre College Oxford; National Institute for Health Research (NIHR) BRC; NIHR BRC; Leona M. and Harry B. Helmsley Charitable Trust; Roche Fibroblast Network Consortium funding; Wellcome Trust [095688/Z/11/Z, 212240/Z/18/Z]; Medical Research Council [MR/N02690X/1]; Translational Histopathology Laboratory at the Oxford Cancer Centre	Roche postdoctoral fellowship (2016-2017); Oxford-UCB-prize fellowship scheme (2017-2021); Kennedy Trust for Rheumatology Research; Linacre College Oxford; National Institute for Health Research (NIHR) BRC(National Institute for Health Research (NIHR)); NIHR BRC; Leona M. and Harry B. Helmsley Charitable Trust; Roche Fibroblast Network Consortium funding; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Translational Histopathology Laboratory at the Oxford Cancer Centre	M.F. was supported by a Roche postdoctoral fellowship (2016-2017) and the Oxford-UCB-prize fellowship scheme (2017-2021). M.P. was supported by the Roche postdoctoral fellowship program (2017-2019). M.A.J. was funded by the Kennedy Trust for Rheumatology Research (no. MSP141501) and supported by a Junior Research Fellowship from Linacre College Oxford. We acknowledge the contribution of the Oxford Biomedical Research Centre (BRC) Gastrointestinal Biobank (TGU Biobank Consortium: H.H.U., S.P.T., F.M.P.) supported by the National Institute for Health Research (NIHR) BRC. We thank members of the Oxford TGU biobank, especially J. Chivenga, A. Isherwood, R. Williams and G. Zavalani for facilitating the collection of patient samples. This work was supported by the NIHR BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. F.M.P. and H.H.U. are supported by the Leona M. and Harry B. Helmsley Charitable Trust. Parts of this work were also supported by Roche Fibroblast Network Consortium funding, NIHR OxBRC mucosal immunology response mode funding, the Wellcome Trust (nos. 095688/Z/11/Z and 212240/Z/18/Z), the Medical Research Council (no. MR/N02690X/1) and the Translational Histopathology Laboratory at the Oxford Cancer Centre. We further thank J. Pott for helping to set up ex vivo functional assays and the following Kennedy Institute core facility members for excellent technical support and training: J. Webber, B. Stott, I. Parisi, C. dos Santos Duarte and V. Nechyporuk-Zloy.	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Arijs I, 2009, GUT, V58, P1612, DOI 10.1136/gut.2009.178665; Arijs I, 2018, GUT, V67, P43, DOI 10.1136/gutjnl-2016-312293; Arijs I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007984; Aschenbrenner D, 2021, GUT, V70, P1023, DOI 10.1136/gutjnl-2020-321731; Atreya R, 2017, VISC MED, V33, P82, DOI 10.1159/000458006; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Bank S, 2014, PHARMACOGENOMICS J, V14, P526, DOI 10.1038/tpj.2014.19; Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329; Boyapati RK, 2016, MUCOSAL IMMUNOL, V9, P567, DOI 10.1038/mi.2016.14; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Cassatella MA, 2019, TRENDS IMMUNOL, V40, P648, DOI 10.1016/j.it.2019.05.003; Castro-Dopico T, 2019, IMMUNITY, V50, P1099, DOI 10.1016/j.immuni.2019.02.006; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; Czarnewski P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10769-x; Friedrich M, 2019, IMMUNITY, V50, P992, DOI 10.1016/j.immuni.2019.03.017; Gaujoux R, 2019, GUT, V68, P604, DOI 10.1136/gutjnl-2017-315494; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Haberman Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07841-3; Haberman Y, 2014, J CLIN INVEST, V124, P3617, DOI 10.1172/JCI75436; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Huang B, 2019, CELL, V179, P1160, DOI 10.1016/j.cell.2019.10.027; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kinchen J, 2018, CELL, V175, P372, DOI 10.1016/j.cell.2018.08.067; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Lamble S, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-104; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Levy M, 2013, PEDIATRICS, V132, pE779, DOI 10.1542/peds.2012-3344; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Loberman-Nachum N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52733-1; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Marchal-Bressenot A, 2017, GUT, V66, P43, DOI 10.1136/gutjnl-2015-310187; Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Peters LA, 2017, NAT GENET, V49, P1437, DOI 10.1038/ng.3947; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Pohin M., 2021, CROSS TISSUE SINGLE; Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675; Scarpa M, 2015, AM J PATHOL, V185, P1624, DOI 10.1016/j.ajpath.2015.02.018; Shouval DS, 2016, GASTROENTEROLOGY, V151, P1100, DOI 10.1053/j.gastro.2016.08.055; Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Thomas MG, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023765; Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1; Uhlig HH, 2018, ANNU REV IMMUNOL, V36, P755, DOI 10.1146/annurev-immunol-042617-053055; Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2; Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586-020-2222-z; West NR, 2017, NAT MED, V23, P579, DOI 10.1038/nm.4307; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; ZHENG GX, 2017, NATURE, V0008	51	25	25	2	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1970	+		10.1038/s41591-021-01520-5	http://dx.doi.org/10.1038/s41591-021-01520-5		OCT 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34675383	hybrid, Green Published			2022-12-27	WOS:000709711200001
J	Begin, P; Callum, J; Jamula, E; Cook, R; Heddle, NM; Tinmouth, A; Zeller, MP; Beaudoin-Bussieres, G; Amorim, L; Bazin, R; Loftsgard, KC; Carl, R; Chasse, M; Cushing, MM; Daneman, N; Devine, DV; Dumaresq, J; Fergusson, DA; Gabe, C; Glesby, MJ; Li, N; Liu, Y; McGeer, A; Robitaille, N; Sachais, BS; Scales, DC; Schwartz, L; Shehata, N; Turgeon, AF; Wood, H; Zarychanski, R; Finzi, A; Arnold, DM				Begin, Philippe; Callum, Jeannie; Jamula, Erin; Cook, Richard; Heddle, Nancy M.; Tinmouth, Alan; Zeller, Michelle P.; Beaudoin-Bussieres, Guillaume; Amorim, Luiz; Bazin, Renee; Loftsgard, Kent Cadogan; Carl, Richard; Chasse, Michael; Cushing, Melissa M.; Daneman, Nick; Devine, Dana, V; Dumaresq, Jeannot; Fergusson, Dean A.; Gabe, Caroline; Glesby, Marshall J.; Li, Na; Liu, Yang; McGeer, Allison; Robitaille, Nancy; Sachais, Bruce S.; Scales, Damon C.; Schwartz, Lisa; Shehata, Nadine; Turgeon, Alexis F.; Wood, Heidi; Zarychanski, Ryan; Finzi, Andres; Arnold, Donald M.		CONCOR-1 Study Grp	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	NATURE MEDICINE			English	Article							EFFICACY; SAFETY	The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset (NCT04348656). Patients were allocated 2:1 to 500 ml of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 d. Exploratory analyses of the effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. In total, 940 patients were randomized, and 921 patients were included in the intention-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) patients in the convalescent plasma arm and 86/307 (28.0%) patients in the standard of care arm-relative risk (RR) = 1.16 (95% confidence interval (CI) 0.94-1.43, P = 0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% versus 26.4%; RR = 1.27, 95% CI 1.02-1.57, P = 0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standardized log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (odds ratio (OR) = 0.74, 95% CI 0.57-0.95 and OR = 0.66, 95% CI 0.50-0.87, respectively), whereas IgG against the full transmembrane spike protein increased it (OR = 1.53, 95% CI 1.14-2.05). Convalescent plasma did not reduce the risk of intubation or death at 30 d in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.	[Begin, Philippe] CHU St Justine, Dept Pediat, Montreal, PQ, Canada; [Begin, Philippe; Chasse, Michael] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada; [Callum, Jeannie] Kingston Hlth Sci Ctr, Dept Pathol & Mol Med, Kingston, ON, Canada; [Callum, Jeannie] Queens Univ, Kingston, ON, Canada; [Callum, Jeannie] Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON, Canada; [Callum, Jeannie; McGeer, Allison] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Callum, Jeannie; Heddle, Nancy M.; Tinmouth, Alan; Zeller, Michelle P.; Fergusson, Dean A.; Shehata, Nadine] Canadian Blood Serv, Ottawa, ON, Canada; [Jamula, Erin; Heddle, Nancy M.; Zeller, Michelle P.; Gabe, Caroline; Li, Na; Liu, Yang; Arnold, Donald M.] McMaster Univ, McMaster Ctr Transfus Res, Hamilton, ON, Canada; [Cook, Richard] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON, Canada; [Heddle, Nancy M.; Zeller, Michelle P.; Arnold, Donald M.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Tinmouth, Alan; Fergusson, Dean A.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Tinmouth, Alan] Ottawa Hosp Res Inst, Ottawa Hosp Ctr Transfus Res, Ottawa, ON, Canada; [Beaudoin-Bussieres, Guillaume; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Beaudoin-Bussieres, Guillaume; Finzi, Andres] CHUM Res Ctr, Montreal, PQ, Canada; [Amorim, Luiz] Hosp & Reg Blood Ctr, Hemorio, Rio De Janeiro, Brazil; [Bazin, Renee] Hema Quebec, Med Affairs & Innovat, Quebec City, PQ, Canada; [Loftsgard, Kent Cadogan] CONCOR 1 Community Advisory Comm, Montreal, PQ, Canada; [Chasse, Michael] Ctr Hosp Univ Montreal, Innovat Hub, Ctr Rech, Montreal, PQ, Canada; [Cushing, Melissa M.] New York Presbyterian, Transfus Med & Cellular Therapy, New York, NY USA; [Cushing, Melissa M.; Sachais, Bruce S.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA; [Daneman, Nick] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Infect Dis, Toronto, ON, Canada; [Devine, Dana, V] Canadian Blood Serv, Vancouver, BC, Canada; [Devine, Dana, V] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Dumaresq, Jeannot] CISSS Chaudiere Appalaches, Dept Med, Levis, PQ, Canada; [Dumaresq, Jeannot] Univ Laval, Fac Med, Dept Microbiol Infectiol & Dimmunol, Quebec City, PQ, Canada; [Fergusson, Dean A.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Glesby, Marshall J.] Weill Cornell Med Coll, Div Infect Dis, New York, NY USA; [Li, Na] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Li, Na] McMaster Univ, Dept Comp & Software, Hamilton, ON, Canada; [McGeer, Allison] Sinai Hlth Syst, Dept Microbiol, Toronto, ON, Canada; [McGeer, Allison] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Robitaille, Nancy] Hema Quebec, Montreal, PQ, Canada; [Robitaille, Nancy] CHU St Justine, Div Hematol & Oncol, Dept Pediat, Montreal, PQ, Canada; [Robitaille, Nancy] Univ Montreal, Dept Pediat, Montreal, PQ, Canada; [Sachais, Bruce S.] New York Blood Ctr Enterprises, New York, NY USA; [Scales, Damon C.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Scales, Damon C.] Univ Toronto, Dept Med, Interdept Div Crit Care Med, Toronto, ON, Canada; [Schwartz, Lisa] McMaster Univ, Fac Hlth Sci, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Shehata, Nadine] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dept Med Lab Med & Pathobiol, Toronto, ON, Canada; [Shehata, Nadine] Mt Sinai Hosp, Div Hematol, Toronto, ON, Canada; [Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol & Crit Care Med, Div Crit Care Med, Fac Med, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval, CHU Quebec Univ Laval Res Ctr, Populat Hlth & Optimal Hlth Practices Res Unit, Trauma Emergency Crit Care Med, Quebec City, PQ, Canada; [Wood, Heidi] Publ Hlth Agcy Canada, Natl Microbiol Lab, Zoonot Dis & Special Pathogens, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Hematol Med Oncol, Winnipeg, MB, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; McMaster University; Queens University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Canadian Blood Services; McMaster University; University of Waterloo; McMaster University; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Universite de Montreal; Universite de Montreal; Hema-Quebec; Universite de Montreal; NewYork-Presbyterian Hospital; Cornell University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Canadian Blood Services; University of British Columbia; Laval University; University of Ottawa; Ottawa Hospital Research Institute; Cornell University; University of Calgary; McMaster University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Hema-Quebec; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; McMaster University; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Laval University; Laval University; Public Health Agency of Canada; University of Manitoba	Arnold, DM (corresponding author), McMaster Univ, McMaster Ctr Transfus Res, Hamilton, ON, Canada.; Arnold, DM (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.	arnold@mcmaster.ca	Zarychanski, Ryan/AAB-6369-2022; Li, Na/GWC-4285-2022; Bégin, Philippe/AAU-9126-2021; Robitaille, Nancy/AAA-8418-2022; Laumaea, Annemarie/AGC-1405-2022; Jomy, Jane/AHC-5946-2022	Li, Na/0000-0002-4803-0984; Jomy, Jane/0000-0001-6066-9548; Veillette, Maxime/0000-0002-0493-3428; Vasovic, Ljiljana/0000-0001-7759-4546; Sonpar, Ashlesha/0000-0003-1676-1384; Dumaresq, Jeannot/0000-0002-7660-7015; Lin, Yi-Chan James/0000-0003-0867-220X; Cook, Richard/0000-0002-1414-4908; Prevost, Jeremie/0000-0002-5260-5154; Cloutier, Marc/0000-0002-0598-8754; Laumaea, Annemarie/0000-0002-4934-597X; Perreault, Josee/0000-0002-9434-2348; Zeller, Michelle/0000-0002-6489-6980; Berardi, Philip/0000-0002-2302-6145; Arnold, Donald/0000-0003-0943-8853; Mateos, Sheila/0000-0001-5416-2724	Canadian Institutes of Health Research [447352]; Ontario COVID-19 Rapid Research Fund; Toronto COVID-19 Action Initiative 2020 (University of Toronto); Fondation du CHU Ste-Justine; Ministere de l'Economie et de l'Innovation du Quebec [2020-2021-COVID-19-PSOv2a-51169]; Fonds de Recherche du Quebec [281662]; University Health Network Emergent Access Innovation Fund; University Health Academic Health Science Centre Alternative Funding Plan (Sunnybrook Health Sciences Centre); Saskatchewan Ministry of Health; University of Alberta Hospital Foundation; Alberta Health Services COVID-19 Foundation Competition; Sunnybrook Health Sciences Centre Foundation; Fondation du CHUM; Ottawa Hospital Academic Medical Organization; Ottawa Hospital Foundation COVID-19 Research Fund; Sinai Health System Foundation; McMaster University	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario COVID-19 Rapid Research Fund; Toronto COVID-19 Action Initiative 2020 (University of Toronto); Fondation du CHU Ste-Justine; Ministere de l'Economie et de l'Innovation du Quebec; Fonds de Recherche du Quebec; University Health Network Emergent Access Innovation Fund; University Health Academic Health Science Centre Alternative Funding Plan (Sunnybrook Health Sciences Centre); Saskatchewan Ministry of Health; University of Alberta Hospital Foundation(University of Alberta); Alberta Health Services COVID-19 Foundation Competition; Sunnybrook Health Sciences Centre Foundation(University of Toronto); Fondation du CHUM; Ottawa Hospital Academic Medical Organization; Ottawa Hospital Foundation COVID-19 Research Fund; Sinai Health System Foundation; McMaster University	The authors acknowledge the recovered patients who donated their plasma; the staff involved in the recruitment, collection, qualification and distribution of COVID-19 convalescent plasma; and the staff of the COVID-19 wards who made the study possible. The authors would also like to thank the members of the independent data safety monitoring committee: K. Karkouti, R. Fowler, M. Delaney, G. Tomlinson, D. Davis and B. Juelg. Funding for the study was provided by Canadian Institutes of Health Research COVID-19 May 2020 Rapid Research Funding Opportunity, operating grant no. 447352 (D.A., P.B. and J.C.); Ontario COVID-19 Rapid Research Fund (D.A.); Toronto COVID-19 Action Initiative 2020 (University of Toronto) (J.C.); Fondation du CHU Ste-Justine (P.B.); Ministere de l'Economie et de l'Innovation du Quebec, no. 2020-2021-COVID-19-PSOv2a-51169 (P.B.); Fonds de Recherche du Quebec, sante no. 281662 (P.B.); University Health Network Emergent Access Innovation Fund (N.S.); University Health Academic Health Science Centre Alternative Funding Plan (Sunnybrook Health Sciences Centre) (N.D.); Saskatchewan Ministry of Health (O.P.T.); University of Alberta Hospital Foundation (S.N.); Alberta Health Services COVID-19 Foundation Competition (S.N.); Sunnybrook Health Sciences Centre Foundation (J.C.); Fondation du CHUM (A.F.); Ottawa Hospital Academic Medical Organization (A.T.); Ottawa Hospital Foundation COVID-19 Research Fund (A.T.); Sinai Health System Foundation (N.S.); and McMaster University (D.A.). These organizations and institutions did not have any role in the writing of the manuscript or the decision to submit it for publication. The authors did not receive payments from any pharmaceutical company or other agency to write this article. All authors had full access to the full data in the study and accept responsibility to submit for publication.	Abe KT, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142362; Agarwal A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3939; AlQahtani M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89444-5; Anand SP, 2021, TRANSFUSION, V61, P1377, DOI 10.1111/trf.16318; Anand Sai Priya, 2021, bioRxiv, DOI [10.1016/j.xcrm.2021.100290, 10.1101/2021.01.25.428097]; Avendano-Sola C., 2020, CONVALESCENT PLASMA, DOI [https://doi.org/10.1101/2020.08.26.20182444, 10.1101/2020.08.26.20182444, DOI 10.1101/2020.08.26.20182444]; Bajpai M., 2020, PREPRINT, DOI [10.25.20219337, 10.1101/2020.10.25.20219337, DOI 10.1101/2020.10.25.20219337]; Beaudoin-Bussieres G, 2020, MBIO, V11, DOI 10.1128/mBio.02590-20; Begin P, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05235-3; Bennett-Guerrero E, 2021, CRIT CARE MED, V49, P1015, DOI 10.1097/CCM.0000000000005066; Blackall D, 2020, TRANSFUSION, V60, P2203, DOI 10.1111/trf.16026; Brunet-Ratnasingham E. A. S., 2021, INTEGRATED IMMUNOVIR, DOI [10.1101/2021.03.18.21253907v1, DOI 10.1101/2021.03.18.21253907V1]; Budhai A, 2020, TRANSFUSION, V60, P1348, DOI 10.1111/trf.15910; Casadevall A, 2021, NEW ENGL J MED, V384, P189, DOI 10.1056/NEJMc2033787; Corman M., 2021, HIGH DOSE CONVALESCE, DOI 10.21256192v1; Devasenapathy N, 2020, CAN MED ASSOC J, V192, pE745, DOI 10.1503/cmaj.200642; Gharbharan A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23469-2; Hamilton FW, 2021, INT J INFECT DIS, V109, P114, DOI 10.1016/j.ijid.2021.06.034; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Joyner MJ, 2021, NEW ENGL J MED, V384, P1015, DOI 10.1056/NEJMoa2031893; Li L, 2020, JAMA-J AM MED ASSOC, V324, P519, DOI 10.1001/jama.2020.13216; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Mendoza Emelissa J, 2020, Curr Protoc Microbiol, V57, pecpmc105, DOI 10.1002/cpmc.105; Narick C, 2012, TRANSFUSION, V52, P160, DOI 10.1111/j.1537-2995.2011.03247.x; O'Donnell MR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150646; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Perreault J, 2020, BLOOD, V136, P2588, DOI 10.1182/blood.2020008367; Piechotta V, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600.pub2; Ray Y., 2020, INFECT DIS EXCEPT HI, V2020, p11.25.20237883, DOI 10.1101/2020.11.25.20237883; Salman OH, 2020, EGYPT J ANAESTH, V36, P264, DOI 10.1080/11101849.2020.1842087; Schafer A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201993; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Simonovich VA, 2021, NEW ENGL J MED, V384, P619, DOI 10.1056/NEJMoa2031304; Suryadevara Naveenchandra, 2021, Cell, V184, P2316, DOI [10.1101/2021.01.19.427324, 10.1016/j.cell.2021.03.029]; Taborda CP, 2003, J IMMUNOL, V170, P3621, DOI 10.4049/jimmunol.170.7.3621; Tauzin Alexandra, 2021, bioRxiv, DOI 10.1101/2021.03.18.435972; The REMAP-CAP investigators Estcourt JL, 2021, CONV PLASM CRIT PAT, DOI [10.1101/2021.06.11.21258760v1, DOI 10.1101/2021.06.11.21258760V1]; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Ullah Irfan, 2021, bioRxiv, DOI 10.1101/2021.03.22.436337; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Wood EM, 2021, BLOOD, V137, P1573, DOI 10.1182/blood.2020008903; Wood S., 2017, GEN ADDITIVE MODELS, V2nd Edn; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x; Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751; Zohar T, 2020, CELL, V183, P1508, DOI 10.1016/j.cell.2020.10.052	47	98	99	5	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					2012	+		10.1038/s41591-021-01488-2	http://dx.doi.org/10.1038/s41591-021-01488-2		SEP 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34504336	hybrid, Green Published			2022-12-27	WOS:000694610500002
J	Cron, RQ; Caricchio, R; Chatham, WW				Cron, Randy Q.; Caricchio, Roberto; Chatham, W. Winn			Calming the cytokine storm in COVID-19	NATURE MEDICINE			English	Editorial Material							MECHANICAL VENTILATION	Cytokine blockade can improve the survival rate of patients with COVID-19 who are at risk of respiratory failure, but timing and patient selection are key.	[Cron, Randy Q.; Chatham, W. Winn] Univ Alabama Birmingham, Sch Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35233 USA; [Caricchio, Roberto] Temple Univ, Lewis Katz Sch Med, Sect Rheumatol, Philadelphia, PA 19122 USA	University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Cron, RQ (corresponding author), Univ Alabama Birmingham, Sch Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35233 USA.	randycron@uabmc.edu						Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Caricchio R, 2021, JAMA-J AM MED ASSOC, V326, P230, DOI 10.1001/jama.2021.9508; Cron RQ, 2020, J RHEUMATOL, V47, P639, DOI 10.3899/jrheum.200334; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fauci AS, 2021, SCIENCE, V372, P109, DOI 10.1126/science.abi8397; Guimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kessel C, 2021, ARTHRITIS RHEUMATOL, V73, P1791, DOI 10.1002/art.41763; Kyriazopoulou E, 2021, NAT MED, V27, P1752, DOI 10.1038/s41591-021-01499-z; Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550; Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330	12	31	32	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1674	1675		10.1038/s41591-021-01500-9	http://dx.doi.org/10.1038/s41591-021-01500-9		SEP 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34480126	Bronze			2022-12-27	WOS:000692308000003
J	Andrews, MC; Duong, CPM; Gopalakrishnan, V; Iebba, V; Chen, WS; Derosa, L; Khan, MAW; Cogdill, AP; White, MG; Wong, MC; Ferrere, G; Fluckiger, A; Roberti, MP; Opolon, P; Alou, MT; Yonekura, S; Roh, W; Spencer, CN; Curbelo, IF; Vence, L; Reuben, A; Johnson, S; Arora, R; Morad, G; Lastrapes, M; Baruch, EN; Little, L; Gumbs, C; Cooper, ZA; Prieto, PA; Wani, K; Lazar, AJ; Tetzlaff, MT; Hudgens, CW; Callahan, MK; Adamow, M; Postow, MA; Ariyan, CE; Gaudreau, PO; Nezi, L; Raoult, D; Mihalcioiu, C; Elkrief, A; Pezo, RC; Haydu, LE; Simon, JM; Tawbi, HA; McQuade, J; Hwu, P; Hwu, WJ; Amaria, RN; Burton, EM; Woodman, SE; Watowich, S; Diab, A; Patel, SP; Glitza, IC; Wong, MK; Zhao, L; Zhang, JH; Ajami, NJ; Petrosino, J; Jenq, RR; Davies, MA; Gershenwald, JE; Futreal, PA; Sharma, P; Allison, JP; Routy, B; Zitvogel, L; Wargo, JA				Andrews, Miles C.; Duong, Connie P. M.; Gopalakrishnan, Vancheswaran; Iebba, Valerio; Chen, Wei-Shen; Derosa, Lisa; Khan, Md Abdul Wadud; Cogdill, Alexandria P.; White, Michael G.; Wong, Matthew C.; Ferrere, Gladys; Fluckiger, Aurelie; Roberti, Maria P.; Opolon, Paule; Alou, Maryam Tidjani; Yonekura, Satoru; Roh, Whijae; Spencer, Christine N.; Curbelo, Irina Fernandez; Vence, Luis; Reuben, Alexandre; Johnson, Sarah; Arora, Reetakshi; Morad, Golnaz; Lastrapes, Matthew; Baruch, Erez N.; Little, Latasha; Gumbs, Curtis; Cooper, Zachary A.; Prieto, Peter A.; Wani, Khalida; Lazar, Alexander J.; Tetzlaff, Michael T.; Hudgens, Courtney W.; Callahan, Margaret K.; Adamow, Matthew; Postow, Michael A.; Ariyan, Charlotte E.; Gaudreau, Pierre-Olivier; Nezi, Luigi; Raoult, Didier; Mihalcioiu, Catalin; Elkrief, Arielle; Pezo, Rossanna C.; Haydu, Lauren E.; Simon, Julie M.; Tawbi, Hussein A.; McQuade, Jennifer; Hwu, Patrick; Hwu, Wen-Jen; Amaria, Rodabe N.; Burton, Elizabeth M.; Woodman, Scott E.; Watowich, Stephanie; Diab, Adi; Patel, Sapna P.; Glitza, Isabella C.; Wong, Michael K.; Zhao, Li; Zhang, Jianhua; Ajami, Nadim J.; Petrosino, Joseph; Jenq, Robert R.; Davies, Michael A.; Gershenwald, Jeffrey E.; Futreal, P. Andrew; Sharma, Padmanee; Allison, James P.; Routy, Bertrand; Zitvogel, Laurence; Wargo, Jennifer A.			Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	NATURE MEDICINE			English	Article							BACTEROIDES-FRAGILIS GROUP; MELANOMA; IPILIMUMAB; NIVOLUMAB; RESISTANCE; EFFICACY; MECHANISMS; SEQUENCES; SURVIVAL; THERAPY	Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers and mechanisms of response and toxicity to CICB are needed. To address this, we profiled the blood, tumor and gut microbiome of 77 patients with advanced melanoma treated with CICB, with a high rate of any >= grade 3 immune-related adverse events (49%) with parallel studies in pre-clinical models. Tumor-associated immune and genomic biomarkers of response to CICB were similar to those identified for ICB monotherapy, and toxicity from CICB was associated with a more diverse peripheral T-cell repertoire. Profiling of gut microbiota demonstrated a significantly higher abundance of Bacteroides intestinalis in patients with toxicity, with upregulation of mucosal IL-1 beta in patient samples of colitis and in pre-clinical models. Together, these data offer potential new therapeutic angles for targeting toxicity to CICB. Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition.	[Andrews, Miles C.; Gopalakrishnan, Vancheswaran; Khan, Md Abdul Wadud; White, Michael G.; Johnson, Sarah; Arora, Reetakshi; Morad, Golnaz; Gaudreau, Pierre-Olivier; Haydu, Lauren E.; Simon, Julie M.; Burton, Elizabeth M.; Gershenwald, Jeffrey E.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Andrews, Miles C.] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Andrews, Miles C.] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia; [Andrews, Miles C.] Monash Univ, Deparment Med, Melbourne, Vic, Australia; [Duong, Connie P. M.; Iebba, Valerio; Derosa, Lisa; Cogdill, Alexandria P.; Ferrere, Gladys; Fluckiger, Aurelie; Roberti, Maria P.; Opolon, Paule; Alou, Maryam Tidjani; Yonekura, Satoru; Routy, Bertrand; Zitvogel, Laurence] Gustave Roussy Canc Campus GRCC, Villejuif, France; [Duong, Connie P. M.; Iebba, Valerio; Derosa, Lisa; Cogdill, Alexandria P.; Ferrere, Gladys; Fluckiger, Aurelie; Roberti, Maria P.; Alou, Maryam Tidjani; Yonekura, Satoru; Routy, Bertrand; Zitvogel, Laurence] Inst Natl Sante & Rech Med INSERM U1015, Equipe Labellisee Ligue Natl Canc, Villejuif, France; [Duong, Connie P. M.; Derosa, Lisa; Cogdill, Alexandria P.; Ferrere, Gladys; Fluckiger, Aurelie; Roberti, Maria P.; Alou, Maryam Tidjani; Yonekura, Satoru; Routy, Bertrand; Zitvogel, Laurence] Univ Paris Saclay, Fac Med Kremlin Bicetre, Le Kremlin Bicetre, France; [Chen, Wei-Shen; Cogdill, Alexandria P.; Wong, Matthew C.; Roh, Whijae; Baruch, Erez N.; Little, Latasha; Gumbs, Curtis; Lazar, Alexander J.; Woodman, Scott E.; Zhao, Li; Zhang, Jianhua; Ajami, Nadim J.; Jenq, Robert R.; Futreal, P. Andrew; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Chen, Wei-Shen] Univ S Florida, Dept Dermatol, Morsani Coll Med, Tampa, FL 33620 USA; [Spencer, Christine N.; Callahan, Margaret K.] Parker Inst Canc Immunotherapy, Dept Informat, San Francisco, CA USA; [Curbelo, Irina Fernandez; Vence, Luis; Watowich, Stephanie; Sharma, Padmanee; Allison, James P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Reuben, Alexandre] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Lastrapes, Matthew] Univ Texas Hlth, MD Anderson Canc Ctr, Grad Sch Biomed Sci GSBS, Houston, TX USA; [Cooper, Zachary A.] AstraZeneca, Gaithersburg, MD USA; [Prieto, Peter A.] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA; [Wani, Khalida; Lazar, Alexander J.; Tetzlaff, Michael T.; Hudgens, Courtney W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Callahan, Margaret K.; Adamow, Matthew; Postow, Michael A.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Adamow, Matthew; Postow, Michael A.] Mem Sloan Kettering Canc Ctr, Div Immunol, 1275 York Ave, New York, NY 10021 USA; [Ariyan, Charlotte E.] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Nezi, Luigi] Ist Europeo Oncol, Milan, Italy; [Raoult, Didier] Aix Marseille Univ, IHU Mediterranee Infect, MEPHI, IRD, Marseille, France; [Mihalcioiu, Catalin] McGill Univ, Fac Med & Hlth Sci, Dept Med, Hlth Ctr, Montreal, PQ, Canada; [Elkrief, Arielle] McGill Univ, Cedars Canc Ctr, Hlth Ctr, Montreal, PQ, Canada; [Pezo, Rossanna C.] Univ Toronto, Sunnybrook Odette Canc Ctr, Div Med Oncol, Toronto, ON, Canada; [Tawbi, Hussein A.; McQuade, Jennifer; Hwu, Patrick; Hwu, Wen-Jen; Amaria, Rodabe N.; Woodman, Scott E.; Diab, Adi; Patel, Sapna P.; Glitza, Isabella C.; Wong, Michael K.; Davies, Michael A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Petrosino, Joseph] Baylor Coll Med, Dept Virol & Microbiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; La Trobe University; Olivia Newton-John Cancer Research Institute; La Trobe University; Monash University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Texas System; UTMD Anderson Cancer Center; State University System of Florida; University of South Florida; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; AstraZeneca; University of Rochester; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; IRCCS European Institute of Oncology (IEO); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; McGill University; McGill University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.; Zitvogel, L (corresponding author), Gustave Roussy Canc Campus GRCC, Villejuif, France.; Zitvogel, L (corresponding author), Inst Natl Sante & Rech Med INSERM U1015, Equipe Labellisee Ligue Natl Canc, Villejuif, France.; Zitvogel, L (corresponding author), Univ Paris Saclay, Fac Med Kremlin Bicetre, Le Kremlin Bicetre, France.; Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	laurence.zitvogel@gustaveroussy.fr; jwargo@mdanderson.org	Yonekura, Satoru/R-2468-2016; Davies, Michael/GWV-2527-2022; RAOULT, Didier/A-8434-2008; Burton, Elizabeth/AAB-9393-2021; DEROSA, LISA/E-6814-2015; Iebba, Valerio/P-1194-2016	Yonekura, Satoru/0000-0003-4047-3016; RAOULT, Didier/0000-0002-0633-5974; Burton, Elizabeth/0000-0002-3424-4922; ZITVOGEL, laurence/0000-0003-1596-0998; Duong, Connie/0000-0002-9067-8557; Nezi, Luigi/0000-0002-4670-7656; Derosa, Lisa/0000-0003-0527-2964; Iebba, Valerio/0000-0002-0716-306X; Andrews, Miles/0000-0003-1231-8641; Morad, Golnaz/0000-0002-9460-618X; White, Michael/0000-0001-5022-5505; Watowich, Stephanie/0000-0003-1969-659X	Cancer Prevention Research Institute of Texas; Welch Foundation; NIH/NCI [1 P50 CA221703-02, 1U54CA224070-03]; American Cancer Society; Melanoma Research Alliance [4022024]; Cancer Fighters of Houston; National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship [1148680]; National Institutes of Health T32 Training Grant [T32CA163185]; CPRIT Research Training Program [RP170067]; Fulbright France Commission Franco-Americaine; John J. Kopchick Foundation; Kimberley Clark Foundation by MD Anderson's Odyssey Fellowship Program; Fonds de Recherche Quebec-Sante's (FRQS) Resident Physician Health Research Career Training Program [32667]; National Institutes of Health [1R01CA219896-01A1, T32CA009599]; MD Anderson Cancer Center [P30 CA016672]; MSK Cancer Center Support Grant/Core Grant [P30 CA008748]; EU; Ligue contre le Cancer (equipe labelisee); Agence Nationale de la Recherche (ANR)-Projets blancs; ANR; ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Fondation de France; Fondation pour la Recherche Medicale (FRM); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); ANR germanofrench; LabEx Immuno-Oncology; French Ministry of Health PIA2 [ANR-16-RHUS-0008]; Swiss Bridge Foundation; Seerave and Carrefour Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); French Government under the 'Investissements d'avenir' (Investments for the Future) program [10-IAHU-03, NIH P30 CA008748]; Region Provence Alpes Cote d'Azur; European funding FEDER PRIMI; Strategic Innovation Grant from the Division of Medical Oncology, University of Toronto; American Association for Cancer Research Stand Up To Cancer [SU2C-AACR-IRG-19-17]; MD Anderson Melanoma Moonshot Program; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; AIM at Melanoma Foundation; Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions	Cancer Prevention Research Institute of Texas; Welch Foundation(The Welch Foundation); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Melanoma Research Alliance; Cancer Fighters of Houston; National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health T32 Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT Research Training Program; Fulbright France Commission Franco-Americaine; John J. Kopchick Foundation; Kimberley Clark Foundation by MD Anderson's Odyssey Fellowship Program; Fonds de Recherche Quebec-Sante's (FRQS) Resident Physician Health Research Career Training Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson Cancer Center; MSK Cancer Center Support Grant/Core Grant; EU(European Commission); Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence Nationale de la Recherche (ANR)-Projets blancs(French National Research Agency (ANR)); ANR(French National Research Agency (ANR)); ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Fondation de France(Fondation de France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Fondation Carrefour; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Inserm (HTE); ANR germanofrench(French National Research Agency (ANR)); LabEx Immuno-Oncology; French Ministry of Health PIA2; Swiss Bridge Foundation; Seerave and Carrefour Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); French Government under the 'Investissements d'avenir' (Investments for the Future) program(French National Research Agency (ANR)); Region Provence Alpes Cote d'Azur(Region Provence-Alpes-Cote d'Azur); European funding FEDER PRIMI; Strategic Innovation Grant from the Division of Medical Oncology, University of Toronto; American Association for Cancer Research Stand Up To Cancer; MD Anderson Melanoma Moonshot Program; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; AIM at Melanoma Foundation; Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions	This research was supported by generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program from the Lyda Hill Foundation and utilized platform assistance from the Cancer Genomics Laboratory and Immunotherapy Platform, from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and the AIM at Melanoma Foundation. Additional support was provided to P.A.F. from the Cancer Prevention Research Institute of Texas and the Welch Foundation. M.A.D. is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI (1 P50 CA221703-02 and 1U54CA224070-03), the American Cancer Society and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. M.C.A. is supported by a National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship (#1148680). W.-S.C. was supported by a National Institutes of Health T32 Training Grant (T32CA163185). A.P.C. is supported by the CPRIT Research Training Program (RP170067), the Fulbright France Commission Franco-Americaine and the John J. Kopchick Foundation. A.R. is supported by the Kimberley Clark Foundation Award for Scientific Achievement provided by MD Anderson's Odyssey Fellowship Program. P.-O.G. was supported by the Fonds de Recherche Quebec-Sante's (FRQS) Resident Physician Health Research Career Training Program (32667). M.G.W. was supported by National Institutes of Health (T32CA009599) and an MD Anderson Cancer Center support grant (P30 CA016672). M.A.P. received support from the MSK Cancer Center Support Grant/Core Grant (P30 CA008748). We acknowledge the assistance of the animal facility team at Gustave Roussy. L. Zitvogel is funded by grants from EU H2020 ONCOBIOME, Ligue contre le Cancer (equipe labelisee); Agence Nationale de la Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Chancellerie des universites de Paris (Legs Poix), Fondation de France; Fondation pour la Recherche Medicale (FRM); a donation by Elior; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); ANR germanofrench; LabEx Immuno-Oncology; the French Ministry of Health PIA2, RHU Torino Lumiere (ANR-16-RHUS-0008); the Swiss Bridge Foundation; the Seerave and Carrefour Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE). This work was supported by the French Government under the 'Investissements d'avenir' (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research, Mediterranee Infection 10-IAHU-03; L. Zitvogel). M.K.C. is supported by an institutional grant (NIH P30 CA008748). L.D. is supported by 'Parcours d'excellence en cancerologie-Fondation Philanthropia'. This work was supported by Region Provence Alpes Cote d'Azur and European funding FEDER PRIMI. R.C.P. was supported by a Strategic Innovation Grant from the Division of Medical Oncology, University of Toronto. R.C.P. was supported by a Strategic Innovation Grant from the Division of Medical Oncology, University of Toronto. J.A.W.; is supported by the National Institutes of Health (1R01CA219896-01A1), the Melanoma Research Alliance (4022024), American Association for Cancer Research Stand Up To Cancer (SU2C-AACR-IRG-19-17) and the MD Anderson Melanoma Moonshot Program. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Angelakis E, 2016, SCI REP-UK, V6, DOI 10.1038/srep26276; Moro-Garcia MA, 2012, CURR GENOMICS, V13, P589, DOI 10.2174/138920212803759749; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Bai Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-325; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chen YX, 2010, J LEUKOCYTE BIOL, V87, P137, DOI 10.1189/jlb.0809562; D'Angelo SP, 2017, J CLIN ONCOL, V35, P226, DOI 10.1200/JCO.2016.67.9258; Das S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0805-8; Dridi B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007063; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ekmekcioglu S, 2016, CLIN CANCER RES, V22, P3016, DOI 10.1158/1078-0432.CCR-15-2226; Enot DP, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462431; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Furet JP, 2009, FEMS MICROBIOL ECOL, V68, P351, DOI 10.1111/j.1574-6941.2009.00671.x; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Million M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26051; Morgan XC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002808; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796; Odamaki T, 2008, APPL ENVIRON MICROB, V74, P6814, DOI 10.1128/AEM.01106-08; Oh DY, 2017, CANCER RES, V77, P1322, DOI 10.1158/0008-5472.CAN-16-2324; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Perez-Ruiz E, 2019, NATURE, V569, P428, DOI 10.1038/s41586-019-1162-y; Peters BA, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0672-4; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Seo SU, 2015, IMMUNITY, V42, P744, DOI 10.1016/j.immuni.2015.03.004; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Subudhi SK, 2016, P NATL ACAD SCI USA, V113, P11919, DOI 10.1073/pnas.1611421113; Suzuki MT, 2000, APPL ENVIRON MICROB, V66, P4605, DOI 10.1128/AEM.66.11.4605-4614.2000; Sznol M, 2017, J CLIN ONCOL, V35, P3815, DOI 10.1200/JCO.2016.72.1167; Tanese K, 2015, J INVEST DERMATOL, V135, P2775, DOI 10.1038/jid.2015.204; Therneau T.M., 2000, MODELING SURVIVAL DA; Tong J, 2011, ANAEROBE, V17, P64, DOI 10.1016/j.anaerobe.2011.03.004; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	60	85	87	25	72	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1432	+		10.1038/s41591-021-01406-6	http://dx.doi.org/10.1038/s41591-021-01406-6		JUL 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34239137	Green Submitted			2022-12-27	WOS:000672339400003
J	Mohassel, P; Donkervoort, S; Lone, MA; Nalls, M; Gable, K; Gupta, SD; Foley, AR; Hu, Y; Saute, JAM; Moreira, AL; Kok, F; Introna, A; Logroscino, G; Grunseich, C; Nickolls, AR; Pourshafie, N; Neuhaus, SB; Saade, D; Gangfuss, A; Kolbel, H; Piccus, Z; Le Pichon, CE; Fiorillo, C; Ly, CV; Topf, A; Brady, L; Specht, S; Zidell, A; Pedro, H; Mittelmann, E; Thomas, FP; Chao, KER; Konersman, CG; Cho, MT; Brandt, T; Straub, V; Connolly, AM; Schara, U; Roos, A; Tarnopolsky, M; Hoke, A; Brown, RH; Lee, CH; Hornemann, T; Dunn, TM; Bonnemann, CG				Mohassel, Payam; Donkervoort, Sandra; Lone, Museer A.; Nalls, Matthew; Gable, Kenneth; Gupta, Sita D.; Foley, A. Reghan; Hu, Ying; Saute, Jonas Alex Morales; Moreira, Ana Lucila; Kok, Fernando; Introna, Alessandro; Logroscino, Giancarlo; Grunseich, Christopher; Nickolls, Alec R.; Pourshafie, Naemeh; Neuhaus, Sarah B.; Saade, Dimah; Gangfuss, Andrea; Koelbel, Heike; Piccus, Zoe; Le Pichon, Claire E.; Fiorillo, Chiara; Ly, Cindy V.; Topf, Ana; Brady, Lauren; Specht, Sabine; Zidell, Aliza; Pedro, Helio; Mittelmann, Eric; Thomas, Florian P.; Chao, Katherine R.; Konersman, Chamindra G.; Cho, Megan T.; Brandt, Tracy; Straub, Volker; Connolly, Anne M.; Schara, Ulrike; Roos, Andreas; Tarnopolsky, Mark; Hoke, Ahmet; Brown, Robert H.; Lee, Chia-Hsueh; Hornemann, Thorsten; Dunn, Teresa M.; Bonnemann, Carsten G.			Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis	NATURE MEDICINE			English	Article							GENES	Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease of the lower and upper motor neurons with sporadic or hereditary occurrence. Age of onset, pattern of motor neuron degeneration and disease progression vary widely among individuals with ALS. Various cellular processes may drive ALS pathomechanisms, but a monogenic direct metabolic disturbance has not been causally linked to ALS. Here we show SPTLC1 variants that result in unrestrained sphingoid base synthesis cause a monogenic form of ALS. We identified four specific, dominantly acting SPTLC1 variants in seven families manifesting as childhood-onset ALS. These variants disrupt the normal homeostatic regulation of serine palmitoyltransferase (SPT) by ORMDL proteins, resulting in unregulated SPT activity and elevated levels of canonical SPT products. Notably, this is in contrast with SPTLC1 variants that shift SPT amino acid usage from serine to alanine, result in elevated levels of deoxysphingolipids and manifest with the alternate phenotype of hereditary sensory and autonomic neuropathy. We custom designed small interfering RNAs that selectively target the SPTLC1 ALS allele for degradation, leave the normal allele intact and normalize sphingolipid levels in vitro. The role of primary metabolic disturbances in ALS has been elusive; this study defines excess sphingolipid biosynthesis as a fundamental metabolic mechanism for motor neuron disease. Clinical and genetic evaluation of individuals with childhood-onset amyotrophic lateral sclerosis identifies a new monogenic cause for early-onset ALS and proposes a specific metabolic mechanism leading to motor neuron disease via sphingolipid excess.	[Mohassel, Payam; Donkervoort, Sandra; Nalls, Matthew; Foley, A. Reghan; Hu, Ying; Nickolls, Alec R.; Neuhaus, Sarah B.; Saade, Dimah; Bonnemann, Carsten G.] NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Lone, Museer A.; Hornemann, Thorsten] Univ Zurich, Univ Hosp Zurich, Inst Clin Chem, Zurich, Switzerland; [Gable, Kenneth; Gupta, Sita D.; Dunn, Teresa M.] Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; [Saute, Jonas Alex Morales] Hosp Clin Porto Alegre, Med Genet Div, Porto Alegre, RS, Brazil; [Saute, Jonas Alex Morales] Hosp Clin Porto Alegre, Neurol Div, Porto Alegre, RS, Brazil; [Saute, Jonas Alex Morales] Univ Fed Rio Grande do Sul, Grad Program Med Med Sci, Porto Alegre, RS, Brazil; [Saute, Jonas Alex Morales] Univ Fed Rio Grande do Sul, Internal Med Dept, Porto Alegre, RS, Brazil; [Saute, Jonas Alex Morales] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil; [Moreira, Ana Lucila] Univ Sao Paulo, Neurol Dept, Fac Med, Sao Paulo, Brazil; [Kok, Fernando] Univ Sao Paulo, Hosp Clin, Neurol Dept, Neurogenet Outpatient Serv, Sao Paulo, Brazil; [Kok, Fernando] Mendelics, Sao Paulo, Brazil; [Introna, Alessandro; Logroscino, Giancarlo] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Neurol Unit, Bari, Italy; [Logroscino, Giancarlo] Univ Bari, Pia Fdn Card G Panico Hosp Tricase Le, Dept Clin Res Neurol, Ctr Neurodegenerat Dis & Aging Brain, Bari, Italy; [Grunseich, Christopher; Pourshafie, Naemeh] NINDS, Neurogenet Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Gangfuss, Andrea; Koelbel, Heike; Schara, Ulrike; Roos, Andreas] Univ Duisburg Essen, Univ Clin Essen, Dept Paediat Neurol, Ctr Neuromuscular Disorders Children & Adolescent, Duisburg, Germany; [Piccus, Zoe; Le Pichon, Claire E.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Fiorillo, Chiara] Univ Genoa, G Gaslini Inst, Paediat Neurol & Muscular Dis Unit, Genoa, Italy; [Fiorillo, Chiara] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy; [Ly, Cindy V.] Washington Univ, Dept Neurol, St Louis Sch Med, St Louis, MO 63110 USA; [Topf, Ana; Specht, Sabine; Straub, Volker] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Topf, Ana; Specht, Sabine; Straub, Volker] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Brady, Lauren; Tarnopolsky, Mark] McMaster Univ, Hamilton Hlth Sci Ctr, Dept Paediat, Div Neuromuscular & Neurometabol Disorders, Hamilton, ON, Canada; [Zidell, Aliza] Hackensack Univ, Med Ctr, Ctr Genet & Genom Med, Hackensack, NJ USA; [Pedro, Helio] Hackensack Univ, Med Ctr, Hackensack Meridian Sch Med, Ctr Genet & Genom Med, Hackensack, NJ USA; [Mittelmann, Eric; Thomas, Florian P.] Hackensack Univ, Hereditary Neuropathy Fdn Ctr Excellence, Hackensack Meridian Sch Med, Dept Neurol,Med Ctr,Neurosci Inst, Hackensack, NJ USA; [Chao, Katherine R.] Broad Inst MIT & Harvard, Ctr Mendelian Genom, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Konersman, Chamindra G.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Cho, Megan T.; Brandt, Tracy] GeneDx, Gaithersburg, MD USA; [Connolly, Anne M.] Ohio State Univ, Dept Pediat, Div Neurol, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Hoke, Ahmet] Johns Hopkins Sch Med, Dept Neurol, Neuromuscular Div, Baltimore, MD USA; [Brown, Robert H.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; [Lee, Chia-Hsueh] St Jude Childrens Res Hosp, Dept Struct Biol, 332 N Lauderdale St, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Zurich; University Zurich Hospital; Uniformed Services University of the Health Sciences - USA; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade de Sao Paulo; Universidade de Sao Paulo; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Duisburg Essen; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; Saint Louis University; Washington University (WUSTL); Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; McMaster University; Hackensack University Medical Center; Hackensack University Medical Center; Hackensack University Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California San Diego; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Johns Hopkins University; Johns Hopkins Medicine; University of Massachusetts System; University of Massachusetts Worcester; St Jude Children's Research Hospital	Bonnemann, CG (corresponding author), NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.; Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA.	teresa.dunn-giroux@usuhs.edu; carsten.bonnemann@nih.gov	Fiorillo, Chiara/AAB-4142-2021; Hu, Ying/GQZ-8100-2022; Saade, Dimah/AAT-9479-2021; Connolly, Anne/GYD-3128-2022	Fiorillo, Chiara/0000-0001-9027-343X; Gangfuss, Andrea/0000-0002-9975-0092; Thomas, Florian P/0000-0002-6103-4138; Mohassel, Payam/0000-0001-5313-9514; Le Pichon, Claire/0000-0002-9274-3615; Straub, Volker/0000-0001-9046-3540; Lone, Museer/0000-0001-9710-775X; Introna, Alessandro/0000-0002-3141-6442; Saade, Dimah/0000-0003-1938-9952; Gable, Kenneth/0000-0002-9122-1006; Moreira, Ana Lucila/0000-0001-8028-5613	NINDS/NIH; CDMRP [W81XWH-20-1-0219]; NIH/NINDS [K08 NS10762, R01 NS072446]; Swiss National Science Foundation [31003A_179371]; Swiss Foundation for Research on Muscle Diseases (FSRMM); Deater foundation; National Human Genome Research Institute; National Eye Institute; National Heart, Lung and Blood Institute [UM1 HG008900]; National Human Genome Research Institute [R01 HG009141]	NINDS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CDMRP(United States Department of Defense); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Foundation for Research on Muscle Diseases (FSRMM); Deater foundation; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank the patients and their families for participating in our research study, C. Mendoza (NINDS/NNDCS) and G. Averion (NINDS/NNDCS) for their help in supporting the clinic, F. Eichler (Massachusetts General Hospital) for helpful discussions, and B. Smith (NINDS) and A. Nath (NINDS) for providing control serum samples. We also thank the NIH Intramural Sequencing Center for performing exome sequencing; K. Linask and J. Zhou from the NHLBI iPSC core for generating the isogenic mutant iPSC lines; and S. Lara and S. J. H. Tao Cheng in the NINDS electron microscopy facility. Work in C.G.B.'s laboratory is supported by intramural funds of NINDS/NIH. Work in T.M.D.'s laboratory was supported by CDMRP grant W81XWH-20-1-0219. C.V.L is supported by a career development grant from NIH/NINDS (K08 NS10762). T.H. is supported by Swiss National Science Foundation grant 31003A_179371. M.A.L is supported by Swiss Foundation for Research on Muscle Diseases (FSRMM). R.H.B. is funded by NIH/NINDS (R01 NS072446) and the Deater foundation. Sequencing and analysis provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) was funded by the National Human Genome Research Institute, the National Eye Institute and the National Heart, Lung and Blood Institute (grant UM1 HG008900) and, in part, by the National Human Genome Research Institute (grant R01 HG009141).	Al-Chalabi A, 2013, NAT REV NEUROL, V9, P617, DOI 10.1038/nrneurol.2013.203; Alterman JF, 2019, NAT BIOTECHNOL, V37, P884, DOI 10.1038/s41587-019-0205-0; Auer-Grumbach M, 2013, EUR J MED GENET, V56, P266, DOI 10.1016/j.ejmg.2013.02.002; Bannwarth S, 2014, BRAIN, V137, P2329, DOI 10.1093/brain/awu138; Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; Blackstone Craig, 2018, Handb Clin Neurol, V148, P633, DOI 10.1016/B978-0-444-64076-5.00041-7; Blasco H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17389-9; Bode H, 2016, HUM MOL GENET, V25, P853, DOI 10.1093/hmg/ddv611; Breslow DK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013326; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Brown RH, 2017, NEW ENGL J MED, V377, P1602, DOI [10.1038/nrdp.2017.85, 10.1056/NEJMra1603471, 10.1056/NEJMc1710379, 10.1016/S0140-6736(17)31287-4, 10.1016/S0140-6736(10)61156-7, 10.1038/nrdp.2017.71]; Cervenakova L, 2000, J NEUROL SCI, V177, P124, DOI 10.1016/S0022-510X(00)00350-6; Clarke BA, 2019, ELIFE, V8, DOI 10.7554/eLife.51067; Connolly O, 2020, J PERS MED, V10, DOI 10.3390/jpm10030058; Cudkowicz ME, 1998, ANN NEUROL, V43, P703, DOI 10.1002/ana.410430604; Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312; Davis DL, 2019, J BIOL CHEM, V294, P5146, DOI 10.1074/jbc.RA118.007291; De Carvalho M, 2009, AMYOTROPH LATERAL SC, V10, P53, DOI 10.1080/17482960802521126; Dodge JC, 2015, P NATL ACAD SCI USA, V112, P8100, DOI 10.1073/pnas.1508767112; Fernandopulle Michael S, 2018, Curr Protoc Cell Biol, V79, pe51, DOI 10.1002/cpcb.51; Fridman V, 2019, NEUROLOGY, V92, pE359, DOI 10.1212/WNL.0000000000006811; Gable K, 2010, J BIOL CHEM, V285, P22844, DOI 10.1074/jbc.M110.122259; Gantner ML, 2019, NEW ENGL J MED, V381, P1422, DOI 10.1056/NEJMoa1815111; Garofalo K, 2011, J CLIN INVEST, V121, P4735, DOI 10.1172/JCI57549; Gupta SD, 2015, J BIOL CHEM, V290, P90, DOI 10.1074/jbc.M114.588236; Han GS, 2019, BBA-MOL CELL BIOL L, V1864, P245, DOI 10.1016/j.bbalip.2018.11.007; Han G, 2009, P NATL ACAD SCI USA, V106, P8186, DOI 10.1073/pnas.0811269106; Han GS, 2004, J BIOL CHEM, V279, P53707, DOI 10.1074/jbc.M410014200; Harmon JM, 2013, J BIOL CHEM, V288, P10144, DOI 10.1074/jbc.M113.451526; Harrison PJ, 2018, NAT PROD REP, V35, P921, DOI 10.1039/c8np00019k; Henriques A, 2018, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00433; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Hojjati MR, 2005, BBA-MOL CELL BIOL L, V1737, P44, DOI 10.1016/j.bbalip.2005.08.006; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Kim J, 2019, NEW ENGL J MED, V381, P1644, DOI 10.1056/NEJMoa1813279; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Li SS, 2021, NAT STRUCT MOL BIOL, V28, DOI 10.1038/s41594-020-00553-7; Lone MA, 2020, P NATL ACAD SCI USA, V117, P15591, DOI 10.1073/pnas.2002391117; Lowther J, 2010, MOL BIOSYST, V6, P1682, DOI 10.1039/c003743e; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Miyaoka Y, 2014, NAT METHODS, V11, P291, DOI 10.1038/nmeth.2840; Mohassel P, 2019, ANN CLIN TRANSL NEUR, V6, P1980, DOI 10.1002/acn3.50882; Nicolas G, 2019, ACTA NEUROPATHOL, V137, P183, DOI 10.1007/s00401-018-1939-3; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Penno A, 2010, J BIOL CHEM, V285, P11178, DOI 10.1074/jbc.M109.092973; Rotthier A, 2009, BRAIN, V132, P2699, DOI 10.1093/brain/awp198; Siow DL, 2012, J BIOL CHEM, V287, P40198, DOI 10.1074/jbc.C112.404012; Suh BC, 2014, MOL MED REP, V9, P481, DOI 10.3892/mmr.2013.1808; Suriyanarayanan S, 2019, NEUROMOL MED, V21, P182, DOI 10.1007/s12017-019-08534-w; Swinnen B, 2014, NAT REV NEUROL, V10, P661, DOI 10.1038/nrneurol.2014.184; Wang Guanghu, 2018, Advances in Biological Regulation, V70, P51, DOI 10.1016/j.jbior.2018.09.013; Wang YD, 2021, NAT STRUCT MOL BIOL, V28, DOI 10.1038/s41594-020-00551-9; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Zhao LH, 2015, P NATL ACAD SCI USA, V112, P12962, DOI 10.1073/pnas.1516733112	55	31	31	2	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1197	+		10.1038/s41591-021-01346-1	http://dx.doi.org/10.1038/s41591-021-01346-1		MAY 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34059824	Green Accepted			2022-12-27	WOS:000656411000002
J	Christophers, B; Macedo, B; Nieblas-Bedolla, E; Marr, M; Andersen, OS; Boothroyd, C				Christophers, Briana; Macedo, Briana; Nieblas-Bedolla, Edwin; Marr, Mollie; Andersen, Olaf S.; Boothroyd, Catharine			First-generation physician-scientists are under-represented and need better support	NATURE MEDICINE			English	Editorial Material							DIVERSITY	First-generation students, whose parents do not have baccalaureate degrees, are less likely to apply to MD-PhD programs than to MD programs, which has led to a worrying lack of diversity among physician-scientists.	[Christophers, Briana; Andersen, Olaf S.; Boothroyd, Catharine] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY 10065 USA; [Macedo, Briana] Princeton Univ, Princeton, NJ 08544 USA; [Nieblas-Bedolla, Edwin] Univ Washington, Sch Med, Seattle, WA USA; [Marr, Mollie] Oregon Hlth & Sci Univ, Med Scientist Training Program, Portland, OR 97201 USA	Princeton University; University of Washington; University of Washington Seattle; Oregon Health & Science University	Christophers, B (corresponding author), Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY 10065 USA.	brc4001@med.cornell.edu	Christophers, Briana/AAE-3550-2020	Christophers, Briana/0000-0001-5248-069X; Nieblas-Bedolla, Edwin/0000-0001-5879-1800; Macedo, Briana/0000-0002-8873-699X; Marr, Mollie/0000-0002-7860-5064	Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health [T32GM007739]; National Institute of Mental Health [F30 MH118762]	Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	B.C. (MD-PhD student), B.M. (undergraduate student), E.N.-B. (MD student) and M.M. (MD-PhD student) are all the first in their families to go to medical or graduate school; E.N.-B. was also the first in his family to complete an undergraduate bachelor's degree. B.C. was supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM007739 to the Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program. M.M. was supported by the National Institute of Mental Health under award number F30 MH118762.	Alsan M, 2019, AM ECON REV, V109, P4071, DOI 10.1257/aer.20181446; Association of American Medical Colleges, 2020, MD PHD APPL MD PHD M; Ball R, 2020, PERSPECT MED EDUC, V9, P147, DOI 10.1007/s40037-020-00580-6; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Cleland J., 2018, SELECTION RECRUITMEN, P249; Dewsbury BM, 2019, J MICROBIOL BIOL EDU, V20, DOI 10.1128/jmbe.v20i3.1775; Freeman RB, 2014, NATURE, V513, P305, DOI 10.1038/513305a; Furquim F, 2017, ANN AM ACAD POLIT SS, V671, P69, DOI 10.1177/0002716217698119; Hebert TP, 2018, GIFTED CHILD QUART, V62, P96, DOI 10.1177/0016986217738051; Jain MK, 2019, NEW ENGL J MED, V381, P399, DOI 10.1056/NEJMp1904482; Kirp D.L, 2021, NEW YORK TIMES; Nicholson S, 2017, ADV HEALTH SCI EDUC, V22, P477, DOI 10.1007/s10459-016-9735-0; Patterson ME, 2005, J ENVIRON PSYCHOL, V25, P361, DOI 10.1016/j.jenvp.2005.10.001; Romero R, 2020, ACAD PSYCHIATR, V44, P467, DOI 10.1007/s40596-020-01235-8; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Sarma GP, 2020, NAT MED, V26, P461, DOI 10.1038/s41591-020-0828-1; Schafer AI, 2010, TRANSL RES, V155, P1, DOI 10.1016/j.trsl.2009.09.006; Shalala DE, 2011, SCIENCE, V333, P1836, DOI 10.1126/science.1213786; Swartz TH, 2019, J INFECT DIS, V220, pS33, DOI 10.1093/infdis/jiz174; Nguyen TH, 2018, REV RES EDUC, V42, P146, DOI 10.3102/0091732X18759280; Vogel EK, 2008, CURR DIR PSYCHOL SCI, V17, P171, DOI 10.1111/j.1467-8721.2008.00569.x	21	6	8	1	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					752	755		10.1038/s41591-021-01352-3	http://dx.doi.org/10.1038/s41591-021-01352-3		MAY 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33958798	Bronze, Green Accepted			2022-12-27	WOS:000647954500004
J	Yao, XX; Rushlow, DR; Inselman, JW; McCoy, RG; Thacher, TD; Behnken, EM; Bernard, ME; Rosas, SL; Akfaly, A; Misra, A; Molling, PE; Krien, JS; Foss, RM; Barry, BA; Siontis, KC; Kapa, S; Pellikka, PA; Lopez-Jimenez, F; Attia, ZI; Shah, NID; Friedman, PA; Noseworthy, PA				Yao, Xiaoxi; Rushlow, David R.; Inselman, Jonathan W.; McCoy, Rozalina G.; Thacher, Thomas D.; Behnken, Emma M.; Bernard, Matthew E.; Rosas, Steven L.; Akfaly, Abdulla; Misra, Artika; Molling, Paul E.; Krien, Joseph S.; Foss, Randy M.; Barry, Barbara A.; Siontis, Konstantinos C.; Kapa, Suraj; Pellikka, Patricia A.; Lopez-Jimenez, Francisco; Attia, Zachi I.; Shah, Nilay D.; Friedman, Paul A.; Noseworthy, Peter A.			Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial	NATURE MEDICINE			English	Article							VENTRICULAR SYSTOLIC DYSFUNCTION; BRAIN NATRIURETIC PEPTIDE; HEART-FAILURE; GENERAL-PRACTICE; CARE; ENALAPRIL; COMMUNITY; SURVIVAL	We have conducted a pragmatic clinical trial aimed to assess whether an electrocardiogram (ECG)-based, artificial intelligence (AI)-powered clinical decision support tool enables early diagnosis of low ejection fraction (EF), a condition that is underdiagnosed but treatable. In this trial (), 120 primary care teams from 45 clinics or hospitals were cluster-randomized to either the intervention arm (access to AI results; 181 clinicians) or the control arm (usual care; 177 clinicians). ECGs were obtained as part of routine care from a total of 22,641 adults (N = 11,573 intervention; N = 11,068 control) without prior heart failure. The primary outcome was a new diagnosis of low EF (<= 50%) within 90 days of the ECG. The trial met the prespecified primary endpoint, demonstrating that the intervention increased the diagnosis of low EF in the overall cohort (1.6% in the control arm versus 2.1% in the intervention arm, odds ratio (OR) 1.32 (1.01-1.61), P = 0.007) and among those who were identified as having a high likelihood of low EF (that is, positive AI-ECG, 6% of the overall cohort) (14.5% in the control arm versus 19.5% in the intervention arm, OR 1.43 (1.08-1.91), P = 0.01). In the overall cohort, echocardiogram utilization was similar between the two arms (18.2% control versus 19.2% intervention, P = 0.17); for patients with positive AI-ECGs, more echocardiograms were obtained in the intervention compared to the control arm (38.1% control versus 49.6% intervention, P < 0.001). These results indicate that use of an AI algorithm based on ECGs can enable the early diagnosis of low EF in patients in the setting of routine primary care.	[Yao, Xiaoxi; Inselman, Jonathan W.; McCoy, Rozalina G.; Barry, Barbara A.; Shah, Nilay D.] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN 55905 USA; [Yao, Xiaoxi; Siontis, Konstantinos C.; Kapa, Suraj; Pellikka, Patricia A.; Lopez-Jimenez, Francisco; Attia, Zachi I.; Friedman, Paul A.; Noseworthy, Peter A.] Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA; [Rushlow, David R.; Thacher, Thomas D.; Bernard, Matthew E.] Mayo Clin, Dept Family Med, Rochester, MN USA; [McCoy, Rozalina G.] Mayo Clin, Dept Med, Div Community Internal Med, Rochester, MN USA; [Behnken, Emma M.] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN USA; [Rosas, Steven L.] Mayo Clin Hlth Syst, Dept Family Med, Menomonie, WI USA; [Akfaly, Abdulla] Mayo Clin Hlth Syst, Dept Community Internal Med, Eau Claire, WI USA; [Misra, Artika] Mayo Clin Hlth Syst, Dept Family Med, Mankato, MN USA; [Molling, Paul E.] Mayo Clin Hlth Syst, Dept Family Med, Onalaska, WI USA; [Krien, Joseph S.] Mayo Clin Hlth Syst, Dept Family Med, La Crosse, WI USA; [Foss, Randy M.] Mayo Clin Hlth Syst, Dept Family Med, Lake City, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Yao, XX (corresponding author), Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN 55905 USA.; Yao, XX (corresponding author), Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA.	yao.xiaoxi@mayo.edu	Pellikka, Patricia A/N-5387-2014	Pellikka, Patricia A/0000-0001-6800-3521; Thacher, Tom/0000-0002-7644-8173; Yao, Xiaoxi/0000-0001-9906-7106; Kapa, Suraj/0000-0003-2283-4340				Attia ZI, 2019, J CARDIOVASC ELECTR, V30, P668, DOI 10.1111/jce.13889; Attia ZI, 2019, NAT MED, V25, P70, DOI 10.1038/s41591-018-0240-2; Davie AP, 1996, BRIT MED J, V312, P222; Goetze JP, 2006, EUR HEART J, V27, P3004, DOI 10.1093/eurheartj/ehl406; Hetmanski DJ, 2000, HEART, V84, P440, DOI 10.1136/heart.84.4.440; Jong P, 2003, LANCET, V361, P1843, DOI 10.1016/S0140-6736(03)13501-5; Kaggal VC, 2016, BIOMED INFORM INSIGH, V8, P13, DOI 10.4137/BII.S37977; Landray MJ, 2000, BRIT MED J, V320, P985, DOI 10.1136/bmj.320.7240.985; Liu XX, 2020, NAT MED, V26, P1364, DOI 10.1038/s41591-020-1034-x; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; McDonagh Theresa A, 2008, Congest Heart Fail, V14, P5; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; Nielsen OW, 2000, BRIT MED J, V320, P220, DOI 10.1136/bmj.320.7229.220; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Redfield MM, 2004, CIRCULATION, V109, P3176, DOI 10.1161/01.CIR.0000130845.38133.8F; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; Simon GE, 2020, NEW ENGL J MED, V382, P1488, DOI 10.1056/NEJMp1915448; Wang TJ, 2003, CIRCULATION, V108, P977, DOI 10.1161/01.CIR.0000085166.44904.79; Wang TJ, 2003, ANN INTERN MED, V138, P907, DOI 10.7326/0003-4819-138-11-200306030-00012; Wen A, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0208-8; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Yao X, 2020, DATA BRIEF, V28, DOI 10.1016/j.dib.2019.104894; Yao XX, 2020, AM HEART J, V219, P31, DOI 10.1016/j.ahj.2019.10.007; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	24	42	41	3	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					815	+		10.1038/s41591-021-01335-4	http://dx.doi.org/10.1038/s41591-021-01335-4		MAY 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33958795				2022-12-27	WOS:000647954500007
J	Muriuki, JM; Mentzer, AJ; Mitchell, R; Webb, EL; Etyang, AO; Kyobutungi, C; Morovat, A; Kimita, W; Ndungu, FM; Macharia, AW; Ngetsa, CJ; Makale, J; Lule, SA; Musani, SK; Raffield, LM; Cutland, CL; Sirima, SB; Diarra, A; Tiono, AB; Fried, M; Gwamaka, M; Adu-Afarwuah, S; Wirth, JP; Wegmuller, R; Madhi, SA; Snow, RW; Hill, AVS; Rockett, KA; Sandhu, MS; Kwiatkowski, DP; Prentice, AM; Byrd, KA; Ndjebayi, A; Stewart, CP; Engle-Stone, R; Green, TJ; Karakochuk, CD; Suchdev, PS; Bejon, P; Duffy, PE; Smith, GD; Elliott, AM; Williams, TN; Atkinson, SH				Muriuki, John Muthii; Mentzer, Alexander J.; Mitchell, Ruth; Webb, Emily L.; Etyang, Anthony O.; Kyobutungi, Catherine; Morovat, Alireza; Kimita, Wandia; Ndungu, Francis M.; Macharia, Alex W.; Ngetsa, Caroline J.; Makale, Johnstone; Lule, Swaib A.; Musani, Solomon K.; Raffield, Laura M.; Cutland, Clare L.; Sirima, Sodiomon B.; Diarra, Amidou; Tiono, Alfred B.; Fried, Michal; Gwamaka, Moses; Adu-Afarwuah, Seth; Wirth, James P.; Wegmueller, Rita; Madhi, Shabir A.; Snow, Robert W.; Hill, Adrian V. S.; Rockett, Kirk A.; Sandhu, Manjinder S.; Kwiatkowski, Dominic P.; Prentice, Andrew M.; Byrd, Kendra A.; Ndjebayi, Alex; Stewart, Christine P.; Engle-Stone, Reina; Green, Tim J.; Karakochuk, Crystal D.; Suchdev, Parminder S.; Bejon, Philip; Duffy, Patrick E.; Davey Smith, George; Elliott, Alison M.; Williams, Thomas N.; Atkinson, Sarah H.			Malaria is a cause of iron deficiency in African children	NATURE MEDICINE			English	Article							BIOMARKERS REFLECTING INFLAMMATION; SOLUBLE TRANSFERRIN RECEPTOR; SICKLE-CELL; PLASMODIUM-FALCIPARUM; NUTRITIONAL DETERMINANTS; HEPCIDIN; ANEMIA; FERRITIN; PREVALENCE; CHILDHOOD	Malaria and iron deficiency (ID) are common and interrelated public health problems in African children. Observational data suggest that interrupting malaria transmission reduces the prevalence of ID1. To test the hypothesis that malaria might cause ID, we used sickle cell trait (HbAS, rs334), a genetic variant that confers specific protection against malaria(2), as an instrumental variable in Mendelian randomization analyses. HbAS was associated with a 30% reduction in ID among children living in malaria-endemic countries in Africa (n = 7,453), but not among individuals living in malaria-free areas (n = 3,818). Genetically predicted malaria risk was associated with an odds ratio of 2.65 for ID per unit increase in the log incidence rate of malaria. This suggests that an intervention that halves the risk of malaria episodes would reduce the prevalence of ID in African children by 49%.	[Muriuki, John Muthii; Etyang, Anthony O.; Kimita, Wandia; Ndungu, Francis M.; Macharia, Alex W.; Ngetsa, Caroline J.; Makale, Johnstone; Snow, Robert W.; Bejon, Philip; Williams, Thomas N.; Atkinson, Sarah H.] KEMRI Wellcome Trust Res Programme, Kenya Med Res Inst KEMRI, Ctr Geog Med Res, Coast, Kilifi, Kenya; [Muriuki, John Muthii] Open Univ, Accredited Res Ctr, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Mentzer, Alexander J.; Hill, Adrian V. S.; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford, England; [Mentzer, Alexander J.; Kwiatkowski, Dominic P.] Univ Oxford, Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, England; [Mitchell, Ruth; Davey Smith, George] Univ Bristol, Med Res Council MRC, Integrat Epidemiol Unit, Populat Hlth Sci,Bristol Med Sch, Bristol, Avon, England; [Webb, Emily L.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, MRC Trop Epidemiol Grp, London, England; [Kyobutungi, Catherine] African Populat & Hlth Res Ctr, Nairobi, Kenya; [Morovat, Alireza] Oxford Univ Hosp, Dept Clin Biochem, Oxford, England; [Lule, Swaib A.; Elliott, Alison M.] MRC Uganda Virus Res Inst, Entebbe, Uganda; [Lule, Swaib A.; Elliott, Alison M.] London Sch Hyg & Trop Med, Uganda Res Unit, Entebbe, Uganda; [Musani, Solomon K.] Univ Mississippi, Dept Med, Med Ctr, Jackson, MS USA; [Raffield, Laura M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Cutland, Clare L.; Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, South African Med Res Council, Vaccines & Infect Dis Analyt Res Unit, Johannesburg, South Africa; [Sirima, Sodiomon B.; Diarra, Amidou; Tiono, Alfred B.] Grp Rech Act Sante, 06 BP 10248, Ouagadougou, Burkina Faso; [Fried, Michal; Duffy, Patrick E.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, Bethesda, MD USA; [Gwamaka, Moses] Seattle Biomed Res Inst, Mother Offspring Malaria Studies MOMS Project, 4 Nickerson St, Seattle, WA 98109 USA; [Gwamaka, Moses] Muheza Designated Dist Hosp, Muheza, Tanzania; [Gwamaka, Moses] Univ Dar Es Salaam, Mbeya Coll Hlth & Allied Sci, Mbeya, Tanzania; [Adu-Afarwuah, Seth] Univ Ghana, Dept Nutr & Food Sci, Legon, Ghana; [Wirth, James P.; Wegmueller, Rita] GroundWork, Flasch, Switzerland; [Snow, Robert W.; Bejon, Philip; Williams, Thomas N.; Atkinson, Sarah H.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Hill, Adrian V. S.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England; [Hill, Adrian V. S.] Univ Oxford, Jenner Inst Labs, Oxford, England; [Rockett, Kirk A.; Sandhu, Manjinder S.; Kwiatkowski, Dominic P.] Wellcome Sanger Inst, Hinxton, England; [Prentice, Andrew M.] London Sch Hyg & Trop Med, Gambia, MRC Unit, Banjul, Gambia; [Byrd, Kendra A.] WorldFish, Bayan Lepas, Malaysia; [Ndjebayi, Alex] Helen Keller Int, Yaounde, Cameroon; [Stewart, Christine P.; Engle-Stone, Reina] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Green, Tim J.] South Australian Hlth & Med Res Inst, SAHMRi Women & Kids, Adelaide, SA, Australia; [Green, Tim J.] Univ Adelaide, Sch Med, Adelaide, SA, Australia; [Karakochuk, Crystal D.] Univ British Columbia, Food Nutr & Hlth, Vancouver, BC, Canada; [Suchdev, Parminder S.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Suchdev, Parminder S.] Emory Global Hlth Inst, Atlanta, GA USA; [Elliott, Alison M.] London Sch Hyg & Trop Med, Dept Clin Res, London, England; [Williams, Thomas N.] Imperial Coll, Dept Infect Dis, London, England; [Williams, Thomas N.] Imperial Coll, Inst Global Hlth Innovat, London, England; [Atkinson, Sarah H.] Univ Oxford, Dept Paediat, Oxford, England	Kenya Medical Research Institute; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Bristol; University of London; London School of Hygiene & Tropical Medicine; African Population & Health Research Centre; University of Mississippi; University of Mississippi Medical Center; University of North Carolina; University of North Carolina Chapel Hill; South African Medical Research Council; University of Witwatersrand; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Center for Infectious Disease Research; University of Dar es Salaam; University of Ghana; University of Oxford; University of Oxford; University of Oxford; Wellcome Trust Sanger Institute; University of London; London School of Hygiene & Tropical Medicine; CGIAR; Worldfish; University of California System; University of California Davis; South Australian Health & Medical Research Institute (SAHMRI); University of Adelaide; University of British Columbia; Emory University; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Imperial College London; University of Oxford	Muriuki, JM; Atkinson, SH (corresponding author), KEMRI Wellcome Trust Res Programme, Kenya Med Res Inst KEMRI, Ctr Geog Med Res, Coast, Kilifi, Kenya.; Muriuki, JM (corresponding author), Open Univ, Accredited Res Ctr, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.; Atkinson, SH (corresponding author), Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England.; Atkinson, SH (corresponding author), Univ Oxford, Dept Paediat, Oxford, England.	jmuriuki@kemri-wellcome.org; satkinson@kemri-wellcome.org	Green, Tim/AAA-8601-2019; Davey Smith, George/A-7407-2013; Snow, Robert William/AFR-1436-2022; Adu-Afarwuah, Seth/GWZ-2033-2022; Cutland, Clare L./GXE-9967-2022; Ndungu, Francis/C-2199-2019	Green, Tim/0000-0002-0667-4300; Davey Smith, George/0000-0002-1407-8314; Snow, Robert William/0000-0003-3725-6088; Cutland, Clare L./0000-0001-8250-8307; Tiono, B. Alfred/0000-0002-5104-3946; Raffield, Laura/0000-0002-7892-193X; Madhi, Shabir/0000-0002-7629-0636; Mentzer, Alexander/0000-0002-4502-2209; Lule, Swaib/0000-0002-6271-2033; Ndungu, Francis/0000-0002-8977-0030; Muriuki, John Muthii/0000-0003-4369-9547; Suchdev, Parmi/0000-0002-0350-3469; Atkinson, Sarah/0000-0002-8360-4402; Adu-Afarwuah, Seth/0000-0002-2720-5474; Elliott, Alison/0000-0003-2818-9549	Wellcome [107769]; Wellcome Centre for Human Genetics [090532, 203141]; Wellcome Sanger Institute [098051, 206194]; Oxford University Clinical Academic School Transitional Fellowship - Wellcome Trust Principal Fellowship [103602, 212176]; DELTAS Africa Initiative [DEL-15-003]; African Academy of Sciences' Alliance for Accelerating Excellence in Science in Africa; New Partnership for Africa's Development Planning and Coordinating (NEPAD) Agency; UK government; MRC IEU [MC_UU_00011/1]; UNICEF; Canada's Ministry of Foreign Affairs, Trade and Development [43210308]; Irish Aid; World Bank; Centers for Disease Control and Prevention and Emory University; Thrasher Research Fund [12144, T32 HL129982]; Bill & Melinda Gates Foundation [OPPGD759]; US Agency for International Development [AID-OAA-F-13-00040]; National Institutes of Health Research Training [R25 TW009343]; Fogarty International Center; University of California Global Health Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health [AI52059]; Intramural Research Program of the NIAID; Sight; UK MRC [U1232661351, U105960371, MC-A760-5QX00]; DFID under the MRC/DFID Concordat [HHSN268201800013I]; Tougaloo College [HHSN268201800014I]; Mississippi State Department of Health [HHSN268201800015I]; University of Mississippi Medical Center [HHSN268201800010I, HHSN268201800011I, HHSN268201800012I]; National Heart, Lung, and Blood Institute (NHLBI); National Institute on Minority Health and Health Disparities; NHLBI [HHSN268201100037C, 3R01HL-117626-02S1, HHSN268201800002I, 3R01HL-120393-02S1, HHSN268201800001I]; MRC [MR/M006212/1, MC_PC_MR/R020183/1, MC_U123292699, MC_UU_00026/3, MC_UU_00027/5] Funding Source: UKRI	Wellcome; Wellcome Centre for Human Genetics; Wellcome Sanger Institute; Oxford University Clinical Academic School Transitional Fellowship - Wellcome Trust Principal Fellowship; DELTAS Africa Initiative; African Academy of Sciences' Alliance for Accelerating Excellence in Science in Africa; New Partnership for Africa's Development Planning and Coordinating (NEPAD) Agency; UK government; MRC IEU(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UNICEF; Canada's Ministry of Foreign Affairs, Trade and Development; Irish Aid(CGIAR); World Bank(The World Bank India); Centers for Disease Control and Prevention and Emory University(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Thrasher Research Fund; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); US Agency for International Development(United States Agency for International Development (USAID)); National Institutes of Health Research Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); University of California Global Health Institute; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Sight; UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DFID under the MRC/DFID Concordat(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tougaloo College; Mississippi State Department of Health; University of Mississippi Medical Center; National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank all study participants who contributed to this study and staff involved with consent, sample and data collection and preparation. This work was funded by Wellcome (grant nos. (110255 to S.H.A.), (202800 to T.N.W.), (103951 to A.O.E.), (106289 to A.J.M.) and (064693, 079110, 095778 to A.M.E.)) and by core awards to the KEMRI-Wellcome Trust Research Programme (203077), the Wellcome Centre for Human Genetics (090532, 203141) and the Wellcome Sanger Institute (098051, 206194). A.J.M. was also supported by an Oxford University Clinical Academic School Transitional Fellowship. R.W.S. is funded by a Wellcome Trust Principal Fellowship (nos. 103602 and 212176). J.M.M. was supported through the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences' Alliance for Accelerating Excellence in Science in Africa and is supported by the New Partnership for Africa's Development Planning and Coordinating (NEPAD) Agency with funding from Wellcome (107769) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of the African Academy of Sciences, the NEPAD Agency, Wellcome or the UK government. G.D.S. and R.M. are supported by the MRC IEU (grant code, MC_UU_00011/1). Funding for the conduct of the micronutrient survey in Ghana was provided by the UNICEF and Canada's Ministry of Foreign Affairs, Trade and Development through an agreement between the UNICEF Ghana and the University of Ghana (43210308). The overall Malawi Demographic Health Survey was funded by Irish Aid, the World Bank and the UNICEF with technical assistance from the Centers for Disease Control and Prevention and Emory University. The Western Kenya study was supported by the Thrasher Research Fund (award no. 11860), the Bill & Melinda Gates Foundation (OPPGD759) and the US Agency for International Development (AID-OAA-F-13-00040), and K.A.B. was supported by a National Institutes of Health Research Training grant R25 TW009343, funded by the Fogarty International Center and the University of California Global Health Institute. The MOMS Project in Muheza, Tanzania was supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (grant AI52059), and M.F. and P.E.D. are supported by the Intramural Research Program of the NIAID. The Cameroon study received support from Sight and Life and from the Thrasher Research Fund (award 12144). L.M.R. was supported by T32 HL129982. The Gambian work was supported by the UK MRC (U1232661351, U105960371 and MC-A760-5QX00) and DFID under the MRC/DFID Concordat. The JHS is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities. We also wish to thank the staff and participants of the JHS. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. Whole-genome sequencing for the Trans-Omics in Precision Medicine (TOPMed) program was supported by NHLBI.; Whole-genome sequencing for 'NHLBI TOPMed: The Jackson Heart Study' (phs000964) was performed at the University of Washington Northwest Genomics Center (HHSN268201100037C). Centralized read mapping and genotype calling along with variant quality metrics and filtering were performed by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sample identity quality control and general study coordination were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.	Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172; Atkinson SH, 2015, EBIOMEDICINE, V2, P1478, DOI 10.1016/j.ebiom.2015.08.016; Atkinson SH, 2014, BLOOD, V123, P3221, DOI 10.1182/blood-2013-10-533000; Band G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13480-z; Barker MK, 2017, J NUTR, V147, P1785, DOI 10.3945/jn.117.252635; Beguy D, 2015, INT J EPIDEMIOL, V44, P462, DOI 10.1093/ije/dyu251; Bejon P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000304; Burgess S, 2018, EUR J EPIDEMIOL, V33, P947, DOI 10.1007/s10654-018-0424-6; Byrd KA, 2018, J NUTR, V148, P1903, DOI 10.1093/jn/nxy229; Camaschella C, 2015, NEW ENGL J MED, V372, P1832, DOI 10.1056/NEJMra1401038; Cercamondi CI, 2010, AM J CLIN NUTR, V92, P1385, DOI 10.3945/ajcn.2010.30051; Chen L, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050052; Chong SS, 2000, BLOOD, V95, P360; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; de Mast Q, 2009, J INFECT DIS, V199, P253, DOI 10.1086/595790; Doherty CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002133; Engle-Stone R, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070693; Erhardt JG, 2004, J NUTR, V134, P3127, DOI 10.1093/jn/134.11.3127; Etyang AO, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011771; Etyang AO, 2018, AM J EPIDEMIOL, V187, P199, DOI 10.1093/aje/kwx232; Evans DM, 2015, ANNU REV GENOM HUM G, V16, P327, DOI 10.1146/annurev-genom-090314-050016; Feelders RA, 1998, EUR J CLIN INVEST, V28, P520; FOY H, 1954, BMJ-BRIT MED J, V1, P294, DOI 10.1136/bmj.1.4857.294; Frosch AEP, 2014, AM J CLIN NUTR, V100, P968, DOI 10.3945/ajcn.114.087114; Glinz D, 2015, AM J CLIN NUTR, V101, P462, DOI 10.3945/ajcn.114.090175; Gwamaka M, 2012, CLIN INFECT DIS, V54, P1137, DOI 10.1093/cid/cis010; Kassebaum NJ, 2016, HEMATOL ONCOL CLIN N, V30, P247, DOI 10.1016/j.hoc.2015.11.002; Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journal.pmed.0020340; McCann JC, 2007, AM J CLIN NUTR, V85, P931, DOI 10.1093/ajcn/85.4.931; McGann PT, 2018, BLOOD ADV, V2, P3035, DOI 10.1182/bloodadvances.2018023069; Mudhune SA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-138; Muriuki JM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-1502-7; Muriuki JM, 2019, SCI ADV, V5, DOI [10.1126/sciadv.aaw0109, 10.112]; Muriuki JM, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040096; Muriuki JM, 2019, CLIN INFECT DIS, V68, P1807, DOI 10.1093/cid/ciy791; Namaste SML, 2017, AM J CLIN NUTR, V106, p359S, DOI 10.3945/ajcn.116.141762; Namaste SML, 2017, AM J CLIN NUTR, V106, p333S, DOI 10.3945/ajcn.116.142273; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nunes MC, 2016, JAMA PEDIATR, V170, P840, DOI 10.1001/jamapediatrics.2016.0921; Paganini D, 2017, AM J CLIN NUTR, V106, p1688S, DOI 10.3945/ajcn.117.156067; Pasricha SR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008249; Peloso GM, 2016, CIRC-CARDIOVASC GENE, V9, P368, DOI 10.1161/CIRCGENETICS.116.001410; Prentice AM, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9020; Prentice AM, 2012, BLOOD, V119, P1922, DOI 10.1182/blood-2011-11-391219; Rautanen A, 2016, AM J HUM GENET, V98, P1092, DOI 10.1016/j.ajhg.2016.03.025; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Snow RW, 2017, NATURE, V550, P515, DOI 10.1038/nature24059; Spiller W, 2019, INT J EPIDEMIOL, V48, P684, DOI 10.1093/ije/dyy195; Spiller W, 2019, INT J EPIDEMIOL, V48, P702, DOI 10.1093/ije/dyy204; Taylor HA, 2005, ETHNIC DIS, V15, pS1; Taylor SM, 2012, LANCET INFECT DIS, V12, P457, DOI 10.1016/S1473-3099(12)70055-5; Tiono AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208328; Uyoga S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08775-0; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Waterfall CM, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.23.e119; Webb EL, 2011, LANCET, V377, P52, DOI 10.1016/S0140-6736(10)61457-2; Wegmuller R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228258; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2011, SER FERR CONC ASS IR; WHO, 2006, WHO CHILD GROWTH STA; Williams TN, 2005, NAT GENET, V37, P1253, DOI 10.1038/ng1660; Wilson JG, 2005, ETHNIC DIS, V15, pS30; World Health Organization, 2001, IR DEF AN ASS PREV C; Wray K, 2017, AM J HEMATOL, V92, P196, DOI 10.1002/ajh.24617	64	14	14	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01238-4	http://dx.doi.org/10.1038/s41591-021-01238-4		FEB 2021	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33619371	Green Submitted, Green Accepted			2022-12-27	WOS:000620458400003
J	Rasmussen, AL				Rasmussen, Angela L.			On the origins of SARS-CoV-2	NATURE MEDICINE			English	Editorial Material								Stakeholders in public health must lobby policy makers to make decisions based on evidence, not political expediency, particularly when the studies that hang in the balance are critical to understanding the origins of epidemics.	[Rasmussen, Angela L.] Georgetown Univ, Ctr Global Hlth Sci & Secur, Washington, DC 20057 USA	Georgetown University	Rasmussen, AL (corresponding author), Georgetown Univ, Ctr Global Hlth Sci & Secur, Washington, DC 20057 USA.	ar1692@georgetown.edu		Rasmussen, Angela/0000-0001-9462-3169					0	22	23	1	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					9	9		10.1038/s41591-020-01205-5	http://dx.doi.org/10.1038/s41591-020-01205-5			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442004	Bronze			2022-12-27	WOS:000607931400007
J	Stower, H				Stower, Hannah			Transparency in medical AI	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	1	1	1	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1804	1804		10.1038/s41591-020-01147-y	http://dx.doi.org/10.1038/s41591-020-01147-y			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288929				2022-12-27	WOS:000596579200002
J	Stower, H				Stower, Hannah			ONCE-A-WEEK INSULIN Metabolism	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1805	1805		10.1038/s41591-020-01153-0	http://dx.doi.org/10.1038/s41591-020-01153-0			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288925				2022-12-27	WOS:000596579200008
J	Lee, KA; Thomas, AM; Bolte, LA; Bjork, JR; de Ruijter, LK; Armanini, F; Asnicar, F; Blanco-Miguez, A; Board, R; Calbet-Llopart, N; Derosa, L; Dhomen, N; Brooks, K; Harland, M; Harries, M; Leeming, ER; Lorigan, P; Manghi, P; Marais, R; Newton-Bishop, J; Nezi, L; Pinto, F; Potrony, M; Puig, S; Serra-Bellver, P; Shaw, HM; Tamburini, S; Valpione, S; Vijay, A; Waldron, L; Zitvogel, L; Zolfo, M; de Vries, EGE; Nathan, P; Fehrmann, RSN; Bataille, V; Hospers, GAP; Spector, TD; Weersma, RK; Segata, N				Lee, Karla A.; Thomas, Andrew Maltez; Bolte, Laura A.; Bjork, Johannes R.; de Ruijter, Laura Kist; Armanini, Federica; Asnicar, Francesco; Blanco-Miguez, Aitor; Board, Ruth; Calbet-Llopart, Neus; Derosa, Lisa; Dhomen, Nathalie; Brooks, Kelly; Harland, Mark; Harries, Mark; Leeming, Emily R.; Lorigan, Paul; Manghi, Paolo; Marais, Richard; Newton-Bishop, Julia; Nezi, Luigi; Pinto, Federica; Potrony, Miriam; Puig, Susana; Serra-Bellver, Patricio; Shaw, Heather M.; Tamburini, Sabrina; Valpione, Sara; Vijay, Amrita; Waldron, Levi; Zitvogel, Laurence; Zolfo, Moreno; de Vries, Elisabeth G. E.; Nathan, Paul; Fehrmann, Rudolf S. N.; Bataille, Veronique; Hospers, Geke A. P.; Spector, Tim D.; Weersma, Rinse K.; Segata, Nicola			Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma	NATURE MEDICINE			English	Article							SHOTGUN METAGENOMICS; RESOURCE; EFFICACY; GENE; DIET	An analysis of metagenomic sequencing of stool samples from multiple cohorts of patients with melanoma treated with immune checkpoint blockade uncovers microbiome correlates of response to therapy and also reveals widespread variability across populations. The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs. We performed shotgun metagenomic sequencing of stool samples collected before ICI initiation from five observational cohorts recruiting ICI-naive patients with advanced cutaneous melanoma (n = 165). Integrating the dataset with 147 metagenomic samples from previously published studies, we found that the gut microbiome has a relevant, but cohort-dependent, association with the response to ICIs. A machine learning analysis confirmed the link between the microbiome and overall response rates (ORRs) and progression-free survival (PFS) with ICIs but also revealed limited reproducibility of microbiome-based signatures across cohorts. Accordingly, a panel of species, including Bifidobacterium pseudocatenulatum, Roseburia spp. and Akkermansia muciniphila, associated with responders was identified, but no single species could be regarded as a fully consistent biomarker across studies. Overall, the role of the human gut microbiome in ICI response appears more complex than previously thought, extending beyond differing microbial species simply present or absent in responders and nonresponders. Future studies should adopt larger sample sizes and take into account the complex interplay of clinical factors with the gut microbiome over the treatment course.	[Lee, Karla A.; Leeming, Emily R.; Vijay, Amrita; Bataille, Veronique; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England; [Thomas, Andrew Maltez; Armanini, Federica; Asnicar, Francesco; Blanco-Miguez, Aitor; Manghi, Paolo; Pinto, Federica; Waldron, Levi; Zolfo, Moreno; Segata, Nicola] Univ Trento, Dept CIBIO, Trento, Italy; [Bolte, Laura A.; Bjork, Johannes R.; Weersma, Rinse K.] Univ Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands; [Bolte, Laura A.; Bjork, Johannes R.; de Ruijter, Laura Kist; de Vries, Elisabeth G. E.; Fehrmann, Rudolf S. N.; Hospers, Geke A. P.; Weersma, Rinse K.] Univ Med Ctr Groningen, Groningen, Netherlands; [de Ruijter, Laura Kist; de Vries, Elisabeth G. E.; Fehrmann, Rudolf S. N.; Hospers, Geke A. P.] Univ Groningen, Dept Med Oncol, Groningen, Netherlands; [Board, Ruth] Lancashire Teaching Hosp NHS Trust, Dept Oncol, Preston, Lancs, England; [Calbet-Llopart, Neus] Univ Barcelona, Hosp Clin Barcelona, Dermatol Dept, IDIBAPS, Barcelona, Spain; [Calbet-Llopart, Neus; Potrony, Miriam; Puig, Susana] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain; [Derosa, Lisa; Zitvogel, Laurence] Univ Paris Saclay, Gustave Roussy Canc Ctr, U1015 INSERM, Groningen, Netherlands; [Derosa, Lisa; Zitvogel, Laurence] Oncobiome Network, Villejuif, France; [Dhomen, Nathalie; Brooks, Kelly; Marais, Richard; Valpione, Sara] Univ Manchester, CRUK Manchester Inst, Mol Oncol Grp, Manchester, Lancs, England; [Harland, Mark; Newton-Bishop, Julia] Univ Leeds, Inst Med Res St Jamess, Div Haematol & Immunol, Leeds, W Yorkshire, England; [Harries, Mark; Potrony, Miriam; Puig, Susana; Nathan, Paul] Hosp Clin Barcelona, Biochem & Mol Genet Dept, IDIBAPS, Barcelona, Spain; [Harries, Mark; Potrony, Miriam; Puig, Susana; Nathan, Paul] Univ Barcelona, Barcelona, Spain; [Harries, Mark] Guys & St Thomass NHS Trust, Guys Canc Ctr, Dept Med Oncol, London, England; [Lorigan, Paul; Serra-Bellver, Patricio; Valpione, Sara] Christie NHS Fdn Trust, Manchester, Lancs, England; [Lorigan, Paul] Univ Manchester, Div Canc Sci, Manchester, Lancs, England; [Nezi, Luigi; Tamburini, Sabrina; Segata, Nicola] IRCSS, European Inst Oncol, Milan, Italy; [Shaw, Heather M.] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England; [Vijay, Amrita] Univ Nottingham, Sch Med, Rheumatol & Orthopaed Div, Nottingham, England; [Waldron, Levi] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA; [Bataille, Veronique] Mt Vernon Canc Ctr, Dept Dermatol, Northwood, Middx, England	University of London; King's College London; University of Trento; University of Groningen; University of Groningen; University of Groningen; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; University of Manchester; University of Leeds; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Christie NHS Foundation Trust; University of Manchester; IRCCS European Institute of Oncology (IEO); Mount Vernon Cancer Centre; University of Nottingham; City University of New York (CUNY) System; Mount Vernon Cancer Centre	Spector, TD (corresponding author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.; Segata, N (corresponding author), Univ Trento, Dept CIBIO, Trento, Italy.; Weersma, RK (corresponding author), Univ Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands.; Weersma, RK (corresponding author), Univ Med Ctr Groningen, Groningen, Netherlands.; Segata, N (corresponding author), IRCSS, European Inst Oncol, Milan, Italy.	tim.spector@kcl.ac.uk; r.k.weersma@umcg.nl; nicola.segata@unitn.it	Shaw, Heather/GQA-5799-2022; Asnicar, Francesco/AAB-9255-2020; Potrony, Miriam/C-6008-2018; DEROSA, LISA/E-6814-2015; Blanco-Miguez, Aitor/H-3628-2017; Lorigan, Paul/J-6898-2015; Zolfo, Moreno/Q-4368-2016; Fehrmann, Rudolf/E-2551-2011	Asnicar, Francesco/0000-0003-3732-1468; Potrony, Miriam/0000-0003-2766-0765; Newton-Bishop, Julia/0000-0001-9147-6802; Blanco-Miguez, Aitor/0000-0001-7386-5572; Bolte, Laura/0000-0001-6036-0831; Tamburini, Sabrina/0000-0002-2485-7418; Nathan, Paul/0000-0002-2327-3250; Puig, Susana/0000-0003-1337-9745; Vijay, Amrita/0000-0002-9595-5680; ZITVOGEL, laurence/0000-0003-1596-0998; Lorigan, Paul/0000-0002-8875-2164; Derosa, Lisa/0000-0003-0527-2964; Zolfo, Moreno/0000-0001-6661-4046; Nezi, Luigi/0000-0002-4670-7656; Fehrmann, Rudolf/0000-0002-7516-315X	Seerave Foundation; European Research Council (ERC-STG project MetaPG); MIUR 'Futuro in Ricerca' [RBFR13EWWI_001]; European H2020 program [ONCOBIOME-825410, MASTER-818368]; National Cancer Institute of the National Institutes of Health [1U01CA230551]; Premio Internazionale Lombardia e Ricerca 2019; Spanish Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III, Spain [PI15/00716, PI15/00956]; European Development Regional Fund "A way to achieve Europe"; Wellcome Trust [100282/Z/12/Z]; Cancer Research UK [A27412, A22902]; Dutch Cancer Society [10034 POINTING]; Ministerio de Educacion, Cultura y Deportes, Spain [FPU17/05453]; Medical Research Council [MR/MO19012/1]; Harry J. Lloyd Charitable Trust Career Development Award; Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain [PI15/00716]	Seerave Foundation; European Research Council (ERC-STG project MetaPG); MIUR 'Futuro in Ricerca'(Ministry of Education, Universities and Research (MIUR)); European H2020 program; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Premio Internazionale Lombardia e Ricerca 2019; Spanish Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III, Spain; European Development Regional Fund "A way to achieve Europe"; Wellcome Trust(Wellcome Trust); Cancer Research UK(Cancer Research UK); Dutch Cancer Society(KWF Kankerbestrijding); Ministerio de Educacion, Cultura y Deportes, Spain(Spanish Government); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Harry J. Lloyd Charitable Trust Career Development Award; Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain(Instituto de Salud Carlos III)	This work was supported by the Seerave Foundation. The work was also supported by the European Research Council (ERC-STG project MetaPG to N.S.); MIUR 'Futuro in Ricerca' (grant RBFR13EWWI_001 to N.S.); the European H2020 program (ONCOBIOME-825410 project and MASTER-818368 project to N.S.); the National Cancer Institute of the National Institutes of Health (grant 1U01CA230551 to N.S. and L.W.); the Premio Internazionale Lombardia e Ricerca 2019 (to N.S.); Spanish Fondo de Investigaciones Sanitarias (grants PI15/00716 and PI15/00956) of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund "A way to achieve Europe" to ERDF; the Wellcome Trust (grant 100282/Z/12/Z to N.C.-L.); Cancer Research UK (grants A27412 and A22902 to N.C.); and the Dutch Cancer Society (grant 10034 POINTING to E.G.E.d.V.). N.C.-L. is the recipient of a PhD fellowship (FPU17/05453) from Ministerio de Educacion, Cultura y Deportes, Spain. The Leeds group was supported by the Medical Research Council (grant MR/MO19012/1). S.V. was supported by a Harry J. Lloyd Charitable Trust Career Development Award. We acknowledge the Seerave Foundation, which funded this work and many other projects investigating the gut microbiome in human health and disease. We thank the team of the NGS Core Facility at University of Trento for support in sample preparation and for metagenomic sequencing and the high-performance computing team at the University of Trento. We also thank Oncobiome and the Institut Gustave Roussy for their involvement and support of our initiative. The collection of samples from the Hospital Clinic in Barcelona was funded by grant PI15/00716 from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain. We would like to thank Ranko Gacesa and the authors of the WindTT_2020 study for kindly providing metagenomic data and metadata for their cohort. Lastly, we would like to thank all the patients who selflessly took the time to collect samples for this project.	AITCHISON J, 1980, BIOMETRIKA, V67, P261, DOI 10.2307/2335470; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Artimo Panu, 2012, Nucleic Acids Res, V40, pW597, DOI 10.1093/nar/gks400; Ascierto PA, 2019, JAMA ONCOL, V5, P187, DOI 10.1001/jamaoncol.2018.4514; Asnicar F, 2021, NAT MED, V27, P321, DOI 10.1038/s41591-020-01183-8; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Beghini F, 2017, ISME J, V11, P2848, DOI 10.1038/ismej.2017.139; Bingham SA, 1997, INT J EPIDEMIOL, V26, pS137, DOI 10.1093/ije/26.suppl_1.S137; Bingham SA, 2001, PUBLIC HEALTH NUTR, V4, P847, DOI 10.1079/PHN2000102; Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207; Calgaro M, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02104-1; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Truong DT, 2017, GENOME RES, V27, P626, DOI 10.1101/gr.216242.116; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Hall AB, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0490-5; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Karcher N, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02042-y; Kettunen J, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.118.002234; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Limeta A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140940; LIN H, 2020, NAT COMMUN, V11; Llorente C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00796-x; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Macke L, 2020, ALIMENT PHARM THER, V51, P505, DOI 10.1111/apt.15604; Mallick H, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009442; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McIver LJ, 2018, BIOINFORMATICS, V34, P1235, DOI 10.1093/bioinformatics/btx754; McQuade JL, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00913-y; Morton JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10656-5; Ni YH, 2017, GASTROENTEROLOGY, V152, pS214, DOI 10.1016/S0016-5085(17)31017-X; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Pasolli E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004977; Peters BA, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0672-4; Quince C, 2017, NAT BIOTECHNOL, V35, P833, DOI 10.1038/nbt.3935; Risso D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02554-5; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Roux D, 2015, J BIOL CHEM, V290, P19261, DOI 10.1074/jbc.M115.648709; Satija A, 2017, J AM COLL CARDIOL, V70, P411, DOI 10.1016/j.jacc.2017.05.047; Silverman Justin D, 2019, FIDO MULTINOMIAL LOG; Thomas AM, 2019, NAT MED, V25, P667, DOI 10.1038/s41591-019-0405-7; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Troge A, 2012, INT J MED MICROBIOL, V302, P304, DOI 10.1016/j.ijmm.2012.09.004; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Valles-Colomer M, 2019, NAT MICROBIOL, V4, P623, DOI 10.1038/s41564-018-0337-x; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; van Lee L, 2016, BRIT J NUTR, V115, P517, DOI 10.1017/S0007114515004705; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wind TT, 2020, MELANOMA RES, V30, P235, DOI 10.1097/CMR.0000000000000656; Wirbel J, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02306-1; Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6; Xie HL, 2016, CELL SYST, V3, P572, DOI 10.1016/j.cels.2016.10.004; Zolfo M, 2019, NAT BIOTECHNOL, V37, P1408, DOI 10.1038/s41587-019-0334-5	62	31	31	13	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					535	+		10.1038/s41591-022-01695-5	http://dx.doi.org/10.1038/s41591-022-01695-5		FEB 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35228751	Green Published, hybrid			2022-12-27	WOS:000762162700004
J	Pajon, R; Paila, YD; Girard, B; Dixon, G; Kacena, K; Baden, LR; El Sahly, HM; Essink, B; Mullane, KM; Frank, I; Denhan, D; Kerwin, E; Zhao, XP; Ding, BY; Deng, WP; Tomassini, JE; Zhou, HH; Leav, B; Schodel, F				Pajon, Rolando; Paila, Yamuna D.; Girard, Bethany; Dixon, Groves; Kacena, Katherine; Baden, Lindsey R.; El Sahly, Hana M.; Essink, Brandon; Mullane, Kathleen M.; Frank, Ian; Denhan, Douglas; Kerwin, Edward; Zhao, Xiaoping; Ding, Baoyu; Deng, Weiping; Tomassini, Joanne E.; Zhou, Honghong; Leav, Brett; Schodel, Florian		COVE Trial Consortium	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial	NATURE MEDICINE			English	Article							COVID-19	The COVID-19 vaccine mRNA-1273 reduced SARS-CoV-2 copy number and duration of virus shedding, in addition to disease burden and infections, in exploratory analyses of breakthrough infections in the COVE trial. The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) trial. While mRNA-1273 demonstrated high efficacy in prevention of COVID-19, including severe disease, its effect on the viral dynamics of SARS-CoV-2 infections is not understood. Here, in exploratory analyses, we assessed the impact of mRNA-1273 vaccination in the ongoing COVE trial (number NCT04470427) on SARS-CoV-2 copy number and shedding, burden of disease and infection, and viral variants. Viral variants were sequenced in all COVID-19 and adjudicated COVID-19 cases (n = 832), from July 2020 in the blinded part A of the study to May 2021 of the open-label part B of the study, in which participants in the placebo arm started to receive the mRNA-1273 vaccine after US Food and Drug Administration emergency use authorization of mRNA-1273 in December 2020. mRNA-1273 vaccination significantly reduced SARS-CoV-2 viral copy number (95% confidence interval) by 100-fold on the day of diagnosis compared with placebo (4.1 (3.4-4.8) versus 6.2 (6.0-6.4) log(10) copies per ml). Median times to undetectable viral copies were 4 days for mRNA-1273 and 7 days for placebo. Vaccination also substantially reduced the burden of disease and infection scores. Vaccine efficacies (95% confidence interval) against SARS-CoV-2 variants circulating in the United States during the trial assessed in this post hoc analysis were 82.4% (40.4-94.8%) for variants Epsilon and Gamma and 81.2% (36.1-94.5%) for Epsilon. The detection of other, non-SARS-CoV-2, respiratory viruses during the trial was similar between groups. While additional study is needed, these data show that in SARS-CoV-2-infected individuals, vaccination reduced both the viral copy number and duration of detectable viral RNA, which may be markers for the risk of virus transmission.	[Pajon, Rolando; Paila, Yamuna D.; Girard, Bethany; Dixon, Groves; Kacena, Katherine; Zhao, Xiaoping; Ding, Baoyu; Deng, Weiping; Tomassini, Joanne E.; Zhou, Honghong; Leav, Brett; Schodel, Florian] Moderna Inc, Cambridge, MA USA; [Baden, Lindsey R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [El Sahly, Hana M.] Baylor Coll Med, Houston, TX USA; [Essink, Brandon] Meridian Clin Res, Omaha, NE USA; [Mullane, Kathleen M.] Univ Chicago, Chicago, IL USA; [Frank, Ian] Univ Penn, Philadelphia, PA 19104 USA; [Denhan, Douglas] Clin Trials Texas, San Antonio, TX USA; [Kerwin, Edward] Criscor Clin Res Inst, Medford, OR USA	Harvard University; Brigham & Women's Hospital; Baylor College of Medicine; University of Chicago; University of Pennsylvania	Pajon, R (corresponding author), Moderna Inc, Cambridge, MA USA.	rolando.pajon@modernatx.com	Farley, E/HHM-4227-2022		Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [75A50120C00034]; National Institute of Allergy and Infectious Diseases (NIAID); NIAID [UM1 AI 68614HVTN, UM1 AI 68635, UM1 AI 68618, UM1 AI 68619, UM1 AI 68636, UM1 AI148684-03]	Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (contract no. 75A50120C00034) and the National Institute of Allergy and Infectious Diseases (NIAID). The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (no. UM1 AI 68614HVTN), the Statistics and Data Management Center (no. UM1 AI 68635), the HVTN Laboratory Center (no. UM1 AI 68618), the HIV Prevention Trials Network Leadership and Operations Center (no. UM1 AI 68619), the AIDS Clinical Trials Group Leadership and Operations Center (no. UM1 AI 68636) and the Infectious Diseases Clinical Research Consortium leadership group 5 (no. UM1 AI148684-03). The study sponsor, Moderna, Inc., was responsible for conceptualization and trial design, site selection and monitoring, data analysis and decision to publish and preparation of the manuscript. We also thank J. Grantham, J. Nutt, S. Cowden, K. Arnett, M. Wissel, C. Marti, S. Schildnecht and S. Kleiboeker, along with the staff of Eurofins Viracor BioPharma Services, for the development, validation and clinical trial sample analyses using SARS-CoV-2 RT-qPCR. With regards to generation of SARS-CoV-2 spike gene sequences, we thank T. Paprotka, T. Brefort, M. Schmitt, Y. Kumar, J. Nutt, S. Cowden, K. Murray, M. Diaz, M. Watters, C. Marti, E. Bixler, T. Moss and R. Sinha, along with the staff of Eurofins Viracor and Eurofins Genomics.	[Anonymous], OV VAR COUNTR; [Anonymous], COVID DAT TRACK VAR; [Anonymous], SARS COV 2 VAR CLASS; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bastos ML, 2021, ANN INTERN MED, V174, P501, DOI 10.7326/M20-6569; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Blanquart F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.37.2100824; Butler-Laporte G, 2021, JAMA INTERN MED, V181, P353, DOI 10.1001/jamainternmed.2020.8876; CHIA PY, PREPRINT MEDRXIV; Corbett KS, 2021, SCIENCE, V373, P1325, DOI 10.1126/science.abj0299; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; HE X, 2020, NAT MED, V26, P672, DOI DOI 10.1038/S41591-020-0869-5; Herrera LA, 2021, INT J INFECT DIS, V105, DOI 10.1016/j.ijid.2021.02.009; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Jones TC, 2021, SCIENCE, V373, P180, DOI 10.1126/science.abi5273; Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266; Kim MC, 2021, NEW ENGL J MED, V384, P671, DOI 10.1056/NEJMc2027040; Kissler S. M., VIRAL DYNAMICS SARS, DOI 10.1101/2021.02.16.21251535; Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Liu Yang, 2021, N Engl J Med, DOI 10.1056/NEJMc2102017; Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2; Luo, 2021, PREPRINT MEDRXIV, DOI 10.1101/2021.08.15.21262077; Lustig Y, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.26.2100557; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Marks M, 2021, LANCET INFECT DIS, V21, P629, DOI 10.1016/S1473-3099(20)30985-3; Miller EH, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab003; Peci A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010130; Pegu A, 2021, SCIENCE, V373, P1372, DOI 10.1126/science.abj4176; Pujadas E, 2020, LANCET RESP MED, V8, pE70, DOI 10.1016/S2213-2600(20)30354-4; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rao SN, 2020, INFECT DIS THER, V9, P573, DOI 10.1007/s40121-020-00324-3; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Singh J, 2021, NAT MED, V27, P1131, DOI 10.1038/s41591-021-01397-4; Tande AJ, 2022, CLIN INFECT DIS, V74, P59, DOI 10.1093/cid/ciab229; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; TENFORDE MW, CLIN INFECT DIS; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Wu K., MRNA 1273 VACCINES I, DOI 10.1101/2021.01.25.427948(2021; Wu K, 2021, VACCINE, V39, P7394, DOI [10.1016/j.vaccine.2021.11.001, 10.1101/2021.04.13.439482]; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179	42	6	6	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					823	+		10.1038/s41591-022-01679-5	http://dx.doi.org/10.1038/s41591-022-01679-5		FEB 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35145311	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000753763500005
J	VanBlargan, LA; Errico, JM; Halfmann, PJ; Zost, SJ; Crowe, JE; Purcell, LA; Kawaoka, Y; Corti, D; Fremont, DH; Diamond, MS				VanBlargan, Laura A.; Errico, John M.; Halfmann, Peter J.; Zost, Seth J.; Crowe, James E., Jr.; Purcell, Lisa A.; Kawaoka, Yoshihiro; Corti, Davide; Fremont, Daved H.; Diamond, Michael S.			An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	NATURE MEDICINE			English	Article								The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, similar to 12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant.	[VanBlargan, Laura A.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Errico, John M.; Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Halfmann, Peter J.; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Influenza Res Inst, Madison, WI 53706 USA; [Zost, Seth J.; Crowe, James E., Jr.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN USA; [Zost, Seth J.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Crowe, James E., Jr.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN USA; [Purcell, Lisa A.] Vir Biotechnol, St Louis, MO USA; [Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo, Japan; [Kawaoka, Yoshihiro] Natl Ctr Global Hlth & Med Res Inst, Res Ctr Global Viral Dis, Tokyo, Japan; [Corti, Davide] Humabs BioMed SA, Bellinzona, Switzerland; [Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Fremont, Daved H.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Immunotherapy Programs, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Ctr Vaccines & Immun Microbial Pathogens, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Tokyo; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Immunotherapy Programs, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Ctr Vaccines & Immun Microbial Pathogens, St Louis, MO 63110 USA.	mdiamond@wustl.edu	Crowe, James/B-5549-2009	Crowe, James/0000-0002-0049-1079; Errico, John/0000-0002-4452-8152; Fremont, Daved/0000-0002-8544-2689; Zost, Seth/0000-0001-6712-5076; VanBlargan, Laura/0000-0002-8922-8946; Corti, Davide/0000-0002-5797-1364	National Institues of Health [R01 AI157155, U01 AI151810, 75N93021C00014, HHSN272201700060C, 75N93019C00062, 75N93019C00051]; Defense Advanced Research Project Agency [HR0011-18-2-0001]; Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development [JP21wm0125002]; Dolly Parton COVID-19 Research Fund at Vanderbilt University Medical Center	National Institues of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Advanced Research Project Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Japan Program for Infectious Diseases Research and Infrastructure from the Japan Agency for Medical Research and Development; Dolly Parton COVID-19 Research Fund at Vanderbilt University Medical Center	This study was supported by grants and contracts from the National Institues of Health (R01 AI157155 (to M.S.D. and J.E.C), U01 AI151810 (to M.S.D.), 75N93021C00014 (to Y.K.), HHSN272201700060C (to D.H.F.), 75N93019C00062 (D.H.F. and M.S.D.), and 75N93019C00051 (to M.S.D.)); the Defense Advanced Research Project Agency (HR0011-18-2-0001 (to J.E.C. and M.S.D)); the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002) from the Japan Agency for Medical Research and Development (to Y.K.); and the Dolly Parton COVID-19 Research Fund at Vanderbilt University Medical Center (to J.E.C.). We thank R. Nargi, R. Carnahan, T. Tan and L. Schimanski for assistance and generosity with mAb generation and purification and S. A. Turner from the Center for Pathogen Evolution at the University of Cambridge for evaluating B.1.1.529 sequences. AZD7442 (AZD8895 and AZD1061) was supplied by AstraZeneca under a material transfer agreement.	Bailey AL, 2021, CELL, V184, P15, DOI 10.1016/j.cell.2020.12.003; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Callaway E, 2021, NATURE, V600, P367, DOI 10.1038/d41586-021-03672-3; Callaway E, 2021, NATURE, V600, P197, DOI 10.1038/d41586-021-03614-z; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cao Y., 2021, B 1 1 529 ESCAPES MA, DOI [10.1101/2021.12.07 .4703922021.12.07.470392, DOI 10.1101/2021.12.07.470392]; Case JB, 2020, CELL HOST MICROBE, V28, P475, DOI 10.1016/j.chom.2020.06.021; Cele S., 2021, SARS COV 2 OMICRON H, DOI [10.1101/2021.12.08.21267417v1, DOI 10.1101/2021.12.08.21267417V1]; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Dejnirattisai W, 2022, LANCET, V399, P234, DOI 10.1016/S0140-6736(21)02844-0; Ford C.T., 2022, FRONT VIROL, V2, DOI 10.1101/2021.12.03.471024; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Golcuk M., 2021, OMICRON VARINT INCRE, DOI 10.1101/2021.12.06.471377v1; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Greaney AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24435-8; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kim C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20602-5; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lempp FA, 2021, NATURE, V598, P342, DOI 10.1038/s41586-021-03925-1; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Rosen L, 2021, BIORXIV, DOI [DOI 10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607v6, 10.1101/2021.03.09.434607]; Schafer A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201993; Sempowski GD, 2020, CELL, V181, P1458, DOI 10.1016/j.cell.2020.05.041; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255; Suryadevara Naveenchandra, 2021, Cell, V184, P2316, DOI [10.1101/2021.01.19.427324, 10.1016/j.cell.2021.03.029]; Tada Takuya, 2021, bioRxiv, DOI 10.1101/2021.02.05.430003; Torjesen I, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2943; Tortorici MA, 2020, SCIENCE, V370, P950, DOI 10.1126/science.abe3354; VanBlargan LA, 2021, IMMUNITY, V54, P2399, DOI 10.1016/j.immuni.2021.08.016; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wang Zijun, 2021, bioRxiv, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wilhelm A, 2021, REDUCED NEUTRALIZATI, DOI [10.1101/2021.12.07.21267432, DOI 10.15585/MMWR.MM7011A1EXTERNALICON]; Winkler ES, 2021, CELL, V184, P1804, DOI 10.1016/j.cell.2021.02.026; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zohar T, 2020, CELL, V183, P1508, DOI 10.1016/j.cell.2020.10.052; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	51	215	218	19	36	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					490	+		10.1038/s41591-021-01678-y	http://dx.doi.org/10.1038/s41591-021-01678-y		JAN 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35046573	Green Published, Green Submitted, Bronze			2022-12-27	WOS:000745735100001
J	Weis, C; Cuenod, A; Rieck, B; Llinares-Lopez, F; Dubuis, O; Graf, S; Lang, C; Oberle, M; Brackmann, M; Sogaard, KK; Osthoff, M; Borgwardt, K; Egli, A				Weis, Caroline; Cuenod, Aline; Rieck, Bastian; Llinares-Lopez, Felipe; Dubuis, Olivier; Graf, Susanne; Lang, Claudia; Oberle, Michael; Brackmann, Maximilian; Sogaard, Kirstine K.; Osthoff, Michael; Borgwardt, Karsten; Egli, Adrian			Direct antimicrobial resistance prediction from clinical MALDI-TOF mass spectra using machine learning	NATURE MEDICINE			English	Article							DESORPTION IONIZATION-TIME; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; IDENTIFICATION; SPECTROMETRY; IMPACT; MUTATIONS; COMPLEX; SWABS	A machine learning method speeds antimicrobial resistance determination to help tailor treatment decisions. Early use of effective antimicrobial treatments is critical for the outcome of infections and the prevention of treatment resistance. Antimicrobial resistance testing enables the selection of optimal antibiotic treatments, but current culture-based techniques can take up to 72 hours to generate results. We have developed a novel machine learning approach to predict antimicrobial resistance directly from matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectra profiles of clinical isolates. We trained calibrated classifiers on a newly created publicly available database of mass spectra profiles from the clinically most relevant isolates with linked antimicrobial susceptibility phenotypes. This dataset combines more than 300,000 mass spectra with more than 750,000 antimicrobial resistance phenotypes from four medical institutions. Validation on a panel of clinically important pathogens, including Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae, resulting in areas under the receiver operating characteristic curve of 0.80, 0.74 and 0.74, respectively, demonstrated the potential of using machine learning to substantially accelerate antimicrobial resistance determination and change of clinical management. Furthermore, a retrospective clinical case study of 63 patients found that implementing this approach would have changed the clinical treatment in nine cases, which would have been beneficial in eight cases (89%). MALDI-TOF mass spectra-based machine learning may thus be an important new tool for treatment optimization and antibiotic stewardship.	[Weis, Caroline; Rieck, Bastian; Borgwardt, Karsten] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland; [Weis, Caroline; Rieck, Bastian; Borgwardt, Karsten] SIB Swiss Inst Bioinformat, Lausanne, Switzerland; [Cuenod, Aline; Sogaard, Kirstine K.; Egli, Adrian] Univ Basel, Dept Biomed, Appl Microbiol Res, Basel, Switzerland; [Cuenod, Aline; Sogaard, Kirstine K.; Egli, Adrian] Univ Hosp Basel, Div Clin Bacteriol & Mycol, Basel, Switzerland; [Dubuis, Olivier; Lang, Claudia] Viollier AG, Allschwil, Switzerland; [Graf, Susanne] Canton Hosp Basel Land, Dept Microbiol, Liestal, Switzerland; [Oberle, Michael] Cantonal Hosp Aarau, Inst Lab Med, Med Microbiol, Aarau, Switzerland; [Brackmann, Maximilian] Fed Off Civil Protect, Prote Bioinformat & Toxins, Spiez Lab, Spiez, Switzerland; [Osthoff, Michael] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland; [Osthoff, Michael] Univ Basel, Basel, Switzerland; [Osthoff, Michael] Univ Hosp Basel, Dept Internal Med, Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Institute of Bioinformatics; University of Basel; University of Basel; Kantonsspital Aarau AG (KSA); University of Basel; University of Basel; University of Basel	Weis, C; Borgwardt, K (corresponding author), Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland.; Weis, C; Borgwardt, K (corresponding author), SIB Swiss Inst Bioinformat, Lausanne, Switzerland.; Egli, A (corresponding author), Univ Basel, Dept Biomed, Appl Microbiol Res, Basel, Switzerland.; Egli, A (corresponding author), Univ Hosp Basel, Div Clin Bacteriol & Mycol, Basel, Switzerland.	caroline.weis@bsse.ethz.ch; karsten.borgwardt@bsse.ethz.ch; adrian.egli@usb.ch	Rieck, Bastian/J-7507-2019	Rieck, Bastian/0000-0003-4335-0302; Brackmann, Maximilian/0000-0003-0079-1693; Cuenod, Aline/0000-0002-8522-6134; Borgwardt, Karsten/0000-0001-7221-2393	Alfried Krupp Prize for Young University Teachers of the Alfried Krupp von Bohlen und Halbach-Stiftung; Swiss National Science Foundation [P1BSP3-184342]; ETH Zurich [PMB-03-17];  [IEC 2019-00729];  [201901860];  [2019-00748]	Alfried Krupp Prize for Young University Teachers of the Alfried Krupp von Bohlen und Halbach-Stiftung; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); ETH Zurich(ETH Zurich); ; ; 	The authors thank O. Gruninger, J. Reist, Y. Mahiddine, D. Lang, C. Straub and M. Schneider for excellent technical assistance in accessing the mass spectra and antimicrobial resistance data at the University Hospital Basel; and B. Rodriguez-Sanchez (Hospital General Universitario Gregorio Maranon, Madrid, Spain), H. Seth-Smith (University Hospital Basel), C. Kaufmann (University Hospital Basel), and V. Pfluger (MabritecAG, Riehen, Switzerland) for valuable advice, technical consultation and feedback throughout the project. The authors also thank X. He (ETH Zurich) for fruitful discussions, and D. Chen (ETH Zurich) and Jacques Schrenzel (Geneva University Hospitals) for assistance with the manuscript and for providing valuable feedback. This study was supported by the Alfried Krupp Prize for Young University Teachers of the Alfried Krupp von Bohlen und Halbach-Stiftung (K.B.), by the two Cantons of Basel through a D-BSSE-Uni-Basel Personalised Medicine grant from the ETH Zurich (PMB-03-17, K.B. and A.E.) and a Doc.Mobility fellowship (A.C.) by the Swiss National Science Foundation (P1BSP3-184342). This study received ethics approval through the local ethics review board (EKNZ number: IEC 2019-00729, 201901860 and 2019-00748).	Banerjee R, 2015, CLIN INFECT DIS, V61, P1071, DOI 10.1093/cid/civ447; Bevan ER, 2017, J ANTIMICROB CHEMOTH, V72, P2145, DOI 10.1093/jac/dkx146; Bourdon N, 2010, DIAGN MICR INFEC DIS, V67, P291, DOI 10.1016/j.diagmicrobio.2010.02.009; Camoez M, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.009; Cassini A, 2019, LANCET INFECT DIS, V19, P56, DOI 10.1016/S1473-3099(18)30605-4; CDC, 2019, ANTIBIOTIC RESISTANC, DOI [DOI 10.15620/CDC:82532, 10.15620/cdc:82532]; Centers for Disease Control and Prevention, 2019, COR EL ANT STEW; Chatterjee SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028781; Croxatto A, 2012, FEMS MICROBIOL REV, V36, P380, DOI 10.1111/j.1574-6976.2011.00298.x; Cuenod A, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.646648; Cury AP, 2020, J MICROBIOL METH, V171, DOI 10.1016/j.mimet.2020.105884; Dierig A, 2015, PEDIATR INFECT DIS J, V34, P97, DOI 10.1097/INF.0000000000000601; European Committee on Antimicrobial Susceptibility Testing (EUCAST), CLIN BREAKP DOS ANT; Gibb S, 2012, BIOINFORMATICS, V28, P2270, DOI 10.1093/bioinformatics/bts447; Hou TY, 2019, J FOOD DRUG ANAL, V27, P404, DOI 10.1016/j.jfda.2019.01.001; Hu YY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02504; Huang AM, 2013, CLIN INFECT DIS, V57, P1237, DOI 10.1093/cid/cit498; Huh HJ, 2012, ANN LAB MED, V32, P407, DOI 10.3343/alm.2012.32.6.407; Josten M, 2014, INT J MED MICROBIOL, V304, P1018, DOI 10.1016/j.ijmm.2014.07.005; Josten M, 2013, J CLIN MICROBIOL, V51, P1809, DOI 10.1128/JCM.00518-13; Ke Guolin, 2017, ADV NEURAL INFORM PR, P3146; Kim JM, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040214; Kim YK, 2002, ANTIMICROB AGENTS CH, V46, P1481, DOI 10.1128/AAC.46.5.1481-1491.2002; Kommedal O, 2016, APMIS, V124, P603, DOI 10.1111/apm.12549; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Lafolie J, 2015, J HOSP INFECT, V90, P208, DOI 10.1016/j.jhin.2014.12.022; Long SW, 2014, ANTIMICROB AGENTS CH, V58, P6668, DOI 10.1128/AAC.03622-14; Ludden C, 2020, MICROB GENOMICS, V6, DOI 10.1099/mgen.0.000352; Nakamura A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45051-z; Oberle M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164260; Ostergaard C, 2015, INT J MED MICROBIOL, V305, P838, DOI 10.1016/j.ijmm.2015.08.002; Osthoff M, 2017, CLIN MICROBIOL INFEC, V23, P78, DOI 10.1016/j.cmi.2016.08.009; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Pereira LA, 2014, J CLIN MICROBIOL, V52, P1259, DOI 10.1128/JCM.03413-13; Pickens C, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115179; Pietsch M, 2017, VET MICROBIOL, V200, P130, DOI 10.1016/j.vetmic.2015.11.028; Potron A, 2013, EUROSURVEILLANCE, V18, P9, DOI 10.2807/1560-7917.ES2013.18.31.20549; Rhoads DD, 2016, DIAGN MICR INFEC DIS, V86, P257, DOI 10.1016/j.diagmicrobio.2016.08.001; Sauget M, 2016, J MICROBIOL METH, V127, P20, DOI 10.1016/j.mimet.2016.05.010; Schmidt A, 2016, NAT BIOTECHNOL, V34, P104, DOI 10.1038/nbt.3418; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Shapley LS, 2016, 17 VALUE N PERSON GA, V17, P307, DOI [10.1515/9781400881970-018, DOI 10.1515/9781400881970-018]; Sogawa K, 2011, ANAL BIOANAL CHEM, V400, P1905, DOI 10.1007/s00216-011-4877-7; UniProt, BET LACT TEM; UniProt, BET LACT SHV 24; UniProt, BET LACT OXA 1; UniProt, BET LACT IND PEN BIN; UniProt, OMPC OUT MEMBR POR C; UniProt, BET LACT CTX M 1; van Belkum A, 2017, ANN LAB MED, V37, P475, DOI 10.3343/alm.2017.37.6.475; Vervier K., 2015, BENCHMARK STRUCTURED; Wang Hsin-Yao, 2021, Brief Bioinform, V22, DOI 10.1093/bib/bbaa138; Weis CV, 2020, CLIN MICROBIOL INFEC, V26, P1310, DOI 10.1016/j.cmi.2020.03.014; Weis C, 2020, BIOINFORMATICS, V36, P30, DOI 10.1093/bioinformatics/btaa429; ( WHO) WHO, 2017, DEPRESSION, DOI DOI 10.1109/IEEESTD.2017.7920364; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609; Wolters M, 2011, INT J MED MICROBIOL, V301, P64, DOI 10.1016/j.ijmm.2010.06.002; World Health Organization, 2016, GLOB ACT PLAN ANT RE; Zhang H., 2021, C HLTH INFERENCE LEA, P2021, DOI [10.1145/3450439.3451878, DOI 10.1145/3450439.3451878]; Zhang TT, 2015, J MICROBIOL METH, V117, P122, DOI 10.1016/j.mimet.2015.08.002	60	10	10	27	54	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					164	+		10.1038/s41591-021-01619-9	http://dx.doi.org/10.1038/s41591-021-01619-9		JAN 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35013613	Green Submitted			2022-12-27	WOS:000741630800004
J	Cho, MLK				Cho, Mildred K.			Rising to the challenge of bias in health care AI	NATURE MEDICINE			English	Editorial Material								AI-based models may amplify pre-existing human bias within datasets; addressing this problem will require a fundamental realignment of the culture of software development.	[Cho, Mildred K.] Stanford Univ, Stanford Ctr Biomed Eth, Stanford, CA 94305 USA	Stanford University	Cho, MLK (corresponding author), Stanford Univ, Stanford Ctr Biomed Eth, Stanford, CA 94305 USA.	micho@stanford.edu						Challen R, 2019, BMJ QUAL SAF, V28, P231, DOI 10.1136/bmjqs-2018-008370; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Kauh TJ, 2021, POPUL RES POLICY REV, V40, P1, DOI 10.1007/s11113-020-09631-6; Miceli M., PREPRINT; Nichol AA, 2021, J MED INTERNET RES, V23, DOI 10.2196/26391; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Powles J., 2018, ONEZERO; Quint JJ, 2021, MMWR-MORBID MORTAL W, V70, P1267, DOI 10.15585/mmwr.mm7037a1; Ross C, STAT-US; Seyyed-Kalantari L, 2021, NAT MED, V27, P2176, DOI 10.1038/s41591-021-01595-0; Stevens M, 2020, SOC SCI MED, V258, DOI 10.1016/j.socscimed.2020.113116; Wong A, 2021, JAMA INTERN MED, V181, P1065, DOI 10.1001/jamainternmed.2021.2626	12	5	6	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2079	2081		10.1038/s41591-021-01577-2	http://dx.doi.org/10.1038/s41591-021-01577-2		DEC 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34893774				2022-12-27	WOS:000729031100006
J	Patone, M; Handunnetthi, L; Saatci, D; Pan, JF; Katikireddi, SV; Razvi, S; Hunt, D; Mei, XW; Dixon, S; Zaccardi, F; Khunti, K; Watkinson, P; Coupland, CAC; Doidge, J; Harrison, DA; Ravanan, R; Sheikh, A; Robertson, C; Hippisley-Cox, J				Patone, Martina; Handunnetthi, Lahiru; Saatci, Defne; Pan, Jiafeng; Katikireddi, Srinivasa Vittal; Razvi, Saif; Hunt, David; Mei, Xue W.; Dixon, Sharon; Zaccardi, Francesco; Khunti, Kamlesh; Watkinson, Peter; Coupland, Carol A. C.; Doidge, James; Harrison, David A.; Ravanan, Rommel; Sheikh, Aziz; Robertson, Chris; Hippisley-Cox, Julia			Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	NATURE MEDICINE			English	Article								Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain-Barre syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15-3.92 at 15-21 days after vaccination) and Bell's palsy (IRR, 1.29; 95% CI: 1.08-1.56 at 15-21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12-1.71 at 15-21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain-Barre syndrome (IRR, 2.32; 95% CI: 1.08-5.02 at 1-28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain-Barre syndrome (IRR, 5.25; 95% CI: 3.00-9.18). Overall, we estimated 38 excess cases of Guillain-Barre syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test. A self-controlled case series analysis of nearly 32 million people in England shows an increased risk of rare neurological complications in those who received COVID-19 vaccines and following SARS-CoV-2 infection. The results highlight 38 excess cases of Guillain-Barre syndrome per 10 million ChAdOx1nCoV-19 vaccinations.	[Patone, Martina; Saatci, Defne] Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England; [Handunnetthi, Lahiru; Mei, Xue W.; Dixon, Sharon; Watkinson, Peter; Coupland, Carol A. C.; Hippisley-Cox, Julia] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Handunnetthi, Lahiru] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England; [Pan, Jiafeng; Sheikh, Aziz; Robertson, Chris] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland; [Katikireddi, Srinivasa Vittal] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Razvi, Saif] Inst Neurol Sci, Glasgow, Lanark, Scotland; [Hunt, David] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Hunt, David] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Zaccardi, Francesco; Khunti, Kamlesh] Univ Leicester, Leicester Diabet Ctr, Leicester Real World Evidence Unit, Leicester, Leics, England; [Watkinson, Peter] Oxford Univ Hosp NHS Trust, NIHR Biomed Res Ctr, Oxford, England; [Coupland, Carol A. C.] Univ Nottingham, Sch Med, Div Primary Care, Nottingham, England; [Doidge, James; Harrison, David A.] Intens Care Natl Audit & Res Ctr, London, England; [Doidge, James; Harrison, David A.] London Sch Hyg & Trop Med, London, England; [Ravanan, Rommel] NHS Blood & Transplant, Bristol, Avon, England; [Sheikh, Aziz] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Robertson, Chris] Publ Hlth Scotland, Glasgow, Lanark, Scotland	University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Strathclyde; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of Glasgow; University of Edinburgh; University of Edinburgh; University of Leicester; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Nottingham; Intensive Care National Audit & Research Centre; University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh	Hippisley-Cox, J (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.	julia.hippisley-cox@phc.ox.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020; Harrison, David A/O-4355-2018; /ABC-9527-2021; Doidge, James/F-3541-2013	Hippisley-Cox, Julia/0000-0002-2479-7283; Harrison, David A/0000-0002-9002-9098; Watkinson, Peter/0000-0003-1023-3927; Razvi, Saif/0000-0003-2307-550X; Katikireddi, Srinivasa/0000-0001-6593-9092; Handunnetthi, Lahiru/0000-0002-8242-3722; Doidge, James/0000-0002-3674-3100; Khunti, Kamlesh/0000-0003-2343-7099; Mei, Xue/0000-0002-6279-4884	National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford; John Fell Oxford University Press Research Fund; Cancer Research UK (CR-UK) [C5255/A18085]; Cancer Research UK Oxford Centre; Oxford Wellcome Institutional Strategic Support Fund [204826/Z/16/Z]; UK Research and Innovation [MC_PC_20029]; National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands; NIHR Lifestyle BRC; NRS Senior Clinical Fellowship [SCAF/15/02]; UK Medical Research Council [MC_UU_00022/2]; Scottish Government Chief Scientist Office [SPHSU17]; NIHR-funded clinical lectureship [CL-2019-13-001]; Office For National Statistics	National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR)); John Fell Oxford University Press Research Fund; Cancer Research UK (CR-UK)(Cancer Research UK); Cancer Research UK Oxford Centre; Oxford Wellcome Institutional Strategic Support Fund; UK Research and Innovation(UK Research & Innovation (UKRI)); National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands(National Institute for Health Research (NIHR)); NIHR Lifestyle BRC; NRS Senior Clinical Fellowship; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Scottish Government Chief Scientist Office; NIHR-funded clinical lectureship; Office For National Statistics	This project involves data derived from patient-level information collected by the National Health Service (NHS), as part of the care and support of cancer patients. The SARS-Cov-2 test data are collated, maintained and quality assured by Public Health England (PHE) and NHS Digital. Access to data was facilitated by the PHE Office for Data Release. The Hospital Episode Statistics (HES), Secondary Users Service (SUS-PLUS) datasets and civil registration data are used by permission from NHS Digital, who retain the copyright in that data. The authors acknowledge the contribution of EMIS GP practices, who contribute to QResearch, and EMIS Health and the Universities of Nottingham and Oxford for expertise in establishing, developing or supporting the QResearch database. QResearch has been supported by funding from the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CR-UK) (grant number C5255/A18085) through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) and other research councils, during the conduct of the study. NHS Digital and PHE bear no responsibility for the analysis or interpretation of the data. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office For National Statistics and funded by UK Research and Innovation (grant ref. MC_PC_20029). K.K. is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC-EM) and NIHR Lifestyle BRC. S.V.K. is supported by an NRS Senior Clinical Fellowship (SCAF/15/02), the UK Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). L.H. is supported by an NIHR-funded clinical lectureship (CL-2019-13-001). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the UK National Institute for Health Research or the Department of Health. This study is supported by a Patient and Public Involvement and Engagement panel who have advised in developing this research and the authors thank them for their support.	Allen CM, 2021, ANN NEUROL, V90, P315, DOI 10.1002/ana.26144; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Chagla Z, 2021, ANN INTERN MED, V174, pJC28, DOI 10.7326/ACPJ202103160-028; Colella G, 2021, J NEUROL, V268, P3589, DOI 10.1007/s00415-021-10462-4; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165; Hippisley-Cox J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1931; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Malhotra HS, 2021, QJM-INT J MED, V114, P591, DOI 10.1093/qjmed/hcab069; Maramattom BV, 2021, ANN NEUROL, V90, P312, DOI 10.1002/ana.26143; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Patel SU, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242956; Paterson RW, 2020, BRAIN, V143, P3104, DOI 10.1093/brain/awaa240; Petersen I, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4515; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Tarawneh O, 2021, AM J HEMATOL, V96, pE133, DOI 10.1002/ajh.26106; VARATHARAJ A, 2020, LANCET PSYCHIAT, V7, P875, DOI [DOI 10.1016/S2215-0366(20)30287-X, 10.1016/S2215-0366(20)30287-X]; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Walgaard C, 2010, ANN NEUROL, V67, P781, DOI 10.1002/ana.21976; Webb AJS, 2015, J NEUROL NEUROSUR PS, V86, P1196, DOI 10.1136/jnnp-2014-309056; Wilson K, 2013, PHARMACOEPIDEM DR S, V22, P108, DOI 10.1002/pds.3337	24	121	120	3	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2144	+		10.1038/s41591-021-01556-7	http://dx.doi.org/10.1038/s41591-021-01556-7		OCT 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34697502	Green Published, hybrid, Green Accepted			2022-12-27	WOS:000710831500001
J	Ishmael, MK; Archangeli, D; Lenzi, T				Ishmael, Marshall K.; Archangeli, Dante; Lenzi, Tommaso			Powered hip exoskeleton improves walking economy in individuals with above-knee amputation	NATURE MEDICINE			English	Article							LOWER-LIMB AMPUTEES; ENERGY-COST; MECHANICAL WORK; PROSTHESIS; LIGHTWEIGHT; ADAPTATION; ENERGETICS; REDUCE; MUSCLE; LEVEL	Above-knee amputation severely reduces the mobility and quality of life of millions of individuals. Walking with available leg prostheses is highly inefficient, and poor walking economy is a major problem limiting mobility. Here we show that an autonomous powered hip exoskeleton assisting the residual limb significantly improves metabolic walking economy by 15.6 +/- 2.9% (mean +/- s.e.m.; two-tailed paired t-test, P = 0.002) in six individuals with above-knee amputation walking on a treadmill. The observed metabolic cost improvement is equivalent to removing a 12-kg backpack from a nonamputee individual. All participants were able to walk overground with the exoskeleton, including starting and stopping, without notable changes in gait balance or stability. This study shows that assistance of the user's residual limb with a powered hip exoskeleton is a viable solution for improving amputee walking economy. By significantly reducing the metabolic cost of walking, the proposed hip exoskeleton may have a considerable positive impact on mobility, improving the quality of life of individuals with above-knee amputations. In individuals with above-knee amputation, a powered hip exoskeleton, which reduces the metabolic cost of walking by adding energy at the hip joint, greatly improves walking economy and has the potential to improve mobility.	[Lenzi, Tommaso] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA; Univ Utah, Robot Ctr, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lenzi, T (corresponding author), Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA.	t.lenzi@utah.edu	Lenzi, Tommaso/E-4156-2015	Lenzi, Tommaso/0000-0003-0957-6412	Congressionally Directed Medical Research Program of the Department of Defense [W81XWH-16-1-0701]; National Science Foundation [2046287]	Congressionally Directed Medical Research Program of the Department of Defense; National Science Foundation(National Science Foundation (NSF))	We wish to acknowledge the contribution of all study participants. We would like to thank M. Tran, S. Sarkisian and C. Buchanan for their help with the development of the powered hip exoskeleton and related interfaces. We would like to thank J. Mendez for assistance in collection and processing of all data from participants and G. Hunt for help proofreading the manuscript. We would also like to thank C. Hansen and C. Duncan for their help with participant recruitment. Funding for this study was provided by the Congressionally Directed Medical Research Program of the Department of Defense under grant number W81XWH-16-1-0701 awarded to T.L. and by the National Science Foundation under grant number 2046287 awarded to T.L.	Alimusaj M, 2009, GAIT POSTURE, V30, P356, DOI 10.1016/j.gaitpost.2009.06.009; Boulton AJM, 2005, LANCET, V366, P1719, DOI 10.1016/S0140-6736(05)67698-2; Browning RC, 2007, MED SCI SPORT EXER, V39, P515, DOI 10.1249/mss.0b013e31802b3562; Collins SH, 2015, NATURE, V522, P212, DOI 10.1038/nature14288; Ding Y, 2018, SCI ROBOT, V3, DOI 10.1126/scirobotics.aar5438; Farris DJ, 2012, J R SOC INTERFACE, V9, P110, DOI 10.1098/rsif.2011.0182; Gabert L, 2020, IEEE ROBOT AUTOM MAG, V27, P87, DOI [10.1109/MRA.2019.2955740, 10.1109/mra.2019.2955740]; Gailey RS, 2002, ARCH PHYS MED REHAB, V83, P613, DOI 10.1053/ampr.2002.32309; Galle S, 2013, GAIT POSTURE, V38, P495, DOI 10.1016/j.gaitpost.2013.01.029; Goldfarb M., 2013, JPO J PROSTHETICS OR, V25, pP65, DOI 10.1097/JPO.0b013e3182a8953e; Goldfarb M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007312; Guidetti L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209925; Hafner BJ, 2009, J REHABIL RES DEV, V46, P417, DOI 10.1682/JRRD.2008.01.0007; Hood S, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0494-7; Ishmael M. K., FIGSHARE, DOI [10.6084/m9.figshare.15180711, DOI 10.6084/M9.FIGSHARE.15180711]; Ishmael MK, 2019, INT C REHAB ROBOT, P925, DOI 10.1109/ICORR.2019.8779412; Johansson JL, 2005, AM J PHYS MED REHAB, V84, P563, DOI 10.1097/01.phm.0000174665.74933.0b; Khemka A, 2015, ACTA ORTHOP, V86, P740, DOI 10.3109/17453674.2015.1068635; Kim J, 2019, SCIENCE, V365, P668, DOI 10.1126/science.aav7536; Kuiken Todd A, 2018, Plast Reconstr Surg Glob Open, V6, pe1632, DOI 10.1097/GOX.0000000000001632; Lenzi T, 2013, IEEE T NEUR SYS REH, V21, P938, DOI 10.1109/TNSRE.2013.2248749; Martini E, 2020, P IEEE RAS-EMBS INT, P809, DOI 10.1109/BioRob49111.2020.9224417; Murphy E, 1989, MEMORIAL TRIBUTES, V3, P259; PELL JP, 1993, EUR J VASCULAR SURG, V7, P448, DOI 10.1016/S0950-821X(05)80265-8; Petrini FM, 2019, NAT MED, V25, P1356, DOI 10.1038/s41591-019-0567-3; Quinlivan BT, 2017, SCI ROBOT, V2, DOI 10.1126/scirobotics.aah4416; Reinkensmeyer DJ, 2002, P ANN INT IEEE EMBS, P2353, DOI 10.1109/IEMBS.2002.1053318; Riley PO, 2007, GAIT POSTURE, V26, P17, DOI 10.1016/j.gaitpost.2006.07.003; Ronsse R, 2013, IEEE T ROBOT, V29, P783, DOI 10.1109/TRO.2013.2240173; Ronsse R, 2011, IEEE T BIO-MED ENG, V58, P1001, DOI 10.1109/TBME.2010.2089629; Sarkisian Sergei V., 2020, IEEE Transactions on Medical Robotics and Bionics, V2, P248, DOI 10.1109/TMRB.2020.2981951; Sarkisian SV, 2021, IEEE T NEUR SYS REH, V29, P629, DOI 10.1109/TNSRE.2021.3064463; Sasaki K, 2009, J EXP BIOL, V212, P738, DOI 10.1242/jeb.023267; Sawicki GS, 2020, J NEUROENG REHABIL, V17, DOI 10.1186/s12984-020-00663-9; Schmalz T, 2002, GAIT POSTURE, V16, P255, DOI 10.1016/S0966-6362(02)00008-5; Seo K, 2016, IEEE INT CONF ROBOT, P4628, DOI 10.1109/ICRA.2016.7487663; Seroussi RE, 1996, ARCH PHYS MED REHAB, V77, P1209, DOI 10.1016/S0003-9993(96)90151-3; Tran M, 2019, IEEE ROBOT AUTOM LET, V4, P1186, DOI 10.1109/LRA.2019.2892204; WATERS RL, 1976, J BONE JOINT SURG AM, V58, P42, DOI 10.2106/00004623-197658010-00007; Welker CG, 2021, ROY SOC OPEN SCI, V8, DOI 10.1098/rsos.202020; Wurdeman SR, 2018, PROSTHET ORTHOT INT, V42, P498, DOI 10.1177/0309364617736089; Zhang JJ, 2017, SCIENCE, V356, P1280, DOI 10.1126/science.aal5054; Zhang JT, 2013, PHYSIOL MEAS, V34, pN63, DOI 10.1088/0967-3334/34/8/N63	43	10	10	13	36	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1783	+		10.1038/s41591-021-01515-2	http://dx.doi.org/10.1038/s41591-021-01515-2		OCT 2021	10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34635852				2022-12-27	WOS:000706015900004
J	Dedrick, RM; Freeman, KG; Nguyen, JA; Bahadirli-Talbott, A; Smith, BE; Wu, AE; Ong, AS; Lin, CT; Ruppel, LC; Parrish, NM; Hatfull, GF; Cohen, KA				Dedrick, Rebekah M.; Freeman, Krista G.; Nguyen, Jan A.; Bahadirli-Talbott, Asli; Smith, Bailey E.; Wu, Andrew E.; Ong, Aaron S.; Lin, Cheng Ting; Ruppel, Lisa C.; Parrish, Nicole M.; Hatfull, Graham F.; Cohen, Keira A.			Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection	NATURE MEDICINE			English	Article							PHAGE THERAPY; SYSTEM; SERA	Initial promise of a bacteriophage therapy for a persistent bacterial infection in an immunocompetent patient was curtailed in conjunction with a rise in phage-specific neutralizing antibodies. Abstractpost An 81-year-old immunocompetent patient with bronchiectasis and refractory Mycobacterium abscessus lung disease was treated for 6 months with a three-phage cocktail active against the strain. In this case study of phage to lower infectious burden, intravenous administration was safe and reduced the M. abscessus sputum load tenfold within one month. However, after two months, M. abscessus counts increased as the patient mounted a robust IgM- and IgG-mediated neutralizing antibody response to the phages, which was associated with limited therapeutic efficacy.	[Dedrick, Rebekah M.; Freeman, Krista G.; Smith, Bailey E.; Hatfull, Graham F.] Univ Pittsburgh, Biol Sci, Pittsburgh, PA 15260 USA; [Nguyen, Jan A.; Bahadirli-Talbott, Asli; Wu, Andrew E.; Ong, Aaron S.; Cohen, Keira A.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA; [Lin, Cheng Ting] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Ruppel, Lisa C.] Johns Hopkins Univ, Sch Med, Invest Pharm, Baltimore, MD USA; [Parrish, Nicole M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Hatfull, GF (corresponding author), Univ Pittsburgh, Biol Sci, Pittsburgh, PA 15260 USA.; Cohen, KA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA.	gfh@pitt.edu; kcohen8@jhmi.edu	Cohen, Keira/S-8617-2018	Cohen, Keira/0000-0002-4521-397X; Lin, Cheng Ting/0000-0003-0275-8037; Smith, Bailey/0000-0002-4613-734X; Dedrick, Rebekah/0000-0002-3666-711X; Freeman, Krista/0000-0002-2944-5076	Cystic Fibrosis Foundation [HATFUL19GO]; National Institutes of Health (NIH) [GM131729]; Howard Hughes Medical Institute [GT12053]; Fowler Fund for Phage Research; National Heart, Lung, and Blood Institute/NIH [K08 HL139994]; Burroughs Wellcome Fund Career Award for Medical Scientists	Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Fowler Fund for Phage Research; National Heart, Lung, and Blood Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund)	We thank D. Jacobs-Sera and H. G. Aull for the phage cocktail preparation, R. Garlena and D. Russell at the University of Pittsburgh for DNA sequencing and analysis and M. Ramsay, C. Lippincott, J. Zenilman, K. Dooley and E. Ignatius at Johns Hopkins University School of Medicine for their clinical discussions regarding the care of this patient. This work was funded by a Cystic Fibrosis Foundation grant no. HATFUL19GO, a National Institutes of Health (NIH) grant no. GM131729, a Howard Hughes Medical Institute grant no. GT12053 and by the Fowler Fund for Phage Research to G.F.H. as well as grants from the National Heart, Lung, and Blood Institute/NIH (no. K08 HL139994) and the Burroughs Wellcome Fund Career Award for Medical Scientists to K.A.C. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank R. Schooley, E. Rubin and B. Bishai for comments on the manuscript.	Aslam S, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa389; Aslam S, 2019, AM J TRANSPLANT, V19, P2631, DOI 10.1111/ajt.15503; Choi H, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01146-17, 10.1128/aac.01146-17]; Choi H, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02189-16; Dedrick RM, 2021, MBIO, V12, DOI 10.1128/mBio.03431-20; Dedrick RM, 2019, NAT MED, V25, P730, DOI 10.1038/s41591-019-0437-z; Dedrick RM, 2019, TUBERCULOSIS, V115, P14, DOI 10.1016/j.tube.2019.01.002; El Haddad L, 2019, CLIN INFECT DIS, V69, P167, DOI 10.1093/cid/ciy947; Gorski A, 2012, ADV VIRUS RES, V83, P41, DOI 10.1016/B978-0-12-394438-2.00002-5; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; Hatfull GF, 2020, ANNU REV VIROL, V7, P37, DOI 10.1146/annurev-virology-122019-070009; Hodyra-Stefaniak K, 2015, SCI REP-UK, V5, DOI 10.1038/srep14802; Jacobs-Sera D, 2012, VIROLOGY, V434, P187, DOI 10.1016/j.virol.2012.09.026; Jault P, 2019, LANCET INFECT DIS, V19, P35, DOI 10.1016/S1473-3099(18)30482-1; JERNE NK, 1956, J IMMUNOL, V76, P200; Johansen MD, 2020, NAT REV MICROBIOL, V18, P392, DOI 10.1038/s41579-020-0331-1; KAMME C, 1973, ACTA PATH MICRO IM B, VB 81, P741; Kortright KE, 2019, CELL HOST MICROBE, V25, P219, DOI 10.1016/j.chom.2019.01.014; Lusiak-Szelachowska M, 2014, VIRAL IMMUNOL, V27, P295, DOI 10.1089/vim.2013.0128; Roach DR, 2017, CELL HOST MICROBE, V22, P38, DOI 10.1016/j.chom.2017.06.018; Salmond GPC, 2015, NAT REV MICROBIOL, V13, P777, DOI 10.1038/nrmicro3564; Schooley RT, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00954-17	23	33	34	4	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1357	+		10.1038/s41591-021-01403-9	http://dx.doi.org/10.1038/s41591-021-01403-9		JUL 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34239133	Green Published, Green Accepted			2022-12-27	WOS:000672339400004
J	Proctor, DM; Dangana, T; Sexton, DJ; Fukuda, C; Yelin, RD; Stanley, M; Bell, PB; Baskaran, S; Deming, C; Chen, Q; Conlan, S; Park, M; Welsh, RM; Vallabhaneni, S; Chiller, T; Forsberg, K; Black, SR; Pacilli, M; Kong, HH; Lin, MY; Schoeny, ME; Litvintseva, AP; Segre, JA; Hayden, MK				Proctor, Diana M.; Dangana, Thelma; Sexton, D. Joseph; Fukuda, Christine; Yelin, Rachel D.; Stanley, Mary; Bell, Pamela B.; Baskaran, Sangeetha; Deming, Clay; Chen, Qiong; Conlan, Sean; Park, Morgan; Welsh, Rory M.; Vallabhaneni, Snigdha; Chiller, Tom; Forsberg, Kaitlin; Black, Stephanie R.; Pacilli, Massimo; Kong, Heidi H.; Lin, Michael Y.; Schoeny, Michael E.; Litvintseva, Anastasia P.; Segre, Julia A.; Hayden, Mary K.		NISC Comparative Sequencing Progra	Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility	NATURE MEDICINE			English	Article							HEALTH-CARE FACILITIES; NEW-YORK; RESISTANT; CHLORHEXIDINE; OUTBREAK; FUNGAL; STATES	Longitudinal skin site sampling of residents in a skilled nursing facility sheds light on persistent niches of the emerging fungal pathogen Candida auris. Candida auris is a fungal pathogen of high concern due to its ability to cause healthcare-associated infections and outbreaks, its resistance to antimicrobials and disinfectants and its persistence on human skin and in the inanimate environment. To inform surveillance and future mitigation strategies, we defined the extent of skin colonization and explored the microbiome associated with C. auris colonization. We collected swab specimens and clinical data at three times points between January and April 2019 from 57 residents (up to ten body sites each) of a ventilator-capable skilled nursing facility with endemic C. auris and routine chlorhexidine gluconate (CHG) bathing. Integrating microbial-genomic and epidemiologic data revealed occult C. auris colonization of multiple body sites not targeted commonly for screening. High concentrations of CHG were associated with suppression of C. auris growth but not with deleterious perturbation of commensal microbes. Modeling human mycobiome dynamics provided insight into underlying alterations to the skin fungal community as a possible modifiable risk factor for acquisition and persistence of C. auris. Failure to detect the extensive, disparate niches of C. auris colonization may reduce the effectiveness of infection-prevention measures that target colonized residents, highlighting the importance of universal strategies to reduce C. auris transmission.	[Proctor, Diana M.; Baskaran, Sangeetha; Deming, Clay; Chen, Qiong; Conlan, Sean; Segre, Julia A.] NHGRI, Microbial Genom Sect, Translat & Funct Genom Branch, NIH, Bethesda, MD 20892 USA; [Dangana, Thelma; Fukuda, Christine; Yelin, Rachel D.; Stanley, Mary; Bell, Pamela B.; Lin, Michael Y.; Hayden, Mary K.] Rush Univ, Dept Internal Med, Div Infect Dis, Med Ctr, Chicago, IL 60612 USA; [Sexton, D. Joseph; Welsh, Rory M.; Vallabhaneni, Snigdha; Chiller, Tom; Forsberg, Kaitlin; Litvintseva, Anastasia P.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA; [Park, Morgan] NHGRI, NIH, Intramural Sequencing Ctr, Bethesda, MD 20892 USA; [Vallabhaneni, Snigdha] CDC, Div Healthcare Qual Promot, NCEZID, Atlanta, GA USA; [Black, Stephanie R.; Pacilli, Massimo] Chicago Dept Publ Hlth, Communicable Dis Program, Chicago, IL USA; [Kong, Heidi H.] NIAMSD, Dermatol Branch, NIH, Bethesda, MD 20892 USA; [Schoeny, Michael E.] Rush Univ, Coll Nursing, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Rush University; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Centers for Disease Control & Prevention - USA; Chicago Department of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Rush University	Segre, JA (corresponding author), NHGRI, Microbial Genom Sect, Translat & Funct Genom Branch, NIH, Bethesda, MD 20892 USA.; Hayden, MK (corresponding author), Rush Univ, Dept Internal Med, Div Infect Dis, Med Ctr, Chicago, IL 60612 USA.	jsegre@nhgri.nih.gov; mhayden@rush.edu	Proctor, Diana/HDO-1332-2022	Forsberg, Kaitlin/0000-0002-5779-2446; Proctor, Diana/0000-0002-7078-0669	CDC [75D30118C02900]; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Human Genome Research Institute	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. This work was supported in part by CDC contract number 75D30118C02900. This study used the computational resources of the National Institutes of Health (NIH) HPC Biowulf Cluster http://hpc.nih.gov).This work was supported by the Intramural Research Programs of the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Human Genome Research Institute. We thank J. Fekecs for assistance rendering publication-ready figures.	Adams E, 2018, EMERG INFECT DIS, V24, P1816, DOI 10.3201/eid2410.180649; Bishop L., 2017, PUBLIC HLTH ENGLAND; Biswal M, 2017, J HOSP INFECT, V97, P363, DOI 10.1016/j.jhin.2017.09.009; Centers for Disease Control and Prevention, 2019, ANTIBIOTIC RESISTANC, DOI [10.15620/cdc:82532, DOI 10.15620/CDC:82532]; Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases, SCR CAND AUR COL; Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Foodborne Waterborne and Environmental Diseases (DFWED), 2020, ANT SUSC TEST INT; CHEN J, 2020, BMC INFECT DIS, V20; Chow NA, 2020, MBIO, V11, DOI 10.1128/mBio.03364-19; CLSI, 2008, REF METH BRO DIL ANT; DiGiulio DB, 2015, P NATL ACAD SCI USA, V112, P11060, DOI 10.1073/pnas.1502875112; Edmiston CE, 2008, J AM COLL SURGEONS, V207, P233, DOI 10.1016/j.jamcollsurg.2007.12.054; Fadrosh DW, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-6; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Horton MV, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00910-19; Huang X, 2021, CELL HOST MICROBE, V29, P210, DOI 10.1016/j.chom.2020.12.002; Jeffery-Smith A, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00029-17; Kampf G, 2008, J HOSP INFECT, V70, P27, DOI 10.1016/S0195-6701(08)60008-0; Khot PD, 2009, APPL ENVIRON MICROB, V75, P1559, DOI 10.1128/AEM.02383-08; Koren S, 2017, GENOME RES, V27, P722, DOI 10.1101/gr.215087.116; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Larkin E, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.02396-16, 10.1128/AAC.02396-16]; Lockhart SR, 2017, CLIN INFECT DIS, V64, P134, DOI 10.1093/cid/ciw691; Moore G, 2017, J HOSP INFECT, V97, P371, DOI 10.1016/j.jhin.2017.08.019; Nutman A, 2020, INFECT CONT HOSP EP, V41, P965, DOI 10.1017/ice.2020.197; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Ostrowsky B, 2020, MMWR-MORBID MORTAL W, V69, P6, DOI 10.15585/mmwr.mm6901a2; Pacilli M, 2020, CLIN INFECT DIS, V71, pE718, DOI 10.1093/cid/ciaa435; Popovich KJ, 2012, INFECT CONT HOSP EP, V33, P889, DOI 10.1086/667371; Prestel C, 2021, MMWR-MORBID MORTAL W, V70, P56, DOI 10.15585/mmwr.mm7002e3; Proctor DM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02900-1; Prohic A, 2016, INT J DERMATOL, V55, P494, DOI 10.1111/ijd.13116; Raz-Pasteur A, 2011, ISRN Dermatol, V2011, P150642, DOI 10.5402/2011/150642; Reichel Mirja, 2008, Ann Clin Microbiol Antimicrob, V7, P20, DOI 10.1186/1476-0711-7-20; ROSSOW J, 2020, CLIN INFECT DIS; Schelenz S, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0132-5; Sherry L, 2017, EMERG INFECT DIS, V23, P328, DOI 10.3201/eid2302.161320; Snitkin ES, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0093; Snitkin ES, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004129; Supple L, 2015, INFECT CONT HOSP EP, V36, P1095, DOI 10.1017/ice.2015.124; Thurlow CJ, 2013, INFECT CONT HOSP EP, V34, P56, DOI 10.1086/668783; Tsay S, 2018, CLIN INFECT DIS, V66, P306, DOI 10.1093/cid/cix744; Tsay S, 2017, MMWR-MORBID MORTAL W, V66, P514, DOI 10.15585/mmwr.mm6619a7; Vallabhaneni S, 2016, MMWR-MORBID MORTAL W, V65, P1234, DOI 10.15585/mmwr.mm6544e1; Vaser R, 2017, GENOME RES, V27, P737, DOI 10.1101/gr.214270.116; Walker BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112963; Weiner LM, 2016, INFECT CONT HOSP EP, V37, P1105, DOI 10.1017/ice.2016.139; Welsh RM, 2017, J CLIN MICROBIOL, V55, P2996, DOI [10.1128/jcm.00921-17, 10.1128/JCM.00921-17]; Weschler CJ, 2011, ENVIRON SCI TECHNOL, V45, P3872, DOI 10.1021/es103894r; Zhu YC, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01503-19	49	21	21	5	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1401	+		10.1038/s41591-021-01383-w	http://dx.doi.org/10.1038/s41591-021-01383-w		JUN 2021	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34155414	Bronze, Green Accepted			2022-12-27	WOS:000664012800002
J	Salloway, S; Farlow, M; McDade, E; Clifford, DB; Wang, GQ; Llibre-Guerra, JJ; Hitchcock, JM; Mills, SL; Santacruz, AM; Aschenbrenner, AJ; Hassenstab, J; Benzinger, TLS; Gordon, BA; Fagan, AM; Coalier, KA; Cruchaga, C; Goate, AA; Perrin, RJ; Xiong, CJ; Li, Y; Morris, JC; Snider, BJ; Mummery, C; Surti, GM; Hannequin, D; Wallon, D; Berman, SB; Lah, JJ; Jimenez-Velazquez, IZ; Roberson, ED; van Dyck, CH; Honig, LS; Sanchez-Valle, R; Brooks, WS; Gauthier, S; Galasko, DR; Masters, CL; Brosch, JR; Hsiung, GYR; Jayadev, S; Formaglio, M; Masellis, M; Clarnette, R; Pariente, J; Dubois, B; Pasquier, F; Jack, CR; Koeppe, R; Snyder, PJ; Aisen, PS; Thomas, RG; Berry, SM; Wendelberger, BA; Andersen, SW; Holdridge, KC; Mintun, MA; Yaari, R; Sims, JR; Baudler, M; Delmar, P; Doody, RS; Fontoura, P; Giacobino, C; Kerchner, GA; Bateman, RJ				Salloway, Stephen; Farlow, Martin; McDade, Eric; Clifford, David B.; Wang, Guoqiao; Llibre-Guerra, Jorge J.; Hitchcock, Janice M.; Mills, Susan L.; Santacruz, Anna M.; Aschenbrenner, Andrew J.; Hassenstab, Jason; Benzinger, Tammie L. S.; Gordon, Brian A.; Fagan, Anne M.; Coalier, Kelley A.; Cruchaga, Carlos; Goate, Alison A.; Perrin, Richard J.; Xiong, Chengjie; Li, Yan; Morris, John C.; Snider, B. Joy; Mummery, Catherine; Surti, G. Mustafa; Hannequin, Didier; Wallon, David; Berman, Sarah B.; Lah, James J.; Jimenez-Velazquez, Ivonne Z.; Roberson, Erik D.; van Dyck, Christopher H.; Honig, Lawrence S.; Sanchez-Valle, Raquel; Brooks, William S.; Gauthier, Serge; Galasko, Douglas R.; Masters, Colin L.; Brosch, Jared R.; Hsiung, Ging-Yuek Robin; Jayadev, Suman; Formaglio, Maite; Masellis, Mario; Clarnette, Roger; Pariente, Jeremie; Dubois, Bruno; Pasquier, Florence; Jack, Clifford R., Jr.; Koeppe, Robert; Snyder, Peter J.; Aisen, Paul S.; Thomas, Ronald G.; Berry, Scott M.; Wendelberger, Barbara A.; Andersen, Scott W.; Holdridge, Karen C.; Mintun, Mark A.; Yaari, Roy; Sims, John R.; Baudler, Monika; Delmar, Paul; Doody, Rachelle S.; Fontoura, Paulo; Giacobino, Caroline; Kerchner, Geoffrey A.; Bateman, Randall J.		Dominantly Inherited Alzheimer Net	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease	NATURE MEDICINE			English	Article							RANDOMIZED-TRIAL; DRUG-DEVELOPMENT; DEMENTIA; RELIABILITY; PREVENTION; MEMORY	Results from the phase 2/3 clinical trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease reveal no beneficial effects on cognitive measures despite a significant reduction in amyloid plaques and other key biomarkers in those treated with gantenerumab. Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. We conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages. Mutation carriers were assigned 3:1 to either drug or placebo and received treatment for 4-7 years. The primary outcome was a cognitive end point; secondary outcomes included clinical, cognitive, imaging and fluid biomarker measures. Fifty-two participants carrying a mutation were assigned to receive gantenerumab, 52 solanezumab and 40 placebo. Both drugs engaged their A beta targets but neither demonstrated a beneficial effect on cognitive measures compared to controls. The solanezumab-treated group showed a greater cognitive decline on some measures and did not show benefits on downstream biomarkers. Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain. Amyloid-related imaging abnormalities edema was observed in 19.2% (3 out of 11 were mildly symptomatic) of the gantenerumab group, 2.5% of the placebo group and 0% of the solanezumab group. Gantenerumab and solanezumab did not slow cognitive decline in symptomatic DIAD. The asymptomatic groups showed no cognitive decline; symptomatic participants had declined before reaching the target doses.	[Salloway, Stephen; Surti, G. Mustafa] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Farlow, Martin; Brosch, Jared R.] Indiana Univ, Sch Med, Indianapolis, IN USA; [McDade, Eric; Clifford, David B.; Wang, Guoqiao; Llibre-Guerra, Jorge J.; Mills, Susan L.; Santacruz, Anna M.; Aschenbrenner, Andrew J.; Hassenstab, Jason; Benzinger, Tammie L. S.; Gordon, Brian A.; Fagan, Anne M.; Coalier, Kelley A.; Cruchaga, Carlos; Perrin, Richard J.; Xiong, Chengjie; Li, Yan; Morris, John C.; Snider, B. Joy; Bateman, Randall J.] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Hitchcock, Janice M.] Hitchcock Regulatory Consulting Inc, Fishers, IN USA; [Goate, Alison A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Mummery, Catherine] UCL, London, England; [Hannequin, Didier; Wallon, David] Ctr Hosp Univ Rouen, Rouen, France; [Berman, Sarah B.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Lah, James J.] Emory Univ, Med Ctr, Atlanta, GA 30322 USA; [Jimenez-Velazquez, Ivonne Z.] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA; [Roberson, Erik D.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [van Dyck, Christopher H.] Yale Univ, Sch Med, New Haven, CT USA; [Honig, Lawrence S.] Columbia Univ, Med Ctr, New York, NY USA; [Sanchez-Valle, Raquel] Univ Barcelona, August Pi & Sunyer Biomed Res Inst, Hosp Clin & Prov Barcelona, Barcelona, Spain; [Brooks, William S.] Univ New South Wales Med, Neurosci Res Australia, Randwick, NSW, Australia; [Gauthier, Serge] McGill Univ, McGill Ctr Studies Aging, Montreal, PQ, Canada; [Galasko, Douglas R.; Thomas, Ronald G.] Univ Calif San Diego, San Diego, CA 92103 USA; [Masters, Colin L.] Univ Melbourne, Melbourne, Vic, Australia; [Hsiung, Ging-Yuek Robin] Univ British Columbia, Vancouver, BC, Canada; [Jayadev, Suman] Univ Washington, Sch Med, Seattle, WA USA; [Formaglio, Maite] Hosp Civils Lyon, Lyon, France; [Masellis, Mario] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Clarnette, Roger] Univ Western Australia, Australian Alzheimers Res Fdn, Perth, WA, Australia; [Pariente, Jeremie] Univ Toulouse, Ctr Hosp, Toulouse, France; [Dubois, Bruno] Salpetriere Univ Hosp, Neurol Inst, Paris, France; [Pasquier, Florence] Ctr Hosp Reg Univ Lille, Lille, France; [Jack, Clifford R., Jr.] Mayo Clin, Rochester, MN USA; [Koeppe, Robert] Univ Michigan, Ann Arbor, MI 48109 USA; [Snyder, Peter J.] Univ Rhode Isl, Kingston, RI 02881 USA; [Aisen, Paul S.] Univ Southern Calif, Keck Sch Med, San Diego, CA USA; [Berry, Scott M.; Wendelberger, Barbara A.] Berry Consultants LLC, Austin, TX USA; [Andersen, Scott W.; Holdridge, Karen C.; Mintun, Mark A.; Yaari, Roy; Sims, John R.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Baudler, Monika; Delmar, Paul; Doody, Rachelle S.; Fontoura, Paulo; Giacobino, Caroline; Kerchner, Geoffrey A.] F Hoffmann La Roche Ltd, Basel, Switzerland	Brown University; Indiana University System; Indiana University-Purdue University Indianapolis; Washington University (WUSTL); Icahn School of Medicine at Mount Sinai; University of London; University College London; CHU de Rouen; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Alabama System; University of Alabama Birmingham; Yale University; Columbia University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Neuroscience Research Australia; University of New South Wales Sydney; McGill University; University of California System; University of California San Diego; University of Melbourne; University of British Columbia; University of Washington; University of Washington Seattle; CHU Lyon; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Western Australia; CHU de Toulouse; Universite de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; Mayo Clinic; University of Michigan System; University of Michigan; University of Rhode Island; University of Southern California; Eli Lilly; Roche Holding	Bateman, RJ (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.	batemanr@wustl.edu	Cruchaga, Carlos/ABF-4065-2020; Gordon, Brian/U-7794-2019; Wallon, David/AAI-1352-2020; Jack, Clifford R/F-2508-2010; Roberson, Erik/A-5718-2009; Sanchez-Valle, Raquel/I-4217-2015; Berman, Sarah/I-2792-2014	Cruchaga, Carlos/0000-0002-0276-2899; Gordon, Brian/0000-0003-2109-2955; Jack, Clifford R/0000-0001-7916-622X; Snyder, Peter/0000-0003-0555-4654; Aschenbrenner, Andrew/0000-0002-4317-7282; Roberson, Erik/0000-0002-1810-9763; Sanchez-Valle, Raquel/0000-0001-7750-896X; Wendelberger, Barbara/0000-0003-4426-9602; Berman, Sarah/0000-0002-5096-4962; Salloway, Stephen/0000-0002-2631-0942; McDade, Eric/0000-0002-6764-3866	DIAN-TU; Alzheimer's Association; GHR Foundation; Avid Radiopharmaceuticals; Signant Health; Cogstate; NIA of the NIH [U01AG042791, U01AG042791-S1, R01AG046179, R01AG053267-S1]; Eli Lilly and Company; F. Hoffman-LaRoche Ltd; Avid Radiopharmaceuticals GHR Foundation; NIA of the NIH (DIAN) [U19AG032438]; German Center for Neurodegenerative Diseases; Raul Carrea Institute for Neurological Research; Japan Agency for Medical Research and Development (AMED); Korea Health Technology R&D Project through the Korea Health Industry Development Institute	DIAN-TU; Alzheimer's Association(Alzheimer's Association); GHR Foundation; Avid Radiopharmaceuticals; Signant Health; Cogstate(CogState Limited); NIA of the NIH; Eli Lilly and Company(Eli Lilly); F. Hoffman-LaRoche Ltd; Avid Radiopharmaceuticals GHR Foundation; NIA of the NIH (DIAN); German Center for Neurodegenerative Diseases; Raul Carrea Institute for Neurological Research; Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Korea Health Technology R&D Project through the Korea Health Industry Development Institute	We gratefully acknowledge the outstanding commitment of the participants, family members and caregivers whose participation was critical to the success of the DIAN-TU trial. We thank the DIAN-TU Funding and Study Team (https://dian.wustl.edu/our-research/clinical-trial/funding/) for their exceptional dedication and accomplishments, which ensured the success of the trial. We thank the DIAN-EXR and DIAN-OBS study teams for their support on recruitment and commitment to family members. We acknowledge the robust intellectual collaboration between the DIAN-TU investigators, participants and family members, F. Hoffmann-La Roche, Ltd/Genentech and Eli Lilly and Company, the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/), the NIH, and regulatory representatives who were critical in making this study possible. We thank the Alzheimer's Association, GHR Foundation, an anonymous organization, other industry partners (Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, Signant Health and Cogstate) and regulatory representatives for their support. We also thank L. Ryan from the National Institute on Aging (NIA) for her key contributions in leadership and scientific guidance on this project. The research reported in this publication was supported by the NIA of the NIH under award nos. U01AG042791, U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), R01AG046179 and R01AG053267-S1. This research was also supported by the Alzheimer's Association, Eli Lilly and Company, F. Hoffman-LaRoche Ltd, Avid Radiopharmaceuticals GHR Foundation and an anonymous organization. Cogstate and Signant Health offered in-kind support. The DIAN-OBS was supported by the NIA of the NIH (DIAN, U19AG032438), the German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, partial support by the Research and Development Grants for Dementia from the Japan Agency for Medical Research and Development (AMED) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute.	Bateman RJ, 2017, ALZHEIMERS DEMENT, V13, P8, DOI 10.1016/j.jalz.2016.07.005; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; BERG L, 1988, ANN NEUROL, V23, P477, DOI 10.1002/ana.410230509; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Breines E., 1988, CAN J OCCUP THER, V55, P135, DOI [10.1177/000841748805500306, DOI 10.1177/000841748805500306]; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Cummings J, 2018, CTS-CLIN TRANSL SCI, V11, P147, DOI 10.1111/cts.12491; Cummings J, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0207-9; Cummings JL, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt269; Egan MF, 2019, NEW ENGL J MED, V380, P1408, DOI 10.1056/NEJMoa1812840; Farlow M, 2012, ALZHEIMERS DEMENT, V8, P261, DOI 10.1016/j.jalz.2011.09.224; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fitzmaurice G.M., 2012, APPL LONGITUDINAL AN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gordon BA, 2019, BRAIN, V142, P1063, DOI 10.1093/brain/awz019; Gordon BA, 2018, LANCET NEUROL, V17, P241, DOI 10.1016/S1474-4422(18)30028-0; Haeberlein SB., 2020, ALZHEIMERS DEMENT, V16, P1, DOI [DOI 10.1002/ALZ.047259, 10.1002/alz.047259]; Henley D, 2019, NEW ENGL J MED, V380, P1483, DOI 10.1056/NEJMc1813435; Honig LS, 2018, NEW ENGL J MED, V378, P321, DOI 10.1056/NEJMoa1705971; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Karran E, 2016, J NEUROCHEM, V139, P237, DOI 10.1111/jnc.13632; Klein G, 2021, JPAD-J PREV ALZHEIM, V8, P3, DOI 10.14283/jpad.2020.68; Lim J, 2020, THER INNOV REGUL SCI, V54, P850, DOI 10.1007/s43441-019-00014-4; Lim YY, 2009, BEHAV RES METHODS, V41, P1190, DOI 10.3758/BRM.41.4.1190; McDade E, 2018, NEUROLOGY, V91, pE1295, DOI 10.1212/WNL.0000000000006277; McDade E, 2017, NATURE, V547, P153, DOI 10.1038/547153a; Mills SM, 2013, REV NEUROL-FRANCE, V169, P737, DOI 10.1016/j.neurol.2013.07.017; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris John C, 2012, Clin Investig (Lond), V2, P975; Moulder KL, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt213; Ostrowitzki S, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0318-y; Ringman JM, 2016, J NEUROPATH EXP NEUR, V75, P284, DOI 10.1093/jnen/nlv028; Robert C.P., 2000, TECHNOMETRICS, V42, P430, DOI [10.2307/1270959, DOI 10.2307/1270959]; Rousset OG, 1998, J NUCL MED, V39, P904; Ryman Davis C, 2014, Neurology, V83, P253, DOI 10.1212/WNL.0000000000000596; Schuck EL, 2019, ALZHEIMERS DEMENT, V15, pP1582, DOI [10.1016/j.jalz.2019.09.023, DOI 10.1016/J.JALZ.2019.09.023]; Selkoe D, 2019, LANCET NEUROL, V18, P624, DOI 10.1016/S1474-4422(19)30202-9; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Shepherd C, 2009, ACTA NEUROPATHOL, V118, P37, DOI 10.1007/s00401-009-0521-4; Siemers ER, 2016, ALZHEIMERS DEMENT, V12, P110, DOI [10.1016/j.jalz.2015.06.1893, 10.1016/j.dadm.2016.02.006]; Sperling R, 2012, LANCET NEUROL, V11, P241, DOI 10.1016/S1474-4422(12)70015-7; Su Y, 2018, NEUROIMAGE-CLIN, V19, P406, DOI 10.1016/j.nicl.2018.04.022; Su Y, 2015, NEUROIMAGE, V107, P55, DOI 10.1016/j.neuroimage.2014.11.058; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Thompson TAC, 2011, ARCH CLIN NEUROPSYCH, V26, P412, DOI 10.1093/arclin/acr039; Viele K, 2014, PHARM STAT, V13, P41, DOI 10.1002/pst.1589; Vlassenko AG, 2016, ANN NEUROL, V80, P379, DOI 10.1002/ana.24719; Wang GQ, 2018, STAT MED, V37, P3047, DOI 10.1002/sim.7811; Wechsler D, 2008, WAIS 3 WECHSLER ADUL, VFourth; Wechsler D., 1984, WMS R WECHSLER MEMOR; Weninger Stacie, 2016, Alzheimers Dement, V12, P631, DOI 10.1016/j.jalz.2016.04.001; Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062	55	88	89	10	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1187	+		10.1038/s41591-021-01369-8	http://dx.doi.org/10.1038/s41591-021-01369-8		JUN 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34155411	Green Accepted			2022-12-27	WOS:000664012800001
J	Milman, O; Yelin, I; Aharony, N; Katz, R; Herzel, E; Ben-Tov, A; Kuint, J; Gazit, S; Chodick, G; Patalon, T; Kishony, R				Milman, Oren; Yelin, Idan; Aharony, Noga; Katz, Rachel; Herzel, Esma; Ben-Tov, Amir; Kuint, Jacob; Gazit, Sivan; Chodick, Gabriel; Patalon, Tal; Kishony, Roy			Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals	NATURE MEDICINE			English	Article								New data from a large healthcare organization in Israel reveal a reduction in new infections in an unvaccinated population in communities with rapid vaccination rollouts, suggesting that mass vaccination strategies confer cross-protection of unvaccinated individuals. Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting individuals who have been vaccinated against the disease and possibly lowering the likelihood of transmission to individuals who have not been vaccinated. The high effectiveness of the widely administered BNT162b vaccine from Pfizer-BioNTech in preventing not only the disease but also infection with SARS-CoV-2 suggests a potential for a population-level effect, which is critical for disease eradication. However, this putative effect is difficult to observe, especially in light of highly fluctuating spatiotemporal epidemic dynamics. Here, by analyzing vaccination records and test results collected during the rapid vaccine rollout in a large population from 177 geographically defined communities, we find that the rates of vaccination in each community are associated with a substantial later decline in infections among a cohort of individuals aged under 16 years, who are unvaccinated. On average, for each 20 percentage points of individuals who are vaccinated in a given population, the positive test fraction for the unvaccinated population decreased approximately twofold. These results provide observational evidence that vaccination not only protects individuals who have been vaccinated but also provides cross-protection to unvaccinated individuals in the community.	[Milman, Oren; Yelin, Idan; Aharony, Noga; Kishony, Roy] Technion Israel Inst Technol, Fac Biol, Haifa, Israel; [Katz, Rachel; Herzel, Esma; Ben-Tov, Amir; Kuint, Jacob; Gazit, Sivan; Chodick, Gabriel; Patalon, Tal] Maccabi Healthcare Serv, Maccabitech, Tel Aviv, Israel; [Ben-Tov, Amir; Kuint, Jacob; Chodick, Gabriel] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Kishony, Roy] Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel	Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Technion Israel Institute of Technology	Kishony, R (corresponding author), Technion Israel Inst Technol, Fac Biol, Haifa, Israel.; Patalon, T (corresponding author), Maccabi Healthcare Serv, Maccabitech, Tel Aviv, Israel.; Kishony, R (corresponding author), Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel.	patalon_t@mac.org.il; rkishony@technion.ac.il		Milman, Oren/0000-0001-8957-4964; Patalon, Tal/0000-0001-7415-1053; Yelin, Idan/0000-0003-2515-4113; /0000-0002-5189-8995	Israel Science Foundation [3633/19]	Israel Science Foundation(Israel Science Foundation)	This work was supported by the Israel Science Foundation (grant no. 3633/19 to R. Kishony and G.C.) as part of the KillCorona-Curbing Coronavirus Research Program.	Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2; Beraud G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133203; Buss LF, 2021, SCIENCE, V371, P288, DOI 10.1126/science.abe9728; Chodick, BIORXIV, DOI [10.1101/2021.01.27.21250612(2021, DOI 10.1101/2021.01.27.21250612(2021]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Harvey RA, 2021, JAMA INTERN MED, V181, P672, DOI 10.1001/jamainternmed.2021.0366; Hayashida, MEDRXIV, DOI [10.1101/2020.09.21.20198796 (2021), DOI 10.1101/2020.09.21.20198796(2021)]; Kadkhoda K, 2021, AM J CLIN PATHOL, V155, P471, DOI 10.1093/ajcp/aqaa272; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Ministry of Health, 2021, CORONAVIRUS CABINET; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rossman H, 2021, NAT MED, V27, P1055, DOI 10.1038/s41591-021-01337-2; Yelin, BIORXIV, DOI [10.1101/2021.03.16.21253686(2021, DOI 10.1101/2021.03.16.21253686(2021]	15	43	43	2	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1367	+		10.1038/s41591-021-01407-5	http://dx.doi.org/10.1038/s41591-021-01407-5		JUN 2021	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34113015	Bronze, Green Submitted			2022-12-27	WOS:000659795100001
J	Singh, N; Frey, NV; Engels, B; Barrett, DM; Shestova, O; Ravikumar, P; Cummins, KD; Lee, YG; Pajarillo, R; Chun, I; Shyu, A; Highfill, SL; Price, A; Zhao, LL; Peng, LM; Granda, B; Ramones, M; Lu, XM; Christian, DA; Perazzelli, J; Lacey, SF; Roy, NH; Burkhardt, JK; Colomb, F; Damra, M; Abdel-Mohsen, M; Liu, T; Liu, DF; Standley, DM; Young, RM; Brogdon, JL; Grupp, SA; June, CH; Maude, SL; Gill, S; Ruella, M				Singh, Nathan; Frey, Noelle, V; Engels, Boris; Barrett, David M.; Shestova, Olga; Ravikumar, Pranali; Cummins, Katherine D.; Lee, Yong Gu; Pajarillo, Raymone; Chun, Inkook; Shyu, Amy; Highfill, Steven L.; Price, Andrew; Zhao, Linlin; Peng, Liaomin; Granda, Brian; Ramones, Melissa; Lu, Xueqing Maggie; Christian, David A.; Perazzelli, Jessica; Lacey, Simon F.; Roy, Nathan H.; Burkhardt, Janis K.; Colomb, Florent; Damra, Mohammad; Abdel-Mohsen, Mohamed; Liu, Ting; Liu, Dongfang; Standley, Daron M.; Young, Regina M.; Brogdon, Jennifer L.; Grupp, Stephan A.; June, Carl H.; Maude, Shannon L.; Gill, Saar; Ruella, Marco			Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells	NATURE MEDICINE			English	Article							RECEPTORS; IDENTIFICATION; REMISSION; CHILDREN; SURVIVAL; SYNAPSE; ADULTS	While CD19-directed chimeric antigen receptor (CAR) T cells can induce remission in patients with B cell acute lymphoblastic leukemia (ALL), a large subset relapse with CD19- disease. Like CD19, CD22 is broadly expressed by B-lineage cells and thus serves as an alternative immunotherapy target in ALL. Here we present the composite outcomes of two pilot clinical trials (NCT02588456 and NCT02650414) of T cells bearing a 4-1BB-based, CD22-targeting CAR in patients with relapsed or refractory ALL. The primary end point of these studies was to assess safety, and the secondary end point was antileukemic efficacy. We observed unexpectedly low response rates, prompting us to perform detailed interrogation of the responsible CAR biology. We found that shortening of the amino acid linker connecting the variable heavy and light chains of the CAR antigen-binding domain drove receptor homodimerization and antigen-independent signaling. In contrast to CD28-based CARs, autonomously signaling 4-1BB-based CARs demonstrated enhanced immune synapse formation, activation of pro-inflammatory genes and superior effector function. We validated this association between autonomous signaling and enhanced function in several CAR constructs and, on the basis of these observations, designed a new short-linker CD22 single-chain variable fragment for clinical evaluation. Our findings both suggest that tonic 4-1BB-based signaling is beneficial to CAR function and demonstrate the utility of bedside-to-bench-to-bedside translation in the design and implementation of CAR T cell therapies.	[Singh, Nathan; Frey, Noelle, V; June, Carl H.; Gill, Saar; Ruella, Marco] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Singh, Nathan; Shestova, Olga; Ravikumar, Pranali; Cummins, Katherine D.; Lee, Yong Gu; Pajarillo, Raymone; Chun, Inkook; Lacey, Simon F.; Young, Regina M.; June, Carl H.; Gill, Saar; Ruella, Marco] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA; [Engels, Boris; Shyu, Amy; Highfill, Steven L.; Price, Andrew; Zhao, Linlin; Peng, Liaomin; Granda, Brian; Ramones, Melissa; Brogdon, Jennifer L.] Novartis Inst Biomed Res, Cambridge, MA USA; [Barrett, David M.; Perazzelli, Jessica; Grupp, Stephan A.; Maude, Shannon L.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Barrett, David M.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lu, Xueqing Maggie] Univ Penn, Perelman Sch Med, Penn Inst Biomed Informat, Philadelphia, PA 19104 USA; [Christian, David A.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Lacey, Simon F.] Univ Penn, Perelman Sch Med, Translat & Correlat Studies Lab, Philadelphia, PA 19104 USA; [Lacey, Simon F.; Roy, Nathan H.; Burkhardt, Janis K.; June, Carl H.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Roy, Nathan H.; Burkhardt, Janis K.] Childrens Hosp, Philadelphia Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Colomb, Florent; Damra, Mohammad; Abdel-Mohsen, Mohamed] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Liu, Ting; Liu, Dongfang] Rutgers New Jersey Med Sch, Dept Pathol Immunol & Lab Med, Newark, NJ USA; [Liu, Dongfang] State Univ New Jersey, Rutgers New Jersey Med Sch, Ctr Immun & Inflammat, Newark, Japan; [Standley, Daron M.] Res Inst Microbial Dis, Osaka, Japan; [Singh, Nathan] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Novartis; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; The Wistar Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL)	Singh, N; Ruella, M (corresponding author), Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Singh, N; Ruella, M (corresponding author), Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.; Singh, N (corresponding author), Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA.	nathan.singh@wustl.edu; mruella@upenn.edu	Ruella, Marco/GQP-8473-2022	Liu, Dongfang/0000-0002-7295-8088; Cummins, Katherine/0000-0001-9041-0828; Abdel-Mohsen, Mohamed/0000-0002-9945-4314; Singh, Nathan/0000-0002-0350-7574	CHOP Immunotherapy Frontier Program; Emily Whitehead Foundation; V Foundation; Curing Kids Cancer; Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship; Breakthrough Bike Challenge Buz Cooper Scholarship; Stand Up To Cancer (SU2C) Innovative Research Grant [SU2C-AACR-IRG 12-17]; National Institutes of Health [R01GM104867]; National Heart, Lung, and Blood Institute [HL125018]; National Institute of Allergy and Infectious Diseases [AI124769, AI129594, AI130197]; Japan Agency for Medical Research and Development [P20am0101108]; NCI [K08CA194256, 1P01CA214278, R01CA226983]; American Society of Hematology Scholar Award, NCI [1K99CA212302, R00CA212302]; University of Pennsylvania-Novartis Alliance; Cancer Research Institute Irvington Fellowship	CHOP Immunotherapy Frontier Program; Emily Whitehead Foundation; V Foundation; Curing Kids Cancer; Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship; Breakthrough Bike Challenge Buz Cooper Scholarship; Stand Up To Cancer (SU2C) Innovative Research Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Society of Hematology Scholar Award, NCI; University of Pennsylvania-Novartis Alliance; Cancer Research Institute Irvington Fellowship	We thank F. Chen and N. Koterba for technical assistance with the cytokine quantification assays and J. Schug for assistance with the RNA sequencing. The pediatric trial was supported by the CHOP Immunotherapy Frontier Program, in addition to support from the Emily Whitehead Foundation, V Foundation and Curing Kids Cancer (S.A.G.). The preclinical research was supported by the Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship (N.S.); a Breakthrough Bike Challenge Buz Cooper Scholarship (N.S.); Stand Up To Cancer (SU2C) Innovative Research Grant no. SU2C-AACR-IRG 12-17 (D.M.B.; SU2C is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C); National Institutes of Health grant no. R01GM104867 (J.K.B.); a Cancer Research Institute Irvington Fellowship (N.H.R.); National Heart, Lung, and Blood Institute grant no. HL125018 and National Institute of Allergy and Infectious Diseases grant nos. AI124769, AI129594 and AI130197 (D.L.); Japan Agency for Medical Research and Development grant no. P20am0101108 (D.M.S.); NCI grant no. K08CA194256 (S.G.); an American Society of Hematology Scholar Award, NCI grant nos. 1K99CA212302 and R00CA212302 (M.R.); University of Pennsylvania-Novartis Alliance (S.G. and C.H.J.); and NCI grant nos. 1P01CA214278 and R01CA226983 (C.H.J.).	Ahmed F, 2009, J IMMUNOL METHODS, V347, P79, DOI 10.1016/j.jim.2009.05.014; Alabanza L, 2017, MOL THER, V25, P2452, DOI 10.1016/j.ymthe.2017.07.013; Barrett DM, 2011, BLOOD, V118, pE112, DOI 10.1182/blood-2011-04-346528; Colomb F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00267; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Dustin ML, 2011, NAT REV IMMUNOL, V11, P672, DOI 10.1038/nri3066; Frigault MJ, 2015, CANCER IMMUNOL RES, V3, P356, DOI 10.1158/2326-6066.CIR-14-0186; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Geyer MB, 2017, BLOOD, V129, P1878, DOI 10.1182/blood-2016-11-749507; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hamieh M, 2019, NATURE, V568, P112, DOI 10.1038/s41586-019-1054-1; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; Hay KA, 2019, BLOOD, V133, P1652, DOI 10.1182/blood-2018-11-883710; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Hudson PJ, 1999, J IMMUNOL METHODS, V231, P177, DOI 10.1016/S0022-1759(99)00157-X; Jonnalagadda M, 2015, MOL THER, V23, P757, DOI 10.1038/mt.2014.208; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lis M., 2011, IMMUNOME RES, V7, P1, DOI DOI 10.4172/1745-7580.1000041; Liu DF, 2012, IMMUNITY, V36, P600, DOI 10.1016/j.immuni.2012.03.007; Liu DF, 2009, IMMUNITY, V31, P99, DOI 10.1016/j.immuni.2009.05.009; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Ma HQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04227; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Orlando EJ, 2018, NAT MED, V24, P1504, DOI 10.1038/s41591-018-0146-z; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; Porter D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0571-y; Richman SA, 2018, CANCER IMMUNOL RES, V6, P36, DOI 10.1158/2326-6066.CIR-17-0211; Ruella M, 2018, NAT MED, V24, P1499, DOI 10.1038/s41591-018-0201-9; Schirrmann T, 2010, MABS-AUSTIN, V2, P73, DOI 10.4161/mabs.2.1.10784; Schritt D, 2019, MOL SYST DES ENG, V4, P761, DOI 10.1039/c9me00020h; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Xiao XD, 2009, MABS-AUSTIN, V1, P297, DOI 10.4161/mabs.1.3.8113; Xiong W, 2018, MOL THER, V26, P963, DOI 10.1016/j.ymthe.2018.01.020; Ying ZT, 2019, NAT MED, V25, P947, DOI 10.1038/s41591-019-0421-7	40	28	32	4	16	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					842	+		10.1038/s41591-021-01326-5	http://dx.doi.org/10.1038/s41591-021-01326-5		APR 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33888899	Green Accepted			2022-12-27	WOS:000642382600002
J	Zhang, T; George, DJ				Zhang, Tian; George, Daniel J.			Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment	NATURE MEDICINE			English	Editorial Material							RENAL-CELL CARCINOMA; PLUS AXITINIB; OPEN-LABEL; SUNITINIB; CABOZANTINIB; EFFICACY	Results from the latest phase 3 clinical trial testing combinations of immunotherapy and tyrosine-kinase inhibitors for advanced kidney cancer improve standard first-line treatment options for patients.	[Zhang, Tian; George, Daniel J.] Div Med Oncol, Dept Med, Durham, NC 27710 USA; [Zhang, Tian; George, Daniel J.] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC 27710 USA	Duke University	Zhang, T (corresponding author), Div Med Oncol, Dept Med, Durham, NC 27710 USA.; Zhang, T (corresponding author), Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC 27710 USA.	tian.zhang2@duke.edu						Albiges L, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-001079; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Choueiri TK, 2021, NEW ENGL J MED, V384, P829, DOI 10.1056/NEJMoa2026982; Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Motzer R, 2021, NEW ENGL J MED, V384, P1289, DOI 10.1056/NEJMoa2035716; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Pal S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5716-z; Pal SK, 2021, LANCET, V397, P695, DOI 10.1016/S0140-6736(21)00152-5; Powles T, 2020, LANCET ONCOL, V21, P1563, DOI 10.1016/S1470-2045(20)30436-8	12	5	5	1	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4					586	588		10.1038/s41591-021-01320-x	http://dx.doi.org/10.1038/s41591-021-01320-x		APR 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33820997				2022-12-27	WOS:000636931100004
J	Wu, JT; Leung, K; Lam, TTY; Ni, MY; Wong, CKH; Peiris, JSM; Leung, GM				Wu, Joseph T.; Leung, Kathy; Lam, Tommy T. Y.; Ni, Michael Y.; Wong, Carlos K. H.; Peiris, J. S. Malik; Leung, Gabriel M.			Nowcasting epidemics of novel pathogens: lessons from COVID-19	NATURE MEDICINE			English	Article							BASIC REPRODUCTIVE NUMBER; HONG-KONG; CORONAVIRUS; TRANSMISSION; INFLUENZA; CHINA; SARS; DISEASE; IMPACT; OSELTAMIVIR	Epidemic nowcasting broadly refers to assessing the current state by understanding key pathogenic, epidemiologic, clinical and socio-behavioral characteristics of an ongoing outbreak. Its primary objective is to provide situational awareness and inform decisions on control responses. In the event of large-scale sustained emergencies, such as the COVID-19 pandemic, scientists need to constantly update their aims and analytics with respect to the rapidly evolving emergence of new questions, data and findings in order to synthesize real-time evidence for policy decisions. In this Perspective, we share our views on the functional aims, rationale, data requirements and challenges of nowcasting at different stages of an epidemic, drawing on the ongoing COVID-19 experience. We highlight how recent advances in the computational and laboratory sciences could be harnessed to complement traditional approaches to enhance the scope, timeliness, reliability and utility of epidemic nowcasting. Recent advances in computational and laboratory sciences are helping researchers to address large-scale sustained emergencies, such as the COVID-19 pandemic, and constantly adapt to the emergence of new questions, data and findings in order to synthesize real-time evidence that will inform policy decisions.	[Wu, Joseph T.; Leung, Kathy; Lam, Tommy T. Y.; Ni, Michael Y.; Peiris, J. S. Malik; Leung, Gabriel M.] Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Hong Kong, Peoples R China; [Wu, Joseph T.; Leung, Kathy; Lam, Tommy T. Y.; Leung, Gabriel M.] Lab Data Discovery Hlth D24H, Hong Kong, Peoples R China; [Lam, Tommy T. Y.] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China; [Lam, Tommy T. Y.] Shantou Univ, Joint Inst Virol Shantou Univ & Univ Hong Kong, Guangdong Hongkong Joint Lab Emerging Infect Dis, Shantou, Peoples R China; [Ni, Michael Y.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China; [Ni, Michael Y.] Univ Hong Kong, Hlth High Dens Cities Lab, HKUrbanLab, Hong Kong, Peoples R China; [Wong, Carlos K. H.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China; [Wong, Carlos K. H.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China; [Peiris, J. S. Malik] Univ Hong Kong, HKU Pasteur Res Pole, Hong Kong, Peoples R China	University of Hong Kong; World Health Organization; University of Hong Kong; Shantou University; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Wu, JT (corresponding author), Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Hong Kong, Peoples R China.; Wu, JT (corresponding author), Lab Data Discovery Hlth D24H, Hong Kong, Peoples R China.	joewu@hku.hk	Lam, Tommy Tsan-Yuk/D-4837-2012; Leung, Kathy/D-5605-2017; Wu, Joseph/ABD-5880-2021; Wu, Joseph Tsz Kei/C-4450-2009; Wong, Carlos King-ho/B-4322-2011	Leung, Kathy/0000-0003-4777-388X; Wu, Joseph Tsz Kei/0000-0002-3155-5987; Leung, Gabriel/0000-0002-2503-6283; Wong, Carlos King-ho/0000-0002-6895-6071				Adam DC, 2020, NAT MED, V26, P1714, DOI 10.1038/s41591-020-1092-0; Ali ST, 2020, SCIENCE, V369, P1106, DOI 10.1126/science.abc9004; Alkhamis MA, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268818002728, 10.1017/s0950268818002728]; [Anonymous], 2020, LANCET DIGIT HEALTH, V2, pE561, DOI 10.1016/S2589-7500(20)30251-X; [Anonymous], 2016, GLOB HLTH RISK FRAM, DOI [10.1038/s41591-021-01278-w, DOI 10.1038/S41591-021-01278-W]; [Anonymous], 2020, QUAR IS; [Anonymous], 2020, WHO CONV GLOB STUD O; Apolone G, 2021, TUMORI J, V107, P446, DOI 10.1177/0300891620974755; Brauner JM, 2021, SCIENCE, V371, P802, DOI 10.1126/science.abd9338; Buckee CO, 2020, SCIENCE, V368, P145, DOI 10.1126/science.abb8021; Burki T, 2020, LANCET INFECT DIS, V20, P1240, DOI 10.1016/S1473-3099(20)30800-8; Buss Lewis F, 2021, Science, V371, P288, DOI 10.1126/science.abe9728; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cauchemez S, 2019, TRENDS PARASITOL, V35, P369, DOI 10.1016/j.pt.2019.01.009; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chang S, 2021, NATURE, V589, P82, DOI 10.1038/s41586-020-2923-3; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057; Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6; Cutler DM, 2020, JAMA-J AM MED ASSOC, V324, P1495, DOI 10.1001/jama.2020.19759; Davies NG, 2021, LANCET INFECT DIS, V21, P482, DOI 10.1016/S1473-3099(20)30984-1; Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1; Dorigatti, 2020, REPORT 3 TRANSMISSIB, DOI DOI 10.25561/77148; Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x; Fancourt D, 2021, LANCET PSYCHIAT, V8, P141, DOI 10.1016/S2215-0366(20)30482-X; Faye O, 2015, LANCET INFECT DIS, V15, P320, DOI 10.1016/S1473-3099(14)71075-8; Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Garg S, 2020, JMIR PUBLIC HLTH SUR, V6, P221, DOI 10.2196/18795; Gianotti R, 2021, BRIT J DERMATOL, V184, P970, DOI 10.1111/bjd.19804; Gostic Katelyn M, 2020, PLoS Comput Biol, V16, pe1008409, DOI [10.1101/2020.06.18.20134858, 10.1371/journal.pcbi.1008409]; Graham F., 2020, NATURE; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Hale T., 2020, VARIATION GOVT RESPO; Haug N, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-01009-0; HE X, 2020, NAT MED, V26, P672, DOI DOI 10.1038/S41591-020-0869-5; Heesterbeek H, 2015, SCIENCE, V347, P1216, DOI 10.1126/science.aaa4339; Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1; Horby PW, 2021, LANCET, V397, P605, DOI 10.1016/S0140-6736(21)00149-5; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Jarvis CI, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01597-8; Jefferson T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2545; Kandun IN, 2006, NEW ENGL J MED, V355, P2186, DOI 10.1056/NEJMoa060930; King AA, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.0347; Lai AL, 2020, J MED VIROL, V92, P675, DOI 10.1002/jmv.25723; Lam TTY, 2016, ANNU REV GENOM HUM G, V17, P193, DOI 10.1146/annurev-genom-083115-022628; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lemey Philippe, 2009, PLoS Curr, V1, pRRN1031; Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6; Leung GM, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009790; Li Q., 2020, NEW ENGL J MED, V382, P1199; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Li Y, 2021, LANCET INFECT DIS, V21, P193, DOI 10.1016/S1473-3099(20)30785-4; Li ZJ, 2020, LANCET, V396, P63, DOI 10.1016/S0140-6736(20)31278-2; Lipsitch M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003846; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Metcalf CJE, 2016, LANCET, V388, P728, DOI 10.1016/S0140-6736(16)30164-7; Ni MY, 2020, LANCET PUBLIC HEALTH, V5, pE631, DOI 10.1016/S2468-2667(20)30265-6; Ni MY, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/19009; Ni MY, 2020, LANCET, V395, P273, DOI 10.1016/S0140-6736(19)33160-5; Ni MY, 2020, INT J EPIDEMIOL, V49, P380, DOI 10.1093/ije/dyz238; Nogrady B, 2020, NATURE, V587, P534, DOI 10.1038/d41586-020-03141-3; Norman M, 2020, NAT BIOMED ENG, V4, P1180, DOI 10.1038/s41551-020-00611-x; Park SW, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2020.0144; Park SW, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2019.0719; Peak CM, 2017, P NATL ACAD SCI USA, V114, P4023, DOI 10.1073/pnas.1616438114; Peccia J, 2020, NAT BIOTECHNOL, V38, P1164, DOI 10.1038/s41587-020-0684-z; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris M, 2020, LANCET, V396, P1467, DOI 10.1016/S0140-6736(20)31976-0; Pierce M, 2020, LANCET PSYCHIAT, V7, P567, DOI 10.1016/S2215-0366(20)30237-6; Principles of Epidemiology in Public Health Practice, 2011, PRINC EP PUBL HLTH P, VThird; Pullano G, 2020, NATURE, DOI 10.1038/s41586-020-03095-6; Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321; Russell TW, 2021, LANCET PUBLIC HEALTH, V6, pE12, DOI 10.1016/S2468-2667(20)30263-2; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Stadler T, 2012, MOL BIOL EVOL, V29, P347, DOI 10.1093/molbev/msr217; Statement on the Sixth Meeting of the International Health Regulations, 2005, EM COMM REG COR DIS; Tsang TK, 2020, LANCET PUBLIC HEALTH, V5, pE289, DOI 10.1016/S2468-2667(20)30089-X; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; VanderWeele TJ, 2019, JAMA-J AM MED ASSOC, V321, P1667, DOI 10.1001/jama.2019.3035; Verbeek H, 2020, J AM MED DIR ASSOC, V21, P900, DOI 10.1016/j.jamda.2020.06.020; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X; Vink MA, 2014, AM J EPIDEMIOL, V180, P865, DOI 10.1093/aje/kwu209; Volz E.M., 2020, SARS COV 2 PHYLODYNA; Volz EM, 2009, GENETICS, V183, P1421, DOI 10.1534/genetics.109.106021; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wong CKH, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100743; Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; Wurtzer S, 2020, EUROSURVEILLANCE, V25, P38, DOI 10.2807/1560-7917.ES.2020.25.50.2000776; Xu B, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0448-0; Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852; Yang BY, 2021, CLIN INFECT DIS, V73, P2298, DOI 10.1093/cid/ciab002; Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	107	17	19	5	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					388	395		10.1038/s41591-021-01278-w	http://dx.doi.org/10.1038/s41591-021-01278-w			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723452	Bronze			2022-12-27	WOS:000629708300016
J	Cohen, YC; Zada, M; Wang, SY; Bornstein, C; David, E; Moshe, A; Li, BG; Shlomi-Loubaton, S; Gatt, ME; Gur, C; Lavi, N; Ganzel, C; Luttwak, E; Chubar, E; Rouvio, O; Vaxman, I; Pasvolsky, O; Ballan, M; Tadmor, T; Nemets, A; Jarchowcky-Dolberg, O; Shvetz, O; Laiba, M; Shpilberg, O; Dally, N; Avivi, I; Weiner, A; Amit, I				Cohen, Yael C.; Zada, Mor; Wang, Shuang-Yin; Bornstein, Chamutal; David, Eyal; Moshe, Adi; Li, Baoguo; Shlomi-Loubaton, Shir; Gatt, Moshe E.; Gur, Chamutal; Lavi, Noa; Ganzel, Chezi; Luttwak, Efrat; Chubar, Evgeni; Rouvio, Ory; Vaxman, Iuliana; Pasvolsky, Oren; Ballan, Mouna; Tadmor, Tamar; Nemets, Anatoly; Jarchowcky-Dolberg, Osnat; Shvetz, Olga; Laiba, Meirav; Shpilberg, Ofer; Dally, Najib; Avivi, Irit; Weiner, Assaf; Amit, Ido			Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing	NATURE MEDICINE			English	Article								Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity within and between treatment-resistant patients is poorly characterized. In the present study, we conduct a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) to study the molecular dynamics of MM resistance mechanisms. Newly diagnosed MM patients (41), who either failed to respond or experienced early relapse after a bortezomib-containing induction regimen, were enrolled to evaluate the safety and efficacy of a daratumumab, carfilzomib, lenalidomide and dexamethasone combination. The primary clinical endpoint was safety and tolerability. Secondary endpoints included overall response rate, progression-free survival and overall survival. Treatment was safe and well tolerated; deep and durable responses were achieved. In prespecified exploratory analyses, comparison of 41 primary refractory and early relapsed patients, with 11 healthy subjects and 15 newly diagnosed MM patients, revealed new MM molecular pathways of resistance, including hypoxia tolerance, protein folding and mitochondria respiration, which generalized to larger clinical cohorts (CoMMpass). We found peptidylprolyl isomerase A (PPIA), a central enzyme in the protein-folding response pathway, as a potential new target for resistant MM. CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with a small molecule inhibitor (ciclosporin) significantly sensitizes MM tumor cells to proteasome inhibitors. Together, our study defines a roadmap for integrating scRNA-seq in clinical trials, identifies a signature of highly resistant MM patients and discovers PPIA as a potent therapeutic target for these tumors. Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and identifies potential actionable targets.	[Cohen, Yael C.; Zada, Mor; Luttwak, Efrat; Vaxman, Iuliana; Pasvolsky, Oren; Avivi, Irit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Cohen, Yael C.; Luttwak, Efrat; Avivi, Irit] Tel Aviv Sourasky Ichilov Med Ctr, Dept Hematol, Tel Aviv, Israel; [Zada, Mor; Wang, Shuang-Yin; Bornstein, Chamutal; David, Eyal; Moshe, Adi; Li, Baoguo; Shlomi-Loubaton, Shir; Gur, Chamutal; Weiner, Assaf; Amit, Ido] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel; [Gatt, Moshe E.; Gur, Chamutal] Hebrew Univ Med Ctr, Hematol Dept, Jerusalem, Israel; [Lavi, Noa] Dept Hematol & Bone Marrow Transplantat, Rambam Hlth Care Campus, Haifa, Israel; [Ganzel, Chezi] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel; [Chubar, Evgeni] HaEmek Med Ctr, Hematol Unit, Afula, Israel; [Rouvio, Ory] Soroka Med Ctr, Beer Sheva, Israel; [Vaxman, Iuliana; Pasvolsky, Oren] Rabin Med Ctr, Hematol, Petah Tiqwa, Israel; [Ballan, Mouna] Carmel Hosp, Haifa, Israel; [Tadmor, Tamar] Bnai Zion Med Ctr, Hematol, Haifa, Israel; [Nemets, Anatoly] Barzilai Govt Hosp, Ashqelon, Israel; [Jarchowcky-Dolberg, Osnat] Meir Med Ctr, Hematol Dept, Kefar Sava, Israel; [Shvetz, Olga] Hadassah & Hebrew Univ, Sch Med, Hematol Kaplan Med Ctr, Rehovot, Israel; [Laiba, Meirav] Assuta Ashdod Med Ctr, Hematol Inst, Ashdod, Israel; [Shpilberg, Ofer] Assuta Med Ctr, Inst Hematol, Tel Aviv, Israel; [Dally, Najib] Rebecca Sieff Govt Hosp, Hematol, Safed, Israel	Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Rambam Health Care Campus; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Emek Medical Center; Ben Gurion University; Soroka Medical Center; Rabin Medical Center; Clalit Health Services; Carmel Medical Center; Bnai Zion Medical Center; Ben Gurion University; Barzilai Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Ziv Medical Center	Weiner, A; Amit, I (corresponding author), Weizmann Inst Sci, Dept Immunol, Rehovot, Israel.	assaf.weiner@weizmann.ac.il; ido.amit@weizmann.ac.il	luttwak, efrat/GXG-7481-2022; Vaxman, Julia/AAU-7912-2021	luttwak, efrat/0000-0003-0212-2135; Wang, Shuang-Yin/0000-0001-9683-4103; Pasvolsky, Oren/0000-0001-9193-0059	Merck KGaA, Darmstadt, Germany; Chan Zuckerberg Initiative; ISF Israel Precision Medicine Program (IPMP) [607/20, P128245]; HHMI International Scholar award; European Research Council Consolidator Grant (ERC-COG) [724471]; SCA award of the Wolfson Foundation; Family Charitable Trust; Thompson Family Foundation; MRA Established Investigator Award [509044]; Israel Science Foundation [703/15]; Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine; Helen and Martin Kimmel award for innovative investigation; NeuroMac DFG/Transregional Collaborative Research Center Grant; International Progressive MS Alliance/NMSS [PA-1604 08459]; Dan and Betty Kahn Foundation; Adelis Foundation; Amgen [KRD-OW-TA009, 20167107]; NWO Rubicon award [019.181EN.038]	Merck KGaA, Darmstadt, Germany; Chan Zuckerberg Initiative; ISF Israel Precision Medicine Program (IPMP); HHMI International Scholar award(Howard Hughes Medical Institute); European Research Council Consolidator Grant (ERC-COG); SCA award of the Wolfson Foundation; Family Charitable Trust; Thompson Family Foundation; MRA Established Investigator Award; Israel Science Foundation(Israel Science Foundation); Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine; Helen and Martin Kimmel award for innovative investigation; NeuroMac DFG/Transregional Collaborative Research Center Grant; International Progressive MS Alliance/NMSS; Dan and Betty Kahn Foundation; Adelis Foundation; Amgen(Amgen); NWO Rubicon award	We thank the following: the patients and their families; the clinical study research teams across all participating sites; the clinical research associates, L. Poor Porges, S. Shaibi and Y. Piltz; N. Lowenton-Spier for managing the study team; K. Bjorklof and F. Suzan from Amgen and A. Grossman from Medison for their support in the setup of the clinical trial; and A. Giladi for a review of the manuscript. We thank T. Wiesel from the Scientific Illustration unit of the Weizmann Institute for artwork, and members of the I. Amit's lab for fruitful discussions. Extended Data Figs. 4d and 9a were created using BioRender. com. I. Amit is an Eden and Steven Romick Professorial Chair, supported by Merck KGaA, Darmstadt, Germany, the Chan Zuckerberg Initiative, the ISF Israel Precision Medicine Program (IPMP; 607/20, grant no. P128245), the HHMI International Scholar award, the European Research Council Consolidator Grant (ERC-COG; grant no. 724471, HemTree2.0), an SCA award of the Wolfson Foundation and Family Charitable Trust, the Thompson Family Foundation, an MRA Established Investigator Award (no. 509044), the Israel Science Foundation (703/15), the Ernest and Bonnie Beutler Research Program for Excellence in Genomic Medicine, the Helen and Martin Kimmel award for innovative investigation, the NeuroMac DFG/Transregional Collaborative Research Center Grant, an International Progressive MS Alliance/NMSS PA-1604 08459, Dan and Betty Kahn Foundation and an Adelis Foundation grant. Y.C. received an investigator-initiated research grant from Amgen for the present study (AMGEN IIS grant protocal KRD-OW-TA009; REF#20167107). S.-Y.W. is an EMBO long-term fellow (ALTF 263-2018) and received the NWO Rubicon award (019.181EN.038).	Baran Y, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1812-2; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Chari A, 2017, BLOOD, V130; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Cohen M, 2018, CELL, V175, P1031, DOI 10.1016/j.cell.2018.09.009; Cohen YC, 2016, LEUKEMIA LYMPHOMA, V57, P1382, DOI 10.3109/10428194.2015.1121258; Corre J, 2020, HAEMATOLOGICA, V105, pE480, DOI 10.3324/haematol.2019.236588; Decaux O, 2008, J CLIN ONCOL, V26, P4798, DOI 10.1200/JCO.2007.13.8545; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Harding T, 2019, LEUKEMIA, V33, P863, DOI 10.1038/s41375-018-0362-z; Jaitin DA, 2014, SCIENCE, V343, P776, DOI 10.1126/science.1247651; Jakubowiak AJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.8000; Kastritis E, 2020, CL LYMPH MYELOM LEUK, V20, P445, DOI 10.1016/j.clml.2019.10.014; Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233; Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood-2012-01-405985; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Khan R, 2015, HAEMATOLOGICA, V100, P1214, DOI 10.3324/haematol.2015.124651; Khoo WH, 2019, BLOOD, V134, P30, DOI 10.1182/blood.2018880930; Klages N, 2000, MOL THER, V2, P170, DOI 10.1006/mthe.2000.0103; Klein AM, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.181396; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Krishnan SR, 2016, INT J ONCOL, V49, P33, DOI 10.3892/ijo.2016.3516; Kumar SK, 2018, LEUKEMIA, V32, P986, DOI 10.1038/leu.2017.331; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Kyle RA, 2009, CLIN LYMPHOMA MYELOM, V9, P278, DOI 10.3816/CLM.2009.n.056; Landgren O, 2018, BLOOD, V132, P3281, DOI DOI 10.1182/BLOOD-2018-99-114311; Ledergor G, 2018, NAT MED, V24, P1867, DOI 10.1038/s41591-018-0269-2; Lee J, 2010, J INT MED RES, V38, P1561, DOI 10.1177/147323001003800501; Ling SCW, 2012, HAEMATOL-HEMATOL J, V97, P64, DOI 10.3324/haematol.2011.043331; Majithia N, 2015, AM J HEMATOL, V90, P981, DOI 10.1002/ajh.24131; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; Medaglia C, 2017, SCIENCE, V358, P1622, DOI 10.1126/science.aao4277; Narayanan S, 2020, DRUG RESIST UPDATE, V48, DOI 10.1016/j.drup.2019.100663; Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; Nijhof IS, 2018, DRUGS, V78, P19, DOI 10.1007/s40265-017-0841-y; Nikesitch N, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1007; Nikesitch N, 2016, J CLIN PATHOL, V69, P97, DOI 10.1136/jclinpath-2015-203414; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Papadas A, 2018, HANDB EXP PHARMACOL, V249, P251, DOI 10.1007/164_2017_10; Paul F, 2015, CELL, V163, P1663, DOI 10.1016/j.cell.2015.11.013; Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791; Robak P, 2018, CANCER TREAT REV, V70, P199, DOI 10.1016/j.ctrv.2018.09.001; Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood-2006-07-038430; Shaughnessy JD, 2011, BLOOD, V118, P3512, DOI 10.1182/blood-2010-12-328252; Tsvetkov P, 2019, NAT CHEM BIOL, V15, P681, DOI 10.1038/s41589-019-0291-9; van de Donk NWCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02134; van de Donk NWCJ, 2011, CANCER TREAT REV, V37, P266, DOI 10.1016/j.ctrv.2010.08.008; Vincenz L, 2013, MOL CANCER THER, V12, P831, DOI 10.1158/1535-7163.MCT-12-0782; Wallington-Beddoe C.T., 2019, UPDATE MULTIPLE MYEL, DOI [10.5772/intechopen.77004, DOI 10.5772/INTECHOPEN.77004]; Yan YT, 2019, BLOOD ADV, V3, P2895, DOI 10.1182/bloodadvances.2019000432; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458	52	43	44	7	55	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					491	+		10.1038/s41591-021-01232-w	http://dx.doi.org/10.1038/s41591-021-01232-w		FEB 2021	38	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33619369	Green Accepted			2022-12-27	WOS:000620458400002
J	Seiglie, JA; Nambiar, D; Beran, D; Miranda, JJ				Seiglie, Jacqueline A.; Nambiar, Devaki; Beran, David; Miranda, J. Jaime			To tackle diabetes, science and health systems must take into account social context	NATURE MEDICINE			English	Editorial Material							HEART; DETERMINANTS; TRANSITION; SYNDEMICS; COVID-19; OBESITY; DISEASE	An increasing amount of publications are recognizing that a person's risk of diabetes and diabetes outcomes are influenced largely by social determinants of health. This renewed understanding of disease should influence health provision and diabetes research, but will it?	[Seiglie, Jacqueline A.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; [Seiglie, Jacqueline A.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Nambiar, Devaki] George Inst Global Hlth, New Delhi, India; [Nambiar, Devaki] Univ New South Wales, Fac Med, Sydney, NSW, Australia; [Nambiar, Devaki] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, Karnataka, India; [Nambiar, Devaki; Miranda, J. Jaime] Harvard TH Chan Sch Publ Hlth, Bernard Lown Scholars Cardiovasc Hlth Program, Boston, MA USA; [Beran, David] Hop Univ Geneve, Div Trop & Humanitarian Med, Geneva, Switzerland; [Beran, David] Univ Geneva, Fac Med, Geneva, Switzerland; [Miranda, J. Jaime] Univ Peruana Cayetano Heredia, Sch Med, Dept Med, Lima, Peru; [Miranda, J. Jaime] Univ Peruana Cayetano Heredia, CRONICAS Ctr Excellence Chron Dis, Lima, Peru; [Miranda, J. Jaime] George Inst Global Hlth, Sydney, NSW, Australia; [Miranda, J. Jaime] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of New South Wales Sydney; Manipal Academy of Higher Education (MAHE); Harvard University; Harvard T.H. Chan School of Public Health; University of Geneva; University of Geneva; Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; George Institute for Global Health; University of Sydney; University of London; London School of Hygiene & Tropical Medicine	Seiglie, JA (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.; Seiglie, JA (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.; Miranda, JJ (corresponding author), Harvard TH Chan Sch Publ Hlth, Bernard Lown Scholars Cardiovasc Hlth Program, Boston, MA USA.; Miranda, JJ (corresponding author), Univ Peruana Cayetano Heredia, Sch Med, Dept Med, Lima, Peru.; Miranda, JJ (corresponding author), Univ Peruana Cayetano Heredia, CRONICAS Ctr Excellence Chron Dis, Lima, Peru.; Miranda, JJ (corresponding author), George Inst Global Hlth, Sydney, NSW, Australia.; Miranda, JJ (corresponding author), London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.	jseiglie@partners.org; jaime.miranda@upch.pe		Miranda, J. Jaime/0000-0002-4738-5468; Seiglie, Jacqueline/0000-0001-9278-4516; Nambiar, Devaki/0000-0001-5682-6109	DBT-Wellcome Trust India Alliance [IA/CPHI/16/1/502653] Funding Source: Medline; Medical Research Council [MR/M007405/1] Funding Source: Medline; NCATS NIH HHS [KL2 TR002542] Funding Source: Medline; NIDDK NIH HHS [T32 DK007028, L30 DK122468] Funding Source: Medline	DBT-Wellcome Trust India Alliance(Wellcome Trust DBT India Alliance); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Pesantes MA, 2019, HUM ORGAN, V78, P85, DOI 10.17730/0018-7259.78.1.85; Beran D, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0591-8; Boulle P, 2019, LANCET DIABETES ENDO, V7, P648, DOI 10.1016/S2213-8587(19)30083-X; Burgess Rochelle, 2020, Nature, DOI 10.1038/d41586-020-01313-9; de Lacy-Vawdon C, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09126-1; Gianella C, 2021, CAN J DEV STUD, V42, P55, DOI 10.1080/02255189.2020.1843009; Hegele RA, 2020, LANCET DIABETES ENDO, V8, P971, DOI 10.1016/S2213-8587(20)30337-5; Hill JO, 2013, DIABETES CARE, V36, P2430, DOI 10.2337/dc13-1161; Hill-Briggs F, 2021, DIABETES CARE, V44, P258, DOI 10.2337/dci20-0053; Horton R, 2020, LANCET, V396, P874, DOI 10.1016/S0140-6736(20)32000-6; Jaacks LM, 2019, LANCET DIABETES ENDO, V7, P231, DOI 10.1016/S2213-8587(19)30026-9; Jiwani SS, 2019, LANCET GLOB HEALTH, V7, pE1644, DOI 10.1016/S2214-109X(19)30421-8; Lawlor DA, 2003, DIABETES CARE, V26, P97, DOI 10.2337/diacare.26.1.97; Liu FF, 2019, ENVIRON POLLUT, V252, P1235, DOI 10.1016/j.envpol.2019.06.033; Ludwig J, 2011, NEW ENGL J MED, V365, P1509, DOI 10.1056/NEJMsa1103216; Marmot M., 2020, BMJ OPINION; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; McKee M, 2018, AM J PUBLIC HEALTH, V108, P1167, DOI 10.2105/AJPH.2018.304510; Mendenhall E, 2020, LANCET, V396, P1731, DOI 10.1016/S0140-6736(20)32218-2; Mendenhall E, 2017, LANCET, V389, P951, DOI 10.1016/S0140-6736(17)30402-6; Nambiar D, 2017, SOCIAL DETERMINANTS, DOI [10.1007/978-981-10-5999-5, DOI 10.1007/978-981-10-5999-5]; Nambiar D, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05914-y; Nolte E, 2006, DIABETES CARE, V29, P1007, DOI 10.2337/dc05-1550; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Pesantes M. Amalia, 2020, Rev. perú. med. exp. salud publica, V37, P541, DOI 10.17843/rpmesp.2020.373.5980; Popkin BM, 1998, PUBLIC HEALTH NUTR, V1, P5, DOI 10.1079/PHN19980004; Reese DM, 1998, WESTERN J MED, V169, P105; Saxena A, 2022, SOC SCI MED, V295, DOI 10.1016/j.socscimed.2020.113503; Sheahan KH, 2020, POSTGRAD MED J, V96, P156, DOI 10.1136/postgradmedj-2019-137186; Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X; Sosa-Rubi SG, 2021, DIABETES CARE, V44, P373, DOI 10.2337/dc20-2192; Taype-Rondan A, 2016, BRIT J GEN PRACT, V66, P197, DOI 10.3399/bjgp16X684541; Thornton PL, 2020, ANN NY ACAD SCI, V1461, P5, DOI 10.1111/nyas.14270; World Bank, 2008, ENVIRON DEV, P1, DOI 10.1596/978-0-8213-7236-4; Zannad F, 2020, LANCET, V396, P819, DOI 10.1016/S0140-6736(20)31824-9	35	2	2	3	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					193	195		10.1038/s41591-021-01231-x	http://dx.doi.org/10.1038/s41591-021-01231-x		FEB 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33526928	Green Accepted, Bronze			2022-12-27	WOS:000613582400002
J	Jerby-Arnon, L; Neftel, C; Shore, ME; Weisman, HR; Mathewson, ND; McBride, MJ; Haas, B; Izar, B; Volorio, A; Boulay, G; Cironi, L; Richman, AR; Broye, LC; Gurski, JM; Luo, CC; Mylvaganam, R; Nguyen, L; Mei, SL; Melms, JC; Georgescu, C; Cohen, O; Buendia-Buendia, JE; Segerstolpe, A; Sud, M; Cuoco, MS; Labes, D; Gritsch, S; Zollinger, DR; Ortogero, N; Beechem, JM; Nielsen, GP; Chebib, I; Nguyen-Ngoc, T; Montemurro, M; Cote, GM; Choy, E; Letovanec, I; Cherix, S; Wagle, N; Sorger, PK; Haynes, AB; Mullen, JT; Stamenkovic, I; Rivera, MN; Kadoch, C; Wucherpfennig, KW; Rozenblatt-Rosen, O; Suva, ML; Riggi, N; Regev, A				Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Mathewson, Nathan D.; McBride, Matthew J.; Haas, Brian; Izar, Benjamin; Volorio, Angela; Boulay, Gaylor; Cironi, Luisa; Richman, Alyssa R.; Broye, Liliane C.; Gurski, Joseph M.; Luo, Christina C.; Mylvaganam, Ravindra; Nguyen, Lan; Mei, Shaolin; Melms, Johannes C.; Georgescu, Christophe; Cohen, Ofir; Buendia-Buendia, Jorge E.; Segerstolpe, Asa; Sud, Malika; Cuoco, Michael S.; Labes, Danny; Gritsch, Simon; Zollinger, Daniel R.; Ortogero, Nicole; Beechem, Joseph M.; Petur Nielsen, G.; Chebib, Ivan; Nguyen-Ngoc, Tu; Montemurro, Michael; Cote, Gregory M.; Choy, Edwin; Letovanec, Igor; Cherix, Stephane; Wagle, Nikhil; Sorger, Peter K.; Haynes, Alex B.; Mullen, John T.; Stamenkovic, Ivan; Rivera, Miguel N.; Kadoch, Cigall; Wucherpfennig, Kai W.; Rozenblatt-Rosen, Orit; Suva, Mario L.; Riggi, Nicolo; Regev, Aviv			Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma	NATURE MEDICINE			English	Article							RNA-SEQ; WHOLE-EXOME; T-CELLS; SINGLE; EXPRESSION; DISCOVERY; MELANOMA; INSIGHTS; TUMORS; FUSION	Single-cell transcriptional profiling of primary human synovial sarcoma tumors suggests that combinatorial treatment with HDAC and CDK4/CDK6 inhibitors could enhance tumor immunogenicity. Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we studied the cancer-immune interplay in SyS using an integrative approach that combines single-cell RNA sequencing (scRNA-seq), spatial profiling and genetic and pharmacological perturbations. scRNA-seq of 16,872 cells from 12 human SyS tumors uncovered a malignant subpopulation that marks immune-deprived niches in situ and is predictive of poor clinical outcomes in two independent cohorts. Functional analyses revealed that this malignant cell state is controlled by the SS18-SSX fusion, is repressed by cytokines secreted by macrophages and T cells, and can be synergistically targeted with a combination of HDAC and CDK4/CDK6 inhibitors. This drug combination enhanced malignant-cell immunogenicity in SyS models, leading to induced T cell reactivity and T cell-mediated killing. Our study provides a blueprint for investigating heterogeneity in fusion-driven malignancies and demonstrates an interplay between immune evasion and oncogenic processes that can be co-targeted in SyS and potentially in other malignancies.	[Jerby-Arnon, Livnat] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Jerby-Arnon, Livnat] Chan Zuckerberg Biohub, San Francisco, CA USA; [Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Haas, Brian; Izar, Benjamin; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Nguyen, Lan; Georgescu, Christophe; Cohen, Ofir; Segerstolpe, Asa; Sud, Malika; Cuoco, Michael S.; Gritsch, Simon; Wagle, Nikhil; Rivera, Miguel N.; Kadoch, Cigall; Wucherpfennig, Kai W.; Rozenblatt-Rosen, Orit; Suva, Mario L.; Regev, Aviv] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Jerby-Arnon, Livnat; Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Haas, Brian; Richman, Alyssa R.; Cohen, Ofir; Gritsch, Simon; Rozenblatt-Rosen, Orit; Suva, Mario L.; Regev, Aviv] Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA; [Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Luo, Christina C.; Mylvaganam, Ravindra; Gritsch, Simon; Petur Nielsen, G.; Rivera, Miguel N.; Suva, Mario L.; Riggi, Nicolo] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Luo, Christina C.; Mylvaganam, Ravindra; Gritsch, Simon; Petur Nielsen, G.; Rivera, Miguel N.; Suva, Mario L.; Riggi, Nicolo] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Neftel, Cyril; Shore, Marni E.; Weisman, Hannah R.; McBride, Matthew J.; Volorio, Angela; Boulay, Gaylor; Richman, Alyssa R.; Luo, Christina C.; Mylvaganam, Ravindra; Cohen, Ofir; Buendia-Buendia, Jorge E.; Gritsch, Simon; Petur Nielsen, G.; Rivera, Miguel N.; Suva, Mario L.; Riggi, Nicolo] Harvard Med Sch, Boston, MA 02115 USA; [Neftel, Cyril; Cironi, Luisa; Broye, Liliane C.; Letovanec, Igor; Stamenkovic, Ivan; Riggi, Nicolo] CHU Vaudois, Inst Pathol, Fac Biol & Med, Lausanne, Switzerland; [Mathewson, Nathan D.; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA; [Mathewson, Nathan D.; Wucherpfennig, Kai W.] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA; [Mathewson, Nathan D.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA; [McBride, Matthew J.; Kadoch, Cigall] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Izar, Benjamin; Melms, Johannes C.] Columbia Ctr Translat Immunol, New York, NY USA; [Izar, Benjamin; Melms, Johannes C.] Columbia Univ, Med Ctr, Div Hematol & Oncol, New York, NY USA; [Gurski, Joseph M.; Chebib, Ivan] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Mei, Shaolin; Sorger, Peter K.] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02115 USA; [Cohen, Ofir; Buendia-Buendia, Jorge E.; Wagle, Nikhil] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Cuoco, Michael S.] Univ Calif San Diego, Bioinformat & Syst Biol Grad Program, La Jolla, CA 92093 USA; [Labes, Danny] Univ Lausanne, Flow Cytometry Facil, Dept Biol & Med, Lausanne, Switzerland; [Zollinger, Daniel R.; Ortogero, Nicole; Beechem, Joseph M.] NanoString Technol, Seattle, WA USA; [Nguyen-Ngoc, Tu; Montemurro, Michael] Univ Lausanne, Dept Oncol, Ctr Hosp Univ Vaudois, Lausanne, Switzerland; [Cote, Gregory M.; Choy, Edwin] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA; [Cherix, Stephane] CHU Vaudois, Fac Biol & Med, Dept Orthoped, Lausanne, Switzerland; [Haynes, Alex B.; Mullen, John T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Regev, Aviv] MIT, Howard Hughes Med Inst, Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA; [Rozenblatt-Rosen, Orit; Regev, Aviv] Genentech Inc, San Francisco, CA 94080 USA	Stanford University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Columbia University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Diego; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Massachusetts General Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Roche Holding; Genentech	Suva, ML; Regev, A (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.; Suva, ML; Regev, A (corresponding author), Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA.; Suva, ML; Riggi, N (corresponding author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.; Suva, ML; Riggi, N (corresponding author), Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.; Suva, ML; Riggi, N (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Riggi, N (corresponding author), CHU Vaudois, Inst Pathol, Fac Biol & Med, Lausanne, Switzerland.; Regev, A (corresponding author), MIT, Howard Hughes Med Inst, Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA.; Regev, A (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	Suva.Mario@mgh.harvard.edu; nicolo.riggi@chuv.ch; aregev@broadinstitute.org	Rozenblatt-Rosen, Orit/HDN-4182-2022; Montemurro, Michael/GQH-8271-2022	Mei, Shaolin/0000-0002-2193-764X; Mathewson, Nathan/0000-0002-8895-2609; Melms, Johannes/0000-0002-5410-6586; Nguyen-Ngoc, Tu/0000-0001-7574-2947	CRI; NCI [1U24CA180922, R33-CA202820]; Koch Institute NCI Support (core) grant [P30-CA14051]; Ludwig Centers at Harvard and MIT; AMRF; Broad Institute; Howard Goodman Fellowship at MGH; Merkin Institute Fellowship at the Broad Institute of MIT and Harvard; Swiss National Science Foundation Sinergia grant [CRSII5_177266]; Center for Cancer Systems Pharmacology at Harvard Medical School [CA225088]; Burroughs Wellcome Fund Career Award for Medical Scientists; Louis V. Gerstner, Jr. Scholars Program; Velocity Fellow Program; Swiss National Science Foundation Professorship grant [PP00P3-157468/1, PP00P3_183724]; Swiss Cancer League [KFS-3973-08-2016]; Fond'Action Contre le Cancer grant; FORCE grant; American Cancer Society [PF-17-042-01-LIB]; NIH - NCI [L30 CA231679-01]; Thomas and Diana Ryan MGH Research Scholar Award; Klarman Cell Observatory; STARR cancer consortium; Scientific Interface from BWF;  [K08CA222663];  [R37CA245523]	CRI; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Koch Institute NCI Support (core) grant; Ludwig Centers at Harvard and MIT; AMRF; Broad Institute; Howard Goodman Fellowship at MGH; Merkin Institute Fellowship at the Broad Institute of MIT and Harvard; Swiss National Science Foundation Sinergia grant(Swiss National Science Foundation (SNSF)); Center for Cancer Systems Pharmacology at Harvard Medical School; Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund); Louis V. Gerstner, Jr. Scholars Program; Velocity Fellow Program; Swiss National Science Foundation Professorship grant; Swiss Cancer League; Fond'Action Contre le Cancer grant; FORCE grant; American Cancer Society(American Cancer Society); NIH - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Thomas and Diana Ryan MGH Research Scholar Award; Klarman Cell Observatory; STARR cancer consortium; Scientific Interface from BWF; ; 	We thank L. Gaffney and A. Hupalowska for help with artwork and L. Gaffney for help in figure preparation. We thank K. Itoh, N. Naka and S. Takenaka (Osaka University, Japan) for providing the Aska cell lines, and Akira Kawai (National Cancer Center Hospital, Japan) for providing the SYO1 cell line. We thank M. Brown for help with CNA visualization. L.J.-A. is a Chan Zuckerberg Biohub investigator and holds a Career Award at the Scientific Interface from BWF. L.J.-A. was a fellow of the Eric and Wendy Schmidt postdoctoral program and a CRI Irvington Fellow supported by the CRI. A.R. is an HHMI Investigator. Work was supported by the Klarman Cell Observatory, STARR cancer consortium, NCI grants 1U24CA180922, R33-CA202820, the Koch Institute NCI Support (core) grant P30-CA14051, Ludwig Centers at Harvard and MIT, AMRF and the Broad Institute (A.R.). Work was also supported by grants from the Howard Goodman Fellowship at MGH (M.L.S.), the Merkin Institute Fellowship at the Broad Institute of MIT and Harvard (M.L.S.), R37CA245523 (M.L.S.), the Swiss National Science Foundation Sinergia grant CRSII5_177266 (M.L.S. and I.S.). Imaging CyCIF work was supported by a grant (CA225088) from the Center for Cancer Systems Pharmacology at Harvard Medical School (P.K.S.), K08CA222663 (B.I.), Burroughs Wellcome Fund Career Award for Medical Scientists (B.I.), Louis V. Gerstner, Jr. Scholars Program (B.I.) and the Velocity Fellow Program (B.I.). N.R. is supported by the Swiss National Science Foundation Professorship grant (PP00P3-157468/1 and PP00P3_183724), the Swiss Cancer League grant KFS-3973-08-2016, the Fond'Action Contre le Cancer grant and the FORCE grant. N.D.M. was supported by a postdoctoral fellowship from the American Cancer Society (PF-17-042-01-LIB) and the NIH education loan repayment program funded by the NCI (L30 CA231679-01). M.N.R. is supported by the Thomas and Diana Ryan MGH Research Scholar Award. Processed scRNA-seq data are available at https://portals.broadinstitute.org/single_cell/study/synovial-sarcoma and GEO GSE131309. Raw scRNA-seq data is deposited in the controlled access repository DUOS (https://duos.broadinstitute.org/#/hom) accession: DUOS-000123 (via the data catalog https://duos.broadinstitute.org/dataset_catalog).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; [Anonymous], 2004, PHYS REV E, DOI DOI 10.1103/PhysRevE.69.026113; Ayyoub M, 2005, J IMMUNOL, V174, P5092, DOI 10.4049/jimmunol.174.8.5092; Ayyoub M, 2003, CANCER RES, V63, P5601; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Balogh KN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197702; Banito A, 2018, CANCER CELL, V33, P527, DOI [10.1016/j.ccell.2018.07.006, 10.1016/j.ccell.2018.01.018]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bottcher JP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9306; Bovolenta LA, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-405; Brin S., 1998, 7 INT WORLD WID WEB; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Cohen O, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.SABCS16-S1-01; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fan J, 2016, NAT METHODS, V13, P241, DOI [10.1038/NMETH.3734, 10.1038/nmeth.3734]; Filbin MG, 2018, SCIENCE, V360, P331, DOI 10.1126/science.aao4750; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Haas BJ., 2017, BIORXIV, DOI [DOI 10.1101/120295, 10.1101/120295]; Haghverdi L, 2015, BIOINFORMATICS, V31, P2989, DOI 10.1093/bioinformatics/btv325; Han H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11432; Herrmann C, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks543; Iura K, 2017, HUM PATHOL, V61, P130, DOI 10.1016/j.humpath.2016.12.006; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Jones KB, 2011, CANCER CONTROL, V18, P196, DOI 10.1177/107327481101800307; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD1284, DOI 10.1093/nar/gkx1188; Lagarde P, 2013, J CLIN ONCOL, V31, P608, DOI 10.1200/JCO.2012.46.0147; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Martin-Broto J, 2020, CLIN CANCER RES, V26, P5801, DOI 10.1158/1078-0432.CCR-19-3335; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; McBride MJ, 2018, CANCER CELL, V33, P1128, DOI 10.1016/j.ccell.2018.05.002; McDavid A, 2013, BIOINFORMATICS, V29, P461, DOI 10.1093/bioinformatics/bts714; Merritt CR, 2020, NAT BIOTECHNOL, V38, P586, DOI 10.1038/s41587-020-0472-9; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Nielsen TO, 2015, CANCER DISCOV, V5, P124, DOI 10.1158/2159-8290.CD-14-1246; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Pollack SM, 2018, EXPERT REV VACCINES, V17, P107, DOI 10.1080/14760584.2018.1419068; Pollack SM, 2017, CANCER-AM CANCER SOC, V123, P3291, DOI 10.1002/cncr.30726; Przybyl J, 2014, INT J BIOCHEM CELL B, V53, P505, DOI 10.1016/j.biocel.2014.05.006; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Smith HA, 2011, J IMMUNOTHER, V34, P569, DOI 10.1097/CJI.0b013e31822b5b1d; Smith HA, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/150591; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tirosh I, 2016, NATURE, V539, P309, DOI 10.1038/nature20123; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Trujillo JA, 2018, CANCER IMMUNOL RES, V6, P990, DOI 10.1158/2326-6066.CIR-18-0277; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478; Waltman L, 2013, EUR PHYS J B, V86, DOI 10.1140/epjb/e2013-40829-0; Welch JD, 2019, CELL, V177, P1873, DOI 10.1016/j.cell.2019.05.006; Yang Z, 2016, BIOINFORMATICS, V32, P1, DOI 10.1093/bioinformatics/btv544; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhou Y, 2017, ONCOL REP, V37, P3351, DOI 10.3892/or.2017.5617	80	30	30	4	26	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					289	+		10.1038/s41591-020-01212-6	http://dx.doi.org/10.1038/s41591-020-01212-6		JAN 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33495604	Green Accepted, Green Submitted			2022-12-27	WOS:000611467500003
J	Flor, LS; Reitsma, MB; Gupta, V; Ng, M; Gakidou, E				Flor, Luisa S.; Reitsma, Marissa B.; Gupta, Vinay; Ng, Marie; Gakidou, Emmanuela			The effects of tobacco control policies on global smoking prevalence	NATURE MEDICINE			English	Article							IMPLEMENTATION; COUNTRIES; GENDER; IMPACT	Substantial global effort has been devoted to curtailing the tobacco epidemic over the past two decades, especially after the adoption of the Framework Convention on Tobacco Control(1) by the World Health Organization in 2003. In 2015, in recognition of the burden resulting from tobacco use, strengthened tobacco control was included as a global development target in the 2030 Agenda for Sustainable Development(2). Here we show that comprehensive tobacco control policies-including smoking bans, health warnings, advertising bans and tobacco taxes-are effective in reducing smoking prevalence; amplified positive effects are seen when these policies are implemented simultaneously within a given country. We find that if all 155 countries included in our counterfactual analysis had adopted smoking bans, health warnings and advertising bans at the strictest level and raised cigarette prices to at least 7.73 international dollars in 2009, there would have been about 100 million fewer smokers in the world in 2017. These findings highlight the urgent need for countries to move toward an accelerated implementation of a set of strong tobacco control practices, thus curbing the burden of smoking-attributable diseases and deaths. Analysis of global smoking prevalence trends from 2009 to 2017 demonstrates that, when implemented, national-level tobacco control policies are highly effective; however, considerable gaps remain in the universal adoption of anti-tobacco interventions.	[Flor, Luisa S.; Reitsma, Marissa B.; Gupta, Vinay; Gakidou, Emmanuela] Univ Washington, Dept Hlth Metr Sci, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Ng, Marie] IBM Watson Hlth, San Jose, CA USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle	Gakidou, E (corresponding author), Univ Washington, Dept Hlth Metr Sci, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.	gakidou@uw.edu		Ng, Marie/0000-0001-8243-4096	Bloomberg Philanthropies [47386]; Tobacco Metrics Team Advisory Group	Bloomberg Philanthropies; Tobacco Metrics Team Advisory Group	The study was funded by Bloomberg Philanthropies (grant 47386, Initiative to Reduce Tobacco Use). We thank the support of the Tobacco Metrics Team Advisory Group, which provided valuable comments and suggestions over several iterations of this manuscript. We also thank the Tobacco Free Initiative team at the WHO and the Campaign for Tobacco-Free Kids for making the tobacco control legislation data available and providing clarifications when necessary. We thank A. Tapp, E. Mullany and J. Whisnant for assisting in the management and execution of this study. We thank the team who worked in a previous iteration of this project, especially A. Reynolds, C. Margono, E. Dansereau, K. Bolt, M. Subart and X. Dai. Lastly, we thank all GBD 2017 Tobacco collaborators for their valuable work in providing feedback to our smoking prevalence estimates throughout the GBD 2017 cycle.	Amos A, 2012, TOB CONTROL, V21, P236, DOI 10.1136/tobaccocontrol-2011-050280; Anderson CL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13101039; [Anonymous], 2015, WHO REP GLOB TOB EP; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bialous SA, 2019, TOB CONTROL, V28, pS94, DOI 10.1136/tobaccocontrol-2018-054808; Chaloupka FJ, 2011, TOB CONTROL, V20, P235, DOI 10.1136/tc.2010.039982; Chestnov O, 2013, WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2013: ENFORCING BANS ON TOBACCO ADVERTISING, PROMOTION AND SPONSORSHIP, P11; Chung-Hall J, 2019, TOB CONTROL, V28, pS119, DOI 10.1136/tobaccocontrol-2018-054389; Dubray J, 2015, TOB CONTROL, V24, P540, DOI 10.1136/tobaccocontrol-2014-051834; Ekpu VU, 2015, TOB USE INSIGHTS, V8, P1, DOI 10.4137/TUI.S15628; Feliu A, 2019, TOB CONTROL, V28, P101, DOI 10.1136/tobaccocontrol-2017-054119; Gravely S, 2017, LANCET PUBLIC HEALTH, V2, pE166, DOI 10.1016/S2468-2667(17)30045-2; Greaves L, 2007, HEALTH SOCIOL REV, V16, P115, DOI 10.5172/hesr.2007.16.2.115; Hoffman SJ, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2041-6; Institute for Health Metrics and Evaluation, 2020, GLOB TOB CONTR SMOK; Institute for Health Metrics and Evaluation, 2017, GBD COMPARE; James SL, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-12; Jha P, 2014, NEW ENGL J MED, V370, P60, DOI 10.1056/NEJMra1308383; Moodie C, 2020, ADDICT RES THEORY, V28, P53, DOI 10.1080/16066359.2019.1579803; Ngo A, 2017, PREV MED, V105, pS10, DOI 10.1016/j.ypmed.2017.05.006; Nilan K, 2017, ADDICTION, V112, P2023, DOI 10.1111/add.13903; Noar SM, 2016, SOC SCI MED, V164, P118, DOI 10.1016/j.socscimed.2016.06.011; ONU, 2015, TRANSF OUR WORLD 203; Reitsma MB, 2017, LANCET, V389, P1885, DOI 10.1016/S0140-6736(17)30819-X; Rice N., 2009, SYSTEMATIC REV EFFEC; Saffer H, 2000, J HEALTH ECON, V19, P1117, DOI 10.1016/S0167-6296(00)00054-0; Secretariat of the WHO Framework Convention on Tobacco Control, 2019, INF NOT CLASS NOV EM; Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140-6736(18)32225-6; Thun M, 2012, TOB CONTROL, V21, P96, DOI 10.1136/tobaccocontrol-2011-050294; Wakefield M, 2015, TOB CONTROL, V24, pII17, DOI 10.1136/tobaccocontrol-2014-052050; World Health Organization, 2008, WHO REP GLOB TOB EP; World Health Organization, 2017, WHO REP GLOB TOB EP; World Health Organization, 2009, WHO REP GLOB TOB EP; World Health Organization, 2018, WHO GLOB REP TRENDS; World Health Organization, 2019, WHO REPORT GLOBAL TO; Zuur AF, 2010, METHODS ECOL EVOL, V1, P3, DOI 10.1111/j.2041-210X.2009.00001.x	36	37	39	2	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					239	+		10.1038/s41591-020-01210-8	http://dx.doi.org/10.1038/s41591-020-01210-8		JAN 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33479500	Green Published, hybrid			2022-12-27	WOS:000609385500003
J	Carvalho, T				Carvalho, Thiago			Silent spread	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1807	1807		10.1038/s41591-020-01165-w	http://dx.doi.org/10.1038/s41591-020-01165-w			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288944	Bronze			2022-12-27	WOS:000596579200018
J	Edwards, KM; Neuzil, KM				Edwards, Kathryn M.; Neuzil, Kathleen M.			Understanding COVID-19 through human challenge models	NATURE MEDICINE			English	Editorial Material								As the pandemic evolves, questions remain but field studies are increasingly difficult; if carefully designed, human challenge models could offer a practical and timely solution.	[Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Monroe Carell Jr Childrens Hosp Vanderbilt, Div Infect Dis,Dept Pediat, Nashville, TN 37212 USA; [Neuzil, Kathleen M.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA	Vanderbilt University; University System of Maryland; University of Maryland Baltimore	Edwards, KM (corresponding author), Vanderbilt Univ, Sch Med, Monroe Carell Jr Childrens Hosp Vanderbilt, Div Infect Dis,Dept Pediat, Nashville, TN 37212 USA.; Neuzil, KM (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.	kathryn.edwards@vumc.org; kneuzil@som.umaryland.edu						Darton TC, 2015, LANCET INFECT DIS, V15, P840, DOI 10.1016/S1473-3099(15)00068-7; Deming ME, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2020076; Douaud G, 2022, NATURE, V604, P697, DOI [10.1038/s41586-022-04569-5, 10.1101/2021.06.11.21258690]; Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152; Killingley B, 2022, NAT MED, V28, P1031, DOI 10.1038/s41591-022-01780-9; Levine MM, 2021, CLIN INFECT DIS, V72, P2035, DOI 10.1093/cid/ciaa1290; Memoli MJ, 2015, CLIN INFECT DIS, V60, P693, DOI 10.1093/cid/ciu924; Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039; Rapeport G, 2021, NEW ENGL J MED, V385, P961, DOI 10.1056/NEJMp2106970; Shah SK, 2020, SCIENCE, V368, P832, DOI 10.1126/science.abc1076	10	1	1	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					903	904		10.1038/s41591-022-01778-3	http://dx.doi.org/10.1038/s41591-022-01778-3		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35361993	Bronze			2022-12-27	WOS:000777221800002
J	Sailor, KA; Cartier, N				Sailor, Kurt A.; Cartier, Nathalie			Bone marrow transplantation chemotherapy disrupts regenerative brain cell populations	NATURE MEDICINE			English	Editorial Material									[Sailor, Kurt A.] Pasteur Inst, Paris, France; [Cartier, Nathalie] Paris Brain Inst, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sailor, KA (corresponding author), Pasteur Inst, Paris, France.		Sailor, Kurt Andrew/AFN-4046-2022; Sailor, Kurt/GSO-2237-2022	Sailor, Kurt Andrew/0000-0002-9574-6838; Sailor, Kurt/0000-0002-9574-6838				Buchbinder D, 2018, BONE MARROW TRANSPL, V53, P535, DOI 10.1038/s41409-017-0055-7; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Peake K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00075; Shemer A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07548-5	5	0	0	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					452	453		10.1038/s41591-022-01722-5	http://dx.doi.org/10.1038/s41591-022-01722-5		FEB 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35210598				2022-12-27	WOS:000761879000002
J	Fatumo, S; Chikowore, T; Choudhury, A; Ayub, M; Martin, AR; Kuchenbaecker, K				Fatumo, Segun; Chikowore, Tinashe; Choudhury, Ananyo; Ayub, Muhammad; Martin, Alicia R.; Kuchenbaecker, Karoline			A roadmap to increase diversity in genomic studies	NATURE MEDICINE			English	Article							AFRICAN POPULATIONS; RISK PREDICTION; DISCOVERY; HISTORY; HEALTH; UGANDA	Two decades ago, the sequence of the first human genome was published. Since then, advances in genome technologies have resulted in whole-genome sequencing and microarray-based genotyping of millions of human genomes. However, genetic and genomic studies are predominantly based on populations of European ancestry. As a result, the potential benefits of genomic research-including better understanding of disease etiology, early detection and diagnosis, rational drug design and improved clinical care-may elude the many underrepresented populations. Here, we describe factors that have contributed to the imbalance in representation of different populations and, leveraging our experiences in setting up genomic studies in diverse global populations, we propose a roadmap to enhancing inclusion and ensuring equal health benefits of genomics advances. Our Perspective highlights the importance of sincere, concerted global efforts toward genomic equity to ensure the benefits of genomic medicine are accessible to all. Based on their experience of setting up genomic studies in underrepresented populations, the authors propose a roadmap to enhancing inclusion and ensuring that the health benefits of genomics advances are accessible to all.	[Fatumo, Segun] MRC UVRI & LSHTM, African Computat Genom TACG Res Grp, Entebbe, Uganda; [Fatumo, Segun] London Sch Hyg & Trop Med, Dept Noncommun Dis Epidemiol, London, England; [Chikowore, Tinashe; Choudhury, Ananyo] Univ Witwatersrand, Fac Hlth Sci, Sydney Brenner Inst Mol Biosci, Johannesburg, South Africa; [Chikowore, Tinashe] Univ Witwatersrand, Fac Hlth Sci, Dept Paediat, MRC Wits Dev Pathways Hlth Res Unit, Johannesburg, South Africa; [Ayub, Muhammad; Kuchenbaecker, Karoline] UCL, Div Psychiat, London, England; [Martin, Alicia R.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Martin, Alicia R.] MIT, Broad Inst Harvard, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Martin, Alicia R.] MIT, Program Med & Populat Genet, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Kuchenbaecker, Karoline] UCL, UCL Genet Inst, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Witwatersrand; University of Witwatersrand; University of London; University College London; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); University of London; University College London	Fatumo, S (corresponding author), MRC UVRI & LSHTM, African Computat Genom TACG Res Grp, Entebbe, Uganda.; Fatumo, S (corresponding author), London Sch Hyg & Trop Med, Dept Noncommun Dis Epidemiol, London, England.	segun.fatumo@lshtm.ac.uk		Fatumo, Segun/0000-0003-4525-3362; Ayub, Muhammad/0000-0002-7111-1571; Chikowore, Tinashe/0000-0002-6743-751X				ACHARYA A, 2021, HUM GENET; Aron S, 2021, FRONT EDUC, V6, DOI 10.3389/feduc.2021.725702; Ascencio-Carbajal T., BMC MED ETHICS, V2021; Asiki G, 2013, INT J EPIDEMIOL, V42, P129, DOI 10.1093/ije/dys234; Asimit JL, 2016, EUR J HUM GENET, V24, P1330, DOI 10.1038/ejhg.2016.1; Atkinson EG, 2021, NAT GENET, V53, P195, DOI 10.1038/s41588-020-00766-y; Auton A., 2015, ASSESSING RARE VARIA, P71; Bentley AR, 2017, J COMMUN GENET, V8, P255, DOI 10.1007/s12687-017-0316-6; Boua PR, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01354; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Chikowore T., 2021, POLYGENIC PREDICTION, DOI 10.1101/2021.02.11.430719; Choudhury A, 2021, AFRICA CRADLE HUMAN, P257, DOI [DOI 10.1163/9789004500228_011, 10.1163/9789004500228_011]; Choudhury A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00663-9; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Dlamini SN, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.687335; Elsum I, 2019, MED J AUSTRALIA, V211, P7, DOI 10.5694/mja2.50219; Fan SH, 2016, SCIENCE, V354, P54, DOI 10.1126/science.aaf5098; Fatumo S, 2021, HUM MOL GENET, V30, P1559, DOI 10.1093/hmg/ddab088; Fatumo S, 2021, STROKE, V52, P2680, DOI 10.1161/STROKEAHA.121.034747; Fatumo S, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102721; Gao C, 2021, J CLIN ONCOL, V39, P2564, DOI 10.1200/JCO.20.01992; Gaskell G, 2013, EUR J HUM GENET, V21, P14, DOI 10.1038/ejhg.2012.104; Genovese G, 2010, KIDNEY INT, V78, P698, DOI 10.1038/ki.2010.251; Global Forum for Health Research, 10 90 REP HLTH RES 2; Gomez-Olive FX, 2017, GLOB HEART, V12, P81, DOI 10.1016/j.gheart.2017.01.007; Gurdasani D, 2019, CELL, V179, P984, DOI 10.1016/j.cell.2019.10.004; Hampshire DJ, 2006, EUR J HUM GENET, V14, P543, DOI 10.1038/sj.ejhg.5201577; Harripaul R, 2018, MOL PSYCHIATR, V23, P973, DOI 10.1038/mp.2017.60; Hindorff LA, 2018, NAT REV GENET, V19, P175, DOI 10.1038/nrg.2017.89; Huang Q. Q., 2021, TRANSFERABILITY GENE, DOI 10.1101/2021.06.22.21259323v1; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Khan AA, 2021, J PAK MED ASSOC, V71, P816, DOI 10.47391/JPMA.256; Khan NM, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.695133; Klarin D, 2018, NAT GENET, V50, P1514, DOI 10.1038/s41588-018-0222-9; Knight HM, 2008, EUR J HUM GENET, V16, P750, DOI 10.1038/ejhg.2008.11; Kowal E., 2012, GENETIC RES ABORIGIN; Kraft SA, 2018, AM J BIOETHICS, V18, P3, DOI 10.1080/15265161.2018.1431322; Kwiatkowski D, 2008, NATURE, V456, P732, DOI 10.1038/nature07632; Lowy I, 2013, AM J PUBLIC HEALTH, V103, P226, DOI 10.2105/AJPH.2012.300901; Majara L., LOW GEN POLYGENIC SC, DOI 10.1101/2021.01.12.426453(2021; Manolio TA, 2019, AM J HUM GENET, V105, P233, DOI 10.1016/j.ajhg.2019.07.008; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Martin AR, 2017, AM J HUM GENET, V100, P635, DOI 10.1016/j.ajhg.2017.03.004; Mbaye R, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001855; McGregor S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108787; Nonterah EA, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011506; Oh SS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001918; Patin E, 2017, SCIENCE, V356, P543, DOI 10.1126/science.aal1988; Reverby SM, 2012, PUBLIC HEALTH REV, V34, DOI 10.1007/BF03391665; Rotimi C, 2014, SCIENCE, V344, P1346, DOI 10.1126/science.1251546; Rotimi CN, 2017, HUM MOL GENET, V26, pR225, DOI 10.1093/hmg/ddx253; Scutari M, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006288; Sengupta D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22207-y; Sengupta D, 2016, GENOME BIOL EVOL, V8, P3460, DOI 10.1093/gbe/evw244; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048; Sridhar D, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001312; Stein CM, 2020, TRENDS GENET, V36, P895, DOI 10.1016/j.tig.2020.07.010; Tan SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041255; Thomson RJ, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00330; Tindana P, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0014-z; Torkamani A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/s41576-018-0018-x; Wright GEB, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-21	63	26	26	5	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					243	250		10.1038/s41591-021-01672-4	http://dx.doi.org/10.1038/s41591-021-01672-4		FEB 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35145307	Green Accepted, Green Submitted			2022-12-27	WOS:000753763500004
J	Derosa, L; Routy, B; Thomas, AM; Iebba, V; Zalcman, G; Friard, S; Mazieres, J; Audigier-Valette, C; Moro-Sibilot, D; Goldwasser, F; Silva, CAC; Terrisse, S; Bonvalet, M; Scherpereel, A; Pegliasco, H; Richard, C; Ghiringhelli, F; Elkrief, A; Desilets, A; Blanc-Durand, F; Cumbo, F; Blanco, A; Boidot, R; Chevrier, S; Daillere, R; Kroemer, G; Alla, L; Pons, N; Le Chatelier, E; Galleron, N; Roume, H; Dubuisson, A; Bouchard, N; Messaoudene, M; Drubay, D; Deutsch, E; Barlesi, F; Planchard, D; Segata, N; Martinez, S; Zitvogel, L; Soria, JC; Besse, B				Derosa, Lisa; Routy, Bertrand; Thomas, Andrew Maltez; Iebba, Valerio; Zalcman, Gerard; Friard, Sylvie; Mazieres, Julien; Audigier-Valette, Clarisse; Moro-Sibilot, Denis; Goldwasser, Francois; Silva, Carolina Alves Costa; Terrisse, Safae; Bonvalet, Melodie; Scherpereel, Arnaud; Pegliasco, Herve; Richard, Corentin; Ghiringhelli, Francois; Elkrief, Arielle; Desilets, Antoine; Blanc-Durand, Felix; Cumbo, Fabio; Blanco, Aitor; Boidot, Romain; Chevrier, Sandy; Daillere, Romain; Kroemer, Guido; Alla, Laurie; Pons, Nicolas; Le Chatelier, Emmanuelle; Galleron, Nathalie; Roume, Hugo; Dubuisson, Agathe; Bouchard, Nicole; Messaoudene, Meriem; Drubay, Damien; Deutsch, Eric; Barlesi, Fabrice; Planchard, David; Segata, Nicola; Martinez, Stephanie; Zitvogel, Laurence; Soria, Jean-Charles; Besse, Benjamin			Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	NATURE MEDICINE			English	Article							GUT; IMMUNOTHERAPY; MICROBIOME; INHIBITION; DOCETAXEL; NIVOLUMAB; ELEMENTS; OUTCOMES	Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI in patients with NSCLC or kidney cancer. In the current study, we performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n = 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk. Baseline stool Akk was associated with increased objective response rates and overall survival in multivariate analyses, independent of PD-L1 expression, antibiotics, and performance status. Intestinal Akk was accompanied by a richer commensalism, including Eubacterium hallii and Bifidobacterium adolescentis, and a more inflamed tumor microenvironment in a subset of patients. However, antibiotic use (20% of cases) coincided with a relative dominance of Akk above 4.8% accompanied with the genus Clostridium, both associated with resistance to ICI. Our study shows significant differences in relative abundance of Akk that may represent potential biomarkers to refine patient stratification in future studies. In a large multicentric study of patients with advanced NSCLC undergoing anti-PD-1 therapy, the relative abundance of intestinal Akkermansia spp. was shown to associate with changes in the gut microbiome ecosystem and clinical outcomes.	[Derosa, Lisa; Silva, Carolina Alves Costa; Terrisse, Safae; Bonvalet, Melodie; Blanc-Durand, Felix; Kroemer, Guido; Dubuisson, Agathe; Deutsch, Eric; Barlesi, Fabrice; Planchard, David; Zitvogel, Laurence; Soria, Jean-Charles; Besse, Benjamin] Gustave Roussy Canc Campus, Villejuif, France; [Derosa, Lisa; Silva, Carolina Alves Costa; Barlesi, Fabrice; Planchard, David; Besse, Benjamin] Gustave Roussy, Canc Med Dept, Villejuif, France; [Derosa, Lisa; Zitvogel, Laurence] Inst Natl Sante & Rech Med INSERM U1015, Ligue Natl Canc, Equipe Labellisee, Villejuif, France; [Derosa, Lisa; Deutsch, Eric; Zitvogel, Laurence; Besse, Benjamin] Univ Paris Saclay, Ile De France, France; [Routy, Bertrand; Richard, Corentin; Elkrief, Arielle; Desilets, Antoine; Messaoudene, Meriem] Ctr Hosp Univ Montreal CHUM, Dept Med, Hematol Oncol Div, Montreal, PQ, Canada; [Routy, Bertrand; Richard, Corentin; Elkrief, Arielle; Desilets, Antoine; Messaoudene, Meriem] Ctr Rech CHUM CRCHUM, Montreal, PQ, Canada; [Thomas, Andrew Maltez; Cumbo, Fabio; Blanco, Aitor; Segata, Nicola] Univ Trento, Dept CIBIO, Trento, Italy; [Thomas, Andrew Maltez; Segata, Nicola] European Inst Oncol IEO IRCCS, Milan, Italy; [Iebba, Valerio] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy; [Zalcman, Gerard] Univ Paris Diderot, Hosp Bichat Claude Bernard, AP HP, Thorac Oncol Dept CIC1425 CLIP2 Paris Nord, Paris, France; [Friard, Sylvie] Foch Hosp, Pneumol Dept, Suresnes, France; [Mazieres, Julien] Toulouse Univ Hosp, Dept Pneumol, Toulouse, France; [Audigier-Valette, Clarisse] Ctr Hosp Toulon St Musse, Pneumol Dept, Toulon, France; [Moro-Sibilot, Denis] Ctr Hosp Univ, Dept Thorac Oncol, Grenoble, France; [Goldwasser, Francois; Kroemer, Guido] Paris Descartes Univ, Sorbonne Paris Cite, UPR 4466, Paris, France; [Goldwasser, Francois] Cochin Hosp, AP HP, Dept Med Oncol, Paris, France; [Goldwasser, Francois] Immunomodulatory Therapies Multidisciplinary Stud, Paris, France; [Scherpereel, Arnaud] Univ Lille, Univ Hosp CHU, Dept Pulm & Thorac Oncol, Lille, France; [Pegliasco, Herve] European Hosp, Pulm Dept, Marseille, France; [Ghiringhelli, Francois] Ctr Georges Francois Leclerc, Canc Biol Transfer Platform, Dijon, France; [Ghiringhelli, Francois] Ctr Rech INSERM LNC UMR1231, Dijon, France; [Ghiringhelli, Francois] Ctr Georges Francois Leclerc, Dept Med Oncol, Dijon, France; [Boidot, Romain; Chevrier, Sandy] UNICANCER, Dept Biol & Pathol Tumors, Unit Mol Biol, Georges Francois Leclerc Canc Ctr, Dijon, France; [Daillere, Romain] Gustave Roussy Canc Campus, Everlmmune, Villejuif, France; [Kroemer, Guido] Univ Paris, Inst Univ France, Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc,INSERM U1138, Paris, France; [Kroemer, Guido] Inst Gustave Roussy, Metabol & Cell Biol Platforms, Villejuif, France; [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Alla, Laurie; Pons, Nicolas; Le Chatelier, Emmanuelle; Galleron, Nathalie; Roume, Hugo] Univ Paris Saclay, MGP, INRAE, Jouy En Josas, France; [Bouchard, Nicole] Ctr Hosp Sherbrooke, Sherbrooke, PQ, Canada; [Drubay, Damien] Oncostat, INSERM U1018, Villejuif, France; [Deutsch, Eric] Gustave Roussy, Dept Radiat Oncol, Villejuif, France; [Deutsch, Eric] INSERM U1030, Radiotherapie Mol & Innovat Therapeut, Villejuif, France; [Martinez, Stephanie] Ctr Hosp Aix En Provence, Serv Malad Resp, Aix En Provence, France; [Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc BIOTHERIS 1428, Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Universite de Montreal; Universite de Montreal; University of Trento; University of Trieste; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Hospital Foch; CHU de Toulouse; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Institut Agro; AgroSup Dijon; UNICANCER; Centre Georges-Francois Leclerc; Universite de Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc; UNICANCER; Centre Georges-Francois Leclerc; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Universitaire de France; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Zitvogel, L (corresponding author), Gustave Roussy Canc Campus, Villejuif, France.; Zitvogel, L (corresponding author), Inst Natl Sante & Rech Med INSERM U1015, Ligue Natl Canc, Equipe Labellisee, Villejuif, France.; Zitvogel, L (corresponding author), Univ Paris Saclay, Ile De France, France.; Zitvogel, L (corresponding author), Ctr Clin Invest Biotherapies Canc BIOTHERIS 1428, Villejuif, France.		DEROSA, LISA/E-6814-2015; ZALCMAN, Gerard/L-7809-2015; Iebba, Valerio/P-1194-2016; Blanco-Miguez, Aitor/H-3628-2017	ZITVOGEL, laurence/0000-0003-1596-0998; ZALCMAN, Gerard/0000-0002-0343-9575; Blanc-Durand, Felix/0000-0002-5277-1515; Derosa, Lisa/0000-0003-0527-2964; MORO-SIBILOT, Denis/0000-0001-6776-8610; Iebba, Valerio/0000-0002-0716-306X; Thomas, Andrew Maltez/0000-0001-5789-3354; Blanco-Miguez, Aitor/0000-0001-7386-5572; MAZIERES, JULIEN/0000-0002-5921-7613	RHU Torino Lumiere [ANR-16-RHUS-0008]; H2020 ONCOBIOME; ANR, French-German Ileobiome [19-CE15-0029-01]; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIGN'IT 2020 ARC foundation; Agence Nationale de la Recherche [ANR-18-IBHU-0002]; Ligue contre le Cancer (equipe labelisee); ANR Projets blancs; ANR; ERA-Net for Research on Rare Diseases; Association Pour La Recherche Sur Le Cancer (ARC); Bristol-Myers Squibb (BMS) (International Immuno-Oncology Network); Canceropole Ile-de-France; Chancellerie des Universites de Paris (Legs Poix); Fondation pour la Recherche Medicale (FRM); Elior; European Commission (ArtForce); European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; LabEx Immuno-Oncology; FHU CARE; Dassault; Badinter Philantropia; Paris Alliance of Cancer Research Institutes (PACRI); Canadian Institutes of Health Research (CIHR); Institut du cancer de Montreal; Prefontaine family; CPRIT Research Training Program [RP170067]; European Research Council (ERC-STG) [MetaPG-716575]; MIUR 'Futuro in Ricerca' [RBFR13EWWI_001]; European H2020 program [ONCOBIOME-825410, MASTER-818368]; National Cancer Institute of the National Institutes of Health [1U01CA230551]; Premio Internazionale Lombardia e Ricerca; BMS; MSD; GlaxoSmithKline (GSK)/Tesaro; Janssen; Roche/Genentech; Pfizer; AstraZeneca; Amgen	RHU Torino Lumiere; H2020 ONCOBIOME; ANR, French-German Ileobiome(French National Research Agency (ANR)); SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIGN'IT 2020 ARC foundation; Agence Nationale de la Recherche(French National Research Agency (ANR)); Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); ANR Projets blancs(French National Research Agency (ANR)); ANR(French National Research Agency (ANR)); ERA-Net for Research on Rare Diseases; Association Pour La Recherche Sur Le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Bristol-Myers Squibb (BMS) (International Immuno-Oncology Network)(Bristol-Myers Squibb); Canceropole Ile-de-France; Chancellerie des Universites de Paris (Legs Poix); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Elior; European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)European Commission); Fondation Carrefour; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation(Leducq Foundation); LabEx Immuno-Oncology; FHU CARE; Dassault; Badinter Philantropia; Paris Alliance of Cancer Research Institutes (PACRI); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Institut du cancer de Montreal; Prefontaine family; CPRIT Research Training Program; European Research Council (ERC-STG)(European Research Council (ERC)); MIUR 'Futuro in Ricerca'(Ministry of Education, Universities and Research (MIUR)); European H2020 program; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Premio Internazionale Lombardia e Ricerca; BMS(Bristol-Myers Squibb); MSD; GlaxoSmithKline (GSK)/Tesaro; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Roche/Genentech(Roche HoldingGenentech); Pfizer(Pfizer); AstraZeneca(AstraZeneca); Amgen(Amgen)	L. Z. and B. B. were funded by the RHU Torino Lumiere (ANR-16-RHUS-0008), while L. Z. was supported by H2020 ONCOBIOME and ANR, French-German Ileobiome, 19-CE15-0029-01. L. Z. and G. K. received a donation from Seerave Foundation. L. Z., L. D., and E. D. were supported by the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE). L. D. and L. Z. were supported by SIGN'IT 2020 ARC foundation. This work was also supported by the Prism project funded by the Agence Nationale de la Recherche under grant number ANR-18-IBHU-0002. L. Z. and G. K. were supported by the Ligue contre le Cancer (equipe labelisee); ANR Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association Pour La Recherche Sur Le Cancer (ARC); Bristol-Myers Squibb (BMS) (International Immuno-Oncology Network), Canceropole Ile-de-France; Chancellerie des Universites de Paris (Legs Poix), Fondation pour la Recherche Medicale (FRM); a donation by Elior; the European Commission (ArtForce); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; FHU CARE, Dassault, and Badinter Philantropia, and the Paris Alliance of Cancer Research Institutes (PACRI). B. R. is supported by the Canadian Institutes of Health Research (CIHR), Institut du cancer de Montreal and the Prefontaine family. A. C. is supported by the CPRIT Research Training Program (RP170067). N. S. was supported by the European Research Council (ERC-STG project MetaPG-716575); MIUR 'Futuro in Ricerca' (grant No. RBFR13EWWI_001); the European H2020 program (ONCOBIOME-825410 project and MASTER-818368 project); the National Cancer Institute of the National Institutes of Health (1U01CA230551); by the Premio Internazionale Lombardia e Ricerca 2019 to G. K. A. M. has been or is currently an investigator in clinical trials sponsored by BMS, MSD, GlaxoSmithKline (GSK)/Tesaro, Janssen, Roche/Genentech, Pfizer, AstraZeneca, Amgen. A. M. has been or is currently a member of Clinical Trial Scientific Steering Committee for AstraZeneca and GSK. A. M. has been or is currently a member of the scientific advisory board of the following companies: Merck Serono, Novartis, BMS, Symphogen, Amgen, Tesaro/GSK, Pfizer, AstraZeneca/Medimmune, Servier, and Sanofi. A. M. has provided scientific and medical consulting to the following companies: Roche, Sanofi. A. M. is a member of the data safety and monitoring board for trial NCT02423863 (TLR3 agonist; Oncovir). A. M. has received research funding and/or drug supply for preclinical and clinical research projects from: BMS, Boehringer Ingelheim, Idera, MSD, Fondation MSD Avenir, and SIRIC (INCa-DGOS-Inserm_12551).	Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Barcena C, 2019, NAT MED, V25, P1234, DOI 10.1038/s41591-019-0504-5; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Benevides L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01790; Blacher E, 2019, NATURE, V572, P474, DOI 10.1038/s41586-019-1443-5; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Cani PD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01765; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Daisley BA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18649-5; Depommier C, 2019, NAT MED, V25, P1096, DOI 10.1038/s41591-019-0495-2; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Derosa L, 2021, CANCER DISCOV, V11, P2396, DOI 10.1158/2159-8290.CD-21-0236; Derosa L, 2020, NAT REV UROL, V17, P605, DOI 10.1038/s41585-020-0373-1; Derosa L, 2020, EUR UROL, V78, P195, DOI 10.1016/j.eururo.2020.04.044; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Elkrief A, 2019, ANN ONCOL, V30, P1572, DOI 10.1093/annonc/mdz206; Ferrara R, 2018, JAMA ONCOL, V4, P1543, DOI 10.1001/jamaoncol.2018.3676; Fumet JD, 2018, BRIT J CANCER, V119, P950, DOI 10.1038/s41416-018-0220-9; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Hakozaki T, 2020, CANCER IMMUNOL RES, V8, P1243, DOI 10.1158/2326-6066.CIR-20-0196; Huck O, 2020, J CLIN PERIODONTOL, V47, P202, DOI 10.1111/jcpe.13214; Hwang S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57218-9; Jin YP, 2019, J THORAC ONCOL, V14, P1378, DOI 10.1016/j.jtho.2019.04.007; Karcher N, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02427-7; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Lee SH, 2021, NAT MICROBIOL, V6, P277, DOI 10.1038/s41564-020-00831-6; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Lin H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17041-7; Mallick R, 2020, EARTH PLANET SC LETT, V543, DOI 10.1016/j.epsl.2020.116351; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Meng XJ, 2019, CLIN LUNG CANCER, V20, P48, DOI 10.1016/j.cllc.2018.09.012; Nakajima K, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1838812; Nielsen HB, 2014, NAT BIOTECHNOL, V32, P822, DOI 10.1038/nbt.2939; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Ouyang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00645; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Romano S, 2021, NPJ PARKINSONS DIS, V7, DOI 10.1038/s41531-021-00156-z; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Ruusunen A, 2019, PSYCHOPHARMACOLOGY, V236, P1545, DOI 10.1007/s00213-018-5159-2; Santoro A, 2018, CELL MOL LIFE SCI, V75, P129, DOI 10.1007/s00018-017-2674-y; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Seo SW, 2015, CELL REP, V12, P1289, DOI 10.1016/j.celrep.2015.07.043; Shi LL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000973; Shono Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2311; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Tsay JCJ, 2021, CANCER DISCOV, V11, P293, DOI 10.1158/2159-8290.CD-20-0263; van der Lugt B, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0145-z; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wu WR, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01804; Young A, 2016, CANCER CELL, V30, P391, DOI 10.1016/j.ccell.2016.06.025; Zhou Q, 2020, NUTR METAB, V17, DOI 10.1186/s12986-020-00516-1	63	37	37	21	66	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					315	+		10.1038/s41591-021-01655-5	http://dx.doi.org/10.1038/s41591-021-01655-5		FEB 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35115705	Green Accepted, Green Published			2022-12-27	WOS:000750724400003
J	Birch, J; Creel, KA; Jha, AK; Plutynski, A				Birch, Jonathan; Creel, Kathleen A.; Jha, Abhinav K.; Plutynski, Anya			Clinical decisions using AI must consider patient values	NATURE MEDICINE			English	Editorial Material								Built-in decision thresholds for AI diagnostics are ethically problematic, as patients may differ in their attitudes about the risk of false-positive and false-negative results, which will require that clinicians assess patient values.	[Birch, Jonathan] London Sch Econ & Polit Sci, Ctr Philosophy Nat & Social Sci, London, England; [Creel, Kathleen A.] Stanford Univ, McCoy Family Ctr Eth Soc, Stanford, CA USA; [Creel, Kathleen A.] Stanford Univ, Inst Human Cent Artificial Intelligence, Stanford, CA USA; [Jha, Abhinav K.] Washington Univ St Louis, Dept Biomed Engn, St Louis, MO USA; [Jha, Abhinav K.] Washington Univ St Louis, Mallinckrodt Inst Radiol, St Louis, MO USA; [Plutynski, Anya] Washington Univ St Louis, Dept Philosophy, St Louis, MO USA; [Plutynski, Anya] Washington Univ St Louis, Div Biol & Biomed Sci, St Louis, MO USA	University of London; London School Economics & Political Science; Stanford University; Stanford University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Birch, J (corresponding author), London Sch Econ & Polit Sci, Ctr Philosophy Nat & Social Sci, London, England.	j.birch2@lse.ac.uk	Birch, Jonathan/GRR-2530-2022	Jha, Abhinav/0000-0002-4795-4878; Creel, Kathleen/0000-0001-7371-2680; Birch, Jonathan/0000-0001-7517-4759	National Institute of Biomedical Imaging and Bioengineering of the US National Institutes of Health [R01-EB031051, R56-EB028287]	National Institute of Biomedical Imaging and Bioengineering of the US National Institutes of Health	We thank S. Bhalla, L. Kofi Bright, A. Houston, L. Hudetz, R. Short, J. Swamidass, K. Vredenburgh, Z. Ward, K. Wright and patient groups at Washington University in St Louis, Stanford University and Johns Hopkins University for their input and advice. A.K.J. acknowledges support from the National Institute of Biomedical Imaging and Bioengineering of the US National Institutes of Health (R01-EB031051 and R56-EB028287).	Bright LK, 2018, SYNTHESE, V195, P2227, DOI 10.1007/s11229-017-1333-z; Buchak L, 2017, J MED ETHICS, V43, P90, DOI 10.1136/medethics-2015-103118; Claassen J, 2019, NEW ENGL J MED, V380, P2497, DOI 10.1056/NEJMoa1812757; Douglas HE, 2009, SCI POLICY VALUE FRE, DOI [DOI 10.2307/J.CTT6WRC78, 10.2307/j.ctt6wrc78]; Grote T, 2020, J MED ETHICS, V46, P205, DOI 10.1136/medethics-2019-105586; Hastie T., 2009, ELEMENTS STAT LEARNI, V2nd ed.; Komorowski M, 2018, NAT MED, V24, P1716, DOI 10.1038/s41591-018-0213-5; Liu ZP, 2021, PHYS MED BIOL, V66, DOI 10.1088/1361-6560/ac01f4; McCradden MD, 2020, NAT MED, V26, P1325, DOI 10.1038/s41591-020-1035-9; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; Nagler RH, 2017, MED CARE, V55, P879, DOI 10.1097/MLR.0000000000000798; Ongena YP, 2021, J AM COLL RADIOL, V18, P79, DOI 10.1016/j.jacr.2020.09.042; Pan C.H., 2012, J INVESTMENT CONSULT, V13, P54; Plutynski Anya, 2017, EXPLORING INDUCTIVE, P149; Tschandl P, 2020, NAT MED, V26, P1229, DOI 10.1038/s41591-020-0942-0; Turbe V, 2021, NAT MED, V27, P1165, DOI 10.1038/s41591-021-01384-9; Wenner DM, 2020, INT J FEM APPROACHES, V13, P28, DOI 10.3138/ijfab.13.2.2020-01-08	17	2	2	3	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					229	232		10.1038/s41591-021-01624-y	http://dx.doi.org/10.1038/s41591-021-01624-y		JAN 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35102337				2022-12-27	WOS:000750421100001
J	Patel, A; Ojji, D; de Silva, HA; MacMahon, S; Rodgers, A				Patel, Anushka; Ojji, Dike; de Silva, H. Asita; MacMahon, Stephen; Rodgers, Anthony			Polypills for the prevention of cardiovascular disease: a framework for wider use	NATURE MEDICINE			English	Editorial Material							LOW-INCOME COUNTRIES; SECONDARY PREVENTION; BLOOD-PRESSURE; MIDDLE-INCOME; MEDICINES; STRATEGY; HYPERTENSION; COMBINATION; RISK; PURE	Combinations of cardiovascular medications taken in a single pill - known as polypills - are effective but not widely used, requiring a global shift from physicians, regulators and drug developers.	[Patel, Anushka; Rodgers, Anthony] Univ NSW, George Inst Global Hlth, Sydney, NSW, Australia; [Ojji, Dike] Univ Abuja, Dept Med, Abuja, Nigeria; [de Silva, H. Asita] Univ Kelaniya, Dept Pharmacol, Clin Trials Unit, Fac Med, Kelaniya, Sri Lanka; [MacMahon, Stephen; Rodgers, Anthony] Imperial Coll London, Sch Publ Hlth, London, England	George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University Kelaniya; Imperial College London	Patel, A (corresponding author), Univ NSW, George Inst Global Hlth, Sydney, NSW, Australia.	apatel@georgeinstitute.org		MacMahon, Stephen/0000-0003-2064-7699; Patel, Anushka/0000-0003-3825-4092				Castellano JM, 2014, J AM COLL CARDIOL, V64, P2071, DOI 10.1016/j.jacc.2014.08.021; Chow CK, 2021, LANCET, V398, P1043, DOI 10.1016/S0140-6736(21)01922-X; Cosin-Sales J, 2021, J COMP EFFECT RES, V10, P975, DOI 10.2217/cer-2021-0105; Do NT, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006523; Gaziano TA, 2019, AM HEART J, V214, P77, DOI 10.1016/j.ahj.2019.04.020; Joseph P, 2021, LANCET, V398, P1133, DOI 10.1016/S0140-6736(21)01827-4; Khatib R, 2016, LANCET, V387, P61, DOI 10.1016/S0140-6736(15)00469-9; Kishore SP, 2018, J AM COLL CARDIOL, V71, P564, DOI 10.1016/j.jacc.2017.11.056; Lin JK, 2019, LANCET GLOB HEALTH, V7, pE1346, DOI 10.1016/S2214-109X(19)30339-0; Liu HM, 2015, CIRC-CARDIOVASC QUAL, V8, P301, DOI 10.1161/CIRCOUTCOMES.115.001483; Lung T, 2019, LANCET GLOB HEALTH, V7, pE1359, DOI 10.1016/S2214-109X(19)30343-2; Munoz D, 2019, NEW ENGL J MED, V381, P1114, DOI 10.1056/NEJMoa1815359; Peiris D, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003485; Roshandel G, 2019, LANCET, V394, P672, DOI 10.1016/S0140-6736(19)31791-X; Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010; Salam A, 2020, J CLIN HYPERTENS, V22, P1769, DOI 10.1111/jch.14009; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wang N, 2021, INT J CARDIOL, V341, P96, DOI 10.1016/j.ijcard.2021.08.023; Webster R, 2018, JAMA-J AM MED ASSOC, V320, P566, DOI 10.1001/jama.2018.10359; Webster R, 2016, INT J CARDIOL, V205, P147, DOI 10.1016/j.ijcard.2015.12.015; WHO, 2021, GUID PHARM TREATM HY; Wood F, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008018; Yusuf S, 2021, NEW ENGL J MED, V384, P216, DOI 10.1056/NEJMoa2028220; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4; Zhou B, 2021, LANCET, V398, P957, DOI 10.1016/S0140-6736(21)01330-1	25	0	0	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					226	229		10.1038/s41591-021-01635-9	http://dx.doi.org/10.1038/s41591-021-01635-9		JAN 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35102336				2022-12-27	WOS:000750421100002
J	Morris, L				Morris, Lynn			mRNA vaccines offer hope for HIV	NATURE MEDICINE			English	Editorial Material								mRNA technology may be uniquely positioned to tackle a major hurdle for HIV vaccines: the elicitation of broadly cross-reactive neutralizing antibodies. A preclinical study takes the first step toward this goal.	[Morris, Lynn] Univ Witwatersrand, Fac Hlth Sci, Antibody Immun Res Unit, Johannesburg, South Africa; [Morris, Lynn] Univ KwaZulu Natal, Ctr AIDS Program Res South Africa, Durban, South Africa	University of Witwatersrand; University of Kwazulu Natal	Morris, L (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Antibody Immun Res Unit, Johannesburg, South Africa.; Morris, L (corresponding author), Univ KwaZulu Natal, Ctr AIDS Program Res South Africa, Durban, South Africa.	lynn.morris@wits.ac.za	, Lynn/V-3941-2018	, Lynn/0000-0003-3961-7828				Chaudhary N, 2021, NAT REV DRUG DISCOV, V20, P817, DOI 10.1038/s41573-021-00283-5; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Gray GE, 2021, NEW ENGL J MED, V384, P1089, DOI 10.1056/NEJMoa2031499; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Mu ZK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020134; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Zhang P, 2021, NAT MED, V27, P2234, DOI 10.1038/s41591-021-01574-5	11	1	1	7	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2082	2084		10.1038/s41591-021-01602-4	http://dx.doi.org/10.1038/s41591-021-01602-4		DEC 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34887576	Bronze			2022-12-27	WOS:000728466100006
J	Nakamura, Y; Okamoto, W; Kato, T; Esaki, T; Kato, K; Komatsu, Y; Yuki, S; Masuishi, T; Nishina, T; Ebi, H; Sawada, K; Taniguchi, H; Fuse, N; Nomura, S; Fukui, M; Matsuda, S; Sakamoto, Y; Uchigata, H; Kitajima, K; Kuramoto, N; Asakawa, T; Olsen, S; Odegaard, JI; Sato, A; Fujii, S; Ohtsu, A; Yoshino, T				Nakamura, Yoshiaki; Okamoto, Wataru; Kato, Takeshi; Esaki, Taito; Kato, Ken; Komatsu, Yoshito; Yuki, Satoshi; Masuishi, Toshiki; Nishina, Tomohiro; Ebi, Hiromichi; Sawada, Kentaro; Taniguchi, Hiroya; Fuse, Nozomu; Nomura, Shogo; Fukui, Makoto; Matsuda, Seiko; Sakamoto, Yasutoshi; Uchigata, Hiroshi; Kitajima, Kana; Kuramoto, Naomi; Asakawa, Takashi; Olsen, Steve; Odegaard, Justin, I; Sato, Akihiro; Fujii, Satoshi; Ohtsu, Atsushi; Yoshino, Takayuki			Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial	NATURE MEDICINE			English	Article							RESISTANCE; MULTICENTER; THERAPY	The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab for metastatic colorectal cancer (mCRC), with human epidermal growth factor receptor 2 (HER2) amplification prospectively confirmed by tumor tissue or ctDNA analysis (UMIN000027887). HER2 amplification was confirmed in tissue and/or ctDNA in 30 patients with mCRC. The study met the primary endpoint with a confirmed objective response rate of 30% in 27 tissue-positive patients and 28% in 25 ctDNA-positive patients, as compared to an objective response rate of 0% in a matched real-world reference population treated with standard-of-care salvage therapy. Post hoc exploratory analyses revealed that baseline ctDNA genotyping of HER2 copy number and concurrent oncogenic alterations adjusted for tumor fraction stratified patients according to efficacy with similar accuracy to tissue genotyping. Decreased ctDNA fraction 3 weeks after treatment initiation associated with therapeutic response. Pertuzumab plus trastuzumab showed similar efficacy in patients with mCRC with HER2 amplification in tissue or ctDNA, showing that ctDNA genotyping can identify patients who benefit from dual-HER2 blockade as well as monitor treatment response. These findings warrant further use of ctDNA genotyping in clinical trials for HER2-amplified mCRC, which might especially benefit patients in first-line treatment.	[Nakamura, Yoshiaki; Okamoto, Wataru; Sawada, Kentaro; Taniguchi, Hiroya; Ohtsu, Atsushi; Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan; [Nakamura, Yoshiaki; Okamoto, Wataru; Taniguchi, Hiroya; Sakamoto, Yasutoshi; Uchigata, Hiroshi; Kitajima, Kana; Kuramoto, Naomi] Natl Canc Ctr Hosp East, Translat Res Support Sect, Kashiwa, Chiba, Japan; [Okamoto, Wataru] Hiroshima Univ Hosp, Canc Treatment Ctr, Hiroshima, Japan; [Kato, Takeshi] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan; [Esaki, Taito] Natl Hosp Org Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan; [Kato, Ken] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan; [Komatsu, Yoshito] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan; [Yuki, Satoshi] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan; [Masuishi, Toshiki; Taniguchi, Hiroya] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan; [Nishina, Tomohiro] Natl Hosp Org Shikoku Canc Ctr, Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan; [Ebi, Hiromichi] Aichi Canc Ctr Res Inst, Div Mol Therapeut, Nagoya, Aichi, Japan; [Sawada, Kentaro] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Hokkaido, Japan; [Fuse, Nozomu; Nomura, Shogo; Fukui, Makoto; Matsuda, Seiko; Sato, Akihiro] Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Chiba, Japan; [Asakawa, Takashi] Chugai Pharmaceut Co Ltd, Tokyo, Japan; [Olsen, Steve] Guardant Hlth AMEA, Clin & Med Affairs, Redwood City, CA USA; [Odegaard, Justin, I] Guardant Hlth, Clin Dev, Redwood City, CA USA; [Fujii, Satoshi] Natl Canc Ctr, Div Pathol, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan; [Fujii, Satoshi] Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Yokohama, Kanagawa, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Hiroshima University; Osaka National Hospital; Kyushu Cancer Center; National Cancer Center - Japan; Hokkaido University; Hokkaido University; Aichi Cancer Center; Aichi Cancer Center; National Cancer Center - Japan; Chugai Pharmaceutical Co., Ltd.; Roche Holding; National Cancer Center - Japan; Yokohama City University	Yoshino, T (corresponding author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan.	tyoshino@east.ncc.go.jp	Ebi, Hiromichi/AAA-7358-2019; Okamoto, Wataru/AIE-0808-2022	Ebi, Hiromichi/0000-0003-3155-7576; Komatsu, Yoshito/0000-0002-1570-6802; Kato, Ken/0000-0002-1733-5072	Japan Agency for Medical Research and Development [16lk0201054h0001, 16lk0201056s0001, 19ck0106445h0002]; National Cancer Center Research and Development Fund [31-A-5]; SCRUM-Japan Funds	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); SCRUM-Japan Funds	The authors would like to thank all of the patients and their families who participated in this study; all investigators, research nurses, study coordinators and research staff members at all the study sites; all the National Cancer Center Exploratory Oncology Research & Clinical Trial Center members; and all the National Cancer Center Hospital East Translational Research Support Section members. This study was supported by grants from the Japan Agency for Medical Research and Development (16lk0201054h0001 to W.O., 16lk0201056s0001 to A.O. and 19ck0106445h0002 to Y.N.), the National Cancer Center Research and Development Fund (31-A-5 to A.O.) and SCRUM-Japan Funds (http://www.scrum-japan.ncc.go.jp/index.html).	Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Di Leo A, 2018, LANCET ONCOL, V19, P87, DOI 10.1016/S1470-2045(17)30688-5; Fujii S, 2020, JCO PRECIS ONCOL, V4, P6, DOI 10.1200/PO.19.00154; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Lih CJ, 2017, J MOL DIAGN, V19, P313, DOI 10.1016/j.jmoldx.2016.10.007; Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325; Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5; Nakamura Y, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1063-5; Nakamura Y, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2019-000600; Nakamura Y, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000530; Nakamura Y, 2018, ONCOLOGIST, V23, P1310, DOI 10.1634/theoncologist.2017-0621; Odegaard JI, 2018, CLIN CANCER RES, V24, P3539, DOI 10.1158/1078-0432.CCR-17-3831; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9; Pietrantonio F, 2018, CLIN CANCER RES, V24, P1082, DOI 10.1158/1078-0432.CCR-17-2781; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389; Takegawa N, 2016, ONCOTARGET, V7, P3443, DOI 10.18632/oncotarget.6498; Turner NC, 2020, LANCET ONCOL, V21, P1296, DOI [10.11016/S1470-2045(20)30444-7, 10.1016/S1470-2045(20)30444-7]	20	25	25	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1899	+		10.1038/s41591-021-01553-w	http://dx.doi.org/10.1038/s41591-021-01553-w		NOV 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34764486	hybrid, Green Published			2022-12-27	WOS:000717406200004
J	Christian, P				Christian, Parul			Anemia in women - an intractable problem that requires innovative solutions	NATURE MEDICINE			English	Editorial Material							INCOME COUNTRIES	A new spatial analysis calls for a tiered and geographically targeted approach to tackling the vast, ongoing burden of anemia in women within low- and middle-income countries.	[Christian, Parul] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Human Nutr, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Christian, P (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Human Nutr, Dept Int Hlth, Baltimore, MD 21205 USA.	pchrist1@jhu.edu						Alderman H, 2009, FOOD NUTR BULL, V30, P265, DOI 10.1177/156482650903000308; Baldi AJ, 2020, AM J CLIN NUTR, V112, P1145, DOI 10.1093/ajcn/nqaa213; Christian P., 2018, Handbook of Nutrition and Pregnancy, P401, DOI 10.1007/978-3-319-90988-2_21; Christian P, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2019-002186; Ferguson EL, 2019, MATERN CHILD HLTH J, V23, P55, DOI 10.1007/s10995-018-2638-3; Haas JD, 2001, J NUTR, V131, p676S, DOI 10.1093/jn/131.2.676S; Horton S, 2003, FOOD POLICY, V28, P51, DOI 10.1016/S0306-9192(02)00070-2; Keats EC, 2019, AM J CLIN NUTR, V109, P1696, DOI 10.1093/ajcn/nqz023; Kinyoki D., NAT MED, DOI [10.1038/s41591-021-01498-0(2021), DOI 10.1038/S41591-021-01498-0(2021)]; Nguyen PH, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-001010; Perumal N., AM J CLIN NUTR, DOI [10.1093/ajcn/nqab234(2021, DOI 10.1093/AJCN/NQAB234(2021]; Sedlander E, 2021, NUTRITION, V86, DOI 10.1016/j.nut.2021.111159	12	2	2	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1675	1677		10.1038/s41591-021-01514-3	http://dx.doi.org/10.1038/s41591-021-01514-3		OCT 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642492	Bronze			2022-12-27	WOS:000706587600006
J	Dagan, N; Barda, N; Biron-Shental, T; Makov-Assif, M; Key, C; Kohane, IS; Hernan, MA; Lipsitch, M; Hernandez-Diaz, S; Reis, BY; Balicer, RD				Dagan, Noa; Barda, Noam; Biron-Shental, Tal; Makov-Assif, Maya; Key, Calanit; Kohane, Isaac S.; Hernan, Miguel A.; Lipsitch, Marc; Hernandez-Diaz, Sonia; Reis, Ben Y.; Balicer, Ran D.			Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	NATURE MEDICINE			English	Article								To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89-100%) for any documented infection, 97% (91-100%) for infections with documented symptoms and 89% (43-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population. In an observational cohort of pregnant women in Israel, the BNT162b2 COVID-19 vaccine was found to have effectiveness similar to that seen in the general population.	[Dagan, Noa; Barda, Noam; Makov-Assif, Maya; Balicer, Ran D.] Clalit Hlth Serv, Clalit Res Inst, Innovat Div, Tel Aviv, Israel; [Dagan, Noa; Barda, Noam] Ben Gurion Univ Negev, Software & Informat Syst Engn, Beer Sheva, Israel; [Dagan, Noa; Barda, Noam] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Dagan, Noa; Barda, Noam; Kohane, Isaac S.; Reis, Ben Y.; Balicer, Ran D.] Harvard Med Sch, Ivan & Francesca Berkowitz Family Living Lab Coll, Boston, MA 02115 USA; [Dagan, Noa; Barda, Noam; Kohane, Isaac S.; Reis, Ben Y.; Balicer, Ran D.] Clalit Res Inst, Boston, MA USA; [Biron-Shental, Tal] Meir Med Ctr, Dept Obstet & Gynecol, Kefar Sava, Israel; [Biron-Shental, Tal] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Key, Calanit] Clalit Hlth Serv, Clalit Community Div, Tel Aviv, Israel; [Hernan, Miguel A.; Hernandez-Diaz, Sonia] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Hernan, Miguel A.; Hernandez-Diaz, Sonia] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, CAUSALab, Boston, MA USA; [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Ctr Communicable Dis Dynam, Boston, MA USA; [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA; [Reis, Ben Y.] Boston Childrens Hosp, Computat Hlth Informat Program, Predict Med Grp, Boston, MA USA; [Reis, Ben Y.] Harvard Med Sch, Boston, MA 02115 USA; [Balicer, Ran D.] Ben Gurion Univ Negev, Fac Hlth Sci, Sch Publ Hlth, Beer Sheva, Israel	Clalit Health Services; Ben Gurion University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Clalit Health Services; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Ben Gurion University	Balicer, RD (corresponding author), Clalit Hlth Serv, Clalit Res Inst, Innovat Div, Tel Aviv, Israel.; Balicer, RD (corresponding author), Harvard Med Sch, Ivan & Francesca Berkowitz Family Living Lab Coll, Boston, MA 02115 USA.; Balicer, RD (corresponding author), Clalit Res Inst, Boston, MA USA.; Balicer, RD (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Sch Publ Hlth, Beer Sheva, Israel.	Rbalicer@clalit.org.il	Dagan, Noa/ABC-3018-2021; Barda, Noam/AAC-9434-2020	Dagan, Noa/0000-0001-8811-7825; Barda, Noam/0000-0002-3400-235X; Lipsitch, Marc/0000-0003-1504-9213; Hernandez Diaz, Sonia/0000-0003-1458-7642; Hernan, Miguel/0000-0003-1619-8456	Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute; Morris-Singer Foundation	Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute; Morris-Singer Foundation	This study was supported by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute. M.L. was supported by the Morris-Singer Foundation.	American College of Obstetricians and Gynecologists, 2021, COVID 19 VACC CONS O; BioNTech SE, STUD EV SAF TOL IMM; Centers for Disease Control and Prevention, 2021, COVID 19 VACC WHILE; Centers for Disease Control and Prevention, 2021, CERT MED COND RISK S; Cohen R., 2017, MEMBERSHIP HLTH FUND; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Goodman T, UPDATE WHO INTERIM R; Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566; National Institutes of Health, COR DIS 2019 COVID 1; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Rasmussen SA, 2021, OBSTET GYNECOL, V137, P408, DOI 10.1097/AOG.0000000000004290; Rubin R, 2021, JAMA-J AM MED ASSOC, V325, P1027, DOI 10.1001/jama.2021.2264; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1097/01.ogx.0000802676.57373.17, 10.1056/NEJMx210016]; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Wei SQ, 2021, CAN MED ASSOC J, V193, pE540, DOI 10.1503/cmaj.202604	18	96	98	8	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1693	+		10.1038/s41591-021-01490-8	http://dx.doi.org/10.1038/s41591-021-01490-8		SEP 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34493859	Bronze, Green Submitted			2022-12-27	WOS:000693564700001
J	Dunn, J; Kidzinski, L; Runge, R; Witt, D; Hicks, JL; Rose, SMSF; Li, X; Bahmani, A; Delp, SL; Hastie, T; Snyder, MP				Dunn, Jessilyn; Kidzinski, Lukasz; Runge, Ryan; Witt, Daniel; Hicks, Jennifer L.; Schussler-Fiorenza Rose, Sophia Miryam; Li, Xiao; Bahmani, Amir; Delp, Scott L.; Hastie, Trevor; Snyder, Michael P.			Wearable sensors enable personalized predictions of clinical laboratory measurements	NATURE MEDICINE			English	Article							HEART-RATE; BLOOD-PRESSURE; MANAGEMENT; OMICS; DEHYDRATION; POPULATION; ACCURACY	Data from wearable sensors, including heart rate, body temperature, electrodermal activity and movement, can predict clinical laboratory measurements, with highest accuracy for hematological tests such as hematocrit. Vital signs, including heart rate and body temperature, are useful in detecting or monitoring medical conditions, but are typically measured in the clinic and require follow-up laboratory testing for more definitive diagnoses. Here we examined whether vital signs as measured by consumer wearable devices (that is, continuously monitored heart rate, body temperature, electrodermal activity and movement) can predict clinical laboratory test results using machine learning models, including random forest and Lasso models. Our results demonstrate that vital sign data collected from wearables give a more consistent and precise depiction of resting heart rate than do measurements taken in the clinic. Vital sign data collected from wearables can also predict several clinical laboratory measurements with lower prediction error than predictions made using clinically obtained vital sign measurements. The length of time over which vital signs are monitored and the proximity of the monitoring period to the date of prediction play a critical role in the performance of the machine learning models. These results demonstrate the value of commercial wearable devices for continuous and longitudinal assessment of physiological measurements that today can be measured only with clinical laboratory tests.	[Dunn, Jessilyn; Runge, Ryan; Schussler-Fiorenza Rose, Sophia Miryam; Li, Xiao; Bahmani, Amir; Snyder, Michael P.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Dunn, Jessilyn; Witt, Daniel] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Dunn, Jessilyn; Witt, Daniel] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA; [Dunn, Jessilyn; Kidzinski, Lukasz; Runge, Ryan; Hicks, Jennifer L.; Delp, Scott L.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Dunn, Jessilyn; Schussler-Fiorenza Rose, Sophia Miryam; Snyder, Michael P.] Stanford Cardiovasc Inst, Stanford, CA 94305 USA; [Schussler-Fiorenza Rose, Sophia Miryam] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Li, Xiao] Case Western Reserve Univ, Dept Biochem, Ctr RNA Sci & Therapeut, Dept Comp & Data Sci, Cleveland, OH 44106 USA; [Delp, Scott L.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Hastie, Trevor] Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Duke University; Duke University; Stanford University; Stanford University; Case Western Reserve University; Stanford University; Stanford University	Dunn, J; Snyder, MP (corresponding author), Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.; Dunn, J (corresponding author), Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.; Dunn, J (corresponding author), Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA.; Dunn, J (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.; Dunn, J; Snyder, MP (corresponding author), Stanford Cardiovasc Inst, Stanford, CA 94305 USA.; Hastie, T (corresponding author), Stanford Univ, Dept Stat, Stanford, CA 94305 USA.	jessilyn.dunn@duke.edu; hastie@stanford.edu; mpsnyder@stanford.edu	Schussler-Fiorenza Rose, Sophia Miryam/E-6411-2013	Schussler-Fiorenza Rose, Sophia Miryam/0000-0002-6311-6671; Hicks, Jennifer/0000-0002-2516-9334; Delp, Scott/0000-0002-9643-7551; Snyder, Michael/0000-0003-0784-7987; Hastie, Trevor/0000-0002-0164-3142; Witt, Daniel/0000-0002-9770-8042	National Institues of Health (NIH) Common Fund Human Microbiome Project (HMP) [1U54DE02378901]; NIH National Center for Advancing Translational Science Clinical and Translational Science Award [UL1TR001085]; Chan Zuckerberg Initiative Donor-Advised Fund (an advised fund of Silicon Valley Community Foundation) [2020-218599]; Mobilize Center grant [NIH U54 EB020405]; NIH Career Development Award [K08 ES028825]	National Institues of Health (NIH) Common Fund Human Microbiome Project (HMP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Center for Advancing Translational Science Clinical and Translational Science Award; Chan Zuckerberg Initiative Donor-Advised Fund (an advised fund of Silicon Valley Community Foundation); Mobilize Center grant; NIH Career Development Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work was supported by grants from the National Institues of Health (NIH) Common Fund Human Microbiome Project (HMP) (1U54DE02378901), an NIH National Center for Advancing Translational Science Clinical and Translational Science Award (UL1TR001085), and the Chan Zuckerberg Initiative Donor-Advised Fund (an advised fund of Silicon Valley Community Foundation; 2020-218599). JD, LK, RR and JH were supported by the Mobilize Center grant (NIH U54 EB020405). SMS-FR was supported by an NIH Career Development Award (no. K08 ES028825). JD is a MEDx Investigator and a Whitehead Scholar. The Stanford Translational Research Integrated Database Environment (STRIDE) is a research and development project at Stanford University that aims to create a standards-based informatics platform supporting clinical and translational research. We thank the participants who generously gave their time and biological samples for this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of Veteran Affairs.	Albanese M, 2016, EUR J CLIN PHARMACOL, V72, P789, DOI 10.1007/s00228-016-2046-9; Armbruster David, 2007, Clin Biochem Rev, V28, P105; Avram R., 2019, LEARNING J AM COLL C, V73; Avram R, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0134-9; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bent B, 2021, J CLIN TRANSL SCI, V5, DOI 10.1017/cts.2020.511; Bloomfield H. E., 2011, VA EVIDENCE BASED SY; Boucsein W, 2012, PSYCHOPHYSIOLOGY, V49, P1017, DOI 10.1111/j.1469-8986.2012.01384.x; Breiman L., 2001, MACH LEARN, V45, P5; Cadmus-Bertram L, 2017, ANN INTERN MED, V166, P610, DOI 10.7326/L16-0353; Chen R, 2012, CELL, V148, P1293, DOI 10.1016/j.cell.2012.02.009; Emaminejad S, 2017, P NATL ACAD SCI USA, V114, P4625, DOI 10.1073/pnas.1701740114; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Hall H, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005143; Hannun AY, 2019, NAT MED, V25, P65, DOI 10.1038/s41591-018-0268-3; Hardoon DR, 2011, MACH LEARN, V83, P331, DOI 10.1007/s10994-010-5222-7; Hastie T., 2013, RESPONSE PERILS LOO; Hatala R, 1997, J GEN INTERN MED, V12, P182, DOI 10.1007/s11606-006-5027-3; Ikeda N, 2010, CIRC J, V74, P730, DOI 10.1253/circj.CJ-09-0758; Kavsaoglu AR, 2015, APPL SOFT COMPUT, V37, P983, DOI 10.1016/j.asoc.2015.04.008; Li X, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2001402; Londeree William, 2014, Hawaii J Med Public Health, V73, P3; Mandal S, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18041084; Nemati S, 2016, IEEE ENG MED BIO, P3394, DOI 10.1109/EMBC.2016.7591456; Palatini P, 2000, AM J HYPERTENS, V13, P92, DOI 10.1016/S0895-7061(99)00170-3; Parlak O, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2904; Piening BD, 2018, CELL SYST, V6, P157, DOI 10.1016/j.cels.2017.12.013; Poldrack R., 2012, PERILS LEAVE ONE OUT; Radin JM, 2020, LANCET DIGIT HEALTH, V2, pE85, DOI 10.1016/S2589-7500(19)30222-5; Reule S, 2012, CURR HYPERTENS REP, V14, P478, DOI 10.1007/s11906-012-0306-3; Rose SMSF, 2019, NAT MED, V25, P792, DOI 10.1038/s41591-019-0414-6; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Shcherbina A, 2017, J PERS MED, V7, DOI 10.3390/jpm7020003; St John Andrew, 2014, Clin Biochem Rev, V35, P155; Steinhubl SR, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000070; Steinhubl SR, 2016, AM HEART J, V175, P77, DOI 10.1016/j.ahj.2016.02.011; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Suzuki T, 2009, IEEE ENG MED BIO, P6080, DOI 10.1109/IEMBS.2009.5335401; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Vaithinathan Asokan G, 2017, J Evid Based Med, V10, P76, DOI 10.1111/jebm.12239; WEINBERG AD, 1995, JAMA-J AM MED ASSOC, V274, P1552, DOI 10.1001/jama.274.19.1552; Welch HG, 1999, J GEN INTERN MED, V14, P223, DOI 10.1046/j.1525-1497.1999.00321.x; Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI [10.1161/HYP.0000000000000065, 10.1161/HYP.0000000000000066]; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Witten DM, 2009, BIOSTATISTICS, V10, P515, DOI 10.1093/biostatistics/kxp008; Xiao H, 2004, AM J HEALTH-SYST PH, V61, P2534, DOI 10.1093/ajhp/61.23.2534; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zhou WY, 2019, NATURE, V569, P663, DOI 10.1038/s41586-019-1236-x	48	40	40	15	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1105	+		10.1038/s41591-021-01339-0	http://dx.doi.org/10.1038/s41591-021-01339-0		MAY 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34031607	Green Accepted			2022-12-27	WOS:000653615900005
J	Choueiri, TK; Bauer, TM; Papadopoulos, KP; Plimack, ER; Merchan, JR; McDermott, DF; Michaelson, MD; Appleman, LJ; Thamake, S; Perini, RF; Zojwalla, NJ; Jonasch, E				Choueiri, Toni K.; Bauer, Todd M.; Papadopoulos, Kyriakos P.; Plimack, Elizabeth R.; Merchan, Jaime R.; McDermott, David F.; Michaelson, M. Dror; Appleman, Leonard J.; Thamake, Sanjay; Perini, Rodolfo F.; Zojwalla, Naseem J.; Jonasch, Eric			Inhibition of hypoxia-inducible factor-2 alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis	NATURE MEDICINE			English	Article							ANTAGONIST	Hypoxia-inducible factor-2 alpha (HIF-2 alpha) is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in constitutive activation of genes involved in carcinogenesis. Belzutifan (MK-6482, previously known as PT2977) is a potent, selective small molecule inhibitor of HIF-2 alpha. Maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of belzutifan were evaluated in this first-in-human phase 1 study (NCT02974738). Patients had advanced solid tumors (dose-escalation cohort) or previously treated advanced ccRCC (dose-expansion cohort). Belzutifan was administered orally using a 3 + 3 dose-escalation design, followed by expansion at the recommended phase 2 dose (RP2D) in patients with ccRCC. In the dose-escalation cohort (n = 43), no dose-limiting toxicities occurred at doses up to 160 mg once daily, and the maximum tolerated dose was not reached; the RP2D was 120 mg once daily. Plasma erythropoietin reductions were observed at all doses; erythropoietin concentrations correlated with plasma concentrations of belzutifan. In patients with ccRCC who received 120 mg once daily (n = 55), the confirmed objective response rate was 25% (all partial responses), and the median progression-free survival was 14.5 months. The most common grade >= 3 adverse events were anemia (27%) and hypoxia (16%). Belzutifan was well tolerated and demonstrated preliminary anti-tumor activity in heavily pre-treated patients, suggesting that HIF-2 alpha inhibition might offer an effective treatment for ccRCC. A first-in-human trial of hypoxia-inducible factor (HIF)-2 alpha inhibitor belzutifan (MK-6482) has a favorable safety profile and shows promising clinical activity for the treatment of patients with renal cell carcinoma who have been heavily pre-treated.	[Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Choueiri, Toni K.] Harvard Med Sch, Boston, MA 02115 USA; [Bauer, Todd M.] Sarah Cannon Res Inst, Tennessee Oncol PLLC, Nashville, TN USA; [Papadopoulos, Kyriakos P.] South Texas Accelerated Res Therapeut START, San Antonio, TX USA; [Plimack, Elizabeth R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Merchan, Jaime R.] Univ Miami, Miami, FL USA; [McDermott, David F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Michaelson, M. Dror] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Appleman, Leonard J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Thamake, Sanjay; Perini, Rodolfo F.; Zojwalla, Naseem J.] Merck & Co Inc, Kenilworth, NJ USA; [Jonasch, Eric] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Sarah Cannon Research Institute; Tennessee Oncology; Fox Chase Cancer Center; University of Miami; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Merck & Company; University of Texas System; UTMD Anderson Cancer Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	toni_choueiri@dfci.harvard.edu; ejonasch@mdanderson.org	Choueiri, Toni/K-5238-2019	Choueiri, Toni/0000-0002-9201-3217; McDermott, David/0000-0002-2675-5095; Plimack, Elizabeth/0000-0002-7618-0744	Merck Sharp Dohme	Merck Sharp Dohme(Merck & Company)	Editorial assistance was provided by R. Steger and M. Grzywacz of ApotheCom. This assistance was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. Funding for this research was provided by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc.	Choueiri TK., 2020, NAT MED, V5, P1; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Courtney KD, 2018, J CLIN ONCOL, V36, P867, DOI 10.1200/JCO.2017.74.2627; Dai ZY, 2018, AM J RESP CRIT CARE, V198, P1423, DOI 10.1164/rccm.201710-2079OC; Haase VH, 2013, BLOOD REV, V27, P41, DOI 10.1016/j.blre.2012.12.003; Kaelin WG, 2018, J CLIN ONCOL, V36, P908, DOI 10.1200/JCO.2017.77.5254; Koehler AN, 2010, CURR OPIN CHEM BIOL, V14, P331, DOI 10.1016/j.cbpa.2010.03.022; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Le Tourneau C, 2009, JNCI-J NATL CANCER I, V101, P708, DOI 10.1093/jnci/djp079; Linehan WM, 2019, NAT REV UROL, V16, P539, DOI 10.1038/s41585-019-0211-5; Martinez-Saez O, 2017, CRIT REV ONCOL HEMAT, V111, P117, DOI 10.1016/j.critrevonc.2017.01.013; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Parikh M, 2020, SEMIN NEPHROL, V40, P76, DOI 10.1016/j.semnephrol.2019.12.009; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Ravaud A, 2011, ONCOLOGIST, V16, P32, DOI 10.1634/theoncologist.2011-S2-32; Scortegagna M, 2005, BLOOD, V105, P3133, DOI 10.1182/blood-2004-05-1695; Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473; Xu R, 2019, J MED CHEM, V62, P6876, DOI 10.1021/acs.jmedchem.9b00719; Yu YC, 2019, DRUG DISCOV TODAY, V24, P2332, DOI 10.1016/j.drudis.2019.09.008; Zhao J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.565	20	73	73	11	25	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					802	+		10.1038/s41591-021-01324-7	http://dx.doi.org/10.1038/s41591-021-01324-7		APR 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33888901	Green Accepted			2022-12-27	WOS:000642382600003
J	Rice, BL; Annapragada, A; Baker, RE; Bruijning, M; Dotse-Gborgbortsi, W; Mensah, K; Miller, IF; Motaze, NV; Raherinandrasana, A; Rajeev, M; Rakotonirina, J; Ramiadantsoa, T; Rasambainarivo, F; Yu, WY; Grenfell, BT; Tatem, AJ; Metcalf, CJE				Rice, Benjamin L.; Annapragada, Akshaya; Baker, Rachel E.; Bruijning, Marjolein; Dotse-Gborgbortsi, Winfred; Mensah, Keitly; Miller, Ian F.; Motaze, Nkengafac Villyen; Raherinandrasana, Antso; Rajeev, Malavika; Rakotonirina, Julio; Ramiadantsoa, Tanjona; Rasambainarivo, Fidisoa; Yu, Weiyu; Grenfell, Bryan T.; Tatem, Andrew J.; Metcalf, C. Jessica E.			Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa	NATURE MEDICINE			English	Article							COVID-19; HEALTH; RISK; MEASLES; TRANSMISSION; POPULATION; MALARIA; DISEASE; TIME	A surprising feature of the SARS-CoV-2 pandemic to date is the low burdens reported in sub-Saharan Africa (SSA) countries relative to other global regions. Potential explanations (for example, warmer environments(1), younger populations(2-4)) have yet to be framed within a comprehensive analysis. We synthesized factors hypothesized to drive the pace and burden of this pandemic in SSA during the period from 25 February to 20 December 2020, encompassing demographic, comorbidity, climatic, healthcare capacity, intervention efforts and human mobility dimensions. Large diversity in the probable drivers indicates a need for caution in interpreting analyses that aggregate data across low- and middle-income settings. Our simulation shows that climatic variation between SSA population centers has little effect on early outbreak trajectories; however, heterogeneity in connectivity, although rarely considered, is likely an important contributor to variance in the pace of viral spread across SSA. Our synthesis points to the potential benefits of context-specific adaptation of surveillance systems during the ongoing pandemic. In particular, characterizing patterns of severity over age will be a priority in settings with high comorbidity burdens and poor access to care. Understanding the spatial extent of outbreaks warrants emphasis in settings where low connectivity could drive prolonged, asynchronous outbreaks resulting in extended stress to health systems.	[Rice, Benjamin L.; Baker, Rachel E.; Bruijning, Marjolein; Miller, Ian F.; Rajeev, Malavika; Rasambainarivo, Fidisoa; Grenfell, Bryan T.; Metcalf, C. Jessica E.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Rice, Benjamin L.] Madagascar Hlth & Environm Res, Maroantsetra, Madagascar; [Annapragada, Akshaya] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Baker, Rachel E.] Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA; [Dotse-Gborgbortsi, Winfred; Tatem, Andrew J.] Univ Southampton, Sch Geog & Environm Sci, WorldPop, Southampton, Hants, England; [Mensah, Keitly] Inst Rech Dev IRD, Ctr Populat & Dev CEPED, Paris, France; [Mensah, Keitly] Univ Paris, INSERM, ERL 1244, Paris, France; [Motaze, Nkengafac Villyen] Natl Inst Comnmunicable Dis, Ctr Vaccines & Immunol, Natl Hlth Lab Serv, Johannesburg, South Africa; [Motaze, Nkengafac Villyen] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Cape Town, South Africa; [Raherinandrasana, Antso; Rakotonirina, Julio] Univ Antananarivo, Fac Med, Antananarivo, Madagascar; [Raherinandrasana, Antso; Rakotonirina, Julio] Teaching Hosp Care & Publ Hlth Analakely, Antananarivo, Madagascar; [Ramiadantsoa, Tanjona] Univ Fianarantsoa, Dept Life Sci, Fianarantsoa, Madagascar; [Ramiadantsoa, Tanjona] Univ Fianarantsoa, Dept Math, Fianarantsoa, Madagascar; [Ramiadantsoa, Tanjona] Univ Wisconsin Madison, Dept Integrat Biol, Madison, WI USA; [Rasambainarivo, Fidisoa] Mahaliana Labs SARL, Antananarivo, Madagascar; [Yu, Weiyu] Univ Southampton, Sch Geog & Environm Sci, Southampton, Hants, England; [Grenfell, Bryan T.; Metcalf, C. Jessica E.] Princeton Univ, Princeton Sch Publ & Int Affairs, Princeton, NJ 08544 USA	Princeton University; Johns Hopkins University; Princeton University; University of Southampton; UDICE-French Research Universities; Universite Paris Cite; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Health Laboratory Service; Stellenbosch University; University Antananarivo; University of Wisconsin System; University of Wisconsin Madison; University of Southampton; Princeton University	Rice, BL (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.; Rice, BL (corresponding author), Madagascar Hlth & Environm Res, Maroantsetra, Madagascar.	b.rice@princeton.edu	Rasambainarivo, Fidisoa/AAJ-5285-2021; Annapragada, Akshaya/GOK-1735-2022	Baker, Rachel/0000-0002-2661-8103; Dotse-Gborgbortsi, Winfred/0000-0001-7627-1809; Annapragada, Akshaya/0000-0002-9097-6511; Tatem, Andrew/0000-0002-7270-941X	Cooperative Institute for Modeling the Earth System; National Institutes of Health Medical Scientist Training Program [1T32GM136577]; Bill & Melinda Gates Foundation [OPP1182425, OPP1134076, INV-002697]; Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Dutch Rsearch Council) Rubicon [019.192EN.017]; ESRC SCDTP [ES/P000673/1]; Center for Health and Wellbeing, Princeton University	Cooperative Institute for Modeling the Earth System; National Institutes of Health Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Dutch Rsearch Council) Rubicon; ESRC SCDTP(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Center for Health and Wellbeing, Princeton University(Princeton University)	R.E.B. is supported by the Cooperative Institute for Modeling the Earth System. A.A. acknowledges support from the National Institutes of Health Medical Scientist Training Program no. 1T32GM136577. A.J.T. is funded by the Bill & Melinda Gates Foundation (nos. OPP1182425, OPP1134076 and INV-002697). M.B. is funded by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Dutch Rsearch Council) Rubicon grant no. 019.192EN.017. W.D.-G. is supported by ESRC SCDTP grant number ES/P000673/1. We thank the Center for Health and Wellbeing, Princeton University for support.	Adams JG, 2020, JAMA-J AM MED ASSOC, V323, P1439, DOI 10.1001/jama.2020.3972; [Anonymous], 2020, MAPPING RISK FACTORS; [Anonymous], 2019, GLOBAL BURDEN DIS ST, DOI 10.1016/S0140-6736(18)32203-7; [Anonymous], 2020, AFRICA COVID COMMUNI; [Anonymous], 2020, COVID 19 COMMUNITY M; [Anonymous], 2020, COVID 19 SIGNIFICANT; [Anonymous], 2020, MAINTAINING ESSENTIA; [Anonymous], 2020, MEASLES RUBELLA SURV; Baker RE, 2020, SCIENCE, V369, P315, DOI 10.1126/science.abc2535; Bjornstad ON, 2002, ECOL MONOGR, V72, P169, DOI 10.1890/0012-9615(2002)072[0169:DOMEES]2.0.CO;2; Cash R, 2020, LANCET, V395, P1687, DOI 10.1016/S0140-6736(20)31089-8; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]; Chanda-Kapata P, 2020, INT J INFECT DIS, V94, P151, DOI 10.1016/j.ijid.2020.04.007; Chin T, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039886; Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3; Conticini E, 2020, ENVIRON POLLUT, V261, DOI 10.1016/j.envpol.2020.114465; Cooper TJ, 2020, HIV MED, V21, P567, DOI 10.1111/hiv.12911; Deng X, 2020, CLIN INFECT DIS; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Ghisolfi S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003094; Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6; Griffith GJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19478-2; Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000424; Hersbach H, 2020, Q J ROY METEOR SOC, V146, P1999, DOI 10.1002/qj.3803; Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202; Kapata N, 2020, INT J INFECT DIS, V93, P233, DOI 10.1016/j.ijid.2020.02.049; Kilmarx PH, 2014, MMWR-MORBID MORTAL W, V63, P1168; Lai S, 2020, ASSESSING EFFECT GLO, DOI [10.1101/2020.06.17.20133843, DOI 10.1101/2020.06.17.20133843]; Lesosky M, 2020, LANCET HIV, V7, pE596, DOI 10.1016/S2352-3018(20)30228-9; Linard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031743; Majiya, 2020, SEROPREVALENCE COVID, P1, DOI [10.1101/2020.08.04.20168112, DOI 10.1101/2020.08.04.20168112]; Mbow M, 2020, SCIENCE, V369, P624, DOI 10.1126/science.abd3902; Mecenas P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238339; Meyerowitz-Katz G, 2020, INT J INFECT DIS, V101, P138, DOI 10.1016/j.ijid.2020.09.1464; Mikkelsen L, 2015, LANCET, V386, P1395, DOI 10.1016/S0140-6736(15)60171-4; Mina MJ, 2020, ELIFE, V9, DOI 10.7554/eLife.58989; Nachega Jean B, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa695; Nepomuceno MR, 2020, P NATL ACAD SCI USA, V117, P13881, DOI 10.1073/pnas.2008760117; Nimpa MM, 2020, PAN AFR MED J, V35, DOI 10.11604/pamj.2020.35.84.19630; Novel CPERE, 2020, CHINA CDC WEEKLY, V41, P145, DOI [DOI 10.1056/NEJMcp2009249, 10.4258/hir.2022.28.2.160]; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; Paradisi M, 2020, EMPIRICAL ESTIMATE I, DOI [DOI 10.1101/2020.04.18.20070912, 10.1101/2020.04.18.20070912]; Pedregosa F., 2011, J MACH LEARN RES, V12, P2825; Pei S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd6370; R Core Team, 2020, R LANG ENV STAT COMP; Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1; Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Shaman J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000316; Shankar AH, 2000, J INFECT DIS, V182, pS37, DOI 10.1086/315906; Sherrard-Smith E, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1025-y; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Skrip LA, 2020, SEEDING COVID 19 SUB, DOI [10.1101/2020.04.01.20050203v1, DOI 10.1101/2020.04.01.20050203]; Takahashi S, 2015, SCIENCE, V347, P1240, DOI 10.1126/science.aaa3438; Tatem AJ, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.4; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Uyoga S, 2021, SCIENCE, V371, P79, DOI 10.1126/science.abe1916; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Walker P.G., 2020, REPORT 22 EQUITY RES; Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035; Weiss DJ, 2018, NATURE, V553, P333, DOI 10.1038/nature25181; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wood S., 2017, GEN ADDITIVE MODELS, V2nd Edn; World Health Organization and United Nations Children's Fund Joint Monitoring Programme for Water Supply Sanitation and Hygiene, 2018, CORE QUESTIONS WATER	64	36	36	1	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					447	+		10.1038/s41591-021-01234-8	http://dx.doi.org/10.1038/s41591-021-01234-8		FEB 2021	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33531710	Green Accepted, Bronze			2022-12-27	WOS:000614000700003
J	Stower, H				Stower, Hannah			A personal approach for Parkinson's disease	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1805	1805		10.1038/s41591-020-01152-1	http://dx.doi.org/10.1038/s41591-020-01152-1			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288932				2022-12-27	WOS:000596579200007
J	Lasky-Su, J				Lasky-Su, Jessica			Inhaled corticosteroid use for asthma is linked to adrenal suppression	NATURE MEDICINE			English	Editorial Material									[Lasky-Su, Jessica] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Lasky-Su, Jessica] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lasky-Su, J (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Lasky-Su, J (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							Global Initiative for Asthma, 2022, GLOB STRAT ASTHM MAN; Hawcutt DB, 2018, LANCET RESP MED, V6, P442, DOI 10.1016/S2213-2600(18)30058-4; Lapi F, 2013, EUR RESPIR J, V42, P79, DOI 10.1183/09031936.00080912; Pietzner M, 2021, NAT MED, V27, P471, DOI 10.1038/s41591-021-01266-0; Szefler S, 2000, NEW ENGL J MED, V343, P1054	5	0	0	1	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					645	646						2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35314845				2022-12-27	WOS:000785007700019
J	Jardine, L; Behjati, S				Jardine, Laura; Behjati, Sam			A distinct hematopoietic differentiation state characterizes aggressive infant leukemia	NATURE MEDICINE			English	Editorial Material								The developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia (B-ALL) was identified by comparison of bulk and single-cell leukemia transcriptomes with those of a human fetal bone marrow reference. Unlike standard-risk childhood B-ALL, this aggressive leukemia was characterized by early lymphocyte precursor (ELP) differentiation. Moreover, in contrast to healthy ELPs, KMT2A-rearranged infant B-ALL cells had both myeloid and lymphoid features and expressed potentially targetable novel combinations of antigens.	[Jardine, Laura] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [Behjati, Sam] Wellcome Sanger Inst, Hinxton, England	Newcastle University - UK; Wellcome Trust Sanger Institute	Jardine, L (corresponding author), Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England.							Jardine L, 2021, NATURE, V598, P327, DOI 10.1038/s41586-021-03929-x	1	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					641	642		10.1038/s41591-022-01719-0	http://dx.doi.org/10.1038/s41591-022-01719-0		MAR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35288696				2022-12-27	WOS:000770060900008
J	Dizman, N; Meza, L; Bergerot, P; Alcantara, M; Dorff, T; Lyou, Y; Frankel, P; Cui, YJ; Mira, V; Llamas, M; Hsu, J; Zengin, Z; Salgia, N; Salgia, S; Malhotra, J; Chawla, N; Chehrazi-Raffle, A; Muddasani, R; Gillece, J; Reining, L; Trent, J; Takahashi, M; Oka, K; Higashi, S; Kortylewski, M; Highlander, SK; Pal, SK				Dizman, Nazli; Meza, Luis; Bergerot, Paulo; Alcantara, Marice; Dorff, Tanya; Lyou, Yung; Frankel, Paul; Cui, Yujie; Mira, Valerie; Llamas, Marian; Hsu, Joann; Zengin, Zeynep; Salgia, Nicholas; Salgia, Sabrina; Malhotra, Jasnoor; Chawla, Neal; Chehrazi-Raffle, Alex; Muddasani, Ramya; Gillece, John; Reining, Lauren; Trent, Jeff; Takahashi, Motomichi; Oka, Kentaro; Higashi, Seiya; Kortylewski, Marcin; Highlander, Sarah K.; Pal, Sumanta K.			Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	NATURE MEDICINE			English	Article							CLOSTRIDIUM-BUTYRICUM; TRANSPLANTATION; MICROBIOME; BUTYRATE; EFFICACY; COLITIS	Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut microbiome. In this open-label, single-center study (NCT03829111), 30 treatment-naive patients with metastatic renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk disease were randomized 2:1 to receive nivolumab and ipilimumab with or without daily oral CBM588, respectively. Stool metagenomic sequencing was performed at multiple timepoints. The primary endpoint to compare the relative abundance of Bifidobacterium spp. at baseline and at 12 weeks was not met, and no significant differences in Bifidobacterium spp. or Shannon index associated with the addition of CBM588 to nivolumab-ipilimumab were detected. Secondary endpoints included response rate, progression-free survival (PFS) and toxicity. PFS was significantly longer in patients receiving nivolumab-ipilimumab with CBM588 than without (12.7 months versus 2.5 months, hazard ratio 0.15, 95% confidence interval 0.05-0.47, P = 0.001). Although not statistically significant, the response rate was also higher in patients receiving CBM588 (58% versus 20%, P = 0.06). No significant difference in toxicity was observed between the study arms. The data suggest that CBM588 appears to enhance the clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab-ipilimumab. Larger studies are warranted to confirm this clinical observation and elucidate the mechanism of action and the effects on microbiome and immune compartments. A randomized trial in treatment-naive patients with metastatic renal cell carcinoma shows that the addition of a live bacterial product to an immunotherapy combination elicits promising clinical benefit in association with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders.	[Dizman, Nazli; Meza, Luis; Dorff, Tanya; Lyou, Yung; Mira, Valerie; Llamas, Marian; Hsu, Joann; Zengin, Zeynep; Salgia, Nicholas; Salgia, Sabrina; Malhotra, Jasnoor; Chawla, Neal; Chehrazi-Raffle, Alex; Muddasani, Ramya; Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA 91010 USA; [Dizman, Nazli] Yale Univ, Sch Med, New Haven, CT USA; [Bergerot, Paulo] Cettro Oncol, Brasilia, DF, Brazil; [Alcantara, Marice; Kortylewski, Marcin] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Immunol, Duarte, CA USA; [Frankel, Paul; Cui, Yujie] City Hope Comprehens Canc Ctr, Div Biostat, Duarte, CA USA; [Gillece, John; Reining, Lauren; Trent, Jeff; Highlander, Sarah K.] Translat Genom Res Inst TGen, Phoenix, AZ 85004 USA; [Takahashi, Motomichi; Oka, Kentaro; Higashi, Seiya] Miyarisan Pharmaceut Co Ltd, Tokyo, Japan	City of Hope; Yale University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Translational Genomics Research Institute	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA 91010 USA.; Highlander, SK (corresponding author), Translat Genom Res Inst TGen, Phoenix, AZ 85004 USA.	sarah@skhighlander.us; spal@coh.org	Zengin, Zeynep Busra/AAW-5912-2021	Zengin, Zeynep Busra/0000-0002-2751-5915; Takahashi, Motomichi/0000-0003-4773-5904; Meza, Luis/0000-0002-0235-297X	Gateway for Cancer Research [G-20-100]	Gateway for Cancer Research	We thank the patients and families for their participation in this study. Funding for the study was provided by a grant from the Gateway for Cancer Research (S.K.P; Grant ID: G-20-100). CBM588 was supplied by Miyarisan Pharmaceuticals Co., Ltd. and OSEL, Inc.	Adams S, 2019, ANN ONCOL, V30, P397, DOI 10.1093/annonc/mdy517; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Ariyoshi T, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.587725; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Busi S. B., 2018, CANCER RES, V78; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Choueiri TK, 2020, ANN ONCOL, V31, pS1159, DOI 10.1016/j.annonc.2020.08.2257; Choueiri TK, 2016, CLIN CANCER RES, V22, P5461, DOI 10.1158/1078-0432.CCR-15-2839; Cremonesi E, 2018, GUT, V67, P1984, DOI 10.1136/gutjnl-2016-313498; DeFilipp Z, 2019, NEW ENGL J MED, V381, P2043, DOI 10.1056/NEJMoa1910437; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Derosa L, 2021, CANCER DISCOV, V11, P2396, DOI 10.1158/2159-8290.CD-21-0236; Dizman N, 2021, CANCER MED-US, V10, P79, DOI 10.1002/cam4.3569; Dudani S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.21869; Escudier B, 2019, ANN ONCOL, V30, P706, DOI 10.1093/annonc/mdz056; Francisco-Anderson L, 2021, CANCER RES, V81; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grasso CS, 2020, CANCER CELL, V38, P500, DOI 10.1016/j.ccell.2020.08.005; Hagihara M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100772; Isa K, 2016, HUM EXP TOXICOL, V35, P818, DOI 10.1177/0960327115607372; Liu CM, 2012, BMC MICROBIOL, V12, DOI [10.1186/1471-2180-12-56, 10.1186/1471-2180-12-255]; Louis P, 2017, ENVIRON MICROBIOL, V19, P29, DOI 10.1111/1462-2920.13589; Lu J, 2017, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.104; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer R, 2019, LANCET ONCOL, V20, P1370, DOI 10.1016/S1470-2045(19)30413-9; Motzer RJ, 2019, J NATL COMPR CANC NE, V17, P1279, DOI 10.6004/jnccn.2019.0054; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Okamoto T, 2000, J GASTROENTEROL, V35, P341, DOI 10.1007/s005350050358; Reichardt N, 2018, ISME J, V12, P610, DOI 10.1038/ismej.2017.196; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Salgia NJ, 2020, EUR UROL, V78, P498, DOI 10.1016/j.eururo.2020.07.011; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Takahashi M, 2004, FEMS IMMUNOL MED MIC, V41, P219, DOI 10.1016/j.femsim.2004.03.010; Tomita Y, 2020, CANCER IMMUNOL RES, V8, P1236, DOI 10.1158/2326-6066.CIR-20-0051; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0; Zhang X, 2021, GUT, V70, P761, DOI 10.1136/gutjnl-2019-319664	43	39	39	18	42	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					704	+		10.1038/s41591-022-01694-6	http://dx.doi.org/10.1038/s41591-022-01694-6		FEB 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35228755	hybrid, Green Published			2022-12-27	WOS:000762162700003
J	Tseng, HF; Ackerson, BK; Luo, Y; Sy, LS; Talarico, CA; Tian, Y; Bruxvoort, KJ; Tubert, JE; Florea, A; Ku, JH; Lee, GS; Choi, SK; Takhar, HS; Aragones, M; Qian, L				Tseng, Hung Fu; Ackerson, Bradley K.; Luo, Yi; Sy, Lina S.; Talarico, Carla A.; Tian, Yun; Bruxvoort, Katia J.; Tubert, Julia E.; Florea, Ana; Ku, Jennifer H.; Lee, Gina S.; Choi, Soon Kyu; Takhar, Harpreet S.; Aragones, Michael; Qian, Lei			Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	NATURE MEDICINE			English	Article								Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case-control study to evaluate mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron or Delta. The large, diverse study population included 26,683 SARS-CoV-2 test-positive cases with variants determined by S gene target failure status (16% Delta and 84% Omicron). The two-dose VE against Omicron infection at 14-90 days was 44.0% (95% confidence interval, 35.1-51.6%) but declined quickly. The three-dose VE was 93.7% (92.2-94.9%) and 86.0% (78.1-91.1%) against Delta infection and 71.6% (69.7-73.4%) and 47.4% (40.5-53.5%) against Omicron infection at 14-60 days and >60 days, respectively. The three-dose VE was 29.4% (0.3-50.0%) against Omicron infection in immunocompromised individuals. The three-dose VE against hospitalization with Delta or Omicron was >99% across the entire study population. Our findings demonstrate high, durable three-dose VE against Delta infection but lower effectiveness against Omicron infection, particularly among immunocompromised people. However, three-dose VE of mRNA-1273 was high against hospitalization with Delta and Omicron variants. A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.	[Tseng, Hung Fu; Ackerson, Bradley K.; Luo, Yi; Sy, Lina S.; Tian, Yun; Tubert, Julia E.; Florea, Ana; Ku, Jennifer H.; Lee, Gina S.; Choi, Soon Kyu; Takhar, Harpreet S.; Aragones, Michael; Qian, Lei] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91107 USA; [Tseng, Hung Fu] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA; [Talarico, Carla A.] Moderna Inc, Cambridge, MA USA; [Bruxvoort, Katia J.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA	Kaiser Permanente; Kaiser Permanente; University of Alabama System; University of Alabama Birmingham	Tseng, HF (corresponding author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91107 USA.	hung-fu.x.tseng@kp.org	Sy, Lina/AFM-9458-2022	Sy, Lina/0000-0003-2762-9266; Tseng, HungFu/0000-0001-6184-6534; Bruxvoort, Katia/0000-0001-8277-2431; Tubert, Julia/0000-0003-0779-888X	Moderna, Inc.	Moderna, Inc.	This study was funded by Moderna, Inc. Manuscript authors, including those employed by the funder, contributed to the conceptualization, design, interpretation of data, decision to publish and preparation of the manuscript. Medical writing and editorial assistance were provided by S. Ramachandran and J. Mackenzie of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, Inc. and under the direction of the authors. Laboratory and database support were provided at KPSC by L. Childs, J. Stern, J. Gelfond, R. Bathala, K. Kottmann, A. Acevedo, E. Ayala, S. Quinones, S. Baluyot, E. Lopez and D. McCarthy. The authors thank the KPSC Lab Leadership and Technician Team for their support of this study. The authors would like to acknowledge Helix OpCo, LLC for their whole-genome sequencing of SARS-CoV-2 specimens. The authors thank the patients of Kaiser Permanente for their partnership with us to improve their health. Their information, collected through our electronic health record systems, leads to findings that help us improve care for our members and can be shared with the larger community. J. Vanas of Moderna, Inc. provided critical operations support, and Y. Paila of Moderna, Inc. provided critical input on specimen sequencing.	Accorsi EK, 2022, JAMA-J AM MED ASSOC, V327, P639, DOI 10.1001/jama.2022.0470; ANDREWS N, 2022, NEW ENGL J MED; Bruxvoort KJ, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj-2021-068848; Bruxvoort Katia J, 2022, Lancet Reg Health Am, V6, P100134, DOI 10.1016/j.lana.2021.100134; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; Doria-Rose N., 2021, BOOSTER MRNA 1273 ST; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Ferguson N., 2021, 49 IMP COLL LOND, DOI [10.25561/93038, DOI 10.25561/93038]; French G, 2021, MMWR-MORBID MORTAL W, V70, P1613, DOI 10.15585/mmwr.mm7046a5; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Hansen C. H., 2021, VACCINE EFFECTIVENES, DOI 10.1101/2021.12.20.21267966v2; Hui KPY, 2022, NATURE, V603, P715, DOI 10.1038/s41586-022-04479-6; Lewnard JA, 2021, EPIDEMIOLOGY, V32, P508, DOI 10.1097/EDE.0000000000001366; Public Health England, 2021, SARS COV 2 VAR VAR; Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064; Thompson Mark G, 2022, MMWR Morb Mortal Wkly Rep, V71, P139, DOI 10.15585/mmwr.mm7104e3; US Centers for Disease Control and Prevention, CHOOS YOUR COVID 19; US Food and Drug Administration, 2021, SARS COV 2 VIR MUT I; Wilhelm A, 2021, REDUCED NEUTRALIZATI, DOI [10.1101/2021.12.07.21267432, DOI 10.15585/MMWR.MM7011A1EXTERNALICON]; Wolter N, 2022, LANCET, V399, P437, DOI 10.1016/S0140-6736(22)00017-4; World Health Organization, 2022, ENH RESP OM SARS COV	23	128	128	11	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1063	+		10.1038/s41591-022-01753-y	http://dx.doi.org/10.1038/s41591-022-01753-y		FEB 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35189624	hybrid, Green Submitted, Green Published			2022-12-27	WOS:000774887200001
J	Korobeynikov, VA; Lyashchenko, AK; Blanco-Redondo, B; Jafar-Nejad, P; Shneider, NA				Korobeynikov, Vladislav A.; Lyashchenko, Alexander K.; Blanco-Redondo, Beatriz; Jafar-Nejad, Paymaan; Shneider, Neil A.			Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis	NATURE MEDICINE			English	Article							LOBAR DEGENERATION; MUTATIONS; ALS; GENE; PROTEIN; TDP-43; MICE	An antisense oligonucleotide targeting the RNA-binding protein FUS transcript lowers FUS levels in mice and in the central nervous system of a single patient with FUS-dependent ALS Fused in sarcoma (FUS) is an RNA-binding protein that is genetically and pathologically associated with rare and aggressive forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). To explore the mechanisms by which mutant FUS causes neurodegeneration in ALS-FTD, we generated a series of FUS knock-in mouse lines that express the equivalent of ALS-associated mutant FUSP525L and FUS Delta EX14 protein. In FUS mutant mice, we show progressive, age-dependent motor neuron loss as a consequence of a dose-dependent gain of toxic function, associated with the insolubility of FUS and related RNA-binding proteins. In this disease-relevant mouse model of ALS-FUS, we show that ION363, a non-allele-specific FUS antisense oligonucleotide, efficiently silences Fus and reduces postnatal levels of FUS protein in the brain and spinal cord, delaying motor neuron degeneration. In a patient with ALS with a FUSP525L mutation, we provide preliminary evidence that repeated intrathecal infusions of ION363 lower wild-type and mutant FUS levels in the central nervous system, resulting in a marked reduction in the burden of FUS aggregates that are a pathological hallmark of disease. In mouse genetic and human clinical studies, we provide evidence in support of FUS silencing as a therapeutic strategy in FUS-dependent ALS and FTD.	[Korobeynikov, Vladislav A.; Lyashchenko, Alexander K.; Blanco-Redondo, Beatriz; Shneider, Neil A.] Columbia Univ, Dept Neurol, Ctr Motor Neuron Biol & Dis, New York, NY 10027 USA; [Korobeynikov, Vladislav A.; Lyashchenko, Alexander K.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA; [Jafar-Nejad, Paymaan] Ionis Pharmaceut, Carlsbad, CA USA; [Shneider, Neil A.] Columbia Univ, Eleanor & Lou Gehrig ALS Ctr, Dept Neurol, New York, NY 10027 USA; [Blanco-Redondo, Beatriz] Univ Leipzig, Rudolf Schonheimer Inst Biochem, Leipzig, Germany	Columbia University; Columbia University; Ionis Pharmaceuticals, Inc.; Columbia University; Leipzig University	Shneider, NA (corresponding author), Columbia Univ, Dept Neurol, Ctr Motor Neuron Biol & Dis, New York, NY 10027 USA.; Shneider, NA (corresponding author), Columbia Univ, Eleanor & Lou Gehrig ALS Ctr, Dept Neurol, New York, NY 10027 USA.	ns327@columbia.edu	Shneider, Neil/ABF-5751-2020; Korobeynikov, Vlad/H-9541-2019	Shneider, Neil/0000-0002-3223-7366; Korobeynikov, Vlad/0000-0002-9127-292X; Blanco Redondo, Beatriz/0000-0003-0246-2893	National Institute of Neurological Disorders and Stroke [5R01NS106236]; Tow Foundation; Project ALS [ION363]; ALS Association; Judith and Jean Pape Adams Charitable Foundation	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Tow Foundation; Project ALS; ALS Association; Judith and Jean Pape Adams Charitable Foundation	This work was supported by the National Institute of Neurological Disorders and Stroke (grant no. 5R01NS106236 to N.A.S.) and the Tow Foundation. Support for the FUS ASO (ION363) expanded access program was provided by Project ALS and the ALS Association. Additional funding was generously provided by Nancy Perlman and Tom Klingenstein and from the Judith and Jean Pape Adams Charitable Foundation. J. Chen provided expert technical assistance. We thank S. Brenner-Morton for generating FUS mutant-specific antibodies; A. Nemes for help with mouse embryonic stem cell targeting; and E. Conlon for technical expertise and guidance with biochemical fractionation. We thank F. Bennett and Ionis Pharmaceuticals for providing access to ION363 and for their support in moving this experimental therapeutic into the clinic. All data presented in the manuscript were generated independently of Ionis Pharmaceuticals. Special thanks to R. Smiley, S. Aziz-Zaman, S. Messina and other members of the Columbia University ALS Center research staff for the management and execution of the FUS ASO expanded access program. Thanks to R. Brown, J. Watts, T. Yu, L. Black, D. Walk, V. Estess and E. Fleming from Project ALS for their many contributions to this effort. We are grateful to S. Przedborski, L. Pellizzoni, H. Phatnani, E. Lowry, P. St. George Hyslop and R. Axel for their comments on the manuscript and for helpful discussions. This work is dedicated to the memory of Jaci and Alex Hermstad.	Almer G, 2002, NEUROLOGY, V58, P1277, DOI 10.1212/WNL.58.8.1277; [Anonymous], 2021, STUD EV EFF SAF PHAR; Arnold Carrie, 2019, Nat Med, DOI 10.1038/d41591-019-00013-w; Broustal O, 2010, J ALZHEIMERS DIS, V22, P765, DOI 10.3233/JAD-2010-100837; Buratti E, 2021, ADV EXP MED BIOL, V1281, P243, DOI 10.1007/978-3-030-51140-1_15; Butler M, 1997, LAB INVEST, V77, P379; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; Conlon EG, 2018, ELIFE, V7, DOI 10.7554/eLife.37754; Conlon EG, 2016, ELIFE, V5, DOI 10.7554/eLife.17820; Conte A, 2012, NEUROMUSCULAR DISORD, V22, P73, DOI 10.1016/j.nmd.2011.08.003; DeJesus-Hernandez M, 2010, HUM MUTAT, V31, pE1377, DOI 10.1002/humu.21241; Deng H, 2014, NAT REV NEUROL, V10, P337, DOI 10.1038/nrneurol.2014.78; Frey D, 2000, J NEUROSCI, V20, P2534; Ghasemi M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a024125; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Humphrey J, 2020, NUCLEIC ACIDS RES, V48, P6889, DOI 10.1093/nar/gkaa410; Kamelgarn M, 2016, BBA-MOL BASIS DIS, V1862, P2004, DOI 10.1016/j.bbadis.2016.07.015; KAWAMATA T, 1992, AM J PATHOL, V140, P691; Kim G, 2020, NEURON, V108, P822, DOI 10.1016/j.neuron.2020.08.022; Kim SH, 2010, J BIOL CHEM, V285, P34097, DOI 10.1074/jbc.M110.154831; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Lalancette-Hebert M, 2016, P NATL ACAD SCI USA, V113, pE8316, DOI 10.1073/pnas.1605210113; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653; Rossi J, 2011, CELL METAB, V13, P195, DOI 10.1016/j.cmet.2011.01.010; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sharma A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10465; Shatunov A, 2021, NEUROBIOL DIS, V147, DOI 10.1016/j.nbd.2020.105156; Shiihashi G, 2016, BRAIN, V139, P2380, DOI 10.1093/brain/aww161; St George-Hyslop P, 2018, BRAIN RES, V1693, P11, DOI 10.1016/j.brainres.2018.04.036; Taylor JP, 2016, NATURE, V539, P197, DOI 10.1038/nature20413; Teplova M, 1999, NAT STRUCT BIOL, V6, P535; Van Langenhove T, 2010, NEUROLOGY, V74, P366, DOI 10.1212/WNL.0b013e3181ccc732; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Wang T, 2015, NEUROBIOL AGING, V36, P527, DOI 10.1016/j.neurobiolaging.2014.07.044; Wu YJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008054; Zou ZY, 2017, J NEUROL NEUROSUR PS, V88, P540, DOI 10.1136/jnnp-2016-315018	37	23	23	10	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					104	+		10.1038/s41591-021-01615-z	http://dx.doi.org/10.1038/s41591-021-01615-z		JAN 2022	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35075293	hybrid, Green Published			2022-12-27	WOS:000746475000004
J	van de Veerdonk, FL; Giamarellos-Bourboulis, E; Pickkers, P; Derde, L; Leavis, H; van Crevel, R; Engel, JJ; Wiersinga, WJ; Vlaar, APJ; Shankar-Hari, M; van der Poll, T; Bonten, M; Angus, DC; van der Meer, JWM; Netea, MG				van de Veerdonk, Frank L.; Giamarellos-Bourboulis, Evangelos; Pickkers, Peter; Derde, Lennie; Leavis, Helen; van Crevel, Reinout; Engel, Job J.; Wiersinga, W. Joost; Vlaar, Alexander P. J.; Shankar-Hari, Manu; van der Poll, Tom; Bonten, Marc; Angus, Derek C.; van der Meer, Jos W. M.; Netea, Mihai G.			A guide to immunotherapy for COVID-19	NATURE MEDICINE			English	Review							KINASE INHIBITORS; TISSUE FACTOR; MULTICENTER; NEUTROPHILS; THROMBOSIS; IMMUNITY; C5A	This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19. Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.	[van de Veerdonk, Frank L.; van Crevel, Reinout; Engel, Job J.; van der Meer, Jos W. M.; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [van de Veerdonk, Frank L.; van Crevel, Reinout; Engel, Job J.; van der Meer, Jos W. M.; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [Giamarellos-Bourboulis, Evangelos] Univ Athens, Attikon Hosp, Dept Infect Dis, Athens, Greece; [Pickkers, Peter] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, Nijmegen, Netherlands; [Pickkers, Peter] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [Derde, Lennie] Univ Med Ctr Utrecht, Dept Intens Care, Utrecht, Netherlands; [Leavis, Helen] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands; [Wiersinga, W. Joost; van der Poll, Tom] Univ Amsterdam, Amsterdam UMC, Ctr Expt Mol Med CEMM, Div Infect Dis, Amsterdam, Netherlands; [Vlaar, Alexander P. J.] Univ Amsterdam, Amsterdam UMC, Dept Intens Care Med, Amsterdam, Netherlands; [Vlaar, Alexander P. J.] Univ Amsterdam, Amsterdam UMC, Lab Expt Intens Care Med & Anesthesiol, Amsterdam, Netherlands; [Shankar-Hari, Manu] Kings Coll London, Sch Immunobiol & Microbial Sci, London, England; [Bonten, Marc] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Angus, Derek C.] UPMC, Pittsburgh, PA USA; [Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, Bonn, Germany	Radboud University Nijmegen; Radboud University Nijmegen; National & Kapodistrian University of Athens; University Hospital Attikon; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam; University of Amsterdam; University of Amsterdam; University of London; King's College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Bonn	van de Veerdonk, FL (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.; van de Veerdonk, FL (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands.; Netea, MG (corresponding author), Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, Bonn, Germany.	frank.vandeveerdonk@radboudumc.nl; mihai.netea@radboudumc.nl	Shankar-Hari, Manu/I-6948-2012; Derde, Lennie/AAF-2725-2021	Shankar-Hari, Manu/0000-0002-5338-2538; Derde, Lennie/0000-0002-3577-5629; Giamarellos-Bourboulis, Evangelos/0000-0003-4713-3911	Netherlands Organization for Scientific Research (Vidi grant from ZonMW ZonMW) [10430012010010]; Spinoza grant of the Netherlands Association for Scientific Research	Netherlands Organization for Scientific Research (Vidi grant from ZonMW ZonMW); Spinoza grant of the Netherlands Association for Scientific Research	F.L.v.d.V. gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (Vidi grant from ZonMW & ZonMW project nr 10430012010010).M.G.N. was supported by a Spinoza grant of the Netherlands Association for Scientific Research.	Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247; Aman J, 2021, LANCET RESP MED, V9, P957, DOI 10.1016/S2213-2600(21)00237-X; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Azam TU, 2020, J AM SOC NEPHROL, V31, P2725, DOI 10.1681/ASN.2020060829; Bastug A, 2021, RHEUMATOL INT, V41, P993, DOI 10.1007/s00296-021-04843-1; Bendib I, 2021, CRIT CARE, V25, DOI 10.1186/s13054-020-03427-y; Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745; Bonaventura A, 2021, NAT REV IMMUNOL, V21, P319, DOI 10.1038/s41577-021-00536-9; Bost P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21702-6; Caricchio R, 2021, JAMA-J AM MED ASSOC, V326, P230, DOI 10.1001/jama.2021.9508; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449; Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; de Bruin S, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103378; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Egloff SAA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI151788; Estcourt LJ, 2021, JAMA-J AM MED ASSOC, V326, P1690, DOI 10.1001/jama.2021.18178; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Guimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1791, DOI 10.1002/art.41454; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P2049, DOI 10.1016/S0140-6736(21)00897-7; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Iskander KN, 2013, PHYSIOL REV, V93, P1247, DOI 10.1152/physrev.00037.2012; Jacobs CF, 2021, BLOOD ADV, V5, P913, DOI 10.1182/bloodadvances.2020003768; Janssen NAF., 2021, J INFECT DIS, V223, p1322 1333 1; Jouan Y, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03513-9; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Kambas K, 2008, J IMMUNOL, V180, P7368, DOI 10.4049/jimmunol.180.11.7368; Kreutmair S, 2021, IMMUNITY, V54, P1578, DOI 10.1016/j.immuni.2021.05.002; Kyriazopoulou E, 2021, NAT MED, V27, P1752, DOI 10.1038/s41591-021-01499-z; Kyriazopoulou E, 2021, ELIFE, V10, DOI 10.7554/eLife.66125; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Laterre PF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16485; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; Lee PY, 2020, J CLIN INVEST, V130, P5942, DOI 10.1172/JCI141113; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Lopes RD, 2021, LANCET, V397, P2253, DOI 10.1016/S0140-6736(21)01203-4; Mandal S, 2021, THORAX, V76, P396, DOI 10.1136/thoraxjnl-2020-215818; Mansour E, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05027-9; Marconi VC, 2021, LANCET RESP MED, V9, P1407, DOI 10.1016/S2213-2600(21)00331-3; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McArdle AJ, 2021, NEW ENGL J MED, V385, P11, DOI 10.1056/NEJMoa2102968; Menshawey R, 2021, CARDIOVASC ENDOCR ME, V10, P80, DOI 10.1097/XCE.0000000000000237; Monk PD, 2021, LANCET RESP MED, V9, P196, DOI 10.1016/S2213-2600(20)30511-7; Morris SB, 2020, MMWR-MORBID MORTAL W, V69, P1450, DOI 10.15585/mmwr.mm6940e1; Munoz-Rivas N, 2021, THROMB RES, V199, P132, DOI 10.1016/j.thromres.2020.12.024; Nakra NA, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7070069; Nguyen LS, 2021, INTENS CARE MED, V47, P619, DOI 10.1007/s00134-021-06377-3; O'Donnell MR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150646; Obi AT, 2021, J VASC SURG-VENOUS L, V9, P23, DOI 10.1016/j.jvsv.2020.08.030; Ouldali N, 2021, JAMA-J AM MED ASSOC, V325, P855, DOI 10.1001/jama.2021.0694; Patel J., RANDOMIZED TRIAL OTI, DOI [10.1101/2021.04.14.21255475(2021, DOI 10.1101/2021.04.14.21255475(2021]; Payen D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580250; Pouletty M, 2020, ANN RHEUM DIS, V79, P999, DOI 10.1136/annrheumdis-2020-217960; Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2; Richeldi L, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-019-1030-4; Richeldi L, 2011, NEW ENGL J MED, V365, P1079, DOI 10.1056/NEJMoa1103690; Riollano-Cruz M, 2021, J MED VIROL, V93, P424, DOI 10.1002/jmv.26224; Ritis K, 2006, J IMMUNOL, V177, P4794, DOI 10.4049/jimmunol.177.7.4794; Rovina N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02897-4; Ruscitti P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01130; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Schurink B, 2020, LANCET MICROBE, V1, pE290, DOI 10.1016/S2666-5247(20)30144-0; Senefeld JW, 2021, TRANSFUSION, V61, P2503, DOI 10.1111/trf.16525; Seshan SV, 2009, BLOOD, V114, P1675, DOI 10.1182/blood-2009-01-199117; Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330; Shankar-Hari M, 2012, CRIT CARE, V16, DOI 10.1186/cc10597; Shatzel JJ, 2020, RES PRACT THROMB HAE, V4, P500, DOI 10.1002/rth2.12349; Son MBF, 2021, NEW ENGL J MED, V385, P23, DOI 10.1056/NEJMoa2102605; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Talasaz AH, 2021, J AM COLL CARDIOL, V77, P1903, DOI 10.1016/j.jacc.2021.02.035; The REMAP-CAP Investigators, EFF TOC SAR AN CRIT, DOI [DOI 10.3389/fimmu.2019.02247, 10.1101/2021.06.18.21259133(2021), DOI 10.1101/2021.06.18.21259133(2021)]; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Uwaydah AK, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242060; Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600; van de Veerdonk FL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.17708; van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555; van Laarhoven A, 2021, MED-CAMBRIDGE, V2, P1163, DOI 10.1016/j.medj.2021.09.003; Vlaar APJ, 2020, LANCET RHEUMATOL, V2, pE764, DOI 10.1016/S2665-9913(20)30341-6; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; ZINSSER HANS, 1930, JOUR EXP MED, V51, P847, DOI 10.1084/jem.51.6.847	104	60	60	23	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					39	50		10.1038/s41591-021-01643-9	http://dx.doi.org/10.1038/s41591-021-01643-9		JAN 2022	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35064248	Green Accepted, Bronze			2022-12-27	WOS:000745382200001
J	Stock, SJ; Carruthers, J; Calvert, C; Denny, C; Donaghy, J; Goulding, A; Hopcroft, LEM; Hopkins, L; McLaughlin, T; Pan, JF; Shi, T; Taylor, B; Agrawal, U; Auyeung, B; Katikireddi, SV; McCowan, C; Murray, J; Simpson, CR; Robertson, C; Vasileiou, E; Sheikh, A; Wood, R				Stock, Sarah J.; Carruthers, Jade; Calvert, Clara; Denny, Cheryl; Donaghy, Jack; Goulding, Anna; Hopcroft, Lisa E. M.; Hopkins, Leanne; McLaughlin, Terry; Pan, Jiafeng; Shi, Ting; Taylor, Bob; Agrawal, Utkarsh; Auyeung, Bonnie; Katikireddi, Srinivasa Vittal; McCowan, Colin; Murray, Josie; Simpson, Colin R.; Robertson, Chris; Vasileiou, Eleftheria; Sheikh, Aziz; Wood, Rachael			SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland	NATURE MEDICINE			English	Article								Population-level data on COVID-19 vaccine uptake in pregnancy and SARS-CoV-2 infection outcomes are lacking. We describe COVID-19 vaccine uptake and SARS-CoV-2 infection in pregnant women in Scotland, using whole-population data from a national, prospective cohort. Between the start of a COVID-19 vaccine program in Scotland, on 8 December 2020 and 31 October 2021, 25,917 COVID-19 vaccinations were given to 18,457 pregnant women. Vaccine coverage was substantially lower in pregnant women than in the general female population of 18-44 years; 32.3% of women giving birth in October 2021 had two doses of vaccine compared to 77.4% in all women. The extended perinatal mortality rate for women who gave birth within 28 d of a COVID-19 diagnosis was 22.6 per 1,000 births (95% CI 12.9-38.5; pandemic background rate 5.6 per 1,000 births; 452 out of 80,456; 95% CI 5.1-6.2). Overall, 77.4% (3,833 out of 4,950; 95% CI 76.2-78.6) of SARS-CoV-2 infections, 90.9% (748 out of 823; 95% CI 88.7-92.7) of SARS-CoV-2 associated with hospital admission and 98% (102 out of 104; 95% CI 92.5-99.7) of SARS-CoV-2 associated with critical care admission, as well as all baby deaths, occurred in pregnant women who were unvaccinated at the time of COVID-19 diagnosis. Addressing low vaccine uptake rates in pregnant women is imperative to protect the health of women and babies in the ongoing pandemic. Findings from the COVID-19 in Pregnancy in Scotland (COPS) study reveals low levels of vaccination uptake by pregnant women compared to women in the general population and that not being vaccinated is associated with increased risk of severe complications of COVID-19 in pregnancy, including perinatal mortality.	[Stock, Sarah J.; Calvert, Clara; Shi, Ting; Simpson, Colin R.; Vasileiou, Eleftheria; Sheikh, Aziz; Wood, Rachael] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Stock, Sarah J.; Carruthers, Jade; Denny, Cheryl; Donaghy, Jack; Goulding, Anna; Hopcroft, Lisa E. M.; Hopkins, Leanne; McLaughlin, Terry; Pan, Jiafeng; Taylor, Bob; Katikireddi, Srinivasa Vittal; Murray, Josie; Robertson, Chris; Wood, Rachael] Publ Hlth Scotland, Edinburgh, Midlothian, Scotland; [Hopcroft, Lisa E. M.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, DataLab, Oxford, England; [Agrawal, Utkarsh; McCowan, Colin] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland; [Auyeung, Bonnie] Univ Edinburgh, Sch Philosophy Psychol & Language Sci, Edinburgh, Midlothian, Scotland; [Katikireddi, Srinivasa Vittal] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [McCowan, Colin] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Simpson, Colin R.] Victoria Univ Wellington, Wellington Fac Hlth, Sch Hlth, Wellington, New Zealand; [Robertson, Chris] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland	University of Edinburgh; University of Oxford; University of St Andrews; University of Edinburgh; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of Glasgow; Victoria University Wellington; University of Strathclyde	Stock, SJ (corresponding author), Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.; Stock, SJ (corresponding author), Publ Hlth Scotland, Edinburgh, Midlothian, Scotland.	sarah.stock@ed.ac.uk	Taylor, John Robert/G-5523-2019; Simpson, Colin/L-7180-2014	Taylor, John Robert/0000-0003-4314-2685; Simpson, Colin/0000-0002-5194-8083; Carruthers, Jade/0000-0002-2777-6824; Goulding, Anna/0000-0002-1288-3256; McCowan, Colin/0000-0002-9466-833X; Murray, Josephine-Louise/0000-0002-1511-7944; Hopkins, Leanne/0000-0002-7487-4363; Katikireddi, Srinivasa/0000-0001-6593-9092; Stock, Sarah Jane/0000-0003-4308-856X; Denny, Cheryl/0000-0003-4616-4732; Hopcroft, Lisa/0000-0002-7022-1322; Wood, Rachael/0000-0003-4453-623X	EAVE II Patient Advisory Group; Sands charity; Medical Research Council [MR/R008345/1, MC_UU_00022/2]; BREATHE; Health Data Research Hub for Respiratory Health through the UK Research and Innovation Industrial Strategy Challenge Fund [MC_PC_19004]; Public Health Scotland; Scottish Government DG Health and Social Care; UK Research and Innovation; Tommy's charity; Wellcome Trust Clinical Career Development Fellowship [209560/Z/17/Z]; NRS Senior Clinical Fellowship [SCAF/15/02]; Scottish Government Chief Scientist Office [SPHSU17]; European Union [813546]; Baily Thomas Charitable Fund [TRUST/VC/AC/SG/469207686]; Data Driven Innovation; UK Economic and Social Research Council [ES/W001519/1]	EAVE II Patient Advisory Group; Sands charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BREATHE; Health Data Research Hub for Respiratory Health through the UK Research and Innovation Industrial Strategy Challenge Fund; Public Health Scotland; Scottish Government DG Health and Social Care; UK Research and Innovation(UK Research & Innovation (UKRI)); Tommy's charity; Wellcome Trust Clinical Career Development Fellowship(Wellcome Trust); NRS Senior Clinical Fellowship; Scottish Government Chief Scientist Office; European Union(European Commission); Baily Thomas Charitable Fund; Data Driven Innovation; UK Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	We thank the EAVE II Patient Advisory Group and Sands charity for their support. COPS is a sub-study of EAVE II, which is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE, the Health Data Research Hub for Respiratory Health (MC_PC_19004; A.S.), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care and the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation. COPS has received additional funding from Tommy's charity and support from Sands charity. S.J.S. is funded by a Wellcome Trust Clinical Career Development Fellowship (209560/Z/17/Z). S.V.K. acknowledges funding from an NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). The funders had no role in the writing of the manuscript or the decision to submit it for publication. B.A. was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Skodowska-Curie grant agreement No. 813546, the Baily Thomas Charitable Fund TRUST/VC/AC/SG/469207686, the Data Driven Innovation and the UK Economic and Social Research Council (ES/W001519/1) during the course of this work.	Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320; [Anonymous], 2019, NSS INFORM INTELLIGE; CDC, 2020, FOOD YOU WHO AR BREA; Goldshtein I, 2021, JAMA-J AM MED ASSOC, V326, P728, DOI 10.1001/jama.2021.11035; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Hillson K, 2021, LANCET, V398, P1683, DOI 10.1016/S0140-6736(21)02282-0; Iacobucci G, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2862; Johns Hopkins Berman Institute of Bioethics and the Johns Hopkins Center for Immunization Research, 2021, COVID 19 MAT IMM TRA; Knight M, 2021, AM J OBSTET GYNECOL, V225, P584, DOI 10.1016/j.ajog.2021.06.086; Knight M, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3305; Knight M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2107; Luxi N, 2021, DRUG SAFETY, V44, P1247, DOI 10.1007/s40264-021-01131-6; Magnus MC, 2022, BJOG-INT J OBSTET GY, V129, P101, DOI 10.1111/1471-0528.16969; Mulholland RH, 2021, INT J EPIDEMIOL, V50, P1064, DOI 10.1093/ije/dyab028; Mullins E, 2021, ULTRASOUND OBST GYN, V57, P573, DOI 10.1002/uog.23619; Papageorghiou AT, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.05.014; Public Health Scotland, 2021, OP DAT; Public Health Scotland, 2020, DAT QUAL ASS ASS SMR; Public Health Scotland, 2021, COPS PUBL GIT HUB; Razzaghi H, 2021, MMWR-MORBID MORTAL W, V70, P895, DOI [10.1101/2021.03.26.21254402v1, 10.15585/mmwr.mm7024e2]; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1097/01.ogx.0000802676.57373.17, 10.1056/NEJMx210016]; Simpson Colin R, 2020, BMJ Open, V10, pe039097, DOI 10.1136/bmjopen-2020-039097; Stock SJ, 2022, INT J EPIDEMIOL, V51, pE245, DOI 10.1093/ije/dyab243; Stock SJ, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042813; The Joint Committee on Vaccination and Immunisation (JCVI), 2021, ADV UK VACC RESP OM; Theiler RN, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2021.100467; UK Health Security Agency, 2021, VACC SURV REP; Villar J, 2021, JAMA PEDIATR, V175, P817, DOI 10.1001/jamapediatrics.2021.1050; Vousden N, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251123; Wainstock T, 2021, VACCINE, V39, P6037, DOI 10.1016/j.vaccine.2021.09.012; Wei SQ, 2021, CAN MED ASSOC J, V193, pE540, DOI 10.1503/cmaj.202604; Zauche LH, 2021, NEW ENGL J MED, V385, P1533, DOI 10.1056/NEJMc2113891	33	52	53	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					504	+		10.1038/s41591-021-01666-2	http://dx.doi.org/10.1038/s41591-021-01666-2		JAN 2022	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35027756	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000742323900009
J	Mirzayi, C; Renson, A; Zohra, F; Elsafoury, S; Geistlinger, L; Kasselman, LJ; Eckenrode, K; van de Wijgert, J; Loughman, A; Marques, FZ; MacIntyre, DA; Arumugam, M; Azhar, R; Beghini, F; Bergstrom, K; Bhatt, A; Bisanz, JE; Braun, J; Bravo, HC; Buck, GA; Bushman, F; Casero, D; Clarke, G; Collado, MC; Cotter, PD; Cryan, JF; Demmer, RT; Devkota, S; Elinav, E; Escobar, JS; Fettweis, J; Finn, RD; Fodor, AA; Forslund, S; Franke, A; Furlanello, C; Gilbert, J; Grice, E; Haibe-Kains, B; Handley, S; Herd, P; Holmes, S; Jacobs, JP; Karstens, L; Knight, R; Knights, D; Koren, O; Kwon, DS; Langille, M; Lindsay, B; McGovern, D; McHardy, AC; McWeeney, S; Mueller, NT; Nezi, L; Olm, M; Palm, N; Pasolli, E; Raes, J; Redinbo, MR; Ruhlemann, M; Sartor, RB; Schloss, PD; Schriml, L; Segal, E; Shardell, M; Sharpton, T; Smirnova, E; Sokol, H; Sonnenburg, JL; Srinivasan, S; Thingholm, LB; Turnbaugh, PJ; Upadhyay, V; Walls, RL; Wilmes, P; Yamada, T; Zeller, G; Zhang, MY; Zhao, N; Zhao, LP; Bao, WJ; Culhane, A; Devanarayan, V; Dopazo, J; Fan, XH; Fischer, M; Jones, W; Kusko, R; Mason, CE; Mercer, TR; Sansone, SA; Scherer, A; Shi, LM; Thakkar, S; Tong, WD; Wolfinger, R; Hunter, C; Segata, N; Huttenhower, C; Dowd, JB; Jones, HE; Waldron, L				Mirzayi, Chloe; Renson, Audrey; Zohra, Fatima; Elsafoury, Shaimaa; Geistlinger, Ludwig; Kasselman, Lora J.; Eckenrode, Kelly; van de Wijgert, Janneke; Loughman, Amy; Marques, Francine Z.; MacIntyre, David A.; Arumugam, Manimozhiyan; Azhar, Rimsha; Beghini, Francesco; Bergstrom, Kirk; Bhatt, Ami; Bisanz, Jordan E.; Braun, Jonathan; Bravo, Hector Corrada; Buck, Gregory A.; Bushman, Frederic; Casero, David; Clarke, Gerard; Carmen Collado, Maria; Cotter, Paul D.; Cryan, John F.; Demmer, Ryan T.; Devkota, Suzanne; Elinav, Eran; Escobar, Juan S.; Fettweis, Jennifer; Finn, Robert D.; Fodor, Anthony A.; Forslund, Sofia; Franke, Andre; Furlanello, Cesare; Gilbert, Jack; Grice, Elizabeth; Haibe-Kains, Benjamin; Handley, Scott; Herd, Pamela; Holmes, Susan; Jacobs, Jonathan P.; Karstens, Lisa; Knight, Rob; Knights, Dan; Koren, Omry; Kwon, Douglas S.; Langille, Morgan; Lindsay, Brianna; McGovern, Dermot; McHardy, Alice C.; McWeeney, Shannon; Mueller, Noel T.; Nezi, Luigi; Olm, Matthew; Palm, Noah; Pasolli, Edoardo; Raes, Jeroen; Redinbo, Matthew R.; Ruhlemann, Malte; Sartor, R. Balfour; Schloss, Patrick D.; Schriml, Lynn; Segal, Eran; Shardell, Michelle; Sharpton, Thomas; Smirnova, Ekaterina; Sokol, Harry; Sonnenburg, Justin L.; Srinivasan, Sujatha; Thingholm, Louise B.; Turnbaugh, Peter J.; Upadhyay, Vaibhav; Walls, Ramona L.; Wilmes, Paul; Yamada, Takuji; Zeller, Georg; Zhang, Mingyu; Zhao, Ni; Zhao, Liping; Bao, Wenjun; Culhane, Aedin; Devanarayan, Viswanath; Dopazo, Joaquin; Fan, Xiaohui; Fischer, Matthias; Jones, Wendell; Kusko, Rebecca; Mason, Christopher E.; Mercer, Tim R.; Sansone, Susanna-Assunta; Scherer, Andreas; Shi, Leming; Thakkar, Shraddha; Tong, Weida; Wolfinger, Russ; Hunter, Christopher; Segata, Nicola; Huttenhower, Curtis; Dowd, Jennifer B.; Jones, Heidi E.; Waldron, Levi		Genomic Stand Consortium; Massive Anal Quality Control Soc	Reporting guidelines for human microbiome research: the STORMS checklist	NATURE MEDICINE			English	Article							GENETIC ASSOCIATION; CAUSAL INFERENCE; EXTENSION; QUALITY; STATEMENT; TRIALS; NULL	The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for observational or genetic epidemiology studies lack key features specific to microbiome studies. Therefore, a multidisciplinary group of microbiome epidemiology researchers adapted guidelines for observational and genetic studies to culture-independent human microbiome studies, and also developed new reporting elements for laboratory, bioinformatics and statistical analyses tailored to microbiome studies. The resulting tool, called 'Strengthening The Organization and Reporting of Microbiome Studies' (STORMS), is composed of a 17-item checklist organized into six sections that correspond to the typical sections of a scientific publication, presented as an editable table for inclusion in supplementary materials. The STORMS checklist provides guidance for concise and complete reporting of microbiome studies that will facilitate manuscript preparation, peer review, and reader comprehension of publications and comparative analysis of published results. The STORMS tool provides guidance for concise and complete reporting of microbiome studies to facilitate manuscript preparation, peer review, reader comprehension of publications, and comparative analysis of published results.	[Mirzayi, Chloe; Zohra, Fatima; Elsafoury, Shaimaa; Geistlinger, Ludwig; Kasselman, Lora J.; Eckenrode, Kelly; Azhar, Rimsha; Jones, Heidi E.; Waldron, Levi] CUNY, Inst Implementat Sci Publ Hlth, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA; [Renson, Audrey] Univ N Carolina, Chapel Hill, NC 27515 USA; [van de Wijgert, Janneke] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Loughman, Amy] Deakin Univ, Food & Mood Ctr, Inst Mental & Phys Hlth & Clin Translat, Geelong, Vic, Australia; [Marques, Francine Z.] Monash Univ, Fac Sci, Sch Biol Sci, Hypertens Res Lab, Melbourne, Vic, Australia; [MacIntyre, David A.] Imperial Coll London, Fac Med, Dept Metab Digest & Reprod, London, England; [Arumugam, Manimozhiyan] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark; [Beghini, Francesco; Segata, Nicola] Univ Trento, Dept CIBIO, Trento, Italy; [Bergstrom, Kirk] Univ British Columbia, Dept Biol, Okanagan Campus, Kelowna, BC, Canada; [Bhatt, Ami] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA; [Bhatt, Ami] Stanford Univ, Dept Med, Div Bone Marrow Transplantat, Stanford, CA 94305 USA; [Bhatt, Ami] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Bisanz, Jordan E.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Braun, Jonathan] Cedars Sinai Med Ctr, Dept Med, Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA; [Bravo, Hector Corrada] Genentech Inc, San Francisco, CA 94080 USA; [Buck, Gregory A.; Fettweis, Jennifer] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Ctr Microbiome Engn & Data Anal, Richmond, VA 23298 USA; [Bushman, Frederic] Univ Penn, Philadelphia, PA 19104 USA; [Casero, David; Devkota, Suzanne; McGovern, Dermot] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, Los Angeles, CA 90048 USA; [Clarke, Gerard] Univ Coll Cork, Dept Psychiat & Neurobehav Sci, Cork, Ireland; [Clarke, Gerard; Cotter, Paul D.; Cryan, John F.] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland; [Carmen Collado, Maria] Inst Agrochem & Food Technol Natl Res Council, Valencia, Spain; [Cotter, Paul D.] TEAGASC, Food Res Ctr Moorepk, Cork, Ireland; [Cotter, Paul D.] VistaMilk, Cork, Ireland; [Cryan, John F.] Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland; [Demmer, Ryan T.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [Elinav, Eran] Weizmann Inst Sci, Immunol Dept, Rehovot, Israel; [Elinav, Eran] Deutsch Krebsforschungszentrum, Microbiome & Canc Div, Heidelberg, Germany; [Escobar, Juan S.] Grp Empresarial Nutresa, Vidarium Nutr Hlth & Wellness Res Ctr, Medellin, Colombia; [Finn, Robert D.] European Bioinformat Inst, European Mol Biol Lab, Wellcome Genome Campus, Hinxton, England; [Fodor, Anthony A.] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA; [Forslund, Sofia] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, Berlin, Germany; [Forslund, Sofia] Charite, Berlin, Germany; [Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Furlanello, Cesare] HK3 Lab, Rovereto, Italy; [Gilbert, Jack] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Gilbert, Jack] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; [Grice, Elizabeth] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Haibe-Kains, Benjamin] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Handley, Scott] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Herd, Pamela] Georgetown Univ, McCourt Sch Publ Policy, Washington, DC USA; [Holmes, Susan] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Jacobs, Jonathan P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA USA; [Karstens, Lisa] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Knight, Rob] Univ Calif San Diego, Ctr Microbiome Innovat, La Jolla, CA 92093 USA; [Knights, Dan] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN USA; [Knights, Dan] Univ Minnesota, Biotechnol Inst, St Paul, MN 55108 USA; [Koren, Omry] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel; [Kwon, Douglas S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Langille, Morgan] Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada; [Lindsay, Brianna] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; [McHardy, Alice C.] Helmholtz Ctr Infect Res, Dept Computat Biol Infect Res, Braunschweig, Germany; [McWeeney, Shannon] OHSU Knight Canc Inst, Portland, OR USA; [Mueller, Noel T.; Zhang, Mingyu] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Nezi, Luigi; Segata, Nicola] Ist Ricovero & Cura Carattere Sci, Dept Expt Oncol, Ist Europeo Oncol, Milan, Italy; [Olm, Matthew; Sonnenburg, Justin L.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Palm, Noah] Yale Univ, Dept Immunobiol, Sch Med, New Haven, CT USA; [Pasolli, Edoardo] Univ Naples Federico II, Dept Agr Sci, Portici, Italy; [Raes, Jeroen] Katholieke Univ Leuven, Rega Inst, Dept Microbiol & Immunol, Leuven, Belgium; [Raes, Jeroen] VIB Ctr Microbiol, Leuven, Belgium; [Redinbo, Matthew R.] Univ N Carolina, Dept Chem, Chapel Hill, NC USA; [Ruhlemann, Malte; Thingholm, Louise B.] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Sartor, R. Balfour] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA; [Schloss, Patrick D.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Schriml, Lynn; Shardell, Michelle] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA; [Segal, Eran] Weizmann Inst Sci, Dept Comp Sci, Rehovot, Israel; [Sharpton, Thomas] Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; [Sharpton, Thomas] Oregon State Univ, Dept Stat, Corvallis, OR 97331 USA; [Smirnova, Ekaterina] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Sokol, Harry] Sorbonne Univ, St Antoine Hosp, Assistance Publ Hop Paris, Gastroenterol Dept,Ctr Rech St Antoine,INSERM, Paris, France; [Srinivasan, Sujatha] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Turnbaugh, Peter J.; Upadhyay, Vaibhav] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Walls, Ramona L.] Crit Path Inst, Tucson, AZ USA; [Wilmes, Paul] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Esch Sur Alzette, Luxembourg; [Wilmes, Paul] Univ Luxembourg, Fac Sci Technol & Med, Dept Life Sci & Med, Esch Sur Alzette, Luxembourg; [Yamada, Takuji] Tokyo Inst Technol, Dept Life Sci & Technol, Tokyo, Japan; [Zeller, Georg] European Mol Biol Lab, Struct & Computat Biol Unit, Heidelberg, Germany; [Zhao, Ni] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Zhao, Liping] Rutgers State Univ, Sch Environm & Biol Sci, Dept Biochem & Microbiol, New Brunswick, NJ USA; [Bao, Wenjun] SAS Inst, JMP Life Sci, Cary, NC USA; [Culhane, Aedin] Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA; [Devanarayan, Viswanath] Eisai, Woodcliff Lake, NJ USA; [Dopazo, Joaquin] Hosp Virgen del Rocio, Clin Bioinformat Area, Seville, Spain; [Fan, Xiaohui] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou, Peoples R China; [Fischer, Matthias] Univ Childrens Hosp, Expt Pediat Oncol, Cologne, Germany; [Fischer, Matthias] Univ Cologne, Med Fac, Ctr Mol Med Cologne, Cologne, Germany; [Jones, Wendell] Q2 Solut EA Genom, Durham, NC USA; [Kusko, Rebecca] Immuneering, Cambridge, MA USA; [Mason, Christopher E.] Weill Cornell Med, New York, NY USA; [Mercer, Tim R.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia; [Sansone, Susanna-Assunta] Univ Oxford, Oxford E Res Ctr, Dept Engn Sci, Oxford, England; [Scherer, Andreas] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Shi, Leming] Fudan Univ, Sch Life Sci, Human Phenome Inst, State Key Lab Genet Engn, Shanghai, Peoples R China; [Shi, Leming] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Thakkar, Shraddha] Ctr Drug Evaluat & Res, Off Translat Sci, Off Computat Sci, Washington, DC USA; [Tong, Weida] US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, Jefferson, AR USA; [Wolfinger, Russ] SAS Inst, Sci Discovery & Genom, Cary, NC USA; [Hunter, Christopher] BGI Hong Kong, GigaSci Database, Hong Kong, Peoples R China; [Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Dowd, Jennifer B.] Univ Oxford, Leverhulme Ctr Demog Sci, Dept Sociol, Oxford, England	City University of New York (CUNY) System; University of North Carolina; University of North Carolina Chapel Hill; Utrecht University; Utrecht University Medical Center; Deakin University; Monash University; Imperial College London; Novo Nordisk Foundation; University of Copenhagen; University of Trento; University of British Columbia; Stanford University; Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Cedars Sinai Medical Center; Roche Holding; Genentech; Virginia Commonwealth University; University of Pennsylvania; Cedars Sinai Medical Center; University College Cork; University College Cork; Teagasc; University College Cork; University of Minnesota System; University of Minnesota Twin Cities; Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); University of North Carolina; University of North Carolina Charlotte; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Washington University (WUSTL); Georgetown University; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Oregon Health & Science University; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Bar Ilan University; Harvard University; Massachusetts General Hospital; Dalhousie University; University System of Maryland; University of Maryland Baltimore; Helmholtz Association; Helmholtz-Center for Infection Research; Oregon Health & Science University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS European Institute of Oncology (IEO); Stanford University; Yale University; University of Naples Federico II; KU Leuven; Flanders Institute for Biotechnology (VIB); University of North Carolina; University of North Carolina Chapel Hill; University of Kiel; University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan; University System of Maryland; University of Maryland Baltimore; Weizmann Institute of Science; Oregon State University; Oregon State University; Virginia Commonwealth University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Fred Hutchinson Cancer Center; University of California System; University of California San Francisco; University of Luxembourg; University of Luxembourg; Tokyo Institute of Technology; European Molecular Biology Laboratory (EMBL); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Rutgers State University New Brunswick; SAS Institute Inc; Harvard University; Dana-Farber Cancer Institute; Eisai Co Ltd; Virgen del Rocio University Hospital; Zhejiang University; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Cologne; Cornell University; University of Queensland; University of Oxford; University of Helsinki; Fudan University; Fudan University; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); SAS Institute Inc; Beijing Genomics Institute (BGI); Harvard University; Harvard T.H. Chan School of Public Health; University of Oxford	Waldron, L (corresponding author), CUNY, Inst Implementat Sci Publ Hlth, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA.	Liping; levi.waldron@sph.cuny.edu	Escobar, Juan S/F-7234-2013; Mason, Christopher/HCH-3977-2022; Franke, Andre/B-2151-2010; FAN, Xiaohui/F-6458-2010; Clarke, Gerard/Y-2551-2019; Sokol, Harry/E-2290-2019; Arumugam, Manimozhiyan/AAJ-2394-2020; Zhang, mingyu/HGB-1069-2022; Arumugam, Manimozhiyan/E-1211-2011; Zhang, Mingyu/O-4477-2018; COLLADO, MARIA CARMEN/H-4924-2012; Beghini, Francesco/ABE-9981-2021; Rühlemann, Malte Christoph/AAA-6528-2019; Thakkar, Shraddha/AAX-7737-2021; Raes, Jeroen/D-7835-2018; Zeller, Georg/M-6484-2013; Pasolli, Edoardo/K-5156-2016; Wilmes, Paul/B-1707-2017	Escobar, Juan S/0000-0001-7304-917X; Franke, Andre/0000-0003-1530-5811; FAN, Xiaohui/0000-0002-6336-3007; Clarke, Gerard/0000-0001-9771-3979; Sokol, Harry/0000-0002-2914-1822; Arumugam, Manimozhiyan/0000-0002-0886-9101; Arumugam, Manimozhiyan/0000-0002-0886-9101; Zhang, Mingyu/0000-0003-3628-0983; COLLADO, MARIA CARMEN/0000-0002-6204-4864; Beghini, Francesco/0000-0002-8105-9607; Rühlemann, Malte Christoph/0000-0002-0685-0052; Raes, Jeroen/0000-0002-1337-041X; Zeller, Georg/0000-0003-1429-7485; Nezi, Luigi/0000-0002-4670-7656; van de Wijgert, Janneke H.H.M./0000-0003-2728-4560; Hunter, Christopher/0000-0002-1335-0881; Jones, Heidi E./0000-0002-4285-3752; Mercer, Timothy/0000-0001-8780-894X; Pasolli, Edoardo/0000-0003-0799-3490; Demmer, Ryan/0000-0003-3429-0379; Finn, Robert/0000-0001-8626-2148; Turnbaugh, Peter/0000-0002-0888-2875; MacIntyre, David/0000-0002-4186-5567; Jones, Wendell/0000-0002-9676-5387; Holmes, Susan/0000-0002-2208-8168; Schloss, Patrick/0000-0002-6935-4275; Knight, Rob/0000-0002-0975-9019; Forslund, Sofia K/0000-0003-4285-6993; Bhatt, Ami/0000-0001-8099-2975; Wilmes, Paul/0000-0002-6478-2924; Scherer, Andreas/0000-0002-4254-7122; Jacobs, Jonathan/0000-0003-4698-0254; Bisanz, Jordan/0000-0002-8649-1706	National Cancer Institute of the National Institutes of Health [5R01CA230551]; Leverhulme Trust	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leverhulme Trust(Leverhulme Trust)	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number 5R01CA230551. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additionally, J.B.D. was supported by the Leverhulme Trust.	Badal VD, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0742-2; Bharucha T, 2020, LANCET INFECT DIS, V20, pE251, DOI 10.1016/S1473-3099(20)30199-7; Chen C., 2020, GIGABYTE, P1, DOI [10.46471/gigabyte.9, DOI 10.46471/GIGABYTE.9]; Chen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23075; Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334; Costea PI, 2017, NAT BIOTECHNOL, V35, P1069, DOI 10.1038/nbt.3960; Gallo V, 2012, EUR J CLIN INVEST, V42, P1, DOI 10.1111/j.1365-2362.2011.02561.x; Ghosh TS, 2020, ELIFE, V9, DOI 10.7554/eLife.50240; Gloor GB, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02224; Hernan M., 2020, CAUSAL INFERENCE WHA; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; Hofler M, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0490-1; Hornung BVH, 2019, FEMS MICROBIOL ECOL, V95, DOI 10.1093/femsec/fiz045; Jin YX, 2017, ENVIRON POLLUT, V222, P1, DOI 10.1016/j.envpol.2016.11.045; Kerns SL, 2014, RADIOTHER ONCOL, V110, P182, DOI 10.1016/j.radonc.2013.07.011; Little J, 2009, GENET EPIDEMIOL, V33, P581, DOI 10.1002/gepi.20410; Loughman A, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102640; Lv BM, 2021, TRENDS MICROBIOL, V29, P736, DOI 10.1016/j.tim.2021.03.015; McLaren MR, 2019, ELIFE, V8, DOI 10.7554/eLife.46923; Min Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10440-5; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Munafo M, 2016, J PSYCHOPHARMACOL, V30, P585, DOI 10.1177/0269881116638813; Nakai M, 2021, HYPERTENSION, V78, P804, DOI 10.1161/HYPERTENSIONAHA.121.17288; Patino CM, 2018, J BRAS PNEUMOL, V44, P84, DOI [10.1590/S1806-37562018000000088, 10.1590/s1806-37562018000000088]; Pearce N, 2012, INT J EPIDEMIOL, V41, P393, DOI 10.1093/ije/dys049; Plint AC, 2006, MED J AUSTRALIA, V185, P263, DOI 10.5694/j.1326-5377.2006.tb00557.x; Raes J, 2007, CURR OPIN MICROBIOL, V10, P490, DOI 10.1016/j.mib.2007.09.001; Rich B., 2021, TABLES DESCRIPTIVE S; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Santiago A, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-112; Schloss PD, 2018, MBIO, V9, DOI 10.1128/mBio.00525-18; Schooling CM, 2018, SOC SCI MED, V210, P70, DOI 10.1016/j.socscimed.2018.04.047; Simoneau J, 2021, BRIEF BIOINFORM, V22, P140, DOI 10.1093/bib/bbz124; Sinha R, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0596-z; Sinha R, 2017, NAT BIOTECHNOL, V35, P1077, DOI 10.1038/nbt.3981; Sinha R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0841-8; Soneson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100335; Szucs D, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00390; ten Hoopen P, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix047; Textor J, 2016, INT J EPIDEMIOL, V45, P1887, DOI 10.1093/ije/dyw341; Thingholm LB, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02337-5; Turner P, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1301-1; VanderWeele TJ, 2019, EUR J EPIDEMIOL, V34, pCP3, DOI 10.1007/s10654-019-00494-6; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Wang QY, 2021, GERONTOLOGY, V67, P639, DOI 10.1159/000514449; Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6; Yan L, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-689; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yilmaz P, 2011, NAT BIOTECHNOL, V29, P415, DOI 10.1038/nbt.1823	49	41	41	11	30	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1885	1892		10.1038/s41591-021-01552-x	http://dx.doi.org/10.1038/s41591-021-01552-x		NOV 2021	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34789871	hybrid, Green Accepted, Green Published, Green Submitted			2022-12-27	WOS:000719700400001
J	Levine-Tiefenbrun, M; Yelin, I; Alapi, H; Katz, R; Herzel, E; Kuint, J; Chodick, G; Gazit, S; Patalon, T; Kishony, R				Levine-Tiefenbrun, Matan; Yelin, Idan; Alapi, Hillel; Katz, Rachel; Herzel, Esma; Kuint, Jacob; Chodick, Gabriel; Gazit, Sivan; Patalon, Tal; Kishony, Roy			Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2	NATURE MEDICINE			English	Article								The effectiveness of the coronavirus disease 2019 (COVID-19) BNT162b2 vaccine in preventing disease and reducing viral loads of breakthrough infections (BTIs) has been decreasing, concomitantly with the rise of the Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, it is unclear whether the observed decreased effectiveness of the vaccine in reducing viral loads is inherent to the Delta variant or is dependent on time from immunization. By analyzing viral loads of over 16,000 infections during the current, Delta-variant-dominated pandemic wave in Israel, we found that BTIs in recently fully vaccinated individuals have lower viral loads than infections in unvaccinated individuals. However, this effect starts to decline 2 months after vaccination and ultimately vanishes 6 months or longer after vaccination. Notably, we found that the effect of BNT162b2 on reducing BTI viral loads is restored after a booster dose. These results suggest that BNT162b2 might decrease the infectiousness of BTIs even with the Delta variant, and that, although this protective effect declines with time, it can be restored, at least temporarily, with a third, booster, vaccine dose. Vaccination with BNT162b2 is associated with lower viral load in breakthrough infections of SARS-CoV-2, but this effect wanes at 2 months and vanishes at 6 months after vaccination. A third vaccine dose-or booster-restores the reduction in viral load.	[Levine-Tiefenbrun, Matan; Yelin, Idan; Kishony, Roy] Technion Israel Inst Technol, Fac Biol, Haifa, Israel; [Levine-Tiefenbrun, Matan; Kuint, Jacob; Chodick, Gabriel] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Alapi, Hillel; Katz, Rachel; Herzel, Esma; Kuint, Jacob; Chodick, Gabriel; Gazit, Sivan; Patalon, Tal] Maccabitech, Maccabi Hlth Serv, Tel Aviv, Israel; [Kishony, Roy] Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel	Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Technion Israel Institute of Technology	Kishony, R (corresponding author), Technion Israel Inst Technol, Fac Biol, Haifa, Israel.; Patalon, T (corresponding author), Maccabitech, Maccabi Hlth Serv, Tel Aviv, Israel.; Kishony, R (corresponding author), Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel.	patalon_t@mac.org.il; rkishony@technion.ac.il		Levine-Tiefenbrun, Matan/0000-0003-0569-3566; Patalon, Tal/0000-0001-7415-1053; Yelin, Idan/0000-0003-2515-4113; /0000-0002-5189-8995	Israel Science Foundation [3633/19]	Israel Science Foundation(Israel Science Foundation)	This work was supported by the Israel Science Foundation (grant no. 3633/19 to R. Kishony and G.C.) as part of the KillCorona-Curbing Coronavirus Research Program. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Chia PY, 2022, CLIN MICROBIOL INFEC, V28, DOI 10.1016/j.cmi.2021.11.010; Chodick G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15985; Corbett Kizzmekia S, 2021, bioRxiv, DOI 10.1101/2021.08.11.456015; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Gazit S., 2021, BNT162B2 MRNA VACCIN, DOI [10.1101/2021.06.29.21259579v1, DOI 10.1101/2021.06.29.21259579V1]; Goldberg Y., 2021, WANING IMMUNITY BNT1, DOI [10.1101/2021.08.24.21262423v1, DOI 10.1101/2021.08.24.21262423V1]; Kissler S. M., 2021, VIRAL DYNAMICS SARS, DOI [10.1101/2021.02.16.21251535v3, DOI 10.1101/2021.02.16.21251535V3]; Levine-Tiefenbrun M., 2020, ASS COVID 19 RT QPCR, DOI [10.1101/2020.10.30.20222935, DOI 10.1101/2020.10.30.20222935, 10.1101/2020.10.30.20222935v2]; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Milman O, 2021, NAT MED, V27, P1367, DOI 10.1038/s41591-021-01407-5; Mizrahi B., 2021, CORRELATION SARS COV, DOI [10.1101/2021.07.29.21261317, DOI 10.1101/2021.07.29.21261317V1, DOI 10.1101/2021.07.29.21261317]; Petter E., INITIAL REAL WORLD E, DOI [10.1101/2021.02.08.21251329v1, DOI 10.1101/2021.02.08.21251329V1, 10.1101/2021.02.08.21251329]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rosenberg ES, 2021, MMWR-MORBID MORTAL W, V70, P1306, DOI 10.15585/mmwr.mm7037a7; Rossman H, 2021, NAT MED, V27, P1055, DOI 10.1038/s41591-021-01337-2; Xin HL, 2021, CLIN INFECT DIS, V73, P2344, DOI 10.1093/cid/ciab501	19	87	88	5	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2108	+		10.1038/s41591-021-01575-4	http://dx.doi.org/10.1038/s41591-021-01575-4		NOV 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34728830	Bronze, Green Submitted			2022-12-27	WOS:000713960400002
J	Stephenson, KE; Julg, B; Tan, CS; Zash, R; Walsh, SR; Rolle, CP; Monczor, AN; Lupo, S; Gelderblom, HC; Ansel, JL; Kanjilal, DG; Maxfield, LF; Nkolola, J; Borducchi, EN; Abbink, P; Liu, JY; Peter, L; Chandrashekar, A; Nityanandam, R; Lin, ZJ; Setaro, A; Sapiente, J; Chen, ZL; Sunner, L; Cassidy, T; Bennett, C; Sato, A; Mayer, B; Perelson, AS; deCamp, A; Priddy, FH; Wagh, K; Giorgi, EE; Yates, NL; Arduino, RC; DeJesus, E; Tomaras, GD; Seaman, MS; Korber, B; Barouch, DH				Stephenson, Kathryn E.; Julg, Boris; Tan, C. Sabrina; Zash, Rebecca; Walsh, Stephen R.; Rolle, Charlotte-Paige; Monczor, Ana N.; Lupo, Sofia; Gelderblom, Huub C.; Ansel, Jessica L.; Kanjilal, Diane G.; Maxfield, Lori F.; Nkolola, Joseph; Borducchi, Erica N.; Abbink, Peter; Liu, Jinyan; Peter, Lauren; Chandrashekar, Abishek; Nityanandam, Ramya; Lin, Zijin; Setaro, Alessandra; Sapiente, Joseph; Chen, Zhilin; Sunner, Lisa; Cassidy, Tyler; Bennett, Chelsey; Sato, Alicia; Mayer, Bryan; Perelson, Alan S.; deCamp, Allan; Priddy, Frances H.; Wagh, Kshitij; Giorgi, Elena E.; Yates, Nicole L.; Arduino, Roberto C.; DeJesus, Edwin; Tomaras, Georgia D.; Seaman, Michael S.; Korber, Bette; Barouch, Dan H.			Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial	NATURE MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; ENV CLONES; BINDING; INFECTIONS; PROTECTION; EFFICACY; VIREMIA; HUMANS; TOOL; IGA	A single dose of a broadly neutralizing, HIV-specific antibody transiently reduces viral load in plasma, and in some individuals is associated with durable virus suppression in the absence of antiretroviral therapy. Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg(-1) in HIV-uninfected adults and HIV-infected adults on antiretroviral therapy (ART), as well as a multicenter, open-label trial of one infusion of PGT121 at 30 mg kg(-1) in viremic HIV-infected adults not on ART (no. NCT02960581). The primary endpoints were safety and tolerability, pharmacokinetics (PK) and antiviral activity in viremic HIV-infected adults not on ART. The secondary endpoints were changes in anti-PGT121 antibody titers and CD4(+) T-cell count, and development of HIV-1 sequence variations associated with PGT121 resistance. Among 48 participants enrolled, no treatment-related serious adverse events, potential immune-mediated diseases or Grade 3 or higher adverse events were reported. The most common reactions among PGT121 recipients were intravenous/injection site tenderness, pain and headache. Absolute and relative CD4(+) T-cell counts did not change following PGT121 infusion in HIV-infected participants. Neutralizing anti-drug antibodies were not elicited. PGT121 reduced plasma HIV RNA levels by a median of 1.77 log in viremic participants, with a viral load nadir at a median of 8.5 days. Two individuals with low baseline viral loads experienced ART-free viral suppression for >= 168 days following antibody infusion, and rebound viruses in these individuals demonstrated full or partial PGT121 sensitivity. The trial met the prespecified endpoints. These data suggest that further investigation of the potential of antibody-based therapeutic strategies for long-term suppression of HIV is warranted, including in individuals off ART and with low viral load.	[Stephenson, Kathryn E.; Julg, Boris; Tan, C. Sabrina; Zash, Rebecca; Walsh, Stephen R.; Ansel, Jessica L.; Kanjilal, Diane G.; Maxfield, Lori F.; Nkolola, Joseph; Borducchi, Erica N.; Abbink, Peter; Liu, Jinyan; Peter, Lauren; Chandrashekar, Abishek; Nityanandam, Ramya; Lin, Zijin; Setaro, Alessandra; Sapiente, Joseph; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA; [Stephenson, Kathryn E.; Tan, C. Sabrina; Zash, Rebecca; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Stephenson, Kathryn E.; Julg, Boris; Chen, Zhilin; Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA; [Julg, Boris] Massachusetts Gen Hosp, Infect Dis Div, Boston, MA 02114 USA; [Rolle, Charlotte-Paige; DeJesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA; [Monczor, Ana N.; Lupo, Sofia; Arduino, Roberto C.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA; [Gelderblom, Huub C.; Sunner, Lisa; Priddy, Frances H.] Int AIDS Vaccine Initiat, New York, NY USA; [Cassidy, Tyler; Perelson, Alan S.; Wagh, Kshitij; Giorgi, Elena E.; Korber, Bette] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM USA; [Monczor, Ana N.; Lupo, Sofia; Bennett, Chelsey; Sato, Alicia; Mayer, Bryan; deCamp, Allan] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA; [Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA; [Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Dept Surg, Durham, NC USA; [Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Dept Immunol & Mol Genet, Durham, NC USA; [Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Dept Microbiol, Durham, NC USA; [Korber, Bette] New Mexico Consortium, Los Alamos, NM USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Massachusetts General Hospital; Orlando Immunology Center; University of Texas System; University of Texas Health Science Center Houston; International AIDS Vaccine Initiative; United States Department of Energy (DOE); Los Alamos National Laboratory; Fred Hutchinson Cancer Center; Duke University; Duke University; Duke University; Duke University	Barouch, DH (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.; Barouch, DH (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.; Barouch, DH (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.	dbarouch@bidmc.harvard.edu	Chandrashekar, Abishek/P-2610-2019	Chandrashekar, Abishek/0000-0001-7821-5552; Juelg, Boris/0000-0002-4687-9626; Setaro, Alessandra/0000-0002-7286-2123; Walsh, Stephen/0000-0002-0817-9370; Hyatt, Ana/0000-0001-8041-4331	Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) [OPP1107669]; National Institutes of Health (NIH) [AI149670, AI145801, AI129797, AI128751, AI126603, AI124377, OD024917, AI106408, TR001102, AI114381]; CAVD [OPP1146996]; US Department of Energy; NIH [AI028433, OD011095, AI131365]; Bill & Melinda Gates Foundation	Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CAVD; US Department of Energy(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	We thank the participants and staff at the Center for Virology and Vaccine Research Clinical Trials Unit, the Harvard Catalyst Clinical Research Center, Orlando Immunology Clinic and Houston AIDS Research Team. This project was supported by the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD; grant no. OPP1107669) and National Institutes of Health (NIH; nos AI149670, AI145801, AI129797, AI128751, AI126603, AI124377 and OD024917 to D.H.B.; AI106408 to B.J.; TR001102 (Harvard Catalyst); and AI114381 to K.E.S.). M.S.S. was supported by CAVD grant no. OPP1146996. Portions of this work were performed under the auspices of the US Department of Energy and supported by NIH grant nos. AI028433, OD011095 and AI131365 (to A.S.P.). We thank A. Podany, College of Pharmacy, University of Nebraska Medical Center, for performing emtricitabine and lamivudine quantification assays. We thank the following members of the International AIDS Vaccine Initiative: A. Lombardo, H. Park, E. Sayeed, K. Syvertsen, J. Ackland, M. Schroeter, V. Sharma, J. Hare, M. Fong Lim, N. Williams and K. Crisafi. BIDMC thanks S. Walsh, A. Hale, R. Fogel and T. Makoni for their contributions. The funding source was the Bill & Melinda Gates Foundation. The funders were involved in the study design, study operations, data collection, data analysis, data interpretations and reviewing and editing the manuscript. The PGT121 program leads (D.H.B., K.E.S. and B.J.) and data and statistical lead (A.D.) had access to all data. The PGT121 program leads had final responsibility for the decision to submit for publication.	Andrade A, 2013, J INFECT DIS, V208, P884, DOI 10.1093/infdis/jit272; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Bar-On Y, 2018, NAT MED, V24, P1701, DOI 10.1038/s41591-018-0186-4; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Borducchi EN, 2016, NATURE, V540, P284, DOI 10.1038/nature20583; Bricault CA, 2019, CELL HOST MICROBE, V25, P59, DOI 10.1016/j.chom.2018.12.001; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Cohen YZ, 2018, J EXP MED, V215, P2311, DOI 10.1084/jem.20180936; Crowell TA, 2019, LANCET HIV, V6, pE297, DOI 10.1016/S2352-3018(19)30053-0; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Jilek BL, 2012, NAT MED, V18, P446, DOI 10.1038/nm.2649; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Julien JP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003342; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Li FS, 2006, VACCINE, V24, P6893, DOI 10.1016/j.vaccine.2006.06.009; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109; Montefiori DC., 2005, CURR PROTOC IMMUNOL, VChapter 12:12.11.11-12.11.15, DOI [10.1002/0471142735.im1211s64, DOI 10.1002/0471142735.IM1211S64]; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Niessl J, 2020, NAT MED, V26, P222, DOI 10.1038/s41591-019-0747-1; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Rong LB, 2007, B MATH BIOL, V69, P2027, DOI 10.1007/s11538-007-9203-3; Rong LB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000544; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Seaman MS, 2020, J IMMUNOL METHODS, V479, DOI 10.1016/j.jim.2020.112736; Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09; Sok D, 2016, IMMUNITY, V45, P31, DOI 10.1016/j.immuni.2016.06.026; Sok D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008104; Song HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04217-5; Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Trifinopoulos J, 2016, NUCLEIC ACIDS RES, V44, pW232, DOI 10.1093/nar/gkw256; Wagh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005520; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Yates NL, 2013, MUCOSAL IMMUNOL, V6, P692, DOI 10.1038/mi.2012.107; Yoon H, 2015, NUCLEIC ACIDS RES, V43, pW213, DOI 10.1093/nar/gkv404	43	15	16	4	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1718	+		10.1038/s41591-021-01509-0	http://dx.doi.org/10.1038/s41591-021-01509-0		OCT 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34621054	hybrid, Green Published			2022-12-27	WOS:000704942800002
J	Buning, H; Schambach, A				Buening, Hildegard; Schambach, Axel			A first step toward in vivo gene editing in patients	NATURE MEDICINE			English	Editorial Material								The first preliminary evidence that in vivo gene editing in a clinical setting is feasible with no early signs of severe adverse events comes from an ongoing clinical trial to treat transthyretin amyloidosis, a fatal monogenetic disease.	[Buening, Hildegard; Schambach, Axel] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany; [Buening, Hildegard; Schambach, Axel] Hannover Med Sch, REBIRTH Res Ctr Translat Regenerat Med, Hannover, Germany; [Buening, Hildegard; Schambach, Axel] Harvard Med Sch, Div Hematol Oncol, Boston Childrens Hosp, Boston, MA 02115 USA	Hannover Medical School; Hannover Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Buning, H; Schambach, A (corresponding author), Hannover Med Sch, Inst Expt Hematol, Hannover, Germany.; Buning, H; Schambach, A (corresponding author), Hannover Med Sch, REBIRTH Res Ctr Translat Regenerat Med, Hannover, Germany.; Buning, H; Schambach, A (corresponding author), Harvard Med Sch, Div Hematol Oncol, Boston Childrens Hosp, Boston, MA 02115 USA.	buening.hildegard@mh-hannover.de; schambach.axel@mh-hannover.de	Schambach, Axel/C-5491-2011; Buening, Hildegard/AAJ-2352-2020					Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4; Buchholz CJ, 2015, TRENDS BIOTECHNOL, V33, P777, DOI 10.1016/j.tibtech.2015.09.008; Buning H, 2019, MOL THER-METH CLIN D, V12, P248, DOI 10.1016/j.omtm.2019.01.008; Cheng Q, 2020, NAT NANOTECHNOL, V15, P313, DOI 10.1038/s41565-020-0669-6; Dammes N., NAT NANOTECHNOL; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Frangoul H, 2021, NEW ENGL J MED, V384, P252, DOI 10.1056/NEJMoa2031054; Gillmore J. D, NEW ENGL J MED, DOI [10.1056/NEJMoa2107454(2021, DOI 10.1056/NEJMOA2107454(2021]; Hirakawa MP, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200127; Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Xu L, 2019, NEW ENGL J MED, V381, P1240, DOI 10.1056/NEJMoa1817426	12	2	2	1	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1515	1517		10.1038/s41591-021-01476-6	http://dx.doi.org/10.1038/s41591-021-01476-6		AUG 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34462600				2022-12-27	WOS:000691154300001
J	Voabil, P; de Bruijn, M; Roelofsen, LM; Hendriks, SH; Brokamp, S; van den Braber, M; Broeks, A; Sanders, J; Herzig, P; Zippelius, A; Blank, CU; Hartemink, KJ; Monkhorst, K; Haanen, JBAG; Schumacher, TN; Thommen, DS				Voabil, Paula; de Bruijn, Marjolein; Roelofsen, Lisanne M.; Hendriks, Sanne H.; Brokamp, Simone; van den Braber, Marlous; Broeks, Annegien; Sanders, Joyce; Herzig, Petra; Zippelius, Alfred; Blank, Christian U.; Hartemink, Koen J.; Monkhorst, Kim; Haanen, John B. A. G.; Schumacher, Ton N.; Thommen, Daniela S.			An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer	NATURE MEDICINE			English	Article							REDUCED CLINICAL BENEFIT; T-CELL DYSFUNCTION; B-CELLS; IMMUNOTHERAPY; SURVIVAL	An ex vivo platform of patient-derived tumor fragments enables the assessment of intratumoral immune reactivation after PD-1 blockade that is predictive of clinical outcomes in patients with cancer. Inhibitors of the PD-1-PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-1 blockade. We developed and employed a patient-derived tumor fragment platform to dissect the early immunological response of human tumor tissue to ex vivo PD-1 blockade. We observed that the capacity of immune cells to be reactivated ex vivo was predictive of clinical response, and perturbation analyses identified tumor-resident T cells as a key component of this immunological response. In addition, through combined analysis of baseline properties and immune response capacity, we identified a new subgroup of infiltrated tumors that lacks the capacity to respond to PD-1 blockade. Finally, the baseline presence of tertiary lymphoid structures and their components correlated with the capacity of cancers to undergo intratumoral immune cell reactivation.	[Voabil, Paula; Schumacher, Ton N.] Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [de Bruijn, Marjolein; Roelofsen, Lisanne M.; Hendriks, Sanne H.; Brokamp, Simone; van den Braber, Marlous; Blank, Christian U.; Haanen, John B. A. G.; Thommen, Daniela S.] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [Broeks, Annegien; Sanders, Joyce; Monkhorst, Kim] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands; [Herzig, Petra; Zippelius, Alfred] Univ Hosp Basel, Dept Biomed, Basel, Switzerland; [Blank, Christian U.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Hartemink, Koen J.] Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands; [Hendriks, Sanne H.; Haanen, John B. A. G.] Leiden Univ, Dept Immunohematol & Blood Transfus, Med Ctr, Leiden, Netherlands; [van den Braber, Marlous] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; University of Basel; Netherlands Cancer Institute; Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Thommen, DS (corresponding author), Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.	d.thommen@nki.nl	Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Schumacher, Ton/Y-2432-2019	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804; Hendriks, Sanne H/0000-0002-0974-3666; Zippelius, Alfred/0000-0003-1933-8178; Thommen, Daniela/0000-0002-7431-2854; Hartemink, Koen/0000-0003-4282-1096; Roelofsen, Lisanne/0000-0001-7686-1614; de Bruijn, Marjolein/0000-0002-2142-4684	Portuguese Foundation for Science and Technology [SFRH/BD/52042/2012]; KWF Young investigator grant [12046]; Swiss National Science Foundation [P300PB_177881]; ERC AdG SENSIT grant [742259]	Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); KWF Young investigator grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); ERC AdG SENSIT grant	We thank D. Peters and the NKI-AVL Core Facility for Molecular Pathology & Biobanking for supplying and processing the NKI-AVL Biobank material, the NKI-AVL flow cytometry facility for assistance with sorting and flow cytometric analyses, L. Rozeman for assistance with the acquisition of clinical data and all members of the Thommen and Schumacher laboratories for helpful discussions. This work was supported by a PhD fellowship from the Portuguese Foundation for Science and Technology (no. SFRH/BD/52042/2012) through the Graduate Program in Basic and Applied Biology to P.V., by a KWF Young investigator grant (no. 12046) and the Swiss National Science Foundation (no. P300PB_177881) to D.S.T. and by an ERC AdG SENSIT grant (no. 742259) to T.N.S.	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; [Anonymous], 2020, UMAP UNIFORM MANIFOL; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Baitsch L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030852; Blank C, 2004, CANCER RES, V64, P1140, DOI 10.1158/0008-5472.CAN-03-3259; Byrne A, 2020, NAT REV CLIN ONCOL, V17, P341, DOI 10.1038/s41571-020-0333-y; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Decalf J, 2019, J PATHOL, V247, P650, DOI 10.1002/path.5223; Dijkgraaf FE, 2019, NAT IMMUNOL, V20, P756, DOI 10.1038/s41590-019-0404-3; Duhen T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05072-0; Edwards J, 2018, CLIN CANCER RES, V24, P3036, DOI 10.1158/1078-0432.CCR-17-2257; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gettinger SN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05032-8; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Kurtulus S, 2019, IMMUNITY, V50, P181, DOI 10.1016/j.immuni.2018.11.014; Mayoux M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav7431; Menares E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12319-x; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Samusik N, 2016, NAT METHODS, V13, P493, DOI [10.1038/nmeth.3863, 10.1038/NMETH.3863]; Sanmamed MF, 2017, ANN ONCOL, V28, P1988, DOI 10.1093/annonc/mdx190; Schalper KA, 2020, NAT MED, V26, P688, DOI 10.1038/s41591-020-0856-x; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Strauss L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay1863; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Thommen DS, 2015, CANCER IMMUNOL RES, V3, P1344, DOI 10.1158/2326-6066.CIR-15-0097; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vickovic S, 2019, NAT METHODS, V16, P987, DOI 10.1038/s41592-019-0548-y; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Yu JX, 2020, NAT REV DRUG DISCOV, V19, P163, DOI 10.1038/d41573-019-00182-w; Yuen KC, 2020, NAT MED, V26, P693, DOI 10.1038/s41591-020-0860-1; Zhang JJ, 2020, CLIN CANCER RES, V26, P1327, DOI 10.1158/1078-0432.CCR-19-2931	50	56	56	5	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1250	+		10.1038/s41591-021-01398-3	http://dx.doi.org/10.1038/s41591-021-01398-3		JUL 2021	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34239134				2022-12-27	WOS:000672339400002
J	Castro, MC; Gurzenda, S; Turra, CM; Kim, S; Andrasfay, T; Goldman, N				Castro, Marcia C.; Gurzenda, Susie; Turra, Cassio M.; Kim, Sun; Andrasfay, Theresa; Goldman, Noreen			Reduction in life expectancy in Brazil after COVID-19	NATURE MEDICINE			English	Article								Brazil has been heavily affected by coronavirus disease 2019 (COVID-19). In this study, we used data on reported total deaths in 2020 and in January-April 2021 to measure and compare the death toll across states. We estimate a decline in 2020 life expectancy at birth (e(0)) of 1.3 years, a mortality level not seen since 2014. The reduction in life expectancy at age 65 (e(65)) in 2020 was 0.9 years, setting Brazil back to 2012 levels. The decline was larger for males, widening by 9.1% the female-male gap in e(0). Among states, Amazonas lost 60.4% of the improvements in e(0) since 2000. In the first 4 months of 2021, COVID-19 deaths represented 107% of the total 2020 figures. Assuming that death rates would have been equal to 2019 all-cause rates in the absence of COVID-19, COVID-19 deaths in 2021 have already reduced e(0) in 2021 by 1.8 years, which is slightly larger than the reduction estimated for 2020 under similar assumptions. New estimates of life expectancy at birth and at age 65 years in Brazil reveal substantial declines as a result of COVID-19, bringing mortality back to levels observed 20 or more years ago.	[Castro, Marcia C.; Gurzenda, Susie; Kim, Sun] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Turra, Cassio M.] Univ Fed Minas Gerais, Demog Dept, Cedeplar, Belo Horizonte, MG, Brazil; [Andrasfay, Theresa] Univ Southern Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90007 USA; [Goldman, Noreen] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA; [Goldman, Noreen] Princeton Univ, Princeton Sch Publ & Int Affairs, Princeton, NJ 08544 USA	Harvard University; Harvard T.H. Chan School of Public Health; Universidade Federal de Minas Gerais; University of Southern California; Princeton University; Princeton University	Castro, MC (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	mcastro@hsph.harvard.edu	Castro, Marcia/S-2681-2019	Castro, Marcia/0000-0003-4606-2795; Goldman, Noreen/0000-0003-2865-9491; Gurzenda, Susie/0000-0001-9210-3661; Turra, Cassio/0000-0003-4051-3567; Andrasfay, Theresa/0000-0003-3885-8718; Kim, Sun/0000-0002-2466-2442	National Institute on Aging [T32 AG000037]; Brazilian National Council for Scientific and Technological Development; National Institutes of Health [2U19AI089681-08]	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Brazilian National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	T.A. is supported by the National Institute on Aging (grant no. T32 AG000037). C.M.T. is supported by the Brazilian National Council for Scientific and Technological Development. M.C.C., S.G.K. and S.K. are supported by the National Institutes of Health (grant no. 2U19AI089681-08).	Abbasi J, 2021, JAMA-J AM MED ASSOC, V325, P808, DOI 10.1001/jama.2021.0107; ABURTO JM, 2021, QUANTIFYING IMPACTS; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Andrasfay T, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2014746118; Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0; Barberia LG, 2020, LANCET, V396, P367, DOI 10.1016/S0140-6736(20)31681-0; Barbosa RJ, 2020, DISTRIBUICAO RENDA N; Buss Lewis F, 2021, Science, V371, P288, DOI 10.1126/science.abe9728; de Carvalho CA, 2021, PUBLIC HEALTH NUTR, V24, P561, DOI 10.1017/S1368980020003973; Castro MC, 2021, SCIENCE, V372, P821, DOI 10.1126/science.abh1558; Castro MC, 2019, LANCET, V394, P345, DOI 10.1016/S0140-6736(19)31243-7; Chiang C., 1968, INTRO STOCHASTIC PRO; Duque, 2020, AUXILIO EMERGENCIAL; Faria N. R., GENOMICS EPIDEMIOLOG, DOI 10.1101/2021.02.26.21252554v1; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Fundacao Oswaldo Cruz, 2021, B EXTR OBS COVID 19; Fundacao Oswaldo Cruz. Rede Genomica Fiocruz, 2021, DEM LINH GEN SARS CO; Heuveline Patrick, 2021, medRxiv, DOI 10.1101/2020.04.29.20085506; Hogan A, 2020, 19 IMP COLL, DOI 10.25561/78670; Holmes L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124322; Hone T, 2019, LANCET GLOB HEALTH, V7, pE1575, DOI 10.1016/S2214-109X(19)30409-7; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; IBGE, 2013, 30116 IBGE; Lotta G, 2020, LANCET, V396, P365, DOI 10.1016/S0140-6736(20)31521-X; Marinho, 2020, VITAL STRATEGIES; Marques NP, 2021, SEMIN ONCOL; Noronha KVMD, 2020, CAD SAUDE PUBLICA, V36, DOI 10.1590/0102-311X00115320; Noymer A, 2000, POPUL DEV REV, V26, P565, DOI 10.1111/j.1728-4457.2000.00565.x; Nuzzo JB, 2020, JAMA-J AM MED ASSOC, V324, P1391, DOI 10.1001/jama.2020.17395; Palloni A., 2015, 2 CENTURIES MORTALIT; Pereira AK, 2020, REV ADM PUBL-RIO JAN, V54, P678, DOI [10.1590/0034-761220200323x, 10.1590/0034-761220200323]; Phillips T., 2021, GUARDIAN; Preston S, 2000, DEMOGRAPHY MEASURING; Ranzani OT, 2021, LANCET RESP MED, V9, P407, DOI 10.1016/S2213-2600(20)30560-9; Rede PENSSAN, VIGISAN INQ NAC INS; Rocha R, 2021, LANCET GLOB HEALTH, V9, pE782, DOI 10.1016/S2214-109X(21)00081-4; Santos M. C., 2021, 1 REPORTED CASES SAR; Silveira MF, 2021, VACCINE, V39, P3404, DOI 10.1016/j.vaccine.2021.04.046; Simoes C. C. S., 2016, BRASIL VISAO GEOGRAF, P40; Smith DW, 2006, DEMOGRAPHY, V43, P647, DOI 10.1353/dem.2006.0039; Barone MTU, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108304; VAUPEL J, 2021, P NATL ACAD SCI US, V118; Ventura Deisy de Freitas Lima, 2020, Ambient. soc., V23, pe0108, DOI 10.1590/1809-4422asoc20200108vu2020l3id; Woolf SH, 2020, JAMA-J AM MED ASSOC, V324, P510, DOI 10.1001/jama.2020.11787	44	27	32	3	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1629	+		10.1038/s41591-021-01437-z	http://dx.doi.org/10.1038/s41591-021-01437-z		JUN 2021	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34188224	Green Submitted, Bronze, Green Accepted			2022-12-27	WOS:000668054300001
J	Au, L; Fendler, A; Shepherd, STC; Rzeniewicz, K; Cerrone, M; Byrne, F; Carlyle, E; Edmonds, K; Del Rosario, L; Shon, J; Haynes, WA; Ward, B; Shum, B; Gordon, W; Gerard, CL; Xie, WY; Joharatnam-Hogan, N; Young, K; Pickering, L; Furness, AJS; Larkin, J; Harvey, R; Kassiotis, G; Gandhi, S; Swanton, C; Fribbens, C; Wilkinson, KA; Wilkinson, RJ; Lau, DK; Banerjee, S; Starling, N; Chau, I; Turajlic, S				Au, Lewis; Fendler, Annika; Shepherd, Scott T. C.; Rzeniewicz, Karolina; Cerrone, Maddalena; Byrne, Fiona; Carlyle, Eleanor; Edmonds, Kim; Del Rosario, Lyra; Shon, John; Haynes, Winston A.; Ward, Barry; Shum, Ben; Gordon, William; Gerard, Camille L.; Xie, Wenyi; Joharatnam-Hogan, Nalinie; Young, Kate; Pickering, Lisa; Furness, Andrew J. S.; Larkin, James; Harvey, Ruth; Kassiotis, George; Gandhi, Sonia; Swanton, Charles; Fribbens, Charlotte; Wilkinson, Katalin A.; Wilkinson, Robert J.; Lau, David K.; Banerjee, Susana; Starling, Naureen; Chau, Ian; Turajlic, Samra		Crick COVID-19 Consortium; CAPTURE Consortium	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2	NATURE MEDICINE			English	Article							RESPONSES	A rare case of cytokine release syndrome in a patient on anti-PD-1 blockade that was likely related to BNT162b2 vaccination supports prospective monitoring of patients with cancer after COVID-19 vaccine administration. Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-gamma/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.	[Au, Lewis; Fendler, Annika; Shepherd, Scott T. C.; Rzeniewicz, Karolina; Byrne, Fiona; Ward, Barry; Shum, Ben; Gordon, William; Gerard, Camille L.; Xie, Wenyi; Turajlic, Samra] Francis Crick Inst, Canc Dynam Lab, London, England; [Au, Lewis; Shepherd, Scott T. C.; Carlyle, Eleanor; Edmonds, Kim; Del Rosario, Lyra; Shum, Ben; Joharatnam-Hogan, Nalinie; Young, Kate; Pickering, Lisa; Furness, Andrew J. S.; Larkin, James; Turajlic, Samra] Royal Marsden NHS Fdn Trust, Skin Unit, London, England; [Au, Lewis; Shepherd, Scott T. C.; Carlyle, Eleanor; Edmonds, Kim; Del Rosario, Lyra; Shum, Ben; Joharatnam-Hogan, Nalinie; Young, Kate; Pickering, Lisa; Furness, Andrew J. S.; Larkin, James; Turajlic, Samra] Royal Marsden NHS Fdn Trust, Renal Unit, London, England; [Cerrone, Maddalena; Wilkinson, Katalin A.; Wilkinson, Robert J.] Francis Crick Inst, TB Lab, London, England; [Cerrone, Maddalena; Wilkinson, Robert J.] Imperial Coll London, Dept Infect Dis, London, England; [Shon, John; Haynes, Winston A.] Serimmune Inc, Goleta, CA USA; [Gerard, Camille L.] Lausanne Univ Hosp CHUV, Precis Oncol Ctr, Lausanne, Switzerland; [Harvey, Ruth] Francis Crick Inst, Worldwide Influenza Ctr, London, England; [Kassiotis, George] Francis Crick Inst, Retroviral Immunol Lab, London, England; [Gandhi, Sonia] Francis Crick Inst, Neurodegenerat Biol Lab, London, England; [Gandhi, Sonia] UCL Queen Sq Inst Neurol, Queen Sq, London, England; [Swanton, Charles; Fribbens, Charlotte] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Fribbens, Charlotte] Royal Marsden NHS Fdn Trust, Acute Oncol Serv, London, England; [Fribbens, Charlotte; Lau, David K.; Starling, Naureen; Chau, Ian] Royal Marsden NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, Sutton, Surrey, England; [Banerjee, Susana] Royal Marsden NHS Fdn Trust, Gynaecol Unit, London, England; [Banerjee, Susana] Inst Canc Res, London, England	Francis Crick Institute; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Francis Crick Institute; Imperial College London; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; University of London; University College London; Francis Crick Institute; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Turajlic, S (corresponding author), Francis Crick Inst, Canc Dynam Lab, London, England.; Turajlic, S (corresponding author), Royal Marsden NHS Fdn Trust, Skin Unit, London, England.; Turajlic, S (corresponding author), Royal Marsden NHS Fdn Trust, Renal Unit, London, England.	samra.turajlic@crick.ac.uk	Wilkinson, Katalin/AAQ-7713-2021; Chau, Ian/ABC-2023-2020; Bussi, Claudio/AIA-8046-2022; Suarez, Paula Ordonez/AAT-9937-2021	Wilkinson, Katalin/0000-0002-9796-2040; Chau, Ian/0000-0003-0286-8703; Bussi, Claudio/0000-0002-9396-9042; Suarez, Paula Ordonez/0000-0001-5588-5369; Joharatnam-Hogan, Nalinie/0000-0001-8406-2732; turajlic, samra/0000-0001-8846-136X; Wilkinson, Robert/0000-0002-2753-1800; Starling, Naureen/0000-0002-1496-6792; Banerjee, Susana/0000-0002-8840-7934; Swanton, Charles/0000-0002-4299-3018; Fribbens, Charlotte/0000-0002-1500-6945; Hewitt, Graeme/0000-0003-2614-6932; Fendler, Annika/0000-0002-7267-0981; Gerard, Camille/0000-0002-6007-1746; Larkin, James/0000-0001-5569-9523	Royal Marsden NHS Foundation Trust; Francis Crick Institute; Cancer Research UK [FC010110, FC0010988, FC001218, FC001030, FC001099, FC001002, FC001169]; UK Medical Research Council [FC010110, FC0010988, FC001218, FC001030, FC001099, FC001002, FC001169]; Wellcome Trust [FC010110, FC0010988, FC001218, FC001030, FC001099, FC001002]; Royal Marsden Cancer Charity Programme [RMCC32]; National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital; Institute of Cancer Research [A109]	Royal Marsden NHS Foundation Trust(Royal Society of New ZealandMarsden Fund (NZ)); Francis Crick Institute; Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Royal Marsden Cancer Charity Programme; National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital(Royal Society of New ZealandMarsden Fund (NZ)); Institute of Cancer Research	We thank the patient for permission to report his case. We thank the CAPTURE trial team, including H. Ahmod, N. Ash, R. Dhaliwal, L. Dowdie, T. Foley, L. Holt, J. Korteweg, C. Lewis, K. Lingard, M. Mangwende, A. Murra, K. Peat, S. Sarker, N. Shaikh and F. Williams. We thank F. Gronthoud, G. Gardner, R. Shea and their teams for support on sample collation. We acknowledge the tremendous support from the clinical and research teams at participating units at the Royal Marsden Hospital, as well as A. Macklin-Doherty for consenting the patient. We thank M. Gavrielides for informatics support and B. Stockinger for valuable discussions. We also thank the Volunteer Staff at the Francis Crick Institute and the Crick COVID-19 Consortium (see Supplementary Material for a list of consortium members). Owing to limitations on cited references and the pace at which the field is evolving, we acknowledge researchers in COVID-19 vaccines and immune responses in patients with cancer. The CAPTURE study is a sub-study of TRACERx Renal and is sponsored by the Royal Marsden NHS Foundation Trust and funded from a grant from the Royal Marsden Cancer Charity Programme (ref. no. RMCC32). TRACERx Renal is partly funded by the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital and the Institute of Cancer Research (A109). This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC010110, FC0010988, FC001218, FC001030, FC001099, FC001002 and FC001169), the UK Medical Research Council (FC010110, FC0010988, FC001218, FC001030, FC001099, FC001002 and FC001169) and the Wellcome Trust (FC010110, FC0010988, FC001218, FC001030, FC001099, FC001002 and FC001099). For the purpose of open access, the author has applied for a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.	Au L, 2020, CELL, V183, P4, DOI 10.1016/j.cell.2020.09.005; Ballhausen A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18514-5; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Ceschi A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00557; Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w; Desai A, 2021, NAT REV CLIN ONCOL, V18, P313, DOI 10.1038/s41571-021-00487-z; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Haynes W. A., 2020, HIGH RESOLUTION MAPP, DOI [10.1101/2020.11.23.20235002v1.full, DOI 10.1101/2020.11.23.20235002V1.FULL]; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Reifert J, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.01836.20; Ribas A, 2021, CANCER DISCOV, V11, P233, DOI 10.1158/2159-8290.CD-20-1817; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vormehr M, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1758004; Waissengrin B, 2021, LANCET ONCOL, V22, P581, DOI 10.1016/S1470-2045(21)00155-8; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wrobel AG, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19146-5	27	38	38	3	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1362	+		10.1038/s41591-021-01387-6	http://dx.doi.org/10.1038/s41591-021-01387-6		MAY 2021	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34040262	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000654957100001
J	Andreano, E; Rappuoli, R				Andreano, Emanuele; Rappuoli, Rino			SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies	NATURE MEDICINE			English	Editorial Material								SARS-CoV-2 can escape natural immune responses, but can the virus evade monoclonal antibodies and vaccine-mediated immunity?	[Andreano, Emanuele; Rappuoli, Rino] Fdn Toscana Life Sci, Monoclonal Antibody Discovery Lab, Siena, Italy; [Rappuoli, Rino] Imperial Coll London, Fac Med, London, England	Imperial College London	Rappuoli, R (corresponding author), Fdn Toscana Life Sci, Monoclonal Antibody Discovery Lab, Siena, Italy.; Rappuoli, R (corresponding author), Imperial Coll London, Fac Med, London, England.	rino.r.rappuoli@gsk.com		Andreano, Emanuele/0000-0003-0088-5788				Andreano E, 2021, CELL, V184, P1821, DOI 10.1016/j.cell.2021.02.035; Andreano Emanuele, 2020, bioRxiv, DOI 10.1101/2020.12.28.424451; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Johnson CY., 2021, WASH POST; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Sridhar D, 2021, SCIENCE, V371, P230, DOI 10.1126/science.abf7921; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Tarke A, 2021, 433180 BIORXIV; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Shi Pei-Yong, 2021, Res Sq, DOI [10.1101/2021.01.07.425740, 10.21203/rs.3.rs-143532/v1]; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321	16	33	35	3	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					759	761		10.1038/s41591-021-01347-0	http://dx.doi.org/10.1038/s41591-021-01347-0		MAY 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33972793	Bronze			2022-12-27	WOS:000648805100003
J	Carraro, G; Langerman, J; Sabri, S; Lorenzana, Z; Purkayastha, A; Zhang, GZ; Konda, B; Aros, CJ; Calvert, BA; Szymaniak, A; Wilson, E; Mulligan, M; Bhatt, P; Lu, JJ; Vijayaraj, P; Yao, CF; Shia, DW; Lund, AJ; Israely, E; Rickabaugh, TM; Ernst, J; Mense, M; Randell, SH; Vladar, EK; Ryan, AL; Plath, K; Mahoney, JE; Stripp, BR; Gomperts, BN				Carraro, Gianni; Langerman, Justin; Sabri, Shan; Lorenzana, Zareeb; Purkayastha, Arunima; Zhang, Guangzhu; Konda, Bindu; Aros, Cody J.; Calvert, Ben A.; Szymaniak, Aleks; Wilson, Emily; Mulligan, Michael; Bhatt, Priyanka; Lu, Junjie; Vijayaraj, Preethi; Yao, Changfu; Shia, David W.; Lund, Andrew J.; Israely, Edo; Rickabaugh, Tammy M.; Ernst, Jason; Mense, Martin; Randell, Scott H.; Vladar, Eszter K.; Ryan, Amy L.; Plath, Kathrin; Mahoney, John E.; Stripp, Barry R.; Gomperts, Brigitte N.			Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition	NATURE MEDICINE			English	Article							BASAL STEM-CELLS; PROMOTES; HOMEOSTASIS; GENES	Single-cell RNA profiling of human cystic fibrosis proximal airway tissue reveals an overabundance of epithelial cells transitioning to specialized ciliated and secretory cells coupled with a decrease in cycling basal cells. Cystic fibrosis (CF) is a lethal autosomal recessive disorder that afflicts more than 70,000 people. People with CF experience multi-organ dysfunction resulting from aberrant electrolyte transport across polarized epithelia due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF-related lung disease is by far the most important determinant of morbidity and mortality. Here we report results from a multi-institute consortium in which single-cell transcriptomics were applied to define disease-related changes by comparing the proximal airway of CF donors (n = 19) undergoing transplantation for end-stage lung disease with that of previously healthy lung donors (n = 19). Disease-dependent differences observed include an overabundance of epithelial cells transitioning to specialized ciliated and secretory cell subsets coupled with an unexpected decrease in cycling basal cells. Our study yields a molecular atlas of the proximal airway epithelium that will provide insights for the development of new targeted therapies for CF airway disease.	[Carraro, Gianni; Zhang, Guangzhu; Konda, Bindu; Yao, Changfu; Israely, Edo; Stripp, Barry R.] Cedars Sinai Med Ctr, Dept Med, Lung & Regenerat Med Inst, Los Angeles, CA 90048 USA; [Langerman, Justin; Sabri, Shan; Ernst, Jason; Plath, Kathrin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Lorenzana, Zareeb; Calvert, Ben A.; Ryan, Amy L.] Univ Southern Calif, Hastings Ctr Pulm Res, Keck Sch Med, Los Angeles, CA 90007 USA; [Lorenzana, Zareeb; Calvert, Ben A.; Ryan, Amy L.] Univ Southern Calif, Div Pulm Crit Care & Sleep Med, Keck Sch Med, Dept Med, Los Angeles, CA 90007 USA; [Lorenzana, Zareeb; Ryan, Amy L.] Univ Southern Calif, Keck Sch Med, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90007 USA; [Purkayastha, Arunima; Aros, Cody J.; Vijayaraj, Preethi; Shia, David W.; Lund, Andrew J.; Rickabaugh, Tammy M.; Gomperts, Brigitte N.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Childrens Discovery & Innovat Inst, Mattel Childrens Hosp UCLA,Dept Pediat, Los Angeles, CA 90095 USA; [Aros, Cody J.; Shia, David W.; Lund, Andrew J.] Univ Calif Los Angeles, Dept Mol Biol, Interdept Program, Los Angeles, CA USA; [Aros, Cody J.; Shia, David W.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Med Scientist Training Program, Los Angeles, CA 90095 USA; [Szymaniak, Aleks; Wilson, Emily; Mulligan, Michael; Bhatt, Priyanka; Lu, Junjie; Mense, Martin; Mahoney, John E.] Cyst Fibrosis Fdn, CFFT Lab, Lexington, MA 02421 USA; [Ernst, Jason; Plath, Kathrin; Gomperts, Brigitte N.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Ernst, Jason; Plath, Kathrin; Gomperts, Brigitte N.] Univ Calif Los Angeles, Eli & Edythe Broad Stem Cell Res Ctr, Los Angeles, CA 90024 USA; [Randell, Scott H.] Univ N Carolina, Cyst Fibrosis Ctr, Marsico Lung Inst, Chapel Hill, NC 27515 USA; [Vladar, Eszter K.] Univ Colorado, Denver Sch Med, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA; [Vladar, Eszter K.] Univ Colorado, Denver Sch Med, Dept Cell & Dev Biol, Aurora, CO USA; [Gomperts, Brigitte N.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cystic Fibrosis Foundation; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Stripp, BR (corresponding author), Cedars Sinai Med Ctr, Dept Med, Lung & Regenerat Med Inst, Los Angeles, CA 90048 USA.; Plath, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.; Gomperts, BN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Childrens Discovery & Innovat Inst, Mattel Childrens Hosp UCLA,Dept Pediat, Los Angeles, CA 90095 USA.; Mahoney, JE (corresponding author), Cyst Fibrosis Fdn, CFFT Lab, Lexington, MA 02421 USA.; Plath, K; Gomperts, BN (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.; Plath, K; Gomperts, BN (corresponding author), Univ Calif Los Angeles, Eli & Edythe Broad Stem Cell Res Ctr, Los Angeles, CA 90024 USA.; Gomperts, BN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.	kplath@mednet.ucla.edu; jmahoney@cff.org; barry.stripp@cshs.org; bgomperts@mednet.ucla.edu	Ryan, Amy L/AFO-2326-2022	Ryan, Amy L/0000-0003-1363-905X; Bhatt, Priyanka/0000-0002-4531-6952	Cystic Fibrosis Foundation [GOMPER17XX0, STRIPP17XX0, CARRAR19G0, BOUCHE15R0]; Tobacco-Related Disease Research Program [HIPRA 29IP-0597]; National Institutes of Health (NIH) [R01CA208303]; National Heart, Lung, and Blood Institute [PO1 HL108793]; NIH [P01 GM099134, DP1DA044371, DK065988]; W. M. Keck Foundation; Celgene/BMS; UCLA Tumor Cell Biology Training Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award) [T32 CA009056]; UCLA Broad Stem Cell Research Center-Rose Hills Foundation Training Award; UCLA Dissertation Year Fellowship; UCLA Broad Stem Cell Research Center; David Geffen School of Medicine; Jonsson Comprehensive Cancer Center; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Ablon Scholars Award; UCLA Medical Scientist Training Program [NIH NIGMS GM008042]; NIH/NCI NRSA Predoctoral F31 Diversity Fellowship [F31CA239655]; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Training Grant; T32 National Research Service Award in Tumor Cell Biology [CA009056]; Parker B. Francis Foundation; UCLA CTSI [KL2- NCATS KL2TR001882]	Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Tobacco-Related Disease Research Program(University of California System); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); W. M. Keck Foundation(W.M. Keck Foundation); Celgene/BMS(Bristol-Myers SquibbCelgene Corporation); UCLA Tumor Cell Biology Training Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA Broad Stem Cell Research Center-Rose Hills Foundation Training Award; UCLA Dissertation Year Fellowship; UCLA Broad Stem Cell Research Center; David Geffen School of Medicine(University of California System); Jonsson Comprehensive Cancer Center; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Ablon Scholars Award; UCLA Medical Scientist Training Program; NIH/NCI NRSA Predoctoral F31 Diversity Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Training Grant; T32 National Research Service Award in Tumor Cell Biology; Parker B. Francis Foundation; UCLA CTSI	We would like to thank S. Reynolds for helpful input in reviewing this manuscript. This work was supported by the Cystic Fibrosis Foundation (GOMPER17XX0 (B.N.G.), STRIPP17XX0 (B.R.S.), CARRAR19G0 (G.C.) and BOUCHE15R0 (S.H.R.)), the Tobacco-Related Disease Research Program (HIPRA 29IP-0597) (B.N.G.), National Institutes of Health (NIH) grant R01CA208303 (B.N.G.), the National Heart, Lung, and Blood Institute (PO1 HL108793) (B.R.S.), NIH grant DK065988 (S.H.R.), a grant from the W. M. Keck Foundation (B.N.G.) and a grant from Celgene/BMS (B.R.S.). J.L. was supported by the UCLA Tumor Cell Biology Training Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award T32 CA009056). S.S. was supported by the UCLA Broad Stem Cell Research Center-Rose Hills Foundation Training Award and, currently, the UCLA Dissertation Year Fellowship. K.P. and B.N.G. were supported by the UCLA Broad Stem Cell Research Center, the David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center, and K.P. was supported by the NIH (P01 GM099134). The research of K.P. was also supported, in part, by a Faculty Scholar grant from the Howard Hughes Medical Institute. J.E. was funded by the NIH (DP1DA044371), and J.E. and B.N.G. were supported by the Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Ablon Scholars Award. C.J.A. and D.W.S. were supported by a UCLA Medical Scientist Training Program grant (NIH NIGMS GM008042), the NIH/NCI NRSA Predoctoral F31 Diversity Fellowship F31CA239655 (C.J.A.), the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Training Grant (C.J.A.), the T32 National Research Service Award in Tumor Cell Biology CA009056 (C.J.A.), the Parker B. Francis Foundation Fellowship (C.Y.) and UCLA CTSI KL2- NCATS KL2TR001882 (C.Y.).	Akram KM, 2018, MUCOSAL IMMUNOL, V11, P71, DOI [10.1038/mi.2017.45, 10.1038/mi.2017.109]; Aros CJ, 2020, CELL REP, V30, P2055, DOI 10.1016/j.celrep.2020.01.059; Ather JL, 2011, J IMMUNOL, V187, P64, DOI 10.4049/jimmunol.1100500; Bals R, 1999, J CLIN INVEST, V103, P303, DOI 10.1172/JCI6277; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Bonser LR, 2015, AM J RESP CELL MOL, V53, P536, DOI 10.1165/rcmb.2014-0318OC; Brooks ER, 2014, CURR BIOL, V24, pR973, DOI 10.1016/j.cub.2014.08.047; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Carraro G, 2020, AM J RESP CRIT CARE, V202, P1540, DOI 10.1164/rccm.201904-0792OC; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Didon L, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-70; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eckmann L, 2005, CURR OPIN GASTROEN, V21, P147, DOI 10.1097/01.mog.0000153311.97832.8c; Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5; Goldfarbmuren KC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16239-z; Hegab AE, 2014, STEM CELLS DEV, V23, P664, DOI 10.1089/scd.2013.0295; Hegab AE, 2012, STEM CELL TRANSL MED, V1, P719, DOI 10.5966/sctm.2012-0056; Hegab AE, 2012, JOVE-J VIS EXP, DOI 10.3791/3731; Hoh RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052166; Horani A, 2018, P NATL ACAD SCI USA, V115, pE1221, DOI 10.1073/pnas.1715915115; King NE, 2020, HUM GENE THER, V31, P956, DOI 10.1089/hum.2020.160; LEIGH MW, 1995, AM J RESP CELL MOL, V12, P605, DOI 10.1165/ajrcmb.12.6.7766425; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Mihalj M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215461; Montoro DT, 2018, NATURE, V560, P319, DOI 10.1038/s41586-018-0393-7; Neuberger T, 2011, METHODS MOL BIOL, V741, P39, DOI 10.1007/978-1-61779-117-8_4; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; Okuda K, 2021, AM J RESP CRIT CARE, V203, P1275, DOI 10.1164/rccm.202008-3198OC; Pan SJ, 2011, METHOD ENZYMOL, V499, P1, DOI 10.1016/B978-0-12-386471-0.00001-8; Paul MK, 2014, CELL STEM CELL, V15, P199, DOI 10.1016/j.stem.2014.05.009; Petralki CD, 2006, BIOL CHEM, V387, P653, DOI 10.1515/BC.2006.084; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Randell SH, 2001, IN VITRO CELL DEV-AN, V37, P480; Rock JR, 2010, DIS MODEL MECH, V3, P545, DOI 10.1242/dmm.006031; Rokicki W, 2016, KARDIOCHIR TORAKOCHI, V13, P26, DOI 10.5114/kitp.2016.58961; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Tang AC, 2017, J INFECT DIS, V215, P293, DOI 10.1093/infdis/jiw516; Teixeira VH, 2013, ELIFE, V2, DOI 10.7554/eLife.00966; Tezuka Tadashi, 1992, Journal of Dermatology (Tokyo), V19, P756; Thomas J, 2010, BIOL CELL, V102, P499, DOI 10.1042/BC20100035; Tirosh I, 2016, NATURE, V539, P309, DOI 10.1038/nature20123; Traag VA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41695-z; Voynow JA, 2005, AM J RESP CRIT CARE, V172, P1013, DOI 10.1164/rccm.200410-1398OC; Wells JM, 2018, NATURE, V557, P322, DOI 10.1038/s41586-018-0073-7; Widdicombe JH, 2015, PHYSIOL REV, V95, P1241, DOI 10.1152/physrev.00039.2014; Xia C, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01908; Xu Y, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90558; Young MD, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa151; Yu XW, 2008, NAT GENET, V40, P1445, DOI 10.1038/ng.263; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	50	33	34	6	13	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					806	+		10.1038/s41591-021-01332-7	http://dx.doi.org/10.1038/s41591-021-01332-7		MAY 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33958799	Green Accepted			2022-12-27	WOS:000647954500002
J	Ramdas, K; Swaminathan, S				Ramdas, Kamalini; Swaminathan, Soumya			Patients could share virtual medical appointments for better access to telemedicine	NATURE MEDICINE			English	Editorial Material							CARE DELIVERY		[Ramdas, Kamalini] London Business Sch, Management Sci & Operat, London, England; [Swaminathan, Soumya] WHO, Geneva, Switzerland	University of London; London Business School; World Health Organization	Ramdas, K (corresponding author), London Business Sch, Management Sci & Operat, London, England.	kramdas@london.edu			World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Agrawal A, 2020, SCIENCE, V369, P1050, DOI 10.1126/science.abc9295; Jones Tania, 2019, Future Healthc J, V6, P8, DOI 10.7861/futurehosp.6-1-8; Menon K, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00263; Noffsinger E.B., 2009, RUNNING GROUP VISITS; Ramdas K, 2020, LANCET DIGIT HEALTH, V2, pE288, DOI 10.1016/S2589-7500(20)30101-1; Ramdas K, 2017, NEW ENGL J MED, V376, P1105, DOI 10.1056/NEJMp1612803; Sharma J, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0476-9; Shibuya K, 2018, ENDOCR PRACT, V24, P1108, DOI 10.4158/1934-2403-24.12.1108; Stevens JA, 2016, AUST FAM PHYSICIAN, V45, P425; Tokuda L, 2016, INT J MED INFORM, V93, P34, DOI 10.1016/j.ijmedinf.2016.05.007; Venkatesh R, 2017, INVEST OPHTH VIS SCI, V58; Zhou C, 2016, ACAD MED, V91, P1439, DOI 10.1097/ACM.0000000000001328	12	5	5	2	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					14	16		10.1038/s41591-020-01187-4	http://dx.doi.org/10.1038/s41591-020-01187-4			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442005	Green Accepted, Bronze			2022-12-27	WOS:000607931400009
J	Stower, H				Stower, Hannah			Air pollution linked to neurodegeneration markers	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	2	2	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					21	21		10.1038/s41591-020-01221-5	http://dx.doi.org/10.1038/s41591-020-01221-5			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442009				2022-12-27	WOS:000607931400014
J	Voors, AA; Angermann, CE; Teerlink, JR; Collins, SP; Kosiborod, M; Biegus, J; Ferreira, JP; Nassif, ME; Psotka, MA; Tromp, J; Borleffs, CJW; Ma, CS; Comin-Colet, J; Fu, M; Janssens, SP; Kiss, RG; Mentz, RJ; Sakata, Y; Schirmer, H; Schou, M; Schulze, PC; Spinarova, L; Volterrani, M; Wranicz, JK; Zeymer, U; Zieroth, S; Brueckmann, M; Blatchford, JP; Salsali, A; Ponikowski, P				Voors, Adriaan A.; Angermann, Christiane E.; Teerlink, John R.; Collins, Sean P.; Kosiborod, Mikhail; Biegus, Jan; Ferreira, Joao Pedro; Nassif, Michael E.; Psotka, Mitchell A.; Tromp, Jasper; Borleffs, C. Jan Willem; Ma, Changsheng; Comin-Colet, Joseph; Fu, Michael; Janssens, Stefan P.; Kiss, Robert G.; Mentz, Robert J.; Sakata, Yasushi; Schirmer, Henrik; Schou, Morten; Schulze, P. Christian; Spinarova, Lenka; Volterrani, Maurizio; Wranicz, Jerzy K.; Zeymer, Uwe; Zieroth, Shelley; Brueckmann, Martina; Blatchford, Jonathan P.; Salsali, Afshin; Ponikowski, Piotr			The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	NATURE MEDICINE			English	Article							MORTALITY; HF	The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days. The primary outcome of the trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90 days, as assessed using a win ratio. More patients treated with empagliflozin had clinical benefit compared with placebo (stratified win ratio, 1.36; 95% confidence interval, 1.09-1.68; P =0.0054), meeting the primary endpoint. Clinical benefit was observed for both acute de novo and decompensated chronic heart failure and was observed regardless of ejection fraction or the presence or absence of diabetes. Empagliflozin was well tolerated; serious adverse events were reported in 32.3% and 43.6% of the empagliflozin- and placebo-treated patients, respectively. These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting treatment.	[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [Angermann, Christiane E.] Univ Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany; [Angermann, Christiane E.] Univ Hosp Wurzburg, Wurzburg, Germany; [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Sect Cardiol, San Francisco, CA 94143 USA; [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Collins, Sean P.] Vanderbilt Univ Sch Med, Dept Emergency Med, Nashville, TN USA; [Collins, Sean P.] Tennessee Valley Healthcare Facil VA Med Ctr, Geriatr Res & Educ Clin Care, Nashville, TN USA; [Kosiborod, Mikhail; Nassif, Michael E.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA; [Kosiborod, Mikhail; Nassif, Michael E.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA; [Kosiborod, Mikhail] George Inst Global Hlth, Sydney, NSW, Australia; [Kosiborod, Mikhail] Univ New South Wales, Sydney, NSW, Australia; [Biegus, Jan; Ponikowski, Piotr] Med Univ, Inst Heart Dis, Wroclaw, Poland; [Ferreira, Joao Pedro] Univ Lorraine, Ctr Hosp Reg Univ, Inserm INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France; [Ferreira, Joao Pedro] Univ Porto, Cardiovasc Res & Dev Ctr, Dept Surg & Physiol, Fac Med, Porto, Portugal; [Psotka, Mitchell A.] Inova Heart & Vasc Inst, Falls Church, VA USA; [Tromp, Jasper] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Tromp, Jasper] Natl Univ Hlth Syst, Singapore, Singapore; [Borleffs, C. Jan Willem] Haga Teaching Hosp, The Hague, Netherlands; [Ma, Changsheng] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China; [Comin-Colet, Joseph] Hosp Univ Bellvitge IDIBELL, Barcelona, Spain; [Fu, Michael] Univ Gothenburg, Sahlgrenska Univ Hosp, Sect Cardiol, Gothenburg, Sweden; [Janssens, Stefan P.] Katholieke Univ Leuven, Belgium Univ Hosp, Dept Cardiovasc Sci, Clin Cardiol, Leuven, Belgium; [Kiss, Robert G.] Mil Hosp, Dept Cardiol, Budapest, Hungary; [Mentz, Robert J.] Duke Univ Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Mentz, Robert J.] Duke Univ Med Ctr, Div Cardiol, Durham, NC USA; [Sakata, Yasushi] Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, Osaka, Japan; [Schirmer, Henrik] Akershus Univ Hosp, Dept Cardiol, Div Med, Lrenskog, Norway; [Schou, Morten] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark; [Schulze, P. Christian] Univ Hosp Jena, Jena, Germany; [Spinarova, Lenka] Masaryk Univ Hosp, Dept Med 1, Brno, Czech Republic; [Volterrani, Maurizio] IRCCS San Raffaele Pisana, Dept Cardiol, Rome, Italy; [Wranicz, Jerzy K.] Med Univ Lodz, Cent Clin Hosp, Dept Electrocardiol, Lodz, Poland; [Zeymer, Uwe] Klinikum Ludwigshafen, Ludwigshafen, Germany; [Zieroth, Shelley] Univ Manitoba, Max Rady Coll Med, Sect Cardiol, Winnipeg, MB, Canada; [Brueckmann, Martina] Boehringer Ingelheim Int GmbH, Ingelheim, Germany; [Brueckmann, Martina] Heidelberg Univ, Fac Med Mannheim, Dept Med 1, Mannheim, Germany; [Blatchford, Jonathan P.] Elderbrook Solut GmbH, Biberach, Germany; [Salsali, Afshin] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [Salsali, Afshin] Rutgers State Univ, Fac Med, New Brunswick, NJ USA	University of Groningen; University of Wurzburg; University of Wurzburg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; Vanderbilt University; Geriatric Research Education & Clinical Center; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; George Institute for Global Health; University of Sydney; University of New South Wales Sydney; Wroclaw Medical University; Universite de Lorraine; Universidade do Porto; Inova Fairfax Hospital; National University of Singapore; National University of Singapore; Haga Hospital; Capital Medical University; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Sahlgrenska University Hospital; University of Gothenburg; KU Leuven; Duke University; Duke University; Osaka University; University of Copenhagen; Herlev & Gentofte Hospital; Friedrich Schiller University of Jena; Masaryk University Brno; IRCCS San Raffaele Pisana; Medical University Lodz; Ludwigshafen Hospital; University of Manitoba; Boehringer Ingelheim; Ruprecht Karls University Heidelberg; Boehringer Ingelheim; Rutgers State University New Brunswick	Voors, AA (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.	a.a.voors@umcg.nl	Kosiborod, Mikhail/HDO-1541-2022; Ferreira, João Pedro/AAB-2489-2022; Voors, Adriaan/ABE-6784-2020; Ponikowski, Piotr/O-6454-2015; Schulze, Christian/AGJ-7744-2022; Biegus, Jan/AAF-4207-2021	Kosiborod, Mikhail/0000-0002-3750-9789; Ferreira, João Pedro/0000-0002-2304-6138; Ponikowski, Piotr/0000-0002-3391-7064; Schulze, Christian/0000-0001-9442-7141; Biegus, Jan/0000-0001-9977-7722; Sakata, Yasushi/0000-0002-5618-4721; Voors, Adriaan/0000-0002-5417-4415; Mentz, Robert/0000-0002-3222-1719	Boehringer Ingelheim; Eli Lilly and Company	Boehringer Ingelheim(Boehringer Ingelheim); Eli Lilly and Company(Eli Lilly)	The sponsors of the trial were Boehringer Ingelheim and Eli Lilly and Company. Boehringer Ingelheim had the organizational oversight over the EMPULSE trial, which included trial conduct, supervision and monitoring of the enrolling study centers, data collection and storage as well as data analysis. The trial design was developed by the academic members of the executive committee in cooperation with representatives from Boehringer Ingelheim, who were also represented in the executive committee of the trial. The executive committee of EMPULSE, consisting of academic members and representatives of Boehringer Ingelheim, designed the protocol and provided oversight of the trial's conduct together with the trial sponsor. The sponsor performed statistical analyses of the trial according to a prespecified statistical analysis plan with oversight by the executive committee. An independent data and safety monitoring committee reviewed the safety data.	Anker SD, 2021, NEW ENGL J MED, V385, P1451, DOI 10.1056/NEJMoa2107038; Bhatt DL, 2021, NEW ENGL J MED, V384, P117, DOI 10.1056/NEJMoa2030183; Damman K, 2020, EUR J HEART FAIL, V22, P713, DOI 10.1002/ejhf.1713; Dong GH, 2018, J BIOPHARM STAT, V28, P778, DOI 10.1080/10543406.2017.1397007; Greene SJ, 2015, NAT REV CARDIOL, V12, P220, DOI 10.1038/nrcardio.2015.14; Konstam MA, 2007, JAMA-J AM MED ASSOC, V297, P1319, DOI 10.1001/jama.297.12.1319; Kozhuharov N, 2019, JAMA-J AM MED ASSOC, V322, P2292, DOI 10.1001/jama.2019.18598; Massie BM, 2010, NEW ENGL J MED, V363, P1419, DOI 10.1056/NEJMoa0912613; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Metra M, 2019, NEW ENGL J MED, V381, P716, DOI 10.1056/NEJMoa1801291; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Packer M, 2017, NEW ENGL J MED, V376, P1956, DOI 10.1056/NEJMoa1601895; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; Tromp J, 2021, EUR J HEART FAIL, V23, P826, DOI 10.1002/ejhf.2137; Tromp J, 2020, LANCET GLOB HEALTH, V8, pE411, DOI 10.1016/S2214-109X(20)30004-8; Velazquez EJ, 2019, NEW ENGL J MED, V380, P539, DOI 10.1056/NEJMoa1812851; Zannad F, 2020, LANCET, V396, P819, DOI 10.1016/S0140-6736(20)31824-9	19	73	77	18	24	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					568	+		10.1038/s41591-021-01659-1	http://dx.doi.org/10.1038/s41591-021-01659-1		FEB 2022	9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35228754	hybrid, Green Published			2022-12-27	WOS:000762162700002
J	Andrews, N; Stowe, J; Kirsebom, F; Toffa, S; Sachdeva, R; Gower, C; Ramsay, M; Bernal, JL				Andrews, Nick; Stowe, Julia; Kirsebom, Freja; Toffa, Samuel; Sachdeva, Ruchira; Gower, Charlotte; Ramsay, Mary; Bernal, Jamie Lopez			Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	NATURE MEDICINE			English	Article								Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case-control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation. Outcomes were symptomatic coronavirus disease 2019 (COVID-19) and hospitalization. The relative effectiveness against symptomatic disease 14-34 days after a BNT162b2 or mRNA-1273 (Moderna) booster after a ChAdOx1-S (AstraZeneca) and BNT162b2 as a primary course ranged from around 85% to 95%. Absolute vaccine effectiveness ranged from 94% to 97% and was similar in all age groups. Limited waning was seen 10 or more weeks after the booster. Against hospitalization or death, absolute effectiveness of a BNT162b2 booster ranged from around 97% to 99% in all age groups irrespective of the primary course, with no evidence of waning up to 10 weeks. This study provides real-world evidence of substantially increased protection from the booster vaccine dose against mild and severe disease irrespective of the primary course. A test-negative case-control analysis of data from the National Immunisation Management System in England demonstrates significant levels of increased protection against hospitalization or death from COVID with mRNA booster vaccines following a primary two-dose course of either ChAdOx1-S or BNT162b2 vaccines.	[Andrews, Nick; Stowe, Julia; Kirsebom, Freja; Toffa, Samuel; Sachdeva, Ruchira; Gower, Charlotte; Ramsay, Mary; Bernal, Jamie Lopez] UK Hlth Secur Agcy, London, England; [Andrews, Nick; Stowe, Julia; Ramsay, Mary; Bernal, Jamie Lopez] London Sch Hyg & Trop Med, NIHR Hlth Protect Res Unit Vaccines & Immunisat, London, England; [Bernal, Jamie Lopez] Imperial Coll London, NIHR Hlth Protect Res Unit Resp Infect, London, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Bernal, JL (corresponding author), UK Hlth Secur Agcy, London, England.; Bernal, JL (corresponding author), London Sch Hyg & Trop Med, NIHR Hlth Protect Res Unit Vaccines & Immunisat, London, England.; Bernal, JL (corresponding author), Imperial Coll London, NIHR Hlth Protect Res Unit Resp Infect, London, England.	Jamie.LopezBernal2@phe.gov.uk		Lopez Bernal, Jamie/0000-0002-1301-5653; Stowe, Julia/0000-0002-3999-6461				Abu-Raddad LJ, 2021, JAMA-J AM MED ASSOC, V326, P1930, DOI 10.1001/jama.2021.19623; Amirthalingam G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27410-5; Andrews N, 2022, NEW ENGL J MED, V386, P340, DOI 10.1056/NEJMoa2115481; [Anonymous], 2021, JCVI STATEMENT REGAR; Arbel R, 2021, NEW ENGL J MED, V385, P2413, DOI 10.1056/NEJMoa2115624; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Barda N, 2021, LANCET, V398, P2093, DOI 10.1016/S0140-6736(21)02249-2; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Hyams C, 2021, LANCET INFECT DIS, V21, P1539, DOI 10.1016/S1473-3099(21)00330-3; Ismail S. A., 2020, LANCET INFECT DIS, DOI [10.1101/2020.08.21.20178574, DOI 10.1016/S1473-3099(20)30882-3]; Israel A, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj-2021-067873; Mizrahi B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26672-3; Munro APS, 2021, LANCET, V398, P2258, DOI 10.1016/S0140-6736(21)02717-3; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2	18	84	84	3	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					831	+		10.1038/s41591-022-01699-1	http://dx.doi.org/10.1038/s41591-022-01699-1		JAN 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35045566	Green Published, hybrid			2022-12-27	WOS:000767748700001
J	Liang, TJ				Liang, T. Jake			Hepatitis B: a new weapon against an old enemy	NATURE MEDICINE			English	Editorial Material							NATURAL-HISTORY; DECLINE	New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B-a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.	[Liang, T. Jake] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, TJ (corresponding author), NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA.	jakel@bdg10.niddk.nih.gov						Allweiss L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060156; Bertoletti A, 2012, GUT, V61, P1754, DOI 10.1136/gutjnl-2011-301073; Chen CJ, 2011, J GASTROEN HEPATOL, V26, P628, DOI 10.1111/j.1440-1746.2011.06695.x; Junt T, 2015, NAT REV IMMUNOL, V15, P529, DOI 10.1038/nri3875; Loomba R, 2017, GASTROENTEROLOGY, V152, P1297, DOI 10.1053/j.gastro.2017.02.009; Raimondo G, 2019, J HEPATOL, V71, P397, DOI 10.1016/j.jhep.2019.03.034; Vaillant A, 2021, GASTROENTEROLOGY, V160, P967, DOI 10.1053/j.gastro.2020.09.020; van den Berg F, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080851; Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Xia YC, 2019, GASTROENTEROLOGY, V156, P311, DOI 10.1053/j.gastro.2018.07.057; Yuen M.-F., NAT MED, DOI [10.1038/s41591-021-01513-4, DOI 10.1038/S41591-021-01513-4]	11	1	1	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1672	1673		10.1038/s41591-021-01512-5	http://dx.doi.org/10.1038/s41591-021-01512-5		OCT 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34642493				2022-12-27	WOS:000706587600009
J	Matthews, RP; Patel, M; Barrett, SE; Haspeslagh, L; Reynders, T; Zhang, SJ; Rottey, S; Goodey, A; Vargo, RC; Grobler, JA; Stoch, SA; Iwamoto, M				Matthews, Randolph P.; Patel, Munjal; Barrett, Stephanie E.; Haspeslagh, Liesbeth; Reynders, Tom; Zhang, Saijuan; Rottey, Sylvie; Goodey, Adrian; Vargo, Ryan C.; Grobler, Jay A.; Stoch, S. Aubrey; Iwamoto, Marian			Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial	NATURE MEDICINE			English	Article							INFECTION; PREVENTION; WOMEN; MEN	A subdermal implant of the HIV-1 antiretroviral islatravir delivers sustained drug release over 12 weeks in humans. Islatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that is in development for the prevention and treatment of HIV-1. We conducted a randomized, double-blind, placebo-controlled, phase 1 trial in adults without HIV-1 infection. Participants received islatravir or placebo subdermal implants for 12 weeks and were monitored throughout this period and after implant removal. The co-primary end points were safety and tolerability of the islatravir implant and pharmacokinetics, including concentration at day 85, of islatravir triphosphate in peripheral blood mononuclear cells (PBMCs). Secondary end points included additional pharmacokinetic parameters for islatravir triphosphate in PBMCs and the plasma pharmacokinetic profile of islatravir. Based on preclinical data, two doses were assessed: 54 mg (n = 8, two placebo) and 62 mg (n = 8, two placebo). The most frequently reported adverse events were mild-to-moderate implant-site reactions (induration, hematoma, pain). Throughout the 12-week trial, geometric mean islatravir triphosphate concentrations were above a pharmacokinetic threshold of 0.05 pmol per 10(6) PBMCs, which was estimated to provide therapeutic reverse transcriptase inhibition (concentration at day 85 (percentage of geometric coefficient of variation): 54 mg, 0.135 pmol per 10(6) cells (27.3); 62 mg, 0.272 pmol per 10(6) cells (45.2)). Islatravir implants at both doses were safe and resulted in mean concentrations above the pharmacokinetic threshold through 12 weeks, warranting further investigation of islatravir implants as a potential HIV prevention strategy.	[Matthews, Randolph P.; Patel, Munjal; Barrett, Stephanie E.; Zhang, Saijuan; Goodey, Adrian; Vargo, Ryan C.; Grobler, Jay A.; Stoch, S. Aubrey; Iwamoto, Marian] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Haspeslagh, Liesbeth; Reynders, Tom] MSD Belgium, Brussels, Belgium; [Rottey, Sylvie] Ghent Univ Hosp, Ghent, Belgium	Merck & Company; Ghent University; Ghent University Hospital	Matthews, RP (corresponding author), Merck & Co Inc, Kenilworth, NJ 07033 USA.	Randolph.Matthews@merck.com		Patel, Munjal/0000-0001-6892-0899	Merck Sharp Dohme (MSD); MSD	Merck Sharp Dohme (MSD)(Merck & Company); MSD	Funding for this research was provided by Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co. We thank the participants and clinical research staff who participated in this trial. MSD pharmacokinetics, pharmacodynamics and drug metabolism scientists (L. Sun, I. Xie, B. Lu, R. Valesky, M. Lyman, K. Fillgrove and M. Anderson) and early clinical scientists (V. Weissler and G. Chen) are acknowledged for their contribution to the study. Additional statistical support was provided by Y. Liu (MSD). Medical writing and/or editorial assistance was provided by Y.-M. Ching in accordance with good publication practice guidelines. This assistance was funded by MSD.	Adams K, 2009, J MIDWIFERY WOM HEAL, V54, P142, DOI 10.1016/j.jmwh.2008.09.004; Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Barrett SE, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01058-18; Coelho LE, 2019, LANCET HIV, V6, pE788, DOI 10.1016/S2352-3018(19)30238-3; Cottrell ML, 2019, CLIN INFECT DIS, V69, P2201, DOI 10.1093/cid/ciz290; Cottrell ML, 2016, J INFECT DIS, V214, P55, DOI 10.1093/infdis/jiw077; Daniels Kimberly, 2020, NCHS Data Brief, P1; Delany-Moretlwe S, 2018, LANCET INFECT DIS, V18, P1241, DOI 10.1016/s1473-3099(18)30428-6; DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2019, GUIDELINES USE ANTIR; European AIDS Clinical Society, 2020, GUIDELINES MANAGEMEN; Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145; Gandhi M, 2015, J INFECT DIS, V212, P1402, DOI 10.1093/infdis/jiv239; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grobler J, 2018, J INT AIDS SOC, V21; Grobler J. A., 2016, CROI; Grobler J. A., 2019, CROI; Gunawardana M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.569373; Johnson AR, 2021, EXPERT OPIN DRUG DEL, V18, P577, DOI 10.1080/17425247.2021.1856072; Johnson L., 2016, METHODS ASSESSING AD; Joint United Nations Programme on HIV/AIDS, 2021, FACT SHEET 2021; Li LY, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111057; Liu AY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0083736, 10.1371/journal.pone.0095291]; Mansour D, 2010, EUR J CONTRACEP REPR, V15, pS19, DOI 10.3109/13625187.2010.532999; Markowitz M., 2020, CROI; Markowitz M, 2020, CURR OPIN HIV AIDS, V15, P27, DOI 10.1097/COH.0000000000000599; Markowitz M, 2020, J INFECT DIS, V221, P1398, DOI 10.1093/infdis/jiz271; Markowitz M, 2018, CURR OPIN HIV AIDS, V13, P294, DOI 10.1097/COH.0000000000000467; Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; Matthews R. P., 2021, CROI; Matthews RP, 2021, CTS-CLIN TRANSL SCI, V14, P1935, DOI 10.1111/cts.13048; Matthews RP., 2018, TOP ANTIVIR MED, V26; Michailidis E, 2014, J BIOL CHEM, V289, P24533, DOI 10.1074/jbc.M114.562694; Owens DK, 2019, JAMA-J AM MED ASSOC, V321, P2203, DOI 10.1001/jama.2019.6390; Patel M., 2021, CROI; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; Pons-Faudoa FP, 2019, J CONTROL RELEASE, V306, P89, DOI 10.1016/j.jconrel.2019.05.037; Ramdhan RC, 2018, CUREUS, V10, DOI 10.7759/cureus.2132; Reynolds SJ, 2011, AIDS, V25, P473, DOI 10.1097/QAD.0b013e3283437c2b; Riddell J, 2018, JAMA-J AM MED ASSOC, V319, P1261, DOI 10.1001/jama.2018.1917; Rudd D. J., 2020, CROI; Salie ZL, 2016, P NATL ACAD SCI USA, V113, P9274, DOI 10.1073/pnas.1605223113; Schurmann D, 2020, LANCET HIV, V7, pE164, DOI 10.1016/S2352-3018(19)30372-8; Stoddart CA, 2015, ANTIMICROB AGENTS CH, V59, P4190, DOI 10.1128/AAC.05036-14; U.S. Food and Drug Administration, 2020, NEXPL ET IMPL PRESCR; U.S. Food and Drug Administration, 2021, DESC EMTR TEN AL PRE; US Public Health Service, 2017, PREEXP PROPH PREV HI, DOI DOI 10.1016/S0040-4039(01)91800-3; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Zhu W., 2019, 1 IN HUMAN TRIAL MK	50	20	20	3	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1712	+		10.1038/s41591-021-01479-3	http://dx.doi.org/10.1038/s41591-021-01479-3		OCT 2021	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34608329				2022-12-27	WOS:000703378900005
J	Olusanya, JO; Ubogu, OI; Njokanma, FO; Olusanya, BO				Olusanya, Jacob O.; Ubogu, Olufunmilayo I.; Njokanma, Fidelis O.; Olusanya, Bolajoko O.			Transforming global health through equity-driven funding	NATURE MEDICINE			English	Editorial Material							POLITICAL PRIORITY; CARE	Black people living in Africa must be involved in setting the priorities for global health research, policies and programs that affect their daily lives, in order to move away from a funding culture that fosters colonialism, racism and white supremacy.	[Olusanya, Jacob O.; Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Lagos, Nigeria; [Ubogu, Olufunmilayo I.] Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa; [Njokanma, Fidelis O.] Lagos State Univ, Dept Pediat & Child Hlth, Coll Med, Lagos, Nigeria	University of Witwatersrand; Lagos State University	Olusanya, BO (corresponding author), Ctr Hlth Start Initiat, Lagos, Nigeria.	bolajoko.olusanya@uclmail.net	Njokanma, Fidelis Olisamedua/CAG-6106-2022; Olusanya, Bolajoko/F-4504-2012	Njokanma, Fidelis Olisamedua/0000-0003-2643-7123; Olusanya, Bolajoko/0000-0002-3826-0583; Olusanya, Jacob/0000-0002-1566-9554				[Anonymous], 2020, NAT MED, V26, P985, DOI 10.1038/s41591-020-0993-2; [Anonymous], GLOB HLTH DAT EXCH; Arregoces L, 2019, ARCH DIS CHILD, V104, pS34, DOI 10.1136/archdischild-2018-315429; Chang AY, 2019, LANCET, V393, P2233, DOI 10.1016/S0140-6736(19)30841-4; Dhillon RS, 2018, NEW ENGL J MED, V378, P1374, DOI 10.1056/NEJMp1800883; Erondu NA, 2021, NAT MED, V27, P742, DOI 10.1038/s41591-021-01307-8; Evans MK, 2020, NEW ENGL J MED, V383, P274, DOI 10.1056/NEJMe2021693; Frenk J, 2013, NEW ENGL J MED, V368, P936, DOI 10.1056/NEJMra1109339; Khan M, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005604; McGuire JW, 2006, WORLD DEV, V34, P405, DOI 10.1016/j.worlddev.2005.08.004; Ogbo FA, 2021, BMJ GLOB HEALTH, V6, P006200, DOI [10.1136/bmjgh-2021-006200, DOI 10.1136/BMJGH-2021-006200]; Olusanya BO, 2018, LANCET CHILD ADOLESC, V2, P772, DOI 10.1016/S2352-4642(18)30281-5; Ottersen OP, 2014, LANCET, V383, P630, DOI 10.1016/S0140-6736(13)62407-1; Packard R.M., 2016, HIST GLOBAL HLTH INT; Shiffman J, 2007, LANCET, V370, P1370, DOI 10.1016/S0140-6736(07)61579-7; Smith SL, 2016, SOC SCI MED, V166, P86, DOI 10.1016/j.socscimed.2016.08.013; United Nations Human Rights High Commission, 2019, WORK GROUP EXP PEOPL	17	11	11	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1136	1138		10.1038/s41591-021-01422-6	http://dx.doi.org/10.1038/s41591-021-01422-6		JUN 2021	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34168335	Bronze			2022-12-27	WOS:000665683600002
J	Saxena, AR; Gorman, DN; Esquejo, RM; Bergman, A; Chidsey, K; Buckeridge, C; Griffith, DA; Kim, AM				Saxena, Aditi R.; Gorman, Donal N.; Esquejo, Ryan M.; Bergman, Arthur; Chidsey, Kristin; Buckeridge, Clare; Griffith, David A.; Kim, Albert M.			Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial	NATURE MEDICINE			English	Article							LIRAGLUTIDE; MELLITUS; DISCOVERY	Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to injectable peptidic GLP-1R agonists in a humanized mouse model. We then completed a placebo-controlled, randomized, double-blind, multiple ascending-dose phase 1 study (NCT03538743), in which we enrolled 98 patients with T2D on background metformin and randomized them to receive multiple ascending doses of danuglipron or placebo for 28 d, across eight cohorts. The primary outcomes were assessment of adverse events (AEs), safety laboratory tests, vital signs and 12-lead electrocardiograms. Most AEs were mild, with nausea, dyspepsia and vomiting most commonly reported. There were no clinically meaningful AEs in laboratory values across groups. Heart rate generally increased with danuglipron treatment at day 28, but no heart-rate AEs were reported. Systolic blood pressure was slightly decreased and changes in diastolic blood pressure were similar with danuglipron treatment at day 28, compared with placebo. There were no clinically meaningful electrocardiogram findings. In this study in T2D, danuglipron was generally well tolerated, with a safety profile consistent with the mechanism of action of GLP-1R agonism.	[Saxena, Aditi R.; Esquejo, Ryan M.; Bergman, Arthur; Chidsey, Kristin; Buckeridge, Clare; Griffith, David A.; Kim, Albert M.] Pfizer Worldwide Res & Dev, Cambridge, MA 92101 USA; [Gorman, Donal N.] Pfizer Worldwide Res & Dev, Cambridge, England	Pfizer; Pfizer	Saxena, AR (corresponding author), Pfizer Worldwide Res & Dev, Cambridge, MA 92101 USA.	aditi.saxena@pfizer.com		Kim, Albert/0000-0002-5269-2155; Griffith, David/0000-0002-7592-2478	Pfizer Inc.	Pfizer Inc.(Pfizer)	This study was sponsored by Pfizer Inc. We thank the clinical study participants, the investigators and site coordinators. We thank J. Garren for providing support for nonclinical statistical analysis. Medical writing support, under the direction of the authors, was provided by E. Comeau, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc. in accordance with Good Publication Practice guidelines.	Ali MK, 2013, NEW ENGL J MED, V368, P1613, DOI 10.1056/NEJMsa1213829; Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS66, DOI 10.2337/dc20-S006; [Anonymous], RYBELSUS SEM PACK IN; Aroda VR, 2018, DIABETES OBES METAB, V20, P22, DOI 10.1111/dom.13162; Buckley ST, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar7047; Cooke CE, 2010, CURR MED RES OPIN, V26, P231, DOI 10.1185/03007990903421994; Coskun T, 2018, MOL METAB, V18, P3, DOI 10.1016/j.molmet.2018.09.009; Deane AM, 2010, J CLIN ENDOCR METAB, V95, P215, DOI 10.1210/jc.2009-1503; Drucker DJ, 2017, J CLIN INVEST, V127, P4217, DOI 10.1172/JCI97233; Drucker DJ, 2016, CELL METAB, V24, P15, DOI 10.1016/j.cmet.2016.06.009; Flint A, 1998, J CLIN INVEST, V101, P515, DOI 10.1172/JCI990; Fonseca VA, 2019, J CLIN ENDOCR METAB, V104, P4078, DOI 10.1210/jc.2018-02685; Gerstein HC, 2019, LANCET, V394, P121, DOI 10.1016/S0140-6736(19)31149-3; Griffith D.A., SMALL MOL ORAL AGONI, DOI [10.1101/2020.09.29.319483(2020, DOI 10.1101/2020.09.29.319483(2020]; Holko P, 2018, EUR J GASTROEN HEPAT, V30, P174, DOI 10.1097/MEG.0000000000001031; International Diabetes Federation, IDF DIABETES ATLAS, V10th; Jun LS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093746; Kjellsson MC, 2013, J CLIN PHARMACOL, V53, P589, DOI 10.1002/jcph.86; KREYMANN B, 1987, LANCET, V2, P1300; Lastra G, 2014, ENDOCRIN METAB CLIN, V43, P103, DOI 10.1016/j.ecl.2013.09.005; Lean MEJ, 2014, INT J OBESITY, V38, P689, DOI 10.1038/ijo.2013.149; Liakos A, 2019, DIABETES OBES METAB, V21, P517, DOI 10.1111/dom.13541; Lin PH, 2003, AM J CLIN NUTR, V77, P639, DOI 10.1093/ajcn/77.3.639; Lledo-Garcia R, 2013, J PHARMACOKINET PHAR, V40, P129, DOI 10.1007/s10928-012-9289-6; Lovshin JA, 2015, DIABETES CARE, V38, P132, DOI 10.2337/dc14-1958; Marso SP, 2016, NEW ENGL J MED, V375, P1834, DOI 10.1056/NEJMoa1607141; Montvida O, 2018, DIABETES CARE, V41, P69, DOI 10.2337/dc17-1414; Nathan DM, 2008, DIABETES CARE, V31, P1473, DOI 10.2337/dc08-0545; Nauck MA, 1997, AM J PHYSIOL-ENDOC M, V273, pE981, DOI 10.1152/ajpendo.1997.273.5.E981; Nauck MA, 2016, DIABETES CARE, V39, P231, DOI 10.2337/dc15-0165; Shankar SS, 2016, DIABETES CARE, V39, P1602, DOI 10.2337/dc15-0931	31	14	16	10	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1079	+		10.1038/s41591-021-01391-w	http://dx.doi.org/10.1038/s41591-021-01391-w		JUN 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34127852				2022-12-27	WOS:000661414900002
J	Simpson, CR; Shi, T; Vasileiou, E; Katikireddi, SV; Kerr, S; Moore, E; McCowan, C; Agrawal, U; Shah, SA; Ritchie, LD; Murray, J; Pan, J; Bradley, DT; Stock, SJ; Wood, R; Chuter, A; Beggs, J; Stagg, HR; Joy, M; Tsang, RSM; de Lusignan, S; Hobbs, R; Lyons, RA; Torabi, F; Bedston, S; O'Leary, M; Akbari, A; McMenamin, J; Robertson, C; Sheikh, A				Simpson, C. R.; Shi, T.; Vasileiou, E.; Katikireddi, S. V.; Kerr, S.; Moore, E.; McCowan, C.; Agrawal, U.; Shah, S. A.; Ritchie, L. D.; Murray, J.; Pan, J.; Bradley, D. T.; Stock, S. J.; Wood, R.; Chuter, A.; Beggs, J.; Stagg, H. R.; Joy, M.; Tsang, R. S. M.; de Lusignan, S.; Hobbs, R.; Lyons, R. A.; Torabi, F.; Bedston, S.; O'Leary, M.; Akbari, A.; McMenamin, J.; Robertson, C.; Sheikh, A.			First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	NATURE MEDICINE			English	Article							VACCINATION; PURPURA	New data from the EAVE II cohort in Scotland suggests that a first dose of the ChAdOx1 nCoV-19 vaccine might be associated with a small increase in the risk of idiopathic thrombocytopenic purpura between 0 and 27 d after vaccination. Reports of ChAdOx1 vaccine-associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse events using a nested incident-matched case-control study and a confirmatory self-controlled case series (SCCS) analysis. An association was found between ChAdOx1 vaccination and idiopathic thrombocytopenic purpura (ITP) (0-27 d after vaccination; adjusted rate ratio (aRR) = 5.77, 95% confidence interval (CI), 2.41-13.83), with an estimated incidence of 1.13 (0.62-1.63) cases per 100,000 doses. An SCCS analysis confirmed that this was unlikely due to bias (RR = 1.98 (1.29-3.02)). There was also an increased risk for arterial thromboembolic events (aRR = 1.22, 1.12-1.34) 0-27 d after vaccination, with an SCCS RR of 0.97 (0.93-1.02). For hemorrhagic events 0-27 d after vaccination, the aRR was 1.48 (1.12-1.96), with an SCCS RR of 0.95 (0.82-1.11). A first dose of ChAdOx1 was found to be associated with small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events. The attenuation of effect found in the SCCS analysis means that there is the potential for overestimation of the reported results, which might indicate the presence of some residual confounding or confounding by indication. Public health authorities should inform their jurisdictions of these relatively small increased risks associated with ChAdOx1. No positive associations were seen between BNT162b2 and thrombocytopenic, thromboembolic and hemorrhagic events.	[Simpson, C. R.] Victoria Univ Wellington, Sch Hlth, Wellington Fac Hlth, Wellington, New Zealand; [Simpson, C. R.; Shi, T.; Vasileiou, E.; Kerr, S.; Shah, S. A.; Stock, S. J.; Wood, R.; Stagg, H. R.; Sheikh, A.] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Katikireddi, S. V.] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Moore, E.; Murray, J.; Wood, R.; O'Leary, M.; McMenamin, J.; Robertson, C.] Publ Hlth Scotland, Glasgow, Lanark, Scotland; [McCowan, C.; Agrawal, U.] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland; [Ritchie, L. D.] Univ Aberdeen, Ctr Acad Primary Care, Aberdeen, Scotland; [Pan, J.; Robertson, C.] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland; [Bradley, D. T.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Bradley, D. T.] Publ Hlth Agcy, Belfast, Antrim, North Ireland; [Chuter, A.; Beggs, J.; Sheikh, A.] BREATHE Hub, Hlth Data Res UK, Edinburgh, Midlothian, Scotland; [Joy, M.; Tsang, R. S. M.; de Lusignan, S.; Hobbs, R.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Lyons, R. A.; Torabi, F.; Bedston, S.; Akbari, A.] Swansea Univ, Populat Data Sci, Swansea, W Glam, Wales	Victoria University Wellington; University of Edinburgh; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of St Andrews; University of Aberdeen; University of Strathclyde; Queens University Belfast; University of Oxford; Swansea University	Sheikh, A (corresponding author), Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.; Sheikh, A (corresponding author), BREATHE Hub, Hlth Data Res UK, Edinburgh, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Tsang, Ruby S. M./D-5111-2014; Chuter, Antony/GNO-9976-2022; Bradley, Declan/AFN-7904-2022; Simpson, Colin R/L-7180-2014; Bradley, Declan T/AFO-1353-2022	Tsang, Ruby S. M./0000-0002-2520-526X; Chuter, Antony/0000-0002-0646-5939; Simpson, Colin R/0000-0002-5194-8083; Akbari, Ashley/0000-0003-0814-0801; Torabi, Fatemeh/0000-0002-5853-4625; Shi, Ting/0000-0002-4101-4535; Bradley, Declan/0000-0003-1468-1823; Agrawal, Utkarsh/0000-0001-5181-6120; Katikireddi, Srinivasa/0000-0001-6593-9092; McCowan, Colin/0000-0002-9466-833X; Shah, Syed Ahmar/0000-0001-5672-0443; Moore, Emily/0000-0002-9634-3299; Wood, Rachael/0000-0003-4453-623X	Medical Research Council [MC_PC_19075]; BREATHE: the Health Data Research Hub for Respiratory Health through the UK Research and Innovation Industrial Strategy Challenge Fund [MC_PC_19004]; Public Health Scotland; Community Health and Social Care Directorate of the Scottish Government; National Institute for Health Research (NIHR) School for Primary Care Research; NIHR Collaboration for Leadership in Applied Health Research and Care Oxford; NIHR Oxford BREATHE Centre	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BREATHE: the Health Data Research Hub for Respiratory Health through the UK Research and Innovation Industrial Strategy Challenge Fund; Public Health Scotland; Community Health and Social Care Directorate of the Scottish Government; National Institute for Health Research (NIHR) School for Primary Care Research(National Institute for Health Research (NIHR)); NIHR Collaboration for Leadership in Applied Health Research and Care Oxford; NIHR Oxford BREATHE Centre	EAVE II is funded by the Medical Research Council (MC_PC_19075) with the support of BREATHE: the Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and the Community Health and Social Care Directorate of the Scottish Government. R.H. acknowledges support from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford and the NIHR Oxford BREATHE Centre. We thank D. Kelly from Albasoft Limited for support with making primary care data available and J. Pickett, W. Inglis-Humphrey, V. Hammersley, M. Georgiou, L. Brook and L. Gonzalez Rienda for support with project management and administration. We thank the EAVE II Public Advisory Group. Our thanks to J. Quint, R. Al-Shahi Salman and Q. Hill for their help with reviewing code lists. Our thanks also to G. Schiff and L. Smeeth for reviewing this work before submission to the UK's Medicines & Healthcare products Regulatory Agency.	American Society of Hematology, THROMB THROMB SYNDR; [Anonymous], 2020, COVID 19 MRNA VACCIN; [Anonymous], 2020, COVID 19 VACCINE MOD; [Anonymous], 2021, BBC; [Anonymous], 2020, COVID 19 VACCINE CHA; Arnold DM, 2017, BLOOD ADV, V1, P2414, DOI 10.1182/bloodadvances.2017010942; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bhattacharjee Sukrita, 2020, SN Compr Clin Med, V2, P2048, DOI 10.1007/s42399-020-00521-8; Boonyawat K, 2020, THROMB J, V18, DOI 10.1186/s12959-020-00248-5; Cecinati V, 2013, HUM VACC IMMUNOTHER, V9, P1158, DOI 10.4161/hv.23601; Centers for Disease Control and Prevention, 2020, DAT STAT VEN THROMB; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; Cresswell Kathrin, 2017, J Innov Health Inform, V23, P904, DOI 10.14236/jhi.v23i4.904; eDRIS Team, 2018, RES GUID REQ OUTP SA; European Medicines Agency, 2021, ASTRAZENECAS COVID 1; European Medicines Agency (EMA), 2021, COVID 19 VACC ASTRAZ; European Medicines Agency Pharmacovigilance Risk Assessment Committee, SIGN ASS REP EMB THR; Glanz JM, 2006, J CLIN EPIDEMIOL, V59, P808, DOI 10.1016/j.jclinepi.2005.11.012; Greinacher A, 2017, J THROMB HAEMOST, V15, P2099, DOI 10.1111/jth.13813; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Joint Committee on Vaccination and Immunisation, 2020, PRIOR GROUPS COR COV; Joint Committee on Vaccination and Immunisation, 2021, JCVI ADV COVID 19 VA; Joint Committee on Vaccination and Immunisation, 2021, JCVI STAT US ASTRAZE; Kewan T, 2021, TRANSFUSION, V61, P2014, DOI 10.1111/trf.16368; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Medicines & Healthcare Products Regulatory Agency, 2021, NEW JCVI ADV US ASTR; Medicines & Healthcare Products Regulatory Agency, 2021, COR VACC WEEKL SUMM; National Services Scotland, NAT DAT CAT RAP PREL; Paul Ehrlich Institut, 2021, COVID 19 VACC ASTRAZ; Perricone C, 2014, IMMUNOL RES, V60, P226, DOI 10.1007/s12026-014-8597-x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Public Benefit and Privacy Panel for Health and Social Care, 2020, CONST TERMS REF; R Code Team, R LANG ENV STAT COMP; Schifferli A, 2021, BLOOD ADV, V5, P1617, DOI 10.1182/bloodadvances.2020003004; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Simpson CR, 2020, LANCET INFECT DIS, V20, P767, DOI 10.1016/S1473-3099(20)30398-4; Simpson Colin R, 2020, BMJ Open, V10, pe039097, DOI 10.1136/bmjopen-2020-039097; Simpson CR, 2019, LANCET INFECT DIS, V19, pE295, DOI 10.1016/S1473-3099(18)30786-2; Simpson CR, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014200; Tarawneh O, 2021, AM J HEMATOL, V96, pE133, DOI 10.1002/ajh.26106; Toom S, 2021, AM J HEMATOL, V96, pE134, DOI 10.1002/ajh.26128; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699	49	127	128	3	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1290	+		10.1038/s41591-021-01408-4	http://dx.doi.org/10.1038/s41591-021-01408-4		JUN 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34108714	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000659384400001
J	Rozeman, EA; Hoefsmit, EP; Reijers, ILM; Saw, RPM; Versluis, JM; Krijgsman, O; Dimitriadis, P; Sikorska, K; van de Wiel, BA; Eriksson, H; Gonzalez, M; Acosta, AT; Grijpink-Ongering, LG; Shannon, K; Haanen, JBAG; Stretch, J; Ch'ng, S; Nieweg, OE; Mallo, HA; Adriaansz, S; Kerkhoven, RM; Cornelissen, S; Broeks, A; Klop, WMC; Zuur, CL; van Houdt, WJ; Peeper, DS; Spillane, AJ; van Akkooi, ACJ; Scolyer, RA; Schumacher, TNM; Menzies, AM; Long, GV; Blank, CU				Rozeman, E. A.; Hoefsmit, E. P.; Reijers, I. L. M.; Saw, R. P. M.; Versluis, J. M.; Krijgsman, O.; Dimitriadis, P.; Sikorska, K.; van de Wiel, B. A.; Eriksson, H.; Gonzalez, M.; Torres Acosta, A.; Grijpink-Ongering, L. G.; Shannon, K.; Haanen, J. B. A. G.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.; Mallo, H. A.; Adriaansz, S.; Kerkhoven, R. M.; Cornelissen, S.; Broeks, A.; Klop, W. M. C.; Zuur, C. L.; van Houdt, W. J.; Peeper, D. S.; Spillane, A. J.; van Akkooi, A. C. J.; Scolyer, R. A.; Schumacher, T. N. M.; Menzies, A. M.; Long, G. V.; Blank, C. U.			Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	NATURE MEDICINE			English	Article							CLINICAL-RESPONSE; NIVOLUMAB; EFFICACY; THERAPY; CHECKPOINTS; IPILIMUMAB; EXPRESSION; SIGNATURES; CELLS; VEGF	Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN () and phase 2 OpACIN-neo () studies(1,2). While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of the patients with a pathologic response (n = 7/9 patients) in the OpACIN study had relapsed. In OpACIN-neo (n = 86), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P < 0.001). High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-gamma score) were associated with pathologic response and low risk of relapse; pRR was 100% in patients with high IFN-gamma score/high TMB; patients with high IFN-gamma score/low TMB or low IFN-gamma score/high TMB had pRRs of 91% and 88%; while patients with low IFN-gamma score/low TMB had a pRR of only 39%. These data demonstrate long-term benefit in patients with a pathologic response and show the predictive potential of TMB and IFN-gamma score. Our findings provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma.	[Rozeman, E. A.; Reijers, I. L. M.; Versluis, J. M.; Haanen, J. B. A. G.; Mallo, H. A.; Adriaansz, S.; Blank, C. U.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Hoefsmit, E. P.; Krijgsman, O.; Dimitriadis, P.; Haanen, J. B. A. G.; Peeper, D. S.; Schumacher, T. N. M.; Blank, C. U.] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands; [Saw, R. P. M.; Gonzalez, M.; Shannon, K.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.; Spillane, A. J.; Scolyer, R. A.; Menzies, A. M.; Long, G. V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Saw, R. P. M.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.; Spillane, A. J.] Mater Hosp, Dept Surg, Sydney, NSW, Australia; [Saw, R. P. M.; Shannon, K.; Stretch, J.; Ch'ng, S.; Nieweg, O. E.] Royal Prince Alfred Hosp, Dept Surg, Sydney, NSW, Australia; [Krijgsman, O.; Peeper, D. S.; Schumacher, T. N. M.] Oncode Inst, Utrecht, Netherlands; [Sikorska, K.; Torres Acosta, A.; Grijpink-Ongering, L. G.] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands; [van de Wiel, B. A.] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands; [Eriksson, H.] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Eriksson, H.] Karolinska Univ Hosp, Theme Canc, Skin Canc Ctr, Dept Oncol, Stockholm, Sweden; [Kerkhoven, R. M.] Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands; [Cornelissen, S.; Broeks, A.] Netherlands Canc Inst, Core Facil Mol Pathol & Biobanking, Amsterdam, Netherlands; [Klop, W. M. C.; Zuur, C. L.; van Houdt, W. J.; van Akkooi, A. C. J.] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands; [Spillane, A. J.] Royal North Shore Hosp, Breast & Melanoma Surg Unit, Sydney, NSW, Australia; [Scolyer, R. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Scolyer, R. A.] New South Wales Hlth Pathol, Sydney, NSW, Australia; [Menzies, A. M.; Long, G. V.] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia	Netherlands Cancer Institute; Netherlands Cancer Institute; Melanoma Institute Australia; University of Sydney; University of Sydney; Netherlands Cancer Institute; Netherlands Cancer Institute; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital	Blank, CU (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.; Blank, CU (corresponding author), Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands.	c.blank@nki.nl	Haanen, John/AAD-8534-2022; Shannon, Kerwin/AAP-8209-2021; Schumacher, Ton/Y-2432-2019; Scolyer, Richard/AAE-8511-2019; Haanen, John/AAD-8578-2022; Long, Georgina/C-1771-2013; Stretch AM D.Phil(Oxon), FRACS, Jonathan/M-7532-2014	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804; Scolyer, Richard/0000-0002-8991-0013; Long, Georgina/0000-0001-8894-3545; Ch'ng, Sydney/0000-0002-4011-1253; Hoefsmit, Esmee/0000-0002-3989-8175; Stretch AM D.Phil(Oxon), FRACS, Jonathan/0000-0002-2556-2005; Shannon, Kerwin/0000-0001-8538-3132; Versluis, Judith M./0000-0002-3423-9912; Dimitriadis, Petros/0000-0002-3546-285X	Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Medical Foundation at the University of Sydney; Cancer Institute New South Wales fellowship; Melanoma Institute Australia; NHMRC Practitioner Fellowship; Australian NHMRC program grant; Ainsworth Foundation; Fairfax Foundation	Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Medical Foundation at the University of Sydney; Cancer Institute New South Wales fellowship; Melanoma Institute Australia; NHMRC Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian NHMRC program grant(National Health and Medical Research Council (NHMRC) of Australia); Ainsworth Foundation; Fairfax Foundation	We thank the patients and their families for participating in the study. We thank all investigators and members of the clinical trial teams in Melanoma Institute Australia, the Netherlands Cancer Institute and the Karolinska Institutet; the Netherlands Cancer Institute-Antoni van Leeuwenhoek Core Facility Molecular Pathology & Biobanking for supplying biobank material and/or laboratory support; the Genomics Core Facility for their support regarding sequencing; and S. Vanhoutvin for financial management. We acknowledge A. Evans and B. Stegenga from Bristol Myers Squibb for scientific input and support. G.V.L. is supported by an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship and the Medical Foundation at the University of Sydney. A.M.M. is supported by Cancer Institute New South Wales fellowship and Melanoma Institute Australia. R.A.S. is supported by NHMRC Practitioner Fellowship. Support from an Australian NHMRC program grant (to G.V.L. and R.A.S.), the Ainsworth Foundation, the Fairfax Foundation and the Cameron family is also gratefully acknowledged. The authors also acknowledge assistance from colleagues at their various institutions.	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Ascierto PA, 2020, LANCET ONCOL, V21, P1465, DOI 10.1016/S1470-2045(20)30494-0; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Blank CU, 2020, J CLIN ONCOL, V38; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Bloemendal M, 2019, ANN SURG ONCOL, V26, P3945, DOI 10.1245/s10434-019-07274-2; Bourgeois-Daigneault MC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao1641; Brockwell NK, 2017, CANCER IMMUNOL RES, V5, P871, DOI 10.1158/2326-6066.CIR-17-0150; Brooks J, 2018, CANCER RES, V78, P475, DOI 10.1158/0008-5472.CAN-17-2415; Chae YK, 2019, ONCOLOGIST, V24, P820, DOI 10.1634/theoncologist.2018-0433; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dummer R, 2020, LANCET ONCOL, V21, P358, DOI 10.1016/S1470-2045(20)30062-0; Eggermont AMM, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.02110; Eggermont AMM, 2020, JAMA ONCOL, V6, P519, DOI 10.1001/jamaoncol.2019.5570; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Fancello L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0647-4; Hauschild A, 2018, J CLIN ONCOL, V36, P3441, DOI 10.1200/JCO.18.01219; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Lee JH, 2019, ANN ONCOL, V30, P815, DOI 10.1093/annonc/mdz075; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Mandala M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9584; Menzies AM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9503; O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641; Ott PA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00202; Rowe SP, 2018, MOL ONCOL, V12, P1661, DOI 10.1002/1878-0261.12373; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Yuan JD, 2014, CANCER IMMUNOL RES, V2, P127, DOI 10.1158/2326-6066.CIR-13-0163	39	80	79	4	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					256	+		10.1038/s41591-020-01211-7	http://dx.doi.org/10.1038/s41591-020-01211-7		FEB 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33558721				2022-12-27	WOS:000616056700002
J	Carvalho, T				Carvalho, Thiago			COVID-19-induced Kawasaki disease	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1807	1807		10.1038/s41591-020-01163-y	http://dx.doi.org/10.1038/s41591-020-01163-y			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288939	Bronze			2022-12-27	WOS:000596579200019
J	Puhach, O; Adea, K; Hulo, N; Sattonnet, P; Genecand, C; Iten, A; Jacquerioz, F; Kaiser, L; Vetter, P; Eckerle, I; Meyer, B				Puhach, Olha; Adea, Kenneth; Hulo, Nicolas; Sattonnet, Pascale; Genecand, Camille; Iten, Anne; Jacquerioz, Frederique; Kaiser, Laurent; Vetter, Pauline; Eckerle, Isabella; Meyer, Benjamin			Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	NATURE MEDICINE			English	Article								The infectious viral load of SARS-CoV-2 Omicron BA.1 is lower than that of Delta in symptomatic breakthrough infections of recipients of two doses of a COVID-19 vaccine, suggesting that the higher transmission of Omicron BA.1 is not linked to higher infectious viral load. Infectious viral load (VL) expelled as droplets and aerosols by infected individuals partly determines transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RNA VL measured by qRT-PCR is only a weak proxy for infectiousness. Studies on the kinetics of infectious VL are important to understand the mechanisms behind the different transmissibility of SARS-CoV-2 variants and the effect of vaccination on transmission, which allows guidance of public health measures. In this study, we quantified infectious VL in individuals infected with SARS-CoV-2 during the first five symptomatic days by in vitro culturability assay in unvaccinated or vaccinated individuals infected with pre-variant of concern (pre-VOC) SARS-CoV-2, Delta or Omicron BA.1. Unvaccinated individuals infected with pre-VOC SARS-CoV-2 had lower infectious VL than Delta-infected unvaccinated individuals. Full vaccination (defined as >2 weeks after receipt of the second dose during the primary vaccination series) significantly reduced infectious VL for Delta breakthrough cases compared to unvaccinated individuals. For Omicron BA.1 breakthrough cases, reduced infectious VL was observed only in boosted but not in fully vaccinated individuals compared to unvaccinated individuals. In addition, infectious VL was lower in fully vaccinated Omicron BA.1-infected individuals compared to fully vaccinated Delta-infected individuals, suggesting that mechanisms other than increased infectious VL contribute to the high infectiousness of SARS-CoV-2 Omicron BA.1. Our findings indicate that vaccines may lower transmission risk and, therefore, have a public health benefit beyond the individual protection from severe disease.	[Puhach, Olha; Adea, Kenneth; Sattonnet, Pascale; Eckerle, Isabella] Univ Geneva, Fac Med, Dept Microbiol & Mol Med, Geneva, Switzerland; [Hulo, Nicolas] Univ Geneva, Inst Genet & Genom, Serv Biomath & Biostat Anal, Geneva, Switzerland; [Genecand, Camille] Gen Directorate Hlth, Cantonal Hlth Serv, Geneva, Switzerland; [Iten, Anne] Geneva Univ Hosp, Serv Prevent & Infect Control, Directorate Med & Qual, Geneva, Switzerland; [Jacquerioz, Frederique; Kaiser, Laurent; Vetter, Pauline; Eckerle, Isabella] Geneva Univ Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland; [Jacquerioz, Frederique] Geneva Univ Hosp, Div Trop & Humanitarian Med, Geneva, Switzerland; [Jacquerioz, Frederique] Geneva Univ Hosp, Primary Care Div, Geneva, Switzerland; [Kaiser, Laurent; Vetter, Pauline] Univ Geneva, Geneva Univ Hosp, Div Lab Med, Lab Virol, Geneva, Switzerland; [Kaiser, Laurent; Vetter, Pauline] Univ Geneva, Fac Med, Geneva, Switzerland; [Kaiser, Laurent; Vetter, Pauline; Eckerle, Isabella] Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland; [Meyer, Benjamin] Univ Geneva, Ctr Vaccinol, Dept Pathol & Immunol, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Eckerle, I (corresponding author), Univ Geneva, Fac Med, Dept Microbiol & Mol Med, Geneva, Switzerland.; Vetter, P; Eckerle, I (corresponding author), Geneva Univ Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland.; Vetter, P (corresponding author), Univ Geneva, Geneva Univ Hosp, Div Lab Med, Lab Virol, Geneva, Switzerland.; Vetter, P (corresponding author), Univ Geneva, Fac Med, Geneva, Switzerland.; Vetter, P; Eckerle, I (corresponding author), Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland.; Meyer, B (corresponding author), Univ Geneva, Ctr Vaccinol, Dept Pathol & Immunol, Geneva, Switzerland.	pauline.vetter@hcuge.ch; Isabella.eckerle@hcuge.ch; benjamin.meyer@unige.ch	Meyer, Benjamin/F-3285-2018	Meyer, Benjamin/0000-0003-0601-3550; Vetter, Pauline/0000-0002-9902-5069; Kaiser, Laurent/0000-0002-0857-2252; Eckerle, Isabella/0000-0002-4850-7172	University Hospitals of Geneva	University Hospitals of Geneva	We thank all patients for their willingness to participate in our research. We thank the staff of the laboratory of virology from the University Hospitals of Geneva for their support. We would like to thank M. Essaidi-Laziosi for helpful advice and Y. Cambet, V. Jaquet and A. R. Corvaglia for technical assistance. We also thank E. Boehm for help with editing the manuscript.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Badu K, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.648660; Blazejewska P, 2011, VIROLOGY, V412, P36, DOI 10.1016/j.virol.2010.12.047; Brandal LT, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.50.2101147; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Case JB, 2020, VIROLOGY, V548, P39, DOI 10.1016/j.virol.2020.05.015; Centers for Disease Control and Prevention, 2021, MMWR-MORBID MORTAL W, V70; Centers for Disease Control and Prevention (CDC), 2018, HPV ASS CANC STAT; Chen PZ, 2021, ELIFE, V10, DOI 10.7554/eLife.70458; Chia PY, 2022, CLIN MICROBIOL INFEC, V28, DOI 10.1016/j.cmi.2021.11.010; Christian von Wintersdorff, PRIPRINTS, DOI [10.21203/rs.3.rs-777577/v1(2021), DOI 10.21203/RS.3.RS-777577/V1(2021)]; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055; Despres HW, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2116518119; Eggink Dirk, 2022, Euro Surveill, V27, DOI 10.2807/1560-7917.ES.2022.27.4.2101196; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Essaidi-Laziosi M, 2021, LANCET MICROBE, V2, pE571, DOI 10.1016/S2666-5247(21)00216-0; European Center For Disease Prevention Control, 2021, RAPID RISK ASSESSMEN, V14; Eyre DW, 2022, NEW ENGL J MED, V386, P744, DOI 10.1056/NEJMoa2116597; Harris RJ, 2021, NEW ENGL J MED, V385, P759, DOI 10.1056/NEJMc2107717; Hay J. A., 2022, VIRAL DYNAMICS DURAT, DOI [10.1101/2022.01.13.22269257v1, DOI 10.1101/2022.01.13.22269257V1]; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; Hui KPY, 2022, NATURE, V603, P715, DOI 10.1038/s41586-022-04479-6; Imai K., PREPRINT, DOI [10.1101/2021.11.29.21266980v1(2021), DOI 10.1101/2021.11.29.21266980V1(2021)]; Jefferson T, 2021, CLIN INFECT DIS, V73, pe3884, DOI [10.1093/cid/ciaa1764, DOI 10.1093/CID/CIAA1764]; Jones TC, 2021, SCIENCE, V373, P180, DOI 10.1126/science.abi5273; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kawasuji H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243597; Killingley B, 2022, NAT MED, V28, P1031, DOI 10.1038/s41591-022-01780-9; Kissler SM, 2021, NEW ENGL J MED, V385, P2489, DOI 10.1056/NEJMc2102507; Kuhlmann C, 2022, LANCET, V399, P625, DOI 10.1016/S0140-6736(22)00090-3; Levine-Tiefenbrun M, 2021, NAT MED, V27, P2108, DOI 10.1038/s41591-021-01575-4; Luo CH, 2022, CLIN INFECT DIS, V75, pE715, DOI 10.1093/cid/ciab986; Lyngse, 2022, PREPRINT, DOI [10.1101/2022.01.28.22270044v1, DOI 10.1101/2022.01.28.22270044V1]; Marc A, 2021, ELIFE, V10, DOI [10.7554/eLife.69302, 10.7554/eLife.69302.sa1, 10.7554/eLife.69302.sa2]; Marks M, 2021, LANCET INFECT DIS, V21, P629, DOI 10.1016/S1473-3099(20)30985-3; Migueres M., 2022, J INFECTION, V84, P7; Mostaghimi D, 2022, LANCET INFECT DIS, V22, pE52, DOI 10.1016/S1473-3099(21)00472-2; Peacock TP., 2022, SARS COV 2 VARIANT O, V1, P2021, DOI [DOI 10.1101/2021.12.31.474653V1, DOI 10.1101/2021.12.31.474653V1:BIOIRXIV]; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Pulliam JRC, 2022, SCIENCE, V376, P596, DOI 10.1126/science.abn4947; Sabine Yerly L. K., 2021, PROTOCOL SPECIFIC RT; Sentis C, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14050919; Shamier MC, 2021, VIROLOGICAL CHARACTE, DOI [10.1101/2021.08.20.21262158, DOI 10.1101/2021.08.20.21262158]; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Singanayagam A, 2022, LANCET INFECT DIS, V22, P183, DOI 10.1016/S1473-3099(21)00648-4; Takahashi Takehiro, 2020, medRxiv, DOI 10.1101/2020.06.06.20123414; Tani-Sassa C, 2022, J MED VIROL, V94, P1707, DOI 10.1002/jmv.27479; Teyssou E, 2021, J INFECTION, V83, pE1, DOI 10.1016/j.jinf.2021.08.027; Vetter P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00827-20; Wang YP, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101129; Wolf RC, 2020, NEUROPSYCHOBIOLOGY, V79, P335, DOI 10.1159/000505601; Wong Lok-Yin Roy, 2020, STAR Protoc, V1, P100169, DOI 10.1016/j.xpro.2020.100169; Xia S, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00349-z	54	52	53	10	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1491	+		10.1038/s41591-022-01816-0	http://dx.doi.org/10.1038/s41591-022-01816-0		APR 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35395151	Bronze, Green Submitted, Green Published			2022-12-27	WOS:000805524200001
J	Smith, M; Dai, AQ; Ghilardi, G; Amelsberg, KV; Devlin, SM; Pajarillo, R; Slingerland, JB; Beghi, S; Herrera, PS; Giardina, P; Clurman, A; Dwomoh, E; Armijo, G; Gomes, ALC; Littmann, ER; Schluter, J; Fontana, E; Taur, Y; Park, JH; Palomba, ML; Halton, E; Ruiz, J; Jain, T; Pennisi, M; Afuye, AO; Perales, MA; Freyer, CW; Garfall, A; Gier, S; Nasta, S; Landsburg, D; Gerson, J; Svoboda, J; Cross, J; Chong, EA; Giralt, S; Gill, SI; Riviere, I; Porter, DL; Schuster, SJ; Sadelain, M; Frey, N; Brentjens, RJ; June, CH; Pamer, EG; Peled, JU; Facciabene, A; van den Brink, MRM; Ruella, M				Smith, Melody; Dai, Anqi; Ghilardi, Guido; Amelsberg, Kimberly, V; Devlin, Sean M.; Pajarillo, Raymone; Slingerland, John B.; Beghi, Silvia; Herrera, Pamela S.; Giardina, Paul; Clurman, Annelie; Dwomoh, Emmanuel; Armijo, Gabriel; Gomes, Antonio L. C.; Littmann, Eric R.; Schluter, Jonas; Fontana, Emily; Taur, Ying; Park, Jae H.; Palomba, Maria Lia; Halton, Elizabeth; Ruiz, Josel; Jain, Tania; Pennisi, Martina; Afuye, Aishat Olaide; Perales, Miguel-Angel; Freyer, Craig W.; Garfall, Alfred; Gier, Shannon; Nasta, Sunita; Landsburg, Daniel; Gerson, James; Svoboda, Jakub; Cross, Justin; Chong, Elise A.; Giralt, Sergio; Gill, Saar, I; Riviere, Isabelle; Porter, David L.; Schuster, Stephen J.; Sadelain, Michel; Frey, Noelle; Brentjens, Renier J.; June, Carl H.; Pamer, Eric G.; Peled, Jonathan U.; Facciabene, Andrea; van den Brink, Marcel R. M.; Ruella, Marco			Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy	NATURE MEDICINE			English	Article							SUSCEPTIBILITY; NEUROTOXICITY; IMMUNOTHERAPY; RESISTANCE; DIVERSITY; CHILDREN; EFFICACY	Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and up to 80% of patients experience CAR-mediated toxicities, such as cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. We investigated the role of the intestinal microbiome on these outcomes in a multicenter study of patients with B cell lymphoma and leukemia. We found in a retrospective cohort (n = 228) that exposure to antibiotics, in particular piperacillin/tazobactam, meropenem and imipenem/cilastatin (P-I-M), in the 4 weeks before therapy was associated with worse survival and increased neurotoxicity. In stool samples from a prospective cohort of CAR T cell recipients (n = 48), the fecal microbiome was altered at baseline compared to healthy controls. Stool sample profiling by 16S ribosomal RNA and metagenomic shotgun sequencing revealed that clinical outcomes were associated with differences in specific bacterial taxa and metabolic pathways. Through both untargeted and hypothesis-driven analysis of 16S sequencing data, we identified species within the class Clostridia that were associated with day 100 complete response. We concluded that changes in the intestinal microbiome are associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B cell malignancies.	[Smith, Melody; Dai, Anqi; Slingerland, John B.; Herrera, Pamela S.; Giardina, Paul; Clurman, Annelie; Dwomoh, Emmanuel; Armijo, Gabriel; Gomes, Antonio L. C.; Ruiz, Josel; Afuye, Aishat Olaide; Perales, Miguel-Angel; Giralt, Sergio; Peled, Jonathan U.; van den Brink, Marcel R. M.] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA; [Smith, Melody; Park, Jae H.; Palomba, Maria Lia; Perales, Miguel-Angel; Giralt, Sergio; Brentjens, Renier J.; Peled, Jonathan U.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Smith, Melody; Park, Jae H.; Palomba, Maria Lia; Halton, Elizabeth; Riviere, Isabelle; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Cellular Therapeut Ctr, Dept Med, New York, NY USA; [Smith, Melody] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Stanford, CA USA; [Ghilardi, Guido; Amelsberg, Kimberly, V; Pajarillo, Raymone; Garfall, Alfred; Gier, Shannon; Nasta, Sunita; Landsburg, Daniel; Gerson, James; Svoboda, Jakub; Chong, Elise A.; Gill, Saar, I; Porter, David L.; Schuster, Stephen J.; Frey, Noelle; June, Carl H.; Facciabene, Andrea; Ruella, Marco] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA; [Ghilardi, Guido; Amelsberg, Kimberly, V; Pajarillo, Raymone; Chong, Elise A.; Gill, Saar, I; Porter, David L.; Schuster, Stephen J.; Frey, Noelle; Ruella, Marco] Hosp Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Devlin, Sean M.] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY USA; [Beghi, Silvia; Facciabene, Andrea] Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA; [Herrera, Pamela S.] Weill Cornell Med Coll, New York, NY USA; [Littmann, Eric R.; Pamer, Eric G.] Univ Chicago, Duchossois Family Inst, Chicago, IL USA; [Schluter, Jonas] New York Univ Langone Hlth, Inst Computat Med, New York, NY USA; [Fontana, Emily] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Microbiol Core Facil, New York, NY USA; [Taur, Ying] Sloan Kettering Inst, Dept Med, Infect Dis Serv, New York, NY USA; [Taur, Ying] Sloan Kettering Inst, Immunol Program, New York, NY USA; [Park, Jae H.; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA; [Palomba, Maria Lia] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA; [Halton, Elizabeth] Mem Sloan Kettering Canc Ctr, Dept Nursing, New York, NY USA; [Jain, Tania] Johns Hopkins Univ, Div Hematol Malignancies & Bone Marrow Transplant, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Pennisi, Martina] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Freyer, Craig W.] Hosp Univ Penn, Dept Pharm, Philadelphia, PA USA; [Nasta, Sunita; Landsburg, Daniel; Gerson, James; Svoboda, Jakub; Chong, Elise A.; Schuster, Stephen J.; Ruella, Marco] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA; [Cross, Justin] Mem Sloan Kettering Canc Ctr, Donald B & Catherine C Marron Canc Metab Ctr, New York, NY USA; [Riviere, Isabelle; Sadelain, Michel; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY USA; [June, Carl H.] Univ Penn, Dept PathPerelman Sch Medol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Facciabene, Andrea] Univ Penn, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA; [van den Brink, Marcel R. M.] Sloan Kettering Inst, Dept Immunol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Stanford University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Cornell University; University of Chicago; New York University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; University of Milan; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Memorial Sloan Kettering Cancer Center	van den Brink, MRM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA.; Facciabene, A; Ruella, M (corresponding author), Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.; Ruella, M (corresponding author), Hosp Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.; Facciabene, A (corresponding author), Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA.; Ruella, M (corresponding author), Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA.; Facciabene, A (corresponding author), Univ Penn, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.; van den Brink, MRM (corresponding author), Sloan Kettering Inst, Dept Immunol, New York, NY 10065 USA.	facciabe@pennmedicine.upenn.edu; vandenbm@mskcc.org; mruella@upenn.edu	van den Brink, Marcel R. M./HGB-9434-2022; Ruella, Marco/GQP-8473-2022; Pennisi, Martina/AIB-6219-2022; Beghi, Silvia/AGE-6566-2022; Jain, Tania/F-2784-2019	Pennisi, Martina/0000-0003-1077-5937; Beghi, Silvia/0000-0002-0029-4737; Peled, Jonathan/0000-0002-4029-7625; Gomes, Antonio LC/0000-0003-3790-3724; Jain, Tania/0000-0001-6854-773X; Schluter, Jonas/0000-0002-6214-9367; Smith, Melody/0000-0002-2702-0381	Damon Runyon Physician-Scientist Award; Burroughs Wellcome Fund Postdoctoral Enrichment Program; American Society of Hematology-Robert Wood Johnson Foundation; Harold Amos Medical Faculty Development Program; Fauci Fellowships - National Italian American Foundation; Mario Luvini fellowship grant - Fondazione Ticinese per la Ricerca sul Cancro; National Cancer Institute (NCI) [K08CA194256]; Lymphoma Research Foundation (LRF) Career Development Award; Gilead Research Scholar Award; Gabrielle's Angel Foundation; Emerson Collective Award; Laffey-McHugh Foundation; Berman and Maguire Funds for Lymphoma Research at the University of Pennsylvania; NCI [1K99CA212302, R00CA212302]; Center for Precision Medicine Accelerator Award [1R01CA219871-01A1]; University of Pennsylvania-Novartis Alliance; Scholar in Clinical Research award from the Leukemia and Lymphoma Society; American-Italian Cancer Foundation Postdoctoral Research Fellowship; Associazione Italiana contro le Leucemie-Linfomi e Mieloma Milano e Provincia Organizzazione Non Lucrativa di Utilita Sociale; National Institutes of Health/NCI MSK Cancer Center Support Grant [P01 CA23766, P30 CA008748]; LRF Postdoctoral Fellowship Grant; Parker Institute for Cancer Immunotherapy; Starr Cancer Consortium; Tri-Institutional Stem Cell Initiative; Lymphoma Foundation; Susan and Peter Solomon Divisional Genomics Program; Cycle for Survival;  [1P01CA214278];  [R01CA226983];  [K08HL143189];  [R01-CA228358];  [R01-CA228308];  [R01-HL147584];  [P01-CA023766];  [R01-HL125571];  [R01-HL123340];  [P01-AG052359]	Damon Runyon Physician-Scientist Award; Burroughs Wellcome Fund Postdoctoral Enrichment Program(Burroughs Wellcome Fund); American Society of Hematology-Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Harold Amos Medical Faculty Development Program; Fauci Fellowships - National Italian American Foundation; Mario Luvini fellowship grant - Fondazione Ticinese per la Ricerca sul Cancro; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lymphoma Research Foundation (LRF) Career Development Award; Gilead Research Scholar Award; Gabrielle's Angel Foundation; Emerson Collective Award; Laffey-McHugh Foundation; Berman and Maguire Funds for Lymphoma Research at the University of Pennsylvania; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Precision Medicine Accelerator Award; University of Pennsylvania-Novartis Alliance; Scholar in Clinical Research award from the Leukemia and Lymphoma Society; American-Italian Cancer Foundation Postdoctoral Research Fellowship; Associazione Italiana contro le Leucemie-Linfomi e Mieloma Milano e Provincia Organizzazione Non Lucrativa di Utilita Sociale; National Institutes of Health/NCI MSK Cancer Center Support Grant; LRF Postdoctoral Fellowship Grant; Parker Institute for Cancer Immunotherapy; Starr Cancer Consortium; Tri-Institutional Stem Cell Initiative; Lymphoma Foundation; Susan and Peter Solomon Divisional Genomics Program; Cycle for Survival; ; ; ; ; ; ; ; ; ; 	We acknowledge the Integrated Genomics Operation at MSK, which performed all the 16S and metagenomic shotgun sequencing for the fecal microbiome cohort and healthy controls. This research was supported by the following funding sources: Damon Runyon Physician-Scientist Award (M.Sm.); Burroughs Wellcome Fund Postdoctoral Enrichment Program (M.Sm.); American Society of Hematology-Robert Wood Johnson Foundation and Harold Amos Medical Faculty Development Program (M.Sm.); Fauci Fellowships - National Italian American Foundation and Mario Luvini fellowship grant - Fondazione Ticinese per la Ricerca sul Cancro (G.G.); National Cancer Institute (NCI) grant no. K08CA194256 (S.G.); Lymphoma Research Foundation (LRF) Career Development Award (M.R.); Gilead Research Scholar Award (M.R.); Gabrielle's Angel Foundation (M.R.); Emerson Collective Award (M.R.); Laffey-McHugh Foundation (M.R.); Berman and Maguire Funds for Lymphoma Research at the University of Pennsylvania (M.R.); NCI grant no. 1K99CA212302 (M.R.); grant no. R00CA212302 (M.R.); Center for Precision Medicine Accelerator Award (M.R. and A.F.); grant no. 1R01CA219871-01A1 (A.F.); University of Pennsylvania-Novartis Alliance (S.G. and C.H.J.); grant no. 1P01CA214278 (C.H.J.); grant no. R01CA226983 (C.H.J.); Scholar in Clinical Research award from the Leukemia and Lymphoma Society (A.G.); American-Italian Cancer Foundation Postdoctoral Research Fellowship and Associazione Italiana contro le Leucemie-Linfomi e Mieloma Milano e Provincia Organizzazione Non Lucrativa di Utilita Sociale (M.P.); grant no. P01 CA23766 (M-A.P.); grant no. P30 CA008748 National Institutes of Health/NCI MSK Cancer Center Support Grant (M-A.P., S.M.D., J.U.P., M.Sm. and M.R.M.B.); LRF Postdoctoral Fellowship Grant (E.A.C.); grant no. K08HL143189 (J.U.P); Parker Institute for Cancer Immunotherapy (J.U.P.); grant nos. R01-CA228358, R01-CA228308, R01-HL147584, P01-CA023766, R01-HL125571, R01-HL123340 and P01-AG052359 (M.R.M.B.); Starr Cancer Consortium (M.R.M.B.); Tri-Institutional Stem Cell Initiative (M.R.M.B.); the Lymphoma Foundation (M.R.M.B.); the Susan and Peter Solomon Divisional Genomics Program (M.R.M.B.); Cycle for Survival (M.R.M.B.); and the Parker Institute for Cancer Immunotherapy (M.R.M.B.).	Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Braniste V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009759; BRAY JR, 1957, ECOL MONOGR, V27, P326, DOI 10.2307/1942268; Brook I, 2013, CLIN MICROBIOL REV, V26, P526, DOI 10.1128/CMR.00086-12; Buffie CG, 2012, INFECT IMMUN, V80, P62, DOI 10.1128/IAI.05496-11; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Cellini B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165823; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chong EA, 2021, NEW ENGL J MED, V384, P673, DOI 10.1056/NEJMc2030164; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Frey NV, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01892; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Guedan S, 2019, ANNU REV IMMUNOL, V37, P145, DOI 10.1146/annurev-immunol-042718-041407; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hirayama AV, 2019, BLOOD, V133, P1876, DOI 10.1182/blood-2018-11-887067; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karschnia P, 2019, BLOOD, V133, P2212, DOI 10.1182/blood-2018-12-893396; Kassambara A., 2020, GGPLOT2 BAS PUBL REA; Kespohl M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01036; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; McElreath R, 2016, TEXT STAT SCI, pXI; Morjaria S, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00206-19, 10.1128/iai.00206-19]; Nastoupil LJ, 2020, J CLIN ONCOL, V38, P3119, DOI 10.1200/JCO.19.02104; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Ochoa-Reparaz J, 2010, J IMMUNOL, V185, P4101, DOI 10.4049/jimmunol.1001443; Orlando EJ, 2018, NAT MED, V24, P1504, DOI 10.1038/s41591-018-0146-z; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Peled JU, 2020, NEW ENGL J MED, V382, P822, DOI 10.1056/NEJMoa1900623; Pflug N, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1150399; Porter D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0571-y; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Ruella M, 2019, BLOOD, V134, P2333, DOI 10.1182/blood.2019003821; Ruella M, 2018, NAT MED, V24, P1499, DOI 10.1038/s41591-018-0201-9; Santomasso Bianca, 2019, Am Soc Clin Oncol Educ Book, V39, P433, DOI 10.1200/EDBK_238691; Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319; Schluter J, 2020, NATURE, V588, DOI 10.1038/s41586-020-2971-8; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Schuster SJ, 2017, NEW ENGL J MED, V377, P2545, DOI 10.1056/NEJMoa1708566; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Shono Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2311; Siegler EL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01973; Sinha R, 2017, NAT BIOTECHNOL, V35, P1077, DOI 10.1038/nbt.3981; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Spiegel JY, 2021, BLOOD, V137, P1832, DOI 10.1182/blood.2020006245; Stein-Thoeringer CK, 2019, SCIENCE, V366, P1143, DOI 10.1126/science.aax3760; Taraseviciute A, 2018, CANCER DISCOV, V8, P750, DOI 10.1158/2159-8290.CD-17-1368; Taur Y, 2014, BLOOD, V124, P1174, DOI 10.1182/blood-2014-02-554725; Doan T, 2017, CLIN INFECT DIS, V64, P1147, DOI 10.1093/cid/cix141; Uribe-Herranz M, 2020, J CLIN INVEST, V130, P466, DOI 10.1172/JCI124332; Uribe-Herranz M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94952; Vercellino L, 2020, BLOOD ADV, V4, P5607, DOI 10.1182/bloodadvances.2020003001; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Wang MH, 2020, NEW ENGL J MED, V382, P1331, DOI 10.1056/NEJMoa1914347; Wickham H., 2019, J OPEN SOURCE SOFTW, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]; Yang KT, 2021, J EXP MED, V218, DOI 10.1084/jem.20201915	72	21	20	15	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					713	+		10.1038/s41591-022-01702-9	http://dx.doi.org/10.1038/s41591-022-01702-9		MAR 2022	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35288695	Green Accepted			2022-12-27	WOS:000770060900005
J	Davis, PB; Meagher, EA; Pomeroy, C; Lowe, WL; Rubenstein, AH; Wu, JY; Curtis, AB; Jackson, RD				Davis, Pamela B.; Meagher, Emma A.; Pomeroy, Claire; Lowe, William L. Jr Jr; Rubenstein, Arthur H.; Wu, Joy Y.; Curtis, Anne B.; Jackson, Rebecca D.			Pandemic-related barriers to the success of women in research: a framework for action comment	NATURE MEDICINE			English	Editorial Material							PHYSICIANS	Women in academia have fallen behind with publications and grant funding during the COVID-19 pandemic and risk dropping out of the research workforce altogether, unless urgent action is taken by institutes and funders.	[Davis, Pamela B.] Case Western Reserve Univ, Sch Med, Ctr Community Hlth Integrat, Cleveland, OH 44106 USA; [Meagher, Emma A.; Rubenstein, Arthur H.] Univ Penn, Dept Med, Raymond & Ruth Perelman Sch Med, Philadelphia, PA 19104 USA; [Pomeroy, Claire] Albert & Mary Lasker Fdn, New York, NY USA; [Lowe, William L. Jr Jr] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Wu, Joy Y.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Curtis, Anne B.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA; [Jackson, Rebecca D.] Ohio State Univ, Dept Med, Columbus, OH 43210 USA	Case Western Reserve University; University of Pennsylvania; Pennsylvania Medicine; Northwestern University; Feinberg School of Medicine; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Ohio; Ohio State University	Davis, PB (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Community Hlth Integrat, Cleveland, OH 44106 USA.	pbd@case.edu		Meagher, Emma/0000-0003-1841-4570; Lowe, William/0000-0001-9467-3422; Davis, Pamela/0000-0002-7113-5338				Antecol H, 2018, AM ECON REV, V108, P2420, DOI 10.1257/aer.20160613; Burstin HR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14787; Chatterjee P, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14509; Hechtman LA, 2018, P NATL ACAD SCI USA, V115, P7943, DOI 10.1073/pnas.1800615115; Higginbotham E., 2021, IMP COVID 19 CAR WOM, DOI [10.17226/26061, DOI 10.17226/26061]; Jagsi R, 2007, ARCH INTERN MED, V167, P343, DOI 10.1001/archinte.167.4.343; Jagsi R, 2021, NEW ENGL J MED, V384, P2265, DOI 10.1056/NEJMp2104228; Jagsi R, 2018, ANN INTERN MED, V169, P128, DOI 10.7326/M17-2676; Jones RD, 2019, ACAD MED, V94, P1746, DOI 10.1097/ACM.0000000000002903; Kibbe MR, 2020, JAMA SURG, V155, P803, DOI 10.1001/jamasurg.2020.3917; Lauer M., 2021, NIH EXTRAMURAL NEXUS; Lo Sasso AT, 2020, HEALTH AFFAIR, V39, P256, DOI 10.1377/hlthaff.2019.00664; Mandavilli A., NEW YORK TIMES; Matulevicius SA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.13539; Myers KR, 2020, NAT HUM BEHAV, V4, P880, DOI 10.1038/s41562-020-0921-y; Oliveira DFM, 2019, JAMA-J AM MED ASSOC, V321, P898, DOI 10.1001/jama.2018.21944; Pinho-Gomes Ana-Catarina, 2020, BMJ Glob Health, V5, DOI 10.1136/bmjgh-2020-002922; Richter KP, 2020, NEW ENGL J MED, V383, P2148, DOI 10.1056/NEJMsa1916935; Wehner MR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.20335	19	5	5	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					436	438		10.1038/s41591-022-01692-8	http://dx.doi.org/10.1038/s41591-022-01692-8		FEB 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35177858	Bronze			2022-12-27	WOS:000757243200007
J	Flotte, TR; Cataltepe, O; Puri, A; Batista, AR; Moser, R; McKenna-Yasek, D; Douthwright, C; Gernoux, G; Blackwood, M; Mueller, C; Tai, PWL; Jiang, XN; Bateman, S; Spanakis, SG; Parzych, J; Keeler, AM; Abayazeed, A; Rohatgi, S; Gibson, L; Finberg, R; Barton, BA; Vardar, Z; Shazeeb, MS; Gounis, M; Tifft, CJ; Eichler, FS; Brown, RH; Martin, DR; Gray-Edwards, HL; Sena-Esteves, M				Flotte, Terence R.; Cataltepe, Oguz; Puri, Ajit; Batista, Ana Rita; Moser, Richard; McKenna-Yasek, Diane; Douthwright, Catherine; Gernoux, Gwladys; Blackwood, Meghan; Mueller, Christian; Tai, Phillip W. L.; Jiang, Xuntian; Bateman, Scot; Spanakis, Spiro G.; Parzych, Julia; Keeler, Allison M.; Abayazeed, Aly; Rohatgi, Saurabh; Gibson, Laura; Finberg, Robert; Barton, Bruce A.; Vardar, Zeynep; Shazeeb, Mohammed Salman; Gounis, Matthew; Tifft, Cynthia J.; Eichler, Florian S.; Brown, Robert H., Jr.; Martin, Douglas R.; Gray-Edwards, Heather L.; Sena-Esteves, Miguel			AAV gene therapy for Tay-Sachs disease	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS; GM2 GANGLIOSIDOSIS; SINGLE INJECTION; FELINE MODEL; SPINAL-CORD; DELIVERY; BRAIN; TRANSDUCTION; VECTOR; MICE	Tay-Sachs disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Here, we describe an adeno-associated virus (AAV) gene therapy expanded-access trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no secondary endpoints. Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 x 10(14) vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction. Patient TSD-002 was treated at 7 months by combined bilateral thalamic (1.5 x 10(12) vg per thalamus) and i.t. infusion (3.9 x 10(13) vg). Both patients were immunosuppressed. Injection procedures were well tolerated, with no vector-related adverse events (AEs) to date. Cerebrospinal fluid (CSF) HexA activity increased from baseline and remained stable in both patients. TSD-002 showed disease stabilization by 3 months after injection with ongoing myelination, a temporary deviation from the natural history of infantile TSD, but disease progression was evident at 6 months after treatment. TSD-001 remains seizure-free at 5 years of age on the same anticonvulsant therapy as before therapy. TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy. First-in-human combined intrathalamic and intrathecal gene therapy in two patients with Tay-Sachs disease provides early evidence on the safety and feasibility of the approach.	[Flotte, Terence R.; Cataltepe, Oguz; Gernoux, Gwladys; Blackwood, Meghan; Mueller, Christian; Keeler, Allison M.; Gibson, Laura] UMass Chan Med Sch, Dept Pediat, Worcester, MA 01655 USA; [Flotte, Terence R.; Cataltepe, Oguz; Gernoux, Gwladys; Blackwood, Meghan; Mueller, Christian; Bateman, Scot; Keeler, Allison M.; Gibson, Laura; Brown, Robert H., Jr.] UMass Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01655 USA; [Flotte, Terence R.; Batista, Ana Rita; Gernoux, Gwladys; Blackwood, Meghan; Mueller, Christian; Tai, Phillip W. L.; Keeler, Allison M.; Brown, Robert H., Jr.; Gray-Edwards, Heather L.; Sena-Esteves, Miguel] UMass Chan Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01655 USA; [Cataltepe, Oguz; Moser, Richard] UMass Chan Med Sch, Dept Neurosurg, Worcester, MA 01655 USA; [Puri, Ajit; Abayazeed, Aly; Rohatgi, Saurabh; Vardar, Zeynep; Shazeeb, Mohammed Salman; Gounis, Matthew; Gray-Edwards, Heather L.] UMass Chan Med Sch, Dept Radiol, Worcester, MA USA; [McKenna-Yasek, Diane; Douthwright, Catherine; Brown, Robert H., Jr.] UMass Chan Med Sch, Dept Neurol, Worcester, MA USA; [Jiang, Xuntian] Washington Univ, Sch Med, Dept Med, St Louis, MO USA; [Jiang, Xuntian] Washington Univ, Sch Med, Cardiovasc Div, St Louis, MO USA; [Spanakis, Spiro G.; Parzych, Julia] UMass Chan Med Sch, Dept Anesthesiol, Worcester, MA USA; [Spanakis, Spiro G.; Parzych, Julia] UMass Chan Med Sch, Dept Perioperat Med, Worcester, MA USA; [Gibson, Laura; Finberg, Robert] UMass Chan Med Sch, Dept Internal Med, Worcester, MA USA; [Barton, Bruce A.] UMass Chan Med Sch, Populat & Quantitat Hlth Sci, Worcester, MA USA; [Tifft, Cynthia J.] NIH, Nat Human Genome Res Inst, Bethesda, MD USA; [Eichler, Florian S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Eichler, Florian S.] Harvard Med Sch, Boston, MA USA; [Martin, Douglas R.] Auburn Univ, Coll Vet Med, Scott Ritchey Res Ctr, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA	Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Auburn University System; Auburn University	Flotte, TR (corresponding author), UMass Chan Med Sch, Dept Pediat, Worcester, MA 01655 USA.; Flotte, TR (corresponding author), UMass Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01655 USA.; Flotte, TR; Sena-Esteves, M (corresponding author), UMass Chan Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01655 USA.	Terry.Flotte@umassmed.edu; Miguel.esteves@umassmed.edu	Keeler, Allison/GYV-3230-2022; GERNOUX, Gwladys/D-3267-2019	GERNOUX, Gwladys/0000-0002-1268-7001; Vardar, Zeynep/0000-0002-7510-9524	BlueGenes Foundation; National Tay-Sachs and Allied Diseases Association; Cure Tay-Sachs Foundation	BlueGenes Foundation; National Tay-Sachs and Allied Diseases Association; Cure Tay-Sachs Foundation	This work was supported in part by the BlueGenes Foundation, which had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We are also grateful for the exceptional support from the National Tay-Sachs and Allied Diseases Association and the Cure Tay-Sachs Foundation during the preclinical development of this AAV gene therapy. We thank the families that provided MRI images from their deceased children with TSD or SD to support this study. We thank A. Singh for allowing us to use the MRI images from healthy children at 7 and 12 months of age for comparison purposes. We thank A. Zimmerman and B. Wong for their assistance during this study. We also thank N. Sanil and C. Dooley in the research pharmacy for their assistance in preparing the AAV doses for administration. We acknowledge the NEALS Biorepository for providing the biofluids from patient with amyotrophic lateral sclerosis used as non-TSD control samples in this study. M. Sena-Esteves was the sponsor of the clinical trial and was responsible for production of the AAVrh8 vectors in his laboratory as described in Methods. The hexosaminidase assays and western blots were also done in his laboratory. He had no role in the clinical aspects of the trial. During the manuscript review process, R.F. passed away in August 2021.	ABE T, 1985, ACTA NEUROPATHOL, V66, P239, DOI 10.1007/BF00688589; Baek RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013468; Baek RC, 2009, LIPIDS, V44, P197, DOI 10.1007/s11745-008-3268-0; Bley AE, 2011, PEDIATRICS, V128, pE1233, DOI 10.1542/peds.2011-0078; Bradbury AM, 2013, MOL THER, V21, P1306, DOI 10.1038/mt.2013.86; Cachon-Gonzalez MB, 2006, P NATL ACAD SCI USA, V103, P10373, DOI 10.1073/pnas.0603765103; Cachon-Gonzalez MB, 2012, MOL THER, V20, P1489, DOI 10.1038/mt.2012.44; Cearley CN, 2008, MOL THER, V16, P1710, DOI 10.1038/mt.2008.166; Cearley CN, 2007, J NEUROSCI, V27, P9928, DOI 10.1523/JNEUROSCI.2185-07.2007; Corti M, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.33; Dodge JC, 2005, P NATL ACAD SCI USA, V102, P17822, DOI 10.1073/pnas.0509062102; Foust KD, 2008, HUM GENE THER, V19, P71, DOI 10.1089/hum.2007.104; Golebiowski D, 2017, HUM GENE THER, V28, P510, DOI 10.1089/hum.2016.109; Gray SJ, 2013, GENE THER, V20, P450, DOI 10.1038/gt.2012.101; Gray-Edwards HL, 2018, HUM GENE THER, V29, P312, DOI 10.1089/hum.2017.163; Hepbildikler ST, 2002, J BIOL CHEM, V277, P2562, DOI 10.1074/jbc.M105457200; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Hinderer C, 2014, MOL THER, V22, P2018, DOI 10.1038/mt.2014.135; Hwu WL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003640; Kells AP, 2009, P NATL ACAD SCI USA, V106, P2407, DOI 10.1073/pnas.0810682106; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; McCurdy VJ, 2015, GENE THER, V22, P181, DOI 10.1038/gt.2014.108; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Meyer K, 2015, MOL THER, V23, P477, DOI 10.1038/mt.2014.210; Miyanohara A, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.46; MIYAZAKI J, 1989, GENE, V79, P269; Mueller C, 2020, NEW ENGL J MED, V383, P151, DOI 10.1056/NEJMoa2005056; Muramatsu S, 2010, MOL THER, V18, P1731, DOI 10.1038/mt.2010.135; Neudorfer O, 2005, GENET MED, V7, P119, DOI 10.1097/01.GIM.0000154300.84107.75; Passini MA, 2002, J NEUROSCI, V22, P6437; Passini MA, 2003, J VIROL, V77, P7034, DOI 10.1128/JVI.77.12.7034-7040.2003; RAPIN I, 1976, ARCH NEUROL-CHICAGO, V33, P120, DOI 10.1001/archneur.1976.00500020048008; Rockwell HE, 2015, ASN NEURO, V7, DOI 10.1177/1759091415569908; Salegio EA, 2013, GENE THER, V20, P348, DOI 10.1038/gt.2012.27; Samaranch L, 2013, HUM GENE THER, V24, P526, DOI 10.1089/hum.2013.005; SCHNECK L, 1964, J PEDIATR-US, V65, P749, DOI 10.1016/S0022-3476(64)80161-X; Singh, 2017, MRI ATLAS NORMAL MYE; SNYDER PD, 1972, J LIPID RES, V13, P128; Taghian T, 2020, HUM GENE THER, V31, P617, DOI 10.1089/hum.2019.288; Taghian T, 2020, MOL THER, V28, P411, DOI 10.1016/j.ymthe.2019.11.012; Tutunji R, 2018, EUR J RADIOL, V109, P27, DOI 10.1016/j.ejrad.2018.10.018; Wendeler M, 2009, GLYCOCONJUGATE J, V26, P945, DOI 10.1007/s10719-008-9137-5	42	8	8	8	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					251	+		10.1038/s41591-021-01664-4	http://dx.doi.org/10.1038/s41591-021-01664-4		FEB 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35145305	Green Submitted			2022-12-27	WOS:000753763500007
J	Van Oekelen, O; Aleman, A; Upadhyaya, B; Schnakenberg, S; Madduri, D; Gavane, S; Teruya-Feldstein, J; Crary, JF; Fowkes, ME; Stacy, CB; Kim-Schulze, S; Rahman, A; Lagana, A; Brody, JD; Merad, M; Jagannath, S; Parekh, S				Van Oekelen, Oliver; Aleman, Adolfo; Upadhyaya, Bhaskar; Schnakenberg, Sandra; Madduri, Deepu; Gavane, Somali; Teruya-Feldstein, Julie; Crary, John F.; Fowkes, Mary E.; Stacy, Charles B.; Kim-Schulze, Seunghee; Rahman, Adeeb; Lagana, Alessandro; Brody, Joshua D.; Merad, Miriam; Jagannath, Sundar; Parekh, Samir			Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy	NATURE MEDICINE			English	Article							MATURATION ANTIGEN; MULTIPLE-MYELOMA; MANAGEMENT	B-cell maturation antigen (BCMA) is a prominent tumorassociated target for chimeric antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case of a patient with MM who was enrolled in the CARTITUDE-1 trial (NCT03548207) and who developed a progressive movement disorder with features of parkinsonism approximately 3 months after ciltacabtagene autoleucel BCMA-targeted CAR-T cell infusion, associated with CAR-T cell persistence in the blood and cerebrospinal fluid, and basal ganglia lymphocytic infiltration. We show BCMA expression on neurons and astrocytes in the patient's basal ganglia. Public transcriptomic datasets further confirm BCMA RNA expression in the caudate of normal human brains, suggesting that this might be an on-target effect of anti-BCMA therapy. Given reports of three patients with grade 3 or higher parkinsonism on the phase 2 ciltacabtagene autoleucel trial and of grade 3 parkinsonism in the idecabtagene vicleucel package insert, our findings support close neurological monitoring of patients on BCMA-targeted T cell therapies.	[Van Oekelen, Oliver; Aleman, Adolfo] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA; [Van Oekelen, Oliver; Aleman, Adolfo; Upadhyaya, Bhaskar; Madduri, Deepu; Brody, Joshua D.; Jagannath, Sundar; Parekh, Samir] Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA; [Upadhyaya, Bhaskar; Madduri, Deepu; Kim-Schulze, Seunghee; Rahman, Adeeb; Lagana, Alessandro; Brody, Joshua D.; Merad, Miriam; Jagannath, Sundar; Parekh, Samir] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Upadhyaya, Bhaskar; Kim-Schulze, Seunghee; Rahman, Adeeb; Merad, Miriam] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA; [Schnakenberg, Sandra; Teruya-Feldstein, Julie; Crary, John F.; Fowkes, Mary E.] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cellbased Med, New York, NY 10029 USA; [Schnakenberg, Sandra; Crary, John F.; Fowkes, Mary E.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA; [Gavane, Somali] Icahn Sch Med Mt Sinai, Dept Diagnost Mol & Intervent Radiol, New York, NY 10029 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Dept Artificial Intelligence & Human Hlth, New York, NY 10029 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Neuropathol Brain Bank & Res Core, New York, NY 10029 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Crary, John F.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Stacy, Charles B.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Kim-Schulze, Seunghee; Rahman, Adeeb; Lagana, Alessandro; Brody, Joshua D.; Merad, Miriam; Parekh, Samir] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Kim-Schulze, Seunghee; Rahman, Adeeb; Brody, Joshua D.; Merad, Miriam; Parekh, Samir] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Rahman, Adeeb] Immunai, New York, NY USA; [Lagana, Alessandro] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Parekh, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA.; Parekh, S (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Parekh, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.; Parekh, S (corresponding author), Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA.	samir.parekh@mssm.edu	Aleman, Adolfo/GPG-1788-2022; Van Oekelen, Oliver/AHH-5449-2022; Upadhyaya, Bhaskar/ADF-4660-2022	Van Oekelen, Oliver/0000-0002-5824-197X; Fowkes, Mary/0000-0003-2699-5555	National Cancer Institute (NCI) [R01 CA244899, R01 CA252222]; Amgen; Celgene/Bristol Myers Squibb; Karyopharm; National Institute of Allergy and Infectious Diseases [U24 AI118644-05S1, U19 AI128949, U19 AI118610]; NCI [R01 CA254104, R01 CA257195, P30 CA196521-05S2, R01 CA246239-01]; George Mason University; Gates Foundation; Samuel Waxman Cancer Research Foundation	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Amgen(Amgen); Celgene/Bristol Myers Squibb(Bristol-Myers SquibbCelgene Corporation); Karyopharm; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); George Mason University; Gates Foundation(Bill & Melinda Gates Foundation); Samuel Waxman Cancer Research Foundation	The authors would like to thank T. Dawson, H. Xie, M. Patel and the rest of the staff members at the Human Immune Monitoring Center at the Icahn School of Medicine for sample management and their help conducting omics assays. Furthermore, we would like to thank M. Garcia-Barros and R. Brody from the Biorepository and Pathology Core at the Icahn School of Medicine for immunohistochemistry staining. S.P. acknowledges support by the National Cancer Institute (NCI) (R01 CA244899 and R01 CA252222) and receives research funding from Amgen, Celgene/Bristol Myers Squibb and Karyopharm. M.M. acknowledges support from the National Institute of Allergy and Infectious Diseases (U24 AI118644-05S1, U19 AI128949 and U19 AI118610), from the NCI (R01 CA254104, R01 CA257195 and P30 CA196521-05S2), from a Fast Grant (George Mason University), from the Gates Foundation and from the Samuel Waxman Cancer Research Foundation. J.B. acknowledges support from the NCI (R01 CA246239-01).	Amezquita RA, 2020, NAT METHODS, V17, P137, DOI 10.1038/s41592-019-0654-x; Berdeja JG, 2021, LANCET, V398, P314, DOI 10.1016/S0140-6736(21)00933-8; Bu De-Xiu, 2018, Oncotarget, V9, P25764, DOI 10.18632/oncotarget.25359; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Carpenter RO, 2013, CLIN CANCER RES, V19, P2048, DOI 10.1158/1078-0432.CCR-12-2422; Ellis B., 2019, FLOWCORE BASIC STRUC; Gagelmann N, 2020, EUR J HAEMATOL, V104, P318, DOI 10.1111/ejh.13380; Hawrylycz MJ, 2012, NATURE, V489, P391, DOI 10.1038/nature11405; Jatiani SS, 2020, CL LYMPH MYELOM LEUK, V20, P632, DOI 10.1016/j.clml.2020.04.020; Khattar P, 2017, BLOOD, V130; Kim HJ, 2020, BIOINFORMATICS, V36, P4137, DOI 10.1093/bioinformatics/btaa282; Kolde Raivo, 2019, CRAN; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee L, 2016, BRIT J HAEMATOL, V174, P911, DOI 10.1111/bjh.14145; Madduri D, 2019, CL LYMPH MYELOM LEUK, V19, P537, DOI 10.1016/j.clml.2019.08.002; Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Sanchez E, 2016, CLIN CANCER RES, V22, P3383, DOI 10.1158/1078-0432.CCR-15-2224; Sanchez E, 2012, BRIT J HAEMATOL, V158, P727, DOI 10.1111/j.1365-2141.2012.09241.x; Shah N, 2020, LEUKEMIA, V34, P985, DOI 10.1038/s41375-020-0734-z; Shah UA, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3176; Shah UA, 2020, BEST PRACT RES CL HA, V33, DOI 10.1016/j.beha.2020.101141; Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood-2016-01-691162; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Weber LM, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0415-5; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Zanotelli V., 2020, BODENMILLER GROUP IM; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	31	18	18	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2099	+		10.1038/s41591-021-01564-7	http://dx.doi.org/10.1038/s41591-021-01564-7		DEC 2021	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34893771	Green Accepted			2022-12-27	WOS:000729031100001
J	Pascoal, TA; Benedet, AL; Ashton, NJ; Kang, MS; Therriault, J; Chamoun, M; Savard, M; Lussier, FZ; Tissot, C; Karikari, TK; Ottoy, J; Mathotaarachchi, S; Stevenson, J; Massarweh, G; Scholl, M; de Leon, MJ; Soucy, JP; Edison, P; Blennow, K; Zetterberg, H; Gauthier, S; Rosa-Neto, P				Pascoal, Tharick A.; Benedet, Andrea L.; Ashton, Nicholas J.; Kang, Min Su; Therriault, Joseph; Chamoun, Mira; Savard, Melissa; Lussier, Firoza Z.; Tissot, Cecile; Karikari, Thomas K.; Ottoy, Julie; Mathotaarachchi, Sulantha; Stevenson, Jenna; Massarweh, Gassan; Scholl, Michael; de Leon, Mony J.; Soucy, Jean-Paul; Edison, Paul; Blennow, Kaj; Zetterberg, Henrik; Gauthier, Serge; Rosa-Neto, Pedro			Microglial activation and tau propagate jointly across Braak stages	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; RADIOLIGAND BINDING; HUMAN BRAIN; NEUROINFLAMMATION; MODEL; PROGRESSION; PARALLELS; TANGLES; DRIVES	Microglial activation and tau accumulation propagate together in patients with Alzheimer's disease, suggesting an interaction that determines disease progression. Compelling experimental evidence suggests that microglial activation is involved in the spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the hypothesis that the spatial propagation of microglial activation and tau accumulation colocalize in a Braak-like pattern in the living human brain. We studied 130 individuals across the aging and AD clinical spectrum with positron emission tomography brain imaging for microglial activation ([C-11]PBR28), amyloid-beta (A beta) ([F-18]AZD4694) and tau ([F-18]MK-6240) pathologies. We further assessed microglial triggering receptor expressed on myeloid cells 2 (TREM2) cerebrospinal fluid (CSF) concentrations and brain gene expression patterns. We found that [C-11]PBR28 correlated with CSF soluble TREM2 and showed regional distribution resembling TREM2 gene expression. Network analysis revealed that microglial activation and tau correlated hierarchically with each other following Braak-like stages. Regression analysis revealed that the longitudinal tau propagation pathways depended on the baseline microglia network rather than the tau network circuits. The co-occurrence of A beta, tau and microglia abnormalities was the strongest predictor of cognitive impairment in our study population. Our findings support a model where an interaction between A beta and activated microglia sets the pace for tau spread across Braak stages.	[Pascoal, Tharick A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; [Pascoal, Tharick A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; [Pascoal, Tharick A.; Benedet, Andrea L.; Kang, Min Su; Therriault, Joseph; Chamoun, Mira; Savard, Melissa; Lussier, Firoza Z.; Tissot, Cecile; Mathotaarachchi, Sulantha; Stevenson, Jenna; Gauthier, Serge; Rosa-Neto, Pedro] McGill Univ, Ctr Integre Univ Sante & Serv Sociaux CIUSSS Oues, Douglas Res Inst,Res Ctr Studies Aging, Alzheimers Dis Res Unit,Translat Neuroimaging Lab, Montreal, PQ, Canada; [Pascoal, Tharick A.; Benedet, Andrea L.; Kang, Min Su; Therriault, Joseph; Chamoun, Mira; Savard, Melissa; Lussier, Firoza Z.; Tissot, Cecile; Mathotaarachchi, Sulantha; Stevenson, Jenna; Gauthier, Serge; Rosa-Neto, Pedro] McGill Univ, Dept Neurol, Montreal, PQ, Canada; [Pascoal, Tharick A.; Benedet, Andrea L.; Kang, Min Su; Therriault, Joseph; Chamoun, Mira; Savard, Melissa; Lussier, Firoza Z.; Tissot, Cecile; Mathotaarachchi, Sulantha; Stevenson, Jenna; Gauthier, Serge; Rosa-Neto, Pedro] McGill Univ, Dept Neurosurg, Montreal, PQ, Canada; [Pascoal, Tharick A.; Benedet, Andrea L.; Kang, Min Su; Therriault, Joseph; Chamoun, Mira; Savard, Melissa; Lussier, Firoza Z.; Tissot, Cecile; Mathotaarachchi, Sulantha; Stevenson, Jenna; Gauthier, Serge; Rosa-Neto, Pedro] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Pascoal, Tharick A.; Benedet, Andrea L.; Kang, Min Su; Therriault, Joseph; Chamoun, Mira; Savard, Melissa; Lussier, Firoza Z.; Tissot, Cecile; Mathotaarachchi, Sulantha; Stevenson, Jenna; Gauthier, Serge; Rosa-Neto, Pedro] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Pascoal, Tharick A.; Kang, Min Su; Massarweh, Gassan; Soucy, Jean-Paul; Rosa-Neto, Pedro] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Ashton, Nicholas J.; Karikari, Thomas K.; Scholl, Michael; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Ashton, Nicholas J.] Kings Coll London, Maurice Wohl Inst Clin Neurosci Inst, Inst Psychiat Psychol & Neurosci, London, England; [Ashton, Nicholas J.] NHS Fdn, NIHR Biomed Res Ctr Mental Hlth, London, England; [Ashton, Nicholas J.] NHS Fdn, Biomed Res Unit Dementia South London & Maudsley, London, England; [Ottoy, Julie] Univ Antwerp, Mol Imaging Ctr Antwerp, Antwerp, Belgium; [Ottoy, Julie] Univ Toronto, Sunnybrook Res Inst, LC Campbell Cognit Neurol Unit, Hurvitz Brain Sci Res Program, Toronto, ON, Canada; [Scholl, Michael] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden; [Scholl, Michael; Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [de Leon, Mony J.] Cornell Univ, Weill Med Ctr, Brain Hlth Imaging Inst, Dept Radiol, Ithaca, NY USA; [Edison, Paul] Imperial Coll London, Dept Brain Sci, Hammersmith Hosp Campus, London, England; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; University of Gothenburg; University of London; King's College London; University of London; King's College London; University of Antwerp; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Gothenburg; University of London; University College London; Cornell University; Imperial College London; Sahlgrenska University Hospital; University of London; University College London	Pascoal, TA (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA.; Pascoal, TA (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.; Pascoal, TA; Rosa-Neto, P (corresponding author), McGill Univ, Ctr Integre Univ Sante & Serv Sociaux CIUSSS Oues, Douglas Res Inst,Res Ctr Studies Aging, Alzheimers Dis Res Unit,Translat Neuroimaging Lab, Montreal, PQ, Canada.; Pascoal, TA; Rosa-Neto, P (corresponding author), McGill Univ, Dept Neurol, Montreal, PQ, Canada.; Pascoal, TA; Rosa-Neto, P (corresponding author), McGill Univ, Dept Neurosurg, Montreal, PQ, Canada.; Pascoal, TA; Rosa-Neto, P (corresponding author), McGill Univ, Dept Psychiat, Montreal, PQ, Canada.; Pascoal, TA; Rosa-Neto, P (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.; Pascoal, TA; Rosa-Neto, P (corresponding author), McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.	PASCOAL@pitt.edu; pedro.rosa@mcgill.ca	Karikari, Thomas/ABC-3367-2020; Tissot, Cecile/GPT-0221-2022; Pascoal, Tharick/N-2352-2019; Schöll, Michael/AAS-4411-2020	Karikari, Thomas/0000-0003-1422-4358; Pascoal, Tharick/0000-0001-9057-8014; Schöll, Michael/0000-0001-7800-1781; Ashton, Nicholas/0000-0002-3579-8804; Therriault, Joseph/0000-0002-7826-4781; Tissot, Cecile/0000-0003-2711-3833; Edison, Paul/0000-0002-6551-2002; Lussier, Firoza Zubeida/0000-0002-6877-4825	Weston Brain Institute, Canadian Institutes of Health Research (CIHR) [MOP-11-51-31, 152985]; Alzheimer's Association [NIRG-12-92090, NIRP-12-259245, AACSF-20-648075]; Fonds de Recherche du Quebec-Sante (FRQS) [2020-VICO-279314]; CIHR-Canadian Consortium of Neurodegeneration in Aging (CCNA), Canada Foundation for Innovation, CFI Project [34874]; Swedish Research Council [2017-00915, 2018-02532]; Alzheimer's Drug Discovery Foundation (ADDF) [RDAPB-201809-2016615]; Swedish Alzheimer's Foundation [AF-742881]; Hjarnfonden [FO2017-0243]; Swedish government [ALFGBG-715986]; County Councils, ALF agreement [ALFGBG-715986]; European Union Joint Program for Neurodegenerative Disorders [JPND2019-466-236]; European Research Council [681712]; Swedish State Support for Clinical Research [ALFGBG-720931]; ADDF [201809-2016862]; UK Dementia Research Institute at University College London	Weston Brain Institute, Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alzheimer's Association(Alzheimer's Association); Fonds de Recherche du Quebec-Sante (FRQS); CIHR-Canadian Consortium of Neurodegeneration in Aging (CCNA), Canada Foundation for Innovation, CFI Project; Swedish Research Council(Swedish Research CouncilEuropean Commission); Alzheimer's Drug Discovery Foundation (ADDF); Swedish Alzheimer's Foundation; Hjarnfonden; Swedish government; County Councils, ALF agreement; European Union Joint Program for Neurodegenerative Disorders; European Research Council(European Research Council (ERC)European Commission); Swedish State Support for Clinical Research; ADDF; UK Dementia Research Institute at University College London	This research was supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR) (no. MOP-11-51-31 and no. FRN, 152985 (P.R.-N.)), the Alzheimer's Association (no. NIRG-12-92090 and no. NIRP-12-259245 (P.R.-N.)) and Fonds de Recherche du Quebec-Sante (FRQS; Chercheur Boursier, no. 2020-VICO-279314 (P.R.-N.)). T.A.P., S.G. and P.R.-N. are members of the CIHR-Canadian Consortium of Neurodegeneration in Aging (CCNA), Canada Foundation for Innovation, CFI Project 34874. T.A.P. is supported by the Alzheimer's Association (no. AACSF-20-648075). K.B. is supported by the Swedish Research Council (no. 2017-00915), the Alzheimer's Drug Discovery Foundation (ADDF) (no. RDAPB-201809-2016615), the Swedish Alzheimer's Foundation (no. AF-742881), Hjarnfonden (no. FO2017-0243), the Swedish State under the agreement between the Swedish government and the County Councils, ALF agreement (no. ALFGBG-715986) and European Union Joint Program for Neurodegenerative Disorders (no. JPND2019-466-236). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (no. 2018-02532), European Research Council (no. 681712), Swedish State Support for Clinical Research (no. ALFGBG-720931), the ADDF (no. 201809-2016862) and UK Dementia Research Institute at University College London. The authors thank all study participants and staff of the McGill University Research Centre for Studies in Aging. We thank D. Jolly, A. Kostikov, M. Samoila-Lactatus, K. Ross, M. Boudjemeline and S. Li for assisting with the radiochemistry production. We also thank G. Gagne, C. Mayhew, T. Vinet-Celluci, K. Wan, S. Sbeiti, M. Jin Joung, M. Olmand, R. Nazar, H.-H. Hsiao, R. Bouhachi and A. Aliaga for consenting participants and/or helping with data acquisition. We thank Cerveau Technologies for the use of [<SUP>18</SUP>F]MK-Y6240.	Bhatt S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15930-5; Bolos M, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0200-1; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Brendel M, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00008; Cantarella G, 2015, BRAIN, V138, P203, DOI 10.1093/brain/awu318; Criscuolo C, 2017, SCI REP-UK, V7, DOI 10.1038/srep42370; Dani M, 2018, BRAIN, V141, P2740, DOI 10.1093/brain/awy188; DeVos SL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0481; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Edison P, 2008, NEUROBIOL DIS, V32, P412, DOI 10.1016/j.nbd.2008.08.001; Eikelenboom P, 2010, NEURODEGENER DIS, V7, P38, DOI 10.1159/000283480; Ekert JO, 2018, INT J GERIATR PSYCH, V33, P688, DOI 10.1002/gps.4871; Faura J, 2020, J ALZHEIMERS DIS, V73, P1585, DOI 10.3233/JAD-190753; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gratuze M, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0298-9; Grubman A, 2019, NAT NEUROSCI, V22, P2087, DOI 10.1038/s41593-019-0539-4; Gryglewski G, 2018, NEUROIMAGE, V176, P259, DOI 10.1016/j.neuroimage.2018.04.068; Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069; Hawrylycz MJ, 2012, NATURE, V489, P391, DOI 10.1038/nature11405; Heslegrave A, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0071-x; Hoppe SC, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1309-z; Ising C, 2019, NATURE, V575, P669, DOI 10.1038/s41586-019-1769-z; Jack CR, 2016, NEUROLOGY, V87, P539, DOI 10.1212/WNL.0000000000002923; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jensen CS, 2019, EXP GERONTOL, V121, P91, DOI 10.1016/j.exger.2019.04.003; Jiang T, 2015, NEUROBIOL AGING, V36, P3176, DOI 10.1016/j.neurobiolaging.2015.08.019; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Klein A, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00171; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Kreisl WC, 2020, LANCET NEUROL, V19, P940, DOI 10.1016/S1474-4422(20)30346-X; Kreisl WC, 2016, NEUROBIOL AGING, V44, P53, DOI 10.1016/j.neurobiolaging.2016.04.011; Kreisl WC, 2013, BRAIN, V136, P2228, DOI 10.1093/brain/awt145; Laurent C, 2018, BIOMED J, V41, P21, DOI 10.1016/j.bj.2018.01.003; Liu D, 2018, NEUROSCI LETT, V686, P10, DOI 10.1016/j.neulet.2018.08.038; Lyoo CH, 2015, J NUCL MED, V56, P701, DOI 10.2967/jnumed.114.146027; Mathotaarachchi S, 2016, FRONT NEUROINFORM, V10, DOI 10.3389/fninf.2016.00020; McMahan RS, 2016, J IMMUNOL, V197, P899, DOI 10.4049/jimmunol.1600502; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Pascoal TA, 2020, BRAIN, V143, P2818, DOI DOI 10.1093/brain/awaa180; Pascoal TA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10217-w; Pascoal TA, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0402-y; Pascoal TA, 2018, EUR J NUCL MED MOL I, V45, P1021, DOI 10.1007/s00259-018-3933-3; Perez-Nievas BG, 2013, BRAIN, V136, P2510, DOI 10.1093/brain/awt171; Piccio L, 2016, ACTA NEUROPATHOL, V131, P925, DOI 10.1007/s00401-016-1533-5; Rodriguez JA, 2008, FRONT BIOSCI-LANDMRK, V13, P2916, DOI 10.2741/2896; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Sanchez JS, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc0655; Serrano-Pozo A, 2011, AM J PATHOL, V179, P1373, DOI 10.1016/j.ajpath.2011.05.047; Sheffield LG, 2000, NEUROSCI LETT, V285, P165, DOI 10.1016/S0304-3940(00)01037-5; Takeda S, 2016, ANN NEUROL, V80, P355, DOI 10.1002/ana.24716; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Therriault J, 2021, J NUCL MED, V62, P247, DOI 10.2967/jnumed.120.245209; Walsh DM, 2016, NAT REV NEUROSCI, V17, P251, DOI 10.1038/nrn.2016.13; Wang XX, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/908636; Willette AA, 2013, AGE, V35, P2215, DOI 10.1007/s11357-013-9518-y; Zhang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072744; Zhang YQ, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030353; Zou J, 2020, NEUROBIOL AGING, V85, P11, DOI 10.1016/j.neurobiolaging.2019.09.019	63	76	80	24	80	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1592	+		10.1038/s41591-021-01456-w	http://dx.doi.org/10.1038/s41591-021-01456-w		AUG 2021	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34446931	Green Submitted			2022-12-27	WOS:000689656700001
J	Deming, ME; Lyke, KE				Deming, Meagan E.; Lyke, Kirsten E.			A 'mix and match' approach to SARS-CoV-2 vaccination	NATURE MEDICINE			English	Editorial Material								Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.	[Deming, Meagan E.; Lyke, Kirsten E.] Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, Baltimore, MD 20742 USA	University System of Maryland; University of Maryland Baltimore	Lyke, KE (corresponding author), Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, Baltimore, MD 20742 USA.	klyke@som.umaryland.edu	Deming, Meagan/AEX-6400-2022	Deming, Meagan/0000-0003-2574-0542; Lyke, Kirsten/0000-0002-4966-0830	Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) [UM1AI148684]; NIH-NIAID [AI-110852]; Henry M. Jackson Foundation [1701447C]; NIAID [UM1AI148698, U01-HD092308, R01-AE141900, AI110820-06]; Geneva Foundation [V-12VAXHRFS-03]; Medical Technology Enterprise Consortium [MTEC-17-01]	Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Henry M. Jackson Foundation; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Geneva Foundation; Medical Technology Enterprise Consortium	M.E.D. is supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under award number UM1AI148684. K.E.L. is supported by NIH-NIAID under a U01 (AI-110852), distributed by the Henry M. Jackson Foundation (#1701447C). K.E.L. is further supported by additional funding from the NIAID (UM1AI148698, U01-HD092308, R01-AE141900, AI110820-06), The Geneva Foundation (V-12VAXHRFS-03) and Medical Technology Enterprise Consortium (MTEC-17-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Borobia AM, 2021, LANCET, V398, P121, DOI 10.1016/S0140-6736(21)01420-3; Corbett Kizzmekia S, 2021, bioRxiv, DOI 10.1101/2021.04.20.440647; Cucchiari D, 2021, AM J TRANSPLANT, V21, P2727, DOI 10.1111/ajt.16701; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Schmidt T, 2021, NAT MED, V27, P1530, DOI 10.1038/s41591-021-01464-w; Spencer AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23173-1; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Thakkar A., 2021, Cancer Cell, DOI 10.1016/j.ccell.2021.06.002; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	14	31	31	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1510	1511		10.1038/s41591-021-01463-x	http://dx.doi.org/10.1038/s41591-021-01463-x		JUL 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34312555	Bronze			2022-12-27	WOS:000679014800001
J	Harrison, SA; Ruane, PJ; Freilich, BL; Neff, G; Patil, R; Behling, CA; Hu, C; Fong, E; de Temple, B; Tillman, EJ; Rolph, TP; Cheng, A; Yale, K				Harrison, Stephen A.; Ruane, Peter J.; Freilich, Bradley L.; Neff, Guy; Patil, Rashmee; Behling, Cynthia A.; Hu, Chen; Fong, Erica; de Temple, Brittany; Tillman, Erik J.; Rolph, Timothy P.; Cheng, Andrew; Yale, Kitty			Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial	NATURE MEDICINE			English	Article							LIVER-DISEASE; HEPATIC STEATOSIS; FGF21; ASSOCIATION; WEIGHT; ACID	Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We assessed the safety and efficacy of efruxifermin, a long-acting Fc-FGF21 fusion protein, for the treatment of NASH. BALANCED was a randomized, placebo-controlled study in patients with NASH conducted at 27 centers in the United States (ClinicalTrials.gov NCT03976401). Eighty patients, stratified by hepatic fat fraction (HFF) and fibrosis stage, were randomized using a centrally administered minimization algorithm 1:1:1:1 to receive placebo (n = 21) or efruxifermin 28 mg (n = 19), efruxifermin 50 mg (n = 20) or efruxifermin 70 mg (n = 20) via weekly subcutaneous injection for 16 weeks. The primary endpoint-absolute change from baseline in HFF measured as magnetic resonance imaging-proton density fat fraction at week 12-was met. For the full analysis set, the least squares mean absolute changes (one-sided 97.5% confidence interval) from baseline in HFF were -12.3% (-infinity (-inf), -10.3), -13.4% (-inf, -11.4) and -14.1% (-inf, -12.1) in the 28-, 50- and 70-mg groups, respectively, versus 0.3% (-inf, 1.6) in the placebo group, with statistically significant differences between efruxifermin groups and placebo (P < 0.0001 each). Overall, 70 of 79 patients who received the study drug (89%) experienced at least one treatment-emergent adverse event (TEAE), with the majority grade 1-2 (64 (81%)), five (6%) grade 3 and one grade 4. The most commonly reported drug-related TEAEs were grade 1-2 gastrointestinal (36 (46%)). Treatment with efruxifermin significantly reduced HFF in patients with F1-F3 stage NASH, with an acceptable safety profile.	[Harrison, Stephen A.] Pinnacle Clin Res, San Antonio, TX USA; [Ruane, Peter J.] Ruane Clin Res, Los Angeles, CA USA; [Freilich, Bradley L.] Kansas City Res Inst, Kansas City, MO USA; [Neff, Guy] Covenant Res LLC, Sarasota, FL USA; [Patil, Rashmee] South Texas Res Inst, Edinburg, TX USA; [Behling, Cynthia A.] Univ Calif San Diego, Div Gastroenterol, NAFLD Res Ctr, San Diego, CA 92103 USA; [Hu, Chen] Medpace Inc, Cincinnati, OH USA; [Fong, Erica; de Temple, Brittany; Tillman, Erik J.; Rolph, Timothy P.; Cheng, Andrew; Yale, Kitty] Aker Therapeut, San Francisco, CA 94080 USA	University of California System; University of California San Diego	Yale, K (corresponding author), Aker Therapeut, San Francisco, CA 94080 USA.	kyale@akerotx.com		cheng, andrew/0000-0002-1121-8051; Tillman, Erik/0000-0003-3599-0297	Akero Therapeutics	Akero Therapeutics	The authors thank the patients and their families. We also thank afPharmative Insights for medical writing support and R. Shringarpure for critical review of the manuscript. The study was funded by Akero Therapeutics.	Afzali A, 2010, HEPATOLOGY, V52, P578, DOI 10.1002/hep.23717; Bayly G.R, 2014, CLIN BIOCH METABOLIC, Vthird, P702; Brunt EM, 2019, HEPATOLOGY, V70, P522, DOI 10.1002/hep.30418; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Charles ED, 2019, OBESITY, V27, P41, DOI 10.1002/oby.22344; DEPAOLI A, 2019, DIABETES, V68; Frayling TM, 2018, CELL REP, V23, P327, DOI 10.1016/j.celrep.2018.03.070; Gaich G, 2013, CELL METAB, V18, P333, DOI 10.1016/j.cmet.2013.08.005; Gallego-Escuredo JM, 2015, INT J OBESITY, V39, P121, DOI 10.1038/ijo.2014.76; Geng LL, 2020, NAT REV ENDOCRINOL, V16, P654, DOI 10.1038/s41574-020-0386-0; Hall KD, 2008, INT J OBESITY, V32, P573, DOI 10.1038/sj.ijo.0803720; Harrison SA, 2021, GASTROENTEROLOGY, V160, P219, DOI 10.1053/j.gastro.2020.08.004; Harrison SA, 2019, LANCET, V394, P2012, DOI 10.1016/S0140-6736(19)32517-6; Harrison SA, 2020, HEPATOLOGY, V71, P1198, DOI 10.1002/hep.30590; Harrison SA, 2018, LANCET, V391, P1174, DOI 10.1016/S0140-6736(18)30474-4; Irvine KM, 2016, LIVER INT, V36, P370, DOI 10.1111/liv.12896; Kaufman A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100057; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kunder R., 2019, AASLD LIV M; Lambert JE, 2014, GASTROENTEROLOGY, V146, P726, DOI 10.1053/j.gastro.2013.11.049; Lanaspa MA, 2012, J BIOL CHEM, V287, P40732, DOI 10.1074/jbc.M112.399899; Neuschwander-Tetri BA, 2020, GASTROENTEROLOGY, V158, P1984, DOI 10.1053/j.gastro.2020.01.051; Nielsen MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137302; Patel J, 2016, THER ADV GASTROENTER, V9, P692, DOI 10.1177/1756283X16656735; Sanyal A, 2018, LANCET, V392, P2705, DOI 10.1016/S0140-6736(18)31785-9; Shafiei MS, 2011, AM J PATHOL, V178, P2690, DOI 10.1016/j.ajpath.2011.02.035; Stanislaus S, 2017, ENDOCRINOLOGY, V158, P1314, DOI 10.1210/en.2016-1917; Talukdar S, 2016, CELL METAB, V23, P427, DOI 10.1016/j.cmet.2016.02.001; Tillman EJ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.601290; Vilar-Gomez E, 2015, GASTROENTEROLOGY, V149, P367, DOI 10.1053/j.gastro.2015.04.005; Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038; Wong C., 2019, AASLD LIV M; Xu J, 2009, DIABETES, V58, P250, DOI 10.2337/db08-0392; Younossi ZM, 2019, LANCET, V394, P2184, DOI 10.1016/S0140-6736(19)33041-7; Younossi ZM, 2015, HEPATOLOGY, V62, p739A	35	52	53	1	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1262	+		10.1038/s41591-021-01425-3	http://dx.doi.org/10.1038/s41591-021-01425-3		JUL 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34239138	Bronze			2022-12-27	WOS:000672339400005
J	Kustin, T; Harel, N; Finkel, U; Perchik, S; Harari, S; Tahor, M; Caspi, I; Levy, R; Leshchinsky, M; Dror, SK; Bergerzon, G; Gadban, H; Gadban, F; Eliassian, E; Shimron, O; Saleh, L; Ben-Zvi, H; Taraday, EK; Amichay, D; Ben-Dor, A; Sagas, D; Strauss, M; Avni, YS; Huppert, A; Kepten, E; Balicer, RD; Netzer, D; Ben-Shachar, S; Stern, A				Kustin, Talia; Harel, Noam; Finkel, Uriah; Perchik, Shay; Harari, Sheri; Tahor, Maayan; Caspi, Itamar; Levy, Rachel; Leshchinsky, Michael; Ken Dror, Shifra; Bergerzon, Galit; Gadban, Hala; Gadban, Faten; Eliassian, Eti; Shimron, Orit; Saleh, Loulou; Ben-Zvi, Haim; Keren Taraday, Elena; Amichay, Doron; Ben-Dor, Anat; Sagas, Dana; Strauss, Merav; Shemer Avni, Yonat; Huppert, Amit; Kepten, Eldad; Balicer, Ran D.; Netzer, Doron; Ben-Shachar, Shay; Stern, Adi			Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	NATURE MEDICINE			English	Article							MUTATIONS	At early time points after vaccination with a single dose or two doses of the BNT162b2 mRNA COVID-19 vaccine, breakthrough SARS-CoV-2 infections can be disproportionately caused by the B.1.1.7 or B.1.351 variants of concern, underlining the need to ensure rapid and complete vaccination. The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to evidence of reduced neutralization of the VOCs B.1.1.7 and B.1.351 by vaccine sera in laboratory assays. We performed a matched cohort study to examine the distribution of VOCs in infections of BNT162b2 mRNA vaccinees from Clalit Health Services (Israel) using viral genomic sequencing, and hypothesized that if vaccine effectiveness against a VOC is reduced, its proportion among breakthrough cases would be higher than in unvaccinated controls. Analyzing 813 viral genome sequences from nasopharyngeal swabs, we showed that vaccinees who tested positive at least 7 days after the second dose were disproportionally infected with B.1.351, compared with controls. Those who tested positive between 2 weeks after the first dose and 6 days after the second dose were disproportionally infected by B.1.1.7. These findings suggest reduced vaccine effectiveness against both VOCs within particular time windows. Our results emphasize the importance of rigorously tracking viral variants, and of increasing vaccination to prevent the spread of VOCs.	[Kustin, Talia; Harel, Noam; Harari, Sheri; Tahor, Maayan; Caspi, Itamar; Levy, Rachel; Stern, Adi] Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel; [Kustin, Talia; Harel, Noam; Harari, Sheri; Stern, Adi] Tel Aviv Univ, Edmond J Safra Ctr Bioinformat, Tel Aviv, Israel; [Finkel, Uriah; Perchik, Shay; Leshchinsky, Michael; Kepten, Eldad; Balicer, Ran D.; Ben-Shachar, Shay] Clalit Hlth Serv, Innovat Div, Clalit Res Inst, Ramat Gan, Israel; [Ken Dror, Shifra; Bergerzon, Galit; Gadban, Hala; Gadban, Faten] Haifa & Western Galilee, Cent Labs, Clalit Hlth Serv, Nesher, Israel; [Eliassian, Eti; Shimron, Orit] Clalit Hlth Serv, Progenin Labs, Tel Aviv, Israel; [Saleh, Loulou; Ben-Zvi, Haim] Beilinson Med Ctr, Rabin Med Ctr, Microbiol Lab, Petah Tiqwa, Israel; [Keren Taraday, Elena; Amichay, Doron; Ben-Dor, Anat] Clalit Hlth Serv, Cent Lab, Tel Aviv, Israel; [Amichay, Doron] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, Beer Sheva, Israel; [Sagas, Dana; Strauss, Merav] Emek Med Ctr, Microbiol Lab, Afula, Israel; [Shemer Avni, Yonat] Soroka Univ, Lab Clin Virol, Med Ctr, Beer Sheva, Israel; [Shemer Avni, Yonat] Ben Gur Univ Negev, Fac Hlth Sci, Beer Sheva, Israel; [Huppert, Amit] Gertner Inst Epidemiol & Hlth Policy Res, Chaim Sheba Med Ctr, Biostat & Biomath Unit, Ramat Gan, Israel; [Huppert, Amit; Ben-Shachar, Shay] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Netzer, Doron] Clalit Hlth Serv, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Clalit Health Services; Clalit Health Services; Clalit Health Services; Rabin Medical Center; Clalit Health Services; Ben Gurion University; Emek Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Clalit Health Services	Stern, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel.; Stern, A (corresponding author), Tel Aviv Univ, Edmond J Safra Ctr Bioinformat, Tel Aviv, Israel.; Ben-Shachar, S (corresponding author), Clalit Hlth Serv, Innovat Div, Clalit Res Inst, Ramat Gan, Israel.; Ben-Shachar, S (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	shayb@clalit.org.il; sternadi@tauex.tau.ac.il			European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [852223]; Israeli Science Foundation [3963/19]; Edmond J. Safra Center for Bioinformatics at Tel Aviv University	European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme(European Research Council (ERC)); Israeli Science Foundation(Israel Science Foundation); Edmond J. Safra Center for Bioinformatics at Tel Aviv University	We thank R. Milo, N. Kopelman, Y. Woodbridge, D. Burstein and T. Hagai for their advice and discussions, S. Krispin for editing support, and O. Tirosh and M. Meir for extensive technical support. We also thank the Technion Genome Center for rapid sequencing services. This publication is part of a project that has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 852223, RNAVirFitness). This study was further supported by an Israeli Science Foundation grant (3963/19) and by kind donations from the Milner and AppsFlyer foundations. This study was supported in part by fellowships to T.K., N.H. and S.H. from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abu-Raddad L. J, NEW ENGL J MED, DOI [10.1056/NEJMc2104974(2021, DOI 10.1056/NEJMC2104974(2021]; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 2021, OPTIMISING COVID 19; [Anonymous], COVID 19 DASHBOARD; [Anonymous], S AFRICAN VARIANT FO; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Dudas, TRAVEL DRIVEN EMERGE, DOI [10.1101/2021.05.04.21256637(2021), DOI 10.1101/2021.05.04.21256637(2021)]; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006, 10.1101/2021.02.14.21251704]; Gelbart M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009029; Greaney, COMPREHENSIVE MAPPIN, DOI [10.1101/2020.12.31.425021(2021, DOI 10.1101/2020.12.31.425021(2021]; Greaney Allison J, 2021, Cell Host Microbe, V29, P44, DOI [10.1101/2020.09.10.292078, 10.1016/j.chom.2020.11.007]; Guindon S, 2009, METHODS MOL BIOL, V537, P113, DOI 10.1007/978-1-59745-251-9_6; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Itokawa K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239403; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kuzmina A, 2021, CELL HOST MICROBE, V29, P522, DOI 10.1016/j.chom.2021.03.008; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Liu Yang, 2021, N Engl J Med, DOI 10.1056/NEJMc2102017; Marks M, 2021, LANCET INFECT DIS, V21, P629, DOI 10.1016/S1473-3099(20)30985-3; McKinney W., 2010, 9 PYTHON SCI C, V445, P51; Naveca F, 2021, SARS COV 2 REINFECTI; Petter E., INITIAL REAL WORLD E, DOI [10.1101/2021.02.08.21251329v1, DOI 10.1101/2021.02.08.21251329V1, 10.1101/2021.02.08.21251329]; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Starr Tyler N, 2021, Science, V371, P850, DOI [10.1101/2020.11.30.405472, 10.1126/science.abf9302]; Tarke Alison, 2021, bioRxiv, DOI 10.1101/2021.02.27.433180; Tegally H, 2020, MEDRXIV, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640, 10.1101/2020.12.21.20248640(2020]; Villanueva R.A.M. Z.J, 2019, GGPLOT2 ELEGANT GRAP; Walker, INCREASED INFECT NOT, DOI [10.1101/2021.01.13.21249721(2021, DOI 10.1101/2021.01.13.21249721(2021]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; Shi Pei-Yong, 2021, Res Sq, DOI [10.1101/2021.01.07.425740, 10.21203/rs.3.rs-143532/v1]; Zhang XL, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2854-x; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	41	157	157	4	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1379	+		10.1038/s41591-021-01413-7	http://dx.doi.org/10.1038/s41591-021-01413-7		JUN 2021	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34127854	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000661414900003
J	Hege, K				Hege, Kristen			Context matters in CAR T cell tonic signaling	NATURE MEDICINE			English	Editorial Material							CHIMERIC ANTIGEN RECEPTORS	Unexpected clinical results unearth a new facet in CAR design that could facilitate the development of more-effective CAR T cell therapies.	[Hege, Kristen] Bristol Myers Squibb, Early Clin Dev Hematol Oncol & Cell Therapy, Redwood City, CA 94063 USA; [Hege, Kristen] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA	Bristol-Myers Squibb; University of California System; University of California San Francisco	Hege, K (corresponding author), Bristol Myers Squibb, Early Clin Dev Hematol Oncol & Cell Therapy, Redwood City, CA 94063 USA.; Hege, K (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA.	kristen.hege@bms.com						Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Ajina A, 2018, MOL CANCER THER, V17, P1795, DOI 10.1158/1535-7163.MCT-17-1097; Alabanza L, 2017, MOL THER, V25, P2452, DOI 10.1016/j.ymthe.2017.07.013; Calderon H, 2020, METHODS MOL BIOL, V2086, P223, DOI 10.1007/978-1-0716-0146-4_17; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; SCHUSTER SJ, 2017, NEW ENGL J MED, V377, P2545, DOI [10.1056/NEJMoa1708566, DOI 10.1056/NEJMOA1708566]; Singh N, 2021, NAT MED, V27, P842, DOI 10.1038/s41591-021-01326-5	13	3	3	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					763	764		10.1038/s41591-021-01340-7	http://dx.doi.org/10.1038/s41591-021-01340-7		MAY 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33972792				2022-12-27	WOS:000648805100001
J	Michie, S; West, R				Michie, Susan; West, Robert			Sustained behavior change is key to preventing and tackling future pandemics	NATURE MEDICINE			English	Editorial Material								Investment in research and programs to discover and apply the principles that underpin sustained behavior change is needed to address the continuing threat from COVID-19 and future pandemics and will require collaboration among behavioral, social, biomedical, public-health and clinical scientists.	[Michie, Susan] UCL, Ctr Behav Change, London, England; [West, Robert] UCL, Inst Epidemiol & Healthcare, Dept Behav Sci & Hlth, London, England	University of London; University College London; University of London; University College London	Michie, S (corresponding author), UCL, Ctr Behav Change, London, England.; West, R (corresponding author), UCL, Inst Epidemiol & Healthcare, Dept Behav Sci & Hlth, London, England.	s.michie@ucl.ac.uk; robertwest100@gmail.com	Michie, Susan/A-1745-2010; West, Robert/B-5414-2009	Michie, Susan/0000-0003-0063-6378; West, Robert/0000-0001-6398-0921				Atchison C, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043577; Brewer M.B., 2008, RATIONALITY SOCIAL R, P215, DOI DOI 10.4324/9780203889695; Fancourt D, 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.10.19.20215376, DOI 10.1101/2020.10.19.20215376]; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Head MG, 2020, LANCET GLOB HEALTH, V8, pE1295, DOI 10.1016/S2214-109X(20)30357-0; Houghton C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013582; Kerrouche E., 2020, PREPRINT, DOI [10.2139/ssrn.3652543, DOI 10.2139/SSRN.3652543]; Lorencatto F, 2020, PUBLIC HLTH ENGLAND; Michie S, 2014, BEHAV CHANGE WHEEL G, DOI DOI 10.1186/s13012-015-0322-1; Michie S, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2982; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Pichler S, 2020, HEALTH AFFAIR, V39, P2197, DOI 10.1377/hlthaff.2020.00863; Rajan S., 2020, Eurohealth, V26, P34; Smith LE, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n608; Tyler TR, 2003, PERS SOC PSYCHOL REV, V7, P349, DOI 10.1207/S15327957PSPR0704_07; West R., 2020, QEIOS, DOI [10.32388/WW04E6.2, DOI 10.32388/WW04E6, DOI 10.32388/WW04E6.2]; West R, 2020, NAT HUM BEHAV, V4, P451, DOI 10.1038/s41562-020-0887-9; Wood P., 2020, CITYAM; World Health Organization, 2020, REG OFF EUR	19	19	19	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					749	752		10.1038/s41591-021-01345-2	http://dx.doi.org/10.1038/s41591-021-01345-2		MAY 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33972794	Bronze, Green Submitted			2022-12-27	WOS:000648805100004
J	[Anonymous]				[Anonymous]			Preparing for the next pandemic	NATURE MEDICINE			English	Editorial Material																			0	11	11	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					357	357		10.1038/s41591-021-01291-z	http://dx.doi.org/10.1038/s41591-021-01291-z			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33723457	Bronze			2022-12-27	WOS:000629708300001
J	Sridhar, D				Sridhar, Devi			COVID-19: what health experts could and could not predict	NATURE MEDICINE			English	Editorial Material								Nearly a year after the first cases of COVID-19 were reported, it is time to look back and assess what could have been predicted by health experts.	[Sridhar, Devi] Univ Edinburgh, Edinburgh Med Sch, Global Hlth Governance Programme, Edinburgh, Midlothian, Scotland	University of Edinburgh	Sridhar, D (corresponding author), Univ Edinburgh, Edinburgh Med Sch, Global Hlth Governance Programme, Edinburgh, Midlothian, Scotland.	devi.sridhar@ed.ac.uk							0	5	5	1	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1812	1812		10.1038/s41591-020-01170-z	http://dx.doi.org/10.1038/s41591-020-01170-z			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288946	Bronze			2022-12-27	WOS:000596579200025
J	Ganan-Gomez, I; Yang, H; Ma, FY; Montalban-Bravo, G; Thongon, N; Marchica, V; Richard-Carpentier, G; Chien, K; Manyam, G; Wang, F; Alfonso, A; Chen, ST; Class, C; Kanagal-Shamanna, R; Ingram, JP; Ogoti, Y; Rose, A; Loghavi, S; Lockyer, P; Cambo, B; Muftuoglu, M; Schneider, S; Adema, V; McLellan, M; Garza, J; Marchesini, M; Giuliani, N; Pellegrini, M; Wang, J; Walker, J; Li, ZY; Takahashi, K; Leverson, JD; Bueso-Ramos, C; Andreeff, M; Clise-Dwyer, K; Garcia-Manero, G; Colla, S				Ganan-Gomez, Irene; Yang, Hui; Ma, Feiyang; Montalban-Bravo, Guillermo; Thongon, Natthakan; Marchica, Valentina; Richard-Carpentier, Guillaume; Chien, Kelly; Manyam, Ganiraju; Wang, Feng; Alfonso, Ana; Chen, Shuaitong; Class, Caleb; Kanagal-Shamanna, Rashmi; Ingram, Justin P.; Ogoti, Yamini; Rose, Ashley; Loghavi, Sanam; Lockyer, Pamela; Cambo, Benedetta; Muftuoglu, Muharrem; Schneider, Sarah; Adema, Vera; McLellan, Michael; Garza, John; Marchesini, Matteo; Giuliani, Nicola; Pellegrini, Matteo; Wang, Jing; Walker, Jason; Li, Ziyi; Takahashi, Koichi; Leverson, Joel D.; Bueso-Ramos, Carlos; Andreeff, Michael; Clise-Dwyer, Karen; Garcia-Manero, Guillermo; Colla, Simona			Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy	NATURE MEDICINE			English	Article							INTERNATIONAL WORKING GROUP; ACUTE MYELOID-LEUKEMIA; MUTATIONS; VALIDATION; MDS; HEMATOPOIESIS; REGULATORS; DISCOVERY; STANDARDS; NEOPLASMS	Extensive characterization of the stem and progenitor cell hierarchies of myelodysplastic syndromes reveals compensatory survival mechanisms underpinning the failure of hypomethylating agents, and uncovers biomarkers that predict second-line clinical response to venetoclax-based therapy. Myelodysplastic syndromes (MDS) are heterogeneous neoplastic disorders of hematopoietic stem cells (HSCs). The current standard of care for patients with MDS is hypomethylating agent (HMA)-based therapy; however, almost 50% of MDS patients fail HMA therapy and progress to acute myeloid leukemia, facing a dismal prognosis due to lack of approved second-line treatment options. As cancer stem cells are the seeds of disease progression, we investigated the biological properties of the MDS HSCs that drive disease evolution, seeking to uncover vulnerabilities that could be therapeutically exploited. Through integrative molecular profiling of HSCs and progenitor cells in large patient cohorts, we found that MDS HSCs in two distinct differentiation states are maintained throughout the clinical course of the disease, and expand at progression, depending on recurrent activation of the anti-apoptotic regulator BCL-2 or nuclear factor-kappa B-mediated survival pathways. Pharmacologically inhibiting these pathways depleted MDS HSCs and reduced tumor burden in experimental systems. Further, patients with MDS who progressed after failure to frontline HMA therapy and whose HSCs upregulated BCL-2 achieved improved clinical responses to venetoclax-based therapy in the clinical setting. Overall, our study uncovers that HSC architectures in MDS are potential predictive biomarkers to guide second-line treatments after HMA failure. These findings warrant further investigation of HSC-specific survival pathways to identify new therapeutic targets of clinical potential in MDS.	[Ganan-Gomez, Irene; Yang, Hui; Montalban-Bravo, Guillermo; Thongon, Natthakan; Richard-Carpentier, Guillaume; Chien, Kelly; Alfonso, Ana; Chen, Shuaitong; Ogoti, Yamini; Rose, Ashley; Lockyer, Pamela; Muftuoglu, Muharrem; Adema, Vera; Marchesini, Matteo; Takahashi, Koichi; Andreeff, Michael; Garcia-Manero, Guillermo; Colla, Simona] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Ma, Feiyang; Pellegrini, Matteo] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA; [Ma, Feiyang] Univ Michigan, Dept Internal Med, Michigan Med, Div Rheumatol, Ann Arbor, MI 48109 USA; [Marchica, Valentina; Cambo, Benedetta; Giuliani, Nicola] Univ Parma, Dept Med & Surg, Parma, Italy; [Manyam, Ganiraju; Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Wang, Feng] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Class, Caleb; Li, Ziyi] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Kanagal-Shamanna, Rashmi; Loghavi, Sanam; Bueso-Ramos, Carlos] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Ingram, Justin P.; Leverson, Joel D.] AbbVie Oncol Discovery, Chicago, IL USA; [Schneider, Sarah; Clise-Dwyer, Karen] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [McLellan, Michael; Garza, John; Walker, Jason] Washington Univ, McDonnell Genome Inst, St Louis, MO 63110 USA; [Marchesini, Matteo] Ist Romagnolo Studio Tumori Dino Amadori, Meldola, Italy	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; University of Parma; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)	Colla, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	scolla@mdanderson.org	Alfonso-Pierola, Ana/N-6349-2015; Richard-Carpentier, Guillaume/AAH-1567-2020; Ganan-Gomez, Irene/GRF-3018-2022; Ma, Feiyang/GLN-6180-2022	Alfonso-Pierola, Ana/0000-0002-2478-5354; Richard-Carpentier, Guillaume/0000-0001-6452-8814; Ganan-Gomez, Irene/0000-0001-8354-3139; Ma, Feiyang/0000-0002-6260-0787; Schneider, Sarah/0000-0001-7027-7978; Class, Caleb/0000-0003-3130-3613; Muftuoglu, Muharrem/0000-0001-8100-8554	National Institutes of Health (NIH) through MD Anderson's Leukemia SPORE grant [P50 CA100632]; Evans MDS Foundation; Cancer Prevention and Research Institute of Texas [RP140500, RP190295]; NIH through MD Anderson's Cancer Center Support Grant [P30 CA16672]; NIH [U54DK106857]; NIH through a Cancer Center Support Grant [5 P30 CA06516]	National Institutes of Health (NIH) through MD Anderson's Leukemia SPORE grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Evans MDS Foundation; Cancer Prevention and Research Institute of Texas; NIH through MD Anderson's Cancer Center Support Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH through a Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by philanthropic contributions to MD Anderson's AML and MDS Moon Shot Program, by the National Institutes of Health (NIH) through MD Anderson's Leukemia SPORE grant (P50 CA100632), by the Evans MDS Foundation, and by grants from the Cancer Prevention and Research Institute of Texas (RP140500 and RP190295). S.C. is a Scholar of the Leukemia and Lymphoma Society. This work used MD Anderson's South Campus Flow Cytometry & Cell Sorting Core Laboratory, Advanced Technology Genomics Core Facility, Research Histology Core Laboratory and Characterized Cell Line Core, all of which are supported in part by the NIH through MD Anderson's Cancer Center Support Grant (P30 CA16672). The authors thank J. Munch for assistance with manuscript writing, V. Papanna for assistance with flow cytometry, and D. Pollock for assistance with scRNA-seq. The authors thank the Yale Cooperative Center of Excellence in Hematology, which is supported by the NIH (U54DK106857), for critical contributions to the mouse experiments. The authors also thank Dana-Farber/Harvard Cancer Center for the use of the Specialized Histopathology Core, which provided IHC services and is supported in part by the NIH through a Cancer Center Support Grant (5 P30 CA06516). Supplementary Figure panels 6f, 8b and 8d were created using BioRender.com.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bejar R, 2014, BLOOD, V124, P2705, DOI 10.1182/blood-2014-06-582809; Chen JH, 2019, NAT MED, V25, P103, DOI 10.1038/s41591-018-0267-4; Chen Y, 2012, BLOOD, V119, P4971, DOI 10.1182/blood-2011-11-389957; Chesnais V, 2017, BLOOD, V129, P484, DOI 10.1182/blood-2016-03-707745; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149; Colla S, 2015, CANCER CELL, V27, P644, DOI 10.1016/j.ccell.2015.04.007; Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111; Craddock C, 2013, LEUKEMIA, V27, P1028, DOI 10.1038/leu.2012.312; da Silva-Coelho P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15099; Dai YT, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859-021-04054-2; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Georgiades P, 2002, GENESIS, V34, P251, DOI 10.1002/gene.10161; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Jabbour E, 2010, CANCER-AM CANCER SOC, V116, P3830, DOI 10.1002/cncr.25247; Kanagal-Shamanna R, 2016, EXPERT REV MOL DIAGN, V16, P461, DOI 10.1586/14737159.2016.1142374; Kanchi KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4156; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim E, 2015, CANCER CELL, V27, P617, DOI 10.1016/j.ccell.2015.04.006; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lin FC, 2014, BLOOD, V124, P3699, DOI 10.1182/blood-2014-01-549527; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Lu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10086; Makishima H, 2017, NAT GENET, V49, P204, DOI 10.1038/ng.3742; Matsuoka A, 2010, LEUKEMIA, V24, P748, DOI 10.1038/leu.2009.296; Montalban-Bravo G, 2019, BLOOD ADV, V3, P922, DOI 10.1182/bloodadvances.2018026989; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Mortera-Blanco T, 2017, BLOOD, V130, P881, DOI 10.1182/blood-2017-03-776070; Nakagawa M, 2011, BLOOD, V118, P6626, DOI 10.1182/blood-2010-12-326710; Notta F, 2016, SCIENCE, V351, P139, DOI 10.1126/science.aab2116; Pang WW, 2013, P NATL ACAD SCI USA, V110, P3011, DOI 10.1073/pnas.1222861110; Pellin D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10291-0; Platzbecker U, 2021, LEUKEMIA, V35, P2182, DOI 10.1038/s41375-021-01265-7; Prebet T, 2011, J CLIN ONCOL, V29, P3322, DOI 10.1200/JCO.2011.35.8135; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; R Core Team. R Foundation for Statistical Computing, 2016, R LANG ENV STAT COMP; Rahman N, 2014, NATURE, V505, P302, DOI 10.1038/nature12981; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Shirai CL, 2015, CANCER CELL, V27, P631, DOI 10.1016/j.ccell.2015.04.008; Shyr C, 2014, BMC MED GENOMICS, V7, DOI 10.1186/s12920-014-0064-y; Sperling AS, 2017, NAT REV CANCER, V17, P5, DOI 10.1038/nrc.2016.112; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Takahashi K, 2017, LANCET ONCOL, V18, P100, DOI 10.1016/S1470-2045(16)30626-X; Takahashi K, 2016, ONCOTARGET, V7, P14172, DOI 10.18632/oncotarget.7290; Tober J, 2013, DEVELOPMENT, V140, P3765, DOI 10.1242/dev.094961; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Will B, 2012, BLOOD, V120, P2076, DOI 10.1182/blood-2011-12-399683; Woll PS, 2014, CANCER CELL, V25, P794, DOI 10.1016/j.ccr.2014.03.036; Yamashita M, 2019, CELL STEM CELL, V25, P357, DOI 10.1016/j.stem.2019.05.019; ZHOU YY, 2019, NAT COMMUN, V10, DOI [DOI 10.1038/S41467-019-09234-6, 10.1038/S41467-019-09234-6, DOI 10.1038/s41587-020-0546-8]	61	5	5	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					557	+		10.1038/s41591-022-01696-4	http://dx.doi.org/10.1038/s41591-022-01696-4		MAR 2022	34	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35241842	Green Published, hybrid			2022-12-27	WOS:000763900400002
J	Wei, J; Pouwels, KB; Stoesser, N; Matthews, PC; Diamond, I; Studley, R; Rourke, E; Cook, D; Bell, JI; Newton, JN; Farrar, J; Howarth, A; Marsden, BD; Hoosdally, S; Jones, EY; Stuart, DI; Crook, DW; Peto, TEA; Walker, AS; Eyre, DW				Wei, Jia; Pouwels, Koen B.; Stoesser, Nicole; Matthews, Philippa C.; Diamond, Ian; Studley, Ruth; Rourke, Emma; Cook, Duncan; Bell, John, I; Newton, John N.; Farrar, Jeremy; Howarth, Alison; Marsden, Brian D.; Hoosdally, Sarah; Jones, E. Yvonne; Stuart, David, I; Crook, Derrick W.; Peto, Tim E. A.; Walker, A. Sarah; Eyre, David W.		COVID-19 Infection Survey Team	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines	NATURE MEDICINE			English	Article							COVID-19 VACCINE; SARS-COV-2; INFECTION	Antibody responses are an important part of immunity after Coronavirus Disease 2019 (COVID-19) vaccination. However, antibody trajectories and the associated duration of protection after a second vaccine dose remain unclear. In this study, we investigated anti-spike IgG antibody responses and correlates of protection after second doses of ChAdOx1 or BNT162b2 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United Kingdom general population. In 222,493 individuals, we found significant boosting of anti-spike IgG by the second doses of both vaccines in all ages and using different dosing intervals, including the 3-week interval for BNT162b2. After second vaccination, BNT162b2 generated higher peak levels than ChAdOX1. Older individuals and males had lower peak levels with BNT162b2 but not ChAdOx1, whereas declines were similar across ages and sexes with ChAdOX1 or BNT162b2. Prior infection significantly increased antibody peak level and half-life with both vaccines. Anti-spike IgG levels were associated with protection from infection after vaccination and, to an even greater degree, after prior infection. At least 67% protection against infection was estimated to last for 2-3 months after two ChAdOx1 doses, for 5-8 months after two BNT162b2 doses in those without prior infection and for 1-2 years for those unvaccinated after natural infection. A third booster dose might be needed, prioritized to ChAdOx1 recipients and those more clinically vulnerable. A large study in the United Kingdom shows that virus-specific antibody levels associated with at least 67% protection against SARS-CoV-2 Delta variant infection last longer after two doses of BNT162b2 vaccine than after two doses of ChAdOx1 vaccine in previously uninfected individuals.	[Wei, Jia; Stoesser, Nicole; Matthews, Philippa C.; Howarth, Alison; Marsden, Brian D.; Hoosdally, Sarah; Jones, E. Yvonne; Stuart, David, I; Crook, Derrick W.; Peto, Tim E. A.; Walker, A. Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England; [Wei, Jia; Walker, A. Sarah; Eyre, David W.] Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Oxford, England; [Pouwels, Koen B.; Stoesser, Nicole; Crook, Derrick W.; Peto, Tim E. A.; Walker, A. Sarah; Eyre, David W.] Univ Oxford, Natl Inst Hlth Res Hlth, Protect Res Unit Healthcare Associated Infect & A, Oxford, England; [Pouwels, Koen B.] Univ Oxford, Hlth Econ Res Ctr, Nuffield Dept Populat Hlth, Oxford, England; [Stoesser, Nicole; Crook, Derrick W.; Peto, Tim E. A.; Eyre, David W.] Univ Oxford, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford, England; [Stoesser, Nicole; Matthews, Philippa C.; Howarth, Alison; Crook, Derrick W.; Peto, Tim E. A.; Eyre, David W.] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Dept Infect Dis & Microbiol, Oxford, England; [Diamond, Ian; Studley, Ruth; Rourke, Emma; Cook, Duncan] Off Natl Stat, Newport, Shrops, England; [Bell, John, I] Univ Oxford, Off Regius Prof Med, Oxford, England; [Newton, John N.] Publ Hlth England, Hlth Improvement Directorate, London, England; [Farrar, Jeremy] Wellcome Trust Res Labs, London, England; [Marsden, Brian D.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Walker, A. Sarah] UCL, VIRC Clin Trials Unit UCL, London, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Public Health England; University of Oxford; University of London; University College London	Eyre, DW (corresponding author), Univ Oxford, Big Data Inst, Nuffield Dept Populat Hlth, Oxford, England.; Eyre, DW (corresponding author), Univ Oxford, Natl Inst Hlth Res Hlth, Protect Res Unit Healthcare Associated Infect & A, Oxford, England.; Eyre, DW (corresponding author), Univ Oxford, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford, England.; Eyre, DW (corresponding author), Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Dept Infect Dis & Microbiol, Oxford, England.	david.eyre@bdi.ox.ac.uk	Brown, Brent/HIR-3281-2022; Walker, Sarah/HDM-8717-2022; Farrar, Jeremy J./HGA-7610-2022; Newton, John/HCH-8693-2022; Eyre, David/P-6887-2016	Brown, Brent/0000-0001-5238-6943; Pouwels, Koen/0000-0001-7097-8950; Eyre, David/0000-0001-5095-6367; Matthews, Philippa/0000-0002-4036-4269; Screaton, Gavin/0000-0002-3549-4309	Department of Health and Social Care; University of Oxford; China Scholarship Council; National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; UK Health Security Agency (UKHSA) [NIHR200915]; NIHR Oxford Biomedical Research Centre; Huo Family Foundation; Medical Research Council UK [MC_UU_12023/22]; Wellcome [110110/Z/15/Z]; NIHR Oxford BRC Senior Fellowship; Robertson Fellowship	Department of Health and Social Care; University of Oxford; China Scholarship Council(China Scholarship Council); National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford; UK Health Security Agency (UKHSA); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Huo Family Foundation; Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome; NIHR Oxford BRC Senior Fellowship; Robertson Fellowship	We are grateful for the support of all COVID-19 Infection Survey participants. This study is funded by the Department of Health and Social Care with in-kind support from the Welsh Government and the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. J.W. is supported by the University of Oxford and the China Scholarship Council. A.S.W., T.E.A.P., N.S., D.E. and K.B.P. are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, in partnership with the UK Health Security Agency (UKHSA) (NIHR200915). A.S.W. and T.E.A.P. are also supported by the NIHR Oxford Biomedical Research Centre. K.B.P. is also supported by the Huo Family Foundation. A.S.W. is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit (MC_UU_12023/22) and is an NIHR Senior Investigator. P.C.M. is funded by Wellcome (intermediate fellowship, grant ref. 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship. D.W.E. is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. N.S. is an Oxford Martin Fellow and holds an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health or UKHSA.	Amirthalingam G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27410-5; Amodio E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070714; [Anonymous], 2021, VACCINATIONS UK; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bunders MJ, 2020, IMMUNITY, V53, P487, DOI 10.1016/j.immuni.2020.08.003; Buonfrate D, 2021, CLIN MICROBIOL INFEC, V27, P1845, DOI 10.1016/j.cmi.2021.07.024; Dejnirattisai W, 2021, CELL, V184, P2183, DOI 10.1016/j.cell.2021.02.032; Department of Health and Social Care, 2021, MOST VULN OFF 2 DOS; Department of Health and Social Care, 2021, PRIOR 1 COVID 19 VAC; Department of Health & Social Care, 2021, UK COVID 19 VACC DEL; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Eyre DW, 2022, NEW ENGL J MED, V386, P744, DOI 10.1056/NEJMoa2116597; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Fraley E., 2021, CLIN INFECT DIS; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI [10.1016/j.chom.2020.06.010, 10.1016/j.chom.2020.07.002]; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; Liu XX, 2021, LANCET, V398, P856, DOI 10.1016/S0140-6736(21)01694-9; Lumley SF, 2021, CLIN INFECT DIS, V73, pE699, DOI 10.1093/cid/ciab004; Maeda K, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-01930-y, 10.1101/2021.07.27.21261237]; Medicines and Healthcare products Regulatory Agency, 2020, REG APPR PFIZ BIONTE; Medicines and Healthcare products Regulatory Agency, 2020, OTEVRISVOUMYS 1116; Nemet I, 2022, NEW ENGL J MED, V386, P492, DOI 10.1056/NEJMc2119358; Noori M, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2277; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Parry H, 2022, NPJ VACCINES, V7, DOI 10.1038/s41541-022-00432-w; Payne RP, 2021, CELL, V184, P5699, DOI 10.1016/j.cell.2021.10.011; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Pouwels KB, 2021, LANCET PUBLIC HEALTH, V6, pE30, DOI 10.1016/S2468-2667(20)30282-6; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shields AM, 2021, BMJ OPEN RESPIR RES, V8, DOI 10.1136/bmjresp-2020-000872; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Supasa P, 2021, CELL, V184, P2201, DOI 10.1016/j.cell.2021.02.033; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; UK Health Security Agency, 2021, ESTIMATING PREVALENC; UK Health Security Agency, SARS COV 2 VAR INV; Urbanowicz RA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abj0847; Van Praet JT, 2021, J INFECT DIS, V224, P1690, DOI 10.1093/infdis/jiab458; Vicenti I, 2022, INFECTION, V50, P541, DOI 10.1007/s15010-021-01680-z; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Ward H., 2021, VACCINE UPTAKE SARS, DOI [10.1101/2021.07.14.21260497v1, DOI 10.1101/2021.07.14.21260497V1]; Wei J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26479-2; Wei J, 2021, NAT MICROBIOL, V6, P1140, DOI 10.1038/s41564-021-00947-3; Zhong D, 2021, JAMA-J AM MED ASSOC, V326, P2524, DOI 10.1001/jama.2021.19996	57	36	36	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1072	+		10.1038/s41591-022-01721-6	http://dx.doi.org/10.1038/s41591-022-01721-6		FEB 2022	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35165453	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000754955000002
J	Gruell, H; Vanshylla, K; Tober-Lau, P; Hillus, D; Schommers, P; Lehmann, C; Kurth, F; Sander, LE; Klein, F				Gruell, Henning; Vanshylla, Kanika; Tober-Lau, Pinkus; Hillus, David; Schommers, Philipp; Lehmann, Clara; Kurth, Florian; Sander, Leif E.; Klein, Florian			mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	NATURE MEDICINE			English	Article								Neutralization of the SARS-CoV-2 Omicron variant is markedly impaired in sera from recipients of two doses of the COVID-19 vaccine BNT162b2 or from convalescent individuals, but is robustly increased in both groups following a booster vaccine dose. The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the globe. This new variant of concern carries an unusually high number of mutations in key epitopes of neutralizing antibodies on the viral spike glycoprotein, suggesting potential immune evasion. Here we assessed serum neutralizing capacity in longitudinal cohorts of vaccinated and convalescent individuals, as well as monoclonal antibody activity against Omicron using pseudovirus neutralization assays. We report a near-complete lack of neutralizing activity against Omicron in polyclonal sera from individuals vaccinated with two doses of the BNT162b2 COVID-19 vaccine and from convalescent individuals, as well as resistance to different monoclonal antibodies in clinical use. However, mRNA booster immunizations in vaccinated and convalescent individuals resulted in a significant increase of serum neutralizing activity against Omicron. This study demonstrates that booster immunizations can critically improve the humoral immune response against the Omicron variant.	[Gruell, Henning; Vanshylla, Kanika; Schommers, Philipp; Klein, Florian] Univ Cologne, Fac Med, Inst Virol, Lab Expt Immunol, Cologne, Germany; [Gruell, Henning; Vanshylla, Kanika; Schommers, Philipp; Lehmann, Clara; Klein, Florian] Univ Cologne, Univ Hosp Cologne, Cologne, Germany; [Tober-Lau, Pinkus; Hillus, David; Kurth, Florian; Sander, Leif E.] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany; [Tober-Lau, Pinkus; Hillus, David; Kurth, Florian; Sander, Leif E.] Free Univ Berlin, Berlin, Germany; [Tober-Lau, Pinkus; Hillus, David; Kurth, Florian; Sander, Leif E.] Humboldt Univ, Berlin, Germany; [Schommers, Philipp; Lehmann, Clara] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany; [Lehmann, Clara; Klein, Florian] German Ctr Infect Res, Partner Site Bonn Cologne, Cologne, Germany; [Lehmann, Clara; Klein, Florian] Univ Cologne, Ctr Mol Med Cologne CMMC, Cologne, Germany; [Kurth, Florian] Univ Med Ctr Hamburg Eppendorf, Bernhard Nocht Inst Trop Med, Dept Trop Med, Hamburg, Germany; [Kurth, Florian] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany	University of Cologne; University of Cologne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; University of Cologne; German Center for Infection Research; University of Cologne; University of Cologne; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Klein, F (corresponding author), Univ Cologne, Fac Med, Inst Virol, Lab Expt Immunol, Cologne, Germany.; Klein, F (corresponding author), Univ Cologne, Univ Hosp Cologne, Cologne, Germany.; Klein, F (corresponding author), German Ctr Infect Res, Partner Site Bonn Cologne, Cologne, Germany.; Klein, F (corresponding author), Univ Cologne, Ctr Mol Med Cologne CMMC, Cologne, Germany.	florian.klein@uk-koeln.de		Sander, Leif Erik/0000-0002-0476-9947; Tober-Lau, Pinkus/0000-0002-9148-3663; Kurth, Florian/0000-0002-3807-473X; Grull, Henning/0000-0002-0725-7138; Vanshylla, Kanika/0000-0003-4552-9170	COVIM: NaFoUniMedCovid19 [FKZ: 01KX2021]; Federal Institute for Drugs and Medical Devices [V-2021.3 / 1503_68403 / 2021-2022]; German Center for Infection Research (DZIF); Deutsche Forschungsgemeinschaft (DFG) [CRC1310]	COVIM: NaFoUniMedCovid19; Federal Institute for Drugs and Medical Devices; German Center for Infection Research (DZIF); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank all of the study participants. We also thank M. Augustin, F. Dewald, L. Gieselmann, B. Kurt, P. Mayer, N. Riet, S. Salomon, R. Scharping, M. Schlotz, R. Stumpf and H. Wustenberg, as well as the members of the EICOV/COVIM Study Group, for sample acquisition and processing: Y. Ahlgrimm, B. Al-Rim, L. Bardtke, K. Behn, N. Bethke, H. Bias, D. Briesemeister, C. Conrad, V. M. Corman, C. Dang-Heine, S. Dieckmann, D. Frey, J.-A. Gabelich, J. Gerdes, U. Glaser, A. Hetey, L. Hasler, E. T. Helbig, A. Horn, C. Hulso, S. Jentzsch, C. von Kalle, L. Kegel, A. Krannich, W. Koch, P. Kopankiewicz, P. Kroneberg, I. Landgraf, H. Le, L. J. Lippert, M. Lisy, C. Luttke, P. de Macedo Gomes, B. Mae ss, J. Michel, F. Munn, A. Nitsche, A.-M. Ollech, C. Peiser, A. Pioch, C. Pley, K. Pohl, A. Richter, M. Ronnefarth, C. Rubisch, L. Ruby, A. Sanchez Rezza, I. Schellenberger, V. Schenkel, J. Schlesinger, S. Schmidt, G. Schwanitz, T. Schwarz, S. Senaydin, J. Seybold, A.-S. Sinnigen, A. Solarek, A. Stege, S. Steinbrecher, P. Stubbemann, C. Thibeault, D. Treue and S. Zvorc. We thank Boehringer Ingelheim for providing the antibodies REGN10933 and REGN10987. This work was supported by grants from COVIM: NaFoUniMedCovid19 (FKZ: 01KX2021) (to L.E.S. and F. Klein), the Federal Institute for Drugs and Medical Devices (V-2021.3 / 1503_68403 / 2021-2022) (to F. Kurth and L.E.S.), by the German Center for Infection Research (DZIF) (to F. Klein), and the Deutsche Forschungsgemeinschaft (DFG) CRC1310 (to F. Klein). The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.	Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006, 10.1101/2021.02.14.21251704]; Goel RR, 2021, SCIENCE, V374, P1214, DOI 10.1126/science.abm0829; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Greaney Allison J, 2021, Cell Host Microbe, V29, P463, DOI 10.1016/j.chom.2021.02.003; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Halwe S, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081498; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Jones BE, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1906; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Muecksch F, 2021, IMMUNITY, V54, P1853, DOI 10.1016/j.immuni.2021.07.008; O'Brien Meagan P, 2021, medRxiv, DOI 10.1101/2021.06.14.21258567; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Pulliam JRC., 2021, INCREASED RISK SARS, DOI [10.1101/2021.11.11.21266068, 10.1101/2021.11.11.21266068:2021.11.11.21266068, DOI 10.1101/2021.11.11.21266068:2021.11.11.21266068]; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Schmidt F, 2021, NATURE, V600, P512, DOI 10.1038/s41586-021-04005-0; Scott L, 2021, SCIENCE, V374, P1454, DOI 10.1126/science.abn4543; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Sholukh AM, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00527-21; Tober-Lau P, 2021, LANCET RESP MED, V9, pE104, DOI 10.1016/S2213-2600(21)00456-2; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Vanshylla K, 2021, CELL HOST MICROBE, V29, P917, DOI 10.1016/j.chom.2021.04.015; Wang PF, 2022, EMERG MICROBES INFEC, V11, P147, DOI [10.1080/22221751.2021.2011623, 10.1101/2021.10.13.464307]	30	148	149	8	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2022	28	3					477	+		10.1038/s41591-021-01676-0	http://dx.doi.org/10.1038/s41591-021-01676-0		JAN 2022	6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZX1PU	35046572	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000745735100002
J	Das, A; Sudhaman, S; Morgenstern, D; Coblentz, A; Chung, J; Stone, SC; Alsafwani, N; Liu, ZA; Abu Al Karsaneh, O; Soleimani, S; Ladany, H; Chen, D; Zatzman, M; Cabric, V; Nobre, L; Bianchi, V; Edwards, M; Nahum, LCS; Ercan, AB; Nabbi, A; Constantini, S; Dvir, R; Yalon-Oren, M; Campino, GA; Caspi, S; Larouche, V; Reddy, A; Osborn, M; Mason, G; Lindhorst, S; Bronsema, A; Magimairajan, V; Opocher, E; De Mola, RL; Sabel, M; Frojd, C; Sumerauer, D; Samuel, D; Cole, K; Chiaravalli, S; Massimino, M; Tomboc, P; Ziegler, DS; George, B; Van Damme, A; Hijiya, N; Gass, D; McGee, RB; Mordechai, O; Bowers, DC; Laetsch, TW; Lossos, A; Blumenthal, DT; Sarosiek, T; Yen, LY; Knipstein, J; Bendel, A; Hoffman, LM; Luna-Fineman, S; Zimmermann, S; Scheers, I; Nichols, KE; Zapotocky, M; Hansford, JR; Maris, JM; Dirks, P; Taylor, MD; Kulkarni, AV; Shroff, M; Tsang, DS; Villani, A; Xu, W; Aronson, M; Durno, C; Shlien, A; Malkin, D; Getz, G; Maruvka, YE; Ohashi, PS; Hawkins, C; Pugh, TJ; Bouffet, E; Tabori, U				Das, Anirban; Sudhaman, Sumedha; Morgenstern, Daniel; Coblentz, Ailish; Chung, Jiil; Stone, Simone C.; Alsafwani, Noor; Liu, Zhihui Amy; Abu Al Karsaneh, Ola; Soleimani, Shirin; Ladany, Hagay; Chen, David; Zatzman, Matthew; Cabric, Vanja; Nobre, Liana; Bianchi, Vanessa; Edwards, Melissa; Nahum, Lauren C. Sambira; Ercan, Ayse B.; Nabbi, Arash; Constantini, Shlomi; Dvir, Rina; Yalon-Oren, Michal; Campino, Gadi Abebe; Caspi, Shani; Larouche, Valerie; Reddy, Alyssa; Osborn, Michael; Mason, Gary; Lindhorst, Scott; Bronsema, Annika; Magimairajan, Vanan; Opocher, Enrico; De Mola, Rebecca Loret; Sabel, Magnus; Frojd, Charlotta; Sumerauer, David; Samuel, David; Cole, Kristina; Chiaravalli, Stefano; Massimino, Maura; Tomboc, Patrick; Ziegler, David S.; George, Ben; Van Damme, An; Hijiya, Nobuko; Gass, David; McGee, Rose B.; Mordechai, Oz; Bowers, Daniel C.; Laetsch, Theodore W.; Lossos, Alexander; Blumenthal, Deborah T.; Sarosiek, Tomasz; Yen, Lee Yi; Knipstein, Jeffrey; Bendel, Anne; Hoffman, Lindsey M.; Luna-Fineman, Sandra; Zimmermann, Stefanie; Scheers, Isabelle; Nichols, Kim E.; Zapotocky, Michal; Hansford, Jordan R.; Maris, John M.; Dirks, Peter; Taylor, Michael D.; Kulkarni, Abhaya, V; Shroff, Manohar; Tsang, Derek S.; Villani, Anita; Xu, Wei; Aronson, Melyssa; Durno, Carol; Shlien, Adam; Malkin, David; Getz, Gad; Maruvka, Yosef E.; Ohashi, Pamela S.; Hawkins, Cynthia; Pugh, Trevor J.; Bouffet, Eric; Tabori, Uri			Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency	NATURE MEDICINE			English	Article							HIGH-GRADE GLIOMAS; SOLID TUMORS; COLON-CANCER; PEDIATRIC-PATIENTS; IMMUNE CELLS; SINGLE-ARM; OPEN-LABEL; SURVIVAL; IMMUNOTHERAPY; PEMBROLIZUMAB	Cancers arising from germline DNA mismatch repair deficiency or polymerase proofreading deficiency (MMRD and PPD) in children harbour the highest mutational and microsatellite insertion-deletion (MS-indel) burden in humans. MMRD and PPD cancers are commonly lethal due to the inherent resistance to chemo-irradiation. Although immune checkpoint inhibitors (ICIs) have failed to benefit children in previous studies, we hypothesized that hypermutation caused by MMRD and PPD will improve outcomes following ICI treatment in these patients. Using an international consortium registry study, we report on the ICI treatment of 45 progressive or recurrent tumors from 38 patients. Durable objective responses were observed in most patients, culminating in a 3 year survival of 41.4%. High mutation burden predicted response for ultra-hypermutant cancers (>100 mutations per Mb) enriched for combined MMRD + PPD, while MS-indels predicted response in MMRD tumors with lower mutation burden (10-100 mutations per Mb). Furthermore, both mechanisms were associated with increased immune infiltration even in 'immunologically cold' tumors such as gliomas, contributing to the favorable response. Pseudo-progression (flare) was common and was associated with immune activation in the tumor microenvironment and systemically. Furthermore, patients with flare who continued ICI treatment achieved durable responses. This study demonstrates improved survival for patients with tumors not previously known to respond to ICI treatment, including central nervous system and synchronous cancers, and identifies the dual roles of mutation burden and MS-indels in predicting sustained response to immunotherapy. Hypermutation and microsatellite burden determine responses and long-term survival following PD-1 blockade in children and young adults with refractory cancers resulting from germline DNA replication repair deficiency.	[Das, Anirban; Morgenstern, Daniel; Nobre, Liana; Nahum, Lauren C. Sambira; Villani, Anita; Malkin, David; Bouffet, Eric; Tabori, Uri] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada; [Das, Anirban; Sudhaman, Sumedha; Chung, Jiil; Chen, David; Zatzman, Matthew; Nobre, Liana; Bianchi, Vanessa; Edwards, Melissa; Ercan, Ayse B.; Shlien, Adam; Malkin, David; Tabori, Uri] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON, Canada; [Das, Anirban; Sudhaman, Sumedha; Chung, Jiil; Nobre, Liana; Bianchi, Vanessa; Edwards, Melissa; Ercan, Ayse B.; Dirks, Peter; Taylor, Michael D.; Tabori, Uri] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada; [Das, Anirban] Tata Med Ctr, Dept Paediat Haematol Oncol, Kolkata, India; [Morgenstern, Daniel; Cabric, Vanja; Villani, Anita; Malkin, David; Bouffet, Eric; Tabori, Uri] Univ Toronto, Dept Paediat, Toronto, ON, Canada; [Coblentz, Ailish; Shroff, Manohar] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON, Canada; [Chung, Jiil; Ercan, Ayse B.] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada; [Stone, Simone C.; Soleimani, Shirin; Nabbi, Arash; Ohashi, Pamela S.; Pugh, Trevor J.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Alsafwani, Noor; Abu Al Karsaneh, Ola; Zatzman, Matthew] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Alsafwani, Noor] Imam Abdulrahman Bin Faisal Univ IAU, Coll Med, Dept Pathol, Dammam, Saudi Arabia; [Liu, Zhihui Amy; Xu, Wei] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada; [Liu, Zhihui Amy; Xu, Wei] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Abu Al Karsaneh, Ola] Hashemite Univ, Fac Med, Dept Basic Med Sci, Zarqa, Jordan; [Soleimani, Shirin; Malkin, David; Pugh, Trevor J.; Tabori, Uri] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Ladany, Hagay; Maruvka, Yosef E.] Technion Israel Inst Technol, Biotechnol & Food Engn, Tel Aviv, Israel; [Constantini, Shlomi] Dana Childrens Hosp, Dept Pediat Neurosurg, Tel Aviv, Israel; [Dvir, Rina] Tel Aviv Sourasky Med Ctr, Dept Pediat Hematol Oncol, Tel Aviv, Israel; [Yalon-Oren, Michal; Campino, Gadi Abebe; Caspi, Shani] Sheba Med Ctr, Dept Pediat Hematol Oncol, Ramat Gan, Israel; [Larouche, Valerie] Ctr Hosp Quebec Univ Laval, Dept Paediat Haematol Oncol, Quebec City, PQ, Canada; [Reddy, Alyssa] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Reddy, Alyssa] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Osborn, Michael] Womens & Childrens Hosp, Adelaide, SA, Australia; [Mason, Gary] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Lindhorst, Scott] Med Univ South Carolina, Dept Neurosurg, Neurooncol, Charleston, SC 29425 USA; [Lindhorst, Scott] Med Univ South Carolina, Dept Med, Div Hematol Med Oncol, Charleston, SC 29425 USA; [Bronsema, Annika] Univ Med Ctr Hamburg Eppendorf, Dept Paediat Haematol & Oncol, Hamburg, Germany; [Magimairajan, Vanan] Univ Manitoba, Res Inst Oncol & Haematol, Dept Paediat Haematol Oncol, Canc Care Manitoba, Winnipeg, MB, Canada; [Opocher, Enrico] Padua Univ Hosp, Paediat Haematol Oncol & Stem Cell Transplant Div, Padua, Italy; [De Mola, Rebecca Loret] Helen DeVos Children S Hosp, Pediat Hematol Oncol, Grand Rapids, MI USA; [Sabel, Magnus] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Inst Clin Sci,Dept Paediat, Gothenburg, Sweden; [Sabel, Magnus] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, Gothenburg, Sweden; [Frojd, Charlotta] Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden; [Sumerauer, David; Zapotocky, Michal] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Samuel, David] Valley Childrens Hosp, Dept Pediat Oncol, Madera, CA USA; [Cole, Kristina; Laetsch, Theodore W.; Maris, John M.] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Dept Pediat,Div Oncol, Philadelpha, PA USA; [Cole, Kristina; Laetsch, Theodore W.; Maris, John M.] Univ Penn, Perelman Sch Med, Dept Pediat, Childrens Hosp Philadelphia,Ctr Childhood Canc Re, Philadelpha, PA USA; [Chiaravalli, Stefano; Massimino, Maura] Fdn IRCCS Ist Nazl Tumori, Paediat Unit, Milan, Italy; [Tomboc, Patrick] West Virginia Univ, Dept Pediat, JW Ruby Mem Hosp, Morgantown, WV USA; [Ziegler, David S.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia; [Ziegler, David S.] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [George, Ben] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [Van Damme, An] Catholic Univ Louvain, Dept Paediat Haematol & Oncol, St Luc Univ Hosp, Brussels, Belgium; [Hijiya, Nobuko] Columbia Univ, Irving Med Ctr, Div Pediat Hematol Oncol Stem Cell Transplantat, New York, NY USA; [Gass, David] Atrium Hlth Levine Childrens Hosp, Charlotte, NC USA; [McGee, Rose B.; Nichols, Kim E.] St Jude Childrens Res Hosp, Canc Predisposit Div, Oncol Dept, 332 N Lauderdale St, Memphis, TN 38105 USA; [Mordechai, Oz] Rambam Hlth Care Campus, Dept Pediat Hematol Oncol, Haifa, Israel; [Bowers, Daniel C.] Univ Texas Southwestern Med Sch Dallas, Dept Pediat, Dallas, TX USA; [Lossos, Alexander] Hadassah Hebrew Univ Med Ctr, Leslie & Michael Gaffin Ctr Neurooncol, Dept Oncol, Jerusalem, Israel; [Blumenthal, Deborah T.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Neurooncol Serv, Tel Aviv, Israel; [Sarosiek, Tomasz] Lux Med Onkol, Warsaw, Poland; [Yen, Lee Yi] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan; [Knipstein, Jeffrey] Med Coll Wisconsin, Div Pediat Hematol Oncol BMT, Milwaukee, WI 53226 USA; [Bendel, Anne] Childrens Hosp & Clin Minnesota, Dept Pediat Hematol Oncol, St Paul, MN USA; [Hoffman, Lindsey M.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Luna-Fineman, Sandra] Childrens Hosp Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO USA; [Zimmermann, Stefanie] Univ Hosp Frankfurt, Paediat Haematol & Oncol, Frankfurt, Germany; [Scheers, Isabelle] Catholic Univ Louvain, Paediat Gastroenterol Hepatol & Nutr Unit, Clin Univ St Luc, Brussels, Belgium; [Hansford, Jordan R.] Univ Melbourne, Royal Childrens Hosp, Childrens Canc Ctr, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Hansford, Jordan R.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Dirks, Peter; Taylor, Michael D.; Kulkarni, Abhaya, V] Hosp Sick Children, Div Neurosurg, Toronto, ON, Canada; [Dirks, Peter; Taylor, Michael D.] Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON, Canada; [Kulkarni, Abhaya, V] Hosp Sick Children, Res Inst, Child Hlth Evaluat Sci, Toronto, ON, Canada; [Tsang, Derek S.] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada; [Aronson, Melyssa; Durno, Carol] Mt Sinai Hosp, Zane Cohen Ctr Digest Dis, Toronto, ON, Canada; [Shlien, Adam; Hawkins, Cynthia] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Getz, Gad] Massachusetts Gen Hosp, Canc Ctr, Charlestown, MA USA; [Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA USA; [Getz, Gad] Broad Inst Harvard & MIT, Cambridge, MA USA; [Ohashi, Pamela S.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Hawkins, Cynthia] Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON, Canada; [Hawkins, Cynthia] Hosp Sick Children, Program Cell Biol, Toronto, ON, Canada; [Pugh, Trevor J.] Ontario Inst Canc Res, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Imam Abdulrahman Bin Faisal University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Hashemite University; University of Toronto; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Chaim Sheba Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Womens & Childrens Hospital Australia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical University of South Carolina; Medical University of South Carolina; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Manitoba; University of Padua; Azienda Ospedaliera - Universita di Padova; Sahlgrenska University Hospital; University of Gothenburg; Queen Silvia Children's Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Charles University Prague; Motol University Hospital; University of Pennsylvania; University of Pennsylvania; Fondazione IRCCS Istituto Nazionale Tumori Milan; West Virginia University; University of New South Wales Sydney; Medical College of Wisconsin; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Columbia University; NewYork-Presbyterian Hospital; St Jude Children's Research Hospital; Rambam Health Care Campus; University of Texas System; University of Texas Southwestern Medical Center Dallas; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Taipei Veterans General Hospital; Medical College of Wisconsin; Children's Hospitals & Clinics of Minnesota; Phoenix Children's Hospital; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Tabori, U (corresponding author), Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada.; Tabori, U (corresponding author), Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON, Canada.; Tabori, U (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada.; Tabori, U (corresponding author), Univ Toronto, Dept Paediat, Toronto, ON, Canada.; Tabori, U (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.	uri.tabori@sickkids.ca	Osborn, Michael/GNM-9195-2022; Tsang, Derek S./I-3007-2019; Pugh, Trevor/Y-2535-2019; xu, wei/HHD-2891-2022; Tsang, Derek S./GQQ-7149-2022; Sabel, Magnus/Q-2816-2016	Tsang, Derek S./0000-0002-9762-6901; Pugh, Trevor/0000-0002-8073-5888; Tsang, Derek S./0000-0002-9762-6901; Alsafwani, Noor/0000-0002-9449-9708; Sabel, Magnus/0000-0002-3072-657X; Das, Anirban/0000-0001-7653-9529; Chen, David/0000-0003-3178-519X; Zimmermann, Stefanie-Yvonne/0000-0003-1967-7292; Bowers, Daniel/0000-0002-3947-2481; Morgenstern, Daniel/0000-0002-4859-1108; Knipstein, Jeffrey/0000-0002-0632-2751; Abu Al karsaneh, Ola/0000-0001-6064-2548	Stand Up to Cancer-Bristol-Meyers Squibb Catalyst Research Grant [SU2C-AACR-CT07-17]; the scientific partner of SU2C, BioCanRx - Canada's Immunotherapy Network (a Network Centre of Excellence) [FY17/18/ES8]; Canadian Institutes for Health Research (CIHR) [PJT-156006]; CIHR Joint Canada-Israel Health Research Program [108188-001]; V Foundation for Cancer Research [T2019-016]; St. Baldrick's Foundation International Scholar Award; Team Campbell Foundation [697257]; LivWise Foundation; Zane Cohen Centre; BRAINchild Foundation; Elmaagacli Family Fund; Guglietti We Love You Connie Foundation; SickKids Research Training Center Clinician-Scientist Training Program; Ontario Ministry of Research and Innovation; Canada Research Chair in Childhood Cancer Genomics; St. Baldrick's Foundation; Meagan's Hug [MW-2014-10]	Stand Up to Cancer-Bristol-Meyers Squibb Catalyst Research Grant; the scientific partner of SU2C, BioCanRx - Canada's Immunotherapy Network (a Network Centre of Excellence); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR Joint Canada-Israel Health Research Program(Canadian Institutes of Health Research (CIHR)); V Foundation for Cancer Research; St. Baldrick's Foundation International Scholar Award; Team Campbell Foundation; LivWise Foundation; Zane Cohen Centre; BRAINchild Foundation; Elmaagacli Family Fund; Guglietti We Love You Connie Foundation; SickKids Research Training Center Clinician-Scientist Training Program; Ontario Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario); Canada Research Chair in Childhood Cancer Genomics; St. Baldrick's Foundation; Meagan's Hug	This research is supported by a Stand Up to Cancer-Bristol-Meyers Squibb Catalyst Research Grant (Grant Number: SU2C-AACR-CT07-17; U.T.), which is administered by the American Association for Cancer Research, the scientific partner of SU2C, BioCanRx (FY17/18/ES8; U.T.)-Canada's Immunotherapy Network (a Network Centre of Excellence), the Canadian Institutes for Health Research (CIHR) grant (PJT-156006; U.T.), the CIHR Joint Canada-Israel Health Research Program (108188-001; U.T.), the V Foundation for Cancer Research (T2019-016; U.T.), St. Baldrick's Foundation International Scholar Award (with generous support from the Team Campbell Foundation; Grant number: 697257; A.D.), Meagan's Hug (MW-2014-10; U.T.), LivWise Foundation, the Zane Cohen Centre, BRAINchild Foundation, the Elmaagacli Family Fund, Guglietti We Love You Connie Foundation (P.O.), SickKids Research Training Center Clinician-Scientist Training Program (Fall 2019 award; A.D.), Early Researcher Award from the Ontario Ministry of Research and Innovation (A.S.), the Canada Research Chair in Childhood Cancer Genomics (A.S.), and the Robert J. Arceci Innovation Award from the St. Baldrick's Foundation (A.S.).	Akinkuotu AC, 2021, AM J SURG, V221, P718, DOI 10.1016/j.amjsurg.2021.02.010; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Amayiri N, 2016, INT J CANCER, V138, P380, DOI 10.1002/ijc.29724; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Antonios JP, 2017, P NATL ACAD SCI USA, V114, P10220, DOI 10.1073/pnas.1706689114; Azad NS, 2020, J CLIN ONCOL, V38, P214, DOI 10.1200/JCO.19.00818; Bai RL, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00209-0; Bajorin DF, 1999, J CLIN ONCOL, V17, P3173, DOI 10.1200/JCO.1999.17.10.3173; Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3; Blumenthal DT, 2016, J NEURO-ONCOL, V129, P453, DOI 10.1007/s11060-016-2190-1; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Campbell BB, 2021, CANCER DISCOV, V11, P1454, DOI 10.1158/2159-8290.CD-20-1050; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chung J, 2021, CANCER DISCOV, V11, P1176, DOI 10.1158/2159-8290.CD-20-0790; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Clouthier DL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0541-0; Cortez D, 2019, MOL CELL, V74, P866, DOI 10.1016/j.molcel.2019.04.027; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Davis KL, 2020, LANCET ONCOL, V21, P541, DOI 10.1016/S1470-2045(20)30023-1; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Geoerger B, 2020, LANCET ONCOL, V21, P121, DOI 10.1016/S1470-2045(19)30671-0; Geoerger B, 2020, LANCET ONCOL, V21, P134, DOI 10.1016/S1470-2045(19)30693-X; Gromeier M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20469-6; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haworth KB, 2015, PEDIATR BLOOD CANCER, V62, P571, DOI 10.1002/pbc.25359; Hayes-Jordan AA, 2020, J AM COLL SURGEONS, V230, P648, DOI 10.1016/j.jamcollsurg.2019.12.043; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Hundal J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0264-5; Iafolla MAJ, 2021, JNCI CANCER SPECT, V5, DOI 10.1093/jncics/pkaa115; Ionescu DN, 2018, CURR ONCOL, V25, pE209, DOI 10.3747/co.25.4031; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kaplinsky J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11881; Kato S, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1708065; Khasraw M, 2020, CLIN CANCER RES, V26, P5287, DOI 10.1158/1078-0432.CCR-20-1135; Kim KH, 2019, CLIN CANCER RES, V25, P2144, DOI 10.1158/1078-0432.CCR-18-1449; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; London WB, 2017, CANCER-AM CANCER SOC, V123, P4914, DOI 10.1002/cncr.30934; Majzner RG, 2017, CANCER-AM CANCER SOC, V123, P3807, DOI 10.1002/cncr.30724; Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Martin-Romano P, 2020, CANCER MED-US, V9, P2643, DOI 10.1002/cam4.2797; Maruvka YE, 2017, NAT BIOTECHNOL, V35, P951, DOI 10.1038/nbt.3966; McGrail DJ, 2021, ANN ONCOL, V32, P661, DOI 10.1016/j.annonc.2021.02.006; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Merchant MS, 2016, CLIN CANCER RES, V22, P1364, DOI 10.1158/1078-0432.CCR-15-0491; Mulder DT, 2018, BLOOD ADV, V2, P3506, DOI 10.1182/bloodadvances.2017014639; Mur P, 2020, GENET MED, V22, P2089, DOI 10.1038/s41436-020-0922-2; Nariai N, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S2-S7; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Platten M, 2021, NATURE, V592, P463, DOI 10.1038/s41586-021-03363-z; Racle J, 2020, METHODS MOL BIOL, V2120, P233, DOI 10.1007/978-1-0716-0327-7_17; Rohr-Udilova N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24437-5; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Rousseau B, 2021, NEW ENGL J MED, V384, P1168, DOI 10.1056/NEJMc2031965; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schrock AB, 2019, ANN ONCOL, V30, P1096, DOI 10.1093/annonc/mdz134; Seppala TT, 2021, BRIT J SURG, V108, P484, DOI 10.1002/bjs.11902; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shlien A, 2015, NAT GENET, V47, P257, DOI 10.1038/ng.3202; Stahl M, 2011, PEDIATR BLOOD CANCER, V57, P549, DOI 10.1002/pbc.23040; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Tabori U, 2017, CLIN CANCER RES, V23, pE32, DOI 10.1158/1078-0432.CCR-17-0574; Terry RL, 2020, J CLIN INVEST, V130, P3391, DOI 10.1172/JCI137181; Thomas R, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-0173-8; Topalian SL, 2019, JAMA ONCOL, V5, P1411, DOI 10.1001/jamaoncol.2019.2187; Touat M, 2020, NATURE, V580, P517, DOI 10.1038/s41586-020-2209-9; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Wang JW, 2020, CANCER MED-US, V9, P361, DOI 10.1002/cam4.2673; Warren RL, 2012, GENOME MED, V4, DOI 10.1186/gm396; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; Yang SYC, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0590-x; Yoshida T, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0895-4	93	11	11	4	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					125	+		10.1038/s41591-021-01581-6	http://dx.doi.org/10.1038/s41591-021-01581-6		JAN 2022	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34992263	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000739773300002
J	Gotlib, J; Reiter, A; Radia, DH; Deininger, MW; George, TI; Panse, J; Vannucchi, AM; Platzbecker, U; Alvarez-Twose, I; Mital, A; Hermine, O; Dybedal, I; Hexner, EO; Hicks, LK; Span, L; Mesa, R; Bose, P; Pettit, KM; Heaney, ML; Oh, ST; Sen, J; Lin, HM; Mar, BG; DeAngelo, DJ				Gotlib, Jason; Reiter, Andreas; Radia, Deepti H.; Deininger, Michael W.; George, Tracy, I; Panse, Jens; Vannucchi, Alessandro M.; Platzbecker, Uwe; Alvarez-Twose, Ivan; Mital, Andrzej; Hermine, Olivier; Dybedal, Ingunn; Hexner, Elizabeth O.; Hicks, Lisa K.; Span, Lambert; Mesa, Ruben; Bose, Prithviraj; Pettit, Kristen M.; Heaney, Mark L.; Oh, Stephen T.; Sen, Jayita; Lin, Hui-Min; Mar, Brenton G.; DeAngelo, Daniel J.			Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial	NATURE MEDICINE			English	Article							MIDOSTAURIN; DIAGNOSIS; LEUKEMIA	Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltration and shortened survival. We report the results of a prespecified interim analysis of an ongoing pivotal single-arm phase 2 trial (no.NCT03580655 ) of avapritinib, a potent, selective KIT D816V inhibitor administered primarily at a once-daily starting dose of 200 mg in patients with AdvSM (n = 62). The primary endpoint was overall response rate (ORR). Secondary endpoints included mean baseline change in AdvSM-Symptom Assessment Form Total Symptom Score and quality of life, time to response, duration of response, progression-free survival, overall survival, changes in measures of disease burden and safety. The primary endpoint was successfully met (P = 1.6 x 10(-9)), with an ORR of 75% (95% confidence interval 57-89) in 32 response-evaluable patients with AdvSM who had sufficient follow-up for response assessment, including 19% with complete remission with full or partial hematologic recovery. Reductions of >= 50% from baseline in serum tryptase (93%), bone marrow mast cells (88%) and KIT D816V variant allele fraction (60%) were observed. The most frequent grade >= 3 adverse events were neutropenia (24%), thrombocytopenia (16%) and anemia (16%). Avapritinib demonstrated a high rate of clinical, morphological and molecular responses and was generally well tolerated in patients with AdvSM.	[Gotlib, Jason] Stanford Univ, Sch Med, Stanford Canc Inst, Div Hematol, Stanford, CA 94305 USA; [Reiter, Andreas] Heidelberg Univ, Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany; [Radia, Deepti H.] Guys & St Thomas NHS Fdn Trust, London, England; [Deininger, Michael W.] Med Coll Wisconsin, Versiti Blood Res Inst, Milwaukee, WI 53226 USA; [Deininger, Michael W.] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [George, Tracy, I] Univ Utah, ARUP Labs, Salt Lake City, UT USA; [Panse, Jens] Univ Hosp RWTH Aachen, Dept Oncol Hematol Hemostaseol & Stem Cell Transp, Aachen, Germany; [Vannucchi, Alessandro M.] Univ Florence, Azienda Osped Univ Careggi, Ctr Res & Innovat Myeloproliferat Neoplasms CRIMM, Florence, Italy; [Platzbecker, Uwe] Univ Leipzig, Leipzig, Germany; [Alvarez-Twose, Ivan] Spanish Reference Ctr Mastocytosis, Inst Mastocytosis Studies Castilla La Mancha, Toledo, Spain; [Mital, Andrzej] Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland; [Hermine, Olivier] Paris Univ, Necker Enfants Malad Hosp, AP HP, Dept Hematol,CEREMAST, Paris, France; [Hermine, Olivier] Paris Univ, INSERM U1163, Imagine Inst, Paris, France; [Dybedal, Ingunn] Oslo Univ Hosp, Dept Hematol, Oslo, Norway; [Hexner, Elizabeth O.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Hicks, Lisa K.] Univ Toronto, Div Hematol Oncol, St Michaels Hosp, Toronto, ON, Canada; [Span, Lambert] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Mesa, Ruben] UT Hlth San Antonio MD Anderson, Mays Canc Ctr, San Antonio, TX USA; [Bose, Prithviraj] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Pettit, Kristen M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Heaney, Mark L.] Columbia Univ, Med Ctr, New York, NY USA; [Oh, Stephen T.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA; [Oh, Stephen T.] Washington Univ, Sch Med, St Louis, MO USA; [Sen, Jayita; Lin, Hui-Min; Mar, Brenton G.] Blueprint Med Corp, Cambridge, MA USA; [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Stanford Cancer Institute; Stanford University; Ruprecht Karls University Heidelberg; Guy's & St Thomas' NHS Foundation Trust; Medical College of Wisconsin; Medical College of Wisconsin; Utah System of Higher Education; University of Utah; ARUP Laboratories; RWTH Aachen University; RWTH Aachen University Hospital; University of Florence; Azienda Ospedaliero Universitaria Careggi; Leipzig University; Fahrenheit Universities; Medical University Gdansk; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oslo; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Groningen; University of Texas System; University of Texas Health San Antonio; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; Columbia University; Barnes-Jewish Hospital; Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute	Gotlib, J (corresponding author), Stanford Univ, Sch Med, Stanford Canc Inst, Div Hematol, Stanford, CA 94305 USA.	jason.gotlib@stanford.edu	George, Tracy I./GRY-0951-2022	Gotlib, Jason/0000-0001-8253-6156; George, Tracy/0000-0001-5478-7847; Hicks, Lisa/0000-0003-1858-7420	Blueprint Medicines Corporation; Good Publication Practice guidelines; Stanford Cancer Institute Clinical Innovation Fund; Deutsche Jose-Carreras Leukamiestiftung grant [DJCLS 08R/2020]; Association Italiana per la Ricerca sul Cancro, Mynerva project [21267]; National Cancer Institute (National Institutes of Health (NIH)) [1UE5CA246744-01, P01-CA214278-03]; National Center for Advancing Translational Sciences (NIH) [NIH-NCATS UL1TR001878]; National Heart, Lung, and Blood Institute (NIH) [R01-HL-148014-01A1]; P30 grant [CA054174]; National Cancer Institute (NIH, MD Anderson Cancer Center support grant P30) [CA016672]	Blueprint Medicines Corporation; Good Publication Practice guidelines; Stanford Cancer Institute Clinical Innovation Fund; Deutsche Jose-Carreras Leukamiestiftung grant; Association Italiana per la Ricerca sul Cancro, Mynerva project; National Cancer Institute (National Institutes of Health (NIH))(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Advancing Translational Sciences (NIH); National Heart, Lung, and Blood Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); P30 grant; National Cancer Institute (NIH, MD Anderson Cancer Center support grant P30)	The trial was funded by Blueprint Medicines Corporation. The Sponsor was involved in the trial design, collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions and data interpretation lies with the authors. We thank the patients, their families and all investigators involved in this trial. Additional pathology support was provided by A. Rets, K. Moser and K. Karner (University of Utah/ARUP Laboratories, Salt Lake City, UT, USA). Data management support was provided by C. Langford (Stanford Cancer Institute, Stanford, CA, USA). Medical writing support, including assisting authors with the development of drafts, preparation of figures, incorporation of comments, data checking and referencing, was provided by K. Tran and C. Tomas (both of Paragon, Knutsford, UK), and editorial support, including formatting, proofreading and submission, was provided by T. Taylor (Paragon, Knutsford, UK, supported by Blueprint Medicines Corporation in accordance with Good Publication Practice guidelines (www.ismpp.org/gpp3).J.G.is supported by an internal grant from the Stanford Cancer Institute Clinical Innovation Fund. A.R. is supported by the Deutsche Jose-Carreras Leukamiestiftung grant (no. DJCLS 08R/2020). A.M.V. is supported in part by a grant from Association Italiana per la Ricerca sul Cancro, Mynerva project (no. 21267). E.O.H. is supported by the National Cancer Institute (National Institutes of Health (NIH) nos. 1UE5CA246744-01 and P01-CA214278-03), the National Center for Advancing Translational Sciences (NIH no. NIH-NCATS UL1TR001878) and the National Heart, Lung, and Blood Institute (NIH no. R01-HL-148014-01A1). R.M. is supported by a P30 grant (no. CA054174). P.B. is supported by the National Cancer Institute (NIH, MD Anderson Cancer Center support grant P30 no. CA016672).	Awada H, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112512; Blueprint Medicines (Netherlands) B.V. AYVAKYT&REG; (avapritinib), 2020, SUMMARY PRODUCT CHAR; Cohen SS, 2014, BRIT J HAEMATOL, V166, P521, DOI 10.1111/bjh.12916; DeAngelo, NAT MED; Evans EK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao1690; EXPLORER, STUD BLU 285 PAT ADV; Gotlib J, 2020, BLOOD, V136, DOI 10.1182/blood-2020-137413; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Gotlib J, 2013, BLOOD, V121, P2393, DOI 10.1182/blood-2012-09-458521; Gotlib JR, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-112017; Heinrich MC, 2020, LANCET ONCOL, V21, P935, DOI 10.1016/S1470-2045(20)30269-2; Jawhar M, 2016, LEUKEMIA, V30, P136, DOI 10.1038/leu.2015.284; Jawhar M, 2017, HAEMATOLOGICA, V102, P1035, DOI 10.3324/haematol.2017.163964; Kang Y. K., J CLIN ONCOL, DOI [10.1200/JCO.21.00217(2021, DOI 10.1200/JCO.21.00217(2021]; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Novartis Europharm Limited, RYDAPT MID SUMM PROD; Novartis Pharmaceuticals Corporation, RYDAPT MID PRESCR IN; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Pardanani A, 2019, AM J HEMATOL, V94, P363, DOI 10.1002/ajh.25371; PATHFINDER, 2020, STUD EV EFF SAF AV B; Reiter A, 2020, BLOOD, V135, P1365, DOI 10.1182/blood.2019000932; Shomali W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062983; Stone RM, 2017, NEW ENGL J MED, V377, P454, DOI 10.1056/NEJMoa1614359; Taylor F, 2021, LEUKEMIA RES, V108, DOI 10.1016/j.leukres.2021.106606; Ustun C, 2016, HAEMATOLOGICA, V101, P1133, DOI 10.3324/haematol.2016.146563; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893	26	25	25	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2192	+		10.1038/s41591-021-01539-8	http://dx.doi.org/10.1038/s41591-021-01539-8		DEC 2021	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34873345	Green Published, hybrid			2022-12-27	WOS:000727136800002
J	Dayan, I; Roth, HR; Zhong, AX; Harouni, A; Gentili, A; Abidin, AZ; Liu, A; Costa, AB; Wood, BJ; Tsai, CS; Wang, CH; Hsu, CN; Lee, CK; Ruan, PY; Xu, DG; Wu, DF; Huang, E; Kitamura, FC; Lacey, G; Corradi, GCD; Nino, G; Shin, HH; Obinata, H; Ren, H; Crane, JC; Tetreault, J; Guan, J; Garrett, JW; Kaggie, JD; Park, JG; Dreyer, K; Juluru, K; Kersten, K; Rockenbach, MABC; Linguraru, MG; Haider, MA; AbdelMaseeh, M; Rieke, N; Damasceno, PF; Silva, PMCE; Wang, PC; Xu, S; Kawano, S; Sriswasdi, S; Park, SY; Grist, TM; Buch, V; Jantarabenjakul, W; Wang, WC; Tak, WY; Li, X; Lin, XH; Kwon, YJ; Quraini, A; Feng, A; Priest, AN; Turkbey, B; Glicksberg, B; Bizzo, B; Kim, BS; Tor-Diez, C; Lee, CC; Hsu, CJ; Lin, C; Lai, CL; Hess, CP; Compas, C; Bhatia, D; Oermann, EK; Leibovitz, E; Sasaki, H; Mori, H; Yang, I; Sohn, JH; Murthy, KNK; Fu, LC; de Mendonca, MRF; Fralick, M; Kang, MK; Adil, M; Gangai, N; Vateekul, P; Elnajjar, P; Hickman, S; Majumdar, S; McLeod, SL; Reed, S; Graf, S; Harmon, S; Kodama, T; Puthanakit, T; Mazzulli, T; de Lavor, VL; Rakvongthai, Y; Lee, YR; Wen, Y; Gilbert, FJ; Flores, MG; Li, QZ				Dayan, Ittai; Roth, Holger R.; Zhong, Aoxiao; Harouni, Ahmed; Gentili, Amilcare; Abidin, Anas Z.; Liu, Andrew; Costa, Anthony Beardsworth; Wood, Bradford J.; Tsai, Chien-Sung; Wang, Chih-Hung; Hsu, Chun-Nan; Lee, C. K.; Ruan, Peiying; Xu, Daguang; Wu, Dufan; Huang, Eddie; Kitamura, Felipe Campos; Lacey, Griffin; de Antonio Corradi, Gustavo Cesar; Nino, Gustavo; Shin, Hao-Hsin; Obinata, Hirofumi; Ren, Hui; Crane, Jason C.; Tetreault, Jesse; Guan, Jiahui; Garrett, John W.; Kaggie, Joshua D.; Park, Jung Gil; Dreyer, Keith; Juluru, Krishna; Kersten, Kristopher; Rockenbach, Marcio Aloisio Bezerra Cavalcanti; Linguraru, Marius George; Haider, Masoom A.; AbdelMaseeh, Meena; Rieke, Nicola; Damasceno, Pablo F.; Silva, Pedro Mario Cruz E.; Wang, Pochuan; Xu, Sheng; Kawano, Shuichi; Sriswasdi, Sira; Park, Soo Young; Grist, Thomas M.; Buch, Varun; Jantarabenjakul, Watsamon; Wang, Weichung; Tak, Won Young; Li, Xiang; Lin, Xihong; Kwon, Young Joon; Quraini, Abood; Feng, Andrew; Priest, Andrew N.; Turkbey, Baris; Glicksberg, Benjamin; Bizzo, Bernardo; Kim, Byung Seok; Tor-Diez, Carlos; Lee, Chia-Cheng; Hsu, Chia-Jung; Lin, Chin; Lai, Chiu-Ling; Hess, Christopher P.; Compas, Colin; Bhatia, Deepeksha; Oermann, Eric K.; Leibovitz, Evan; Sasaki, Hisashi; Mori, Hitoshi; Yang, Isaac; Sohn, Jae Ho; Murthy, Krishna Nand Keshava; Fu, Li-Chen; Furtado de Mendonca, Matheus Ribeiro; Fralick, Mike; Kang, Min Kyu; Adil, Mohammad; Gangai, Natalie; Vateekul, Peerapon; Elnajjar, Pierre; Hickman, Sarah; Majumdar, Sharmila; McLeod, Shelley L.; Reed, Sheridan; Graf, Stefan; Harmon, Stephanie; Kodama, Tatsuya; Puthanakit, Thanyawee; Mazzulli, Tony; de Lavor, Vitor Lima; Rakvongthai, Yothin; Lee, Yu Rim; Wen, Yuhong; Gilbert, Fiona J.; Flores, Mona G.; Li, Quanzheng			Federated learning for predicting clinical outcomes in patients with COVID-19	NATURE MEDICINE			English	Article							PRIVACY; CHALLENGES; MODELS	Federated learning (FL) is a method used for training artificial intelligence models with data from multiple sources while maintaining data anonymity, thus removing many barriers to data sharing. Here we used data from 20 institutes across the globe to train a FL model, called EXAM (electronic medical record (EMR) chest X-ray AI model), that predicts the future oxygen requirements of symptomatic patients with COVID-19 using inputs of vital signs, laboratory data and chest X-rays. EXAM achieved an average area under the curve (AUC) >0.92 for predicting outcomes at 24 and 72 h from the time of initial presentation to the emergency room, and it provided 16% improvement in average AUC measured across all participating sites and an average increase in generalizability of 38% when compared with models trained at a single site using that site's data. For prediction of mechanical ventilation treatment or death at 24 h at the largest independent test site, EXAM achieved a sensitivity of 0.950 and specificity of 0.882. In this study, FL facilitated rapid data science collaboration without data exchange and generated a model that generalized across heterogeneous, unharmonized datasets for prediction of clinical outcomes in patients with COVID-19, setting the stage for the broader use of FL in healthcare. Federated learning, a method for training artificial intelligence algorithms that protects data privacy, was used to predict future oxygen requirements of symptomatic patients with COVID-19 using data from 20 different institutes across the globe.	[Dayan, Ittai; Dreyer, Keith] MGH Radiol, Boston, MA USA; [Dayan, Ittai; Dreyer, Keith] Harvard Med Sch, Boston, MA 02115 USA; [Roth, Holger R.; Harouni, Ahmed; Abidin, Anas Z.; Liu, Andrew; Lee, C. K.; Ruan, Peiying; Xu, Daguang; Huang, Eddie; Lacey, Griffin; Tetreault, Jesse; Guan, Jiahui; Kersten, Kristopher; Rieke, Nicola; Silva, Pedro Mario Cruz E.; Quraini, Abood; Feng, Andrew; Compas, Colin; Bhatia, Deepeksha; Yang, Isaac; Adil, Mohammad; Wen, Yuhong; Flores, Mona G.] NVIDIA, Santa Clara, CA 95051 USA; [Zhong, Aoxiao; Wu, Dufan; Ren, Hui; Li, Xiang; Li, Quanzheng] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Med Comp & Anal, Boston, MA 02115 USA; [Zhong, Aoxiao] Harvard Univ, Sch Engn & Appl Sci, Boston, MA 02115 USA; [Gentili, Amilcare] San Diego VA Hlth Care Syst, San Diego, CA USA; [Costa, Anthony Beardsworth; Kwon, Young Joon] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA; [Wood, Bradford J.; Xu, Sheng; Reed, Sheridan] NIH, Radiol & Imaging Sci Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Wood, Bradford J.; Xu, Sheng; Turkbey, Baris; Reed, Sheridan; Harmon, Stephanie] NCI, NIH, Bethesda, MD 20892 USA; [Tsai, Chien-Sung] Triserv Gen Hosp, Natl Def Med Ctr, Dept Surg, Div Cardiovasc Surg, Taipei, Taiwan; [Wang, Chih-Hung] Triserv Gen Hosp, Natl Def Med Ctr, Dept Otolaryngol Head & Neck Surg, Taipei, Taiwan; [Wang, Chih-Hung] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan; [Hsu, Chun-Nan] Univ Calif San Diego, Ctr Res Biol Syst, San Diego, CA 92103 USA; [Kitamura, Felipe Campos; de Antonio Corradi, Gustavo Cesar; Furtado de Mendonca, Matheus Ribeiro; de Lavor, Vitor Lima] DasaInova, Diagnost Amer SA, Barueri, Brazil; [Nino, Gustavo] Childrens Natl Hosp, Div Pediat Pulm & Sleep Med, Washington, DC USA; [Shin, Hao-Hsin; Juluru, Krishna; Murthy, Krishna Nand Keshava; Gangai, Natalie; Elnajjar, Pierre] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Obinata, Hirofumi; Kawano, Shuichi; Sasaki, Hisashi; Mori, Hitoshi; Kodama, Tatsuya] Self Def Forces Cent Hosp, Tokyo, Japan; [Crane, Jason C.; Damasceno, Pablo F.; Hess, Christopher P.; Sohn, Jae Ho; Majumdar, Sharmila] Univ Calif San Francisco, Ctr Intelligent Imaging, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Garrett, John W.; Grist, Thomas M.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Garrett, John W.; Grist, Thomas M.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, 1530 Med Sci Ctr, Madison, WI 53706 USA; [Kaggie, Joshua D.; Hickman, Sarah; Gilbert, Fiona J.] Univ Cambridge, NIHR Cambridge Biomed Resource Ctr, Dept Radiol, Cambridge, England; [Park, Jung Gil; Kang, Min Kyu] Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; [Dreyer, Keith; Rockenbach, Marcio Aloisio Bezerra Cavalcanti; Buch, Varun; Bizzo, Bernardo; Leibovitz, Evan] Massachusetts Gen Brigham, Ctr Clin Data Sci, Boston, MA USA; [Linguraru, Marius George; Tor-Diez, Carlos] Childrens Natl Hosp, Sheikh Zayed Inst Pediat Surg Innovat, Washington, DC USA; [Linguraru, Marius George] George Washington Univ, Dept Radiol, Sch Med & Hlth Sci, Washington, DC USA; [Haider, Masoom A.] Univ Toronto, Joint Dept Med Imaging, Sinai Hlth Syst, Toronto, ON, Canada; [Haider, Masoom A.; AbdelMaseeh, Meena] Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Wang, Pochuan; Wang, Weichung] Natl Taiwan Univ, MeDA Lab Inst Appl Math Sci, Taipei, Taiwan; [Wang, Pochuan; Wang, Weichung] Natl Taiwan Univ, Dept Comp Sci & Informat Engn, Taipei, Taiwan; [Sriswasdi, Sira] Chulalongkorn Univ, Fac Med, Res Affairs, Bangkok, Thailand; [Sriswasdi, Sira] Chulalongkorn Univ, Fac Med, Ctr Artificial Intelligence Med, Bangkok, Thailand; [Park, Soo Young; Tak, Won Young; Lee, Yu Rim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; [Grist, Thomas M.] Univ Wisconsin, Dept Biomed Engn, Sch Med & Publ Hlth, Madison, WI USA; [Jantarabenjakul, Watsamon; Puthanakit, Thanyawee] Chulalongkorn Univ, Fac Med, Dept Pediat, Bangkok, Thailand; [Jantarabenjakul, Watsamon; Puthanakit, Thanyawee] King Chulalongkorn Mem Hosp, Thai Red Cross Emerging Infect Dis Clin Ctr, Bangkok, Thailand; [Lin, Xihong] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Priest, Andrew N.] Cambridge Univ Hosp, NIHR Cambridge Biomed Resource Ctr, Dept Radiol, Cambridge, England; [Turkbey, Baris] NIH, Dept Radiol & Imaging Sci, Bldg 10, Bethesda, MD 20892 USA; [Glicksberg, Benjamin] Icahn Sch Med Mt Sinai, Hass Plattner Inst Digital Hlth Mt Sinai, New York, NY 10029 USA; [Glicksberg, Benjamin] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Kim, Byung Seok] Catholic Univ Daegu, Dept Internal Med, Sch Med, Daegu, South Korea; [Lee, Chia-Cheng; Hsu, Chia-Jung] Triserv Gen Hosp, Natl Def Med Ctr, Planning & Management Off, Taipei, Taiwan; [Lin, Chin] Natl Def Med Ctr, Sch Med, Taipei, Taiwan; [Lin, Chin] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Lin, Chin] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Lai, Chiu-Ling] Natl Hlth Insurance Adm, Med Review & Pharmaceut Benefits Div, Taipei, Taiwan; [Oermann, Eric K.] NYU Grossman Sch Med, Dept Neurosurg, New York, NY USA; [Fu, Li-Chen] Natl Taiwan Univ, MOST NTU All Vista Healthcare Ctr, Ctr Artificial Intelligence & Adv Robot, Taipei, Taiwan; [Fralick, Mike] Sinai Hlth Syst, Div Gen Internal Med & Geriatr Fralick, Toronto, ON, Canada; [Vateekul, Peerapon] Chulalongkorn Univ, Fac Engn, Dept Comp Engn, Bangkok, Thailand; [McLeod, Shelley L.] Sinai Hlth, Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada; [McLeod, Shelley L.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Graf, Stefan] Univ Cambridge, NIHR Cambridge Biomed Res Ctr, Dept Med, Cambridge, England; [Graf, Stefan] Univ Cambridge, NIHR Cambridge Biomed Res Ctr, NIHR BioResource Translat Res, Cambridge, England; [Harmon, Stephanie] NCI, Clin Res Directorate, Frederick Natl Lab Canc, Frederick, MD 21701 USA; [Mazzulli, Tony] Univ Hlth Network, Dept Microbiol, Sinai Hlth, Toronto, ON, Canada; [Mazzulli, Tony] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Mazzulli, Tony] Publ Hlth Ontario Labs, Toronto, ON, Canada; [Rakvongthai, Yothin] Chulalongkorn Univ, Biomed Imaging Grp, Fac Med, Bangkok, Thailand; [Rakvongthai, Yothin] Chulalongkorn Univ, Fac Med, Dept Radiol, Div Nucl Med, Bangkok, Thailand	Harvard University; Harvard Medical School; Nvidia Corporation; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; University of California System; University of California San Diego; Children's National Health System; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Cambridge; Yeungnam University; Children's National Health System; George Washington University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Taiwan University; National Taiwan University; Chulalongkorn University; Chulalongkorn University; Kyungpook National University; University of Wisconsin System; University of Wisconsin Madison; Chulalongkorn University; Chulalongkorn University; Harvard University; Harvard T.H. Chan School of Public Health; University of Cambridge; National Institutes of Health (NIH) - USA; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Catholic University of Daegu; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; National Taiwan University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Chulalongkorn University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Cambridge; University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; University of Toronto; Chulalongkorn University; Chulalongkorn University	Flores, MG (corresponding author), NVIDIA, Santa Clara, CA 95051 USA.	mflores@nvidia.com	Kitamura, Felipe Campos/AAC-7075-2021; McLeod, Shelley/AAE-9636-2019; Rockenbach, Marcio/AAZ-3329-2020; Abidin, Anas/L-6428-2019; Wood, Bradford/M-7995-2017; Li, Xiang/J-6924-2019; Costa, Anthony/C-5471-2009	Kitamura, Felipe Campos/0000-0002-9992-5630; McLeod, Shelley/0000-0003-2686-6307; Rockenbach, Marcio/0000-0003-1783-0441; Abidin, Anas/0000-0003-0032-0664; Hickman, Sarah/0000-0002-4637-7300; Wood, Bradford/0000-0002-4297-0051; Roth, Holger/0000-0002-3662-8743; Zhong, Aoxiao/0000-0002-7584-5476; Li, Xiang/0000-0002-9851-6376; Rieke, Nicola/0000-0003-0241-9334; Grist, Thomas/0000-0003-3279-6931; Costa, Anthony/0000-0002-2202-6450	J. Brink, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; M. Kalra, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; N. Neumark, Center for Clinical Data Science, Massachusetts General Brigham, Boston; T. Schultz, Department of Radiology, Massachusetts General Hospital, Boston; N. Guo, Center for Advanced Medical Computing and Analysis, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; J. K. Cramer, Director, QTIM lab at the Athinoula A. Martinos Center for Biomedical Imaging at MGH; S. Pomerantz, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; G. Boland, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston; W. Mayo-Smith, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston; Ratchadapisek Sompoch Endowment Fund RA [001/63]; NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust); NIH; Doris Duke Charitable Foundation; American Association for Dental Research; Colgate-Palmolive Company; Genentech, alumni of student research programs	J. Brink, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; M. Kalra, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; N. Neumark, Center for Clinical Data Science, Massachusetts General Brigham, Boston; T. Schultz, Department of Radiology, Massachusetts General Hospital, Boston; N. Guo, Center for Advanced Medical Computing and Analysis, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; J. K. Cramer, Director, QTIM lab at the Athinoula A. Martinos Center for Biomedical Imaging at MGH; S. Pomerantz, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; G. Boland, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston; W. Mayo-Smith, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston; Ratchadapisek Sompoch Endowment Fund RA; NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); American Association for Dental Research; Colgate-Palmolive Company; Genentech, alumni of student research programs	The views expressed in this study are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or any of the organizations associated with the authors. MGB thank the following individuals for their support: J. Brink, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; M. Kalra, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; N. Neumark, Center for Clinical Data Science, Massachusetts General Brigham, Boston, MA; T. Schultz, Department of Radiology, Massachusetts General Hospital, Boston, MA; N. Guo, Center for Advanced Medical Computing and Analysis, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; J. K. Cramer, Director, QTIM lab at the Athinoula A. Martinos Center for Biomedical Imaging at MGH; S. Pomerantz, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; G. Boland, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; W. Mayo-Smith, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. UCSF thank P. B. Storey, J. Chan and J. Block for implementing the UCSF FL client infrastructure, and W. Tellis for providing the source imaging repository for this work. The UCSF EMR and clinical notes for this study were accessed via the COVID-19 Research Data Mart, https://data.ucsf.edu/covid19.The Faculty of Medicine, Chulalongkorn University thank the Ratchadapisek Sompoch Endowment Fund RA (PO) (no. 001/63) for the collection and management of COVID-19-related clinical data and biological specimens for the Research Task Force, Faculty of Medicine, Chulalongkorn University. NIHR Cambridge Biomedical Research Centre thank A. Priest, who is supported by the NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust). National Taiwan University MeDA Lab and the MAHC and Taiwan National Health Insurance Administration thank the MOST Joint Research Center for AI technology, the All Vista Healthcare National Health Insurance Administration, Taiwan, the Ministry of Science and Technology, Taiwan and the National Center for Theoretical Sciences Mathematics Division. National Institutes of Health (NIH) acknowledge that the NIH Medical Research Scholars Program is a public-private partnership supported jointly by the NIH and by generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, alumni of student research programs and other individual supporters via contributions to the Foundation for the NIH.	Abadi M, 2016, PROCEEDINGS OF OSDI'16: 12TH USENIX SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION, P265; Ai JW, 2020, CELL RES, V30, P370, DOI 10.1038/s41422-020-0329-2; American College of Radiology, 2020, CR REC US CHEST RAD; [Anonymous], 2020, NVIDIA CLARA IMAGING; [Anonymous], 2020, COR TREATM ACC PROGR; [Anonymous], 2020, COVID 19 STUDIES WOR; [Anonymous], 2020, NVIDIA NGC CATALOG C; Brisimi TS, 2018, INT J MED INFORM, V112, P59, DOI 10.1016/j.ijmedinf.2018.01.007; Buch V., DEV VALIDATION DEEP; Budd J, 2020, NAT MED, V26, P1183, DOI 10.1038/s41591-020-1011-4; Cahan EM, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0157-2; Candelon F., 2020, RISE AI POWERED CO P; Chao HQ, 2021, MED IMAGE ANAL, V67, DOI 10.1016/j.media.2020.101844; Chen QY, 2020, NATURE, V579, P193, DOI 10.1038/d41586-020-00694-1; Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054; Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z; Estiri H, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00383-x; Fabbri F., 2020, BCG IT SPEND PULSE C; Fredrikson M, 2015, CCS'15: PROCEEDINGS OF THE 22ND ACM SIGSAC CONFERENCE ON COMPUTER AND COMMUNICATIONS SECURITY, P1322, DOI 10.1145/2810103.2813677; Galloway JB, 2020, J INFECTION, V81, P282, DOI 10.1016/j.jinf.2020.05.064; Gao Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18918-3; Gleeson P, 2017, NEURON, V96, P964, DOI 10.1016/j.neuron.2017.10.013; He K., 2016, CVPR, P770; Hsieh K, 2020, PR MACH LEARN RES, V119; Hutter F, 2019, SPRING SER CHALLENGE, P1, DOI 10.1007/978-3-030-05318-5; Ioffe S, 2015, PR MACH LEARN RES, V37, P448; Irvin J, 2019, AAAI CONF ARTIF INTE, P590; Jamil Shazia, 2020, Am J Respir Crit Care Med, V201, pP19, DOI 10.1164/rccm.2020C1; Jiang G, 2015, METHOD INFORM MED, V54, P65, DOI 10.3414/ME13-02-0019; Kaissis GA, 2020, NAT MACH INTELL, V2, P305, DOI 10.1038/s42256-020-0186-1; Kaufman S, 2012, ACM T KNOWL DISCOV D, V6, DOI 10.1145/2382577.2382579; Kilaru AS, 2020, ACAD EMERG MED, V27, P1039, DOI 10.1111/acem.14117; Li WQ, 2019, LECT NOTES COMPUT SC, V11861, P133, DOI 10.1007/978-3-030-32692-0_16; Li XX, 2020, MED IMAGE ANAL, V65, DOI 10.1016/j.media.2020.101765; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Lyons C, 2020, ANAESTHESIA, V75, P843, DOI 10.1111/anae.15073; Ma C, 2020, IEEE NETWORK, V34, P242, DOI 10.1109/MNET.001.1900506; Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825; McMahan H.B., 2017, COMMUNICATION EFFICI; Minaee S, 2020, MED IMAGE ANAL, V65, DOI 10.1016/j.media.2020.101794; Moorthy V, 2020, B WORLD HEALTH ORGAN, V98, P150, DOI 10.2471/BLT.20.251561; Neri E, 2019, INSIGHTS IMAGING, V10, DOI 10.1186/s13244-019-0738-2; Nino G, 2021, PEDIATR PULM, V56, P252, DOI 10.1002/ppul.25070; Pesapane Filippo, 2018, Eur Radiol Exp, V2, P35, DOI 10.1186/s41747-018-0061-6; Piwowar H, 2018, PEERJ, V6, DOI 10.7717/peerj.4375; Price WN, 2019, NAT MED, V25, P37, DOI 10.1038/s41591-018-0272-7; Raisaro JL, 2020, J AM MED INFORM ASSN, V27, P1721, DOI 10.1093/jamia/ocaa172; Redmond CE, 2020, CAN ASSOC RADIOL J, V71, P425, DOI 10.1177/0846537120930344; Remedios S. W., 2020, FEDERATED GRADIENT A; Rieke N, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00323-1; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roth Holger R., 2020, Domain Adaptation and Representation Transfer, and Distributed and Collaborative Learning. Second MICCAI Workshop, DART 2020 and First MICCAI Workshop, DCL 2020 Held in Conjunction with MICCAI 2020. Proceedings. Lecture Notes in Computer Science (LNCS 12444), P181, DOI 10.1007/978-3-030-60548-3_18; Rubin GD, 2020, RADIOLOGY, V296, P172, DOI [10.1016/j.chest.2020.04.003, 10.1148/radiol.2020201365]; Sands KE, 2021, INFECT CONT HOSP EP, V42, P399, DOI 10.1017/ice.2020.461; Sheller MJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69250-1; Shilo S, 2020, NAT MED, V26, P29, DOI 10.1038/s41591-019-0727-5; Shokri R, 2015, ANN ALLERTON CONF, P909, DOI 10.1109/ALLERTON.2015.7447103; Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597; Thrall JH, 2018, J AM COLL RADIOL, V15, P504, DOI 10.1016/j.jacr.2017.12.026; Vaid A, 2021, JMIR MED INF, V9, DOI 10.2196/24207; Wang RX, 2017, ADKDD'17: 23RD ACM SIGKDD CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD 2017), DOI 10.1145/3124749.3124754; Whittle Jessica S, 2020, J Am Coll Emerg Physicians Open, V1, P95, DOI 10.1002/emp2.12071; World Health Organisation, 2020, US CHEST IM COVID 19; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Xu Yongchao, 2020, medRxiv, DOI 10.1101/2020.05.10.20096073; Yang D, 2021, MED IMAGE ANAL, V70, DOI 10.1016/j.media.2021.101992; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Yao Q., 2019, TAKING HUMAN LEARNIN; Zhang CL, 2020, PROCEEDINGS OF THE 2020 USENIX ANNUAL TECHNICAL CONFERENCE, P493; Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859; Zhu L., 2019, P NEURIPS; Zhu XF, 2021, MED IMAGE ANAL, V67, DOI 10.1016/j.media.2020.101824	73	54	56	17	42	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1735	+		10.1038/s41591-021-01506-3	http://dx.doi.org/10.1038/s41591-021-01506-3		SEP 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34526699	Bronze, Green Published, Green Accepted			2022-12-27	WOS:000696140200002
J	Dam, T; Boxer, AL; Golbe, LI; Hoglinger, GU; Morris, HR; Litvan, I; Lang, AE; Corvol, JC; Aiba, I; Grundman, M; Yang, LL; Tidemann-Miller, B; Kupferman, J; Harper, K; Kamisoglu, K; Wald, MJ; Graham, DL; Gedney, L; O'Gorman, J; Haeberlein, SB				Dam, Tien; Boxer, Adam L.; Golbe, Lawrence, I; Hoeglinger, Gunter U.; Morris, Huw R.; Litvan, Irene; Lang, Anthony E.; Corvol, Jean-Christophe; Aiba, Ikuko; Grundman, Michael; Yang, Lili; Tidemann-Miller, Beth; Kupferman, Joseph; Harper, Kristine; Kamisoglu, Kubra; Wald, Michael J.; Graham, Danielle L.; Gedney, Liz; O'Gorman, John; Haeberlein, Samantha Budd		PASSPORT Study Grp	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial	NATURE MEDICINE			English	Article							QUALITY-OF-LIFE; DIAGNOSTIC-CRITERIA; EXTRACELLULAR TAU; RATING-SCALE; DISEASE; NEUROPATHOLOGY; BIOMARKERS; DISORDERS; VARIANTS; PSP	In the phase 2 PASSPORT study, treatment with the anti-tau antibody gosuranemab did not show clinical benefit in participants with supranuclear palsy, suggesting that N-terminal tau neutralization does not translate into clinical efficacy. A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants dosed were assigned to either gosuranemab (n = 321) or placebo (n = 165). Efficacy was not demonstrated on adjusted mean change of PSP Rating Scale score at week 52 between gosuranemab and placebo (10.4 versus 10.6, P = 0.85, primary endpoint), or at secondary endpoints, resulting in discontinuation of the open-label, long-term extension. Unbound N-terminal tau in cerebrospinal fluid decreased by 98% with gosuranemab and increased by 11% with placebo (P < 0.0001). Incidences of adverse events and deaths were similar between groups. This well-powered study suggests that N-terminal tau neutralization does not translate into clinical efficacy.	[Dam, Tien; Yang, Lili; Tidemann-Miller, Beth; Kupferman, Joseph; Harper, Kristine; Kamisoglu, Kubra; Wald, Michael J.; Graham, Danielle L.; Gedney, Liz; O'Gorman, John; Haeberlein, Samantha Budd] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA; [Boxer, Adam L.] Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94143 USA; [Golbe, Lawrence, I] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA; [Hoeglinger, Gunter U.] Tech Univ Munich, Dept Neurol, Munich, Germany; [Hoeglinger, Gunter U.] German Ctr Neurodegenerat Dis, Munich, Germany; [Hoeglinger, Gunter U.] Hannover Med Sch, Dept Neurol, Hannover, Germany; [Morris, Huw R.] Natl Hosp Neurol & Neurosurg, London, England; [Litvan, Irene; Grundman, Michael] Univ Calif San Diego, Parkinson & Other Movement Disorders Ctr, San Diego, CA 92103 USA; [Lang, Anthony E.] Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada; [Lang, Anthony E.] Toronto Western Hosp, Rossy PSP Ctr, Toronto, ON, Canada; [Lang, Anthony E.] Univ Toronto, Toronto, ON, Canada; [Corvol, Jean-Christophe] Sorbonne Univ, Assistance Publ Hop Paris, INSERM, CNRS,Inst Cerveau,Paris Brain Inst ICM,Hop Pitie, Paris, France; [Aiba, Ikuko] Natl Hosp Org, Dept Neurol, Higashinagoya Natl Hosp, Nagoya, Aichi, Japan; [Grundman, Michael] Global R&D Partners LLC, San Diego, CA USA	Biogen; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center; Technical University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Hannover Medical School; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of California System; University of California San Diego; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Dam, T (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	tien.dam@biogen.com	Corvol, Jean-Christophe/F-2124-2017; Morris, Huw R/B-8527-2008; Lang, Anthony/ABF-8114-2021; Hoglinger, Gunter/F-2388-2015; Litvan, Irene/X-9319-2018	Corvol, Jean-Christophe/0000-0001-7325-0199; Morris, Huw R/0000-0002-5473-3774; Hoglinger, Gunter/0000-0001-7587-6187; Tonges, Lars/0000-0001-6621-144X; Litvan, Irene/0000-0002-3485-3445	Association for Frontotemporal Degeneration, Biogen, Bluefield Project to Cure Frontotemporal Dementia, Eli Lilly, Eisai, National Institutes of Health [U19AG063911, U54NS092089, R01AG031278]; Tau Research Consortium; AbbVie; American Parkinson's Disease Association; Biogen; GE Health; Neuropore; German Research Foundation (DFG) [EXC 2145, 390857198, HO2402/6-2, HO2402/18-1]; German Federal Ministry of Education and Research (BMBF) [01KU1403A, 01EK1605A]; NOMIS foundation (FTLD project); EU/EFPIA/Innovative Medicines Initiative (2) Joint Undertaking (IMPRIND) [116060]; VolkswagenStiftung/Lower Saxony Ministry for Science/Petermax-Muller Foundation (Niedersachsisches Vorab); CBD Solutions; Cure Parkinson's Trust; Drake Foundation; Medical Research Council; MND Association; Parkinson's UK; PSP Association; method for diagnosing a neurodegenerative disease [PCT/GB2012/052140]; Biohaven; EIP-Pharma; Roche; Lewy Body Association; Michael J. Fox Foundation; National Institutes of Health [5P50AG005131-33, 2R01AG038791-06A, U01NS090259, U01NS100610, U01NS80818, R25NS098999, P20GM109025, U19AG063911-1, 1R21NS114764-01A1]; Parkinson Foundation; Parkinson Study Group; University of California San Diego and Chief Editor of Frontiers in Neurology; Actelion	Association for Frontotemporal Degeneration, Biogen, Bluefield Project to Cure Frontotemporal Dementia, Eli Lilly, Eisai, National Institutes of Health; Tau Research Consortium; AbbVie(AbbVie); American Parkinson's Disease Association; Biogen(Biogen); GE Health(General ElectricGE Healthcare); Neuropore; German Research Foundation (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); NOMIS foundation (FTLD project); EU/EFPIA/Innovative Medicines Initiative (2) Joint Undertaking (IMPRIND); VolkswagenStiftung/Lower Saxony Ministry for Science/Petermax-Muller Foundation (Niedersachsisches Vorab); CBD Solutions; Cure Parkinson's Trust; Drake Foundation(Smithsonian InstitutionSmithsonian National Museum of Natural History); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MND Association; Parkinson's UK(Parkinson's UK); PSP Association; method for diagnosing a neurodegenerative disease; Biohaven; EIP-Pharma; Roche(Roche Holding); Lewy Body Association; Michael J. Fox Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parkinson Foundation; Parkinson Study Group; University of California San Diego and Chief Editor of Frontiers in Neurology; Actelion	A.L.B. reports consultancies for AGTC, Alector, Arkuda, Arvinas, Asceneuron, AZTherapies, Bioage, GSK, Humana, Lundbeck, Ono, Roche, Samumed, Sangamo, Stealth Therapeutics, Third Rock, Transposon, UCB and Wave, and research support from the Association for Frontotemporal Degeneration, Biogen, Bluefield Project to Cure Frontotemporal Dementia, Eli Lilly, Eisai, National Institutes of Health (grant nos. U19AG063911, U54NS092089 and R01AG031278) and Tau Research Consortium. L.I.G. reports consultancies for AbbVie, AlzProtect, Asceneuron, Biogen, CurePSP, Martin, Mitochon, Mitsubishi Tanabe, Pinteon, Retrotope, Roche, Stealth BioTherapeutics and UCB, and research support from AbbVie, American Parkinson's Disease Association and Biogen. G.U.H. reports consultancies for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi and UCB; honoraria for scientific presentations from AbbVie, Bayer Vital, Bial, Biogen, Bristol-Myers Squibb, Roche, Teva, UCB and Zambon; research collaborations with Orion, Prothena and Roche; research support from GE Health, Neuropore, German Research Foundation (DFG; EXC 2145 SyNergy, nos. 390857198, HO2402/6-2 and HO2402/18-1), the German Federal Ministry of Education and Research (BMBF, nos. 01KU1403A and 01EK1605A), the NOMIS foundation (FTLD project), the EU/EFPIA/Innovative Medicines Initiative (2) Joint Undertaking (IMPRIND, grant no. 116060) and VolkswagenStiftung/Lower Saxony Ministry for Science/Petermax-Muller Foundation (Niedersachsisches Vorab). H.R.M. reports consultancies for AbbVie, Biogen, Biohaven, Denali and UCB; employment by North Thames National Institute for Health Research and University College London; lecture fees/honoraria from Biogen, C4X Discovery, Movement Disorders Society, UCB and Wellcome Trust; research grants from CBD Solutions, Cure Parkinson's Trust, Drake Foundation, Medical Research Council, MND Association, Parkinson's UK and PSP Association; and being a coapplicant on a patent application related to C9ORF72 (method for diagnosing a neurodegenerative disease (no. PCT/GB2012/052140)). I.L. reports scientific advisory board membership for Corticobasal Degeneration Solutions and Lundbeck; research support from AbbVie, Biogen, Biohaven, EIP-Pharma, Roche, Lewy Body Association, Michael J. Fox Foundation, National Institutes of Health (grant nos. 5P50AG005131-33, 2R01AG038791-06A, U01NS090259, U01NS100610, U01NS80818, R25NS098999, P20GM109025, U19AG063911-1 and 1R21NS114764-01A1) and Parkinson Foundation and Parkinson Study Group; and employment at University of California San Diego and Chief Editor of Frontiers in Neurology. A.E.L. reports advisory board membership for AbbVie, AFFiRis, Biogen, Corticobasal Degeneration Solutions, Janssen, Jazz Pharma, Lilly, Lundbeck, Merck, Paladin, PhotoPharmics, Roche, Sunovion, Sun Pharma and Theravance; honoraria from AbbVie, Sunovion and Sun Pharma; grants from Brain Canada, Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, Edmond J. Safra Philanthropic Foundation, Michael J. Fox Foundation, Ontario Brain Institute, the Parkinson Foundation and Parkinson Society Canada. J.-C.C. reports advisory board membership for Pfizer; consultancies for Air Liquide, AlzProtect, Biogen, Bristol-Myers Squibb, Denali and Theranexus; speaker fees from Biogen and Ever Pharma; research grants from Actelion and Michael J. Fox Foundation; and travel grants from MDS. I.A. reports consultancies for AbbVie and Biogen. M.G. reports consultancies for Biogen and Bristol-Myers Squibb. T.D., L.Y., B.T.-M., K.K., M.J.; W., D.L.G., L.G., J.O. and S.B.H. are employees of, and hold stock in, Biogen. J.K. is a former employee of, and holds stock in, Biogen. K.H. reports being an independent physician pharmacovigilance professional at Biogen for the PASSPORT study.	Ali F, 2019, MOVEMENT DISORD, V34, P1144, DOI 10.1002/mds.27619; Armstrong RA, 2011, CLIN EXP OPTOM, V94, P150, DOI 10.1111/j.1444-0938.2010.00504.x; Bensimon G, 2009, BRAIN, V132, P156, DOI 10.1093/brain/awn291; Boxer AL, 2019, LANCET NEUROL, V18, P549, DOI 10.1016/S1474-4422(19)30139-5; Boxer AL, 2017, LANCET NEUROL, V16, P552, DOI 10.1016/S1474-4422(17)30157-6; Boxer AL, 2014, LANCET NEUROL, V13, P676, DOI 10.1016/S1474-4422(14)70088-2; Bright J, 2015, NEUROBIOL AGING, V36, P693, DOI 10.1016/j.neurobiolaging.2014.09.007; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Courade JP, 2018, ACTA NEUROPATHOL, V136, P729, DOI 10.1007/s00401-018-1911-2; Czerkowicz J, 2019, ALZHEIMERS DEMENT, V15, P1288; Czerkowicz J., 2018, ALZHEIMERS DEMENT, V14, P1441, DOI [10.1016/j.jalz.2018.06.2423, DOI 10.1016/J.JALZ.2018.06.2423]; D'Elia L.F., 1996, COLOR TRAILS TEST; Dal Bello-Haas V, 2011, PHYSIOTHER CAN, V63, P47, DOI 10.3138/ptc.2009-08; Dickson DW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009258; Dickson DW, 2010, CURR OPIN NEUROL, V23, P394, DOI 10.1097/WCO.0b013e32833be924; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; Fuster-Matanzo A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030645; Gibbons GS, 2019, JAMA NEUROL, V76, P101, DOI 10.1001/jamaneurol.2018.2505; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Golbe LI, 2007, BRAIN, V130, P1552, DOI 10.1093/brain/awm032; Golbe LI, 2014, SEMIN NEUROL, V34, P151, DOI 10.1055/s-0034-1381736; Golonzhka O, 2019, 14 INT C ALZH PARK D; Gomez-Ramos A, 2008, MOL CELL NEUROSCI, V37, P673, DOI 10.1016/j.mcn.2007.12.010; Gomez-Ramos A, 2006, FEBS LETT, V580, P4842, DOI 10.1016/j.febslet.2006.07.078; Grimm MJ, 2020, MOVEMENT DISORD, V35, P2301, DOI 10.1002/mds.28263; Guo JL, 2016, J EXP MED, V213, P2635, DOI 10.1084/jem.20160833; Guy W, 1976, ECDEU ASSESSMENT MAN, P217; Hall S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31517-z; Hall S, 2012, ARCH NEUROL-CHICAGO, V69, P1445, DOI 10.1001/archneurol.2012.1654; Hoglinger GU, 2021, LANCET NEUROL, V20, P182, DOI 10.1016/S1474-4422(20)30489-0; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P842, DOI 10.1002/mds.26973; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987; Hoglinger GU, 2011, NAT GENET, V43, P699, DOI 10.1038/ng.859; Josephs KA, 2013, MOVEMENT DISORD, V28, P1117, DOI 10.1002/mds.25437; Karantzoulis S, 2013, ARCH CLIN NEUROPSYCH, V28, P837, DOI 10.1093/arclin/act057; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Mamarabadi M, 2018, MOV DISORD CLIN PRAC, V5, P603, DOI 10.1002/mdc3.12678; Martinez-Martin P, 2015, PARKINSONISM RELAT D, V21, P50, DOI 10.1016/j.parkreldis.2014.10.026; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; Mocanu MM, 2008, J NEUROSCI, V28, P737, DOI 10.1523/JNEUROSCI.2824-07.2008; Papapetropoulos S, 2005, PARKINSONISM RELAT D, V11, P459, DOI 10.1016/j.parkreldis.2005.06.003; Paton D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067364; Picillo M, 2019, J NEUROL, V266, P1727, DOI 10.1007/s00415-019-09324-x; Qureshi Irfan A, 2018, Alzheimers Dement (N Y), V4, P746, DOI 10.1016/j.trci.2018.10.007; Respondek G, 2017, MOVEMENT DISORD, V32, P995, DOI 10.1002/mds.27034; Respondek G, 2014, MOVEMENT DISORD, V29, P1758, DOI 10.1002/mds.26054; Respondek G, 2013, MOVEMENT DISORD, V28, P504, DOI 10.1002/mds.25327; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Scheres SHW, 2020, CURR OPIN STRUC BIOL, V64, P17, DOI 10.1016/j.sbi.2020.05.011; Schrag A, 2006, NEUROLOGY, V67, P39, DOI 10.1212/01.wnl.0000223826.84080.97; Shoeibi A, 2019, PARKINSONISM RELAT D, V69, P34, DOI 10.1016/j.parkreldis.2019.10.012; Shoeibi A, 2018, EXPERT OPIN INV DRUG, V27, P349, DOI 10.1080/13543784.2018.1460356; Sopko R, 2020, NEUROBIOL DIS, V146, DOI 10.1016/j.nbd.2020.105120; Stamelou M, 2016, MOVEMENT DISORD, V31, P742, DOI 10.1002/mds.26580; Tolosa E, 2014, MOVEMENT DISORD, V29, P470, DOI 10.1002/mds.25824; Tsai RM, 2016, PARKINSONISM RELAT D, V28, P29, DOI 10.1016/j.parkreldis.2016.04.006; Vaswani PA, 2020, CURR OPIN NEUROL, V33, P527, DOI 10.1097/WCO.0000000000000836; Wagshal D, 2015, J NEUROL NEUROSUR PS, V86, P244, DOI 10.1136/jnnp-2014-308004; Whitwell JL, 2017, MOVEMENT DISORD, V32, P955, DOI 10.1002/mds.27038; Wolz R, 2010, NEUROIMAGE, V49, P1316, DOI 10.1016/j.neuroimage.2009.09.069; Yamada K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00667	64	20	20	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1451	+		10.1038/s41591-021-01455-x	http://dx.doi.org/10.1038/s41591-021-01455-x		AUG 2021	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385707	Green Submitted			2022-12-27	WOS:000684533600001
J	Zekavat, SM; Lin, SH; Bick, AG; Liu, AX; Paruchuri, K; Wang, C; Uddin, MM; Ye, YX; Yu, ZL; Liu, XX; Kamatani, Y; Bhattacharya, R; Pirruccello, JP; Pampana, A; Loh, PR; Kohli, P; McCarroll, SA; Kiryluk, K; Neale, B; Ionita-Laza, I; Engels, EA; Brown, DW; Smoller, JW; Green, R; Karlson, EW; Lebo, M; Ellinor, PT; Weiss, ST; Daly, MJ; Terao, C; Zhao, HY; Ebert, BL; Reilly, MP; Ganna, A; Machiela, MJ; Genovese, G; Natarajan, P				Zekavat, Seyedeh M.; Lin, Shu-Hong; Bick, Alexander G.; Liu, Aoxing; Paruchuri, Kaavya; Wang, Chen; Uddin, Md Mesbah; Ye, Yixuan; Yu, Zhaolong; Liu, Xiaoxi; Kamatani, Yoichiro; Bhattacharya, Romit; Pirruccello, James P.; Pampana, Akhil; Loh, Po-Ru; Kohli, Puja; McCarroll, Steven A.; Kiryluk, Krzysztof; Neale, Benjamin; Ionita-Laza, Iuliana; Engels, Eric A.; Brown, Derek W.; Smoller, Jordan W.; Green, Robert; Karlson, Elizabeth W.; Lebo, Matthew; Ellinor, Patrick T.; Weiss, Scott T.; Daly, Mark J.; Terao, Chikashi; Zhao, Hongyu; Ebert, Benjamin L.; Reilly, Muredach P.; Ganna, Andrea; Machiela, Mitchell J.; Genovese, Giulio; Natarajan, Pradeep		Biobank Japan Project; FinnGen Consortium	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection	NATURE MEDICINE			English	Article							DETECTABLE CLONAL MOSAICISM; VIRAL-INFECTION; CANCER; AGE; IMMUNOSENESCENCE; INNATE; BLOOD	The burden of mosaic chromosomal alterations in blood-derived DNA, a type of clonal hematopoiesis, is associated with an increased risk for diverse types of infections, including sepsis and pneumonia. Age is the dominant risk factor for infectious diseases, but the mechanisms linking age to infectious disease risk are incompletely understood. Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA, are structural somatic variants indicative of clonal hematopoiesis, and are associated with aberrant leukocyte cell counts, hematological malignancy, and mortality. Here, we show that mCAs predispose to diverse types of infections. We analyzed mCAs from 768,762 individuals without hematological cancer at the time of DNA acquisition across five biobanks. Expanded autosomal mCAs were associated with diverse incident infections (hazard ratio (HR) 1.25; 95% confidence interval (CI) = 1.15-1.36; P = 1.8 x 10(-7)), including sepsis (HR 2.68; 95% CI = 2.25-3.19; P = 3.1 x 10(-28)), pneumonia (HR 1.76; 95% CI = 1.53-2.03; P = 2.3 x 10(-15)), digestive system infections (HR 1.51; 95% CI = 1.32-1.73; P = 2.2 x 10(-9)) and genitourinary infections (HR 1.25; 95% CI = 1.11-1.41; P = 3.7 x 10(-4)). A genome-wide association study of expanded mCAs identified 63 loci, which were enriched at transcriptional regulatory sites for immune cells. These results suggest that mCAs are a marker of impaired immunity and confer increased predisposition to infections.	[Zekavat, Seyedeh M.; Ye, Yixuan; Yu, Zhaolong; Zhao, Hongyu] Yale Univ, Computat Biol & Bioinformat Program, New Haven, CT USA; [Zekavat, Seyedeh M.; Bick, Alexander G.; Paruchuri, Kaavya; Uddin, Md Mesbah; Pirruccello, James P.; Pampana, Akhil; Loh, Po-Ru; Green, Robert; Ellinor, Patrick T.; Ebert, Benjamin L.; Ganna, Andrea; Genovese, Giulio; Natarajan, Pradeep] Broad Inst Harvard & MIT, Med & Populat Genet & Cardiovasc Dis Initiat, Cambridge, MA 02142 USA; [Zekavat, Seyedeh M.; Paruchuri, Kaavya; Uddin, Md Mesbah; Bhattacharya, Romit; Pirruccello, James P.; Pampana, Akhil; Ellinor, Patrick T.; Natarajan, Pradeep] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Lin, Shu-Hong; Brown, Derek W.; Machiela, Mitchell J.] NCI, Integrat Tumor Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA; [Bick, Alexander G.] Vanderbilt Univ, Med Ctr, Dept Med, Div Genet Med, Nashville, TN USA; [Liu, Aoxing; Daly, Mark J.; Ganna, Andrea] Inst Mol Med Finland, Helsinki, Finland; [Paruchuri, Kaavya; Pirruccello, James P.; Loh, Po-Ru; Green, Robert; Karlson, Elizabeth W.; Ellinor, Patrick T.; Weiss, Scott T.; Natarajan, Pradeep] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Wang, Chen; Ionita-Laza, Iuliana] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA; [Wang, Chen; Kiryluk, Krzysztof] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY USA; [Liu, Xiaoxi; Kamatani, Yoichiro; Terao, Chikashi] RIKEN, Ctr Integrat Med Sci, Lab Stat & Translat Genet, Yokohama, Kanagawa, Japan; [Kohli, Puja] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Kohli, Puja; Lebo, Matthew] Harvard Med Sch, Boston, MA 02115 USA; [Kohli, Puja] Vertex Pharmaceut, Boston, MA USA; [McCarroll, Steven A.; Neale, Benjamin; Smoller, Jordan W.; Genovese, Giulio] Broad Inst Harvard & MIT, Stanley Ctr, Cambridge, MA USA; [McCarroll, Steven A.; Green, Robert; Genovese, Giulio] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA; [Kiryluk, Krzysztof; Reilly, Muredach P.] Columbia Univ, Irving Inst Clin & Translat Res, New York, NY USA; [Neale, Benjamin; Ganna, Andrea] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Engels, Eric A.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA; [Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Smoller, Jordan W.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [Karlson, Elizabeth W.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA; [Lebo, Matthew] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Lebo, Matthew] Partners Healthcare, Lab Mol Med, Cambridge, MA USA; [Weiss, Scott T.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Terao, Chikashi] Shizuoka Prefectural Gen Hosp, Clin Res Ctr, Shizuoka, Japan; [Terao, Chikashi] Univ Shizuoka, Sch Pharmaceut Sci, Dept Appl Genet, Shizuoka, Japan; [Zhao, Hongyu] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA; [Ebert, Benjamin L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Ebert, Benjamin L.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Reilly, Muredach P.] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY USA	Yale University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Columbia University; Columbia University; RIKEN; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Columbia University; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Harvard University; Brigham & Women's Hospital; Shizuoka General Hospital; University of Shizuoka; Yale University; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Columbia University	Natarajan, P (corresponding author), Broad Inst Harvard & MIT, Med & Populat Genet & Cardiovasc Dis Initiat, Cambridge, MA 02142 USA.; Natarajan, P (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.; Natarajan, P (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.	pnatarajan@mgh.harvard.edu	Natarajan, Pradeep/H-9764-2019; Machiela, Mitchell J/H-7335-2019; Brown, Derek/AAW-7130-2021; Uddin, Md Mesbah/J-1276-2014; Laivuori, Hannele/F-2953-2011	Natarajan, Pradeep/0000-0001-8402-7435; Machiela, Mitchell J/0000-0001-6538-9705; Pylkas, Katri/0000-0002-2449-0521; Uddin, Md Mesbah/0000-0003-1846-0411; Kuopio, Teijo/0000-0003-3503-4094; Turunen, Joni/0000-0002-9569-9146; Luukkaala, Tiina/0000-0003-4636-9586; Maranville, Joseph/0000-0002-1688-1573; Ye, Yixuan/0000-0002-2643-665X; Vaarasmaki, Marja/0000-0002-8234-4434; Paul, Dirk/0000-0002-8230-0116; pampana, Akhil/0000-0002-4167-0540; Podgornaia, Anna/0000-0002-7163-7901; Liu, Aoxing/0000-0002-9155-1494; Yu, Zhaolong/0000-0001-9585-2465; Kujala, Urho/0000-0002-9262-1992; Laivuori, Hannele/0000-0003-3212-7826; Lebo, Matthew/0000-0002-9733-5207; LIN, SHU-HONG/0000-0002-4020-7714; Kahonen, Mika/0000-0002-4510-7341	Massachusetts General Hospital; National Heart, Lung, and Blood Institute [R01HL1427, R01HL148565, R01HL148050]; Fondation Leducq [TNE-18CVD04]; NIH National Heart, Lung, and Blood Institute [1F30HL149180-01]; NIH Medical Scientist Training Program Training Grant [T32GM136651]; Burroughs Wellcome Fund Career Award for Medical Scientists; NIH [R01 HG006855, R01 MH104964, 5-T32HL007208-43, DP2 ES030554]; Stanley Center for Psychiatric Research; John S. LaDue Memorial Fellowship; National Institutes of Health [1RO1HL092577, R01HL128914, K24HL105780]; American Heart Association [18SFRN34110082]; Foundation Leducq [14CVD01]; National Cancer Institute, National Institutes of Health; National Heart, Lung, and Blood Institute; Fondation Leducq; Vagelos College of Physicians and Surgeons; Precision Medicine Resource and Biomedical Informatics Resource of Irving Institute for Clinical and Translational Research, home of the Columbia University's Clinical and Translational Science Award (CTSA)- National Center for Advancing Translational Scie [UL1TR001873]; Burroughs Wellcome Fund Career Award at the Scientific Interfaces	Massachusetts General Hospital(General Electric); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fondation Leducq(Leducq Foundation); NIH National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH Medical Scientist Training Program Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanley Center for Psychiatric Research; John S. LaDue Memorial Fellowship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Foundation Leducq(Leducq Foundation); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fondation Leducq(Leducq Foundation); Vagelos College of Physicians and Surgeons; Precision Medicine Resource and Biomedical Informatics Resource of Irving Institute for Clinical and Translational Research, home of the Columbia University's Clinical and Translational Science Award (CTSA)- National Center for Advancing Translational Scie; Burroughs Wellcome Fund Career Award at the Scientific Interfaces	The authors thank C. Whelan, C. Llanwarne, J. Cerrato, K. Vernest and K. Shakir, and many other members of the Terra/Cromwell team, for their help and advice in the development of the MoChA pipeline. The authors also thank P. Danecek for implementing critical features needed in BCFtools, S. Chanock for critical input and comments, E. Loftfield for assistance with the 25-level smoking adjustment variable, and the participants and staff of the UKB, MGBB, and BBJ. The UKB analyses were conducted using applications 7089 and 21552. The authors thank all of the study participants and their families for contributing to the CUB COVID-19 cohort. The genotyping was made possible by the CUB and its COVID-19 Genomics Workgroup members, including A. Califano, W. Chung, C. K. Garcia, D. B. Goldstein, I. Ionita-Laza, K. Kiryluk, R. Mayeux, S. M. O'Byrne, D. Pendrick, M. P. Reilly, S. Sengupta, P. Sims and A.-C. Uhlemann. The authors acknowledge the COVID-19 Host Genetics Initiative consortium for providing infrastructure for collaboration (the members are listed in the Supplementary Information). P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General Hospital, and grants from the National Heart, Lung, and Blood Institute (R01HL1427, R01HL148565 and R01HL148050). P.N. and B.L.E. are supported by a grant from Fondation Leducq (TNE-18CVD04). S.M.Z. is supported by the NIH National Heart, Lung, and Blood Institute (1F30HL149180-01) and the NIH Medical Scientist Training Program Training Grant (T32GM136651). A.G. B. is supported by a Burroughs Wellcome Fund Career Award for Medical Scientists. G.G. is supported by NIH grant R01 HG006855, NIH grant R01 MH104964, and the Stanley Center for Psychiatric Research. J.P.P. is supported by a John S. LaDue Memorial Fellowship. K.P. is supported by NIH grant 5-T32HL007208-43. P.T.E. is supported by supported grants from the National Institutes of Health (1RO1HL092577, R01HL128914, K24HL105780), the American Heart Association (18SFRN34110082), and by the Foundation Leducq (14CVD01). P.-R.L. is supported by NIH grant DP2 ES030554 and a Burroughs Wellcome Fund Career Award at the Scientific Interfaces. This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, extramural grants from the National Heart, Lung, and Blood Institute, and Fondation Leducq. The opinions expressed by the authors are their own and this material should not be interpreted as representing the official viewpoint of the US Department of Health and Human Services, the National Institutes of Health, or the National Cancer Institute. The CUB is supported by the Vagelos College of Physicians and Surgeons as well as the Precision Medicine Resource and Biomedical Informatics Resource of Irving Institute for Clinical and Translational Research, home of the Columbia University's Clinical and Translational Science Award (CTSA), funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR001873.	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Aoshi T, 2011, CURR OPIN VIROL, V1, P226, DOI 10.1016/j.coviro.2011.07.002; Arruga F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051825; Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bartik MM, 1998, SEMIN ONCOL, V25, P27; Bick AG, 2020, CIRCULATION, V141, P124, DOI 10.1161/CIRCULATIONAHA.119.044362; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Cunha LL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01748; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404; Forsberg LA, 2014, NAT GENET, V46, P624, DOI 10.1038/ng.2966; Franceschi C, 2000, VACCINE, V18, P1717, DOI 10.1016/S0264-410X(99)00513-7; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; GARDNER ID, 1980, REV INFECT DIS, V2, P801; Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Holly MK, 2017, ANNU REV VIROL, V4, P369, DOI 10.1146/annurev-virology-101416-041734; Hu YM, 2019, NAT GENET, V51, P568, DOI 10.1038/s41588-019-0345-7; Huang C., 2020, CHINA LANCET, V395; Jacobs KB, 2012, NAT GENET, V44, P651, DOI 10.1038/ng.2270; Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Lin SH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59963-8; Loftfield E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30759-1; Loh PR, 2020, NATURE, V584, P136, DOI 10.1038/s41586-020-2430-6; Loh PR, 2018, NATURE, V559, P350, DOI 10.1038/s41586-018-0321-x; Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679; Lu QS, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006933; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Machiela MJ, 2015, AM J HUM GENET, V96, P487, DOI 10.1016/j.ajhg.2015.01.011; MACKENBACH JP, 1988, HEALTH POLICY, V10, P207, DOI 10.1016/0168-8510(88)90006-1; Pallett LJ, 2019, CLIN EXP IMMUNOL, V197, P143, DOI 10.1111/cei.13308; Panda A, 2009, TRENDS IMMUNOL, V30, P325, DOI 10.1016/j.it.2009.05.004; Smoller JW, 2016, J PERS MED, V6, DOI 10.3390/jpm6010005; Terao C, 2020, NATURE, V584, P130, DOI 10.1038/s41586-020-2426-2; Thompson DJ, 2019, NATURE, V575, P652, DOI 10.1038/s41586-019-1765-3; Tian C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00257-5; Voss K., 2017, 18 ANN BIOINFORMATIC, DOI [10.7490/f1000research.1114634.1, DOI 10.7490/F1000RESEARCH.1114634.1]; Wang LL, 2017, GENOME RES, V27, P1300, DOI 10.1101/gr.217331.116; Wu P, 2019, JMIR MED INF, V7, P360, DOI 10.2196/14325; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733; Zhou WY, 2016, NAT GENET, V48, P563, DOI 10.1038/ng.3545	46	34	34	2	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					1012	+		10.1038/s41591-021-01371-0	http://dx.doi.org/10.1038/s41591-021-01371-0		JUN 2021	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34099924	Bronze, Green Published, Green Accepted			2022-12-27	WOS:000658604700002
J	Gygli, SM; Loiseau, C; Jugheli, L; Adamia, N; Trauner, A; Reinhard, M; Ross, A; Borrell, S; Aspindzelashvili, R; Maghradze, N; Reither, K; Beisel, C; Tukvadze, N; Avaliani, Z; Gagneux, S				Gygli, Sebastian M.; Loiseau, Chloe; Jugheli, Levan; Adamia, Natia; Trauner, Andrej; Reinhard, Miriam; Ross, Amanda; Borrell, Sonia; Aspindzelashvili, Rusudan; Maghradze, Nino; Reither, Klaus; Beisel, Christian; Tukvadze, Nestani; Avaliani, Zaza; Gagneux, Sebastien			Prisons as ecological drivers of fitness-compensated multidrug-resistant Mycobacteritum tuberculosis	NATURE MEDICINE			English	Article							ANTIBIOTIC-RESISTANCE; GENOME; COST; TRANSMISSION; BEDAQUILINE; PREVALENCE; MUTATIONS; EVOLUTION; PROGRAM; GEORGIA	Multidrug-resistant tuberculosis (MDR-TB) accounts for one third of the annual deaths due to antimicrobial resistance(1). Drug resistance-conferring mutations frequently cause fitness costs in bacteria(2-5). Experimental work indicates that these drug resistance-related fitness costs might be mitigated by compensatory mutations(6-10). However, the clinical relevance of compensatory evolution remains poorly understood. Here we show that, in the country of Georgia, during a 6-year nationwide study, 63% of MDR-TB was due to patient-to-patient transmission. Compensatory mutations and patient incarceration were independently associated with transmission. Furthermore, compensatory mutations were overrepresented among isolates from incarcerated individuals that also frequently spilled over into the non-incarcerated population. As a result, up to 31% of MDR-TB in Georgia was directly or indirectly linked to prisons. We conclude that prisons fuel the epidemic of MDR-TB in Georgia by acting as ecological drivers of fitness-compensated strains with high transmission potential.	[Gygli, Sebastian M.; Loiseau, Chloe; Jugheli, Levan; Trauner, Andrej; Reinhard, Miriam; Ross, Amanda; Borrell, Sonia; Maghradze, Nino; Reither, Klaus; Tukvadze, Nestani; Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Gygli, Sebastian M.; Loiseau, Chloe; Jugheli, Levan; Trauner, Andrej; Reinhard, Miriam; Ross, Amanda; Borrell, Sonia; Maghradze, Nino; Reither, Klaus; Tukvadze, Nestani; Gagneux, Sebastien] Univ Basel, Basel, Switzerland; [Jugheli, Levan; Adamia, Natia; Aspindzelashvili, Rusudan; Maghradze, Nino; Tukvadze, Nestani; Avaliani, Zaza] Natl Ctr TB & Lung Dis NCTLD, Tbilisi, Georgia; [Beisel, Christian] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich	Gagneux, S (corresponding author), Swiss Trop & Publ Hlth Inst, Basel, Switzerland.; Gagneux, S (corresponding author), Univ Basel, Basel, Switzerland.	sebastien.gagneux@swisstph.ch		Ross, Amanda/0000-0001-6027-5645; Beisel, Christian/0000-0001-5360-2193; Trauner, Andrej/0000-0002-6260-9829; Maghradze, Nino/0000-0003-1227-1900; Reither, Klaus/0000-0001-6195-8237	Swiss National Science Foundation [310030_188888, IZRJZ3_164171, IZLSZ3_170834, CRSII5_177163]; European Research Council [309540-EVODRTB, 883582-ECOEVODRTB]; SystemsX.ch	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council(European Research Council (ERC)European Commission); SystemsX.ch	Calculations were performed at the sciCORE (http://scicore.unibas.ch/) scientific computing core facility at the University of Basel. We would like to thank D. Klinkenberg (Dutch National Institute for Public Health and the Environment) for help with the phybreak analysis and D. Brites for feedback on the manuscript. We also thank J. Andrews and the two other anonymous reviewers for their excellent comments that helped us improve our manuscript. Funding: This work was supported by the Swiss National Science Foundation (grants 310030_188888, IZRJZ3_164171, IZLSZ3_170834 and CRSII5_177163, all to S.G.), the European Research Council (309540-EVODRTB and 883582-ECOEVODRTB, both to S.G.) and SystemsX.ch (to S.G. and C.B.).	Aerts A, 2000, INT J TUBERC LUNG D, V4, P1104; Ahmad N, 2018, LANCET, V392, P821, DOI 10.1016/S0140-6736(18)31644-1; Andersson DI, 2010, NAT REV MICROBIOL, V8, P260, DOI 10.1038/nrmicro2319; Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; Baussano I, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000381; Behr MA, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2738; Brandis G, 2012, MOL MICROBIOL, V85, P142, DOI 10.1111/j.1365-2958.2012.08099.x; Casali N, 2014, NAT GENET, V46, P279, DOI 10.1038/ng.2878; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Coll F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5812; Comas I, 2012, NAT GENET, V44, P106, DOI 10.1038/ng.1038; de Vos M, 2013, ANTIMICROB AGENTS CH, V57, P827, DOI 10.1128/AAC.01541-12; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Dye C, 2001, P ROY SOC B-BIOL SCI, V268, P45, DOI 10.1098/rspb.2000.1328; Dye C, 2009, NAT REV MICROBIOL, V7, P81, DOI 10.1038/nrmicro2048; Eldholm V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8119; Gagneux S, 2006, PLOS PATHOG, V2, P603, DOI 10.1371/journal.ppat.0020061; Gagneux S, 2006, SCIENCE, V312, P1944, DOI 10.1126/science.1124410; Gegia M, 2011, HEALTH HUM RIGHTS, V13, P73; Gygli SM, 2017, FEMS MICROBIOL REV, V41, P354, DOI 10.1093/femsre/fux011; Ismail NA, 2018, EBIOMEDICINE, V28, P136, DOI 10.1016/j.ebiom.2018.01.005; Kenyon G, 2009, LANCET INFECT DIS, V9, P594, DOI 10.1016/S1473-3099(09)70245-2; Klinkenberg D, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005495; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Lanfear R, 2016, GENOME BIOL EVOL, V8, P2319, DOI 10.1093/gbe/evw171; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; LIU QY, 2018, EMERG MICROBES INFEC, V7; Lomtadze N, 2009, INT J TUBERC LUNG D, V13, P68; Maisnier-Patin S, 2002, MOL MICROBIOL, V46, P355, DOI 10.1046/j.1365-2958.2002.03173.x; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Menardo F, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008067; Menardo F, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2164-8; Merker M, 2018, ELIFE, V7, DOI 10.7554/eLife.38200; Niemann S, 2010, J CLIN MICROBIOL, V48, P3544, DOI 10.1128/JCM.00715-10; Nimmo C, 2020, LANCET MICROBE, V1, pE165, DOI 10.1016/S2666-5247(20)30031-8; ONeill J., 2014, REV ANTIMICROB RESIS; Qi Q, 2014, MBIO, V5, DOI 10.1128/mBio.01562-14; Reynolds MG, 2000, GENETICS, V156, P1471; Song T, 2014, MOL MICROBIOL, V91, P1106, DOI 10.1111/mmi.12520; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Stefan MA, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.00164-18, 10.1128/AAC.00164-18]; Stuckler D, 2008, P NATL ACAD SCI USA, V105, P13280, DOI 10.1073/pnas.0801200105; Walker TM, 2013, LANCET INFECT DIS, V13, P137, DOI 10.1016/S1473-3099(12)70277-3; World Health Organization, 2019, GLOB TURB REP 2019; World Health Organization, 2014, EXT REV TUB PREV CON; World Health Organization, 2014, COMP HDB WHO GUID PR; World Health Organization, 2021, 10 THREATS GLOB HLTH; Yang C, 2016, LANCET INFECT DIS, V3099, P1; Yates TA, 2016, LANCET INFECT DIS, V16, P227, DOI 10.1016/S1473-3099(15)00499-5	49	11	11	3	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1171	+		10.1038/s41591-021-01358-x	http://dx.doi.org/10.1038/s41591-021-01358-x		MAY 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34031604	Green Accepted			2022-12-27	WOS:000653615900007
J	Manberg, A; Skene, N; Sanders, F; Trusohamn, M; Remnestal, J; Szczepinska, A; Aksoylu, IS; Lonnerberg, P; Ebarasi, L; Wouters, S; Lehmann, M; Olofsson, J; Antequera, IV; Domaniku, A; De Schaepdryver, M; De Vocht, J; Poesen, K; Uhlen, M; Anink, J; Mijnsbergen, C; Vergunst-Bosch, H; Hubers, A; Klappe, U; Rodriguez-Vieitez, E; Gilthorpe, JD; Hedlund, E; Harris, RA; Aronica, E; Van Damme, P; Ludolph, A; Veldink, J; Ingre, C; Nilsson, P; Lewandowski, SA				Manberg, Anna; Skene, Nathan; Sanders, Folkert; Trusohamn, Marta; Remnestal, Julia; Szczepinska, Anna; Aksoylu, Inci Sevval; Lonnerberg, Peter; Ebarasi, Lwaki; Wouters, Stefan; Lehmann, Manuela; Olofsson, Jennie; von Gohren Antequera, Inti; Domaniku, Aylin; De Schaepdryver, Maxim; De Vocht, Joke; Poesen, Koen; Uhlen, Mathias; Anink, Jasper; Mijnsbergen, Caroline; Vergunst-Bosch, Hermieneke; Hubers, Annemarie; Klappe, Ulf; Rodriguez-Vieitez, Elena; Gilthorpe, Jonathan D.; Hedlund, Eva; Harris, Robert A.; Aronica, Eleonora; Van Damme, Philip; Ludolph, Albert; Veldink, Jan; Ingre, Caroline; Nilsson, Peter; Lewandowski, Sebastian A.			Altered perivascular fibroblast activity precedes ALS disease onset	NATURE MEDICINE			English	Article							MOUSE MODEL; DEGENERATION; PROGRESSION; ACTIVATION; EXPRESSION; PROTEINS	Apart from well-defined factors in neuronal cells(1), only a few reports consider that the variability of sporadic amyotrophic lateral sclerosis (ALS) progression can depend on less-defined contributions from glia(2,3) and blood vessels(4). In this study we use an expression-weighted cell-type enrichment method to infer cell activity in spinal cord samples from patients with sporadic ALS and mouse models of this disease. Here we report that patients with sporadic ALS present cell activity patterns consistent with two mouse models in which enrichments of vascular cell genes preceded microglial response. Notably, during the presymptomatic stage, perivascular fibroblast cells showed the strongest gene enrichments, and their marker proteins SPP1 and COL6A1 accumulated in enlarged perivascular spaces in patients with sporadic ALS. Moreover, in plasma of 574 patients with ALS from four independent cohorts, increased levels of SPP1 at disease diagnosis repeatedly predicted shorter survival with stronger effect than the established risk factors of bulbar onset or neurofilament levels in cerebrospinal fluid. We propose that the activity of the recently discovered perivascular fibroblast can predict survival of patients with ALS and provide a new conceptual framework to re-evaluate definitions of ALS etiology. Increased perivascular fibroblast activity and vascular remodeling occurs early in ALS pathogenesis and can predict patient survival time	[Manberg, Anna; Remnestal, Julia; Olofsson, Jennie; Nilsson, Peter; Lewandowski, Sebastian A.] KTH Royal Inst Technol, Div Affin Prote, Dept Prot Sci, SciLifeLab, Stockholm, Sweden; [Skene, Nathan; Trusohamn, Marta; Lonnerberg, Peter] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Skene, Nathan] Imperial Coll London, Div Neurosci, Dept Brain Sci, London, England; [Skene, Nathan] United Kingdom Dementia Res Inst, London, England; [Sanders, Folkert; Szczepinska, Anna; Aksoylu, Inci Sevval; Wouters, Stefan; von Gohren Antequera, Inti; Domaniku, Aylin; Harris, Robert A.; Lewandowski, Sebastian A.] Karolinska Hosp, Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden; [Ebarasi, Lwaki] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Lehmann, Manuela; Gilthorpe, Jonathan D.] Umea Univ, Dept Integrat Med Biol, Umea, Sweden; [De Schaepdryver, Maxim; Poesen, Koen] KU Leuven Univ Leuven, Leuven Brain Inst, Dept Neurol, Lab Neurobiomarker Res, Leuven, Belgium; [De Vocht, Joke; Van Damme, Philip] Katholieke Univ Leuven, Neurol Dept, Leuven, Belgium; [De Vocht, Joke; Van Damme, Philip] Katholieke Univ Leuven, Ctr Brain & Dis Res, Leuven, Belgium; [Poesen, Koen] UZ Leuven Univ Hosp Leuven, Lab Med, Leuven, Belgium; [Uhlen, Mathias] KTH Royal Inst Technol, Dept Prot Sci, Div Syst Biol, SciLifeLab, Stockholm, Sweden; [Uhlen, Mathias; Hedlund, Eva] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Anink, Jasper; Mijnsbergen, Caroline; Aronica, Eleonora] Univ Amsterdam, Amsterdam Neurosci, Amsterdam UMC, Dept NeuroPathol, Amsterdam, Netherlands; [Vergunst-Bosch, Hermieneke; Veldink, Jan] Univ Utrecht, Univ Med Ctr Utrecht, Dept Neurol, UMC Utrecht Brain Ctr, Utrecht, Netherlands; [Hubers, Annemarie; Ludolph, Albert] Univ Ulm, Neurol Clin, Ulm, Germany; [Klappe, Ulf; Ingre, Caroline] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden; [Vergunst-Bosch, Hermieneke; Rodriguez-Vieitez, Elena] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Stockholm, Sweden; [Ludolph, Albert] Deutsches Zentrum Neurodegenerat Erkrankungen DZN, Bonn, Germany; [Ingre, Caroline] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Hubers, Annemarie] Geneva Univ Hosp, Div Neurol, Geneva, Switzerland	Royal Institute of Technology; SciLifeLab; Karolinska Institutet; Imperial College London; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Umea University; KU Leuven; KU Leuven; KU Leuven; Royal Institute of Technology; SciLifeLab; Karolinska Institutet; University of Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center; Ulm University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; University of Geneva	Lewandowski, SA (corresponding author), KTH Royal Inst Technol, Div Affin Prote, Dept Prot Sci, SciLifeLab, Stockholm, Sweden.; Lewandowski, SA (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden.	sebastian.lewandowski@ki.se	Van Damme, Philip/A-6464-2009; Uhlen, Mathias/AAV-8746-2021; Wouters, Stefan/AAQ-6654-2021	Van Damme, Philip/0000-0002-4010-2357; Klappe, Ulf/0000-0001-5832-038X; Skene, Nathan/0000-0002-6807-3180; Gilthorpe, Jonathan/0000-0002-6884-4774; Szczepinska, Anna/0000-0002-8341-4473; Manberg (Haggmark), Anna/0000-0002-0056-1313; De Vocht, Joke/0000-0003-4116-192X; Veldink, Jan/0000-0001-5572-9657; Hedlund, Eva/0000-0001-6347-0075; Harris, Robert/0000-0003-4990-509X; De Schaepdryver, Maxim/0000-0003-2480-863X; Lewandowski, Sebastian A./0000-0002-5935-0211				ALCHALABI A, 2014, NEW ENGL J MED, V0013, P01108, DOI DOI 10.1016/S1474-4422(14)70219-4; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; BRAAK H, 2013, BRAIN RES BULL, V0009, P00708, DOI DOI 10.1038/nrneurol.2013.221; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; BROWN R, 2018, J ALZHEIMERS DIS, V0114, P01462, DOI DOI 10.1093/cvr/cvy113; Brown RH, 2017, NEW ENGL J MED, V377, P1602, DOI [10.1038/nrdp.2017.85, 10.1056/NEJMra1603471, 10.1056/NEJMc1710379, 10.1016/S0140-6736(17)31287-4, 10.1016/S0140-6736(10)61156-7, 10.1038/nrdp.2017.71]; CASULA M, 2011, AMYOTROPH LAT SCL FR, V0179, P00233, DOI DOI 10.1016/j.neuroscience.2011.02.001; CHIOCCHETTI A, 2016, ATHEROSCLEROSIS, V2016, P75437, DOI DOI 10.1155/2016/7675437; CHIU A, 1995, NAT REV NEUROL, V0006, P00349; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; CLARK J, 2016, FRONT NEUROSCI-SWITZ, V0076, P00035, DOI DOI 10.1016/j.jchemneu.2016.03.003; Cook C, 2019, NEURON, V101, P1057, DOI 10.1016/j.neuron.2019.02.032; Ding J, 2017, JAMA NEUROL, V74, P1105, DOI 10.1001/jamaneurol.2017.1397; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Garton FC, 2021, EUR J NEUROL, V28, P421, DOI 10.1111/ene.14554; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gille B, 2019, J NEUROL NEUROSUR PS, V90, P1338, DOI 10.1136/jnnp-2018-319586; Haggmark A, 2014, ANN CLIN TRANSL NEUR, V1, P544, DOI 10.1002/acn3.83; HALL E, 1998, J CHEM NEUROANAT, V0023, P00249; HUISMAN M, 2011, NEUROSCIENCE, V0082, P01165, DOI DOI 10.1136/jnnp.2011.244939; Kang SH, 2013, NAT NEUROSCI, V16, P571, DOI 10.1038/nn.3357; KAPOOR K, 2008, NATURE, V0077, P00327, DOI DOI 10.1016/j.brainresbull.2008.08.009; LERMAN B, 2012, NEUROLOGY, V0002, P00563, DOI DOI 10.1002/brb3.75; Lewandowski SA, 2016, ACTA NEUROPATHOL, V131, P453, DOI 10.1007/s00401-015-1520-2; Longinetti E, 2018, AMYOTROPH LAT SCL FR, V19, P528, DOI 10.1080/21678421.2018.1497065; LUDOLPH A, 2015, HUM MOL GENET, V0016, P00291, DOI DOI 10.3109/21678421.2015.1049183; Lutz C., 2009, WORKING ALS MICE GUI; Ma QL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01484-6; Marques S, 2016, SCIENCE, V352, P1326, DOI 10.1126/science.aaf6463; MURPHY M, 2012, NEUROLOGY, V0013, P00202, DOI DOI 10.3109/17482968.2011.625569; Pin E, 2019, METHODS MOL BIOL, V2044, P303, DOI 10.1007/978-1-4939-9706-0_19; POESEN K, 2017, CARDIOVASC RES, V0088, P02302, DOI DOI 10.1212/WNL.0000000000004029; RABIN S, 2009, NUCLEIC ACIDS RES, V0019, P00313, DOI DOI 10.1093/hmg/ddp498; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RULE R, 2010, J NEUROL NEUROSUR PS, V0074, P00821, DOI DOI 10.1212/WNL.0b013e3181d3e2dd; SCHWENK J, 2008, AMYOTROPH LATERAL SC, V0007, P03168, DOI DOI doi:10.1021/pr700890b; SKENE N, 2016, CELL, V0010, P00016, DOI DOI 10.3389/fnins.2016.00016; Smeijer D, 2019, J ALZHEIMERS DIS, V72, P247, DOI 10.3233/JAD-190527; Spiller KJ, 2018, NAT NEUROSCI, V21, P329, DOI 10.1038/s41593-018-0083-7; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; SUN S, 2015, CELL REP, V0112, pE6993, DOI DOI 10.1073/pnas.1520639112; Tam OH, 2019, CELL REP, V29, P1164, DOI 10.1016/j.celrep.2019.09.066; TURNER M, 2016, MOL CELL NEUROSCI, V0087, P00244, DOI DOI 10.1136/jnnp-2015-311157; van Vliet EA, 2020, J NEUROPATH EXP NEUR, V79, P266, DOI 10.1093/jnen/nlz142; VANLAERE K, 2014, AMYOTROPH LATERAL SC, V0071, P00553, DOI DOI 10.1001/jamaneurol.2014.62; VANLANDEWIJCK M, 2018, P NATL ACAD SCI USA, V0554, P00475, DOI DOI 10.1038/nature25739; Westeneng HJ, 2018, LANCET NEUROL, V17, P423, DOI 10.1016/S1474-4422(18)30089-9; WEYDT P, 2003, GLIA, V0014, P01051, DOI DOI 10.1097/01.wnr.0000073685.00308.89; White MA, 2018, NAT NEUROSCI, V21, P552, DOI 10.1038/s41593-018-0113-5; Wolak T, 2014, ATHEROSCLEROSIS, V236, P327, DOI 10.1016/j.atherosclerosis.2014.07.004; WU CH, 2012, SCIENCE, V0488, P00499, DOI DOI 10.1038/nature11280; ZEISEL A, 2015, NAT NEUROSCI, V0347, P01138, DOI DOI 10.1126/science.aaa1934; Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021; Zhao HJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0230-1; Zhong ZH, 2008, NAT NEUROSCI, V11, P420, DOI 10.1038/nn2073	56	30	30	3	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01295-9	http://dx.doi.org/10.1038/s41591-021-01295-9			25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33859435	Green Submitted, Green Accepted			2022-12-27	WOS:000640612600022
J	Blaak, EE; De Vos, WM				Blaak, Ellen E.; de Vos, Willem M.			Before the heart attack	NATURE MEDICINE			English	Editorial Material								Integrated analysis of microbiome and metabolome profiles in unique cohorts reveals early and late markers of the transition towards ischemic heart disease.	[Blaak, Ellen E.] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Human Biol, NUTRIM, Maastricht, Netherlands; [de Vos, Willem M.] Univ Helsinki, Fac Med, Human Microbiome Res Program, Helsinki, Finland; [de Vos, Willem M.] Wageningen Univ, Lab Microbiol, Wageningen, Netherlands	Maastricht University; University of Helsinki; Wageningen University & Research	Blaak, EE (corresponding author), Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Human Biol, NUTRIM, Maastricht, Netherlands.	e.blaak@maastrichtuniversity.nl	Blaak, Ellen/E-3459-2015	Blaak, Ellen/0000-0002-2496-3464; De Vos, Willem M/0000-0002-0273-3166				Blaak EE, 2020, P NUTR SOC, V79, P331, DOI 10.1017/S0029665120000117; Canfora EE, 2019, NAT REV ENDOCRINOL, V15, P261, DOI 10.1038/s41574-019-0156-z; Depommier C, 2019, NAT MED, V25, P1096, DOI 10.1038/s41591-019-0495-2; Forslund SK, 2021, NATURE, V600, P500, DOI 10.1038/s41586-021-04177-9; Fromentin S, 2022, NAT MED, V28, P303, DOI 10.1038/s41591-022-01688-4; Haak BW, 2021, TRANSL STROKE RES, V12, P581, DOI 10.1007/s12975-020-00863-4; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Talmor-Barkan Y, 2022, NAT MED, V28, P295, DOI 10.1038/s41591-022-01686-6; Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400; Verdonschot JAJ, 2021, EUR HEART J, V42, DOI 10.1093/eurheartj/ehaa841; Wagner R, 2021, NAT MED, V27, P49, DOI 10.1038/s41591-020-1116-9; Zhao LP, 2018, SCIENCE, V359, P1151, DOI 10.1126/science.aao5774	12	1	1	2	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					237	238		10.1038/s41591-022-01685-7	http://dx.doi.org/10.1038/s41591-022-01685-7		FEB 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35177861				2022-12-27	WOS:000757243200003
J	Senage, T; Paul, A; Le Tourneau, T; Fellah-Hebia, I; Vadori, M; Bashir, S; Galinanes, M; Bottio, T; Gerosa, G; Evangelista, A; Badano, LP; Nassi, A; Costa, C; Cesare, G; Manji, RA; de Monchy, CC; Piriou, N; Capoulade, R; Serfaty, JM; Guimbretiere, G; Dantan, E; Ruiz-Majoral, A; du Fou, GC; Ben-Arye, SL; Govani, L; Yehuda, S; Abramovitch, SB; Amon, R; Reuven, EM; Atiya-Nasagi, Y; Yu, H; Iop, L; Casos, K; Kuguel, SG; Blasco-Lucas, A; Permanyer, E; Sbraga, F; Llatjos, R; Moreno-Gonzalez, G; Sanchez-Martinez, M; Breimer, ME; Holgersson, J; Teneberg, S; Pascual-Gilabert, M; Nonell-Canals, A; Takeuchi, Y; Chen, X; Manez, R; Roussel, JC; Soulillou, JP; Cozzi, E; Padler-Karavani, V				Senage, Thomas; Paul, Anu; Le Tourneau, Thierry; Fellah-Hebia, Imen; Vadori, Marta; Bashir, Salam; Galinanes, Manuel; Bottio, Tomaso; Gerosa, Gino; Evangelista, Arturo; Badano, Luigi P.; Nassi, Alberto; Costa, Cristina; Cesare, Galli; Manji, Rizwan A.; de Monchy, Caroline Cueff; Piriou, Nicolas; Capoulade, Romain; Serfaty, Jean-Michel; Guimbretiere, Guillaume; Dantan, Etienne; Ruiz-Majoral, Alejandro; du Fou, Guenola Coste; Ben-Arye, Shani Leviatan; Govani, Liana; Yehuda, Sharon; Abramovitch, Shirley Bachar; Amon, Ron; Reuven, Eliran Moshe; Atiya-Nasagi, Yafit; Yu, Hai; Iop, Laura; Casos, Kelly; Kuguel, Sebastian G.; Blasco-Lucas, Arnau; Permanyer, Eduard; Sbraga, Fabrizio; Llatjos, Roger; Moreno-Gonzalez, Gabriel; Sanchez-Martinez, Melchor; Breimer, Michael E.; Holgersson, Jan; Teneberg, Susann; Pascual-Gilabert, Marta; Nonell-Canals, Alfons; Takeuchi, Yasuhiro; Chen, Xi; Manez, Rafael; Roussel, Jean-Christian; Soulillou, Jean-Paul; Cozzi, Emanuele; Padler-Karavani, Vered			The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration	NATURE MEDICINE			English	Article							N-GLYCOLYLNEURAMINIC ACID; ALPHA-GAL; STRUCTURAL DETERIORATION; INFLAMMATORY RESPONSE; EUROPEAN ASSOCIATION; IMMUNOGLOBULIN-G; IMMUNE-RESPONSE; IMPLANTATION; PORCINE; NEU5GC	Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-alpha 1,3-galactose (alpha Gal) and N-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 +/- 43 months of follow-up (0.1-182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in <5% of BHV recipients within 2 years. The levels of both anti-alpha Gal and anti-Neu5Gc IgGs significantly increased one month after BHV implantation. The levels of these IgGs declined thereafter but anti-alpha Gal IgG levels declined significantly faster in control patients compared to BHV recipients. Neu5Gc, anti-Neu5Gc IgG and complement deposition were found in calcified BHVs at much higher levels than in calcified native aortic valves. Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack alpha Gal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in alpha Gal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability. In a large cohort of patients who underwent aortic valve replacement, antibody responses to glycans present in bioprosthetic heart valves, notably galactose-alpha 1,3-galactose and N-glycolylneuraminic acid, were implicated in valve calcification and deterioration.	[Senage, Thomas; Le Tourneau, Thierry; Fellah-Hebia, Imen; de Monchy, Caroline Cueff; Piriou, Nicolas; Capoulade, Romain; Serfaty, Jean-Michel; Guimbretiere, Guillaume; du Fou, Guenola Coste; Roussel, Jean-Christian] Univ Hosp, Inst Thorax, Inst Natl Sante & Rech Med UMR1087, Nantes, France; [Senage, Thomas; Dantan, Etienne] Tours Univ, Nantes Univ, Inst Natl Sante & Rech Med UMR 1246 SPHERE, Nantes, France; [Paul, Anu; Bashir, Salam; Ben-Arye, Shani Leviatan; Govani, Liana; Yehuda, Sharon; Abramovitch, Shirley Bachar; Amon, Ron; Reuven, Eliran Moshe; Atiya-Nasagi, Yafit; Padler-Karavani, Vered] Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Dept Cell Res & Immunol, Tel Aviv, Israel; [Vadori, Marta] Osped Giustinianeo, Consortium Res Organ Transplantat, Padua, Italy; [Galinanes, Manuel; Casos, Kelly; Blasco-Lucas, Arnau; Permanyer, Eduard] Univ Autanoma Barcelona, Univ Hosp Vall dHebron, Vall dHebron Res Inst, Dept Cardiac Surg & Reparat Therapy Heart, Barcelona, Spain; [Bottio, Tomaso; Iop, Laura] Univ Padua, Dept Cardiac Thorac & Vasc Surg, Cardiovasc Regenerat Med Grp, Padua, Italy; [Gerosa, Gino; Iop, Laura] Univ Padua, Dept Cardiac Vasc & Thorac Sci & Publ Hlth, LIFELAB Program Veneto Reg, Padua, Italy; [Evangelista, Arturo] Hosp Valle De Hebron, Vall dHebron Res Inst, Dept Cardiol, Barcelona, Spain; [Badano, Luigi P.] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy; [Badano, Luigi P.] San Luca Hosp, Dept Cardiol Neural & Metab Sci, Ist Ricovero & Cura Carattere Sci, Ist Auxol Italiano, Milan, Italy; [Nassi, Alberto; Cozzi, Emanuele] Padova Univ Hosp, Transplantat Immunol Unit, Padua, Italy; [Costa, Cristina; Casos, Kelly; Kuguel, Sebastian G.; Moreno-Gonzalez, Gabriel; Manez, Rafael] Inst Invest Biomed Bellvitge, Infect Dis & Transplantat Div, Barcelona, Spain; [Cesare, Galli] Avantea, Cremona, Italy; [Manji, Rizwan A.] Univ Manitoba, Max Rady Coll Med, Dept Surg, St Boniface Hosp,Cardiac Sci Program, Winnipeg, MB, Canada; [Ruiz-Majoral, Alejandro] Bellvitge Univ Hosp, Dept Cardiol, Barcelona, Spain; [Yu, Hai; Chen, Xi] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; [Blasco-Lucas, Arnau; Sbraga, Fabrizio] Bellvitge Univ Hosp, Cardiac Surg Dept, Barcelona, Spain; [Llatjos, Roger] Bellvitge Univ Hosp, Pathol Dept, Barcelona, Spain; [Moreno-Gonzalez, Gabriel; Manez, Rafael] Bellvitge Univ Hosp, Intens Care Dept, Barcelona, Spain; [Sanchez-Martinez, Melchor; Nonell-Canals, Alfons] Mind Byte, Barcelona, Spain; [Breimer, Michael E.] Univ Gothenburg, Inst Clin Sci, Dept Surg, Sahlgrenska Acad, Gothenburg, Sweden; [Holgersson, Jan] Univ Gothenburg, Inst Biomed, Dept Lab Med, Sahlgrenska Acad, Gothenburg, Sweden; [Teneberg, Susann] Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Sahlgrenska Acad, Gothenburg, Sweden; [Pascual-Gilabert, Marta] Inst Univ Ciin & Tecnol, Inkemia Grp, Barcelona, Spain; [Takeuchi, Yasuhiro] UCL, Div Infect & Immun, London, England; [Soulillou, Jean-Paul] Ctr Hosp Univ Nantes, Inst Transplantat Urol Nephrol, Unit Mixte Rech 1064, Inst Natl Sante & Rech Med, Nantes, France; [Paul, Anu] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Atiya-Nasagi, Yafit] Israel Inst Biol Res, Ness Ziona, Israel; [Iop, Laura] Univ Padua, Dept Cardiac Thorac & Vasc Sci & Publ Hlth, Padua, Italy; [Casos, Kelly] Univ Autanoma Barcelona, Univ Hosp Vall dHebron, Vall dHebron Inst Res, Dept Cardiovasc Dis, Barcelona, Spain; [Permanyer, Eduard] Quironsalud Teknon Heart Inst, Dept Cardiac Surg, Barcelona, Spain; [Sanchez-Martinez, Melchor] Molomics, Barcelona, Spain; [Nonell-Canals, Alfons] DevsHealth, Barcelona, Spain	Nantes Universite; CHU de Nantes; Nantes Universite; Tel Aviv University; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Padua; University of Padua; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Milano-Bicocca; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Auxologico Italiano; University of Padua; Azienda Ospedaliera - Universita di Padova; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Manitoba; Children's Hospital Research Institute of Manitoba; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of California System; University of California Davis; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Padua; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; quironsalud Group	Roussel, JC (corresponding author), Univ Hosp, Inst Thorax, Inst Natl Sante & Rech Med UMR1087, Nantes, France.; Padler-Karavani, V (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Dept Cell Res & Immunol, Tel Aviv, Israel.; Cozzi, E (corresponding author), Padova Univ Hosp, Transplantat Immunol Unit, Padua, Italy.; Manez, R (corresponding author), Inst Invest Biomed Bellvitge, Infect Dis & Transplantat Div, Barcelona, Spain.; Manez, R (corresponding author), Bellvitge Univ Hosp, Intens Care Dept, Barcelona, Spain.; Soulillou, JP (corresponding author), Ctr Hosp Univ Nantes, Inst Transplantat Urol Nephrol, Unit Mixte Rech 1064, Inst Natl Sante & Rech Med, Nantes, France.	rmanez@bellvitgehospital.cat; jeanchristian.roussel@chu-nantes.fr; jean-paul.soulillou@univ-nantes.fr; emanuele.cozzi@unipd.it; vkaravani@tauex.tau.ac.il	Nicolas, Piriou/CAH-2512-2022; Capoulade, Romain/A-3966-2019; Costa, Cristina/AAP-4005-2020; Le Tourneau, Thierry/D-5428-2015; Dantan, Etienne/O-2946-2015; Piriou, Nicolas/D-9154-2015; Sanchez-Martinez, Melchor/A-3392-2014; Iop, Laura/A-3761-2015	Nicolas, Piriou/0000-0002-6677-6552; Capoulade, Romain/0000-0002-7233-7409; Costa, Cristina/0000-0002-1837-4268; Dantan, Etienne/0000-0001-7137-5051; Piriou, Nicolas/0000-0002-6677-6552; Sanchez-Martinez, Melchor/0000-0002-3674-8577; Iop, Laura/0000-0002-7034-9414; Manez, Rafael/0000-0002-0884-5564; PAUL, ANU/0000-0003-2479-8398; BOTTIO, TOMASO/0000-0001-7299-2983; Moreno Gonzalez, Gabriel Jesus/0000-0003-3281-1126	European Union Seventh Framework Program (FP7/2007/2013) [603049]; European Union H2020 Program [ERC-2016-STG-716220]; Elizabeth and Nicholas Slezak Super Center for Cardiac Research and Medical Engineering; Institut National de la Sante et de la Recherche Medicale [2012-2016]; Ministerio de Economia y Competitividad-ISCiii [PI15/00181]; Department of Health of Generalitat de Catalunya [PERIS SLT002/16/00445]; FEDER (European Regional Development Fund), a way to build Europe; Israel Ministry of Science & Technology PhD fellowship	European Union Seventh Framework Program (FP7/2007/2013); European Union H2020 Program; Elizabeth and Nicholas Slezak Super Center for Cardiac Research and Medical Engineering; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ministerio de Economia y Competitividad-ISCiii; Department of Health of Generalitat de Catalunya(Generalitat de Catalunya); FEDER (European Regional Development Fund), a way to build Europe; Israel Ministry of Science & Technology PhD fellowship	This work was supported by the European Union Seventh Framework Program (FP7/2007/2013) under grant agreement no. 603049 for the Translink Consortium. This research was also funded by a European Union H2020 Program grant no. ERC-2016-STG-716220 to V.P-K. and by the Elizabeth and Nicholas Slezak Super Center for Cardiac Research and Medical Engineering (to V.P-K.). This work was supported by an Institut National de la Sante et de la Recherche Medicale translational grant no. 2012-2016 to T.L.T. This work was supported by the Ministerio de Economia y Competitividad-ISCiii (PI15/00181) and the PERIS SLT002/16/00445 funded by the Department of Health of Generalitat de Catalunya (both granted to C.C.), and cofunded by FEDER (European Regional Development Fund), a way to build Europe. This work was supported by an Israel Ministry of Science & Technology PhD fellowship to S.B. We thank L. Adler for her assistance in the affinity purification of anti-Neu5Gc antibodies and IgG subclass analysis. Finally, we thank N. Bovin from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, who provided the Bdi-C3 PAA substrate needed to develop the anti-alpha Gal assays.	Amon R, 2017, ONCOTARGET, V8, P112236, DOI 10.18632/oncotarget.23096; Amon R, 2014, CARBOHYD RES, V389, P115, DOI 10.1016/j.carres.2014.02.004; Bardor M, 2005, J BIOL CHEM, V280, P4228, DOI 10.1074/jbc.M412040200; Barone A, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12406; Barone A, 2014, XENOTRANSPLANTATION, V21, P510, DOI 10.1111/xen.12123; Bashir S, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01721-8; Bashir S, 2019, BIOCONJUGATE CHEM, V30, P161, DOI 10.1021/acs.bioconjchem.8b00817; Ben-Arye SL, 2019, BIOCONJUGATE CHEM, V30, P1565, DOI 10.1021/acs.bioconjchem.9b00273; Ben-Arye SL, 2017, JOVE-J VIS EXP, DOI 10.3791/56094; Breimer ME, 2011, XENOTRANSPLANTATION, V18, P215, DOI 10.1111/j.1399-3089.2011.00644.x; Brown JM, 2009, J THORAC CARDIOV SUR, V137, P82, DOI 10.1016/j.jtcvs.2008.08.015; Capodanno D, 2017, EUR HEART J, V38, P3382, DOI 10.1093/eurheartj/ehx303; Cohen M, 2012, JOVE-J VIS EXP, DOI 10.3791/3928; COOPER DKC, 1992, CLIN TRANSPLANT, V6, P178; Cote N, 2017, CURR OPIN CARDIOL, V32, P123, DOI 10.1097/HCO.0000000000000372; Couvrat-Desvergnes G, 2015, J CLIN INVEST, V125, P4655, DOI 10.1172/JCI82267; Dhar C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00807; DIGGLE P, 1994, J R STAT SOC C-APPL, V43, P49; Dvir D, 2018, CIRCULATION, V137, P388, DOI 10.1161/CIRCULATIONAHA.117.030729; Dweck MR, 2013, EUR HEART J, V34, P1567, DOI 10.1093/eurheartj/eht034; Fischer K, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12560; FISHBEIN MC, 1982, J THORAC CARDIOV SUR, V83, P602; Fitzmaurice G, 2011, APPL LONGITUDINAL AN, V2nd; Galeone A., 2013, THESCIENTIFICWORLDJO, V2013, P875363; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; Galili U, 2013, IMMUNOLOGY, V140, P1, DOI 10.1111/imm.12110; Gendron N, 2021, ARTERIOSCL THROM VAS, V41, P415, DOI 10.1161/ATVBAHA.120.314287; Goody PR, 2020, ARTERIOSCL THROM VAS, V40, P885, DOI 10.1161/ATVBAHA.119.313067; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; Helske S, 2008, ATHEROSCLEROSIS, V196, P190, DOI 10.1016/j.atherosclerosis.2007.03.040; Jin CS, 2020, GLYCOCONJUGATE J, V37, P485, DOI 10.1007/s10719-020-09931-1; Johnston DR, 2015, ANN THORAC SURG, V99, P1239, DOI 10.1016/j.athoracsur.2014.10.070; Kawanishi K, 2019, P NATL ACAD SCI USA, V116, P16036, DOI 10.1073/pnas.1902902116; Kim MS, 2015, EUR J CARDIO-THORAC, V48, P392, DOI 10.1093/ejcts/ezu501; Konakci KZ, 2005, EUR J CLIN INVEST, V35, P17; Kooner AS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02004; Kostyunin A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207434; Kraft F, 2015, BEST PRACT RES-CLIN, V29, P113, DOI 10.1016/j.bpa.2015.03.001; Laffey JG, 2002, ANESTHESIOLOGY, V97, P215; Lancellotti P, 2016, EUR HEART J-CARD IMG, V17, P589, DOI 10.1093/ehjci/jew025; Laudanski K, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1518-3; Le Berre L, 2017, CLIN IMMUNOL, V180, P128, DOI 10.1016/j.clim.2017.05.006; Le Berre L, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12535; Lila N, 2010, J HEART LUNG TRANSPL, V29, P538, DOI 10.1016/j.healun.2009.10.007; Lu QZ, 2012, ANAL CHEM, V84, P2761, DOI 10.1021/ac2030893; Mako WJ, 1999, J BIOMED MATER RES, V45, P209, DOI 10.1002/(SICI)1097-4636(19990605)45:3<209::AID-JBM8>3.0.CO;2-N; Manji RA, 2015, INT J SURG, V23, P280, DOI 10.1016/j.ijsu.2015.07.009; Manji RA, 2014, XENOTRANSPLANTATION, V21, P1, DOI 10.1111/xen.12080; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Moczar M, 1996, ASAIO J, V42, pM375, DOI 10.1097/00002480-199609000-00015; Montassier E, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03000; Naso F, 2017, TISSUE ENG PT A, V23, P1181, DOI 10.1089/ten.tea.2016.0474; Naso F, 2013, XENOTRANSPLANTATION, V20, P252, DOI 10.1111/xen.12044; Okerblom J, 2017, CHEMBIOCHEM, V18, P1155, DOI 10.1002/cbic.201700077; Padler-Karavani V, 2008, GLYCOBIOLOGY, V18, P818, DOI 10.1093/glycob/cwn072; Padler-Karavani V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058443; Padler-Karavani V, 2011, XENOTRANSPLANTATION, V18, P1, DOI 10.1111/j.1399-3089.2011.00622.x; Park CS, 2013, J HEART VALVE DIS, V22, P222; Paul A, 2020, METHODS MOL BIOL, V2110, P59, DOI 10.1007/978-1-0716-0255-3_4; Paul A, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12424; Perota A, 2019, XENOTRANSPLANTATION, V26, DOI 10.1111/xen.12524; Reuven EM, 2019, ACS NANO, V13, P2936, DOI 10.1021/acsnano.8b07241; Reuven EM, 2016, XENOTRANSPLANTATION, V23, P381, DOI 10.1111/xen.12260; Salama A, 2017, TRANSPLANTATION, V101, P2501, DOI 10.1097/TP.0000000000001686; Salama A, 2017, DIABETES, V66, P987, DOI 10.2337/db16-1060; Samraj AN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00033; Scobie L, 2013, J IMMUNOL, V191, P2907, DOI 10.4049/jimmunol.1301195; Senage T, 2014, CIRCULATION, V130, P2012, DOI 10.1161/CIRCULATIONAHA.114.010400; Soulillou JP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00834; Vadori M, 2015, TISSUE ANTIGENS, V86, P239, DOI 10.1111/tan.12669; Yacoub N, 2005, NAT CLIN PRACT CARD, V2, P60, DOI 10.1038/ncpcardio0112; Zhao ZG, 2015, NAT REV CARDIOL, V12, P123, DOI 10.1038/nrcardio.2014.161	72	6	6	7	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					283	+		10.1038/s41591-022-01682-w	http://dx.doi.org/10.1038/s41591-022-01682-w		FEB 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35177855	Green Published, hybrid			2022-12-27	WOS:000757243200008
J	Du, YY; Liang, Z; Wang, S; Sun, D; Wang, XF; Liew, SY; Lu, SY; Wu, SS; Jiang, Y; Wang, YQ; Zhang, BY; Yu, WH; Lu, Z; Pu, Y; Zhang, Y; Long, HT; Xiao, SS; Liang, R; Zhang, ZY; Guan, JY; Wang, JL; Ren, HX; Wei, YL; Zhao, JX; Sun, SC; Liu, TL; Meng, GF; Wang, L; Gu, JB; Wang, T; Liu, YN; Li, C; Tang, C; Shen, ZY; Peng, XZ; Deng, HK				Du, Yuanyuan; Liang, Zhen; Wang, Shusen; Sun, Dong; Wang, Xiaofeng; Liew, Soon Yi; Lu, Shuaiyao; Wu, Shuangshuang; Jiang, Yong; Wang, Yaqi; Zhang, Boya; Yu, Wenhai; Lu, Zhi; Pu, Yue; Zhang, Yun; Long, Haiting; Xiao, Shanshan; Liang, Rui; Zhang, Zhengyuan; Guan, Jingyang; Wang, Jinlin; Ren, Huixia; Wei, Yanling; Zhao, Jiaxu; Sun, Shicheng; Liu, Tengli; Meng, Gaofan; Wang, Le; Gu, Jiabin; Wang, Tao; Liu, Yinan; Li, Cheng; Tang, Chao; Shen, Zhongyang; Peng, Xiaozhong; Deng, Hongkui			Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates	NATURE MEDICINE			English	Article							RNA-SEQ DATA; IN-VITRO; TRANSPLANTATION; COMPLICATIONS; PROGRESS; PANCREAS; STREPTOZOTOCIN; ASSOCIATION; RAPAMYCIN	Human pluripotent stem-cell-derived islets (hPSC-islets) are a promising cell resource for diabetes treatment(1,2). However, this therapeutic strategy has not been systematically assessed in large animal models physiologically similar to humans, such as non-human primates(3). In this study, we generated islets from human chemically induced pluripotent stem cells (hCiPSC-islets) and show that a one-dose intraportal infusion of hCiPSC-islets into diabetic non-human primates effectively restored endogenous insulin secretion and improved glycemic control. Fasting and average pre-prandial blood glucose levels significantly decreased in all recipients, accompanied by meal or glucose-responsive C-peptide release and overall increase in body weight. Notably, in the four long-term follow-up macaques, average hemoglobin A1c dropped by over 2% compared with peak values, whereas the average exogenous insulin requirement reduced by 49% 15 weeks after transplantation. Collectively, our findings show the feasibility of hPSC-islets for diabetic treatment in a preclinical context, marking a substantial step forward in clinical translation of hPSC-islets.	[Du, Yuanyuan; Liang, Zhen; Sun, Dong; Liew, Soon Yi; Zhang, Zhengyuan; Guan, Jingyang; Wang, Jinlin; Sun, Shicheng; Meng, Gaofan; Liu, Yinan; Deng, Hongkui] Peking Univ, Peking Tsinghua Ctr Life Sci,Coll Life Sci, MOE Engn Res Ctr Regenerat Med,Peking Univ Hlth S, Sch Basic Med Sci,State Key Lab Nat & Biomimet Dr, Beijing, Peoples R China; [Du, Yuanyuan; Liang, Zhen; Sun, Dong; Liew, Soon Yi; Zhang, Zhengyuan; Guan, Jingyang; Wang, Jinlin; Sun, Shicheng; Meng, Gaofan; Liu, Yinan; Deng, Hongkui] Peking Univ, Peking Tsinghua Ctr Life Sci, Coll Life Sci, MOE Key Lab Cell Proliferat & Differentiat, Beijing, Peoples R China; [Du, Yuanyuan; Liang, Zhen; Wang, Xiaofeng; Wu, Shuangshuang; Jiang, Yong; Lu, Zhi; Wei, Yanling; Meng, Gaofan; Gu, Jiabin] Hangzhou Reprogenix Biosci, Hangzhou, Peoples R China; [Wang, Shusen; Zhang, Boya; Zhang, Yun; Liang, Rui; Liu, Tengli; Wang, Le; Shen, Zhongyang] Nankai Univ, Tianjin Cent Hosp 1, Organ Transplant Ctr, NHC Key Lab Crit Care Med, Tianjin, Peoples R China; [Lu, Shuaiyao; Yu, Wenhai; Long, Haiting; Peng, Xiaozhong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China; [Wang, Yaqi; Li, Cheng] Peking Univ, Ctr Bioinformat, Sch Life Sci, Beijing, Peoples R China; [Pu, Yue; Xiao, Shanshan; Wang, Tao] Hangzhou Repugene Technol, Hangzhou, Peoples R China; [Ren, Huixia; Tang, Chao] Peking Univ, Ctr Quantitat Biol, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Zhao, Jiaxu] Chinese Acad Sci, Univ Chinese Acad Sci, Ctr Excellence Mol Cell Sci, State Key Lab Cell Biol,Shanghai Inst Biochem & C, Shanghai, Peoples R China; [Peng, Xiaozhong] Chinese Acad Med Sci, State Key Lab Med Mol Biol, Dept Mol Biol & Biochem, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China	Peking University; Peking University; Nankai University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; Peking University; Peking University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College	Deng, HK (corresponding author), Peking Univ, Peking Tsinghua Ctr Life Sci,Coll Life Sci, MOE Engn Res Ctr Regenerat Med,Peking Univ Hlth S, Sch Basic Med Sci,State Key Lab Nat & Biomimet Dr, Beijing, Peoples R China.; Deng, HK (corresponding author), Peking Univ, Peking Tsinghua Ctr Life Sci, Coll Life Sci, MOE Key Lab Cell Proliferat & Differentiat, Beijing, Peoples R China.; Shen, ZY (corresponding author), Nankai Univ, Tianjin Cent Hosp 1, Organ Transplant Ctr, NHC Key Lab Crit Care Med, Tianjin, Peoples R China.; Peng, XZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China.; Peng, XZ (corresponding author), Chinese Acad Med Sci, State Key Lab Med Mol Biol, Dept Mol Biol & Biochem, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China.	zhongyangshen@vip.sina.com; pengxiaozhong@pumc.edu.cn; hongkui_deng@pku.edu.cn		Guan, Jingyang/0000-0002-1638-3339; Liew, Soon Yi/0000-0002-9546-2229; Ren, Huixia/0000-0002-1761-6018; Sun, Shicheng/0000-0002-9584-9909; Du, Yuanyuan/0000-0002-8293-328X	National Key Research and Development Program of China [2017YFA0103000, 2018YFA0108102, 2020YFA0803704]; National Natural Science Foundation of China [31521004, 31730059, 82070805, 81870535, 82100840, 82100841]; Key Project and Team Program of Tianjin [XB202011]; CAMS Innovation Fund for Medical Sciences [2021-1-I2M-024]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project and Team Program of Tianjin; CAMS Innovation Fund for Medical Sciences	This work was supported by the National Key Research and Development Program of China (2017YFA0103000 to H.D., 2018YFA0108102 to H.D. and 2020YFA0803704 to S.W.); the National Natural Science Foundation of China (31521004 to H.D., 31730059 to H.D., 82070805 to S.W., 81870535 to S.W., 82100840 to T.L. and 82100841 to R.L.); the Key Project and Team Program of Tianjin (XB202011 to S.W.); and the CAMS Innovation Fund for Medical Sciences (2021-1-I2M-024 to X.P.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank S. Lu at the Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing, for assistance with providing hADFs; Z. Chen at Shanghai Institute of Biochemistry and Cell Biology for assistance with the dynamic glucose-stimulated insulin secretion assay; Y. Li of the Institute of Medical Biology of CAMS for routine blood and biochemical tests; Q. Yao at the Department of Clinical Pharmacology of First Affiliated Hospital of Kunming Medical University for therapeutic drug monitoring; C. Yang of the Center of Cryo-Electron Microscopy of Zhejiang University for assistance on cryo-electron microscopy; and Y. Hu, Y. Xie and P. Dong at the Core Facilities of School of Life Sciences and the National Center for Protein Sciences at Peking University for their professional technical assistance in electron microscopy sample preparation and image analysis. We thank J. Vaughan at the Salk Institute for Biological Studies and M. Huising at the University of California, Davis for their kind provision of the UCN3 antibody. We thank the following people for their contributions to this study: J. Cao, L. Zou, J. Bai, Y. Yan, F. Bai and L. Xu for clinical assistance with the macaques; Y. Yang and D. Zhang for guidance on immune response experiments; X. Fang, L. Zhao, T. Zhang, J. Ma and H. Liu for technical assistance; X. Zhou for assistance with animal care; C. Wang for guidance on matters of animal research ethics; and B. Liu, W. Lai, J. Xu, Y. Fu, L. Cheng and Y. Lv for discussions in the course of the preparation of this manuscript.	Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Augsornworawat P, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108067; Baron M, 2016, CELL SYST, V3, P346, DOI 10.1016/j.cels.2016.08.011; Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063; Bastidas-Ponce A, 2017, MOL METAB, V6, P524, DOI 10.1016/j.molmet.2017.03.007; Blau HM, 2019, NEW ENGL J MED, V380, P1748, DOI 10.1056/NEJMra1716145; Bochenek MA, 2018, NAT BIOMED ENG, V2, P810, DOI 10.1038/s41551-018-0275-1; Bottino R, 2009, DIABETES, V58, P442, DOI 10.2337/db08-1127; Coe TM, 2020, CURR OPIN ORGAN TRAN, V25, P449, DOI 10.1097/MOT.0000000000000794; de Sena Brandine Guilherme, 2019, F1000Res, V8, P1874, DOI 10.12688/f1000research.21142.1; Delaune V, 2017, TRANSPL INT, V30, P227, DOI 10.1111/tri.12919; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dufrane D, 2006, TRANSPLANTATION, V81, P36, DOI 10.1097/01.tp.0000189712.74495.82; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Enge M, 2017, CELL, V171, P321, DOI 10.1016/j.cell.2017.09.004; Gibly RF, 2011, DIABETOLOGIA, V54, P2494, DOI 10.1007/s00125-011-2243-0; Graham ML, 2011, XENOTRANSPLANTATION, V18, P328, DOI 10.1111/j.1399-3089.2011.00676.x; Gruessner RWG, 2014, TRANSPL P, V46, P1898, DOI 10.1016/j.transproceed.2014.06.004; Harding J, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt171; Harding JD, 2017, ILAR J, V58, P141, DOI 10.1093/ilar/ilx033; Hecht G, 2009, P NATL ACAD SCI USA, V106, P8659, DOI 10.1073/pnas.0812253106; Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002; Hirsch IB, 2021, J DIABETES COMPLICAT, V35, DOI 10.1016/j.jdiacomp.2020.107646; Hogrebe NJ, 2020, NAT BIOTECHNOL, V38, P460, DOI 10.1038/s41587-020-0430-6; Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278; Johnson JD, 2009, CELL TRANSPLANT, V18, P833, DOI 10.3727/096368909X471198; Katsarou A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.16; Kim JM, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12659; Kimura Y, 2019, STEM CELL TRANSL MED, V8, P627, DOI 10.1002/sctm.18-0039; Kojayan GG, 2018, ISLETS, V10, P40, DOI 10.1080/19382014.2017.1405202; Koulmanda M, 2003, AM J TRANSPLANT, V3, P267, DOI 10.1034/j.1600-6143.2003.00040.x; Lablanche S, 2018, LANCET DIABETES ENDO, V6, P527, DOI 10.1016/S2213-8587(18)30078-0; Lacotte S, 2011, EXPERT OPIN BIOL TH, V11, P55, DOI 10.1517/14712598.2011.536530; Lembert N, 2003, CELL TRANSPLANT, V12, P33, DOI 10.3727/000000003783985214; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21357-3; Li X, 2015, CELL STEM CELL, V17, P195, DOI 10.1016/j.stem.2015.06.003; Lin Y, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/929756; Liu HS, 2014, CELL RES, V24, P1181, DOI 10.1038/cr.2014.118; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Ludwig B, 2013, P NATL ACAD SCI USA, V110, P19054, DOI 10.1073/pnas.1317561110; Lun ATL, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1662-y; Lun Aaron T L, 2016, F1000Res, V5, P2122; Martin RM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16455-7; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; Muthyala S, 2017, XENOTRANSPLANTATION, V24, DOI 10.1111/xen.12275; Nair GG, 2020, NAT REV ENDOCRINOL, V16, P506, DOI 10.1038/s41574-020-0375-3; Nordmann TM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06731-w; Pagliuca FW, 2014, CELL, V159, P428, DOI 10.1016/j.cell.2014.09.040; Peters A, 2017, AM J TRANSPLANT, V17, P2474, DOI 10.1111/ajt.14303; Peters PJ, 2008, METHOD CELL BIOL, V88, P131, DOI [10.1016/S0091-679X(08)00409-1, 10.1016/S0091-679X(08)00408-1]; Ponticelli C, 2005, TRANSPL INT, V18, P643, DOI 10.1111/j.1432-2277.2005.00134.x; Rezania A, 2014, NAT BIOTECHNOL, V32, P1121, DOI 10.1038/nbt.3033; Rickels MR, 2019, ENDOCR REV, V40, P631, DOI 10.1210/er.2018-00154; Saisho Y, 2011, DIABETES, V60, P848, DOI 10.2337/db09-1368; Secnik P, 2019, TRANSPL IMMUNOL, V57, DOI 10.1016/j.trim.2019.101229; Shapiro AMJ, 2017, NAT REV ENDOCRINOL, V13, P268, DOI 10.1038/nrendo.2016.178; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sherwani SI, 2016, BIOMARK INSIGHTS, V11, P95, DOI [10.4137/BMIMI.S38440, 10.4137/BMI.S38440]; Shin JS, 2015, AM J TRANSPLANT, V15, P2837, DOI 10.1111/ajt.13345; Shin JS, 2016, XENOTRANSPLANTATION, V23, P300, DOI 10.1111/xen.12246; Slot JW, 2007, NAT PROTOC, V2, P2480, DOI 10.1038/nprot.2007.365; Sneddon JB, 2018, CELL STEM CELL, V22, P810, DOI 10.1016/j.stem.2018.05.016; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Suman S, 2019, ADV EXP MED BIOL, V1201, P1, DOI 10.1007/978-3-030-31206-0_1; Tanemura M, 2009, TRANSPL P, V41, P334, DOI 10.1016/j.transproceed.2008.10.032; Tattersall RB, 1997, DIABETIC MED, V14, P99, DOI 10.1002/(SICI)1096-9136(199702)14:2<99::AID-DIA320>3.0.CO;2-I; Trinanes J, 2017, AM J TRANSPLANT, V17, P2829, DOI 10.1111/ajt.14323; Vantyghem MC, 2019, LANCET, V394, P1274, DOI 10.1016/S0140-6736(19)31334-0; Veres A, 2019, NATURE, V569, P368, DOI 10.1038/s41586-019-1168-5; Warnock GL, 2008, TRANSPLANTATION, V86, P1762, DOI 10.1097/TP.0b013e318190b052; Wiebking V, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0580-6; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang BB, 2020, J EXP MED, V217, DOI 10.1084/jem.20182365; Zhao T, 2018, CELL STEM CELL, V23, P31, DOI 10.1016/j.stem.2018.05.025; ZHENG GX, 2017, NATURE, V0008; Zhu YX, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0694-z	79	10	11	21	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					272	+		10.1038/s41591-021-01645-7	http://dx.doi.org/10.1038/s41591-021-01645-7		FEB 2022	38	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35115708				2022-12-27	WOS:000750724400002
J	Nolen, LT; Mukerji, SS; Mejia, NI				Nolen, LaShyra T.; Mukerji, Shibani S.; Mejia, Nicte I.			Post-acute neurological consequences of COVID-19: an unequal burden	NATURE MEDICINE			English	Editorial Material							DISPARITIES		[Nolen, LaShyra T.; Mukerji, Shibani S.; Mejia, Nicte I.] Harvard Med Sch, Boston, MA 02115 USA; [Mukerji, Shibani S.; Mejia, Nicte I.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Mejia, NI (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Mejia, NI (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.	nmejia@partners.org						Alsan M, 2021, ANN INTERN MED, V174, P484, DOI 10.7326/M20-6141; Cervantes L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0684; Chou SHY, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.12131; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; de Havenon A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.10314; Dmytriw AA, 2020, J NEUROL NEUROSUR PS, V91, P1362, DOI 10.1136/jnnp-2020-324653; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Editorial, 2021, NATURE, V593, P313; Estiri H, 2021, BMC MED, V19, DOI [10.1101/2021.04.25.21255923, 10.1186/s12916-021-02115-0]; Frieden TR, 2015, NEW ENGL J MED, V373, P1748, DOI 10.1056/NEJMsa1511248; Mandsager P, 2018, AM J PUBLIC HEALTH, V108, pS246, DOI [10.2105/AJPH.2018.304689, 10.2105/ajph.2018.304689]; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Nolen L, 2021, NAT REV NEUROL, V17, P67, DOI 10.1038/s41582-020-00452-x; Robinson-Lane SG, 2021, J AM MED DIR ASSOC, V22, P2245, DOI 10.1016/j.jamda.2021.08.023; RUSSELL AR, 2021, BRAIN COMMUN, V3, DOI DOI 10.1093/BRAINCOMMS/FCAB168; Saadi A, 2017, NEUROLOGY, V88, P2268, DOI [10.1212/WNL.0000000000004025, 10.1212/wnl.0000000000004025]; Verguet S, 2021, NAT MED, V27, P380, DOI 10.1038/s41591-021-01268-y	17	17	17	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					20	23		10.1038/s41591-021-01647-5	http://dx.doi.org/10.1038/s41591-021-01647-5		JAN 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	35039657	Bronze			2022-12-27	WOS:000743459500003
J	Boulad, F; Maggio, A; Wang, XY; Moi, P; Acuto, S; Kogel, F; Takpradit, C; Prockop, S; Mansilla-Soto, J; Cabriolu, A; Odak, A; Qu, J; Thummar, K; Du, F; Shen, LB; Raso, S; Barone, R; Di Maggio, R; Pitrolo, L; Giambona, A; Mingoia, M; Everett, JK; Hokama, P; Roche, AM; Cantu, VA; Adhikari, H; Reddy, S; Bouhassira, E; Mohandas, N; Bushman, FD; Riviere, I; Sadelain, M				Boulad, Farid; Maggio, Aurelio; Wang, Xiuyan; Moi, Paolo; Acuto, Santina; Kogel, Friederike; Takpradit, Chayamon; Prockop, Susan; Mansilla-Soto, Jorge; Cabriolu, Annalisa; Odak, Ashlesha; Qu, Jinrong; Thummar, Keyur; Du, Fang; Shen, Lingbo; Raso, Simona; Barone, Rita; Di Maggio, Rosario; Pitrolo, Lorella; Giambona, Antonino; Mingoia, Maura; Everett, John K.; Hokama, Pascha; Roche, Aoife M.; Cantu, Vito Adrian; Adhikari, Hriju; Reddy, Shantan; Bouhassira, Eric; Mohandas, Narla; Bushman, Frederic D.; Riviere, Isabelle; Sadelain, Michel			Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial	NATURE MEDICINE			English	Article							SICKLE-CELL-DISEASE; DNA INTEGRATION; CD34(+) CELLS; TRANSFUSION; STEM; HMGA2; TRANSPLANTATION; ACTIVATION; CHILDREN; EFFICACY	beta-Thalassemias are inherited anemias that are caused by the absent or insufficient production of the beta chain of hemoglobin. Here we report 6-8-year follow-up of four adult patients with transfusion-dependent beta-thalassemia who were infused with autologous CD34(+) cells transduced with the TNS9.3.55 lentiviral globin vector after reduced-intensity conditioning (RIC) in a phase 1 clinical trial (. Patients were monitored for insertional mutagenesis and the generation of a replication-competent lentivirus (safety and tolerability of the infusion product after RIC-primary endpoint) and engraftment of genetically modified autologous CD34(+) cells, expression of the transduced beta-globin gene and post-transplant transfusion requirements (efficacy-secondary endpoint). No unexpected safety issues occurred during conditioning and cell product infusion. Hematopoietic gene marking was very stable but low, reducing transfusion requirements in two patients, albeit not achieving transfusion independence. Our findings suggest that non-myeloablative conditioning can achieve durable stem cell engraftment but underscore a minimum CD34(+) cell transduction requirement for effective therapy. Moderate clonal expansions were associated with integrations near cancer-related genes, suggestive of non-erythroid activity of globin vectors in stem/progenitor cells. These correlative findings highlight the necessity of cautiously monitoring patients harboring globin vectors.	[Boulad, Farid; Takpradit, Chayamon; Prockop, Susan] Mem Sloan Kettering Canc Ctr, Dept Pediat, Stem Cell Transplant & Cellular Therapy Serv, 1275 York Ave, New York, NY 10021 USA; [Boulad, Farid; Wang, Xiuyan; Kogel, Friederike; Mansilla-Soto, Jorge; Cabriolu, Annalisa; Odak, Ashlesha; Riviere, Isabelle; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA; [Maggio, Aurelio; Acuto, Santina; Raso, Simona; Barone, Rita; Di Maggio, Rosario; Pitrolo, Lorella; Giambona, Antonino] Azienda Osped Osped Riuniti Villa Sofia Cervello, Dept Hematol & Rare Dis, Palermo, Italy; [Wang, Xiuyan; Qu, Jinrong; Thummar, Keyur; Du, Fang; Shen, Lingbo; Riviere, Isabelle] Mem Sloan Kettering Canc Ctr, Cell Therapy & Cell Engn Lab, 1275 York Ave, New York, NY 10021 USA; [Moi, Paolo; Mingoia, Maura] AO G Brotzu, Osped Pediatr Microcitemie A Cao, Cagliari, Italy; [Takpradit, Chayamon] Mahidol Univ, Siriraj Hosp, Dept Pediat, Bangkok, Thailand; [Everett, John K.; Hokama, Pascha; Roche, Aoife M.; Cantu, Vito Adrian; Adhikari, Hriju; Reddy, Shantan; Bushman, Frederic D.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Bouhassira, Eric] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; [Mohandas, Narla] New York Blood Ctr, Lab Red Cell Physiol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Mahidol University; University of Pennsylvania; Pennsylvania Medicine; Yeshiva University; Albert Einstein College of Medicine; New York Blood Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org			MSKCC Support Grant [P30 CA008748]	MSKCC Support Grant	The authors would first like to thank the patients and families of those included in the trial and further acknowledge the expert care provided to patients by staff members of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center. We thank R. Cristantielli, G. Gunset and E. Bechard for their further assistance in making our patients' journeys and their follow-up pleasant and efficient. This clinical trial was supported by the Stavros Niarchos Foundation (to M.S.), the Memorial Hospital Research Fund (to F.B.), the Leonardo Giambrone Foundation (to M.S.) and the Cooley's Anemia Foundation (to M.S.) for transduction, biosafety and clinical costs, and Errant Gene Therapy (to M.S.) for the TNS9.3.55 vector lot, produced at the Center for Biomedicine and Genetics in Duarte, California, and the MSKCC Support Grant (P30 CA008748). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We also thank S. Avecilla, Q. He, C. Taylor, M. Fink, T. Wasielewska, S. Bartido, Y. Wang and the members of the Cell Therapy and Cell Engineering Facility who, for 7 years, have assisted in the manufacturing and monitoring of the CD34+ cell infusion products for our patients.	ALTER BP, 1976, BLOOD, V48, P843; Bank A, 2005, ANN NY ACAD SCI, V1054, P308, DOI 10.1196/annals.1345.007; Baronciani D, 2018, BLOOD, V132, DOI 10.1182/blood-2018-168; Bartelink IH, 2016, LANCET HAEMATOL, V3, pE526, DOI 10.1016/S2352-3026(16)30114-4; Berry CC, 2017, MOL THER-METH CLIN D, V4, P17, DOI 10.1016/j.omtm.2016.11.003; Berry CC, 2014, BIOINFORMATICS, V30, P1493, DOI 10.1093/bioinformatics/btu035; Berry CC, 2012, BIOINFORMATICS, V28, P755, DOI 10.1093/bioinformatics/bts004; Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187; Bottardi S, 2006, EMBO J, V25, P3586, DOI 10.1038/sj.emboj.7601232; Boulad F, 2014, BLOOD, V123, P1483, DOI 10.1182/blood-2013-06-507178; Brunson A, 2017, BLOOD, V130, P1597, DOI 10.1182/blood-2017-05-783233; Bushman FD, 2020, MOL THER, V28, P352, DOI 10.1016/j.ymthe.2019.12.009; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; Charrier S, 2011, GENE THER, V18, P479, DOI 10.1038/gt.2010.163; Drysdale CM, 2021, CELL STEM CELL, V28, P191, DOI 10.1016/j.stem.2021.01.001; Felfly H, 2010, BRIT J HAEMATOL, V148, P646, DOI 10.1111/j.1365-2141.2009.07985.x; Ferrari G, 2021, NAT REV GENET, V22, P216, DOI 10.1038/s41576-020-00298-5; Fitzhugh CD, 2017, ADV EXP MED BIOL, V1013, P123, DOI 10.1007/978-1-4939-7299-9_5; Frangoul H, 2020, BLOOD, V136, DOI 10.1182/blood-2020-139575; Grimley M, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140963; GROCHOW LB, 1989, CANCER CHEMOTH PHARM, V25, P55, DOI 10.1007/BF00694339; Hsieh MM, 2020, BLOOD ADV, V4, P2058, DOI 10.1182/bloodadvances.2019001330; Hu JP, 2013, BLOOD, V121, P3246, DOI 10.1182/blood-2013-01-476390; Ikeda K, 2011, BLOOD, V117, P5860, DOI 10.1182/blood-2011-02-334425; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; Jones RJ, 2021, BLOOD, V138, P942, DOI 10.1182/blood.2021011488; Katano H, 2007, MICROBES INFECT, V9, P1581, DOI 10.1016/j.micinf.2007.09.008; Kountouris P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103020; La Nasa G, 2013, BLOOD, V122, P2262, DOI 10.1182/blood-2013-05-502658; Ladis V, 2011, EUR J HAEMATOL, V86, P332, DOI 10.1111/j.1600-0609.2011.01582.x; Lawson R, 2021, CLIN PHARMACOKINET, V60, P17, DOI 10.1007/s40262-020-00947-2; Li Y, 2019, MODERN PATHOL, V32, P1712, DOI 10.1038/s41379-019-0325-6; Lisowski L, 2007, BLOOD, V110, P4175, DOI 10.1182/blood-2007-08-108647; Lucarelli G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011825; Magrin E, 2019, BLOOD, V134, P1203, DOI 10.1182/blood.2019000949; Mancuso A, 2006, HEMOGLOBIN, V30, P119, DOI 10.1080/03630260500455565; Mansilla-Soto J, 2016, HUM GENE THER, V27, P295, DOI 10.1089/hum.2016.037; Marktel S, 2019, NAT MED, V25, P234, DOI 10.1038/s41591-018-0301-6; Marktel S, 2010, PEDIATR TRANSPLANT, V14, P393, DOI 10.1111/j.1399-3046.2009.01282.x; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; May C, 2002, BLOOD, V99, P1902, DOI 10.1182/blood.V99.6.1902; Murakami Y, 2012, BRIT J HAEMATOL, V156, P383, DOI 10.1111/j.1365-2141.2011.08914.x; Orkin S, 1998, HEMATOLOGY INFANCY C; Persons DA, 2004, SEMIN HEMATOL, V41, P279, DOI 10.1053/j.seminhematol.2004.07.004; Perumbeti A, 2010, ANN NY ACAD SCI, V1202, P36, DOI 10.1111/j.1749-6632.2010.05584.x; Quek L, 2007, BRIT J HAEMATOL, V136, P353, DOI 10.1111/j.1365-2141.2006.06408.x; Rivella S, 2003, BLOOD, V101, P2932, DOI 10.1182/blood-2002-10-3305; Sadelain M, 2007, HUM GENE THER, V18, P1, DOI 10.1089/hum.2006.151; Sadelain M, 2006, CURR OPIN HEMATOL, V13, P142, DOI 10.1097/01.moh.0000219658.57915.d4; Saito AM, 2007, BONE MARROW TRANSPL, V40, P209, DOI 10.1038/sj.bmt.1705733; Scaramuzza S, 2020, MOL THER, V28, P169; Schneiderman J, 2020, BIOL BLOOD MARROW TR, V26, pS87; Schumm M, 1999, J HEMATOTHER, V8, P209, DOI 10.1089/106161299320488; Seminog OO, 2016, J ROY SOC MED, V109, P303, DOI 10.1177/0141076816651037; Shear HL, 1998, BLOOD, V92, P2520, DOI 10.1182/blood.V92.7.2520.2520_2520_2526; Sherman E, 2017, MOL THER-METH CLIN D, V4, P39, DOI 10.1016/j.omtm.2016.11.002; Stamatoyannopoulos G, 2001, MOL BASIS BLOOD DIS; Strouse C, 2018, BIOL BLOOD MARROW TR, V24, P2072, DOI 10.1016/j.bbmt.2018.06.013; Svahn BM, 2006, TRANSPLANTATION, V82, P147, DOI 10.1097/01.tp.0000226171.43943.d3; Taher AT, 2018, LANCET, V391, P155, DOI 10.1016/S0140-6736(17)31822-6; Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342; Villa E, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03258-3; Weatherall DJ, 2011, BRIT J HAEMATOL, V154, P736, DOI 10.1111/j.1365-2141.2011.08742.x; Weatherall DJ, 1981, THALASSEMIA SYNDROME; Yang SC, 2012, HUM GENE THER METHOD, V23, P73, DOI 10.1089/hgtb.2011.199; Yoon JK, 2020, P NATL ACAD SCI USA, V117, P32880, DOI 10.1073/pnas.2013194117; Yu KR, 2013, STEM CELL RES, V10, P156, DOI 10.1016/j.scr.2012.11.002	67	4	4	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2022	28	1					63	+		10.1038/s41591-021-01554-9	http://dx.doi.org/10.1038/s41591-021-01554-9		JAN 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZE7IJ	34980909				2022-12-27	WOS:000737769800002
J	Castells, M; Akin, C				Castells, Mariana; Akin, Cem			Finding the right KIT inhibitor for advanced systemic mastocytosis	NATURE MEDICINE			English	Editorial Material							CLASSIFICATION; DIAGNOSIS; CELLS	Two early-phase clinical trials show impressive response rates and symptom improvement with the selective KIT inhibitor avapritinib, which will provide a much-needed new treatment option for patients.	[Castells, Mariana] Brigham & Womens Hosp, Div Allergy & Clin Immunol, 75 Francis St, Boston, MA 02115 USA; [Castells, Mariana] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Akin, Cem] Univ Michigan, Dept Internal Med, Div Allergy & Immunol, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	Castells, M (corresponding author), Brigham & Womens Hosp, Div Allergy & Clin Immunol, 75 Francis St, Boston, MA 02115 USA.; Castells, M (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	mcastells@bwh.harvard.edu						Akin, 2020, J ALLERGY CLIN IMMUN, V145, pAB336, DOI [10.1016/j.jaci.2019.12.062, DOI 10.1016/J.JACI.2019.12.062]; Castells M, 2002, INT ARCH ALLERGY IMM, V127, P147, DOI 10.1159/000048188; Castells M, 2019, J ALLER CL IMM-PRACT, V7, P1097, DOI 10.1016/j.jaip.2019.02.002; DeAngelo D. J, NAT MED, DOI [10.1038/s41591-021-01538-9(2021), DOI 10.1038/S41591-021-01538-9(2021)]; Escribano L, 2002, ANN HEMATOL, V81, P677, DOI 10.1007/s00277-002-0575-z; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Gotlib J., NAT MED, DOI [10.1038/s41591-021-01539-8(2021), DOI 10.1038/S41591-021-01539-8(2021)]; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893	13	0	0	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2081	2082		10.1038/s41591-021-01588-z	http://dx.doi.org/10.1038/s41591-021-01588-z		DEC 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34873346				2022-12-27	WOS:000727136800004
J	Ratziu, V; de Guevara, L; Safadi, R; Poordad, F; Fuster, F; Flores-Figueroa, J; Arrese, M; Fracanzani, AL; Ben Bashat, D; Lackner, K; Gorfine, T; Kadosh, S; Oren, R; Halperin, M; Hayardeny, L; Loomba, R; Friedman, S; Sanyal, AJ				Ratziu, V.; de Guevara, L.; Safadi, R.; Poordad, F.; Fuster, F.; Flores-Figueroa, J.; Arrese, M.; Fracanzani, Anna L.; Ben Bashat, D.; Lackner, K.; Gorfine, T.; Kadosh, S.; Oren, R.; Halperin, M.; Hayardeny, L.; Loomba, R.; Friedman, S.; Sanyal, Arun J.		ARREST Investigator Study Grp	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial	NATURE MEDICINE			English	Article							COENZYME-A DESATURASE; INDUCED FATTY LIVER; OBETICHOLIC ACID; FIBROSIS; STEATOSIS; MULTICENTER; EXPRESSION; OXIDATION; BIOPSIES	Y Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. ARREST, a 52-week, double-blind, placebo-controlled, phase 2b trial randomized 247 patients with NASH (n = 101, n = 98 and n = 48 in the Aramchol 400 mg, 600 mg and placebo arms, respectively; NCT02279524). The primary end point was a decrease in hepatic triglycerides by magnetic resonance spectroscopy at 52 weeks with a dose of 600 mg of Aramchol. Key secondary end points included liver histology and alanine aminotransferase (ALT). Aramchol 600 mg produced a placebo-corrected decrease in liver triglycerides without meeting the prespecified significance (-3.1, 95% confidence interval (CI) -6.4 to 0.2, P = 0.066), precluding further formal statistical analysis. NASH resolution without worsening fibrosis was achieved in 16.7% (13 out of 78) of Aramchol 600 mg versus 5% (2 out of 40) of the placebo arm (odds ratio (OR) = 4.74, 95% CI = 0.99 to 22.7) and fibrosis improvement by >= 1 stage without worsening NASH in 29.5% versus 17.5% (OR = 1.88, 95% CI = 0.7 to 5.0), respectively. The placebo-corrected decrease in ALT for 600 mg was -29.1 IU l(-1) (95% CI = -41.6 to -16.5). Early termination due to adverse events (AEs) was <5%, and Aramchol 600 and 400 mg were safe, well tolerated and without imbalance in serious or severe AEs between arms. Although the primary end point of a reduction in liver fat did not meet the prespecified significance level with Aramchol 600 mg, the observed safety and changes in liver histology and enzymes provide a rationale for SCD1 modulation as a promising therapy for NASH and fibrosis and are being evaluated in an ongoing phase 3 program.	[Ratziu, V.] Sorbonne Univ, Inst Cardiometab & Nutr, Paris, France; [Ratziu, V.] Hop La Pitie Salpetriere, INSERM UMRS 1138 CRC, Paris, France; [de Guevara, L.] Hosp Angeles Clin Londres, Mexico City, DF, Mexico; [Safadi, R.] Hadassah Hebrew Univ Med Ctr, Hadassah Med Org, Jerusalem, Israel; [Safadi, R.] Holy Family Hosp, Nazareth, Israel; [Poordad, F.] Texas Liver Inst UT Hlth San Antonio San Antonio, San Antonio, TX USA; [Fuster, F.] Ctr Invest Clin Vina del Mar, Vina Del Mar, Chile; [Flores-Figueroa, J.] JM Res, Cuernavaca, Morelos, Mexico; [Arrese, M.] Pontificia Univ Catolica Chile, Dept Gastroenterol, Fac Med, Santiago, Chile; [Arrese, M.] Pontificia Univ Catolica Chile, Ctr Envejecimiento & Regenerac, Fac Ciencias Biol, Santiago, Chile; [Fracanzani, Anna L.] Univ Milan, Dept Internal Med, Ca Granda IRCCS Fdn, Policlin Maggiore Hosp, Milan, Italy; [Ben Bashat, D.] Tel Aviv Univ, Sagol Brain Inst, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Tel Aviv, Israel; [Ben Bashat, D.] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel; [Lackner, K.] Med Univ Graz, Inst Pathol, Graz, Austria; [Gorfine, T.; Oren, R.; Halperin, M.; Hayardeny, L.] Galmed Pharmaceut Ltd, Tel Aviv, Israel; [Kadosh, S.] Statexcellence Ltd, Tel Aviv, Israel; [Loomba, R.] Univ Calif San Diego, NAFLD Res Ctr, La Jolla, CA 92093 USA; [Friedman, S.] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA; [Sanyal, Arun J.] Virginia Commonwealth Univ, Dept Gastroenterol, Richmond, VA USA	UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Hebrew University of Jerusalem; Hadassah University Medical Center; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Medical University of Graz; University of California System; University of California San Diego; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University	Ratziu, V (corresponding author), Sorbonne Univ, Inst Cardiometab & Nutr, Paris, France.; Ratziu, V (corresponding author), Hop La Pitie Salpetriere, INSERM UMRS 1138 CRC, Paris, France.	vlad.ratziu@inserm.fr	Flores Figueroa, Jose de Jesus/GXF-0417-2022	Morales Garza, Luis Alonso/0000-0003-2945-9969; Ratziu, Vlad/0000-0002-6865-3791	Galmed Pharmaceuticals	Galmed Pharmaceuticals	Financial support for medical editorial assistance was provided by Galmed Pharmaceuticals. We thank medical writer S Diskin (Bioforum Group) for editorial assistance with this manuscript. This study was sponsored by Galmed Pharmaceuticals. The protocol was written by a panel of experts and sponsor representatives. Authors participated actively in drafting and reviewing the manuscript. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.	Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Anania FA, 2021, HEPATOLOGY, V73, P2023, DOI 10.1002/hep.31687; Bedossa P, 2014, HEPATOLOGY, V60, P565, DOI 10.1002/hep.27173; Bhattacharya D, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2021.100237; Bril F, 2020, J HEPATOL, V72, P401, DOI 10.1016/j.jhep.2019.09.018; Brown JM, 2010, CURR OPIN LIPIDOL, V21, P192, DOI 10.1097/MOL.0b013e32833854ac; Chalasani N, 2019, LIVER INT, V39, P924, DOI 10.1111/liv.13974; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Dulai PS, 2016, J HEPATOL, V65, P1006, DOI 10.1016/j.jhep.2016.06.005; European Medicines Agency, 2018, REFL PAP REG REQ DEV; Fernandez-Ramos D, 2020, WORLD J GASTROENTERO, V26, P5101, DOI 10.3748/wjg.v26.i34.5101; Gilat T, 2003, HEPATOLOGY, V38, P436, DOI 10.1053/jhep.2003.50348; Golan-Gerstl R, 2017, J HEPATOL, V66, pS655, DOI 10.1016/S0168-8278(17)31776-2; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Harrison SA, 2021, GASTROENTEROLOGY, V160, P219, DOI 10.1053/j.gastro.2020.08.004; Harrison SA, 2019, LANCET, V394, P2012, DOI 10.1016/S0140-6736(19)32517-6; Harrison SA, 2020, J HEPATOL, V72, P613, DOI 10.1016/j.jhep.2019.10.023; Iruarrizaga-Lejarreta M, 2017, HEPATOL COMMUN, V1, P911, DOI 10.1002/hep4.1107; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kurikawa N, 2013, BIOL PHARM BULL, V36, P259, DOI 10.1248/bpb.b12-00702; Lambert JE, 2014, GASTROENTEROLOGY, V146, P726, DOI 10.1053/j.gastro.2013.11.049; Leikin-Frenkel A, 2008, EUR J GASTROEN HEPAT, V20, P1205, DOI 10.1097/MEG.0b013e3282fc9743; Leikin-Frenkel A, 2010, ARCH MED RES, V41, P397, DOI 10.1016/j.arcmed.2010.09.001; Li ZZ, 2009, J BIOL CHEM, V284, P5637, DOI 10.1074/jbc.M807616200; Liu XQ, 2016, J HEPATOL, V65, P103, DOI 10.1016/j.jhep.2016.03.001; Loomba R, 2020, HEPATOLOGY, V72, P1219, DOI 10.1002/hep.31121; Loomba R, 2019, GASTROENTEROLOGY, V156, P88, DOI 10.1053/j.gastro.2018.09.021; Loomba R, 2018, GASTROENTEROLOGY, V155, P1463, DOI 10.1053/j.gastro.2018.07.027; Middleton MS, 2017, GASTROENTEROLOGY, V153, P753, DOI 10.1053/j.gastro.2017.06.005; Miyazaki M, 2004, J BIOL CHEM, V279, P25164, DOI 10.1074/jbc.M402781200; Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4; Newsome PN, 2021, NEW ENGL J MED, V384, P1113, DOI 10.1056/NEJMoa2028395; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Poletto AC, 2015, MOL CELL ENDOCRINOL, V401, P65, DOI 10.1016/j.mce.2014.12.001; Powell DA, 2014, EXPERT OPIN THER PAT, V24, P155, DOI 10.1517/13543776.2014.851669; Powell EE, 2021, LANCET, V397, P2212, DOI 10.1016/S0140-6736(20)32511-3; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Ratziu V, 2016, GASTROENTEROLOGY, V150, P1147, DOI 10.1053/j.gastro.2016.01.038; Safadi R, 2014, CLIN GASTROENTEROL H, V12, P2085, DOI 10.1016/j.cgh.2014.04.038; Samuel VT, 2018, CELL METAB, V27, P22, DOI 10.1016/j.cmet.2017.08.002; Sanyal A, 2018, LANCET, V392, P2705, DOI 10.1016/S0140-6736(18)31785-9; Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929; Siddiqui MS, 2019, CLIN GASTROENTEROL H, V17, P1877, DOI 10.1016/j.cgh.2018.12.031; Taylor RS, 2020, GASTROENTEROLOGY, V158, P1611, DOI 10.1053/j.gastro.2020.01.043; Trepo E, 2020, J HEPATOL, V72, P1196, DOI 10.1016/j.jhep.2020.02.020; Warensjo E, 2006, NUTR METAB CARDIOVAS, V16, P128, DOI 10.1016/j.numecd.2005.06.001; Younossi ZM, 2019, LANCET, V394, P2184, DOI 10.1016/S0140-6736(19)33041-7	49	25	25	1	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1825	+		10.1038/s41591-021-01495-3	http://dx.doi.org/10.1038/s41591-021-01495-3		OCT 2021	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34621052	Green Submitted			2022-12-27	WOS:000704942800001
J	Munnink, BBO; Worp, N; Nieuwenhuijse, DF; Sikkema, RS; Haagmans, B; Fouchier, RAM; Koopmans, M				Oude Munnink, Bas B.; Worp, Nathalie; Nieuwenhuijse, David F.; Sikkema, Reina S.; Haagmans, Bart; Fouchier, Ron A. M.; Koopmans, Marion			The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology	NATURE MEDICINE			English	Review							RECEPTOR-BINDING DOMAIN; ZIKA VIRUS; TRANSMISSION; MUTATIONS; COVID-19; ESTABLISHMENT; EMERGENCE; ANTIBODY	This Review summarizes the current knowledge on key viral mutations and variants and looks to the next phase of pandemic surveillance with a focus on genotype-to-phenotype characterization. The current coronavirus disease 2019 (COVID-19) pandemic is the first to apply whole-genome sequencing near to real time, with over 2 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole-genome sequences generated and shared through the GISAID platform. This genomic resource informed public health decision-making throughout the pandemic; it also allowed detection of mutations that might affect virulence, pathogenesis, host range or immune escape as well as the effectiveness of SARS-CoV-2 diagnostics and therapeutics. However, genotype-to-phenotype predictions cannot be performed at the rapid pace of genomic sequencing. To prepare for the next phase of the pandemic, a systematic approach is needed to link global genomic surveillance and timely assessment of the phenotypic characteristics of novel variants, which will support the development and updating of diagnostics, vaccines, therapeutics and nonpharmaceutical interventions. This Review summarizes the current knowledge on key viral mutations and variants and looks to the next phase of surveillance of the evolving pandemic.	[Oude Munnink, Bas B.; Worp, Nathalie; Nieuwenhuijse, David F.; Sikkema, Reina S.; Haagmans, Bart; Fouchier, Ron A. M.; Koopmans, Marion] Erasmus MC, WHO Collaborating Ctr Arbovirus & Viral Hemorrhag, Dept Virosci, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Koopmans, M (corresponding author), Erasmus MC, WHO Collaborating Ctr Arbovirus & Viral Hemorrhag, Dept Virosci, Rotterdam, Netherlands.	m.koopmans@erasmusmc.nl	Fouchier, Ron A/A-1911-2014; Haagmans, Bart/E-9791-2015	Fouchier, Ron A/0000-0001-8095-2869; Haagmans, Bart/0000-0001-6221-2015; Oude Munnink, Bas/0000-0002-9394-1189; Nieuwenhuijse, David/0000-0003-1310-5031	European Union's Horizon 2020 research and innovation program [874735]; ZonMW [10150062010005]	European Union's Horizon 2020 research and innovation program; ZonMW(Netherlands Organization for Health Research and Development)	This work has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 874735 (VEO) and from ZonMW (grant agreement no. 10150062010005).	Alm E, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.32.2001410; Ampofo WK, 2015, VACCINE, V33, P4368, DOI 10.1016/j.vaccine.2015.06.090; Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Bakhshandeh B, 2021, MICROB PATHOGENESIS, V154, DOI 10.1016/j.micpath.2021.104831; Banerjee A, 2021, TRENDS ECOL EVOL, V36, P180, DOI 10.1016/j.tree.2020.12.002; Bedford J, 2019, NATURE, V575, P130, DOI 10.1038/s41586-019-1717-y; Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5; Boklund A, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11010164; Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4; Callaway E, 2021, NATURE, V589, P339, DOI 10.1038/d41586-021-00097-w; Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; Candido DS, 2020, SCIENCE, V369, P1255, DOI 10.1126/science.abd2161; Cherian S., 2021, CONVERGENT EVOLUTION, DOI [10.1101/2021.04.22.440932, DOI 10.1101/2021.04.22.440932]; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Davis C, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010022; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; du Plessis L, 2021, SCIENCE, V371, P708, DOI 10.1126/science.abf2946; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036; Fischer Robert J, 2021, bioRxiv, DOI 10.1101/2021.03.11.435000; Fournier PE, 2021, INT J INFECT DIS, V106, P228, DOI 10.1016/j.ijid.2021.03.068; Frampton D, 2021, LANCET INFECT DIS, V21, P1246, DOI 10.1016/S1473-3099(21)00170-5; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006, 10.1101/2021.02.14.21251704]; Gardy JL, 2018, NAT REV GENET, V19, P9, DOI 10.1038/nrg.2017.88; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Giandhari J, 2021, INT J INFECT DIS, V103, P234, DOI 10.1016/j.ijid.2020.11.128; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Greaney AJ, 2021, CELL HOST MICROBE, V29, P44, DOI 10.1016/j.chom.2020.11.007; Grubaugh ND, 2021, CELL, V184, P1127, DOI 10.1016/j.cell.2021.01.044; Grubaugh ND, 2018, CELL, V172, P1160, DOI 10.1016/j.cell.2018.02.027; Haagmans BL, 2021, J INFECT DIS, V223, P2020, DOI 10.1093/infdis/jiab289; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400; Han GZ, 2020, TRENDS MICROBIOL, V28, P515, DOI 10.1016/j.tim.2020.04.001; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Hou YXJ, 2020, SCIENCE, V370, P1464, DOI 10.1126/science.abe8499; Hufsky F, 2021, BRIEF BIOINFORM, V22, P642, DOI 10.1093/bib/bbaa232; Ismail SA, 2021, LANCET INFECT DIS, V21, P344, DOI 10.1016/S1473-3099(20)30882-3; Kemp SA, 2021, NATURE, V592, P277, DOI 10.1038/s41586-021-03291-y; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Konings F, 2021, NAT MICROBIOL, V6, P821, DOI 10.1038/s41564-021-00932-w; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Ladhani SN, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100533; Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0; Lamers M. M., 2021, HUMAN ORGANOID SYSTE, DOI [10.1101/2021.05.03.441080, DOI 10.1101/2021.05.03.441080]; Lamers MM, 2021, ELIFE, V10, DOI 10.7554/eLife.66815; Li R, 2021, CELL MOL IMMUNOL, V18, P1058, DOI 10.1038/s41423-021-00641-8; Liu Zhuoming, 2021, bioRxiv, DOI 10.1101/2020.11.06.372037; Lu J, 2020, CELL, V181, P997, DOI 10.1016/j.cell.2020.04.023; Marquitti FMD, 2021, MODEL BASED ESTIMATI, DOI [10.1101/2021.03.03.21252706, DOI 10.1101/2021.03.03.21252706, 10.1101/2021.01.14.21249386, DOI 10.1101/2021.01.14.21249386]; McCallum M, 2021, SCIENCE, V373, P648, DOI 10.1126/science.abi7994; Meredith LW, 2020, LANCET INFECT DIS, V20, P1263, DOI 10.1016/S1473-3099(20)30562-4; Mohanan M, 2021, JAMA-J AM MED ASSOC, V325, P1001, DOI 10.1001/jama.2021.0332; Mohandas S., 2021, COMPARISON PATHOGENI, DOI [10.1101/2021.02.25.432136, DOI 10.1101/2021.02.25.432136]; Montagutelli X., 2021, B1351 P1 VARIANTS EX, DOI 10.1101/2021.03.18.436013; Munnink BBO, 2021, SCIENCE, V371, P172, DOI 10.1126/science.abe5901; National Institute of Infectious Diseases Japan, 2021, BRIEF REP NEW VAR ST, DOI [10.1101/2021.03.03.21252706, DOI 10.1038/S43856-021-00048-6]; New and Emerging Respiratory Virus Threats Advisory Group, 2020, NERVTAG SPI M EXTR M; Nunez IA, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00507-21; Organization WH., 2020, WHO DIR GEN OP REM M; Munnink BOB, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0997-y; Peacock TP, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001584; Pearson C. A. B., ESTIMATES SEVERITY T, DOI DOI 10.1038/s41423-021-00641-8; Petrova VN, 2018, NAT REV MICROBIOL, V16, P60, DOI [10.1038/nrmicro.2017.146, 10.1038/nrmicro.2017.118]; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; PROMED International Society for Infectious Diseases, 2020, COVID 19 UPD 536 AN; Public Health England, 2021, INV NOV SARS COV 2 V; Public Health England, 2021, SARS COV 2 VAR VAR I; Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Adelino TER, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22607-0; Richard M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17367-2; Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314; Romero PE, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00789-21; Sailleau C, 2020, TRANSBOUND EMERG DIS, V67, P2324, DOI 10.1111/tbed.13659; Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Singer J., 2020, COV GLUE WEB APPL TR, DOI [10.20944/preprints202006.0225.v1, DOI 10.20944/PREPRINTS202006.0225.V1]; Sit THC, 2020, NATURE, V586, P776, DOI 10.1038/s41586-020-2334-5; Tada T, 2021, MBIO, V12, DOI 10.1128/mBio.00696-21; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Vogels CBF, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001236; Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x; Volz E, 2021, CELL, V184, P64, DOI 10.1016/j.cell.2020.11.020; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; WHO, 2021, COVID 19 VACC TRACK; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; World Health Organization, 2020, COR DIS COVID 19 VIR; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu SL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18272-4; Yurkovetskiy L, 2020, CELL, V183, P739, DOI 10.1016/j.cell.2020.09.032; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	103	82	83	6	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1518	1524		10.1038/s41591-021-01472-w	http://dx.doi.org/10.1038/s41591-021-01472-w		SEP 2021	7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34504335	Bronze			2022-12-27	WOS:000694610500001
J	Savulescu, J; Pugh, J; Wilkinson, D				Savulescu, Julian; Pugh, Jonathan; Wilkinson, Dominic			Balancing incentives and disincentives for vaccination in a pandemic	NATURE MEDICINE			English	Editorial Material								Mandates and incentives are being considered to increase uptake of vaccines against COVID-19, but payment for vaccination may be the fairest approach.	[Savulescu, Julian; Pugh, Jonathan; Wilkinson, Dominic] Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford, England; [Savulescu, Julian] Murdoch Childrens Res Inst, Biomed Eth Res Grp, Melbourne, Vic, Australia; [Savulescu, Julian] Univ Melbourne, Melbourne Law Sch, Melbourne, Vic, Australia; [Wilkinson, Dominic] John Radcliffe Hosp, Newborn Care Unit, Oxford, England	University of Oxford; Murdoch Children's Research Institute; University of Melbourne; University of Oxford	Savulescu, J (corresponding author), Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford, England.; Savulescu, J (corresponding author), Murdoch Childrens Res Inst, Biomed Eth Res Grp, Melbourne, Vic, Australia.; Savulescu, J (corresponding author), Univ Melbourne, Melbourne Law Sch, Melbourne, Vic, Australia.	julian.savulescu@philosophy.ox.cw.uk		Savulescu, Julian/0000-0003-1691-6403	Arts and Humanities Research Council [AH/V013947/1]; Wellcome Trust [WT203132, WT104848]; Victorian State Government through the Operational Infrastructure Support Program	Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Victorian State Government through the Operational Infrastructure Support Program	This research was funded in whole, or in part, by the Arts and Humanities Research Council as part of the UK Research and Innovation Pandemic Ethics accelerator (https://ukpandemicethics.org; AH/V013947/1). This research was also funded in whole, or in part, by the Wellcome Trust (grant numbers WT203132 and WT104848). For the purpose of open access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. J.S., through his involvement with the Murdoch Children's Research Institute, received funding through from the Victorian State Government through the Operational Infrastructure Support Program.	[Anonymous], 2021, UK DEP HLTH SOCIAL C; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Becker DM, 2019, GER ECON REV, V20, pE973, DOI 10.1111/geer.12204; Blanc F, 2021, GEROSCIENCE, V43, P2333, DOI 10.1007/s11357-021-00397-z; Brown RCH, 2021, LANCET INFECT DIS, V21, pE58, DOI 10.1016/S1473-3099(20)30766-0; FT Visual & Data Journalism team, FINANCIAL TIMES; Giubilini A, 2018, MED HEALTH CARE PHIL, V21, P547, DOI 10.1007/s11019-018-9829-y; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Higgins ST, 2021, PREV MED, V145, DOI 10.1016/j.ypmed.2021.106421; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jecker N.S., J MED ETHICS, DOI [10.1136/medethics-2021-107235(2021, DOI 10.1136/MEDETHICS-2021-107235(2021]; Kadkhoda K, 2021, AM J CLIN PATHOL, V155, P471, DOI 10.1093/ajcp/aqaa272; Ledford H, 2021, NATURE, V594, P164, DOI 10.1038/d41586-021-01505-x; Mejia, PREPRINT MEDRXIV, DOI [10.1101/2021.04.20.21255821(2021, DOI 10.1101/2021.04.20.21255821(2021]; Mill J. S., 2003, LIBERTY, P80; Razai MS, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1138; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Reality Check team, 2018, BBC NEWS; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Savulescu J, 2021, J MED ETHICS, V47, P78, DOI 10.1136/medethics-2020-106821; Sprengholz P, 2021, J MED ETHICS, V47, P547, DOI 10.1136/medethics-2020-107122; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Walkey AJ, 2021, JAMA-J AM MED ASSOC, V326, P766, DOI 10.1001/jama.2021.11048	24	8	8	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1500	1503		10.1038/s41591-021-01466-8	http://dx.doi.org/10.1038/s41591-021-01466-8		SEP 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34489607	hybrid, Green Submitted			2022-12-27	WOS:000692960600002
J	Creelan, BC; Wang, C; Teer, JK; Toloza, EM; Yao, JQ; Kim, S; Landin, AM; Mullinax, JE; Saller, JJ; Saltos, AN; Noyes, DR; Montoya, LB; Curry, W; Pilon-Thomas, SA; Chiappori, AA; Tanvetyanon, T; Kaye, FJ; Thompson, ZJ; Yoder, SJ; Fang, B; Koomen, JM; Sarnaik, AA; Chen, DT; Conejo-Garcia, JR; Haura, EB; Antonia, SJ				Creelan, Benjamin C.; Wang, Chao; Teer, Jamie K.; Toloza, Eric M.; Yao, Jiqiang; Kim, Sungjune; Landin, Ana M.; Mullinax, John E.; Saller, James J.; Saltos, Andreas N.; Noyes, David R.; Montoya, Leighann B.; Curry, Wesley; Pilon-Thomas, Shari A.; Chiappori, Alberto A.; Tanvetyanon, Tawee; Kaye, Frederic J.; Thompson, Zachary J.; Yoder, Sean J.; Fang, Bin; Koomen, John M.; Sarnaik, Amod A.; Chen, Dung-Tsa; Conejo-Garcia, Jose R.; Haura, Eric B.; Antonia, Scott J.			Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial	NATURE MEDICINE			English	Article							ADOPTIVE CELL IMMUNOTHERAPY; T-CELLS; COMPLETE RESPONSES; MELANOMA; THERAPY; MUTATIONS; IDENTIFICATION; NIVOLUMAB; RECURRENT; RATES	Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial (NCT03215810) of TILs administered with nivolumab in 20 patients with advanced non-small cell lung cancer following initial progression on nivolumab monotherapy. The primary end point was safety and secondary end points included objective response rate, duration of response and T cell persistence. Autologous TILs were expanded ex vivo from minced tumors cultured with interleukin-2. Patients received cyclophosphamide and fludarabine lymphodepletion, TIL infusion and interleukin-2, followed by maintenance nivolumab. The end point of safety was met according to the prespecified criteria of <= 17% rate of severe toxicity (95% confidence interval, 3-29%). Of 13 evaluable patients, 3 had confirmed responses and 11 had reduction in tumor burden, with a median best change of 35%. Two patients achieved complete responses that were ongoing 1.5 years later. In exploratory analyses, we found T cells recognizing multiple types of cancer mutations were detected after TIL treatment and were enriched in responding patients. Neoantigen-reactive T cell clonotypes increased and persisted in peripheral blood after treatment. Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer.	[Creelan, Benjamin C.; Wang, Chao; Toloza, Eric M.; Saltos, Andreas N.; Chiappori, Alberto A.; Tanvetyanon, Tawee; Thompson, Zachary J.; Sarnaik, Amod A.; Conejo-Garcia, Jose R.; Haura, Eric B.] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA; [Teer, Jamie K.; Yao, Jiqiang; Chen, Dung-Tsa] H Lee Moffitt Canc Ctr & Res Inst, Dept Bioinformat & Biostat, Tampa, FL USA; [Kim, Sungjune; Noyes, David R.; Pilon-Thomas, Shari A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL USA; [Landin, Ana M.] H Lee Moffitt Canc Ctr & Res Inst, Cell Therapy Facil, Tampa, FL USA; [Mullinax, John E.] H Lee Moffitt Canc Ctr & Res Inst, Dept Sarcoma, Tampa, FL USA; [Saller, James J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA; [Montoya, Leighann B.; Curry, Wesley] H Lee Moffitt Canc Ctr & Res Inst, Immune & Cellular Therapy Program, Tampa, FL USA; [Kaye, Frederic J.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA; [Yoder, Sean J.; Fang, Bin; Koomen, John M.] H Lee Moffitt Canc Ctr & Res Inst, Chem Biol & Mol Med, Tampa, FL USA; [Antonia, Scott J.] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of Florida; H Lee Moffitt Cancer Center & Research Institute; Duke University	Creelan, BC (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA.	ben.creelan@moffitt.org		Conejo-Garcia, Jose/0000-0001-6431-4074; Creelan, Ben/0000-0002-2728-8070	Catalyst Award Clinical Trial grant through the Stand Up to Cancer Foundation [SU2C-AACR-CT04-17]; Barbara Bauer Prelude to a Cure Foundation; Clinigen; NCI Cancer Center Support Grant [P30-CA076292]; NCI Cancer Center [P30-CA076292]; Moffitt Immune and Cellular Therapies department	Catalyst Award Clinical Trial grant through the Stand Up to Cancer Foundation; Barbara Bauer Prelude to a Cure Foundation; Clinigen; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Moffitt Immune and Cellular Therapies department	This work was supported by a Catalyst Award Clinical Trial grant through the Stand Up to Cancer Foundation (SU2C-AACR-CT04-17; to E.B.H., S.J.A.); Barbara Bauer Prelude to a Cure Foundation grant to B.C.C.; ER Squibb for nivolumab supply; Iovance Biotherapeutics as a research grant, Clinigen for aldesleukin supply, an NCI Cancer Center Support Grant (P30-CA076292; to E.B.H.) and 2018 Young Investigator award from Adaptive Biotechnologies to B.C.C. Stand Up 2 Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. We thank the patients and their families who participated in this research; members of the Moffitt Cell Therapies Facility, including L. Kelley and C. Cox for cell manufacturing; C. Yang and T. Mesa at the Moffitt Molecular Genomics Facility, M. Wloch, N. Smith and K. Fahrner at the Moffitt Tissue Core and P. Cano at the Moffitt Histocompatibility Leukocyte Antigen laboratory; T. Boyle and G. Zhang for assistance with clinical specimens; C. Ulge for grant administration; M. Avedon for translational project management; and other members of our clinical and laboratory research teams. Cell sorting for this project was performed on instruments in the Moffitt Flow Cytometry Core. Sequencing was performed by the Moffitt Molecular Genomics and Proteomics & Metabolomics Core Facilities (supported in part by NCI Cancer Center Support Grant P30-CA076292). Clinical care and trial coordination was provided by the Moffitt Immune and Cellular Therapies department. We thank B. Banbury for assistance with the graphs of T cell clonotypes.	Addeo A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00264; Ahmed M, 2018, RESPIRATION, V96, P138, DOI 10.1159/000487957; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Andersen R, 2016, CLIN CANCER RES, V22, P3734, DOI 10.1158/1078-0432.CCR-15-1879; Blumenschein G, 2020, J IMMUNOTHER CANCER, V8, pA169, DOI 10.1136/jitc-2020-SITC2020.0278; Cafri G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08304-z; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; D'Angelo SP, 2018, CANCER DISCOV, V8, P944, DOI 10.1158/2159-8290.CD-17-1417; Danilova L, 2018, CANCER IMMUNOL RES, V6, P888, DOI 10.1158/2326-6066.CIR-18-0129; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Doebele RC, 2012, CANCER-AM CANCER SOC, V118, P4502, DOI 10.1002/cncr.27409; Duinkerken CW, 2019, OTOL NEUROTOL, V40, pE674, DOI 10.1097/MAO.0000000000002332; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Fultz PJ, 2002, RADIOLOGY, V222, P245, DOI 10.1148/radiol.2221010431; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Golubovskaya V, 2016, CANCERS, V8, DOI 10.3390/cancers8030036; Gros A, 2019, J CLIN INVEST, V129, P4992, DOI 10.1172/JCI127967; Haas AR, 2019, MOL THER, V27, P1919, DOI 10.1016/j.ymthe.2019.07.015; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Ivanova A, 2005, BIOMETRICS, V61, P540, DOI 10.1111/j.1541-0420.2005.00311.x; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kast F, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2020.1869389; Katz SI, 2018, J THORAC ONCOL, V13, P978, DOI 10.1016/j.jtho.2018.04.010; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Lauss M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01460-0; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Guerra JLL, 2012, INT J RADIAT ONCOL, V83, pE537, DOI 10.1016/j.ijrobp.2012.01.019; Lu YC, 2017, J CLIN ONCOL, V35, P3322, DOI 10.1200/JCO.2017.74.5463; Malekzadeh P, 2020, CLIN CANCER RES, V26, P1267, DOI 10.1158/1078-0432.CCR-19-1874; Man J., 2021, JNCI CANCER SPECT, V5, ppkab012, DOI [10.1093/jncics/pkab012, DOI 10.1093/jncics/pkab012, DOI 10.1172/JCI98689]; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Niwa H, 1994, Nihon Kyobu Geka Gakkai Zasshi, V42, P1142; Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Salas-Benito D., BRIT J CANCER, DOI [10.1038/s41416-020-01218-4(2021, DOI 10.1038/S41416-020-01218-4(2021]; Sarnaik A, 2020, J CLIN ONCOL, V38; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schoenfeld AJ, 2020, CANCER CELL, V37, P443, DOI 10.1016/j.ccell.2020.03.017; Simpson-Abelson M., 2019, SITC ANN M SITC; Simpson-Abelson MR, 2020, ANN ONCOL, V31, pS720, DOI 10.1016/j.annonc.2020.08.1173; Stevanovic S, 2015, J CLIN ONCOL, V33, P1543, DOI 10.1200/JCO.2014.58.9093; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Veatch JR, 2018, J CLIN INVEST, V128, P1563, DOI 10.1172/JCI98689; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389; Xia Y, 2018, ONCOL LETT, V16, P6998, DOI 10.3892/ol.2018.9534; Xue Q, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0293-7; Yeh S, 2009, OPHTHALMOLOGY, V116, P981, DOI 10.1016/j.ophtha.2008.12.004; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8	60	49	51	4	30	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1410	+		10.1038/s41591-021-01462-y	http://dx.doi.org/10.1038/s41591-021-01462-y		AUG 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385708	Green Accepted			2022-12-27	WOS:000684533600004
J	van de Haar, J; Hoes, LR; Roepman, P; Lolkema, MP; Verheul, HMW; Gelderblom, H; de Langen, AJ; Smit, EF; Cuppen, E; Wessels, LFA; Voest, EE				van de Haar, Joris; Hoes, Louisa R.; Roepman, Paul; Lolkema, Martijn P.; Verheul, Henk M. W.; Gelderblom, Hans; de Langen, Adrianus J.; Smit, Egbert F.; Cuppen, Edwin; Wessels, Lodewyk F. A.; Voest, Emile E.			Limited evolution of the actionable metastatic cancer genome under therapeutic pressure	NATURE MEDICINE			English	Article							ESR1 MUTATIONS; VEMURAFENIB; HETEROGENEITY; EFFICACY; TUMORS; GENE	Genomic profiling is critical for the identification of treatment options for patients with metastatic cancer, but it remains unclear how frequently this procedure should be repeated during the course of the disease. To address this, we analyzed whole-genome sequencing (WGS) data of 250 biopsy pairs, longitudinally collected over the treatment course of 231 adult patients with a representative variety of metastatic solid malignancies. Within the biopsy interval (median, 6.4 months), patients received one or multiple lines of (mostly) standard-of-care (SOC) treatments, with all major treatment modalities being broadly represented. SOC biomarkers and biomarkers for clinical trial enrollment could be identified in 23% and 72% of biopsies, respectively. For SOC genomic biomarkers, we observed full concordance between the first and the second biopsy in 99% of pairs. Of the 219 biomarkers for clinical trial enrollment that were identified in the first biopsies, we recovered 94% in the follow-up biopsies. Furthermore, a second WGS analysis did not identify additional biomarkers for clinical trial enrollment in 91% of patients. More-frequent genomic evolution was observed when considering specific genes targeted by small-molecule inhibitors or hormonal therapies (21% and 22% of cases, respectively). Together, our data demonstrate that there is limited evolution of the actionable genome of treated metastases. A single WGS analysis of a metastatic biopsy is generally sufficient to identify SOC genomic biomarkers and to identify investigational treatment opportunities. Whole-genome sequencing of metastatic biopsies longitudinally sampled during the course of anticancer treatment reveals that the actionable metastatic cancer genome remains relatively stable over time.	[van de Haar, Joris; Hoes, Louisa R.; Voest, Emile E.] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [van de Haar, Joris; Wessels, Lodewyk F. A.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; [van de Haar, Joris; Hoes, Louisa R.; Cuppen, Edwin; Wessels, Lodewyk F. A.; Voest, Emile E.] Oncode Inst, Amsterdam, Netherlands; [Roepman, Paul; Cuppen, Edwin] Hartwig Med Fdn, Amsterdam, Netherlands; [Lolkema, Martijn P.] Erasmus Univ, Erasmus Med Ctr Canc Inst, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands; [Verheul, Henk M. W.] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands; [Gelderblom, Hans] Leiden Univ, Dept Med Oncol, Med Ctr, Leiden, Netherlands; [de Langen, Adrianus J.; Smit, Egbert F.] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands; [Cuppen, Edwin] Univ Med Ctr Utrecht, Ctr Mol Med, Utrecht, Netherlands; [Wessels, Lodewyk F. A.] Delft Univ Technol, Fac EEMCS, Delft, Netherlands; [Voest, Emile E.] Ctr Personalized Canc Treatment, Rotterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Delft University of Technology	Voest, EE (corresponding author), Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.; Voest, EE (corresponding author), Oncode Inst, Amsterdam, Netherlands.; Voest, EE (corresponding author), Ctr Personalized Canc Treatment, Rotterdam, Netherlands.	e.voest@nki.nl	Verheul, Henk/V-6462-2019	Verheul, Henk/0000-0001-5981-922X; Lolkema, Martijn/0000-0003-0466-2928; Smit, Egbert/0000-0002-7329-6995	Josephine Nefkens Foundation; Oncode Institute	Josephine Nefkens Foundation; Oncode Institute	We acknowledge the Hartwig Medical Foundation and the Center of Personalised Cancer Treatment (CPCT) for providing the data used in this the study. This work was supported by funding from the Josephine Nefkens Foundation and the Oncode Institute.	Aitken M., 2020, OPTIMIZING ONCOLOGY; Angus L, 2019, NAT GENET, V51, P1450, DOI 10.1038/s41588-019-0507-7; [Anonymous], 2019, GRIDSS PURPLE LINX U, DOI [10.1101/781013, DOI 10.1101/781013]; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Gerstung M, 2020, NATURE, V578, P122, DOI 10.1038/s41586-019-1907-7; Griffith M, 2017, NAT GENET, V49, P170, DOI 10.1038/ng.3774; Huang MN, 2015, SCI REP-UK, V5, DOI 10.1038/srep13321; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Hyman DM, 2017, CELL, V168, P584, DOI 10.1016/j.cell.2016.12.015; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; Mateo J, 2018, ANN ONCOL, V29, P1895, DOI 10.1093/annonc/mdy263; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Okamura R, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00183; Pich O, 2019, NAT GENET, V51, P1732, DOI 10.1038/s41588-019-0525-5; Poplin R., 2018, BIORXIV, DOI DOI 10.1101/201178; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Riaz N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00921-w; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Roepman P, 2021, J MOL DIAGN, V23, P816, DOI 10.1016/j.jmoldx.2021.04.011; Samsom KG, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00814-w; Stockley TL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0364-2; Subbiah V, 2020, CANCER DISCOV, V10, P657, DOI 10.1158/2159-8290.CD-19-1265; Tamborero D, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0531-8; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Van der Velden DL, 2019, NATURE, V574, P127, DOI 10.1038/s41586-019-1600-x; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Waltering KK, 2012, MOL CELL ENDOCRINOL, V360, P38, DOI 10.1016/j.mce.2011.12.019; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037	45	17	17	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1553	+		10.1038/s41591-021-01448-w	http://dx.doi.org/10.1038/s41591-021-01448-w		AUG 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34373653				2022-12-27	WOS:000683329400001
J	Krammer, F				Krammer, Florian			A correlate of protection for SARS-CoV-2 vaccines is urgently needed	NATURE MEDICINE			English	Editorial Material									[Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Krammer, F (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Krammer, F (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.	florian.krammer@mssm.edu	Krammer, Florian/H-3237-2019	Krammer, Florian/0000-0003-4121-776X	NIAID Collaborative Influenza Vaccine Innovation Centers [75N93019C00051]; NIAID Center of Excellence for Influenza Research and Surveillance [HHSN272201400008C]; JPB Foundation; Open Philanthropy Project [2020-215611 (5384)]	NIAID Collaborative Influenza Vaccine Innovation Centers; NIAID Center of Excellence for Influenza Research and Surveillance(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); JPB Foundation; Open Philanthropy Project	Work on SARS-CoV-2 in the Krammer laboratory is funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (contract 75N93019C00051), NIAID Center of Excellence for Influenza Research and Surveillance (contract HHSN272201400008C), by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384)), and by anonymous donors.	Aleman, PREPRINT MEDRXIV, DOI [10.1101/2021.05.15.21256814(2021, DOI 10.1101/2021.05.15.21256814(2021]; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Deepak, PREPRINT MEDRXIV, DOI [10.1101/2021.04.05.21254656(2021, DOI 10.1101/2021.04.05.21254656(2021]; Earle K.A., VACCINE, DOI [10.1016/j.vaccine.2021.05.063(2021, DOI 10.1016/J.VACCINE.2021.05.063(2021]; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Haidar, PREPRINT MEDRXIV, DOI [10.1101/2021.04.06.21254949(2021, DOI 10.1101/2021.04.06.21254949(2021]; Khoury, NAT MED, DOI [10.1038/s41591-021-01377-8(2021), DOI 10.1038/S41591-021-01377-8(2021)]; Krammer F, 2021, LANCET, V397, P1421, DOI 10.1016/S0140-6736(21)00782-0; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10	12	91	90	1	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1147	1148		10.1038/s41591-021-01432-4	http://dx.doi.org/10.1038/s41591-021-01432-4		JUL 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34239135	Bronze			2022-12-27	WOS:000672339400001
J	Raoof, S; Kennedy, CJ; Wallach, DA; Bitton, A; Green, RC				Raoof, Sana; Kennedy, Caleb J.; Wallach, D. A.; Bitton, Asaf; Green, Robert C.			Molecular cancer screening: in search of evidence	NATURE MEDICINE			English	Editorial Material							CIRCULATING TUMOR DNA	Cancer screening with germline genetic sequencing and liquid biopsy could facilitate early cancer detection. But testing if these technologies reduce the burden of cancer mortality will require rethinking how clinical trials are run.	[Raoof, Sana] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Raoof, Sana; Bitton, Asaf; Green, Robert C.] Harvard Med Sch, Boston, MA 02115 USA; [Kennedy, Caleb J.] OptumLabs, UnitedHlth Grp, Minnetonka, MN USA; [Wallach, D. A.] Time BioVentures, Los Angeles, CA USA; [Bitton, Asaf; Green, Robert C.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Bitton, Asaf; Green, Robert C.] Ariadne Labs, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Raoof, S (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Raoof, S (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	sraoof@mgh.harvard.edu			US National Institutes of Health [HG006500, HD077671, HD090019, HG009922, HL143295, TR003201]; Franca Sozzani Fund	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Franca Sozzani Fund	The viewpoints expressed herein are those of the authors and do not reflect official viewpoints of the US National Institutes of Health, The Center for Medicare & Medicaid Innovation, CMS or the companies mentioned. The authors appreciate helpful comments on earlier drafts of this article from S. Aldubayan, H. Hampel, A. Kesselheim and R. Weinberg. R.C.G. is supported by US National Institutes of Health grants HG006500, HD077671, HD090019, HG009922, HL143295 and TR003201 and by the Franca Sozzani Fund.	[Anonymous], 2007, J ONCOL PRACT, V3, P296, DOI 10.1200/JOP.0763501; Aravanis AM, 2017, CELL, V168, P571, DOI 10.1016/j.cell.2017.01.030; Bradley SH, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4933; Chen M, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0220-8; Chen XD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17316-z; Curran GM, 2012, MED CARE, V50, P217, DOI 10.1097/MLR.0b013e3182408812; De Rubis G, 2018, PHARMACOL RES, V136, P35, DOI 10.1016/j.phrs.2018.08.017; Hall MJ, 2014, J NATL COMPR CANC NE, V12, P1339, DOI 10.6004/jnccn.2014.0128; Haverfield E., BMC MED; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Johnston JL, 2020, NAT BIOTECHNOL, V38, P933, DOI 10.1038/s41587-020-0636-7; Lennon AM, 2020, SCIENCE, V369, P49, DOI 10.1126/science.abb9601; Liu MC, 2020, ANN ONCOL, V31, P745, DOI 10.1016/j.annonc.2020.02.011; Luo HY, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax7533; Manchanda R, 2020, ANNU REV GENOM HUM G, V21, P373, DOI 10.1146/annurev-genom-083118-015253; Mathews SC, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0111-3; Plichta JK, 2016, ONCOLOGY-NY, V30, P787; Rathi VK, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14496; Resnic FS, 2017, NEW ENGL J MED, V376, P526, DOI 10.1056/NEJMoa1516333; Reynolds IS, 2014, JAMA INTERN MED, V174, P1773, DOI 10.1001/jamainternmed.2014.4194; Srivastava S, 2019, NAT REV CANCER, V19, P349, DOI 10.1038/s41568-019-0142-8; Turnbull C, 2018, NAT GENET, V50, P1212, DOI 10.1038/s41588-018-0202-0; Wallach JD, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2031; Yurgelun MB, 2017, CELL, V168, P566, DOI 10.1016/j.cell.2017.01.031	24	5	5	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1139	1142		10.1038/s41591-021-01431-5	http://dx.doi.org/10.1038/s41591-021-01431-5		JUL 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34211183				2022-12-27	WOS:000668799200001
J	Hansson, O				Hansson, Oskar			Biomarkers for neurodegenerative diseases	NATURE MEDICINE			English	Review							FIBRILLARY ACIDIC PROTEIN; POSITRON-EMISSION-TOMOGRAPHY; DOMINANT ALZHEIMERS-DISEASE; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA PLAQUES; CLINICAL-DIAGNOSIS; TAU PATHOLOGY; LEWY BODIES; DEMENTIA; PET	Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic but also to facilitate the development and monitoring of effective disease-modifying therapies. Positron emission tomography methods detecting amyloid-beta and tau pathology in Alzheimer's disease have been increasingly used to improve the design of clinical trials and observational studies. In recent years, easily accessible and cost-effective blood-based biomarkers detecting the same Alzheimer's disease pathologies have been developed, which might revolutionize the diagnostic workup of Alzheimer's disease globally. Relevant biomarkers for alpha-synuclein pathology in Parkinson's disease are also emerging, as well as blood-based markers of general neurodegeneration and glial activation. This review presents an overview of the latest advances in the field of biomarkers for neurodegenerative diseases. Future directions are discussed regarding implementation of novel biomarkers in clinical practice and trials. As the development of biomarkers for neurodegenerative diseases advances, new opportunities arise for their implementation in clinical practice and trials.	[Hansson, Oskar] Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden; [Hansson, Oskar] Skane Univ Hosp, Memory Clin, Malmo, Sweden	Lund University; Lund University; Skane University Hospital	Hansson, O (corresponding author), Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden.; Hansson, O (corresponding author), Skane Univ Hosp, Memory Clin, Malmo, Sweden.	oskar.hansson@med.lu.se	Hansson, Oskar/A-7134-2013	Hansson, Oskar/0000-0001-8467-7286	Swedish Research Council [2016-00906]; Knut and Alice Wallenberg foundation [2017-0383]; Marianne and Marcus Wallenberg foundation [2015.0125]; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University; Swedish Alzheimer Foundation [AF-939932]; Swedish Brain Foundation [FO2019-0326]; Parkinson Foundation of Sweden [1280/20]; Skane University Hospital Foundation [2020-O000028]; Swedish federal government under the ALF agreement [2018-Projekt0279]; Regionalt Forskningsstod [2020-0314]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Knut and Alice Wallenberg foundation(Knut & Alice Wallenberg Foundation); Marianne and Marcus Wallenberg foundation; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University; Swedish Alzheimer Foundation; Swedish Brain Foundation; Parkinson Foundation of Sweden; Skane University Hospital Foundation; Swedish federal government under the ALF agreement; Regionalt Forskningsstod	I thank the following researchers who provided important input to this paper: A. Leuzy, J. Vogel, N. Mattsson-Carlgren, N. Cullen, O. Strandberg, R. Ossenkoppele, R. Smith, S. Palmqvist and S. Janelidze. O.H. was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2019-0326), The Parkinson Foundation of Sweden (1280/20), the Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279).	Ashton N., 2021, NAT COMMUN, DOI 10.1038/s41467-021-23620-z; Bang J, 2015, LANCET, V386, P1672, DOI 10.1016/S0140-6736(15)00461-4; Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Bateman RJ, 2008, NEUROTHERAPEUTICS, V5, P381, DOI 10.1016/j.nurt.2008.05.009; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Bejanin A, 2017, BRAIN, V140, P3286, DOI 10.1093/brain/awx243; Blennow K, 2018, J INTERN MED, V284, P643, DOI 10.1111/joim.12816; Blennow K, 2020, BRAIN, V143, P650, DOI 10.1093/brain/awz346; Blennow K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54204-z; Borghammer P, 2019, J PARKINSON DIS, V9, pS281, DOI 10.3233/JPD-191721; Braak H, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a023630; Bradford A, 2009, ALZ DIS ASSOC DIS, V23, P306, DOI 10.1097/WAD.0b013e3181a6bebc; Brooks DJ, 2010, J NUCL MED, V51, P596, DOI 10.2967/jnumed.108.059998; Brown RH, 2017, NEW ENGL J MED, V377, P1602, DOI [10.1038/nrdp.2017.85, 10.1056/NEJMra1603471, 10.1056/NEJMc1710379, 10.1016/S0140-6736(17)31287-4, 10.1016/S0140-6736(10)61156-7, 10.1038/nrdp.2017.71]; Buchhave P, 2012, ARCH GEN PSYCHIAT, V69, P98, DOI 10.1001/archgenpsychiatry.2011.155; Chen MK, 2021, J CEREBR BLOOD F MET, V41, P2395, DOI 10.1177/0271678X211004312; Chetelat G, 2020, LANCET NEUROL, V19, P951, DOI 10.1016/S1474-4422(20)30314-8; Cho H, 2016, ANN NEUROL, V80, P247, DOI 10.1002/ana.24711; Cicognola C, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00804-9; Clark CM, 2012, LANCET NEUROL, V11, P669, DOI 10.1016/S1474-4422(12)70142-4; CONNOR A, 2020, MOL PSYCHIATR; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; Cullen, 2021, PLASMA BIOMARK UNPUB; Cullen NC., 2020, NAT AGING, V1, P114, DOI [10.1038/s43587-020-00003-5, DOI 10.1038/S43587-020-00003-5]; Cullen NC, 2020, ANN CLIN TRANSL NEUR, V7, P1661, DOI 10.1002/acn3.51158; Curtis C, 2015, JAMA NEUROL, V72, P287, DOI 10.1001/jamaneurol.2014.4144; De Strooper B, 2016, CELL, V164, P603, DOI 10.1016/j.cell.2015.12.056; Delcoigne B, 2020, NEUROLOGY, V94, pE1201, DOI 10.1212/WNL.0000000000009097; DeTure MA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0333-5; Donohue MC, 2017, JAMA-J AM MED ASSOC, V317, P2305, DOI 10.1001/jama.2017.6669; Elschot EP, 2021, INVEST RADIOL, V56, P10, DOI 10.1097/RLI.0000000000000723; Fairfoul G, 2016, ANN CLIN TRANSL NEUR, V3, P812, DOI 10.1002/acn3.338; Fleisher AS, 2020, JAMA NEUROL, V77, P829, DOI 10.1001/jamaneurol.2020.0528; Franzmeier N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14159-1; Goedert M, 2013, NAT REV NEUROL, V9, P13, DOI 10.1038/nrneurol.2012.242; Gordon BA, 2018, LANCET NEUROL, V17, P241, DOI 10.1016/S1474-4422(18)30028-0; Hanes J, 2020, NEUROLOGY, V95, pE3026, DOI 10.1212/WNL.0000000000010814; HANSSON O, 2021, ALZHEIMERS DEMENT; Hansson O, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0485-0; Hansson O, 2018, ALZHEIMERS DEMENT, V14, P1470, DOI 10.1016/j.jalz.2018.01.010; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heller C, 2020, J NEUROL NEUROSUR PS, V91, P263, DOI 10.1136/jnnp-2019-321954; Horie K., 2020, BRAIN, V144, P515; Hunter CA, 2015, ALZHEIMERS DEMENT, V11, P887, DOI 10.1016/j.jalz.2015.06.1889; Jack CR, 2020, BRAIN, V143, P3136, DOI 10.1093/brain/awaa248; Jack CR, 2018, BRAIN, V141, P1517, DOI 10.1093/brain/awy059; Jacobs HIL, 2018, NAT NEUROSCI, V21, P424, DOI 10.1038/s41593-018-0070-z; Janelidze, ALZHEIMERS DEMENT; Janelidze S, 2021, JAMA NEUROL, V78, P149, DOI 10.1001/jamaneurol.2020.4201; Janelidze S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15436-0; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Janelidze S, 2017, NEUROBIOL AGING, V51, P104, DOI 10.1016/j.neurobiolaging.2016.11.017; Janelidze S, 2016, SCI REP-UK, V6, DOI 10.1038/srep26801; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Johnson KA, 2016, ANN NEUROL, V79, P110, DOI 10.1002/ana.24546; Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2012.10.007, 10.1016/j.jalz.2013.06.001]; Josephs KA, 2017, ACTA NEUROPATHOL, V133, P705, DOI 10.1007/s00401-017-1681-2; Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3; Kang UJ, 2019, MOVEMENT DISORD, V34, P536, DOI 10.1002/mds.27646; Kaplow J, 2020, ALZHEIMERS DEMENT, V16, P144, DOI 10.1002/alz.12000; Karikari TK, 2021, MOL PSYCHIATR, V26, P429, DOI 10.1038/s41380-020-00923-z; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Kuhlmann J, 2017, CLIN CHIM ACTA, V467, P27, DOI 10.1016/j.cca.2016.05.014; La Joie R, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aau5732; Rodriguez JL, 2020, ACTA NEUROPATHOL, V140, P267, DOI 10.1007/s00401-020-02195-x; Leuzy A, 2020, JAMA NEUROL, V77, P955, DOI 10.1001/jamaneurol.2020.0989; Maass A, 2018, J NEUROSCI, V38, P530, DOI 10.1523/JNEUROSCI.2028-17.2017; Manne S, 2020, MOVEMENT DISORD, V35, P2230, DOI 10.1002/mds.28242; Masters CL, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.56; Mattsson N, 2019, JAMA NEUROL, V76, P1319, DOI 10.1001/jamaneurol.2019.2214; Mattsson N, 2017, NEUROBIOL AGING, V52, P196, DOI 10.1016/j.neurobiolaging.2016.02.034; Mattsson-Carlgren N, 2020, BRAIN, V143, P3234, DOI 10.1093/brain/awaa286; Mattsson-Carlgren N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz2387; MATTSSONCARLGRE.N, 2021, EMBO MOL MED; Matuskey D, 2020, ANN NEUROL, V87, P329, DOI 10.1002/ana.25682; McKeith IG, 2017, NEUROLOGY, V89, P88, DOI 10.1212/WNL.0000000000004058; Mecca AP, 2020, ALZHEIMERS DEMENT, V16, P974, DOI 10.1002/alz.12097; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; Nakamura A, 2018, NATURE, V554, P249, DOI 10.1038/nature25456; Nation DA, 2019, NAT MED, V25, P270, DOI 10.1038/s41591-018-0297-y; Nelson PT, 2019, BRAIN, V142, P1503, DOI 10.1093/brain/awz099; Nichols E, 2019, LANCET NEUROL, V18, P88, DOI 10.1016/S1474-4422(18)30403-4; Olsson B, 2019, J NEUROL, V266, P2129, DOI 10.1007/s00415-019-09389-8; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Ossenkoppele R., 2021, JAMA NEUROL; Ossenkoppele R, 2019, NEUROLOGY, V92, pE601, DOI 10.1212/WNL.0000000000006875; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Ossenkoppele R, 2016, BRAIN, V139, P1551, DOI 10.1093/brain/aww027; Ovod V, 2017, ALZHEIMERS DEMENT, V13, P841, DOI 10.1016/j.jalz.2017.06.2266; Palmqvist S, 2021, NAT MED, V27, P1034, DOI 10.1038/s41591-021-01348-z; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Palmqvist S, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201911170; Palmqvist S, 2019, JAMA NEUROL, V76, P1060, DOI 10.1001/jamaneurol.2019.1632; Palmqvist S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01150-x; Palmqvist S, 2016, BRAIN, V139, P1226, DOI 10.1093/brain/aww015; Parnetti L, 2019, LANCET NEUROL, V18, P573, DOI 10.1016/S1474-4422(19)30024-9; Pascoal TA, 2020, BRAIN, V143, P2818, DOI 10.1093/brain/awaa180; Peng C, 2020, NAT REV NEUROL, V16, P199, DOI 10.1038/s41582-020-0333-7; Petersen RC, 2011, NEW ENGL J MED, V364, P2227, DOI 10.1056/NEJMcp0910237; Pontecorvo MJ, 2020, EJNMMI RES, V10, DOI 10.1186/s13550-020-00653-x; Pontecorvo MJ, 2019, BRAIN, V142, P1723, DOI 10.1093/brain/awz090; Portelius E, 2018, ACTA NEUROPATHOL, V136, P363, DOI 10.1007/s00401-018-1851-x; Portelius E, 2015, BRAIN, V138, DOI 10.1093/brain/awv267; Power MC, 2018, ANN NEUROL, V84, P10, DOI 10.1002/ana.25246; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Prince M, 2015, WORLD ALZHEIMER REPO; Rabinovici GD, 2019, JAMA-J AM MED ASSOC, V321, P1286, DOI 10.1001/jama.2019.2000; Reimand J, 2020, NEUROLOGY, V95, pE2648, DOI 10.1212/WNL.0000000000010739; Respondek G, 2020, MOVEMENT DISORD, V35, P171, DOI 10.1002/mds.27872; Rizzo G, 2018, J NEUROL NEUROSUR PS, V89, P358, DOI 10.1136/jnnp-2017-316844; Rizzo G, 2016, NEUROLOGY, V86, P566, DOI 10.1212/WNL.0000000000002350; Rossi M, 2020, ACTA NEUROPATHOL, V140, P49, DOI 10.1007/s00401-020-02160-8; Sabri O, 2015, ALZHEIMERS DEMENT, V11, P964, DOI 10.1016/j.jalz.2015.02.004; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Sanchez JS, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc0655; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Savva GM, 2009, NEW ENGL J MED, V360, P2302, DOI 10.1056/NEJMoa0806142; Scheres SHW, 2020, CURR OPIN STRUC BIOL, V64, P17, DOI 10.1016/j.sbi.2020.05.011; Schindler SE, 2019, NEUROLOGY, V93, pE1647, DOI 10.1212/WNL.0000000000008081; Scholl M, 2019, MOL CELL NEUROSCI, V97, P18, DOI 10.1016/j.mcn.2018.12.001; Seshadri S, 2007, LANCET NEUROL, V6, P1106, DOI 10.1016/S1474-4422(07)70291-0; Sevigny J, 2016, ALZ DIS ASSOC DIS, V30, P1, DOI 10.1097/WAD.0000000000000144; Shahnawaz M, 2020, NATURE, V578, P273, DOI 10.1038/s41586-020-1984-7; Shaw LM, 2018, ALZHEIMERS DEMENT, V14, P1505, DOI 10.1016/j.jalz.2018.07.220; Sierksma A, 2020, SCIENCE, V370, P61, DOI 10.1126/science.abb8575; Singer W, 2020, ANN NEUROL, V88, P503, DOI 10.1002/ana.25824; Smedinga M, 2021, J NEUROL, V268, P724, DOI 10.1007/s00415-020-10162-5; Smith R, 2020, BRAIN, V143, P3805, DOI 10.1093/brain/awaa327; Smith R, 2019, JAMA NEUROL, V76, P310, DOI 10.1001/jamaneurol.2018.3692; Soleimani-Meigooni DN, 2020, BRAIN, V143, P3477, DOI 10.1093/brain/awaa276; Sperling RA, 2019, ANN NEUROL, V85, P181, DOI 10.1002/ana.25395; Spillantini MG, 2018, CELL TISSUE RES, V373, P137, DOI 10.1007/s00441-017-2706-9; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; Tornquist M, 2018, CHEM COMMUN, V54, P8667, DOI 10.1039/c8cc02204f; Verberk IMW, 2021, LANCET HEALTH LONGEV, V2, pE87, DOI 10.1016/S2666-7568(20)30061-1; Verberk IMW, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00682-7; Verberk IMW, 2018, ANN NEUROL, V84, P648, DOI 10.1002/ana.25334; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; VOGEL J, 2020, NAT COMMUN, V11; Vogel JW, 2021, NAT MED, V27, P871, DOI 10.1038/s41591-021-01309-6; Walker Z, 2015, LANCET, V386, P1683, DOI 10.1016/S0140-6736(15)00462-6; Wang Z., 2020, JAMA NEUROL, V78, P1; Wesseling H, 2020, CELL, V183, P1699, DOI 10.1016/j.cell.2020.10.029; Wolk DA, 2018, JAMA NEUROL, V75, P1114, DOI 10.1001/jamaneurol.2018.0894	148	110	108	51	133	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2021	27	6					954	963		10.1038/s41591-021-01382-x	http://dx.doi.org/10.1038/s41591-021-01382-x		JUN 2021	10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SS8QE	34083813				2022-12-27	WOS:000657623700001
J	Powles, T; Carroll, D; Chowdhury, S; Gravis, G; Joly, F; Carles, J; Flechon, A; Maroto, P; Petrylak, D; Rolland, F; Cook, N; Balar, AV; Sridhar, SS; Galsky, MD; Grivas, P; Ravaud, A; Jones, R; Cosaert, J; Hodgson, D; Kozarewa, I; Mather, R; McEwen, R; Mercier, F; Landers, D				Powles, Thomas; Carroll, Danielle; Chowdhury, Simon; Gravis, Gwenaelle; Joly, Florence; Carles, Joan; Flechon, Aude; Maroto, Pablo; Petrylak, Daniel; Rolland, Frederic; Cook, Natalie; Balar, Arjun V.; Sridhar, Srikala S.; Galsky, Matthew D.; Grivas, Petros; Ravaud, Alain; Jones, Robert; Cosaert, Jan; Hodgson, Darren; Kozarewa, Iwanka; Mather, Richard; McEwen, Robert; Mercier, Florence; Landers, Donal			An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer	NATURE MEDICINE			English	Article							BLADDER-CANCER; OPEN-LABEL; PHASE-II; CARCINOMA; MULTICENTER; MANAGEMENT; SURVIVAL	Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC)(1). AUC is characterized by several recurrent targetable genomic alterations(2-5). This study (, BISCAY) combined durvalumab with relevant targeted therapies in biomarker-selected chemotherapy-refractory AUC populations including: (1) fibroblast growth factor receptor (FGFR) inhibitors in tumors with FGFR DNA alterations (FGFRm); (2) pharmacological inhibitor of the enzyme poly-ADP ribose polymerase (PARP) in tumors with and without DNA homologous recombination repair deficiency (HRRm); and (3) TORC1/2 inhibitors in tumors with DNA alteration to the mTOR/PI3K pathway(3-5).This trial adopted a new, biomarker-driven, multiarm adaptive design. Safety, efficacy and relevant biomarkers were evaluated. Overall, 391 patients were screened of whom 135 were allocated to one of six study arms. Response rates (RRs) ranged 9-36% across the study arms, which did not meet efficacy criteria for further development. Overall survival (OS) and progression-free survival (PFS) were similar in the combination arms and durvalumab monotherapy arm. Biomarker analysis showed a correlation between circulating plasma-based DNA (ctDNA) and tissue for FGFRm. Sequential circulating tumor DNA analysis showed that changes to FGFRm correlated with clinical outcome. Our data support the clinical activity of FGFR inhibition and durvalumab monotherapy but do not show increased activity for any of the combinations. These findings question the targeted/immune therapy approach in AUC.	[Powles, Thomas] Barts Canc Ctr, Barts Canc Inst, QMUL, London, England; [Carroll, Danielle; Hodgson, Darren; Kozarewa, Iwanka; McEwen, Robert] AstraZeneca IMED Biotech Unit, Cambridge, England; [Chowdhury, Simon] Guys & St Thomas Hosp, London, England; [Gravis, Gwenaelle] Inst Paoli Calmettes, Marseille, France; [Joly, Florence] Ctr Leon Berard, UNICANC, Lyon, France; [Carles, Joan] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Flechon, Aude] Ctr Leon Berard, Lyon, France; [Maroto, Pablo] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Petrylak, Daniel] Yale Sch Med, New Haven, CT USA; [Rolland, Frederic] Inst Cancerol Ouest, St Herblain, France; [Cook, Natalie] Christie NHS Fdn Trust, Manchester, Lancs, England; [Cook, Natalie] Univ Manchester, Manchester, Lancs, England; [Balar, Arjun V.] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA; [Sridhar, Srikala S.] Princess Margaret Hosp, Toronto, ON, Canada; [Galsky, Matthew D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Grivas, Petros] Univ Washington, Seattle, WA 98195 USA; [Ravaud, Alain] Bordeaux Univ Hosp, Bordeaux, France; [Jones, Robert] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Cosaert, Jan; Mather, Richard; Mercier, Florence] AstraZeneca Oncol R&D, Res & Early Dev, Cambridge, England; [Landers, Donal] CRUK Manchester Inst Canc Biomarker Ctr, Manchester, Lancs, England	University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Leon Berard; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); UNICANCER; Centre Leon Berard; Hospital of Santa Creu i Sant Pau; Yale University; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Christie NHS Foundation Trust; University of Manchester; NYU Langone Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle; CHU Bordeaux; Beatson Oncology Centre; University of Glasgow	Powles, T (corresponding author), Barts Canc Ctr, Barts Canc Inst, QMUL, London, England.	Thomas.Powles@bartshealth.nhs.uk	Gravis, Gwenaelle/CAG-3019-2022	Gravis, Gwenaelle/0000-0002-3127-1554; Powles, Thomas/0000-0001-7760-4724; ROLLAND, FREDERIC/0000-0001-6957-0894; Landers, Donal/0000-0001-8376-9779; Balar, Arjun/0000-0003-3949-5656	NIHR Manchester Clinical Research Facility; Manchester Experimental Cancer Medicine Centre award; AstraZeneca	NIHR Manchester Clinical Research Facility; Manchester Experimental Cancer Medicine Centre award; AstraZeneca(AstraZeneca)	We thank the patients and their families who gave their time and commitment to participate in this study; the CRUK Experimental Cancer Medicine Centre; and staff and investigators at participating sites, including the following. Canada: M. Sawyer, University of Alberta-Cross Cancer Institute; S. S. Sridhar, Princess Margaret Cancer Centre, Toronto; C. Ferrario, Jewish General Hospital, Montreal. France: A. Flechon, Centre Leon Berard, Lyon; G. Gravis, Institute Paoli-Calmettes, Marseille; F. Joly, Centre Francois Baclesse, Caen; L. Mourey, Institut Claudius Regaud, Toulouse; A. Ravaud, Bordeaux University Hospital; F. Rolland, Institut de Cancerologie de l'Ouest, Saint-Herblain. Spain: J. Carles, Vall D'Hebron Institute of Oncology, Barcelona; J. P. Maroto, Hospital de la Santa Creu i San Pau, Barcelona; J. P. Vasquez, Hospital Clinico San Carlos, Madrid; A. Rodriquez-Vida, IMIM Hospital del Mar Medical Research Instutute, Barcelona. UK: H.-T. Arkenau, Sarah Cannon Research Institute, London; S. Chowdhury, Guys and St Thomas' Medical School, London; N. Cook, The Christie NHS Foundation Trust, Manchester (Research at the Christie NHS Foundation Trust was supported by the NIHR Manchester Clinical Research Facility and Manchester Experimental Cancer Medicine Centre award); S. Crabb, University of Southampton; R. Jones, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow; T. Powles, Barts Cancer Institute, London. USA: A. V. Balar, Perlmutter Cancer Center, NYU Langone Health, New York; J. Bendell, Tennessee Oncology, Nashville; A. Drakaki, Ronald Reagan UCLA Medical Center, Hematology Oncology, Santa Monica; P. Grivas, University of Washington, Seattle; M. Galsky, Icahn School of Medicine at Mount Sinai, New York; N. Hahn, Johns Hopkins University School of Medicine, Baltimore; E. Lim, New York Presbyterian, Columbia University Irving Medical Centre, New York; D. Petrylak, Yale School of Medicine, New Haven; J. Reeves Jr., Florida Cancer Specialists and Research Institute; B. Rini and P. Grivas, Cleveland Clinic, Cleveland; P. Van Veldhuizen, HCA Midwest, Kansas City. We thank the staff at Sarah Cannon Development Innovations and AstraZeneca who supported this clinical study. Medical writing support was provided by S. Hurrell (Bioscript Medical) and was funded by AstraZeneca. We thank A. Reddy (AstraZeneca) for support with data analysis.	[Anonymous], 2019, UPDATE PHASE 3 NEPTU; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2010, J CLIN ONCOL, V28, P1850, DOI 10.1200/JCO.2009.25.4599; Bellmunt J, 2017, CANCER TREAT REV, V54, P58, DOI 10.1016/j.ctrv.2017.01.007; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Christensen E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.18.02052; Friedlander M, 2019, LANCET ONCOL, V20, P1306, DOI 10.1016/S1470-2045(19)30396-1; Garcia JA, 2008, MOL CANCER THER, V7, P1347, DOI 10.1158/1535-7163.MCT-07-2408; Grivas P, 2020, J CLIN ONCOL, V38; Grivas P, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0665-y; Jones RJ, 2017, J CLIN ONCOL, V35, P1770, DOI 10.1200/JCO.2016.70.7828; Kamoun A, 2020, EUR UROL, V77, P420, DOI 10.1016/j.eururo.2019.09.006; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Necchi A, 2018, EUR J CANCER, V96, P128, DOI 10.1016/j.ejca.2018.03.021; Pairawan S, 2020, CLIN CANCER RES, V26, P1924, DOI 10.1158/1078-0432.CCR-19-0306; Powles T, 2019, NAT MED, V25, P1706, DOI 10.1038/s41591-019-0628-7; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Taber A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18640-0; Teo MY, 2017, CLIN CANCER RES, V23, P3610, DOI 10.1158/1078-0432.CCR-16-2520; Vandekerkhove G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20493-6; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Xing PY, 2019, J CELL MOL MED, V23, P6812, DOI 10.1111/jcmm.14565; Zhang Q, 2020, CANCER DISCOV, V10, P1842, DOI 10.1158/2159-8290.CD-20-0047	31	28	28	5	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					793	+		10.1038/s41591-021-01317-6	http://dx.doi.org/10.1038/s41591-021-01317-6		MAY 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33941921	Green Accepted			2022-12-27	WOS:000646516200002
J	Wilkinson, JE; Franzosa, EA; Everett, C; Li, CC; Hu, FB; Wirth, DF; Song, MY; Chan, ANT; Rimm, E; Garrett, WS; Huttenhower, C				Wilkinson, Jeremy E.; Franzosa, Eric A.; Everett, Christine; Li, Chengchen; Hu, Frank B.; Wirth, Dyann F.; Song, Mingyang; Chan, Andrew T.; Rimm, Eric; Garrett, Wendy S.; Huttenhower, Curtis		HCMPH Researchers Trainees; HCMPH Investigators	A framework for microbiome science in public health	NATURE MEDICINE			English	Article							GUT MICROBIOTA; PROBIOTICS; TRANSPLANTATION; ASSOCIATION; BENEFITS; IMMUNITY; VIROME; OMICS; DIET	Microbiome science is fast advancing and its careful integration into public health is detailed in this Perspective. Human microbiome science has advanced rapidly and reached a scale at which basic biology, clinical translation and population health are increasingly integrated. It is thus now possible for public health researchers, practitioners and policymakers to take specific action leveraging current and future microbiome-based opportunities and best practices. Here we provide an outline of considerations for research, education, interpretation and scientific communication concerning the human microbiome and public health. This includes guidelines for population-scale microbiome study design; necessary physical platforms and analysis methods; integration into public health areas such as epidemiology, nutrition, chronic disease, and global and environmental health; entrepreneurship and technology transfer; and educational curricula. Particularly in the near future, there are both opportunities for the incorporation of microbiome-based technologies into public health practice, and a growing need for policymaking and regulation around related areas such as prebiotic and probiotic supplements, novel live-cell therapies and fecal microbiota transplants.	[Wilkinson, Jeremy E.; Franzosa, Eric A.; Everett, Christine; Li, Chengchen; Hu, Frank B.; Wirth, Dyann F.; Song, Mingyang; Chan, Andrew T.; Rimm, Eric; Garrett, Wendy S.; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Harvard Chan Microbiome Publ Hlth Ctr, Boston, MA USA; [Wilkinson, Jeremy E.; Franzosa, Eric A.; Li, Chengchen; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Franzosa, Eric A.; Wirth, Dyann F.; Chan, Andrew T.; Huttenhower, Curtis] Broad Inst, Infect Dis & Microbiome Program, Cambridge, MA USA; [Everett, Christine; Hu, Frank B.; Chan, Andrew T.; Rimm, Eric] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Everett, Christine; Song, Mingyang; Chan, Andrew T.; Rimm, Eric; Garrett, Wendy S.] Harvard Med Sch, Boston, MA 02115 USA; [Hu, Frank B.; Song, Mingyang; Rimm, Eric] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Hu, Frank B.; Song, Mingyang; Rimm, Eric] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Wirth, Dyann F.; Chan, Andrew T.; Garrett, Wendy S.; Huttenhower, Curtis] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA; [Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Mongan Inst, Boston, MA 02114 USA; [Garrett, Wendy S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Garrett, Wendy S.] Harvard TH Chan Sch Publ Hlth, Dept Mol Metab, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health	Garrett, WS; Huttenhower, C (corresponding author), Harvard TH Chan Sch Publ Hlth, Harvard Chan Microbiome Publ Hlth Ctr, Boston, MA USA.; Huttenhower, C (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.; Huttenhower, C (corresponding author), Broad Inst, Infect Dis & Microbiome Program, Cambridge, MA USA.; Garrett, WS (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Garrett, WS; Huttenhower, C (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.; Garrett, WS (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Garrett, WS (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Mol Metab, Boston, MA USA.	wgarrett@hsph.harvard.edu; chuttenh@hsph.harvard.edu	Bjornevik, Kjetil/J-8888-2019; Wang, YA/AAW-5930-2021; Fonseca-Pereira, Diogo/U-1275-2018; Li, Chengchen/GLR-7268-2022; da Fonseca Pereira, Diogo/O-9894-2019; Song, Mingyang/M-6701-2013; Wang, Kai/O-7754-2019; Chan, Andrew/P-8293-2014	Bjornevik, Kjetil/0000-0002-2892-6986; Wang, YA/0000-0001-9985-8039; Fonseca-Pereira, Diogo/0000-0002-7400-9804; Garrett, Wendy/0000-0002-5092-0150; Song, Mingyang/0000-0002-1324-0316; Clay, Slater/0000-0002-1966-892X; Franzosa, Eric/0000-0002-8798-7068; Wang, Kai/0000-0002-5614-5618; Chan, Andrew/0000-0001-7284-6767; Bhosle, Amrisha/0000-0001-8669-4979; Brennan, Caitlin/0000-0002-6074-9502	Harvard Chan School administration; NIH NIDDK [R24DK110499]; Cancer Research UK Grand Challenge Initiative [C10674/A27140]	Harvard Chan School administration; NIH NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Cancer Research UK Grand Challenge Initiative	We thank the Harvard Chan School administration for their support of the Microbiome in Public Health Center. This work was supported in part by NIH NIDDK R24DK110499 (W.S.G. and C.H.) and by the Cancer Research UK Grand Challenge Initiative C10674/A27140 (W.S.G.).	Aagaard K, 2013, FASEB J, V27, P1012, DOI 10.1096/fj.12-220806; Aron-Wisnewsky J, 2020, NAT REV GASTRO HEPAT, V17, P279, DOI 10.1038/s41575-020-0269-9; Attwood GT, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00107; Ballal SA, 2015, P NATL ACAD SCI USA, V112, P7803, DOI 10.1073/pnas.1501897112; Blanton LV, 2016, SCIENCE, V352, DOI 10.1126/science.aad9359; Carmody RN, 2014, J CLIN INVEST, V124, P4173, DOI 10.1172/JCI72335; Chuong KH, 2017, BMC MED ETHICS, V18, DOI 10.1186/s12910-016-0160-y; Claus SP, 2016, NPJ BIOFILMS MICROBI, V2, DOI 10.1038/npjbiofilms.2016.3; Costea PI, 2017, NAT BIOTECHNOL, V35, P1069, DOI 10.1038/nbt.3960; Cryan JF, 2019, PHYSIOL REV, V99, P1877, DOI 10.1152/physrev.00018.2018; DeFilipp Z, 2019, NEW ENGL J MED, V381, P2043, DOI 10.1056/NEJMoa1910437; Donia MS, 2015, SCIENCE, V349, DOI 10.1126/science.1254766; Dreher-Lesnick SM, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD-0017-2017; Drekonja D, 2015, ANN INTERN MED, V162, P630, DOI 10.7326/M14-2693; Everett C., NAT PROTOC; Eyre DW, 2018, NEW ENGL J MED, V379, P1322, DOI 10.1056/NEJMoa1714373; Fahimipour AK, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00200-18; Franzosa EA, 2015, P NATL ACAD SCI USA, V112, pE2930, DOI 10.1073/pnas.1423854112; Franzosa EA, 2015, NAT REV MICROBIOL, V13, P360, DOI 10.1038/nrmicro3451; Garrett WS, 2019, SCIENCE, V364, P1133, DOI 10.1126/science.aaw2367; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Gehrig JL, 2019, SCIENCE, V365, P139, DOI 10.1126/science.aau4732; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gensollen T, 2017, J ALLERGY CLIN IMMUN, V139, P1084, DOI 10.1016/j.jaci.2017.02.011; Georges M, 2019, NAT REV GENET, V20, P135, DOI 10.1038/s41576-018-0082-2; Gibson GR, 2017, NAT REV GASTRO HEPAT, V14, P491, DOI 10.1038/nrgastro.2017.75; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gosmann C, 2017, IMMUNITY, V46, P29, DOI 10.1016/j.immuni.2016.12.013; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Haiser HJ, 2013, SCIENCE, V341, P295, DOI 10.1126/science.1235872; Hendriksen RS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08853-3; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Hsu BB, 2019, CELL HOST MICROBE, V25, P803, DOI 10.1016/j.chom.2019.05.001; Kelly BJ, 2015, BIOINFORMATICS, V31, P2461, DOI 10.1093/bioinformatics/btv183; Kelly CR, 2017, GASTROENTEROLOGY, V152, P681, DOI 10.1053/j.gastro.2017.01.028; Khoruts A, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0592-8; Kim S, 2018, GERONTOLOGY, V64, P513, DOI 10.1159/000490615; Kolodziejczyk AA, 2019, NAT REV MICROBIOL, V17, P742, DOI 10.1038/s41579-019-0256-8; Krismer B, 2017, NAT REV MICROBIOL, V15, P675, DOI 10.1038/nrmicro.2017.104; Lam KN, 2019, CELL HOST MICROBE, V26, P22, DOI 10.1016/j.chom.2019.06.011; Libertucci J, 2019, NAT MICROBIOL, V4, P35, DOI 10.1038/s41564-018-0278-4; Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9; Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889; Lloyd-Price J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0307-y; Maier L, 2018, NATURE, V555, P623, DOI 10.1038/nature25979; Mallick H, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1359-z; Marco ML, 2017, CURR OPIN BIOTECH, V44, P94, DOI 10.1016/j.copbio.2016.11.010; Markey KA, 2020, BLOOD, V136, P130, DOI 10.1182/blood.2019003369; McNulty NP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002701; Meadow JF, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-7; Mukherjee D, 2020, TRENDS PARASITOL, V36, P11, DOI 10.1016/j.pt.2019.11.001; National Academies of Sciences Engineering and Medicine Environmental Chemicals, 2018, HUM MICR HLTH RISK R; Negatu DA, 2019, MBIO, V10, DOI 10.1128/mBio.02781-18; Norman JM, 2015, CELL, V160, P447, DOI 10.1016/j.cell.2015.01.002; Ossorio PN, 2019, GUT MICROBES, V10, P105, DOI 10.1080/19490976.2018.1502537; Pasolli E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004977; Sinha R, 2017, NAT BIOTECHNOL, V35, P1077, DOI 10.1038/nbt.3981; Song SJ, 2016, MSYSTEMS, V1, DOI 10.1128/mSystems.00021-16; Suez J, 2018, CELL, V174, P1406, DOI 10.1016/j.cell.2018.08.047; Sze MA, 2016, MBIO, V7, DOI 10.1128/mBio.01018-16; Thomas AM, 2019, NAT MED, V25, P667, DOI 10.1038/s41591-019-0405-7; Turnbaugh PJ, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00154-17; Vehik K, 2019, NAT MED, V25, P1865, DOI 10.1038/s41591-019-0667-0; Wang DD, 2021, NAT MED, V27, P333, DOI 10.1038/s41591-020-01223-3; Wang YH, 2014, APPL MICROBIOL BIOT, V98, P411, DOI 10.1007/s00253-013-5394-8; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369	66	22	22	5	21	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					766	774		10.1038/s41591-021-01258-0	http://dx.doi.org/10.1038/s41591-021-01258-0		APR 2021	9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33820996				2022-12-27	WOS:000636931100001
J	Huang, N; Perez, P; Kato, T; Mikami, Y; Okuda, K; Gilmore, RC; Conde, CD; Gasmi, B; Stein, S; Beach, M; Pelayo, E; Maldonado, JO; Lafont, BA; Jang, SI; Nasir, N; Padilla, RJ; Murrah, VA; Maile, R; Lovell, W; Wallet, SM; Bowman, NM; Meinig, SL; Wolfgang, MC; Choudhury, SN; Novotny, M; Aevermann, BD; Scheuermann, RH; Cannon, G; Anderson, CW; Lee, RNE; Marchesan, JT; Bush, M; Freire, M; Kimple, AJ; Herr, DL; Rabin, J; Grazioli, A; Das, S; French, BN; Pranzatelli, T; Chiorini, JA; Kleiner, DE; Pittaluga, S; Hewitt, SM; Burbelo, PD; Chertow, D; Frank, K; Lee, J; Boucher, RC; Teichmann, SA; Warner, BM; Byrd, KM				Huang, Ni; Perez, Paola; Kato, Takafumi; Mikami, Yu; Okuda, Kenichi; Gilmore, Rodney C.; Conde, Cecilia Dominguez; Gasmi, Billel; Stein, Sydney; Beach, Margaret; Pelayo, Eileen; Maldonado, Jose O.; Lafont, Bernard A.; Jang, Shyh-Ing; Nasir, Nadia; Padilla, Ricardo J.; Murrah, Valerie A.; Maile, Robert; Lovell, William; Wallet, Shannon M.; Bowman, Natalie M.; Meinig, Suzanne L.; Wolfgang, Matthew C.; Choudhury, Saibyasachi N.; Novotny, Mark; Aevermann, Brian D.; Scheuermann, Richard H.; Cannon, Gabrielle; Anderson, Carlton W.; Lee, Rhianna E.; Marchesan, Julie T.; Bush, Mandy; Freire, Marcelo; Kimple, Adam J.; Herr, Daniel L.; Rabin, Joseph; Grazioli, Alison; Das, Sanchita; French, Benjamin N.; Pranzatelli, Thomas; Chiorini, John A.; Kleiner, David E.; Pittaluga, Stefania; Hewitt, Stephen M.; Burbelo, Peter D.; Chertow, Daniel; Frank, Karen; Lee, Janice; Boucher, Richard C.; Teichmann, Sarah A.; Warner, Blake M.; Byrd, Kevin M.		NIH COVID-19 Autopsy Consortium; HCA Oral Craniofacial Biol Network	SARS-CoV-2 infection of the oral cavity and saliva	NATURE MEDICINE			English	Article							EXPERIMENTAL GINGIVITIS; EXPRESSION; CELLS	Single-cell transcriptomics and protein expression analyses of salivary glands and gingiva, along with the detection of infectious virus and virus-specific antibodies in saliva from SARS-CoV-2-infected individuals, support a potential role for the oral cavity in COVID-19 pathogenesis. Despite signs of infection-including taste loss, dry mouth and mucosal lesions such as ulcerations, enanthema and macules-the involvement of the oral cavity in coronavirus disease 2019 (COVID-19) is poorly understood. To address this, we generated and analyzed two single-cell RNA sequencing datasets of the human minor salivary glands and gingiva (9 samples, 13,824 cells), identifying 50 cell clusters. Using integrated cell normalization and annotation, we classified 34 unique cell subpopulations between glands and gingiva. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral entry factors such as ACE2 and TMPRSS members were broadly enriched in epithelial cells of the glands and oral mucosae. Using orthogonal RNA and protein expression assessments, we confirmed SARS-CoV-2 infection in the glands and mucosae. Saliva from SARS-CoV-2-infected individuals harbored epithelial cells exhibiting ACE2 and TMPRSS expression and sustained SARS-CoV-2 infection. Acellular and cellular salivary fractions from asymptomatic individuals were found to transmit SARS-CoV-2 ex vivo. Matched nasopharyngeal and saliva samples displayed distinct viral shedding dynamics, and salivary viral burden correlated with COVID-19 symptoms, including taste loss. Upon recovery, this asymptomatic cohort exhibited sustained salivary IgG antibodies against SARS-CoV-2. Collectively, these data show that the oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission.	[Huang, Ni; Conde, Cecilia Dominguez; Teichmann, Sarah A.] Wellcome Genome Campus, Wellcome Sanger Inst, Cambridge, England; [Perez, Paola; Gasmi, Billel; Beach, Margaret; Pelayo, Eileen; Maldonado, Jose O.; Jang, Shyh-Ing; Warner, Blake M.] Natl Inst Dent & Craniofacial Res, Salivary Disorders Unit, NIH, Bethesda, MD 20892 USA; [Kato, Takafumi; Mikami, Yu; Okuda, Kenichi; Gilmore, Rodney C.; Meinig, Suzanne L.; Wolfgang, Matthew C.; Lee, Rhianna E.; Kimple, Adam J.; Boucher, Richard C.] Univ N Carolina, Marsico Lung Inst, Chapel Hill, NC 27515 USA; [Gasmi, Billel; Nasir, Nadia; Kleiner, David E.; Pittaluga, Stefania; Hewitt, Stephen M.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Stein, Sydney; Chertow, Daniel] NIH, Emerging Pathogens Sect, Dept Crit Care Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Maldonado, Jose O.; French, Benjamin N.; Pranzatelli, Thomas; Chiorini, John A.; Burbelo, Peter D.] Natl Inst Dent & Craniofacial Res, AAV Biol Sect, NIH, Bethesda, MD USA; [Lafont, Bernard A.] NIAID, SARS CoV 2 Virol Core, Viral Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Padilla, Ricardo J.; Murrah, Valerie A.] Univ N Carolina, Div Diagnost Sci, Adams Sch Dent, Chapel Hill, NC 27515 USA; [Maile, Robert; Wallet, Shannon M.; Wolfgang, Matthew C.] Univ N Carolina, Sch Hlth Sci, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA; [Maile, Robert] Univ N Carolina, Dept Surg, Chapel Hill, NC 27515 USA; [Lovell, William; Wallet, Shannon M.; Byrd, Kevin M.] Univ N Carolina, Adams Sch Dent, Div Oral & Craniofacial Hlth Sci, Chapel Hill, NC 27515 USA; [Bowman, Natalie M.] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA; [Choudhury, Saibyasachi N.; Freire, Marcelo] J Craig Venter Inst, Dept Genom Med & Infect Dis, La Jolla, CA USA; [Novotny, Mark; Aevermann, Brian D.; Freire, Marcelo] J Craig Venter Inst, Dept Infect Dis, La Jolla, CA USA; [Scheuermann, Richard H.] J Craig Venter Inst, Dept Informat, La Jolla, CA USA; [Scheuermann, Richard H.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Cannon, Gabrielle; Anderson, Carlton W.] Univ N Carolina, Sch Med, Adv Analyt Core, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27515 USA; [Lee, Rhianna E.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27515 USA; [Marchesan, Julie T.; Bush, Mandy] Univ N Carolina, Adams Sch Dent, Div Comprehens Oral Hlth, Chapel Hill, NC 27515 USA; [Kimple, Adam J.] Univ N Carolina, Sch Med, Dept Otolaryngol Head & Neck Surg, Chapel Hill, NC 27515 USA; [Herr, Daniel L.] Univ Maryland, Sch Med, Dept Shock Trauma Crit Care, Baltimore, MD 21201 USA; [Rabin, Joseph] Univ Maryland, Sch Med, Dept Surg, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Grazioli, Alison] Natl Inst Diabet & Digest & Kidney Dis, Kidney Dis Branch, NIH, Bethesda, MD USA; [Das, Sanchita; Frank, Karen] NIH, Div Microbiol, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Lee, Janice] Natl Inst Dent & Craniofacial Res, Craniofacial Anomalies & Regenerat Sect, NIH, Bethesda, MD USA; [Teichmann, Sarah A.] Cavendish Lab, Dept Phys, Cambridge, England; [Byrd, Kevin M.] ADA Sci & Res Inst, Dept Innovat & Technol Res, Gaithersburg, MD 20899 USA	Wellcome Trust Sanger Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Cambridge	Warner, BM (corresponding author), Natl Inst Dent & Craniofacial Res, Salivary Disorders Unit, NIH, Bethesda, MD 20892 USA.; Byrd, KM (corresponding author), Univ N Carolina, Adams Sch Dent, Div Oral & Craniofacial Hlth Sci, Chapel Hill, NC 27515 USA.; Byrd, KM (corresponding author), ADA Sci & Res Inst, Dept Innovat & Technol Res, Gaithersburg, MD 20899 USA.	blake.warner@nih.gov; kevinmbyrd@gmail.com	Freire, Marcelo/AAQ-7519-2020; , Advanced Analytics Core/AAE-5263-2022; Lafont, Bernard A. P./B-7236-2014; Dominguez Conde, Cecilia/U-4890-2017	Freire, Marcelo/0000-0003-4906-7698; Lafont, Bernard A. P./0000-0003-2140-6205; Ramos-Benitez, Marcos J./0000-0001-9445-3294; Kimple, Adam/0000-0003-1670-8401; Sequeira, Ines/0000-0003-3342-665X; Maile, Robert/0000-0002-9126-4188; Okuda, Kenichi/0000-0001-9341-2730; Babyak, Ashley/0000-0002-2399-5122; Dominguez Conde, Cecilia/0000-0002-8684-4655; Pranzatelli, Thomas/0000-0002-5763-1036; MIKAMI, YU/0000-0003-3262-2958; Kato, Takafumi/0000-0003-2248-3376; Smith, Grace/0000-0001-6381-0391; Perez Valencia, Luis/0000-0001-8967-4869; Stein, Sydney/0000-0002-0259-4485; Byrd, DDS, Ph.D., Dr. Kevin Matthew/0000-0002-5565-0524; Wu, Jocelyn/0000-0001-7122-494X				Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; dos Santos JA, 2021, J DENT RES, V100, P141, DOI 10.1177/0022034520957289; Arrieta JJ, 2001, AM J PATHOL, V158, P259, DOI 10.1016/S0002-9440(10)63964-8; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801; Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273; Byrd KM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620124; Byrd KM, 2019, CELL STEM CELL, V25, P814, DOI 10.1016/j.stem.2019.11.005; Byrd KM, 2016, DEVELOPMENT, V143, P2803, DOI 10.1242/dev.136010; Caetano AJ, 2021, ELIFE, V10, DOI 10.7554/eLife.62810; Chen LL, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12923; Ching KH, 2011, J DENT RES, V90, P445, DOI 10.1177/0022034510390811; Choudhury S. N., 2020, PROTOCOL REVEALING N, DOI 10.21203/rs.3.pex-953/v1; Dawes C, 2003, ARCH ORAL BIOL, V48, P329, DOI 10.1016/S0003-9969(03)00014-1; Dutzan N, 2016, MUCOSAL IMMUNOL, V9, P1163, DOI 10.1038/mi.2015.136; Fergusson JR, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02902; Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758; Ghinai I, 2020, LANCET, V395, P1137, DOI 10.1016/S0140-6736(20)30607-3; Hamner L, 2020, MMWR-MORBID MORTAL W, V69, P606, DOI 10.15585/mmwr.mm6919e6; Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Hviid A, 2008, LANCET, V371, P932, DOI 10.1016/S0140-6736(08)60419-5; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Jimenez-Cauhe J, 2020, JAMA DERMATOL, V156, P1134, DOI 10.1001/jamadermatol.2020.2550; Jones KB, 2019, CELL STEM CELL, V24, P183, DOI 10.1016/j.stem.2018.10.015; Jones KB, 2013, INT J ORAL SCI, V5, P121, DOI 10.1038/ijos.2013.46; Karlsson AC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe8063; Kitamoto S, 2020, CELL, V182, P447, DOI 10.1016/j.cell.2020.05.048; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Krivanek J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18512-7; La Rosa GRM, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.571214; LAMSTER IB, 1982, J PERIODONTOL, V53, P231, DOI 10.1902/jop.1982.53.4.231; Loe H, 1967, J Periodontol, V38; LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177; MacNeil AJ, 2011, J IMMUNOL, V187, P3374, DOI 10.4049/jimmunol.1003126; Moutsopoulos NM, 2018, TRENDS IMMUNOL, V39, P276, DOI 10.1016/j.it.2017.08.005; Muhlebach MS, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006798; Muus C, 2020, INTEGRATED ANAL SING, DOI [10.1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254, 10.1101/2020.04.19.049254v1]; Nakamura H, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0773-1; Offenbacher S, 2009, J PERIODONTOL, V80, P1963, DOI 10.1902/jop.2009.080645; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Polanski K, 2020, BIOINFORMATICS, V36, P964, DOI 10.1093/bioinformatics/btz625; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Pung R, 2020, LANCET, V395, P1039, DOI 10.1016/S0140-6736(20)30528-6; Schurink B, 2020, LANCET MICROBE, V1, pE290, DOI 10.1016/S2666-5247(20)30144-0; Silva Julio, 2021, medRxiv, DOI 10.1101/2021.01.04.21249236; Singh M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108175; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; Song L, 2018, MOL ORAL MICROBIOL, V33, P13, DOI 10.1111/omi.12195; SPEIGHT PM, 1989, J ORAL PATHOL MED, V18, P178, DOI 10.1111/j.1600-0714.1989.tb00758.x; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Theda C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25311-0; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Wyllie AL, 2020, NEW ENGL J MED, V383, P1283, DOI 10.1056/NEJMc2016359; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zemmour D, 2018, NAT IMMUNOL, V19, P291, DOI 10.1038/s41590-018-0051-0; Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117; Zhong M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.580796; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	61	246	249	15	59	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					892	+		10.1038/s41591-021-01296-8	http://dx.doi.org/10.1038/s41591-021-01296-8		MAR 2021	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33767405	Bronze, Green Accepted			2022-12-27	WOS:000632770500001
J	Da Via, MC; Dietrich, O; Truger, M; Arampatzi, P; Duell, J; Heidemeier, A; Zhou, X; Danhof, S; Kraus, S; Chatterjee, M; Meggendorfer, M; Twardziok, S; Goebeler, ME; Topp, MS; Hudecek, M; Prommersberger, S; Hege, K; Kaiser, S; Fuhr, V; Weinhold, N; Rosenwald, A; Erhard, F; Haferlach, C; Einsele, H; Kortum, KM; Saliba, AE; Rasche, L				Da Via, Matteo C.; Dietrich, Oliver; Truger, Marietta; Arampatzi, Panagiota; Duell, Johannes; Heidemeier, Anke; Zhou, Xiang; Danhof, Sophia; Kraus, Sabrina; Chatterjee, Manik; Meggendorfer, Manja; Twardziok, Sven; Goebeler, Maria-Elisabeth; Topp, Max S.; Hudecek, Michael; Prommersberger, Sabrina; Hege, Kristen; Kaiser, Shari; Fuhr, Viktoria; Weinhold, Niels; Rosenwald, Andreas; Erhard, Florian; Haferlach, Claudia; Einsele, Hermann; Kortuem, K. Martin; Saliba, Antoine-Emmanuel; Rasche, Leo			Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma	NATURE MEDICINE			English	Article								B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial (NCT03361748) and progressed after anti-BCMA CAR T cell therapy. We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.	[Da Via, Matteo C.; Duell, Johannes; Zhou, Xiang; Danhof, Sophia; Kraus, Sabrina; Chatterjee, Manik; Goebeler, Maria-Elisabeth; Topp, Max S.; Hudecek, Michael; Prommersberger, Sabrina; Einsele, Hermann; Kortuem, K. Martin; Rasche, Leo] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany; [Dietrich, Oliver; Saliba, Antoine-Emmanuel] Helmholtz Ctr Infect Res, Helmholtz Inst RNA Based Infect Res, Wurzburg, Germany; [Truger, Marietta; Meggendorfer, Manja; Twardziok, Sven; Haferlach, Claudia] Munich Leukemia Lab, Munich, Germany; [Arampatzi, Panagiota] Univ Wurzburg, Core Unit Syst Med, Wurzburg, Germany; [Heidemeier, Anke] Univ Hosp Wurzburg, Dept Radiol, Wurzburg, Germany; [Hege, Kristen; Kaiser, Shari] Bristol Myers Squibb, San Francisco, CA USA; [Fuhr, Viktoria; Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Weinhold, Niels] Univ Hosp Heidelberg, Med Klin 5, Heidelberg, Germany; [Erhard, Florian] Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany; [Rasche, Leo] Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center for Infection Research; MLL Munich Leukemia Laboratory; University of Wurzburg; University of Wurzburg; Bristol-Myers Squibb; University of Wurzburg; Ruprecht Karls University Heidelberg; University of Wurzburg; University of Wurzburg	Rasche, L (corresponding author), Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany.; Rasche, L (corresponding author), Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany.	Rasche_L@ukw.de	Danhof, Sophia/AAS-7268-2021; da via, matteo claudio/AAE-3897-2019; Saliba, Antoine-Emmanuel/AAC-1252-2022	da via, matteo claudio/0000-0002-5396-6584; Twardziok, Sven/0000-0002-0326-5704; Kortum, K. Martin/0000-0002-7011-0286; Danhof, Sophia/0000-0003-1316-0241; ARAMPATZI, PANAGIOTA/0000-0001-7925-8984; Kraus, Sabrina/0000-0001-8954-4220; Saliba, Antoine-Emmanuel/0000-0001-8539-2784	German Cancer Aid via the MSNZ program; IZKF Wurzburg; DFG [SFB/TR 221 project A3]; German Research Society graduate college [2157]	German Cancer Aid via the MSNZ program; IZKF Wurzburg; DFG(German Research Foundation (DFG)); German Research Society graduate college	We thank S. Roth for her excellent technical support. We acknowledge the work and contribution of T. Mack from Bristol Myers Squibb. L.R. was supported by the German Cancer Aid via the MSNZ program and IZKF Wurzburg. H.E and M.H. were supported by the DFG via SFB/TR 221 project A3. A.-E.S. and O.D. were supported by the German Research Society graduate college 2157. Bristol Myers Squibb provided clinical trial data related to the presented case but no financial support for the study.	Bannerji R, 2019, BLOOD, V134, DOI 10.1182/blood-2019-122451; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Casucci M, 2013, BLOOD, V122, P3461, DOI 10.1182/blood-2013-04-493361; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; Cheng JQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01355-0; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; de Larrea CF, 2020, BLOOD CANCER DISCOV, V1, P146, DOI 10.1158/2643-3230.BCD-20-0020; Erhard F, 2018, BIOINFORMATICS, V34, P4054, DOI 10.1093/bioinformatics/bty471; Garfall AL, 2019, NATURE, V575, P450, DOI 10.1038/d41586-019-03495-3; Gogishvili T, 2017, BLOOD, V130, P2838, DOI 10.1182/blood-2017-04-778423; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Kowalczyk MS, 2015, GENOME RES, V25, P1860, DOI 10.1101/gr.192237.115; Martin, 2020, HEMASPHERE, DOI [10.1097/HS9.0000000000000404, DOI 10.1097/HS9.0000000000000404]; McInnes L., 2018, J OPEN SOURCE SOFTW, V3, P861, DOI [DOI 10.21105/JOSS.00861, 10.21105/joss.00861]; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Orlando EJ, 2018, NAT MED, V24, P1504, DOI 10.1038/s41591-018-0146-z; Paul MR, 2019, J PEDIAT HEMATOL ONC, V41, pE546, DOI 10.1097/MPH.0000000000001440; Pillarisetti K, 2020, BLOOD, V135, P1232, DOI 10.1182/blood.2019003342; Raczy C, 2013, BIOINFORMATICS, V29, P2041, DOI 10.1093/bioinformatics/btt314; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Rasche L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00296-y; Rustad EH, 2020, BLOOD CANCER DISCOV, V1, P258, DOI 10.1158/2643-3230.BCD-20-0132; Sawyer JR, 2017, LEUKEMIA, V31, P637, DOI 10.1038/leu.2016.253; Shah N, 2020, LEUKEMIA, V34, P985, DOI 10.1038/s41375-020-0734-z; Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood-2016-01-691162; Waltman L, 2013, EUR PHYS J B, V86, DOI 10.1140/epjb/e2013-40829-0; Weinhold N, 2016, BLOOD, V128, P1735, DOI 10.1182/blood-2016-06-723007	28	54	54	4	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01245-5	http://dx.doi.org/10.1038/s41591-021-01245-5		FEB 2021	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33619368				2022-12-27	WOS:000620458400001
J	Stower, H				Stower, Hannah			Early cancer detection	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12					1804	1804		10.1038/s41591-020-01148-x	http://dx.doi.org/10.1038/s41591-020-01148-x			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33288933				2022-12-27	WOS:000596579200003
J	Killingley, B; Mann, AJ; Kalinova, M; Boyers, A; Goonawardane, N; Zhou, J; Lindsell, K; Hare, SS; Brown, J; Frise, R; Smith, E; Hopkins, C; Noulin, N; Londt, B; Wilkinson, T; Harden, S; McShane, H; Baillet, M; Gilbert, A; Jacobs, M; Charman, C; Mande, P; Nguyen-Van-Tam, JS; Semple, MG; Read, RC; Ferguson, NM; Openshaw, PJ; Rapeport, G; Barclay, WS; Catchpole, AP; Chiu, C				Killingley, Ben; Mann, Alex J.; Kalinova, Mariya; Boyers, Alison; Goonawardane, Niluka; Zhou, Jie; Lindsell, Kate; Hare, Samanjit S.; Brown, Jonathan; Frise, Rebecca; Smith, Emma; Hopkins, Claire; Noulin, Nicolas; Londt, Brandon; Wilkinson, Tom; Harden, Stephen; McShane, Helen; Baillet, Mark; Gilbert, Anthony; Jacobs, Michael; Charman, Christine; Mande, Priya; Nguyen-Van-Tam, Jonathan S.; Semple, Malcolm G.; Read, Robert C.; Ferguson, Neil M.; Openshaw, Peter J.; Rapeport, Garth; Barclay, Wendy S.; Catchpole, Andrew P.; Chiu, Christopher			Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	NATURE MEDICINE			English	Article							LOAD; INFECTION; INFLUENZA; COVID-19; DISEASE; MODEL	Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of cases and continues to circulate globally. To establish a novel SARS-CoV-2 human challenge model that enables controlled investigation of pathogenesis, correlates of protection and efficacy testing of forthcoming interventions, 36 volunteers aged 18-29 years without evidence of previous infection or vaccination were inoculated with 10 TCID50 of a wild-type virus (SARS-CoV-2/human/GBR/484861/2020) intranasally in an open-label, non-randomized study (ClinicalTrials.gov identifier NCT04865237; funder, UK Vaccine Taskforce). After inoculation, participants were housed in a high-containment quarantine unit, with 24-hour close medical monitoring and full access to higher-level clinical care. The study's primary objective was to identify an inoculum dose that induced well-tolerated infection in more than 50% of participants, with secondary objectives to assess virus and symptom kinetics during infection. All pre-specified primary and secondary objectives were met. Two participants were excluded from the per-protocol analysis owing to seroconversion between screening and inoculation, identified post hoc. Eighteen (similar to 53%) participants became infected, with viral load (VL) rising steeply and peaking at similar to 5 days after inoculation. Virus was first detected in the throat but rose to significantly higher levels in the nose, peaking at similar to 8.87 log(10) copies per milliliter (median, 95% confidence interval (8.41, 9.53)). Viable virus was recoverable from the nose up to similar to 10 days after inoculation, on average. There were no serious adverse events. Mild-to-moderate symptoms were reported by 16 (89%) infected participants, beginning 2-4 days after inoculation, whereas two (11%) participants remained asymptomatic (no reportable symptoms). Anosmia or dysosmia developed more slowly in 15 (83%) participants. No quantitative correlation was noted between VL and symptoms, with high VLs present even in asymptomatic infection. All infected individuals developed serum spike-specific IgG and neutralizing antibodies. Results from lateral flow tests were strongly associated with viable virus, and modeling showed that twice-weekly rapid antigen tests could diagnose infection before 70-80% of viable virus had been generated. Thus, with detailed characterization and safety analysis of this first SARS-CoV-2 human challenge study in young adults, viral kinetics over the course of primary infection with SARS-CoV-2 were established, with implications for public health recommendations and strategies to affect SARS-CoV-2 transmission. Future studies will identify the immune factors associated with protection in those participants who did not develop infection or symptoms and define the effect of prior immunity and viral variation on clinical outcome.	[Killingley, Ben] Univ Coll London Hosp, Dept Infect Dis, London, England; [Mann, Alex J.; Kalinova, Mariya; Boyers, Alison; Noulin, Nicolas; Londt, Brandon; Catchpole, Andrew P.] hVIVO Serv Ltd, London, England; [Goonawardane, Niluka; Zhou, Jie; Brown, Jonathan; Frise, Rebecca; Barclay, Wendy S.; Chiu, Christopher] Imperial Coll London, Dept Infect Dis, London, England; [Lindsell, Kate; Gilbert, Anthony; Charman, Christine; Mande, Priya] UK Vaccine Taskforce, Dept Business Energy & Ind Strategy, London, England; [Hare, Samanjit S.] Royal Free London NHS Fdn Trust, Dept Radiol, London, England; [Smith, Emma; Openshaw, Peter J.; Rapeport, Garth] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Hopkins, Claire] Guys & St Thomas NHS Fdn Trust, ENT Dept, London, England; [Wilkinson, Tom; Read, Robert C.] Univ Southampton, Fac Med, Southampton, Hants, England; [Wilkinson, Tom; Read, Robert C.] Univ Southampton, Inst Life Sci, Southampton, Hants, England; [Wilkinson, Tom; Read, Robert C.] Univ Hosp Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England; [Harden, Stephen] Southampton Gen Hosp, Dept Radiol, Southampton, Hants, England; [McShane, Helen] Univ Oxford, Dept Paediat, Oxford, England; [Baillet, Mark] S Cubed Biometr, Abingdon, Oxon, England; [Jacobs, Michael] Royal Free London NHS Fdn Trust, Dept Infect Dis, London, England; [Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Div Epidemiol & Publ Hlth, Sch Med, Nottingham, England; [Semple, Malcolm G.] Univ Liverpool, Hlth Protect Res Unit Emerging & Zoonot Infect, Inst Infect Vet & Ecol Sci, Fac Hlth & Life Sci, Liverpool, Merseyside, England; [Semple, Malcolm G.] Alder Hey Childrens Hosp, Resp Dept, Liverpool, Merseyside, England; [Ferguson, Neil M.] Imperial Coll London, Sch Publ Hlth, MRC Ctr Global Infect Dis Anal, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of Southampton; University of Southampton; University of Southampton; University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; University of Nottingham; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; Imperial College London	Chiu, C (corresponding author), Imperial Coll London, Dept Infect Dis, London, England.	c.chiu@imperial.ac.uk	Goonawardane, Niluka/HHS-4988-2022; Semple, Malcolm Gracie/A-8790-2008	Goonawardane, Niluka/0000-0003-2906-5513; Read, Robert/0000-0002-4297-6728; Barclay, Wendy/0000-0002-3948-0895; McShane, Helen/0000-0002-2126-5142; Brown, Jonathan/0000-0001-6849-3962; Rapeport, Garth/0000-0002-5795-6500; Mann, Alexander/0000-0002-3744-4604; Semple, Malcolm Gracie/0000-0001-9700-0418	UK Vaccine Taskforce of the Department for Business, Energy and Industrial Strategy (BEIS) of Her Majesty's Government; NIHR Imperial Biomedical Research Centre award; NIHR Senior Investigator Award [NIHR201385, NF-SI-0617-10010]; UKRI MRC CIC Award [MR/V028448/1]; NIHR Oxford Biomedical Research Centre [NIHR-BRC-1215-20008]; NIHR Southampton Biomedical Research Centre [IS-BRC-1215-20004)]; NIHR [CO-CIN-01]; Medical Research Council (MRC) [MC_PC_19059]; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool; Public Health England; Liverpool School of Tropical Medicine; University of Oxford (NIHR) [200907]; Liverpool Experimental Cancer Medicine Centre [C18616/A25153]; NIHR Health Protection Research Unit in Respiratory Infections [200927]; NIHR Health Protection Research Unit in Modelling and Health Economics; MRC Centre for Global Infectious Disease Analysis; Jameel Institute	UK Vaccine Taskforce of the Department for Business, Energy and Industrial Strategy (BEIS) of Her Majesty's Government; NIHR Imperial Biomedical Research Centre award; NIHR Senior Investigator Award; UKRI MRC CIC Award; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Southampton Biomedical Research Centre; NIHR(National Institute for Health Research (NIHR)); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool; Public Health England; Liverpool School of Tropical Medicine; University of Oxford (NIHR); Liverpool Experimental Cancer Medicine Centre; NIHR Health Protection Research Unit in Respiratory Infections; NIHR Health Protection Research Unit in Modelling and Health Economics; MRC Centre for Global Infectious Disease Analysis(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Jameel Institute	We thank the study participants for their time and commitment. The authors gratefully acknowledge support from the UK Vaccine Taskforce of the Department for Business, Energy and Industrial Strategy (BEIS) of Her Majesty's Government. The funder had no role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript. We thank the following individuals and organizations for their invaluable contributions to the development and implementation of the SARS-CoV-2 human challenge project: A. Anandakumar, K. Baillie, S. Casserly, S. Cleiff, C. Chu and the NIHR Clinical Research Network staff at the Royal Bolton Hospital; K. Fenton, B. Flutter and the team at the Zayed Centre for Research at Great Ormond Street Hospital; G. Gainsborough, F. Gleason, L. Grey, R. Heyderman, J. Hippisley-Cox, M. Johnson, K. Khunti, M. Mayer, M. Moshe, M. Ocampo, C. Skinner, C. Steves, P. Subudhi, D. Thomas, G. Towers, H. Ward, O. Watson and J. Zhou; the Royal Free London NHS Foundation Trust; the North Central London Critical Care Network (clinical leads D. Howell, G. Smith and G. Bellingan); the Human Infection Challenge Network for Vaccine Development; and ISARIC4C investigators . We are grateful to Gilead for providing remdesivir for the study. We thank the members of the independent data and safety monitoring board (S. Gordon (chair, Liverpool School of Tropical Medicine), P. Smith (chair, London School of Hygiene and Tropical Medicine), A. Durbin (Johns Hopkins University), F. Hayden (University of Virginia School of Medicine) and D. Dockrell (University of Edinburgh)) and the Medical Oversight Committee/Trial Steering Committee (R.C.R. (chair), D. Ferreira (Liverpool School of Tropical Medicine), H.M., P.O. and A.C.) for their invaluable advice. C. Chiu and P.O. are supported by the NIHR Imperial Biomedical Research Centre award to Imperial College Healthcare NHS Trust and Imperial College London. P.O. is supported by an NIHR Senior Investigator Award (NIHR201385) and a UKRI MRC CIC Award (MR/V028448/1). H.M. is supported by the NIHR Oxford Biomedical Research Centre (NIHR-BRC-1215-20008). R.C.R. is supported by an NIHR Senior Investigator Award (NF-SI-0617-10010) and by the NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004). The viral swab from which the challenge virus was grown was provided by ISARIC4C, which is funded by the NIHR (award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059) and the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool, in partnership with Public Health England and in collaboration with the Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907). The Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research (grant reference C18616/A25153). This work was also supported by the NIHR Health Protection Research Unit in Respiratory Infections (NIHR award 200927). N.M.F. acknowledges funding from the NIHR Health Protection Research Unit in Modelling and Health Economics, the MRC Centre for Global Infectious Disease Analysis and the Jameel Institute. J.S.N.-V.-T. is seconded to the Department of Health and Social Care (DHSC), England. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, the DHSC or BEIS.	Abdelnabi R, 2021, EBIOMEDICINE, V68, DOI 10.1016/j.ebiom.2021.103403; Baay M, 2020, BIOLOGICALS, V67, P69, DOI 10.1016/j.biologicals.2020.08.006; Bagga B, 2013, ANTIVIR THER, V18, P785, DOI 10.3851/IMP2629; Baggio S, 2021, CLIN INFECT DIS, V73, P148, DOI 10.1093/cid/ciaa1157; Barker Caroline, 2022, Wellcome Open Res, V7, P49, DOI 10.12688/wellcomeopenres.17516.1; Barratt-Due A, 2021, ANN INTERN MED, V174, P1261, DOI 10.7326/M21-0653; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Butowt R, 2021, NEUROSCIENTIST, V27, P582, DOI 10.1177/1073858420956905; Centers for Disease Control and Prevention, CDCS DIAGN TEST COVI; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Coronavirus Clinical Characterisation Consortium, ISARIC 4C; Deming ME, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2020076; DeVincenzo JP, 2010, AM J RESP CRIT CARE, V182, P1305, DOI 10.1164/rccm.201002-0221OC; DOTY RL, 1989, PERCEPT PSYCHOPHYS, V45, P381, DOI 10.3758/BF03210709; Drake TM, 2021, LANCET, V398, P223, DOI 10.1016/S0140-6736(21)00799-6; Eberhardt KA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091045; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Fischer WA, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl7430; Gbesemete D, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01670-2; Gottlieb RL, 2022, NEW ENGL J MED, V386, P305, DOI 10.1056/NEJMoa2116846; Habibi MS, 2020, SCIENCE, V370, P188, DOI 10.1126/science.aba9301; He JJ, 2021, J MED VIROL, V93, P820, DOI 10.1002/jmv.26326; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Jozwik A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10224; Ke R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2111477118; Kim MC, 2021, NEW ENGL J MED, V384, P671, DOI 10.1056/NEJMc2027040; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Levine MM, 2021, CLIN INFECT DIS, V72, P2035, DOI 10.1093/cid/ciaa1290; Levine-Tiefenbrun M, 2021, NAT MED, V27, P2108, DOI 10.1038/s41591-021-01575-4; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Marks M, 2021, LANCET INFECT DIS, V21, P629, DOI 10.1016/S1473-3099(20)30985-3; Munker D, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.02724-2020; Nguyen-Van-Tam JS, 2020, PLOS PATHOG, V16, DOI [10.1371/journal.ppat.1008704, 10.1371/journal.ppat.1008704.r001, 10.1371/journal.ppat.1008704.r002, 10.1371/journal.ppat.1008704.r003]; Paterson S, 2021, AM J RESP CRIT CARE, V204, P826, DOI 10.1164/rccm.202103-0620OC; Petersen I, 2021, CLIN EPIDEMIOL, V13, P935, DOI 10.2147/CLEP.S311977; Quilty Billy J, 2021, Lancet Public Health, V6, pe175, DOI 10.1016/S2468-2667(20)30308-X; Rapeport G, 2021, NEW ENGL J MED, V385, P961, DOI 10.1056/NEJMp2106970; REED SE, 1984, J MED VIROL, V13, P179, DOI 10.1002/jmv.1890130208; Renaud M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15352; Rosenau MJ, 1919, J AMER MED ASSOC, V73, P311, DOI 10.1001/jama.1919.02610310005002; Rosenke Kyle, 2020, bioRxiv, DOI 10.1101/2020.09.25.314070; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Singanayagam A, 2022, LANCET INFECT DIS, V22, P183, DOI 10.1016/S1473-3099(21)00648-4; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Syangtan G, 2021, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.587374; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh KA, 2020, J INFECTION, V81, P357, DOI 10.1016/j.jinf.2020.06.067; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077; Zar J.H., 1996, BIOSTAT ANAL; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	55	52	54	15	46	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1031	+		10.1038/s41591-022-01780-9	http://dx.doi.org/10.1038/s41591-022-01780-9		MAR 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35361992	Green Submitted, Bronze, Green Accepted			2022-12-27	WOS:000777221800001
J	Chu, L; Vrbicky, K; Montefiori, D; Huang, W; Nestorova, B; Chang, Y; Carfi, A; Edwards, DK; Oestreicher, J; Legault, H; Dutko, FJ; Girard, B; Pajon, R; Miller, JM; Das, R; Leav, B; McPhee, R				Chu, Laurence; Vrbicky, Keith; Montefiori, David; Huang, Wenmei; Nestorova, Biliana; Chang, Ying; Carfi, Andrea; Edwards, Darin K.; Oestreicher, Judy; Legault, Holly; Dutko, Frank J.; Girard, Bethany; Pajon, Rolando; Miller, Jacqueline M.; Das, Rituparna; Leav, Brett; McPhee, Roderick			Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial	NATURE MEDICINE			English	Article							OMICRON VARIANT; PROTECTION; SEVERITY; VACCINES; MEMORY	Rising breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously immunized individuals have raised concerns for the need for a booster vaccine dose to combat waning antibody levels and new variants. Here we report the results of the open-label, non-randomized part B of a phase 2 trial in which we evaluated the safety and immunogenicity of a booster injection of 50 mu g of the coronavirus disease 2019 (COVID-19) vaccine mRNA-1273 in 344 adult participants immunized 6-8 months earlier with a primary series of two doses of 50 mu g or 100 mu g of mRNA-1273 (NCT04405076). Neutralizing antibody (nAb) titers against wild-type SARS-CoV-2 at 1 month after the booster were 1.7-fold (95% confidence interval (CI): 1.5,1.9) higher than those at 28 days after the second injection of the primary series, which met the pre-specified non-inferiority criterion (primary immunogenicity objective) and might indicate a memory B cell response. The nAb titers against the Delta variant (B.1.617.2) (exploratory objective) at 1 month after the booster were 2.1-fold (95% CI: 1.8, 2.4) higher than those at 28 days after the second injection of the primary series. The seroresponse rate (95% CI (four-fold rise from baseline)) was 100% (98.7,100.0) at 28 days after the booster compared to 98.3% (96.0, 99.4) after the primary series. The higher antibody titers at 28 days after the booster dose compared to 28 days after the second dose in the phase 3 COVE study were also observed in two assays for anti-spike IgG antibody measured by ELISA and by Meso Scale Discovery (MSD) Multiplex. The frequency of solicited local and systemic adverse reactions after the booster dose was similar to that after the second dose in the primary two-dose series of mRNA-1273 (50 mu g or 100 mu g); no new signals were observed in the unsolicited adverse events; and no serious adverse events were reported in the 1-month follow-up period. These results show that a booster injection of mRNA-1273 more than 6 months after completing the primary two-dose series is safe and elicited nAb titers that were statistically significantly higher than the peak titers detected after the primary vaccination series, suggesting that a booster dose of mRNA-1273 might result in increased vaccine effectiveness against infection and disease caused by SARS-Cov-2.	[Chu, Laurence] Benchmark Res, Austin, TX USA; [Vrbicky, Keith] Meridian Clin Res, Norfolk, NE USA; [Montefiori, David] Dept Surg, Durham, NC USA; [Montefiori, David] Duke Human Vaccine Inst, Durham, NC USA; [Huang, Wenmei; Nestorova, Biliana; Chang, Ying; Carfi, Andrea; Edwards, Darin K.; Oestreicher, Judy; Legault, Holly; Dutko, Frank J.; Girard, Bethany; Pajon, Rolando; Miller, Jacqueline M.; Das, Rituparna; Leav, Brett; McPhee, Roderick] Moderna Inc, Cambridge, MA 02139 USA		McPhee, R (corresponding author), Moderna Inc, Cambridge, MA 02139 USA.	roderick.mcphee@modernatx.com			Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [75A50120C00034]; Moderna, Inc.	Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority; Moderna, Inc.	We thank the participants in this trial and the phase 2 study investigators. We also thank the Immune Assay Team at Duke University Medical Center: R. Beerman, K. Bradley, J. Chen, X. Daniell, E. Domin, A. Eaton, K. Engle, W. Feng, J. Gao, H. Gao, K. Greene, S. Hiles, M. Jessup-Cumming, M. Sarzotti-Kelsoe, K. Long, K. Lund, K. Lyons, C. McDanal, F. Suman, H. Tang, J. Tong and O. Widman; the mRNA-1273 Product Coordination Team from the Biomedical Advanced Research and Development Authority: R. Bruno, R. Gorman, H. Hamilton, G. Horwith, C. Huynh, N. Mytle, C. Pavetto, X. Tong and J. Treanor; the team at PPD, Hamilton, New Jersey, for their support of this study; and J. E. Tomassini, Moderna consultant, for contributions to writing the manuscript. Funding: Parts A and B of the phase 2 trial ('Dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 COVID-19 vaccine in adults aged 18 years and older', NCT04405076) were supported, in part, with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number 75A50120C00034, and by Moderna, Inc. Role of the funding source: employees of the study sponsor, Moderna, Inc., contributed to the study design, data collection, analysis and interpretation and writing of this manuscript.	Accorsi EK, 2022, JAMA-J AM MED ASSOC, V327, P639, DOI 10.1001/jama.2022.0470; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Ali K, 2021, NEW ENGL J MED, V385, P2241, DOI 10.1056/NEJMoa2109522; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V385, P2485, DOI 10.1056/NEJMc2115597; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Chu L., 2021, IMMUNE MEMORY RESPON, DOI [10.1101/2021.09.29.21264089v1, DOI 10.1101/2021.09.29.21264089V1]; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Control CfD Prevention, 1998, MMWR-MORBID MORTAL W, V47, pi, DOI DOI 10.1001/jamahealthforum.2021.0325; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Das PJ, 2022, EDUC PRIM CARE, DOI 10.1080/14739879.2022.2137856; Doria-Rose N. A., 2021, BOOSTER MRNA 1273 ST, DOI [10.1101/2021.12.15.21267805v2.full, DOI 10.1101/2021.12.15.21267805V2.FULL]; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Fowlkes A, 2021, MMWR-MORBID MORTAL W, V70, P1167, DOI 10.15585/mmwr.mm7034e4; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; Girard B., 2022, MRNA 1273 VACCINE EL, DOI [10.1101/2022.01.24.22269666v1, DOI 10.1101/2022.01.24.22269666V1]; Goel RR, 2021, SCIENCE, V374, P1214, DOI 10.1126/science.abm0829; Goldblatt D, 2022, VACCINE, V40, P306, DOI 10.1016/j.vaccine.2021.12.006; Iuliano AD, 2022, MMWR-MORBID MORTAL W, V71, P146, DOI [10.1101/2021.12.30.21268560v2, 10.15585/mmwr.mm7104e4]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Janssen Products LP., 2022, FDA YOND TRAB INJ; Johnson Amelia G, 2022, MMWR Morb Mortal Wkly Rep, V71, P132, DOI 10.15585/mmwr.mm7104e2; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lewnard J. A., 2022, CLIN OUTCOMES PATIEN, DOI [10.1101/2022.01.11.22269045v1, DOI 10.1101/2022.01.11.22269045V1]; Lusvarghi Sabrina, 2021, bioRxiv, DOI 10.1101/2021.12.22.473880; Nanduri S, 2021, MMWR-MORBID MORTAL W, V70, P1163, DOI 10.15585/mmwr.mm7034e3; Pajon R, 2022, NEW ENGL J MED, V386, P1088, DOI 10.1056/NEJMc2119912; Perry J., 2022, DOES HUMORAL CORRELA, DOI [10.1101/2022.01.21.22269667v1, DOI 10.1101/2022.01.21.22269667V1]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Puranik Arjun, 2021, medRxiv, DOI 10.1101/2021.08.06.21261707; Ritchie H., 2020, CO2 GREENHOUSE GAS E; Rossler A, 2022, NEW ENGL J MED, V386, P698, DOI 10.1056/NEJMc2119236; Rosenberg Eli S, 2021, MMWR Morb Mortal Wkly Rep, V70, P1150, DOI 10.15585/mmwr.mm7034e1; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Schmidt F, 2022, NEW ENGL J MED, V386, P599, DOI 10.1056/NEJMc2119641; Self WH, 2021, MMWR-MORBID MORTAL W, V70, P1337, DOI 10.15585/mmwr.mm7038e1; Tang P, 2021, NAT MED, V27, P2136, DOI 10.1038/s41591-021-01583-4; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P1156, DOI 10.15585/mmwr.mm7034e2; Thompson Mark G, 2022, MMWR Morb Mortal Wkly Rep, V71, P139, DOI 10.15585/mmwr.mm7104e3; Tseng H. F., 2022, EFFECTIVENESS MRNA 1, DOI [10.1101/2022.01.07.22268919v2.full, DOI 10.1101/2022.01.07.22268919V2.FULL]; U.S. Food Drug Administration, 2021, MODERNA COVID 19 VAC; Wang YC, 2022, EMERG MICROBES INFEC, V11, P1, DOI 10.1080/22221751.2021.2017757; Wilhelm A., 2021, REDUCED NEUTRALIZATI, DOI [10.1101/2021.12.07.21267432v4, DOI 10.1101/2021.12.07.21267432V4]; Wolter N, 2022, LANCET, V399, P437, DOI 10.1016/S0140-6736(22)00017-4; Yang W., 2021, SARS COV 2 TRANSMISS, DOI [10.1101/2021.12.19.21268073v1, DOI 10.1101/2021.12.19.21268073V1]	49	13	13	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1042	+		10.1038/s41591-022-01739-w	http://dx.doi.org/10.1038/s41591-022-01739-w		MAR 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35241844	hybrid, Green Published			2022-12-27	WOS:000763900400001
J	Auladell, M; Phuong, HVM; Mai, LTQ; Tseng, YY; Carolan, L; Wilks, S; Thai, PQ; Price, D; Duong, NT; Hang, NLK; Thanh, LT; Thuong, NTH; Huong, TTK; Diep, NTN; Bich, VTN; Khvorov, A; Hensen, L; Duong, TN; Kedzierska, K; Anh, DD; Wertheim, H; Boyd, SD; Good-Jacobson, KL; Smith, D; Barr, I; Sullivan, S; van Doorn, HR; Fox, A				Auladell, Maria; Hoang Vu Mai Phuong; Le Thi Quynh Mai; Tseng, Yeu-Yang; Carolan, Louise; Wilks, Sam; Pham Quang Thai; Price, David; Nguyen Thanh Duong; Nguyen Le Khang Hang; Le Thi Thanh; Nguyen Thi Hong Thuong; Tran Thi Kieu Huong; Nguyen Thi Ngoc Diep; Vu Thi Ngoc Bich; Khvorov, Arseniy; Hensen, Luca; Tran Nhu Duong; Kedzierska, Katherine; Dang Duc Anh; Wertheim, Heiman; Boyd, Scott D.; Good-Jacobson, Kim L.; Smith, Derek; Barr, Ian; Sullivan, Sheena; van Doorn, H. Rogier; Fox, Annette			Influenza virus infection history shapes antibody responses to influenza vaccination	NATURE MEDICINE			English	Article							PANDEMIC INFLUENZA; IMMUNE HISTORY; A-VIRUS; BINDING; SITE; HEMAGGLUTININ; VARIANTS; IMPACT; IDENTIFICATION; COMMUNITY	Recent prior influenza A infection is associated with elevated hemagglutinin-inhibiting antibody responses and greater breadth of reactivity to influenza strains following vaccination, suggesting that infection history boosts vaccine responses. Studies of successive vaccination suggest that immunological memory against past influenza viruses may limit responses to vaccines containing current strains. The impact of memory induced by prior infection is rarely considered and is difficult to ascertain, because infections are often subclinical. This study investigated influenza vaccination among adults from the Ha Nam cohort (Vietnam), who were purposefully selected to include 72 with and 28 without documented influenza A(H3N2) infection during the preceding 9 years (Australian New Zealand Clinical Trials Registry 12621000110886). The primary outcome was the effect of prior influenza A(H3N2) infection on hemagglutinin-inhibiting antibody responses induced by a locally available influenza vaccine administered in November 2016. Baseline and postvaccination sera were titrated against 40 influenza A(H3N2) strains spanning 1968-2018. At each time point (baseline, day 14 and day 280), geometric mean antibody titers against 2008-2018 strains were higher among participants with recent infection (34 (29-40), 187 (154-227) and 86 (72-103)) than among participants without recent infection (19 (17-22), 91 (64-130) and 38 (30-49)). On days 14 and 280, mean titer rises against 2014-2018 strains were 6.1-fold (5.0- to 7.4-fold) and 2.6-fold (2.2- to 3.1-fold) for participants with recent infection versus 4.8-fold (3.5- to 6.7-fold) and 1.9-fold (1.5- to 2.3-fold) for those without. One of 72 vaccinees with recent infection versus 4 of 28 without developed symptomatic A(H3N2) infection in the season after vaccination (P = 0.021). The range of A(H3N2) viruses recognized by vaccine-induced antibodies was associated with the prior infection strain. These results suggest that recall of immunological memory induced by prior infection enhances antibody responses to inactivated influenza vaccine and is important to attain protective antibody titers.	[Auladell, Maria; Hensen, Luca; Kedzierska, Katherine; Fox, Annette] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Hoang Vu Mai Phuong; Le Thi Quynh Mai; Pham Quang Thai; Nguyen Le Khang Hang; Le Thi Thanh; Tran Nhu Duong; Dang Duc Anh] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; [Tseng, Yeu-Yang; Carolan, Louise; Khvorov, Arseniy; Barr, Ian; Sullivan, Sheena; Fox, Annette] Royal Melbourne Hosp, WHO Collaborating Ctr Reference & Res Influenza, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Tseng, Yeu-Yang; Khvorov, Arseniy; Sullivan, Sheena; Fox, Annette] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia; [Wilks, Sam; Smith, Derek] Univ Cambridge, Ctr Pathogen Evolut, Dept Zool, Cambridge, England; [Price, David] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Price, David] Univ Melbourne, Victorian Infect Dis Reference Lab, Epidemiol Unit, Melbourne, Vic, Australia; [Price, David] Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Price, David] Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic, Australia; [Nguyen Thanh Duong] Ha Nam Ctr Prevent Med, Ha Nam, Vietnam; [Nguyen Thi Hong Thuong; Tran Thi Kieu Huong; Nguyen Thi Ngoc Diep; Vu Thi Ngoc Bich; Wertheim, Heiman; van Doorn, H. Rogier] Univ Oxford, Natl Hosp Trop Dis, Clin Res Unit, Wellcome Africa Asia Programme, Hanoi, Vietnam; [Wertheim, Heiman] Radboudumc, Dept Med Microbiol, Radboudumc Ctr Infect Dis, Nijmegen, Netherlands; [Boyd, Scott D.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA; [Good-Jacobson, Kim L.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Good-Jacobson, Kim L.] Monash Univ, Biomed Discovery Inst, Clayton, Vic, Australia; [van Doorn, H. Rogier] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England	University of Melbourne; National Institute of Hygiene & Epidemiology (NIHE); Royal Melbourne Hospital; World Health Organization; University of Melbourne; University of Cambridge; University of Melbourne; University of Melbourne; Victorian Infectious Diseases Reference Laboratory; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; National Hospital of Tropical Diseases; University of Oxford; Radboud University Nijmegen; Stanford University; Monash University; Monash University; University of Oxford	Fox, A (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Fox, A (corresponding author), Royal Melbourne Hosp, WHO Collaborating Ctr Reference & Res Influenza, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.; Fox, A (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia.	annette.fox@unimelb.edu.au		Smith, Derek/0000-0002-2393-1890; Auladell, Maria/0000-0001-9179-3568; Khvorov, Arseniy/0000-0002-2423-2848; Price, David/0000-0003-0076-3123	National Health and Medical Research Council, Australia [1103367]; National Foundation for Science and Technology Development [NAFOSTED 108.04-2019.08]; Australian Government Department of Health; Wellcome Africa Asia program [089276/Z/09/Z, 106680/Z/14/Z]; Ha Nam Preventive Medicine Centre; People's Committees of Thanh Liem District; Ministry of Health of Vietnam; Australian National Health and Medical Research Council [1173871]; Melbourne International Research Scholarship; Melbourne International Fee Remission Scholarship from the University of Melbourne	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); National Foundation for Science and Technology Development; Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Wellcome Africa Asia program; Ha Nam Preventive Medicine Centre; People's Committees of Thanh Liem District; Ministry of Health of Vietnam; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Melbourne International Research Scholarship; Melbourne International Fee Remission Scholarship from the University of Melbourne	Funding for this study was provided by the National Health and Medical Research Council, Australia (grant 1103367 to A.F.) and National Foundation for Science and Technology Development (NAFOSTED 108.04-2019.08, L.T.Q.M.). The WHO Collaborating Centre for Reference and Research on Influenza is funded by the Australian Government Department of Health. The Oxford University Clinical Research Unit - Hanoi and H.R.v.D. are funded through Wellcome Africa Asia program grants (089276/Z/09/Z and 106680/Z/14/Z). We are grateful to the Ha Nam Preventive Medicine Centre and People's Committees of Thanh Liem District for their support and the people of Thanh Ha Commune for participating in this study. We would like to thank the Thanh Ha Commune health workers for their dedication to conducting active surveillance and cross-sectional surveys. We also wish to thank the Ministry of Health of Vietnam for their continuing support of the research collaboration between the Oxford University Clinical Research Unit and the National Institute for Hygiene and Epidemiology. We are grateful to members of the Oxford University Clinical Research Unit, including P. Horby for his role in establishing the Ha Nam cohort, N. Nguyen Minh Trang for project coordination and B. Huyen Trang for administrative support. A. Malet, H. Peck and Y.-M. Deng and their staff at Melbourne WHO Collaborating Centre for Reference and Research performed initial isolation and characterization of many of the influenza viruses used. We thank S. Sanchez for assisting with microneutralization assays. Thanks also to K. Subbarao and N. Thi Hoang Oanh for helpful comments on the manuscript. K.K. was supported by the Australian National Health and Medical Research Council (Leadership Investigator Fellowship 1173871). M.A. and L.H. were supported by the Melbourne International Research Scholarship and the Melbourne International Fee Remission Scholarship from the University of Melbourne. The funders had no role in the conduct of the study.	Andraud M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002418; Auladell M, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1090; Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Cauchemez S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003061; Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004; Fonville JM, 2014, SCIENCE, V346, P996, DOI 10.1126/science.1256427; Francis T, 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; Good KL, 2009, J IMMUNOL, V182, P890, DOI 10.4049/jimmunol.182.2.890; Hayward AC, 2014, LANCET RESP MED, V2, P445, DOI 10.1016/S2213-2600(14)70034-7; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Horby P, 2012, AM J EPIDEMIOL, V175, P1062, DOI 10.1093/aje/kws121; Houser KV, 2013, J VIROL, V87, P13480, DOI 10.1128/JVI.02434-13; Kim JH, 2016, VACCINE, V34, P495, DOI 10.1016/j.vaccine.2015.11.077; Koel BF, 2013, SCIENCE, V342, P976, DOI 10.1126/science.1244730; Kreijtz JHCM, 2011, VIRUS RES, V162, P19, DOI 10.1016/j.virusres.2011.09.022; Hoa LNM, 2022, J INFECT DIS, V226, P59, DOI 10.1093/infdis/jiaa293; Lee MS, 2004, EMERG INFECT DIS, V10, P1385, DOI 10.3201/eid1008.040107; Lessler J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002802; Li Y, 2013, J EXP MED, V210, P1493, DOI 10.1084/jem.20130212; Lin YP, 2010, J VIROL, V84, P6769, DOI 10.1128/JVI.00458-10; Linderman SL, 2014, P NATL ACAD SCI USA, V111, P15798, DOI 10.1073/pnas.1409171111; McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680; Meade P, 2020, MBIO, V11, DOI 10.1128/mBio.03243-19; MURPHY BR, 1982, INFECT IMMUN, V36, P1102, DOI 10.1128/IAI.36.3.1102-1108.1982; Ohmit SE, 2013, CLIN INFECT DIS, V56, P1363, DOI 10.1093/cid/cit060; Ranjeva S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09652-6; RCore Team, 2020, R LANG ENV STAT COMP; Sangster MY, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040167; Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10; Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176; Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001; Sullivan SG, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.43.17-00707; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Thompson MG, 2016, VACCINE, V34, P981, DOI 10.1016/j.vaccine.2015.10.119; Tricoche AD, 2021, J INFECT DIS, V223, P838, DOI 10.1093/infdis/jiaa426; WHO Global Influenza Surveillance Network, 2011, WHO GLOB INFL SURV N; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wu NC, 2019, CELL HOST MICROBE, V25, P836, DOI 10.1016/j.chom.2019.04.013; Zost SJ, 2019, CELL REP, V29, P4460, DOI 10.1016/j.celrep.2019.11.084; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	44	8	8	12	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					363	+		10.1038/s41591-022-01690-w	http://dx.doi.org/10.1038/s41591-022-01690-w		FEB 2022	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35177857	Green Submitted			2022-12-27	WOS:000757243200001
J	Sacco, K; Castagnoli, R; Vakkilainen, S; Liu, C; Delmonte, OM; Oguz, C; Kaplan, IM; Alehashemi, S; Burbelo, PD; Bhuyan, F; de Jesus, AA; Dobbs, K; Rosen, LB; Cheng, A; Shaw, E; Vakkilainen, MS; Pala, F; Lack, J; Zhang, Y; Fink, DL; Oikonomou, V; Snow, AL; Dalgard, CL; Chen, JG; Sellers, BA; Sanchez, GAM; Barron, K; Rey-Jurado, E; Vial, C; Poli, MC; Licari, A; Montagna, D; Marseglia, GL; Licciardi, F; Ramenghi, U; Discepolo, V; Lo Vecchio, A; Guarino, A; Eisenstein, EM; Imberti, L; Sottini, A; Biondi, A; Mato, S; Gerstbacher, D; Truong, M; Stack, MA; Magliocco, M; Bosticardo, M; Kawai, T; Danielson, JJ; Hulett, T; Askenazi, M; Hu, SH; Cohen, JI; Su, HC; Kuhns, DB; Lionakis, MS; Snyder, TM; Holland, SM; Goldbach-Mansky, R; Tsang, JS; Notarangelo, LD				Sacco, Keith; Castagnoli, Riccardo; Vakkilainen, Svetlana; Liu, Can; Delmonte, Ottavia M.; Oguz, Cihan; Kaplan, Ian M.; Alehashemi, Sara; Burbelo, Peter D.; Bhuyan, Farzana; de Jesus, Adriana A.; Dobbs, Kerry; Rosen, Lindsey B.; Cheng, Aristine; Shaw, Elana; Vakkilainen, Mikko S.; Pala, Francesca; Lack, Justin; Zhang, Yu; Fink, Danielle L.; Oikonomou, Vasileios; Snow, Andrew L.; Dalgard, Clifton L.; Chen, Jinguo; Sellers, Brian A.; Sanchez, Gina A. Montealegre; Barron, Karyl; Rey-Jurado, Emma; Vial, Cecilia; Poli, Maria Cecilia; Licari, Amelia; Montagna, Daniela; Marseglia, Gian Luigi; Licciardi, Francesco; Ramenghi, Ugo; Discepolo, Valentina; Lo Vecchio, Andrea; Guarino, Alfredo; Eisenstein, Eli M.; Imberti, Luisa; Sottini, Alessandra; Biondi, Andrea; Mato, Sayonara; Gerstbacher, Dana; Truong, Meng; Stack, Michael A.; Magliocco, Mary; Bosticardo, Marita; Kawai, Tomoki; Danielson, Jeffrey J.; Hulett, Tyler; Askenazi, Manor; Hu, Shaohui; Cohen, Jeffrey, I; Su, Helen C.; Kuhns, Douglas B.; Lionakis, Michail S.; Snyder, Thomas M.; Holland, Steven M.; Goldbach-Mansky, Raphaela; Tsang, John S.; Notarangelo, Luigi D.		NIAID Immune Response Covid Grp; Chile MIS-C Grp; Pavia Pediat COVID-19 Grp	Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19	NATURE MEDICINE			English	Article							APOPTOSIS; DISEASE; IL-33; REPERTOIRE; REVEALS; VACCINE	Transcriptomic, proteomic and immune repertoire profiling reveals distinct peripheral features of MIS-C and pediatric COVID-19, including elevated soluble spike protein levels, more pronounced type II IFN-dependent gene expression and a higher B cell mutation rate in patients with MIS-C. Pediatric Coronavirus Disease 2019 (pCOVID-19) is rarely severe; however, a minority of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might develop multisystem inflammatory syndrome in children (MIS-C), with substantial morbidity. In this longitudinal multi-institutional study, we applied multi-omics (analysis of soluble biomarkers, proteomics, single-cell gene expression and immune repertoire analysis) to profile children with COVID-19 (n = 110) and MIS-C (n = 76), along with pediatric healthy controls (pHCs; n = 76). pCOVID-19 was characterized by robust type I interferon (IFN) responses, whereas prominent type II IFN-dependent and NF-kappa B-dependent signatures, matrisome activation and increased levels of circulating spike protein were detected in MIS-C, with no correlation with SARS-CoV-2 PCR status around the time of admission. Transient expansion of TRBV11-2 T cell clonotypes in MIS-C was associated with signatures of inflammation and T cell activation. The association of MIS-C with the combination of HLA A*02, B*35 and C*04 alleles suggests genetic susceptibility. MIS-C B cells showed higher mutation load than pCOVID-19 and pHC. These results identify distinct immunopathological signatures in pCOVID-19 and MIS-C that might help better define the pathophysiology of these disorders and guide therapy.	[Sacco, Keith; Castagnoli, Riccardo; Vakkilainen, Svetlana; Delmonte, Ottavia M.; Alehashemi, Sara; Bhuyan, Farzana; de Jesus, Adriana A.; Dobbs, Kerry; Rosen, Lindsey B.; Cheng, Aristine; Shaw, Elana; Pala, Francesca; Zhang, Yu; Oikonomou, Vasileios; Truong, Meng; Stack, Michael A.; Bosticardo, Marita; Kawai, Tomoki; Danielson, Jeffrey J.; Su, Helen C.; Lionakis, Michail S.; Holland, Steven M.; Goldbach-Mansky, Raphaela; Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Castagnoli, Riccardo; Licari, Amelia; Montagna, Daniela; Marseglia, Gian Luigi] Fdn IRCCS Policlin San Matteo, Pediat Clin, Pavia, Italy; [Castagnoli, Riccardo; Licari, Amelia; Montagna, Daniela; Marseglia, Gian Luigi] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy; [Liu, Can; Lack, Justin; Tsang, John S.] NIAID, Multiscale Syst Biol Sect, Lab Immune Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Liu, Can] Univ Maryland, Grad Program Biol Sci, College Pk, MD 20742 USA; [Oguz, Cihan; Lack, Justin] NIAID, NIAID Collaborat Bioinformat Resource NCBR, NIH, Bethesda, MD 20892 USA; [Oguz, Cihan] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Adv Biomed Computat Sci, Frederick, MD USA; [Kaplan, Ian M.; Snyder, Thomas M.] Adapt Biotechnol, Seattle, WA USA; [Burbelo, Peter D.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA; [Vakkilainen, Mikko S.] Aalto Univ, Dept Comp Sci, Helsinki, Finland; [Fink, Danielle L.; Kuhns, Douglas B.] Frederick Natl Lab Canc Res, Appl Dev Res Directorate, Frederick, MD USA; [Snow, Andrew L.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol & Mol Therapeut, Bethesda, MD 20814 USA; [Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Dalgard, Clifton L.] Uniformed Serv Univ Hlth Sci, Amer Genome Ctr, Bethesda, MD 20814 USA; [Chen, Jinguo; Sellers, Brian A.] NIH, TransNIH Ctr Human Immunol Autoimmun & Inflammat, Bldg 10, Bethesda, MD 20892 USA; [Sanchez, Gina A. Montealegre] NIAID, Intramural Clin Management & Operat Branch ICMOB, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Barron, Karyl] NIAID, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rey-Jurado, Emma; Vial, Cecilia; Poli, Maria Cecilia] Univ Desarrollo, Fac Med Clin Alemana, Santiago, Chile; [Poli, Maria Cecilia] Hosp Ninos Dr Roberto Rio, Unidad Inmunol & Reumatol, Santiago, Chile; [Montagna, Daniela] Fdn IRCCS Policlin San Matteo, Lab Immunol & Transplantat, Pavia, Italy; [Licciardi, Francesco; Ramenghi, Ugo] Univ Turin, Regina Margherita Childrens Hosp, Dept Pediat & Publ Hlth Sci, AOU Citta Salute & Sci Torino, Turin, Italy; [Discepolo, Valentina; Lo Vecchio, Andrea; Guarino, Alfredo] Univ Naples Federico II, Dept Translat Med Sci, Sect Pediat, Naples, Italy; [Eisenstein, Eli M.] Hadassah Hebrew Univ, Dept Pediat, Med Ctr, Jerusalem, Israel; [Imberti, Luisa; Sottini, Alessandra] ASST Spedali Civili Brescia, Diagnost Dept, CREA Lab AIL Ctr Hematooncol Res, Brescia, Italy; [Biondi, Andrea] Univ Milano Bicocca, Pediat Dept, Fdn MBBM, Osped San Gerardo, Monza, Italy; [Biondi, Andrea] Univ Milano Bicocca, Ctr Tettamanti European Reference Network PaedCan, EuroBloodNet, MetabERN,Fdn MBBM,Osped San Gerardo, Monza, Italy; [Mato, Sayonara] Randall Childrens Hosp Legacy Emanuel, Portland, OR USA; [Gerstbacher, Dana] Stanford Childrens Hosp, Div Pediat Rheumatol, Stanford, CA USA; [Magliocco, Mary] NIAID, Mol Dev Immune Syst Sect, Lab Immune Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Hulett, Tyler; Askenazi, Manor; Hu, Shaohui] CDI Labs, Antygen Div, Baltimore, MD USA; [Cohen, Jeffrey, I] NIAID, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Tsang, John S.] NIAID, NIH, Ctr Human Immunol, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); IRCCS Fondazione San Matteo; University of Pavia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Aalto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidad del Desarrollo; IRCCS Fondazione San Matteo; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin; University of Naples Federico II; Hebrew University of Jerusalem; Hadassah University Medical Center; Hospital Spedali Civili Brescia; San Gerardo Hospital; University of Milano-Bicocca; San Gerardo Hospital; University of Milano-Bicocca; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Notarangelo, LD (corresponding author), NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Licari, Amelia/J-5898-2016; Vial, Maria Cecilia/GVS-4266-2022; Castagnoli, Riccardo/AAF-8555-2019; Votto, Martina/ABP-8046-2022; Palterer, Boaz/K-1072-2018	Licari, Amelia/0000-0002-1773-6482; Castagnoli, Riccardo/0000-0003-0029-9383; Votto, Martina/0000-0002-4271-8649; Palterer, Boaz/0000-0003-2499-8250; DE FILIPPO, MARIA/0000-0003-2900-9642; Lo Vecchio, Andrea/0000-0003-4181-6842; Cheng, Aristine/0000-0002-1182-7375; Sacco, Keith/0000-0001-8189-7769; Oguz, Cihan/0000-0002-2860-3546; MARSEGLIA, GIAN LUIGI/0000-0003-3662-0159; Poli, Maria Cecilia/0000-0001-6817-0573; Imberti, Luisa/0000-0002-2075-8391; Guarino, Alfredo/0000-0003-0199-0336; Vial, Cecilia/0000-0002-0399-6144; Alehashemi, Sara/0000-0002-6531-6108	Division of Intramural Research, National Institute of Allergy and Infectious Diseases [ZIA AI001270-01, ZIA AI001265]; National Institute of Dental and Craniofacial Research, National Institutes of Health; Regione Lombardia, Italy; ANID [COVID 0999]; Fondecyt [1201240, 11181222]; National Cancer Institute, National Institutes of Health [75N91019D00024]; Finnish Medical Foundation; Orion Research Foundation	Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Dental and Craniofacial Research, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Regione Lombardia, Italy(Regione Lombardia); ANID; Fondecyt(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Finnish Medical Foundation; Orion Research Foundation	We thank the patients, their families and healthy donors for placing their trust in us. We thank A. Catzola and L. Pierri from the Pediatric COVID19 Hub at the University of Naples Federico II and E. Nunez from the Unidad de Inmunologia y Reumatologia, Hospital de ninos Dr. Roberto del Rio, for helping with consenting patients and sample collection, without any compensation. We thank CDI Antygen HuProt Division (Baltimore, Maryland, and Mayaguez, Puerto Rico) and, in particular, S. Liu, B. Moore, P. Ramos and O. Candelario for HuProt auto-antibody analysis. This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (grants ZIA AI001270-01 to L.D.N. and ZIA AI001265 to H.C.S.); the National Institute of Dental and Craniofacial Research, National Institutes of Health; Regione Lombardia, Italy (project 'Risposta immune in pazienti con COVID-19 e co-morbidita' to R.C., A.L., D.M. and G.L.M. for Pavia, Italy and to L.I. and A.S. for Brescia, Italy); ANID COVID 0999 to C.V. and M.C.P.; Fondecyt n degrees 1201240 to C.V.; and Fondecyt nO 11181222 to M.C.P. (Chile). In addition, this project has been funded, in part, with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024 (to D.B.K.). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. Moreover, the opinions and assertions expressed herein are those of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences or the US Department of Defense. R.C. is a participant in the National Institutes of Health Graduate Partnership Program between the National Institutes of Health and the University of Pavia. S.V. is funded by the Finnish Medical Foundation and the Orion Research Foundation.	Abdel-Haq N, 2021, EUR J PEDIATR, V180, P1581, DOI 10.1007/s00431-021-03935-1; Abers MS, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.144455; Asano T, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4348; Bastard P, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4340; Blay N, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz776; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; BRUNETTI M, 1995, BLOOD, V86, P4199, DOI 10.1182/blood.V86.11.4199.bloodjournal86114199; Brusilovsky M, 2021, NAT IMMUNOL, V22, P1316, DOI 10.1038/s41590-021-01011-2; Burbelo P. D., AUTOANTIBODIES DETEC, DOI [10.1101/2021.11.03.21265769v1(2021), DOI 10.1101/2021.11.03.21265769V1(2021)]; Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273; Candia J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14755-5; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Chen YR, 2018, J MED VIROL, V90, P1383, DOI 10.1002/jmv.25187; Cheng Mary Hongying, 2020, bioRxiv, DOI 10.1101/2020.05.21.109272; Clarke LA, 2010, ARTHRITIS RHEUM-US, V62, P1770, DOI 10.1002/art.27418; Consiglio CR, 2020, CELL, V183, P968, DOI 10.1016/j.cell.2020.09.016; DeBiasi RL, 2021, NEW ENGL J MED, V385, P74, DOI 10.1056/NEJMe2108276; Dilthey AT, 2019, BIOINFORMATICS, V35, P4394, DOI 10.1093/bioinformatics/btz235; Ding L, 2012, J CLIN IMMUNOL, V32, P238, DOI 10.1007/s10875-011-9621-8; Dowell AC, 2022, NAT IMMUNOL, V23, P40, DOI 10.1038/s41590-021-01089-8; Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101; Esteve-Sole A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144554; Faust GG, 2014, BIOINFORMATICS, V30, P2503, DOI 10.1093/bioinformatics/btu314; Fong JJ, 2018, P NATL ACAD SCI USA, V115, P10410, DOI 10.1073/pnas.1804108115; Gadala-Maria D, 2015, P NATL ACAD SCI USA, V112, pE862, DOI 10.1073/pnas.1417683112; Gruber Conor N, 2020, Cell, V183, P982, DOI [10.1101/2020.07.04.20142752, 10.1016/j.cell.2020.09.034]; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y; Hoste L, 2021, J EXP MED, V219, DOI 10.1084/jem.20211381; Huynh-Thu VA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012776; ImmunoMind Team, 2019, IMM R PACK PAINL AN; Jin HL, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923449; Kim H, 2018, J INTERF CYTOK RES, V38, P171, DOI 10.1089/jir.2017.0127; Kokkinopoulou I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116054; Kopach P, 2014, J BIOL CHEM, V289, P11829, DOI 10.1074/jbc.M113.534396; Lanza L, 1996, CLIN EXP IMMUNOL, V103, P482; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Liu C, 2021, CELL, V184, P1836, DOI 10.1016/j.cell.2021.02.018; Liu SY, 2012, P NATL ACAD SCI USA, V109, P4239, DOI 10.1073/pnas.1114981109; Loske J, 2022, NAT BIOTECHNOL, V40, P319, DOI 10.1038/s41587-021-01037-9; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Loyal L, 2021, SCIENCE, V374, P171, DOI 10.1126/science.abh1823; Mathew NR, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109286; McArdle AJ, 2021, NEW ENGL J MED, V385, P11, DOI 10.1056/NEJMoa2102968; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; McKinstry KK, 2010, IMMUNOL REV, V236, P110, DOI 10.1111/j.1600-065X.2010.00921.x; Moreews M, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abh1516; Mule M. P., NORMALIZING DENOISIN; Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003; National Institutes of Health, COVID 19 TREATM GUID; Nolan S., 2020, LARGE SCALE DATABASE; Peine M, 2016, TRENDS IMMUNOL, V37, P321, DOI 10.1016/j.it.2016.03.007; Pierce CA, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd5487; Porritt RA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI151520; Porritt RA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146614; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Ramaswamy A, 2021, IMMUNITY, V54, P1083, DOI 10.1016/j.immuni.2021.04.003; Rapp M, 2019, J EXP MED, V216, P1170, DOI 10.1084/jem.20170277; Reyes M, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe9599; Riphagen Shelley, 2020, Lancet, V395, P1607, DOI 10.1016/S0140-6736(20)31094-1; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948; Snyder T. M., 2020, PREPRINT, DOI [10.1101/2020.07.31.20165647v3, DOI 10.1101/2020.07.31.20165647V3]; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/nmeth.4380, 10.1038/NMETH.4380]; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Trouillet-Assant S, 2020, J ALLERGY CLIN IMMUN, V146, P206, DOI 10.1016/j.jaci.2020.04.029; Vella LA, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf7570; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Villarreal DO, 2015, VACCINE, V33, P4313, DOI 10.1016/j.vaccine.2015.03.086; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Woodruff MC, 2020, NAT IMMUNOL, V21, P1506, DOI 10.1038/s41590-020-00814-z; Woods CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052198; World Health Organization, 2020, MULT INFL SYNDR CHIL, DOI DOI 10.1007/S00246-021-02738-3; Yamashita U, 2002, CRIT REV IMMUNOL, V22, P105; Yonker LM, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149633; Yoshida M., NATURE, DOI [10.1038/s41586-021-04345-x(2021), DOI 10.1038/S41586-021-04345-X(2021)]; Yoshie O, 2015, INT IMMUNOL, V27, P11, DOI 10.1093/intimm/dxu079; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067430	82	37	38	8	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1050	+		10.1038/s41591-022-01724-3	http://dx.doi.org/10.1038/s41591-022-01724-3		FEB 2022	36	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35177862	Green Accepted, Bronze, Green Published			2022-12-27	WOS:000757243200002
J	Rowald, A; Komi, S; Demesmaeker, R; Baaklini, E; Hernandez-Charpak, SD; Paoles, E; Montanaro, H; Cassara, A; Becce, F; Lloyd, B; Newton, T; Ravier, J; Kinany, N; D'Ercole, M; Paley, A; Hankov, N; Varescon, C; McCracken, L; Vat, M; Caban, M; Watrin, A; Jacquet, C; Bole-Feysot, L; Harte, C; Lorach, H; Galvez, A; Tschopp, M; Herrmann, N; Wacker, M; Geernaert, L; Fodor, I; Radevich, V; van den Keybus, K; Eberle, G; Pralong, E; Roulet, M; Ledoux, JB; Fornari, E; Mandija, S; Mattera, L; Martuzzi, R; Nazarian, B; Benkler, S; Callegari, S; Greiner, N; Fuhrer, B; Froeling, M; Buse, N; Denison, T; Buschman, R; Wende, C; Ganty, D; Bakker, J; Delattre, V; Lambert, H; Minassian, K; van den Berg, CAT; Kavounoudias, A; Micera, S; van de Ville, D; Barraud, Q; Kurt, E; Kuster, N; Neufeld, E; Capogrosso, M; Asboth, L; Wagner, FB; Bloch, J; Courtine, G				Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Paoles, Edoardo; Montanaro, Hazael; Cassara, Antonino; Becce, Fabio; Lloyd, Bryn; Newton, Taylor; Ravier, Jimmy; Kinany, Nawa; D'Ercole, Marina; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Caban, Miroslav; Watrin, Anne; Jacquet, Charlotte; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Tschopp, Manon; Herrmann, Natacha; Wacker, Moira; Geernaert, Lionel; Fodor, Isabelle; Radevich, Valentin; van den Keybus, Katrien; Eberle, Gregoire; Pralong, Etienne; Roulet, Maxime; Ledoux, Jean-Baptiste; Fornari, Eleonora; Mandija, Stefano; Mattera, Loan; Martuzzi, Roberto; Nazarian, Bruno; Benkler, Stefan; Callegari, Simone; Greiner, Nathan; Fuhrer, Benjamin; Froeling, Martijn; Buse, Nik; Denison, Tim; Buschman, Rik; Wende, Christian; Ganty, Damien; Bakker, Jurriaan; Delattre, Vincent; Lambert, Hendrik; Minassian, Karen; van den Berg, Cornelis A. T.; Kavounoudias, Anne; Micera, Silvestro; van de Ville, Dimitri; Barraud, Quentin; Kurt, Erkan; Kuster, Niels; Neufeld, Esra; Capogrosso, Marco; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire			Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	NATURE MEDICINE			English	Article							PHYSIOLOGICAL NOISE; ELECTRICAL-STIMULATION; EPIDURAL STIMULATION; TENDON VIBRATION; MUSCLE; ACTIVATION; MECHANISMS; LOCOMOTION; RECOVERY; DEFICITS	Epidural electrical stimulation (EES) targeting the dorsal roots of lumbosacral segments restores walking in people with spinal cord injury (SCI). However, EES is delivered with multielectrode paddle leads that were originally designed to target the dorsal column of the spinal cord. Here, we hypothesized that an arrangement of electrodes targeting the ensemble of dorsal roots involved in leg and trunk movements would result in superior efficacy, restoring more diverse motor activities after the most severe SCI. To test this hypothesis, we established a computational framework that informed the optimal arrangement of electrodes on a new paddle lead and guided its neurosurgical positioning. We also developed software supporting the rapid configuration of activity-specific stimulation programs that reproduced the natural activation of motor neurons underlying each activity. We tested these neurotechnologies in three individuals with complete sensorimotor paralysis as part of an ongoing clinical trial (www.clinicaltrials.gov identifier NCT02936453). Within a single day, activity-specific stimulation programs enabled these three individuals to stand, walk, cycle, swim and control trunk movements. Neurorehabilitation mediated sufficient improvement to restore these activities in community settings, opening a realistic path to support everyday mobility with EES in people with SCI.	[Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Kinany, Nawa; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Greiner, Nathan; Fuhrer, Benjamin; Capogrosso, Marco; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet & Brain Mind Inst, Lausanne, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Tschopp, Manon; Herrmann, Natacha; Wacker, Moira; Geernaert, Lionel; Fodor, Isabelle; Radevich, Valentin; van den Keybus, Katrien; Eberle, Gregoire; Greiner, Nathan; Fuhrer, Benjamin; Barraud, Quentin; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Tschopp, Manon; Herrmann, Natacha; Wacker, Moira; Geernaert, Lionel; Fodor, Isabelle; Radevich, Valentin; van den Keybus, Katrien; Eberle, Gregoire; Greiner, Nathan; Fuhrer, Benjamin; Barraud, Quentin; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] Univ Lausanne UNIL, Lausanne, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Baaklini, Edeny; Hernandez-Charpak, Sergio Daniel; Ravier, Jimmy; Paley, Aurelie; Hankov, Nicolas; Varescon, Camille; McCracken, Laura; Vat, Molywan; Bole-Feysot, Lea; Harte, Cathal; Lorach, Henri; Galvez, Andrea; Roulet, Maxime; Greiner, Nathan; Barraud, Quentin; Asboth, Leonie; Wagner, Fabien B.; Bloch, Jocelyne; Courtine, Gregoire] EPFL CHUV UNIL, Defitech Ctr Intervent Neurotherapies NeuroRestor, Lausanne, Switzerland; [Paoles, Edoardo; D'Ercole, Marina; Caban, Miroslav; Watrin, Anne; Jacquet, Charlotte; Ganty, Damien; Bakker, Jurriaan; Delattre, Vincent; Lambert, Hendrik] ONWARD Med, Lausanne, Switzerland; [Montanaro, Hazael; Cassara, Antonino; Lloyd, Bryn; Newton, Taylor; Benkler, Stefan; Kuster, Niels; Neufeld, Esra] Fdn Res Informat Technol Soc, Zurich, Switzerland; [Montanaro, Hazael; Kuster, Niels; Neufeld, Esra] Swiss Fed Inst Technol, Dept Informat Technol & Elect Engn, Zurich, Switzerland; [Rowald, Andreas; Komi, Salif; Demesmaeker, Robin; Becce, Fabio; Ledoux, Jean-Baptiste; Fornari, Eleonora] CHUV UNIL, Dept Diagnost & Intervent Radiol, Lausanne, Switzerland; [Kinany, Nawa; Caban, Miroslav; van de Ville, Dimitri] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland; [Kinany, Nawa] Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy; [Pralong, Etienne; Roulet, Maxime; Bloch, Jocelyne; Courtine, Gregoire] CHU Vaudois, Dept Neurosurg, Lausanne, Switzerland; [Ledoux, Jean-Baptiste; Fornari, Eleonora] CHU Vaudois, MR Sect, Biomed Imaging Ctr, Lausanne, Switzerland; [Mandija, Stefano; Froeling, Martijn] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Mattera, Loan; Martuzzi, Roberto] Fdn Campus Biotech Geneve, Geneva, Switzerland; [Nazarian, Bruno] Aix Marseille Univ, CNRS, Inst Neurosci Timone, Marseille, France; [Callegari, Simone; Kuster, Niels; Neufeld, Esra] ZurichMedTech, Zurich, Switzerland; [Buse, Nik; Denison, Tim; Buschman, Rik] Medtronic, Minneapolis, MN USA; [Denison, Tim] Univ Oxford, Dept Engn Sci, Oxford, England; [Wende, Christian] Tech Univ Munich, Med Mat & Implants, Munich, Germany; [Minassian, Karen] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria; [Kavounoudias, Anne] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria; [van den Berg, Cornelis A. T.; Micera, Silvestro] Aix Marseille Univ, CNRS, Lab Neurosci Cognit, Marseille, France; [van den Berg, Cornelis A. T.; Micera, Silvestro] Ecole Polytech Fed Lausanne, Bertarelli Fdn, Translat Neuroengn, Ctr Neuroprosthet, Lausanne, Switzerland; [van den Berg, Cornelis A. T.; Micera, Silvestro] Ecole Polytech Fed Lausanne, Inst Bioengn, Sch Bioengn, Lausanne, Switzerland; [van de Ville, Dimitri] Univ Geneva, Dept Radiol & Med Informat, Geneva, Switzerland; [Kurt, Erkan] Radboud Univ Nijmegen Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; [Capogrosso, Marco] Univ Fribourg, Dept Neurosci & Movement Sci, Fribourg, Switzerland; [Capogrosso, Marco] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wagner, Fabien B.] Univ Bordeaux, CNRS, UMR 5293, Inst Malad Neurodegenerat, Bordeaux, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Scuola Superiore Sant'Anna; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Utrecht University; Utrecht University Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Medtronic; University of Oxford; Technical University of Munich; Medical University of Vienna; Medical University of Vienna; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva; Radboud University Nijmegen; University of Fribourg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Bloch, J; Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet & Brain Mind Inst, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), Univ Lausanne UNIL, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), EPFL CHUV UNIL, Defitech Ctr Intervent Neurotherapies NeuroRestor, Lausanne, Switzerland.; Bloch, J; Courtine, G (corresponding author), CHU Vaudois, Dept Neurosurg, Lausanne, Switzerland.	jocelyne.bloch@chuv.ch; gregoire.courtine@epfl.ch	Becce, Fabio/I-6781-2019; Froeling, Martijn/E-7865-2012; Wagner, Fabien/ABC-4084-2020; Cassara, Antonino Mario/G-2498-2018	Becce, Fabio/0000-0001-8444-8504; Froeling, Martijn/0000-0003-3841-0497; Wagner, Fabien/0000-0002-9582-6109; Asboth, Leonie/0000-0003-2414-9574; Cassara, Antonino Mario/0000-0003-3375-7440; Kuster, Niels/0000-0002-5827-3728; Minassian, Karen/0000-0003-4197-6141; Rowald, Andreas/0000-0001-5493-195X; Demesmaeker, Robin/0000-0003-0856-0929; courtine, gregoire/0000-0002-5744-4142; Baaklini, Edeny/0000-0003-0942-0768; Barraud, Quentin/0000-0003-0894-1959; Montanaro Ochoa, Hazael Fabrizio/0000-0002-5373-1646; McCracken, Laura/0000-0003-1663-2558; Hernandez Charpak, Sergio Daniel/0000-0003-0477-8138; Komi, Salif/0000-0002-2655-6213	Wings for Life; Defitech Foundation; International Foundation for Research in Paraplegia, Rolex for Enterprise, Carigest Promex, Riders4Riders, ALARME; Panacee Foundation; Pictet Group Charitable Foundation; Firmenich Foundation; ONWARD Medical; European Union [785907]; RESTORE: Eurostars [E10889]; Swiss National Science Foundation (NCCR Robotics); European Research Council [ERC-2015-CoG HOW2WALKAGAIN 682999]; Commission of Technology and Innovation Innosuisse [CTI 41871.1 IP_LS, CTI 25761.1]; H2020-MSCACOFUND-2015 EPFL fellows program [665667]	Wings for Life; Defitech Foundation; International Foundation for Research in Paraplegia, Rolex for Enterprise, Carigest Promex, Riders4Riders, ALARME; Panacee Foundation; Pictet Group Charitable Foundation; Firmenich Foundation; ONWARD Medical; European Union(European Commission); RESTORE: Eurostars; Swiss National Science Foundation (NCCR Robotics)(Swiss National Science Foundation (SNSF)); European Research Council(European Research Council (ERC)European Commission); Commission of Technology and Innovation Innosuisse; H2020-MSCACOFUND-2015 EPFL fellows program	We thank our study participants for their commitment and trust. All participants gave their informed consent for publication of their images. We thank A. Curt for support; A. van der Kolk and F. Visser for support in imaging data collection and inspection; and many students, interns and former employees for various contributions, including R. Wang, C. Puffay, Y. L. R. Wan, I. Perret, E. Revol, M. Van Campenhoudt, I. Youssef,I. Turcu, F. Sellet, G. Carparelli, C. Moerman, D. Scherrer-Ma, F. Magaud, M. Damiani and N. Regazzi. Investigational implantable stimulators and paddle leads were donated by Medtronic and ONWARD Medical. This work was supported by Wings for Life, the Defitech Foundation, the International Foundation for Research in Paraplegia, Rolex for Enterprise, Carigest Promex, Riders4Riders, ALARME, the Panacee Foundation, the Pictet Group Charitable Foundation, the Firmenich Foundation, ONWARD Medical, European Union's Horizon 2020 (785907 Human Brain Project SGA2), RESTORE: Eurostars E10889, CONFIRM!: Eurostars E!12743, the Swiss National Science Foundation (NCCR Robotics), the European Research Council (ERC-2015-CoG HOW2WALKAGAIN 682999), the Commission of Technology and Innovation Innosuisse (CTI 41871.1 IP_LS and CTI 25761.1) and the H2020-MSCACOFUND-2015 EPFL fellows program (grant 665667 to F.B.W.).	Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Asboth L, 2018, NAT NEUROSCI, V21, P576, DOI 10.1038/s41593-018-0093-5; BAROLAT G, 1986, APPL NEUROPHYSIOL, V49, P307; Barra B., EPIDURAL ELECT STIMU, DOI [10.1101/2020.11.13.379750(2021, DOI 10.1101/2020.11.13.379750(2021]; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Benabid AL, 2019, LANCET NEUROL, V18, P1112, DOI 10.1016/S1474-4422(19)30321-7; Bonizzato M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05282-6; Brooks JCW, 2008, NEUROIMAGE, V39, P680, DOI 10.1016/j.neuroimage.2007.09.018; Capogrosso M, 2018, NAT PROTOC, V13, P2031, DOI 10.1038/s41596-018-0030-9; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Cappellini G, 2010, J NEUROPHYSIOL, V104, P3064, DOI 10.1152/jn.00318.2010; Chen CL, 2003, ARCH PHYS MED REHAB, V84, P1276, DOI 10.1016/S0003-9993(03)00200-4; Cohen-Adad J., 2009, NEUROIMAGE S1, V47, pS186; Courtine G, 2007, J NEUROPHYSIOL, V97, P772, DOI 10.1152/jn.00764.2006; Courtine G, 2019, NAT MED, V25, P898, DOI 10.1038/s41591-019-0475-6; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Danner SM, 2015, BRAIN, V138, P577, DOI 10.1093/brain/awu372; Darrow D, 2019, J NEUROTRAUM, V36, P2325, DOI 10.1089/neu.2018.6006; De Leener B, 2017, NEUROIMAGE, V145, P24, DOI 10.1016/j.neuroimage.2016.10.009; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Edgerton VR, 2011, EXPERT REV NEUROTHER, V11, P1351, DOI [10.1586/ern.11.129, 10.1586/ERN.11.129]; Eippert F, 2017, NEUROIMAGE, V154, P255, DOI 10.1016/j.neuroimage.2016.09.065; Formento E, 2018, NAT NEUROSCI, V21, P1728, DOI 10.1038/s41593-018-0262-6; Gerasimenko YP, 2006, J NEUROSCI METH, V157, P253, DOI 10.1016/j.jneumeth.2006.05.004; Gill M, 2020, FRONT SYST NEUROSCI, V14, DOI 10.3389/fnsys.2020.569337; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Gomez-Perez SL, 2016, JPEN-PARENTER ENTER, V40, P308, DOI 10.1177/0148607115604149; Greiner N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20703-1; Gros C, 2019, NEUROIMAGE, V184, P901, DOI 10.1016/j.neuroimage.2018.09.081; Gros C, 2018, MED IMAGE ANAL, V44, P215, DOI 10.1016/j.media.2017.12.001; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Herman R, 2002, SPINAL CORD, V40, P65, DOI 10.1038/sj.sc.3101263; Herrity AN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26602-2; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kasper L, 2017, J NEUROSCI METH, V276, P56, DOI 10.1016/j.jneumeth.2016.10.019; Kavounoudias A, 2008, NEUROPSYCHOLOGIA, V46, P567, DOI 10.1016/j.neuropsychologia.2007.10.002; Kinany N, 2020, NEURON, V108, P424, DOI 10.1016/j.neuron.2020.07.024; Kirshblum S, 2014, PHYS MED REH CLIN N, V25, P505, DOI 10.1016/j.pmr.2014.04.001; Kong YZ, 2012, NEUROIMAGE, V60, P1538, DOI 10.1016/j.neuroimage.2011.11.077; Landelle C, 2018, NEUROSCIENCE, V381, P91, DOI 10.1016/j.neuroscience.2018.04.015; Landelle C, 2020, NEUROIMAGE, V220, DOI 10.1016/j.neuroimage.2020.117056; Ditterline BEL, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.554018; Lempka SF, 2020, NEUROMODULATION, V23, P572, DOI 10.1111/ner.13037; Mignardot JB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3621; Minassian K, 2012, CLIN NEUROL NEUROSUR, V114, P489, DOI 10.1016/j.clineuro.2012.03.013; Minev IR, 2015, SCIENCE, V347, P159, DOI 10.1126/science.1260318; Molnar G, 2014, NEUROMODULATION, V17, P12, DOI 10.1111/ner.12171; Moraud EM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18293-y; Moraud EM, 2016, NEURON, V89, P814, DOI 10.1016/j.neuron.2016.01.009; Morse LR, 2021, J NEUROTRAUM, V38, P1251, DOI 10.1089/neu.2020.7174; Neufeld E, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0058; PierrotDeseilligny E, 2005, CIRCUITRY OF THE HUMAN SPINAL CORD: ITS ROLE IN MOTOR CONTROL AND MOVEMENT DISORDERS, P1, DOI 10.1017/CBO9780511545047; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Rattay F, 2003, NEUROMODULATION, V6, P42, DOI 10.1046/j.1525-1403.2003.03006.x; ROLL JP, 1982, EXP BRAIN RES, V47, P177; ROLL JP, 1989, EXP BRAIN RES, V76, P213; Schiavone G, 2020, ADV MATER, V32, DOI 10.1002/adma.201906512; Schirmer CM, 2011, J NEUROSURG-SPINE, V15, P64, DOI 10.3171/2011.2.SPINE1068; Shokur S, 2021, MED-CAMBRIDGE, V2, P912, DOI 10.1016/j.medj.2021.05.002; Soloukey S, 2021, NEUROMODULATION, V24, P779, DOI 10.1111/ner.13235; Squair JW, 2021, NATURE, V590, DOI 10.1038/s41586-020-03180-w; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2; Wenger N, 2016, NAT MED, V22, P138, DOI 10.1038/nm.4025; Wenger N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008325; Woolrich MW, 2004, NEUROIMAGE, V21, P1748, DOI 10.1016/j.neuroimage.2003.12.024; Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931; Yakovenko S, 2002, J NEUROPHYSIOL, V87, P1542, DOI 10.1152/jn.00479.2001	72	34	33	39	82	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					260	+		10.1038/s41591-021-01663-5	http://dx.doi.org/10.1038/s41591-021-01663-5		FEB 2022	41	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35132264				2022-12-27	WOS:000752184200001
J	Miller, JS; Davis, ZB; Helgeson, E; Reilly, C; Thorkelson, A; Anderson, J; Lima, NS; Jorstad, S; Hart, GT; Lee, JH; Safrit, JT; Wong, H; Cooley, S; Gharu, L; Chung, H; Soon-Shiong, P; Dobrowolski, C; Fletcher, CV; Karn, J; Douek, DC; Schacker, TW				Miller, Jeffrey S.; Davis, Zachary B.; Helgeson, Erika; Reilly, Cavan; Thorkelson, Ann; Anderson, Jodi; Lima, Noemia S.; Jorstad, Siri; Hart, Geoffrey T.; Lee, John H.; Safrit, Jeffrey T.; Wong, Hing; Cooley, Sarah; Gharu, Lavina; Chung, Hyunsoo; Soon-Shiong, Patrick; Dobrowolski, Curtis; Fletcher, Courtney, V; Karn, Jonathan; Douek, Daniel C.; Schacker, Timothy W.			Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; CD4(+) T-CELLS; INTERFERON-GAMMA; REPLICATION; INFECTION; INTERLEUKIN-15; INDIVIDUALS; PROVIDES; THERAPY; BIOLOGY	There is no cure for HIV infection, and lifelong antiretroviral therapy (ART) is required. N-803 is an IL-15 superagonist comprised of an N72D mutant IL-15 molecule attached to its alpha receptor and a human IgG1 fragment designed to increase IL-15 activity. Preclinical studies with both HIV and SIV suggest that the drug has potential to reduce virus reservoirs by activating virus from latency and enhancing effector function. We conducted a phase 1 study of N-803 (NCT02191098) in people living with HIV, the primary objective of which was to assess the safety and tolerability of the drug, with an exploratory objective of assessing the impact on peripheral virus reservoirs. ART-suppressed individuals were enrolled into a dose-escalation study of N-803 in four different cohorts (0.3, 1.0, 3.0 and 6.0 mcg kg(-1)). Each cohort received three doses total, separated by at least 1 week. We enrolled 16 individuals, of whom 11 completed all three doses. The maximum tolerated dose was 6.0 mcg kg(-1). The primary clinical adverse events (AEs) reported were injection site rash and adenopathy, and four participants experienced a grade 1 or grade 2 QTc prolongation. No significant laboratory AEs attributable to N-803 were observed. In exploratory analyses, N-803 was associated with proliferation and/or activation of CD4(+) and CD8(+) T cells and natural killer cells that peaked at 4 d after dosing. IFN-gamma, IP-10, MCP-1 and IL-15 increased during treatment. HIV transcription in memory CD4 T cells and intact proviral DNA initially increased after N-803 treatment; however, there was a small but significant decrease in the frequency of peripheral blood mononuclear cells with an inducible HIV provirus that persisted for up to 6 months after therapy. These data suggest that N-803 administration in ART-suppressed people living with HIV is safe and that larger clinical trials are needed to further investigate the effects of N-803 on HIV reservoirs.	[Miller, Jeffrey S.; Davis, Zachary B.; Thorkelson, Ann; Anderson, Jodi; Jorstad, Siri; Hart, Geoffrey T.; Cooley, Sarah; Schacker, Timothy W.] Univ Minnesota, Dept Med, Med Sch, Box 736 UMHC, Minneapolis, MN 55455 USA; [Helgeson, Erika; Reilly, Cavan] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; [Lima, Noemia S.; Gharu, Lavina; Chung, Hyunsoo; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lee, John H.; Safrit, Jeffrey T.; Soon-Shiong, Patrick] ImmunityBio, Culver City, CA USA; [Wong, Hing] HCW Biol, Miramar, FL USA; [Dobrowolski, Curtis; Karn, Jonathan] Case Western Reserve Univ, Med Sch, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; [Fletcher, Courtney, V] Univ Nebraska Med Ctr, UNMC Ctr Drug Discovery, Antiviral Pharmacol Lab, Omaha, NE USA; [Wong, Hing] Altor BioSci, Miramar, FL USA; [Cooley, Sarah] Fate Therapeut, San Diego, CA USA; [Dobrowolski, Curtis] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Dobrowolski, Curtis] Emory Sch Med, Atlanta, GA 30332 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Case Western Reserve University; University of Nebraska System; University of Nebraska Medical Center; University System of Georgia; Georgia Institute of Technology; Emory University	Schacker, TW (corresponding author), Univ Minnesota, Dept Med, Med Sch, Box 736 UMHC, Minneapolis, MN 55455 USA.	schacker@umn.edu		Miller, Jeffrey S/0000-0002-0339-4944; Lima, Noemia/0000-0003-4399-487X; dobrowolski, Curtis/0000-0001-6576-8318	Altor BioSciences; NIH [U24AI143502]; ImmunityBio	Altor BioSciences; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ImmunityBio	This research was funded entirely by a grant from Altor BioSciences and ImmunityBio to T.W.S. and by NIH U24AI143502 to Accelevir to help support the IPDA analyses. Neither Altor BioSciences nor ImmunityBio played any role in study design or execution of the study. P.S.-S. and J.L. are affiliated with ImmunityBio, and H.W. was CEO of Altor BioSciences when the study was initiated. We would like to thank E. Jeng for assistance with setting up the trial and A. T. Haase for insight and assistance in the analysis of data.	Bruner KM, 2019, NATURE, V566, P120, DOI 10.1038/s41586-019-0898-8; Conlon KC, 2015, J CLIN ONCOL, V33, P74, DOI 10.1200/JCO.2014.57.3329; Cooley S, 2019, BLOOD ADV, V3, P1970, DOI 10.1182/bloodadvances.2018028332; Das B, 2018, P NATL ACAD SCI USA, V115, pE7795, DOI 10.1073/pnas.1803468115; Dobrowolski C, 2019, MBIO, V10, DOI 10.1128/mBio.00337-19; Ellis-Connell AL, 2018, J VIROL, V92, DOI 10.1128/JVI.01748-17; Estes JD, 2017, NAT MED, V23, P1271, DOI 10.1038/nm.4411; Falcinelli SD, 2021, J INFECT DIS, V224, P92, DOI 10.1093/infdis/jiaa718; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111; Gianella S, 2022, CLIN INFECT DIS, V75, P73, DOI 10.1093/cid/ciab873; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Huang J, 2019, J IMMUNOTHER, V42, P354, DOI 10.1097/CJI.0000000000000269; Jones RB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005545; Josefsson L, 2011, P NATL ACAD SCI USA, V108, P11199, DOI 10.1073/pnas.1107729108; Nguyen K, 2017, MBIO, V8, DOI 10.1128/mBio.00133-17; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lorenzo-Redondo R, 2016, NATURE, V530, P51, DOI 10.1038/nature16933; Maldarelli F, 2014, SCIENCE, V345, P179, DOI 10.1126/science.1254194; Oliva A, 1998, J CLIN INVEST, V102, P223, DOI 10.1172/JCI2323; Rhode PR, 2016, CANCER IMMUNOL RES, V4, P49, DOI 10.1158/2326-6066.CIR-15-0093-T; Romee R, 2018, BLOOD, V131, P2515, DOI 10.1182/blood-2017-12-823757; Rosario M, 2016, CLIN CANCER RES, V22, P596, DOI 10.1158/1078-0432.CCR-15-1419; Rosenbloom DIS, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006849; Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Scully EP, 2019, J INFECT DIS, V219, P1084, DOI 10.1093/infdis/jiy617; Simonetti FR, 2020, P NATL ACAD SCI USA, V117, P18692, DOI 10.1073/pnas.2006816117; Stone M, 2021, J INFECT DIS, V224, P1209, DOI 10.1093/infdis/jiaa089; Wagner TA, 2014, SCIENCE, V345, P570, DOI 10.1126/science.1256304; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901	32	11	11	3	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2022	28	2					392	+		10.1038/s41591-021-01651-9	http://dx.doi.org/10.1038/s41591-021-01651-9		JAN 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ZF7EE	35102335				2022-12-27	WOS:000750421100003
J	Seyyed-Kalantari, L; Zhang, HR; McDermott, MBA; Chen, IY; Ghassemi, M				Seyyed-Kalantari, Laleh; Zhang, Haoran; McDermott, Matthew B. A.; Chen, Irene Y.; Ghassemi, Marzyeh			Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	NATURE MEDICINE			English	Article							HEALTH; DISPARITIES; CARE	Artificial intelligence algorithms trained using chest X-rays consistently underdiagnose pulmonary abnormalities or diseases in historically under-served patient populations, raising ethical concerns about the clinical use of such algorithms. Artificial intelligence (AI) systems have increasingly achieved expert-level performance in medical imaging applications. However, there is growing concern that such AI systems may reflect and amplify human bias, and reduce the quality of their performance in historically under-served populations such as female patients, Black patients, or patients of low socioeconomic status. Such biases are especially troubling in the context of underdiagnosis, whereby the AI algorithm would inaccurately label an individual with a disease as healthy, potentially delaying access to care. Here, we examine algorithmic underdiagnosis in chest X-ray pathology classification across three large chest X-ray datasets, as well as one multi-source dataset. We find that classifiers produced using state-of-the-art computer vision techniques consistently and selectively underdiagnosed under-served patient populations and that the underdiagnosis rate was higher for intersectional under-served subpopulations, for example, Hispanic female patients. Deployment of AI systems using medical imaging for disease diagnosis with such biases risks exacerbation of existing care biases and can potentially lead to unequal access to medical treatment, thereby raising ethical concerns for the use of these models in the clinic.	[Seyyed-Kalantari, Laleh] Univ Toronto, Toronto, ON, Canada; [Seyyed-Kalantari, Laleh; Ghassemi, Marzyeh] Vector Inst, Toronto, ON, Canada; [Zhang, Haoran; McDermott, Matthew B. A.; Chen, Irene Y.; Ghassemi, Marzyeh] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA	University of Toronto; Massachusetts Institute of Technology (MIT)	Seyyed-Kalantari, L (corresponding author), Univ Toronto, Toronto, ON, Canada.; Seyyed-Kalantari, L (corresponding author), Vector Inst, Toronto, ON, Canada.	laleh@cs.toronto.edu		Ghassemi, Marzyeh/0000-0001-6349-7251	Natural Sciences and Engineering Research Council of Canada (NSERC) [PDF-516984]; Microsoft Research; Canadian Institute for Advanced Research (CIFAR); NSERC Discovery Grant	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Microsoft Research(Microsoft); Canadian Institute for Advanced Research (CIFAR)(Canadian Institute for Advanced Research (CIFAR)); NSERC Discovery Grant(Natural Sciences and Engineering Research Council of Canada (NSERC))	The authors thank M. Haider for helpful discussions and acknowledge the support of the Natural Sciences and Engineering Research Council of Canada (NSERC, grant PDF-516984 to L.S.-K.), Microsoft Research (M.G.), Canadian Institute for Advanced Research (CIFAR) (M.G.) and an NSERC Discovery Grant (to M.G.). The authors also thank Vector Institute for providing high-performance computing platforms.	Aarti Bagul, 2017, Arxiv, DOI arXiv:1711.05225; Akbarian S., 2020, EVALUATING KNOWLEDGE; Allaouzi I, 2019, IEEE ACCESS, V7, P64279, DOI 10.1109/ACCESS.2019.2916849; Banerjee I., READING RACE AI RECO; Barocas S., 2019, FAIRNESS MACHINE LEA; Bhatt MLB, 2012, SOUTH ASIAN J CANCER, V1, P36, DOI 10.4103/2278-330X.96507; Buolamwini J., 2018, C FAIRNESS ACCOUNTAB, P77; Char DS, 2018, NEW ENGL J MED, V378, P981, DOI 10.1056/NEJMp1714229; Chen IY, 2020, NAT MED, V26, P16, DOI 10.1038/s41591-019-0649-2; Cohen J. P., 2020, P 3 C MED IM DEEP LE, V121, P136; Cowgill B, 2019, WORKING PAPER; CynthiaDwork Moritz Hardt, 2012, P 3 INNOVATIONS THEO, P214; De-Arteaga M, 2019, FAT*'19: PROCEEDINGS OF THE 2019 CONFERENCE ON FAIRNESS, ACCOUNTABILITY, AND TRANSPARENCY, P120, DOI 10.1145/3287560.3287572; DelBarrio E., 2020, REV MATH FRAMEWORKS; Gianfrancesco MA, 2018, JAMA INTERN MED, V178, P1544, DOI 10.1001/jamainternmed.2018.3763; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Haoran Zhang, 2020, CHIL '20: Proceedings of the Conference on Health, Inference, and Learning, P110, DOI 10.1145/3368555.3384448; Hardt M., 2016, ADV NEURAL INFORM PR, P3315, DOI 10.1109/ICCV.2015.169; Iandola F., 2014, ARXIV14041869; Irvin J, 2019, AAAI CONF ARTIF INTE, P590; James JT, 2013, J PATIENT SAF, V9, P122, DOI 10.1097/PTS.0b013e3182948a69; Johnson A, 2020, MIMIC-IV (version 0.4), DOI [10.13026/a3wn-hq05, DOI 10.13026/A3WN-HQ05]; Johnson A.E.W., 2019, PHYSIONET, DOI [10.13026/C2JT1Q, DOI 10.13026/C2JT1Q]; Johnson AEW, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0322-0; Larrazabal AJ, 2020, P NATL ACAD SCI USA, V117, P12592, DOI 10.1073/pnas.1919012117; Mamary AJ, 2018, COPD-J COPD FDN, V5, P177, DOI 10.15326/jcopdf.5.3.2017.0145; Morning Ann., 2001, J ETHN MIGR STUD, V27, P61, DOI [DOI 10.1080/13691830125692, 10.1080/13691830125692]; Oakden-Rayner Luke, 2020, Proc ACM Conf Health Inference Learn (2020), V2020, P151, DOI 10.1145/3368555.3384468; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Raghavan M, 2020, FAT* '20: PROCEEDINGS OF THE 2020 CONFERENCE ON FAIRNESS, ACCOUNTABILITY, AND TRANSPARENCY, P469, DOI 10.1145/3351095.3372828; Rao B, 2021, ACAD RADIOL, V28, P85, DOI 10.1016/j.acra.2020.01.035; Rimmer A, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4683; Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y; Seyyed-Kalantari L, 2021, PACIFIC SYMPOSIUM ON BICOMPUTING 2021, P232; Sim Y, 2020, RADIOLOGY, V294, P199, DOI 10.1148/radiol.2019182465; Spencer CS, 2013, HEALTH AFFAIR, V32, P1731, DOI 10.1377/hlthaff.2012.1400; Sun TY, 2020, ARXIV201106100CSSTAT; Tanno R, 2019, PROC CVPR IEEE, P11236, DOI 10.1109/CVPR.2019.01150; Verma S, 2018, 2018 IEEE/ACM INTERNATIONAL WORKSHOP ON SOFTWARE FAIRNESS (FAIRWARE 2018), P1, DOI 10.1145/3194770.3194776; Vyas DA, 2020, NEW ENGL J MED, V383, P874, DOI 10.1056/NEJMms2004740; Wang X., 2020, LEARNING IMAGE LABEL; Wang XS, 2017, PROC CVPR IEEE, P3462, DOI 10.1109/CVPR.2017.369; Whang JS, 2013, RADIOLOGY, V266, P548, DOI 10.1148/radiol.12111119; Wiens J, 2019, NAT MED, V25, P1337, DOI 10.1038/s41591-019-0548-6; Zhang H., 2021, C HLTH INFERENCE LEA, P2021, DOI [10.1145/3450439.3451878, DOI 10.1145/3450439.3451878]; Zhao J., 2017, P 2017 C EMP METH NA, P2979	46	22	22	5	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2021	27	12					2176	+		10.1038/s41591-021-01595-0	http://dx.doi.org/10.1038/s41591-021-01595-0		DEC 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XP3FG	34893776	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000729031100002
J	Metz, M; Sussman, G; Gagnon, R; Staubach, P; Tanus, T; Yang, WH; Lim, JJ; Clarke, HJ; Galanter, J; Chinn, LW; Chu, T; Teterina, A; Burgess, T; Haddon, DJ; Lu, TT; Maurer, M				Metz, Martin; Sussman, Gordon; Gagnon, Remi; Staubach, Petra; Tanus, Tonny; Yang, William H.; Lim, Jeremy J.; Clarke, Holly J.; Galanter, Joshua; Chinn, Leslie W.; Chu, Tom; Teterina, Anastasia; Burgess, Tracy; Haddon, D. James; Lu, Timothy T.; Maurer, Marcus			Fenebrutinib in H-1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial	NATURE MEDICINE			English	Article							CHRONIC IDIOPATHIC URTICARIA; BRUTONS TYROSINE KINASE; ANTI-IGE AUTOANTIBODIES; FC-EPSILON-RI; HISTAMINE-RELEASE; BASOPHIL ACTIVATION; SKIN-TEST; OMALIZUMAB; RECEPTOR; INHIBITOR	Bruton's tyrosine kinase (BTK) is crucial for Fc epsilon RI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID ) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 <= 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-Fc epsilon RI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU.	[Metz, Martin; Maurer, Marcus] Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, Dermatol Allergol, Berlin, Germany; [Metz, Martin; Maurer, Marcus] Fraunhofer Inst Translat Med & Pharmacol ITMP, Allergol, Berlin, Germany; [Sussman, Gordon] St Michaels Hosp, Div Allergy & Clin Immunol, Toronto, ON, Canada; [Sussman, Gordon] Univ Toronto, Toronto, ON, Canada; [Gagnon, Remi] Ctr Hosp Univ Quebec, Dept Med, Serv Allergie & Immunol, Quebec City, PQ, Canada; [Staubach, Petra] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany; [Tanus, Tonny] Kern Allergy Med Clin Inc, Bakersfield, CA USA; [Yang, William H.] Univ Ottawa, Dept Med, Ottawa Allergy Res Corp, Ottawa, ON, Canada; [Lim, Jeremy J.; Clarke, Holly J.; Galanter, Joshua; Chinn, Leslie W.; Chu, Tom; Burgess, Tracy; Haddon, D. James; Lu, Timothy T.] Genentech Inc, San Francisco, CA USA; [Teterina, Anastasia] Hoffman LaRoche Ltd, Mississauga, ON, Canada	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Laval University; Johannes Gutenberg University of Mainz; University of Ottawa; Roche Holding; Genentech	Maurer, M (corresponding author), Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, Dermatol Allergol, Berlin, Germany.	marcus.maurer@charite.de	Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X	Genentech	Genentech(Roche HoldingGenentech)	This trial was supported by Genentech. Genentech was involved in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review and approval of the manuscript and decision to submit the manuscript for publication. We thank the patients and their families who participated in this trial. We also thank S. Limb and D. Musselman for their expertise and assistance throughout the study, as well as the investigators, healthcare providers and the staff who conducted the study. Editing and writing assistance was provided by D. Solymar (Genentech) and was funded by Genentech.	Altrichter S, 2021, ALLERGY ASTHMA IMMUN, V13, P206, DOI 10.4168/aair.2021.13.2.206; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Asero R, 2020, CLIN EXP IMMUNOL, V200, P242, DOI 10.1111/cei.13428; Atallah E, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01825-2; Biagtan MJ, 2011, J ALLERGY CLIN IMMUN, V127, P1626, DOI 10.1016/j.jaci.2011.01.045; Cho CB, 2013, ANN ALLERG ASTHMA IM, V110, P29, DOI 10.1016/j.anai.2012.10.020; Cohen S, 2020, ARTHRITIS RHEUMATOL, V72, P1435, DOI 10.1002/art.41275; Crawford JJ, 2018, J MED CHEM, V61, P2227, DOI 10.1021/acs.jmedchem.7b01712; De Swerdt A, 2005, J ALLERGY CLIN IMMUN, V116, P662, DOI 10.1016/j.jaci.2005.04.042; Deza G, 2019, J ALLER CL IMM-PRACT, V7, P1619, DOI 10.1016/j.jaip.2019.01.026; Dispenza MC, 2020, J CLIN INVEST, V130, P4759, DOI 10.1172/JCI138448; Dispenza MC, 2018, J ALLERGY CLIN IMMUN, V141, P1914, DOI 10.1016/j.jaci.2017.12.987; Ertas R, 2018, ALLERGY, V73, P705, DOI 10.1111/all.13345; Fricke J, 2020, ALLERGY, V75, P423, DOI 10.1111/all.14037; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Ghazanfar MN, 2016, BRIT J DERMATOL, V175, P404, DOI 10.1111/bjd.14540; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Griffith QK, 2011, J IMMUNOL, V186, P1060, DOI 10.4049/jimmunol.1002709; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Guidance for industry, 2009, DRUG IND LIV INJ PRE; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Herman AE, 2018, CLIN PHARMACOL THER, V103, P1020, DOI 10.1002/cpt.1056; HIBI T, 1986, EUR J IMMUNOL, V16, P139, DOI 10.1002/eji.1830160206; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Holowka D, 2007, IMMUNOL REV, V217, P269, DOI 10.1111/j.1600-065X.2007.00517.x; Isenberg D, 2021, ARTHRITIS RHEUMATOL, V73, P1835, DOI 10.1002/art.41811; Kaplan A, 2016, J ALLERGY CLIN IMMUN, V137, P474, DOI 10.1016/j.jaci.2015.08.023; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kaplan AP, 2017, ALLERGY ASTHMA IMMUN, V9, P477, DOI 10.4168/aair.2017.9.6.477; Katewa A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90111; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; Kneidinger M, 2008, BLOOD, V111, P3097, DOI 10.1182/blood-2007-08-104372; Kolkhir P, 2018, J ALLERGY CLIN IMMUN, V141, P1166, DOI 10.1016/j.jaci.2017.09.010; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; Kulthanan K, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0466-y; Lakin E, 2019, THERANOSTICS, V9, P829, DOI 10.7150/thno.29902; Mathias SD, 2012, ANN ALLERG ASTHMA IM, V108, P20, DOI 10.1016/j.anai.2011.09.008; Maurer M, 2019, NEW ENGL J MED, V381, P1321, DOI 10.1056/NEJMoa1900408; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Montalban X, 2019, NEW ENGL J MED, V380, P2406, DOI 10.1056/NEJMoa1901981; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Niu XL, 2019, EXP THER MED, V17, P2603, DOI 10.3892/etm.2019.7266; OKelly M, 2014, STAT PRACT, P1, DOI 10.1002/9781118762516; Puccetti A, 2005, CLIN EXP ALLERGY, V35, P1599, DOI 10.1111/j.1365-2222.2005.02380.x; Regan JA, 2017, J ALLERGY CLIN IMMUN, V140, P875, DOI 10.1016/j.jaci.2017.03.013; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Sanchez J, 2019, ALLERGY ASTHMA IMMUN, V11, P29, DOI 10.4168/aair.2019.11.1.29; Schmetzer O, 2018, J ALLERGY CLIN IMMUN, V142, P876, DOI 10.1016/j.jaci.2017.10.035; SMITH CIE, 1994, J IMMUNOL, V152, P557; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Vonakis BM, 2008, J ALLERGY CLIN IMMUN, V121, P262, DOI 10.1016/j.jaci.2007.10.010; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	57	16	16	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2021	27	11					1961	+		10.1038/s41591-021-01537-w	http://dx.doi.org/10.1038/s41591-021-01537-w		NOV 2021	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	XA5DB	34750553	hybrid, Green Published			2022-12-27	WOS:000715714300003
J	Kundu, S				Kundu, Shinjini			AI in medicine must be explainable	NATURE MEDICINE			English	Editorial Material									[Kundu, Shinjini] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Kundu, S (corresponding author), Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.	skundu2@jhmi.edu							0	35	35	3	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1328	1328		10.1038/s41591-021-01461-z	http://dx.doi.org/10.1038/s41591-021-01461-z		JUL 2021	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34326551				2022-12-27	WOS:000679255200001
J	Stephenson, E; Reynolds, G; Botting, RA; Calero-Nieto, FJ; Morgan, MD; Tuong, ZK; Bach, K; Sungnak, W; Worlock, KB; Yoshida, M; Kumasaka, N; Kania, K; Engelbert, J; Olabi, B; Spegarova, JS; Wilson, NK; Mende, N; Jardine, L; Gardner, LCS; Goh, I; Horsfall, D; McGrath, J; Webb, S; Mather, MW; Lindeboom, RGH; Dann, E; Huang, N; Polanski, K; Prigmore, E; Gothe, F; Scott, J; Payne, RP; Baker, KF; Hanrath, AT; van der Loeff, ICDS; Barr, AS; Sanchez-Gonzalez, A; Bergamaschi, L; Mescia, F; Barnes, JL; Kilich, E; de Wilton, A; Saigal, A; Saleh, A; Janes, SM; Smith, CM; Gopee, N; Wilson, C; Coupland, P; Coxhead, JM; Kiselev, VY; van Dongen, S; Bacardit, J; King, HW; Rostron, AJ; Simpson, AJ; Hambleton, S; Laurenti, E; Lyons, PA; Meyer, KB; Nikolic, MZ; Duncan, CJA; Smith, KGC; Teichmann, SA; Clatworthy, MR; Marioni, JC; Gottgens, B; Haniffa, M				Stephenson, Emily; Reynolds, Gary; Botting, Rachel A.; Calero-Nieto, Fernando J.; Morgan, Michael D.; Tuong, Zewen Kelvin; Bach, Karsten; Sungnak, Waradon; Worlock, Kaylee B.; Yoshida, Masahiro; Kumasaka, Natsuhiko; Kania, Katarzyna; Engelbert, Justin; Olabi, Bayan; Spegarova, Jarmila Stremenova; Wilson, Nicola K.; Mende, Nicole; Jardine, Laura; Gardner, Louis C. S.; Goh, Issac; Horsfall, Dave; McGrath, Jim; Webb, Simone; Mather, Michael W.; Lindeboom, Rik G. H.; Dann, Emma; Huang, Ni; Polanski, Krzysztof; Prigmore, Elena; Gothe, Florian; Scott, Jonathan; Payne, Rebecca P.; Baker, Kenneth F.; Hanrath, Aidan T.; van der Loeff, Ina C. D. Schim; Barr, Andrew S.; Sanchez-Gonzalez, Amada; Bergamaschi, Laura; Mescia, Federica; Barnes, Josephine L.; Kilich, Eliz; de Wilton, Angus; Saigal, Anita; Saleh, Aarash; Janes, Sam M.; Smith, Claire M.; Gopee, Nusayhah; Wilson, Caroline; Coupland, Paul; Coxhead, Jonathan M.; Kiselev, Vladimir Yu; van Dongen, Stijn; Bacardit, Jaume; King, Hamish W.; Rostron, Anthony J.; Simpson, A. John; Hambleton, Sophie; Laurenti, Elisa; Lyons, Paul A.; Meyer, Kerstin B.; Nikolic, Marko Z.; Duncan, Christopher J. A.; Smith, Kenneth G. C.; Teichmann, Sarah A.; Clatworthy, Menna R.; Marioni, John C.; Gottgens, Berthold; Haniffa, Muzlifah		Cambridge Inst Therapeutic Immunol	Single-cell multi-omics analysis of the immune response in COVID-19	NATURE MEDICINE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; VIRUS-INFECTION; SEQUENCING DATA; INFLAMMATION; DISCOVERY; ABUNDANCE; DEPENDS	Analysis of human blood immune cells provides insights into the coordinated response to viral infections such as severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19). We performed single-cell transcriptome, surface proteome and T and B lymphocyte antigen receptor analyses of over 780,000 peripheral blood mononuclear cells from a cross-sectional cohort of 130 patients with varying severities of COVID-19. We identified expansion of nonclassical monocytes expressing complement transcripts (CD16(+)C1QA/B/C+) that sequester platelets and were predicted to replenish the alveolar macrophage pool in COVID-19. Early, uncommitted CD34(+) hematopoietic stem/progenitor cells were primed toward megakaryopoiesis, accompanied by expanded megakaryocyte-committed progenitors and increased platelet activation. Clonally expanded CD8(+) T cells and an increased ratio of CD8(+) effector T cells to effector memory T cells characterized severe disease, while circulating follicular helper T cells accompanied mild disease. We observed a relative loss of IgA2 in symptomatic disease despite an overall expansion of plasmablasts and plasma cells. Our study highlights the coordinated immune response that contributes to COVID-19 pathogenesis and reveals discrete cellular components that can be targeted for therapy. Transcriptomic and proteomic profiling of blood samples from individuals with COVID-19 reveals immune cell and hematopoietic progenitor cell alterations that are differentially associated with disease severity.	[Stephenson, Emily; Reynolds, Gary; Botting, Rachel A.; Engelbert, Justin; Olabi, Bayan; Jardine, Laura; Gardner, Louis C. S.; Goh, Issac; Horsfall, Dave; McGrath, Jim; Webb, Simone; Mather, Michael W.; Gopee, Nusayhah; Wilson, Caroline; Coxhead, Jonathan M.; Haniffa, Muzlifah] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Calero-Nieto, Fernando J.; Wilson, Nicola K.; Mende, Nicole; Laurenti, Elisa; Gottgens, Berthold] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England; [Morgan, Michael D.; Bach, Karsten; Marioni, John C.] European Bioinformat Inst EMBL EBI, European Mol Biol Lab, Wellcome Genome Campus, Cambridge, England; [Morgan, Michael D.; Bach, Karsten; Kania, Katarzyna; Coupland, Paul; Marioni, John C.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Tuong, Zewen Kelvin; Clatworthy, Menna R.] Univ Cambridge, Dept Med, Mol Immun Unit, Cambridge, England; [Tuong, Zewen Kelvin; Sungnak, Waradon; Kumasaka, Natsuhiko; Lindeboom, Rik G. H.; Dann, Emma; Huang, Ni; Polanski, Krzysztof; Prigmore, Elena; Kiselev, Vladimir Yu; van Dongen, Stijn; King, Hamish W.; Meyer, Kerstin B.; Teichmann, Sarah A.; Clatworthy, Menna R.; Marioni, John C.; Haniffa, Muzlifah] Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge, England; [Worlock, Kaylee B.; Yoshida, Masahiro; Barnes, Josephine L.; Janes, Sam M.; Nikolic, Marko Z.] UCL, Div Med, UCL Resp, London, England; [Spegarova, Jarmila Stremenova; Gothe, Florian; Scott, Jonathan; Payne, Rebecca P.; Baker, Kenneth F.; Hanrath, Aidan T.; van der Loeff, Ina C. D. Schim; Rostron, Anthony J.; Simpson, A. John; Hambleton, Sophie; Duncan, Christopher J. A.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Baker, Kenneth F.; Haniffa, Muzlifah] Newcastle Hosp NHS Fdn Trust, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Hanrath, Aidan T.; Barr, Andrew S.; Sanchez-Gonzalez, Amada; Duncan, Christopher J. A.] Newcastle Upon Tyne Hosp NHS Fdn, Dept Infect & Trop Med, Newcastle Upon Tyne, Tyne & Wear, England; [Bergamaschi, Laura; Mescia, Federica; Lyons, Paul A.; Smith, Kenneth G. C.] Jeffrey Cheah Biomed Ctr, Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge Biomed Campus, Cambridge, England; [Bergamaschi, Laura; Mescia, Federica; Lyons, Paul A.; Smith, Kenneth G. C.; Clatworthy, Menna R.] Univ Cambridge, Dept Med, Cambridge Biomed Campus, Cambridge, England; [Kilich, Eliz; de Wilton, Angus; Janes, Sam M.; Nikolic, Marko Z.] Univ Coll London Hosp NHS Fdn Trust, London, England; [Saigal, Anita; Saleh, Aarash] Royal Free Hosp NHS Fdn Trust, London, England; [Smith, Claire M.] UCL Great Ormond St Inst Child Hlth, London, England; [Gopee, Nusayhah; Haniffa, Muzlifah] Newcastle Hosp NHS Fdn Trust, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England; [Wilson, Caroline] Innovat Lab Integrated COVID Hub North East, Newcastle Upon Tyne, Tyne & Wear, England; [Bacardit, Jaume] Newcastle Univ, Sch Comp, Newcastle Upon Tyne, Tyne & Wear, England; [King, Hamish W.] Queen Mary Univ London, Blizard Inst, Ctr Immunobiol, London, England; [Rostron, Anthony J.] South Tyneside & Sunderland NHS Fdn Trust, Sunderland Royal Hosp, Integrated Crit Care Unit, Sunderland, England; [Teichmann, Sarah A.] Univ Cambridge, Dept Phys, Theory Condensed Matter Grp, Cavendish Lab, Cambridge, England; [Clatworthy, Menna R.] Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge Biomed Campus, Cambridge, England; [Clatworthy, Menna R.] NIHR Cambridge Biomed Res Ctr, Cambridge, England; [Clatworthy, Menna R.] Ludwig Maximilians Univ Munchen, Univ Hosp, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany	Newcastle University - UK; University of Cambridge; European Molecular Biology Laboratory (EMBL); Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; Wellcome Trust Sanger Institute; University of London; University College London; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Cambridge; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; University of London; Queen Mary University London; Sunderland Royal Hospital; University of Cambridge; University of Cambridge; University of Munich	Haniffa, M (corresponding author), Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.; Gottgens, B (corresponding author), Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England.; Marioni, JC (corresponding author), European Bioinformat Inst EMBL EBI, European Mol Biol Lab, Wellcome Genome Campus, Cambridge, England.; Marioni, JC (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.; Clatworthy, MR (corresponding author), Univ Cambridge, Dept Med, Mol Immun Unit, Cambridge, England.; Teichmann, SA; Clatworthy, MR; Marioni, JC (corresponding author), Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge, England.; Haniffa, M (corresponding author), Newcastle Hosp NHS Fdn Trust, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.; Clatworthy, MR (corresponding author), Univ Cambridge, Dept Med, Cambridge Biomed Campus, Cambridge, England.; Haniffa, M (corresponding author), Newcastle Hosp NHS Fdn Trust, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England.; Teichmann, SA (corresponding author), Univ Cambridge, Dept Phys, Theory Condensed Matter Grp, Cavendish Lab, Cambridge, England.; Clatworthy, MR (corresponding author), Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge Biomed Campus, Cambridge, England.; Clatworthy, MR (corresponding author), NIHR Cambridge Biomed Res Ctr, Cambridge, England.; Clatworthy, MR (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany.	st9@sanger.ac.uk; mrc38@cam.ac.uk; marioni@ebi.ac.uk; bg200@cam.ac.uk; m.a.haniffa@ncl.ac.uk	Tuong, Zewen Kelvin/E-4419-2017; King, Hamish/U-9808-2019; Bunclark, Katherine/GLN-3109-2022; Mende, Nicole/CAF-3541-2022; Payne, Rebecca/AAC-4783-2022; Baker, Kenneth Frank/AAD-6644-2019; Morgan, Michael/A-4840-2015; Summers, Charlotte/A-6973-2012; Duncan, Christopher/A-2018-2012	Tuong, Zewen Kelvin/0000-0002-6735-6808; King, Hamish/0000-0001-5972-8926; Bunclark, Katherine/0000-0002-8785-0715; Payne, Rebecca/0000-0002-9037-7367; Baker, Kenneth Frank/0000-0002-6735-2911; Yoshida, Masahiro/0000-0002-3521-5322; Stephenson, Emily/0000-0002-4244-4019; Toshner, Mark/0000-0002-3969-6143; Stremenova Spegarova, Jarmila/0000-0002-0710-9266; Clatworthy, Menna/0000-0002-3340-9828; Kingston, Nathalie/0000-0002-9190-2231; Goh, Issac/0000-0002-6397-3518; Webb, Simone/0000-0003-3058-8952; Ireland, Aidan Taeke/0000-0001-9513-2302; Engelbert, Justin/0000-0002-4255-9668; Simpson, John/0000-0003-4731-7294; Reynolds, Gary/0000-0002-8142-8708; Gardner, Louis/0000-0002-7200-978X; Morgan, Michael/0000-0003-0757-0711; Summers, Charlotte/0000-0002-7269-2873; Schim van der Loeff, Ina/0000-0003-1196-6196; Bradley, John/0000-0002-7774-8805; Rostron, Anthony/0000-0002-9336-1723; Walker, Neil/0000-0001-9796-7688; Calero-Nieto, Fernando/0000-0003-3358-8253; Smith, Claire/0000-0002-8913-0009; Worlock, Kaylee/0000-0002-5656-7634; Kania, Katarzyna/0000-0001-8206-1349; Marioni, John/0000-0001-9092-0852; Baker, Stephen/0000-0003-1308-5755; Duncan, Christopher/0000-0003-4181-2315	Wellcome Human Cell Atlas Strategic Science Support [WT211276/Z/18/Z]; Wellcome [WT211276/Z/18/Z, WT107931/Z/15/Z, 206328/Z/17/Z, WT206194, 207556_Z_17_Z, 211153/Z/18/Z, 203151/Z/16/Z]; Lister Institute for Preventive Medicine; Newcastle NIHR Biomedical Research Centre; MRC [203151/Z/16/Z, MR/S036113/1]; Aging Biology Foundation; ERC; EU MRG-Grammar awards; Medical Research Council Human Cell Atlas Research Grant [MR/S035842/1]; Cancer Research UK [C9545/A29580]; European Molecular Biology Laboratory; Versus Arthritis Cure Challenge Research Grant [21777]; NIHR Research Professorship [RP-2017-08-ST2-002]; Sir Henry Wellcome Postdoctoral Fellowship [213555/Z/18/Z]; Chan Zuckerberg Initiative [2017-174169]; Sanger Core [WT206194]; UKRI Innovation/Rutherford Fund Fellowship by the MRC; UK Regenerative Medicine Platform [MR/5005579/1]; Rosetrees Trust [M944]; University College London, Birkbeck MRC Doctoral Training Programme.; Jikei University School of Medicine; NIHR [ACF-2018-01-004]; BMA Foundation; NIHR Clinical Lectureship [CL-2017-01-004]; Action Medical Research [GN2779]; DFG Research Fellowship [ME 5209/11]; Barbour Foundation; Barbour Foundation PhD studentship; Wellcome/Royal Society [107630/Z/15/Z]; BBSRC [BB/P002293/1, BB/V006738/1]; GOSH Children's charity [COVID_CSmith_017]; Wellcome Trust [212516/Z/18/Z]; NIHR GOSH Biomedical research centre; UKRI/NIHR through the UK Coronavirus Immunology Consortium.; MRC	Wellcome Human Cell Atlas Strategic Science Support; Wellcome; Lister Institute for Preventive Medicine; Newcastle NIHR Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Aging Biology Foundation; ERC(European Research Council (ERC)European Commission); EU MRG-Grammar awards; Medical Research Council Human Cell Atlas Research Grant; Cancer Research UK(Cancer Research UK); European Molecular Biology Laboratory; Versus Arthritis Cure Challenge Research Grant; NIHR Research Professorship; Sir Henry Wellcome Postdoctoral Fellowship; Chan Zuckerberg Initiative; Sanger Core; UKRI Innovation/Rutherford Fund Fellowship by the MRC; UK Regenerative Medicine Platform; Rosetrees Trust(Rosetrees Trust); University College London, Birkbeck MRC Doctoral Training Programme.(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Jikei University School of Medicine(Jikei University); NIHR(National Institute for Health Research (NIHR)); BMA Foundation; NIHR Clinical Lectureship; Action Medical Research; DFG Research Fellowship(German Research Foundation (DFG)); Barbour Foundation; Barbour Foundation PhD studentship; Wellcome/Royal Society; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); GOSH Children's charity; Wellcome Trust(Wellcome Trust); NIHR GOSH Biomedical research centre; UKRI/NIHR through the UK Coronavirus Immunology Consortium.; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This publication is part of the Human Cell Atlas (https://www.humancellatlas.org/publications/).We acknowledge assistance from P. Vegh, J. Fletcher and D. Dixon to the IV-LPS study and funding from the Wellcome Human Cell Atlas Strategic Science Support (WT211276/Z/18/Z). We acknowledge B. Yeung and K. `Kit' Nazor from BioLegend for helpful discussions in the optimization of the CITE-seq protocol. We acknowledge B. Stewart for his helpful contributions toward curation of the final dataset. We acknowledge R. Queen and R. Hussain from Newcastle University Genomics Core Facility for technical assistance. We acknowledge M. Glanville and the Newcastle University Infectious Diseases Facility for biosafety level 3 laboratory access and assistance. We acknowledge M. Prete for assistance with online data hosting and interactivity. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centers, NHS Trusts and staff for their contribution. We thank the NIHR, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. A.J.S. is an NIHR senior investigator; the views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. M.H. is funded by Wellcome (WT107931/Z/15/Z), The Lister Institute for Preventive Medicine and Newcastle NIHR Biomedical Research Centre. B.G. is funded by Wellcome (206328/Z/17/Z), MRC (MR/S036113/1), and the Aging Biology Foundation. S.A.T. is funded by Wellcome (WT206194), ERC Consolidator and EU MRG-Grammar awards. Z.K.T. and M.R.C. are supported by a Medical Research Council Human Cell Atlas Research Grant (MR/S035842/1). J.C.M. is supported by core funding from Cancer Research UK (C9545/A29580) and from the European Molecular Biology Laboratory. M.R.C. is supported by a Versus Arthritis Cure Challenge Research Grant (21777), and an NIHR Research Professorship (RP-2017-08-ST2-002). S.H. is funded by Wellcome (207556_Z_17_Z). H.W.K. is supported by a Sir Henry Wellcome Postdoctoral Fellowship (213555/Z/18/Z). K.B.M. acknowledges funding from the Chan Zuckerberg Initiative (2017-174169), Wellcome (WT211276/Z/18/Z) and Sanger Core (WT206194). M.Z.N. acknowledges funding from a UKRI Innovation/Rutherford Fund Fellowship allocated by the MRC and the UK Regenerative Medicine Platform (MR/5005579/1). M.Z.N. and K.B.M. have been funded by the Rosetrees Trust (M944). K.B.W. is funded by University College London, Birkbeck MRC Doctoral Training Programme. J.L.B. acknowledges funding from the MRC and the UK Regenerative Medicine Platform (MR/5005579/1). M.Y. is funded by The Jikei University School of Medicine. A.T.H. is funded by the NIHR (ACF-2018-01-004) and the BMA Foundation. K.F.B is funded by an NIHR Clinical Lectureship (CL-2017-01-004). M.W.M. is funded by Action Medical Research (GN2779). N.M. is supported by a DFG Research Fellowship (ME 5209/11). C.J.A.D. is funded by Wellcome (211153/Z/18/Z) and acknowledges support from the Barbour Foundation. S.W. is funded by a Barbour Foundation PhD studentship. E.L. is supported by a Sir Henry Dale fellowship from Wellcome/Royal Society (107630/Z/15/Z), BBSRC (BB/P002293/1), and core support grants from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute (203151/Z/16/Z) C.M.S is currently supported by grants from BBSRC (BB/V006738/1), GOSH Children's charity (COVID_CSmith_017), Wellcome Trust (212516/Z/18/Z) and NIHR GOSH Biomedical research centre.; r This work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium.	Adlowitz DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128269; [Anonymous], LANCET, DOI [10.1016/S0140-6736%2820%2930211-7, DOI 10.1016/S0140-6736(20)30211-7]; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bashford-Rogers RJM, 2013, GENOME RES, V23, P1874, DOI 10.1101/gr.154815.113; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardes JP, 2020, IMMUNITY, V53, P1296, DOI 10.1016/j.immuni.2020.11.017; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Boothby M, 2017, IMMUNITY, V46, P743, DOI 10.1016/j.immuni.2017.04.009; Buttner M, 2019, NAT METHODS, V16, P43, DOI 10.1038/s41592-018-0254-1; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Desai Niyati, 2020, medRxiv, DOI 10.1101/2020.07.30.20165241; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Doughty CA, 2006, BLOOD, V107, P4458, DOI 10.1182/blood-2005-12-4788; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Evren E, 2021, IMMUNITY, V54, P259, DOI 10.1016/j.immuni.2020.12.003; Gadala-Maria D, 2015, P NATL ACAD SCI USA, V112, pE862, DOI 10.1073/pnas.1417683112; Ghazanfar S, 2019, BIOINFORMATICS, V35, P823, DOI 10.1093/bioinformatics/bty698; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Haghverdi L, 2018, NAT BIOTECHNOL, V36, P421, DOI 10.1038/nbt.4091; Hay SB, 2018, EXP HEMATOL, V68, P51, DOI 10.1016/j.exphem.2018.09.004; Heaton H, 2020, NAT METHODS, V17, P615, DOI 10.1038/s41592-020-0820-1; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hottz ED, 2020, BLOOD, V136, P1330, DOI 10.1182/blood.2020007252; Ivanov S, 2013, J VIROL, V87, P6911, DOI 10.1128/JVI.02943-12; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Jardine L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09913-4; John Hopkins University, 2020, COVID 19 MAP; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Kaneko Naoki, 2020, SSRN, P3652322, DOI [10.1016/j.cell.2020.08.025, 10.2139/ssrn.3652322]; Korotkevich G., 2016, BIORXIV, DOI [10.1101/060012, DOI 10.1101/060012, 10.1101/060012v3]; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Le Bert N, 2021, J EXP MED, V218, DOI 10.1084/jem.20202617; Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554; Lefranc M.-P., 2008, NOVARTIS FDN S, V254, P126; Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu C, 2021, CELL, V184, P1836, DOI 10.1016/j.cell.2021.02.018; Lun ATL, 2017, NAT METHODS, V14, P707, DOI 10.1038/nmeth.4295; Maloy KJ, 2000, J EXP MED, V191, P2159, DOI 10.1084/jem.191.12.2159; Mann ER, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6197; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Mende N., QUANTITATIVE MOL DIF, DOI [10.1101/2020.01.26.919753, DOI 10.1101/2020.01.26.919753]; Meng XY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02683-x; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Monaco G, 2019, CELL REP, V26, P1627, DOI 10.1016/j.celrep.2019.01.041; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Parrot T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe1670; Pritchard NR, 2003, IMMUNOLOGY, V108, P263, DOI 10.1046/j.1365-2567.2003.01592.x; Ren XW, 2021, CELL, V184, P1895, DOI 10.1016/j.cell.2021.01.053; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Velten L, 2017, NAT CELL BIOL, V19, P271, DOI 10.1038/ncb3493; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; WHO, 2021, CLIN MAN COVID 19; Woodruff MC, 2020, NAT IMMUNOL, V21, P1506, DOI 10.1038/s41590-020-00814-z; Zhang JY, 2020, NAT IMMUNOL, V21, P1107, DOI 10.1038/s41590-020-0762-x	68	143	145	16	63	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					904	+		10.1038/s41591-021-01329-2	http://dx.doi.org/10.1038/s41591-021-01329-2		APR 2021	41	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33879890	Green Published, hybrid			2022-12-27	WOS:000641678100001
J	Pietzner, M; Stewart, ID; Raffler, J; Khaw, KT; Michelotti, GA; Kastenmuller, G; Wareham, NJ; Langenberg, C				Pietzner, Maik; Stewart, Isobel D.; Raffler, Johannes; Khaw, Kay-Tee; Michelotti, Gregory A.; Kastenmueller, Gabi; Wareham, Nicholas J.; Langenberg, Claudia			Plasma metabolites to profile pathways in noncommunicable disease multimorbidity	NATURE MEDICINE			English	Article							HEALTH-CARE; METABOLOMICS; RISK; EPIDEMIOLOGY; OMICS; ACID	Multimorbidity, the simultaneous presence of multiple chronic conditions, is an increasing global health problem and research into its determinants is of high priority. We used baseline untargeted plasma metabolomics profiling covering >1,000 metabolites as a comprehensive readout of human physiology to characterize pathways associated with and across 27 incident noncommunicable diseases (NCDs) assessed using electronic health record hospitalization and cancer registry data from over 11,000 participants (219,415 person years). We identified 420 metabolites shared between at least 2 NCDs, representing 65.5% of all 640 significant metabolite-disease associations. We integrated baseline data on over 50 diverse clinical risk factors and characteristics to identify actionable shared pathways represented by those metabolites. Our study highlights liver and kidney function, lipid and glucose metabolism, low-grade inflammation, surrogates of gut microbial diversity and specific health-related behaviors as antecedents of common NCD multimorbidity with potential for early prevention. We integrated results into an open-access webserver (https://omicscience.org/apps/mwasdisease/) to facilitate future research and meta-analyses. Untargeted metabolomics profiling coupled with analysis of electronic health records in over 11,000 participants in the EPIC-Norfolk cohort reveals shared pathways that contribute to multimorbidity of noncommunicable diseases.	[Pietzner, Maik; Stewart, Isobel D.; Kastenmueller, Gabi; Wareham, Nicholas J.; Langenberg, Claudia] Univ Cambridge, MRC, Epidemiol Unit, Cambridge, England; [Raffler, Johannes; Kastenmueller, Gabi] Helmholtz Zentrum Munchen, Inst Computat Biol, Munich, Germany; [Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Michelotti, Gregory A.] Metabolon Inc, Durham, NC USA; [Langenberg, Claudia] Hlth Data Res UK, Wellcome Genome Campus, Cambridge, England; [Langenberg, Claudia] Univ Cambridge, Cambridge, England; [Langenberg, Claudia] Charite, Berlin Inst Hlth, Computat Med, Berlin, Germany	University of Cambridge; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Cambridge; Metabolon; University of Cambridge; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Langenberg, C (corresponding author), Univ Cambridge, MRC, Epidemiol Unit, Cambridge, England.; Langenberg, C (corresponding author), Hlth Data Res UK, Wellcome Genome Campus, Cambridge, England.; Langenberg, C (corresponding author), Univ Cambridge, Cambridge, England.; Langenberg, C (corresponding author), Charite, Berlin Inst Hlth, Computat Med, Berlin, Germany.	claudia.langenberg@mrc-epid.cam.ac.uk	Langenberg, Claudia/ABG-9067-2021; Khaw, Kay-Tee/AAZ-3209-2021	Langenberg, Claudia/0000-0002-5017-7344; Wareham, Nicholas/0000-0003-1422-2993; Raffler, Johannes/0000-0003-2495-4020; Pietzner, Maik/0000-0003-3437-9963; Kastenmuller, Gabi/0000-0002-2368-7322				Alpert A, 2019, NAT MED, V25, P487, DOI 10.1038/s41591-019-0381-y; [Anonymous], 2018, ACAD MED SCI MULTIMO; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Busija L, 2019, EUR J EPIDEMIOL, V34, P1025, DOI 10.1007/s10654-019-00568-5; Canfora EE, 2019, NAT REV ENDOCRINOL, V15, P261, DOI 10.1038/s41574-019-0156-z; Day N, 1999, BRIT J CANCER, V80, P95; Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2; Freisling H, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1474-7; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; Guasch-Ferre M, 2016, DIABETES CARE, V39, P833, DOI 10.2337/dc15-2251; Heianza Y, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004947; Hoyles L, 2018, NAT MED, V24, P1070, DOI 10.1038/s41591-018-0061-3; Huang YT, 2017, EPIDEMIOLOGY, V28, P370, DOI 10.1097/EDE.0000000000000651; Hussin NM, 2019, AGING CLIN EXP RES, V31, P215, DOI 10.1007/s40520-018-1007-9; Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05184-7; Jensen AB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5022; Jourde-Chiche N, 2019, NAT REV NEPHROL, V15, P87, DOI 10.1038/s41581-018-0098-z; Karczewski KJ, 2018, NAT REV GENET, V19, P299, DOI 10.1038/nrg.2018.4; Lebenbaum M, 2018, PREV MED, V116, P173, DOI 10.1016/j.ypmed.2018.08.025; Liu J, 2020, NAT MED, V26, P110, DOI 10.1038/s41591-019-0722-x; Marx P, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005487; Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708; Partridge L, 2018, NATURE, V561, P45, DOI 10.1038/s41586-018-0457-8; Pedersen HK, 2016, NATURE, V535, P376, DOI 10.1038/nature18646; Rose SMSF, 2019, NAT MED, V25, P792, DOI 10.1038/s41591-019-0414-6; Rowland I, 2018, EUR J NUTR, V57, P1, DOI 10.1007/s00394-017-1445-8; Smith SM, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006560.pub3, 10.1002/14651858.CD006560.pub4]; Soga T, 2011, J HEPATOL, V55, P896, DOI 10.1016/j.jhep.2011.01.031; Sommer A, 2011, BBA-MOL BASIS DIS, V1812, P685, DOI 10.1016/j.bbadis.2011.03.005; Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140-6736(18)32225-6; Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2; Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P2493, DOI 10.1001/jama.2012.5265; van Oostrom SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160264; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Whitty CJM, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6964; Wikstrom K, 2015, EUR J INTERN MED, V26, P211, DOI 10.1016/j.ejim.2015.02.012; Williams SA, 2019, NAT MED, V25, P1851, DOI 10.1038/s41591-019-0665-2; Yao SS, 2018, LANCET, V392, P84; Zhang L, 2018, CIRCULATION, V137, P1374, DOI 10.1161/CIRCULATIONAHA.117.031139; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369; Zhou WY, 2019, NATURE, V569, P663, DOI 10.1038/s41586-019-1236-x	42	26	26	5	32	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2021	27	3					471	+		10.1038/s41591-021-01266-0	http://dx.doi.org/10.1038/s41591-021-01266-0		MAR 2021	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QY0CR	33707775	Green Submitted, Green Accepted			2022-12-27	WOS:000627703000002
J	Figee, M; Mayberg, H				Figee, Martijn; Mayberg, Helen			The future of personalized brain stimulation	NATURE MEDICINE			English	Editorial Material							CONNECTIVITY	New personalized brain-stimulation methods for the treatment of depression and obsessive-compulsive symptoms provide hope for future treatment applications.	[Figee, Martijn; Mayberg, Helen] Icahn Sch Med Mt Sinai, Nash Family Ctr Adv Circuit Therapeut, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Mayberg, H (corresponding author), Icahn Sch Med Mt Sinai, Nash Family Ctr Adv Circuit Therapeut, New York, NY 10029 USA.	helen.mayberg@mssm.edu	Figee, Martijn/N-5659-2019	Figee, Martijn/0000-0003-3679-284X; Mayberg, Helen/0000-0002-1672-2716	NINDS NIH HHS [UH3 NS103550] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH) [UH3 NS111137-01] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)		Amare AT, 2021, MOL PSYCHIATR, V26, P2457, DOI 10.1038/s41380-020-0689-5; Bergfeld IO, 2016, JAMA PSYCHIAT, V73, P456, DOI 10.1001/jamapsychiatry.2016.0152; Drysdale AT, 2017, NAT MED, V23, P28, DOI 10.1038/nm.4246; Dunlop BW, 2017, AM J PSYCHIAT, V174, P533, DOI 10.1176/appi.ajp.2016.16050518; Figee M, 2016, EUR NEUROPSYCHOPHARM, V26, P856, DOI 10.1016/j.euroneuro.2015.12.003; Figee M, 2013, NAT NEUROSCI, V16, P386, DOI 10.1038/nn.3344; Graat I, 2021, BIOL PSYCHIAT, V90, P714, DOI 10.1016/j.biopsych.2020.08.018; Grover S, 2021, NAT MED, V27, P232, DOI 10.1038/s41591-020-01173-w; Hitti FL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092796; Krystal AD, 2020, NAT MED, V26, P760, DOI 10.1038/s41591-020-0806-7; Riva-Posse P, 2018, MOL PSYCHIATR, V23, P843, DOI 10.1038/mp.2017.59; Scangos KW, 2021, NAT MED, V27, P229, DOI 10.1038/s41591-020-01175-8; Smith AH, 2021, BRAIN STIMUL, V14, P1, DOI 10.1016/j.brs.2020.10.016	13	21	21	3	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					196	197		10.1038/s41591-021-01243-7	http://dx.doi.org/10.1038/s41591-021-01243-7		FEB 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33526929				2022-12-27	WOS:000613582400001
J	Ganesh, K; Massague, J				Ganesh, Karuna; Massague, Joan			Targeting metastatic cancer	NATURE MEDICINE			English	Review							CELL LUNG-CANCER; CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; NIVOLUMAB PLUS IPILIMUMAB; ACUTE MYELOID-LEUKEMIA; COLON-CANCER; STEM-CELLS; PROSTATE-CANCER; STAGE-III; EARLY DISSEMINATION	Increased understanding of the biology of metastases allows improved targeting and outcomes for patients with both micro- and macrometastases. Despite recent therapeutic advances in cancer treatment, metastasis remains the principal cause of cancer death. Recent work has uncovered the unique biology of metastasis-initiating cells that results in tumor growth in distant organs, evasion of immune surveillance and co-option of metastatic microenvironments. Here we review recent progress that is enabling therapeutic advances in treating both micro- and macrometastases. Such insights were gained from cancer sequencing, mechanistic studies and clinical trials, including of immunotherapy. These studies reveal both the origins and nature of metastases and identify new opportunities for developing more effective strategies to target metastatic relapse and improve patient outcomes.	[Ganesh, Karuna] Sloan Kettering Inst, Mol Pharmacol Program, New York, NY 10065 USA; [Ganesh, Karuna] Mem Hosp, Dept Med, New York, NY 10065 USA; [Massague, Joan] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ganesh, K (corresponding author), Sloan Kettering Inst, Mol Pharmacol Program, New York, NY 10065 USA.; Ganesh, K (corresponding author), Mem Hosp, Dept Med, New York, NY 10065 USA.; Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA.	ganeshk@mskcc.org; j-massague@ski.mskcc.org		Ganesh, Karuna/0000-0002-4948-1082				Aceto N, 2015, TRENDS CANCER, V1, P44, DOI 10.1016/j.trecan.2015.07.006; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adams EJ, 2019, NATURE, V571, P408, DOI 10.1038/s41586-019-1318-9; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Ali FR, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/404615; Alix-Panabieres C, 2012, ANNU REV MED, V63, P199, DOI 10.1146/annurev-med-062310-094219; Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711; Altevogt P, 2016, INT J CANCER, V138, P1565, DOI 10.1002/ijc.29658; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Biswas D, 2019, NAT MED, V25, P1540, DOI 10.1038/s41591-019-0595-z; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Boire A, 2020, NAT REV CANCER, V20, P4, DOI 10.1038/s41568-019-0220-y; Boire A, 2017, CELL, V168, P1101, DOI 10.1016/j.cell.2017.02.025; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240; Carlson P, 2019, NAT CELL BIOL, V21, P238, DOI 10.1038/s41556-018-0267-0; Caswell-Jin JL, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky062; Celia-Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556-018-0145-9; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chemi F, 2019, NAT MED, V25, P1534, DOI 10.1038/s41591-019-0593-1; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chi Y, 2020, SCIENCE, V369, P276, DOI 10.1126/science.aaz2193; Clark ME, 2014, J GASTROINTEST ONCOL, V5, P374, DOI 10.3978/j.issn.2078-6891.2014.064; Coakley M, 2019, CLIN CANCER RES, V25, P6026, DOI 10.1158/1078-0432.CCR-19-0152; Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247; Creasy JM, 2018, SURGERY, V163, P1238, DOI 10.1016/j.surg.2018.01.004; Cristofanilli M, 2019, CRIT REV ONCOL HEMAT, V134, P39, DOI 10.1016/j.critrevonc.2018.12.004; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; De La Rochere P, 2018, TRENDS IMMUNOL, V39, P748, DOI 10.1016/j.it.2018.07.001; Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052; Doebele RC, 2020, LANCET ONCOL, V21, P271, DOI 10.1016/S1470-2045(19)30691-6; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Early Breast Cancer Trialists' Collaborative Group, 2015, LANCET, V386, P1353, DOI [DOI 10.1016/S0140-6736(15)60908-4, 10.1016/S0140-6736(15)60908-4]; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8; Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fontebasso Yari, 2015, Critical Reviews in Oncogenesis, V20, P449, DOI 10.1615/CritRevOncog.v20.i5-6.150; Forbes NS, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0381-3; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296; Fumagalli A, 2020, CELL STEM CELL, V26, P569, DOI 10.1016/j.stem.2020.02.008; Ganesh K, 2020, NAT CANCER, V1, P28, DOI 10.1038/s43018-019-0006-x; Ganesh K, 2019, NAT MED, V25, P1607, DOI 10.1038/s41591-019-0584-2; Garner H, 2020, NAT REV IMMUNOL, V20, P483, DOI 10.1038/s41577-019-0271-z; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Gomes AP, 2019, CANCER CELL, V36, P402, DOI 10.1016/j.ccell.2019.08.006; Gomez DR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.19.00201; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709; Haibe Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00221; Hamilton K, 2000, MODERN PATHOL, V13, P475, DOI 10.1038/modpathol.3880081; Hapach LA, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0092-3; Haro MA, 2019, CANCER RES, V79, P159, DOI 10.1158/0008-5472.CAN-18-0981; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Haslam A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0423; Heller G, 2018, J CLIN ONCOL, V36, P572, DOI 10.1200/JCO.2017.75.2998; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Howlader N, 2019, SEER CANC STAT REV 1, P1423; Hu Z, 2020, NAT GENET, V52, P701, DOI 10.1038/s41588-020-0628-z; Hu Z, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16995-y; Iheanacho K, 2020, CLIN ADV HEMATOL ONC, V18, P56; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562; Jassem J, 2019, TRANSL LUNG CANCER R, V8, pS387, DOI 10.21037/tlcr.2019.09.02; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kaur J, 2019, CURR MOL PHARMACOL, V12, P215, DOI 10.2174/1874467212666190215112915; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kuol N, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0674-x; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Laughney AM, 2020, NAT MED, V26, P259, DOI 10.1038/s41591-019-0750-6; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Long GV, 2018, LANCET ONCOL, V19, P672, DOI 10.1016/S1470-2045(18)30139-6; Lugassy C, 2020, ANGIOGENESIS, V23, P27, DOI 10.1007/s10456-019-09695-9; Majem M, 2020, J CLIN ONCOL, V38; Makker V, 2019, LANCET ONCOL, V20, P711, DOI 10.1016/S1470-2045(19)30020-8; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Mateo J, 2019, ANN ONCOL, V30, P1437, DOI 10.1093/annonc/mdz192; May M, 2019, NAT MED, V25, P2, DOI 10.1038/s41591-018-0314-1; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Micalizzi DS, 2017, GENE DEV, V31, P1827, DOI 10.1101/gad.305805.117; Mohme M, 2017, NAT REV CLIN ONCOL, V14, P155, DOI 10.1038/nrclinonc.2016.144; Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189; O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ombrato L, 2019, NATURE, V572, P603, DOI 10.1038/s41586-019-1487-6; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; PAGET S, 1989, CANCER METAST REV, V8, P98; Palma DA, 2019, LANCET, V393, P2051, DOI 10.1016/S0140-6736(18)32487-5; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; PANTEL K, 1991, CANCER RES, V51, P4712; Pantel K, 2019, NAT REV CLIN ONCOL, V16, P409, DOI 10.1038/s41571-019-0187-3; Pantel K, 2019, CLIN CHEM, V65, P87, DOI 10.1373/clinchem.2018.287102; Parhi L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16967-2; Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Parsons S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2488; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Phallen J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2415; Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Pommier A, 2018, SCIENCE, V360, P1202, DOI 10.1126/science.aao4908; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Priego N, 2018, NAT MED, V24, P1024, DOI 10.1038/s41591-018-0044-4; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Prunier C, 2019, TRENDS CANCER, V5, P66, DOI 10.1016/j.trecan.2018.10.010; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Quintanal-Villalonga A, 2020, NAT REV CLIN ONCOL, V17, P360, DOI 10.1038/s41571-020-0340-z; Razavi P, 2019, NAT MED, V25, P1928, DOI 10.1038/s41591-019-0652-7; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; Reiter JG, 2019, NAT REV CANCER, V19, P639, DOI 10.1038/s41568-019-0185-x; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Risson E, 2020, NAT CANCER, V1, P672, DOI 10.1038/s43018-020-0088-5; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rozenblatt-Rosen O, 2020, CELL, V181, P236, DOI 10.1016/j.cell.2020.03.053; Sabnis AJ, 2019, TRENDS MOL MED, V25, P185, DOI 10.1016/j.molmed.2018.12.009; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Scadden DT, 2014, CELL, V157, P41, DOI 10.1016/j.cell.2014.02.013; Schumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402; Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; SOBRERO AF, 2020, J CLIN ONCOL S, V38; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sparano JA, 2019, NEW ENGL J MED, V380, P2395, DOI 10.1056/NEJMoa1904819; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spring LM, 2020, LANCET, V395, P817, DOI 10.1016/S0140-6736(20)30165-3; Steeg PS, 2012, NATURE, V485, pS58, DOI 10.1038/485S58a; Su J, 2020, NATURE, V577, P566, DOI 10.1038/s41586-019-1897-5; Suva ML, 2019, MOL CELL, V75, P7, DOI 10.1016/j.molcel.2019.05.003; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Tikhonova AN, 2020, CELL STEM CELL, V27, P19, DOI 10.1016/j.stem.2020.06.013; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Tuveson D, 2019, SCIENCE, V364, P952, DOI 10.1126/science.aaw6985; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1; Versluis JM, 2020, NAT MED, V26, P475, DOI 10.1038/s41591-020-0829-0; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Wu YL, 2020, J CLIN ONCOL, V38; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Yuki K, 2020, TRENDS IMMUNOL, V41, P652, DOI 10.1016/j.it.2020.06.010; Zeng QQ, 2019, NATURE, V573, P526, DOI 10.1038/s41586-019-1576-6; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685; Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002; Zimmer L, 2020, LANCET, V395, P1558, DOI 10.1016/S0140-6736(20)30417-7	198	163	168	34	187	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					34	44		10.1038/s41591-020-01195-4	http://dx.doi.org/10.1038/s41591-020-01195-4			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442008	Green Accepted			2022-12-27	WOS:000607931400020
J	Stower, H				Stower, Hannah			A map of lung cell types	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	2	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					21	21		10.1038/s41591-020-01217-1	http://dx.doi.org/10.1038/s41591-020-01217-1			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442012				2022-12-27	WOS:000607931400015
J	Stower, H				Stower, Hannah			Microbiome transplant-induced response to immunotherapy	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	2	2	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2021	27	1					21	21		10.1038/s41591-020-01220-6	http://dx.doi.org/10.1038/s41591-020-01220-6			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PS4ZO	33442010				2022-12-27	WOS:000607931400011
J	Wibmer, CK; Ayres, F; Hermanus, T; Madzivhandila, M; Kgagudi, P; Oosthuysen, B; Lambson, BE; de Oliveira, T; Vermeulen, M; van der Berg, K; Rossouw, T; Boswell, M; Ueckermann, V; Meiring, S; von Gottberg, A; Cohen, C; Morris, L; Bhiman, JN; Moore, PL				Wibmer, Constantinos Kurt; Ayres, Frances; Hermanus, Tandile; Madzivhandila, Mashudu; Kgagudi, Prudence; Oosthuysen, Brent; Lambson, Bronwen E.; de Oliveira, Tulio; Vermeulen, Marion; van der Berg, Karin; Rossouw, Theresa; Boswell, Michael; Ueckermann, Veronica; Meiring, Susan; von Gottberg, Anne; Cohen, Cheryl; Morris, Lynn; Bhiman, Jinal N.; Moore, Penny L.			SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	NATURE MEDICINE			English	Article								Substitutions in SARS-CoV-2 spike protein present in the B.1.351 variant first detected in South Africa, when expressed in pseudoviruses, mediate escape from neutralization by monoclonal antibodies under clinical development and by plasma from individuals previously infected with SARS-CoV-2, but do not prevent binding of convalescent plasma to recombinant spike protein containing B.1.351 lineage substitutions. SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.	[Wibmer, Constantinos Kurt; Ayres, Frances; Hermanus, Tandile; Madzivhandila, Mashudu; Kgagudi, Prudence; Oosthuysen, Brent; Lambson, Bronwen E.; Meiring, Susan; von Gottberg, Anne; Cohen, Cheryl; Morris, Lynn; Bhiman, Jinal N.; Moore, Penny L.] Natl Hlth Lab Serv NHLS, Natl Inst Communicable Dis NICD, Johannesburg, South Africa; [Lambson, Bronwen E.; Morris, Lynn; Moore, Penny L.] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Antibody Immun Res Unit, Johannesburg, South Africa; [de Oliveira, Tulio] Univ KwaZulu Natal, Dept Lab Med & Med Sci, KwaZulu Natal Res Innovat & Sequencing Platform K, Durban, South Africa; [Vermeulen, Marion; van der Berg, Karin] South African Natl Blood Serv, Weltevreden Pk, South Africa; [van der Berg, Karin] Univ Cape Town, Fac Hlth Sci, Div Clin Haematol, Cape Town, South Africa; [Rossouw, Theresa] Univ Pretoria, Fac Hlth Sci, Dept Immunol, Pretoria, South Africa; [Boswell, Michael; Ueckermann, Veronica] Steve Biko Acad Hosp, Dept Internal Med, Div Infect Dis, Pretoria, South Africa; [Boswell, Michael; Ueckermann, Veronica] Univ Pretoria, Pretoria, South Africa; [von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Dept Clin Microbiol & Infect Dis, Johannesburg, South Africa; [Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa; [Bhiman, Jinal N.] Univ Witwatersrand, Fac Hlth Sci, Dept Virol, Johannesburg, South Africa	National Health Laboratory Service; National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Kwazulu Natal; University of Cape Town; University of Pretoria; University of Pretoria; University of Pretoria; University of Witwatersrand; University of Witwatersrand; University of Witwatersrand	Moore, PL (corresponding author), Natl Hlth Lab Serv NHLS, Natl Inst Communicable Dis NICD, Johannesburg, South Africa.; Moore, PL (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Antibody Immun Res Unit, Johannesburg, South Africa.	pennym@nicd.ac.za	Ueckermann, Veronica/GXV-4532-2022; Wibmer, Constantinos Kurt/AAO-3035-2021; Wibmer, Constantinos Kurt/AAH-8669-2019	Wibmer, Constantinos Kurt/0000-0003-2329-2280; Ayres, Frances/0000-0002-7238-0415; von Gottberg, Anne/0000-0002-0243-7455; Boswell, Michael/0000-0003-2152-1617; Rossouw, Theresa/0000-0003-4066-922X; de Oliveira, Tulio/0000-0002-3027-5254; Van den Berg, Karin/0000-0001-9805-8013	South African Medical Research Council [96825, SHIPNCD 76756, DST/CON 0250/2012]; Wellcome Trust [221003/Z/20/Z]; US Centers for Disease Control and Prevention [5 U01IP001048-05-00]; ELMA South Africa Foundation [20-ESA011]; South African Research Chairs Initiative of the Department of Science and Innovation; National Research Foundation of South Africa [98341]; Fogarty International Center of the National Institutes of Health [R21TW011454]; FLAIR Fellowship Program [FLR\R1\201782]; UK Government's Global Challenges Research Fund; Fogarty International Centre or the National Institutes of Health [1D43TW010345]	South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); ELMA South Africa Foundation; South African Research Chairs Initiative of the Department of Science and Innovation; National Research Foundation of South Africa(National Research Foundation - South Africa); Fogarty International Center of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FLAIR Fellowship Program; UK Government's Global Challenges Research Fund; Fogarty International Centre or the National Institutes of Health	We thank the COVID-19 convalescent plasma donors, the staff of the South African National Blood Services for contributing samples that enabled this work, Z. van der Walt, T. de Villiers, W. van Hougenhouck-Tulleken for contributing to patient management and sample collection and A. Buys for technical support. We thank the participants of the Novel Coronavirus (COVID-19) Viral Shedding and Clinical Characterization Study (University of the Witwatersrand Health Research Ethics (Medical) committee reference M160667) who contributed samples and the GERMS-SA clinical staff for their contributions to sample and data collection. We acknowledge funding from the South African Medical Research Council (ref. nos. 96825, SHIPNCD 76756 and DST/CON 0250/2012), the Wellcome Trust (grant no. 221003/Z/20/Z), US Centers for Disease Control and Prevention (grant no. 5 U01IP001048-05-00) and the ELMA South Africa Foundation (grant no. 20-ESA011). P.L.M. is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation of South Africa (grant no. 98341). C.K.W. is supported by Fogarty International Center of the National Institutes of Health under Award Number R21TW011454 (this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health) as well as the FLAIR Fellowship Program under award number FLR\R1\201782 (the FLAIR Fellowship Program is a partnership between the African Academy of Sciences and the Royal Society funded by the UK Government's Global Challenges Research Fund). K.v.d.B. is supported in part by the Fogarty International Centre or the National Institutes of Health under award no. 1D43TW010345. We thank N. Doria-Rose, D. Montefiori, E. Landais and M. Farzan for reagents and assistance in establishing the SARS-CoV-2 pseudotyped neutralization assay and enabling equivalency and proficiency testing. We thank D. Sok, E. Landais, D. Burton, N. Doria-Rose and P. Kwong for SARS-Co-V-2-directed monoclonal antibodies. We are grateful to T. Moyo-Gwete and Z. Molaudzi for expressing monoclonal antibodies. We thank the informal 501Y.V2 consortium of South African scientists, chaired by W. Hanekom and T. D'Oliveira for suggestions and discussion of data. We also thank all NGS-SA laboratories in South Africa that were responsible for producing the SARS-CoV-2 genomes that enabled the rapid dissemination of SARS-CoV-2 sequences and the identification of 501Y.V2.	[Anonymous], 2015, PYMOL MOL GRAPHICS S; Atyeo C, 2020, IMMUNITY, V53, P524, DOI 10.1016/j.immuni.2020.07.020; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cele S, 2021, MEDRXIV, DOI [10.1101/2021.01.26.21250224, DOI 10.1101/2021.01.26.21250224, 10.1101/2021.03.07.21252647]; CERUTTI G, 2021, BIORXIV; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Koenig PA, 2021, SCIENCE, V371, P691, DOI 10.1126/science.abe6230; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Li Dapeng, 2021, bioRxiv, DOI 10.1101/2020.12.31.424729; Marovich M, 2020, JAMA-J AM MED ASSOC, V324, P131, DOI 10.1001/jama.2020.10245; McCallum M, 2021, CELL, V184, P2332, DOI [10.1101/2021.01.14.426475, 10.1016/j.cell.2021.03.028]; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Rapp M, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108950; Schoof M, 2020, SCIENCE, V370, P1473, DOI 10.1126/science.abe3255; Sholukh Anton M, 2020, medRxiv, DOI 10.1101/2020.12.07.20245431; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Suryadevara Naveenchandra, 2021, Cell, V184, P2316, DOI [10.1101/2021.01.19.427324, 10.1016/j.cell.2021.03.029]; Tegally H, 2020, MEDRXIV, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640, 10.1101/2020.12.21.20248640(2020]; Tegally H, 2021, NAT MED, V27, P440, DOI 10.1038/s41591-021-01255-3; Voss William N, 2020, bioRxiv, DOI 10.1101/2020.12.20.423708; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; Xiang YF, 2020, SCIENCE, V370, P1479, DOI 10.1126/science.abe4747; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	35	677	690	9	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01285-x	http://dx.doi.org/10.1038/s41591-021-01285-x		MAR 2021	9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33501446	Green Submitted, Green Published, Bronze			2022-12-27	WOS:000624452300002
J	Xie, XP; Liu, Y; Liu, JY; Zhang, XW; Zou, J; Fontes-Garfias, CR; Xia, HJ; Swanson, KA; Cutler, M; Cooper, D; Menachery, VD; Weaver, SC; Dormitzer, PR; Shi, PY				Xie, Xuping; Liu, Yang; Liu, Jianying; Zhang, Xianwen; Zou, Jing; Fontes-Garfias, Camila R.; Xia, Hongjie; Swanson, Kena A.; Cutler, Mark; Cooper, David; Menachery, Vineet D.; Weaver, Scott C.; Dormitzer, Philip R.; Shi, Pei-Yong			Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	NATURE MEDICINE			English	Article								We engineered three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion + N501Y + D614G from UK; and E484K + N501Y + D614G from SA. Neutralization geometric mean titers (GMTs) of 20 BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses. Human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing spike mutations present in globally circulating variants of concern.	[Xie, Xuping; Liu, Yang; Zhang, Xianwen; Zou, Jing; Fontes-Garfias, Camila R.; Xia, Hongjie; Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Liu, Jianying; Menachery, Vineet D.; Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol, Galveston, TX 77555 USA; [Liu, Jianying; Menachery, Vineet D.; Weaver, Scott C.] Univ Texas Med Branch, Dept Immunol, Galveston, TX USA; [Liu, Jianying; Menachery, Vineet D.; Weaver, Scott C.; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA; [Swanson, Kena A.; Cutler, Mark; Cooper, David; Dormitzer, Philip R.] Pfizer, Pearl River, NY 10965 USA; [Shi, Pei-Yong] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA; [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA; [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Pfizer; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Shi, PY (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.; Dormitzer, PR (corresponding author), Pfizer, Pearl River, NY 10965 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.	philip.dormitzer@pfizer.com; peshi@utmb.edu	zhang, xian/GYA-0290-2022; Xie, Xuping/AAD-7406-2019	Xia, Hongjie/0000-0002-2520-7038; Fontes-Garfias, Camila/0000-0002-1912-8413	Pfizer; BioNTech; National Institutes of Health [AI142759, AI134907, AI145617, UL1TR001439]; Sealy AMP; Smith Foundation; Kleberg Foundation; John S. Dunn Foundation; Amon G. Carter Foundation; Gilson Longenbaugh Foundation; Summerfield Robert Foundation	Pfizer(Pfizer); BioNTech; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sealy AMP; Smith Foundation; Kleberg Foundation; John S. Dunn Foundation; Amon G. Carter Foundation; Gilson Longenbaugh Foundation; Summerfield Robert Foundation	This work was supported by Pfizer and BioNTech. We thank colleagues at Pfizer, BioNTech and the University of Texas Medical Branch for helpful discussions and support during the study. We thank the Pfizer-BioNTech clinical trial C4591001 participants, from whom the post-immunization human sera were obtained. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. P.-Y.S. was supported by National Institutes of Health grants AI142759, AI134907, AI145617 and UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation and the Summerfield Robert Foundation.	Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Hou YXJ, 2020, SCIENCE, V370, P1464, DOI 10.1126/science.abe8499; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Ku Z., 2021, NAT COMMUN, V12, DOI [10.1038/s41467-020-20789-7, DOI 10.1038/s41467-020-20789-7]; MRC Centre for Global Infectious Disease Analysis, 2021, REPORT 42 TRANSMISSI; Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sahin U, 2020, BNT162B2 INDUCES SAR, DOI [10.1101/2020.12.09.20245175v1, DOI 10.1101/2020.12.09.20245175V1]; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang Z., 2021, MRNA VACCINE ELICITE, DOI [10.1101/2021.01.15.426911v1, DOI 10.1101/2021.01.15.426911V1, 10.1038/s41596-021-00491-8, DOI 10.1038/s41596-021-00491-8]; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xie XP, 2021, NAT PROTOC, V16, P1761, DOI 10.1038/s41596-021-00491-8; Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004	18	368	370	1	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2021	27	4								10.1038/s41591-021-01270-4	http://dx.doi.org/10.1038/s41591-021-01270-4		FEB 2021	6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RN8OZ	33532771	Green Published, Bronze			2022-12-27	WOS:000616056700004
